papers,HYPOTHESIS,paperinfo,disprove_info,budget_info,plan,first_number,specific_plan,data,corr
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8dee3397d5b0d6ff5900ae6e855d053cffbb095f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/025a7983132d724a0bb8e949311f8b3063b09619.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8e1c7f8fc0cf6afa33a52493bfc70652fd36c099.summary']","Can AU-007, in combination with Granzyme B PET imaging, selectively activate naïve B cells in the tumor microenvironment to enhance anti-tumor immunity and improve treatment outcomes in cancer patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that AU-007, in combination with Granzyme B PET imaging, can selectively activate naïve B cells in the tumor microenvironment to enhance anti-tumor immunity and improve treatment outcomes in cancer patients, I propose the following experimental plan:

**Experiment:** ""AU-007-mediated activation of naïve B cells in the tumor microenvironment: A Granzyme B PET imaging study""

**Objective:** To investigate whether AU-007 can selectively activate naïve B cells in the tumor microenvironment, leading to enhanced anti-tumor immunity, and to non-invasively monitor this process using Granzyme B PET imaging.

**Design:**

1. **In vitro** study:
	* Isolate naïve B cells from healthy donors and cancer patients using fluorescence-activated cell sorting (FACS).
	* Co-culture naïve B cells with AU-007 and tumor cells (e.g., HCC cell lines) in the presence or absence of Granzyme B PET imaging agents.
	* Measure the activation of naïve B cells using flow cytometry (e.g., CD69, CD86, and CD25 expression) and ELISA (e.g., anti-tumor antibody production).
2. **In vivo** study:
	* Establish a tumor-bearing mouse model (e.g., HCC) and administer AU-007 with or without Granzyme B PET imaging agents.
	* Monitor tumor growth and immune cell infiltration using Granzyme B PET imaging and flow cytometry.
	* Analyze the activation of naïve B cells in the tumor microenvironment using flow cytometry and ELISA.

**Granzyme B PET imaging protocol:**

* Inject Granzyme B PET imaging agents into mice and perform PET/CT scans at baseline, 24 hours, and 48 hours after AU-007 administration.
* Analyze PET images to quantify Granzyme B activity in the tumor and tumor-draining lymph nodes.

**Endpoints:**

* Activation of naïve B cells in the tumor microenvironment (in vitro and in vivo)
* Tumor growth and immune cell infiltration (in vivo)
* Granzyme B activity in the tumor and tumor-draining lymph nodes (in vivo)

**Resources:**

* AU-007 antibody
* Granzyme B PET imaging agents
* Tumor-bearing mice (e.g., HCC)
* Flow cytometer
* ELISA reader
* PET/CT scanner
* Cell culture facilities
* FACS sorter

**Timeline:**

* In vitro study: 2-3 months
* In vivo study: 4-6 months
* Data analysis and manuscript preparation: 3-4 months

**Budget:**

* AU-007 antibody: $10,000
* Granzyme B PET imaging agents: $15,000
* Tumor-bearing mice: $5,000
* Flow cytometer and ELISA reader: $10,000 (already available in the lab)
* PET/CT scanner: $20,000 (already available in the lab)
* Cell culture facilities and FACS sorter: $5,000 (already available in the lab)
* Personnel and miscellaneous: $20,000

Total budget: $80,000

This experimental plan aims to test the hypothesis that AU-007, in combination with Granzyme B PET imaging, can selectively activate naïve B cells in the tumor microenvironment, leading to enhanced anti-tumor immunity and improved treatment outcomes in cancer patients. The study will provide valuable insights into the mechanisms of AU-007-mediated immune activation and the potential of Granzyme B PET imaging as a non-invasive biomarker for monitoring treatment response.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**In Vitro Study:**

**Protocol 1: Isolation of Naïve B Cells from Healthy Donors and Cancer Patients**

1.1. Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors and cancer patients through venipuncture or leukapheresis.

1.2. Isolate PBMCs using Ficoll-Paque density gradient centrifugation.

1.3. Stain PBMCs with fluorescently labeled antibodies against CD19, CD27, and CD38 to identify naïve B cells (CD19+CD27-CD38-).

1.4. Sort naïve B cells using fluorescence-activated cell sorting (FACS) with a purity threshold of >95%.

**Protocol 2: Co-Culture of Naïve B Cells with AU-007 and Tumor Cells**

2.1. Culture naïve B cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

2.2. Add AU-007 antibody to the culture medium at a concentration of 1 μg/mL.

2.3. Co-culture naïve B cells with HCC cell lines (e.g., HepG2) at a ratio of 1:1.

2.4. Incubate the co-culture for 48 hours at 37°C, 5% CO2.

**Protocol 3: Measurement of Naïve B Cell Activation**

3.1. Harvest co-cultured cells and stain with fluorescently labeled antibodies against CD69, CD86, and CD25.

3.2. Analyze stained cells using flow cytometry to measure the expression of activation markers.

3.3. Collect supernatants from co-cultures and measure anti-tumor antibody production using ELISA.

**In Vivo Study:**

**Protocol 4: Establishment of Tumor-Bearing Mouse Model**

4.1. Obtain HCC tumor-bearing mice (e.g., HepG2 xenografts) from a reputable vendor or generate them in-house.

4.2. Monitor tumor growth using caliper measurements and ultrasound imaging.

**Protocol 5: Administration of AU-007 and Granzyme B PET Imaging Agents**

5.1. Administer AU-007 antibody to mice via intravenous injection at a dose of 10 mg/kg.

5.2. Inject Granzyme B PET imaging agents (e.g., [18F]FB-IL2) via tail vein injection at a dose of 100 μCi.

**Protocol 6: Granzyme B PET Imaging**

6.1. Perform PET/CT scans on mice at baseline, 24 hours, and 48 hours after AU-007 administration using a small-animal PET/CT scanner.

6.2. Analyze PET images using dedicated software to quantify Granzyme B activity in the tumor and tumor-draining lymph nodes.

**Protocol 7: Tumor Growth and Immune Cell Infiltration Analysis**

7.1. Monitor tumor growth using caliper measurements and ultrasound imaging.

7.2. Harvest tumors and tumor-draining lymph nodes at the end of the study.

7.3. Analyze immune cell infiltration using flow cytometry and immunohistochemistry.

**Protocol 8: Naïve B Cell Activation Analysis**

8.1. Isolate naïve B cells from tumor-bearing mice using FACS.

8.2. Analyze naïve B cell activation using flow cytometry and ELISA.

**Granzyme B PET Imaging Protocol:**

**Protocol 9: Granzyme B PET Imaging Agent Preparation**

9.1. Prepare [18F]FB-IL2 according to the manufacturer's instructions.

9.2. Quality control the radiotracer using HPLC and TLC.

**Protocol 10: PET/CT Scanning**

10.1. Anesthetize mice using isoflurane.

10.2. Position mice in the PET/CT scanner.

10.3. Acquire PET and CT images using the scanner's software.

10.4. Reconstruct and analyze PET images using dedicated software.

These detailed protocols should provide a clear guide for executing the experiment and ensure replicability and specificity in the results.","```
   Healthy_Donors_PBMCs  Cancer_Patients_PBMCs  AU_007_Concentration  HCC_Cell_Line_Ratio  Naive_B_Cell_Activation  Anti_Tumor_Antibody_Production  Granzyme_B_Activity  Tumor_Growth
0                  10000                  8000                  0.5                 0.5                    20.1                       1500               3000          1500
1                  12000                 10000                  1.0                 0.7                    25.5                       2000               3500          1800
2                   9000                  7000                  0.8                 0.6                    22.8                       1800               3200          1600
3                  11000                 9000                  0.9                 0.8                    28.2                       2200               3800          2000
4                  13000                11000                  1.2                 0.9                    30.5                       2500               4000          2200
5                   8000                  6000                  0.4                 0.4                    18.5                       1200               2800          1400
6                  14000                12000                  1.5                 1.0                    32.8                       2800               4200          2400
7                   9500                  7500                  0.6                 0.5                    21.2                       1900               3100          1700
8                  12500                10000                  1.1                 0.8                    26.5                       2100               3600          1900
9                   8500                  6500                  0.3                 0.3                    16.8                       1100               2600          1300
10                 13500                11500                  1.6                 0.9                    34.2                       2900               4400          2500
11                  10500                 8500                  0.7                 0.6                    23.5                       2000               3300          1800
12                 14500                12500                  1.8                 1.0                    36.5                       3100               4600          2600
13                  10000                 8000                  0.9                 0.7                    25.8                       2200               3700          2000
14                  11500                9500                  1.0                 0.8                    27.2                       2300               3900          2100
15                   9000                  7000                  0.5                 0.5                    20.5                       1600               3000          1500
16                 13000                11000                  1.3                 0.9                    31.2                       2600               4100          2300
17                  12000                10000                  1.2                 0.8                    29.5                       2400               3800          2100
18                  14000                12000                  1.7                 1.0                    35.8                       3000               4500          2500
19                  11000                 9000                  0.8                 0.7                    24.2                       2100               3500          1900
20                  12500                10500                  1.1                 0.9                    28.8                       2500               4000          2200
21                  13500                11500                  1.4                 1.0                    33.5                       2800               4300          2400
22                  10000                 8000                  0.6                 0.6                    22.1                       1900               3200          1700
23                  14500                12500                  1.9                 1.0                    38.2                       3200               4700          2600
24                  10500                 8500                  0.9                 0.8                    26.2                       2300               3700          2000
```",0.968713079743223
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/381c6adf6b02214fe839494c0703f3d7bc5b0826.summary'],"Can CD30-positive extracellular vesicles also transfer functional CD30 receptors to non-malignant immune cells, thereby enhancing their ability to target and eliminate CD30-negative cancer cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Transfer of Functional CD30 Receptors from CD30-Positive Extracellular Vesicles to Non-Malignant Immune Cells

**Objective:** To determine if CD30-positive extracellular vesicles can transfer functional CD30 receptors to non-malignant immune cells, enhancing their ability to target and eliminate CD30-negative cancer cells.

**Equipment:**

* Flow cytometer
* Confocal microscope
* Cell culture facilities
* CD30-positive extracellular vesicles
* Non-malignant immune cells (e.g., T cells or natural killer cells)
* CD30-negative cancer cells
* Brentuximab Vedotin (BV)
* Antibodies against CD30 and immune cell surface markers

**Steps:**

1. Isolate CD30-positive extracellular vesicles from CD30-positive cells.
2. Incubate non-malignant immune cells with CD30-positive extracellular vesicles for various time periods (e.g., 1, 2, 4, and 24 hours).
3. Analyze CD30 expression on non-malignant immune cells by flow cytometry and confocal microscopy.
4. Co-culture CD30-negative cancer cells with CD30-positive extracellular vesicle-treated non-malignant immune cells.
5. Assess the ability of the treated non-malignant immune cells to target and eliminate CD30-negative cancer cells using flow cytometry, confocal microscopy, and cell viability assays.
6. Compare the results with untreated non-malignant immune cells and CD30-positive cancer cells as controls.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of CD30 Receptor Transfer from CD30-Positive Extracellular Vesicles to Non-Malignant Immune Cells

**Objective:** To demonstrate that CD30-positive extracellular vesicles do not transfer functional CD30 receptors to non-malignant immune cells, thereby failing to enhance their ability to target and eliminate CD30-negative cancer cells.

**Equipment:**

* Same as above

**Steps:**

1. Isolate CD30-positive extracellular vesicles from CD30-positive cells.
2. Incubate non-malignant immune cells with CD30-positive extracellular vesicles for an extended period (e.g., 48 hours) to maximize potential CD30 receptor transfer.
3. Treat the CD30-positive extracellular vesicle-treated non-malignant immune cells with a CD30-blocking antibody to prevent any potential CD30 receptor binding.
4. Co-culture CD30-negative cancer cells with the treated non-malignant immune cells.
5. Assess the ability of the treated non-malignant immune cells to target and eliminate CD30-negative cancer cells using flow cytometry, confocal microscopy, and cell viability assays.
6. Compare the results with untreated non-malignant immune cells and CD30-positive cancer cells as controls.

**Rationale:**

The experiment to disprove the hypothesis aims to demonstrate that even under optimal conditions, CD30-positive extracellular vesicles do not transfer functional CD30 receptors to non-malignant immune cells. By using a CD30-blocking antibody, we can rule out any potential CD30 receptor binding and assess the ability of the treated non-malignant immune cells to target CD30-negative cancer cells. If the results show no significant difference in targeting and elimination of CD30-negative cancer cells compared to untreated non-malignant immune cells, it would suggest that CD30-positive extracellular vesicles do not transfer functional CD30 receptors to non-malignant immune cells, disproving the hypothesis.

**Time and Resource Considerations:**

Both experiments can be completed within a reasonable time frame (approximately 2-3 months) and with a moderate budget. The required equipment and reagents are readily available in most cell biology and immunology laboratories. The experiments can be performed by a single researcher or a small team, and the results can be analyzed using standard statistical methods.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Isolation of CD30-Positive Extracellular Vesicles**

1.1. Obtain CD30-positive cells (e.g., lymphoma cells) and culture them in a suitable medium (e.g., RPMI 1640 with 10% FBS) at 37°C, 5% CO2.

1.2. Collect the cell culture supernatant after 48-72 hours and centrifuge at 300 x g for 10 minutes to remove cells and debris.

1.3. Filter the supernatant through a 0.22 μm filter to remove any remaining cells and debris.

1.4. Concentrate the supernatant using a centrifugal filter device (e.g., Amicon Ultra-15) with a 100 kDa molecular weight cutoff.

1.5. Wash the concentrated supernatant with PBS and resuspend in a suitable buffer (e.g., PBS with 1% BSA) for further use.

**Step 2: Incubation of Non-Malignant Immune Cells with CD30-Positive Extracellular Vesicles**

2.1. Obtain non-malignant immune cells (e.g., T cells or natural killer cells) and culture them in a suitable medium (e.g., RPMI 1640 with 10% FBS) at 37°C, 5% CO2.

2.2. Add CD30-positive extracellular vesicles to the non-malignant immune cells at a ratio of 1:1 (vesicles:cells) and incubate for various time periods (e.g., 1, 2, 4, and 24 hours).

2.3. Gently mix the cells and vesicles every 30 minutes to ensure uniform interaction.

**Step 3: Analysis of CD30 Expression on Non-Malignant Immune Cells**

3.1. Harvest the non-malignant immune cells and wash them with PBS.

3.2. Stain the cells with antibodies against CD30 and immune cell surface markers (e.g., CD3, CD56) using standard flow cytometry protocols.

3.3. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) to determine CD30 expression.

3.4. Fix the cells with 4% paraformaldehyde and analyze using confocal microscopy (e.g., Zeiss LSM 710) to visualize CD30 expression.

**Step 4: Co-Culture of CD30-Negative Cancer Cells with CD30-Positive Extracellular Vesicle-Treated Non-Malignant Immune Cells**

4.1. Obtain CD30-negative cancer cells (e.g., breast cancer cells) and culture them in a suitable medium (e.g., DMEM with 10% FBS) at 37°C, 5% CO2.

4.2. Co-culture the CD30-negative cancer cells with the CD30-positive extracellular vesicle-treated non-malignant immune cells at a ratio of 1:1 (cancer cells:immune cells) for 24-48 hours.

**Step 5: Assessment of Targeting and Elimination of CD30-Negative Cancer Cells**

5.1. Harvest the co-cultured cells and stain them with antibodies against CD30 and immune cell surface markers using standard flow cytometry protocols.

5.2. Analyze the cells using a flow cytometer to determine the percentage of CD30-negative cancer cells targeted and eliminated by the CD30-positive extracellular vesicle-treated non-malignant immune cells.

5.3. Perform cell viability assays (e.g., MTT, Annexin V) to assess the cytotoxicity of the CD30-positive extracellular vesicle-treated non-malignant immune cells against CD30-negative cancer cells.

**Step 6: Comparison with Controls**

6.1. Repeat Steps 2-5 using untreated non-malignant immune cells and CD30-positive cancer cells as controls.

6.2. Compare the results from the treated and control groups to determine if CD30-positive extracellular vesicles enhance the ability of non-malignant immune cells to target and eliminate CD30-negative cancer cells.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

**Step 1: Isolation of CD30-Positive Extracellular Vesicles**

( Same as Step 1 in the experiment to test the hypothesis)

**Step 2: Incubation of Non-Malignant Immune Cells with CD30-Positive Extracellular Vesicles**

2.1. Obtain non-malignant immune cells (e.g., T cells or natural killer cells) and culture them in a suitable medium (e.g., RPMI 1640 with 10% FBS) at 37°C, 5% CO2.

2.2. Add CD30-positive extracellular vesicles to the non-malignant immune cells at a ratio of 1:1 (vesicles:cells) and incubate for an extended period (e.g., 48 hours) to maximize potential CD30 receptor transfer.

**Step 3: Treatment with CD30-Blocking Antibody**

3.1. Add a CD30-blocking antibody (e.g., Brentuximab Vedotin) to the CD30-positive extracellular vesicle-treated non-malignant immune cells at a concentration of 10 μg/mL and incubate for 30 minutes.

**Step 4: Co-Culture of CD30-Negative Cancer Cells with Treated Non-Malignant Immune Cells**

4.1. Obtain CD30-negative cancer cells (e.g., breast cancer cells) and culture them in a suitable medium (e.g., DMEM with 10% FBS) at 37°C, 5% CO2.

4.2. Co-culture the CD30-negative cancer cells with the treated non-malignant immune cells at a ratio of 1:1 (cancer cells:immune cells) for 24-48 hours.

**Step 5: Assessment of Targeting and Elimination of CD30-Negative Cancer Cells**

5.1. Harvest the co-cultured cells and stain them with antibodies against CD30 and immune cell surface markers using standard flow cytometry protocols.

5.2. Analyze the cells using a flow cytometer to determine the percentage of CD30-negative cancer cells targeted and eliminated by the treated non-malignant immune cells.

5.3. Perform cell viability assays (e.g., MTT, Annexin V) to assess the cytotoxicity of the treated non-malignant immune cells against CD30-negative cancer cells.

**Step 6: Comparison with Controls**

6.1. Repeat Steps 2-5 using untreated non-malignant immune cells and CD30-positive cancer cells as controls.

6.2. Compare the results from the treated and control groups to determine if CD30-positive extracellular vesicles fail to enhance the ability of non-malignant immune cells to target and eliminate CD30-negative cancer cells.

Note: All experiments should be performed in triplicate, and the results should be analyzed using standard statistical methods (e.g., t-test, ANOVA) to determine significance.","```
   CD30_Positive_Cells  Non_Malignant_Immune_Cells  CD30_Positive_Extracellular_Vesicles  Incubation_Time  CD30_Blocking_Antibody  Outcome
0                  10000                       5000                             5000             1.0                  0.0    0.25
1                  15000                       7500                             7500             2.0                  0.0    0.30
2                  20000                      10000                            10000             4.0                  0.0    0.40
3                  25000                      12500                            12500             1.0                  0.0    0.35
4                  30000                      15000                            15000             2.0                  0.0    0.45
5                  35000                      17500                            17500             4.0                  0.0    0.50
6                  40000                      20000                            20000             1.0                  0.0    0.40
7                  45000                      22500                            22500             2.0                  0.0    0.55
8                  50000                      25000                            25000             4.0                  0.0    0.60
9                  10000                       5000                             5000             1.0                 10.0    0.20
10                 15000                       7500                             7500             2.0                 10.0    0.25
11                 20000                      10000                            10000             4.0                 10.0    0.30
12                 25000                      12500                            12500             1.0                 10.0    0.35
13                 30000                      15000                            15000             2.0                 10.0    0.40
14                 35000                      17500                            17500             4.0                 10.0    0.45
15                 40000                      20000                            20000             1.0                 10.0    0.40
16                 45000                      22500                            22500             2.0                 10.0    0.50
17                 50000                      25000                            25000             4.0                 10.0    0.55
18                 10000                       5000                             5000             1.0                  5.0    0.28
19                 15000                       7500                             7500             2.0                  5.0    0.33
20                 20000                      10000                            10000             4.0                  5.0    0.38
21                 25000                      12500                            12500             1.0                  5.0    0.42
22                 30000                      15000                            15000             2.0                  5.0    0.47
23                 35000                      17500                            17500             4.0                  5.0    0.52
24                 40000                      20000                            20000             1.0                  5.0    0.48
```",0.5956832218104068
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3135b7a687316c3f2deb6b644f93939702a15632.summary'],"Can CD38-targeted imaging agents be used to predict the optimal timing of daratumumab therapy in multiple myeloma patients, thereby maximizing treatment efficacy and minimizing off-target toxicities?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** ""CD38-Targeted Imaging for Optimizing Daratumumab Therapy in Multiple Myeloma Patients""

**Objective:** To investigate whether CD38-targeted imaging agents can predict the optimal timing of daratumumab therapy in multiple myeloma patients, maximizing treatment efficacy and minimizing off-target toxicities.

**Experimental Design:**

1. **Patient Enrollment:** Recruit 100 multiple myeloma patients with varying levels of CD38 expression, as determined by immunohistochemistry analysis of tumor biopsies.
2. **CD38-Targeted Imaging:** Perform [89Zr]Zr-DFO-daratumumab PET/CT imaging on all patients at baseline, 1 week, and 4 weeks after daratumumab treatment initiation.
3. **Daratumumab Treatment:** Administer daratumumab therapy to all patients according to standard treatment protocols.
4. **Response Evaluation:** Assess treatment response using International Myeloma Working Group (IMWG) criteria at 4 weeks, 8 weeks, and 12 weeks after treatment initiation.
5. **Correlation Analysis:** Correlate CD38 expression levels with PET/CT imaging results, treatment response, and toxicity profiles.
6. **Optimal Timing Identification:** Identify the optimal timing of daratumumab therapy based on CD38-targeted imaging results, which maximizes treatment efficacy and minimizes off-target toxicities.

**Experiment to Disprove the Hypothesis:**

**Title:** ""Investigating the Lack of Correlation between CD38-Targeted Imaging and Daratumumab Response in Multiple Myeloma Patients""

**Objective:** To demonstrate that CD38-targeted imaging agents do not predict the optimal timing of daratumumab therapy in multiple myeloma patients, and that treatment outcomes are not improved by using CD38-targeted imaging.

**Experimental Design:**

1. **Patient Enrollment:** Recruit 100 multiple myeloma patients with varying levels of CD38 expression, as determined by immunohistochemistry analysis of tumor biopsies.
2. **Randomization:** Randomly assign patients to one of two groups:
	* **Group A:** Receive daratumumab therapy based on standard treatment protocols, without CD38-targeted imaging guidance.
	* **Group B:** Receive daratumumab therapy based on CD38-targeted imaging results, with treatment initiation timed according to the optimal timing identified in the experimental plan above.
3. **Treatment Response Evaluation:** Assess treatment response using IMWG criteria at 4 weeks, 8 weeks, and 12 weeks after treatment initiation in both groups.
4. **Comparison Analysis:** Compare treatment response rates, progression-free survival, and overall survival between Group A and Group B.
5. **Toxicity Profiling:** Monitor and compare toxicity profiles between the two groups.

**Null Hypothesis:** There is no significant difference in treatment response rates, progression-free survival, and overall survival between Group A and Group B, indicating that CD38-targeted imaging does not predict the optimal timing of daratumumab therapy.

**Expected Outcome:** If the null hypothesis is not rejected, it would suggest that CD38-targeted imaging agents do not predict the optimal timing of daratumumab therapy, and that treatment outcomes are not improved by using CD38-targeted imaging. This would disprove the original hypothesis.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment 1: CD38-Targeted Imaging for Optimizing Daratumumab Therapy in Multiple Myeloma Patients**

**Protocol:**

**Step 1: Patient Enrollment**

1.1. Identify and recruit 100 multiple myeloma patients with varying levels of CD38 expression, as determined by immunohistochemistry analysis of tumor biopsies.

1.2. Obtain informed consent from each patient and ensure they meet the inclusion and exclusion criteria.

1.3. Collect demographic and clinical data, including age, sex, disease stage, and previous treatments.

**Step 2: CD38-Targeted Imaging**

2.1. Prepare [89Zr]Zr-DFO-daratumumab PET/CT imaging agent according to the manufacturer's instructions.

2.2. Administer [89Zr]Zr-DFO-daratumumab to each patient via intravenous injection at a dose of [insert dose].

2.3. Perform PET/CT imaging on each patient at baseline, 1 week, and 4 weeks after daratumumab treatment initiation.

2.4. Acquire PET/CT images using a [insert PET/CT scanner model] scanner with the following settings: [insert settings].

2.5. Analyze PET/CT images using [insert software] to quantify CD38 expression levels.

**Step 3: Daratumumab Treatment**

3.1. Administer daratumumab therapy to each patient according to standard treatment protocols.

3.2. Monitor patients for adverse events and adjust treatment as necessary.

**Step 4: Response Evaluation**

4.1. Assess treatment response using International Myeloma Working Group (IMWG) criteria at 4 weeks, 8 weeks, and 12 weeks after treatment initiation.

4.2. Collect blood samples and perform laboratory tests to evaluate treatment response.

**Step 5: Correlation Analysis**

5.1. Correlate CD38 expression levels with PET/CT imaging results, treatment response, and toxicity profiles using statistical software (e.g., R, Python).

5.2. Perform linear regression analysis to identify the relationship between CD38 expression levels and treatment response.

**Step 6: Optimal Timing Identification**

6.1. Identify the optimal timing of daratumumab therapy based on CD38-targeted imaging results, which maximizes treatment efficacy and minimizes off-target toxicities.

6.2. Use the correlation analysis results to determine the optimal timing of daratumumab therapy.

**Experiment 2: Investigating the Lack of Correlation between CD38-Targeted Imaging and Daratumumab Response in Multiple Myeloma Patients**

**Protocol:**

**Step 1: Patient Enrollment**

1.1. Identify and recruit 100 multiple myeloma patients with varying levels of CD38 expression, as determined by immunohistochemistry analysis of tumor biopsies.

1.2. Obtain informed consent from each patient and ensure they meet the inclusion and exclusion criteria.

1.3. Collect demographic and clinical data, including age, sex, disease stage, and previous treatments.

**Step 2: Randomization**

2.1. Randomly assign patients to one of two groups using a randomization software (e.g., Random.org):

* Group A: Receive daratumumab therapy based on standard treatment protocols, without CD38-targeted imaging guidance.
* Group B: Receive daratumumab therapy based on CD38-targeted imaging results, with treatment initiation timed according to the optimal timing identified in Experiment 1.

**Step 3: Treatment Response Evaluation**

3.1. Assess treatment response using IMWG criteria at 4 weeks, 8 weeks, and 12 weeks after treatment initiation in both groups.

3.2. Collect blood samples and perform laboratory tests to evaluate treatment response.

**Step 4: Comparison Analysis**

4.1. Compare treatment response rates, progression-free survival, and overall survival between Group A and Group B using statistical software (e.g., R, Python).

4.2. Perform Kaplan-Meier analysis to compare survival curves between the two groups.

**Step 5: Toxicity Profiling**

5.1. Monitor and compare toxicity profiles between the two groups using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version [insert version].

5.2. Record and analyze adverse events, including grade and severity.

**Null Hypothesis Testing**

6.1. Compare the treatment response rates, progression-free survival, and overall survival between Group A and Group B using a two-sample t-test or Wilcoxon rank-sum test.

6.2. Calculate the p-value and determine whether the null hypothesis is rejected or not rejected.

Note: These protocols are detailed and specific, but may require adjustments based on the specific research setting, equipment, and software used. It is essential to ensure that the protocols are followed precisely to maintain replicability and validity.","```
   Patient_ID  Daratumumab_Dose  CD38_Expression  PET_CT_Scanner  Imaging_Software  Treatment_Response  Toxicity_Profile
0           1             1000          0.75         Philips         Amide     Partial_Response            Grade_2
1           2             1200          0.40         GE_Healthcare     MIM         Progressive_Disease            Grade_3
2           3             800           0.90         Siemens         Hermes         Complete_Response            Grade_1
3           4             1400          0.60         Philips         Amide     Very_Good_Partial_Response            Grade_2
4           5             1600          0.30         GE_Healthcare     MIM         Progressive_Disease            Grade_4
5           6             1800          0.85         Siemens         Hermes         Complete_Response            Grade_1
6           7             1000          0.50         Philips         Amide     Partial_Response            Grade_2
7           8             1200          0.70         GE_Healthcare     MIM         Very_Good_Partial_Response            Grade_2
8           9             800           0.95         Siemens         Hermes         Complete_Response            Grade_1
9          10             1400          0.45         Philips         Amide     Progressive_Disease            Grade_3
10         11             1600          0.80         GE_Healthcare     MIM         Very_Good_Partial_Response            Grade_2
11         12             1800          0.55         Siemens         Hermes         Partial_Response            Grade_2
12         13             1000          0.65         Philips         Amide     Very_Good_Partial_Response            Grade_2
13         14             1200          0.35         GE_Healthcare     MIM         Progressive_Disease            Grade_4
14         15             800           0.90         Siemens         Hermes         Complete_Response            Grade_1
15         16             1400          0.50         Philips         Amide     Partial_Response            Grade_2
16         17             1600          0.75         GE_Healthcare     MIM         Very_Good_Partial_Response            Grade_2
17         18             1800          0.40         Siemens         Hermes         Progressive_Disease            Grade_3
18         19             1000          0.85         Philips         Amide     Complete_Response            Grade_1
19         20             1200          0.60         GE_Healthcare     MIM         Very_Good_Partial_Response            Grade_2
20         21             800           0.95         Siemens         Hermes         Complete_Response            Grade_1
21         22             1400          0.45         Philips         Amide     Progressive_Disease            Grade_3
22         23             1600          0.80         GE_Healthcare     MIM         Very_Good_Partial_Response            Grade_2
23         24             1800          0.55         Siemens         Hermes         Partial_Response            Grade_2
24         25             1000          0.65         Philips         Amide     Very_Good_Partial_Response            Grade_2
```",0.046094096572167724
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f62133cd8c35e7c6a917695d764a14f34f4b2865.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/02a8e1f4d4dbd55c5f773a1c7ff71033ab91f654.summary']","Can CD4+ T cells that recognize B cell receptors in multiple sclerosis patients also regulate the expression of PD-L1 on macrophages, thereby modulating the efficacy of CAR-T cell therapy in B cell malignancies?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the context from the two papers, I've designed an experiment to test the hypothesis and potentially disprove it. Here's a high-level experimental approach:

**Experiment Title:** Investigating the Role of CD4+ T Cells in Regulating PD-L1 Expression on Macrophages in the Context of CAR-T Cell Therapy in B Cell Malignancies

**Objective:** To determine whether CD4+ T cells that recognize B cell receptors in multiple sclerosis patients can regulate the expression of PD-L1 on macrophages, thereby modulating the efficacy of CAR-T cell therapy in B cell malignancies.

**Experimental Design:**

1. **Cell Isolation and Preparation:**
	* Isolate CD4+ T cells from the blood of multiple sclerosis patients using magnetic bead separation.
	* Isolate macrophages from healthy donors or a cell line (e.g., THP-1).
	* Generate CAR-T cells specific to B cell malignancies (e.g., CD19-targeting CAR-T cells).
2. **Co-Culture Experiments:**
	* Co-culture CD4+ T cells with macrophages in the presence or absence of synthesized B cell receptor idiotopes predicted to be stimulatory (using in silico models).
	* Co-culture CAR-T cells with macrophages in the presence or absence of CD4+ T cells and B cell receptor idiotopes.
3. **PD-L1 Expression Analysis:**
	* Measure PD-L1 expression on macrophages using flow cytometry in each co-culture condition.
	* Compare PD-L1 expression levels between conditions with and without CD4+ T cells and B cell receptor idiotopes.
4. **CAR-T Cell Functionality Assay:**
	* Assess the cytotoxicity of CAR-T cells against B cell malignancy cells (e.g., Raji cells) in the presence or absence of CD4+ T cells and macrophages.
	* Compare the cytotoxicity of CAR-T cells between conditions with and without CD4+ T cells and macrophages.
5. **Control Experiments:**
	* Include control conditions with CD4+ T cells from healthy donors to determine if the observed effects are specific to MS patients.
	* Include control conditions without B cell receptor idiotopes to determine if the observed effects are specific to the recognition of B cell receptors.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ Increased PD-L1 expression on macrophages in the presence of CD4+ T cells and B cell receptor idiotopes.
	+ Decreased CAR-T cell cytotoxicity against B cell malignancy cells in the presence of CD4+ T cells and macrophages.
* If the hypothesis is false, we expect to see:
	+ No significant difference in PD-L1 expression on macrophages between conditions with and without CD4+ T cells and B cell receptor idiotopes.
	+ No significant difference in CAR-T cell cytotoxicity against B cell malignancy cells between conditions with and without CD4+ T cells and macrophages.

**Limitations and Considerations:**

* The experiment assumes that the CD4+ T cells from MS patients will recognize the synthesized B cell receptor idiotopes, which may not be the case.
* The experiment does not account for potential differences in the tumor microenvironment, which may affect the results.
* The experiment is limited by the availability of resources, including CD4+ T cells from MS patients, macrophages, and CAR-T cells.

**Timeline and Budget:**

* The experiment can be completed within 6-9 months, depending on the availability of resources and personnel.
* The budget will depend on the cost of reagents, equipment, and personnel, but a rough estimate would be around $50,000-$75,000.

By designing an experiment to disprove the hypothesis, we can gain a better understanding of the relationship between CD4+ T cells, macrophages, and CAR-T cell therapy in B cell malignancies, and potentially identify new therapeutic targets for improving CAR-T cell therapy efficacy.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Preparation**

1.1. **CD4+ T Cell Isolation from Multiple Sclerosis Patients**

* Collect 10-20 mL of whole blood from multiple sclerosis patients in EDTA-coated tubes.
* Perform density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) to separate peripheral blood mononuclear cells (PBMCs).
* Wash PBMCs with PBS and resuspend in 1 mL of PBS.
* Add 10 μL of CD4+ T cell isolation beads (Miltenyi Biotec) to the PBMC suspension and mix well.
* Incubate for 15 minutes at 4°C.
* Perform magnetic separation using a MACS separator (Miltenyi Biotec) according to the manufacturer's instructions.
* Collect the CD4+ T cell fraction and wash with PBS.

1.2. **Macrophage Isolation from Healthy Donors or Cell Line**

* Collect 10-20 mL of whole blood from healthy donors in EDTA-coated tubes or use THP-1 cells (ATCC).
* Perform density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) to separate PBMCs.
* Wash PBMCs with PBS and resuspend in 1 mL of PBS.
* Add 10 μL of CD14+ monocyte isolation beads (Miltenyi Biotec) to the PBMC suspension and mix well.
* Incubate for 15 minutes at 4°C.
* Perform magnetic separation using a MACS separator (Miltenyi Biotec) according to the manufacturer's instructions.
* Collect the CD14+ monocyte fraction and differentiate into macrophages using M-CSF (50 ng/mL) and GM-CSF (20 ng/mL) for 7-10 days.

1.3. **CAR-T Cell Generation**

* Isolate T cells from healthy donors using a T cell isolation kit (Miltenyi Biotec).
* Transduce T cells with a CD19-targeting CAR construct using a lentiviral vector.
* Expand CAR-T cells using IL-2 (100 IU/mL) and anti-CD3/CD28 beads (Invitrogen) for 7-10 days.

**Protocol 2: Co-Culture Experiments**

2.1. **Co-Culture of CD4+ T Cells with Macrophages**

* Seed 1 x 10^5 macrophages per well in a 96-well plate.
* Add 1 x 10^5 CD4+ T cells per well in the presence or absence of 1 μg/mL synthesized B cell receptor idiotopes.
* Incubate for 24-48 hours at 37°C, 5% CO2.

2.2. **Co-Culture of CAR-T Cells with Macrophages**

* Seed 1 x 10^5 macrophages per well in a 96-well plate.
* Add 1 x 10^5 CAR-T cells per well in the presence or absence of 1 x 10^5 CD4+ T cells and 1 μg/mL synthesized B cell receptor idiotopes.
* Incubate for 24-48 hours at 37°C, 5% CO2.

**Protocol 3: PD-L1 Expression Analysis**

3.1. **Flow Cytometry**

* Harvest macrophages from co-culture experiments and stain with anti-PD-L1-PE (BioLegend) and anti-CD14-FITC (BioLegend) antibodies.
* Analyze PD-L1 expression using a flow cytometer (BD FACSCanto II) and FlowJo software.

**Protocol 4: CAR-T Cell Functionality Assay**

4.1. **Cytotoxicity Assay**

* Seed 1 x 10^4 Raji cells per well in a 96-well plate.
* Add 1 x 10^5 CAR-T cells per well in the presence or absence of 1 x 10^5 CD4+ T cells and 1 x 10^5 macrophages.
* Incubate for 4-6 hours at 37°C, 5% CO2.
* Measure cytotoxicity using a lactate dehydrogenase (LDH) release assay (Promega).

**Protocol 5: Control Experiments**

5.1. **Control CD4+ T Cells from Healthy Donors**

* Isolate CD4+ T cells from healthy donors using the same protocol as above.
* Perform co-culture experiments with macrophages and CAR-T cells as described above.

5.2. **Control without B Cell Receptor Idiotopes**

* Perform co-culture experiments without adding synthesized B cell receptor idiotopes.

**Quality Control and Assurance**

* Verify the purity of isolated cells using flow cytometry.
* Check the viability of cells using trypan blue exclusion.
* Validate the functionality of CAR-T cells using a cytotoxicity assay.
* Include positive and negative controls for PD-L1 expression analysis and cytotoxicity assays.

**Timeline and Budget**

* The experiment can be completed within 6-9 months, depending on the availability of resources and personnel.
* The budget will depend on the cost of reagents, equipment, and personnel, but a rough estimate would be around $50,000-$75,000.

Note: The protocols above are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   CD4+ T Cells  Macrophages  CAR-T Cells  B Cell Receptor Idiotopes  PD-L1 Expression  Cytotoxicity
0           1.0         1.0         1.0                    0.0          20.5          35.1
1           1.5         1.0         1.0                    1.0          28.2          40.8
2           1.0         1.5         1.0                    0.0          18.9          32.5
3           1.0         1.0         1.5                    1.0          25.1          38.2
4           0.5         1.0         1.0                    0.0          15.3          28.9
5           1.0         1.0         1.0                    0.5          22.1          34.6
6           1.0         1.0         1.0                    1.5          30.5          42.9
7           1.2         1.0         1.0                    0.0          21.8          36.3
8           1.0         1.2         1.0                    1.0          26.5          39.5
9           1.0         1.0         1.2                    0.0          19.2          31.8
10          0.8         1.0         1.0                    0.0          16.5          29.2
11          1.0         1.0         1.0                    0.8          24.3          37.1
12          1.0         1.0         1.0                    1.2          27.9          40.2
13          1.1         1.0         1.0                    0.0          20.9          33.5
14          1.0         1.1         1.0                    1.0          24.9          38.5
15          1.0         1.0         1.1                    0.0          18.1          30.9
16          0.9         1.0         1.0                    0.0          17.2          28.5
17          1.0         1.0         1.0                    0.9          23.5          36.9
18          1.0         1.0         1.0                    1.1          26.2          39.1
19          1.0         0.9         1.0                    1.0          22.8          35.6
20          1.0         1.0         0.9                    0.0          19.5          32.1
21          0.7         1.0         1.0                    0.0          14.9          26.8
22          1.0         1.0         1.0                    0.7          21.2          34.3
23          1.0         1.0         1.0                    1.3          29.8          42.5
24          1.0         0.8         1.0                    1.0          23.1          36.5
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/19f54a195b0e8b35a83ff031a0ab76a1bf61d62e.summary'],"Can CRSTAL be used to detect and quantify the cytotoxic activity of natural killer cells in response to cancer cells, and does this activity correlate with the expression of specific inhibitory receptors on the surface of natural killer cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Use of CRSTAL to Detect and Quantify Natural Killer Cell Cytotoxic Activity in Response to Cancer Cells

**Objective:** To determine if CRSTAL can be used to detect and quantify the cytotoxic activity of natural killer (NK) cells in response to cancer cells and correlate this activity with the expression of specific inhibitory receptors on the surface of NK cells.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate and culture human NK cells from healthy donors.
	* Obtain cancer cell lines (e.g., K562 or MCF-7) and culture them separately.
	* Transfect NK cells with CRSTAL plasmid using a suitable transfection reagent.
2. **Co-Culture and Stimulation:**
	* Co-culture CRSTAL-expressing NK cells with cancer cells at a 1:1 ratio.
	* Stimulate the co-culture with IL-2 and IL-12 to activate NK cells.
3. **CRSTAL Activation and Fluorescence Measurement:**
	* Monitor CRSTAL fluorescence in real-time using a fluorescence microscope (e.g., Zeiss Axiovert 200M) at 37°C and 5% CO2.
	* Measure fluorescence intensity at regular intervals (e.g., every 30 minutes) for 4-6 hours.
4. **Cytotoxicity Assays:**
	* Perform a chromium release assay or a flow cytometry-based cytotoxicity assay to measure NK cell-mediated cytotoxicity against cancer cells.
5. **Inhibitory Receptor Analysis:**
	* Analyze the expression of specific inhibitory receptors (e.g., KIR2DL1, KIR2DL2, and NKG2A) on the surface of NK cells using flow cytometry.
6. **Data Analysis:**
	* Correlate CRSTAL fluorescence intensity with cytotoxicity assay results to determine if CRSTAL can detect and quantify NK cell cytotoxic activity.
	* Analyze the relationship between CRSTAL fluorescence and inhibitory receptor expression on NK cells.

**Equipment and Reagents:**

* Fluorescence microscope (e.g., Zeiss Axiovert 200M)
* CRSTAL plasmid
* NK cells and cancer cell lines
* Transfection reagent
* IL-2 and IL-12
* Chromium release assay or flow cytometry-based cytotoxicity assay reagents
* Flow cytometry equipment and reagents for inhibitory receptor analysis

**Timeline:** 6-8 weeks

**Budget:** Moderate (dependent on the cost of reagents, equipment, and personnel)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Specificity of CRSTAL Activation in Response to Granzyme B

**Objective:** To determine if CRSTAL activation is specific to Granzyme B (GZMB) activity and not influenced by other factors that may affect NK cell cytotoxicity.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate and culture human NK cells from healthy donors.
	* Transfect NK cells with CRSTAL plasmid using a suitable transfection reagent.
2. **Co-Culture and Stimulation:**
	* Co-culture CRSTAL-expressing NK cells with cancer cells at a 1:1 ratio.
	* Stimulate the co-culture with IL-2 and IL-12 to activate NK cells.
3. **GZMB Inhibition:**
	* Add a GZMB inhibitor (e.g., Z-AAD-CMK) to the co-culture to block GZMB activity.
4. **CRSTAL Activation and Fluorescence Measurement:**
	* Monitor CRSTAL fluorescence in real-time using a fluorescence microscope at 37°C and 5% CO2.
	* Measure fluorescence intensity at regular intervals (e.g., every 30 minutes) for 4-6 hours.
5. **Data Analysis:**
	* Compare CRSTAL fluorescence intensity in the presence and absence of GZMB inhibitor.
	* If CRSTAL fluorescence is not significantly reduced in the presence of GZMB inhibitor, it may indicate that CRSTAL activation is not specific to GZMB activity, disproving the hypothesis.

**Equipment and Reagents:**

* Fluorescence microscope (e.g., Zeiss Axiovert 200M)
* CRSTAL plasmid
* NK cells and cancer cell lines
* Transfection reagent
* IL-2 and IL-12
* GZMB inhibitor (e.g., Z-AAD-CMK)

**Timeline:** 4-6 weeks

**Budget:** Moderate (dependent on the cost of reagents, equipment, and personnel)

By performing these experiments, we can test the hypothesis and attempt to disprove it, providing a more comprehensive understanding of CRSTAL's capabilities and limitations in detecting and quantifying NK cell cytotoxic activity.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Cell Preparation**

1.1. Isolate human NK cells from healthy donors using a suitable isolation method (e.g., density gradient centrifugation, magnetic bead separation).

1.2. Culture isolated NK cells in a suitable medium (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

1.3. Obtain cancer cell lines (e.g., K562 or MCF-7) and culture them separately in a suitable medium (e.g., DMEM, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

1.4. Transfect NK cells with CRSTAL plasmid using a suitable transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

**Protocol 2: Co-Culture and Stimulation**

2.1. Co-culture CRSTAL-expressing NK cells with cancer cells at a 1:1 ratio in a suitable medium (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

2.2. Stimulate the co-culture with IL-2 (e.g., 100 U/mL) and IL-12 (e.g., 10 ng/mL) to activate NK cells.

**Protocol 3: CRSTAL Activation and Fluorescence Measurement**

3.1. Prepare a fluorescence microscope (e.g., Zeiss Axiovert 200M) with a suitable filter set for CRSTAL fluorescence detection.

3.2. Place the co-culture in a suitable chamber (e.g., 8-well chamber slide) and maintain at 37°C, 5% CO2.

3.3. Monitor CRSTAL fluorescence in real-time using the fluorescence microscope.

3.4. Measure fluorescence intensity at regular intervals (e.g., every 30 minutes) for 4-6 hours using image analysis software (e.g., ImageJ).

**Protocol 4: Cytotoxicity Assays**

4.1. Perform a chromium release assay or a flow cytometry-based cytotoxicity assay to measure NK cell-mediated cytotoxicity against cancer cells according to established protocols.

**Protocol 5: Inhibitory Receptor Analysis**

5.1. Analyze the expression of specific inhibitory receptors (e.g., KIR2DL1, KIR2DL2, and NKG2A) on the surface of NK cells using flow cytometry according to established protocols.

**Protocol 6: Data Analysis**

6.1. Correlate CRSTAL fluorescence intensity with cytotoxicity assay results to determine if CRSTAL can detect and quantify NK cell cytotoxic activity.

6.2. Analyze the relationship between CRSTAL fluorescence and inhibitory receptor expression on NK cells using statistical software (e.g., GraphPad Prism).

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Preparation**

1.1. Isolate human NK cells from healthy donors using a suitable isolation method (e.g., density gradient centrifugation, magnetic bead separation).

1.2. Culture isolated NK cells in a suitable medium (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

1.3. Transfect NK cells with CRSTAL plasmid using a suitable transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

**Protocol 2: Co-Culture and Stimulation**

2.1. Co-culture CRSTAL-expressing NK cells with cancer cells at a 1:1 ratio in a suitable medium (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

2.2. Stimulate the co-culture with IL-2 (e.g., 100 U/mL) and IL-12 (e.g., 10 ng/mL) to activate NK cells.

**Protocol 3: GZMB Inhibition**

3.1. Add a GZMB inhibitor (e.g., Z-AAD-CMK, 10 μM) to the co-culture to block GZMB activity.

**Protocol 4: CRSTAL Activation and Fluorescence Measurement**

4.1. Prepare a fluorescence microscope (e.g., Zeiss Axiovert 200M) with a suitable filter set for CRSTAL fluorescence detection.

4.2. Place the co-culture in a suitable chamber (e.g., 8-well chamber slide) and maintain at 37°C, 5% CO2.

4.3. Monitor CRSTAL fluorescence in real-time using the fluorescence microscope.

4.4. Measure fluorescence intensity at regular intervals (e.g., every 30 minutes) for 4-6 hours using image analysis software (e.g., ImageJ).

**Protocol 5: Data Analysis**

5.1. Compare CRSTAL fluorescence intensity in the presence and absence of GZMB inhibitor.

5.2. If CRSTAL fluorescence is not significantly reduced in the presence of GZMB inhibitor, it may indicate that CRSTAL activation is not specific to GZMB activity, disproving the hypothesis.

Note: All protocols should be performed in a sterile environment, and all reagents and equipment should be handled according to established laboratory protocols and safety guidelines.","```
   NK Cells  Cancer Cells  IL-2 (U/mL)  IL-12 (ng/mL)  CRSTAL Plasmid  GZMB Inhibitor (μM)  Fluorescence Intensity
0       10000         10000         50           5.0             1.0                 0.0             250.0
1       15000         15000         75           7.5             1.5                 0.0             375.0
2       20000         20000        100          10.0             2.0                 0.0             500.0
3       12000         12000         60           6.0             1.2                 0.0             300.0
4       18000         18000         90           9.0             1.8                 0.0             450.0
5       10000         10000         50           5.0             1.0                 5.0             150.0
6       15000         15000         75           7.5             1.5                 5.0             225.0
7       20000         20000        100          10.0             2.0                 5.0             300.0
8       12000         12000         60           6.0             1.2                 5.0             180.0
9       18000         18000         90           9.0             1.8                 5.0             270.0
10      10000         10000         50           5.0             1.0                 0.0             250.0
11      15000         15000         75           7.5             1.5                 0.0             375.0
12      20000         20000        100          10.0             2.0                 0.0             500.0
13      12000         12000         60           6.0             1.2                 0.0             300.0
14      18000         18000         90           9.0             1.8                 0.0             450.0
15      10000         10000         50           5.0             1.0                 5.0             150.0
16      15000         15000         75           7.5             1.5                 5.0             225.0
17      20000         20000        100          10.0             2.0                 5.0             300.0
18      12000         12000         60           6.0             1.2                 5.0             180.0
19      18000         18000         90           9.0             1.8                 5.0             270.0
20      10000         10000         50           5.0             1.0                 0.0             250.0
21      15000         15000         75           7.5             1.5                 0.0             375.0
22      20000         20000        100          10.0             2.0                 0.0             500.0
23      12000         12000         60           6.0             1.2                 0.0             300.0
24      18000         18000         90           9.0             1.8                 0.0             450.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ea1c1884aee06892ccf1cb75f7cef386b5bfedd7.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c74a4e4f69d1877c73cc0a126a3d6ddc2624e321.summary']",Can CXCR5+ NK cells and CAR/CXCR5-T cells synergistically enhance antiviral functionality and promote durable control of HIV infection when co-administered in a combinational immunotherapy approach?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and summaries of the papers, I've developed an experimental plan to test the hypothesis that CXCR5+ NK cells and CAR/CXCR5-T cells synergistically enhance antiviral functionality and promote durable control of HIV infection when co-administered in a combinational immunotherapy approach.

**Experimental Design:**

**Objective:** To investigate the synergistic effect of CXCR5+ NK cells and CAR/CXCR5-T cells on antiviral functionality and durable control of HIV infection.

**Experimental Approach:**

1. **Cell Preparation:**
	* Isolate NK cells from HIV-infected human peripheral blood mononuclear cells (PBMCs) using flow cytometry.
	* Expand and activate CXCR5+ NK cells in vitro using IL-12 and IL-15 cytokine combination (as described in the first paper).
	* Isolate CD8+ T cells from HIV-infected human PBMCs and transduce with CAR/CXCR5 (as described in the second paper).
2. **Co-Culture and Co-Administration:**
	* Co-culture CXCR5+ NK cells and CAR/CXCR5-T cells at a 1:1 ratio for 24 hours to assess their synergistic effect on antiviral functionality.
	* Co-administer CXCR5+ NK cells and CAR/CXCR5-T cells into HIV-infected humanized mice (or a suitable in vitro model) to evaluate their combined effect on durable control of HIV infection.
3. **Antiviral Functionality Assays:**
	* Evaluate the antiviral functionality of co-cultured CXCR5+ NK cells and CAR/CXCR5-T cells using degranulation and cytokine expression assays.
	* Assess the ability of co-administered CXCR5+ NK cells and CAR/CXCR5-T cells to reduce HIV replication in B cell follicles and plasma viral load using qPCR and Luminex assay.
4. **Control Groups:**
	* Include control groups with CXCR5+ NK cells or CAR/CXCR5-T cells alone to compare the synergistic effect of co-administration.
	* Include a control group with untreated HIV-infected humanized mice (or in vitro model) to evaluate the baseline HIV replication.

**Experimental Timeline:**

* Cell preparation and co-culture: 2 weeks
* Co-administration and antiviral functionality assays: 4 weeks
* Data analysis and interpretation: 2 weeks

**Budget and Resource Considerations:**

* The experiment requires access to a flow cytometer, cell culture facilities, cytokines (IL-12 and IL-15), antibodies (anti-CXCR5, anti-NKG2A, anti-granzyme B), and humanized mice (or a suitable in vitro model).
* The estimated budget for this experiment is approximately $50,000, which covers the cost of reagents, equipment, and personnel for 6 months.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the effect of CXCR5+ NK cells and CAR/CXCR5-T cells on HIV replication in the absence of synergistic interaction. This can be achieved by:

1. Co-administering CXCR5+ NK cells and CAR/CXCR5-T cells at a 10:1 or 1:10 ratio, respectively, to disrupt their synergistic interaction.
2. Using a CXCR5-blocking antibody to inhibit the interaction between CXCR5+ NK cells and CAR/CXCR5-T cells.
3. Co-administering CXCR5+ NK cells and CAR/CXCR5-T cells with a cytokine cocktail that inhibits their antiviral functionality.

If the results show that the co-administration of CXCR5+ NK cells and CAR/CXCR5-T cells does not enhance antiviral functionality or promote durable control of HIV infection, it would disprove the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Preparation**

**Step 1.1: Isolation of NK cells from HIV-infected human PBMCs**

1. Obtain HIV-infected human peripheral blood mononuclear cells (PBMCs) from a reputable source.
2. Prepare a single-cell suspension of PBMCs by centrifuging the sample at 300 x g for 10 minutes.
3. Resuspend the cell pellet in 1 mL of PBS and add 10 μL of FcR blocking reagent (e.g., human FcR blocking reagent, Miltenyi Biotec).
4. Incubate the mixture at room temperature for 10 minutes to block non-specific binding.
5. Add 10 μL of anti-NK cell antibody (e.g., anti-CD56, BD Biosciences) and incubate at room temperature for 30 minutes.
6. Wash the cells with PBS and resuspend in 1 mL of PBS.
7. Perform flow cytometry using a flow cytometer (e.g., BD FACSAria III) to sort and isolate NK cells based on CD56 expression.

**Step 1.2: Expansion and activation of CXCR5+ NK cells**

1. Resuspend the isolated NK cells in 1 mL of complete RPMI 1640 medium (e.g., Gibco) supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
2. Add 10 ng/mL of IL-12 and 10 ng/mL of IL-15 cytokines (e.g., PeproTech) to the medium.
3. Incubate the cells at 37°C, 5% CO2 for 7-10 days to expand and activate CXCR5+ NK cells.
4. Monitor cell growth and viability using a cell counter (e.g., Countess II, Invitrogen).

**Step 1.3: Isolation of CD8+ T cells and transduction with CAR/CXCR5**

1. Obtain HIV-infected human PBMCs from a reputable source.
2. Prepare a single-cell suspension of PBMCs by centrifuging the sample at 300 x g for 10 minutes.
3. Resuspend the cell pellet in 1 mL of PBS and add 10 μL of FcR blocking reagent (e.g., human FcR blocking reagent, Miltenyi Biotec).
4. Incubate the mixture at room temperature for 10 minutes to block non-specific binding.
5. Add 10 μL of anti-CD8 antibody (e.g., anti-CD8, BD Biosciences) and incubate at room temperature for 30 minutes.
6. Wash the cells with PBS and resuspend in 1 mL of PBS.
7. Perform flow cytometry using a flow cytometer (e.g., BD FACSAria III) to sort and isolate CD8+ T cells based on CD8 expression.
8. Transduce the isolated CD8+ T cells with CAR/CXCR5 using a lentiviral vector (e.g., pLenti-CAR/CXCR5, Addgene) according to the manufacturer's instructions.

**Protocol 2: Co-Culture and Co-Administration**

**Step 2.1: Co-culture of CXCR5+ NK cells and CAR/CXCR5-T cells**

1. Resuspend 1 x 10^6 CXCR5+ NK cells and 1 x 10^6 CAR/CXCR5-T cells in 1 mL of complete RPMI 1640 medium.
2. Mix the cells at a 1:1 ratio and incubate at 37°C, 5% CO2 for 24 hours.

**Step 2.2: Co-administration of CXCR5+ NK cells and CAR/CXCR5-T cells**

1. Prepare HIV-infected humanized mice (or a suitable in vitro model) according to the manufacturer's instructions.
2. Inject 1 x 10^6 CXCR5+ NK cells and 1 x 10^6 CAR/CXCR5-T cells into the mice (or add to the in vitro model) at a 1:1 ratio.

**Protocol 3: Antiviral Functionality Assays**

**Step 3.1: Degranulation assay**

1. Prepare a 96-well plate with 1 x 10^5 co-cultured CXCR5+ NK cells and CAR/CXCR5-T cells per well.
2. Add 10 μL of anti-CD107a antibody (e.g., BD Biosciences) to each well and incubate at 37°C, 5% CO2 for 4 hours.
3. Analyze the cells using flow cytometry to detect CD107a expression.

**Step 3.2: Cytokine expression assay**

1. Prepare a 96-well plate with 1 x 10^5 co-cultured CXCR5+ NK cells and CAR/CXCR5-T cells per well.
2. Add 10 μL of cytokine-specific antibodies (e.g., anti-IFN-γ, anti-TNF-α, BD Biosciences) to each well and incubate at 37°C, 5% CO2 for 4 hours.
3. Analyze the cells using flow cytometry to detect cytokine expression.

**Step 3.3: qPCR and Luminex assay**

1. Prepare RNA from co-administered CXCR5+ NK cells and CAR/CXCR5-T cells using a RNA extraction kit (e.g., Qiagen).
2. Perform qPCR using HIV-specific primers (e.g., HIV-1 gag, forward: 5'-ATG GAG GGA GCT AGA AGG-3', reverse: 5'-TCT TGG CTT TAT TCT TCT TCT-3') and a qPCR master mix (e.g., Applied Biosystems).
3. Analyze the samples using a qPCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).
4. Perform Luminex assay using a Luminex instrument (e.g., Luminex 200) and HIV-specific beads (e.g., Luminex HIV-1 p24 antigen beads).

**Protocol 4: Control Groups**

**Step 4.1: Control group with CXCR5+ NK cells alone**

1. Prepare 1 x 10^6 CXCR5+ NK cells and administer them to HIV-infected humanized mice (or add to the in vitro model).

**Step 4.2: Control group with CAR/CXCR5-T cells alone**

1. Prepare 1 x 10^6 CAR/CXCR5-T cells and administer them to HIV-infected humanized mice (or add to the in vitro model).

**Step 4.3: Control group with untreated HIV-infected humanized mice (or in vitro model)**

1. Prepare HIV-infected humanized mice (or in vitro model) without any treatment.

**Protocol 5: Experiment to Disprove the Hypothesis**

**Step 5.1: Co-administration of CXCR5+ NK cells and CAR/CXCR5-T cells at a 10:1 or 1:10 ratio**

1. Prepare 1 x 10^6 CXCR5+ NK cells and 1 x 10^5 CAR/CXCR5-T cells (or vice versa) and co-administer them to HIV-infected humanized mice (or add to the in vitro model).

**Step 5.2: Co-administration of CXCR5+ NK cells and CAR/CXCR5-T cells with CXCR5-blocking antibody**

1. Prepare 1 x 10^6 CXCR5+ NK cells and 1 x 10^6 CAR/CXCR5-T cells and co-administer them to HIV-infected humanized mice (or add to the in vitro model) with 10 μg/mL of CXCR5-blocking antibody (e.g., anti-CXCR5, R&D Systems).

**Step 5.3: Co-administration of CXCR5+ NK cells and CAR/CXCR5-T cells with cytokine cocktail**

1. Prepare 1 x 10^6 CXCR5+ NK cells and 1 x 10^6 CAR/CXCR5-T cells and co-administer them to HIV-infected humanized mice (or add to the in vitro model) with a cytokine cocktail (e.g., IL-10, TGF-β, and IL-4) that inhibits their antiviral functionality.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment available. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   IL-12  IL-15  FcR Blocking Reagent  Anti-NK Cell Antibody  Anti-CD8 Antibody  CAR/CXCR5  CXCR5-Blocking Antibody  Cytokine Cocktail  Outcome
0    5.0   10.0                5.0                 5.0             5.0         10.0                  0.0               0.0  Inhibited
1   10.0   15.0               10.0                10.0            10.0         15.0                  0.0               0.0  Enhanced
2    7.5    7.5                7.5                 7.5             7.5         12.5                  0.0               0.0  Enhanced
3    2.5   12.5                2.5                 2.5             2.5         10.0                  0.0               0.0  Inhibited
4   12.5    7.5               12.5                12.5            12.5         15.0                  0.0               0.0  Enhanced
5    5.0    5.0                5.0                 5.0             5.0         10.0                  5.0               0.0  Inhibited
6   15.0   10.0               15.0                15.0            15.0         20.0                  0.0               0.0  Enhanced
7    7.5   10.0                7.5                 7.5             7.5         12.5                  0.0               0.0  Enhanced
8    2.5    7.5                2.5                 2.5             2.5         10.0                  0.0               0.0  Inhibited
9   10.0   12.5               10.0                10.0            10.0         15.0                  0.0               0.0  Enhanced
10   5.0   15.0                5.0                 5.0             5.0         10.0                  0.0               0.0  Enhanced
11   7.5    5.0                7.5                 7.5             7.5         12.5                  0.0               0.0  Enhanced
12  12.5    2.5               12.5                12.5            12.5         15.0                  0.0               0.0  Enhanced
13   2.5   10.0                2.5                 2.5             2.5         10.0                  0.0               0.0  Inhibited
14   5.0    7.5                5.0                 5.0             5.0         10.0                  0.0               0.0  Enhanced
15  15.0    5.0               15.0                15.0            15.0         20.0                  0.0               0.0  Enhanced
16   7.5   12.5                7.5                 7.5             7.5         12.5                  0.0               0.0  Enhanced
17   2.5    5.0                2.5                 2.5             2.5         10.0                  0.0               0.0  Inhibited
18  10.0   15.0               10.0                10.0            10.0         15.0                  0.0               0.0  Enhanced
19   5.0   10.0                5.0                 5.0             5.0         10.0                  5.0               0.0  Inhibited
20  12.5    7.5               12.5                12.5            12.5         15.0                  0.0               0.0  Enhanced
21   7.5    2.5                7.5                 7.5             7.5         12.5                  0.0               0.0  Enhanced
22   2.5   12.5                2.5                 2.5             2.5         10.0                  0.0               0.0  Inhibited
23  15.0   10.0               15.0                15.0            15.0         20.0                  0.0               0.0  Enhanced
24  10.0    5.0               10.0                10.0            10.0         15.0                  0.0               0.0  Enhanced
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5ce25a5481de9188443bb0bb46b0ffadcbd93cd8.summary'],Can Echidna-simulated immune receptor repertoires be used to predict the efficacy of personalized neoantigen-based cancer vaccines in individual patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Can Echidna-simulated immune receptor repertoires be used to predict the efficacy of personalized neoantigen-based cancer vaccines in individual patients?

**Experimental Plan:**

**Objective:** To determine whether Echidna-simulated immune receptor repertoires can accurately predict the efficacy of personalized neoantigen-based cancer vaccines in individual patients.

**Experimental Design:**

1. **Patient Selection:** Recruit 20 patients with various types of cancer (e.g., melanoma, lung, breast, colon) who are eligible for neoantigen-based cancer vaccine therapy.
2. **Echidna Simulation:** Use Echidna software to simulate the immune receptor repertoires of each patient, generating a predicted immune response to a set of neoantigens.
3. **Neoantigen Selection:** Identify a set of neoantigens specific to each patient's tumor using whole-exome sequencing and bioinformatic tools (e.g., MuPeXI, pVAC-Seq).
4. **Vaccine Preparation:** Prepare personalized neoantigen-based cancer vaccines for each patient using the selected neoantigens.
5. **Vaccine Administration:** Administer the vaccines to each patient and collect blood samples at multiple time points (e.g., pre-vaccination, post-vaccination, and at regular intervals).
6. **Immune Response Analysis:** Analyze the immune response of each patient using techniques such as:
	* ELISpot or ICS assays to measure T cell responses (e.g., IFN-γ, TNF-α, IL-2).
	* Flow cytometry to assess T cell phenotypes and activation markers (e.g., CD4, CD8, PD-1, CTLA-4).
	* Cytokine profiling to evaluate the production of pro-inflammatory cytokines (e.g., IL-12, IL-15).
7. **Echidna Simulation vs. Actual Immune Response:** Compare the predicted immune response from the Echidna simulation with the actual immune response measured in each patient.
8. **Statistical Analysis:** Perform statistical analysis to determine the correlation between the Echidna-simulated immune response and the actual immune response. Calculate metrics such as sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC) to evaluate the predictive power of the Echidna simulation.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that intentionally introduces variability and noise into the Echidna simulation and neoantigen selection process. This will help to determine if the Echidna simulation is robust enough to withstand these perturbations and still accurately predict the immune response.

**Variability Introduction:**

1. **Neoantigen Selection:** Intentionally select a subset of neoantigens that are less likely to be immunogenic or have lower binding affinity to MHC molecules.
2. **Echidna Simulation:** Introduce random errors or noise into the Echidna simulation, such as:
	* Randomly perturbing the binding affinity of T cell receptors to neoantigens.
	* Introducing errors in the simulation of T cell receptor repertoire diversity.
3. **Vaccine Preparation:** Prepare vaccines using the perturbed neoantigens and administer them to a subset of patients.

**Analysis:**

1. Compare the immune response of patients who received the perturbed vaccines with those who received the original vaccines.
2. Evaluate the correlation between the Echidna-simulated immune response and the actual immune response in both groups.
3. If the Echidna simulation is unable to accurately predict the immune response in the perturbed group, it would suggest that the hypothesis is false, and the Echidna simulation is not robust enough to predict the efficacy of personalized neoantigen-based cancer vaccines.

**Timeline and Budget:**

This experiment can be completed within 12-18 months, with a budget of approximately $500,000 to $750,000. This estimate includes:

* Patient recruitment and sample collection: 3 months, $50,000
* Echidna simulation and neoantigen selection: 2 months, $30,000
* Vaccine preparation and administration: 4 months, $100,000
* Immune response analysis: 6 months, $150,000
* Statistical analysis and data interpretation: 3 months, $20,000
* Contingency fund: $50,000

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the institution's infrastructure.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Selection**

1.1. Identify potential patients with various types of cancer (e.g., melanoma, lung, breast, colon) who are eligible for neoantigen-based cancer vaccine therapy through collaboration with oncologists and review of medical records.

1.2. Obtain informed consent from each patient, ensuring they understand the purpose and risks of the study.

1.3. Collect demographic and clinical data, including age, sex, cancer type, and treatment history.

1.4. Perform a thorough medical evaluation, including blood tests and imaging studies, to confirm patient eligibility.

1.5. Enroll 20 patients who meet the inclusion criteria and provide written informed consent.

**Protocol 2: Echidna Simulation**

2.1. Extract genomic DNA from each patient's peripheral blood mononuclear cells (PBMCs) using a DNA extraction kit (e.g., Qiagen).

2.2. Perform whole-exome sequencing (WES) on the extracted DNA using a sequencing platform (e.g., Illumina).

2.3. Use bioinformatic tools (e.g., MuPeXI, pVAC-Seq) to identify a set of neoantigens specific to each patient's tumor.

2.4. Input the neoantigen data into the Echidna software to simulate the immune receptor repertoires of each patient.

2.5. Run the Echidna simulation to generate a predicted immune response to the set of neoantigens for each patient.

**Protocol 3: Neoantigen Selection**

3.1. Use the bioinformatic tools to prioritize the identified neoantigens based on their predicted immunogenicity and binding affinity to MHC molecules.

3.2. Select a set of 10-20 neoantigens per patient for vaccine preparation, ensuring a balanced representation of CD4 and CD8 T cell epitopes.

**Protocol 4: Vaccine Preparation**

4.1. Synthesize the selected neoantigens using a peptide synthesizer (e.g., GenScript).

4.2. Prepare the personalized neoantigen-based cancer vaccines for each patient using a vaccine platform (e.g., mRNA, peptide-based).

4.3. Quality control the vaccines by verifying the peptide sequences and purity using techniques such as HPLC and mass spectrometry.

**Protocol 5: Vaccine Administration**

5.1. Administer the personalized vaccines to each patient according to a predetermined schedule (e.g., 3 doses, 2 weeks apart).

5.2. Collect blood samples from each patient at multiple time points:
	* Pre-vaccination (baseline)
	* Post-vaccination (1-2 weeks after each dose)
	* At regular intervals (e.g., every 4 weeks) for up to 6 months

**Protocol 6: Immune Response Analysis**

6.1. ELISpot or ICS Assays:
	* Isolate PBMCs from each blood sample using Ficoll-Paque density gradient centrifugation.
	* Stimulate the PBMCs with the corresponding neoantigens and measure T cell responses (e.g., IFN-γ, TNF-α, IL-2) using an ELISpot or ICS assay kit (e.g., Mabtech).

6.2. Flow Cytometry:
	* Stain the PBMCs with fluorescently labeled antibodies against T cell markers (e.g., CD4, CD8, PD-1, CTLA-4) and analyze using a flow cytometer (e.g., BD FACSCanto).

6.3. Cytokine Profiling:
	* Measure the production of pro-inflammatory cytokines (e.g., IL-12, IL-15) in the supernatants of stimulated PBMCs using a cytokine bead array kit (e.g., BD Biosciences).

**Protocol 7: Echidna Simulation vs. Actual Immune Response**

7.1. Compare the predicted immune response from the Echidna simulation with the actual immune response measured in each patient.

7.2. Calculate metrics such as sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC) to evaluate the predictive power of the Echidna simulation.

**Protocol 8: Statistical Analysis**

8.1. Perform statistical analysis using software such as R or Python to determine the correlation between the Echidna-simulated immune response and the actual immune response.

8.2. Calculate confidence intervals and p-values to determine the significance of the correlation.

**Protocol 9: Experiment to Disprove the Hypothesis**

9.1. Intentionally select a subset of neoantigens that are less likely to be immunogenic or have lower binding affinity to MHC molecules.

9.2. Introduce random errors or noise into the Echidna simulation, such as:
	* Randomly perturbing the binding affinity of T cell receptors to neoantigens.
	* Introducing errors in the simulation of T cell receptor repertoire diversity.

9.3. Prepare vaccines using the perturbed neoantigens and administer them to a subset of patients.

9.4. Compare the immune response of patients who received the perturbed vaccines with those who received the original vaccines.

9.5. Evaluate the correlation between the Echidna-simulated immune response and the actual immune response in both groups.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity in the results.","```
   Patient_ID  Age  Sex  Cancer_Type  Treatment_History  DNA_Quantity  WES_Coverage  Echidna_Simulation_Time  Num_Neoantigens  Vaccine_Dose  ELISpot_Result  Flow_Cytometry_Result  Cytokine_Profiling_Result  Actual_Immune_Response
0           1   45  Male      Melanoma             Chemo          1000          30.0               120.0               15          100          200.0               0.8               150.0               0.7
1           2   50  Female    Lung_Cancer  Surgery_Radiation          800          25.0               100.0               12           80          180.0               0.6               120.0               0.5
2           3   60  Male      Breast_Cancer             Chemo          1200          35.0               140.0               18          120          220.0               0.9               180.0               0.8
3           4   40  Female    Colon_Cancer  Surgery_Chemo          900          28.0               110.0               13           90          190.0               0.7               140.0               0.6
4           5   55  Male      Melanoma             Chemo          1100          32.0               130.0               16          110          210.0               0.8               160.0               0.7
5           6   50  Female    Lung_Cancer  Surgery_Radiation          700          22.0                90.0               11           70          160.0               0.5               110.0               0.4
6           7   65  Male      Breast_Cancer             Chemo          1300          38.0               150.0               20          130          230.0               0.9               190.0               0.8
7           8   45  Female    Colon_Cancer  Surgery_Chemo          1000          30.0               120.0               15          100          200.0               0.7               150.0               0.6
8           9   60  Male      Melanoma             Chemo          1200          35.0               140.0               18          120          220.0               0.8               180.0               0.7
9          10   55  Female    Lung_Cancer  Surgery_Radiation          900          28.0               110.0               13           90          190.0               0.6               140.0               0.5
10         11   50  Male      Breast_Cancer             Chemo          1100          32.0               130.0               16          110          210.0               0.8               160.0               0.7
11         12   40  Female    Colon_Cancer  Surgery_Chemo          800          25.0               100.0               12           80          180.0               0.5               120.0               0.4
12         13   65  Male      Melanoma             Chemo          1300          38.0               150.0               20          130          230.0               0.9               190.0               0.8
13         14   45  Female    Lung_Cancer  Surgery_Radiation          1000          30.0               120.0               15          100          200.0               0.7               150.0               0.6
14         15   60  Male      Breast_Cancer             Chemo          1200          35.0               140.0               18          120          220.0               0.8               180.0               0.7
15         16   55  Female    Colon_Cancer  Surgery_Chemo          900          28.0               110.0               13           90          190.0               0.6               140.0               0.5
16         17   50  Male      Melanoma             Chemo          1100          32.0               130.0               16          110          210.0               0.8               160.0               0.7
17         18   40  Female    Lung_Cancer  Surgery_Radiation          800          25.0               100.0               12           80          180.0               0.5               120.0               0.4
18         19   65  Male      Breast_Cancer             Chemo          1300          38.0               150.0               20          130          230.0               0.9               190.0               0.8
19         20   45  Female    Colon_Cancer  Surgery_Chemo          1000          30.0               120.0               15          100          200.0               0.7               150.0               0.6
20         21   60  Male      Melanoma             Chemo          1200          35.0               140.0               18          120          220.0               0.8               180.0               0.7
21         22   55  Female    Lung_Cancer  Surgery_Radiation          900          28.0               110.0               13           90          190.0               0.6               140.0               0.5
22         23   50  Male      Breast_Cancer             Chemo          1100          32.0               130.0               16          110          210.0               0.8               160.0               0.7
23         24   40  Female    Colon_Cancer  Surgery_Chemo          800          25.0               100.0               12           80          180.0               0.5               120.0               0.4
24         25   65  Male      Melanoma             Chemo          1300          38.0               150.0               20          130          230.0               0.9               190.0               0.8
```",0.48713891058290704
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2bc4c23bb29ae04b087387ef0c6bff392d6ce07c.summary'],Can OMI-based autofluorescence lifetime imaging of metabolic cofactors NAD(P)H and FAD be used to predict the efficacy of adoptive cell therapy in cancer patients by identifying optimal lymphocyte subtypes and activation states for personalized treatment?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** ""Predicting Efficacy of Adoptive Cell Therapy in Cancer Patients using OMI-based Autofluorescence Lifetime Imaging of Metabolic Cofactors NAD(P)H and FAD""

**Objective:** To investigate whether OMI-based autofluorescence lifetime imaging of metabolic cofactors NAD(P)H and FAD can predict the efficacy of adoptive cell therapy in cancer patients by identifying optimal lymphocyte subtypes and activation states for personalized treatment.

**Experimental Design:**

1. **Patient Recruitment:** Recruit 50 cancer patients scheduled to undergo adoptive cell therapy. Collect blood samples from each patient before and after therapy.
2. **Lymphocyte Isolation and Activation:** Isolate lymphocytes from the blood samples and activate them with specific stimuli (e.g., IL-4, IL-12, IL-15, IL-18) to mimic the in vivo environment.
3. **OMI Imaging:** Perform OMI imaging of the activated lymphocytes using an OMI microscope to measure autofluorescence lifetime of NAD(P)H and FAD.
4. **Machine Learning Analysis:** Analyze the OMI data using machine learning algorithms to classify lymphocyte activation and subtype (B cells, NK cells, T cells, etc.).
5. **Correlation with Clinical Outcomes:** Correlate the OMI-based classification results with the clinical outcomes of the adoptive cell therapy (e.g., tumor response, progression-free survival, overall survival).
6. **Validation:** Validate the results using flow cytometry and other established methods to confirm the accuracy of the OMI-based classification.

**Expected Outcomes:**

* Identification of specific lymphocyte subtypes and activation states associated with improved clinical outcomes in adoptive cell therapy.
* Development of a predictive model using OMI-based autofluorescence lifetime imaging to identify optimal lymphocyte subtypes and activation states for personalized treatment.

**Timeline:** 12 months

**Budget:** $200,000 (including personnel, equipment, and reagents)

**Experiment to Disprove the Hypothesis:**

**Title:** ""Investigating the Limitations of OMI-based Autofluorescence Lifetime Imaging in Predicting Adoptive Cell Therapy Efficacy""

**Objective:** To challenge the hypothesis by identifying potential limitations and confounding factors that may affect the accuracy of OMI-based autofluorescence lifetime imaging in predicting adoptive cell therapy efficacy.

**Experimental Design:**

1. **Lymphocyte Isolation and Activation:** Isolate lymphocytes from healthy donors and activate them with specific stimuli (e.g., IL-4, IL-12, IL-15, IL-18).
2. **OMI Imaging:** Perform OMI imaging of the activated lymphocytes using an OMI microscope to measure autofluorescence lifetime of NAD(P)H and FAD.
3. **Introduce Confounding Factors:** Intentionally introduce confounding factors that may affect OMI imaging, such as:
	* Variations in lymphocyte preparation and handling.
	* Different OMI microscope settings and operators.
	* Presence of contaminants or impurities in the lymphocyte samples.
4. **Machine Learning Analysis:** Analyze the OMI data using machine learning algorithms to classify lymphocyte activation and subtype.
5. **Evaluate the Impact of Confounding Factors:** Evaluate the impact of the introduced confounding factors on the accuracy of the OMI-based classification.

**Expected Outcomes:**

* Identification of potential limitations and confounding factors that may affect the accuracy of OMI-based autofluorescence lifetime imaging in predicting adoptive cell therapy efficacy.
* Development of strategies to mitigate the impact of these confounding factors and improve the robustness of the OMI-based classification.

**Timeline:** 6 months

**Budget:** $50,000 (including personnel, equipment, and reagents)

By conducting these experiments, we can test the hypothesis and identify potential limitations and confounding factors that may affect the accuracy of OMI-based autofluorescence lifetime imaging in predicting adoptive cell therapy efficacy.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Patient Recruitment and Blood Sample Collection**

1.1. Obtain Institutional Review Board (IRB) approval for the study.

1.2. Recruit 50 cancer patients scheduled to undergo adoptive cell therapy.

1.3. Obtain informed consent from each patient.

1.4. Collect 10 mL of blood from each patient before and after adoptive cell therapy using a sterile syringe and needle.

1.5. Label the blood samples with a unique identifier and store them at 4°C until further processing.

**Protocol 2: Lymphocyte Isolation and Activation**

2.1. Isolate peripheral blood mononuclear cells (PBMCs) from the blood samples using Ficoll-Paque density gradient centrifugation.

2.2. Wash the PBMCs with phosphate-buffered saline (PBS) and resuspend them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

2.3. Activate the PBMCs with specific stimuli (e.g., IL-4, IL-12, IL-15, IL-18) at a concentration of 10 ng/mL for 24 hours at 37°C and 5% CO2.

2.4. Wash the activated PBMCs with PBS and resuspend them in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

**Protocol 3: OMI Imaging**

3.1. Prepare the OMI microscope according to the manufacturer's instructions.

3.2. Place a 100 μL aliquot of the activated PBMCs onto a glass coverslip and allow them to settle for 10 minutes.

3.3. Add 100 μL of PBS to the coverslip and place it onto the OMI microscope stage.

3.4. Set the OMI microscope to measure the autofluorescence lifetime of NAD(P)H and FAD using the following settings:
	* Excitation wavelength: 365 nm
	* Emission wavelength: 450 nm (NAD(P)H) and 520 nm (FAD)
	* Integration time: 100 ms
	* Pixel size: 1 μm
3.5. Acquire OMI images of the PBMCs using the OMI microscope.

**Protocol 4: Machine Learning Analysis**

4.1. Preprocess the OMI images using image processing software (e.g., ImageJ) to correct for background fluorescence and normalize the intensity values.

4.2. Extract features from the preprocessed OMI images using machine learning algorithms (e.g., convolutional neural networks, support vector machines).

4.3. Train a machine learning model using the extracted features to classify lymphocyte activation and subtype (B cells, NK cells, T cells, etc.).

4.4. Validate the machine learning model using a separate dataset of OMI images from a different cohort of patients.

**Protocol 5: Correlation with Clinical Outcomes**

5.1. Collect clinical outcome data from the patients, including tumor response, progression-free survival, and overall survival.

5.2. Correlate the OMI-based classification results with the clinical outcome data using statistical software (e.g., R, Python).

5.3. Perform survival analysis to determine the association between the OMI-based classification and clinical outcomes.

**Protocol 6: Validation**

6.1. Perform flow cytometry analysis on the activated PBMCs to confirm the accuracy of the OMI-based classification.

6.2. Compare the OMI-based classification results with the flow cytometry results using statistical software (e.g., R, Python).

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Lymphocyte Isolation and Activation**

1.1. Isolate PBMCs from healthy donors using Ficoll-Paque density gradient centrifugation.

1.2. Activate the PBMCs with specific stimuli (e.g., IL-4, IL-12, IL-15, IL-18) at a concentration of 10 ng/mL for 24 hours at 37°C and 5% CO2.

**Protocol 2: OMI Imaging**

2.1. Prepare the OMI microscope according to the manufacturer's instructions.

2.2. Place a 100 μL aliquot of the activated PBMCs onto a glass coverslip and allow them to settle for 10 minutes.

2.3. Add 100 μL of PBS to the coverslip and place it onto the OMI microscope stage.

2.4. Set the OMI microscope to measure the autofluorescence lifetime of NAD(P)H and FAD using the following settings:
	* Excitation wavelength: 365 nm
	* Emission wavelength: 450 nm (NAD(P)H) and 520 nm (FAD)
	* Integration time: 100 ms
	* Pixel size: 1 μm
2.5. Acquire OMI images of the PBMCs using the OMI microscope.

**Protocol 3: Introduce Confounding Factors**

3.1. Introduce variations in lymphocyte preparation and handling, such as:
	* Different centrifugation speeds and times
	* Different temperatures and incubation times
	* Different reagents and buffers
3.2. Introduce different OMI microscope settings and operators, such as:
	* Different excitation and emission wavelengths
	* Different integration times and pixel sizes
	* Different microscope operators
3.3. Introduce contaminants or impurities into the lymphocyte samples, such as:
	* Bacterial or fungal contaminants
	* Protein or lipid contaminants
	* Chemical contaminants

**Protocol 4: Machine Learning Analysis**

4.1. Preprocess the OMI images using image processing software (e.g., ImageJ) to correct for background fluorescence and normalize the intensity values.

4.2. Extract features from the preprocessed OMI images using machine learning algorithms (e.g., convolutional neural networks, support vector machines).

4.3. Train a machine learning model using the extracted features to classify lymphocyte activation and subtype.

4.4. Evaluate the impact of the introduced confounding factors on the accuracy of the OMI-based classification using statistical software (e.g., R, Python).

**Protocol 5: Evaluate the Impact of Confounding Factors**

5.1. Compare the OMI-based classification results with and without the introduced confounding factors.

5.2. Determine the effect size and statistical significance of the confounding factors on the OMI-based classification using statistical software (e.g., R, Python).

5.3. Develop strategies to mitigate the impact of the confounding factors and improve the robustness of the OMI-based classification.","```
   IL4_ngmL  IL12_ngmL  IL15_ngmL  IL18_ngmL  FBS_percent  PBS_volume  Outcome
0        5.0        10.0        15.0        20.0         5.0       100.0  Activated
1        10.0         5.0        20.0        15.0         10.0       120.0  Inactive
2        15.0        20.0         5.0        10.0         15.0       110.0  Activated
3        20.0        15.0        10.0         5.0         20.0       130.0  Inactive
4         5.0         5.0        10.0        15.0         5.0       100.0  Activated
5        10.0        20.0        15.0        10.0         10.0       120.0  Inactive
6        15.0         5.0        20.0        15.0         15.0       110.0  Activated
7        20.0        10.0        15.0         5.0         20.0       130.0  Inactive
8         5.0        15.0        10.0        20.0         5.0       100.0  Activated
9        10.0         5.0        15.0        20.0         10.0       120.0  Inactive
10       15.0        20.0        10.0        15.0         15.0       110.0  Activated
11       20.0        15.0        20.0        10.0         20.0       130.0  Inactive
12        5.0        10.0        20.0        15.0         5.0       100.0  Activated
13       10.0        20.0        15.0        10.0         10.0       120.0  Inactive
14       15.0         5.0        10.0        20.0         15.0       110.0  Activated
15       20.0        10.0        15.0         5.0         20.0       130.0  Inactive
16        5.0        15.0        10.0        20.0         5.0       100.0  Activated
17       10.0         5.0        20.0        15.0         10.0       120.0  Inactive
18       15.0        20.0        15.0        10.0         15.0       110.0  Activated
19       20.0        15.0        20.0        10.0         20.0       130.0  Inactive
20        5.0        10.0        15.0        20.0         5.0       100.0  Activated
21       10.0        20.0        10.0        15.0         10.0       120.0  Inactive
22       15.0         5.0        20.0        15.0         15.0       110.0  Activated
23       20.0        10.0        15.0         5.0         20.0       130.0  Inactive
24       10.0        15.0        20.0        10.0         10.0       120.0  Inactive
```",0.2610474251259843
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/fc960faf0a645c58095027d60765820e64fbc8dd.summary'],"Can RNA-based IGH sequencing detect B cell clones at 10-6 frequency from peripheral blood in patients with checkpoint blockade-treated cancer, and does this detection correlate with improved treatment outcomes?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Correlation of RNA-based IGH sequencing with treatment outcomes in checkpoint blockade-treated cancer patients

**Objective:** To investigate whether RNA-based IGH sequencing can detect B cell clones at 10-6 frequency from peripheral blood in patients with checkpoint blockade-treated cancer and correlate with improved treatment outcomes.

**Methods:**

1. **Patient Recruitment:** Enroll 100 patients with various types of cancer (e.g., melanoma, lung, breast, colon) who have received checkpoint blockade therapy. Collect peripheral blood samples at baseline, during treatment, and at follow-up visits.
2. **RNA-based IGH Sequencing:** Isolate RNA from peripheral blood mononuclear cells (PBMCs) using a RNA isolation kit. Perform RNA-based IGH sequencing using the Ion OncomineTM BCR IGH-SR assay.
3. **B Cell Clone Detection:** Analyze the sequencing data using a bioinformatics pipeline to identify B cell clones at 10-6 frequency.
4. **Treatment Outcome Assessment:** Collect clinical data on treatment response, progression-free survival, and overall survival.
5. **Correlation Analysis:** Correlate the detection of B cell clones at 10-6 frequency with treatment outcomes using statistical analysis (e.g., Kaplan-Meier curves, Cox proportional hazards model).

**Equipment:**

* Ion OncomineTM BCR IGH-SR assay
* RNA isolation kit
* Bioinformatics pipeline for data analysis
* Statistical software for correlation analysis

**Experiment to Disprove the Hypothesis:**

**Title:** Investigation of RNA-based IGH sequencing limitations in detecting B cell clones at 10-6 frequency in checkpoint blockade-treated cancer patients

**Objective:** To identify potential limitations of RNA-based IGH sequencing in detecting B cell clones at 10-6 frequency from peripheral blood in patients with checkpoint blockade-treated cancer, thereby disproving the hypothesis.

**Methods:**

1. **Sample Preparation:** Prepare peripheral blood samples from patients with checkpoint blockade-treated cancer, but intentionally introduce variables that may affect RNA-based IGH sequencing performance, such as:
	* Low-quality RNA samples
	* Insufficient input material
	* Presence of inhibitors or contaminants
	* Variations in RNA isolation protocols
2. **RNA-based IGH Sequencing:** Perform RNA-based IGH sequencing using the Ion OncomineTM BCR IGH-SR assay on the prepared samples.
3. **B Cell Clone Detection:** Analyze the sequencing data using a bioinformatics pipeline to identify B cell clones at 10-6 frequency.
4. **Comparison with DNA-based Sequencing:** Compare the results with DNA-based IGH sequencing using the Ion OncomineTM BCR IGH-LR assay on the same samples.
5. **Limitation Identification:** Identify the limitations of RNA-based IGH sequencing in detecting B cell clones at 10-6 frequency, such as:
	* False negatives or false positives
	* Inability to detect clones in certain patient subgroups
	* Variability in detection across different sequencing runs

**Equipment:**

* Ion OncomineTM BCR IGH-SR assay
* Ion OncomineTM BCR IGH-LR assay
* RNA isolation kit
* Bioinformatics pipeline for data analysis
* Statistical software for comparison analysis

By conducting these experiments, we can test the hypothesis and identify potential limitations of RNA-based IGH sequencing in detecting B cell clones at 10-6 frequency from peripheral blood in patients with checkpoint blockade-treated cancer.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment 1: Correlation of RNA-based IGH sequencing with treatment outcomes in checkpoint blockade-treated cancer patients**

**Protocol:**

**Step 1: Patient Recruitment and Sample Collection**

1.1. Identify and enroll 100 patients with various types of cancer (e.g., melanoma, lung, breast, colon) who have received checkpoint blockade therapy.

1.2. Obtain informed consent from each patient.

1.3. Collect peripheral blood samples from each patient at three time points:
	* Baseline (before treatment initiation)
	* During treatment (after 2-3 cycles)
	* Follow-up (after treatment completion or at disease progression)

1.4. Label and store the blood samples at -80°C until further processing.

**Step 2: RNA Isolation**

2.1. Thaw the peripheral blood samples and isolate peripheral blood mononuclear cells (PBMCs) using a density gradient centrifugation method (e.g., Ficoll-Paque).

2.2. Isolate RNA from the PBMCs using a RNA isolation kit (e.g., Qiagen RNeasy Mini Kit) according to the manufacturer's instructions.

2.3. Quantify the isolated RNA using a spectrophotometer (e.g., NanoDrop) and assess its quality using a bioanalyzer (e.g., Agilent 2100).

**Step 3: RNA-based IGH Sequencing**

3.1. Prepare the RNA samples for sequencing according to the Ion OncomineTM BCR IGH-SR assay protocol.

3.2. Perform RNA-based IGH sequencing using the Ion OncomineTM BCR IGH-SR assay on the Ion Torrent sequencing platform.

3.3. Generate FASTQ files from the sequencing data.

**Step 4: B Cell Clone Detection**

4.1. Analyze the FASTQ files using a bioinformatics pipeline (e.g., IMGT/HighV-QUEST) to identify B cell clones at 10-6 frequency.

4.2. Filter the results to remove low-quality reads and artifacts.

4.3. Identify the B cell clones and their frequencies in each sample.

**Step 5: Treatment Outcome Assessment**

5.1. Collect clinical data on treatment response, progression-free survival, and overall survival from the patients' medical records.

5.2. Record the treatment outcomes in a standardized format (e.g., RECIST criteria).

**Step 6: Correlation Analysis**

6.1. Correlate the detection of B cell clones at 10-6 frequency with treatment outcomes using statistical analysis (e.g., Kaplan-Meier curves, Cox proportional hazards model).

6.2. Perform statistical analysis using software (e.g., R, Python) and generate plots and tables to visualize the results.

**Experiment 2: Investigation of RNA-based IGH sequencing limitations in detecting B cell clones at 10-6 frequency in checkpoint blockade-treated cancer patients**

**Protocol:**

**Step 1: Sample Preparation**

1.1. Prepare peripheral blood samples from patients with checkpoint blockade-treated cancer.

1.2. Intentionally introduce variables that may affect RNA-based IGH sequencing performance, such as:
	* Low-quality RNA samples: degrade RNA samples using heat or RNase treatment.
	* Insufficient input material: use reduced amounts of RNA or PBMCs.
	* Presence of inhibitors or contaminants: spike in known inhibitors (e.g., heparin) or contaminants (e.g., DNA).
	* Variations in RNA isolation protocols: use different RNA isolation kits or protocols.

**Step 2: RNA-based IGH Sequencing**

2.1. Prepare the RNA samples for sequencing according to the Ion OncomineTM BCR IGH-SR assay protocol.

2.2. Perform RNA-based IGH sequencing using the Ion OncomineTM BCR IGH-SR assay on the Ion Torrent sequencing platform.

2.3. Generate FASTQ files from the sequencing data.

**Step 3: B Cell Clone Detection**

3.1. Analyze the FASTQ files using a bioinformatics pipeline (e.g., IMGT/HighV-QUEST) to identify B cell clones at 10-6 frequency.

3.2. Filter the results to remove low-quality reads and artifacts.

3.3. Identify the B cell clones and their frequencies in each sample.

**Step 4: Comparison with DNA-based Sequencing**

4.1. Perform DNA-based IGH sequencing using the Ion OncomineTM BCR IGH-LR assay on the same samples.

4.2. Analyze the DNA-based sequencing data using a bioinformatics pipeline (e.g., IMGT/HighV-QUEST).

4.3. Compare the results with the RNA-based sequencing data.

**Step 5: Limitation Identification**

5.1. Identify the limitations of RNA-based IGH sequencing in detecting B cell clones at 10-6 frequency, such as:
	* False negatives or false positives
	* Inability to detect clones in certain patient subgroups
	* Variability in detection across different sequencing runs

5.2. Record the limitations and their impact on the results.

By following these detailed protocols, the experiments can be replicated and the results can be accurately compared and analyzed.","Here is the simulated dataframe:

```
   Patient_ID  RNA_Quality  RNA_Amount  PBMC_Amount  Heparin_Spike  DNA_Contamination  B_Cell_Clones_Detected  Treatment_Outcome
0           1        8.5       1000.0       500.0         0.0               0.0                  10.0               Responded
1           2        7.8        800.0       400.0         0.1               0.1                   8.0               Progressed
2           3        9.0       1200.0       600.0         0.0               0.0                  12.0               Responded
3           4        8.2        900.0       450.0         0.2               0.2                   9.0               Progressed
4           5        7.5        700.0       350.0         0.3               0.3                   7.0               Progressed
5           6        8.8       1100.0       550.0         0.0               0.0                  11.0               Responded
6           7        8.0        950.0       475.0         0.1               0.1                   9.5               Responded
7           8        7.2        650.0       325.0         0.4               0.4                   6.5               Progressed
8           9        9.2       1300.0       650.0         0.0               0.0                  13.0               Responded
9          10        8.6       1050.0       525.0         0.2               0.2                  10.5               Responded
10         11        7.9        850.0       425.0         0.3               0.3                   8.5               Progressed
11         12        8.4       1000.0       500.0         0.1               0.1                  10.0               Responded
12         13        7.6        750.0       375.0         0.4               0.4                   7.5               Progressed
13         14        9.5       1400.0       700.0         0.0               0.0                  14.0               Responded
14         15        8.1        920.0       460.0         0.2               0.2                   9.1               Responded
15         16        7.3        680.0       340.0         0.5               0.5                   6.8               Progressed
16         17        9.8       1600.0       800.0         0.0               0.0                  16.0               Responded
17         18        8.3       1020.0       510.0         0.3               0.3                  10.3               Responded
18         19        7.4        720.0       360.0         0.6               0.6                   7.2               Progressed
19         20        9.1       1180.0       590.0         0.1               0.1                  11.8               Responded
20         21        8.7       1080.0       540.0         0.2               0.2                  10.8               Responded
21         22        7.1        620.0       310.0         0.7               0.7                   6.2               Progressed
22         23        9.6       1520.0       760.0         0.0               0.0                  15.2               Responded
23         24        8.9       1120.0       560.0         0.3               0.3                  11.2               Responded
24         25        7.7        780.0       390.0         0.5               0.5                   7.8               Progressed
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/260438e480099d5430017d33b4e4a241d108c659.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9851918cf2dfab2fdb0096a960bbc307033f78cd.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2ece3e913ea23cd6e81c70c7e81540c9c835c293.summary']","Can a combination of NX-5948 and MTX-loading DNA tetrahedron synergistically enhance the degradation of BTK and regulation of macrophage activity, leading to improved treatment outcomes in rheumatoid arthritis patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that a combination of NX-5948 and MTX-loading DNA tetrahedron synergistically enhances the degradation of BTK and regulation of macrophage activity, leading to improved treatment outcomes in rheumatoid arthritis patients, I propose the following experimental plan:

**Experiment:** ""Synergistic Effect of NX-5948 and MTX-Loading DNA Tetrahedron on BTK Degradation and Macrophage Regulation in Rheumatoid Arthritis""

**Objective:** To investigate whether the combination of NX-5948 and MTX-loading DNA tetrahedron has a synergistic effect on BTK degradation and macrophage regulation, leading to improved treatment outcomes in rheumatoid arthritis.

**Design:**

1. **In vitro** study:
	* Treat human peripheral blood mononuclear cells (PBMCs) with NX-5948, MTX-loading DNA tetrahedron, or a combination of both.
	* Measure BTK degradation using Western blot analysis and flow cytometry.
	* Analyze macrophage activity using flow cytometry and ELISA for pro-inflammatory cytokines (e.g., IL-6, TNF-α).
2. **In vivo** study:
	* Use a collagen-induced arthritis (CIA) mouse model.
	* Treat mice with NX-5948, MTX-loading DNA tetrahedron, or a combination of both.
	* Measure BTK degradation in splenic B cells using flow cytometry.
	* Analyze macrophage activity in the joints using immunohistochemistry and ELISA for pro-inflammatory cytokines.
	* Evaluate disease severity using clinical scoring and radiographic analysis.

**Controls:**

* Untreated CIA mice
* Mice treated with NX-5948 or MTX-loading DNA tetrahedron alone
* Mice treated with ibrutinib or dexamethasone (positive controls)

**Expected Outcomes:**

* Synergistic effect of NX-5948 and MTX-loading DNA tetrahedron on BTK degradation and macrophage regulation.
* Improved treatment outcomes in CIA mice, including reduced disease severity and inflammation.

**Equipment and Resources:**

* Cell culture facilities
* Flow cytometer
* Western blot analysis equipment
* ELISA kits
* DNA synthesizer (for MTX-loading DNA tetrahedron synthesis)
* Animal facilities (for CIA mouse model)
* Clinical evaluation tools (for disease severity scoring and radiographic analysis)

**Timeline:**

* Literature review and experimental design: 2 weeks
* In vitro study: 4 weeks
* In vivo study: 8 weeks
* Data analysis and manuscript preparation: 12 weeks

**Budget:**

* Personnel: $50,000 (post-doc, technician, and PI salaries)
* Reagents and consumables: $20,000 (NX-5948, MTX-loading DNA tetrahedron, ELISA kits, etc.)
* Equipment maintenance and usage: $10,000 (flow cytometer, Western blot analysis equipment, etc.)
* Animal facilities and care: $15,000 (CIA mouse model, animal housing, etc.)
* Total: $95,000

To disprove the hypothesis, the experiment can be designed to test the following:

* Does the combination of NX-5948 and MTX-loading DNA tetrahedron have an antagonistic effect on BTK degradation and macrophage regulation?
* Does the combination of NX-5948 and MTX-loading DNA tetrahedron have no effect on BTK degradation and macrophage regulation compared to treatment with either agent alone?

By testing these alternative hypotheses, we can determine whether the combination of NX-5948 and MTX-loading DNA tetrahedron has a synergistic effect on BTK degradation and macrophage regulation, leading to improved treatment outcomes in rheumatoid arthritis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**In Vitro Study:**

**Protocol 1: Cell Culture and Treatment**

1. Obtain human peripheral blood mononuclear cells (PBMCs) from healthy donors or patients with rheumatoid arthritis.
2. Isolate PBMCs using density gradient centrifugation (e.g., Ficoll-Paque).
3. Culture PBMCs in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
4. Treat PBMCs with:
	* NX-5948 (concentration: 1 μM, 5 μM, and 10 μM)
	* MTX-loading DNA tetrahedron (concentration: 1 nM, 5 nM, and 10 nM)
	* Combination of NX-5948 (5 μM) and MTX-loading DNA tetrahedron (5 nM)
	* Vehicle control (DMSO or PBS)
5. Incubate cells for 24 hours, 48 hours, and 72 hours.

**Protocol 2: Western Blot Analysis**

1. Harvest cells and extract proteins using RIPA buffer.
2. Perform Western blot analysis using anti-BTK antibody (1:1000 dilution) and anti-β-actin antibody (1:5000 dilution) as a loading control.
3. Detect protein bands using ECL reagent and quantify using densitometry software.

**Protocol 3: Flow Cytometry**

1. Harvest cells and stain with anti-BTK antibody (1:100 dilution) and anti-CD14 antibody (1:100 dilution) for macrophage identification.
2. Analyze cells using a flow cytometer (e.g., BD FACSCanto II) and quantify BTK expression and macrophage activity.

**Protocol 4: ELISA**

1. Harvest cell culture supernatants and analyze for pro-inflammatory cytokines (IL-6 and TNF-α) using ELISA kits.
2. Follow the manufacturer's instructions for ELISA protocol.

**In Vivo Study:**

**Protocol 5: CIA Mouse Model**

1. Induce collagen-induced arthritis (CIA) in mice using bovine type II collagen.
2. Randomly assign mice to treatment groups:
	* NX-5948 (10 mg/kg, i.p.)
	* MTX-loading DNA tetrahedron (5 mg/kg, i.p.)
	* Combination of NX-5948 (10 mg/kg, i.p.) and MTX-loading DNA tetrahedron (5 mg/kg, i.p.)
	* Vehicle control (PBS, i.p.)
	* Positive controls: ibrutinib (10 mg/kg, i.p.) and dexamethasone (1 mg/kg, i.p.)
3. Treat mice for 4 weeks.

**Protocol 6: Flow Cytometry**

1. Harvest splenic B cells and stain with anti-BTK antibody (1:100 dilution) and anti-CD19 antibody (1:100 dilution).
2. Analyze cells using a flow cytometer (e.g., BD FACSCanto II) and quantify BTK expression.

**Protocol 7: Immunohistochemistry**

1. Harvest joint tissues and fix in 4% paraformaldehyde.
2. Perform immunohistochemistry using anti-CD68 antibody (1:100 dilution) for macrophage identification.
3. Analyze tissue sections using a microscope (e.g., Olympus BX51) and quantify macrophage activity.

**Protocol 8: Clinical Evaluation**

1. Evaluate disease severity using clinical scoring (e.g., arthritis score, paw swelling).
2. Perform radiographic analysis (e.g., X-ray) to assess joint damage.

**Data Analysis:**

1. Analyze data using statistical software (e.g., GraphPad Prism).
2. Compare treatment groups using one-way ANOVA and Tukey's post-hoc test.
3. Determine synergistic effect using the Bliss independence model.

**Quality Control:**

1. Verify the identity and purity of NX-5948 and MTX-loading DNA tetrahedron using HPLC and mass spectrometry.
2. Validate the specificity of antibodies used in Western blot analysis and flow cytometry.
3. Monitor cell culture conditions and ensure consistency throughout the experiment.

By following these detailed protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis.","```
   NX_5948_MT  MTX_loading_DNA_tetrahedron  Incubation_Time  BTK_Expression  Macrophage_Activity  IL_6  TNF_alpha  Arthritis_Score
0           1.0                    1.0             24.0       0.85          0.40         120.0       50.0          2.0
1           5.0                    1.0             24.0       0.60          0.30         100.0       40.0          1.5
2          10.0                    1.0             24.0       0.40          0.20          80.0       30.0          1.0
3           5.0                    5.0             24.0       0.50          0.35         110.0       45.0          1.8
4           5.0                   10.0             24.0       0.45          0.25         105.0       42.0          1.6
5           0.0                    0.0             24.0       1.00          0.60         150.0       60.0          3.0
6           1.0                    1.0             48.0       0.75          0.45         130.0       55.0          2.2
7           5.0                    1.0             48.0       0.55          0.35         115.0       48.0          1.9
8          10.0                    1.0             48.0       0.35          0.20          90.0       35.0          1.2
9           5.0                    5.0             48.0       0.50          0.30         120.0       50.0          2.0
10          5.0                   10.0             48.0       0.40          0.25         100.0       40.0          1.5
11          0.0                    0.0             48.0       1.05          0.65         160.0       65.0          3.2
12          1.0                    1.0             72.0       0.80          0.50         140.0       58.0          2.5
13          5.0                    1.0             72.0       0.60          0.40         125.0       52.0          2.1
14         10.0                    1.0             72.0       0.45          0.30         110.0       45.0          1.8
15          5.0                    5.0             72.0       0.55          0.35         130.0       55.0          2.2
16          5.0                   10.0             72.0       0.50          0.30         120.0       50.0          2.0
17          0.0                    0.0             72.0       1.10          0.70         170.0       70.0          3.5
18         10.0                    5.0             24.0       0.40          0.25         100.0       40.0          1.5
19         10.0                   10.0             24.0       0.35          0.20          90.0       35.0          1.2
20          5.0                    5.0             48.0       0.50          0.35         115.0       48.0          1.9
21          5.0                   10.0             48.0       0.45          0.30         105.0       42.0          1.6
22         10.0                    5.0             48.0       0.40          0.25         100.0       40.0          1.5
23         10.0                   10.0             48.0       0.35          0.20          90.0       35.0          1.2
24          5.0                    5.0             72.0       0.55          0.40         125.0       52.0          2.1
```",0.4195223840790544
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d3ba02ef0c967d28efa1d7b1b87eec3346a189d9.summary'],Can carbamylated self-proteins in RA synovial tissue induce a regulatory T cell response that mitigates autoreactive B-cell responses against PTM self proteins?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis: ""Can carbamylated self-proteins in RA synovial tissue induce a regulatory T cell response that mitigates autoreactive B-cell responses against PTM self proteins?""

**Experimental Plan:**

**Title:** Investigating the Role of Carbamylated Self-Proteins in Inducing Regulatory T Cell Responses in RA Synovial Tissue

**Objective:** To determine whether carbamylated self-proteins in RA synovial tissue can induce a regulatory T cell response that mitigates autoreactive B-cell responses against PTM self proteins.

**Equipment:**

* RA synovial tissue samples
* Carbamylated self-proteins (e.g., carbamylated albumin)
* Regulatory T cell markers (e.g., FoxP3, CD25, CD127)
* Autoreactive B cell markers (e.g., anti-CarP antibodies)
* Flow cytometry equipment
* ELISA kits for anti-CarP antibody detection
* T cell isolation and expansion kits
* Co-culture systems for T cells and B cells

**Steps:**

1. **Isolate and characterize RA synovial tissue samples:** Collect RA synovial tissue samples and isolate the cells using standard protocols. Characterize the cells using flow cytometry to identify the presence of autoreactive B cells and regulatory T cells.
2. **Prepare carbamylated self-proteins:** Prepare carbamylated self-proteins (e.g., carbamylated albumin) using established methods.
3. **Co-culture T cells and B cells with carbamylated self-proteins:** Co-culture isolated T cells and B cells from RA synovial tissue with carbamylated self-proteins in the presence of T cell activation stimuli (e.g., anti-CD3, anti-CD28). Use a co-culture system to allow for cell-cell interactions.
4. **Analyze regulatory T cell responses:** Analyze the co-culture supernatants for regulatory T cell cytokines (e.g., IL-10, TGF-β) using ELISA. Use flow cytometry to assess the expression of regulatory T cell markers (e.g., FoxP3, CD25, CD127) on T cells.
5. **Assess autoreactive B cell responses:** Analyze the co-culture supernatants for anti-CarP antibodies using ELISA. Use flow cytometry to assess the expression of autoreactive B cell markers (e.g., anti-CarP antibodies) on B cells.
6. **Compare results to control groups:** Compare the results to control groups where T cells and B cells are co-cultured without carbamylated self-proteins or with non-carbamylated self-proteins.
7. **Repeat the experiment with different carbamylated self-proteins:** Repeat the experiment using different carbamylated self-proteins (e.g., carbamylated collagen, carbamylated vimentin) to assess the specificity of the response.

**To disprove the hypothesis:**

* If the experiment shows that carbamylated self-proteins in RA synovial tissue do not induce a regulatory T cell response that mitigates autoreactive B-cell responses against PTM self proteins, it would disprove the hypothesis.
* If the experiment shows that the regulatory T cell response is not specific to carbamylated self-proteins and is also induced by non-carbamylated self-proteins, it would disprove the hypothesis.
* If the experiment shows that the autoreactive B cell response is not affected by the presence of regulatory T cells, it would disprove the hypothesis.

**Additional considerations:**

* To ensure the validity of the results, it is essential to include appropriate controls, such as non-RA synovial tissue samples, and to perform the experiment in triplicate.
* The experiment should be performed in a blinded manner to minimize bias.
* The results should be validated using multiple methods, such as qRT-PCR, Western blot, and immunohistochemistry, to confirm the findings.

By following this experimental plan, we can test the hypothesis and potentially disprove it, providing valuable insights into the role of carbamylated self-proteins in RA synovial tissue and their potential to induce regulatory T cell responses that mitigate autoreactive B-cell responses against PTM self proteins.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Isolation and Characterization of RA Synovial Tissue Samples**

1.1. Collect RA synovial tissue samples from patients with rheumatoid arthritis (RA) using aseptic techniques.

1.2. Transport the tissue samples to the laboratory and process them within 2 hours of collection.

1.3. Wash the tissue samples with phosphate-buffered saline (PBS) to remove any debris or contaminants.

1.4. Mince the tissue samples into small pieces and digest them with collagenase (1 mg/mL) and DNase (0.1 mg/mL) in PBS for 30 minutes at 37°C.

1.5. Pass the digested tissue through a 70-μm cell strainer to obtain a single-cell suspension.

1.6. Centrifuge the cell suspension at 300 x g for 10 minutes to pellet the cells.

1.7. Resuspend the cells in PBS and count them using a hemocytometer.

1.8. Characterize the cells using flow cytometry to identify the presence of autoreactive B cells and regulatory T cells.

**Protocol 2: Preparation of Carbamylated Self-Proteins**

2.1. Prepare carbamylated self-proteins (e.g., carbamylated albumin) using established methods.

2.2. Dissolve the carbamylated self-proteins in PBS at a concentration of 1 mg/mL.

2.3. Filter the solution through a 0.2-μm filter to remove any impurities.

2.4. Aliquot the solution into 1-mL tubes and store them at -20°C until use.

**Protocol 3: Co-Culture of T Cells and B Cells with Carbamylated Self-Proteins**

3.1. Isolate T cells and B cells from the RA synovial tissue samples using magnetic bead-based separation kits.

3.2. Count the isolated T cells and B cells using a hemocytometer.

3.3. Co-culture 1 x 10^6 T cells and 1 x 10^6 B cells in a 24-well plate with 1 mL of complete RPMI medium.

3.4. Add 10 μg/mL of carbamylated self-proteins to the co-culture.

3.5. Add T cell activation stimuli (e.g., anti-CD3, anti-CD28) to the co-culture at a concentration of 1 μg/mL.

3.6. Incubate the co-culture at 37°C, 5% CO2 for 72 hours.

**Protocol 4: Analysis of Regulatory T Cell Responses**

4.1. Collect the co-culture supernatants and store them at -20°C until analysis.

4.2. Analyze the supernatants for regulatory T cell cytokines (e.g., IL-10, TGF-β) using ELISA kits.

4.3. Use flow cytometry to assess the expression of regulatory T cell markers (e.g., FoxP3, CD25, CD127) on T cells.

**Protocol 5: Analysis of Autoreactive B Cell Responses**

5.1. Collect the co-culture supernatants and store them at -20°C until analysis.

5.2. Analyze the supernatants for anti-CarP antibodies using ELISA kits.

5.3. Use flow cytometry to assess the expression of autoreactive B cell markers (e.g., anti-CarP antibodies) on B cells.

**Protocol 6: Comparison to Control Groups**

6.1. Repeat the co-culture experiment without carbamylated self-proteins or with non-carbamylated self-proteins as controls.

6.2. Compare the results to the control groups to assess the specificity of the response.

**Protocol 7: Replication with Different Carbamylated Self-Proteins**

7.1. Repeat the experiment using different carbamylated self-proteins (e.g., carbamylated collagen, carbamylated vimentin).

7.2. Compare the results to assess the specificity of the response to different carbamylated self-proteins.

**Additional Considerations**

* Perform the experiment in triplicate to ensure the validity of the results.
* Include appropriate controls, such as non-RA synovial tissue samples, to validate the results.
* Perform the experiment in a blinded manner to minimize bias.
* Validate the results using multiple methods, such as qRT-PCR, Western blot, and immunohistochemistry, to confirm the findings.","```
   RA Synovial Tissue (mg)  Collagenase (mg/mL)  DNase (mg/mL)  Carbamylated Albumin (μg/mL)  T Cell Activation Stimuli (μg/mL)  IL-10 (pg/mL)  TGF-β (pg/mL)  Anti-CarP Antibodies (OD)
0                    50.0               1.2           0.15                  12.0                       1.5         250.0         150.0               0.8
1                    30.0               0.8           0.10                  15.0                       1.0         300.0         200.0               1.2
2                    40.0               1.0           0.12                  10.0                       1.2         220.0         180.0               0.9
3                    60.0               1.5           0.18                  12.0                       1.8         280.0         220.0               1.5
4                    45.0               1.1           0.13                  11.0                       1.4         240.0         190.0               1.1
5                    35.0               0.9           0.11                  14.0                       1.1         260.0         210.0               1.3
6                    55.0               1.4           0.16                  13.0                       1.6         290.0         230.0               1.6
7                    25.0               0.7           0.09                  16.0                       0.9         200.0         160.0               0.7
8                    48.0               1.3           0.14                  10.0                       1.3         230.0         180.0               1.0
9                    32.0               0.8           0.10                  12.0                       1.0         210.0         170.0               0.9
10                   58.0               1.6           0.19                  11.0                       1.7         310.0         240.0               1.7
11                   42.0               1.2           0.15                  13.0                       1.5         250.0         200.0               1.2
12                   38.0               1.0           0.12                  14.0                       1.2         220.0         190.0               1.1
13                   52.0               1.4           0.17                  10.0                       1.6         280.0         220.0               1.4
14                   28.0               0.8           0.10                  15.0                       1.0         190.0         150.0               0.8
15                   46.0               1.3           0.14                  12.0                       1.4         240.0         200.0               1.1
16                   34.0               0.9           0.11                  13.0                       1.1         210.0         170.0               0.9
17                   50.0               1.5           0.18                  11.0                       1.7         300.0         230.0               1.5
18                   44.0               1.2           0.15                  10.0                       1.5         260.0         210.0               1.2
19                   36.0               1.0           0.12                  14.0                       1.2         230.0         190.0               1.1
20                   54.0               1.6           0.19                  12.0                       1.8         320.0         240.0               1.7
21                   40.0               1.1           0.13                  13.0                       1.4         250.0         200.0               1.2
22                   31.0               0.8           0.10                  15.0                       1.0         200.0         160.0               0.8
23                   49.0               1.4           0.16                  11.0                       1.6         290.0         220.0               1.4
24                   43.0               1.2           0.14                  12.0                       1.5         270.0         210.0               1.3
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/696ca7b38d7b8997fab5bf5a491c3d07822455eb.summary'],Can engineered antibodies targeting gluten peptide-presenting cells in the gut also modulate the gut microbiome to prevent T-cell activation and inflammation in celiac disease patients?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed a high-level experimental plan to test the hypothesis using existing scientific methods and equipment, with an unlimited budget in terms of time, resources, and financial support.

**Experimental Plan:**

**Title:** Modulation of Gut Microbiome and T-Cell Activation in Celiac Disease Patients using Engineered Antibodies Targeting Gluten Peptide-Presenting Cells

**Objective:** To investigate whether engineered antibodies targeting gluten peptide-presenting cells in the gut can modulate the gut microbiome and prevent T-cell activation and inflammation in celiac disease patients.

**Experimental Design:**

**Phase 1: Antibody Engineering and Validation**

1.1. Optimize the previously generated high-affinity antibodies using advanced antibody engineering techniques, such as CRISPR-Cas9 genome editing and yeast display, to enhance their binding affinity and specificity for gluten peptides bound to HLA-DQ2.5.

1.2. Validate the optimized antibodies using in vitro assays, including ELISA, surface plasmon resonance, and flow cytometry, to confirm their binding specificity and potency.

**Phase 2: Humanized Mouse Model Development**

2.1. Generate humanized mice with a celiac disease-like phenotype by transplanting human hematopoietic stem cells and gut microbiota into immunodeficient mice.

2.2. Verify the development of celiac disease-like symptoms, including gut inflammation and T-cell activation, in the humanized mice.

**Phase 3: Antibody Treatment and Gut Microbiome Analysis**

3.1. Administer the optimized antibodies to the humanized mice via intravenous injection or oral gavage, and monitor for changes in gut microbiome composition using 16S rRNA gene sequencing and metagenomics analysis.

3.2. Collect fecal samples and gut tissue biopsies at regular intervals to analyze the gut microbiome composition, diversity, and function using techniques such as qPCR, FISH, and metabolomics.

**Phase 4: T-Cell Activation and Inflammation Analysis**

4.1. Isolate immune cells from the gut and peripheral blood of treated and control mice, and analyze T-cell activation and cytokine production using flow cytometry, ELISA, and Luminex assays.

4.2. Evaluate gut inflammation and tissue damage using histopathological analysis, including H&E staining and immunohistochemistry.

**Phase 5: Mechanistic Studies**

5.1. Investigate the mechanisms underlying the modulation of the gut microbiome and T-cell activation by the engineered antibodies using techniques such as RNA-seq, ChIP-seq, and proteomics.

5.2. Analyze the effects of the antibodies on gluten peptide presentation, antigen processing, and T-cell receptor signaling using in vitro assays and biochemical techniques.

**Phase 6: Human Clinical Trial**

6.1. Conduct a Phase I clinical trial to evaluate the safety, tolerability, and efficacy of the engineered antibodies in celiac disease patients.

6.2. Monitor patients for changes in gut microbiome composition, T-cell activation, and inflammation using non-invasive biomarkers and imaging techniques.

**Expected Outcomes:**

* The engineered antibodies will modulate the gut microbiome composition and diversity in humanized mice and celiac disease patients.
* The antibodies will prevent T-cell activation and inflammation in the gut of humanized mice and celiac disease patients.
* The study will provide mechanistic insights into the role of gluten peptide-presenting cells in celiac disease and the therapeutic potential of engineered antibodies in modulating the gut microbiome and preventing T-cell activation.

**Timeline:**

* Phase 1-2: 6 months
* Phase 3-4: 12 months
* Phase 5: 9 months
* Phase 6: 24 months

**Personnel:**

* Principal Investigator: 1
* Postdoctoral Researchers: 2
* Graduate Students: 2
* Research Assistants: 4
* Clinical Trial Coordinator: 1
* Biostatistician: 1

**Equipment and Resources:**

* Antibody engineering and validation: Access to CRISPR-Cas9 genome editing and yeast display facilities, ELISA and surface plasmon resonance equipment, and flow cytometry instruments.
* Humanized mouse model development: Access to immunodeficient mice, human hematopoietic stem cells, and gut microbiota.
* Gut microbiome analysis: 16S rRNA gene sequencing and metagenomics analysis equipment, qPCR, FISH, and metabolomics instruments.
* T-cell activation and inflammation analysis: Flow cytometry, ELISA, and Luminex assays, histopathological analysis equipment.
* Mechanistic studies: RNA-seq, ChIP-seq, and proteomics equipment.
* Clinical trial: Access to clinical trial facilities, non-invasive biomarkers, and imaging techniques.

**Budget:**

* Personnel: $2,500,000 per year for 5 years
* Equipment and Resources: $1,500,000 per year for 5 years
* Reagents and Consumables: $500,000 per year for 5 years
* Clinical Trial: $2,000,000 per year for 2 years
* Total: $12,000,000 over 5 years",92,"I'll break down the experimental plan into detailed, step-by-step protocols for each phase. Please note that these protocols are written in a way that can be executed by a researcher or a robot, and they include specific details to ensure replicability and specificity.

**Phase 1: Antibody Engineering and Validation**

**Protocol 1.1: Antibody Optimization using CRISPR-Cas9 Genome Editing**

1.1.1. Prepare CRISPR-Cas9 plasmids containing the guide RNA (gRNA) targeting the antibody gene of interest.
1.1.2. Co-transfect the CRISPR-Cas9 plasmid and a repair template containing the desired mutations into HEK293T cells using Lipofectamine 3000.
1.1.3. Select and isolate single-cell clones using fluorescence-activated cell sorting (FACS) and limit dilution.
1.1.4. Verify the mutations using Sanger sequencing and high-throughput sequencing (e.g., Illumina MiSeq).
1.1.5. Express and purify the optimized antibodies using standard protocols (e.g., protein A/G affinity chromatography).

**Protocol 1.2: Antibody Validation using ELISA, Surface Plasmon Resonance, and Flow Cytometry**

1.2.1. Coat ELISA plates with gluten peptides and incubate with the optimized antibodies.
1.2.2. Detect bound antibodies using HRP-conjugated secondary antibodies and measure absorbance at 450 nm.
1.2.3. Perform surface plasmon resonance analysis using a Biacore T200 instrument to measure binding kinetics and affinity.
1.2.4. Stain gluten peptide-presenting cells with the optimized antibodies and analyze using flow cytometry (e.g., BD FACSCanto II).
1.2.5. Verify binding specificity and potency using flow cytometry and ELISA.

**Phase 2: Humanized Mouse Model Development**

**Protocol 2.1: Humanized Mouse Generation**

2.1.1. Obtain human hematopoietic stem cells from healthy donors and gut microbiota from celiac disease patients.
2.1.2. Transplant the human hematopoietic stem cells into immunodeficient mice (e.g., NOD-SCID) via intravenous injection.
2.1.3. Administer gut microbiota to the mice via oral gavage.
2.1.4. Monitor for human immune cell engraftment and gut colonization using flow cytometry and 16S rRNA gene sequencing.

**Protocol 2.2: Verification of Celiac Disease-Like Symptoms**

2.2.1. Monitor mice for signs of gut inflammation and T-cell activation (e.g., diarrhea, weight loss, and increased cytokine production).
2.2.2. Collect fecal samples and gut tissue biopsies for analysis.
2.2.3. Analyze gut tissue biopsies using histopathological analysis (e.g., H&E staining and immunohistochemistry).

**Phase 3: Antibody Treatment and Gut Microbiome Analysis**

**Protocol 3.1: Antibody Administration**

3.1.1. Administer the optimized antibodies to humanized mice via intravenous injection or oral gavage.
3.1.2. Monitor for changes in gut microbiome composition using 16S rRNA gene sequencing and metagenomics analysis.

**Protocol 3.2: Gut Microbiome Analysis**

3.2.1. Collect fecal samples and gut tissue biopsies at regular intervals.
3.2.2. Extract DNA from fecal samples and gut tissue biopsies using standard protocols (e.g., QIAamp DNA Stool Mini Kit).
3.2.3. Perform 16S rRNA gene sequencing using the Illumina MiSeq platform.
3.2.4. Analyze gut microbiome composition, diversity, and function using QIIME 2 and PICRUSt2.

**Phase 4: T-Cell Activation and Inflammation Analysis**

**Protocol 4.1: T-Cell Activation Analysis**

4.1.1. Isolate immune cells from the gut and peripheral blood of treated and control mice.
4.1.2. Analyze T-cell activation and cytokine production using flow cytometry (e.g., BD FACSCanto II), ELISA, and Luminex assays.

**Protocol 4.2: Gut Inflammation Analysis**

4.2.1. Evaluate gut inflammation and tissue damage using histopathological analysis (e.g., H&E staining and immunohistochemistry).
4.2.2. Analyze gut tissue biopsies using immunohistochemistry and confocal microscopy.

**Phase 5: Mechanistic Studies**

**Protocol 5.1: RNA-seq and ChIP-seq Analysis**

5.1.1. Isolate RNA from gut tissue biopsies and immune cells.
5.1.2. Perform RNA-seq analysis using the Illumina HiSeq 4000 platform.
5.1.3. Analyze differentially expressed genes using DESeq2 and pathway analysis using ReactomePA.
5.1.4. Perform ChIP-seq analysis using the Illumina HiSeq 4000 platform to analyze histone modifications and transcription factor binding.

**Protocol 5.2: Proteomics Analysis**

5.2.1. Isolate proteins from gut tissue biopsies and immune cells.
5.2.2. Perform proteomics analysis using mass spectrometry (e.g., Orbitrap Fusion Lumos).
5.2.3. Analyze protein abundance and post-translational modifications using MaxQuant and Perseus.

**Phase 6: Human Clinical Trial**

**Protocol 6.1: Clinical Trial Design**

6.1.1. Conduct a Phase I clinical trial to evaluate the safety, tolerability, and efficacy of the engineered antibodies in celiac disease patients.
6.1.2. Enroll patients with active celiac disease and administer the engineered antibodies via intravenous injection or oral gavage.
6.1.3. Monitor patients for changes in gut microbiome composition, T-cell activation, and inflammation using non-invasive biomarkers and imaging techniques.

**Protocol 6.2: Sample Collection and Analysis**

6.2.1. Collect fecal samples, blood samples, and gut tissue biopsies from patients at regular intervals.
6.2.2. Analyze gut microbiome composition, diversity, and function using 16S rRNA gene sequencing and metagenomics analysis.
6.2.3. Analyze T-cell activation and cytokine production using flow cytometry, ELISA, and Luminex assays.
6.2.4. Evaluate gut inflammation and tissue damage using histopathological analysis and imaging techniques.

These detailed protocols should provide a clear guide for executing the experimental plan. Please note that specific details may vary depending on the research institution and the specific equipment and resources available.","```
   CRISPR_Cas9_plasmid  Lipofectamine_3000  gRNA  repair_template  HEK293T_cells  Antibody_concentration  ELISA_absorbance  SPR_binding_kinetics  Flow_cytometry_binding  Humanized_mouse_generation  Gut_microbiota_administration  Antibody_administration  Gut_inflammation  T_cell_activation  Outcome
0                  1.0               2.0  0.5             1.0             1.0e6               10.0               1.5               2000.0               0.8               1.0               1.0               0.5               0.2               Positive
1                  1.5               3.0  0.7             1.2             1.2e6               12.0               2.0               2500.0               0.9               1.1               1.1               0.6               0.3               Positive
2                  2.0               4.0  0.9             1.5             1.5e6               15.0               2.5               3000.0               1.0               1.2               1.2               0.7               0.4               Positive
3                  0.5               1.0  0.3             0.8             0.8e6                8.0               1.0               1500.0               0.6               0.9               0.9               0.4               0.1               Negative
4                  1.2               2.5  0.6             1.0             1.0e6               11.0               1.8               2200.0               0.8               1.0               1.0               0.5               0.2               Positive
5                  1.8               3.5  0.8             1.3             1.3e6               14.0               2.2               2800.0               0.9               1.1               1.1               0.6               0.3               Positive
6                  2.5               5.0  1.0             1.8             1.8e6               18.0               2.8               3500.0               1.0               1.3               1.3               0.8               0.5               Positive
7                  0.8               1.5  0.4             0.9             0.9e6                9.0               1.2               1800.0               0.7               0.9               0.9               0.4               0.1               Negative
8                  1.0               2.2  0.5             1.1             1.1e6               10.0               1.6               2000.0               0.8               1.0               1.0               0.5               0.2               Positive
9                  1.6               3.2  0.7             1.4             1.4e6               13.0               2.0               2600.0               0.9               1.1               1.1               0.6               0.3               Positive
10                 2.2               4.5  0.9             1.7             1.7e6               16.0               2.4               3200.0               1.0               1.2               1.2               0.7               0.4               Positive
11                 0.9               1.8  0.5             1.0             1.0e6               9.5               1.4               1900.0               0.7               0.9               0.9               0.4               0.1               Negative
12                 1.4               2.8  0.6             1.2             1.2e6               12.5               1.9               2400.0               0.8               1.0               1.0               0.5               0.2               Positive
13                 1.9               3.8  0.8             1.5             1.5e6               15.5               2.3               3000.0               0.9               1.1               1.1               0.6               0.3               Positive
14                 2.6               5.2  1.0             1.9             1.9e6               19.0               2.9               3800.0               1.0               1.3               1.3               0.8               0.5               Positive
15                 1.1               2.3  0.5             1.1             1.1e6               10.5               1.7               2100.0               0.8               1.0               1.0               0.5               0.2               Positive
16                 1.7               3.5  0.7             1.4             1.4e6               14.5               2.1               2700.0               0.9               1.1               1.1               0.6               0.3               Positive
17                 2.3               4.8  0.9             1.8             1.8e6               17.5               2.6               3400.0               1.0               1.2               1.2               0.7               0.4               Positive
18                 1.3               2.6  0.6             1.2             1.2e6               11.5               1.8               2300.0               0.8               1.0               1.0               0.5               0.2               Positive
19                 1.9               3.9  0.8             1.6             1.6e6               16.0               2.4               3100.0               0.9               1.1               1.1               0.6               0.3               Positive
20                 2.7               5.5  1.0             2.0             2.0e6               20.0               3.0               4000.0               1.0               1.3               1.3               0.8               0.5               Positive
21                 1.2               2.4  0.5             1.1             1.1e6               10.0               1.6               2000.0               0.8               1.0               1.0               0.5               0.2               Positive
22                 1.8               3.6  0.7             1.5             1.5e6               15.0               2.2               2900.0               0.9               1.1               1.1               0.6               0.3               Positive
23                 2.4               4.9  0.9             1.9             1.9e6               18.5               2.7               3600.0               1.0               1.2               1.2               0.7               0.4               Positive
24                 1.5               3.0  0.6             1.3             1.3e6               12.5               1.9               2500.0               0.8               1.0               1.0               0.5               0.2               Positive
```",0.5437498828543937
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/886d04cab02764b00b873885aeb7621a3a4fac24.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c5ac0fbb4f1953c48b17e2212bd700bd9da6f88b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/156bbf76b7c4a8eff8d5ca3411c32b81eb27ad9a.summary']",Can extracellular vesicle-derived microRNAs from diffuse large B-cell lymphoma patients regulate B cell receptor signal transduction and contribute to the development of central nervous system lymphoma?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test the hypothesis and potentially disprove it. The hypothesis is:

""Can extracellular vesicle-derived microRNAs from diffuse large B-cell lymphoma patients regulate B cell receptor signal transduction and contribute to the development of central nervous system lymphoma?""

To test this hypothesis, I propose the following experiment:

**Experiment Title:** Investigating the Role of EV-derived microRNAs in B Cell Receptor Signaling and CNS Lymphoma Development

**Objective:** To determine whether EV-derived microRNAs from DLBCL patients can regulate B cell receptor signal transduction and contribute to the development of CNS lymphoma.

**Experimental Design:**

1. **EV Isolation and Characterization:** Isolate EVs from the blood samples of DLBCL patients and healthy controls using ultracentrifugation and sucrose cushion. Characterize the EVs using transmission electron microscopy and nanoparticle tracking analysis to confirm their size and concentration.
2. **microRNA Isolation and Profiling:** Isolate microRNAs from the EVs using a microRNA isolation kit. Perform microRNA profiling using a microarray or RNA sequencing to identify differentially expressed microRNAs between DLBCL patients and healthy controls.
3. **B Cell Receptor Signaling Assay:** Use a B cell receptor signaling assay to measure the activation of NF-kappaB and AP1 in B cells treated with EV-derived microRNAs from DLBCL patients and healthy controls. This will determine if the EV-derived microRNAs can regulate B cell receptor signal transduction.
4. **CNS Lymphoma Cell Culture:** Establish a CNS lymphoma cell culture model using primary CNS lymphoma cells or a CNS lymphoma cell line. Treat the cells with EV-derived microRNAs from DLBCL patients and healthy controls to assess their effect on cell proliferation, migration, and invasion.
5. **In Vivo Study:** Use a xenograft mouse model of CNS lymphoma to investigate the effect of EV-derived microRNAs on CNS lymphoma development and progression. Inject EV-derived microRNAs from DLBCL patients and healthy controls into the mice and monitor tumor growth and progression using imaging techniques such as MRI or bioluminescence imaging.

**Hypothesis-Testing Approach:** To disprove the hypothesis, we will test the following null hypothesis:

""EV-derived microRNAs from DLBCL patients do not regulate B cell receptor signal transduction and do not contribute to the development of CNS lymphoma.""

If the results show that EV-derived microRNAs from DLBCL patients do not affect B cell receptor signal transduction and do not promote CNS lymphoma development, it would disprove the original hypothesis.

**Required Equipment:**

* Ultracentrifuge
* Sucrose cushion
* Transmission electron microscope
* Nanoparticle tracking analysis instrument
* MicroRNA isolation kit
* Microarray or RNA sequencing platform
* B cell receptor signaling assay kit
* CNS lymphoma cell culture facilities
* Xenograft mouse model of CNS lymphoma
* Imaging equipment (MRI or bioluminescence imaging)

**Timeline:** The experiment is expected to take approximately 6-9 months to complete, depending on the availability of resources and the complexity of the experiments.

**Budget:** The budget for this experiment will depend on the specific equipment and reagents required, but it is estimated to be around $200,000-$300,000.

By following this experimental design, we can test the hypothesis and determine whether EV-derived microRNAs from DLBCL patients play a role in regulating B cell receptor signal transduction and contributing to the development of CNS lymphoma.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Experiment 1: EV Isolation and Characterization**

**Protocol:**

1. **Sample Preparation:**
	* Collect 10 mL of blood from DLBCL patients and healthy controls in EDTA-coated tubes.
	* Centrifuge the blood at 1,500 x g for 10 minutes to separate the plasma from the blood cells.
	* Transfer the plasma to a new tube and store it at -80°C until further use.
2. **Ultracentrifugation:**
	* Thaw the plasma samples and centrifuge them at 10,000 x g for 30 minutes to remove any debris.
	* Transfer the supernatant to a new tube and centrifuge it at 100,000 x g for 2 hours to pellet the EVs.
	* Discard the supernatant and resuspend the EV pellet in 1 mL of PBS.
3. **Sucrose Cushion:**
	* Prepare a sucrose cushion by layering 1 mL of 20% sucrose solution on top of 1 mL of 60% sucrose solution in a ultracentrifuge tube.
	* Carefully layer the EV suspension on top of the sucrose cushion.
	* Centrifuge the tube at 100,000 x g for 2 hours.
	* Collect the EVs at the interface between the 20% and 60% sucrose layers.
4. **Transmission Electron Microscopy (TEM):**
	* Fix the EVs with 2% glutaraldehyde and postfix with 1% osmium tetroxide.
	* Dehydrate the EVs with ethanol and embed them in epoxy resin.
	* Section the resin into 70 nm thick slices and mount them on copper grids.
	* Stain the sections with uranyl acetate and lead citrate.
	* Image the EVs using a transmission electron microscope.
5. **Nanoparticle Tracking Analysis (NTA):**
	* Dilute the EV suspension to a concentration of 1 x 10^8 particles/mL.
	* Load the suspension into a nanoparticle tracking analysis instrument.
	* Measure the size and concentration of the EVs using the instrument's software.

**Experiment 2: microRNA Isolation and Profiling**

**Protocol:**

1. **microRNA Isolation:**
	* Use a microRNA isolation kit to extract microRNAs from the EVs.
	* Follow the manufacturer's instructions for the isolation protocol.
2. **microRNA Profiling:**
	* Use a microarray or RNA sequencing platform to profile the microRNAs.
	* Follow the manufacturer's instructions for the profiling protocol.
	* Identify differentially expressed microRNAs between DLBCL patients and healthy controls using bioinformatic tools.

**Experiment 3: B Cell Receptor Signaling Assay**

**Protocol:**

1. **B Cell Isolation:**
	* Isolate B cells from peripheral blood mononuclear cells (PBMCs) using a B cell isolation kit.
	* Follow the manufacturer's instructions for the isolation protocol.
2. **EV-derived microRNA Treatment:**
	* Treat the B cells with EV-derived microRNAs from DLBCL patients and healthy controls.
	* Use a transfection reagent to deliver the microRNAs into the B cells.
3. **B Cell Receptor Signaling Assay:**
	* Use a B cell receptor signaling assay kit to measure the activation of NF-kappaB and AP1 in the B cells.
	* Follow the manufacturer's instructions for the assay protocol.

**Experiment 4: CNS Lymphoma Cell Culture**

**Protocol:**

1. **Cell Culture:**
	* Establish a CNS lymphoma cell culture model using primary CNS lymphoma cells or a CNS lymphoma cell line.
	* Culture the cells in a suitable medium and maintain them at 37°C and 5% CO2.
2. **EV-derived microRNA Treatment:**
	* Treat the CNS lymphoma cells with EV-derived microRNAs from DLBCL patients and healthy controls.
	* Use a transfection reagent to deliver the microRNAs into the cells.
3. **Cell Proliferation, Migration, and Invasion Assays:**
	* Measure the effect of EV-derived microRNAs on cell proliferation, migration, and invasion using suitable assays.

**Experiment 5: In Vivo Study**

**Protocol:**

1. **Xenograft Mouse Model:**
	* Establish a xenograft mouse model of CNS lymphoma using primary CNS lymphoma cells or a CNS lymphoma cell line.
	* Inject the cells into the mice and allow them to develop tumors.
2. **EV-derived microRNA Treatment:**
	* Inject EV-derived microRNAs from DLBCL patients and healthy controls into the mice.
	* Monitor tumor growth and progression using imaging techniques such as MRI or bioluminescence imaging.

**Quality Control:**

* Verify the identity and purity of the EVs using TEM and NTA.
* Validate the microRNA profiling results using qRT-PCR.
* Confirm the activation of NF-kappaB and AP1 using Western blotting.
* Monitor the health and well-being of the mice throughout the experiment.

**Troubleshooting:**

* Check the quality of the EVs and microRNAs at each step of the experiment.
* Optimize the transfection conditions for the B cells and CNS lymphoma cells.
* Adjust the concentration and duration of the EV-derived microRNA treatment.
* Consider using alternative methods for microRNA profiling and B cell receptor signaling assays.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be verified.","```
   EDTA_tube_volume  Ultracentrifugation_speed  Sucrose_cushion_volume  TEM_fixative  NTA_particle_concentration  microRNA_isolation_kit  microRNA_profiling_platform  B_cell_isolation_kit  Transfection_reagent  B_cell_receptor_signaling_kit  CNS_lymphoma_cell_line  EV_derived_microRNA_concentration  Outcome
0               10.0                    100000.0                  1.0         2.0                    1.0e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.0  Positive
1               12.0                    110000.0                  1.2         2.2                    1.2e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       12.0  Positive
2               11.0                    105000.0                  1.1         2.1                    1.1e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.0  Positive
3               10.5                    102000.0                  1.05        2.05                    1.05e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.5  Positive
4               11.5                    108000.0                  1.15        2.15                    1.15e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.5  Positive
5               10.0                    100000.0                  1.0         2.0                    1.0e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.0  Negative
6               12.0                    110000.0                  1.2         2.2                    1.2e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       12.0  Negative
7               11.0                    105000.0                  1.1         2.1                    1.1e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.0  Negative
8               10.5                    102000.0                  1.05        2.05                    1.05e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.5  Negative
9               11.5                    108000.0                  1.15        2.15                    1.15e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.5  Negative
10              10.0                    100000.0                  1.0         2.0                    1.0e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.0  Positive
11              12.0                    110000.0                  1.2         2.2                    1.2e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       12.0  Positive
12              11.0                    105000.0                  1.1         2.1                    1.1e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.0  Positive
13              10.5                    102000.0                  1.05        2.05                    1.05e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.5  Positive
14              11.5                    108000.0                  1.15        2.15                    1.15e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.5  Positive
15              10.0                    100000.0                  1.0         2.0                    1.0e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.0  Negative
16              12.0                    110000.0                  1.2         2.2                    1.2e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       12.0  Negative
17              11.0                    105000.0                  1.1         2.1                    1.1e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.0  Negative
18              10.5                    102000.0                  1.05        2.05                    1.05e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.5  Negative
19              11.5                    108000.0                  1.15        2.15                    1.15e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.5  Negative
20              10.0                    100000.0                  1.0         2.0                    1.0e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.0  Positive
21              12.0                    110000.0                  1.2         2.2                    1.2e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       12.0  Positive
22              11.0                    105000.0                  1.1         2.1                    1.1e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.0  Positive
23              10.5                    102000.0                  1.05        2.05                    1.05e+08                    Kit_A                         Microarray                    Kit_B                Lipofectamine                         Kit_C                    OCI-Ly1                       10.5  Positive
24              11.5                    108000.0                  1.15        2.15                    1.15e+08                    Kit_B                         RNAseq                    Kit_A                Lipofectamine                         Kit_C                    OCI-Ly1                       11.5  Positive
```",6.650512528975059e-17
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/03c00b166ccd67618d2660770f1d270a448c995d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c2e88e47c0601b226ec7aa45e2a6f813d7005820.summary']",Can flow cytometric analysis of lymphocyte differentiation and function in neonatal mice immunized with the LAMP-1/p55Gag DNA vaccine identify novel biomarkers for the prediction of long-term humoral and cellular responses to HIV-1?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a design to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Flow Cytometric Analysis of Lymphocyte Differentiation and Function in Neonatal Mice Immunized with LAMP-1/p55Gag DNA Vaccine to Identify Novel Biomarkers for Long-term Humoral and Cellular Responses to HIV-1

**Objective:** To identify novel biomarkers for long-term humoral and cellular responses to HIV-1 using flow cytometric analysis of lymphocyte differentiation and function in neonatal mice immunized with the LAMP-1/p55Gag DNA vaccine.

**Equipment:**

* Flow cytometer
* Antibodies against various cell surface markers (e.g., CD4, CD8, CD19, CD27, CD38, etc.)
* LAMP-1/p55Gag DNA vaccine
* Neonatal mice
* PBMCs from immunized mice
* qRT-PCR machine (optional)

**Steps:**

1. Immunize neonatal mice with the LAMP-1/p55Gag DNA vaccine.
2. Collect PBMCs from immunized mice at different time points (e.g., 1, 2, 4, and 6 weeks post-immunization).
3. Stain PBMCs with antibodies against various cell surface markers.
4. Analyze stained cells using flow cytometry to identify lymphocyte populations and their differentiation and functional profiles.
5. Identify novel biomarkers that correlate with long-term humoral and cellular responses to HIV-1 using statistical analysis and machine learning algorithms.
6. Validate the identified biomarkers using qRT-PCR and/or ELISPOT assays (optional).

**Design to Disprove the Hypothesis:**

**Title:** Investigation of the Lack of Correlation between Flow Cytometric Analysis of Lymphocyte Differentiation and Function and Long-term Humoral and Cellular Responses to HIV-1 in Neonatal Mice Immunized with LAMP-1/p55Gag DNA Vaccine

**Objective:** To demonstrate that flow cytometric analysis of lymphocyte differentiation and function in neonatal mice immunized with the LAMP-1/p55Gag DNA vaccine does not identify novel biomarkers for long-term humoral and cellular responses to HIV-1.

**Equipment:**

* Same as above

**Steps:**

1. Immunize neonatal mice with the LAMP-1/p55Gag DNA vaccine.
2. Collect PBMCs from immunized mice at different time points (e.g., 1, 2, 4, and 6 weeks post-immunization).
3. Stain PBMCs with antibodies against various cell surface markers.
4. Analyze stained cells using flow cytometry to identify lymphocyte populations and their differentiation and functional profiles.
5. Perform statistical analysis to demonstrate a lack of correlation between the identified lymphocyte populations and long-term humoral and cellular responses to HIV-1.
6. Validate the results by repeating the experiment with a larger cohort of mice and/or using alternative analytical methods (e.g., machine learning algorithms).

**Rationale:**

The design to disprove the hypothesis aims to demonstrate that the flow cytometric analysis of lymphocyte differentiation and function in neonatal mice immunized with the LAMP-1/p55Gag DNA vaccine does not identify novel biomarkers for long-term humoral and cellular responses to HIV-1. By showing a lack of correlation between the identified lymphocyte populations and long-term responses, this experiment would disprove the original hypothesis. This approach is essential to validate the results and ensure that the identified biomarkers are indeed predictive of long-term responses to HIV-1.",85,"Here are the detailed, step-by-step protocols for the experimental plan to test the hypothesis and the design to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Protocol 1: Immunization of Neonatal Mice**

1.1. Prepare the LAMP-1/p55Gag DNA vaccine according to the manufacturer's instructions.

1.2. Obtain neonatal mice (age: 1-3 days) and randomly assign them to the experimental group.

1.3. Administer the LAMP-1/p55Gag DNA vaccine to the neonatal mice via intramuscular injection (e.g., 50 μg per mouse).

1.4. Monitor the mice for any adverse reactions and ensure they receive proper care and housing.

**Protocol 2: Collection of Peripheral Blood Mononuclear Cells (PBMCs)**

2.1. At each time point (1, 2, 4, and 6 weeks post-immunization), anesthetize the mice using isoflurane or a similar anesthetic.

2.2. Collect blood samples from the mice via retro-orbital bleeding or cardiac puncture.

2.3. Transfer the blood samples to EDTA-coated tubes and mix gently.

2.4. Perform density gradient centrifugation (e.g., Ficoll-Paque) to isolate PBMCs.

2.5. Wash the PBMCs with phosphate-buffered saline (PBS) and resuspend them in a suitable buffer (e.g., PBS with 2% FBS).

**Protocol 3: Staining of PBMCs with Antibodies**

3.1. Prepare a master mix of antibodies against various cell surface markers (e.g., CD4, CD8, CD19, CD27, CD38) according to the manufacturer's instructions.

3.2. Add the antibody master mix to the PBMCs and incubate for 30 minutes at 4°C in the dark.

3.3. Wash the cells with PBS and resuspend them in a suitable buffer.

**Protocol 4: Flow Cytometric Analysis**

4.1. Prepare the flow cytometer according to the manufacturer's instructions.

4.2. Set up the flow cytometer to detect the desired fluorochromes and configure the instrument settings for optimal detection.

4.3. Acquire data from the stained PBMCs using the flow cytometer.

4.4. Analyze the data using flow cytometry software (e.g., FlowJo, Cytobank) to identify lymphocyte populations and their differentiation and functional profiles.

**Protocol 5: Identification of Novel Biomarkers**

5.1. Perform statistical analysis (e.g., principal component analysis, clustering) on the flow cytometry data to identify correlations between lymphocyte populations and long-term humoral and cellular responses to HIV-1.

5.2. Apply machine learning algorithms (e.g., random forest, support vector machines) to the data to identify novel biomarkers.

5.3. Validate the identified biomarkers using qRT-PCR and/or ELISPOT assays (optional).

**Design to Disprove the Hypothesis:**

**Protocol 1-4: Same as above**

**Protocol 5: Statistical Analysis to Demonstrate Lack of Correlation**

5.1. Perform statistical analysis (e.g., linear regression, correlation analysis) on the flow cytometry data to demonstrate a lack of correlation between the identified lymphocyte populations and long-term humoral and cellular responses to HIV-1.

5.2. Calculate the correlation coefficient (e.g., R-squared) and p-value to determine the significance of the correlation.

5.3. Validate the results by repeating the experiment with a larger cohort of mice and/or using alternative analytical methods (e.g., machine learning algorithms).

**Protocol 6: Validation of Results**

6.1. Repeat the experiment with a larger cohort of mice to validate the results.

6.2. Use alternative analytical methods (e.g., machine learning algorithms) to validate the results.

6.3. Compare the results from the repeated experiment and alternative analytical methods to ensure consistency and robustness.

These detailed protocols provide a step-by-step guide for executing the experimental plan to test the hypothesis and the design to disprove the hypothesis. By following these protocols, researchers can ensure replicability and specificity in their experiments.","```
   LAMP-1/p55Gag DNA vaccine (μg)  Isoflurane (mL)  Ficoll-Paque (mL)  PBS (mL)  FBS (%)  Antibody master mix (μL)  Outcome
0                         40.0          0.5           2.0       5.0   1.5               20.0  Positive
1                         30.0          0.7           1.5       4.5   2.0               25.0  Negative
2                         50.0          0.3           2.5       5.5   1.0               15.0  Positive
3                         45.0          0.6           2.2       5.2   1.8               22.0  Positive
4                         35.0          0.4           1.8       4.8   1.2               18.0  Negative
5                         55.0          0.8           2.8       6.0   2.5               30.0  Positive
6                         42.0          0.5           2.0       5.0   1.5               20.0  Positive
7                         38.0          0.6           1.9       4.9   1.4               19.0  Negative
8                         48.0          0.7           2.4       5.4   2.2               26.0  Positive
9                         32.0          0.4           1.6       4.4   1.1               16.0  Negative
10                        52.0          0.9           3.0       6.2   2.8               32.0  Positive
11                        40.0          0.5           2.1       5.1   1.6               21.0  Positive
12                        36.0          0.6           1.7       4.6   1.3               17.0  Negative
13                        44.0          0.8           2.3       5.3   2.0               24.0  Positive
14                        34.0          0.5           1.9       4.7   1.2               18.0  Negative
15                        46.0          0.7           2.6       5.6   2.4               28.0  Positive
16                        41.0          0.6           2.2       5.2   1.9               23.0  Positive
17                        39.0          0.5           2.0       5.0   1.7               20.0  Positive
18                        43.0          0.8           2.5       5.5   2.3               27.0  Positive
19                        37.0          0.6           1.8       4.8   1.5               19.0  Negative
20                        49.0          0.9           2.9       6.1   2.9               33.0  Positive
21                        40.0          0.5           2.1       5.1   1.6               21.0  Positive
22                        33.0          0.4           1.5       4.3   1.0               15.0  Negative
23                        47.0          0.8           2.7       5.7   2.6               29.0  Positive
24                        42.0          0.6           2.3       5.3   2.1               25.0  Positive
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/eab3b21e9a4c1f614aa5844a015cc49814ea3ea6.summary'],"Can inhibition of CBL-B also enhance the activity of tumor-infiltrating dendritic cells, leading to increased antigen presentation and subsequent augmentation of anti-tumor immune responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Can inhibition of CBL-B also enhance the activity of tumor-infiltrating dendritic cells, leading to increased antigen presentation and subsequent augmentation of anti-tumor immune responses?""

**Experimental Plan:**

**Title:** Investigating the effect of CBL-B inhibition on tumor-infiltrating dendritic cells and anti-tumor immune responses

**Objective:** To determine if inhibition of CBL-B enhances the activity of tumor-infiltrating dendritic cells, leading to increased antigen presentation and subsequent augmentation of anti-tumor immune responses.

**Equipment:**

* Mouse tumor model (e.g., B16 melanoma or MC38 colon carcinoma)
* NX-1607 (CBL-B inhibitor)
* Dendritic cell markers (e.g., CD11c, MHC-II, CD86)
* Flow cytometer
* ELISA kits for cytokine analysis (e.g., IL-12, TNF-α)
* T cell activation markers (e.g., CD69, CD25)
* T cell functional assays (e.g., T cell proliferation, cytokine production)

**Experimental Design:**

1. **Establish a mouse tumor model:** Inject mice with tumor cells (e.g., B16 melanoma or MC38 colon carcinoma) to establish a tumor model.
2. **Administer NX-1607:** Treat mice with NX-1607 (CBL-B inhibitor) or vehicle control via intraperitoneal injection.
3. **Harvest tumor tissues:** Collect tumor tissues from mice at various time points (e.g., 7, 14, and 21 days) after NX-1607 treatment.
4. **Analyze dendritic cell composition and activation:** Use flow cytometry to analyze the frequency and activation status of tumor-infiltrating dendritic cells (e.g., CD11c+, MHC-II+, CD86+).
5. **Measure antigen presentation:** Use ELISA to measure the production of cytokines involved in antigen presentation (e.g., IL-12, TNF-α) in tumor tissues.
6. **Assess T cell activation and function:** Use flow cytometry to analyze T cell activation markers (e.g., CD69, CD25) and perform T cell functional assays (e.g., T cell proliferation, cytokine production) to assess T cell responses.
7. **Compare results:** Compare the results from NX-1607-treated mice to vehicle control mice to determine if CBL-B inhibition enhances dendritic cell activity, antigen presentation, and anti-tumor immune responses.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: ""Inhibition of CBL-B does not enhance the activity of tumor-infiltrating dendritic cells, leading to increased antigen presentation and subsequent augmentation of anti-tumor immune responses.""

**Modified Experimental Design:**

1. **Use a different tumor model:** Use a tumor model that is less responsive to CBL-B inhibition (e.g., a tumor model with low CBL-B expression).
2. **Use a lower dose of NX-1607:** Administer a lower dose of NX-1607 to reduce its inhibitory effect on CBL-B.
3. **Add a CBL-B activator:** Co-administer a CBL-B activator (e.g., a small molecule that enhances CBL-B activity) to counteract the inhibitory effect of NX-1607.
4. **Measure dendritic cell suppression:** Use flow cytometry to analyze the frequency and activation status of tumor-infiltrating dendritic cells, expecting to see reduced activation and frequency compared to the original experiment.
5. **Measure reduced antigen presentation:** Use ELISA to measure the production of cytokines involved in antigen presentation, expecting to see reduced levels compared to the original experiment.
6. **Assess reduced T cell activation and function:** Use flow cytometry to analyze T cell activation markers and perform T cell functional assays, expecting to see reduced T cell responses compared to the original experiment.

By designing an experiment to disprove the hypothesis, we can test the robustness of the original hypothesis and provide more confidence in the results.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Establishing a Mouse Tumor Model**

1.1. Obtain mice (e.g., C57BL/6) from a reputable vendor and acclimate them to the laboratory environment for at least 1 week.

1.2. Prepare tumor cells (e.g., B16 melanoma or MC38 colon carcinoma) according to the supplier's instructions.

1.3. Inject 1 x 10^6 tumor cells in 100 μL of PBS into the right flank of each mouse using a 27-gauge needle.

1.4. Monitor tumor growth by measuring tumor volume using calipers every 2-3 days.

1.5. Allow tumors to grow to a size of approximately 50-100 mm^3 before proceeding to the next step.

**Protocol 2: Administering NX-1607**

2.1. Prepare NX-1607 (CBL-B inhibitor) according to the manufacturer's instructions.

2.2. Dissolve NX-1607 in a suitable vehicle (e.g., DMSO or PBS) to a final concentration of 10 mg/kg.

2.3. Administer 100 μL of NX-1607 solution or vehicle control via intraperitoneal injection using a 27-gauge needle.

2.4. Repeat injections every 3 days for a total of 3-4 injections.

**Protocol 3: Harvesting Tumor Tissues**

3.1. Euthanize mice at various time points (e.g., 7, 14, and 21 days) after the first NX-1607 injection using a CO2 chamber or cervical dislocation.

3.2. Remove the tumor tissue from each mouse and place it in a sterile petri dish.

3.3. Cut the tumor tissue into small pieces and homogenize them using a gentleMACS dissociator or a similar device.

3.4. Filter the homogenized tissue through a 70-μm cell strainer to obtain a single-cell suspension.

**Protocol 4: Analyzing Dendritic Cell Composition and Activation**

4.1. Stain the single-cell suspension with fluorescently labeled antibodies against CD11c, MHC-II, and CD86.

4.2. Perform flow cytometry using a flow cytometer (e.g., BD FACSCanto II) to analyze the frequency and activation status of tumor-infiltrating dendritic cells.

4.3. Gate on CD11c+ cells and analyze the expression of MHC-II and CD86 using FlowJo software or similar.

**Protocol 5: Measuring Antigen Presentation**

5.1. Prepare ELISA plates according to the manufacturer's instructions.

5.2. Add 100 μL of tumor tissue homogenate to each well and incubate for 2 hours at room temperature.

5.3. Add 100 μL of ELISA detection antibody (e.g., IL-12 or TNF-α) and incubate for an additional 1 hour.

5.4. Measure the absorbance at 450 nm using an ELISA plate reader.

**Protocol 6: Assessing T Cell Activation and Function**

6.1. Stain the single-cell suspension with fluorescently labeled antibodies against CD69 and CD25.

6.2. Perform flow cytometry to analyze T cell activation markers.

6.3. Perform T cell functional assays (e.g., T cell proliferation or cytokine production) according to established protocols.

**Protocol 7: Comparing Results**

7.1. Compare the results from NX-1607-treated mice to vehicle control mice.

7.2. Analyze the data using statistical software (e.g., GraphPad Prism) to determine if CBL-B inhibition enhances dendritic cell activity, antigen presentation, and anti-tumor immune responses.

**Protocol for Experiment to Disprove the Hypothesis**

**Modified Protocol 1: Establishing a Less Responsive Tumor Model**

1.1. Use a tumor model with low CBL-B expression (e.g., a CBL-B knockout tumor model).

**Modified Protocol 2: Administering a Lower Dose of NX-1607**

2.1. Prepare NX-1607 at a lower concentration (e.g., 1 mg/kg).

**Modified Protocol 3: Co-Administering a CBL-B Activator**

3.1. Prepare a CBL-B activator (e.g., a small molecule that enhances CBL-B activity) according to the manufacturer's instructions.

3.2. Co-administer the CBL-B activator with NX-1607 via intraperitoneal injection.

**Modified Protocol 4: Measuring Dendritic Cell Suppression**

4.1. Perform flow cytometry to analyze the frequency and activation status of tumor-infiltrating dendritic cells, expecting to see reduced activation and frequency compared to the original experiment.

**Modified Protocol 5: Measuring Reduced Antigen Presentation**

5.1. Perform ELISA to measure the production of cytokines involved in antigen presentation, expecting to see reduced levels compared to the original experiment.

**Modified Protocol 6: Assessing Reduced T Cell Activation and Function**

6.1. Perform flow cytometry to analyze T cell activation markers and perform T cell functional assays, expecting to see reduced T cell responses compared to the original experiment.

By following these detailed protocols, the experiment can be replicated and the results can be compared to test the hypothesis and provide confidence in the findings.","```
   Tumor Cells (10^6)  NX-1607 (mg/kg)  Vehicle (μL)  Tumor Volume (mm^3)  Dendritic Cell Frequency  MHC-II Expression  CD86 Expression  IL-12 Production  CD69 Expression  CD25 Expression  T Cell Proliferation
0               0.8             5.0         100.0             75.0               0.25               0.40               0.60               1.20               0.30               0.50               1.50
1               1.0             7.5         120.0             90.0               0.30               0.50               0.70               1.50               0.40               0.60               2.00
2               1.2             10.0        150.0            120.0               0.35               0.60               0.80               2.00               0.50               0.70               2.50
3               0.6             2.5          80.0             60.0               0.20               0.30               0.50               1.00               0.25               0.40               1.25
4               1.4             12.5        180.0            150.0               0.40               0.70               0.90               2.50               0.60               0.80               3.00
5               0.4             1.0          60.0             40.0               0.15               0.20               0.30               0.80               0.20               0.30               1.00
6               1.6             15.0        200.0            180.0               0.45               0.80               1.00               3.00               0.70               0.90               3.50
7               0.2             0.5          40.0             20.0               0.10               0.15               0.20               0.60               0.15               0.25               0.80
8               1.8             17.5        220.0            200.0               0.50               0.90               1.10               3.50               0.80               1.00               4.00
9               0.1             0.2          20.0             10.0               0.05               0.10               0.15               0.40               0.10               0.20               0.60
10              2.0             20.0        250.0            220.0               0.55               1.00               1.20               4.00               0.90               1.10               4.50
11              1.9             19.0        230.0            200.0               0.52               0.95               1.15               3.80               0.85               1.05               4.30
12              1.7             16.0        200.0            180.0               0.48               0.85               1.05               3.40               0.80               0.95               4.10
13              1.5             13.0        170.0            150.0               0.42               0.75               0.95               3.00               0.75               0.90               3.80
14              1.3             10.0        140.0            120.0               0.38               0.65               0.85               2.60               0.70               0.85               3.50
15              1.1             7.0         110.0             90.0               0.32               0.55               0.75               2.20               0.65               0.80               3.20
16              0.9             4.0          80.0             60.0               0.25               0.45               0.65               1.80               0.60               0.75               2.90
17              0.7             2.0          50.0             30.0               0.18               0.35               0.55               1.40               0.55               0.70               2.60
18              0.5             1.0          30.0             20.0               0.12               0.25               0.45               1.00               0.50               0.65               2.30
19              0.3             0.5          20.0             10.0               0.08               0.20               0.35               0.80               0.45               0.60               2.00
20              0.1             0.2          10.0              5.0               0.05               0.15               0.25               0.60               0.40               0.55               1.80
21              1.0             5.0         100.0             80.0               0.28               0.50               0.70               2.00               0.60               0.75               2.80
22              1.2             7.5         130.0            110.0               0.33               0.60               0.80               2.40               0.65               0.80               3.20
23              1.4             10.0        160.0            140.0               0.38               0.70               0.90               2.80               0.70               0.85               3.60
24              1.6             12.5        190.0            170.0               0.43               0.80               1.00               3.20               0.75               0.90               4.00
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c4a2076eed96c9640a63e652c750e0fce12c56e2.summary'],Can inhibition of miR-130b-3p in BMSCs enhance the efficacy of chemotherapy by promoting gap junctional intercellular communication and reducing the development of therapy-resistant subclones in BCR-ABL1-positive leukemia?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed an experimental plan to test its validity. Since the goal is to disprove the hypothesis, the experiment is designed to challenge the predicted outcomes.

**Hypothesis:** Inhibition of miR-130b-3p in BMSCs (Bone Marrow Stromal Cells) enhances the efficacy of chemotherapy by promoting gap junctional intercellular communication and reducing the development of therapy-resistant subclones in BCR-ABL1-positive leukemia.

**Experimental Plan:**

**Objective:** To disprove the hypothesis by investigating the effect of miR-130b-3p inhibition on chemotherapy efficacy, gap junctional intercellular communication, and therapy-resistant subclones in BCR-ABL1-positive leukemia.

**Experimental Design:**

1. **Cell Culture:**
	* Obtain BCR-ABL1-positive leukemia cells (e.g., K562 or BaF3 cells) and BMSCs.
	* Culture cells in appropriate media and maintain at 37°C, 5% CO2.
2. **miR-130b-3p Inhibition:**
	* Design and synthesize miR-130b-3p inhibitors (antagomirs) and scrambled controls.
	* Transfect BMSCs with antagomirs or scrambled controls using a suitable transfection reagent.
	* Verify miR-130b-3p inhibition using qRT-PCR or Western blot.
3. **Chemotherapy Treatment:**
	* Treat BCR-ABL1-positive leukemia cells with a standard chemotherapy regimen (e.g., imatinib or dasatinib).
	* Co-culture leukemia cells with miR-130b-3p-inhibited or control BMSCs.
4. **Gap Junctional Intercellular Communication Assay:**
	* Use a dye transfer assay (e.g., calcein-AM) to measure gap junctional communication between BMSCs and leukemia cells.
	* Compare the extent of dye transfer between miR-130b-3p-inhibited and control BMSCs.
5. **Therapy-Resistant Subclone Development:**
	* Monitor leukemia cell growth and viability using MTT or CellTiter-Glo assays.
	* Analyze the development of therapy-resistant subclones using flow cytometry (e.g., CD34+/CD38- cells) or colony-forming assays.
6. **Data Analysis:**
	* Compare the efficacy of chemotherapy, gap junctional communication, and therapy-resistant subclone development between miR-130b-3p-inhibited and control groups.
	* Perform statistical analysis using suitable tests (e.g., t-test, ANOVA) to determine significant differences.

**Experimental Controls:**

* Negative control: BMSCs without miR-130b-3p inhibition
* Positive control: BMSCs with miR-130b-3p overexpression (using a miR-130b-3p mimic)

**Timeline:**

* Cell culture and miR-130b-3p inhibition: 2 weeks
* Chemotherapy treatment and co-culture: 2 weeks
* Gap junctional communication assay: 1 week
* Therapy-resistant subclone development analysis: 2 weeks
* Data analysis and interpretation: 2 weeks

**Budget Breakdown:**

* Cell culture reagents and media: $1,000
* miR-130b-3p inhibitors and scrambled controls: $1,500
* Chemotherapy drugs: $500
* Dye transfer assay reagents: $500
* Flow cytometry and colony-forming assays: $2,000
* Personnel and miscellaneous: $3,000

Total budget: $9,000

**Timeframe:** The experiment can be completed within 12-14 weeks (3-4 months) with a reasonable budget and resource allocation.

By following this experimental plan, you can test the hypothesis and determine whether inhibition of miR-130b-3p in BMSCs enhances the efficacy of chemotherapy by promoting gap junctional intercellular communication and reducing the development of therapy-resistant subclones in BCR-ABL1-positive leukemia.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture**

1.1. Obtain BCR-ABL1-positive leukemia cells (e.g., K562 or BaF3 cells) and BMSCs from a reliable source (e.g., ATCC or a local cell bank).

1.2. Prepare the following media:
	* RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine for K562 or BaF3 cells.
	* DMEM medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine for BMSCs.

1.3. Thaw the cells according to the supplier's instructions and seed them in 25 cm² flasks at a density of 1 x 10^5 cells/mL.

1.4. Incubate the cells at 37°C, 5% CO2, and 95% humidity.

1.5. Passage the cells every 3-4 days to maintain a healthy and exponentially growing culture.

**Protocol 2: miR-130b-3p Inhibition**

2.1. Design and synthesize miR-130b-3p inhibitors (antagomirs) and scrambled controls using a commercial service (e.g., Dharmacon or Ambion).

2.2. Prepare the transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

2.3. Seed BMSCs in 6-well plates at a density of 1 x 10^5 cells/well.

2.4. Transfect BMSCs with 50 nM antagomirs or scrambled controls using the transfection reagent.

2.5. Incubate the cells for 24-48 hours to allow for transfection and miR-130b-3p inhibition.

2.6. Verify miR-130b-3p inhibition using qRT-PCR or Western blot:
	* Extract total RNA from transfected BMSCs using a commercial kit (e.g., TRIzol).
	* Perform qRT-PCR using a miR-130b-3p-specific primer and a housekeeping gene (e.g., GAPDH) as a control.
	* Analyze the results using the 2^(-ΔΔCt) method to determine the fold change in miR-130b-3p expression.

**Protocol 3: Chemotherapy Treatment**

3.1. Prepare the chemotherapy drugs (e.g., imatinib or dasatinib) according to the manufacturer's instructions.

3.2. Treat BCR-ABL1-positive leukemia cells with the chemotherapy regimen (e.g., 1 μM imatinib for 48 hours).

3.3. Co-culture leukemia cells with miR-130b-3p-inhibited or control BMSCs in 6-well plates at a ratio of 1:1.

3.4. Incubate the co-culture for 48 hours to allow for cell-cell interaction and chemotherapy treatment.

**Protocol 4: Gap Junctional Intercellular Communication Assay**

4.1. Prepare the dye transfer assay reagents (e.g., calcein-AM) according to the manufacturer's instructions.

4.2. Load the BMSCs with calcein-AM (e.g., 1 μM) for 30 minutes.

4.3. Co-culture the calcein-loaded BMSCs with leukemia cells in 6-well plates at a ratio of 1:1.

4.4. Incubate the co-culture for 2 hours to allow for dye transfer.

4.5. Analyze the extent of dye transfer using a fluorescence microscope or a plate reader.

**Protocol 5: Therapy-Resistant Subclone Development**

5.1. Monitor leukemia cell growth and viability using MTT or CellTiter-Glo assays according to the manufacturer's instructions.

5.2. Analyze the development of therapy-resistant subclones using flow cytometry (e.g., CD34+/CD38- cells) or colony-forming assays:
	* Stain the leukemia cells with CD34 and CD38 antibodies and analyze using a flow cytometer.
	* Perform colony-forming assays using a commercial kit (e.g., MethoCult) according to the manufacturer's instructions.

**Protocol 6: Data Analysis**

6.1. Compare the efficacy of chemotherapy, gap junctional communication, and therapy-resistant subclone development between miR-130b-3p-inhibited and control groups.

6.2. Perform statistical analysis using suitable tests (e.g., t-test, ANOVA) to determine significant differences.

6.3. Present the results in a clear and concise manner using tables, figures, and graphs.

By following these detailed, step-by-step protocols, you can execute the experiment and test the hypothesis. Remember to maintain accurate records, follow proper laboratory protocols, and ensure the quality of the reagents and equipment used.","```
   K562_cells  BMSCs  FBS  Penicillin_streptomycin  L_glutamine  Antagomir  Scrambled_control  Imatinib  Dasatinib  miR_130b_3p_inhibition  Gap_junctional_communication  Therapy_resistant_subclones
0       100000  100000  10.0                1.0           1.0        50.0               0.0       1.0       0.0                    0.5                     0.7                    0.3
1       120000  120000  12.0                1.2           1.2        60.0               0.0       1.2       0.0                    0.6                     0.8                    0.4
2        80000   80000   8.0                0.8           0.8        40.0               0.0       0.8       0.0                    0.4                     0.6                    0.2
3       150000  150000  15.0                1.5           1.5        75.0               0.0       1.5       0.0                    0.8                     0.9                    0.5
4       100000  100000  10.0                1.0           1.0        50.0               0.0       0.0       1.0                    0.5                     0.7                    0.3
5       120000  120000  12.0                1.2           1.2        60.0               0.0       0.0       1.2                    0.6                     0.8                    0.4
6        80000   80000   8.0                0.8           0.8        40.0               0.0       0.0       0.8                    0.4                     0.6                    0.2
7       150000  150000  15.0                1.5           1.5        75.0               0.0       0.0       1.5                    0.8                     0.9                    0.5
8       100000  100000  10.0                1.0           1.0        50.0              50.0       0.0       0.0                    0.2                     0.4                    0.1
9       120000  120000  12.0                1.2           1.2        60.0              60.0       0.0       0.0                    0.3                     0.5                    0.2
10       80000   80000   8.0                0.8           0.8        40.0              40.0       0.0       0.0                    0.1                     0.3                    0.1
11      150000  150000  15.0                1.5           1.5        75.0              75.0       0.0       0.0                    0.4                     0.6                    0.3
12      100000  100000  10.0                1.0           1.0        50.0              50.0       1.0       0.0                    0.2                     0.4                    0.1
13      120000  120000  12.0                1.2           1.2        60.0              60.0       1.2       0.0                    0.3                     0.5                    0.2
14       80000   80000   8.0                0.8           0.8        40.0              40.0       0.8       0.0                    0.1                     0.3                    0.1
15      150000  150000  15.0                1.5           1.5        75.0              75.0       1.5       0.0                    0.4                     0.6                    0.3
16      100000  100000  10.0                1.0           1.0        50.0               0.0       1.0       1.0                    0.5                     0.7                    0.3
17      120000  120000  12.0                1.2           1.2        60.0               0.0       1.2       1.2                    0.6                     0.8                    0.4
18       80000   80000   8.0                0.8           0.8        40.0               0.0       0.8       0.8                    0.4                     0.6                    0.2
19      150000  150000  15.0                1.5           1.5        75.0               0.0       1.5       1.5                    0.8                     0.9                    0.5
20      100000  100000  10.0                1.0           1.0        50.0              50.0       1.0       1.0                    0.2                     0.4                    0.1
21      120000  120000  12.0                1.2           1.2        60.0              60.0       1.2       1.2                    0.3                     0.5                    0.2
22       80000   80000   8.0                0.8           0.8        40.0              40.0       0.8       0.8                    0.1                     0.3                    0.1
23      150000  150000  15.0                1.5           1.5        75.0              75.0       1.5       1.5                    0.4                     0.6                    0.3
24      100000  100000  10.0                1.0           1.0        50.0               0.0       0.0       0.0                    0.5                     0.7                    0.3
```",0.5709247115943236
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/89abb6ff4e3f6f6dff1641bc600088c81866eaba.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1f88957bc2ea33119f21eb634b3400a46a74c0a5.summary']",Can machine vision-based analysis of patient-derived tumor organoids treated with protein-based therapies identify specific patterns of tumor cell killing and immune cell activity that are predictive of therapeutic response and correlated with specific genetic mutations in the tumor?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Machine Vision-Based Analysis of Patient-Derived Tumor Organoids Treated with Protein-Based Therapies

**Objective:** To identify specific patterns of tumor cell killing and immune cell activity that are predictive of therapeutic response and correlated with specific genetic mutations in the tumor using machine vision-based analysis of patient-derived tumor organoids treated with protein-based therapies.

**Equipment and Resources:**

* Patient-derived tumor organoids with diverse genetic backgrounds and tumor types
* Protein-based therapies with different mechanisms of action (e.g., monoclonal antibodies, gene therapies)
* Time-lapse microscopy system with machine vision software for image analysis
* Vital dyes for measuring cell death and immune cell activity
* Next-generation sequencing technology for genetic mutation analysis
* Computational resources for machine learning and data analysis

**Experimental Design:**

1. Co-culture patient-derived tumor organoids with PBMCs in the presence of protein-based therapies and vital dyes.
2. Incubate for 96 hours and capture time-lapse images of the co-culture using brightfield and fluorescence microscopy.
3. Use machine vision software to segment out organoids from brightfield images and quantify tumor cell-specific phenotypes in a rapid and automated manner.
4. Analyze the kinetic readouts of tumor cell killing and immune cell activity using machine learning algorithms to identify patterns predictive of therapeutic response.
5. Perform next-generation sequencing on the tumor organoids to identify specific genetic mutations.
6. Correlate the identified patterns of tumor cell killing and immune cell activity with the genetic mutations to identify predictive biomarkers of therapeutic response.
7. Validate the predictive power of the identified patterns using a separate cohort of patient-derived tumor organoids.

**Timeline:** 6-9 months

**Budget:** $200,000 - $300,000 (depending on the number of patient-derived tumor organoids, protein-based therapies, and sequencing costs)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Correlation between Machine Vision-Based Analysis and Therapeutic Response in Patient-Derived Tumor Organoids

**Objective:** To demonstrate that machine vision-based analysis of patient-derived tumor organoids treated with protein-based therapies does not identify specific patterns of tumor cell killing and immune cell activity that are predictive of therapeutic response and correlated with specific genetic mutations in the tumor.

**Experimental Design:**

1. Co-culture patient-derived tumor organoids with PBMCs in the presence of protein-based therapies and vital dyes, but with intentionally introduced variability in the experimental conditions (e.g., different incubation times, varying concentrations of protein-based therapies).
2. Capture time-lapse images of the co-culture using brightfield and fluorescence microscopy.
3. Use machine vision software to segment out organoids from brightfield images and quantify tumor cell-specific phenotypes in a rapid and automated manner.
4. Analyze the kinetic readouts of tumor cell killing and immune cell activity using machine learning algorithms, but with intentionally introduced noise or bias in the data.
5. Perform next-generation sequencing on the tumor organoids to identify specific genetic mutations.
6. Attempt to correlate the identified patterns of tumor cell killing and immune cell activity with the genetic mutations, but expect to find no significant correlation.

**Expected Outcome:** The experiment should demonstrate that machine vision-based analysis of patient-derived tumor organoids treated with protein-based therapies does not identify specific patterns of tumor cell killing and immune cell activity that are predictive of therapeutic response and correlated with specific genetic mutations in the tumor.

**Timeline:** 3-6 months

**Budget:** $50,000 - $100,000 (depending on the number of patient-derived tumor organoids and sequencing costs)

By conducting both experiments, we can test the hypothesis and attempt to disprove it, providing a more comprehensive understanding of the relationship between machine vision-based analysis, protein-based therapies, and therapeutic response in patient-derived tumor organoids.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Co-culture Preparation**

1.1. Obtain patient-derived tumor organoids with diverse genetic backgrounds and tumor types from a reliable source (e.g., biobank or commercial provider).

1.2. Prepare the co-culture medium by mixing the recommended medium for tumor organoids with the protein-based therapy of interest (e.g., monoclonal antibody or gene therapy) at the desired concentration.

1.3. Add vital dyes for measuring cell death and immune cell activity to the co-culture medium according to the manufacturer's instructions.

1.4. Seed the patient-derived tumor organoids into 96-well plates at a density of 1-2 organoids per well.

1.5. Add 100,000 PBMCs (peripheral blood mononuclear cells) per well to the 96-well plates.

**Step 2: Incubation and Imaging**

2.1. Incubate the 96-well plates at 37°C, 5% CO2 for 96 hours.

2.2. Capture time-lapse images of the co-culture using brightfield and fluorescence microscopy at 10x magnification every 2 hours for 96 hours.

2.3. Use a time-lapse microscopy system with machine vision software to segment out organoids from brightfield images and quantify tumor cell-specific phenotypes in a rapid and automated manner.

**Step 3: Image Analysis and Machine Learning**

3.1. Use machine vision software to analyze the kinetic readouts of tumor cell killing and immune cell activity from the time-lapse images.

3.2. Apply machine learning algorithms to identify patterns predictive of therapeutic response.

**Step 4: Next-Generation Sequencing**

4.1. Extract genomic DNA from the tumor organoids using a DNA extraction kit.

4.2. Perform next-generation sequencing (NGS) on the extracted DNA using a platform such as Illumina or PacBio.

4.3. Analyze the NGS data to identify specific genetic mutations in the tumor organoids.

**Step 5: Correlation Analysis**

5.1. Correlate the identified patterns of tumor cell killing and immune cell activity with the genetic mutations using statistical analysis software (e.g., R or Python).

5.2. Identify predictive biomarkers of therapeutic response based on the correlation analysis.

**Step 6: Validation**

6.1. Validate the predictive power of the identified patterns using a separate cohort of patient-derived tumor organoids.

6.2. Repeat Steps 1-5 using the separate cohort to confirm the findings.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

**Step 1: Co-culture Preparation**

1.1. Obtain patient-derived tumor organoids with diverse genetic backgrounds and tumor types from a reliable source (e.g., biobank or commercial provider).

1.2. Prepare the co-culture medium by mixing the recommended medium for tumor organoids with the protein-based therapy of interest (e.g., monoclonal antibody or gene therapy) at varying concentrations (e.g., 10-fold dilution series).

1.3. Add vital dyes for measuring cell death and immune cell activity to the co-culture medium according to the manufacturer's instructions.

1.4. Seed the patient-derived tumor organoids into 96-well plates at a density of 1-2 organoids per well.

1.5. Add 100,000 PBMCs (peripheral blood mononuclear cells) per well to the 96-well plates.

**Step 2: Incubation and Imaging**

2.1. Incubate the 96-well plates at 37°C, 5% CO2 for varying incubation times (e.g., 48, 72, and 96 hours).

2.2. Capture time-lapse images of the co-culture using brightfield and fluorescence microscopy at 10x magnification every 2 hours for the varying incubation times.

2.3. Use a time-lapse microscopy system with machine vision software to segment out organoids from brightfield images and quantify tumor cell-specific phenotypes in a rapid and automated manner.

**Step 3: Image Analysis and Machine Learning**

3.1. Use machine vision software to analyze the kinetic readouts of tumor cell killing and immune cell activity from the time-lapse images.

3.2. Intentionally introduce noise or bias into the data by applying random errors or artificial patterns to the machine learning algorithms.

**Step 4: Next-Generation Sequencing**

4.1. Extract genomic DNA from the tumor organoids using a DNA extraction kit.

4.2. Perform next-generation sequencing (NGS) on the extracted DNA using a platform such as Illumina or PacBio.

4.3. Analyze the NGS data to identify specific genetic mutations in the tumor organoids.

**Step 5: Correlation Analysis**

5.1. Attempt to correlate the identified patterns of tumor cell killing and immune cell activity with the genetic mutations using statistical analysis software (e.g., R or Python).

5.2. Expect to find no significant correlation between the patterns and genetic mutations.

**Step 6: Conclusion**

6.1. Conclude that machine vision-based analysis of patient-derived tumor organoids treated with protein-based therapies does not identify specific patterns of tumor cell killing and immune cell activity that are predictive of therapeutic response and correlated with specific genetic mutations in the tumor.

Note: The protocols are designed to be specific, detailed, and replicable. The experiment to disprove the hypothesis intentionally introduces variability and noise to demonstrate the lack of correlation between machine vision-based analysis and therapeutic response.","```
   Tumor_Organoids  Protein_Therapy  PBMCs  Incubation_Time  Vital_Dyes  Outcome
0               1.5          10.0  100000           96.0       0.5  0.823
1               1.0           5.0  120000           72.0       0.3  0.421
2               1.8          15.0   90000           48.0       0.7  0.951
3               1.2           8.0  110000           96.0       0.4  0.756
4               1.6          12.0  100000           72.0       0.6  0.893
5               1.4           9.0  120000           48.0       0.5  0.639
6               1.1           6.0   90000           96.0       0.3  0.512
7               1.9          18.0  110000           72.0       0.8  0.982
8               1.3          11.0  100000           48.0       0.4  0.741
9               1.7          14.0  120000           96.0       0.6  0.859
10              1.0           4.0   90000           72.0       0.2  0.395
11              1.5          13.0  110000           48.0       0.5  0.819
12              1.2           7.0  100000           96.0       0.3  0.623
13              1.8          16.0  120000           72.0       0.7  0.938
14              1.4          10.0   90000           48.0       0.4  0.763
15              1.1           5.0  110000           96.0       0.2  0.467
16              1.6          12.0  100000           72.0       0.5  0.853
17              1.3           9.0  120000           48.0       0.4  0.729
18              1.9          17.0   90000           96.0       0.8  0.964
19              1.2           6.0  110000           72.0       0.3  0.599
20              1.7          15.0  100000           48.0       0.6  0.875
21              1.0           4.0  120000           96.0       0.2  0.439
22              1.5          11.0   90000           72.0       0.5  0.811
23              1.4           8.0  110000           48.0       0.4  0.755
24              1.8          16.0  100000           96.0       0.7  0.943
```",0.4935066213566247
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4ecaffb2a4ab55ee35a0b9d905947bf4ec35e3df.summary'],Can retinal vessel loss be used to predict the efficacy of immunomodulatory therapies in multiple sclerosis patients by monitoring changes in retinal vasculature in response to treatment?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** ""Retinal Vessel Loss as a Biomarker for Predicting Efficacy of Immunomodulatory Therapies in Multiple Sclerosis Patients""

**Objective:** To investigate whether retinal vessel loss can be used to predict the efficacy of immunomodulatory therapies in multiple sclerosis patients by monitoring changes in retinal vasculature in response to treatment.

**Equipment:**

* Optical coherence tomography angiography (OCT-A) device
* CSF analysis equipment
* Clinical evaluation tools
* Immunomodulatory therapy administration equipment (e.g., infusion pumps, injection devices)

**Steps:**

1. **Patient Recruitment:** Recruit 50 patients with relapsing-remitting multiple sclerosis (RRMS) who are scheduled to start immunomodulatory therapy.
2. **Baseline Measurements:**
	* Perform OCT-A analysis to assess retinal vessel density.
	* Collect CSF samples and analyze for immune cell frequencies and cytokine levels.
	* Perform clinical evaluations to assess disease activity and disability.
3. **Immunomodulatory Therapy Administration:** Administer immunomodulatory therapy to patients according to standard treatment protocols.
4. **Follow-up Measurements:** At 3, 6, and 12 months after treatment initiation, repeat OCT-A analysis, CSF sampling, and clinical evaluations.
5. **Data Analysis:**
	* Correlate changes in retinal vessel density with changes in CSF immune cell frequencies and cytokine levels.
	* Correlate changes in retinal vessel density with clinical evaluation results (disease activity and disability).
	* Analyze the predictive value of retinal vessel loss in determining treatment response and disease progression.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see a correlation between changes in retinal vessel density and treatment response, as well as a correlation between retinal vessel loss and disease progression.
* If the hypothesis is false, we expect to see no correlation between retinal vessel density and treatment response or disease progression.

**Experiment to Disprove the Hypothesis:**

**Title:** ""Retinal Vessel Loss as a Non-Predictive Biomarker for Immunomodulatory Therapy Efficacy in Multiple Sclerosis Patients""

**Objective:** To demonstrate that retinal vessel loss is not a reliable biomarker for predicting the efficacy of immunomodulatory therapies in multiple sclerosis patients.

**Design:**

1. **Patient Recruitment:** Recruit 25 patients with RRMS who are scheduled to start immunomodulatory therapy.
2. **Randomization:** Randomly assign patients to one of two groups:
	* Group A: Receive immunomodulatory therapy and undergo OCT-A analysis at baseline and 3 months.
	* Group B: Receive a sham treatment (e.g., placebo infusion) and undergo OCT-A analysis at baseline and 3 months.
3. **OCT-A Analysis:** Perform OCT-A analysis at baseline and 3 months to assess retinal vessel density.
4. **Clinical Evaluations:** Perform clinical evaluations at 3 months to assess disease activity and disability.
5. **Data Analysis:**
	* Compare changes in retinal vessel density between Group A and Group B.
	* Correlate changes in retinal vessel density with clinical evaluation results (disease activity and disability) in Group A.

**Expected Outcomes:**

* If the hypothesis is false, we expect to see no significant difference in retinal vessel density changes between Group A and Group B, and no correlation between retinal vessel density and clinical evaluation results in Group A.
* If the hypothesis is true, we expect to see a significant difference in retinal vessel density changes between Group A and Group B, and a correlation between retinal vessel density and clinical evaluation results in Group A.

**Budget and Timeframe:**

The experimental plan and the experiment to disprove the hypothesis can be completed within a reasonable timeframe (approximately 12-18 months) and budget. The estimated costs include:

* Patient recruitment and compensation: $50,000
* OCT-A device rental and maintenance: $20,000
* CSF analysis equipment and reagents: $15,000
* Clinical evaluation tools and personnel: $10,000
* Immunomodulatory therapy administration equipment and personnel: $30,000
* Data analysis software and personnel: $20,000
* Miscellaneous (study coordination, etc.): $10,000

Total estimated budget: $155,000

Note: The budget and timeframe may vary depending on the specific requirements of the study and the institution conducting the research.",85,"Here are the detailed, step-by-step protocols for the experimental plan and the experiment to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Protocol 1: Patient Recruitment**

1.1. Identify potential patients with relapsing-remitting multiple sclerosis (RRMS) who are scheduled to start immunomodulatory therapy through collaboration with neurologists and patient registries.

1.2. Screen patients for eligibility using the following criteria:
	* Diagnosis of RRMS
	* Scheduled to start immunomodulatory therapy
	* Ability to provide informed consent
	* No history of ocular disease or retinal damage

1.3. Recruit 50 eligible patients and obtain informed consent.

**Protocol 2: Baseline Measurements**

2.1. OCT-A Analysis:
	* Calibrate the OCT-A device according to the manufacturer's instructions.
	* Ensure the patient's eyes are dilated and comfortable.
	* Perform OCT-A scans of both eyes, capturing 3D images of the retinal vasculature.
	* Analyze the scans using proprietary software to quantify retinal vessel density.

2.2. CSF Sampling:
	* Collect 10 mL of CSF using a sterile lumbar puncture procedure.
	* Store the sample in a sterile container and transport to the laboratory for analysis.
	* Analyze the CSF sample for immune cell frequencies and cytokine levels using flow cytometry and ELISA, respectively.

2.3. Clinical Evaluations:
	* Perform a comprehensive neurological examination to assess disease activity and disability using standardized scales (e.g., Expanded Disability Status Scale (EDSS)).
	* Record patient-reported outcomes and quality of life metrics.

**Protocol 3: Immunomodulatory Therapy Administration**

3.1. Administer immunomodulatory therapy to patients according to standard treatment protocols, as prescribed by their neurologist.

**Protocol 4: Follow-up Measurements**

4.1. Repeat OCT-A analysis, CSF sampling, and clinical evaluations at 3, 6, and 12 months after treatment initiation.

**Protocol 5: Data Analysis**

5.1. Correlate changes in retinal vessel density with changes in CSF immune cell frequencies and cytokine levels using statistical software (e.g., R, Python).
5.2. Correlate changes in retinal vessel density with clinical evaluation results (disease activity and disability) using statistical software.
5.3. Analyze the predictive value of retinal vessel loss in determining treatment response and disease progression using machine learning algorithms and statistical software.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Patient Recruitment**

1.1. Identify potential patients with relapsing-remitting multiple sclerosis (RRMS) who are scheduled to start immunomodulatory therapy through collaboration with neurologists and patient registries.

1.2. Screen patients for eligibility using the following criteria:
	* Diagnosis of RRMS
	* Scheduled to start immunomodulatory therapy
	* Ability to provide informed consent
	* No history of ocular disease or retinal damage

1.3. Recruit 25 eligible patients and obtain informed consent.

**Protocol 2: Randomization**

2.1. Randomly assign patients to one of two groups using a computer-generated randomization protocol:
	* Group A: Receive immunomodulatory therapy
	* Group B: Receive a sham treatment (e.g., placebo infusion)

**Protocol 3: OCT-A Analysis**

3.1. Perform OCT-A analysis at baseline and 3 months using the same protocol as described in Protocol 2.1.

**Protocol 4: Clinical Evaluations**

4.1. Perform clinical evaluations at 3 months to assess disease activity and disability using standardized scales (e.g., EDSS).

**Protocol 5: Data Analysis**

5.1. Compare changes in retinal vessel density between Group A and Group B using statistical software.
5.2. Correlate changes in retinal vessel density with clinical evaluation results (disease activity and disability) in Group A using statistical software.

**Quality Control and Assurance**

* Regularly calibrate and maintain the OCT-A device according to the manufacturer's instructions.
* Ensure all personnel involved in the study are trained and certified in OCT-A analysis, CSF sampling, and clinical evaluations.
* Implement a data management plan to ensure accurate and secure data collection, storage, and analysis.
* Conduct regular quality control checks on data and results to ensure accuracy and consistency.

**Timeline and Budget**

The experimental plan and the experiment to disprove the hypothesis can be completed within a reasonable timeframe (approximately 12-18 months) and budget. The estimated costs include:

* Patient recruitment and compensation: $50,000
* OCT-A device rental and maintenance: $20,000
* CSF analysis equipment and reagents: $15,000
* Clinical evaluation tools and personnel: $10,000
* Immunomodulatory therapy administration equipment and personnel: $30,000
* Data analysis software and personnel: $20,000
* Miscellaneous (study coordination, etc.): $10,000

Total estimated budget: $155,000","```
   Patient_ID  OCT_A_Device_Calibration  Patient_Dilation  CSF_Sample_Volume  Immunomodulatory_Therapy  Retinal_Vessel_Density_Baseline  Retinal_Vessel_Density_3_Months  Disease_Activity_Disability_Baseline  Disease_Activity_Disability_3_Months  Outcome
0           1                    1.0             1.0               10.0                    1.0                         0.85                         0.80                             2.5                             2.2       Improved
1           2                    1.1             0.9               9.5                    1.0                         0.90                         0.88                             3.0                             2.8       Improved
2           3                    0.9             1.1               10.2                    1.0                         0.78                         0.75                             2.2                             2.0       Improved
3           4                    1.0             0.8               9.8                    0.0                         0.92                         0.90                             3.2                             3.0       No_Change
4           5                    1.1             1.0               10.5                    1.0                         0.88                         0.85                             2.8                             2.5       Improved
5           6                    0.9             0.9               9.2                    0.0                         0.80                         0.78                             2.5                             2.3       No_Change
6           7                    1.0             1.1               10.8                    1.0                         0.95                         0.92                             3.5                             3.2       Improved
7           8                    1.1             0.8               9.0                    0.0                         0.85                         0.83                             2.2                             2.0       No_Change
8           9                    0.9             1.0               10.1                    1.0                         0.90                         0.88                             3.0                             2.8       Improved
9          10                    1.0             0.9               9.6                    0.0                         0.78                         0.75                             2.5                             2.2       No_Change
10         11                    1.1             1.1               10.9                    1.0                         0.92                         0.90                             3.2                             3.0       Improved
11         12                    0.9             0.8               9.4                    0.0                         0.80                         0.78                             2.2                             2.0       No_Change
12         13                    1.0             1.0               10.4                    1.0                         0.95                         0.92                             3.5                             3.2       Improved
13         14                    1.1             0.9               9.1                    0.0                         0.85                         0.83                             2.5                             2.2       No_Change
14         15                    0.9             1.1               10.6                    1.0                         0.90                         0.88                             3.0                             2.8       Improved
15         16                    1.0             0.8               9.7                    0.0                         0.78                         0.75                             2.2                             2.0       No_Change
16         17                    1.1             1.0               10.3                    1.0                         0.92                         0.90                             3.2                             3.0       Improved
17         18                    0.9             0.9               9.3                    0.0                         0.80                         0.78                             2.5                             2.2       No_Change
18         19                    1.0             1.1               10.7                    1.0                         0.95                         0.92                             3.5                             3.2       Improved
19         20                    1.1             0.8               9.9                    0.0                         0.85                         0.83                             2.2                             2.0       No_Change
20         21                    0.9             1.0               10.2                    1.0                         0.90                         0.88                             3.0                             2.8       Improved
21         22                    1.0             0.9               9.5                    0.0                         0.78                         0.75                             2.5                             2.2       No_Change
22         23                    1.1             1.1               10.5                    1.0                         0.92                         0.90                             3.2                             3.0       Improved
23         24                    0.9             0.8               9.1                    0.0                         0.80                         0.78                             2.2                             2.0       No_Change
24         25                    1.0             1.0               10.8                    1.0                         0.95                         0.92                             3.5                             3.2       Improved
```",0.6012881760232746
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/43fa74b0ff717e0d1bf476e9c1e4105e72df71bd.summary'],"Can simultaneous inhibition of EGFR and TGFb signaling by BCA101 also enhance the expression of tumor-specific neoantigens, leading to increased recognition and killing of cancer cells by cytotoxic T cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you design an experiment to test this hypothesis.

**Hypothesis:** Simultaneous inhibition of EGFR and TGFb signaling by BCA101 enhances the expression of tumor-specific neoantigens, leading to increased recognition and killing of cancer cells by cytotoxic T cells.

**Experimental Plan:**

**Objective:** To test whether BCA101-mediated inhibition of EGFR and TGFb signaling increases tumor-specific neoantigen expression, leading to enhanced recognition and killing of cancer cells by cytotoxic T cells.

**Experimental Design:**

1. **Cell Culture:**
	* Use human cancer cell lines (e.g., lung, breast, or colon cancer) with known EGFR and TGFb expression.
	* Culture cells in vitro with or without BCA101 treatment (dose-response curve to determine optimal concentration).
2. **Neoantigen Expression Analysis:**
	* Use RNA sequencing (RNA-seq) or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure the expression of tumor-specific neoantigens (e.g., MUC1, NY-ESO-1, or p53) in BCA101-treated and untreated cancer cells.
	* Validate RNA-seq results using Western blot or immunofluorescence staining for protein expression.
3. **Cytotoxic T Cell Assay:**
	* Isolate and expand cytotoxic T cells (e.g., CD8+ T cells) from healthy donor peripheral blood mononuclear cells (PBMCs) using standard protocols.
	* Co-culture BCA101-treated or untreated cancer cells with cytotoxic T cells at various effector-to-target ratios.
	* Measure T cell activation and cytotoxicity using flow cytometry (e.g., CD107a, IFN-γ, and granzyme B) and chromium release assays.
4. **Control Experiments:**
	* Use EGFR and TGFb inhibitors separately to test the specificity of BCA101's effect on neoantigen expression and T cell recognition.
	* Include a negative control (e.g., non-specific IgG) to rule out non-specific effects.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test whether BCA101-mediated inhibition of EGFR and TGFb signaling has no effect on tumor-specific neoantigen expression and cytotoxic T cell recognition.

**Experimental Design:**

1. **Cell Culture:**
	* Use the same cancer cell lines as above, but with a focus on cell lines with low or no EGFR and TGFb expression.
	* Treat cells with BCA101 at a high concentration (e.g., 10-fold higher than the optimal concentration determined in the initial experiment).
2. **Neoantigen Expression Analysis:**
	* Perform RNA-seq or qRT-PCR to measure neoantigen expression in BCA101-treated and untreated cells.
	* Expect no significant difference in neoantigen expression between treated and untreated cells.
3. **Cytotoxic T Cell Assay:**
	* Co-culture BCA101-treated and untreated cancer cells with cytotoxic T cells as above.
	* Expect no significant difference in T cell activation and cytotoxicity between treated and untreated cells.

**Rationale:**

By using cancer cell lines with low or no EGFR and TGFb expression, we can test whether BCA101's effect on neoantigen expression and T cell recognition is specific to EGFR and TGFb inhibition. If BCA101 has no effect on neoantigen expression and T cell recognition in these cells, it would suggest that the initial hypothesis is false.

**Timeline and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $150,000-$200,000. This estimate includes:

* Cell culture and reagents: $30,000
* RNA-seq or qRT-PCR: $20,000
* Western blot and immunofluorescence staining: $10,000
* Cytotoxic T cell isolation and expansion: $20,000
* Flow cytometry and chromium release assays: $30,000
* Personnel and overhead: $40,000-$60,000

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the institution's policies.",92,"Here are the detailed, step-by-step protocols for the experiment:

**Experiment to Test the Hypothesis:**

**Objective:** To test whether BCA101-mediated inhibition of EGFR and TGFb signaling increases tumor-specific neoantigen expression, leading to enhanced recognition and killing of cancer cells by cytotoxic T cells.

**Protocol:**

**Step 1: Cell Culture**

1.1. Obtain human cancer cell lines (e.g., lung, breast, or colon cancer) with known EGFR and TGFb expression from a reputable cell bank or laboratory.

1.2. Culture cells in vitro in a humidified incubator at 37°C and 5% CO2 using a suitable medium (e.g., RPMI-1640 or DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

1.3. Treat cells with BCA101 at various concentrations (e.g., 0.1, 1, 10, and 100 μM) for 24-48 hours to determine the optimal concentration for inhibition of EGFR and TGFb signaling.

1.4. Use a dose-response curve to determine the optimal concentration of BCA101 that inhibits EGFR and TGFb signaling without affecting cell viability.

**Step 2: Neoantigen Expression Analysis**

2.1. Extract total RNA from BCA101-treated and untreated cancer cells using a RNA extraction kit (e.g., TRIzol or RNeasy).

2.2. Perform RNA sequencing (RNA-seq) or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure the expression of tumor-specific neoantigens (e.g., MUC1, NY-ESO-1, or p53).

2.3. For RNA-seq, prepare libraries using a RNA-seq library preparation kit (e.g., TruSeq or NEBNext) and sequence on a next-generation sequencing platform (e.g., Illumina or PacBio).

2.4. For qRT-PCR, design primers specific to the target neoantigens and perform PCR using a qRT-PCR machine (e.g., ABI 7500 or Bio-Rad CFX96).

2.5. Validate RNA-seq results using Western blot or immunofluorescence staining for protein expression.

**Step 3: Cytotoxic T Cell Assay**

3.1. Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors using a density gradient centrifugation method (e.g., Ficoll-Paque).

3.2. Isolate and expand CD8+ T cells from PBMCs using a T cell isolation kit (e.g., Miltenyi Biotec or STEMCELL Technologies).

3.3. Co-culture BCA101-treated or untreated cancer cells with cytotoxic T cells at various effector-to-target ratios (e.g., 1:1, 5:1, and 10:1) in a 96-well plate.

3.4. Measure T cell activation and cytotoxicity using flow cytometry (e.g., CD107a, IFN-γ, and granzyme B) and chromium release assays.

**Step 4: Control Experiments**

4.1. Use EGFR and TGFb inhibitors separately to test the specificity of BCA101's effect on neoantigen expression and T cell recognition.

4.2. Include a negative control (e.g., non-specific IgG) to rule out non-specific effects.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test whether BCA101-mediated inhibition of EGFR and TGFb signaling has no effect on tumor-specific neoantigen expression and cytotoxic T cell recognition.

**Protocol:**

**Step 1: Cell Culture**

1.1. Obtain human cancer cell lines with low or no EGFR and TGFb expression from a reputable cell bank or laboratory.

1.2. Culture cells in vitro as described in Step 1.2 of the experiment to test the hypothesis.

1.3. Treat cells with BCA101 at a high concentration (e.g., 10-fold higher than the optimal concentration determined in the initial experiment) for 24-48 hours.

**Step 2: Neoantigen Expression Analysis**

2.1. Extract total RNA from BCA101-treated and untreated cancer cells as described in Step 2.1 of the experiment to test the hypothesis.

2.2. Perform RNA-seq or qRT-PCR to measure neoantigen expression as described in Step 2.2-2.5 of the experiment to test the hypothesis.

**Step 3: Cytotoxic T Cell Assay**

3.1. Isolate and expand CD8+ T cells from PBMCs as described in Step 3.1-3.2 of the experiment to test the hypothesis.

3.2. Co-culture BCA101-treated and untreated cancer cells with cytotoxic T cells as described in Step 3.3-3.4 of the experiment to test the hypothesis.

**Step 4: Data Analysis**

4.1. Analyze RNA-seq or qRT-PCR data to determine if there is no significant difference in neoantigen expression between BCA101-treated and untreated cells.

4.2. Analyze flow cytometry and chromium release assay data to determine if there is no significant difference in T cell activation and cytotoxicity between BCA101-treated and untreated cells.

**Timeline and Budget:**

The experiment can be completed within 6-9 months with a budget of approximately $150,000-$200,000. This estimate includes:

* Cell culture and reagents: $30,000
* RNA-seq or qRT-PCR: $20,000
* Western blot and immunofluorescence staining: $10,000
* Cytotoxic T cell isolation and expansion: $20,000
* Flow cytometry and chromium release assays: $30,000
* Personnel and overhead: $40,000-$60,000

Note: The budget and timeline may vary depending on the specific requirements of the experiment and the institution's policies.","```
   BCA101_concentration  FBS_concentration  Penicillin_streptomycin_concentration  EGFR_expression  TGFb_expression  Neoantigen_expression  T_cell_activation  Cytotoxicity
0                  0.1               10.0                         1.0             0.8             0.7               0.4             0.3             0.2
1                  1.0               10.0                         1.0             0.6             0.5               0.6             0.5             0.4
2                 10.0               10.0                         1.0             0.4             0.3               0.8             0.7             0.6
3                 100.0               10.0                         1.0             0.2             0.1               0.9             0.8             0.7
4                  0.1                5.0                         1.0             0.9             0.8               0.3             0.2             0.1
5                  1.0                5.0                         1.0             0.7             0.6               0.5             0.4             0.3
6                 10.0                5.0                         1.0             0.5             0.4               0.7             0.6             0.5
7                 100.0                5.0                         1.0             0.3             0.2               0.8             0.7             0.6
8                  0.1               15.0                         1.0             0.8             0.7               0.4             0.3             0.2
9                  1.0               15.0                         1.0             0.6             0.5               0.6             0.5             0.4
10                10.0               15.0                         1.0             0.4             0.3               0.8             0.7             0.6
11               100.0               15.0                         1.0             0.2             0.1               0.9             0.8             0.7
12                 0.1                5.0                         0.5             0.9             0.8               0.3             0.2             0.1
13                 1.0                5.0                         0.5             0.7             0.6               0.5             0.4             0.3
14                10.0                5.0                         0.5             0.5             0.4               0.7             0.6             0.5
15               100.0                5.0                         0.5             0.3             0.2               0.8             0.7             0.6
16                 0.1               10.0                         0.5             0.8             0.7               0.4             0.3             0.2
17                 1.0               10.0                         0.5             0.6             0.5               0.6             0.5             0.4
18                10.0               10.0                         0.5             0.4             0.3               0.8             0.7             0.6
19               100.0               10.0                         0.5             0.2             0.1               0.9             0.8             0.7
20                 0.1               15.0                         0.5             0.9             0.8               0.3             0.2             0.1
21                 1.0               15.0                         0.5             0.7             0.6               0.5             0.4             0.3
22                10.0               15.0                         0.5             0.5             0.4               0.7             0.6             0.5
23               100.0               15.0                         0.5             0.3             0.2               0.8             0.7             0.6
24                 0.1                5.0                         1.5             0.8             0.7               0.4             0.3             0.2
```",0.1204172377945522
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/03a1f4ee12dc605ecd6ebe6d3c6d9ab8d6046222.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e9f9d4c5961735b2aa7fcb1a882302dc2c752af7.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/086accada88791d54972327bc83084eafba77c56.summary']","Can simultaneous targeting of BTK, MEK, and FLT3 pathways in combination with CD19-targeted immunotherapy prevent antigen loss relapse and improve treatment outcomes in patients with acute lymphoblastic leukemia?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Can simultaneous targeting of BTK, MEK, and FLT3 pathways in combination with CD19-targeted immunotherapy prevent antigen loss relapse and improve treatment outcomes in patients with acute lymphoblastic leukemia?

**Experimental Design:**

**Objective:** To investigate the efficacy of combination therapy targeting BTK, MEK, and FLT3 pathways in combination with CD19-targeted immunotherapy in preventing antigen loss relapse and improving treatment outcomes in acute lymphoblastic leukemia.

**Experimental Approach:**

1. **Cell Culture:** Establish a panel of acute lymphoblastic leukemia (ALL) cell lines with varying levels of CD19, FLT3, and BTK expression. These cell lines will be used to model different scenarios of antigen loss relapse.
2. **Combination Therapy:** Treat the ALL cell lines with the following combinations:
	* CD19-targeted immunotoxin (e.g., blinatumomab) alone
	* BTK inhibitor (e.g., ibrutinib) alone
	* MEK inhibitor (e.g., trametinib) alone
	* FLT3-directed chimeric antigen receptor T-cell (FLT3CART) alone
	* Combination of CD19-targeted immunotoxin, BTK inhibitor, and MEK inhibitor
	* Combination of CD19-targeted immunotoxin, FLT3CART, and MEK inhibitor
	* Combination of CD19-targeted immunotoxin, BTK inhibitor, FLT3CART, and MEK inhibitor
3. **Antigen Loss Relapse Assay:** Monitor the expression of CD19, FLT3, and BTK on the surface of ALL cells using flow cytometry and Western blot analysis. Assess the ability of each treatment combination to prevent antigen loss relapse.
4. **Cell Viability and Proliferation Assay:** Evaluate the effect of each treatment combination on ALL cell viability and proliferation using cell viability assays (e.g., MTT, Annexin V) and cell cycle analysis.
5. **In Vivo Studies:** Perform in vivo studies using xenograft models of ALL to validate the findings from the in vitro studies. Treat mice with the different combination therapies and monitor tumor burden, antigen expression, and overall survival.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we will design an experiment to test the following:

**Null Hypothesis:** Simultaneous targeting of BTK, MEK, and FLT3 pathways in combination with CD19-targeted immunotherapy does not prevent antigen loss relapse or improve treatment outcomes in patients with acute lymphoblastic leukemia.

**Experimental Approach:**

1. **Cell Culture:** Establish a panel of ALL cell lines with high levels of CD19, FLT3, and BTK expression.
2. **Combination Therapy:** Treat the ALL cell lines with the combination of CD19-targeted immunotoxin, BTK inhibitor, FLT3CART, and MEK inhibitor.
3. **Antigen Loss Relapse Assay:** Monitor the expression of CD19, FLT3, and BTK on the surface of ALL cells using flow cytometry and Western blot analysis. If the combination therapy fails to prevent antigen loss relapse, it would support the null hypothesis.
4. **Cell Viability and Proliferation Assay:** Evaluate the effect of the combination therapy on ALL cell viability and proliferation using cell viability assays and cell cycle analysis. If the combination therapy does not improve treatment outcomes, it would support the null hypothesis.

**Equipment and Resources:**

* Cell culture facilities and equipment
* Flow cytometer
* Western blot equipment
* Cell viability assay reagents (e.g., MTT, Annexin V)
* In vivo xenograft models of ALL
* CD19-targeted immunotoxin (e.g., blinatumomab)
* BTK inhibitor (e.g., ibrutinib)
* MEK inhibitor (e.g., trametinib)
* FLT3CART
* Animal housing and care facilities

**Timeline:**

* Cell culture and in vitro studies: 6 months
* In vivo studies: 12 months
* Data analysis and manuscript preparation: 6 months

**Budget:**

* Personnel: $500,000 per year for 2 years
* Reagents and consumables: $200,000 per year for 2 years
* Equipment and infrastructure: $300,000 one-time investment
* Animal studies: $150,000 per year for 2 years
* Total budget: $1,450,000 over 2 years",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Establishing a Panel of Acute Lymphoblastic Leukemia (ALL) Cell Lines**

1.1. Obtain ALL cell lines with varying levels of CD19, FLT3, and BTK expression from a reputable cell bank or through collaboration with other researchers.

1.2. Thaw the cell lines according to the supplier's instructions and culture them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.3. Expand the cell lines to a sufficient number of cells for the experiment (approximately 1 x 10^7 cells per cell line).

1.4. Verify the expression levels of CD19, FLT3, and BTK on the surface of each cell line using flow cytometry and Western blot analysis.

**Protocol 2: Combination Therapy Treatment**

2.1. Prepare the following treatment combinations:
	* CD19-targeted immunotoxin (e.g., blinatumomab) alone: 10 μg/mL
	* BTK inhibitor (e.g., ibrutinib) alone: 1 μM
	* MEK inhibitor (e.g., trametinib) alone: 10 nM
	* FLT3-directed chimeric antigen receptor T-cell (FLT3CART) alone: 1 x 10^6 cells/mL
	* Combination of CD19-targeted immunotoxin, BTK inhibitor, and MEK inhibitor: 10 μg/mL, 1 μM, and 10 nM, respectively
	* Combination of CD19-targeted immunotoxin, FLT3CART, and MEK inhibitor: 10 μg/mL, 1 x 10^6 cells/mL, and 10 nM, respectively
	* Combination of CD19-targeted immunotoxin, BTK inhibitor, FLT3CART, and MEK inhibitor: 10 μg/mL, 1 μM, 1 x 10^6 cells/mL, and 10 nM, respectively

2.2. Treat the ALL cell lines with the respective treatment combinations for 72 hours.

2.3. Harvest the cells and wash them twice with phosphate-buffered saline (PBS).

**Protocol 3: Antigen Loss Relapse Assay**

3.1. Stain the harvested cells with fluorochrome-conjugated antibodies against CD19, FLT3, and BTK.

3.2. Analyze the cells using flow cytometry to determine the expression levels of CD19, FLT3, and BTK.

3.3. Perform Western blot analysis to validate the flow cytometry results.

**Protocol 4: Cell Viability and Proliferation Assay**

4.1. Seed 1 x 10^4 cells per well in a 96-well plate.

4.2. Treat the cells with the respective treatment combinations for 72 hours.

4.3. Perform an MTT assay to evaluate cell viability.

4.4. Perform Annexin V staining to evaluate apoptosis.

4.5. Perform cell cycle analysis using propidium iodide staining.

**Protocol 5: In Vivo Studies**

5.1. Establish xenograft models of ALL in immunodeficient mice.

5.2. Treat the mice with the respective treatment combinations.

5.3. Monitor tumor burden using bioluminescence imaging.

5.4. Monitor antigen expression using flow cytometry and Western blot analysis.

5.5. Evaluate overall survival.

**Protocol 6: Experimental Design to Disprove the Hypothesis**

6.1. Establish a panel of ALL cell lines with high levels of CD19, FLT3, and BTK expression.

6.2. Treat the ALL cell lines with the combination of CD19-targeted immunotoxin, BTK inhibitor, FLT3CART, and MEK inhibitor.

6.3. Monitor the expression of CD19, FLT3, and BTK on the surface of ALL cells using flow cytometry and Western blot analysis.

6.4. Evaluate the effect of the combination therapy on ALL cell viability and proliferation using cell viability assays and cell cycle analysis.

Note: The protocols above are detailed and specific, but they may require adjustments based on the specific requirements of the laboratory and the researchers conducting the experiment.","```
   CD19-targeted immunotoxin (μg/mL)  BTK inhibitor (μM)  MEK inhibitor (nM)  FLT3CART (cells/mL)  CD19 expression  FLT3 expression  BTK expression  Cell Viability
0                         5.0             0.5             5.0             0.5e+06         0.60         0.40         0.30         0.70
1                         7.5             1.0             7.5             0.75e+06         0.55         0.45         0.35         0.65
2                         2.5             0.2             2.5             0.25e+06         0.65         0.35         0.40         0.75
3                         10.0            1.5             10.0            1.00e+06         0.50         0.50         0.30         0.60
4                         5.0             0.5             5.0             0.50e+06         0.58         0.42         0.32         0.68
5                         7.5             1.0             7.5             0.75e+06         0.53         0.47         0.36         0.63
6                         2.5             0.2             2.5             0.25e+06         0.62         0.38         0.39         0.72
7                         10.0            1.5             10.0            1.00e+06         0.48         0.52         0.31         0.58
8                         5.0             0.5             5.0             0.50e+06         0.59         0.41         0.34         0.69
9                         7.5             1.0             7.5             0.75e+06         0.51         0.49         0.37         0.61
10                        2.5             0.2             2.5             0.25e+06         0.61         0.39         0.38         0.71
11                        10.0            1.5             10.0            1.00e+06         0.46         0.54         0.32         0.56
12                        5.0             0.5             5.0             0.50e+06         0.57         0.43         0.33         0.67
13                        7.5             1.0             7.5             0.75e+06         0.52         0.48         0.35         0.62
14                        2.5             0.2             2.5             0.25e+06         0.60         0.40         0.36         0.70
15                        10.0            1.5             10.0            1.00e+06         0.45         0.55         0.31         0.55
16                        5.0             0.5             5.0             0.50e+06         0.56         0.44         0.32         0.66
17                        7.5             1.0             7.5             0.75e+06         0.50         0.50         0.34         0.60
18                        2.5             0.2             2.5             0.25e+06         0.59         0.41         0.37         0.69
19                        10.0            1.5             10.0            1.00e+06         0.43         0.57         0.30         0.53
20                        5.0             0.5             5.0             0.50e+06         0.55         0.45         0.33         0.65
21                        7.5             1.0             7.5             0.75e+06         0.49         0.51         0.35         0.59
22                        2.5             0.2             2.5             0.25e+06         0.58         0.42         0.36         0.68
23                        10.0            1.5             10.0            1.00e+06         0.41         0.59         0.29         0.51
24                        5.0             0.5             5.0             0.50e+06         0.54         0.46         0.32         0.64
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ced1beaca444367c59a5abc7bcbdd224d3285c7e.summary'],Can specific microRNAs that regulate epigenetic modifiers be used to selectively target and revert the epigenetic reprogramming of cancer stem cells in leukemia and hepatocellular carcinoma?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis. Since the goal is to disprove the hypothesis, I will focus on identifying potential flaws or limitations in the original hypothesis.

**Experiment: ""Disproving the Hypothesis: Can specific microRNAs that regulate epigenetic modifiers be used to selectively target and revert the epigenetic reprogramming of cancer stem cells in leukemia and hepatocellular carcinoma?""**

**Objective:** To investigate whether specific microRNAs that regulate epigenetic modifiers can selectively target and revert the epigenetic reprogramming of cancer stem cells in leukemia and hepatocellular carcinoma, and to identify potential limitations or flaws in the original hypothesis.

**Experimental Design:**

1. **Cell Line Selection:** Use established leukemia (e.g., K562) and hepatocellular carcinoma (e.g., HepG2) cell lines, as well as their corresponding normal stem cell counterparts (e.g., human hematopoietic stem cells and human liver stem cells).
2. **MicroRNA Selection:** Choose a panel of microRNAs that are known to regulate epigenetic modifiers (e.g., miR-29, miR-101, and miR-200) and have been implicated in cancer development.
3. **MicroRNA Overexpression:** Use lentiviral vectors to overexpress each microRNA in the cancer stem cells and normal stem cells.
4. **Epigenetic Profiling:** Perform DNA methylation arrays and ChIP-seq analysis to profile the epigenetic landscape of the microRNA-overexpressing cancer stem cells and normal stem cells.
5. **Cellular Assays:** Evaluate the effect of microRNA overexpression on cancer stem cell proliferation, differentiation, and self-renewal using cell culture and flow cytometry techniques.
6. **Control Experiments:** Include control experiments to account for potential off-target effects of microRNA overexpression, such as using scrambled microRNA controls or microRNA inhibitors.

**Potential Limitations and Flaws to Investigate:**

1. **Off-target effects:** Investigate whether microRNA overexpression has off-target effects on non-epigenetic modifier genes, which could confound the results.
2. **Cellular heterogeneity:** Examine whether the cancer stem cell population is heterogeneous, and if so, whether microRNA overexpression affects different subpopulations differently.
3. **Epigenetic complexity:** Investigate whether the epigenetic landscape of cancer stem cells is more complex than anticipated, making it difficult to target specific epigenetic modifiers.
4. **MicroRNA specificity:** Evaluate whether the selected microRNAs specifically target epigenetic modifiers or have broader effects on gene expression.

**Expected Outcomes:**

1. If the hypothesis is true, microRNA overexpression should selectively target and revert the epigenetic reprogramming of cancer stem cells, leading to a more normal epigenetic landscape and reduced cancer stem cell properties.
2. If the hypothesis is false or incomplete, microRNA overexpression may not selectively target epigenetic modifiers, or may have off-target effects, leading to inconsistent or unexpected results.

**Timeline and Budget:**

This experiment can be completed within 6-9 months, with a budget of approximately $150,000-$200,000. This includes costs for:

* Cell lines and reagents: $20,000
* Lentiviral vectors and microRNA synthesis: $30,000
* Epigenetic profiling (DNA methylation arrays and ChIP-seq): $40,000
* Cellular assays and flow cytometry: $20,000
* Personnel and overhead: $40,000-$60,000

By designing an experiment to disprove the hypothesis, we can identify potential limitations and flaws, which can help refine the original hypothesis and guide future research directions.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Line Selection and Preparation**

1.1. Obtain the following cell lines from a reputable cell bank or repository:
	* K562 (leukemia cell line)
	* HepG2 (hepatocellular carcinoma cell line)
	* Human hematopoietic stem cells (normal stem cell counterpart for leukemia)
	* Human liver stem cells (normal stem cell counterpart for hepatocellular carcinoma)

1.2. Thaw and culture the cell lines according to the supplier's instructions.
1.3. Verify the identity and purity of the cell lines using STR profiling or other authentication methods.
1.4. Expand the cell lines to the required numbers for the experiment.

**Protocol 2: MicroRNA Selection and Synthesis**

2.1. Choose a panel of microRNAs that regulate epigenetic modifiers, such as:
	* miR-29
	* miR-101
	* miR-200
2.2. Design and synthesize the microRNA sequences using a commercial supplier or in-house facilities.
2.3. Verify the quality and purity of the synthesized microRNAs using techniques such as HPLC or mass spectrometry.

**Protocol 3: Lentiviral Vector Preparation and MicroRNA Overexpression**

3.1. Design and construct lentiviral vectors containing the microRNA sequences using a commercial supplier or in-house facilities.
3.2. Verify the quality and titer of the lentiviral vectors using techniques such as qPCR or Western blot.
3.3. Infect the cancer stem cells and normal stem cells with the lentiviral vectors at a multiplicity of infection (MOI) of 10-20.
3.4. Select for infected cells using antibiotics or other selection markers.
3.5. Verify microRNA overexpression using qRT-PCR or Western blot.

**Protocol 4: Epigenetic Profiling**

4.1. Extract genomic DNA from the microRNA-overexpressing cancer stem cells and normal stem cells using a commercial kit or in-house protocol.
4.2. Perform DNA methylation arrays using a commercial platform (e.g., Illumina Infinium MethylationEPIC BeadChip) according to the manufacturer's instructions.
4.3. Analyze the DNA methylation data using bioinformatic tools (e.g., R, Bioconductor) to identify differentially methylated regions.
4.4. Perform ChIP-seq analysis using a commercial platform (e.g., Illumina TruSeq ChIP Library Prep Kit) according to the manufacturer's instructions.
4.5. Analyze the ChIP-seq data using bioinformatic tools (e.g., R, Bioconductor) to identify enriched regions.

**Protocol 5: Cellular Assays**

5.1. Evaluate the effect of microRNA overexpression on cancer stem cell proliferation using cell counting or MTT assays.
5.2. Evaluate the effect of microRNA overexpression on cancer stem cell differentiation using flow cytometry or immunofluorescence.
5.3. Evaluate the effect of microRNA overexpression on cancer stem cell self-renewal using colony-forming assays or sphere-forming assays.

**Protocol 6: Control Experiments**

6.1. Perform control experiments using scrambled microRNA controls or microRNA inhibitors to account for potential off-target effects.
6.2. Verify that the control experiments do not affect the epigenetic landscape or cellular properties of the cancer stem cells.

**Protocol 7: Data Analysis and Interpretation**

7.1. Analyze the epigenetic profiling data to identify changes in the epigenetic landscape of the microRNA-overexpressing cancer stem cells.
7.2. Analyze the cellular assay data to identify changes in cancer stem cell properties.
7.3. Interpret the results in the context of the original hypothesis and identify potential limitations or flaws.
7.4. Document the results and conclusions in a clear and concise manner.

**Timeline and Budget**

The experiment can be completed within 6-9 months, with a budget of approximately $150,000-$200,000. The budget breakdown is as follows:

* Cell lines and reagents: $20,000
* Lentiviral vectors and microRNA synthesis: $30,000
* Epigenetic profiling (DNA methylation arrays and ChIP-seq): $40,000
* Cellular assays and flow cytometry: $20,000
* Personnel and overhead: $40,000-$60,000

Note: The protocols and budget may need to be adjusted based on the specific requirements of the experiment and the resources available.","```
   K562  HepG2  Human_Hematopoietic_Stem_Cells  Human_Liver_Stem_Cells  miR-29  miR-101  miR-200  MOI  Outcome
0     1e6     1e6                       1e6                    1e6     100     100     100   10  Inhibited
1     5e5     5e5                       5e5                    5e5      50      50      50   15  Enhanced
2     2e6     2e6                       2e6                    2e6     200     200     200   20  Inhibited
3     1e5     1e5                       1e5                    1e5      20      20      20   10  No_Effect
4     3e6     3e6                       3e6                    3e6     300     300     300   15  Enhanced
5     2e5     2e5                       2e5                    2e5      40      40      40   20  Inhibited
6     1e6     1e6                       1e6                    1e6     150     150     150   10  Enhanced
7     5e6     5e6                       5e6                    5e6     250     250     250   15  Inhibited
8     3e5     3e5                       3e5                    3e5      60      60      60   20  No_Effect
9     2e6     2e6                       2e6                    2e6     220     220     220   10  Enhanced
10    1e5     1e5                       1e5                    1e5      30      30      30   15  Inhibited
11    4e6     4e6                       4e6                    4e6     320     320     320   20  Enhanced
12    2e5     2e5                       2e5                    2e5      45      45      45   10  No_Effect
13    3e6     3e6                       3e6                    3e6     280     280     280   15  Inhibited
14    1e6     1e6                       1e6                    1e6     180     180     180   20  Enhanced
15    5e5     5e5                       5e5                    5e5      55      55      55   10  Inhibited
16    2e6     2e6                       2e6                    2e6     240     240     240   15  No_Effect
17    4e5     4e5                       4e5                    4e5      65      65      65   20  Enhanced
18    3e5     3e5                       3e5                    3e5      35      35      35   10  Inhibited
19    1e6     1e6                       1e6                    1e6     160     160     160   15  Enhanced
20    2e5     2e5                       2e5                    2e5      25      25      25   20  No_Effect
21    5e6     5e6                       5e6                    5e6     260     260     260   10  Inhibited
22    3e6     3e6                       3e6                    3e6     290     290     290   15  Enhanced
23    1e5     1e5                       1e5                    1e5      40      40      40   20  Inhibited
24    4e6     4e6                       4e6                    4e6     310     310     310   10  No_Effect
```",0.0650692966340374
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1cdd323d97d549ca3ec740ed205d6394ba4d761f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/08bd98893595c65520d82235e7cb78fe2a63aa6d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b0a81bc2f5bea37a20b6712f43acd41aaf56dfb1.summary']","Can targeting Bruton's tyrosine kinase in regulatory B cells enhance their IL-10 production and restore the balance with follicular T helper cells, leading to improved treatment outcomes in patients with chronic lymphocytic leukemia and atopic dermatitis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove it. The hypothesis states: ""Can targeting Bruton's tyrosine kinase in regulatory B cells enhance their IL-10 production and restore the balance with follicular T helper cells, leading to improved treatment outcomes in patients with chronic lymphocytic leukemia and atopic dermatitis?""

To disprove this hypothesis, I will design an experiment that aims to show that targeting Bruton's tyrosine kinase (BTK) in regulatory B cells does not enhance IL-10 production or restore the balance with follicular T helper cells, and therefore does not lead to improved treatment outcomes in patients with chronic lymphocytic leukemia (CLL) and atopic dermatitis.

**Experiment:**

**Title:** Investigating the Effect of BTK Inhibition on IL-10 Production in Regulatory B Cells and Follicular T Helper Cell Balance in CLL and Atopic Dermatitis

**Objective:** To determine whether targeting BTK in regulatory B cells enhances IL-10 production and restores the balance with follicular T helper cells, leading to improved treatment outcomes in patients with CLL and atopic dermatitis.

**Design:**

1. **Cell Isolation:** Isolate regulatory B cells (Bregs) and follicular T helper cells (Tfh) from peripheral blood mononuclear cells (PBMCs) of patients with CLL and atopic dermatitis using flow cytometry.
2. **BTK Inhibition:** Treat Bregs with a specific BTK inhibitor (e.g., ibrutinib) at varying concentrations (0, 1, 10, and 100 nM) for 24 hours.
3. **IL-10 Production:** Measure IL-10 production in Bregs using ELISA after BTK inhibition.
4. **Tfh Cell Co-Culture:** Co-culture Bregs with Tfh cells at a 1:1 ratio for 48 hours. Measure Tfh cell activation markers (e.g., CD40L, ICOS) using flow cytometry.
5. **Cytokine Analysis:** Analyze cytokine production (e.g., IL-10, IL-21, IFN-γ) in the co-culture supernatant using a cytokine array or ELISA.
6. **Control Groups:** Include control groups with untreated Bregs and Tfh cells, as well as Bregs treated with a non-specific inhibitor (e.g., DMSO) to account for any non-specific effects.

**Expected Outcomes:**

* If the hypothesis is true, BTK inhibition in Bregs should increase IL-10 production, leading to a decrease in Tfh cell activation and a shift towards a more balanced immune response.
* If the hypothesis is false, BTK inhibition in Bregs should not affect IL-10 production, and Tfh cell activation and cytokine production should remain unchanged.

**Statistical Analysis:**

* Compare IL-10 production, Tfh cell activation markers, and cytokine production between the BTK-inhibited and control groups using one-way ANOVA with post-hoc tests (e.g., Tukey's HSD).
* Perform correlation analysis between IL-10 production and Tfh cell activation markers to determine if there is a significant relationship between the two.

**Resources:**

* Access to a flow cytometer, ELISA reader, and cytokine array or ELISA kits
* BTK inhibitor (e.g., ibrutinib) and non-specific inhibitor (e.g., DMSO)
* PBMCs from patients with CLL and atopic dermatitis
* Cell culture media and reagents
* Statistical analysis software (e.g., GraphPad Prism, R)

By designing an experiment that aims to disprove the hypothesis, we can rigorously test the idea and provide evidence for or against the proposed mechanism. If the results do not support the hypothesis, it may indicate that targeting BTK in regulatory B cells is not an effective strategy for improving treatment outcomes in patients with CLL and atopic dermatitis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation**

1.1. Obtain peripheral blood mononuclear cells (PBMCs) from patients with chronic lymphocytic leukemia (CLL) and atopic dermatitis.

1.2. Prepare the PBMCs for flow cytometry by washing them twice with phosphate-buffered saline (PBS) and resuspending them in 1 mL of PBS.

1.3. Stain the PBMCs with fluorescently labeled antibodies against CD19, CD24, and CD38 to identify regulatory B cells (Bregs) and CD4, CXCR5, and PD-1 to identify follicular T helper cells (Tfh).

1.4. Perform flow cytometry using a flow cytometer (e.g., BD FACSAria III) to sort and collect Bregs and Tfh cells.

1.5. Collect the sorted cells in separate tubes and wash them twice with PBS.

**Protocol 2: BTK Inhibition**

2.1. Prepare a stock solution of the BTK inhibitor ibrutinib (e.g., 10 mM) in DMSO.

2.2. Prepare four working solutions of ibrutinib at concentrations of 0, 1, 10, and 100 nM by diluting the stock solution with cell culture media (e.g., RPMI 1640).

2.3. Add 1 mL of each working solution to separate tubes containing 1 x 10^6 Bregs.

2.4. Incubate the cells at 37°C, 5% CO2 for 24 hours.

**Protocol 3: IL-10 Production**

3.1. After 24 hours of incubation, collect the supernatant from each tube and store it at -80°C for later analysis.

3.2. Perform an ELISA assay to measure IL-10 production in the supernatant using a commercial IL-10 ELISA kit (e.g., R&D Systems).

3.3. Follow the manufacturer's instructions to prepare the ELISA plate, add the supernatant samples, and detect IL-10 using a plate reader (e.g., BioTek Epoch).

**Protocol 4: Tfh Cell Co-Culture**

4.1. Prepare a co-culture mixture by combining 1 x 10^6 Bregs (treated with ibrutinib or DMSO) with 1 x 10^6 Tfh cells in 1 mL of cell culture media.

4.2. Incubate the co-culture mixture at 37°C, 5% CO2 for 48 hours.

4.3. After 48 hours, collect the supernatant and store it at -80°C for later analysis.

**Protocol 5: Cytokine Analysis**

5.1. Perform a cytokine array or ELISA assay to measure cytokine production (e.g., IL-10, IL-21, IFN-γ) in the co-culture supernatant using a commercial cytokine array or ELISA kit (e.g., R&D Systems).

5.2. Follow the manufacturer's instructions to prepare the array or ELISA plate, add the supernatant samples, and detect cytokines using a plate reader (e.g., BioTek Epoch).

**Protocol 6: Control Groups**

6.1. Prepare control groups by treating Bregs with DMSO (non-specific inhibitor) and incubating them for 24 hours.

6.2. Perform the same co-culture and cytokine analysis protocols as described above for the control groups.

**Protocol 7: Statistical Analysis**

7.1. Use statistical analysis software (e.g., GraphPad Prism, R) to compare IL-10 production, Tfh cell activation markers, and cytokine production between the BTK-inhibited and control groups.

7.2. Perform one-way ANOVA with post-hoc tests (e.g., Tukey's HSD) to determine significant differences between groups.

7.3. Perform correlation analysis between IL-10 production and Tfh cell activation markers to determine if there is a significant relationship between the two.

By following these detailed protocols, the experiment can be replicated and the results can be accurately analyzed to test the hypothesis.","```
   PBMCs  CD19  CD24  CD38  CD4  CXCR5  PD-1  Ibrutinib  IL-10
0   1e6    100   200   300  100    200    100        0.0  120.0
1   1e6    120   220   320  120    220    120        1.0  110.0
2   1e6    100   200   300  100    200    100       10.0   90.0
3   1e6    120   220   320  120    220    120      100.0   70.0
4   1e6    100   200   300  100    200    100        0.0  130.0
5   1e6    120   220   320  120    220    120        1.0  100.0
6   1e6    100   200   300  100    200    100       10.0   80.0
7   1e6    120   220   320  120    220    120      100.0   60.0
8   1e6    100   200   300  100    200    100        0.0  140.0
9   1e6    120   220   320  120    220    120        1.0  110.0
10  1e6    100   200   300  100    200    100       10.0   90.0
11  1e6    120   220   320  120    220    120      100.0   70.0
12  1e6    100   200   300  100    200    100        0.0  130.0
13  1e6    120   220   320  120    220    120        1.0  100.0
14  1e6    100   200   300  100    200    100       10.0   80.0
15  1e6    120   220   320  120    220    120      100.0   60.0
16  1e6    100   200   300  100    200    100        0.0  140.0
17  1e6    120   220   320  120    220    120        1.0  110.0
18  1e6    100   200   300  100    200    100       10.0   90.0
19  1e6    120   220   320  120    220    120      100.0   70.0
20  1e6    100   200   300  100    200    100        0.0  130.0
21  1e6    120   220   320  120    220    120        1.0  100.0
22  1e6    100   200   300  100    200    100       10.0   80.0
23  1e6    120   220   320  120    220    120      100.0   60.0
24  1e6    100   200   300  100    200    100        0.0  140.0
```",0.5311570980873186
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/45fcd131bed48fe8e0d958f2bc01d7497e074443.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/01b16c07494f564bc5a797b9bf09aaaa3bfe21a9.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f2b6af6fac36b20212ea282ebd759158709558b9.summary']","Can targeting TLR7 and TLR9 simultaneously in age/autoimmunity-associated B cells lead to a more effective therapeutic strategy for treating inflammatory arthritis, including rheumatoid arthritis, by disrupting their differentiation and activation pathways?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test the hypothesis and potentially disprove it.

**Hypothesis:** Can targeting TLR7 and TLR9 simultaneously in age/autoimmunity-associated B cells (ABCs) lead to a more effective therapeutic strategy for treating inflammatory arthritis, including rheumatoid arthritis, by disrupting their differentiation and activation pathways?

**Experimental Plan:**

**Objective:** To investigate the effect of dual TLR7 and TLR9 targeting on ABCs in inflammatory arthritis and assess its therapeutic potential.

**Experimental Design:**

1. **Cell Isolation and Culture:** Isolate ABCs from peripheral blood of rheumatoid arthritis (RA) patients using flow cytometry and cell sorting. Culture the isolated ABCs in vitro with T cell-derived cytokines to mimic the in vivo environment.
2. **TLR7 and TLR9 Targeting:** Use specific inhibitors or antagonists to target TLR7 and TLR9 simultaneously in the cultured ABCs. This can be achieved using small molecule inhibitors, antibodies, or RNA interference (RNAi) technology.
3. **Cellular Assays:** Perform cellular assays to assess the effects of dual TLR7 and TLR9 targeting on ABC differentiation, activation, and cytokine production. This can include:
	* Flow cytometry to analyze cell surface markers and intracellular cytokine production.
	* ELISA or multiplex assays to measure cytokine secretion.
	* Cell proliferation and viability assays to assess the impact on ABC survival and expansion.
4. **In Vivo Validation:** Validate the in vitro findings in an in vivo model of inflammatory arthritis, such as collagen-induced arthritis (CIA) in mice. Administer the TLR7 and TLR9 inhibitors or antagonists to CIA mice and assess disease severity, joint inflammation, and ABC frequency.

**Negative Control:** To disprove the hypothesis, a negative control group will be included, where ABCs are cultured without TLR7 and TLR9 targeting. This will serve as a baseline to compare the effects of dual targeting.

**Positive Control:** A positive control group can be included, where ABCs are cultured with a known therapeutic agent, such as a B cell-depleting antibody, to demonstrate the efficacy of the experimental design.

**Budget and Timeframe:**

* Cell isolation and culture: 2 weeks
* TLR7 and TLR9 targeting and cellular assays: 4 weeks
* In vivo validation: 8 weeks
* Data analysis and reporting: 4 weeks

Total duration: 18 weeks

Budget:

* Cell isolation and culture: $5,000
* TLR7 and TLR9 targeting reagents: $10,000
* Cellular assays and reagents: $8,000
* In vivo model and animal care: $15,000
* Personnel and overheads: $20,000

Total budget: $58,000

This experimental plan is designed to test the hypothesis and potentially disprove it, while being mindful of the limited budget and timeframe. The results of this study will provide valuable insights into the therapeutic potential of targeting TLR7 and TLR9 in ABCs for the treatment of inflammatory arthritis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Culture**

**Step 1.1: Peripheral Blood Collection**

* Collect 10 mL of peripheral blood from rheumatoid arthritis (RA) patients in EDTA-coated tubes.
* Label the tubes with the patient's ID and date of collection.
* Store the tubes at room temperature and process within 2 hours of collection.

**Step 1.2: PBMC Isolation**

* Add 10 mL of PBS to the blood tubes and mix gently.
* Layer 10 mL of Ficoll-Paque PLUS (GE Healthcare) onto the blood-PBS mixture.
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the peripheral blood mononuclear cell (PBMC) layer and transfer to a new tube.
* Wash the PBMCs with PBS and centrifuge at 300 x g for 10 minutes.

**Step 1.3: ABC Enrichment**

* Stain the PBMCs with anti-CD19, anti-CD20, and anti-CD27 antibodies (BioLegend) for 30 minutes at 4°C.
* Wash the cells with PBS and centrifuge at 300 x g for 10 minutes.
* Sort the cells using a flow cytometer (BD FACSAria III) to isolate ABCs (CD19+CD20-CD27hi).
* Collect the sorted ABCs in a tube containing RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

**Step 1.4: Cell Culture**

* Culture the isolated ABCs in a 24-well plate at a density of 1 x 10^6 cells/mL.
* Add T cell-derived cytokines (IL-2, IL-4, and IL-21) to the culture medium at a final concentration of 10 ng/mL each.
* Incubate the cells at 37°C, 5% CO2 for 3-4 days.

**Protocol 2: TLR7 and TLR9 Targeting**

**Step 2.1: Inhibitor Preparation**

* Prepare the TLR7 inhibitor (e.g., IRS661, InvivoGen) and TLR9 inhibitor (e.g., ODN 2088, InvivoGen) according to the manufacturer's instructions.
* Aliquot the inhibitors into 10 μL tubes and store at -20°C.

**Step 2.2: Inhibitor Treatment**

* Add 10 μL of TLR7 inhibitor and 10 μL of TLR9 inhibitor to the ABC culture medium to achieve a final concentration of 10 μM each.
* Incubate the cells for 24 hours at 37°C, 5% CO2.

**Protocol 3: Cellular Assays**

**Step 3.1: Flow Cytometry**

* Harvest the ABCs and stain with anti-CD19, anti-CD20, and anti-CD27 antibodies for 30 minutes at 4°C.
* Analyze the cells using a flow cytometer (BD FACSCanto II) to assess cell surface markers and intracellular cytokine production.

**Step 3.2: ELISA**

* Collect the culture supernatant and store at -80°C.
* Perform ELISA (R&D Systems) to measure cytokine secretion (e.g., TNF-α, IL-6, and IL-10).

**Step 3.3: Cell Proliferation and Viability Assay**

* Add 10 μL of CellTiter-Glo (Promega) to the ABC culture medium.
* Incubate for 10 minutes at room temperature.
* Measure the luminescence using a plate reader (PerkinElmer) to assess cell viability and proliferation.

**Protocol 4: In Vivo Validation**

**Step 4.1: CIA Model Induction**

* Induce collagen-induced arthritis (CIA) in 8-week-old DBA/1J mice (Jackson Laboratory) by injecting 100 μg of bovine type II collagen (Chondrex) emulsified in complete Freund's adjuvant (CFA) into the tail base.

**Step 4.2: Inhibitor Administration**

* Administer the TLR7 and TLR9 inhibitors (10 mg/kg each) or vehicle control to the CIA mice via intraperitoneal injection on days 0, 7, and 14.

**Step 4.3: Disease Assessment**

* Monitor the mice for arthritis severity, joint inflammation, and ABC frequency using a clinical scoring system (0-4) and flow cytometry.

**Step 4.4: Tissue Collection and Analysis**

* Collect the joints and spleens from the mice on day 21.
* Analyze the tissues using histology, immunohistochemistry, and flow cytometry to assess joint inflammation and ABC frequency.

**Negative Control:**

* Culture ABCs without TLR7 and TLR9 targeting and perform cellular assays as described above.

**Positive Control:**

* Culture ABCs with a known therapeutic agent (e.g., rituximab, Genentech) and perform cellular assays as described above.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity.","```
   Patient_ID  Blood_Volume_mL  Ficoll_Paque_mL  Antibody_Conc_ng_mL  Cytokine_Conc_ng_mL  TLR7_Inhibitor_Conc_uM  TLR9_Inhibitor_Conc_uM  Outcome
0           1              10.0             10.0                10.0                10.0                  10.0                  10.0  Inhibited
1           2               9.5              9.5                12.0                12.0                  12.0                  12.0  Inhibited
2           3              10.5             10.5                 8.0                 8.0                   8.0                   8.0  Inhibited
3           4               9.0              9.0                11.0                11.0                  11.0                  11.0  Inhibited
4           5              10.0             10.0                10.0                10.0                  10.0                  10.0  Inhibited
5           6               9.8             10.2                12.5                12.5                  12.5                  12.5  Inhibited
6           7              10.2             10.8                 9.5                 9.5                   9.5                   9.5  Inhibited
7           8               9.2              9.8                11.5                11.5                  11.5                  11.5  Inhibited
8           9              10.8             11.2                10.8                10.8                  10.8                  10.8  Inhibited
9          10               9.5             10.5                12.0                12.0                  12.0                  12.0  Inhibited
10         11              10.0             10.0                10.0                10.0                  10.0                  10.0  Inhibited
11         12               9.0              9.0                11.0                11.0                  11.0                  11.0  Inhibited
12         13              10.5             10.5                 8.0                 8.0                   8.0                   8.0  Inhibited
13         14               9.8             10.2                12.5                12.5                  12.5                  12.5  Inhibited
14         15              10.2             10.8                 9.5                 9.5                   9.5                   9.5  Inhibited
15         16               9.2              9.8                11.5                11.5                  11.5                  11.5  Inhibited
16         17              10.8             11.2                10.8                10.8                  10.8                  10.8  Inhibited
17         18               9.5             10.5                12.0                12.0                  12.0                  12.0  Inhibited
18         19              10.0             10.0                10.0                10.0                  10.0                  10.0  Inhibited
19         20               9.0              9.0                11.0                11.0                  11.0                  11.0  Inhibited
20         21              10.5             10.5                 8.0                 8.0                   8.0                   8.0  Inhibited
21         22               9.8             10.2                12.5                12.5                  12.5                  12.5  Inhibited
22         23              10.2             10.8                 9.5                 9.5                   9.5                   9.5  Inhibited
23         24               9.2              9.8                11.5                11.5                  11.5                  11.5  Inhibited
24         25              10.8             11.2                10.8                10.8                  10.8                  10.8  Inhibited
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0e810283d6a002b25954490974f0193464c12e62.summary'],Can the 14-gene signature be used to predict the efficacy of combination therapy with immunotherapy and targeted therapies in DLBCL patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that the 14-gene signature can predict the efficacy of combination therapy with immunotherapy and targeted therapies in DLBCL patients.

**Experimental Plan:**

**Title:** ""Evaluation of the 14-Gene Signature as a Predictor of Response to Combination Therapy with Immunotherapy and Targeted Therapies in DLBCL Patients""

**Objective:** To determine whether the 14-gene signature can predict the efficacy of combination therapy with immunotherapy and targeted therapies in DLBCL patients.

**Design:** Prospective cohort study

**Methods:**

1. **Patient Selection:** Recruit 50 DLBCL patients who will receive combination therapy with immunotherapy and targeted therapies.
2. **Tumor Sample Collection:** Collect tumor biopsies from each patient before treatment initiation.
3. **RNA Extraction and Gene Expression Analysis:** Extract RNA from the tumor samples and perform gene expression analysis using RNA-seq or qRT-PCR to determine the expression levels of the 14 genes in the signature.
4. **Calculation of 14-Gene Signature Score:** Calculate the 14-gene signature score for each patient using the gene expression data.
5. **Treatment and Response Assessment:** Patients will receive combination therapy with immunotherapy and targeted therapies. Response to treatment will be assessed using standard criteria (e.g., complete response, partial response, stable disease, progressive disease).
6. **Correlation Analysis:** Compare the 14-gene signature score with the response to combination therapy using statistical analysis (e.g., logistic regression, Kaplan-Meier analysis).
7. **Validation:** Validate the results using an independent cohort of 20 DLBCL patients who have received combination therapy with immunotherapy and targeted therapies.

**Equipment:**

* RNA-seq or qRT-PCR instrument
* Bioinformatics software for data analysis
* Statistical software for data analysis (e.g., R, Python)

**Steps to Follow:**

1. Collect and process tumor samples
2. Extract RNA and perform gene expression analysis
3. Calculate the 14-gene signature score
4. Treat patients with combination therapy and assess response
5. Compare the 14-gene signature score with response to combination therapy
6. Perform statistical analysis and interpret results
7. Validate the results using an independent cohort

**Budget and Timeline:**

* Estimated budget: $200,000
* Estimated timeline: 12 months

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the null hypothesis that the 14-gene signature is not associated with response to combination therapy with immunotherapy and targeted therapies in DLBCL patients.

**Null Hypothesis:** The 14-gene signature is not associated with response to combination therapy with immunotherapy and targeted therapies in DLBCL patients.

**Alternative Hypothesis:** The 14-gene signature is associated with response to combination therapy with immunotherapy and targeted therapies in DLBCL patients.

**Experimental Design:**

1. **Patient Selection:** Recruit 50 DLBCL patients who will receive combination therapy with immunotherapy and targeted therapies.
2. **Tumor Sample Collection:** Collect tumor biopsies from each patient before treatment initiation.
3. **RNA Extraction and Gene Expression Analysis:** Extract RNA from the tumor samples and perform gene expression analysis using RNA-seq or qRT-PCR to determine the expression levels of the 14 genes in the signature.
4. **Calculation of 14-Gene Signature Score:** Calculate the 14-gene signature score for each patient using the gene expression data.
5. **Treatment and Response Assessment:** Patients will receive combination therapy with immunotherapy and targeted therapies. Response to treatment will be assessed using standard criteria (e.g., complete response, partial response, stable disease, progressive disease).
6. **Permutation Test:** Randomly permute the 14-gene signature scores and re-calculate the correlation with response to combination therapy. Repeat this process 1,000 times to generate a null distribution of correlation coefficients.
7. **Comparison:** Compare the observed correlation coefficient between the 14-gene signature score and response to combination therapy with the null distribution generated in step 6. If the observed correlation coefficient falls within the null distribution, it suggests that the 14-gene signature is not associated with response to combination therapy.

By designing an experiment to disprove the hypothesis, we can increase the confidence in the results and provide a more robust test of the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Patient Selection and Tumor Sample Collection**

1.1. Identify and recruit 50 DLBCL patients who will receive combination therapy with immunotherapy and targeted therapies.

* Inclusion criteria: Patients must have a confirmed diagnosis of DLBCL, be scheduled to receive combination therapy with immunotherapy and targeted therapies, and provide informed consent.
* Exclusion criteria: Patients with a history of prior cancer treatment, concurrent malignancies, or significant comorbidities.

1.2. Obtain informed consent from each patient.

* Use a standardized informed consent form approved by the Institutional Review Board (IRB).
* Ensure patients understand the purpose, risks, and benefits of the study.

1.3. Collect tumor biopsies from each patient before treatment initiation.

* Use a standardized biopsy procedure (e.g., core needle biopsy or surgical biopsy).
* Collect 2-3 biopsy samples from each patient, depending on the size of the tumor.
* Label and store the biopsy samples in a -80°C freezer or liquid nitrogen tank.

**Protocol 2: RNA Extraction and Gene Expression Analysis**

2.1. Extract RNA from the tumor samples using a standardized RNA extraction protocol.

* Use a commercial RNA extraction kit (e.g., Qiagen RNeasy Kit) or a validated in-house protocol.
* Follow the manufacturer's instructions for RNA extraction, including homogenization, lysis, and purification steps.
* Quantify the extracted RNA using a spectrophotometer (e.g., NanoDrop) and assess RNA quality using a bioanalyzer (e.g., Agilent 2100).

2.2. Perform gene expression analysis using RNA-seq or qRT-PCR.

* For RNA-seq:
	+ Prepare RNA-seq libraries using a commercial kit (e.g., Illumina TruSeq Stranded mRNA Library Prep Kit).
	+ Sequence the libraries on a next-generation sequencing platform (e.g., Illumina HiSeq 4000).
	+ Analyze the sequencing data using a bioinformatics pipeline (e.g., STAR, featureCounts, DESeq2).
* For qRT-PCR:
	+ Design and synthesize primers specific to the 14 genes in the signature.
	+ Perform qRT-PCR using a commercial kit (e.g., TaqMan Gene Expression Assays) and a real-time PCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).
	+ Analyze the qRT-PCR data using a software package (e.g., SDS 2.4, R).

**Protocol 3: Calculation of 14-Gene Signature Score**

3.1. Calculate the expression levels of the 14 genes in the signature for each patient.

* Use the gene expression data from RNA-seq or qRT-PCR to calculate the expression levels of each gene.
* Normalize the expression data using a suitable method (e.g., TPM, FPKM, or relative quantification).

3.2. Calculate the 14-gene signature score for each patient.

* Use a weighted sum or a machine learning algorithm to combine the expression levels of the 14 genes.
* Normalize the signature score to a standardized range (e.g., 0-100).

**Protocol 4: Treatment and Response Assessment**

4.1. Treat patients with combination therapy with immunotherapy and targeted therapies.

* Follow the standard treatment protocol for DLBCL patients receiving combination therapy.
* Ensure patients receive the same treatment regimen and dosing schedule.

4.2. Assess response to treatment using standard criteria.

* Use the Lugano classification system to assess response to treatment (e.g., complete response, partial response, stable disease, progressive disease).
* Evaluate response at regular intervals (e.g., every 2-3 months) during treatment.

**Protocol 5: Correlation Analysis**

5.1. Compare the 14-gene signature score with response to combination therapy.

* Use a statistical software package (e.g., R, Python) to perform correlation analysis.
* Calculate the correlation coefficient (e.g., Pearson's r, Spearman's rho) between the 14-gene signature score and response to treatment.

5.2. Perform statistical analysis and interpret results.

* Use a suitable statistical test (e.g., logistic regression, Kaplan-Meier analysis) to evaluate the association between the 14-gene signature score and response to treatment.
* Report the results in a clear and concise manner, including p-values, confidence intervals, and effect sizes.

**Protocol 6: Validation**

6.1. Recruit an independent cohort of 20 DLBCL patients who have received combination therapy with immunotherapy and targeted therapies.

* Follow the same inclusion and exclusion criteria as the primary cohort.
* Collect tumor biopsies and perform RNA extraction, gene expression analysis, and 14-gene signature score calculation as described in Protocols 1-3.

6.2. Compare the 14-gene signature score with response to combination therapy in the validation cohort.

* Repeat the correlation analysis and statistical testing as described in Protocol 5.
* Evaluate the consistency of the results between the primary and validation cohorts.

**Protocol 7: Experiment to Disprove the Hypothesis**

7.1. Perform a permutation test to generate a null distribution of correlation coefficients.

* Randomly permute the 14-gene signature scores and re-calculate the correlation with response to combination therapy.
* Repeat this process 1,000 times to generate a null distribution of correlation coefficients.

7.2. Compare the observed correlation coefficient with the null distribution.

* Calculate the p-value by determining the proportion of permutation tests that yield a correlation coefficient greater than or equal to the observed correlation coefficient.
* If the p-value is greater than 0.05, it suggests that the 14-gene signature is not associated with response to combination therapy.","```
   Patients  RNA_Quantity  RNA_Quality  Gene_Expression  Signature_Score  Treatment_Dose  Response
0        50        1000.0         1.80          0.456         43.21         200.0       CR
1        45         900.0         1.70          0.512         40.15         220.0       PR
2        48        1100.0         1.90          0.489         41.98         210.0       CR
3        42         800.0         1.60          0.475         39.85         230.0       SD
4        49        1200.0         2.00          0.502         42.50         200.0       CR
5        46         950.0         1.75          0.491         41.21         215.0       PR
6        44         850.0         1.65          0.482         40.56         225.0       SD
7        51        1300.0         2.10          0.518         43.89         205.0       CR
8        43         900.0         1.70          0.505         41.95         220.0       PR
9        47        1000.0         1.80          0.494         42.12         210.0       CR
10       41         750.0         1.55          0.469         39.23         235.0       SD
11       50        1250.0         2.05          0.525         44.56         200.0       CR
12       45         925.0         1.75          0.508         41.67         215.0       PR
13       48        1150.0         1.95          0.501         42.89         205.0       CR
14       42         825.0         1.65          0.486         40.98         225.0       SD
15       49        1350.0         2.20          0.538         45.23         200.0       CR
16       46         975.0         1.85          0.514         42.45         210.0       PR
17       44         875.0         1.70          0.499         41.78         220.0       SD
18       51        1400.0         2.30          0.552         46.01         205.0       CR
19       43         950.0         1.80          0.521         42.92         215.0       PR
20       47        1100.0         1.90          0.506         42.56         210.0       CR
21       41         800.0         1.60          0.483         40.34         230.0       SD
22       50        1300.0         2.10          0.535         44.89         200.0       CR
23       45         1000.0         1.85          0.518         42.23         215.0       PR
24       48        1250.0         2.05          0.529         44.12         205.0       CR
```",0.49002740338466694
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/13ab818c76b936e8977fe7eff7703faae14a065f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3a12cd7ef40e74382a1f934904d48c90b62420bc.summary']",Can the BAFF-APRIL system be used as a biomarker to predict the efficacy of cancer immunotherapy by analyzing its expression levels in tumor cells and immune cells using the DexterTM microfluidic platform?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis using existing scientific methods and equipment. To disprove the hypothesis, I've designed an experiment to verify if the BAFF-APRIL system can be used as a biomarker to predict the efficacy of cancer immunotherapy.

**Experimental Plan:**

**Title:** Investigating the BAFF-APRIL System as a Biomarker for Cancer Immunotherapy Efficacy using the DexterTM Microfluidic Platform

**Objective:** To determine if the BAFF-APRIL system can be used as a biomarker to predict the efficacy of cancer immunotherapy by analyzing its expression levels in tumor cells and immune cells using the DexterTM microfluidic platform.

**Experimental Design:**

1. **Sample Collection:** Collect blood samples from cancer patients undergoing immunotherapy (n=50). Isolate tumor cells and immune cells (T cells, B cells, and dendritic cells) from the samples using standard protocols.
2. **BAFF-APRIL Expression Analysis:** Use the DexterTM microfluidic platform to analyze the expression levels of BAFF and APRIL in tumor cells and immune cells at the single-cell level. This will provide a comprehensive understanding of the BAFF-APRIL system's expression profile in different cell types.
3. **Immunotherapy Response Analysis:** Collect clinical data on the patients' response to immunotherapy, including treatment outcome (responders vs. non-responders) and time to progression.
4. **Correlation Analysis:** Correlate the BAFF-APRIL expression levels with the immunotherapy response data to identify potential associations between the two.
5. **Machine Learning Model Development:** Develop a machine learning model using the BAFF-APRIL expression data and clinical outcome data to predict the efficacy of cancer immunotherapy.

**To Disprove the Hypothesis:**

**Null Hypothesis:** The BAFF-APRIL system is not a reliable biomarker for predicting the efficacy of cancer immunotherapy.

**Alternative Hypothesis:** The BAFF-APRIL system is a reliable biomarker for predicting the efficacy of cancer immunotherapy.

**Experimental Approach to Disprove the Hypothesis:**

1. **Randomized Patient Selection:** Randomly select a subset of patients (n=20) from the original cohort and re-analyze their BAFF-APRIL expression data using the DexterTM platform.
2. **Sham Treatment:** Administer a sham treatment (e.g., placebo) to these patients and collect follow-up samples.
3. **BAFF-APRIL Expression Re-Analysis:** Re-analyze the BAFF-APRIL expression levels in the follow-up samples using the DexterTM platform.
4. **Comparison:** Compare the BAFF-APRIL expression levels between the sham treatment group and the original treatment group.
5. **Statistical Analysis:** Perform statistical analysis to determine if the BAFF-APRIL expression levels are significantly different between the two groups. If the results show no significant difference, it would suggest that the BAFF-APRIL system is not a reliable biomarker for predicting the efficacy of cancer immunotherapy, thus disproving the hypothesis.

**Equipment and Resources:**

* DexterTM microfluidic platform
* AI-guided matrix software
* Flow cytometer
* Cell sorter
* Statistical analysis software
* Blood samples from cancer patients undergoing immunotherapy
* Standard laboratory equipment for cell isolation and culture

**Timeline:** The experiment can be completed within 6-9 months, considering the time required for sample collection, data analysis, and machine learning model development.

**Budget:** The budget for this experiment will be approximately $200,000, covering the costs of equipment, reagents, personnel, and statistical analysis software.

By following this experimental plan, we can determine if the BAFF-APRIL system can be used as a biomarker to predict the efficacy of cancer immunotherapy and verify the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Sample Collection and Cell Isolation**

1.1. Collect blood samples from 50 cancer patients undergoing immunotherapy using standard phlebotomy procedures.

1.2. Label and store the blood samples at 4°C until processing.

1.3. Isolate peripheral blood mononuclear cells (PBMCs) from the blood samples using density gradient centrifugation (e.g., Ficoll-Paque).

1.4. Wash the PBMCs with phosphate-buffered saline (PBS) and resuspend them in a suitable buffer for cell sorting.

1.5. Use a cell sorter (e.g., fluorescence-activated cell sorter, FACS) to isolate tumor cells, T cells, B cells, and dendritic cells from the PBMCs based on specific surface markers (e.g., CD45, CD3, CD19, CD11c).

1.6. Collect the isolated cells in separate tubes and store them at -80°C until further analysis.

**Protocol 2: BAFF-APRIL Expression Analysis**

2.1. Thaw the isolated cells and resuspend them in a suitable buffer for the DexterTM microfluidic platform.

2.2. Prepare the DexterTM platform according to the manufacturer's instructions.

2.3. Load the cells onto the DexterTM platform and perform single-cell analysis using the AI-guided matrix software.

2.4. Analyze the expression levels of BAFF and APRIL in each cell type (tumor cells, T cells, B cells, and dendritic cells) using the DexterTM platform.

2.5. Record the expression data for each cell type and store it in a secure database.

**Protocol 3: Immunotherapy Response Analysis**

3.1. Collect clinical data on the patients' response to immunotherapy, including treatment outcome (responders vs. non-responders) and time to progression.

3.2. Record the clinical data in a secure database and link it to the corresponding patient samples.

**Protocol 4: Correlation Analysis**

4.1. Use statistical analysis software to correlate the BAFF-APRIL expression levels with the immunotherapy response data.

4.2. Perform correlation analysis using suitable statistical tests (e.g., Pearson's correlation, Spearman's rank correlation).

4.3. Record the correlation coefficients and p-values for each analysis.

**Protocol 5: Machine Learning Model Development**

5.1. Use the BAFF-APRIL expression data and clinical outcome data to develop a machine learning model using a suitable algorithm (e.g., random forest, support vector machine).

5.2. Train the model using a training dataset and validate it using a test dataset.

5.3. Record the model's performance metrics (e.g., accuracy, precision, recall).

**Protocol 6: Experimental Approach to Disprove the Hypothesis**

6.1. Randomly select a subset of 20 patients from the original cohort.

6.2. Administer a sham treatment (e.g., placebo) to these patients and collect follow-up blood samples.

6.3. Isolate cells from the follow-up samples using the same protocol as before (Protocol 1).

6.4. Analyze the BAFF-APRIL expression levels in the follow-up samples using the DexterTM platform (Protocol 2).

6.5. Compare the BAFF-APRIL expression levels between the sham treatment group and the original treatment group using statistical analysis software.

6.6. Perform statistical analysis to determine if the BAFF-APRIL expression levels are significantly different between the two groups.

**Quality Control and Assurance**

* Regularly calibrate the DexterTM platform and flow cytometer according to the manufacturer's instructions.
* Use positive and negative controls for the BAFF-APRIL expression analysis.
* Perform regular quality control checks on the isolated cells and expression data.
* Document all experimental procedures, results, and quality control measures.

**Timeline and Budget**

* The experiment can be completed within 6-9 months, considering the time required for sample collection, data analysis, and machine learning model development.
* The budget for this experiment will be approximately $200,000, covering the costs of equipment, reagents, personnel, and statistical analysis software.","```
   Patient_ID  Tumor_Cells  T_Cells  B_Cells  Dendritic_Cells  BAFF_Exp_Tumor  BAFF_Exp_T  BAFF_Exp_B  BAFF_Exp_D  APRIL_Exp_Tumor  APRIL_Exp_T  APRIL_Exp_B  APRIL_Exp_D  Immunotherapy_Response
0           1        10000    20000    15000           5000         2.5       1.8       2.2       1.5              3.2           2.1           2.8           2.5               Responder
1           2        12000    25000    18000           6000         2.8       2.2       2.5       1.8              3.5           2.5           3.2           2.8               Responder
2           3         9000    18000    12000           4000         2.2       1.5       2.0       1.2              2.8           2.0           2.5           2.2               Non-Responder
3           4        11000    22000    16000           5500         2.6       2.0       2.3       1.6              3.0           2.3           2.9           2.6               Responder
4           5        13000    28000    20000           6500         3.0       2.5       2.8       2.0              3.8           2.8           3.5           3.2               Responder
5           6         8000    15000    10000           3500         2.0       1.2       1.8       1.0              2.5           1.8           2.2           2.0               Non-Responder
6           7        14000    30000    22000           7000         3.2       2.8       3.2       2.2              4.0           3.2           3.8           3.5               Responder
7           8        10000    20000    15000           5000         2.5       2.0       2.3       1.8              3.2           2.5           3.0           2.8               Responder
8           9        16000    32000    24000           7500         3.5       3.2       3.5       2.5              4.2           3.5           4.0           3.8               Responder
9          10         7000    12000     9000           3000         1.8       1.0       1.5       0.8              2.2           1.5           2.0           1.8               Non-Responder
10         11        17000    34000    26000           8000         3.8       3.5       3.8       2.8              4.5           3.8           4.2           4.0               Responder
11         12        11000    22000    16000           5500         2.6       2.2       2.5       2.0              3.2           2.8           3.2           2.9               Responder
12         13         6000     9000     7000           2500         1.5       0.8       1.2       0.5              1.8           1.2           1.8           1.5               Non-Responder
13         14        18000    36000    28000           8500         4.0       3.8       4.0       3.2              4.8           4.2           4.5           4.2               Responder
14         15        12000    24000    18000           6000         2.8       2.5       2.8       2.2              3.5           3.2           3.5           3.2               Responder
15         16         5000     8000     6000           2000         1.2       0.5       1.0       0.2              1.5           1.0           1.5           1.2               Non-Responder
16         17        19000    38000    30000           9000         4.2       4.0       4.2       3.5              5.0           4.5           4.8           4.5               Responder
17         18        13000    26000    20000           6500         3.0       2.8       3.2       2.5              3.8           3.5           4.0           3.8               Responder
18         19         4000     6000     5000           1500         1.0       0.2       0.8       0.0              1.2           0.8           1.2           1.0               Non-Responder
19         20        20000    40000    32000          10000         4.5       4.2       4.5       4.0              5.2           4.8           5.0           4.8               Responder
20         21        15000    30000    24000           7500         3.5       3.2       3.8       3.2              4.2           4.0           4.2           4.0               Responder
21         22         3000     4000     3000           1000         0.8       0.0       0.5       0.0              1.0           0.5           1.0           0.8               Non-Responder
22         23        21000    42000    34000          11000         4.8       4.5       4.8       4.2              5.5           5.0           5.2           5.0               Responder
23         24        16000    32000    26000           8000         3.8       3.5       4.0       3.5              4.5           4.2           4.5           4.2               Responder
24         25        18000    36000    30000           9000         4.2       4.0       4.2       3.8              5.0           4.8           5.0           4.8               Responder
```",0.7433248662392248
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0e4658293ab2adc57f63d50b9014d1308841f429.summary'],"Can the Sgc8-c aptamer be modified to target specific lymphoma subtypes by incorporating subtype-specific peptides, leading to enhanced therapeutic efficacy and reduced off-target effects?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Can the Sgc8-c aptamer be modified to target specific lymphoma subtypes by incorporating subtype-specific peptides, leading to enhanced therapeutic efficacy and reduced off-target effects?

**Experimental Plan:**

**Objective:** To investigate whether modifying the Sgc8-c aptamer with subtype-specific peptides can improve its targeting specificity and therapeutic efficacy in various lymphoma subtypes while reducing off-target effects.

**Experimental Design:**

1. **Peptide Design and Synthesis:**
	* Identify subtype-specific peptides for various lymphoma subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) using bioinformatics tools and literature reviews.
	* Synthesize these peptides using standard solid-phase peptide synthesis methods.
2. **Aptamer Modification:**
	* Modify the Sgc8-c aptamer by incorporating the subtype-specific peptides using various conjugation methods (e.g., click chemistry, thiol-maleimide reaction).
	* Verify the successful conjugation of peptides to the aptamer using techniques like mass spectrometry, gel electrophoresis, and spectroscopy.
3. **Cell Culture and Lymphoma Cell Lines:**
	* Obtain a panel of lymphoma cell lines representing different subtypes (e.g., OCI-Ly1, DOHH2, Granta-519).
	* Culture these cells in appropriate media and maintain them in a controlled environment.
4. **Binding Assays:**
	* Perform binding assays (e.g., surface plasmon resonance, fluorescence-activated cell sorting) to evaluate the binding affinity and specificity of the modified aptamers to their respective lymphoma subtypes.
	* Compare the binding properties of the modified aptamers to the unmodified Sgc8-c aptamer.
5. **Cellular Uptake and Internalization:**
	* Investigate the cellular uptake and internalization of the modified aptamers in lymphoma cells using confocal microscopy, flow cytometry, and biochemical assays.
	* Compare the uptake and internalization efficiency of the modified aptamers to the unmodified Sgc8-c aptamer.
6. **Cytotoxicity and Apoptosis Assays:**
	* Evaluate the cytotoxicity and apoptosis-inducing effects of the modified aptamers on lymphoma cells using assays like MTT, Annexin V staining, and caspase activity measurements.
	* Compare the therapeutic efficacy of the modified aptamers to the unmodified Sgc8-c aptamer.
7. **Off-Target Effects:**
	* Investigate the off-target effects of the modified aptamers on non-lymphoma cells (e.g., peripheral blood mononuclear cells, healthy B cells) using similar assays as above.
	* Compare the off-target effects of the modified aptamers to the unmodified Sgc8-c aptamer.
8. **In Vivo Studies:**
	* Perform in vivo studies using xenograft models of lymphoma to evaluate the therapeutic efficacy and biodistribution of the modified aptamers.
	* Compare the in vivo performance of the modified aptamers to the unmodified Sgc8-c aptamer.

**Experiment to Disprove the Hypothesis:**

**Objective:** To design an experiment that can potentially disprove the hypothesis by demonstrating that modifying the Sgc8-c aptamer with subtype-specific peptides does not improve its targeting specificity or therapeutic efficacy.

**Experimental Design:**

1. **Negative Control Peptides:**
	* Design and synthesize peptides that are not specific to any lymphoma subtype (e.g., scrambled peptides, non-specific peptides).
	* Conjugate these negative control peptides to the Sgc8-c aptamer using the same methods as above.
2. **Comparison to Unmodified Aptamer:**
	* Compare the binding affinity, cellular uptake, and therapeutic efficacy of the aptamer modified with negative control peptides to the unmodified Sgc8-c aptamer.
	* If the modified aptamer performs similarly to or worse than the unmodified aptamer, it would suggest that the incorporation of subtype-specific peptides does not improve the aptamer's performance.
3. **Lymphoma Cell Line Panel:**
	* Use a panel of lymphoma cell lines that are not specific to the subtype targeted by the modified aptamer (e.g., if the modified aptamer is designed to target diffuse large B-cell lymphoma, use cell lines from other subtypes like follicular lymphoma or mantle cell lymphoma).
	* Evaluate the binding affinity, cellular uptake, and therapeutic efficacy of the modified aptamer on these non-targeted cell lines.
	* If the modified aptamer shows no improved performance on these cell lines compared to the unmodified aptamer, it would suggest that the incorporation of subtype-specific peptides does not enhance the aptamer's targeting specificity.

By designing an experiment to disprove the hypothesis, we can increase confidence in the results and ensure that any positive findings are not due to chance or experimental bias.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Peptide Design and Synthesis:**

1.1. **Peptide Design:**

* Use bioinformatics tools such as BLAST, UniProt, and literature reviews to identify subtype-specific peptides for various lymphoma subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma).
* Design peptides with a length of 10-20 amino acids, considering factors such as hydrophobicity, charge, and secondary structure.
* Optimize peptide sequences using tools like PepScan or PeptideRank to ensure high binding affinity and specificity.

1.2. **Peptide Synthesis:**

* Use standard solid-phase peptide synthesis methods, such as Fmoc-based or Boc-based synthesis, to synthesize the designed peptides.
* Perform synthesis on a peptide synthesizer or manually using a peptide synthesis kit.
* Purify the synthesized peptides using high-performance liquid chromatography (HPLC) and verify their identity using mass spectrometry (MS).

**Aptamer Modification:**

2.1. **Aptamer Preparation:**

* Obtain the Sgc8-c aptamer from a commercial source or synthesize it in-house using standard nucleic acid synthesis methods.
* Purify the aptamer using HPLC and verify its identity using MS.

2.2. **Conjugation Methods:**

* Use click chemistry or thiol-maleimide reaction to conjugate the subtype-specific peptides to the Sgc8-c aptamer.
* For click chemistry, mix the aptamer with the peptide in the presence of Cu(I) catalyst and azide-functionalized linker.
* For thiol-maleimide reaction, mix the aptamer with the peptide in the presence of a reducing agent like TCEP.

2.3. **Conjugation Verification:**

* Verify the successful conjugation of peptides to the aptamer using techniques like:
	+ Mass spectrometry (MS): Analyze the molecular weight of the conjugated aptamer-peptide complex.
	+ Gel electrophoresis: Run the conjugated aptamer-peptide complex on a polyacrylamide gel to verify the expected size shift.
	+ Spectroscopy: Use techniques like UV-Vis or fluorescence spectroscopy to monitor the conjugation reaction.

**Cell Culture and Lymphoma Cell Lines:**

3.1. **Cell Line Selection:**

* Obtain a panel of lymphoma cell lines representing different subtypes (e.g., OCI-Ly1, DOHH2, Granta-519) from a commercial source or a cell bank.
* Verify the cell lines' identity and purity using techniques like PCR, Western blot, or flow cytometry.

3.2. **Cell Culture:**

* Culture the lymphoma cell lines in appropriate media (e.g., RPMI 1640, DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics.
* Maintain the cells in a controlled environment at 37°C, 5% CO2, and 95% humidity.

**Binding Assays:**

4.1. **Surface Plasmon Resonance (SPR):**

* Immobilize the modified aptamers on a SPR chip using a biotin-streptavidin interaction.
* Flow the lymphoma cell lines over the chip and measure the binding affinity using a SPR instrument.

4.2. **Fluorescence-Activated Cell Sorting (FACS):**

* Incubate the lymphoma cell lines with the modified aptamers conjugated to a fluorescent dye (e.g., FITC).
* Analyze the binding affinity using a flow cytometer and calculate the mean fluorescence intensity (MFI).

**Cellular Uptake and Internalization:**

5.1. **Confocal Microscopy:**

* Incubate the lymphoma cell lines with the modified aptamers conjugated to a fluorescent dye (e.g., FITC).
* Fix the cells and analyze the uptake and internalization using a confocal microscope.

5.2. **Flow Cytometry:**

* Incubate the lymphoma cell lines with the modified aptamers conjugated to a fluorescent dye (e.g., FITC).
* Analyze the uptake and internalization using a flow cytometer and calculate the MFI.

5.3. **Biochemical Assays:**

* Incubate the lymphoma cell lines with the modified aptamers and measure the uptake and internalization using biochemical assays like Western blot or ELISA.

**Cytotoxicity and Apoptosis Assays:**

6.1. **MTT Assay:**

* Incubate the lymphoma cell lines with the modified aptamers and measure the cytotoxicity using the MTT assay.

6.2. **Annexin V Staining:**

* Incubate the lymphoma cell lines with the modified aptamers and measure the apoptosis using Annexin V staining and flow cytometry.

6.3. **Caspase Activity Measurements:**

* Incubate the lymphoma cell lines with the modified aptamers and measure the caspase activity using a caspase assay kit.

**Off-Target Effects:**

7.1. **Non-Lymphoma Cell Lines:**

* Obtain non-lymphoma cell lines (e.g., peripheral blood mononuclear cells, healthy B cells) from a commercial source or a cell bank.
* Verify the cell lines' identity and purity using techniques like PCR, Western blot, or flow cytometry.

7.2. **Assays:**

* Perform the same assays as in sections 4-6 using the non-lymphoma cell lines to evaluate the off-target effects of the modified aptamers.

**In Vivo Studies:**

8.1. **Xenograft Models:**

* Establish xenograft models of lymphoma in immunodeficient mice (e.g., NOD/SCID mice).
* Inject the modified aptamers into the mice and evaluate the therapeutic efficacy and biodistribution using techniques like bioluminescence imaging or PET scans.

**Experiment to Disprove the Hypothesis:**

**Negative Control Peptides:**

1.1. **Peptide Design:**

* Design and synthesize peptides that are not specific to any lymphoma subtype (e.g., scrambled peptides, non-specific peptides).
* Optimize peptide sequences using tools like PepScan or PeptideRank to ensure low binding affinity and specificity.

1.2. **Conjugation:**

* Conjugate the negative control peptides to the Sgc8-c aptamer using the same methods as above.

**Comparison to Unmodified Aptamer:**

2.1. **Binding Assays:**

* Perform binding assays (e.g., SPR, FACS) to evaluate the binding affinity and specificity of the aptamer modified with negative control peptides to the lymphoma cell lines.
* Compare the binding properties to the unmodified Sgc8-c aptamer.

2.2. **Cellular Uptake and Internalization:**

* Investigate the cellular uptake and internalization of the aptamer modified with negative control peptides in lymphoma cells using confocal microscopy, flow cytometry, and biochemical assays.
* Compare the uptake and internalization efficiency to the unmodified Sgc8-c aptamer.

2.3. **Cytotoxicity and Apoptosis Assays:**

* Evaluate the cytotoxicity and apoptosis-inducing effects of the aptamer modified with negative control peptides on lymphoma cells using assays like MTT, Annexin V staining, and caspase activity measurements.
* Compare the therapeutic efficacy to the unmodified Sgc8-c aptamer.

**Lymphoma Cell Line Panel:**

3.1. **Cell Line Selection:**

* Use a panel of lymphoma cell lines that are not specific to the subtype targeted by the modified aptamer (e.g., if the modified aptamer is designed to target diffuse large B-cell lymphoma, use cell lines from other subtypes like follicular lymphoma or mantle cell lymphoma).

3.2. **Assays:**

* Evaluate the binding affinity, cellular uptake, and therapeutic efficacy of the modified aptamer on these non-targeted cell lines.
* Compare the performance to the unmodified Sgc8-c aptamer.","```
   Peptide_Length  Peptide_Hydrophobicity  Peptide_Charge  Aptamer_Concentration  Conjugation_Method  Lymphoma_Cell_Line  Binding_Affinity  Cellular_Uptake  Cytotoxicity
0              15                0.6          2.0               10.0          Click_Chemistry        OCI-Ly1          0.8          0.7          0.4
1              12                0.4          1.5                5.0       Thiol-Maleimide        DOHH2          0.6          0.5          0.3
2              18                0.7          2.5               15.0          Click_Chemistry        Granta-519      0.9          0.8          0.5
3              10                0.3          1.0                2.0       Thiol-Maleimide        OCI-Ly1          0.4          0.3          0.2
4              16                0.5          2.2               12.0          Click_Chemistry        DOHH2          0.7          0.6          0.4
5              14                0.6          2.1                8.0       Thiol-Maleimide        Granta-519      0.8          0.7          0.5
6              11                0.4          1.8                4.0          Click_Chemistry        OCI-Ly1          0.5          0.4          0.3
7              17                0.7          2.4               14.0       Thiol-Maleimide        DOHH2          0.9          0.8          0.6
8              13                0.5          2.0                6.0          Click_Chemistry        Granta-519      0.7          0.6          0.4
9              19                0.8          2.6               16.0       Thiol-Maleimide        OCI-Ly1          0.9          0.8          0.6
10             12                0.4          1.6                3.0          Click_Chemistry        DOHH2          0.5          0.4          0.3
11             15                0.6          2.3               11.0       Thiol-Maleimide        Granta-519      0.8          0.7          0.5
12             10                0.3          1.2                1.0          Click_Chemistry        OCI-Ly1          0.4          0.3          0.2
13             16                0.5          2.1               13.0       Thiol-Maleimide        DOHH2          0.7          0.6          0.4
14             14                0.6          2.2                9.0          Click_Chemistry        Granta-519      0.8          0.7          0.5
15             11                0.4          1.9                5.0       Thiol-Maleimide        OCI-Ly1          0.5          0.4          0.3
16             17                0.7          2.5               15.0          Click_Chemistry        DOHH2          0.9          0.8          0.6
17             13                0.5          2.0                7.0       Thiol-Maleimide        Granta-519      0.7          0.6          0.4
18             19                0.8          2.7               17.0          Click_Chemistry        OCI-Ly1          0.9          0.8          0.6
19             12                0.4          1.7                4.0       Thiol-Maleimide        DOHH2          0.5          0.4          0.3
20             15                0.6          2.4               12.0          Click_Chemistry        Granta-519      0.8          0.7          0.5
21             10                0.3          1.3                2.0       Thiol-Maleimide        OCI-Ly1          0.4          0.3          0.2
22             16                0.5          2.2               14.0          Click_Chemistry        DOHH2          0.7          0.6          0.4
23             14                0.6          2.1                9.0       Thiol-Maleimide        Granta-519      0.8          0.7          0.5
24             11                0.4          1.8                5.0          Click_Chemistry        OCI-Ly1          0.5          0.4          0.3
```",0.7476027824227647
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0b41d43cc5bec67f42e5d940705234d76351ee50.summary'],"Can the aRP105-TM vector also enhance the activation of CD4+ T cells, leading to an increased production of cytokines that promote a more robust immune response against influenza?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** The aRP105-TM vector can enhance the activation of CD4+ T cells, leading to an increased production of cytokines that promote a more robust immune response against influenza.

**Experimental Plan:**

**Objective:** To determine if the aRP105-TM vector enhances CD4+ T cell activation and cytokine production, thereby promoting a more robust immune response against influenza.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate CD4+ T cells from human peripheral blood mononuclear cells (PBMCs) using magnetic bead separation or fluorescence-activated cell sorting (FACS).
	* Stimulate CD4+ T cells with influenza antigen (e.g., influenza A/PR8/34) in the presence or absence of the aRP105-TM vector.
2. **Vector Transfection:**
	* Transfect CD4+ T cells with the aRP105-TM vector using a suitable transfection reagent (e.g., lipofectamine).
	* Use a control group with a mock transfection (e.g., empty vector or no vector).
3. **Cell Activation and Cytokine Analysis:**
	* Measure CD4+ T cell activation by assessing:
		+ Surface marker expression (e.g., CD25, CD69) using flow cytometry.
		+ Proliferation using CFSE (carboxyfluorescein succinimidyl ester) staining and flow cytometry.
	* Analyze cytokine production (e.g., IFN-γ, IL-2, TNF-α) using:
		+ ELISA (enzyme-linked immunosorbent assay) or multiplex bead-based assays.
		+ Intracellular cytokine staining and flow cytometry.
4. **Influenza-Specific Immune Response:**
	* Measure the production of influenza-specific antibodies (e.g., hemagglutination inhibition assay).
	* Evaluate the ability of CD4+ T cells to recognize and respond to influenza-infected cells (e.g., using a chromium release assay).

**Experimental Controls:**

* Untransfected CD4+ T cells (no vector)
* CD4+ T cells transfected with a control vector (e.g., empty vector or a vector with a non-specific insert)
* CD4+ T cells stimulated with influenza antigen alone (no vector)

**Sample Size and Replication:**

* Use a minimum of 3-4 biological replicates (independent experiments) with 2-3 technical replicates ( duplicate/triplicate samples) for each condition.

**Timeline and Budget:**

* Estimated duration: 6-8 weeks
* Budget:
	+ Reagents and consumables: $5,000 - $7,000
	+ Equipment and facility costs: $2,000 - $3,000
	+ Personnel and labor costs: $8,000 - $12,000

**To Disprove the Hypothesis:**

To verify the hypothesis, we will focus on finding evidence that contradicts the expected outcome. Specifically, we will look for:

* No significant difference in CD4+ T cell activation and cytokine production between the aRP105-TM vector-transfected group and the control groups.
* No enhancement of the influenza-specific immune response in the aRP105-TM vector-transfected group compared to the control groups.

By designing an experiment to disprove the hypothesis, we can increase confidence in the results and ensure that any positive findings are not due to chance or experimental bias.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Preparation**

1.1. Isolation of CD4+ T cells from human peripheral blood mononuclear cells (PBMCs)

* Step 1.1.1: Collect 10-20 mL of human peripheral blood in a heparinized tube.
* Step 1.1.2: Isolate PBMCs using Ficoll-Paque density gradient centrifugation (e.g., Ficoll-Paque PLUS, GE Healthcare).
* Step 1.1.3: Wash PBMCs with PBS and resuspend in 1 mL of PBS.
* Step 1.1.4: Add 10 μL of CD4+ T cell isolation cocktail (e.g., Miltenyi Biotec) to the PBMC suspension and mix well.
* Step 1.1.5: Incubate the mixture at room temperature for 15 minutes.
* Step 1.1.6: Add 2 mL of PBS and mix well.
* Step 1.1.7: Pass the mixture through a magnetic column (e.g., Miltenyi Biotec) to isolate CD4+ T cells.
* Step 1.1.8: Collect the CD4+ T cell fraction and wash with PBS.

**Protocol 2: Vector Transfection**

2.1. Transfection of CD4+ T cells with aRP105-TM vector

* Step 2.1.1: Prepare the aRP105-TM vector DNA (e.g., 1 μg/μL) and lipofectamine transfection reagent (e.g., Lipofectamine 3000, Invitrogen).
* Step 2.1.2: Mix 1 μg of aRP105-TM vector DNA with 2 μL of lipofectamine reagent in 100 μL of Opti-MEM medium (Invitrogen).
* Step 2.1.3: Incubate the mixture at room temperature for 15 minutes to form lipoplexes.
* Step 2.1.4: Add the lipoplexes to 1 x 10^6 CD4+ T cells in 1 mL of complete RPMI medium (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin).
* Step 2.1.5: Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

**Protocol 3: Cell Activation and Cytokine Analysis**

3.1. Stimulation of CD4+ T cells with influenza antigen

* Step 3.1.1: Prepare influenza antigen (e.g., influenza A/PR8/34, 1 μg/mL) in complete RPMI medium.
* Step 3.1.2: Add 1 μg/mL of influenza antigen to 1 x 10^6 CD4+ T cells in 1 mL of complete RPMI medium.
* Step 3.1.3: Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

3.2. Measurement of CD4+ T cell activation

* Step 3.2.1: Harvest the cells and stain with fluorochrome-conjugated antibodies against CD25 and CD69 (e.g., FITC-CD25, PE-CD69, BioLegend).
* Step 3.2.2: Analyze the cells using flow cytometry (e.g., BD FACSCanto II).
* Step 3.2.3: Measure proliferation using CFSE staining and flow cytometry.

3.3. Analysis of cytokine production

* Step 3.3.1: Harvest the supernatant from the cell culture and store at -80°C.
* Step 3.3.2: Perform ELISA or multiplex bead-based assays (e.g., Bio-Plex Pro, Bio-Rad) to measure cytokine production (e.g., IFN-γ, IL-2, TNF-α).
* Step 3.3.3: Perform intracellular cytokine staining and flow cytometry to measure cytokine production.

**Protocol 4: Influenza-Specific Immune Response**

4.1. Measurement of influenza-specific antibodies

* Step 4.1.1: Collect the supernatant from the cell culture and store at -80°C.
* Step 4.1.2: Perform hemagglutination inhibition assay to measure influenza-specific antibody production.

4.2. Evaluation of CD4+ T cell recognition and response to influenza-infected cells

* Step 4.2.1: Prepare influenza-infected cells (e.g., A549 cells infected with influenza A/PR8/34).
* Step 4.2.2: Co-culture CD4+ T cells with influenza-infected cells at a 1:1 ratio.
* Step 4.2.3: Measure chromium release using a chromium release assay (e.g., Chromium Release Assay, PerkinElmer).

**Experimental Controls**

* Untransfected CD4+ T cells (no vector)
* CD4+ T cells transfected with a control vector (e.g., empty vector or a vector with a non-specific insert)
* CD4+ T cells stimulated with influenza antigen alone (no vector)

**Sample Size and Replication**

* Use a minimum of 3-4 biological replicates (independent experiments) with 2-3 technical replicates (duplicate/triplicate samples) for each condition.

**Timeline and Budget**

* Estimated duration: 6-8 weeks
* Budget:
	+ Reagents and consumables: $5,000 - $7,000
	+ Equipment and facility costs: $2,000 - $3,000
	+ Personnel and labor costs: $8,000 - $12,000

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be verified.","```
   Blood Volume (mL)  PBMC Isolation Cocktail (μL)  aRP105-TM Vector DNA (μg)  Lipofectamine Reagent (μL)  Influenza Antigen (μg/mL)  CD4+ T Cell Activation (%)  IFN-γ (pg/mL)  IL-2 (pg/mL)  TNF-α (pg/mL)  Influenza-Specific Antibodies (HAI titer)
0               15.0                         12.0                    1.2                    2.4                    1.5                    35.0          250.0         150.0         120.0                         128.0
1               18.0                         10.0                    1.0                    2.0                    1.2                    30.0          220.0         130.0         110.0                         112.0
2               12.0                         14.0                    1.4                    2.6                    1.8                    40.0          280.0         160.0         140.0                         144.0
3               19.0                         11.0                    1.1                    2.2                    1.6                    38.0          260.0         140.0         130.0                         136.0
4               13.0                         13.0                    1.3                    2.5                    1.4                    32.0          240.0         120.0         100.0                         104.0
5               16.0                         12.0                    1.2                    2.4                    1.5                    36.0          250.0         130.0         120.0                         128.0
6               11.0                         15.0                    1.5                    2.8                    1.9                    42.0          300.0         170.0         150.0                         152.0
7               17.0                         10.0                    1.0                    2.0                    1.3                    34.0          230.0         110.0         100.0                         108.0
8               14.0                         14.0                    1.4                    2.6                    1.7                    39.0          270.0         150.0         130.0                         140.0
9               19.0                         11.0                    1.1                    2.2                    1.6                    37.0          260.0         140.0         120.0                         136.0
10              12.0                         13.0                    1.3                    2.5                    1.4                    33.0          240.0         120.0         100.0                         104.0
11              16.0                         12.0                    1.2                    2.4                    1.5                    35.0          250.0         130.0         120.0                         128.0
12              15.0                         10.0                    1.0                    2.0                    1.2                    31.0          220.0         110.0         100.0                         108.0
13              18.0                         14.0                    1.4                    2.6                    1.8                    41.0          280.0         160.0         140.0                         144.0
14              13.0                         11.0                    1.1                    2.2                    1.4                    34.0          230.0         120.0         100.0                         112.0
15              19.0                         12.0                    1.2                    2.4                    1.6                    38.0          260.0         140.0         130.0                         136.0
16              11.0                         15.0                    1.5                    2.8                    1.9                    43.0          310.0         170.0         150.0                         156.0
17              17.0                         10.0                    1.0                    2.0                    1.3                    32.0          220.0         110.0         100.0                         108.0
18              14.0                         14.0                    1.4                    2.6                    1.7                    40.0          270.0         150.0         130.0                         140.0
19              16.0                         11.0                    1.1                    2.2                    1.5                    36.0          250.0         130.0         120.0                         128.0
20              12.0                         13.0                    1.3                    2.5                    1.4                    33.0          240.0         120.0         100.0                         104.0
21              18.0                         12.0                    1.2                    2.4                    1.6                    38.0          260.0         140.0         130.0                         136.0
22              15.0                         10.0                    1.0                    2.0                    1.2                    30.0          210.0         100.0          90.0                         102.0
23              19.0                         14.0                    1.4                    2.6                    1.8                    42.0          290.0         160.0         140.0                         144.0
24              13.0                         11.0                    1.1                    2.2                    1.4                    35.0          240.0         120.0         100.0                         112.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/32a5f583e95831370981893186aa11c1c9d6b9dd.summary'],"Can the adenoviral vector-based platform be optimized to induce a balanced Th1/Th2 response by modulating the ratio of ICOSL to CD40L costimulatory ligands, leading to enhanced protection against infectious diseases?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Optimizing Adenoviral Vector-Based Platform for Balanced Th1/Th2 Response by Modulating ICOSL to CD40L Ratio

**Objective:** To investigate whether modulating the ratio of ICOSL to CD40L costimulatory ligands in an adenoviral vector-based platform can induce a balanced Th1/Th2 response, leading to enhanced protection against infectious diseases.

**Experimental Design:**

1. **Platform Preparation:** Prepare adenoviral vectors with varying ratios of ICOSL to CD40L costimulatory ligands (e.g., 1:1, 2:1, 1:2, 3:1, 1:3) and recombinant nonglycosylated spike protein rRBD as the antigen.
2. **Cell Isolation and Stimulation:** Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors and stimulate them with the prepared adenoviral vectors or control stimuli.
3. **Th1/Th2 Response Analysis:** Analyze the Th1/Th2 response by measuring cytokine production (e.g., IFN-γ, IL-4, IL-10) using ELISA or multiplex assays.
4. **Flow Cytometry:** Perform flow cytometry to assess the frequency and phenotype of Th1 (e.g., CD4+IFN-γ+) and Th2 (e.g., CD4+IL-4+) cells.
5. **Gene Expression Profiling:** Perform RNA sequencing or quantitative real-time PCR to analyze the gene expression profiles of Th1 and Th2 cells, focusing on genes involved in Th1/Th2 differentiation and cytokine production.
6. **Data Analysis:** Analyze the data to identify the optimal ICOSL to CD40L ratio that induces a balanced Th1/Th2 response and correlates with enhanced protection against infectious diseases.

**Required Equipment:**

* Adenoviral vector preparation equipment
* Cell culture facilities
* ELISA or multiplex assay equipment
* Flow cytometer
* RNA sequencing platform or quantitative real-time PCR machine
* Bioinformatic software

**Timeline:** 6-9 months

**Budget:** Moderate (dependent on the number of samples, reagents, and equipment required)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of ICOSL and CD40L in Th1/Th2 Response: A Knockdown Approach

**Objective:** To investigate whether the ICOSL to CD40L ratio has no significant impact on the Th1/Th2 response, thereby disproving the hypothesis.

**Experimental Design:**

1. **siRNA-Mediated Knockdown:** Use siRNA to knockdown ICOSL and CD40L expression in PBMCs isolated from healthy donors.
2. **Platform Stimulation:** Stimulate the knockdown cells with the adenoviral vector-based platform (with a fixed ICOSL to CD40L ratio) and recombinant nonglycosylated spike protein rRBD as the antigen.
3. **Th1/Th2 Response Analysis:** Analyze the Th1/Th2 response by measuring cytokine production (e.g., IFN-γ, IL-4, IL-10) using ELISA or multiplex assays.
4. **Flow Cytometry:** Perform flow cytometry to assess the frequency and phenotype of Th1 (e.g., CD4+IFN-γ+) and Th2 (e.g., CD4+IL-4+) cells.
5. **Data Analysis:** Analyze the data to determine if the knockdown of ICOSL and CD40L expression affects the Th1/Th2 response.

**Required Equipment:**

* siRNA transfection equipment
* Cell culture facilities
* ELISA or multiplex assay equipment
* Flow cytometer

**Timeline:** 3-6 months

**Budget:** Moderate (dependent on the number of samples, reagents, and equipment required)

By performing these experiments, we can test the hypothesis and attempt to disprove it, providing a more comprehensive understanding of the role of ICOSL and CD40L in modulating the Th1/Th2 response and its implications for vaccine development.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Optimizing Adenoviral Vector-Based Platform for Balanced Th1/Th2 Response by Modulating ICOSL to CD40L Ratio**

**Step 1: Platform Preparation**

1.1. Prepare adenoviral vectors with varying ratios of ICOSL to CD40L costimulatory ligands (e.g., 1:1, 2:1, 1:2, 3:1, 1:3) using standard molecular biology techniques (e.g., PCR, cloning, and viral vector production).

1.2. Verify the expression of ICOSL and CD40L in the adenoviral vectors using Western blot or ELISA.

1.3. Prepare recombinant nonglycosylated spike protein rRBD as the antigen using standard protein expression and purification techniques.

**Step 2: Cell Isolation and Stimulation**

2.1. Collect peripheral blood samples from healthy donors and isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation (e.g., Ficoll-Paque).

2.2. Wash the PBMCs with PBS and resuspend them in complete RPMI 1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

2.3. Stimulate the PBMCs with the prepared adenoviral vectors (1:1, 2:1, 1:2, 3:1, 1:3) or control stimuli (e.g., PBS or mock vector) at a multiplicity of infection (MOI) of 10-100.

2.4. Incubate the cells at 37°C, 5% CO2 for 3-5 days.

**Step 3: Th1/Th2 Response Analysis**

3.1. Collect the supernatants from the stimulated PBMCs and store them at -80°C for cytokine analysis.

3.2. Perform ELISA or multiplex assays to measure cytokine production (e.g., IFN-γ, IL-4, IL-10) according to the manufacturer's instructions.

**Step 4: Flow Cytometry**

4.1. Harvest the stimulated PBMCs and stain them with fluorescently labeled antibodies against CD4, IFN-γ, and IL-4.

4.2. Perform flow cytometry using a flow cytometer (e.g., BD FACSCanto) to assess the frequency and phenotype of Th1 (e.g., CD4+IFN-γ+) and Th2 (e.g., CD4+IL-4+) cells.

**Step 5: Gene Expression Profiling**

5.1. Isolate RNA from the stimulated PBMCs using a RNA isolation kit (e.g., TRIzol).

5.2. Perform RNA sequencing or quantitative real-time PCR to analyze the gene expression profiles of Th1 and Th2 cells, focusing on genes involved in Th1/Th2 differentiation and cytokine production.

**Step 6: Data Analysis**

6.1. Analyze the data to identify the optimal ICOSL to CD40L ratio that induces a balanced Th1/Th2 response and correlates with enhanced protection against infectious diseases.

6.2. Perform statistical analysis (e.g., ANOVA, t-test) to compare the cytokine production, flow cytometry, and gene expression data between the different ICOSL to CD40L ratios.

**Experiment to Disprove the Hypothesis: Investigating the Role of ICOSL and CD40L in Th1/Th2 Response: A Knockdown Approach**

**Step 1: siRNA-Mediated Knockdown**

1.1. Design and synthesize siRNA targeting ICOSL and CD40L using a siRNA design tool (e.g., siRNA Wizard).

1.2. Transfect the siRNA into PBMCs isolated from healthy donors using a transfection reagent (e.g., Lipofectamine).

1.3. Verify the knockdown of ICOSL and CD40L expression using Western blot or ELISA.

**Step 2: Platform Stimulation**

2.1. Stimulate the knockdown cells with the adenoviral vector-based platform (with a fixed ICOSL to CD40L ratio) and recombinant nonglycosylated spike protein rRBD as the antigen.

2.2. Incubate the cells at 37°C, 5% CO2 for 3-5 days.

**Step 3: Th1/Th2 Response Analysis**

3.1. Collect the supernatants from the stimulated PBMCs and store them at -80°C for cytokine analysis.

3.2. Perform ELISA or multiplex assays to measure cytokine production (e.g., IFN-γ, IL-4, IL-10) according to the manufacturer's instructions.

**Step 4: Flow Cytometry**

4.1. Harvest the stimulated PBMCs and stain them with fluorescently labeled antibodies against CD4, IFN-γ, and IL-4.

4.2. Perform flow cytometry using a flow cytometer (e.g., BD FACSCanto) to assess the frequency and phenotype of Th1 (e.g., CD4+IFN-γ+) and Th2 (e.g., CD4+IL-4+) cells.

**Step 5: Data Analysis**

5.1. Analyze the data to determine if the knockdown of ICOSL and CD40L expression affects the Th1/Th2 response.

5.2. Perform statistical analysis (e.g., ANOVA, t-test) to compare the cytokine production and flow cytometry data between the knockdown and control groups.

Note: These protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment available. It is essential to follow proper laboratory protocols, safety guidelines, and quality control measures to ensure the accuracy and reproducibility of the results.","```
   ICOSL  CD40L  rRBD  MOI  IFN-γ  IL-4  IL-10  Th1_Response  Th2_Response
0      1      1     1   10  200.0  150.0   50.0         0.4         0.3
1      2      1     1   50  350.0  200.0  100.0         0.6         0.4
2      1      2     1   20  150.0  250.0   75.0         0.3         0.5
3      3      1     1   30  400.0  250.0  120.0         0.7         0.5
4      1      3     1   40  100.0  300.0   90.0         0.2         0.6
5      1      1     2   10  250.0  180.0   60.0         0.5         0.4
6      2      1     1   60  420.0  280.0  140.0         0.8         0.6
7      1      2     1   80  180.0  320.0  100.0         0.4         0.7
8      3      1     1   90  450.0  300.0  150.0         0.9         0.7
9      1      3     1  100  120.0  350.0  110.0         0.3         0.8
10     1      1     1   50  300.0  220.0   80.0         0.6         0.5
11     2      1     1   20  380.0  240.0  110.0         0.7         0.6
12     1      2     1   30  220.0  280.0   90.0         0.5         0.6
13     3      1     1   40  480.0  320.0  160.0         1.0         0.8
14     1      3     1   10  180.0  300.0   70.0         0.4         0.7
15     1      1     2   60  320.0  260.0  100.0         0.7         0.6
16     2      1     1   80  440.0  300.0  140.0         0.9         0.8
17     1      2     1   90  240.0  340.0  120.0         0.6         0.8
18     3      1     1  100  500.0  350.0  180.0         1.1         0.9
19     1      3     1   50  200.0  360.0  130.0         0.5         0.9
20     1      1     1   20  280.0  200.0   80.0         0.6         0.5
21     2      1     1   30  400.0  280.0  130.0         0.8         0.7
22     1      2     1   40  260.0  320.0  110.0         0.6         0.8
23     3      1     1   10  520.0  380.0  190.0         1.2         1.0
24     1      3     1   60  240.0  380.0  150.0         0.6         1.0
```",0.39971797388703045
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3e4d3bef66a7b0870a014996b421dfcc4d425a34.summary'],Can the adoptive transfer of EBNA-3C-specific TRUCKs that recognize an epitope presented on HLA-B*35 also enhance the anti-tumor activity of endogenous T cells in patients with EBV-associated lymphoproliferation?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it. Here's a high-level approach to investigate whether adoptive transfer of EBNA-3C-specific TRUCKs (T cells redirected for universal cytokine killing) that recognize an epitope presented on HLA-B*35 can enhance the anti-tumor activity of endogenous T cells in patients with EBV-associated lymphoproliferation.

**Experimental Plan:**

**Objective:** To evaluate the efficacy of adoptive transfer of EBNA-3C-specific TRUCKs in enhancing anti-tumor activity of endogenous T cells in patients with EBV-associated lymphoproliferation.

**Study Design:**

1. **Patient Selection:** Recruit patients with EBV-associated lymphoproliferation (e.g., post-transplant lymphoproliferative disorder, lymphoma) who are HLA-B*35 positive.
2. **TRUCK Generation:**
	* Isolate T cells from healthy donors or patients with EBV-associated lymphoproliferation.
	* Transduce T cells with a lentiviral vector encoding EBNA-3C-specific T cell receptor (TCR) and a cytokine (e.g., IL-12) to generate TRUCKs.
	* Expand and characterize TRUCKs for EBNA-3C-specificity, cytokine production, and cytotoxicity.
3. **Adoptive Transfer:**
	* Infuse TRUCKs into patients with EBV-associated lymphoproliferation.
	* Monitor patients for safety, toxicity, and response to treatment.
4. **Endogenous T Cell Analysis:**
	* Collect peripheral blood mononuclear cells (PBMCs) from patients at multiple time points before and after TRUCK infusion.
	* Analyze endogenous T cell responses using:
		+ Flow cytometry: assess T cell subsets, activation markers, and cytokine production.
		+ ELISPOT: measure EBNA-3C-specific T cell responses.
		+ T cell receptor sequencing: track clonal expansion and diversity of endogenous T cells.
5. **Tumor Response Evaluation:**
	* Monitor tumor burden using imaging techniques (e.g., PET-CT, MRI).
	* Analyze tumor biopsies for EBV DNA, T cell infiltration, and cytokine expression.
6. **Correlative Studies:**
	* Investigate the relationship between TRUCK infusion, endogenous T cell responses, and tumor regression.
	* Analyze the impact of TRUCKs on the tumor microenvironment, including immune cell infiltration and cytokine profiles.

**Experimental Methods:**

* Flow cytometry: use antibodies against T cell markers (e.g., CD3, CD4, CD8), activation markers (e.g., CD25, CD69), and cytokines (e.g., IFN-γ, TNF-α).
* ELISPOT: use EBNA-3C peptides as antigens to stimulate T cells and detect cytokine production.
* T cell receptor sequencing: use next-generation sequencing (NGS) to analyze TCR repertoire diversity and clonal expansion.
* Lentiviral vector production: use standard molecular biology techniques to generate and validate the lentiviral vector.
* TRUCK expansion and characterization: use standard cell culture techniques and functional assays (e.g., cytotoxicity, cytokine production).

**Resources and Equipment:**

* Cell culture facilities and equipment (e.g., incubators, centrifuges, flow cytometers)
* Molecular biology equipment (e.g., PCR machines, sequencing instruments)
* Lentiviral vector production and purification equipment
* Flow cytometry and cell sorting instruments
* ELISPOT and cytokine analysis equipment
* Next-generation sequencing platform
* Imaging equipment (e.g., PET-CT, MRI)
* Tissue processing and histology equipment

**Timeline:**

* Patient recruitment and screening: 6 months
* TRUCK generation and characterization: 3 months
* Adoptive transfer and patient monitoring: 6 months
* Endogenous T cell analysis and correlative studies: 12 months
* Data analysis and manuscript preparation: 12 months

**Budget:**

* Personnel: 10 researchers, 2 technicians, 1 study coordinator (salaries, benefits, and training)
* Reagents and consumables: cell culture media, antibodies, cytokines, lentiviral vectors, sequencing reagents, etc.
* Equipment maintenance and upgrades: flow cytometers, sequencing instruments, etc.
* Patient care and monitoring: hospitalization, imaging, and clinical testing costs
* Travel and training: conferences, workshops, and training courses for researchers

With an unlimited budget, the timeline can be accelerated, and the scope of the study can be expanded to include additional patients, correlative studies, and exploratory analyses.",92,"Here are the detailed, step-by-step protocols for each section of the experimental plan:

**Patient Selection:**

1.1. Identify potential patients with EBV-associated lymphoproliferation (e.g., post-transplant lymphoproliferative disorder, lymphoma) through medical records and clinical databases.

1.2. Screen patients for HLA-B*35 positivity using molecular typing techniques (e.g., PCR-SSP, SSO).

1.3. Obtain informed consent from eligible patients and collect medical history, including previous treatments and medications.

1.4. Perform baseline blood draws for complete blood counts, liver function tests, and renal function tests.

**TRUCK Generation:**

2.1. Isolate T cells from healthy donors or patients with EBV-associated lymphoproliferation using density gradient centrifugation and magnetic bead separation.

2.2. Transduce T cells with a lentiviral vector encoding EBNA-3C-specific T cell receptor (TCR) and a cytokine (e.g., IL-12) using standard molecular biology techniques.

2.3. Expand TRUCKs in culture using T cell growth media and cytokines (e.g., IL-2, IL-7).

2.4. Characterize TRUCKs for EBNA-3C-specificity using flow cytometry and ELISPOT assays.

2.5. Analyze TRUCKs for cytokine production using ELISA or cytokine bead arrays.

2.6. Assess TRUCK cytotoxicity using chromium release or flow cytometry-based assays.

**Adoptive Transfer:**

3.1. Infuse TRUCKs into patients with EBV-associated lymphoproliferation through intravenous injection.

3.2. Monitor patients for safety and toxicity using clinical evaluations, laboratory tests, and imaging studies.

3.3. Collect blood samples at regular intervals (e.g., days 1, 7, 14, 28) for TRUCK persistence and endogenous T cell analysis.

**Endogenous T Cell Analysis:**

4.1. Collect peripheral blood mononuclear cells (PBMCs) from patients at multiple time points before and after TRUCK infusion.

4.2. Perform flow cytometry analysis using antibodies against T cell markers (e.g., CD3, CD4, CD8), activation markers (e.g., CD25, CD69), and cytokines (e.g., IFN-γ, TNF-α).

4.3. Perform ELISPOT assays using EBNA-3C peptides as antigens to stimulate T cells and detect cytokine production.

4.4. Perform T cell receptor sequencing using next-generation sequencing (NGS) to analyze TCR repertoire diversity and clonal expansion.

**Tumor Response Evaluation:**

5.1. Monitor tumor burden using imaging techniques (e.g., PET-CT, MRI) at baseline, 6 weeks, and 12 weeks after TRUCK infusion.

5.2. Collect tumor biopsies at baseline and 12 weeks after TRUCK infusion for analysis of EBV DNA, T cell infiltration, and cytokine expression.

5.3. Perform immunohistochemistry and immunofluorescence staining for T cell markers, cytokines, and EBV antigens.

**Correlative Studies:**

6.1. Investigate the relationship between TRUCK infusion, endogenous T cell responses, and tumor regression using statistical analysis and data visualization tools.

6.2. Analyze the impact of TRUCKs on the tumor microenvironment, including immune cell infiltration and cytokine profiles, using bioinformatic tools and pathway analysis.

**Flow Cytometry:**

7.1. Prepare PBMCs for flow cytometry analysis by washing and staining with antibodies against T cell markers, activation markers, and cytokines.

7.2. Acquire flow cytometry data using a flow cytometer and analyze using flow cytometry software.

**ELISPOT:**

7.3. Prepare PBMCs for ELISPOT analysis by washing and stimulating with EBNA-3C peptides.

7.4. Add cytokine detection reagents and incubate for 24-48 hours.

7.5. Develop and count ELISPOTs using an ELISPOT reader.

**T Cell Receptor Sequencing:**

7.6. Extract genomic DNA from PBMCs using standard molecular biology techniques.

7.7. Perform T cell receptor sequencing using next-generation sequencing (NGS) platforms.

7.8. Analyze TCR repertoire diversity and clonal expansion using bioinformatic tools.

**Lentiviral Vector Production:**

7.9. Design and construct the lentiviral vector encoding EBNA-3C-specific TCR and cytokine using standard molecular biology techniques.

7.10. Produce and purify the lentiviral vector using standard protocols.

**TRUCK Expansion and Characterization:**

7.11. Expand TRUCKs in culture using T cell growth media and cytokines.

7.12. Characterize TRUCKs for EBNA-3C-specificity, cytokine production, and cytotoxicity using functional assays.

These detailed protocols should provide a clear guide for executing the experimental plan.","```
   Patient_HLA_B35  Donor_T_Cell_Count  Lentiviral_Vector_Dose  IL_12_Dose  TRUCK_Expansion_Days  TRUCK_Infusion_Dose  Outcome
0               1.0               1000000               1.0e+09       100.0                  14               1.0e+07       Responded
1               1.0               1500000               1.5e+09       150.0                  14               1.5e+07       Responded
2               0.0                500000               5.0e+08        50.0                  10               5.0e+06  Non-Responded
3               1.0               2000000               2.0e+09       200.0                  14               2.0e+07       Responded
4               1.0                800000               8.0e+08        80.0                  12               8.0e+06       Responded
5               0.0               1200000               1.2e+09       120.0                  10               1.2e+07  Non-Responded
6               1.0               1800000               1.8e+09       180.0                  14               1.8e+07       Responded
7               1.0                900000               9.0e+08        90.0                  12               9.0e+06       Responded
8               0.0               1500000               1.5e+09       150.0                  10               1.5e+07  Non-Responded
9               1.0               2100000               2.1e+09       210.0                  14               2.1e+07       Responded
10              1.0               1000000               1.0e+09       100.0                  12               1.0e+07       Responded
11              0.0                600000               6.0e+08        60.0                  10               6.0e+06  Non-Responded
12              1.0               2400000               2.4e+09       240.0                  14               2.4e+07       Responded
13              1.0               1100000               1.1e+09       110.0                  12               1.1e+07       Responded
14              0.0               1800000               1.8e+09       180.0                  10               1.8e+07  Non-Responded
15              1.0               2500000               2.5e+09       250.0                  14               2.5e+07       Responded
16              1.0               1300000               1.3e+09       130.0                  12               1.3e+07       Responded
17              0.0                700000               7.0e+08        70.0                  10               7.0e+06  Non-Responded
18              1.0               2600000               2.6e+09       260.0                  14               2.6e+07       Responded
19              1.0               1400000               1.4e+09       140.0                  12               1.4e+07       Responded
20              0.0               2000000               2.0e+09       200.0                  10               2.0e+07  Non-Responded
21              1.0               2700000               2.7e+09       270.0                  14               2.7e+07       Responded
22              1.0               1500000               1.5e+09       150.0                  12               1.5e+07       Responded
23              0.0                800000               8.0e+08        80.0                  10               8.0e+06  Non-Responded
24              1.0               2800000               2.8e+09       280.0                  14               2.8e+07       Responded
```",0.5814546751565263
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1bc2406a30100949b4f42d156ed6d9b4c5303b61.summary'],Can the analysis of intraclonal diversities using ViCloD identify specific clonal lineages that are predictive of treatment response to immunotherapy in B-cell tumors?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed a high-level experimental plan to test its validity. Since the goal is to disprove the hypothesis, the experiment is designed to identify potential flaws or inconsistencies in the hypothesis.

**Hypothesis:** Can the analysis of intraclonal diversities using ViCloD identify specific clonal lineages that are predictive of treatment response to immunotherapy in B-cell tumors?

**Experimental Plan:**

**Objective:** To determine if ViCloD analysis of intraclonal diversities can predict treatment response to immunotherapy in B-cell tumors.

**Study Design:**

1. **Sample Collection:**
	* Collect tumor samples from 50 B-cell tumor patients who have received immunotherapy (e.g., checkpoint inhibitors).
	* Ensure samples are representative of various B-cell tumor subtypes and treatment outcomes (responders and non-responders).
2. **ViCloD Analysis:**
	* Perform ViCloD analysis on the collected tumor samples to identify intraclonal diversities and clonal lineages.
	* Use existing bioinformatic pipelines and tools (e.g., IgBLAST, IMGT/HighV-QUEST) to analyze the data.
3. **Treatment Response Assessment:**
	* Collect clinical data on treatment response for each patient, including response duration, progression-free survival, and overall survival.
	* Categorize patients as responders or non-responders based on established clinical criteria.
4. **Statistical Analysis:**
	* Perform statistical analysis to correlate ViCloD-identified clonal lineages with treatment response.
	* Use machine learning algorithms (e.g., random forest, logistic regression) to identify potential predictive models.

**Experiment to Disprove the Hypothesis:**

**Null Hypothesis:** ViCloD analysis of intraclonal diversities does not identify specific clonal lineages that are predictive of treatment response to immunotherapy in B-cell tumors.

**Experimental Design:**

1. **Randomized Sample Selection:**
	* Randomly select 25 samples from the original 50 samples, ensuring an equal number of responders and non-responders.
	* Use these samples to create a ""shuffled"" dataset, where the treatment response labels are randomly reassigned.
2. **ViCloD Analysis (Shuffled Dataset):**
	* Perform ViCloD analysis on the shuffled dataset using the same bioinformatic pipelines and tools as before.
3. **Statistical Analysis (Shuffled Dataset):**
	* Perform statistical analysis on the shuffled dataset to identify any correlations between ViCloD-identified clonal lineages and treatment response.
4. **Comparison with Original Results:**
	* Compare the results from the shuffled dataset with the original results.
	* If the shuffled dataset yields similar or better predictive models than the original dataset, it would suggest that the ViCloD analysis is not identifying specific clonal lineages predictive of treatment response.

**Rationale:**

By shuffling the treatment response labels, we are essentially removing any potential correlation between the ViCloD-identified clonal lineages and treatment response. If the ViCloD analysis is truly identifying predictive clonal lineages, the shuffled dataset should not yield meaningful correlations. However, if the shuffled dataset produces similar or better results, it would indicate that the original results are likely due to chance or biases in the analysis, rather than a true predictive relationship.

**Timeline and Budget:**

This experiment can be completed within 6-9 months, depending on the availability of resources and personnel. The budget will be primarily allocated to:

1. Sample collection and processing (20%): $10,000 - $15,000
2. ViCloD analysis and bioinformatic support (40%): $20,000 - $30,000
3. Statistical analysis and machine learning support (20%): $10,000 - $15,000
4. Personnel and overheads (20%): $10,000 - $15,000

Total budget: $50,000 - $75,000

This experiment is designed to be feasible within a reasonable time frame and budget, while providing a robust test of the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Sample Collection**

1.1. Identify and recruit 50 B-cell tumor patients who have received immunotherapy (e.g., checkpoint inhibitors) and have available tumor samples.

1.2. Ensure the sample collection includes a representative distribution of various B-cell tumor subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) and treatment outcomes (responders and non-responders).

1.3. Obtain informed consent from each patient and collect tumor samples (e.g., formalin-fixed paraffin-embedded (FFPE) tissue blocks, frozen tissue, or blood samples) according to institutional review board (IRB) approved protocols.

1.4. Label and store the samples in a secure, temperature-controlled environment (e.g., -80°C freezer) with unique identifiers and associated clinical data.

**Protocol 2: ViCloD Analysis**

2.1. Extract genomic DNA from the collected tumor samples using a DNA extraction kit (e.g., QIAamp DNA FFPE Tissue Kit) according to the manufacturer's instructions.

2.2. Perform PCR amplification of the immunoglobulin heavy chain (IGH) gene using primers specific to the IGH variable region (e.g., FR1, FR2, FR3).

2.3. Sequence the PCR products using a high-throughput sequencing platform (e.g., Illumina MiSeq) with a minimum of 100,000 reads per sample.

2.4. Analyze the sequencing data using IgBLAST and IMGT/HighV-QUEST bioinformatic pipelines to identify intraclonal diversities and clonal lineages.

2.5. Use the output from IgBLAST and IMGT/HighV-QUEST to generate a comprehensive report detailing the clonal lineages, including the frequency and distribution of each clone.

**Protocol 3: Treatment Response Assessment**

3.1. Collect clinical data on treatment response for each patient, including:

* Response duration (e.g., complete response, partial response, stable disease, progressive disease)
* Progression-free survival (PFS)
* Overall survival (OS)

3.2. Categorize patients as responders or non-responders based on established clinical criteria (e.g., RECIST 1.1).

3.3. Record the treatment response data in a secure, electronic database with unique patient identifiers.

**Protocol 4: Statistical Analysis**

4.1. Perform statistical analysis to correlate ViCloD-identified clonal lineages with treatment response using machine learning algorithms (e.g., random forest, logistic regression).

4.2. Use the R programming language and relevant packages (e.g., caret, dplyr) to perform the statistical analysis.

4.3. Evaluate the performance of the predictive models using metrics such as area under the receiver operating characteristic curve (AUC-ROC), accuracy, precision, and recall.

**Protocol 5: Experiment to Disprove the Hypothesis**

5.1. Randomly select 25 samples from the original 50 samples, ensuring an equal number of responders and non-responders.

5.2. Create a ""shuffled"" dataset by randomly reassigning the treatment response labels to the selected samples.

5.3. Perform ViCloD analysis on the shuffled dataset using the same bioinformatic pipelines and tools as before (Protocol 2).

5.4. Perform statistical analysis on the shuffled dataset to identify any correlations between ViCloD-identified clonal lineages and treatment response (Protocol 4).

5.5. Compare the results from the shuffled dataset with the original results to determine if the ViCloD analysis is identifying specific clonal lineages predictive of treatment response.

**Protocol 6: Data Management and Quality Control**

6.1. Store all experimental data, including raw sequencing data, ViCloD analysis output, and statistical analysis results, in a secure, electronic database with unique identifiers.

6.2. Implement quality control measures to ensure data integrity, including:

* Data backup and redundancy
* Data validation and verification
* Error tracking and correction

6.3. Document all experimental procedures, protocols, and results in a laboratory notebook or electronic laboratory information management system (ELN/LIMS).

By following these detailed, step-by-step protocols, the experiment can be executed with precision and accuracy, ensuring the results are reliable and reproducible.","```
   Sample_ID  DNA_Quantity  Primer_FR1  Primer_FR2  Primer_FR3  Reads_Per_Sample  Response_Duration  Progression_Free_Survival  Overall_Survival  Treatment_Response
0         1        100.0         2.0         1.5         1.0             120000               12.0                  18.0             24.0           Responder
1         2         80.0         1.8         1.2         0.8              90000               10.0                  15.0             20.0           Responder
2         3        120.0         2.2         1.8         1.2             150000               14.0                  20.0             26.0           Responder
3         4         90.0         2.0         1.5         1.0             110000               11.0                  16.0             22.0           Responder
4         5        110.0         2.1         1.6         1.1             130000               13.0                  19.0             25.0           Responder
5         6         70.0         1.6         1.1         0.9              80000                9.0                  13.0             18.0           Non-Responder
6         7        100.0         2.0         1.5         1.0             120000               12.0                  18.0             24.0           Responder
7         8         85.0         1.9         1.4         1.0             100000               11.0                  16.0             22.0           Responder
8         9        105.0         2.1         1.6         1.1             125000               13.0                  19.0             25.0           Responder
9        10         95.0         2.0         1.5         1.0             115000               12.0                  18.0             24.0           Responder
10       11         75.0         1.7         1.2         0.9              85000               10.0                  14.0             20.0           Non-Responder
11       12        115.0         2.2         1.7         1.2             135000               14.0                  20.0             26.0           Responder
12       13         80.0         1.8         1.3         1.0              95000               11.0                  16.0             22.0           Responder
13       14        125.0         2.3         1.8         1.3             140000               15.0                  21.0             27.0           Responder
14       15         90.0         2.0         1.5         1.0             110000               12.0                  18.0             24.0           Responder
15       16         65.0         1.5         1.0         0.8              75000                9.0                  13.0             18.0           Non-Responder
16       17        130.0         2.4         1.9         1.4             145000               16.0                  22.0             28.0           Responder
17       18         85.0         1.9         1.4         1.0             100000               11.0                  16.0             22.0           Responder
18       19        120.0         2.2         1.7         1.2             130000               14.0                  20.0             26.0           Responder
19       20         70.0         1.6         1.1         0.9              80000                9.0                  13.0             18.0           Non-Responder
20       21        110.0         2.1         1.6         1.1             125000               13.0                  19.0             25.0           Responder
21       22         95.0         2.0         1.5         1.0             115000               12.0                  18.0             24.0           Responder
22       23         80.0         1.8         1.3         1.0              95000               11.0                  16.0             22.0           Responder
23       24        105.0         2.1         1.6         1.1             120000               13.0                  19.0             25.0           Responder
24       25         90.0         2.0         1.5         1.0             110000               12.0                  18.0             24.0           Responder
```",0.60200382960216
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/846784cb1b387d59f4a053e2bb52d555ad9675ad.summary'],Can the anti-tumor effects of CAR T cells targeting mHsp70 be further enhanced by preconditioning the tumor microenvironment with low-dose chemotherapy to increase mHsp70 expression on tumor cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will outline an experimental plan to test it. Since the goal is to disprove the hypothesis, the experiment will aim to show that preconditioning the tumor microenvironment with low-dose chemotherapy does not increase mHsp70 expression on tumor cells, and therefore, does not enhance the anti-tumor effects of CAR T cells targeting mHsp70.

**Experiment Title:** Investigating the Effect of Low-Dose Chemotherapy on mHsp70 Expression and CAR T Cell Anti-Tumor Activity

**Objective:** To determine whether preconditioning the tumor microenvironment with low-dose chemotherapy increases mHsp70 expression on tumor cells, leading to enhanced anti-tumor effects of CAR T cells targeting mHsp70.

**Experimental Design:**

1. **Tumor Cell Preparation:**
	* Use human colorectal adenocarcinoma cells (LS174T and LoVo) as the tumor model.
	* Culture the cells in vitro and verify their mHsp70 expression levels using flow cytometry.
2. **Low-Dose Chemotherapy Treatment:**
	* Treat the tumor cells with a low dose of chemotherapy (e.g., doxorubicin or cisplatin) for 24-48 hours to mimic the preconditioning of the tumor microenvironment.
	* Use a control group without chemotherapy treatment.
3. **mHsp70 Expression Analysis:**
	* Analyze mHsp70 expression on tumor cells using flow cytometry after chemotherapy treatment.
	* Compare the mHsp70 expression levels between the chemotherapy-treated and control groups.
4. **CAR T Cell Preparation:**
	* Generate CAR T cells targeting mHsp70 using established protocols.
	* Verify the CAR T cell functionality and specificity using flow cytometry and cytotoxicity assays.
5. **Co-Culture and Anti-Tumor Activity Assay:**
	* Co-culture the CAR T cells with chemotherapy-treated or control tumor cells at different effector-to-target ratios.
	* Measure the anti-tumor effects by flow cytometry, including cell viability, apoptosis, and cytokine production.
6. **Statistical Analysis:**
	* Compare the anti-tumor effects of CAR T cells against chemotherapy-treated and control tumor cells.
	* Analyze the data using statistical methods to determine if there is a significant difference in anti-tumor activity between the two groups.

**Equipment and Reagents:**

* Flow cytometer
* Cell culture facilities
* CAR T cells targeting mHsp70
* Human colorectal adenocarcinoma cells (LS174T and LoVo)
* Low-dose chemotherapy (e.g., doxorubicin or cisplatin)
* Antibodies for flow cytometry
* Cytokines (e.g., IL-2) for CAR T cell expansion and activation

**Timeline:**

* Week 1-2: Tumor cell preparation and low-dose chemotherapy treatment
* Week 3-4: mHsp70 expression analysis and CAR T cell preparation
* Week 5-6: Co-culture and anti-tumor activity assay
* Week 7-8: Data analysis and statistical evaluation

**Budget:**

* Reagents and consumables: $5,000
* Equipment usage (flow cytometer, cell culture facilities): $3,000
* Personnel (researcher, technician): $10,000
* Total: $18,000

This experiment is designed to test the hypothesis in a controlled and cost-effective manner, using existing scientific methods and equipment. By showing that low-dose chemotherapy does not increase mHsp70 expression on tumor cells, we can disprove the hypothesis and provide valuable insights into the limitations of this approach.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Tumor Cell Preparation**

1.1. Obtain human colorectal adenocarcinoma cells (LS174T and LoVo) from a reliable cell bank or culture collection.

1.2. Thaw the cells according to the supplier's instructions and resuspend them in complete growth medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).

1.3. Culture the cells in a humidified incubator at 37°C, 5% CO2, and 95% humidity.

1.4. Verify the cell viability and morphology using a hemocytometer and a microscope.

1.5. Passage the cells every 3-4 days to maintain a healthy and exponentially growing culture.

1.6. Verify the mHsp70 expression levels on the tumor cells using flow cytometry (Protocol 3.1).

**Protocol 2: Low-Dose Chemotherapy Treatment**

2.1. Prepare a stock solution of low-dose chemotherapy (e.g., doxorubicin or cisplatin) according to the manufacturer's instructions.

2.2. Dilute the stock solution to the desired concentration (e.g., 0.1-1 μM) in complete growth medium.

2.3. Add the diluted chemotherapy solution to the tumor cells in culture and incubate for 24-48 hours.

2.4. Use a control group without chemotherapy treatment as a negative control.

2.5. Verify the cell viability and morphology after chemotherapy treatment using a hemocytometer and a microscope.

**Protocol 3: mHsp70 Expression Analysis**

3.1. Harvest the tumor cells after chemotherapy treatment and wash them with PBS.

3.2. Stain the cells with a fluorescently labeled anti-mHsp70 antibody (e.g., FITC-conjugated) according to the manufacturer's instructions.

3.3. Analyze the mHsp70 expression levels using a flow cytometer (e.g., BD FACSCanto II).

3.4. Gate the cells based on forward and side scatter to exclude debris and dead cells.

3.5. Record the mean fluorescence intensity (MFI) of mHsp70 expression for each sample.

**Protocol 4: CAR T Cell Preparation**

4.1. Obtain CAR T cells targeting mHsp70 from a reliable source or generate them using established protocols.

4.2. Expand and activate the CAR T cells using cytokines (e.g., IL-2) and feeder cells (e.g., PBMCs) according to established protocols.

4.3. Verify the CAR T cell functionality and specificity using flow cytometry and cytotoxicity assays.

4.4. Verify the CAR T cell viability and morphology using a hemocytometer and a microscope.

**Protocol 5: Co-Culture and Anti-Tumor Activity Assay**

5.1. Prepare the tumor cells (chemotherapy-treated and control) and CAR T cells for co-culture.

5.2. Mix the tumor cells and CAR T cells at different effector-to-target ratios (e.g., 1:1, 5:1, 10:1) in complete growth medium.

5.3. Incubate the co-culture for 24-48 hours in a humidified incubator at 37°C, 5% CO2, and 95% humidity.

5.4. Harvest the co-culture and analyze the anti-tumor effects using flow cytometry.

5.5. Measure cell viability, apoptosis, and cytokine production (e.g., IFN-γ, TNF-α) using flow cytometry and ELISA.

**Protocol 6: Statistical Analysis**

6.1. Compare the anti-tumor effects of CAR T cells against chemotherapy-treated and control tumor cells.

6.2. Analyze the data using statistical methods (e.g., t-test, ANOVA) to determine if there is a significant difference in anti-tumor activity between the two groups.

6.3. Calculate the mean and standard deviation of the data and present the results in a graphical format (e.g., bar graphs, scatter plots).

These detailed protocols should provide a clear and concise guide for executing the experiment.","```
   LS174T Cells  LoVo Cells  Doxorubicin (μM)  Cisplatin (μM)  CAR T Cells (E:T)  mHsp70 MFI  Anti-Tumor Activity (%)
0           50000       50000             0.5             0.0             1:1  234.12          45.67
1           75000       25000             1.0             0.0             5:1  198.76          62.15
2           25000       75000             0.0             0.5             10:1  256.89          51.23
3           50000       50000             0.5             0.5             1:1  220.56          58.92
4           25000       25000             1.0             1.0             5:1  182.34          70.12
5           75000       75000             0.0             0.0             10:1  240.98          42.19
6           50000       25000             0.5             0.0             1:1  208.90          48.56
7           25000       50000             1.0             0.5             5:1  194.23          65.78
8           75000       50000             0.0             1.0             10:1  226.14          53.45
9           50000       75000             0.5             0.5             1:1  202.67          61.29
10          25000       25000             1.0             1.0             5:1  176.54          72.56
11          75000       75000             0.0             0.0             10:1  236.79          44.82
12          50000       25000             0.5             0.0             1:1  214.12          50.98
13          25000       50000             1.0             0.5             5:1  188.90          68.23
14          75000       50000             0.0             1.0             10:1  222.45          55.67
15          50000       75000             0.5             0.5             1:1  206.34          63.45
16          25000       25000             1.0             1.0             5:1  170.12          75.12
17          75000       75000             0.0             0.0             10:1  230.56          46.56
18          50000       25000             0.5             0.0             1:1  210.67          52.34
19          25000       50000             1.0             0.5             5:1  184.56          71.12
20          75000       50000             0.0             1.0             10:1  218.90          57.89
21          50000       75000             0.5             0.5             1:1  204.12          64.56
22          25000       25000             1.0             1.0             5:1  172.34          77.12
23          75000       75000             0.0             0.0             10:1  228.23          48.12
24          50000       25000             0.5             0.0             1:1  212.45          54.12
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0050112ccaba6d4fe6152aeb17e417f6df3c5dc8.summary'],Can the antitumor activity of EC17 CAR-T cell therapy be further enhanced by combining it with a folate-targeting nanoparticle delivery system to increase the local concentration of EC17 at the tumor site?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's break it down and design an experiment to test it.

**Hypothesis:** Combining EC17 CAR-T cell therapy with a folate-targeting nanoparticle delivery system increases the local concentration of EC17 at the tumor site, thereby enhancing its antitumor activity.

**Experimental Plan:**

**Objective:** To investigate whether the combination of EC17 CAR-T cell therapy with a folate-targeting nanoparticle delivery system enhances the antitumor activity of EC17.

**Experimental Design:**

1. **Cell Culture and Preparation:**
	* Obtain EC17 CAR-T cells and folate-targeting nanoparticles.
	* Prepare EC17 CAR-T cells according to standard protocols.
	* Load EC17 onto the folate-targeting nanoparticles (NP-EC17) using established methods.
2. **In Vitro Studies:**
	* Co-culture EC17 CAR-T cells with tumor cells (e.g., ovarian cancer cells) in the presence or absence of NP-EC17.
	* Measure tumor cell viability, apoptosis, and EC17 concentration using standard assays (e.g., MTT, Annexin V, ELISA).
3. **In Vivo Studies:**
	* Establish a xenograft tumor model in immunodeficient mice using ovarian cancer cells.
	* Divide mice into three groups: (1) control (no treatment), (2) EC17 CAR-T cell therapy alone, and (3) EC17 CAR-T cell therapy + NP-EC17.
	* Administer treatments and monitor tumor growth, EC17 concentration in tumors, and mouse survival.
4. **Data Analysis:**
	* Compare the antitumor activity of EC17 CAR-T cell therapy with and without NP-EC17 in vitro and in vivo.
	* Analyze the correlation between EC17 concentration and antitumor activity.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the following:

**Null Hypothesis:** The combination of EC17 CAR-T cell therapy with a folate-targeting nanoparticle delivery system does not enhance the antitumor activity of EC17.

**Experimental Approach:**

1. **In Vitro Studies:**
	* Perform the same co-culture experiment as above, but with a non-targeting nanoparticle (NP-control) instead of NP-EC17.
	* Compare the antitumor activity of EC17 CAR-T cell therapy with NP-control to EC17 CAR-T cell therapy alone.
2. **In Vivo Studies:**
	* Repeat the in vivo experiment with the same three groups as above, but with NP-control instead of NP-EC17.
	* Compare the antitumor activity of EC17 CAR-T cell therapy with NP-control to EC17 CAR-T cell therapy alone.

**Rationale:** If the null hypothesis is true, we should not observe a significant difference in antitumor activity between EC17 CAR-T cell therapy with NP-control and EC17 CAR-T cell therapy alone, both in vitro and in vivo. This would suggest that the folate-targeting nanoparticle delivery system does not enhance the antitumor activity of EC17.

**Budget and Timeframe:**

This experiment can be completed within 6-9 months with a budget of approximately $200,000. This estimate includes:

* Personnel: 1 postdoc, 1 graduate student, and 1 technician (6 months)
* Reagents and consumables: EC17 CAR-T cells, folate-targeting nanoparticles, tumor cells, cell culture media, antibodies, and other reagents (approx. $50,000)
* Animal studies: mouse xenograft model, animal housing, and veterinary care (approx. $30,000)
* Equipment and infrastructure: access to cell culture facilities, flow cytometry, and animal imaging equipment (approx. $20,000)

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the institution's resources.",92,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Preparation**

1.1. Obtain EC17 CAR-T cells and folate-targeting nanoparticles from a reputable supplier or prepare them in-house according to established protocols.

1.2. Thaw EC17 CAR-T cells and resuspend them in complete cell culture medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine) at a concentration of 1 x 10^6 cells/mL.

1.3. Prepare folate-targeting nanoparticles according to the manufacturer's instructions or established protocols.

1.4. Load EC17 onto the folate-targeting nanoparticles (NP-EC17) using established methods, such as incubation at room temperature for 30 minutes or according to the manufacturer's instructions.

1.5. Wash NP-EC17 twice with PBS to remove excess EC17 and resuspend in complete cell culture medium at a concentration of 1 x 10^6 particles/mL.

**Protocol 2: In Vitro Studies**

2.1. Prepare ovarian cancer cells (e.g., SKOV3 or OVCAR3) according to standard protocols and resuspend them in complete cell culture medium at a concentration of 1 x 10^5 cells/mL.

2.2. Co-culture EC17 CAR-T cells with ovarian cancer cells in 96-well plates at a ratio of 1:1 (EC17 CAR-T cells:tumor cells) in the presence or absence of NP-EC17.

2.3. Incubate the co-culture at 37°C, 5% CO2 for 48-72 hours.

2.4. Measure tumor cell viability using the MTT assay:
	* Add 10 μL of MTT reagent to each well and incubate for 2-4 hours.
	* Measure absorbance at 570 nm using a microplate reader.

2.5. Measure apoptosis using Annexin V staining:
	* Harvest cells and stain with Annexin V-FITC and propidium iodide according to the manufacturer's instructions.
	* Analyze by flow cytometry using a flow cytometer (e.g., BD FACSCanto II).

2.6. Measure EC17 concentration using ELISA:
	* Harvest supernatants from the co-culture and store at -80°C until analysis.
	* Perform ELISA according to the manufacturer's instructions using a commercial EC17 ELISA kit.

**Protocol 3: In Vivo Studies**

3.1. Establish a xenograft tumor model in immunodeficient mice (e.g., NOD/SCID or NSG mice) using ovarian cancer cells.

3.2. Divide mice into three groups: (1) control (no treatment), (2) EC17 CAR-T cell therapy alone, and (3) EC17 CAR-T cell therapy + NP-EC17.

3.3. Administer treatments:
	* Inject 1 x 10^6 EC17 CAR-T cells intravenously (i.v.) into mice in groups 2 and 3.
	* Inject 1 x 10^6 NP-EC17 particles i.v. into mice in group 3.

3.4. Monitor tumor growth:
	* Measure tumor volume using calipers twice a week.
	* Calculate tumor volume using the formula: V = (L x W x H) / 2, where L, W, and H are the length, width, and height of the tumor, respectively.

3.5. Monitor EC17 concentration in tumors:
	* Harvest tumors at the end of the study and homogenize in PBS.
	* Measure EC17 concentration using ELISA as described in Protocol 2.6.

3.6. Monitor mouse survival:
	* Record mouse survival daily.
	* Perform Kaplan-Meier analysis to compare survival curves between groups.

**Protocol 4: Data Analysis**

4.1. Compare the antitumor activity of EC17 CAR-T cell therapy with and without NP-EC17 in vitro and in vivo using statistical software (e.g., GraphPad Prism).

4.2. Analyze the correlation between EC17 concentration and antitumor activity using linear regression analysis.

**Protocol 5: Experiment to Disprove the Hypothesis**

5.1. Perform the same co-culture experiment as Protocol 2, but with a non-targeting nanoparticle (NP-control) instead of NP-EC17.

5.2. Repeat the in vivo experiment with the same three groups as Protocol 3, but with NP-control instead of NP-EC17.

5.3. Compare the antitumor activity of EC17 CAR-T cell therapy with NP-control to EC17 CAR-T cell therapy alone using statistical software.

Note: These protocols are detailed and specific, but may require adjustments based on the specific requirements of the experiment and the institution's resources.","```
   EC17 CAR-T cells  Folate-targeting NPs  Ovarian Cancer Cells  NP-EC17  Tumor Cell Viability  Apoptosis  EC17 Concentration
0              1e+06              1e+06              1e+05  1e+06               0.45      0.25           500.0
1              5e+05              5e+05              1e+05  5e+05               0.52      0.30           350.0
2              1e+06              2e+06              1e+05  1e+06               0.38      0.20           600.0
3              2e+06              1e+06              1e+05  2e+06               0.42      0.28           450.0
4              1e+06              1e+06              5e+04  1e+06               0.50      0.32           400.0
5              5e+05              1e+06              1e+05  5e+05               0.48      0.26           320.0
6              1e+06              5e+05              1e+05  1e+06               0.40      0.22           480.0
7              2e+06              2e+06              1e+05  2e+06               0.36      0.24           520.0
8              1e+06              1e+06              1e+05  1e+06               0.44      0.29           420.0
9              5e+05              5e+05              5e+04  5e+05               0.54      0.34           300.0
10             1e+06              2e+06              5e+04  1e+06               0.46      0.31           460.0
11             2e+06              1e+06              5e+04  2e+06               0.40      0.27           440.0
12             1e+06              1e+06              1e+05  1e+06               0.43      0.25           410.0
13             5e+05              1e+06              5e+04  5e+05               0.51      0.33           330.0
14             1e+06              5e+05              5e+04  1e+06               0.39      0.23           490.0
15             2e+06              2e+06              5e+04  2e+06               0.35      0.26           510.0
16             1e+06              1e+06              1e+05  1e+06               0.41      0.28           430.0
17             5e+05              5e+05              1e+05  5e+05               0.53      0.35           310.0
18             1e+06              2e+06              1e+05  1e+06               0.37      0.21           590.0
19             2e+06              1e+06              1e+05  2e+06               0.45      0.30           470.0
20             1e+06              1e+06              5e+04  1e+06               0.49      0.36           390.0
21             5e+05              1e+06              1e+05  5e+05               0.47      0.29           360.0
22             1e+06              5e+05              1e+05  1e+06               0.39      0.24           500.0
23             2e+06              2e+06              1e+05  2e+06               0.34      0.25           530.0
24             1e+06              1e+06              1e+05  1e+06               0.42      0.27           450.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/529e0df5c660e0b470cbbdff7b449c7762aadf96.summary'],"Can the application of a multi-target inhibition approach to the Wnt pathway in CLL also modulate the tumor microenvironment, leading to enhanced anti-tumor immune responses and improved treatment outcomes?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Modulation of Tumor Microenvironment and Anti-Tumor Immune Responses by Multi-Target Inhibition of the Wnt Pathway in CLL

**Objective:** To determine if the application of a multi-target inhibition approach to the Wnt pathway in CLL modulates the tumor microenvironment, leading to enhanced anti-tumor immune responses and improved treatment outcomes.

**Equipment:**

* Cell culture facilities
* RNA interference (RNAi) technology
* Western blot analysis
* Cell viability assays
* Flow cytometry
* Cytokine bead arrays
* Tumor microenvironment analysis tools (e.g., immunohistochemistry, qRT-PCR)

**Steps:**

1. Identify the specific set of proteins in the Wnt pathway associated with CLL using RNA-seq data and protein-protein interaction networks (as described in the previous experiment).
2. Use RNAi technology to knockdown the expression of each protein in the identified set in CLL cell lines.
3. Co-culture CLL cells with immune cells (e.g., T cells, dendritic cells) and analyze the effects of protein knockdown on immune cell activation and cytokine production using flow cytometry and cytokine bead arrays.
4. Analyze the tumor microenvironment by assessing the expression of immune-related genes and proteins in CLL cells and immune cells using qRT-PCR and immunohistochemistry.
5. Compare the results to a control group with no protein knockdown.
6. Repeat the experiment with different combinations of protein knockdown to validate the multi-target inhibition approach.
7. Analyze the correlation between Wnt pathway inhibition, tumor microenvironment modulation, and anti-tumor immune responses.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Modulation of Tumor Microenvironment and Anti-Tumor Immune Responses by Multi-Target Inhibition of the Wnt Pathway in CLL

**Objective:** To demonstrate that the application of a multi-target inhibition approach to the Wnt pathway in CLL does not modulate the tumor microenvironment or enhance anti-tumor immune responses.

**Equipment:**

* Same as above

**Steps:**

1. Identify the specific set of proteins in the Wnt pathway associated with CLL using RNA-seq data and protein-protein interaction networks (as described in the previous experiment).
2. Use RNAi technology to knockdown the expression of each protein in the identified set in CLL cell lines.
3. Co-culture CLL cells with immune cells (e.g., T cells, dendritic cells) and analyze the effects of protein knockdown on immune cell activation and cytokine production using flow cytometry and cytokine bead arrays.
4. Analyze the tumor microenvironment by assessing the expression of immune-related genes and proteins in CLL cells and immune cells using qRT-PCR and immunohistochemistry.
5. Compare the results to a control group with no protein knockdown.
6. Repeat the experiment with different combinations of protein knockdown to validate the lack of effect.
7. Analyze the correlation between Wnt pathway inhibition, tumor microenvironment modulation, and anti-tumor immune responses.

**Key differences between the two experiments:**

* The experiment to test the hypothesis aims to demonstrate a positive correlation between Wnt pathway inhibition, tumor microenvironment modulation, and anti-tumor immune responses.
* The experiment to disprove the hypothesis aims to demonstrate a lack of correlation or a negative correlation between Wnt pathway inhibition, tumor microenvironment modulation, and anti-tumor immune responses.

**Time and Resource Considerations:**

* Both experiments can be completed within a reasonable time frame (6-12 months) with a moderate budget.
* The experiments require access to cell culture facilities, RNAi technology, and flow cytometry, which are commonly available in most research institutions.
* The experiments can be performed with a team of 2-3 researchers, including a principal investigator, a postdoctoral researcher, and a graduate student.

By designing an experiment to disprove the hypothesis, we can increase the confidence in the results and provide a more comprehensive understanding of the role of Wnt pathway inhibition in modulating the tumor microenvironment and anti-tumor immune responses in CLL.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Identify specific set of proteins in the Wnt pathway associated with CLL**

1.1. Obtain RNA-seq data from CLL patient samples and healthy controls.
1.2. Perform bioinformatic analysis using tools such as DESeq2 or edgeR to identify differentially expressed genes between CLL and healthy controls.
1.3. Use protein-protein interaction networks such as STRING or BioGRID to identify proteins in the Wnt pathway that interact with the differentially expressed genes.
1.4. Filter the results to select a set of 5-10 proteins that are most strongly associated with CLL.

**Step 2: Use RNAi technology to knockdown protein expression in CLL cell lines**

2.1. Design and synthesize siRNA or shRNA constructs targeting each of the selected proteins.
2.2. Transfect CLL cell lines (e.g., MEC-1, JVM-3) with the RNAi constructs using a transfection reagent such as Lipofectamine.
2.3. Verify knockdown efficiency using Western blot analysis or qRT-PCR.

**Step 3: Co-culture CLL cells with immune cells and analyze immune cell activation and cytokine production**

3.1. Isolate immune cells (e.g., T cells, dendritic cells) from healthy donors using Ficoll-Paque density gradient centrifugation.
3.2. Co-culture CLL cells with immune cells at a 1:1 ratio in a 96-well plate.
3.3. Incubate the co-culture for 24-48 hours at 37°C, 5% CO2.
3.4. Analyze immune cell activation using flow cytometry (e.g., CD69, CD25, CD45RO).
3.5. Analyze cytokine production using cytokine bead arrays (e.g., IL-2, IFN-γ, TNF-α).

**Step 4: Analyze tumor microenvironment**

4.1. Extract RNA from CLL cells and immune cells using TRIzol or similar reagent.
4.2. Perform qRT-PCR to analyze the expression of immune-related genes (e.g., PD-1, PD-L1, CTLA-4).
4.3. Perform immunohistochemistry to analyze protein expression in CLL cells and immune cells.

**Step 5: Compare results to control group and repeat with different combinations of protein knockdown**

5.1. Compare the results from Step 3 and 4 to a control group with no protein knockdown.
5.2. Repeat the experiment with different combinations of protein knockdown to validate the multi-target inhibition approach.

**Step 6: Analyze correlation between Wnt pathway inhibition, tumor microenvironment modulation, and anti-tumor immune responses**

6.1. Perform statistical analysis (e.g., Pearson correlation, linear regression) to analyze the correlation between Wnt pathway inhibition, tumor microenvironment modulation, and anti-tumor immune responses.
6.2. Generate graphs and figures to visualize the results.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

The protocol for the experiment to disprove the hypothesis is identical to the experiment to test the hypothesis, with the following modifications:

* In Step 6, the analysis will focus on demonstrating a lack of correlation or a negative correlation between Wnt pathway inhibition, tumor microenvironment modulation, and anti-tumor immune responses.
* The experiment will aim to show that the application of a multi-target inhibition approach to the Wnt pathway in CLL does not modulate the tumor microenvironment or enhance anti-tumor immune responses.

**Common Protocols:**

**Cell Culture:**

* Maintain CLL cell lines in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubate cells at 37°C, 5% CO2.

**Western Blot Analysis:**

* Lyse cells in RIPA buffer and separate proteins using SDS-PAGE.
* Transfer proteins to a PVDF membrane and block with 5% milk.
* Incubate with primary antibodies (e.g., anti-Wnt pathway proteins) and secondary antibodies.
* Develop the blot using ECL reagent.

**Flow Cytometry:**

* Stain cells with fluorescently labeled antibodies (e.g., CD69, CD25, CD45RO).
* Analyze cells using a flow cytometer (e.g., BD FACSCanto).
* Gate on live cells using forward and side scatter.

**Cytokine Bead Arrays:**

* Incubate supernatants from co-culture with cytokine bead arrays (e.g., BD Cytometric Bead Array).
* Analyze using a flow cytometer (e.g., BD FACSCanto).

**qRT-PCR:**

* Extract RNA from cells using TRIzol or similar reagent.
* Perform qRT-PCR using a thermocycler (e.g., Applied Biosystems 7500) and primers specific to immune-related genes.
* Analyze data using the ΔΔCt method.

**Immunohistochemistry:**

* Fix cells or tissue sections in formalin and embed in paraffin.
* Section and stain with primary antibodies (e.g., anti-Wnt pathway proteins) and secondary antibodies.
* Develop the stain using DAB reagent.

These detailed protocols should provide a clear guide for executing the experiments to test and disprove the hypothesis.","```
   Protein1  Protein2  Protein3  Protein4  Protein5  RNAi_Construct  Immune_Cell_Type  Co_Culture_Time  CD69  CD25  CD45RO  IL2  IFNg  TNFa  Outcome
0       0.5      0.2      0.8      0.1      0.4           siRNA           T_cells           24.0   20.1   15.6   12.5   8.9   10.2   Positive
1       0.8      0.5      0.3      0.6      0.9           shRNA         Dendritic           48.0   18.5   12.1   15.8   9.5   11.9   Positive
2       0.2      0.9      0.6      0.8      0.1           siRNA           T_cells           24.0   22.3   16.8   11.2   8.1   10.5   Positive
3       0.9      0.1      0.4      0.3      0.7           shRNA         Dendritic           48.0   19.2   13.5   14.1   9.2   11.1   Positive
4       0.6      0.8      0.2      0.9      0.5           siRNA           T_cells           24.0   20.9   15.2   12.9   8.5   10.8   Positive
5       0.4      0.3      0.9      0.2      0.6           shRNA         Dendritic           48.0   18.1   12.8   15.5   9.8   11.6   Positive
6       0.1      0.6      0.5      0.4      0.8           siRNA           T_cells           24.0   21.5   16.1   11.9   8.3   10.1   Positive
7       0.7      0.2      0.1      0.5      0.9           shRNA         Dendritic           48.0   19.5   13.9   14.5   9.1   11.3   Positive
8       0.3      0.9      0.8      0.6      0.2           siRNA           T_cells           24.0   20.5   15.9   12.1   8.7   10.6   Positive
9       0.5      0.4      0.3      0.1      0.7           shRNA         Dendritic           48.0   18.8   13.2   15.2   9.6   11.5   Positive
10      0.9      0.7      0.2      0.8      0.5           siRNA           T_cells           24.0   21.1   16.4   12.3   8.9   10.9   Positive
11      0.2      0.1      0.9      0.4      0.6           shRNA         Dendritic           48.0   19.1   13.6   14.8   9.3   11.2   Positive
12      0.6      0.5      0.1      0.3      0.8           siRNA           T_cells           24.0   20.7   15.5   12.6   8.5   10.7   Positive
13      0.8      0.2      0.7      0.9      0.4           shRNA         Dendritic           48.0   18.4   12.9   15.9   9.9   11.8   Positive
14      0.4      0.9      0.6      0.2      0.5           siRNA           T_cells           24.0   21.3   16.6   11.8   8.2   10.3   Positive
15      0.1      0.3      0.8      0.5      0.9           shRNA         Dendritic           48.0   19.3   14.1   14.2   9.5   11.4   Positive
16      0.7      0.6      0.4      0.8      0.2           siRNA           T_cells           24.0   20.3   15.8   12.8   8.6   10.9   Positive
17      0.5      0.1      0.9      0.3      0.7           shRNA         Dendritic           48.0   18.6   13.1   15.6   9.7   11.6   Positive
18      0.9      0.8      0.5      0.6      0.4           siRNA           T_cells           24.0   21.7   16.9   12.5   9.1   11.1   Positive
19      0.2      0.4      0.3      0.1      0.8           shRNA         Dendritic           48.0   19.8   14.3   14.9   9.4   11.5   Positive
20      0.6      0.9      0.2      0.7      0.5           siRNA           T_cells           24.0   20.9   16.2   12.2   8.8   10.8   Positive
21      0.8      0.5      0.9      0.4      0.6           shRNA         Dendritic           48.0   18.2   12.5   16.1   10.1   11.9   Positive
22      0.4      0.2      0.7      0.9      0.3           siRNA           T_cells           24.0   21.5   16.7   11.6   8.4   10.2   Positive
23      0.1      0.8      0.5      0.2      0.9           shRNA         Dendritic           48.0   19.6   14.2   15.3   9.8   11.7   Positive
24      0.7      0.3      0.1      0.5      0.8           siRNA           T_cells           24.0   20.1   15.4   13.1   8.9   10.6   Negative
```",0.03900593454484664
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/712009706bee0c3896046140035d1cdbaaa7cafa.summary'],"Can the application of machine learning algorithms to integrate multi-omics data from DLBCL patients identify novel, subtype-agnostic biomarkers that can be targeted by a single, universally effective therapeutic strategy?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Integrating Multi-Omics Data to Identify Novel, Subtype-Agnostic Biomarkers for Diffuse Large B Cell Lymphoma (DLBCL)

**Objective:** To apply machine learning algorithms to integrate multi-omics data from DLBCL patients and identify novel, subtype-agnostic biomarkers that can be targeted by a single, universally effective therapeutic strategy.

**Experimental Design:**

1. **Data Collection:**
	* Collect existing multi-omics data (genomics, transcriptomics, proteomics, and metabolomics) from publicly available datasets or collaborate with hospitals to obtain data from DLBCL patients.
	* Ensure the dataset includes both ABC and GCB subtypes.
2. **Data Preprocessing:**
	* Clean and preprocess the data using standard bioinformatics tools (e.g., Trimmomatic, STAR, DESeq2).
	* Normalize and transform the data for machine learning analysis.
3. **Machine Learning Analysis:**
	* Apply machine learning algorithms (e.g., random forest, gradient boosting, neural networks) to integrate the multi-omics data.
	* Use feature selection techniques (e.g., recursive feature elimination, permutation importance) to identify the most informative biomarkers.
4. **Biomarker Identification:**
	* Identify novel, subtype-agnostic biomarkers that are common across both ABC and GCB subtypes.
	* Validate the biomarkers using techniques such as pathway analysis, gene set enrichment analysis, and protein-protein interaction networks.
5. **Therapeutic Strategy Development:**
	* Use the identified biomarkers to develop a single, universally effective therapeutic strategy.
	* Design and optimize a drug or combination of drugs to target the identified biomarkers.

**Equipment and Resources:**

* High-performance computing infrastructure (e.g., cluster, cloud computing)
* Bioinformatics software and tools (e.g., Python, R, Bioconductor)
* Machine learning libraries and frameworks (e.g., scikit-learn, TensorFlow)
* Access to publicly available datasets or collaboration with hospitals for data collection

**Timeline:** 6-12 months

**Budget:** Moderate to high (dependent on the scale of data collection and computational resources)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Subtype-Specificity of Biomarkers in DLBCL

**Objective:** To demonstrate that the application of machine learning algorithms to integrate multi-omics data from DLBCL patients cannot identify novel, subtype-agnostic biomarkers that can be targeted by a single, universally effective therapeutic strategy.

**Experimental Design:**

1. **Data Collection:**
	* Collect existing multi-omics data from publicly available datasets or collaborate with hospitals to obtain data from DLBCL patients.
	* Ensure the dataset includes both ABC and GCB subtypes.
2. **Data Preprocessing:**
	* Clean and preprocess the data using standard bioinformatics tools (e.g., Trimmomatic, STAR, DESeq2).
	* Normalize and transform the data for machine learning analysis.
3. **Machine Learning Analysis:**
	* Apply machine learning algorithms (e.g., random forest, gradient boosting, neural networks) to integrate the multi-omics data.
	* Use feature selection techniques (e.g., recursive feature elimination, permutation importance) to identify the most informative biomarkers.
4. **Biomarker Identification:**
	* Identify biomarkers that are specific to either ABC or GCB subtypes.
	* Validate the biomarkers using techniques such as pathway analysis, gene set enrichment analysis, and protein-protein interaction networks.
5. **Therapeutic Strategy Development:**
	* Attempt to develop a single, universally effective therapeutic strategy targeting the identified subtype-specific biomarkers.
	* Evaluate the efficacy of the therapeutic strategy using in vitro and in vivo experiments.

**Equipment and Resources:**

* High-performance computing infrastructure (e.g., cluster, cloud computing)
* Bioinformatics software and tools (e.g., Python, R, Bioconductor)
* Machine learning libraries and frameworks (e.g., scikit-learn, TensorFlow)
* Access to publicly available datasets or collaboration with hospitals for data collection
* In vitro and in vivo experimental equipment (e.g., cell culture facilities, animal models)

**Timeline:** 6-12 months

**Budget:** Moderate to high (dependent on the scale of data collection, computational resources, and experimental equipment)

By attempting to disprove the hypothesis, this experiment will provide a more comprehensive understanding of the limitations and challenges in identifying novel, subtype-agnostic biomarkers for DLBCL. If the experiment fails to disprove the hypothesis, it will provide strong evidence for the validity of the original hypothesis.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Integrating Multi-Omics Data to Identify Novel, Subtype-Agnostic Biomarkers for Diffuse Large B Cell Lymphoma (DLBCL)**

**Step 1: Data Collection**

1.1. Identify publicly available datasets containing multi-omics data (genomics, transcriptomics, proteomics, and metabolomics) from DLBCL patients.

1.2. Search online databases such as The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and ProteomicsDB to find relevant datasets.

1.3. Collaborate with hospitals to obtain additional data from DLBCL patients, ensuring the dataset includes both ABC and GCB subtypes.

1.4. Document the data sources, including dataset IDs, accession numbers, and publication references.

**Step 2: Data Preprocessing**

2.1. Clean and preprocess the genomic data using Trimmomatic (v0.39) with the following parameters:
	* Adapter trimming: ILLUMINACLIP:TruSeq3-PE.fa:2:30:10
	* Quality trimming: LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:36

2.2. Align the preprocessed genomic data to the human reference genome (GRCh38) using STAR (v2.7.3a) with the following parameters:
	* --outFilterMismatchNmax 2
	* --outFilterMismatchNoverLmax 0.04
	* --alignEndsType SoftClip

2.3. Perform differential gene expression analysis using DESeq2 (v1.28.1) with the following parameters:
	* Design formula: ~ condition + subtype
	* Independent filtering: yes
	* p-value threshold: 0.05

2.4. Normalize and transform the data for machine learning analysis using the following steps:
	* Log2 transformation
	* Standardization (mean = 0, standard deviation = 1)

**Step 3: Machine Learning Analysis**

3.1. Split the preprocessed data into training (80%) and testing (20%) sets using stratified sampling.

3.2. Apply random forest algorithm (scikit-learn v0.24.2) with the following parameters:
	* Number of trees: 1000
	* Maximum depth: 5
	* Feature selection: recursive feature elimination (RFE) with 10-fold cross-validation

3.3. Apply gradient boosting algorithm (scikit-learn v0.24.2) with the following parameters:
	* Number of trees: 1000
	* Learning rate: 0.1
	* Maximum depth: 5
	* Feature selection: permutation importance with 10-fold cross-validation

3.4. Apply neural network algorithm (TensorFlow v2.4.1) with the following parameters:
	* Number of hidden layers: 2
	* Number of neurons per layer: 128
	* Activation function: ReLU
	* Dropout rate: 0.2
	* Feature selection: recursive feature elimination (RFE) with 10-fold cross-validation

**Step 4: Biomarker Identification**

4.1. Identify novel, subtype-agnostic biomarkers that are common across both ABC and GCB subtypes using the feature selection techniques from Step 3.

4.2. Validate the biomarkers using techniques such as:
	* Pathway analysis: ReactomePA (v1.32.0) with a p-value threshold of 0.05
	* Gene set enrichment analysis: GSEA (v4.1.0) with a p-value threshold of 0.05
	* Protein-protein interaction networks: STRING (v11.5) with a confidence score threshold of 0.7

**Step 5: Therapeutic Strategy Development**

5.1. Use the identified biomarkers to develop a single, universally effective therapeutic strategy.

5.2. Design and optimize a drug or combination of drugs to target the identified biomarkers using molecular dynamics simulations and docking studies.

**Experiment to Disprove the Hypothesis: Investigating the Subtype-Specificity of Biomarkers in DLBCL**

**Step 1: Data Collection**

1.1. Collect existing multi-omics data from publicly available datasets or collaborate with hospitals to obtain data from DLBCL patients.

1.2. Ensure the dataset includes both ABC and GCB subtypes.

**Step 2: Data Preprocessing**

2.1. Clean and preprocess the genomic data using Trimmomatic (v0.39) with the same parameters as in Step 2.1 of the first experiment.

2.2. Align the preprocessed genomic data to the human reference genome (GRCh38) using STAR (v2.7.3a) with the same parameters as in Step 2.2 of the first experiment.

2.3. Perform differential gene expression analysis using DESeq2 (v1.28.1) with the same parameters as in Step 2.3 of the first experiment.

2.4. Normalize and transform the data for machine learning analysis using the same steps as in Step 2.4 of the first experiment.

**Step 3: Machine Learning Analysis**

3.1. Split the preprocessed data into training (80%) and testing (20%) sets using stratified sampling.

3.2. Apply machine learning algorithms (random forest, gradient boosting, and neural networks) with the same parameters as in Step 3 of the first experiment.

**Step 4: Biomarker Identification**

4.1. Identify biomarkers that are specific to either ABC or GCB subtypes using the feature selection techniques from Step 3.

4.2. Validate the biomarkers using techniques such as:
	* Pathway analysis: ReactomePA (v1.32.0) with a p-value threshold of 0.05
	* Gene set enrichment analysis: GSEA (v4.1.0) with a p-value threshold of 0.05
	* Protein-protein interaction networks: STRING (v11.5) with a confidence score threshold of 0.7

**Step 5: Therapeutic Strategy Development**

5.1. Attempt to develop a single, universally effective therapeutic strategy targeting the identified subtype-specific biomarkers.

5.2. Evaluate the efficacy of the therapeutic strategy using in vitro and in vivo experiments.

Note: The specific software versions and parameters used in these protocols are examples and may need to be updated or modified based on the latest available versions and best practices.","```
   Trimmomatic  STAR  DESeq2  Log2  Standardization  Random_Forest  Gradient_Boosting  Neural_Network  Outcome
0           0.4  0.39  1.28.1  0.05           0.5           1000             0.1           128       0.8
1           0.3  0.38  1.27.1  0.04           0.6           900             0.2           120       0.7
2           0.5  0.40  1.29.1  0.06           0.4           1100             0.3           130       0.9
3           0.2  0.37  1.26.1  0.03           0.7           800             0.4           110       0.6
4           0.6  0.41  1.30.1  0.07           0.3           1200             0.5           140       1.0
5           0.1  0.36  1.25.1  0.02           0.8           700             0.6           100       0.5
6           0.7  0.42  1.31.1  0.08           0.2           1300             0.7           150       1.1
7           0.8  0.43  1.32.1  0.09           0.1           1400             0.8           160       1.2
8           0.9  0.44  1.33.1  0.10           0.0           1500             0.9           170       1.3
9           1.0  0.45  1.34.1  0.11           0.9           1600             1.0           180       1.4
10          0.5  0.40  1.29.1  0.06           0.4           1100             0.3           130       0.9
11          0.3  0.38  1.27.1  0.04           0.6           900             0.2           120       0.7
12          0.2  0.37  1.26.1  0.03           0.7           800             0.4           110       0.6
13          0.6  0.41  1.30.1  0.07           0.3           1200             0.5           140       1.0
14          0.1  0.36  1.25.1  0.02           0.8           700             0.6           100       0.5
15          0.7  0.42  1.31.1  0.08           0.2           1300             0.7           150       1.1
16          0.8  0.43  1.32.1  0.09           0.1           1400             0.8           160       1.2
17          0.9  0.44  1.33.1  0.10           0.0           1500             0.9           170       1.3
18          1.0  0.45  1.34.1  0.11           0.9           1600             1.0           180       1.4
19          0.4  0.39  1.28.1  0.05           0.5           1000             0.1           128       0.8
20          0.3  0.38  1.27.1  0.04           0.6           900             0.2           120       0.7
21          0.5  0.40  1.29.1  0.06           0.4           1100             0.3           130       0.9
22          0.2  0.37  1.26.1  0.03           0.7           800             0.4           110       0.6
23          0.6  0.41  1.30.1  0.07           0.3           1200             0.5           140       1.0
24          0.1  0.36  1.25.1  0.02           0.8           700             0.6           100       0.5
```",0.7290645223166226
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/433fbaae85d5cdd75292450e11e259bf916bd49c.summary'],Can the application of nonparametric Bayesian statistics to single-molecule tracking data from multiple spatially-resolved regions within a living cell reveal coordinated dynamics and communication between distinct subcellular compartments?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating Coordinated Dynamics and Communication between Subcellular Compartments using Nonparametric Bayesian Statistics and Single-Molecule Tracking

**Objective:** To determine if the application of nonparametric Bayesian statistics to single-molecule tracking data from multiple spatially-resolved regions within a living cell can reveal coordinated dynamics and communication between distinct subcellular compartments.

**Experimental Design:**

1. **Cell Preparation:** Use a cell line with well-characterized subcellular compartments (e.g., HeLa cells) and fluorescently label specific proteins or molecules of interest (e.g., using GFP or RFP tags).
2. **Single-Molecule Tracking:** Use a microscope capable of single-molecule imaging (e.g., TIRF or STORM) to acquire trajectories of the labeled molecules in multiple spatially-resolved regions within the cell (e.g., nucleus, cytoplasm, and plasma membrane).
3. **Data Analysis:** Apply nonparametric Bayesian statistics (using SMAUG) to the acquired trajectories to identify mobility states, diffusion coefficients, localization noise, and transition probabilities between states for each region.
4. **Comparison and Integration:** Compare the results from each region to identify potential coordinated dynamics and communication between subcellular compartments. Integrate the results to generate a comprehensive understanding of the cellular dynamics.

**Expected Outcomes:**

* Identification of distinct mobility states and dynamics in each subcellular compartment
* Detection of coordinated dynamics and communication between subcellular compartments
* Insights into the underlying mechanisms governing cellular behavior and function

**Resources and Timeline:**

* Microscope and imaging equipment: 1 month
* Cell preparation and labeling: 2 weeks
* Data acquisition: 2 weeks
* Data analysis and integration: 3 months
* Total duration: 6 months
* Budget: $150,000 (including equipment, reagents, and personnel costs)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Limitations of Nonparametric Bayesian Statistics in Revealing Coordinated Dynamics and Communication between Subcellular Compartments

**Objective:** To design an experiment that attempts to disprove the hypothesis by demonstrating the inability of nonparametric Bayesian statistics to reveal coordinated dynamics and communication between subcellular compartments.

**Experimental Design:**

1. **Cell Preparation:** Use a cell line with minimal or no communication between subcellular compartments (e.g., cells with disrupted cytoskeleton or compromised membrane structure).
2. **Single-Molecule Tracking:** Acquire trajectories of labeled molecules in multiple spatially-resolved regions within the cell using the same microscope and imaging conditions as the main experiment.
3. **Data Analysis:** Apply nonparametric Bayesian statistics (using SMAUG) to the acquired trajectories, but intentionally introduce noise or artifacts into the data to simulate real-world limitations (e.g., photobleaching, instrumental noise, or sample drift).
4. **Comparison and Integration:** Compare the results from each region and attempt to identify coordinated dynamics and communication between subcellular compartments.

**Expected Outcomes:**

* Failure to detect coordinated dynamics and communication between subcellular compartments
* Identification of limitations and potential pitfalls in the application of nonparametric Bayesian statistics to single-molecule tracking data

**Resources and Timeline:**

* Microscope and imaging equipment: 1 month
* Cell preparation and labeling: 2 weeks
* Data acquisition: 2 weeks
* Data analysis and integration: 2 months
* Total duration: 5 months
* Budget: $100,000 (including equipment, reagents, and personnel costs)

By designing an experiment to disprove the hypothesis, we can test the robustness of the approach and identify potential limitations, which will ultimately strengthen the conclusions drawn from the main experiment.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Cell Preparation**

1.1. Obtain HeLa cells from a reliable source (e.g., ATCC) and maintain them in a sterile environment at 37°C, 5% CO2, and 95% humidity.

1.2. Grow cells to 70-80% confluency in a 10 cm dish using Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

1.3. Transfect cells with a plasmid encoding a fluorescently labeled protein of interest (e.g., GFP-tagged histone H2B or RFP-tagged tubulin) using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.4. Incubate cells for 24-48 hours to allow for protein expression.

1.5. Verify protein expression using fluorescence microscopy and Western blotting.

**Protocol 2: Single-Molecule Tracking**

2.1. Prepare a microscope capable of single-molecule imaging (e.g., TIRF or STORM) with a 100x oil immersion objective and a high-sensitivity camera (e.g., EMCCD or sCMOS).

2.2. Prepare a sample chamber by coating a glass coverslip with a thin layer of poly-L-lysine and washing with PBS.

2.3. Add 1-2 mL of cell culture medium to the sample chamber and place the coverslip on the microscope stage.

2.4. Identify cells with suitable morphology and fluorescent labeling using bright-field and fluorescence microscopy.

2.5. Acquire single-molecule trajectories in multiple spatially-resolved regions within the cell (e.g., nucleus, cytoplasm, and plasma membrane) using the microscope's acquisition software.

2.6. Set the acquisition parameters to capture 10,000-20,000 frames at 10-20 Hz with an exposure time of 10-50 ms.

2.7. Repeat the acquisition process for 3-5 cells to ensure sufficient data for analysis.

**Protocol 3: Data Analysis**

3.1. Import the acquired trajectories into a data analysis software (e.g., MATLAB or Python) and apply a particle tracking algorithm (e.g., TrackMate or u-track) to identify and link individual molecules.

3.2. Apply nonparametric Bayesian statistics (using SMAUG) to the tracked trajectories to identify mobility states, diffusion coefficients, localization noise, and transition probabilities between states for each region.

3.3. Use a Markov chain Monte Carlo (MCMC) algorithm to sample from the posterior distribution and estimate the model parameters.

3.4. Visualize the results using plots and heatmaps to identify coordinated dynamics and communication between subcellular compartments.

**Protocol 4: Comparison and Integration**

4.1. Compare the results from each region to identify potential coordinated dynamics and communication between subcellular compartments.

4.2. Integrate the results to generate a comprehensive understanding of the cellular dynamics using a systems biology approach.

4.3. Validate the findings using additional experiments (e.g., FRAP, FRET, or biochemical assays) and literature reviews.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Preparation**

1.1. Obtain cells with minimal or no communication between subcellular compartments (e.g., cells with disrupted cytoskeleton or compromised membrane structure) from a reliable source (e.g., ATCC) or generate them using CRISPR-Cas9 genome editing.

1.2. Grow cells to 70-80% confluency in a 10 cm dish using DMEM supplemented with 10% FBS and 1% penicillin-streptomycin.

1.3. Transfect cells with a plasmid encoding a fluorescently labeled protein of interest (e.g., GFP-tagged histone H2B or RFP-tagged tubulin) using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.4. Incubate cells for 24-48 hours to allow for protein expression.

1.5. Verify protein expression using fluorescence microscopy and Western blotting.

**Protocol 2: Single-Molecule Tracking**

2.1. Prepare the microscope and sample chamber as described in Protocol 2 of the main experiment.

2.2. Acquire single-molecule trajectories in multiple spatially-resolved regions within the cell using the same microscope and imaging conditions as the main experiment.

2.3. Intentionally introduce noise or artifacts into the data to simulate real-world limitations (e.g., photobleaching, instrumental noise, or sample drift).

**Protocol 3: Data Analysis**

3.1. Import the acquired trajectories into a data analysis software (e.g., MATLAB or Python) and apply a particle tracking algorithm (e.g., TrackMate or u-track) to identify and link individual molecules.

3.2. Apply nonparametric Bayesian statistics (using SMAUG) to the tracked trajectories, but ignore the introduced noise or artifacts.

3.3. Use a Markov chain Monte Carlo (MCMC) algorithm to sample from the posterior distribution and estimate the model parameters.

3.4. Visualize the results using plots and heatmaps to attempt to identify coordinated dynamics and communication between subcellular compartments.

**Protocol 4: Comparison and Integration**

4.1. Compare the results from each region and attempt to identify coordinated dynamics and communication between subcellular compartments.

4.2. Identify the limitations and potential pitfalls in the application of nonparametric Bayesian statistics to single-molecule tracking data.

4.3. Validate the findings using additional experiments (e.g., FRAP, FRET, or biochemical assays) and literature reviews.

These detailed protocols should provide a clear guide for executing the experiments and testing the hypothesis.","```
   HeLa Cells  DMEM  FBS  Penicillin-Streptomycin  Lipofectamine 2000  Plasmid  Microscope  Camera  Acquisition Time  Frames  Exposure Time  Outcome
0          10000  10.0  10.0                  1.0               2.0     1.0       TIRF  EMCCD          10.0     15000        20.0  Successful
1          12000  12.0  12.0                  1.2               2.5     1.2       TIRF  EMCCD          12.0     18000        25.0  Successful
2           8000   8.0   8.0                  0.8               1.5     0.8       TIRF  EMCCD           8.0     12000        15.0  Unsuccessful
3          15000  15.0  15.0                  1.5               3.0     1.5       STORM  sCMOS          15.0     20000        30.0  Successful
4           9000   9.0   9.0                  0.9               1.8     0.9       TIRF  EMCCD           9.0     14000        20.0  Unsuccessful
5          11000  11.0  11.0                  1.1               2.2     1.1       STORM  sCMOS          11.0     16000        25.0  Successful
6          13000  13.0  13.0                  1.3               2.8     1.3       TIRF  EMCCD          13.0     19000        30.0  Successful
7           7000   7.0   7.0                  0.7               1.2     0.7       STORM  sCMOS           7.0     11000        15.0  Unsuccessful
8          14000  14.0  14.0                  1.4               3.2     1.4       TIRF  EMCCD          14.0     21000        35.0  Successful
9           1000   1.0   1.0                  0.1               0.2     0.1       STORM  sCMOS           1.0      5000         5.0  Unsuccessful
10         16000  16.0  16.0                  1.6               3.5     1.6       TIRF  EMCCD          16.0     23000        40.0  Successful
11         17000  17.0  17.0                  1.7               3.8     1.7       STORM  sCMOS          17.0     25000        45.0  Successful
12          6000   6.0   6.0                  0.6               1.0     0.6       TIRF  EMCCD           6.0     10000        10.0  Unsuccessful
13         18000  18.0  18.0                  1.8               4.0     1.8       TIRF  EMCCD          18.0     27000        50.0  Successful
14         19000  19.0  19.0                  1.9               4.2     1.9       STORM  sCMOS          19.0     29000        55.0  Successful
15          5000   5.0   5.0                  0.5               0.8     0.5       TIRF  EMCCD           5.0      9000         5.0  Unsuccessful
16         20000  20.0  20.0                  2.0               4.5     2.0       TIRF  EMCCD          20.0     31000        60.0  Successful
17         21000  21.0  21.0                  2.1               4.8     2.1       STORM  sCMOS          21.0     33000        65.0  Successful
18          4000   4.0   4.0                  0.4               0.6     0.4       TIRF  EMCCD           4.0      8000         5.0  Unsuccessful
19         22000  22.0  22.0                  2.2               5.0     2.2       TIRF  EMCCD          22.0     35000        70.0  Successful
20         23000  23.0  23.0                  2.3               5.2     2.3       STORM  sCMOS          23.0     37000        75.0  Successful
21          3000   3.0   3.0                  0.3               0.4     0.3       TIRF  EMCCD           3.0      7000         5.0  Unsuccessful
22         24000  24.0  24.0                  2.4               5.5     2.4       TIRF  EMCCD          24.0     39000        80.0  Successful
23         25000  25.0  25.0                  2.5               5.8     2.5       STORM  sCMOS          25.0     41000        85.0  Successful
24          2000   2.0   2.0                  0.2               0.3     0.2       TIRF  EMCCD           2.0      6000         5.0  Unsuccessful
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1b7ded56b0a447e34b7a059738a59d8ab9bd2914.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8afd881f01412a6148e65c67278cfbdf713d0dbc.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/05c465fccfa8d714e24d324e3e2c344e86871293.summary']","Can the cell-type specific targeting of ligand-receptor interactions in CD14 monocytes modulate the T-cell receptor and B-cell receptor repertoires in juvenile idiopathic arthritis patients, leading to improved treatment outcomes?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Can the cell-type specific targeting of ligand-receptor interactions in CD14 monocytes modulate the T-cell receptor and B-cell receptor repertoires in juvenile idiopathic arthritis (JIA) patients, leading to improved treatment outcomes?

**Experimental Plan:**

**Objective:** To investigate whether targeting ligand-receptor interactions in CD14 monocytes can modulate the T-cell receptor and B-cell receptor repertoires in JIA patients, and to assess the potential impact on treatment outcomes.

**Experimental Design:**

1. **Patient Sample Collection:** Collect peripheral blood mononuclear cells (PBMCs) from JIA patients and healthy controls.
2. **Cell Sorting:** Use flow cytometry to sort CD14 monocytes from the PBMCs.
3. **Ligand-Receptor Interaction Targeting:** Use siRNA to knockdown specific ligand-receptor interactions in the sorted CD14 monocytes. This will be done using a targeted approach, focusing on ligand-receptor interactions that are known to be involved in JIA pathogenesis.
4. **T-cell Receptor and B-cell Receptor Repertoire Analysis:** Use single-cell RNA sequencing and Ibex (variational autoencoder) to analyze the T-cell receptor and B-cell receptor repertoires in the CD14 monocytes before and after ligand-receptor interaction targeting.
5. **Comparison and Analysis:** Compare the T-cell receptor and B-cell receptor repertoires between the JIA patients and healthy controls, as well as between the CD14 monocytes with and without ligand-receptor interaction targeting. Analyze the data using dimensionality reduction techniques (e.g., UMAP) and clustering algorithms to identify novel patterns and correlations.
6. **Functional Assays:** Validate the findings using functional assays, such as cell sorting and flow cytometry, to assess the impact of ligand-receptor interaction targeting on T-cell and B-cell function.

**Equipment and Resources:**

* Flow cytometer
* Antibodies against CD14 and other immune cell markers
* siRNA transfection reagents
* Single-cell RNA sequencing platform
* Ibex R package
* Computational resources for data analysis
* Cell culture facilities

**Timeframe and Budget:**

This experiment can be completed within 6-12 months, depending on the availability of resources and the complexity of the data analysis. The budget will depend on the cost of the equipment, reagents, and personnel required for the experiment. However, the use of existing resources and equipment, such as flow cytometers and single-cell RNA sequencing platforms, can help reduce the overall cost.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, the experiment can be designed to test the opposite scenario: that targeting ligand-receptor interactions in CD14 monocytes has no effect on the T-cell receptor and B-cell receptor repertoires in JIA patients.

In this case, the experiment would involve the same steps as above, but with a negative control group where the CD14 monocytes are not targeted with siRNA. The comparison between the targeted and non-targeted groups would allow us to determine if the ligand-receptor interaction targeting has a significant impact on the T-cell receptor and B-cell receptor repertoires.

If the results show no significant difference between the targeted and non-targeted groups, it would suggest that the hypothesis is false, and that targeting ligand-receptor interactions in CD14 monocytes does not modulate the T-cell receptor and B-cell receptor repertoires in JIA patients.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Sample Collection**

1.1. Obtain informed consent from JIA patients and healthy controls.

1.2. Collect 10-20 mL of peripheral blood from each participant using a sterile needle and syringe.

1.3. Transfer the blood to a sterile tube containing an anticoagulant (e.g., EDTA or heparin).

1.4. Store the blood samples at room temperature and process within 24 hours.

**Protocol 2: Cell Sorting**

2.1. Prepare the PBMCs by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare).

2.2. Wash the PBMCs with phosphate-buffered saline (PBS) and resuspend in 1 mL of PBS.

2.3. Stain the PBMCs with fluorescently labeled antibodies against CD14 (e.g., CD14-PE, BioLegend) and other immune cell markers (e.g., CD3, CD19, CD45).

2.4. Perform flow cytometry using a flow cytometer (e.g., BD FACSAria III) to sort CD14+ monocytes.

2.5. Collect the sorted CD14+ monocytes in a sterile tube and wash with PBS.

**Protocol 3: Ligand-Receptor Interaction Targeting**

3.1. Design and synthesize siRNA molecules targeting specific ligand-receptor interactions involved in JIA pathogenesis (e.g., siRNA against CD40L-CD40 interaction).

3.2. Transfect the sorted CD14+ monocytes with the siRNA molecules using a transfection reagent (e.g., Lipofectamine RNAiMAX, Thermo Fisher Scientific).

3.3. Incubate the transfected cells at 37°C, 5% CO2 for 24-48 hours to allow for siRNA-mediated knockdown.

**Protocol 4: T-cell Receptor and B-cell Receptor Repertoire Analysis**

4.1. Prepare single-cell suspensions of the CD14+ monocytes before and after ligand-receptor interaction targeting.

4.2. Perform single-cell RNA sequencing using a platform (e.g., 10x Genomics Chromium) to generate transcriptome data.

4.3. Analyze the transcriptome data using the Ibex R package to identify T-cell receptor and B-cell receptor repertoire profiles.

4.4. Perform dimensionality reduction techniques (e.g., UMAP) and clustering algorithms to identify novel patterns and correlations in the T-cell receptor and B-cell receptor repertoires.

**Protocol 5: Comparison and Analysis**

5.1. Compare the T-cell receptor and B-cell receptor repertoires between JIA patients and healthy controls.

5.2. Compare the T-cell receptor and B-cell receptor repertoires between CD14+ monocytes with and without ligand-receptor interaction targeting.

5.3. Analyze the data using statistical software (e.g., R, Python) to identify significant differences and correlations.

**Protocol 6: Functional Assays**

6.1. Perform cell sorting and flow cytometry to assess the impact of ligand-receptor interaction targeting on T-cell and B-cell function.

6.2. Measure T-cell and B-cell activation markers (e.g., CD69, CD25, CD86) and cytokine production (e.g., IL-2, IFN-γ, TNF-α).

6.3. Analyze the data using statistical software to identify significant differences and correlations.

**Protocol for Disproving the Hypothesis**

To disprove the hypothesis, repeat Protocols 1-6 with a negative control group where the CD14+ monocytes are not targeted with siRNA. Compare the results between the targeted and non-targeted groups to determine if ligand-receptor interaction targeting has a significant impact on the T-cell receptor and B-cell receptor repertoires.

Note: These protocols are detailed and specific, but may require adjustments based on the specific equipment, reagents, and resources available in the laboratory. It is essential to follow proper laboratory protocols, safety guidelines, and quality control measures to ensure the accuracy and reproducibility of the results.","```
   EDTA_volume  Ficoll_Paque_volume  CD14_PE_volume  siRNA_molecules  Lipofectamine_volume  Incubation_time  Outcome
0           10.0               5.0           2.0           50.0               10.0           24.0  Positive
1           15.0               7.0           3.0           60.0               12.0           36.0  Negative
2           12.0               6.0           2.5           55.0               11.0           30.0  Positive
3           18.0               8.0           3.5           65.0               13.0           42.0  Negative
4           11.0               5.5           2.2           52.0               10.5           27.0  Positive
5           16.0               7.5           3.2           62.0               12.5           39.0  Negative
6           13.0               6.5           2.8           58.0               11.5           33.0  Positive
7           19.0               9.0           3.8           70.0               14.0           45.0  Negative
8           10.5               5.2           2.1           51.0               10.2           25.0  Positive
9           17.0               8.2           3.4           64.0               13.2           41.0  Negative
10          12.5               6.2           2.6           56.0               11.2           31.0  Positive
11          15.5               7.2           3.0           61.0               12.2           37.0  Negative
12          11.2               5.8           2.4           53.0               10.8           29.0  Positive
13          18.5               8.5           3.6           67.0               13.5           43.0  Negative
14          13.2               6.8           2.9           59.0               11.8           35.0  Positive
15          16.2               7.8           3.3           63.0               12.8           40.0  Negative
16          10.8               5.4           2.3           54.0               10.4           26.0  Positive
17          17.8               8.8           3.9           71.0               14.2           46.0  Negative
18          12.8               6.4           2.7           57.0               11.4           32.0  Positive
19          15.8               7.4           3.1           60.0               12.4           38.0  Negative
20          11.5               5.9           2.5           55.0               10.9           28.0  Positive
21          18.2               9.2           4.0           72.0               14.5           47.0  Negative
22          13.5               7.0           3.2           62.0               12.0           39.0  Positive
23          16.5               8.0           3.5           65.0               13.0           42.0  Negative
24          12.2               6.1           2.9           58.0               11.1           34.0  Positive
```",0.8379189531253318
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/084ef8d13a6d3672619a0e65339ca9d95f67012d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/094d09bb73ed396756e8968cc5b00a574c509823.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f98f11e039d5c84164b84008ec81765319ceec26.summary']","Can the co-expression of LRP6 with the modified FcγRI receptor on antigen presenting cells enhance their tolerogenic phenotype and promote the generation of regulatory T cells, leading to improved immunomodulation and tolerance in individuals with type 1 diabetes?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed a high-level experimental plan to test its validity. Since the goal is to disprove the hypothesis, the experiment is designed to challenge the predicted outcome.

**Hypothesis:** Co-expression of LRP6 with the modified FcγRI receptor on antigen-presenting cells (APCs) enhances their tolerogenic phenotype, promoting regulatory T cell (Treg) generation and improving immunomodulation and tolerance in individuals with type 1 diabetes.

**Experimental Plan:**

**Objective:** To disprove the hypothesis by demonstrating that co-expression of LRP6 with modified FcγRI receptor on APCs does not enhance their tolerogenic phenotype or promote Treg generation in the context of type 1 diabetes.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate dendritic cells (DCs) from healthy donors and individuals with type 1 diabetes.
	* Transfect DCs with LRP6 and modified FcγRI receptor (LRP6-FcγRI) or control vectors using established transfection methods (e.g., lentiviral vectors).
	* Verify transfection efficiency and protein expression using flow cytometry and Western blotting.
2. **Tolerogenic Phenotype Analysis:**
	* Co-culture LRP6-FcγRI-expressing DCs with autologous T cells from individuals with type 1 diabetes.
	* Measure the expression of tolerogenic markers (e.g., PD-L1, IDO, and IL-10) on DCs using flow cytometry and qRT-PCR.
	* Compare the results to control DCs (without LRP6-FcγRI expression).
3. **Treg Generation and Function:**
	* Co-culture LRP6-FcγRI-expressing DCs with naive CD4+ T cells from individuals with type 1 diabetes.
	* Analyze the generation of Tregs (CD4+CD25+FoxP3+) using flow cytometry.
	* Assess Treg function by measuring their ability to suppress T cell proliferation and cytokine production in a mixed lymphocyte reaction (MLR) assay.
4. **In Vivo Validation:**
	* Use a type 1 diabetes mouse model (e.g., NOD mice) to test the efficacy of LRP6-FcγRI-expressing DCs in promoting tolerance.
	* Inject LRP6-FcγRI-expressing DCs or control DCs into mice and monitor disease progression (e.g., blood glucose levels, insulitis, and pancreatic islet function).

**Negative Control:**

* Use DCs without LRP6-FcγRI expression as a negative control to demonstrate that the observed effects are specific to the co-expression of LRP6 and modified FcγRI receptor.

**Expected Outcomes:**

* If the hypothesis is true, LRP6-FcγRI-expressing DCs should exhibit an enhanced tolerogenic phenotype, promote Treg generation, and improve immunomodulation and tolerance in individuals with type 1 diabetes.
* If the hypothesis is false, LRP6-FcγRI-expressing DCs should not demonstrate a significant difference in tolerogenic phenotype, Treg generation, or immunomodulation compared to control DCs.

**Timeline and Budget:**

* This experiment can be completed within 6-9 months with a budget of approximately $200,000.
* The budget will cover:
	+ Cell isolation and culture reagents
	+ Transfection reagents and vectors
	+ Flow cytometry and qRT-PCR analysis
	+ Mouse model and in vivo experimentation
	+ Personnel and laboratory costs

By following this experimental plan, you can test the hypothesis and determine whether co-expression of LRP6 with modified FcγRI receptor on APCs truly enhances their tolerogenic phenotype and promotes Treg generation in the context of type 1 diabetes.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Preparation**

1.1. **Dendritic Cell Isolation**

* Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors and individuals with type 1 diabetes using Ficoll-Paque density gradient centrifugation.
* Isolate dendritic cells (DCs) from PBMCs using CD14+ magnetic bead selection (e.g., Miltenyi Biotec).
* Wash DCs with PBS and resuspend in complete RPMI 1640 medium (10% FBS, 1% penicillin-streptomycin, 1% L-glutamine).

1.2. **Transfection**

* Prepare lentiviral vectors encoding LRP6 and modified FcγRI receptor (LRP6-FcγRI) or control vectors (e.g., empty vector or GFP).
* Transfect DCs with lentiviral vectors using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.
* Incubate DCs with the transfection mixture for 24 hours at 37°C, 5% CO2.

1.3. **Verification of Transfection Efficiency and Protein Expression**

* Harvest DCs and analyze transfection efficiency using flow cytometry (e.g., BD FACSCanto II) with antibodies against LRP6 and FcγRI.
* Verify protein expression using Western blotting with antibodies against LRP6 and FcγRI.

**Protocol 2: Tolerogenic Phenotype Analysis**

2.1. **Co-Culture of DCs with Autologous T Cells**

* Isolate autologous T cells from individuals with type 1 diabetes using CD3+ magnetic bead selection (e.g., Miltenyi Biotec).
* Co-culture LRP6-FcγRI-expressing DCs with autologous T cells at a 1:10 ratio in complete RPMI 1640 medium.
* Incubate for 48 hours at 37°C, 5% CO2.

2.2. **Flow Cytometry Analysis**

* Harvest DCs and stain with antibodies against tolerogenic markers (e.g., PD-L1, IDO, and IL-10).
* Analyze using flow cytometry (e.g., BD FACSCanto II).

2.3. **qRT-PCR Analysis**

* Extract RNA from DCs using a RNA isolation kit (e.g., Qiagen RNeasy).
* Perform qRT-PCR using primers specific to tolerogenic markers (e.g., PD-L1, IDO, and IL-10) and a housekeeping gene (e.g., GAPDH).
* Analyze using a qRT-PCR instrument (e.g., Applied Biosystems 7500).

**Protocol 3: Treg Generation and Function**

3.1. **Co-Culture of DCs with Naive CD4+ T Cells**

* Isolate naive CD4+ T cells from individuals with type 1 diabetes using CD4+ and CD25- magnetic bead selection (e.g., Miltenyi Biotec).
* Co-culture LRP6-FcγRI-expressing DCs with naive CD4+ T cells at a 1:10 ratio in complete RPMI 1640 medium.
* Incubate for 7 days at 37°C, 5% CO2.

3.2. **Flow Cytometry Analysis**

* Harvest T cells and stain with antibodies against Treg markers (e.g., CD4, CD25, and FoxP3).
* Analyze using flow cytometry (e.g., BD FACSCanto II).

3.3. **Mixed Lymphocyte Reaction (MLR) Assay**

* Isolate responder T cells from individuals with type 1 diabetes using CD3+ magnetic bead selection (e.g., Miltenyi Biotec).
* Co-culture responder T cells with Tregs generated in 3.1 at a 1:1 ratio in complete RPMI 1640 medium.
* Incubate for 3 days at 37°C, 5% CO2.
* Measure T cell proliferation using a cell proliferation assay (e.g., MTT or CFSE).

**Protocol 4: In Vivo Validation**

4.1. **Mouse Model Preparation**

* Obtain NOD mice (e.g., Jackson Laboratory) and maintain them in a specific pathogen-free facility.
* Monitor blood glucose levels and insulitis development in mice.

4.2. **DC Injection**

* Prepare LRP6-FcγRI-expressing DCs or control DCs as described in Protocol 1.
* Inject 1x10^6 DCs intravenously into NOD mice.
* Monitor disease progression (e.g., blood glucose levels, insulitis, and pancreatic islet function) for 6-8 weeks.

**Negative Control**

* Use DCs without LRP6-FcγRI expression as a negative control in all experiments.

**Expected Outcomes**

* If the hypothesis is true, LRP6-FcγRI-expressing DCs should exhibit an enhanced tolerogenic phenotype, promote Treg generation, and improve immunomodulation and tolerance in individuals with type 1 diabetes.
* If the hypothesis is false, LRP6-FcγRI-expressing DCs should not demonstrate a significant difference in tolerogenic phenotype, Treg generation, or immunomodulation compared to control DCs.

**Timeline and Budget**

* This experiment can be completed within 6-9 months with a budget of approximately $200,000.
* The budget will cover:
	+ Cell isolation and culture reagents
	+ Transfection reagents and vectors
	+ Flow cytometry and qRT-PCR analysis
	+ Mouse model and in vivo experimentation
	+ Personnel and laboratory costs","```
   PBMCs  CD14_beads  Lentiviral_vectors  Transfection_reagent  Autologous_T_cells  Naive_CD4+_T_cells  Outcome
0      1e6         10          1e7 particles          10 ul            1e7 cells            1e6 cells  Tolerogenic
1      5e5         20          5e6 particles          20 ul            5e6 cells            5e5 cells  Non-tolerogenic
2      2e6         15          2e7 particles          15 ul            2e7 cells            2e6 cells  Tolerogenic
3      3e5         12          3e6 particles          12 ul            3e6 cells            3e5 cells  Non-tolerogenic
4      1e7         18          1e8 particles          18 ul            1e8 cells            1e7 cells  Tolerogenic
5      6e5         22          6e6 particles          22 ul            6e6 cells            6e5 cells  Non-tolerogenic
6      4e6         11          4e7 particles          11 ul            4e7 cells            4e6 cells  Tolerogenic
7      2e5         16          2e6 particles          16 ul            2e6 cells            2e5 cells  Non-tolerogenic
8      8e6         14          8e7 particles          14 ul            8e7 cells            8e6 cells  Tolerogenic
9      9e5         19          9e6 particles          19 ul            9e6 cells            9e5 cells  Non-tolerogenic
10     1e6         13          1e7 particles          13 ul            1e7 cells            1e6 cells  Tolerogenic
11     7e5         21          7e6 particles          21 ul            7e6 cells            7e5 cells  Non-tolerogenic
12     3e6         17          3e7 particles          17 ul            3e7 cells            3e6 cells  Tolerogenic
13     4e5         10          4e6 particles          10 ul            4e6 cells            4e5 cells  Non-tolerogenic
14     2e7         12          2e8 particles          12 ul            2e8 cells            2e7 cells  Tolerogenic
15     1e5         20          1e6 particles          20 ul            1e6 cells            1e5 cells  Non-tolerogenic
16     6e6         15          6e7 particles          15 ul            6e7 cells            6e6 cells  Tolerogenic
17     8e5         19          8e6 particles          19 ul            8e6 cells            8e5 cells  Non-tolerogenic
18     5e6         11          5e7 particles          11 ul            5e7 cells            5e6 cells  Tolerogenic
19     3e5         16          3e6 particles          16 ul            3e6 cells            3e5 cells  Non-tolerogenic
20     9e6         14          9e7 particles          14 ul            9e7 cells            9e6 cells  Tolerogenic
21     2e5         21          2e6 particles          21 ul            2e6 cells            2e5 cells  Non-tolerogenic
22     7e6         13          7e7 particles          13 ul            7e7 cells            7e6 cells  Tolerogenic
23     1e5         18          1e6 particles          18 ul            1e6 cells            1e5 cells  Non-tolerogenic
24     4e6         12          4e7 particles          12 ul            4e7 cells            4e6 cells  Tolerogenic
```",0.03875064272528452
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d2d8c61eb5d16d38470faa62a2132de368476499.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/a7da8eaab000c51713a8344c4cfefa9785aa1af4.summary']",Can the co-expression of tTRII-I7R and TYK2 in CAR-T cells enhance their anti-tumor efficacy and prevent tumor recurrence in B cell lymphoma by converting immunosuppressive TGF-β signaling into immune-activating IL-7 signaling and restoring IFNα-mediated immune surveillance?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and summaries of the papers, I propose the following experimental plan to test the generated hypothesis:

**Title:** Co-expression of tTRII-I7R and TYK2 in CAR-T cells: Enhancing anti-tumor efficacy and preventing tumor recurrence in B cell lymphoma

**Objective:** To investigate whether the co-expression of tTRII-I7R and TYK2 in CAR-T cells can enhance their anti-tumor efficacy and prevent tumor recurrence in B cell lymphoma by converting immunosuppressive TGF-β signaling into immune-activating IL-7 signaling and restoring IFNα-mediated immune surveillance.

**Experimental Design:**

**Part 1: Generation of CAR-T cells co-expressing tTRII-I7R and TYK2**

1. Isolate and expand human T cells from healthy donors or patients with B cell lymphoma.
2. Design and construct lentiviral vectors encoding CD19 CAR, tTRII-I7R, and TYK2.
3. Transduce T cells with the lentiviral vectors using a lentiviral transduction protocol.
4. Select and expand transduced T cells using fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS).

**Part 2: In vitro functional analysis of CAR-T cells co-expressing tTRII-I7R and TYK2**

1. Treat CAR-T cells with TGF-β and measure phosphorylated SMAD2 levels by Western blotting to assess TGF-β signaling.
2. Measure IL-7 signaling pathway activation by qRT-PCR analysis of IL-7R and downstream target genes.
3. Analyze the correlation between TGF-β signaling inhibition and IL-7 signaling activation in tTRII-I7R-expressing T cells.
4. Treat CAR-T cells with IFNα and measure STAT1/2 phosphorylation by Western blot to assess IFNα signaling.
5. Analyze cell surface expression of immune checkpoint molecules (e.g. PD-L1) by flow cytometry.

**Part 3: In vivo evaluation of CAR-T cells co-expressing tTRII-I7R and TYK2 in a B cell lymphoma mouse model**

1. Establish a B cell lymphoma mouse model using CD19+ tumor cells.
2. Inject CAR-T cells co-expressing tTRII-I7R and TYK2 into the mice and monitor tumor growth and survival.
3. Compare the anti-tumor efficacy and tumor recurrence rates between mice treated with CAR-T cells co-expressing tTRII-I7R and TYK2 versus those treated with CAR-T cells expressing only CD19 CAR.
4. Analyze the immune cell composition and cytokine production in the tumor microenvironment using flow cytometry and ELISA.

**Part 4: Mechanistic studies**

1. Perform RNA sequencing (RNA-seq) analysis to identify differentially expressed genes in CAR-T cells co-expressing tTRII-I7R and TYK2 versus those expressing only CD19 CAR.
2. Validate the RNA-seq results using qRT-PCR and Western blotting.
3. Investigate the role of TYK2 in restoring IFNα-mediated immune surveillance using co-culture assays with immune cells (e.g. T cells, NK cells).

**Equipment and Resources:**

* Lentiviral vectors and packaging plasmids
* T cells and B cell lymphoma cell lines
* TGF-β, IL-7, and IFNα
* Western blotting equipment and reagents
* qRT-PCR machine and reagents
* Flow cytometer and reagents
* FACS and MACS machines
* Mouse model facilities and equipment
* RNA-seq platform and bioinformatics tools

**Timeline:**

* Part 1: 2-3 months
* Part 2: 3-4 months
* Part 3: 4-6 months
* Part 4: 3-4 months

**Budget:**

* Personnel: 2-3 postdoctoral researchers, 1-2 graduate students, 1 technician
* Reagents and consumables: $200,000 - $300,000 per year
* Equipment and facilities: $500,000 - $1,000,000 (one-time investment)
* Animal studies: $100,000 - $200,000 per year
* RNA-seq and bioinformatics: $50,000 - $100,000 per year

Total budget: $1,350,000 - $2,600,000 per year for 2-3 years.",92,"Here are the detailed, step-by-step protocols for each part of the experimental plan:

**Part 1: Generation of CAR-T cells co-expressing tTRII-I7R and TYK2**

**Step 1.1: Isolate and expand human T cells from healthy donors or patients with B cell lymphoma**

* Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors or patients with B cell lymphoma through venipuncture or apheresis.
* Isolate T cells from PBMCs using Ficoll-Paque density gradient centrifugation and magnetic-activated cell sorting (MACS) with anti-CD3 microbeads.
* Expand T cells in culture using T cell growth medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine) supplemented with 100 U/mL IL-2 and 5 ng/mL PHA.
* Monitor T cell expansion and viability using trypan blue exclusion and flow cytometry.

**Step 1.2: Design and construct lentiviral vectors encoding CD19 CAR, tTRII-I7R, and TYK2**

* Design the lentiviral vector constructs using molecular biology software (e.g., SnapGene) to ensure correct orientation and spacing of the genes.
* Clone the CD19 CAR, tTRII-I7R, and TYK2 genes into the lentiviral vector backbone using standard molecular biology techniques (e.g., PCR, restriction enzyme digestion, ligation).
* Verify the construct sequences using Sanger sequencing.

**Step 1.3: Transduce T cells with the lentiviral vectors using a lentiviral transduction protocol**

* Prepare lentiviral particles by transfecting 293T cells with the lentiviral vector constructs and packaging plasmids using a transfection reagent (e.g., Lipofectamine 2000).
* Harvest the lentiviral particles 48-72 hours post-transfection and concentrate them using ultracentrifugation or filtration.
* Transduce T cells with the lentiviral particles at a multiplicity of infection (MOI) of 10-20 in the presence of 8 μg/mL polybrene.
* Incubate the transduced T cells at 37°C, 5% CO2 for 24-48 hours.

**Step 1.4: Select and expand transduced T cells using FACS and MACS**

* Stain the transduced T cells with fluorescently labeled antibodies against CD3, CD4, and CD8 to identify transduced cells.
* Sort the transduced T cells using FACS (e.g., BD FACSAria) to isolate CD3+CD4+ or CD3+CD8+ cells.
* Expand the sorted T cells in culture using T cell growth medium supplemented with 100 U/mL IL-2 and 5 ng/mL PHA.
* Monitor T cell expansion and viability using trypan blue exclusion and flow cytometry.

**Part 2: In vitro functional analysis of CAR-T cells co-expressing tTRII-I7R and TYK2**

**Step 2.1: Treat CAR-T cells with TGF-β and measure phosphorylated SMAD2 levels by Western blotting**

* Treat CAR-T cells with 10 ng/mL TGF-β for 30 minutes to 1 hour.
* Lyse the cells in RIPA buffer and perform Western blotting using antibodies against phosphorylated SMAD2 and total SMAD2.
* Quantify the phosphorylated SMAD2 levels using densitometry software (e.g., ImageJ).

**Step 2.2: Measure IL-7 signaling pathway activation by qRT-PCR analysis of IL-7R and downstream target genes**

* Treat CAR-T cells with 10 ng/mL IL-7 for 30 minutes to 1 hour.
* Extract RNA from the cells using a RNA extraction kit (e.g., RNeasy).
* Perform qRT-PCR using primers specific to IL-7R and downstream target genes (e.g., STAT5, BCL2).
* Analyze the qRT-PCR data using the ΔΔCt method.

**Step 2.3: Analyze the correlation between TGF-β signaling inhibition and IL-7 signaling activation in tTRII-I7R-expressing T cells**

* Perform a correlation analysis between the phosphorylated SMAD2 levels and IL-7R expression using statistical software (e.g., GraphPad Prism).
* Calculate the Pearson correlation coefficient (r) and p-value.

**Step 2.4: Treat CAR-T cells with IFNα and measure STAT1/2 phosphorylation by Western blot**

* Treat CAR-T cells with 100 U/mL IFNα for 30 minutes to 1 hour.
* Lyse the cells in RIPA buffer and perform Western blotting using antibodies against phosphorylated STAT1/2 and total STAT1/2.
* Quantify the phosphorylated STAT1/2 levels using densitometry software (e.g., ImageJ).

**Step 2.5: Analyze cell surface expression of immune checkpoint molecules by flow cytometry**

* Stain the CAR-T cells with fluorescently labeled antibodies against PD-L1 and other immune checkpoint molecules.
* Analyze the cell surface expression using flow cytometry (e.g., BD FACSCanto).
* Calculate the mean fluorescence intensity (MFI) and percentage of positive cells.

**Part 3: In vivo evaluation of CAR-T cells co-expressing tTRII-I7R and TYK2 in a B cell lymphoma mouse model**

**Step 3.1: Establish a B cell lymphoma mouse model using CD19+ tumor cells**

* Inject 1x10^6 CD19+ tumor cells into the flanks of immunodeficient mice (e.g., NOD/SCID).
* Monitor tumor growth using caliper measurements and bioluminescence imaging.

**Step 3.2: Inject CAR-T cells co-expressing tTRII-I7R and TYK2 into the mice and monitor tumor growth and survival**

* Inject 1x10^6 CAR-T cells into the mice via tail vein injection.
* Monitor tumor growth and mouse survival using caliper measurements, bioluminescence imaging, and Kaplan-Meier analysis.

**Step 3.3: Compare the anti-tumor efficacy and tumor recurrence rates between mice treated with CAR-T cells co-expressing tTRII-I7R and TYK2 versus those treated with CAR-T cells expressing only CD19 CAR**

* Compare the tumor growth curves and survival rates between the two groups using statistical software (e.g., GraphPad Prism).
* Calculate the log-rank test p-value and hazard ratio.

**Step 3.4: Analyze the immune cell composition and cytokine production in the tumor microenvironment using flow cytometry and ELISA**

* Harvest tumor tissues and perform flow cytometry analysis using antibodies against immune cell markers (e.g., CD4, CD8, CD11b, Gr-1).
* Analyze the immune cell composition and calculate the frequency of each immune cell subset.
* Perform ELISA to measure cytokine production (e.g., IFNγ, TNFα, IL-12) in the tumor microenvironment.

**Part 4: Mechanistic studies**

**Step 4.1: Perform RNA sequencing (RNA-seq) analysis to identify differentially expressed genes in CAR-T cells co-expressing tTRII-I7R and TYK2 versus those expressing only CD19 CAR**

* Extract RNA from CAR-T cells using a RNA extraction kit (e.g., RNeasy).
* Perform RNA-seq using a sequencing platform (e.g., Illumina HiSeq).
* Analyze the RNA-seq data using bioinformatics tools (e.g., DESeq2, edgeR) to identify differentially expressed genes.

**Step 4.2: Validate the RNA-seq results using qRT-PCR and Western blotting**

* Validate the differentially expressed genes using qRT-PCR and Western blotting.
* Analyze the qRT-PCR data using the ΔΔCt method and Western blot data using densitometry software (e.g., ImageJ).

**Step 4.3: Investigate the role of TYK2 in restoring IFNα-mediated immune surveillance using co-culture assays with immune cells**

* Co-culture CAR-T cells with immune cells (e.g., T cells, NK cells) in the presence or absence of IFNα.
* Analyze the immune cell activation and cytokine production using flow cytometry and ELISA.
* Calculate the fold change in immune cell activation and cytokine production.

These detailed, step-by-step protocols should enable the execution of the experimental plan with high replicability and specificity.","```
   PBMCs  Ficoll-Paque  MACS  IL-2  PHA  Lentiviral_Vector  MOI  Polybrene  TGF-β  IL-7  IFNα  Outcome
0      10         1.5   0.5   100   5.0             10.0  15.0       8.0    10.0  10.0  100.0  0.80
1      15         2.0   0.7   120   6.0             12.0  18.0       9.0    12.0  12.0  120.0  0.85
2       8         1.2   0.4   90    4.5             9.0  12.0       7.0     9.0   9.0   90.0  0.75
3      12         1.8   0.6   110   5.5             11.0  16.0       8.5    11.0  11.0  110.0  0.82
4      18         2.5   0.8   130   7.0             14.0  20.0      10.0    14.0  14.0  130.0  0.90
5      10         1.5   0.5   100   5.0             10.0  15.0       8.0    10.0  10.0  100.0  0.80
6       9         1.3   0.4   95    4.8             9.5  13.0       7.5     9.5   9.5   95.0  0.78
7      14         2.2   0.7   125   6.5             13.0  19.0       9.5    13.0  13.0  125.0  0.88
8      11         1.6   0.5   105   5.2             10.5  14.0       8.2    10.5  10.5  105.0  0.81
9      16         2.8   0.9   140   7.5             15.0  22.0      11.0    15.0  15.0  140.0  0.92
10     13         2.0   0.6   115   5.8             11.5  16.5       9.0    11.5  11.5  115.0  0.84
11     12         1.9   0.6   110   5.5             11.0  15.5       8.5    11.0  11.0  110.0  0.82
12      9         1.4   0.5   95    4.9             9.5  13.5       7.8     9.5   9.5   95.0  0.79
13     15         2.4   0.8   130   6.8             13.5  20.5      10.2    13.5  13.5  130.0  0.89
14     11         1.7   0.5   105   5.3             10.8  14.8       8.5    10.8  10.8  105.0  0.82
15     17         3.0   1.0   145   8.0             16.0  24.0      12.0    16.0  16.0  145.0  0.94
16     14         2.3   0.7   120   6.2             12.5  17.5       9.8    12.5  12.5  120.0  0.86
17     10         1.6   0.5   100   5.1             10.2  14.2       8.1    10.2  10.2  100.0  0.80
18     13         2.1   0.6   115   5.9             11.8  16.8       9.3    11.8  11.8  115.0  0.84
19     12         1.9   0.6   110   5.6             11.2  15.2       8.6    11.2  11.2  110.0  0.83
20     16         2.6   0.8   135   7.2             14.2  21.2      10.8    14.2  14.2  135.0  0.91
21     11         1.8   0.5   105   5.4             10.9  14.9       8.4    10.9  10.9  105.0  0.82
22     15         2.5   0.8   130   6.9             13.8  20.8      10.5    13.8  13.8  130.0  0.90
23     14         2.2   0.7   125   6.4             12.8  18.8       9.9    12.8  12.8  125.0  0.88
24     13         2.0   0.6   115   5.7             11.5  16.5       9.1    11.5  11.5  115.0  0.84
```",0.9841120379516609
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3d356935fab5ecdb3602ddbd48a78314a0ccdc80.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/01f57887d51ce2e1f60071bc0c19bef81d890293.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1221e653d61144c72b256487cc1486fcddd9f9f8.summary']",Can the combination of AMP-modified CD19 peptides and DGK-a/z RNAi enhance the persistence and anti-tumor activity of CAR-T cells by modulating the tumor microenvironment and optimizing T cell function in B-cell malignancies?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis:

**Hypothesis:** Can the combination of AMP-modified CD19 peptides and DGK-a/z RNAi enhance the persistence and anti-tumor activity of CAR-T cells by modulating the tumor microenvironment and optimizing T cell function in B-cell malignancies?

**Experimental Plan:**

**Objective:** To evaluate the efficacy of combining AMP-modified CD19 peptides and DGK-a/z RNAi in enhancing the persistence and anti-tumor activity of CAR-T cells in a murine model of B-cell lymphoma.

**Equipment:**

* Murine B-cell lymphoma model
* CAR-T cells
* AMP-modified CD19 peptides
* DGK-a/z RNAi compounds (INTASYL technology)
* Flow cytometer
* Bioluminescence imaging system
* Luciferase-expressing tumor cells

**Experimental Design:**

1. Establish a murine B-cell lymphoma model using luciferase-expressing tumor cells.
2. Engineer CAR-T cells to express FMC63-based CARs and administer them to the mice.
3. Co-administer AMP-modified CD19 peptides and DGK-a/z RNAi compounds or controls (soluble peptides and scrambled RNAi) to the mice.
4. Monitor tumor growth and CAR-T cell expansion using bioluminescence imaging and flow cytometry.
5. Evaluate the persistence and anti-tumor activity of CAR-T cells using flow cytometry and tumor burden analysis.
6. Analyze the tumor microenvironment using flow cytometry and immunohistochemistry to assess immune cell infiltration and activation.

**Control Groups:**

* CAR-T cells alone
* CAR-T cells + AMP-modified CD19 peptides
* CAR-T cells + DGK-a/z RNAi compounds
* CAR-T cells + soluble peptides and scrambled RNAi (control)

**Expected Outcomes:**

* Enhanced persistence and anti-tumor activity of CAR-T cells in the combination treatment group (AMP-modified CD19 peptides + DGK-a/z RNAi) compared to the control groups.
* Increased immune cell activation and infiltration in the tumor microenvironment in the combination treatment group.
* Improved tumor burden reduction in the combination treatment group.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to test the following:

* Does the combination of AMP-modified CD19 peptides and DGK-a/z RNAi compromise the function of CAR-T cells or enhance the immunosuppressive tumor microenvironment?
* Does the combination treatment lead to increased toxicity or off-target effects?

To test this, we can:

1. Co-administer AMP-modified CD19 peptides and DGK-a/z RNAi compounds to CAR-T cells in vitro and assess their function using flow cytometry and cytotoxicity assays.
2. Analyze the expression of immunosuppressive genes and cytokines in the tumor microenvironment using qRT-PCR and ELISA.
3. Evaluate the toxicity of the combination treatment using in vitro and in vivo models.

If the results show that the combination treatment compromises CAR-T cell function, enhances the immunosuppressive tumor microenvironment, or leads to increased toxicity, it would disprove the hypothesis.

**Timeline and Budget:**

The experiment can be completed within 6-9 months, depending on the availability of resources and equipment. The budget will depend on the cost of the equipment, reagents, and personnel required for the experiment. A rough estimate would be around $200,000-$300,000.

This experimental plan is designed to test the hypothesis in a murine model of B-cell lymphoma, and the results can provide valuable insights into the potential of combining AMP-modified CD19 peptides and DGK-a/z RNAi to enhance the persistence and anti-tumor activity of CAR-T cells in B-cell malignancies.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Establishing a Murine B-Cell Lymphoma Model**

1.1. Obtain luciferase-expressing tumor cells (e.g., Raji-luc cells) and maintain them in culture according to the supplier's instructions.

1.2. Prepare a 1x10^6 cells/mL suspension of tumor cells in sterile PBS.

1.3. Inject 100 μL of the tumor cell suspension (1x10^5 cells) into the tail vein of 6-8 week old female C57BL/6 mice (n=10-12 per group).

1.4. Monitor tumor growth using bioluminescence imaging (e.g., IVIS Spectrum) on days 7, 14, and 21 post-injection.

**Protocol 2: Engineering CAR-T Cells**

2.1. Isolate human T cells from peripheral blood mononuclear cells (PBMCs) using a T cell isolation kit (e.g., Miltenyi Biotec).

2.2. Activate T cells using anti-CD3/CD28 beads (e.g., Dynabeads) and expand them in culture with IL-2 (e.g., 100 IU/mL) and IL-7 (e.g., 10 ng/mL) for 7-10 days.

2.3. Transduce T cells with a lentiviral vector encoding FMC63-based CARs using a lentiviral transduction kit (e.g., Sigma-Aldrich).

2.4. Select CAR-T cells using a CAR-specific antibody (e.g., FMC63-PE) and a cell sorter (e.g., BD FACSAria).

**Protocol 3: Co-Administration of AMP-Modified CD19 Peptides and DGK-a/z RNAi Compounds**

3.1. Prepare AMP-modified CD19 peptides (e.g., 100 μg/mL) and DGK-a/z RNAi compounds (e.g., 10 μM) according to the manufacturer's instructions.

3.2. Administer 100 μL of AMP-modified CD19 peptides and 100 μL of DGK-a/z RNAi compounds or controls (soluble peptides and scrambled RNAi) via intravenous injection on days 7 and 14 post-tumor injection.

**Protocol 4: Monitoring Tumor Growth and CAR-T Cell Expansion**

4.1. Perform bioluminescence imaging on days 7, 14, and 21 post-tumor injection to monitor tumor growth.

4.2. Collect blood samples (100 μL) on days 7, 14, and 21 post-tumor injection and analyze CAR-T cell expansion using flow cytometry (e.g., BD FACSCanto).

4.3. Stain blood samples with anti-CD3, anti-CD8, and anti-CAR antibodies (e.g., FMC63-PE) and analyze using flow cytometry.

**Protocol 5: Evaluating Persistence and Anti-Tumor Activity of CAR-T Cells**

5.1. Collect spleen and tumor samples on day 21 post-tumor injection and analyze CAR-T cell persistence using flow cytometry.

5.2. Perform tumor burden analysis by measuring tumor weight and volume.

5.3. Analyze immune cell infiltration and activation in the tumor microenvironment using flow cytometry and immunohistochemistry (e.g., CD3, CD8, CD45, and PD-1).

**Protocol 6: Analyzing Tumor Microenvironment**

6.1. Collect tumor samples on day 21 post-tumor injection and analyze immune cell infiltration and activation using flow cytometry.

6.2. Perform immunohistochemistry on tumor sections using antibodies against CD3, CD8, CD45, and PD-1.

**Protocol 7: Experiment to Disprove the Hypothesis**

7.1. Co-administer AMP-modified CD19 peptides and DGK-a/z RNAi compounds to CAR-T cells in vitro and assess their function using flow cytometry and cytotoxicity assays.

7.2. Analyze the expression of immunosuppressive genes and cytokines in the tumor microenvironment using qRT-PCR and ELISA.

7.3. Evaluate the toxicity of the combination treatment using in vitro and in vivo models.

**Quality Control and Assurance**

* Verify the quality and purity of reagents and cells used in the experiment.
* Perform regular calibration and maintenance of equipment (e.g., flow cytometer, bioluminescence imaging system).
* Implement proper sterile technique and handling of animals to minimize contamination and ensure animal welfare.
* Document all experimental procedures, results, and observations in a laboratory notebook.

**Timeline and Budget**

* The experiment can be completed within 6-9 months, depending on the availability of resources and equipment.
* The budget will depend on the cost of the equipment, reagents, and personnel required for the experiment. A rough estimate would be around $200,000-$300,000.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the results.","```
   Raji-luc Cells  Anti-CD3/CD28 Beads  IL-2  IL-7  FMC63-based CARs  AMP-modified CD19 Peptides  DGK-a/z RNAi Compounds  Outcome
0           1.0e+06               10.0  100.0  10.0               1.0                  100.0                  10.0        0.8
1           1.2e+06               12.0  120.0  12.0               1.2                  120.0                  12.0        0.9
2           0.8e+06                8.0   80.0   8.0               0.8                   80.0                   8.0        0.6
3           1.5e+06               15.0  150.0  15.0               1.5                  150.0                  15.0        1.1
4           1.1e+06               11.0  110.0  11.0               1.1                  110.0                  11.0        0.9
5           0.9e+06                9.0   90.0   9.0               0.9                   90.0                   9.0        0.7
6           1.3e+06               13.0  130.0  13.0               1.3                  130.0                  13.0        1.0
7           1.0e+06               10.0  100.0  10.0               1.0                  100.0                  10.0        0.8
8           1.4e+06               14.0  140.0  14.0               1.4                  140.0                  14.0        1.1
9           0.7e+06                7.0   70.0   7.0               0.7                   70.0                   7.0        0.5
10          1.2e+06               12.0  120.0  12.0               1.2                  120.0                  12.0        0.9
11          1.6e+06               16.0  160.0  16.0               1.6                  160.0                  16.0        1.2
12          0.9e+06                9.0   90.0   9.0               0.9                   90.0                   9.0        0.7
13          1.1e+06               11.0  110.0  11.0               1.1                  110.0                  11.0        0.9
14          1.3e+06               13.0  130.0  13.0               1.3                  130.0                  13.0        1.0
15          1.0e+06               10.0  100.0  10.0               1.0                  100.0                  10.0        0.8
16          1.5e+06               15.0  150.0  15.0               1.5                  150.0                  15.0        1.1
17          0.8e+06                8.0   80.0   8.0               0.8                   80.0                   8.0        0.6
18          1.2e+06               12.0  120.0  12.0               1.2                  120.0                  12.0        0.9
19          1.4e+06               14.0  140.0  14.0               1.4                  140.0                  14.0        1.1
20          0.6e+06                6.0   60.0   6.0               0.6                   60.0                   6.0        0.4
21          1.1e+06               11.0  110.0  11.0               1.1                  110.0                  11.0        0.9
22          1.6e+06               16.0  160.0  16.0               1.6                  160.0                  16.0        1.2
23          0.9e+06                9.0   90.0   9.0               0.9                   90.0                   9.0        0.7
24          1.3e+06               13.0  130.0  13.0               1.3                  130.0                  13.0        1.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/800c7f1e4021189dbfced709ca624e5e015d0f2b.summary'],Can the combination of BDB001 and CPI-006 enhance the anti-tumor immunity of tumor-infiltrating lymphocytes and simultaneously provide protection against SARS-CoV-2 infection in patients with epithelial cancer?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed a high-level experimental plan to test its validity. Since the goal is to disprove the hypothesis, the experiment is designed to identify potential flaws or inconsistencies in the proposed combination therapy.

**Hypothesis:** Can the combination of BDB001 and CPI-006 enhance the anti-tumor immunity of tumor-infiltrating lymphocytes and simultaneously provide protection against SARS-CoV-2 infection in patients with epithelial cancer?

**Experimental Plan:**

**Objective:** To investigate the efficacy and safety of the combination therapy (BDB001 + CPI-006) in enhancing anti-tumor immunity and providing protection against SARS-CoV-2 infection in epithelial cancer patients.

**Experimental Design:**

1. **In vitro studies:**
	* Obtain tumor-infiltrating lymphocytes (TILs) from epithelial cancer patients and culture them in the presence of BDB001 and CPI-006, individually and in combination.
	* Assess TIL activation, proliferation, and cytokine production (e.g., IFN-γ, TNF-α) using flow cytometry, ELISA, and qRT-PCR.
	* Evaluate the expression of immune checkpoint molecules (e.g., PD-1, PD-L1) on TILs using flow cytometry and Western blot.
2. **In vivo studies:**
	* Establish a syngeneic tumor model using epithelial cancer cell lines (e.g., A549, MCF-7) in immunocompetent mice.
	* Treat mice with BDB001, CPI-006, or the combination therapy, and monitor tumor growth and regression.
	* Assess TIL infiltration, activation, and cytokine production in tumor tissues using IHC, flow cytometry, and qRT-PCR.
3. **SARS-CoV-2 challenge:**
	* Infect mice with SARS-CoV-2 (e.g., using a mouse-adapted strain) and monitor viral load, weight loss, and survival.
	* Treat infected mice with BDB001, CPI-006, or the combination therapy, and evaluate the effect on SARS-CoV-2 clearance and disease severity.
4. **Safety assessment:**
	* Monitor mice for signs of toxicity, such as weight loss, organ damage, and hematological changes, using clinical observations, histopathology, and blood chemistry analysis.

**Experimental Controls:**

* Untreated tumor-bearing mice (negative control)
* Mice treated with individual agents (BDB001 or CPI-006) as positive controls
* Mice infected with SARS-CoV-2 without treatment (positive control for SARS-CoV-2 infection)

**Sample Size and Statistical Analysis:**

* In vitro studies: 3-4 replicates per group, with 3-4 technical replicates each
* In vivo studies: 8-10 mice per group, with 2-3 biological replicates
* Statistical analysis: Two-way ANOVA, Student's t-test, and Kaplan-Meier survival analysis using GraphPad Prism or R software

**Timeline and Budget:**

* In vitro studies: 2-3 months, $10,000 - $15,000
* In vivo studies: 4-6 months, $20,000 - $30,000
* SARS-CoV-2 challenge: 2-3 months, $10,000 - $15,000
* Safety assessment: 1-2 months, $5,000 - $10,000
* Total duration: 9-14 months, $55,000 - $80,000

**Limitations and Future Directions:**

* This experiment focuses on the combination therapy's efficacy and safety in a preclinical setting. Future studies should investigate the optimal dosing, scheduling, and potential biomarkers for patient selection.
* The SARS-CoV-2 challenge model may not perfectly mimic human infection, and future studies should consider using more advanced models or humanized mice.

By following this experimental plan, you can test the hypothesis and identify potential flaws or inconsistencies in the combination therapy. If the results do not support the hypothesis, it may indicate that the combination of BDB001 and CPI-006 is not effective in enhancing anti-tumor immunity and providing protection against SARS-CoV-2 infection in epithelial cancer patients.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**In Vitro Studies:**

**Protocol 1: TIL Isolation and Culture**

1. Obtain tumor tissue samples from epithelial cancer patients and process them according to established protocols for TIL isolation (e.g., density gradient centrifugation, magnetic bead separation).
2. Isolate TILs and count them using a hemocytometer or automated cell counter.
3. Culture TILs in complete RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
4. Split TILs into four groups: control (no treatment), BDB001, CPI-006, and combination therapy (BDB001 + CPI-006).
5. Treat TILs with the respective agents at the following concentrations: BDB001 (10 μM), CPI-006 (1 μM), and combination therapy (10 μM BDB001 + 1 μM CPI-006).
6. Incubate TILs for 48-72 hours to allow for activation and proliferation.

**Protocol 2: Flow Cytometry Analysis**

1. Harvest TILs and stain them with fluorescently labeled antibodies against CD3, CD4, CD8, and CD25 (e.g., FITC, PE, PerCP-Cy5.5).
2. Analyze TIL activation and proliferation using flow cytometry (e.g., BD FACSCanto II).
3. Gate on CD3+ T cells and assess the expression of activation markers (e.g., CD25, CD69) and proliferation markers (e.g., Ki-67).

**Protocol 3: ELISA and qRT-PCR Analysis**

1. Collect supernatants from TIL cultures and store them at -80°C for ELISA analysis.
2. Perform ELISA assays for IFN-γ and TNF-α using commercial kits (e.g., R&D Systems).
3. Extract RNA from TILs using a commercial kit (e.g., Qiagen RNeasy) and perform qRT-PCR analysis for cytokine gene expression (e.g., IFN-γ, TNF-α) using primers and probes specific to the target genes.

**Protocol 4: Western Blot Analysis**

1. Lyse TILs in RIPA buffer and separate proteins using SDS-PAGE.
2. Transfer proteins to a PVDF membrane and block with 5% milk or BSA.
3. Probe the membrane with antibodies against PD-1 and PD-L1 (e.g., Cell Signaling Technology).
4. Detect protein bands using ECL reagents and quantify using densitometry software (e.g., ImageJ).

**In Vivo Studies:**

**Protocol 5: Syngeneic Tumor Model Establishment**

1. Obtain epithelial cancer cell lines (e.g., A549, MCF-7) and culture them according to established protocols.
2. Inject 1 x 10^6 cancer cells subcutaneously into the flank of immunocompetent mice (e.g., C57BL/6).
3. Monitor tumor growth and establish a palpable tumor burden (e.g., 5-7 days).

**Protocol 6: Treatment and Tumor Monitoring**

1. Randomly assign mice to treatment groups: control (no treatment), BDB001, CPI-006, and combination therapy (BDB001 + CPI-006).
2. Administer treatments via intraperitoneal injection: BDB001 (10 mg/kg), CPI-006 (1 mg/kg), and combination therapy (10 mg/kg BDB001 + 1 mg/kg CPI-006).
3. Monitor tumor growth using calipers and calculate tumor volume (e.g., V = (L x W x H) / 2).
4. Sacrifice mice at the end of the study (e.g., 14-21 days) and collect tumor tissues for further analysis.

**Protocol 7: IHC and Flow Cytometry Analysis**

1. Fix and paraffin-embed tumor tissues for IHC analysis.
2. Stain tumor sections with antibodies against CD3, CD4, CD8, and CD25 (e.g., DAB, IHC).
3. Analyze TIL infiltration and activation using IHC and flow cytometry (e.g., BD FACSCanto II).
4. Gate on CD3+ T cells and assess the expression of activation markers (e.g., CD25, CD69) and proliferation markers (e.g., Ki-67).

**SARS-CoV-2 Challenge:**

**Protocol 8: SARS-CoV-2 Infection**

1. Obtain a mouse-adapted SARS-CoV-2 strain (e.g., SARS-CoV-2 MA15) and prepare viral stocks according to established protocols.
2. Infect mice with SARS-CoV-2 via intranasal instillation (e.g., 10^5 PFU/mouse).
3. Monitor mice for signs of infection (e.g., weight loss, lethargy) and collect blood and tissue samples for viral load analysis.

**Protocol 9: Treatment and Viral Load Analysis**

1. Randomly assign infected mice to treatment groups: control (no treatment), BDB001, CPI-006, and combination therapy (BDB001 + CPI-006).
2. Administer treatments via intraperitoneal injection: BDB001 (10 mg/kg), CPI-006 (1 mg/kg), and combination therapy (10 mg/kg BDB001 + 1 mg/kg CPI-006).
3. Collect blood and tissue samples at various time points (e.g., 3, 7, 14 days) and analyze viral load using qRT-PCR or plaque assays.

**Safety Assessment:**

**Protocol 10: Clinical Observations and Histopathology**

1. Monitor mice for signs of toxicity (e.g., weight loss, lethargy, diarrhea) and record clinical observations.
2. Sacrifice mice at the end of the study (e.g., 14-21 days) and collect organs (e.g., liver, kidney, spleen) for histopathological analysis.
3. Fix and paraffin-embed organs for H&E staining and evaluate for signs of toxicity (e.g., inflammation, necrosis).

**Protocol 11: Blood Chemistry Analysis**

1. Collect blood samples from mice at various time points (e.g., 3, 7, 14 days) and analyze for hematological parameters (e.g., WBC, RBC, platelet count) using an automated analyzer (e.g., Beckman Coulter).
2. Analyze blood chemistry parameters (e.g., ALT, AST, creatinine) using a clinical chemistry analyzer (e.g., Beckman Coulter).

These detailed protocols should provide a clear guide for executing the experimental plan and ensuring replicability and specificity in the results.","```
   TILs  BDB001 CPI-006  RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  Outcome
0   10000    10.0     1.0       100.0  10.0                1.0          1.0  Activated
1   15000     5.0     0.5       120.0  12.0                1.2          1.2  Proliferated
2    8000    15.0     1.5       110.0  11.0                1.1          1.1  Activated
3   12000     8.0     0.8       130.0  13.0                1.3          1.3  Proliferated
4   18000    12.0     1.2       140.0  14.0                1.4          1.4  Activated
5   10000     6.0     0.6       100.0  10.0                1.0          1.0  Proliferated
6   14000    10.0     1.0       120.0  12.0                1.2          1.2  Activated
7   16000    14.0     1.4       130.0  13.0                1.3          1.3  Proliferated
8    9000     9.0     0.9       110.0  11.0                1.1          1.1  Activated
9   13000    11.0     1.1       140.0  14.0                1.4          1.4  Proliferated
10  11000     7.0     0.7       120.0  12.0                1.2          1.2  Activated
11  17000    13.0     1.3       130.0  13.0                1.3          1.3  Proliferated
12  15000    12.0     1.2       140.0  14.0                1.4          1.4  Activated
13  12000     9.0     0.9       110.0  11.0                1.1          1.1  Proliferated
14  18000    15.0     1.5       130.0  13.0                1.3          1.3  Activated
15  10000     8.0     0.8       100.0  10.0                1.0          1.0  Proliferated
16  14000    11.0     1.1       120.0  12.0                1.2          1.2  Activated
17  16000    14.0     1.4       130.0  13.0                1.3          1.3  Proliferated
18  13000    10.0     1.0       140.0  14.0                1.4          1.4  Activated
19  11000     7.0     0.7       110.0  11.0                1.1          1.1  Proliferated
20  17000    13.0     1.3       130.0  13.0                1.3          1.3  Activated
21  15000    12.0     1.2       140.0  14.0                1.4          1.4  Proliferated
22  12000     9.0     0.9       110.0  11.0                1.1          1.1  Activated
23  18000    15.0     1.5       130.0  13.0                1.3          1.3  Proliferated
24  10000     8.0     0.8       100.0  10.0                1.0          1.0  Activated
```",0.020022586111698888
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/20d6d643d13eba3e272562e356dd648386d3538a.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2407921d7caaa915979e328027b49f6fc0d0afbf.summary']",Can the combination of CAR-T cell therapy and TTFields enhance the penetration of CAR-T cells across the blood-brain barrier and improve treatment outcomes in patients with secondary central nervous system lymphoma?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the combination of CAR-T cell therapy and TTFields enhances the penetration of CAR-T cells across the blood-brain barrier and improves treatment outcomes in patients with secondary central nervous system lymphoma, I propose the following experimental plan:

**Experiment:** ""Investigating the effect of TTFields on CAR-T cell penetration across the blood-brain barrier in a mouse model of secondary central nervous system lymphoma""

**Objective:** To determine if the combination of CAR-T cell therapy and TTFields increases the penetration of CAR-T cells across the blood-brain barrier and improves treatment outcomes in a mouse model of secondary central nervous system lymphoma.

**Experimental Design:**

1. **Mouse Model:** Establish a mouse model of secondary central nervous system lymphoma using a syngeneic lymphoma cell line.
2. **CAR-T Cell Preparation:** Engineer CAR-T cells to target CD19 and label them with a fluorescent marker to track their migration.
3. **TTFields Treatment:** Use a TTFields device to treat the mouse model for varying durations (e.g., 1, 3, and 7 days) to disrupt the blood-brain barrier.
4. **CAR-T Cell Infusion:** Infuse the CAR-T cells into the mouse model via intravenous injection.
5. **Imaging and Analysis:**
	* Use confocal microscopy to visualize CAR-T cell penetration of the blood-brain barrier at different time points (e.g., 1, 3, and 7 days) after CAR-T cell infusion.
	* Use flow cytometry to analyze CAR-T cell infiltration into the central nervous system at different time points.
	* Compare the results to a control group without TTFields treatment to determine the effect of TTFields on CAR-T cell penetration.
6. **Tumor Response:** Monitor tumor response using bioluminescence imaging or MRI to assess the effect of CAR-T cell therapy with and without TTFields on tumor growth and regression.

**Experimental Groups:**

1. Control group: CAR-T cell therapy alone
2. TTFields group: CAR-T cell therapy + TTFields treatment (1, 3, and 7 days)
3. Sham group: TTFields treatment alone (no CAR-T cells)

**Endpoints:**

1. CAR-T cell penetration across the blood-brain barrier
2. CAR-T cell infiltration into the central nervous system
3. Tumor response (tumor growth/regression)

**Sample Size:** 10 mice per group, with 3-5 replicates per experiment

**Timeline:** 12 weeks

**Equipment:**

* TTFields device
* Confocal microscope
* Flow cytometer
* Bioluminescence imaging system or MRI
* Mouse model of secondary central nervous system lymphoma
* CAR-T cells engineered to target CD19
* Fluorescent marker for CAR-T cell tracking

**Budget:** Unlimited

This experiment is designed to test the hypothesis that the combination of CAR-T cell therapy and TTFields enhances the penetration of CAR-T cells across the blood-brain barrier and improves treatment outcomes in a mouse model of secondary central nervous system lymphoma. By comparing the results of the control group (CAR-T cell therapy alone) to the TTFields group (CAR-T cell therapy + TTFields treatment), we can determine if the addition of TTFields improves CAR-T cell penetration and tumor response. The sham group (TTFields treatment alone) will serve as a control to ensure that TTFields does not have a direct effect on tumor growth or regression.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Establishing the Mouse Model of Secondary Central Nervous System Lymphoma**

1.1. Obtain a syngeneic lymphoma cell line from a reputable source.

1.2. Culture the lymphoma cells in a sterile environment using a suitable medium (e.g., RPMI 1640 with 10% FBS) at 37°C and 5% CO2.

1.3. Inject 1 x 10^6 lymphoma cells into the tail vein of 10-week-old mice (n = 30) to establish the mouse model of secondary central nervous system lymphoma.

1.4. Monitor the mice for signs of disease progression (e.g., weight loss, lethargy, neurological symptoms) and sacrifice them when they reach a humane endpoint.

**Protocol 2: CAR-T Cell Preparation**

2.1. Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors or a commercial source.

2.2. Isolate T cells from PBMCs using a T cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

2.3. Activate the T cells using anti-CD3/CD28 beads (e.g., Dynabeads) and culture them in a T cell expansion medium (e.g., X-VIVO 15 with 10% FBS) at 37°C and 5% CO2.

2.4. Transduce the T cells with a lentiviral vector encoding a CD19-specific CAR and a fluorescent marker (e.g., GFP) using a lentiviral transduction kit (e.g., Sigma-Aldrich) according to the manufacturer's instructions.

2.5. Expand the CAR-T cells in a T cell expansion medium at 37°C and 5% CO2 for 7-10 days.

2.6. Harvest the CAR-T cells and wash them twice with PBS.

**Protocol 3: TTFields Treatment**

3.1. Place the mice in a TTFields device (e.g., Novocure's Optune) and treat them for varying durations (1, 3, and 7 days) according to the manufacturer's instructions.

3.2. Monitor the mice for signs of distress or discomfort during TTFields treatment.

**Protocol 4: CAR-T Cell Infusion**

4.1. Infuse 1 x 10^6 CAR-T cells into the tail vein of each mouse using a 1 mL syringe and a 27G needle.

4.2. Monitor the mice for signs of acute toxicity (e.g., anaphylaxis) after CAR-T cell infusion.

**Protocol 5: Imaging and Analysis**

5.1. Anesthetize the mice using isoflurane and perform confocal microscopy (e.g., Zeiss LSM 880) to visualize CAR-T cell penetration of the blood-brain barrier at different time points (1, 3, and 7 days) after CAR-T cell infusion.

5.2. Use a 20x objective lens and a 488 nm laser to excite the fluorescent marker on the CAR-T cells.

5.3. Acquire z-stacks of the brain tissue and analyze them using image analysis software (e.g., ImageJ) to quantify CAR-T cell penetration.

5.4. Perform flow cytometry (e.g., BD FACSCanto II) to analyze CAR-T cell infiltration into the central nervous system at different time points.

5.5. Use a gating strategy to identify CAR-T cells (e.g., CD3+ GFP+) and quantify their frequency in the central nervous system.

**Protocol 6: Tumor Response Monitoring**

6.1. Perform bioluminescence imaging (e.g., IVIS Spectrum) or MRI (e.g., Bruker BioSpec 7T) to monitor tumor response (tumor growth/regression) at different time points.

6.2. Use a bioluminescence imaging system to detect luciferase-expressing tumor cells or an MRI contrast agent to enhance tumor visibility.

6.3. Analyze the images using image analysis software (e.g., Living Image or MRIcroGL) to quantify tumor volume and growth rate.

**Protocol 7: Data Analysis**

7.1. Compare the results of the control group (CAR-T cell therapy alone) to the TTFields group (CAR-T cell therapy + TTFields treatment) to determine if the addition of TTFields improves CAR-T cell penetration and tumor response.

7.2. Use statistical software (e.g., GraphPad Prism) to perform two-way ANOVA with Bonferroni post-hoc tests to compare the groups.

7.3. Calculate the mean and standard error of the mean (SEM) for each group and present the data in a graphical format (e.g., bar graphs, scatter plots).

**Quality Control**

* Verify the identity and purity of the lymphoma cell line and CAR-T cells using flow cytometry and PCR.
* Monitor the mice for signs of disease progression and sacrifice them when they reach a humane endpoint.
* Perform regular maintenance and calibration of the TTFields device, confocal microscope, flow cytometer, and bioluminescence imaging system or MRI according to the manufacturers' instructions.

**Timeline**

* Week 1-2: Establish the mouse model of secondary central nervous system lymphoma
* Week 3-4: Prepare CAR-T cells
* Week 5-6: Treat mice with TTFields and infuse CAR-T cells
* Week 7-12: Perform imaging and analysis, and monitor tumor response

**Budget**

* Mouse model of secondary central nervous system lymphoma: $5,000
* CAR-T cell preparation: $10,000
* TTFields device: $20,000
* Confocal microscope: $50,000
* Flow cytometer: $30,000
* Bioluminescence imaging system or MRI: $100,000
* Reagents and consumables: $10,000
* Total budget: $225,000","```
   Lymphoma Cells  T Cells  CAR-T Cells  TTFields Duration  Outcome
0          1e+06    1e+06      1e+06               1  0.432109
1          1e+06    5e+05      1e+06               3  0.567821
2          5e+05    1e+06      5e+05               1  0.219434
3          1e+06    1e+06      5e+05               7  0.812345
4          5e+05    5e+05      1e+06               3  0.654321
5          1e+06    1e+06      1e+06               1  0.567890
6          5e+05    1e+06      1e+06               7  0.901234
7          1e+06    5e+05      5e+05               3  0.345678
8          5e+05    5e+05      5e+05               1  0.123456
9          1e+06    1e+06      1e+06               7  0.987654
10         5e+05    1e+06      1e+06               3  0.765432
11         1e+06    5e+05      5e+05               1  0.543210
12         5e+05    5e+05      1e+06               7  0.876543
13         1e+06    1e+06      5e+05               3  0.678901
14         5e+05    1e+06      1e+06               1  0.234567
15         1e+06    5e+05      1e+06               7  0.945678
16         5e+05    5e+05      5e+05               3  0.456789
17         1e+06    1e+06      1e+06               1  0.678901
18         5e+05    1e+06      5e+05               7  0.812345
19         1e+06    5e+05      1e+06               3  0.567890
20         5e+05    5e+05      1e+06               1  0.345678
21         1e+06    1e+06      5e+05               7  0.987654
22         5e+05    1e+06      1e+06               3  0.765432
23         1e+06    5e+05      5e+05               1  0.123456
24         5e+05    5e+05      5e+05               7  0.876543
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0b7110ed0551ee229bbbe43f2205942bfc773cfe.summary'],"Can the combination of CART-BCMA therapy with a Th1-polarizing adjuvant enhance the expansion and persistence of CART-BCMA cells, leading to improved clinical responses in patients with relapsed/refractory multiple myeloma?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis and potentially disprove it. This plan leverages existing scientific methods and equipment, with an unlimited budget in terms of time, resources, and financial support.

**Experimental Plan:**

**Title:** Investigating the Combination of CART-BCMA Therapy with Th1-Polarizing Adjuvants to Enhance CART-BCMA Cell Expansion and Persistence in Relapsed/Refractory Multiple Myeloma

**Objective:** To determine whether the combination of CART-BCMA therapy with a Th1-polarizing adjuvant enhances the expansion and persistence of CART-BCMA cells, leading to improved clinical responses in patients with relapsed/refractory multiple myeloma.

**Experimental Design:**

1. **Patient Enrollment:** Recruit 50 patients with relapsed/refractory multiple myeloma, with a 1:1:1 randomization to one of three treatment arms:
	* Arm 1: CART-BCMA therapy alone (control group)
	* Arm 2: CART-BCMA therapy + Th1-polarizing adjuvant (e.g., CpG oligonucleotides, poly-ICLC, or other Th1-inducing agents)
	* Arm 3: CART-BCMA therapy + Th2-polarizing adjuvant (e.g., IL-4, IL-10, or other Th2-inducing agents; serves as a negative control)
2. **CART-BCMA Cell Preparation and Infusion:** Prepare and infuse autologous T cells expressing a fully human BCMA-specific CAR (CART-BCMA) in all patients, following the same protocol as the original study.
3. **Adjuvant Administration:** Administer the assigned adjuvant (Th1-polarizing or Th2-polarizing) concurrently with CART-BCMA infusion and at predetermined time points post-infusion (e.g., days 7, 14, and 21).
4. **Blood Sampling and Analysis:** Collect blood samples from patients at baseline, pre-infusion, and at multiple time points post-infusion (e.g., days 7, 14, 21, 28, and 42). Analyze samples using:
	* Flow cytometry to quantify CART-BCMA cells, Th1 cytokine-producing T cells (e.g., IFN-γ, TNF-α), and Th2 cytokine-producing T cells (e.g., IL-4, IL-10)
	* ELISA or multiplex assays to measure Th1 cytokine levels (e.g., IFN-γ, TNF-α) and Th2 cytokine levels (e.g., IL-4, IL-10)
5. **Clinical Response Evaluation:** Assess clinical responses using the International Myeloma Working Group (IMWG) criteria, including complete response (CR), very good partial response (VGPR), partial response (PR), and stable disease (SD).
6. **Statistical Analysis:** Compare the expansion and persistence of CART-BCMA cells, Th1 cytokine production, and clinical responses between the three treatment arms using appropriate statistical tests (e.g., ANOVA, t-tests, regression analysis).

**To Disprove the Hypothesis:**

To disprove the hypothesis, the experiment should aim to show that the combination of CART-BCMA therapy with a Th1-polarizing adjuvant does not enhance the expansion and persistence of CART-BCMA cells or improve clinical responses in patients with relapsed/refractory multiple myeloma.

**Key Predictions:**

* If the hypothesis is true, the CART-BCMA + Th1-polarizing adjuvant arm (Arm 2) will demonstrate:
	+ Significantly higher CART-BCMA cell expansion and persistence compared to the control arm (Arm 1)
	+ Increased Th1 cytokine production (e.g., IFN-γ, TNF-α) compared to the control arm
	+ Improved clinical responses (e.g., higher CR, VGPR, and PR rates) compared to the control arm
* If the hypothesis is false, the CART-BCMA + Th1-polarizing adjuvant arm (Arm 2) will not demonstrate significant differences in CART-BCMA cell expansion and persistence, Th1 cytokine production, or clinical responses compared to the control arm.

**Timeline:**

* Patient enrollment and treatment: 6 months
* Blood sampling and analysis: 12 months
* Data analysis and manuscript preparation: 12 months

**Budget:**

* Patient enrollment and treatment: $1,500,000
* Blood sampling and analysis: $750,000
* Data analysis and manuscript preparation: $500,000
* Total budget: $2,750,000

This experimental plan is designed to rigorously test the hypothesis and provide conclusive evidence for or against the combination of CART-BCMA therapy with a Th1-polarizing adjuvant in relapsed/refractory multiple myeloma.",90,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Enrollment and Randomization**

1.1. Patient Screening:

* Identify patients with relapsed/refractory multiple myeloma through medical records and clinical evaluations.
* Verify patient eligibility based on inclusion and exclusion criteria (e.g., age, disease status, previous treatments).
* Obtain informed consent from eligible patients.

1.2. Randomization:

* Use a computer-generated randomization program to assign patients to one of three treatment arms (Arm 1, Arm 2, or Arm 3) in a 1:1:1 ratio.
* Ensure randomization is stratified by factors such as age, disease status, and previous treatments to minimize bias.

**Protocol 2: CART-BCMA Cell Preparation and Infusion**

2.1. T Cell Collection and Activation:

* Collect peripheral blood mononuclear cells (PBMCs) from patients using apheresis or leukapheresis.
* Activate T cells using anti-CD3/CD28 beads or other activation methods.
* Expand T cells in culture using IL-2 and other growth factors.

2.2. CART-BCMA Vector Transduction:

* Transduce activated T cells with a lentiviral vector encoding a fully human BCMA-specific CAR.
* Verify transduction efficiency using flow cytometry and qPCR.

2.3. CART-BCMA Cell Expansion and Quality Control:

* Expand transduced T cells in culture using IL-2 and other growth factors.
* Perform quality control tests, including flow cytometry, ELISA, and functional assays, to ensure CART-BCMA cell purity, viability, and functionality.

2.4. CART-BCMA Cell Infusion:

* Infuse autologous CART-BCMA cells into patients at a dose of [insert dose] cells/kg body weight.
* Monitor patients for adverse reactions and toxicity.

**Protocol 3: Adjuvant Administration**

3.1. Adjuvant Preparation:

* Prepare Th1-polarizing adjuvants (e.g., CpG oligonucleotides, poly-ICLC) according to manufacturer's instructions.
* Prepare Th2-polarizing adjuvants (e.g., IL-4, IL-10) according to manufacturer's instructions.

3.2. Adjuvant Administration:

* Administer the assigned adjuvant concurrently with CART-BCMA infusion and at predetermined time points post-infusion (e.g., days 7, 14, and 21).
* Monitor patients for adverse reactions and toxicity.

**Protocol 4: Blood Sampling and Analysis**

4.1. Blood Sample Collection:

* Collect blood samples from patients at baseline, pre-infusion, and at multiple time points post-infusion (e.g., days 7, 14, 21, 28, and 42).
* Process blood samples according to standard protocols for flow cytometry, ELISA, and multiplex assays.

4.2. Flow Cytometry Analysis:

* Stain blood samples with antibodies against CART-BCMA, Th1 cytokine-producing T cells (e.g., IFN-γ, TNF-α), and Th2 cytokine-producing T cells (e.g., IL-4, IL-10).
* Analyze samples using a flow cytometer and quantify CART-BCMA cells, Th1 cytokine-producing T cells, and Th2 cytokine-producing T cells.

4.3. ELISA and Multiplex Assays:

* Measure Th1 cytokine levels (e.g., IFN-γ, TNF-α) and Th2 cytokine levels (e.g., IL-4, IL-10) using ELISA or multiplex assays.
* Analyze samples according to manufacturer's instructions.

**Protocol 5: Clinical Response Evaluation**

5.1. Clinical Response Assessment:

* Evaluate clinical responses using the International Myeloma Working Group (IMWG) criteria, including complete response (CR), very good partial response (VGPR), partial response (PR), and stable disease (SD).
* Assess clinical responses at multiple time points post-infusion (e.g., days 28, 42, and 56).

**Protocol 6: Statistical Analysis**

6.1. Data Collection and Management:

* Collect and manage data from all patients, including demographics, treatment assignments, CART-BCMA cell expansion and persistence, Th1 cytokine production, and clinical responses.

6.2. Statistical Analysis:

* Compare the expansion and persistence of CART-BCMA cells, Th1 cytokine production, and clinical responses between the three treatment arms using appropriate statistical tests (e.g., ANOVA, t-tests, regression analysis).
* Perform statistical analysis using software such as R or SAS.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the experimental design.","```
   Patient_Age  Disease_Status  Previous_Treatments  CART_BCMA_Dose  Th1_Adjuvant_Dose  Th2_Adjuvant_Dose  CART_BCMA_Cells_Expanded  Th1_Cytokine_Production  Th2_Cytokine_Production  Clinical_Response
0           65             2                  1          1.0e+06             100.0             50.0                8.0e+07                500.0                200.0                CR
1           70             1                  2          5.0e+05              50.0             25.0                4.0e+07                300.0                150.0                VGPR
2           60             3                  1          2.0e+06             150.0             75.0                1.2e+08                700.0                350.0                PR
3           75             2                  3          1.5e+06             120.0             60.0                9.0e+07                600.0                250.0                SD
4           68             1                  2          3.0e+05              80.0             40.0                6.0e+07                400.0                200.0                CR
5           72             3                  1          2.5e+06             180.0             90.0                1.1e+08                800.0                400.0                VGPR
6           65             2                  3          1.2e+06             100.0             50.0                8.5e+07                550.0                220.0                PR
7           70             1                  2          4.0e+05              60.0             30.0                5.0e+07                350.0                180.0                SD
8           60             3                  1          2.8e+06             160.0             80.0                1.3e+08                900.0                450.0                CR
9           75             2                  3          1.8e+06             140.0             70.0                1.0e+08                650.0                280.0                VGPR
10          68             1                  2          2.2e+05              90.0             45.0                7.0e+07                450.0                210.0                PR
11          72             3                  1          2.2e+06             190.0             95.0                1.2e+08                850.0                420.0                SD
12          65             2                  3          1.0e+06              90.0             45.0                8.0e+07                500.0                220.0                CR
13          70             1                  2          3.5e+05              70.0             35.0                5.5e+07                380.0                190.0                VGPR
14          60             3                  1          2.9e+06             170.0             85.0                1.4e+08                950.0                480.0                PR
15          75             2                  3          2.0e+06             130.0             65.0                1.1e+08                700.0                300.0                SD
16          68             1                  2          2.5e+05              95.0             47.5                7.5e+07                480.0                230.0                CR
17          72             3                  1          2.4e+06             200.0             100.0               1.3e+08                900.0                450.0                VGPR
18          65             2                  3          1.4e+06             110.0             55.0                9.0e+07                580.0                240.0                PR
19          70             1                  2          4.2e+05              75.0             37.5                6.0e+07                410.0                200.0                SD
20          60             3                  1          3.1e+06             185.0             92.5                1.5e+08               1000.0                500.0                CR
21          75             2                  3          2.3e+06             145.0             72.5                1.2e+08                750.0                320.0                VGPR
22          68             1                  2          2.8e+05             100.0             50.0                8.0e+07                520.0                240.0                PR
23          72             3                  1          2.6e+06             210.0             105.0               1.4e+08                960.0                480.0                SD
24          65             2                  3          1.6e+06             120.0             60.0                9.5e+07                620.0                260.0                CR
```",0.07101969416313046
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/473bb2ab0cd82423964c377586e68cf61499f8d9.summary'],Can the combination of CD19-targeted butyrophilin heterodimer with a gamma-delta T cell-specific checkpoint inhibitor enhance the anti-tumor response and reduce peripheral B cell depletion in B-cell lymphoma treatment?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Enhancing Anti-Tumor Response and Reducing Peripheral B Cell Depletion in B-Cell Lymphoma Treatment using CD19-Targeted Butyrophilin Heterodimer and Gamma-Delta T Cell-Specific Checkpoint Inhibitor

**Objective:** To investigate whether the combination of CD19-targeted butyrophilin heterodimer with a gamma-delta T cell-specific checkpoint inhibitor enhances the anti-tumor response and reduces peripheral B cell depletion in B-cell lymphoma treatment.

**Experimental Design:**

1. **Cell Preparation:**
	* Prepare CD19-targeted butyrophilin heterodimer and gamma-delta T cell-specific checkpoint inhibitor proteins.
	* Isolate and culture murine B-cell lymphoma cells.
2. **In Vivo Experiment:**
	* Divide mice with B-cell lymphoma tumors into four groups:
		+ Group 1: Control (no treatment)
		+ Group 2: CD19-targeted butyrophilin heterodimer only
		+ Group 3: Gamma-delta T cell-specific checkpoint inhibitor only
		+ Group 4: Combination of CD19-targeted butyrophilin heterodimer and gamma-delta T cell-specific checkpoint inhibitor
	* Administer the respective treatments to each group.
3. **Monitoring and Analysis:**
	* Monitor tumor growth and regression over time using caliper measurements and bioluminescence imaging.
	* Analyze immune cell populations in the tumor and peripheral blood using flow cytometry.
	* Measure cytokine and chemokine levels in the tumor and peripheral blood using ELISA.
4. **Endpoints:**
	* Tumor volume and regression
	* Peripheral B cell depletion
	* Immune cell populations (gamma-delta T cells, CD4+ T cells, CD8+ T cells, etc.)
	* Cytokine and chemokine levels (e.g., IFN-γ, TNF-α, IL-2, etc.)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Inability of CD19-Targeted Butyrophilin Heterodimer and Gamma-Delta T Cell-Specific Checkpoint Inhibitor to Enhance Anti-Tumor Response and Reduce Peripheral B Cell Depletion in B-Cell Lymphoma Treatment

**Objective:** To demonstrate that the combination of CD19-targeted butyrophilin heterodimer with a gamma-delta T cell-specific checkpoint inhibitor does not enhance the anti-tumor response and does not reduce peripheral B cell depletion in B-cell lymphoma treatment.

**Experimental Design:**

1. **Cell Preparation:**
	* Prepare CD19-targeted butyrophilin heterodimer and gamma-delta T cell-specific checkpoint inhibitor proteins with a mutated or inactivated form to abolish their functionality.
	* Isolate and culture murine B-cell lymphoma cells.
2. **In Vivo Experiment:**
	* Divide mice with B-cell lymphoma tumors into two groups:
		+ Group 1: Control (no treatment)
		+ Group 2: Combination of mutated/inactivated CD19-targeted butyrophilin heterodimer and gamma-delta T cell-specific checkpoint inhibitor
	* Administer the respective treatments to each group.
3. **Monitoring and Analysis:**
	* Monitor tumor growth and regression over time using caliper measurements and bioluminescence imaging.
	* Analyze immune cell populations in the tumor and peripheral blood using flow cytometry.
	* Measure cytokine and chemokine levels in the tumor and peripheral blood using ELISA.
4. **Endpoints:**
	* Tumor volume and regression
	* Peripheral B cell depletion
	* Immune cell populations (gamma-delta T cells, CD4+ T cells, CD8+ T cells, etc.)
	* Cytokine and chemokine levels (e.g., IFN-γ, TNF-α, IL-2, etc.)

**Rationale:**

The experiment to disprove the hypothesis aims to demonstrate that the combination of CD19-targeted butyrophilin heterodimer and gamma-delta T cell-specific checkpoint inhibitor does not enhance the anti-tumor response and does not reduce peripheral B cell depletion. By using mutated or inactivated forms of the proteins, we can test the hypothesis in a scenario where the expected effects are abolished. If the results show no significant differences between the treatment and control groups, it would suggest that the combination of CD19-targeted butyrophilin heterodimer and gamma-delta T cell-specific checkpoint inhibitor does not have the proposed effects, thus disproving the hypothesis.

**Timeline and Budget:**

The experiments can be completed within 6-8 months, with the following budget allocation:

* Personnel: 30% (post-doc, graduate student, and technician)
* Reagents and consumables: 40% (proteins, cells, antibodies, ELISA kits, etc.)
* Equipment and maintenance: 15% (flow cytometer, ELISA reader, etc.)
* Animal costs: 10% (mice, housing, and care)
* Miscellaneous: 5% (literature review, data analysis software, etc.)

This experimental plan is designed to test the hypothesis and provide a clear answer to the research question while being mindful of the limited budget and resources.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Cell Preparation**

1.1. Preparation of CD19-targeted butyrophilin heterodimer protein:

* Obtain the CD19-targeted butyrophilin heterodimer gene sequence and clone it into an expression vector (e.g., pET-28a).
* Transform the vector into an E. coli expression strain (e.g., BL21(DE3)).
* Grow the bacteria in LB medium at 37°C until OD600 reaches 0.6-0.8.
* Induce protein expression with 1 mM IPTG and incubate for 4 hours at 30°C.
* Harvest the bacteria by centrifugation and resuspend in lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 1% Triton X-100).
* Lyse the bacteria using a French press or sonication.
* Purify the protein using Ni-NTA affinity chromatography and size exclusion chromatography.
* Verify the protein purity and concentration using SDS-PAGE and Bradford assay.

1.2. Preparation of gamma-delta T cell-specific checkpoint inhibitor protein:

* Obtain the gamma-delta T cell-specific checkpoint inhibitor gene sequence and clone it into an expression vector (e.g., pET-28a).
* Follow the same protocol as above to express and purify the protein.

1.3. Isolation and culture of murine B-cell lymphoma cells:

* Obtain murine B-cell lymphoma cells (e.g., A20 cells) from a reputable cell bank or generate them in-house.
* Culture the cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
* Verify the cell identity and purity using flow cytometry and morphology analysis.

**Protocol 2: In Vivo Experiment**

2.1. Mouse preparation:

* Obtain 40-50 mice (e.g., C57BL/6) from a reputable vendor.
* House the mice in a specific pathogen-free facility with ad libitum access to food and water.
* Randomly divide the mice into four groups: Group 1 (control), Group 2 (CD19-targeted butyrophilin heterodimer only), Group 3 (gamma-delta T cell-specific checkpoint inhibitor only), and Group 4 (combination of CD19-targeted butyrophilin heterodimer and gamma-delta T cell-specific checkpoint inhibitor).

2.2. Tumor inoculation:

* Inject 1 x 10^6 A20 cells in 100 μL PBS into the right flank of each mouse using a 27-gauge needle.
* Monitor tumor growth using caliper measurements and bioluminescence imaging.

2.3. Treatment administration:

* Prepare the treatment solutions by dissolving the proteins in PBS at the desired concentrations (e.g., 10 mg/kg for CD19-targeted butyrophilin heterodimer and 5 mg/kg for gamma-delta T cell-specific checkpoint inhibitor).
* Administer the treatments via intraperitoneal injection on days 7, 14, and 21 post-tumor inoculation.

**Protocol 3: Monitoring and Analysis**

3.1. Tumor monitoring:

* Measure tumor volume using caliper measurements every 3-4 days.
* Perform bioluminescence imaging on days 14, 21, and 28 post-tumor inoculation using a Xenogen IVIS system.

3.2. Immune cell analysis:

* Collect peripheral blood and tumor tissue on days 14, 21, and 28 post-tumor inoculation.
* Perform flow cytometry analysis using antibodies against gamma-delta T cells, CD4+ T cells, CD8+ T cells, and other immune cell markers.

3.3. Cytokine and chemokine analysis:

* Collect peripheral blood and tumor tissue on days 14, 21, and 28 post-tumor inoculation.
* Perform ELISA analysis using commercial kits for IFN-γ, TNF-α, IL-2, and other cytokines and chemokines.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Preparation**

1.1. Preparation of mutated/inactivated CD19-targeted butyrophilin heterodimer protein:

* Introduce point mutations or deletions into the CD19-targeted butyrophilin heterodimer gene sequence to abolish its functionality.
* Follow the same protocol as above to express and purify the protein.

1.2. Preparation of mutated/inactivated gamma-delta T cell-specific checkpoint inhibitor protein:

* Introduce point mutations or deletions into the gamma-delta T cell-specific checkpoint inhibitor gene sequence to abolish its functionality.
* Follow the same protocol as above to express and purify the protein.

1.3. Isolation and culture of murine B-cell lymphoma cells:

* Follow the same protocol as above to isolate and culture the murine B-cell lymphoma cells.

**Protocol 2: In Vivo Experiment**

2.1. Mouse preparation:

* Follow the same protocol as above to prepare the mice.

2.2. Tumor inoculation:

* Follow the same protocol as above to inoculate the mice with A20 cells.

2.3. Treatment administration:

* Prepare the treatment solutions by dissolving the mutated/inactivated proteins in PBS at the desired concentrations.
* Administer the treatments via intraperitoneal injection on days 7, 14, and 21 post-tumor inoculation.

**Protocol 3: Monitoring and Analysis**

3.1. Tumor monitoring:

* Follow the same protocol as above to monitor tumor growth using caliper measurements and bioluminescence imaging.

3.2. Immune cell analysis:

* Follow the same protocol as above to analyze immune cell populations using flow cytometry.

3.3. Cytokine and chemokine analysis:

* Follow the same protocol as above to analyze cytokine and chemokine levels using ELISA.

Note: The protocols above are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols, safety guidelines, and animal welfare regulations when conducting these experiments.","```
   CD19-targeted butyrophilin (mg/kg)  gamma-delta T cell-specific checkpoint inhibitor (mg/kg)  Tumor Volume (mm^3)
0                              5.0                                    2.5                         150.0
1                              7.5                                    5.0                         120.0
2                              10.0                                   7.5                         100.0
3                              5.0                                    5.0                         180.0
4                              7.5                                   2.5                         140.0
5                              10.0                                   10.0                         80.0
6                              5.0                                    7.5                         160.0
7                              7.5                                   10.0                         120.0
8                              10.0                                   5.0                         100.0
9                              5.0                                    2.5                         200.0
10                             7.5                                    5.0                         140.0
11                             10.0                                   7.5                         90.0
12                             5.0                                    10.0                         160.0
13                             7.5                                   2.5                         130.0
14                             10.0                                   5.0                         110.0
15                             5.0                                    7.5                         190.0
16                             7.5                                   10.0                         130.0
17                             10.0                                   5.0                         100.0
18                             5.0                                    2.5                         210.0
19                             7.5                                    5.0                         150.0
20                             10.0                                   7.5                         90.0
21                             5.0                                    10.0                         170.0
22                             7.5                                   2.5                         140.0
23                             10.0                                   5.0                         110.0
24                             5.0                                    7.5                         200.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/009b0d32990b0f60292dc0bf20c940d2f037b515.summary'],"Can the combination of CLN-049 with checkpoint inhibitors enhance T cell-mediated cytotoxicity against FLT3-expressing AML and B-ALL cells, leading to improved treatment outcomes in patients with minimal residual disease?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"Based on the provided hypothesis, I've developed a comprehensive experimental plan to test the combination of CLN-049 with checkpoint inhibitors in enhancing T cell-mediated cytotoxicity against FLT3-expressing AML and B-ALL cells.

**Experimental Plan:**

**Objective:**

* Investigate the efficacy of combining CLN-049 with checkpoint inhibitors in enhancing T cell-mediated cytotoxicity against FLT3-expressing AML and B-ALL cells.
* Evaluate the potential of this combination therapy in improving treatment outcomes in patients with minimal residual disease.

**Experimental Design:**

1. **Cell Line Establishment and Characterization:**
	* Obtain FLT3-expressing AML and B-ALL cell lines (e.g., MV4-11, Kasumi-1, and NALM-6).
	* Characterize the cell lines using flow cytometry, Western blot, and qRT-PCR to confirm FLT3 expression and functionality.
2. **T Cell Isolation and Expansion:**
	* Isolate T cells from healthy donors or patients with AML/B-ALL using Ficoll-Paque density gradient centrifugation and magnetic bead-based separation.
	* Expand T cells using anti-CD3/CD28 beads and IL-2 in a 37°C, 5% CO2 incubator.
3. **CLN-049 and Checkpoint Inhibitor Preparation:**
	* Obtain CLN-049 and checkpoint inhibitors (e.g., pembrolizumab, nivolumab, or atezolizumab) from commercial sources or synthesize in-house using established protocols.
	* Prepare stock solutions and working concentrations according to the manufacturer's instructions.
4. **Co-Culture Assays:**
	* Co-culture T cells with FLT3-expressing AML/B-ALL cells at a 1:1 ratio in the presence or absence of CLN-049 and checkpoint inhibitors.
	* Use 96-well plates and perform triplicate experiments.
	* Incubate at 37°C, 5% CO2 for 24-48 hours.
5. **Cytotoxicity Assays:**
	* Measure T cell-mediated cytotoxicity using:
		+ Calcein-AM release assay: quantify calcein release from target cells using a fluorescence plate reader.
		+ LDH release assay: measure lactate dehydrogenase release from target cells using a colorimetric assay.
		+ Flow cytometry: analyze target cell death using Annexin V and PI staining.
6. **Immune Cell Profiling:**
	* Analyze T cell subsets, activation markers, and cytokine production using flow cytometry and ELISA.
	* Investigate the expression of immune checkpoint molecules (e.g., PD-1, CTLA-4) on T cells.
7. **In Vivo Studies:**
	* Establish FLT3-expressing AML/B-ALL xenograft models in immunodeficient mice (e.g., NSG or NOD-SCID).
	* Treat mice with CLN-049, checkpoint inhibitors, or the combination, and monitor tumor growth and survival.
	* Perform immune cell profiling and cytotoxicity assays on tumor-infiltrating lymphocytes.
8. **Data Analysis:**
	* Use statistical software (e.g., GraphPad Prism, R) to analyze data and perform comparisons between treatment groups.
	* Determine the optimal combination and dosing regimen for CLN-049 and checkpoint inhibitors.

**Resources and Equipment:**

* Cell culture facilities with CO2 incubators, biosafety cabinets, and centrifuges
* Flow cytometry and cell sorting equipment (e.g., BD FACSAria, Beckman Coulter MoFlo)
* Molecular biology equipment (e.g., PCR, Western blot, qRT-PCR)
* Immunoassay equipment (e.g., ELISA, Luminex)
* Animal facilities for in vivo studies
* High-performance computing resources for data analysis and simulation

**Timeline:**

* Cell line establishment and characterization: 2 weeks
* T cell isolation and expansion: 2 weeks
* Co-culture and cytotoxicity assays: 4 weeks
* Immune cell profiling: 4 weeks
* In vivo studies: 12 weeks
* Data analysis and manuscript preparation: 16 weeks

**Budget:**

* Personnel: 5 researchers, 2 technicians, and 1 post-doc (salaries, benefits, and training)
* Reagents and consumables: cell lines, antibodies, cytokines, checkpoint inhibitors, CLN-049, and other chemicals
* Equipment maintenance and upgrades: flow cytometry, molecular biology, and immunoassay equipment
* Animal facilities and husbandry: mouse maintenance, housing, and veterinary care
* Travel and training: conferences, workshops, and courses for researchers and technicians
* Miscellaneous: laboratory supplies, software, and computational resources

With an unlimited budget, the estimated total cost for this project would be approximately $5-7 million over 2-3 years, depending on the specific resources and equipment required.",92,"Here are the detailed, step-by-step protocols for each section of the experimental plan:

**Cell Line Establishment and Characterization:**

1.1. Obtain FLT3-expressing AML and B-ALL cell lines (e.g., MV4-11, Kasumi-1, and NALM-6) from a reputable cell bank or commercial source.

1.2. Thaw the cell lines according to the supplier's instructions and culture them in their recommended media (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin) at 37°C, 5% CO2.

1.3. Characterize the cell lines using flow cytometry to confirm FLT3 expression:
	* Stain 1x10^6 cells with anti-FLT3-PE antibody (1:100 dilution) and incubate for 30 minutes at 4°C.
	* Wash cells with PBS and analyze using a flow cytometer (e.g., BD FACSCanto II).
	* Record the percentage of FLT3-positive cells and mean fluorescence intensity.

1.4. Characterize the cell lines using Western blot to confirm FLT3 protein expression:
	* Lyse 1x10^6 cells in RIPA buffer and separate proteins using SDS-PAGE.
	* Transfer proteins to a PVDF membrane and probe with anti-FLT3 antibody (1:1000 dilution) and anti-β-actin antibody (1:5000 dilution).
	* Detect proteins using ECL reagents and record the FLT3 protein band intensity.

1.5. Characterize the cell lines using qRT-PCR to confirm FLT3 mRNA expression:
	* Extract RNA from 1x10^6 cells using a commercial RNA extraction kit.
	* Perform qRT-PCR using FLT3-specific primers and a housekeeping gene (e.g., GAPDH) as a control.
	* Record the relative FLT3 mRNA expression levels.

**T Cell Isolation and Expansion:**

2.1. Isolate T cells from healthy donors or patients with AML/B-ALL using Ficoll-Paque density gradient centrifugation:
	* Collect 10 mL of peripheral blood or bone marrow aspirate in a heparinized tube.
	* Add 10 mL of Ficoll-Paque to the tube and centrifuge at 400g for 30 minutes.
	* Collect the buffy coat and wash with PBS.

2.2. Isolate T cells using magnetic bead-based separation:
	* Label T cells with anti-CD3 and anti-CD28 antibodies (1:100 dilution) and incubate for 30 minutes at 4°C.
	* Add magnetic beads (e.g., Dynabeads) and incubate for 30 minutes at 4°C.
	* Separate T cells using a magnet and wash with PBS.

2.3. Expand T cells using anti-CD3/CD28 beads and IL-2:
	* Culture T cells in RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 100 IU/mL IL-2.
	* Add anti-CD3/CD28 beads (1:1 ratio) and incubate at 37°C, 5% CO2 for 7-10 days.
	* Monitor T cell expansion and viability using trypan blue exclusion.

**CLN-049 and Checkpoint Inhibitor Preparation:**

3.1. Obtain CLN-049 and checkpoint inhibitors (e.g., pembrolizumab, nivolumab, or atezolizumab) from commercial sources or synthesize in-house using established protocols.

3.2. Prepare stock solutions of CLN-049 and checkpoint inhibitors according to the manufacturer's instructions:
	* Reconstitute lyophilized powders with sterile water or buffer.
	* Aliquot and store at -20°C or -80°C.

3.3. Prepare working concentrations of CLN-049 and checkpoint inhibitors:
	* Dilute stock solutions with culture media or buffer to the desired concentration (e.g., 1 μM, 10 μM, 100 μM).
	* Store working solutions at 4°C or -20°C.

**Co-Culture Assays:**

4.1. Prepare FLT3-expressing AML/B-ALL cells for co-culture:
	* Culture cells in RPMI 1640 with 10% FBS and 1% penicillin-streptomycin at 37°C, 5% CO2.
	* Harvest cells at 80-90% confluence and wash with PBS.

4.2. Prepare T cells for co-culture:
	* Harvest expanded T cells and wash with PBS.
	* Count and adjust T cell numbers to 1x10^5 cells per well.

4.3. Co-culture T cells with FLT3-expressing AML/B-ALL cells:
	* Add 1x10^5 T cells and 1x10^5 FLT3-expressing AML/B-ALL cells to each well of a 96-well plate.
	* Add CLN-049 and/or checkpoint inhibitors to the desired wells.
	* Incubate at 37°C, 5% CO2 for 24-48 hours.

**Cytotoxicity Assays:**

5.1. Calcein-AM release assay:
	* Add 1 μM calcein-AM to the co-culture wells and incubate for 30 minutes at 37°C, 5% CO2.
	* Measure calcein release using a fluorescence plate reader (e.g., Tecan Infinite M200).

5.2. LDH release assay:
	* Add 1% Triton X-100 to the co-culture wells and incubate for 30 minutes at 37°C, 5% CO2.
	* Measure LDH release using a colorimetric assay (e.g., Promega CytoTox 96).

5.3. Flow cytometry:
	* Stain target cells with Annexin V-FITC and PI (1:100 dilution) and incubate for 30 minutes at 4°C.
	* Analyze target cell death using a flow cytometer (e.g., BD FACSCanto II).

**Immune Cell Profiling:**

6.1. Analyze T cell subsets and activation markers using flow cytometry:
	* Stain T cells with anti-CD3, anti-CD4, anti-CD8, anti-CD25, and anti-CD69 antibodies (1:100 dilution) and incubate for 30 minutes at 4°C.
	* Analyze T cell subsets and activation markers using a flow cytometer (e.g., BD FACSCanto II).

6.2. Analyze cytokine production using ELISA:
	* Collect supernatants from co-culture wells and store at -80°C.
	* Perform ELISA for cytokines (e.g., IFN-γ, TNF-α, IL-2) using commercial kits.

**In Vivo Studies:**

7.1. Establish FLT3-expressing AML/B-ALL xenograft models in immunodeficient mice (e.g., NSG or NOD-SCID):
	* Inject 1x10^6 FLT3-expressing AML/B-ALL cells into the tail vein of mice.
	* Monitor tumor growth and survival.

7.2. Treat mice with CLN-049, checkpoint inhibitors, or the combination:
	* Administer CLN-049 and/or checkpoint inhibitors via intraperitoneal injection or oral gavage.
	* Monitor tumor growth and survival.

7.3. Perform immune cell profiling and cytotoxicity assays on tumor-infiltrating lymphocytes:
	* Isolate tumor-infiltrating lymphocytes using Ficoll-Paque density gradient centrifugation and magnetic bead-based separation.
	* Analyze T cell subsets, activation markers, and cytokine production using flow cytometry and ELISA.
	* Perform cytotoxicity assays using calcein-AM release, LDH release, and flow cytometry.

**Data Analysis:**

8.1. Use statistical software (e.g., GraphPad Prism, R) to analyze data and perform comparisons between treatment groups:
	* Compare cytotoxicity, immune cell profiling, and tumor growth/survival data between treatment groups.
	* Determine the optimal combination and dosing regimen for CLN-049 and checkpoint inhibitors.

8.2. Determine the optimal combination and dosing regimen for CLN-049 and checkpoint inhibitors:
	* Analyze data from co-culture assays, immune cell profiling, and in vivo studies.
	* Identify the most effective combination and dosing regimen for CLN-049 and checkpoint inhibitors.

These detailed, step-by-step protocols should provide a clear guide for executing the experimental plan.","```
   FLT3-expressing AML/B-ALL cells  T cells  CLN-049 (μM)  Checkpoint Inhibitor (μM)  Cytotoxicity (%)
0                         1x10^5  1x10^5           1.0                    0.0        20.5
1                         1x10^5  1x10^5           0.1                    0.0        15.2
2                         1x10^5  1x10^5           0.0                    1.0        12.8
3                         1x10^5  1x10^5           1.0                    1.0        35.1
4                         1x10^5  1x10^5           0.5                    0.5        28.4
5                         1x10^5  2x10^5           1.0                    0.0        25.9
6                         1x10^5  2x10^5           0.1                    0.0        20.1
7                         1x10^5  2x10^5           0.0                    1.0        18.5
8                         1x10^5  2x10^5           1.0                    1.0        40.2
9                         1x10^5  2x10^5           0.5                    0.5        33.7
10                        2x10^5  1x10^5           1.0                    0.0        30.4
11                        2x10^5  1x10^5           0.1                    0.0        24.8
12                        2x10^5  1x10^5           0.0                    1.0        22.1
13                        2x10^5  1x10^5           1.0                    1.0        45.6
14                        2x10^5  1x10^5           0.5                    0.5        39.2
15                        2x10^5  2x10^5           1.0                    0.0        35.9
16                        2x10^5  2x10^5           0.1                    0.0        30.5
17                        2x10^5  2x10^5           0.0                    1.0        28.2
18                        2x10^5  2x10^5           1.0                    1.0        50.8
19                        2x10^5  2x10^5           0.5                    0.5        44.5
20                        5x10^5  1x10^5           1.0                    0.0        40.1
21                        5x10^5  1x10^5           0.1                    0.0        35.6
22                        5x10^5  1x10^5           0.0                    1.0        33.4
23                        5x10^5  1x10^5           1.0                    1.0        55.3
24                        5x10^5  1x10^5           0.5                    0.5        49.1
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/01326364a95f3d96be65095013707c882856b2bd.summary'],"Can the combination of NK-EVs and carboplatin modulate the tumor microenvironment by reducing the expression of immunosuppressive cytokines, thereby enhancing the efficacy of cancer immunotherapy in Osimertinib-resistant lung cancer cells with EGFR mutations?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Modulation of Tumor Microenvironment by NK-EVs and Carboplatin in Osimertinib-Resistant Lung Cancer Cells with EGFR Mutations

**Objective:** To investigate whether the combination of NK-EVs and carboplatin can modulate the tumor microenvironment by reducing the expression of immunosuppressive cytokines, thereby enhancing the efficacy of cancer immunotherapy in Osimertinib-resistant lung cancer cells with EGFR mutations.

**Experimental Design:**

1. **Cell Culture:** Culture Osimertinib-resistant lung cancer cells (H1975) with EGFR mutations in a controlled environment.
2. **NK-EV Preparation:** Isolate and characterize NK-EVs from IL-15-stimulated natural killer cells using established protocols.
3. **Treatment Groups:** Divide the cultured cells into four groups:
	* Control (untreated)
	* NK-EVs only
	* Carboplatin only
	* Combination of NK-EVs and carboplatin
4. **Cytokine Analysis:** Measure the expression of immunosuppressive cytokines (e.g., TGF-β, IL-10, PD-L1) in the cell culture supernatant using ELISA or multiplex assays.
5. **Flow Cytometry:** Analyze the expression of PD-L1/PD-1 on the surface of treated cells using flow cytometry.
6. **Western Blotting:** Perform Western blotting to analyze the expression of PD-L1/PD-1 proteins in the cells.
7. **Cell Viability and Apoptosis Assays:** Evaluate cell viability and apoptosis using MTT or Annexin V assays.

**Expected Outcomes:**

* Reduced expression of immunosuppressive cytokines in the combination treatment group
* Decreased PD-L1/PD-1 expression on the surface of treated cells
* Enhanced apoptosis and reduced cell viability in the combination treatment group

**Equipment and Resources:**

* Cell culture facilities
* Flow cytometer
* Western blotting apparatus
* ELISA or multiplex assay equipment
* MTT or Annexin V assay kits
* NK-EV isolation and characterization equipment (e.g., ultracentrifuge, nanoparticle tracking analysis)

**Timeline:** 12-16 weeks

**Budget:** Moderate (dependent on equipment and reagent costs)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Inability of NK-EVs and Carboplatin to Modulate the Tumor Microenvironment in Osimertinib-Resistant Lung Cancer Cells with EGFR Mutations

**Objective:** To demonstrate that the combination of NK-EVs and carboplatin does not modulate the tumor microenvironment by reducing the expression of immunosuppressive cytokines in Osimertinib-resistant lung cancer cells with EGFR mutations.

**Experimental Design:**

1. **Cell Culture:** Culture Osimertinib-resistant lung cancer cells (H1975) with EGFR mutations in a controlled environment.
2. **NK-EV Preparation:** Isolate and characterize NK-EVs from IL-15-stimulated natural killer cells using established protocols.
3. **Treatment Groups:** Divide the cultured cells into two groups:
	* Control (untreated)
	* Combination of NK-EVs and carboplatin
4. **Cytokine Analysis:** Measure the expression of immunosuppressive cytokines (e.g., TGF-β, IL-10, PD-L1) in the cell culture supernatant using ELISA or multiplex assays.
5. **Flow Cytometry:** Analyze the expression of PD-L1/PD-1 on the surface of treated cells using flow cytometry.

**Expected Outcomes:**

* No significant difference in immunosuppressive cytokine expression between the control and combination treatment groups
* No significant difference in PD-L1/PD-1 expression on the surface of treated cells

**Equipment and Resources:**

* Cell culture facilities
* Flow cytometer
* ELISA or multiplex assay equipment
* NK-EV isolation and characterization equipment (e.g., ultracentrifuge, nanoparticle tracking analysis)

**Timeline:** 8-12 weeks

**Budget:** Moderate (dependent on equipment and reagent costs)

By designing an experiment to disprove the hypothesis, we can attempt to falsify the claim and provide evidence that the combination of NK-EVs and carboplatin does not modulate the tumor microenvironment in Osimertinib-resistant lung cancer cells with EGFR mutations. If the results of this experiment contradict the hypothesis, it would suggest that the original hypothesis may not be true.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Cell Culture**

1. Obtain Osimertinib-resistant lung cancer cells (H1975) with EGFR mutations from a reliable source (e.g., ATCC).
2. Thaw the cells according to the supplier's instructions and resuspend them in complete growth medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin).
3. Seed the cells in 75-cm² flasks at a density of 1 x 10⁶ cells/mL.
4. Incubate the cells at 37°C, 5% CO₂, and 95% humidity for 24-48 hours to allow for cell attachment and recovery.
5. Replace the growth medium with fresh medium every 2-3 days to maintain optimal cell growth.

**Protocol 2: NK-EV Preparation**

1. Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors using Ficoll-Paque density gradient centrifugation.
2. Stimulate the PBMCs with 10 ng/mL IL-15 for 24 hours to induce NK cell activation.
3. Collect the supernatant and centrifuge it at 300 x g for 10 minutes to remove cells and debris.
4. Filter the supernatant through a 0.22-μm filter to remove any remaining cells and debris.
5. Concentrate the supernatant using ultracentrifugation (e.g., 100,000 x g for 2 hours) to obtain NK-EVs.
6. Characterize the NK-EVs using nanoparticle tracking analysis (NTA) to determine their size, concentration, and purity.

**Protocol 3: Treatment Groups**

1. Divide the cultured cells into four groups:
	* Control (untreated)
	* NK-EVs only (10 μg/mL)
	* Carboplatin only (10 μM)
	* Combination of NK-EVs (10 μg/mL) and carboplatin (10 μM)
2. Treat the cells with the respective agents for 48 hours.

**Protocol 4: Cytokine Analysis**

1. Collect the cell culture supernatant and centrifuge it at 300 x g for 10 minutes to remove cells and debris.
2. Measure the expression of immunosuppressive cytokines (e.g., TGF-β, IL-10, PD-L1) using ELISA or multiplex assays according to the manufacturer's instructions.

**Protocol 5: Flow Cytometry**

1. Harvest the treated cells and wash them with PBS.
2. Stain the cells with fluorochrome-conjugated antibodies against PD-L1 and PD-1 according to the manufacturer's instructions.
3. Analyze the stained cells using a flow cytometer (e.g., BD FACSCanto II) to determine the expression of PD-L1 and PD-1 on the cell surface.

**Protocol 6: Western Blotting**

1. Harvest the treated cells and lyse them using RIPA buffer.
2. Separate the proteins using SDS-PAGE and transfer them to a PVDF membrane.
3. Probe the membrane with antibodies against PD-L1 and PD-1 according to the manufacturer's instructions.
4. Detect the proteins using chemiluminescence or fluorescence.

**Protocol 7: Cell Viability and Apoptosis Assays**

1. Harvest the treated cells and wash them with PBS.
2. Perform MTT or Annexin V assays according to the manufacturer's instructions to evaluate cell viability and apoptosis.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Culture**

1. Obtain Osimertinib-resistant lung cancer cells (H1975) with EGFR mutations from a reliable source (e.g., ATCC).
2. Thaw the cells according to the supplier's instructions and resuspend them in complete growth medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin).
3. Seed the cells in 75-cm² flasks at a density of 1 x 10⁶ cells/mL.
4. Incubate the cells at 37°C, 5% CO₂, and 95% humidity for 24-48 hours to allow for cell attachment and recovery.
5. Replace the growth medium with fresh medium every 2-3 days to maintain optimal cell growth.

**Protocol 2: NK-EV Preparation**

1. Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors using Ficoll-Paque density gradient centrifugation.
2. Stimulate the PBMCs with 10 ng/mL IL-15 for 24 hours to induce NK cell activation.
3. Collect the supernatant and centrifuge it at 300 x g for 10 minutes to remove cells and debris.
4. Filter the supernatant through a 0.22-μm filter to remove any remaining cells and debris.
5. Concentrate the supernatant using ultracentrifugation (e.g., 100,000 x g for 2 hours) to obtain NK-EVs.
6. Characterize the NK-EVs using nanoparticle tracking analysis (NTA) to determine their size, concentration, and purity.

**Protocol 3: Treatment Groups**

1. Divide the cultured cells into two groups:
	* Control (untreated)
	* Combination of NK-EVs (10 μg/mL) and carboplatin (10 μM)
2. Treat the cells with the respective agents for 48 hours.

**Protocol 4: Cytokine Analysis**

1. Collect the cell culture supernatant and centrifuge it at 300 x g for 10 minutes to remove cells and debris.
2. Measure the expression of immunosuppressive cytokines (e.g., TGF-β, IL-10, PD-L1) using ELISA or multiplex assays according to the manufacturer's instructions.

**Protocol 5: Flow Cytometry**

1. Harvest the treated cells and wash them with PBS.
2. Stain the cells with fluorochrome-conjugated antibodies against PD-L1 and PD-1 according to the manufacturer's instructions.
3. Analyze the stained cells using a flow cytometer (e.g., BD FACSCanto II) to determine the expression of PD-L1 and PD-1 on the cell surface.

Note: The protocols are designed to be specific, detailed, and replicable. The equipment and resources required are listed in the original experimental plan. The timeline and budget for each experiment are also provided in the original plan.","```
   NK-EVs (μg/mL)  Carboplatin (μM)  Cell Density (cells/mL)  Outcome
0             5.0             5.0               500000.0  Inhibited
1            10.0             5.0               750000.0  Inhibited
2             5.0            10.0               500000.0  Inhibited
3            10.0            10.0               750000.0  Inhibited
4             2.5             2.5               250000.0  No Effect
5             7.5             7.5               500000.0  Inhibited
6             5.0             2.5               500000.0  Inhibited
7            10.0             7.5               750000.0  Inhibited
8             2.5            10.0               250000.0  No Effect
9             7.5             5.0               500000.0  Inhibited
10           10.0             2.5               750000.0  Inhibited
11            5.0             7.5               500000.0  Inhibited
12            2.5             5.0               250000.0  No Effect
13           10.0            10.0               750000.0  Inhibited
14            5.0             5.0               500000.0  Inhibited
15            7.5            10.0               500000.0  Inhibited
16            2.5             7.5               250000.0  No Effect
17           10.0             5.0               750000.0  Inhibited
18            5.0            10.0               500000.0  Inhibited
19            7.5             2.5               500000.0  Inhibited
20           10.0             7.5               750000.0  Inhibited
21            2.5            10.0               250000.0  No Effect
22            5.0             5.0               500000.0  Inhibited
23            7.5             5.0               500000.0  Inhibited
24            10.0             2.5               750000.0  Inhibited
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/61c30ee3a8d7b1bb50aaff60c22d96ec87082d6c.summary'],Can the combination of Quisinostat and SynNotch CAR T cells enhance the radiosensitization of glioblastoma cells by increasing the expression of CNS-specific antigens?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Can the combination of Quisinostat and SynNotch CAR T cells enhance the radiosensitization of glioblastoma cells by increasing the expression of CNS-specific antigens?""

**Experimental Approach:**

**Objective:** To investigate whether the combination of Quisinostat and SynNotch CAR T cells can enhance the radiosensitization of glioblastoma cells by increasing the expression of CNS-specific antigens.

**Experimental Design:**

1. **Cell Culture:** Establish glioblastoma cell lines (e.g., U87, U251) and maintain them in a controlled environment.
2. **Quisinostat Treatment:** Treat glioblastoma cells with Quisinostat at varying concentrations (e.g., 0.1, 1, 10 μM) for 24-48 hours to assess its effect on cell viability and CNS-specific antigen expression.
3. **SynNotch CAR T Cell Generation:** Generate SynNotch CAR T cells specific to CNS-specific antigens (e.g., EGFRvIII, IL13Rα2) using established protocols.
4. **Combination Treatment:** Co-culture glioblastoma cells with SynNotch CAR T cells and treat with Quisinostat (at optimal concentration) for 24-48 hours.
5. **Radiation Therapy:** Expose glioblastoma cells to radiation therapy (e.g., 2, 4, 6 Gy) with or without Quisinostat and SynNotch CAR T cells.
6. **Cell Viability Assays:** Perform cell viability assays (e.g., MTT, Annexin V/PI staining) to assess the effect of Quisinostat, SynNotch CAR T cells, and radiation therapy on glioblastoma cell viability.
7. **CNS-Specific Antigen Expression:** Analyze the expression of CNS-specific antigens (e.g., EGFRvIII, IL13Rα2) using Western blot, qRT-PCR, or flow cytometry.
8. **Statistical Analysis:** Compare the results using one-way ANOVA and post-hoc tests to determine the significance of the combination treatment on glioblastoma cell viability and CNS-specific antigen expression.

**Experimental Controls:**

* Untreated glioblastoma cells (control)
* Quisinostat-treated glioblastoma cells
* SynNotch CAR T cell-treated glioblastoma cells
* Radiation therapy-treated glioblastoma cells
* Combination treatment (Quisinostat + SynNotch CAR T cells + radiation therapy)

**Equipment and Reagents:**

* Glioblastoma cell lines (U87, U251)
* Quisinostat
* SynNotch CAR T cells
* Radiation therapy equipment
* Cell viability assays (MTT, Annexin V/PI staining)
* Western blot analysis equipment
* qRT-PCR equipment
* Flow cytometry equipment
* Antibodies for CNS-specific antigens (e.g., EGFRvIII, IL13Rα2)

**Timeline:**

* Cell culture and Quisinostat treatment: 1 week
* SynNotch CAR T cell generation: 2 weeks
* Combination treatment and radiation therapy: 2 weeks
* Cell viability assays and CNS-specific antigen expression analysis: 2 weeks
* Data analysis and interpretation: 2 weeks

**Budget:**

* Cell lines and reagents: $5,000
* Quisinostat: $2,000
* SynNotch CAR T cell generation: $10,000
* Radiation therapy equipment rental: $5,000
* Cell viability assays and Western blot analysis: $3,000
* qRT-PCR and flow cytometry: $2,000
* Personnel and miscellaneous: $10,000

Total budget: $37,000

**To disprove the hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: ""The combination of Quisinostat and SynNotch CAR T cells does not enhance the radiosensitization of glioblastoma cells by increasing the expression of CNS-specific antigens.""

In this experiment, we would:

1. Treat glioblastoma cells with Quisinostat and SynNotch CAR T cells, but without radiation therapy.
2. Analyze the expression of CNS-specific antigens and cell viability using the same methods as above.
3. Compare the results to the control group (untreated glioblastoma cells) and the radiation therapy-only group.

If the results show that the combination treatment does not increase the expression of CNS-specific antigens or enhance radiosensitization, it would disprove the original hypothesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Maintenance**

1.1. Obtain glioblastoma cell lines (U87, U251) from a reputable source (e.g., ATCC).

1.2. Thaw the cells according to the supplier's instructions and resuspend them in complete growth medium (e.g., DMEM + 10% FBS + 1% penicillin-streptomycin).

1.3. Seed the cells in a 75-cm² tissue culture flask at a density of 1 x 10⁵ cells/mL.

1.4. Incubate the cells at 37°C, 5% CO₂, and 95% humidity.

1.5. Passage the cells every 3-4 days to maintain a healthy and exponentially growing culture.

**Protocol 2: Quisinostat Treatment**

2.1. Prepare a stock solution of Quisinostat (10 mM) in DMSO.

2.2. Dilute the Quisinostat stock solution in complete growth medium to achieve the desired concentrations (0.1, 1, 10 μM).

2.3. Add the Quisinostat-containing medium to the glioblastoma cells and incubate for 24-48 hours.

2.4. Use a control group with DMSO-only treatment to account for any solvent effects.

**Protocol 3: SynNotch CAR T Cell Generation**

3.1. Follow established protocols for generating SynNotch CAR T cells specific to CNS-specific antigens (e.g., EGFRvIII, IL13Rα2).

3.2. Use a lentiviral vector to transduce the CAR construct into T cells.

3.3. Expand the transduced T cells in the presence of IL-2 and anti-CD3/CD28 beads.

3.4. Verify the expression of the CAR construct using flow cytometry and functional assays.

**Protocol 4: Combination Treatment and Radiation Therapy**

4.1. Co-culture glioblastoma cells with SynNotch CAR T cells at a 1:1 ratio in complete growth medium.

4.2. Add Quisinostat (at the optimal concentration determined in Protocol 2) to the co-culture and incubate for 24-48 hours.

4.3. Expose the co-culture to radiation therapy (2, 4, 6 Gy) using a radiation therapy equipment.

4.4. Use a control group without Quisinostat and/or SynNotch CAR T cells to assess the individual effects of each treatment.

**Protocol 5: Cell Viability Assays**

5.1. Perform MTT assays according to the manufacturer's instructions.

5.2. Add 10 μL of MTT reagent to each well and incubate for 2-4 hours.

5.3. Measure the absorbance at 570 nm using a microplate reader.

5.4. Perform Annexin V/PI staining according to the manufacturer's instructions.

5.5. Analyze the stained cells using flow cytometry to determine the percentage of apoptotic and dead cells.

**Protocol 6: CNS-Specific Antigen Expression Analysis**

6.1. Harvest the cells and extract total protein using a lysis buffer (e.g., RIPA).

6.2. Perform Western blot analysis using antibodies specific to CNS-specific antigens (e.g., EGFRvIII, IL13Rα2).

6.3. Use qRT-PCR to analyze the mRNA expression of CNS-specific antigens.

6.4. Perform flow cytometry to analyze the surface expression of CNS-specific antigens.

**Protocol 7: Statistical Analysis**

7.1. Compare the results using one-way ANOVA and post-hoc tests to determine the significance of the combination treatment on glioblastoma cell viability and CNS-specific antigen expression.

7.2. Use a significance level of 0.05 and correct for multiple comparisons using the Bonferroni method.

**Protocol 8: Experimental Controls**

8.1. Use untreated glioblastoma cells as a control group.

8.2. Use Quisinostat-treated glioblastoma cells as a control group.

8.3. Use SynNotch CAR T cell-treated glioblastoma cells as a control group.

8.4. Use radiation therapy-treated glioblastoma cells as a control group.

8.5. Use the combination treatment (Quisinostat + SynNotch CAR T cells + radiation therapy) as the experimental group.

By following these detailed protocols, the experiment can be replicated and the results can be accurately compared to test the hypothesis.","```
   U87 Cells  U251 Cells  Quisinostat (μM)  SynNotch CAR T Cells  Radiation (Gy)  Outcome
0       1e+05       1e+05             0.1               1e+05           2.0  0.456
1       1e+05       1e+05             1.0               1e+05           4.0  0.289
2       1e+05       1e+05            10.0               1e+05           6.0  0.123
3       5e+04       5e+04             0.1               5e+04           2.0  0.512
4       5e+04       5e+04             1.0               5e+04           4.0  0.356
5       5e+04       5e+04            10.0               5e+04           6.0  0.219
6       2e+05       2e+05             0.1               2e+05           2.0  0.398
7       2e+05       2e+05             1.0               2e+05           4.0  0.245
8       2e+05       2e+05            10.0               2e+05           6.0  0.156
9       1e+05       1e+05             0.1               5e+04           2.0  0.473
10      1e+05       1e+05             1.0               5e+04           4.0  0.312
11      1e+05       1e+05            10.0               5e+04           6.0  0.189
12      5e+04       5e+04             0.1               2e+05           2.0  0.542
13      5e+04       5e+04             1.0               2e+05           4.0  0.381
14      5e+04       5e+04            10.0               2e+05           6.0  0.231
15      1e+05       1e+05             0.1               1e+05           0.0  0.501
16      1e+05       1e+05             1.0               1e+05           0.0  0.341
17      1e+05       1e+05            10.0               1e+05           0.0  0.209
18      5e+04       5e+04             0.1               5e+04           0.0  0.561
19      5e+04       5e+04             1.0               5e+04           0.0  0.401
20      5e+04       5e+04            10.0               5e+04           0.0  0.251
21      2e+05       2e+05             0.1               2e+05           0.0  0.521
22      2e+05       2e+05             1.0               2e+05           0.0  0.361
23      2e+05       2e+05            10.0               2e+05           0.0  0.221
24      1e+05       1e+05             0.0               1e+05           2.0  0.581
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/01979d36908449d8347c453f70a96afc4259ecc2.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/121ce884708dcbaa9d1ad378dbcb37521c1c420d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/03152dedf6db0d171dd3e22acf598f87bc3d8578.summary']",Can the combination of TriMAb and RIG-I ligands enhance the antiviral response of T cells against HBV-infected cells by promoting a sustained and coordinated activation of both T cells and antigen-presenting cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Can the combination of TriMAb and RIG-I ligands enhance the antiviral response of T cells against HBV-infected cells by promoting a sustained and coordinated activation of both T cells and antigen-presenting cells?

**Experimental Design:**

**Objective:** To investigate the effect of combining TriMAb and RIG-I ligands on the antiviral response of T cells against HBV-infected cells.

**Experimental Approach:**

1. **Cell Preparation:**
	* Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors.
	* Infect HepG2-NTCP cells with HBV.
	* Prepare TriMAb and RIG-I ligands according to the manufacturer's instructions.
2. **Co-Culture Experiment:**
	* Set up a co-culture system with TriMAb-treated PBMCs and HBV-infected HepG2-NTCP cells in the presence or absence of RIG-I ligands.
	* Use a 96-well plate with a 1:1 ratio of PBMCs to HepG2-NTCP cells.
	* Add TriMAb and RIG-I ligands to the co-culture system at the following concentrations:
		+ TriMAb: 1 μg/mL
		+ RIG-I ligands: 10 μg/mL
	* Incubate the co-culture system for 14 days at 37°C, 5% CO2.
3. **Cell Viability and Cytokine Release:**
	* Monitor cell viability using the xCELLigence RTCA system.
	* Measure cytokine release (e.g., IFN-γ, TNF-α, IL-2) using ELISA kits.
4. **Viral DNA Quantification:**
	* Quantify HBV DNA using qPCR.
5. **Flow Cytometry:**
	* Analyze the expression of activation markers (e.g., CD69, CD25) and cytokine production (e.g., IFN-γ, TNF-α) on T cells using flow cytometry.
6. **Comparison Groups:**
	* Include the following comparison groups:
		+ TriMAb alone
		+ RIG-I ligands alone
		+ No treatment (control)
		+ S-CAR T cells (as a positive control)

**Expected Outcomes:**

* Enhanced antiviral response of T cells against HBV-infected cells in the presence of both TriMAb and RIG-I ligands.
* Increased cytokine release and T cell activation in the combination group compared to the single-treatment groups.
* Reduced HBV DNA levels in the combination group compared to the single-treatment groups.

**To disprove the hypothesis:**

* If the combination of TriMAb and RIG-I ligands does not enhance the antiviral response of T cells against HBV-infected cells, or if the combination group does not show significant differences compared to the single-treatment groups, the hypothesis would be disproven.

**Resources and Equipment:**

* xCELLigence RTCA system
* ELISA kits for cytokine quantification
* qPCR machine for viral DNA quantification
* Flow cytometer
* Antibodies against CD69, CD25, IFN-γ, and TNF-α
* TriMAb and RIG-I ligands
* HepG2-NTCP cells
* PBMCs from healthy donors
* HBV virus

**Timeline:**

* Cell preparation and co-culture setup: 2 weeks
* Co-culture experiment: 14 days
* Data analysis and interpretation: 4 weeks

**Budget:**

* Unlimited budget for reagents, equipment, and personnel.

This experimental design aims to investigate the effect of combining TriMAb and RIG-I ligands on the antiviral response of T cells against HBV-infected cells. By using a co-culture system and measuring cell viability, cytokine release, and viral DNA levels, we can determine whether the combination of TriMAb and RIG-I ligands enhances the antiviral response of T cells.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Preparation**

1.1. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Donors:

* Obtain blood samples from healthy donors and collect them in EDTA-coated tubes.
* Perform density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) to separate PBMCs from other blood components.
* Collect the PBMC layer and wash it twice with PBS (phosphate-buffered saline) at 300 x g for 10 minutes.
* Resuspend the PBMCs in RPMI 1640 medium (Gibco) supplemented with 10% FBS (fetal bovine serum) and 1% penicillin-streptomycin.
* Count the cells using a hemocytometer and adjust the concentration to 1 x 10^6 cells/mL.

1.2. Infection of HepG2-NTCP Cells with HBV:

* Obtain HepG2-NTCP cells (a human hepatocellular carcinoma cell line) and culture them in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FBS and 1% penicillin-streptomycin.
* Infect the HepG2-NTCP cells with HBV (hepatitis B virus) at a multiplicity of infection (MOI) of 10.
* Incubate the infected cells at 37°C, 5% CO2 for 3 days to allow for viral replication.

1.3. Preparation of TriMAb and RIG-I Ligands:

* Obtain TriMAb (a trivalent monoclonal antibody) and RIG-I ligands (retinoic acid-inducible gene I ligands) from the manufacturer.
* Follow the manufacturer's instructions to prepare the TriMAb and RIG-I ligands according to the recommended concentrations (1 μg/mL for TriMAb and 10 μg/mL for RIG-I ligands).

**Protocol 2: Co-Culture Experiment**

2.1. Co-Culture Setup:

* Prepare a 96-well plate by adding 100 μL of RPMI 1640 medium to each well.
* Add 1 x 10^5 PBMCs (prepared in Protocol 1.1) to each well.
* Add 1 x 10^5 HBV-infected HepG2-NTCP cells (prepared in Protocol 1.2) to each well.
* Add TriMAb and RIG-I ligands to the co-culture system at the following concentrations:
	+ TriMAb: 1 μg/mL
	+ RIG-I ligands: 10 μg/mL
* Incubate the co-culture system at 37°C, 5% CO2 for 14 days.

2.2. Cell Viability Monitoring:

* Use the xCELLigence RTCA system to monitor cell viability every 24 hours.
* Record the cell index values and calculate the cell viability percentage using the xCELLigence software.

**Protocol 3: Cytokine Release and Viral DNA Quantification**

3.1. Cytokine Release Measurement:

* Collect the supernatant from the co-culture system on days 7 and 14.
* Use ELISA kits to measure the levels of IFN-γ, TNF-α, and IL-2 in the supernatant.
* Follow the manufacturer's instructions for the ELISA kits.

3.2. Viral DNA Quantification:

* Collect the cells from the co-culture system on days 7 and 14.
* Extract the DNA from the cells using a DNA extraction kit (e.g., QIAamp DNA Mini Kit, Qiagen).
* Use qPCR to quantify the HBV DNA levels.
* Follow the manufacturer's instructions for the qPCR machine and primers.

**Protocol 4: Flow Cytometry**

4.1. Cell Staining:

* Collect the cells from the co-culture system on days 7 and 14.
* Stain the cells with antibodies against CD69, CD25, IFN-γ, and TNF-α using a flow cytometry staining protocol.
* Use a flow cytometer to analyze the expression of activation markers and cytokine production on T cells.

**Protocol 5: Data Analysis and Interpretation**

5.1. Data Collection:

* Collect the data from the xCELLigence RTCA system, ELISA kits, qPCR machine, and flow cytometer.
* Record the data in a spreadsheet or database.

5.2. Data Analysis:

* Analyze the data using statistical software (e.g., GraphPad Prism, R) to compare the treatment groups.
* Calculate the mean and standard deviation for each group.
* Perform statistical tests (e.g., t-test, ANOVA) to determine significant differences between the groups.

5.3. Data Interpretation:

* Interpret the results in the context of the hypothesis.
* Determine whether the combination of TriMAb and RIG-I ligands enhances the antiviral response of T cells against HBV-infected cells.
* Compare the results to the expected outcomes and discuss the implications of the findings.

Note: The protocols above assume that the necessary equipment, reagents, and personnel are available. The protocols should be followed carefully to ensure reproducibility and accuracy of the results.","```
   PBMCs  HepG2-NTCP  TriMAb  RIG-I Ligands  Cell Viability  IFN-γ  TNF-α  IL-2  HBV DNA  CD69  CD25  IFN-γ+  TNF-α+
0   1e+05       1e+05     1.0          10.0         80.12  200.0  150.0  50.0  1e+04  20.0  15.0    30.0    20.0
1   5e+04       5e+04     0.5           5.0         70.50  180.0  120.0  40.0  8e+03  18.0  12.0    25.0    18.0
2   1e+05       2e+05     1.5          15.0         85.00  220.0  160.0  60.0  1.2e+04  22.0  18.0    35.0    22.0
3   2e+05       1e+05     2.0          20.0         90.00  240.0  180.0  70.0  1.5e+04  25.0  20.0    40.0    25.0
4   5e+04       1e+05     0.8           8.0         75.00  190.0  130.0  45.0  9e+03  19.0  14.0    28.0    20.0
5   1e+05       5e+04     1.2          12.0         82.00  210.0  150.0  55.0  1.1e+04  21.0  16.0    32.0    21.0
6   2e+05       2e+05     2.5          25.0         92.00  250.0  190.0  75.0  1.8e+04  28.0  22.0    45.0    28.0
7   5e+04       2e+05     0.9           9.0         78.00  200.0  140.0  50.0  1e+04  20.0  15.0    30.0    20.0
8   1e+05       1e+05     1.0          10.0         80.00  200.0  150.0  50.0  1e+04  20.0  15.0    30.0    20.0
9   2e+05       5e+04     2.2          22.0         88.00  230.0  170.0  65.0  1.4e+04  24.0  19.0    38.0    24.0
10  5e+04       1e+05     0.6           6.0         72.00  170.0  110.0  40.0  7e+03  17.0  13.0    25.0    18.0
11  1e+05       2e+05     1.8          18.0         86.00  220.0  160.0  60.0  1.3e+04  23.0  18.0    36.0    23.0
12  2e+05       1e+05     2.8          28.0         94.00  260.0  200.0  80.0  2e+04  30.0  24.0    50.0    30.0
13  5e+04       5e+04     0.7           7.0         74.00  190.0  130.0  45.0  8e+03  19.0  14.0    28.0    20.0
14  1e+05       1e+05     1.4          14.0         84.00  210.0  150.0  55.0  1.2e+04  22.0  17.0    34.0    22.0
15  2e+05       2e+05     3.0          30.0         96.00  270.0  210.0  85.0  2.2e+04  32.0  26.0    55.0    32.0
16  5e+04       1e+05     0.9           9.0         79.00  200.0  140.0  50.0  1e+04  20.0  15.0    30.0    20.0
17  1e+05       5e+04     1.6          16.0         83.00  220.0  160.0  60.0  1.4e+04  24.0  19.0    38.0    24.0
18  2e+05       1e+05     3.2          32.0         98.00  280.0  220.0  90.0  2.5e+04  35.0  28.0    60.0    35.0
19  5e+04       2e+05     0.8           8.0         76.00  190.0  130.0  45.0  9e+03  19.0  14.0    28.0    20.0
20  1e+05       1e+05     1.2          12.0         82.00  210.0  150.0  55.0  1.1e+04  21.0  16.0    32.0    21.0
21  2e+05       5e+04     3.5          35.0        100.00  290.0  230.0  95.0  2.8e+04  38.0  30.0    65.0    38.0
22  5e+04       1e+05     0.5           5.0         71.00  170.0  110.0  40.0  7e+03  17.0  13.0    25.0    18.0
23  1e+05       2e+05     1.9          19.0         87.00  230.0  170.0  65.0  1.5e+04  25.0  20.0    40.0    25.0
24  2e+05       1e+05     3.8          38.0        102.00  300.0  240.0 100.0  3e+04  40.0  32.0    70.0    40.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7111a27c197ebe526e5a8c0f4ff867f278faf847.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e0f991cff76d559a3996fd01f2c56e4c2167b946.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6f185bc943b624e54ee6d4afb07bc6afaf811126.summary']",Can the combination of anti-CD19 CAR-T cells and CD62L+ NKT cells enhance the persistence and antitumor activity of CAR-T cells in the central nervous system and improve long-term remission in pediatric B-ALL patients with extramedullary relapse?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the combination of anti-CD19 CAR-T cells and CD62L+ NKT cells can enhance the persistence and antitumor activity of CAR-T cells in the central nervous system and improve long-term remission in pediatric B-ALL patients with extramedullary relapse, I propose the following experimental plan:

**Experiment:** ""Combination Therapy with Anti-CD19 CAR-T Cells and CD62L+ NKT Cells in Pediatric B-ALL with Extramedullary Relapse""

**Objective:** To determine if the combination of anti-CD19 CAR-T cells and CD62L+ NKT cells can improve the persistence and antitumor activity of CAR-T cells in the central nervous system and enhance long-term remission in pediatric B-ALL patients with extramedullary relapse.

**Design:**

1. Patient enrollment: Enroll 20 pediatric B-ALL patients with extramedullary relapse in the study.
2. Treatment arms:
	* Arm 1: Anti-CD19 CAR-T cells alone (n=10)
	* Arm 2: Anti-CD19 CAR-T cells + CD62L+ NKT cells (n=10)
3. CD62L+ NKT cell isolation and expansion: Isolate CD62L+ NKT cells from peripheral blood using flow cytometry and cell sorting. Expand the cells ex vivo using IL-2 and TCR-stimulation.
4. CAR-T cell preparation: Prepare anti-CD19 CAR-T cells using standard protocols.
5. Treatment: Infuse patients with either anti-CD19 CAR-T cells alone (Arm 1) or anti-CD19 CAR-T cells + CD62L+ NKT cells (Arm 2).
6. CSF sampling: Collect CSF samples from patients at baseline, 1 week, 2 weeks, and 4 weeks post-infusion.
7. Flow cytometry analysis: Analyze CSF samples using flow cytometry to detect CAR-T cells, CD62L+ NKT cells, and leukemic cells.
8. Real-time qPCR: Use real-time qPCR to quantify the CAR gene in CSF samples.
9. Outcome measurement: Monitor patients for disease response, event-free survival, and overall survival.

**Primary endpoint:** Compare the persistence of CAR-T cells in the CSF and the antitumor activity in the CNS between the two treatment arms.

**Secondary endpoints:**

* Compare the event-free survival and overall survival between the two treatment arms.
* Correlate the presence of CD62L+ NKT cells in the CSF with the persistence of CAR-T cells and antitumor activity.
* Evaluate the safety and toxicity of the combination therapy.

**Equipment and resources:**

* Flow cytometer
* Cell sorter
* Cell culture facilities
* Real-time qPCR machine
* CSF collection tubes
* Anti-CD19 CAR-T cells
* CD62L antibody
* IL-2
* TCR-stimulation reagents

**Timeline:** The study is expected to take 2 years to complete, with patient enrollment and treatment taking place over the first 6 months, and follow-up and data analysis taking place over the remaining 18 months.

**Budget:** The estimated budget for this study is $500,000, which includes costs for patient enrollment, treatment, and follow-up, as well as equipment and personnel costs.

To disprove the hypothesis, we can design an experiment that tests the opposite hypothesis: ""The combination of anti-CD19 CAR-T cells and CD62L+ NKT cells does not enhance the persistence and antitumor activity of CAR-T cells in the central nervous system and does not improve long-term remission in pediatric B-ALL patients with extramedullary relapse.""

In this experiment, we would use the same design and methods as above, but with a different primary endpoint: ""The combination of anti-CD19 CAR-T cells and CD62L+ NKT cells does not improve the persistence of CAR-T cells in the CSF or the antitumor activity in the CNS compared to anti-CD19 CAR-T cells alone."" If the results of this experiment show no significant difference in the persistence of CAR-T cells or antitumor activity between the two treatment arms, it would suggest that the combination of anti-CD19 CAR-T cells and CD62L+ NKT cells does not enhance the persistence and antitumor activity of CAR-T cells in the central nervous system.",85,"Here are the detailed, step-by-step protocols for the experiment ""Combination Therapy with Anti-CD19 CAR-T Cells and CD62L+ NKT Cells in Pediatric B-ALL with Extramedullary Relapse"":

**Protocol 1: Patient Enrollment and Treatment Arm Assignment**

1.1. Identify and recruit 20 pediatric B-ALL patients with extramedullary relapse who meet the inclusion criteria.

1.2. Obtain informed consent from patients or their legal guardians.

1.3. Randomly assign patients to one of two treatment arms using a computer-generated randomization protocol:
	* Arm 1: Anti-CD19 CAR-T cells alone (n=10)
	* Arm 2: Anti-CD19 CAR-T cells + CD62L+ NKT cells (n=10)

**Protocol 2: CD62L+ NKT Cell Isolation and Expansion**

2.1. Collect 20 mL of peripheral blood from each patient in Arm 2 using a sterile syringe and needle.

2.2. Perform density gradient centrifugation to separate peripheral blood mononuclear cells (PBMCs) from whole blood.

2.3. Stain PBMCs with CD62L antibody and perform flow cytometry to identify and sort CD62L+ NKT cells.

2.4. Expand CD62L+ NKT cells ex vivo using IL-2 (100 IU/mL) and TCR-stimulation reagents (e.g., anti-CD3/CD28 beads) in a 37°C, 5% CO2 incubator.

2.5. Monitor cell growth and viability daily, and adjust culture conditions as necessary.

2.6. After 7-10 days, harvest expanded CD62L+ NKT cells and wash them twice with PBS.

**Protocol 3: CAR-T Cell Preparation**

3.1. Prepare anti-CD19 CAR-T cells using standard protocols, including:
	* Isolation of T cells from patient peripheral blood or apheresis product
	* Transduction with anti-CD19 CAR lentivirus
	* Expansion and activation of CAR-T cells using IL-2 and TCR-stimulation reagents

3.2. Verify CAR-T cell identity and function using flow cytometry and functional assays (e.g., cytotoxicity assays).

**Protocol 4: Treatment Infusion**

4.1. Infuse patients in Arm 1 with anti-CD19 CAR-T cells alone (dose: 1x10^6 cells/kg).

4.2. Infuse patients in Arm 2 with anti-CD19 CAR-T cells (dose: 1x10^6 cells/kg) and CD62L+ NKT cells (dose: 1x10^5 cells/kg).

4.3. Monitor patients for adverse reactions and manage toxicities according to established protocols.

**Protocol 5: CSF Sampling and Analysis**

5.1. Collect CSF samples from patients at baseline, 1 week, 2 weeks, and 4 weeks post-infusion using a sterile lumbar puncture procedure.

5.2. Perform flow cytometry analysis on CSF samples to detect:
	* CAR-T cells (using anti-CD19 and anti-CD3 antibodies)
	* CD62L+ NKT cells (using anti-CD62L and anti-CD3 antibodies)
	* Leukemic cells (using anti-CD19 and anti-CD45 antibodies)

5.3. Perform real-time qPCR on CSF samples to quantify the CAR gene.

**Protocol 6: Outcome Measurement and Follow-up**

6.1. Monitor patients for disease response, event-free survival, and overall survival.

6.2. Perform regular follow-up visits and assessments, including:
	* Physical examinations
	* Laboratory tests (e.g., complete blood counts, liver function tests)
	* Imaging studies (e.g., MRI, CT scans)

6.3. Record and analyze data on adverse events, toxicities, and treatment-related complications.

**Protocol 7: Data Analysis**

7.1. Compare the persistence of CAR-T cells in the CSF and the antitumor activity in the CNS between the two treatment arms using statistical software (e.g., R, Prism).

7.2. Analyze secondary endpoints, including:
	* Event-free survival and overall survival between the two treatment arms
	* Correlation between CD62L+ NKT cells in the CSF and CAR-T cell persistence and antitumor activity
	* Safety and toxicity of the combination therapy

7.3. Present results in a clear and concise manner, including tables, figures, and graphs.

These detailed protocols should provide a clear roadmap for executing the experiment and collecting high-quality data to test the hypothesis.","```
   Anti-CD19 CAR-T cells  CD62L+ NKT cells  Outcome
0                0.8e+06          0.0e+00  Responded
1                1.2e+06          0.5e+05  Responded
2                1.0e+06          1.0e+05  Responded
3                0.9e+06          0.0e+00  Non-Responded
4                1.1e+06          0.8e+05  Responded
5                1.0e+06          1.2e+05  Responded
6                0.7e+06          0.0e+00  Non-Responded
7                1.3e+06          1.0e+05  Responded
8                1.0e+06          0.9e+05  Responded
9                0.6e+06          0.0e+00  Non-Responded
10               1.2e+06          1.1e+05  Responded
11               1.0e+06          0.7e+05  Responded
12               0.9e+06          0.0e+00  Non-Responded
13               1.1e+06          1.3e+05  Responded
14               1.0e+06          1.0e+05  Responded
15               0.8e+06          0.0e+00  Non-Responded
16               1.3e+06          1.2e+05  Responded
17               1.0e+06          0.8e+05  Responded
18               0.7e+06          0.0e+00  Non-Responded
19               1.2e+06          1.1e+05  Responded
20               1.0e+06          0.9e+05  Responded
21               0.9e+06          0.0e+00  Non-Responded
22               1.1e+06          1.3e+05  Responded
23               1.0e+06          1.0e+05  Responded
24               0.8e+06          0.0e+00  Non-Responded
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ee148c4ab3b1f721cc625f766ca26c24dd556813.summary'],Can the combination of bispecific antibodies targeting CD40 and tumor-associated antigens with checkpoint inhibitors enhance the anti-tumor response by increasing the diversity of tumor-targeting T cells and promoting the formation of long-lived memory T cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** The combination of bispecific antibodies targeting CD40 and tumor-associated antigens with checkpoint inhibitors enhances the anti-tumor response by increasing the diversity of tumor-targeting T cells and promoting the formation of long-lived memory T cells.

**Experimental Plan:**

**Objective:** To test the hypothesis and determine if the combination therapy enhances the anti-tumor response by increasing tumor-targeting T cell diversity and promoting long-lived memory T cells.

**Experimental Design:**

1. **In vitro experiments:**
	* Isolate human T cells from healthy donors and tumor-infiltrating lymphocytes (TILs) from cancer patients.
	* Treat T cells with bispecific antibodies targeting CD40 and tumor-associated antigens (e.g., HER2, MUC1) in the presence or absence of checkpoint inhibitors (e.g., PD-1, CTLA-4).
	* Analyze T cell activation, proliferation, and cytokine production using flow cytometry, ELISA, and qRT-PCR.
2. **In vivo experiments:**
	* Use a syngeneic tumor model (e.g., B16 melanoma in C57BL/6 mice) to evaluate the anti-tumor response.
	* Divide mice into four groups:
		+ Control (no treatment)
		+ Bispecific antibodies targeting CD40 and tumor-associated antigens
		+ Checkpoint inhibitors (PD-1 or CTLA-4)
		+ Combination therapy (bispecific antibodies + checkpoint inhibitors)
	* Monitor tumor growth, T cell infiltration, and immune cell populations using bioluminescence imaging, flow cytometry, and IHC.
3. **T cell receptor (TCR) sequencing:**
	* Isolate T cells from tumor-infiltrating lymphocytes and perform TCR sequencing to analyze T cell diversity.
	* Compare TCR diversity between treatment groups to determine if the combination therapy increases tumor-targeting T cell diversity.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the hypothesis and determine if the combination therapy does not enhance the anti-tumor response.

**Experimental Design:**

1. **In vitro experiments:**
	* Perform the same in vitro experiments as above, but with a twist:
		+ Use a non-specific antibody (e.g., isotype control) instead of the bispecific antibody targeting CD40 and tumor-associated antigens.
		+ Use a checkpoint inhibitor with a different mechanism of action (e.g., PD-L1 instead of PD-1).
	* Analyze T cell activation, proliferation, and cytokine production to determine if the non-specific antibody and alternative checkpoint inhibitor combination has a similar effect to the original combination therapy.
2. **In vivo experiments:**
	* Use the same syngeneic tumor model as above, but with a different tumor type (e.g., colon cancer) or a different mouse strain (e.g., BALB/c).
	* Divide mice into two groups:
		+ Control (no treatment)
		+ Combination therapy (bispecific antibodies + checkpoint inhibitors)
	* Monitor tumor growth, T cell infiltration, and immune cell populations to determine if the combination therapy has a similar effect in a different tumor model or mouse strain.

**Rationale:**

By designing an experiment to disprove the hypothesis, we can test the robustness of the original hypothesis and identify potential limitations or flaws. If the experiment to disprove the hypothesis fails to show a significant difference between the treatment groups, it would suggest that the original hypothesis is indeed true.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a budget of approximately $200,000-$300,000. This estimate includes:

* Personnel: 1 postdoc, 1 graduate student, and 1 technician (6-12 months)
* Reagents and consumables: Bispecific antibodies, checkpoint inhibitors, T cells, tumor cells, antibodies, and other reagents (approx. $50,000-$70,000)
* Equipment and infrastructure: Flow cytometer, qRT-PCR machine, bioluminescence imager, and animal housing (approx. $30,000-$50,000)
* Animal costs: Mice, tumor cells, and husbandry (approx. $20,000-$30,000)

Note: The budget and timeframe may vary depending on the specific requirements of the experiment and the institution's resources.",92,"I'd be happy to help you with that! Here are the detailed, step-by-step protocols for the experimental plan:

**In Vitro Experiments:**

**Protocol 1: T Cell Isolation and Treatment**

1.1. Obtain human peripheral blood mononuclear cells (PBMCs) from healthy donors and tumor-infiltrating lymphocytes (TILs) from cancer patients.

1.2. Isolate T cells from PBMCs and TILs using magnetic bead-based separation (e.g., Miltenyi Biotec) or fluorescence-activated cell sorting (FACS).

1.3. Count and resuspend T cells in complete RPMI-1640 medium (10% FBS, 1% penicillin-streptomycin, 1% L-glutamine) at a concentration of 1 x 10^6 cells/mL.

1.4. Treat T cells with:
	* Bispecific antibodies targeting CD40 and tumor-associated antigens (e.g., HER2, MUC1) at a concentration of 1-10 μg/mL.
	* Checkpoint inhibitors (e.g., PD-1, CTLA-4) at a concentration of 1-10 μg/mL.
	* Combination therapy (bispecific antibodies + checkpoint inhibitors).
	* Control (no treatment).

1.5. Incubate T cells at 37°C, 5% CO2 for 24-48 hours.

**Protocol 2: T Cell Activation, Proliferation, and Cytokine Production Analysis**

2.1. Analyze T cell activation using flow cytometry:
	* Stain T cells with anti-CD25, anti-CD69, and anti-CD137 antibodies.
	* Acquire data using a flow cytometer (e.g., BD FACSCanto II) and analyze using FlowJo software.

2.2. Analyze T cell proliferation using a cell proliferation assay (e.g., CellTiter 96 AQueous One Solution Cell Proliferation Assay).

2.3. Analyze cytokine production using ELISA:
	* Collect supernatants from T cell cultures.
	* Measure cytokine levels (e.g., IFN-γ, TNF-α, IL-2) using ELISA kits (e.g., R&D Systems).

2.4. Analyze gene expression using qRT-PCR:
	* Isolate RNA from T cells using a RNA isolation kit (e.g., Qiagen RNeasy Mini Kit).
	* Perform qRT-PCR using a qRT-PCR machine (e.g., Applied Biosystems 7500 Fast Real-Time PCR System) and analyze using the ΔΔCt method.

**In Vivo Experiments:**

**Protocol 3: Syngeneic Tumor Model and Treatment**

3.1. Obtain C57BL/6 mice and B16 melanoma cells.

3.2. Inject 1 x 10^5 B16 melanoma cells subcutaneously into the right flank of each mouse.

3.3. Divide mice into four groups:
	* Control (no treatment)
	* Bispecific antibodies targeting CD40 and tumor-associated antigens
	* Checkpoint inhibitors (PD-1 or CTLA-4)
	* Combination therapy (bispecific antibodies + checkpoint inhibitors)

3.4. Administer treatments via intraperitoneal injection:
	* Bispecific antibodies: 10-50 μg/mouse, twice a week for 2-3 weeks.
	* Checkpoint inhibitors: 10-50 μg/mouse, twice a week for 2-3 weeks.
	* Combination therapy: bispecific antibodies + checkpoint inhibitors, twice a week for 2-3 weeks.

3.5. Monitor tumor growth using bioluminescence imaging (e.g., IVIS Spectrum).

**Protocol 4: T Cell Infiltration and Immune Cell Population Analysis**

4.1. Harvest tumors and spleens from mice.

4.2. Isolate T cells from tumors and spleens using magnetic bead-based separation or FACS.

4.3. Analyze T cell infiltration and immune cell populations using flow cytometry:
	* Stain T cells with anti-CD4, anti-CD8, anti-CD25, and anti-CD69 antibodies.
	* Acquire data using a flow cytometer and analyze using FlowJo software.

4.4. Perform immunohistochemistry (IHC) on tumor sections:
	* Stain for CD4, CD8, and CD25 using IHC kits (e.g., Dako).
	* Analyze using a microscope (e.g., Olympus BX53).

**TCR Sequencing:**

**Protocol 5: TCR Sequencing**

5.1. Isolate T cells from tumor-infiltrating lymphocytes.

5.2. Perform TCR sequencing using a TCR sequencing kit (e.g., Adaptive Biotechnologies).

5.3. Analyze TCR diversity using computational tools (e.g., ImmunoSEQ Analyzer).

**Experiment to Disprove the Hypothesis:**

**Protocol 6: In Vitro Experiments with Non-Specific Antibody and Alternative Checkpoint Inhibitor**

6.1. Perform Protocol 1 with a non-specific antibody (e.g., isotype control) instead of the bispecific antibody targeting CD40 and tumor-associated antigens.

6.2. Perform Protocol 1 with a checkpoint inhibitor with a different mechanism of action (e.g., PD-L1 instead of PD-1).

**Protocol 7: In Vivo Experiments with Different Tumor Model or Mouse Strain**

7.1. Perform Protocol 3 with a different tumor type (e.g., colon cancer) or a different mouse strain (e.g., BALB/c).

7.2. Divide mice into two groups:
	* Control (no treatment)
	* Combination therapy (bispecific antibodies + checkpoint inhibitors)

7.3. Monitor tumor growth, T cell infiltration, and immune cell populations as described in Protocols 3-4.

These detailed protocols should provide a clear guide for executing the experimental plan. Remember to follow proper laboratory protocols, safety guidelines, and animal welfare regulations when conducting these experiments.","```
   Bispecific Antibody (μg/mL)  Checkpoint Inhibitor (μg/mL)  T Cell Concentration (cells/mL)  T Cell Activation (%)  T Cell Proliferation (%)  IFN-γ (pg/mL)  TNF-α (pg/mL)  IL-2 (pg/mL)  Tumor Growth (mm³)
0                       1.0                       0.0                  1.0e+06                20.0                15.0          100.0          50.0          20.0           500.0
1                       5.0                       0.0                  1.0e+06                40.0                30.0          200.0         100.0          40.0           300.0
2                       10.0                      0.0                  1.0e+06                60.0                45.0          300.0         150.0          60.0           200.0
3                       1.0                       1.0                  1.0e+06                30.0                20.0          150.0          75.0          30.0           400.0
4                       5.0                       1.0                  1.0e+06                50.0                35.0          250.0         125.0          50.0           250.0
5                       10.0                      1.0                  1.0e+06                70.0                50.0          350.0         175.0          70.0           150.0
6                       1.0                       5.0                  1.0e+06                40.0                25.0          200.0         100.0          40.0           300.0
7                       5.0                       5.0                  1.0e+06                60.0                40.0          300.0         150.0          60.0           200.0
8                       10.0                      5.0                  1.0e+06                80.0                55.0          400.0         200.0          80.0           100.0
9                       1.0                       10.0                 1.0e+06                50.0                30.0          250.0         125.0          50.0           250.0
10                      5.0                       10.0                 1.0e+06                70.0                45.0          350.0         175.0          70.0           150.0
11                      10.0                      10.0                 1.0e+06                90.0                60.0          450.0         225.0          90.0            50.0
12                      0.0                       0.0                  1.0e+06                10.0                5.0           50.0          25.0          10.0           600.0
13                      0.0                       1.0                  1.0e+06                20.0                10.0          100.0          50.0          20.0           500.0
14                      0.0                       5.0                  1.0e+06                30.0                15.0          150.0          75.0          30.0           400.0
15                      0.0                       10.0                 1.0e+06                40.0                20.0          200.0         100.0          40.0           300.0
16                      1.0                       0.0                  5.0e+05                15.0                10.0           75.0          37.5          15.0           550.0
17                      5.0                       0.0                  5.0e+05                30.0                20.0          150.0          75.0          30.0           400.0
18                      10.0                      0.0                  5.0e+05                45.0                30.0          225.0         112.5          45.0           250.0
19                      1.0                       1.0                  5.0e+05                25.0                15.0          125.0          62.5          25.0           450.0
20                      5.0                       1.0                  5.0e+05                40.0                25.0          200.0         100.0          40.0           300.0
21                      10.0                      1.0                  5.0e+05                60.0                40.0          300.0         150.0          60.0           200.0
22                      1.0                       5.0                  5.0e+05                35.0                20.0          175.0          87.5          35.0           350.0
23                      5.0                       5.0                  5.0e+05                50.0                30.0          250.0         125.0          50.0           250.0
24                      10.0                      5.0                  5.0e+05                70.0                45.0          350.0         175.0          70.0           150.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1461361086f5ca84d34587a323453dd195a8d9d5.summary'],Can the combination of dasatinib with mTOR inhibitors also enhance the efficacy of other tyrosine kinase inhibitors in treating Ph-like B-ALL with ABL-class alterations?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** The combination of dasatinib with mTOR inhibitors can enhance the efficacy of other tyrosine kinase inhibitors in treating Ph-like B-ALL with ABL-class alterations.

**Experimental Plan:**

**Objective:** To test the hypothesis and determine if the combination of dasatinib with mTOR inhibitors can enhance the efficacy of other tyrosine kinase inhibitors in treating Ph-like B-ALL with ABL-class alterations.

**Experimental Design:**

1. **Cell Culture:** Use established Ph-like B-ALL cell lines with ABL-class alterations (e.g., Ba/F3-ABL1, Ba/F3-ABL2, or patient-derived xenografts) and maintain them in standard culture conditions.
2. **Treatment Groups:**
	* Control group: Vehicle-treated cells (DMSO or equivalent)
	* Dasatinib group: Cells treated with dasatinib (10-100 nM)
	* mTOR inhibitor group: Cells treated with an mTOR inhibitor (e.g., rapamycin, 10-100 nM)
	* Combination group: Cells treated with dasatinib (10-100 nM) and an mTOR inhibitor (10-100 nM)
	* Tyrosine kinase inhibitor group: Cells treated with another tyrosine kinase inhibitor (e.g., imatinib, 10-100 nM)
	* Combination + TKI group: Cells treated with dasatinib (10-100 nM), an mTOR inhibitor (10-100 nM), and another tyrosine kinase inhibitor (10-100 nM)
3. **Assays:**
	* Cell viability: Measure cell viability using MTT or CellTiter-Glo assays
	* Apoptosis: Assess apoptosis using Annexin V/PI staining and flow cytometry
	* Western Blot: Analyze protein expression of ABL-class proteins, mTOR, and downstream targets (e.g., p-S6, p-4EBP1)
4. **Experimental Timeline:**
	* Day 0: Seed cells and treat with respective compounds
	* Day 3-5: Perform cell viability and apoptosis assays
	* Day 5-7: Harvest cells for Western Blot analysis
5. **Replication and Statistical Analysis:**
	* Perform each experiment in triplicate
	* Analyze data using one-way ANOVA with Tukey's post-hoc test to compare treatment groups

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: that the combination of dasatinib with mTOR inhibitors does not enhance the efficacy of other tyrosine kinase inhibitors in treating Ph-like B-ALL with ABL-class alterations.

**Modified Experimental Design:**

1. **Cell Culture:** Same as above
2. **Treatment Groups:**
	* Control group: Vehicle-treated cells (DMSO or equivalent)
	* Dasatinib group: Cells treated with dasatinib (10-100 nM)
	* mTOR inhibitor group: Cells treated with an mTOR inhibitor (e.g., rapamycin, 10-100 nM)
	* Combination group: Cells treated with dasatinib (10-100 nM) and an mTOR inhibitor (10-100 nM)
	* Tyrosine kinase inhibitor group: Cells treated with another tyrosine kinase inhibitor (e.g., imatinib, 10-100 nM)
	* Combination + TKI group: Cells treated with dasatinib (10-100 nM), an mTOR inhibitor (10-100 nM), and another tyrosine kinase inhibitor (10-100 nM) **with a suboptimal concentration of the tyrosine kinase inhibitor** (e.g., 1-10 nM)
3. **Assays:** Same as above
4. **Experimental Timeline:** Same as above
5. **Replication and Statistical Analysis:** Same as above

By using a suboptimal concentration of the tyrosine kinase inhibitor in the combination + TKI group, we can test the hypothesis that the combination of dasatinib with mTOR inhibitors does not enhance the efficacy of other tyrosine kinase inhibitors in treating Ph-like B-ALL with ABL-class alterations. If the results show no significant difference between the combination + TKI group and the tyrosine kinase inhibitor group, it would suggest that the combination of dasatinib with mTOR inhibitors does not enhance the efficacy of other tyrosine kinase inhibitors, thereby disproving the original hypothesis.

**Budget and Timeframe:**

This experiment can be completed within 2-3 months with a budget of approximately $10,000-$15,000, which covers the cost of:

* Cell lines and reagents (e.g., dasatinib, mTOR inhibitors, tyrosine kinase inhibitors)
* Cell culture media and consumables
* Assay kits and reagents (e.g., MTT, CellTiter-Glo, Annexin V/PI)
* Western Blot reagents and antibodies
* Laboratory personnel and equipment usage

Note: The budget and timeframe may vary depending on the specific requirements of the laboratory and the availability of resources.",92,"Here are the detailed, step-by-step protocols for the experiment:

**Experiment to Test the Hypothesis:**

**Step 1: Cell Culture Preparation**

1.1. Obtain Ph-like B-ALL cell lines with ABL-class alterations (e.g., Ba/F3-ABL1, Ba/F3-ABL2, or patient-derived xenografts) and maintain them in standard culture conditions.

1.2. Ensure cells are healthy and in exponential growth phase before starting the experiment.

1.3. Count cells using a hemocytometer or automated cell counter to determine the number of cells per mL.

**Step 2: Treatment Group Preparation**

2.1. Prepare the following treatment groups:
	* Control group: Vehicle-treated cells (DMSO or equivalent)
	* Dasatinib group: Cells treated with dasatinib (10-100 nM)
	* mTOR inhibitor group: Cells treated with an mTOR inhibitor (e.g., rapamycin, 10-100 nM)
	* Combination group: Cells treated with dasatinib (10-100 nM) and an mTOR inhibitor (10-100 nM)
	* Tyrosine kinase inhibitor group: Cells treated with another tyrosine kinase inhibitor (e.g., imatinib, 10-100 nM)
	* Combination + TKI group: Cells treated with dasatinib (10-100 nM), an mTOR inhibitor (10-100 nM), and another tyrosine kinase inhibitor (10-100 nM)

2.2. Prepare stock solutions of dasatinib, mTOR inhibitor, and tyrosine kinase inhibitor in DMSO or equivalent solvent.

2.3. Dilute stock solutions to the desired concentrations (10-100 nM) in cell culture media.

**Step 3: Cell Treatment and Incubation**

3.1. Seed 1-2 x 10^5 cells per well in a 96-well plate or 6-well plate, depending on the assay requirements.

3.2. Add the respective treatment solutions to each well, ensuring accurate pipetting and minimal contamination.

3.3. Incubate cells at 37°C, 5% CO2 for 3-5 days.

**Step 4: Cell Viability Assay**

4.1. On Day 3-5, perform cell viability assays using MTT or CellTiter-Glo according to the manufacturer's instructions.

4.2. Measure absorbance or luminescence using a plate reader.

**Step 5: Apoptosis Assay**

5.1. On Day 3-5, harvest cells for apoptosis analysis using Annexin V/PI staining and flow cytometry.

5.2. Stain cells with Annexin V-FITC and PI according to the manufacturer's instructions.

5.3. Analyze stained cells using flow cytometry to determine the percentage of apoptotic cells.

**Step 6: Western Blot Analysis**

6.1. On Day 5-7, harvest cells for Western Blot analysis.

6.2. Lyse cells in RIPA buffer and quantify protein concentrations using a protein assay (e.g., BCA).

6.3. Run Western Blot analysis using antibodies against ABL-class proteins, mTOR, and downstream targets (e.g., p-S6, p-4EBP1) according to standard protocols.

**Step 7: Data Analysis and Replication**

7.1. Analyze data using one-way ANOVA with Tukey's post-hoc test to compare treatment groups.

7.2. Perform each experiment in triplicate to ensure reproducibility.

7.3. Report results as mean ± SEM and include statistical significance (p-values).

**Experiment to Disprove the Hypothesis:**

**Modified Step 2: Treatment Group Preparation**

2.1. Prepare the same treatment groups as above, except for the Combination + TKI group.

2.2. For the Combination + TKI group, use a suboptimal concentration of the tyrosine kinase inhibitor (e.g., 1-10 nM) in addition to dasatinib (10-100 nM) and an mTOR inhibitor (10-100 nM).

**All other steps remain the same as above.**

**Budget and Timeframe:**

* Cell lines and reagents (e.g., dasatinib, mTOR inhibitors, tyrosine kinase inhibitors): $3,000-$5,000
* Cell culture media and consumables: $1,000-$2,000
* Assay kits and reagents (e.g., MTT, CellTiter-Glo, Annexin V/PI): $2,000-$3,000
* Western Blot reagents and antibodies: $1,000-$2,000
* Laboratory personnel and equipment usage: $2,000-$3,000

Total budget: $10,000-$15,000

Timeframe: 2-3 months

Note: The budget and timeframe may vary depending on the specific requirements of the laboratory and the availability of resources.","```
   Control_DMSO  Dasatinib  mTOR_Inhibitor  Tyrosine_Kinase_Inhibitor  Combination  Combination_TKI  Outcome
0             0.0       50.0             0.0                    0.0       50.0           50.0    0.75
1             0.0       20.0             0.0                    0.0       20.0           20.0    0.80
2             0.0        0.0             0.0                    0.0        0.0            0.0    0.95
3             0.0       80.0             0.0                    0.0       80.0           80.0    0.60
4             0.0        0.0             0.0                    0.0        0.0            0.0    0.90
5             0.0       30.0             0.0                    0.0       30.0           30.0    0.85
6             0.0       10.0             0.0                    0.0       10.0           10.0    0.92
7             0.0        0.0             0.0                    0.0        0.0            0.0    0.98
8             0.0       40.0             0.0                    0.0       40.0           40.0    0.78
9             0.0       60.0             0.0                    0.0       60.0           60.0    0.65
10            0.0        0.0             0.0                    0.0        0.0            0.0    0.96
11            0.0       90.0             0.0                    0.0       90.0           90.0    0.55
12            0.0        0.0             0.0                    0.0        0.0            0.0    0.99
13            0.0       70.0             0.0                    0.0       70.0           70.0    0.70
14            0.0        0.0             0.0                    0.0        0.0            0.0    0.97
15            0.0       25.0             0.0                    0.0       25.0           25.0    0.88
16            0.0        0.0             0.0                    0.0        0.0            0.0    0.94
17            0.0       15.0             0.0                    0.0       15.0           15.0    0.91
18            0.0        0.0             0.0                    0.0        0.0            0.0    0.93
19            0.0       35.0             0.0                    0.0       35.0           35.0    0.82
20            0.0        0.0             0.0                    0.0        0.0            0.0    0.98
21            0.0       45.0             0.0                    0.0       45.0           45.0    0.76
22            0.0        0.0             0.0                    0.0        0.0            0.0    0.95
23            0.0       65.0             0.0                    0.0       65.0           65.0    0.68
24            0.0        0.0             0.0                    0.0        0.0            0.0    0.99
```",0.9760993756482179
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/08d383231f87facccf2e4ada3cad8e53003290ee.summary'],Can the combination of ibrutinib and venetoclax modulate the microenvironment in CLL to prevent the activation of bypass pathways and thereby delay the development of resistance to targeted therapies?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's break it down and design an experiment to test it.

**Hypothesis:** The combination of ibrutinib and venetoclax can modulate the microenvironment in Chronic Lymphocytic Leukemia (CLL) to prevent the activation of bypass pathways, thereby delaying the development of resistance to targeted therapies.

**Experimental Plan:**

**Objective:** To investigate whether the combination of ibrutinib and venetoclax can prevent the activation of bypass pathways and delay resistance to targeted therapies in CLL.

**Experimental Design:**

1. **Cell Culture Model:** Establish a CLL cell culture model using primary CLL cells or CLL cell lines (e.g., MEC-1, MEC-2) to mimic the in vivo microenvironment.
2. **Treatment Groups:**
	* Control group: untreated CLL cells
	* Ibrutinib group: CLL cells treated with ibrutinib (BTK inhibitor)
	* Venetoclax group: CLL cells treated with venetoclax (BCL-2 inhibitor)
	* Combination group: CLL cells treated with both ibrutinib and venetoclax
3. **Bypass Pathway Analysis:**
	* Measure the expression of key proteins involved in bypass pathways (e.g., PI3K/AKT, MAPK, NF-κB) using Western blotting or flow cytometry.
	* Analyze the phosphorylation status of these proteins to assess their activation.
4. **Resistance Assay:**
	* Expose each treatment group to increasing concentrations of ibrutinib or venetoclax to assess the development of resistance.
	* Measure cell viability, proliferation, and apoptosis using MTT, BrdU, or Annexin V assays.
5. **Microenvironment Analysis:**
	* Analyze the expression of immune checkpoint molecules (e.g., PD-1, PD-L1) and cytokines (e.g., IL-10, TGF-β) in the microenvironment using qRT-PCR, ELISA, or flow cytometry.
	* Investigate the impact of the combination treatment on the tumor microenvironment using immunofluorescence staining or confocal microscopy.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that focuses on the opposite outcome: the combination of ibrutinib and venetoclax does not prevent the activation of bypass pathways and does not delay the development of resistance to targeted therapies.

**Modified Experimental Design:**

1. **Cell Culture Model:** Same as above.
2. **Treatment Groups:**
	* Control group: untreated CLL cells
	* Combination group: CLL cells treated with both ibrutinib and venetoclax
3. **Bypass Pathway Analysis:**
	* Measure the expression and phosphorylation of key proteins involved in bypass pathways (e.g., PI3K/AKT, MAPK, NF-κB) using Western blotting or flow cytometry.
	* Expect to see increased activation of bypass pathways in the combination group compared to the control group.
4. **Resistance Assay:**
	* Expose the combination group to increasing concentrations of ibrutinib or venetoclax.
	* Measure cell viability, proliferation, and apoptosis using MTT, BrdU, or Annexin V assays.
	* Expect to see rapid development of resistance in the combination group.
5. **Microenvironment Analysis:**
	* Analyze the expression of immune checkpoint molecules and cytokines in the microenvironment using qRT-PCR, ELISA, or flow cytometry.
	* Expect to see no significant changes or even an increase in immune suppressive factors in the combination group.

**Budget and Timeframe:**

This experiment can be completed within 6-9 months with a budget of approximately $150,000-$200,000. This estimate includes:

* Cell culture reagents and consumables: $30,000
* Antibodies and reagents for Western blotting and flow cytometry: $20,000
* qRT-PCR and ELISA reagents: $10,000
* Confocal microscopy and imaging software: $20,000
* Personnel and labor costs: $60,000-$80,000
* Miscellaneous (contingency fund): $10,000-$20,000

By designing an experiment to disprove the hypothesis, we can rigorously test the idea and increase confidence in the results. If the data support the hypothesis, it will provide strong evidence for the combination of ibrutinib and venetoclax as a potential strategy to prevent resistance to targeted therapies in CLL.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture Model Establishment**

1.1. Obtain primary CLL cells or CLL cell lines (e.g., MEC-1, MEC-2) from a reputable source.

1.2. Culture the cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

1.3. Verify the identity and purity of the cells using flow cytometry or PCR-based methods.

1.4. Passage the cells every 3-4 days to maintain a healthy and viable culture.

**Protocol 2: Treatment Groups**

2.1. Prepare the following treatment groups:
	* Control group: untreated CLL cells
	* Ibrutinib group: CLL cells treated with ibrutinib (BTK inhibitor) at a concentration of 1 μM
	* Venetoclax group: CLL cells treated with venetoclax (BCL-2 inhibitor) at a concentration of 1 μM
	* Combination group: CLL cells treated with both ibrutinib (1 μM) and venetoclax (1 μM)

2.2. Treat the cells with the respective inhibitors for 24-48 hours before harvesting for further analysis.

**Protocol 3: Bypass Pathway Analysis**

3.1. Harvest the treated cells and lyse them using a suitable lysis buffer (e.g., RIPA buffer).

3.2. Perform Western blotting to measure the expression of key proteins involved in bypass pathways (e.g., PI3K, AKT, MAPK, NF-κB).

3.3. Use specific antibodies against the proteins of interest and detect the signals using a chemiluminescent substrate.

3.4. Analyze the phosphorylation status of the proteins using phospho-specific antibodies.

3.5. Alternatively, perform flow cytometry to measure the expression and phosphorylation of the proteins.

**Protocol 4: Resistance Assay**

4.1. Expose each treatment group to increasing concentrations of ibrutinib or venetoclax (e.g., 0.1 μM, 1 μM, 10 μM) for 24-48 hours.

4.2. Measure cell viability using the MTT assay:
	* Add 10 μL of MTT reagent to each well and incubate for 2-4 hours.
	* Measure the absorbance at 570 nm using a microplate reader.

4.3. Measure cell proliferation using the BrdU assay:
	* Add 10 μM BrdU to each well and incubate for 2-4 hours.
	* Fix the cells and detect BrdU incorporation using a specific antibody.

4.4. Measure apoptosis using the Annexin V assay:
	* Stain the cells with Annexin V-FITC and propidium iodide.
	* Analyze the cells using flow cytometry.

**Protocol 5: Microenvironment Analysis**

5.1. Analyze the expression of immune checkpoint molecules (e.g., PD-1, PD-L1) and cytokines (e.g., IL-10, TGF-β) in the microenvironment using qRT-PCR:
	* Extract RNA from the cells using a suitable method (e.g., TRIzol).
	* Perform qRT-PCR using specific primers and probes.

5.2. Alternatively, perform ELISA to measure the protein levels of the immune checkpoint molecules and cytokines.

5.3. Investigate the impact of the combination treatment on the tumor microenvironment using immunofluorescence staining or confocal microscopy:
	* Fix the cells and stain them with specific antibodies against the immune checkpoint molecules and cytokines.
	* Analyze the cells using a confocal microscope.

**Protocol 6: Experiment to Disprove the Hypothesis**

6.1. Repeat Protocols 1-5 using the modified experimental design:
	* Control group: untreated CLL cells
	* Combination group: CLL cells treated with both ibrutinib (1 μM) and venetoclax (1 μM)

6.2. Expect to see increased activation of bypass pathways, rapid development of resistance, and no significant changes or an increase in immune suppressive factors in the combination group.

**Note:** The above protocols are detailed and specific, but it is essential to optimize and validate each protocol for the specific laboratory setting and equipment. Additionally, the experiment should be performed in triplicates, and the results should be analyzed using appropriate statistical methods.","```
   Ibrutinib  Venetoclax  RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  Outcome
0       0.5        0.5       100%  10%                1%           1%  Resistant
1       1.0        0.0       100%  10%                1%           1%  Sensitive
2       0.0        1.0       100%  10%                1%           1%  Sensitive
3       1.5        0.5       100%  10%                1%           1%  Resistant
4       0.5        1.5       100%  10%                1%           1%  Resistant
5       1.0        1.0       100%  10%                1%           1%  Sensitive
6       0.0        0.0       100%  10%                1%           1%  Sensitive
7       2.0        0.0       100%  10%                1%           1%  Resistant
8       0.0        2.0       100%  10%                1%           1%  Resistant
9       1.5        1.5       100%  10%                1%           1%  Resistant
10      1.0        0.5       100%  10%                1%           1%  Sensitive
11      0.5        1.0       100%  10%                1%           1%  Sensitive
12      2.5        0.5       100%  10%                1%           1%  Resistant
13      0.5        2.5       100%  10%                1%           1%  Resistant
14      1.0        1.5       100%  10%                1%           1%  Sensitive
15      1.5        1.0       100%  10%                1%           1%  Sensitive
16      0.0        0.5       100%  10%                1%           1%  Sensitive
17      0.5        0.0       100%  10%                1%           1%  Sensitive
18      2.0        1.0       100%  10%                1%           1%  Resistant
19      1.0        2.0       100%  10%                1%           1%  Resistant
20      1.5        1.5       100%  10%                1%           1%  Resistant
21      1.0        0.5       100%  10%                1%           1%  Sensitive
22      0.5        1.0       100%  10%                1%           1%  Sensitive
23      2.5        0.5       100%  10%                1%           1%  Resistant
24      0.5        2.5       100%  10%                1%           1%  Resistant
```",0.4136676484652678
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/273f174305da1b50815ee5c5260b7401a2fc968a.summary'],Can the conjugation of indocyanine green with a monoclonal antibody targeting a specific tumor-associated antigen on cancer cells enhance the accuracy of sentinel lymph node imaging in other types of cancer beyond breast cancer?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and potentially disprove it.

**Hypothesis:** Can the conjugation of indocyanine green with a monoclonal antibody targeting a specific tumor-associated antigen on cancer cells enhance the accuracy of sentinel lymph node imaging in other types of cancer beyond breast cancer?

**Experimental Plan:**

**Objective:** To investigate whether the conjugation of indocyanine green with a monoclonal antibody targeting a specific tumor-associated antigen can enhance the accuracy of sentinel lymph node imaging in other types of cancer beyond breast cancer.

**Experimental Design:**

1. **Cancer Cell Lines:** Select three different types of cancer cell lines (e.g., lung, colon, and ovarian cancer) that express specific tumor-associated antigens (e.g., EGFR, CEACAM5, and MUC1, respectively).
2. **Monoclonal Antibodies:** Obtain monoclonal antibodies targeting the specific tumor-associated antigens for each cancer cell line.
3. **Indocyanine Green Conjugation:** Conjugate indocyanine green with each monoclonal antibody to create receptor-targeted tracers (e.g., ICG-anti-EGFR, ICG-anti-CEACAM5, and ICG-anti-MUC1).
4. **Animal Models:** Establish xenograft models for each cancer cell line in mice.
5. **Tracer Injection and Imaging:** Inject the conjugated tracers into the tumor site of each mouse model and perform near-infrared fluorescence imaging at different time points (e.g., 1, 2, 4, and 6 hours) to detect sentinel lymph nodes.
6. **Control Group:** Include a control group with non-conjugated indocyanine green (ICG) as a negative control.
7. **Image Analysis:** Quantify the fluorescence intensity of sentinel lymph nodes in each group using image analysis software.
8. **Comparison:** Compare the fluorescence intensity of sentinel lymph nodes between the conjugated tracer groups and the control group.

**Null Hypothesis:** The conjugation of indocyanine green with a monoclonal antibody targeting a specific tumor-associated antigen does not enhance the accuracy of sentinel lymph node imaging in other types of cancer beyond breast cancer.

**Alternative Hypothesis:** The conjugation of indocyanine green with a monoclonal antibody targeting a specific tumor-associated antigen enhances the accuracy of sentinel lymph node imaging in other types of cancer beyond breast cancer.

**Expected Outcomes:**

* If the null hypothesis is true, the fluorescence intensity of sentinel lymph nodes in the conjugated tracer groups will not be significantly different from the control group.
* If the alternative hypothesis is true, the fluorescence intensity of sentinel lymph nodes in the conjugated tracer groups will be significantly higher than the control group, indicating enhanced accuracy of sentinel lymph node imaging.

**Resources and Timeline:**

* Estimated time frame: 6-9 months
* Budget: Moderate (approximately $50,000 - $75,000)
* Required resources:
	+ Cancer cell lines and monoclonal antibodies
	+ Indocyanine green and conjugation reagents
	+ Animal models and housing
	+ Near-infrared fluorescence imaging equipment and software
	+ Image analysis software and personnel

This experimental plan is designed to test the hypothesis in a controlled and systematic manner, with a focus on disproving the hypothesis. By using multiple cancer cell lines and monoclonal antibodies, we can assess the generalizability of the conjugation approach beyond breast cancer. The results of this study will provide valuable insights into the potential of receptor-targeted tracers for sentinel lymph node imaging in various types of cancer.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cancer Cell Line Selection and Preparation**

1.1. Obtain three different types of cancer cell lines (e.g., lung, colon, and ovarian cancer) from a reputable cell bank or culture collection.

1.2. Verify the identity and authenticity of each cell line using DNA fingerprinting or STR profiling.

1.3. Expand the cell lines in vitro using appropriate culture media and conditions.

1.4. Freeze aliquots of each cell line at early passages (e.g., passage 3-5) for future use.

**Protocol 2: Monoclonal Antibody Selection and Preparation**

2.1. Obtain monoclonal antibodies targeting specific tumor-associated antigens (e.g., EGFR, CEACAM5, and MUC1) from a reputable supplier or generate in-house using hybridoma technology.

2.2. Verify the specificity and purity of each monoclonal antibody using Western blot, ELISA, or other immunological assays.

2.3. Aliquot and store the monoclonal antibodies at -20°C or -80°C for future use.

**Protocol 3: Indocyanine Green Conjugation**

3.1. Prepare a stock solution of indocyanine green (ICG) in PBS or DMSO.

3.2. Conjugate ICG to each monoclonal antibody using a suitable conjugation method (e.g., NHS-ester or maleimide-based conjugation).

3.3. Purify the conjugated tracers using size exclusion chromatography or dialysis.

3.4. Verify the conjugation efficiency and purity using spectroscopy (e.g., UV-Vis or fluorescence) and SDS-PAGE.

**Protocol 4: Animal Model Establishment**

4.1. Obtain female athymic nude mice (e.g., BALB/c or NOD-SCID) from a reputable supplier.

4.2. House the mice in a specific pathogen-free (SPF) facility with controlled temperature, humidity, and lighting.

4.3. Subcutaneously inject 1-2 x 10^6 cancer cells (from Protocol 1) into the flank of each mouse.

4.4. Monitor tumor growth and wait until the tumors reach a size of approximately 5-10 mm in diameter (typically 1-2 weeks).

**Protocol 5: Tracer Injection and Imaging**

5.1. Prepare the conjugated tracers (from Protocol 3) in PBS or saline at a concentration of 1-10 μg/mL.

5.2. Inject 100-200 μL of the conjugated tracer into the tumor site of each mouse using a 27-gauge needle.

5.3. Perform near-infrared fluorescence imaging at different time points (e.g., 1, 2, 4, and 6 hours) using a suitable imaging system (e.g., IVIS or Odyssey).

5.4. Acquire images with a resolution of at least 100 μm/pixel and a field of view of 10-15 cm.

**Protocol 6: Control Group and Image Analysis**

6.1. Prepare a control group by injecting non-conjugated ICG (from Protocol 3) into the tumor site of separate mice.

6.2. Perform near-infrared fluorescence imaging of the control group at the same time points as the conjugated tracer groups.

6.3. Use image analysis software (e.g., ImageJ or MATLAB) to quantify the fluorescence intensity of sentinel lymph nodes in each group.

6.4. Calculate the mean fluorescence intensity and standard deviation for each group.

**Protocol 7: Data Analysis and Comparison**

7.1. Compare the fluorescence intensity of sentinel lymph nodes between the conjugated tracer groups and the control group using a suitable statistical test (e.g., ANOVA or t-test).

7.2. Determine the significance level (α) and calculate the p-value for each comparison.

7.3. If the p-value is < 0.05, reject the null hypothesis and conclude that the conjugation of indocyanine green with a monoclonal antibody targeting a specific tumor-associated antigen enhances the accuracy of sentinel lymph node imaging in other types of cancer beyond breast cancer.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the results.","```
   Cancer Cell Line  Monoclonal Antibody  ICG Concentration  Tracer Concentration  Tumor Size  Fluorescence Intensity
0           Lung Cancer          EGFR Antibody             5.0               5.0         7.5               120.0
1           Colon Cancer        CEACAM5 Antibody             2.5               2.5         6.0               100.0
2           Ovarian Cancer          MUC1 Antibody             7.5               7.5         8.5               140.0
3           Lung Cancer          EGFR Antibody             2.0               2.0         6.5               110.0
4           Colon Cancer        CEACAM5 Antibody             5.0               5.0         7.0               130.0
5           Ovarian Cancer          MUC1 Antibody             3.0               3.0         6.0               100.0
6           Lung Cancer          EGFR Antibody             7.0               7.0         8.0               150.0
7           Colon Cancer        CEACAM5 Antibody             2.0               2.0         5.5               90.0
8           Ovarian Cancer          MUC1 Antibody             5.5               5.5         7.5               120.0
9           Lung Cancer          EGFR Antibody             3.5               3.5         6.5               110.0
10          Colon Cancer        CEACAM5 Antibody             6.0               6.0         7.5               130.0
11          Ovarian Cancer          MUC1 Antibody             2.0               2.0         5.0               80.0
12          Lung Cancer          EGFR Antibody             4.0               4.0         7.0               120.0
13          Colon Cancer        CEACAM5 Antibody             3.0               3.0         6.0               100.0
14          Ovarian Cancer          MUC1 Antibody             6.5               6.5         8.0               140.0
15          Lung Cancer          EGFR Antibody             2.5               2.5         6.0               100.0
16          Colon Cancer        CEACAM5 Antibody             4.5               4.5         7.5               130.0
17          Ovarian Cancer          MUC1 Antibody             3.5               3.5         6.5               110.0
18          Lung Cancer          EGFR Antibody             6.0               6.0         8.0               150.0
19          Colon Cancer        CEACAM5 Antibody             2.0               2.0         5.5               90.0
20          Ovarian Cancer          MUC1 Antibody             4.0               4.0         7.0               120.0
21          Lung Cancer          EGFR Antibody             3.0               3.0         6.0               100.0
22          Colon Cancer        CEACAM5 Antibody             5.5               5.5         7.5               130.0
23          Ovarian Cancer          MUC1 Antibody             2.5               2.5         6.0               100.0
24          Lung Cancer          EGFR Antibody             4.5               4.5         7.5               130.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e4513674be79e1860b4e93d187f3f57604a7a8b8.summary'],"Can the consumption of cow's milk-derived exosomal microRNAs also induce epigenetic changes in T cells, leading to an increased risk of autoimmune diseases such as rheumatoid arthritis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help design an experiment to test this hypothesis.

**Hypothesis:** Can the consumption of cow's milk-derived exosomal microRNAs induce epigenetic changes in T cells, leading to an increased risk of autoimmune diseases such as rheumatoid arthritis?

**Experimental Plan:**

**Objective:** To design an experiment to test the hypothesis and attempt to disprove it, thereby verifying its validity.

**Experimental Approach:**

1. **Cell Culture Model:**
	* Use human T cells (e.g., Jurkat cells) as the cell model to study the effects of cow's milk-derived exosomal microRNAs.
	* Culture T cells in a controlled environment with standard cell culture media.
2. **Exosomal microRNA Isolation:**
	* Obtain cow's milk samples from a local dairy farm or purchase from a commercial supplier.
	* Isolate exosomes from cow's milk using established methods (e.g., ultracentrifugation, density gradient centrifugation, or commercial exosome isolation kits).
	* Verify exosome isolation using techniques like transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), or Western blotting.
3. **MicroRNA Extraction and Quantification:**
	* Extract microRNAs from isolated exosomes using commercial kits or established protocols (e.g., TRIzol, miRNeasy).
	* Quantify microRNA levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR) or microarray analysis.
4. **T Cell Treatment and Epigenetic Analysis:**
	* Treat T cells with isolated exosomal microRNAs at varying concentrations (e.g., 10, 50, 100 nM) for 24-48 hours.
	* Analyze epigenetic changes in T cells using techniques like:
		+ DNA methylation analysis (e.g., bisulfite sequencing, methylation-specific PCR)
		+ Histone modification analysis (e.g., chromatin immunoprecipitation sequencing, ChIP-seq)
		+ Gene expression analysis (e.g., RNA-seq, qRT-PCR)
5. **Control Groups:**
	* Include negative control groups:
		- T cells without exosomal microRNA treatment
		- T cells treated with scrambled microRNA controls
	* Include positive control groups:
		- T cells treated with known epigenetic modifiers (e.g., 5-azacytidine, trichostatin A)
6. **Data Analysis:**
	* Compare epigenetic changes in T cells treated with exosomal microRNAs to control groups.
	* Analyze data using statistical software (e.g., R, Python) to determine significance (p < 0.05).

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on showing that exosomal microRNAs from cow's milk do not induce epigenetic changes in T cells. We will:

1. Use a high concentration of exosomal microRNAs (e.g., 500 nM) to maximize the potential effect.
2. Include multiple control groups to ensure that any observed effects are specific to the exosomal microRNAs.
3. Analyze multiple epigenetic markers to increase the chances of detecting changes.
4. Perform the experiment in triplicate to ensure reproducibility.

**Budget and Timeframe:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000. This estimate includes:

* Cell culture reagents and consumables: $10,000
* Exosome isolation and microRNA extraction kits: $5,000
* qRT-PCR and epigenetic analysis reagents: $10,000
* Labor costs (postdoc or graduate student): $20,000-$30,000
* Miscellaneous (equipment maintenance, travel, etc.): $5,000-$10,000

By following this experimental plan, we can test the hypothesis and attempt to disprove it, thereby verifying its validity.",85,"Here is the detailed, step-by-step protocol for the experiment:

**Protocol: Investigating the Effect of Cow's Milk-Derived Exosomal microRNAs on Epigenetic Changes in T Cells**

**Step 1: Cell Culture Model**

1.1. Obtain Jurkat cells (human T cell line) from a reputable cell bank or culture collection.

1.2. Culture Jurkat cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine in a humidified incubator at 37°C and 5% CO2.

1.3. Maintain cell cultures at a density of 1-2 x 10^6 cells/mL and passage every 3-4 days.

**Step 2: Exosomal microRNA Isolation**

2.1. Obtain cow's milk samples from a local dairy farm or purchase from a commercial supplier.

2.2. Centrifuge milk samples at 3000 x g for 10 minutes at 4°C to remove fat and debris.

2.3. Filter the supernatant through a 0.22 μm filter to remove bacteria and other contaminants.

2.4. Isolate exosomes using a commercial exosome isolation kit (e.g., ExoQuick-TC) according to the manufacturer's instructions.

2.5. Verify exosome isolation using transmission electron microscopy (TEM):

a. Fix exosomes with 2% paraformaldehyde and 1% glutaraldehyde in PBS for 1 hour at room temperature.
b. Stain with 2% uranyl acetate for 1 hour at room temperature.
c. Visualize using a TEM microscope (e.g., FEI Tecnai G2 Spirit).

2.6. Verify exosome isolation using nanoparticle tracking analysis (NTA):

a. Dilute exosomes in PBS to a concentration of 1 x 10^9 particles/mL.
b. Analyze using a nanoparticle tracking analyzer (e.g., Malvern NanoSight NS300).

2.7. Verify exosome isolation using Western blotting:

a. Lyse exosomes in RIPA buffer and separate proteins using SDS-PAGE.
b. Blot onto a PVDF membrane and probe with antibodies against exosomal markers (e.g., CD63, CD81).

**Step 3: MicroRNA Extraction and Quantification**

3.1. Extract microRNAs from isolated exosomes using a commercial kit (e.g., miRNeasy) according to the manufacturer's instructions.

3.2. Quantify microRNA levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR):

a. Convert microRNAs to cDNA using a reverse transcription kit (e.g., TaqMan MicroRNA Reverse Transcription Kit).
b. Perform qRT-PCR using a microRNA-specific primer set (e.g., hsa-miR-21) and a qRT-PCR master mix (e.g., TaqMan Universal Master Mix II).

**Step 4: T Cell Treatment and Epigenetic Analysis**

4.1. Treat Jurkat cells with isolated exosomal microRNAs at varying concentrations (10, 50, 100 nM) for 24-48 hours.

4.2. Analyze epigenetic changes in T cells using DNA methylation analysis:

a. Extract genomic DNA from treated T cells using a DNA extraction kit (e.g., DNeasy Blood & Tissue Kit).
b. Perform bisulfite sequencing or methylation-specific PCR to analyze DNA methylation levels.

4.3. Analyze epigenetic changes in T cells using histone modification analysis:

a. Extract chromatin from treated T cells using a chromatin extraction kit (e.g., Chromatin Extraction Kit).
b. Perform chromatin immunoprecipitation sequencing (ChIP-seq) or chromatin immunoprecipitation (ChIP) to analyze histone modification levels.

4.4. Analyze epigenetic changes in T cells using gene expression analysis:

a. Extract total RNA from treated T cells using a RNA extraction kit (e.g., RNeasy Mini Kit).
b. Perform RNA-seq or qRT-PCR to analyze gene expression levels.

**Step 5: Control Groups**

5.1. Include negative control groups:

a. T cells without exosomal microRNA treatment.
b. T cells treated with scrambled microRNA controls.

5.2. Include positive control groups:

a. T cells treated with known epigenetic modifiers (e.g., 5-azacytidine, trichostatin A).

**Step 6: Data Analysis**

6.1. Compare epigenetic changes in T cells treated with exosomal microRNAs to control groups.

6.2. Analyze data using statistical software (e.g., R, Python) to determine significance (p < 0.05).

**Experimental Design to Disprove the Hypothesis**

To disprove the hypothesis, the following modifications will be made:

1. Use a high concentration of exosomal microRNAs (e.g., 500 nM) to maximize the potential effect.
2. Include multiple control groups to ensure that any observed effects are specific to the exosomal microRNAs.
3. Analyze multiple epigenetic markers to increase the chances of detecting changes.
4. Perform the experiment in triplicate to ensure reproducibility.

**Budget and Timeframe**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000. This estimate includes:

* Cell culture reagents and consumables: $10,000
* Exosome isolation and microRNA extraction kits: $5,000
* qRT-PCR and epigenetic analysis reagents: $10,000
* Labor costs (postdoc or graduate student): $20,000-$30,000
* Miscellaneous (equipment maintenance, travel, etc.): $5,000-$10,000","```
   Jurkat Cells (x10^6)  FBS (%)  Penicillin-Streptomycin (%)  L-Glutamine (%)  Cow's Milk (mL)  Exosomal microRNA (nM)  Epigenetic Change
0                1.5       12.0                    1.2             1.5           5.0                10.0           0.25
1                1.0       10.0                    1.0             1.0           3.0                50.0           0.50
2                1.2       11.0                    1.1             1.2           4.0                20.0           0.30
3                1.8       13.0                    1.4             1.8           6.0                15.0           0.40
4                1.1       10.5                    1.0             1.1           3.5                30.0           0.35
5                1.4       11.5                    1.2             1.4           4.5                25.0           0.45
6                1.6       12.5                    1.3             1.6           5.5                40.0           0.55
7                1.3       11.0                    1.1             1.3           4.0                35.0           0.50
8                1.9       13.5                    1.5             1.9           6.5                20.0           0.60
9                1.0       10.0                    1.0             1.0           3.0                10.0           0.20
10               1.7       12.0                    1.4             1.7           5.0                45.0           0.65
11               1.2       11.2                    1.1             1.2           4.2                30.0           0.40
12               1.5       11.8                    1.3             1.5           4.8                25.0           0.50
13               1.1       10.8                    1.0             1.1           3.8                20.0           0.35
14               1.9       13.2                    1.5             1.9           6.2                40.0           0.70
15               1.4       11.5                    1.2             1.4           4.5                35.0           0.55
16               1.7       12.5                    1.4             1.7           5.5                50.0           0.80
17               1.0       10.2                    1.0             1.0           3.2                15.0           0.30
18               1.6       12.2                    1.3             1.6           4.2                30.0           0.50
19               1.3       11.0                    1.1             1.3           4.0                25.0           0.45
20               1.8       13.0                    1.5             1.8           6.0                45.0           0.75
21               1.2       11.5                    1.2             1.2           4.5                35.0           0.60
22               1.5       12.0                    1.3             1.5           5.0                50.0           0.85
23               1.1       10.5                    1.0             1.1           3.5                20.0           0.40
24               1.7       12.8                    1.4             1.7           5.8                40.0           0.80
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/240dbf6fbf86a9e442ba19e5db1187e8ca4f3816.summary'],"Can the controlled covalent attachment of a targeting ligand to gold nanoparticles also enhance the delivery of immunotherapeutic agents to cancer cells, leading to increased anti-tumor immune responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that the controlled covalent attachment of a targeting ligand to gold nanoparticles can enhance the delivery of immunotherapeutic agents to cancer cells, leading to increased anti-tumor immune responses.

**Experimental Plan:**

**Title:** Investigating the Enhanced Delivery of Immunotherapeutic Agents to Cancer Cells using Targeted Gold Nanoparticles

**Objective:** To determine if the controlled covalent attachment of a targeting ligand to gold nanoparticles can enhance the delivery of immunotherapeutic agents to cancer cells, leading to increased anti-tumor immune responses.

**Hypothesis to be Disproven:** The controlled covalent attachment of a targeting ligand to gold nanoparticles does not enhance the delivery of immunotherapeutic agents to cancer cells, leading to increased anti-tumor immune responses.

**Experimental Design:**

1. **Preparation of Targeted Gold Nanoparticles:**
	* Synthesize gold nanoparticles with a controlled covalent attachment of a targeting ligand (e.g., glycan ligand) using established methods.
	* Characterize the nanoparticles using techniques such as transmission electron microscopy (TEM), dynamic light scattering (DLS), and Fourier transform infrared (FTIR) spectroscopy.
2. **Immunotherapeutic Agent Loading:**
	* Load the targeted gold nanoparticles with an immunotherapeutic agent (e.g., checkpoint inhibitor, cytokine, or tumor antigen) using established methods.
	* Characterize the loaded nanoparticles using techniques such as UV-Vis spectroscopy, fluorescence spectroscopy, and gel electrophoresis.
3. **Cell Culture and Treatment:**
	* Culture cancer cells (e.g., CD22 (+) lymphoma cells) in cell culture media.
	* Treat the cells with:
		+ Free immunotherapeutic agent (control group)
		+ Targeted gold nanoparticles loaded with immunotherapeutic agent (experimental group)
		+ Non-targeted gold nanoparticles loaded with immunotherapeutic agent (negative control group)
4. **Immune Response Analysis:**
	* Measure the immune response using techniques such as:
		+ Flow cytometry to analyze T cell activation and proliferation
		+ Enzyme-linked immunosorbent assay (ELISA) to measure cytokine production
		+ Western blot to analyze protein expression
5. **Comparison and Statistical Analysis:**
	* Compare the immune response between the control group, experimental group, and negative control group.
	* Perform statistical analysis using techniques such as ANOVA and t-test to determine significant differences.

**Equipment and Resources:**

* Gold nanoparticles
* Targeting ligand (e.g., glycan ligand)
* Immunotherapeutic agent (e.g., checkpoint inhibitor, cytokine, or tumor antigen)
* Cancer cells (e.g., CD22 (+) lymphoma cells)
* Cell culture media
* Fluorescence microscope
* Flow cytometer
* UV-Vis spectrophotometer
* Fluorescence spectrophotometer
* Gel electrophoresis equipment
* Western blot equipment
* ELISA kit

**Timeline:**

* Week 1-2: Synthesize and characterize targeted gold nanoparticles
* Week 3-4: Load immunotherapeutic agent onto targeted gold nanoparticles
* Week 5-6: Culture cancer cells and treat with different groups
* Week 7-8: Analyze immune response using flow cytometry, ELISA, and Western blot
* Week 9-10: Compare and analyze results, perform statistical analysis

**Budget:**

* Gold nanoparticles: $1,000
* Targeting ligand: $500
* Immunotherapeutic agent: $1,500
* Cancer cells: $500
* Cell culture media: $500
* Equipment and consumables: $2,000
* Total: $6,000

This experimental plan is designed to test the hypothesis in a controlled and systematic manner, using existing scientific methods and equipment. The budget and timeline are reasonable, and the experiment can be completed within a few months.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Synthesis and Characterization of Targeted Gold Nanoparticles**

**Step 1.1: Synthesis of Gold Nanoparticles**

1. Weigh 0.1 g of gold(III) chloride trihydrate (HAuCl4·3H2O) and dissolve it in 100 mL of deionized water in a 250 mL round-bottom flask.
2. Add 1 mL of 1% sodium citrate solution to the flask and stir for 10 minutes.
3. Heat the mixture to 100°C and maintain the temperature for 10 minutes.
4. Remove the flask from the heat and let it cool to room temperature.
5. Centrifuge the mixture at 10,000 rpm for 10 minutes to collect the gold nanoparticles.

**Step 1.2: Covalent Attachment of Targeting Ligand**

1. Weigh 0.01 g of the targeting ligand (e.g., glycan ligand) and dissolve it in 10 mL of deionized water.
2. Add 1 mL of the ligand solution to the gold nanoparticle suspension and stir for 2 hours.
3. Add 1 mL of 1% EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) solution to the mixture and stir for 2 hours.
4. Centrifuge the mixture at 10,000 rpm for 10 minutes to collect the targeted gold nanoparticles.

**Step 1.3: Characterization of Targeted Gold Nanoparticles**

1. Measure the size and shape of the targeted gold nanoparticles using transmission electron microscopy (TEM).
2. Measure the hydrodynamic diameter and zeta potential of the targeted gold nanoparticles using dynamic light scattering (DLS).
3. Analyze the surface chemistry of the targeted gold nanoparticles using Fourier transform infrared (FTIR) spectroscopy.

**Protocol 2: Immunotherapeutic Agent Loading**

**Step 2.1: Preparation of Immunotherapeutic Agent Solution**

1. Weigh 0.01 g of the immunotherapeutic agent (e.g., checkpoint inhibitor, cytokine, or tumor antigen) and dissolve it in 10 mL of phosphate-buffered saline (PBS).

**Step 2.2: Loading of Immunotherapeutic Agent onto Targeted Gold Nanoparticles**

1. Add 1 mL of the immunotherapeutic agent solution to 1 mL of the targeted gold nanoparticle suspension.
2. Stir the mixture for 2 hours at room temperature.
3. Centrifuge the mixture at 10,000 rpm for 10 minutes to collect the loaded targeted gold nanoparticles.

**Step 2.3: Characterization of Loaded Targeted Gold Nanoparticles**

1. Measure the UV-Vis absorption spectrum of the loaded targeted gold nanoparticles using a UV-Vis spectrophotometer.
2. Measure the fluorescence emission spectrum of the loaded targeted gold nanoparticles using a fluorescence spectrophotometer.
3. Analyze the protein expression of the loaded targeted gold nanoparticles using gel electrophoresis.

**Protocol 3: Cell Culture and Treatment**

**Step 3.1: Cell Culture**

1. Culture CD22 (+) lymphoma cells in cell culture media (e.g., RPMI 1640) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
2. Incubate the cells at 37°C in a humidified atmosphere with 5% CO2.

**Step 3.2: Treatment of Cells**

1. Divide the cells into three groups: control group, experimental group, and negative control group.
2. Treat the control group with 1 mL of free immunotherapeutic agent solution.
3. Treat the experimental group with 1 mL of loaded targeted gold nanoparticle suspension.
4. Treat the negative control group with 1 mL of non-targeted gold nanoparticle suspension loaded with immunotherapeutic agent.

**Protocol 4: Immune Response Analysis**

**Step 4.1: Flow Cytometry**

1. Harvest the cells and stain them with fluorescent antibodies against T cell markers (e.g., CD4, CD8).
2. Analyze the stained cells using a flow cytometer to measure T cell activation and proliferation.

**Step 4.2: ELISA**

1. Harvest the cells and collect the supernatant.
2. Measure the cytokine production using an ELISA kit according to the manufacturer's instructions.

**Step 4.3: Western Blot**

1. Harvest the cells and extract the proteins using a protein extraction buffer.
2. Analyze the protein expression using Western blot according to the manufacturer's instructions.

**Protocol 5: Comparison and Statistical Analysis**

**Step 5.1: Data Collection**

1. Collect the data from the flow cytometry, ELISA, and Western blot analyses.

**Step 5.2: Statistical Analysis**

1. Perform statistical analysis using techniques such as ANOVA and t-test to determine significant differences between the control group, experimental group, and negative control group.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific equipment and resources available in the laboratory. Additionally, the protocols should be followed with proper safety precautions and sterile techniques to ensure the integrity of the experiment.","```
   HAuCl4·3H2O  sodium_citrate  targeting_ligand  EDC  immunotherapeutic_agent  outcome
0           0.1           1.0           0.005     1.0                  0.01  0.85
1           0.12          1.2           0.006     1.2                  0.012  0.92
2           0.08          0.8           0.004     0.8                  0.008  0.78
3           0.11          1.1           0.0055    1.1                  0.011  0.88
4           0.09          0.9           0.0045    0.9                  0.009  0.82
5           0.13          1.3           0.007     1.3                  0.013  0.95
6           0.07          0.7           0.0035    0.7                  0.007  0.75
7           0.1           1.0           0.005     1.0                  0.01  0.85
8           0.12          1.2           0.006     1.2                  0.012  0.92
9           0.08          0.8           0.004     0.8                  0.008  0.78
10          0.11          1.1           0.0055    1.1                  0.011  0.88
11          0.09          0.9           0.0045    0.9                  0.009  0.82
12          0.13          1.3           0.007     1.3                  0.013  0.95
13          0.07          0.7           0.0035    0.7                  0.007  0.75
14          0.1           1.0           0.005     1.0                  0.01  0.85
15          0.12          1.2           0.006     1.2                  0.012  0.92
16          0.08          0.8           0.004     0.8                  0.008  0.78
17          0.11          1.1           0.0055    1.1                  0.011  0.88
18          0.09          0.9           0.0045    0.9                  0.009  0.82
19          0.13          1.3           0.007     1.3                  0.013  0.95
20          0.07          0.7           0.0035    0.7                  0.007  0.75
21          0.1           1.0           0.005     1.0                  0.01  0.85
22          0.12          1.2           0.006     1.2                  0.012  0.92
23          0.08          0.8           0.004     0.8                  0.008  0.78
24          0.11          1.1           0.0055    1.1                  0.011  0.88
```",0.9975289278851968
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7d5c64f3b5e9c0f03af9248cd996aba155609f59.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0faf911519ef1a7cef62f4bedf68ca5a4e1970e5.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4d28f5775396681d3f2bc5de1278a0422c085cc9.summary']","Can the expression levels of novel miRNAs (novel_229, novel_609, and novel_973) in human peripheral blood mononuclear cells (PBMCs) predict the susceptibility to influenza A/H3N2 infection and modulate the immune response by regulating the expression of genes involved in B cell receptor signaling and immune response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed a high-level experimental plan to test and potentially disprove the hypothesis. This plan is designed to be feasible within a reasonable time frame and budget.

**Hypothesis:** Can the expression levels of novel miRNAs (novel_229, novel_609, and novel_973) in human peripheral blood mononuclear cells (PBMCs) predict the susceptibility to influenza A/H3N2 infection and modulate the immune response by regulating the expression of genes involved in B cell receptor signaling and immune response?

**Experimental Plan:**

**Objective:** To investigate the correlation between novel miRNA expression levels in PBMCs and susceptibility to influenza A/H3N2 infection, as well as their potential role in modulating the immune response.

**Step 1: Sample Collection and Preparation**

* Recruit a cohort of healthy individuals (n=50) and collect peripheral blood samples.
* Isolate PBMCs from the blood samples using density gradient centrifugation (e.g., Ficoll-Paque).
* Store the isolated PBMCs in RNA-stable conditions (e.g., RNAlater) for subsequent RNA extraction.

**Step 2: miRNA Expression Profiling**

* Extract total RNA from the PBMCs using a commercial RNA extraction kit (e.g., TRIzol).
* Perform miRNA expression profiling using a microarray platform (e.g., Affymetrix) or next-generation sequencing (NGS) technology (e.g., Illumina) to quantify the expression levels of novel_229, novel_609, and novel_973 miRNAs.
* Normalize the miRNA expression data using established methods (e.g., RMA, DESeq2).

**Step 3: Influenza A/H3N2 Infection and Immune Response Analysis**

* Infect a subset of the PBMC samples (n=25) with influenza A/H3N2 virus in vitro.
* Measure the immune response by analyzing the expression of genes involved in B cell receptor signaling and immune response using quantitative real-time PCR (qRT-PCR) or RNA-seq.
* Compare the immune response between infected and uninfected samples.

**Step 4: Correlation Analysis and Prediction Model Development**

* Correlate the miRNA expression levels with the immune response data using statistical methods (e.g., Pearson correlation, linear regression).
* Develop a prediction model using machine learning algorithms (e.g., logistic regression, random forest) to predict the susceptibility to influenza A/H3N2 infection based on the miRNA expression levels.

**Step 5: Validation and Verification**

* Validate the prediction model using an independent cohort of samples (n=25).
* Verify the results by comparing the predicted susceptibility with the actual infection status of the individuals.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the null hypothesis: ""The expression levels of novel miRNAs (novel_229, novel_609, and novel_973) in human PBMCs do not predict the susceptibility to influenza A/H3N2 infection and do not modulate the immune response.""

**Alternative Experimental Design:**

* Use a different cohort of individuals with a known history of influenza A/H3N2 infection (n=25) and collect PBMC samples.
* Perform miRNA expression profiling and immune response analysis as described in Steps 2 and 3.
* Compare the miRNA expression levels and immune response between the infected and uninfected groups.
* If the results show no significant correlation between miRNA expression levels and immune response, or no difference in miRNA expression levels between infected and uninfected groups, it would suggest that the novel miRNAs do not play a role in predicting susceptibility to influenza A/H3N2 infection or modulating the immune response.

**Budget and Timeframe:**

This experimental plan can be completed within 6-9 months with a budget of approximately $150,000-$200,000. The budget breakdown is as follows:

* Sample collection and preparation: $10,000
* miRNA expression profiling: $30,000 (microarray) or $50,000 (NGS)
* Influenza A/H3N2 infection and immune response analysis: $20,000
* Correlation analysis and prediction model development: $10,000
* Validation and verification: $20,000
* Alternative experimental design: $30,000

Note: The budget and timeframe may vary depending on the specific requirements of the laboratory, equipment, and personnel.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Sample Collection and Preparation**

1.1. Recruit 50 healthy individuals and obtain informed consent.

1.2. Collect 10 mL of peripheral blood from each individual using a sterile needle and syringe.

1.3. Transfer the blood samples to 15 mL tubes containing 1 mL of anticoagulant (e.g., EDTA or heparin).

1.4. Mix the blood samples gently and store them at room temperature (20-25°C) for up to 2 hours.

1.5. Isolate PBMCs from the blood samples using density gradient centrifugation:
	* Add 10 mL of Ficoll-Paque to a 15 mL tube.
	* Carefully layer 10 mL of blood sample on top of the Ficoll-Paque.
	* Centrifuge at 400 x g for 30 minutes at room temperature.
	* Collect the PBMC layer (interface between the plasma and Ficoll-Paque) and transfer it to a new 15 mL tube.
	* Wash the PBMCs with 10 mL of phosphate-buffered saline (PBS) and centrifuge at 200 x g for 10 minutes.
	* Discard the supernatant and resuspend the PBMCs in 1 mL of RNAlater.

1.6. Store the isolated PBMCs in RNAlater at -80°C for subsequent RNA extraction.

**Step 2: miRNA Expression Profiling**

2.1. Extract total RNA from the PBMCs using a commercial RNA extraction kit (e.g., TRIzol):
	* Add 1 mL of TRIzol to the PBMCs in RNAlater and mix well.
	* Incubate at room temperature for 5 minutes.
	* Add 200 μL of chloroform and mix well.
	* Centrifuge at 12,000 x g for 15 minutes at 4°C.
	* Transfer the upper aqueous phase to a new tube and add 500 μL of isopropanol.
	* Mix well and incubate at room temperature for 10 minutes.
	* Centrifuge at 12,000 x g for 10 minutes at 4°C.
	* Discard the supernatant and wash the RNA pellet with 1 mL of 75% ethanol.
	* Centrifuge at 7,500 x g for 5 minutes at 4°C.
	* Discard the supernatant and air-dry the RNA pellet.

2.2. Perform miRNA expression profiling using a microarray platform (e.g., Affymetrix):
	* Label the extracted RNA with a fluorescent dye (e.g., Cy3 or Cy5) according to the manufacturer's instructions.
	* Hybridize the labeled RNA to the microarray chip according to the manufacturer's instructions.
	* Scan the microarray chip using a microarray scanner.
	* Analyze the microarray data using established methods (e.g., RMA, DESeq2) to quantify the expression levels of novel_229, novel_609, and novel_973 miRNAs.

**Step 3: Influenza A/H3N2 Infection and Immune Response Analysis**

3.1. Infect a subset of the PBMC samples (n=25) with influenza A/H3N2 virus in vitro:
	* Prepare the influenza A/H3N2 virus stock according to the manufacturer's instructions.
	* Add 100 μL of the virus stock to 1 mL of PBMCs in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
	* Incubate at 37°C and 5% CO2 for 24 hours.

3.2. Measure the immune response by analyzing the expression of genes involved in B cell receptor signaling and immune response using qRT-PCR or RNA-seq:
	* Extract total RNA from the infected and uninfected PBMCs using a commercial RNA extraction kit (e.g., TRIzol).
	* Convert the RNA to cDNA using a reverse transcription kit (e.g., SuperScript III).
	* Perform qRT-PCR or RNA-seq to quantify the expression levels of genes involved in B cell receptor signaling and immune response.

**Step 4: Correlation Analysis and Prediction Model Development**

4.1. Correlate the miRNA expression levels with the immune response data using statistical methods (e.g., Pearson correlation, linear regression):
	* Use a statistical software package (e.g., R, Python) to perform correlation analysis between the miRNA expression levels and immune response data.

4.2. Develop a prediction model using machine learning algorithms (e.g., logistic regression, random forest) to predict the susceptibility to influenza A/H3N2 infection based on the miRNA expression levels:
	* Use a machine learning software package (e.g., scikit-learn, TensorFlow) to develop a prediction model using the correlated data.

**Step 5: Validation and Verification**

5.1. Validate the prediction model using an independent cohort of samples (n=25):
	* Collect PBMC samples from an independent cohort of healthy individuals.
	* Perform miRNA expression profiling and immune response analysis as described in Steps 2 and 3.
	* Use the prediction model to predict the susceptibility to influenza A/H3N2 infection based on the miRNA expression levels.

5.2. Verify the results by comparing the predicted susceptibility with the actual infection status of the individuals:
	* Compare the predicted susceptibility with the actual infection status of the individuals using statistical methods (e.g., receiver operating characteristic (ROC) curve analysis).

**Experimental Design to Disprove the Hypothesis**

To disprove the hypothesis, repeat Steps 1-5 using a different cohort of individuals with a known history of influenza A/H3N2 infection (n=25). If the results show no significant correlation between miRNA expression levels and immune response, or no difference in miRNA expression levels between infected and uninfected groups, it would suggest that the novel miRNAs do not play a role in predicting susceptibility to influenza A/H3N2 infection or modulating the immune response.","```
   Ficoll-Paque  Anticoagulant  TRIzol  Chloroform  Isopropanol  miRNA_229  miRNA_609  miRNA_973  Influenza_Virus  Immune_Response  Outcome
0           9.5           0.9     0.8        0.18         0.45       12.1       8.5       10.2           100.0           0.6       1.0
1          10.2           1.1     0.9        0.20         0.50       11.5       9.0       11.0           120.0           0.7       1.0
2           9.8           1.0     0.8        0.19         0.48       12.5       8.8       10.5           110.0           0.8       1.0
3          10.5           1.2     0.9        0.21         0.52       11.2       9.2       11.2           130.0           0.9       1.0
4           9.2           0.8     0.7        0.17         0.42       12.8       8.2       10.8           100.0           0.5       0.0
5          10.8           1.3     0.9        0.22         0.55       11.8       9.5       11.5           140.0           1.0       1.0
6           9.5           0.9     0.8        0.18         0.45       12.2       8.5       10.3           110.0           0.6       1.0
7          10.0           1.0     0.8        0.19         0.48       12.0       8.8       10.8           120.0           0.7       1.0
8           9.2           0.8     0.7        0.17         0.42       13.0       8.2       11.0           100.0           0.5       0.0
9          10.5           1.2     0.9        0.21         0.52       11.5       9.2       11.2           130.0           0.9       1.0
10         9.8           1.0     0.8        0.19         0.48       12.5       8.8       10.5           110.0           0.8       1.0
11         10.2           1.1     0.9        0.20         0.50       11.2       9.0       11.0           120.0           0.7       1.0
12         9.5           0.9     0.8        0.18         0.45       12.8       8.5       10.8           100.0           0.6       1.0
13         10.8           1.3     0.9        0.22         0.55       11.8       9.5       11.5           140.0           1.0       1.0
14         9.2           0.8     0.7        0.17         0.42       13.2       8.2       11.2           100.0           0.5       0.0
15         10.0           1.0     0.8        0.19         0.48       12.2       8.8       10.8           120.0           0.7       1.0
16         9.8           1.0     0.8        0.19         0.48       12.5       8.8       10.5           110.0           0.8       1.0
17         10.5           1.2     0.9        0.21         0.52       11.5       9.2       11.2           130.0           0.9       1.0
18         9.5           0.9     0.8        0.18         0.45       12.8       8.5       10.8           100.0           0.6       1.0
19         10.2           1.1     0.9        0.20         0.50       11.2       9.0       11.0           120.0           0.7       1.0
20         9.2           0.8     0.7        0.17         0.42       13.5       8.2       11.5           100.0           0.5       0.0
21         10.8           1.3     0.9        0.22         0.55       11.8       9.5       11.5           140.0           1.0       1.0
22         10.0           1.0     0.8        0.19         0.48       12.2       8.8       10.8           120.0           0.7       1.0
23         9.8           1.0     0.8        0.19         0.48       12.5       8.8       10.5           110.0           0.8       1.0
24         10.5           1.2     0.9        0.21         0.52       11.5       9.2       11.2           130.0           0.9       1.0
```",0.43258009851795587
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0e453fea5982861c1de4a8da95ceb55270e3240e.summary'],Can the incorporation of SIRPα-based CARs with additional immune checkpoint inhibitors enhance their anti-tumor activity and reduce side effects in B-cell acute lymphoblastic leukemia treatment?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis and potentially disprove it. Since the goal is to test the incorporation of SIRPα-based CARs with additional immune checkpoint inhibitors, we'll focus on evaluating the anti-tumor activity and side effects in B-cell acute lymphoblastic leukemia treatment.

**Experimental Plan:**

**Title:** Evaluating the Efficacy and Safety of SIRPα-based CARs with Immune Checkpoint Inhibitors in B-ALL Treatment

**Objective:** To investigate whether the combination of SIRPα-based CARs with immune checkpoint inhibitors enhances anti-tumor activity and reduces side effects in B-cell acute lymphoblastic leukemia treatment.

**Experimental Design:**

1. **Cell Preparation:**
	* Generate SIRPα-based CAR T cells and traditional IgG1-based CAR T cells using established protocols.
	* Prepare human B-ALL cells for xenografting.
2. **Xenograft Mouse Model:**
	* Establish a xenograft mouse model of B-ALL by engrafting human B-ALL cells into immunodeficient mice (e.g., NSG or NOD-SCID mice).
3. **Treatment Groups:**
	* Group 1: SIRPα-based CAR T cells alone (control)
	* Group 2: SIRPα-based CAR T cells + immune checkpoint inhibitor (e.g., PD-1 or CTLA-4 inhibitor)
	* Group 3: Traditional IgG1-based CAR T cells alone (control)
	* Group 4: Traditional IgG1-based CAR T cells + immune checkpoint inhibitor (e.g., PD-1 or CTLA-4 inhibitor)
4. **Treatment and Monitoring:**
	* Inject the respective CAR T cells and/or immune checkpoint inhibitors into the mice via tail vein injection.
	* Monitor tumor burden using bioluminescence imaging (BLI) or flow cytometry.
	* Evaluate CAR T cell persistence and cytokine profiles (e.g., IL-2, IFN-γ, TNF-α) using flow cytometry and ELISA or cytokine bead array.
	* Assess side effects by monitoring mouse weight, behavior, and blood chemistry.
5. **Endpoint Analysis:**
	* Compare tumor burden, CAR T cell persistence, and cytokine profiles between groups.
	* Evaluate the incidence and severity of side effects in each group.

**To Disprove the Hypothesis:**

To disprove the hypothesis, we'll focus on demonstrating that the combination of SIRPα-based CARs with immune checkpoint inhibitors does not enhance anti-tumor activity or reduce side effects compared to traditional IgG1-based CAR T cells. Specifically, we'll look for:

* No significant difference in tumor burden reduction between Group 2 (SIRPα-based CAR T cells + immune checkpoint inhibitor) and Group 4 (traditional IgG1-based CAR T cells + immune checkpoint inhibitor).
* No significant difference in CAR T cell persistence or cytokine profiles between Group 2 and Group 4.
* No significant reduction in side effects in Group 2 compared to Group 4.

**Equipment and Resources:**

* Xenograft mouse model
* Human B-ALL cells
* SIRPα-based CAR T cells
* Traditional IgG1-based CAR T cells
* Immune checkpoint inhibitors (e.g., PD-1 or CTLA-4 inhibitor)
* Flow cytometer
* ELISA or cytokine bead array
* Bioluminescence imaging system (optional)

**Timeline:**

* Cell preparation and xenografting: 2-3 weeks
* Treatment and monitoring: 4-6 weeks
* Endpoint analysis: 2-3 weeks

**Budget:**

* Cell preparation and xenografting: $5,000 - $10,000
* Treatment and monitoring: $10,000 - $20,000
* Endpoint analysis: $5,000 - $10,000
* Total: $20,000 - $40,000

This experimental plan should provide a comprehensive evaluation of the hypothesis within a reasonable time frame and budget.",85,"Here is the detailed, step-by-step protocol for the experimental plan:

**Protocol: Evaluating the Efficacy and Safety of SIRPα-based CARs with Immune Checkpoint Inhibitors in B-ALL Treatment**

**Step 1: Cell Preparation (Weeks 1-2)**

1.1. Generate SIRPα-based CAR T cells:

* Isolate human T cells from peripheral blood mononuclear cells (PBMCs) using Ficoll-Paque density gradient centrifugation.
* Activate T cells with anti-CD3/CD28 beads and expand in culture with IL-2 (100 IU/mL) and IL-7 (10 ng/mL) for 7-10 days.
* Transduce T cells with SIRPα-based CAR lentiviral vector using a multiplicity of infection (MOI) of 5-10.
* Select transduced cells using puromycin (1 μg/mL) for 7-10 days.
* Expand and freeze SIRPα-based CAR T cells in aliquots of 1x10^7 cells/mL.

1.2. Generate traditional IgG1-based CAR T cells:

* Follow the same protocol as 1.1, but use an IgG1-based CAR lentiviral vector.

1.3. Prepare human B-ALL cells for xenografting:

* Obtain human B-ALL cells from a reputable cell bank or generate them in-house using established protocols.
* Expand B-ALL cells in culture with RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Freeze B-ALL cells in aliquots of 1x10^7 cells/mL.

**Step 2: Xenograft Mouse Model (Weeks 2-3)**

2.1. Establish a xenograft mouse model of B-ALL:

* Obtain immunodeficient mice (e.g., NSG or NOD-SCID mice) from a reputable vendor.
* Inject 1x10^6 human B-ALL cells into the tail vein of each mouse.
* Monitor mice for engraftment using bioluminescence imaging (BLI) or flow cytometry.

**Step 3: Treatment Groups (Weeks 3-4)**

3.1. Prepare treatment groups:

* Group 1: SIRPα-based CAR T cells alone (control)
* Group 2: SIRPα-based CAR T cells + immune checkpoint inhibitor (e.g., PD-1 or CTLA-4 inhibitor)
* Group 3: Traditional IgG1-based CAR T cells alone (control)
* Group 4: Traditional IgG1-based CAR T cells + immune checkpoint inhibitor (e.g., PD-1 or CTLA-4 inhibitor)

3.2. Inject CAR T cells and/or immune checkpoint inhibitors into mice:

* Inject 1x10^7 CAR T cells into the tail vein of each mouse in Groups 1-4.
* Inject immune checkpoint inhibitor (e.g., 100 μg/mouse) into the tail vein of mice in Groups 2 and 4.

**Step 4: Treatment and Monitoring (Weeks 4-6)**

4.1. Monitor tumor burden:

* Perform bioluminescence imaging (BLI) or flow cytometry to monitor tumor burden in mice every 7-10 days.

4.2. Evaluate CAR T cell persistence and cytokine profiles:

* Collect blood samples from mice every 7-10 days and analyze CAR T cell persistence using flow cytometry.
* Measure cytokine profiles (e.g., IL-2, IFN-γ, TNF-α) using ELISA or cytokine bead array.

4.3. Assess side effects:

* Monitor mouse weight, behavior, and blood chemistry every 7-10 days.

**Step 5: Endpoint Analysis (Weeks 7-9)**

5.1. Compare tumor burden, CAR T cell persistence, and cytokine profiles between groups:

* Analyze data using statistical software (e.g., GraphPad Prism) to compare tumor burden, CAR T cell persistence, and cytokine profiles between groups.

5.2. Evaluate the incidence and severity of side effects in each group:

* Analyze data using statistical software to compare side effects between groups.

**To Disprove the Hypothesis:**

* Compare Group 2 (SIRPα-based CAR T cells + immune checkpoint inhibitor) to Group 4 (traditional IgG1-based CAR T cells + immune checkpoint inhibitor) for:
	+ No significant difference in tumor burden reduction.
	+ No significant difference in CAR T cell persistence or cytokine profiles.
	+ No significant reduction in side effects.

**Equipment and Resources:**

* Xenograft mouse model
* Human B-ALL cells
* SIRPα-based CAR T cells
* Traditional IgG1-based CAR T cells
* Immune checkpoint inhibitors (e.g., PD-1 or CTLA-4 inhibitor)
* Flow cytometer
* ELISA or cytokine bead array
* Bioluminescence imaging system (optional)

**Timeline:**

* Cell preparation and xenografting: 2-3 weeks
* Treatment and monitoring: 4-6 weeks
* Endpoint analysis: 2-3 weeks

**Budget:**

* Cell preparation and xenografting: $5,000 - $10,000
* Treatment and monitoring: $10,000 - $20,000
* Endpoint analysis: $5,000 - $10,000
* Total: $20,000 - $40,000","```
   SIRPα CAR T cells  IgG1 CAR T cells  PD-1 inhibitor  CTLA-4 inhibitor  Outcome
0               1e+07             0.0           100.0             0.0  Tumor_free
1               5e+06             0.0           200.0             0.0  Partial_response
2               1e+07             0.0             0.0             50.0  Stable_disease
3               2e+06             0.0           150.0             0.0  Progressive_disease
4               1e+07             0.0           100.0             0.0  Tumor_free
5               5e+06             0.0             0.0             25.0  Partial_response
6               1e+07             0.0           200.0             0.0  Tumor_free
7               2e+06             0.0           150.0             0.0  Stable_disease
8               1e+07             0.0             0.0             50.0  Partial_response
9               5e+06             0.0           100.0             0.0  Progressive_disease
10              1e+07             0.0           200.0             0.0  Tumor_free
11              2e+06             0.0             0.0             25.0  Stable_disease
12              1e+07             0.0           150.0             0.0  Partial_response
13              5e+06             0.0           100.0             0.0  Progressive_disease
14              1e+07             0.0             0.0             50.0  Tumor_free
15              2e+06             0.0           200.0             0.0  Stable_disease
16              1e+07             0.0           150.0             0.0  Partial_response
17              5e+06             0.0             0.0             25.0  Progressive_disease
18              1e+07             0.0           100.0             0.0  Tumor_free
19              2e+06             0.0             0.0             50.0  Stable_disease
20              1e+07             0.0           200.0             0.0  Partial_response
21              5e+06             0.0           150.0             0.0  Progressive_disease
22              1e+07             0.0             0.0             25.0  Tumor_free
23              2e+06             0.0           100.0             0.0  Stable_disease
24              1e+07             0.0           200.0             0.0  Partial_response
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7b445443362b84bfd1c8a1428cfba36d8eb91678.summary'],Can the incorporation of a protease-cleavable peptide sequence into the self-immolative linker enhance the selective release of budesonide in CD19-expressing cells while minimizing off-target effects?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis. Here's a high-level experimental approach:

**Hypothesis:** Can the incorporation of a protease-cleavable peptide sequence into the self-immolative linker enhance the selective release of budesonide in CD19-expressing cells while minimizing off-target effects?

**Experimental Design:**

**Objective:** To investigate whether the incorporation of a protease-cleavable peptide sequence into the self-immolative linker improves the selective release of budesonide in CD19-expressing cells and reduces off-target effects.

**Experimental Approach:**

1. **Linker Design and Synthesis:**
	* Design and synthesize three types of linkers:
		+ Linker A: Self-immolative linker without protease-cleavable peptide sequence (control)
		+ Linker B: Self-immolative linker with a protease-cleavable peptide sequence (e.g., Gly-Pro-Leu-Gly)
		+ Linker C: Self-immolative linker with a non-cleavable peptide sequence (e.g., Gly-Ala-Leu-Gly) as a negative control
2. **ADC Preparation:**
	* Conjugate each linker to the CD19 antibody using standard conjugation protocols
	* Prepare ADCs with varying linker types (A, B, and C)
3. **In Vitro Studies:**
	* **Protease-Mediated Cleavage Assay:**
		+ Incubate ADCs with a protease (e.g., cathepsin B) and measure the release of budesonide using HPLC or LC-MS/MS
		+ Compare the rate and extent of budesonide release between Linker A, B, and C
	* **Cell-Based Assays:**
		+ Evaluate the potency and selectivity of ADCs in CD19-expressing and non-expressing cell lines using a glucocorticoid response element (GRE) luciferase reporter assay
		+ Assess the cytotoxicity of ADCs in CD19-expressing and non-expressing cell lines using a cell viability assay (e.g., MTT or CellTiter-Glo)
4. **In Vivo Studies:**
	* **Pharmacokinetic and Pharmacodynamic Studies:**
		+ Administer ADCs to mice and measure the plasma concentrations of budesonide and its metabolites using LC-MS/MS
		+ Evaluate the efficacy of ADCs in a CD19-expressing tumor model using tumor volume measurements and immunohistochemistry
	* **Toxicity Studies:**
		+ Monitor animal weights, behavior, and clinical signs of toxicity
		+ Perform histopathological analysis of major organs to assess potential off-target effects

**Equipment and Resources:**

* HPLC or LC-MS/MS for budesonide quantitation
* Luciferase reporter assay kit
* Cell culture facilities
* Animal housing facilities
* Protease (e.g., cathepsin B)
* CD19 antibody
* Budesonide
* Linker synthesis reagents
* Conjugation reagents
* Mice (for in vivo studies)

**Timeline:**

* Linker design and synthesis: 2 weeks
* ADC preparation: 2 weeks
* In vitro studies: 4 weeks
* In vivo studies: 8 weeks
* Data analysis and interpretation: 4 weeks

**Budget:**

* Reagents and consumables: $10,000
* Equipment maintenance and operation: $5,000
* Animal costs: $8,000
* Personnel and labor: $20,000
* Total: $43,000

This experimental design aims to test the hypothesis by comparing the performance of ADCs with different linker types in vitro and in vivo. By including a negative control linker (Linker C), we can assess the specificity of the protease-cleavable peptide sequence. If the results show that Linker B (with the protease-cleavable peptide sequence) does not improve the selective release of budesonide in CD19-expressing cells or reduce off-target effects, it would disprove the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Linker Design and Synthesis (Weeks 1-2)**

1.1. Design the three types of linkers:
	* Linker A: Self-immolative linker without protease-cleavable peptide sequence (control)
	* Linker B: Self-immolative linker with a protease-cleavable peptide sequence (e.g., Gly-Pro-Leu-Gly)
	* Linker C: Self-immolative linker with a non-cleavable peptide sequence (e.g., Gly-Ala-Leu-Gly) as a negative control

1.2. Synthesize the linkers using standard peptide synthesis protocols:
	* Use Fmoc-based solid-phase peptide synthesis or other suitable methods
	* Purify the linkers using HPLC or other chromatographic techniques
	* Verify the linker structures using mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy

**ADC Preparation (Weeks 3-4)**

2.1. Conjugate each linker to the CD19 antibody using standard conjugation protocols:
	* Use a suitable conjugation method (e.g., maleimide-thiol chemistry or click chemistry)
	* Optimize the conjugation conditions (e.g., linker:antibody ratio, reaction time, and temperature)
	* Purify the ADCs using size exclusion chromatography (SEC) or other suitable methods

2.2. Prepare ADCs with varying linker types (A, B, and C):
	* Prepare multiple batches of each ADC to ensure consistency and reproducibility
	* Characterize the ADCs using SDS-PAGE, Western blot, and MS to confirm the conjugation and linker incorporation

**In Vitro Studies (Weeks 5-8)**

**Protease-Mediated Cleavage Assay**

3.1. Prepare the protease-mediated cleavage reaction mixture:
	* Dissolve the ADCs in a suitable buffer (e.g., PBS or Tris-HCl) at a concentration of 1-10 μM
	* Add the protease (e.g., cathepsin B) at a concentration of 1-10 nM
	* Incubate the mixture at 37°C for 0-24 hours

3.2. Measure the release of budesonide using HPLC or LC-MS/MS:
	* Inject the reaction mixture into the HPLC or LC-MS/MS system
	* Monitor the budesonide peak area or peak height using a suitable detection method (e.g., UV or MS)
	* Calculate the rate and extent of budesonide release using a calibration curve or standard addition method

**Cell-Based Assays**

3.3. Prepare the cell culture media and reagents:
	* Use a suitable cell culture medium (e.g., RPMI-1640 or DMEM) supplemented with 10% FBS and antibiotics
	* Prepare the glucocorticoid response element (GRE) luciferase reporter assay reagents according to the manufacturer's instructions

3.4. Evaluate the potency and selectivity of ADCs in CD19-expressing and non-expressing cell lines:
	* Seed the cells in 96-well plates at a density of 1-5 × 10^4 cells/well
	* Treat the cells with ADCs at varying concentrations (e.g., 0.1-100 nM) for 24-48 hours
	* Measure the luciferase activity using a plate reader or luminometer
	* Calculate the IC50 values using a suitable software (e.g., GraphPad Prism)

3.5. Assess the cytotoxicity of ADCs in CD19-expressing and non-expressing cell lines:
	* Use a cell viability assay kit (e.g., MTT or CellTiter-Glo) according to the manufacturer's instructions
	* Measure the absorbance or luminescence using a plate reader
	* Calculate the IC50 values using a suitable software (e.g., GraphPad Prism)

**In Vivo Studies (Weeks 9-16)**

**Pharmacokinetic and Pharmacodynamic Studies**

4.1. Administer ADCs to mice:
	* Use a suitable mouse model (e.g., CD19-expressing tumor model)
	* Administer the ADCs via a suitable route (e.g., intravenous or intraperitoneal) at a dose of 1-10 mg/kg
	* Collect blood samples at various time points (e.g., 0, 1, 2, 4, 8, and 24 hours) using a suitable method (e.g., retro-orbital bleeding or cardiac puncture)

4.2. Measure the plasma concentrations of budesonide and its metabolites using LC-MS/MS:
	* Extract the plasma samples using a suitable method (e.g., protein precipitation or solid-phase extraction)
	* Analyze the extracts using LC-MS/MS with a suitable detection method (e.g., MRM or SRM)
	* Calculate the pharmacokinetic parameters (e.g., Cmax, Tmax, and AUC) using a suitable software (e.g., Phoenix WinNonlin)

4.3. Evaluate the efficacy of ADCs in a CD19-expressing tumor model:
	* Measure the tumor volume using a suitable method (e.g., caliper or MRI)
	* Perform immunohistochemistry to assess the expression of CD19 and other markers
	* Calculate the tumor growth inhibition (TGI) using a suitable software (e.g., GraphPad Prism)

**Toxicity Studies**

4.4. Monitor animal weights, behavior, and clinical signs of toxicity:
	* Weigh the animals daily or weekly
	* Observe the animals for signs of toxicity (e.g., lethargy, diarrhea, or skin lesions)
	* Record any adverse events or mortalities

4.5. Perform histopathological analysis of major organs:
	* Collect tissue samples from major organs (e.g., liver, kidney, and spleen) at the end of the study
	* Fix and process the tissues using a suitable method (e.g., formalin fixation and paraffin embedding)
	* Stain the tissues with a suitable stain (e.g., H&E or IHC) and examine them using a microscope

**Data Analysis and Interpretation (Weeks 17-20)**

5.1. Analyze the data from the in vitro and in vivo studies:
	* Use suitable software (e.g., GraphPad Prism, Phoenix WinNonlin, or R) to analyze the data
	* Calculate the statistical significance using suitable tests (e.g., t-test, ANOVA, or regression analysis)

5.2. Interpret the results in the context of the hypothesis:
	* Compare the performance of ADCs with different linker types
	* Evaluate the specificity of the protease-cleavable peptide sequence
	* Determine whether the results support or disprove the hypothesis

Note: The protocols above are detailed and step-by-step, but they may require modifications based on the specific requirements of the experiment and the equipment available. It is essential to follow proper laboratory protocols, safety guidelines, and animal welfare regulations when conducting these experiments.","```
   Linker_A  Linker_B  Linker_C  Protease  Budesonide  Outcome
0       0.5       0.0       0.0      5.0       10.0  0.800000
1       0.0       0.5       0.0      2.0        5.0  0.400000
2       0.0       0.0       0.5      1.0        2.0  0.200000
3       0.3       0.2       0.0      4.0        8.0  0.600000
4       0.2       0.3       0.0      3.0        6.0  0.500000
5       0.1       0.4       0.0      2.5        5.5  0.450000
6       0.4       0.1       0.0      3.5        7.0  0.550000
7       0.0       0.0       0.3      1.5        3.0  0.300000
8       0.5       0.0       0.0      5.5       11.0  0.850000
9       0.0       0.5       0.0      2.2        5.2  0.420000
10      0.0       0.0       0.5      1.2        2.4  0.240000
11      0.3       0.2       0.0      4.2        8.4  0.620000
12      0.2       0.3       0.0      3.2        6.4  0.520000
13      0.1       0.4       0.0      2.8        5.8  0.480000
14      0.4       0.1       0.0      3.8        7.6  0.580000
15      0.0       0.0       0.3      1.8        3.6  0.360000
16      0.5       0.0       0.0      5.8       11.6  0.880000
17      0.0       0.5       0.0      2.5        5.5  0.450000
18      0.0       0.0       0.5      1.5        3.0  0.300000
19      0.3       0.2       0.0      4.5        9.0  0.650000
20      0.2       0.3       0.0      3.5        7.0  0.550000
21      0.1       0.4       0.0      3.0        6.0  0.500000
22      0.4       0.1       0.0      4.0        8.0  0.600000
23      0.0       0.0       0.3      2.0        4.0  0.400000
24      0.5       0.0       0.0      6.0       12.0  0.900000
```",0.41046346213873497
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/46d183ce66a050840eb450818686898470f53452.summary'],Can the integration of machine learning-based analysis of immune receptor sequences with electronic health records (EHRs) and medical imaging data improve the accuracy of disease diagnosis and prognosis by identifying complex patterns and correlations between immune responses and disease manifestations?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Experimental Plan to Test the Hypothesis:**

**Title:** Integrating Machine Learning-based Immune Receptor Sequence Analysis with EHRs and Medical Imaging Data for Improved Disease Diagnosis and Prognosis

**Objective:** To investigate whether the integration of machine learning-based analysis of immune receptor sequences with electronic health records (EHRs) and medical imaging data can improve the accuracy of disease diagnosis and prognosis by identifying complex patterns and correlations between immune responses and disease manifestations.

**Experimental Design:**

1. **Data Collection:**
	* Collect a dataset of immune receptor sequences (e.g., T-cell receptor or B-cell receptor sequences) from patients with various diseases (e.g., cancer, autoimmune disorders, infectious diseases).
	* Obtain corresponding EHRs and medical imaging data (e.g., MRI, CT scans) for each patient.
	* Ensure data quality, integrity, and anonymization.
2. **Machine Learning Model Development:**
	* Develop and train machine learning models (e.g., deep learning, random forest) to analyze immune receptor sequences and identify patterns associated with disease diagnosis and prognosis.
	* Integrate EHRs and medical imaging data into the machine learning model to identify correlations between immune responses and disease manifestations.
3. **Model Evaluation:**
	* Split the dataset into training (70%) and testing sets (30%).
	* Evaluate the performance of the machine learning model using metrics such as accuracy, precision, recall, F1-score, and area under the receiver operating characteristic curve (AUC-ROC).
4. **Comparison with Traditional Diagnostic Methods:**
	* Compare the performance of the machine learning model with traditional diagnostic methods (e.g., clinical diagnosis, laboratory tests) using the same dataset.
5. **Statistical Analysis:**
	* Perform statistical analysis to determine the significance of the results and identify potential confounding variables.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Correlation between Immune Receptor Sequences and Disease Diagnosis/Prognosis

**Objective:** To test the null hypothesis that there is no correlation between immune receptor sequences and disease diagnosis/prognosis, and that the integration of machine learning-based analysis with EHRs and medical imaging data does not improve disease diagnosis and prognosis.

**Experimental Design:**

1. **Data Collection:**
	* Collect a dataset of immune receptor sequences from healthy individuals and patients with various diseases.
	* Ensure data quality, integrity, and anonymization.
2. **Randomized Data Shuffling:**
	* Randomly shuffle the immune receptor sequences and reassign them to different patients, while keeping the EHRs and medical imaging data unchanged.
	* This will break any potential correlations between immune receptor sequences and disease diagnosis/prognosis.
3. **Machine Learning Model Development:**
	* Develop and train machine learning models to analyze the shuffled immune receptor sequences and predict disease diagnosis and prognosis.
4. **Model Evaluation:**
	* Evaluate the performance of the machine learning model using the same metrics as before.
5. **Comparison with Original Model:**
	* Compare the performance of the machine learning model with the original model developed using the correct immune receptor sequences.

**Rationale:**

By shuffling the immune receptor sequences, we are effectively removing any potential correlations between the sequences and disease diagnosis/prognosis. If the machine learning model still performs well in predicting disease diagnosis and prognosis, it would suggest that the integration of immune receptor sequences with EHRs and medical imaging data does not provide any additional value. This would disprove the original hypothesis.

**Budget and Timeframe:**

* Estimated budget: $200,000 - $300,000
* Estimated timeframe: 6-12 months

This experiment can be executed within a reasonable time frame and budget by leveraging existing datasets, computational resources, and machine learning tools. The results of this experiment will provide valuable insights into the potential of integrating machine learning-based immune receptor sequence analysis with EHRs and medical imaging data for improved disease diagnosis and prognosis.",85,"I'd be happy to help you with that! Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Protocol 1: Data Collection**

1.1. Identify and obtain datasets of immune receptor sequences (e.g., T-cell receptor or B-cell receptor sequences) from patients with various diseases (e.g., cancer, autoimmune disorders, infectious diseases) from public databases (e.g., ImmuneDB, VDJdb) or through collaborations with hospitals and research institutions.

1.2. Ensure data quality and integrity by:
	* Checking for errors in sequencing data
	* Removing low-quality or ambiguous sequences
	* Normalizing sequence lengths and formats

1.3. Obtain corresponding EHRs and medical imaging data (e.g., MRI, CT scans) for each patient from the same sources.

1.4. Anonymize patient data by:
	* Removing identifiable information (e.g., names, dates of birth)
	* Assigning unique identifiers to each patient
	* Encrypting data storage and transmission

**Protocol 2: Machine Learning Model Development**

2.1. Preprocess immune receptor sequences by:
	* Tokenizing sequences into individual amino acids or nucleotides
	* Encoding sequences using techniques (e.g., one-hot encoding, k-mer encoding)
	* Normalizing sequence lengths and formats

2.2. Split the dataset into training (70%) and testing sets (30%) using stratified sampling to maintain class balance.

2.3. Develop and train machine learning models (e.g., deep learning, random forest) using the training set, with the following hyperparameters:
	* Model architecture: specify the number of layers, neurons, and activation functions
	* Optimization algorithm: specify the algorithm (e.g., Adam, SGD) and learning rate
	* Regularization techniques: specify the type (e.g., dropout, L1/L2 regularization) and strength

2.4. Integrate EHRs and medical imaging data into the machine learning model by:
	* Encoding EHRs using techniques (e.g., bag-of-words, TF-IDF)
	* Extracting features from medical imaging data using techniques (e.g., convolutional neural networks, transfer learning)
	* Concatenating or fusing the encoded EHRs and medical imaging features with the immune receptor sequence features

**Protocol 3: Model Evaluation**

3.1. Evaluate the performance of the machine learning model using the testing set, with the following metrics:
	* Accuracy
	* Precision
	* Recall
	* F1-score
	* Area under the receiver operating characteristic curve (AUC-ROC)

3.2. Calculate confidence intervals for each metric using bootstrapping or cross-validation.

**Protocol 4: Comparison with Traditional Diagnostic Methods**

4.1. Collect data on traditional diagnostic methods (e.g., clinical diagnosis, laboratory tests) for the same patients.

4.2. Evaluate the performance of traditional diagnostic methods using the same metrics as in Protocol 3.

4.3. Compare the performance of the machine learning model with traditional diagnostic methods using statistical tests (e.g., t-test, ANOVA).

**Protocol 5: Statistical Analysis**

5.1. Perform statistical analysis to determine the significance of the results using techniques (e.g., regression analysis, principal component analysis).

5.2. Identify potential confounding variables and adjust for them using techniques (e.g., matching, propensity scoring).

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Data Collection**

1.1. Collect a dataset of immune receptor sequences from healthy individuals and patients with various diseases.

1.2. Ensure data quality, integrity, and anonymization as in Protocol 1 of the main experiment.

**Protocol 2: Randomized Data Shuffling**

2.1. Randomly shuffle the immune receptor sequences and reassign them to different patients, while keeping the EHRs and medical imaging data unchanged.

2.2. Verify that the shuffling process has broken any potential correlations between immune receptor sequences and disease diagnosis/prognosis.

**Protocol 3: Machine Learning Model Development**

3.1. Develop and train machine learning models to analyze the shuffled immune receptor sequences and predict disease diagnosis and prognosis, using the same hyperparameters as in Protocol 2 of the main experiment.

**Protocol 4: Model Evaluation**

4.1. Evaluate the performance of the machine learning model using the same metrics as in Protocol 3 of the main experiment.

4.2. Compare the performance of the machine learning model with the original model developed using the correct immune receptor sequences.

**Protocol 5: Comparison with Original Model**

5.1. Calculate the difference in performance between the two models using statistical tests (e.g., t-test, ANOVA).

5.2. Interpret the results in the context of the null hypothesis, and determine whether the integration of machine learning-based analysis with EHRs and medical imaging data provides any additional value for disease diagnosis and prognosis.

These detailed protocols should provide a clear roadmap for executing the experiment and ensuring replicability and specificity in the results.","```
   Immune_Receptor_Seq  EHR_Data  Medical_Imaging_Data  Model_Architecture  Optimization_Algorithm  Regularization_Technique  Accuracy  Precision  Recall  F1-score  AUC-ROC
0                  1000       500                2000             2_Layers         Adam_Optimizer           Dropout_0.2     0.85     0.82     0.88     0.85     0.92
1                  1500       750                3000             3_Layers         SGD_Optimizer           L1_Regularization     0.80     0.78     0.83     0.80     0.88
2                  2000      1000                4000             2_Layers         Adam_Optimizer           Dropout_0.5     0.90     0.88     0.92     0.90     0.95
3                  1200       600                2500             3_Layers         SGD_Optimizer           L2_Regularization     0.82     0.80     0.85     0.82     0.90
4                  1800      1200                3500             2_Layers         Adam_Optimizer           Dropout_0.3     0.88     0.86     0.90     0.88     0.93
5                  2500      1500                4500             3_Layers         SGD_Optimizer           L1_Regularization     0.85     0.83     0.88     0.85     0.91
6                  3000      2000                5000             2_Layers         Adam_Optimizer           Dropout_0.4     0.92     0.90     0.94     0.92     0.96
7                  2200      1400                3800             3_Layers         SGD_Optimizer           L2_Regularization     0.83     0.81     0.86     0.83     0.90
8                  2800      1800                4200             2_Layers         Adam_Optimizer           Dropout_0.5     0.90     0.88     0.92     0.90     0.95
9                  3500      2200                4800             3_Layers         SGD_Optimizer           L1_Regularization     0.86     0.84     0.89     0.86     0.92
10                 4000      2500                5500             2_Layers         Adam_Optimizer           Dropout_0.3     0.94     0.92     0.96     0.94     0.98
11                 4500      2800                5800             3_Layers         SGD_Optimizer           L2_Regularization     0.89     0.87     0.91     0.89     0.94
12                 5000      3000                6000             2_Layers         Adam_Optimizer           Dropout_0.4     0.96     0.94     0.98     0.96     0.99
13                 5500      3200                6200             3_Layers         SGD_Optimizer           L1_Regularization     0.91     0.89     0.93     0.91     0.95
14                 6000      3500                6500             2_Layers         Adam_Optimizer           Dropout_0.5     0.98     0.96     0.99     0.98     1.00
15                 6500      3800                6800             3_Layers         SGD_Optimizer           L2_Regularization     0.93     0.91     0.95     0.93     0.97
16                 7000      4000                7000             2_Layers         Adam_Optimizer           Dropout_0.3     0.99     0.97     1.00     0.99     1.00
17                 7500      4200                7200             3_Layers         SGD_Optimizer           L1_Regularization     0.95     0.93     0.97     0.95     0.98
18                 8000      4500                7500             2_Layers         Adam_Optimizer           Dropout_0.4     1.00     0.99     1.00     1.00     1.00
19                 8500      4800                7800             3_Layers         SGD_Optimizer           L2_Regularization     0.97     0.95     0.99     0.97     0.99
20                 9000      5000                8000             2_Layers         Adam_Optimizer           Dropout_0.5     1.00     1.00     1.00     1.00     1.00
21                10000      5500                8500             3_Layers         SGD_Optimizer           L1_Regularization     0.99     0.98     1.00     0.99     1.00
22                11000      6000                9000             2_Layers         Adam_Optimizer           Dropout_0.3     1.00     1.00     1.00     1.00     1.00
23                12000      6500                9500             3_Layers         SGD_Optimizer           L2_Regularization     1.00     1.00     1.00     1.00     1.00
24                13000      7000               10000             2_Layers         Adam_Optimizer           Dropout_0.4     1.00     1.00     1.00     1.00     1.00
```",0.6113034109485926
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9d2eac6e1ab1a135b44aebea55dbc506a8bba5ce.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c39a7d2e53824610191e93370cf79ef1735d89f7.summary']","Can the mechanical forces generated by cell surface receptors be modulated by altering the local concentration of PI(4,5)P2 in the plasma membrane, and can this modulation be visualized and measured using molecular tension fluorescence microscopy probes?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the context from the two papers, I propose an experimental plan to test the hypothesis:

**Hypothesis:** Can the mechanical forces generated by cell surface receptors be modulated by altering the local concentration of PI(4,5)P2 in the plasma membrane, and can this modulation be visualized and measured using molecular tension fluorescence microscopy probes?

**Experimental Plan:**

**Objective:** To investigate whether altering the local concentration of PI(4,5)P2 in the plasma membrane affects the mechanical forces generated by cell surface receptors and to visualize and measure this modulation using molecular tension fluorescence microscopy (MTFM) probes.

**Experimental Design:**

1. **Cell Preparation:**
	* Use a cell line expressing integrin receptors (e.g., HeLa or CHO cells).
	* Transfect the cells with a PI(4,5)P2-targeting CRISPR-Cas9 system to either knockdown or overexpress PI(4,5)P2.
	* Validate the knockdown or overexpression of PI(4,5)P2 using Western blot or flow cytometry.
2. **MTFM Probe Preparation:**
	* Prepare MTFM probes with an RGD peptide motif as the ligand, as described in the 2017 paper.
	* Immobilize the probes onto a glass coverslip.
3. **Cell Culture and Imaging:**
	* Culture the transfected cells on the probe-functionalized surface.
	* Use fluorescence microscopy to image the cells and measure the fluorescence intensity changes, which will infer the forces generated by the integrin receptors.
4. **Data Analysis:**
	* Analyze the fluorescence intensity changes to quantify the mechanical forces generated by the integrin receptors.
	* Compare the forces generated by cells with altered PI(4,5)P2 levels to those with normal PI(4,5)P2 levels.

**Experimental Controls:**

* Use cells with normal PI(4,5)P2 levels as a control.
* Use a non-targeting CRISPR-Cas9 system as a control for the PI(4,5)P2-targeting CRISPR-Cas9 system.

**Equipment and Resources:**

* Fluorescence microscope
* Cell culture facility
* Microfluidic device for cell culturing
* CRISPR-Cas9 system
* IgG-BCR-expressing B cells (optional)
* Mechanical force sensor (optional)

**Time and Budget:**

* The experiment can be completed within 2-3 months, depending on the availability of resources and the complexity of the CRISPR-Cas9 system.
* The budget will depend on the cost of the CRISPR-Cas9 system, cell culture reagents, and microscopy equipment. A rough estimate would be around $10,000-$20,000.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to show that altering the local concentration of PI(4,5)P2 in the plasma membrane does not affect the mechanical forces generated by cell surface receptors.

**Experimental Design:**

1. **Cell Preparation:**
	* Use a cell line expressing integrin receptors (e.g., HeLa or CHO cells).
	* Transfect the cells with a non-targeting CRISPR-Cas9 system as a control.
2. **MTFM Probe Preparation:**
	* Prepare MTFM probes with an RGD peptide motif as the ligand, as described in the 2017 paper.
	* Immobilize the probes onto a glass coverslip.
3. **Cell Culture and Imaging:**
	* Culture the transfected cells on the probe-functionalized surface.
	* Use fluorescence microscopy to image the cells and measure the fluorescence intensity changes, which will infer the forces generated by the integrin receptors.
4. **Data Analysis:**
	* Analyze the fluorescence intensity changes to quantify the mechanical forces generated by the integrin receptors.
	* Compare the forces generated by cells with normal PI(4,5)P2 levels to those with altered PI(4,5)P2 levels.

If the results show no significant difference in the mechanical forces generated by cells with altered PI(4,5)P2 levels compared to those with normal PI(4,5)P2 levels, it would suggest that altering the local concentration of PI(4,5)P2 in the plasma membrane does not affect the mechanical forces generated by cell surface receptors, thus disproving the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Preparation**

**Step 1.1: Cell Culture**

* Obtain HeLa or CHO cells expressing integrin receptors from a reliable cell bank or culture them in-house.
* Culture the cells in a suitable medium (e.g., DMEM or RPMI 1640) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C and 5% CO2.

**Step 1.2: Transfection with PI(4,5)P2-targeting CRISPR-Cas9 System**

* Design and synthesize guide RNAs (gRNAs) targeting PI(4,5)P2 using a CRISPR-Cas9 design tool (e.g., CRISPR Design or CRISPOR).
* Prepare the CRISPR-Cas9 plasmid by cloning the gRNA into a suitable vector (e.g., pSpCas9(BB)-2A-GFP).
* Transfect the cells with the CRISPR-Cas9 plasmid using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.
* Incubate the cells for 48-72 hours to allow for gene editing.

**Step 1.3: Validation of PI(4,5)P2 Knockdown or Overexpression**

* Harvest the transfected cells and extract total protein using a suitable lysis buffer (e.g., RIPA buffer).
* Perform Western blot analysis using an anti-PI(4,5)P2 antibody to detect changes in PI(4,5)P2 levels.
* Alternatively, perform flow cytometry analysis using an anti-PI(4,5)P2 antibody to detect changes in PI(4,5)P2 levels.

**Protocol 2: MTFM Probe Preparation**

**Step 2.1: Preparation of MTFM Probes**

* Synthesize the RGD peptide motif according to the 2017 paper's protocol.
* Conjugate the RGD peptide to a fluorescent dye (e.g., Alexa Fluor 488) using a suitable linker (e.g., NHS-ester).
* Purify the conjugated probe using high-performance liquid chromatography (HPLC) or gel filtration.

**Step 2.2: Immobilization of MTFM Probes onto Glass Coverslips**

* Clean and silanize glass coverslips according to the manufacturer's instructions.
* Incubate the coverslips with a solution of the MTFM probe (1-10 μM) in phosphate-buffered saline (PBS) for 1-2 hours at room temperature.
* Rinse the coverslips with PBS and dry them under a nitrogen stream.

**Protocol 3: Cell Culture and Imaging**

**Step 3.1: Cell Culture on Probe-Functionalized Surface**

* Seed the transfected cells onto the probe-functionalized coverslips at a density of 1-5 x 10^4 cells/cm^2.
* Culture the cells in a suitable medium (e.g., DMEM or RPMI 1640) supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO2.

**Step 3.2: Fluorescence Microscopy**

* Use a fluorescence microscope (e.g., Olympus IX83 or Zeiss Axiovert 200M) equipped with a suitable objective lens (e.g., 40x or 63x) and a camera (e.g., EMCCD or sCMOS).
* Acquire fluorescence images of the cells using a suitable software (e.g., MetaMorph or ImageJ).
* Measure the fluorescence intensity changes using a suitable software (e.g., ImageJ or Fiji).

**Protocol 4: Data Analysis**

**Step 4.1: Quantification of Mechanical Forces**

* Analyze the fluorescence intensity changes to quantify the mechanical forces generated by the integrin receptors using a suitable software (e.g., ImageJ or Fiji).
* Calculate the force values using the fluorescence intensity changes and a calibration curve obtained from a force sensor (e.g., a cantilever-based force sensor).

**Step 4.2: Comparison of Forces**

* Compare the forces generated by cells with altered PI(4,5)P2 levels to those with normal PI(4,5)P2 levels using a suitable statistical test (e.g., t-test or ANOVA).

**Protocol for Disproving the Hypothesis**

The protocol for disproving the hypothesis is similar to the above protocols, except that the cells are transfected with a non-targeting CRISPR-Cas9 system as a control. The same steps are followed, and the results are compared to those obtained with cells with altered PI(4,5)P2 levels. If no significant difference is observed, it would suggest that altering the local concentration of PI(4,5)P2 in the plasma membrane does not affect the mechanical forces generated by cell surface receptors, thus disproving the hypothesis.","```
   HeLa_Cells  FBS  Penicillin_Streptomycin  gRNA  Lipofectamine_3000  RGD_Peptide  Alexa_Fluor_488  PI_4_5_P2_Level  Fluorescence_Intensity  Force_Value
0           1e5  10.0                  1.0  100          2.0          5.0           1.0           0.8             150.0       0.015
1           2e5   8.0                  0.8   80          1.5          4.0           0.8           0.9             120.0       0.012
2           3e5   9.0                  0.9   90          2.2          5.5           1.1           0.85            180.0       0.018
3           1e5  11.0                  1.1  110          2.5          6.0           1.2           0.8             200.0       0.020
4           2e5   9.5                  0.95  95          2.1          5.2           1.0           0.88            160.0       0.016
5           3e5  10.5                  1.05 105          2.3          5.8           1.1           0.83            190.0       0.019
6           1e5   8.5                  0.85  85          1.8          4.5           0.9           0.92            140.0       0.014
7           2e5  10.0                  1.0  100          2.0          5.0           1.0           0.87            170.0       0.017
8           3e5   9.2                  0.92  92          2.2          5.6           1.1           0.84            185.0       0.019
9           1e5  11.2                  1.12 112          2.6          6.2           1.2           0.79            210.0       0.022
10          2e5   9.8                  0.98  98          2.4          5.9           1.1           0.86            195.0       0.020
11          3e5  10.8                  1.08 108          2.5          6.1           1.2           0.82            205.0       0.021
12          1e5   8.2                  0.82  82          1.7          4.2           0.9           0.93            130.0       0.013
13          2e5  10.2                  1.02 102          2.1          5.3           1.0           0.89            165.0       0.016
14          3e5   9.5                  0.95  95          2.3          5.7           1.1           0.81            190.0       0.019
15          1e5  11.5                  1.15 115          2.7          6.5           1.2           0.78            220.0       0.023
16          2e5  10.5                  1.05 105          2.4          6.0           1.1           0.85            200.0       0.021
17          3e5   9.0                  0.9   90          2.0          5.1           1.0           0.83            175.0       0.018
18          1e5   8.8                  0.88  88          1.9          4.8           0.9           0.91            145.0       0.015
19          2e5  10.8                  1.08 108          2.5          6.2           1.2           0.82            210.0       0.022
20          3e5  10.2                  1.02 102          2.2          5.5           1.1           0.84            195.0       0.020
21          1e5  11.8                  1.18 118          2.8          6.8           1.2           0.77            230.0       0.024
22          2e5   9.2                  0.92  92          2.1          5.4           1.0           0.87            180.0       0.019
23          3e5  10.5                  1.05 105          2.4          6.1           1.1           0.83            205.0       0.021
24          1e5   8.5                  0.85  85          1.8          4.6           0.9           0.92            140.0       0.014
```",0.08334344189658832
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d00b0c28f7b005b1c325249d864c8587907f457d.summary'],Can the noninvasive detection of glomerulonephritis using NIRF-based optical imaging be improved by incorporating machine learning algorithms that integrate single-cell transcriptomic data to identify specific patterns of stress response genes and regulatory pathway perturbations in antinuclear antibody positive individuals?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll break down the experimental plan to test and potentially disprove it.

**Hypothesis:** Can the noninvasive detection of glomerulonephritis using NIRF-based optical imaging be improved by incorporating machine learning algorithms that integrate single-cell transcriptomic data to identify specific patterns of stress response genes and regulatory pathway perturbations in antinuclear antibody positive individuals?

**Experimental Plan:**

**Objective:** To investigate whether incorporating machine learning algorithms with single-cell transcriptomic data can improve the noninvasive detection of glomerulonephritis using NIRF-based optical imaging in antinuclear antibody positive individuals.

**Experimental Design:**

1. **Patient Recruitment:** Recruit 100 antinuclear antibody positive individuals with suspected glomerulonephritis and 50 healthy controls.
2. **NIRF-based Optical Imaging:** Perform NIRF-based optical imaging on all participants to obtain baseline images.
3. **Single-Cell Transcriptomic Analysis:** Collect blood samples from all participants and perform single-cell RNA sequencing (scRNA-seq) to generate transcriptomic data.
4. **Machine Learning Algorithm Development:** Develop and train machine learning algorithms to integrate scRNA-seq data with NIRF-based optical imaging data to identify patterns of stress response genes and regulatory pathway perturbations associated with glomerulonephritis.
5. **Data Integration and Analysis:** Integrate scRNA-seq data with NIRF-based optical imaging data using the developed machine learning algorithms.
6. **Glomerulonephritis Diagnosis:** Use the integrated data to predict glomerulonephritis diagnosis and compare with clinical diagnosis (gold standard).
7. **Validation:** Validate the results using an independent cohort of 50 antinuclear antibody positive individuals.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the null hypothesis that incorporating machine learning algorithms with single-cell transcriptomic data does not improve the noninvasive detection of glomerulonephritis using NIRF-based optical imaging in antinuclear antibody positive individuals.

**Experimental Design:**

1. **Sham Machine Learning Algorithm:** Develop a sham machine learning algorithm that randomly assigns glomerulonephritis diagnosis based on NIRF-based optical imaging data alone (without scRNA-seq data integration).
2. **Comparison:** Compare the diagnostic accuracy of the sham machine learning algorithm with the actual machine learning algorithm developed in the main experiment.
3. **Permutation Test:** Perform a permutation test to randomly shuffle the scRNA-seq data and re-run the machine learning algorithm to assess the significance of the results.

**Expected Outcomes:**

* If the hypothesis is true, the machine learning algorithm incorporating scRNA-seq data will show improved diagnostic accuracy compared to the sham algorithm.
* If the hypothesis is false, the sham algorithm will perform equally well or better than the actual machine learning algorithm, indicating that scRNA-seq data integration does not improve glomerulonephritis diagnosis.

**Unlimited Budget Considerations:**

* Utilize cutting-edge scRNA-seq technologies, such as 10x Genomics or Drop-seq, to generate high-quality transcriptomic data.
* Employ a large, diverse cohort of participants to ensure robust results.
* Collaborate with experts in machine learning, bioinformatics, and nephrology to develop and validate the machine learning algorithms.
* Utilize high-performance computing resources to process and analyze the large datasets generated in this study.

By following this experimental plan, we can rigorously test the hypothesis and determine whether incorporating machine learning algorithms with single-cell transcriptomic data can improve the noninvasive detection of glomerulonephritis using NIRF-based optical imaging in antinuclear antibody positive individuals.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Recruitment**

1.1. Define the inclusion and exclusion criteria for antinuclear antibody positive individuals with suspected glomerulonephritis and healthy controls.

1.2. Obtain Institutional Review Board (IRB) approval for the study.

1.3. Recruit 100 antinuclear antibody positive individuals with suspected glomerulonephritis and 50 healthy controls through advertisements, social media, and collaborations with nephrology clinics.

1.4. Obtain informed consent from all participants.

1.5. Collect demographic and medical history data from all participants.

**Protocol 2: NIRF-based Optical Imaging**

2.1. Prepare the NIRF-based optical imaging system according to the manufacturer's instructions.

2.2. Ensure the imaging system is calibrated and validated for use in human subjects.

2.3. Perform NIRF-based optical imaging on all participants to obtain baseline images.

2.4. Use a standardized imaging protocol to ensure consistency across all participants.

2.5. Save the images in a secure, de-identified database.

**Protocol 3: Single-Cell Transcriptomic Analysis**

3.1. Collect 10 mL of whole blood from each participant in EDTA tubes.

3.2. Process the blood samples within 2 hours of collection to isolate peripheral blood mononuclear cells (PBMCs).

3.3. Use a single-cell RNA sequencing (scRNA-seq) platform (e.g., 10x Genomics or Drop-seq) to generate transcriptomic data from the PBMCs.

3.4. Follow the manufacturer's instructions for library preparation, sequencing, and data analysis.

3.5. Generate a count matrix of gene expression levels for each cell.

**Protocol 4: Machine Learning Algorithm Development**

4.1. Collaborate with machine learning experts to develop and train machine learning algorithms to integrate scRNA-seq data with NIRF-based optical imaging data.

4.2. Use a supervised learning approach to train the algorithm on a subset of the data (e.g., 80% of the participants).

4.3. Use techniques such as feature selection, dimensionality reduction, and hyperparameter tuning to optimize the algorithm's performance.

4.4. Validate the algorithm on the remaining subset of the data (e.g., 20% of the participants).

**Protocol 5: Data Integration and Analysis**

5.1. Integrate the scRNA-seq data with the NIRF-based optical imaging data using the developed machine learning algorithm.

5.2. Use the integrated data to predict glomerulonephritis diagnosis for each participant.

5.3. Compare the predicted diagnoses with the clinical diagnosis (gold standard) to evaluate the algorithm's performance.

**Protocol 6: Glomerulonephritis Diagnosis**

6.1. Use the clinical diagnosis (gold standard) to determine the presence or absence of glomerulonephritis in each participant.

6.2. Compare the clinical diagnosis with the predicted diagnosis from the machine learning algorithm.

**Protocol 7: Validation**

7.1. Recruit an independent cohort of 50 antinuclear antibody positive individuals.

7.2. Repeat Protocols 2-6 on the independent cohort.

7.3. Compare the results from the independent cohort with the original cohort to validate the findings.

**Protocol 8: Experiment to Disprove the Hypothesis**

8.1. Develop a sham machine learning algorithm that randomly assigns glomerulonephritis diagnosis based on NIRF-based optical imaging data alone (without scRNA-seq data integration).

8.2. Compare the diagnostic accuracy of the sham algorithm with the actual machine learning algorithm developed in the main experiment.

8.3. Perform a permutation test to randomly shuffle the scRNA-seq data and re-run the machine learning algorithm to assess the significance of the results.

**Protocol 9: Data Management and Analysis**

9.1. Store all data in a secure, de-identified database.

9.2. Use standardized data formats and protocols for data analysis.

9.3. Perform statistical analysis using R or Python programming languages.

9.4. Use techniques such as cross-validation and bootstrapping to ensure the robustness of the results.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be validated.","```
   NIRF_Signal  scRNA_Seq_Samples  Machine_Learning_Algorithm  Glomerulonephritis_Diagnosis
0           100                  5                    0.8                         1
1           120                  7                    0.9                         1
2            90                  4                    0.7                         0
3           110                  6                    0.85                        1
4           130                  8                    0.95                        1
5            80                  3                    0.6                         0
6           100                  5                    0.8                         1
7           140                  9                    0.98                        1
8            70                  2                    0.5                         0
9           120                  7                    0.9                         1
10          150                 10                   0.99                        1
11           90                  4                    0.7                         0
12          110                  6                    0.85                        1
13           80                  3                    0.6                         0
14          130                  8                    0.95                        1
15          160                 11                   0.995                       1
16           70                  2                    0.5                         0
17          100                  5                    0.8                         1
18          140                  9                    0.98                        1
19           90                  4                    0.7                         0
20          120                  7                    0.9                         1
21          170                 12                   0.998                       1
22           80                  3                    0.6                         0
23          110                  6                    0.85                        1
24          180                 13                   0.999                       1
```",0.7863781621501512
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3874591960f08fa86d5f4d05f064608cd2fb9e47.summary'],"Can the optimal hinge length for a CAR construct be further fine-tuned by incorporating the flexibility of the target protein's extracellular domain into the in silico prediction model, leading to even more enhanced cytotoxicity against antigen-low leukemic cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! I'll break down the experimental plan to test and potentially disprove it.

**Hypothesis:** Can the optimal hinge length for a CAR (Chimeric Antigen Receptor) construct be further fine-tuned by incorporating the flexibility of the target protein's extracellular domain into the in silico prediction model, leading to even more enhanced cytotoxicity against antigen-low leukemic cells?

**Experimental Plan:**

**Objective:** To determine if incorporating the flexibility of the target protein's extracellular domain into the in silico prediction model improves the optimal hinge length for CAR constructs, resulting in enhanced cytotoxicity against antigen-low leukemic cells.

**Experimental Design:**

1. **In silico modeling:**
	* Use existing molecular dynamics simulations and protein structure prediction tools (e.g., Rosetta, GROMACS, or AMBER) to generate a set of CAR constructs with varying hinge lengths.
	* Incorporate the flexibility of the target protein's extracellular domain into the prediction model using techniques like molecular dynamics simulations, normal mode analysis, or elastic network models.
	* Predict the optimal hinge length for each CAR construct using the modified in silico model.
2. **CAR construct design and production:**
	* Design and produce a set of CAR constructs with varying hinge lengths, including those predicted to be optimal using the modified in silico model.
	* Use established methods for CAR construct design, cloning, and production (e.g., lentiviral or retroviral vectors).
3. **Cell preparation and transduction:**
	* Prepare antigen-low leukemic cell lines (e.g., K562 or Jurkat cells) and healthy donor T cells.
	* Transduce T cells with the designed CAR constructs using established protocols.
4. **Cytotoxicity assays:**
	* Co-culture transduced T cells with antigen-low leukemic cells and measure cytotoxicity using assays like chromium release, flow cytometry, or impedance-based assays.
	* Compare the cytotoxicity of T cells transduced with CAR constructs of varying hinge lengths, including those predicted to be optimal using the modified in silico model.
5. **Data analysis:**
	* Analyze the cytotoxicity data to determine if the incorporation of flexibility into the in silico model improves the prediction of optimal hinge length for CAR constructs.
	* Compare the cytotoxicity of T cells transduced with CAR constructs designed using the modified in silico model to those designed using traditional methods.

**Experiment to Disprove the Hypothesis:**

**Null Hypothesis:** Incorporating the flexibility of the target protein's extracellular domain into the in silico prediction model does not improve the optimal hinge length for CAR constructs, and therefore does not enhance cytotoxicity against antigen-low leukemic cells.

**Experimental Design:**

1. **In silico modeling:**
	* Use the same in silico modeling approach as above, but without incorporating the flexibility of the target protein's extracellular domain.
	* Predict the optimal hinge length for CAR constructs using the traditional in silico model.
2. **CAR construct design and production:**
	* Design and produce CAR constructs with varying hinge lengths, including those predicted to be optimal using the traditional in silico model.
3. **Cell preparation and transduction:**
	* Prepare antigen-low leukemic cell lines and healthy donor T cells as above.
	* Transduce T cells with the designed CAR constructs using established protocols.
4. **Cytotoxicity assays:**
	* Co-culture transduced T cells with antigen-low leukemic cells and measure cytotoxicity using the same assays as above.
5. **Data analysis:**
	* Compare the cytotoxicity of T cells transduced with CAR constructs designed using the traditional in silico model to those designed using the modified in silico model (from the main experiment).
	* If the cytotoxicity is similar or not significantly different, it would suggest that incorporating flexibility into the in silico model does not improve the optimal hinge length for CAR constructs, thus disproving the hypothesis.

**Budget and Timeframe:**

* This experiment can be completed within 6-12 months, depending on the availability of resources and personnel.
* The budget will depend on the specific reagents, equipment, and personnel required, but a rough estimate would be:
	+ In silico modeling and CAR construct design: $10,000 - $20,000
	+ CAR construct production and cell preparation: $20,000 - $40,000
	+ Cytotoxicity assays and data analysis: $15,000 - $30,000
	Total: $45,000 - $90,000

This experimental plan is designed to test the hypothesis in a controlled and rigorous manner, while also being mindful of the limited budget and resources.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: In Silico Modeling**

1.1. Install and configure molecular dynamics simulation software (e.g., Rosetta, GROMACS, or AMBER) on a high-performance computing cluster or a local machine.

1.2. Obtain the crystal structure of the target protein's extracellular domain from the Protein Data Bank (PDB) or generate a homology model using a protein structure prediction tool (e.g., Phyre2 or I-TASSER).

1.3. Perform molecular dynamics simulations of the target protein's extracellular domain using the chosen software, with a simulation time of at least 100 ns to capture the protein's flexibility.

1.4. Analyze the simulation trajectories using techniques like normal mode analysis or elastic network models to quantify the flexibility of the extracellular domain.

1.5. Use the flexibility data to modify the in silico prediction model for CAR construct design, incorporating the flexibility of the target protein's extracellular domain.

1.6. Generate a set of CAR constructs with varying hinge lengths using the modified in silico model, and predict the optimal hinge length for each construct.

**Step 2: CAR Construct Design and Production**

2.1. Design the CAR constructs using a molecular biology software (e.g., SnapGene or Geneious) based on the predicted optimal hinge lengths from Step 1.6.

2.2. Clone the CAR constructs into a lentiviral or retroviral vector using standard molecular biology techniques (e.g., PCR, restriction enzyme digestion, and ligation).

2.3. Produce the CAR constructs using a viral production system (e.g., HEK293T cells) and purify the viral particles using ultracentrifugation or chromatography.

**Step 3: Cell Preparation and Transduction**

3.1. Obtain antigen-low leukemic cell lines (e.g., K562 or Jurkat cells) and healthy donor T cells from a cell bank or a local hospital.

3.2. Culture the leukemic cells in a suitable medium (e.g., RPMI-1640 with 10% FBS) and maintain them at 37°C, 5% CO2.

3.3. Isolate T cells from healthy donor blood using a T cell isolation kit (e.g., Miltenyi Biotec) and culture them in a suitable medium (e.g., RPMI-1640 with 10% FBS and 100 U/mL IL-2).

3.4. Transduce the T cells with the designed CAR constructs using a viral transduction protocol (e.g., spinfection or electroporation).

**Step 4: Cytotoxicity Assays**

4.1. Co-culture the transduced T cells with antigen-low leukemic cells at a 1:1 ratio in a 96-well plate.

4.2. Incubate the co-culture for 4-6 hours at 37°C, 5% CO2.

4.3. Measure cytotoxicity using a chromium release assay, flow cytometry, or an impedance-based assay (e.g., xCELLigence).

4.4. Repeat the cytotoxicity assay in triplicate for each CAR construct.

**Step 5: Data Analysis**

5.1. Analyze the cytotoxicity data using a statistical software (e.g., GraphPad Prism or R) to determine if the incorporation of flexibility into the in silico model improves the prediction of optimal hinge length for CAR constructs.

5.2. Compare the cytotoxicity of T cells transduced with CAR constructs designed using the modified in silico model to those designed using traditional methods.

**Experiment to Disprove the Hypothesis:**

**Step 1: In Silico Modeling (Traditional Method)**

1.1. Use the same in silico modeling approach as above, but without incorporating the flexibility of the target protein's extracellular domain.

1.2. Predict the optimal hinge length for CAR constructs using the traditional in silico model.

**Step 2: CAR Construct Design and Production**

2.1. Design the CAR constructs using a molecular biology software based on the predicted optimal hinge lengths from Step 1.2.

2.2. Clone and produce the CAR constructs as described in Steps 2.2-2.3 above.

**Step 3: Cell Preparation and Transduction**

3.1. Prepare antigen-low leukemic cell lines and healthy donor T cells as described in Steps 3.1-3.4 above.

3.2. Transduce the T cells with the designed CAR constructs using a viral transduction protocol.

**Step 4: Cytotoxicity Assays**

4.1. Co-culture the transduced T cells with antigen-low leukemic cells and measure cytotoxicity as described in Steps 4.1-4.4 above.

**Step 5: Data Analysis**

5.1. Compare the cytotoxicity of T cells transduced with CAR constructs designed using the traditional in silico model to those designed using the modified in silico model (from the main experiment).

5.2. If the cytotoxicity is similar or not significantly different, it would suggest that incorporating flexibility into the in silico model does not improve the optimal hinge length for CAR constructs, thus disproving the hypothesis.

Note: The protocols above assume a certain level of expertise in molecular biology, cell culture, and bioinformatics. It is essential to follow proper laboratory protocols, safety guidelines, and quality control measures to ensure the accuracy and reproducibility of the results.","```
   Protein_Structure  Simulation_Time  Hinge_Length  CAR_Construct  T_Cell_Count  Leukemic_Cell_Count  Cytotoxicity
0               1.0           100.0         10.0           1.0           100000           100000         0.80
1               1.2           120.0         12.0           1.1           120000           120000         0.85
2               1.5           150.0         15.0           1.2           150000           150000         0.90
3               1.0           100.0         10.0           1.0            80000            80000         0.75
4               1.2           120.0         12.0           1.1            90000            90000         0.80
5               1.5           150.0         15.0           1.2           110000           110000         0.85
6               1.0           100.0         10.0           1.0           130000           130000         0.80
7               1.2           120.0         12.0           1.1           140000           140000         0.85
8               1.5           150.0         15.0           1.2           150000           150000         0.90
9               1.0           100.0         10.0           1.0           170000           170000         0.80
10              1.2           120.0         12.0           1.1           180000           180000         0.85
11              1.5           150.0         15.0           1.2           190000           190000         0.90
12              1.0           100.0         10.0           1.0           200000           200000         0.80
13              1.2           120.0         12.0           1.1           210000           210000         0.85
14              1.5           150.0         15.0           1.2           220000           220000         0.90
15              1.0           100.0         10.0           1.0           230000           230000         0.80
16              1.2           120.0         12.0           1.1           240000           240000         0.85
17              1.5           150.0         15.0           1.2           250000           250000         0.90
18              1.0           100.0         10.0           1.0           260000           260000         0.80
19              1.2           120.0         12.0           1.1           270000           270000         0.85
20              1.5           150.0         15.0           1.2           280000           280000         0.90
21              1.0           100.0         10.0           1.0           290000           290000         0.80
22              1.2           120.0         12.0           1.1           300000           300000         0.85
23              1.5           150.0         15.0           1.2           310000           310000         0.90
24              1.0           100.0         10.0           1.0           320000           320000         0.80
```",0.7002212032480615
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/017a4a30cf9831168c1ac27fdc137a6637d44fd5.summary'],"Can the simultaneous administration of TT-117 and TT-140 monoclonal antibodies exhibit a synergistic effect in preventing TeNT internalization in primary rat spinal cord neurons, resulting in enhanced neuroprotection compared to individual antibody treatment?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I've developed an experimental plan to test the generated hypothesis using existing scientific methods and equipment. To disprove the hypothesis, I've designed an experiment to verify if the simultaneous administration of TT-117 and TT-140 monoclonal antibodies exhibits a synergistic effect in preventing TeNT internalization in primary rat spinal cord neurons.

**Experimental Plan:**

**Title:** Investigating the Synergistic Effect of TT-117 and TT-140 Monoclonal Antibodies on TeNT Internalization in Primary Rat Spinal Cord Neurons

**Objective:** To determine if the simultaneous administration of TT-117 and TT-140 monoclonal antibodies exhibits a synergistic effect in preventing TeNT internalization in primary rat spinal cord neurons, resulting in enhanced neuroprotection compared to individual antibody treatment.

**Experimental Design:**

1. **Cell Culture:** Primary rat spinal cord neurons will be cultured in a 96-well plate using a standardized protocol.
2. **TeNT Treatment:** TeNT will be added to the cultured neurons at a concentration of 100 nM for 30 minutes to allow for internalization.
3. **Antibody Treatment:** Four treatment groups will be established:
	* Group 1: TT-117 (10 μg/mL) alone
	* Group 2: TT-140 (10 μg/mL) alone
	* Group 3: TT-117 (5 μg/mL) + TT-140 (5 μg/mL) (simultaneous administration)
	* Group 4: No antibody treatment (control)
4. **Internalization Assay:** After 30 minutes of TeNT treatment, the neurons will be washed, and the internalized TeNT will be measured using a fluorescently labeled TeNT antibody (e.g., Alexa Fluor 488) and a plate reader.
5. **Data Analysis:** The percentage of internalized TeNT will be calculated for each treatment group, and the data will be analyzed using one-way ANOVA followed by Tukey's post-hoc test to compare the means between groups.

**Expected Outcomes:**

* If the hypothesis is true, the simultaneous administration of TT-117 and TT-140 (Group 3) will exhibit a synergistic effect, resulting in a significantly lower percentage of internalized TeNT compared to individual antibody treatments (Groups 1 and 2).
* If the hypothesis is false, the simultaneous administration of TT-117 and TT-140 will not exhibit a synergistic effect, and the percentage of internalized TeNT will be similar to or higher than individual antibody treatments.

**Equipment and Reagents:**

* Primary rat spinal cord neurons
* TeNT
* TT-117 and TT-140 monoclonal antibodies
* Fluorescently labeled TeNT antibody (e.g., Alexa Fluor 488)
* 96-well plate
* Plate reader
* Cell culture media and reagents

**Timeline:**

* Cell culture and TeNT treatment: 2 days
* Antibody treatment and internalization assay: 1 day
* Data analysis: 1 day

**Budget:**

* Primary rat spinal cord neurons: $500
* TeNT: $200
* TT-117 and TT-140 monoclonal antibodies: $1,000
* Fluorescently labeled TeNT antibody: $300
* Cell culture media and reagents: $500
* Plate reader: $1,000 (assuming access to a shared facility or existing equipment)
* Total: $3,500

This experimental plan is designed to test the hypothesis within a reasonable time frame (5 days) and budget ($3,500). The results will provide valuable insights into the potential synergistic effect of TT-117 and TT-140 monoclonal antibodies in preventing TeNT internalization in primary rat spinal cord neurons.",85,"Here is the detailed, step-by-step protocol for the experiment:

**Protocol: Investigating the Synergistic Effect of TT-117 and TT-140 Monoclonal Antibodies on TeNT Internalization in Primary Rat Spinal Cord Neurons**

**Day 1-2: Cell Culture and TeNT Treatment**

1.1. Prepare the cell culture media according to the manufacturer's instructions.

1.2. Thaw the primary rat spinal cord neurons and resuspend them in the prepared cell culture media.

1.3. Plate the neurons in a 96-well plate at a density of 1 x 10^5 cells per well.

1.4. Incubate the plate in a humidified incubator at 37°C, 5% CO2 for 24-48 hours to allow the neurons to adhere and recover.

1.5. After 24-48 hours, prepare a 100 nM TeNT solution in cell culture media.

1.6. Add 100 μL of the TeNT solution to each well, making sure to handle the plate gently to avoid disturbing the neurons.

1.7. Incubate the plate for 30 minutes at 37°C, 5% CO2 to allow for TeNT internalization.

**Day 3: Antibody Treatment and Internalization Assay**

2.1. Prepare the following antibody solutions:
	* TT-117: 10 μg/mL in cell culture media
	* TT-140: 10 μg/mL in cell culture media
	* TT-117 + TT-140: 5 μg/mL each in cell culture media

2.2. Remove the TeNT solution from each well by gently aspirating the media.

2.3. Add 100 μL of the corresponding antibody solution to each well:
	* Group 1: TT-117 (10 μg/mL)
	* Group 2: TT-140 (10 μg/mL)
	* Group 3: TT-117 (5 μg/mL) + TT-140 (5 μg/mL)
	* Group 4: No antibody treatment (control)

2.4. Incubate the plate for 30 minutes at 37°C, 5% CO2 to allow for antibody binding.

2.5. Prepare a fluorescently labeled TeNT antibody solution (e.g., Alexa Fluor 488) according to the manufacturer's instructions.

2.6. Add 100 μL of the fluorescently labeled TeNT antibody solution to each well.

2.7. Incubate the plate for 30 minutes at 37°C, 5% CO2 to allow for antibody binding.

2.8. Wash the plate three times with 100 μL of PBS to remove excess antibody.

2.9. Add 100 μL of PBS to each well to maintain the cells.

**Day 3: Internalization Assay**

3.1. Read the fluorescence intensity of each well using a plate reader set to the appropriate excitation and emission wavelengths for the fluorescent label (e.g., Alexa Fluor 488).

3.2. Calculate the percentage of internalized TeNT for each well using the following formula:

% Internalized TeNT = (Fluorescence intensity of well - Background fluorescence) / (Maximum fluorescence intensity - Background fluorescence) x 100

**Day 4: Data Analysis**

4.1. Calculate the mean percentage of internalized TeNT for each treatment group.

4.2. Perform one-way ANOVA followed by Tukey's post-hoc test to compare the means between groups.

4.3. Interpret the results based on the expected outcomes:
	* If the hypothesis is true, the simultaneous administration of TT-117 and TT-140 (Group 3) will exhibit a synergistic effect, resulting in a significantly lower percentage of internalized TeNT compared to individual antibody treatments (Groups 1 and 2).
	* If the hypothesis is false, the simultaneous administration of TT-117 and TT-140 will not exhibit a synergistic effect, and the percentage of internalized TeNT will be similar to or higher than individual antibody treatments.

**Note:**

* All incubations should be performed in a humidified incubator at 37°C, 5% CO2.
* All solutions should be prepared fresh and used within the same day.
* The plate reader should be calibrated according to the manufacturer's instructions before use.
* The experiment should be performed in triplicate to ensure reproducibility.
* The results should be documented and reported in a clear and concise manner.","```
   TT-117 (μg/mL)  TT-140 (μg/mL)  % Internalized TeNT
0             5.0             0.0          45.123
1             0.0             5.0          42.567
2             2.5             2.5          38.421
3             7.5             0.0          48.935
4             0.0             0.0          50.000
5             1.25            3.75          40.189
6             3.75            1.25          41.852
7             0.0             7.5          44.219
8             5.0             5.0          35.678
9             2.5             0.0          46.321
10            0.0             2.5          43.945
11            1.25            1.25          42.135
12            3.75            3.75          36.549
13            7.5             2.5          40.982
14            2.5             7.5          39.756
15            0.0             1.25          44.821
16            5.0             1.25          38.654
17            1.25            5.0          37.289
18            3.75            0.0          47.563
19            2.5             3.75          39.421
20            7.5             5.0          34.219
21            0.0             3.75          45.678
22            5.0             3.75          36.189
23            1.25            2.5          41.945
24            3.75            5.0          35.135
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/049f4c24fd5af17eba3e45a5d38d12a22c25bb1c.summary'],"Can the simultaneous knockout of Rag2 and Il2rg genes in rats also lead to increased susceptibility to cancer development and progression due to the compromised immune system, and can this be exploited to create a novel cancer model for therapeutic testing?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Role of Rag2 and Il2rg Gene Knockout on Cancer Susceptibility in Rats

**Objective:** To determine if the simultaneous knockout of Rag2 and Il2rg genes in rats leads to increased susceptibility to cancer development and progression due to a compromised immune system.

**Equipment:**

* CRISPR/Cas9 genome editing system
* Rat embryos
* PCR
* Sequencing
* Flow cytometry
* ELISA
* Cancer cell lines (e.g., breast, lung, or colon cancer)
* Tumor implantation equipment
* Tumor measurement tools (e.g., calipers, imaging software)

**Steps:**

1. Generate double knockout SCID rats for Rag2 and Il2rg genes using CRISPR/Cas9 genome editing.
2. Verify the knockout efficiency and immunodeficiency phenotype using PCR, sequencing, flow cytometry, and ELISA.
3. Implant cancer cells (e.g., breast, lung, or colon cancer) into the double knockout SCID rats and wild-type rats (control group).
4. Monitor tumor growth and development in both groups using tumor measurement tools.
5. Compare the tumor growth rates, sizes, and metastatic potential between the double knockout SCID rats and wild-type rats.
6. Analyze the immune cell populations and cytokine profiles in both groups using flow cytometry and ELISA to determine the impact of the Rag2 and Il2rg gene knockout on the immune system.
7. Evaluate the potential of the double knockout SCID rats as a novel cancer model for therapeutic testing.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of Rag2 and Il2rg Gene Knockout on Cancer Resistance in Rats

**Objective:** To determine if the simultaneous knockout of Rag2 and Il2rg genes in rats leads to increased resistance to cancer development and progression due to an unexpected immune system adaptation.

**Equipment:**

* Same as above

**Steps:**

1. Generate double knockout SCID rats for Rag2 and Il2rg genes using CRISPR/Cas9 genome editing.
2. Verify the knockout efficiency and immunodeficiency phenotype using PCR, sequencing, flow cytometry, and ELISA.
3. Implant cancer cells (e.g., breast, lung, or colon cancer) into the double knockout SCID rats and wild-type rats (control group).
4. Monitor tumor growth and development in both groups using tumor measurement tools.
5. Compare the tumor growth rates, sizes, and metastatic potential between the double knockout SCID rats and wild-type rats.
6. Analyze the immune cell populations and cytokine profiles in both groups using flow cytometry and ELISA to determine if the Rag2 and Il2rg gene knockout leads to an unexpected immune system adaptation that confers cancer resistance.
7. Evaluate the potential of the double knockout SCID rats as a novel cancer-resistant model for understanding immune system adaptations.

**Rationale:**

The experiment to disprove the hypothesis aims to test the opposite scenario, where the simultaneous knockout of Rag2 and Il2rg genes leads to increased resistance to cancer development and progression. This could be due to an unexpected immune system adaptation that compensates for the immunodeficiency phenotype. By comparing the tumor growth and immune profiles between the double knockout SCID rats and wild-type rats, we can determine if the Rag2 and Il2rg gene knockout has an unexpected effect on cancer susceptibility.

**Time and Resource Considerations:**

Both experiments can be completed within a reasonable time frame (6-12 months) and with a moderate budget. The CRISPR/Cas9 genome editing system, PCR, sequencing, flow cytometry, and ELISA are standard equipment in most molecular biology and immunology laboratories. The cancer cell lines and tumor implantation equipment can be obtained from commercial sources or collaborations with other research groups. The number of animals required for the experiment can be minimized by using a robust study design and statistical analysis.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Investigating the Role of Rag2 and Il2rg Gene Knockout on Cancer Susceptibility in Rats**

**Step 1: Generate Double Knockout SCID Rats for Rag2 and Il2rg Genes using CRISPR/Cas9 Genome Editing**

1.1. Prepare CRISPR/Cas9 genome editing reagents:
	* Design and synthesize guide RNAs (gRNAs) specific to the Rag2 and Il2rg genes.
	* Prepare Cas9 enzyme and tracrRNA.
	* Mix gRNAs, Cas9 enzyme, and tracrRNA according to the manufacturer's instructions.

1.2. Microinject CRISPR/Cas9 reagents into rat embryos:
	* Obtain rat embryos at the one-cell stage.
	* Microinject the CRISPR/Cas9 reagents into the pronucleus of each embryo using a microinjection system.
	* Transfer the injected embryos to a pseudopregnant female rat.

1.3. Breed and genotype the founder rats:
	* Allow the injected embryos to develop to term and breed the resulting founder rats.
	* Extract genomic DNA from the founder rats and perform PCR and sequencing to identify those with successful knockout of the Rag2 and Il2rg genes.

**Step 2: Verify Knockout Efficiency and Immunodeficiency Phenotype**

2.1. Perform PCR and sequencing to confirm the knockout of Rag2 and Il2rg genes:
	* Extract genomic DNA from the founder rats and perform PCR using primers specific to the Rag2 and Il2rg genes.
	* Sequence the PCR products to confirm the presence of the desired mutations.

2.2. Analyze immune cell populations using flow cytometry:
	* Collect blood samples from the founder rats and wild-type rats (control group).
	* Stain the samples with antibodies specific to immune cell markers (e.g., CD4, CD8, CD19).
	* Analyze the samples using flow cytometry to determine the immune cell populations.

2.3. Measure cytokine profiles using ELISA:
	* Collect serum samples from the founder rats and wild-type rats (control group).
	* Perform ELISA to measure the levels of cytokines (e.g., IL-2, IFN-γ, TNF-α).

**Step 3: Implant Cancer Cells into Double Knockout SCID Rats and Wild-Type Rats**

3.1. Prepare cancer cells:
	* Obtain cancer cell lines (e.g., breast, lung, or colon cancer) and culture them according to the manufacturer's instructions.
	* Harvest the cells and prepare them for implantation.

3.2. Implant cancer cells into rats:
	* Anesthetize the rats and make a small incision in the skin.
	* Implant the cancer cells into the subcutaneous tissue using a syringe.
	* Close the incision and monitor the rats for tumor growth.

**Step 4: Monitor Tumor Growth and Development**

4.1. Measure tumor size using calipers:
	* Measure the length, width, and height of the tumors at regular intervals (e.g., weekly).
	* Calculate the tumor volume using the formula: V = (L x W x H) / 2.

4.2. Monitor tumor growth using imaging software:
	* Use imaging software (e.g., MRI, CT) to monitor tumor growth and development.

**Step 5: Compare Tumor Growth Rates, Sizes, and Metastatic Potential**

5.1. Compare tumor growth rates:
	* Plot the tumor volume over time for each group.
	* Calculate the tumor growth rate using the formula: Growth rate = (V2 - V1) / (T2 - T1), where V1 and V2 are the tumor volumes at times T1 and T2, respectively.

5.2. Compare tumor sizes:
	* Compare the mean tumor volume at the end of the experiment between the double knockout SCID rats and wild-type rats.

5.3. Analyze metastatic potential:
	* Perform histopathological analysis of the tumors to determine the presence of metastases.

**Step 6: Analyze Immune Cell Populations and Cytokine Profiles**

6.1. Analyze immune cell populations using flow cytometry:
	* Collect blood samples from the rats and stain the samples with antibodies specific to immune cell markers (e.g., CD4, CD8, CD19).
	* Analyze the samples using flow cytometry to determine the immune cell populations.

6.2. Measure cytokine profiles using ELISA:
	* Collect serum samples from the rats and perform ELISA to measure the levels of cytokines (e.g., IL-2, IFN-γ, TNF-α).

**Step 7: Evaluate the Potential of the Double Knockout SCID Rats as a Novel Cancer Model**

7.1. Analyze the data:
	* Compare the tumor growth rates, sizes, and metastatic potential between the double knockout SCID rats and wild-type rats.
	* Analyze the immune cell populations and cytokine profiles between the two groups.

7.2. Interpret the results:
	* Determine if the simultaneous knockout of Rag2 and Il2rg genes leads to increased susceptibility to cancer development and progression.
	* Evaluate the potential of the double knockout SCID rats as a novel cancer model for therapeutic testing.

**Experiment to Disprove the Hypothesis: Investigating the Role of Rag2 and Il2rg Gene Knockout on Cancer Resistance in Rats**

The steps for this experiment are identical to those in the experiment to test the hypothesis, with the exception of the analysis and interpretation of the results. In this experiment, the goal is to determine if the simultaneous knockout of Rag2 and Il2rg genes leads to increased resistance to cancer development and progression due to an unexpected immune system adaptation.

**Step 6: Analyze Immune Cell Populations and Cytokine Profiles**

6.1. Analyze immune cell populations using flow cytometry:
	* Collect blood samples from the rats and stain the samples with antibodies specific to immune cell markers (e.g., CD4, CD8, CD19).
	* Analyze the samples using flow cytometry to determine the immune cell populations.

6.2. Measure cytokine profiles using ELISA:
	* Collect serum samples from the rats and perform ELISA to measure the levels of cytokines (e.g., IL-2, IFN-γ, TNF-α).

**Step 7: Evaluate the Potential of the Double Knockout SCID Rats as a Novel Cancer-Resistant Model**

7.1. Analyze the data:
	* Compare the tumor growth rates, sizes, and metastatic potential between the double knockout SCID rats and wild-type rats.
	* Analyze the immune cell populations and cytokine profiles between the two groups.

7.2. Interpret the results:
	* Determine if the simultaneous knockout of Rag2 and Il2rg genes leads to increased resistance to cancer development and progression due to an unexpected immune system adaptation.
	* Evaluate the potential of the double knockout SCID rats as a novel cancer-resistant model for understanding immune system adaptations.","```
   gRNA_Rag2  gRNA_Il2rg  Cas9  tracrRNA  Cancer_Cell_Line  Tumor_Volume  Outcome
0        0.5        0.3   0.2       0.1            Breast        1500.0  Susceptible
1        0.7        0.5   0.3       0.2            Lung         2000.0  Susceptible
2        0.3        0.2   0.1       0.1            Colon        1000.0  Resistant
3        0.9        0.8   0.5       0.4            Breast        2500.0  Susceptible
4        0.1        0.1   0.1       0.1            Lung         500.0   Resistant
5        0.6        0.4   0.3       0.2            Colon        1800.0  Susceptible
6        0.8        0.6   0.4       0.3            Breast        2200.0  Susceptible
7        0.4        0.3   0.2       0.2            Lung         1200.0  Susceptible
8        0.2        0.2   0.1       0.1            Colon        800.0   Resistant
9        0.5        0.4   0.3       0.2            Breast        1900.0  Susceptible
10       0.7        0.5   0.4       0.3            Lung         2300.0  Susceptible
11       0.3        0.2   0.2       0.1            Colon        1100.0  Susceptible
12       0.9        0.8   0.5       0.4            Breast        2600.0  Susceptible
13       0.1        0.1   0.1       0.1            Lung         600.0   Resistant
14       0.6        0.4   0.3       0.2            Colon        2000.0  Susceptible
15       0.8        0.6   0.4       0.3            Breast        2400.0  Susceptible
16       0.4        0.3   0.2       0.2            Lung         1400.0  Susceptible
17       0.2        0.2   0.1       0.1            Colon        900.0   Resistant
18       0.5        0.4   0.3       0.2            Breast        2100.0  Susceptible
19       0.7        0.5   0.4       0.3            Lung         2500.0  Susceptible
20       0.3        0.2   0.2       0.1            Colon        1300.0  Susceptible
21       0.9        0.8   0.5       0.4            Breast        2800.0  Susceptible
22       0.1        0.1   0.1       0.1            Lung         700.0   Resistant
23       0.6        0.4   0.3       0.2            Colon        2200.0  Susceptible
24       0.8        0.6   0.4       0.3            Breast        2700.0  Susceptible
```",0.5240304119322404
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f0da7af25b9f333b6c98eb43cb8818baac7378bb.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/63c25467e077004ada971cf14d03a5b3c9c578ab.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/14adbc54bce30e8ef762c32ae1179eca3f9c702e.summary']","Can the simultaneous knockout of specific oncogenic drivers and immune checkpoint genes in AML cells, combined with the adoptive transfer of CD45-knockout CAR-T cells, enhance the anti-tumor activity and persistence of CAR-T cells in vivo?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Can the simultaneous knockout of specific oncogenic drivers and immune checkpoint genes in AML cells, combined with the adoptive transfer of CD45-knockout CAR-T cells, enhance the anti-tumor activity and persistence of CAR-T cells in vivo?

**Experimental Design:**

1. **AML Cell Preparation:**
	* Use CRISPR-Cas9 gene editing to knockout specific oncogenic drivers (e.g., FLT3, NPM1) and immune checkpoint genes (e.g., PD-1, CTLA-4) in AML cells.
	* Verify the knockout efficiency using PCR, Western blot, and flow cytometry.
2. **CD45-Knockout CAR-T Cell Preparation:**
	* Use CRISPR-Cas9 gene editing to knockout CD45 in T cells.
	* Transduce the CD45-knockout T cells with a CAR construct specific to AML cells (e.g., CD33, CD123).
	* Verify the CAR expression and CD45 knockout using flow cytometry.
3. **In Vivo Experiment:**
	* Inject the knockout AML cells into immunodeficient mice (e.g., NSG mice) to establish a xenograft model of AML.
	* Infuse the CD45-knockout CAR-T cells into the mice bearing AML tumors.
	* Monitor the anti-tumor activity and persistence of CAR-T cells using bioluminescence imaging, flow cytometry, and tumor volume measurement.
4. **Control Groups:**
	* Include control groups with:
		+ AML cells without knockout of oncogenic drivers and immune checkpoint genes.
		+ CD45-expressing CAR-T cells.
		+ No CAR-T cell infusion.

**To disprove the hypothesis:**

* Use a similar experimental design, but with the following modifications:
	+ Use a different oncogenic driver or immune checkpoint gene knockout combination that is not expected to enhance anti-tumor activity.
	+ Use a CAR construct with lower affinity or specificity to AML cells.
	+ Infuse a lower dose of CAR-T cells or delay the infusion until the tumor is more established.

**Equipment and Resources:**

* CRISPR-Cas9 gene editing tools
* CAR construct and lentiviral vectors
* Flow cytometer
* Bioluminescence imaging system
* Xenograft model of AML (NSG mice)
* Tumor volume measurement equipment
* PCR and Western blot equipment
* Luminometer (optional)

**Timeline:**

* AML cell preparation and CD45-knockout CAR-T cell preparation: 2-3 weeks
* In vivo experiment: 4-6 weeks
* Data analysis and interpretation: 2-3 weeks

**Budget:**

* CRISPR-Cas9 gene editing tools: $5,000 - $10,000
* CAR construct and lentiviral vectors: $2,000 - $5,000
* Flow cytometer and bioluminescence imaging system: $10,000 - $20,000 (assuming existing equipment is available)
* Xenograft model of AML (NSG mice): $5,000 - $10,000
* Tumor volume measurement equipment: $1,000 - $2,000
* PCR and Western blot equipment: $2,000 - $5,000 (assuming existing equipment is available)
* Luminometer (optional): $1,000 - $2,000
* Personnel and miscellaneous costs: $10,000 - $20,000

Total estimated budget: $40,000 - $80,000

This experimental design should provide a comprehensive evaluation of the hypothesis and can be completed within a reasonable timeframe and budget.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: AML Cell Preparation**

**Step 1.1: CRISPR-Cas9 Gene Editing**

1. Prepare AML cells according to the laboratory's standard protocol for cell culture and maintenance.
2. Design and synthesize guide RNAs (gRNAs) specific to the target oncogenic drivers (e.g., FLT3, NPM1) and immune checkpoint genes (e.g., PD-1, CTLA-4) using a CRISPR-Cas9 design tool.
3. Prepare CRISPR-Cas9 ribonucleoprotein (RNP) complexes by mixing the gRNAs with the Cas9 enzyme and a transfection reagent (e.g., Lipofectamine).
4. Transfect the AML cells with the CRISPR-Cas9 RNP complexes using a nucleofection protocol (e.g., Amaxa Nucleofector).
5. Incubate the transfected cells at 37°C, 5% CO2 for 24-48 hours to allow for gene editing.

**Step 1.2: Verification of Knockout Efficiency**

1. Extract genomic DNA from the edited AML cells using a DNA extraction kit (e.g., Qiagen DNeasy).
2. Perform PCR amplification of the target genes using primers flanking the CRISPR-Cas9 cut site.
3. Analyze the PCR products using agarose gel electrophoresis to detect the presence of indels (insertions or deletions) indicative of gene knockout.
4. Perform Western blot analysis using antibodies specific to the target proteins to verify protein knockout.
5. Perform flow cytometry analysis using antibodies specific to the target proteins to verify protein knockout and quantify the knockout efficiency.

**Protocol 2: CD45-Knockout CAR-T Cell Preparation**

**Step 2.1: CRISPR-Cas9 Gene Editing**

1. Prepare T cells according to the laboratory's standard protocol for cell culture and maintenance.
2. Design and synthesize gRNAs specific to the CD45 gene using a CRISPR-Cas9 design tool.
3. Prepare CRISPR-Cas9 RNP complexes by mixing the gRNAs with the Cas9 enzyme and a transfection reagent (e.g., Lipofectamine).
4. Transfect the T cells with the CRISPR-Cas9 RNP complexes using a nucleofection protocol (e.g., Amaxa Nucleofector).
5. Incubate the transfected cells at 37°C, 5% CO2 for 24-48 hours to allow for gene editing.

**Step 2.2: CAR Construct Transduction**

1. Prepare the CAR construct specific to AML cells (e.g., CD33, CD123) using a lentiviral vector system.
2. Transduce the CD45-knockout T cells with the CAR construct using a lentiviral transduction protocol (e.g., spinfection).
3. Incubate the transduced cells at 37°C, 5% CO2 for 24-48 hours to allow for CAR expression.

**Step 2.3: Verification of CAR Expression and CD45 Knockout**

1. Perform flow cytometry analysis using antibodies specific to the CAR protein to verify CAR expression.
2. Perform flow cytometry analysis using antibodies specific to CD45 to verify CD45 knockout and quantify the knockout efficiency.

**Protocol 3: In Vivo Experiment**

**Step 3.1: AML Cell Injection**

1. Prepare the knockout AML cells for injection by washing and resuspending them in PBS.
2. Inject 1-5 x 10^6 AML cells into the tail vein of immunodeficient mice (e.g., NSG mice) to establish a xenograft model of AML.

**Step 3.2: CAR-T Cell Infusion**

1. Prepare the CD45-knockout CAR-T cells for infusion by washing and resuspending them in PBS.
2. Infuse 1-5 x 10^6 CAR-T cells into the tail vein of mice bearing AML tumors.

**Step 3.3: Monitoring Anti-Tumor Activity and Persistence**

1. Monitor tumor growth using bioluminescence imaging (e.g., IVIS) at regular intervals (e.g., weekly).
2. Perform flow cytometry analysis of peripheral blood and tumor samples to monitor CAR-T cell persistence and phenotype.
3. Measure tumor volume using calipers or imaging techniques (e.g., MRI) at regular intervals (e.g., weekly).

**Protocol 4: Control Groups**

**Step 4.1: AML Cells without Knockout**

1. Prepare AML cells without CRISPR-Cas9 gene editing as a control group.

**Step 4.2: CD45-Expressing CAR-T Cells**

1. Prepare CD45-expressing CAR-T cells using a CAR construct and lentiviral transduction as a control group.

**Step 4.3: No CAR-T Cell Infusion**

1. Inject AML cells into mice without CAR-T cell infusion as a control group.

**To Disprove the Hypothesis**

**Step 5.1: Alternative Oncogenic Driver or Immune Checkpoint Gene Knockout**

1. Use a different oncogenic driver or immune checkpoint gene knockout combination that is not expected to enhance anti-tumor activity.

**Step 5.2: Lower Affinity or Specificity CAR Construct**

1. Use a CAR construct with lower affinity or specificity to AML cells.

**Step 5.3: Lower Dose or Delayed CAR-T Cell Infusion**

1. Infuse a lower dose of CAR-T cells or delay the infusion until the tumor is more established.

These detailed protocols should provide a clear and replicable guide for executing the experimental plan.","```
   AML Cells (x10^6)  gRNA (μg)  Cas9 (μg)  Transfection Reagent (μL)  CD45 gRNA (μg)  CD45 Cas9 (μg)  CAR Construct (μg)  CAR-T Cells (x10^6)  Outcome
0               1.0       2.0       1.0                  10.0           1.5           1.0           5.0               2.0  Tumor Regression
1               2.0       1.5       1.5                  12.0           2.0           1.5           6.0               3.0  Tumor Regression
2               3.0       1.0       2.0                  15.0           1.0           2.0           7.0               4.0  Tumor Regression
3               4.0       2.5       1.0                  18.0           2.5           1.0           8.0               5.0  Tumor Regression
4               5.0       1.0       1.5                  20.0           1.0           1.5           9.0               6.0  Tumor Regression
5               1.0       1.5       2.0                  10.0           1.5           2.0           5.0               2.0  Tumor Regression
6               2.0       2.0       1.0                  12.0           2.0           1.0           6.0               3.0  Tumor Regression
7               3.0       1.5       1.5                  15.0           1.5           1.5           7.0               4.0  Tumor Regression
8               4.0       1.0       2.5                  18.0           1.0           2.5           8.0               5.0  Tumor Regression
9               5.0       2.5       1.5                  20.0           2.5           1.5           9.0               6.0  Tumor Regression
10              1.0       1.0       1.0                  10.0           1.0           1.0           5.0               2.0  No Response
11              2.0       1.5       1.5                  12.0           1.5           1.5           6.0               3.0  No Response
12              3.0       2.0       2.0                  15.0           2.0           2.0           7.0               4.0  No Response
13              4.0       1.5       1.0                  18.0           1.5           1.0           8.0               5.0  No Response
14              5.0       2.0       1.5                  20.0           2.0           1.5           9.0               6.0  No Response
15              1.0       2.5       2.5                  10.0           2.5           2.5           5.0               2.0  Tumor Progression
16              2.0       1.0       2.5                  12.0           1.0           2.5           6.0               3.0  Tumor Progression
17              3.0       2.5       1.0                  15.0           2.5           1.0           7.0               4.0  Tumor Progression
18              4.0       1.0       1.5                  18.0           1.0           1.5           8.0               5.0  Tumor Progression
19              5.0       2.5       2.0                  20.0           2.5           2.0           9.0               6.0  Tumor Progression
20              1.0       1.0       1.0                  10.0           1.0           1.0           5.0               2.0  No Response
21              2.0       1.5       1.5                  12.0           1.5           1.5           6.0               3.0  No Response
22              3.0       2.0       2.0                  15.0           2.0           2.0           7.0               4.0  No Response
23              4.0       1.5       1.0                  18.0           1.5           1.0           8.0               5.0  No Response
24              5.0       2.0       1.5                  20.0           2.0           1.5           9.0               6.0  No Response
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2f739ec033515ea8d1d7bb7f49eaee7a528cd865.summary'],Can the simultaneous tracking of alloreactive T and B cells using peptide-MHC complex multimers and antigen receptor transgenic lymphocytes predict the likelihood of allograft rejection more accurately than tracking either cell type alone?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** Can the simultaneous tracking of alloreactive T and B cells using peptide-MHC complex multimers and antigen receptor transgenic lymphocytes predict the likelihood of allograft rejection more accurately than tracking either cell type alone?

**Experimental Plan:**

**Objective:** To test the hypothesis that simultaneous tracking of alloreactive T and B cells can predict allograft rejection more accurately than tracking either cell type alone.

**Experimental Design:**

1. **Animal Model:** Use a well-established mouse model of allogenic skin transplantation, such as the C57BL/6 (H-2b) to BALB/c (H-2d) model.
2. **Cell Isolation and Preparation:**
	* Isolate T cells and B cells from spleens of recipient mice using magnetic bead-based separation.
	* Generate antigen receptor transgenic lymphocytes specific for a defined allogenic epitope (e.g., H-2Kb/H-2Db) using established protocols.
	* Prepare peptide-MHC complex multimers (e.g., H-2Kb/H-2Db-peptide complexes) using recombinant MHC molecules and peptides.
3. **Experimental Groups:**
	* Group 1: Track alloreactive T cells only (using peptide-MHC complex multimers)
	* Group 2: Track alloreactive B cells only (using antigen receptor transgenic lymphocytes)
	* Group 3: Simultaneously track alloreactive T and B cells (using both peptide-MHC complex multimers and antigen receptor transgenic lymphocytes)
4. **Allograft Rejection Model:**
	* Perform skin transplantation from C57BL/6 donors to BALB/c recipients.
	* Monitor graft survival and rejection using established criteria (e.g., graft appearance, histology, and flow cytometry).
5. **Cell Tracking and Analysis:**
	* Use flow cytometry to track the frequency and phenotype of alloreactive T and B cells in each group at multiple time points post-transplantation.
	* Analyze the correlation between cell tracking data and graft rejection outcomes.
6. **Statistical Analysis:**
	* Compare the predictive power of each group using receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) calculations.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the null hypothesis that simultaneous tracking of alloreactive T and B cells does not improve the prediction of allograft rejection compared to tracking either cell type alone.

**Modified Experimental Design:**

1. **Introduce a confounding variable:** Add a third, irrelevant antigen (e.g., ovalbumin) to the peptide-MHC complex multimers used in Group 3. This will introduce noise and potentially reduce the predictive power of simultaneous tracking.
2. **Reduce the sensitivity of cell tracking:** Use a lower affinity peptide-MHC complex multimer or reduce the number of cells analyzed in Group 3 to decrease the sensitivity of simultaneous tracking.
3. **Increase the variability of the allograft rejection model:** Use a more heterogeneous donor-recipient combination (e.g., C57BL/6 to C3H) or introduce additional immunological challenges (e.g., co-infection with a virus) to increase the variability of graft rejection outcomes.

By introducing these modifications, the experiment is designed to disprove the hypothesis and test the robustness of the simultaneous tracking approach.

**Budget and Timeframe:**

* Estimated budget: $50,000 - $75,000
* Estimated timeframe: 6-9 months

This experiment can be performed within a reasonable timeframe and budget, using existing scientific methods and equipment. The modified design to disprove the hypothesis will help to rigorously test the simultaneous tracking approach and provide a more comprehensive understanding of its predictive power.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Animal Model and Cell Isolation**

1.1. Obtain C57BL/6 (H-2b) and BALB/c (H-2d) mice from a reputable supplier.

1.2. House the mice in a specific pathogen-free (SPF) facility with ad libitum access to food and water.

1.3. Sacrifice the mice using a humane method (e.g., CO2 asphyxiation) and collect the spleens.

1.4. Isolate T cells and B cells from the spleens using magnetic bead-based separation (e.g., Miltenyi Biotec's MACS system).

1.5. Follow the manufacturer's protocol for cell isolation, including:

a. Homogenize the spleens in a gentleMACS dissociator.

b. Filter the cell suspension through a 70-μm cell strainer.

c. Incubate the cells with magnetic beads conjugated to anti-CD4, anti-CD8, and anti-CD19 antibodies.

d. Separate the cells using a magnetic column, following the manufacturer's instructions.

1.6. Count and assess the purity of the isolated T cells and B cells using flow cytometry.

**Protocol 2: Antigen Receptor Transgenic Lymphocyte Generation**

2.1. Obtain antigen receptor transgenic mice specific for a defined allogenic epitope (e.g., H-2Kb/H-2Db) from a reputable supplier or generate them in-house using established protocols.

2.2. Isolate T cells from the antigen receptor transgenic mice using the same protocol as in 1.4-1.6.

2.3. Verify the specificity and functionality of the antigen receptor transgenic T cells using flow cytometry and functional assays (e.g., ELISPOT).

**Protocol 3: Peptide-MHC Complex Multimer Preparation**

3.1. Obtain recombinant MHC molecules (e.g., H-2Kb and H-2Db) from a reputable supplier or express them in-house using established protocols.

3.2. Synthesize peptides corresponding to the allogenic epitope (e.g., H-2Kb/H-2Db) using a peptide synthesizer.

3.3. Prepare peptide-MHC complex multimers by incubating the recombinant MHC molecules with the synthesized peptides, following the manufacturer's protocol.

3.4. Verify the quality and specificity of the peptide-MHC complex multimers using biochemical and biophysical assays (e.g., gel filtration, surface plasmon resonance).

**Protocol 4: Experimental Groups and Allograft Rejection Model**

4.1. Divide the mice into three experimental groups:

a. Group 1: Track alloreactive T cells only (using peptide-MHC complex multimers).

b. Group 2: Track alloreactive B cells only (using antigen receptor transgenic lymphocytes).

c. Group 3: Simultaneously track alloreactive T and B cells (using both peptide-MHC complex multimers and antigen receptor transgenic lymphocytes).

4.2. Perform skin transplantation from C57BL/6 donors to BALB/c recipients, following established protocols.

4.3. Monitor graft survival and rejection using established criteria, including:

a. Graft appearance: Observe the graft daily for signs of rejection (e.g., erythema, edema, necrosis).

b. Histology: Perform histological analysis of the graft tissue at multiple time points post-transplantation.

c. Flow cytometry: Analyze the immune cell infiltrate in the graft tissue using flow cytometry.

**Protocol 5: Cell Tracking and Analysis**

5.1. Collect blood samples from the mice at multiple time points post-transplantation (e.g., days 3, 7, 10, 14).

5.2. Stain the blood samples with fluorescently labeled antibodies against T cell and B cell markers (e.g., CD4, CD8, CD19).

5.3. Use flow cytometry to track the frequency and phenotype of alloreactive T and B cells in each group.

5.4. Analyze the correlation between cell tracking data and graft rejection outcomes using statistical software (e.g., R, Prism).

**Protocol 6: Statistical Analysis**

6.1. Compare the predictive power of each group using receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) calculations.

6.2. Perform statistical analysis using software (e.g., R, Prism) to determine the significance of the results.

**Protocol 7: Experiment to Disprove the Hypothesis**

7.1. Introduce a confounding variable: Add a third, irrelevant antigen (e.g., ovalbumin) to the peptide-MHC complex multimers used in Group 3.

7.2. Reduce the sensitivity of cell tracking: Use a lower affinity peptide-MHC complex multimer or reduce the number of cells analyzed in Group 3.

7.3. Increase the variability of the allograft rejection model: Use a more heterogeneous donor-recipient combination (e.g., C57BL/6 to C3H) or introduce additional immunological challenges (e.g., co-infection with a virus).

7.4. Repeat the experiment using the modified design and analyze the results as in Protocols 5 and 6.

These detailed protocols should provide a clear guide for executing the experiment. Remember to follow all relevant safety protocols and guidelines when working with animals and biological materials.","```
   C57BL/6 Mice  BALB/c Mice  Antigen Receptor Transgenic Mice  Peptide-MHC Complex Multimers  Allograft Rejection Model  Outcome
0             5            5                             10                         20                         1        Rejected
1             3            7                              8                         18                         2        Accepted
2             4            6                              9                         22                         1        Rejected
3             6            4                             11                         19                         3        Rejected
4             7            3                              7                         21                         2        Accepted
5             5            5                              9                         20                         1        Rejected
6             4            6                             10                         18                         3        Rejected
7             3            7                              8                         22                         2        Accepted
8             6            4                             11                         19                         1        Rejected
9             5            5                              9                         20                         3        Rejected
10            7            3                              7                         21                         2        Accepted
11            4            6                             10                         18                         1        Rejected
12            3            7                              8                         22                         3        Rejected
13            6            4                             11                         19                         2        Accepted
14            5            5                              9                         20                         1        Rejected
15            7            3                              7                         21                         3        Rejected
16            4            6                             10                         18                         2        Accepted
17            3            7                              8                         22                         1        Rejected
18            6            4                             11                         19                         3        Rejected
19            5            5                              9                         20                         2        Accepted
20            7            3                              7                         21                         1        Rejected
21            4            6                             10                         18                         3        Rejected
22            3            7                              8                         22                         2        Accepted
23            6            4                             11                         19                         1        Rejected
24            5            5                              9                         20                         3        Rejected
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/990aadb4184c1f4d1bfb07f16ba14d4259f7e979.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/72653239230ad232f95848d63ef9f8a2547514e1.summary']",Can the simultaneous upregulation of pattern recognition receptors and demethylation of specific epigenetic targets in immune cells enhance the antiviral immune response and promote HBsAg seroconversion in chronic hepatitis B patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** Can the simultaneous upregulation of pattern recognition receptors (PRRs) and demethylation of specific epigenetic targets in immune cells enhance the antiviral immune response and promote HBsAg seroconversion in chronic hepatitis B patients?

**Experimental Plan:**

**Objective:** To test the hypothesis by investigating the effect of simultaneous PRR upregulation and epigenetic demethylation on the antiviral immune response and HBsAg seroconversion in chronic hepatitis B patients.

**Experimental Design:**

1. **Cell Isolation and Culture:** Isolate peripheral blood mononuclear cells (PBMCs) from chronic hepatitis B patients and healthy controls. Culture the cells in vitro with or without PRR agonists (e.g., TLR7/8 agonist, R848) and epigenetic demethylating agents (e.g., 5-azacytidine).
2. **PRR Upregulation:** Treat PBMCs with PRR agonists to upregulate PRR expression. Verify PRR upregulation using qRT-PCR, Western blot, or flow cytometry.
3. **Epigenetic Demethylation:** Treat PBMCs with epigenetic demethylating agents to demethylate specific epigenetic targets (e.g., HBV-specific promoters). Verify demethylation using methylation-specific PCR, bisulfite sequencing, or ChIP-qPCR.
4. **Antiviral Immune Response:** Measure the antiviral immune response by assessing:
	* Cytokine production (e.g., IFN-γ, TNF-α) using ELISA or multiplex assays.
	* HBV-specific T cell responses using ELISPOT or ICS.
	* Viral load reduction using qRT-PCR or viral culture.
5. **HBsAg Seroconversion:** Monitor HBsAg levels using ELISA or chemiluminescent immunoassays.

**Experimental Groups:**

1. Control group: PBMCs from chronic hepatitis B patients without treatment.
2. PRR upregulation group: PBMCs treated with PRR agonists.
3. Epigenetic demethylation group: PBMCs treated with epigenetic demethylating agents.
4. Combination group: PBMCs treated with both PRR agonists and epigenetic demethylating agents.

**Experimental Timeline:**

* Cell isolation and culture: 1 week
* PRR upregulation and epigenetic demethylation: 2 weeks
* Antiviral immune response and HBsAg seroconversion analysis: 4 weeks
* Data analysis and interpretation: 2 weeks

**Budget Breakdown:**

* Cell isolation and culture reagents: $5,000
* PRR agonists and epigenetic demethylating agents: $3,000
* qRT-PCR, Western blot, and flow cytometry reagents: $8,000
* ELISA, multiplex assays, and viral load measurement reagents: $10,000
* Personnel and laboratory costs: $15,000
* Total budget: $41,000

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to test the following:

**Null Hypothesis:** Simultaneous PRR upregulation and epigenetic demethylation do not enhance the antiviral immune response or promote HBsAg seroconversion in chronic hepatitis B patients.

**Experimental Design:**

1. Use a similar experimental design as above, but with the following modifications:
	* Use a lower concentration of PRR agonists and epigenetic demethylating agents to minimize potential effects.
	* Use a shorter treatment duration (e.g., 1 week) to reduce the impact of PRR upregulation and epigenetic demethylation.
	* Include a "" mock-treated"" control group to account for any non-specific effects.
2. Analyze the data using a non-parametric statistical test (e.g., Wilcoxon rank-sum test) to compare the antiviral immune response and HBsAg seroconversion between the treatment groups and the control group.
3. If the results show no significant difference between the treatment groups and the control group, it would suggest that simultaneous PRR upregulation and epigenetic demethylation do not enhance the antiviral immune response or promote HBsAg seroconversion, thereby disproving the original hypothesis.

By designing an experiment to disprove the hypothesis, we can increase the confidence in the results and provide a more comprehensive understanding of the underlying mechanisms.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Culture**

1.1. Peripheral Blood Mononuclear Cell (PBMC) Isolation:

* Collect 10 mL of whole blood from chronic hepatitis B patients and healthy controls in EDTA-coated tubes.
* Add 10 mL of PBS to the blood samples and mix gently.
* Layer the blood-PBS mixture over 15 mL of Ficoll-Paque Plus in a 50 mL conical tube.
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the PBMC layer and wash with PBS.
* Resuspend the PBMCs in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. Cell Culture:

* Seed 1 x 10^6 PBMCs per well in a 24-well plate.
* Incubate the cells at 37°C, 5% CO2 for 1 week.
* Replace the medium every 3-4 days.

**Protocol 2: PRR Upregulation**

2.1. PRR Agonist Treatment:

* Prepare a stock solution of 1 mg/mL R848 (TLR7/8 agonist) in DMSO.
* Add 1 μL of R848 stock solution to 1 mL of cell culture medium to achieve a final concentration of 1 μg/mL.
* Treat the PBMCs with R848-containing medium for 2 weeks.

2.2. PRR Upregulation Verification:

* Collect cells and extract RNA using the RNeasy Mini Kit.
* Perform qRT-PCR using primers specific to PRR genes (e.g., TLR7, TLR8) and normalize to GAPDH.
* Alternatively, perform Western blot or flow cytometry to detect PRR protein expression.

**Protocol 3: Epigenetic Demethylation**

3.1. Epigenetic Demethylating Agent Treatment:

* Prepare a stock solution of 10 mM 5-azacytidine in DMSO.
* Add 1 μL of 5-azacytidine stock solution to 1 mL of cell culture medium to achieve a final concentration of 10 μM.
* Treat the PBMCs with 5-azacytidine-containing medium for 2 weeks.

3.2. Epigenetic Demethylation Verification:

* Collect cells and extract DNA using the DNeasy Blood & Tissue Kit.
* Perform methylation-specific PCR or bisulfite sequencing to detect demethylation of specific epigenetic targets (e.g., HBV-specific promoters).
* Alternatively, perform ChIP-qPCR to detect changes in histone modifications.

**Protocol 4: Antiviral Immune Response Analysis**

4.1. Cytokine Production:

* Collect cell culture supernatants and store at -80°C.
* Perform ELISA or multiplex assays to measure cytokine production (e.g., IFN-γ, TNF-α).

4.2. HBV-Specific T Cell Responses:

* Collect cells and perform ELISPOT or ICS to detect HBV-specific T cell responses.

4.3. Viral Load Reduction:

* Collect cell culture supernatants and perform qRT-PCR or viral culture to measure viral load.

**Protocol 5: HBsAg Seroconversion Analysis**

5.1. HBsAg Measurement:

* Collect cell culture supernatants and perform ELISA or chemiluminescent immunoassays to measure HBsAg levels.

**Protocol 6: Data Analysis and Interpretation**

6.1. Data Collection:

* Collect data from all experimental groups and controls.
* Perform statistical analysis using parametric or non-parametric tests as appropriate.

6.2. Data Interpretation:

* Compare the antiviral immune response and HBsAg seroconversion between the treatment groups and the control group.
* Determine if the results support or reject the hypothesis.

**Protocol 7: Experiment to Disprove the Hypothesis**

7.1. Modified Experimental Design:

* Use a lower concentration of PRR agonists and epigenetic demethylating agents (e.g., 0.1 μg/mL R848 and 1 μM 5-azacytidine).
* Treat the PBMCs for 1 week instead of 2 weeks.
* Include a ""mock-treated"" control group.

7.2. Data Analysis:

* Perform non-parametric statistical tests (e.g., Wilcoxon rank-sum test) to compare the antiviral immune response and HBsAg seroconversion between the treatment groups and the control group.
* If the results show no significant difference, it would suggest that simultaneous PRR upregulation and epigenetic demethylation do not enhance the antiviral immune response or promote HBsAg seroconversion, thereby disproving the original hypothesis.

These detailed protocols should provide a clear guide for executing the experiment and testing the hypothesis.","```
   R848 (μg/mL)  5-azacytidine (μM)  PBMCs (x10^6)  FBS (%)  PRR Upregulation  Epigenetic Demethylation  Cytokine Production  HBV-Specific T Cell Responses  Viral Load Reduction  HBsAg Seroconversion
0           0.5               5.0           0.8       12.0               High                    High               High                     High                    High               Yes
1           1.0               2.0           1.2       10.0               High                    Low                Medium                   Medium                   Medium               No
2           0.1               1.0           1.0       11.0               Low                     Low                Low                      Low                     Low                No
3           1.5               7.0           1.5       13.0               High                    High               High                     High                    High               Yes
4           0.8               3.0           1.1       12.0               Medium                  Medium             Medium                   Medium                   Medium               No
5           1.2               4.0           1.4       11.0               High                    High               High                     High                    High               Yes
6           0.6               2.5           0.9       10.0               Low                     Low                Low                      Low                     Low                No
7           1.8               6.0           1.6       13.0               High                    High               High                     High                    High               Yes
8           0.4               1.5           0.7       12.0               Low                     Low                Low                      Low                     Low                No
9           1.0               3.5           1.3       11.0               Medium                  Medium             Medium                   Medium                   Medium               No
10          0.9               2.8           1.0       10.0               Low                     Low                Low                      Low                     Low                No
11          1.6               5.5           1.7       13.0               High                    High               High                     High                    High               Yes
12          0.7               2.2           0.8       12.0               Low                     Low                Low                      Low                     Low                No
13          1.4               4.2           1.5       11.0               High                    High               High                     High                    High               Yes
14          0.3               1.2           0.6       10.0               Low                     Low                Low                      Low                     Low                No
15          1.1               3.8           1.2       11.0               Medium                  Medium             Medium                   Medium                   Medium               No
16          0.8               2.9           0.9       10.0               Low                     Low                Low                      Low                     Low                No
17          1.7               6.2           1.8       13.0               High                    High               High                     High                    High               Yes
18          0.5               1.8           0.7       12.0               Low                     Low                Low                      Low                     Low                No
19          1.3               4.5           1.4       11.0               High                    High               High                     High                    High               Yes
20          0.9               3.2           1.0       10.0               Low                     Low                Low                      Low                     Low                No
21          1.5               5.8           1.6       13.0               High                    High               High                     High                    High               Yes
22          0.6               2.4           0.8       12.0               Low                     Low                Low                      Low                     Low                No
23          1.2               4.8           1.3       11.0               High                    High               High                     High                    High               Yes
24          0.4               1.6           0.6       10.0               Low                     Low                Low                      Low                     Low                No
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/85829918f32c03af406652b8482362219f117de9.summary'],Can the specific gene expression modules identified in muscle tissue be used to predict the distribution and kinetics of lymph node activation in response to different vaccines?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** Can the specific gene expression modules identified in muscle tissue be used to predict the distribution and kinetics of lymph node activation in response to different vaccines?

**Experimental Plan:**

**Objective:** To test the hypothesis that specific gene expression modules in muscle tissue can predict lymph node activation in response to different vaccines.

**Experimental Design:**

1. **Sample Collection:**
	* Collect muscle tissue samples from healthy individuals (n=20) before and after vaccination with different types of vaccines (e.g., inactivated, live-attenuated, mRNA-based).
	* Collect lymph node samples from the same individuals at various time points post-vaccination (e.g., 1, 3, 7, 14 days).
2. **Gene Expression Analysis:**
	* Perform RNA sequencing (RNA-seq) on muscle tissue samples to identify specific gene expression modules associated with vaccine response.
	* Use bioinformatic tools (e.g., clustering algorithms, pathway analysis) to identify co-expressed gene modules.
3. **Lymph Node Activation Analysis:**
	* Perform immunohistochemistry (IHC) or flow cytometry on lymph node samples to assess immune cell activation (e.g., CD4+, CD8+, dendritic cells).
	* Measure cytokine production (e.g., IFN-γ, IL-2) in lymph node samples using ELISA or multiplex assays.
4. **Correlation Analysis:**
	* Correlate gene expression modules in muscle tissue with lymph node activation markers (e.g., immune cell activation, cytokine production) using statistical models (e.g., linear regression, machine learning algorithms).

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the null hypothesis that specific gene expression modules in muscle tissue are not associated with lymph node activation in response to different vaccines.

**Experimental Design:**

1. **Sample Collection:**
	* Collect muscle tissue samples from healthy individuals (n=20) before and after vaccination with a placebo (e.g., saline injection).
	* Collect lymph node samples from the same individuals at various time points post-vaccination (e.g., 1, 3, 7, 14 days).
2. **Gene Expression Analysis:**
	* Perform RNA-seq on muscle tissue samples to identify gene expression profiles.
3. **Lymph Node Activation Analysis:**
	* Perform IHC or flow cytometry on lymph node samples to assess immune cell activation.
	* Measure cytokine production in lymph node samples using ELISA or multiplex assays.
4. **Correlation Analysis:**
	* Correlate gene expression profiles in muscle tissue with lymph node activation markers using statistical models.

**Rationale:** If the gene expression modules in muscle tissue are not associated with lymph node activation in response to the placebo, it would suggest that the observed correlations in the initial experiment are specific to the vaccine response and not due to chance or confounding factors.

**Budget and Timeframe:**

* Estimated budget: $200,000 - $300,000
* Estimated timeframe: 12-18 months

**Justification:**

* The proposed experiment is feasible within a reasonable timeframe and budget.
* The use of existing methods and equipment (e.g., RNA-seq, IHC, flow cytometry) minimizes costs and accelerates the experimental process.
* The experiment is designed to test the hypothesis and its null hypothesis, providing a comprehensive understanding of the relationship between gene expression in muscle tissue and lymph node activation.

By following this experimental plan, you can test the hypothesis and determine whether specific gene expression modules in muscle tissue can predict lymph node activation in response to different vaccines.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: Sample Collection**

1.1. Recruit 20 healthy individuals and obtain informed consent.

1.2. Collect muscle tissue samples (e.g., biopsy or muscle fibers) from each individual before vaccination (time point 0).

1.3. Administer different types of vaccines (e.g., inactivated, live-attenuated, mRNA-based) to each individual.

1.4. Collect muscle tissue samples from each individual at various time points post-vaccination (e.g., 1, 3, 7, 14 days).

1.5. Collect lymph node samples from each individual at various time points post-vaccination (e.g., 1, 3, 7, 14 days).

**Step 2: Gene Expression Analysis**

2.1. Extract total RNA from muscle tissue samples using a RNA extraction kit (e.g., TRIzol, RNeasy).

2.2. Perform RNA sequencing (RNA-seq) on extracted RNA using a sequencing platform (e.g., Illumina, PacBio).

2.3. Use bioinformatic tools (e.g., STAR, HISAT2) to map RNA-seq reads to a reference genome (e.g., human genome).

2.4. Use clustering algorithms (e.g., k-means, hierarchical clustering) to identify co-expressed gene modules.

2.5. Perform pathway analysis (e.g., Gene Ontology, KEGG) to identify biological pathways associated with co-expressed gene modules.

**Step 3: Lymph Node Activation Analysis**

3.1. Perform immunohistochemistry (IHC) on lymph node samples to assess immune cell activation (e.g., CD4+, CD8+, dendritic cells).

3.2. Use antibodies specific to immune cell markers (e.g., CD4, CD8, CD11c) and detect using a detection system (e.g., HRP, AP).

3.3. Perform flow cytometry on lymph node samples to assess immune cell activation.

3.4. Use antibodies specific to immune cell markers and detect using a flow cytometer (e.g., BD FACSCanto, Beckman Coulter CytoFLEX).

3.5. Measure cytokine production (e.g., IFN-γ, IL-2) in lymph node samples using ELISA or multiplex assays.

**Step 4: Correlation Analysis**

4.1. Correlate gene expression modules in muscle tissue with lymph node activation markers (e.g., immune cell activation, cytokine production) using statistical models (e.g., linear regression, machine learning algorithms).

4.2. Use software (e.g., R, Python) to perform statistical analysis and generate correlation plots.

**Experiment to Disprove the Hypothesis:**

**Step 1: Sample Collection**

1.1. Recruit 20 healthy individuals and obtain informed consent.

1.2. Collect muscle tissue samples from each individual before administration of a placebo (e.g., saline injection).

1.3. Administer a placebo to each individual.

1.4. Collect muscle tissue samples from each individual at various time points post-administration (e.g., 1, 3, 7, 14 days).

1.5. Collect lymph node samples from each individual at various time points post-administration (e.g., 1, 3, 7, 14 days).

**Step 2: Gene Expression Analysis**

2.1. Extract total RNA from muscle tissue samples using a RNA extraction kit.

2.2. Perform RNA sequencing (RNA-seq) on extracted RNA using a sequencing platform.

2.3. Use bioinformatic tools to map RNA-seq reads to a reference genome.

2.4. Identify gene expression profiles in muscle tissue.

**Step 3: Lymph Node Activation Analysis**

3.1. Perform IHC on lymph node samples to assess immune cell activation.

3.2. Use antibodies specific to immune cell markers and detect using a detection system.

3.3. Perform flow cytometry on lymph node samples to assess immune cell activation.

3.4. Use antibodies specific to immune cell markers and detect using a flow cytometer.

3.5. Measure cytokine production in lymph node samples using ELISA or multiplex assays.

**Step 4: Correlation Analysis**

4.1. Correlate gene expression profiles in muscle tissue with lymph node activation markers using statistical models.

4.2. Use software to perform statistical analysis and generate correlation plots.

**Quality Control and Assurance:**

* Verify the quality of RNA-seq data using metrics such as read quality, mapping rate, and gene expression levels.
* Validate IHC and flow cytometry results using positive and negative controls.
* Use standardized protocols for ELISA and multiplex assays to ensure accurate cytokine measurements.
* Perform regular instrument maintenance and calibration to ensure accurate results.

**Data Management and Storage:**

* Store RNA-seq data in a secure database (e.g., NCBI's Sequence Read Archive).
* Store IHC and flow cytometry data in a secure database (e.g., ImageJ, FlowJo).
* Store ELISA and multiplex assay data in a secure database (e.g., Excel, GraphPad Prism).
* Use version control software (e.g., Git) to track changes to data and analysis scripts.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be verified.","```
   Vaccine_Type  Muscle_Tissue_Sample  Lymph_Node_Sample  RNA_Extraction_Kit  Sequencing_Platform  Gene_Expression_Module  Immune_Cell_Activation  Cytokine_Production  Outcome
0        mRNA            100             50               TRIzol             Illumina                  0.8                     0.6               200          Positive
1  Inactivated            80             40               RNeasy             PacBio                  0.4                     0.3               150          Negative
2        mRNA            120             60               TRIzol             Illumina                  0.9                     0.7               250          Positive
3  Live-Attenuated        90             45               RNeasy             PacBio                  0.5                     0.4               180          Positive
4        mRNA             70             35               TRIzol             Illumina                  0.3                     0.2               120          Negative
5  Inactivated           110             55               RNeasy             PacBio                  0.6                     0.5               220          Positive
6        mRNA            130             65               TRIzol             Illumina                  1.0                     0.8               280          Positive
7  Live-Attenuated        80             40               RNeasy             PacBio                  0.4                     0.3               160          Negative
8        mRNA             90             45               TRIzol             Illumina                  0.5                     0.4               190          Positive
9  Inactivated           100             50               RNeasy             PacBio                  0.7                     0.6               240          Positive
10       mRNA             60             30               TRIzol             Illumina                  0.2                     0.1               100          Negative
11 Live-Attenuated       120             60               RNeasy             PacBio                  0.8                     0.7               260          Positive
12       mRNA            140             70               TRIzol             Illumina                  1.1                     0.9               300          Positive
13 Inactivated           90             45               RNeasy             PacBio                  0.5                     0.4               200          Positive
14       mRNA             70             35               TRIzol             Illumina                  0.3                     0.2               140          Negative
15 Live-Attenuated       110             55               RNeasy             PacBio                  0.6                     0.5               230          Positive
16       mRNA            130             65               TRIzol             Illumina                  1.0                     0.8               290          Positive
17 Inactivated           80             40               RNeasy             PacBio                  0.4                     0.3               170          Negative
18       mRNA             90             45               TRIzol             Illumina                  0.5                     0.4               210          Positive
19 Live-Attenuated       100             50               RNeasy             PacBio                  0.7                     0.6               250          Positive
20       mRNA             60             30               TRIzol             Illumina                  0.2                     0.1               110          Negative
21 Inactivated           120             60               RNeasy             PacBio                  0.8                     0.7               270          Positive
22       mRNA            140             70               TRIzol             Illumina                  1.1                     0.9               310          Positive
23 Live-Attenuated       90             45               RNeasy             PacBio                  0.5                     0.4               220          Positive
24       mRNA             70             35               TRIzol             Illumina                  0.3                     0.2               150          Negative
25 Inactivated           110             55               RNeasy             PacBio                  0.6                     0.5               240          Positive
```",0.3306986689754142
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0afa680805a978ea006c571f2a9ad7c165de9c8a.summary'],"Can the stabilization of G-quadruplex structures in the promoter regions of other oncogenes, beyond CARD11, also be exploited as a therapeutic strategy for treating various types of cancer by targeting them with small molecules?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** Can the stabilization of G-quadruplex structures in the promoter regions of other oncogenes, beyond CARD11, also be exploited as a therapeutic strategy for treating various types of cancer by targeting them with small molecules?

**Experimental Plan:**

**Objective:** To test the hypothesis by identifying and validating G-quadruplex structures in the promoter regions of other oncogenes and evaluating their potential as therapeutic targets for cancer treatment.

**Step 1: Bioinformatics Analysis (Weeks 1-4)**

* Use existing bioinformatics tools (e.g., QGRS, G4Hunter, and G4RNA) to identify potential G-quadruplex-forming sequences in the promoter regions of a panel of oncogenes (e.g., MYC, KRAS, and BRAF).
* Analyze the predicted G-quadruplex structures for their stability, conservation, and potential to be targeted by small molecules.

**Step 2: G-Quadruplex Stabilization Assay (Weeks 5-8)**

* Design and synthesize small molecules (e.g., porphyrins, quindolines, and naphthalene diimides) that can selectively stabilize G-quadruplex structures.
* Use a fluorescence-based assay (e.g., FRET or ThT) to evaluate the ability of these small molecules to stabilize the predicted G-quadruplex structures in vitro.

**Step 3: Cell-Based Assays (Weeks 9-16)**

* Use CRISPR-Cas9 genome editing to introduce the predicted G-quadruplex-forming sequences into the promoter regions of the selected oncogenes in cancer cell lines (e.g., HeLa, MCF-7, and A549).
* Treat the edited cell lines with the small molecules that showed promising G-quadruplex stabilization activity in Step 2.
* Evaluate the effects of G-quadruplex stabilization on oncogene expression, cell proliferation, and apoptosis using techniques such as qRT-PCR, Western blotting, and flow cytometry.

**Step 4: Validation and Verification (Weeks 17-20)**

* Validate the results from Step 3 using additional cell lines and oncogenes.
* Verify the specificity of the small molecules for the targeted G-quadruplex structures using competition assays and mutagenesis studies.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the hypothesis by attempting to demonstrate that G-quadruplex stabilization in the promoter regions of oncogenes does not affect their expression or cancer cell proliferation.

**Design:**

* Use the same cell lines and oncogenes as in Step 3.
* Introduce mutations into the predicted G-quadruplex-forming sequences to disrupt their formation.
* Treat the mutated cell lines with the small molecules that showed promising G-quadruplex stabilization activity in Step 2.
* Evaluate the effects of G-quadruplex disruption on oncogene expression, cell proliferation, and apoptosis using techniques such as qRT-PCR, Western blotting, and flow cytometry.

**Rationale:** If the hypothesis is true, disrupting the G-quadruplex structures should abolish the effects of small molecule treatment on oncogene expression and cancer cell proliferation. If the results show no significant differences between the mutated and wild-type cell lines, it would suggest that G-quadruplex stabilization is not a viable therapeutic strategy for cancer treatment.

**Timeline and Budget:**

* The proposed experiment can be completed within 20 weeks (approximately 5 months).
* The budget for this experiment would be approximately $150,000, broken down into:
	+ Bioinformatics analysis and small molecule synthesis: $20,000
	+ G-quadruplex stabilization assay and cell-based assays: $60,000
	+ Validation and verification: $30,000
	+ Experiment to disprove the hypothesis: $40,000

This experimental plan is designed to be feasible within a reasonable time frame and budget, while providing a comprehensive evaluation of the hypothesis.",85,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Bioinformatics Analysis (Weeks 1-4)**

**Protocol:**

1.1. **Data Collection**

* Collect the genomic sequences of the promoter regions of the selected oncogenes (e.g., MYC, KRAS, and BRAF) from publicly available databases such as Ensembl or UCSC Genome Browser.
* Save the sequences in a FASTA format.

1.2. **G-Quadruplex Prediction**

* Use the following bioinformatics tools to predict potential G-quadruplex-forming sequences in the promoter regions:
	+ QGRS: Run the QGRS algorithm on the collected sequences using the default parameters.
	+ G4Hunter: Run the G4Hunter algorithm on the collected sequences using the default parameters.
	+ G4RNA: Run the G4RNA algorithm on the collected sequences using the default parameters.
* Save the output files from each tool in a tab-delimited format.

1.3. **G-Quadruplex Structure Analysis**

* Use a tool such as G-quadruplex Explorer or G4RNA to analyze the predicted G-quadruplex structures for their stability, conservation, and potential to be targeted by small molecules.
* Calculate the following parameters for each predicted G-quadruplex structure:
	+ Stability: Calculate the free energy change (ΔG) using a tool such as G-quadruplex Explorer.
	+ Conservation: Calculate the conservation score using a tool such as PhastCons or PhyloP.
	+ Targetability: Calculate the targetability score using a tool such as G4RNA.
* Save the results in a tab-delimited format.

**Step 2: G-Quadruplex Stabilization Assay (Weeks 5-8)**

**Protocol:**

2.1. **Small Molecule Synthesis**

* Design and synthesize small molecules (e.g., porphyrins, quindolines, and naphthalene diimides) that can selectively stabilize G-quadruplex structures using standard organic chemistry techniques.
* Purify the synthesized small molecules using techniques such as HPLC or LC-MS.

2.2. **Fluorescence-Based Assay**

* Prepare a 10 μM solution of each small molecule in a buffer solution (e.g., 10 mM Tris-HCl, pH 7.5, 100 mM KCl).
* Prepare a 1 μM solution of the predicted G-quadruplex-forming sequence in the same buffer solution.
* Mix 10 μL of the small molecule solution with 10 μL of the G-quadruplex solution in a 96-well plate.
* Incubate the mixture at room temperature for 30 minutes.
* Measure the fluorescence intensity using a plate reader (e.g., excitation at 488 nm, emission at 520 nm).
* Calculate the fluorescence intensity ratio (FIR) using the following formula: FIR = (F - F0) / F0, where F is the fluorescence intensity in the presence of the small molecule and F0 is the fluorescence intensity in the absence of the small molecule.
* Repeat the experiment in triplicate and calculate the average FIR value.

**Step 3: Cell-Based Assays (Weeks 9-16)**

**Protocol:**

3.1. **CRISPR-Cas9 Genome Editing**

* Design guide RNAs (gRNAs) targeting the predicted G-quadruplex-forming sequences in the promoter regions of the selected oncogenes using a tool such as CRISPR Design.
* Clone the gRNAs into a CRISPR-Cas9 vector (e.g., pSpCas9(BB)-2A-GFP) using standard molecular biology techniques.
* Transfect the CRISPR-Cas9 vector into the cancer cell lines (e.g., HeLa, MCF-7, and A549) using a transfection reagent (e.g., Lipofectamine 2000).
* Select for edited cells using a selection marker (e.g., puromycin).

3.2. **Small Molecule Treatment**

* Treat the edited cell lines with the small molecules that showed promising G-quadruplex stabilization activity in Step 2.
* Use a concentration range of 0.1-10 μM and incubate the cells for 24-48 hours.

3.3. **Cell-Based Assays**

* Evaluate the effects of G-quadruplex stabilization on oncogene expression using qRT-PCR.
* Evaluate the effects of G-quadruplex stabilization on cell proliferation using techniques such as MTT or BrdU incorporation.
* Evaluate the effects of G-quadruplex stabilization on apoptosis using techniques such as Annexin V staining or caspase-3 activity assays.

**Step 4: Validation and Verification (Weeks 17-20)**

**Protocol:**

4.1. **Validation**

* Repeat the cell-based assays in Step 3 using additional cell lines and oncogenes.
* Evaluate the consistency of the results across different cell lines and oncogenes.

4.2. **Verification**

* Design competition assays to verify the specificity of the small molecules for the targeted G-quadruplex structures.
* Use mutagenesis studies to verify the role of the G-quadruplex structures in oncogene expression and cancer cell proliferation.

**Experiment to Disprove the Hypothesis**

**Protocol:**

* Introduce mutations into the predicted G-quadruplex-forming sequences to disrupt their formation using CRISPR-Cas9 genome editing.
* Treat the mutated cell lines with the small molecules that showed promising G-quadruplex stabilization activity in Step 2.
* Evaluate the effects of G-quadruplex disruption on oncogene expression, cell proliferation, and apoptosis using techniques such as qRT-PCR, Western blotting, and flow cytometry.
* Compare the results with the wild-type cell lines to determine if disrupting the G-quadruplex structures abolishes the effects of small molecule treatment.","```
   QGRS  G4Hunter  G4RNA  Small_Molecule_Conc  FIR  Oncogene  Cell_Line  qRT_PCR  MTT  Annexin_V
0    0.8      0.9    0.7               1.0  2.5      MYC      HeLa     0.4   0.6      0.3
1    0.9      0.8    0.6               5.0  3.2      KRAS     MCF-7     0.5   0.7      0.4
2    0.7      0.6    0.8               0.5  2.1      BRAF     A549     0.3   0.5      0.2
3    0.6      0.7    0.9               2.0  2.8      MYC      HeLa     0.5   0.6      0.3
4    0.8      0.9    0.7               1.5  3.0      KRAS     MCF-7     0.6   0.8      0.5
5    0.9      0.8    0.6               0.1  1.8      BRAF     A549     0.2   0.4      0.1
6    0.7      0.6    0.8               3.0  2.9      MYC      HeLa     0.7   0.9      0.6
7    0.6      0.7    0.9               4.0  3.5      KRAS     MCF-7     0.8   1.0      0.7
8    0.8      0.9    0.7               2.5  3.1      BRAF     A549     0.5   0.7      0.4
9    0.9      0.8    0.6               1.0  2.6      MYC      HeLa     0.4   0.6      0.3
10   0.7      0.6    0.8               5.0  3.3      KRAS     MCF-7     0.6   0.8      0.5
11   0.6      0.7    0.9               0.5  2.2      BRAF     A549     0.3   0.5      0.2
12   0.8      0.9    0.7               1.5  2.9      MYC      HeLa     0.5   0.7      0.4
13   0.9      0.8    0.6               2.0  3.1      KRAS     MCF-7     0.7   0.9      0.6
14   0.7      0.6    0.8               3.5  3.2      BRAF     A549     0.6   0.8      0.5
15   0.6      0.7    0.9               4.5  3.6      MYC      HeLa     0.8   1.0      0.7
16   0.8      0.9    0.7               2.5  3.3      KRAS     MCF-7     0.7   0.9      0.6
17   0.9      0.8    0.6               1.0  2.7      BRAF     A549     0.5   0.7      0.4
18   0.7      0.6    0.8               5.0  3.4      MYC      HeLa     0.6   0.8      0.5
19   0.6      0.7    0.9               0.5  2.3      KRAS     MCF-7     0.4   0.6      0.3
20   0.8      0.9    0.7               1.5  2.9      BRAF     A549     0.5   0.7      0.4
21   0.9      0.8    0.6               2.0  3.2      MYC      HeLa     0.7   0.9      0.6
22   0.7      0.6    0.8               3.0  3.1      KRAS     MCF-7     0.6   0.8      0.5
23   0.6      0.7    0.9               4.0  3.5      BRAF     A549     0.7   0.9      0.6
24   0.8      0.9    0.7               2.5  3.3      MYC      HeLa     0.7   0.9      0.6
```",0.3181136208494666
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9364fba66d111773e2c33afe2623aeaba633f87e.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/07ab23a0d9b962597ce6492a3ec5e65ab12da394.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/06ae5438bdc08ebf0dbb9b447d2156c427c5314f.summary']",Can the synergistic activation of B cells by CD40L and thymus-independent antigens enhance the control of Mycobacterium tuberculosis infection in asymptomatic individuals?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Can the synergistic activation of B cells by CD40L and thymus-independent antigens enhance the control of Mycobacterium tuberculosis infection in asymptomatic individuals?

**Experimental Design:**

**Objective:** To investigate whether the synergistic activation of B cells by CD40L and thymus-independent antigens can enhance the control of M. tuberculosis infection in asymptomatic individuals.

**Equipment:**

* Diversity Outbred mice
* M. tuberculosis strain Erdman
* CD40L
* Thymus-independent antigens (TI-1)
* B cell-depleting antibodies (e.g. anti-CD20)
* Flow cytometry equipment
* Real-time PCR equipment
* Histopathology equipment
* ELISA equipment

**Experimental Steps:**

1. Infect mice with M. tuberculosis and monitor for asymptomatic infection.
2. Divide the infected mice into four groups:
	* Group 1: Control group (no treatment)
	* Group 2: CD40L treatment only
	* Group 3: TI-1 antigen treatment only
	* Group 4: CD40L and TI-1 antigen treatment (synergistic activation)
3. Treat the mice with the respective treatments and monitor disease progression.
4. Deplete B cells in a subset of mice from each group using B cell-depleting antibodies.
5. Analyze lung tissue for M. tuberculosis burden, granuloma formation, and B-cell gene expression using real-time PCR and histopathology.
6. Measure the production of antibodies against M. tuberculosis using ELISA.
7. Compare the results between the groups to determine the effect of CD40L and TI-1 antigens on B cell activation and M. tuberculosis control.

**To disprove the hypothesis:**

* If the synergistic activation of B cells by CD40L and TI-1 antigens does not enhance the control of M. tuberculosis infection in asymptomatic individuals, we would expect to see:
	+ No significant difference in M. tuberculosis burden, granuloma formation, and B-cell gene expression between the control group and the CD40L and TI-1 antigen treatment groups.
	+ No significant difference in antibody production against M. tuberculosis between the control group and the CD40L and TI-1 antigen treatment groups.
	+ No significant difference in disease progression between the control group and the CD40L and TI-1 antigen treatment groups.

By designing an experiment to disprove the hypothesis, we can test the validity of the hypothesis and determine whether the synergistic activation of B cells by CD40L and TI-1 antigens truly enhances the control of M. tuberculosis infection in asymptomatic individuals.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Mouse Infection and Monitoring**

1.1. Obtain Diversity Outbred mice (n=40) and acclimate them to the laboratory environment for 1 week.

1.2. Prepare M. tuberculosis strain Erdman for infection by growing it in Middlebrook 7H9 broth and adjusting the concentration to 1 x 10^6 CFU/mL.

1.3. Infect mice intravenously with 100 μL of the M. tuberculosis suspension (1 x 10^5 CFU/mouse) using a 26-gauge needle.

1.4. Monitor mice for asymptomatic infection by weighing them daily and observing for signs of disease (e.g., lethargy, ruffled fur, labored breathing) for 4 weeks.

**Protocol 2: Group Assignment and Treatment**

2.1. Divide the infected mice into four groups of 10 mice each:
	* Group 1: Control group (no treatment)
	* Group 2: CD40L treatment only
	* Group 3: TI-1 antigen treatment only
	* Group 4: CD40L and TI-1 antigen treatment (synergistic activation)

2.2. Prepare CD40L and TI-1 antigens according to the manufacturer's instructions.

2.3. Administer the respective treatments to each group via intraperitoneal injection:
	* Group 2: 10 μg of CD40L in 100 μL of PBS
	* Group 3: 10 μg of TI-1 antigen in 100 μL of PBS
	* Group 4: 10 μg of CD40L and 10 μg of TI-1 antigen in 100 μL of PBS

2.4. Treat mice on days 7, 14, and 21 post-infection.

**Protocol 3: B Cell Depletion**

3.1. Prepare B cell-depleting antibodies (e.g., anti-CD20) according to the manufacturer's instructions.

3.2. Deplete B cells in a subset of mice from each group (n=5) by administering 100 μg of anti-CD20 antibodies via intraperitoneal injection on days 7, 14, and 21 post-infection.

**Protocol 4: Tissue Collection and Analysis**

4.1. Euthanize mice on day 28 post-infection using CO2 asphyxiation.

4.2. Collect lung tissue from each mouse and divide it into three parts:
	* Part 1: Fix in 10% formalin for histopathology analysis
	* Part 2: Store in RNA later for real-time PCR analysis
	* Part 3: Homogenize in PBS for ELISA analysis

4.3. Analyze lung tissue for:
	* M. tuberculosis burden using real-time PCR (targeting the 16S rRNA gene)
	* Granuloma formation using histopathology (H&E staining)
	* B-cell gene expression using real-time PCR (targeting CD20, CD40, and IgG genes)

**Protocol 5: ELISA Analysis**

5.1. Prepare ELISA plates coated with M. tuberculosis antigens according to the manufacturer's instructions.

5.2. Add 100 μL of lung homogenate from each mouse to the ELISA plate and incubate for 2 hours at room temperature.

5.3. Detect bound antibodies using HRP-conjugated secondary antibodies and measure the absorbance at 450 nm.

**Protocol 6: Data Analysis**

6.1. Compare the results between the groups using one-way ANOVA and Tukey's post-hoc test.

6.2. Determine the effect of CD40L and TI-1 antigens on B cell activation and M. tuberculosis control by comparing the results between the control group and the CD40L and TI-1 antigen treatment groups.

6.3. Evaluate the results in the context of the hypothesis and determine whether the synergistic activation of B cells by CD40L and TI-1 antigens enhances the control of M. tuberculosis infection in asymptomatic individuals.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately compared between groups to test the validity of the hypothesis.","```
   Mice  M_tuberculosis_CFU  CD40L_ug  TI_1_ug  Anti_CD20_ug  Outcome
0     10           100000      5.0      5.0         50.0  0.450000
1     10           120000      7.5      7.5         75.0  0.520000
2     10           110000      2.5      2.5         25.0  0.380000
3     10           130000     10.0     10.0        100.0  0.600000
4     10           100000      0.0      0.0          0.0  0.300000
5     10           120000      5.0      5.0         50.0  0.480000
6     10           110000      7.5      7.5         75.0  0.550000
7     10           130000      2.5      2.5         25.0  0.420000
8     10           100000     10.0     10.0        100.0  0.650000
9     10           120000      0.0      0.0          0.0  0.350000
10    10           110000      5.0      5.0         50.0  0.500000
11    10           130000      7.5      7.5         75.0  0.580000
12    10           100000      2.5      2.5         25.0  0.440000
13    10           120000     10.0     10.0        100.0  0.680000
14    10           110000      0.0      0.0          0.0  0.320000
15    10           130000      5.0      5.0         50.0  0.520000
16    10           100000      7.5      7.5         75.0  0.560000
17    10           120000      2.5      2.5         25.0  0.460000
18    10           110000     10.0     10.0        100.0  0.700000
19    10           130000      0.0      0.0          0.0  0.330000
20    10           100000      5.0      5.0         50.0  0.540000
21    10           120000      7.5      7.5         75.0  0.600000
22    10           110000      2.5      2.5         25.0  0.480000
23    10           130000     10.0     10.0        100.0  0.720000
24    10           100000      0.0      0.0          0.0  0.340000
```",0.7680257379770685
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1c08f636ce2b14a4e90a56f6635fbfc32852595c.summary'],Can the use of retrogenic TCRs and MHC multimers in combination with intravital imaging enable the prediction of alloimmune response outcomes in transplantation patients based on in vivo tracking of antigen-specific T cell dynamics?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Can the use of retrogenic TCRs and MHC multimers in combination with intravital imaging enable the prediction of alloimmune response outcomes in transplantation patients based on in vivo tracking of antigen-specific T cell dynamics?

**Experimental Plan:**

**Objective:** To determine whether the combination of retrogenic TCRs, MHC multimers, and intravital imaging can predict alloimmune response outcomes in transplantation patients by tracking antigen-specific T cell dynamics in vivo.

**Experimental Design:**

1. **Retrogenic TCR Generation:**
	* Isolate T cells from transplantation patients and generate retrogenic TCRs specific to donor-derived antigens using established protocols (e.g., retroviral transduction).
	* Validate the specificity and functionality of the generated TCRs using in vitro assays (e.g., ELISA, flow cytometry).
2. **MHC Multimer Generation:**
	* Generate MHC multimers specific to the same donor-derived antigens using established protocols (e.g., peptide-MHC tetramer technology).
	* Validate the specificity and binding affinity of the MHC multimers using in vitro assays (e.g., flow cytometry, surface plasmon resonance).
3. **Intravital Imaging:**
	* Use two-photon microscopy or other intravital imaging techniques to track the dynamics of antigen-specific T cells in vivo in a transplantation model (e.g., mouse or humanized mouse).
	* Label the retrogenic T cells with a fluorescent marker (e.g., GFP) to enable visualization.
4. **Alloimmune Response Outcome Analysis:**
	* Monitor the transplantation outcome (e.g., graft rejection, tolerance) in the animal model.
	* Correlate the in vivo T cell dynamics (e.g., migration, activation, proliferation) with the alloimmune response outcome.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will design an experiment that intentionally introduces variability and noise in the system to test the robustness of the approach.

**Disproof Experiment:**

1. **Variable TCR Specificity:**
	* Generate retrogenic TCRs with varying levels of specificity to the donor-derived antigens (e.g., using different peptide sequences or affinities).
	* Use these TCRs to track T cell dynamics in vivo and analyze the correlation with alloimmune response outcomes.
2. **MHC Multimer Variability:**
	* Generate MHC multimers with varying binding affinities or specificities to the donor-derived antigens.
	* Use these MHC multimers to track T cell dynamics in vivo and analyze the correlation with alloimmune response outcomes.
3. **Intravital Imaging Variability:**
	* Introduce variability in the intravital imaging setup (e.g., different imaging modalities, varying laser power, or acquisition settings).
	* Analyze the impact of these variations on the tracking of T cell dynamics and the correlation with alloimmune response outcomes.

**Rationale:**

By introducing variability in the TCR specificity, MHC multimer binding, and intravital imaging, we can test the robustness of the approach and determine whether the correlation between T cell dynamics and alloimmune response outcomes is still maintained. If the correlation is lost or significantly reduced, it would suggest that the approach is not reliable for predicting alloimmune response outcomes.

**Timeline and Budget:**

This experiment can be completed within 12-18 months with a budget of approximately $200,000-$300,000. This estimate includes the costs of:

* Personnel (postdoc, graduate student, technician): $100,000-$150,000
* Reagents and consumables (TCR generation, MHC multimers, imaging reagents): $30,000-$50,000
* Equipment and maintenance (intravital imaging setup, flow cytometer): $20,000-$30,000
* Animal costs (mouse or humanized mouse model): $20,000-$30,000
* Miscellaneous (travel, training, etc.): $10,000-$20,000

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the institution's policies.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Retrogenic TCR Generation**

**Step 1.1: T Cell Isolation**

* Obtain peripheral blood mononuclear cells (PBMCs) from transplantation patients using Ficoll-Paque density gradient centrifugation.
* Isolate CD4+ or CD8+ T cells from PBMCs using magnetic bead-based separation (e.g., Miltenyi Biotec).
* Wash the isolated T cells with PBS and count the cells using a hemocytometer.

**Step 1.2: Retroviral Transduction**

* Prepare retroviral vectors encoding the TCR alpha and beta chains specific to donor-derived antigens using established protocols (e.g., Gibson Assembly).
* Transduce the isolated T cells with the retroviral vectors using a spinfection protocol (e.g., 1,000 x g, 30 minutes, 32°C).
* Incubate the transduced T cells in complete media (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2 for 48-72 hours.

**Step 1.3: TCR Validation**

* Validate the specificity and functionality of the generated TCRs using in vitro assays:
	+ ELISA: Coat 96-well plates with the donor-derived antigen and detect TCR binding using an anti-TCR antibody.
	+ Flow cytometry: Stain the transduced T cells with a fluorescently labeled anti-TCR antibody and analyze using a flow cytometer (e.g., BD FACSCanto).

**Protocol 2: MHC Multimer Generation**

**Step 2.1: Peptide-MHC Tetramer Preparation**

* Prepare MHC class I or II molecules using established protocols (e.g., refolding, purification).
* Conjugate the MHC molecules with the donor-derived peptide using a peptide-MHC tetramer technology (e.g., ProImmune).
* Validate the specificity and binding affinity of the MHC multimers using in vitro assays:
	+ Flow cytometry: Stain the MHC multimers with a fluorescently labeled anti-MHC antibody and analyze using a flow cytometer.
	+ Surface plasmon resonance: Measure the binding affinity of the MHC multimers to the donor-derived peptide using a surface plasmon resonance instrument (e.g., Biacore).

**Protocol 3: Intravital Imaging**

**Step 3.1: Animal Model Preparation**

* Obtain a transplantation model (e.g., mouse or humanized mouse) and perform the transplantation procedure according to established protocols.
* Allow the animal to recover for 7-10 days before imaging.

**Step 3.2: Retrogenic T Cell Labeling**

* Label the retrogenic T cells with a fluorescent marker (e.g., GFP) using a lentiviral vector or a fluorescent dye (e.g., CFSE).
* Validate the labeling efficiency using flow cytometry.

**Step 3.3: Intravital Imaging**

* Anesthetize the animal and prepare for two-photon microscopy or other intravital imaging techniques.
* Inject the labeled retrogenic T cells into the animal via tail vein injection.
* Acquire images of the T cell dynamics in vivo using the intravital imaging setup (e.g., 20x objective, 1-2 frames per second).

**Protocol 4: Alloimmune Response Outcome Analysis**

**Step 4.1: Transplantation Outcome Monitoring**

* Monitor the transplantation outcome (e.g., graft rejection, tolerance) in the animal model using established protocols (e.g., histology, flow cytometry).

**Step 4.2: T Cell Dynamics Analysis**

* Analyze the in vivo T cell dynamics (e.g., migration, activation, proliferation) using image analysis software (e.g., ImageJ, Imaris).
* Correlate the T cell dynamics with the alloimmune response outcome using statistical analysis software (e.g., R, Prism).

**Disproof Experiment Protocols**

**Protocol 5: Variable TCR Specificity**

**Step 5.1: TCR Generation with Varying Specificity**

* Generate retrogenic TCRs with varying levels of specificity to the donor-derived antigens using different peptide sequences or affinities.
* Validate the specificity and functionality of the generated TCRs using in vitro assays (e.g., ELISA, flow cytometry).

**Step 5.2: T Cell Dynamics Analysis**

* Track the T cell dynamics in vivo using the intravital imaging setup and analyze the correlation with alloimmune response outcomes.

**Protocol 6: MHC Multimer Variability**

**Step 6.1: MHC Multimer Generation with Varying Binding Affinity**

* Generate MHC multimers with varying binding affinities to the donor-derived antigens using different peptide-MHC tetramer technologies or peptide sequences.
* Validate the specificity and binding affinity of the MHC multimers using in vitro assays (e.g., flow cytometry, surface plasmon resonance).

**Step 6.2: T Cell Dynamics Analysis**

* Track the T cell dynamics in vivo using the intravital imaging setup and analyze the correlation with alloimmune response outcomes.

**Protocol 7: Intravital Imaging Variability**

**Step 7.1: Intravital Imaging Setup Variability**

* Introduce variability in the intravital imaging setup (e.g., different imaging modalities, varying laser power, or acquisition settings).
* Track the T cell dynamics in vivo using the modified intravital imaging setup and analyze the correlation with alloimmune response outcomes.

These detailed protocols should enable the execution of the experimental plan and provide a robust test of the hypothesis.","```
   PBMCs  CD4+ T cells  Retroviral Vectors  MHC Molecules  Peptide  TCR Specificity  MHC Binding Affinity  Imaging Modality  Alloimmune Response
0    10000         5000             1000          2000     1000             0.8               1000            Two-Photon         Rejection
1    12000         6000             1200          2400     1200             0.9               1200            Two-Photon         Tolerance
2     8000         4000              800          1600      800             0.7                800            Two-Photon         Rejection
3    15000         7500             1500          3000     1500             0.85              1500            Confocal         Tolerance
4    11000         5500             1100          2200     1100             0.82              1100            Two-Photon         Rejection
5     9000         4500              900          1800      900             0.78               900            Confocal         Tolerance
6    13000         6500             1300          2600     1300             0.88              1300            Two-Photon         Rejection
7    10000         5000             1000          2000     1000             0.8               1000            Wide-Field         Tolerance
8    14000         7000             1400          2800     1400             0.9               1400            Two-Photon         Rejection
9     8500         4250              850          1700      850             0.79              850            Confocal         Tolerance
10   10500         5250             1050          2100     1050             0.81              1050            Two-Photon         Rejection
11   12500         6250             1250          2500     1250             0.87              1250            Wide-Field         Tolerance
12    9500         4750              950          1900      950             0.77               950            Confocal         Tolerance
13   13500         6750             1350          2700     1350             0.89              1350            Two-Photon         Rejection
14   10000         5000             1000          2000     1000             0.8               1000            Wide-Field         Tolerance
15   14500         7250             1450          2900     1450             0.91              1450            Two-Photon         Rejection
16    9000         4500              900          1800      900             0.78               900            Confocal         Tolerance
17   15500         7750             1550          3100     1550             0.92              1550            Two-Photon         Rejection
18   11000         5500             1100          2200     1100             0.82              1100            Wide-Field         Tolerance
19    9500         4750              950          1900      950             0.77               950            Confocal         Tolerance
20   16000         8000             1600          3200     1600             0.93              1600            Two-Photon         Rejection
21   12000         6000             1200          2400     1200             0.9               1200            Wide-Field         Tolerance
22    8500         4250              850          1700      850             0.79              850            Confocal         Tolerance
23   16500         8250             1650          3300     1650             0.94              1650            Two-Photon         Rejection
24   13000         6500             1300          2600     1300             0.88              1300            Wide-Field         Tolerance
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/59b0a20e0cefae61e538834a2d8fcffdfb101ed6.summary'],"Do APOE+ pre-osteoblasts regulate the expression of TNFRSF21 in fibroblasts, thereby modulating the pro-inflammatory response and osteogenic differentiation in periodontal tissues?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I've developed an experimental plan to test it using existing scientific methods and equipment. To disprove the hypothesis, I'll design an experiment that attempts to show that APOE+ pre-osteoblasts do not regulate the expression of TNFRSF21 in fibroblasts, thereby not modulating the pro-inflammatory response and osteogenic differentiation in periodontal tissues.

**Experimental Plan:**

**Title:** Investigating the Role of APOE+ Pre-Osteoblasts in Regulating TNFRSF21 Expression in Fibroblasts and Osteogenic Differentiation in Periodontal Tissues

**Objective:** To determine if APOE+ pre-osteoblasts regulate the expression of TNFRSF21 in fibroblasts, thereby modulating the pro-inflammatory response and osteogenic differentiation in periodontal tissues.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate APOE+ pre-osteoblasts and fibroblasts from periodontal tissues using flow cytometry and cell sorting.
	* Culture APOE+ pre-osteoblasts and fibroblasts separately in appropriate media.
2. **Co-Culture Experiment:**
	* Co-culture APOE+ pre-osteoblasts with fibroblasts at a 1:1 ratio in a transwell system, allowing for cell-cell communication without direct contact.
	* Include control groups with APOE- pre-osteoblasts or no pre-osteoblasts to serve as negative controls.
3. **TNFRSF21 Expression Analysis:**
	* Measure TNFRSF21 expression in fibroblasts using qRT-PCR and Western blot after 24, 48, and 72 hours of co-culture.
	* Compare TNFRSF21 expression levels between co-culture groups and control groups.
4. **Osteogenic Differentiation Assay:**
	* Induce osteogenic differentiation in fibroblasts using osteogenic media and assess alkaline phosphatase activity, a marker of osteogenic differentiation, using a colorimetric assay.
	* Compare osteogenic differentiation levels between co-culture groups and control groups.
5. **Pro-Inflammatory Response Analysis:**
	* Measure pro-inflammatory cytokine expression (e.g., IL-1β, TNF-α) in fibroblasts using qRT-PCR and ELISA after 24, 48, and 72 hours of co-culture.
	* Compare pro-inflammatory cytokine expression levels between co-culture groups and control groups.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ Increased TNFRSF21 expression in fibroblasts co-cultured with APOE+ pre-osteoblasts compared to control groups.
	+ Enhanced osteogenic differentiation in fibroblasts co-cultured with APOE+ pre-osteoblasts compared to control groups.
	+ Increased pro-inflammatory cytokine expression in fibroblasts co-cultured with APOE+ pre-osteoblasts compared to control groups.
* If the hypothesis is false, we expect to see no significant differences in TNFRSF21 expression, osteogenic differentiation, and pro-inflammatory cytokine expression between co-culture groups and control groups.

**Equipment and Resources:**

* Flow cytometry and cell sorting equipment
* Cell culture facilities
* qRT-PCR and Western blot equipment
* Osteogenic media and alkaline phosphatase assay kit
* ELISA kit for pro-inflammatory cytokine detection
* Transwell system for co-culture experiments

**Timeline:**

* Cell isolation and culture: 2 weeks
* Co-culture experiment: 3 weeks
* TNFRSF21 expression analysis: 2 weeks
* Osteogenic differentiation assay: 2 weeks
* Pro-inflammatory response analysis: 2 weeks
* Data analysis and interpretation: 4 weeks

**Budget:**

* Cell isolation and culture reagents: $1,000
* Co-culture experiment reagents: $1,500
* TNFRSF21 expression analysis reagents: $1,000
* Osteogenic differentiation assay reagents: $500
* Pro-inflammatory response analysis reagents: $1,000
* Equipment maintenance and consumables: $2,000
* Total budget: $7,000

This experimental plan is designed to test the hypothesis in a controlled and rigorous manner, using existing scientific methods and equipment. The budget and timeline are reasonable, and the experiment can be completed within a reasonable timeframe.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Culture**

**Step 1.1: Prepare Cell Isolation Reagents**

* Prepare 1x PBS (phosphate-buffered saline) and store at 4°C.
* Prepare 0.25% trypsin-EDTA solution and store at -20°C.
* Prepare FACS (fluorescence-activated cell sorting) buffer (1x PBS, 2% FBS, 1 mM EDTA) and store at 4°C.

**Step 1.2: Isolate APOE+ Pre-Osteoblasts and Fibroblasts**

* Obtain periodontal tissue samples and mince them into small pieces.
* Incubate the tissue pieces in 0.25% trypsin-EDTA solution for 30 minutes at 37°C.
* Add 1x PBS to stop the trypsinization reaction.
* Filter the cell suspension through a 70-μm cell strainer to remove debris.
* Centrifuge the cell suspension at 300 x g for 5 minutes.
* Resuspend the cell pellet in FACS buffer.
* Stain the cells with APOE-specific antibodies and sort APOE+ pre-osteoblasts and fibroblasts using flow cytometry.

**Step 1.3: Culture APOE+ Pre-Osteoblasts and Fibroblasts**

* Plate APOE+ pre-osteoblasts and fibroblasts in separate culture dishes at a density of 1 x 10^5 cells/cm^2.
* Culture the cells in appropriate media (e.g., DMEM, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.
* Change the media every 3-4 days.

**Protocol 2: Co-Culture Experiment**

**Step 2.1: Prepare Co-Culture System**

* Prepare a transwell system with 0.4-μm pore size inserts.
* Sterilize the transwell system by autoclaving or UV irradiation.

**Step 2.2: Co-Culture APOE+ Pre-Osteoblasts with Fibroblasts**

* Plate fibroblasts in the bottom chamber of the transwell system at a density of 1 x 10^5 cells/cm^2.
* Add APOE+ pre-osteoblasts to the top chamber of the transwell system at a density of 1 x 10^5 cells/cm^2.
* Add control groups with APOE- pre-osteoblasts or no pre-osteoblasts to serve as negative controls.
* Culture the co-culture system in appropriate media (e.g., DMEM, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

**Protocol 3: TNFRSF21 Expression Analysis**

**Step 3.1: Harvest Cells**

* Harvest fibroblasts from the co-culture system at 24, 48, and 72 hours.
* Centrifuge the cell suspension at 300 x g for 5 minutes.
* Resuspend the cell pellet in TRIzol reagent for RNA extraction.

**Step 3.2: RNA Extraction and cDNA Synthesis**

* Extract total RNA from the cell pellet using TRIzol reagent according to the manufacturer's instructions.
* Synthesize cDNA from the extracted RNA using a reverse transcription kit according to the manufacturer's instructions.

**Step 3.3: qRT-PCR**

* Design and synthesize primers specific to TNFRSF21.
* Perform qRT-PCR using a qRT-PCR machine and a SYBR Green-based detection system.
* Analyze the qRT-PCR data using the 2^(-ΔΔCt) method.

**Step 3.4: Western Blot**

* Harvest fibroblasts from the co-culture system at 24, 48, and 72 hours.
* Lyse the cells in RIPA buffer and extract protein.
* Perform Western blot using a TNFRSF21-specific antibody and a secondary antibody.
* Analyze the Western blot data using densitometry software.

**Protocol 4: Osteogenic Differentiation Assay**

**Step 4.1: Induce Osteogenic Differentiation**

* Add osteogenic media (e.g., DMEM, 10% FBS, 1% penicillin-streptomycin, 50 μg/mL ascorbic acid, 10 mM β-glycerophosphate) to the fibroblasts in the co-culture system.
* Culture the cells for 7-10 days.

**Step 4.2: Alkaline Phosphatase Assay**

* Harvest the fibroblasts from the co-culture system.
* Lyse the cells in alkaline phosphatase assay buffer.
* Perform the alkaline phosphatase assay using a colorimetric kit according to the manufacturer's instructions.
* Analyze the alkaline phosphatase activity using a spectrophotometer.

**Protocol 5: Pro-Inflammatory Response Analysis**

**Step 5.1: Harvest Cells**

* Harvest fibroblasts from the co-culture system at 24, 48, and 72 hours.
* Centrifuge the cell suspension at 300 x g for 5 minutes.
* Resuspend the cell pellet in TRIzol reagent for RNA extraction.

**Step 5.2: RNA Extraction and cDNA Synthesis**

* Extract total RNA from the cell pellet using TRIzol reagent according to the manufacturer's instructions.
* Synthesize cDNA from the extracted RNA using a reverse transcription kit according to the manufacturer's instructions.

**Step 5.3: qRT-PCR**

* Design and synthesize primers specific to pro-inflammatory cytokines (e.g., IL-1β, TNF-α).
* Perform qRT-PCR using a qRT-PCR machine and a SYBR Green-based detection system.
* Analyze the qRT-PCR data using the 2^(-ΔΔCt) method.

**Step 5.4: ELISA**

* Harvest the cell culture supernatant from the co-culture system at 24, 48, and 72 hours.
* Perform ELISA using a pro-inflammatory cytokine-specific ELISA kit according to the manufacturer's instructions.
* Analyze the ELISA data using a spectrophotometer.

These detailed, step-by-step protocols should allow for the successful execution of the experimental plan and the collection of high-quality data.","```
   PBS  trypsin-EDTA  FACS_buffer  APOE+_pre-osteoblasts  Fibroblasts  TNFRSF21_expression  Osteogenic_differentiation  Pro-inflammatory_response
0    1.0         0.25         1.0                1.0e+05        1.0e+05               2.5                    0.8                    1.2
1    1.2         0.30         1.1                1.2e+05        1.1e+05               2.8                    0.9                    1.5
2    0.8         0.20         0.9                9.0e+04        9.0e+04               2.2                    0.7                    1.0
3    1.0         0.25         1.0                1.0e+05        1.0e+05               2.5                    0.8                    1.2
4    1.1         0.28         1.0                1.1e+05        1.0e+05               2.7                    0.9                    1.4
5    0.9         0.22         0.9                9.0e+04        9.0e+04               2.3                    0.7                    1.1
6    1.2         0.30         1.1                1.2e+05        1.1e+05               2.9                    1.0                    1.6
7    1.0         0.25         1.0                1.0e+05        1.0e+05               2.5                    0.8                    1.2
8    0.8         0.20         0.9                9.0e+04        9.0e+04               2.1                    0.7                    0.9
9    1.1         0.28         1.0                1.1e+05        1.0e+05               2.6                    0.9                    1.3
10   0.9         0.22         0.9                9.0e+04        9.0e+04               2.4                    0.7                    1.2
11   1.2         0.30         1.1                1.2e+05        1.1e+05               2.8                    1.0                    1.5
12   1.0         0.25         1.0                1.0e+05        1.0e+05               2.5                    0.8                    1.2
13   0.8         0.20         0.9                9.0e+04        9.0e+04               2.2                    0.7                    1.0
14   1.1         0.28         1.0                1.1e+05        1.0e+05               2.7                    0.9                    1.4
15   0.9         0.22         0.9                9.0e+04        9.0e+04               2.3                    0.7                    1.1
16   1.2         0.30         1.1                1.2e+05        1.1e+05               2.9                    1.0                    1.6
17   1.0         0.25         1.0                1.0e+05        1.0e+05               2.5                    0.8                    1.2
18   0.8         0.20         0.9                9.0e+04        9.0e+04               2.1                    0.7                    0.9
19   1.1         0.28         1.0                1.1e+05        1.0e+05               2.6                    0.9                    1.3
20   0.9         0.22         0.9                9.0e+04        9.0e+04               2.4                    0.7                    1.2
21   1.2         0.30         1.1                1.2e+05        1.1e+05               2.8                    1.0                    1.5
22   1.0         0.25         1.0                1.0e+05        1.0e+05               2.5                    0.8                    1.2
23   0.8         0.20         0.9                9.0e+04        9.0e+04               2.2                    0.7                    1.0
24   1.1         0.28         1.0                1.1e+05        1.0e+05               2.7                    0.9                    1.4
```",0.9374854505790972
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/180f48789550fe70c85447c1b585f7e5e941043d.summary'],Do B cells from MS patients with high neurodegeneration on MRI scans induce a specific epigenetic signature in microglia that contributes to the progression of neurodegeneration in MS?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis. Here's a high-level experimental approach:

**Experiment Title:** Investigating the Role of B Cells in MS Neurodegeneration: Epigenetic Signature in Microglia

**Objective:** To determine whether B cells from MS patients with high neurodegeneration on MRI scans induce a specific epigenetic signature in microglia that contributes to the progression of neurodegeneration in MS.

**Experimental Design:**

**Step 1: B Cell Isolation and Co-Culture with Microglia**

* Isolate B cells from MS patients with high neurodegeneration on MRI scans (n=10) and healthy controls (n=10) using flow cytometry and magnetic bead-based separation.
* Culture microglia cells (e.g., BV-2 or primary microglia) in vitro.
* Co-culture B cells with microglia at a 1:1 ratio for 24-48 hours.

**Step 2: Epigenetic Analysis**

* Extract DNA and RNA from microglia cells after co-culture with B cells.
* Perform reduced representation bisulfite sequencing (RRBS) or whole-genome bisulfite sequencing to analyze DNA methylation patterns in microglia.
* Use RNA-seq or qRT-PCR to analyze gene expression changes in microglia.

**Step 3: Epigenetic Signature Analysis**

* Compare DNA methylation and gene expression profiles between microglia co-cultured with B cells from MS patients with high neurodegeneration and healthy controls.
* Identify differentially methylated regions (DMRs) and differentially expressed genes (DEGs) associated with B cells from MS patients with high neurodegeneration.

**Step 4: Functional Validation**

* Validate the epigenetic signature by performing chromatin immunoprecipitation sequencing (ChIP-seq) for specific transcription factors (e.g., NF-κB) and histone modifications (e.g., H3K27me3) in microglia.
* Use CRISPR-Cas9 genome editing to knockout or overexpress specific genes identified in the epigenetic signature in microglia and assess their impact on neurodegeneration in vitro.

**Step 5: In Vivo Validation**

* Inject B cells from MS patients with high neurodegeneration into a mouse model of MS (e.g., experimental autoimmune encephalomyelitis, EAE).
* Monitor mice for signs of neurodegeneration using MRI and behavioral tests.
* Analyze microglia epigenetic signature and gene expression in the mouse brain using techniques from Steps 2-3.

**Control Experiments:**

* Co-culture microglia with B cells from MS patients with low neurodegeneration on MRI scans to serve as a control.
* Use a scrambled siRNA or shRNA control to validate the specificity of the epigenetic signature.

**Budget and Timeline:**

* Estimated budget: $200,000 - $300,000
* Estimated timeline: 12-18 months

**Rationale:**

This experiment is designed to test the hypothesis by investigating the epigenetic signature induced by B cells from MS patients with high neurodegeneration in microglia. By co-culturing B cells with microglia and analyzing the epigenetic signature, we can determine whether B cells from MS patients with high neurodegeneration induce a specific epigenetic signature that contributes to neurodegeneration. The in vivo validation step will help to confirm the findings in a more physiologically relevant context. The control experiments will help to rule out non-specific effects and validate the specificity of the epigenetic signature.

By following this experimental design, we can potentially disprove the hypothesis and gain a better understanding of the role of B cells in MS neurodegeneration.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Step 1: B Cell Isolation and Co-Culture with Microglia**

1.1. **B Cell Isolation**

* Prepare 10 mL of whole blood from MS patients with high neurodegeneration on MRI scans (n=10) and healthy controls (n=10) in EDTA-coated tubes.
* Add 100 μL of Ficoll-Paque PLUS (GE Healthcare) to each tube and mix gently.
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the buffy coat layer and transfer it to a new tube.
* Add 10 mL of PBS and centrifuge at 300 x g for 10 minutes.
* Resuspend the pellet in 100 μL of PBS and add 10 μL of B cell isolation cocktail (e.g., Miltenyi Biotec) containing antibodies against CD19, CD20, and CD22.
* Incubate for 15 minutes at 4°C.
* Add 10 mL of PBS and centrifuge at 300 x g for 10 minutes.
* Resuspend the pellet in 100 μL of PBS and sort B cells using a flow cytometer (e.g., BD FACSAria III) based on CD19+ and CD20+ expression.

1.2. **Microglia Culture**

* Obtain BV-2 microglia cells (or primary microglia) and culture them in DMEM/F12 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Maintain the cells at 37°C, 5% CO2, and 95% humidity.

1.3. **Co-Culture**

* Seed 1 x 10^5 microglia cells per well in a 24-well plate.
* Add 1 x 10^5 B cells per well (isolated in 1.1) to the microglia cells at a 1:1 ratio.
* Incubate for 24-48 hours at 37°C, 5% CO2, and 95% humidity.

**Step 2: Epigenetic Analysis**

2.1. **DNA Extraction**

* Harvest microglia cells after co-culture with B cells and wash them with PBS.
* Extract DNA using a DNA extraction kit (e.g., Qiagen DNeasy Blood & Tissue Kit) according to the manufacturer's instructions.
* Elute DNA in 50 μL of elution buffer.

2.2. **RRBS or Whole-Genome Bisulfite Sequencing**

* Prepare DNA libraries for RRBS or whole-genome bisulfite sequencing using a kit (e.g., Illumina TruSeq DNA Methylation Kit) according to the manufacturer's instructions.
* Perform sequencing on an Illumina HiSeq 4000 or similar platform.

2.3. **RNA Extraction and Sequencing**

* Harvest microglia cells after co-culture with B cells and wash them with PBS.
* Extract RNA using an RNA extraction kit (e.g., Qiagen RNeasy Mini Kit) according to the manufacturer's instructions.
* Prepare RNA libraries for RNA-seq using a kit (e.g., Illumina TruSeq RNA Library Prep Kit) according to the manufacturer's instructions.
* Perform sequencing on an Illumina HiSeq 4000 or similar platform.

**Step 3: Epigenetic Signature Analysis**

3.1. **Data Analysis**

* Analyze RRBS or whole-genome bisulfite sequencing data using a bioinformatics pipeline (e.g., Bismark, MethPipe) to identify differentially methylated regions (DMRs) between microglia co-cultured with B cells from MS patients with high neurodegeneration and healthy controls.
* Analyze RNA-seq data using a bioinformatics pipeline (e.g., STAR, DESeq2) to identify differentially expressed genes (DEGs) between microglia co-cultured with B cells from MS patients with high neurodegeneration and healthy controls.

3.2. **DMR and DEG Identification**

* Identify DMRs and DEGs using a statistical threshold (e.g., p-value < 0.05, fold change > 2) and filter out regions with low coverage or poor quality.
* Annotate DMRs and DEGs using a genome annotation tool (e.g., UCSC Genome Browser, Ensembl) to identify functional regions and genes.

**Step 4: Functional Validation**

4.1. **ChIP-seq**

* Perform ChIP-seq for specific transcription factors (e.g., NF-κB) and histone modifications (e.g., H3K27me3) in microglia using a ChIP-seq kit (e.g., Illumina ChIP-seq Kit) according to the manufacturer's instructions.
* Analyze ChIP-seq data using a bioinformatics pipeline (e.g., MACS, PeakRanger) to identify enriched regions.

4.2. **CRISPR-Cas9 Genome Editing**

* Design guide RNAs targeting specific genes identified in the epigenetic signature using a CRISPR design tool (e.g., CRISPR Design, CRISPOR).
* Transfect microglia with CRISPR-Cas9 plasmids and guide RNAs using a transfection reagent (e.g., Lipofectamine 3000).
* Validate gene knockout or overexpression using qRT-PCR or Western blot.

**Step 5: In Vivo Validation**

5.1. **Mouse Model of MS**

* Obtain a mouse model of MS (e.g., experimental autoimmune encephalomyelitis, EAE) and inject B cells from MS patients with high neurodegeneration into the mice.
* Monitor mice for signs of neurodegeneration using MRI and behavioral tests.

5.2. **Microglia Epigenetic Signature Analysis**

* Isolate microglia from the mouse brain using a microglia isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Analyze the epigenetic signature in microglia using techniques from Steps 2-3.

**Control Experiments**

* Co-culture microglia with B cells from MS patients with low neurodegeneration on MRI scans to serve as a control.
* Use a scrambled siRNA or shRNA control to validate the specificity of the epigenetic signature.

**Budget and Timeline**

* Estimated budget: $200,000 - $300,000
* Estimated timeline: 12-18 months

Note: The protocols provided are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols, safety guidelines, and ethical considerations when conducting this experiment.","```
   Ficoll-Paque_PLUS  B_cell_isolation_cocktail  Microglia_cells  B_cells  Co-culture_time  Epigenetic_signature
0               90.0                    8.0         1.2e+05    1.2e+05           24.0           DMR_DEG_present
1              110.0                    9.0         1.1e+05    1.1e+05           24.0           DMR_DEG_absent
2               95.0                    8.5         1.3e+05    1.3e+05           24.0           DMR_DEG_present
3              105.0                    9.5         1.0e+05    1.0e+05           24.0           DMR_DEG_absent
4               92.0                    8.2         1.2e+05    1.2e+05           24.0           DMR_DEG_present
5              108.0                    9.8         1.1e+05    1.1e+05           24.0           DMR_DEG_absent
6               98.0                    9.0         1.3e+05    1.3e+05           24.0           DMR_DEG_present
7              102.0                    9.2         1.0e+05    1.0e+05           24.0           DMR_DEG_absent
8               94.0                    8.5         1.2e+05    1.2e+05           24.0           DMR_DEG_present
9              110.0                    9.5         1.1e+05    1.1e+05           24.0           DMR_DEG_absent
10              96.0                    8.8         1.3e+05    1.3e+05           24.0           DMR_DEG_present
11              104.0                    9.0         1.0e+05    1.0e+05           24.0           DMR_DEG_absent
12              92.0                    8.2         1.2e+05    1.2e+05           24.0           DMR_DEG_present
13              108.0                    9.8         1.1e+05    1.1e+05           24.0           DMR_DEG_absent
14              98.0                    9.0         1.3e+05    1.3e+05           24.0           DMR_DEG_present
15              102.0                    9.2         1.0e+05    1.0e+05           24.0           DMR_DEG_absent
16              94.0                    8.5         1.2e+05    1.2e+05           24.0           DMR_DEG_present
17              110.0                    9.5         1.1e+05    1.1e+05           24.0           DMR_DEG_absent
18              96.0                    8.8         1.3e+05    1.3e+05           24.0           DMR_DEG_present
19              104.0                    9.0         1.0e+05    1.0e+05           24.0           DMR_DEG_absent
20              92.0                    8.2         1.2e+05    1.2e+05           24.0           DMR_DEG_present
21              108.0                    9.8         1.1e+05    1.1e+05           24.0           DMR_DEG_absent
22              98.0                    9.0         1.3e+05    1.3e+05           24.0           DMR_DEG_present
23              102.0                    9.2         1.0e+05    1.0e+05           24.0           DMR_DEG_absent
24              94.0                    8.5         1.2e+05    1.2e+05           24.0           DMR_DEG_present
```",0.023069880630361972
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/77b90403f75d310ad594517790932468a261d1d4.summary'],"Do B cells with altered Ca2+ flux response patterns exhibit changes in their epigenetic landscape, particularly in genes involved in B cell receptor signaling and differentiation, which may contribute to the development of autoimmune disorders or B-cell malignancies?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! Here's a comprehensive experimental plan to test the hypothesis, leveraging existing scientific methods and equipment, with an unlimited budget:

**Experimental Approach:**

**Objective:** Investigate the relationship between altered Ca2+ flux response patterns in B cells and changes in their epigenetic landscape, particularly in genes involved in B cell receptor signaling and differentiation, and their potential contribution to autoimmune disorders or B-cell malignancies.

**Experimental Design:**

1. **B Cell Isolation and Culture**:
	* Isolate B cells from healthy donors and patients with autoimmune disorders or B-cell malignancies using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS).
	* Culture B cells in vitro using optimized media and conditions to maintain their viability and functionality.
2. **Ca2+ Flux Analysis**:
	* Use fluorescent Ca2+ indicators (e.g., Fluo-4 or Indo-1) to measure Ca2+ flux responses in B cells upon stimulation with various agonists (e.g., anti-IgM, anti-CD40, or PMA/ionomycin).
	* Employ high-throughput imaging techniques, such as confocal microscopy or flow cytometry, to analyze Ca2+ flux patterns in individual B cells.
	* Identify B cells with altered Ca2+ flux response patterns using clustering algorithms and statistical analysis.
3. **Epigenetic Profiling**:
	* Perform chromatin immunoprecipitation sequencing (ChIP-seq) to analyze histone modifications (e.g., H3K4me3, H3K27me3) and transcription factor binding (e.g., NF-κB, NFAT) in B cells with altered Ca2+ flux response patterns.
	* Use reduced representation bisulfite sequencing (RRBS) or whole-genome bisulfite sequencing (WGBS) to analyze DNA methylation patterns in these B cells.
	* Employ RNA sequencing (RNA-seq) to analyze gene expression profiles in B cells with altered Ca2+ flux response patterns.
4. **Integration of Epigenetic and Ca2+ Flux Data**:
	* Use bioinformatic tools (e.g., ChIPseeker, GenomicRanges) to integrate ChIP-seq, RRBS/WGBS, and RNA-seq data to identify genes with altered epigenetic marks and expression levels in B cells with altered Ca2+ flux response patterns.
	* Perform pathway analysis (e.g., Gene Ontology, KEGG) to identify enriched biological processes and signaling pathways associated with altered epigenetic marks and Ca2+ flux responses.
5. **Functional Validation**:
	* Use CRISPR-Cas9 genome editing to introduce specific epigenetic modifications (e.g., DNA methylation, histone modifications) in B cells and assess their impact on Ca2+ flux responses and gene expression.
	* Employ RNA interference (RNAi) or CRISPR-Cas9 to knockdown or knockout genes identified in the epigenetic profiling step and evaluate their effects on Ca2+ flux responses and B cell function.
6. **In Vivo Validation**:
	* Use mouse models of autoimmune disorders (e.g., lupus, rheumatoid arthritis) or B-cell malignancies (e.g., lymphoma) to investigate the in vivo relevance of the findings.
	* Employ adoptive transfer of B cells with altered Ca2+ flux response patterns and/or epigenetic modifications to assess their contribution to disease development and progression.

**Equipment and Resources:**

* Flow cytometer (e.g., BD FACSAria, Beckman Coulter CytoFLEX)
* Confocal microscope (e.g., Zeiss LSM 880, Leica TCS SP8)
* High-performance computing cluster for bioinformatic analysis
* Next-generation sequencing platforms (e.g., Illumina HiSeq, PacBio Sequel)
* CRISPR-Cas9 genome editing system
* RNAi/CRISPR-Cas9 knockdown/knockout tools
* Mouse models of autoimmune disorders and B-cell malignancies
* Access to human samples from patients with autoimmune disorders and B-cell malignancies

**Timeline:**

* Months 1-3: B cell isolation, culture, and Ca2+ flux analysis
* Months 4-6: Epigenetic profiling (ChIP-seq, RRBS/WGBS, RNA-seq)
* Months 7-9: Integration of epigenetic and Ca2+ flux data, pathway analysis
* Months 10-12: Functional validation using CRISPR-Cas9 and RNAi
* Months 13-18: In vivo validation using mouse models
* Months 19-24: Data analysis, manuscript preparation, and publication

This experimental plan is designed to provide a comprehensive understanding of the relationship between Ca2+ flux responses and epigenetic changes in B cells, and their potential contribution to autoimmune disorders and B-cell malignancies. With an unlimited budget, the plan can be executed in a timely and efficient manner, leveraging cutting-edge technologies and expertise in immunology, epigenetics, and bioinformatics.",95,"Here are the detailed, step-by-step protocols for each experimental step:

**B Cell Isolation and Culture**

1. **B Cell Isolation using FACS**:
	* Prepare 100 mL of whole blood from healthy donors or patients with autoimmune disorders or B-cell malignancies.
	* Add 10 mL of FACS buffer (PBS, 2% FBS, 1 mM EDTA) to the blood and mix well.
	* Stain the cells with fluorescently labeled antibodies against CD19, CD20, and CD27 (e.g., FITC-CD19, PE-CD20, APC-CD27) for 30 minutes at 4°C.
	* Wash the cells twice with FACS buffer and resuspend in 1 mL of FACS buffer.
	* Sort B cells using a flow cytometer (e.g., BD FACSAria) based on CD19+, CD20+, and CD27+ expression.
	* Collect the sorted B cells in a 15 mL tube and wash twice with FACS buffer.
2. **B Cell Isolation using MACS**:
	* Prepare 100 mL of whole blood from healthy donors or patients with autoimmune disorders or B-cell malignancies.
	* Add 10 mL of MACS buffer (PBS, 2% FBS, 1 mM EDTA) to the blood and mix well.
	* Stain the cells with magnetic beads conjugated to anti-CD19, anti-CD20, and anti-CD27 antibodies (e.g., Miltenyi Biotec) for 30 minutes at 4°C.
	* Wash the cells twice with MACS buffer and resuspend in 1 mL of MACS buffer.
	* Separate the B cells using a magnetic separator (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
	* Collect the isolated B cells in a 15 mL tube and wash twice with MACS buffer.
3. **B Cell Culture**:
	* Resuspend the isolated B cells in 10 mL of complete RPMI 1640 medium (10% FBS, 1% penicillin-streptomycin, 1% L-glutamine) and count the cells using a hemocytometer.
	* Plate the B cells at a density of 1 x 10^6 cells/mL in a 24-well plate and incubate at 37°C, 5% CO2.
	* Replace the medium every 3-4 days and maintain the cells for up to 2 weeks.

**Ca2+ Flux Analysis**

1. **Fluorescent Ca2+ Indicator Loading**:
	* Prepare a 1 mM stock solution of Fluo-4 or Indo-1 in DMSO.
	* Add 1 μL of the stock solution to 1 mL of complete RPMI 1640 medium and mix well.
	* Incubate the B cells with the Fluo-4 or Indo-1 solution for 30 minutes at 37°C, 5% CO2.
2. **Ca2+ Flux Stimulation**:
	* Prepare agonist solutions (e.g., anti-IgM, anti-CD40, PMA/ionomycin) according to the manufacturer's instructions.
	* Add 10 μL of the agonist solution to 1 mL of complete RPMI 1640 medium and mix well.
	* Add the agonist solution to the B cells and incubate for 10-30 minutes at 37°C, 5% CO2.
3. **High-Throughput Imaging**:
	* Use a confocal microscope (e.g., Zeiss LSM 880) or flow cytometer (e.g., Beckman Coulter CytoFLEX) to analyze Ca2+ flux patterns in individual B cells.
	* Acquire images or flow cytometry data using the manufacturer's software.
4. **Clustering and Statistical Analysis**:
	* Use clustering algorithms (e.g., k-means, hierarchical clustering) to identify B cells with altered Ca2+ flux response patterns.
	* Perform statistical analysis (e.g., t-test, ANOVA) to compare Ca2+ flux responses between healthy donors and patients with autoimmune disorders or B-cell malignancies.

**Epigenetic Profiling**

1. **ChIP-seq**:
	* Cross-link B cells with 1% formaldehyde for 10 minutes at room temperature.
	* Sonicate the cross-linked cells to generate chromatin fragments.
	* Immunoprecipitate the chromatin fragments using antibodies against histone modifications (e.g., H3K4me3, H3K27me3) or transcription factors (e.g., NF-κB, NFAT).
	* Purify the immunoprecipitated chromatin fragments using a ChIP-seq kit (e.g., Illumina).
	* Perform sequencing using a next-generation sequencing platform (e.g., Illumina HiSeq).
2. **RRBS/WGBS**:
	* Isolate genomic DNA from B cells using a DNA isolation kit (e.g., Qiagen).
	* Perform bisulfite conversion of the genomic DNA using a bisulfite conversion kit (e.g., Zymo Research).
	* Prepare libraries for RRBS or WGBS using a library preparation kit (e.g., Illumina).
	* Perform sequencing using a next-generation sequencing platform (e.g., Illumina HiSeq).
3. **RNA-seq**:
	* Isolate total RNA from B cells using an RNA isolation kit (e.g., Qiagen).
	* Prepare libraries for RNA-seq using a library preparation kit (e.g., Illumina).
	* Perform sequencing using a next-generation sequencing platform (e.g., Illumina HiSeq).

**Integration of Epigenetic and Ca2+ Flux Data**

1. **Bioinformatic Analysis**:
	* Use bioinformatic tools (e.g., ChIPseeker, GenomicRanges) to integrate ChIP-seq, RRBS/WGBS, and RNA-seq data.
	* Identify genes with altered epigenetic marks and expression levels in B cells with altered Ca2+ flux response patterns.
2. **Pathway Analysis**:
	* Perform pathway analysis (e.g., Gene Ontology, KEGG) to identify enriched biological processes and signaling pathways associated with altered epigenetic marks and Ca2+ flux responses.

**Functional Validation**

1. **CRISPR-Cas9 Genome Editing**:
	* Design guide RNAs targeting specific epigenetic modifications (e.g., DNA methylation, histone modifications) using a CRISPR-Cas9 design tool (e.g., CRISPR Design).
	* Transfect B cells with the CRISPR-Cas9 system and guide RNAs using a transfection reagent (e.g., Lipofectamine).
	* Validate the introduction of epigenetic modifications using ChIP-qPCR or bisulfite sequencing.
2. **RNAi/CRISPR-Cas9 Knockdown/Knockout**:
	* Design siRNAs or guide RNAs targeting genes identified in the epigenetic profiling step using a RNAi design tool (e.g., siRNA Wizard).
	* Transfect B cells with the siRNAs or CRISPR-Cas9 system using a transfection reagent (e.g., Lipofectamine).
	* Validate the knockdown or knockout of gene expression using qRT-PCR or Western blot.

**In Vivo Validation**

1. **Mouse Models**:
	* Use mouse models of autoimmune disorders (e.g., lupus, rheumatoid arthritis) or B-cell malignancies (e.g., lymphoma).
	* Adoptively transfer B cells with altered Ca2+ flux response patterns and/or epigenetic modifications into the mouse models.
	* Monitor disease development and progression using clinical and histopathological assessments.

These detailed protocols should provide a comprehensive understanding of the relationship between Ca2+ flux responses and epigenetic changes in B cells, and their potential contribution to autoimmune disorders and B-cell malignancies.","```
   FACS_Buffer  MACS_Buffer  RPMI_1640  Fluo-4  Anti-IgM  PMA/ionomycin  Ca2_Flux  ChIP-seq  RRBS/WGBS  RNA-seq  CRISPR-Cas9  Outcome
0         10.0         10.0      10.0    1.0      10.0           10.0      High      1000       500     1000       1000  Altered
1         12.0         12.0      12.0    1.2      12.0           12.0      Low       800       400     800       800  Normal
2         8.0          8.0       8.0    0.8       8.0            8.0      High      1200       600     1200       1200  Altered
3         11.0         11.0      11.0    1.1      11.0           11.0      Low       900       450     900       900  Normal
4         9.0          9.0       9.0    0.9       9.0            9.0      High      1100       550     1100       1100  Altered
5         13.0         13.0      13.0    1.3      13.0           13.0      Low       700       350     700       700  Normal
6         10.5         10.5      10.5    1.05     10.5           10.5      High      1050       525     1050       1050  Altered
7         11.5         11.5      11.5    1.15     11.5           11.5      Low       850       425     850       850  Normal
8         9.5          9.5       9.5    0.95      9.5            9.5      High      1150       575     1150       1150  Altered
9         12.5         12.5      12.5    1.25     12.5           12.5      Low       750       375     750       750  Normal
10        10.0         10.0      10.0    1.0      10.0           10.0      High      1000       500     1000       1000  Altered
11        11.0         11.0      11.0    1.1      11.0           11.0      Low       900       450     900       900  Normal
12        9.0          9.0       9.0    0.9       9.0            9.0      High      1100       550     1100       1100  Altered
13        13.0         13.0      13.0    1.3      13.0           13.0      Low       700       350     700       700  Normal
14        10.5         10.5      10.5    1.05     10.5           10.5      High      1050       525     1050       1050  Altered
15        11.5         11.5      11.5    1.15     11.5           11.5      Low       850       425     850       850  Normal
16        9.5          9.5       9.5    0.95      9.5            9.5      High      1150       575     1150       1150  Altered
17        12.5         12.5      12.5    1.25     12.5           12.5      Low       750       375     750       750  Normal
18        10.0         10.0      10.0    1.0      10.0           10.0      High      1000       500     1000       1000  Altered
19        11.0         11.0      11.0    1.1      11.0           11.0      Low       900       450     900       900  Normal
20        9.0          9.0       9.0    0.9       9.0            9.0      High      1100       550     1100       1100  Altered
21        13.0         13.0      13.0    1.3      13.0           13.0      Low       700       350     700       700  Normal
22        10.5         10.5      10.5    1.05     10.5           10.5      High      1050       525     1050       1050  Altered
23        11.5         11.5      11.5    1.15     11.5           11.5      Low       850       425     850       850  Normal
24        9.5          9.5       9.5    0.95      9.5            9.5      High      1150       575     1150       1150  Altered
```",0.2265562529649774
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/04ba0051eeb18473496c9103575f5bfcaabaa11b.summary'],"Do B cells with concurrent deficiencies in UNG and MSH2 exhibit a synergistic reduction in somatic hypermutation frequency compared to single-deficient cells, and can this effect be rescued by overexpressing PMS2?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Synergistic Effect of UNG and MSH2 Deficiencies on Somatic Hypermutation Frequency and Rescue by PMS2 Overexpression

**Objective:** To determine if B cells with concurrent deficiencies in UNG and MSH2 exhibit a synergistic reduction in somatic hypermutation frequency compared to single-deficient cells and if this effect can be rescued by overexpressing PMS2.

**Equipment:**

* Next-generation sequencing (NGS) platform
* B cells from UNG-deficient mice, MSH2-deficient mice, UNG/MSH2 double-deficient mice, and wild-type mice
* PMS2 overexpression vector
* Cell culture facilities
* Flow cytometry equipment

**Steps:**

1. Isolate B cells from UNG-deficient mice, MSH2-deficient mice, UNG/MSH2 double-deficient mice, and wild-type mice.
2. Transfect the UNG/MSH2 double-deficient B cells with the PMS2 overexpression vector.
3. Culture the B cells under conditions that induce somatic hypermutation (e.g., with CD40L and IL-4).
4. Perform NGS of the B cell receptor (BCR) heavy chain (IGHG and IGHA transcripts) from each group.
5. Analyze the SHM patterns and mutation spectra using ARGalaxy.
6. Compare the results between the groups to determine the effect of UNG and MSH2 deficiencies on somatic hypermutation frequency and the rescue effect of PMS2 overexpression.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Independent Effects of UNG and MSH2 Deficiencies on Somatic Hypermutation Frequency

**Objective:** To demonstrate that the deficiencies in UNG and MSH2 have independent and additive effects on somatic hypermutation frequency, rather than a synergistic effect.

**Equipment:**

* Same as above

**Steps:**

1. Isolate B cells from UNG-deficient mice, MSH2-deficient mice, and wild-type mice.
2. Culture the B cells under conditions that induce somatic hypermutation (e.g., with CD40L and IL-4).
3. Perform NGS of the B cell receptor (BCR) heavy chain (IGHG and IGHA transcripts) from each group.
4. Analyze the SHM patterns and mutation spectra using ARGalaxy.
5. Compare the results between the groups to determine the individual effects of UNG and MSH2 deficiencies on somatic hypermutation frequency.
6. If the results show an additive effect of UNG and MSH2 deficiencies, rather than a synergistic effect, it would disprove the original hypothesis.

**Rationale:**

The experiment to test the hypothesis aims to directly investigate the synergistic effect of UNG and MSH2 deficiencies on somatic hypermutation frequency and the rescue effect of PMS2 overexpression. The experiment to disprove the hypothesis, on the other hand, focuses on demonstrating the independent and additive effects of UNG and MSH2 deficiencies, which would contradict the original hypothesis. By designing an experiment to disprove the hypothesis, we can increase confidence in the results and provide a more comprehensive understanding of the underlying mechanisms.

**Time and Resource Considerations:**

Both experiments can be completed within a reasonable time frame (approximately 6-12 months) and with a moderate budget. The experiments require access to NGS facilities, cell culture facilities, and flow cytometry equipment, which are commonly available in most research institutions. The use of existing mouse models and established protocols will also help reduce costs and accelerate the experimental process.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Isolate B cells from mice**

* Obtain UNG-deficient mice, MSH2-deficient mice, UNG/MSH2 double-deficient mice, and wild-type mice from a reputable supplier or breeding facility.
* Sacrifice the mice according to institutional animal care and use committee (IACUC) guidelines.
* Harvest spleens from each mouse and process them into single-cell suspensions using a gentleMACS Dissociator (Miltenyi Biotec) or a similar device.
* Enrich for B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Verify the purity of the B cell population using flow cytometry (e.g., BD FACSCanto II) and antibodies against B cell markers (e.g., CD19, CD20).

**Step 2: Transfect UNG/MSH2 double-deficient B cells with PMS2 overexpression vector**

* Prepare the PMS2 overexpression vector according to the manufacturer's instructions or using a standard molecular biology protocol.
* Transfect the UNG/MSH2 double-deficient B cells with the PMS2 overexpression vector using a nucleofection device (e.g., Lonza 4D-Nucleofector) or a similar device, following the manufacturer's instructions.
* Verify the transfection efficiency using flow cytometry and antibodies against PMS2 or a fluorescent protein (e.g., GFP) encoded by the vector.

**Step 3: Culture B cells under conditions that induce somatic hypermutation**

* Culture the isolated B cells in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 50 μM β-mercaptoethanol.
* Add CD40L (e.g., 1 μg/mL) and IL-4 (e.g., 10 ng/mL) to the culture medium to induce somatic hypermutation.
* Incubate the cells at 37°C, 5% CO2 for 3-5 days or until the desired level of somatic hypermutation is achieved.

**Step 4: Perform NGS of B cell receptor heavy chain transcripts**

* Isolate total RNA from the cultured B cells using a RNA isolation kit (e.g., Qiagen RNeasy) according to the manufacturer's instructions.
* Prepare a cDNA library using a reverse transcription kit (e.g., Invitrogen SuperScript IV) and a PCR amplification kit (e.g., Illumina TruSeq) according to the manufacturer's instructions.
* Perform NGS of the IGHG and IGHA transcripts using an Illumina MiSeq or similar platform, following the manufacturer's instructions.

**Step 5: Analyze SHM patterns and mutation spectra using ARGalaxy**

* Upload the NGS data to the ARGalaxy platform and perform the following analyses:
	+ Calculate the somatic hypermutation frequency using the ARGalaxy's built-in tools.
	+ Analyze the SHM patterns and mutation spectra using ARGalaxy's visualization tools.
	+ Compare the results between the groups to determine the effect of UNG and MSH2 deficiencies on somatic hypermutation frequency and the rescue effect of PMS2 overexpression.

**Step 6: Compare results between groups**

* Compare the somatic hypermutation frequencies and SHM patterns between the UNG-deficient, MSH2-deficient, UNG/MSH2 double-deficient, and wild-type groups.
* Determine if the UNG/MSH2 double-deficient group shows a synergistic reduction in somatic hypermutation frequency compared to the single-deficient groups.
* Evaluate the rescue effect of PMS2 overexpression on somatic hypermutation frequency in the UNG/MSH2 double-deficient group.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

**Step 1: Isolate B cells from mice**

* Follow the same protocol as in the experiment to test the hypothesis.

**Step 2: Culture B cells under conditions that induce somatic hypermutation**

* Follow the same protocol as in the experiment to test the hypothesis.

**Step 3: Perform NGS of B cell receptor heavy chain transcripts**

* Follow the same protocol as in the experiment to test the hypothesis.

**Step 4: Analyze SHM patterns and mutation spectra using ARGalaxy**

* Follow the same protocol as in the experiment to test the hypothesis.

**Step 5: Compare results between groups**

* Compare the somatic hypermutation frequencies and SHM patterns between the UNG-deficient, MSH2-deficient, and wild-type groups.
* Determine if the UNG-deficient and MSH2-deficient groups show independent and additive effects on somatic hypermutation frequency.
* Evaluate if the results contradict the original hypothesis of a synergistic effect of UNG and MSH2 deficiencies on somatic hypermutation frequency.

**Step 6: Interpret results**

* If the results show an additive effect of UNG and MSH2 deficiencies, it would disprove the original hypothesis.
* If the results do not show an additive effect, it would support the original hypothesis.

Note: These protocols are detailed and specific, but they may require adjustments based on the specific laboratory setup and equipment available. It is essential to follow proper laboratory protocols, safety guidelines, and animal care regulations when conducting these experiments.","```
   UNG-deficient  MSH2-deficient  PMS2_overexpression  CD40L  IL-4  β-mercaptoethanol  Somatic_Hypermutation_Frequency
0             0.0             0.0                0.0    1.0   10.0               50.0                    0.012
1             0.5             0.0                0.0    1.5   12.0               55.0                    0.015
2             1.0             0.0                0.0    2.0   15.0               60.0                    0.020
3             0.0             0.5                0.0    1.0   10.0               50.0                    0.010
4             0.0             1.0                0.0    1.5   12.0               55.0                    0.012
5             0.5             0.5                0.0    2.0   15.0               60.0                    0.018
6             1.0             1.0                0.0    2.5   18.0               65.0                    0.025
7             0.0             0.0                0.5    1.0   10.0               50.0                    0.015
8             0.5             0.0                0.5    1.5   12.0               55.0                    0.020
9             1.0             0.0                0.5    2.0   15.0               60.0                    0.025
10            0.0             0.5                0.5    1.0   10.0               50.0                    0.012
11            0.0             1.0                0.5    1.5   12.0               55.0                    0.015
12            0.5             0.5                0.5    2.0   15.0               60.0                    0.020
13            1.0             1.0                0.5    2.5   18.0               65.0                    0.025
14            0.0             0.0                1.0    1.0   10.0               50.0                    0.020
15            0.5             0.0                1.0    1.5   12.0               55.0                    0.025
16            1.0             0.0                1.0    2.0   15.0               60.0                    0.030
17            0.0             0.5                1.0    1.0   10.0               50.0                    0.018
18            0.0             1.0                1.0    1.5   12.0               55.0                    0.020
19            0.5             0.5                1.0    2.0   15.0               60.0                    0.025
20            1.0             1.0                1.0    2.5   18.0               65.0                    0.030
21            0.5             0.0                0.0    1.0   10.0               45.0                    0.010
22            1.0             0.5                0.0    1.5   12.0               50.0                    0.012
23            0.0             1.0                0.5    1.0   10.0               45.0                    0.015
24            0.5             1.0                0.5    1.5   12.0               50.0                    0.018
```",0.5954640043369698
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/09e5a7801c8d03676c6c6d553e4fd78cd8aeeecd.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/024bfd902d2428c06820bdedab50ba27b3a5f313.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0171d162a8431e05e8205b10b465074dd556f98d.summary']","Do BTK inhibitors modulate citrullination and anti-citrullinated protein/peptide antibodies production in autoimmune arthritis by targeting macrophages in lymphoid tissues, thereby reducing disease severity?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I have developed an experimental plan to test the hypothesis using existing scientific methods and equipment. To disprove the hypothesis, I will design an experiment that aims to show that BTK inhibitors do not modulate citrullination and anti-citrullinated protein/peptide antibodies production in autoimmune arthritis by targeting macrophages in lymphoid tissues.

**Experimental Plan:**

**Title:** Investigating the Role of BTK Inhibitors on Citrullination and ACPA Production in Autoimmune Arthritis

**Objective:** To determine if BTK inhibitors modulate citrullination and anti-citrullinated protein/peptide antibodies production in autoimmune arthritis by targeting macrophages in lymphoid tissues.

**Equipment:**

* BTK inhibitors (e.g., ibrutinib)
* Collagen-induced arthritis (CIA) mouse model
* Macrophage-specific PAD4 knockout mice (generated using CRISPR-Cas9 technology)
* Flow cytometer
* Western blot apparatus
* ELISA kits for ACPA measurement
* Lymphoid tissue and joint tissue samples

**Experimental Design:**

1. **Control Group:** Induce CIA in wild-type mice and treat with vehicle control.
2. **BTK Inhibitor Group:** Induce CIA in wild-type mice and treat with BTK inhibitors (e.g., ibrutinib).
3. **Macrophage-specific PAD4 Knockout Group:** Induce CIA in macrophage-specific PAD4 knockout mice and treat with vehicle control.
4. **Combination Group:** Induce CIA in macrophage-specific PAD4 knockout mice and treat with BTK inhibitors.

**Steps:**

1. Induce CIA in mice using the collagen-induced arthritis model.
2. Administer BTK inhibitors or vehicle control to the respective groups.
3. Analyze ACPA levels in serum and citrullinated proteins in lymphoid tissues by ELISA and Western blotting, respectively.
4. Compare ACPA levels and citrullinated protein expression between the control group and BTK inhibitor group to determine if BTK inhibitors modulate ACPA production and citrullination.
5. Compare ACPA levels and citrullinated protein expression between the macrophage-specific PAD4 knockout group and the combination group to determine if BTK inhibitors have an additive effect on ACPA production and citrullination in the absence of macrophage-specific PAD4.
6. Analyze macrophage populations in lymphoid tissues using flow cytometry to determine if BTK inhibitors affect macrophage numbers or activation.

**Expected Outcomes:**

* If the hypothesis is true, the BTK inhibitor group will show reduced ACPA levels and citrullinated protein expression compared to the control group.
* If the hypothesis is false, the BTK inhibitor group will not show a significant difference in ACPA levels and citrullinated protein expression compared to the control group.
* The macrophage-specific PAD4 knockout group will show reduced ACPA levels and citrullinated protein expression compared to the control group, indicating the importance of macrophages in ACPA production and citrullination.
* The combination group will show an additive effect of BTK inhibitors on ACPA production and citrullination in the absence of macrophage-specific PAD4.

**Timeline:**

* 6 weeks: Induce CIA in mice and administer BTK inhibitors or vehicle control.
* 12 weeks: Analyze ACPA levels and citrullinated protein expression.
* 16 weeks: Complete data analysis and prepare results for publication.

**Budget:**

* BTK inhibitors: $5,000
* CIA mouse model: $10,000
* Macrophage-specific PAD4 knockout mice: $15,000
* Flow cytometer: $20,000
* Western blot apparatus: $10,000
* ELISA kits: $5,000
* Lymphoid tissue and joint tissue samples: $5,000
* Total: $70,000

This experiment is designed to test the hypothesis and can be completed within a reasonable time frame (16 weeks) and budget ($70,000).",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Induction of Collagen-Induced Arthritis (CIA) in Mice**

1.1. Obtain 40 wild-type mice and 40 macrophage-specific PAD4 knockout mice (generated using CRISPR-Cas9 technology).

1.2. Prepare the collagen-induced arthritis (CIA) induction mixture according to the manufacturer's instructions.

1.3. Inject 100 μl of the CIA induction mixture intradermally into the base of the tail of each mouse.

1.4. Monitor the mice for signs of arthritis, such as paw swelling and redness, starting from day 21 after injection.

**Protocol 2: Administration of BTK Inhibitors or Vehicle Control**

2.1. Prepare the BTK inhibitor (e.g., ibrutinib) solution according to the manufacturer's instructions.

2.2. Divide the mice into four groups:
	* Control Group: 10 wild-type mice receiving vehicle control (e.g., PBS).
	* BTK Inhibitor Group: 10 wild-type mice receiving BTK inhibitor (e.g., ibrutinib) at a dose of 10 mg/kg body weight.
	* Macrophage-specific PAD4 Knockout Group: 10 macrophage-specific PAD4 knockout mice receiving vehicle control (e.g., PBS).
	* Combination Group: 10 macrophage-specific PAD4 knockout mice receiving BTK inhibitor (e.g., ibrutinib) at a dose of 10 mg/kg body weight.

2.3. Administer the BTK inhibitor or vehicle control to the respective groups via oral gavage or intraperitoneal injection, starting from day 21 after CIA induction and continuing for 8 weeks.

**Protocol 3: Sample Collection and Preparation**

3.1. Collect blood samples from the mice via retro-orbital bleeding or cardiac puncture at weeks 6, 12, and 16 after CIA induction.

3.2. Prepare serum samples by centrifuging the blood samples at 3,000 rpm for 10 minutes and storing them at -80°C.

3.3. Collect lymphoid tissue and joint tissue samples from the mice at weeks 12 and 16 after CIA induction.

3.4. Homogenize the tissue samples in RIPA buffer and store them at -80°C.

**Protocol 4: ELISA for ACPA Measurement**

4.1. Thaw the serum samples and prepare them according to the ELISA kit manufacturer's instructions.

4.2. Perform the ELISA assay according to the manufacturer's instructions to measure ACPA levels in the serum samples.

4.3. Record the absorbance values and calculate the ACPA concentrations using the standard curve.

**Protocol 5: Western Blotting for Citrullinated Protein Expression**

5.1. Thaw the tissue homogenates and prepare them according to the Western blotting protocol.

5.2. Perform Western blotting using antibodies specific to citrullinated proteins (e.g., anti-citrullinated vimentin).

5.3. Detect the protein bands using chemiluminescence or fluorescence and quantify the band intensities using image analysis software.

**Protocol 6: Flow Cytometry for Macrophage Analysis**

6.1. Prepare single-cell suspensions from the lymphoid tissue samples.

6.2. Stain the cells with antibodies specific to macrophage markers (e.g., CD11b, F4/80) and fix them according to the manufacturer's instructions.

6.3. Analyze the cells using a flow cytometer and record the macrophage population data.

**Protocol 7: Data Analysis and Interpretation**

7.1. Compare the ACPA levels and citrullinated protein expression between the control group and BTK inhibitor group to determine if BTK inhibitors modulate ACPA production and citrullination.

7.2. Compare the ACPA levels and citrullinated protein expression between the macrophage-specific PAD4 knockout group and the combination group to determine if BTK inhibitors have an additive effect on ACPA production and citrullination in the absence of macrophage-specific PAD4.

7.3. Analyze the macrophage population data to determine if BTK inhibitors affect macrophage numbers or activation.

7.4. Interpret the results in the context of the hypothesis and prepare the data for publication.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   Mouse_Type  CIA_Induction_Mixture  BTK_Inhibitor_Dose  Vehicle_Control  Macrophage_Pad4_Knockout  ACPA_Level  Citrullinated_Protein_Expression  Macrophage_Population
0        Wild-Type                  100                  0               1                       0         250.0                         0.5                    20.0
1        Wild-Type                  120                  5               0                       0         220.0                         0.4                    18.0
2        Wild-Type                  110                  0               1                       0         280.0                         0.6                    22.0
3        Macrophage_Pad4_Knockout    90                  0               1                       1         180.0                         0.3                    15.0
4        Wild-Type                  130                  10              0                       0         200.0                         0.4                    19.0
5        Macrophage_Pad4_Knockout   100                  5               0                       1         190.0                         0.3                    16.0
6        Wild-Type                  120                  0               1                       0         260.0                         0.5                    21.0
7        Wild-Type                  110                  10              0                       0         210.0                         0.4                    20.0
8        Macrophage_Pad4_Knockout    90                  0               1                       1         170.0                         0.2                    14.0
9        Wild-Type                  130                  5               0                       0         230.0                         0.5                    22.0
10       Macrophage_Pad4_Knockout   100                  10              0                       1         200.0                         0.4                    18.0
11       Wild-Type                  120                  0               1                       0         240.0                         0.5                    20.0
12       Wild-Type                  110                  5               0                       0         220.0                         0.4                    19.0
13       Macrophage_Pad4_Knockout    90                  5               0                       1         180.0                         0.3                    16.0
14       Wild-Type                  130                  0               1                       0         270.0                         0.6                    23.0
15       Macrophage_Pad4_Knockout   100                  0               1                       1         190.0                         0.3                    17.0
16       Wild-Type                  120                  10              0                       0         210.0                         0.4                    21.0
17       Wild-Type                  110                  0               1                       0         250.0                         0.5                    20.0
18       Macrophage_Pad4_Knockout    90                  10              0                       1         200.0                         0.4                    19.0
19       Wild-Type                  130                  5               0                       0         230.0                         0.5                    22.0
20       Macrophage_Pad4_Knockout   100                  5               0                       1         190.0                         0.3                    17.0
21       Wild-Type                  120                  0               1                       0         240.0                         0.5                    20.0
22       Wild-Type                  110                  10              0                       0         220.0                         0.4                    21.0
23       Macrophage_Pad4_Knockout    90                  0               1                       1         180.0                         0.3                    16.0
24       Wild-Type                  130                  0               1                       0         270.0                         0.6                    23.0
```",0.1446424997431939
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1390ec27fe9763ab53ef27300d53522b185b7c85.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5ddfb426e71ca9bdaa4dc0e326eb6cf35f3cbdf8.summary']",Do Blimp1-expressing TFH cells with specific MHC haplotypes preferentially induce plasma cell differentiation in response to antigens presented by B cells with matching MHC haplotypes?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! I'll break down the experimental plan to test and potentially disprove it.

**Hypothesis:** Blimp1-expressing TFH cells with specific MHC haplotypes preferentially induce plasma cell differentiation in response to antigens presented by B cells with matching MHC haplotypes.

**Experimental Plan:**

**Objective:** Design an experiment to test and potentially disprove the hypothesis, ensuring efficient use of time, resources, and budget.

**Step 1: Cell Isolation and Preparation**

* Isolate Blimp1-expressing TFH cells and B cells from mice with different MHC haplotypes (e.g., H-2b, H-2d, and H-2k) using fluorescence-activated cell sorting (FACS) or magnetic bead-based separation.
* Purify and culture the isolated cells in vitro.

**Step 2: Antigen Presentation and Co-Culture**

* Prepare antigens (e.g., ovalbumin, hen egg lysozyme) and conjugate them to MHC class II molecules with different haplotypes (e.g., H-2b, H-2d, and H-2k).
* Co-culture Blimp1-expressing TFH cells with B cells presenting antigens with matching or mismatching MHC haplotypes.
* Use a 1:1 ratio of TFH cells to B cells and incubate for 3-5 days.

**Step 3: Plasma Cell Differentiation Assay**

* Measure plasma cell differentiation using flow cytometry or ELISA to detect CD138+ cells, IgG secretion, or other plasma cell markers.
* Compare the frequency and absolute numbers of plasma cells generated in response to antigens presented by B cells with matching versus mismatching MHC haplotypes.

**Step 4: Controls and Replicates**

* Include negative controls: TFH cells alone, B cells alone, or TFH cells with B cells without antigen presentation.
* Perform at least three biological replicates for each condition to ensure robustness and statistical significance.

**Step 5: Data Analysis and Interpretation**

* Compare the plasma cell differentiation responses between matching and mismatching MHC haplotypes using statistical tests (e.g., t-test, ANOVA).
* If the data show no significant difference in plasma cell differentiation between matching and mismatching MHC haplotypes, it would suggest that the hypothesis is false.

**Budget-Friendly Considerations:**

* Utilize existing laboratory equipment and reagents to minimize costs.
* Opt for in vitro co-culture assays instead of in vivo experiments, which are more resource-intensive.
* Limit the number of MHC haplotypes and antigens tested to reduce costs and complexity.
* Perform the experiment in a relatively short timeframe (e.g., 2-3 months) to minimize personnel and facility costs.

**Timeline:**

* Week 1-2: Cell isolation, preparation, and culture
* Week 3-4: Antigen preparation, conjugation, and co-culture setup
* Week 5-6: Plasma cell differentiation assay and data collection
* Week 7-8: Data analysis and interpretation

**Budget Estimate:**

* Personnel: $10,000 - $15,000 (2-3 months of technician or postdoc salary)
* Reagents and Consumables: $5,000 - $10,000 (cell culture media, antibodies, antigens, etc.)
* Equipment and Facility Costs: $5,000 - $10,000 (access to flow cytometer, cell sorter, and laboratory space)
* Total: $20,000 - $35,000

This experimental plan is designed to test the hypothesis in a cost-effective and time-efficient manner. By following this approach, you can generate data to support or refute the hypothesis, providing valuable insights into the role of MHC haplotypes in TFH cell-mediated plasma cell differentiation.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Cell Isolation and Preparation**

1.1. Mouse selection and sacrifice:

* Select mice with different MHC haplotypes (e.g., H-2b, H-2d, and H-2k) and sacrifice them according to institutional animal care and use committee (IACUC) guidelines.
* Ensure mice are 6-8 weeks old and have not been previously immunized or exposed to antigens.

1.2. Spleen and lymph node harvesting:

* Harvest spleens and lymph nodes from sacrificed mice and place them in a petri dish containing 10 mL of cold phosphate-buffered saline (PBS).
* Gently tease the spleens and lymph nodes apart using forceps to release cells into the PBS.

1.3. Cell preparation and counting:

* Filter the cell suspension through a 40-μm cell strainer to remove debris and clumps.
* Centrifuge the cell suspension at 300 x g for 5 minutes to pellet the cells.
* Resuspend the cells in 10 mL of PBS and count the cells using a hemocytometer or an automated cell counter.

1.4. Fluorescence-activated cell sorting (FACS) or magnetic bead-based separation:

* Stain the cells with fluorescently labeled antibodies specific to Blimp1-expressing TFH cells (e.g., CD4, CXCR5, PD-1) and B cells (e.g., CD19, CD20).
* Use FACS or magnetic bead-based separation to isolate Blimp1-expressing TFH cells and B cells from the cell suspension.
* Sort or separate cells into separate tubes or wells based on their surface marker expression.

1.5. Cell culture:

* Culture the isolated cells in vitro using RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubate the cells at 37°C, 5% CO2, and 95% humidity.

**Step 2: Antigen Presentation and Co-Culture**

2.1. Antigen preparation:

* Prepare antigens (e.g., ovalbumin, hen egg lysozyme) according to the manufacturer's instructions.
* Conjugate the antigens to MHC class II molecules with different haplotypes (e.g., H-2b, H-2d, and H-2k) using a peptide-MHC conjugation kit.

2.2. Antigen loading and B cell preparation:

* Load the conjugated antigens onto B cells at a concentration of 1-10 μg/mL.
* Incubate the B cells with the antigens for 2-4 hours at 37°C, 5% CO2, and 95% humidity.

2.3. Co-culture setup:

* Mix Blimp1-expressing TFH cells with B cells presenting antigens with matching or mismatching MHC haplotypes at a 1:1 ratio.
* Add 1-2 mL of RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine to each well.
* Incubate the co-culture at 37°C, 5% CO2, and 95% humidity for 3-5 days.

**Step 3: Plasma Cell Differentiation Assay**

3.1. Cell harvesting and staining:

* Harvest the co-cultured cells and stain them with fluorescently labeled antibodies specific to plasma cell markers (e.g., CD138, IgG).
* Use a fixable viability dye to exclude dead cells.

3.2. Flow cytometry:

* Analyze the stained cells using a flow cytometer to detect CD138+ cells and IgG secretion.
* Use a gating strategy to identify plasma cells based on their surface marker expression.

3.3. ELISA:

* Alternatively, use an ELISA kit to detect IgG secretion in the co-culture supernatant.
* Follow the manufacturer's instructions for the ELISA protocol.

**Step 4: Controls and Replicates**

4.1. Negative controls:

* Include negative controls: TFH cells alone, B cells alone, or TFH cells with B cells without antigen presentation.
* Perform the plasma cell differentiation assay on these controls to establish a baseline.

4.2. Biological replicates:

* Perform at least three biological replicates for each condition to ensure robustness and statistical significance.
* Use different mice and cell preparations for each replicate.

**Step 5: Data Analysis and Interpretation**

5.1. Data analysis:

* Compare the plasma cell differentiation responses between matching and mismatching MHC haplotypes using statistical tests (e.g., t-test, ANOVA).
* Calculate the frequency and absolute numbers of plasma cells generated in response to antigens presented by B cells with matching versus mismatching MHC haplotypes.

5.2. Data interpretation:

* If the data show a significant difference in plasma cell differentiation between matching and mismatching MHC haplotypes, it would suggest that the hypothesis is true.
* If the data show no significant difference, it would suggest that the hypothesis is false.

**Budget-Friendly Considerations**

* Utilize existing laboratory equipment and reagents to minimize costs.
* Opt for in vitro co-culture assays instead of in vivo experiments, which are more resource-intensive.
* Limit the number of MHC haplotypes and antigens tested to reduce costs and complexity.
* Perform the experiment in a relatively short timeframe (e.g., 2-3 months) to minimize personnel and facility costs.

**Timeline**

* Week 1-2: Cell isolation, preparation, and culture
* Week 3-4: Antigen preparation, conjugation, and co-culture setup
* Week 5-6: Plasma cell differentiation assay and data collection
* Week 7-8: Data analysis and interpretation

**Budget Estimate**

* Personnel: $10,000 - $15,000 (2-3 months of technician or postdoc salary)
* Reagents and Consumables: $5,000 - $10,000 (cell culture media, antibodies, antigens, etc.)
* Equipment and Facility Costs: $5,000 - $10,000 (access to flow cytometer, cell sorter, and laboratory space)
* Total: $20,000 - $35,000","```
   MHC_Haplotype  Antigen_Concentration  TFH_Cells  B_Cells  FBS_Concentration  Penicillin_Streptomycin_Concentration  L_Glutamine_Concentration  Outcome
0           H-2b                   5.0      10000      10000                  10.0                             1.0                         1.0       0.45
1           H-2d                   2.5      15000      15000                  10.0                             1.0                         1.0       0.38
2           H-2k                   7.5       5000       5000                  10.0                             1.0                         1.0       0.52
3           H-2b                   1.0      20000      20000                  10.0                             1.0                         1.0       0.28
4           H-2d                   3.0      12000      12000                  10.0                             1.0                         1.0       0.42
5           H-2k                   9.0       8000       8000                  10.0                             1.0                         1.0       0.58
6           H-2b                   4.0      18000      18000                  10.0                             1.0                         1.0       0.48
7           H-2d                   6.0      10000      10000                  10.0                             1.0                         1.0       0.50
8           H-2k                   8.0      14000      14000                  10.0                             1.0                         1.0       0.55
9           H-2b                   3.5      16000      16000                  10.0                             1.0                         1.0       0.43
10          H-2d                   1.5      19000      19000                  10.0                             1.0                         1.0       0.32
11          H-2k                   6.5      11000      11000                  10.0                             1.0                         1.0       0.51
12          H-2b                   2.0      13000      13000                  10.0                             1.0                         1.0       0.36
13          H-2d                   4.5      17000      17000                  10.0                             1.0                         1.0       0.46
14          H-2k                   9.5       9000       9000                  10.0                             1.0                         1.0       0.60
15          H-2b                   5.5      14000      14000                  10.0                             1.0                         1.0       0.49
16          H-2d                   3.5      15000      15000                  10.0                             1.0                         1.0       0.44
17          H-2k                   7.0      12000      12000                  10.0                             1.0                         1.0       0.53
18          H-2b                   1.5      18000      18000                  10.0                             1.0                         1.0       0.31
19          H-2d                   6.0      11000      11000                  10.0                             1.0                         1.0       0.49
20          H-2k                   8.5      13000      13000                  10.0                             1.0                         1.0       0.56
21          H-2b                   4.5      16000      16000                  10.0                             1.0                         1.0       0.47
22          H-2d                   2.5      19000      19000                  10.0                             1.0                         1.0       0.39
23          H-2k                   9.0      10000      10000                  10.0                             1.0                         1.0       0.59
24          H-2b                   3.0      17000      17000                  10.0                             1.0                         1.0       0.41
```",0.05777979855026566
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/27edb5cd058b8b922725062a2dbf4b3402c2a55b.summary'],"Do CD11c+T-bet+ B cells regulate the expression of Ezrin and Lyn in B cells, thereby modulating their activation and autoantibody production in lupus?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis: ""Do CD11c+T-bet+ B cells regulate the expression of Ezrin and Lyn in B cells, thereby modulating their activation and autoantibody production in lupus?""

**Experimental Plan:**

**Title:** Investigating the Role of CD11c+T-bet+ B cells in Regulating Ezrin and Lyn Expression in Lupus

**Objective:** To determine if CD11c+T-bet+ B cells regulate the expression of Ezrin and Lyn in B cells, and subsequently modulate their activation and autoantibody production in lupus.

**Experimental Design:**

1. **Cell Isolation and Sorting:**
	* Isolate B cells from peripheral blood mononuclear cells (PBMCs) of lupus patients and healthy controls using magnetic bead-based separation.
	* Sort CD11c+T-bet+ B cells from the isolated B cells using fluorescence-activated cell sorting (FACS).
2. **Co-Culture Experiments:**
	* Co-culture CD11c+T-bet+ B cells with autologous B cells (from the same individual) in the presence or absence of Ezrin and Lyn siRNA.
	* Use a transwell system to separate the CD11c+T-bet+ B cells from the autologous B cells, allowing for cell-cell contact but preventing cell mixing.
3. **Ezrin and Lyn Expression Analysis:**
	* Measure Ezrin and Lyn protein expression in the autologous B cells using Western blot analysis.
	* Quantify Ezrin and Lyn mRNA levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
4. **B Cell Activation and Autoantibody Production:**
	* Measure B cell activation markers (e.g., CD69, CD86) on the autologous B cells using flow cytometry.
	* Analyze autoantibody production (e.g., anti-dsDNA, anti-nucleosome) using enzyme-linked immunosorbent assay (ELISA).
5. **Control Experiments:**
	* Perform control co-culture experiments using CD11c-T-bet- B cells (sorted from the same individuals) to rule out non-specific effects.
	* Use scrambled siRNA as a negative control for Ezrin and Lyn siRNA.

**Expected Outcomes:**

* If the hypothesis is true, CD11c+T-bet+ B cells will regulate Ezrin and Lyn expression in autologous B cells, leading to modulation of B cell activation and autoantibody production.
* If the hypothesis is false, CD11c+T-bet+ B cells will not affect Ezrin and Lyn expression, and B cell activation and autoantibody production will remain unchanged.

**Equipment and Resources:**

* Flow cytometer
* Western blot machine
* Cell culture facilities
* FACS sorter
* Transwell system
* qRT-PCR machine
* ELISA reader
* Magnetic bead-based separation equipment
* siRNA transfection reagents
* Antibodies for flow cytometry and Western blot

**Timeline:**

* Cell isolation and sorting: 2 weeks
* Co-culture experiments: 4 weeks
* Ezrin and Lyn expression analysis: 2 weeks
* B cell activation and autoantibody production analysis: 2 weeks
* Data analysis and interpretation: 4 weeks

**Budget:**

* Personnel: 2 postdoctoral researchers, 1 graduate student, 1 technician (12 months)
* Reagents and consumables: $100,000
* Equipment maintenance and upgrade: $50,000
* Travel and training: $20,000
* Total budget: $220,000

This experimental plan is designed to test the hypothesis and provide conclusive evidence for or against the role of CD11c+T-bet+ B cells in regulating Ezrin and Lyn expression in lupus.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Sorting**

**Step 1.1: Peripheral Blood Mononuclear Cell (PBMC) Isolation**

1. Collect 10 mL of peripheral blood from lupus patients and healthy controls in EDTA-coated tubes.
2. Add 10 mL of PBS to the blood samples and mix gently.
3. Layer the blood-PBS mixture over 15 mL of Ficoll-Paque in a 50 mL conical tube.
4. Centrifuge at 400 x g for 30 minutes at room temperature.
5. Collect the PBMC layer and transfer it to a new 50 mL conical tube.
6. Wash the PBMCs with PBS and centrifuge at 300 x g for 10 minutes.
7. Resuspend the PBMCs in 10 mL of PBS.

**Step 1.2: B Cell Isolation using Magnetic Bead-Based Separation**

1. Add 100 μL of B cell isolation cocktail (e.g., CD19 microbeads) to the PBMC suspension and mix well.
2. Incubate for 15 minutes at 4°C.
3. Add 10 mL of PBS and centrifuge at 300 x g for 10 minutes.
4. Discard the supernatant and resuspend the cells in 10 mL of PBS.
5. Repeat steps 2-4 until the desired purity of B cells is achieved (>95%).

**Step 1.3: CD11c+T-bet+ B Cell Sorting using FACS**

1. Stain the isolated B cells with CD11c-APC, T-bet-PE, and CD19-FITC antibodies for 30 minutes at 4°C.
2. Wash the cells with PBS and resuspend in 1 mL of PBS.
3. Sort CD11c+T-bet+ B cells using a FACS sorter with a purity gate set to >95%.
4. Collect the sorted cells in a 15 mL conical tube containing 10 mL of complete RPMI medium.

**Protocol 2: Co-Culture Experiments**

**Step 2.1: Co-Culture Setup**

1. Prepare autologous B cells by isolating B cells from the same individual using the same protocol as above.
2. Resuspend the autologous B cells in complete RPMI medium at a concentration of 1 x 10^6 cells/mL.
3. Add 1 mL of autologous B cells to the bottom chamber of a transwell system.
4. Add 1 mL of CD11c+T-bet+ B cells (sorted in Protocol 1.3) to the top chamber of the transwell system.

**Step 2.2: siRNA Transfection**

1. Prepare Ezrin and Lyn siRNA according to the manufacturer's instructions.
2. Add 100 nM of Ezrin siRNA, Lyn siRNA, or scrambled siRNA to the top chamber of the transwell system.
3. Incubate the co-culture for 48 hours at 37°C, 5% CO2.

**Protocol 3: Ezrin and Lyn Expression Analysis**

**Step 3.1: Western Blot Analysis**

1. Harvest the autologous B cells from the bottom chamber of the transwell system.
2. Lyse the cells in RIPA buffer and quantify protein concentration using a BCA assay.
3. Load 20 μg of protein onto a 10% SDS-PAGE gel.
4. Transfer the proteins to a PVDF membrane and block with 5% milk.
5. Incubate with Ezrin and Lyn antibodies overnight at 4°C.
6. Detect protein bands using ECL reagents and quantify using ImageJ software.

**Step 3.2: qRT-PCR Analysis**

1. Harvest the autologous B cells from the bottom chamber of the transwell system.
2. Extract RNA using a RNA isolation kit and quantify using a NanoDrop spectrophotometer.
3. Perform qRT-PCR using Ezrin and Lyn primers and a qRT-PCR machine.
4. Analyze the data using the ΔΔCt method.

**Protocol 4: B Cell Activation and Autoantibody Production Analysis**

**Step 4.1: Flow Cytometry Analysis**

1. Harvest the autologous B cells from the bottom chamber of the transwell system.
2. Stain the cells with CD69-APC, CD86-PE, and CD19-FITC antibodies for 30 minutes at 4°C.
3. Analyze the cells using a flow cytometer and quantify the percentage of activated B cells.

**Step 4.2: ELISA Analysis**

1. Collect the supernatant from the bottom chamber of the transwell system.
2. Perform ELISA using anti-dsDNA and anti-nucleosome antibodies according to the manufacturer's instructions.
3. Quantify the autoantibody production using a plate reader.

**Protocol 5: Control Experiments**

**Step 5.1: CD11c-T-bet- B Cell Co-Culture**

1. Repeat Protocol 2 using CD11c-T-bet- B cells sorted from the same individuals.
2. Analyze the data as described in Protocols 3 and 4.

**Step 5.2: Scrambled siRNA Control**

1. Repeat Protocol 2 using scrambled siRNA instead of Ezrin and Lyn siRNA.
2. Analyze the data as described in Protocols 3 and 4.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity.","```
   PBMC_volume  Ficoll_volume  B_cell_isolation_cocktail_volume  CD11c_T_bet_B_cell_sorting_purity  Autologous_B_cell_concentration  Ezrin_siRNA_concentration  Lyn_siRNA_concentration  Scrambled_siRNA_concentration  Ezrin_expression  Lyn_expression  CD69_expression  CD86_expression  Autoantibody_production
0           10.0           15.0                         100.0                         96.0                         1.0e+06                     100.0                     100.0                     0.0         0.8         0.9         20.0         30.0         150.0
1           12.0           18.0                         120.0                         97.0                         1.2e+06                     120.0                     120.0                     0.0         0.9         1.0         25.0         35.0         180.0
2            8.0           12.0                          80.0                         94.0                         0.8e+06                      80.0                      80.0                     0.0         0.7         0.8         15.0         20.0         100.0
3           11.0           16.0                         110.0                         95.0                         1.1e+06                     110.0                     110.0                     0.0         0.8         0.9         22.0         28.0         140.0
4           13.0           19.0                         130.0                         98.0                         1.3e+06                     130.0                     130.0                     0.0         1.0         1.1         30.0         40.0         200.0
5            9.0           14.0                          90.0                         93.0                         0.9e+06                      90.0                      90.0                     0.0         0.7         0.8         18.0         22.0         110.0
6           10.0           15.0                         100.0                         96.0                         1.0e+06                     100.0                     100.0                     0.0         0.8         0.9         20.0         30.0         150.0
7           12.0           18.0                         120.0                         97.0                         1.2e+06                     120.0                     120.0                     0.0         0.9         1.0         25.0         35.0         180.0
8            8.0           12.0                          80.0                         94.0                         0.8e+06                      80.0                      80.0                     0.0         0.7         0.8         15.0         20.0         100.0
9           11.0           16.0                         110.0                         95.0                         1.1e+06                     110.0                     110.0                     0.0         0.8         0.9         22.0         28.0         140.0
10          13.0           19.0                         130.0                         98.0                         1.3e+06                     130.0                     130.0                     0.0         1.0         1.1         30.0         40.0         200.0
11           9.0           14.0                          90.0                         93.0                         0.9e+06                      90.0                      90.0                     0.0         0.7         0.8         18.0         22.0         110.0
12          10.0           15.0                         100.0                         96.0                         1.0e+06                     100.0                     100.0                     0.0         0.8         0.9         20.0         30.0         150.0
13          12.0           18.0                         120.0                         97.0                         1.2e+06                     120.0                     120.0                     0.0         0.9         1.0         25.0         35.0         180.0
14           8.0           12.0                          80.0                         94.0                         0.8e+06                      80.0                      80.0                     0.0         0.7         0.8         15.0         20.0         100.0
15          11.0           16.0                         110.0                         95.0                         1.1e+06                     110.0                     110.0                     0.0         0.8         0.9         22.0         28.0         140.0
16          13.0           19.0                         130.0                         98.0                         1.3e+06                     130.0                     130.0                     0.0         1.0         1.1         30.0         40.0         200.0
17           9.0           14.0                          90.0                         93.0                         0.9e+06                      90.0                      90.0                     0.0         0.7         0.8         18.0         22.0         110.0
18          10.0           15.0                         100.0                         96.0                         1.0e+06                     100.0                     100.0                     0.0         0.8         0.9         20.0         30.0         150.0
19          12.0           18.0                         120.0                         97.0                         1.2e+06                     120.0                     120.0                     0.0         0.9         1.0         25.0         35.0         180.0
20           8.0           12.0                          80.0                         94.0                         0.8e+06                      80.0                      80.0                     0.0         0.7         0.8         15.0         20.0         100.0
21          11.0           16.0                         110.0                         95.0                         1.1e+06                     110.0                     110.0                     0.0         0.8         0.9         22.0         28.0         140.0
22          13.0           19.0                         130.0                         98.0                         1.3e+06                     130.0                     130.0                     0.0         1.0         1.1         30.0         40.0         200.0
23           9.0           14.0                          90.0                         93.0                         0.9e+06                      90.0                      90.0                     0.0         0.7         0.8         18.0         22.0         110.0
24          10.0           15.0                         100.0                         96.0                         1.0e+06                     100.0                     100.0                     0.0         0.8         0.9         20.0         30.0         150.0
```",0.9685544051327786
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/116ea69de79ffc53e3a21fd1bf97834aebfdc53d.summary'],Do CD19-dependent germinal center-derived antibody-secreting cells in the CNS exhibit a distinct epigenetic signature that enhances their ability to recognize and respond to viral antigens in the CNS?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Epigenetic Profiling of CD19-Dependent Germinal Center-Derived Antibody-Secreting Cells in the CNS

**Objective:** To determine if CD19-dependent germinal center-derived antibody-secreting cells in the CNS exhibit a distinct epigenetic signature that enhances their ability to recognize and respond to viral antigens in the CNS.

**Equipment:**

* Next-generation sequencing (NGS) platform (e.g., Illumina or PacBio)
* Epigenetic profiling kits (e.g., ChIP-seq or ATAC-seq)
* Flow cytometer
* Cell sorter
* JHMV-infected mice
* CD19-deficient mice
* WT mice

**Steps:**

1. Infect WT and CD19-deficient mice with JHMV and harvest cervical lymph nodes at day 14 post-infection.
2. Isolate and sort antibody-secreting cells from WT and CD19-deficient mice using flow cytometry.
3. Perform ChIP-seq or ATAC-seq on sorted antibody-secreting cells to generate epigenetic profiles.
4. Analyze epigenetic profiles using bioinformatic tools (e.g., MACS2, HOMER, or DESeq2) to identify differentially regulated genes and epigenetic marks between WT and CD19-deficient antibody-secreting cells.
5. Validate findings using qRT-PCR and Western blotting.
6. Compare epigenetic profiles of antibody-secreting cells from WT and CD19-deficient mice to identify a distinct signature associated with CD19-dependent germinal center formation.
7. Correlate epigenetic signature with functional assays (e.g., ELISA, neutralization assays) to determine if the signature enhances the ability of antibody-secreting cells to recognize and respond to viral antigens in the CNS.

**Experiment to Disprove the Hypothesis:**

**Title:** Epigenetic Profiling of CD19-Independent Germinal Center-Derived Antibody-Secreting Cells in the CNS

**Objective:** To determine if CD19-independent germinal center-derived antibody-secreting cells in the CNS exhibit a similar epigenetic signature to CD19-dependent cells, thereby disproving the hypothesis.

**Equipment:**

* Same as above

**Steps:**

1. Infect CD19-deficient mice with JHMV and harvest cervical lymph nodes at day 14 post-infection.
2. Isolate and sort antibody-secreting cells from CD19-deficient mice using flow cytometry.
3. Perform ChIP-seq or ATAC-seq on sorted antibody-secreting cells to generate epigenetic profiles.
4. Analyze epigenetic profiles using bioinformatic tools to identify differentially regulated genes and epigenetic marks compared to CD19-dependent antibody-secreting cells (from the main experiment).
5. Validate findings using qRT-PCR and Western blotting.
6. Compare epigenetic profiles of CD19-independent antibody-secreting cells to those of CD19-dependent cells to determine if they exhibit a similar signature.
7. If the epigenetic signature is similar, it would suggest that CD19 is not essential for the development of a distinct epigenetic signature in antibody-secreting cells, thereby disproving the hypothesis.

**Rationale:**

The main experiment aims to identify a distinct epigenetic signature associated with CD19-dependent germinal center-derived antibody-secreting cells in the CNS. The experiment to disprove the hypothesis focuses on CD19-independent germinal center-derived antibody-secreting cells to determine if they exhibit a similar epigenetic signature. If the signatures are similar, it would suggest that CD19 is not essential for the development of a distinct epigenetic signature, thereby disproving the hypothesis. This approach allows for a more comprehensive understanding of the role of CD19 in shaping the epigenetic landscape of antibody-secreting cells in the CNS.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experimental Plan to Test the Hypothesis:**

**Title:** Epigenetic Profiling of CD19-Dependent Germinal Center-Derived Antibody-Secreting Cells in the CNS

**Objective:** To determine if CD19-dependent germinal center-derived antibody-secreting cells in the CNS exhibit a distinct epigenetic signature that enhances their ability to recognize and respond to viral antigens in the CNS.

**Step 1: Infection and Harvesting of Cervical Lymph Nodes**

1.1. Obtain 10-15 wild-type (WT) mice and 10-15 CD19-deficient mice.

1.2. Infect each mouse with 10^4 plaque-forming units (PFU) of JHMV via intracranial injection.

1.3. Monitor mice for 14 days post-infection and ensure they do not exhibit severe symptoms.

1.4. Euthanize mice and harvest cervical lymph nodes using sterile instruments and aseptic techniques.

**Step 2: Isolation and Sorting of Antibody-Secreting Cells**

2.1. Prepare a single-cell suspension of cervical lymph node cells using a gentleMACS dissociator and a 40-μm cell strainer.

2.2. Stain cells with fluorescently labeled antibodies against CD19, CD138, and IgG (e.g., PE-conjugated anti-CD19, FITC-conjugated anti-CD138, and APC-conjugated anti-IgG).

2.3. Perform flow cytometry using a BD FACSAria III or similar instrument to sort antibody-secreting cells (CD19+CD138+IgG+).

2.4. Collect sorted cells in a 1.5-mL tube containing 100 μL of PBS with 2% FBS.

**Step 3: Epigenetic Profiling using ChIP-seq or ATAC-seq**

3.1. Prepare chromatin from sorted antibody-secreting cells using a ChIP-seq or ATAC-seq kit (e.g., Illumina TruSeq ChIP Library Prep Kit or Active Motif's ATAC-seq Kit).

3.2. Perform ChIP-seq or ATAC-seq according to the manufacturer's instructions.

3.3. Generate sequencing libraries using a Next-generation sequencing (NGS) platform (e.g., Illumina HiSeq 4000 or PacBio Sequel).

**Step 4: Bioinformatic Analysis**

4.1. Map sequencing reads to the mouse genome (e.g., mm10) using a bioinformatic tool (e.g., BWA or Bowtie).

4.2. Identify peaks and regions of enrichment using a peak-calling algorithm (e.g., MACS2 or HOMER).

4.3. Perform differential analysis using a tool (e.g., DESeq2) to identify differentially regulated genes and epigenetic marks between WT and CD19-deficient antibody-secreting cells.

**Step 5: Validation using qRT-PCR and Western Blotting**

5.1. Extract RNA from sorted antibody-secreting cells using a RNA extraction kit (e.g., Qiagen RNeasy Mini Kit).

5.2. Perform qRT-PCR using primers specific to differentially regulated genes identified in Step 4.

5.3. Extract protein from sorted antibody-secreting cells using a protein extraction kit (e.g., RIPA buffer).

5.4. Perform Western blotting using antibodies against proteins of interest.

**Step 6: Correlation with Functional Assays**

6.1. Perform ELISA to measure antibody titers against JHMV in serum or CSF.

6.2. Perform neutralization assays to measure the ability of antibody-secreting cells to neutralize JHMV.

6.3. Correlate epigenetic signature with functional assays to determine if the signature enhances the ability of antibody-secreting cells to recognize and respond to viral antigens in the CNS.

**Experiment to Disprove the Hypothesis:**

**Title:** Epigenetic Profiling of CD19-Independent Germinal Center-Derived Antibody-Secreting Cells in the CNS

**Objective:** To determine if CD19-independent germinal center-derived antibody-secreting cells in the CNS exhibit a similar epigenetic signature to CD19-dependent cells, thereby disproving the hypothesis.

**Step 1: Infection and Harvesting of Cervical Lymph Nodes**

1.1. Obtain 10-15 CD19-deficient mice.

1.2. Infect each mouse with 10^4 PFU of JHMV via intracranial injection.

1.3. Monitor mice for 14 days post-infection and ensure they do not exhibit severe symptoms.

1.4. Euthanize mice and harvest cervical lymph nodes using sterile instruments and aseptic techniques.

**Step 2: Isolation and Sorting of Antibody-Secreting Cells**

2.1. Prepare a single-cell suspension of cervical lymph node cells using a gentleMACS dissociator and a 40-μm cell strainer.

2.2. Stain cells with fluorescently labeled antibodies against CD138 and IgG (e.g., FITC-conjugated anti-CD138 and APC-conjugated anti-IgG).

2.3. Perform flow cytometry using a BD FACSAria III or similar instrument to sort antibody-secreting cells (CD138+IgG+).

2.4. Collect sorted cells in a 1.5-mL tube containing 100 μL of PBS with 2% FBS.

**Step 3: Epigenetic Profiling using ChIP-seq or ATAC-seq**

3.1. Prepare chromatin from sorted antibody-secreting cells using a ChIP-seq or ATAC-seq kit (e.g., Illumina TruSeq ChIP Library Prep Kit or Active Motif's ATAC-seq Kit).

3.2. Perform ChIP-seq or ATAC-seq according to the manufacturer's instructions.

3.3. Generate sequencing libraries using a Next-generation sequencing (NGS) platform (e.g., Illumina HiSeq 4000 or PacBio Sequel).

**Step 4: Bioinformatic Analysis**

4.1. Map sequencing reads to the mouse genome (e.g., mm10) using a bioinformatic tool (e.g., BWA or Bowtie).

4.2. Identify peaks and regions of enrichment using a peak-calling algorithm (e.g., MACS2 or HOMER).

4.3. Perform differential analysis using a tool (e.g., DESeq2) to identify differentially regulated genes and epigenetic marks compared to CD19-dependent antibody-secreting cells (from the main experiment).

**Step 5: Validation using qRT-PCR and Western Blotting**

5.1. Extract RNA from sorted antibody-secreting cells using a RNA extraction kit (e.g., Qiagen RNeasy Mini Kit).

5.2. Perform qRT-PCR using primers specific to differentially regulated genes identified in Step 4.

5.3. Extract protein from sorted antibody-secreting cells using a protein extraction kit (e.g., RIPA buffer).

5.4. Perform Western blotting using antibodies against proteins of interest.

**Step 6: Comparison of Epigenetic Signatures**

6.1. Compare epigenetic profiles of CD19-independent antibody-secreting cells to those of CD19-dependent cells.

6.2. If the epigenetic signature is similar, it would suggest that CD19 is not essential for the development of a distinct epigenetic signature in antibody-secreting cells, thereby disproving the hypothesis.","```
   Mice  JHMV_PFU  CD19_Stain  CD138_Stain  IgG_Stain  ChIPseq_Kits  NGS_Platform  Epigenetic_Signature  Outcome
0     10     10000        1.0         1.0       1.0         1.0         1.0            Distinct         Positive
1     12     12000        0.8         1.2       1.1         1.1         1.1            Similar         Negative
2     11     11000        1.1         1.1       1.0         1.0         1.0            Distinct         Positive
3     10     10000        0.9         1.0       1.1         1.1         1.1            Similar         Negative
4     13     13000        1.2         1.2       1.2         1.2         1.2            Distinct         Positive
5     12     12000        1.0         1.1       1.0         1.0         1.0            Distinct         Positive
6     11     11000        0.8         1.0       1.2         1.2         1.2            Similar         Negative
7     10     10000        1.1         1.2       1.1         1.1         1.1            Distinct         Positive
8     13     13000        0.9         1.1       1.2         1.2         1.2            Similar         Negative
9     12     12000        1.2         1.2       1.2         1.2         1.2            Distinct         Positive
10    11     11000        1.0         1.1       1.0         1.0         1.0            Distinct         Positive
11    10     10000        0.8         1.0       1.1         1.1         1.1            Similar         Negative
12    13     13000        1.1         1.2       1.1         1.1         1.1            Distinct         Positive
13    12     12000        0.9         1.1       1.2         1.2         1.2            Similar         Negative
14    11     11000        1.2         1.2       1.2         1.2         1.2            Distinct         Positive
15    10     10000        1.0         1.1       1.0         1.0         1.0            Distinct         Positive
16    13     13000        0.8         1.0       1.1         1.1         1.1            Similar         Negative
17    12     12000        1.1         1.2       1.1         1.1         1.1            Distinct         Positive
18    11     11000        0.9         1.1       1.2         1.2         1.2            Similar         Negative
19    10     10000        1.2         1.2       1.2         1.2         1.2            Distinct         Positive
20    13     13000        1.0         1.1       1.0         1.0         1.0            Distinct         Positive
21    12     12000        0.8         1.0       1.1         1.1         1.1            Similar         Negative
22    11     11000        1.1         1.2       1.1         1.1         1.1            Distinct         Positive
23    10     10000        0.9         1.1       1.2         1.2         1.2            Similar         Negative
24    13     13000        1.2         1.2       1.2         1.2         1.2            Distinct         Positive
```",0.06944375431376723
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1c6618274b4834505fafb23d7f6ef0aabfa9137b.summary'],"Do CXCL13+CD4+ T cells in skin TLSs of pemphigus patients also regulate Treg function through a feedback loop, thereby modulating the chronic blister microenvironment?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that CXCL13+CD4+ T cells in skin TLSs of pemphigus patients regulate Treg function through a feedback loop, thereby modulating the chronic blister microenvironment.

**Experiment: ""Disproving the Feedback Loop Hypothesis""**

**Objective:** To investigate whether CXCL13+CD4+ T cells in skin TLSs of pemphigus patients regulate Treg function through a feedback loop, and to determine if disrupting this potential feedback loop affects the chronic blister microenvironment.

**Experimental Design:**

1. **Cell Isolation and Sorting:**
	* Isolate skin TLSs from pemphigus patients using enzymatic digestion and mechanical disruption.
	* Sort CXCL13+CD4+ T cells, Tregs, and CD4+ T cells (as a control) using flow cytometry and cell sorting.
2. **Co-Culture Experiments:**
	* Set up co-cultures of CXCL13+CD4+ T cells with Tregs, CD4+ T cells, or without any additional cells (control) in the presence of anti-CD3 and anti-CD28 antibodies to stimulate T cell activation.
	* Add a CXCL13-neutralizing antibody to a subset of co-cultures to block CXCL13 signaling.
3. **Treg Function Assays:**
	* Measure Treg function using a suppression assay, where Tregs are co-cultured with responder T cells and their ability to suppress T cell proliferation is assessed.
	* Use a Treg-specific functional assay, such as a FOXP3 reporter assay, to evaluate Treg activity.
4. **CXCL13 Production and Signaling:**
	* Measure CXCL13 production in the co-culture supernatants using ELISA.
	* Use a CXCL13 receptor (CXCR5) antagonist to block CXCL13 signaling in a subset of co-cultures.
5. **Chronic Blister Microenvironment Analysis:**
	* Analyze the expression of inflammatory markers (e.g., IL-1β, TNF-α) and blister-associated genes (e.g., desmoglein 1) in the skin TLSs using qRT-PCR or RNA-seq.
	* Evaluate the presence and activation status of immune cells (e.g., T cells, macrophages) in the skin TLSs using flow cytometry or immunohistochemistry.

**Disproving the Hypothesis:**

To disprove the hypothesis, we will look for the following outcomes:

* No significant difference in Treg function or CXCL13 production between co-cultures with or without CXCL13+CD4+ T cells.
* No effect of CXCL13-neutralizing antibody or CXCR5 antagonist on Treg function or CXCL13 production.
* No correlation between CXCL13 production and Treg function in the co-cultures.
* No changes in the chronic blister microenvironment (inflammatory markers, blister-associated genes, immune cell presence/activation) upon disrupting the potential feedback loop.

**Required Equipment and Reagents:**

* Flow cytometer and cell sorter
* ELISA plate reader
* Antibodies (anti-CD3, anti-CD28, anti-CD25, anti-CXCL13, anti-CXCR5)
* CXCL13-neutralizing antibody
* CXCR5 antagonist
* qRT-PCR or RNA-seq equipment
* Immunohistochemistry reagents

**Timeline:**

This experiment is expected to take approximately 6-9 months to complete, assuming a team of 2-3 researchers working full-time.

**Budget:**

The budget for this experiment will depend on the specific reagents and equipment required. However, with an unlimited budget, we can assume that all necessary resources will be available.

By designing an experiment to disprove the hypothesis, we can rigorously test the idea that CXCL13+CD4+ T cells in skin TLSs of pemphigus patients regulate Treg function through a feedback loop, and gain a deeper understanding of the mechanisms underlying chronic blister formation in pemphigus.",85,"Here are the detailed, step-by-step protocols for the ""Disproving the Feedback Loop Hypothesis"" experiment:

**Protocol 1: Cell Isolation and Sorting**

1.1. **Skin TLS Isolation**

* Obtain skin biopsies from pemphigus patients (n=10-15) and store them in RPMI 1640 medium on ice.
* Wash the biopsies with PBS and mince them into small pieces using a sterile scalpel.
* Add 1 mL of collagenase IV (1 mg/mL) and 1 mL of DNase I (100 U/mL) to the minced tissue and incubate at 37°C for 1 hour.
* Use a gentleMACS Dissociator to mechanically disrupt the tissue and release the cells.
* Pass the cell suspension through a 70-μm cell strainer to remove debris.

1.2. **Cell Sorting**

* Stain the isolated cells with the following antibodies:
	+ Anti-CD4-APC (1:100)
	+ Anti-CXCL13-PE (1:50)
	+ Anti-CD25-FITC (1:100)
* Use a flow cytometer (e.g., BD FACSAria III) to sort the cells into three populations:
	+ CXCL13+CD4+ T cells (gate on CD4+CXCL13+ cells)
	+ Tregs (gate on CD4+CD25+ cells)
	+ CD4+ T cells (gate on CD4+ cells, excluding CXCL13+ and CD25+ cells)
* Collect the sorted cells in separate tubes containing RPMI 1640 medium with 10% FBS and 1% penicillin-streptomycin.

**Protocol 2: Co-Culture Experiments**

2.1. **Co-Culture Setup**

* Prepare 96-well plates with 100 μL of RPMI 1640 medium per well.
* Add 1 × 10^5 CXCL13+CD4+ T cells, Tregs, or CD4+ T cells (as a control) to each well.
* Add 1 μg/mL of anti-CD3 and 1 μg/mL of anti-CD28 antibodies to each well to stimulate T cell activation.
* Add a CXCL13-neutralizing antibody (1 μg/mL) to a subset of co-cultures to block CXCL13 signaling.

2.2. **Co-Culture Incubation**

* Incubate the co-cultures at 37°C, 5% CO2 for 3-4 days.
* Harvest the supernatants and store them at -80°C for ELISA analysis.

**Protocol 3: Treg Function Assays**

3.1. **Suppression Assay**

* Co-culture 1 × 10^5 responder T cells with 1 × 10^5 Tregs or CXCL13+CD4+ T cells in the presence of 1 μg/mL of anti-CD3 and 1 μg/mL of anti-CD28 antibodies.
* Incubate the co-cultures for 3-4 days and measure T cell proliferation using a [³H]-thymidine incorporation assay.

3.2. **FOXP3 Reporter Assay**

* Transfect Tregs with a FOXP3 reporter plasmid using a nucleofection kit.
* Co-culture the transfected Tregs with 1 × 10^5 CXCL13+CD4+ T cells or CD4+ T cells in the presence of 1 μg/mL of anti-CD3 and 1 μg/mL of anti-CD28 antibodies.
* Measure FOXP3 reporter activity using a luciferase assay.

**Protocol 4: CXCL13 Production and Signaling**

4.1. **ELISA**

* Use a CXCL13 ELISA kit to measure CXCL13 production in the co-culture supernatants.

4.2. **CXCR5 Antagonist Treatment**

* Add a CXCR5 antagonist (1 μM) to a subset of co-cultures to block CXCL13 signaling.
* Incubate the co-cultures for an additional 24 hours and measure Treg function using the suppression assay or FOXP3 reporter assay.

**Protocol 5: Chronic Blister Microenvironment Analysis**

5.1. **qRT-PCR or RNA-seq**

* Extract RNA from the skin TLSs using a RNA extraction kit.
* Perform qRT-PCR or RNA-seq to analyze the expression of inflammatory markers (e.g., IL-1β, TNF-α) and blister-associated genes (e.g., desmoglein 1).

5.2. **Flow Cytometry or Immunohistochemistry**

* Stain the skin TLSs with antibodies against immune cells (e.g., T cells, macrophages) and analyze using flow cytometry or immunohistochemistry.

**Quality Control and Replicability**

* Perform each experiment in triplicate to ensure reproducibility.
* Include positive and negative controls for each assay to validate the results.
* Use standardized protocols and reagents to minimize variability.
* Document all experimental procedures, results, and data analysis in a laboratory notebook.

**Timeline and Budget**

* The experiment is expected to take approximately 6-9 months to complete, assuming a team of 2-3 researchers working full-time.
* The budget will depend on the specific reagents and equipment required, but with an unlimited budget, all necessary resources will be available.","```
   Collagenase_IV  DNase_I  Anti_CD4_APC  Anti_CXCL13_PE  Anti_CD25_FITC  CXCL13_neutralizing_antibody  Tregs  CXCL13_CD4_T_cells  CD4_T_cells  Outcome
0             0.8      100.0           0.08             0.04             0.08                    0.5     50000          50000        50000  0.456
1             1.2      120.0           0.12             0.06             0.12                    0.6     60000          60000        60000  0.512
2             0.6       80.0           0.06             0.03             0.06                    0.4     40000          40000        40000  0.392
3             1.0      100.0           0.10             0.05             0.10                    0.5     50000          50000        50000  0.468
4             1.4      140.0           0.14             0.07             0.14                    0.7     70000          70000        70000  0.542
5             0.4       60.0           0.04             0.02             0.04                    0.3     30000          30000        30000  0.348
6             1.6      160.0           0.16             0.08             0.16                    0.8     80000          80000        80000  0.576
7             0.2       40.0           0.02             0.01             0.02                    0.2     20000          20000        20000  0.292
8             1.8      180.0           0.18             0.09             0.18                    0.9     90000          90000        90000  0.612
9             0.6       80.0           0.06             0.03             0.06                    0.4     40000          40000        40000  0.392
10            1.0      100.0           0.10             0.05             0.10                    0.5     50000          50000        50000  0.468
11            1.2      120.0           0.12             0.06             0.12                    0.6     60000          60000        60000  0.512
12            0.8      100.0           0.08             0.04             0.08                    0.5     50000          50000        50000  0.456
13            1.4      140.0           0.14             0.07             0.14                    0.7     70000          70000        70000  0.542
14            0.4       60.0           0.04             0.02             0.04                    0.3     30000          30000        30000  0.348
15            1.6      160.0           0.16             0.08             0.16                    0.8     80000          80000        80000  0.576
16            0.2       40.0           0.02             0.01             0.02                    0.2     20000          20000        20000  0.292
17            1.8      180.0           0.18             0.09             0.18                    0.9     90000          90000        90000  0.612
18            0.6       80.0           0.06             0.03             0.06                    0.4     40000          40000        40000  0.392
19            1.0      100.0           0.10             0.05             0.10                    0.5     50000          50000        50000  0.468
20            1.2      120.0           0.12             0.06             0.12                    0.6     60000          60000        60000  0.512
21            0.8      100.0           0.08             0.04             0.08                    0.5     50000          50000        50000  0.456
22            1.4      140.0           0.14             0.07             0.14                    0.7     70000          70000        70000  0.542
23            0.4       60.0           0.04             0.02             0.04                    0.3     30000          30000        30000  0.348
24            1.6      160.0           0.16             0.08             0.16                    0.8     80000          80000        80000  0.576
```",0.9905537663591288
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/349f49358f423ee71bfb0f461fc3928307e25f19.summary'],"Do IGHV1-69 clones exhibit increased resistance to chemotherapy-induced apoptosis due to their distinct gene expression profile, leading to a higher likelihood of relapse in CLL patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis and potentially disprove it. This experiment will utilize existing scientific methods and equipment, with an unlimited budget in terms of time, resources, and financial support.

**Experiment Title:** Investigating the Role of IGHV1-69 Clones in Chemotherapy-Induced Apoptosis Resistance in CLL Patients

**Objective:** To determine whether IGHV1-69 clones exhibit increased resistance to chemotherapy-induced apoptosis due to their distinct gene expression profile, leading to a higher likelihood of relapse in CLL patients.

**Experimental Design:**

**Step 1: Cell Isolation and Culture**

* Isolate IGHV1-69 clones and other CLL clones from CLL patient samples using peptide-based cell sorting.
* Culture the isolated clones in vitro using standard cell culture conditions.

**Step 2: Chemotherapy Treatment and Apoptosis Induction**

* Treat the cultured IGHV1-69 clones and other CLL clones with a range of chemotherapeutic agents (e.g., fludarabine, cyclophosphamide, doxorubicin) at varying concentrations.
* Use Annexin V staining and flow cytometry to assess apoptosis induction in response to chemotherapy treatment.

**Step 3: Gene Expression Profiling**

* Extract RNA from the chemotherapy-treated IGHV1-69 clones and other CLL clones.
* Perform RNA sequencing (RNA-seq) to generate a comprehensive gene expression profile of the treated clones.
* Analyze the RNA-seq data to identify differentially expressed genes between the IGHV1-69 clones and other CLL clones.

**Step 4: Functional Assays**

* Perform functional assays to validate the role of the differentially expressed genes in chemotherapy-induced apoptosis resistance:
	+ CRISPR-Cas9 gene editing to knockdown or knockout specific genes in IGHV1-69 clones.
	+ Overexpression of specific genes in other CLL clones.
	+ Measure apoptosis induction in response to chemotherapy treatment using Annexin V staining and flow cytometry.

**Step 5: Data Analysis and Integration**

* Integrate the gene expression profiling data with the functional assay results to identify key genes and pathways involved in chemotherapy-induced apoptosis resistance in IGHV1-69 clones.
* Perform statistical analysis to determine the correlation between gene expression profiles and chemotherapy response.

**Step 6: Validation and Verification**

* Validate the findings using an independent cohort of CLL patient samples.
* Verify the results using alternative methods, such as Western blotting and immunofluorescence microscopy, to confirm the expression and localization of key proteins.

**Experimental Controls:**

* Include untreated IGHV1-69 clones and other CLL clones as controls to assess baseline apoptosis levels.
* Use non-CLL cell lines (e.g., healthy B cells) as negative controls to ensure specificity of the findings.

**Potential Outcomes:**

* If the experiment confirms the hypothesis, it would suggest that IGHV1-69 clones exhibit increased resistance to chemotherapy-induced apoptosis due to their distinct gene expression profile, leading to a higher likelihood of relapse in CLL patients.
* If the experiment disproves the hypothesis, it would indicate that the distinct gene expression profile of IGHV1-69 clones does not confer chemotherapy resistance, and alternative mechanisms may be involved in CLL relapse.

**Timeline:**

* Cell isolation and culture: 2 weeks
* Chemotherapy treatment and apoptosis induction: 4 weeks
* Gene expression profiling: 8 weeks
* Functional assays: 12 weeks
* Data analysis and integration: 16 weeks
* Validation and verification: 20 weeks

Total duration: 52 weeks (approximately 1 year)

This experimental design aims to comprehensively investigate the role of IGHV1-69 clones in chemotherapy-induced apoptosis resistance in CLL patients, with a focus on disproving the hypothesis. The unlimited budget allows for the use of cutting-edge techniques, such as RNA-seq and CRISPR-Cas9 gene editing, to ensure a thorough and rigorous investigation.",92,"Here are the detailed, step-by-step protocols for each step of the experiment:

**Step 1: Cell Isolation and Culture**

1.1. Sample Collection:

* Collect peripheral blood or bone marrow samples from CLL patients with informed consent.
* Ensure samples are stored at 4°C and processed within 24 hours of collection.

1.2. Cell Isolation:

* Use peptide-based cell sorting to isolate IGHV1-69 clones and other CLL clones from the patient samples.
* Use a cell sorter (e.g., FACS Aria III) to sort cells based on surface markers (e.g., CD19, CD5, CD23).
* Collect sorted cells in 1.5 mL tubes containing 100 μL of PBS with 2% FBS.

1.3. Cell Culture:

* Culture the isolated clones in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubate cells at 37°C, 5% CO2, and 95% humidity.
* Monitor cell viability and density daily using a hemocytometer and trypan blue staining.

**Step 2: Chemotherapy Treatment and Apoptosis Induction**

2.1. Chemotherapy Treatment:

* Prepare stock solutions of chemotherapeutic agents (e.g., fludarabine, cyclophosphamide, doxorubicin) according to the manufacturer's instructions.
* Dilute the stock solutions to the desired concentrations (e.g., 1 μM, 10 μM, 100 μM) in RPMI-1640 medium.
* Add the diluted chemotherapeutic agents to the cultured IGHV1-69 clones and other CLL clones.
* Incubate cells for 24, 48, or 72 hours to assess apoptosis induction.

2.2. Apoptosis Induction:

* Use Annexin V staining to assess apoptosis induction in response to chemotherapy treatment.
* Add 1 μL of Annexin V-FITC to 100 μL of cell suspension (1 x 10^6 cells/mL).
* Incubate for 15 minutes at room temperature in the dark.
* Analyze cells using flow cytometry (e.g., BD FACSCanto II) to detect Annexin V-positive cells.

**Step 3: Gene Expression Profiling**

3.1. RNA Extraction:

* Extract RNA from the chemotherapy-treated IGHV1-69 clones and other CLL clones using a RNA extraction kit (e.g., Qiagen RNeasy Mini Kit).
* Follow the manufacturer's instructions to extract high-quality RNA.

3.2. RNA Sequencing:

* Prepare RNA libraries using a RNA-seq library preparation kit (e.g., Illumina TruSeq Stranded mRNA Library Prep Kit).
* Sequence the RNA libraries using a next-generation sequencing platform (e.g., Illumina HiSeq 4000).
* Generate a minimum of 30 million reads per sample.

3.3. Data Analysis:

* Use a bioinformatics pipeline (e.g., STAR, featureCounts, DESeq2) to analyze the RNA-seq data.
* Identify differentially expressed genes between the IGHV1-69 clones and other CLL clones using a fold change cutoff of 2 and an adjusted p-value < 0.05.

**Step 4: Functional Assays**

4.1. CRISPR-Cas9 Gene Editing:

* Design guide RNAs (gRNAs) targeting specific genes of interest using a CRISPR design tool (e.g., CRISPR Design).
* Transfect IGHV1-69 clones with the gRNAs and Cas9 enzyme using a transfection reagent (e.g., Lipofectamine 3000).
* Validate gene knockout or knockdown using Western blotting or qRT-PCR.

4.2. Gene Overexpression:

* Clone the genes of interest into a mammalian expression vector (e.g., pCDH-CMV-MCS-EF1-Puro).
* Transfect other CLL clones with the expression vector using a transfection reagent (e.g., Lipofectamine 3000).
* Validate gene overexpression using Western blotting or qRT-PCR.

4.3. Apoptosis Assay:

* Treat the gene-edited or overexpressing cells with chemotherapy agents as described in Step 2.
* Assess apoptosis induction using Annexin V staining and flow cytometry.

**Step 5: Data Analysis and Integration**

5.1. Data Integration:

* Integrate the gene expression profiling data with the functional assay results to identify key genes and pathways involved in chemotherapy-induced apoptosis resistance.
* Use a bioinformatics tool (e.g., Ingenuity Pathway Analysis) to identify enriched biological pathways.

5.2. Statistical Analysis:

* Perform statistical analysis to determine the correlation between gene expression profiles and chemotherapy response.
* Use a statistical software (e.g., R, Python) to perform correlation analysis and generate heatmaps.

**Step 6: Validation and Verification**

6.1. Validation:

* Validate the findings using an independent cohort of CLL patient samples.
* Repeat the experimental design using the new samples to confirm the results.

6.2. Verification:

* Verify the results using alternative methods, such as Western blotting and immunofluorescence microscopy, to confirm the expression and localization of key proteins.
* Use a different antibody or detection method to validate the results.

**Experimental Controls**

* Include untreated IGHV1-69 clones and other CLL clones as controls to assess baseline apoptosis levels.
* Use non-CLL cell lines (e.g., healthy B cells) as negative controls to ensure specificity of the findings.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be verified.","```
   RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  Fludarabine  Cyclophosphamide  Doxorubicin  Annexin V  Outcome
0        10.0  10.0                 1.0          1.0         1.0             10.0        100.0       1.0  Apoptosis
1        10.0  10.0                 1.0          1.0         10.0             1.0         10.0       1.0  Resistance
2        10.0  10.0                 1.0          1.0         1.0             1.0         1.0       1.0  Apoptosis
3        10.0  10.0                 1.0          1.0         100.0            10.0        1.0       1.0  Resistance
4        10.0  10.0                 1.0          1.0         1.0             100.0       10.0       1.0  Apoptosis
5        10.0  10.0                 1.0          1.0         10.0            1.0        100.0       1.0  Resistance
6        10.0  10.0                 1.0          1.0         1.0             1.0        1.0       1.0  Apoptosis
7        10.0  10.0                 1.0          1.0         100.0            10.0       1.0       1.0  Resistance
8        10.0  10.0                 1.0          1.0         1.0             100.0      10.0       1.0  Apoptosis
9        10.0  10.0                 1.0          1.0         10.0            1.0       100.0       1.0  Resistance
10       10.0  10.0                 1.0          1.0         1.0             1.0        1.0       1.0  Apoptosis
11       10.0  10.0                 1.0          1.0         100.0            10.0       1.0       1.0  Resistance
12       10.0  10.0                 1.0          1.0         1.0             100.0      10.0       1.0  Apoptosis
13       10.0  10.0                 1.0          1.0         10.0            1.0       100.0       1.0  Resistance
14       10.0  10.0                 1.0          1.0         1.0             1.0        1.0       1.0  Apoptosis
15       10.0  10.0                 1.0          1.0         100.0            10.0       1.0       1.0  Resistance
16       10.0  10.0                 1.0          1.0         1.0             100.0      10.0       1.0  Apoptosis
17       10.0  10.0                 1.0          1.0         10.0            1.0       100.0       1.0  Resistance
18       10.0  10.0                 1.0          1.0         1.0             1.0        1.0       1.0  Apoptosis
19       10.0  10.0                 1.0          1.0         100.0            10.0       1.0       1.0  Resistance
20       10.0  10.0                 1.0          1.0         1.0             100.0      10.0       1.0  Apoptosis
21       10.0  10.0                 1.0          1.0         10.0            1.0       100.0       1.0  Resistance
22       10.0  10.0                 1.0          1.0         1.0             1.0        1.0       1.0  Apoptosis
23       10.0  10.0                 1.0          1.0         100.0            10.0       1.0       1.0  Resistance
24       10.0  10.0                 1.0          1.0         1.0             100.0      10.0       1.0  Apoptosis
```",0.1281215502085814
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/227b699c2211667c7b8b49d8257286dbd21e1cdc.summary'],Do LLPCs modulate the expression of CXCR4 on bone marrow stromal cells to create a self-sustaining niche that supports their longevity?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan:**

**Objective:** To investigate whether LLPCs modulate the expression of CXCR4 on bone marrow stromal cells to create a self-sustaining niche that supports their longevity.

**Experimental Approach:**

1. **Co-culture System:** Establish a co-culture system using bone marrow stromal cells and LLPCs in a 1:1 ratio.
2. **CXCR4 Modulation:** Treat the co-culture system with a CXCR4-neutralizing antibody to block CXCR4 signaling.
3. **CXCR4 Expression Analysis:** Use flow cytometry to measure the expression of CXCR4 on bone marrow stromal cells in the presence and absence of LLPCs, with and without CXCR4-neutralizing antibody treatment.
4. **LLPC Survival Analysis:** Use cell viability assays (e.g., MTT or Annexin V staining) to measure the survival of LLPCs in the co-culture system with and without CXCR4-neutralizing antibody treatment.
5. **Control Groups:** Include control groups with bone marrow stromal cells alone, LLPCs alone, and a co-culture system without CXCR4-neutralizing antibody treatment.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that LLPCs do not modulate the expression of CXCR4 on bone marrow stromal cells to create a self-sustaining niche that supports their longevity.

**Experimental Design:**

1. **CXCR4 Overexpression:** Transfect bone marrow stromal cells with a CXCR4-overexpressing plasmid to artificially increase CXCR4 expression.
2. **Co-culture System:** Establish a co-culture system using the CXCR4-overexpressing bone marrow stromal cells and LLPCs.
3. **LLPC Survival Analysis:** Measure the survival of LLPCs in the co-culture system using cell viability assays.
4. **Comparison:** Compare the survival of LLPCs in the CXCR4-overexpressing co-culture system to the control co-culture system without CXCR4 overexpression.

**Rationale:** If the hypothesis is true, LLPCs should modulate CXCR4 expression on bone marrow stromal cells to create a self-sustaining niche. However, if CXCR4 is artificially overexpressed on bone marrow stromal cells, LLPCs should not be able to modulate its expression, and their survival should not be affected. If the results show that LLPC survival is not affected by CXCR4 overexpression, it would disprove the hypothesis.

**Timeline and Budget:**

* Experimental setup and co-culture system establishment: 2 weeks
* CXCR4-neutralizing antibody treatment and flow cytometry analysis: 2 weeks
* Cell viability assays and data analysis: 2 weeks
* CXCR4 overexpression and co-culture system establishment: 2 weeks
* LLPC survival analysis and data analysis: 2 weeks

Total duration: 10 weeks

Budget:

* Reagents and consumables: $5,000
* Equipment usage (flow cytometry, cell culture facilities): $3,000
* Personnel (research assistant, technician): $10,000
* Total: $18,000

This experiment can be completed within a reasonable time frame (10 weeks) and budget ($18,000). The results will provide valuable insights into the role of LLPCs in modulating CXCR4 expression on bone marrow stromal cells and their impact on LLPC longevity.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: Co-culture System Establishment**

1.1. Prepare bone marrow stromal cells (BMSCs) and Leukemic Progenitor Cells (LLPCs) according to established protocols.

1.2. Count and adjust the cell concentrations to achieve a 1:1 ratio of BMSCs to LLPCs.

1.3. Mix the cells in a sterile tube and centrifuge at 300 x g for 5 minutes to pellet the cells.

1.4. Resuspend the cell pellet in 10 mL of complete culture medium (e.g., DMEM + 10% FBS + 1% penicillin-streptomycin) and transfer to a 25 cm² tissue culture flask.

1.5. Incubate the co-culture system at 37°C, 5% CO₂ for 24 hours to allow cell attachment and interaction.

**Step 2: CXCR4 Modulation**

2.1. Prepare a CXCR4-neutralizing antibody (e.g., clone 12G5) according to the manufacturer's instructions.

2.2. Add the CXCR4-neutralizing antibody to the co-culture system at a final concentration of 10 μg/mL.

2.3. Incubate the co-culture system for an additional 24 hours to allow for antibody binding and CXCR4 signaling blockade.

**Step 3: CXCR4 Expression Analysis**

3.1. Harvest the co-culture system by centrifugation at 300 x g for 5 minutes.

3.2. Resuspend the cell pellet in 1 mL of flow cytometry buffer (e.g., PBS + 2% FBS + 0.1% NaN₃).

3.3. Stain the cells with a CXCR4-specific antibody (e.g., clone 12G5) and a fluorochrome-conjugated secondary antibody according to the manufacturer's instructions.

3.4. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) to measure CXCR4 expression on BMSCs.

3.5. Record the mean fluorescence intensity (MFI) of CXCR4 expression on BMSCs in the presence and absence of LLPCs, with and without CXCR4-neutralizing antibody treatment.

**Step 4: LLPC Survival Analysis**

4.1. Harvest the co-culture system by centrifugation at 300 x g for 5 minutes.

4.2. Resuspend the cell pellet in 1 mL of complete culture medium.

4.3. Perform a cell viability assay (e.g., MTT or Annexin V staining) according to the manufacturer's instructions to measure LLPC survival.

4.4. Record the percentage of viable LLPCs in the co-culture system with and without CXCR4-neutralizing antibody treatment.

**Step 5: Control Groups**

5.1. Establish control groups with BMSCs alone, LLPCs alone, and a co-culture system without CXCR4-neutralizing antibody treatment.

5.2. Repeat Steps 3 and 4 for each control group.

**Experiment to Disprove the Hypothesis:**

**Step 1: CXCR4 Overexpression**

1.1. Prepare a CXCR4-overexpressing plasmid (e.g., pCMV-CXCR4) according to the manufacturer's instructions.

1.2. Transfect BMSCs with the CXCR4-overexpressing plasmid using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.3. Incubate the transfected BMSCs for 24 hours to allow for plasmid expression.

**Step 2: Co-culture System Establishment**

2.1. Prepare LLPCs according to established protocols.

2.2. Mix the CXCR4-overexpressing BMSCs with LLPCs at a 1:1 ratio.

2.3. Repeat Steps 1.3-1.5 to establish the co-culture system.

**Step 3: LLPC Survival Analysis**

3.1. Repeat Steps 4.1-4.4 to measure LLPC survival in the CXCR4-overexpressing co-culture system.

3.2. Compare the survival of LLPCs in the CXCR4-overexpressing co-culture system to the control co-culture system without CXCR4 overexpression.

**Timeline and Budget:**

* Experimental setup and co-culture system establishment: 2 weeks
* CXCR4-neutralizing antibody treatment and flow cytometry analysis: 2 weeks
* Cell viability assays and data analysis: 2 weeks
* CXCR4 overexpression and co-culture system establishment: 2 weeks
* LLPC survival analysis and data analysis: 2 weeks

Total duration: 10 weeks

Budget:

* Reagents and consumables: $5,000
* Equipment usage (flow cytometry, cell culture facilities): $3,000
* Personnel (research assistant, technician): $10,000
* Total: $18,000","```
   BMSCs  LLPCs  CXCR4_Ab  CXCR4_Plasmid  CXCR4_MFI  LLPC_Survival
0    10000   10000       10.0             0  234.56        75.21
1    12000   12000       12.0             0  201.12        68.53
2     8000    8000        8.0             0  256.78        81.25
3    15000   15000       15.0             0  189.01        65.12
4     9000    9000        9.0             0  242.19        78.56
5    11000   11000       11.0             0  216.34        72.19
6     7000    7000        7.0             0  270.45        84.21
7    13000   13000       13.0             0  204.56        69.85
8    10000   10000        0.0             0  300.00        90.00
9    12000   12000        0.0             0  280.00        85.00
10    8000    8000        0.0             0  320.00        95.00
11   15000   15000        0.0             0  260.00        80.00
12    9000    9000        0.0             0  290.00        88.00
13   11000   11000        0.0             0  270.00        83.00
14    7000    7000        0.0             0  330.00        98.00
15   13000   13000        0.0             0  250.00        78.00
16    10000   10000       10.0             1  180.00        60.00
17    12000   12000       12.0             1  160.00        55.00
18     8000    8000        8.0             1  200.00        65.00
19   15000   15000       15.0             1  140.00        50.00
20     9000    9000        9.0             1  190.00        62.00
21   11000   11000       11.0             1  170.00        58.00
22     7000    7000        7.0             1  210.00        68.00
23   13000   13000       13.0             1  150.00        53.00
24   10000   10000        0.0             1  220.00        70.00
```",0.29069585304611484
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8be7bb72af6d55851dc8b64b8d7eeec4949a01a0.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1cf248c26fbb84c073bf33f9054f008b1c8525d1.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/78ec2425e63ebbfb4c0a9502da60ac772173124f.summary']","Do MAIT cells play a role in the recall of preexisting cross-reactive B cell memory after SARS-CoV-2 breakthrough infection, and does their TNFhigh signature influence the breadth and durability of the resulting neutralizing antibody response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** MAIT cells play a role in the recall of preexisting cross-reactive B cell memory after SARS-CoV-2 breakthrough infection, and their TNFhigh signature influences the breadth and durability of the resulting neutralizing antibody response.

**Experimental Plan:**

**Objective:** To investigate the role of MAIT cells in the recall of preexisting cross-reactive B cell memory and their impact on the neutralizing antibody response after SARS-CoV-2 breakthrough infection.

**Experimental Design:**

1. **Study Population:** Recruit a cohort of individuals with a history of SARS-CoV-2 infection and a confirmed breakthrough infection. Ensure a diverse age range, sex, and ethnicity to minimize bias.
2. **Sample Collection:** Collect blood samples from participants at multiple time points:
	* Pre-breakthrough infection ( baseline)
	* Acute phase of breakthrough infection (days 7-10)
	* Convalescent phase (days 28-30)
	* Long-term follow-up (3-6 months)
3. **MAIT Cell Isolation and Characterization:**
	* Isolate peripheral blood mononuclear cells (PBMCs) from each sample using density gradient centrifugation.
	* Use flow cytometry to identify and sort MAIT cells (CD3+CD161+CD4-CD8-) and assess their TNFhigh signature (TNF-α+).
	* Perform RNA sequencing (RNA-seq) on sorted MAIT cells to analyze gene expression profiles.
4. **B Cell Memory Recall Assay:**
	* Isolate B cells from PBMCs using magnetic bead-based separation.
	* Stimulate B cells with SARS-CoV-2 antigens (e.g., spike protein) and assess their ability to produce antibodies using ELISpot or ELISA.
	* Analyze the breadth and durability of the neutralizing antibody response using pseudovirus neutralization assays.
5. **MAIT Cell Depletion and Reconstitution:**
	* Use CRISPR-Cas9 gene editing to specifically deplete MAIT cells in a subset of participants.
	* Reconstitute MAIT cells in these individuals using autologous MAIT cells with either a TNFhigh or TNFlow signature.
6. **Comparison and Statistical Analysis:**
	* Compare the neutralizing antibody response, B cell memory recall, and MAIT cell gene expression profiles between:
		+ Participants with and without MAIT cell depletion
		+ Participants with TNFhigh vs. TNFlow MAIT cell reconstitution
	* Perform statistical analysis using appropriate tests (e.g., t-tests, ANOVA, regression analysis) to determine the significance of the results.

**Experiment to Disprove the Hypothesis:**

**Objective:** To design an experiment that, if successful, would disprove the hypothesis that MAIT cells play a role in the recall of preexisting cross-reactive B cell memory after SARS-CoV-2 breakthrough infection.

**Experimental Design:**

1. **MAIT Cell Depletion:** Use CRISPR-Cas9 gene editing to deplete MAIT cells in a cohort of participants with a history of SARS-CoV-2 infection.
2. **B Cell Memory Recall Assay:** Stimulate B cells from these participants with SARS-CoV-2 antigens and assess their ability to produce antibodies using ELISpot or ELISA.
3. **Neutralizing Antibody Response:** Analyze the breadth and durability of the neutralizing antibody response using pseudovirus neutralization assays.
4. **Comparison:** Compare the results from the MAIT cell-depleted participants to a control group with intact MAIT cells.

**Expected Outcome:** If the hypothesis is true, the MAIT cell-depleted group should exhibit a significantly impaired neutralizing antibody response and reduced B cell memory recall compared to the control group. If the results show no significant difference between the two groups, it would suggest that MAIT cells do not play a role in the recall of preexisting cross-reactive B cell memory after SARS-CoV-2 breakthrough infection, thereby disproving the hypothesis.

This experimental plan is designed to provide a comprehensive understanding of the role of MAIT cells in the recall of preexisting cross-reactive B cell memory after SARS-CoV-2 breakthrough infection. The unlimited budget allows for the use of cutting-edge techniques, such as CRISPR-Cas9 gene editing and RNA-seq, to ensure the highest level of precision and accuracy in the results.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Study Population Recruitment and Sample Collection**

1.1. Recruit participants with a history of SARS-CoV-2 infection and a confirmed breakthrough infection through online advertisements, social media, and hospital records.

1.2. Ensure a diverse age range, sex, and ethnicity by using stratified sampling and recruiting participants from different demographics.

1.3. Obtain informed consent from each participant and collect demographic information, medical history, and vaccination status.

1.4. Collect blood samples from participants at the following time points:
	* Pre-breakthrough infection (baseline): 10 mL of whole blood in EDTA tubes
	* Acute phase of breakthrough infection (days 7-10): 10 mL of whole blood in EDTA tubes
	* Convalescent phase (days 28-30): 10 mL of whole blood in EDTA tubes
	* Long-term follow-up (3-6 months): 10 mL of whole blood in EDTA tubes

1.5. Label and store the blood samples at -80°C until further processing.

**Protocol 2: MAIT Cell Isolation and Characterization**

2.1. Thaw the frozen blood samples and isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation (e.g., Ficoll-Paque).

2.2. Wash the PBMCs with PBS and resuspend them in 1 mL of PBS.

2.3. Use flow cytometry to identify and sort MAIT cells (CD3+CD161+CD4-CD8-) using the following antibodies:
	* CD3-APC (clone OKT3)
	* CD161-PE (clone 191B8)
	* CD4-FITC (clone RPA-T4)
	* CD8-PerCP (clone SK1)

2.4. Sort MAIT cells into a 1.5 mL tube containing 500 μL of PBS.

2.5. Assess the TNFhigh signature (TNF-α+) of the sorted MAIT cells using intracellular staining with TNF-α-PE (clone MAb11) and flow cytometry.

2.6. Perform RNA sequencing (RNA-seq) on the sorted MAIT cells using a commercial RNA-seq kit (e.g., Illumina TruSeq).

**Protocol 3: B Cell Memory Recall Assay**

3.1. Isolate B cells from PBMCs using magnetic bead-based separation (e.g., Miltenyi Biotec).

3.2. Stimulate the isolated B cells with SARS-CoV-2 antigens (e.g., spike protein) at a concentration of 1 μg/mL for 7 days.

3.3. Assess the ability of the stimulated B cells to produce antibodies using ELISpot or ELISA.

3.4. Analyze the breadth and durability of the neutralizing antibody response using pseudovirus neutralization assays.

**Protocol 4: MAIT Cell Depletion and Reconstitution**

4.1. Use CRISPR-Cas9 gene editing to specifically deplete MAIT cells in a subset of participants.

4.2. Design guide RNAs targeting the CD161 gene and perform CRISPR-Cas9 gene editing using a commercial kit (e.g., CRISPR-Cas9 System from Thermo Fisher).

4.3. Verify MAIT cell depletion using flow cytometry.

4.4. Reconstitute MAIT cells in these individuals using autologous MAIT cells with either a TNFhigh or TNFlow signature.

4.5. Verify the reconstitution of MAIT cells using flow cytometry.

**Protocol 5: Comparison and Statistical Analysis**

5.1. Compare the neutralizing antibody response, B cell memory recall, and MAIT cell gene expression profiles between:
	* Participants with and without MAIT cell depletion
	* Participants with TNFhigh vs. TNFlow MAIT cell reconstitution

5.2. Perform statistical analysis using appropriate tests (e.g., t-tests, ANOVA, regression analysis) to determine the significance of the results.

**Protocol 6: Experiment to Disprove the Hypothesis**

6.1. Use CRISPR-Cas9 gene editing to deplete MAIT cells in a cohort of participants with a history of SARS-CoV-2 infection.

6.2. Stimulate B cells from these participants with SARS-CoV-2 antigens and assess their ability to produce antibodies using ELISpot or ELISA.

6.3. Analyze the breadth and durability of the neutralizing antibody response using pseudovirus neutralization assays.

6.4. Compare the results from the MAIT cell-depleted participants to a control group with intact MAIT cells.

6.5. If the results show no significant difference between the two groups, it would suggest that MAIT cells do not play a role in the recall of preexisting cross-reactive B cell memory after SARS-CoV-2 breakthrough infection, thereby disproving the hypothesis.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the results.","```
   Participant_Age  Participant_Sex  Participant_Ethnicity  Blood_Sample_Timepoint  EDTA_Tubes  PBMCs  CD3_APC  CD161_PE  CD4_FITC  CD8_PerCP  TNF_alpha_PE  RNA_Seq  B_Cell_Stimulation  Antibody_Production  Pseudovirus_Neutralization  MAIT_Cell_Depletion  CRISPR_Cas9  Guide_RNAs  MAIT_Cell_Reconstitution  TNFhigh_Signature  Outcome
0              35           Male               Caucasian            Pre-breakthrough          10mL     1e6      1000       500       2000       1500          800        1000            1ug/mL             1000               80%                No           No          No               No              No         Positive
1              40           Female             African American            Acute_phase          10mL     1.2e6      1200       600       2400       1800          900        1200            1.5ug/mL             1200               90%                No           No          No               No              No         Positive
2              25           Male               Asian            Convalescent_phase          10mL     1.5e6      1500       750       3000       2200         1000        1500            2ug/mL             1500               95%                No           No          No               No              No         Positive
3              50           Female             Caucasian            Long-term_follow-up          10mL     1.8e6      1800       900       3600       2500         1100        1800            2.5ug/mL             1800               98%                No           No          No               No              No         Positive
4              30           Male               African American            Pre-breakthrough          10mL     1.1e6      1100       550       2200       1600          850        1100            1.2ug/mL             1100               85%                Yes          Yes         Yes               Yes              Yes         Negative
5              45           Female             Asian            Acute_phase          10mL     1.4e6      1400       700       2800       2000         1000        1400            1.8ug/mL             1400               92%                Yes          Yes         Yes               Yes              Yes         Negative
6              20           Male               Caucasian            Convalescent_phase          10mL     1.6e6      1600       800       3200       2300         1050        1600            2.2ug/mL             1600               96%                Yes          Yes         Yes               Yes              Yes         Negative
7              55           Female             African American            Long-term_follow-up          10mL     2e6      2000      1000       4000       2800         1200        2000            3ug/mL             2000               99%                Yes          Yes         Yes               Yes              Yes         Negative
8              38           Male               Asian            Pre-breakthrough          10mL     1.3e6      1300       650       2600       1900          950        1300            1.6ug/mL             1300               88%                No           No          No               No              No         Positive
9              42           Female             Caucasian            Acute_phase          10mL     1.7e6      1700       850       3400       2400         1100        1700            2.4ug/mL             1700               94%                No           No          No               No              No         Positive
10             28           Male               African American            Convalescent_phase          10mL     1.9e6      1900      1000       3800       2600         1150        1900            2.8ug/mL             1900               97%                No           No          No               No              No         Positive
11             48           Female             Asian            Long-term_follow-up          10mL     2.1e6      2100      1100       4200       2900         1250        2100            3.2ug/mL             2100               99%                No           No          No               No              No         Positive
12             32           Male               Caucasian            Pre-breakthrough          10mL     1.2e6      1200       600       2400       1800          900        1200            1.5ug/mL             1200               90%                Yes          Yes         Yes               Yes              Yes         Negative
13             39           Female             African American            Acute_phase          10mL     1.6e6      1600       800       3200       2300         1050        1600            2.2ug/mL             1600               96%                Yes          Yes         Yes               Yes              Yes         Negative
14             24           Male               Asian            Convalescent_phase          10mL     1.8e6      1800       900       3600       2500         1100        1800            2.5ug/mL             1800               98%                Yes          Yes         Yes               Yes              Yes         Negative
15             51           Female             Caucasian            Long-term_follow-up          10mL     2.2e6      2200      1200       4400       3000         1300        2200            3.5ug/mL             2200               99%                Yes          Yes         Yes               Yes              Yes         Negative
16             36           Male               African American            Pre-breakthrough          10mL     1.4e6      1400       700       2800       2000         1000        1400            1.8ug/mL             1400               92%                No           No          No               No              No         Positive
17             44           Female             Asian            Acute_phase          10mL     1.9e6      1900      1000       3800       2600         1150        1900            2.8ug/mL             1900               97%                No           No          No               No              No         Positive
18             29           Male               Caucasian            Convalescent_phase          10mL     2e6      2000      1000       4000       2800         1200        2000            3ug/mL             2000               99%                No           No          No               No              No         Positive
19             46           Female             African American            Long-term_follow-up          10mL     2.3e6      2300      1300       4600       3100         1350        2300            3.8ug/mL             2300               99%                No           No          No               No              No         Positive
20             33           Male               Asian            Pre-breakthrough          10mL     1.5e6      1500       750       3000       2200         1000        1500            2ug/mL             1500               95%                Yes          Yes         Yes               Yes              Yes         Negative
21             41           Female             Caucasian            Acute_phase          10mL     1.8e6      1800       900       3600       2500         1100        1800            2.5ug/mL             1800               98%                Yes          Yes         Yes               Yes              Yes         Negative
22             26           Male               African American            Convalescent_phase          10mL     2e6      2000      1000       4000       2800         1200        2000            3ug/mL             2000               99%                Yes          Yes         Yes               Yes              Yes         Negative
23             49           Female             Asian            Long-term_follow-up          10mL     2.4e6      2400      1400       4800       3200         1400        2400            4ug/mL             2400               99%                Yes          Yes         Yes               Yes              Yes         Negative
24             34           Male               Caucasian            Pre-breakthrough          10mL     1.6e6      1600       800       3200       2300         1050        1600            2.2ug/mL             1600               96%                No           No          No               No              No         Positive",0.28062917985427777
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0700a8f8c0a424665e9f40779cd848b5aad8b443.summary'],"Do Min pigs' enhanced immune responses to pathogens also lead to increased production of antimicrobial peptides, which could contribute to their disease resistance?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** Do Min pigs' enhanced immune responses to pathogens also lead to increased production of antimicrobial peptides, which could contribute to their disease resistance?

**Experimental Plan:**

**Objective:** To investigate whether Min pigs' enhanced immune responses to pathogens result in increased production of antimicrobial peptides, contributing to their disease resistance.

**Experimental Design:**

1. **Animal Selection:** Obtain a group of Min pigs and a control group of conventional pigs (e.g., Yorkshire or Landrace).
2. **Pathogen Challenge:** Infect both groups with a well-characterized pathogen (e.g., Salmonella Typhimurium or Pseudomonas aeruginosa) using a standardized inoculation protocol.
3. **Sample Collection:** Collect blood and tissue samples (e.g., spleen, liver, and lung) from both groups at multiple time points post-infection (e.g., 1, 3, 7, and 14 days).
4. **Antimicrobial Peptide Analysis:** Measure the expression levels of antimicrobial peptides (e.g., cathelicidins, defensins, and cecropins) in the collected samples using techniques such as:
	* Real-time PCR (qRT-PCR) to quantify mRNA levels.
	* Enzyme-linked immunosorbent assay (ELISA) or Western blot to measure protein levels.
5. **Immune Response Analysis:** Assess the immune response in both groups by:
	* Measuring cytokine levels (e.g., IL-1β, IL-6, TNF-α) in serum and tissue samples using ELISA or multiplex assays.
	* Analyzing immune cell populations (e.g., neutrophils, macrophages, T cells) in blood and tissue samples using flow cytometry.
6. **Disease Resistance Assessment:** Monitor the animals for signs of disease (e.g., fever, weight loss, diarrhea) and measure the bacterial load in tissues and organs.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on finding evidence that Min pigs do not produce more antimicrobial peptides in response to pathogen challenge, despite their enhanced immune response.

**Null Hypothesis:** Min pigs do not produce more antimicrobial peptides than conventional pigs in response to pathogen challenge.

**Alternative Experimental Design:**

1. **Antimicrobial Peptide Inhibition:** Use a specific inhibitor of antimicrobial peptide production (e.g., a cathelicidin inhibitor) in Min pigs before pathogen challenge.
2. **Immune Response Modulation:** Use immunomodulatory agents (e.g., anti-inflammatory cytokines or immunosuppressive drugs) to dampen the immune response in Min pigs before pathogen challenge.
3. **Antimicrobial Peptide Depletion:** Use RNA interference (RNAi) or CRISPR-Cas9 gene editing to specifically knockdown or knockout antimicrobial peptide genes in Min pigs before pathogen challenge.

**Expected Outcomes:**

* If the hypothesis is true, Min pigs will show increased antimicrobial peptide production, enhanced immune responses, and improved disease resistance compared to conventional pigs.
* If the null hypothesis is true, Min pigs will not produce more antimicrobial peptides than conventional pigs, and their disease resistance will not be significantly different.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a moderate budget (approximately $200,000-$500,000). The budget will cover:

* Animal costs (pigs, housing, and care)
* Reagents and consumables (e.g., PCR primers, ELISA kits, antibodies)
* Equipment and instrumentation (e.g., qRT-PCR machine, flow cytometer)
* Personnel costs (researcher, technician, and animal care staff)

By following this experimental plan, we can test the hypothesis and determine whether Min pigs' enhanced immune responses to pathogens are indeed linked to increased production of antimicrobial peptides, contributing to their disease resistance.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Animal Selection and Housing**

1.1. Obtain a group of 10-12 Min pigs (e.g., from a reputable breeder or supplier) and a control group of 10-12 conventional pigs (e.g., Yorkshire or Landrace).

1.2. Ensure all pigs are healthy, 6-8 weeks old, and weigh between 10-15 kg.

1.3. House the pigs in a controlled environment with a 12-hour light-dark cycle, temperature range of 20-25°C, and humidity of 50-60%.

1.4. Provide ad libitum access to food and water, and ensure the diet is nutritionally balanced and free of antibiotics.

**Protocol 2: Pathogen Challenge**

2.1. Prepare a standardized inoculum of Salmonella Typhimurium or Pseudomonas aeruginosa (e.g., 10^8 CFU/mL) in sterile phosphate-buffered saline (PBS).

2.2. Infect both groups of pigs via oral gavage or intranasal instillation with 1 mL of the inoculum.

2.3. Monitor the pigs for signs of disease (e.g., fever, weight loss, diarrhea) and record any adverse reactions.

**Protocol 3: Sample Collection**

3.1. Collect blood samples (5 mL) from the jugular vein of each pig at 1, 3, 7, and 14 days post-infection using a sterile needle and syringe.

3.2. Collect tissue samples (e.g., spleen, liver, and lung) from each pig at 1, 3, 7, and 14 days post-infection using aseptic techniques.

3.3. Store blood samples in EDTA-coated tubes and tissue samples in RNA later or frozen at -80°C for later analysis.

**Protocol 4: Antimicrobial Peptide Analysis**

4.1. Extract RNA from tissue samples using a commercial RNA extraction kit (e.g., TRIzol) and quantify using a spectrophotometer.

4.2. Perform real-time PCR (qRT-PCR) using specific primers for cathelicidins, defensins, and cecropins to quantify mRNA levels.

4.3. Analyze protein levels using ELISA or Western blot with specific antibodies against antimicrobial peptides.

**Protocol 5: Immune Response Analysis**

5.1. Measure cytokine levels (e.g., IL-1β, IL-6, TNF-α) in serum and tissue samples using ELISA or multiplex assays.

5.2. Analyze immune cell populations (e.g., neutrophils, macrophages, T cells) in blood and tissue samples using flow cytometry.

**Protocol 6: Disease Resistance Assessment**

6.1. Monitor the pigs for signs of disease (e.g., fever, weight loss, diarrhea) and record any adverse reactions.

6.2. Measure the bacterial load in tissues and organs using quantitative PCR or culture-based methods.

**Protocol 7: Data Analysis**

7.1. Compare the expression levels of antimicrobial peptides, cytokine levels, and immune cell populations between Min pigs and conventional pigs.

7.2. Analyze the correlation between antimicrobial peptide production and disease resistance in Min pigs.

7.3. Perform statistical analysis using appropriate software (e.g., GraphPad Prism, R) to determine significance (p < 0.05).

**Alternative Experimental Design Protocols**

**Protocol 8: Antimicrobial Peptide Inhibition**

8.1. Administer a specific inhibitor of antimicrobial peptide production (e.g., a cathelicidin inhibitor) to Min pigs 24 hours before pathogen challenge.

8.2. Monitor the pigs for signs of disease and collect samples as described in Protocols 3-6.

**Protocol 9: Immune Response Modulation**

9.1. Administer immunomodulatory agents (e.g., anti-inflammatory cytokines or immunosuppressive drugs) to Min pigs 24 hours before pathogen challenge.

9.2. Monitor the pigs for signs of disease and collect samples as described in Protocols 3-6.

**Protocol 10: Antimicrobial Peptide Depletion**

10.1. Use RNA interference (RNAi) or CRISPR-Cas9 gene editing to specifically knockdown or knockout antimicrobial peptide genes in Min pigs before pathogen challenge.

10.2. Monitor the pigs for signs of disease and collect samples as described in Protocols 3-6.

These detailed protocols should provide a clear guide for executing the experiment and testing the hypothesis.","```
   Min_pigs  Conventional_pigs  Salmonella_Typhimurium  Pseudomonas_aeruginosa  Inhibitor  Immunomodulatory_Agent  RNAi_CRISPR  Outcome
0         10                10                10^8                  0.0         0.0                0.0         0.0  Resistant
1         12                10                10^7                  0.0         0.0                0.0         0.0  Susceptible
2         11                11                10^8                  0.0         0.0                0.0         0.0  Resistant
3         10                12                10^7                  0.0         0.0                0.0         0.0  Susceptible
4         10                10                10^8                  1.0         0.0                0.0         0.0  Susceptible
5         12                10                10^7                  0.0         1.0                0.0         0.0  Resistant
6         11                11                10^8                  0.0         0.0                1.0         0.0  Susceptible
7         10                12                10^7                  0.0         0.0                0.0         1.0  Resistant
8         10                10                10^8                  1.0         1.0                0.0         0.0  Susceptible
9         12                10                10^7                  0.0         0.0                1.0         1.0  Resistant
10        11                11                10^8                  1.0         0.0                1.0         0.0  Susceptible
11        10                12                10^7                  0.0         1.0                0.0         1.0  Resistant
12        10                10                10^8                  1.0         1.0                1.0         0.0  Susceptible
13        12                10                10^7                  0.0         0.0                1.0         1.0  Resistant
14        11                11                10^8                  1.0         1.0                1.0         1.0  Susceptible
15        10                12                10^7                  1.0         0.0                0.0         1.0  Resistant
16        10                10                10^8                  0.0         1.0                1.0         1.0  Susceptible
17        12                10                10^7                  1.0         1.0                0.0         1.0  Resistant
18        11                11                10^8                  0.0         1.0                1.0         1.0  Susceptible
19        10                12                10^7                  1.0         1.0                1.0         1.0  Resistant
20        10                10                10^8                  1.0         1.0                1.0         1.0  Susceptible
21        12                10                10^7                  1.0         1.0                1.0         1.0  Resistant
22        11                11                10^8                  1.0         1.0                1.0         1.0  Susceptible
23        10                12                10^7                  1.0         1.0                1.0         1.0  Resistant
24        10                10                10^8                  1.0         1.0                1.0         1.0  Susceptible
```",0.11987466934925257
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9beec80d1eac382f0427807cacfe24a25db374b7.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f8f9ee8cf4553a0dcac921e0e713fb4c4592adf0.summary']","Do MuSK autoantibodies modulate the expression of neonatal Fc receptor on B cells, thereby influencing the pathogenesis of MuSK-positive Myasthenia Gravis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, ""Do MuSK autoantibodies modulate the expression of neonatal Fc receptor on B cells, thereby influencing the pathogenesis of MuSK-positive Myasthenia Gravis?"", I propose the following experimental plan to test this hypothesis:

**Experiment:** ""Investigating the effect of MuSK autoantibodies on neonatal Fc receptor expression on B cells in MuSK-positive Myasthenia Gravis""

**Objective:** To determine whether MuSK autoantibodies modulate the expression of neonatal Fc receptor on B cells, and if so, how this modulation contributes to the pathogenesis of MuSK-positive Myasthenia Gravis.

**Experimental Design:**

1. **Cell isolation and culture:** Isolate B cells from peripheral blood mononuclear cells (PBMCs) of MuSK-positive Myasthenia Gravis patients using magnetic bead-based separation or fluorescence-activated cell sorting (FACS). Culture the isolated B cells in vitro with or without MuSK autoantibodies.
2. **MuSK autoantibody treatment:** Treat the cultured B cells with different concentrations of MuSK autoantibodies (e.g., 1, 10, and 100 μg/mL) for various time periods (e.g., 24, 48, and 72 hours).
3. **Neonatal Fc receptor expression analysis:** Use flow cytometry or Western blotting to analyze the expression of neonatal Fc receptor on the surface of B cells. Measure the mean fluorescence intensity (MFI) or protein levels of neonatal Fc receptor in the presence and absence of MuSK autoantibodies.
4. **Control experiments:** Include control experiments with isotype-matched antibodies or irrelevant antibodies to rule out non-specific effects.
5. **Replication and validation:** Repeat the experiment with multiple patient samples and different MuSK autoantibody clones to confirm the results.

**To disprove the hypothesis:**

**Experiment:** ""Investigating the effect of MuSK autoantibodies on neonatal Fc receptor expression on B cells in MuSK-positive Myasthenia Gravis: A blocking experiment""

**Objective:** To determine whether blocking the interaction between MuSK autoantibodies and B cells prevents the modulation of neonatal Fc receptor expression.

**Experimental Design:**

1. **Cell isolation and culture:** Isolate B cells from PBMCs of MuSK-positive Myasthenia Gravis patients as described above.
2. **MuSK autoantibody blocking:** Pre-treat the B cells with a blocking antibody against the MuSK autoantibody-binding site on B cells (e.g., an anti-Fc receptor antibody) before adding MuSK autoantibodies.
3. **MuSK autoantibody treatment:** Add MuSK autoantibodies to the pre-treated B cells and incubate for the same time periods as in the initial experiment.
4. **Neonatal Fc receptor expression analysis:** Analyze the expression of neonatal Fc receptor on the surface of B cells using flow cytometry or Western blotting.
5. **Comparison:** Compare the neonatal Fc receptor expression levels in the presence and absence of the blocking antibody.

**Expected outcome:** If the hypothesis is true, blocking the interaction between MuSK autoantibodies and B cells should prevent the modulation of neonatal Fc receptor expression. If the hypothesis is false, blocking the interaction should not affect neonatal Fc receptor expression.

**Equipment and resources:**

* Cell culture facilities
* Flow cytometer
* Western blotting equipment
* Antibodies against neonatal Fc receptor, MuSK, and isotype-matched controls
* MuSK autoantibodies
* Blocking antibodies against the MuSK autoantibody-binding site on B cells
* PBMCs from MuSK-positive Myasthenia Gravis patients

This experimental design should provide a comprehensive understanding of the relationship between MuSK autoantibodies and neonatal Fc receptor expression on B cells in MuSK-positive Myasthenia Gravis.",85,"Here are the detailed, step-by-step protocols for the experiments outlined in the plan:

**Experiment 1: Investigating the effect of MuSK autoantibodies on neonatal Fc receptor expression on B cells in MuSK-positive Myasthenia Gravis**

**Step 1: Cell isolation and culture**

1.1. Obtain PBMCs from MuSK-positive Myasthenia Gravis patients through venipuncture or other approved methods.

1.2. Isolate B cells from PBMCs using magnetic bead-based separation or fluorescence-activated cell sorting (FACS) according to the manufacturer's instructions.

1.3. Culture the isolated B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

**Step 2: MuSK autoantibody treatment**

2.1. Prepare MuSK autoantibody stock solutions at concentrations of 1, 10, and 100 μg/mL in PBS.

2.2. Add the MuSK autoantibody stock solutions to the cultured B cells at the desired concentrations (1, 10, and 100 μg/mL) and incubate for 24, 48, and 72 hours.

2.3. Include control wells with isotype-matched antibodies or irrelevant antibodies at the same concentrations to rule out non-specific effects.

**Step 3: Neonatal Fc receptor expression analysis**

3.1. Harvest the B cells after the incubation period and wash them twice with PBS.

3.2. Stain the B cells with a fluorescently labeled antibody against neonatal Fc receptor (e.g., PE-conjugated anti-neonatal Fc receptor antibody) according to the manufacturer's instructions.

3.3. Analyze the stained B cells using flow cytometry to measure the mean fluorescence intensity (MFI) of neonatal Fc receptor.

3.4. Alternatively, perform Western blotting to analyze the protein levels of neonatal Fc receptor.

**Step 4: Replication and validation**

4.1. Repeat the experiment with multiple patient samples to ensure reproducibility.

4.2. Use different MuSK autoantibody clones to confirm the results.

**Experiment 2: Investigating the effect of MuSK autoantibodies on neonatal Fc receptor expression on B cells in MuSK-positive Myasthenia Gravis: A blocking experiment**

**Step 1: Cell isolation and culture**

1.1. Isolate B cells from PBMCs of MuSK-positive Myasthenia Gravis patients as described in Experiment 1.

**Step 2: MuSK autoantibody blocking**

2.1. Prepare a blocking antibody against the MuSK autoantibody-binding site on B cells (e.g., an anti-Fc receptor antibody) at a concentration of 10 μg/mL in PBS.

2.2. Pre-treat the B cells with the blocking antibody for 30 minutes at 4°C.

**Step 3: MuSK autoantibody treatment**

3.1. Add MuSK autoantibodies to the pre-treated B cells at concentrations of 1, 10, and 100 μg/mL and incubate for 24, 48, and 72 hours.

**Step 4: Neonatal Fc receptor expression analysis**

4.1. Analyze the expression of neonatal Fc receptor on the surface of B cells using flow cytometry or Western blotting as described in Experiment 1.

**Step 5: Comparison**

5.1. Compare the neonatal Fc receptor expression levels in the presence and absence of the blocking antibody.

**Equipment and resources:**

* Cell culture facilities
* Flow cytometer
* Western blotting equipment
* Antibodies against neonatal Fc receptor, MuSK, and isotype-matched controls
* MuSK autoantibodies
* Blocking antibodies against the MuSK autoantibody-binding site on B cells
* PBMCs from MuSK-positive Myasthenia Gravis patients

These detailed protocols should provide a clear guide for executing the experiments and ensuring replicability and specificity in the results.","```
   MuSK Autoantibody (μg/mL)  Blocking Antibody (μg/mL)  Incubation Time (hours)  Neonatal Fc Receptor MFI
0                       1.0                     0.0                  24.0           234.21
1                      10.0                     0.0                  24.0           198.56
2                     100.0                     0.0                  24.0           145.12
3                       1.0                     0.0                  48.0           201.34
4                      10.0                     0.0                  48.0           165.78
5                     100.0                     0.0                  48.0           120.56
6                       1.0                     0.0                  72.0           180.12
7                      10.0                     0.0                  72.0           140.90
8                     100.0                     0.0                  72.0           100.23
9                       1.0                    10.0                  24.0           220.56
10                     10.0                    10.0                  24.0           185.12
11                    100.0                    10.0                  24.0           150.78
12                      1.0                    10.0                  48.0           190.34
13                     10.0                    10.0                  48.0           155.56
14                    100.0                    10.0                  48.0           120.12
15                      1.0                    10.0                  72.0           160.90
16                     10.0                    10.0                  72.0           130.23
17                    100.0                    10.0                  72.0           100.56
18                      1.0                     0.0                  24.0           230.12
19                     10.0                     0.0                  24.0           195.78
20                    100.0                     0.0                  24.0           140.34
21                      1.0                     0.0                  48.0           200.56
22                     10.0                     0.0                  48.0           170.12
23                    100.0                     0.0                  48.0           125.90
24                      1.0                     0.0                  72.0           175.23
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0b3d263c81fd58b48d55c4f6d57bdf11b410643c.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8c5ff5091d5ce0b74b991e962e37f0226e6f3ca0.summary']",Do NF-κB target genes regulate the stochastic gene expression patterns that influence B cell fate decisions in germinal centers?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test whether NF-κB target genes regulate stochastic gene expression patterns that influence B cell fate decisions in germinal centers, I've outlined a comprehensive experimental plan. This plan leverages existing scientific methods and equipment, assuming an unlimited budget in terms of time, resources, and financial support.

**Hypothesis:** NF-κB target genes regulate stochastic gene expression patterns that influence B cell fate decisions in germinal centers.

**Experimental Plan:**

**Objective 1: Identify NF-κB target genes in germinal center B cells**

1.1. **Cell isolation and sorting**: Isolate germinal center B cells from mouse spleens using fluorescence-activated cell sorting (FACS) based on surface markers (e.g., CD19, CD38, GL7).

1.2. **ChIP-seq**: Perform chromatin immunoprecipitation sequencing (ChIP-seq) using an NF-κB p65 antibody to identify NF-κB binding sites in the genome of germinal center B cells.

1.3. **RNA-seq**: Perform RNA sequencing (RNA-seq) on germinal center B cells to identify genes that are differentially expressed in response to NF-κB activation.

1.4. **Integrate ChIP-seq and RNA-seq data**: Use bioinformatic tools (e.g., ChIPseeker, HOMER) to identify genes with NF-κB binding sites that are also differentially expressed in response to NF-κB activation.

**Objective 2: Investigate the role of NF-κB target genes in regulating stochastic gene expression patterns**

2.1. **CRISPR-Cas9 genome editing**: Use CRISPR-Cas9 to knockout or knockdown selected NF-κB target genes in germinal center B cells.

2.2. **Single-cell RNA-seq**: Perform single-cell RNA-seq on edited germinal center B cells to analyze stochastic gene expression patterns.

2.3. **Computational analysis**: Use computational tools (e.g., Monocle, Seurat) to identify changes in stochastic gene expression patterns and correlate them with B cell fate decisions (e.g., plasma cell differentiation, memory B cell formation).

**Objective 3: Determine the impact of NF-κB target genes on B cell fate decisions**

3.1. **In vitro B cell differentiation assays**: Use in vitro B cell differentiation assays (e.g., ELISA, flow cytometry) to assess the effect of NF-κB target gene knockout/knockdown on B cell fate decisions.

3.2. **In vivo adoptive transfer experiments**: Perform adoptive transfer experiments in mice to assess the impact of NF-κB target gene knockout/knockdown on B cell fate decisions in vivo.

**Objective 4: Validate findings using orthogonal approaches**

4.1. **siRNA-mediated knockdown**: Validate findings using siRNA-mediated knockdown of NF-κB target genes in germinal center B cells.

4.2. **Overexpression of NF-κB target genes**: Overexpress NF-κB target genes in germinal center B cells to assess the effect on stochastic gene expression patterns and B cell fate decisions.

**Additional Considerations:**

* Use appropriate controls and replicates throughout the experiment.
* Validate the specificity of CRISPR-Cas9 editing using sequencing and functional assays.
* Consider using single-molecule RNA FISH to visualize stochastic gene expression patterns in individual cells.
* Perform experiments in multiple mouse strains and/or human samples to ensure generalizability of findings.

This experimental plan provides a comprehensive approach to test the hypothesis that NF-κB target genes regulate stochastic gene expression patterns that influence B cell fate decisions in germinal centers. With unlimited resources, this plan can be executed in a laboratory setting to generate high-quality data and provide insights into the complex regulation of B cell fate decisions.",92,"Here are the detailed, step-by-step protocols for each objective:

**Objective 1: Identify NF-κB target genes in germinal center B cells**

**Protocol 1.1: Cell isolation and sorting**

1. Obtain mouse spleens from a reliable source (e.g., Jackson Laboratory).
2. Prepare a single-cell suspension of spleen cells using a gentle dissociation method (e.g., mechanical dissociation using a gentleMACS Dissociator).
3. Stain the cells with fluorescently labeled antibodies against CD19, CD38, and GL7 (e.g., CD19-PE, CD38-APC, GL7-FITC) according to the manufacturer's instructions.
4. Perform fluorescence-activated cell sorting (FACS) using a high-speed cell sorter (e.g., BD FACSAria III) to isolate germinal center B cells based on the following gating strategy:
	* Gate on live cells using forward and side scatter.
	* Gate on CD19+ cells.
	* Gate on CD38-GL7+ cells.
5. Collect the sorted cells in a sterile tube containing RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.
6. Count the cells using a hemocytometer or an automated cell counter.

**Protocol 1.2: ChIP-seq**

1. Prepare chromatin from 1-2 million sorted germinal center B cells using a chromatin preparation kit (e.g., Diagenode Chromatin Preparation Kit).
2. Perform chromatin immunoprecipitation (ChIP) using an NF-κB p65 antibody (e.g., Abcam ab16502) and a ChIP-grade protein A/G magnetic bead (e.g., Diagenode).
3. Wash the beads according to the manufacturer's instructions and elute the immunoprecipitated chromatin using a ChIP elution buffer (e.g., Diagenode).
4. Purify the eluted chromatin using a DNA purification kit (e.g., Qiagen QIAquick PCR Purification Kit).
5. Prepare sequencing libraries using a ChIP-seq library preparation kit (e.g., Illumina TruSeq ChIP Library Prep Kit).
6. Sequence the libraries on a high-throughput sequencing platform (e.g., Illumina HiSeq 4000).

**Protocol 1.3: RNA-seq**

1. Isolate total RNA from 1-2 million sorted germinal center B cells using a RNA isolation kit (e.g., Qiagen RNeasy Mini Kit).
2. Prepare sequencing libraries using a RNA-seq library preparation kit (e.g., Illumina TruSeq RNA Library Prep Kit).
3. Sequence the libraries on a high-throughput sequencing platform (e.g., Illumina HiSeq 4000).

**Protocol 1.4: Integrate ChIP-seq and RNA-seq data**

1. Map the ChIP-seq reads to the mouse genome (e.g., mm10) using a read alignment tool (e.g., Bowtie2).
2. Identify NF-κB binding sites using a peak calling tool (e.g., MACS2).
3. Map the RNA-seq reads to the mouse genome (e.g., mm10) using a read alignment tool (e.g., STAR).
4. Identify differentially expressed genes using a differential expression analysis tool (e.g., DESeq2).
5. Use bioinformatic tools (e.g., ChIPseeker, HOMER) to identify genes with NF-κB binding sites that are also differentially expressed in response to NF-κB activation.

**Objective 2: Investigate the role of NF-κB target genes in regulating stochastic gene expression patterns**

**Protocol 2.1: CRISPR-Cas9 genome editing**

1. Design guide RNAs (gRNAs) targeting the selected NF-κB target genes using a CRISPR design tool (e.g., CRISPR Design).
2. Prepare CRISPR-Cas9 ribonucleoproteins (RNPs) using a CRISPR-Cas9 kit (e.g., IDT Alt-R CRISPR-Cas9 System).
3. Electroporate the RNPs into germinal center B cells using a nucleofector (e.g., Lonza 4D-Nucleofector).
4. Culture the edited cells in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

**Protocol 2.2: Single-cell RNA-seq**

1. Prepare single-cell suspensions of edited germinal center B cells using a gentle dissociation method (e.g., mechanical dissociation using a gentleMACS Dissociator).
2. Stain the cells with a live/dead marker (e.g., DAPI) and a surface marker (e.g., CD19-PE).
3. Perform single-cell RNA-seq using a droplet-based platform (e.g., 10x Genomics Chromium System).
4. Sequence the libraries on a high-throughput sequencing platform (e.g., Illumina HiSeq 4000).

**Protocol 2.3: Computational analysis**

1. Map the single-cell RNA-seq reads to the mouse genome (e.g., mm10) using a read alignment tool (e.g., STAR).
2. Perform clustering and dimensionality reduction using a single-cell analysis tool (e.g., Seurat).
3. Identify changes in stochastic gene expression patterns and correlate them with B cell fate decisions using a computational tool (e.g., Monocle).

**Objective 3: Determine the impact of NF-κB target genes on B cell fate decisions**

**Protocol 3.1: In vitro B cell differentiation assays**

1. Culture edited germinal center B cells in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.
2. Add differentiation factors (e.g., IL-4, IL-21) to the culture medium to induce plasma cell differentiation or memory B cell formation.
3. Analyze the cells using ELISA (e.g., IgG1, IgM) and flow cytometry (e.g., CD138, CD27).

**Protocol 3.2: In vivo adoptive transfer experiments**

1. Prepare edited germinal center B cells for adoptive transfer by labeling them with a fluorescent dye (e.g., CFSE).
2. Transfer the labeled cells into recipient mice via intravenous injection.
3. Analyze the cells in the recipient mice using flow cytometry and ELISA.

**Objective 4: Validate findings using orthogonal approaches**

**Protocol 4.1: siRNA-mediated knockdown**

1. Design siRNAs targeting the selected NF-κB target genes using a siRNA design tool (e.g., Dharmacon siDESIGN).
2. Transfect the siRNAs into germinal center B cells using a transfection reagent (e.g., Lipofectamine RNAiMAX).
3. Analyze the cells using qRT-PCR and Western blot to validate the knockdown.

**Protocol 4.2: Overexpression of NF-κB target genes**

1. Clone the NF-κB target genes into a mammalian expression vector (e.g., pCMV6).
2. Transfect the expression vector into germinal center B cells using a transfection reagent (e.g., Lipofectamine 3000).
3. Analyze the cells using qRT-PCR and Western blot to validate the overexpression.

**Additional Considerations**

* Use appropriate controls and replicates throughout the experiment.
* Validate the specificity of CRISPR-Cas9 editing using sequencing and functional assays.
* Consider using single-molecule RNA FISH to visualize stochastic gene expression patterns in individual cells.
* Perform experiments in multiple mouse strains and/or human samples to ensure generalizability of findings.","```
   Mouse_Spleens  CD19_Antibody  CD38_Antibody  GL7_Antibody  NFkB_p65_Antibody  ChIP_Seq_Reads  RNA_Seq_Reads  CRISPR_Cas9_RNPs  Single_Cell_RNA_Seq_Reads  IL4_Concentration  IL21_Concentration  Outcome
0             2.0           1.5           1.0           1.5               2.0         1000000         5000000               1.0                    2000000             10.0             20.0  Positive
1             1.5           1.0           1.5           2.0               1.5          800000         4000000               0.8                    1800000             12.0             18.0  Negative
2             2.5           2.0           1.0           1.0               2.5         1200000         6000000               1.2                    2200000             11.0             19.0  Positive
3             1.0           1.5           2.0           1.5               1.0          900000         4500000               0.9                    1900000             13.0             17.0  Negative
4             2.0           1.0           1.5           2.0               2.0         1100000         5500000               1.1                    2100000             10.0             20.0  Positive
5             1.8           1.2           1.8           1.2               1.8         1000000         5000000               1.0                    2000000             11.0             19.0  Positive
6             2.2           1.8           1.2           1.8               2.2         1200000         6000000               1.2                    2200000             12.0             18.0  Positive
7             1.2           1.5           1.0           1.5               1.2          800000         4000000               0.8                    1800000             13.0             17.0  Negative
8             2.5           2.2           1.0           1.0               2.5         1300000         6500000               1.3                    2300000             10.0             20.0  Positive
9             1.0           1.2           2.2           1.2               1.0          900000         4500000               0.9                    1900000             12.0             18.0  Negative
10            2.0           1.8           1.2           1.8               2.0         1100000         5500000               1.1                    2100000             11.0             19.0  Positive
11            1.5           1.0           1.8           1.2               1.5          850000         4250000               0.9                    1850000             13.0             17.0  Negative
12            2.2           2.0           1.0           1.0               2.2         1250000         6250000               1.2                    2250000             10.0             20.0  Positive
13            1.2           1.2           2.0           1.5               1.2          950000         4750000               0.9                    1950000             12.0             18.0  Negative
14            2.5           2.5           1.0           1.0               2.5         1350000         6750000               1.3                    2350000             11.0             19.0  Positive
15            1.0           1.5           2.5           1.2               1.0         1000000         5000000               1.0                    2000000             13.0             17.0  Negative
16            2.0           2.2           1.2           1.8               2.0         1150000         5750000               1.1                    2150000             10.0             20.0  Positive
17            1.8           1.0           1.5           1.2               1.8          850000         4250000               0.9                    1850000             12.0             18.0  Negative
18            2.2           2.5           1.0           1.0               2.2         1300000         6500000               1.2                    2300000             11.0             19.0  Positive
19            1.2           1.8           2.2           1.5               1.2          900000         4500000               0.9                    1900000             13.0             17.0  Negative
20            2.5           2.0           1.2           1.8               2.5         1400000         7000000               1.3                    2400000             10.0             20.0  Positive
21            1.0           1.2           2.5           1.2               1.0         1000000         5000000               1.0                    2000000             12.0             18.0  Negative
22            2.0           2.5           1.5           1.2               2.0         1200000         6000000               1.1                    2200000             11.0             19.0  Positive
23            1.5           1.0           1.2           1.5               1.5          800000         4000000               0.8                    1800000             13.0             17.0  Negative
24            2.2           2.2           1.0           1.0               2.2         1250000         6250000               1.2                    2250000             10.0             20.0  Positive
```",0.46180121515787326
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ca4e803aae33c69c832fc5cd188cbd4f1319accc.summary'],"Do RAG mutations also influence the expression of non-canonical V, D, and J genes, leading to the generation of unconventional T and B cell receptors with altered antigen recognition properties?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** RAG mutations influence the expression of non-canonical V, D, and J genes, leading to the generation of unconventional T and B cell receptors with altered antigen recognition properties.

**Experimental Plan:**

**Objective:** To determine if RAG mutations affect the expression of non-canonical V, D, and J genes and subsequently alter the antigen recognition properties of T and B cell receptors.

**Approach:**

1. **RAG mutation generation and validation**:
	* Use CRISPR-Cas9 genome editing to introduce specific RAG mutations in human T and B cell lines (e.g., Jurkat and Ramos cells).
	* Validate the mutations using Sanger sequencing, PCR, and Western blotting.
2. **RNA sequencing and gene expression analysis**:
	* Perform RNA sequencing (RNA-seq) on RAG-mutated and wild-type T and B cells to identify differentially expressed genes, including non-canonical V, D, and J genes.
	* Analyze the RNA-seq data using tools like DESeq2, edgeR, or limma to identify differentially expressed genes.
3. **V, D, and J gene expression analysis**:
	* Use quantitative real-time PCR (qRT-PCR) to validate the expression of non-canonical V, D, and J genes in RAG-mutated and wild-type cells.
	* Perform chromatin immunoprecipitation sequencing (ChIP-seq) to investigate the binding of RAG proteins to non-canonical V, D, and J genes.
4. **T and B cell receptor analysis**:
	* Use flow cytometry and single-cell RNA sequencing to analyze the expression of T and B cell receptors on the surface of RAG-mutated and wild-type cells.
	* Perform immunoprecipitation and mass spectrometry to identify the composition of T and B cell receptors.
5. **Antigen recognition assays**:
	* Use peptide-MHC tetramer staining and flow cytometry to assess the antigen recognition properties of T cells from RAG-mutated and wild-type cells.
	* Perform ELISA and surface plasmon resonance (SPR) assays to measure the binding affinity of B cell receptors to antigens.

**Experiment to DISPROVE the hypothesis:**

**Objective:** To demonstrate that RAG mutations do not influence the expression of non-canonical V, D, and J genes or alter the antigen recognition properties of T and B cell receptors.

**Approach:**

1. **RAG mutation generation and validation** (same as above).
2. **RNA sequencing and gene expression analysis** (same as above).
3. **V, D, and J gene expression analysis** (same as above).
4. **T and B cell receptor analysis** (same as above).
5. **Antigen recognition assays** (same as above).

**Key differences:**

* Use a different RAG mutation that is predicted to have no effect on non-canonical V, D, and J gene expression (e.g., a mutation in a non-catalytic domain).
* Include additional controls, such as RAG-mutated cells with a rescue construct that restores wild-type RAG function.
* Perform additional experiments to rule out off-target effects of the RAG mutation, such as RNA-seq analysis of non-immune cells.

**Unlimited budget considerations:**

* Perform the experiment in triplicate to ensure robustness and reproducibility.
* Use cutting-edge technologies, such as single-cell RNA sequencing and mass cytometry, to gain a more comprehensive understanding of the effects of RAG mutations.
* Collaborate with experts in bioinformatics and biostatistics to develop custom analysis pipelines and ensure accurate interpretation of the data.
* Perform additional experiments to explore the mechanisms underlying the observed effects, such as ChIP-seq analysis of RAG protein binding to non-canonical V, D, and J genes.

By following this experimental plan, we can rigorously test the hypothesis and determine whether RAG mutations indeed influence the expression of non-canonical V, D, and J genes and alter the antigen recognition properties of T and B cell receptors.",90,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: RAG Mutation Generation and Validation**

**Step 1.1: Design CRISPR-Cas9 guide RNAs**

* Use online tools (e.g., CRISPR Design, CRISPOR) to design guide RNAs targeting specific RAG mutations in human T and B cell lines (Jurkat and Ramos cells).
* Select guide RNAs with high specificity and efficiency scores.

**Step 1.2: Prepare CRISPR-Cas9 reagents**

* Obtain CRISPR-Cas9 plasmids and guide RNA oligos from commercial sources or prepare in-house.
* Prepare CRISPR-Cas9 ribonucleoprotein (RNP) complexes according to the manufacturer's instructions.

**Step 1.3: Transfect cells with CRISPR-Cas9 RNP**

* Prepare Jurkat and Ramos cells for transfection by washing and resuspending them in electroporation buffer.
* Electroporate cells with CRISPR-Cas9 RNP using a nucleofector or electroporator.
* Plate cells in selective media and allow them to recover for 48-72 hours.

**Step 1.4: Validate RAG mutations using Sanger sequencing**

* Extract genomic DNA from transfected cells using a DNA extraction kit.
* Amplify the RAG gene region using PCR and primers flanking the target mutation site.
* Perform Sanger sequencing on the PCR products using a sequencing primer.
* Analyze sequencing data using software (e.g., Sequencher, FinchTV) to identify the presence of the desired RAG mutation.

**Step 1.5: Validate RAG mutations using PCR and Western blotting**

* Extract RNA from transfected cells using an RNA extraction kit.
* Perform PCR using primers specific to the RAG gene and analyze the products using agarose gel electrophoresis.
* Extract protein from transfected cells using a protein extraction kit.
* Perform Western blotting using an anti-RAG antibody and analyze the results to confirm the presence of the RAG mutation.

**Protocol 2: RNA Sequencing and Gene Expression Analysis**

**Step 2.1: Prepare RNA samples**

* Extract RNA from RAG-mutated and wild-type T and B cells using an RNA extraction kit.
* Perform RNA quality control using a bioanalyzer or spectrophotometer.

**Step 2.2: Library preparation and sequencing**

* Prepare RNA-seq libraries using a commercial kit (e.g., TruSeq, NEBNext).
* Sequence the libraries on a high-throughput sequencing platform (e.g., Illumina, PacBio).

**Step 2.3: Data analysis**

* Use software (e.g., STAR, HISAT2) to map the sequencing reads to the human genome.
* Use software (e.g., DESeq2, edgeR, limma) to identify differentially expressed genes between RAG-mutated and wild-type cells.
* Perform pathway analysis using software (e.g., Reactome, KEGG) to identify enriched biological pathways.

**Protocol 3: V, D, and J Gene Expression Analysis**

**Step 3.1: Prepare cDNA samples**

* Extract RNA from RAG-mutated and wild-type T and B cells using an RNA extraction kit.
* Perform reverse transcription using a commercial kit (e.g., SuperScript, High-Capacity cDNA Reverse Transcription).

**Step 3.2: qRT-PCR**

* Design primers specific to non-canonical V, D, and J genes.
* Perform qRT-PCR using a commercial kit (e.g., PowerUp SYBR Green, TaqMan) and a real-time PCR instrument.
* Analyze the results using software (e.g., SDS, Rotor-Gene) to determine the relative expression levels of non-canonical V, D, and J genes.

**Step 3.3: ChIP-seq**

* Cross-link RAG-mutated and wild-type T and B cells using formaldehyde.
* Sonicate the cross-linked cells to fragment the chromatin.
* Immunoprecipitate the RAG protein using a specific antibody and protein A/G beads.
* Perform ChIP-seq library preparation and sequencing using a commercial kit (e.g., TruSeq, NEBNext).
* Analyze the data using software (e.g., MACS, PeakRanger) to identify RAG protein binding sites on non-canonical V, D, and J genes.

**Protocol 4: T and B Cell Receptor Analysis**

**Step 4.1: Flow cytometry**

* Stain RAG-mutated and wild-type T and B cells with antibodies specific to T and B cell receptors.
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto, Beckman Coulter CytoFLEX).
* Use software (e.g., FlowJo, Cytobank) to analyze the data and determine the expression levels of T and B cell receptors.

**Step 4.2: Single-cell RNA sequencing**

* Prepare single-cell RNA-seq libraries using a commercial kit (e.g., 10x Genomics, Drop-seq).
* Sequence the libraries on a high-throughput sequencing platform (e.g., Illumina, PacBio).
* Analyze the data using software (e.g., Cell Ranger, Seurat) to identify the expression levels of T and B cell receptors at the single-cell level.

**Step 4.3: Immunoprecipitation and mass spectrometry**

* Immunoprecipitate T and B cell receptors from RAG-mutated and wild-type cells using specific antibodies and protein A/G beads.
* Perform mass spectrometry analysis using a commercial instrument (e.g., Orbitrap, Q Exactive).
* Analyze the data using software (e.g., MaxQuant, Proteome Discoverer) to identify the composition of T and B cell receptors.

**Protocol 5: Antigen Recognition Assays**

**Step 5.1: Peptide-MHC tetramer staining**

* Prepare peptide-MHC tetramers specific to the antigen of interest.
* Stain RAG-mutated and wild-type T cells with the peptide-MHC tetramers.
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto, Beckman Coulter CytoFLEX).
* Use software (e.g., FlowJo, Cytobank) to analyze the data and determine the antigen recognition properties of T cells.

**Step 5.2: ELISA and SPR assays**

* Prepare ELISA plates coated with the antigen of interest.
* Add RAG-mutated and wild-type B cell receptors to the ELISA plates.
* Measure the binding affinity using an ELISA reader.
* Perform SPR assays using a commercial instrument (e.g., Biacore, ForteBio).
* Analyze the data using software (e.g., BIAevaluation, ForteBio Analysis) to determine the binding affinity of B cell receptors to antigens.

**Experiment to DISPROVE the Hypothesis**

The protocols for the experiment to disprove the hypothesis are identical to those above, with the following modifications:

* Use a different RAG mutation predicted to have no effect on non-canonical V, D, and J gene expression.
* Include additional controls, such as RAG-mutated cells with a rescue construct that restores wild-type RAG function.
* Perform additional experiments to rule out off-target effects of the RAG mutation, such as RNA-seq analysis of non-immune cells.

**Unlimited Budget Considerations**

* Perform the experiment in triplicate to ensure robustness and reproducibility.
* Use cutting-edge technologies, such as single-cell RNA sequencing and mass cytometry, to gain a more comprehensive understanding of the effects of RAG mutations.
* Collaborate with experts in bioinformatics and biostatistics to develop custom analysis pipelines and ensure accurate interpretation of the data.
* Perform additional experiments to explore the mechanisms underlying the observed effects, such as ChIP-seq analysis of RAG protein binding to non-canonical V, D, and J genes.","```
   CRISPR_Cas9_plasmid  guide_RNA_oligos  Jurkat_cells  Ramos_cells  Electroporation_buffer  RAG_mutation  Outcome
0                  0.5               1.0         100000         100000                10.0        Present
1                  1.0               0.5         150000         150000                15.0        Absent
2                  1.5               1.5         200000         200000                20.0        Present
3                  2.0               2.0         250000         250000                25.0        Absent
4                  0.5               1.0         100000         100000                10.0        Present
5                  1.0               0.5         150000         150000                15.0        Absent
6                  1.5               1.5         200000         200000                20.0        Present
7                  2.0               2.0         250000         250000                25.0        Absent
8                  0.5               1.0         100000         100000                10.0        Present
9                  1.0               0.5         150000         150000                15.0        Absent
10                 1.5               1.5         200000         200000                20.0        Present
11                 2.0               2.0         250000         250000                25.0        Absent
12                 0.5               1.0         100000         100000                10.0        Present
13                 1.0               0.5         150000         150000                15.0        Absent
14                 1.5               1.5         200000         200000                20.0        Present
15                 2.0               2.0         250000         250000                25.0        Absent
16                 0.5               1.0         100000         100000                10.0        Present
17                 1.0               0.5         150000         150000                15.0        Absent
18                 1.5               1.5         200000         200000                20.0        Present
19                 2.0               2.0         250000         250000                25.0        Absent
20                 0.5               1.0         100000         100000                10.0        Present
21                 1.0               0.5         150000         150000                15.0        Absent
22                 1.5               1.5         200000         200000                20.0        Present
23                 2.0               2.0         250000         250000                25.0        Absent
24                 0.5               1.0         100000         100000                10.0        Present
```",0.31915983785768626
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c11ccaa98e31f4395d98c77e120362b7316c73e1.summary'],"Do RTEs from RA and PsA patients exhibit altered DNA methylation patterns in genes involved in T cell development and tolerance, contributing to their activated phenotype and autoreactive potential?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis. Since the goal is to disprove the hypothesis, the experiment will focus on finding evidence that contradicts the idea that RTEs from RA and PsA patients exhibit altered DNA methylation patterns in genes involved in T cell development and tolerance, contributing to their activated phenotype and autoreactive potential.

**Experiment: ""Disproving Altered DNA Methylation in RTEs from RA and PsA Patients""**

**Objective:** To investigate whether RTEs from RA and PsA patients exhibit similar DNA methylation patterns in genes involved in T cell development and tolerance compared to healthy controls, contradicting the hypothesis.

**Experimental Design:**

1. **Sample Collection:** Collect peripheral blood samples from 10 RA patients, 10 PsA patients, and 10 healthy controls. Isolate CD4+ and CD8+ RTEs from each sample using flow cytometry.
2. **DNA Isolation and Bisulfite Conversion:** Extract genomic DNA from isolated RTEs and perform bisulfite conversion to convert unmethylated cytosines to uracils, while leaving methylated cytosines unchanged.
3. **Targeted Bisulfite Sequencing:** Perform targeted bisulfite sequencing on a panel of genes involved in T cell development and tolerance (e.g., TCF7, LEF1, CD3E, CD28, and FOXP3) using a sequencing platform (e.g., Illumina MiSeq).
4. **Data Analysis:** Analyze the bisulfite sequencing data using software such as Bismark or MethPipe to determine the DNA methylation levels at each CpG site within the targeted genes. Compare the methylation profiles between RA, PsA, and healthy control groups.
5. **Statistical Analysis:** Perform statistical analysis using tools like R or Python to compare the methylation levels between groups. Use non-parametric tests (e.g., Wilcoxon rank-sum test) to account for potential non-normality in the data.

**Expected Outcome:**

If the hypothesis is incorrect, the experiment should show that:

* The DNA methylation patterns in genes involved in T cell development and tolerance are similar between RTEs from RA and PsA patients and healthy controls.
* There are no significant differences in methylation levels between the three groups.

**Resources and Timeline:**

* Personnel: 1 post-doc, 1 graduate student, and 1 technician
* Equipment: Flow cytometer, bisulfite conversion kit, sequencing platform (e.g., Illumina MiSeq), and computational resources for data analysis
* Reagents and Consumables: Bisulfite conversion reagents, sequencing library preparation kits, and flow cytometry reagents
* Timeline: 6 months
* Budget: Approximately $150,000 (including personnel, equipment, reagents, and sequencing costs)

By following this experimental design, you can test the hypothesis and potentially disprove it, providing evidence that RTEs from RA and PsA patients do not exhibit altered DNA methylation patterns in genes involved in T cell development and tolerance.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disproving Altered DNA Methylation in RTEs from RA and PsA Patients"":

**Protocol 1: Sample Collection and RTE Isolation**

1.1. **Peripheral Blood Sample Collection**

* Collect 10 mL of peripheral blood from each of the 10 RA patients, 10 PsA patients, and 10 healthy controls using vacutainer tubes containing EDTA as an anticoagulant.
* Label each tube with a unique identifier and store at room temperature.

1.2. **PBMC Isolation**

* Centrifuge the blood samples at 400 x g for 10 minutes to separate the plasma from the peripheral blood mononuclear cells (PBMCs).
* Discard the plasma and resuspend the PBMCs in 10 mL of phosphate-buffered saline (PBS).
* Centrifuge the PBMCs at 400 x g for 10 minutes to remove any remaining plasma.

1.3. **RTE Isolation using Flow Cytometry**

* Stain the PBMCs with the following antibodies:
	+ CD4-APC (clone OKT4, BioLegend)
	+ CD8-PE (clone HIT8a, BioLegend)
	+ CD45RA-FITC (clone HI100, BioLegend)
	+ CD62L-PerCP-Cy5.5 (clone DREG-56, BioLegend)
* Use a flow cytometer (e.g., BD FACSAria III) to sort CD4+ and CD8+ RTEs based on the following gating strategy:
	+ Gate on CD45RA+ and CD62L+ cells to identify RTEs
	+ Gate on CD4+ or CD8+ cells to separate CD4+ and CD8+ RTEs
* Collect the sorted cells in 1.5 mL microcentrifuge tubes containing 100 μL of PBS.

**Protocol 2: DNA Isolation and Bisulfite Conversion**

2.1. **DNA Isolation**

* Use a DNA isolation kit (e.g., QIAamp DNA Micro Kit, Qiagen) to extract genomic DNA from the sorted RTEs.
* Follow the manufacturer's instructions to isolate DNA from each sample.
* Elute the DNA in 50 μL of elution buffer.

2.2. **Bisulfite Conversion**

* Use a bisulfite conversion kit (e.g., EpiTect Bisulfite Kit, Qiagen) to convert unmethylated cytosines to uracils.
* Follow the manufacturer's instructions to perform bisulfite conversion on each DNA sample.
* Use 1 μg of DNA as input for the bisulfite conversion reaction.

**Protocol 3: Targeted Bisulfite Sequencing**

3.1. **Library Preparation**

* Use a sequencing library preparation kit (e.g., TruSeq DNA Methylation Kit, Illumina) to prepare libraries for targeted bisulfite sequencing.
* Follow the manufacturer's instructions to prepare libraries for each bisulfite-converted DNA sample.
* Use a panel of genes involved in T cell development and tolerance (e.g., TCF7, LEF1, CD3E, CD28, and FOXP3) as targets for sequencing.

3.2. **Targeted Bisulfite Sequencing**

* Use a sequencing platform (e.g., Illumina MiSeq) to perform targeted bisulfite sequencing on the prepared libraries.
* Follow the manufacturer's instructions to set up the sequencing run.
* Use a minimum of 10 million reads per sample to ensure sufficient coverage.

**Protocol 4: Data Analysis**

4.1. **Data Quality Control**

* Use software such as FastQC to assess the quality of the sequencing data.
* Remove any low-quality reads or adapters from the data.

4.2. **Bisulfite Sequencing Data Analysis**

* Use software such as Bismark or MethPipe to analyze the bisulfite sequencing data.
* Determine the DNA methylation levels at each CpG site within the targeted genes.
* Calculate the methylation levels as a percentage of methylated cytosines at each CpG site.

4.3. **Statistical Analysis**

* Use software such as R or Python to perform statistical analysis on the methylation data.
* Compare the methylation levels between RA, PsA, and healthy control groups using non-parametric tests (e.g., Wilcoxon rank-sum test).
* Calculate the p-values and adjust for multiple testing using the Benjamini-Hochberg method.

**Protocol 5: Data Interpretation and Reporting**

5.1. **Data Visualization**

* Use software such as R or Python to visualize the methylation data using heatmaps or box plots.
* Compare the methylation profiles between RA, PsA, and healthy control groups.

5.2. **Result Interpretation**

* Interpret the results in the context of the hypothesis.
* If the methylation patterns are similar between RA, PsA, and healthy control groups, it would suggest that the hypothesis is incorrect.
* Report the results in a clear and concise manner, including any statistical analysis and data visualization.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis.","```
   RA_Patients  PsA_Patients  Healthy_Controls  CD4_APC  CD8_PE  CD45RA_FITC  CD62L_PerCP_Cy5.5  DNA_Input  Bisulfite_Conversion  Methylation_Level
0           10           10              10       0.5      0.5            0.5               0.5           1.0                0.8           0.42
1           12           8               9       0.6      0.4            0.6               0.4           1.2                0.9           0.45
2            9           11              8       0.4      0.6            0.5               0.5           0.9                0.7           0.38
3           11           9              10       0.5      0.5            0.6               0.4           1.1                0.8           0.40
4           10           8               9       0.5      0.5            0.5               0.5           1.0                0.8           0.42
5            9           12              8       0.4      0.6            0.5               0.5           0.9                0.7           0.38
6           11           10              9       0.5      0.5            0.6               0.4           1.1                0.8           0.40
7           12           9              10       0.6      0.4            0.6               0.4           1.2                0.9           0.45
8           10           11              8       0.5      0.5            0.5               0.5           1.0                0.8           0.42
9            8           12              9       0.4      0.6            0.5               0.5           0.8                0.7           0.38
10          11           9              10       0.5      0.5            0.6               0.4           1.1                0.8           0.40
11          10           8               9       0.5      0.5            0.5               0.5           1.0                0.8           0.42
12           9           11              8       0.4      0.6            0.5               0.5           0.9                0.7           0.38
13          12           10              9       0.6      0.4            0.6               0.4           1.2                0.9           0.45
14          11           9              10       0.5      0.5            0.6               0.4           1.1                0.8           0.40
15           8           12              9       0.4      0.6            0.5               0.5           0.8                0.7           0.38
16          10           11              8       0.5      0.5            0.5               0.5           1.0                0.8           0.42
17          12           9              10       0.6      0.4            0.6               0.4           1.2                0.9           0.45
18           9           10              9       0.4      0.6            0.5               0.5           0.9                0.7           0.38
19          11           8              10       0.5      0.5            0.6               0.4           1.1                0.8           0.40
20          10           9               9       0.5      0.5            0.5               0.5           1.0                0.8           0.42
21           8           11              9       0.4      0.6            0.5               0.5           0.8                0.7           0.38
22          12           10              9       0.6      0.4            0.6               0.4           1.2                0.9           0.45
23          11           9              10       0.5      0.5            0.6               0.4           1.1                0.8           0.40
24          10           8               9       0.5      0.5            0.5               0.5           1.0                0.8           0.42
```",0.2550466880162964
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/32fe2ba4eb7279db4f2cf2ec8f441e546e4fdc67.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/13afd253d45da4d77f05f9b3192f2d4cc89f4933.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d60d174c922a17813e6603adcd4af6472099d2f7.summary']","Do TCF7+ naive-like T cells and non-switched memory B cells interact to enhance the production of anti-tumor antibodies in the tumor microenvironment, and does this interaction rely on the presence of specific chemokines, such as CXCL13?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Do TCF7+ naive-like T cells and non-switched memory B cells interact to enhance the production of anti-tumor antibodies in the tumor microenvironment, and does this interaction rely on the presence of specific chemokines, such as CXCL13?

**Experimental Approach:**

**Experiment 1: Co-culture of TCF7+ naive-like T cells, non-switched memory B cells, and tumor cells**

1. Isolate TCF7+ naive-like T cells and non-switched memory B cells from healthy donors using flow cytometry.
2. Co-culture TCF7+ naive-like T cells, non-switched memory B cells, and tumor cells (e.g., melanoma or neuroblastoma cells) in a 3D cell culture system (e.g., microfluidic device or collagen gel) to mimic the tumor microenvironment.
3. Add CXCL13 to the culture system at different concentrations (e.g., 0, 10, 50, and 100 ng/mL) to assess its role in the interaction.
4. Monitor the formation of tertiary lymphoid structures and the recruitment of B cells using live-cell imaging and immunofluorescence staining.
5. Measure the production of anti-tumor antibodies in the culture supernatant using ELISA.

**Experiment 2: Blocking CXCL13 to disrupt the interaction**

1. Repeat Experiment 1, but add a CXCL13-blocking antibody to the culture system to disrupt the interaction between TCF7+ naive-like T cells and non-switched memory B cells.
2. Compare the results with Experiment 1 to determine if blocking CXCL13 reduces the production of anti-tumor antibodies.

**Experiment 3: Single-cell RNA sequencing to analyze the immune cell populations**

1. Perform single-cell RNA sequencing on the co-cultured cells from Experiment 1 to analyze the immune cell populations and their gene expression profiles.
2. Identify the specific immune cell subsets and their interactions that are involved in the production of anti-tumor antibodies.

**Resources and Timeline:**

* Personnel: 1 postdoc, 1 graduate student, and 1 technician
* Equipment: Flow cytometer, cell culture facilities, microfluidic device or collagen gel, live-cell imaging system, immunofluorescence microscope, ELISA reader, and single-cell RNA sequencing platform
* Reagents: TCF7+ naive-like T cells, non-switched memory B cells, tumor cells, CXCL13, CXCL13-blocking antibody, and reagents for flow cytometry, immunofluorescence, and ELISA
* Timeline: 6-9 months

**Budget:**

* Personnel: $150,000
* Equipment and reagents: $100,000
* Total: $250,000

This experimental plan aims to test the hypothesis by co-culturing TCF7+ naive-like T cells, non-switched memory B cells, and tumor cells in the presence or absence of CXCL13, and measuring the production of anti-tumor antibodies. The plan also includes single-cell RNA sequencing to analyze the immune cell populations and their interactions. The budget and timeline are reasonable for a small-scale research project.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Experiment 1: Co-culture of TCF7+ naive-like T cells, non-switched memory B cells, and tumor cells**

**Step 1: Isolation of TCF7+ naive-like T cells and non-switched memory B cells**

1.1. Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors through venipuncture or leukapheresis.

1.2. Perform density gradient centrifugation (e.g., Ficoll-Paque) to separate PBMCs from other blood components.

1.3. Stain PBMCs with fluorescently labeled antibodies against CD3, CD4, CD45RA, CD27, and TCF7 to identify TCF7+ naive-like T cells.

1.4. Stain PBMCs with fluorescently labeled antibodies against CD19, CD27, and IgD to identify non-switched memory B cells.

1.5. Use flow cytometry to sort and isolate TCF7+ naive-like T cells and non-switched memory B cells into separate tubes.

**Step 2: Co-culture setup**

2.1. Prepare the 3D cell culture system (e.g., microfluidic device or collagen gel) according to the manufacturer's instructions.

2.2. Seed tumor cells (e.g., melanoma or neuroblastoma cells) into the 3D cell culture system at a density of 1x10^5 cells/mL.

2.3. Add TCF7+ naive-like T cells and non-switched memory B cells to the 3D cell culture system at a ratio of 1:1:1 (T cells:B cells:tumor cells) and a total cell density of 1x10^6 cells/mL.

2.4. Add CXCL13 to the culture system at different concentrations (0, 10, 50, and 100 ng/mL).

2.5. Incubate the co-culture system at 37°C, 5% CO2 for 7-10 days.

**Step 3: Live-cell imaging and immunofluorescence staining**

3.1. Use live-cell imaging to monitor the formation of tertiary lymphoid structures and the recruitment of B cells at days 3, 5, and 7.

3.2. Fix the co-culture system with 4% paraformaldehyde at day 10.

3.3. Perform immunofluorescence staining using antibodies against CD3, CD19, and CD20 to visualize T cells and B cells.

**Step 4: ELISA**

4.1. Collect the culture supernatant from the co-culture system at day 10.

4.2. Perform ELISA to measure the production of anti-tumor antibodies using a commercial ELISA kit specific for the tumor antigen.

**Experiment 2: Blocking CXCL13 to disrupt the interaction**

**Step 1: Co-culture setup**

1.1. Repeat Steps 2.1-2.5 from Experiment 1.

**Step 2: CXCL13 blocking**

2.1. Add a CXCL13-blocking antibody to the culture system at a concentration of 10 μg/mL.

2.2. Incubate the co-culture system at 37°C, 5% CO2 for 7-10 days.

**Step 3: Live-cell imaging and immunofluorescence staining**

3.1. Repeat Steps 3.1-3.3 from Experiment 1.

**Step 4: ELISA**

4.1. Repeat Steps 4.1-4.2 from Experiment 1.

**Experiment 3: Single-cell RNA sequencing**

**Step 1: Cell preparation**

1.1. Collect the co-cultured cells from Experiment 1 at day 10.

1.2. Perform cell sorting using flow cytometry to isolate T cells, B cells, and tumor cells.

**Step 2: Single-cell RNA sequencing**

2.1. Prepare single-cell RNA sequencing libraries using a commercial kit (e.g., 10x Genomics).

2.2. Perform single-cell RNA sequencing using a sequencing platform (e.g., Illumina NovaSeq).

2.3. Analyze the sequencing data using bioinformatic tools (e.g., Cell Ranger, Seurat) to identify immune cell subsets and their gene expression profiles.

**Note:** The above protocols assume a basic understanding of cell culture, flow cytometry, and molecular biology techniques. The specific reagents, equipment, and software used may vary depending on the laboratory setup and availability.","```
   TCF7+ naive-like T cells  non-switched memory B cells  Tumor cells  CXCL13 (ng/mL)  Outcome
0                         50000                         50000       50000             0  Negative
1                         75000                         75000       75000             0  Negative
2                         100000                        100000      100000             0  Negative
3                         50000                         50000       50000            10  Positive
4                         75000                         75000       75000            10  Positive
5                         100000                        100000      100000            10  Positive
6                         50000                         50000       50000            50  Strongly Positive
7                         75000                         75000       75000            50  Strongly Positive
8                         100000                        100000      100000            50  Strongly Positive
9                         50000                         50000       50000           100  Strongly Positive
10                        75000                         75000       75000           100  Strongly Positive
11                       100000                        100000      100000           100  Strongly Positive
12                        50000                         50000       50000             0  Negative
13                       75000                         75000       75000             0  Negative
14                      100000                        100000      100000             0  Negative
15                        50000                         50000       50000            10  Positive
16                       75000                         75000       75000            10  Positive
17                      100000                        100000      100000            10  Positive
18                        50000                         50000       50000            50  Strongly Positive
19                       75000                         75000       75000            50  Strongly Positive
20                      100000                        100000      100000            50  Strongly Positive
21                        50000                         50000       50000           100  Strongly Positive
22                       75000                         75000       75000           100  Strongly Positive
23                      100000                        100000      100000           100  Strongly Positive
24                        50000                         50000       50000             0  Negative
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/09fc5e5b3a6d7c7f183328d76e1db3c5346b08fd.summary'],Do Yangtze finless porpoises in ex situ environments exhibit increased expression of vision-related genes in response to changes in water turbidity and light intensity compared to those in captive environments?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experiment to test it.

**Experimental Plan:**

**Objective:** To investigate whether Yangtze finless porpoises in ex situ environments exhibit increased expression of vision-related genes in response to changes in water turbidity and light intensity compared to those in captive environments.

**Experimental Design:**

1. **Sample Collection:**
	* Obtain tissue samples (e.g., eye tissue, brain tissue) from Yangtze finless porpoises in:
		+ Ex situ environments (e.g., aquariums, artificial pools) with controlled water turbidity and light intensity levels.
		+ Captive environments (e.g., zoos, breeding centers) with standard water quality and lighting conditions.
	* Ensure a sufficient sample size (n ≥ 10) for each group to ensure statistical significance.
2. **Water Turbidity and Light Intensity Manipulation:**
	* In the ex situ environments, manipulate water turbidity levels using a turbidity meter and adjust light intensity using LED lights or other controlled lighting systems.
	* Create three treatment groups:
		+ Low turbidity (0-10 NTU) and low light intensity (10-50 lux)
		+ Medium turbidity (10-50 NTU) and medium light intensity (50-100 lux)
		+ High turbidity (50-100 NTU) and high light intensity (100-200 lux)
3. **Gene Expression Analysis:**
	* Extract RNA from the collected tissue samples using standard protocols (e.g., TRIzol, RNAeasy).
	* Perform quantitative real-time PCR (qRT-PCR) to measure the expression levels of vision-related genes (e.g., rhodopsin, opsin, recoverin) in each sample.
	* Normalize gene expression data using housekeeping genes (e.g., GAPDH, β-actin).
4. **Statistical Analysis:**
	* Compare gene expression levels between the ex situ and captive environments using two-way ANOVA or mixed-effects models to account for individual variation.
	* Analyze the interaction between water turbidity and light intensity on gene expression levels.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that attempts to show no significant difference in vision-related gene expression between ex situ and captive environments, despite changes in water turbidity and light intensity.

**Null Hypothesis:** There is no significant difference in vision-related gene expression between Yangtze finless porpoises in ex situ environments with varying water turbidity and light intensity levels compared to those in captive environments.

**Modified Experimental Design:**

1. **Sample Collection:** Same as above.
2. **Water Turbidity and Light Intensity Manipulation:** Same as above, but with a twist:
	* In the ex situ environments, maintain a constant, optimal water quality and lighting condition (e.g., low turbidity, medium light intensity) to minimize any potential effects on gene expression.
	* In the captive environments, introduce random, controlled variations in water turbidity and light intensity to simulate the natural fluctuations found in ex situ environments.
3. **Gene Expression Analysis:** Same as above.
4. **Statistical Analysis:** Same as above, but with a focus on testing the null hypothesis.

**Rationale:**

By maintaining optimal conditions in the ex situ environments and introducing random variations in the captive environments, we can test whether the porpoises in ex situ environments still exhibit increased expression of vision-related genes. If the null hypothesis is supported, it would suggest that the changes in water turbidity and light intensity do not significantly affect vision-related gene expression, disproving the original hypothesis.

**Budget and Time Considerations:**

This experiment can be conducted within a reasonable time frame (6-12 months) and budget, considering the following:

* Sample collection and RNA extraction: 2-3 months, $10,000 - $15,000
* Water turbidity and light intensity manipulation: 2-3 months, $5,000 - $10,000
* Gene expression analysis: 3-4 months, $15,000 - $25,000
* Statistical analysis and data interpretation: 2-3 months, $5,000 - $10,000

Total estimated budget: $40,000 - $70,000

This experiment is designed to be feasible within a limited budget and timeframe, while still providing valuable insights into the effects of water turbidity and light intensity on vision-related gene expression in Yangtze finless porpoises.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Sample Collection**

1.1. Obtain necessary permits and approvals for sample collection from Yangtze finless porpoises in ex situ environments (aquariums, artificial pools) and captive environments (zoos, breeding centers).

1.2. Ensure a sufficient sample size (n ≥ 10) for each group to ensure statistical significance.

1.3. Prepare necessary equipment:
	* Tissue sampling tools (e.g., biopsy needles, forceps)
	* Sample containers (e.g., cryovials, tubes)
	* RNA preservation reagents (e.g., RNAlater, TRIzol)

1.4. Collect tissue samples (eye tissue, brain tissue) from Yangtze finless porpoises in ex situ and captive environments using the following procedures:
	* Anesthetize the porpoises using approved protocols to minimize stress and discomfort.
	* Use sterile techniques to collect tissue samples, taking care to avoid contamination.
	* Immediately place the samples in RNA preservation reagents and store at -80°C or in liquid nitrogen.

**Protocol 2: Water Turbidity and Light Intensity Manipulation**

2.1. Prepare the ex situ environments (aquariums, artificial pools) with controlled water turbidity and light intensity levels.

2.2. Calibrate the turbidity meter and adjust the water turbidity levels to the following treatments:
	* Low turbidity (0-10 NTU)
	* Medium turbidity (10-50 NTU)
	* High turbidity (50-100 NTU)

2.3. Adjust the light intensity levels using LED lights or other controlled lighting systems to the following treatments:
	* Low light intensity (10-50 lux)
	* Medium light intensity (50-100 lux)
	* High light intensity (100-200 lux)

2.4. Create three treatment groups:
	* Low turbidity (0-10 NTU) and low light intensity (10-50 lux)
	* Medium turbidity (10-50 NTU) and medium light intensity (50-100 lux)
	* High turbidity (50-100 NTU) and high light intensity (100-200 lux)

**Protocol 3: Gene Expression Analysis**

3.1. Extract RNA from the collected tissue samples using standard protocols (e.g., TRIzol, RNAeasy).

3.2. Perform quantitative real-time PCR (qRT-PCR) to measure the expression levels of vision-related genes (e.g., rhodopsin, opsin, recoverin) in each sample.

3.3. Normalize gene expression data using housekeeping genes (e.g., GAPDH, β-actin).

3.4. Use the following qRT-PCR protocol:
	* Prepare the qRT-PCR reaction mixture according to the manufacturer's instructions.
	* Add the RNA template and primers to the reaction mixture.
	* Perform the qRT-PCR reaction using the following conditions:
		+ Denaturation: 95°C, 10 minutes
		+ Amplification: 40 cycles of 95°C, 15 seconds; 60°C, 30 seconds; 72°C, 30 seconds
		+ Melting curve analysis: 95°C, 15 seconds; 60°C, 30 seconds; 95°C, 15 seconds

**Protocol 4: Statistical Analysis**

4.1. Compare gene expression levels between the ex situ and captive environments using two-way ANOVA or mixed-effects models to account for individual variation.

4.2. Analyze the interaction between water turbidity and light intensity on gene expression levels.

4.3. Use the following statistical software and settings:
	* R software (version 3.6.1 or later)
	* Two-way ANOVA: aov() function with the following settings:
		+ Response variable: gene expression levels
		+ Predictor variables: water turbidity, light intensity, and their interaction
	* Mixed-effects models: lme4 package with the following settings:
		+ Response variable: gene expression levels
		+ Predictor variables: water turbidity, light intensity, and their interaction
		+ Random effects: individual porpoise ID

**Modified Protocol for Disproving the Hypothesis**

**Protocol 1: Sample Collection** (same as above)

**Protocol 2: Water Turbidity and Light Intensity Manipulation**

2.1. Prepare the ex situ environments (aquariums, artificial pools) with a constant, optimal water quality and lighting condition (e.g., low turbidity, medium light intensity).

2.2. Introduce random, controlled variations in water turbidity and light intensity in the captive environments to simulate the natural fluctuations found in ex situ environments.

**Protocol 3: Gene Expression Analysis** (same as above)

**Protocol 4: Statistical Analysis** (same as above, but with a focus on testing the null hypothesis)

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately compared and analyzed.","```
   Turbidity  Light_Intensity  RNA_Sample_Size  Rhodopsin_Expression  Opsin_Expression  Recoverin_Expression  Environment
0           5             30              12           1.234567        0.987654         1.111111        Ex_situ
1          20             80              15           1.567890        1.234567         1.333333        Captive
2           8             40              10           1.012345        0.876543         1.000000        Ex_situ
3          15             60              12           1.345678        1.012345         1.200000        Captive
4           3             20              11           0.987654        0.765432         0.933333        Ex_situ
5          25             90              14           1.678901        1.345678         1.466667        Captive
6           6             35              13           1.123456        0.934579         1.066667        Ex_situ
7          18             70              16           1.789012        1.567890         1.600000        Captive
8           4             25              10           0.876543        0.654321         0.866667        Ex_situ
9          22             85              15           1.890123        1.678901         1.733333        Captive
10          9             45              12           1.234567        1.012345         1.133333        Ex_situ
11         12             50              14           1.456789        1.234567         1.400000        Captive
12          7             38              11           1.012345        0.876543         1.000000        Ex_situ
13         19             75              16           1.901234        1.789012         1.866667        Captive
14          2             18              10           0.765432        0.543210         0.800000        Ex_situ
15         24             95              15           2.012345        1.890123         2.000000        Captive
16         11             48              13           1.345678        1.123456         1.266667        Ex_situ
17         16             62              14           1.678901        1.456789         1.533333        Captive
18          1             12              11           0.654321        0.432109         0.733333        Ex_situ
19         21             82              16           2.123456        1.901234         2.133333        Captive
20         10             42              12           1.567890        1.234567         1.400000        Ex_situ
21         17             65              15           1.789012        1.678901         1.733333        Captive
22          6             30              11           1.012345        0.876543         1.000000        Ex_situ
23         23             92              16           2.234567        2.012345         2.266667        Captive
24         14             55              13           1.678901        1.456789         1.533333        Ex_situ
25         13             52              14           1.789012        1.678901         1.733333        Captive
```",0.805590924351168
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1300f82ace5304bfae618ef377956e2895199cee.summary'],"Do alterations in the PPAR pathway, identified in follicular lymphoma, influence the expression of cell adhesion molecules and contribute to the development of resistance to therapies targeting B-cell receptor signaling?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Do alterations in the PPAR pathway, identified in follicular lymphoma, influence the expression of cell adhesion molecules and contribute to the development of resistance to therapies targeting B-cell receptor signaling?

**Experimental Plan:**

**Objective:** To investigate the relationship between PPAR pathway alterations, cell adhesion molecule expression, and resistance to B-cell receptor signaling therapies in follicular lymphoma.

**Experimental Approach:**

1. **Cell Culture and PPAR Pathway Modulation:**
	* Obtain follicular lymphoma (FL) cell lines and culture them in vitro.
	* Use RNA interference (RNAi) or CRISPR-Cas9 system to modulate PPAR pathway components (e.g., PPARα, PPARγ, or RXRα) in FL cells.
	* Validate the modulation using Western blot or qRT-PCR.
2. **Cell Adhesion Molecule Expression Analysis:**
	* Use Western blot, qRT-PCR, or flow cytometry to analyze the expression of cell adhesion molecules (e.g., ICAM-1, VCAM-1, or E-cadherin) in PPAR-modulated FL cells.
	* Compare the expression levels to control FL cells.
3. **B-cell Receptor Signaling Inhibition:**
	* Treat PPAR-modulated FL cells with B-cell receptor signaling inhibitors (e.g., ibrutinib or idelalisib).
	* Analyze the effect of PPAR modulation on the response to B-cell receptor signaling inhibition using cell viability assays (e.g., MTT or CellTiter-Glo).
4. **Resistance Assay:**
	* Perform a resistance assay to assess the ability of PPAR-modulated FL cells to resist B-cell receptor signaling inhibition.
	* Use a cell viability assay to measure the IC50 values of B-cell receptor signaling inhibitors in PPAR-modulated FL cells.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that PPAR pathway alterations do not influence cell adhesion molecule expression or contribute to resistance to B-cell receptor signaling therapies in follicular lymphoma.

**Experimental Approach:**

1. **PPAR Pathway Modulation:**
	* Use RNAi or CRISPR-Cas9 system to modulate PPAR pathway components in FL cells, as described above.
2. **Cell Adhesion Molecule Expression Analysis:**
	* Analyze the expression of cell adhesion molecules in PPAR-modulated FL cells, as described above.
3. **B-cell Receptor Signaling Inhibition:**
	* Treat PPAR-modulated FL cells with B-cell receptor signaling inhibitors, as described above.
4. **Resistance Assay:**
	* Perform a resistance assay, as described above.

**Key Predictions:**

* If the hypothesis is true, PPAR pathway modulation will alter cell adhesion molecule expression and contribute to resistance to B-cell receptor signaling therapies.
* If the hypothesis is false, PPAR pathway modulation will not affect cell adhesion molecule expression or resistance to B-cell receptor signaling therapies.

**Expected Outcomes:**

* If the hypothesis is true, the experiment will show:
	+ Altered cell adhesion molecule expression in PPAR-modulated FL cells.
	+ Increased resistance to B-cell receptor signaling inhibitors in PPAR-modulated FL cells.
* If the hypothesis is false, the experiment will show:
	+ No significant changes in cell adhesion molecule expression in PPAR-modulated FL cells.
	+ No significant difference in resistance to B-cell receptor signaling inhibitors between PPAR-modulated and control FL cells.

**Timeline and Budget:**

* The experiment can be completed within 6-9 months.
* The budget will be approximately $50,000-$75,000, covering the costs of:
	+ Cell culture reagents and media
	+ RNAi or CRISPR-Cas9 reagents
	+ Western blot and qRT-PCR reagents
	+ Flow cytometry and cell viability assay reagents
	+ B-cell receptor signaling inhibitors
	+ Laboratory personnel and equipment costs

This experimental plan is designed to test the hypothesis and provide conclusive evidence to support or refute it. The experiment to disprove the hypothesis is designed to demonstrate the absence of a relationship between PPAR pathway alterations, cell adhesion molecule expression, and resistance to B-cell receptor signaling therapies in follicular lymphoma.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and PPAR Pathway Modulation**

**Objective:** To obtain and culture follicular lymphoma (FL) cell lines and modulate PPAR pathway components using RNA interference (RNAi) or CRISPR-Cas9 system.

**Materials:**

* FL cell lines (e.g., DOHH-2, WSU-FSCCL, or OCI-Ly1)
* Cell culture media (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin)
* RNAi reagents (e.g., siRNA or shRNA targeting PPARα, PPARγ, or RXRα)
* CRISPR-Cas9 reagents (e.g., guide RNA and Cas9 enzyme)
* Transfection reagent (e.g., Lipofectamine 2000)
* Western blot reagents (e.g., antibodies, ECL substrate, and membrane)
* qRT-PCR reagents (e.g., primers, probes, and master mix)

**Step-by-Step Protocol:**

1. Obtain FL cell lines and culture them in vitro in cell culture media at 37°C, 5% CO2.
2. Design and synthesize RNAi reagents (siRNA or shRNA) targeting PPARα, PPARγ, or RXRα.
3. Transfect FL cells with RNAi reagents using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
4. Incubate cells for 24-48 hours to allow for RNAi-mediated knockdown of PPAR pathway components.
5. Validate the modulation of PPAR pathway components using Western blot or qRT-PCR.
6. For CRISPR-Cas9 modulation, design and synthesize guide RNA targeting PPARα, PPARγ, or RXRα.
7. Transfect FL cells with guide RNA and Cas9 enzyme using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
8. Incubate cells for 24-48 hours to allow for CRISPR-Cas9-mediated knockout of PPAR pathway components.
9. Validate the modulation of PPAR pathway components using Western blot or qRT-PCR.

**Protocol 2: Cell Adhesion Molecule Expression Analysis**

**Objective:** To analyze the expression of cell adhesion molecules (e.g., ICAM-1, VCAM-1, or E-cadherin) in PPAR-modulated FL cells.

**Materials:**

* PPAR-modulated FL cells
* Western blot reagents (e.g., antibodies, ECL substrate, and membrane)
* qRT-PCR reagents (e.g., primers, probes, and master mix)
* Flow cytometry reagents (e.g., antibodies, buffer, and fixative)

**Step-by-Step Protocol:**

1. Harvest PPAR-modulated FL cells and extract total protein or RNA using standard protocols.
2. Perform Western blot analysis using antibodies against cell adhesion molecules (e.g., ICAM-1, VCAM-1, or E-cadherin).
3. Analyze the expression levels of cell adhesion molecules using densitometry or image analysis software.
4. Perform qRT-PCR analysis using primers and probes specific to cell adhesion molecules.
5. Analyze the expression levels of cell adhesion molecules using the 2^(-ΔΔCt) method.
6. Perform flow cytometry analysis using antibodies against cell adhesion molecules.
7. Analyze the expression levels of cell adhesion molecules using flow cytometry software.

**Protocol 3: B-cell Receptor Signaling Inhibition**

**Objective:** To treat PPAR-modulated FL cells with B-cell receptor signaling inhibitors (e.g., ibrutinib or idelalisib).

**Materials:**

* PPAR-modulated FL cells
* B-cell receptor signaling inhibitors (e.g., ibrutinib or idelalisib)
* Cell culture media
* Cell viability assay reagents (e.g., MTT or CellTiter-Glo)

**Step-by-Step Protocol:**

1. Treat PPAR-modulated FL cells with B-cell receptor signaling inhibitors at various concentrations (e.g., 0-10 μM) for 24-48 hours.
2. Incubate cells in cell culture media at 37°C, 5% CO2.
3. Perform cell viability assays (e.g., MTT or CellTiter-Glo) according to the manufacturer's instructions.
4. Analyze the effect of PPAR modulation on the response to B-cell receptor signaling inhibition using cell viability assays.

**Protocol 4: Resistance Assay**

**Objective:** To assess the ability of PPAR-modulated FL cells to resist B-cell receptor signaling inhibition.

**Materials:**

* PPAR-modulated FL cells
* B-cell receptor signaling inhibitors (e.g., ibrutinib or idelalisib)
* Cell culture media
* Cell viability assay reagents (e.g., MTT or CellTiter-Glo)

**Step-by-Step Protocol:**

1. Treat PPAR-modulated FL cells with B-cell receptor signaling inhibitors at various concentrations (e.g., 0-10 μM) for 24-48 hours.
2. Incubate cells in cell culture media at 37°C, 5% CO2.
3. Perform cell viability assays (e.g., MTT or CellTiter-Glo) according to the manufacturer's instructions.
4. Calculate the IC50 values of B-cell receptor signaling inhibitors in PPAR-modulated FL cells.
5. Compare the IC50 values between PPAR-modulated and control FL cells.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the results.","```
   FL Cell Line  RNAi Reagent  CRISPR Reagent  Transfection Reagent  PPARα Modulation  PPARγ Modulation  RXRα Modulation  ICAM-1 Expression  VCAM-1 Expression  E-cadherin Expression  Ibrutinib Concentration  Idelalisib Concentration  Cell Viability
0        DOHH-2           20           10               5            0.5            0.7            0.3            1.2            0.8            1.5               5.0               2.0         0.8
1        WSU-FSCCL           15           12               4            0.6            0.5            0.4            1.0            0.9            1.2               3.0               1.5         0.9
2        OCI-Ly1           25           15               6            0.4            0.8            0.6            1.5            1.1            1.8               7.0               3.5         0.7
3        DOHH-2           10           8               3            0.7            0.6            0.5            0.8            0.7            1.0               2.0               1.0         0.8
4        WSU-FSCCL           30           20               7            0.5            0.9            0.7            1.8            1.3            2.0               9.0               4.5         0.6
5        OCI-Ly1           18           12               5            0.6            0.7            0.5            1.2            0.9            1.4               4.0               2.0         0.8
6        DOHH-2           22           18               6            0.5            0.8            0.6            1.4            1.0            1.6               6.0               3.0         0.7
7        WSU-FSCCL           12           10               4            0.7            0.6            0.5            0.9            0.8            1.1               2.5               1.2         0.9
8        OCI-Ly1           28           22               7            0.4            0.9            0.7            1.6            1.2            1.9               8.0               4.0         0.6
9        DOHH-2           16           14               5            0.6            0.7            0.5            1.1            0.9            1.3               3.5               1.8         0.8
10       WSU-FSCCL           24           20               6            0.5            0.8            0.6            1.3            1.0            1.5               5.5               2.5         0.7
11       OCI-Ly1           20           16               5            0.6            0.7            0.5            1.2            0.9            1.4               4.0               2.0         0.8
12       DOHH-2           14           12               4            0.7            0.6            0.5            0.9            0.8            1.1               2.0               1.0         0.9
13       WSU-FSCCL           26           22               7            0.5            0.9            0.7            1.5            1.1            1.8               7.0               3.5         0.6
14       OCI-Ly1           18           14               5            0.6            0.7            0.5            1.2            0.9            1.4               4.0               2.0         0.8
15       DOHH-2           10           8               3            0.7            0.6            0.5            0.8            0.7            1.0               2.0               1.0         0.8
16       WSU-FSCCL           22           18               6            0.5            0.8            0.6            1.4            1.0            1.6               6.0               3.0         0.7
17       OCI-Ly1           24           20               6            0.5            0.9            0.7            1.6            1.2            1.9               8.0               4.0         0.6
18       DOHH-2           16           14               5            0.6            0.7            0.5            1.1            0.9            1.3               3.5               1.8         0.8
19       WSU-FSCCL           20           16               5            0.6            0.7            0.5            1.2            0.9            1.4               4.0               2.0         0.8
20       OCI-Ly1           26           22               7            0.5            0.9            0.7            1.5            1.1            1.8               7.0               3.5         0.6
21       DOHH-2           14           12               4            0.7            0.6            0.5            0.9            0.8            1.1               2.0               1.0         0.9
22       WSU-FSCCL           18           14               5            0.6            0.7            0.5            1.2            0.9            1.4               4.0               2.0         0.8
23       OCI-Ly1           22           18               6            0.5            0.8            0.6            1.4            1.0            1.6               6.0               3.0         0.7
24       DOHH-2           12           10               4            0.7            0.6            0.5            0.9            0.8            1.1               2.5               1.2         0.9",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7d16213572581ab56a96591615c98656d613124f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/fbaa49a24f645b4fecff2bf4f5da9cef41a01b5a.summary']","Do alterations in the immune system, specifically in the NK cell compartment, following severe COVID-19 infection increase the susceptibility to MIS-C in children?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help design an experiment to test the hypothesis.

**Hypothesis:** Do alterations in the immune system, specifically in the NK cell compartment, following severe COVID-19 infection increase the susceptibility to MIS-C in children?

**Experimental Plan:**

**Objective:** To investigate whether alterations in the NK cell compartment following severe COVID-19 infection increase the susceptibility to Multisystem Inflammatory Syndrome in Children (MIS-C).

**Experimental Design:**

1. **Study Population:** Collect blood samples from three groups of children:
	* Group 1: Healthy controls (n=20)
	* Group 2: Children who have recovered from severe COVID-19 infection (n=20)
	* Group 3: Children with MIS-C (n=20)
2. **NK Cell Isolation and Characterization:**
	* Isolate NK cells from peripheral blood mononuclear cells (PBMCs) using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
	* Characterize NK cells using flow cytometry to assess:
		+ NK cell frequency and absolute count
		+ Expression of activation markers (e.g., CD69, CD25)
		+ Cytotoxicity markers (e.g., granzyme B, perforin)
3. **Functional Assays:**
	* Perform functional assays to assess NK cell activity:
		+ Cytotoxicity assay using K562 cells as targets
		+ IFN-γ production in response to stimulation with IL-12 and IL-18
4. **Statistical Analysis:**
	* Compare NK cell characteristics and functional responses between the three groups using appropriate statistical tests (e.g., ANOVA, t-test, Mann-Whitney U test).

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we will test the following:

**Null Hypothesis:** Alterations in the NK cell compartment following severe COVID-19 infection do not increase the susceptibility to MIS-C in children.

**Experimental Approach:**

1. **Matched Case-Control Study:** Identify children who have recovered from severe COVID-19 infection but did not develop MIS-C (n=20). Match these children with those who developed MIS-C (n=20) based on age, sex, and severity of COVID-19 infection.
2. **NK Cell Analysis:** Compare NK cell characteristics and functional responses between the two groups using the same methods as described above.
3. **Statistical Analysis:** If no significant differences are found between the two groups, it would suggest that alterations in the NK cell compartment do not increase the susceptibility to MIS-C.

**Budget and Timeframe:**

* Estimated budget: $100,000 - $150,000
* Estimated timeframe: 6-9 months

**Rationale:**

This experiment is designed to test the hypothesis by comparing NK cell characteristics and functional responses between children who have recovered from severe COVID-19 infection and those who developed MIS-C. By including a matched case-control study to disprove the hypothesis, we can increase the confidence in the results. The budget and timeframe are reasonable, considering the scope of the experiment and the availability of existing methods and equipment.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Blood Sample Collection**

1.1. **Recruitment and Informed Consent**

* Recruit 60 children (20 per group) and obtain informed consent from their parents or legal guardians.
* Ensure that the children meet the inclusion criteria for each group:
	+ Group 1: Healthy controls with no history of COVID-19 infection or MIS-C.
	+ Group 2: Children who have recovered from severe COVID-19 infection (defined as requiring hospitalization or oxygen therapy).
	+ Group 3: Children with MIS-C (defined as meeting the CDC criteria for MIS-C).

1.2. **Blood Sample Collection**

* Collect 10 mL of whole blood from each participant using a sterile needle and syringe.
* Use EDTA or heparin as the anticoagulant.
* Label the samples with a unique identifier and store them at room temperature (20-25°C) for up to 24 hours before processing.

**Protocol 2: NK Cell Isolation and Characterization**

2.1. **PBMC Isolation**

* Isolate peripheral blood mononuclear cells (PBMCs) from the whole blood samples using density gradient centrifugation (e.g., Ficoll-Paque).
* Resuspend the PBMCs in 10 mL of phosphate-buffered saline (PBS) and count the cells using a hemocytometer or an automated cell counter.

2.2. **NK Cell Isolation**

* Use magnetic bead-based separation (e.g., Miltenyi Biotec) or fluorescence-activated cell sorting (FACS) to isolate NK cells from the PBMCs.
* Use the following markers to identify NK cells: CD3-, CD56+, and CD16+.
* Resuspend the isolated NK cells in 1 mL of PBS and count the cells using a hemocytometer or an automated cell counter.

2.3. **Flow Cytometry**

* Stain the isolated NK cells with the following antibodies:
	+ CD69-FITC
	+ CD25-PE
	+ Granzyme B-APC
	+ Perforin-PE-Cy7
* Use a flow cytometer (e.g., BD FACSCanto) to acquire data on the expression of these markers.
* Analyze the data using flow cytometry software (e.g., FlowJo) to determine the frequency and absolute count of NK cells, as well as the expression of activation and cytotoxicity markers.

**Protocol 3: Functional Assays**

3.1. **Cytotoxicity Assay**

* Use the K562 cell line as targets for the NK cell-mediated cytotoxicity assay.
* Label the K562 cells with 51Cr or CFSE and incubate them with the isolated NK cells at an effector-to-target ratio of 10:1.
* Measure the release of 51Cr or CFSE using a gamma counter or a flow cytometer, respectively.
* Calculate the percentage of specific lysis using the following formula: (experimental release - spontaneous release) / (maximum release - spontaneous release) x 100.

3.2. **IFN-γ Production Assay**

* Stimulate the isolated NK cells with IL-12 and IL-18 (10 ng/mL each) for 24 hours.
* Measure the production of IFN-γ using an ELISA kit (e.g., R&D Systems).
* Calculate the concentration of IFN-γ in pg/mL using a standard curve.

**Protocol 4: Statistical Analysis**

4.1. **Data Analysis**

* Compare the NK cell characteristics and functional responses between the three groups using appropriate statistical tests (e.g., ANOVA, t-test, Mann-Whitney U test).
* Use a significance level of 0.05 for all tests.

4.2. **Data Visualization**

* Use graphs and tables to visualize the data and present the results in a clear and concise manner.

**Protocol 5: Matched Case-Control Study**

5.1. **Case Selection**

* Identify 20 children who have recovered from severe COVID-19 infection but did not develop MIS-C.
* Match these children with 20 children who developed MIS-C based on age, sex, and severity of COVID-19 infection.

5.2. **NK Cell Analysis**

* Perform the same NK cell isolation, characterization, and functional assays as described in Protocols 2 and 3.

5.3. **Statistical Analysis**

* Compare the NK cell characteristics and functional responses between the two groups using the same statistical tests as described in Protocol 4.
* If no significant differences are found between the two groups, it would suggest that alterations in the NK cell compartment do not increase the susceptibility to MIS-C.

**Quality Control and Assurance**

* Ensure that all reagents and equipment are of high quality and validated for use in the experiment.
* Perform regular quality control checks on the flow cytometer and other equipment to ensure accuracy and precision.
* Use positive and negative controls for each assay to ensure the validity of the results.

**Timeline and Budget**

* Estimated timeframe: 6-9 months
* Estimated budget: $100,000 - $150,000

Note: The protocols above are detailed and specific, but they may need to be adapted to the specific requirements of the laboratory and the research team. It is essential to follow proper laboratory protocols and safety guidelines when conducting the experiment.","```
   Group  Blood_Volume_mL  EDTA_or_Heparin  PBMC_Isolation_Method  NK_Cell_Isolation_Method  CD69_FITC  CD25_PE  Granzyme_B_APC  Perforin_PE_Cy7  Cytotoxicity_Assay_Effector_Target_Ratio  IFN_gamma_Production_ng_mL  Outcome
0     1             10.0             EDTA            Ficoll-Paque            Magnetic_Bead         20.5    15.2          30.1             25.0                         10:1                500.0  Normal
1     2             9.5             Heparin            Ficoll-Paque            FACS                 18.0    12.5          28.0             22.0                         10:1                450.0  Severe
2     1             10.5             EDTA            Ficoll-Paque            Magnetic_Bead         22.0    16.0          32.0             27.0                         10:1                550.0  Normal
3     3             9.0             EDTA            Ficoll-Paque            FACS                 15.0    10.0          25.0             20.0                         10:1                400.0  MIS-C
4     2             10.0             Heparin            Ficoll-Paque            Magnetic_Bead         19.0    13.0          29.0             23.0                         10:1                480.0  Severe
5     1             9.8             EDTA            Ficoll-Paque            FACS                 21.0    14.5          31.0             25.5                         10:1                520.0  Normal
6     3             10.2             Heparin            Ficoll-Paque            Magnetic_Bead         16.5    11.5          26.5             21.5                         10:1                420.0  MIS-C
7     2             9.2             EDTA            Ficoll-Paque            FACS                 17.5    12.0          27.5             22.5                         10:1                460.0  Severe
8     1             10.8             Heparin            Ficoll-Paque            Magnetic_Bead         23.0    16.5          33.0             28.0                         10:1                580.0  Normal
9     3             9.5             EDTA            Ficoll-Paque            FACS                 14.5    9.5          24.5             19.5                         10:1                380.0  MIS-C
10    2             10.1             Heparin            Ficoll-Paque            Magnetic_Bead         18.5    13.5          28.5             23.5                         10:1                490.0  Severe
11    1             9.9             EDTA            Ficoll-Paque            FACS                 20.5    14.0          30.5             25.0                         10:1                510.0  Normal
12    3             10.4             Heparin            Ficoll-Paque            Magnetic_Bead         15.5    10.5          25.5             20.5                         10:1                410.0  MIS-C
13    2             9.6             EDTA            Ficoll-Paque            FACS                 17.0    11.5          27.0             22.0                         10:1                440.0  Severe
14    1             10.6             Heparin            Ficoll-Paque            Magnetic_Bead         22.5    16.0          32.5             27.5                         10:1                560.0  Normal
15    3             9.1             EDTA            Ficoll-Paque            FACS                 14.0    9.0          24.0             19.0                         10:1                360.0  MIS-C
16    2             10.3             Heparin            Ficoll-Paque            Magnetic_Bead         19.0    13.0          29.0             23.0                         10:1                480.0  Severe
17    1             9.7             EDTA            Ficoll-Paque            FACS                 21.0    14.2          31.0             25.2                         10:1                500.0  Normal
18    3             10.0             Heparin            Ficoll-Paque            Magnetic_Bead         16.0    11.0          26.0             21.0                         10:1                400.0  MIS-C
19    2             9.4             EDTA            Ficoll-Paque            FACS                 17.2    12.2          27.2             22.2                         10:1                450.0  Severe
20    1             10.9             Heparin            Ficoll-Paque            Magnetic_Bead         23.5    16.8          33.5             28.5                         10:1                590.0  Normal
21    3             9.8             EDTA            Ficoll-Paque            FACS                 15.0    10.2          25.0             20.2                         10:1                390.0  MIS-C
22    2             10.2             Heparin            Ficoll-Paque            Magnetic_Bead         18.8    13.8          28.8             23.8                         10:1                470.0  Severe
23    1             9.3             EDTA            Ficoll-Paque            FACS                 20.8    14.5          30.8             25.5                         10:1                520.0  Normal
24    3             10.5             Heparin            Ficoll-Paque            Magnetic_Bead         16.2    11.2          26.2             21.2                         10:1                420.0  MIS-C
```",0.41658357948301483
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b9d0ad3d945db11fd6a9033911cf3b11e4f93538.summary'],"Do asymptomatic children with SARS-CoV-2 infection have a unique immune response that reduces their viral load and infectivity, leading to a lower transmission rate compared to symptomatic individuals with similar viral loads?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** Asymptomatic children with SARS-CoV-2 infection have a unique immune response that reduces their viral load and infectivity, leading to a lower transmission rate compared to symptomatic individuals with similar viral loads.

**Experimental Plan:**

**Objective:** To investigate whether asymptomatic children with SARS-CoV-2 infection have a distinct immune response that reduces their viral load and infectivity, leading to a lower transmission rate compared to symptomatic individuals.

**Study Design:**

1. **Recruitment:** Enroll 100 children (50 asymptomatic and 50 symptomatic) with confirmed SARS-CoV-2 infection, aged 5-18 years, in a hospital or clinical setting.
2. **Sample Collection:** Collect nasopharyngeal swabs, blood samples, and saliva samples from each participant at the time of enrollment and at 3, 7, and 14 days post-enrollment.
3. **Viral Load Measurement:** Quantify SARS-CoV-2 viral load in nasopharyngeal swabs using real-time PCR (RT-PCR) or digital PCR (dPCR).
4. **Immune Response Analysis:** Measure cytokine profiles (e.g., IFN-γ, IL-6, TNF-α) and antibody responses (e.g., IgG, IgM) in blood samples using ELISA or multiplex assays.
5. **Infectivity Assay:** Use a viral culture system (e.g., Vero E6 cells) to assess the infectivity of SARS-CoV-2 isolates from each participant.
6. **Transmission Study:** Conduct a controlled transmission study using a surrogate model (e.g., ferrets or hamsters) to assess the transmission rate of SARS-CoV-2 from asymptomatic and symptomatic children.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on finding evidence that asymptomatic children do not have a unique immune response that reduces their viral load and infectivity.

**Null Hypothesis:** Asymptomatic children with SARS-CoV-2 infection do not have a distinct immune response that reduces their viral load and infectivity compared to symptomatic individuals.

**Alternative Approach:**

1. **Compare Viral Loads:** Compare the viral loads between asymptomatic and symptomatic children at each time point (days 0, 3, 7, and 14) using RT-PCR or dPCR. If the viral loads are similar between the two groups, it would suggest that asymptomatic children do not have a unique immune response that reduces their viral load.
2. **Immune Response Profiling:** Compare the cytokine profiles and antibody responses between asymptomatic and symptomatic children. If the immune responses are similar between the two groups, it would indicate that asymptomatic children do not have a distinct immune response.
3. **Infectivity Assay:** Compare the infectivity of SARS-CoV-2 isolates from asymptomatic and symptomatic children using a viral culture system. If the infectivity is similar between the two groups, it would suggest that asymptomatic children do not have a reduced infectivity.
4. **Transmission Study:** Compare the transmission rates of SARS-CoV-2 from asymptomatic and symptomatic children using a surrogate model. If the transmission rates are similar between the two groups, it would indicate that asymptomatic children do not have a lower transmission rate.

**Budget and Timeline:**

* Estimated budget: $200,000 - $300,000
* Estimated duration: 6-9 months

This experimental plan is designed to test the hypothesis while being mindful of the limited budget, time, and resources. By disproving the null hypothesis, we can gain insights into the immune response of asymptomatic children with SARS-CoV-2 infection and its implications for transmission dynamics.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Recruitment and Sample Collection**

1.1. **Informed Consent**: Obtain informed consent from the parents or legal guardians of the children participating in the study.

1.2. **Screening**: Screen children aged 5-18 years with confirmed SARS-CoV-2 infection in a hospital or clinical setting using PCR or antigen tests.

1.3. **Enrollment**: Enroll 100 children (50 asymptomatic and 50 symptomatic) who meet the inclusion criteria.

1.4. **Sample Collection**:
	* Collect nasopharyngeal swabs using a sterile swab and transport medium.
	* Collect 5 mL of blood from each participant using a sterile needle and syringe.
	* Collect 2 mL of saliva from each participant using a sterile tube.
	* Label and store samples at -80°C or -20°C for further analysis.

**Protocol 2: Viral Load Measurement**

2.1. **RNA Extraction**: Extract RNA from nasopharyngeal swabs using a commercial RNA extraction kit (e.g., QIAamp Viral RNA Mini Kit).

2.2. **RT-PCR or dPCR**: Perform RT-PCR or dPCR using a commercial kit (e.g., TaqMan 2019-nCoV Assay Kit) to quantify SARS-CoV-2 viral load.

2.3. **Standard Curve Generation**: Generate a standard curve using a known concentration of SARS-CoV-2 RNA to quantify the viral load.

2.4. **Viral Load Calculation**: Calculate the viral load in copies/mL using the standard curve and the Ct value obtained from the RT-PCR or dPCR reaction.

**Protocol 3: Immune Response Analysis**

3.1. **Serum Preparation**: Prepare serum from blood samples by centrifugation at 1,500 x g for 10 minutes.

3.2. **Cytokine Profiling**:
	* Use a commercial ELISA kit (e.g., Human IFN-γ ELISA Kit) to measure cytokine levels (e.g., IFN-γ, IL-6, TNF-α).
	* Follow the manufacturer's instructions for sample preparation, antibody coating, and detection.

3.3. **Antibody Response Analysis**:
	* Use a commercial ELISA kit (e.g., Human IgG ELISA Kit) to measure antibody levels (e.g., IgG, IgM).
	* Follow the manufacturer's instructions for sample preparation, antibody coating, and detection.

**Protocol 4: Infectivity Assay**

4.1. **Viral Isolation**: Isolate SARS-CoV-2 from nasopharyngeal swabs using a viral culture system (e.g., Vero E6 cells).

4.2. **Viral Titration**: Titrate the isolated virus using a plaque assay or TCID50 assay.

4.3. **Infectivity Assay**:
	* Infect Vero E6 cells with the isolated virus at a multiplicity of infection (MOI) of 0.01.
	* Incubate the cells for 3-5 days at 37°C and 5% CO2.
	* Measure the cytopathic effect (CPE) using a microscope or a commercial kit (e.g., CellTiter-Glo).

**Protocol 5: Transmission Study**

5.1. **Surrogate Model Preparation**: Prepare ferrets or hamsters as a surrogate model for SARS-CoV-2 transmission.

5.2. **Viral Inoculation**: Inoculate the surrogate model with SARS-CoV-2 isolates from asymptomatic and symptomatic children.

5.3. **Transmission Study**:
	* House the inoculated surrogate models in separate cages with naive animals.
	* Monitor the animals for 14 days for signs of infection (e.g., weight loss, fever).
	* Collect nasal swabs and blood samples from the animals at days 3, 7, and 14 post-inoculation.

**Protocol 6: Data Analysis**

6.1. **Data Collection**: Collect data from all experiments, including viral load, immune response, infectivity, and transmission studies.

6.2. **Statistical Analysis**: Perform statistical analysis using software (e.g., R, Prism) to compare the data between asymptomatic and symptomatic groups.

6.3. **Data Interpretation**: Interpret the results in the context of the hypothesis and null hypothesis.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity in the results.","```
   Nasopharyngeal_Swab_Amount  Blood_Sample_Amount  Saliva_Sample_Amount  Viral_Load  IFN_gamma  IL_6  TNF_alpha  IgG  IgM  Infectivity_Assay_Result  Transmission_Result
0                    0.5 mL             3 mL             1.5 mL     1.23e+06    100.0   50.0      20.0  10.0  5.0                    0.8             1
1                    0.7 mL             4 mL             2.0 mL     2.56e+06    120.0   60.0      25.0  12.0  6.0                    0.9             1
2                    0.3 mL             2 mL             1.0 mL     0.56e+06     80.0   40.0      15.0   8.0  4.0                    0.6             0
3                    0.6 mL             3.5 mL             1.8 mL     1.89e+06    110.0   55.0      22.0  11.0  5.5                    0.85            1
4                    0.4 mL             2.5 mL             1.2 mL     0.89e+06     90.0   45.0      18.0   9.0  4.5                    0.7             0
5                    0.8 mL             4.5 mL             2.5 mL     3.45e+06    130.0   65.0      28.0  13.0  6.5                    0.95            1
6                    0.2 mL             1.5 mL             0.8 mL     0.23e+06     60.0   30.0      12.0   6.0  3.0                    0.4             0
7                    0.9 mL             5 mL             3.0 mL     4.21e+06    140.0   70.0      30.0  14.0  7.0                    1.0             1
8                    0.1 mL             1 mL             0.5 mL     0.12e+06     40.0   20.0       9.0   5.0  2.5                    0.3             0
9                    0.6 mL             3.2 mL             1.6 mL     1.67e+06    100.0   50.0      20.0  10.0  5.0                    0.8             1
10                   0.5 mL             2.8 mL             1.4 mL     1.23e+06     95.0   47.0      19.0   9.5  4.75                    0.78            1
11                   0.7 mL             4.2 mL             2.2 mL     2.89e+06    125.0   62.0      26.0  12.5  6.25                    0.92            1
12                   0.3 mL             2.2 mL             1.1 mL     0.67e+06     85.0   42.0      17.0   8.5  4.25                    0.68            0
13                   0.6 mL             3.8 mL             2.0 mL     2.12e+06    115.0   57.0      23.0  11.5  5.75                    0.88            1
14                   0.4 mL             2.9 mL             1.5 mL     1.01e+06     92.0   46.0      19.0   9.0  4.5                    0.76            0
15                   0.8 mL             5.2 mL             2.8 mL     3.89e+06    135.0   67.0      29.0  13.5  6.75                    0.98            1
16                   0.2 mL             1.8 mL             0.9 mL     0.34e+06     70.0   35.0      14.0   7.0  3.5                    0.52            0
17                   0.9 mL             5.5 mL             3.2 mL     4.56e+06    145.0   72.0      31.0  14.5  7.25                    1.02            1
18                   0.1 mL             1.2 mL             0.6 mL     0.15e+06     50.0   25.0      11.0   5.5  2.75                    0.38            0
19                   0.6 mL             3.5 mL             1.7 mL     1.83e+06    105.0   52.0      21.0  10.5  5.25                    0.82            1
20                   0.5 mL             3.0 mL             1.3 mL     1.39e+06     98.0   49.0      20.0   9.8  4.9                    0.79            1
21                   0.7 mL             4.5 mL             2.4 mL     3.14e+06    128.0   64.0      27.0  12.8  6.4                    0.94            1
22                   0.3 mL             2.5 mL             1.2 mL     0.79e+06     88.0   44.0      18.0   8.8  4.4                    0.72            0
23                   0.6 mL             4.0 mL             2.1 mL     2.45e+06    118.0   59.0      24.0  11.8  5.9                    0.9             1
24                   0.4 mL             3.2 mL             1.6 mL     1.15e+06     96.0   48.0      20.0   9.6  4.8                    0.8             0
```",0.5253540933263839
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f6ce76346ebc01e62f92dc72af8132294a24cd3f.summary'],Do atypical memory B cells and plasma cells in severe COVID-19 patients exhibit altered epigenetic marks that influence their inflammatory features and somatic hypermutation patterns?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that atypical memory B cells and plasma cells in severe COVID-19 patients exhibit altered epigenetic marks that influence their inflammatory features and somatic hypermutation patterns.

**Experiment Title:** Investigating Epigenetic Marks and Inflammatory Features of Atypical Memory B Cells and Plasma Cells in Severe COVID-19 Patients

**Objective:** To determine if atypical memory B cells and plasma cells in severe COVID-19 patients exhibit altered epigenetic marks that influence their inflammatory features and somatic hypermutation patterns.

**Experimental Design:**

1. **Sample Collection:** Collect peripheral blood mononuclear cells (PBMCs) from severe COVID-19 patients and healthy controls.
2. **Cell Isolation:** Isolate B cells from PBMCs using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
3. **Cell Sorting:** Sort atypical memory B cells and plasma cells from the isolated B cells using markers such as CD27, CD38, and CD138.
4. **Epigenetic Analysis:** Perform reduced representation bisulfite sequencing (RRBS) or chromatin immunoprecipitation sequencing (ChIP-seq) to analyze the epigenetic marks (DNA methylation and histone modifications) on the sorted atypical memory B cells and plasma cells.
5. **Inflammatory Feature Analysis:** Measure the expression of inflammatory genes (e.g., TNF-α, IL-6, IL-1β) in the sorted atypical memory B cells and plasma cells using quantitative reverse transcription polymerase chain reaction (qRT-PCR) or RNA sequencing.
6. **Somatic Hypermutation Analysis:** Analyze the somatic hypermutation patterns in the immunoglobulin heavy chain genes of the sorted atypical memory B cells and plasma cells using high-throughput sequencing.
7. **Comparison and Statistical Analysis:** Compare the epigenetic marks, inflammatory features, and somatic hypermutation patterns between atypical memory B cells and plasma cells from severe COVID-19 patients and healthy controls. Perform statistical analysis to identify significant differences.

**To Disprove the Hypothesis:**

* If the epigenetic marks, inflammatory features, and somatic hypermutation patterns of atypical memory B cells and plasma cells from severe COVID-19 patients are similar to those of healthy controls, it would suggest that the hypothesis is false.
* If the analysis reveals no correlation between the epigenetic marks and inflammatory features or somatic hypermutation patterns, it would also disprove the hypothesis.

**Required Equipment:**

* Flow cytometer
* Cell sorter (FACS or magnetic bead-based)
* RRBS or ChIP-seq platform
* qRT-PCR or RNA sequencing platform
* High-throughput sequencing platform
* Bioinformatics tools for data analysis

**Expected Outcome:**

* The experiment is expected to provide insights into the epigenetic marks, inflammatory features, and somatic hypermutation patterns of atypical memory B cells and plasma cells in severe COVID-19 patients.
* If the hypothesis is true, the experiment should reveal altered epigenetic marks that influence the inflammatory features and somatic hypermutation patterns of atypical memory B cells and plasma cells in severe COVID-19 patients.

**Timeline:**

* Sample collection and cell isolation: 2 weeks
* Cell sorting and epigenetic analysis: 4 weeks
* Inflammatory feature and somatic hypermutation analysis: 4 weeks
* Data analysis and interpretation: 6 weeks

**Budget:**

* Sample collection and cell isolation: $5,000
* Cell sorting and epigenetic analysis: $15,000
* Inflammatory feature and somatic hypermutation analysis: $10,000
* Data analysis and interpretation: $10,000
* Total budget: $40,000

This experiment is designed to test the hypothesis and can be completed within a reasonable time frame (approximately 20 weeks) and budget ($40,000).",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Sample Collection**

1.1. Obtain informed consent from severe COVID-19 patients and healthy controls.

1.2. Collect 10 mL of peripheral blood from each participant using a sterile needle and syringe.

1.3. Transfer the blood to a 15 mL conical tube containing 1 mL of anticoagulant (e.g., EDTA or heparin).

1.4. Mix the blood gently and store it at room temperature (20-25°C) for up to 24 hours before processing.

**Protocol 2: Cell Isolation**

2.1. Prepare a density gradient medium (e.g., Ficoll-Paque) according to the manufacturer's instructions.

2.2. Carefully layer 10 mL of blood onto 10 mL of density gradient medium in a 50 mL conical tube.

2.3. Centrifuge the tube at 400 x g for 30 minutes at room temperature.

2.4. Collect the peripheral blood mononuclear cells (PBMCs) from the interface between the plasma and density gradient medium using a sterile pipette.

2.5. Wash the PBMCs with 10 mL of phosphate-buffered saline (PBS) and centrifuge at 300 x g for 10 minutes.

2.6. Resuspend the PBMCs in 1 mL of PBS and count the cells using a hemocytometer or automated cell counter.

**Protocol 3: Cell Sorting**

3.1. Prepare the following antibodies for cell sorting:
	* CD27-PE (phycoerythrin)
	* CD38-APC (allophycocyanin)
	* CD138-FITC (fluorescein isothiocyanate)

3.2. Add 1 μL of each antibody to 100 μL of PBMCs and incubate at room temperature for 30 minutes.

3.3. Wash the cells with 10 mL of PBS and centrifuge at 300 x g for 10 minutes.

3.4. Resuspend the cells in 1 mL of PBS and sort the atypical memory B cells (CD27+CD38-) and plasma cells (CD138+CD38+) using a flow cytometer or cell sorter.

3.5. Collect the sorted cells in 1.5 mL microcentrifuge tubes and store them at -80°C for further analysis.

**Protocol 4: Epigenetic Analysis (RRBS or ChIP-seq)**

4.1. Prepare genomic DNA from the sorted cells using a DNA extraction kit according to the manufacturer's instructions.

4.2. Perform reduced representation bisulfite sequencing (RRBS) or chromatin immunoprecipitation sequencing (ChIP-seq) according to the platform's protocol.

4.3. For RRBS:
	* Bisulfite-convert 100 ng of genomic DNA using a bisulfite conversion kit.
	* Perform PCR amplification using primers specific to the target regions.
	* Sequence the amplified DNA using a next-generation sequencing platform.

4.4. For ChIP-seq:
	* Cross-link the chromatin using formaldehyde and sonicate the DNA to an average size of 200-500 bp.
	* Immunoprecipitate the chromatin using antibodies specific to the target histone modifications (e.g., H3K4me3, H3K27me3).
	* Sequence the immunoprecipitated DNA using a next-generation sequencing platform.

**Protocol 5: Inflammatory Feature Analysis (qRT-PCR or RNA-seq)**

5.1. Extract total RNA from the sorted cells using an RNA extraction kit according to the manufacturer's instructions.

5.2. Perform quantitative reverse transcription polymerase chain reaction (qRT-PCR) or RNA sequencing (RNA-seq) according to the platform's protocol.

5.3. For qRT-PCR:
	* Reverse-transcribe 100 ng of RNA using a reverse transcription kit.
	* Perform PCR amplification using primers specific to the target inflammatory genes (e.g., TNF-α, IL-6, IL-1β).
	* Analyze the PCR products using a qRT-PCR instrument.

5.4. For RNA-seq:
	* Prepare a sequencing library using a RNA-seq kit according to the manufacturer's instructions.
	* Sequence the library using a next-generation sequencing platform.

**Protocol 6: Somatic Hypermutation Analysis**

6.1. Extract genomic DNA from the sorted cells using a DNA extraction kit according to the manufacturer's instructions.

6.2. Amplify the immunoglobulin heavy chain genes using PCR primers specific to the target regions.

6.3. Sequence the amplified DNA using a next-generation sequencing platform.

6.4. Analyze the sequencing data using bioinformatics tools to identify somatic hypermutations.

**Protocol 7: Comparison and Statistical Analysis**

7.1. Compare the epigenetic marks, inflammatory features, and somatic hypermutation patterns between atypical memory B cells and plasma cells from severe COVID-19 patients and healthy controls.

7.2. Perform statistical analysis using tools such as R or Python to identify significant differences between the groups.

7.3. Use a false discovery rate (FDR) of 0.05 to correct for multiple testing.

**Note:** The above protocols are general guidelines and may need to be optimized for specific laboratory settings and equipment. It is essential to follow proper laboratory safety protocols and to validate the results using appropriate controls and replicates.","```
   EDTA_volume  Ficoll_volume  CD27_volume  CD38_volume  CD138_volume  PBMC_count  Epigenetic_analysis  Inflammatory_features  Somatic_hypermutation  Outcome
0           0.8          10.0         0.5         0.5          0.5       1000000             0.75               2.5               0.8       1
1           1.0          12.0         0.7         0.3          0.6       1200000             0.80               3.0               0.9       1
2           0.9          11.0         0.6         0.4          0.7       1100000             0.78               2.8               0.85      1
3           1.1          13.0         0.8         0.2          0.8       1300000             0.82               3.2               0.95      1
4           0.7          9.0          0.4         0.6          0.4        900000             0.72               2.2               0.75      0
5           1.2          14.0         0.9         0.1          0.9       1400000             0.85               3.5               1.00      1
6           0.8          10.5         0.5         0.5          0.5       1050000             0.77               2.6               0.83      1
7           1.0          12.5         0.7         0.3          0.6       1250000             0.81               3.1               0.92      1
8           0.9          11.5         0.6         0.4          0.7       1150000             0.79               2.9               0.88      1
9           1.1          13.5         0.8         0.2          0.8       1350000             0.84               3.3               0.98      1
10          0.7          9.5          0.4         0.6          0.4        950000             0.73               2.3               0.80      0
11          1.2          14.5         0.9         0.1          0.9       1450000             0.87               3.6               1.05      1
12          0.8          10.8         0.5         0.5          0.5       1080000             0.78               2.7               0.86      1
13          1.0          12.8         0.7         0.3          0.6       1280000             0.82               3.2               0.94      1
14          0.9          11.8         0.6         0.4          0.7       1180000             0.80               3.0               0.90      1
15          1.1          13.8         0.8         0.2          0.8       1380000             0.85               3.4               1.02      1
16          0.7          9.8          0.4         0.6          0.4        980000             0.74               2.4               0.82      0
17          1.2          14.8         0.9         0.1          0.9       1480000             0.89               3.7               1.10      1
18          0.8          11.0         0.5         0.5          0.5       1100000             0.79               2.8               0.87      1
19          1.0          12.0         0.7         0.3          0.6       1200000             0.83               3.3               0.96      1
20          0.9          11.2         0.6         0.4          0.7       1120000             0.81               3.1               0.92      1
21          1.1          13.2         0.8         0.2          0.8       1320000             0.86               3.5               1.04      1
22          0.7          9.2          0.4         0.6          0.4        920000             0.75               2.5               0.84      0
23          1.2          14.2         0.9         0.1          0.9       1420000             0.90               3.8               1.12      1
24          0.8          10.2         0.5         0.5          0.5       1020000             0.80               2.9               0.89      1
```",0.48527829975722053
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0da0069e84ed549f728098d73f8a31ea38c2492f.summary'],"Do atypical memory B cells in AML patients also modulate the function of natural killer cells, leading to impaired anti-tumor responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Atypical memory B cells in AML (Acute Myeloid Leukemia) patients modulate the function of natural killer (NK) cells, leading to impaired anti-tumor responses.

**Experimental Plan:**

**Objective:** To investigate whether atypical memory B cells in AML patients impair anti-tumor responses by modulating NK cell function.

**Approach:** To disprove the hypothesis, we will design an experiment to demonstrate that atypical memory B cells do not affect NK cell function or anti-tumor responses in AML patients.

**Experimental Design:**

**Step 1: Sample Collection**

* Collect peripheral blood mononuclear cells (PBMCs) from AML patients and healthy donors.
* Isolate atypical memory B cells (CD19+CD27-CD38-CD24hi) and NK cells (CD3-CD56+CD16+) using fluorescence-activated cell sorting (FACS).

**Step 2: Co-Culture Experiments**

* Set up co-culture experiments with isolated atypical memory B cells and NK cells from AML patients and healthy donors.
* Use a transwell system to separate the two cell types, allowing for cell-cell contact and soluble factor exchange.
* Incubate the co-cultures for 24-48 hours to allow for potential modulation of NK cell function.

**Step 3: NK Cell Functional Assays**

* Perform functional assays to assess NK cell activity, including:
	+ Cytotoxicity assays (e.g., chromium release or flow cytometry-based assays) to measure NK cell-mediated killing of tumor cells (e.g., K562 or AML cell lines).
	+ IFN-γ production assays (e.g., ELISA or intracellular cytokine staining) to evaluate NK cell activation.
	+ Proliferation assays (e.g., CFSE or BrdU incorporation) to assess NK cell expansion.

**Step 4: Comparison and Controls**

* Compare the results from co-cultures with atypical memory B cells from AML patients to those with atypical memory B cells from healthy donors.
* Include controls with NK cells alone (no co-culture) and with autologous or allogenic B cells (to account for non-specific effects).

**Step 5: Mechanistic Insights**

* Perform additional experiments to investigate potential mechanisms underlying any observed modulation of NK cell function, such as:
	+ Cytokine profiling (e.g., IL-10, TGF-β, or IL-12) using ELISA or multiplex assays.
	+ Cell surface marker analysis (e.g., CD107a, CD25, or PD-1) using flow cytometry.

**Step 6: Data Analysis and Interpretation**

* Analyze the data using appropriate statistical methods (e.g., t-tests, ANOVA, or regression analysis).
* Interpret the results in the context of the hypothesis: if atypical memory B cells from AML patients do not modulate NK cell function or anti-tumor responses, the hypothesis is disproven.

**Unlimited Budget Considerations:**

* Utilize cutting-edge technologies, such as single-cell RNA sequencing or mass cytometry, to gain deeper insights into the interactions between atypical memory B cells and NK cells.
* Perform large-scale screens for potential therapeutic targets or biomarkers using CRISPR-Cas9 genome editing or proteomics approaches.
* Collaborate with experts in bioinformatics and computational biology to develop predictive models of NK cell function and anti-tumor responses based on atypical memory B cell characteristics.

By following this experimental plan, we can rigorously test the hypothesis and determine whether atypical memory B cells in AML patients indeed modulate NK cell function and anti-tumor responses.",85,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Sample Collection**

1.1. Obtain informed consent from AML patients and healthy donors.

1.2. Collect 20-30 mL of peripheral blood from each participant using a sterile needle and syringe.

1.3. Transfer the blood to a 50 mL conical tube containing 5 mL of anticoagulant (e.g., EDTA or heparin).

1.4. Mix the blood gently and store it at room temperature (RT) for up to 2 hours before processing.

1.5. Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation (e.g., Ficoll-Paque) according to the manufacturer's instructions.

1.6. Wash the PBMCs twice with phosphate-buffered saline (PBS) and resuspend them in 10 mL of PBS.

**Step 1.7: Cell Counting and Viability Assessment**

1.7.1. Determine the total cell count using a hemocytometer or an automated cell counter.

1.7.2. Assess cell viability using trypan blue exclusion or a viability dye (e.g., 7-AAD) and a flow cytometer.

**Step 1.8: Cell Staining and FACS Sorting**

1.8.1. Stain the PBMCs with the following antibodies:
	* CD19-APC (clone HIB19)
	* CD27-PE (clone M-T271)
	* CD38-PerCP-Cy5.5 (clone HIT2)
	* CD24-FITC (clone ML5)
	* CD3-APC-Cy7 (clone SK7)
	* CD56-PE-Cy7 (clone B159)
	* CD16-FITC (clone 3G8)

1.8.2. Incubate the cells with the antibodies for 30 minutes at 4°C in the dark.

1.8.3. Wash the cells twice with PBS and resuspend them in 1 mL of PBS.

1.8.4. Sort the cells using a fluorescence-activated cell sorter (FACS) to isolate atypical memory B cells (CD19+CD27-CD38-CD24hi) and NK cells (CD3-CD56+CD16+).

**Step 2: Co-Culture Experiments**

2.1. Prepare 24-well plates with a 0.4 μm pore size transwell insert.

2.2. Add 1 x 10^5 atypical memory B cells or autologous/allogenic B cells to the upper chamber of the transwell insert.

2.3. Add 1 x 10^5 NK cells to the lower chamber of the 24-well plate.

2.4. Add 500 μL of complete RPMI-1640 medium (supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine) to the lower chamber.

2.5. Incubate the co-cultures at 37°C, 5% CO2 for 24-48 hours.

**Step 3: NK Cell Functional Assays**

3.1. **Cytotoxicity Assay**

3.1.1. Label target cells (e.g., K562 or AML cell lines) with 100 μCi of 51Cr for 1 hour at 37°C.

3.1.2. Wash the target cells twice with PBS and resuspend them in 1 mL of complete RPMI-1640 medium.

3.1.3. Add 1 x 10^4 target cells to each well of a 96-well plate.

3.1.4. Add 1 x 10^5 NK cells from the co-culture to each well.

3.1.5. Incubate the plates at 37°C, 5% CO2 for 4 hours.

3.1.6. Harvest the supernatant and measure the 51Cr release using a gamma counter.

3.2. **IFN-γ Production Assay**

3.2.1. Add 1 x 10^5 NK cells from the co-culture to each well of a 96-well plate.

3.2.2. Add 100 μL of complete RPMI-1640 medium containing 10 ng/mL of IL-12 and 10 ng/mL of IL-18.

3.2.3. Incubate the plates at 37°C, 5% CO2 for 24 hours.

3.2.4. Harvest the supernatant and measure IFN-γ production using an ELISA kit.

3.3. **Proliferation Assay**

3.3.1. Label NK cells from the co-culture with 1 μM of CFSE or 10 μM of BrdU.

3.3.2. Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

3.3.3. Analyze the cells using a flow cytometer to assess proliferation.

**Step 4: Comparison and Controls**

4.1. Compare the results from co-cultures with atypical memory B cells from AML patients to those with atypical memory B cells from healthy donors.

4.2. Include controls with NK cells alone (no co-culture) and with autologous or allogenic B cells (to account for non-specific effects).

**Step 5: Mechanistic Insights**

5.1. **Cytokine Profiling**

5.1.1. Harvest the supernatant from the co-culture and measure cytokine levels (e.g., IL-10, TGF-β, or IL-12) using an ELISA kit or multiplex assay.

5.2. **Cell Surface Marker Analysis**

5.2.1. Stain the NK cells from the co-culture with antibodies against CD107a, CD25, or PD-1.

5.2.2. Analyze the cells using a flow cytometer to assess cell surface marker expression.

**Step 6: Data Analysis and Interpretation**

6.1. Analyze the data using appropriate statistical methods (e.g., t-tests, ANOVA, or regression analysis).

6.2. Interpret the results in the context of the hypothesis: if atypical memory B cells from AML patients do not modulate NK cell function or anti-tumor responses, the hypothesis is disproven.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity.","```
   AML_Patient  Healthy_Donor  Atypical_Memory_B_Cells  NK_Cells  IL-12  IL-18  Cytotoxicity  IFN-γ_Production  Proliferation  CD107a_Expression  CD25_Expression  PD-1_Expression
0           1.0           0.0                50000.0  50000.0   10.0   10.0       20.0              100.0         20.0             30.0             20.0             10.0
1           0.0           1.0                40000.0  60000.0   15.0   15.0       25.0              120.0         25.0             35.0             25.0             15.0
2           1.0           0.0                60000.0  40000.0   12.0   12.0       22.0              110.0         22.0             32.0             22.0             12.0
3           0.0           1.0                30000.0  70000.0   18.0   18.0       28.0              130.0         28.0             38.0             28.0             18.0
4           1.0           0.0                70000.0  30000.0   10.0   10.0       20.0              100.0         20.0             30.0             20.0             10.0
5           0.0           1.0                20000.0  80000.0   20.0   20.0       30.0              140.0         30.0             40.0             30.0             20.0
6           1.0           0.0                80000.0  20000.0   12.0   12.0       22.0              110.0         22.0             32.0             22.0             12.0
7           0.0           1.0                10000.0  90000.0   22.0   22.0       32.0              150.0         32.0             42.0             32.0             22.0
8           1.0           0.0                90000.0  10000.0   15.0   15.0       25.0              120.0         25.0             35.0             25.0             15.0
9           0.0           1.0                50000.0  50000.0   18.0   18.0       28.0              130.0         28.0             38.0             28.0             18.0
10          1.0           0.0                40000.0  60000.0   12.0   12.0       22.0              110.0         22.0             32.0             22.0             12.0
11          0.0           1.0                60000.0  40000.0   20.0   20.0       30.0              140.0         30.0             40.0             30.0             20.0
12          1.0           0.0                30000.0  70000.0   15.0   15.0       25.0              120.0         25.0             35.0             25.0             15.0
13          0.0           1.0                70000.0  30000.0   18.0   18.0       28.0              130.0         28.0             38.0             28.0             18.0
14          1.0           0.0                20000.0  80000.0   12.0   12.0       22.0              110.0         22.0             32.0             22.0             12.0
15          0.0           1.0                80000.0  20000.0   20.0   20.0       30.0              140.0         30.0             40.0             30.0             20.0
16          1.0           0.0                10000.0  90000.0   15.0   15.0       25.0              120.0         25.0             35.0             25.0             15.0
17          0.0           1.0                90000.0  10000.0   18.0   18.0       28.0              130.0         28.0             38.0             28.0             18.0
18          1.0           0.0                50000.0  50000.0   12.0   12.0       22.0              110.0         22.0             32.0             22.0             12.0
19          0.0           1.0                40000.0  60000.0   20.0   20.0       30.0              140.0         30.0             40.0             30.0             20.0
20          1.0           0.0                60000.0  40000.0   15.0   15.0       25.0              120.0         25.0             35.0             25.0             15.0
21          0.0           1.0                30000.0  70000.0   18.0   18.0       28.0              130.0         28.0             38.0             28.0             18.0
22          1.0           0.0                70000.0  30000.0   12.0   12.0       22.0              110.0         22.0             32.0             22.0             12.0
23          0.0           1.0                20000.0  80000.0   20.0   20.0       30.0              140.0         30.0             40.0             30.0             20.0
24          1.0           0.0                80000.0  20000.0   15.0   15.0       25.0              120.0         25.0             35.0             25.0             15.0
```",0.6359873159848092
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7808fd1bdb4a665f3660786e53d16dac824fc6cd.summary'],"Do dynamic pre-BCR homodimers also regulate the expression of genes involved in DNA repair, thereby contributing to the development of resistance to chemotherapy in B cell precursor acute lymphoblastic leukemia?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Dynamic pre-BCR homodimers regulate the expression of genes involved in DNA repair, contributing to the development of resistance to chemotherapy in B cell precursor acute lymphoblastic leukemia (BCP-ALL).

**Experimental Plan:**

**Objective:** To investigate whether dynamic pre-BCR homodimers regulate DNA repair gene expression, leading to chemotherapy resistance in BCP-ALL.

**Approach:**

1. **Cell Culture and Model Systems:**
	* Establish BCP-ALL cell lines with inducible pre-BCR homodimer expression (e.g., using CRISPR-Cas9 or lentiviral vectors).
	* Generate isogenic cell lines with pre-BCR homodimer knockout or knockdown using CRISPR-Cas9 or shRNA, respectively.
	* Use primary BCP-ALL patient samples with varying levels of pre-BCR homodimer expression.
2. **RNA Sequencing and Gene Expression Analysis:**
	* Perform RNA sequencing (RNA-seq) on the above cell lines and primary patient samples to identify differentially expressed genes involved in DNA repair.
	* Validate the expression of selected DNA repair genes using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting.
3. **ChIP-Seq and Chromatin Immunoprecipitation (ChIP):**
	* Perform ChIP-seq to identify pre-BCR homodimer binding sites on DNA repair gene promoters.
	* Validate ChIP-seq results using ChIP-qPCR and ChIP-sequencing.
4. **Functional Assays:**
	* Measure DNA repair capacity using assays such as the comet assay, γH2AX foci formation, and homologous recombination repair (HRR) assays.
	* Evaluate chemotherapy resistance using cell viability assays (e.g., MTT, CellTiter-Glo) and apoptosis assays (e.g., Annexin V, TUNEL).
5. **Protein-Protein Interaction Analysis:**
	* Investigate pre-BCR homodimer interactions with DNA repair proteins using co-immunoprecipitation (co-IP), proximity ligation assay (PLA), and bioluminescence resonance energy transfer (BRET) assays.
6. **In Vivo Studies:**
	* Use xenograft models of BCP-ALL to evaluate the effect of pre-BCR homodimer expression on chemotherapy response and DNA repair gene expression in vivo.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that pre-BCR homodimers do not regulate DNA repair gene expression, leading to chemotherapy resistance in BCP-ALL.

**Approach:**

1. **Rescue Experiment:**
	* Use CRISPR-Cas9 to knockout a key DNA repair gene (e.g., BRCA1) in BCP-ALL cells with high pre-BCR homodimer expression.
	* Evaluate chemotherapy resistance and DNA repair capacity in these cells.
	* If pre-BCR homodimers do not regulate DNA repair gene expression, chemotherapy resistance should not be affected by the knockout of the DNA repair gene.
2. **Dominant-Negative Experiment:**
	* Express a dominant-negative mutant of a DNA repair protein (e.g., BRCA1) in BCP-ALL cells with high pre-BCR homodimer expression.
	* Evaluate chemotherapy resistance and DNA repair capacity in these cells.
	* If pre-BCR homodimers do not regulate DNA repair gene expression, the dominant-negative mutant should not affect chemotherapy resistance.

**Rationale:** By designing an experiment to disprove the hypothesis, we can test the robustness of the hypothesis and identify potential flaws in the experimental design. If the experiment fails to disprove the hypothesis, it would strengthen the evidence supporting the original hypothesis.

**Unlimited Budget:** With unlimited resources, we can:

* Perform high-throughput RNA-seq and ChIP-seq analyses to identify comprehensive lists of differentially expressed genes and pre-BCR homodimer binding sites.
* Use cutting-edge techniques like single-cell RNA-seq and single-molecule localization microscopy to gain a deeper understanding of pre-BCR homodimer regulation of DNA repair gene expression.
* Conduct large-scale xenograft studies to evaluate the in vivo relevance of the findings.

By following this experimental plan, we can rigorously test the hypothesis and gain a deeper understanding of the role of pre-BCR homodimers in chemotherapy resistance in BCP-ALL.",92,"Here are the detailed, step-by-step protocols for each experiment outlined in the plan:

**Experiment 1: Cell Culture and Model Systems**

**Objective:** Establish BCP-ALL cell lines with inducible pre-BCR homodimer expression and generate isogenic cell lines with pre-BCR homodimer knockout or knockdown.

**Protocol:**

1.1. **CRISPR-Cas9 mediated pre-BCR homodimer knockout:**

* Design guide RNAs (gRNAs) targeting the pre-BCR homodimer gene using online tools (e.g., CRISPR Design).
* Clone the gRNAs into a CRISPR-Cas9 vector (e.g., pSpCas9(BB)-2A-GFP).
* Transfect the vector into BCP-ALL cells using a transfection reagent (e.g., Lipofectamine 3000).
* Select for GFP-positive cells using fluorescence-activated cell sorting (FACS).
* Validate knockout using Western blotting and qRT-PCR.

1.2. **Lentiviral vector-mediated pre-BCR homodimer overexpression:**

* Clone the pre-BCR homodimer gene into a lentiviral vector (e.g., pLenti-CMV-Puro-DEST).
* Produce lentivirus using a packaging cell line (e.g., HEK293T).
* Infect BCP-ALL cells with the lentivirus and select for puromycin-resistant cells.
* Validate overexpression using Western blotting and qRT-PCR.

1.3. **shRNA-mediated pre-BCR homodimer knockdown:**

* Design shRNAs targeting the pre-BCR homodimer gene using online tools (e.g., RNAi Designer).
* Clone the shRNAs into a lentiviral vector (e.g., pLenti-U6-shRNA-Puro-DEST).
* Produce lentivirus using a packaging cell line (e.g., HEK293T).
* Infect BCP-ALL cells with the lentivirus and select for puromycin-resistant cells.
* Validate knockdown using Western blotting and qRT-PCR.

**Experiment 2: RNA Sequencing and Gene Expression Analysis**

**Objective:** Identify differentially expressed genes involved in DNA repair using RNA sequencing and validate using qRT-PCR and Western blotting.

**Protocol:**

2.1. **RNA sequencing:**

* Isolate total RNA from BCP-ALL cell lines and primary patient samples using a RNA isolation kit (e.g., TRIzol).
* Prepare RNA-seq libraries using a commercial kit (e.g., TruSeq Stranded mRNA Library Prep Kit).
* Sequence the libraries using a next-generation sequencing platform (e.g., Illumina HiSeq 4000).
* Analyze the data using a bioinformatics pipeline (e.g., STAR, DESeq2) to identify differentially expressed genes.

2.2. **qRT-PCR validation:**

* Design primers for selected DNA repair genes using online tools (e.g., Primer3).
* Perform qRT-PCR using a commercial kit (e.g., PowerUp SYBR Green Master Mix) and a qPCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).
* Analyze the data using the 2^(-ΔΔCt) method to calculate fold changes.

2.3. **Western blotting validation:**

* Isolate protein lysates from BCP-ALL cell lines and primary patient samples using a lysis buffer (e.g., RIPA buffer).
* Perform Western blotting using a commercial kit (e.g., ECL Western Blotting Substrate) and a primary antibody against the DNA repair protein of interest.
* Analyze the data using image analysis software (e.g., ImageJ) to calculate band intensities.

**Experiment 3: ChIP-Seq and Chromatin Immunoprecipitation (ChIP)**

**Objective:** Identify pre-BCR homodimer binding sites on DNA repair gene promoters using ChIP-seq and validate using ChIP-qPCR and ChIP-sequencing.

**Protocol:**

3.1. **ChIP-seq:**

* Cross-link BCP-ALL cells with formaldehyde and sonicate the chromatin using a sonication device (e.g., Covaris S220).
* Immunoprecipitate the chromatin using a pre-BCR homodimer antibody and a commercial ChIP kit (e.g., Magna ChIP A Kit).
* Prepare ChIP-seq libraries using a commercial kit (e.g., TruSeq ChIP Library Prep Kit).
* Sequence the libraries using a next-generation sequencing platform (e.g., Illumina HiSeq 4000).
* Analyze the data using a bioinformatics pipeline (e.g., MACS2, PeakRanger) to identify pre-BCR homodimer binding sites.

3.2. **ChIP-qPCR validation:**

* Design primers for selected DNA repair gene promoters using online tools (e.g., Primer3).
* Perform ChIP-qPCR using a commercial kit (e.g., PowerUp SYBR Green Master Mix) and a qPCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).
* Analyze the data using the 2^(-ΔΔCt) method to calculate fold enrichments.

3.3. **ChIP-sequencing validation:**

* Perform ChIP-sequencing using a commercial kit (e.g., TruSeq ChIP Library Prep Kit).
* Sequence the libraries using a next-generation sequencing platform (e.g., Illumina HiSeq 4000).
* Analyze the data using a bioinformatics pipeline (e.g., MACS2, PeakRanger) to validate pre-BCR homodimer binding sites.

**Experiment 4: Functional Assays**

**Objective:** Measure DNA repair capacity using assays such as the comet assay, γH2AX foci formation, and homologous recombination repair (HRR) assays, and evaluate chemotherapy resistance using cell viability assays and apoptosis assays.

**Protocol:**

4.1. **Comet assay:**

* Treat BCP-ALL cells with a DNA-damaging agent (e.g., etoposide) and allow for DNA repair.
* Isolate cells and perform the comet assay using a commercial kit (e.g., Trevigen CometAssay Kit).
* Analyze the data using image analysis software (e.g., ImageJ) to calculate tail moments.

4.2. **γH2AX foci formation:**

* Treat BCP-ALL cells with a DNA-damaging agent (e.g., etoposide) and allow for DNA repair.
* Fix and permeabilize cells using a commercial kit (e.g., BD Cytofix/Cytoperm Kit).
* Stain cells with a γH2AX antibody and a secondary antibody conjugated to a fluorophore (e.g., Alexa Fluor 488).
* Analyze the data using a fluorescence microscope (e.g., Zeiss Axiovert 200M) to count γH2AX foci.

4.3. **HRR assay:**

* Transfect BCP-ALL cells with a plasmid containing a DNA repair substrate (e.g., DR-GFP).
* Treat cells with a DNA-damaging agent (e.g., etoposide) and allow for DNA repair.
* Analyze the data using flow cytometry (e.g., BD FACSCanto II) to measure GFP-positive cells.

4.4. **Cell viability assay:**

* Treat BCP-ALL cells with a chemotherapeutic agent (e.g., doxorubicin) and measure cell viability using a commercial kit (e.g., CellTiter-Glo).
* Analyze the data using a plate reader (e.g., PerkinElmer EnVision) to calculate cell viability.

4.5. **Apoptosis assay:**

* Treat BCP-ALL cells with a chemotherapeutic agent (e.g., doxorubicin) and measure apoptosis using a commercial kit (e.g., Annexin V-FITC Apoptosis Detection Kit).
* Analyze the data using flow cytometry (e.g., BD FACSCanto II) to measure Annexin V-positive cells.

**Experiment 5: Protein-Protein Interaction Analysis**

**Objective:** Investigate pre-BCR homodimer interactions with DNA repair proteins using co-IP, PLA, and BRET assays.

**Protocol:**

5.1. **Co-IP:**

* Transfect BCP-ALL cells with a plasmid expressing a DNA repair protein (e.g., BRCA1) and a plasmid expressing the pre-BCR homodimer.
* Immunoprecipitate the pre-BCR homodimer using a commercial co-IP kit (e.g., Pierce Co-Immunoprecipitation Kit).
* Analyze the data using Western blotting to detect the DNA repair protein.

5.2. **PLA:**

* Transfect BCP-ALL cells with a plasmid expressing a DNA repair protein (e.g., BRCA1) and a plasmid expressing the pre-BCR homodimer.
* Perform PLA using a commercial kit (e.g., Duolink PLA Kit).
* Analyze the data using a fluorescence microscope (e.g., Zeiss Axiovert 200M) to count PLA signals.

5.3. **BRET:**

* Transfect BCP-ALL cells with a plasmid expressing a DNA repair protein (e.g., BRCA1) fused to a luciferase and a plasmid expressing the pre-BCR homodimer fused to a fluorescent protein (e.g., GFP).
* Measure BRET signals using a commercial kit (e.g., Promega BRET System).
* Analyze the data using a plate reader (e.g., PerkinElmer EnVision) to calculate BRET ratios.

**Experiment 6: In Vivo Studies**

**Objective:** Evaluate the effect of pre-BCR homodimer expression on chemotherapy response and DNA repair gene expression in vivo using xenograft models of BCP-ALL.

**Protocol:**

6.1. **Xenograft model establishment:**

* Inject BCP-ALL cells into immunodeficient mice (e.g., NOD/SCID) using a commercial kit (e.g., Xenograft Tumor Model Kit).
* Allow tumors to grow and treat with a chemotherapeutic agent (e.g., doxorubicin).

6.2. **Tumor analysis:**

* Harvest tumors and isolate RNA and protein using commercial kits (e.g., TRIzol, RIPA buffer).
* Analyze RNA and protein expression using qRT-PCR and Western blotting, respectively.

**Experiment to Disprove the Hypothesis**

**Objective:** Demonstrate that pre-BCR homodimers do not regulate DNA repair gene expression, leading to chemotherapy resistance in BCP-ALL.

**Protocol:**

**Rescue Experiment:**

* Use CRISPR-Cas9 to knockout a key DNA repair gene (e.g., BRCA1) in BCP-ALL cells with high pre-BCR homodimer expression.
* Evaluate chemotherapy resistance and DNA repair capacity in these cells using the comet assay, γH2AX foci formation, and HRR assays.

**Dominant-Negative Experiment:**

* Express a dominant-negative mutant of a DNA repair protein (e.g., BRCA1) in BCP-ALL cells with high pre-BCR homodimer expression.
* Evaluate chemotherapy resistance and DNA repair capacity in these cells using the comet assay, γH2AX foci formation, and HRR assays.

These detailed protocols should provide a comprehensive approach to testing the hypothesis and gaining a deeper understanding of the role of pre-BCR homodimers in chemotherapy resistance in BCP-ALL.","Here is the simulated dataframe:

```
   CRISPR_Cas9_gRNA  Lentiviral_Vector  shRNA  RNA_Seq_Reads  qRT_PCR_Fold_Change  Western_Blot_Band_Intensity  ChIP_Seq_Peak_Calls  Comet_Assay_Tail_Moment  γH2AX_Foci_Count  HRR_Assay_GFP_Positive_Cells  Cell_Viability_Assay  Apoptosis_Assay_Annexin_V_Positive_Cells  Co_IP_Band_Intensity  PLA_Signal_Count  BRET_Ratio  Xenograft_Tumor_Volume  Outcome
0               0.5             1.0  0.2         10000.0               2.5                     150.0               500.0                  10.0                    20.0                       30.0               0.8                     0.4               1.2               2.0               1000.0
1               0.8             0.5  0.1         12000.0               3.0                     180.0               600.0                  12.0                    25.0                       35.0               0.9                     0.5               1.5               2.5               1200.0
2               0.2             1.2  0.3          8000.0               2.0                     120.0               400.0                   8.0                    18.0                       25.0               0.7                     0.3               1.0               1.8               900.0
3               0.9             0.8  0.4         15000.0               3.5                     200.0               700.0                  15.0                    30.0                       40.0               0.95                    0.6               1.8               3.0               1500.0
4               0.6             1.1  0.5         11000.0               2.8                     160.0               550.0                  11.0                    22.0                       32.0               0.85                    0.45               1.4               2.2               1100.0
5               0.4             0.9  0.6          9000.0               2.2                     140.0               450.0                   9.0                    20.0                       28.0               0.8                     0.4               1.2               2.0               1000.0
6               0.7             1.0  0.3         13000.0               3.2                     190.0               650.0                  14.0                    28.0                       38.0               0.92                    0.55               1.7               2.8               1300.0
7               0.3             1.3  0.7          7000.0               1.8                     110.0               350.0                   7.0                    16.0                       22.0               0.75                    0.35               1.1               1.9               900.0
8               0.9             0.6  0.2         16000.0               3.8                     220.0               750.0                  17.0                    35.0                       45.0               0.98                    0.65               2.0               3.2               1600.0
9               0.5             1.2  0.8         10000.0               2.6                     170.0               500.0                  12.0                    24.0                       32.0               0.88                    0.5               1.5               2.4               1200.0
10              0.8             0.9  0.6         14000.0               3.4                     200.0               600.0                  15.0                    30.0                       40.0               0.95                    0.6               1.8               2.9               1400.0
11              0.2             1.1  0.4          8000.0               2.0                     130.0               400.0                   9.0                    20.0                       26.0               0.8                     0.4               1.2               2.1               1000.0
12              0.6             0.8  0.3         12000.0               2.9                     180.0               550.0                  13.0                    26.0                       35.0               0.9                     0.5               1.6               2.6               1300.0
13              0.9             1.0  0.5         15000.0               3.6                     210.0               700.0                  16.0                    32.0                       42.0               0.97                    0.65               1.9               3.1               1500.0
14              0.4             1.2  0.7          9000.0               2.4                     150.0               450.0                  10.0                    22.0                       28.0               0.85                    0.45               1.4               2.3               1100.0
15              0.7             0.9  0.4         13000.0               3.0                     190.0               600.0                  14.0                    28.0                       38.0               0.92                    0.55               1.7               2.8               1300.0
16              0.3             1.1  0.6          7000.0               1.9                     120.0               350.0                   8.0                    18.0                       24.0               0.8                     0.4               1.2               2.0               1000.0
17              0.9             0.7  0.3         16000.0               3.9                     230.0               750.0                  18.0                    36.0                       46.0               0.99                    0.7               2.1               3.3               1600.0
18              0.5             1.3  0.9         10000.0               2.7                     170.0               500.0                  12.0                    24.0                       32.0               0.9                     0.5               1.5               2.5               1200.0
19              0.8             1.0  0.7         14000.0               3.5                     200.0               600.0                  15.0                    30.0                       40.0               0.96                    0.6               1.8               2.9               1400.0
20              0.2             1.2  0.5          8000.0               2.1                     140.0               400.0                   9.0                    20.0                       26.0               0.82                    0.45               1.3               2.2               1100.0
21              0.6             0.9  0.4         12000.0               2.8                     180.0               550.0                  13.0                    26.0                       35.0               0.9                     0.5               1.6               2.7               1300.0
22              0.9             1.1  0.6         15000.0               3.7                     220.0               700.0                  17.0                    34.0                       43.0               0.98                    0.7               2.0               3.2               1500.0
23              0.4             1.3  0.8          9000.0               2.5                     160.0               450.0                  11.0                    23.0                       29.0               0.87                    0.5               1.5               2.4               1200.0
24              0.7             1.0  0.5         13000.0               3.1                     190.0               600.0                  14.0                    29.0                       39.0               0.93                    0.6               1.8               2.9               1400.0
```",0.3106359919038887
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/09f208af3b15feaff711ee8d7e56e354b904e913.summary'],Do environmental toxins that alter DNA methylation patterns in the NLRP3 gene contribute to the development of juvenile spondyloarthritis in individuals with a family history of rheumatic diseases?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that environmental toxins that alter DNA methylation patterns in the NLRP3 gene contribute to the development of juvenile spondyloarthritis in individuals with a family history of rheumatic diseases, I propose the following experimental plan:

**Experiment:** ""Environmental Toxin-Induced DNA Methylation Alterations in NLRP3 Gene and Juvenile Spondyloarthritis Development""

**Objective:** To investigate whether exposure to environmental toxins that alter DNA methylation patterns in the NLRP3 gene contributes to the development of juvenile spondyloarthritis in individuals with a family history of rheumatic diseases.

**Design:**

1. **Cell Culture Model:** Use human peripheral blood mononuclear cells (PBMCs) from individuals with a family history of rheumatic diseases.
2. **Environmental Toxin Exposure:** Expose PBMCs to a panel of environmental toxins known to alter DNA methylation patterns, such as bisphenol A (BPA), polycyclic aromatic hydrocarbons (PAHs), and pesticides (e.g., dichlorodiphenyltrichloroethane, DDT).
3. **NLRP3 Gene Methylation Analysis:** Use bisulfite sequencing or methylation-specific PCR to analyze DNA methylation patterns in the NLRP3 gene promoter region before and after toxin exposure.
4. **Cellular Assays:** Measure NLRP3 gene expression, cytokine production (e.g., IL-1β, IL-18), and inflammasome activation in response to toxin exposure.
5. **Control Group:** Include a control group of PBMCs not exposed to environmental toxins.

**To Disprove the Hypothesis:**

1. **Negative Control Toxin:** Include a negative control toxin that does not alter DNA methylation patterns in the NLRP3 gene, such as a non-toxic chemical compound.
2. **NLRP3 Gene Methylation Inhibition:** Use a DNA methyltransferase inhibitor (e.g., 5-azacytidine) to prevent DNA methylation changes in the NLRP3 gene promoter region, and then expose cells to environmental toxins.
3. **Rescue Experiment:** If toxin exposure leads to increased NLRP3 gene expression and inflammasome activation, attempt to rescue the phenotype by demethylating the NLRP3 gene promoter region using a demethylating agent (e.g., 5-aza-2'-deoxycytidine).

**Expected Outcomes:**

* If the hypothesis is true, exposure to environmental toxins will alter DNA methylation patterns in the NLRP3 gene, leading to increased NLRP3 gene expression, cytokine production, and inflammasome activation.
* If the hypothesis is false, exposure to environmental toxins will not alter DNA methylation patterns in the NLRP3 gene, and NLRP3 gene expression, cytokine production, and inflammasome activation will not be affected.

**Equipment and Resources:**

* Cell culture facilities and equipment
* Bisulfite sequencing or methylation-specific PCR equipment
* Real-time PCR and ELISA equipment
* Inflammasome activation assay equipment
* Toxins and control compounds
* DNA methyltransferase inhibitor and demethylating agent
* Statistical analysis software

**Timeline:**

* Literature review and experimental design: 2 weeks
* Cell culture and toxin exposure: 4 weeks
* DNA methylation analysis and cellular assays: 8 weeks
* Data analysis and interpretation: 4 weeks
* Total duration: 18 weeks

**Budget:**

* Cell culture reagents and equipment: $5,000
* Toxins and control compounds: $2,000
* DNA methyltransferase inhibitor and demethylating agent: $1,000
* Bisulfite sequencing or methylation-specific PCR equipment: $3,000
* Real-time PCR and ELISA equipment: $2,000
* Inflammasome activation assay equipment: $1,500
* Statistical analysis software: $1,000
* Total budget: $15,500

This experimental plan is designed to test the hypothesis in a controlled laboratory setting, using existing scientific methods and equipment, within a reasonable time frame and budget.",85,"Here are the detailed, step-by-step protocols for the ""Environmental Toxin-Induced DNA Methylation Alterations in NLRP3 Gene and Juvenile Spondyloarthritis Development"" experiment:

**Protocol 1: Cell Culture and Toxin Exposure**

1.1. Obtain human peripheral blood mononuclear cells (PBMCs) from individuals with a family history of rheumatic diseases through a reputable biobank or by collecting blood samples from participants.

1.2. Isolate PBMCs using density gradient centrifugation (e.g., Ficoll-Paque) according to the manufacturer's instructions.

1.3. Culture PBMCs in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.4. Divide PBMCs into 6 groups:
	* Control group (no toxin exposure)
	* BPA exposure group
	* PAHs exposure group
	* DDT exposure group
	* Negative control toxin exposure group (non-toxic chemical compound)
	* NLRP3 gene methylation inhibition group (with 5-azacytidine)

1.5. Expose PBMCs to the respective toxins at a concentration of 10 μM for 24 hours. For the negative control toxin, use a non-toxic chemical compound at the same concentration.

1.6. After toxin exposure, wash cells with PBS and resuspend in fresh medium.

**Protocol 2: NLRP3 Gene Methylation Analysis**

2.1. Extract genomic DNA from PBMCs using a DNA extraction kit (e.g., Qiagen) according to the manufacturer's instructions.

2.2. Convert genomic DNA to bisulfite-converted DNA using a bisulfite conversion kit (e.g., Zymo Research) according to the manufacturer's instructions.

2.3. Perform bisulfite sequencing or methylation-specific PCR to analyze DNA methylation patterns in the NLRP3 gene promoter region.

2.4. For bisulfite sequencing:
	* Amplify the NLRP3 gene promoter region using primers specific to the bisulfite-converted DNA.
	* Perform next-generation sequencing (e.g., Illumina) according to the manufacturer's instructions.
	* Analyze sequencing data using bioinformatic tools (e.g., Bismark, MethPipe) to determine DNA methylation levels.

2.5. For methylation-specific PCR:
	* Design primers specific to the methylated or unmethylated NLRP3 gene promoter region.
	* Perform PCR using a real-time PCR machine (e.g., Applied Biosystems) according to the manufacturer's instructions.
	* Analyze PCR data using the ΔΔCt method to determine DNA methylation levels.

**Protocol 3: Cellular Assays**

3.1. Measure NLRP3 gene expression using real-time PCR:
	* Extract total RNA from PBMCs using an RNA extraction kit (e.g., Qiagen) according to the manufacturer's instructions.
	* Convert RNA to cDNA using a reverse transcription kit (e.g., Applied Biosystems) according to the manufacturer's instructions.
	* Perform real-time PCR using primers specific to the NLRP3 gene and a housekeeping gene (e.g., GAPDH).

3.2. Measure cytokine production (e.g., IL-1β, IL-18) using ELISA:
	* Collect cell culture supernatants and store at -80°C.
	* Perform ELISA according to the manufacturer's instructions (e.g., R&D Systems).

3.3. Measure inflammasome activation using an inflammasome activation assay kit (e.g., InvivoGen) according to the manufacturer's instructions.

**Protocol 4: NLRP3 Gene Methylation Inhibition and Rescue Experiment**

4.1. Treat PBMCs with 5-azacytidine (DNA methyltransferase inhibitor) at a concentration of 10 μM for 24 hours to prevent DNA methylation changes in the NLRP3 gene promoter region.

4.2. Expose PBMCs to environmental toxins as described in Protocol 1.

4.3. Perform DNA methylation analysis and cellular assays as described in Protocols 2 and 3.

4.4. For the rescue experiment:
	* Treat PBMCs with 5-aza-2'-deoxycytidine (demethylating agent) at a concentration of 10 μM for 24 hours to demethylate the NLRP3 gene promoter region.
	* Perform DNA methylation analysis and cellular assays as described in Protocols 2 and 3.

**Protocol 5: Data Analysis and Interpretation**

5.1. Analyze DNA methylation data using bioinformatic tools (e.g., Bismark, MethPipe) to determine DNA methylation levels.

5.2. Analyze gene expression data using the ΔΔCt method to determine NLRP3 gene expression levels.

5.3. Analyze cytokine production and inflammasome activation data using statistical software (e.g., GraphPad Prism) to determine significant differences between groups.

5.4. Interpret results in the context of the hypothesis and expected outcomes.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity in the results.","```
   PBMCs  FBS  Penicillin_streptomycin  L_glutamine  Toxin  Toxin_concentration  NLRP3_methylation  NLRP3_expression  IL_1β  IL_18  Inflammasome_activation
0     100  10.0                  1.0           1.0    None               0.0         0.450000        1.200000  50.0  20.0                0.500000
1     120  12.0                  1.2           1.2    BPA               10.0         0.600000        1.500000  60.0  30.0                0.600000
2     100  10.0                  1.0           1.0   PAHs               10.0         0.550000        1.300000  55.0  25.0                0.550000
3     110  11.0                  1.1           1.1   DDT               10.0         0.500000        1.400000  50.0  20.0                0.500000
4     130  13.0                  1.3           1.3  Negative               10.0         0.400000        1.100000  40.0  15.0                0.400000
5     100  10.0                  1.0           1.0  5_azacytidine               10.0         0.300000        0.900000  30.0  10.0                0.300000
6     120  12.0                  1.2           1.2    BPA                5.0         0.650000        1.600000  65.0  35.0                0.650000
7     100  10.0                  1.0           1.0   PAHs                5.0         0.600000        1.400000  60.0  30.0                0.600000
8     110  11.0                  1.1           1.1   DDT                5.0         0.550000        1.350000  55.0  25.0                0.550000
9     130  13.0                  1.3           1.3  Negative                5.0         0.450000        1.200000  45.0  20.0                0.450000
10    100  10.0                  1.0           1.0  5_azacytidine                5.0         0.350000        0.950000  35.0  15.0                0.350000
11    120  12.0                  1.2           1.2    BPA               15.0         0.700000        1.700000  70.0  40.0                0.700000
12    100  10.0                  1.0           1.0   PAHs               15.0         0.650000        1.500000  65.0  35.0                0.650000
13    110  11.0                  1.1           1.1   DDT               15.0         0.600000        1.450000  60.0  30.0                0.600000
14    130  13.0                  1.3           1.3  Negative               15.0         0.500000        1.300000  50.0  25.0                0.500000
15    100  10.0                  1.0           1.0  5_azacytidine               15.0         0.400000        1.100000  40.0  20.0                0.400000
16    120  12.0                  1.2           1.2    BPA                8.0         0.620000        1.550000  62.0  32.0                0.620000
17    100  10.0                  1.0           1.0   PAHs                8.0         0.580000        1.380000  58.0  28.0                0.580000
18    110  11.0                  1.1           1.1   DDT                8.0         0.530000        1.320000  53.0  23.0                0.530000
19    130  13.0                  1.3           1.3  Negative                8.0         0.480000        1.220000  48.0  22.0                0.480000
20    100  10.0                  1.0           1.0  5_azacytidine                8.0         0.380000        1.080000  38.0  18.0                0.380000
21    120  12.0                  1.2           1.2    BPA               12.0         0.680000        1.620000  68.0  38.0                0.680000
22    100  10.0                  1.0           1.0   PAHs               12.0         0.630000        1.420000  63.0  33.0                0.630000
23    110  11.0                  1.1           1.1   DDT               12.0         0.580000        1.380000  58.0  28.0                0.580000
24    130  13.0                  1.3           1.3  Negative               12.0         0.520000        1.280000  52.0  26.0                0.520000
```",0.37982032589111814
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8b88805b65c64dc93a49e3bbd9893f203bfbffa1.summary'],"Do genetic variants in ABC and SLC transporter genes also affect the efficacy of tyrosine kinase inhibitors in other types of cancer, such as acute lymphoblastic leukemia or gastrointestinal stromal tumors?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that genetic variants in ABC and SLC transporter genes also affect the efficacy of tyrosine kinase inhibitors in other types of cancer, such as acute lymphoblastic leukemia (ALL) or gastrointestinal stromal tumors (GIST).

**Experimental Plan:**

**Title:** Investigating the Impact of ABC and SLC Transporter Gene Variants on Tyrosine Kinase Inhibitor Efficacy in Acute Lymphoblastic Leukemia and Gastrointestinal Stromal Tumors

**Objective:** To determine if genetic variants in ABC and SLC transporter genes affect the response to tyrosine kinase inhibitors in ALL and GIST cell lines.

**Hypothesis to be Disproven:** Genetic variants in ABC and SLC transporter genes do not affect the efficacy of tyrosine kinase inhibitors in ALL and GIST.

**Experimental Design:**

1. **Cell Line Selection:** Obtain ALL and GIST cell lines with known genetic variants in ABC and SLC transporter genes (e.g., ABCB1, ABCG2, SLC22A1, and SLC22A5). Ensure that the cell lines have been previously characterized for their response to tyrosine kinase inhibitors.
2. **Tyrosine Kinase Inhibitor Treatment:** Treat the cell lines with a tyrosine kinase inhibitor (e.g., imatinib or dasatinib) at varying concentrations to assess their response.
3. **Cell Viability Assay:** Perform a cell viability assay (e.g., MTT or CellTiter-Glo) to measure the response of each cell line to the tyrosine kinase inhibitor.
4. **Transporter Protein Expression Analysis:** Use Western blot or qRT-PCR to analyze the expression of ABC and SLC transporter proteins in each cell line.
5. **Statistical Analysis:** Compare the response to tyrosine kinase inhibitors between cell lines with different genetic variants using statistical analysis (e.g., ANOVA or t-test).

**Expected Outcomes:**

* If the hypothesis is true, cell lines with genetic variants in ABC and SLC transporter genes will show altered response to tyrosine kinase inhibitors compared to cell lines without these variants.
* If the hypothesis is false, no significant differences in response to tyrosine kinase inhibitors will be observed between cell lines with and without genetic variants in ABC and SLC transporter genes.

**Equipment and Resources:**

* ALL and GIST cell lines with known genetic variants in ABC and SLC transporter genes
* Tyrosine kinase inhibitors (e.g., imatinib or dasatinib)
* Cell culture media and reagents
* MTT or CellTiter-Glo assay kit
* Western blot or qRT-PCR equipment
* Statistical analysis software

**Timeline:**

* Cell line selection and preparation: 2 weeks
* Tyrosine kinase inhibitor treatment and cell viability assay: 4 weeks
* Transporter protein expression analysis: 4 weeks
* Statistical analysis and data interpretation: 4 weeks

**Budget:**

* Cell lines and reagents: $5,000
* Tyrosine kinase inhibitors: $2,000
* Equipment and consumables: $8,000
* Personnel and overheads: $10,000

Total budget: $25,000

This experimental plan is designed to test the hypothesis in a controlled and efficient manner, using existing cell lines and equipment. The results will provide valuable insights into the role of ABC and SLC transporter gene variants in tyrosine kinase inhibitor response in ALL and GIST, and may have implications for personalized medicine approaches in these diseases.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Line Selection and Preparation**

1.1. Obtain ALL and GIST cell lines with known genetic variants in ABC and SLC transporter genes (e.g., ABCB1, ABCG2, SLC22A1, and SLC22A5) from a reputable cell bank or repository.

1.2. Verify the genetic variants in each cell line using DNA sequencing or genotyping techniques.

1.3. Thaw the cell lines according to the supplier's instructions and culture them in the recommended medium (e.g., RPMI 1640 or DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

1.4. Expand the cell lines to a sufficient number of cells for the experiment (approximately 1 x 10^6 cells per cell line).

1.5. Freeze the expanded cell lines in aliquots of 1 x 10^6 cells per vial in cryopreservation medium (e.g., 90% FBS and 10% DMSO) and store them at -80°C.

**Protocol 2: Tyrosine Kinase Inhibitor Treatment**

2.1. Prepare a stock solution of the tyrosine kinase inhibitor (e.g., imatinib or dasatinib) in DMSO at a concentration of 10 mM.

2.2. Serially dilute the stock solution in culture medium to create a range of concentrations (e.g., 0.01, 0.1, 1, 10, and 100 μM).

2.3. Seed 5 x 10^3 cells per well in a 96-well plate in 100 μL of culture medium.

2.4. Add 100 μL of the tyrosine kinase inhibitor solution at the desired concentration to each well.

2.5. Incubate the plates at 37°C, 5% CO2 for 72 hours.

**Protocol 3: Cell Viability Assay**

3.1. Prepare the MTT or CellTiter-Glo reagent according to the manufacturer's instructions.

3.2. Add 20 μL of the MTT or CellTiter-Glo reagent to each well.

3.3. Incubate the plates at 37°C, 5% CO2 for 2-4 hours (MTT) or 10-30 minutes (CellTiter-Glo).

3.4. Measure the absorbance at 570 nm (MTT) or luminescence (CellTiter-Glo) using a plate reader.

3.5. Calculate the percentage of cell viability relative to the untreated control.

**Protocol 4: Transporter Protein Expression Analysis**

4.1. Harvest the cells from the 96-well plate and wash them with PBS.

4.2. Lyse the cells in RIPA buffer (e.g., 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease inhibitors.

4.3. Perform Western blot analysis using antibodies specific to the ABC and SLC transporter proteins (e.g., ABCB1, ABCG2, SLC22A1, and SLC22A5).

4.4. Alternatively, perform qRT-PCR analysis using primers specific to the transporter genes.

4.5. Normalize the protein or mRNA expression levels to a housekeeping gene (e.g., GAPDH or β-actin).

**Protocol 5: Statistical Analysis**

5.1. Compare the response to tyrosine kinase inhibitors between cell lines with different genetic variants using ANOVA or t-test.

5.2. Calculate the IC50 values for each cell line and compare them between groups.

5.3. Perform multiple comparison tests (e.g., Tukey's or Bonferroni's) to identify significant differences between groups.

5.4. Present the results as mean ± SEM and include the p-values for each comparison.

By following these detailed protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis.","```
   Cell_Line  ABCB1_Variant  SLC22A1_Variant  Imatinib_Conc  Dasatinib_Conc  Cell_Viability  ABCB1_Expression  SLC22A1_Expression
0       ALL          WT             WT           0.01           0.0       0.85          1.20           0.80
1       ALL          WT             WT           0.10           0.0       0.70          1.15           0.75
2       ALL          WT             WT           1.00           0.0       0.40          0.90           0.60
3       ALL          WT             WT          10.00           0.0       0.20          0.60           0.40
4       ALL          WT             WT           0.01           0.1       0.80          1.10           0.70
5       ALL          WT             WT           0.10           1.0       0.60          0.95           0.55
6       GIST         Mut           WT           0.01           0.0       0.90          1.30           0.85
7       GIST         Mut           WT           0.10           0.0       0.75          1.20           0.70
8       GIST         Mut           WT           1.00           0.0       0.50          0.90           0.50
9       GIST         Mut           WT          10.00           0.0       0.30          0.60           0.30
10      GIST         Mut           WT           0.01           0.1       0.85          1.25           0.80
11      GIST         Mut           WT           0.10           1.0       0.65          1.05           0.60
12      ALL          Mut           WT           0.01           0.0       0.80          1.15           0.75
13      ALL          Mut           WT           0.10           0.0       0.65          1.00           0.60
14      ALL          Mut           WT           1.00           0.0       0.40          0.80           0.45
15      ALL          Mut           WT          10.00           0.0       0.25          0.50           0.30
16      ALL          Mut           WT           0.01           0.1       0.75          1.05           0.70
17      ALL          Mut           WT           0.10           1.0       0.55          0.90           0.55
18      GIST         WT           Mut           0.01           0.0       0.90          1.20           0.90
19      GIST         WT           Mut           0.10           0.0       0.75          1.10           0.85
20      GIST         WT           Mut           1.00           0.0       0.50          0.90           0.70
21      GIST         WT           Mut          10.00           0.0       0.35          0.60           0.50
22      GIST         WT           Mut           0.01           0.1       0.85          1.15           0.90
23      GIST         WT           Mut           0.10           1.0       0.65          1.00           0.80
24      ALL          WT           Mut           0.01           0.0       0.80          1.10           0.95
```",0.1890580053210756
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2d79e9054cc9f9aca9a96a532f30289660064615.summary'],"Do glomerular parietal epithelial cells in antibody-negative primary membranous nephropathy patients exhibit altered expression of surface receptors that facilitate the interaction with transitional B cells, thereby contributing to the development of autoantibody production?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis. Here's a high-level experimental approach:

**Experiment Title:** Investigating the Role of Glomerular Parietal Epithelial Cells in Autoantibody Production in Antibody-Negative Primary Membranous Nephropathy Patients

**Objective:** To determine if glomerular parietal epithelial cells (GPECs) from antibody-negative primary membranous nephropathy (PMN) patients exhibit altered expression of surface receptors that facilitate interaction with transitional B cells, contributing to autoantibody production.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Obtain kidney biopsy samples from antibody-negative PMN patients and healthy controls.
	* Isolate GPECs using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) based on specific surface markers (e.g., podocalyxin, CD10).
	* Culture GPECs in vitro using a suitable medium and conditions.
2. **Transitional B Cell Isolation and Co-Culture:**
	* Isolate transitional B cells from peripheral blood mononuclear cells (PBMCs) of antibody-negative PMN patients using FACS or MACS based on specific surface markers (e.g., CD19, CD24, CD38).
	* Co-culture GPECs with transitional B cells in a 1:1 ratio in a transwell system or a direct co-culture setup.
3. **Surface Receptor Analysis:**
	* Perform flow cytometry or immunofluorescence staining to analyze the expression of surface receptors on GPECs, such as CD40, CD80, CD86, and ICAM-1, which are known to interact with B cells.
	* Compare the expression levels of these receptors between GPECs from antibody-negative PMN patients and healthy controls.
4. **Autoantibody Production Assay:**
	* Stimulate the co-cultured GPECs and transitional B cells with podocyte antigens (e.g., nephrin, podocin) for 7-10 days.
	* Measure the production of autoantibodies against podocyte antigens using enzyme-linked immunosorbent assay (ELISA) or Western blot.
5. **Blocking Experiment:**
	* To specifically test the role of surface receptors on GPECs, perform a blocking experiment using neutralizing antibodies against the identified receptors (e.g., CD40, CD80, CD86).
	* Co-culture GPECs with transitional B cells in the presence of these blocking antibodies and assess autoantibody production.

**Expected Outcomes:**

* If the hypothesis is true, GPECs from antibody-negative PMN patients will exhibit altered expression of surface receptors that facilitate interaction with transitional B cells, leading to increased autoantibody production.
* If the hypothesis is false, GPECs from antibody-negative PMN patients will not exhibit altered expression of surface receptors, and autoantibody production will not be affected.

**Resources and Timeline:**

* Personnel: 1-2 researchers with expertise in cell culture, flow cytometry, and immunology
* Equipment: Flow cytometer, cell culture facilities, transwell system or direct co-culture setup, ELISA or Western blot equipment
* Reagents: Cell culture media, FACS or MACS reagents, antibodies for surface receptor analysis, podocyte antigens, neutralizing antibodies for blocking experiment
* Timeline: 6-9 months

**Budget:**

* Personnel: $50,000 - $100,000
* Equipment and Reagents: $20,000 - $30,000
* Total: $70,000 - $130,000

This experiment is designed to test the hypothesis in a controlled and specific manner, using existing scientific methods and equipment. The blocking experiment will help to specifically address the role of surface receptors on GPECs in autoantibody production. The results of this experiment will provide valuable insights into the pathogenesis of antibody-negative PMN and may lead to the development of novel therapeutic strategies.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Culture**

**Step 1.1: Kidney Biopsy Sample Collection**

* Obtain kidney biopsy samples from antibody-negative primary membranous nephropathy (PMN) patients and healthy controls.
* Ensure informed consent is obtained from all participants.
* Store the biopsy samples in a sterile container with a suitable transport medium (e.g., RPMI 1640 with 10% FBS) at 4°C.

**Step 1.2: Glomerular Parietal Epithelial Cell (GPEC) Isolation**

* Transport the biopsy samples to the laboratory and process them within 24 hours.
* Wash the biopsy samples with PBS to remove any debris.
* Digest the biopsy samples with collagenase IV (1 mg/mL) and DNase I (100 U/mL) for 30 minutes at 37°C.
* Filter the digested tissue through a 40-μm cell strainer to obtain a single-cell suspension.
* Stain the cells with fluorescently labeled antibodies against podocalyxin (e.g., PE-conjugated anti-podocalyxin) and CD10 (e.g., FITC-conjugated anti-CD10).
* Perform fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) to isolate GPECs based on the expression of podocalyxin and CD10.
* Collect the sorted GPECs in a sterile tube and wash them with PBS.

**Step 1.3: GPEC Culture**

* Resuspend the isolated GPECs in a suitable culture medium (e.g., DMEM/F12 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).
* Plate the GPECs in a 24-well plate at a density of 1 × 10^5 cells per well.
* Incubate the cells at 37°C, 5% CO2, and 95% humidity.
* Change the culture medium every 3-4 days.

**Protocol 2: Transitional B Cell Isolation and Co-Culture**

**Step 2.1: Peripheral Blood Mononuclear Cell (PBMC) Isolation**

* Obtain peripheral blood samples from antibody-negative PMN patients.
* Isolate PBMCs using Ficoll-Paque density gradient centrifugation.
* Wash the PBMCs with PBS and resuspend them in a suitable medium (e.g., RPMI 1640 with 10% FBS).

**Step 2.2: Transitional B Cell Isolation**

* Stain the PBMCs with fluorescently labeled antibodies against CD19 (e.g., PE-conjugated anti-CD19), CD24 (e.g., FITC-conjugated anti-CD24), and CD38 (e.g., APC-conjugated anti-CD38).
* Perform FACS or MACS to isolate transitional B cells based on the expression of CD19, CD24, and CD38.
* Collect the sorted transitional B cells in a sterile tube and wash them with PBS.

**Step 2.3: Co-Culture Setup**

* Resuspend the isolated transitional B cells in a suitable culture medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).
* Add the transitional B cells to the GPEC culture at a 1:1 ratio.
* Incubate the co-culture at 37°C, 5% CO2, and 95% humidity.

**Protocol 3: Surface Receptor Analysis**

**Step 3.1: Cell Harvesting**

* Harvest the co-cultured GPECs and transitional B cells after 7-10 days.
* Wash the cells with PBS and resuspend them in a suitable buffer (e.g., FACS buffer).

**Step 3.2: Flow Cytometry**

* Stain the cells with fluorescently labeled antibodies against CD40 (e.g., PE-conjugated anti-CD40), CD80 (e.g., FITC-conjugated anti-CD80), CD86 (e.g., APC-conjugated anti-CD86), and ICAM-1 (e.g., PerCP-conjugated anti-ICAM-1).
* Perform flow cytometry to analyze the expression of surface receptors on GPECs.
* Compare the expression levels of these receptors between GPECs from antibody-negative PMN patients and healthy controls.

**Protocol 4: Autoantibody Production Assay**

**Step 4.1: Stimulation with Podocyte Antigens**

* Stimulate the co-cultured GPECs and transitional B cells with podocyte antigens (e.g., nephrin, podocin) for 7-10 days.
* Use a suitable concentration of podocyte antigens (e.g., 10 μg/mL).

**Step 4.2: Autoantibody Measurement**

* Collect the culture supernatant and measure the production of autoantibodies against podocyte antigens using enzyme-linked immunosorbent assay (ELISA) or Western blot.
* Use a suitable ELISA kit or Western blot protocol.

**Protocol 5: Blocking Experiment**

**Step 5.1: Blocking Antibody Preparation**

* Prepare neutralizing antibodies against the identified surface receptors (e.g., CD40, CD80, CD86).
* Use a suitable concentration of blocking antibodies (e.g., 10 μg/mL).

**Step 5.2: Co-Culture with Blocking Antibodies**

* Co-culture GPECs with transitional B cells in the presence of blocking antibodies.
* Incubate the co-culture at 37°C, 5% CO2, and 95% humidity.

**Step 5.3: Autoantibody Measurement**

* Collect the culture supernatant and measure the production of autoantibodies against podocyte antigens using ELISA or Western blot.
* Compare the results with the control group without blocking antibodies.

These detailed protocols should provide a clear guide for executing the experiment. Remember to follow proper laboratory safety protocols and guidelines throughout the experiment.","```
   Collagenase_IV  DNase_I  Podocalyxin_Antibody  CD10_Antibody  RPMI_1640  FBS  Penicillin_Streptomycin  L_Glutamine  CD19_Antibody  CD24_Antibody  CD38_Antibody  Nephrin  Podocin  CD40_Blocking_Antibody  CD80_Blocking_Antibody  CD86_Blocking_Antibody  ICAM_1_Blocking_Antibody  Autoantibody_Production
0             0.8      80.0               1.0             1.0       100.0  10.0                  1.0           1.0             1.0             1.0       5.0      5.0                  5.0                  5.0                  5.0                  5.0                  0.5
1             1.2      120.0               1.2             1.2       120.0  12.0                  1.2           1.2             1.2             1.2       6.0      6.0                  6.0                  6.0                  6.0                  6.0                  0.7
2             0.5      50.0               0.8             0.8        80.0   8.0                  0.8           0.8             0.8             0.8       4.0      4.0                  4.0                  4.0                  4.0                  4.0                  0.3
3             1.0      100.0               1.5             1.5       150.0  15.0                  1.5           1.5             1.5             1.5       7.0      7.0                  7.0                  7.0                  7.0                  7.0                  0.9
4             0.9      90.0               1.1             1.1       110.0  11.0                  1.1           1.1             1.1             1.1       5.5      5.5                  5.5                  5.5                  5.5                  5.5                  0.6
5             1.1      110.0               1.3             1.3       130.0  13.0                  1.3           1.3             1.3             1.3       6.5      6.5                  6.5                  6.5                  6.5                  6.5                  0.8
6             0.7      70.0               0.9             0.9        90.0   9.0                  0.9           0.9             0.9             0.9       4.5      4.5                  4.5                  4.5                  4.5                  4.5                  0.4
7             1.4      140.0               1.6             1.6       160.0  16.0                  1.6           1.6             1.6             1.6       8.0      8.0                  8.0                  8.0                  8.0                  8.0                  1.0
8             0.6      60.0               0.7             0.7        70.0   7.0                  0.7           0.7             0.7             0.7       3.5      3.5                  3.5                  3.5                  3.5                  3.5                  0.2
9             1.3      130.0               1.4             1.4       140.0  14.0                  1.4           1.4             1.4             1.4       7.0      7.0                  7.0                  7.0                  7.0                  7.0                  0.9
10            0.9      90.0               1.0             1.0       100.0  10.0                  1.0           1.0             1.0             1.0       5.0      5.0                  5.0                  5.0                  5.0                  5.0                  0.5
11            1.2      120.0               1.3             1.3       130.0  13.0                  1.3           1.3             1.3             1.3       6.5      6.5                  6.5                  6.5                  6.5                  6.5                  0.8
12            0.8      80.0               0.9             0.9        90.0   9.0                  0.9           0.9             0.9             0.9       4.5      4.5                  4.5                  4.5                  4.5                  4.5                  0.4
13            1.5      150.0               1.7             1.7       170.0  17.0                  1.7           1.7             1.7             1.7       8.5      8.5                  8.5                  8.5                  8.5                  8.5                  1.1
14            0.5      50.0               0.6             0.6        60.0   6.0                  0.6           0.6             0.6             0.6       3.0      3.0                  3.0                  3.0                  3.0                  3.0                  0.1
15            1.1      110.0               1.2             1.2       120.0  12.0                  1.2           1.2             1.2             1.2       6.0      6.0                  6.0                  6.0                  6.0                  6.0                  0.7
16            0.7      70.0               0.8             0.8        80.0   8.0                  0.8           0.8             0.8             0.8       4.0      4.0                  4.0                  4.0                  4.0                  4.0                  0.3
17            1.4      140.0               1.5             1.5       150.0  15.0                  1.5           1.5             1.5             1.5       7.5      7.5                  7.5                  7.5                  7.5                  7.5                  1.0
18            0.9      90.0               1.0             1.0       100.0  10.0                  1.0           1.0             1.0             1.0       5.0      5.0                  5.0                  5.0                  5.0                  5.0                  0.5
19            1.3      130.0               1.4             1.4       140.0  14.0                  1.4           1.4             1.4             1.4       7.0      7.0                  7.0                  7.0                  7.0                  7.0                  0.9
20            0.6      60.0               0.7             0.7        70.0   7.0                  0.7           0.7             0.7             0.7       3.5      3.5                  3.5                  3.5                  3.5                  3.5                  0.2
21            1.2      120.0               1.3             1.3       130.0  13.0                  1.3           1.3             1.3             1.3       6.5      6.5                  6.5                  6.5                  6.5                  6.5                  0.8
22            0.8      80.0               0.9             0.9        90.0   9.0                  0.9           0.9             0.9             0.9       4.5      4.5                  4.5                  4.5                  4.5                  4.5                  0.4
23            1.5      150.0               1.6             1.6       160.0  16.0                  1.6           1.6             1.6             1.6       8.0      8.0                  8.0                  8.0                  8.0                  8.0                  1.1
24            0.5      50.0               0.6             0.6        60.0   6.0                  0.6           0.6             0.6             0.6       3.0      3.0                  3.0                  3.0                  3.0                  3.0                  0.1
```",0.9315797247601633
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/94d2d2855ddecdcf30eac04b68109f0fdc637a1e.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/57e52ae1dacf7b7cc2c4b752be6b6011dd2a28e4.summary']","Do high-affinity insulin-reactive B cells in VH125.NOD mice exhibit altered antigen-presenting cell function, leading to enhanced activation of diabetogenic T cells and accelerated type 1 diabetes development?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that high-affinity insulin-reactive B cells in VH125.NOD mice exhibit altered antigen-presenting cell function, leading to enhanced activation of diabetogenic T cells and accelerated type 1 diabetes development, I propose the following experimental plan:

**Experiment:** ""Disproving the Hypothesis: Investigating the Role of High-Affinity Insulin-Reactive B Cells in Type 1 Diabetes Development""

**Objective:** To determine if high-affinity insulin-reactive B cells in VH125.NOD mice exhibit altered antigen-presenting cell function, leading to enhanced activation of diabetogenic T cells and accelerated type 1 diabetes development.

**Experimental Design:**

1. **B cell isolation and sorting:** Isolate splenocytes from VH125.NOD mice and sort high-affinity insulin-reactive B cells using flow cytometry and antibodies specific to insulin. This will be done using a FACS sorter.
2. **Co-culture with T cells:** Co-culture the sorted high-affinity insulin-reactive B cells with diabetogenic T cells (e.g., CD4+ T cells) in the presence of insulin as an antigen.
3. **T cell activation and proliferation assessment:** Assess T cell activation and proliferation using flow cytometry and cell counting. Measure T cell activation markers such as CD69, CD25, and CD44, and proliferation markers such as Ki-67.
4. **Antigen presentation assay:** Perform an antigen presentation assay to assess the ability of high-affinity insulin-reactive B cells to present insulin to T cells. This can be done using a T cell activation assay, where T cells are co-cultured with B cells and insulin, and T cell activation is measured.
5. **Type 1 diabetes development:** Transfer the co-cultured T cells into VH125.NOD mice and monitor for type 1 diabetes development.

**Control Groups:**

* VH125.NOD mice without high-affinity insulin-reactive B cells (negative control)
* VH125.NOD mice with low-affinity insulin-reactive B cells (control for B cell affinity)
* VH125.NOD mice with high-affinity insulin-reactive B cells, but without co-culture with T cells (control for T cell activation)

**Expected Outcomes:**

* If the hypothesis is true, high-affinity insulin-reactive B cells will exhibit altered antigen-presenting cell function, leading to enhanced activation of diabetogenic T cells and accelerated type 1 diabetes development.
* If the hypothesis is false, high-affinity insulin-reactive B cells will not exhibit altered antigen-presenting cell function, and T cell activation and type 1 diabetes development will not be enhanced.

**Equipment and Resources:**

* FACS sorter
* Flow cytometer
* Antibodies specific to insulin and T cell activation markers
* VH125.NOD mice
* Diabetogenic T cells (e.g., CD4+ T cells)
* Insulin
* Cell culture media and reagents
* Single-cell RNA sequencing platform (optional)

**Timeline:**

* Week 1-2: B cell isolation and sorting
* Week 3-4: Co-culture with T cells and T cell activation assessment
* Week 5-6: Antigen presentation assay and type 1 diabetes development
* Week 7-8: Data analysis and interpretation

**Budget:**

* Equipment and reagents: $10,000
* Mouse and cell culture costs: $5,000
* Personnel and overhead: $10,000
* Total: $25,000

This experiment is designed to test the hypothesis and can be completed within a reasonable time frame (8 weeks) and budget ($25,000). The results will provide valuable insights into the role of high-affinity insulin-reactive B cells in type 1 diabetes development and may lead to the development of new therapeutic strategies for the prevention and treatment of type 1 diabetes.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disproving the Hypothesis: Investigating the Role of High-Affinity Insulin-Reactive B Cells in Type 1 Diabetes Development"":

**Protocol 1: B Cell Isolation and Sorting**

1.1. Prepare the following materials:
	* VH125.NOD mice (n=10)
	* FACS sorter
	* Antibodies specific to insulin (e.g., insulin-FITC)
	* FACS buffer (e.g., PBS with 2% FBS and 0.1% NaN3)
	* 70-μm cell strainer
	* Sterile tubes and pipettes

1.2. Euthanize the VH125.NOD mice and harvest the spleens.

1.3. Prepare a single-cell suspension of splenocytes by gently pressing the spleens through a 70-μm cell strainer into a sterile tube.

1.4. Centrifuge the cell suspension at 300 x g for 5 minutes to remove debris.

1.5. Resuspend the cell pellet in 1 mL of FACS buffer and stain with insulin-FITC antibody (1:100 dilution) for 30 minutes at 4°C.

1.6. Wash the cells twice with FACS buffer and resuspend in 1 mL of FACS buffer.

1.7. Sort high-affinity insulin-reactive B cells using a FACS sorter, gating on insulin-FITC+ cells.

1.8. Collect the sorted cells in a sterile tube and count the cell number using a hemocytometer.

**Protocol 2: Co-Culture with T Cells**

2.1. Prepare the following materials:
	* Sorted high-affinity insulin-reactive B cells (from Protocol 1)
	* Diabetogenic T cells (e.g., CD4+ T cells)
	* Insulin (10 μg/mL)
	* Cell culture media (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin)
	* 96-well plate

2.2. Prepare a co-culture mixture by combining 1 x 10^5 sorted B cells with 1 x 10^5 diabetogenic T cells in 200 μL of cell culture media.

2.3. Add insulin (10 μg/mL) to the co-culture mixture and mix well.

2.4. Plate the co-culture mixture in a 96-well plate and incubate at 37°C, 5% CO2 for 3 days.

**Protocol 3: T Cell Activation and Proliferation Assessment**

3.1. Prepare the following materials:
	* Co-culture mixture (from Protocol 2)
	* Antibodies specific to T cell activation markers (e.g., CD69-PE, CD25-APC, CD44-FITC)
	* Flow cytometer

3.2. Harvest the co-culture mixture and stain with antibodies specific to T cell activation markers (1:100 dilution) for 30 minutes at 4°C.

3.3. Wash the cells twice with FACS buffer and resuspend in 1 mL of FACS buffer.

3.4. Analyze the cells using a flow cytometer, gating on CD4+ T cells.

3.5. Measure T cell activation markers (CD69, CD25, CD44) and proliferation markers (Ki-67).

**Protocol 4: Antigen Presentation Assay**

4.1. Prepare the following materials:
	* Co-culture mixture (from Protocol 2)
	* T cells (e.g., CD4+ T cells)
	* Insulin (10 μg/mL)
	* Cell culture media (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin)
	* 96-well plate

4.2. Prepare a T cell activation assay mixture by combining 1 x 10^5 T cells with 1 x 10^5 co-cultured B cells in 200 μL of cell culture media.

4.3. Add insulin (10 μg/mL) to the T cell activation assay mixture and mix well.

4.4. Plate the T cell activation assay mixture in a 96-well plate and incubate at 37°C, 5% CO2 for 3 days.

4.5. Measure T cell activation using a flow cytometer, gating on CD4+ T cells.

**Protocol 5: Type 1 Diabetes Development**

5.1. Prepare the following materials:
	* Co-cultured T cells (from Protocol 2)
	* VH125.NOD mice (n=10)

5.2. Transfer 1 x 10^6 co-cultured T cells into VH125.NOD mice via intravenous injection.

5.3. Monitor the mice for type 1 diabetes development by measuring blood glucose levels weekly using a glucometer.

5.4. Sacrifice the mice at 12 weeks post-transfer and analyze pancreatic islets for insulitis and beta-cell destruction.

**Control Groups**

* VH125.NOD mice without high-affinity insulin-reactive B cells (negative control)
* VH125.NOD mice with low-affinity insulin-reactive B cells (control for B cell affinity)
* VH125.NOD mice with high-affinity insulin-reactive B cells, but without co-culture with T cells (control for T cell activation)

**Data Analysis and Interpretation**

* Analyze the data using statistical software (e.g., GraphPad Prism) to compare the results between the experimental and control groups.
* Interpret the results in the context of the hypothesis, considering the expected outcomes and potential limitations of the experiment.

Note: The protocols above are detailed and step-by-step, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   VH125.NOD Mice  Insulin-FITC Antibody  Diabetogenic T Cells  Insulin (μg/mL)  Co-Culture Time (days)  T Cell Activation (CD69+)  T Cell Proliferation (Ki-67+)  Type 1 Diabetes Development
0             8             1:50                1.5e+05               5.0                  2.5                  0.35                    0.20                    0.40
1             9             1:75                1.2e+05               7.5                  3.0                  0.42                    0.30                    0.50
2             7             1:25                1.8e+05               2.5                  2.0                  0.28                    0.18                    0.30
3             10            1:100               1.0e+05               10.0                 3.5                  0.50                    0.40                    0.60
4             8             1:60                1.4e+05               6.0                  2.8                  0.38                    0.25                    0.45
5             9             1:80                1.6e+05               8.0                  3.2                  0.45                    0.35                    0.55
6             7             1:40                1.1e+05               4.0                  2.2                  0.32                    0.22                    0.38
7             10            1:120               1.3e+05               12.0                 3.8                  0.55                    0.45                    0.65
8             8             1:90                1.7e+05               9.0                  3.0                  0.40                    0.30                    0.50
9             9             1:110               1.5e+05               11.0                 3.6                  0.48                    0.38                    0.58
10            7             1:30                1.0e+05               3.0                  1.8                  0.25                    0.18                    0.35
11            10            1:130               1.4e+05               13.0                 4.0                  0.60                    0.50                    0.70
12            8             1:50                1.2e+05               5.5                  2.6                  0.36                    0.24                    0.42
13            9             1:70                1.6e+05               7.0                  2.9                  0.40                    0.30                    0.48
14            7             1:20                1.3e+05               2.0                  1.5                  0.20                    0.15                    0.30
15            10            1:140               1.1e+05               14.0                 4.2                  0.65                    0.55                    0.75
16            8             1:60                1.5e+05               6.5                  3.1                  0.42                    0.34                    0.52
17            9             1:80                1.7e+05               8.5                  3.4                  0.48                    0.38                    0.58
18            7             1:40                1.2e+05               4.5                  2.4                  0.34                    0.26                    0.42
19            10            1:150               1.3e+05               15.0                 4.4                  0.70                    0.60                    0.80
20            8             1:90                1.4e+05               9.5                  3.2                  0.45                    0.36                    0.55
21            9             1:100               1.6e+05               10.5                 3.6                  0.50                    0.40                    0.60
22            7             1:30                1.1e+05               3.5                  2.0                  0.28                    0.20                    0.38
23            10            1:160               1.2e+05               16.0                 4.6                  0.75                    0.65                    0.85
24            8             1:50                1.3e+05               5.0                  2.7                  0.38                    0.28                    0.45
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b3750eca3936a2bf99156c571c976a66ec84224c.summary'],"Do hypomorphic mutations in the BCR signalosome genes also affect the production of IgA and IgG antibodies, leading to a broader impairment of humoral immunity in patients with selective IgM deficiency?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that hypomorphic mutations in the BCR signalosome genes also affect the production of IgA and IgG antibodies, leading to a broader impairment of humoral immunity in patients with selective IgM deficiency.

**Experimental Plan:**

**Title:** Investigating the Impact of Hypomorphic Mutations in BCR Signalosome Genes on IgA and IgG Production in Patients with Selective IgM Deficiency

**Objective:** To determine whether hypomorphic mutations in BCR signalosome genes affect the production of IgA and IgG antibodies in patients with selective IgM deficiency, leading to a broader impairment of humoral immunity.

**Experimental Design:**

1. **Patient Selection:** Recruit 20 patients with selective IgM deficiency and 20 healthy controls. Ensure that the patients have hypomorphic mutations in BCR signalosome genes (BTK and BLNK).
2. **Sample Collection:** Collect peripheral blood mononuclear cells (PBMCs) from patients and healthy controls.
3. **B Cell Isolation and Stimulation:** Isolate B cells from PBMCs using magnetic bead separation or fluorescence-activated cell sorting (FACS). Stimulate B cells with antigens such as pneumococcal polysaccharides or lipopolysaccharides to induce IgA and IgG production.
4. **IgA and IgG Production Assay:** Measure IgA and IgG production using enzyme-linked immunosorbent assay (ELISA) or multiplex bead-based assays. Compare IgA and IgG production between patients and healthy controls.
5. **Flow Cytometry Analysis:** Analyze B cell subsets (e.g., marginal zone B cells, switched memory B cells) and their expression of activation markers (e.g., CD69, CD86) using flow cytometry.
6. **Gene Expression Analysis:** Perform RNA sequencing or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to analyze the expression of genes involved in IgA and IgG production, such as AICDA, CD40, and TACI.
7. **Statistical Analysis:** Compare IgA and IgG production, B cell subsets, and gene expression between patients and healthy controls using appropriate statistical tests (e.g., t-test, ANOVA).

**Equipment and Resources:**

* Flow cytometer
* ELISA plate reader
* Cell culture facilities
* Magnetic bead separator or FACS machine
* RNA sequencing or qRT-PCR equipment
* Bioinformatics tools for data analysis

**Expected Outcomes:**

* If the hypothesis is true, patients with selective IgM deficiency will show impaired IgA and IgG production, altered B cell subsets, and dysregulated gene expression compared to healthy controls.
* If the hypothesis is false, patients with selective IgM deficiency will show normal or near-normal IgA and IgG production, B cell subsets, and gene expression compared to healthy controls.

**Alternative Explanations:**

* The hypomorphic mutations in BCR signalosome genes may specifically affect IgM production, leaving IgA and IgG production intact.
* Other genetic or environmental factors may contribute to the observed immune defects in patients with selective IgM deficiency.

By designing an experiment to disprove the hypothesis, we can gain a deeper understanding of the molecular mechanisms underlying selective IgM deficiency and its potential impact on humoral immunity.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Patient Selection and Sample Collection**

1.1. **Inclusion Criteria:**

* Patients with selective IgM deficiency diagnosed by a healthcare professional
* Presence of hypomorphic mutations in BCR signalosome genes (BTK and BLNK) confirmed by genetic testing
* Age range: 18-65 years old
* No history of immunodeficiency disorders other than selective IgM deficiency
* No current or recent infections

1.2. **Exclusion Criteria:**

* Patients with a history of immunodeficiency disorders other than selective IgM deficiency
* Patients with active infections or inflammatory diseases
* Patients taking immunosuppressive medications

1.3. **Recruitment:**

* Recruit 20 patients with selective IgM deficiency and 20 healthy controls through hospital clinics, patient registries, or online advertisements
* Obtain informed consent from all participants
* Collect demographic and medical history information from participants

1.4. **Sample Collection:**

* Collect 20 mL of peripheral blood from each participant in EDTA-coated tubes
* Label tubes with unique identifiers and store at room temperature
* Process samples within 24 hours of collection

**Protocol 2: B Cell Isolation and Stimulation**

2.1. **PBMC Isolation:**

* Centrifuge blood samples at 400 x g for 10 minutes to separate plasma and PBMCs
* Resuspend PBMCs in 10 mL of PBS and count using a hemocytometer
* Aliquot 10^7 PBMCs per tube for B cell isolation

2.2. **B Cell Isolation:**

* Use magnetic bead separation or FACS to isolate B cells from PBMCs
* Use anti-CD19 or anti-CD20 antibodies for B cell enrichment
* Verify B cell purity using flow cytometry (>95% CD19+ or CD20+ cells)

2.3. **B Cell Stimulation:**

* Resuspend isolated B cells in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine
* Add 10 μg/mL pneumococcal polysaccharides or 1 μg/mL lipopolysaccharides to stimulate B cells
* Incubate at 37°C, 5% CO2 for 72 hours

**Protocol 3: IgA and IgG Production Assay**

3.1. **ELISA:**

* Coat 96-well ELISA plates with 100 μL of anti-human IgA or IgG antibodies (1 μg/mL) overnight at 4°C
* Block plates with 200 μL of 1% BSA in PBS for 1 hour at room temperature
* Add 100 μL of stimulated B cell culture supernatants to each well
* Incubate for 2 hours at room temperature
* Add 100 μL of HRP-conjugated anti-human IgA or IgG antibodies (1:1000) and incubate for 1 hour at room temperature
* Develop with TMB substrate and measure absorbance at 450 nm using an ELISA plate reader

3.2. **Multiplex Bead-Based Assay:**

* Use a commercial multiplex bead-based assay kit for IgA and IgG detection
* Follow the manufacturer's instructions for sample preparation and assay setup
* Analyze using a Luminex or similar instrument

**Protocol 4: Flow Cytometry Analysis**

4.1. **Staining:**

* Stain stimulated B cells with fluorochrome-conjugated antibodies against CD19, CD69, CD86, and other markers of interest
* Use a staining panel optimized for B cell subset analysis

4.2. **Acquisition:**

* Acquire data using a flow cytometer (e.g., BD FACSCanto or similar)
* Collect at least 10,000 events per sample

4.3. **Analysis:**

* Use flow cytometry analysis software (e.g., FlowJo or similar) to identify B cell subsets and analyze marker expression
* Gate on CD19+ cells and analyze expression of CD69, CD86, and other markers

**Protocol 5: Gene Expression Analysis**

5.1. **RNA Isolation:**

* Isolate RNA from stimulated B cells using a commercial RNA isolation kit
* Quantify RNA using a spectrophotometer (e.g., NanoDrop)

5.2. **RNA Sequencing or qRT-PCR:**

* Perform RNA sequencing using a commercial platform (e.g., Illumina or similar)
* Analyze gene expression using bioinformatics tools (e.g., DESeq2 or similar)
* Alternatively, perform qRT-PCR using primers specific to genes involved in IgA and IgG production (e.g., AICDA, CD40, TACI)

**Protocol 6: Statistical Analysis**

6.1. **Data Preparation:**

* Compile data from all experiments, including IgA and IgG production, B cell subsets, and gene expression
* Normalize data as necessary

6.2. **Statistical Tests:**

* Compare IgA and IgG production, B cell subsets, and gene expression between patients and healthy controls using appropriate statistical tests (e.g., t-test, ANOVA)
* Correct for multiple comparisons using Bonferroni or similar methods

6.3. **Data Interpretation:**

* Interpret results in the context of the hypothesis and alternative explanations
* Discuss implications for our understanding of selective IgM deficiency and humoral immunity","```
   Patient_ID  Age  BTK_Mutation  BLNK_Mutation  IgM_Deficiency  Pneumococcal_Polysaccharides  Lipopolysaccharides  IgA_Production  IgG_Production  CD19_Expression  CD69_Expression  CD86_Expression  AICDA_Expression  CD40_Expression  TACI_Expression  Outcome
0           1   32.0          1.0           1.0             1.0                    5.0               0.5          120.0          200.0          0.8          0.4          0.6          2.0          1.5          1.2          1
1           2   45.0          0.0           1.0             1.0                    7.5               1.0          150.0          250.0          0.9          0.5          0.7          2.5          1.8          1.5          1
2           3   28.0          1.0           0.0             1.0                    2.5               0.5          100.0          180.0          0.7          0.3          0.5          1.8          1.2          1.0          1
3           4   50.0          0.0           0.0             1.0                    10.0              1.5          200.0          300.0          1.0          0.6          0.8          3.0          2.0          1.8          1
4           5   35.0          1.0           1.0             1.0                    5.0               0.5          130.0          220.0          0.8          0.4          0.6          2.2          1.6          1.3          1
5           6   42.0          0.0           1.0             1.0                    7.5               1.0          160.0          260.0          0.9          0.5          0.7          2.8          1.9          1.6          1
6           7   29.0          1.0           0.0             1.0                    2.5               0.5          110.0          190.0          0.7          0.3          0.5          2.0          1.4          1.1          1
7           8   48.0          0.0           0.0             1.0                    10.0              1.5          210.0          310.0          1.0          0.6          0.8          3.2          2.1          1.9          1
8           9   33.0          1.0           1.0             1.0                    5.0               0.5          140.0          230.0          0.8          0.4          0.6          2.4          1.7          1.4          1
9          10   40.0          0.0           1.0             1.0                    7.5               1.0          170.0          270.0          0.9          0.5          0.7          3.0          2.0          1.7          1
10         11   27.0          1.0           0.0             1.0                    2.5               0.5          120.0          200.0          0.7          0.3          0.5          2.2          1.5          1.2          1
11         12   46.0          0.0           0.0             1.0                    10.0              1.5          220.0          320.0          1.0          0.6          0.8          3.4          2.2          2.0          1
12         13   34.0          1.0           1.0             1.0                    5.0               0.5          150.0          240.0          0.8          0.4          0.6          2.6          1.8          1.5          1
13         14   41.0          0.0           1.0             1.0                    7.5               1.0          180.0          280.0          0.9          0.5          0.7          3.2          2.1          1.8          1
14         15   30.0          1.0           0.0             1.0                    2.5               0.5          130.0          210.0          0.7          0.3          0.5          2.4          1.6          1.3          1
15         16   49.0          0.0           0.0             1.0                    10.0              1.5          230.0          330.0          1.0          0.6          0.8          3.6          2.3          2.1          1
16         17   36.0          1.0           1.0             1.0                    5.0               0.5          160.0          250.0          0.8          0.4          0.6          2.8          1.9          1.6          1
17         18   43.0          0.0           1.0             1.0                    7.5               1.0          190.0          290.0          0.9          0.5          0.7          3.4          2.2          1.9          1
18         19   31.0          1.0           0.0             1.0                    2.5               0.5          140.0          220.0          0.7          0.3          0.5          2.6          1.7          1.4          1
19         20   47.0          0.0           0.0             1.0                    10.0              1.5          240.0          340.0          1.0          0.6          0.8          3.8          2.4          2.2          1
20         21   38.0          1.0           1.0             1.0                    5.0               0.5          170.0          260.0          0.8          0.4          0.6          3.0          2.0          1.7          1
21         22   44.0          0.0           1.0             1.0                    7.5               1.0          200.0          300.0          0.9          0.5          0.7          3.6          2.3          2.0          1
22         23   32.0          1.0           0.0             1.0                    2.5               0.5          150.0          230.0          0.7          0.3          0.5          2.8          1.8          1.5          1
23         24   48.0          0.0           0.0             1.0                    10.0              1.5          250.0          350.0          1.0          0.6          0.8          4.0          2.5          2.3          1
24         25   39.0          1.0           1.0             1.0                    5.0               0.5          180.0          270.0          0.8          0.4          0.6          3.2          2.1          1.8          1
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0a31ad892ec2a20e5093684ecb0d476b7ddeb402.summary'],"Do metallothioneins play a crucial role in regulating the selective induction of apoptosis in DLBCL cells by ZnO nanoparticles through their ability to bind and sequester zinc ions, thereby modulating the oxidative stress response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I've developed an experimental plan to test it using existing scientific methods and equipment. To disprove the hypothesis, I'll design an experiment that attempts to show that metallothioneins do not play a crucial role in regulating the selective induction of apoptosis in DLBCL cells by ZnO nanoparticles.

**Experiment:**

**Title:** Investigating the Role of Metallothioneins in ZnO Nanoparticle-Induced Apoptosis in DLBCL Cells

**Objective:** To determine if metallothioneins are essential for the selective induction of apoptosis in DLBCL cells by ZnO nanoparticles through their ability to bind and sequester zinc ions.

**Experimental Design:**

1. **Cell Culture:** Use a DLBCL cell line (e.g., OCI-Ly1 or SU-DHL-4) and maintain it in a suitable cell culture medium.
2. **Metallothionein Knockdown:** Use siRNA or CRISPR-Cas9 to specifically knockdown metallothionein genes (e.g., MT1A, MT1B, MT2A) in DLBCL cells. This will help to reduce the expression of metallothioneins and their ability to bind and sequester zinc ions.
3. **ZnO Nanoparticle Treatment:** Treat the metallothionein-knockdown DLBCL cells with ZnO nanoparticles at various concentrations (e.g., 10, 20, 50 μM) for 24-48 hours.
4. **Apoptosis Assay:** Measure the apoptosis rate in the treated cells using flow cytometry (e.g., Annexin V/PI staining) or other apoptosis detection methods (e.g., TUNEL assay, caspase-3 activity assay).
5. **Control Groups:** Include the following control groups:
	* Non-transfected DLBCL cells treated with ZnO nanoparticles (positive control)
	* Metallothionein-knockdown DLBCL cells without ZnO nanoparticle treatment (negative control)
	* Non-transfected DLBCL cells without ZnO nanoparticle treatment (baseline control)
6. **Data Analysis:** Compare the apoptosis rates in the metallothionein-knockdown cells treated with ZnO nanoparticles to the control groups. If metallothioneins play a crucial role in regulating apoptosis, the knockdown of metallothioneins should reduce the apoptotic effect of ZnO nanoparticles.

**Expected Outcome:**

If the hypothesis is true, the metallothionein-knockdown cells should exhibit a reduced apoptotic response to ZnO nanoparticles compared to the non-transfected cells. If the hypothesis is false, the metallothionein-knockdown cells should still exhibit a significant apoptotic response to ZnO nanoparticles, indicating that metallothioneins are not essential for the selective induction of apoptosis.

**Equipment and Resources:**

* siRNA or CRISPR-Cas9 system
* DLBCL cell line
* ZnO nanoparticles
* Cell culture medium
* Flow cytometer
* Annexin V/PI staining kit (or other apoptosis detection reagents)
* PCR and qRT-PCR equipment (for verifying metallothionein knockdown)

**Timeline:**

* Cell culture and metallothionein knockdown: 1-2 weeks
* ZnO nanoparticle treatment and apoptosis assay: 1-2 weeks
* Data analysis and interpretation: 1-2 weeks

**Budget:**

* siRNA or CRISPR-Cas9 system: $500-$1,000
* DLBCL cell line: $100-$300
* ZnO nanoparticles: $100-$300
* Cell culture medium and reagents: $500-$1,000
* Flow cytometer and apoptosis detection reagents: $1,000-$2,000
* PCR and qRT-PCR equipment: $1,000-$2,000
* Total: $4,100-$7,300

This experiment should be feasible within a reasonable time frame (6-12 weeks) and budget. The results will help to determine whether metallothioneins play a crucial role in regulating the selective induction of apoptosis in DLBCL cells by ZnO nanoparticles.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Maintenance**

1. Obtain the DLBCL cell line (e.g., OCI-Ly1 or SU-DHL-4) and store it in a sterile container at -80°C.
2. Thaw the cell line according to the manufacturer's instructions and resuspend it in 10 mL of complete cell culture medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).
3. Transfer the cell suspension to a 25 cm² tissue culture flask and incubate at 37°C, 5% CO₂, and 95% humidity.
4. Monitor cell growth and viability daily using a microscope and perform cell counting using a hemocytometer or an automated cell counter.
5. Passage the cells every 3-4 days to maintain a healthy and exponentially growing culture.

**Protocol 2: Metallothionein Knockdown using siRNA**

1. Design and synthesize siRNA oligonucleotides targeting metallothionein genes (e.g., MT1A, MT1B, MT2A) using a siRNA design tool (e.g., siRNA Wizard).
2. Transfect the siRNA oligonucleotides into the DLBCL cells using a transfection reagent (e.g., Lipofectamine RNAiMAX) according to the manufacturer's instructions.
3. Incubate the transfected cells for 24-48 hours to allow for siRNA-mediated knockdown of metallothionein genes.
4. Verify the knockdown efficiency using qRT-PCR or Western blot analysis.

**Protocol 2 (Alternative): Metallothionein Knockdown using CRISPR-Cas9**

1. Design and synthesize CRISPR-Cas9 guide RNAs targeting metallothionein genes (e.g., MT1A, MT1B, MT2A) using a CRISPR design tool (e.g., CRISPR Design).
2. Transfect the CRISPR-Cas9 plasmid into the DLBCL cells using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.
3. Incubate the transfected cells for 24-48 hours to allow for CRISPR-Cas9-mediated knockdown of metallothionein genes.
4. Verify the knockdown efficiency using qRT-PCR or Western blot analysis.

**Protocol 3: ZnO Nanoparticle Treatment**

1. Prepare a stock solution of ZnO nanoparticles (e.g., 10 mM) in sterile water or cell culture medium.
2. Dilute the stock solution to the desired concentrations (e.g., 10, 20, 50 μM) in cell culture medium.
3. Add the ZnO nanoparticle solution to the metallothionein-knockdown DLBCL cells and incubate for 24-48 hours.
4. Use a control group with non-transfected DLBCL cells treated with ZnO nanoparticles as a positive control.

**Protocol 4: Apoptosis Assay using Annexin V/PI Staining**

1. Harvest the treated cells by centrifugation (e.g., 300 x g, 5 minutes) and resuspend them in 100 μL of Annexin V binding buffer.
2. Add 5 μL of Annexin V-FITC and 5 μL of propidium iodide (PI) to the cell suspension and incubate for 15 minutes at room temperature.
3. Analyze the stained cells using a flow cytometer (e.g., BD FACSCalibur) and gate on the Annexin V-positive and PI-negative population to quantify apoptotic cells.
4. Use a control group with non-transfected DLBCL cells without ZnO nanoparticle treatment as a baseline control.

**Protocol 5: Data Analysis**

1. Calculate the apoptosis rate as the percentage of Annexin V-positive and PI-negative cells in each treatment group.
2. Compare the apoptosis rates between the metallothionein-knockdown cells treated with ZnO nanoparticles and the control groups using a statistical analysis software (e.g., GraphPad Prism).
3. Determine the significance of the results using a two-tailed t-test or ANOVA with a significance level of 0.05.

**Quality Control and Replicability**

* Verify the identity and purity of the DLBCL cell line using STR analysis or other authentication methods.
* Use a consistent lot of ZnO nanoparticles and cell culture reagents throughout the experiment.
* Perform the experiment in triplicate to ensure reproducibility and minimize experimental variability.
* Include positive and negative controls in each experiment to validate the results.
* Document all experimental procedures, results, and data analysis in a laboratory notebook or electronic lab record.","```
   siRNA_amount  CRISPR_amount  ZnO_concentration  Apoptosis_Rate
0           10.0           0.0               10.0       0.235000
1            5.0           0.0               20.0       0.312000
2            0.0           5.0               10.0       0.278000
3           15.0           0.0               50.0       0.421000
4            0.0           10.0               20.0       0.352000
5           20.0           0.0               10.0       0.289000
6            5.0           5.0               50.0       0.456000
7            0.0           0.0               10.0       0.198000
8           10.0           5.0               20.0       0.375000
9            5.0           0.0               50.0       0.402000
10           0.0           15.0               10.0       0.308000
11          20.0           5.0               50.0       0.482000
12           5.0           10.0               20.0       0.392000
13           0.0           0.0               20.0       0.222000
14          15.0           10.0               50.0       0.512000
15           5.0           5.0               10.0       0.258000
16           0.0           20.0               20.0       0.328000
17          10.0           15.0               50.0       0.542000
18           5.0           0.0               20.0       0.282000
19           0.0           5.0               50.0       0.438000
20          20.0           10.0               10.0       0.299000
21           5.0           15.0               20.0       0.412000
22           0.0           0.0               50.0       0.242000
23          15.0           5.0               20.0       0.382000
24          10.0           20.0               50.0       0.562000
```",0.5365458246250422
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/56aad7ffb7d30dba2310757a7fd486957994b085.summary'],"Do microbiome-derived metabolites influence the epigenetic landscape of tissue-resident memory T cells, thereby modulating their function and contributing to the heterogeneity of immunological memory?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Microbiome-derived metabolites influence the epigenetic landscape of tissue-resident memory T cells, thereby modulating their function and contributing to the heterogeneity of immunological memory.

**Experimental Plan:**

**Objective:** To investigate whether microbiome-derived metabolites affect the epigenetic landscape of tissue-resident memory T cells and their function.

**Approach:**

1. **Sample Collection:**
	* Collect tissue-resident memory T cells from mice or human subjects with varying microbiome compositions (e.g., germ-free, specific pathogen-free, or with altered microbiota).
	* Isolate T cells from tissues of interest (e.g., skin, lung, or gut).
2. **Metabolite Exposure:**
	* Prepare microbiome-derived metabolite extracts from the collected samples or use commercially available metabolite libraries.
	* Expose isolated T cells to these metabolites in vitro, using a controlled, dose-dependent manner.
3. **Epigenetic Analysis:**
	* Perform chromatin immunoprecipitation sequencing (ChIP-seq) or reduced representation bisulfite sequencing (RRBS) to analyze the epigenetic landscape of T cells before and after metabolite exposure.
	* Focus on histone modifications (e.g., H3K27me3, H3K4me3) and DNA methylation marks associated with gene regulation.
4. **Functional Assays:**
	* Evaluate T cell function using assays such as:
		+ Proliferation assays (e.g., CFSE, BrdU incorporation)
		+ Cytokine production (e.g., ELISA, intracellular staining)
		+ Cytotoxicity assays (e.g., chromium release, flow cytometry)
5. **Data Analysis:**
	* Compare epigenetic profiles and functional responses between T cells exposed to different metabolite extracts or concentrations.
	* Identify differentially regulated genes and pathways using bioinformatic tools (e.g., DESeq2, GSEA).

**Experiment to Disprove the Hypothesis:**

**Null Hypothesis:** Microbiome-derived metabolites do not influence the epigenetic landscape of tissue-resident memory T cells or their function.

**Experimental Design:**

1. **Controlled Metabolite Exposure:**
	* Use a metabolite extract from a microbiome-depleted or axenic environment (e.g., germ-free mice) as a negative control.
	* Expose T cells to this control metabolite extract and compare the results to those obtained with metabolites from a normal or altered microbiome.
2. **Epigenetic Analysis:**
	* Perform the same epigenetic analysis as described above, focusing on the same histone modifications and DNA methylation marks.
3. **Functional Assays:**
	* Conduct the same functional assays as described above to evaluate T cell function.
4. **Data Analysis:**
	* Compare the epigenetic profiles and functional responses between T cells exposed to the control metabolite extract and those exposed to metabolites from a normal or altered microbiome.

**Rationale:** If the null hypothesis is true, we would expect to see no significant differences in the epigenetic landscape or functional responses between T cells exposed to the control metabolite extract and those exposed to metabolites from a normal or altered microbiome. This would suggest that microbiome-derived metabolites do not influence the epigenetic landscape of tissue-resident memory T cells or their function.

**Budget and Timeframe:**

* This experiment can be completed within 6-12 months, depending on the availability of resources and personnel.
* The budget will depend on the specific reagents, equipment, and personnel required. However, a rough estimate for the entire experiment could be around $200,000-$500,000, broken down into:
	+ Sample collection and processing: $20,000-$50,000
	+ Metabolite preparation and exposure: $10,000-$20,000
	+ Epigenetic analysis: $50,000-$100,000
	+ Functional assays: $20,000-$40,000
	+ Data analysis and bioinformatics: $10,000-$20,000
	+ Personnel and miscellaneous: $50,000-$100,000

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the institution's resources.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Sample Collection**

1.1. Mouse or human subject selection:

* Select mice or human subjects with varying microbiome compositions (e.g., germ-free, specific pathogen-free, or with altered microbiota).
* Ensure that the selected subjects are healthy and free of any underlying diseases or conditions that may affect the experiment.

1.2. Tissue collection:

* Collect tissues of interest (e.g., skin, lung, or gut) from the selected subjects using sterile techniques.
* Store the tissues in a sterile container or bag and keep them on ice until processing.

1.3. T cell isolation:

* Isolate tissue-resident memory T cells from the collected tissues using a T cell isolation kit or a protocol optimized for the specific tissue type.
* Use a cell sorter or magnetic beads to enrich for CD4+ or CD8+ T cells, depending on the experimental design.
* Count and assess the purity of the isolated T cells using flow cytometry.

**Protocol 2: Metabolite Exposure**

2.1. Metabolite preparation:

* Prepare microbiome-derived metabolite extracts from the collected samples or use commercially available metabolite libraries.
* Extract metabolites using a solvent (e.g., methanol, ethanol, or water) and filter the extract through a 0.2 μm filter.
* Concentrate the extract using a speed vacuum or lyophilization.

2.2. Metabolite exposure:

* Expose isolated T cells to the prepared metabolite extracts in vitro using a controlled, dose-dependent manner.
* Use a 96-well plate or a similar format to expose T cells to different concentrations of metabolites (e.g., 1 μM, 10 μM, 100 μM).
* Incubate the T cells with metabolites for 24-48 hours at 37°C, 5% CO2.

**Protocol 3: Epigenetic Analysis**

3.1. Chromatin immunoprecipitation sequencing (ChIP-seq):

* Cross-link T cells with formaldehyde and sonicate the chromatin to generate fragments.
* Immunoprecipitate the chromatin fragments using antibodies against specific histone modifications (e.g., H3K27me3, H3K4me3).
* Purify the immunoprecipitated DNA and prepare it for sequencing using a ChIP-seq library preparation kit.
* Sequence the libraries using a next-generation sequencing platform (e.g., Illumina, PacBio).

3.2. Reduced representation bisulfite sequencing (RRBS):

* Treat T cell DNA with bisulfite to convert unmethylated cytosines to uracils.
* Perform PCR amplification of the bisulfite-treated DNA using primers specific to the regions of interest.
* Sequence the amplified DNA using a next-generation sequencing platform (e.g., Illumina, PacBio).

**Protocol 4: Functional Assays**

4.1. Proliferation assays:

* Label T cells with CFSE or BrdU and incubate them with metabolites for 24-48 hours.
* Analyze the proliferation of T cells using flow cytometry or a plate reader.

4.2. Cytokine production:

* Stimulate T cells with metabolites and measure cytokine production using ELISA or intracellular staining.
* Analyze the cytokine production using a plate reader or flow cytometry.

4.3. Cytotoxicity assays:

* Co-culture T cells with target cells (e.g., tumor cells) and measure cytotoxicity using a chromium release assay or flow cytometry.
* Analyze the cytotoxicity using a plate reader or flow cytometry.

**Protocol 5: Data Analysis**

5.1. Epigenetic data analysis:

* Map the ChIP-seq or RRBS reads to a reference genome using a bioinformatic tool (e.g., BWA, Bowtie).
* Identify differentially regulated genes and pathways using a bioinformatic tool (e.g., DESeq2, GSEA).

5.2. Functional data analysis:

* Analyze the functional data using a statistical software (e.g., R, Prism).
* Compare the functional responses between T cells exposed to different metabolite extracts or concentrations.

**Protocol 6: Experiment to Disprove the Hypothesis**

6.1. Controlled metabolite exposure:

* Prepare a metabolite extract from a microbiome-depleted or axenic environment (e.g., germ-free mice).
* Expose T cells to this control metabolite extract and compare the results to those obtained with metabolites from a normal or altered microbiome.

6.2. Epigenetic analysis:

* Perform the same epigenetic analysis as described above, focusing on the same histone modifications and DNA methylation marks.

6.3. Functional assays:

* Conduct the same functional assays as described above to evaluate T cell function.

6.4. Data analysis:

* Compare the epigenetic profiles and functional responses between T cells exposed to the control metabolite extract and those exposed to metabolites from a normal or altered microbiome.

These detailed protocols should provide a clear guide for executing the experiment and testing the hypothesis.","```
   Mouse/Human  Tissue  Metabolite_Conc  CD4+  CD8+  H3K27me3  H3K4me3  Proliferation  Cytokine_Production  Cytotoxicity
0        Mouse    Skin           1.0   80.0   20.0       0.5       0.8          0.6             0.4           0.7
1        Human    Lung          10.0   70.0   30.0       0.7       0.9          0.8             0.6           0.9
2        Mouse    Gut           0.1   90.0   10.0       0.3       0.6          0.4             0.3           0.5
3        Human    Skin           5.0   85.0   15.0       0.6       0.8          0.7             0.5           0.8
4        Mouse    Lung           0.5   75.0   25.0       0.4       0.7          0.5             0.4           0.6
5        Human    Gut          20.0   60.0   40.0       0.9       1.0          0.9             0.8           1.0
6        Mouse    Skin           2.0   80.0   20.0       0.5       0.8          0.6             0.4           0.7
7        Human    Lung           1.5   70.0   30.0       0.7       0.9          0.8             0.6           0.9
8        Mouse    Gut           0.8   90.0   10.0       0.3       0.6          0.4             0.3           0.5
9        Human    Skin           4.0   85.0   15.0       0.6       0.8          0.7             0.5           0.8
10       Mouse    Lung           0.3   75.0   25.0       0.4       0.7          0.5             0.4           0.6
11       Human    Gut          15.0   60.0   40.0       0.9       1.0          0.9             0.8           1.0
12       Mouse    Skin           1.2   80.0   20.0       0.5       0.8          0.6             0.4           0.7
13       Human    Lung           1.8   70.0   30.0       0.7       0.9          0.8             0.6           0.9
14       Mouse    Gut           0.6   90.0   10.0       0.3       0.6          0.4             0.3           0.5
15       Human    Skin           3.5   85.0   15.0       0.6       0.8          0.7             0.5           0.8
16       Mouse    Lung           0.4   75.0   25.0       0.4       0.7          0.5             0.4           0.6
17       Human    Gut          12.0   60.0   40.0       0.9       1.0          0.9             0.8           1.0
18       Mouse    Skin           1.0   80.0   20.0       0.5       0.8          0.6             0.4           0.7
19       Human    Lung           1.0   70.0   30.0       0.7       0.9          0.8             0.6           0.9
20       Mouse    Gut           0.2   90.0   10.0       0.3       0.6          0.4             0.3           0.5
21       Human    Skin           2.5   85.0   15.0       0.6       0.8          0.7             0.5           0.8
22       Mouse    Lung           0.6   75.0   25.0       0.4       0.7          0.5             0.4           0.6
23       Human    Gut          10.0   60.0   40.0       0.9       1.0          0.9             0.8           1.0
24       Mouse    Skin           1.5   80.0   20.0       0.5       0.8          0.6             0.4           0.7
```",0.6177726078839766
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/607a6d8540f627aabd90bd24520b5cbb0f2589ca.summary'],"Do omega-3 fatty acids modulate the expression of microRNAs involved in the regulation of the STAT6 phosphorylation pathway in HEK-Blue cells, thereby influencing IgE production?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Modulation of microRNA Expression by Omega-3 Fatty Acids in the Regulation of STAT6 Phosphorylation Pathway in HEK-Blue Cells

**Objective:** To determine if omega-3 fatty acids modulate the expression of microRNAs involved in the regulation of the STAT6 phosphorylation pathway in HEK-Blue cells, thereby influencing IgE production.

**Equipment:**

* HEK-Blue cells
* Omega-3 fatty acids (DHA, EPA, and DPA)
* microRNA isolation kit
* qRT-PCR machine
* microRNA microarray or RNA sequencing platform
* Bioinformatics tools for data analysis

**Steps:**

1. Culture HEK-Blue cells in a 6-well plate and treat them with different concentrations of omega-3 fatty acids (DHA, EPA, and DPA) for 24 hours.
2. Isolate total RNA from the treated cells using a microRNA isolation kit.
3. Perform qRT-PCR to validate the expression of specific microRNAs involved in the STAT6 phosphorylation pathway (e.g., miR-21, miR-155, and miR-221).
4. Perform microRNA microarray or RNA sequencing to profile the global microRNA expression in response to omega-3 fatty acid treatment.
5. Analyze the data using bioinformatics tools to identify differentially expressed microRNAs and their potential targets in the STAT6 phosphorylation pathway.
6. Validate the findings using qRT-PCR and Western blotting to measure the expression of STAT6 and IgE.

**Expected Outcome:** If the hypothesis is true, omega-3 fatty acids should modulate the expression of microRNAs involved in the regulation of the STAT6 phosphorylation pathway, leading to decreased IgE production.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Involvement of microRNAs in Omega-3 Fatty Acid-Mediated Inhibition of IgE Production in HEK-Blue Cells

**Objective:** To determine if omega-3 fatty acids inhibit IgE production in HEK-Blue cells independently of microRNA regulation of the STAT6 phosphorylation pathway.

**Equipment:**

* HEK-Blue cells
* Omega-3 fatty acids (DHA, EPA, and DPA)
* microRNA inhibitors (e.g., antagomirs) specific to microRNAs involved in the STAT6 phosphorylation pathway
* IgE ELISA kit

**Steps:**

1. Culture HEK-Blue cells in a 6-well plate and treat them with different concentrations of omega-3 fatty acids (DHA, EPA, and DPA) for 24 hours.
2. Transfect the cells with microRNA inhibitors specific to microRNAs involved in the STAT6 phosphorylation pathway (e.g., miR-21, miR-155, and miR-221).
3. Measure IgE production using an IgE ELISA kit.
4. Compare IgE production in omega-3 fatty acid-treated cells with and without microRNA inhibition.

**Expected Outcome:** If the hypothesis is false, omega-3 fatty acids should still inhibit IgE production in HEK-Blue cells even when microRNA regulation of the STAT6 phosphorylation pathway is disrupted.

**Rationale:** By attempting to disprove the hypothesis, we can gain confidence in the results if the experiment fails to disprove it. This approach can help to rule out alternative explanations and provide stronger evidence for the original hypothesis.

**Time and Resource Considerations:**

* Both experiments can be completed within 6-8 weeks, depending on the availability of resources and equipment.
* The experiments require a moderate budget for reagents, equipment, and personnel.
* The use of existing equipment and resources, such as the HEK-Blue cell line and omega-3 fatty acids, can help reduce costs.

By following these experimental plans, we can test the hypothesis and attempt to disprove it, providing a more comprehensive understanding of the role of omega-3 fatty acids in modulating the STAT6 phosphorylation pathway and IgE production in HEK-Blue cells.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Cell Culture and Omega-3 Fatty Acid Treatment**

1.1. Obtain HEK-Blue cells from a reliable source and thaw them according to the supplier's instructions.

1.2. Culture the cells in a 6-well plate at a density of 1 x 10^5 cells per well in 2 mL of complete growth medium (e.g., DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).

1.3. Incubate the cells at 37°C, 5% CO2 for 24 hours to allow for cell attachment and recovery.

1.4. Prepare stock solutions of omega-3 fatty acids (DHA, EPA, and DPA) in DMSO at concentrations of 10 mM, 50 mM, and 100 mM.

1.5. Add the omega-3 fatty acid stock solutions to the cell culture medium to achieve final concentrations of 1 μM, 5 μM, and 10 μM. Mix well to ensure uniform distribution.

1.6. Incubate the cells for 24 hours at 37°C, 5% CO2.

**Step 2: RNA Isolation**

2.1. Remove the cell culture medium and wash the cells twice with 1x PBS.

2.2. Add 1 mL of TRIzol reagent to each well and incubate for 5 minutes at room temperature.

2.3. Scrape the cells and transfer the mixture to a microcentrifuge tube.

2.4. Add 200 μL of chloroform and mix well.

2.5. Centrifuge at 12,000 x g for 15 minutes at 4°C.

2.6. Transfer the aqueous phase to a new microcentrifuge tube and add 500 μL of isopropanol.

2.7. Mix well and incubate at -20°C for 1 hour.

2.8. Centrifuge at 12,000 x g for 15 minutes at 4°C.

2.9. Wash the pellet with 75% ethanol and centrifuge at 7,500 x g for 5 minutes at 4°C.

2.10. Air-dry the pellet and resuspend in 20 μL of nuclease-free water.

**Step 3: qRT-PCR**

3.1. Prepare a master mix containing 2x qRT-PCR buffer, 0.5 μM forward and reverse primers, and 0.1 μM probe.

3.2. Add 2 μL of RNA template to each well of a 96-well plate.

3.3. Add 18 μL of master mix to each well.

3.4. Perform qRT-PCR using the following conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.

3.5. Analyze the data using the ΔΔCt method to determine the relative expression of microRNAs.

**Step 4: MicroRNA Microarray or RNA Sequencing**

4.1. Prepare the RNA samples according to the manufacturer's instructions for microRNA microarray or RNA sequencing.

4.2. Perform microRNA microarray or RNA sequencing using a platform such as Affymetrix or Illumina.

4.3. Analyze the data using bioinformatics tools such as Partek Genomics Suite or DESeq2 to identify differentially expressed microRNAs.

**Step 5: Data Analysis and Validation**

5.1. Use bioinformatics tools to identify differentially expressed microRNAs and their potential targets in the STAT6 phosphorylation pathway.

5.2. Validate the findings using qRT-PCR and Western blotting to measure the expression of STAT6 and IgE.

**Step 6: Western Blotting**

6.1. Prepare protein lysates from the treated cells using a lysis buffer (e.g., RIPA buffer).

6.2. Separate the proteins using SDS-PAGE and transfer to a PVDF membrane.

6.3. Probe the membrane with antibodies against STAT6 and IgE.

6.4. Detect the proteins using a chemiluminescent substrate and quantify using densitometry.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

**Step 1: Cell Culture and Omega-3 Fatty Acid Treatment**

1.1-1.6. Follow the same steps as in the experiment to test the hypothesis.

**Step 2: MicroRNA Inhibition**

2.1. Prepare microRNA inhibitors (e.g., antagomirs) specific to microRNAs involved in the STAT6 phosphorylation pathway (e.g., miR-21, miR-155, and miR-221).

2.2. Transfect the cells with the microRNA inhibitors using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

2.3. Incubate the cells for 24 hours at 37°C, 5% CO2.

**Step 3: IgE ELISA**

3.1. Prepare the IgE ELISA kit according to the manufacturer's instructions.

3.2. Add 100 μL of cell culture supernatant to each well of the ELISA plate.

3.3. Incubate for 2 hours at room temperature.

3.4. Detect IgE using a horseradish peroxidase-conjugated secondary antibody and a chromogenic substrate.

3.5. Measure the absorbance at 450 nm using a plate reader.

**Step 4: Data Analysis**

4.1. Compare IgE production in omega-3 fatty acid-treated cells with and without microRNA inhibition.

4.2. Analyze the data using a two-tailed t-test to determine if there is a significant difference in IgE production between the two groups.

By following these detailed, step-by-step protocols, the experiments can be replicated and the results can be validated.","```
   DHA  EPA  DPA  IgE_Expression  STAT6_Phosphorylation
0   1.0  0.0  0.0           0.85                 0.40
1   5.0  0.0  0.0           0.92                 0.45
2  10.0  0.0  0.0           0.98                 0.50
3   0.0  1.0  0.0           0.80                 0.35
4   0.0  5.0  0.0           0.88                 0.42
5   0.0 10.0  0.0           0.95                 0.48
6   0.0  0.0  1.0           0.78                 0.32
7   0.0  0.0  5.0           0.85                 0.40
8   0.0  0.0 10.0           0.90                 0.45
9   1.0  1.0  0.0           0.90                 0.45
10  1.0  0.0  1.0           0.88                 0.42
11  0.0  1.0  1.0           0.85                 0.40
12  5.0  5.0  0.0           0.95                 0.48
13  5.0  0.0  5.0           0.92                 0.45
14  0.0  5.0  5.0           0.90                 0.45
15 10.0 10.0  0.0           0.98                 0.50
16 10.0  0.0 10.0           0.95                 0.48
17  0.0 10.0 10.0           0.92                 0.45
18  1.0  5.0  1.0           0.92                 0.45
19  5.0  1.0  5.0           0.95                 0.48
20  1.0 10.0  1.0           0.95                 0.48
21  5.0  5.0  5.0           0.98                 0.50
22 10.0  1.0 10.0           0.98                 0.50
23 10.0  5.0 10.0           0.98                 0.50
24  5.0 10.0  5.0           0.98                 0.50
```",0.04399334672249339
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5eef1279221a0f9f77f448ef96189262637fb747.summary'],"Do other scavenger receptors, such as CD36 or CD91, also interact with Echinococcus granulosus sensu lato tegumental components and modulate the host immune response to secondary cystic echinococcosis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test whether other scavenger receptors, such as CD36 or CD91, also interact with Echinococcus granulosus sensu lato tegumental components and modulate the host immune response to secondary cystic echinococcosis.

**Experimental Plan:**

**Objective:** To investigate the interaction between CD36 and CD91 scavenger receptors with Echinococcus granulosus sensu lato tegumental components and their potential role in modulating the host immune response to secondary cystic echinococcosis.

**Hypothesis:** CD36 and CD91 scavenger receptors interact with Echinococcus granulosus sensu lato tegumental components and modulate the host immune response to secondary cystic echinococcosis.

**Experimental Design:**

1. **Preparation of E. granulosus sensu lato tegumental components:** Isolate and purify E. granulosus sensu lato tegumental components using established protocols.
2. **Expression and purification of CD36 and CD91 proteins:** Express and purify CD36 and CD91 proteins using recombinant DNA technology and affinity chromatography.
3. **Co-immunoprecipitation assays:** Perform co-immunoprecipitation assays using biotinylated CD36 and CD91 proteins and E. granulosus sensu lato tegumental components to investigate the interaction between these molecules.
4. **Western blot analysis:** Analyze the immunoprecipitated complexes by Western blot to identify interacting signaling molecules and investigate the phosphorylation status of key signaling molecules downstream of CD36 and CD91.
5. **Cell-based assays:** Use cell-based assays, such as ELISA or flow cytometry, to measure the production of cytokines and chemokines by host cells in response to CD36- and CD91-E. granulosus sensu lato tegumental component interaction.
6. **Comparison with CD5 and CD6:** Compare the results obtained with CD36 and CD91 to those previously reported for CD5 and CD6 to determine if these scavenger receptors exhibit similar interactions and immune modulatory effects.

**Equipment and Reagents:**

* Co-immunoprecipitation kit
* Western blot apparatus
* ELISA plate reader
* Flow cytometer
* Recombinant DNA technology equipment (e.g., PCR, cloning vectors)
* Affinity chromatography equipment (e.g., Ni-NTA agarose)
* Cell culture facilities and reagents (e.g., cell lines, media, antibodies)

**Timeframe and Budget:**

This experiment can be completed within 6-9 months, depending on the availability of resources and personnel. The budget will be approximately $50,000-$75,000, which will cover the costs of reagents, equipment, and personnel.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the interaction between CD36 and CD91 with E. granulosus sensu lato tegumental components in the presence of a specific inhibitor or competitor. For example:

* Use a specific inhibitor of CD36 or CD91, such as a blocking antibody or a small molecule inhibitor, to block the interaction between these receptors and E. granulosus sensu lato tegumental components.
* Use a competitor protein, such as a soluble form of CD5 or CD6, to compete with CD36 and CD91 for binding to E. granulosus sensu lato tegumental components.

If the interaction between CD36 and CD91 with E. granulosus sensu lato tegumental components is significantly reduced or abolished in the presence of the inhibitor or competitor, it would suggest that these receptors do not interact with the parasite components and do not modulate the host immune response to secondary cystic echinococcosis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Preparation of E. granulosus sensu lato tegumental components**

1.1. Obtain E. granulosus sensu lato parasites from an established source (e.g., infected animal tissue or in vitro culture).

1.2. Homogenize the parasites in a buffer solution (e.g., PBS, pH 7.4) using a tissue grinder or sonicator.

1.3. Centrifuge the homogenate at 10,000 x g for 10 minutes to remove debris.

1.4. Collect the supernatant and filter it through a 0.2 μm filter to remove any remaining debris.

1.5. Concentrate the filtrate using a centrifugal filter device (e.g., Amicon Ultra-15) with a 10 kDa molecular weight cutoff.

1.6. Wash the concentrated filtrate with PBS (pH 7.4) to remove any contaminants.

1.7. Aliquot the purified tegumental components into smaller volumes (e.g., 100 μL) and store them at -80°C until use.

**Protocol 2: Expression and purification of CD36 and CD91 proteins**

2.1. Design and synthesize DNA constructs encoding CD36 and CD91 proteins with a C-terminal His-tag using standard molecular biology techniques (e.g., PCR, cloning vectors).

2.2. Express the CD36 and CD91 proteins in a suitable host cell line (e.g., HEK293T) using a transient transfection protocol.

2.3. Harvest the cells 48 hours post-transfection and lyse them in a buffer solution (e.g., PBS, pH 7.4) containing 1% Triton X-100.

2.4. Centrifuge the lysate at 10,000 x g for 10 minutes to remove debris.

2.5. Incubate the supernatant with Ni-NTA agarose beads (e.g., Qiagen) for 1 hour at 4°C to bind the His-tagged proteins.

2.6. Wash the beads with a buffer solution (e.g., PBS, pH 7.4) containing 20 mM imidazole to remove non-specifically bound proteins.

2.7. Elute the bound proteins with a buffer solution (e.g., PBS, pH 7.4) containing 250 mM imidazole.

2.8. Concentrate the eluted proteins using a centrifugal filter device (e.g., Amicon Ultra-15) with a 10 kDa molecular weight cutoff.

2.9. Aliquot the purified proteins into smaller volumes (e.g., 100 μL) and store them at -80°C until use.

**Protocol 3: Co-immunoprecipitation assays**

3.1. Biotinylate the purified CD36 and CD91 proteins using a biotinylation kit (e.g., Pierce) according to the manufacturer's instructions.

3.2. Incubate 1 μg of biotinylated CD36 or CD91 protein with 1 μg of E. granulosus sensu lato tegumental components in a buffer solution (e.g., PBS, pH 7.4) for 1 hour at 4°C.

3.3. Add 20 μL of streptavidin-conjugated agarose beads (e.g., Pierce) to the mixture and incubate for an additional 1 hour at 4°C.

3.4. Centrifuge the mixture at 1,000 x g for 1 minute to pellet the beads.

3.5. Wash the beads with a buffer solution (e.g., PBS, pH 7.4) three times to remove non-specifically bound proteins.

3.6. Elute the immunoprecipitated complexes with a buffer solution (e.g., PBS, pH 7.4) containing 2% SDS and 1% β-mercaptoethanol.

**Protocol 4: Western blot analysis**

4.1. Resolve the immunoprecipitated complexes by SDS-PAGE using a 10% polyacrylamide gel.

4.2. Transfer the proteins to a nitrocellulose membrane using a Western blot apparatus.

4.3. Block the membrane with a blocking solution (e.g., 5% milk in TBST) for 1 hour at room temperature.

4.4. Incubate the membrane with primary antibodies against CD36, CD91, and signaling molecules (e.g., p-ERK, p-p38) in a blocking solution for 1 hour at room temperature.

4.5. Wash the membrane with TBST three times to remove non-specifically bound antibodies.

4.6. Incubate the membrane with secondary antibodies conjugated to HRP in a blocking solution for 1 hour at room temperature.

4.7. Develop the membrane using a chemiluminescent substrate (e.g., ECL) and detect the signals using a Western blot imaging system.

**Protocol 5: Cell-based assays**

5.1. Culture host cells (e.g., macrophages, dendritic cells) in a suitable medium (e.g., RPMI 1640) supplemented with 10% FBS and antibiotics.

5.2. Stimulate the cells with E. granulosus sensu lato tegumental components (1 μg/mL) in the presence or absence of CD36 or CD91 proteins (1 μg/mL) for 24 hours.

5.3. Measure the production of cytokines and chemokines (e.g., IL-12, TNF-α, CCL2) using ELISA or flow cytometry.

**Protocol 6: Comparison with CD5 and CD6**

6.1. Repeat Protocols 3-5 using CD5 and CD6 proteins instead of CD36 and CD91.

6.2. Compare the results obtained with CD36 and CD91 to those obtained with CD5 and CD6 to determine if these scavenger receptors exhibit similar interactions and immune modulatory effects.

**Protocol 7: Experiment to disprove the hypothesis**

7.1. Repeat Protocol 3 using a specific inhibitor of CD36 or CD91 (e.g., blocking antibody, small molecule inhibitor) or a competitor protein (e.g., soluble CD5 or CD6).

7.2. Analyze the immunoprecipitated complexes by Western blot to determine if the interaction between CD36 or CD91 and E. granulosus sensu lato tegumental components is significantly reduced or abolished in the presence of the inhibitor or competitor.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific requirements of the experiment and the equipment available. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   E_granulosus  CD36  CD91  CD5  CD6  Inhibitor  Outcome
0           0.5   0.2   0.1  0.0  0.0       0.0  Positive
1           1.0   0.5   0.2  0.0  0.0       0.0  Positive
2           1.5   0.8   0.3  0.0  0.0       0.0  Positive
3           2.0   1.0   0.4  0.0  0.0       0.0  Positive
4           2.5   1.2   0.5  0.0  0.0       0.0  Positive
5           0.5   0.1   0.2  0.0  0.0       0.0  Negative
6           1.0   0.3   0.5  0.0  0.0       0.0  Positive
7           1.5   0.6   0.7  0.0  0.0       0.0  Positive
8           2.0   0.9   0.8  0.0  0.0       0.0  Positive
9           2.5   1.1   0.9  0.0  0.0       0.0  Positive
10          0.5   0.2   0.1  0.5  0.0       0.0  Negative
11          1.0   0.5   0.2  1.0  0.0       0.0  Negative
12          1.5   0.8   0.3  1.5  0.0       0.0  Negative
13          2.0   1.0   0.4  2.0  0.0       0.0  Negative
14          2.5   1.2   0.5  2.5  0.0       0.0  Negative
15          0.5   0.1   0.2  0.0  0.5       0.0  Negative
16          1.0   0.3   0.5  0.0  1.0       0.0  Negative
17          1.5   0.6   0.7  0.0  1.5       0.0  Negative
18          2.0   0.9   0.8  0.0  2.0       0.0  Negative
19          2.5   1.1   0.9  0.0  2.5       0.0  Negative
20          0.5   0.2   0.1  0.0  0.0       1.0  Negative
21          1.0   0.5   0.2  0.0  0.0       1.0  Negative
22          1.5   0.8   0.3  0.0  0.0       1.0  Negative
23          2.0   1.0   0.4  0.0  0.0       1.0  Negative
24          2.5   1.2   0.5  0.0  0.0       1.0  Negative
```",0.10589051688620155
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0836bdcc6f5b67f12eaefac90417b9c2cdeb979a.summary'],"Do pyrimido[5,4-b]indoles that prolong NF-κB activation without intrinsic activity also modulate the expression of co-stimulatory molecules on antigen-presenting cells, thereby enhancing T cell activation and differentiation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Modulation of Co-stimulatory Molecules on Antigen-Presenting Cells by Pyrimido[5,4-b]indoles

**Objective:** To investigate whether pyrimido[5,4-b]indoles that prolong NF-κB activation without intrinsic activity modulate the expression of co-stimulatory molecules on antigen-presenting cells, thereby enhancing T cell activation and differentiation.

**Equipment:**

* Mouse model
* Pyrimido[5,4-b]indoles
* LPS
* Flow cytometer
* Antibodies against co-stimulatory molecules (e.g., CD80, CD86, CD40)
* T cell isolation kit
* T cell activation and differentiation assays (e.g., CFSE proliferation assay, cytokine ELISA)

**Steps:**

1. Immunize mice with LPS and pyrimido[5,4-b]indoles, and isolate antigen-presenting cells (APCs) at different time points.
2. Analyze the expression of co-stimulatory molecules on APCs using flow cytometry.
3. Co-culture APCs with T cells and measure T cell activation and differentiation using CFSE proliferation assay and cytokine ELISA.
4. Compare the expression of co-stimulatory molecules and T cell responses in mice immunized with LPS alone versus LPS and pyrimido[5,4-b]indoles.

**Expected Outcomes:**

* Increased expression of co-stimulatory molecules on APCs in mice immunized with LPS and pyrimido[5,4-b]indoles compared to LPS alone.
* Enhanced T cell activation and differentiation in response to co-culture with APCs from mice immunized with LPS and pyrimido[5,4-b]indoles.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigation of Pyrimido[5,4-b]indole-Mediated Immune Suppression

**Objective:** To investigate whether pyrimido[5,4-b]indoles that prolong NF-κB activation without intrinsic activity actually suppress T cell activation and differentiation by modulating the expression of co-stimulatory molecules on antigen-presenting cells.

**Equipment:**

* Same as above

**Steps:**

1. Immunize mice with LPS and pyrimido[5,4-b]indoles, and isolate APCs at different time points.
2. Analyze the expression of co-stimulatory molecules on APCs using flow cytometry.
3. Co-culture APCs with T cells and measure T cell activation and differentiation using CFSE proliferation assay and cytokine ELISA.
4. Compare the expression of co-stimulatory molecules and T cell responses in mice immunized with LPS alone versus LPS and pyrimido[5,4-b]indoles.

**Expected Outcomes:**

* Decreased expression of co-stimulatory molecules on APCs in mice immunized with LPS and pyrimido[5,4-b]indoles compared to LPS alone.
* Suppressed T cell activation and differentiation in response to co-culture with APCs from mice immunized with LPS and pyrimido[5,4-b]indoles.

**Rationale:**

The experiment to disprove the hypothesis is designed to test the opposite outcome, where pyrimido[5,4-b]indoles suppress T cell activation and differentiation by modulating the expression of co-stimulatory molecules on APCs. If the results show that pyrimido[5,4-b]indoles indeed suppress T cell responses, it would disprove the original hypothesis. This experiment will help to rule out alternative explanations and increase confidence in the results of the initial experiment.

**Timeline and Budget:**

Both experiments can be completed within 6-8 weeks, with a budget of approximately $10,000-$15,000. This includes the cost of mice, reagents, equipment, and personnel. The timeline and budget can be adjusted based on the specific requirements of the laboratory and the availability of resources.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Modulation of Co-stimulatory Molecules on Antigen-Presenting Cells by Pyrimido[5,4-b]indoles**

**Step 1: Immunization and Antigen-Presenting Cell Isolation**

1.1. Obtain 20-25 mice (e.g., C57BL/6) and divide them into two groups: Group 1 (LPS alone) and Group 2 (LPS + pyrimido[5,4-b]indoles).

1.2. Prepare LPS (e.g., 10 μg/mouse) and pyrimido[5,4-b]indoles (e.g., 1 mg/kg) in sterile PBS.

1.3. Immunize mice in Group 1 with LPS via intraperitoneal injection.

1.4. Immunize mice in Group 2 with LPS and pyrimido[5,4-b]indoles via intraperitoneal injection.

1.5. Allow mice to rest for 24 hours.

1.6. Sacrifice mice at 24, 48, and 72 hours post-immunization.

1.7. Isolate spleens and lymph nodes from each mouse.

1.8. Prepare single-cell suspensions from spleens and lymph nodes using a gentleMACS Dissociator (Miltenyi Biotec).

1.9. Enrich for antigen-presenting cells (APCs) using a mouse APC isolation kit (e.g., Miltenyi Biotec).

**Step 2: Flow Cytometry Analysis**

2.1. Stain APCs with fluorescently labeled antibodies against co-stimulatory molecules (e.g., CD80, CD86, CD40) and a viability dye (e.g., Zombie Aqua).

2.2. Perform flow cytometry analysis using a flow cytometer (e.g., BD FACSCanto II).

2.3. Gate on live, single cells and analyze the expression of co-stimulatory molecules on APCs.

**Step 3: Co-culture and T Cell Activation Assays**

3.1. Isolate T cells from naive mice using a T cell isolation kit (e.g., Miltenyi Biotec).

3.2. Label T cells with CFSE (e.g., 5 μM) for 10 minutes at 37°C.

3.3. Co-culture APCs from Step 1 with CFSE-labeled T cells at a 1:1 ratio in a 96-well plate.

3.4. Incubate co-cultures for 3-4 days at 37°C, 5% CO2.

3.5. Analyze T cell proliferation using flow cytometry.

3.6. Measure cytokine production (e.g., IL-2, IFN-γ) in the co-culture supernatant using ELISA.

**Step 4: Data Analysis**

4.1. Compare the expression of co-stimulatory molecules on APCs from Group 1 and Group 2.

4.2. Compare T cell activation and differentiation responses (proliferation and cytokine production) between Group 1 and Group 2.

**Experiment to Disprove the Hypothesis: Investigation of Pyrimido[5,4-b]indole-Mediated Immune Suppression**

**Step 1: Immunization and Antigen-Presenting Cell Isolation**

( identical to Step 1 in the first experiment)

**Step 2: Flow Cytometry Analysis**

( identical to Step 2 in the first experiment)

**Step 3: Co-culture and T Cell Activation Assays**

( identical to Step 3 in the first experiment)

**Step 4: Data Analysis**

4.1. Compare the expression of co-stimulatory molecules on APCs from Group 1 and Group 2.

4.2. Compare T cell activation and differentiation responses (proliferation and cytokine production) between Group 1 and Group 2.

**Note:** The same equipment, reagents, and personnel can be used for both experiments. The only difference is the expected outcome, which is opposite in the two experiments.","```
   LPS (μg/mouse)  Pyrimido[5,4-b]indoles (mg/kg)  CD80  CD86  CD40  T Cell Proliferation  IL-2 (pg/mL)  IFN-γ (pg/mL)  Outcome
0              5.0                    0.5  20.1  30.5  15.2               25.0         100.0         200.0  Immune Enhancement
1              7.5                    1.0  18.5  28.0  12.8               30.0         120.0         250.0  Immune Enhancement
2             10.0                    1.5  22.0  32.0  18.0               35.0         150.0         300.0  Immune Enhancement
3              5.0                    0.2  19.0  29.0  13.5               20.0          90.0         180.0  Immune Enhancement
4              7.5                    0.8  21.0  31.0  16.0               28.0         110.0         220.0  Immune Enhancement
5             12.5                    2.0  25.0  35.0  20.0               40.0         180.0         350.0  Immune Enhancement
6              5.0                    0.1  17.0  26.0  11.0               18.0          80.0         160.0  Immune Enhancement
7              7.5                    0.6  20.0  30.0  14.0               24.0         100.0         200.0  Immune Enhancement
8             10.0                    1.2  23.0  33.0  19.0               32.0         140.0         280.0  Immune Enhancement
9              5.0                    0.4  19.5  29.5  13.0               22.0          95.0         190.0  Immune Enhancement
10             7.5                    0.9  21.5  31.5  16.5               29.0         115.0         230.0  Immune Enhancement
11            12.5                    1.8  26.0  36.0  21.0               42.0         190.0         370.0  Immune Enhancement
12             5.0                    0.3  18.0  27.0  12.0               19.0          85.0         170.0  Immune Enhancement
13             7.5                    0.7  20.5  30.5  14.5               25.5         105.0         210.0  Immune Enhancement
14            10.0                    1.1  22.5  32.5  17.5               31.5         130.0         260.0  Immune Enhancement
15             5.0                    0.6  19.0  28.0  13.0               21.0          90.0         180.0  Immune Enhancement
16             7.5                    0.5  20.0  29.0  14.0               23.0         100.0         200.0  Immune Enhancement
17            12.5                    1.4  24.0  34.0  19.0               36.0         160.0         310.0  Immune Enhancement
18             5.0                    0.2  17.5  26.5  11.5               19.5          80.0         165.0  Immune Enhancement
19             7.5                    0.8  21.0  30.0  15.0               26.0         110.0         220.0  Immune Enhancement
20            10.0                    1.6  23.5  33.5  18.5               33.5         145.0         290.0  Immune Enhancement
21             5.0                    0.4  19.0  28.0  12.5               20.5          90.0         185.0  Immune Enhancement
22             7.5                    0.9  20.5  30.5  14.5               24.5         105.0         215.0  Immune Enhancement
23            12.5                    1.7  25.5  35.5  20.5               39.5         175.0         340.0  Immune Enhancement
24             5.0                    0.1  16.5  25.5  10.5               17.5          75.0         155.0  Immune Enhancement
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/107adcc60d7f0ec4757300f7228aa52c5cabfd4f.summary'],"Do specific HCDR3 sequences in DLBCL cases influence the binding affinity of the B cell receptor to self-antigens, thereby contributing to the development of autonomous BCR signaling?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Influence of Specific HCDR3 Sequences on BCR Binding Affinity to Self-Antigens in DLBCL

**Objective:** To determine if specific HCDR3 sequences in DLBCL cases affect the binding affinity of the B cell receptor to self-antigens, contributing to autonomous BCR signaling.

**Equipment:**

* DLBCL patient samples
* BCR sequencing equipment
* Surface plasmon resonance (SPR) or biolayer interferometry (BLI) instrument
* Recombinant BCR proteins with specific HCDR3 sequences
* Self-antigen proteins (e.g., DNA, histones, or other potential autoantigens)

**Steps:**

1. Sequence the BCR genes from DLBCL patient samples to identify specific HCDR3 sequences associated with autonomous BCR signaling.
2. Express and purify recombinant BCR proteins with the identified HCDR3 sequences.
3. Perform SPR or BLI assays to measure the binding affinity of the recombinant BCR proteins to self-antigens.
4. Compare the binding affinities of BCR proteins with different HCDR3 sequences to determine if specific sequences exhibit increased binding to self-antigens.
5. Analyze the results to determine if the binding affinity of BCR to self-antigens correlates with autonomous BCR signaling in DLBCL.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of HCDR3 Sequences in Autonomous BCR Signaling using a Randomized HCDR3 Library

**Objective:** To test if the observed correlation between specific HCDR3 sequences and autonomous BCR signaling is due to chance or if it's a specific property of the HCDR3 sequences.

**Equipment:**

* TKO cells
* CRISPR/Cas9 system
* BCR sequencing equipment
* Calcium flux assay equipment
* Randomized HCDR3 library (generated using a combination of PCR-based mutagenesis and DNA shuffling)

**Steps:**

1. Generate a randomized HCDR3 library with a diverse range of sequences.
2. Use CRISPR/Cas9 to introduce the randomized HCDR3 sequences into the BCR genes of TKO cells.
3. Measure calcium flux in the TKO cells to assess autonomous BCR signaling activity.
4. Sequence the BCR genes of the TKO cells to identify the introduced HCDR3 sequences.
5. Analyze the results to determine if the randomized HCDR3 sequences exhibit a similar correlation with autonomous BCR signaling as the specific sequences identified in DLBCL cases.
6. If the randomized HCDR3 sequences do not exhibit a correlation with autonomous BCR signaling, it would suggest that the observed correlation in DLBCL cases is due to chance, disproving the hypothesis.

**Rationale:**

The experiment to disprove the hypothesis uses a randomized HCDR3 library to test if the observed correlation between specific HCDR3 sequences and autonomous BCR signaling is due to chance. If the randomized sequences do not exhibit a correlation with autonomous BCR signaling, it would suggest that the observed correlation in DLBCL cases is not specific to the HCDR3 sequences, but rather due to other factors. This experiment provides a control to test the specificity of the observed correlation and helps to rule out alternative explanations.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Investigating the Influence of Specific HCDR3 Sequences on BCR Binding Affinity to Self-Antigens in DLBCL**

**Step 1: BCR Sequencing from DLBCL Patient Samples**

1.1. Obtain DLBCL patient samples and extract genomic DNA using a DNA extraction kit (e.g., Qiagen DNeasy Blood & Tissue Kit).

1.2. Design and synthesize primers specific to the BCR heavy chain gene (e.g., IGHV, IGHJ, and IGHG).

1.3. Perform PCR amplification of the BCR heavy chain gene using the designed primers and a high-fidelity DNA polymerase (e.g., Phusion High-Fidelity DNA Polymerase).

1.4. Purify the PCR products using a PCR cleanup kit (e.g., Qiagen QIAquick PCR Purification Kit).

1.5. Perform Sanger sequencing or Next-Generation Sequencing (NGS) to determine the BCR heavy chain sequence, focusing on the HCDR3 region.

**Step 2: Expression and Purification of Recombinant BCR Proteins**

2.1. Design and synthesize DNA constructs encoding the recombinant BCR proteins with the identified HCDR3 sequences.

2.2. Clone the DNA constructs into an expression vector (e.g., pFUSE2-CLIg-hIgG1-Fc2) using a cloning kit (e.g., In-Fusion HD Cloning Kit).

2.3. Transform the expression vector into a suitable host cell line (e.g., HEK293T) using a transfection reagent (e.g., Lipofectamine 3000).

2.4. Express the recombinant BCR proteins in the host cell line and purify them using a protein purification kit (e.g., Pierce Protein A IgG Plus Agarose).

2.5. Verify the purity and integrity of the recombinant BCR proteins using SDS-PAGE and Western blotting.

**Step 3: SPR or BLI Assays**

3.1. Prepare the self-antigen proteins (e.g., DNA, histones, or other potential autoantigens) by expressing and purifying them using a protein purification kit.

3.2. Immobilize the self-antigen proteins on a sensor chip (e.g., Biacore CM5 chip) using a coupling kit (e.g., Biacore Amine Coupling Kit).

3.3. Perform SPR or BLI assays using a surface plasmon resonance instrument (e.g., Biacore 3000) or a biolayer interferometry instrument (e.g., ForteBio Octet RED96).

3.4. Measure the binding affinity of the recombinant BCR proteins to the self-antigens by injecting the proteins over the immobilized self-antigens and monitoring the binding response.

**Step 4: Data Analysis**

4.1. Analyze the SPR or BLI data using software (e.g., Biacore Evaluation Software or ForteBio Data Analysis Software) to determine the binding affinity (KD) of each recombinant BCR protein to the self-antigens.

4.2. Compare the binding affinities of BCR proteins with different HCDR3 sequences to determine if specific sequences exhibit increased binding to self-antigens.

4.3. Correlate the binding affinity data with autonomous BCR signaling activity in DLBCL cases to determine if there is a significant association.

**Experiment to Disprove the Hypothesis: Investigating the Role of HCDR3 Sequences in Autonomous BCR Signaling using a Randomized HCDR3 Library**

**Step 1: Generation of Randomized HCDR3 Library**

1.1. Design and synthesize a set of primers with degenerate bases at the HCDR3 region to introduce random mutations.

1.2. Perform PCR-based mutagenesis using the degenerate primers and a high-fidelity DNA polymerase to generate a library of randomized HCDR3 sequences.

1.3. Use DNA shuffling to further diversify the library by recombining the randomized HCDR3 sequences.

**Step 2: CRISPR/Cas9-Mediated Introduction of Randomized HCDR3 Sequences into TKO Cells**

2.1. Design and synthesize guide RNAs (gRNAs) targeting the BCR heavy chain gene in TKO cells.

2.2. Perform CRISPR/Cas9 genome editing using the gRNAs and a CRISPR/Cas9 system (e.g., CRISPR-Cas9 Nickase) to introduce the randomized HCDR3 sequences into the BCR genes of TKO cells.

2.3. Verify the introduction of the randomized HCDR3 sequences using PCR and Sanger sequencing.

**Step 3: Calcium Flux Assay**

3.1. Measure calcium flux in the TKO cells using a calcium flux assay kit (e.g., Fluo-4 NW Calcium Assay Kit).

3.2. Stimulate the TKO cells with a BCR cross-linking antibody (e.g., anti-human IgG) to induce calcium flux.

3.3. Measure the calcium flux response using a plate reader (e.g., FlexStation 3) or a flow cytometer (e.g., BD FACSCanto II).

**Step 4: Data Analysis**

4.1. Analyze the calcium flux data to determine the autonomous BCR signaling activity in the TKO cells.

4.2. Sequence the BCR genes of the TKO cells to identify the introduced HCDR3 sequences.

4.3. Correlate the autonomous BCR signaling activity with the introduced HCDR3 sequences to determine if there is a significant association.

4.4. Compare the results with the data from the experiment to test the hypothesis to determine if the randomized HCDR3 sequences exhibit a similar correlation with autonomous BCR signaling as the specific sequences identified in DLBCL cases.","```
   Qiagen_DNeasy_Blood_Tissue_Kit  Phusion_High_Fidelity_DNA_Polymerase  pFUSE2_CLIg_hIgG1_Fc2  Lipofectamine_3000  Pierce_Protein_A_IgG_Plus_Agarose  Biacore_CM5_chip  Biacore_Amine_Coupling_Kit  outcome
0                         1.5                    2.0                    1.0                    1.5                    2.0                    1.0                    1.0  0.034
1                         2.0                    1.5                    1.5                    2.0                    1.0                    1.5                    1.0  0.041
2                         1.0                    1.0                    2.0                    1.0                    1.5                    2.0                    1.5  0.028
3                         1.5                    2.5                    1.0                    1.5                    2.0                    1.0                    1.0  0.036
4                         2.5                    1.0                    1.5                    2.5                    1.0                    1.5                    1.0  0.045
5                         1.0                    1.5                    2.5                    1.0                    1.0                    2.0                    1.5  0.031
6                         1.5                    1.0                    1.0                    1.5                    2.5                    1.0                    1.0  0.038
7                         2.0                    2.0                    1.5                    2.0                    1.5                    1.0                    1.5  0.042
8                         1.0                    2.5                    1.5                    1.0                    1.0                    1.5                    2.0  0.029
9                         1.5                    1.5                    2.0                    1.5                    2.0                    1.5                    1.0  0.035
10                        2.5                    1.5                    1.0                    2.5                    1.5                    2.0                    1.0  0.048
11                        1.0                    1.0                    1.5                    1.0                    2.5                    1.5                    1.5  0.026
12                        1.5                    2.0                    2.5                    1.5                    1.0                    1.0                    2.0  0.039
13                        2.0                    1.5                    1.0                    2.0                    1.0                    2.5                    1.5  0.044
14                        1.5                    1.0                    2.0                    1.5                    2.5                    1.5                    1.0  0.037
15                        2.5                    2.5                    1.5                    2.5                    1.5                    1.0                    1.5  0.051
16                        1.0                    2.0                    1.5                    1.0                    1.5                    2.0                    2.0  0.030
17                        1.5                    1.5                    1.0                    1.5                    2.0                    1.0                    2.5  0.033
18                        2.0                    1.0                    2.5                    2.0                    1.5                    1.5                    1.0  0.043
19                        1.0                    1.5                    2.0                    1.0                    1.0                    1.5                    1.5  0.027
20                        1.5                    2.5                    1.5                    1.5                    2.5                    2.0                    1.0  0.040
21                        2.5                    1.0                    1.0                    2.5                    1.0                    1.5                    2.5  0.049
22                        1.0                    1.0                    1.0                    1.0                    2.0                    2.5                    1.5  0.024
23                        1.5                    2.0                    2.0                    1.5                    1.5                    1.0                    2.0  0.036
24                        2.0                    1.5                    1.5                    2.0                    2.5                    1.5                    1.5  0.046
```",0.19350682667496316
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0c7465c09ba1ff385f9c0af81cf7fe198923462d.summary'],Do specific changes in the gut microbiota composition during appendicitis influence the development of ulcerative colitis by modulating the migration and polarization of appendiceal B lymphocytes?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis and potentially disprove it. Since the goal is to disprove the hypothesis, the experiment will aim to show that changes in the gut microbiota composition during appendicitis do not influence the development of ulcerative colitis by modulating the migration and polarization of appendiceal B lymphocytes.

**Experiment:**

**Title:** Investigating the Role of Gut Microbiota in Appendicitis on Ulcerative Colitis Development

**Objective:** To determine if changes in the gut microbiota composition during appendicitis affect the development of ulcerative colitis by modulating the migration and polarization of appendiceal B lymphocytes.

**Experimental Design:**

1. **Mouse Model:** Use a mouse model of appendicitis, such as the cecal ligation and puncture (CLP) model, to induce appendicitis.
2. **Gut Microbiota Manipulation:** Divide the mice into three groups:
	* **Group 1:** Control group with normal gut microbiota.
	* **Group 2:** Antibiotic-treated group to alter the gut microbiota composition during appendicitis.
	* **Group 3:** Fecal microbiota transplantation (FMT) group, where fecal samples from healthy mice are transplanted into mice with appendicitis to restore a normal gut microbiota.
3. **Ulcerative Colitis Induction:** Induce ulcerative colitis in all mice using dextran sulfate sodium (DSS) in their drinking water.
4. **Sample Collection:** Collect appendiceal and colonic tissue samples at different time points (e.g., 7, 14, and 21 days) after DSS administration.
5. **Analysis:**
	* **Microbiota Analysis:** Perform 16S rRNA gene sequencing to analyze the gut microbiota composition in each group.
	* **Flow Cytometry:** Analyze the migration and polarization of appendiceal B lymphocytes in the colon using flow cytometry.
	* **Histopathology:** Evaluate the severity of colitis using histological scoring and disease activity index (DAI).
	* **Cytokine Analysis:** Measure the levels of IFN-γ and IL-17 in the colonic lamina propria using ELISA.

**Expected Outcomes:**

* If the hypothesis is true, the antibiotic-treated group (Group 2) should exhibit altered gut microbiota composition, which would lead to changes in the migration and polarization of appendiceal B lymphocytes, resulting in a more severe colitis phenotype.
* If the hypothesis is false, the antibiotic-treated group (Group 2) should not exhibit significant differences in gut microbiota composition, migration and polarization of appendiceal B lymphocytes, or colitis severity compared to the control group (Group 1).
* The FMT group (Group 3) should exhibit a restored gut microbiota composition, which would lead to a reduced severity of colitis.

**Resources and Timeline:**

* Equipment: Mouse models, antibiotics, FMT equipment, flow cytometer, ELISA kits, histopathology equipment, and sequencing equipment.
* Timeframe: 6-8 weeks for the experiment, including 2-3 weeks for mouse model establishment, 2-3 weeks for DSS administration and sample collection, and 1-2 weeks for data analysis.
* Budget: The budget will depend on the specific equipment and resources required, but a rough estimate would be around $10,000-$15,000.

By designing an experiment to disprove the hypothesis, we can test the validity of the hypothesis and gain a better understanding of the relationship between gut microbiota, appendicitis, and ulcerative colitis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Mouse Model Establishment and Appendicitis Induction**

1.1. Obtain 30-40 mice (e.g., C57BL/6) from a reputable supplier and acclimate them to the laboratory environment for 1 week.

1.2. Perform cecal ligation and puncture (CLP) surgery on all mice to induce appendicitis, following established protocols (e.g., [1]).

1.3. Monitor mice for signs of appendicitis, such as weight loss, lethargy, and abdominal tenderness, and provide analgesics and antibiotics as necessary.

**Protocol 2: Gut Microbiota Manipulation**

2.1. Divide the mice into three groups of 10-13 mice each:
	* Group 1: Control group with normal gut microbiota.
	* Group 2: Antibiotic-treated group to alter the gut microbiota composition during appendicitis.
	* Group 3: Fecal microbiota transplantation (FMT) group, where fecal samples from healthy mice are transplanted into mice with appendicitis to restore a normal gut microbiota.

2.2. For Group 2, administer a broad-spectrum antibiotic cocktail (e.g., vancomycin, metronidazole, and ampicillin) via oral gavage at a dose of 100 mg/kg/day for 7 days, starting 3 days after CLP surgery.

2.3. For Group 3, collect fecal samples from healthy mice and prepare the FMT solution according to established protocols (e.g., [2]). Administer the FMT solution to mice with appendicitis via oral gavage at a dose of 100 μL/mouse, 3 days after CLP surgery.

**Protocol 3: Ulcerative Colitis Induction**

3.1. Induce ulcerative colitis in all mice by adding 2.5% dextran sulfate sodium (DSS) to their drinking water for 7 days, starting 7 days after CLP surgery.

3.2. Monitor mice for signs of colitis, such as diarrhea, weight loss, and rectal bleeding, and adjust the DSS concentration as necessary.

**Protocol 4: Sample Collection**

4.1. Euthanize mice at 7, 14, and 21 days after DSS administration, and collect appendiceal and colonic tissue samples.

4.2. Store tissue samples in RNAlater or 10% formalin for subsequent analysis.

**Protocol 5: Microbiota Analysis**

5.1. Extract DNA from fecal samples using a commercial DNA extraction kit (e.g., QIAamp DNA Stool Mini Kit).

5.2. Perform 16S rRNA gene sequencing using a platform such as Illumina MiSeq or PacBio Sequel, following established protocols (e.g., [3]).

5.3. Analyze sequencing data using software such as QIIME2 or Mothur to determine the gut microbiota composition in each group.

**Protocol 6: Flow Cytometry**

6.1. Isolate appendiceal B lymphocytes from tissue samples using a commercial isolation kit (e.g., Miltenyi Biotec).

6.2. Stain cells with fluorescently labeled antibodies against CD19, CD20, and CD45, and analyze using a flow cytometer (e.g., BD FACSCanto II).

6.3. Analyze data using software such as FlowJo to determine the migration and polarization of appendiceal B lymphocytes.

**Protocol 7: Histopathology**

7.1. Fix colonic tissue samples in 10% formalin and embed in paraffin.

7.2. Section tissues and stain with hematoxylin and eosin (H&E) or other specialized stains (e.g., PAS, Alcian blue).

7.3. Evaluate the severity of colitis using histological scoring and disease activity index (DAI) according to established protocols (e.g., [4]).

**Protocol 8: Cytokine Analysis**

8.1. Isolate colonic lamina propria cells using a commercial isolation kit (e.g., Miltenyi Biotec).

8.2. Measure the levels of IFN-γ and IL-17 in the colonic lamina propria using ELISA kits (e.g., R&D Systems), following the manufacturer's instructions.

**References:**

[1] R. M. Peek et al., ""Cecal ligation and puncture: a model of sepsis in mice,"" Journal of Surgical Research, vol. 143, no. 2, pp. 211-216, 2007.

[2] J. L. Sonnenburg et al., ""Diet-induced extinctions in the human gut microbiota compound over generations,"" Nature, vol. 529, no. 7586, pp. 212-215, 2016.

[3] J. G. Caporaso et al., ""Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms,"" The ISME Journal, vol. 6, no. 8, pp. 1621-1624, 2012.

[4] M. F. Neurath et al., ""Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease,"" The Lancet, vol. 354, no. 9180, pp. 221-225, 1999.

Note: The protocols provided are detailed and specific, but may require adjustments based on the specific equipment and resources available in the laboratory. Additionally, the experiment should be performed in accordance with relevant animal welfare guidelines and regulations.","```
   Mice  Antibiotic_Dose  FMT_Dose  DSS_Concentration  Outcome
0     12           80.0      90.0               2.3  Mild Colitis
1     10           120.0      80.0               2.5  Severe Colitis
2     11           100.0      100.0              2.4  Moderate Colitis
3     13           90.0       70.0               2.2  Mild Colitis
4     12           110.0      90.0               2.5  Severe Colitis
5     10           80.0       80.0               2.3  Mild Colitis
6     11           100.0      100.0              2.4  Moderate Colitis
7     13           120.0      110.0              2.6  Severe Colitis
8     12           90.0       90.0               2.3  Mild Colitis
9     10           100.0      80.0               2.4  Moderate Colitis
10    11           110.0      100.0              2.5  Severe Colitis
11    13           80.0       70.0               2.2  Mild Colitis
12    12           120.0      90.0               2.5  Severe Colitis
13    10           90.0       80.0               2.3  Mild Colitis
14    11           100.0      100.0              2.4  Moderate Colitis
15    13           110.0      110.0              2.6  Severe Colitis
16    12           80.0       90.0               2.3  Mild Colitis
17    10           100.0      80.0               2.4  Moderate Colitis
18    11           120.0      100.0              2.5  Severe Colitis
19    13           90.0       70.0               2.2  Mild Colitis
20    12           110.0      90.0               2.5  Severe Colitis
21    10           80.0       80.0               2.3  Mild Colitis
22    11           100.0      100.0              2.4  Moderate Colitis
23    13           120.0      110.0              2.6  Severe Colitis
24    12           90.0       90.0               2.3  Mild Colitis
```",0.30668595692272704
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ef0f69586991db422a62b70035d3139462af531e.summary'],"Do specific combinations of FCER2, KHDRBS2, and IGSF9 expression levels in nasopharyngeal carcinoma cells predict the efficacy of immunotherapy in individual patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan:**

**Title:** Investigating the Predictive Value of FCER2, KHDRBS2, and IGSF9 Expression Levels in Nasopharyngeal Carcinoma Cells for Immunotherapy Efficacy

**Objective:** To determine whether specific combinations of FCER2, KHDRBS2, and IGSF9 expression levels in nasopharyngeal carcinoma cells can predict the efficacy of immunotherapy in individual patients.

**Experimental Design:**

1. **Cell Culture and Sample Collection:**
	* Obtain nasopharyngeal carcinoma cell lines and primary tumor samples from patients who have undergone immunotherapy.
	* Culture the cells in vitro and extract RNA and protein for analysis.
2. **Expression Analysis:**
	* Perform qRT-PCR and Western blot to measure the expression levels of FCER2, KHDRBS2, and IGSF9 in the nasopharyngeal carcinoma cells.
	* Normalize the expression data using housekeeping genes.
3. **Immunotherapy Efficacy Assessment:**
	* Collect clinical data on the patients' response to immunotherapy, including tumor regression, progression-free survival, and overall survival.
	* Categorize patients into responders and non-responders based on their clinical outcomes.
4. **Statistical Analysis:**
	* Perform correlation analysis between the expression levels of FCER2, KHDRBS2, and IGSF9 and the immunotherapy efficacy outcomes.
	* Use machine learning algorithms to identify the optimal combination of expression levels that can predict immunotherapy efficacy.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Association between FCER2, KHDRBS2, and IGSF9 Expression Levels and Immunotherapy Efficacy in Nasopharyngeal Carcinoma

**Objective:** To demonstrate that the expression levels of FCER2, KHDRBS2, and IGSF9 in nasopharyngeal carcinoma cells do not predict the efficacy of immunotherapy in individual patients.

**Experimental Design:**

1. **Cell Culture and Sample Collection:**
	* Obtain nasopharyngeal carcinoma cell lines and primary tumor samples from patients who have undergone immunotherapy.
	* Culture the cells in vitro and extract RNA and protein for analysis.
2. **Expression Analysis:**
	* Perform qRT-PCR and Western blot to measure the expression levels of FCER2, KHDRBS2, and IGSF9 in the nasopharyngeal carcinoma cells.
	* Normalize the expression data using housekeeping genes.
3. **Immunotherapy Efficacy Assessment:**
	* Collect clinical data on the patients' response to immunotherapy, including tumor regression, progression-free survival, and overall survival.
	* Categorize patients into responders and non-responders based on their clinical outcomes.
4. **Statistical Analysis:**
	* Perform correlation analysis between the expression levels of FCER2, KHDRBS2, and IGSF9 and the immunotherapy efficacy outcomes.
	* Use statistical tests (e.g., Pearson's correlation, ANOVA) to determine if there is no significant association between the expression levels and immunotherapy efficacy.

**Key Differences:**

* The experiment to disprove the hypothesis focuses on demonstrating the lack of association between the expression levels and immunotherapy efficacy, whereas the original experiment aims to identify a predictive relationship.
* The statistical analysis in the disproving experiment will focus on testing the null hypothesis of no association, whereas the original experiment will focus on identifying a significant correlation.

**Budget and Timeframe:**

* The experiment can be completed within 6-9 months with a budget of approximately $100,000-$150,000.
* The budget will cover the costs of cell culture reagents, RNA and protein extraction kits, qRT-PCR and Western blot reagents, and statistical analysis software.
* The timeframe can be reduced by optimizing the experimental design, using existing cell lines and patient samples, and leveraging existing laboratory infrastructure.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Protocol 1: Cell Culture and Sample Collection**

1.1. Obtain nasopharyngeal carcinoma cell lines and primary tumor samples from patients who have undergone immunotherapy.

* Source: Obtain cell lines from a reputable cell bank (e.g., ATCC) and primary tumor samples from a hospital or biobank.
* Storage: Store cell lines at -80°C and primary tumor samples at -150°C.

1.2. Culture the cells in vitro.

* Media: Use RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubation: Incubate cells at 37°C, 5% CO2, and 95% humidity.
* Passage: Passage cells every 3-4 days to maintain exponential growth.

1.3. Extract RNA and protein for analysis.

* RNA extraction: Use a commercial RNA extraction kit (e.g., Qiagen RNeasy) according to the manufacturer's instructions.
* Protein extraction: Use a commercial protein extraction kit (e.g., Pierce RIPA buffer) according to the manufacturer's instructions.

**Protocol 2: Expression Analysis**

2.1. Perform qRT-PCR to measure the expression levels of FCER2, KHDRBS2, and IGSF9.

* Primers: Design and validate primers specific to each gene using a primer design tool (e.g., Primer3).
* qRT-PCR: Use a commercial qRT-PCR kit (e.g., Applied Biosystems PowerUp SYBR Green) according to the manufacturer's instructions.
* Cycling conditions: Use the following cycling conditions: 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute.
* Data analysis: Analyze data using the 2^(-ΔΔCt) method.

2.2. Perform Western blot to measure the expression levels of FCER2, KHDRBS2, and IGSF9.

* Antibodies: Use commercial antibodies specific to each protein (e.g., Abcam).
* Western blot: Use a commercial Western blot kit (e.g., Bio-Rad) according to the manufacturer's instructions.
* Protein loading: Load 20-30 μg of protein per lane.
* Detection: Use a chemiluminescent substrate (e.g., ECL) and detect using a Western blot imaging system (e.g., ChemiDoc).

2.3. Normalize the expression data using housekeeping genes.

* Housekeeping genes: Use GAPDH and ACTB as housekeeping genes.
* Normalization: Normalize expression data to the geometric mean of the housekeeping genes.

**Protocol 3: Immunotherapy Efficacy Assessment**

3.1. Collect clinical data on the patients' response to immunotherapy.

* Data collection: Collect data on tumor regression, progression-free survival, and overall survival from patient records.
* Data management: Manage data using a spreadsheet (e.g., Excel) or a clinical data management system (e.g., REDCap).

3.2. Categorize patients into responders and non-responders based on their clinical outcomes.

* Response criteria: Use RECIST 1.1 criteria to categorize patients as responders (complete response, partial response, or stable disease) or non-responders (progressive disease).

**Protocol 4: Statistical Analysis**

4.1. Perform correlation analysis between the expression levels of FCER2, KHDRBS2, and IGSF9 and the immunotherapy efficacy outcomes.

* Correlation analysis: Use Pearson's correlation coefficient to analyze the correlation between expression levels and immunotherapy efficacy outcomes.
* Statistical software: Use R or Python with relevant libraries (e.g., stats, scipy) for statistical analysis.

4.2. Use machine learning algorithms to identify the optimal combination of expression levels that can predict immunotherapy efficacy.

* Machine learning algorithms: Use algorithms such as random forest, support vector machines, or neural networks to identify the optimal combination of expression levels.
* Feature selection: Use techniques such as recursive feature elimination to select the most informative features.

**Experiment to Disprove the Hypothesis:**

The protocols for the experiment to disprove the hypothesis are identical to those for the experiment to test the hypothesis, with the following modifications:

**Protocol 4: Statistical Analysis**

4.1. Perform correlation analysis between the expression levels of FCER2, KHDRBS2, and IGSF9 and the immunotherapy efficacy outcomes.

* Correlation analysis: Use Pearson's correlation coefficient to analyze the correlation between expression levels and immunotherapy efficacy outcomes.
* Statistical software: Use R or Python with relevant libraries (e.g., stats, scipy) for statistical analysis.

4.2. Use statistical tests (e.g., Pearson's correlation, ANOVA) to determine if there is no significant association between the expression levels and immunotherapy efficacy.

* Null hypothesis: Test the null hypothesis of no association between the expression levels and immunotherapy efficacy.
* Significance level: Set the significance level at α = 0.05.

Note: The protocols are designed to be specific, detailed, and replicable. The experimental design and statistical analysis are tailored to test the hypothesis and disprove it, respectively. The protocols can be executed by a researcher or a robot, and the results can be analyzed and interpreted using statistical software.","```
   RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  FCER2_Primer  KHDRBS2_Primer  IGSF9_Primer  Antibody_FCER2  Antibody_KHDRBS2  Antibody_IGSF9  GAPDH_Primer  ACTB_Primer  Tumor_Regression  Progression_Free_Survival  Overall_Survival  Response
0        10.0  10.0                  1.0           1.0           0.5           0.5           0.5           1.0           1.0           1.0           0.5           0.5           0.8           12.0           24.0  Responder
1        12.0  12.0                  1.2           1.2           0.6           0.6           0.6           1.2           1.2           1.2           0.6           0.6           0.9           15.0           30.0  Responder
2         8.0   8.0                  0.8           0.8           0.4           0.4           0.4           0.8           0.8           0.8           0.4           0.4           0.7           10.0           20.0  Responder
3        11.0  11.0                  1.1           1.1           0.55          0.55          0.55          1.1           1.1           1.1           0.55          0.55          0.85          13.0           26.0  Responder
4        13.0  13.0                  1.3           1.3           0.65          0.65          0.65          1.3           1.3           1.3           0.65          0.65          0.95          18.0           36.0  Responder
5         9.0   9.0                  0.9           0.9           0.45          0.45          0.45          0.9           0.9           0.9           0.45          0.45          0.75          11.0           22.0  Responder
6        10.5  10.5                  1.05          1.05          0.525         0.525         0.525         1.05          1.05          1.05          0.525         0.525         0.825         14.0           28.0  Responder
7        12.5  12.5                  1.25          1.25          0.625         0.625         0.625         1.25          1.25          1.25          0.625         0.625         0.925         16.0           32.0  Responder
8         8.5   8.5                  0.85          0.85          0.425         0.425         0.425         0.85          0.85          0.85          0.425         0.425         0.725         12.0           24.0  Responder
9        11.5  11.5                  1.15          1.15          0.575         0.575         0.575         1.15          1.15          1.15          0.575         0.575         0.875         15.0           30.0  Responder
10       13.5  13.5                  1.35          1.35          0.675         0.675         0.675         1.35          1.35          1.35          0.675         0.675         0.975         19.0           38.0  Responder
11        9.5   9.5                  0.95          0.95          0.475         0.475         0.475         0.95          0.95          0.95          0.475         0.475         0.775         13.0           26.0  Responder
12       10.2  10.2                  1.02          1.02          0.51          0.51          0.51          1.02          1.02          1.02          0.51          0.51          0.82          14.0           28.0  Responder
13       12.2  12.2                  1.22          1.22          0.61          0.61          0.61          1.22          1.22          1.22          0.61          0.61          0.92          17.0           34.0  Responder
14        8.2   8.2                  0.82          0.82          0.41          0.41          0.41          0.82          0.82          0.82          0.41          0.41          0.72          11.0           22.0  Responder
15       11.2  11.2                  1.12          1.12          0.56          0.56          0.56          1.12          1.12          1.12          0.56          0.56          0.86          15.0           30.0  Responder
16       13.2  13.2                  1.32          1.32          0.66          0.66          0.66          1.32          1.32          1.32          0.66          0.66          0.96          19.0           38.0  Responder
17        9.2   9.2                  0.92          0.92          0.46          0.46          0.46          0.92          0.92          0.92          0.46          0.46          0.76          12.0           24.0  Responder
18       10.8  10.8                  1.08          1.08          0.54          0.54          0.54          1.08          1.08          1.08          0.54          0.54          0.84          14.0           28.0  Responder
19       12.8  12.8                  1.28          1.28          0.64          0.64          0.64          1.28          1.28          1.28          0.64          0.64          0.94          18.0           36.0  Responder
20        8.8   8.8                  0.88          0.88          0.44          0.44          0.44          0.88          0.88          0.88          0.44          0.44          0.74          11.0           22.0  Responder
21       11.8  11.8                  1.18          1.18          0.58          0.58          0.58          1.18          1.18          1.18          0.58          0.58          0.88          16.0           32.0  Responder
22       13.8  13.8                  1.38          1.38          0.68          0.68          0.68          1.38          1.38          1.38          0.68          0.68          0.98          20.0           40.0  Responder
23        9.8   9.8                  0.98          0.98          0.48          0.48          0.48          0.98          0.98          0.98          0.48          0.48          0.78          13.0           26.0  Responder
24       10.9  10.9                  1.09          1.09          0.545         0.545         0.545         1.09          1.09          1.09          0.545         0.545         0.835         15.0           30.0  Responder
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7932b566fce6f3f95e80457e025ec65f75666ef4.summary'],Do specific lipid compositions in the plasma membrane of B cells influence the formation of ordered phase-like domains and subsequent signaling responses upon engagement with bilayer-presented ligands or cross-linkers?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of Specific Lipid Compositions in the Formation of Ordered Phase-Like Domains and Signaling Responses in B Cells

**Objective:** To determine whether specific lipid compositions in the plasma membrane of B cells influence the formation of ordered phase-like domains and subsequent signaling responses upon engagement with bilayer-presented ligands or cross-linkers.

**Experimental Design:**

1. **Lipid Bilayer Preparation:** Prepare lipid bilayers with varying lipid compositions (e.g., different cholesterol levels, sphingolipid content, or phospholipid headgroup modifications) using established methods (e.g., Langmuir-Blodgett deposition or vesicle fusion).
2. **B Cell Isolation and Activation:** Isolate B cells from mouse spleens or human blood and activate them using bilayer-presented ligands or cross-linkers (e.g., anti-IgM or anti-CD40 antibodies).
3. **Lipid Composition Manipulation:** Use lipid-modifying agents (e.g., cholesterol oxidase, sphingomyelinase, or phospholipase A2) to alter the lipid composition of the plasma membrane in activated B cells.
4. **Ordered Phase-Like Domain Formation:** Use super-resolution microscopy (e.g., STORM or STED) to visualize and quantify the formation of ordered phase-like domains in the plasma membrane of B cells with different lipid compositions.
5. **Signaling Response Analysis:** Measure B cell signaling responses (e.g., calcium mobilization, phosphorylation of signaling molecules, or gene expression) using techniques such as flow cytometry, Western blotting, or qRT-PCR.
6. **Data Analysis:** Compare the formation of ordered phase-like domains and signaling responses in B cells with different lipid compositions to determine the influence of specific lipid compositions on these processes.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of Lipid Composition in B Cell Signaling Responses: A Disproof Experiment

**Objective:** To demonstrate that specific lipid compositions in the plasma membrane of B cells do not influence the formation of ordered phase-like domains and subsequent signaling responses upon engagement with bilayer-presented ligands or cross-linkers.

**Experimental Design:**

1. **Lipid Bilayer Preparation:** Prepare lipid bilayers with identical lipid compositions (e.g., a standard phosphatidylcholine bilayer).
2. **B Cell Isolation and Activation:** Isolate B cells from mouse spleens or human blood and activate them using bilayer-presented ligands or cross-linkers (e.g., anti-IgM or anti-CD40 antibodies).
3. **Lipid Composition Masking:** Use a lipid-binding protein (e.g., annexin V) or a lipid-masking agent (e.g., a lipid-binding peptide) to mask the lipid composition of the plasma membrane in activated B cells.
4. **Ordered Phase-Like Domain Formation:** Use super-resolution microscopy to visualize and quantify the formation of ordered phase-like domains in the plasma membrane of B cells with masked lipid compositions.
5. **Signaling Response Analysis:** Measure B cell signaling responses (e.g., calcium mobilization, phosphorylation of signaling molecules, or gene expression) using techniques such as flow cytometry, Western blotting, or qRT-PCR.
6. **Data Analysis:** Compare the formation of ordered phase-like domains and signaling responses in B cells with masked lipid compositions to those with unmasked lipid compositions. If the results show no significant differences, it would suggest that specific lipid compositions do not influence the formation of ordered phase-like domains and signaling responses, disproving the hypothesis.

**Budget and Timeframe:**

Both experiments can be completed within a reasonable timeframe (6-12 months) and budget (< $200,000). The budget will cover:

* Reagents and consumables (lipids, bilayer-presented ligands, cross-linkers, lipid-modifying agents, lipid-binding proteins, and signaling response analysis reagents)
* Equipment and maintenance (super-resolution microscopy, flow cytometer, Western blotting apparatus, and qRT-PCR machine)
* Personnel (postdoctoral researcher, graduate student, and technician)
* Miscellaneous expenses (travel, training, and contingency funds)

Note: The budget and timeframe may vary depending on the specific requirements of the experiments and the institution's resources.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Lipid Bilayer Preparation**

1.1. Prepare a clean and sterile workspace, including a laminar flow hood and a microscope.

1.2. Dissolve lipids (e.g., phosphatidylcholine, cholesterol, sphingomyelin, and phospholipids with modified headgroups) in organic solvents (e.g., chloroform or hexane) to create stock solutions.

1.3. Mix the lipid stock solutions in various ratios to create lipid bilayer compositions with different cholesterol levels, sphingolipid content, or phospholipid headgroup modifications.

1.4. Deposit the lipid mixtures onto a solid support (e.g., glass or mica) using the Langmuir-Blodgett deposition method or vesicle fusion.

1.5. Verify the lipid bilayer formation and composition using techniques such as ellipsometry, atomic force microscopy, or fluorescence microscopy.

**Protocol 2: B Cell Isolation and Activation**

2.1. Obtain mouse spleens or human blood samples and isolate B cells using density gradient centrifugation and magnetic bead separation.

2.2. Wash the isolated B cells with phosphate-buffered saline (PBS) and resuspend them in a suitable medium (e.g., RPMI 1640 with 10% fetal bovine serum).

2.3. Activate the B cells by incubating them with bilayer-presented ligands or cross-linkers (e.g., anti-IgM or anti-CD40 antibodies) for 30 minutes to 1 hour at 37°C.

**Protocol 3: Lipid Composition Manipulation**

3.1. Treat the activated B cells with lipid-modifying agents (e.g., cholesterol oxidase, sphingomyelinase, or phospholipase A2) to alter the lipid composition of the plasma membrane.

3.2. Incubate the B cells with the lipid-modifying agents for 15-30 minutes at 37°C.

3.3. Wash the B cells with PBS to remove excess lipid-modifying agents.

**Protocol 4: Ordered Phase-Like Domain Formation**

4.1. Fix the B cells with 4% paraformaldehyde for 15 minutes at room temperature.

4.2. Permeabilize the B cells with 0.1% Triton X-100 for 10 minutes at room temperature.

4.3. Label the B cells with fluorescent probes (e.g., DiI or DiO) to visualize the plasma membrane.

4.4. Use super-resolution microscopy (e.g., STORM or STED) to visualize and quantify the formation of ordered phase-like domains in the plasma membrane.

**Protocol 5: Signaling Response Analysis**

5.1. Measure B cell signaling responses (e.g., calcium mobilization, phosphorylation of signaling molecules, or gene expression) using techniques such as flow cytometry, Western blotting, or qRT-PCR.

5.2. Analyze the signaling responses in B cells with different lipid compositions to determine the influence of specific lipid compositions on these processes.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Lipid Bilayer Preparation**

1.1. Prepare a clean and sterile workspace, including a laminar flow hood and a microscope.

1.2. Dissolve lipids (e.g., phosphatidylcholine) in organic solvents (e.g., chloroform or hexane) to create a standard lipid bilayer composition.

1.3. Deposit the lipid mixture onto a solid support (e.g., glass or mica) using the Langmuir-Blodgett deposition method or vesicle fusion.

1.4. Verify the lipid bilayer formation and composition using techniques such as ellipsometry, atomic force microscopy, or fluorescence microscopy.

**Protocol 2: B Cell Isolation and Activation**

2.1. Obtain mouse spleens or human blood samples and isolate B cells using density gradient centrifugation and magnetic bead separation.

2.2. Wash the isolated B cells with PBS and resuspend them in a suitable medium (e.g., RPMI 1640 with 10% fetal bovine serum).

2.3. Activate the B cells by incubating them with bilayer-presented ligands or cross-linkers (e.g., anti-IgM or anti-CD40 antibodies) for 30 minutes to 1 hour at 37°C.

**Protocol 3: Lipid Composition Masking**

3.1. Treat the activated B cells with a lipid-binding protein (e.g., annexin V) or a lipid-masking agent (e.g., a lipid-binding peptide) to mask the lipid composition of the plasma membrane.

3.2. Incubate the B cells with the lipid-binding protein or lipid-masking agent for 15-30 minutes at 37°C.

3.3. Wash the B cells with PBS to remove excess lipid-binding protein or lipid-masking agent.

**Protocol 4: Ordered Phase-Like Domain Formation**

4.1. Fix the B cells with 4% paraformaldehyde for 15 minutes at room temperature.

4.2. Permeabilize the B cells with 0.1% Triton X-100 for 10 minutes at room temperature.

4.3. Label the B cells with fluorescent probes (e.g., DiI or DiO) to visualize the plasma membrane.

4.4. Use super-resolution microscopy (e.g., STORM or STED) to visualize and quantify the formation of ordered phase-like domains in the plasma membrane.

**Protocol 5: Signaling Response Analysis**

5.1. Measure B cell signaling responses (e.g., calcium mobilization, phosphorylation of signaling molecules, or gene expression) using techniques such as flow cytometry, Western blotting, or qRT-PCR.

5.2. Compare the formation of ordered phase-like domains and signaling responses in B cells with masked lipid compositions to those with unmasked lipid compositions. If the results show no significant differences, it would suggest that specific lipid compositions do not influence the formation of ordered phase-like domains and signaling responses, disproving the hypothesis.

Note: The protocols above are detailed and step-by-step, but they may require adjustments based on the specific requirements of the experiments and the institution's resources.","```
   Phosphatidylcholine  Cholesterol  Sphingomyelin  Phospholipids  Lipid_Modifying_Agent  Ordered_Phase_Like_Domains  Signaling_Response
0                30.0       20.0         10.0          40.0                0.5                    0.8               0.6
1                25.0       25.0         15.0          35.0                0.3                    0.7               0.5
2                20.0       30.0         20.0          30.0                0.7                    0.9               0.8
3                35.0       15.0         10.0          40.0                0.4                    0.6               0.4
4                30.0       20.0         15.0          35.0                0.6                    0.8               0.7
5                25.0       25.0         20.0          30.0                0.5                    0.7               0.6
6                20.0       30.0         25.0          25.0                0.8                    0.9               0.8
7                35.0       15.0         15.0          35.0                0.4                    0.6               0.5
8                30.0       20.0         20.0          30.0                0.7                    0.8               0.7
9                25.0       25.0         25.0          25.0                0.6                    0.7               0.6
10               20.0       30.0         30.0          20.0                0.9                    0.9               0.8
11               35.0       15.0         20.0          30.0                0.5                    0.6               0.5
12               30.0       20.0         25.0          25.0                0.8                    0.8               0.7
13               25.0       25.0         30.0          20.0                0.7                    0.7               0.6
14               20.0       30.0         35.0          15.0                0.9                    0.9               0.8
15               35.0       15.0         25.0          25.0                0.6                    0.6               0.5
16               30.0       20.0         30.0          20.0                0.8                    0.8               0.7
17               25.0       25.0         35.0          15.0                0.7                    0.7               0.6
18               20.0       30.0         40.0          10.0                0.9                    0.9               0.8
19               35.0       15.0         30.0          20.0                0.6                    0.6               0.5
20               30.0       20.0         35.0          15.0                0.8                    0.8               0.7
21               25.0       25.0         40.0          10.0                0.7                    0.7               0.6
22               20.0       30.0         45.0           5.0                0.9                    0.9               0.8
23               35.0       15.0         35.0          15.0                0.6                    0.6               0.5
24               30.0       20.0         40.0          10.0                0.8                    0.8               0.7
```",0.30130378186201434
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/08b843573b532100d2d44401e7c7f89ab6a196f3.summary'],"Do specific microRNA expression patterns, correlated with BcR IG stereotypy, contribute to the distinct signaling profiles and clinical behavior of aggressive CLL subsets by regulating the expression of key genes involved in B-cell receptor signaling and cell survival?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Specific microRNA (miRNA) expression patterns, correlated with B-cell receptor (BcR) IG stereotypy, contribute to the distinct signaling profiles and clinical behavior of aggressive chronic lymphocytic leukemia (CLL) subsets by regulating the expression of key genes involved in B-cell receptor signaling and cell survival.

**Experimental Plan:**

**Objective:** To determine whether specific miRNA expression patterns, associated with BcR IG stereotypy, influence the signaling profiles and clinical behavior of aggressive CLL subsets by regulating key genes involved in B-cell receptor signaling and cell survival.

**Approach:**

1. **Sample Collection:**
	* Collect peripheral blood mononuclear cells (PBMCs) from CLL patients with aggressive disease (n=50) and non-aggressive disease (n=50).
	* Isolate CD19+ B cells from PBMCs using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS).
2. **miRNA Profiling:**
	* Perform miRNA sequencing (e.g., Illumina TruSeq Small RNA Library Prep) on isolated B cells to identify specific miRNA expression patterns correlated with BcR IG stereotypy.
	* Validate miRNA expression using quantitative reverse transcription polymerase chain reaction (qRT-PCR) or digital PCR.
3. **BcR IG Stereotypy Analysis:**
	* Perform high-throughput sequencing (e.g., Illumina MiSeq) of the immunoglobulin heavy chain (IGH) gene to identify BcR IG stereotypy in CLL cells.
	* Analyze IGH sequences using bioinformatic tools (e.g., IMGT/HighV-QUEST) to identify stereotyped BcR sequences.
4. **Signaling Profile Analysis:**
	* Perform phospho-protein analysis using mass cytometry (e.g., CyTOF) or Western blotting to assess signaling profiles in CLL cells.
	* Investigate key signaling pathways involved in B-cell receptor signaling and cell survival (e.g., BCR, PI3K/AKT, NF-κB).
5. **Gene Expression Analysis:**
	* Perform RNA sequencing (e.g., Illumina TruSeq RNA Library Prep) or qRT-PCR to analyze the expression of key genes involved in B-cell receptor signaling and cell survival.
	* Validate gene expression using Western blotting or immunofluorescence.
6. **Functional Assays:**
	* Perform functional assays (e.g., cell proliferation, apoptosis, and migration) to assess the impact of miRNA expression on CLL cell behavior.
	* Use CRISPR-Cas9 genome editing to knockdown or overexpress specific miRNAs and assess the effects on signaling profiles and cell behavior.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that specific miRNA expression patterns, correlated with BcR IG stereotypy, do not contribute to the distinct signaling profiles and clinical behavior of aggressive CLL subsets.

**Approach:**

1. **miRNA Inhibition:**
	* Use antisense oligonucleotides or miRNA sponges to inhibit the expression of specific miRNAs correlated with BcR IG stereotypy in CLL cells.
	* Assess the effects of miRNA inhibition on signaling profiles and cell behavior using phospho-protein analysis, gene expression analysis, and functional assays.
2. **BcR IG Stereotypy Disruption:**
	* Use CRISPR-Cas9 genome editing to disrupt the BcR IG stereotypy in CLL cells.
	* Assess the effects of BcR IG stereotypy disruption on miRNA expression, signaling profiles, and cell behavior.
3. **Rescue Experiment:**
	* Overexpress specific miRNAs correlated with BcR IG stereotypy in CLL cells with disrupted BcR IG stereotypy.
	* Assess the effects of miRNA overexpression on signaling profiles and cell behavior.

**Expected Outcomes:**

* If the hypothesis is true, miRNA inhibition or BcR IG stereotypy disruption should abrogate the distinct signaling profiles and clinical behavior of aggressive CLL subsets.
* If the hypothesis is false, miRNA inhibition or BcR IG stereotypy disruption should not affect the signaling profiles and clinical behavior of aggressive CLL subsets.

**Timeline:**

* Sample collection and miRNA profiling: 6 months
* BcR IG stereotypy analysis and signaling profile analysis: 9 months
* Gene expression analysis and functional assays: 12 months
* Experiment to disprove the hypothesis: 18 months
* Data analysis and manuscript preparation: 6 months

**Budget:**

* Personnel: 5 researchers, 2 technicians, and 1 bioinformatician (salaries, benefits, and training)
* Reagents and consumables: miRNA sequencing, qRT-PCR, Western blotting, mass cytometry, CRISPR-Cas9 genome editing, and other reagents (estimated cost: $500,000 per year)
* Equipment: Illumina sequencing platform, CyTOF, and other specialized equipment (estimated cost: $1,000,000)
* Travel and training: attendance at conferences, workshops, and training sessions (estimated cost: $20,000 per year)

Total estimated budget: $3,500,000 over 3 years.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Sample Collection and Isolation of CD19+ B Cells**

1.1. Collect peripheral blood mononuclear cells (PBMCs) from CLL patients with aggressive disease (n=50) and non-aggressive disease (n=50) using standard phlebotomy procedures.

1.2. Isolate PBMCs from whole blood using Ficoll-Paque density gradient centrifugation.

1.3. Wash PBMCs with phosphate-buffered saline (PBS) and resuspend in 1% bovine serum albumin (BSA) in PBS.

1.4. Label PBMCs with CD19 antibodies conjugated to magnetic beads (e.g., Miltenyi Biotec) and perform magnetic-activated cell sorting (MACS) according to the manufacturer's instructions.

1.5. Collect the CD19+ fraction and wash with PBS.

1.6. Count and verify the purity of CD19+ B cells using flow cytometry.

**Protocol 2: miRNA Profiling**

2.1. Extract total RNA from isolated CD19+ B cells using a miRNA-specific extraction kit (e.g., Qiagen miRNeasy).

2.2. Perform miRNA sequencing (e.g., Illumina TruSeq Small RNA Library Prep) according to the manufacturer's instructions.

2.3. Validate miRNA expression using quantitative reverse transcription polymerase chain reaction (qRT-PCR) or digital PCR.

2.4. Analyze miRNA sequencing data using bioinformatic tools (e.g., miRDeep2, miRanda) to identify specific miRNA expression patterns correlated with BcR IG stereotypy.

**Protocol 3: BcR IG Stereotypy Analysis**

3.1. Extract genomic DNA from isolated CD19+ B cells using a DNA extraction kit (e.g., Qiagen DNeasy).

3.2. Perform high-throughput sequencing (e.g., Illumina MiSeq) of the immunoglobulin heavy chain (IGH) gene according to the manufacturer's instructions.

3.3. Analyze IGH sequences using bioinformatic tools (e.g., IMGT/HighV-QUEST) to identify stereotyped BcR sequences.

3.4. Correlate BcR IG stereotypy with miRNA expression patterns identified in Protocol 2.

**Protocol 4: Signaling Profile Analysis**

4.1. Stimulate CD19+ B cells with anti-IgM antibodies (e.g., 10 μg/mL) for 10 minutes to activate B-cell receptor signaling.

4.2. Perform phospho-protein analysis using mass cytometry (e.g., CyTOF) or Western blotting to assess signaling profiles in CLL cells.

4.3. Investigate key signaling pathways involved in B-cell receptor signaling and cell survival (e.g., BCR, PI3K/AKT, NF-κB).

**Protocol 5: Gene Expression Analysis**

5.1. Extract total RNA from isolated CD19+ B cells using a RNA extraction kit (e.g., Qiagen RNeasy).

5.2. Perform RNA sequencing (e.g., Illumina TruSeq RNA Library Prep) or qRT-PCR to analyze the expression of key genes involved in B-cell receptor signaling and cell survival.

5.3. Validate gene expression using Western blotting or immunofluorescence.

**Protocol 6: Functional Assays**

6.1. Perform cell proliferation assays using a cell proliferation kit (e.g., MTT assay).

6.2. Perform apoptosis assays using a apoptosis detection kit (e.g., Annexin V/PI staining).

6.3. Perform cell migration assays using a transwell migration assay.

6.4. Use CRISPR-Cas9 genome editing to knockdown or overexpress specific miRNAs and assess the effects on signaling profiles and cell behavior.

**Protocol 7: Experiment to Disprove the Hypothesis**

7.1. miRNA Inhibition:

7.1.1. Design and synthesize antisense oligonucleotides or miRNA sponges targeting specific miRNAs correlated with BcR IG stereotypy.

7.1.2. Transfect CD19+ B cells with antisense oligonucleotides or miRNA sponges using a transfection reagent (e.g., Lipofectamine).

7.1.3. Assess the effects of miRNA inhibition on signaling profiles and cell behavior using phospho-protein analysis, gene expression analysis, and functional assays.

7.2. BcR IG Stereotypy Disruption:

7.2.1. Design and synthesize guide RNAs targeting the IGH gene.

7.2.2. Perform CRISPR-Cas9 genome editing to disrupt the BcR IG stereotypy in CD19+ B cells.

7.2.3. Assess the effects of BcR IG stereotypy disruption on miRNA expression, signaling profiles, and cell behavior.

7.3. Rescue Experiment:

7.3.1. Overexpress specific miRNAs correlated with BcR IG stereotypy in CD19+ B cells with disrupted BcR IG stereotypy.

7.3.2. Assess the effects of miRNA overexpression on signaling profiles and cell behavior.

These detailed protocols should provide a clear and replicable guide for executing the experimental plan.","Here is the simulated dataframe:

```
   PBMCs  CD19_antibodies  miRNA_extraction_kit  miRNA_sequencing_kit  IGH_sequencing_kit  anti_IgM_antibodies  miRNA_inhibition  BcR_IG_stereotypy_disruption  miRNA_overexpression  Outcome
0      50               10                  Qiagen                  Illumina                  Illumina                  10               0                         0                       0  Inhibited
1      30               20                  Qiagen                  Illumina                  Illumina                  20               1                         0                       0  Activated
2      40               15                  Qiagen                  Illumina                  Illumina                  15               0                         1                       0  Inhibited
3      20               25                  Qiagen                  Illumina                  Illumina                  25               1                         0                       0  Activated
4      45               12                  Qiagen                  Illumina                  Illumina                  12               0                         0                       1  Rescued
5      35               18                  Qiagen                  Illumina                  Illumina                  18               1                         1                       0  Inhibited
6      25               22                  Qiagen                  Illumina                  Illumina                  22               0                         0                       0  Activated
7      55               10                  Qiagen                  Illumina                  Illumina                  10               1                         0                       0  Activated
8      40               13                  Qiagen                  Illumina                  Illumina                  13               0                         1                       0  Inhibited
9      30               20                  Qiagen                  Illumina                  Illumina                  20               1                         0                       0  Activated
10     50               15                  Qiagen                  Illumina                  Illumina                  15               0                         0                       1  Rescued
11     20               25                  Qiagen                  Illumina                  Illumina                  25               1                         1                       0  Inhibited
12     45               12                  Qiagen                  Illumina                  Illumina                  12               0                         0                       0  Activated
13     35               18                  Qiagen                  Illumina                  Illumina                  18               1                         1                       0  Inhibited
14     25               22                  Qiagen                  Illumina                  Illumina                  22               0                         0                       0  Activated
15     55               10                  Qiagen                  Illumina                  Illumina                  10               1                         0                       0  Activated
16     40               13                  Qiagen                  Illumina                  Illumina                  13               0                         1                       0  Inhibited
17     30               20                  Qiagen                  Illumina                  Illumina                  20               1                         0                       0  Activated
18     50               15                  Qiagen                  Illumina                  Illumina                  15               0                         0                       1  Rescued
19     20               25                  Qiagen                  Illumina                  Illumina                  25               1                         1                       0  Inhibited
20     45               12                  Qiagen                  Illumina                  Illumina                  12               0                         0                       0  Activated
21     35               18                  Qiagen                  Illumina                  Illumina                  18               1                         1                       0  Inhibited
22     25               22                  Qiagen                  Illumina                  Illumina                  22               0                         0                       0  Activated
23     55               10                  Qiagen                  Illumina                  Illumina                  10               1                         0                       0  Activated
24     40               13                  Qiagen                  Illumina                  Illumina                  13               0                         1                       0  Inhibited
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/51c11716f55085e785a79da143beb7ad7ec5802d.summary'],"Do specific non-BCR-associated markers influence the efficiency of V(D)J-recombination-driven checkpoints, leading to variations in B cell precursor development and selection?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test this hypothesis, I've outlined a comprehensive experimental plan that leverages existing scientific methods and equipment. With an unlimited budget, we can design a rigorous and thorough investigation to uncover the potential influence of non-BCR-associated markers on V(D)J-recombination-driven checkpoints in B cell precursor development and selection.

**Experimental Approach:**

**Objective 1: Identify and Validate Non-BCR-Associated Markers**

1. **Bioinformatics Analysis**: Utilize existing datasets (e.g., RNA-seq, ChIP-seq, and proteomics) to identify potential non-BCR-associated markers that may influence V(D)J-recombination-driven checkpoints. Perform gene ontology (GO) and pathway analysis to prioritize candidate markers.
2. **Marker Validation**: Validate the expression of selected markers in B cell precursors using quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting, and immunofluorescence microscopy.

**Objective 2: Investigate the Role of Non-BCR-Associated Markers in V(D)J-Recombination-Driven Checkpoints**

1. **CRISPR-Cas9 Genome Editing**: Use CRISPR-Cas9 to generate B cell precursor lines with specific knockout or knockdown of the validated non-BCR-associated markers.
2. **V(D)J-Recombination Assays**: Perform V(D)J-recombination assays using the edited B cell precursor lines to assess the efficiency of V(D)J-recombination-driven checkpoints. This can be done using:
	* PCR-based assays (e.g., ligation-mediated PCR, inverse PCR) to measure recombination efficiency.
	* Flow cytometry to analyze the expression of recombination-activated genes (e.g., RAG1, RAG2).
3. **Checkpoint Analysis**: Investigate the activation of V(D)J-recombination-driven checkpoints by analyzing the expression of checkpoint-related genes (e.g., ATM, ATR, p53) and proteins (e.g., γ-H2AX, p-Chk2) using Western blotting, qRT-PCR, and immunofluorescence microscopy.

**Objective 3: Examine the Impact of Non-BCR-Associated Markers on B Cell Precursor Development and Selection**

1. **In Vitro Differentiation Assays**: Use the edited B cell precursor lines to perform in vitro differentiation assays to assess the impact of non-BCR-associated markers on B cell development. Analyze the expression of B cell lineage-specific markers (e.g., CD19, CD20) and the formation of immature B cells.
2. **In Vivo Transplantation Assays**: Perform in vivo transplantation assays using the edited B cell precursor lines to investigate the impact of non-BCR-associated markers on B cell development and selection in a physiological context. Analyze the reconstitution of the B cell compartment and the formation of mature B cells.

**Objective 4: Investigate the Mechanisms Underlying the Influence of Non-BCR-Associated Markers**

1. **Protein-Protein Interaction Analysis**: Perform co-immunoprecipitation and mass spectrometry to identify potential protein-protein interactions between non-BCR-associated markers and V(D)J-recombination machinery components.
2. **Chromatin Immunoprecipitation Sequencing (ChIP-seq)**: Perform ChIP-seq to investigate the binding of non-BCR-associated markers to specific genomic regions involved in V(D)J-recombination.

**Additional Considerations:**

* **Control Experiments**: Include appropriate control experiments to account for potential off-target effects of CRISPR-Cas9 editing and to validate the specificity of the observed results.
* **Replication and Validation**: Perform replicate experiments to ensure the reproducibility of the results and validate the findings using multiple approaches.
* **Data Analysis and Integration**: Utilize bioinformatic tools and statistical methods to analyze and integrate the data generated from each objective, ensuring a comprehensive understanding of the role of non-BCR-associated markers in V(D)J-recombination-driven checkpoints.

With an unlimited budget, this experimental plan can be executed in a state-of-the-art laboratory, leveraging cutting-edge technologies and expertise to provide a thorough understanding of the hypothesis.",92,"Here are the detailed, step-by-step protocols for each objective:

**Objective 1: Identify and Validate Non-BCR-Associated Markers**

**Step 1.1: Bioinformatics Analysis**

1.1.1. Collect and curate existing datasets (RNA-seq, ChIP-seq, and proteomics) from public databases (e.g., GEO, ENCODE, ProteomicsDB) or in-house experiments.

1.1.2. Perform gene ontology (GO) analysis using tools like DAVID, GSEA, or Reactome to identify biological processes and pathways related to V(D)J-recombination-driven checkpoints.

1.1.3. Use pathway analysis tools like KEGG, Pathway Studio, or Ingenuity Pathway Analysis to prioritize candidate markers based on their involvement in relevant pathways.

1.1.4. Filter the results to select markers with high expression levels in B cell precursors and potential regulatory roles in V(D)J-recombination-driven checkpoints.

**Step 1.2: Marker Validation**

1.2.1. Isolate total RNA from B cell precursors using TRIzol or similar reagents.

1.2.2. Perform qRT-PCR using specific primers for the selected markers and housekeeping genes (e.g., GAPDH, ACTB) to validate their expression.

1.2.3. Perform Western blotting using specific antibodies against the selected markers to validate their protein expression.

1.2.4. Perform immunofluorescence microscopy using specific antibodies against the selected markers to validate their subcellular localization.

**Objective 2: Investigate the Role of Non-BCR-Associated Markers in V(D)J-Recombination-Driven Checkpoints**

**Step 2.1: CRISPR-Cas9 Genome Editing**

2.1.1. Design guide RNAs (gRNAs) targeting the validated non-BCR-associated markers using online tools like CRISPR Design or CRISPR-ERA.

2.1.2. Clone the gRNAs into a CRISPR-Cas9 vector (e.g., pSpCas9(BB)-2A-GFP) and verify the construct by Sanger sequencing.

2.1.3. Transfect the CRISPR-Cas9 vector into B cell precursor lines using electroporation or lipofection.

2.1.4. Select and expand edited cells using antibiotics (e.g., puromycin) and fluorescence-activated cell sorting (FACS).

**Step 2.2: V(D)J-Recombination Assays**

2.2.1. Perform ligation-mediated PCR (LM-PCR) or inverse PCR to measure V(D)J-recombination efficiency.

2.2.2. Analyze the expression of recombination-activated genes (e.g., RAG1, RAG2) by qRT-PCR and Western blotting.

2.2.3. Perform flow cytometry to analyze the expression of recombination-activated genes and proteins (e.g., γ-H2AX, p-Chk2).

**Step 2.3: Checkpoint Analysis**

2.3.1. Perform Western blotting to analyze the expression of checkpoint-related genes (e.g., ATM, ATR, p53) and proteins (e.g., γ-H2AX, p-Chk2).

2.3.2. Perform qRT-PCR to analyze the expression of checkpoint-related genes.

2.3.3. Perform immunofluorescence microscopy to analyze the subcellular localization of checkpoint-related proteins.

**Objective 3: Examine the Impact of Non-BCR-Associated Markers on B Cell Precursor Development and Selection**

**Step 3.1: In Vitro Differentiation Assays**

3.1.1. Culture the edited B cell precursor lines in vitro using differentiation media (e.g., RPMI 1640, FBS, cytokines).

3.1.2. Analyze the expression of B cell lineage-specific markers (e.g., CD19, CD20) by flow cytometry and qRT-PCR.

3.1.3. Analyze the formation of immature B cells by flow cytometry and microscopy.

**Step 3.2: In Vivo Transplantation Assays**

3.2.1. Inject the edited B cell precursor lines into immunodeficient mice (e.g., NSG, Rag2-/-) via tail vein injection.

3.2.2. Analyze the reconstitution of the B cell compartment by flow cytometry and qRT-PCR.

3.2.3. Analyze the formation of mature B cells by flow cytometry and microscopy.

**Objective 4: Investigate the Mechanisms Underlying the Influence of Non-BCR-Associated Markers**

**Step 4.1: Protein-Protein Interaction Analysis**

4.1.1. Perform co-immunoprecipitation using antibodies against non-BCR-associated markers and V(D)J-recombination machinery components.

4.1.2. Analyze the immunoprecipitated proteins by mass spectrometry (e.g., LC-MS/MS).

**Step 4.2: Chromatin Immunoprecipitation Sequencing (ChIP-seq)**

4.2.1. Perform ChIP using antibodies against non-BCR-associated markers and V(D)J-recombination machinery components.

4.2.2. Analyze the ChIP-seq data using tools like MACS, PeakRanger, or HOMER to identify binding sites.

**Additional Considerations**

* **Control Experiments**: Include control experiments using non-targeting gRNAs, wild-type B cell precursors, and mock-transfected cells to account for potential off-target effects and validate the specificity of the observed results.
* **Replication and Validation**: Perform replicate experiments to ensure the reproducibility of the results and validate the findings using multiple approaches.
* **Data Analysis and Integration**: Utilize bioinformatic tools and statistical methods to analyze and integrate the data generated from each objective, ensuring a comprehensive understanding of the role of non-BCR-associated markers in V(D)J-recombination-driven checkpoints.",,0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/04eab2eb0f6a897468a439f3feae89a55330a21d.summary'],Do specific patterns of variable domain glycan modification on autoreactive B cells influence the recognition of self-antigens by T cells and contribute to the development of autoimmune diseases?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Do specific patterns of variable domain glycan modification on autoreactive B cells influence the recognition of self-antigens by T cells and contribute to the development of autoimmune diseases?

**Experimental Plan:**

**Objective:** To investigate whether specific patterns of variable domain glycan modification on autoreactive B cells affect T cell recognition of self-antigens and contribute to autoimmune disease development.

**Approach:**

1. **Cell Isolation and Preparation**:
	* Isolate autoreactive B cells from autoimmune disease models (e.g., lupus-prone mice) and healthy controls using fluorescence-activated cell sorting (FACS) or magnetic bead-based separation.
	* Purify T cells from the same models and controls using similar methods.
2. **Glycan Modification Analysis**:
	* Perform glycan analysis on isolated autoreactive B cells using techniques like lectin microarray, mass spectrometry (MS), or glycan-specific antibodies to identify specific patterns of glycan modification.
	* Compare glycan modification patterns between autoreactive B cells from autoimmune disease models and healthy controls.
3. **T Cell Activation Assays**:
	* Co-culture autoreactive B cells with T cells from the same models and controls in the presence of self-antigens (e.g., DNA, histones).
	* Measure T cell activation markers (e.g., CD25, CD69, IFN-γ) using flow cytometry or ELISA.
	* Compare T cell activation levels between co-cultures with autoreactive B cells from autoimmune disease models and healthy controls.
4. **Glycan Modification Inhibition**:
	* Use glycan-modifying enzymes (e.g., glycosidases) or inhibitors (e.g., glycan-binding lectins) to specifically alter or block glycan modification on autoreactive B cells.
	* Repeat T cell activation assays with modified autoreactive B cells to assess the impact of glycan modification on T cell recognition.

**Experiment to Disprove the Hypothesis:**

**Null Hypothesis:** Specific patterns of variable domain glycan modification on autoreactive B cells do not influence the recognition of self-antigens by T cells and do not contribute to the development of autoimmune diseases.

**Experimental Design:**

1. **Glycan Modification Randomization**:
	* Use a glycan-modifying enzyme to randomly modify glycans on autoreactive B cells from autoimmune disease models, creating a heterogeneous glycan profile.
	* Repeat T cell activation assays with these modified autoreactive B cells.
2. **T Cell Activation Comparison**:
	* Compare T cell activation levels between co-cultures with randomly modified autoreactive B cells and unmodified autoreactive B cells from the same autoimmune disease models.
	* If the null hypothesis is true, T cell activation levels should be similar between the two groups, indicating that glycan modification patterns do not affect T cell recognition.

**Budget and Time Considerations:**

* This experiment can be completed within 6-12 months with a moderate budget (~$200,000).
* The budget will cover:
	+ Cell isolation and preparation reagents
	+ Glycan analysis equipment and consumables (e.g., lectin microarray, MS)
	+ T cell activation assay reagents (e.g., antibodies, ELISA kits)
	+ Glycan-modifying enzymes and inhibitors
	+ Personnel and laboratory costs

By following this experimental plan, we can test the hypothesis and determine whether specific patterns of glycan modification on autoreactive B cells influence T cell recognition of self-antigens and contribute to autoimmune disease development.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Preparation**

**Objective:** Isolate autoreactive B cells and T cells from autoimmune disease models and healthy controls.

**Materials:**

* Autoimmune disease models (e.g., lupus-prone mice)
* Healthy control mice
* FACS machine
* Magnetic bead-based separation kit
* Cell culture media
* FACS antibodies (e.g., anti-CD19, anti-CD4, anti-CD8)
* Magnetic beads (e.g., anti-CD19, anti-CD4, anti-CD8)

**Step-by-Step Protocol:**

1.1. Sacrifice autoimmune disease model mice and healthy control mice according to institutional animal care guidelines.

1.2. Harvest spleens and lymph nodes from each mouse.

1.3. Prepare single-cell suspensions from spleens and lymph nodes using mechanical disruption and filtering.

1.4. Stain cells with FACS antibodies (e.g., anti-CD19, anti-CD4, anti-CD8) according to the manufacturer's instructions.

1.5. Perform FACS sorting to isolate autoreactive B cells (CD19+CD4-CD8-) and T cells (CD4+ or CD8+) from autoimmune disease models and healthy controls.

1.6. Alternatively, use magnetic bead-based separation to isolate autoreactive B cells and T cells.

1.7. Wash and resuspend isolated cells in cell culture media.

**Protocol 2: Glycan Modification Analysis**

**Objective:** Analyze glycan modification patterns on isolated autoreactive B cells.

**Materials:**

* Isolated autoreactive B cells
* Lectin microarray kit
* Mass spectrometry (MS) equipment
* Glycan-specific antibodies
* Lectin microarray scanner
* MS software

**Step-by-Step Protocol:**

2.1. Prepare autoreactive B cells for glycan analysis by washing and resuspending them in an appropriate buffer.

2.2. Perform lectin microarray analysis:
	* Print lectin microarrays according to the manufacturer's instructions.
	* Incubate autoreactive B cells with the lectin microarray.
	* Scan the microarray using a lectin microarray scanner.
	* Analyze the data using the manufacturer's software.

2.3. Perform MS analysis:
	* Prepare autoreactive B cells for MS analysis by washing and resuspending them in an appropriate buffer.
	* Perform MS analysis using a suitable instrument (e.g., MALDI-TOF, ESI-MS).
	* Analyze the data using MS software.

2.4. Perform glycan-specific antibody staining:
	* Stain autoreactive B cells with glycan-specific antibodies according to the manufacturer's instructions.
	* Analyze the data using flow cytometry or microscopy.

**Protocol 3: T Cell Activation Assays**

**Objective:** Measure T cell activation in response to autoreactive B cells and self-antigens.

**Materials:**

* Isolated autoreactive B cells
* Isolated T cells
* Self-antigens (e.g., DNA, histones)
* Cell culture media
* T cell activation markers (e.g., CD25, CD69, IFN-γ)
* Flow cytometry equipment
* ELISA kits

**Step-by-Step Protocol:**

3.1. Co-culture autoreactive B cells with T cells in the presence of self-antigens:
	* Prepare autoreactive B cells and T cells by washing and resuspending them in cell culture media.
	* Co-culture autoreactive B cells and T cells at a 1:1 ratio in the presence of self-antigens.
	* Incubate the co-culture for 3-5 days.

3.2. Measure T cell activation markers:
	* Stain co-cultured cells with T cell activation markers (e.g., CD25, CD69, IFN-γ) according to the manufacturer's instructions.
	* Analyze the data using flow cytometry.

3.3. Measure T cell activation using ELISA:
	* Collect supernatants from co-cultures.
	* Perform ELISA according to the manufacturer's instructions.
	* Analyze the data using an ELISA reader.

**Protocol 4: Glycan Modification Inhibition**

**Objective:** Alter or block glycan modification on autoreactive B cells and assess the impact on T cell recognition.

**Materials:**

* Isolated autoreactive B cells
* Glycan-modifying enzymes (e.g., glycosidases)
* Glycan-binding lectins
* Cell culture media
* T cell activation markers (e.g., CD25, CD69, IFN-γ)
* Flow cytometry equipment
* ELISA kits

**Step-by-Step Protocol:**

4.1. Treat autoreactive B cells with glycan-modifying enzymes or glycan-binding lectins:
	* Prepare autoreactive B cells by washing and resuspending them in cell culture media.
	* Treat autoreactive B cells with glycan-modifying enzymes or glycan-binding lectins according to the manufacturer's instructions.

4.2. Repeat T cell activation assays with modified autoreactive B cells:
	* Co-culture modified autoreactive B cells with T cells in the presence of self-antigens.
	* Measure T cell activation markers using flow cytometry or ELISA.

**Protocol 5: Experiment to Disprove the Hypothesis**

**Objective:** Test the null hypothesis by randomizing glycan modification on autoreactive B cells.

**Materials:**

* Isolated autoreactive B cells
* Glycan-modifying enzyme
* Cell culture media
* T cell activation markers (e.g., CD25, CD69, IFN-γ)
* Flow cytometry equipment
* ELISA kits

**Step-by-Step Protocol:**

5.1. Randomize glycan modification on autoreactive B cells:
	* Prepare autoreactive B cells by washing and resuspending them in cell culture media.
	* Treat autoreactive B cells with a glycan-modifying enzyme to create a heterogeneous glycan profile.

5.2. Repeat T cell activation assays with randomly modified autoreactive B cells:
	* Co-culture randomly modified autoreactive B cells with T cells in the presence of self-antigens.
	* Measure T cell activation markers using flow cytometry or ELISA.

5.3. Compare T cell activation levels between co-cultures with randomly modified autoreactive B cells and unmodified autoreactive B cells:
	* Analyze the data to determine if T cell activation levels are similar between the two groups. If the null hypothesis is true, T cell activation levels should be similar.","```
   Autoimmune_Disease_Models  Healthy_Control_Mice  FACS_Machine  Magnetic_Beads  FACS_Antibodies  Cell_Culture_Media  Lectin_Microarray_Kits  MS_Equipment  Glycan_Specific_Antibodies  T_Cell_Activation_Markers  ELISA_Kits  Glycan_Modifying_Enzymes  Glycan_Binding_Lectins  Outcome
0                    10.0                5.0         1.0           20.0              5.0                10.0                    2.0           1.0                       5.0               2.0           1.0                1.0               0.5  High
1                     8.0                4.0         1.0           18.0              4.0                 9.0                    2.0           1.0                       4.0               2.0           1.0                1.0               0.5  High
2                    12.0                6.0         1.0           22.0              6.0                11.0                    2.0           1.0                       6.0               2.0           1.0                1.0               0.5  High
3                     9.0                4.5         1.0           19.0              4.5                10.0                    2.0           1.0                       4.5               2.0           1.0                1.0               0.5  High
4                    11.0                5.5         1.0           21.0              5.5                10.5                    2.0           1.0                       5.5               2.0           1.0                1.0               0.5  High
5                     7.0                3.5         1.0           17.0              3.5                 8.0                    2.0           1.0                       3.5               2.0           1.0                1.0               0.5  Low
6                    13.0                6.5         1.0           23.0              6.5                12.0                    2.0           1.0                       6.5               2.0           1.0                1.0               0.5  High
7                     8.5                4.0         1.0           18.5              4.0                 9.5                    2.0           1.0                       4.0               2.0           1.0                1.0               0.5  High
8                    10.5                5.0         1.0           20.5              5.0                10.5                    2.0           1.0                       5.0               2.0           1.0                1.0               0.5  High
9                     9.5                4.5         1.0           19.5              4.5                10.0                    2.0           1.0                       4.5               2.0           1.0                1.0               0.5  High
10                    7.5                3.5         1.0           17.5              3.5                 8.5                    2.0           1.0                       3.5               2.0           1.0                1.0               0.5  Low
11                   11.5                5.5         1.0           21.5              5.5                11.0                    2.0           1.0                       5.5               2.0           1.0                1.0               0.5  High
12                    8.0                4.0         1.0           18.0              4.0                 9.0                    2.0           1.0                       4.0               2.0           1.0                1.0               0.5  High
13                    9.0                4.5         1.0           19.0              4.5                10.0                    2.0           1.0                       4.5               2.0           1.0                1.0               0.5  High
14                   12.0                6.0         1.0           22.0              6.0                11.0                    2.0           1.0                       6.0               2.0           1.0                1.0               0.5  High
15                    7.0                3.5         1.0           17.0              3.5                 8.0                    2.0           1.0                       3.5               2.0           1.0                1.0               0.5  Low
16                    9.5                4.5         1.0           19.5              4.5                10.0                    2.0           1.0                       4.5               2.0           1.0                1.0               0.5  High
17                   11.0                5.5         1.0           21.0              5.5                10.5                    2.0           1.0                       5.5               2.0           1.0                1.0               0.5  High
18                    8.5                4.0         1.0           18.5              4.0                 9.5                    2.0           1.0                       4.0               2.0           1.0                1.0               0.5  High
19                    9.0                4.5         1.0           19.0              4.5                10.0                    2.0           1.0                       4.5               2.0           1.0                1.0               0.5  High
20                   12.5                6.5         1.0           22.5              6.5                12.0                    2.0           1.0                       6.5               2.0           1.0                1.0               0.5  High
21                    7.5                3.5         1.0           17.5              3.5                 8.5                    2.0           1.0                       3.5               2.0           1.0                1.0               0.5  Low
22                   10.5                5.0         1.0           20.5              5.0                10.5                    2.0           1.0                       5.0               2.0           1.0                1.0               0.5  High
23                    9.5                4.5         1.0           19.5              4.5                10.0                    2.0           1.0                       4.5               2.0           1.0                1.0               0.5  High
24                    8.0                4.0         1.0           18.0              4.0                 9.0                    2.0           1.0                       4.0               2.0           1.0                1.0               0.5  High
```",0.6008581277584581
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7a701352aefd12f0c04adf9a709fdd57b2a65ae0.summary'],"Do specific purine/pyrimidine motifs in the RSS heptamer influence the binding affinity of RAG1/2 proteins to the recombination signal sequences, thereby modulating V(D)J recombination efficiency?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Do specific purine/pyrimidine motifs in the RSS heptamer influence the binding affinity of RAG1/2 proteins to the recombination signal sequences, thereby modulating V(D)J recombination efficiency?

**Experimental Plan:**

**Objective:** To investigate the role of specific purine/pyrimidine motifs in the RSS heptamer on RAG1/2 binding affinity and V(D)J recombination efficiency.

**Approach:**

1. **RSS Heptamer Library Construction:**
	* Design and synthesize a comprehensive library of RSS heptamer variants with systematic permutations of purine/pyrimidine motifs.
	* Use a combination of DNA synthesis and PCR-based methods to generate a diverse library of RSS heptamer variants.
2. **RAG1/2 Protein Expression and Purification:**
	* Express and purify recombinant RAG1 and RAG2 proteins using established protocols (e.g., bacterial expression systems, affinity chromatography).
	* Verify protein purity and functionality using Western blotting, gel shift assays, and/or enzymatic activity assays.
3. **Binding Affinity Assays:**
	* Perform surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to measure the binding affinity of RAG1/2 proteins to the RSS heptamer library.
	* Use a high-throughput format (e.g., microfluidics, array-based SPR) to screen the entire RSS heptamer library.
4. **V(D)J Recombination Assays:**
	* Develop a cell-based or cell-free V(D)J recombination assay system using a reporter gene (e.g., GFP, luciferase) to measure recombination efficiency.
	* Co-transfect or co-incubate RAG1/2 proteins with the RSS heptamer library and a substrate DNA containing the recombination signal sequences.
	* Measure recombination efficiency using flow cytometry, qPCR, or luminescence assays.
5. **Data Analysis and Modeling:**
	* Analyze binding affinity data using computational models (e.g., Langmuir isotherm, Hill equation) to determine the binding constants (Kd) for each RSS heptamer variant.
	* Correlate binding affinity data with V(D)J recombination efficiency to identify specific purine/pyrimidine motifs that influence RAG1/2 binding and recombination outcomes.

**Experiment to Disprove the Hypothesis:**

**Null Hypothesis:** The specific purine/pyrimidine motifs in the RSS heptamer do not influence the binding affinity of RAG1/2 proteins to the recombination signal sequences, and therefore do not modulate V(D)J recombination efficiency.

**Experimental Design:**

1. **RSS Heptamer Randomization:**
	* Randomize the purine/pyrimidine motifs in the RSS heptamer using a degenerate nucleotide approach (e.g., NNN or NNK codons).
	* Generate a library of RSS heptamer variants with randomized motifs.
2. **RAG1/2 Binding and V(D)J Recombination Assays:**
	* Perform binding affinity assays (SPR or ITC) and V(D)J recombination assays (cell-based or cell-free) using the randomized RSS heptamer library.
3. **Data Analysis:**
	* Analyze the binding affinity and recombination efficiency data to determine if the randomized RSS heptamer motifs affect RAG1/2 binding and V(D)J recombination outcomes.

**Expected Outcome:**

If the hypothesis is true, the randomized RSS heptamer motifs should result in a loss of correlation between binding affinity and recombination efficiency, indicating that specific purine/pyrimidine motifs are essential for RAG1/2 binding and V(D)J recombination. Conversely, if the null hypothesis is true, the randomized RSS heptamer motifs should not affect RAG1/2 binding and V(D)J recombination outcomes, suggesting that the specific motifs are not crucial for these processes.

With an unlimited budget, this experiment could be executed using cutting-edge technologies, such as:

* High-throughput DNA synthesis and sequencing
* Advanced protein expression and purification systems
* High-sensitivity binding affinity assays (e.g., SPR, ITC)
* High-throughput V(D)J recombination assays (e.g., microfluidics, array-based systems)
* Advanced computational modeling and data analysis tools

This experimental plan should provide a comprehensive understanding of the role of specific purine/pyrimidine motifs in the RSS heptamer on RAG1/2 binding affinity and V(D)J recombination efficiency.",90,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: RSS Heptamer Library Construction**

1.1. Design the RSS heptamer library:

* Use a computer program (e.g., Python, R) to generate a list of all possible permutations of purine/pyrimidine motifs in the RSS heptamer (7-mer).
* Consider using a combinatorial approach to generate a diverse library of RSS heptamer variants.
* Design primers for PCR amplification and DNA synthesis.

1.2. Synthesize the RSS heptamer library:

* Use a DNA synthesizer (e.g., IDT, Eurofins) to synthesize the designed RSS heptamer variants.
* Verify the synthesized DNA sequences using Sanger sequencing or next-generation sequencing (NGS).

1.3. Amplify the RSS heptamer library using PCR:

* Set up PCR reactions using the synthesized RSS heptamer variants as templates and the designed primers.
* Perform PCR amplification using a thermocycler (e.g., Bio-Rad, Thermo Fisher).
* Verify the PCR products using agarose gel electrophoresis and sequencing.

**Protocol 2: RAG1/2 Protein Expression and Purification**

2.1. Clone the RAG1 and RAG2 genes:

* Use a cloning vector (e.g., pET, pGEX) to clone the RAG1 and RAG2 genes from a suitable source (e.g., human, mouse).
* Verify the cloned genes using sequencing and restriction enzyme digestion.

2.2. Express the RAG1 and RAG2 proteins:

* Transform the cloned genes into a suitable expression host (e.g., E. coli, insect cells).
* Induce protein expression using a suitable method (e.g., IPTG, heat shock).
* Verify protein expression using Western blotting and SDS-PAGE.

2.3. Purify the RAG1 and RAG2 proteins:

* Use affinity chromatography (e.g., Ni-NTA, GST) to purify the RAG1 and RAG2 proteins.
* Verify protein purity using SDS-PAGE, Western blotting, and mass spectrometry.

**Protocol 3: Binding Affinity Assays**

3.1. Prepare the RSS heptamer library for binding assays:

* Label the RSS heptamer library with a suitable fluorescent or biotinylated tag.
* Verify the labeling efficiency using spectroscopy or Western blotting.

3.2. Perform surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) assays:

* Use a SPR instrument (e.g., Biacore, Reichert) or ITC instrument (e.g., MicroCal, TA Instruments) to measure the binding affinity of RAG1/2 proteins to the RSS heptamer library.
* Set up the binding assays according to the manufacturer's instructions.
* Measure the binding affinity using a high-throughput format (e.g., microfluidics, array-based SPR).

**Protocol 4: V(D)J Recombination Assays**

4.1. Develop a cell-based or cell-free V(D)J recombination assay system:

* Use a reporter gene (e.g., GFP, luciferase) to measure recombination efficiency.
* Design a substrate DNA containing the recombination signal sequences.
* Co-transfect or co-incubate RAG1/2 proteins with the RSS heptamer library and the substrate DNA.

4.2. Measure recombination efficiency:

* Use flow cytometry, qPCR, or luminescence assays to measure recombination efficiency.
* Verify the recombination products using sequencing and restriction enzyme digestion.

**Protocol 5: Data Analysis and Modeling**

5.1. Analyze binding affinity data:

* Use computational models (e.g., Langmuir isotherm, Hill equation) to determine the binding constants (Kd) for each RSS heptamer variant.
* Correlate binding affinity data with V(D)J recombination efficiency.

5.2. Identify specific purine/pyrimidine motifs that influence RAG1/2 binding and recombination outcomes:

* Use statistical analysis (e.g., t-test, ANOVA) to identify significant correlations between binding affinity and recombination efficiency.
* Use machine learning algorithms (e.g., decision trees, random forests) to identify specific motifs that influence RAG1/2 binding and recombination outcomes.

**Protocol 6: Experiment to Disprove the Hypothesis**

6.1. Randomize the purine/pyrimidine motifs in the RSS heptamer:

* Use a degenerate nucleotide approach (e.g., NNN or NNK codons) to randomize the purine/pyrimidine motifs in the RSS heptamer.
* Generate a library of RSS heptamer variants with randomized motifs.

6.2. Perform binding affinity assays and V(D)J recombination assays:

* Use the randomized RSS heptamer library in binding affinity assays (SPR or ITC) and V(D)J recombination assays (cell-based or cell-free).
* Measure binding affinity and recombination efficiency as described in Protocols 3 and 4.

6.3. Analyze the data:

* Analyze the binding affinity and recombination efficiency data to determine if the randomized RSS heptamer motifs affect RAG1/2 binding and V(D)J recombination outcomes.
* Compare the results to the original hypothesis to determine if the null hypothesis is supported.","```
   RAG1_protein  RAG2_protein  RSS_heptamer  Binding_Affinity  Recombination_Efficiency
0           0.5          0.3          1000          1.23e-07                  0.45
1           0.8          0.6          2000          2.56e-06                  0.67
2           0.2          0.4          1500          9.87e-08                  0.32
3           0.9          0.7          2500          4.21e-06                  0.81
4           0.1          0.2          1200          5.67e-08                  0.21
5           0.6          0.5          1800          1.98e-07                  0.58
6           0.4          0.8          2200          3.45e-06                  0.73
7           0.7          0.9          2800          5.12e-06                  0.85
8           0.3          0.1          1600          1.23e-07                  0.39
9           0.2          0.6          1900          2.34e-07                  0.51
10          0.8          0.4          2400          3.89e-06                  0.76
11          0.5          0.7          2100          2.98e-06                  0.63
12          0.9          0.2          2600          4.56e-06                  0.82
13          0.1          0.5          1300          7.89e-08                  0.29
14          0.6          0.8          2300          3.67e-06                  0.75
15          0.4          0.9          2700          5.34e-06                  0.87
16          0.7          0.3          2000          2.12e-06                  0.59
17          0.2          0.1          1400          9.45e-08                  0.35
18          0.8          0.5          2500          4.01e-06                  0.79
19          0.5          0.2          1800          1.67e-07                  0.53
20          0.9          0.6          2900          5.67e-06                  0.91
21          0.1          0.4          1100          5.12e-08                  0.25
22          0.6          0.7          2400          3.23e-06                  0.72
23          0.4          0.8          2600          4.23e-06                  0.83
24          0.7          0.9          3000          6.12e-06                  0.95
```",0.8413565224774008
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/53782609701cd132ec9348424b873ca8b87d8a92.summary'],Do the hub genes identified in SLE T and B cells also play a role in the regulation of viral latency and reactivation in SLE patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that the hub genes identified in SLE T and B cells also play a role in the regulation of viral latency and reactivation in SLE patients.

**Experimental Plan:**

**Title:** Investigating the Role of Hub Genes in SLE T and B Cells on Viral Latency and Reactivation

**Objective:** To determine if the hub genes identified in SLE T and B cells (PLSCR1, GINS2, ISG15, and TOP2A) play a role in regulating viral latency and reactivation in SLE patients.

**Experimental Design:**

1. **Cell Culture and Infection:** Obtain primary T and B cells from SLE patients and healthy controls. Infect the cells with a latent virus (e.g., Epstein-Barr virus, EBV) using a low multiplicity of infection (MOI) to establish latency.
2. **Hub Gene Knockdown/Overexpression:** Use RNA interference (RNAi) or CRISPR-Cas9 gene editing tools to knockdown or overexpress the hub genes in the infected T and B cells.
3. **Viral Reactivation Assay:** Treat the infected cells with a viral reactivation stimulus (e.g., phorbol 12-myristate 13-acetate, PMA) and measure viral gene expression (e.g., EBV immediate-early gene, BZLF1) using real-time PCR or RNA-seq.
4. **Viral Latency Assay:** Measure the expression of viral latency-associated genes (e.g., EBV latency-associated protein, LMP1) using real-time PCR or RNA-seq.
5. **Immune Response Analysis:** Analyze the immune response to viral reactivation by measuring cytokine production (e.g., IFN-γ, TNF-α) and T cell activation markers (e.g., CD69, CD25) using flow cytometry.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on showing that the hub genes do not play a role in regulating viral latency and reactivation. We will use a combination of loss-of-function and gain-of-function approaches to test the hypothesis.

**Loss-of-Function Approach:**

* Knockdown the hub genes in SLE T and B cells using RNAi or CRISPR-Cas9.
* Infect the cells with a latent virus and measure viral gene expression and latency-associated gene expression.
* If the hub genes are not involved in regulating viral latency and reactivation, we would expect to see no significant difference in viral gene expression and latency-associated gene expression between hub gene-knockdown cells and control cells.

**Gain-of-Function Approach:**

* Overexpress the hub genes in SLE T and B cells using CRISPR-Cas9 or lentiviral vectors.
* Infect the cells with a latent virus and measure viral gene expression and latency-associated gene expression.
* If the hub genes are not involved in regulating viral latency and reactivation, we would expect to see no significant difference in viral gene expression and latency-associated gene expression between hub gene-overexpressing cells and control cells.

**Expected Outcomes:**

* If the hub genes play a role in regulating viral latency and reactivation, we would expect to see changes in viral gene expression and latency-associated gene expression in response to hub gene knockdown or overexpression.
* If the hub genes do not play a role in regulating viral latency and reactivation, we would expect to see no significant changes in viral gene expression and latency-associated gene expression in response to hub gene knockdown or overexpression.

**Timeline and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000. The budget will cover the costs of:

* Cell culture and reagents
* RNAi or CRISPR-Cas9 reagents
* Viral infection and reactivation reagents
* Real-time PCR and RNA-seq reagents
* Flow cytometry reagents
* Personnel and laboratory costs

This experimental plan is designed to test the hypothesis that the hub genes identified in SLE T and B cells play a role in regulating viral latency and reactivation in SLE patients. By using a combination of loss-of-function and gain-of-function approaches, we can determine if the hub genes are involved in this process and provide insights into their potential therapeutic applications.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Infection**

1.1. Obtain primary T and B cells from SLE patients and healthy controls through venipuncture or leukapheresis.

1.2. Isolate T and B cells using magnetic bead separation or fluorescence-activated cell sorting (FACS).

1.3. Culture the isolated cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

1.4. Infect the cells with Epstein-Barr virus (EBV) at a low multiplicity of infection (MOI) of 0.01-0.1 using a viral stock with a titer of 10^6-10^7 plaque-forming units (PFU)/mL.

1.5. Incubate the infected cells for 2-3 days to allow for viral latency to establish.

**Protocol 2: Hub Gene Knockdown/Overexpression**

2.1. Design and synthesize small interfering RNA (siRNA) or short hairpin RNA (shRNA) targeting the hub genes (PLSCR1, GINS2, ISG15, and TOP2A) using online tools or commercial software.

2.2. Transfect the siRNA or shRNA into the infected T and B cells using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

2.3. Incubate the transfected cells for 24-48 hours to allow for gene knockdown.

2.4. Alternatively, use CRISPR-Cas9 gene editing to knockdown or overexpress the hub genes.

2.5. Validate the knockdown or overexpression of the hub genes using real-time PCR or Western blot.

**Protocol 3: Viral Reactivation Assay**

3.1. Treat the infected cells with phorbol 12-myristate 13-acetate (PMA) at a final concentration of 10-50 ng/mL to induce viral reactivation.

3.2. Incubate the cells for 24-48 hours to allow for viral gene expression.

3.3. Extract total RNA from the cells using a commercial RNA extraction kit (e.g., TRIzol).

3.4. Perform real-time PCR or RNA-seq to measure the expression of EBV immediate-early gene (BZLF1) and other viral genes.

**Protocol 4: Viral Latency Assay**

4.1. Extract total RNA from the cells using a commercial RNA extraction kit (e.g., TRIzol).

4.2. Perform real-time PCR or RNA-seq to measure the expression of EBV latency-associated protein (LMP1) and other latency-associated genes.

**Protocol 5: Immune Response Analysis**

5.1. Stimulate the infected cells with PMA and ionomycin for 4-6 hours to induce cytokine production.

5.2. Collect the supernatant and measure cytokine production (e.g., IFN-γ, TNF-α) using enzyme-linked immunosorbent assay (ELISA) or multiplex bead-based assays.

5.3. Stain the cells with fluorescently labeled antibodies against T cell activation markers (e.g., CD69, CD25) and analyze using flow cytometry.

**Protocol 6: Data Analysis**

6.1. Analyze the real-time PCR or RNA-seq data using commercial software (e.g., Prism, R) to determine the fold change in viral gene expression and latency-associated gene expression.

6.2. Compare the data between hub gene-knockdown or -overexpressing cells and control cells to determine if the hub genes play a role in regulating viral latency and reactivation.

6.3. Perform statistical analysis (e.g., t-test, ANOVA) to determine the significance of the results.

**Quality Control and Replicability**

* Use multiple biological replicates (n=3-5) and technical replicates (n=2-3) to ensure reproducibility.
* Validate the results using multiple methods (e.g., real-time PCR, RNA-seq, Western blot).
* Use positive and negative controls for each experiment to ensure specificity.
* Document all experimental procedures, reagents, and results in a laboratory notebook or electronic database.

**Timeline and Budget**

* The experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget will cover the costs of:
	+ Cell culture and reagents
	+ RNAi or CRISPR-Cas9 reagents
	+ Viral infection and reactivation reagents
	+ Real-time PCR and RNA-seq reagents
	+ Flow cytometry reagents
	+ Personnel and laboratory costs","```
   T_cells  B_cells  FBS  Penicillin_streptomycin  L_glutamine  EBV_MOI  siRNA_shRNA  PMA  Gene_knockdown  BZLF1_expression  LMP1_expression  IFN_gamma  TNF_alpha  CD69_expression  CD25_expression  Outcome
0       10000     5000  10.0                1.0           1.0      0.05         20.0   20.0           0.5             2.5            1.2           100.0       50.0             30.0           20.0  Reactivation
1       12000     6000  12.0                1.2           1.2      0.08         25.0   25.0           0.6             3.0            1.5           120.0       60.0             35.0           25.0  Reactivation
2        8000     4000   8.0                0.8           0.8      0.03         15.0   15.0           0.3             1.8            0.9           80.0       40.0             25.0           18.0  Latency
3       15000     7500  15.0                1.5           1.5      0.12         30.0   30.0           0.8             4.0            2.0           150.0       75.0             40.0           30.0  Reactivation
4       10000     5000  10.0                1.0           1.0      0.05         20.0   20.0           0.5             2.5            1.2           100.0       50.0             30.0           20.0  Reactivation
5       12000     6000  12.0                1.2           1.2      0.08         25.0   25.0           0.6             3.0            1.5           120.0       60.0             35.0           25.0  Reactivation
6        8000     4000   8.0                0.8           0.8      0.03         15.0   15.0           0.3             1.8            0.9           80.0       40.0             25.0           18.0  Latency
7       15000     7500  15.0                1.5           1.5      0.12         30.0   30.0           0.8             4.0            2.0           150.0       75.0             40.0           30.0  Reactivation
8       10000     5000  10.0                1.0           1.0      0.05         20.0   20.0           0.5             2.5            1.2           100.0       50.0             30.0           20.0  Reactivation
9       12000     6000  12.0                1.2           1.2      0.08         25.0   25.0           0.6             3.0            1.5           120.0       60.0             35.0           25.0  Reactivation
10       8000     4000   8.0                0.8           0.8      0.03         15.0   15.0           0.3             1.8            0.9           80.0       40.0             25.0           18.0  Latency
11      15000     7500  15.0                1.5           1.5      0.12         30.0   30.0           0.8             4.0            2.0           150.0       75.0             40.0           30.0  Reactivation
12       10000     5000  10.0                1.0           1.0      0.05         20.0   20.0           0.5             2.5            1.2           100.0       50.0             30.0           20.0  Reactivation
13       12000     6000  12.0                1.2           1.2      0.08         25.0   25.0           0.6             3.0            1.5           120.0       60.0             35.0           25.0  Reactivation
14       8000     4000   8.0                0.8           0.8      0.03         15.0   15.0           0.3             1.8            0.9           80.0       40.0             25.0           18.0  Latency
15      15000     7500  15.0                1.5           1.5      0.12         30.0   30.0           0.8             4.0            2.0           150.0       75.0             40.0           30.0  Reactivation
16       10000     5000  10.0                1.0           1.0      0.05         20.0   20.0           0.5             2.5            1.2           100.0       50.0             30.0           20.0  Reactivation
17       12000     6000  12.0                1.2           1.2      0.08         25.0   25.0           0.6             3.0            1.5           120.0       60.0             35.0           25.0  Reactivation
18       8000     4000   8.0                0.8           0.8      0.03         15.0   15.0           0.3             1.8            0.9           80.0       40.0             25.0           18.0  Latency
19      15000     7500  15.0                1.5           1.5      0.12         30.0   30.0           0.8             4.0            2.0           150.0       75.0             40.0           30.0  Reactivation
20       10000     5000  10.0                1.0           1.0      0.05         20.0   20.0           0.5             2.5            1.2           100.0       50.0             30.0           20.0  Reactivation
21       12000     6000  12.0                1.2           1.2      0.08         25.0   25.0           0.6             3.0            1.5           120.0       60.0             35.0           25.0  Reactivation
22       8000     4000   8.0                0.8           0.8      0.03         15.0   15.0           0.3             1.8            0.9           80.0       40.0             25.0           18.0  Latency
23      15000     7500  15.0                1.5           1.5      0.12         30.0   30.0           0.8             4.0            2.0           150.0       75.0             40.0           30.0  Reactivation
24       10000     5000  10.0                1.0           1.0      0.05         20.0   20.0           0.5             2.5            1.2           100.0       50.0             30.0           20.0  Reactivation
```",0.7131783859049511
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/03f8ddc1868d0a8c9ec1f2bbfcdb5136fb126394.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d5f1fb2b1bd88ace2357a1130f9391fa8e2e00b7.summary']","Do tumor-infiltrating B cells with less mature and less specific BCR repertoires exhibit altered V(D)J segment usage and CDR3 length compared to circulating B cells, and is this associated with an interferon signature in the tumor microenvironment?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed a high-level experimental plan to test it. Since the goal is to disprove the hypothesis, the experiment is designed to test the null hypothesis: ""Tumor-infiltrating B cells with less mature and less specific BCR repertoires do not exhibit altered V(D)J segment usage and CDR3 length compared to circulating B cells, and this is not associated with an interferon signature in the tumor microenvironment.""

**Experimental Approach:**

1. **Sample Collection:**
	* Collect tumor tissue samples from patients with cancer (e.g., breast, lung, or colon cancer) and isolate tumor-infiltrating B cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS).
	* Collect peripheral blood mononuclear cells (PBMCs) from the same patients and isolate circulating B cells using FACS or MACS.
2. **BCR Repertoire Analysis:**
	* Perform high-throughput sequencing of the BCR heavy chain (IgH) and light chain (IgL) genes from both tumor-infiltrating and circulating B cells using platforms like Illumina MiSeq or PacBio Sequel.
	* Analyze the sequencing data using bioinformatic tools (e.g., IMGT/HighV-QUEST, IgBLAST, or pRESTO) to determine:
		+ V(D)J segment usage (V, D, and J gene segment frequencies)
		+ CDR3 length distribution
		+ BCR repertoire diversity and clonality
3. **Interferon Signature Analysis:**
	* Extract RNA from tumor tissue samples and perform RNA sequencing (RNA-seq) or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure the expression of interferon-stimulated genes (ISGs) and interferon-related genes (e.g., IFN-α, IFN-β, and IRF7).
	* Analyze the expression data using bioinformatic tools (e.g., DESeq2, edgeR, or limma) to identify differentially expressed genes between tumor and normal tissues.
4. **Statistical Analysis:**
	* Compare the V(D)J segment usage, CDR3 length distribution, and BCR repertoire diversity between tumor-infiltrating and circulating B cells using statistical tests (e.g., Wilcoxon rank-sum test, Kruskal-Wallis test, or Fisher's exact test).
	* Correlate the BCR repertoire features with the interferon signature in the tumor microenvironment using statistical tests (e.g., Spearman's rank correlation or linear regression).

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, the experiment should aim to show that there is no significant difference in V(D)J segment usage, CDR3 length, and BCR repertoire diversity between tumor-infiltrating and circulating B cells, and that there is no association with the interferon signature in the tumor microenvironment.

**Key Predictions:**

1. No significant difference in V(D)J segment usage and CDR3 length distribution between tumor-infiltrating and circulating B cells.
2. No correlation between BCR repertoire features and interferon signature in the tumor microenvironment.
3. No enrichment of ISGs and interferon-related genes in the tumor tissue samples.

**Timeline and Budget:**

This experiment can be completed within 6-9 months, depending on the availability of samples and resources. The estimated budget for this experiment is approximately $50,000-$75,000, broken down into:

* Sample collection and processing: $10,000-$15,000
* BCR repertoire analysis (sequencing and bioinformatics): $15,000-$20,000
* Interferon signature analysis (RNA-seq or qRT-PCR): $10,000-$15,000
* Statistical analysis and bioinformatics: $5,000-$10,000
* Miscellaneous (reagents, consumables, and personnel): $10,000-$15,000

This experiment is designed to be cost-effective and can be completed within a reasonable timeframe, while still providing valuable insights into the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Sample Collection and Processing**

1.1. Tumor Tissue Sample Collection:

* Obtain tumor tissue samples from patients with cancer (e.g., breast, lung, or colon cancer) through collaboration with a hospital or tissue bank.
* Ensure that the samples are collected with informed consent and in accordance with institutional review board (IRB) guidelines.
* Store the samples in a -80°C freezer or liquid nitrogen until processing.

1.2. Peripheral Blood Mononuclear Cell (PBMC) Collection:

* Collect peripheral blood samples from the same patients using a sterile needle and syringe.
* Isolate PBMCs using Ficoll-Paque density gradient centrifugation or a similar method.
* Store the PBMCs in a -80°C freezer or liquid nitrogen until processing.

1.3. Tumor-Infiltrating B Cell Isolation:

* Thaw the tumor tissue samples and dissociate them into single cells using a gentle dissociation buffer (e.g., RPMI 1640 with 1% FBS and 1 mM EDTA).
* Stain the cells with fluorescently labeled antibodies against CD19, CD20, and CD45 to identify B cells.
* Use fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) to isolate CD19+CD20+CD45+ B cells from the tumor tissue.
* Store the isolated B cells in a -80°C freezer or liquid nitrogen until further analysis.

1.4. Circulating B Cell Isolation:

* Thaw the PBMCs and stain them with fluorescently labeled antibodies against CD19, CD20, and CD45 to identify B cells.
* Use FACS or MACS to isolate CD19+CD20+CD45+ B cells from the PBMCs.
* Store the isolated B cells in a -80°C freezer or liquid nitrogen until further analysis.

**Protocol 2: BCR Repertoire Analysis**

2.1. RNA Extraction:

* Extract total RNA from the isolated tumor-infiltrating and circulating B cells using a RNA extraction kit (e.g., TRIzol or RNeasy).
* Quantify the RNA concentration using a spectrophotometer (e.g., NanoDrop).

2.2. cDNA Synthesis:

* Synthesize cDNA from the extracted RNA using a reverse transcription kit (e.g., SuperScript III).
* Quantify the cDNA concentration using a spectrophotometer.

2.3. PCR Amplification:

* Design primers specific to the BCR heavy chain (IgH) and light chain (IgL) genes.
* Perform PCR amplification of the IgH and IgL genes using a high-fidelity PCR kit (e.g., Phusion).
* Purify the PCR products using a PCR cleanup kit (e.g., QIAquick).

2.4. Library Preparation:

* Prepare sequencing libraries from the purified PCR products using a library preparation kit (e.g., TruSeq).
* Quantify the library concentration using a spectrophotometer.

2.5. High-Throughput Sequencing:

* Perform high-throughput sequencing of the IgH and IgL libraries using a platform like Illumina MiSeq or PacBio Sequel.
* Generate FASTQ files from the sequencing data.

2.6. Bioinformatic Analysis:

* Analyze the FASTQ files using bioinformatic tools (e.g., IMGT/HighV-QUEST, IgBLAST, or pRESTO) to determine:
	+ V(D)J segment usage (V, D, and J gene segment frequencies)
	+ CDR3 length distribution
	+ BCR repertoire diversity and clonality

**Protocol 3: Interferon Signature Analysis**

3.1. RNA Extraction:

* Extract total RNA from the tumor tissue samples using a RNA extraction kit (e.g., TRIzol or RNeasy).
* Quantify the RNA concentration using a spectrophotometer.

3.2. RNA Sequencing (RNA-seq) or qRT-PCR:

* Perform RNA-seq using a platform like Illumina HiSeq or NovaSeq.
* Alternatively, perform qRT-PCR using a platform like QuantStudio or BioMark.
* Generate FASTQ files from the RNA-seq data or Ct values from the qRT-PCR data.

3.3. Bioinformatic Analysis:

* Analyze the FASTQ files or Ct values using bioinformatic tools (e.g., DESeq2, edgeR, or limma) to identify differentially expressed genes between tumor and normal tissues.
* Identify interferon-stimulated genes (ISGs) and interferon-related genes (e.g., IFN-α, IFN-β, and IRF7).

**Protocol 4: Statistical Analysis**

4.1. Data Integration:

* Integrate the BCR repertoire data from Protocol 2 with the interferon signature data from Protocol 3.

4.2. Statistical Tests:

* Compare the V(D)J segment usage, CDR3 length distribution, and BCR repertoire diversity between tumor-infiltrating and circulating B cells using statistical tests (e.g., Wilcoxon rank-sum test, Kruskal-Wallis test, or Fisher's exact test).
* Correlate the BCR repertoire features with the interferon signature in the tumor microenvironment using statistical tests (e.g., Spearman's rank correlation or linear regression).

**Quality Control and Assurance**

* Perform quality control checks at each step of the protocol to ensure the integrity and accuracy of the data.
* Use positive and negative controls to validate the results.
* Document all experimental procedures, results, and quality control checks in a laboratory notebook or electronic laboratory information management system (ELN).","```
   Tumor_Tissue_Sample_Amount  PBMC_Amount  Tumor_Infiltrating_B_Cell_Amount  Circulating_B_Cell_Amount  RNA_Extraction_Concentration  cDNA_Synthesis_Concentration  PCR_Amplification_Efficiency  Library_Preparation_Concentration  Interferon_Signature  VDJ_Segment_Usage  CDR3_Length_Distribution  BCR_Repertoire_Diversity  Outcome
0                       100.0         500.0                         20000.0                    30000.0                    500.0                    200.0                    0.8                    100.0            0.5            0.3            0.7            0.9            Positive
1                       120.0         600.0                         22000.0                    35000.0                    550.0                    220.0                    0.9                    120.0            0.6            0.4            0.8            0.8            Positive
2                       140.0         700.0                         24000.0                    40000.0                    600.0                    240.0                    0.8                    140.0            0.7            0.5            0.9            0.7            Positive
3                       160.0         800.0                         26000.0                    45000.0                    650.0                    260.0                    0.9                    160.0            0.8            0.6            0.8            0.6            Positive
4                       180.0         900.0                         28000.0                    50000.0                    700.0                    280.0                    0.8                    180.0            0.9            0.7            0.7            0.5            Positive
5                       100.0         500.0                         20000.0                    30000.0                    500.0                    200.0                    0.7                    100.0            0.4            0.3            0.6            0.8            Negative
6                       120.0         600.0                         22000.0                    35000.0                    550.0                    220.0                    0.8                    120.0            0.5            0.4            0.7            0.7            Negative
7                       140.0         700.0                         24000.0                    40000.0                    600.0                    240.0                    0.9                    140.0            0.6            0.5            0.8            0.6            Negative
8                       160.0         800.0                         26000.0                    45000.0                    650.0                    260.0                    0.8                    160.0            0.7            0.6            0.7            0.5            Negative
9                       180.0         900.0                         28000.0                    50000.0                    700.0                    280.0                    0.9                    180.0            0.8            0.7            0.6            0.4            Negative
10                      100.0         500.0                         20000.0                    30000.0                    500.0                    200.0                    0.8                    100.0            0.3            0.2            0.5            0.9            Positive
11                      120.0         600.0                         22000.0                    35000.0                    550.0                    220.0                    0.9                    120.0            0.4            0.3            0.6            0.8            Positive
12                      140.0         700.0                         24000.0                    40000.0                    600.0                    240.0                    0.8                    140.0            0.5            0.4            0.7            0.7            Positive
13                      160.0         800.0                         26000.0                    45000.0                    650.0                    260.0                    0.9                    160.0            0.6            0.5            0.8            0.6            Positive
14                      180.0         900.0                         28000.0                    50000.0                    700.0                    280.0                    0.8                    180.0            0.7            0.6            0.7            0.5            Positive
15                      100.0         500.0                         20000.0                    30000.0                    500.0                    200.0                    0.7                    100.0            0.2            0.1            0.4            0.9            Negative
16                      120.0         600.0                         22000.0                    35000.0                    550.0                    220.0                    0.8                    120.0            0.3            0.2            0.5            0.8            Negative
17                      140.0         700.0                         24000.0                    40000.0                    600.0                    240.0                    0.9                    140.0            0.4            0.3            0.6            0.7            Negative
18                      160.0         800.0                         26000.0                    45000.0                    650.0                    260.0                    0.8                    160.0            0.5            0.4            0.7            0.6            Negative
19                      180.0         900.0                         28000.0                    50000.0                    700.0                    280.0                    0.9                    180.0            0.6            0.5            0.8            0.5            Negative
20                      100.0         500.0                         20000.0                    30000.0                    500.0                    200.0                    0.8                    100.0            0.1            0.1            0.3            0.9            Positive
21                      120.0         600.0                         22000.0                    35000.0                    550.0                    220.0                    0.9                    120.0            0.2            0.2            0.4            0.8            Positive
22                      140.0         700.0                         24000.0                    40000.0                    600.0                    240.0                    0.8                    140.0            0.3            0.3            0.5            0.7            Positive
23                      160.0         800.0                         26000.0                    45000.0                    650.0                    260.0                    0.9                    160.0            0.4            0.4            0.6            0.6            Positive
24                      180.0         900.0                         28000.0                    50000.0                    700.0                    280.0                    0.8                    180.0            0.5            0.5            0.7            0.5            Positive
```",0.02906047077373276
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4aacee211837bc4b80dd7f85fbe30b6733288125.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/91d0913086cac86d0d4b562e73db8b7255e021a4.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0b729b2f5bf471ff4cc2f1a4cb3c10342f2fac39.summary']",Does ARHGEF1 regulate INPP5B-mediated PIP2 hydrolysis to modulate actin dynamics and B cell activation in response to antigen stimulation?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis!

To test this hypothesis, I'll outline a high-level experimental plan to investigate the role of ARHGEF1 in regulating INPP5B-mediated PIP2 hydrolysis, actin dynamics, and B cell activation in response to antigen stimulation.

**Hypothesis:** ARHGEF1 regulates INPP5B-mediated PIP2 hydrolysis to modulate actin dynamics and B cell activation in response to antigen stimulation.

**Experimental Approach:**

**Objective:** Design an experiment to disprove the hypothesis, thereby verifying its validity.

**Step 1: Cell Culture and Stimulation**

* Obtain B cells from a suitable source (e.g., human peripheral blood or mouse spleen).
* Culture B cells in a suitable medium (e.g., RPMI 1640 with 10% FBS) and maintain at 37°C, 5% CO2.
* Stimulate B cells with a specific antigen (e.g., anti-IgM or anti-CD40) to activate them.

**Step 2: ARHGEF1 Knockdown/Knockout**

* Use RNA interference (RNAi) or CRISPR-Cas9 gene editing to knockdown or knockout ARHGEF1 in B cells.
* Verify the efficiency of ARHGEF1 knockdown/knockout using Western blotting or qRT-PCR.

**Step 3: INPP5B Activity Assay**

* Measure INPP5B activity in control and ARHGEF1-knockdown/knockout B cells using a PIP2 hydrolysis assay (e.g., malachite green-based assay).
* Compare INPP5B activity between control and ARHGEF1-knockdown/knockout B cells to determine if ARHGEF1 regulates INPP5B-mediated PIP2 hydrolysis.

**Step 4: Actin Dynamics Analysis**

* Use live-cell imaging (e.g., confocal microscopy) to analyze actin dynamics in control and ARHGEF1-knockdown/knockout B cells.
* Measure actin polymerization, depolymerization, and cytoskeleton organization using image analysis software (e.g., ImageJ).

**Step 5: B Cell Activation Assay**

* Measure B cell activation markers (e.g., CD69, CD86, and CD25) using flow cytometry or Western blotting.
* Compare B cell activation between control and ARHGEF1-knockdown/knockout B cells to determine if ARHGEF1 regulates B cell activation.

**Step 6: Data Analysis and Interpretation**

* Analyze data from Steps 3-5 to determine if ARHGEF1 knockdown/knockout affects INPP5B activity, actin dynamics, and B cell activation.
* If the data show no significant differences between control and ARHGEF1-knockdown/knockout B cells, it would suggest that the hypothesis is false, and ARHGEF1 does not regulate INPP5B-mediated PIP2 hydrolysis, actin dynamics, and B cell activation.

**Budget and Timeframe:**

* This experiment can be completed within 6-12 months with a budget of approximately $50,000-$100,000.
* The budget will cover the costs of:
	+ Cell culture reagents and media
	+ RNAi or CRISPR-Cas9 reagents
	+ Antibodies and reagents for Western blotting and flow cytometry
	+ Imaging software and equipment (e.g., confocal microscope)
	+ Personnel and laboratory expenses

By following this experimental plan, we can test the hypothesis and determine if ARHGEF1 regulates INPP5B-mediated PIP2 hydrolysis, actin dynamics, and B cell activation in response to antigen stimulation.",85,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Culture and Stimulation**

1.1. Obtain B cells from a suitable source:

* Collect human peripheral blood or mouse spleen samples from a reputable supplier or through in-house collection protocols.
* Isolate B cells using density gradient centrifugation (e.g., Ficoll-Paque) or magnetic bead-based separation (e.g., Miltenyi Biotec).

1.2. Culture B cells:

* Resuspend isolated B cells in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
* Culture B cells in a 37°C, 5% CO2 incubator at a density of 1-2 x 10^6 cells/mL.

1.3. Stimulate B cells:

* Prepare a stock solution of anti-IgM or anti-CD40 antibody (e.g., 1 mg/mL) in PBS.
* Add the antibody to the B cell culture at a final concentration of 10-20 μg/mL.
* Incubate the cells for 24-48 hours to allow for activation.

**Step 2: ARHGEF1 Knockdown/Knockout**

2.1. RNA interference (RNAi):

* Design and synthesize ARHGEF1-specific siRNA oligonucleotides (e.g., 20-25 nucleotides) using a reputable supplier (e.g., Dharmacon).
* Transfect B cells with siRNA using a transfection reagent (e.g., Lipofectamine RNAiMAX) according to the manufacturer's protocol.
* Incubate the cells for 24-48 hours to allow for knockdown.

2.2. CRISPR-Cas9 gene editing:

* Design and synthesize ARHGEF1-specific guide RNA (gRNA) and Cas9 enzyme using a reputable supplier (e.g., IDT).
* Transfect B cells with gRNA and Cas9 using a transfection reagent (e.g., Lipofectamine CRISPRMAX) according to the manufacturer's protocol.
* Incubate the cells for 24-48 hours to allow for knockout.

2.3. Verify ARHGEF1 knockdown/knockout:

* Extract total protein from control and ARHGEF1-knockdown/knockout B cells using a lysis buffer (e.g., RIPA).
* Perform Western blotting using an ARHGEF1-specific antibody (e.g., Abcam) to detect protein levels.
* Alternatively, perform qRT-PCR using ARHGEF1-specific primers to detect mRNA levels.

**Step 3: INPP5B Activity Assay**

3.1. Prepare PIP2 substrate:

* Purchase PIP2 substrate (e.g., Echelon Biosciences) or synthesize in-house using a reputable protocol.
* Resuspend the substrate in a buffer (e.g., 20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.4) to a final concentration of 10 μM.

3.2. Perform PIP2 hydrolysis assay:

* Incubate control and ARHGEF1-knockdown/knockout B cells with PIP2 substrate for 30 minutes at 37°C.
* Add malachite green reagent (e.g., Sigma-Aldrich) to the reaction mixture to detect released phosphate.
* Measure absorbance at 620 nm using a plate reader (e.g., Tecan).

3.3. Calculate INPP5B activity:

* Calculate the rate of PIP2 hydrolysis using the following formula: (ΔA620 / min) x (1 / protein concentration).
* Compare INPP5B activity between control and ARHGEF1-knockdown/knockout B cells.

**Step 4: Actin Dynamics Analysis**

4.1. Prepare live-cell imaging medium:

* Prepare a live-cell imaging medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine) supplemented with 10 μM Hoechst 33342 (e.g., Thermo Fisher) for nuclear staining.

4.2. Perform live-cell imaging:

* Seed control and ARHGEF1-knockdown/knockout B cells on a glass-bottom dish (e.g., MatTek) at a density of 1-2 x 10^5 cells/mL.
* Image cells using a confocal microscope (e.g., Zeiss LSM 880) with a 63x oil immersion objective.
* Acquire images at 1-2 minute intervals for 30-60 minutes.

4.3. Analyze actin dynamics:

* Use image analysis software (e.g., ImageJ) to measure actin polymerization, depolymerization, and cytoskeleton organization.
* Calculate the following parameters: actin filament length, actin filament density, and actin dynamics rate.

**Step 5: B Cell Activation Assay**

5.1. Prepare antibodies and reagents:

* Prepare a panel of antibodies against B cell activation markers (e.g., CD69, CD86, and CD25) using a reputable supplier (e.g., BD Biosciences).
* Prepare a fixation and permeabilization buffer (e.g., BD Cytofix/Cytoperm) according to the manufacturer's protocol.

5.2. Perform flow cytometry:

* Stain control and ARHGEF1-knockdown/knockout B cells with the antibody panel according to the manufacturer's protocol.
* Analyze cells using a flow cytometer (e.g., BD FACSCanto II) to detect B cell activation markers.

5.3. Perform Western blotting:

* Extract total protein from control and ARHGEF1-knockdown/knockout B cells using a lysis buffer (e.g., RIPA).
* Perform Western blotting using the antibody panel to detect B cell activation markers.

**Step 6: Data Analysis and Interpretation**

6.1. Analyze data:

* Compare INPP5B activity, actin dynamics, and B cell activation between control and ARHGEF1-knockdown/knockout B cells.
* Perform statistical analysis (e.g., t-test, ANOVA) to determine significant differences.

6.2. Interpret data:

* If the data show no significant differences between control and ARHGEF1-knockdown/knockout B cells, it would suggest that the hypothesis is false, and ARHGEF1 does not regulate INPP5B-mediated PIP2 hydrolysis, actin dynamics, and B cell activation.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols, safety guidelines, and quality control measures to ensure the accuracy and reproducibility of the results.","```
   FBS  Penicillin-Streptomycin  L-Glutamine  Anti-IgM  ARHGEF1 siRNA  CRISPR-Cas9  PIP2  Malachite Green  Hoechst 33342  INPP5B Activity  Actin Filament Length  Actin Dynamics Rate  CD69  CD86  CD25
0   8.0               0.8           0.8      15.0           20.0           0.0   8.0           0.5           8.0           0.012           1.20           0.050           30.0  40.0  20.0
1   9.0               0.9           0.9      18.0           22.0           0.0   9.0           0.6           9.0           0.015           1.30           0.060           35.0  45.0  25.0
2  10.0               1.0           1.0      20.0           25.0           0.0  10.0           0.7           10.0           0.018           1.40           0.070           40.0  50.0  30.0
3   8.5               0.85          0.85      16.5           21.5           0.0   8.5           0.55          8.5           0.013           1.25           0.055           32.5  42.5  22.5
4   9.5               0.95          0.95      19.5           24.5           0.0   9.5           0.65          9.5           0.017           1.35           0.065           37.5  47.5  27.5
5   7.0               0.7           0.7      12.0           17.0           0.0   7.0           0.4           7.0           0.010           1.10           0.040           25.0  35.0  18.0
6   8.0               0.8           0.8      14.0           19.0           0.0   8.0           0.5           8.0           0.012           1.20           0.050           28.0  38.0  20.0
7   9.0               0.9           0.9      16.0           21.0           0.0   9.0           0.6           9.0           0.015           1.30           0.060           32.0  42.0  24.0
8  10.0               1.0           1.0      18.0           23.0           0.0  10.0           0.7           10.0           0.018           1.40           0.070           36.0  46.0  28.0
9   7.5               0.75          0.75      13.5           18.5           0.0   7.5           0.45          7.5           0.011           1.15           0.045           26.5  36.5  19.5
10  8.5               0.85          0.85      15.5           20.5           0.0   8.5           0.55          8.5           0.014           1.25           0.055           30.5  40.5  22.5
11  9.5               0.95          0.95      17.5           22.5           0.0   9.5           0.65          9.5           0.017           1.35           0.065           34.5  44.5  26.5
12  7.0               0.7           0.7      12.0           17.0           0.0   7.0           0.4           7.0           0.010           1.10           0.040           24.0  34.0  17.0
13  8.0               0.8           0.8      14.0           19.0           0.0   8.0           0.5           8.0           0.012           1.20           0.050           27.0  37.0  20.0
14  9.0               0.9           0.9      16.0           21.0           0.0   9.0           0.6           9.0           0.015           1.30           0.060           31.0  41.0  23.0
15 10.0               1.0           1.0      18.0           23.0           0.0  10.0           0.7           10.0           0.018           1.40           0.070           35.0  45.0  27.0
16  7.5               0.75          0.75      13.5           18.5           0.0   7.5           0.45          7.5           0.011           1.15           0.045           25.5  35.5  19.5
17  8.5               0.85          0.85      15.5           20.5           0.0   8.5           0.55          8.5           0.014           1.25           0.055           29.5  39.5  22.5
18  9.5               0.95          0.95      17.5           22.5           0.0   9.5           0.65          9.5           0.017           1.35           0.065           33.5  43.5  26.5
19  7.0               0.7           0.7      12.0           17.0           0.0   7.0           0.4           7.0           0.010           1.10           0.040           23.0  33.0  17.0
20  8.0               0.8           0.8      14.0           19.0           0.0   8.0           0.5           8.0           0.012           1.20           0.050           26.0  36.0  20.0
21  9.0               0.9           0.9      16.0           21.0           0.0   9.0           0.6           9.0           0.015           1.30           0.060           30.0  40.0  23.0
22 10.0               1.0           1.0      18.0           23.0           0.0  10.0           0.7           10.0           0.018           1.40           0.070           34.0  44.0  27.0
23  7.5               0.75          0.75      13.5           18.5           0.0   7.5           0.45          7.5           0.011           1.15           0.045           24.5  34.5  19.5
24  8.5               0.85          0.85      15.5           20.5           0.0   8.5           0.55          8.5           0.014           1.25           0.055           28.5  38.5  22.5
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/016a66c182442bf672c85a13339ce723e2655f59.summary'],Does ATF4-mediated suppression of RTA promoter activity during ER stress also lead to the upregulation of antiviral interferon-stimulated genes in infected B cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Does ATF4-mediated suppression of RTA promoter activity during ER stress also lead to the upregulation of antiviral interferon-stimulated genes in infected B cells?""

**Experimental Approach:**

To disprove the hypothesis, we will design an experiment to test the following:

1. ATF4-mediated suppression of RTA promoter activity during ER stress
2. Upregulation of antiviral interferon-stimulated genes in infected B cells

**Experiment 1: ATF4-mediated suppression of RTA promoter activity during ER stress**

* Objective: To investigate if ATF4 suppresses RTA promoter activity during ER stress in infected B cells.
* Methodology:
	+ Infect M12 cells with MHV68 and treat them with ER stress inducers (e.g., tunicamycin or thapsigargin) to activate the unfolded protein response (UPR).
	+ Co-transfect the cells with an RTA promoter-luciferase reporter plasmid and an ATF4 expression plasmid.
	+ Measure luciferase activity using a luminometer to assess RTA promoter activity.
	+ Compare the results to a control group without ATF4 overexpression.
* Expected outcome: If the hypothesis is true, ATF4 overexpression should suppress RTA promoter activity during ER stress.

**Experiment 2: Upregulation of antiviral interferon-stimulated genes in infected B cells**

* Objective: To investigate if ATF4-mediated suppression of RTA promoter activity during ER stress leads to the upregulation of antiviral interferon-stimulated genes in infected B cells.
* Methodology:
	+ Infect M12 cells with MHV68 and treat them with ER stress inducers (e.g., tunicamycin or thapsigargin) to activate the UPR.
	+ Overexpress ATF4 in the infected cells using a lentiviral vector or transfection.
	+ Perform RNA sequencing (RNA-seq) or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to analyze the expression of antiviral interferon-stimulated genes (e.g., IFN-β, ISG15, or OAS1).
	+ Compare the results to a control group without ATF4 overexpression.
* Expected outcome: If the hypothesis is true, ATF4 overexpression should lead to the upregulation of antiviral interferon-stimulated genes in infected B cells during ER stress.

**Experiment 3: Rescue experiment**

* Objective: To investigate if the upregulation of antiviral interferon-stimulated genes is dependent on ATF4-mediated suppression of RTA promoter activity.
* Methodology:
	+ Infect M12 cells with MHV68 and treat them with ER stress inducers (e.g., tunicamycin or thapsigargin) to activate the UPR.
	+ Overexpress ATF4 in the infected cells using a lentiviral vector or transfection.
	+ Co-transfect the cells with an RTA expression plasmid to rescue RTA promoter activity.
	+ Perform RNA sequencing (RNA-seq) or qRT-PCR to analyze the expression of antiviral interferon-stimulated genes.
	+ Compare the results to a control group without ATF4 overexpression or RTA rescue.
* Expected outcome: If the hypothesis is true, rescuing RTA promoter activity should abolish the upregulation of antiviral interferon-stimulated genes.

**Equipment and Resources:**

* M12 cells
* MHV68 virus
* ER stress inducers (e.g., tunicamycin or thapsigargin)
* Luciferase reporter plasmid
* ATF4 expression plasmid
* RTA expression plasmid
* Lentiviral vector
* Luminometer
* RNA sequencing (RNA-seq) or qRT-PCR equipment
* Bioinformatics tools for data analysis

**Timeline:**

* Experiment 1: 2-3 weeks
* Experiment 2: 4-6 weeks
* Experiment 3: 6-8 weeks
* Data analysis and interpretation: 2-3 months

**Budget:**

* Reagents and consumables: $10,000 - $15,000
* Equipment and instrumentation: $50,000 - $100,000
* Personnel and labor: $100,000 - $200,000
* Total budget: $160,000 - $315,000

This experimental plan is designed to test the hypothesis and provide a comprehensive understanding of the role of ATF4 in regulating RTA promoter activity and antiviral interferon-stimulated genes in infected B cells during ER stress.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Experiment 1: ATF4-mediated suppression of RTA promoter activity during ER stress**

**Step 1: Cell Culture and Infection**

1.1. Obtain M12 cells and maintain them in a humidified incubator at 37°C, 5% CO2 in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. Infect M12 cells with MHV68 virus at a multiplicity of infection (MOI) of 1-5. Incubate the cells for 1-2 hours to allow for virus attachment and entry.

**Step 2: ER Stress Induction and ATF4 Overexpression**

2.1. Treat the infected M12 cells with ER stress inducers (e.g., tunicamycin or thapsigargin) at a final concentration of 1-5 μg/mL for 24-48 hours to activate the unfolded protein response (UPR).

2.2. Co-transfect the cells with an RTA promoter-luciferase reporter plasmid (1 μg) and an ATF4 expression plasmid (1 μg) using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

**Step 3: Luciferase Assay**

3.1. Harvest the cells 24-48 hours post-transfection and wash them with PBS.

3.2. Lyse the cells using a lysis buffer (e.g., Passive Lysis Buffer) and centrifuge at 12,000 x g for 1 minute to remove cell debris.

3.3. Measure luciferase activity using a luminometer (e.g., Promega GloMax) according to the manufacturer's instructions.

**Step 4: Data Analysis**

4.1. Calculate the relative luciferase activity by normalizing the luciferase readings to the protein concentration or cell number.

4.2. Compare the luciferase activity between the ATF4-overexpressing group and the control group without ATF4 overexpression.

**Experiment 2: Upregulation of antiviral interferon-stimulated genes in infected B cells**

**Step 1: Cell Culture and Infection**

1.1. Obtain M12 cells and maintain them in a humidified incubator at 37°C, 5% CO2 in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. Infect M12 cells with MHV68 virus at a multiplicity of infection (MOI) of 1-5. Incubate the cells for 1-2 hours to allow for virus attachment and entry.

**Step 2: ER Stress Induction and ATF4 Overexpression**

2.1. Treat the infected M12 cells with ER stress inducers (e.g., tunicamycin or thapsigargin) at a final concentration of 1-5 μg/mL for 24-48 hours to activate the UPR.

2.2. Overexpress ATF4 in the infected cells using a lentiviral vector or transfection with an ATF4 expression plasmid (1 μg) using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

**Step 3: RNA Isolation and Sequencing**

3.1. Harvest the cells 24-48 hours post-infection and wash them with PBS.

3.2. Isolate total RNA using a RNA isolation kit (e.g., TRIzol) according to the manufacturer's instructions.

3.3. Perform RNA sequencing (RNA-seq) or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to analyze the expression of antiviral interferon-stimulated genes (e.g., IFN-β, ISG15, or OAS1).

**Step 4: Data Analysis**

4.1. Analyze the RNA-seq or qRT-PCR data using bioinformatics tools (e.g., DESeq2 or edgeR) to identify differentially expressed genes.

4.2. Compare the expression levels of antiviral interferon-stimulated genes between the ATF4-overexpressing group and the control group without ATF4 overexpression.

**Experiment 3: Rescue Experiment**

**Step 1: Cell Culture and Infection**

1.1. Obtain M12 cells and maintain them in a humidified incubator at 37°C, 5% CO2 in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. Infect M12 cells with MHV68 virus at a multiplicity of infection (MOI) of 1-5. Incubate the cells for 1-2 hours to allow for virus attachment and entry.

**Step 2: ER Stress Induction and ATF4 Overexpression**

2.1. Treat the infected M12 cells with ER stress inducers (e.g., tunicamycin or thapsigargin) at a final concentration of 1-5 μg/mL for 24-48 hours to activate the UPR.

2.2. Overexpress ATF4 in the infected cells using a lentiviral vector or transfection with an ATF4 expression plasmid (1 μg) using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

**Step 3: RTA Rescue and RNA Isolation**

3.1. Co-transfect the cells with an RTA expression plasmid (1 μg) using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

3.2. Harvest the cells 24-48 hours post-transfection and wash them with PBS.

3.3. Isolate total RNA using a RNA isolation kit (e.g., TRIzol) according to the manufacturer's instructions.

**Step 4: RNA Sequencing and Data Analysis**

4.1. Perform RNA sequencing (RNA-seq) or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to analyze the expression of antiviral interferon-stimulated genes.

4.2. Analyze the RNA-seq or qRT-PCR data using bioinformatics tools (e.g., DESeq2 or edgeR) to identify differentially expressed genes.

4.3. Compare the expression levels of antiviral interferon-stimulated genes between the ATF4-overexpressing group with RTA rescue and the control group without ATF4 overexpression or RTA rescue.

These detailed protocols should provide a clear guide for executing the experiments and collecting data to test the hypothesis.","```
   MOI  Tunicamycin ATF4_plasmid RTA_plasmid Luciferase_Activity
0    1.0         2.0         0.5         0.0         0.800000
1    3.0         1.0         1.0         0.0         0.600000
2    2.0         3.0         0.8         0.0         0.450000
3    1.0         1.0         0.2         0.0         0.900000
4    4.0         2.0         1.2         0.0         0.350000
5    2.0         1.0         0.5         0.0         0.750000
6    3.0         3.0         0.8         0.0         0.400000
7    1.0         2.0         0.2         0.0         0.850000
8    4.0         1.0         1.0         0.0         0.500000
9    2.0         2.0         0.5         0.0         0.650000
10   3.0         1.0         0.8         0.0         0.550000
11   1.0         3.0         0.2         0.0         0.700000
12   4.0         2.0         1.2         0.0         0.400000
13   2.0         1.0         0.5         0.0         0.600000
14   3.0         3.0         0.8         0.0         0.450000
15   1.0         2.0         0.2         0.0         0.800000
16   4.0         1.0         1.0         0.0         0.500000
17   2.0         2.0         0.5         0.5         0.900000
18   3.0         1.0         0.8         0.5         0.700000
19   1.0         3.0         0.2         0.5         0.850000
20   4.0         2.0         1.2         0.5         0.600000
21   2.0         1.0         0.5         0.5         0.750000
22   3.0         3.0         0.8         0.5         0.550000
23   1.0         2.0         0.2         0.5         0.800000
24   4.0         1.0         1.0         0.5         0.500000
```",0.3639126617009649
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0264ee630388b3d80d2e19245a7e9906774ce2c2.summary'],"Does BAFF depletion in aged mice also improve cognitive function by increasing thermogenesis in brown adipose tissue, leading to enhanced neurotrophic factor production and reduced neuroinflammation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of BAFF Depletion on Cognitive Function, Thermogenesis, and Neurotrophic Factor Production in Aged Mice

**Objective:** To determine if BAFF depletion in aged mice improves cognitive function by increasing thermogenesis in brown adipose tissue, leading to enhanced neurotrophic factor production and reduced neuroinflammation.

**Equipment:**

* Mouse models of BAFF depletion and age-matched wild-type controls
* Morris water maze or radial arm maze for cognitive function assessment
* Thermocouples for measuring body temperature
* qRT-PCR and Western blot for gene and protein expression analysis
* ELISA for serum neurotrophic factor measurement
* Flow cytometry for immune cell analysis
* Brain tissue collection and processing equipment

**Steps:**

1. Generate BAFF-depleted mice and age-match them to wild-type controls.
2. Assess cognitive function using the Morris water maze or radial arm maze at baseline and after 4-6 weeks of BAFF depletion.
3. Measure rectal temperature and glucose tolerance in both groups.
4. Isolate brown adipose tissue and analyze gene expression of thermogenic genes (UCP1, Dio2, PGC1α) and neurotrophic factors (BDNF, NGF) using qRT-PCR.
5. Analyze protein expression of UCP1 and neurotrophic factors using Western blot.
6. Measure serum concentrations of neurotrophic factors using ELISA.
7. Isolate immune cells from brain tissue and analyze neuroinflammation markers (TNF-α, IL-1β) using flow cytometry.
8. Perform histological analysis of brain tissue to assess neuroinflammation and neuronal health.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of BAFF Depletion on Cognitive Function in Aged Mice with Inhibited Thermogenesis

**Objective:** To determine if BAFF depletion in aged mice fails to improve cognitive function when thermogenesis in brown adipose tissue is inhibited.

**Equipment:**

* Mouse models of BAFF depletion and age-matched wild-type controls
* β3-adrenergic receptor antagonist (e.g., SR59230A) to inhibit thermogenesis
* Morris water maze or radial arm maze for cognitive function assessment
* Thermocouples for measuring body temperature
* qRT-PCR and Western blot for gene and protein expression analysis
* ELISA for serum neurotrophic factor measurement
* Flow cytometry for immune cell analysis
* Brain tissue collection and processing equipment

**Steps:**

1. Generate BAFF-depleted mice and age-match them to wild-type controls.
2. Treat BAFF-depleted mice with β3-adrenergic receptor antagonist to inhibit thermogenesis.
3. Assess cognitive function using the Morris water maze or radial arm maze at baseline and after 4-6 weeks of BAFF depletion and thermogenesis inhibition.
4. Measure rectal temperature and glucose tolerance in both groups.
5. Isolate brown adipose tissue and analyze gene expression of thermogenic genes (UCP1, Dio2, PGC1α) and neurotrophic factors (BDNF, NGF) using qRT-PCR.
6. Analyze protein expression of UCP1 and neurotrophic factors using Western blot.
7. Measure serum concentrations of neurotrophic factors using ELISA.
8. Isolate immune cells from brain tissue and analyze neuroinflammation markers (TNF-α, IL-1β) using flow cytometry.
9. Perform histological analysis of brain tissue to assess neuroinflammation and neuronal health.

By designing an experiment to disprove the hypothesis, we can test the robustness of the original hypothesis and provide more confidence in the results. If the experiment to disprove the hypothesis fails to do so, it would strengthen the evidence supporting the original hypothesis.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Investigating the Role of BAFF Depletion on Cognitive Function, Thermogenesis, and Neurotrophic Factor Production in Aged Mice**

**Step 1: Generate BAFF-depleted mice and age-match them to wild-type controls**

* Obtain BAFF knockout mice (BAFF-/-) and age-match them to wild-type (WT) mice.
* Verify the genotype of the mice using PCR or Southern blot analysis.
* House the mice in a controlled environment with a 12-hour light-dark cycle and ad libitum access to food and water.
* Monitor the mice for 4-6 weeks to ensure they are healthy and acclimated to their environment.

**Step 2: Assess cognitive function using the Morris water maze or radial arm maze**

* Train the mice to perform the Morris water maze or radial arm maze task according to established protocols.
* Record the time taken to complete the task and the number of errors made.
* Perform the task at baseline (before BAFF depletion) and after 4-6 weeks of BAFF depletion.

**Step 3: Measure rectal temperature and glucose tolerance**

* Measure rectal temperature using a thermocouple inserted 1-2 cm into the rectum.
* Record the temperature in degrees Celsius.
* Perform a glucose tolerance test by injecting 2 g/kg glucose intraperitoneally and measuring blood glucose levels at 0, 15, 30, 60, and 120 minutes using a glucometer.

**Step 4: Isolate brown adipose tissue and analyze gene expression**

* Sacrifice the mice and dissect out the brown adipose tissue (BAT) from the interscapular region.
* Homogenize the BAT tissue in TRIzol reagent and extract RNA using a standard protocol.
* Perform qRT-PCR analysis using primers specific for thermogenic genes (UCP1, Dio2, PGC1α) and neurotrophic factors (BDNF, NGF).
* Normalize the data to a housekeeping gene (e.g., GAPDH) and calculate the fold change in gene expression.

**Step 5: Analyze protein expression using Western blot**

* Homogenize the BAT tissue in RIPA buffer and extract protein using a standard protocol.
* Perform Western blot analysis using antibodies specific for UCP1 and neurotrophic factors (BDNF, NGF).
* Normalize the data to a loading control (e.g., β-actin) and calculate the fold change in protein expression.

**Step 6: Measure serum concentrations of neurotrophic factors**

* Collect blood samples from the mice via cardiac puncture or tail vein bleeding.
* Isolate serum using a standard protocol.
* Perform ELISA analysis using kits specific for BDNF and NGF.
* Calculate the concentration of neurotrophic factors in pg/mL.

**Step 7: Isolate immune cells from brain tissue and analyze neuroinflammation markers**

* Sacrifice the mice and dissect out the brain tissue.
* Isolate immune cells (e.g., microglia, astrocytes) using a standard protocol (e.g., density gradient centrifugation).
* Perform flow cytometry analysis using antibodies specific for neuroinflammation markers (TNF-α, IL-1β).
* Calculate the percentage of positive cells and the mean fluorescence intensity.

**Step 8: Perform histological analysis of brain tissue**

* Fix the brain tissue in 4% paraformaldehyde and embed in paraffin.
* Section the tissue into 5-μm thick slices and stain with hematoxylin and eosin.
* Analyze the tissue for signs of neuroinflammation and neuronal health using a microscope.

**Experiment to Disprove the Hypothesis: Investigating the Role of BAFF Depletion on Cognitive Function in Aged Mice with Inhibited Thermogenesis**

**Step 1: Generate BAFF-depleted mice and age-match them to wild-type controls**

* Follow the same protocol as Step 1 in the experiment to test the hypothesis.

**Step 2: Treat BAFF-depleted mice with β3-adrenergic receptor antagonist**

* Administer the β3-adrenergic receptor antagonist (e.g., SR59230A) to the BAFF-depleted mice via intraperitoneal injection at a dose of 1 mg/kg body weight.
* Treat the mice for 4-6 weeks to inhibit thermogenesis.

**Step 3: Assess cognitive function using the Morris water maze or radial arm maze**

* Follow the same protocol as Step 2 in the experiment to test the hypothesis.

**Step 4: Measure rectal temperature and glucose tolerance**

* Follow the same protocol as Step 3 in the experiment to test the hypothesis.

**Step 5: Isolate brown adipose tissue and analyze gene expression**

* Follow the same protocol as Step 4 in the experiment to test the hypothesis.

**Step 6: Analyze protein expression using Western blot**

* Follow the same protocol as Step 5 in the experiment to test the hypothesis.

**Step 7: Measure serum concentrations of neurotrophic factors**

* Follow the same protocol as Step 6 in the experiment to test the hypothesis.

**Step 8: Isolate immune cells from brain tissue and analyze neuroinflammation markers**

* Follow the same protocol as Step 7 in the experiment to test the hypothesis.

**Step 9: Perform histological analysis of brain tissue**

* Follow the same protocol as Step 8 in the experiment to test the hypothesis.

By following these detailed, step-by-step protocols, the experiments can be replicated and the results can be compared to test the hypothesis and provide confidence in the findings.","```
   BAFF_depletion  β3_antagonist  Cognitive_function  Rectal_temperature  Glucose_tolerance  UCP1_expression  BDNF_expression  NGF_expression  Neuroinflammation
0               1.0           0.0          80.123111         36.543210         120.000000       1.234567       2.345678       3.456789       0.123456
1               0.5           0.5          70.432109         35.678543         110.000000       1.111111       2.222222       3.333333       0.234567
2               0.0           1.0          60.741096         34.812345         100.000000       0.987654       1.987654       2.987654       0.345678
3               1.0           0.5          85.678543         37.234567         130.000000       1.456789       2.678543       3.890123       0.456789
4               0.5           0.0          75.345678         36.012345         115.000000       1.234567       2.345678       3.456789       0.567890
5               0.0           0.0          65.901234         35.456789         105.000000       0.876543       1.876543       2.876543       0.678901
6               1.0           1.0          90.123456         38.567890         140.000000       1.678901       2.890123       4.123456       0.789012
7               0.5           0.5          80.567890         36.890123         125.000000       1.345678       2.567890       3.789012       0.890123
8               0.0           0.5          70.234567         35.678901         110.000000       1.012345       2.012345       3.012345       0.901234
9               1.0           0.0          85.901234         37.012345         130.000000       1.567890       2.789012       3.901234       0.012345
10              0.5           1.0          75.678901         36.345678         115.000000       1.234567       2.345678       3.456789       0.123456
11              0.0           0.0          65.456789         35.123456         105.000000       0.987654       1.987654       2.987654       0.234567
12              1.0           0.5          90.345678         38.234567         140.000000       1.789012       2.901234       4.012345       0.345678
13              0.5           0.0          80.012345         36.567890         120.000000       1.345678       2.567890       3.789012       0.456789
14              0.0           1.0          70.890123         35.901234         110.000000       1.012345       2.012345       3.012345       0.567890
15              1.0           1.0          95.678901         39.012345         150.000000       1.901234       3.012345       4.234567       0.678901
16              0.5           0.5          80.901234         37.012345         125.000000       1.456789       2.678543       3.890123       0.789012
17              0.0           0.0          65.123456         34.890123         100.000000       0.876543       1.876543       2.876543       0.890123
18              1.0           0.0          90.012345         38.456789         140.000000       1.678901       2.890123       4.123456       0.901234
19              0.5           1.0          75.234567         36.789012         115.000000       1.234567       2.345678       3.456789       0.012345
20              0.0           0.5          70.567890         35.901234         110.000000       1.012345       2.012345       3.012345       0.123456
21              1.0           0.5          95.123456         39.345678         150.000000       1.890123       3.012345       4.345678       0.234567
22              0.5           0.0          80.456789         37.234567         125.000000       1.567890       2.789012       3.901234       0.345678
23              0.0           1.0          70.012345         35.678901         105.000000       0.987654       1.987654       2.987654       0.456789
24              1.0           1.0          100.123456       40.123456         160.000000       2.012345       3.234567       4.567890       0.567890
```",0.04083662004368677
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/62299b2adb068bfaa5a94c759330e00753fd5388.summary'],"Does CD55-mediated regulation of heat shock proteins in marginal zone B cells also influence the expression of TLR9, thereby modulating the immune response to nucleic acid-based antigens?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** CD55-mediated regulation of heat shock proteins in marginal zone B cells also influences the expression of TLR9, thereby modulating the immune response to nucleic acid-based antigens.

**Experimental Plan:**

**Objective:** To determine whether CD55-mediated regulation of heat shock proteins in marginal zone B cells affects TLR9 expression and the immune response to nucleic acid-based antigens.

**Equipment:**

* Flow cytometer
* qRT-PCR machine
* Western blot equipment
* Heat shock protein antibodies
* TLR9 antibodies
* Nucleic acid-based antigens (e.g., CpG oligonucleotides)
* Cell culture facilities

**Steps:**

1. Isolate marginal zone B cells from CD55-deficient and wild-type mice.
2. Perform qRT-PCR to measure the expression of TLR9 mRNA in CD55-deficient and wild-type marginal zone B cells.
3. Perform Western blot to measure the protein levels of TLR9 in CD55-deficient and wild-type marginal zone B cells.
4. Use flow cytometry to measure the surface expression of TLR9 on CD55-deficient and wild-type marginal zone B cells.
5. Stimulate CD55-deficient and wild-type marginal zone B cells with nucleic acid-based antigens (e.g., CpG oligonucleotides) and measure the immune response (e.g., cytokine production, cell proliferation).
6. Use a heat shock protein inhibitor to block the activity of heat shock proteins in wild-type marginal zone B cells and measure the effect on TLR9 expression and the immune response to nucleic acid-based antigens.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that CD55-mediated regulation of heat shock proteins in marginal zone B cells does not influence TLR9 expression or the immune response to nucleic acid-based antigens.

**Design:**

1. Use CRISPR-Cas9 gene editing to specifically knockdown heat shock protein genes (e.g., HSP90, HSP70) in CD55-deficient marginal zone B cells.
2. Measure TLR9 expression and the immune response to nucleic acid-based antigens in these cells.
3. Compare the results to CD55-deficient marginal zone B cells without heat shock protein knockdown.

**Rationale:** If the hypothesis is true, knocking down heat shock proteins in CD55-deficient marginal zone B cells should rescue TLR9 expression and the immune response to nucleic acid-based antigens. If the results show no difference or an opposite effect, it would suggest that CD55-mediated regulation of heat shock proteins does not influence TLR9 expression or the immune response to nucleic acid-based antigens, thereby disproving the hypothesis.

**Time and Resource Considerations:**

* This experiment can be completed within 3-4 months with a moderate budget.
* The required equipment is already listed in the provided paper, and the necessary reagents and antibodies can be obtained from commercial sources.
* The experiment requires a moderate level of technical expertise in molecular biology, cell culture, and flow cytometry.

By following this experimental plan, you can test the hypothesis and determine whether CD55-mediated regulation of heat shock proteins in marginal zone B cells influences TLR9 expression and the immune response to nucleic acid-based antigens.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: Isolate Marginal Zone B Cells from CD55-Deficient and Wild-Type Mice**

1.1. Obtain CD55-deficient and wild-type mice from a reputable supplier or breeding facility.

1.2. Euthanize the mice according to institutional animal care and use committee (IACUC) guidelines.

1.3. Harvest the spleens from the mice and place them in a sterile petri dish.

1.4. Prepare a single-cell suspension of splenocytes by gently teasing the spleen apart with forceps and passing the cells through a 40-μm cell strainer.

1.5. Centrifuge the cell suspension at 300 x g for 5 minutes to remove debris.

1.6. Resuspend the cells in 1 mL of phosphate-buffered saline (PBS) and count the cells using a hemocytometer.

1.7. Stain the cells with anti-mouse CD1d (PE) and anti-mouse CD23 (FITC) antibodies to identify marginal zone B cells.

1.8. Sort the stained cells using a fluorescence-activated cell sorter (FACS) to isolate marginal zone B cells (CD1d+CD23-).

**Step 2: Measure TLR9 mRNA Expression by qRT-PCR**

2.1. Extract total RNA from the isolated marginal zone B cells using a commercial RNA extraction kit (e.g., TRIzol).

2.2. Perform DNase treatment to remove genomic DNA.

2.3. Reverse transcribe the RNA to cDNA using a commercial reverse transcription kit (e.g., SuperScript III).

2.4. Design and synthesize TLR9-specific primers and probes for qRT-PCR.

2.5. Perform qRT-PCR using a commercial qRT-PCR machine (e.g., ABI 7500) with the following conditions:
	* 95°C for 10 minutes
	* 40 cycles of 95°C for 15 seconds, 60°C for 1 minute
	* Melt curve analysis to verify specificity

2.6. Normalize TLR9 mRNA expression to a housekeeping gene (e.g., GAPDH) and calculate the relative expression using the 2^(-ΔΔCt) method.

**Step 3: Measure TLR9 Protein Expression by Western Blot**

3.1. Lyse the isolated marginal zone B cells in RIPA buffer with protease inhibitors.

3.2. Centrifuge the lysate at 10,000 x g for 10 minutes to remove debris.

3.3. Determine the protein concentration using a commercial protein assay kit (e.g., Bradford).

3.4. Separate 20 μg of protein per lane on a 10% SDS-PAGE gel.

3.5. Transfer the proteins to a PVDF membrane using a commercial transfer kit (e.g., iBlot).

3.6. Block the membrane with 5% milk in TBST for 1 hour.

3.7. Incubate the membrane with anti-TLR9 antibody (1:1000) overnight at 4°C.

3.8. Wash the membrane with TBST and incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour.

3.9. Develop the membrane using a commercial ECL kit (e.g., SuperSignal West Pico).

**Step 4: Measure Surface TLR9 Expression by Flow Cytometry**

4.1. Stain the isolated marginal zone B cells with anti-TLR9 antibody (1:100) and a live/dead marker (e.g., Zombie Aqua) for 30 minutes on ice.

4.2. Wash the cells with PBS and resuspend in 1 mL of PBS.

4.3. Analyze the cells using a flow cytometer (e.g., BD LSRFortessa) with the following settings:
	* Forward scatter (FSC) vs. side scatter (SSC) to gate on live cells
	* TLR9-PE vs. FSC to gate on TLR9+ cells

4.4. Calculate the percentage of TLR9+ cells and mean fluorescence intensity (MFI) using flow cytometry software (e.g., FlowJo).

**Step 5: Stimulate Marginal Zone B Cells with Nucleic Acid-Based Antigens**

5.1. Culture the isolated marginal zone B cells in complete RPMI medium with 10% FBS and 1% penicillin-streptomycin.

5.2. Stimulate the cells with 1 μM CpG oligonucleotides (e.g., ODN 1826) for 24 hours.

5.3. Measure cytokine production (e.g., IL-6, TNF-α) using a commercial ELISA kit (e.g., R&D Systems).

5.4. Measure cell proliferation using a commercial cell proliferation kit (e.g., CellTiter 96 AQueous One).

**Step 6: Use a Heat Shock Protein Inhibitor to Block Heat Shock Protein Activity**

6.1. Treat wild-type marginal zone B cells with 10 μM of a heat shock protein inhibitor (e.g., 17-AAG) for 1 hour.

6.2. Stimulate the cells with 1 μM CpG oligonucleotides for 24 hours.

6.3. Measure TLR9 expression and the immune response to nucleic acid-based antigens as described in Steps 2-5.

**Experiment to Disprove the Hypothesis:**

**Step 1: CRISPR-Cas9 Gene Editing to Knockdown Heat Shock Protein Genes**

1.1. Design and synthesize guide RNAs (gRNAs) targeting heat shock protein genes (e.g., HSP90, HSP70) using a commercial CRISPR design tool (e.g., CRISPR Design).

1.2. Prepare CRISPR-Cas9 ribonucleoprotein (RNP) complexes according to the manufacturer's instructions.

1.3. Electroporate the RNP complexes into CD55-deficient marginal zone B cells using a commercial electroporation system (e.g., Neon).

1.4. Culture the cells in complete RPMI medium with 10% FBS and 1% penicillin-streptomycin.

**Step 2: Measure TLR9 Expression and the Immune Response to Nucleic Acid-Based Antigens**

2.1. Measure TLR9 mRNA expression and protein levels using qRT-PCR and Western blot, respectively, as described in Steps 2 and 3.

2.2. Stimulate the cells with 1 μM CpG oligonucleotides for 24 hours.

2.3. Measure cytokine production and cell proliferation as described in Step 5.

**Step 3: Compare Results to CD55-Deficient Marginal Zone B Cells without Heat Shock Protein Knockdown**

3.1. Compare the results from Step 2 to CD55-deficient marginal zone B cells without heat shock protein knockdown.

3.2. If the results show no difference or an opposite effect, it would suggest that CD55-mediated regulation of heat shock proteins does not influence TLR9 expression or the immune response to nucleic acid-based antigens, thereby disproving the hypothesis.

Note: All experiments should be performed in triplicate, and the results should be analyzed using appropriate statistical software (e.g., GraphPad Prism) to determine significance.","```
   CD55-deficient  Wild-type  CpG oligonucleotides  Heat Shock Protein Inhibitor  TLR9 mRNA  TLR9 Protein  Surface TLR9  IL-6  TNF-α  Cell Proliferation
0              1.0       0.0                    1.0                     0.0  2.345678  1.234567    0.567890  100.0  50.0           0.8
1              0.5       0.5                    1.0                     0.0  1.987654  1.111111    0.444444  80.0  40.0           0.6
2              0.0       1.0                    1.0                     0.0  1.654321  0.987654    0.333333  60.0  30.0           0.4
3              1.0       0.0                    0.5                     0.0  2.111111  1.444444    0.666667  120.0  60.0           1.0
4              0.5       0.5                    0.5                     0.0  1.777778  1.222222    0.555556  90.0  45.0           0.7
5              0.0       1.0                    0.5                     0.0  1.555556  0.888889    0.400000  70.0  35.0           0.5
6              1.0       0.0                    1.0                     5.0  2.500000  1.666667    0.800000  140.0  70.0           1.2
7              0.5       0.5                    1.0                     5.0  2.250000  1.500000    0.700000  110.0  55.0           0.9
8              0.0       1.0                    1.0                     5.0  2.000000  1.333333    0.600000  100.0  50.0           0.8
9              1.0       0.0                    0.5                     5.0  2.333333  1.555556    0.733333  130.0  65.0           1.1
10             0.5       0.5                    0.5                     5.0  2.100000  1.400000    0.650000  100.0  50.0           0.8
11             0.0       1.0                    0.5                     5.0  1.866667  1.200000    0.533333  90.0  45.0           0.7
12             1.0       0.0                    1.0                     0.0  2.200000  1.400000    0.600000  110.0  55.0           0.9
13             0.5       0.5                    1.0                     0.0  2.000000  1.250000    0.550000  90.0  45.0           0.7
14             0.0       1.0                    1.0                     0.0  1.800000  1.100000    0.500000  80.0  40.0           0.6
15             1.0       0.0                    0.5                     0.0  2.100000  1.350000    0.650000  100.0  50.0           0.8
16             0.5       0.5                    0.5                     0.0  1.950000  1.200000    0.575000  90.0  45.0           0.7
17             0.0       1.0                    0.5                     0.0  1.750000  1.050000    0.475000  80.0  40.0           0.6
18             1.0       0.0                    1.0                     5.0  2.400000  1.600000    0.800000  130.0  65.0           1.1
19             0.5       0.5                    1.0                     5.0  2.250000  1.450000    0.725000  110.0  55.0           0.9
20             0.0       1.0                    1.0                     5.0  2.100000  1.350000    0.650000  100.0  50.0           0.8
21             1.0       0.0                    0.5                     5.0  2.300000  1.500000    0.750000  120.0  60.0           1.0
22             0.5       0.5                    0.5                     5.0  2.150000  1.300000    0.675000  100.0  50.0           0.8
23             0.0       1.0                    0.5                     5.0  2.050000  1.250000    0.625000  90.0  45.0           0.7
24             1.0       0.0                    1.0                     0.0  2.350000  1.550000    0.750000  130.0  65.0           1.1
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/057142211713eb27dcb2f9235b591cdce127c39b.summary'],"Does CDX-1140-induced activation of antigen-presenting cells lead to the production of specific cytokines that enhance the recruitment and activation of natural killer cells, thereby augmenting the anti-tumor immune response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** CDX-1140-induced activation of antigen-presenting cells leads to the production of specific cytokines that enhance the recruitment and activation of natural killer cells, thereby augmenting the anti-tumor immune response.

**Experimental Plan:**

**Objective:** To investigate whether CDX-1140-induced activation of antigen-presenting cells (APCs) leads to the production of specific cytokines that enhance the recruitment and activation of natural killer (NK) cells, ultimately augmenting the anti-tumor immune response.

**Experimental Design:**

1. **Cell Culture:**
	* Isolate and culture human peripheral blood mononuclear cells (PBMCs) from healthy donors.
	* Isolate and culture human tumor cells (e.g., melanoma or breast cancer cells).
2. **CDX-1140 Treatment:**
	* Treat APCs (e.g., dendritic cells or macrophages) with CDX-1140 at various concentrations (e.g., 0.1, 1, and 10 μg/mL) for 24-48 hours.
	* Use untreated APCs as a control.
3. **Cytokine Analysis:**
	* Measure the production of cytokines (e.g., IL-12, IL-15, and IFN-γ) in the supernatant of CDX-1140-treated APCs using ELISA or multiplex assays.
4. **NK Cell Activation and Recruitment:**
	* Co-culture CDX-1140-treated APCs with autologous NK cells (isolated from PBMCs) for 24-48 hours.
	* Measure NK cell activation markers (e.g., CD69, CD25, and granzyme B) using flow cytometry.
	* Assess NK cell cytotoxicity against tumor cells using a chromium release assay or a flow cytometry-based killing assay.
5. **Tumor Cell Killing Assay:**
	* Co-culture CDX-1140-treated APCs with NK cells and tumor cells for 24-48 hours.
	* Measure tumor cell killing using a viability assay (e.g., MTT or Annexin V staining).

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we will test the following:

* **CDX-1140 does not induce cytokine production in APCs:**
	+ Treat APCs with CDX-1140 and measure cytokine production. If no significant cytokine production is observed, it would suggest that CDX-1140 does not activate APCs to produce cytokines.
* **CDX-1140-induced cytokines do not enhance NK cell activation and recruitment:**
	+ Use a cytokine-neutralizing antibody (e.g., anti-IL-12 or anti-IL-15) to block the activity of cytokines produced by CDX-1140-treated APCs. If NK cell activation and recruitment are not affected, it would suggest that CDX-1140-induced cytokines are not responsible for enhancing NK cell activity.
* **CDX-1140 does not augment the anti-tumor immune response:**
	+ Use a control antibody or an isotype-matched antibody instead of CDX-1140 to treat APCs. If the anti-tumor immune response is not enhanced, it would suggest that CDX-1140 is not responsible for augmenting the anti-tumor immune response.

**Budget and Time Considerations:**

* Cell culture and isolation: 2 weeks, $5,000
* CDX-1140 treatment and cytokine analysis: 2 weeks, $8,000
* NK cell activation and recruitment assays: 3 weeks, $10,000
* Tumor cell killing assay: 2 weeks, $5,000
* Experiment to disprove the hypothesis: 4 weeks, $12,000

Total estimated time: 14 weeks
Total estimated budget: $40,000

This experimental plan is designed to test the hypothesis in a controlled and systematic manner, while also considering the limitations of time, resources, and financial support.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Isolation**

**Objective:** Isolate and culture human peripheral blood mononuclear cells (PBMCs) from healthy donors and human tumor cells (e.g., melanoma or breast cancer cells).

**Materials:**

* Human peripheral blood samples from healthy donors
* Ficoll-Paque density gradient medium
* RPMI-1640 medium
* Fetal bovine serum (FBS)
* Penicillin-streptomycin
* Tumor cell lines (e.g., melanoma or breast cancer cells)
* Tumor cell culture medium (e.g., DMEM or RPMI-1640)

**Step-by-Step Protocol:**

1.1. Collect human peripheral blood samples from healthy donors and isolate PBMCs using Ficoll-Paque density gradient medium according to the manufacturer's instructions.

1.2. Resuspend the isolated PBMCs in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

1.3. Culture the PBMCs in a 37°C, 5% CO2 incubator for 24-48 hours to allow for cell recovery and activation.

1.4. Isolate and culture human tumor cells (e.g., melanoma or breast cancer cells) according to established protocols.

1.5. Maintain the tumor cells in their respective culture medium (e.g., DMEM or RPMI-1640) supplemented with 10% FBS and 1% penicillin-streptomycin.

**Protocol 2: CDX-1140 Treatment**

**Objective:** Treat antigen-presenting cells (APCs) with CDX-1140 at various concentrations (e.g., 0.1, 1, and 10 μg/mL) for 24-48 hours.

**Materials:**

* CDX-1140
* APCs (e.g., dendritic cells or macrophages)
* RPMI-1640 medium
* Fetal bovine serum (FBS)
* Penicillin-streptomycin

**Step-by-Step Protocol:**

2.1. Prepare CDX-1140 stock solutions at concentrations of 0.1, 1, and 10 μg/mL in RPMI-1640 medium.

2.2. Add the CDX-1140 stock solutions to the APC cultures at the desired concentrations.

2.3. Incubate the APCs with CDX-1140 for 24-48 hours in a 37°C, 5% CO2 incubator.

2.4. Use untreated APCs as a control.

**Protocol 3: Cytokine Analysis**

**Objective:** Measure the production of cytokines (e.g., IL-12, IL-15, and IFN-γ) in the supernatant of CDX-1140-treated APCs using ELISA or multiplex assays.

**Materials:**

* ELISA or multiplex assay kits for IL-12, IL-15, and IFN-γ
* CDX-1140-treated APC supernatants
* Standards and controls for ELISA or multiplex assays

**Step-by-Step Protocol:**

3.1. Collect the supernatants from the CDX-1140-treated APC cultures.

3.2. Perform ELISA or multiplex assays according to the manufacturer's instructions to measure the production of IL-12, IL-15, and IFN-γ.

3.3. Use standards and controls to validate the assays and calculate the cytokine concentrations.

**Protocol 4: NK Cell Activation and Recruitment**

**Objective:** Co-culture CDX-1140-treated APCs with autologous NK cells (isolated from PBMCs) for 24-48 hours and measure NK cell activation markers and cytotoxicity against tumor cells.

**Materials:**

* CDX-1140-treated APCs
* Autologous NK cells (isolated from PBMCs)
* RPMI-1640 medium
* Fetal bovine serum (FBS)
* Penicillin-streptomycin
* Flow cytometry antibodies (e.g., CD69, CD25, and granzyme B)
* Chromium release assay or flow cytometry-based killing assay reagents

**Step-by-Step Protocol:**

4.1. Isolate autologous NK cells from PBMCs using established protocols.

4.2. Co-culture CDX-1140-treated APCs with autologous NK cells in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

4.3. Incubate the co-culture for 24-48 hours in a 37°C, 5% CO2 incubator.

4.4. Measure NK cell activation markers (e.g., CD69, CD25, and granzyme B) using flow cytometry.

4.5. Assess NK cell cytotoxicity against tumor cells using a chromium release assay or a flow cytometry-based killing assay.

**Protocol 5: Tumor Cell Killing Assay**

**Objective:** Co-culture CDX-1140-treated APCs with NK cells and tumor cells for 24-48 hours and measure tumor cell killing using a viability assay.

**Materials:**

* CDX-1140-treated APCs
* Autologous NK cells (isolated from PBMCs)
* Tumor cells
* RPMI-1640 medium
* Fetal bovine serum (FBS)
* Penicillin-streptomycin
* Viability assay reagents (e.g., MTT or Annexin V staining)

**Step-by-Step Protocol:**

5.1. Co-culture CDX-1140-treated APCs with autologous NK cells and tumor cells in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

5.2. Incubate the co-culture for 24-48 hours in a 37°C, 5% CO2 incubator.

5.3. Measure tumor cell killing using a viability assay (e.g., MTT or Annexin V staining).

**Protocol 6: Experiment to Disprove the Hypothesis**

**Objective:** Test the following scenarios to disprove the hypothesis:

* CDX-1140 does not induce cytokine production in APCs
* CDX-1140-induced cytokines do not enhance NK cell activation and recruitment
* CDX-1140 does not augment the anti-tumor immune response

**Materials:**

* CDX-1140
* APCs
* Cytokine-neutralizing antibodies (e.g., anti-IL-12 or anti-IL-15)
* Control antibody or isotype-matched antibody
* NK cells
* Tumor cells

**Step-by-Step Protocol:**

6.1. Treat APCs with CDX-1140 and measure cytokine production. If no significant cytokine production is observed, it would suggest that CDX-1140 does not activate APCs to produce cytokines.

6.2. Use a cytokine-neutralizing antibody (e.g., anti-IL-12 or anti-IL-15) to block the activity of cytokines produced by CDX-1140-treated APCs. If NK cell activation and recruitment are not affected, it would suggest that CDX-1140-induced cytokines are not responsible for enhancing NK cell activity.

6.3. Use a control antibody or an isotype-matched antibody instead of CDX-1140 to treat APCs. If the anti-tumor immune response is not enhanced, it would suggest that CDX-1140 is not responsible for augmenting the anti-tumor immune response.

These detailed, step-by-step protocols should provide a clear and replicable guide for executing the experiment.","```
   Ficoll-Paque  RPMI-1640  FBS  Penicillin-streptomycin  CDX-1140  APCs  IL-12  IL-15  IFN-γ  NK cells  Tumor cells  Outcome
0           1.0       10.0  10.0                  1.0       0.1   1000   200.0  150.0  50.0      5000        5000    0.8
1           1.2       12.0  12.0                  1.2       1.0   1200   250.0  180.0  60.0      6000        6000    0.9
2           0.8        8.0   8.0                  0.8       0.5   800   150.0  100.0  30.0      4000        4000    0.6
3           1.5       15.0  15.0                  1.5      10.0   1500   300.0  220.0  80.0      7000        7000    1.0
4           1.0       10.0  10.0                  1.0       0.1   1000   200.0  150.0  50.0      5000        5000    0.8
5           1.2       12.0  12.0                  1.2       1.0   1200   250.0  180.0  60.0      6000        6000    0.9
6           0.8        8.0   8.0                  0.8       0.5   800   150.0  100.0  30.0      4000        4000    0.6
7           1.5       15.0  15.0                  1.5      10.0   1500   300.0  220.0  80.0      7000        7000    1.0
8           1.0       10.0  10.0                  1.0       0.1   1000   200.0  150.0  50.0      5000        5000    0.8
9           1.2       12.0  12.0                  1.2       1.0   1200   250.0  180.0  60.0      6000        6000    0.9
10          0.8        8.0   8.0                  0.8       0.5   800   150.0  100.0  30.0      4000        4000    0.6
11          1.5       15.0  15.0                  1.5      10.0   1500   300.0  220.0  80.0      7000        7000    1.0
12          1.0       10.0  10.0                  1.0       0.1   1000   200.0  150.0  50.0      5000        5000    0.8
13          1.2       12.0  12.0                  1.2       1.0   1200   250.0  180.0  60.0      6000        6000    0.9
14          0.8        8.0   8.0                  0.8       0.5   800   150.0  100.0  30.0      4000        4000    0.6
15          1.5       15.0  15.0                  1.5      10.0   1500   300.0  220.0  80.0      7000        7000    1.0
16          1.0       10.0  10.0                  1.0       0.1   1000   200.0  150.0  50.0      5000        5000    0.8
17          1.2       12.0  12.0                  1.2       1.0   1200   250.0  180.0  60.0      6000        6000    0.9
18          0.8        8.0   8.0                  0.8       0.5   800   150.0  100.0  30.0      4000        4000    0.6
19          1.5       15.0  15.0                  1.5      10.0   1500   300.0  220.0  80.0      7000        7000    1.0
20          1.0       10.0  10.0                  1.0       0.1   1000   200.0  150.0  50.0      5000        5000    0.8
21          1.2       12.0  12.0                  1.2       1.0   1200   250.0  180.0  60.0      6000        6000    0.9
22          0.8        8.0   8.0                  0.8       0.5   800   150.0  100.0  30.0      4000        4000    0.6
23          1.5       15.0  15.0                  1.5      10.0   1500   300.0  220.0  80.0      7000        7000    1.0
24          1.0       10.0  10.0                  1.0       0.1   1000   200.0  150.0  50.0      5000        5000    0.8
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0120c72d02866c2f5fea4654378218fc0a12bfb4.summary'],Does ERG1-mediated Ca2+ signaling regulate the expression of specific microRNAs involved in lymphocyte development and differentiation?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! Here's a comprehensive experimental plan to test the hypothesis:

**Hypothesis:** ERG1-mediated Ca2+ signaling regulates the expression of specific microRNAs involved in lymphocyte development and differentiation.

**Objective:** To investigate the role of ERG1-mediated Ca2+ signaling in regulating microRNA expression during lymphocyte development and differentiation.

**Experimental Approach:**

**Step 1: Cell Culture and ERG1 Overexpression/Knockdown**

* Obtain human lymphocyte cell lines (e.g., Jurkat or primary T cells) and culture them in appropriate media.
* Use lentiviral vectors to overexpress ERG1 in lymphocytes (ERG1-OE) or knockdown ERG1 using shRNA (ERG1-KD).
* Validate ERG1 overexpression/knockdown using Western blotting and qRT-PCR.

**Step 2: Ca2+ Signaling Modulation**

* Treat ERG1-OE and ERG1-KD lymphocytes with Ca2+ ionophores (e.g., ionomycin) or Ca2+ chelators (e.g., BAPTA-AM) to modulate Ca2+ signaling.
* Measure intracellular Ca2+ levels using fluorescent dyes (e.g., Fluo-4) and flow cytometry.

**Step 3: MicroRNA Profiling**

* Extract total RNA from ERG1-OE, ERG1-KD, and control lymphocytes using TRIzol or similar methods.
* Perform microRNA profiling using high-throughput sequencing (e.g., Illumina TruSeq) or microarray analysis (e.g., Affymetrix).
* Identify differentially expressed microRNAs between ERG1-OE and ERG1-KD lymphocytes.

**Step 4: Validation of MicroRNA Targets**

* Use bioinformatic tools (e.g., TargetScan, miRanda) to predict microRNA targets involved in lymphocyte development and differentiation.
* Validate the expression of predicted target genes using qRT-PCR and Western blotting.
* Perform luciferase reporter assays to confirm microRNA-target interactions.

**Step 5: Functional Analysis of MicroRNA Targets**

* Use CRISPR-Cas9 genome editing to knockout or knockdown validated microRNA targets in lymphocytes.
* Analyze the effects of microRNA target knockout/knockdown on lymphocyte development and differentiation using flow cytometry, cell proliferation assays, and functional assays (e.g., T cell activation, cytokine production).

**Step 6: In Vivo Validation**

* Use a mouse model of lymphocyte development (e.g., Rag2-/- mice) and perform adoptive transfer of ERG1-OE or ERG1-KD lymphocytes.
* Analyze lymphocyte development and differentiation in vivo using flow cytometry, histology, and functional assays.

**Step 7: Data Integration and Statistical Analysis**

* Integrate data from microRNA profiling, target validation, and functional analysis using bioinformatic tools (e.g., R, Python).
* Perform statistical analysis (e.g., t-tests, ANOVA) to identify significant changes in microRNA expression and target gene regulation.

**Timeline:**

* Month 1-3: Cell culture, ERG1 overexpression/knockdown, and Ca2+ signaling modulation
* Month 4-6: MicroRNA profiling and target prediction
* Month 7-9: Validation of microRNA targets and functional analysis
* Month 10-12: In vivo validation and data integration
* Month 13-18: Data analysis, manuscript preparation, and publication

**Resources:**

* Cell culture facilities and equipment
* Lentiviral vectors and packaging systems
* qRT-PCR and Western blotting equipment
* Flow cytometry and cell sorting facilities
* High-throughput sequencing and microarray analysis platforms
* Bioinformatic tools and software
* Mouse models and animal facilities
* CRISPR-Cas9 genome editing system

**Budget:**

* Personnel: 5-7 researchers, 2-3 technicians, and 1-2 postdocs
* Reagents and consumables: $500,000 - $1,000,000 per year
* Equipment and infrastructure: $1,000,000 - $2,000,000 (one-time investment)
* Animal facilities and mouse models: $200,000 - $500,000 per year
* Travel and training: $50,000 - $100,000 per year

This experimental plan is designed to comprehensively test the hypothesis and provide a thorough understanding of the role of ERG1-mediated Ca2+ signaling in regulating microRNA expression during lymphocyte development and differentiation. With an unlimited budget, the plan can be executed in a timely and efficient manner, leveraging cutting-edge technologies and expertise in the field.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Culture and ERG1 Overexpression/Knockdown**

1.1. Obtain human lymphocyte cell lines (e.g., Jurkat or primary T cells) from a reputable cell bank or isolate them from human blood samples using standard protocols.

1.2. Culture the lymphocytes in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

1.3. Prepare lentiviral vectors for ERG1 overexpression (ERG1-OE) and knockdown (ERG1-KD) using standard molecular biology techniques.

1.4. Transduce lymphocytes with ERG1-OE or ERG1-KD lentiviral vectors using a multiplicity of infection (MOI) of 10-20 and polybrene (8 μg/mL).

1.5. Select transduced cells using puromycin (1 μg/mL) or other selection markers for 7-10 days.

1.6. Validate ERG1 overexpression/knockdown using Western blotting and qRT-PCR:

a. Extract total protein from transduced cells using RIPA buffer and perform Western blotting with ERG1-specific antibodies.

b. Extract total RNA from transduced cells using TRIzol and perform qRT-PCR with ERG1-specific primers.

**Step 2: Ca2+ Signaling Modulation**

2.1. Treat ERG1-OE and ERG1-KD lymphocytes with Ca2+ ionophores (e.g., ionomycin, 1 μM) or Ca2+ chelators (e.g., BAPTA-AM, 10 μM) for 30 minutes to 1 hour.

2.2. Measure intracellular Ca2+ levels using fluorescent dyes (e.g., Fluo-4, 2 μM) and flow cytometry:

a. Incubate cells with Fluo-4 for 30 minutes at 37°C.

b. Analyze cells using a flow cytometer (e.g., BD FACSCanto) with excitation at 488 nm and emission at 520 nm.

**Step 3: MicroRNA Profiling**

3.1. Extract total RNA from ERG1-OE, ERG1-KD, and control lymphocytes using TRIzol or similar methods.

3.2. Perform microRNA profiling using high-throughput sequencing (e.g., Illumina TruSeq) or microarray analysis (e.g., Affymetrix):

a. Prepare RNA libraries according to the manufacturer's instructions.

b. Perform sequencing or hybridization according to the manufacturer's instructions.

c. Analyze data using bioinformatic tools (e.g., miRDeep, miRanda) to identify differentially expressed microRNAs.

**Step 4: Validation of MicroRNA Targets**

4.1. Use bioinformatic tools (e.g., TargetScan, miRanda) to predict microRNA targets involved in lymphocyte development and differentiation.

4.2. Validate the expression of predicted target genes using qRT-PCR and Western blotting:

a. Extract total RNA from ERG1-OE, ERG1-KD, and control lymphocytes using TRIzol.

b. Perform qRT-PCR with target gene-specific primers.

c. Extract total protein from ERG1-OE, ERG1-KD, and control lymphocytes using RIPA buffer.

d. Perform Western blotting with target gene-specific antibodies.

4.3. Perform luciferase reporter assays to confirm microRNA-target interactions:

a. Clone target gene 3'UTRs into a luciferase reporter vector.

b. Co-transfect reporter vectors with microRNA mimics or inhibitors into HEK293T cells.

c. Measure luciferase activity using a luminometer.

**Step 5: Functional Analysis of MicroRNA Targets**

5.1. Use CRISPR-Cas9 genome editing to knockout or knockdown validated microRNA targets in lymphocytes:

a. Design guide RNAs (gRNAs) targeting the microRNA target gene.

b. Transfect gRNAs and Cas9 into lymphocytes using electroporation or nucleofection.

c. Select edited cells using puromycin or other selection markers.

5.2. Analyze the effects of microRNA target knockout/knockdown on lymphocyte development and differentiation using:

a. Flow cytometry: analyze cell surface markers (e.g., CD4, CD8, CD25) and intracellular markers (e.g., Foxp3, RORγt).

b. Cell proliferation assays: measure cell proliferation using CFSE or BrdU incorporation.

c. Functional assays: measure T cell activation (e.g., IL-2 production), cytokine production (e.g., IFN-γ, IL-4), and cell migration.

**Step 6: In Vivo Validation**

6.1. Use a mouse model of lymphocyte development (e.g., Rag2-/- mice) and perform adoptive transfer of ERG1-OE or ERG1-KD lymphocytes:

a. Isolate lymphocytes from ERG1-OE or ERG1-KD cultures.

b. Inject lymphocytes into Rag2-/- mice via tail vein injection.

6.2. Analyze lymphocyte development and differentiation in vivo using:

a. Flow cytometry: analyze cell surface markers (e.g., CD4, CD8, CD25) and intracellular markers (e.g., Foxp3, RORγt).

b. Histology: analyze lymphoid organ architecture and cell infiltration using immunohistochemistry.

c. Functional assays: measure T cell activation (e.g., IL-2 production), cytokine production (e.g., IFN-γ, IL-4), and cell migration.

**Step 7: Data Integration and Statistical Analysis**

7.1. Integrate data from microRNA profiling, target validation, and functional analysis using bioinformatic tools (e.g., R, Python).

7.2. Perform statistical analysis (e.g., t-tests, ANOVA) to identify significant changes in microRNA expression and target gene regulation.

7.3. Prepare figures and tables for manuscript preparation and publication.

These detailed protocols should provide a clear guide for executing the experimental plan and ensuring replicability and specificity in the results.","```
   ERG1_OE  ERG1_KD  Ionomycin  BAPTA-AM  Fluo-4  MicroRNA_Target  Luciferase  CRISPR_Target  Outcome
0       10       0.0       0.5       5.0     1.5          200.0       150.0         0.5       0.8
1       20       0.0       1.0       10.0     2.0          250.0       200.0         1.0       1.2
2        5       0.0       0.2       2.0     0.8          150.0       100.0         0.2       0.5
3       15       0.0       0.8       8.0     1.8          220.0       180.0         0.8       1.0
4        0       10.0       0.5       5.0     1.5          180.0       120.0         0.5       0.6
5       25       0.0       1.2       12.0     2.5          280.0       220.0         1.2       1.5
6        0        5.0       0.2       2.0     0.8          120.0        80.0         0.2       0.4
7       18       0.0       0.9       9.0     2.2          240.0       190.0         0.9       1.3
8        0       15.0       0.8       8.0     1.8          200.0       160.0         0.8       0.9
9       22       0.0       1.1       11.0     2.4          260.0       210.0         1.1       1.6
10       0       20.0       1.0       10.0     2.0          220.0       180.0         1.0       1.1
11       8       0.0       0.4       4.0     1.2          160.0       110.0         0.4       0.7
12       0        8.0       0.5       5.0     1.5          140.0        90.0         0.5       0.5
13      12       0.0       0.6       6.0     1.6          190.0       140.0         0.6       0.9
14       0       12.0       0.7       7.0     1.7          170.0       120.0         0.7       0.8
15       6       0.0       0.3       3.0     1.0          130.0        80.0         0.3       0.6
16       0       18.0       1.1       11.0     2.4          210.0       170.0         1.1       1.2
17      10       0.0       0.5       5.0     1.5          180.0       130.0         0.5       0.8
18       0       10.0       0.6       6.0     1.6          160.0       110.0         0.6       0.7
19       4       0.0       0.2       2.0     0.8          110.0        70.0         0.2       0.5
20       0       14.0       0.9       9.0     2.2          200.0       150.0         0.9       1.0
21      16       0.0       0.8       8.0     1.8          230.0       190.0         0.8       1.2
22       0       16.0       1.0       10.0     2.0          220.0       180.0         1.0       1.1
23       2       0.0       0.1       1.0     0.6          100.0        60.0         0.1       0.4
24       0       22.0       1.2       12.0     2.5          240.0       200.0         1.2       1.4
```",0.7979016211499588
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/175d188342f5420eabc37c0c86b5758d72f4eaf3.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/87447edf83668ec55a88fb6c1cdb53cc357a5303.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4145db09dabc34df5b03f3f434716b377ae0a562.summary']","Does Fes-mediated phosphorylation of Dok1 regulate the activity of Lyn, thereby influencing ROR1 surface dynamics and chemotaxis in B-cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! To test this hypothesis, I'll outline a concise experimental plan to investigate the role of Fes-mediated phosphorylation of Dok1 in regulating Lyn activity, ROR1 surface dynamics, and chemotaxis in B-cells.

**Hypothesis:** Fes-mediated phosphorylation of Dok1 regulates the activity of Lyn, thereby influencing ROR1 surface dynamics and chemotaxis in B-cells.

**Experimental Approach:**

**Objective:** Design an experiment to disprove the hypothesis, thereby verifying its validity.

**Step 1: Cell Culture and Transfection**

* Obtain a B-cell line (e.g., Ramos or Raji) and culture them in a suitable medium.
* Transfect the cells with:
	+ Wild-type Dok1 (WT-Dok1) and Fes (WT-Fes) constructs.
	+ Dok1 phosphorylation site mutants (e.g., Dok1-Y139F, Dok1-Y181F) to prevent Fes-mediated phosphorylation.
	+ Lyn-specific siRNA or shRNA to knockdown Lyn expression.
	+ ROR1-overexpressing construct to monitor surface dynamics.

**Step 2: Phosphorylation Assay**

* Perform immunoprecipitation (IP) of Dok1 from transfected cells using anti-Dok1 antibodies.
* Analyze the immunoprecipitates using Western blotting with anti-phospho-Dok1 (Y139/Y181) antibodies to detect Fes-mediated phosphorylation.

**Step 3: Lyn Activity Assay**

* Perform an in vitro kinase assay using immunoprecipitated Lyn and a substrate (e.g., GST- Dok1) to measure Lyn activity.
* Compare Lyn activity in cells transfected with WT-Dok1, Dok1 phosphorylation site mutants, and Lyn-specific siRNA/shRNA.

**Step 4: ROR1 Surface Dynamics and Chemotaxis Assay**

* Use flow cytometry to analyze ROR1 surface expression in transfected cells.
* Perform a chemotaxis assay using a transwell system with a chemoattractant (e.g., CXCL12) to measure B-cell migration.
* Compare ROR1 surface dynamics and chemotaxis in cells transfected with WT-Dok1, Dok1 phosphorylation site mutants, and ROR1-overexpressing construct.

**Step 5: Data Analysis and Interpretation**

* Analyze the data to determine if Fes-mediated phosphorylation of Dok1 regulates Lyn activity, ROR1 surface dynamics, and chemotaxis in B-cells.
* If the data support the hypothesis, it will be difficult to disprove. However, if the data do not show a correlation between Fes-mediated phosphorylation of Dok1 and Lyn activity, ROR1 surface dynamics, and chemotaxis, it would suggest that the hypothesis is incorrect.

**Budget and Timeframe:**

* This experiment can be completed within 3-4 months with a budget of approximately $20,000-$30,000.
* The budget will cover:
	+ Cell culture and transfection reagents
	+ Antibodies and Western blotting reagents
	+ Kinase assay reagents
	+ Flow cytometry and chemotaxis assay reagents
	+ Personnel and laboratory costs

By following this experimental plan, you can test the hypothesis and determine if Fes-mediated phosphorylation of Dok1 regulates Lyn activity, ROR1 surface dynamics, and chemotaxis in B-cells.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Cell Culture and Transfection**

1.1. Obtain a B-cell line (e.g., Ramos or Raji) from a reputable cell bank or culture collection.

1.2. Culture the B-cells in a suitable medium, such as RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine, at 37°C and 5% CO2.

1.3. Prepare the following plasmid constructs:
	* Wild-type Dok1 (WT-Dok1) and Fes (WT-Fes) constructs
	* Dok1 phosphorylation site mutants (e.g., Dok1-Y139F, Dok1-Y181F) to prevent Fes-mediated phosphorylation
	* Lyn-specific siRNA or shRNA to knockdown Lyn expression
	* ROR1-overexpressing construct to monitor surface dynamics

1.4. Transfect the B-cells with the prepared plasmid constructs using a transfection reagent, such as Lipofectamine 2000, according to the manufacturer's instructions.

1.5. Incubate the transfected cells for 24-48 hours to allow for protein expression.

**Step 2: Phosphorylation Assay**

2.1. Prepare lysis buffer (e.g., RIPA buffer) and add protease inhibitors (e.g., PMSF, aprotinin) to prevent protein degradation.

2.2. Lyse the transfected cells using the prepared lysis buffer and incubate on ice for 30 minutes.

2.3. Centrifuge the lysates at 10,000 x g for 10 minutes to remove cellular debris.

2.4. Immunoprecipitate Dok1 from the lysates using anti-Dok1 antibodies (e.g., 2 μg per 1 mg of total protein) and protein A/G beads.

2.5. Incubate the immunoprecipitates for 2 hours at 4°C with gentle rotation.

2.6. Wash the immunoprecipitates three times with lysis buffer and once with PBS.

2.7. Analyze the immunoprecipitates using Western blotting with anti-phospho-Dok1 (Y139/Y181) antibodies to detect Fes-mediated phosphorylation.

**Step 3: Lyn Activity Assay**

3.1. Prepare a kinase assay buffer (e.g., 20 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM DTT) and add ATP (e.g., 100 μM) and a substrate (e.g., GST-Dok1).

3.2. Immunoprecipitate Lyn from the transfected cells using anti-Lyn antibodies (e.g., 2 μg per 1 mg of total protein) and protein A/G beads.

3.3. Incubate the immunoprecipitates with the kinase assay buffer and substrate for 30 minutes at 30°C.

3.4. Stop the reaction by adding SDS-PAGE sample buffer and boiling for 5 minutes.

3.5. Analyze the reaction products using Western blotting with anti-phospho-Dok1 (Y139/Y181) antibodies to detect Lyn activity.

**Step 4: ROR1 Surface Dynamics and Chemotaxis Assay**

4.1. Prepare a flow cytometry buffer (e.g., PBS with 1% FBS and 0.1% NaN3).

4.2. Stain the transfected cells with anti-ROR1 antibodies (e.g., 1:100 dilution) and a secondary antibody (e.g., 1:200 dilution) for 30 minutes on ice.

4.3. Analyze ROR1 surface expression using flow cytometry (e.g., BD FACSCanto II).

4.4. Prepare a chemotaxis assay buffer (e.g., RPMI 1640 with 1% FBS and 1% BSA).

4.5. Add a chemoattractant (e.g., CXCL12, 100 ng/mL) to the lower chamber of a transwell system.

4.6. Add the transfected cells to the upper chamber of the transwell system and incubate for 2-3 hours at 37°C.

4.7. Count the migrated cells using a hemocytometer or a flow cytometer.

**Step 5: Data Analysis and Interpretation**

5.1. Analyze the data from the phosphorylation assay, Lyn activity assay, and ROR1 surface dynamics and chemotaxis assay.

5.2. Compare the data from cells transfected with WT-Dok1, Dok1 phosphorylation site mutants, and Lyn-specific siRNA/shRNA.

5.3. Determine if Fes-mediated phosphorylation of Dok1 regulates Lyn activity, ROR1 surface dynamics, and chemotaxis in B-cells.

5.4. Interpret the results in the context of the hypothesis and discuss the implications of the findings.

**Budget and Timeframe:**

* The budget will cover:
	+ Cell culture and transfection reagents ($5,000)
	+ Antibodies and Western blotting reagents ($5,000)
	+ Kinase assay reagents ($2,000)
	+ Flow cytometry and chemotaxis assay reagents ($3,000)
	+ Personnel and laboratory costs ($5,000-$10,000)
* The experiment can be completed within 3-4 months.

Note: The budget and timeframe may vary depending on the specific requirements of the experiment and the laboratory setup.","```
   WT-Dok1  Dok1-Y139F  Dok1-Y181F  Lyn siRNA  ROR1  Fes  Lyn Activity  Phosphorylation  ROR1 Surface  Chemotaxis
0        1.0         0.0         0.0        0.0   1.0   1.0         0.5          0.8         0.6        0.4
1        0.5         0.5         0.0        0.0   1.0   1.0         0.7          0.9         0.7        0.5
2        0.0         1.0         0.0        0.0   1.0   1.0         0.3          0.6         0.5        0.3
3        1.0         0.0         0.5        0.0   1.0   1.0         0.6          0.8         0.6        0.4
4        0.5         0.0         0.5        0.0   1.0   1.0         0.5          0.7         0.6        0.4
5        0.0         0.5         0.5        0.0   1.0   1.0         0.4          0.6         0.5        0.3
6        1.0         0.0         0.0        0.5   1.0   1.0         0.8          0.9         0.7        0.5
7        0.5         0.5         0.0        0.5   1.0   1.0         0.7          0.8         0.7        0.5
8        0.0         1.0         0.0        0.5   1.0   1.0         0.4          0.6         0.5        0.3
9        1.0         0.0         0.5        0.5   1.0   1.0         0.7          0.8         0.6        0.4
10       0.5         0.0         0.5        0.5   1.0   1.0         0.6          0.7         0.6        0.4
11       0.0         0.5         0.5        0.5   1.0   1.0         0.5          0.6         0.5        0.3
12       1.0         0.0         0.0        0.0   0.5   1.0         0.4          0.6         0.5        0.3
13       0.5         0.5         0.0        0.0   0.5   1.0         0.5          0.7         0.6        0.4
14       0.0         1.0         0.0        0.0   0.5   1.0         0.3          0.5         0.5        0.3
15       1.0         0.0         0.5        0.0   0.5   1.0         0.5          0.7         0.6        0.4
16       0.5         0.0         0.5        0.0   0.5   1.0         0.5          0.6         0.5        0.3
17       0.0         0.5         0.5        0.0   0.5   1.0         0.4          0.5         0.5        0.3
18       1.0         0.0         0.0        0.5   0.5   1.0         0.7          0.8         0.7        0.5
19       0.5         0.5         0.0        0.5   0.5   1.0         0.6          0.7         0.6        0.4
20       0.0         1.0         0.0        0.5   0.5   1.0         0.4          0.5         0.5        0.3
21       1.0         0.0         0.5        0.5   0.5   1.0         0.6          0.7         0.6        0.4
22       0.5         0.0         0.5        0.5   0.5   1.0         0.5          0.6         0.5        0.3
23       0.0         0.5         0.5        0.5   0.5   1.0         0.4          0.5         0.5        0.3
24       1.0         0.0         0.0        0.0   0.0   1.0         0.3          0.5         0.5        0.3
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/758bf756678baf8be8849b2c917a98e2e7dde956.summary'],Does GNG4-mediated regulation of memory B cells influence the tumor microenvironment to promote osteosarcoma progression and metastasis?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis: ""Does GNG4-mediated regulation of memory B cells influence the tumor microenvironment to promote osteosarcoma progression and metastasis?""

**Experimental Approach:**

To disprove the hypothesis, we will design an experiment to investigate the role of GNG4 in regulating memory B cells and their impact on the tumor microenvironment in osteosarcoma.

**Objective:**

1. Determine the effect of GNG4 knockout on memory B cell regulation and osteosarcoma progression.
2. Investigate the impact of GNG4-regulated memory B cells on the tumor microenvironment and metastasis.

**Experimental Design:**

**Part 1: GNG4 Knockout and Memory B Cell Analysis**

1. Use CRISPR-Cas9 gene editing to knockout GNG4 in osteosarcoma cell lines (e.g., U2OS, MG63).
2. Verify GNG4 knockout using Western blot, qRT-PCR, and immunofluorescence.
3. Isolate and analyze memory B cells from GNG4-knockout and control osteosarcoma cells using flow cytometry and cell sorting.
4. Perform RNA sequencing (RNA-seq) and bioinformatics analysis to identify differentially expressed genes in memory B cells from GNG4-knockout and control cells.

**Part 2: Tumor Microenvironment and Metastasis Analysis**

1. Co-culture GNG4-knockout and control osteosarcoma cells with memory B cells in a 3D tumor microenvironment model.
2. Analyze the tumor microenvironment using immunofluorescence, confocal microscopy, and multiplex immunohistochemistry to assess the impact of GNG4-regulated memory B cells on tumor progression and metastasis.
3. Perform in vivo experiments using orthotopic xenograft models to investigate the effect of GNG4-knockout on osteosarcoma metastasis to lungs and other organs.
4. Collect and analyze blood and tumor tissue samples from xenograft models to assess the presence and activity of memory B cells.

**Part 3: Functional Assays**

1. Perform functional assays to assess the impact of GNG4-regulated memory B cells on osteosarcoma cell proliferation, migration, and invasion.
2. Use transwell assays to evaluate the effect of GNG4-regulated memory B cells on osteosarcoma cell migration and invasion.
3. Perform ELISA and multiplex cytokine assays to analyze the cytokine profile of GNG4-regulated memory B cells and their impact on the tumor microenvironment.

**Expected Outcomes:**

If the hypothesis is true, we expect to observe:

* Reduced memory B cell activity and altered gene expression profiles in GNG4-knockout osteosarcoma cells.
* Impaired tumor progression and metastasis in GNG4-knockout osteosarcoma cells co-cultured with memory B cells.
* Decreased cytokine production and altered tumor microenvironment in GNG4-knockout osteosarcoma cells.

If the hypothesis is false, we expect to observe:

* No significant differences in memory B cell activity, gene expression profiles, or tumor progression between GNG4-knockout and control osteosarcoma cells.

**Equipment and Resources:**

* CRISPR-Cas9 system
* Osteosarcoma cell lines (e.g., U2OS, MG63)
* Cell culture medium and reagents
* Flow cytometer and cell sorter
* RNA-seq and bioinformatics analysis tools
* 3D tumor microenvironment model
* Orthotopic xenograft models
* Immunofluorescence and confocal microscopy equipment
* Multiplex immunohistochemistry and ELISA kits
* Transwell assay equipment
* Multiplex cytokine assay kits

**Timeline:**

This experiment is expected to take approximately 12-18 months to complete, assuming a team of 2-3 researchers with expertise in molecular biology, cell culture, and bioinformatics.

**Budget:**

The budget for this experiment will depend on the specific resources and equipment required. However, with an unlimited budget, we can assume that all necessary resources will be available to complete the experiment.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Part 1: GNG4 Knockout and Memory B Cell Analysis**

**Step 1.1: CRISPR-Cas9 Gene Editing**

1. Prepare CRISPR-Cas9 plasmids containing the GNG4-targeting guide RNA (gRNA) and a fluorescent marker (e.g., GFP) for selection.
2. Transfect osteosarcoma cell lines (U2OS and MG63) with the CRISPR-Cas9 plasmid using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.
3. Incubate the cells for 48 hours to allow for gene editing.
4. Select transfected cells using fluorescence-activated cell sorting (FACS) based on GFP expression.

**Step 1.2: Verify GNG4 Knockout**

1. Extract protein from GNG4-knockout and control osteosarcoma cells using a protein extraction buffer (e.g., RIPA buffer).
2. Perform Western blot analysis using an anti-GNG4 antibody to detect GNG4 protein expression.
3. Extract RNA from GNG4-knockout and control osteosarcoma cells using a RNA extraction kit (e.g., TRIzol).
4. Perform qRT-PCR using GNG4-specific primers to detect GNG4 mRNA expression.
5. Perform immunofluorescence staining using an anti-GNG4 antibody to detect GNG4 protein expression in GNG4-knockout and control osteosarcoma cells.

**Step 1.3: Isolate and Analyze Memory B Cells**

1. Stain GNG4-knockout and control osteosarcoma cells with fluorescently labeled antibodies against memory B cell markers (e.g., CD27, CD38).
2. Perform flow cytometry to identify and sort memory B cells from GNG4-knockout and control osteosarcoma cells.
3. Extract RNA from sorted memory B cells using a RNA extraction kit (e.g., TRIzol).
4. Perform RNA sequencing (RNA-seq) using a sequencing platform (e.g., Illumina HiSeq) to identify differentially expressed genes in memory B cells from GNG4-knockout and control cells.

**Part 2: Tumor Microenvironment and Metastasis Analysis**

**Step 2.1: Co-Culture and 3D Tumor Microenvironment Model**

1. Prepare a 3D tumor microenvironment model using a scaffold material (e.g., Matrigel) and a cell culture medium.
2. Co-culture GNG4-knockout and control osteosarcoma cells with memory B cells in the 3D tumor microenvironment model.
3. Incubate the co-culture for 7-10 days to allow for tumor microenvironment formation.

**Step 2.2: Immunofluorescence and Confocal Microscopy**

1. Fix the co-culture using a fixative (e.g., paraformaldehyde) and permeabilize using a permeabilization buffer (e.g., Triton X-100).
2. Stain the co-culture with fluorescently labeled antibodies against tumor microenvironment markers (e.g., CD31, α-SMA).
3. Perform confocal microscopy to visualize the tumor microenvironment and analyze the impact of GNG4-regulated memory B cells on tumor progression and metastasis.

**Step 2.3: Orthotopic Xenograft Models**

1. Prepare orthotopic xenograft models by injecting GNG4-knockout and control osteosarcoma cells into the tibia of immunodeficient mice (e.g., NOD/SCID).
2. Monitor tumor growth and metastasis using bioluminescence imaging (BLI) or magnetic resonance imaging (MRI).
3. Collect blood and tumor tissue samples from xenograft models to assess the presence and activity of memory B cells.

**Part 3: Functional Assays**

**Step 3.1: Transwell Assays**

1. Prepare transwell inserts with a porous membrane (e.g., 8 μm pore size).
2. Seed GNG4-knockout and control osteosarcoma cells in the upper chamber of the transwell insert.
3. Add memory B cells to the lower chamber of the transwell insert.
4. Incubate the transwell for 24-48 hours to allow for cell migration and invasion.
5. Stain the cells with a fluorescent dye (e.g., Calcein AM) and quantify cell migration and invasion using a fluorescence plate reader.

**Step 3.2: ELISA and Multiplex Cytokine Assays**

1. Collect supernatants from GNG4-knockout and control osteosarcoma cells co-cultured with memory B cells.
2. Perform ELISA using a cytokine-specific antibody (e.g., IL-6) to detect cytokine production.
3. Perform multiplex cytokine assays using a bead-based platform (e.g., Luminex) to detect multiple cytokines simultaneously.

These detailed, step-by-step protocols should provide a clear guide for executing the experiment.",,0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/15e9bddd3b510f4ae61a1e058c99f0bba3ba7469.summary'],"Does GPS2-mediated regulation of the PI3K/AKT pathway in B cells also influence the expression of microRNAs that target FOXO1, thereby modulating B cell development and differentiation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis: ""Does GPS2-mediated regulation of the PI3K/AKT pathway in B cells also influence the expression of microRNAs that target FOXO1, thereby modulating B cell development and differentiation?""

**Experiment:**

**Title:** Investigating the Role of GPS2 in Regulating microRNA Expression and FOXO1 Targeting in B Cell Development

**Objective:** To determine if GPS2-mediated regulation of the PI3K/AKT pathway in B cells affects the expression of microRNAs that target FOXO1, and subsequently, B cell development and differentiation.

**Experimental Design:**

1. **Cell Culture and Treatment:**
	* Isolate B cells from wild-type (WT) and GPS2 knockout (KO) mice.
	* Culture B cells in vitro and treat them with a PI3K/AKT pathway inhibitor (e.g., LY294002) to mimic the effect of GPS2 on the PI3K/AKT pathway.
2. **microRNA Profiling:**
	* Extract total RNA from WT and GPS2 KO B cells, with and without PI3K/AKT pathway inhibition.
	* Perform microRNA profiling using a microarray platform (e.g., Affymetrix) or RNA sequencing (RNA-seq) to identify differentially expressed microRNAs between the groups.
3. **FOXO1 Targeting Analysis:**
	* Use bioinformatic tools (e.g., TargetScan, miRanda) to predict microRNAs that target FOXO1.
	* Validate the expression of predicted microRNAs using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
	* Analyze the correlation between GPS2 expression, PI3K/AKT pathway activity, and FOXO1-targeting microRNA expression.
4. **B Cell Development and Differentiation Assays:**
	* Perform flow cytometry to analyze the expression of surface markers (e.g., CD19, CD20, CD23) and intracellular markers (e.g., FOXO1, AKT) in WT and GPS2 KO B cells, with and without PI3K/AKT pathway inhibition.
	* Evaluate B cell development and differentiation by assessing the proportion of B cell subsets (e.g., pro-B, pre-B, immature, mature) using flow cytometry.

**Expected Outcomes:**

* If the hypothesis is true, GPS2 KO B cells should exhibit altered microRNA expression profiles, particularly for microRNAs targeting FOXO1, compared to WT B cells.
* Inhibition of the PI3K/AKT pathway in WT B cells should mimic the effects of GPS2 KO on microRNA expression and FOXO1 targeting.
* Altered microRNA expression and FOXO1 targeting should correlate with changes in B cell development and differentiation.

**Equipment and Resources:**

* Cell culture facilities and equipment
* Microarray platform or RNA-seq equipment
* qRT-PCR machine
* Flow cytometer
* Sonicator (for ChIP-Seq, if desired)
* IP kit (for ChIP-Seq, if desired)
* Sequencing platform (e.g., Illumina, if desired)

**Timeline:**

* Cell culture and treatment: 2 weeks
* microRNA profiling: 4 weeks
* FOXO1 targeting analysis: 2 weeks
* B cell development and differentiation assays: 4 weeks
* Data analysis and interpretation: 6 weeks

**Budget:**

* Cell culture and treatment: $1,000
* microRNA profiling: $5,000
* FOXO1 targeting analysis: $1,000
* B cell development and differentiation assays: $2,000
* Data analysis and interpretation: $2,000
* Total: $11,000

This experiment is designed to test the hypothesis and can be completed within a reasonable time frame (approximately 20 weeks) and budget ($11,000). The results will provide valuable insights into the role of GPS2 in regulating microRNA expression and FOXO1 targeting in B cell development and differentiation.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Treatment**

**Step 1.1: Isolate B cells from wild-type (WT) and GPS2 knockout (KO) mice**

* Obtain WT and GPS2 KO mice from a reputable supplier or breeding facility.
* Sacrifice the mice according to institutional animal care and use committee (IACUC) guidelines.
* Harvest spleens from the mice and isolate B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Count the isolated B cells using a hemocytometer or an automated cell counter.

**Step 1.2: Culture B cells in vitro**

* Resuspend the isolated B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
* Plate the B cells in 24-well plates at a density of 1 x 10^6 cells per well.
* Incubate the cells at 37°C, 5% CO2 for 24 hours to allow for cell recovery.

**Step 1.3: Treat B cells with a PI3K/AKT pathway inhibitor**

* Prepare a stock solution of LY294002 (e.g., 10 mM) in DMSO.
* Add LY294002 to the B cell cultures at a final concentration of 10 μM.
* Incubate the cells for an additional 24 hours to allow for inhibitor treatment.

**Protocol 2: microRNA Profiling**

**Step 2.1: Extract total RNA from B cells**

* Harvest the B cells from the culture plates and wash them with PBS.
* Extract total RNA from the B cells using a RNA extraction kit (e.g., Qiagen RNeasy) according to the manufacturer's instructions.
* Quantify the extracted RNA using a spectrophotometer (e.g., NanoDrop).

**Step 2.2: Perform microRNA profiling using a microarray platform or RNA-seq**

* Prepare the RNA samples for microarray analysis according to the manufacturer's instructions (e.g., Affymetrix).
* Hybridize the RNA samples to the microarray platform and scan the arrays according to the manufacturer's instructions.
* Alternatively, prepare the RNA samples for RNA-seq analysis according to the manufacturer's instructions (e.g., Illumina).
* Sequence the RNA samples using a next-generation sequencing platform (e.g., Illumina HiSeq).

**Protocol 3: FOXO1 Targeting Analysis**

**Step 3.1: Predict microRNAs that target FOXO1 using bioinformatic tools**

* Use bioinformatic tools (e.g., TargetScan, miRanda) to predict microRNAs that target FOXO1.
* Identify the top 10-20 predicted microRNAs for further analysis.

**Step 3.2: Validate the expression of predicted microRNAs using qRT-PCR**

* Design and synthesize primers specific to the predicted microRNAs.
* Perform qRT-PCR using a qRT-PCR machine (e.g., Applied Biosystems) according to the manufacturer's instructions.
* Analyze the qRT-PCR data using a software package (e.g., SDS software).

**Step 3.3: Analyze the correlation between GPS2 expression, PI3K/AKT pathway activity, and FOXO1-targeting microRNA expression**

* Use statistical software (e.g., R, Prism) to analyze the correlation between GPS2 expression, PI3K/AKT pathway activity, and FOXO1-targeting microRNA expression.
* Perform correlation analysis using Pearson's correlation coefficient or Spearman's rank correlation coefficient.

**Protocol 4: B Cell Development and Differentiation Assays**

**Step 4.1: Perform flow cytometry to analyze surface and intracellular markers**

* Harvest the B cells from the culture plates and wash them with PBS.
* Stain the B cells with fluorescently labeled antibodies specific to surface markers (e.g., CD19, CD20, CD23) and intracellular markers (e.g., FOXO1, AKT).
* Analyze the stained cells using a flow cytometer (e.g., BD FACSCanto) according to the manufacturer's instructions.

**Step 4.2: Evaluate B cell development and differentiation**

* Use flow cytometry data to evaluate the proportion of B cell subsets (e.g., pro-B, pre-B, immature, mature).
* Analyze the data using a software package (e.g., FlowJo) to determine the percentage of each B cell subset.

These detailed protocols should provide a clear guide for executing the experiment and obtaining reliable results.","```
   WT_Mice  GPS2_KO_Mice  LY294002  FBS  Penicillin_Streptomycin  L_Glutamine  microRNA_Profiling  FOXO1_Targeting  B_Cell_Development
0        5.0           5.0      10.0  10.0                1.0           1.0               2000.0           0.8           0.60
1        4.0           4.0       8.0  12.0                1.2           1.1               1800.0           0.7           0.55
2        3.0           3.0       6.0  11.0                1.1           1.0               2200.0           0.9           0.65
3        6.0           6.0      12.0  13.0                1.3           1.2               1900.0           0.8           0.58
4        5.5           5.5      11.0  12.5                1.2           1.1               2100.0           0.85          0.62
5        4.5           4.5       9.0  11.5                1.1           1.0               2000.0           0.8           0.60
6        3.5           3.5       7.0  10.5                1.0           0.9               2300.0           0.95          0.68
7        6.5           6.5      13.0  14.0                1.4           1.3               1800.0           0.7           0.55
8        5.0           5.0      10.0  12.0                1.2           1.1               2200.0           0.9           0.65
9        4.0           4.0       8.0  11.0                1.1           1.0               1900.0           0.8           0.58
10       3.0           3.0       6.0  10.0                1.0           0.9               2100.0           0.85          0.62
11       5.5           5.5      11.0  12.5                1.2           1.1               2000.0           0.8           0.60
12       4.5           4.5       9.0  11.5                1.1           1.0               2300.0           0.95          0.68
13       3.5           3.5       7.0  10.5                1.0           0.9               1800.0           0.7           0.55
14       6.5           6.5      13.0  14.0                1.4           1.3               2200.0           0.9           0.65
15       5.0           5.0      10.0  12.0                1.2           1.1               1900.0           0.8           0.58
16       4.0           4.0       8.0  11.0                1.1           1.0               2100.0           0.85          0.62
17       3.0           3.0       6.0  10.0                1.0           0.9               2000.0           0.8           0.60
18       5.5           5.5      11.0  12.5                1.2           1.1               2300.0           0.95          0.68
19       4.5           4.5       9.0  11.5                1.1           1.0               1800.0           0.7           0.55
20       3.5           3.5       7.0  10.5                1.0           0.9               2200.0           0.9           0.65
21       6.5           6.5      13.0  14.0                1.4           1.3               1900.0           0.8           0.58
22       5.0           5.0      10.0  12.0                1.2           1.1               2100.0           0.85          0.62
23       4.0           4.0       8.0  11.0                1.1           1.0               2000.0           0.8           0.60
24       3.0           3.0       6.0  10.0                1.0           0.9               2300.0           0.95          0.68
```",0.0818613228289185
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/59c0d6afdc3046269ac4e0c67c044df35ba59c5e.summary'],"Does Gal-9-mediated inhibition of TLR7 signaling in pDC and B cells also involve the suppression of the NLRP3 inflammasome, thereby reducing IL-1β production and further contributing to the alleviation of autoimmune manifestations in lupus models?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of Gal-9 in Suppressing NLRP3 Inflammasome and IL-1β Production in pDC and B Cells

**Objective:** To determine if Gal-9-mediated inhibition of TLR7 signaling in pDC and B cells involves the suppression of the NLRP3 inflammasome, leading to reduced IL-1β production and alleviation of autoimmune manifestations in lupus models.

**Equipment:**

* Flow cytometer
* Western blot
* pDC and B cell isolation kits
* Gal-9 protein
* TLR7 ligands
* NLRP3 inflammasome activators (e.g., ATP, nigericin)
* IL-1β ELISA kit
* qRT-PCR machine
* Primers for NLRP3, ASC, and IL-1β genes

**Steps:**

1. Isolate pDC and B cells from lupus-prone mice.
2. Treat cells with Gal-9 protein and TLR7 ligands, with or without NLRP3 inflammasome activators.
3. Analyze NLRP3 inflammasome activation by Western blot (NLRP3, ASC, and caspase-1) and qRT-PCR (NLRP3, ASC, and IL-1β mRNA).
4. Measure IL-1β production by ELISA.
5. Compare results to untreated controls, Gal-9-treated cells, and cells treated with NLRP3 inflammasome activators alone.
6. Perform flow cytometry to assess pDC and B cell activation and maturation markers.
7. Repeat the experiment using pDC and B cells from Gal-9 knockout mice to confirm the specific role of Gal-9 in NLRP3 inflammasome suppression.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Independence of Gal-9-Mediated TLR7 Inhibition and NLRP3 Inflammasome Suppression in pDC and B Cells

**Objective:** To demonstrate that Gal-9-mediated inhibition of TLR7 signaling in pDC and B cells does not involve the suppression of the NLRP3 inflammasome, and that IL-1β production is not affected.

**Equipment:**

* Same as above, with the addition of:
	+ NLRP3 inflammasome-specific inhibitors (e.g., MCC950)
	+ IL-1β-neutralizing antibodies

**Steps:**

1. Isolate pDC and B cells from lupus-prone mice.
2. Treat cells with Gal-9 protein and TLR7 ligands, with or without NLRP3 inflammasome inhibitors or IL-1β-neutralizing antibodies.
3. Analyze NLRP3 inflammasome activation by Western blot (NLRP3, ASC, and caspase-1) and qRT-PCR (NLRP3, ASC, and IL-1β mRNA).
4. Measure IL-1β production by ELISA.
5. Compare results to untreated controls, Gal-9-treated cells, and cells treated with NLRP3 inflammasome inhibitors or IL-1β-neutralizing antibodies alone.
6. Perform flow cytometry to assess pDC and B cell activation and maturation markers.
7. Repeat the experiment using pDC and B cells from Gal-9 knockout mice to confirm the specific role of Gal-9 in TLR7 inhibition.

By designing an experiment to disprove the hypothesis, we can attempt to rule out alternative explanations and increase confidence in the results. If the experiment to disprove the hypothesis fails to do so, it would provide strong evidence supporting the original hypothesis.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of Gal-9 in Suppressing NLRP3 Inflammasome and IL-1β Production in pDC and B Cells

**Objective:** To determine if Gal-9-mediated inhibition of TLR7 signaling in pDC and B cells involves the suppression of the NLRP3 inflammasome, leading to reduced IL-1β production and alleviation of autoimmune manifestations in lupus models.

**Step 1: Isolate pDC and B cells from lupus-prone mice**

* Obtain lupus-prone mice (e.g., MRL/lpr mice) and sacrifice them according to institutional guidelines.
* Harvest spleens and lymph nodes, and process them into single-cell suspensions using a gentleMACS Dissociator (Miltenyi Biotec) or a similar device.
* Use pDC and B cell isolation kits (e.g., Miltenyi Biotec) to isolate pDC and B cells according to the manufacturer's instructions.
* Count and verify the purity of isolated cells using flow cytometry (e.g., BD FACSCanto II) and antibodies specific to pDC (e.g., CD11c, Siglec-H) and B cells (e.g., CD19, CD20).

**Step 2: Treat cells with Gal-9 protein and TLR7 ligands, with or without NLRP3 inflammasome activators**

* Prepare Gal-9 protein (e.g., recombinant human Gal-9, R&D Systems) according to the manufacturer's instructions.
* Prepare TLR7 ligands (e.g., R848, InvivoGen) according to the manufacturer's instructions.
* Prepare NLRP3 inflammasome activators (e.g., ATP, nigericin, Sigma-Aldrich) according to the manufacturer's instructions.
* Treat isolated pDC and B cells with:
	+ Gal-9 protein (e.g., 10 μg/mL) for 30 minutes at 37°C.
	+ TLR7 ligands (e.g., 1 μg/mL) for 2 hours at 37°C.
	+ NLRP3 inflammasome activators (e.g., 5 mM ATP or 10 μM nigericin) for 1 hour at 37°C.
	+ Combinations of the above treatments (e.g., Gal-9 + TLR7 ligands, Gal-9 + NLRP3 inflammasome activators, etc.).

**Step 3: Analyze NLRP3 inflammasome activation by Western blot and qRT-PCR**

* Prepare cell lysates from treated cells using a lysis buffer (e.g., RIPA buffer, Thermo Fisher Scientific) and a protease inhibitor cocktail (e.g., cOmplete, Roche).
* Perform Western blot analysis using antibodies specific to NLRP3, ASC, and caspase-1 (e.g., Cell Signaling Technology).
* Perform qRT-PCR analysis using primers specific to NLRP3, ASC, and IL-1β genes (e.g., Qiagen) and a qRT-PCR machine (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).

**Step 4: Measure IL-1β production by ELISA**

* Prepare cell culture supernatants from treated cells.
* Perform ELISA analysis using an IL-1β ELISA kit (e.g., R&D Systems) according to the manufacturer's instructions.

**Step 5: Compare results to untreated controls, Gal-9-treated cells, and cells treated with NLRP3 inflammasome activators alone**

* Compare the results of Western blot, qRT-PCR, and ELISA analyses between different treatment groups.
* Perform statistical analysis (e.g., one-way ANOVA, Tukey's post-hoc test) to determine significant differences between groups.

**Step 6: Perform flow cytometry to assess pDC and B cell activation and maturation markers**

* Stain treated cells with antibodies specific to pDC (e.g., CD11c, Siglec-H) and B cell (e.g., CD19, CD20) activation and maturation markers (e.g., CD40, CD86, CD69).
* Perform flow cytometry analysis using a flow cytometer (e.g., BD FACSCanto II).

**Step 7: Repeat the experiment using pDC and B cells from Gal-9 knockout mice**

* Obtain Gal-9 knockout mice (e.g., Gal-9-/- mice) and isolate pDC and B cells as described in Step 1.
* Repeat the experiment using Gal-9 knockout pDC and B cells to confirm the specific role of Gal-9 in NLRP3 inflammasome suppression.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Independence of Gal-9-Mediated TLR7 Inhibition and NLRP3 Inflammasome Suppression in pDC and B Cells

**Objective:** To demonstrate that Gal-9-mediated inhibition of TLR7 signaling in pDC and B cells does not involve the suppression of the NLRP3 inflammasome, and that IL-1β production is not affected.

**Steps:**

* Repeat Steps 1-3 of the experiment to test the hypothesis, with the addition of:
	+ NLRP3 inflammasome-specific inhibitors (e.g., MCC950, Sigma-Aldrich) at a concentration of 10 μM for 1 hour at 37°C.
	+ IL-1β-neutralizing antibodies (e.g., R&D Systems) at a concentration of 10 μg/mL for 1 hour at 37°C.
* Perform Steps 4-6 of the experiment to test the hypothesis, with the addition of:
	+ Comparing results to cells treated with NLRP3 inflammasome inhibitors or IL-1β-neutralizing antibodies alone.
* Repeat the experiment using pDC and B cells from Gal-9 knockout mice to confirm the specific role of Gal-9 in TLR7 inhibition.

Note: The detailed protocols provided are specific to the equipment and reagents listed, and may need to be modified based on the specific requirements of the laboratory and the experiment.","```
   Gal-9 (μg/mL)  TLR7 Ligands (μg/mL)  NLRP3 Activators (mM)  IL-1β Production (pg/mL)
0             5.0                 0.5                2.5                120.0
1             2.5                 1.0                5.0                180.0
2            10.0                 0.2                1.0                 80.0
3             7.5                 1.5                3.5                150.0
4             5.0                 0.8                4.0                130.0
5             2.5                 1.2                2.0                110.0
6            12.5                 0.5                3.0                140.0
7             7.5                 1.0                1.5                100.0
8             5.0                 1.5                4.5                160.0
9             2.5                 0.8                3.5                120.0
10           10.0                 1.2                2.5                130.0
11            7.5                 0.5                4.0                140.0
12           12.5                 1.0                3.0                150.0
13            5.0                 1.5                2.0                110.0
14            2.5                 0.2                1.5                90.0
15           10.0                 0.8                3.5                120.0
16            7.5                 1.2                4.5                160.0
17           12.5                 1.5                2.5                140.0
18            5.0                 0.5                1.0                 80.0
19            2.5                 1.0                2.0                100.0
20           10.0                 1.5                3.0                130.0
21            7.5                 0.8                4.0                140.0
22           12.5                 1.2                2.5                150.0
23            5.0                 1.0                3.5                120.0
24            2.5                 0.5                1.5                90.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ed2f4fca5cb85bc6173c81f0d5ed345083d36df8.summary'],"Does Hrd1-mediated ubiquitination of pre-BCR also regulate the expression of other key transcription factors involved in B cell development, such as Pax5 or E2A, to ensure proper B cell maturation and function?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Hrd1-mediated ubiquitination of pre-BCR also regulates the expression of other key transcription factors involved in B cell development, such as Pax5 or E2A, to ensure proper B cell maturation and function.

**Experimental Plan:**

**Objective:** To investigate whether Hrd1-mediated ubiquitination of pre-BCR regulates the expression of Pax5 and E2A transcription factors in B cell development.

**Equipment:**

* Mouse models with conditional deletion of Hrd1 in B cells (generated using Cre-LoxP system)
* Antibodies against Hrd1, pre-BCR, Pax5, E2A, and ubiquitin
* Western blotting and immunoprecipitation reagents
* Flow cytometry equipment
* qRT-PCR equipment
* Chromatin immunoprecipitation (ChIP) equipment (optional)

**Steps:**

1. Isolate B cells from bone marrow and spleen of WT and Hrd1 KO mice.
2. Perform Western blotting and immunoprecipitation to detect ubiquitination of pre-BCR, Pax5, and E2A in WT and Hrd1 KO B cells.
3. Analyze protein expression levels of Pax5 and E2A in WT and Hrd1 KO B cells using Western blotting.
4. Perform qRT-PCR to measure mRNA levels of Pax5 and E2A in WT and Hrd1 KO B cells.
5. Analyze B cell development stages using flow cytometry and compare between WT and Hrd1 KO mice.
6. Perform ChIP assays (if possible within the budget and time constraints) to investigate whether Hrd1 regulates the binding of Pax5 and E2A to their target genes.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that Hrd1-mediated ubiquitination of pre-BCR does not regulate the expression of Pax5 and E2A transcription factors in B cell development.

**Design:**

1. Use a rescue experiment: Express a ubiquitination-resistant pre-BCR mutant in Hrd1 KO B cells and analyze Pax5 and E2A expression levels.
2. If Hrd1-mediated ubiquitination of pre-BCR regulates Pax5 and E2A expression, the rescue of pre-BCR ubiquitination should restore Pax5 and E2A expression to WT levels.
3. If Pax5 and E2A expression levels remain unaffected, it would suggest that Hrd1-mediated ubiquitination of pre-BCR does not regulate their expression.

**Rationale:** By using a ubiquitination-resistant pre-BCR mutant, we can specifically rescue the ubiquitination of pre-BCR without affecting other potential Hrd1 substrates. If Pax5 and E2A expression levels are not restored, it would imply that Hrd1-mediated ubiquitination of pre-BCR is not involved in their regulation.

**Time and Resource Considerations:**

* The experiment can be completed within 6-9 months, depending on the availability of resources and the complexity of the ChIP assays.
* The budget will be primarily allocated to:
	+ Generating the mouse models with conditional deletion of Hrd1 in B cells
	+ Purchasing antibodies and reagents for Western blotting, immunoprecipitation, and qRT-PCR
	+ Flow cytometry and ChIP equipment usage (if applicable)

This experimental plan is designed to test the hypothesis and provide evidence for or against the role of Hrd1-mediated ubiquitination of pre-BCR in regulating Pax5 and E2A expression in B cell development.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Isolation of B cells from bone marrow and spleen of WT and Hrd1 KO mice**

1.1. Prepare the necessary materials:
	* WT and Hrd1 KO mice
	* Sterile scissors and forceps
	* 70% ethanol
	* RPMI 1640 medium
	* Fetal bovine serum (FBS)
	* Red blood cell lysis buffer
	* B cell isolation kit (e.g., Miltenyi Biotec)

1.2. Euthanize the mice according to institutional guidelines.

1.3. Remove the bone marrow from the femur and tibia using sterile scissors and forceps.

1.4. Place the bone marrow in a sterile tube containing 10 mL of RPMI 1640 medium with 10% FBS.

1.5. Homogenize the bone marrow using a gentleMACS Dissociator (Miltenyi Biotec) or a similar device.

1.6. Filter the homogenate through a 40 μm cell strainer to remove debris.

1.7. Centrifuge the cells at 300 x g for 10 minutes.

1.8. Resuspend the cells in 1 mL of red blood cell lysis buffer and incubate for 5 minutes at room temperature.

1.9. Add 10 mL of RPMI 1640 medium with 10% FBS to stop the lysis reaction.

1.10. Centrifuge the cells at 300 x g for 10 minutes.

1.11. Resuspend the cells in 1 mL of RPMI 1640 medium with 10% FBS.

1.12. Perform B cell isolation using a B cell isolation kit according to the manufacturer's instructions.

1.13. Collect the isolated B cells and count them using a hemocytometer or an automated cell counter.

**Protocol 2: Western blotting and immunoprecipitation**

2.1. Prepare the necessary materials:
	* Isolated B cells from WT and Hrd1 KO mice
	* Lysis buffer (e.g., RIPA buffer)
	* Protease inhibitor cocktail
	* Antibodies against Hrd1, pre-BCR, Pax5, E2A, and ubiquitin
	* Protein A/G beads
	* Western blotting reagents (e.g., ECL substrate, PVDF membrane)

2.2. Lyse the B cells in 1 mL of lysis buffer with protease inhibitor cocktail.

2.3. Incubate the lysate on ice for 30 minutes.

2.4. Centrifuge the lysate at 10,000 x g for 10 minutes.

2.5. Collect the supernatant and perform immunoprecipitation using antibodies against Hrd1, pre-BCR, Pax5, E2A, and ubiquitin according to the manufacturer's instructions.

2.6. Elute the immunoprecipitated proteins using 2x Laemmli buffer.

2.7. Perform Western blotting using the eluted proteins and the corresponding antibodies.

2.8. Detect the proteins using ECL substrate and expose the PVDF membrane to X-ray film or a chemiluminescence imager.

**Protocol 3: Analysis of protein expression levels using Western blotting**

3.1. Prepare the necessary materials:
	* Isolated B cells from WT and Hrd1 KO mice
	* Lysis buffer (e.g., RIPA buffer)
	* Protease inhibitor cocktail
	* Antibodies against Pax5 and E2A
	* Western blotting reagents (e.g., ECL substrate, PVDF membrane)

3.2. Lyse the B cells in 1 mL of lysis buffer with protease inhibitor cocktail.

3.3. Incubate the lysate on ice for 30 minutes.

3.4. Centrifuge the lysate at 10,000 x g for 10 minutes.

3.5. Collect the supernatant and perform Western blotting using antibodies against Pax5 and E2A.

3.6. Detect the proteins using ECL substrate and expose the PVDF membrane to X-ray film or a chemiluminescence imager.

**Protocol 4: qRT-PCR analysis of mRNA levels**

4.1. Prepare the necessary materials:
	* Isolated B cells from WT and Hrd1 KO mice
	* RNA isolation kit (e.g., TRIzol)
	* cDNA synthesis kit (e.g., iScript)
	* qRT-PCR primers for Pax5 and E2A
	* qRT-PCR reagents (e.g., SYBR Green)

4.2. Isolate RNA from the B cells using an RNA isolation kit according to the manufacturer's instructions.

4.3. Synthesize cDNA from the isolated RNA using a cDNA synthesis kit according to the manufacturer's instructions.

4.4. Perform qRT-PCR using the synthesized cDNA, qRT-PCR primers, and qRT-PCR reagents.

4.5. Analyze the qRT-PCR data using a software (e.g., Bio-Rad CFX Manager) to determine the relative mRNA levels of Pax5 and E2A.

**Protocol 5: Flow cytometry analysis of B cell development stages**

5.1. Prepare the necessary materials:
	* Isolated B cells from WT and Hrd1 KO mice
	* Flow cytometry antibodies (e.g., CD19, CD20, IgM, IgD)
	* Flow cytometry buffer (e.g., PBS with 2% FBS)

5.2. Stain the B cells with flow cytometry antibodies according to the manufacturer's instructions.

5.3. Analyze the stained cells using a flow cytometer (e.g., BD FACSCanto II).

5.4. Gate the B cells based on CD19 and CD20 expression.

5.5. Analyze the expression of IgM and IgD on the gated B cells to determine the B cell development stages.

**Protocol 6: Chromatin immunoprecipitation (ChIP) assay (optional)**

6.1. Prepare the necessary materials:
	* Isolated B cells from WT and Hrd1 KO mice
	* ChIP-grade antibodies against Pax5 and E2A
	* ChIP kit (e.g., Millipore ChIP Assay Kit)
	* qRT-PCR primers for target genes of Pax5 and E2A

6.2. Cross-link the B cells with formaldehyde according to the manufacturer's instructions.

6.3. Sonicate the cross-linked cells to fragment the chromatin.

6.4. Perform ChIP using the ChIP-grade antibodies and the sonicated chromatin according to the manufacturer's instructions.

6.5. Analyze the immunoprecipitated DNA using qRT-PCR with primers specific to the target genes of Pax5 and E2A.

**Protocol 7: Rescue experiment using a ubiquitination-resistant pre-BCR mutant**

7.1. Prepare the necessary materials:
	* Hrd1 KO B cells
	* Ubiquitination-resistant pre-BCR mutant plasmid
	* Transfection reagent (e.g., Lipofectamine 2000)

7.2. Transfect the Hrd1 KO B cells with the ubiquitination-resistant pre-BCR mutant plasmid using a transfection reagent according to the manufacturer's instructions.

7.3. Analyze the expression levels of Pax5 and E2A in the transfected cells using Western blotting and qRT-PCR.

7.4. Compare the expression levels of Pax5 and E2A in the transfected cells to those in WT and Hrd1 KO B cells.

These detailed protocols should provide a clear guide for executing the experimental plan and testing the hypothesis.","```
   WT_mice  Hrd1_KO_mice  RPMI_1640_medium  FBS  Red_blood_cell_lysis_buffer  B_cell_isolation_kit  Lysis_buffer  Protease_inhibitor_cocktail  Antibodies  Protein_A_G_beeds  Western_blotting_reagents  Outcome
0        2          2               10.0  10.0                         1.0               1.0               1.0                         1.0             1.0                  1.0                    1.0  Success
1        3          1               12.0  12.0                         1.5               1.5               1.5                         1.5             1.5                  1.5                    1.5  Success
2        1          3               8.0   8.0                         0.5               0.5               0.5                         0.5             0.5                  0.5                    0.5  Failure
3        2          2               11.0  11.0                         1.2               1.2               1.2                         1.2             1.2                  1.2                    1.2  Success
4        4          0               13.0  13.0                         2.0               2.0               2.0                         2.0             2.0                  2.0                    2.0  Success
5        0          4               7.0   7.0                         0.3               0.3               0.3                         0.3             0.3                  0.3                    0.3  Failure
6        2          2               9.0   9.0                         0.8               0.8               0.8                         0.8             0.8                  0.8                    0.8  Success
7        3          1               14.0  14.0                         2.5               2.5               2.5                         2.5             2.5                  2.5                    2.5  Success
8        1          3               6.0   6.0                         0.2               0.2               0.2                         0.2             0.2                  0.2                    0.2  Failure
9        2          2               10.5  10.5                         1.1               1.1               1.1                         1.1             1.1                  1.1                    1.1  Success
10       4          0               15.0  15.0                         3.0               3.0               3.0                         3.0             3.0                  3.0                    3.0  Success
11       0          4               5.0   5.0                         0.1               0.1               0.1                         0.1             0.1                  0.1                    0.1  Failure
12       2          2               9.5   9.5                         0.9               0.9               0.9                         0.9             0.9                  0.9                    0.9  Success
13       3          1               16.0  16.0                         3.5               3.5               3.5                         3.5             3.5                  3.5                    3.5  Success
14       1          3               4.0   4.0                         0.4               0.4               0.4                         0.4             0.4                  0.4                    0.4  Failure
15       2          2               11.5  11.5                         1.4               1.4               1.4                         1.4             1.4                  1.4                    1.4  Success
16       4          0               17.0  17.0                         4.0               4.0               4.0                         4.0             4.0                  4.0                    4.0  Success
17       0          4               3.0   3.0                         0.6               0.6               0.6                         0.6             0.6                  0.6                    0.6  Failure
18       2          2               10.0  10.0                         1.0               1.0               1.0                         1.0             1.0                  1.0                    1.0  Success
19       3          1               18.0  18.0                         4.5               4.5               4.5                         4.5             4.5                  4.5                    4.5  Success
20       1          3               2.0   2.0                         0.7               0.7               0.7                         0.7             0.7                  0.7                    0.7  Failure
21       2          2               12.0  12.0                         1.6               1.6               1.6                         1.6             1.6                  1.6                    1.6  Success
22       4          0               19.0  19.0                         5.0               5.0               5.0                         5.0             5.0                  5.0                    5.0  Success
23       0          4               1.0   1.0                         0.8               0.8               0.8                         0.8             0.8                  0.8                    0.8  Failure
24       2          2               13.0  13.0                         1.8               1.8               1.8                         1.8             1.8                  1.8                    1.8  Success
```",0.525466734479961
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/022dc2aeae70a5e9c44516de773b767a88c90e84.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/620cb906daa5919d237cd715f4715246e5d76e88.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ae5a332a74e8e21e8db97d2f10c0b35d4d536381.summary']","Does IL-17A-induced Blimp-1 expression in B-1a cells also regulate the PI3K pathway, thereby influencing the function of regulatory B cells in autoimmune diseases?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! To test this hypothesis, I'll outline a concise experimental plan to investigate the role of IL-17A-induced Blimp-1 expression in B-1a cells on the PI3K pathway and its impact on regulatory B cells in autoimmune diseases.

**Hypothesis:** IL-17A-induced Blimp-1 expression in B-1a cells regulates the PI3K pathway, influencing the function of regulatory B cells in autoimmune diseases.

**Experimental Approach:**

**Objective:** Design an experiment to disprove the hypothesis, thereby verifying its validity.

**Step 1: Cell Isolation and Culture**

* Isolate B-1a cells from mouse spleens using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS).
* Culture B-1a cells in vitro with or without IL-17A stimulation.

**Step 2: Blimp-1 Expression Analysis**

* Use quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure Blimp-1 mRNA expression in IL-17A-stimulated and unstimulated B-1a cells.
* Perform Western blotting to analyze Blimp-1 protein expression.

**Step 3: PI3K Pathway Analysis**

* Use Western blotting to examine the phosphorylation status of key PI3K pathway components (e.g., Akt, PDK1) in IL-17A-stimulated and unstimulated B-1a cells.
* Perform a PI3K activity assay (e.g., PI3K ELISA) to measure PI3K activity in response to IL-17A stimulation.

**Step 4: Regulatory B Cell Function Analysis**

* Co-culture B-1a cells with CD4+ T cells and measure T cell proliferation using a cell proliferation assay (e.g., CFSE).
* Analyze the expression of regulatory B cell markers (e.g., CD25, CD1d) on B-1a cells using flow cytometry.

**Step 5: Inhibition of Blimp-1 or PI3K**

* Use small interfering RNA (siRNA) or CRISPR-Cas9 to knockdown Blimp-1 expression in B-1a cells.
* Treat B-1a cells with a PI3K inhibitor (e.g., LY294002) to block PI3K activity.
* Repeat Steps 2-4 to assess the effects of Blimp-1 or PI3K inhibition on PI3K pathway activity and regulatory B cell function.

**Step 6: Data Analysis and Interpretation**

* Compare the results from IL-17A-stimulated and unstimulated B-1a cells, as well as Blimp-1 or PI3K-inhibited cells, to determine if IL-17A-induced Blimp-1 expression regulates the PI3K pathway and influences regulatory B cell function.

**Budget and Timeframe:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget will cover the costs of:
	+ Cell isolation and culture reagents
	+ qRT-PCR and Western blotting reagents
	+ PI3K activity assay kit
	+ Cell proliferation assay kit
	+ Flow cytometry reagents
	+ siRNA or CRISPR-Cas9 reagents
	+ PI3K inhibitor
	+ Laboratory consumables and personnel costs

By following this experimental plan, we can test the hypothesis and determine if IL-17A-induced Blimp-1 expression in B-1a cells regulates the PI3K pathway, influencing the function of regulatory B cells in autoimmune diseases.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Cell Isolation and Culture**

1.1. Mouse Spleen Collection:

* Obtain 5-10 mice (specific strain and age to be determined based on experimental requirements)
* Euthanize mice according to institutional guidelines
* Remove spleens and place them in a sterile petri dish containing 10 mL of cold phosphate-buffered saline (PBS)

1.2. Spleen Dissociation:

* Use a sterile scalpel to mince the spleens into small pieces
* Transfer the minced spleen tissue to a 50 mL conical tube
* Add 10 mL of cold PBS and gently pipette up and down to dissociate the tissue
* Filter the mixture through a 70 μm cell strainer into a new 50 mL conical tube

1.3. B-1a Cell Isolation using FACS or MACS:

* If using FACS:
	+ Stain the cells with fluorescently labeled antibodies against B-1a cell surface markers (e.g., CD19, CD11b, CD5)
	+ Sort B-1a cells using a flow cytometer (e.g., BD FACSAria)
	+ Collect sorted cells in a 15 mL conical tube containing 5 mL of complete RPMI 1640 medium
* If using MACS:
	+ Stain the cells with magnetic beads conjugated to antibodies against B-1a cell surface markers (e.g., CD19, CD11b, CD5)
	+ Separate the cells using a magnetic separator (e.g., Miltenyi Biotec)
	+ Collect the isolated B-1a cells in a 15 mL conical tube containing 5 mL of complete RPMI 1640 medium

1.4. Cell Culture:

* Centrifuge the isolated B-1a cells at 300 x g for 5 minutes
* Resuspend the cells in complete RPMI 1640 medium containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine
* Plate the cells in a 24-well plate at a density of 1 x 10^6 cells/mL
* Incubate the cells at 37°C, 5% CO2 for 24 hours

**Step 2: Blimp-1 Expression Analysis**

2.1. RNA Isolation:

* After 24 hours of culture, collect the cells and centrifuge at 300 x g for 5 minutes
* Resuspend the cells in 1 mL of TRIzol reagent
* Incubate at room temperature for 5 minutes
* Add 200 μL of chloroform and mix well
* Centrifuge at 12,000 x g for 15 minutes
* Collect the aqueous phase and add 500 μL of isopropanol
* Incubate at -20°C for 1 hour
* Centrifuge at 12,000 x g for 15 minutes
* Wash the pellet with 75% ethanol and centrifuge at 12,000 x g for 5 minutes
* Air-dry the pellet and resuspend in 20 μL of RNase-free water

2.2. qRT-PCR:

* Prepare a master mix containing 10 μL of 2x qRT-PCR mix, 1 μL of forward primer, 1 μL of reverse primer, and 1 μL of RNA template
* Perform qRT-PCR using a thermocycler (e.g., Applied Biosystems 7500) with the following conditions:
	+ 95°C for 10 minutes
	+ 40 cycles of 95°C for 15 seconds, 60°C for 1 minute
	+ 72°C for 10 minutes
* Analyze the data using the ΔΔCt method

2.3. Western Blotting:

* After 24 hours of culture, collect the cells and centrifuge at 300 x g for 5 minutes
* Resuspend the cells in 100 μL of RIPA buffer containing protease inhibitors
* Incubate on ice for 30 minutes
* Centrifuge at 12,000 x g for 15 minutes
* Collect the supernatant and determine protein concentration using a protein assay (e.g., Bradford)
* Load 20 μg of protein onto a 10% SDS-PAGE gel
* Transfer the proteins to a PVDF membrane
* Block the membrane with 5% milk in TBST for 1 hour
* Incubate with a Blimp-1 antibody (e.g., Abcam) at 1:1000 dilution overnight at 4°C
* Wash the membrane with TBST and incubate with a secondary antibody (e.g., HRP-conjugated anti-rabbit) at 1:5000 dilution for 1 hour
* Develop the membrane using an ECL substrate (e.g., Amersham)

**Step 3: PI3K Pathway Analysis**

3.1. Western Blotting:

* Perform Western blotting as described in Step 2.3, using antibodies against phosphorylated PI3K pathway components (e.g., p-Akt, p-PDK1)

3.2. PI3K Activity Assay:

* Use a PI3K activity assay kit (e.g., Echelon Biosciences) according to the manufacturer's instructions
* Measure PI3K activity in IL-17A-stimulated and unstimulated B-1a cells

**Step 4: Regulatory B Cell Function Analysis**

4.1. Co-Culture with CD4+ T Cells:

* Isolate CD4+ T cells from mouse spleens using FACS or MACS
* Co-culture 1 x 10^5 B-1a cells with 1 x 10^5 CD4+ T cells in a 96-well plate
* Add 100 μL of complete RPMI 1640 medium containing 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine
* Incubate at 37°C, 5% CO2 for 72 hours

4.2. Cell Proliferation Assay:

* Add 1 μCi of [3H]-thymidine to each well
* Incubate for an additional 18 hours
* Harvest the cells and measure [3H]-thymidine incorporation using a scintillation counter

4.3. Flow Cytometry:

* Stain the co-cultured cells with fluorescently labeled antibodies against regulatory B cell markers (e.g., CD25, CD1d)
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto)

**Step 5: Inhibition of Blimp-1 or PI3K**

5.1. siRNA Transfection:

* Design siRNA oligonucleotides targeting Blimp-1
* Transfect 1 x 10^6 B-1a cells with 100 nM siRNA using a transfection reagent (e.g., Lipofectamine)
* Incubate at 37°C, 5% CO2 for 24 hours

5.2. CRISPR-Cas9 Gene Editing:

* Design guide RNAs targeting Blimp-1
* Transfect 1 x 10^6 B-1a cells with 100 nM guide RNA and 100 nM Cas9 protein using a transfection reagent (e.g., Lipofectamine)
* Incubate at 37°C, 5% CO2 for 24 hours

5.3. PI3K Inhibition:

* Treat 1 x 10^6 B-1a cells with 10 μM LY294002 (PI3K inhibitor) for 24 hours

**Step 6: Data Analysis and Interpretation**

6.1. Compare the results from IL-17A-stimulated and unstimulated B-1a cells, as well as Blimp-1 or PI3K-inhibited cells
6.2. Analyze the data using statistical software (e.g., GraphPad Prism)
6.3. Interpret the results in the context of the hypothesis and discuss the implications for autoimmune diseases

Note: The above protocols are detailed and specific, but may require adjustments based on the specific requirements of the experiment and the laboratory equipment available. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.",,0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/116dbe384b031942527962c03b1d87faa0eb3554.summary'],"Does IRF4-mediated regulation of NFAT activity in EBV-infected B cells also influence the expression of epithelial-mesenchymal transition genes, thereby modulating the invasive potential of these cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis and potentially disprove it. Since the goal is to test the influence of IRF4-mediated regulation of NFAT activity on the expression of epithelial-mesenchymal transition (EMT) genes and invasive potential in EBV-infected B cells, the experiment will focus on these specific aspects.

**Experiment:**

**Title:** Investigating the role of IRF4-mediated NFAT regulation on EMT gene expression and invasive potential in EBV-infected B cells

**Objective:** To determine if IRF4-mediated regulation of NFAT activity in EBV-infected B cells influences the expression of EMT genes and modulates the invasive potential of these cells.

**Experimental Design:**

1. **Cell Culture:** Use T2 EBV-infected B cells (as described in the provided paper) and maintain them in a suitable culture medium.
2. **IRF4 Knockdown:** Use RNA interference (RNAi) or CRISPR-Cas9 gene editing to knockdown IRF4 expression in T2 EBV-infected B cells. This will allow us to investigate the effect of reduced IRF4 expression on NFAT activity, EMT gene expression, and invasive potential.
3. **NFAT Activity Assay:** Measure NFAT activity in IRF4-knockdown cells using an NFAT activity assay kit. Compare the results to control cells with normal IRF4 expression.
4. **EMT Gene Expression Analysis:** Use qRT-PCR to measure the expression of EMT-related genes (e.g., Snail, Slug, Twist, ZEB1, and ZEB2) in IRF4-knockdown cells. Compare the results to control cells.
5. **Invasive Potential Assay:** Use a transwell invasion assay or a Boyden chamber assay to measure the invasive potential of IRF4-knockdown cells. Compare the results to control cells.
6. **Western Blot:** Verify IRF4 protein expression in IRF4-knockdown cells using Western blot.

**Negative Control:** Use a non-targeting RNAi or a control CRISPR-Cas9 guide RNA to ensure that the observed effects are specific to IRF4 knockdown.

**Positive Control:** Use a known inducer of EMT (e.g., TGF-β) to stimulate EMT gene expression and invasive potential in control cells.

**Expected Outcomes:**

* If the hypothesis is true, IRF4 knockdown should lead to increased NFAT activity, upregulation of EMT genes, and enhanced invasive potential in T2 EBV-infected B cells.
* If the hypothesis is false, IRF4 knockdown should not affect NFAT activity, EMT gene expression, or invasive potential in T2 EBV-infected B cells.

**Timeline:** This experiment can be completed within 6-8 weeks, assuming a moderate pace and availability of resources.

**Budget:** The estimated budget for this experiment is moderate, as it requires RNAi or CRISPR-Cas9 reagents, NFAT activity assay kits, qRT-PCR reagents, transwell invasion assay or Boyden chamber, and Western blot reagents. The total cost should be around $5,000-$7,000.

By designing an experiment to disprove the hypothesis, we can gain a deeper understanding of the relationship between IRF4, NFAT, and EMT gene expression in EBV-infected B cells, and potentially uncover new insights into the mechanisms underlying EBV-mediated B-cell transformation.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture**

1.1. Obtain T2 EBV-infected B cells from a reliable source or generate them according to the provided paper.

1.2. Maintain the cells in a suitable culture medium, such as RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.3. Incubate the cells at 37°C in a humidified atmosphere with 5% CO2.

1.4. Passage the cells every 3-4 days to maintain a healthy and exponentially growing culture.

**Protocol 2: IRF4 Knockdown**

2.1. Design and synthesize RNAi oligonucleotides or CRISPR-Cas9 guide RNAs targeting IRF4.

2.2. For RNAi:
	* Transfect 1-2 x 10^6 T2 EBV-infected B cells with 10-20 nM IRF4-targeting RNAi oligonucleotides using a transfection reagent (e.g., Lipofectamine RNAiMAX) according to the manufacturer's instructions.
	* Incubate the cells for 24-48 hours to allow for RNAi-mediated knockdown of IRF4.

2.3. For CRISPR-Cas9:
	* Transfect 1-2 x 10^6 T2 EBV-infected B cells with 1-2 μg of CRISPR-Cas9 plasmid containing the IRF4-targeting guide RNA using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.
	* Incubate the cells for 24-48 hours to allow for CRISPR-Cas9-mediated knockout of IRF4.

2.4. Verify IRF4 knockdown using Western blot (Protocol 6).

**Protocol 3: NFAT Activity Assay**

3.1. Prepare cell lysates from IRF4-knockdown and control cells using a lysis buffer (e.g., RIPA buffer).

3.2. Measure NFAT activity using an NFAT activity assay kit according to the manufacturer's instructions.

3.3. Normalize NFAT activity to total protein concentration or a housekeeping gene (e.g., GAPDH).

3.4. Compare NFAT activity between IRF4-knockdown and control cells.

**Protocol 4: EMT Gene Expression Analysis**

4.1. Extract total RNA from IRF4-knockdown and control cells using a RNA extraction kit (e.g., TRIzol).

4.2. Reverse transcribe 1-2 μg of total RNA into cDNA using a reverse transcription kit (e.g., SuperScript III).

4.3. Perform qRT-PCR using a qRT-PCR kit (e.g., PowerUp SYBR Green) and primers specific to EMT-related genes (e.g., Snail, Slug, Twist, ZEB1, and ZEB2).

4.4. Normalize gene expression to a housekeeping gene (e.g., GAPDH) and calculate the fold change in gene expression between IRF4-knockdown and control cells.

**Protocol 5: Invasive Potential Assay**

5.1. Prepare a transwell invasion assay or Boyden chamber according to the manufacturer's instructions.

5.2. Seed 1-2 x 10^5 IRF4-knockdown and control cells into the upper chamber of the transwell or Boyden chamber.

5.3. Incubate the cells for 24-48 hours to allow for invasion.

5.4. Fix and stain the cells that have invaded through the membrane using a staining solution (e.g., crystal violet).

5.5. Count the number of invaded cells using a microscope or an automated cell counter.

5.6. Calculate the invasive potential as a percentage of invaded cells relative to the total number of cells seeded.

**Protocol 6: Western Blot**

6.1. Prepare cell lysates from IRF4-knockdown and control cells using a lysis buffer (e.g., RIPA buffer).

6.2. Separate 20-30 μg of protein from each sample by SDS-PAGE using a 10% polyacrylamide gel.

6.3. Transfer the proteins to a PVDF membrane using a wet transfer apparatus.

6.4. Block the membrane with 5% non-fat milk in TBST for 1 hour.

6.5. Incubate the membrane with a primary antibody against IRF4 (1:1000 dilution) overnight at 4°C.

6.6. Incubate the membrane with a secondary antibody (1:5000 dilution) for 1 hour at room temperature.

6.7. Detect the protein bands using an ECL substrate and a chemiluminescence imager.

6.8. Verify IRF4 knockdown by comparing the protein band intensity between IRF4-knockdown and control cells.

**Negative Control:**

* Use a non-targeting RNAi or a control CRISPR-Cas9 guide RNA to ensure that the observed effects are specific to IRF4 knockdown.

**Positive Control:**

* Use a known inducer of EMT (e.g., TGF-β) to stimulate EMT gene expression and invasive potential in control cells.

By following these detailed protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis and potentially disprove it.","```
   T2_EBV_Infected_B_Cells  RNAi_Oligonucleotides  CRISPR_Cas9_Plasmid  IRF4_Knockdown  NFAT_Activity  Snail_Expression  Slug_Expression  Twist_Expression  ZEB1_Expression  ZEB2_Expression  Invasive_Potential
0                    1.5e+06               15.0             1.5         0.7         1.2         2.1         1.8         1.5         1.9         2.3         0.45
1                    1.2e+06               12.0             1.2         0.8         1.5         2.5         2.2         1.8         2.1         2.6         0.50
2                    1.8e+06               18.0             1.8         0.6         1.0         1.9         1.6         1.4         1.7         2.0         0.40
3                    1.1e+06               11.0             1.1         0.9         1.8         3.1         2.9         2.5         2.8         3.2         0.60
4                    1.6e+06               16.0             1.6         0.7         1.3         2.3         2.0         1.7         2.0         2.4         0.48
5                    1.4e+06               14.0             1.4         0.8         1.6         2.8         2.5         2.2         2.5         2.9         0.55
6                    1.7e+06               17.0             1.7         0.6         1.1         2.0         1.8         1.6         1.9         2.2         0.42
7                    1.3e+06               13.0             1.3         0.9         1.9         3.4         3.1         2.8         3.1         3.5         0.65
8                    1.9e+06               19.0             1.9         0.7         1.4         2.6         2.3         2.0         2.3         2.7         0.50
9                    1.0e+06               10.0             1.0         0.8         1.7         3.0         2.7         2.4         2.7         3.1         0.58
10                   1.6e+06               16.0             1.6         0.6         1.2         2.2         2.0         1.8         2.1         2.5         0.45
11                   1.5e+06               15.0             1.5         0.9         1.8         3.2         2.9         2.6         2.9         3.3         0.62
12                   1.2e+06               12.0             1.2         0.7         1.3         2.4         2.1         1.9         2.2         2.6         0.48
13                   1.8e+06               18.0             1.8         0.8         1.6         2.9         2.6         2.3         2.6         3.0         0.55
14                   1.4e+06               14.0             1.4         0.6         1.1         2.1         1.9         1.7         2.0         2.3         0.43
15                   1.7e+06               17.0             1.7         0.9         1.9         3.5         3.2         2.9         3.2         3.6         0.68
16                   1.3e+06               13.0             1.3         0.7         1.4         2.6         2.3         2.1         2.4         2.8         0.50
17                   1.9e+06               19.0             1.9         0.8         1.7         3.1         2.8         2.5         2.8         3.2         0.60
18                   1.1e+06               11.0             1.1         0.6         1.2         2.3         2.0         1.8         2.1         2.5         0.46
19                   1.6e+06               16.0             1.6         0.9         1.8         3.3         3.0         2.7         3.0         3.4         0.63
20                   1.5e+06               15.0             1.5         0.7         1.3         2.5         2.2         2.0         2.3         2.7         0.49
21                   1.2e+06               12.0             1.2         0.8         1.6         2.8         2.5         2.2         2.5         2.9         0.56
22                   1.8e+06               18.0             1.8         0.6         1.1         2.2         1.9         1.7         2.0         2.4         0.44
23                   1.4e+06               14.0             1.4         0.9         1.9         3.4         3.1         2.8         3.1         3.5         0.66
24                   1.7e+06               17.0             1.7         0.7         1.4         2.7         2.4         2.2         2.5         2.9         0.52
```",0.6436877328556825
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1dc2dbcc8cd49258241d6afe8b53a0abd371b6ca.summary'],"Does LMBR1L also regulate the expression of Wnt/β-catenin target genes involved in lymphocyte migration and homing, thereby influencing lymphocyte trafficking and immune responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that LMBR1L regulates the expression of Wnt/β-catenin target genes involved in lymphocyte migration and homing, thereby influencing lymphocyte trafficking and immune responses.

**Experimental Approach:**

To disprove the hypothesis, we will investigate whether LMBR1L deficiency or knockdown affects the expression of Wnt/β-catenin target genes involved in lymphocyte migration and homing.

**Experiment 1: LMBR1L Knockdown and RNA Sequencing**

1. Design and synthesize LMBR1L-specific siRNAs or shRNAs to knockdown LMBR1L expression in lymphocytes.
2. Transfect lymphocytes with LMBR1L siRNAs/shRNAs and control siRNAs/shRNAs using a suitable transfection reagent.
3. Perform RNA sequencing (RNA-seq) on the transfected lymphocytes to identify differentially expressed genes.
4. Analyze the RNA-seq data using bioinformatic tools (e.g., DESeq2, edgeR) to identify Wnt/β-catenin target genes involved in lymphocyte migration and homing that are differentially expressed between LMBR1L-knockdown and control lymphocytes.

**Experiment 2: qRT-PCR Validation**

1. Validate the RNA-seq results by performing quantitative real-time PCR (qRT-PCR) on a subset of Wnt/β-catenin target genes involved in lymphocyte migration and homing.
2. Use specific primers and probes for the target genes and normalize the expression levels to a housekeeping gene (e.g., GAPDH, ACTB).
3. Compare the expression levels of the target genes between LMBR1L-knockdown and control lymphocytes.

**Experiment 3: Lymphocyte Migration and Homing Assays**

1. Perform lymphocyte migration and homing assays using a transwell migration assay or a lymphocyte homing assay kit.
2. Compare the migration and homing abilities of LMBR1L-knockdown lymphocytes to control lymphocytes.
3. Analyze the results to determine if LMBR1L knockdown affects lymphocyte migration and homing.

**Equipment and Reagents:**

* LMBR1L-specific siRNAs/shRNAs
* Transfection reagent
* RNA sequencing platform (e.g., Illumina, PacBio)
* Bioinformatic tools (e.g., DESeq2, edgeR)
* qRT-PCR machine and reagents
* Primers and probes for target genes
* Housekeeping gene primers and probes
* Transwell migration assay or lymphocyte homing assay kit
* Lymphocyte culture media and supplements

**Timeline and Budget:**

This experiment can be completed within 3-4 months with a budget of approximately $10,000-$15,000. The budget breakdown is as follows:

* RNA sequencing: $3,000-$5,000
* qRT-PCR reagents and primers: $1,000-$2,000
* Transfection reagent and siRNAs/shRNAs: $1,000-$2,000
* Lymphocyte culture media and supplements: $1,000-$2,000
* Transwell migration assay or lymphocyte homing assay kit: $1,000-$2,000
* Labor and miscellaneous costs: $2,000-$3,000

By following this experimental plan, we can determine whether LMBR1L regulates the expression of Wnt/β-catenin target genes involved in lymphocyte migration and homing, thereby influencing lymphocyte trafficking and immune responses. If the results show no significant differences in gene expression or lymphocyte migration/homing between LMBR1L-knockdown and control lymphocytes, it would disprove the hypothesis.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Experiment 1: LMBR1L Knockdown and RNA Sequencing**

**Step 1: Design and Synthesize LMBR1L-specific siRNAs or shRNAs**

* Use a siRNA design tool (e.g., siRNA Wizard, siDESIGN) to design LMBR1L-specific siRNAs or shRNAs with the following criteria:
	+ Target sequence: LMBR1L mRNA sequence (obtained from a reliable database such as NCBI or Ensembl)
	+ siRNA length: 19-23 nucleotides
	+ GC content: 40-60%
	+ Off-target effects: minimize off-target effects using algorithms such as BLAST or Sfold
* Synthesize the designed siRNAs or shRNAs using a commercial supplier (e.g., Dharmacon, Sigma-Aldrich)

**Step 2: Transfect Lymphocytes with LMBR1L siRNAs/shRNAs and Control siRNAs/shRNAs**

* Prepare lymphocytes for transfection:
	+ Isolate lymphocytes from a suitable source (e.g., human peripheral blood, mouse spleen)
	+ Wash the cells with PBS and resuspend in a suitable transfection medium (e.g., RPMI 1640, DMEM)
* Transfect the lymphocytes using a suitable transfection reagent (e.g., Lipofectamine RNAiMAX, DharmaFECT):
	+ Mix the transfection reagent with the LMBR1L siRNAs/shRNAs and control siRNAs/shRNAs according to the manufacturer's instructions
	+ Incubate the mixture with the lymphocytes for 24-48 hours
* Verify the transfection efficiency using a fluorescently labeled siRNA or a reporter gene (e.g., GFP)

**Step 3: Perform RNA Sequencing (RNA-seq)**

* Isolate total RNA from the transfected lymphocytes using a suitable RNA isolation kit (e.g., TRIzol, RNeasy)
* Prepare the RNA samples for sequencing:
	+ Quantify the RNA concentration using a spectrophotometer (e.g., NanoDrop)
	+ Assess the RNA quality using a bioanalyzer (e.g., Agilent 2100)
	+ Prepare the RNA libraries using a suitable RNA-seq library preparation kit (e.g., TruSeq, NEBNext)
* Perform RNA-seq using a suitable sequencing platform (e.g., Illumina HiSeq, PacBio Sequel):
	+ Load the RNA libraries onto the sequencing platform according to the manufacturer's instructions
	+ Run the sequencing reaction according to the manufacturer's instructions

**Step 4: Analyze the RNA-seq Data**

* Use bioinformatic tools (e.g., DESeq2, edgeR) to analyze the RNA-seq data:
	+ Map the sequencing reads to a reference genome (e.g., human genome, mouse genome)
	+ Identify differentially expressed genes between LMBR1L-knockdown and control lymphocytes
	+ Filter the results to identify Wnt/β-catenin target genes involved in lymphocyte migration and homing

**Experiment 2: qRT-PCR Validation**

**Step 1: Prepare Primers and Probes for Target Genes**

* Design specific primers and probes for the Wnt/β-catenin target genes involved in lymphocyte migration and homing:
	+ Use a primer design tool (e.g., Primer3, Primer-BLAST) to design primers with the following criteria:
		- Primer length: 18-24 nucleotides
		- GC content: 40-60%
		- Tm: 55-65°C
	+ Design probes with a suitable fluorescent label (e.g., FAM, HEX)

**Step 2: Perform qRT-PCR**

* Prepare the RNA samples for qRT-PCR:
	+ Isolate total RNA from the transfected lymphocytes using a suitable RNA isolation kit
	+ Reverse transcribe the RNA to cDNA using a suitable reverse transcription kit (e.g., SuperScript, iScript)
* Perform qRT-PCR using a suitable qRT-PCR machine (e.g., ABI 7500, Bio-Rad CFX96):
	+ Mix the cDNA with the primers, probes, and a suitable qRT-PCR master mix (e.g., TaqMan, SYBR Green)
	+ Run the qRT-PCR reaction according to the manufacturer's instructions
* Normalize the expression levels to a housekeeping gene (e.g., GAPDH, ACTB)

**Experiment 3: Lymphocyte Migration and Homing Assays**

**Step 1: Prepare Lymphocytes for Migration and Homing Assays**

* Prepare lymphocytes for the migration and homing assays:
	+ Isolate lymphocytes from a suitable source (e.g., human peripheral blood, mouse spleen)
	+ Wash the cells with PBS and resuspend in a suitable migration medium (e.g., RPMI 1640, DMEM)

**Step 2: Perform Lymphocyte Migration and Homing Assays**

* Perform a transwell migration assay or a lymphocyte homing assay kit:
	+ Load the lymphocytes into the transwell or homing assay device according to the manufacturer's instructions
	+ Incubate the device for a suitable time (e.g., 2-4 hours)
	+ Analyze the results to determine the migration and homing abilities of the lymphocytes

**Step 3: Analyze the Results**

* Compare the migration and homing abilities of LMBR1L-knockdown lymphocytes to control lymphocytes:
	+ Calculate the percentage of migrated or homed lymphocytes
	+ Perform statistical analysis (e.g., t-test, ANOVA) to determine significant differences between the groups","```
   LMBR1L_siRNA_amount  Control_siRNA_amount  Lymphocyte_concentration  Transfection_reagent_amount  RNA_sequencing_reads  qRT_PCR_Ct_value  Lymphocyte_migration_percentage
0                  10.0                  5.0                    1.0e6                    2.0              10000000.0              25.0                    40.0
1                  20.0                  5.0                    1.0e6                    2.0              12000000.0              22.0                    50.0
2                  10.0                 10.0                    1.0e6                    2.0              11000000.0              24.0                    45.0
3                  15.0                  5.0                    1.5e6                    2.5              13000000.0              20.0                    55.0
4                  20.0                 10.0                    1.5e6                    2.5              14000000.0              18.0                    60.0
5                  10.0                  5.0                    2.0e6                    3.0              15000000.0              16.0                    65.0
6                  15.0                 10.0                    2.0e6                    3.0              16000000.0              14.0                    70.0
7                  20.0                 15.0                    2.0e6                    3.5              17000000.0              12.0                    75.0
8                  10.0                  5.0                    2.5e6                    3.5              18000000.0              10.0                    80.0
9                  15.0                 10.0                    2.5e6                    4.0              19000000.0               8.0                    85.0
10                 20.0                 15.0                    2.5e6                    4.0              20000000.0               6.0                    90.0
11                 10.0                  5.0                    3.0e6                    4.5              21000000.0               4.0                    95.0
12                 15.0                 10.0                    3.0e6                    4.5              22000000.0               2.0                   100.0
13                 20.0                 15.0                    3.0e6                    5.0              23000000.0               0.0                   105.0
14                 10.0                  5.0                    3.5e6                    5.0              24000000.0               2.0                   110.0
15                 15.0                 10.0                    3.5e6                    5.5              25000000.0               4.0                   115.0
16                 20.0                 15.0                    3.5e6                    5.5              26000000.0               6.0                   120.0
17                 10.0                  5.0                    4.0e6                    6.0              27000000.0               8.0                   125.0
18                 15.0                 10.0                    4.0e6                    6.0              28000000.0              10.0                   130.0
19                 20.0                 15.0                    4.0e6                    6.5              29000000.0              12.0                   135.0
20                 10.0                  5.0                    4.5e6                    6.5              30000000.0              14.0                   140.0
21                 15.0                 10.0                    4.5e6                    7.0              31000000.0              16.0                   145.0
22                 20.0                 15.0                    4.5e6                    7.0              32000000.0              18.0                   150.0
23                 10.0                  5.0                    5.0e6                    7.5              33000000.0              20.0                   155.0
24                 15.0                 10.0                    5.0e6                    7.5              34000000.0              22.0                   160.0
```",0.5048935401381947
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/cb5fa833a228807c38ccdd3c07254d2b3906d4c7.summary'],"Does LNC000093-mediated regulation of RUNX1 expression also influence the DNA repair machinery, leading to increased genomic instability and contributing to TKI resistance in CML?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that LNC000093-mediated regulation of RUNX1 expression influences the DNA repair machinery, leading to increased genomic instability and contributing to TKI resistance in CML.

**Experiment:**

**Title:** Investigating the Role of LNC000093 in DNA Repair Machinery and Genomic Instability in CML

**Objective:** To determine if LNC000093-mediated regulation of RUNX1 expression affects the DNA repair machinery, leading to increased genomic instability and TKI resistance in CML.

**Experimental Design:**

1. **Cell Culture and Transfection:**
	* Use K562 cells, a human CML cell line, and maintain them in a cell culture facility.
	* Transfect K562 cells with LNC000093 siRNA or overexpression plasmid using transfection reagents.
	* Include a control group with scrambled siRNA or empty vector transfection.
2. **DNA Damage and Repair Assays:**
	* Treat transfected cells with a DNA-damaging agent (e.g., etoposide or camptothecin) to induce DNA double-strand breaks.
	* Measure DNA repair efficiency using the following assays:
		+ Comet assay to assess DNA fragmentation and repair.
		+ γH2AX foci formation to evaluate DNA double-strand break repair.
		+ Homologous recombination (HR) and non-homologous end joining (NHEJ) repair assays to assess the efficiency of different repair pathways.
3. **RUNX1 Expression and Genomic Instability Analysis:**
	* Measure RUNX1 expression levels in transfected cells using qRT-PCR and Western blot.
	* Analyze genomic instability using:
		+ Fluorescence in situ hybridization (FISH) to detect chromosomal aberrations.
		+ Whole-genome sequencing or array comparative genomic hybridization (aCGH) to identify copy number variations and structural rearrangements.
4. **TKI Resistance Assay:**
	* Treat transfected cells with a TKI (e.g., imatinib) and measure cell viability using MTT or CellTiter-Glo assays.
	* Compare the IC50 values of TKI-resistant and sensitive cells to determine if LNC000093-mediated regulation of RUNX1 expression affects TKI resistance.

**Expected Outcomes:**

* If the hypothesis is true, LNC000093 knockdown or overexpression will affect DNA repair efficiency, leading to increased genomic instability and TKI resistance in CML cells.
* If the hypothesis is false, LNC000093-mediated regulation of RUNX1 expression will not influence DNA repair machinery, genomic instability, or TKI resistance.

**Equipment and Resources:**

* Cell culture facility
* Transfection reagents
* qRT-PCR machine
* Western blot equipment
* Comet assay kit
* γH2AX antibody
* HR and NHEJ repair assay kits
* FISH probes
* Whole-genome sequencing or aCGH platform
* MTT or CellTiter-Glo assay kit
* TKI (e.g., imatinib)

**Timeline:**

* Cell culture and transfection: 2 weeks
* DNA damage and repair assays: 4 weeks
* RUNX1 expression and genomic instability analysis: 4 weeks
* TKI resistance assay: 2 weeks
* Data analysis and interpretation: 4 weeks

**Budget:**

* Cell culture and transfection reagents: $1,000
* DNA damage and repair assay kits: $2,000
* qRT-PCR and Western blot equipment: $3,000 (assuming shared access to existing equipment)
* FISH probes and whole-genome sequencing or aCGH platform: $5,000 (assuming shared access to existing equipment)
* TKI and MTT or CellTiter-Glo assay kit: $1,000
* Personnel and miscellaneous costs: $10,000

Total budget: $22,000

This experiment is designed to test the hypothesis and can be completed within a reasonable timeframe (approximately 20 weeks) and budget. The results will provide valuable insights into the role of LNC000093 in DNA repair machinery, genomic instability, and TKI resistance in CML.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Transfection**

1.1. Cell Culture:

* Obtain K562 cells from a reliable source (e.g., ATCC) and maintain them in a cell culture facility at 37°C, 5% CO2, and 95% humidity.
* Grow cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
* Passage cells every 3-4 days to maintain a healthy and exponentially growing culture.

1.2. Transfection:

* Prepare LNC000093 siRNA or overexpression plasmid according to the manufacturer's instructions.
* Transfect K562 cells with 50 nM LNC000093 siRNA or 1 μg of overexpression plasmid using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's protocol.
* Include a control group with scrambled siRNA or empty vector transfection.
* Incubate cells for 24-48 hours to allow for transfection and gene expression.

**Protocol 2: DNA Damage and Repair Assays**

2.1. DNA Damage Induction:

* Treat transfected cells with 10 μM etoposide or 1 μM camptothecin for 1 hour to induce DNA double-strand breaks.
* Wash cells with PBS and return them to normal growth medium.

2.2. Comet Assay:

* Harvest cells 24 hours after DNA damage induction and resuspend them in PBS at a concentration of 1 × 10^5 cells/mL.
* Mix 10 μL of cell suspension with 90 μL of low-melting-point agarose and spread onto a CometSlide.
* Incubate slides in lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% Triton X-100) for 1 hour at 4°C.
* Rinse slides with cold PBS and incubate in alkaline solution (300 mM NaOH, 1 mM EDTA) for 20 minutes at room temperature.
* Neutralize slides with 0.4 M Tris-HCl (pH 7.5) and stain with SYBR Gold.
* Analyze comet tails using a fluorescence microscope and image analysis software.

2.3. γH2AX Foci Formation:

* Harvest cells 24 hours after DNA damage induction and fix them with 4% paraformaldehyde for 15 minutes.
* Permeabilize cells with 0.1% Triton X-100 for 10 minutes.
* Incubate cells with γH2AX antibody (1:500) for 1 hour at room temperature.
* Wash cells with PBS and incubate with Alexa Fluor 488-conjugated secondary antibody (1:500) for 1 hour at room temperature.
* Analyze γH2AX foci using a fluorescence microscope and image analysis software.

2.4. Homologous Recombination (HR) and Non-Homologous End Joining (NHEJ) Repair Assays:

* Use HR and NHEJ repair assay kits according to the manufacturer's instructions.
* Measure repair efficiency using a plate reader or qPCR.

**Protocol 3: RUNX1 Expression and Genomic Instability Analysis**

3.1. RUNX1 Expression Analysis:

* Harvest cells 48 hours after transfection and extract total RNA using a RNA extraction kit.
* Perform qRT-PCR using RUNX1-specific primers and a housekeeping gene (e.g., GAPDH) as a control.
* Analyze RUNX1 expression levels using the 2^(-ΔΔCt) method.

3.2. Western Blot:

* Harvest cells 48 hours after transfection and extract total protein using a protein extraction kit.
* Perform Western blot using a RUNX1-specific antibody and a housekeeping protein (e.g., β-actin) as a control.
* Analyze RUNX1 protein levels using densitometry software.

3.3. Fluorescence In Situ Hybridization (FISH):

* Harvest cells 48 hours after transfection and fix them with 3:1 methanol:acetic acid for 10 minutes.
* Perform FISH using probes specific to chromosomes 9 and 22 (e.g., BCR-ABL1 fusion) according to the manufacturer's instructions.
* Analyze chromosomal aberrations using a fluorescence microscope and image analysis software.

3.4. Whole-Genome Sequencing or Array Comparative Genomic Hybridization (aCGH):

* Extract genomic DNA from cells 48 hours after transfection using a DNA extraction kit.
* Perform whole-genome sequencing or aCGH according to the manufacturer's instructions.
* Analyze copy number variations and structural rearrangements using bioinformatic tools.

**Protocol 4: TKI Resistance Assay**

4.1. Cell Viability Assay:

* Treat transfected cells with increasing concentrations of imatinib (e.g., 0-10 μM) for 72 hours.
* Measure cell viability using MTT or CellTiter-Glo assays according to the manufacturer's instructions.
* Calculate IC50 values using nonlinear regression analysis.

4.2. TKI Resistance Analysis:

* Compare IC50 values of TKI-resistant and sensitive cells to determine if LNC000093-mediated regulation of RUNX1 expression affects TKI resistance.

**Data Analysis and Interpretation**

* Analyze data using statistical software (e.g., GraphPad Prism, R) and perform appropriate statistical tests (e.g., t-test, ANOVA) to determine significance.
* Interpret results in the context of the hypothesis and discuss potential implications for CML treatment.

Note: The protocols provided are detailed and specific, but may require adjustments based on the specific equipment and resources available in the laboratory. It is essential to follow proper laboratory protocols, safety guidelines, and quality control measures to ensure the accuracy and reliability of the results.","```
   LNC000093_siRNA  Overexpression_Plasmid  Etoposide  Camptothecin  Comet_Tail_Length  γH2AX_Foci  HR_Repair_Efficiency  NHEJ_Repair_Efficiency  RUNX1_Expression  RUNX1_Protein_Level  Chromosomal_Aberrations  IC50_Value
0               50.0                 0.0       10.0         0.0           15.23         20.0               0.45               0.60           1.20           1.50               0.30         5.00
1               30.0                 0.5       12.0         0.5           18.50         25.0               0.50               0.65           1.40           1.70               0.40         6.50
2               70.0                 1.0        8.0         1.0           12.10         18.0               0.40               0.55           1.10           1.30               0.25         4.00
3               40.0                 0.0       11.0         0.0           16.50         22.0               0.48               0.62           1.30           1.60               0.35         5.50
4               60.0                 0.5       13.0         0.5           20.20         28.0               0.55               0.70           1.50           1.80               0.45         7.00
5               20.0                 1.0        9.0         1.0           14.80         20.0               0.42               0.58           1.20           1.40               0.30         4.50
6               50.0                 0.0       10.0         0.0           15.50         21.0               0.46               0.61           1.25           1.50               0.32         5.20
7               35.0                 0.5       12.0         0.5           19.20         26.0               0.52               0.68           1.40           1.70               0.40         6.20
8               65.0                 1.0        8.0         1.0           13.50         19.0               0.44               0.59           1.15           1.35               0.28         4.80
9               45.0                 0.0       11.0         0.0           17.20         23.0               0.49               0.63           1.35           1.65               0.38         5.80
10              55.0                 0.5       13.0         0.5           21.50         29.0               0.58               0.72           1.55           1.85               0.48         7.50
11              25.0                 1.0        9.0         1.0           15.80         22.0               0.43               0.60           1.25           1.45               0.32         5.00
12              40.0                 0.0       10.0         0.0           16.80         24.0               0.47               0.64           1.30           1.60               0.36         5.60
13              60.0                 0.5       12.0         0.5           20.80         27.0               0.54               0.69           1.45           1.75               0.42         6.80
14              30.0                 1.0        8.0         1.0           14.20         20.0               0.41               0.57           1.20           1.40               0.30         4.80
15              50.0                 0.0       11.0         0.0           17.50         25.0               0.48               0.65           1.35           1.65               0.38         6.00
16              65.0                 0.5       13.0         0.5           22.20         30.0               0.59               0.73           1.60           1.90               0.50         8.00
17              20.0                 1.0        9.0         1.0           16.20         23.0               0.44               0.61           1.25           1.45               0.33         5.20
18              45.0                 0.0       10.0         0.0           18.50         26.0               0.50               0.66           1.40           1.70               0.40         6.40
19              55.0                 0.5       12.0         0.5           21.80         29.0               0.56               0.71           1.50           1.80               0.45         7.20
20              35.0                 1.0        8.0         1.0           15.50         22.0               0.45               0.62           1.25           1.45               0.32         5.40
21              40.0                 0.0       11.0         0.0           19.20         27.0               0.51               0.67           1.40           1.70               0.42         6.60
22              60.0                 0.5       13.0         0.5           23.50         31.0               0.61               0.75           1.65           2.00               0.52         8.50
23              25.0                 1.0        9.0         1.0           17.20         24.0               0.46               0.63           1.30           1.55               0.35         5.80
24              50.0                 0.0       10.0         0.0           19.80         28.0               0.53               0.69           1.45           1.75               0.43         7.00
```",0.6766540922814452
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2f1642d038195d7060722a43335b9a72ff625836.summary'],"Does MyD88 inhibition in PBMCs also modulate the expression of microRNAs involved in the regulation of inflammatory responses in RA patients, thereby contributing to the downregulation of pro-inflammatory gene expression signatures?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Role of MyD88 Inhibition on microRNA Expression in PBMCs from RA Patients

**Objective:** To determine if MyD88 inhibition in PBMCs from RA patients modulates the expression of microRNAs involved in the regulation of inflammatory responses, contributing to the downregulation of pro-inflammatory gene expression signatures.

**Experimental Design:**

1. **Sample Collection:** Collect PBMCs from RA patients and healthy controls.
2. **MyD88 Inhibition:** Treat PBMCs with ST2825, a MyD88 inhibitor, and a vehicle control.
3. **microRNA Isolation:** Isolate total RNA from treated PBMCs using a miRNA isolation kit.
4. **microRNA Profiling:** Perform microRNA profiling using a microarray platform or next-generation sequencing (NGS) to identify differentially expressed microRNAs between ST2825-treated and control PBMCs.
5. **Validation:** Validate the expression of selected microRNAs using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
6. **Pathway Analysis:** Perform pathway analysis to identify the biological pathways regulated by the differentially expressed microRNAs.
7. **Correlation Analysis:** Correlate the expression of microRNAs with pro-inflammatory gene expression signatures in PBMCs from RA patients.

**Expected Outcomes:**

* Identification of microRNAs differentially expressed between ST2825-treated and control PBMCs from RA patients.
* Validation of the expression of selected microRNAs using qRT-PCR.
* Identification of biological pathways regulated by the differentially expressed microRNAs.
* Correlation between microRNA expression and pro-inflammatory gene expression signatures in PBMCs from RA patients.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of MyD88 Inhibition on microRNA Expression in PBMCs from RA Patients: A Negative Control Study

**Objective:** To demonstrate that MyD88 inhibition in PBMCs from RA patients does not modulate the expression of microRNAs involved in the regulation of inflammatory responses.

**Experimental Design:**

1. **Sample Collection:** Collect PBMCs from RA patients and healthy controls.
2. **MyD88 Inhibition:** Treat PBMCs with a non-specific inhibitor (e.g., DMSO) and a vehicle control.
3. **microRNA Isolation:** Isolate total RNA from treated PBMCs using a miRNA isolation kit.
4. **microRNA Profiling:** Perform microRNA profiling using a microarray platform or NGS to identify differentially expressed microRNAs between non-specific inhibitor-treated and control PBMCs.
5. **Validation:** Validate the expression of selected microRNAs using qRT-PCR.
6. **Pathway Analysis:** Perform pathway analysis to identify the biological pathways regulated by the differentially expressed microRNAs.

**Expected Outcomes:**

* No significant differences in microRNA expression between non-specific inhibitor-treated and control PBMCs from RA patients.
* No correlation between microRNA expression and pro-inflammatory gene expression signatures in PBMCs from RA patients.

**Rationale:**

By designing an experiment to disprove the hypothesis, we can test the null hypothesis that MyD88 inhibition does not modulate microRNA expression in PBMCs from RA patients. If the results show no significant differences in microRNA expression between non-specific inhibitor-treated and control PBMCs, it would suggest that the original hypothesis may not be true. This experiment will help to validate the findings of the original experiment and provide a more comprehensive understanding of the role of MyD88 inhibition in modulating microRNA expression in PBMCs from RA patients.

**Budget and Timeframe:**

The experimental plan and the experiment to disprove the hypothesis can be completed within a reasonable timeframe (6-12 months) and budget, considering the use of existing laboratory equipment and resources. The budget will primarily cover the costs of:

* Sample collection and processing
* Reagents and consumables for microRNA isolation, profiling, and validation
* Personnel and laboratory costs for data analysis and interpretation

The estimated budget for this project is approximately $50,000-$75,000, depending on the specific requirements and resources available.",85,"Here are the detailed, step-by-step protocols for the experimental plan to test the hypothesis and the experiment to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Protocol 1: Sample Collection**

1.1. Collect peripheral blood samples from RA patients and healthy controls using vacutainer tubes containing EDTA as an anticoagulant.

1.2. Label the samples with unique identifiers and store them at room temperature.

1.3. Perform Ficoll-Hypaque density gradient centrifugation to isolate PBMCs from the blood samples.

1.4. Wash the PBMCs with phosphate-buffered saline (PBS) and resuspend them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

**Protocol 2: MyD88 Inhibition**

2.1. Prepare a stock solution of ST2825 (MyD88 inhibitor) in DMSO at a concentration of 10 mM.

2.2. Add ST2825 to the PBMCs at a final concentration of 10 μM and incubate for 24 hours at 37°C, 5% CO2.

2.3. Prepare a vehicle control by adding an equal volume of DMSO to the PBMCs and incubating for 24 hours at 37°C, 5% CO2.

**Protocol 3: microRNA Isolation**

3.1. Isolate total RNA from the treated PBMCs using a miRNA isolation kit (e.g., Qiagen miRNeasy Mini Kit) according to the manufacturer's instructions.

3.2. Elute the RNA in 30 μL of RNase-free water and store it at -80°C.

**Protocol 4: microRNA Profiling**

4.1. Perform microRNA profiling using a microarray platform (e.g., Affymetrix GeneChip miRNA 4.0 Array) or next-generation sequencing (NGS) (e.g., Illumina HiSeq 2500) according to the manufacturer's instructions.

4.2. Analyze the microRNA expression data using bioinformatic tools (e.g., Partek Genomics Suite, edgeR) to identify differentially expressed microRNAs between ST2825-treated and control PBMCs.

**Protocol 5: Validation**

5.1. Select a subset of differentially expressed microRNAs for validation using qRT-PCR.

5.2. Design and synthesize microRNA-specific primers and probes (e.g., TaqMan MicroRNA Assays) according to the manufacturer's instructions.

5.3. Perform qRT-PCR using a real-time PCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System) according to the manufacturer's instructions.

5.4. Analyze the qRT-PCR data using the ΔΔCt method to validate the expression of the selected microRNAs.

**Protocol 6: Pathway Analysis**

6.1. Perform pathway analysis using bioinformatic tools (e.g., Ingenuity Pathway Analysis, Gene Ontology) to identify biological pathways regulated by the differentially expressed microRNAs.

6.2. Analyze the pathway analysis results to identify key biological processes and networks involved in the regulation of inflammatory responses.

**Protocol 7: Correlation Analysis**

7.1. Correlate the expression of microRNAs with pro-inflammatory gene expression signatures in PBMCs from RA patients using bioinformatic tools (e.g., R, Python).

7.2. Analyze the correlation analysis results to identify potential relationships between microRNA expression and pro-inflammatory gene expression signatures.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Sample Collection**

1.1. Collect peripheral blood samples from RA patients and healthy controls using vacutainer tubes containing EDTA as an anticoagulant.

1.2. Label the samples with unique identifiers and store them at room temperature.

1.3. Perform Ficoll-Hypaque density gradient centrifugation to isolate PBMCs from the blood samples.

1.4. Wash the PBMCs with PBS and resuspend them in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

**Protocol 2: MyD88 Inhibition (Negative Control)**

2.1. Prepare a stock solution of DMSO (non-specific inhibitor) at a concentration of 10%.

2.2. Add DMSO to the PBMCs at a final concentration of 0.1% and incubate for 24 hours at 37°C, 5% CO2.

2.3. Prepare a vehicle control by adding an equal volume of PBS to the PBMCs and incubating for 24 hours at 37°C, 5% CO2.

**Protocol 3: microRNA Isolation**

3.1. Isolate total RNA from the treated PBMCs using a miRNA isolation kit (e.g., Qiagen miRNeasy Mini Kit) according to the manufacturer's instructions.

3.2. Elute the RNA in 30 μL of RNase-free water and store it at -80°C.

**Protocol 4: microRNA Profiling**

4.1. Perform microRNA profiling using a microarray platform (e.g., Affymetrix GeneChip miRNA 4.0 Array) or NGS (e.g., Illumina HiSeq 2500) according to the manufacturer's instructions.

4.2. Analyze the microRNA expression data using bioinformatic tools (e.g., Partek Genomics Suite, edgeR) to identify differentially expressed microRNAs between non-specific inhibitor-treated and control PBMCs.

**Protocol 5: Validation**

5.1. Select a subset of differentially expressed microRNAs for validation using qRT-PCR.

5.2. Design and synthesize microRNA-specific primers and probes (e.g., TaqMan MicroRNA Assays) according to the manufacturer's instructions.

5.3. Perform qRT-PCR using a real-time PCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System) according to the manufacturer's instructions.

5.4. Analyze the qRT-PCR data using the ΔΔCt method to validate the expression of the selected microRNAs.

**Protocol 6: Pathway Analysis**

6.1. Perform pathway analysis using bioinformatic tools (e.g., Ingenuity Pathway Analysis, Gene Ontology) to identify biological pathways regulated by the differentially expressed microRNAs.

6.2. Analyze the pathway analysis results to identify key biological processes and networks involved in the regulation of inflammatory responses.

Note: The protocols for the experiment to disprove the hypothesis are similar to those for the experimental plan to test the hypothesis, with the exception of the MyD88 inhibition step, where a non-specific inhibitor (DMSO) is used instead of ST2825.","```
   EDTA  Ficoll-Hypaque  PBS  FBS  Penicillin-Streptomycin  ST2825  DMSO  Outcome
0     1.0           2.0  1.0  0.1               0.01      10.0   0.0  Inhibited
1     1.2           2.2  1.1  0.12              0.012      12.0   0.0  Inhibited
2     0.8           1.8  0.9  0.08              0.008       8.0   0.0  Inhibited
3     1.0           2.0  1.0  0.1               0.01       9.0   0.0  Inhibited
4     1.1           2.1  1.0  0.11              0.011      11.0   0.0  Inhibited
5     0.9           1.9  0.9  0.09              0.009       7.0   0.0  Inhibited
6     1.0           2.0  1.0  0.1               0.01      10.0   0.1  Not Inhibited
7     1.2           2.2  1.1  0.12              0.012       9.0   0.2  Not Inhibited
8     0.8           1.8  0.9  0.08              0.008       8.0   0.3  Not Inhibited
9     1.0           2.0  1.0  0.1               0.01      11.0   0.0  Inhibited
10    1.1           2.1  1.0  0.11              0.011      12.0   0.0  Inhibited
11    0.9           1.9  0.9  0.09              0.009       7.0   0.0  Inhibited
12    1.0           2.0  1.0  0.1               0.01       9.0   0.1  Not Inhibited
13    1.2           2.2  1.1  0.12              0.012      10.0   0.2  Not Inhibited
14    0.8           1.8  0.9  0.08              0.008       8.0   0.3  Not Inhibited
15    1.0           2.0  1.0  0.1               0.01      11.0   0.0  Inhibited
16    1.1           2.1  1.0  0.11              0.011      12.0   0.0  Inhibited
17    0.9           1.9  0.9  0.09              0.009       7.0   0.0  Inhibited
18    1.0           2.0  1.0  0.1               0.01       9.0   0.1  Not Inhibited
19    1.2           2.2  1.1  0.12              0.012      10.0   0.2  Not Inhibited
20    0.8           1.8  0.9  0.08              0.008       8.0   0.3  Not Inhibited
21    1.0           2.0  1.0  0.1               0.01      11.0   0.0  Inhibited
22    1.1           2.1  1.0  0.11              0.011      12.0   0.0  Inhibited
23    0.9           1.9  0.9  0.09              0.009       7.0   0.0  Inhibited
24    1.0           2.0  1.0  0.1               0.01       9.0   0.1  Not Inhibited
```",0.11869266736646475
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d77a416af1d9d1df1591b05286460522273119a3.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/01334d7e7f78e22fe9865768d7442ec7eb20630b.summary']","Does NOTCH1 Val1744 expression modulate the B-cell receptor signaling pathway, thereby influencing the development and progression of pulmonary arterial hypertension in cancer patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the context from the two papers, I will design an experiment to test the hypothesis that NOTCH1 Val1744 expression modulates the B-cell receptor signaling pathway, thereby influencing the development and progression of pulmonary arterial hypertension (PAH) in cancer patients.

**Experimental Plan:**

**Title:** Investigating the Role of NOTCH1 Val1744 in Modulating B-Cell Receptor Signaling and PAH Development in Cancer Patients

**Objective:** To determine whether NOTCH1 Val1744 expression affects the B-cell receptor signaling pathway and contributes to the development and progression of PAH in cancer patients.

**Experimental Design:**

1. **Cell Culture and NOTCH1 Val1744 Knockdown:**
	* Obtain cancer cell lines with high NOTCH1 Val1744 expression (e.g., lung cancer cells).
	* Transfect cells with NOTCH1 Val1744 shRNA or siRNA to knockdown NOTCH1 Val1744 expression.
	* Validate NOTCH1 Val1744 knockdown using Western blot or qRT-PCR.
2. **B-Cell Receptor Signaling Pathway Analysis:**
	* Treat NOTCH1 Val1744-knockdown cells with a B-cell receptor signaling pathway activator (e.g., anti-IgM antibody).
	* Measure the expression of B-cell receptor signaling pathway-related genes (e.g., BANK1, FOXF1, TLE1, CLEC4A1, and CLEC4A3) using qRT-PCR and Western blot.
	* Compare the expression levels between NOTCH1 Val1744-knockdown cells and control cells.
3. **PAH Mouse Model and NOTCH1 Val1744 Overexpression:**
	* Generate a PAH mouse model using monocrotaline (MCT) injection.
	* Overexpress NOTCH1 Val1744 in the PAH mouse model using a lentiviral vector or adenoviral vector.
	* Validate NOTCH1 Val1744 overexpression using Western blot or qRT-PCR.
4. **PAH Severity Evaluation:**
	* Measure mean pulmonary arterial pressure (mPAP), right ventricular hypertrophy index (RVHI), and pulmonary vascular remodeling in the PAH mouse model with and without NOTCH1 Val1744 overexpression.
	* Compare the PAH severity between the two groups.
5. **B-Cell Receptor Signaling Pathway Analysis in PAH Mouse Model:**
	* Measure the expression of B-cell receptor signaling pathway-related genes in the lungs of PAH mouse models with and without NOTCH1 Val1744 overexpression using qRT-PCR and Western blot.
	* Compare the expression levels between the two groups.

**Expected Outcomes:**

* If NOTCH1 Val1744 knockdown in cancer cells reduces B-cell receptor signaling pathway activity, it would suggest that NOTCH1 Val1744 modulates the B-cell receptor signaling pathway.
* If NOTCH1 Val1744 overexpression in the PAH mouse model exacerbates PAH severity and increases B-cell receptor signaling pathway activity, it would support the hypothesis that NOTCH1 Val1744 contributes to PAH development and progression by modulating the B-cell receptor signaling pathway.

**Equipment and Resources:**

* Cell culture facilities and equipment
* NOTCH1 Val1744 shRNA or siRNA
* Cancer cell lines with high NOTCH1 Val1744 expression
* B-cell receptor signaling pathway activator (e.g., anti-IgM antibody)
* qRT-PCR and Western blot systems
* PAH mouse model generation equipment (e.g., microinjection system)
* Blood pressure measurement system
* Western blot system
* Lentiviral or adenoviral vector for NOTCH1 Val1744 overexpression

**Timeline:**

* Cell culture and NOTCH1 Val1744 knockdown: 2 weeks
* B-cell receptor signaling pathway analysis: 4 weeks
* PAH mouse model generation and NOTCH1 Val1744 overexpression: 6 weeks
* PAH severity evaluation and B-cell receptor signaling pathway analysis in PAH mouse model: 8 weeks
* Data analysis and manuscript preparation: 12 weeks

**Budget:**

* Personnel: 2 postdoctoral researchers, 1 graduate student, and 1 technician
* Reagents and consumables: $50,000
* Equipment and maintenance: $100,000
* Animal care and housing: $30,000
* Total budget: $230,000

This experiment is designed to test the hypothesis that NOTCH1 Val1744 expression modulates the B-cell receptor signaling pathway, thereby influencing the development and progression of PAH in cancer patients. By using a combination of cell culture, molecular biology, and animal model approaches, we can gain a deeper understanding of the molecular mechanisms underlying PAH and identify potential therapeutic targets for this devastating disease.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and NOTCH1 Val1744 Knockdown**

**Step 1.1: Obtain Cancer Cell Lines**

* Obtain lung cancer cell lines with high NOTCH1 Val1744 expression from a reputable cell bank or laboratory.
* Verify the cell lines using STR profiling or other authentication methods.

**Step 1.2: Culture Cells**

* Culture the cells in a humidified incubator at 37°C and 5% CO2 in a suitable medium (e.g., RPMI-1640) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
* Passage the cells every 3-4 days to maintain exponential growth.

**Step 1.3: Transfect Cells with NOTCH1 Val1744 shRNA or siRNA**

* Design and synthesize NOTCH1 Val1744 shRNA or siRNA oligonucleotides using a commercial vendor or in-house facility.
* Transfect the cells with the NOTCH1 Val1744 shRNA or siRNA using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
* Incubate the cells for 24-48 hours to allow for gene knockdown.

**Step 1.4: Validate NOTCH1 Val1744 Knockdown**

* Harvest the cells and extract total protein or RNA using standard protocols.
* Perform Western blot or qRT-PCR to detect NOTCH1 Val1744 expression.
* Compare the expression levels between transfected and control cells to validate knockdown.

**Protocol 2: B-Cell Receptor Signaling Pathway Analysis**

**Step 2.1: Treat Cells with B-Cell Receptor Signaling Pathway Activator**

* Treat the NOTCH1 Val1744-knockdown cells and control cells with a B-cell receptor signaling pathway activator (e.g., anti-IgM antibody) at a concentration of 10 μg/mL for 30 minutes.
* Incubate the cells at 37°C and 5% CO2.

**Step 2.2: Measure Gene Expression**

* Harvest the cells and extract total RNA using standard protocols.
* Perform qRT-PCR to detect the expression of B-cell receptor signaling pathway-related genes (e.g., BANK1, FOXF1, TLE1, CLEC4A1, and CLEC4A3).
* Compare the expression levels between NOTCH1 Val1744-knockdown cells and control cells.

**Step 2.3: Perform Western Blot**

* Harvest the cells and extract total protein using standard protocols.
* Perform Western blot to detect the expression of B-cell receptor signaling pathway-related proteins.
* Compare the expression levels between NOTCH1 Val1744-knockdown cells and control cells.

**Protocol 3: PAH Mouse Model and NOTCH1 Val1744 Overexpression**

**Step 3.1: Generate PAH Mouse Model**

* Inject 60 mg/kg monocrotaline (MCT) into the tail vein of 6-8 week old C57BL/6 mice to induce PAH.
* Monitor the mice for 3-4 weeks to allow for PAH development.

**Step 3.2: Overexpress NOTCH1 Val1744 in PAH Mouse Model**

* Design and synthesize a lentiviral or adenoviral vector encoding NOTCH1 Val1744.
* Administer the vector to the PAH mice via tail vein injection or intratracheal instillation.
* Validate NOTCH1 Val1744 overexpression using Western blot or qRT-PCR.

**Protocol 4: PAH Severity Evaluation**

**Step 4.1: Measure Mean Pulmonary Arterial Pressure (mPAP)**

* Anesthetize the mice and perform right heart catheterization to measure mPAP using a pressure transducer.

**Step 4.2: Measure Right Ventricular Hypertrophy Index (RVHI)**

* Harvest the hearts and measure the right ventricular weight to total ventricular weight ratio (RV/LV + S).

**Step 4.3: Measure Pulmonary Vascular Remodeling**

* Harvest the lungs and perform histological analysis to evaluate pulmonary vascular remodeling.

**Step 4.4: Compare PAH Severity**

* Compare the mPAP, RVHI, and pulmonary vascular remodeling between PAH mice with and without NOTCH1 Val1744 overexpression.

**Protocol 5: B-Cell Receptor Signaling Pathway Analysis in PAH Mouse Model**

**Step 5.1: Harvest Lungs**

* Harvest the lungs from PAH mice with and without NOTCH1 Val1744 overexpression.

**Step 5.2: Measure Gene Expression**

* Extract total RNA from the lungs and perform qRT-PCR to detect the expression of B-cell receptor signaling pathway-related genes.
* Compare the expression levels between PAH mice with and without NOTCH1 Val1744 overexpression.

**Step 5.3: Perform Western Blot**

* Extract total protein from the lungs and perform Western blot to detect the expression of B-cell receptor signaling pathway-related proteins.
* Compare the expression levels between PAH mice with and without NOTCH1 Val1744 overexpression.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity.","```
   NOTCH1_shRNA(siRNA)  FBS  Penicillin-Streptomycin  Anti-IgM_Antibody  MCT  NOTCH1_Val1744_Vector  mPAP  RVHI  Pulmonary_Vascular_Remodeling  B-Cell_Receptor_Signaling_Pathway_Activation
0                  20.0  10.0                  1.0               5.0   60.0                    1.0  25.0  0.5                    2.0                             1.5
1                  15.0  12.0                  0.5               7.0   50.0                    0.5  20.0  0.4                    1.5                             1.2
2                  25.0   8.0                  1.5               3.0   70.0                    1.5  30.0  0.6                    2.5                             1.8
3                  18.0  11.0                  0.8               6.0   55.0                    1.2  22.0  0.5                    2.0                             1.4
4                  22.0   9.0                  1.2               4.0   65.0                    1.8  28.0  0.7                    2.8                             1.9
5                  12.0  13.0                  0.3               8.0   45.0                    0.8  18.0  0.3                    1.2                             1.0
6                  19.0  10.0                  1.0               5.5   58.0                    1.4  24.0  0.6                    2.2                             1.6
7                  16.0  12.5                  0.6               6.5   52.0                    1.0  20.5  0.5                    1.8                             1.3
8                  24.0   8.5                  1.8               3.5   72.0                    2.0  32.0  0.8                    3.0                             2.2
9                  17.0  11.5                  0.9               6.0   56.0                    1.3  23.0  0.6                    2.1                             1.5
10                 21.0   9.5                  1.4               4.5   68.0                    1.9  29.0  0.7                    2.9                             2.0
11                 13.0  13.5                  0.4               7.5   48.0                    0.9  19.0  0.4                    1.4                             1.1
12                 20.0  10.5                  1.1               5.0   60.0                    1.6  25.5  0.6                    2.4                             1.7
13                 14.0  12.0                  0.5               6.5   50.0                    1.1  21.0  0.5                    1.9                             1.4
14                 23.0   8.0                  1.7               3.0   70.0                    2.2  33.0  0.9                    3.2                             2.4
15                 18.5  11.0                  1.0               5.5   57.0                    1.5  24.5  0.7                    2.6                             1.8
16                 15.5  12.5                  0.7               6.0   53.0                    1.2  22.0  0.5                    2.0                             1.5
17                 21.5   9.0                  1.3               4.0   66.0                    2.0  30.0  0.8                    3.0                             2.1
18                 12.5  13.0                  0.4               7.0   47.0                    0.9  19.5  0.4                    1.5                             1.2
19                 19.5  10.5                  1.2               5.0   59.0                    1.7  26.0  0.7                    2.7                             1.9
20                 16.5  12.0                  0.8               6.5   54.0                    1.4  23.5  0.6                    2.3                             1.6
21                 22.5   8.5                  1.9               3.5   71.0                    2.4  34.0  1.0                    3.4                             2.5
22                 17.5  11.5                  1.1               5.5   58.0                    1.8  25.5  0.7                    2.8                             2.0
23                 14.5  12.5                  0.6               6.0   51.0                    1.3  22.0  0.5                    2.1                             1.6
24                 20.5   9.5                  1.5               4.5   67.0                    2.1  31.0  0.8                    3.1                             2.2
```",0.538412079391671
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/48c3ab1dc3c511c1851f6ace5c0c09b5a7dc8fa8.summary'],"Does PC-PLC inhibition also reduce the expression of other oncogenic receptors, such as EGFR, in HER2-positive ovarian cancer cells, leading to a broader anti-tumor effect?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** PC-PLC inhibition reduces the expression of other oncogenic receptors, such as EGFR, in HER2-positive ovarian cancer cells, leading to a broader anti-tumor effect.

**Experimental Plan:**

**Objective:** To investigate whether PC-PLC inhibition decreases EGFR expression in HER2-positive ovarian cancer cells and assess its impact on tumor growth.

**Experimental Design:**

1. **Cell Culture:**
	* Obtain HER2-positive ovarian cancer cell lines (e.g., SKOV3, OVCAR3) and maintain them in standard culture conditions.
	* Treat cells with a PC-PLC inhibitor (e.g., D609) at varying concentrations (e.g., 1, 5, 10 μM) for 24, 48, and 72 hours.
	* Use vehicle-treated cells as controls.
2. **EGFR Expression Analysis:**
	* Perform Western blotting or qRT-PCR to measure EGFR protein and mRNA levels, respectively, in treated and control cells.
	* Normalize EGFR expression to a housekeeping gene (e.g., GAPDH, β-actin).
3. **Cell Proliferation and Viability Assays:**
	* Use MTT or CellTiter-Glo assays to assess cell proliferation and viability in treated and control cells.
4. **Tumor Xenograft Model:**
	* Inject HER2-positive ovarian cancer cells into immunodeficient mice (e.g., nude mice).
	* Treat mice with PC-PLC inhibitor (e.g., D609) or vehicle control via intraperitoneal injection.
	* Monitor tumor growth and measure tumor volume using calipers.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we'll design an experiment to show that PC-PLC inhibition does not affect EGFR expression or tumor growth.

**Modified Experimental Design:**

1. **Cell Culture:**
	* Use a different HER2-positive ovarian cancer cell line (e.g., OVCAR8) that is less responsive to PC-PLC inhibition.
	* Treat cells with a higher concentration of PC-PLC inhibitor (e.g., 20 μM) to maximize potential effects.
2. **EGFR Expression Analysis:**
	* Perform Western blotting or qRT-PCR to measure EGFR protein and mRNA levels, respectively, in treated and control cells.
	* Expect to see no significant difference in EGFR expression between treated and control cells.
3. **Cell Proliferation and Viability Assays:**
	* Use MTT or CellTiter-Glo assays to assess cell proliferation and viability in treated and control cells.
	* Expect to see no significant difference in cell proliferation and viability between treated and control cells.
4. **Tumor Xenograft Model:**
	* Use a different tumor xenograft model, such as a subcutaneous injection of HER2-positive ovarian cancer cells into immunodeficient mice.
	* Treat mice with PC-PLC inhibitor or vehicle control via intraperitoneal injection.
	* Expect to see no significant difference in tumor growth between treated and control groups.

**Budget and Timeframe:**

This experiment can be completed within 6-8 weeks with a budget of approximately $10,000-$15,000. This estimate includes:

* Cell culture reagents and consumables: $2,000
* PC-PLC inhibitor and vehicle control: $1,000
* Western blotting and qRT-PCR reagents: $1,500
* Cell proliferation and viability assay kits: $1,000
* Tumor xenograft model and animal care: $4,000
* Labor and miscellaneous costs: $2,000

By following this experimental plan, we can test the hypothesis and determine whether PC-PLC inhibition reduces EGFR expression and leads to a broader anti-tumor effect in HER2-positive ovarian cancer cells.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Treatment**

**Objective:** To culture HER2-positive ovarian cancer cells and treat them with PC-PLC inhibitor at varying concentrations and time points.

**Materials:**

* HER2-positive ovarian cancer cell lines (e.g., SKOV3, OVCAR3)
* PC-PLC inhibitor (e.g., D609)
* Vehicle control (e.g., DMSO)
* Cell culture medium (e.g., RPMI-1640)
* Fetal bovine serum (FBS)
* Penicillin-streptomycin
* Cell culture flasks and plates

**Step-by-Step Protocol:**

1.1. Obtain HER2-positive ovarian cancer cell lines (e.g., SKOV3, OVCAR3) and maintain them in standard culture conditions (37°C, 5% CO2).

1.2. Prepare cell culture medium by supplementing RPMI-1640 with 10% FBS and 1% penicillin-streptomycin.

1.3. Seed 1 x 10^5 cells per well in 6-well plates and incubate for 24 hours to allow cells to adhere.

1.4. Prepare PC-PLC inhibitor stock solution by dissolving D609 in DMSO to a final concentration of 10 mM.

1.5. Treat cells with PC-PLC inhibitor at varying concentrations (1, 5, 10 μM) by adding the appropriate volume of stock solution to the cell culture medium.

1.6. Treat control cells with vehicle control (DMSO) at the same volume as the highest concentration of PC-PLC inhibitor.

1.7. Incubate cells for 24, 48, and 72 hours.

1.8. Harvest cells for EGFR expression analysis, cell proliferation, and viability assays.

**Protocol 2: EGFR Expression Analysis**

**Objective:** To measure EGFR protein and mRNA levels in treated and control cells using Western blotting and qRT-PCR.

**Materials:**

* Cell lysates from Protocol 1
* Western blotting reagents (e.g., antibodies, buffers, membranes)
* qRT-PCR reagents (e.g., primers, probes, master mix)
* GAPDH or β-actin antibodies for normalization

**Step-by-Step Protocol:**

2.1. Prepare cell lysates by lysing cells in RIPA buffer and centrifuging at 10,000 x g for 10 minutes.

2.2. Perform Western blotting to measure EGFR protein levels:
	* Separate 20 μg of protein per lane on a 10% SDS-PAGE gel.
	* Transfer proteins to a PVDF membrane.
	* Block membrane with 5% milk in TBST for 1 hour.
	* Incubate with EGFR antibody (1:1000) overnight at 4°C.
	* Detect using HRP-conjugated secondary antibody and ECL substrate.

2.3. Perform qRT-PCR to measure EGFR mRNA levels:
	* Extract RNA from cell lysates using a RNA extraction kit.
	* Synthesize cDNA using a reverse transcription kit.
	* Perform qRT-PCR using EGFR-specific primers and probes.
	* Normalize EGFR expression to GAPDH or β-actin.

**Protocol 3: Cell Proliferation and Viability Assays**

**Objective:** To assess cell proliferation and viability in treated and control cells using MTT or CellTiter-Glo assays.

**Materials:**

* Cell culture plates from Protocol 1
* MTT or CellTiter-Glo reagents

**Step-by-Step Protocol:**

3.1. Perform MTT assay:
	* Add 10 μL of MTT reagent to each well and incubate for 4 hours.
	* Add 100 μL of DMSO to each well and incubate for 10 minutes.
	* Measure absorbance at 570 nm using a plate reader.

3.2. Perform CellTiter-Glo assay:
	* Add 100 μL of CellTiter-Glo reagent to each well and incubate for 10 minutes.
	* Measure luminescence using a plate reader.

**Protocol 4: Tumor Xenograft Model**

**Objective:** To assess tumor growth in mice treated with PC-PLC inhibitor or vehicle control.

**Materials:**

* HER2-positive ovarian cancer cells
* Immunodeficient mice (e.g., nude mice)
* PC-PLC inhibitor (e.g., D609)
* Vehicle control (e.g., DMSO)
* Calipers

**Step-by-Step Protocol:**

4.1. Inject 1 x 10^6 HER2-positive ovarian cancer cells subcutaneously into immunodeficient mice.

4.2. Treat mice with PC-PLC inhibitor (e.g., 10 mg/kg) or vehicle control via intraperitoneal injection every 3 days.

4.3. Monitor tumor growth by measuring tumor volume using calipers every 3 days.

4.4. Sacrifice mice after 4-6 weeks and harvest tumors for further analysis.

**Protocol 5: Experiment to Disprove the Hypothesis**

**Objective:** To design an experiment to show that PC-PLC inhibition does not affect EGFR expression or tumor growth.

**Modified Step-by-Step Protocol:**

5.1. Use a different HER2-positive ovarian cancer cell line (e.g., OVCAR8) that is less responsive to PC-PLC inhibition.

5.2. Treat cells with a higher concentration of PC-PLC inhibitor (e.g., 20 μM) to maximize potential effects.

5.3. Perform EGFR expression analysis, cell proliferation, and viability assays as described in Protocols 2 and 3.

5.4. Use a different tumor xenograft model, such as a subcutaneous injection of HER2-positive ovarian cancer cells into immunodeficient mice.

5.5. Treat mice with PC-PLC inhibitor or vehicle control via intraperitoneal injection and monitor tumor growth as described in Protocol 4.

By following these detailed, step-by-step protocols, the experiment can be replicated and the hypothesis can be tested.","```
   Cell_Line  PC-PLC_Inhibitor_Conc  Incubation_Time  Vehicle_Control  FBS_Conc  Penicillin_Streptomycin_Conc  EGFR_Protein_Levels  EGFR_mRNA_Levels  Cell_Proliferation  Cell_Viability  Tumor_Volume
0      SKOV3                    1             24           0.1             10                    1                0.8               0.9             0.7             0.8         150
1      SKOV3                    5             24           0.1             10                    1                0.6               0.7             0.5             0.6         120
2      SKOV3                   10             24           0.1             10                    1                0.4               0.5             0.3             0.4         100
3      OVCAR3                   1             24           0.1             10                    1                0.9               1.0             0.8             0.9         180
4      OVCAR3                   5             24           0.1             10                    1                0.7               0.8             0.6             0.7         140
5      OVCAR3                  10             24           0.1             10                    1                0.5               0.6             0.4             0.5         110
6      SKOV3                    1             48           0.1             10                    1                0.7               0.8             0.6             0.7         130
7      SKOV3                    5             48           0.1             10                    1                0.5               0.6             0.4             0.5         100
8      SKOV3                   10             48           0.1             10                    1                0.3               0.4             0.2             0.3          80
9      OVCAR3                   1             48           0.1             10                    1                0.8               0.9             0.7             0.8         160
10     OVCAR3                   5             48           0.1             10                    1                0.6               0.7             0.5             0.6         120
11     OVCAR3                  10             48           0.1             10                    1                0.4               0.5             0.3             0.4         100
12     SKOV3                    1             72           0.1             10                    1                0.6               0.7             0.5             0.6         110
13     SKOV3                    5             72           0.1             10                    1                0.4               0.5             0.3             0.4          90
14     SKOV3                   10             72           0.1             10                    1                0.2               0.3             0.1             0.2          70
15     OVCAR3                   1             72           0.1             10                    1                0.7               0.8             0.6             0.7         140
16     OVCAR3                   5             72           0.1             10                    1                0.5               0.6             0.4             0.5         110
17     OVCAR3                  10             72           0.1             10                    1                0.3               0.4             0.2             0.3          90
18     SKOV3                    1             24           0.05            10                    1                0.9               1.0             0.8             0.9         190
19     SKOV3                    5             24           0.05            10                    1                0.8               0.9             0.7             0.8         160
20     SKOV3                   10             24           0.05            10                    1                0.6               0.7             0.5             0.6         130
21     OVCAR3                   1             24           0.05            10                    1                1.0               1.1             0.9             1.0         200
22     OVCAR3                   5             24           0.05            10                    1                0.9               1.0             0.8             0.9         180
23     OVCAR3                  10             24           0.05            10                    1                0.7               0.8             0.6             0.7         150
24     SKOV3                    1             24           0.2             10                    1                0.5               0.6             0.4             0.5         100
```",0.3186231423195309
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c59185cfc6bdf29165729ab4cf21bc24c95dc740.summary'],"Does PI3Kδ inhibition also modulate the release of pro-inflammatory cytokines in autoimmune bullous diseases, thereby contributing to its therapeutic effect?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis and potentially disprove it. Here's a high-level experimental approach:

**Experiment:** ""Investigating the Effect of PI3Kδ Inhibition on Pro-inflammatory Cytokine Release in Autoimmune Bullous Diseases""

**Objective:** To determine if PI3Kδ inhibition modulates the release of pro-inflammatory cytokines in autoimmune bullous diseases, contributing to its therapeutic effect.

**Experimental Design:**

1. **Cell Culture Model:** Use human keratinocytes and myeloid cells (e.g., THP-1 cells) to create an in vitro model of autoimmune bullous disease.
2. **PI3Kδ Inhibition:** Treat the cell culture model with LAS191954, a PI3Kδ inhibitor, at varying concentrations (e.g., 0.1, 1, and 10 μM) to assess dose-dependent effects.
3. **Control Groups:** Include a vehicle-only control group and a group treated with a PI3Kδ activator (e.g., IGF-1) to serve as a positive control.
4. **Pro-inflammatory Cytokine Measurement:** Use ELISA or multiplex assays to measure the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6, and IL-8) in the cell culture supernatant.
5. **Immune Cell Activation:** Assess immune cell activation by measuring the expression of activation markers (e.g., CD69, CD86) on myeloid cells using flow cytometry.
6. **ROS Release:** Measure ROS release using a fluorescent probe (e.g., DCFDA) and flow cytometry.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on the following aspects:

* **No effect on pro-inflammatory cytokine release:** If PI3Kδ inhibition does not significantly reduce the release of pro-inflammatory cytokines, it would suggest that the therapeutic effect of PI3Kδ inhibition is not mediated by modulation of cytokine release.
* **No correlation between PI3Kδ inhibition and immune cell activation:** If there is no correlation between PI3Kδ inhibition and reduced immune cell activation, it would imply that the therapeutic effect is not related to immune cell modulation.
* **No effect on ROS release:** If PI3Kδ inhibition does not reduce ROS release, it would suggest that the therapeutic effect is not related to ROS-mediated mechanisms.

**Timeline and Budget:**

This experiment can be completed within 6-8 weeks, with the following budget allocation:

* Cell culture reagents and consumables: $1,500
* LAS191954 and PI3Kδ activator: $1,000
* ELISA and multiplex assay kits: $2,000
* Flow cytometry reagents and consumables: $1,500
* Personnel and overheads: $5,000

Total budget: $11,000

This experiment is designed to provide a concise and cost-effective approach to test the hypothesis and potentially disprove it. The results will help determine whether PI3Kδ inhibition modulates pro-inflammatory cytokine release in autoimmune bullous diseases, contributing to its therapeutic effect.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture Model Preparation**

1.1. Obtain human keratinocytes and THP-1 cells from a reputable cell bank or culture them in-house according to established protocols.

1.2. Culture keratinocytes in Keratinocyte Growth Medium (KGM) supplemented with 0.05 mg/mL bovine pituitary extract, 0.5 ng/mL human recombinant epidermal growth factor, and 1% penicillin-streptomycin at 37°C, 5% CO2.

1.3. Culture THP-1 cells in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.4. Passage cells every 3-4 days to maintain optimal cell density and viability.

**Protocol 2: PI3Kδ Inhibition and Treatment**

2.1. Prepare a stock solution of LAS191954 (PI3Kδ inhibitor) in DMSO at a concentration of 10 mM.

2.2. Dilute the LAS191954 stock solution in cell culture medium to achieve the desired concentrations (0.1, 1, and 10 μM).

2.3. Add the diluted LAS191954 solution to the cell culture model (keratinocytes and THP-1 cells) and incubate for 24 hours at 37°C, 5% CO2.

2.4. Prepare a stock solution of IGF-1 (PI3Kδ activator) in PBS at a concentration of 10 μg/mL.

2.5. Add the IGF-1 stock solution to the cell culture model (positive control group) and incubate for 24 hours at 37°C, 5% CO2.

**Protocol 3: Pro-inflammatory Cytokine Measurement**

3.1. Collect cell culture supernatant from each treatment group (LAS191954-treated, IGF-1-treated, and vehicle-only control) and centrifuge at 1,000 x g for 5 minutes to remove debris.

3.2. Measure the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-8) using ELISA or multiplex assays according to the manufacturer's instructions.

3.3. Perform the ELISA or multiplex assay in triplicate for each treatment group.

**Protocol 4: Immune Cell Activation**

4.1. Harvest THP-1 cells from each treatment group and wash with PBS.

4.2. Stain THP-1 cells with fluorescently labeled antibodies against CD69 and CD86 (activation markers) according to the manufacturer's instructions.

4.3. Analyze the stained cells using flow cytometry to measure the expression of activation markers.

4.4. Perform flow cytometry analysis in triplicate for each treatment group.

**Protocol 5: ROS Release Measurement**

5.1. Harvest THP-1 cells from each treatment group and wash with PBS.

5.2. Incubate THP-1 cells with 10 μM DCFDA (fluorescent probe) for 30 minutes at 37°C, 5% CO2.

5.3. Analyze the cells using flow cytometry to measure ROS release.

5.4. Perform flow cytometry analysis in triplicate for each treatment group.

**Protocol 6: Data Analysis and Interpretation**

6.1. Calculate the mean and standard deviation of pro-inflammatory cytokine release, immune cell activation, and ROS release for each treatment group.

6.2. Compare the results between treatment groups using statistical analysis software (e.g., ANOVA, t-test).

6.3. Determine if PI3Kδ inhibition modulates pro-inflammatory cytokine release, immune cell activation, and ROS release in autoimmune bullous diseases.

6.4. Interpret the results in the context of the hypothesis and experimental design.

**Quality Control and Assurance**

* Verify the identity and purity of cell lines using STR profiling and mycoplasma testing.
* Validate the specificity and sensitivity of ELISA and multiplex assays using positive and negative controls.
* Calibrate flow cytometry instruments according to the manufacturer's instructions.
* Perform regular quality control checks on reagents and consumables.

**Timeline and Budget**

* Week 1-2: Cell culture model preparation and treatment
* Week 3-4: Pro-inflammatory cytokine measurement and immune cell activation analysis
* Week 5-6: ROS release measurement and data analysis
* Week 7-8: Data interpretation and manuscript preparation

Budget allocation:

* Cell culture reagents and consumables: $1,500
* LAS191954 and PI3Kδ activator: $1,000
* ELISA and multiplex assay kits: $2,000
* Flow cytometry reagents and consumables: $1,500
* Personnel and overheads: $5,000

Total budget: $11,000","```
   Keratinocyte_Growth_Medium  bovine_pituitary_extract  human_recombinant_epidermal_growth_factor  penicillin_streptomycin  LAS191954  IGF_1  TNF_alpha  IL_1_beta  IL_6  IL_8  CD69  CD86  ROS_Release
0                    100.0                  0.05                  0.5                  1.0         0.1    0.0  120.0       150.0  200.0  250.0  30.0  40.0       500.0
1                    120.0                  0.06                  0.6                  1.2         1.0    0.0  140.0       180.0  220.0  280.0  35.0  45.0       550.0
2                    100.0                  0.05                  0.5                  1.0         10.0    0.0  100.0       130.0  180.0  230.0  25.0  35.0       450.0
3                    110.0                  0.055                 0.55                  1.1         0.1    0.0  130.0       160.0  200.0  250.0  30.0  40.0       500.0
4                    130.0                  0.07                  0.7                  1.3         1.0    0.0  160.0       200.0  240.0  300.0  40.0  50.0       600.0
5                    100.0                  0.05                  0.5                  1.0         10.0    0.0  110.0       140.0  190.0  240.0  25.0  35.0       450.0
6                    120.0                  0.06                  0.6                  1.2         0.1    0.0  140.0       180.0  220.0  280.0  35.0  45.0       550.0
7                    110.0                  0.055                 0.55                  1.1         1.0    0.0  150.0       190.0  230.0  290.0  35.0  45.0       550.0
8                    130.0                  0.07                  0.7                  1.3         10.0    0.0  120.0       150.0  200.0  250.0  30.0  40.0       500.0
9                    100.0                  0.05                  0.5                  1.0         0.1    10.0  180.0       220.0  280.0  350.0  40.0  50.0       600.0
10                   120.0                  0.06                  0.6                  1.2         1.0    10.0  200.0       250.0  310.0  380.0  45.0  55.0       650.0
11                   110.0                  0.055                 0.55                  1.1         10.0    10.0  190.0       230.0  290.0  360.0  40.0  50.0       600.0
12                   130.0                  0.07                  0.7                  1.3         0.1    10.0  160.0       200.0  250.0  310.0  35.0  45.0       550.0
13                   100.0                  0.05                  0.5                  1.0         1.0    10.0  170.0       210.0  270.0  330.0  40.0  50.0       600.0
14                   120.0                  0.06                  0.6                  1.2         10.0    10.0  180.0       220.0  280.0  350.0  40.0  50.0       600.0
15                   110.0                  0.055                 0.55                  1.1         0.1    10.0  150.0       190.0  240.0  300.0  35.0  45.0       550.0
16                   130.0                  0.07                  0.7                  1.3         1.0    10.0  190.0       230.0  290.0  360.0  40.0  50.0       600.0
17                   100.0                  0.05                  0.5                  1.0         10.0    10.0  160.0       200.0  250.0  310.0  35.0  45.0       550.0
18                   120.0                  0.06                  0.6                  1.2         0.1    10.0  170.0       210.0  270.0  330.0  40.0  50.0       600.0
19                   110.0                  0.055                 0.55                  1.1         1.0    10.0  180.0       220.0  280.0  350.0  40.0  50.0       600.0
20                   130.0                  0.07                  0.7                  1.3         10.0    10.0  190.0       230.0  290.0  360.0  40.0  50.0       600.0
21                   100.0                  0.05                  0.5                  1.0         0.1    10.0  140.0       180.0  220.0  280.0  35.0  45.0       550.0
22                   120.0                  0.06                  0.6                  1.2         1.0    10.0  160.0       200.0  250.0  310.0  35.0  45.0       550.0
23                   110.0                  0.055                 0.55                  1.1         10.0    10.0  170.0       210.0  270.0  330.0  40.0  50.0       600.0
24                   130.0                  0.07                  0.7                  1.3         0.1    10.0  150.0       190.0  240.0  300.0  35.0  45.0       550.0
```",0.6158773309040274
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7dc456fcaa8c34e556fa0b74aaea2a8aaa79f09a.summary'],Does PLCG1-mediated RAS activation also play a critical role in the development of resistance to BCR-ABL1 and FLT3 tyrosine kinase inhibitors in CML and AML cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that PLCG1-mediated RAS activation plays a critical role in the development of resistance to BCR-ABL1 and FLT3 tyrosine kinase inhibitors in CML and AML cells.

**Experimental Plan:**

**Title:** Investigating the Role of PLCG1 in Resistance to BCR-ABL1 and FLT3 Tyrosine Kinase Inhibitors in CML and AML Cells

**Objective:** To determine whether PLCG1-mediated RAS activation contributes to the development of resistance to BCR-ABL1 and FLT3 tyrosine kinase inhibitors in CML and AML cells.

**Hypothesis to be Disproven:** PLCG1-mediated RAS activation does not play a critical role in the development of resistance to BCR-ABL1 and FLT3 tyrosine kinase inhibitors in CML and AML cells.

**Experimental Design:**

1. **Cell Culture and Treatment:**
	* Culture CML and AML cell lines (e.g., K562 and MV4-11) in the presence or absence of BCR-ABL1 and FLT3 tyrosine kinase inhibitors (e.g., imatinib and AC220) for 2-3 weeks to induce resistance.
	* Treat resistant cells with a PLCG1 inhibitor (e.g., U73122) or a vehicle control.
2. **Cell Viability and Proliferation Assays:**
	* Perform Cell Titer Glo assays to assess cell viability and proliferation in response to PLCG1 inhibition.
	* Compare the effects of PLCG1 inhibition on cell viability and proliferation in resistant and sensitive cells.
3. **Western Blotting:**
	* Perform Western blotting to evaluate RAS-GTP levels, PLCG1 phosphorylation, and downstream signaling molecules (e.g., ERK, AKT) in resistant and sensitive cells.
	* Compare the effects of PLCG1 inhibition on RAS-GTP levels and downstream signaling in resistant and sensitive cells.
4. **Resistance Reversal Assay:**
	* Treat resistant cells with a combination of PLCG1 inhibitor and BCR-ABL1 or FLT3 tyrosine kinase inhibitors.
	* Assess cell viability and proliferation to determine if PLCG1 inhibition reverses resistance to tyrosine kinase inhibitors.

**Expected Outcomes:**

* If PLCG1-mediated RAS activation plays a critical role in resistance to BCR-ABL1 and FLT3 tyrosine kinase inhibitors, we expect to observe:
	+ Increased cell viability and proliferation in resistant cells treated with PLCG1 inhibitor.
	+ Decreased RAS-GTP levels and downstream signaling in resistant cells treated with PLCG1 inhibitor.
	+ Reversal of resistance to tyrosine kinase inhibitors in combination with PLCG1 inhibition.
* If PLCG1-mediated RAS activation does not play a critical role in resistance, we expect to observe no significant differences in cell viability, proliferation, and signaling between resistant and sensitive cells treated with PLCG1 inhibitor.

**Equipment and Resources:**

* Cell culture facilities
* PLCG1 inhibitor (e.g., U73122)
* BCR-ABL1 and FLT3 tyrosine kinase inhibitors (e.g., imatinib and AC220)
* Cell viability assays (e.g., Cell Titer Glo)
* Western blotting equipment
* Antibodies for Western blotting (e.g., RAS, PLCG1, ERK, AKT)

**Timeline:**

* Cell culture and treatment: 2-3 weeks
* Cell viability and proliferation assays: 1-2 weeks
* Western blotting: 1-2 weeks
* Resistance reversal assay: 1-2 weeks
* Data analysis and interpretation: 2-3 weeks

**Budget:**

* Cell culture reagents and media: $1,000
* PLCG1 inhibitor and tyrosine kinase inhibitors: $2,000
* Cell viability assays and Western blotting reagents: $1,500
* Antibodies and other consumables: $1,000
* Total budget: $5,500

This experimental plan is designed to test the hypothesis that PLCG1-mediated RAS activation plays a critical role in the development of resistance to BCR-ABL1 and FLT3 tyrosine kinase inhibitors in CML and AML cells. By using a combination of cell viability assays, Western blotting, and resistance reversal assays, we can determine whether PLCG1 inhibition can reverse resistance to tyrosine kinase inhibitors and provide insights into the underlying mechanisms.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Treatment**

**Step 1.1: Cell Line Preparation**

* Obtain CML and AML cell lines (e.g., K562 and MV4-11) from a reliable source (e.g., ATCC).
* Thaw and expand the cells in a 37°C, 5% CO2 incubator using appropriate cell culture media (e.g., RPMI 1640 with 10% FBS).

**Step 1.2: Treatment with Tyrosine Kinase Inhibitors**

* Prepare stock solutions of BCR-ABL1 and FLT3 tyrosine kinase inhibitors (e.g., imatinib and AC220) according to the manufacturer's instructions.
* Add the tyrosine kinase inhibitors to the cell culture media at the desired concentrations (e.g., 1 μM imatinib and 100 nM AC220).
* Incubate the cells for 2-3 weeks to induce resistance.

**Step 1.3: Treatment with PLCG1 Inhibitor**

* Prepare a stock solution of PLCG1 inhibitor (e.g., U73122) according to the manufacturer's instructions.
* Add the PLCG1 inhibitor to the cell culture media at the desired concentration (e.g., 10 μM).
* Incubate the cells for 24-48 hours.

**Protocol 2: Cell Viability and Proliferation Assays**

**Step 2.1: Cell Titer Glo Assay**

* Prepare a Cell Titer Glo reagent according to the manufacturer's instructions.
* Add 100 μL of Cell Titer Glo reagent to each well of a 96-well plate containing 10,000 cells.
* Incubate the plate for 10-15 minutes at room temperature.
* Measure the luminescence using a plate reader.

**Step 2.2: Data Analysis**

* Calculate the cell viability and proliferation rates using the Cell Titer Glo data.
* Compare the results between resistant and sensitive cells treated with PLCG1 inhibitor.

**Protocol 3: Western Blotting**

**Step 3.1: Cell Lysis**

* Harvest the cells and wash them with PBS.
* Lyse the cells using a lysis buffer (e.g., RIPA buffer) containing protease and phosphatase inhibitors.
* Centrifuge the lysates at 10,000 x g for 10 minutes.

**Step 3.2: Protein Quantification**

* Determine the protein concentration using a protein assay (e.g., Bradford assay).

**Step 3.3: Western Blotting**

* Prepare a 10% SDS-PAGE gel and load 20-30 μg of protein per lane.
* Transfer the proteins to a PVDF membrane using a wet transfer apparatus.
* Block the membrane with 5% milk in TBST for 1 hour.
* Incubate the membrane with primary antibodies (e.g., RAS, PLCG1, ERK, AKT) overnight at 4°C.
* Incubate the membrane with secondary antibodies (e.g., HRP-conjugated anti-rabbit or anti-mouse) for 1 hour at room temperature.
* Develop the membrane using an ECL substrate.

**Step 3.4: Data Analysis**

* Quantify the Western blot bands using image analysis software (e.g., ImageJ).
* Compare the results between resistant and sensitive cells treated with PLCG1 inhibitor.

**Protocol 4: Resistance Reversal Assay**

**Step 4.1: Cell Treatment**

* Treat resistant cells with a combination of PLCG1 inhibitor and BCR-ABL1 or FLT3 tyrosine kinase inhibitors.
* Incubate the cells for 24-48 hours.

**Step 4.2: Cell Viability and Proliferation Assays**

* Perform Cell Titer Glo assays as described in Protocol 2.

**Step 4.3: Data Analysis**

* Calculate the cell viability and proliferation rates using the Cell Titer Glo data.
* Compare the results between resistant cells treated with PLCG1 inhibitor alone and in combination with tyrosine kinase inhibitors.

These detailed protocols should provide a clear guide for executing the experimental plan and obtaining reliable results.","```
   CML_cells  AML_cells  Imatinib  AC220  U73122  Cell_Viability
0        10000       10000      0.5    50.0     5.0       0.853211
1        15000       15000      1.0   100.0    10.0       0.921053
2         5000        5000      0.2    20.0     2.0       0.765432
3        20000       20000      1.5   150.0    15.0       0.956521
4         8000        8000      0.8    80.0     8.0       0.893617
5        12000       12000      1.2   120.0    12.0       0.934579
6         4000        4000      0.4    40.0     4.0       0.823529
7        18000       18000      1.8   180.0    18.0       0.973684
8        10000       10000      0.6    60.0     6.0       0.876923
9        14000       14000      1.4   140.0    14.0       0.948718
10        6000        6000      0.3    30.0     3.0       0.809524
11       22000       22000      2.2   220.0    22.0       0.990196
12        9000        9000      0.9    90.0     9.0       0.913043
13       16000       16000      1.6   160.0    16.0       0.963855
14        7000        7000      0.7    70.0     7.0       0.857143
15       20000       20000      2.0   200.0    20.0       0.994118
16       11000       11000      1.1   110.0    11.0       0.933333
17        5000        5000      0.1    10.0     1.0       0.741935
18       19000       19000      1.9   190.0    19.0       0.984127
19       13000       13000      1.3   130.0    13.0       0.953488
20        8000        8000      0.4    40.0     4.0       0.823529
21       21000       21000      2.1   210.0    21.0       0.992537
22       15000       15000      1.5   150.0    15.0       0.956521
23        9000        9000      0.5    50.0     5.0       0.853211
24       17000       17000      1.7   170.0    17.0       0.971429
```",0.9333736912800568
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/181c6f059090d37c008355c49831d4e4719c049c.summary'],"Does PPARγ-mediated degradation of phosphorylated STAT6 also regulate the production of other inflammatory cytokines in addition to IgE, thereby modulating the overall immune response in asthma?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Does PPARγ-mediated degradation of phosphorylated STAT6 also regulate the production of other inflammatory cytokines in addition to IgE, thereby modulating the overall immune response in asthma?

**Experimental Plan:**

**Objective:** To investigate whether PPARγ-mediated degradation of phosphorylated STAT6 regulates the production of other inflammatory cytokines in addition to IgE, and to determine its impact on the overall immune response in asthma.

**Experimental Design:**

1. **Cell Culture and Stimulation:**
	* Isolate B cells, T cells, and macrophages from mice and culture them in the presence or absence of PPARγ agonist (e.g., pioglitazone).
	* Stimulate cells with anti-CD40, IL-4, and/or LPS to induce cytokine production.
2. **Cytokine Profiling:**
	* Measure the production of various inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α, IL-12, IL-23, and IFN-γ) using ELISA, Luminex, or qRT-PCR.
	* Compare cytokine production in cells treated with or without PPARγ agonist.
3. **STAT6 Phosphorylation and Ubiquitination:**
	* Perform Western blotting to detect the levels of phosphorylated STAT6 and ubiquitinated STAT6 in cells treated with or without PPARγ agonist.
	* Analyze the data to determine whether PPARγ agonist promotes the degradation of phosphorylated STAT6.
4. **Immune Response Analysis:**
	* Use flow cytometry to analyze the expression of surface markers (e.g., CD4, CD8, CD25, and CD69) on T cells and macrophages.
	* Evaluate the production of reactive oxygen species (ROS) and nitric oxide (NO) in macrophages.
5. **In Vivo Validation:**
	* Use a mouse model of asthma (e.g., OVA-induced asthma) to investigate the effects of PPARγ agonist on cytokine production and immune response in vivo.
	* Measure cytokine levels in bronchoalveolar lavage fluid (BALF) and lung tissue using ELISA or Luminex.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that PPARγ-mediated degradation of phosphorylated STAT6 does not regulate the production of other inflammatory cytokines in addition to IgE, and does not modulate the overall immune response in asthma.

**Experimental Design:**

1. **STAT6 Knockdown:**
	* Use siRNA or CRISPR-Cas9 to knockdown STAT6 expression in B cells, T cells, and macrophages.
	* Measure cytokine production in cells with or without PPARγ agonist treatment.
2. **PPARγ Inhibitor:**
	* Use a PPARγ inhibitor (e.g., GW9662) to block PPARγ activity in cells.
	* Measure cytokine production in cells with or without PPARγ inhibitor treatment.
3. **Cytokine Profiling:**
	* Measure the production of various inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α, IL-12, IL-23, and IFN-γ) using ELISA, Luminex, or qRT-PCR.
	* Compare cytokine production in cells with or without PPARγ agonist or inhibitor treatment.
4. **Immune Response Analysis:**
	* Use flow cytometry to analyze the expression of surface markers (e.g., CD4, CD8, CD25, and CD69) on T cells and macrophages.
	* Evaluate the production of ROS and NO in macrophages.

**Rationale:**

By knocking down STAT6 expression or inhibiting PPARγ activity, we can determine whether PPARγ-mediated degradation of phosphorylated STAT6 is necessary for regulating cytokine production and immune response in asthma. If the results show that cytokine production and immune response are not affected by PPARγ agonist or inhibitor treatment, it would suggest that PPARγ-mediated degradation of phosphorylated STAT6 does not regulate the production of other inflammatory cytokines in addition to IgE, and does not modulate the overall immune response in asthma, thereby disproving the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: Cell Culture and Stimulation**

1.1. Isolate B cells, T cells, and macrophages from mice using standard protocols (e.g., density gradient centrifugation, magnetic bead separation).

1.2. Culture cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.3. Treat cells with 10 μM pioglitazone (PPARγ agonist) or vehicle control (DMSO) for 24 hours.

1.4. Stimulate cells with 10 μg/mL anti-CD40, 10 ng/mL IL-4, and/or 100 ng/mL LPS for 24 hours.

**Step 2: Cytokine Profiling**

2.1. Collect cell culture supernatants and store at -80°C until analysis.

2.2. Perform ELISA or Luminex assays to measure the production of IL-1β, IL-6, TNF-α, IL-12, IL-23, and IFN-γ according to the manufacturer's instructions.

2.3. Alternatively, perform qRT-PCR to measure cytokine mRNA levels using specific primers and probes.

**Step 3: STAT6 Phosphorylation and Ubiquitination**

3.1. Lyse cells in RIPA buffer containing protease and phosphatase inhibitors.

3.2. Perform Western blotting using antibodies against phosphorylated STAT6 (p-STAT6), ubiquitinated STAT6 (Ub-STAT6), and total STAT6.

3.3. Analyze Western blot data using densitometry software to determine the levels of p-STAT6 and Ub-STAT6.

**Step 4: Immune Response Analysis**

4.1. Stain cells with fluorescently labeled antibodies against CD4, CD8, CD25, and CD69.

4.2. Analyze cell surface marker expression using flow cytometry (e.g., BD FACSCanto II).

4.3. Measure ROS production in macrophages using the DCFDA assay.

4.4. Measure NO production in macrophages using the Griess assay.

**Step 5: In Vivo Validation**

5.1. Induce asthma in mice using the OVA-induced asthma model (e.g., 2 weeks of OVA sensitization and challenge).

5.2. Treat mice with 10 mg/kg pioglitazone or vehicle control (DMSO) via oral gavage daily for 2 weeks.

5.3. Collect bronchoalveolar lavage fluid (BALF) and lung tissue at the end of the experiment.

5.4. Measure cytokine levels in BALF and lung tissue using ELISA or Luminex assays.

**Experiment to Disprove the Hypothesis:**

**Step 1: STAT6 Knockdown**

1.1. Design and synthesize siRNA or CRISPR-Cas9 constructs targeting STAT6.

1.2. Transfect B cells, T cells, and macrophages with siRNA or CRISPR-Cas9 constructs using standard protocols (e.g., lipofection, electroporation).

1.3. Verify STAT6 knockdown using Western blotting or qRT-PCR.

**Step 2: PPARγ Inhibitor**

2.1. Treat cells with 10 μM GW9662 (PPARγ inhibitor) or vehicle control (DMSO) for 24 hours.

2.2. Stimulate cells with anti-CD40, IL-4, and/or LPS as described in Step 1.4.

**Step 3: Cytokine Profiling**

3.1. Collect cell culture supernatants and store at -80°C until analysis.

3.2. Perform ELISA or Luminex assays to measure cytokine production as described in Step 2.2.

**Step 4: Immune Response Analysis**

4.1. Stain cells with fluorescently labeled antibodies against CD4, CD8, CD25, and CD69.

4.2. Analyze cell surface marker expression using flow cytometry.

4.3. Measure ROS production in macrophages using the DCFDA assay.

4.4. Measure NO production in macrophages using the Griess assay.

These detailed protocols should provide a clear guide for executing the experiments to test and disprove the hypothesis.","```
   Pioglitazone  Anti-CD40  IL-4  LPS  IL-1β  IL-6  TNF-α  IL-12  IL-23  IFN-γ  p-STAT6  Ub-STAT6  CD4  CD8  CD25  CD69  ROS  NO
0           5.0      5.0  5.0  50.0  200.0  150.0  100.0  50.0  20.0  10.0  0.8   0.5   30.0  20.0  10.0  5.0  0.5  0.2
1           0.0      0.0  0.0   0.0   50.0   30.0   20.0  10.0  5.0   2.0  0.2   0.1   20.0  15.0   8.0  4.0  0.3  0.1
2           2.5      2.5  2.5  25.0  150.0  100.0   80.0  40.0  20.0  10.0  0.5   0.3   25.0  18.0  12.0  6.0  0.4  0.2
3           7.5      7.5  7.5  75.0  250.0  180.0  120.0  60.0  30.0  15.0  1.0   0.7   35.0  25.0  15.0  8.0  0.6  0.3
4           0.0      0.0  0.0   0.0   30.0   20.0   15.0   8.0  4.0   2.0  0.1   0.1   18.0  12.0   8.0  4.0  0.2  0.1
5           5.0      5.0  5.0  50.0  220.0  160.0  100.0  50.0  25.0  12.0  0.9   0.6   32.0  22.0  14.0  7.0  0.5  0.3
6           2.5      2.5  2.5  25.0  180.0  120.0   90.0  45.0  22.0  11.0  0.6   0.4   28.0  20.0  12.0  6.0  0.4  0.2
7           7.5      7.5  7.5  75.0  280.0  200.0  140.0  70.0  35.0  18.0  1.1   0.8   38.0  28.0  18.0  9.0  0.7  0.4
8           0.0      0.0  0.0   0.0   40.0   25.0   18.0  10.0  5.0   2.5  0.2   0.2   22.0  16.0  10.0  5.0  0.3  0.2
9           5.0      5.0  5.0  50.0  240.0  170.0  110.0  55.0  28.0  14.0  1.0   0.7   34.0  24.0  16.0  8.0  0.6  0.3
10          2.5      2.5  2.5  25.0  200.0  140.0  100.0  50.0  25.0  12.5  0.8   0.5   30.0  22.0  14.0  7.0  0.5  0.3
11          7.5      7.5  7.5  75.0  300.0  220.0  160.0  80.0  40.0  20.0  1.2   0.9   40.0  30.0  20.0 10.0  0.8  0.5
12          0.0      0.0  0.0   0.0   50.0   35.0   25.0  12.0  6.0   3.0  0.3   0.3   25.0  18.0  12.0  6.0  0.4  0.2
13          5.0      5.0  5.0  50.0  260.0  190.0  130.0  65.0  32.0  16.0  1.1   0.8   36.0  26.0  18.0  9.0  0.7  0.4
14          2.5      2.5  2.5  25.0  220.0  160.0  110.0  55.0  28.0  14.0  0.9   0.6   32.0  24.0  16.0  8.0  0.6  0.3
15          7.5      7.5  7.5  75.0  320.0  240.0  180.0  90.0  45.0  22.0  1.3   1.0   42.0  32.0  22.0 11.0  0.9  0.5
16          0.0      0.0  0.0   0.0   60.0   40.0   30.0  15.0  8.0   4.0  0.4   0.4   28.0  20.0  14.0  7.0  0.5  0.3
17          5.0      5.0  5.0  50.0  280.0  210.0  150.0  75.0  38.0  19.0  1.2   0.9   38.0  28.0  20.0 10.0  0.8  0.5
18          2.5      2.5  2.5  25.0  240.0  180.0  130.0  65.0  32.0  16.0  1.0   0.7   34.0  26.0  18.0  9.0  0.7  0.4
19          7.5      7.5  7.5  75.0  340.0  260.0  200.0 100.0  50.0  25.0  1.4   1.1   44.0  34.0  24.0 12.0  1.0  0.6
20          0.0      0.0  0.0   0.0   70.0   50.0   35.0  18.0  9.0   4.5  0.5   0.5   30.0  22.0  16.0  8.0  0.6  0.3
21          5.0      5.0  5.0  50.0  300.0  230.0  170.0  85.0  42.0  21.0  1.3   1.0   40.0  30.0  22.0 11.0  0.9  0.5
22          2.5      2.5  2.5  25.0  260.0  200.0  150.0  75.0  38.0  19.0  1.1   0.8   36.0  28.0  20.0 10.0  0.8  0.5
23          7.5      7.5  7.5  75.0  360.0  280.0  220.0 110.0  55.0  28.0  1.5   1.2   46.0  36.0  26.0 13.0  1.1  0.7
24          0.0      0.0  0.0   0.0   80.0   60.0   40.0  20.0  10.0   5.0  0.6   0.6   32.0  24.0  18.0  9.0  0.7  0.4",0.14102783566193455
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/05b2705022375b78fa76378b4d74387c5291cd43.summary'],Does PTEN-mediated suppression of antibody responses during viral infections also lead to increased susceptibility to secondary bacterial infections?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A great hypothesis! Let's break it down and design an experiment to test it.

**Hypothesis:** PTEN-mediated suppression of antibody responses during viral infections leads to increased susceptibility to secondary bacterial infections.

**Experimental Plan:**

**Objective:** To investigate whether PTEN-mediated suppression of antibody responses during viral infections increases susceptibility to secondary bacterial infections.

**Experimental Design:**

1. **Viral Infection Model:** Use a well-established viral infection model, such as influenza A virus (IAV) infection in mice.
2. **PTEN Knockdown/Knockout:** Use CRISPR-Cas9 or shRNA to knockdown or knockout PTEN in immune cells (e.g., B cells, T cells) in mice.
3. **Antibody Response Analysis:** Measure antibody responses (e.g., IgG, IgM) against IAV in PTEN-knockdown/knockout mice and control mice using ELISA or other immunological assays.
4. **Secondary Bacterial Infection:** Infect mice with a secondary bacterial pathogen, such as Streptococcus pneumoniae, at a specific time point after IAV infection.
5. **Susceptibility Assessment:** Monitor mice for signs of bacterial infection (e.g., weight loss, morbidity, mortality) and measure bacterial burden in lungs and other organs.

**Experimental Groups:**

1. Control group: Wild-type mice infected with IAV
2. PTEN-knockdown/knockout group: PTEN-knockdown/knockout mice infected with IAV
3. Secondary infection control group: Wild-type mice infected with S. pneumoniae only

**Experimental Timeline:**

* Day 0: IAV infection
* Day 7: PTEN knockdown/knockout verification
* Day 14: Secondary bacterial infection with S. pneumoniae
* Day 21: Endpoint analysis (antibody responses, bacterial burden, morbidity, mortality)

**Resources and Budget:**

* Mice (wild-type and PTEN-knockout/knockdown)
* IAV and S. pneumoniae strains
* CRISPR-Cas9 or shRNA reagents
* ELISA kits and immunological assays
* Laboratory equipment (e.g., microscopes, centrifuges, incubators)
* Personnel (1-2 researchers, 1-2 technicians)

**Time Frame:** 6-8 weeks

**Budget:** Approximately $50,000 - $75,000 (depending on the specific resources and equipment required)

**Rationale:**

By knocking down or knocking out PTEN in immune cells, we can investigate whether PTEN-mediated suppression of antibody responses during viral infections leads to increased susceptibility to secondary bacterial infections. If the hypothesis is true, we would expect to see:

* Reduced antibody responses against IAV in PTEN-knockdown/knockout mice
* Increased susceptibility to secondary bacterial infection with S. pneumoniae in PTEN-knockdown/knockout mice
* Higher bacterial burden and morbidity/mortality rates in PTEN-knockdown/knockout mice compared to control mice

By designing an experiment to disprove the hypothesis, we can verify its validity and gain insights into the role of PTEN in regulating immune responses during viral infections.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Viral Infection Model**

1.1. Obtain 30-40 wild-type mice (C57BL/6 or similar strain) from a reputable supplier.

1.2. Acclimate mice to the laboratory environment for 7-10 days prior to infection.

1.3. Prepare influenza A virus (IAV) stock (e.g., A/PR/8/34) according to established protocols.

1.4. Infect mice with 10^4 PFU of IAV via intranasal instillation on Day 0.

1.5. Monitor mice for signs of illness (e.g., weight loss, lethargy) and provide supportive care as needed.

**Protocol 2: PTEN Knockdown/Knockout**

2.1. Design and synthesize CRISPR-Cas9 guide RNAs (gRNAs) or shRNAs targeting PTEN in immune cells (e.g., B cells, T cells).

2.2. Prepare CRISPR-Cas9 or shRNA vectors according to the manufacturer's instructions.

2.3. Deliver CRISPR-Cas9 or shRNA vectors to mice via hydrodynamic injection or electroporation on Day -3 (3 days prior to IAV infection).

2.4. Verify PTEN knockdown/knockout efficiency using Western blot, qRT-PCR, or flow cytometry on Day 7.

**Protocol 3: Antibody Response Analysis**

3.1. Collect blood samples from mice on Days 7, 14, and 21 via retro-orbital bleeding or cardiac puncture.

3.2. Isolate serum from blood samples using centrifugation and store at -80°C.

3.3. Perform ELISA or other immunological assays (e.g., Western blot, immunofluorescence) to measure IgG and IgM antibody responses against IAV.

3.4. Use a standard curve to quantify antibody titers and calculate the area under the curve (AUC) for each sample.

**Protocol 4: Secondary Bacterial Infection**

4.1. Prepare Streptococcus pneumoniae (e.g., serotype 3) stock according to established protocols.

4.2. Infect mice with 10^5 CFU of S. pneumoniae via intranasal instillation on Day 14.

4.3. Monitor mice for signs of bacterial infection (e.g., weight loss, morbidity, mortality) and provide supportive care as needed.

**Protocol 5: Susceptibility Assessment**

5.1. Monitor mice daily for signs of illness and record weight, morbidity, and mortality rates.

5.2. Collect lung and other organ tissues (e.g., spleen, liver) on Day 21 for bacterial burden analysis.

5.3. Perform CFU assays to quantify bacterial burden in lung and other organs.

5.4. Calculate the bacterial burden as CFU per gram of tissue.

**Protocol 6: Endpoint Analysis**

6.1. Collect and analyze data from all experimental groups, including antibody responses, bacterial burden, morbidity, and mortality rates.

6.2. Compare data between PTEN-knockdown/knockout and control groups using statistical software (e.g., GraphPad Prism, R).

6.3. Perform power calculations to determine the sample size required for future experiments.

**Quality Control and Assurance**

* Verify the identity and purity of IAV and S. pneumoniae stocks using PCR, sequencing, or other methods.
* Validate the specificity and efficiency of CRISPR-Cas9 or shRNA vectors using Western blot, qRT-PCR, or flow cytometry.
* Monitor mouse health and welfare throughout the experiment, and provide humane endpoints as necessary.
* Perform regular equipment maintenance and calibration to ensure accurate and reliable data collection.

**Timeline and Budget**

* Week 1-2: Acclimate mice, prepare IAV and S. pneumoniae stocks, and design CRISPR-Cas9 or shRNA vectors.
* Week 3-4: Infect mice with IAV, deliver CRISPR-Cas9 or shRNA vectors, and verify PTEN knockdown/knockout efficiency.
* Week 5-6: Infect mice with S. pneumoniae, collect blood samples, and perform antibody response analysis.
* Week 7-8: Collect lung and other organ tissues, perform bacterial burden analysis, and analyze data.

Budget Breakdown:

* Mice and husbandry: $10,000 - $15,000
* IAV and S. pneumoniae stocks: $5,000 - $10,000
* CRISPR-Cas9 or shRNA reagents: $5,000 - $10,000
* ELISA kits and immunological assays: $5,000 - $10,000
* Laboratory equipment and consumables: $10,000 - $20,000
* Personnel and training: $10,000 - $20,000
* Total: $50,000 - $75,000","```
   Mice  IAV_PFU  CRISPR_dose  shRNA_dose  S_pneumoniae_CFU  Antibody_titer  Bacterial_burden  Morbidity  Mortality
0     35     1e+04        100         50          1e+05        1024.0         1.23e+05       0.4       0.2
1     30     5e+03         50         25          5e+04        512.0          6.12e+04       0.3       0.1
2     38     2e+04        150         75          2e+05        2048.0         2.45e+05       0.5       0.3
3     32     1e+04         80         40          1e+05        1024.0         1.01e+05       0.4       0.2
4     36     3e+04        120         60          3e+05        4096.0         3.78e+05       0.6       0.4
5     31     4e+03         30         15          4e+04        256.0          4.56e+04       0.2       0.1
6     39     1e+05        200         100         1e+06        8192.0         9.87e+05       0.8       0.6
7     33     2e+04         90         45          2e+05        2048.0         2.01e+05       0.5       0.3
8     37     5e+04        180         90          5e+05        4096.0         4.92e+05       0.7       0.5
9     34     3e+04        110         55          3e+05        2048.0         3.14e+05       0.6       0.4
10    35     1e+04         70         35          1e+05        1024.0         1.23e+05       0.4       0.2
11    32     4e+04        130         65          4e+05        4096.0         4.21e+05       0.7       0.5
12    36     2e+04         80         40          2e+05        2048.0         2.45e+05       0.5       0.3
13    38     5e+04        190         95          5e+05        8192.0         6.54e+05       0.8       0.6
14    31     3e+04        100         50          3e+05        2048.0         3.14e+05       0.6       0.4
15    39     1e+05        220         110         1e+06       16384.0        1.23e+06       0.9       0.7
16    33     4e+04        140         70          4e+05        4096.0         4.92e+05       0.7       0.5
17    37     2e+04         90         45          2e+05        2048.0         2.01e+05       0.5       0.3
18    34     5e+04        160         80          5e+05        8192.0         6.12e+04       0.8       0.6
19    35     3e+04        120         60          3e+05        4096.0         3.78e+05       0.6       0.4
20    32     1e+04         60         30          1e+05        512.0          1.01e+05       0.3       0.2
21    36     4e+04        150         75          4e+05        4096.0         4.21e+05       0.7       0.5
22    38     2e+04         100         50          2e+05        2048.0         2.45e+05       0.5       0.3
23    39     5e+04        200         100         5e+05        8192.0         6.54e+05       0.8       0.6
24    33     3e+04        130         65          3e+05        4096.0         3.78e+05       0.6       0.4
```",0.8578122670523874
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9b0d24cc8929bfe25101c9e60b59fc582c88b01a.summary'],"Does Rora regulate the expression of microRNAs involved in B cell development and BCR/ABL1-induced B-ALL, thereby modulating the balance between cell proliferation and apoptosis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis and potentially disprove it. This experiment will utilize existing scientific methods and equipment, with an unlimited budget in terms of time, resources, and financial support.

**Experiment Title:** Investigating the Role of Rora in Regulating microRNAs Involved in B Cell Development and BCR/ABL1-Induced B-ALL

**Objective:** To determine if Rora regulates the expression of microRNAs involved in B cell development and BCR/ABL1-induced B-ALL, thereby modulating the balance between cell proliferation and apoptosis.

**Experimental Approach:**

**Step 1: microRNA Profiling**

* Use high-throughput sequencing technologies (e.g., RNA-seq or microRNA-seq) to profile the microRNA expression in BCR/ABL1-induced B-ALL cells with Rora overexpression or knockout.
* Compare the microRNA expression profiles between Rora-overexpressing and control cells to identify differentially expressed microRNAs.
* Validate the results using quantitative real-time PCR (qRT-PCR) or Northern blotting.

**Step 2: microRNA Target Prediction and Validation**

* Use bioinformatic tools (e.g., TargetScan, miRanda, or PicTar) to predict the target genes of the differentially expressed microRNAs.
* Validate the predicted targets using luciferase reporter assays, Western blotting, or qRT-PCR.
* Focus on targets involved in cell proliferation and apoptosis pathways.

**Step 3: Functional Analysis of microRNA Targets**

* Use CRISPR-Cas9 genome editing to knockout or knockdown the validated microRNA targets in BCR/ABL1-induced B-ALL cells.
* Analyze the effects of target gene modulation on cell proliferation and apoptosis using FACS, Western blotting, and cell viability assays.
* Compare the results with control cells to determine if the microRNA targets are functionally relevant.

**Step 4: Rora-microRNA Axis Disruption**

* Use CRISPR-Cas9 genome editing to knockout or knockdown Rora in BCR/ABL1-induced B-ALL cells.
* Analyze the effects of Rora disruption on microRNA expression, cell proliferation, and apoptosis using the methods described above.
* Compare the results with control cells to determine if Rora regulates the microRNA expression and subsequent cellular responses.

**Step 5: Rescue Experiment**

* Co-transfect BCR/ABL1-induced B-ALL cells with Rora overexpression plasmid and microRNA mimics or inhibitors targeting the validated microRNA targets.
* Analyze the effects of microRNA rescue on cell proliferation and apoptosis using the methods described above.
* Compare the results with control cells to determine if the Rora-microRNA axis is functionally relevant.

**Step 6: In Vivo Validation**

* Use a B-ALL mouse model to investigate the in vivo effects of Rora overexpression or knockout on microRNA expression, cell proliferation, and apoptosis.
* Analyze the results using flow cytometry, Western blotting, and histopathological analysis.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: Rora does not regulate microRNAs involved in B cell development and BCR/ABL1-induced B-ALL.

* Use a Rora-overexpressing BCR/ABL1-induced B-ALL cell line and perform microRNA profiling to identify microRNAs that are not differentially expressed compared to control cells.
* Validate the results using qRT-PCR or Northern blotting.
* Perform functional analysis of the non-differentially expressed microRNAs using CRISPR-Cas9 genome editing and analyze the effects on cell proliferation and apoptosis.
* If the results show no significant changes in microRNA expression or cellular responses, it would suggest that Rora does not regulate microRNAs involved in B cell development and BCR/ABL1-induced B-ALL, thereby disproving the hypothesis.

**Equipment and Resources:**

* High-throughput sequencing technologies (e.g., RNA-seq or microRNA-seq)
* qRT-PCR and Northern blotting equipment
* CRISPR-Cas9 genome editing system
* FACS analyzer
* Western blot equipment
* Cell culture medium and reagents
* BCR/ABL1-induced B-ALL cell lines
* Rora overexpression plasmid
* microRNA mimics and inhibitors
* B-ALL mouse model

**Timeline:**

* Literature review and experimental design: 2 weeks
* microRNA profiling and validation: 8 weeks
* microRNA target prediction and validation: 8 weeks
* Functional analysis of microRNA targets: 12 weeks
* Rora-microRNA axis disruption: 12 weeks
* Rescue experiment: 8 weeks
* In vivo validation: 16 weeks
* Data analysis and manuscript preparation: 20 weeks

Total duration: 84 weeks (approximately 1.6 years)

This experimental plan is designed to comprehensively test the hypothesis and provide a thorough understanding of the role of Rora in regulating microRNAs involved in B cell development and BCR/ABL1-induced B-ALL.",95,"Here are the detailed, step-by-step protocols for each step of the experiment:

**Step 1: microRNA Profiling**

1.1. Cell Culture Preparation:

* Obtain BCR/ABL1-induced B-ALL cell lines with Rora overexpression or knockout.
* Culture cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.
* Harvest cells at 80% confluency.

1.2. RNA Isolation:

* Use TRIzol reagent to isolate total RNA from harvested cells according to the manufacturer's instructions.
* Measure RNA concentration and purity using a spectrophotometer (e.g., NanoDrop).

1.3. Library Preparation:

* Prepare RNA-seq or microRNA-seq libraries using a commercial kit (e.g., Illumina TruSeq) according to the manufacturer's instructions.
* Perform quality control checks on the libraries using a bioanalyzer (e.g., Agilent 2100).

1.4. Sequencing:

* Perform high-throughput sequencing using a platform (e.g., Illumina HiSeq) according to the manufacturer's instructions.
* Generate at least 10 million reads per sample.

1.5. Data Analysis:

* Use bioinformatic tools (e.g., STAR, featureCounts) to map reads to the human genome and quantify microRNA expression.
* Normalize data using a suitable method (e.g., DESeq2) and identify differentially expressed microRNAs between Rora-overexpressing and control cells.

**Step 2: microRNA Target Prediction and Validation**

2.1. Target Prediction:

* Use bioinformatic tools (e.g., TargetScan, miRanda, PicTar) to predict target genes of the differentially expressed microRNAs.
* Filter predictions based on conservation, seed region, and free energy.

2.2. Luciferase Reporter Assay:

* Clone the 3'UTR of predicted target genes into a luciferase reporter vector (e.g., psiCHECK-2).
* Co-transfect BCR/ABL1-induced B-ALL cells with the reporter vector and microRNA mimics or inhibitors.
* Measure luciferase activity using a plate reader (e.g., Promega GloMax).

2.3. Western Blotting:

* Perform Western blotting to validate the protein expression of predicted target genes.
* Use specific antibodies and a suitable detection system (e.g., ECL).

2.4. qRT-PCR Validation:

* Perform qRT-PCR to validate the mRNA expression of predicted target genes.
* Use specific primers and a suitable detection system (e.g., SYBR Green).

**Step 3: Functional Analysis of microRNA Targets**

3.1. CRISPR-Cas9 Genome Editing:

* Design guide RNAs targeting the validated microRNA targets using a CRISPR design tool (e.g., CRISPR Design).
* Transfect BCR/ABL1-induced B-ALL cells with the CRISPR-Cas9 system and guide RNAs.
* Select and validate edited cells using PCR and sequencing.

3.2. Cell Proliferation and Apoptosis Assays:

* Analyze cell proliferation using a cell viability assay (e.g., MTT).
* Analyze apoptosis using a flow cytometer (e.g., FACSVerse) and Annexin V staining.

3.3. Western Blotting:

* Perform Western blotting to analyze the protein expression of cell proliferation and apoptosis markers.

**Step 4: Rora-microRNA Axis Disruption**

4.1. CRISPR-Cas9 Genome Editing:

* Design guide RNAs targeting Rora using a CRISPR design tool (e.g., CRISPR Design).
* Transfect BCR/ABL1-induced B-ALL cells with the CRISPR-Cas9 system and guide RNAs.
* Select and validate edited cells using PCR and sequencing.

4.2. microRNA Profiling:

* Repeat Step 1 to analyze the effects of Rora disruption on microRNA expression.

4.3. Cell Proliferation and Apoptosis Assays:

* Repeat Step 3.2 to analyze the effects of Rora disruption on cell proliferation and apoptosis.

**Step 5: Rescue Experiment**

5.1. Co-Transfection:

* Co-transfect BCR/ABL1-induced B-ALL cells with Rora overexpression plasmid and microRNA mimics or inhibitors.
* Analyze the effects of microRNA rescue on cell proliferation and apoptosis using the methods described above.

**Step 6: In Vivo Validation**

6.1. Mouse Model Preparation:

* Obtain a B-ALL mouse model (e.g., NSG mice).
* Inject BCR/ABL1-induced B-ALL cells with Rora overexpression or knockout into the mice.

6.2. Tissue Collection and Analysis:

* Collect bone marrow and spleen tissues from mice at specific time points.
* Analyze microRNA expression, cell proliferation, and apoptosis using the methods described above.

6.3. Histopathological Analysis:

* Perform histopathological analysis of tissues using H&E staining and immunohistochemistry.

**Experimental Design to Disprove the Hypothesis**

* Repeat Steps 1-3 using a Rora-overexpressing BCR/ABL1-induced B-ALL cell line.
* Analyze the results to identify microRNAs that are not differentially expressed compared to control cells.
* Perform functional analysis of the non-differentially expressed microRNAs using CRISPR-Cas9 genome editing and analyze the effects on cell proliferation and apoptosis.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific equipment and resources available in the laboratory.","```
   RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  TRIzol  RNA_Concentration  microRNA_Seq_Reads  microRNA_Target_Prediction  Luciferase_Activity  Western_Blotting  qRT-PCR_Validation  CRISPR_Cas9_Editing  Cell_Proliferation  Apoptosis  Rora_Disruption  microRNA_Rescue  Outcome
0        10.0  10.0                  1.0           1.0     100.0           500.0             12000000.0                  50.0           200.0           0.8           0.9           0.7           0.6           0.5           0.4           1
1        12.0  12.0                  1.2           1.2     120.0           600.0             15000000.0                  60.0           250.0           0.9           1.0           0.8           0.7           0.6           0.5           1
2         8.0   8.0                  0.8           0.8      80.0           400.0              9000000.0                  40.0           180.0           0.7           0.8           0.6           0.5           0.4           0.3           0
3        11.0  11.0                  1.1           1.1     110.0           550.0             13000000.0                  55.0           220.0           0.8           0.9           0.7           0.6           0.5           0.4           1
4        13.0  13.0                  1.3           1.3     130.0           650.0             16000000.0                  65.0           280.0           0.9           1.0           0.8           0.7           0.6           0.5           1
5         9.0   9.0                  0.9           0.9      90.0           450.0             10000000.0                  45.0           190.0           0.7           0.8           0.6           0.5           0.4           0.3           0
6        10.5  10.5                  1.05          1.05     105.0           525.0             12500000.0                  52.5           210.0           0.8           0.9           0.7           0.6           0.5           0.4           1
7        11.5  11.5                  1.15          1.15     115.0           575.0             13500000.0                  57.5           230.0           0.8           0.9           0.7           0.6           0.5           0.4           1
8         8.5   8.5                  0.85          0.85      85.0           425.0              9500000.0                  42.5           185.0           0.7           0.8           0.6           0.5           0.4           0.3           0
9        12.5  12.5                  1.25          1.25     125.0           625.0             15000000.0                  62.5           260.0           0.9           1.0           0.8           0.7           0.6           0.5           1
10        9.5   9.5                  0.95          0.95      95.0           475.0             10500000.0                  47.5           195.0           0.7           0.8           0.6           0.5           0.4           0.3           0
11       10.0  10.0                  1.0           1.0     100.0           500.0             12000000.0                  50.0           200.0           0.8           0.9           0.7           0.6           0.5           0.4           1
12       12.0  12.0                  1.2           1.2     120.0           600.0             15000000.0                  60.0           250.0           0.9           1.0           0.8           0.7           0.6           0.5           1
13        8.0   8.0                  0.8           0.8      80.0           400.0              9000000.0                  40.0           180.0           0.7           0.8           0.6           0.5           0.4           0.3           0
14       11.0  11.0                  1.1           1.1     110.0           550.0             13000000.0                  55.0           220.0           0.8           0.9           0.7           0.6           0.5           0.4           1
15       13.0  13.0                  1.3           1.3     130.0           650.0             16000000.0                  65.0           280.0           0.9           1.0           0.8           0.7           0.6           0.5           1
16        9.0   9.0                  0.9           0.9      90.0           450.0             10000000.0                  45.0           190.0           0.7           0.8           0.6           0.5           0.4           0.3           0
17       10.5  10.5                  1.05          1.05     105.0           525.0             12500000.0                  52.5           210.0           0.8           0.9           0.7           0.6           0.5           0.4           1
18       11.5  11.5                  1.15          1.15     115.0           575.0             13500000.0                  57.5           230.0           0.8           0.9           0.7           0.6           0.5           0.4           1
19        8.5   8.5                  0.85          0.85      85.0           425.0              9500000.0                  42.5           185.0           0.7           0.8           0.6           0.5           0.4           0.3           0
20       12.5  12.5                  1.25          1.25     125.0           625.0             15000000.0                  62.5           260.0           0.9           1.0           0.8           0.7           0.6           0.5           1
21        9.5   9.5                  0.95          0.95      95.0           475.0             10500000.0                  47.5           195.0           0.7           0.8           0.6           0.5           0.4           0.3           0
22       10.0  10.0                  1.0           1.0     100.0           500.0             12000000.0                  50.0           200.0           0.8           0.9           0.7           0.6           0.5           0.4           1
23       12.0  12.0                  1.2           1.2     120.0           600.0             15000000.0                  60.0           250.0           0.9           1.0           0.8           0.7           0.6           0.5           1
24       11.0  11.0                  1.1           1.1     110.0           550.0             13000000.0                  55.0           220.0           0.8           0.9           0.7           0.6           0.5           0.4           1
```",0.7752568852703507
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/557c9845e63f6e61df1deacf1ec15bbd494e7f8e.summary'],"Does SHARPIN-mediated regulation of integrin activity in the tumor microenvironment also influence the recruitment and differentiation of endothelial progenitor cells, thereby modulating tumor angiogenesis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** SHARPIN-mediated regulation of integrin activity in the tumor microenvironment also influences the recruitment and differentiation of endothelial progenitor cells, thereby modulating tumor angiogenesis.

**Experimental Plan:**

**Objective:** To investigate the role of SHARPIN in regulating endothelial progenitor cell recruitment and differentiation in the tumor microenvironment and its impact on tumor angiogenesis.

**Equipment:**

* SHARPIN-deficient mice
* Wild-type mice
* Tumor cells
* Matrigel
* Endothelial progenitor cells (EPCs)
* Fluorescently labeled EPCs (e.g., GFP or RFP)
* Microscope
* Flow cytometer
* qRT-PCR machine
* Angiogenesis assay kit

**Experimental Design:**

1. **Tumor Model Establishment:** Inject SHARPIN-deficient mice and wild-type mice with tumor cells mixed with Matrigel to create a tumor model.
2. **EPC Isolation and Labeling:** Isolate EPCs from mouse bone marrow and label them with a fluorescent marker (e.g., GFP or RFP).
3. **EPC Injection:** Inject labeled EPCs into the tumor-bearing mice (SHARPIN-deficient and wild-type) via tail vein injection.
4. **Tumor Harvesting and Analysis:** Harvest tumors from both groups at different time points (e.g., 7, 14, and 21 days) and analyze:
	* EPC recruitment: Use flow cytometry to quantify the number of fluorescently labeled EPCs in the tumor tissue.
	* EPC differentiation: Use qRT-PCR to analyze the expression of endothelial cell markers (e.g., CD31, VE-cadherin) in the tumor tissue.
	* Angiogenesis: Use an angiogenesis assay kit to measure the formation of new blood vessels in the tumor tissue.
5. **Immunofluorescence Staining:** Perform immunofluorescence staining on tumor sections to visualize EPC recruitment and differentiation.
6. **Statistical Analysis:** Compare the results between SHARPIN-deficient and wild-type mice using statistical analysis (e.g., t-test, ANOVA).

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that SHARPIN-mediated regulation of integrin activity in the tumor microenvironment does not influence endothelial progenitor cell recruitment and differentiation.

**Modified Experimental Design:**

1. **Integrin Inhibition:** Use an integrin inhibitor (e.g., cilengitide) to block integrin activity in the tumor microenvironment of SHARPIN-deficient mice.
2. **EPC Injection and Analysis:** Follow the same protocol as above, injecting labeled EPCs into integrin-inhibited SHARPIN-deficient mice and analyzing EPC recruitment, differentiation, and angiogenesis.
3. **Comparison:** Compare the results with the SHARPIN-deficient mice without integrin inhibition. If the results show no significant difference, it would suggest that SHARPIN-mediated regulation of integrin activity does not influence endothelial progenitor cell recruitment and differentiation, thereby disproving the hypothesis.

**Rationale:** By inhibiting integrin activity in SHARPIN-deficient mice, we can test whether the observed effects on EPC recruitment and differentiation are indeed due to SHARPIN-mediated regulation of integrin activity. If the results show no significant difference, it would indicate that SHARPIN's role in regulating integrin activity is not crucial for EPC recruitment and differentiation, disproving the hypothesis.

**Time and Resource Considerations:**

* The experiment can be completed within 3-4 months, considering the time required for tumor model establishment, EPC isolation and labeling, and data analysis.
* The budget for this experiment would be reasonable, as it utilizes existing equipment and reagents, with the main costs being associated with the purchase of SHARPIN-deficient mice, EPCs, and integrin inhibitors.

This experimental plan is designed to test the hypothesis and provide a clear answer to the question. The experiment to disprove the hypothesis is a crucial step in verifying the results and ensuring the validity of the findings.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Tumor Model Establishment**

1.1. Prepare tumor cells:
	* Thaw frozen tumor cells and culture them in a suitable medium (e.g., DMEM) supplemented with 10% FBS and antibiotics.
	* Allow the cells to grow to 70-80% confluency.
	* Harvest the cells using trypsin-EDTA and wash them with PBS.

1.2. Prepare Matrigel:
	* Thaw Matrigel on ice according to the manufacturer's instructions.
	* Mix 1 mL of Matrigel with 1 mL of PBS to create a 1:1 ratio.

1.3. Inject tumor cells and Matrigel into mice:
	* Anesthetize SHARPIN-deficient and wild-type mice using isoflurane or ketamine.
	* Inject 100 μL of the tumor cell-Matrigel mixture subcutaneously into the flank of each mouse using a 27-gauge needle.
	* Monitor the mice for tumor growth and health.

**Protocol 2: EPC Isolation and Labeling**

2.1. Isolate EPCs from mouse bone marrow:
	* Euthanize mice using CO2 asphyxiation or cervical dislocation.
	* Harvest the femurs and tibias, and flush the bone marrow cells into a sterile tube using PBS.
	* Centrifuge the cells at 300 x g for 5 minutes and discard the supernatant.
	* Resuspend the cells in 1 mL of PBS and filter them through a 40-μm cell strainer.

2.2. Label EPCs with a fluorescent marker:
	* Centrifuge the EPCs at 300 x g for 5 minutes and discard the supernatant.
	* Resuspend the cells in 1 mL of PBS and add 1 μL of fluorescent marker (e.g., GFP or RFP) according to the manufacturer's instructions.
	* Incubate the cells at room temperature for 30 minutes.
	* Wash the cells with PBS and centrifuge at 300 x g for 5 minutes.

**Protocol 3: EPC Injection**

3.1. Prepare EPCs for injection:
	* Resuspend the labeled EPCs in 100 μL of PBS.
	* Count the cells using a hemocytometer or an automated cell counter.

3.2. Inject EPCs into tumor-bearing mice:
	* Anesthetize the tumor-bearing mice using isoflurane or ketamine.
	* Inject 100 μL of the EPC suspension into the tail vein of each mouse using a 27-gauge needle.

**Protocol 4: Tumor Harvesting and Analysis**

4.1. Harvest tumors:
	* Euthanize the mice at different time points (e.g., 7, 14, and 21 days) using CO2 asphyxiation or cervical dislocation.
	* Dissect the tumors and weigh them.

4.2. Analyze EPC recruitment:
	* Homogenize the tumors using a tissue homogenizer or a mortar and pestle.
	* Centrifuge the homogenate at 300 x g for 5 minutes and discard the supernatant.
	* Resuspend the cells in 1 mL of PBS and filter them through a 40-μm cell strainer.
	* Analyze the cells using flow cytometry to quantify the number of fluorescently labeled EPCs.

4.3. Analyze EPC differentiation:
	* Extract RNA from the tumor tissue using a RNA extraction kit.
	* Perform qRT-PCR to analyze the expression of endothelial cell markers (e.g., CD31, VE-cadherin).

4.4. Analyze angiogenesis:
	* Use an angiogenesis assay kit to measure the formation of new blood vessels in the tumor tissue.

**Protocol 5: Immunofluorescence Staining**

5.1. Fix and section tumor tissue:
	* Fix the tumor tissue in 4% paraformaldehyde for 24 hours.
	* Embed the tissue in paraffin and section it into 5-μm thick slices.

5.2. Perform immunofluorescence staining:
	* Block the sections with 5% BSA and 0.1% Triton X-100 in PBS for 1 hour.
	* Incubate the sections with primary antibodies (e.g., anti-CD31, anti-VE-cadherin) overnight at 4°C.
	* Wash the sections with PBS and incubate with secondary antibodies (e.g., Alexa Fluor 488, Alexa Fluor 594) for 1 hour.
	* Mount the sections with a fluorescent mounting medium and visualize using a microscope.

**Protocol 6: Statistical Analysis**

6.1. Compare the results between SHARPIN-deficient and wild-type mice:
	* Use statistical software (e.g., GraphPad Prism, R) to perform t-tests or ANOVA to compare the results between the two groups.

**Protocol 7: Experiment to Disprove the Hypothesis**

7.1. Integrate integrin inhibition:
	* Inject an integrin inhibitor (e.g., cilengitide) into SHARPIN-deficient mice at a dose of 1 mg/kg body weight.
	* Allow the mice to recover for 24 hours before injecting labeled EPCs.

7.2. Follow the same protocol as above, injecting labeled EPCs into integrin-inhibited SHARPIN-deficient mice and analyzing EPC recruitment, differentiation, and angiogenesis.

7.3. Compare the results with SHARPIN-deficient mice without integrin inhibition:
	* Use statistical software to compare the results between the two groups.
	* If the results show no significant difference, it would suggest that SHARPIN-mediated regulation of integrin activity does not influence endothelial progenitor cell recruitment and differentiation, thereby disproving the hypothesis.","```
   Tumor Cells (10^6)  Matrigel (mL)  EPCs (10^5)  Integrin Inhibitor (mg/kg)  Tumor Weight (mg)  EPC Recruitment (%)  EPC Differentiation (%)  Angiogenesis (%)
0               1.0           0.5         5.0                  0.0          250.0          20.0                15.0             30.0
1               1.5           0.7         7.0                  0.0          300.0          25.0                20.0             35.0
2               2.0           1.0         9.0                  0.0          350.0          30.0                25.0             40.0
3               1.0           0.5         5.0                  1.0          200.0          15.0                10.0             25.0
4               1.5           0.7         7.0                  1.0          250.0          20.0                15.0             30.0
5               2.0           1.0         9.0                  1.0          300.0          25.0                20.0             35.0
6               1.0           0.3         3.0                  0.0          150.0          10.0                 5.0             20.0
7               1.5           0.5         5.0                  0.0          200.0          15.0                10.0             25.0
8               2.0           0.7         7.0                  0.0          250.0          20.0                15.0             30.0
9               1.0           0.3         3.0                  1.0          120.0           8.0                 5.0             20.0
10              1.5           0.5         5.0                  1.0          180.0          12.0                10.0             25.0
11              2.0           0.7         7.0                  1.0          220.0          18.0                15.0             30.0
12              1.0           0.8         9.0                  0.0          350.0          30.0                25.0             40.0
13              1.5           1.0        11.0                  0.0          400.0          35.0                30.0             45.0
14              2.0           1.2        13.0                  0.0          450.0          40.0                35.0             50.0
15              1.0           0.8         9.0                  1.0          300.0          25.0                20.0             35.0
16              1.5           1.0        11.0                  1.0          350.0          30.0                25.0             40.0
17              2.0           1.2        13.0                  1.0          400.0          35.0                30.0             45.0
18              1.0           0.2         2.0                  0.0          100.0           5.0                 5.0             20.0
19              1.5           0.3         3.0                  0.0          150.0          10.0                 5.0             25.0
20              2.0           0.5         5.0                  0.0          200.0          15.0                10.0             30.0
21              1.0           0.2         2.0                  1.0           80.0           4.0                 5.0             20.0
22              1.5           0.3         3.0                  1.0          120.0           8.0                 5.0             25.0
23              2.0           0.5         5.0                  1.0          180.0          12.0                10.0             30.0
24              1.0           1.5        15.0                  0.0          500.0          45.0                40.0             55.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c24955926e30c9164db4f82863df0ea6faf8a225.summary'],"Does SOX11-mediated BCR signaling in B cells also regulate the expression of inhibitory receptors, such as PD-1, to modulate the immune response in mantle cell lymphoma?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** SOX11-mediated BCR signaling in B cells also regulates the expression of inhibitory receptors, such as PD-1, to modulate the immune response in mantle cell lymphoma.

**Experimental Plan:**

**Objective:** To investigate whether SOX11-mediated BCR signaling in B cells regulates the expression of inhibitory receptors, such as PD-1, and modulates the immune response in mantle cell lymphoma.

**Experimental Approach:**

1. **Cell Culture and Transfection:**
	* Isolate B cells from SOX11-overexpressing mice and wild-type (WT) mice.
	* Transfect SOX11-overexpressing B cells with a PD-1 promoter-driven reporter construct (e.g., luciferase or GFP) to monitor PD-1 expression.
	* Use WT B cells as a control.
2. **BCR Stimulation and Inhibitor Treatment:**
	* Stimulate B cells with anti-IgM antibodies to activate BCR signaling.
	* Treat SOX11-overexpressing B cells with a BCR signaling inhibitor (e.g., ibrutinib) to block BCR signaling.
	* Use DMSO as a vehicle control.
3. **Flow Cytometry and Western Blotting:**
	* Analyze PD-1 expression on the surface of B cells using flow cytometry.
	* Perform Western blotting to detect PD-1 protein levels in whole-cell lysates.
4. **Co-Immunoprecipitation and Chromatin Immunoprecipitation (ChIP):**
	* Perform co-immunoprecipitation to investigate the interaction between SOX11 and PD-1.
	* Conduct ChIP to determine if SOX11 binds to the PD-1 promoter region.
5. **In Vivo Studies:**
	* Use a syngeneic mouse model of mantle cell lymphoma to investigate the role of SOX11-mediated BCR signaling in regulating PD-1 expression in vivo.
	* Inject SOX11-overexpressing B cells into mice and monitor tumor growth and PD-1 expression.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that SOX11-mediated BCR signaling in B cells does not regulate the expression of inhibitory receptors, such as PD-1, in mantle cell lymphoma.

**Experimental Approach:**

1. **CRISPR-Cas9 Gene Editing:**
	* Use CRISPR-Cas9 to knockout PD-1 in SOX11-overexpressing B cells.
	* Verify the knockout using Western blotting and flow cytometry.
2. **BCR Stimulation and Inhibitor Treatment:**
	* Stimulate PD-1-knockout SOX11-overexpressing B cells with anti-IgM antibodies.
	* Treat cells with a BCR signaling inhibitor (e.g., ibrutinib) or DMSO as a control.
3. **Flow Cytometry and Western Blotting:**
	* Analyze the expression of other inhibitory receptors (e.g., CTLA-4, LAG-3) on the surface of PD-1-knockout SOX11-overexpressing B cells using flow cytometry.
	* Perform Western blotting to detect protein levels of other inhibitory receptors.
4. **In Vivo Studies:**
	* Inject PD-1-knockout SOX11-overexpressing B cells into mice and monitor tumor growth and the expression of other inhibitory receptors.

**Rationale:**

If the hypothesis is true, SOX11-mediated BCR signaling should regulate PD-1 expression in B cells. By knocking out PD-1, we can test whether SOX11-mediated BCR signaling still affects the expression of other inhibitory receptors. If the expression of other inhibitory receptors is not affected, it would suggest that SOX11-mediated BCR signaling specifically regulates PD-1 expression, supporting the hypothesis. However, if the expression of other inhibitory receptors is affected, it would indicate that SOX11-mediated BCR signaling has a broader impact on the immune response, disproving the hypothesis.

This experimental plan and the designed experiment to disprove the hypothesis can be executed with an unlimited budget in terms of time, resources, and financial support.",85,"Here are the detailed, step-by-step protocols for the experimental plan and the experiment to disprove the hypothesis:

**Experimental Plan:**

**Step 1: Cell Culture and Transfection**

1.1. Isolate B cells from SOX11-overexpressing mice and wild-type (WT) mice using a mouse B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

1.2. Culture the isolated B cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.3. Transfect SOX11-overexpressing B cells with a PD-1 promoter-driven reporter construct (e.g., luciferase or GFP) using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.

1.4. Use WT B cells as a control and maintain them in the same culture conditions.

**Step 2: BCR Stimulation and Inhibitor Treatment**

2.1. Stimulate B cells with anti-IgM antibodies (e.g., 10 μg/mL) for 24 hours to activate BCR signaling.

2.2. Treat SOX11-overexpressing B cells with a BCR signaling inhibitor (e.g., ibrutinib, 1 μM) for 24 hours to block BCR signaling.

2.3. Use DMSO as a vehicle control and treat WT B cells with DMSO for 24 hours.

**Step 3: Flow Cytometry and Western Blotting**

3.1. Analyze PD-1 expression on the surface of B cells using flow cytometry.

* Stain cells with a PD-1-specific antibody (e.g., PE-conjugated anti-PD-1) and a viability dye (e.g., 7-AAD).
* Acquire data using a flow cytometer (e.g., BD FACSCanto II) and analyze using flow cytometry software (e.g., FlowJo).

3.2. Perform Western blotting to detect PD-1 protein levels in whole-cell lysates.

* Lyse cells in RIPA buffer and quantify protein concentrations using a protein assay (e.g., BCA).
* Separate proteins by SDS-PAGE and transfer to a PVDF membrane.
* Probe the membrane with a PD-1-specific antibody (e.g., rabbit anti-PD-1) and detect using an HRP-conjugated secondary antibody and ECL substrate.

**Step 4: Co-Immunoprecipitation and Chromatin Immunoprecipitation (ChIP)**

4.1. Perform co-immunoprecipitation to investigate the interaction between SOX11 and PD-1.

* Lyse cells in IP buffer and immunoprecipitate SOX11 using a SOX11-specific antibody (e.g., rabbit anti-SOX11).
* Analyze the immunoprecipitate by Western blotting using a PD-1-specific antibody.

4.2. Conduct ChIP to determine if SOX11 binds to the PD-1 promoter region.

* Cross-link chromatin using formaldehyde and sonicate to fragment DNA.
* Immunoprecipitate chromatin using a SOX11-specific antibody.
* Analyze the immunoprecipitate by qPCR using primers specific to the PD-1 promoter region.

**Step 5: In Vivo Studies**

5.1. Use a syngeneic mouse model of mantle cell lymphoma to investigate the role of SOX11-mediated BCR signaling in regulating PD-1 expression in vivo.

* Inject SOX11-overexpressing B cells into mice and monitor tumor growth and PD-1 expression using flow cytometry and Western blotting.

**Experiment to Disprove the Hypothesis:**

**Step 1: CRISPR-Cas9 Gene Editing**

1.1. Design CRISPR-Cas9 guide RNAs targeting the PD-1 gene and clone them into a CRISPR-Cas9 vector (e.g., pSpCas9).

1.2. Transfect SOX11-overexpressing B cells with the CRISPR-Cas9 vector using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.

1.3. Select and expand PD-1-knockout clones using puromycin selection and verify the knockout using Western blotting and flow cytometry.

**Step 2: BCR Stimulation and Inhibitor Treatment**

2.1. Stimulate PD-1-knockout SOX11-overexpressing B cells with anti-IgM antibodies (e.g., 10 μg/mL) for 24 hours to activate BCR signaling.

2.2. Treat cells with a BCR signaling inhibitor (e.g., ibrutinib, 1 μM) for 24 hours to block BCR signaling.

2.3. Use DMSO as a vehicle control and treat cells with DMSO for 24 hours.

**Step 3: Flow Cytometry and Western Blotting**

3.1. Analyze the expression of other inhibitory receptors (e.g., CTLA-4, LAG-3) on the surface of PD-1-knockout SOX11-overexpressing B cells using flow cytometry.

* Stain cells with specific antibodies (e.g., PE-conjugated anti-CTLA-4, PE-conjugated anti-LAG-3) and a viability dye (e.g., 7-AAD).
* Acquire data using a flow cytometer (e.g., BD FACSCanto II) and analyze using flow cytometry software (e.g., FlowJo).

3.2. Perform Western blotting to detect protein levels of other inhibitory receptors.

* Lyse cells in RIPA buffer and quantify protein concentrations using a protein assay (e.g., BCA).
* Separate proteins by SDS-PAGE and transfer to a PVDF membrane.
* Probe the membrane with specific antibodies (e.g., rabbit anti-CTLA-4, rabbit anti-LAG-3) and detect using an HRP-conjugated secondary antibody and ECL substrate.

**Step 4: In Vivo Studies**

4.1. Inject PD-1-knockout SOX11-overexpressing B cells into mice and monitor tumor growth and the expression of other inhibitory receptors using flow cytometry and Western blotting.

These detailed, step-by-step protocols should enable the execution of the experimental plan and the experiment to disprove the hypothesis with high replicability and specificity.","```
   SOX11_overexpressing_B_cells  WT_B_cells  anti_IgM_antibodies  ibrutinib  PD-1_expression
0                         10000         5000               5.0       0.5           20.0
1                         12000         6000               7.0       0.7           25.0
2                          8000         4000               3.0       0.3           15.0
3                         15000         7000               9.0       0.9           30.0
4                         11000         5500               6.0       0.6           22.0
5                          9000         4500               4.0       0.4           18.0
6                         13000         6500               8.0       0.8           28.0
7                         14000         7000              10.0       1.0           32.0
8                          8500         4250               4.5       0.45          19.0
9                         12500         6250               7.5       0.75          26.0
10                        10500         5250               5.5       0.55          21.0
11                        14500         7250              11.0       1.1           34.0
12                         9500         4750               4.8       0.48          20.5
13                        13500         6750               8.5       0.85          29.0
14                        16000         8000              12.0       1.2           36.0
15                         9800         4900               5.2       0.52          22.2
16                        12000         6000               7.2       0.72          24.0
17                        15500         7750              13.0       1.3           38.0
18                        10200         5100               5.8       0.58          23.0
19                        14800         7400              14.0       1.4           40.0
20                        11200         5600               6.5       0.65          25.5
21                        16200         8100              15.0       1.5           42.0
22                         9900         4950               5.9       0.59          24.5
23                        13800         6900               9.5       0.95          31.0
24                        16700         8350              16.0       1.6           44.0
```",0.9745180463967896
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/13219dd31baba5f25046b4cf4e92ad6af61ea883.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2f3a8b1d4b6a3184b4cc5d0a2d77e5b9fd6fc317.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/647e36d87abb2f3e35d6ed50e664167a5e60ac9a.summary']","Does TLR9-mediated regulation of FOXO1 expression in B cells modulate the suppressive effects of TGF-β3 on antibody production, thereby influencing disease activity in systemic lupus erythematosus?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** TLR9-mediated regulation of FOXO1 expression in B cells modulates the suppressive effects of TGF-β3 on antibody production, thereby influencing disease activity in systemic lupus erythematosus (SLE).

**Experimental Plan:**

**Objective:** To investigate whether TLR9-mediated regulation of FOXO1 expression in B cells affects the suppressive effects of TGF-β3 on antibody production in SLE.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate B cells from SLE patients and healthy controls using magnetic bead separation or fluorescence-activated cell sorting (FACS).
	* Culture B cells in vitro with or without TGF-β3 (10 ng/mL) and/or TLR9 agonist (CpG ODN 2006, 1 μM) for 24-48 hours.
2. **FOXO1 Expression Analysis:**
	* Perform quantitative real-time PCR (qRT-PCR) to measure FOXO1 mRNA levels in B cells treated with TGF-β3 and/or TLR9 agonist.
	* Validate FOXO1 protein expression using Western blotting or flow cytometry.
3. **Antibody Production Assay:**
	* Measure antibody production (e.g., IgG, IgM) in B cell cultures using ELISA or bead-based assays.
4. **TLR9 Knockdown/Knockout:**
	* Use siRNA or CRISPR-Cas9 to knockdown/knockout TLR9 in B cells to assess the effect on FOXO1 expression and antibody production.
5. **Statistical Analysis:**
	* Compare FOXO1 expression and antibody production between SLE patients and healthy controls, as well as between TGF-β3 and/or TLR9 agonist-treated and untreated B cells.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that TLR9-mediated regulation of FOXO1 expression in B cells does not modulate the suppressive effects of TGF-β3 on antibody production in SLE.

**Experimental Design:**

1. **TLR9 Overexpression:**
	* Overexpress TLR9 in B cells using lentiviral vectors or transfection with TLR9-expressing plasmids.
2. **FOXO1 Knockdown:**
	* Use siRNA or CRISPR-Cas9 to knockdown FOXO1 in B cells overexpressing TLR9.
3. **Antibody Production Assay:**
	* Measure antibody production in TLR9-overexpressing, FOXO1-knockdown B cells treated with TGF-β3.
4. **Comparison:**
	* Compare antibody production in TLR9-overexpressing, FOXO1-knockdown B cells with that in control B cells (without TLR9 overexpression and FOXO1 knockdown) treated with TGF-β3.

**Rationale:** If the hypothesis is true, overexpressing TLR9 and knocking down FOXO1 should rescue the suppressive effects of TGF-β3 on antibody production. If the experiment shows no difference in antibody production between the two groups, it would suggest that TLR9-mediated regulation of FOXO1 expression does not modulate the suppressive effects of TGF-β3 on antibody production, thereby disproving the hypothesis.

**Budget and Timeframe:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000, depending on the specific reagents and equipment required.
* The budget will cover the costs of:
	+ Cell isolation and culture reagents
	+ TGF-β3 and TLR9 agonist
	+ siRNA or CRISPR-Cas9 reagents
	+ Lentiviral vectors or transfection reagents
	+ qRT-PCR and Western blotting reagents
	+ ELISA or bead-based assay kits
	+ Personnel and laboratory costs

Please note that this is a high-level experimental plan, and specific details may need to be adjusted based on the laboratory's resources and expertise.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Culture**

**Objective:** Isolate B cells from SLE patients and healthy controls and culture them in vitro with or without TGF-β3 and/or TLR9 agonist.

**Materials:**

* Blood samples from SLE patients and healthy controls
* Magnetic bead separation kit (e.g., Miltenyi Biotec)
* FACS buffer (e.g., PBS with 2% FBS and 1 mM EDTA)
* TGF-β3 (10 ng/mL)
* TLR9 agonist (CpG ODN 2006, 1 μM)
* RPMI 1640 medium with 10% FBS and 1% penicillin-streptomycin
* 24-well tissue culture plates

**Step-by-Step Protocol:**

1. Collect blood samples from SLE patients and healthy controls and store them at room temperature.
2. Isolate B cells using magnetic bead separation according to the manufacturer's instructions.
3. Wash the isolated B cells with FACS buffer and resuspend them in RPMI 1640 medium with 10% FBS and 1% penicillin-streptomycin.
4. Count the B cells using a hemocytometer and adjust the concentration to 1 x 10^6 cells/mL.
5. Add TGF-β3 (10 ng/mL) and/or TLR9 agonist (1 μM) to the B cell cultures as desired.
6. Incubate the B cell cultures at 37°C, 5% CO2 for 24-48 hours.

**Protocol 2: FOXO1 Expression Analysis**

**Objective:** Measure FOXO1 mRNA levels in B cells treated with TGF-β3 and/or TLR9 agonist using qRT-PCR.

**Materials:**

* RNA extraction kit (e.g., Qiagen RNeasy Mini Kit)
* cDNA synthesis kit (e.g., Thermo Fisher Scientific)
* qRT-PCR master mix (e.g., Thermo Fisher Scientific)
* FOXO1 primers (e.g., forward: 5'-GCTGCGCTGCTGCTG-3', reverse: 5'-CGCTGCTGCTGCTG-3')
* Housekeeping gene primers (e.g., GAPDH)
* qRT-PCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System)

**Step-by-Step Protocol:**

1. Extract RNA from the B cell cultures using the RNA extraction kit according to the manufacturer's instructions.
2. Synthesize cDNA from the extracted RNA using the cDNA synthesis kit according to the manufacturer's instructions.
3. Prepare the qRT-PCR reaction mixture according to the manufacturer's instructions.
4. Add the FOXO1 primers and housekeeping gene primers to the reaction mixture.
5. Run the qRT-PCR reaction using the following conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
6. Analyze the qRT-PCR data using the instrument's software.

**Protocol 3: Antibody Production Assay**

**Objective:** Measure antibody production in B cell cultures using ELISA.

**Materials:**

* ELISA plate (e.g., Nunc MaxiSorp)
* Antibody coating buffer (e.g., PBS with 1% BSA)
* Antibody detection reagents (e.g., HRP-conjugated anti-human IgG)
* TMB substrate (e.g., Thermo Fisher Scientific)
* Stop solution (e.g., 2N H2SO4)
* Plate reader (e.g., BioTek Synergy H1)

**Step-by-Step Protocol:**

1. Coat the ELISA plate with antibody coating buffer according to the manufacturer's instructions.
2. Add the B cell culture supernatants to the ELISA plate and incubate at room temperature for 1 hour.
3. Add the antibody detection reagents to the ELISA plate and incubate at room temperature for 1 hour.
4. Add the TMB substrate to the ELISA plate and incubate at room temperature for 30 minutes.
5. Add the stop solution to the ELISA plate and read the absorbance at 450 nm using the plate reader.

**Protocol 4: TLR9 Knockdown/Knockout**

**Objective:** Knockdown/knockout TLR9 in B cells using siRNA or CRISPR-Cas9.

**Materials:**

* siRNA targeting TLR9 (e.g., Thermo Fisher Scientific)
* CRISPR-Cas9 plasmid targeting TLR9 (e.g., Addgene)
* Lipofectamine RNAiMAX (e.g., Thermo Fisher Scientific)
* Opti-MEM medium (e.g., Thermo Fisher Scientific)

**Step-by-Step Protocol:**

1. Design and synthesize siRNA targeting TLR9 according to the manufacturer's instructions.
2. Transfect the siRNA into B cells using Lipofectamine RNAiMAX according to the manufacturer's instructions.
3. Incubate the transfected B cells at 37°C, 5% CO2 for 24-48 hours.
4. Alternatively, use CRISPR-Cas9 to knockout TLR9 in B cells according to the manufacturer's instructions.

**Protocol 5: Statistical Analysis**

**Objective:** Compare FOXO1 expression and antibody production between SLE patients and healthy controls, as well as between TGF-β3 and/or TLR9 agonist-treated and untreated B cells.

**Materials:**

* Statistical software (e.g., GraphPad Prism)

**Step-by-Step Protocol:**

1. Import the qRT-PCR and ELISA data into the statistical software.
2. Perform two-way ANOVA with Bonferroni post-hoc test to compare FOXO1 expression and antibody production between SLE patients and healthy controls, as well as between TGF-β3 and/or TLR9 agonist-treated and untreated B cells.
3. Calculate the p-values and report the results.

**Protocol 6: Experiment to Disprove the Hypothesis**

**Objective:** Overexpress TLR9 in B cells and knockdown FOXO1 to demonstrate that TLR9-mediated regulation of FOXO1 expression does not modulate the suppressive effects of TGF-β3 on antibody production.

**Materials:**

* Lentiviral vector expressing TLR9 (e.g., Addgene)
* siRNA targeting FOXO1 (e.g., Thermo Fisher Scientific)
* Lipofectamine RNAiMAX (e.g., Thermo Fisher Scientific)
* Opti-MEM medium (e.g., Thermo Fisher Scientific)

**Step-by-Step Protocol:**

1. Transfect the lentiviral vector expressing TLR9 into B cells using Lipofectamine RNAiMAX according to the manufacturer's instructions.
2. Incubate the transfected B cells at 37°C, 5% CO2 for 24-48 hours.
3. Knockdown FOXO1 in the TLR9-overexpressing B cells using siRNA according to the manufacturer's instructions.
4. Treat the TLR9-overexpressing, FOXO1-knockdown B cells with TGF-β3 and measure antibody production using ELISA.
5. Compare the antibody production in the TLR9-overexpressing, FOXO1-knockdown B cells with that in control B cells (without TLR9 overexpression and FOXO1 knockdown) treated with TGF-β3.

Note: The above protocols are detailed and step-by-step, but may require adjustments based on the laboratory's resources and expertise.","```
   SLE_Patient  TGF_beta3  TLR9_Agonist  FOXO1_Expression  Antibody_Production
0           1        10.0           1.0           0.85               0.40
1           0         5.0           0.5           0.70               0.60
2           1         0.0           1.0           0.90               0.30
3           0        10.0           0.0           0.60               0.80
4           1         5.0           1.0           0.80               0.50
5           0         0.0           0.5           0.65               0.75
6           1        10.0           1.0           0.95               0.20
7           0         5.0           0.0           0.55               0.90
8           1         0.0           0.5           0.75               0.45
9           0        10.0           1.0           0.70               0.60
10          1         5.0           0.5           0.85               0.40
11          0         0.0           1.0           0.60               0.80
12          1        10.0           0.0           0.90               0.30
13          0         5.0           1.0           0.80               0.50
14          1         0.0           0.5           0.65               0.75
15          0        10.0           1.0           0.95               0.20
16          1         5.0           0.0           0.55               0.90
17          0         0.0           0.5           0.75               0.45
18          1        10.0           1.0           0.70               0.60
19          0         5.0           0.5           0.85               0.40
20          1         0.0           1.0           0.60               0.80
21          0        10.0           0.0           0.90               0.30
22          1         5.0           1.0           0.80               0.50
23          0         0.0           0.5           0.65               0.75
24          1        10.0           1.0           0.95               0.20
```",0.4936477623693313
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/461f2ab6f7a57fcbc4f9a22d5b7d111f3ecf80f7.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/467842e16745b747b92af91908f9b01ec612a23d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0fecd0633759dac200361cc0db8b251dd941d98f.summary']",Does WAVE2 regulate the self-renewal of B cell-derived lymphoma stem cells by modulating the KLF4-DYRK2 pathway and actin-dependent processes?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test this hypothesis, I'll outline a comprehensive experimental plan to investigate the role of WAVE2 in regulating the self-renewal of B cell-derived lymphoma stem cells through the KLF4-DYRK2 pathway and actin-dependent processes.

**Experimental Approach:**

**Objective:** To determine if WAVE2 regulates the self-renewal of B cell-derived lymphoma stem cells by modulating the KLF4-DYRK2 pathway and actin-dependent processes.

**Experimental Design:**

1. **Cell Culture and Isolation:**
	* Obtain B cell-derived lymphoma cell lines (e.g., Ramos, Daudi) and primary lymphoma cells from patient samples.
	* Isolate lymphoma stem cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) based on surface markers (e.g., CD34, CD38, CD19).
2. **WAVE2 Knockdown/Knockout:**
	* Use CRISPR-Cas9 genome editing to generate WAVE2 knockout (KO) lymphoma cell lines.
	* Validate WAVE2 KO using Western blot, qRT-PCR, and immunofluorescence.
	* Use shRNA-mediated WAVE2 knockdown (KD) as an alternative approach.
3. **Self-Renewal Assays:**
	* Perform serial replating assays to assess the self-renewal capacity of WAVE2 KO/KD lymphoma stem cells compared to control cells.
	* Use colony-forming cell (CFC) assays to evaluate the ability of WAVE2 KO/KD cells to form colonies.
4. **KLF4-DYRK2 Pathway Analysis:**
	* Perform Western blot, qRT-PCR, and immunofluorescence to analyze KLF4 and DYRK2 protein expression and localization in WAVE2 KO/KD cells.
	* Use co-immunoprecipitation (Co-IP) and proximity ligation assays (PLA) to investigate the interaction between KLF4 and DYRK2 in WAVE2 KO/KD cells.
5. **Actin-Dependent Process Analysis:**
	* Use phalloidin staining and confocal microscopy to examine actin cytoskeleton organization in WAVE2 KO/KD cells.
	* Perform actin polymerization assays to assess the effect of WAVE2 KO/KD on actin dynamics.
6. **Rescue Experiments:**
	* Reconstitute WAVE2 expression in WAVE2 KO cells using lentiviral vectors to rescue the self-renewal phenotype.
	* Use dominant-negative or constitutively active mutants of KLF4 and DYRK2 to investigate their role in WAVE2-mediated self-renewal regulation.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that WAVE2 does not regulate the self-renewal of B cell-derived lymphoma stem cells through the KLF4-DYRK2 pathway and actin-dependent processes.

**Experimental Design:**

1. **WAVE2 Overexpression:**
	* Use lentiviral vectors to overexpress WAVE2 in lymphoma cell lines and primary lymphoma cells.
	* Validate WAVE2 overexpression using Western blot, qRT-PCR, and immunofluorescence.
2. **Self-Renewal Assays:**
	* Perform serial replating assays and CFC assays to assess the self-renewal capacity of WAVE2-overexpressing cells.
	* Compare the results to control cells and WAVE2 KO/KD cells.
3. **KLF4-DYRK2 Pathway Analysis:**
	* Analyze KLF4 and DYRK2 protein expression and localization in WAVE2-overexpressing cells using Western blot, qRT-PCR, and immunofluorescence.
	* Investigate the interaction between KLF4 and DYRK2 in WAVE2-overexpressing cells using Co-IP and PLA.
4. **Actin-Dependent Process Analysis:**
	* Examine actin cytoskeleton organization in WAVE2-overexpressing cells using phalloidin staining and confocal microscopy.
	* Assess actin dynamics in WAVE2-overexpressing cells using actin polymerization assays.

**Rationale:**

If WAVE2 does not regulate the self-renewal of B cell-derived lymphoma stem cells through the KLF4-DYRK2 pathway and actin-dependent processes, then:

* WAVE2 overexpression should not affect self-renewal capacity.
* KLF4 and DYRK2 expression and interaction should not be altered in WAVE2-overexpressing cells.
* Actin cytoskeleton organization and dynamics should remain unchanged in WAVE2-overexpressing cells.

By designing an experiment to disprove the hypothesis, we can rigorously test the role of WAVE2 in regulating the self-renewal of B cell-derived lymphoma stem cells and provide strong evidence for or against the hypothesis.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Isolation**

1.1. Obtain B cell-derived lymphoma cell lines (e.g., Ramos, Daudi) and primary lymphoma cells from patient samples.

* Obtain cell lines from a reputable cell bank or culture them in-house using standard cell culture protocols.
* Collect primary lymphoma cells from patient samples using standard protocols for blood or tissue collection.
* Store cells in a -80°C freezer or liquid nitrogen until use.

1.2. Isolate lymphoma stem cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) based on surface markers (e.g., CD34, CD38, CD19).

* Prepare cells for sorting by washing them in PBS and resuspending them in FACS buffer (e.g., PBS with 2% FBS and 1 mM EDTA).
* Stain cells with fluorochrome-conjugated antibodies against CD34, CD38, and CD19 (e.g., FITC-CD34, PE-CD38, APC-CD19).
* Perform FACS sorting using a flow cytometer (e.g., BD FACSAria) to isolate cells with the desired surface marker profile.
* Alternatively, use MACS beads conjugated to antibodies against CD34, CD38, and CD19 to isolate cells using a magnetic separator (e.g., Miltenyi Biotec).

**Protocol 2: WAVE2 Knockdown/Knockout**

2.1. Use CRISPR-Cas9 genome editing to generate WAVE2 knockout (KO) lymphoma cell lines.

* Design guide RNAs (gRNAs) targeting the WAVE2 gene using online tools (e.g., CRISPR Design) and synthesize them using a DNA synthesizer.
* Prepare CRISPR-Cas9 ribonucleoprotein (RNP) complexes by mixing gRNAs with Cas9 enzyme and electroporating them into lymphoma cells.
* Select for edited cells using puromycin or other selection markers and expand them in culture.

2.2. Validate WAVE2 KO using Western blot, qRT-PCR, and immunofluorescence.

* Extract protein from WAVE2 KO cells using RIPA buffer and perform Western blotting using an anti-WAVE2 antibody.
* Perform qRT-PCR using WAVE2-specific primers to detect WAVE2 mRNA levels.
* Fix WAVE2 KO cells with paraformaldehyde and stain them with an anti-WAVE2 antibody for immunofluorescence microscopy.

2.3. Use shRNA-mediated WAVE2 knockdown (KD) as an alternative approach.

* Design shRNAs targeting WAVE2 mRNA using online tools (e.g., RNAi Designer) and clone them into a lentiviral vector.
* Transfect shRNA-expressing lentiviral vectors into lymphoma cells and select for infected cells using puromycin.
* Validate WAVE2 KD using Western blot, qRT-PCR, and immunofluorescence.

**Protocol 3: Self-Renewal Assays**

3.1. Perform serial replating assays to assess the self-renewal capacity of WAVE2 KO/KD lymphoma stem cells compared to control cells.

* Plate 100-1000 WAVE2 KO/KD cells in 96-well plates with methylcellulose-based medium (e.g., MethoCult).
* Incubate plates at 37°C, 5% CO2 for 7-14 days and count colonies using a microscope.
* Repeat the replating process 2-3 times to assess self-renewal capacity.

3.2. Use colony-forming cell (CFC) assays to evaluate the ability of WAVE2 KO/KD cells to form colonies.

* Plate 100-1000 WAVE2 KO/KD cells in 96-well plates with CFC medium (e.g., StemMACS).
* Incubate plates at 37°C, 5% CO2 for 7-14 days and count colonies using a microscope.

**Protocol 4: KLF4-DYRK2 Pathway Analysis**

4.1. Perform Western blot, qRT-PCR, and immunofluorescence to analyze KLF4 and DYRK2 protein expression and localization in WAVE2 KO/KD cells.

* Extract protein from WAVE2 KO/KD cells using RIPA buffer and perform Western blotting using anti-KLF4 and anti-DYRK2 antibodies.
* Perform qRT-PCR using KLF4- and DYRK2-specific primers to detect mRNA levels.
* Fix WAVE2 KO/KD cells with paraformaldehyde and stain them with anti-KLF4 and anti-DYRK2 antibodies for immunofluorescence microscopy.

4.2. Use co-immunoprecipitation (Co-IP) and proximity ligation assays (PLA) to investigate the interaction between KLF4 and DYRK2 in WAVE2 KO/KD cells.

* Perform Co-IP using anti-KLF4 or anti-DYRK2 antibodies and Western blotting to detect the interacting protein.
* Perform PLA using anti-KLF4 and anti-DYRK2 antibodies and a PLA kit (e.g., Duolink) to detect protein-protein interactions.

**Protocol 5: Actin-Dependent Process Analysis**

5.1. Use phalloidin staining and confocal microscopy to examine actin cytoskeleton organization in WAVE2 KO/KD cells.

* Fix WAVE2 KO/KD cells with paraformaldehyde and stain them with phalloidin conjugated to a fluorophore (e.g., Alexa Fluor 488).
* Image cells using confocal microscopy (e.g., Zeiss LSM 880) to examine actin cytoskeleton organization.

5.2. Perform actin polymerization assays to assess the effect of WAVE2 KO/KD on actin dynamics.

* Prepare actin monomers (e.g., Actin-Atto 488) and add them to WAVE2 KO/KD cells in a 96-well plate.
* Measure actin polymerization using a plate reader (e.g., Tecan Infinite M200) and analyze data using software (e.g., GraphPad Prism).

**Protocol 6: Rescue Experiments**

6.1. Reconstitute WAVE2 expression in WAVE2 KO cells using lentiviral vectors to rescue the self-renewal phenotype.

* Clone WAVE2 cDNA into a lentiviral vector and transfect it into WAVE2 KO cells.
* Select for infected cells using puromycin and validate WAVE2 expression using Western blot, qRT-PCR, and immunofluorescence.

6.2. Use dominant-negative or constitutively active mutants of KLF4 and DYRK2 to investigate their role in WAVE2-mediated self-renewal regulation.

* Clone KLF4 and DYRK2 mutants into lentiviral vectors and transfect them into WAVE2 KO cells.
* Perform self-renewal assays (Protocol 3) to assess the effect of KLF4 and DYRK2 mutants on WAVE2-mediated self-renewal regulation.

**Protocol 7: WAVE2 Overexpression**

7.1. Use lentiviral vectors to overexpress WAVE2 in lymphoma cell lines and primary lymphoma cells.

* Clone WAVE2 cDNA into a lentiviral vector and transfect it into lymphoma cells.
* Select for infected cells using puromycin and validate WAVE2 overexpression using Western blot, qRT-PCR, and immunofluorescence.

7.2. Perform self-renewal assays (Protocol 3) to assess the effect of WAVE2 overexpression on self-renewal capacity.

7.3. Analyze KLF4 and DYRK2 protein expression and localization in WAVE2-overexpressing cells using Western blot, qRT-PCR, and immunofluorescence.

7.4. Examine actin cytoskeleton organization in WAVE2-overexpressing cells using phalloidin staining and confocal microscopy.

7.5. Assess actin dynamics in WAVE2-overexpressing cells using actin polymerization assays.

These detailed protocols should provide a clear guide for executing the experimental plan and testing the hypothesis.","```
   Ramos_cells  Daudi_cells  Primary_lymphoma_cells  CD34  CD38  CD19  WAVE2_KO  WAVE2_KD  KLF4  DYRK2  Self_Renewal_Capacity  Actin_Polymerization
0           1000          500                  2000   0.5   0.2   0.8       1.0       0.0   2.0   1.5                0.8             1.2
1           2000          1000                 1500   0.8   0.5   0.9       0.0       1.0   1.8   1.2                0.9             1.5
2           1500          2000                 2500   0.2   0.8   0.7       1.0       0.0   1.5   1.8                0.7             1.1
3           500          1500                 1000   0.9   0.1   0.6       0.0       1.0   2.2   1.1                0.6             1.4
4           2000          500                  3000   0.1   0.9   0.4       1.0       0.0   1.2   1.9                0.4             1.0
5           1000          2000                 2000   0.6   0.3   0.9       0.0       1.0   2.5   1.4                0.9             1.6
6           1500          1000                 2500   0.8   0.2   0.7       1.0       0.0   1.8   1.6                0.7             1.3
7           500          2000                 1500   0.4   0.6   0.8       0.0       1.0   2.1   1.3                0.8             1.7
8           2000          1500                 3000   0.9   0.1   0.5       1.0       0.0   1.4   1.8                0.5             1.2
9           1000          500                  2000   0.2   0.8   0.6       0.0       1.0   2.3   1.2                0.6             1.5
10          1500          2000                 2500   0.5   0.4   0.9       1.0       0.0   1.9   1.5                0.9             1.4
11          500          1000                 1500   0.7   0.3   0.8       0.0       1.0   2.4   1.1                0.8             1.6
12          2000          1500                 3000   0.1   0.9   0.4       1.0       0.0   1.3   1.9                0.4             1.1
13          1000          2000                 2000   0.9   0.1   0.6       0.0       1.0   2.6   1.2                0.6             1.7
14          1500          500                  2500   0.4   0.6   0.7       1.0       0.0   1.7   1.4                0.7             1.3
15          500          2000                 1500   0.2   0.8   0.5       0.0       1.0   2.2   1.1                0.5             1.5
16          2000          1000                 3000   0.8   0.2   0.9       1.0       0.0   1.9   1.6                0.9             1.4
17          1000          1500                 2000   0.5   0.4   0.8       0.0       1.0   2.5   1.3                0.8             1.6
18          1500          2000                 2500   0.9   0.1   0.7       1.0       0.0   1.8   1.5                0.7             1.3
19          500          1000                 1500   0.7   0.3   0.6       0.0       1.0   2.3   1.2                0.6             1.5
20          2000          1500                 3000   0.2   0.8   0.5       1.0       0.0   1.4   1.9                0.5             1.2
21          1000          2000                 2000   0.4   0.6   0.9       0.0       1.0   2.6   1.1                0.9             1.7
22          1500          500                  2500   0.8   0.2   0.7       1.0       0.0   1.9   1.4                0.7             1.4
23          500          2000                 1500   0.5   0.4   0.8       0.0       1.0   2.4   1.2                0.8             1.6
24          2000          1000                 3000   0.9   0.1   0.6       1.0       0.0   1.7   1.5                0.6             1.3",0.01722423954002965
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/79a47dbe38ff1d96a32feb97ecbb979027df87d3.summary'],Does bryostatin-induced epigenetic modulation of pre-B ALL cells lead to the expression of specific microRNAs that regulate the ligands responsible for CAR-T cell antigen-non-specific killing and NK-like killing?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll outline a comprehensive experimental plan to test it. Please note that this plan assumes an unlimited budget, which allows for the use of cutting-edge techniques and equipment.

**Hypothesis:** Bryostatin-induced epigenetic modulation of pre-B ALL cells leads to the expression of specific microRNAs that regulate the ligands responsible for CAR-T cell antigen-non-specific killing and NK-like killing.

**Experimental Plan:**

**Objective:** Investigate the effect of bryostatin on pre-B ALL cells, focusing on the expression of specific microRNAs and their role in regulating ligands involved in CAR-T cell antigen-non-specific killing and NK-like killing.

**Step 1: Cell Culture and Bryostatin Treatment**

1. Obtain pre-B ALL cell lines (e.g., NALM-6, REH) and maintain them in culture using standard protocols.
2. Treat pre-B ALL cells with bryostatin (e.g., 10 nM, 24 hours) to induce epigenetic modulation.
3. Use a control group without bryostatin treatment.

**Step 2: RNA Isolation and MicroRNA Profiling**

1. Isolate total RNA from bryostatin-treated and control pre-B ALL cells using a high-quality RNA extraction kit (e.g., TRIzol, Qiagen).
2. Perform microRNA profiling using a microarray platform (e.g., Affymetrix, Agilent) or next-generation sequencing (NGS) technology (e.g., Illumina, Ion Torrent) to identify differentially expressed microRNAs.
3. Validate the expression of selected microRNAs using quantitative reverse transcription polymerase chain reaction (qRT-PCR).

**Step 3: Target Prediction and Validation**

1. Use bioinformatic tools (e.g., TargetScan, miRanda, PicTar) to predict the target genes of the differentially expressed microRNAs.
2. Focus on targets involved in CAR-T cell antigen-non-specific killing and NK-like killing, such as ligands for NKG2D, DNAM-1, and CD16.
3. Validate the expression of predicted target genes using qRT-PCR and Western blotting.

**Step 4: Functional Assays**

1. Perform co-culture assays to evaluate the effect of bryostatin-treated pre-B ALL cells on CAR-T cell cytotoxicity and NK cell-mediated killing.
2. Use flow cytometry to assess the expression of ligands on pre-B ALL cells and the activation of CAR-T cells and NK cells.
3. Measure cytokine production (e.g., IFN-γ, TNF-α) using ELISA or multiplex assays.

**Step 5: Mechanistic Studies**

1. Investigate the epigenetic changes induced by bryostatin using chromatin immunoprecipitation sequencing (ChIP-seq) or reduced representation bisulfite sequencing (RRBS).
2. Analyze the enrichment of histone modifications (e.g., H3K27me3, H3K4me3) at microRNA promoters and target gene loci.
3. Use CRISPR-Cas9 genome editing to knockout or overexpress specific microRNAs and evaluate the effects on ligand expression and CAR-T cell/NK cell-mediated killing.

**Step 6: Data Analysis and Integration**

1. Perform statistical analysis of microRNA profiling data using tools like R or Python.
2. Integrate the results from Steps 2-5 to identify key microRNAs and their target genes involved in regulating CAR-T cell antigen-non-specific killing and NK-like killing.
3. Use pathway analysis tools (e.g., Ingenuity Pathway Analysis, Reactome) to visualize the regulatory networks and identify potential therapeutic targets.

**Timeline:**

* Month 1-2: Cell culture, bryostatin treatment, and RNA isolation
* Month 3-4: MicroRNA profiling and target prediction
* Month 5-6: Target validation and functional assays
* Month 7-9: Mechanistic studies and data analysis
* Month 10-12: Data integration, manuscript preparation, and submission

**Personnel:**

* Principal Investigator (PI)
* Postdoctoral Researcher (2)
* Graduate Student (2)
* Research Technician (2)
* Bioinformatician (1)

**Equipment and Resources:**

* Cell culture facilities
* Microarray or NGS platform
* qRT-PCR and Western blotting equipment
* Flow cytometer
* Co-culture and functional assay equipment
* ChIP-seq and RRBS equipment
* CRISPR-Cas9 genome editing tools
* Bioinformatic software and computing resources
* Access to relevant databases and literature

This experimental plan provides a comprehensive approach to test the hypothesis, leveraging cutting-edge techniques and equipment. The unlimited budget allows for the use of high-throughput methods and the recruitment of a skilled team to execute the project.",90,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Culture and Bryostatin Treatment**

1.1. Obtain pre-B ALL cell lines (e.g., NALM-6, REH) from a reputable cell bank or culture collection.

1.2. Thaw the cells according to the supplier's instructions and resuspend them in complete growth medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).

1.3. Culture the cells in a humidified incubator at 37°C, 5% CO2, and maintain a cell density between 0.5 x 10^6 and 1 x 10^6 cells/mL.

1.4. Treat the cells with bryostatin (10 nM) for 24 hours. Prepare a 10 mM bryostatin stock solution in DMSO and dilute it to the working concentration in complete growth medium.

1.5. Use a control group without bryostatin treatment, maintaining the same cell culture conditions.

1.6. Monitor cell viability and morphology using a hemocytometer and a microscope.

**Step 2: RNA Isolation and MicroRNA Profiling**

2.1. Harvest the bryostatin-treated and control pre-B ALL cells by centrifugation (300 x g, 5 minutes) and wash them with PBS.

2.2. Isolate total RNA using a high-quality RNA extraction kit (e.g., TRIzol, Qiagen) according to the manufacturer's instructions.

2.3. Measure the RNA concentration and purity using a spectrophotometer (e.g., NanoDrop) and a bioanalyzer (e.g., Agilent 2100).

2.4. Perform microRNA profiling using a microarray platform (e.g., Affymetrix, Agilent) or next-generation sequencing (NGS) technology (e.g., Illumina, Ion Torrent) according to the manufacturer's instructions.

2.5. For microarray analysis, hybridize the labeled RNA samples to the microarray chip and scan the chip using a microarray scanner.

2.6. For NGS analysis, prepare the RNA libraries using a commercial kit (e.g., TruSeq, Illumina) and sequence the libraries on a NGS platform.

2.7. Validate the expression of selected microRNAs using quantitative reverse transcription polymerase chain reaction (qRT-PCR) with specific primers and a qRT-PCR instrument (e.g., ABI 7500).

**Step 3: Target Prediction and Validation**

3.1. Use bioinformatic tools (e.g., TargetScan, miRanda, PicTar) to predict the target genes of the differentially expressed microRNAs.

3.2. Focus on targets involved in CAR-T cell antigen-non-specific killing and NK-like killing, such as ligands for NKG2D, DNAM-1, and CD16.

3.3. Validate the expression of predicted target genes using qRT-PCR and Western blotting.

3.4. For qRT-PCR, design specific primers for the target genes and perform the reaction using a qRT-PCR instrument.

3.5. For Western blotting, prepare protein lysates from the bryostatin-treated and control pre-B ALL cells, separate the proteins using SDS-PAGE, and detect the target proteins using specific antibodies.

**Step 4: Functional Assays**

4.1. Perform co-culture assays to evaluate the effect of bryostatin-treated pre-B ALL cells on CAR-T cell cytotoxicity and NK cell-mediated killing.

4.2. Co-culture the bryostatin-treated or control pre-B ALL cells with CAR-T cells or NK cells at a 1:1 ratio for 4-6 hours.

4.3. Use flow cytometry to assess the expression of ligands on pre-B ALL cells and the activation of CAR-T cells and NK cells.

4.4. Stain the cells with specific antibodies (e.g., anti-NKG2D, anti-DNAM-1, anti-CD16) and analyze the samples using a flow cytometer (e.g., BD FACSCanto).

4.5. Measure cytokine production (e.g., IFN-γ, TNF-α) using ELISA or multiplex assays.

**Step 5: Mechanistic Studies**

5.1. Investigate the epigenetic changes induced by bryostatin using chromatin immunoprecipitation sequencing (ChIP-seq) or reduced representation bisulfite sequencing (RRBS).

5.2. Prepare chromatin from the bryostatin-treated and control pre-B ALL cells using a ChIP kit (e.g., Magna ChIP, Millipore).

5.3. Immunoprecipitate the chromatin with specific antibodies (e.g., anti-H3K27me3, anti-H3K4me3) and analyze the precipitated DNA using NGS.

5.4. Use CRISPR-Cas9 genome editing to knockout or overexpress specific microRNAs and evaluate the effects on ligand expression and CAR-T cell/NK cell-mediated killing.

5.5. Design guide RNAs (gRNAs) targeting the microRNA genes and prepare the CRISPR-Cas9 complex using a commercial kit (e.g., CRISPR-Cas9, Thermo Fisher).

5.6. Transfect the CRISPR-Cas9 complex into the pre-B ALL cells and select the edited cells using antibiotics.

**Step 6: Data Analysis and Integration**

6.1. Perform statistical analysis of microRNA profiling data using tools like R or Python.

6.2. Integrate the results from Steps 2-5 to identify key microRNAs and their target genes involved in regulating CAR-T cell antigen-non-specific killing and NK-like killing.

6.3. Use pathway analysis tools (e.g., Ingenuity Pathway Analysis, Reactome) to visualize the regulatory networks and identify potential therapeutic targets.

6.4. Prepare the data for publication and manuscript submission.

These detailed protocols should provide a clear guide for executing the experimental plan.","```
   Bryostatin (nM)  Cell Density (cells/mL)  RNA Concentration (ng/μL)  MicroRNA Profiling Method  Ligand Expression  CAR-T Cell Cytotoxicity  NK Cell-Mediated Killing
0              5.0               0.75e+06                    150.0                Microarray          0.8               0.4               0.6
1              7.5               0.50e+06                    120.0                Microarray          0.9               0.5               0.7
2             10.0               0.75e+06                    180.0                Microarray          1.0               0.6               0.8
3              5.0               0.50e+06                    100.0                NGS                  0.7               0.3               0.5
4              7.5               0.75e+06                    140.0                NGS                  0.8               0.4               0.6
5             10.0               0.50e+06                    160.0                NGS                  0.9               0.5               0.7
6              5.0               0.75e+06                    130.0                Microarray          0.8               0.4               0.6
7              7.5               0.50e+06                    110.0                Microarray          0.7               0.3               0.5
8             10.0               0.75e+06                    190.0                Microarray          1.0               0.6               0.8
9              5.0               0.50e+06                    120.0                NGS                  0.7               0.3               0.5
10             7.5               0.75e+06                    150.0                NGS                  0.8               0.4               0.6
11            10.0               0.50e+06                    170.0                NGS                  0.9               0.5               0.7
12             5.0               0.75e+06                    140.0                Microarray          0.8               0.4               0.6
13             7.5               0.50e+06                    130.0                Microarray          0.7               0.3               0.5
14            10.0               0.75e+06                    200.0                Microarray          1.0               0.6               0.8
15             5.0               0.50e+06                    110.0                NGS                  0.7               0.3               0.5
16             7.5               0.75e+06                    160.0                NGS                  0.8               0.4               0.6
17            10.0               0.50e+06                    180.0                NGS                  0.9               0.5               0.7
18             5.0               0.75e+06                    120.0                Microarray          0.8               0.4               0.6
19             7.5               0.50e+06                    140.0                Microarray          0.7               0.3               0.5
20            10.0               0.75e+06                    190.0                Microarray          1.0               0.6               0.8
21             5.0               0.50e+06                    130.0                NGS                  0.7               0.3               0.5
22             7.5               0.75e+06                    170.0                NGS                  0.8               0.4               0.6
23            10.0               0.50e+06                    200.0                NGS                  0.9               0.5               0.7
24             5.0               0.75e+06                    150.0                Microarray          0.8               0.4               0.6
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/023016320699cddf648671adc5d8d4184f7e5c71.summary'],"Does daratumumab treatment also modulate the expression of CD38 on non-immune cells, such as cancer stem cells, contributing to its anti-myeloma activity?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that daratumumab treatment modulates the expression of CD38 on non-immune cells, such as cancer stem cells, contributing to its anti-myeloma activity.

**Experimental Plan:**

**Title:** Investigating Daratumumab-Induced CD38 Modulation on Cancer Stem Cells in Multiple Myeloma

**Objective:** To determine if daratumumab treatment modulates CD38 expression on cancer stem cells in multiple myeloma patients, contributing to its anti-myeloma activity.

**Equipment:**

* Flow cytometer
* Cell culture facilities
* Cancer stem cell isolation kit (e.g., CD138+ selection)
* CD38 antibody for flow cytometry
* Daratumumab
* Multiple myeloma cell lines or primary patient samples

**Steps:**

1. **Cancer Stem Cell Isolation:** Isolate CD138+ cancer stem cells from multiple myeloma cell lines or primary patient samples using a cancer stem cell isolation kit.
2. **Daratumumab Treatment:** Treat the isolated cancer stem cells with daratumumab at various concentrations (e.g., 10 μg/mL, 50 μg/mL, 100 μg/mL) for 24-48 hours.
3. **Flow Cytometry Analysis:** Analyze the CD38 expression on the treated cancer stem cells using flow cytometry. Compare the CD38 expression levels between untreated and daratumumab-treated cells.
4. **CD38 Modulation Assessment:** Evaluate the effect of daratumumab on CD38 expression by calculating the mean fluorescence intensity (MFI) of CD38 on the cancer stem cells. Compare the MFI values between untreated and daratumumab-treated cells.
5. **Dose-Response Analysis:** Perform a dose-response analysis to determine the optimal concentration of daratumumab required to modulate CD38 expression on cancer stem cells.
6. **Control Experiments:** Include control experiments using non-daratumumab-treated cancer stem cells and/or isotype-matched antibody controls to ensure specificity of the results.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to show that daratumumab treatment does not modulate CD38 expression on cancer stem cells. Here's an example:

**Null Hypothesis:** Daratumumab treatment does not modulate CD38 expression on cancer stem cells in multiple myeloma.

**Experimental Design:**

1. Treat cancer stem cells with daratumumab at a high concentration (e.g., 100 μg/mL) for 48 hours.
2. Analyze CD38 expression on the treated cancer stem cells using flow cytometry.
3. Compare the CD38 expression levels between untreated and daratumumab-treated cells.
4. If the results show no significant difference in CD38 expression between untreated and daratumumab-treated cells, it would suggest that daratumumab does not modulate CD38 expression on cancer stem cells, disproving the hypothesis.

**Time and Resource Considerations:**

This experiment can be completed within 2-3 weeks, depending on the availability of resources and equipment. The required resources include:

* Cancer stem cell isolation kit
* Daratumumab
* Flow cytometer
* Cell culture facilities
* Personnel with expertise in flow cytometry and cell culture

The estimated cost for this experiment is moderate, primarily due to the cost of daratumumab and the cancer stem cell isolation kit. However, the experiment can be optimized to reduce costs by using smaller sample sizes and fewer replicates.

By following this experimental plan, we can determine if daratumumab treatment modulates CD38 expression on cancer stem cells in multiple myeloma, contributing to its anti-myeloma activity.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cancer Stem Cell Isolation**

1.1. Prepare the cancer stem cell isolation kit according to the manufacturer's instructions.

1.2. Obtain multiple myeloma cell lines or primary patient samples and wash them with phosphate-buffered saline (PBS) to remove any debris or contaminants.

1.3. Resuspend the cells in the recommended buffer provided with the isolation kit and add the CD138+ selection antibody according to the manufacturer's instructions.

1.4. Incubate the cells with the antibody for 30 minutes at 4°C to allow for binding.

1.5. Wash the cells with PBS to remove any unbound antibody.

1.6. Use a magnet or column-based separation method to isolate the CD138+ cancer stem cells according to the manufacturer's instructions.

1.7. Collect the isolated cancer stem cells and wash them with PBS to remove any remaining antibodies or debris.

1.8. Count the isolated cells using a hemocytometer or automated cell counter to determine the total number of cells.

**Protocol 2: Daratumumab Treatment**

2.1. Prepare a stock solution of daratumumab at a concentration of 1 mg/mL in PBS.

2.2. Dilute the daratumumab stock solution to the desired concentrations (10 μg/mL, 50 μg/mL, 100 μg/mL) in cell culture medium.

2.3. Add the diluted daratumumab solution to the isolated cancer stem cells at a volume of 1 mL per 1 x 10^6 cells.

2.4. Incubate the cells with daratumumab for 24-48 hours at 37°C, 5% CO2.

2.5. Use a control group of cells without daratumumab treatment as a negative control.

**Protocol 3: Flow Cytometry Analysis**

3.1. Prepare a staining buffer containing 1% bovine serum albumin (BSA) and 0.1% sodium azide in PBS.

3.2. Add the CD38 antibody to the staining buffer at a concentration of 1:100.

3.3. Add 1 x 10^6 cells to the staining buffer and incubate for 30 minutes at 4°C to allow for antibody binding.

3.4. Wash the cells with PBS to remove any unbound antibody.

3.5. Resuspend the cells in 500 μL of PBS and analyze using a flow cytometer.

3.6. Set the flow cytometer to detect CD38 expression using the appropriate laser and filter settings.

3.7. Acquire data for 10,000 events per sample.

**Protocol 4: CD38 Modulation Assessment**

4.1. Use flow cytometry analysis software to calculate the mean fluorescence intensity (MFI) of CD38 on the cancer stem cells.

4.2. Compare the MFI values between untreated and daratumumab-treated cells.

4.3. Calculate the percentage change in MFI between untreated and daratumumab-treated cells.

**Protocol 5: Dose-Response Analysis**

5.1. Repeat Protocols 2-4 using different concentrations of daratumumab (e.g., 10 μg/mL, 50 μg/mL, 100 μg/mL).

5.2. Plot the percentage change in MFI against the concentration of daratumumab.

5.3. Determine the optimal concentration of daratumumab required to modulate CD38 expression on cancer stem cells.

**Protocol 6: Control Experiments**

6.1. Repeat Protocols 2-4 using non-daratumumab-treated cancer stem cells as a negative control.

6.2. Repeat Protocols 2-4 using an isotype-matched antibody control to ensure specificity of the results.

**Protocol 7: Null Hypothesis Experiment**

7.1. Treat cancer stem cells with daratumumab at a high concentration (e.g., 100 μg/mL) for 48 hours.

7.2. Analyze CD38 expression on the treated cancer stem cells using flow cytometry.

7.3. Compare the CD38 expression levels between untreated and daratumumab-treated cells.

7.4. If the results show no significant difference in CD38 expression between untreated and daratumumab-treated cells, it would suggest that daratumumab does not modulate CD38 expression on cancer stem cells, disproving the hypothesis.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the results.","```
   CD138+ Antibody (μL)  Daratumumab (μg/mL)  CD38 Antibody (μL)  MFI Untreated  MFI Treated  % Change MFI
0                  10.0               10.0           5.0       100.0       80.0       -20.0
1                  15.0               50.0           7.5       120.0       90.0       -25.0
2                  20.0              100.0          10.0       140.0      100.0       -28.6
3                  12.5               20.0           6.25      110.0       95.0       -13.6
4                  17.5               30.0           8.75      130.0      105.0       -19.2
5                  22.5               40.0          11.25      150.0      115.0       -23.3
6                  10.0               50.0           5.0       100.0       80.0       -20.0
7                  15.0              100.0           7.5       120.0       90.0       -25.0
8                  20.0               10.0          10.0       140.0      100.0       -28.6
9                  12.5               30.0           6.25      110.0       95.0       -13.6
10                 17.5               20.0           8.75      130.0      105.0       -19.2
11                 22.5               40.0          11.25      150.0      115.0       -23.3
12                 10.0              100.0           5.0       100.0       80.0       -20.0
13                 15.0               10.0           7.5       120.0       90.0       -25.0
14                 20.0               50.0          10.0       140.0      100.0       -28.6
15                 12.5               40.0           6.25      110.0       95.0       -13.6
16                 17.5               30.0           8.75      130.0      105.0       -19.2
17                 22.5               20.0          11.25      150.0      115.0       -23.3
18                 10.0               50.0           5.0       100.0       80.0       -20.0
19                 15.0              100.0           7.5       120.0       90.0       -25.0
20                 20.0               10.0          10.0       140.0      100.0       -28.6
21                 12.5               20.0           6.25      110.0       95.0       -13.6
22                 17.5               40.0           8.75      130.0      105.0       -19.2
23                 22.5               30.0          11.25      150.0      115.0       -23.3
24                 10.0              100.0           5.0       100.0       80.0       -20.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/a99d4bc7fb268ee0fb01ce290b57d6ff89edcd6b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/fa04449092a0d6147faac8ef430e527d26702f8f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6a10da7f015652180d1aaeaecb0ad87979f8493a.summary']","Does dasatinib treatment modulate the expression of CD38 on B cells in RA patients, leading to reduced autoantibody production and inflammation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed an experimental plan to test it. Since the goal is to disprove the hypothesis, the experiment is designed to detect any potential flaws or inconsistencies in the hypothesis.

**Hypothesis:** Dasatinib treatment modulates the expression of CD38 on B cells in RA patients, leading to reduced autoantibody production and inflammation.

**Experimental Plan:**

**Objective:** To investigate whether dasatinib treatment affects CD38 expression on B cells, autoantibody production, and inflammation in RA patients.

**Study Design:**

1. **Patient Selection:** Recruit 20 RA patients with active disease (as determined by DAS28 score) and 10 healthy controls.
2. **Dasatinib Treatment:** Administer dasatinib (100 mg/day) to RA patients for 12 weeks.
3. **Blood Sampling:** Collect blood samples from RA patients at baseline, 6 weeks, and 12 weeks post-dasatinib treatment. Collect blood samples from healthy controls at a single time point.
4. **CD38 Expression Analysis:** Use flow cytometry to analyze CD38 expression on B cells (CD19+CD20+) in blood samples. Measure the percentage of CD38+ B cells and mean fluorescence intensity (MFI) of CD38.
5. **Autoantibody Production:** Measure levels of anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) in serum using ELISA.
6. **Inflammation Markers:** Measure C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in serum as indicators of inflammation.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on detecting any inconsistencies or lack of correlation between dasatinib treatment, CD38 expression, autoantibody production, and inflammation.

**Key Measurements:**

1. **CD38 Expression:** If dasatinib treatment does not decrease CD38 expression on B cells or if CD38 expression increases, it would contradict the hypothesis.
2. **Autoantibody Production:** If ACPA and RF levels do not decrease or increase after dasatinib treatment, it would suggest that dasatinib does not affect autoantibody production.
3. **Inflammation Markers:** If CRP and ESR levels do not decrease or increase after dasatinib treatment, it would indicate that dasatinib does not affect inflammation.

**Data Analysis:**

1. Compare CD38 expression, autoantibody production, and inflammation markers between RA patients and healthy controls at baseline.
2. Analyze changes in CD38 expression, autoantibody production, and inflammation markers in RA patients after 6 and 12 weeks of dasatinib treatment.
3. Perform correlation analysis between CD38 expression, autoantibody production, and inflammation markers to identify any potential relationships.

**Budget and Timeframe:**

This experiment can be completed within 6-9 months with a budget of approximately $150,000. This includes:

* Patient recruitment and sampling: $20,000
* Dasatinib treatment and monitoring: $30,000
* Flow cytometry and ELISA reagents: $20,000
* Laboratory personnel and equipment: $30,000
* Data analysis and statistical software: $10,000
* Miscellaneous (study coordination, etc.): $20,000

**Conclusion:**

This experimental plan is designed to test the hypothesis that dasatinib treatment modulates CD38 expression on B cells, leading to reduced autoantibody production and inflammation in RA patients. By focusing on detecting inconsistencies and lack of correlation between dasatinib treatment and the outcome measures, we can disprove the hypothesis if it is not supported by the data.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Selection and Recruitment**

1.1. Define the inclusion and exclusion criteria for RA patients:
	* Inclusion criteria: RA patients with active disease (DAS28 score ≥ 3.2), age 18-75, and willing to provide informed consent.
	* Exclusion criteria: patients with severe comorbidities, pregnant or breastfeeding women, and patients taking immunosuppressive medications.

1.2. Recruit 20 RA patients and 10 healthy controls through advertisements, social media, and collaborations with local rheumatology clinics.

1.3. Obtain informed consent from all participants and collect demographic information (age, sex, disease duration, etc.).

**Protocol 2: Dasatinib Treatment**

2.1. Obtain dasatinib (100 mg/day) from a licensed pharmacy or supplier.

2.2. Administer dasatinib to RA patients for 12 weeks, with regular monitoring of adverse events and compliance.

2.3. Ensure patients take dasatinib at the same time every day, with or without food, and report any missed doses.

**Protocol 3: Blood Sampling**

3.1. Collect 10 mL of whole blood from RA patients at baseline (before dasatinib treatment), 6 weeks, and 12 weeks post-dasatinib treatment.

3.2. Collect 10 mL of whole blood from healthy controls at a single time point.

3.3. Label and store blood samples at -80°C until further analysis.

**Protocol 4: CD38 Expression Analysis**

4.1. Thaw frozen blood samples and isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation.

4.2. Stain PBMCs with fluorochrome-conjugated antibodies against CD19, CD20, and CD38.

4.3. Analyze stained cells using a flow cytometer (e.g., BD FACSCanto II) to determine the percentage of CD38+ B cells (CD19+CD20+) and mean fluorescence intensity (MFI) of CD38.

4.4. Use flow cytometry software (e.g., FlowJo) to analyze and quantify CD38 expression.

**Protocol 5: Autoantibody Production**

5.1. Thaw frozen serum samples and measure levels of anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) using ELISA kits (e.g., Orgentec Diagnostika).

5.2. Follow the manufacturer's instructions for ELISA protocols, including sample preparation, antibody incubation, and detection.

5.3. Calculate ACPA and RF levels in units/mL using a standard curve.

**Protocol 6: Inflammation Markers**

6.1. Thaw frozen serum samples and measure C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) using automated analyzers (e.g., Roche Cobas).

6.2. Follow the manufacturer's instructions for CRP and ESR assays, including sample preparation and detection.

6.3. Calculate CRP levels in mg/L and ESR in mm/h.

**Protocol 7: Data Analysis**

7.1. Compare CD38 expression, autoantibody production, and inflammation markers between RA patients and healthy controls at baseline using statistical software (e.g., R or Prism).

7.2. Analyze changes in CD38 expression, autoantibody production, and inflammation markers in RA patients after 6 and 12 weeks of dasatinib treatment using paired t-tests or non-parametric tests (e.g., Wilcoxon signed-rank test).

7.3. Perform correlation analysis between CD38 expression, autoantibody production, and inflammation markers using Pearson's correlation coefficient or Spearman's rank correlation coefficient.

**Quality Control and Assurance**

* Regularly calibrate and maintain flow cytometry and ELISA equipment.
* Use positive and negative controls for CD38 expression, autoantibody production, and inflammation markers.
* Implement a data management plan to ensure accurate and secure data storage and analysis.

**Timeline and Budget**

* Patient recruitment and sampling: 2 months, $20,000
* Dasatinib treatment and monitoring: 3 months, $30,000
* Flow cytometry and ELISA reagents: 1 month, $20,000
* Laboratory personnel and equipment: 6 months, $30,000
* Data analysis and statistical software: 2 months, $10,000
* Miscellaneous (study coordination, etc.): 2 months, $20,000

Total duration: 6-9 months, Total budget: $150,000","```
   Dasatinib_Dose  Patient_Age  Disease_Duration  CD38_Expression_Baseline  CD38_Expression_6weeks  CD38_Expression_12weeks  ACPA_Baseline  ACPA_6weeks  ACPA_12weeks  CRP_Baseline  CRP_6weeks  CRP_12weeks  ESR_Baseline  ESR_6weeks  ESR_12weeks  Outcome
0           100.0         45.0           10.0               20.0               18.0               15.0         500.0       450.0       400.0        10.0        8.0        6.0         20.0        18.0        15.0  Improved
1           120.0         50.0           12.0               22.0               20.0               18.0         550.0       500.0       450.0        12.0       10.0        8.0         22.0        20.0        18.0  Improved
2            80.0         40.0            8.0               18.0               16.0               14.0         400.0       350.0       300.0         8.0        6.0        4.0         18.0        16.0        14.0  Improved
3           100.0         55.0           15.0               25.0               23.0               20.0         600.0       550.0       500.0        15.0       12.0       10.0         25.0        23.0        20.0  Improved
4           110.0         48.0           11.0               21.0               19.0               17.0         480.0       430.0       380.0        11.0        9.0        7.0         21.0        19.0        17.0  Improved
5            90.0         42.0            9.0               19.0               17.0               15.0         420.0       380.0       330.0         9.0        7.0        5.0         19.0        17.0        15.0  Improved
6           130.0         52.0           14.0               28.0               25.0               22.0         650.0       600.0       550.0        14.0       12.0       10.0         28.0        25.0        22.0  Improved
7           100.0         49.0           13.0               24.0               22.0               19.0         580.0       530.0       480.0        13.0       11.0        9.0         24.0        22.0        19.0  Improved
8            80.0         44.0           10.0               20.0               18.0               16.0         440.0       400.0       350.0        10.0        8.0        6.0         20.0        18.0        16.0  Improved
9           120.0         51.0           12.0               23.0               21.0               19.0         520.0       480.0       430.0        12.0       10.0        8.0         23.0        21.0        19.0  Improved
10          110.0         46.0           11.0               22.0               20.0               18.0         500.0       450.0       400.0        11.0        9.0        7.0         22.0        20.0        18.0  Improved
11           90.0         43.0           10.0               21.0               19.0               17.0         460.0       420.0       380.0        10.0        8.0        6.0         21.0        19.0        17.0  Improved
12          130.0         54.0           16.0               30.0               27.0               24.0         700.0       650.0       600.0        16.0       14.0       12.0         30.0        27.0        24.0  Improved
13           100.0         47.0           12.0               24.0               22.0               20.0         540.0       490.0       440.0        12.0       10.0        8.0         24.0        22.0        20.0  Improved
14           80.0         41.0            9.0               19.0               17.0               15.0         400.0       360.0       320.0         9.0        7.0        5.0         19.0        17.0        15.0  Improved
15          110.0         50.0           13.0               26.0               24.0               21.0         620.0       570.0       520.0        13.0       11.0        9.0         26.0        24.0        21.0  Improved
16           90.0         45.0           11.0               22.0               20.0               18.0         480.0       430.0       380.0        11.0        9.0        7.0         22.0        20.0        18.0  Improved
17          130.0         53.0           15.0               29.0               26.0               23.0         680.0       630.0       580.0        15.0       13.0       11.0         29.0        26.0        23.0  Improved
18           100.0         48.0           12.0               25.0               23.0               20.0         600.0       550.0       500.0        12.0       10.0        8.0         25.0        23.0        20.0  Improved
19           80.0         42.0           10.0               20.0               18.0               16.0         420.0       380.0       330.0        10.0        8.0        6.0         20.0        18.0        16.0  Improved
20          120.0         51.0           14.0               28.0               25.0               22.0         660.0       610.0       560.0        14.0       12.0       10.0         28.0        25.0        22.0  Improved
21           90.0         44.0           11.0               23.0               21.0               19.0         520.0       480.0       430.0        11.0        9.0        7.0         23.0        21.0        19.0  Improved
22          110.0         49.0           13.0               27.0               24.0               21.0         640.0       590.0       540.0        13.0       11.0        9.0         27.0        24.0        21.0  Improved
23           80.0         40.0            9.0               20.0               18.0               16.0         400.0       360.0       320.0         9.0        7.0        5.0         20.0        18.0        16.0  Improved
24          130.0         55.0           17.0               32.0               29.0               26.0         720.0       670.0       620.0        17.0       15.0       13.0         32.0        29.0        26.0  Improved
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/389b76d6089b76ef1fde44dd3c632d57cae28016.summary'],"Does deimination of specific proteins in serum-EVs of Bos taurus also play a role in regulating metabolic pathways, and if so, can it be exploited to improve cattle growth and productivity?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that deimination of specific proteins in serum-EVs of Bos taurus plays a role in regulating metabolic pathways and can be exploited to improve cattle growth and productivity.

**Experimental Plan:**

**Title:** Investigating the Role of Deimination in Regulating Metabolic Pathways in Bos taurus Serum-EVs

**Objective:** To determine if deimination of specific proteins in serum-EVs of Bos taurus regulates metabolic pathways and can be exploited to improve cattle growth and productivity.

**Hypothesis:** Deimination of specific proteins in serum-EVs of Bos taurus plays a role in regulating metabolic pathways, and modulating deimination can improve cattle growth and productivity.

**Experimental Design:**

1. **Serum-EV Isolation and Treatment:** Isolate serum-EVs from Bos taurus and treat them with either a deimination inhibitor (e.g., Cl-amidine) or a control (e.g., DMSO). This will allow us to compare the effects of deimination on metabolic pathways.
2. **Metabolic Pathway Analysis:** Use a metabolomics approach (e.g., GC-MS or LC-MS) to analyze the metabolic profiles of the treated serum-EVs. This will help identify changes in metabolic pathways affected by deimination.
3. **Protein Analysis:** Use LC-MS/MS to analyze the protein content of the treated serum-EVs and identify the deiminated proteins involved in metabolic pathways.
4. **Cell Culture Model:** Use a cell culture model (e.g., bovine adipocytes or hepatocytes) to investigate the effect of deiminated proteins on metabolic pathways. Treat the cells with the deimination inhibitor or control and measure changes in metabolic activity (e.g., glucose uptake, lipid metabolism).
5. **Cattle Growth and Productivity:** Collaborate with a cattle farm or research facility to conduct a pilot study on a small group of cattle. Treat the cattle with a deimination inhibitor or control and monitor their growth and productivity (e.g., weight gain, milk production).

**Experimental Controls:**

* Untreated serum-EVs as a negative control
* Serum-EVs treated with a deimination activator (e.g., calcium ionophore) as a positive control
* Cell culture model without deimination treatment as a negative control

**Expected Outcomes:**

* Identification of deiminated proteins involved in metabolic pathways in serum-EVs
* Changes in metabolic profiles of serum-EVs treated with deimination inhibitor or control
* Modulation of metabolic activity in cell culture model treated with deiminated proteins
* Improved cattle growth and productivity in animals treated with deimination inhibitor

**Equipment and Resources:**

* LC-MS/MS instrument
* GC-MS or LC-MS instrument for metabolomics analysis
* Cell culture facilities
* Deimination inhibitor and activator
* Cattle farm or research facility for pilot study

**Timeline:**

* Serum-EV isolation and treatment: 2 weeks
* Metabolic pathway analysis: 4 weeks
* Protein analysis: 4 weeks
* Cell culture model: 6 weeks
* Cattle pilot study: 12 weeks
* Data analysis and interpretation: 12 weeks

**Budget:**

* Equipment and reagents: $50,000
* Personnel and labor: $100,000
* Cattle pilot study: $20,000
* Total: $170,000

This experimental plan is designed to test the hypothesis that deimination of specific proteins in serum-EVs of Bos taurus regulates metabolic pathways and can be exploited to improve cattle growth and productivity. The plan is feasible within a reasonable time frame and budget, and the expected outcomes will provide valuable insights into the role of deimination in regulating metabolic pathways in cattle.",85,"Here are the detailed, step-by-step protocols for each experiment in the plan:

**Experiment 1: Serum-EV Isolation and Treatment**

**Protocol:**

1. **Serum Collection:** Collect 10 mL of blood from healthy Bos taurus cattle using a sterile needle and syringe. Store the blood in a sterile tube at 4°C.
2. **Serum Preparation:** Centrifuge the blood at 1,500 x g for 10 minutes to separate the serum from the blood cells. Transfer the serum to a new tube and store it at -80°C.
3. **Serum-EV Isolation:** Thaw the serum and add 1 mL of ExoQuick-TC (System Biosciences) to 10 mL of serum. Mix well and incubate at room temperature for 30 minutes. Centrifuge at 1,500 x g for 30 minutes to pellet the EVs. Discard the supernatant and resuspend the EV pellet in 1 mL of PBS.
4. **Deimination Inhibitor Treatment:** Divide the EV suspension into two equal parts. Add 10 μM Cl-amidine (deimination inhibitor) to one part and 0.1% DMSO (control) to the other part. Incubate at 37°C for 2 hours.
5. **EV Washing:** Centrifuge the EV suspensions at 1,500 x g for 30 minutes to pellet the EVs. Discard the supernatant and resuspend the EV pellet in 1 mL of PBS.

**Experiment 2: Metabolic Pathway Analysis**

**Protocol:**

1. **Metabolite Extraction:** Add 100 μL of methanol to 100 μL of treated EV suspension. Vortex and incubate at -20°C for 30 minutes. Centrifuge at 10,000 x g for 10 minutes to pellet the protein. Transfer the supernatant to a new tube.
2. **GC-MS or LC-MS Analysis:** Inject 1 μL of the metabolite extract into a GC-MS or LC-MS instrument. Use a metabolomics analysis software (e.g., MetaboAnalyst) to identify and quantify the metabolites.
3. **Data Analysis:** Compare the metabolic profiles of the deimination inhibitor-treated and control EVs to identify changes in metabolic pathways.

**Experiment 3: Protein Analysis**

**Protocol:**

1. **Protein Extraction:** Add 100 μL of RIPA buffer to 100 μL of treated EV suspension. Vortex and incubate on ice for 30 minutes. Centrifuge at 10,000 x g for 10 minutes to pellet the debris. Transfer the supernatant to a new tube.
2. **Protein Digestion:** Add 10 μL of trypsin (1 μg/μL) to the protein extract and incubate at 37°C for 2 hours.
3. **LC-MS/MS Analysis:** Inject 1 μL of the digested protein into an LC-MS/MS instrument. Use a protein analysis software (e.g., MaxQuant) to identify and quantify the proteins.
4. **Data Analysis:** Compare the protein profiles of the deimination inhibitor-treated and control EVs to identify deiminated proteins involved in metabolic pathways.

**Experiment 4: Cell Culture Model**

**Protocol:**

1. **Cell Culture:** Culture bovine adipocytes or hepatocytes in a 6-well plate at 37°C and 5% CO2. Use a cell culture medium supplemented with 10% FBS and 1% antibiotics.
2. **Deimination Inhibitor Treatment:** Add 10 μM Cl-amidine (deimination inhibitor) or 0.1% DMSO (control) to the cell culture medium. Incubate for 24 hours.
3. **Metabolic Activity Assay:** Measure glucose uptake or lipid metabolism using a commercial assay kit (e.g., Glucose Uptake Assay Kit, Lipid Metabolism Assay Kit).
4. **Data Analysis:** Compare the metabolic activity of the deimination inhibitor-treated and control cells to determine the effect of deiminated proteins on metabolic pathways.

**Experiment 5: Cattle Pilot Study**

**Protocol:**

1. **Cattle Selection:** Select 10 healthy Bos taurus cattle and divide them into two groups: deimination inhibitor-treated and control.
2. **Deimination Inhibitor Administration:** Administer 10 mg/kg Cl-amidine (deimination inhibitor) or 0.1% DMSO (control) to the cattle via intravenous injection once a week for 12 weeks.
3. **Growth and Productivity Monitoring:** Monitor the weight gain, milk production, and other growth parameters of the cattle every 2 weeks.
4. **Data Analysis:** Compare the growth and productivity of the deimination inhibitor-treated and control cattle to determine the effect of modulating deimination on cattle growth and productivity.

These detailed protocols should provide a clear guide for executing each experiment in the plan.","```
   Serum Volume (mL)  ExoQuick-TC Volume (mL)  Cl-amidine Concentration (μM)  DMSO Concentration (%)  Metabolite Extraction Volume (μL)  Protein Extraction Volume (μL)  Trypsin Concentration (μg/μL)  Cell Culture Medium Volume (mL)  FBS Concentration (%)  Antibiotics Concentration (%)  Deimination Inhibitor Dose (mg/kg)  Outcome
0               10.0                    1.0                       10.0                0.1                    100.0                    100.0                       1.0                    2.0                10.0                1.0                    10.0  Increased glucose uptake
1               12.0                    1.2                       12.0                0.2                    120.0                    120.0                       1.2                    2.2                12.0                1.2                    12.0  Increased lipid metabolism
2                8.0                    0.8                        8.0                0.0                     80.0                     80.0                       0.8                    1.8                 8.0                0.8                     8.0  No significant change
3               11.0                    1.1                       11.0                0.3                    110.0                    110.0                       1.1                    2.1                11.0                1.1                    11.0  Increased weight gain
4               13.0                    1.3                       13.0                0.4                    130.0                    130.0                       1.3                    2.3                13.0                1.3                    13.0  Increased milk production
5                9.0                    0.9                        9.0                0.1                     90.0                     90.0                       0.9                    1.9                 9.0                0.9                     9.0  No significant change
6               10.5                    1.05                      10.5                0.2                    105.0                    105.0                       1.05                    2.05                10.5                1.05                    10.5  Increased glucose uptake
7               11.5                    1.15                      11.5                0.3                    115.0                    115.0                       1.15                    2.15                11.5                1.15                    11.5  Increased lipid metabolism
8                8.5                    0.85                       8.5                0.0                     85.0                     85.0                       0.85                    1.85                 8.5                0.85                     8.5  No significant change
9               12.5                    1.25                      12.5                0.4                    125.0                    125.0                       1.25                    2.25                12.5                1.25                    12.5  Increased weight gain
10              13.5                    1.35                      13.5                0.5                    135.0                    135.0                       1.35                    2.35                13.5                1.35                    13.5  Increased milk production
11               9.5                    0.95                       9.5                0.2                     95.0                     95.0                       0.95                    1.95                 9.5                0.95                     9.5  No significant change
12              10.8                    1.08                      10.8                0.3                    108.0                    108.0                       1.08                    2.08                10.8                1.08                    10.8  Increased glucose uptake
13              11.8                    1.18                      11.8                0.4                    118.0                    118.0                       1.18                    2.18                11.8                1.18                    11.8  Increased lipid metabolism
14               8.8                    0.88                       8.8                0.1                     88.0                     88.0                       0.88                    1.88                 8.8                0.88                     8.8  No significant change
15              12.8                    1.28                      12.8                0.5                    128.0                    128.0                       1.28                    2.28                12.8                1.28                    12.8  Increased weight gain
16              13.8                    1.38                      13.8                0.6                    138.0                    138.0                       1.38                    2.38                13.8                1.38                    13.8  Increased milk production
17               9.8                    0.98                       9.8                0.3                     98.0                     98.0                       0.98                    1.98                 9.8                0.98                     9.8  No significant change
18              11.2                    1.12                      11.2                0.4                    112.0                    112.0                       1.12                    2.12                11.2                1.12                    11.2  Increased glucose uptake
19              12.2                    1.22                      12.2                0.5                    122.0                    122.0                       1.22                    2.22                12.2                1.22                    12.2  Increased lipid metabolism
20               9.2                    0.92                       9.2                0.2                     92.0                     92.0                       0.92                    1.92                 9.2                0.92                     9.2  No significant change
21              13.2                    1.32                      13.2                0.6                    132.0                    132.0                       1.32                    2.32                13.2                1.32                    13.2  Increased weight gain
22              14.2                    1.42                      14.2                0.7                    142.0                    142.0                       1.42                    2.42                14.2                1.42                    14.2  Increased milk production
23               9.2                    0.92                       9.2                0.3                     92.0                     92.0                       0.92                    1.92                 9.2                0.92                     9.2  No significant change
24              11.9                    1.19                      11.9                0.5                    119.0                    119.0                       1.19                    2.19                11.9                1.19                    11.9  Increased glucose uptake
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/029f49946f391e34a436aee71ab1cc5e66f97773.summary'],"Does estrogen-mediated regulation of miRNAs targeting Aicda mRNA also influence the expression of other genes involved in B cell development and differentiation, leading to a broader impact on immune responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating Estrogen-Mediated Regulation of miRNAs Targeting Aicda mRNA and Its Impact on B Cell Development and Differentiation

**Objective:** To determine if estrogen-mediated regulation of miRNAs targeting Aicda mRNA influences the expression of other genes involved in B cell development and differentiation, leading to a broader impact on immune responses.

**Equipment:**

* Mouse B cells
* Estrogen
* HDAC inhibitors
* miRNA expression profiling platform
* qRT-PCR
* Western blot
* Flow cytometry
* RNA interference (RNAi) or CRISPR-Cas9 system for loss-of-function and gain-of-function approaches

**Steps:**

1. **miRNA Expression Profiling:** Treat mouse B cells with estrogen and/or HDAC inhibitors and analyze miRNA expression profiles using a miRNA expression profiling platform.
2. **Validation of miRNA Targets:** Validate the expression of miRNAs that target Aicda mRNA using qRT-PCR.
3. **AID Expression and CSR Analysis:** Analyze the effect of estrogen on AID expression and CSR using Western blot and flow cytometry.
4. **Functional Analysis of Estrogen-Regulated miRNAs:** Investigate the functional role of estrogen-regulated miRNAs on antibody and autoantibody responses using loss-of-function and gain-of-function approaches.
5. **Gene Expression Analysis:** Analyze the expression of genes involved in B cell development and differentiation using qRT-PCR or RNA-seq.
6. **Correlation Analysis:** Correlate the expression of estrogen-regulated miRNAs with the expression of genes involved in B cell development and differentiation.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Specificity of Estrogen-Mediated Regulation of Aicda mRNA

**Objective:** To determine if estrogen-mediated regulation of miRNAs targeting Aicda mRNA is specific to Aicda mRNA and does not influence the expression of other genes involved in B cell development and differentiation.

**Design:**

1. **Control Group:** Treat mouse B cells with vehicle control (no estrogen or HDAC inhibitors).
2. **Estrogen-Treated Group:** Treat mouse B cells with estrogen.
3. **HDAC Inhibitor-Treated Group:** Treat mouse B cells with HDAC inhibitors.
4. **Estrogen + HDAC Inhibitor-Treated Group:** Treat mouse B cells with both estrogen and HDAC inhibitors.

**Analysis:**

1. **miRNA Expression Profiling:** Analyze miRNA expression profiles in each group using a miRNA expression profiling platform.
2. **Aicda mRNA Expression:** Analyze Aicda mRNA expression in each group using qRT-PCR.
3. **Gene Expression Analysis:** Analyze the expression of genes involved in B cell development and differentiation in each group using qRT-PCR or RNA-seq.

**Expected Outcome:**

If the hypothesis is true, the estrogen-treated group and the estrogen + HDAC inhibitor-treated group should show a significant change in the expression of miRNAs targeting Aicda mRNA and genes involved in B cell development and differentiation compared to the control group and HDAC inhibitor-treated group. If the hypothesis is false, the estrogen-treated group and the estrogen + HDAC inhibitor-treated group should not show a significant change in the expression of miRNAs targeting Aicda mRNA and genes involved in B cell development and differentiation compared to the control group and HDAC inhibitor-treated group.

**Time Frame and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000, depending on the cost of reagents, equipment, and personnel.",85,"Here are the detailed, step-by-step protocols for the experimental plan to test the hypothesis and the experiment to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Step 1: miRNA Expression Profiling**

1.1. Prepare mouse B cells: Isolate mouse B cells from spleen or lymph nodes using a cell separation protocol (e.g., magnetic-activated cell sorting or fluorescence-activated cell sorting).

1.2. Treat mouse B cells: Divide the isolated B cells into four groups:
	* Group 1: Treat with vehicle control (e.g., DMSO or PBS)
	* Group 2: Treat with estrogen (e.g., 10 nM 17β-estradiol) for 24-48 hours
	* Group 3: Treat with HDAC inhibitors (e.g., 1 μM trichostatin A) for 24-48 hours
	* Group 4: Treat with both estrogen and HDAC inhibitors for 24-48 hours

1.3. Extract total RNA: Use a RNA extraction kit (e.g., TRIzol or RNeasy) to extract total RNA from each group of treated B cells.

1.4. Perform miRNA expression profiling: Use a miRNA expression profiling platform (e.g., microarray or RNA-seq) to analyze the expression of miRNAs in each group.

**Step 2: Validation of miRNA Targets**

2.1. Select miRNAs: Identify miRNAs that target Aicda mRNA based on the miRNA expression profiling results.

2.2. Design qRT-PCR primers: Design qRT-PCR primers specific to the selected miRNAs.

2.3. Perform qRT-PCR: Use qRT-PCR to validate the expression of the selected miRNAs in each group of treated B cells.

**Step 3: AID Expression and CSR Analysis**

3.1. Extract protein: Use a protein extraction kit (e.g., RIPA buffer) to extract protein from each group of treated B cells.

3.2. Perform Western blot: Use Western blot to analyze the expression of AID protein in each group.

3.3. Perform flow cytometry: Use flow cytometry to analyze the expression of surface markers associated with CSR (e.g., IgG1, IgG2a, and IgA) in each group.

**Step 4: Functional Analysis of Estrogen-Regulated miRNAs**

4.1. Design RNAi or CRISPR-Cas9 constructs: Design RNAi or CRISPR-Cas9 constructs to knockdown or knockout the estrogen-regulated miRNAs.

4.2. Transfect B cells: Transfect the RNAi or CRISPR-Cas9 constructs into B cells using a transfection reagent (e.g., Lipofectamine).

4.3. Analyze antibody and autoantibody responses: Use ELISA or other assays to analyze the effect of estrogen-regulated miRNAs on antibody and autoantibody responses.

**Step 5: Gene Expression Analysis**

5.1. Extract RNA: Use a RNA extraction kit to extract RNA from each group of treated B cells.

5.2. Perform qRT-PCR or RNA-seq: Use qRT-PCR or RNA-seq to analyze the expression of genes involved in B cell development and differentiation in each group.

**Step 6: Correlation Analysis**

6.1. Analyze data: Analyze the data from Steps 1-5 to identify correlations between the expression of estrogen-regulated miRNAs and genes involved in B cell development and differentiation.

**Experiment to Disprove the Hypothesis:**

**Step 1: Treat B Cells**

1.1. Prepare mouse B cells: Isolate mouse B cells from spleen or lymph nodes using a cell separation protocol.

1.2. Treat B cells: Divide the isolated B cells into four groups:
	* Group 1: Treat with vehicle control (e.g., DMSO or PBS)
	* Group 2: Treat with estrogen (e.g., 10 nM 17β-estradiol) for 24-48 hours
	* Group 3: Treat with HDAC inhibitors (e.g., 1 μM trichostatin A) for 24-48 hours
	* Group 4: Treat with both estrogen and HDAC inhibitors for 24-48 hours

**Step 2: miRNA Expression Profiling**

2.1. Extract total RNA: Use a RNA extraction kit to extract total RNA from each group of treated B cells.

2.2. Perform miRNA expression profiling: Use a miRNA expression profiling platform to analyze the expression of miRNAs in each group.

**Step 3: Aicda mRNA Expression**

3.1. Extract RNA: Use a RNA extraction kit to extract RNA from each group of treated B cells.

3.2. Perform qRT-PCR: Use qRT-PCR to analyze the expression of Aicda mRNA in each group.

**Step 4: Gene Expression Analysis**

4.1. Extract RNA: Use a RNA extraction kit to extract RNA from each group of treated B cells.

4.2. Perform qRT-PCR or RNA-seq: Use qRT-PCR or RNA-seq to analyze the expression of genes involved in B cell development and differentiation in each group.

**Data Analysis**

1. Analyze the data from Steps 2-4 to determine if estrogen-mediated regulation of miRNAs targeting Aicda mRNA is specific to Aicda mRNA and does not influence the expression of other genes involved in B cell development and differentiation.

2. Compare the results from the estrogen-treated group and the estrogen + HDAC inhibitor-treated group to the control group and HDAC inhibitor-treated group to determine if the hypothesis is true or false.

Note: The above protocols are detailed and step-by-step, but may require adjustments based on specific laboratory settings and equipment. It is essential to follow proper laboratory protocols, including safety protocols, and to validate the results using multiple experiments and controls.","```
   Estrogen (nM)  HDAC Inhibitor (μM)  miRNA Expression  AID Protein Expression  CSR Analysis  Outcome
0           0.0               0.0           100.0               50.0          20.0       True
1           5.0               0.5           120.0               60.0          25.0       True
2           10.0              1.0           140.0               70.0          30.0       True
3           15.0              1.5           160.0               80.0          35.0       True
4           20.0              2.0           180.0               90.0          40.0       True
5           0.0               1.0           110.0               55.0          22.0       False
6           5.0               0.0           105.0               52.0          21.0       False
7           10.0              0.5           125.0               62.0          26.0       True
8           15.0              1.0           145.0               72.0          31.0       True
9           20.0              1.5           165.0               82.0          36.0       True
10          0.0               2.0           130.0               65.0          28.0       False
11          5.0               1.5           135.0               67.0          29.0       True
12         10.0              2.0           150.0               75.0          32.0       True
13         15.0              0.5           120.0               58.0          24.0       True
14         20.0              1.0           140.0               68.0          30.0       True
15          0.0               1.5           115.0               56.0          23.0       False
16          5.0               2.0           145.0               72.0          31.0       True
17         10.0              0.0           100.0               50.0          20.0       False
18         15.0              1.5           155.0               78.0          34.0       True
19         20.0              2.0           170.0               85.0          39.0       True
20          0.0               0.5           105.0               52.0          21.0       False
21          5.0               1.0           130.0               63.0          27.0       True
22         10.0              1.5           140.0               69.0          30.0       True
23         15.0              2.0           160.0               80.0          35.0       True
24          20.0              0.0           110.0               54.0          22.0       False
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/005c3f8c37d437cfcd9d9bd7cd2454e219ec80dc.summary'],"Does ibrutinib-mediated inhibition of BTK signaling in tumor-infiltrated B cells also enhance the activity of CD4+ T cells, leading to a broader antitumor immune response in metastatic prostate cancer?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I've designed an experimental plan to test the hypothesis and potentially disprove it. This experiment will utilize existing scientific methods and equipment, with an unlimited budget in terms of time, resources, and financial support.

**Experiment Title:** Investigating the Role of Ibrutinib-Mediated BTK Signaling Inhibition in CD4+ T Cell Activity and Antitumor Immune Response in Metastatic Prostate Cancer

**Objective:** To determine whether ibrutinib-mediated inhibition of BTK signaling in tumor-infiltrated B cells enhances the activity of CD4+ T cells, leading to a broader antitumor immune response in metastatic prostate cancer.

**Experimental Design:**

1. **Mouse Model:** Use a well-established murine orthotopic prostate cancer model, such as the TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) model, to mimic human metastatic prostate cancer.
2. **Treatment Groups:**
	* Group 1: Vehicle control (no treatment)
	* Group 2: Ibrutinib monotherapy
	* Group 3: PD-1 checkpoint blockade monotherapy
	* Group 4: Combination therapy with ibrutinib and PD-1 checkpoint blockade
3. **Tumor Inoculation and Treatment:**
	* Inoculate mice with prostate cancer cells and allow tumors to establish (approximately 7-10 days).
	* Administer treatments to respective groups: ibrutinib (oral gavage), PD-1 checkpoint blockade (intraperitoneal injection), or combination therapy.
4. **Tissue and Blood Sample Collection:**
	* Collect tumor biopsies and blood samples at baseline (pre-treatment), 7 days post-treatment, and 14 days post-treatment.
5. **Flow Cytometry Analysis:**
	* Analyze tumor-infiltrated immune cells, including CD4+ T cells, CD8+ T cells, and B cells, using flow cytometry.
	* Measure the expression of activation markers (e.g., CD25, CD69) and cytokines (e.g., IFN-γ, IL-2) on CD4+ T cells.
6. **Tumor Volume and Overall Survival:**
	* Measure tumor volume using calipers or imaging techniques (e.g., MRI, CT scans).
	* Monitor overall survival and record the time to tumor progression or death.
7. **Statistical Analysis:**
	* Compare the differences in CD4+ T cell activity, tumor-infiltrated immune cells, and tumor volume between treatment groups using appropriate statistical tests (e.g., ANOVA, t-test).
	* Analyze the correlation between CD4+ T cell activity and antitumor immune response.

**To Disprove the Hypothesis:**

1. **Negative Control:** Include a negative control group that receives a BTK inhibitor that does not affect CD4+ T cell activity, such as a BTK inhibitor with a different mechanism of action.
2. **CD4+ T Cell Depletion:** Deplete CD4+ T cells in a subset of mice using anti-CD4 antibodies or genetic knockout models to assess the specific contribution of CD4+ T cells to the antitumor immune response.
3. **Alternative Mechanisms:** Investigate alternative mechanisms by which ibrutinib may enhance antitumor immunity, such as modulation of the tumor microenvironment or effects on other immune cell subsets.

**Required Equipment:**

* Flow cytometer
* Tumor biopsy equipment
* Mouse housing and handling facilities
* Ibrutinib and PD-1 checkpoint blockade reagents
* Anti-CD4 antibodies (for depletion experiments)
* Genetic knockout models (for CD4+ T cell depletion)
* Imaging equipment (e.g., MRI, CT scans)
* Statistical analysis software

By following this experimental design, we can comprehensively investigate the role of ibrutinib-mediated BTK signaling inhibition in CD4+ T cell activity and antitumor immune response in metastatic prostate cancer, and potentially disprove the hypothesis if the results do not support the predicted outcome.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Mouse Model Preparation**

1.1. Obtain TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice from a reputable vendor or breeding facility.

1.2. House the mice in a specific pathogen-free (SPF) facility with controlled temperature (20-24°C), humidity (50-60%), and light-dark cycle (12 hours light, 12 hours dark).

1.3. Provide mice with standard rodent chow and water ad libitum.

1.4. Acclimate mice to the housing facility for at least 7 days before tumor inoculation.

**Protocol 2: Tumor Inoculation**

2.1. Prepare prostate cancer cells (e.g., TRAMP-C1) according to established protocols.

2.2. Anesthetize mice using isoflurane or ketamine/xylazine.

2.3. Inoculate 1 x 10^6 prostate cancer cells in 50 μL of PBS into the prostate gland of each mouse using a 27-gauge needle.

2.4. Monitor mice for tumor establishment and growth using calipers or imaging techniques (e.g., MRI, CT scans).

**Protocol 3: Treatment Administration**

3.1. Prepare ibrutinib and PD-1 checkpoint blockade reagents according to the manufacturer's instructions.

3.2. Administer treatments to respective groups:
	* Group 1: Vehicle control (no treatment)
	* Group 2: Ibrutinib monotherapy (oral gavage, 25 mg/kg, daily)
	* Group 3: PD-1 checkpoint blockade monotherapy (intraperitoneal injection, 10 mg/kg, every 3 days)
	* Group 4: Combination therapy with ibrutinib and PD-1 checkpoint blockade

3.3. Start treatment 7-10 days after tumor inoculation and continue for 14 days.

**Protocol 4: Tissue and Blood Sample Collection**

4.1. Anesthetize mice using isoflurane or ketamine/xylazine.

4.2. Collect tumor biopsies (approximately 5 mm^3) using a biopsy punch or surgical excision.

4.3. Collect blood samples (approximately 100 μL) via retro-orbital bleeding or cardiac puncture.

4.4. Collect samples at baseline (pre-treatment), 7 days post-treatment, and 14 days post-treatment.

**Protocol 5: Flow Cytometry Analysis**

5.1. Prepare single-cell suspensions from tumor biopsies using enzymatic digestion (e.g., collagenase, DNase) and mechanical dissociation.

5.2. Stain cells with fluorescently labeled antibodies against CD4, CD8, CD25, CD69, IFN-γ, and IL-2.

5.3. Analyze cells using a flow cytometer (e.g., BD FACSCanto II) with appropriate settings for each fluorochrome.

5.4. Gate on CD4+ T cells and analyze the expression of activation markers and cytokines.

**Protocol 6: Tumor Volume and Overall Survival**

6.1. Measure tumor volume using calipers or imaging techniques (e.g., MRI, CT scans) at baseline, 7 days post-treatment, and 14 days post-treatment.

6.2. Monitor overall survival and record the time to tumor progression or death.

**Protocol 7: Statistical Analysis**

7.1. Compare the differences in CD4+ T cell activity, tumor-infiltrated immune cells, and tumor volume between treatment groups using appropriate statistical tests (e.g., ANOVA, t-test).

7.2. Analyze the correlation between CD4+ T cell activity and antitumor immune response using linear regression or Spearman's rank correlation.

**Protocol 8: Negative Control and CD4+ T Cell Depletion**

8.1. Prepare a negative control group that receives a BTK inhibitor with a different mechanism of action (e.g., dasatinib).

8.2. Deplete CD4+ T cells in a subset of mice using anti-CD4 antibodies (e.g., GK1.5, 200 μg/mouse, intraperitoneal injection) or genetic knockout models.

8.3. Analyze the effects of CD4+ T cell depletion on antitumor immune response and tumor growth.

**Protocol 9: Alternative Mechanisms**

9.1. Investigate alternative mechanisms by which ibrutinib may enhance antitumor immunity, such as modulation of the tumor microenvironment or effects on other immune cell subsets.

9.2. Analyze the expression of immune-related genes and proteins in tumor biopsies using techniques such as qRT-PCR, Western blot, or immunohistochemistry.

By following these detailed protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis and potentially disprove it.","```
   TRAMP Mice  Prostate Cancer Cells  Ibrutinib (mg/kg)  PD-1 Checkpoint Blockade (mg/kg)  Tumor Volume (mm^3)  CD4+ T Cell Activity
0          5                  1e+06               0.0                         0.0               150.0               20.0
1          5                  1e+06              25.0                         0.0               120.0               30.0
2          5                  1e+06               0.0                        10.0               180.0               25.0
3          5                  1e+06              25.0                        10.0               100.0               40.0
4          5                  5e+05               0.0                         0.0               200.0               15.0
5          5                  5e+05              25.0                         0.0               150.0               25.0
6          5                  5e+05               0.0                        10.0               220.0               20.0
7          5                  5e+05              25.0                        10.0               120.0               35.0
8          5                  2e+06               0.0                         0.0               250.0               10.0
9          5                  2e+06              25.0                         0.0               180.0               20.0
10         5                  2e+06               0.0                        10.0               280.0               15.0
11         5                  2e+06              25.0                        10.0               150.0               30.0
12         4                  1e+06               0.0                         0.0               160.0               25.0
13         4                  1e+06              25.0                         0.0               130.0               35.0
14         4                  1e+06               0.0                        10.0               190.0               20.0
15         4                  1e+06              25.0                        10.0               110.0               40.0
16         4                  5e+05               0.0                         0.0               210.0               15.0
17         4                  5e+05              25.0                         0.0               160.0               25.0
18         4                  5e+05               0.0                        10.0               230.0               20.0
19         4                  5e+05              25.0                        10.0               130.0               35.0
20         4                  2e+06               0.0                         0.0               260.0               10.0
21         4                  2e+06              25.0                         0.0               190.0               20.0
22         4                  2e+06               0.0                        10.0               290.0               15.0
23         4                  2e+06              25.0                        10.0               160.0               30.0
24         3                  1e+06               0.0                         0.0               170.0               20.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4b17849ab74ad6128c15168ce224a613d05e73e4.summary'],"Does inhibition of AP-1 also suppress HCK expression and cell survival in MYD88-mutated B-cell lymphomas, and if so, is this effect dependent on JunB regulation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Inhibition of AP-1 suppresses HCK expression and cell survival in MYD88-mutated B-cell lymphomas: Role of JunB regulation

**Objective:** To investigate whether inhibition of AP-1 suppresses HCK expression and cell survival in MYD88-mutated B-cell lymphomas and to determine if this effect is dependent on JunB regulation.

**Equipment:**

* AP-1 inhibitor (e.g., T-5224)
* MYD88-mutated B-cell lymphoma cell lines (e.g., BCWM.1, MWCL-1)
* Western blotting equipment
* Cell viability assays
* JunB shRNA (from previous experiment)
* Lentiviral vectors
* qRT-PCR equipment (optional)

**Steps:**

1. Treat MYD88-mutated B-cell lymphoma cell lines with AP-1 inhibitor (T-5224) at varying concentrations for 24-48 hours.
2. Measure HCK protein levels by western blotting.
3. Perform cell viability assays to assess the effect of AP-1 inhibition on cell survival.
4. Transduce MYD88-mutated B-cell lymphoma cell lines with JunB shRNA or control shRNA.
5. Treat transduced cells with AP-1 inhibitor (T-5224) and measure HCK protein levels by western blotting.
6. Perform cell viability assays to assess the effect of AP-1 inhibition on cell survival in JunB-depleted cells.
7. Analyze data to determine the effect of AP-1 inhibition on HCK expression and cell survival, and to determine if this effect is dependent on JunB regulation.

**Optional:**

* Perform qRT-PCR to measure HCK mRNA levels in AP-1-inhibited cells to determine if the effect is transcriptional or post-transcriptional.

**Experiment to Disprove the Hypothesis:**

**Title:** AP-1 inhibition does not affect HCK expression and cell survival in MYD88-mutated B-cell lymphomas

**Objective:** To demonstrate that inhibition of AP-1 does not suppress HCK expression and cell survival in MYD88-mutated B-cell lymphomas, and that JunB regulation is not involved in this process.

**Equipment:**

* AP-1 inhibitor (e.g., T-5224)
* MYD88-mutated B-cell lymphoma cell lines (e.g., BCWM.1, MWCL-1)
* Western blotting equipment
* Cell viability assays
* JunB overexpression plasmid
* Transfection reagent

**Steps:**

1. Treat MYD88-mutated B-cell lymphoma cell lines with AP-1 inhibitor (T-5224) at varying concentrations for 24-48 hours.
2. Measure HCK protein levels by western blotting.
3. Perform cell viability assays to assess the effect of AP-1 inhibition on cell survival.
4. Transfect MYD88-mutated B-cell lymphoma cell lines with JunB overexpression plasmid.
5. Treat transfected cells with AP-1 inhibitor (T-5224) and measure HCK protein levels by western blotting.
6. Perform cell viability assays to assess the effect of AP-1 inhibition on cell survival in JunB-overexpressing cells.
7. Analyze data to determine if AP-1 inhibition has no effect on HCK expression and cell survival, and if JunB overexpression does not rescue the effect.

**Rationale:**

The experiment to disprove the hypothesis aims to show that AP-1 inhibition does not affect HCK expression and cell survival in MYD88-mutated B-cell lymphomas, and that JunB regulation is not involved in this process. By overexpressing JunB, we can test if JunB is necessary for the potential effect of AP-1 inhibition on HCK expression and cell survival. If AP-1 inhibition still has no effect on HCK expression and cell survival in JunB-overexpressing cells, it would suggest that the hypothesis is false.

**Time and Resource Considerations:**

Both experiments can be completed within a reasonable time frame (6-8 weeks) and with a limited budget. The required equipment and reagents are readily available, and the experiments can be performed using existing laboratory resources. The experiments are designed to be concise and focused, minimizing the use of resources and time.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Cell Culture and AP-1 Inhibitor Treatment**

1.1. Obtain MYD88-mutated B-cell lymphoma cell lines (e.g., BCWM.1, MWCL-1) and culture them in a suitable medium (e.g., RPMI 1640) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

1.2. Prepare a stock solution of AP-1 inhibitor (T-5224) in DMSO at a concentration of 10 mM.

1.3. Treat the cell lines with varying concentrations of AP-1 inhibitor (e.g., 1, 5, 10, 20 μM) for 24-48 hours. Use DMSO as a vehicle control.

**Step 2: Western Blotting**

2.1. Harvest the treated cells and wash them with ice-cold PBS.

2.2. Lyse the cells in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitors.

2.3. Perform western blotting using a primary antibody against HCK (e.g., rabbit polyclonal, 1:1000) and a secondary antibody (e.g., goat anti-rabbit, 1:5000).

2.4. Detect the protein bands using a chemiluminescent substrate (e.g., ECL) and quantify the band intensities using image analysis software (e.g., ImageJ).

**Step 3: Cell Viability Assays**

3.1. Seed the treated cells in a 96-well plate at a density of 1 x 10^4 cells/well.

3.2. Perform a cell viability assay (e.g., MTT, CellTiter-Glo) according to the manufacturer's instructions.

3.3. Measure the absorbance or luminescence at the recommended wavelength and calculate the percentage of viable cells.

**Step 4: JunB Depletion**

4.1. Prepare lentiviral vectors encoding JunB shRNA and a control shRNA.

4.2. Transduce the MYD88-mutated B-cell lymphoma cell lines with the lentiviral vectors according to the manufacturer's instructions.

4.3. Select the transduced cells using puromycin (e.g., 1 μg/mL) for 3-5 days.

**Step 5: AP-1 Inhibitor Treatment and Western Blotting in JunB-Depleted Cells**

5.1. Treat the JunB-depleted cells with AP-1 inhibitor (T-5224) at varying concentrations (e.g., 1, 5, 10, 20 μM) for 24-48 hours.

5.2. Perform western blotting as described in Step 2.

**Step 6: Cell Viability Assays in JunB-Depleted Cells**

6.1. Perform cell viability assays as described in Step 3.

**Optional: qRT-PCR**

7.1. Extract total RNA from the AP-1-inhibited cells using a RNA extraction kit (e.g., TRIzol).

7.2. Perform qRT-PCR using a primer set specific to HCK mRNA and a housekeeping gene (e.g., GAPDH).

7.3. Calculate the relative mRNA levels using the ΔΔCt method.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

**Step 1: Cell Culture and AP-1 Inhibitor Treatment**

1.1. Obtain MYD88-mutated B-cell lymphoma cell lines (e.g., BCWM.1, MWCL-1) and culture them in a suitable medium (e.g., RPMI 1640) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

1.2. Prepare a stock solution of AP-1 inhibitor (T-5224) in DMSO at a concentration of 10 mM.

1.3. Treat the cell lines with varying concentrations of AP-1 inhibitor (e.g., 1, 5, 10, 20 μM) for 24-48 hours. Use DMSO as a vehicle control.

**Step 2: Western Blotting**

2.1. Harvest the treated cells and wash them with ice-cold PBS.

2.2. Lyse the cells in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitors.

2.3. Perform western blotting using a primary antibody against HCK (e.g., rabbit polyclonal, 1:1000) and a secondary antibody (e.g., goat anti-rabbit, 1:5000).

2.4. Detect the protein bands using a chemiluminescent substrate (e.g., ECL) and quantify the band intensities using image analysis software (e.g., ImageJ).

**Step 3: Cell Viability Assays**

3.1. Seed the treated cells in a 96-well plate at a density of 1 x 10^4 cells/well.

3.2. Perform a cell viability assay (e.g., MTT, CellTiter-Glo) according to the manufacturer's instructions.

3.3. Measure the absorbance or luminescence at the recommended wavelength and calculate the percentage of viable cells.

**Step 4: JunB Overexpression**

4.1. Prepare a JunB overexpression plasmid.

4.2. Transfect the MYD88-mutated B-cell lymphoma cell lines with the JunB overexpression plasmid using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

**Step 5: AP-1 Inhibitor Treatment and Western Blotting in JunB-Overexpressing Cells**

5.1. Treat the JunB-overexpressing cells with AP-1 inhibitor (T-5224) at varying concentrations (e.g., 1, 5, 10, 20 μM) for 24-48 hours.

5.2. Perform western blotting as described in Step 2.

**Step 6: Cell Viability Assays in JunB-Overexpressing Cells**

6.1. Perform cell viability assays as described in Step 3.

By following these detailed protocols, the experiments can be replicated and the results can be accurately interpreted to test or disprove the hypothesis.","```
   AP-1 Inhibitor (μM)  JunB Level  HCK Protein Level  Cell Viability (%)
0                    1    Control         0.8             95.2
1                    5    Control         0.6             88.5
2                   10    Control         0.4             80.1
3                   20    Control         0.2             70.5
4                    1  Depleted         0.9             92.1
5                    5  Depleted         0.7             85.8
6                   10  Depleted         0.5             78.2
7                   20  Depleted         0.3             69.5
8                    1  Overexpressed     1.1             98.5
9                    5  Overexpressed     1.0             95.1
10                  10  Overexpressed     0.9             90.2
11                  20  Overexpressed     0.8             84.5
12                    1    Control         0.7             90.5
13                    5    Control         0.5             83.2
14                   10    Control         0.3             75.8
15                   20    Control         0.1             67.2
16                    1  Depleted         0.8             91.5
17                    5  Depleted         0.6             86.1
18                   10  Depleted         0.4             79.5
19                   20  Depleted         0.2             71.9
20                    1  Overexpressed     1.2             99.2
21                    5  Overexpressed     1.1             96.5
22                  10  Overexpressed     1.0             92.8
23                  20  Overexpressed     0.9             88.2
24                    5    Control         0.6             89.5
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1b53513618f1189b13d651c718ef5e85c94d1f40.summary'],"Does inhibition of Bruton's tyrosine kinase by ibrutinib also reduce the production of reactive oxygen species in orbital fibroblasts from patients with Graves' orbitopathy, thereby contributing to its therapeutic effect?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib reduces the production of reactive oxygen species (ROS) in orbital fibroblasts from patients with Graves' orbitopathy, contributing to its therapeutic effect.

**Experimental Plan:**

**Objective:** To investigate whether ibrutinib-mediated BTK inhibition decreases ROS production in orbital fibroblasts from patients with Graves' orbitopathy, thereby contributing to its therapeutic effect.

**Experimental Design:**

1. **Cell Culture:**
	* Obtain orbital fibroblasts from patients with Graves' orbitopathy through biopsy or existing cell banks.
	* Culture cells in a controlled environment (e.g., DMEM, 10% FBS, 37°C, 5% CO2) to ensure optimal growth and viability.
2. **Ibrutinib Treatment:**
	* Treat orbital fibroblasts with varying concentrations of ibrutinib (e.g., 0, 1, 5, 10, 20 μM) for 24, 48, and 72 hours to assess dose- and time-dependent effects.
	* Use a vehicle control (e.g., DMSO) to account for any solvent effects.
3. **ROS Measurement:**
	* Utilize a fluorescent probe (e.g., DCFDA, H2DCFDA) to measure ROS levels in treated and control cells.
	* Perform flow cytometry or plate-based assays to quantify ROS production.
4. **BTK Inhibition Verification:**
	* Use Western blotting or immunofluorescence to confirm BTK inhibition in ibrutinib-treated cells.
	* Measure BTK phosphorylation levels to ensure effective inhibition.
5. **Cell Viability and Proliferation:**
	* Assess cell viability using MTT or CellTiter-Glo assays to ensure ibrutinib treatment does not induce significant cytotoxicity.
	* Evaluate cell proliferation using BrdU incorporation or Ki-67 staining to determine if ibrutinib affects cell growth.
6. **ROS-Related Gene Expression:**
	* Perform qRT-PCR or RNA-seq to analyze the expression of ROS-related genes (e.g., NADPH oxidase, SOD, catalase) in ibrutinib-treated cells.
7. **Statistical Analysis:**
	* Use ANOVA or t-tests to compare ROS levels, BTK phosphorylation, and cell viability/proliferation between control and ibrutinib-treated groups.
	* Perform correlation analysis to examine the relationship between BTK inhibition and ROS production.

**Experiment to Disprove the Hypothesis:**

**Objective:** To design an experiment that, if successful, would disprove the hypothesis that ibrutinib-mediated BTK inhibition reduces ROS production in orbital fibroblasts from patients with Graves' orbitopathy.

**Experimental Design:**

1. **Overexpress BTK in Orbital Fibroblasts:**
	* Use lentiviral vectors or plasmid transfection to overexpress BTK in orbital fibroblasts.
	* Verify BTK overexpression using Western blotting or immunofluorescence.
2. **Ibrutinib Treatment:**
	* Treat BTK-overexpressing orbital fibroblasts with ibrutinib (e.g., 10 μM) for 24, 48, and 72 hours.
3. **ROS Measurement:**
	* Measure ROS levels using the same fluorescent probe and methods as in the original experiment.
4. **Comparison:**
	* Compare ROS levels between BTK-overexpressing cells treated with ibrutinib and control cells (without BTK overexpression) treated with ibrutinib.
5. **Interpretation:**
	* If ROS levels in BTK-overexpressing cells treated with ibrutinib are similar to or higher than those in control cells, it would suggest that ibrutinib-mediated BTK inhibition does not reduce ROS production, thereby disproving the hypothesis.

**Rationale:**

By overexpressing BTK in orbital fibroblasts, we can create a scenario where BTK activity is increased, making it more challenging for ibrutinib to inhibit ROS production. If ibrutinib still reduces ROS levels in these cells, it would suggest that the effect is not specific to BTK inhibition. However, if ROS levels remain high or increase despite ibrutinib treatment, it would imply that BTK inhibition is not the primary mechanism by which ibrutinib reduces ROS production, disproving the hypothesis.

With an unlimited budget, we can perform multiple replicates, use advanced techniques like single-cell RNA-seq, and explore additional mechanistic aspects of ibrutinib's effects on orbital fibroblasts.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Investigating the effect of ibrutinib on ROS production in orbital fibroblasts**

**Step 1.1: Cell Culture**

1. Obtain orbital fibroblasts from patients with Graves' orbitopathy through biopsy or existing cell banks.
2. Culture cells in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified incubator at 37°C and 5% CO2.
3. Passage cells every 3-4 days to maintain optimal growth and viability.

**Step 1.2: Ibrutinib Treatment**

1. Prepare a stock solution of ibrutinib (10 mM) in DMSO.
2. Dilute the stock solution to the desired concentrations (0, 1, 5, 10, and 20 μM) in DMEM.
3. Add the ibrutinib solutions to the orbital fibroblasts and incubate for 24, 48, and 72 hours.
4. Use a vehicle control (DMSO) to account for any solvent effects.

**Step 1.3: ROS Measurement**

1. Prepare a stock solution of 2',7'-dichlorofluorescein diacetate (DCFDA) or H2DCFDA (10 mM) in DMSO.
2. Add the DCFDA or H2DCFDA solution to the ibrutinib-treated and control cells at a final concentration of 10 μM.
3. Incubate the cells for 30 minutes at 37°C and 5% CO2.
4. Analyze ROS production using flow cytometry or a plate-based assay.

**Step 1.4: BTK Inhibition Verification**

1. Harvest cells and lyse them in RIPA buffer containing protease and phosphatase inhibitors.
2. Perform Western blotting using an anti-BTK antibody to detect BTK protein levels.
3. Use an anti-phospho-BTK antibody to detect BTK phosphorylation levels.
4. Alternatively, perform immunofluorescence staining using an anti-BTK antibody to visualize BTK expression and phosphorylation.

**Step 1.5: Cell Viability and Proliferation**

1. Perform an MTT or CellTiter-Glo assay to assess cell viability.
2. Add the MTT or CellTiter-Glo reagent to the ibrutinib-treated and control cells according to the manufacturer's instructions.
3. Measure the absorbance or luminescence to determine cell viability.
4. Perform BrdU incorporation or Ki-67 staining to evaluate cell proliferation.

**Step 1.6: ROS-Related Gene Expression**

1. Isolate total RNA from ibrutinib-treated and control cells using a RNA isolation kit.
2. Perform qRT-PCR or RNA-seq to analyze the expression of ROS-related genes (e.g., NADPH oxidase, SOD, catalase).
3. Use primers specific to the target genes and a housekeeping gene (e.g., GAPDH) as a control.

**Step 1.7: Statistical Analysis**

1. Use ANOVA or t-tests to compare ROS levels, BTK phosphorylation, and cell viability/proliferation between control and ibrutinib-treated groups.
2. Perform correlation analysis to examine the relationship between BTK inhibition and ROS production.

**Experiment 2: Disproving the Hypothesis**

**Step 2.1: Overexpress BTK in Orbital Fibroblasts**

1. Design and clone a lentiviral vector or plasmid containing the BTK gene.
2. Transfect or transduce the vector into orbital fibroblasts using a suitable transfection reagent or viral particles.
3. Verify BTK overexpression using Western blotting or immunofluorescence.

**Step 2.2: Ibrutinib Treatment**

1. Treat BTK-overexpressing orbital fibroblasts with ibrutinib (10 μM) for 24, 48, and 72 hours.
2. Use a vehicle control (DMSO) to account for any solvent effects.

**Step 2.3: ROS Measurement**

1. Measure ROS levels using the same fluorescent probe and methods as in Experiment 1.

**Step 2.4: Comparison**

1. Compare ROS levels between BTK-overexpressing cells treated with ibrutinib and control cells (without BTK overexpression) treated with ibrutinib.

**Step 2.5: Interpretation**

1. If ROS levels in BTK-overexpressing cells treated with ibrutinib are similar to or higher than those in control cells, it would suggest that ibrutinib-mediated BTK inhibition does not reduce ROS production, thereby disproving the hypothesis.

These detailed protocols should provide a clear guide for executing the experiments and collecting reliable data to test the hypothesis.","```
   Ibrutinib (μM)  DMSO (%)  FBS (%)  Penicillin (U/mL)  Streptomycin (μg/mL)  ROS Production
0             0.0     0.10    10.0             100.0               100.0          100.0
1             1.0     0.10    10.0             100.0               100.0           90.0
2             5.0     0.10    10.0             100.0               100.0           70.0
3            10.0     0.10    10.0             100.0               100.0           50.0
4            20.0     0.10    10.0             100.0               100.0           30.0
5             0.0     0.05    10.0             100.0               100.0          110.0
6             1.0     0.05    10.0             100.0               100.0          100.0
7             5.0     0.05    10.0             100.0               100.0           80.0
8            10.0     0.05    10.0             100.0               100.0           60.0
9            20.0     0.05    10.0             100.0               100.0           40.0
10            0.0     0.10     5.0             100.0               100.0          120.0
11            1.0     0.10     5.0             100.0               100.0          110.0
12            5.0     0.10     5.0             100.0               100.0           90.0
13           10.0     0.10     5.0             100.0               100.0           70.0
14           20.0     0.10     5.0             100.0               100.0           50.0
15            0.0     0.05     5.0             100.0               100.0          130.0
16            1.0     0.05     5.0             100.0               100.0          120.0
17            5.0     0.05     5.0             100.0               100.0          100.0
18           10.0     0.05     5.0             100.0               100.0           80.0
19           20.0     0.05     5.0             100.0               100.0           60.0
20            0.0     0.10    15.0             100.0               100.0          140.0
21            1.0     0.10    15.0             100.0               100.0          130.0
22            5.0     0.10    15.0             100.0               100.0          110.0
23           10.0     0.10    15.0             100.0               100.0           90.0
24           20.0     0.10    15.0             100.0               100.0           70.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/22264ee213714435ad68128e177b1c051d42c50b.summary'],Does inhibition of CDK5/CAMK2-AMPK signaling pathway also sensitize non-CML cancer cells to tyrosine kinase inhibitors by disrupting DRP1-mediated mitochondrial fission and autophagy?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis!

To test this hypothesis, I'll outline a high-level experimental plan to investigate whether inhibition of the CDK5/CAMK2-AMPK signaling pathway sensitizes non-CML cancer cells to tyrosine kinase inhibitors by disrupting DRP1-mediated mitochondrial fission and autophagy.

**Experimental Approach:**

**Objective:** To determine if inhibition of the CDK5/CAMK2-AMPK signaling pathway sensitizes non-CML cancer cells to tyrosine kinase inhibitors by disrupting DRP1-mediated mitochondrial fission and autophagy.

**Cell Lines:** Select 2-3 non-CML cancer cell lines (e.g., breast, lung, or colon cancer) and their corresponding tyrosine kinase inhibitor-resistant variants.

**Experimental Design:**

1. **Inhibition of CDK5/CAMK2-AMPK signaling pathway:**
	* Use small molecule inhibitors (e.g., Roscovitine for CDK5, KN-93 for CAMK2, and Compound C for AMPK) to inhibit the CDK5/CAMK2-AMPK signaling pathway in non-CML cancer cells.
	* Validate the inhibition using Western blotting or immunofluorescence to detect changes in phosphorylation levels of downstream targets (e.g., AMPK, ACC).
2. **Tyrosine kinase inhibitor treatment:**
	* Treat cells with a tyrosine kinase inhibitor (e.g., Imatinib for BCR-ABL) at a concentration that is ineffective in killing the cells.
	* Measure cell viability using MTT or CellTiter-Glo assays.
3. **Mitochondrial fission and autophagy analysis:**
	* Use fluorescence microscopy to visualize mitochondrial morphology and quantify mitochondrial fission using Mitotracker or TMRE staining.
	* Analyze autophagy using Western blotting for LC3B, p62, and ATG5, or by monitoring autophagic flux using the mRFP-GFP-LC3 reporter.
4. **Combination treatment:**
	* Treat cells with both the CDK5/CAMK2-AMPK signaling pathway inhibitor and the tyrosine kinase inhibitor.
	* Measure cell viability, mitochondrial fission, and autophagy as described above.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to show that inhibition of the CDK5/CAMK2-AMPK signaling pathway does not sensitize non-CML cancer cells to tyrosine kinase inhibitors.

**Negative Control:**

* Use a non-specific inhibitor (e.g., DMSO) instead of the CDK5/CAMK2-AMPK signaling pathway inhibitor.
* Perform the same experimental design as above, including combination treatment with the tyrosine kinase inhibitor.

**Expected Outcome:**

If the hypothesis is true, we expect to see:

* Increased sensitivity to tyrosine kinase inhibitors in non-CML cancer cells when the CDK5/CAMK2-AMPK signaling pathway is inhibited.
* Disruption of DRP1-mediated mitochondrial fission and autophagy in response to CDK5/CAMK2-AMPK signaling pathway inhibition.

If the hypothesis is false, we expect to see:

* No significant difference in sensitivity to tyrosine kinase inhibitors between cells treated with the CDK5/CAMK2-AMPK signaling pathway inhibitor and the negative control.
* No disruption of DRP1-mediated mitochondrial fission and autophagy in response to CDK5/CAMK2-AMPK signaling pathway inhibition.

**Timeline and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000, depending on the specific reagents and equipment required. The budget will cover:

* Cell lines and reagents (e.g., inhibitors, antibodies, dyes) ($15,000-$20,000)
* Equipment and consumables (e.g., microscopes, Western blotting equipment, cell culture supplies) ($10,000-$15,000)
* Personnel and overhead costs (e.g., researcher salary, lab maintenance) ($25,000-$40,000)

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the laboratory setup.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Preparation**

1. Obtain 2-3 non-CML cancer cell lines (e.g., breast, lung, or colon cancer) and their corresponding tyrosine kinase inhibitor-resistant variants from a reputable cell bank or laboratory.
2. Culture cells in a humidified incubator at 37°C and 5% CO2 in a suitable growth medium (e.g., DMEM, RPMI-1640) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
3. Passage cells every 3-4 days to maintain exponential growth.
4. For each experiment, seed 1-2 x 10^5 cells per well in a 6-well plate or 5-10 x 10^4 cells per well in a 96-well plate, depending on the assay requirements.

**Protocol 2: Inhibition of CDK5/CAMK2-AMPK Signaling Pathway**

1. Prepare stock solutions of small molecule inhibitors:
	* Roscovitine (CDK5 inhibitor): 10 mM in DMSO
	* KN-93 (CAMK2 inhibitor): 10 mM in DMSO
	* Compound C (AMPK inhibitor): 10 mM in DMSO
2. Add the inhibitors to the cell culture medium at the following concentrations:
	* Roscovitine: 10-20 μM
	* KN-93: 10-20 μM
	* Compound C: 10-20 μM
3. Incubate cells with the inhibitors for 24-48 hours to allow for effective inhibition of the CDK5/CAMK2-AMPK signaling pathway.
4. Validate the inhibition using Western blotting or immunofluorescence to detect changes in phosphorylation levels of downstream targets (e.g., AMPK, ACC).

**Protocol 3: Tyrosine Kinase Inhibitor Treatment**

1. Prepare a stock solution of the tyrosine kinase inhibitor (e.g., Imatinib) at 10 mM in DMSO.
2. Add the tyrosine kinase inhibitor to the cell culture medium at a concentration that is ineffective in killing the cells (e.g., 1-5 μM).
3. Incubate cells with the tyrosine kinase inhibitor for 24-48 hours.
4. Measure cell viability using MTT or CellTiter-Glo assays according to the manufacturer's instructions.

**Protocol 4: Mitochondrial Fission and Autophagy Analysis**

1. For mitochondrial fission analysis:
	* Stain cells with Mitotracker or TMRE (100 nM) for 30 minutes at 37°C.
	* Visualize mitochondrial morphology using fluorescence microscopy (e.g., Zeiss Axiovert 200M).
	* Quantify mitochondrial fission using ImageJ software or a similar image analysis tool.
2. For autophagy analysis:
	* Perform Western blotting for LC3B, p62, and ATG5 using specific antibodies.
	* Monitor autophagic flux using the mRFP-GFP-LC3 reporter according to the manufacturer's instructions.

**Protocol 5: Combination Treatment**

1. Treat cells with both the CDK5/CAMK2-AMPK signaling pathway inhibitor and the tyrosine kinase inhibitor.
2. Incubate cells for 24-48 hours.
3. Measure cell viability, mitochondrial fission, and autophagy as described above.

**Protocol 6: Negative Control**

1. Use a non-specific inhibitor (e.g., DMSO) instead of the CDK5/CAMK2-AMPK signaling pathway inhibitor.
2. Perform the same experimental design as above, including combination treatment with the tyrosine kinase inhibitor.

**Protocol 7: Data Analysis**

1. Analyze data using appropriate statistical software (e.g., GraphPad Prism, R).
2. Compare the results from the combination treatment group to the negative control group.
3. Determine the significance of the results using a suitable statistical test (e.g., t-test, ANOVA).

**Protocol 8: Experiment to Disprove the Hypothesis**

1. Design an experiment to show that inhibition of the CDK5/CAMK2-AMPK signaling pathway does not sensitize non-CML cancer cells to tyrosine kinase inhibitors.
2. Perform the same experimental design as above, but with a different inhibitor or a different cell line.
3. Analyze the results and compare them to the original experiment.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   Cell_Line  Roscovitine  KN-93  Compound_C  Imatinib  Cell_Viability  Mitochondrial_Fission  Autophagy
0    Breast_1        15.0   12.0       18.0      2.0         0.60           0.45          0.70
1    Breast_2        10.0   15.0       12.0      3.0         0.55           0.50          0.65
2    Lung_1         18.0   10.0       15.0      1.0         0.65           0.40          0.75
3    Lung_2         12.0   18.0       10.0      4.0         0.50           0.55          0.60
4    Colon_1        15.0   12.0       18.0      2.0         0.60           0.45          0.70
5    Colon_2        10.0   15.0       12.0      3.0         0.55           0.50          0.65
6    Breast_1        18.0   10.0       15.0      1.0         0.65           0.40          0.75
7    Breast_2        12.0   18.0       10.0      4.0         0.50           0.55          0.60
8    Lung_1         15.0   12.0       18.0      2.0         0.60           0.45          0.70
9    Lung_2         10.0   15.0       12.0      3.0         0.55           0.50          0.65
10   Colon_1        18.0   10.0       15.0      1.0         0.65           0.40          0.75
11   Colon_2        12.0   18.0       10.0      4.0         0.50           0.55          0.60
12   Breast_1        15.0   12.0       18.0      2.0         0.60           0.45          0.70
13   Breast_2        10.0   15.0       12.0      3.0         0.55           0.50          0.65
14   Lung_1         18.0   10.0       15.0      1.0         0.65           0.40          0.75
15   Lung_2         12.0   18.0       10.0      4.0         0.50           0.55          0.60
16   Colon_1        15.0   12.0       18.0      2.0         0.60           0.45          0.70
17   Colon_2        10.0   15.0       12.0      3.0         0.55           0.50          0.65
18   Breast_1        18.0   10.0       15.0      1.0         0.65           0.40          0.75
19   Breast_2        12.0   18.0       10.0      4.0         0.50           0.55          0.60
20   Lung_1         15.0   12.0       18.0      2.0         0.60           0.45          0.70
21   Lung_2         10.0   15.0       12.0      3.0         0.55           0.50          0.65
22   Colon_1        18.0   10.0       15.0      1.0         0.65           0.40          0.75
23   Colon_2        12.0   18.0       10.0      4.0         0.50           0.55          0.60
24   Breast_1        15.0   12.0       18.0      2.0         0.60           0.45          0.70
```",0.09351329552468861
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b16a244d366c6ec1b0d50e70db74597c8d322111.summary'],"Does inhibition of LIMK also sensitize BCR::ABL- acute lymphoblastic leukemia cells to chemotherapy by disrupting the ROCK-LIMK-cofilin axis, leading to increased apoptosis and reduced cell proliferation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of LIMK Inhibition in Sensitizing BCR::ABL+ Acute Lymphoblastic Leukemia Cells to Chemotherapy

**Objective:** To determine whether inhibition of LIMK sensitizes BCR::ABL+ acute lymphoblastic leukemia cells to chemotherapy by disrupting the ROCK-LIMK-cofilin axis, leading to increased apoptosis and reduced cell proliferation.

**Equipment:**

* BCR::ABL+ acute lymphoblastic leukemia cell lines
* CEL_Amide (LIMK inhibitor)
* Chemotherapeutic agents (e.g., doxorubicin, cytarabine)
* MTS assay
* Flow cytometry
* Western blot
* ROCK inhibitor (e.g., Y-27632)
* Cofilin antibody

**Steps:**

1. Treat BCR::ABL+ acute lymphoblastic leukemia cell lines with CEL_Amide alone or in combination with chemotherapeutic agents.
2. Measure cell viability using MTS assay to determine the effect of LIMK inhibition on chemotherapy sensitivity.
3. Analyze apoptosis and cell cycle distribution using flow cytometry to assess the impact of LIMK inhibition on apoptosis and cell proliferation.
4. Determine protein expression of LIMK1/2, cofilin, and phosphorylated cofilin using Western blot to evaluate the disruption of the ROCK-LIMK-cofilin axis.
5. Compare results to determine whether LIMK inhibition sensitizes BCR::ABL+ acute lymphoblastic leukemia cells to chemotherapy.
6. To further validate the role of the ROCK-LIMK-cofilin axis, treat cells with a ROCK inhibitor (Y-27632) and assess the effect on chemotherapy sensitivity.

**Expected Outcomes:**

* Increased apoptosis and reduced cell proliferation in BCR::ABL+ acute lymphoblastic leukemia cells treated with CEL_Amide and chemotherapy compared to chemotherapy alone.
* Disruption of the ROCK-LIMK-cofilin axis, as evidenced by decreased phosphorylated cofilin and increased cofilin expression.
* Enhanced chemotherapy sensitivity in BCR::ABL+ acute lymphoblastic leukemia cells treated with CEL_Amide and ROCK inhibitor.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of LIMK Inhibition in Chemotherapy Resistance in BCR::ABL+ Acute Lymphoblastic Leukemia Cells

**Objective:** To determine whether inhibition of LIMK does not sensitize BCR::ABL+ acute lymphoblastic leukemia cells to chemotherapy, and instead, promotes chemotherapy resistance.

**Equipment:**

* BCR::ABL+ acute lymphoblastic leukemia cell lines
* CEL_Amide (LIMK inhibitor)
* Chemotherapeutic agents (e.g., doxorubicin, cytarabine)
* MTS assay
* Flow cytometry
* Western blot
* ROCK inhibitor (e.g., Y-27632)
* Cofilin antibody

**Steps:**

1. Treat BCR::ABL+ acute lymphoblastic leukemia cell lines with CEL_Amide alone or in combination with chemotherapeutic agents.
2. Measure cell viability using MTS assay to determine the effect of LIMK inhibition on chemotherapy resistance.
3. Analyze apoptosis and cell cycle distribution using flow cytometry to assess the impact of LIMK inhibition on apoptosis and cell proliferation.
4. Determine protein expression of LIMK1/2, cofilin, and phosphorylated cofilin using Western blot to evaluate the disruption of the ROCK-LIMK-cofilin axis.
5. Compare results to determine whether LIMK inhibition promotes chemotherapy resistance in BCR::ABL+ acute lymphoblastic leukemia cells.
6. To further validate the role of the ROCK-LIMK-cofilin axis, treat cells with a ROCK inhibitor (Y-27632) and assess the effect on chemotherapy resistance.

**Expected Outcomes:**

* Decreased apoptosis and increased cell proliferation in BCR::ABL+ acute lymphoblastic leukemia cells treated with CEL_Amide and chemotherapy compared to chemotherapy alone.
* No disruption of the ROCK-LIMK-cofilin axis, as evidenced by unchanged phosphorylated cofilin and cofilin expression.
* Reduced chemotherapy sensitivity in BCR::ABL+ acute lymphoblastic leukemia cells treated with CEL_Amide and ROCK inhibitor.

By designing an experiment to disprove the hypothesis, we can increase the confidence in the results and provide a more comprehensive understanding of the role of LIMK inhibition in BCR::ABL+ acute lymphoblastic leukemia cells.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of LIMK Inhibition in Sensitizing BCR::ABL+ Acute Lymphoblastic Leukemia Cells to Chemotherapy

**Objective:** To determine whether inhibition of LIMK sensitizes BCR::ABL+ acute lymphoblastic leukemia cells to chemotherapy by disrupting the ROCK-LIMK-cofilin axis, leading to increased apoptosis and reduced cell proliferation.

**Protocol:**

**Step 1: Cell Culture and Treatment**

1.1. Obtain BCR::ABL+ acute lymphoblastic leukemia cell lines (e.g., K562, SUP-B15) and maintain them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C and 5% CO2.

1.2. Prepare CEL_Amide (LIMK inhibitor) stock solution at 10 mM in DMSO and store at -20°C.

1.3. Prepare chemotherapeutic agents (e.g., doxorubicin, cytarabine) stock solutions according to the manufacturer's instructions.

1.4. Treat cells with:
	* CEL_Amide alone (10 μM) for 24 hours
	* Chemotherapeutic agents alone (e.g., doxorubicin 1 μM, cytarabine 10 μM) for 24 hours
	* CEL_Amide (10 μM) + chemotherapeutic agents (e.g., doxorubicin 1 μM, cytarabine 10 μM) for 24 hours
	* Vehicle control (DMSO) for 24 hours

**Step 2: MTS Assay**

2.1. Seed 5,000 cells per well in a 96-well plate.

2.2. Add 20 μL of MTS reagent to each well and incubate for 2 hours at 37°C.

2.3. Measure absorbance at 490 nm using a microplate reader.

**Step 3: Flow Cytometry**

3.1. Harvest cells and wash with PBS.

3.2. Stain cells with Annexin V-FITC and propidium iodide (PI) according to the manufacturer's instructions.

3.3. Analyze apoptosis and cell cycle distribution using a flow cytometer (e.g., BD FACSCanto II).

**Step 4: Western Blot**

4.1. Harvest cells and lyse in RIPA buffer with protease inhibitors.

4.2. Separate proteins by SDS-PAGE and transfer to a PVDF membrane.

4.3. Probe with primary antibodies against LIMK1/2, cofilin, and phosphorylated cofilin (e.g., 1:1000 dilution).

4.4. Detect proteins using HRP-conjugated secondary antibodies and ECL reagents.

**Step 5: Data Analysis**

5.1. Calculate cell viability using MTS assay data.

5.2. Analyze apoptosis and cell cycle distribution using flow cytometry data.

5.3. Quantify protein expression using Western blot data.

5.4. Compare results to determine whether LIMK inhibition sensitizes BCR::ABL+ acute lymphoblastic leukemia cells to chemotherapy.

**Step 6: ROCK Inhibitor Treatment**

6.1. Treat cells with Y-27632 (ROCK inhibitor, 10 μM) for 24 hours.

6.2. Repeat Steps 2-5 to assess the effect of ROCK inhibition on chemotherapy sensitivity.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of LIMK Inhibition in Chemotherapy Resistance in BCR::ABL+ Acute Lymphoblastic Leukemia Cells

**Objective:** To determine whether inhibition of LIMK does not sensitize BCR::ABL+ acute lymphoblastic leukemia cells to chemotherapy, and instead, promotes chemotherapy resistance.

**Protocol:**

The protocol is identical to the experiment to test the hypothesis, with the exception of the expected outcomes.

**Expected Outcomes:**

* Decreased apoptosis and increased cell proliferation in BCR::ABL+ acute lymphoblastic leukemia cells treated with CEL_Amide and chemotherapy compared to chemotherapy alone.
* No disruption of the ROCK-LIMK-cofilin axis, as evidenced by unchanged phosphorylated cofilin and cofilin expression.
* Reduced chemotherapy sensitivity in BCR::ABL+ acute lymphoblastic leukemia cells treated with CEL_Amide and ROCK inhibitor.

By following these detailed, step-by-step protocols, the experiments can be replicated and the results can be accurately compared to determine the role of LIMK inhibition in BCR::ABL+ acute lymphoblastic leukemia cells.","```
   CEL_Amide  Doxorubicin  Cytarabine  Y-27632  Apoptosis  Proliferation
0       5.0         0.5        5.0      0.0       0.25         0.80
1       7.5         1.0        7.5      0.0       0.30         0.75
2       2.5         0.5        2.5      0.0       0.20         0.85
3       5.0         1.5        5.0      0.0       0.35         0.70
4       10.0        1.0       10.0      0.0       0.40         0.65
5       5.0         0.5        5.0      5.0       0.20         0.80
6       7.5         1.0        7.5      5.0       0.25         0.75
7       2.5         0.5        2.5      5.0       0.15         0.85
8       5.0         1.5        5.0      5.0       0.30         0.70
9       10.0        1.0       10.0      5.0       0.35         0.65
10      5.0         0.5        5.0      0.0       0.25         0.80
11      7.5         1.0        7.5      0.0       0.30         0.75
12      2.5         0.5        2.5      0.0       0.20         0.85
13      5.0         1.5        5.0      0.0       0.35         0.70
14      10.0        1.0       10.0      0.0       0.40         0.65
15      5.0         0.5        5.0      5.0       0.20         0.80
16      7.5         1.0        7.5      5.0       0.25         0.75
17      2.5         0.5        2.5      5.0       0.15         0.85
18      5.0         1.5        5.0      5.0       0.30         0.70
19      10.0        1.0       10.0      5.0       0.35         0.65
20      5.0         0.5        5.0      0.0       0.25         0.80
21      7.5         1.0        7.5      0.0       0.30         0.75
22      2.5         0.5        2.5      0.0       0.20         0.85
23      5.0         1.5        5.0      0.0       0.35         0.70
24      10.0        1.0       10.0      0.0       0.40         0.65
```",0.6729881434434422
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0fdbd17f5e6a08fd43525448d66b76375655791c.summary'],"Does inhibition of eIF4GI activity, in addition to eIF4A, enhance the selective targeting of CLL cells while sparing normal B cells, leading to a more effective therapeutic strategy?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Does inhibition of eIF4GI activity, in addition to eIF4A, enhance the selective targeting of CLL cells while sparing normal B cells, leading to a more effective therapeutic strategy?""

**Experimental Plan:**

**Objective:** To investigate whether inhibiting eIF4GI activity, in addition to eIF4A, selectively targets CLL cells while sparing normal B cells, and to identify potential therapeutic strategies.

**Experimental Design:**

1. **Cell Culture:** Obtain CLL cells and normal B cells from healthy donors or cell banks. Culture cells in appropriate media and conditions.
2. **Inhibitor Treatment:** Treat CLL cells and normal B cells with:
	* eIF4A inhibitors (identified in the previous study)
	* eIF4GI inhibitors (selective inhibitors or siRNA-mediated knockdown)
	* Combination of eIF4A and eIF4GI inhibitors
	* Vehicle control (DMSO or equivalent)
3. **mRNA Translation Assay:** Measure mRNA translation using metabolic labeling reagents (e.g., [35S]-methionine) in treated cells. Analyze the incorporation of radiolabeled amino acids into newly synthesized proteins using scintillation counting or autoradiography.
4. **Cell Viability Assay:** Evaluate cell viability using flow cytometry (e.g., Annexin V/PI staining) or MTT assay to assess the effects of inhibitor treatments on CLL cell viability and normal B cell viability.
5. **Western Blot Analysis:** Perform Western blotting to assess the expression levels of eIF4A, eIF4GI, and downstream targets (e.g., MYC) in treated cells.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on identifying conditions where inhibiting eIF4GI activity, in addition to eIF4A, does not selectively target CLL cells while sparing normal B cells. Specifically:

1. **Identify non-selective inhibitors:** Screen for eIF4GI inhibitors that do not selectively inhibit mRNA translation in CLL cells compared to normal B cells.
2. **Use high concentrations of inhibitors:** Treat cells with high concentrations of eIF4A and eIF4GI inhibitors to assess if this leads to non-selective toxicity in both CLL and normal B cells.
3. **Assess off-target effects:** Investigate potential off-target effects of eIF4GI inhibitors on normal B cells, such as changes in cell cycle regulation or apoptosis.

**Equipment and Resources:**

* eIF4A inhibitor library
* eIF4GI inhibitors (selective inhibitors or siRNA)
* CLL cells and normal B cells
* Metabolic labeling reagents (e.g., [35S]-methionine)
* Flow cytometer
* Western blotting equipment
* Cell culture facilities and reagents
* siRNA transfection reagents (if using siRNA-mediated knockdown)

**Timeline and Budget:**

This experiment can be completed within 6-9 months, depending on the availability of resources and personnel. The budget will be allocated as follows:

* Cell culture and reagents: 30%
* Inhibitor libraries and siRNA: 20%
* Metabolic labeling reagents and flow cytometry: 20%
* Western blotting equipment and reagents: 15%
* Personnel and miscellaneous: 15%

By following this experimental plan, we can test the hypothesis and identify potential therapeutic strategies for selectively targeting CLL cells while sparing normal B cells.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture**

1.1. Obtain CLL cells and normal B cells from healthy donors or cell banks.

* Source: Obtain cells from a reputable cell bank or collect blood samples from healthy donors after obtaining informed consent.
* Cell type: CLL cells (e.g., MEC-1 or EHEB) and normal B cells (e.g., peripheral blood mononuclear cells (PBMCs) or B cells isolated from PBMCs).

1.2. Culture cells in appropriate media and conditions.

* Media: RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubation: Maintain cells at 37°C, 5% CO2, and 95% humidity.
* Cell density: Seed cells at a density of 1 x 10^6 cells/mL.

**Protocol 2: Inhibitor Treatment**

2.1. Prepare inhibitor stocks.

* eIF4A inhibitors: Dissolve inhibitors in DMSO to a final concentration of 10 mM. Store at -20°C.
* eIF4GI inhibitors: Dissolve inhibitors in DMSO to a final concentration of 10 mM. Store at -20°C.
* siRNA-mediated knockdown: Prepare siRNA duplexes according to the manufacturer's instructions.

2.2. Treat cells with inhibitors.

* eIF4A inhibitors: Add 1-10 μM of eIF4A inhibitor to the cell culture media.
* eIF4GI inhibitors: Add 1-10 μM of eIF4GI inhibitor to the cell culture media.
* Combination treatment: Add 1-10 μM of eIF4A inhibitor and 1-10 μM of eIF4GI inhibitor to the cell culture media.
* Vehicle control: Add an equivalent volume of DMSO to the cell culture media.
* siRNA-mediated knockdown: Transfect cells with 10-50 nM siRNA using a transfection reagent according to the manufacturer's instructions.

2.3. Incubate cells for 24-48 hours.

**Protocol 3: mRNA Translation Assay**

3.1. Prepare metabolic labeling reagents.

* [35S]-methionine: Prepare a stock solution of 1 mCi/mL in PBS.

3.2. Label cells with [35S]-methionine.

* Add 10 μCi/mL of [35S]-methionine to the cell culture media.
* Incubate cells for 1-2 hours.

3.3. Harvest cells and analyze mRNA translation.

* Collect cells by centrifugation and wash with PBS.
* Lyse cells in RIPA buffer and clarify by centrifugation.
* Measure the incorporation of radiolabeled amino acids into newly synthesized proteins using scintillation counting or autoradiography.

**Protocol 4: Cell Viability Assay**

4.1. Prepare Annexin V/PI staining solution.

* Annexin V-FITC: Prepare a stock solution of 1 mg/mL in PBS.
* Propidium iodide (PI): Prepare a stock solution of 1 mg/mL in PBS.

4.2. Stain cells with Annexin V/PI.

* Add 1 μL of Annexin V-FITC and 1 μL of PI to 100 μL of cell suspension.
* Incubate for 15 minutes at room temperature.

4.3. Analyze cell viability using flow cytometry.

* Acquire data using a flow cytometer and analyze using flow cytometry software.

**Protocol 5: Western Blot Analysis**

5.1. Prepare cell lysates.

* Lyse cells in RIPA buffer and clarify by centrifugation.

5.2. Separate proteins by SDS-PAGE.

* Load 20-50 μg of protein per lane.
* Run the gel at 100 V for 1-2 hours.

5.3. Transfer proteins to a membrane.

* Transfer proteins to a PVDF membrane using a semi-dry transfer apparatus.

5.4. Probe with primary antibodies.

* eIF4A: Use a 1:1000 dilution of a rabbit polyclonal antibody.
* eIF4GI: Use a 1:1000 dilution of a rabbit polyclonal antibody.
* MYC: Use a 1:1000 dilution of a rabbit polyclonal antibody.

5.5. Detect proteins using secondary antibodies and chemiluminescence.

* Use a 1:5000 dilution of a goat anti-rabbit IgG-HRP secondary antibody.
* Detect proteins using a chemiluminescence substrate and a chemiluminescence imager.

**Protocol 6: Experimental Approach to Disprove the Hypothesis**

6.1. Identify non-selective inhibitors.

* Screen a library of eIF4GI inhibitors for compounds that do not selectively inhibit mRNA translation in CLL cells compared to normal B cells.

6.2. Use high concentrations of inhibitors.

* Treat cells with high concentrations (10-50 μM) of eIF4A and eIF4GI inhibitors to assess non-selective toxicity in both CLL and normal B cells.

6.3. Assess off-target effects.

* Investigate potential off-target effects of eIF4GI inhibitors on normal B cells, such as changes in cell cycle regulation or apoptosis, using flow cytometry and Western blot analysis.

These detailed protocols should provide a clear guide for executing the experimental plan and testing the hypothesis.","```
   CLL_cells  Normal_B_cells  eIF4A_inhibitor  eIF4GI_inhibitor  siRNA  Vehicle_control  Outcome
0       1e6          1e6             5.0             2.0     20.0           0.0  Inhibited
1       1e6          1e6             1.0             5.0     10.0           0.0  Inhibited
2       1e6          1e6             2.0             1.0     30.0           0.0  Inhibited
3       1e6          1e6             8.0             3.0     15.0           0.0  Inhibited
4       1e6          1e6             4.0             6.0     25.0           0.0  Inhibited
5       1e6          1e6             3.0             4.0     18.0           0.0  Inhibited
6       1e6          1e6             6.0             2.0     12.0           0.0  Inhibited
7       1e6          1e6             9.0             1.0     22.0           0.0  Inhibited
8       1e6          1e6             7.0             8.0     11.0           0.0  Inhibited
9       1e6          1e6             2.0             9.0     16.0           0.0  Inhibited
10      1e6          1e6             1.0             7.0     14.0           0.0  Inhibited
11      1e6          1e6             6.0             5.0     21.0           0.0  Inhibited
12      1e6          1e6             8.0             4.0     19.0           0.0  Inhibited
13      1e6          1e6             3.0             6.0     13.0           0.0  Inhibited
14      1e6          1e6             5.0             3.0     17.0           0.0  Inhibited
15      1e6          1e6             4.0             1.0     24.0           0.0  Inhibited
16      1e6          1e6             9.0             8.0     10.0           0.0  Inhibited
17      1e6          1e6             7.0             2.0     23.0           0.0  Inhibited
18      1e6          1e6             1.0             9.0     15.0           0.0  Inhibited
19      1e6          1e6             6.0             7.0     12.0           0.0  Inhibited
20      1e6          1e6             3.0             5.0     20.0           0.0  Inhibited
21      1e6          1e6             8.0             6.0     18.0           0.0  Inhibited
22      1e6          1e6             4.0             3.0     14.0           0.0  Inhibited
23      1e6          1e6             2.0             8.0     16.0           0.0  Inhibited
24      1e6          1e6             5.0             4.0     22.0           0.0  Inhibited
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d22e4d7ed72d8882467b29b438aa47ebe28c91de.summary'],"Does iosH2-mediated inhibition of LILRB1/2 and KIR3DL1 receptors also enhance the activity of cancer-specific natural killer cells, leading to improved anti-tumor responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that iosH2-mediated inhibition of LILRB1/2 and KIR3DL1 receptors also enhances the activity of cancer-specific natural killer (NK) cells, leading to improved anti-tumor responses.

**Experimental Plan:**

**Title:** Investigating the Effect of iosH2 on Cancer-Specific Natural Killer Cell Activity

**Objective:** To determine if iosH2-mediated inhibition of LILRB1/2 and KIR3DL1 receptors enhances the activity of cancer-specific NK cells, leading to improved anti-tumor responses.

**Experimental Design:**

1. **NK Cell Isolation and Culture:** Isolate NK cells from healthy donors or cancer patients using a NK cell isolation kit. Culture the isolated NK cells in the presence or absence of iosH2 protein.
2. **Cancer Cell Lines:** Use established cancer cell lines (e.g., K562, MCF-7, or others) as targets for NK cell-mediated cytotoxicity.
3. **NK Cell Activation and Cytotoxicity Assays:**
	* Co-culture NK cells with cancer cell lines in the presence or absence of iosH2.
	* Analyze NK cell activation using flow cytometry, assessing the expression of activation markers (e.g., CD69, CD25, NKG2D).
	* Evaluate NK cell cytotoxicity against cancer cells using a chromium release assay or a flow cytometry-based assay (e.g., CD107a degranulation).
4. **Comparison and Statistical Analysis:** Compare the results between the iosH2-treated and untreated groups to determine if iosH2 enhances cancer-specific NK cell activity. Perform statistical analysis using appropriate tests (e.g., t-test, ANOVA) to determine significance.

**Equipment and Reagents:**

* NK cell isolation kit
* iosH2 protein
* Cancer cell lines
* Flow cytometer
* Antibodies for NK cell markers (e.g., CD56, CD16, NKG2D)
* Chromium release assay or flow cytometry-based cytotoxicity assay reagents

**Timeframe and Budget:**

This experiment can be completed within 6-8 weeks, with a budget of approximately $10,000-$15,000. This estimate includes the cost of reagents, equipment, and personnel.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: iosH2 does not enhance the activity of cancer-specific NK cells.

**Modified Experimental Design:**

1. **NK Cell Isolation and Culture:** Isolate NK cells from healthy donors or cancer patients using a NK cell isolation kit. Culture the isolated NK cells in the presence of iosH2 protein.
2. **Cancer Cell Lines:** Use established cancer cell lines (e.g., K562, MCF-7, or others) as targets for NK cell-mediated cytotoxicity.
3. **NK Cell Activation and Cytotoxicity Assays:**
	* Co-culture NK cells with cancer cell lines in the presence of iosH2.
	* Analyze NK cell activation using flow cytometry, assessing the expression of activation markers (e.g., CD69, CD25, NKG2D).
	* Evaluate NK cell cytotoxicity against cancer cells using a chromium release assay or a flow cytometry-based assay (e.g., CD107a degranulation).
4. **Comparison and Statistical Analysis:** Compare the results to a control group where NK cells are cultured without iosH2. If the results show no significant difference in NK cell activity between the iosH2-treated and control groups, it would suggest that iosH2 does not enhance the activity of cancer-specific NK cells.

By designing an experiment to disprove the hypothesis, we can increase confidence in the results and provide a more comprehensive understanding of the role of iosH2 in cancer immunotherapy.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: NK Cell Isolation and Culture**

**Step 1.1: Prepare NK Cell Isolation Kit**

* Obtain the NK cell isolation kit and follow the manufacturer's instructions to prepare the necessary reagents and buffers.
* Ensure all reagents and equipment are sterile and stored at the recommended temperatures.

**Step 1.2: Collect Blood Samples**

* Collect 10-20 mL of peripheral blood from healthy donors or cancer patients in EDTA-coated tubes.
* Label the tubes with the donor/patient ID and date.

**Step 1.3: Isolate NK Cells**

* Follow the manufacturer's instructions to isolate NK cells from the blood samples using the NK cell isolation kit.
* Perform the isolation procedure in a laminar flow hood to maintain sterility.

**Step 1.4: Culture NK Cells**

* Resuspend the isolated NK cells in complete RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Culture the NK cells in a 24-well plate at a density of 1 x 10^6 cells/mL.
* Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

**Protocol 2: Cancer Cell Line Preparation**

**Step 2.1: Thaw Cancer Cell Lines**

* Obtain established cancer cell lines (e.g., K562, MCF-7) and thaw them according to the supplier's instructions.
* Resuspend the cells in complete RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

**Step 2.2: Culture Cancer Cells**

* Culture the cancer cells in a 75-cm² flask at a density of 1 x 10^5 cells/mL.
* Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

**Protocol 3: NK Cell Activation and Cytotoxicity Assays**

**Step 3.1: Co-Culture NK Cells with Cancer Cells**

* Harvest the cultured NK cells and resuspend them in complete RPMI-1640 medium at a density of 1 x 10^6 cells/mL.
* Add 100 μL of NK cells to each well of a 96-well plate.
* Add 100 μL of cancer cells (1 x 10^5 cells/mL) to each well.
* Add 10 μL of iosH2 protein (10 μg/mL) to the treatment group wells.
* Incubate the co-culture at 37°C, 5% CO2 for 4-6 hours.

**Step 3.2: Flow Cytometry Analysis**

* Harvest the co-cultured cells and stain them with antibodies against CD56, CD16, NKG2D, CD69, and CD25.
* Analyze the cells using a flow cytometer to assess NK cell activation.

**Step 3.3: Chromium Release Assay or CD107a Degranulation Assay**

* Perform a chromium release assay or CD107a degranulation assay according to the manufacturer's instructions to evaluate NK cell cytotoxicity.
* Calculate the percentage of specific lysis or degranulation using the following formula:

% Specific Lysis/Degranulation = (Experimental Release - Spontaneous Release) / (Maximum Release - Spontaneous Release) x 100

**Protocol 4: Comparison and Statistical Analysis**

**Step 4.1: Data Collection**

* Collect the data from the flow cytometry analysis and chromium release assay or CD107a degranulation assay.
* Record the data in a spreadsheet or statistical software.

**Step 4.2: Statistical Analysis**

* Perform a t-test or ANOVA to compare the results between the iosH2-treated and untreated groups.
* Determine the significance level (p-value) and calculate the mean and standard deviation for each group.

**Modified Protocol for Experiment to Disprove the Hypothesis**

**Step 1-3: Follow the same protocols as above**

**Step 4: Comparison and Statistical Analysis**

* Compare the results to a control group where NK cells are cultured without iosH2.
* Perform a t-test or ANOVA to compare the results between the iosH2-treated and control groups.
* Determine the significance level (p-value) and calculate the mean and standard deviation for each group.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately compared and analyzed.","```
   NK Cells (x10^6)  Cancer Cells (x10^5)  iosH2 (μg/mL)  RPMI-1640 (%)  FBS (%)  Penicillin-Streptomycin (%)  L-Glutamine (%)  Outcome (% Specific Lysis)
0               0.5               0.5             5.0         90.0       10.0                    1.0             1.0               23.12
1               1.0               1.0             5.0         90.0       10.0                    1.0             1.0               35.67
2               1.5               1.5             5.0         90.0       10.0                    1.0             1.0               42.19
3               0.5               1.0             2.5         90.0       10.0                    1.0             1.0               18.56
4               1.0               0.5             7.5         90.0       10.0                    1.0             1.0               40.85
5               1.5               1.0             5.0         85.0       10.0                    1.0             1.0               38.21
6               0.5               1.5             5.0         95.0       10.0                    1.0             1.0               26.98
7               1.0               1.0             5.0         90.0        5.0                    1.0             1.0               31.45
8               1.5               1.0             5.0         90.0       15.0                    1.0             1.0               44.92
9               0.5               1.0             5.0         90.0       10.0                    0.5             1.0               20.13
10              1.0               1.0             5.0         90.0       10.0                    1.5             1.0               36.79
11              1.5               1.0             5.0         90.0       10.0                    1.0             0.5               41.35
12              0.5               1.0             5.0         90.0       10.0                    1.0             1.5               24.67
13              1.0               1.0             5.0         85.0       10.0                    1.0             1.0               33.19
14              1.5               1.0             5.0         95.0       10.0                    1.0             1.0               46.58
15              0.5               1.0             5.0         90.0       10.0                    1.0             1.0               21.89
16              1.0               1.0             5.0         90.0       10.0                    1.0             1.0               34.52
17              1.5               1.0             5.0         90.0       10.0                    1.0             1.0               43.14
18              0.5               1.0             5.0         90.0       10.0                    1.0             1.0               22.35
19              1.0               1.0             5.0         90.0       10.0                    1.0             1.0               36.19
20              1.5               1.0             5.0         90.0       10.0                    1.0             1.0               45.67
21              0.5               1.0             5.0         90.0       10.0                    1.0             1.0               23.56
22              1.0               1.0             5.0         90.0       10.0                    1.0             1.0               37.85
23              1.5               1.0             5.0         90.0       10.0                    1.0             1.0               47.29
24              0.5               1.0             5.0         90.0       10.0                    1.0             1.0               24.98
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3de05d983ebb2411d14f1f32f4321b2635b3be12.summary'],"Does lactic acidosis-induced impairment of T cell killing activity also lead to the upregulation of immune checkpoint molecules on T cells, thereby further suppressing anti-tumor immune responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! I'd be happy to help design an experiment to test it.

**Hypothesis:** Lactic acidosis-induced impairment of T cell killing activity leads to the upregulation of immune checkpoint molecules on T cells, thereby further suppressing anti-tumor immune responses.

**Experimental Plan:**

**Objective:** To investigate whether lactic acidosis impairs T cell killing activity and upregulates immune checkpoint molecules, thereby suppressing anti-tumor immune responses.

**Experimental Design:**

1. **Cell Culture:**
	* Isolate human T cells from healthy donors or use established T cell lines (e.g., Jurkat cells).
	* Culture T cells in a controlled environment with varying levels of lactic acid (e.g., 0, 5, 10, and 20 mM) to mimic lactic acidosis conditions.
2. **T Cell Killing Assay:**
	* Co-culture T cells with tumor cells (e.g., melanoma or breast cancer cells) at a 1:1 ratio.
	* Measure T cell killing activity using a cytotoxicity assay (e.g., LDH release or flow cytometry-based assays).
3. **Immune Checkpoint Molecule Analysis:**
	* Analyze the expression of immune checkpoint molecules (e.g., PD-1, CTLA-4, LAG-3) on T cells using flow cytometry or Western blotting.
4. **Control and Treatment Groups:**
	* Control group: T cells cultured without lactic acid.
	* Treatment group: T cells cultured with lactic acid (at varying concentrations).
5. **Data Analysis:**
	* Compare T cell killing activity and immune checkpoint molecule expression between control and treatment groups.
	* Perform statistical analysis to determine the significance of differences between groups.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: lactic acidosis does not lead to the upregulation of immune checkpoint molecules on T cells.

**Modified Experimental Design:**

1. **Cell Culture:**
	* Culture T cells with lactic acid (e.g., 20 mM) and a specific inhibitor of immune checkpoint molecules (e.g., PD-1 inhibitor, pembrolizumab).
2. **T Cell Killing Assay:**
	* Co-culture T cells with tumor cells as described above.
3. **Immune Checkpoint Molecule Analysis:**
	* Analyze the expression of immune checkpoint molecules on T cells using flow cytometry or Western blotting.
4. **Control and Treatment Groups:**
	* Control group: T cells cultured without lactic acid and inhibitor.
	* Treatment group: T cells cultured with lactic acid and inhibitor.
5. **Data Analysis:**
	* Compare T cell killing activity and immune checkpoint molecule expression between control and treatment groups.
	* If the inhibitor prevents the upregulation of immune checkpoint molecules, it would suggest that lactic acidosis does not lead to their upregulation, disproving the hypothesis.

**Budget and Time Considerations:**

* Cell culture and T cell isolation: 2-3 weeks, $1,000 - $2,000
* Lactic acid and inhibitors: $500 - $1,000
* Cytotoxicity assay and flow cytometry: 1-2 weeks, $1,500 - $3,000
* Western blotting: 1-2 weeks, $1,000 - $2,000
* Statistical analysis and data interpretation: 1-2 weeks, $1,000 - $2,000

Total estimated time: 6-12 weeks
Total estimated budget: $6,000 - $12,000

This experiment can be completed within a reasonable time frame and budget, and the results will provide valuable insights into the relationship between lactic acidosis, T cell killing activity, and immune checkpoint molecules.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and T Cell Isolation**

**Step 1.1: Prepare Cell Culture Media**

* Prepare 500 mL of RPMI-1640 media supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Sterilize the media by filtering it through a 0.22 μm filter.

**Step 1.2: Isolate Human T Cells**

* Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors or use established T cell lines (e.g., Jurkat cells).
* Isolate T cells from PBMCs using a T cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Count the isolated T cells using a hemocytometer and adjust the concentration to 1 x 10^6 cells/mL.

**Step 1.3: Culture T Cells with Lactic Acid**

* Prepare four separate cultures with varying levels of lactic acid: 0 mM (control), 5 mM, 10 mM, and 20 mM.
* Add the appropriate amount of lactic acid to each culture medium and mix well.
* Add 1 mL of the T cell suspension to each culture and mix gently.
* Incubate the cultures at 37°C, 5% CO2 for 24-48 hours.

**Protocol 2: T Cell Killing Assay**

**Step 2.1: Prepare Tumor Cells**

* Obtain tumor cells (e.g., melanoma or breast cancer cells) and culture them in RPMI-1640 media supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Count the tumor cells using a hemocytometer and adjust the concentration to 1 x 10^5 cells/mL.

**Step 2.2: Co-Culture T Cells and Tumor Cells**

* Add 1 mL of the T cell suspension to a 24-well plate.
* Add 1 mL of the tumor cell suspension to each well.
* Mix gently and incubate at 37°C, 5% CO2 for 4-6 hours.

**Step 2.3: Measure T Cell Killing Activity**

* Use a cytotoxicity assay (e.g., LDH release or flow cytometry-based assays) to measure T cell killing activity.
* Follow the manufacturer's instructions for the specific assay used.

**Protocol 3: Immune Checkpoint Molecule Analysis**

**Step 3.1: Harvest T Cells**

* After the co-culture, harvest the T cells by centrifugation at 300 x g for 5 minutes.
* Wash the T cells with PBS and resuspend them in 100 μL of PBS.

**Step 3.2: Stain T Cells with Antibodies**

* Add the appropriate antibodies (e.g., anti-PD-1, anti-CTLA-4, anti-LAG-3) to the T cell suspension and mix well.
* Incubate at room temperature for 30 minutes.

**Step 3.3: Analyze T Cells by Flow Cytometry**

* Analyze the stained T cells using a flow cytometer (e.g., BD FACSCanto II).
* Use the appropriate software (e.g., FlowJo) to analyze the data.

**Protocol 4: Data Analysis**

**Step 4.1: Compare T Cell Killing Activity**

* Compare the T cell killing activity between the control and treatment groups using a statistical analysis software (e.g., GraphPad Prism).
* Perform a one-way ANOVA with a post-hoc test (e.g., Tukey's test) to determine the significance of differences between groups.

**Step 4.2: Compare Immune Checkpoint Molecule Expression**

* Compare the expression of immune checkpoint molecules between the control and treatment groups using a statistical analysis software (e.g., GraphPad Prism).
* Perform a one-way ANOVA with a post-hoc test (e.g., Tukey's test) to determine the significance of differences between groups.

**Protocol 5: Experiment to Disprove the Hypothesis**

**Step 5.1: Culture T Cells with Lactic Acid and Inhibitor**

* Prepare two separate cultures: one with 20 mM lactic acid and one with 20 mM lactic acid and a specific inhibitor of immune checkpoint molecules (e.g., PD-1 inhibitor, pembrolizumab).
* Follow the same protocol as Step 1.3.

**Step 5.2: Co-Culture T Cells and Tumor Cells**

* Follow the same protocol as Step 2.2.

**Step 5.3: Measure T Cell Killing Activity and Immune Checkpoint Molecule Expression**

* Follow the same protocols as Steps 2.3 and 3.1-3.3.

**Step 5.4: Analyze Data**

* Follow the same protocol as Step 4.1 and 4.2.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  Lactic Acid  T Cell Concentration  Tumor Cell Concentration  T Cell Killing Activity  PD-1 Expression  CTLA-4 Expression  LAG-3 Expression
0        500.0  50.0                  5.0           5.0           0.0               1.0e+06               1.0e+05               0.2               20.0               15.0               10.0
1        500.0  50.0                  5.0           5.0           5.0               1.0e+06               1.0e+05               0.4               25.0               18.0               12.0
2        500.0  50.0                  5.0           5.0          10.0               1.0e+06               1.0e+05               0.6               30.0               22.0               15.0
3        500.0  50.0                  5.0           5.0          20.0               1.0e+06               1.0e+05               0.8               35.0               25.0               18.0
4        450.0  45.0                  4.5           4.5           0.0               1.0e+06               1.0e+05               0.1               18.0               12.0                8.0
5        450.0  45.0                  4.5           4.5           5.0               1.0e+06               1.0e+05               0.3               22.0               16.0               11.0
6        450.0  45.0                  4.5           4.5          10.0               1.0e+06               1.0e+05               0.5               28.0               20.0               14.0
7        450.0  45.0                  4.5           4.5          20.0               1.0e+06               1.0e+05               0.7               32.0               24.0               17.0
8        550.0  55.0                  5.5           5.5           0.0               1.0e+06               1.0e+05               0.3               23.0               17.0               12.0
9        550.0  55.0                  5.5           5.5           5.0               1.0e+06               1.0e+05               0.5               27.0               20.0               14.0
10       550.0  55.0                  5.5           5.5          10.0               1.0e+06               1.0e+05               0.7               32.0               24.0               17.0
11       550.0  55.0                  5.5           5.5          20.0               1.0e+06               1.0e+05               0.9               37.0               28.0               20.0
12       400.0  40.0                  4.0           4.0           0.0               1.0e+06               1.0e+05               0.1               15.0               10.0                7.0
13       400.0  40.0                  4.0           4.0           5.0               1.0e+06               1.0e+05               0.2               19.0               13.0                9.0
14       400.0  40.0                  4.0           4.0          10.0               1.0e+06               1.0e+05               0.4               24.0               18.0               13.0
15       400.0  40.0                  4.0           4.0          20.0               1.0e+06               1.0e+05               0.6               29.0               22.0               16.0
16       600.0  60.0                  6.0           6.0           0.0               1.0e+06               1.0e+05               0.4               26.0               20.0               14.0
17       600.0  60.0                  6.0           6.0           5.0               1.0e+06               1.0e+05               0.6               31.0               24.0               17.0
18       600.0  60.0                  6.0           6.0          10.0               1.0e+06               1.0e+05               0.8               36.0               28.0               20.0
19       600.0  60.0                  6.0           6.0          20.0               1.0e+06               1.0e+05               1.0               40.0               32.0               23.0
20       500.0  50.0                  5.0           5.0           0.0               0.8e+06               1.0e+05               0.2               20.0               15.0               10.0
21       500.0  50.0                  5.0           5.0           5.0               0.8e+06               1.0e+05               0.4               25.0               18.0               12.0
22       500.0  50.0                  5.0           5.0          10.0               0.8e+06               1.0e+05               0.6               30.0               22.0               15.0
23       500.0  50.0                  5.0           5.0          20.0               0.8e+06               1.0e+05               0.8               35.0               25.0               18.0
24       500.0  50.0                  5.0           5.0          20.0               1.0e+06               0.8e+05               0.9               38.0               29.0               21.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/10e858bcd9e770c8707ae8e0680d10f477d045a4.summary'],Does maternal SLE-induced dysregulation of phospho-signaling and pro-inflammatory soluble mediators in the placenta contribute to the development of cryptorchidism in offspring by disrupting the balance of testicular descent-regulating hormones?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Maternal SLE (Systemic Lupus Erythematosus)-induced dysregulation of phospho-signaling and pro-inflammatory soluble mediators in the placenta contributes to the development of cryptorchidism in offspring by disrupting the balance of testicular descent-regulating hormones.

**Experimental Plan:**

**Objective:** To investigate whether maternal SLE-induced placental dysregulation leads to cryptorchidism in offspring by disrupting testicular descent-regulating hormones.

**Experimental Design:**

1. **Animal Model:** Use a well-established mouse model of SLE (e.g., MRL/lpr mice) and breed them with healthy males to generate offspring.
2. **Placental Tissue Collection:** Collect placentas from SLE and control (healthy) mice at embryonic day 12.5 (E12.5) and E18.5, which correspond to critical periods of testicular development.
3. **Protein Analysis:** Perform Western blotting and/or ELISA to analyze the expression of phospho-signaling proteins (e.g., p-AKT, p-ERK) and pro-inflammatory soluble mediators (e.g., TNF-α, IL-1β) in placental tissue from SLE and control mice.
4. **Hormone Analysis:** Measure the levels of testicular descent-regulating hormones (e.g., INSL3, testosterone) in fetal testes and placentas from SLE and control mice using ELISA or LC-MS/MS.
5. **Cryptorchidism Assessment:** Evaluate the incidence of cryptorchidism in offspring from SLE and control mice at birth and postnatally (e.g., at 3 weeks of age).
6. **Statistical Analysis:** Compare the expression of phospho-signaling proteins, pro-inflammatory soluble mediators, and hormone levels between SLE and control groups using appropriate statistical tests (e.g., t-test, ANOVA).

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the following:

**Null Hypothesis:** Maternal SLE-induced placental dysregulation does not contribute to the development of cryptorchidism in offspring.

**Experimental Approach:**

1. **Placental-Specific Knockdown:** Use siRNA or CRISPR-Cas9 to specifically knockdown the expression of phospho-signaling proteins (e.g., AKT, ERK) or pro-inflammatory soluble mediators (e.g., TNF-α, IL-1β) in the placenta of SLE mice.
2. **Rescue Experiment:** Treat SLE mice with a specific inhibitor of phospho-signaling pathways (e.g., AKT inhibitor) or an anti-inflammatory agent (e.g., dexamethasone) during pregnancy to rescue the potential dysregulation of testicular descent-regulating hormones.
3. **Cryptorchidism Assessment:** Evaluate the incidence of cryptorchidism in offspring from treated SLE mice and compare it to untreated SLE mice and control mice.

**Rationale:** If the null hypothesis is true, knocking down or inhibiting the putative dysregulated pathways in the placenta should not affect the incidence of cryptorchidism in offspring. Conversely, if the incidence of cryptorchidism is reduced or eliminated in treated SLE mice, it would suggest that maternal SLE-induced placental dysregulation contributes to the development of cryptorchidism.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a budget of approximately $50,000-$100,000, depending on the specific reagents, equipment, and personnel required. The budget will cover:

* Animal costs (mice, breeding, and maintenance)
* Reagents and consumables (antibodies, siRNA, CRISPR-Cas9, inhibitors, etc.)
* Equipment and instrumentation (Western blotting, ELISA, LC-MS/MS, etc.)
* Personnel (postdoc or graduate student, technician, and PI)

Please note that this is a high-level experimental plan, and specific details may need to be adjusted based on the laboratory's resources and expertise.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Breeding and Placental Tissue Collection**

1.1. Obtain MRL/lpr mice (SLE model) and healthy male mice from a reputable supplier.

1.2. Set up breeding pairs of MRL/lpr females with healthy males in a controlled environment (e.g., specific pathogen-free facility).

1.3. Monitor the females for pregnancy and record the date of mating.

1.4. At embryonic day 12.5 (E12.5) and E18.5, sacrifice the pregnant females using a humane method (e.g., CO2 asphyxiation).

1.5. Dissect the uterus and collect the placentas from each embryo.

1.6. Rinse the placentas with cold PBS and snap-freeze them in liquid nitrogen or store them at -80°C for later analysis.

**Protocol 2: Protein Analysis (Western Blotting and ELISA)**

2.1. Homogenize the frozen placental tissue in RIPA buffer (e.g., 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) using a tissue homogenizer.

2.2. Centrifuge the homogenate at 10,000 x g for 10 minutes at 4°C to remove debris.

2.3. Measure the protein concentration using a protein assay kit (e.g., Bradford or BCA).

2.4. Perform Western blotting:
	* Load 20-30 μg of protein per lane onto a 10% SDS-PAGE gel.
	* Transfer the proteins to a PVDF membrane using a wet transfer apparatus.
	* Block the membrane with 5% non-fat milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature.
	* Incubate the membrane with primary antibodies against phospho-signaling proteins (e.g., p-AKT, p-ERK) and pro-inflammatory soluble mediators (e.g., TNF-α, IL-1β) overnight at 4°C.
	* Detect the proteins using HRP-conjugated secondary antibodies and ECL substrate.

2.5. Perform ELISA:
	* Coat a 96-well plate with capture antibodies against phospho-signaling proteins and pro-inflammatory soluble mediators.
	* Add 100 μL of placental homogenate to each well and incubate for 2 hours at room temperature.
	* Detect the proteins using HRP-conjugated detection antibodies and TMB substrate.

**Protocol 3: Hormone Analysis (ELISA or LC-MS/MS)**

3.1. Collect fetal testes and placentas from SLE and control mice at E12.5 and E18.5.

3.2. Homogenize the tissues in PBS using a tissue homogenizer.

3.3. Measure the levels of testicular descent-regulating hormones (e.g., INSL3, testosterone) using ELISA or LC-MS/MS according to the manufacturer's instructions.

**Protocol 4: Cryptorchidism Assessment**

4.1. Allow the offspring to develop to birth and postnatal day 3 weeks.

4.2. Sacrifice the offspring using a humane method (e.g., CO2 asphyxiation).

4.3. Dissect the abdominal cavity and examine the testes for cryptorchidism (i.e., undescended testes).

4.4. Record the incidence of cryptorchidism in each group (SLE and control).

**Protocol 5: Placental-Specific Knockdown (siRNA or CRISPR-Cas9)**

5.1. Design and synthesize siRNA or CRISPR-Cas9 constructs targeting phospho-signaling proteins (e.g., AKT, ERK) or pro-inflammatory soluble mediators (e.g., TNF-α, IL-1β).

5.2. Inject the siRNA or CRISPR-Cas9 constructs into the placenta of SLE mice at E12.5 using a microinjection apparatus.

5.3. Allow the offspring to develop to birth and postnatal day 3 weeks.

5.4. Assess the incidence of cryptorchidism in the offspring as described in Protocol 4.

**Protocol 6: Rescue Experiment**

6.1. Treat SLE mice with a specific inhibitor of phospho-signaling pathways (e.g., AKT inhibitor) or an anti-inflammatory agent (e.g., dexamethasone) during pregnancy.

6.2. Administer the inhibitor or anti-inflammatory agent via intraperitoneal injection or oral gavage according to the manufacturer's instructions.

6.3. Allow the offspring to develop to birth and postnatal day 3 weeks.

6.4. Assess the incidence of cryptorchidism in the offspring as described in Protocol 4.

**Statistical Analysis**

7.1. Compare the expression of phospho-signaling proteins, pro-inflammatory soluble mediators, and hormone levels between SLE and control groups using appropriate statistical tests (e.g., t-test, ANOVA).

7.2. Compare the incidence of cryptorchidism between SLE and control groups, as well as between treated and untreated SLE groups, using Fisher's exact test or chi-squared test.

Note: These protocols are detailed and specific, but may require adjustments based on the laboratory's resources and expertise. It is essential to follow proper laboratory protocols, safety guidelines, and animal welfare regulations when conducting these experiments.","```
   MRL/lpr Mice  Healthy Males  RIPA Buffer  Triton X-100  SDS  NaCl  Tris-HCl  Primary Antibodies  HRP-Conjugated Secondary Antibodies  ECL Substrate  Capture Antibodies  HRP-Conjugated Detection Antibodies  TMB Substrate  INSL3 ELISA Kit  Testosterone ELISA Kit  siRNA/CRISPR-Cas9 Constructs  AKT Inhibitor  Dexamethasone  Outcome
0           5          5          10mL         1%         0.1%  150mM     50mM                  2          1                         1                1                    1                1                1                1                1                1         0.8
1           3          3           8mL         0.8%         0.08%  120mM     40mM                  1.5        0.8                       0.8                0.8                    0.8                0.8                0.8                0.8                0.8         0.6
2           4          4           9mL         0.9%         0.09%  135mM     45mM                  1.8        1.2                       1.2                1.2                    1.2                1.2                1.2                1.2                1.2         0.7
3           2          2           6mL         0.6%         0.06%  90mM      30mM                  1.2        0.6                       0.6                0.6                    0.6                0.6                0.6                0.6                0.6         0.4
4           6          6          12mL         1.2%         0.12%  180mM     60mM                  2.5        1.5                       1.5                1.5                    1.5                1.5                1.5                1.5                1.5         0.9
5           3          3           8mL         0.8%         0.08%  120mM     40mM                  1.5        0.8                       0.8                0.8                    0.8                0.8                0.8                0.8                0.8         0.6
6           5          5          10mL         1%         0.1%  150mM     50mM                  2          1                         1                1                    1                1                1                1                1         0.8
7           4          4           9mL         0.9%         0.09%  135mM     45mM                  1.8        1.2                       1.2                1.2                    1.2                1.2                1.2                1.2                1.2         0.7
8           2          2           6mL         0.6%         0.06%  90mM      30mM                  1.2        0.6                       0.6                0.6                    0.6                0.6                0.6                0.6                0.6         0.4
9           6          6          12mL         1.2%         0.12%  180mM     60mM                  2.5        1.5                       1.5                1.5                    1.5                1.5                1.5                1.5                1.5         0.9
10          3          3           8mL         0.8%         0.08%  120mM     40mM                  1.5        0.8                       0.8                0.8                    0.8                0.8                0.8                0.8                0.8         0.6
11          5          5          10mL         1%         0.1%  150mM     50mM                  2          1                         1                1                    1                1                1                1                1         0.8
12          4          4           9mL         0.9%         0.09%  135mM     45mM                  1.8        1.2                       1.2                1.2                    1.2                1.2                1.2                1.2                1.2         0.7
13          2          2           6mL         0.6%         0.06%  90mM      30mM                  1.2        0.6                       0.6                0.6                    0.6                0.6                0.6                0.6                0.6         0.4
14          6          6          12mL         1.2%         0.12%  180mM     60mM                  2.5        1.5                       1.5                1.5                    1.5                1.5                1.5                1.5                1.5         0.9
15          3          3           8mL         0.8%         0.08%  120mM     40mM                  1.5        0.8                       0.8                0.8                    0.8                0.8                0.8                0.8                0.8         0.6
16          5          5          10mL         1%         0.1%  150mM     50mM                  2          1                         1                1                    1                1                1                1                1         0.8
17          4          4           9mL         0.9%         0.09%  135mM     45mM                  1.8        1.2                       1.2                1.2                    1.2                1.2                1.2                1.2                1.2         0.7
18          2          2           6mL         0.6%         0.06%  90mM      30mM                  1.2        0.6                       0.6                0.6                    0.6                0.6                0.6                0.6                0.6         0.4
19          6          6          12mL         1.2%         0.12%  180mM     60mM                  2.5        1.5                       1.5                1.5                    1.5                1.5                1.5                1.5                1.5         0.9
20          3          3           8mL         0.8%         0.08%  120mM     40mM                  1.5        0.8                       0.8                0.8                    0.8                0.8                0.8                0.8                0.8         0.6
21          5          5          10mL         1%         0.1%  150mM     50mM                  2          1                         1                1                    1                1                1                1                1         0.8
22          4          4           9mL         0.9%         0.09%  135mM     45mM                  1.8        1.2                       1.2                1.2                    1.2                1.2                1.2                1.2                1.2         0.7
23          2          2           6mL         0.6%         0.06%  90mM      30mM                  1.2        0.6                       0.6                0.6                    0.6                0.6                0.6                0.6                0.6         0.4
24          6          6          12mL         1.2%         0.12%  180mM     60mM                  2.5        1.5                       1.5                1.5                    1.5                1.5                1.5                1.5                1.5         0.9",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9d53f9963535aca34de7ca98bf33c27d1111c51f.summary'],"Does miR-139-5p regulate the expression of genes involved in DNA repair pathways in hematopoietic stem cells, thereby modulating their susceptibility to leukemogenic mutations?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test this hypothesis, I'll outline a comprehensive experimental plan to investigate the role of miR-139-5p in regulating DNA repair pathways in hematopoietic stem cells and its potential impact on leukemogenic mutations.

**Experimental Approach:**

**Objective:** To determine if miR-139-5p regulates the expression of genes involved in DNA repair pathways in hematopoietic stem cells, thereby modulating their susceptibility to leukemogenic mutations.

**Step 1: miR-139-5p Overexpression and Knockdown in Hematopoietic Stem Cells**

* Isolate hematopoietic stem cells from healthy donors or use established cell lines (e.g., HSC-CD34+).
* Design and synthesize miR-139-5p mimics and inhibitors for overexpression and knockdown experiments, respectively.
* Transfect hematopoietic stem cells with miR-139-5p mimics or inhibitors using electroporation or lentiviral vectors.
* Validate miR-139-5p overexpression or knockdown using qRT-PCR and Western blotting.

**Step 2: RNA Sequencing and Gene Expression Analysis**

* Perform RNA sequencing (RNA-seq) on miR-139-5p-overexpressing and -knockdown hematopoietic stem cells to identify differentially expressed genes involved in DNA repair pathways.
* Analyze RNA-seq data using bioinformatic tools (e.g., DESeq2, edgeR) to identify genes with significant changes in expression.
* Validate the expression of selected genes using qRT-PCR and Western blotting.

**Step 3: DNA Repair Pathway Analysis**

* Investigate the activity of DNA repair pathways (e.g., base excision repair, nucleotide excision repair, homologous recombination) in miR-139-5p-overexpressing and -knockdown hematopoietic stem cells using assays such as:
	+ Comet assay for DNA damage assessment
	+ γ-H2AX foci formation for DNA double-strand break detection
	+ Homologous recombination repair assay using reporter constructs
* Analyze the data to determine if miR-139-5p regulates DNA repair pathway activity.

**Step 4: Leukemogenic Mutation Analysis**

* Introduce known leukemogenic mutations (e.g., FLT3-ITD, NPM1) into miR-139-5p-overexpressing and -knockdown hematopoietic stem cells using CRISPR-Cas9 genome editing.
* Analyze the frequency and spectrum of leukemogenic mutations using next-generation sequencing (NGS) and digital PCR.
* Compare the mutation frequency and spectrum between miR-139-5p-overexpressing and -knockdown cells to determine if miR-139-5p modulates susceptibility to leukemogenic mutations.

**Step 5: In Vivo Validation**

* Use a xenograft model of human hematopoietic stem cell transplantation in immunodeficient mice to validate the in vitro findings.
* Transplant miR-139-5p-overexpressing or -knockdown hematopoietic stem cells into mice and monitor for leukemic transformation and disease progression.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: miR-139-5p has no effect on DNA repair pathways in hematopoietic stem cells and does not modulate their susceptibility to leukemogenic mutations.

**Alternative Hypothesis:** miR-139-5p does not regulate the expression of genes involved in DNA repair pathways in hematopoietic stem cells, and its overexpression or knockdown does not affect their susceptibility to leukemogenic mutations.

**Experimental Approach:**

1. Perform Steps 1-4 as described above, but with a focus on demonstrating no significant differences in DNA repair pathway activity and leukemogenic mutation frequency between miR-139-5p-overexpressing and -knockdown hematopoietic stem cells.
2. Use a more stringent statistical analysis (e.g., Bayesian inference) to test the null hypothesis that miR-139-5p has no effect on DNA repair pathways and leukemogenic mutations.
3. Perform additional experiments to rule out potential confounding factors, such as off-target effects of miR-139-5p or indirect effects on DNA repair pathways.

By following this experimental plan, we can comprehensively test the hypothesis and determine if miR-139-5p regulates DNA repair pathways in hematopoietic stem cells, thereby modulating their susceptibility to leukemogenic mutations.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: miR-139-5p Overexpression and Knockdown in Hematopoietic Stem Cells**

1.1. Isolation of Hematopoietic Stem Cells:

* Obtain healthy donor bone marrow or peripheral blood samples and isolate CD34+ hematopoietic stem cells using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) with anti-CD34 antibodies.
* Alternatively, use established hematopoietic stem cell lines (e.g., HSC-CD34+) and culture them according to the manufacturer's instructions.

1.2. Design and Synthesis of miR-139-5p Mimics and Inhibitors:

* Design miR-139-5p mimics and inhibitors using online tools (e.g., miRBase, RNAi Designer) and synthesize them using commercial vendors (e.g., Dharmacon, Ambion).
* Validate the sequences and purity of the synthesized miR-139-5p mimics and inhibitors using PAGE, HPLC, and mass spectrometry.

1.3. Transfection of Hematopoietic Stem Cells:

* Prepare hematopoietic stem cells for transfection by washing them with PBS and resuspending them in electroporation buffer (e.g., Neon Electroporation Buffer) or lentiviral vector packaging medium.
* Transfect hematopoietic stem cells with miR-139-5p mimics or inhibitors using electroporation (e.g., Neon Transfection System) or lentiviral vectors (e.g., pLKO.1-puro) according to the manufacturer's instructions.
* Incubate the transfected cells at 37°C, 5% CO2 for 24-48 hours to allow for miR-139-5p overexpression or knockdown.

1.4. Validation of miR-139-5p Overexpression or Knockdown:

* Extract total RNA from transfected hematopoietic stem cells using TRIzol or RNeasy kits.
* Perform qRT-PCR using miR-139-5p-specific primers and probes to quantify miR-139-5p expression levels.
* Perform Western blotting using anti-miR-139-5p antibodies to detect miR-139-5p protein levels.
* Normalize miR-139-5p expression levels to internal controls (e.g., GAPDH, U6) and calculate the fold change in miR-139-5p expression between miR-139-5p-overexpressing and -knockdown cells.

**Step 2: RNA Sequencing and Gene Expression Analysis**

2.1. RNA Sequencing:

* Extract total RNA from miR-139-5p-overexpressing and -knockdown hematopoietic stem cells using TRIzol or RNeasy kits.
* Prepare RNA-seq libraries using commercial kits (e.g., TruSeq RNA Library Prep Kit) and sequence them on a next-generation sequencing platform (e.g., Illumina HiSeq).
* Generate FASTQ files and perform quality control checks using tools like FastQC and Trimmomatic.

2.2. RNA-seq Data Analysis:

* Map RNA-seq reads to the human genome (e.g., GRCh38) using tools like STAR or HISAT2.
* Perform differential gene expression analysis using tools like DESeq2 or edgeR to identify genes with significant changes in expression between miR-139-5p-overexpressing and -knockdown cells.
* Filter genes with a fold change > 2 and p-value < 0.05 for further analysis.

2.3. Validation of Differentially Expressed Genes:

* Perform qRT-PCR using gene-specific primers and probes to validate the expression levels of selected genes.
* Perform Western blotting using gene-specific antibodies to detect protein levels of selected genes.
* Normalize gene expression levels to internal controls (e.g., GAPDH, ACTB) and calculate the fold change in gene expression between miR-139-5p-overexpressing and -knockdown cells.

**Step 3: DNA Repair Pathway Analysis**

3.1. Comet Assay:

* Treat miR-139-5p-overexpressing and -knockdown hematopoietic stem cells with DNA-damaging agents (e.g., H2O2, etoposide) for 30 minutes to 1 hour.
* Perform the comet assay using commercial kits (e.g., Trevigen CometAssay) according to the manufacturer's instructions.
* Measure the tail moment and Olive tail moment using software like CometScore or OpenComet.

3.2. γ-H2AX Foci Formation:

* Treat miR-139-5p-overexpressing and -knockdown hematopoietic stem cells with DNA-damaging agents (e.g., H2O2, etoposide) for 30 minutes to 1 hour.
* Fix the cells with paraformaldehyde and permeabilize them with Triton X-100.
* Stain the cells with anti-γ-H2AX antibodies and DAPI, and image them using a fluorescence microscope.
* Count the number of γ-H2AX foci per cell using software like ImageJ or CellProfiler.

3.3. Homologous Recombination Repair Assay:

* Transfect miR-139-5p-overexpressing and -knockdown hematopoietic stem cells with reporter constructs containing a GFP gene flanked by direct repeats (e.g., DR-GFP).
* Treat the cells with DNA-damaging agents (e.g., H2O2, etoposide) for 30 minutes to 1 hour.
* Measure the frequency of GFP-positive cells using flow cytometry or fluorescence microscopy.

**Step 4: Leukemogenic Mutation Analysis**

4.1. CRISPR-Cas9 Genome Editing:

* Design guide RNAs targeting known leukemogenic mutations (e.g., FLT3-ITD, NPM1) using online tools (e.g., CRISPR Design) and synthesize them using commercial vendors (e.g., IDT, Synthego).
* Transfect miR-139-5p-overexpressing and -knockdown hematopoietic stem cells with CRISPR-Cas9 complexes using electroporation or lentiviral vectors.
* Validate the editing efficiency using T7 endonuclease I assay or high-resolution melting analysis.

4.2. Next-Generation Sequencing:

* Extract genomic DNA from edited hematopoietic stem cells using commercial kits (e.g., DNeasy Blood & Tissue Kit).
* Prepare NGS libraries using commercial kits (e.g., TruSeq DNA Library Prep Kit) and sequence them on a next-generation sequencing platform (e.g., Illumina HiSeq).
* Analyze the NGS data using tools like CRISPResso or Cas-Analyzer to identify the frequency and spectrum of leukemogenic mutations.

4.3. Digital PCR:

* Extract genomic DNA from edited hematopoietic stem cells using commercial kits (e.g., DNeasy Blood & Tissue Kit).
* Perform digital PCR using commercial kits (e.g., QuantStudio 3D Digital PCR System) and primers specific to the leukemogenic mutations.
* Analyze the digital PCR data using software like QuantStudio 3D Analysis Software to quantify the frequency of leukemogenic mutations.

**Step 5: In Vivo Validation**

5.1. Xenograft Model:

* Transplant miR-139-5p-overexpressing or -knockdown hematopoietic stem cells into immunodeficient mice (e.g., NOD-SCID) using a tail vein injection.
* Monitor the mice for leukemic transformation and disease progression using blood cell counts, flow cytometry, and histopathological analysis.

5.2. Leukemic Transformation Assay:

* Isolate bone marrow cells from the transplanted mice and perform flow cytometry to detect the presence of leukemic cells.
* Perform histopathological analysis of the bone marrow and spleen to detect leukemic infiltration.

**Experiment to Disprove the Hypothesis**

Perform Steps 1-4 as described above, but with a focus on demonstrating no significant differences in DNA repair pathway activity and leukemogenic mutation frequency between miR-139-5p-overexpressing and -knockdown hematopoietic stem cells.

Use a more stringent statistical analysis (e.g., Bayesian inference) to test the null hypothesis that miR-139-5p has no effect on DNA repair pathways and leukemogenic mutations.

Perform additional experiments to rule out potential confounding factors, such as off-target effects of miR-139-5p or indirect effects on DNA repair pathways.","```
   miR-139-5p Mimics (nM)  miR-139-5p Inhibitors (nM)  Hematopoietic Stem Cells (x10^6)  Outcome (DNA Repair Pathway Activity)
0                    50.0                       0.0                         1.0                         1.23
1                    25.0                       0.0                         0.5                         1.15
2                    50.0                       0.0                         2.0                         1.41
3                     0.0                      25.0                         1.0                         0.87
4                    50.0                       0.0                         1.5                         1.31
5                    25.0                       0.0                         2.0                         1.21
6                     0.0                      50.0                         1.0                         0.73
7                    50.0                       0.0                         0.5                         1.19
8                    25.0                       0.0                         1.0                         1.11
9                     0.0                      25.0                         2.0                         0.93
10                   50.0                       0.0                         1.0                         1.35
11                   25.0                       0.0                         1.5                         1.25
12                    0.0                      50.0                         0.5                         0.81
13                   50.0                       0.0                         2.0                         1.47
14                   25.0                       0.0                         1.0                         1.17
15                    0.0                      25.0                         1.5                         0.89
16                   50.0                       0.0                         1.0                         1.29
17                   25.0                       0.0                         2.0                         1.23
18                    0.0                      50.0                         1.0                         0.75
19                   50.0                       0.0                         0.5                         1.13
20                   25.0                       0.0                         1.0                         1.09
21                    0.0                      25.0                         2.0                         0.95
22                   50.0                       0.0                         1.5                         1.39
23                   25.0                       0.0                         1.0                         1.19
24                   50.0                       0.0                         2.0                         1.43
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c5af11d9bb5e926cd92c15ede8e2cca5c5224bcf.summary'],Does nor-NOHA induce apoptosis in leukemic cells under hypoxic conditions by inhibiting the activity of a specific transcription factor that regulates the expression of genes involved in arginine metabolism?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Role of a Specific Transcription Factor in Nor-NOHA-Induced Apoptosis in Leukemic Cells under Hypoxic Conditions

**Objective:** To determine if nor-NOHA induces apoptosis in leukemic cells under hypoxic conditions by inhibiting the activity of a specific transcription factor that regulates the expression of genes involved in arginine metabolism.

**Experimental Design:**

1. **Cell Culture:** Use human leukemic cell lines (e.g., K562, THP-1) and maintain them in a hypoxic environment (1% O2) using a hypoxia chamber or a hypoxia-mimicking agent.
2. **Nor-NOHA Treatment:** Treat leukemic cells with nor-NOHA at various concentrations (e.g., 1-10 μM) for 24-48 hours.
3. **Transcription Factor Analysis:** Use techniques such as Western blot, qRT-PCR, or ChIP-sequencing to analyze the expression and activity of transcription factors involved in arginine metabolism, such as c-Myc, HIF-1α, or ATF4.
4. **Apoptosis Assay:** Measure apoptosis using Annexin V/PI staining, caspase-3/7 activity, or TUNEL assay.
5. **Gene Expression Analysis:** Perform RNA-seq or qRT-PCR to analyze the expression of genes involved in arginine metabolism, such as ARG1, ARG2, ODC1, and ASS1.

**Expected Outcomes:**

* Nor-NOHA treatment under hypoxic conditions induces apoptosis in leukemic cells.
* Nor-NOHA inhibits the activity of a specific transcription factor (e.g., c-Myc, HIF-1α, or ATF4) involved in arginine metabolism.
* The inhibited transcription factor regulates the expression of genes involved in arginine metabolism.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of Non-Transcriptional Mechanisms in Nor-NOHA-Induced Apoptosis in Leukemic Cells under Hypoxic Conditions

**Objective:** To determine if nor-NOHA induces apoptosis in leukemic cells under hypoxic conditions through a non-transcriptional mechanism, independent of transcription factor inhibition.

**Experimental Design:**

1. **Cell Culture:** Use human leukemic cell lines (e.g., K562, THP-1) and maintain them in a hypoxic environment (1% O2) using a hypoxia chamber or a hypoxia-mimicking agent.
2. **Nor-NOHA Treatment:** Treat leukemic cells with nor-NOHA at various concentrations (e.g., 1-10 μM) for 24-48 hours.
3. **Protein Synthesis Inhibition:** Treat cells with a protein synthesis inhibitor (e.g., cycloheximide) to block de novo protein synthesis.
4. **Apoptosis Assay:** Measure apoptosis using Annexin V/PI staining, caspase-3/7 activity, or TUNEL assay.
5. **Western Blot:** Analyze the expression of proteins involved in arginine metabolism, such as ARG1, ARG2, ODC1, and ASS1.

**Expected Outcomes:**

* Nor-NOHA treatment under hypoxic conditions induces apoptosis in leukemic cells, even in the presence of a protein synthesis inhibitor.
* The expression of proteins involved in arginine metabolism is not affected by nor-NOHA treatment.

**Rationale:** If nor-NOHA induces apoptosis through a non-transcriptional mechanism, the inhibition of protein synthesis should not affect the apoptotic response. This experiment aims to disprove the hypothesis by showing that nor-NOHA's effect is not dependent on transcription factor inhibition.

**Budget and Timeframe:**

* The experimental plan can be completed within 3-6 months, depending on the availability of resources and personnel.
* The budget will be approximately $10,000-$20,000, covering the costs of cell lines, reagents, equipment, and personnel.

By conducting these experiments, we can test the hypothesis and attempt to disprove it, providing a more comprehensive understanding of nor-NOHA's mechanism of action in leukemic cells under hypoxic conditions.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment 1: Investigating the Role of a Specific Transcription Factor in Nor-NOHA-Induced Apoptosis in Leukemic Cells under Hypoxic Conditions**

**Protocol 1.1: Cell Culture and Hypoxia Induction**

1. Obtain human leukemic cell lines (e.g., K562, THP-1) from a reputable cell bank or culture collection.
2. Grow cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine in a humidified incubator at 37°C and 5% CO2.
3. To induce hypoxia, place cells in a hypoxia chamber set to 1% O2 or treat cells with a hypoxia-mimicking agent (e.g., CoCl2) according to the manufacturer's instructions.
4. Incubate cells for 24 hours to allow for adaptation to hypoxic conditions.

**Protocol 1.2: Nor-NOHA Treatment**

1. Prepare a stock solution of nor-NOHA (e.g., 10 mM) in DMSO.
2. Add nor-NOHA to the cell culture medium at various concentrations (e.g., 1-10 μM) and mix well.
3. Incubate cells for 24-48 hours to allow for nor-NOHA treatment.

**Protocol 1.3: Transcription Factor Analysis**

1. Harvest cells and extract total protein using a lysis buffer (e.g., RIPA buffer) containing protease inhibitors.
2. Perform Western blot analysis using specific antibodies against transcription factors involved in arginine metabolism (e.g., c-Myc, HIF-1α, ATF4).
3. Alternatively, perform qRT-PCR or ChIP-sequencing to analyze transcription factor expression and activity.

**Protocol 1.4: Apoptosis Assay**

1. Harvest cells and stain with Annexin V-FITC and propidium iodide (PI) according to the manufacturer's instructions.
2. Analyze cells using flow cytometry to detect apoptotic cells (Annexin V+/PI-).
3. Alternatively, measure caspase-3/7 activity using a commercial kit or perform a TUNEL assay.

**Protocol 1.5: Gene Expression Analysis**

1. Extract total RNA from cells using a RNA extraction kit (e.g., TRIzol).
2. Perform RNA-seq or qRT-PCR to analyze the expression of genes involved in arginine metabolism (e.g., ARG1, ARG2, ODC1, ASS1).

**Experiment 2: Investigating the Role of Non-Transcriptional Mechanisms in Nor-NOHA-Induced Apoptosis in Leukemic Cells under Hypoxic Conditions**

**Protocol 2.1: Cell Culture and Hypoxia Induction**

1. Follow the same protocol as Experiment 1.1 to culture and induce hypoxia in leukemic cells.

**Protocol 2.2: Nor-NOHA Treatment and Protein Synthesis Inhibition**

1. Prepare a stock solution of nor-NOHA (e.g., 10 mM) in DMSO.
2. Add nor-NOHA to the cell culture medium at various concentrations (e.g., 1-10 μM) and mix well.
3. Add a protein synthesis inhibitor (e.g., cycloheximide) to the cell culture medium at a final concentration of 10-20 μg/mL.
4. Incubate cells for 24-48 hours to allow for nor-NOHA treatment and protein synthesis inhibition.

**Protocol 2.3: Apoptosis Assay**

1. Follow the same protocol as Experiment 1.4 to analyze apoptosis using Annexin V/PI staining, caspase-3/7 activity, or TUNEL assay.

**Protocol 2.4: Western Blot Analysis**

1. Harvest cells and extract total protein using a lysis buffer (e.g., RIPA buffer) containing protease inhibitors.
2. Perform Western blot analysis using specific antibodies against proteins involved in arginine metabolism (e.g., ARG1, ARG2, ODC1, ASS1).

These detailed protocols provide a step-by-step guide for executing the experiments, ensuring replicability and specificity in the results.","```
   Cell_Line  FBS  Penicillin_Streptomycin  L_Glutamine  CoCl2  Nor_NOHA  Cycloheximide  Apoptosis_Rate
0       K562   10%               1%           1%     100uM       5uM           10ug/mL       0.35
1       THP-1   12%               1%           1%     150uM       3uM           15ug/mL       0.42
2       K562    8%               1%           1%      50uM       7uM           12ug/mL       0.28
3       THP-1   11%               1%           1%     120uM       4uM           18ug/mL       0.38
4       K562   10%               1%           1%     100uM       6uM           11ug/mL       0.32
5       THP-1    9%               1%           1%      80uM       5uM           14ug/mL       0.30
6       K562   12%               1%           1%     140uM       8uM           16ug/mL       0.45
7       THP-1   10%               1%           1%     110uM       4uM           13ug/mL       0.36
8       K562    9%               1%           1%      90uM       6uM           10ug/mL       0.29
9       THP-1   11%               1%           1%     130uM       5uM           17ug/mL       0.40
10      K562   10%               1%           1%     100uM       7uM           12ug/mL       0.34
11      THP-1   12%               1%           1%     150uM       4uM           19ug/mL       0.43
12      K562    8%               1%           1%      60uM       5uM           11ug/mL       0.26
13      THP-1   10%               1%           1%     100uM       6uM           14ug/mL       0.33
14      K562   11%               1%           1%     120uM       8uM           15ug/mL       0.41
15      THP-1    9%               1%           1%      90uM       5uM           13ug/mL       0.31
16      K562   10%               1%           1%     110uM       7uM           12ug/mL       0.37
17      THP-1   12%               1%           1%     140uM       4uM           18ug/mL       0.44
18      K562    8%               1%           1%      70uM       6uM           10ug/mL       0.27
19      THP-1   11%               1%           1%     130uM       5uM           16ug/mL       0.39
20      K562   10%               1%           1%     100uM       8uM           11ug/mL       0.35
21      THP-1   10%               1%           1%     100uM       6uM           14ug/mL       0.34
22      K562    9%               1%           1%      80uM       5uM           12ug/mL       0.29
23      THP-1   12%               1%           1%     150uM       4uM           19ug/mL       0.45
24      K562   11%               1%           1%     120uM       7uM           15ug/mL       0.42
```",0.09042093101642223
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/66da0676a211a4169171ea1e24a13fbdb1c2d41d.summary'],Does simultaneous inhibition of ABCB1 and ABCG2 enhance the efficacy of asciminib by reducing the emergence of resistant BCR-ABL1+ subclones in patients with refractory CML or Ph+ ALL?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Simultaneous Inhibition of ABCB1 and ABCG2 Enhances the Efficacy of Asciminib in Refractory CML or Ph+ ALL Patients

**Objective:** To investigate whether simultaneous inhibition of ABCB1 and ABCG2 improves the efficacy of asciminib in patients with refractory CML or Ph+ ALL.

**Design:** Randomized controlled trial

**Participants:** Patients with refractory CML or Ph+ ALL

**Intervention:**

* Arm 1: Asciminib (standard treatment)
* Arm 2: Asciminib + ABCB1 inhibitor (e.g., elacridar)
* Arm 3: Asciminib + ABCG2 inhibitor (e.g., Ko143)
* Arm 4: Asciminib + ABCB1 and ABCG2 inhibitors (combination therapy)

**Outcome Measures:**

* Response rate (complete hematological response, major molecular response, and molecular response)
* Progression-free survival
* Overall survival
* ABCB1 and ABCG2 expression levels (using flow cytometry and Western blot)
* BCR-ABL1 transcript levels (using qRT-PCR)

**Equipment:**

* Flow cytometer
* PCR machine
* Western blot apparatus
* Cell culture facilities
* Clinical trial infrastructure (patient recruitment, randomization, and monitoring)

**Steps:**

1. Recruit patients with refractory CML or Ph+ ALL and randomize them to one of the four arms.
2. Administer the assigned treatment regimen and monitor patients for response rate, progression-free survival, and overall survival.
3. Collect blood samples at baseline, 3 months, 6 months, and 12 months to analyze ABCB1 and ABCG2 expression levels using flow cytometry and Western blot.
4. Analyze BCR-ABL1 transcript levels using qRT-PCR at the same time points.
5. Compare outcomes between the four arms to determine if simultaneous inhibition of ABCB1 and ABCG2 enhances the efficacy of asciminib.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Efficacy of Simultaneous ABCB1 and ABCG2 Inhibition on Asciminib Resistance in Refractory CML or Ph+ ALL

**Objective:** To demonstrate that simultaneous inhibition of ABCB1 and ABCG2 does not improve the efficacy of asciminib in patients with refractory CML or Ph+ ALL.

**Design:** Non-inferiority trial

**Participants:** Patients with refractory CML or Ph+ ALL

**Intervention:**

* Arm 1: Asciminib (standard treatment)
* Arm 2: Asciminib + ABCB1 and ABCG2 inhibitors (combination therapy)

**Outcome Measures:**

* Response rate (complete hematological response, major molecular response, and molecular response)
* Progression-free survival
* Overall survival
* ABCB1 and ABCG2 expression levels (using flow cytometry and Western blot)
* BCR-ABL1 transcript levels (using qRT-PCR)

**Equipment:**

* Flow cytometer
* PCR machine
* Western blot apparatus
* Cell culture facilities
* Clinical trial infrastructure (patient recruitment, randomization, and monitoring)

**Steps:**

1. Recruit patients with refractory CML or Ph+ ALL and randomize them to one of the two arms.
2. Administer the assigned treatment regimen and monitor patients for response rate, progression-free survival, and overall survival.
3. Collect blood samples at baseline, 3 months, 6 months, and 12 months to analyze ABCB1 and ABCG2 expression levels using flow cytometry and Western blot.
4. Analyze BCR-ABL1 transcript levels using qRT-PCR at the same time points.
5. Compare outcomes between the two arms to determine if simultaneous inhibition of ABCB1 and ABCG2 does not improve the efficacy of asciminib.

**Rationale for the Disproving Experiment:**

By designing a non-inferiority trial, we can test the hypothesis that simultaneous inhibition of ABCB1 and ABCG2 does not improve the efficacy of asciminib. If the results show that the combination therapy (Arm 2) is not superior to the standard treatment (Arm 1), it would suggest that the hypothesis is false, and simultaneous inhibition of ABCB1 and ABCG2 does not enhance the efficacy of asciminib. This experiment would provide strong evidence against the original hypothesis and would be a crucial step in understanding the role of ABCB1 and ABCG2 in asciminib resistance.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment 1: Simultaneous Inhibition of ABCB1 and ABCG2 Enhances the Efficacy of Asciminib in Refractory CML or Ph+ ALL Patients**

**Protocol:**

**Step 1: Patient Recruitment and Randomization**

1.1. Identify patients with refractory CML or Ph+ ALL through medical records and clinical evaluations.

1.2. Obtain informed consent from eligible patients.

1.3. Randomize patients to one of the four arms using a computer-generated randomization algorithm.

1.4. Assign patients to Arm 1 (asciminib), Arm 2 (asciminib + ABCB1 inhibitor), Arm 3 (asciminib + ABCG2 inhibitor), or Arm 4 (asciminib + ABCB1 and ABCG2 inhibitors).

**Step 2: Treatment Administration and Monitoring**

2.1. Administer the assigned treatment regimen to each patient according to the randomization arm.

2.2. Monitor patients for response rate, progression-free survival, and overall survival through regular clinical evaluations and laboratory tests.

2.3. Record adverse events and serious adverse events throughout the treatment period.

**Step 3: Blood Sample Collection and Analysis**

3.1. Collect blood samples from each patient at baseline, 3 months, 6 months, and 12 months.

3.2. Isolate peripheral blood mononuclear cells (PBMCs) from each blood sample using density gradient centrifugation.

3.3. Analyze ABCB1 and ABCG2 expression levels using flow cytometry:

a. Stain PBMCs with fluorescently labeled antibodies against ABCB1 and ABCG2.
b. Acquire data using a flow cytometer.
c. Analyze data using flow cytometry software to determine the percentage of cells expressing ABCB1 and ABCG2.

3.4. Analyze ABCB1 and ABCG2 expression levels using Western blot:

a. Isolate protein from PBMCs using a protein extraction buffer.
b. Separate proteins using SDS-PAGE.
c. Transfer proteins to a membrane.
d. Probe the membrane with antibodies against ABCB1 and ABCG2.
e. Detect protein bands using chemiluminescence or other detection methods.

3.5. Analyze BCR-ABL1 transcript levels using qRT-PCR:

a. Isolate RNA from PBMCs using a RNA extraction kit.
b. Synthesize cDNA using a reverse transcription kit.
c. Perform qRT-PCR using primers specific to BCR-ABL1.
d. Analyze data using qRT-PCR software to determine the relative expression of BCR-ABL1.

**Step 4: Data Analysis**

4.1. Compare outcomes between the four arms to determine if simultaneous inhibition of ABCB1 and ABCG2 enhances the efficacy of asciminib.

4.2. Analyze response rate, progression-free survival, and overall survival using Kaplan-Meier curves and log-rank tests.

4.3. Compare ABCB1 and ABCG2 expression levels, and BCR-ABL1 transcript levels between the four arms using ANOVA or t-tests.

**Experiment 2: Investigating the Lack of Efficacy of Simultaneous ABCB1 and ABCG2 Inhibition on Asciminib Resistance in Refractory CML or Ph+ ALL**

**Protocol:**

**Step 1: Patient Recruitment and Randomization**

1.1. Identify patients with refractory CML or Ph+ ALL through medical records and clinical evaluations.

1.2. Obtain informed consent from eligible patients.

1.3. Randomize patients to one of the two arms using a computer-generated randomization algorithm.

1.4. Assign patients to Arm 1 (asciminib) or Arm 2 (asciminib + ABCB1 and ABCG2 inhibitors).

**Step 2: Treatment Administration and Monitoring**

2.1. Administer the assigned treatment regimen to each patient according to the randomization arm.

2.2. Monitor patients for response rate, progression-free survival, and overall survival through regular clinical evaluations and laboratory tests.

2.3. Record adverse events and serious adverse events throughout the treatment period.

**Step 3: Blood Sample Collection and Analysis**

3.1. Collect blood samples from each patient at baseline, 3 months, 6 months, and 12 months.

3.2. Isolate peripheral blood mononuclear cells (PBMCs) from each blood sample using density gradient centrifugation.

3.3. Analyze ABCB1 and ABCG2 expression levels using flow cytometry and Western blot as described in Experiment 1.

3.4. Analyze BCR-ABL1 transcript levels using qRT-PCR as described in Experiment 1.

**Step 4: Data Analysis**

4.1. Compare outcomes between the two arms to determine if simultaneous inhibition of ABCB1 and ABCG2 does not improve the efficacy of asciminib.

4.2. Analyze response rate, progression-free survival, and overall survival using Kaplan-Meier curves and log-rank tests.

4.3. Compare ABCB1 and ABCG2 expression levels, and BCR-ABL1 transcript levels between the two arms using ANOVA or t-tests.

4.4. Perform a non-inferiority test to determine if the combination therapy (Arm 2) is not superior to the standard treatment (Arm 1).","```
   Asciminib  ABCB1_Inhibitor  ABCG2_Inhibitor  Response_Rate  Progression_Free_Survival  Overall_Survival
0        100               0               0         0.20                  6.5               12.0
1        120               5               0         0.30                  8.0               15.0
2        100               0               5         0.25                  7.0               13.5
3        120               5               5         0.40                  9.5               18.0
4        100               0               0         0.15                  5.5               10.5
5        120               5               0         0.35                  8.5               16.0
6        100               0               5         0.20                  6.0               11.5
7        120               5               5         0.45                  10.0               19.5
8        100               0               0         0.10                  4.5               9.0
9        120               5               0         0.30                  7.5               14.0
10       100               0               5         0.25                  6.5               12.5
11       120               5               5         0.40                  9.0               17.5
12       100               0               0         0.20                  5.0               10.0
13       120               5               0         0.35                  8.0               15.5
14       100               0               5         0.20                  6.0               11.0
15       120               5               5         0.45                  10.5               20.0
16       100               0               0         0.15                  4.0               8.5
17       120               5               0         0.30                  7.0               13.0
18       100               0               5         0.25                  6.0               11.5
19       120               5               5         0.40                  9.0               17.0
20       100               0               0         0.10                  3.5               7.5
21       120               5               0         0.35                  7.5               14.5
22       100               0               5         0.20                  5.5               10.5
23       120               5               5         0.45                  10.0               19.0
24       100               0               0         0.20                  5.0               9.5
```",0.82174413096807
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0002be930ce135aae242cb73345dce5c785d8f72.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4ca3b2906b504bed5680d9d6c32d9237ea628fb5.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0a5785708015fa7d1d5d09313a45360951a1f4e8.summary']",Does simultaneous inhibition of BRD4 and VLA-4 lead to enhanced therapeutic efficacy in mantle cell lymphoma by disrupting both B-cell receptor signaling and integrin-mediated cell adhesion and activation?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that simultaneous inhibition of BRD4 and VLA-4 leads to enhanced therapeutic efficacy in mantle cell lymphoma by disrupting both B-cell receptor signaling and integrin-mediated cell adhesion and activation, I propose the following experimental plan:

**Experiment:** ""Simultaneous Inhibition of BRD4 and VLA-4 in Mantle Cell Lymphoma: A Therapeutic Strategy""

**Objective:** To investigate the therapeutic efficacy of simultaneous inhibition of BRD4 and VLA-4 in mantle cell lymphoma cell lines and primary cells.

**Equipment:**

* Mantle cell lymphoma cell lines (e.g., Jeko-1, Mino, and Granta-519)
* Primary mantle cell lymphoma cells
* BRD4 inhibitor (e.g., I-BET151)
* VLA-4 inhibitor (e.g., Natalizumab)
* Cell viability assays (e.g., MTT, Annexin V/PI)
* Flow cytometry equipment
* Western blot equipment
* Cell culture facilities

**Experimental Design:**

1. **Cell Culture and Treatment:** Culture mantle cell lymphoma cell lines and primary cells in the presence or absence of BRD4 inhibitor (I-BET151) and/or VLA-4 inhibitor (Natalizumab) for 24-48 hours.
2. **Cell Viability Assays:** Measure cell viability using MTT assays and Annexin V/PI staining followed by flow cytometry.
3. **Western Blot Analysis:** Analyze protein expression of BRD4-regulated molecules (e.g., BCL6, MYC, and CDK6) and VLA-4-regulated molecules (e.g., pFAK, pERK, and pAKT) using Western blotting.
4. **Flow Cytometry Analysis:** Analyze cell surface expression of VLA-4 and B-cell receptor signaling molecules (e.g., CD19, CD20, and CD79a) using flow cytometry.
5. **Combination Index Analysis:** Calculate the combination index (CI) using the Chou-Talalay method to determine the synergistic effect of BRD4 and VLA-4 inhibition.

**To disprove the hypothesis:**

* Use a high concentration of BRD4 inhibitor (e.g., 10 μM) and a low concentration of VLA-4 inhibitor (e.g., 0.1 μM) to test if the simultaneous inhibition of BRD4 and VLA-4 still leads to enhanced therapeutic efficacy.
* Use a BRD4 inhibitor-resistant mantle cell lymphoma cell line to test if the simultaneous inhibition of BRD4 and VLA-4 can overcome resistance to BRD4 inhibition.
* Use a VLA-4 inhibitor that specifically targets the α4β1 integrin heterodimer to test if the simultaneous inhibition of BRD4 and VLA-4 is specific to the α4β1 integrin.

**Timeline:**

* Cell culture and treatment: 2 weeks
* Cell viability assays: 1 week
* Western blot analysis: 2 weeks
* Flow cytometry analysis: 1 week
* Data analysis and interpretation: 2 weeks

**Budget:**

* Reagents and consumables: $5,000
* Equipment maintenance and usage: $2,000
* Personnel and labor: $10,000
* Total: $17,000

This experimental plan is designed to test the hypothesis that simultaneous inhibition of BRD4 and VLA-4 leads to enhanced therapeutic efficacy in mantle cell lymphoma by disrupting both B-cell receptor signaling and integrin-mediated cell adhesion and activation. The experiment is designed to be completed within a reasonable time frame (6-8 weeks) and budget ($17,000).",85,"Here are the detailed, step-by-step protocols for the experiment ""Simultaneous Inhibition of BRD4 and VLA-4 in Mantle Cell Lymphoma: A Therapeutic Strategy"":

**Protocol 1: Cell Culture and Treatment**

1.1. Prepare cell culture media:
	* Use RPMI-1640 media supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
	* Sterilize the media by filtering through a 0.22 μm filter.

1.2. Thaw and culture mantle cell lymphoma cell lines (Jeko-1, Mino, and Granta-519):
	* Thaw frozen cells in a 37°C water bath.
	* Centrifuge the cells at 300 x g for 5 minutes to remove cryoprotectant.
	* Resuspend the cells in 10 mL of prepared media and transfer to a 25 cm² tissue culture flask.
	* Incubate the cells at 37°C, 5% CO₂ for 24-48 hours to allow for recovery.

1.3. Prepare primary mantle cell lymphoma cells:
	* Obtain primary cells from a reputable source (e.g., blood samples from patients with mantle cell lymphoma).
	* Isolate mononuclear cells using Ficoll-Paque density gradient centrifugation.
	* Culture the primary cells in prepared media at 37°C, 5% CO₂ for 24-48 hours.

1.4. Treat cells with BRD4 inhibitor (I-BET151) and/or VLA-4 inhibitor (Natalizumab):
	* Prepare stock solutions of I-BET151 (10 mM) and Natalizumab (10 mg/mL) in DMSO and PBS, respectively.
	* Add the inhibitors to the cell culture media at the desired concentrations (e.g., 1 μM I-BET151 and 10 μg/mL Natalizumab).
	* Incubate the cells for 24-48 hours.

**Protocol 2: Cell Viability Assays**

2.1. MTT Assay:
	* Prepare MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) at 5 mg/mL in PBS.
	* Add 10 μL of MTT reagent to each well of a 96-well plate containing 100 μL of cell culture media.
	* Incubate the plate at 37°C, 5% CO₂ for 4 hours.
	* Add 100 μL of DMSO to each well to solubilize the formazan crystals.
	* Measure the absorbance at 570 nm using a microplate reader.

2.2. Annexin V/PI Staining:
	* Prepare Annexin V-FITC and PI staining solutions according to the manufacturer's instructions.
	* Add 5 μL of Annexin V-FITC and 5 μL of PI to each tube containing 100 μL of cell suspension.
	* Incubate the tubes at room temperature for 15 minutes.
	* Analyze the samples using flow cytometry.

**Protocol 3: Western Blot Analysis**

3.1. Cell Lysis:
	* Harvest cells by centrifugation at 300 x g for 5 minutes.
	* Lyse the cells in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors.
	* Incubate the lysates on ice for 30 minutes.

3.2. Protein Extraction:
	* Centrifuge the lysates at 12,000 x g for 10 minutes.
	* Collect the supernatant and measure the protein concentration using a Bradford assay.

3.3. Western Blotting:
	* Prepare 10% SDS-PAGE gels and transfer the proteins to PVDF membranes.
	* Block the membranes with 5% non-fat milk in TBST (Tris-buffered saline with 0.1% Tween-20).
	* Incubate the membranes with primary antibodies against BRD4-regulated molecules (e.g., BCL6, MYC, and CDK6) and VLA-4-regulated molecules (e.g., pFAK, pERK, and pAKT).
	* Detect the proteins using HRP-conjugated secondary antibodies and ECL reagents.

**Protocol 4: Flow Cytometry Analysis**

4.1. Cell Staining:
	* Prepare staining solutions for VLA-4 (e.g., CD49d-PE) and B-cell receptor signaling molecules (e.g., CD19-FITC, CD20-APC, and CD79a-PE-Cy7).
	* Add 5 μL of each staining solution to each tube containing 100 μL of cell suspension.
	* Incubate the tubes at room temperature for 30 minutes.

4.2. Flow Cytometry:
	* Analyze the samples using a flow cytometer equipped with a 488 nm laser and appropriate filters.
	* Gate the cells based on forward and side scatter to exclude debris and dead cells.
	* Measure the mean fluorescence intensity (MFI) of each marker.

**Protocol 5: Combination Index Analysis**

5.1. Calculate the combination index (CI) using the Chou-Talalay method:
	* Use the IC50 values of I-BET151 and Natalizumab obtained from the MTT assay.
	* Calculate the CI using the following formula: CI = (D1/Dx) + (D2/Dy), where D1 and D2 are the doses of I-BET151 and Natalizumab, respectively, and Dx and Dy are the IC50 values of each inhibitor.

**Protocol 6: Disproving the Hypothesis**

6.1. High concentration of BRD4 inhibitor and low concentration of VLA-4 inhibitor:
	* Treat cells with 10 μM I-BET151 and 0.1 μM Natalizumab.
	* Perform cell viability assays and Western blot analysis as described above.

6.2. BRD4 inhibitor-resistant mantle cell lymphoma cell line:
	* Obtain a BRD4 inhibitor-resistant mantle cell lymphoma cell line (e.g., Jeko-1-R).
	* Treat the cells with 1 μM I-BET151 and 10 μg/mL Natalizumab.
	* Perform cell viability assays and Western blot analysis as described above.

6.3. VLA-4 inhibitor specific to the α4β1 integrin heterodimer:
	* Use a VLA-4 inhibitor that specifically targets the α4β1 integrin heterodimer (e.g., Natalizumab-α4β1).
	* Treat cells with 10 μg/mL Natalizumab-α4β1 and 1 μM I-BET151.
	* Perform cell viability assays and Western blot analysis as described above.

These detailed protocols should provide a clear and concise guide for executing the experiment ""Simultaneous Inhibition of BRD4 and VLA-4 in Mantle Cell Lymphoma: A Therapeutic Strategy"".","```
   I-BET151 Natalizumab Cell_Line  MTT_Assay Annexin_V_PI Western_Blot Flow_Cytometry Combination_Index
0       0.5         5.0      Jeko-1  0.823421    0.456789  0.234567    0.678901        0.912345
1       1.0         2.5      Mino    0.741852    0.398745  0.198765    0.567890        0.823456
2       0.2         7.5      Granta  0.935678    0.623456  0.345678    0.812345        0.956789
3       1.5         1.0      Jeko-1  0.654321    0.456123  0.234567    0.678901        0.823456
4       0.8         3.0      Mino    0.812345    0.567890  0.345678    0.901234        0.945678
5       0.1         9.0      Granta  0.987654    0.789012  0.567890    0.945678        0.983456
6       1.2         0.5      Jeko-1  0.567890    0.345678  0.198765    0.567890        0.812345
7       0.6         4.0      Mino    0.901234    0.678901  0.456789    0.823456        0.923456
8       0.4         6.0      Granta  0.823456    0.567890  0.345678    0.812345        0.901234
9       1.8         1.5      Jeko-1  0.456789    0.234567  0.123456    0.456789        0.745678
10      0.9         2.0      Mino    0.945678    0.789012  0.567890    0.901234        0.965678
11      0.3         8.0      Granta  0.965678    0.823456  0.678901    0.945678        0.983456
12      1.1         0.8      Jeko-1  0.678901    0.456789  0.234567    0.678901        0.845678
13      0.7         3.5      Mino    0.812345    0.567890  0.345678    0.812345        0.901234
14      0.2         9.5      Granta  0.983456    0.856789  0.678901    0.945678        0.993456
15      1.4         1.2      Jeko-1  0.567890    0.345678  0.198765    0.567890        0.789012
16      0.5         4.5      Mino    0.901234    0.678901  0.456789    0.823456        0.923456
17      0.6         6.5      Granta  0.923456    0.789012  0.567890    0.901234        0.953456
18      1.9         1.8      Jeko-1  0.456789    0.234567  0.123456    0.456789        0.745678
19      1.0         2.8      Mino    0.945678    0.789012  0.567890    0.901234        0.965678
20      0.4         8.5      Granta  0.965678    0.823456  0.678901    0.945678        0.983456
21      1.3         1.0      Jeko-1  0.678901    0.456789  0.234567    0.678901        0.845678
22      0.8         3.8      Mino    0.812345    0.567890  0.345678    0.812345        0.901234
23      0.1         9.8      Granta  0.983456    0.856789  0.678901    0.945678        0.993456
24      1.6         1.6      Jeko-1  0.567890    0.345678  0.198765    0.567890        0.789012
```",0.6477990638842938
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2a18ade4d1ea55188d0ea351b90e9cd86908ca53.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c867577ba94b228304ee0a09e5840cebf123f478.summary']",Does simultaneous inhibition of MALT1 and B-cell receptor signaling lead to enhanced suppression of MYC activity and improved therapeutic efficacy in mantle cell lymphoma?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test this hypothesis, I'll outline a comprehensive experimental plan to investigate the effect of simultaneous inhibition of MALT1 and B-cell receptor (BCR) signaling on MYC activity and therapeutic efficacy in mantle cell lymphoma (MCL).

**Hypothesis:** Simultaneous inhibition of MALT1 and BCR signaling leads to enhanced suppression of MYC activity and improved therapeutic efficacy in mantle cell lymphoma.

**Experimental Approach:**

**Objective 1: Validate the hypothesis in vitro**

1. **Cell culture:** Establish MCL cell lines (e.g., Jeko-1, Granta-519) and primary MCL cells from patient samples.
2. **Inhibitors:** Use specific inhibitors for MALT1 (e.g., MI-2) and BCR signaling (e.g., ibrutinib).
3. **Combination treatment:** Treat MCL cells with:
	* MALT1 inhibitor alone
	* BCR inhibitor alone
	* Combination of MALT1 and BCR inhibitors
4. **MYC activity assessment:** Measure MYC protein levels, mRNA expression, and transcriptional activity using Western blot, qRT-PCR, and luciferase reporter assays, respectively.
5. **Cell viability and apoptosis:** Evaluate cell viability using MTT or CellTiter-Glo assays and apoptosis using Annexin V/PI staining and flow cytometry.

**Objective 2: Investigate the mechanism of action**

1. **Protein-protein interactions:** Perform co-immunoprecipitation and mass spectrometry to identify proteins interacting with MALT1 and BCR signaling components.
2. **Signaling pathway analysis:** Use phospho-protein arrays or Western blot to analyze the activation status of key signaling molecules (e.g., NF-κB, ERK, AKT) in response to inhibitor treatments.
3. **Gene expression profiling:** Perform RNA-seq or microarray analysis to identify differentially expressed genes in response to combination treatment.

**Objective 3: Evaluate therapeutic efficacy in vivo**

1. **Mouse models:** Establish MCL xenograft models using immunodeficient mice (e.g., NOD/SCID).
2. **Treatment groups:** Divide mice into four groups:
	* Vehicle control
	* MALT1 inhibitor alone
	* BCR inhibitor alone
	* Combination of MALT1 and BCR inhibitors
3. **Tumor monitoring:** Measure tumor volume, weight, and bioluminescence (if applicable).
4. **Survival analysis:** Monitor mouse survival and perform Kaplan-Meier analysis.

**Objective 4: Investigate potential biomarkers**

1. **Patient samples:** Collect MCL patient samples and analyze MYC expression, MALT1 and BCR signaling activity, and response to combination treatment.
2. **Correlative studies:** Correlate in vitro and in vivo results with clinical outcomes (e.g., response rate, progression-free survival).

**Experiment to DISPROVE the hypothesis:**

**Design:** Perform a ""rescue"" experiment to test if re-activating MALT1 or BCR signaling can reverse the suppressive effects of combination treatment on MYC activity.

1. **MALT1 or BCR signaling re-activation:** Use CRISPR-Cas9 genome editing to introduce constitutively active MALT1 or BCR signaling mutants in MCL cells.
2. **Combination treatment:** Treat MCL cells with MALT1 and BCR inhibitors, followed by re-activation of MALT1 or BCR signaling.
3. **MYC activity assessment:** Measure MYC protein levels, mRNA expression, and transcriptional activity as described above.

If the combination treatment fails to suppress MYC activity in the presence of re-activated MALT1 or BCR signaling, it would suggest that the hypothesis is false, and simultaneous inhibition of MALT1 and BCR signaling does not lead to enhanced suppression of MYC activity and improved therapeutic efficacy in MCL.

This experimental plan is designed to provide a comprehensive understanding of the hypothesis and its underlying mechanisms. With unlimited resources, this study can be conducted in a timely and thorough manner, ensuring the generation of high-quality data to support or refute the hypothesis.",92,"Here are the detailed, step-by-step protocols for each objective:

**Objective 1: Validate the hypothesis in vitro**

**Protocol 1.1: Cell Culture**

1. Obtain MCL cell lines (e.g., Jeko-1, Granta-519) and primary MCL cells from patient samples.
2. Culture cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
3. Maintain cell lines at a density of 1-2 x 10^6 cells/mL and passage every 3-4 days.

**Protocol 1.2: Inhibitor Preparation**

1. Obtain specific inhibitors for MALT1 (e.g., MI-2) and BCR signaling (e.g., ibrutinib).
2. Prepare stock solutions of inhibitors in DMSO at a concentration of 10 mM.
3. Store stock solutions at -20°C and thaw as needed.

**Protocol 1.3: Combination Treatment**

1. Seed 1 x 10^6 MCL cells in 6-well plates and incubate for 24 hours.
2. Treat cells with:
	* MALT1 inhibitor alone (1 μM final concentration)
	* BCR inhibitor alone (1 μM final concentration)
	* Combination of MALT1 and BCR inhibitors (1 μM each)
	* Vehicle control (DMSO)
3. Incubate cells for 24, 48, or 72 hours.

**Protocol 1.4: MYC Activity Assessment**

1. **Western Blot**
	* Harvest cells and extract protein using RIPA buffer.
	* Separate proteins by SDS-PAGE and transfer to PVDF membranes.
	* Probe membranes with anti-MYC antibody (1:1000) and detect using ECL.
2. **qRT-PCR**
	* Extract RNA using TRIzol and convert to cDNA using reverse transcriptase.
	* Perform qRT-PCR using MYC-specific primers and detect using SYBR Green.
3. **Luciferase Reporter Assay**
	* Transfect cells with a MYC-luciferase reporter plasmid.
	* Treat cells as described above and measure luciferase activity using a luminometer.

**Protocol 1.5: Cell Viability and Apoptosis**

1. **MTT Assay**
	* Add MTT reagent to cells and incubate for 4 hours.
	* Measure absorbance at 570 nm using a plate reader.
2. **CellTiter-Glo Assay**
	* Add CellTiter-Glo reagent to cells and incubate for 10 minutes.
	* Measure luminescence using a plate reader.
3. **Annexin V/PI Staining and Flow Cytometry**
	* Stain cells with Annexin V-FITC and PI.
	* Analyze cells using flow cytometry and gate on Annexin V+ and PI+ populations.

**Objective 2: Investigate the mechanism of action**

**Protocol 2.1: Co-Immunoprecipitation and Mass Spectrometry**

1. **Co-Immunoprecipitation**
	* Lyse cells using IP lysis buffer and immunoprecipitate proteins using anti-MALT1 or anti-BCR antibodies.
	* Elute proteins using IP elution buffer.
2. **Mass Spectrometry**
	* Analyze eluted proteins using LC-MS/MS.
	* Identify interacting proteins using protein database searches.

**Protocol 2.2: Signaling Pathway Analysis**

1. **Phospho-Protein Arrays**
	* Lyse cells using phospho-protein lysis buffer.
	* Analyze phosphorylated proteins using phospho-protein arrays.
2. **Western Blot**
	* Analyze key signaling molecules (e.g., NF-κB, ERK, AKT) using Western blot.

**Protocol 2.3: Gene Expression Profiling**

1. **RNA-seq**
	* Extract RNA using TRIzol and prepare libraries using TruSeq RNA Library Prep Kit.
	* Sequence libraries using Illumina HiSeq.
2. **Microarray Analysis**
	* Extract RNA using TRIzol and label using Cy3 or Cy5.
	* Hybridize labeled RNA to microarray slides and scan using a microarray scanner.

**Objective 3: Evaluate therapeutic efficacy in vivo**

**Protocol 3.1: Mouse Models**

1. **MCL Xenograft Models**
	* Inject 1 x 10^6 MCL cells into the flanks of immunodeficient mice (e.g., NOD/SCID).
	* Monitor tumor growth and volume using calipers.

**Protocol 3.2: Treatment Groups**

1. **Vehicle Control**
	* Inject vehicle control (PBS) into mice.
2. **MALT1 Inhibitor Alone**
	* Inject MALT1 inhibitor (1 mg/kg) into mice.
3. **BCR Inhibitor Alone**
	* Inject BCR inhibitor (1 mg/kg) into mice.
4. **Combination Treatment**
	* Inject combination of MALT1 and BCR inhibitors (1 mg/kg each) into mice.

**Protocol 3.3: Tumor Monitoring**

1. **Tumor Volume**
	* Measure tumor volume using calipers.
2. **Tumor Weight**
	* Harvest tumors and weigh using a balance.
3. **Bioluminescence**
	* Inject luciferin into mice and measure bioluminescence using a bioluminescence imager.

**Protocol 3.4: Survival Analysis**

1. **Kaplan-Meier Analysis**
	* Monitor mouse survival and perform Kaplan-Meier analysis using GraphPad Prism.

**Objective 4: Investigate potential biomarkers**

**Protocol 4.1: Patient Samples**

1. **MCL Patient Samples**
	* Collect MCL patient samples and extract RNA and protein.
2. **MYC Expression**
	* Analyze MYC expression using qRT-PCR and Western blot.
3. **MALT1 and BCR Signaling Activity**
	* Analyze MALT1 and BCR signaling activity using Western blot and phospho-protein arrays.

**Protocol 4.2: Correlative Studies**

1. **Correlate In Vitro and In Vivo Results**
	* Correlate in vitro and in vivo results with clinical outcomes (e.g., response rate, progression-free survival).

**Experiment to DISPROVE the hypothesis**

**Protocol 5.1: CRISPR-Cas9 Genome Editing**

1. **MALT1 or BCR Signaling Re-activation**
	* Design guide RNAs targeting MALT1 or BCR signaling components.
	* Transfect guide RNAs and Cas9 into MCL cells using electroporation.
	* Select for edited cells using puromycin selection.

**Protocol 5.2: Combination Treatment**

1. **MALT1 and BCR Inhibitors**
	* Treat edited MCL cells with MALT1 and BCR inhibitors (1 μM each).
2. **Re-activation of MALT1 or BCR Signaling**
	* Re-activate MALT1 or BCR signaling using CRISPR-Cas9 edited cells.

**Protocol 5.3: MYC Activity Assessment**

1. **Western Blot**
	* Analyze MYC protein levels using Western blot.
2. **qRT-PCR**
	* Analyze MYC mRNA expression using qRT-PCR.
3. **Luciferase Reporter Assay**
	* Analyze MYC transcriptional activity using luciferase reporter assay.

These detailed protocols provide a step-by-step guide for executing the experimental plan and ensuring replicability and specificity in the results.","```
   MCL Cells  FBS  Penicillin-Streptomycin  L-Glutamine  MALT1 Inhibitor  BCR Inhibitor  Incubation Time  MYC Activity  Cell Viability
0    1.0e+06  10.0             1.0            1.0           1.0           0.0             24.0       0.8         0.9
1    1.5e+06  12.0             1.2            1.2           0.0           1.0             48.0       0.6         0.7
2    2.0e+06  15.0             1.5            1.5           1.0           1.0             72.0       0.4         0.5
3    1.0e+06  10.0             1.0            1.0           0.5           0.5             24.0       0.7         0.8
4    1.2e+06  11.0             1.1            1.1           1.0           0.0             48.0       0.9         0.8
5    1.8e+06  14.0             1.4            1.4           0.0           1.0             72.0       0.5         0.6
6    1.0e+06  10.0             1.0            1.0           1.0           1.0             24.0       0.6         0.7
7    1.5e+06  12.0             1.2            1.2           0.5           0.5             48.0       0.8         0.9
8    2.0e+06  15.0             1.5            1.5           1.0           0.0             72.0       0.4         0.5
9    1.0e+06  10.0             1.0            1.0           0.0           1.0             24.0       0.7         0.8
10   1.2e+06  11.0             1.1            1.1           1.0           1.0             48.0       0.9         0.8
11   1.8e+06  14.0             1.4            1.4           0.5           0.5             72.0       0.5         0.6
12   1.0e+06  10.0             1.0            1.0           1.0           0.0             24.0       0.8         0.9
13   1.5e+06  12.0             1.2            1.2           0.0           1.0             48.0       0.6         0.7
14   2.0e+06  15.0             1.5            1.5           1.0           1.0             72.0       0.4         0.5
15   1.0e+06  10.0             1.0            1.0           0.5           0.5             24.0       0.7         0.8
16   1.2e+06  11.0             1.1            1.1           1.0           0.0             48.0       0.9         0.8
17   1.8e+06  14.0             1.4            1.4           0.0           1.0             72.0       0.5         0.6
18   1.0e+06  10.0             1.0            1.0           1.0           1.0             24.0       0.6         0.7
19   1.5e+06  12.0             1.2            1.2           0.5           0.5             48.0       0.8         0.9
20   2.0e+06  15.0             1.5            1.5           1.0           0.0             72.0       0.4         0.5
21   1.0e+06  10.0             1.0            1.0           0.0           1.0             24.0       0.7         0.8
22   1.2e+06  11.0             1.1            1.1           1.0           1.0             48.0       0.9         0.8
23   1.8e+06  14.0             1.4            1.4           0.5           0.5             72.0       0.5         0.6
24   1.0e+06  10.0             1.0            1.0           1.0           0.0             24.0       0.8         0.9
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5f05ca3c1cb7544add86c99b3964ee8149a535ef.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1ffd7f77b4bb2805992648aabd10f2e8a0357923.summary']",Does simultaneous inhibition of canonical and non-canonical NF-kB signalling in both B cells and synovial cells lead to a synergistic reduction in disease severity and angiogenesis in rheumatoid arthritis patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis:

**Hypothesis:** Does simultaneous inhibition of canonical and non-canonical NF-kB signalling in both B cells and synovial cells lead to a synergistic reduction in disease severity and angiogenesis in rheumatoid arthritis patients?

**Experimental Plan:**

**Objective:** To investigate the effect of simultaneous inhibition of canonical and non-canonical NF-kB signalling in B cells and synovial cells on disease severity and angiogenesis in rheumatoid arthritis patients.

**Design:**

1. **In vitro study:**
	* Isolate B cells and synovial cells from rheumatoid arthritis patients.
	* Treat B cells with a canonical NF-kB inhibitor (e.g., BAY 11-7082) and synovial cells with a non-canonical NF-kB inhibitor (e.g., NIK inhibitor).
	* Co-culture B cells and synovial cells in a 3D model of synovial angiogenesis (as described in the 2017 paper).
	* Measure angiogenesis using techniques such as tube formation assays, cell migration assays, and confocal microscopy.
	* Analyze the expression of angiogenic factors (e.g., VEGF, bFGF) and inflammatory markers (e.g., TNF-α, IL-1β) using qRT-PCR, ELISA, or Western blot.
2. **In vivo study:**
	* Recruit rheumatoid arthritis patients and randomly assign them to one of four groups:
		+ Group 1: Placebo control
		+ Group 2: Canonical NF-kB inhibitor (BAY 11-7082) treatment
		+ Group 3: Non-canonical NF-kB inhibitor (NIK inhibitor) treatment
		+ Group 4: Combination of canonical and non-canonical NF-kB inhibitors
	* Administer the inhibitors or placebo for a predetermined period (e.g., 12 weeks).
	* Assess disease severity using DAS28 and HAQ scores at baseline, 6 weeks, and 12 weeks.
	* Collect blood samples at each time point to analyze biomarkers of angiogenesis and inflammation.

**To disprove the hypothesis:**

**Null Hypothesis:** Simultaneous inhibition of canonical and non-canonical NF-kB signalling in both B cells and synovial cells does not lead to a synergistic reduction in disease severity and angiogenesis in rheumatoid arthritis patients.

**Alternative Experimental Design:**

1. **In vitro study:**
	* Perform the same co-culture experiment as described above, but with a twist: use a non-specific inhibitor (e.g., DMSO) instead of the canonical NF-kB inhibitor in the B cells.
	* This would test whether the non-canonical NF-kB inhibitor alone is responsible for the potential synergistic effect.
2. **In vivo study:**
	* Recruit rheumatoid arthritis patients and randomly assign them to one of two groups:
		+ Group 1: Non-canonical NF-kB inhibitor (NIK inhibitor) treatment
		+ Group 2: Combination of non-canonical NF-kB inhibitor and a non-specific inhibitor (e.g., DMSO) treatment
	* Assess disease severity and biomarkers as described above.

**Rationale:**

By using a non-specific inhibitor in the alternative design, we can test whether the combination of canonical and non-canonical NF-kB inhibitors is truly synergistic or if the non-canonical inhibitor alone is responsible for the effect. If the results show no significant difference between the groups, it would suggest that the hypothesis is false, and the combination of inhibitors does not lead to a synergistic reduction in disease severity and angiogenesis.

**Timeline and Budget:**

The experiment can be completed within 12-18 months, depending on the availability of resources and the complexity of the in vivo study. The budget will depend on the cost of the inhibitors, cell culture reagents, and equipment, as well as the number of patients recruited for the in vivo study. A rough estimate for the budget would be $200,000 - $500,000.

**Limitations:**

1. The in vitro study may not accurately reflect the in vivo situation.
2. The in vivo study may be limited by the small sample size and the complexity of the disease.
3. The inhibitors used may have off-target effects or interact with other signalling pathways.

By following this experimental plan, we can test the hypothesis and determine whether simultaneous inhibition of canonical and non-canonical NF-kB signalling in both B cells and synovial cells leads to a synergistic reduction in disease severity and angiogenesis in rheumatoid arthritis patients.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**In Vitro Study:**

**Protocol 1: Cell Isolation and Culture**

1.1. Obtain blood samples from rheumatoid arthritis patients and isolate B cells using a magnetic-activated cell sorting (MACS) system or fluorescence-activated cell sorting (FACS) according to the manufacturer's instructions.

1.2. Isolate synovial cells from rheumatoid arthritis patients using enzymatic digestion and subsequent cell sorting.

1.3. Culture B cells and synovial cells in separate flasks with complete RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

**Protocol 2: Inhibitor Treatment and Co-Culture**

2.1. Treat B cells with 10 μM BAY 11-7082 (canonical NF-kB inhibitor) or DMSO (control) for 2 hours.

2.2. Treat synovial cells with 10 μM NIK inhibitor (non-canonical NF-kB inhibitor) or DMSO (control) for 2 hours.

2.3. Co-culture B cells and synovial cells in a 3D model of synovial angiogenesis using a collagen-based scaffold or a microfluidic device.

2.4. Incubate the co-culture for 24-48 hours at 37°C, 5% CO2.

**Protocol 3: Angiogenesis Assays**

3.1. Perform tube formation assays using a commercial kit according to the manufacturer's instructions.

3.2. Perform cell migration assays using a transwell migration chamber according to the manufacturer's instructions.

3.3. Perform confocal microscopy to visualize and quantify angiogenic structures.

**Protocol 4: Gene Expression Analysis**

4.1. Extract total RNA from co-cultured cells using a commercial RNA extraction kit according to the manufacturer's instructions.

4.2. Perform qRT-PCR using specific primers for angiogenic factors (e.g., VEGF, bFGF) and inflammatory markers (e.g., TNF-α, IL-1β).

4.3. Analyze protein expression using ELISA or Western blot according to standard protocols.

**In Vivo Study:**

**Protocol 1: Patient Recruitment and Randomization**

1.1. Recruit rheumatoid arthritis patients and randomly assign them to one of four groups: placebo control, canonical NF-kB inhibitor (BAY 11-7082) treatment, non-canonical NF-kB inhibitor (NIK inhibitor) treatment, or combination of canonical and non-canonical NF-kB inhibitors.

**Protocol 2: Inhibitor Administration**

2.1. Administer the assigned treatment or placebo to patients for a predetermined period (e.g., 12 weeks).

2.2. Monitor patients for adverse effects and adjust dosages as necessary.

**Protocol 3: Disease Severity Assessment**

3.1. Assess disease severity using DAS28 and HAQ scores at baseline, 6 weeks, and 12 weeks.

3.2. Collect blood samples at each time point to analyze biomarkers of angiogenesis and inflammation.

**Protocol 4: Biomarker Analysis**

4.1. Analyze biomarkers of angiogenesis and inflammation using ELISA or multiplex assays according to standard protocols.

**Alternative Experimental Design:**

**In Vitro Study:**

**Protocol 1: Cell Isolation and Culture**

1.1. Perform the same cell isolation and culture protocol as described above.

**Protocol 2: Inhibitor Treatment and Co-Culture**

2.1. Treat B cells with 10 μM DMSO (non-specific inhibitor) instead of BAY 11-7082.

2.2. Perform the same co-culture and incubation protocol as described above.

**Protocol 3: Angiogenesis Assays and Gene Expression Analysis**

3.1. Perform the same angiogenesis assays and gene expression analysis as described above.

**In Vivo Study:**

**Protocol 1: Patient Recruitment and Randomization**

1.1. Recruit rheumatoid arthritis patients and randomly assign them to one of two groups: non-canonical NF-kB inhibitor (NIK inhibitor) treatment or combination of non-canonical NF-kB inhibitor and a non-specific inhibitor (e.g., DMSO) treatment.

**Protocol 2: Inhibitor Administration and Disease Severity Assessment**

2.1. Perform the same inhibitor administration and disease severity assessment protocols as described above.

**Protocol 3: Biomarker Analysis**

3.1. Perform the same biomarker analysis as described above.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   BAY 11-7082 (μM)  NIK inhibitor (μM)  FBS (%)  L-glutamine (%)  Outcome
0               5.0               5.0      10.0           1.0  Inhibited
1               7.5               2.5      12.0           1.2  Partially Inhibited
2              10.0               0.0      11.0           1.1  Not Inhibited
3               2.5               7.5      9.0            0.9  Partially Inhibited
4               0.0               10.0      13.0           1.3  Not Inhibited
5               5.0               5.0      10.0           1.0  Inhibited
6               7.5               2.5      12.0           1.2  Partially Inhibited
7              10.0               0.0      11.0           1.1  Not Inhibited
8               2.5               7.5      9.0            0.9  Partially Inhibited
9               0.0               10.0      13.0           1.3  Not Inhibited
10              5.0               5.0      10.0           1.0  Inhibited
11              7.5               2.5      12.0           1.2  Partially Inhibited
12             10.0               0.0      11.0           1.1  Not Inhibited
13              2.5               7.5      9.0            0.9  Partially Inhibited
14              0.0               10.0      13.0           1.3  Not Inhibited
15              5.0               5.0      10.0           1.0  Inhibited
16              7.5               2.5      12.0           1.2  Partially Inhibited
17             10.0               0.0      11.0           1.1  Not Inhibited
18              2.5               7.5      9.0            0.9  Partially Inhibited
19              0.0               10.0      13.0           1.3  Not Inhibited
20              5.0               5.0      10.0           1.0  Inhibited
21              7.5               2.5      12.0           1.2  Partially Inhibited
22             10.0               0.0      11.0           1.1  Not Inhibited
23              2.5               7.5      9.0            0.9  Partially Inhibited
24              0.0               10.0      13.0           1.3  Not Inhibited
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3a2e8df1b9999460545e5ce88f6e852febf21cca.summary'],"Does simultaneous inhibition of eIF4E and TEHsp90 also disrupt the oncogenic network in other types of aggressive cancers, such as solid tumors, by modulating the translation and nuclear export of key oncogenic mRNAs?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Efficacy of Combinatorial Inhibition of eIF4E and TEHsp90 in Solid Tumors

**Objective:** To determine if simultaneous inhibition of eIF4E and TEHsp90 disrupts the oncogenic network in solid tumors by modulating the translation and nuclear export of key oncogenic mRNAs.

**Equipment:**

* Cell lines from various solid tumor types (e.g., breast, lung, colon, etc.)
* eIF4E inhibitor (ribavirin)
* TEHsp90 inhibitor (PU-H71)
* siRNA for eIF4E and TEHsp90
* qRT-PCR equipment
* Western blot equipment
* Cell culture facilities
* Microscopy equipment

**Steps:**

1. Select and culture cell lines from various solid tumor types.
2. Treat cells with eIF4E inhibitor (ribavirin), TEHsp90 inhibitor (PU-H71), or a combination of both.
3. Perform qRT-PCR to analyze the expression of key oncogenic mRNAs (e.g., MYC, BCL2, BCL6) in treated cells.
4. Perform Western blot analysis to confirm inhibition of eIF4E and TEHsp90 in treated cells.
5. Use microscopy to observe changes in cell morphology and proliferation.
6. Repeat steps 2-5 using siRNA-mediated knockdown of eIF4E and TEHsp90 to validate the results.
7. Compare the results across different solid tumor types to identify potential differences in response to combinatorial inhibition.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Inefficacy of Combinatorial Inhibition of eIF4E and TEHsp90 in Solid Tumors

**Objective:** To demonstrate that simultaneous inhibition of eIF4E and TEHsp90 does not disrupt the oncogenic network in solid tumors.

**Equipment:**

* Same as above

**Steps:**

1. Select a solid tumor cell line that is known to be resistant to eIF4E inhibition (e.g., a cell line with high levels of eIF4E phosphorylation).
2. Treat cells with a high dose of eIF4E inhibitor (ribavirin) and TEHsp90 inhibitor (PU-H71) simultaneously.
3. Perform qRT-PCR to analyze the expression of key oncogenic mRNAs (e.g., MYC, BCL2, BCL6) in treated cells.
4. Perform Western blot analysis to confirm inhibition of eIF4E and TEHsp90 in treated cells.
5. Use microscopy to observe changes in cell morphology and proliferation.
6. Compare the results to untreated controls and cells treated with single inhibitors to demonstrate that combinatorial inhibition does not have a significant effect on the oncogenic network.

**Rationale:**

The experiment to disprove the hypothesis is designed to test the hypothesis in a scenario where it is least likely to be true. By using a cell line resistant to eIF4E inhibition and high doses of both inhibitors, we can attempt to demonstrate that combinatorial inhibition is ineffective in disrupting the oncogenic network. If the results show that combinatorial inhibition has no significant effect, it would suggest that the hypothesis is false. However, if the results still show a significant effect, it would further support the original hypothesis.

**Timeline and Budget:**

The experimental plan can be completed within 6-9 months, depending on the availability of resources and personnel. The budget will be primarily allocated to:

* Cell lines and reagents (30%)
* Equipment maintenance and consumables (20%)
* Personnel and labor costs (30%)
* Miscellaneous (20%)

The estimated budget for the entire project is approximately $150,000-$200,000.",85,"Here are the detailed, step-by-step protocols for the experimental plan to test the hypothesis and the experiment to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Protocol 1: Cell Line Selection and Culture**

1.1. Obtain cell lines from various solid tumor types (e.g., breast, lung, colon, etc.) from a reputable cell bank or laboratory.

1.2. Thaw the cell lines according to the supplier's instructions and culture them in a humidified incubator at 37°C, 5% CO2.

1.3. Use a sterile technique to passage the cells every 3-4 days to maintain a healthy and exponentially growing culture.

1.4. Verify the identity and authenticity of the cell lines using short tandem repeat (STR) profiling or other methods.

**Protocol 2: Inhibitor Treatment**

2.1. Prepare stock solutions of eIF4E inhibitor (ribavirin) and TEHsp90 inhibitor (PU-H71) according to the manufacturer's instructions.

2.2. Dilute the stock solutions to the desired working concentrations (e.g., 10 μM ribavirin and 1 μM PU-H71) in cell culture medium.

2.3. Treat the cells with the following conditions:
	* Control: untreated cells
	* eIF4E inhibitor: cells treated with 10 μM ribavirin
	* TEHsp90 inhibitor: cells treated with 1 μM PU-H71
	* Combinatorial inhibition: cells treated with 10 μM ribavirin and 1 μM PU-H71

2.4. Incubate the cells for 24-48 hours to allow for inhibitor uptake and effect.

**Protocol 3: qRT-PCR Analysis**

3.1. Harvest the cells and extract total RNA using a commercial RNA extraction kit (e.g., TRIzol).

3.2. Perform cDNA synthesis using a reverse transcription kit (e.g., High-Capacity cDNA Reverse Transcription Kit).

3.3. Design and synthesize primers for the target oncogenic mRNAs (e.g., MYC, BCL2, BCL6) using a primer design tool (e.g., Primer3).

3.4. Perform qRT-PCR using a commercial qRT-PCR kit (e.g., PowerUp SYBR Green Master Mix) and a qRT-PCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).

3.5. Analyze the qRT-PCR data using the ΔΔCt method to calculate the relative expression levels of the target mRNAs.

**Protocol 4: Western Blot Analysis**

4.1. Harvest the cells and extract total protein using a commercial protein extraction kit (e.g., RIPA buffer).

4.2. Perform SDS-PAGE using a commercial protein gel (e.g., NuPAGE 4-12% Bis-Tris Gel) and transfer the proteins to a PVDF membrane.

4.3. Block the membrane with a commercial blocking buffer (e.g., 5% non-fat milk) and incubate with primary antibodies against eIF4E and TEHsp90.

4.4. Detect the proteins using a commercial ECL kit (e.g., SuperSignal West Pico PLUS Chemiluminescent Substrate) and a chemiluminescent imaging system (e.g., ChemiDoc XRS+).

4.5. Analyze the Western blot data to confirm inhibition of eIF4E and TEHsp90.

**Protocol 5: Microscopy**

5.1. Seed the cells on a glass coverslip or a 96-well plate.

5.2. Treat the cells with the inhibitors as described in Protocol 2.

5.3. Fix the cells with a commercial fixative (e.g., 4% paraformaldehyde) and permeabilize with a commercial permeabilization buffer (e.g., 0.1% Triton X-100).

5.4. Stain the cells with a commercial nuclear stain (e.g., DAPI) and a commercial cytoskeletal stain (e.g., phalloidin).

5.5. Image the cells using a fluorescence microscope (e.g., Zeiss Axiovert 200M) and analyze the cell morphology and proliferation.

**Protocol 6: siRNA-Mediated Knockdown**

6.1. Design and synthesize siRNAs against eIF4E and TEHsp90 using a commercial siRNA design tool (e.g., siRNA Wizard).

6.2. Transfect the siRNAs into the cells using a commercial transfection reagent (e.g., Lipofectamine RNAiMAX).

6.3. Incubate the cells for 24-48 hours to allow for siRNA uptake and effect.

6.4. Repeat Protocols 3-5 to analyze the effects of siRNA-mediated knockdown on the oncogenic network.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Line Selection and Culture**

1.1. Obtain a solid tumor cell line that is known to be resistant to eIF4E inhibition (e.g., a cell line with high levels of eIF4E phosphorylation).

1.2. Culture the cells as described in Protocol 1 of the experimental plan to test the hypothesis.

**Protocol 2: Inhibitor Treatment**

2.1. Prepare stock solutions of eIF4E inhibitor (ribavirin) and TEHsp90 inhibitor (PU-H71) as described in Protocol 2 of the experimental plan to test the hypothesis.

2.2. Treat the cells with a high dose of eIF4E inhibitor (e.g., 50 μM ribavirin) and TEHsp90 inhibitor (e.g., 5 μM PU-H71) simultaneously.

2.3. Incubate the cells for 24-48 hours to allow for inhibitor uptake and effect.

**Protocol 3: qRT-PCR Analysis**

3.1. Perform qRT-PCR analysis as described in Protocol 3 of the experimental plan to test the hypothesis.

**Protocol 4: Western Blot Analysis**

4.1. Perform Western blot analysis as described in Protocol 4 of the experimental plan to test the hypothesis.

**Protocol 5: Microscopy**

5.1. Perform microscopy as described in Protocol 5 of the experimental plan to test the hypothesis.

**Protocol 6: Data Analysis**

6.1. Compare the results of the experiment to disprove the hypothesis to the results of the experimental plan to test the hypothesis.

6.2. Analyze the data to determine if combinatorial inhibition has a significant effect on the oncogenic network in the resistant cell line.

Note: The protocols above are detailed and specific, but may require adjustments based on the specific requirements of the laboratory and the research question. It is essential to follow proper laboratory protocols, safety guidelines, and quality control measures to ensure the accuracy and reproducibility of the results.","```
   Cell_Line  Ribavirin  PU-H71  MYC  BCL2  BCL6  eIF4E  TEHsp90  Outcome
0       Breast       5.0     0.5  0.8  0.6  0.4    0.3     0.2  Inhibited
1       Lung        10.0     1.0  0.5  0.4  0.3    0.2     0.1  Inhibited
2       Colon        7.5     0.75  0.6  0.5  0.4    0.3     0.2  Inhibited
3       Breast       2.5     0.25  0.9  0.7  0.5    0.4     0.3  Not_Inhibited
4       Lung         5.0     0.5  0.8  0.6  0.4    0.3     0.2  Inhibited
5       Colon       12.5     1.25  0.4  0.3  0.2    0.2     0.1  Inhibited
6       Breast       7.5     0.75  0.6  0.5  0.4    0.3     0.2  Inhibited
7       Lung         2.5     0.25  0.9  0.7  0.5    0.4     0.3  Not_Inhibited
8       Colon       10.0     1.0  0.5  0.4  0.3    0.2     0.1  Inhibited
9       Breast       5.0     0.5  0.8  0.6  0.4    0.3     0.2  Inhibited
10      Lung        12.5     1.25  0.4  0.3  0.2    0.2     0.1  Inhibited
11      Colon        7.5     0.75  0.6  0.5  0.4    0.3     0.2  Inhibited
12      Breast       2.5     0.25  0.9  0.7  0.5    0.4     0.3  Not_Inhibited
13      Lung         5.0     0.5  0.8  0.6  0.4    0.3     0.2  Inhibited
14      Colon       10.0     1.0  0.5  0.4  0.3    0.2     0.1  Inhibited
15      Breast       7.5     0.75  0.6  0.5  0.4    0.3     0.2  Inhibited
16      Lung         2.5     0.25  0.9  0.7  0.5    0.4     0.3  Not_Inhibited
17      Colon       12.5     1.25  0.4  0.3  0.2    0.2     0.1  Inhibited
18      Breast       5.0     0.5  0.8  0.6  0.4    0.3     0.2  Inhibited
19      Lung        10.0     1.0  0.5  0.4  0.3    0.2     0.1  Inhibited
20      Colon        7.5     0.75  0.6  0.5  0.4    0.3     0.2  Inhibited
21      Breast       2.5     0.25  0.9  0.7  0.5    0.4     0.3  Not_Inhibited
22      Lung         5.0     0.5  0.8  0.6  0.4    0.3     0.2  Inhibited
23      Colon       10.0     1.0  0.5  0.4  0.3    0.2     0.1  Inhibited
24      Breast       7.5     0.75  0.6  0.5  0.4    0.3     0.2  Inhibited
```",0.23779139663948587
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/21364863f247a51d71aa8d692bca52221913d152.summary'],"Does siponimod's neuroprotective effect in secondary progressive multiple sclerosis patients involve the modulation of microglial activation and subsequent reduction of pro-inflammatory cytokine release, thereby contributing to the observed reduction in disability progression?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that siponimod's neuroprotective effect in secondary progressive multiple sclerosis patients involves the modulation of microglial activation and subsequent reduction of pro-inflammatory cytokine release, thereby contributing to the observed reduction in disability progression.

**Experiment Title:** Investigating the Role of Microglial Activation and Pro-Inflammatory Cytokine Release in Siponimod's Neuroprotective Effects in Secondary Progressive Multiple Sclerosis

**Objective:** To determine if siponimod's neuroprotective effects in secondary progressive multiple sclerosis patients are mediated by the modulation of microglial activation and subsequent reduction of pro-inflammatory cytokine release.

**Experimental Design:**

**In Vitro Study:**

1. **Cell Culture:** Isolate and culture human microglial cells (e.g., THP-1 or primary human microglia) and astrocytes (e.g., human astrocyte cell lines).
2. **Siponimod Treatment:** Treat microglial cells with siponimod at various concentrations (e.g., 0.1-10 μM) for 24-48 hours.
3. **Microglial Activation Assay:** Measure microglial activation using flow cytometry or immunofluorescence staining for markers such as CD40, CD86, and MHC-II.
4. **Cytokine Release Assay:** Measure pro-inflammatory cytokine release (e.g., TNF-α, IL-1β, and IL-6) in the supernatant using ELISA or multiplex assays.
5. **Co-Culture Experiment:** Co-culture siponimod-treated microglial cells with astrocytes and measure astrocyte viability and activation using Western blotting and cell viability assays.

**In Vivo Study:**

1. **Animal Model:** Use a well-established animal model of secondary progressive multiple sclerosis, such as the Theiler's murine encephalomyelitis virus (TMEV) model.
2. **Siponimod Administration:** Administer siponimod to animals via oral gavage or intraperitoneal injection at a dose equivalent to the human therapeutic dose.
3. **Microglial Activation and Cytokine Release Analysis:** Analyze microglial activation and pro-inflammatory cytokine release in the central nervous system (CNS) using immunohistochemistry, flow cytometry, or ELISA.
4. **Behavioral and Histopathological Analysis:** Assess disability progression using behavioral tests (e.g., rotarod, open field) and histopathological analysis of CNS tissue.

**Experimental Controls:**

* Vehicle-treated microglial cells and animals
* Siponimod-treated microglial cells and animals with microglial activation and cytokine release inhibitors (e.g., minocycline, anti-TNF-α antibodies)

**Expected Outcomes:**

* If the hypothesis is true, siponimod treatment should reduce microglial activation and pro-inflammatory cytokine release in vitro and in vivo, leading to improved astrocyte viability and reduced disability progression in animals.
* If the hypothesis is false, siponimod treatment should not affect microglial activation and pro-inflammatory cytokine release, and astrocyte viability and disability progression should remain unchanged.

**Equipment and Resources:**

* Cell culture facilities and equipment
* Flow cytometer and immunofluorescence microscope
* ELISA and multiplex assay equipment
* Western blotting equipment
* Animal housing and behavioral testing facilities
* Histopathology equipment and expertise
* Siponimod and microglial activation and cytokine release inhibitors

**Timeline:**

* In vitro study: 6-9 months
* In vivo study: 12-18 months
* Data analysis and manuscript preparation: 6-12 months

This experiment is designed to test the hypothesis and provide mechanistic insights into siponimod's neuroprotective effects in secondary progressive multiple sclerosis. The unlimited budget allows for the use of cutting-edge techniques and equipment, ensuring a comprehensive and rigorous investigation.",85,"Here are the detailed, step-by-step protocols for the experiment:

**In Vitro Study:**

**Protocol 1: Cell Culture**

1.1. Obtain human microglial cells (THP-1 or primary human microglia) and astrocytes (human astrocyte cell lines) from a reputable cell bank or isolate them from human brain tissue using established protocols.

1.2. Culture microglial cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.3. Culture astrocytes in DMEM/F-12 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.4. Passage cells every 3-4 days to maintain optimal cell density and viability.

**Protocol 2: Siponimod Treatment**

2.1. Prepare siponimod stock solutions in DMSO at concentrations of 1 mM, 10 mM, and 100 mM.

2.2. Dilute siponimod stock solutions in culture medium to achieve final concentrations of 0.1 μM, 1 μM, and 10 μM.

2.3. Treat microglial cells with siponimod at the desired concentrations for 24-48 hours.

2.4. Use vehicle-treated microglial cells as controls (DMSO at the same concentration as the highest siponimod concentration).

**Protocol 3: Microglial Activation Assay**

3.1. Harvest microglial cells and stain with fluorescently labeled antibodies against CD40, CD86, and MHC-II (e.g., FITC-conjugated anti-CD40, PE-conjugated anti-CD86, and APC-conjugated anti-MHC-II).

3.2. Analyze microglial activation using flow cytometry (e.g., BD FACSCanto II) and quantify the percentage of positive cells and mean fluorescence intensity.

3.3. Alternatively, perform immunofluorescence staining on fixed microglial cells using the same antibodies and analyze using a fluorescence microscope (e.g., Zeiss Axiovert 200M).

**Protocol 4: Cytokine Release Assay**

4.1. Collect supernatants from siponimod-treated microglial cells and centrifuge at 1,000 x g for 5 minutes to remove debris.

4.2. Measure pro-inflammatory cytokine release (TNF-α, IL-1β, and IL-6) using ELISA kits (e.g., R&D Systems) according to the manufacturer's instructions.

4.3. Alternatively, use multiplex assays (e.g., Luminex) to measure multiple cytokines simultaneously.

**Protocol 5: Co-Culture Experiment**

5.1. Co-culture siponimod-treated microglial cells with astrocytes at a 1:1 ratio in a 24-well plate.

5.2. Incubate co-cultures for 24-48 hours and analyze astrocyte viability using a cell viability assay (e.g., MTT or CellTiter-Glo).

5.3. Perform Western blotting to analyze astrocyte activation markers (e.g., GFAP, S100B) using specific antibodies.

**In Vivo Study:**

**Protocol 6: Animal Model**

6.1. Obtain Theiler's murine encephalomyelitis virus (TMEV) from a reputable source and infect C57BL/6 mice (6-8 weeks old) via intracerebral injection.

6.2. Monitor mice for signs of disease progression (e.g., weight loss, paralysis) and sacrifice at 6-8 weeks post-infection.

**Protocol 7: Siponimod Administration**

7.1. Prepare siponimod stock solutions in vehicle (e.g., 0.5% carboxymethylcellulose, 0.25% Tween-80) at a concentration of 10 mg/mL.

7.2. Administer siponimod to mice via oral gavage or intraperitoneal injection at a dose of 10 mg/kg/day, equivalent to the human therapeutic dose.

7.3. Use vehicle-treated mice as controls.

**Protocol 8: Microglial Activation and Cytokine Release Analysis**

8.1. Perfuse mice with PBS and isolate CNS tissue (brain and spinal cord).

8.2. Analyze microglial activation and pro-inflammatory cytokine release in CNS tissue using immunohistochemistry, flow cytometry, or ELISA.

8.3. Use antibodies against microglial markers (e.g., Iba1, CD68) and cytokines (e.g., TNF-α, IL-1β, IL-6) for immunohistochemistry and flow cytometry.

**Protocol 9: Behavioral and Histopathological Analysis**

9.1. Perform behavioral tests (e.g., rotarod, open field) to assess disability progression in mice.

9.2. Fix CNS tissue in 4% paraformaldehyde and section for histopathological analysis (e.g., H&E, Luxol fast blue).

9.3. Analyze CNS tissue for demyelination, axonal damage, and inflammation using established protocols.

**Experimental Controls:**

* Vehicle-treated microglial cells and animals
* Siponimod-treated microglial cells and animals with microglial activation and cytokine release inhibitors (e.g., minocycline, anti-TNF-α antibodies)

**Data Analysis:**

* Compare microglial activation, cytokine release, and astrocyte viability between siponimod-treated and vehicle-treated groups using statistical software (e.g., GraphPad Prism).
* Analyze behavioral and histopathological data using established methods (e.g., two-way ANOVA, Student's t-test).

**Timeline:**

* In vitro study: 6-9 months
* In vivo study: 12-18 months
* Data analysis and manuscript preparation: 6-12 months","```
   Microglial Cells  Astrocytes  Siponimod (μM)  FBS (%)  L-Glutamine (%)  Penicillin-Streptomycin (%)  Outcome
0              10000       5000           0.1       10               1                    1        20.5
1              15000       7500           1.0       10               1                    1        35.1
2               5000       2500           0.1       15               1                    1        18.2
3              20000      10000           10.0       10               1                    1        50.8
4               7500       3750           0.1       10               1                    1        22.9
5              12000       6000           1.0       15               1                    1        40.3
6               8000       4000           0.1       10               1                    1        25.6
7              18000       9000           10.0       10               1                    1        55.2
8              10000       5000           0.1       10               1                    1        21.1
9              14000       7000           1.0       15               1                    1        42.5
10              6000       3000           0.1       10               1                    1        19.8
11              22000      11000           10.0       10               1                    1        58.5
12              9000       4500           0.1       10               1                    1        24.3
13              16000       8000           1.0       15               1                    1        45.7
14              7000       3500           0.1       10               1                    1        20.9
15              24000      12000           10.0       10               1                    1        61.8
16              10000       5000           0.1       10               1                    1        22.5
17              18000       9000           1.0       15               1                    1        48.9
18              5000       2500           0.1       10               1                    1        19.2
19              26000      13000           10.0       10               1                    1        65.1
20              11000       5500           0.1       10               1                    1        23.8
21              20000      10000           1.0       15               1                    1        51.3
22              6000       3000           0.1       10               1                    1        20.2
23              28000      14000           10.0       10               1                    1        68.4
24              13000       6500           0.1       10               1                    1        25.1
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/98b1deec7bf25693007d08472c21c910589370ec.summary'],Does survivin-mediated regulation of PBX1 expression in CD4+ T cells influence the development of the CD4+CD161+CCR2+CCR5+ T cell subset associated with therapeutic resistance in Rheumatoid Arthritis?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis: ""Does survivin-mediated regulation of PBX1 expression in CD4+ T cells influence the development of the CD4+CD161+CCR2+CCR5+ T cell subset associated with therapeutic resistance in Rheumatoid Arthritis?""

**Experimental Plan:**

**Objective:** To investigate the role of survivin-mediated regulation of PBX1 expression in CD4+ T cells on the development of the CD4+CD161+CCR2+CCR5+ T cell subset associated with therapeutic resistance in Rheumatoid Arthritis.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate CD4+ T cells from peripheral blood mononuclear cells (PBMCs) of Rheumatoid Arthritis patients using magnetic bead separation.
	* Culture the isolated CD4+ T cells in the presence of anti-CD3 and anti-CD28 antibodies to stimulate T cell activation.
2. **Survivin Inhibition:**
	* Use a survivin-specific inhibitor (e.g., YM155) to inhibit survivin activity in the cultured CD4+ T cells.
	* Validate the inhibition of survivin using Western blot or qPCR.
3. **PBX1 Expression Analysis:**
	* Measure PBX1 expression in the survivin-inhibited CD4+ T cells using qPCR or Western blot.
	* Compare PBX1 expression levels between survivin-inhibited and control CD4+ T cells.
4. **CD4+CD161+CCR2+CCR5+ T Cell Subset Analysis:**
	* Use flow cytometry to analyze the expression of CD161, CCR2, and CCR5 on the surface of CD4+ T cells.
	* Compare the frequency and phenotype of the CD4+CD161+CCR2+CCR5+ T cell subset between survivin-inhibited and control CD4+ T cells.
5. **Functional Assays:**
	* Measure the production of pro-inflammatory cytokines (e.g., TNF-α, IL-17) from the CD4+CD161+CCR2+CCR5+ T cell subset using ELISA or intracellular cytokine staining.
	* Compare the functional responses of the CD4+CD161+CCR2+CCR5+ T cell subset between survivin-inhibited and control CD4+ T cells.

**Hypothesis Testing:**

* If the frequency and phenotype of the CD4+CD161+CCR2+CCR5+ T cell subset are reduced in survivin-inhibited CD4+ T cells, it would support the hypothesis that survivin-mediated regulation of PBX1 expression influences the development of this T cell subset.
* If the functional responses of the CD4+CD161+CCR2+CCR5+ T cell subset are impaired in survivin-inhibited CD4+ T cells, it would further support the hypothesis.

**Control Experiments:**

* Use a non-specific inhibitor or a vehicle control to validate the specificity of the survivin inhibitor.
* Use CD4+ T cells from healthy donors as a control to compare with Rheumatoid Arthritis patient-derived CD4+ T cells.

**Equipment and Reagents:**

* Flow cytometer
* qPCR machine
* Western blot equipment
* ELISA plate reader
* Magnetic bead separator
* Anti-CD3 and anti-CD28 antibodies
* Survivin-specific inhibitor (e.g., YM155)
* Non-specific inhibitor or vehicle control
* CD4+ T cell isolation kit
* PBX1-specific antibodies for Western blot or qPCR
* CD161, CCR2, and CCR5-specific antibodies for flow cytometry

**Timeline:**

* Cell isolation and culture: 2-3 days
* Survivin inhibition and PBX1 expression analysis: 3-4 days
* CD4+CD161+CCR2+CCR5+ T cell subset analysis: 2-3 days
* Functional assays: 2-3 days
* Data analysis and interpretation: 2-3 weeks

**Budget:**

* Reagents and consumables: $5,000 - $7,000
* Equipment usage fees: $2,000 - $3,000
* Personnel and labor costs: $10,000 - $15,000
* Total budget: $17,000 - $25,000

This experiment is designed to test the hypothesis and can be completed within a reasonable timeframe (approximately 6-8 weeks) and budget. The results will provide valuable insights into the role of survivin-mediated regulation of PBX1 expression in CD4+ T cells on the development of the CD4+CD161+CCR2+CCR5+ T cell subset associated with therapeutic resistance in Rheumatoid Arthritis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Culture**

1.1. Prepare the necessary materials:
	* Peripheral blood mononuclear cells (PBMCs) from Rheumatoid Arthritis patients
	* CD4+ T cell isolation kit
	* Anti-CD3 and anti-CD28 antibodies
	* Cell culture medium (e.g., RPMI 1640 with 10% FBS)
	* 24-well plate

1.2. Isolate CD4+ T cells from PBMCs using magnetic bead separation:
	* Follow the manufacturer's instructions for the CD4+ T cell isolation kit
	* Resuspend the isolated CD4+ T cells in cell culture medium at a concentration of 1 x 10^6 cells/mL

1.3. Culture the isolated CD4+ T cells:
	* Add 1 mL of the CD4+ T cell suspension to each well of a 24-well plate
	* Add 1 μg/mL of anti-CD3 and 1 μg/mL of anti-CD28 antibodies to each well
	* Incubate the plate at 37°C, 5% CO2 for 2-3 days to stimulate T cell activation

**Protocol 2: Survivin Inhibition**

2.1. Prepare the necessary materials:
	* Survivin-specific inhibitor (e.g., YM155)
	* DMSO (vehicle control)
	* Non-specific inhibitor (control)

2.2. Inhibit survivin activity in the cultured CD4+ T cells:
	* Add 1 μM of YM155 to the culture medium of half of the wells (survivin-inhibited group)
	* Add an equal volume of DMSO to the culture medium of the other half of the wells (vehicle control group)
	* Add 1 μM of non-specific inhibitor to the culture medium of a separate set of wells (non-specific inhibitor control group)
	* Incubate the plate at 37°C, 5% CO2 for 3-4 days

2.3. Validate the inhibition of survivin:
	* Collect the cells from each group and perform Western blot or qPCR to measure survivin expression
	* Compare the survivin expression levels between the survivin-inhibited, vehicle control, and non-specific inhibitor control groups

**Protocol 3: PBX1 Expression Analysis**

3.1. Prepare the necessary materials:
	* PBX1-specific antibodies for Western blot or qPCR
	* Western blot equipment or qPCR machine

3.2. Measure PBX1 expression in the survivin-inhibited CD4+ T cells:
	* Collect the cells from the survivin-inhibited and control groups
	* Perform Western blot or qPCR to measure PBX1 expression
	* Compare the PBX1 expression levels between the survivin-inhibited and control groups

**Protocol 4: CD4+CD161+CCR2+CCR5+ T Cell Subset Analysis**

4.1. Prepare the necessary materials:
	* CD161, CCR2, and CCR5-specific antibodies for flow cytometry
	* Flow cytometer

4.2. Analyze the expression of CD161, CCR2, and CCR5 on the surface of CD4+ T cells:
	* Collect the cells from the survivin-inhibited and control groups
	* Stain the cells with CD161, CCR2, and CCR5-specific antibodies
	* Analyze the cells using flow cytometry
	* Compare the frequency and phenotype of the CD4+CD161+CCR2+CCR5+ T cell subset between the survivin-inhibited and control groups

**Protocol 5: Functional Assays**

5.1. Prepare the necessary materials:
	* ELISA plate reader
	* Cytokine-specific antibodies for ELISA or intracellular cytokine staining

5.2. Measure the production of pro-inflammatory cytokines:
	* Collect the cells from the survivin-inhibited and control groups
	* Stimulate the cells with PMA and ionomycin for 4-6 hours
	* Measure the production of pro-inflammatory cytokines (e.g., TNF-α, IL-17) using ELISA or intracellular cytokine staining
	* Compare the functional responses of the CD4+CD161+CCR2+CCR5+ T cell subset between the survivin-inhibited and control groups

**Control Experiments**

* Repeat the above protocols using CD4+ T cells from healthy donors as a control to compare with Rheumatoid Arthritis patient-derived CD4+ T cells.

**Data Analysis and Interpretation**

* Analyze the data from each protocol and compare the results between the survivin-inhibited and control groups
* Interpret the results in the context of the hypothesis and draw conclusions about the role of survivin-mediated regulation of PBX1 expression in CD4+ T cells on the development of the CD4+CD161+CCR2+CCR5+ T cell subset associated with therapeutic resistance in Rheumatoid Arthritis.","```
   PBMCs  CD4+ T cell isolation kit  Anti-CD3  Anti-CD28  YM155  DMSO  Non-specific inhibitor  Survivin expression  PBX1 expression  CD4+CD161+CCR2+CCR5+ T cell subset  TNF-α  IL-17
0   1e6  1x  1  1  1  0.1  0  0.5  0.8  0.2  150  100
1   1e6  0.5x  1  1  1  0.1  0  0.4  0.7  0.3  120  90
2   1e6  1x  0.5  1  1  0.1  0  0.6  0.9  0.4  180  120
3   1e6  1x  1  0.5  1  0.1  0  0.5  0.8  0.2  150  100
4   1e6  1x  1  1  0.5  0.1  0  0.3  0.6  0.1  100  80
5   1e6  0.5x  1  1  1  0.1  0  0.4  0.7  0.3  120  90
6   1e6  1x  0.5  1  1  0.1  0  0.6  0.9  0.4  180  120
7   1e6  1x  1  0.5  1  0.1  0  0.5  0.8  0.2  150  100
8   1e6  1x  1  1  0.5  0.1  0  0.3  0.6  0.1  100  80
9   0.5e6  1x  1  1  1  0.1  0  0.4  0.7  0.3  120  90
10  0.5e6  0.5x  1  1  1  0.1  0  0.3  0.6  0.1  100  80
11  0.5e6  1x  0.5  1  1  0.1  0  0.6  0.9  0.4  180  120
12  0.5e6  1x  1  0.5  1  0.1  0  0.5  0.8  0.2  150  100
13  0.5e6  1x  1  1  0.5  0.1  0  0.3  0.6  0.1  100  80
14  2e6  1x  1  1  1  0.1  0  0.5  0.8  0.2  150  100
15  2e6  0.5x  1  1  1  0.1  0  0.4  0.7  0.3  120  90
16  2e6  1x  0.5  1  1  0.1  0  0.6  0.9  0.4  180  120
17  2e6  1x  1  0.5  1  0.1  0  0.5  0.8  0.2  150  100
18  2e6  1x  1  1  0.5  0.1  0  0.3  0.6  0.1  100  80
19  1e6  1x  1  1  1  0.2  0  0.6  0.9  0.4  180  120
20  1e6  0.5x  1  1  1  0.2  0  0.5  0.8  0.2  150  100
21  1e6  1x  0.5  1  1  0.2  0  0.7  1.0  0.5  200  140
22  1e6  1x  1  0.5  1  0.2  0  0.6  0.9  0.4  180  120
23  1e6  1x  1  1  0.5  0.2  0  0.4  0.7  0.3  120  90
24  1e6  1x  1  1  1  0  1  0.2  0.5  0.1  100  80
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/41af7f484680764c469bddc1333e91d570a37b6e.summary'],"Does tRF-3009 modulate the expression of antioxidant enzymes in CD4+ T lymphocytes, thereby influencing the balance between oxidative phosphorylation and oxidative stress in SLE pathogenesis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that tRF-3009 modulates the expression of antioxidant enzymes in CD4+ T lymphocytes, thereby influencing the balance between oxidative phosphorylation and oxidative stress in SLE pathogenesis.

**Experimental Plan:**

**Objective:** To determine if tRF-3009 modulates the expression of antioxidant enzymes in CD4+ T lymphocytes, affecting the balance between oxidative phosphorylation and oxidative stress in SLE pathogenesis.

**Hypothesis to be disproven:** tRF-3009 does not modulate the expression of antioxidant enzymes in CD4+ T lymphocytes, and therefore does not influence the balance between oxidative phosphorylation and oxidative stress in SLE pathogenesis.

**Experimental Design:**

1. **Cell Culture and Transfection:**
	* Isolate CD4+ T lymphocytes from healthy donors and SLE patients.
	* Transfect cells with tRF-3009 or a scrambled control RNA using a suitable transfection reagent.
	* Verify transfection efficiency using qRT-PCR or Western blot.
2. **Antioxidant Enzyme Expression Analysis:**
	* Measure the expression of antioxidant enzymes (e.g., SOD1, CAT, GPx1) in transfected CD4+ T lymphocytes using qRT-PCR and Western blot.
	* Compare the expression levels between tRF-3009-transfected and control cells.
3. **Oxidative Phosphorylation and Oxidative Stress Analysis:**
	* Measure the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using a Seahorse XF analyzer to assess oxidative phosphorylation.
	* Measure reactive oxygen species (ROS) levels using a fluorescent probe (e.g., DCFDA) to assess oxidative stress.
	* Compare the results between tRF-3009-transfected and control cells.
4. **siRNA-mediated Knockdown of Antioxidant Enzymes:**
	* Transfect CD4+ T lymphocytes with siRNA against antioxidant enzymes (e.g., SOD1, CAT, GPx1) to knockdown their expression.
	* Measure the effect of tRF-3009 on oxidative phosphorylation and oxidative stress in siRNA-transfected cells.
5. **Data Analysis:**
	* Compare the results from steps 2-4 to determine if tRF-3009 modulates the expression of antioxidant enzymes and influences the balance between oxidative phosphorylation and oxidative stress in CD4+ T lymphocytes.

**Equipment and Reagents:**

* CD4+ T lymphocytes from healthy donors and SLE patients
* tRF-3009 and scrambled control RNA
* Transfection reagent
* qRT-PCR and Western blot equipment
* Seahorse XF analyzer
* Fluorescent probe (e.g., DCFDA) for ROS measurement
* siRNA against antioxidant enzymes
* Cell culture media and reagents

**Time and Budget:**

* Estimated time: 6-8 weeks
* Estimated budget: $10,000 - $15,000 (depending on the cost of reagents and equipment)

**Rationale:**

This experimental plan aims to disprove the hypothesis that tRF-3009 modulates the expression of antioxidant enzymes in CD4+ T lymphocytes, thereby influencing the balance between oxidative phosphorylation and oxidative stress in SLE pathogenesis. By transfecting CD4+ T lymphocytes with tRF-3009 and measuring the expression of antioxidant enzymes, oxidative phosphorylation, and oxidative stress, we can determine if tRF-3009 has a significant impact on these processes. The siRNA-mediated knockdown of antioxidant enzymes will help to further elucidate the role of tRF-3009 in modulating antioxidant enzyme expression. If the results show no significant difference between tRF-3009-transfected and control cells, it would suggest that tRF-3009 does not modulate the expression of antioxidant enzymes, and therefore does not influence the balance between oxidative phosphorylation and oxidative stress in SLE pathogenesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Transfection**

**Step 1.1: Isolation of CD4+ T Lymphocytes**

* Obtain blood samples from healthy donors and SLE patients.
* Isolate peripheral blood mononuclear cells (PBMCs) using Ficoll-Paque density gradient centrifugation.
* Isolate CD4+ T lymphocytes from PBMCs using magnetic bead-based separation (e.g., Miltenyi Biotec CD4 MicroBeads).
* Wash cells with phosphate-buffered saline (PBS) and resuspend in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

**Step 1.2: Transfection of CD4+ T Lymphocytes**

* Prepare tRF-3009 and scrambled control RNA according to the manufacturer's instructions.
* Transfect 1 x 10^6 CD4+ T lymphocytes with 50 nM tRF-3009 or scrambled control RNA using a suitable transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
* Incubate cells at 37°C, 5% CO2 for 24-48 hours.

**Step 1.3: Verification of Transfection Efficiency**

* Extract total RNA from transfected cells using a RNA extraction kit (e.g., TRIzol).
* Perform qRT-PCR using primers specific to tRF-3009 to verify transfection efficiency.
* Alternatively, perform Western blot analysis using an antibody specific to tRF-3009 to verify transfection efficiency.

**Protocol 2: Antioxidant Enzyme Expression Analysis**

**Step 2.1: RNA Extraction and cDNA Synthesis**

* Extract total RNA from transfected cells using a RNA extraction kit (e.g., TRIzol).
* Synthesize cDNA using a reverse transcription kit (e.g., High-Capacity cDNA Reverse Transcription Kit).

**Step 2.2: qRT-PCR Analysis**

* Perform qRT-PCR using primers specific to antioxidant enzymes (e.g., SOD1, CAT, GPx1) and a reference gene (e.g., GAPDH).
* Analyze the expression levels of antioxidant enzymes in tRF-3009-transfected and control cells.

**Step 2.3: Western Blot Analysis**

* Extract protein from transfected cells using a protein extraction kit (e.g., RIPA buffer).
* Perform Western blot analysis using antibodies specific to antioxidant enzymes (e.g., SOD1, CAT, GPx1) and a reference protein (e.g., β-actin).
* Analyze the expression levels of antioxidant enzymes in tRF-3009-transfected and control cells.

**Protocol 3: Oxidative Phosphorylation and Oxidative Stress Analysis**

**Step 3.1: Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) Measurement**

* Prepare cells for Seahorse XF analyzer analysis according to the manufacturer's instructions.
* Measure OCR and ECAR in tRF-3009-transfected and control cells using a Seahorse XF analyzer.

**Step 3.2: Reactive Oxygen Species (ROS) Measurement**

* Prepare cells for ROS measurement according to the manufacturer's instructions.
* Measure ROS levels in tRF-3009-transfected and control cells using a fluorescent probe (e.g., DCFDA).

**Protocol 4: siRNA-mediated Knockdown of Antioxidant Enzymes**

**Step 4.1: siRNA Transfection**

* Prepare siRNA against antioxidant enzymes (e.g., SOD1, CAT, GPx1) according to the manufacturer's instructions.
* Transfect 1 x 10^6 CD4+ T lymphocytes with 50 nM siRNA using a suitable transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
* Incubate cells at 37°C, 5% CO2 for 24-48 hours.

**Step 4.2: Verification of Knockdown Efficiency**

* Extract protein from siRNA-transfected cells using a protein extraction kit (e.g., RIPA buffer).
* Perform Western blot analysis using antibodies specific to antioxidant enzymes (e.g., SOD1, CAT, GPx1) and a reference protein (e.g., β-actin).
* Verify knockdown efficiency of antioxidant enzymes.

**Step 4.3: Measurement of Oxidative Phosphorylation and Oxidative Stress**

* Measure OCR, ECAR, and ROS levels in siRNA-transfected cells using the same protocols as in Protocol 3.

**Protocol 5: Data Analysis**

* Compare the results from Protocols 2-4 to determine if tRF-3009 modulates the expression of antioxidant enzymes and influences the balance between oxidative phosphorylation and oxidative stress in CD4+ T lymphocytes.
* Perform statistical analysis using suitable software (e.g., GraphPad Prism) to determine significant differences between tRF-3009-transfected and control cells.

Note: The above protocols are detailed and step-by-step, but may require adjustments based on specific laboratory settings and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   tRF-3009 (nM)  Scrambled RNA (nM)  Lipofectamine 2000 (μL)  SOD1 Expression  CAT Expression  GPx1 Expression  OCR  ECAR  ROS Levels
0             50               0               5.0          1.20          1.05          0.90  150.0  120.0       200.0
1             25               0               2.5          1.10          0.95          0.80  140.0  110.0       180.0
2             50              25               5.0          1.30          1.15          1.00  160.0  130.0       220.0
3             75               0               7.5          1.40          1.25          1.10  170.0  140.0       240.0
4             50               0               5.0          1.25          1.10          0.95  155.0  125.0       210.0
5             25              25               2.5          1.15          1.00          0.85  145.0  115.0       190.0
6             50               0               5.0          1.35          1.20          1.05  165.0  135.0       230.0
7             75              25               7.5          1.45          1.30          1.15  175.0  145.0       250.0
8             50               0               5.0          1.20          1.05          0.90  150.0  120.0       200.0
9             25               0               2.5          1.10          0.95          0.80  140.0  110.0       180.0
10            50              25               5.0          1.30          1.15          1.00  160.0  130.0       220.0
11            75               0               7.5          1.40          1.25          1.10  170.0  140.0       240.0
12            50               0               5.0          1.25          1.10          0.95  155.0  125.0       210.0
13            25              25               2.5          1.15          1.00          0.85  145.0  115.0       190.0
14            50               0               5.0          1.35          1.20          1.05  165.0  135.0       230.0
15            75              25               7.5          1.45          1.30          1.15  175.0  145.0       250.0
16            50               0               5.0          1.20          1.05          0.90  150.0  120.0       200.0
17            25               0               2.5          1.10          0.95          0.80  140.0  110.0       180.0
18            50              25               5.0          1.30          1.15          1.00  160.0  130.0       220.0
19            75               0               7.5          1.40          1.25          1.10  170.0  140.0       240.0
20            50               0               5.0          1.25          1.10          0.95  155.0  125.0       210.0
21            25              25               2.5          1.15          1.00          0.85  145.0  115.0       190.0
22            50               0               5.0          1.35          1.20          1.05  165.0  135.0       230.0
23            75              25               7.5          1.45          1.30          1.15  175.0  145.0       250.0
24            50               0               5.0          1.20          1.05          0.90  150.0  120.0       200.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0afd02871c3edc7119551e82338638ed146e4e0e.summary'],Does targeting the ER-mitochondrial interface with PS89 also modulate the unfolded protein response to enhance chemotherapy sensitivity in acute leukemia cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Does targeting the ER-mitochondrial interface with PS89 also modulate the unfolded protein response to enhance chemotherapy sensitivity in acute leukemia cells?""

**Experimental Plan:**

**Objective:** To investigate whether PS89 modulates the unfolded protein response (UPR) to enhance chemotherapy sensitivity in acute leukemia cells by targeting the ER-mitochondrial interface.

**Hypothesis to be disproven:** PS89 does not modulate the UPR to enhance chemotherapy sensitivity in acute leukemia cells.

**Experimental Design:**

1. **Cell Culture and Treatment:**
	* Culture acute leukemia cells (e.g., Jurkat cells) with or without PS89 (at varying concentrations) and chemotherapy (e.g., etoposide) for 24-48 hours.
	* Include a control group without PS89 and chemotherapy.
2. **Unfolded Protein Response (UPR) Analysis:**
	* Measure the expression of UPR-related genes (e.g., ATF4, XBP1, CHOP) using qRT-PCR or Western blotting.
	* Analyze the phosphorylation status of eIF2α, a key regulator of the UPR, using Western blotting.
3. **ER-Mitochondrial Interface Disruption:**
	* Investigate ER-mitochondrial interface disruption using confocal microscopy and co-staining for ER and mitochondrial markers (e.g., calnexin, TOM20).
	* Measure mitochondrial membrane potential and cytosolic calcium levels using flow cytometry and fluorescent dyes (e.g., TMRE, Fluo-4).
4. **Apoptosis Induction:**
	* Analyze apoptosis induction using flow cytometry (e.g., Annexin V/PI staining) and Western blotting for caspase-3 and PARP cleavage.
5. **siRNA Knockdown:**
	* Perform siRNA knockdown of key UPR-related genes (e.g., ATF4, XBP1) to investigate their role in PS89-mediated chemotherapy sensitivity.

**Expected Outcomes:**

* If the hypothesis is true, PS89 treatment will:
	+ Increase the expression of UPR-related genes and phosphorylation of eIF2α.
	+ Disrupt the ER-mitochondrial interface, leading to increased mitochondrial membrane permeabilization and cytosolic calcium levels.
	+ Enhance chemotherapy-induced apoptosis in acute leukemia cells.
* If the hypothesis is false, PS89 treatment will not modulate the UPR or enhance chemotherapy sensitivity in acute leukemia cells.

**Equipment and Resources:**

* Cell culture facilities
* Flow cytometer
* Confocal microscope
* Western blot equipment
* qRT-PCR machine
* siRNA transfection reagents
* Fluorescent dyes (e.g., TMRE, Fluo-4)
* Antibodies for Western blotting and immunofluorescence

**Timeline:**

* Cell culture and treatment: 2-3 weeks
* UPR analysis: 1-2 weeks
* ER-mitochondrial interface disruption analysis: 1-2 weeks
* Apoptosis induction analysis: 1-2 weeks
* siRNA knockdown: 2-3 weeks
* Data analysis and interpretation: 2-3 weeks

**Budget:**

* Cell culture reagents and media: $1,000
* PS89 and chemotherapy: $500
* Antibodies and fluorescent dyes: $1,500
* siRNA transfection reagents: $500
* Equipment maintenance and consumables: $1,000
* Total: $5,000

This experimental plan is designed to test the hypothesis in a reasonable time frame (approximately 12-16 weeks) and within a limited budget. The results will provide valuable insights into the role of PS89 in modulating the UPR and enhancing chemotherapy sensitivity in acute leukemia cells.",85,"Here are the detailed, step-by-step protocols for each experiment outlined in the plan:

**Experiment 1: Cell Culture and Treatment**

**Objective:** To culture acute leukemia cells with or without PS89 and chemotherapy for 24-48 hours.

**Materials:**

* Jurkat cells (acute leukemia cell line)
* PS89 (at varying concentrations: 0.1, 1, 10 μM)
* Etoposide (chemotherapy agent)
* Cell culture media (RPMI-1640 with 10% FBS and 1% penicillin-streptomycin)
* Cell culture flasks (25 cm²)
* Incubator (37°C, 5% CO₂)

**Protocol:**

1.1. Thaw Jurkat cells and culture them in RPMI-1640 media with 10% FBS and 1% penicillin-streptomycin in a 25 cm² cell culture flask.

1.2. Incubate the cells at 37°C, 5% CO₂ for 24 hours to allow for cell recovery.

1.3. Prepare PS89 stock solutions (0.1, 1, 10 μM) in DMSO.

1.4. Add PS89 (0.1, 1, 10 μM) or DMSO (control) to the cell culture media and mix well.

1.5. Add etoposide (10 μM) to the cell culture media and mix well.

1.6. Incubate the cells for 24-48 hours at 37°C, 5% CO₂.

1.7. Harvest the cells for further analysis (UPR analysis, ER-mitochondrial interface disruption, apoptosis induction).

**Experiment 2: Unfolded Protein Response (UPR) Analysis**

**Objective:** To measure the expression of UPR-related genes and phosphorylation of eIF2α.

**Materials:**

* RNA extraction kit
* cDNA synthesis kit
* qRT-PCR primers (ATF4, XBP1, CHOP)
* Western blot equipment
* Antibodies (eIF2α, p-eIF2α)
* Cell lysates from Experiment 1

**Protocol:**

2.1. Extract total RNA from the harvested cells using an RNA extraction kit.

2.2. Synthesize cDNA from the extracted RNA using a cDNA synthesis kit.

2.3. Perform qRT-PCR using the cDNA and primers for ATF4, XBP1, and CHOP.

2.4. Analyze the qRT-PCR data using the ΔΔCt method.

2.5. Prepare cell lysates from the harvested cells for Western blotting.

2.6. Perform Western blotting using antibodies against eIF2α and p-eIF2α.

2.7. Analyze the Western blot data using densitometry software.

**Experiment 3: ER-Mitochondrial Interface Disruption**

**Objective:** To investigate ER-mitochondrial interface disruption using confocal microscopy and flow cytometry.

**Materials:**

* Confocal microscope
* Flow cytometer
* Fluorescent dyes (TMRE, Fluo-4)
* Antibodies (calnexin, TOM20)
* Cell lysates from Experiment 1

**Protocol:**

3.1. Fix the harvested cells with 4% paraformaldehyde for 15 minutes.

3.2. Permeabilize the cells with 0.1% Triton X-100 for 10 minutes.

3.3. Stain the cells with calnexin and TOM20 antibodies for 1 hour.

3.4. Image the cells using a confocal microscope.

3.5. Analyze the images using image analysis software.

3.6. Stain the cells with TMRE and Fluo-4 for 30 minutes.

3.7. Analyze the cells using flow cytometry.

**Experiment 4: Apoptosis Induction**

**Objective:** To analyze apoptosis induction using flow cytometry and Western blotting.

**Materials:**

* Flow cytometer
* Annexin V/PI staining kit
* Western blot equipment
* Antibodies (caspase-3, PARP)
* Cell lysates from Experiment 1

**Protocol:**

4.1. Stain the harvested cells with Annexin V and PI for 15 minutes.

4.2. Analyze the cells using flow cytometry.

4.3. Prepare cell lysates from the harvested cells for Western blotting.

4.4. Perform Western blotting using antibodies against caspase-3 and PARP.

4.5. Analyze the Western blot data using densitometry software.

**Experiment 5: siRNA Knockdown**

**Objective:** To perform siRNA knockdown of key UPR-related genes.

**Materials:**

* siRNA transfection reagents
* siRNA oligos (ATF4, XBP1)
* Cell culture media
* Jurkat cells

**Protocol:**

5.1. Prepare siRNA oligos (ATF4, XBP1) according to the manufacturer's instructions.

5.2. Transfect the siRNA oligos into Jurkat cells using siRNA transfection reagents.

5.3. Incubate the cells for 24-48 hours at 37°C, 5% CO₂.

5.4. Harvest the cells for further analysis (UPR analysis, ER-mitochondrial interface disruption, apoptosis induction).

These detailed protocols should provide a clear guide for executing the experiments outlined in the plan.","```
   PS89 (μM)  Etoposide (μM)  ATF4  XBP1  CHOP  p-eIF2α  ER-Mitochondrial Interface Disruption  Apoptosis Induction
0        0.1           10.0  0.50  0.30  0.20               0.4                       0.30               0.20
1        1.0           10.0  0.70  0.50  0.40               0.6                       0.50               0.40
2       10.0           10.0  0.90  0.70  0.60               0.8                       0.70               0.60
3        0.1            5.0  0.40  0.20  0.10               0.3                       0.20               0.10
4        1.0            5.0  0.60  0.40  0.30               0.5                       0.40               0.30
5       10.0            5.0  0.80  0.60  0.50               0.7                       0.60               0.50
6        0.1           15.0  0.30  0.10  0.00               0.2                       0.10               0.00
7        1.0           15.0  0.50  0.30  0.20               0.4                       0.30               0.20
8       10.0           15.0  0.70  0.50  0.40               0.6                       0.50               0.40
9        0.1            0.0  0.20  0.10  0.00               0.1                       0.00               0.00
10       1.0            0.0  0.40  0.20  0.10               0.3                       0.20               0.10
11      10.0            0.0  0.60  0.40  0.30               0.5                       0.40               0.30
12       0.1           20.0  0.10  0.00  0.00               0.1                       0.00               0.00
13       1.0           20.0  0.30  0.10  0.00               0.2                       0.10               0.00
14      10.0           20.0  0.50  0.30  0.20               0.4                       0.30               0.20
15       0.1            7.5  0.35  0.15  0.05               0.25                      0.15               0.05
16       1.0            7.5  0.55  0.35  0.25               0.45                      0.35               0.25
17      10.0            7.5  0.75  0.55  0.45               0.65                      0.55               0.45
18       0.1           12.5  0.25  0.05  0.00               0.15                      0.05               0.00
19       1.0           12.5  0.45  0.25  0.15               0.35                      0.25               0.15
20      10.0           12.5  0.65  0.45  0.35               0.55                      0.45               0.35
21       0.1            2.5  0.45  0.25  0.15               0.35                      0.25               0.15
22       1.0            2.5  0.65  0.45  0.35               0.55                      0.45               0.35
23      10.0            2.5  0.85  0.65  0.55               0.75                      0.65               0.55
24       0.1            8.0  0.40  0.20  0.10               0.30                      0.20               0.10
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/02be4702905f1957b2009f48966fb8e65de25a55.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/198febefa974be576b11b34991559d210503923f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/70bfe20cb8b0e638e684da85e327a289bd50d884.summary']","Does the ABL kinase regulate the spatial organization of B-cell receptor microclusters and the formation of a central supramolecular activation cluster (cSMAC) through phosphorylation of Arp2/3 complex components, thereby modulating B-cell activation and immune synapse formation?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Does the ABL kinase regulate the spatial organization of B-cell receptor microclusters and the formation of a central supramolecular activation cluster (cSMAC) through phosphorylation of Arp2/3 complex components, thereby modulating B-cell activation and immune synapse formation?

**Experimental Approach:**

**Step 1: Identify ABL phosphorylation sites on Arp2/3 complex components**

* Use kinase assays linked to phosphoproteomics with multiple drug treatments (as described in the 2013 paper) to identify ABL phosphorylation sites on Arp2/3 complex components.
* Validate the identified phosphorylation sites using in vitro and in vivo experiments.

**Step 2: Investigate the effect of ABL on Arp2/3 complex activity and cSMAC formation**

* Use RNAi or CRISPR-Cas9 system to knockdown or knockout ABL in B cells.
* Transfect B cells with a fluorescently-labeled actin probe (e.g. LifeAct-GFP) and a control or Arp2/3 complex-specific siRNA.
* Co-culture the transfected B cells with APCs expressing a membrane-bound antigen.
* Image the B cell-APC contact site using total internal reflection fluorescence (TIRF) microscopy to visualize the actin dynamics.
* Analyze the retrograde flow of actin filaments using kymograph analysis and quantify the velocity and direction of actin flow.
* Compare the results between control and ABL-knockdown/knockout B cells to determine the role of ABL in regulating Arp2/3 complex activity and cSMAC formation.

**Step 3: Investigate the effect of ABL on B-cell activation and immune synapse formation**

* Use flow cytometry to measure the phosphorylation levels of proximal BCR signaling molecules (e.g. CD79a, Syk, PLCγ2) in B cells treated with ABL activators or inhibitors.
* Compare the phosphorylation levels between control and ABL-knockdown/knockout B cells to determine the role of ABL in regulating B-cell activation.
* Use confocal microscopy to visualize the immune synapse formation and cSMAC structure in B cells treated with ABL activators or inhibitors.
* Compare the results between control and ABL-knockdown/knockout B cells to determine the role of ABL in regulating immune synapse formation.

**Step 4: Investigate the effect of Arp2/3 complex phosphorylation on cSMAC formation and B-cell activation**

* Use site-directed mutagenesis to introduce phosphorylation-mimicking mutations on the identified ABL phosphorylation sites on Arp2/3 complex components.
* Transfect B cells with the mutated Arp2/3 complex components and a control or ABL-specific siRNA.
* Co-culture the transfected B cells with APCs expressing a membrane-bound antigen.
* Image the B cell-APC contact site using TIRF microscopy to visualize the actin dynamics.
* Analyze the retrograde flow of actin filaments using kymograph analysis and quantify the velocity and direction of actin flow.
* Compare the results between control and phosphorylation-mimicking mutant B cells to determine the role of Arp2/3 complex phosphorylation in regulating cSMAC formation and B-cell activation.

**Equipment needed:**

* Kinase assays linked to phosphoproteomics with multiple drug treatments
* RNAi or CRISPR-Cas9 system
* Cell culture facilities
* Western blotting equipment
* Flow cytometer
* TIRF microscope
* Fluorescently-labeled actin probe
* siRNA transfection reagents
* APCs expressing membrane-bound antigen
* Image analysis software
* Confocal microscope

**Timeline:**

* Step 1: 2-3 months
* Step 2: 3-4 months
* Step 3: 3-4 months
* Step 4: 4-5 months

**Budget:**

* Personnel: 2-3 postdoctoral researchers, 1-2 graduate students, 1 technician
* Reagents and consumables: $50,000 - $100,000 per year
* Equipment: $200,000 - $500,000 (depending on the specific equipment needed)
* Total budget: $500,000 - $1,500,000 per year for 2-3 years.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Identify ABL phosphorylation sites on Arp2/3 complex components**

**Protocol 1.1: Kinase assays linked to phosphoproteomics with multiple drug treatments**

1. Prepare Arp2/3 complex components (e.g., Arp2, Arp3, p21, p16) by expressing and purifying them from E. coli or insect cells using standard protocols.
2. Perform kinase assays using ABL kinase and the purified Arp2/3 complex components in the presence of ATP and various drug treatments (e.g., ABL inhibitors, activators, and DMSO as a control).
3. Use a phosphoproteomics approach (e.g., TiO2 enrichment, IMAC enrichment, or phospho-specific antibodies) to enrich for phosphorylated peptides from the kinase assay reactions.
4. Analyze the enriched peptides using mass spectrometry (e.g., LC-MS/MS) to identify phosphorylated residues on the Arp2/3 complex components.
5. Validate the identified phosphorylation sites using in vitro and in vivo experiments, such as:
	* In vitro kinase assays with mutated Arp2/3 complex components (e.g., alanine substitutions at the identified phosphorylation sites).
	* In vivo experiments using cells expressing wild-type or mutated Arp2/3 complex components and analyzing phosphorylation levels using Western blotting or immunoprecipitation.

**Protocol 1.2: Validation of phosphorylation sites using in vitro and in vivo experiments**

1. Design and generate mutated Arp2/3 complex components (e.g., alanine substitutions at the identified phosphorylation sites) using site-directed mutagenesis.
2. Express and purify the mutated Arp2/3 complex components using standard protocols.
3. Perform in vitro kinase assays using ABL kinase and the mutated Arp2/3 complex components to validate the identified phosphorylation sites.
4. Transfect cells (e.g., HEK293T or B cells) with the mutated Arp2/3 complex components and analyze phosphorylation levels using Western blotting or immunoprecipitation.
5. Compare the phosphorylation levels between wild-type and mutated Arp2/3 complex components to validate the identified phosphorylation sites.

**Step 2: Investigate the effect of ABL on Arp2/3 complex activity and cSMAC formation**

**Protocol 2.1: RNAi or CRISPR-Cas9 system to knockdown or knockout ABL in B cells**

1. Design and synthesize siRNA or CRISPR-Cas9 guide RNA targeting ABL in B cells.
2. Transfect B cells with the siRNA or CRISPR-Cas9 system using standard protocols (e.g., electroporation or lipofection).
3. Validate the knockdown or knockout of ABL using Western blotting or qRT-PCR.

**Protocol 2.2: Transfection of B cells with fluorescently-labeled actin probe and Arp2/3 complex-specific siRNA**

1. Design and synthesize siRNA targeting Arp2/3 complex components (e.g., Arp2 or Arp3).
2. Transfect B cells with the siRNA and a fluorescently-labeled actin probe (e.g., LifeAct-GFP) using standard protocols (e.g., electroporation or lipofection).
3. Validate the knockdown of Arp2/3 complex components using Western blotting or qRT-PCR.

**Protocol 2.3: Co-culture of transfected B cells with APCs expressing a membrane-bound antigen**

1. Prepare APCs (e.g., Raji cells) expressing a membrane-bound antigen (e.g., anti-IgM).
2. Co-culture the transfected B cells with the APCs at a 1:1 ratio in a 96-well plate.
3. Incubate the co-culture at 37°C, 5% CO2 for 30 minutes to 1 hour.

**Protocol 2.4: Imaging and analysis of actin dynamics using TIRF microscopy**

1. Image the B cell-APC contact site using TIRF microscopy with a 100x oil immersion objective.
2. Acquire images at 1-2 frames per second for 1-2 minutes.
3. Analyze the images using kymograph analysis software (e.g., ImageJ or Fiji) to quantify the velocity and direction of actin flow.
4. Compare the results between control and ABL-knockdown/knockout B cells to determine the role of ABL in regulating Arp2/3 complex activity and cSMAC formation.

**Step 3: Investigate the effect of ABL on B-cell activation and immune synapse formation**

**Protocol 3.1: Flow cytometry to measure phosphorylation levels of proximal BCR signaling molecules**

1. Prepare B cells treated with ABL activators or inhibitors.
2. Stain the B cells with antibodies against proximal BCR signaling molecules (e.g., CD79a, Syk, PLCγ2) and a fluorescent secondary antibody.
3. Analyze the phosphorylation levels using flow cytometry (e.g., BD FACSCanto or BD LSRFortessa).
4. Compare the phosphorylation levels between control and ABL-knockdown/knockout B cells to determine the role of ABL in regulating B-cell activation.

**Protocol 3.2: Confocal microscopy to visualize immune synapse formation and cSMAC structure**

1. Prepare B cells treated with ABL activators or inhibitors.
2. Stain the B cells with antibodies against immune synapse markers (e.g., CD81, CD82) and a fluorescent secondary antibody.
3. Image the immune synapse formation and cSMAC structure using confocal microscopy (e.g., Zeiss LSM 880 or Leica TCS SP8).
4. Compare the results between control and ABL-knockdown/knockout B cells to determine the role of ABL in regulating immune synapse formation.

**Step 4: Investigate the effect of Arp2/3 complex phosphorylation on cSMAC formation and B-cell activation**

**Protocol 4.1: Site-directed mutagenesis to introduce phosphorylation-mimicking mutations on Arp2/3 complex components**

1. Design and generate mutated Arp2/3 complex components (e.g., aspartic acid substitutions at the identified phosphorylation sites) using site-directed mutagenesis.
2. Express and purify the mutated Arp2/3 complex components using standard protocols.

**Protocol 4.2: Transfection of B cells with mutated Arp2/3 complex components and ABL-specific siRNA**

1. Transfect B cells with the mutated Arp2/3 complex components and ABL-specific siRNA using standard protocols (e.g., electroporation or lipofection).
2. Validate the expression of the mutated Arp2/3 complex components using Western blotting or qRT-PCR.

**Protocol 4.3: Co-culture of transfected B cells with APCs expressing a membrane-bound antigen**

1. Prepare APCs (e.g., Raji cells) expressing a membrane-bound antigen (e.g., anti-IgM).
2. Co-culture the transfected B cells with the APCs at a 1:1 ratio in a 96-well plate.
3. Incubate the co-culture at 37°C, 5% CO2 for 30 minutes to 1 hour.

**Protocol 4.4: Imaging and analysis of actin dynamics using TIRF microscopy**

1. Image the B cell-APC contact site using TIRF microscopy with a 100x oil immersion objective.
2. Acquire images at 1-2 frames per second for 1-2 minutes.
3. Analyze the images using kymograph analysis software (e.g., ImageJ or Fiji) to quantify the velocity and direction of actin flow.
4. Compare the results between control and phosphorylation-mimicking mutant B cells to determine the role of Arp2/3 complex phosphorylation in regulating cSMAC formation and B-cell activation.

These detailed protocols should provide a clear and replicable guide for executing the experimental plan.","```
   ABL Kinase (nM)  Arp2 (μg)  Arp3 (μg)  p21 (μg)  p16 (μg)  ATP (mM)  DMSO (%)  Outcome
0           10.0       2.0       1.0       0.5       0.5       1.0       0.1  Phosphorylated
1           20.0       4.0       2.0       1.0       1.0       2.0       0.2  Phosphorylated
2            5.0       1.0       0.5       0.2       0.2       0.5       0.05  Not Phosphorylated
3           15.0       3.0       1.5       0.7       0.7       1.5       0.15  Phosphorylated
4           25.0       5.0       2.5       1.2       1.2       2.5       0.25  Phosphorylated
5            8.0       1.6       0.8       0.4       0.4       0.8       0.08  Phosphorylated
6           12.0       2.4       1.2       0.6       0.6       1.2       0.12  Phosphorylated
7           18.0       3.6       1.8       0.9       0.9       1.8       0.18  Phosphorylated
8            6.0       1.2       0.6       0.3       0.3       0.6       0.06  Not Phosphorylated
9           22.0       4.4       2.2       1.1       1.1       2.2       0.22  Phosphorylated
10          11.0       2.2       1.1       0.5       0.5       1.1       0.11  Phosphorylated
11          16.0       3.2       1.6       0.8       0.8       1.6       0.16  Phosphorylated
12           9.0       1.8       0.9       0.4       0.4       0.9       0.09  Not Phosphorylated
13          14.0       2.8       1.4       0.7       0.7       1.4       0.14  Phosphorylated
14          21.0       4.2       2.1       1.0       1.0       2.1       0.21  Phosphorylated
15           7.0       1.4       0.7       0.3       0.3       0.7       0.07  Not Phosphorylated
16          13.0       2.6       1.3       0.6       0.6       1.3       0.13  Phosphorylated
17          19.0       3.8       1.9       0.9       0.9       1.9       0.19  Phosphorylated
18          10.0       2.0       1.0       0.5       0.5       1.0       0.10  Phosphorylated
19          17.0       3.4       1.7       0.8       0.8       1.7       0.17  Phosphorylated
20           4.0       0.8       0.4       0.2       0.2       0.4       0.04  Not Phosphorylated
21          24.0       4.8       2.4       1.2       1.2       2.4       0.24  Phosphorylated
22          12.0       2.4       1.2       0.6       0.6       1.2       0.12  Phosphorylated
23          15.0       3.0       1.5       0.7       0.7       1.5       0.15  Phosphorylated
24          20.0       4.0       2.0       1.0       1.0       2.0       0.20  Phosphorylated
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/64b7942b03851c5b49e93e3e84c71ac7e80ae7af.summary'],"Does the AMPK-CREB-Nrf2 pathway regulate S100A11 protein expression in idiopathic inflammatory myopathies, and can its modulation be a therapeutic strategy to alleviate disease activity?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! Here's a comprehensive experimental plan to test the hypothesis:

**Hypothesis:** The AMPK-CREB-Nrf2 pathway regulates S100A11 protein expression in idiopathic inflammatory myopathies, and its modulation can be a therapeutic strategy to alleviate disease activity.

**Experimental Approach:**

**Objective 1: Investigate the expression of S100A11 and AMPK-CREB-Nrf2 pathway components in idiopathic inflammatory myopathies**

1. **Tissue collection**: Collect muscle biopsy samples from patients with idiopathic inflammatory myopathies (e.g., dermatomyositis, polymyositis) and healthy controls.
2. **RNA extraction and qRT-PCR**: Extract RNA from muscle samples and perform quantitative real-time PCR (qRT-PCR) to measure the expression levels of S100A11, AMPK, CREB, and Nrf2.
3. **Western blot analysis**: Perform Western blotting to analyze protein expression levels of S100A11, AMPK, CREB, and Nrf2 in muscle samples.

**Objective 2: Investigate the regulation of S100A11 by the AMPK-CREB-Nrf2 pathway**

1. **Cell culture**: Establish primary human muscle cell cultures from healthy donors and idiopathic inflammatory myopathy patients.
2. **siRNA-mediated knockdown**: Use siRNA to knockdown AMPK, CREB, or Nrf2 in muscle cells and measure the effect on S100A11 expression using qRT-PCR and Western blotting.
3. **Overexpression studies**: Overexpress AMPK, CREB, or Nrf2 in muscle cells using plasmid transfection and measure the effect on S100A11 expression.
4. **Chromatin immunoprecipitation (ChIP) assay**: Perform ChIP assays to investigate the binding of CREB and Nrf2 to the S100A11 promoter region.

**Objective 3: Investigate the therapeutic potential of modulating the AMPK-CREB-Nrf2 pathway in idiopathic inflammatory myopathies**

1. **In vitro disease modeling**: Establish an in vitro disease model using muscle cells from idiopathic inflammatory myopathy patients and treat them with AMPK activators (e.g., metformin), CREB activators (e.g., forskolin), or Nrf2 activators (e.g., sulforaphane).
2. **Measure disease activity markers**: Measure disease activity markers, such as inflammatory cytokines (e.g., TNF-α, IL-1β) and muscle damage markers (e.g., creatine kinase), in response to treatment.
3. **In vivo studies**: Use a mouse model of idiopathic inflammatory myopathy (e.g., the MRL/lpr mouse model) to investigate the therapeutic potential of modulating the AMPK-CREB-Nrf2 pathway in vivo. Treat mice with AMPK activators, CREB activators, or Nrf2 activators and measure disease activity markers and muscle damage.

**Additional experiments**

1. **Immunofluorescence staining**: Perform immunofluorescence staining to investigate the localization of S100A11, AMPK, CREB, and Nrf2 in muscle cells and tissues.
2. **Co-immunoprecipitation**: Perform co-immunoprecipitation assays to investigate the interaction between AMPK, CREB, and Nrf2 in muscle cells.
3. **Bioinformatics analysis**: Perform bioinformatics analysis to identify potential transcription factor binding sites in the S100A11 promoter region and predict the impact of AMPK-CREB-Nrf2 pathway modulation on S100A11 expression.

**Resources and equipment**

* Tissue collection and processing equipment (e.g., cryostat, microtome)
* Molecular biology equipment (e.g., PCR machines, Western blotting apparatus)
* Cell culture facilities and equipment (e.g., incubators, microscopes)
* siRNA and plasmid transfection reagents
* ChIP assay kits and antibodies
* In vivo animal facilities and equipment (e.g., mouse cages, injectors)
* Bioinformatics software and computing resources

**Timeline**

* Objective 1: 6 months
* Objective 2: 9 months
* Objective 3: 12 months
* Additional experiments: 6 months
* Data analysis and manuscript preparation: 6 months

**Budget**

* Personnel: 5 postdoctoral researchers, 2 graduate students, 1 technician
* Reagents and consumables: $500,000 per year
* Equipment: $200,000 (one-time purchase)
* Animal facilities and maintenance: $150,000 per year
* Travel and training: $20,000 per year
* Total budget: $2,420,000 over 3 years

This experimental plan is designed to comprehensively investigate the hypothesis and provide a thorough understanding of the AMPK-CREB-Nrf2 pathway's role in regulating S100A11 expression in idiopathic inflammatory myopathies. The unlimited budget allows for the use of cutting-edge techniques and equipment, ensuring the highest quality of data and results.",92,"Here are the detailed, step-by-step protocols for each objective:

**Objective 1: Investigate the expression of S100A11 and AMPK-CREB-Nrf2 pathway components in idiopathic inflammatory myopathies**

**Protocol 1.1: Tissue Collection**

1.1.1. Obtain informed consent from patients with idiopathic inflammatory myopathies (e.g., dermatomyositis, polymyositis) and healthy controls.
1.1.2. Collect muscle biopsy samples from patients and healthy controls using a sterile biopsy needle.
1.1.3. Immediately snap-freeze the biopsy samples in liquid nitrogen and store them at -80°C.

**Protocol 1.2: RNA Extraction and qRT-PCR**

1.2.1. Extract total RNA from muscle biopsy samples using a commercial RNA extraction kit (e.g., TRIzol).
1.2.2. Quantify RNA concentration using a spectrophotometer (e.g., NanoDrop).
1.2.3. Perform qRT-PCR using a commercial qRT-PCR kit (e.g., SYBR Green) and primers specific to S100A11, AMPK, CREB, and Nrf2.
1.2.4. Normalize gene expression to a housekeeping gene (e.g., GAPDH) and calculate relative expression levels using the 2^(-ΔΔCt) method.

**Protocol 1.3: Western Blot Analysis**

1.3.1. Extract protein from muscle biopsy samples using a commercial protein extraction kit (e.g., RIPA buffer).
1.3.2. Quantify protein concentration using a spectrophotometer (e.g., Bradford assay).
1.3.3. Separate proteins by SDS-PAGE and transfer to a PVDF membrane.
1.3.4. Probe the membrane with primary antibodies specific to S100A11, AMPK, CREB, and Nrf2, followed by secondary antibodies conjugated to horseradish peroxidase.
1.3.5. Detect protein bands using a chemiluminescent substrate (e.g., ECL) and quantify band intensity using image analysis software (e.g., ImageJ).

**Objective 2: Investigate the regulation of S100A11 by the AMPK-CREB-Nrf2 pathway**

**Protocol 2.1: Cell Culture**

2.1.1. Establish primary human muscle cell cultures from healthy donors and idiopathic inflammatory myopathy patients using a commercial cell culture medium (e.g., DMEM).
2.1.2. Maintain cells at 37°C, 5% CO2, and 95% humidity.

**Protocol 2.2: siRNA-Mediated Knockdown**

2.2.1. Design and synthesize siRNA oligonucleotides specific to AMPK, CREB, or Nrf2.
2.2.2. Transfect muscle cells with siRNA using a commercial transfection reagent (e.g., Lipofectamine).
2.2.3. Incubate cells for 48-72 hours to allow for siRNA-mediated knockdown.
2.2.4. Extract RNA and protein from transfected cells and analyze using qRT-PCR and Western blotting, respectively.

**Protocol 2.3: Overexpression Studies**

2.3.1. Design and synthesize plasmids encoding AMPK, CREB, or Nrf2.
2.3.2. Transfect muscle cells with plasmids using a commercial transfection reagent (e.g., Lipofectamine).
2.3.3. Incubate cells for 48-72 hours to allow for protein overexpression.
2.3.4. Extract RNA and protein from transfected cells and analyze using qRT-PCR and Western blotting, respectively.

**Protocol 2.4: Chromatin Immunoprecipitation (ChIP) Assay**

2.4.1. Cross-link chromatin in muscle cells using formaldehyde.
2.4.2. Sonicate chromatin to generate fragments of 200-500 bp.
2.4.3. Immunoprecipitate chromatin fragments using antibodies specific to CREB and Nrf2.
2.4.4. Analyze immunoprecipitated chromatin using qPCR and primers specific to the S100A11 promoter region.

**Objective 3: Investigate the therapeutic potential of modulating the AMPK-CREB-Nrf2 pathway in idiopathic inflammatory myopathies**

**Protocol 3.1: In Vitro Disease Modeling**

3.1.1. Establish an in vitro disease model using muscle cells from idiopathic inflammatory myopathy patients.
3.1.2. Treat cells with AMPK activators (e.g., metformin), CREB activators (e.g., forskolin), or Nrf2 activators (e.g., sulforaphane) for 24-48 hours.
3.1.3. Measure disease activity markers, such as inflammatory cytokines (e.g., TNF-α, IL-1β) and muscle damage markers (e.g., creatine kinase), using commercial ELISA kits.

**Protocol 3.2: In Vivo Studies**

3.2.1. Use a mouse model of idiopathic inflammatory myopathy (e.g., the MRL/lpr mouse model).
3.2.2. Treat mice with AMPK activators, CREB activators, or Nrf2 activators via intraperitoneal injection.
3.2.3. Measure disease activity markers and muscle damage in response to treatment using commercial ELISA kits and histological analysis.

**Additional Experiments**

**Protocol 4.1: Immunofluorescence Staining**

4.1.1. Fix muscle cells or tissue sections using paraformaldehyde.
4.1.2. Permeabilize cells or tissue sections using Triton X-100.
4.1.3. Incubate with primary antibodies specific to S100A11, AMPK, CREB, and Nrf2, followed by secondary antibodies conjugated to fluorophores (e.g., Alexa Fluor).
4.1.4. Visualize using a confocal microscope and analyze using image analysis software (e.g., ImageJ).

**Protocol 4.2: Co-Immunoprecipitation**

4.2.1. Extract protein from muscle cells using a commercial protein extraction kit (e.g., RIPA buffer).
4.2.2. Immunoprecipitate protein complexes using antibodies specific to AMPK, CREB, and Nrf2.
4.2.3. Analyze immunoprecipitated protein complexes using Western blotting and antibodies specific to AMPK, CREB, and Nrf2.

**Protocol 4.3: Bioinformatics Analysis**

4.3.1. Use bioinformatics software (e.g., UCSC Genome Browser) to identify potential transcription factor binding sites in the S100A11 promoter region.
4.3.2. Use bioinformatics software (e.g., MatInspector) to predict the impact of AMPK-CREB-Nrf2 pathway modulation on S100A11 expression.

These detailed protocols should provide a clear guide for executing the experiments outlined in the original plan.","```
   TRIzol  SYBR_Green  RIPA_Buffer  Lipofectamine  Metformin  Forskolin  Sulforaphane  Outcome
0       10         5          20           10         0.1         0.5           0.2  0.854321
1       15         7          25           12         0.2         0.7           0.3  0.923456
2       12         6          22           11         0.3         0.6           0.4  0.812345
3       18         8          28           14         0.4         0.8           0.5  0.956789
4       11         5          21           10         0.2         0.5           0.3  0.789012
5       16         9          26           13         0.3         0.7           0.4  0.901234
6       13         6          23           12         0.1         0.6           0.2  0.845678
7       19         8          29           15         0.4         0.8           0.5  0.967890
8       10         5          20           10         0.2         0.5           0.3  0.812345
9       14         7          24           12         0.3         0.6           0.4  0.923456
10      17         9          27           14         0.4         0.7           0.5  0.956789
11      12         6          22           11         0.2         0.5           0.3  0.789012
12      15         8          25           13         0.3         0.6           0.4  0.901234
13      11         5          21           10         0.1         0.5           0.2  0.845678
14      18         9          28           15         0.4         0.7           0.5  0.967890
15      13         7          23           12         0.2         0.6           0.3  0.812345
16      16         8          26           14         0.3         0.7           0.4  0.923456
17      10         5          20           10         0.1         0.5           0.2  0.789012
18      14         7          24           12         0.2         0.6           0.3  0.845678
19      17         9          27           14         0.3         0.7           0.4  0.901234
20      12         6          22           11         0.2         0.5           0.3  0.812345
21      15         8          25           13         0.3         0.6           0.4  0.923456
22      11         5          21           10         0.1         0.5           0.2  0.789012
23      18         9          28           15         0.4         0.7           0.5  0.967890
24      13         7          23           12         0.2         0.6           0.3  0.845678
```",0.8564519144101185
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2c36c2f928cad972eb9e2a05b6cdd9ca76240579.summary'],"Does the BCR/TLR9 crosstalk in autoreactive B cells also enhance the production of pro-inflammatory cytokines, thereby exacerbating systemic autoimmunity in mixed cryoglobulinemia patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed an experimental plan to test it. Since the goal is to disprove the hypothesis, the experiment is designed to test the null hypothesis: ""BCR/TLR9 crosstalk in autoreactive B cells does not enhance the production of pro-inflammatory cytokines, thereby exacerbating systemic autoimmunity in mixed cryoglobulinemia patients.""

**Experimental Approach:**

1. **Cell Isolation and Culture**:
	* Isolate peripheral blood mononuclear cells (PBMCs) from mixed cryoglobulinemia patients and healthy controls using density gradient centrifugation.
	* Enrich autoreactive B cells using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
	* Culture the isolated autoreactive B cells in vitro with or without TLR9 agonists (e.g., CpG oligodeoxynucleotides) and/or BCR stimulants (e.g., anti-IgM antibodies).
2. **Cytokine Production Analysis**:
	* Measure the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) in the culture supernatants using enzyme-linked immunosorbent assays (ELISAs) or multiplex bead-based assays.
	* Compare cytokine production between autoreactive B cells from mixed cryoglobulinemia patients and healthy controls, with or without TLR9 agonists and/or BCR stimulants.
3. **BCR/TLR9 Crosstalk Assessment**:
	* Use Western blotting or flow cytometry to analyze the expression of BCR and TLR9 in autoreactive B cells from mixed cryoglobulinemia patients and healthy controls.
	* Investigate the co-localization of BCR and TLR9 using confocal microscopy or proximity ligation assays.
4. **Statistical Analysis**:
	* Compare the cytokine production and BCR/TLR9 crosstalk data between mixed cryoglobulinemia patients and healthy controls using appropriate statistical tests (e.g., t-tests, ANOVA).
	* Perform correlation analysis to examine the relationship between BCR/TLR9 crosstalk and cytokine production.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, the experiment will focus on showing that BCR/TLR9 crosstalk does not enhance pro-inflammatory cytokine production in autoreactive B cells from mixed cryoglobulinemia patients.

**Null Hypothesis:** BCR/TLR9 crosstalk in autoreactive B cells does not enhance the production of pro-inflammatory cytokines in mixed cryoglobulinemia patients.

**Predictions:**

* Autoreactive B cells from mixed cryoglobulinemia patients will not show increased pro-inflammatory cytokine production in response to TLR9 agonists and/or BCR stimulants compared to healthy controls.
* BCR/TLR9 crosstalk will not be significantly different between autoreactive B cells from mixed cryoglobulinemia patients and healthy controls.

**Experimental Controls:**

* Healthy control PBMCs and autoreactive B cells will serve as negative controls.
* Autoreactive B cells from mixed cryoglobulinemia patients without TLR9 agonists and/or BCR stimulants will serve as internal controls.

**Timeline and Budget:**

* Cell isolation and culture: 2 weeks
* Cytokine production analysis: 2 weeks
* BCR/TLR9 crosstalk assessment: 3 weeks
* Statistical analysis: 1 week
* Total duration: 8 weeks

* Budget:
	+ Reagents and consumables: $5,000
	+ Equipment and maintenance: $2,000
	+ Personnel and training: $10,000
	Total budget: $17,000

This experimental plan is designed to be completed within a reasonable time frame (8 weeks) and budget ($17,000). The experiment aims to disprove the hypothesis by showing that BCR/TLR9 crosstalk does not enhance pro-inflammatory cytokine production in autoreactive B cells from mixed cryoglobulinemia patients.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Culture**

**Step 1.1: Peripheral Blood Mononuclear Cell (PBMC) Isolation**

1. Collect 10 mL of peripheral blood from mixed cryoglobulinemia patients and healthy controls in EDTA-coated tubes.
2. Add 10 mL of phosphate-buffered saline (PBS) to the blood samples and mix gently.
3. Layer the blood-PBS mixture over 15 mL of Ficoll-Paque PLUS (density gradient medium) in a 50 mL conical tube.
4. Centrifuge at 400 x g for 30 minutes at room temperature.
5. Collect the PBMC layer (interface between the plasma and Ficoll-Paque PLUS) and transfer it to a new 50 mL conical tube.
6. Wash the PBMCs with PBS by centrifuging at 300 x g for 10 minutes, discarding the supernatant, and resuspending the cells in 10 mL of PBS.

**Step 1.2: Autoreactive B Cell Enrichment**

1. Use magnetic bead-based separation or fluorescence-activated cell sorting (FACS) to enrich autoreactive B cells from the PBMCs.
	* For magnetic bead-based separation:
		+ Add 10 μL of anti-CD19 microbeads to 1 x 10^7 PBMCs in 100 μL of PBS.
		+ Incubate for 15 minutes at 4°C.
		+ Wash the cells with PBS by centrifuging at 300 x g for 10 minutes, discarding the supernatant, and resuspending the cells in 10 mL of PBS.
		+ Pass the cells through a magnetic column to separate the CD19+ cells.
	* For FACS:
		+ Stain the PBMCs with anti-CD19-PE and anti-CD27-FITC antibodies.
		+ Sort the CD19+CD27+ cells using a flow cytometer.

**Step 1.3: Cell Culture**

1. Resuspend the enriched autoreactive B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
2. Seed 1 x 10^5 cells per well in a 96-well plate.
3. Add TLR9 agonists (e.g., CpG oligodeoxynucleotides) and/or BCR stimulants (e.g., anti-IgM antibodies) to the culture medium as follows:
	* TLR9 agonist: 1 μM CpG oligodeoxynucleotides
	* BCR stimulant: 10 μg/mL anti-IgM antibodies
4. Incubate the cells at 37°C, 5% CO2 for 48 hours.

**Protocol 2: Cytokine Production Analysis**

**Step 2.1: Cytokine Measurement**

1. Collect the culture supernatants from the 96-well plate.
2. Measure the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) using enzyme-linked immunosorbent assays (ELISAs) or multiplex bead-based assays according to the manufacturer's instructions.

**Protocol 3: BCR/TLR9 Crosstalk Assessment**

**Step 3.1: Western Blotting**

1. Lyse the autoreactive B cells in RIPA buffer.
2. Separate the proteins by SDS-PAGE and transfer them to a PVDF membrane.
3. Probe the membrane with anti-BCR and anti-TLR9 antibodies.
4. Detect the proteins using an ECL detection system.

**Step 3.2: Flow Cytometry**

1. Stain the autoreactive B cells with anti-BCR-FITC and anti-TLR9-PE antibodies.
2. Analyze the cells using a flow cytometer.

**Step 3.3: Confocal Microscopy**

1. Fix the autoreactive B cells with 4% paraformaldehyde.
2. Stain the cells with anti-BCR-Alexa Fluor 488 and anti-TLR9-Alexa Fluor 647 antibodies.
3. Image the cells using a confocal microscope.

**Protocol 4: Statistical Analysis**

**Step 4.1: Data Analysis**

1. Compare the cytokine production and BCR/TLR9 crosstalk data between mixed cryoglobulinemia patients and healthy controls using appropriate statistical tests (e.g., t-tests, ANOVA).
2. Perform correlation analysis to examine the relationship between BCR/TLR9 crosstalk and cytokine production.

**Step 4.2: Data Interpretation**

1. If the data show no significant difference in cytokine production and BCR/TLR9 crosstalk between mixed cryoglobulinemia patients and healthy controls, the null hypothesis is supported, and the experiment fails to disprove the hypothesis.
2. If the data show significant differences, the null hypothesis is rejected, and the experiment provides evidence to support the alternative hypothesis.

Note: The protocols above are detailed and specific, but they may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   Blood Volume (mL)  PBS Volume (mL)  Ficoll-Paque PLUS Volume (mL)  Anti-CD19 Microbeads (μL)  TLR9 Agonist (μM)  BCR Stimulant (μg/mL)  Cytokine Production (pg/mL)
0               10.0             10.0                       15.0                  10.0             1.0               10.0                250.0
1               12.0             12.0                       18.0                  12.0             1.2               12.0                300.0
2                8.0              8.0                       12.0                   8.0             0.8               8.0                200.0
3               11.0             11.0                       16.5                  11.0             1.1               11.0                270.0
4               13.0             13.0                       19.5                  13.0             1.3               13.0                320.0
5                9.0              9.0                       13.5                   9.0             0.9               9.0                230.0
6               10.5             10.5                       15.75                 10.5             1.05              10.5                260.0
7               12.5             12.5                       18.75                 12.5             1.25              12.5                310.0
8                7.0              7.0                       10.5                   7.0             0.7               7.0                190.0
9               11.5             11.5                       17.25                 11.5             1.15              11.5                280.0
10              14.0             14.0                       21.0                  14.0             1.4               14.0                330.0
11               8.5              8.5                       12.75                  8.5             0.85              8.5                220.0
12              10.0             10.0                       15.0                  10.0             1.0               10.0                250.0
13              13.5             13.5                       20.25                 13.5             1.35              13.5                320.0
14               9.5              9.5                       14.25                  9.5             0.95              9.5                240.0
15              11.0             11.0                       16.5                  11.0             1.1               11.0                270.0
16              14.5             14.5                       21.75                 14.5             1.45              14.5                340.0
17               7.5              7.5                       11.25                  7.5             0.75              7.5                200.0
18              10.0             10.0                       15.0                  10.0             1.0               10.0                250.0
19              12.0             12.0                       18.0                  12.0             1.2               12.0                300.0
20               9.0              9.0                       13.5                   9.0             0.9               9.0                230.0
21              11.5             11.5                       17.25                 11.5             1.15              11.5                280.0
22              13.0             13.0                       19.5                  13.0             1.3               13.0                310.0
23               8.0              8.0                       12.0                   8.0             0.8               8.0                210.0
24              10.5             10.5                       15.75                 10.5             1.05              10.5                260.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c8506b98accbb5b6469b1371bd368cc7426cfc11.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/172551042c2c4bfe8ba09f4676a010a2d4fc5443.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f80f893a8d4f4454f2cc9507e8ad73c56f540a22.summary']","Does the CD40-OX40L axis on mesenchymal cells regulate NOTCH2-BCR signaling in B cells, thereby influencing the development of chronic graft-versus-host disease in hematopoietic stem cell transplantation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** The CD40-OX40L axis on mesenchymal cells regulates NOTCH2-BCR signaling in B cells, thereby influencing the development of chronic graft-versus-host disease (cGVHD) in hematopoietic stem cell transplantation.

**Experimental Plan:**

**Objective:** To investigate the role of the CD40-OX40L axis on mesenchymal cells in regulating NOTCH2-BCR signaling in B cells and its impact on cGVHD development in hematopoietic stem cell transplantation.

**Experimental Design:**

**Step 1: Mesenchymal Cell Isolation and Culture**

* Isolate mesenchymal cells from human bone marrow or umbilical cord tissue using established protocols (e.g., density gradient centrifugation, magnetic bead separation).
* Culture mesenchymal cells in vitro and verify their phenotype using flow cytometry (e.g., CD105, CD73, CD90).

**Step 2: CD40-OX40L Axis Modulation**

* Use CRISPR-Cas9 gene editing to knockdown or knockout CD40 or OX40L in mesenchymal cells to create CD40- or OX40L-deficient cells.
* Use lentiviral vectors to overexpress CD40 or OX40L in mesenchymal cells to create CD40- or OX40L-overexpressing cells.

**Step 3: Co-Culture with B Cells**

* Isolate human B cells from peripheral blood or bone marrow using established protocols (e.g., density gradient centrifugation, magnetic bead separation).
* Co-culture B cells with either CD40- or OX40L-deficient, or CD40- or OX40L-overexpressing mesenchymal cells in vitro.
* Analyze NOTCH2-BCR signaling in B cells using Western blot, qRT-PCR, or flow cytometry.

**Step 4: Hematopoietic Stem Cell Transplantation Model**

* Use a well-established murine model of hematopoietic stem cell transplantation (e.g., C57BL/6 → BALB/c) to study cGVHD development.
* Transplant hematopoietic stem cells from CD40- or OX40L-deficient, or CD40- or OX40L-overexpressing donors into recipient mice.
* Monitor cGVHD development using clinical scoring, histopathology, and flow cytometry.

**Step 5: In Vivo Validation**

* Use in vivo imaging techniques (e.g., bioluminescence, PET) to track B cell activation and migration in real-time.
* Analyze NOTCH2-BCR signaling in B cells isolated from transplanted mice using Western blot, qRT-PCR, or flow cytometry.

**Step 6: Data Analysis and Interpretation**

* Compare NOTCH2-BCR signaling in B cells co-cultured with CD40- or OX40L-deficient, or CD40- or OX40L-overexpressing mesenchymal cells.
* Correlate NOTCH2-BCR signaling with cGVHD development in transplanted mice.
* Perform statistical analysis to determine the significance of the results.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario:

**Alternative Hypothesis:** The CD40-OX40L axis on mesenchymal cells does not regulate NOTCH2-BCR signaling in B cells, and therefore does not influence cGVHD development in hematopoietic stem cell transplantation.

**Experimental Design:**

* Use the same experimental design as above, but with the following modifications:
	+ Use mesenchymal cells with intact CD40-OX40L axis (no knockdown or overexpression).
	+ Co-culture B cells with these mesenchymal cells and analyze NOTCH2-BCR signaling.
	+ Transplant hematopoietic stem cells from donors with intact CD40-OX40L axis into recipient mice.
	+ Monitor cGVHD development and analyze NOTCH2-BCR signaling in B cells isolated from transplanted mice.

If the results show no significant difference in NOTCH2-BCR signaling or cGVHD development between the control and experimental groups, it would suggest that the CD40-OX40L axis on mesenchymal cells does not regulate NOTCH2-BCR signaling in B cells, thereby disproving the original hypothesis.

With an unlimited budget, we can perform multiple replicates, use advanced technologies (e.g., single-cell RNA-seq, mass cytometry), and explore additional aspects of the hypothesis to ensure the results are robust and reliable.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Mesenchymal Cell Isolation and Culture**

1.1. Isolation of Mesenchymal Cells from Human Bone Marrow or Umbilical Cord Tissue:

* Obtain human bone marrow or umbilical cord tissue samples from a reputable source (e.g., bone marrow donation center, umbilical cord blood bank).
* Process the samples according to established protocols for mesenchymal cell isolation, such as density gradient centrifugation or magnetic bead separation.
* Use a density gradient medium (e.g., Ficoll-Paque) to separate mononuclear cells from the sample.
* Wash the cells with phosphate-buffered saline (PBS) and resuspend them in a suitable culture medium (e.g., Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin).

1.2. Verification of Mesenchymal Cell Phenotype:

* Stain the isolated cells with fluorescently labeled antibodies against CD105, CD73, and CD90 (e.g., PE-conjugated anti-CD105, FITC-conjugated anti-CD73, and APC-conjugated anti-CD90).
* Analyze the cells using flow cytometry (e.g., BD FACSCanto II) to verify the expression of these markers, which are characteristic of mesenchymal cells.
* Gate the cells based on forward and side scatter to exclude debris and dead cells.
* Set the compensation and threshold settings according to the manufacturer's instructions.
* Acquire at least 10,000 events and analyze the data using flow cytometry software (e.g., FlowJo).

**Step 2: CD40-OX40L Axis Modulation**

2.1. CRISPR-Cas9 Gene Editing:

* Design guide RNAs (gRNAs) targeting the CD40 or OX40L genes using online tools (e.g., CRISPR Design Tool).
* Prepare the gRNAs and Cas9 enzyme according to the manufacturer's instructions (e.g., CRISPR-Cas9 System from Thermo Fisher Scientific).
* Transfect the gRNAs and Cas9 enzyme into the mesenchymal cells using a suitable transfection reagent (e.g., Lipofectamine 3000).
* Incubate the cells for 48-72 hours to allow for gene editing.
* Verify the knockout or knockdown of CD40 or OX40L using Western blot, qRT-PCR, or flow cytometry.

2.2. Lentiviral Vector-Mediated Overexpression:

* Design and clone the CD40 or OX40L genes into a lentiviral vector (e.g., pLenti-CMV-Puro-DEST) using standard molecular biology techniques.
* Produce lentiviral particles using a suitable packaging cell line (e.g., HEK293T) and a transfection reagent (e.g., Lipofectamine 3000).
* Infect the mesenchymal cells with the lentiviral particles and select for transduced cells using puromycin (e.g., 1 μg/mL).
* Verify the overexpression of CD40 or OX40L using Western blot, qRT-PCR, or flow cytometry.

**Step 3: Co-Culture with B Cells**

3.1. Isolation of Human B Cells:

* Obtain human peripheral blood or bone marrow samples from a reputable source (e.g., blood bank, bone marrow donation center).
* Process the samples according to established protocols for B cell isolation, such as density gradient centrifugation or magnetic bead separation.
* Use a density gradient medium (e.g., Ficoll-Paque) to separate mononuclear cells from the sample.
* Wash the cells with PBS and resuspend them in a suitable culture medium (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin).

3.2. Co-Culture of B Cells with Mesenchymal Cells:

* Seed the mesenchymal cells (CD40- or OX40L-deficient, or CD40- or OX40L-overexpressing) in a 24-well plate at a density of 1 x 10^5 cells per well.
* Add the isolated B cells to the wells at a density of 1 x 10^6 cells per well.
* Incubate the co-culture for 48-72 hours to allow for cell-cell interactions.
* Analyze NOTCH2-BCR signaling in the B cells using Western blot, qRT-PCR, or flow cytometry.

**Step 4: Hematopoietic Stem Cell Transplantation Model**

4.1. Preparation of Hematopoietic Stem Cells:

* Obtain hematopoietic stem cells from CD40- or OX40L-deficient, or CD40- or OX40L-overexpressing donors using established protocols (e.g., bone marrow harvest, peripheral blood mobilization).
* Process the cells according to established protocols for hematopoietic stem cell transplantation (e.g., density gradient centrifugation, magnetic bead separation).

4.2. Transplantation of Hematopoietic Stem Cells:

* Use a well-established murine model of hematopoietic stem cell transplantation (e.g., C57BL/6 → BALB/c).
* Transplant the hematopoietic stem cells into recipient mice via tail vein injection (e.g., 1 x 10^6 cells per mouse).
* Monitor the mice for signs of cGVHD development (e.g., weight loss, skin lesions, diarrhea).

**Step 5: In Vivo Validation**

5.1. In Vivo Imaging:

* Use in vivo imaging techniques (e.g., bioluminescence, PET) to track B cell activation and migration in real-time.
* Inject the mice with a suitable imaging agent (e.g., luciferin, 18F-FDG) and acquire images using a suitable imaging system (e.g., IVIS, PET scanner).

5.2. Analysis of NOTCH2-BCR Signaling:

* Isolate B cells from the transplanted mice using established protocols (e.g., density gradient centrifugation, magnetic bead separation).
* Analyze NOTCH2-BCR signaling in the B cells using Western blot, qRT-PCR, or flow cytometry.

**Step 6: Data Analysis and Interpretation**

6.1. Data Analysis:

* Compare NOTCH2-BCR signaling in B cells co-cultured with CD40- or OX40L-deficient, or CD40- or OX40L-overexpressing mesenchymal cells.
* Correlate NOTCH2-BCR signaling with cGVHD development in transplanted mice.
* Perform statistical analysis (e.g., t-test, ANOVA) to determine the significance of the results.

6.2. Data Interpretation:

* Interpret the results in the context of the hypothesis and experimental design.
* Discuss the implications of the findings and potential limitations of the study.
* Suggest future directions for further investigation.

**Experiment to Disprove the Hypothesis**

* Follow the same experimental design as above, but with the modifications outlined in the alternative hypothesis.
* Analyze the results and interpret them in the context of the alternative hypothesis.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific requirements of the laboratory and the research question. It is essential to follow proper laboratory protocols, safety guidelines, and animal welfare regulations when conducting these experiments.","```
   Mesenchymal Cells  CD40  OX40L  B Cells  NOTCH2-BCR Signaling  cGVHD Development
0               10000   0.5    1.0   100000                0.8             0.2
1               15000   1.0    0.5   120000                0.9             0.4
2               20000   0.8    1.2   150000                0.7             0.3
3               25000   1.2    0.8   180000                0.6             0.5
4               30000   0.9    1.5   200000                0.5             0.6
5               10000   1.5    0.9   100000                0.4             0.7
6               15000   0.8    1.8   120000                0.3             0.8
7               20000   1.8    0.7   150000                0.2             0.9
8               25000   0.9    2.0   180000                0.1             1.0
9               30000   2.0    0.8   200000                0.0             1.1
10              10000   0.5    2.2   100000                0.1             1.2
11              15000   1.0    1.9   120000                0.2             1.3
12              20000   0.8    2.5   150000                0.3             1.4
13              25000   1.2    2.0   180000                0.4             1.5
14              30000   0.9    2.8   200000                0.5             1.6
15              10000   1.5    2.2   100000                0.6             1.7
16              15000   0.8    3.0   120000                0.7             1.8
17              20000   1.8    2.5   150000                0.8             1.9
18              25000   0.9    3.2   180000                0.9             2.0
19              30000   2.0    2.8   200000                1.0             2.1
20              10000   0.5    3.5   100000                0.1             2.2
21              15000   1.0    3.0   120000                0.2             2.3
22              20000   0.8    3.8   150000                0.3             2.4
23              25000   1.2    3.2   180000                0.4             2.5
24              30000   0.9    4.0   200000                0.5             2.6
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/053922e5a327be19618f7f5d32e1e018c84fd84d.summary'],"Does the DNA methylation-mediated repression of Pax5 also regulate the expression of other transcription factors involved in B cell activation, leading to a coordinated epigenetic program for immune response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! To test this hypothesis, I'll outline a high-level experimental plan to investigate the role of DNA methylation-mediated repression of Pax5 in regulating the expression of other transcription factors involved in B cell activation.

**Hypothesis:** DNA methylation-mediated repression of Pax5 regulates the expression of other transcription factors involved in B cell activation, leading to a coordinated epigenetic program for immune response.

**Experimental Approach:**

**Objective:** Design an experiment to disprove the hypothesis, thereby verifying its validity.

**Step 1: Cell Culture and Pax5 Knockdown**

* Obtain a B cell line (e.g., Ramos or Raji cells) and culture them in a suitable medium.
* Use RNA interference (RNAi) or CRISPR-Cas9 technology to specifically knockdown Pax5 expression in these cells.
* Verify Pax5 knockdown using qRT-PCR and Western blotting.

**Step 2: DNA Methylation Analysis**

* Perform whole-genome bisulfite sequencing (WGBS) or reduced representation bisulfite sequencing (RRBS) on Pax5-knockdown cells to identify differentially methylated regions (DMRs) associated with transcription factor genes involved in B cell activation.
* Validate the methylation status of selected DMRs using pyrosequencing or methylation-specific PCR.

**Step 3: Transcription Factor Expression Analysis**

* Perform RNA sequencing (RNA-seq) or qRT-PCR on Pax5-knockdown cells to analyze the expression of transcription factors involved in B cell activation (e.g., NF-κB, IRF4, and E2A).
* Compare the expression profiles of these transcription factors between Pax5-knockdown and control cells.

**Step 4: Functional Assays**

* Perform functional assays to assess B cell activation, such as:
	+ Cell proliferation assays (e.g., BrdU incorporation or CFSE staining).
	+ Cytokine production assays (e.g., ELISA or Luminex).
	+ Cell surface marker analysis (e.g., flow cytometry).

**Step 5: Data Integration and Analysis**

* Integrate the DNA methylation, transcription factor expression, and functional assay data to identify correlations between Pax5-mediated DNA methylation and the regulation of transcription factors involved in B cell activation.
* Perform statistical analysis (e.g., differential expression analysis, clustering, and pathway analysis) to identify significant changes in transcription factor expression and B cell activation.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment with the following modifications:

* Use a Pax5-overexpressing B cell line or transiently overexpress Pax5 in B cells using a lentiviral vector.
* Perform the same DNA methylation, transcription factor expression, and functional assays as described above.
* If the hypothesis is true, we would expect to see a decrease in DNA methylation at transcription factor gene promoters, increased expression of these transcription factors, and enhanced B cell activation upon Pax5 overexpression. If we observe the opposite or no significant changes, it would suggest that the hypothesis is false.

**Budget and Timeframe:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000. This estimate includes:

* Cell culture and RNAi/CRISPR reagents: $5,000-$10,000
* WGBS/RRBS and RNA-seq library preparation: $10,000-$15,000
* Sequencing costs (WGBS/RRBS and RNA-seq): $15,000-$25,000
* Reagents and consumables for functional assays: $5,000-$10,000
* Personnel and overhead costs: $10,000-$20,000

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the institution's infrastructure.",92,"Here are the detailed, step-by-step protocols for the experiment:

**Step 1: Cell Culture and Pax5 Knockdown**

1.1. Obtain a B cell line (e.g., Ramos or Raji cells) from a reputable cell bank or culture collection.

1.2. Culture the cells in a suitable medium, such as RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.3. Verify the cell line identity and purity using flow cytometry or PCR-based methods.

1.4. Design and synthesize Pax5-specific small interfering RNA (siRNA) or short hairpin RNA (shRNA) constructs.

1.5. Transfect the siRNA or shRNA constructs into the B cells using a transfection reagent, such as Lipofectamine RNAiMAX or DharmaFECT, according to the manufacturer's instructions.

1.6. Incubate the cells for 24-48 hours to allow for Pax5 knockdown.

1.7. Verify Pax5 knockdown using quantitative real-time PCR (qRT-PCR) and Western blotting.

**qRT-PCR Protocol:**

1.7.1. Extract total RNA from the transfected cells using a RNA extraction kit, such as TRIzol or RNeasy.

1.7.2. Reverse transcribe the RNA into cDNA using a reverse transcription kit, such as SuperScript III or iScript.

1.7.3. Design and synthesize Pax5-specific primers and probes for qRT-PCR.

1.7.4. Perform qRT-PCR using a real-time PCR instrument, such as the Applied Biosystems 7500 or the Bio-Rad CFX96.

1.7.5. Analyze the qRT-PCR data using the instrument's software or a third-party software, such as Prism or Excel.

**Western Blotting Protocol:**

1.7.6. Extract total protein from the transfected cells using a protein extraction kit, such as RIPA or NP-40.

1.7.7. Separate the proteins using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

1.7.8. Transfer the proteins to a nitrocellulose or PVDF membrane.

1.7.9. Incubate the membrane with a Pax5-specific antibody, such as a rabbit polyclonal or mouse monoclonal antibody.

1.7.10. Detect the antibody-bound Pax5 protein using a chemiluminescent substrate, such as ECL or SuperSignal.

**Step 2: DNA Methylation Analysis**

2.1. Perform whole-genome bisulfite sequencing (WGBS) or reduced representation bisulfite sequencing (RRBS) on the Pax5-knockdown cells.

**WGBS Protocol:**

2.1.1. Extract genomic DNA from the Pax5-knockdown cells using a DNA extraction kit, such as DNeasy or QIAamp.

2.1.2. Treat the DNA with bisulfite using a bisulfite conversion kit, such as the EZ DNA Methylation Kit.

2.1.3. Prepare a WGBS library using a library preparation kit, such as the TruSeq DNA Methylation Kit.

2.1.4. Sequence the library using a next-generation sequencing platform, such as the Illumina HiSeq or NovaSeq.

**RRBS Protocol:**

2.1.5. Extract genomic DNA from the Pax5-knockdown cells using a DNA extraction kit, such as DNeasy or QIAamp.

2.1.6. Digest the DNA with a restriction enzyme, such as MspI or TaqI.

2.1.7. Perform size selection and library preparation using a RRBS library preparation kit, such as the NEBNext RRBS Kit.

2.1.8. Sequence the library using a next-generation sequencing platform, such as the Illumina HiSeq or NovaSeq.

2.2. Validate the methylation status of selected differentially methylated regions (DMRs) using pyrosequencing or methylation-specific PCR.

**Pyrosequencing Protocol:**

2.2.1. Design and synthesize primers specific to the DMRs of interest.

2.2.2. Perform PCR amplification of the DMRs using a PCR kit, such as the PyroMark PCR Kit.

2.2.3. Perform pyrosequencing using a pyrosequencer, such as the PyroMark Q96.

2.2.4. Analyze the pyrosequencing data using the instrument's software or a third-party software, such as PyroMark Q96 Software or BiQ Analyzer.

**Methylation-Specific PCR Protocol:**

2.2.5. Design and synthesize primers specific to the DMRs of interest.

2.2.6. Perform PCR amplification of the DMRs using a PCR kit, such as the EpiTect Methylation-Specific PCR Kit.

2.2.7. Analyze the PCR products using agarose gel electrophoresis or melting curve analysis.

**Step 3: Transcription Factor Expression Analysis**

3.1. Perform RNA sequencing (RNA-seq) or qRT-PCR on the Pax5-knockdown cells to analyze the expression of transcription factors involved in B cell activation.

**RNA-seq Protocol:**

3.1.1. Extract total RNA from the Pax5-knockdown cells using a RNA extraction kit, such as TRIzol or RNeasy.

3.1.2. Prepare an RNA-seq library using a library preparation kit, such as the TruSeq RNA Library Prep Kit.

3.1.3. Sequence the library using a next-generation sequencing platform, such as the Illumina HiSeq or NovaSeq.

**qRT-PCR Protocol:**

3.1.4. Extract total RNA from the Pax5-knockdown cells using a RNA extraction kit, such as TRIzol or RNeasy.

3.1.5. Reverse transcribe the RNA into cDNA using a reverse transcription kit, such as SuperScript III or iScript.

3.1.6. Design and synthesize primers and probes specific to the transcription factors of interest.

3.1.7. Perform qRT-PCR using a real-time PCR instrument, such as the Applied Biosystems 7500 or the Bio-Rad CFX96.

3.1.8. Analyze the qRT-PCR data using the instrument's software or a third-party software, such as Prism or Excel.

**Step 4: Functional Assays**

4.1. Perform functional assays to assess B cell activation, such as:

**Cell Proliferation Assay:**

4.1.1. Label the Pax5-knockdown cells with a proliferation dye, such as BrdU or CFSE.

4.1.2. Incubate the cells for 24-48 hours to allow for proliferation.

4.1.3. Analyze the proliferation using flow cytometry or a plate reader.

**Cytokine Production Assay:**

4.1.4. Stimulate the Pax5-knockdown cells with a cytokine, such as IL-4 or CD40L.

4.1.5. Incubate the cells for 24-48 hours to allow for cytokine production.

4.1.6. Analyze the cytokine production using an ELISA or Luminex assay.

**Cell Surface Marker Analysis:**

4.1.7. Stain the Pax5-knockdown cells with antibodies specific to cell surface markers, such as CD19, CD20, or CD86.

4.1.8. Analyze the cell surface marker expression using flow cytometry.

**Step 5: Data Integration and Analysis**

5.1. Integrate the DNA methylation, transcription factor expression, and functional assay data to identify correlations between Pax5-mediated DNA methylation and the regulation of transcription factors involved in B cell activation.

5.2. Perform statistical analysis, such as differential expression analysis, clustering, and pathway analysis, to identify significant changes in transcription factor expression and B cell activation.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, repeat the experiment with the following modifications:

* Use a Pax5-overexpressing B cell line or transiently overexpress Pax5 in B cells using a lentiviral vector.

* Perform the same DNA methylation, transcription factor expression, and functional assays as described above.

* If the hypothesis is true, we would expect to see a decrease in DNA methylation at transcription factor gene promoters, increased expression of these transcription factors, and enhanced B cell activation upon Pax5 overexpression. If we observe the opposite or no significant changes, it would suggest that the hypothesis is false.

Note: The protocols provided are general guidelines and may need to be optimized for specific laboratory settings and equipment. Additionally, the experimental design and protocols should be reviewed and approved by the relevant institutional review boards and ethics committees before commencement.","```
   Pax5_siRNA_amount  FBS_amount  Penicillin_streptomycin_amount  L_glutamine_amount  Pax5_knockdown_efficiency  DNA_methylation_level  Transcription_factor_expression  Cell_proliferation  Cytokine_production  Cell_surface_marker_expression
0               20.0         10.0                       1.0                1.0                    0.8               0.4                     2.5             1500.0               200.0                    0.6
1               15.0         12.0                       0.8                0.8                    0.6               0.5                     2.0             1200.0               180.0                    0.5
2               25.0         11.0                       1.2                1.2                    0.9               0.3                     3.0             1800.0               220.0                    0.7
3               18.0         13.0                       0.9                0.9                    0.7               0.6                     2.2             1400.0               200.0                    0.6
4               22.0         10.0                       1.1                1.1                    0.8               0.4                     2.8             1600.0               210.0                    0.7
5               19.0         12.0                       0.7                0.7                    0.6               0.5                     2.1             1300.0               190.0                    0.5
6               24.0         11.0                       1.3                1.3                    0.9               0.3                     3.2             1900.0               230.0                    0.8
7               16.0         13.0                       0.8                0.8                    0.6               0.6                     2.0             1200.0               180.0                    0.5
8               21.0         10.0                       1.0                1.0                    0.8               0.4                     2.6             1500.0               200.0                    0.6
9               17.0         12.0                       0.9                0.9                    0.7               0.5                     2.3             1400.0               200.0                    0.6
10              23.0         11.0                       1.2                1.2                    0.9               0.3                     3.0             1800.0               220.0                    0.7
11              19.0         13.0                       0.7                0.7                    0.6               0.6                     2.1             1300.0               190.0                    0.5
12              20.0         10.0                       1.1                1.1                    0.8               0.4                     2.8             1600.0               210.0                    0.7
13              16.0         12.0                       0.8                0.8                    0.6               0.5                     2.0             1200.0               180.0                    0.5
14              22.0         11.0                       1.3                1.3                    0.9               0.3                     3.2             1900.0               230.0                    0.8
15              18.0         13.0                       0.9                0.9                    0.7               0.6                     2.2             1400.0               200.0                    0.6
16              21.0         10.0                       1.0                1.0                    0.8               0.4                     2.6             1500.0               200.0                    0.6
17              17.0         12.0                       0.7                0.7                    0.6               0.5                     2.1             1300.0               190.0                    0.5
18              23.0         11.0                       1.2                1.2                    0.9               0.3                     3.0             1800.0               220.0                    0.7
19              19.0         13.0                       0.8                0.8                    0.6               0.6                     2.0             1200.0               180.0                    0.5
20              20.0         10.0                       1.1                1.1                    0.8               0.4                     2.8             1600.0               210.0                    0.7
21              16.0         12.0                       0.9                0.9                    0.7               0.5                     2.3             1400.0               200.0                    0.6
22              22.0         11.0                       1.3                1.3                    0.9               0.3                     3.2             1900.0               230.0                    0.8
23              18.0         13.0                       0.7                0.7                    0.6               0.6                     2.1             1300.0               190.0                    0.5
24              21.0         10.0                       1.0                1.0                    0.8               0.4                     2.6             1500.0               200.0                    0.6
```",0.5672962753476859
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/43ba8fe32b6520c3489615ab36fb4451ef6b3e73.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0149c159dee324713572e0d8c2d9b1a92d20f542.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4b81e2f14aab34190d1b9826a2f75689f113a56f.summary']","Does the Epstein-Barr virus protein BALF0/1 also target EBF-1 for degradation during lytic replication, thereby contributing to the attenuation of B cell receptor signalling in EBV-infected cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A great hypothesis! Let's design an experiment to test it.

**Hypothesis:** The Epstein-Barr virus (EBV) protein BALF0/1 targets EBF-1 for degradation during lytic replication, contributing to the attenuation of B cell receptor signaling in EBV-infected cells.

**Experimental Plan:**

**Objective:** To investigate whether BALF0/1 degrades EBF-1, leading to reduced B cell receptor signaling in EBV-infected cells.

**Approach:**

1. **Cell Culture and Infection:**
	* Use a B cell line (e.g., BJAB or Ramos) and infect them with EBV (B95-8 strain).
	* Establish a control group with uninfected B cells.
2. **Protein Expression Analysis:**
	* Use Western blotting to detect EBF-1 protein levels in infected and uninfected B cells at different time points (e.g., 24, 48, and 72 hours post-infection).
	* Quantify EBF-1 protein levels using densitometry or image analysis software.
3. **BALF0/1 Overexpression:**
	* Transfect B cells with a plasmid expressing BALF0/1 (or a control plasmid) using a suitable transfection reagent (e.g., Lipofectamine).
	* Verify BALF0/1 overexpression using Western blotting.
4. **EBF-1 Degradation Assay:**
	* Co-transfect B cells with EBF-1 and BALF0/1 (or control plasmid) expression plasmids.
	* Treat cells with a proteasome inhibitor (e.g., MG132) to prevent protein degradation.
	* Analyze EBF-1 protein levels using Western blotting to determine if BALF0/1 promotes EBF-1 degradation.
5. **B Cell Receptor Signaling Analysis:**
	* Use a B cell receptor signaling reporter assay (e.g., NF-κB luciferase reporter) to measure signaling activity in infected and uninfected B cells.
	* Compare signaling activity in cells with and without BALF0/1 overexpression.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we will test whether EBF-1 degradation is independent of BALF0/1. We will use a dominant-negative mutant of BALF0/1 (e.g., a catalytically inactive mutant) and co-express it with EBF-1 in B cells. If EBF-1 degradation still occurs in the presence of the dominant-negative BALF0/1 mutant, it would suggest that BALF0/1 is not responsible for EBF-1 degradation, thus disproving the hypothesis.

**Budget and Timeframe:**

This experiment can be completed within 3-4 months with a moderate budget. The required resources include:

* Cell culture reagents and media
* EBV (B95-8 strain)
* Plasmids for BALF0/1 and EBF-1 expression
* Transfection reagents
* Western blotting reagents
* Proteasome inhibitor (MG132)
* B cell receptor signaling reporter assay reagents
* Dominant-negative BALF0/1 mutant plasmid

The estimated budget for this experiment is approximately $10,000-$15,000, which should be reasonable for a small-scale research project.

By following this experimental plan, we can test the hypothesis and determine whether BALF0/1 indeed targets EBF-1 for degradation, contributing to the attenuation of B cell receptor signaling in EBV-infected cells.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Infection**

1.1. Prepare B cell line (BJAB or Ramos) culture medium:
	* Use RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
	* Sterilize the medium by filtering it through a 0.22 μm filter.

1.2. Thaw and expand B cells:
	* Thaw frozen B cells and resuspend them in 10 mL of prepared culture medium.
	* Incubate the cells at 37°C, 5% CO2 for 24-48 hours to allow them to recover and expand.

1.3. Infect B cells with EBV (B95-8 strain):
	* Prepare EBV stock by thawing frozen virus and diluting it to the desired concentration (e.g., 1:100) in culture medium.
	* Add 1 mL of EBV stock to 10 mL of B cell culture and mix gently.
	* Incubate the infected cells at 37°C, 5% CO2 for 24-48 hours to allow for viral replication.

1.4. Establish a control group with uninfected B cells:
	* Prepare a separate culture of uninfected B cells using the same culture medium and conditions as above.

**Protocol 2: Protein Expression Analysis**

2.1. Harvest cells for Western blotting:
	* Collect 1 x 10^6 infected and uninfected B cells at 24, 48, and 72 hours post-infection.
	* Wash the cells with PBS and resuspend them in 100 μL of RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (e.g., PMSF, aprotinin).

2.2. Perform Western blotting:
	* Separate proteins by SDS-PAGE using a 10% polyacrylamide gel.
	* Transfer proteins to a PVDF membrane using a semi-dry transfer apparatus.
	* Block the membrane with 5% non-fat milk in TBST (20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) for 1 hour.
	* Incubate the membrane with a primary antibody against EBF-1 (e.g., rabbit polyclonal, 1:1000) overnight at 4°C.
	* Wash the membrane with TBST and incubate with a secondary antibody (e.g., goat anti-rabbit, 1:5000) for 1 hour at room temperature.
	* Develop the blot using an ECL detection system.

2.3. Quantify EBF-1 protein levels:
	* Use densitometry or image analysis software (e.g., ImageJ) to quantify EBF-1 protein levels in infected and uninfected B cells at each time point.

**Protocol 3: BALF0/1 Overexpression**

3.1. Prepare plasmids for BALF0/1 expression:
	* Use a plasmid expressing BALF0/1 (e.g., pCMV-BALF0/1) and a control plasmid (e.g., pCMV-empty).
	* Verify the plasmid sequences and prepare sufficient amounts for transfection.

3.2. Transfect B cells with BALF0/1 plasmid:
	* Use a suitable transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
	* Transfect 1 x 10^6 B cells with 1 μg of BALF0/1 plasmid or control plasmid.
	* Incubate the cells at 37°C, 5% CO2 for 24-48 hours to allow for protein expression.

3.3. Verify BALF0/1 overexpression:
	* Perform Western blotting using a primary antibody against BALF0/1 (e.g., mouse monoclonal, 1:1000) to detect overexpressed BALF0/1 protein.

**Protocol 4: EBF-1 Degradation Assay**

4.1. Co-transfect B cells with EBF-1 and BALF0/1 plasmids:
	* Use a plasmid expressing EBF-1 (e.g., pCMV-EBF-1) and co-transfect it with the BALF0/1 plasmid or control plasmid.
	* Transfect 1 x 10^6 B cells with 1 μg of EBF-1 plasmid and 1 μg of BALF0/1 plasmid or control plasmid.

4.2. Treat cells with proteasome inhibitor:
	* Add 10 μM MG132 to the culture medium 24 hours post-transfection to prevent protein degradation.
	* Incubate the cells for an additional 24 hours.

4.3. Analyze EBF-1 protein levels:
	* Perform Western blotting using a primary antibody against EBF-1 (e.g., rabbit polyclonal, 1:1000) to detect EBF-1 protein levels.
	* Compare EBF-1 protein levels in cells co-transfected with BALF0/1 and control plasmids.

**Protocol 5: B Cell Receptor Signaling Analysis**

5.1. Prepare B cell receptor signaling reporter assay:
	* Use a NF-κB luciferase reporter plasmid (e.g., pNF-κB-Luc) and a control plasmid (e.g., pRL-TK).
	* Transfect 1 x 10^6 B cells with 1 μg of NF-κB luciferase reporter plasmid and 0.1 μg of control plasmid.

5.2. Measure signaling activity:
	* Use a luminometer to measure luciferase activity in infected and uninfected B cells.
	* Compare signaling activity in cells with and without BALF0/1 overexpression.

**Protocol 6: Experiment to Disprove the Hypothesis**

6.1. Prepare dominant-negative BALF0/1 mutant plasmid:
	* Use a plasmid expressing a catalytically inactive mutant of BALF0/1 (e.g., pCMV-BALF0/1-DN).
	* Verify the plasmid sequence and prepare sufficient amounts for transfection.

6.2. Co-transfect B cells with EBF-1 and dominant-negative BALF0/1 plasmids:
	* Transfect 1 x 10^6 B cells with 1 μg of EBF-1 plasmid and 1 μg of dominant-negative BALF0/1 plasmid.

6.3. Analyze EBF-1 protein levels:
	* Perform Western blotting using a primary antibody against EBF-1 (e.g., rabbit polyclonal, 1:1000) to detect EBF-1 protein levels.
	* Compare EBF-1 protein levels in cells co-transfected with dominant-negative BALF0/1 and control plasmids.

By following these detailed protocols, the experiment can be replicated and the hypothesis tested.","```
   RPMI_1640  FBS  Penicillin_Streptomycin  L_Glutamine  EBV_Stock  B_Cells  Time_Post_Infection  BALF0_1_Plasmid  EBF_1_Plasmid  MG132  Outcome
0        10.0  10.0                  1.0           1.0        0.1  1.00e+06                  24.0             1.0         1.0   10.0  0.8
1        10.5  10.5                  1.1           1.1        0.2  1.20e+06                  48.0             1.2         1.2   12.0  0.9
2         9.5   9.5                  0.9           0.9        0.3  9.00e+05                  72.0             0.8         0.8    8.0  0.7
3        10.0  10.0                  1.0           1.0        0.1  1.00e+06                  24.0             1.0         1.0   10.0  0.8
4        10.2  10.8                  1.2           1.2        0.4  1.40e+06                  48.0             1.4         1.4   14.0  1.0
5         9.8   9.2                  0.8           0.8        0.2  9.20e+05                  72.0             0.6         0.6    6.0  0.6
6        10.5  10.5                  1.1           1.1        0.3  1.20e+06                  24.0             1.2         1.2   12.0  0.9
7        10.8  10.2                  1.3           1.3        0.4  1.40e+06                  48.0             1.6         1.6   16.0  1.1
8         9.2   9.8                  0.7           0.7        0.1  9.00e+05                  72.0             0.4         0.4    4.0  0.5
9        10.0  10.0                  1.0           1.0        0.2  1.00e+06                  24.0             1.0         1.0   10.0  0.8
10       10.3  10.7                  1.4           1.4        0.5  1.60e+06                  48.0             1.8         1.8   18.0  1.2
11        9.5   9.5                  0.9           0.9        0.3  9.50e+05                  72.0             0.7         0.7    7.0  0.7
12       10.1  10.9                  1.5           1.5        0.6  1.80e+06                  24.0             2.0         2.0   20.0  1.3
13        9.0   9.0                  0.6           0.6        0.2  8.00e+05                  48.0             0.3         0.3    3.0  0.4
14       10.4  10.6                  1.6           1.6        0.7  1.90e+06                  72.0             2.2         2.2   22.0  1.4
15        9.3   9.7                  0.8           0.8        0.4  9.30e+05                  24.0             0.9         0.9    9.0  0.8
16       10.2  10.8                  1.7           1.7        0.8  2.00e+06                  48.0             2.4         2.4   24.0  1.5
17        8.8   8.8                  0.5           0.5        0.3  8.80e+05                  72.0             0.2         0.2    2.0  0.3
18       10.5  10.5                  1.8           1.8        0.9  2.10e+06                  24.0             2.6         2.6   26.0  1.6
19        9.1   9.9                  0.9           0.9        0.5  9.10e+05                  48.0             1.0         1.0   10.0  0.9
20       10.7  10.3                  1.9           1.9       1.0  2.20e+06                  72.0             2.8         2.8   28.0  1.7
21        8.5   8.5                  0.4           0.4        0.4  8.50e+05                  24.0             0.1         0.1    1.0  0.2
22       10.9  10.1                  2.0           2.0       1.1  2.30e+06                  48.0             3.0         3.0   30.0  1.8
23        9.4   9.6                  1.0           1.0        0.6  9.40e+05                  72.0             1.1         1.1   11.0  1.0
24       10.6  10.4                  2.1           2.1       1.2  2.40e+06                  24.0             3.2         3.2   32.0  1.9
```",0.8202170338514974
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/280dcc8d479fe99238456dc114c31f42a0841d20.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/336d2d44ffede9d662e261fcebf621bb01f8245d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/34fa9fb8acf4a71b36128093da6d68a08e02c8ba.summary']",Does the G396R variant of the mIgG-tail portion of human IgG1-BCR modulate the therapeutic effects of triptolide on B-cell activation and autoimmune responses in Systemic Lupus Erythematosus by regulating miR-146a expression and TLR7/NF-κB signaling pathway?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll break down the experimental plan to test this hypothesis into several sections. Since we have an unlimited budget, we can design a comprehensive and rigorous experiment to thoroughly investigate the role of the G396R variant of the mIgG-tail portion of human IgG1-BCR in modulating the therapeutic effects of triptolide on B-cell activation and autoimmune responses in Systemic Lupus Erythematosus (SLE).

**Hypothesis:** The G396R variant of the mIgG-tail portion of human IgG1-BCR modulates the therapeutic effects of triptolide on B-cell activation and autoimmune responses in SLE by regulating miR-146a expression and TLR7/NF-κB signaling pathway.

**Experimental Approach:**

**Section 1: Cell Culture and Transfection**

1. Obtain human B cells from healthy donors and SLE patients with and without the G396R variant.
2. Culture B cells in vitro and transfect them with either a control vector or a vector expressing the G396R variant of the mIgG-tail portion of human IgG1-BCR.
3. Verify the expression of the G396R variant using Western blot, qRT-PCR, and flow cytometry.

**Section 2: Triptolide Treatment and B-cell Activation**

1. Treat transfected B cells with triptolide at various concentrations (e.g., 10 nM, 100 nM, 1 μM) for 24, 48, and 72 hours.
2. Assess B-cell activation by measuring:
	* CD69 and CD86 expression using flow cytometry.
	* Proliferation using CFSE (carboxyfluorescein succinimidyl ester) staining and flow cytometry.
	* Cytokine production (e.g., IL-6, TNF-α) using ELISA.

**Section 3: miR-146a Expression and TLR7/NF-κB Signaling**

1. Measure miR-146a expression using qRT-PCR and in situ hybridization.
2. Investigate TLR7/NF-κB signaling by:
	* Measuring TLR7 expression using Western blot and qRT-PCR.
	* Assessing NF-κB activity using a luciferase reporter assay.
	* Evaluating the phosphorylation of NF-κB subunits (e.g., p65) using Western blot.

**Section 4: Autoimmune Response Analysis**

1. Co-culture transfected B cells with autologous T cells and measure:
	* T-cell activation (e.g., CD25, CD69 expression) using flow cytometry.
	* Cytokine production (e.g., IFN-γ, IL-17) using ELISA.
2. Analyze the production of autoantibodies (e.g., anti-dsDNA, anti-Sm) using ELISA.

**Section 5: In Vivo Validation**

1. Generate a mouse model of SLE using a humanized IgG1-BCR transgenic mouse.
2. Introduce the G396R variant into the mouse model using CRISPR-Cas9 genome editing.
3. Treat mice with triptolide and assess disease severity, B-cell activation, and autoimmune responses.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: the G396R variant has no effect on the therapeutic effects of triptolide on B-cell activation and autoimmune responses in SLE.

**Alternative Hypothesis:** The G396R variant of the mIgG-tail portion of human IgG1-BCR does not modulate the therapeutic effects of triptolide on B-cell activation and autoimmune responses in SLE.

**Experimental Approach:**

1. Repeat the experiments outlined in Sections 1-4, but use a control vector without the G396R variant as the transfection control.
2. Compare the results from the G396R-transfected cells to the control-transfected cells.
3. If the results show no significant differences in B-cell activation, miR-146a expression, TLR7/NF-κB signaling, and autoimmune responses between the two groups, it would suggest that the G396R variant does not modulate the therapeutic effects of triptolide.

By designing an experiment to disprove the hypothesis, we can increase the confidence in the results and provide a more comprehensive understanding of the role of the G396R variant in SLE.",95,"Here are the detailed, step-by-step protocols for each section of the experiment:

**Section 1: Cell Culture and Transfection**

1.1. Obtain human B cells from healthy donors and SLE patients with and without the G396R variant:
	* Collect peripheral blood mononuclear cells (PBMCs) from healthy donors and SLE patients using Ficoll-Paque density gradient centrifugation.
	* Isolate B cells from PBMCs using magnetic-activated cell sorting (MACS) with anti-CD19 beads.
	* Verify the purity of B cells using flow cytometry (>95% CD19+ cells).

1.2. Culture B cells in vitro:
	* Culture B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
	* Maintain cell density at 1-2 x 10^6 cells/mL.

1.3. Transfect B cells with either a control vector or a vector expressing the G396R variant of the mIgG-tail portion of human IgG1-BCR:
	* Prepare plasmid DNA encoding the G396R variant or control vector using a plasmid purification kit.
	* Transfect B cells using a nucleofection kit according to the manufacturer's instructions (e.g., Amaxa Nucleofector).
	* Verify transfection efficiency using flow cytometry (>80% GFP+ cells).

1.4. Verify the expression of the G396R variant:
	* Perform Western blot analysis using an anti-mIgG-tail antibody to detect the G396R variant.
	* Perform qRT-PCR using primers specific to the G396R variant to detect mRNA expression.
	* Perform flow cytometry using an anti-mIgG-tail antibody to detect surface expression of the G396R variant.

**Section 2: Triptolide Treatment and B-cell Activation**

2.1. Treat transfected B cells with triptolide at various concentrations (e.g., 10 nM, 100 nM, 1 μM) for 24, 48, and 72 hours:
	* Prepare triptolide stock solutions in DMSO and dilute to the desired concentrations in culture medium.
	* Add triptolide to the culture medium and incubate for the specified time periods.

2.2. Assess B-cell activation:
	* Measure CD69 and CD86 expression using flow cytometry:
		+ Stain cells with anti-CD69 and anti-CD86 antibodies and analyze using a flow cytometer.
	* Measure proliferation using CFSE staining and flow cytometry:
		+ Stain cells with CFSE and incubate for 10 minutes at 37°C.
		+ Analyze CFSE dilution using a flow cytometer.
	* Measure cytokine production (e.g., IL-6, TNF-α) using ELISA:
		+ Collect culture supernatants and store at -80°C.
		+ Perform ELISA according to the manufacturer's instructions.

**Section 3: miR-146a Expression and TLR7/NF-κB Signaling**

3.1. Measure miR-146a expression:
	* Extract total RNA from B cells using a RNA isolation kit.
	* Perform qRT-PCR using primers specific to miR-146a.
	* Normalize miR-146a expression to a housekeeping gene (e.g., U6).

3.2. Investigate TLR7/NF-κB signaling:
	* Measure TLR7 expression using Western blot and qRT-PCR:
		+ Perform Western blot analysis using an anti-TLR7 antibody.
		+ Perform qRT-PCR using primers specific to TLR7.
	* Assess NF-κB activity using a luciferase reporter assay:
		+ Transfect B cells with a NF-κB luciferase reporter plasmid.
		+ Measure luciferase activity using a luminometer.
	* Evaluate the phosphorylation of NF-κB subunits (e.g., p65) using Western blot:
		+ Perform Western blot analysis using an anti-p65 antibody.

**Section 4: Autoimmune Response Analysis**

4.1. Co-culture transfected B cells with autologous T cells:
	* Isolate T cells from PBMCs using MACS with anti-CD3 beads.
	* Co-culture B cells with T cells at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

4.2. Measure T-cell activation and cytokine production:
	* Measure T-cell activation (e.g., CD25, CD69 expression) using flow cytometry:
		+ Stain cells with anti-CD25 and anti-CD69 antibodies and analyze using a flow cytometer.
	* Measure cytokine production (e.g., IFN-γ, IL-17) using ELISA:
		+ Collect culture supernatants and store at -80°C.
		+ Perform ELISA according to the manufacturer's instructions.

4.3. Analyze the production of autoantibodies:
	* Measure autoantibody production (e.g., anti-dsDNA, anti-Sm) using ELISA:
		+ Collect culture supernatants and store at -80°C.
		+ Perform ELISA according to the manufacturer's instructions.

**Section 5: In Vivo Validation**

5.1. Generate a mouse model of SLE using a humanized IgG1-BCR transgenic mouse:
	* Obtain humanized IgG1-BCR transgenic mice from a reputable vendor or generate in-house using CRISPR-Cas9 genome editing.

5.2. Introduce the G396R variant into the mouse model using CRISPR-Cas9 genome editing:
	* Design guide RNAs specific to the G396R variant and perform CRISPR-Cas9 genome editing according to the manufacturer's instructions.

5.3. Treat mice with triptolide and assess disease severity, B-cell activation, and autoimmune responses:
	* Administer triptolide to mice via intraperitoneal injection at a dose of 1 mg/kg body weight.
	* Monitor disease severity using a disease activity index (e.g., proteinuria, skin lesions).
	* Analyze B-cell activation and autoimmune responses using flow cytometry, ELISA, and Western blot.

**Experiment to Disprove the Hypothesis**

To disprove the hypothesis, repeat the experiments outlined in Sections 1-4 using a control vector without the G396R variant as the transfection control. Compare the results from the G396R-transfected cells to the control-transfected cells. If the results show no significant differences in B-cell activation, miR-146a expression, TLR7/NF-κB signaling, and autoimmune responses between the two groups, it would suggest that the G396R variant does not modulate the therapeutic effects of triptolide.","```
   Donor_Type  G396R_Vector  Triptolide_Conc  Triptolide_Time  CD69_Expr  CD86_Expr  Proliferation  IL6_Production  TNFa_Production  miR146a_Expr  TLR7_Expr  NFkB_Activity  Autoantibody_Production
0    Healthy      Control           10 nM           24 hours     0.25      0.30         0.40          100.0          50.0          0.50          0.60          0.70                0.20
1    SLE_noG396R  G396R_Vector           10 nM           24 hours     0.30      0.35         0.50          120.0          60.0          0.60          0.70          0.80                0.30
2    SLE_G396R    G396R_Vector           10 nM           24 hours     0.35      0.40         0.60          140.0          70.0          0.70          0.80          0.90                0.40
3    Healthy      Control           100 nM           24 hours     0.20      0.25         0.30          90.0          40.0          0.40          0.50          0.60                0.15
4    SLE_noG396R  G396R_Vector           100 nM           24 hours     0.25      0.30         0.40          110.0          50.0          0.50          0.60          0.70                0.25
5    SLE_G396R    G396R_Vector           100 nM           24 hours     0.30      0.35         0.50          130.0          60.0          0.60          0.70          0.80                0.35
6    Healthy      Control           1 μM           24 hours     0.15      0.20         0.25          80.0          30.0          0.30          0.40          0.50                0.10
7    SLE_noG396R  G396R_Vector           1 μM           24 hours     0.20      0.25         0.35          100.0          40.0          0.40          0.50          0.60                0.20
8    SLE_G396R    G396R_Vector           1 μM           24 hours     0.25      0.30         0.45          120.0          50.0          0.50          0.60          0.70                0.30
9    Healthy      Control           10 nM           48 hours     0.30      0.35         0.45          110.0          50.0          0.50          0.60          0.70                0.25
10   SLE_noG396R  G396R_Vector           10 nM           48 hours     0.35      0.40         0.55          130.0          60.0          0.60          0.70          0.80                0.35
11   SLE_G396R    G396R_Vector           10 nM           48 hours     0.40      0.45         0.65          150.0          70.0          0.70          0.80          0.90                0.45
12   Healthy      Control           100 nM           48 hours     0.25      0.30         0.40          100.0          40.0          0.40          0.50          0.60                0.20
13   SLE_noG396R  G396R_Vector           100 nM           48 hours     0.30      0.35         0.50          120.0          50.0          0.50          0.60          0.70                0.30
14   SLE_G396R    G396R_Vector           100 nM           48 hours     0.35      0.40         0.60          140.0          60.0          0.60          0.70          0.80                0.40
15   Healthy      Control           1 μM           48 hours     0.20      0.25         0.35          90.0          30.0          0.30          0.40          0.50                0.15
16   SLE_noG396R  G396R_Vector           1 μM           48 hours     0.25      0.30         0.45          110.0          40.0          0.40          0.50          0.60                0.25
17   SLE_G396R    G396R_Vector           1 μM           48 hours     0.30      0.35         0.55          130.0          50.0          0.50          0.60          0.70                0.35
18   Healthy      Control           10 nM           72 hours     0.35      0.40         0.50          120.0          50.0          0.50          0.60          0.70                0.30
19   SLE_noG396R  G396R_Vector           10 nM           72 hours     0.40      0.45         0.60          140.0          60.0          0.60          0.70          0.80                0.40
20   SLE_G396R    G396R_Vector           10 nM           72 hours     0.45      0.50         0.70          160.0          70.0          0.70          0.80          0.90                0.50
21   Healthy      Control           100 nM           72 hours     0.30      0.35         0.45          110.0          40.0          0.40          0.50          0.60                0.25
22   SLE_noG396R  G396R_Vector           100 nM           72 hours     0.35      0.40         0.55          130.0          50.0          0.50          0.60          0.70                0.35
23   SLE_G396R    G396R_Vector           100 nM           72 hours     0.40      0.45         0.65          150.0          60.0          0.60          0.70          0.80                0.45
24   Healthy      Control           1 μM           72 hours     0.25      0.30         0.40          100.0          30.0          0.30          0.40          0.50                0.20",0.7390670587504188
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/060fc95c30dac9274aacdd98c56f8cdf724e2364.summary'],"Does the GARP-TGF-β axis on B cells also regulate the activity of regulatory T cells, thereby modulating the balance between immune tolerance and autoimmunity?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that the GARP-TGF-β axis on B cells also regulates the activity of regulatory T cells, thereby modulating the balance between immune tolerance and autoimmunity.

**Experimental Plan:**

**Title:** Investigating the Role of GARP-TGF-β Axis on B Cells in Regulating Regulatory T Cell Activity

**Objective:** To determine if the GARP-TGF-β axis on B cells modulates the activity of regulatory T cells, thereby influencing the balance between immune tolerance and autoimmunity.

**Experimental Design:**

1. **Mouse Model:** Use a mouse model with a conditional knockout of GARP specifically in B cells (GARPfl/fl CD19-Cre) and a control group with intact GARP expression.
2. **Regulatory T Cell Isolation:** Isolate regulatory T cells (Tregs) from the spleens of both GARP-knockout and control mice using magnetic bead-based separation or flow cytometry.
3. **Treg Suppression Assay:** Co-culture Tregs with responder T cells (Teffs) and antigen-presenting cells (APCs) in the presence or absence of TGF-β. Measure the suppression of Teff proliferation using ³H-thymidine incorporation or CFSE dilution assays.
4. **Treg Phenotyping:** Analyze the expression of Treg-specific markers (e.g., Foxp3, CD25, CD127) and activation markers (e.g., CD44, CD69) on Tregs from both groups using flow cytometry.
5. **Cytokine Analysis:** Measure the production of cytokines (e.g., IL-10, TGF-β, IL-2) by Tregs and Teffs in the co-culture supernatants using ELISA or multiplex assays.
6. **In Vivo Experiment:** Induce autoimmune disease (e.g., experimental autoimmune encephalomyelitis, EAE) in both GARP-knockout and control mice. Monitor disease progression and analyze the frequency and function of Tregs in the peripheral blood and lymphoid organs.

**Expected Outcomes:**

* If the GARP-TGF-β axis on B cells regulates Treg activity, GARP-knockout mice should exhibit impaired Treg function, leading to increased Teff proliferation and cytokine production.
* Tregs from GARP-knockout mice should display altered phenotypes, such as reduced Foxp3 expression or increased CD44 expression.
* In the in vivo experiment, GARP-knockout mice should exhibit exacerbated autoimmune disease symptoms and reduced Treg frequencies.

**Equipment and Resources:**

* CRISPR-Cas9 system for generating GARP-knockout mice
* Mouse models (GARPfl/fl CD19-Cre and control)
* Flow cytometer
* Magnetic bead-based separation system
* ³H-thymidine or CFSE for Treg suppression assay
* ELISA or multiplex assay for cytokine analysis
* EAE induction protocol and relevant reagents

**Timeline:**

* Generation of GARP-knockout mice: 2-3 months
* Regulatory T cell isolation and phenotyping: 1-2 months
* Treg suppression assay and cytokine analysis: 1-2 months
* In vivo experiment: 2-3 months
* Data analysis and manuscript preparation: 2-3 months

**Budget:**

* CRISPR-Cas9 system and mouse models: $10,000 - $15,000
* Flow cytometer and reagents: $5,000 - $10,000
* Magnetic bead-based separation system: $2,000 - $5,000
* ³H-thymidine or CFSE: $1,000 - $2,000
* ELISA or multiplex assay: $2,000 - $5,000
* EAE induction protocol and reagents: $2,000 - $5,000
* Personnel and miscellaneous costs: $10,000 - $20,000

Total budget: $42,000 - $72,000

This experimental plan is designed to test the hypothesis that the GARP-TGF-β axis on B cells regulates Treg activity, thereby modulating the balance between immune tolerance and autoimmunity. The expected outcomes should provide valuable insights into the role of GARP-TGF-β axis in regulating Treg function and its implications for autoimmune disease.",85,"Here are the detailed, step-by-step protocols for each experiment outlined in the plan:

**Protocol 1: Generation of GARP-Knockout Mice**

1.1. Design and synthesize guide RNAs (gRNAs) targeting the GARP gene using CRISPR-Cas9 system.

1.2. Prepare Cas9 mRNA and gRNA complexes according to the manufacturer's instructions.

1.3. Microinject the Cas9-gRNA complexes into fertilized mouse eggs (GARPfl/fl CD19-Cre) using a microinjection system.

1.4. Transfer the injected eggs to pseudopregnant female mice and allow them to develop to term.

1.5. Genotype the offspring using PCR and sequencing to identify mice with the desired GARP knockout.

1.6. Breed the GARP-knockout mice to generate a stable colony.

**Protocol 2: Regulatory T Cell Isolation**

2.1. Sacrifice GARP-knockout and control mice, and harvest their spleens.

2.2. Prepare a single-cell suspension of splenocytes using a gentleMACS dissociator or manual dissociation.

2.3. Stain the cells with anti-CD4, anti-CD25, and anti-Foxp3 antibodies for 30 minutes at 4°C.

2.4. Use a magnetic bead-based separation system (e.g., Miltenyi Biotec) to isolate CD4+CD25+Foxp3+ regulatory T cells (Tregs) according to the manufacturer's instructions.

2.5. Alternatively, use flow cytometry to sort Tregs based on their surface markers.

**Protocol 3: Treg Suppression Assay**

3.1. Prepare responder T cells (Teffs) by stimulating CD4+ T cells from wild-type mice with anti-CD3 and anti-CD28 antibodies for 3-4 days.

3.2. Co-culture Tregs with Teffs at a 1:1 ratio in the presence or absence of 10 ng/mL TGF-β.

3.3. Add 1 μCi of ³H-thymidine or 1 μM CFSE to the co-culture and incubate for 3-4 days.

3.4. Measure the incorporation of ³H-thymidine using a scintillation counter or analyze CFSE dilution using flow cytometry.

**Protocol 4: Treg Phenotyping**

4.1. Stain Tregs with anti-Foxp3, anti-CD25, anti-CD127, anti-CD44, and anti-CD69 antibodies for 30 minutes at 4°C.

4.2. Analyze the expression of these markers using flow cytometry.

**Protocol 5: Cytokine Analysis**

5.1. Collect the co-culture supernatants from the Treg suppression assay.

5.2. Measure the production of IL-10, TGF-β, and IL-2 using ELISA or multiplex assays according to the manufacturer's instructions.

**Protocol 6: In Vivo Experiment (EAE Induction)**

6.1. Induce EAE in GARP-knockout and control mice using a standard protocol (e.g., MOG35-55 peptide emulsified in CFA).

6.2. Monitor disease progression by scoring clinical signs (e.g., paralysis, weight loss) daily.

6.3. Sacrifice mice at peak disease (around 14-16 days post-induction) and harvest their peripheral blood, spleens, and lymphoid organs.

6.4. Analyze the frequency and function of Tregs in the peripheral blood and lymphoid organs using flow cytometry and Treg suppression assays.

These detailed protocols should provide a clear guide for executing the experiments outlined in the plan.","```
   gRNA_amount  Cas9_mRNA_amount  mouse_eggs  TGF_beta  IL10  IL2  Treg_suppression  EAE_score
0           50              20          10       5.0  200  100              0.8       2.5
1           30              30          15       7.5  250  120              0.9       3.0
2           40              25          12       6.0  220  110              0.85      2.8
3           60              20          18       8.0  280  130              0.95      3.5
4           45              28          16       6.5  240  115              0.9       3.2
5           35              22          14       5.5  210  105              0.8       2.6
6           55              24          19       7.0  260  125              0.92      3.4
7           48              26          17       6.2  230  112              0.88      3.0
8           42              21          13       5.8  200  100              0.82      2.7
9           38              29          15       6.8  240  118              0.91      3.1
10          52              23          18       7.2  270  128              0.94      3.6
11          32              27          12       5.2  190  95              0.78      2.4
12          44              25          16       6.4  220  110              0.89      3.3
13          50              20          14       5.6  210  105              0.83      2.9
14          36              24          13       5.9  200  100              0.81      2.8
15          58              26          19       7.6  290  135              0.97      3.8
16          40              22          15       6.1  230  115              0.87      3.2
17          46              28          17       6.9  250  122              0.93      3.5
18          34              21          12       5.4  190  95              0.79      2.5
19          54              25          18       7.4  280  130              0.96      3.7
20          39              23          14       6.3  220  112              0.89      3.1
21          43              27          16       6.6  240  118              0.92      3.4
22          51              20          15       5.7  210  105              0.84      2.9
23          33              24          13       5.1  190  95              0.77      2.3
24          49              26          17       6.7  260  125              0.94      3.6
```",0.7951850738807936
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/002acdacade1affbf356b9e723fe308c74ab16a9.summary'],"Does the GSK3β/β-catenin/c-Myc signaling pathway in tumor-associated macrophages also regulate the expression of ENO2 in exosomes derived from other types of cancer cells, contributing to their immune evasion and progression?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis. The goal is to determine if the GSK3β/β-catenin/c-Myc signaling pathway in tumor-associated macrophages regulates the expression of ENO2 in exosomes derived from other types of cancer cells, contributing to their immune evasion and progression.

**Experiment:**

**Title:** Investigating the Role of GSK3β/β-catenin/c-Myc Signaling in ENO2 Expression in Exosomes from Various Cancer Cells

**Objective:** To test the hypothesis that the GSK3β/β-catenin/c-Myc signaling pathway in tumor-associated macrophages regulates ENO2 expression in exosomes derived from other types of cancer cells, contributing to their immune evasion and progression.

**Experimental Design:**

1. **Cell Culture:**
	* Obtain cell lines from different types of cancer (e.g., breast, lung, colon, and ovarian cancer).
	* Culture these cells in vitro and collect exosomes using established protocols (e.g., ultracentrifugation or commercial exosome isolation kits).
2. **Macrophage Co-Culture:**
	* Isolate and culture human macrophages (e.g., THP-1 cells) and polarize them towards an M2-like phenotype using established protocols (e.g., IL-4 and IL-13 treatment).
	* Co-culture the macrophages with each type of cancer cell line for 24-48 hours to allow for exosome exchange.
3. **ENO2 Expression Analysis:**
	* Isolate exosomes from the co-culture supernatants using established protocols.
	* Analyze ENO2 expression in the exosomes using Western blotting or ELISA.
4. **GSK3β/β-catenin/c-Myc Signaling Inhibition:**
	* Treat the macrophages with specific inhibitors of the GSK3β/β-catenin/c-Myc signaling pathway (e.g., GSK3β inhibitor, β-catenin siRNA, or c-Myc inhibitor) before co-culture with cancer cells.
	* Repeat steps 2-3 to analyze ENO2 expression in exosomes.
5. **Control Experiments:**
	* Perform control experiments using macrophages without GSK3β/β-catenin/c-Myc signaling inhibition to serve as a baseline for ENO2 expression.
	* Use exosomes from cancer cells without macrophage co-culture as a negative control.

**Expected Outcomes:**

* If the hypothesis is true, ENO2 expression in exosomes from various cancer cells will be regulated by the GSK3β/β-catenin/c-Myc signaling pathway in tumor-associated macrophages.
* Inhibition of the GSK3β/β-catenin/c-Myc signaling pathway in macrophages will decrease ENO2 expression in exosomes from cancer cells.
* If the hypothesis is false, ENO2 expression in exosomes will not be affected by the GSK3β/β-catenin/c-Myc signaling pathway in macrophages.

**Resources and Timeline:**

* Equipment: Cell culture facilities, ultracentrifuge, Western blot equipment, ELISA reader, and flow cytometer.
* Reagents: Cancer cell lines, macrophage cell line, exosome isolation kits, GSK3β/β-catenin/c-Myc signaling inhibitors, antibodies for Western blotting and ELISA.
* Timeframe: 6-8 weeks (cell culture, co-culture, and exosome isolation: 2-3 weeks; ENO2 expression analysis: 2-3 weeks; data analysis and interpretation: 1-2 weeks).

**Budget:**

* Cell culture reagents and media: $1,000
* Exosome isolation kits: $500
* GSK3β/β-catenin/c-Myc signaling inhibitors: $500
* Antibodies and ELISA kits: $1,000
* Labor and miscellaneous costs: $2,000

Total budget: $5,000

This experiment is designed to test the hypothesis in a controlled and systematic manner, using existing scientific methods and equipment. The results will provide valuable insights into the role of the GSK3β/β-catenin/c-Myc signaling pathway in regulating ENO2 expression in exosomes from various cancer cells, contributing to our understanding of immune evasion and cancer progression.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Exosome Isolation**

**Step 1.1: Cell Line Preparation**

* Obtain cell lines from different types of cancer (e.g., breast, lung, colon, and ovarian cancer) and store them in a -80°C freezer.
* Thaw the cell lines according to the manufacturer's instructions and culture them in a 37°C, 5% CO2 incubator.
* Use the following cell culture media:
	+ Breast cancer cells: RPMI-1640 with 10% FBS and 1% penicillin-streptomycin.
	+ Lung cancer cells: DMEM with 10% FBS and 1% penicillin-streptomycin.
	+ Colon cancer cells: McCoy's 5A with 10% FBS and 1% penicillin-streptomycin.
	+ Ovarian cancer cells: DMEM with 10% FBS and 1% penicillin-streptomycin.

**Step 1.2: Cell Culture and Exosome Collection**

* Culture the cancer cells in 10 cm dishes until they reach 80-90% confluence.
* Collect the cell culture supernatant and centrifuge it at 300 x g for 10 minutes to remove cells and debris.
* Transfer the supernatant to a new tube and store it at 4°C for exosome isolation.

**Step 1.3: Exosome Isolation**

* Use an exosome isolation kit (e.g., ExoQuick-TC) according to the manufacturer's instructions.
* Add the exosome isolation reagent to the cell culture supernatant and incubate at room temperature for 30 minutes.
* Centrifuge the mixture at 1,500 x g for 30 minutes to pellet the exosomes.
* Resuspend the exosome pellet in 100 μL of PBS and store it at -80°C for further analysis.

**Protocol 2: Macrophage Co-Culture**

**Step 2.1: Macrophage Preparation**

* Obtain THP-1 cells (human macrophage cell line) and culture them in RPMI-1640 with 10% FBS and 1% penicillin-streptomycin.
* Polarize the THP-1 cells towards an M2-like phenotype by treating them with 20 ng/mL IL-4 and 20 ng/mL IL-13 for 24 hours.

**Step 2.2: Co-Culture**

* Seed 1 x 10^5 cancer cells per well in a 6-well plate.
* Add 1 x 10^5 polarized THP-1 cells per well to the cancer cells.
* Co-culture the cells for 24-48 hours to allow for exosome exchange.

**Protocol 3: ENO2 Expression Analysis**

**Step 3.1: Exosome Isolation from Co-Culture**

* Collect the co-culture supernatant and centrifuge it at 300 x g for 10 minutes to remove cells and debris.
* Use an exosome isolation kit to isolate exosomes from the supernatant according to the manufacturer's instructions.

**Step 3.2: Western Blotting**

* Resuspend the exosome pellet in 100 μL of RIPA buffer and sonicate for 10 seconds.
* Run 20 μg of exosomal protein on a 10% SDS-PAGE gel.
* Transfer the proteins to a PVDF membrane and block with 5% milk for 1 hour.
* Incubate the membrane with an anti-ENO2 antibody (1:1,000) overnight at 4°C.
* Detect the protein using an HRP-conjugated secondary antibody and ECL reagent.

**Step 3.3: ELISA**

* Use an ENO2 ELISA kit according to the manufacturer's instructions.
* Add 100 μL of exosomal protein to each well and incubate for 2 hours at room temperature.
* Detect the protein using the provided detection reagents and calculate the absorbance at 450 nm.

**Protocol 4: GSK3β/β-catenin/c-Myc Signaling Inhibition**

**Step 4.1: Inhibitor Treatment**

* Treat the polarized THP-1 cells with the following inhibitors:
	+ GSK3β inhibitor (10 μM) for 1 hour.
	+ β-catenin siRNA (50 nM) for 24 hours.
	+ c-Myc inhibitor (10 μM) for 1 hour.

**Step 4.2: Co-Culture and Exosome Isolation**

* Repeat steps 2.2 and 3.1 to co-culture the inhibitor-treated THP-1 cells with cancer cells and isolate exosomes.

**Step 4.3: ENO2 Expression Analysis**

* Repeat steps 3.2 and 3.3 to analyze ENO2 expression in exosomes using Western blotting and ELISA.

**Protocol 5: Control Experiments**

**Step 5.1: Control Co-Culture**

* Co-culture cancer cells with untreated THP-1 cells (without GSK3β/β-catenin/c-Myc signaling inhibition) to serve as a baseline for ENO2 expression.

**Step 5.2: Negative Control**

* Use exosomes from cancer cells without macrophage co-culture as a negative control.

**Step 5.3: ENO2 Expression Analysis**

* Repeat steps 3.2 and 3.3 to analyze ENO2 expression in exosomes from control co-culture and negative control samples.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   Cancer_Type  RPMI-1640  DMEM  McCoy's_5A  FBS  Penicillin-Streptomycin  IL-4  IL-13  GSK3β_Inhibitor  β-catenin_siRNA  c-Myc_Inhibitor  ENO2_Expression
0    Breast Cancer       10.0   0.0        0.0  10.0                1.0   0.0    0.0             0.0             0.0             0.0         0.85
1    Lung Cancer        0.0  10.0        0.0  10.0                1.0   0.0    0.0             0.0             0.0             0.0         0.92
2    Colon Cancer       0.0   0.0       10.0  10.0                1.0   0.0    0.0             0.0             0.0             0.0         0.78
3    Ovarian Cancer     0.0  10.0        0.0  10.0                1.0   0.0    0.0             0.0             0.0             0.0         0.95
4    Breast Cancer       8.0   0.0        0.0  12.0                1.0   0.0    0.0             5.0             0.0             0.0         0.70
5    Lung Cancer        0.0  12.0        0.0  8.0                 1.0   0.0    0.0             0.0             0.0             5.0         0.88
6    Colon Cancer       0.0   0.0       12.0  8.0                 1.0   0.0    0.0             0.0             5.0             0.0         0.82
7    Ovarian Cancer     0.0  12.0        0.0  8.0                 1.0   0.0    0.0             0.0             0.0             5.0         0.98
8    Breast Cancer       9.0   0.0        0.0  11.0                1.0   0.0    0.0             0.0             5.0             0.0         0.75
9    Lung Cancer        0.0  11.0        0.0  9.0                 1.0   0.0    0.0             5.0             0.0             0.0         0.90
10   Colon Cancer       0.0   0.0       11.0  9.0                 1.0   0.0    0.0             0.0             0.0             5.0         0.85
11   Ovarian Cancer     0.0  11.0        0.0  9.0                 1.0   0.0    0.0             0.0             5.0             0.0         1.02
12   Breast Cancer       9.5   0.0        0.0  10.5                1.0   0.0    0.0             0.0             0.0             5.0         0.80
13   Lung Cancer        0.0  10.5        0.0  9.5                 1.0   0.0    0.0             5.0             0.0             0.0         0.95
14   Colon Cancer       0.0   0.0       10.5  9.5                 1.0   0.0    0.0             0.0             5.0             0.0         0.90
15   Ovarian Cancer     0.0  10.5        0.0  9.5                 1.0   0.0    0.0             0.0             0.0             5.0         1.05
16   Breast Cancer       9.0   0.0        0.0  11.0                1.0   0.0    0.0             0.0             5.0             0.0         0.78
17   Lung Cancer        0.0  11.0        0.0  9.0                 1.0   0.0    0.0             5.0             0.0             0.0         0.98
18   Colon Cancer       0.0   0.0       11.0  9.0                 1.0   0.0    0.0             0.0             0.0             5.0         0.92
19   Ovarian Cancer     0.0  11.0        0.0  9.0                 1.0   0.0    0.0             0.0             5.0             0.0         1.10
20   Breast Cancer       9.5   0.0        0.0  10.5                1.0   0.0    0.0             0.0             0.0             5.0         0.85
21   Lung Cancer        0.0  10.5        0.0  9.5                 1.0   0.0    0.0             5.0             0.0             0.0         1.02
22   Colon Cancer       0.0   0.0       10.5  9.5                 1.0   0.0    0.0             0.0             5.0             0.0         0.98
23   Ovarian Cancer     0.0  10.5        0.0  9.5                 1.0   0.0    0.0             0.0             0.0             5.0         1.15
24   Breast Cancer       9.0   0.0        0.0  11.0                1.0   0.0    0.0             0.0             5.0             0.0         0.90
```",0.027645925684353312
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/256590d39942e91b446da3c6709e1e02fc4da2dc.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/747a201617b5863921a6649fdf7bf0f22d4c305a.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c11a0aefca156eab30b7cc7bd60605c59293f8c7.summary']","Does the Gαi signaling pathway regulate the expression of NOTCH2 in splenic marginal zone lymphoma, leading to a potential therapeutic target for personalized treatment?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, ""Does the Gαi signaling pathway regulate the expression of NOTCH2 in splenic marginal zone lymphoma, leading to a potential therapeutic target for personalized treatment?"", I propose an experimental plan to test this hypothesis.

**Experimental Approach:**

To disprove the hypothesis, we will investigate whether the Gαi signaling pathway regulates NOTCH2 expression in splenic marginal zone lymphoma (SMZL) cells. We will use a combination of molecular biology, cell culture, and biochemical techniques to assess the relationship between Gαi signaling and NOTCH2 expression.

**Objective:**

To determine whether Gαi signaling regulates NOTCH2 expression in SMZL cells and to identify potential therapeutic targets for personalized treatment.

**Experimental Design:**

1. **Cell Culture:** Obtain SMZL cell lines or primary cells from patients with SMZL. Culture the cells in a suitable medium with or without Gαi signaling inhibitors (e.g., pertussis toxin) to modulate Gαi activity.
2. **NOTCH2 Expression Analysis:** Use quantitative real-time PCR (qRT-PCR) and Western blotting to measure NOTCH2 mRNA and protein levels, respectively, in SMZL cells with or without Gαi signaling inhibition.
3. **Gαi Signaling Analysis:** Use Western blotting to assess the activation status of Gαi proteins (e.g., Gαi1, Gαi2, Gαi3) in SMZL cells with or without Gαi signaling inhibition.
4. **Co-Immunoprecipitation:** Perform co-immunoprecipitation assays to investigate the interaction between Gαi proteins and NOTCH2 in SMZL cells.
5. ** Luciferase Reporter Assay:** Use a luciferase reporter assay to measure the activity of the NOTCH2 promoter in SMZL cells with or without Gαi signaling inhibition.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see a decrease in NOTCH2 expression and activity in SMZL cells with Gαi signaling inhibition.
* If the hypothesis is false, we expect to see no significant change in NOTCH2 expression and activity in SMZL cells with Gαi signaling inhibition.

**Equipment and Resources:**

* Cell culture facilities
* qRT-PCR machine
* Western blotting equipment
* Co-immunoprecipitation kit
* Luciferase reporter assay kit
* Gαi signaling inhibitors (e.g., pertussis toxin)
* SMZL cell lines or primary cells
* Antibodies against NOTCH2, Gαi proteins, and other relevant proteins

**Timeline:**

* Cell culture and treatment: 2 weeks
* NOTCH2 expression analysis: 1 week
* Gαi signaling analysis: 1 week
* Co-immunoprecipitation: 1 week
* Luciferase reporter assay: 1 week
* Data analysis and interpretation: 2 weeks

**Budget:**

* Cell culture reagents and media: $1,000
* qRT-PCR and Western blotting reagents: $2,000
* Co-immunoprecipitation kit: $500
* Luciferase reporter assay kit: $1,000
* Gαi signaling inhibitors: $500
* Antibodies: $2,000
* Total: $7,000

This experimental plan is designed to test the hypothesis in a reasonable timeframe and within a limited budget. The results of this study will provide valuable insights into the regulation of NOTCH2 expression in SMZL and may identify potential therapeutic targets for personalized treatment.",85,"Here are the detailed, step-by-step protocols for each experiment outlined in the experimental plan:

**Experiment 1: Cell Culture and Treatment**

**Objective:** To culture SMZL cells with or without Gαi signaling inhibitors to modulate Gαi activity.

**Materials:**

* SMZL cell lines or primary cells
* Cell culture medium (e.g., RPMI 1640)
* Fetal bovine serum (FBS)
* Penicillin-streptomycin
* Gαi signaling inhibitors (e.g., pertussis toxin)
* Cell culture flasks and plates

**Protocol:**

1.1. Thaw SMZL cell lines or primary cells and resuspend in cell culture medium supplemented with 10% FBS and 1% penicillin-streptomycin.

1.2. Seed 1 x 10^6 cells per well in a 6-well plate or 2 x 10^6 cells per flask in a 25 cm^2 flask.

1.3. Incubate cells at 37°C, 5% CO2 for 24 hours to allow for cell attachment and recovery.

1.4. Treat cells with Gαi signaling inhibitors (e.g., 100 ng/mL pertussis toxin) or vehicle control (e.g., PBS) for 24-48 hours.

1.5. Harvest cells for subsequent experiments (e.g., NOTCH2 expression analysis, Gαi signaling analysis).

**Experiment 2: NOTCH2 Expression Analysis**

**Objective:** To measure NOTCH2 mRNA and protein levels in SMZL cells with or without Gαi signaling inhibition.

**Materials:**

* RNA extraction kit
* cDNA synthesis kit
* qRT-PCR primers for NOTCH2
* qRT-PCR machine
* Western blotting equipment
* Antibodies against NOTCH2
* Protein extraction buffer
* SDS-PAGE gels and running buffer

**Protocol:**

2.1. Extract total RNA from SMZL cells using an RNA extraction kit according to the manufacturer's instructions.

2.2. Synthesize cDNA from 1 μg of total RNA using a cDNA synthesis kit according to the manufacturer's instructions.

2.3. Perform qRT-PCR using NOTCH2-specific primers and a qRT-PCR machine according to the manufacturer's instructions.

2.4. Extract protein from SMZL cells using protein extraction buffer according to the manufacturer's instructions.

2.5. Separate proteins by SDS-PAGE and transfer to a PVDF membrane.

2.6. Probe the membrane with antibodies against NOTCH2 and detect using a chemiluminescent substrate.

**Experiment 3: Gαi Signaling Analysis**

**Objective:** To assess the activation status of Gαi proteins in SMZL cells with or without Gαi signaling inhibition.

**Materials:**

* Western blotting equipment
* Antibodies against Gαi proteins (e.g., Gαi1, Gαi2, Gαi3)
* Protein extraction buffer
* SDS-PAGE gels and running buffer

**Protocol:**

3.1. Extract protein from SMZL cells using protein extraction buffer according to the manufacturer's instructions.

3.2. Separate proteins by SDS-PAGE and transfer to a PVDF membrane.

3.3. Probe the membrane with antibodies against Gαi proteins and detect using a chemiluminescent substrate.

**Experiment 4: Co-Immunoprecipitation**

**Objective:** To investigate the interaction between Gαi proteins and NOTCH2 in SMZL cells.

**Materials:**

* Co-immunoprecipitation kit
* Antibodies against Gαi proteins and NOTCH2
* Protein extraction buffer
* Protein A/G beads

**Protocol:**

4.1. Extract protein from SMZL cells using protein extraction buffer according to the manufacturer's instructions.

4.2. Immunoprecipitate Gαi proteins using antibodies against Gαi proteins and protein A/G beads according to the manufacturer's instructions.

4.3. Elute immunoprecipitated proteins and separate by SDS-PAGE.

4.4. Probe the membrane with antibodies against NOTCH2 and detect using a chemiluminescent substrate.

**Experiment 5: Luciferase Reporter Assay**

**Objective:** To measure the activity of the NOTCH2 promoter in SMZL cells with or without Gαi signaling inhibition.

**Materials:**

* Luciferase reporter assay kit
* NOTCH2 promoter construct
* SMZL cells
* Gαi signaling inhibitors (e.g., pertussis toxin)
* Luciferase substrate

**Protocol:**

5.1. Transfect SMZL cells with the NOTCH2 promoter construct using a transfection reagent according to the manufacturer's instructions.

5.2. Treat cells with Gαi signaling inhibitors (e.g., 100 ng/mL pertussis toxin) or vehicle control (e.g., PBS) for 24 hours.

5.3. Lyse cells and measure luciferase activity using a luciferase substrate according to the manufacturer's instructions.

These detailed protocols should provide a clear guide for executing each experiment outlined in the original plan.","```
   SMZL Cells  FBS  Penicillin-Streptomycin  Pertussis Toxin  NOTCH2 mRNA  NOTCH2 Protein  Gαi Activity  Luciferase Activity
0       1e+06  10%                  1%           100 ng/mL     2.5         0.8          0.4             1500
1       2e+06  15%                  2%           200 ng/mL     3.2         1.2          0.6             2000
2       1e+06  12%                  1.5%         150 ng/mL     2.8         1.0          0.5             1800
3       3e+06  18%                  3%           250 ng/mL     3.8         1.5          0.8             2500
4       1e+06  10%                  1%           100 ng/mL     2.5         0.8          0.4             1500
5       2e+06  12%                  2%           200 ng/mL     3.0         1.1          0.5             1900
6       1e+06  15%                  1.5%         150 ng/mL     2.9         1.0          0.5             1700
7       3e+06  20%                  3.5%         300 ng/mL     4.2         1.8          1.0             3000
8       1e+06  10%                  1%           100 ng/mL     2.5         0.8          0.4             1500
9       2e+06  18%                  2.5%         250 ng/mL     3.5         1.4          0.7             2200
10      1e+06  12%                  1.5%         150 ng/mL     2.8         1.0          0.5             1800
11      3e+06  22%                  4%           350 ng/mL     4.5         2.0          1.2             3500
12      1e+06  10%                  1%           100 ng/mL     2.5         0.8          0.4             1500
13      2e+06  20%                  3%           300 ng/mL     3.8         1.6          0.9             2800
14      1e+06  15%                  1.5%         150 ng/mL     2.9         1.0          0.5             1700
15      3e+06  25%                  4.5%         400 ng/mL     4.8         2.2          1.4             4000
16      1e+06  10%                  1%           100 ng/mL     2.5         0.8          0.4             1500
17      2e+06  22%                  3.5%         350 ng/mL     4.0         1.7          1.0             3200
18      1e+06  12%                  1.5%         150 ng/mL     2.8         1.0          0.5             1800
19      3e+06  28%                  5%           450 ng/mL     5.0         2.4          1.6             4500
20      1e+06  10%                  1%           100 ng/mL     2.5         0.8          0.4             1500
21      2e+06  25%                  4%           400 ng/mL     4.2         1.9          1.2             3800
22      1e+06  15%                  1.5%         150 ng/mL     2.9         1.0          0.5             1700
23      3e+06  30%                  5.5%         500 ng/mL     5.2         2.6          1.8             5000
24      1e+06  10%                  1%           100 ng/mL     2.5         0.8          0.4             1500
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/16b167a0a9b2e4544688df964def696f2231dbea.summary'],"Does the Lyn-mediated phosphorylation of SHIP-1 and PTEN also regulate the anergy of T cells, and if so, does this pathway play a role in the development of T cell-mediated autoimmune diseases?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I will design an experiment to test the hypothesis that Lyn-mediated phosphorylation of SHIP-1 and PTEN also regulates the anergy of T cells and plays a role in the development of T cell-mediated autoimmune diseases.

**Experiment:**

**Title:** Investigating the Role of Lyn-mediated Phosphorylation of SHIP-1 and PTEN in T Cell Anergy and Autoimmune Disease

**Objective:** To determine if Lyn-mediated phosphorylation of SHIP-1 and PTEN regulates T cell anergy and contributes to the development of T cell-mediated autoimmune diseases.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate T cells from wild-type and Lyn-/- mice using magnetic bead separation or flow cytometry.
	* Activate T cells with anti-CD3 and anti-CD28 antibodies to induce anergy.
2. **Phosphorylation Analysis:**
	* Use Western blotting or flow cytometry to analyze the phosphorylation status of SHIP-1 and PTEN in wild-type and Lyn-/- T cells.
	* Use phospho-specific antibodies against SHIP-1 and PTEN to detect phosphorylation.
3. **T Cell Anergy Assay:**
	* Measure T cell proliferation and cytokine production (e.g., IL-2, IFN-γ) in response to antigen stimulation using a T cell anergy assay.
	* Compare the response of wild-type and Lyn-/- T cells to determine if Lyn deficiency affects T cell anergy.
4. **Autoimmune Disease Model:**
	* Use a T cell-mediated autoimmune disease model, such as experimental autoimmune encephalomyelitis (EAE), to assess the role of Lyn-mediated phosphorylation of SHIP-1 and PTEN in disease development.
	* Compare the disease severity and T cell responses in wild-type and Lyn-/- mice.

**To Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to show that Lyn-mediated phosphorylation of SHIP-1 and PTEN does not regulate T cell anergy or contribute to autoimmune disease development.

**Alternative Experiment:**

1. **Overexpress SHIP-1 and PTEN in T cells:**
	* Use lentiviral vectors to overexpress SHIP-1 and PTEN in T cells from wild-type mice.
	* Analyze T cell anergy and autoimmune disease development in these mice.
	* If overexpression of SHIP-1 and PTEN does not affect T cell anergy or autoimmune disease, it would suggest that Lyn-mediated phosphorylation of these proteins is not crucial for these processes.

**Resources and Timeline:**

* Mice: Wild-type and Lyn-/- mice (available from commercial sources or generated in-house)
* Reagents: Antibodies, lentiviral vectors, and other reagents for Western blotting, flow cytometry, and T cell anergy assays
* Equipment: Flow cytometer, Western blotting equipment, and cell culture facilities
* Timeframe: 6-12 months

**Budget:**

* Mice and reagents: $10,000 - $20,000
* Equipment and facilities: $5,000 - $10,000 (assuming access to existing facilities and equipment)
* Personnel: $20,000 - $40,000 (depending on the number of researchers and technicians involved)
* Total: $35,000 - $70,000

This experiment is designed to test the hypothesis that Lyn-mediated phosphorylation of SHIP-1 and PTEN regulates T cell anergy and contributes to autoimmune disease development. By using a combination of biochemical and functional assays, we can determine the role of this pathway in T cell biology and autoimmune disease. The alternative experiment is designed to disprove the hypothesis by overexpressing SHIP-1 and PTEN in T cells and analyzing the effects on T cell anergy and autoimmune disease.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Experiment 1: Investigating the Role of Lyn-mediated Phosphorylation of SHIP-1 and PTEN in T Cell Anergy and Autoimmune Disease**

**Step 1.1: Cell Preparation**

1. Obtain wild-type and Lyn-/- mice from commercial sources or generate them in-house.
2. Sacrifice the mice and harvest the spleens.
3. Prepare a single-cell suspension of splenocytes by gently pressing the spleens through a 70-μm cell strainer into a petri dish containing RPMI-1640 medium.
4. Centrifuge the cell suspension at 300 x g for 5 minutes to remove debris.
5. Resuspend the cells in 1 mL of RPMI-1640 medium and count the cells using a hemocytometer.
6. Isolate T cells from the splenocyte suspension using magnetic bead separation or flow cytometry.
	* For magnetic bead separation:
		+ Add 10 μL of anti-CD3 and anti-CD4 magnetic beads to 1 mL of cell suspension and incubate for 15 minutes at 4°C.
		+ Place the tube in a magnetic separator and wait for 5 minutes.
		+ Remove the supernatant and wash the beads with 1 mL of RPMI-1640 medium.
		+ Repeat the washing step twice.
	* For flow cytometry:
		+ Stain the cells with anti-CD3 and anti-CD4 antibodies and sort the T cells using a flow cytometer.
7. Activate the isolated T cells with 1 μg/mL anti-CD3 and 1 μg/mL anti-CD28 antibodies in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.
8. Incubate the cells at 37°C, 5% CO2 for 24-48 hours to induce anergy.

**Step 1.2: Phosphorylation Analysis**

1. Harvest the activated T cells and wash them twice with ice-cold PBS.
2. Lyse the cells in 1 mL of RIPA buffer containing protease and phosphatase inhibitors.
3. Centrifuge the lysate at 10,000 x g for 10 minutes to remove debris.
4. Collect the supernatant and determine the protein concentration using a protein assay kit.
5. Perform Western blotting or flow cytometry to analyze the phosphorylation status of SHIP-1 and PTEN.
	* For Western blotting:
		+ Resolve 20-30 μg of protein on a 10% SDS-PAGE gel.
		+ Transfer the proteins to a PVDF membrane and block with 5% BSA in TBST.
		+ Incubate the membrane with phospho-specific antibodies against SHIP-1 and PTEN (1:1000 dilution) overnight at 4°C.
		+ Detect the proteins using an ECL detection kit.
	* For flow cytometry:
		+ Stain the cells with phospho-specific antibodies against SHIP-1 and PTEN (1:100 dilution) for 30 minutes at 4°C.
		+ Analyze the cells using a flow cytometer.

**Step 1.3: T Cell Anergy Assay**

1. Prepare a T cell anergy assay plate by coating 96-well plates with 1 μg/mL anti-CD3 antibody.
2. Add 1 x 10^5 activated T cells per well in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.
3. Add 1 μg/mL of antigen (e.g., ovalbumin) to the wells and incubate at 37°C, 5% CO2 for 24-48 hours.
4. Measure T cell proliferation using a cell proliferation assay kit (e.g., MTT or BrdU).
5. Measure cytokine production (e.g., IL-2, IFN-γ) using an ELISA kit.

**Step 1.4: Autoimmune Disease Model**

1. Induce experimental autoimmune encephalomyelitis (EAE) in wild-type and Lyn-/- mice using a standard protocol.
2. Monitor the mice for disease severity and T cell responses.
3. Collect blood and tissue samples at various time points to analyze T cell responses and disease progression.

**Alternative Experiment: Overexpressing SHIP-1 and PTEN in T cells**

**Step 2.1: Lentiviral Vector Preparation**

1. Design and clone the SHIP-1 and PTEN genes into a lentiviral vector.
2. Produce lentiviral particles using a packaging cell line (e.g., 293T).
3. Concentrate the lentiviral particles using a centrifugation method.

**Step 2.2: T Cell Transduction**

1. Isolate T cells from wild-type mice as described in Step 1.1.
2. Activate the T cells with 1 μg/mL anti-CD3 and 1 μg/mL anti-CD28 antibodies in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.
3. Transduce the activated T cells with the lentiviral vector containing SHIP-1 and PTEN genes.
4. Incubate the cells at 37°C, 5% CO2 for 24-48 hours to allow for gene expression.

**Step 2.3: T Cell Anergy Assay and Autoimmune Disease Model**

1. Perform the T cell anergy assay and autoimmune disease model as described in Steps 1.3 and 1.4.

These detailed protocols should provide a clear guide for executing the experiment. Remember to follow proper laboratory protocols, including safety guidelines and quality control measures, to ensure the accuracy and reproducibility of the results.","```
   Lyn-/- Mice  Anti-CD3 (μg/mL)  Anti-CD28 (μg/mL)  SHIP-1 (μg)  PTEN (μg)  Ovalbumin (μg)  T Cell Proliferation  Cytokine Production  EAE Severity
0           1.0             0.5             0.5         10.0       5.0          1.0             0.8             200.0          2.0
1           0.0             1.0             1.0         20.0       10.0         2.0             0.9             300.0          3.0
2           1.0             0.8             0.8         15.0        7.5         1.5             0.7             250.0          2.5
3           0.0             0.6             0.6         12.0        6.0         1.2             0.6             220.0          2.2
4           1.0             1.2             1.2         25.0       12.5         2.5             1.0             350.0          3.5
5           0.0             0.9             0.9         18.0        9.0         1.8             0.8             280.0          2.8
6           1.0             0.7             0.7         14.0        7.0         1.4             0.7             240.0          2.4
7           0.0             1.1             1.1         22.0       11.0         2.2             0.9             320.0          3.2
8           1.0             0.4             0.4         10.0        5.0         1.0             0.6             200.0          2.0
9           0.0             0.8             0.8         16.0        8.0         1.6             0.7             260.0          2.6
10          1.0             1.0             1.0         20.0       10.0         2.0             0.9             300.0          3.0
11          0.0             0.5             0.5         12.0        6.0         1.2             0.6             220.0          2.2
12          1.0             1.3             1.3         28.0       14.0         2.8             1.1             380.0          3.8
13          0.0             0.6             0.6         13.0        6.5         1.3             0.7             230.0          2.3
14          1.0             0.9             0.9         19.0        9.5         1.9             0.8             290.0          2.9
15          0.0             1.2             1.2         24.0       12.0         2.4             1.0             330.0          3.3
16          1.0             0.8             0.8         17.0        8.5         1.7             0.8             270.0          2.7
17          0.0             0.7             0.7         15.0        7.5         1.5             0.7             250.0          2.5
18          1.0             1.1             1.1         23.0       11.5         2.3             1.0             310.0          3.1
19          0.0             0.9             0.9         20.0       10.0         2.0             0.9             300.0          3.0
20          1.0             0.6             0.6         13.0        6.5         1.3             0.7             230.0          2.3
21          0.0             1.3             1.3         27.0       13.5         2.7             1.1             360.0          3.6
22          1.0             0.8             0.8         18.0        9.0         1.8             0.8             280.0          2.8
23          0.0             0.5             0.5         11.0        5.5         1.1             0.6             210.0          2.1
24          1.0             1.2             1.2         26.0       13.0         2.6             1.1             340.0          3.4
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/dd66ecf0f7d1448efc806758bbe781df69da26d2.summary'],Does the MALT1-mediated cleavage of HOIL-1 regulate the expression of specific microRNAs that fine-tune NF-κB signaling and immune responses in lymphocytes?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis: ""Does the MALT1-mediated cleavage of HOIL-1 regulate the expression of specific microRNAs that fine-tune NF-κB signaling and immune responses in lymphocytes?""

**Experiment:**

**Title:** Investigating the Role of MALT1-Mediated HOIL-1 Cleavage in microRNA Regulation and NF-κB Signaling in Lymphocytes

**Objective:** To determine if MALT1-mediated HOIL-1 cleavage regulates the expression of specific microRNAs that fine-tune NF-κB signaling and immune responses in lymphocytes.

**Experimental Design:**

1. **Cell Culture and Stimulation:**
	* Isolate T cells and B cells from wild-type (WT) and MALT1 protease-resistant HOIL-1 knock-in (KI) mice.
	* Stimulate the cells with PMA/Iono to activate MALT1.
2. **microRNA Isolation and Profiling:**
	* Isolate total RNA from stimulated T cells and B cells using a miRNeasy kit.
	* Perform microRNA profiling using a microarray platform (e.g., Affymetrix GeneChip miRNA 4.0) or next-generation sequencing (NGS) technology (e.g., Illumina TruSeq Small RNA Library Prep Kit).
3. **microRNA Target Prediction and Validation:**
	* Use bioinformatic tools (e.g., TargetScan, miRanda) to predict microRNA targets involved in NF-κB signaling and immune responses.
	* Validate the predicted targets using quantitative real-time PCR (qRT-PCR) and Western blotting.
4. **NF-κB Signaling Assays:**
	* Measure NF-κB activity using a luciferase reporter assay or an ELISA-based assay (e.g., NF-κB p65 Transcription Factor Assay Kit).
	* Analyze the expression of NF-κB target genes using qRT-PCR.
5. **HOIL-1 Cleavage and MALT1 Activity Assays:**
	* Measure HOIL-1 cleavage using Western blotting with a cleavage-specific antibody.
	* Assess MALT1 activity using a fluorogenic peptide substrate assay (e.g., MALT1 Activity Assay Kit).

**Hypothesis-Testing Approach:**

To disprove the hypothesis, we will test the following predictions:

1. If MALT1-mediated HOIL-1 cleavage regulates microRNA expression, we expect to see differences in microRNA profiles between WT and MALT1 protease-resistant HOIL-1 KI cells.
2. If specific microRNAs fine-tune NF-κB signaling and immune responses, we expect to see correlations between microRNA expression and NF-κB activity/target gene expression.
3. If HOIL-1 cleavage is essential for MALT1-mediated regulation of NF-κB signaling, we expect to see impaired NF-κB activity in MALT1 protease-resistant HOIL-1 KI cells.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ Differential microRNA expression between WT and MALT1 protease-resistant HOIL-1 KI cells.
	+ Correlations between microRNA expression and NF-κB activity/target gene expression.
	+ Impaired NF-κB activity in MALT1 protease-resistant HOIL-1 KI cells.
* If the hypothesis is false, we expect to see:
	+ No significant differences in microRNA expression between WT and MALT1 protease-resistant HOIL-1 KI cells.
	+ No correlations between microRNA expression and NF-κB activity/target gene expression.
	+ Normal NF-κB activity in MALT1 protease-resistant HOIL-1 KI cells.

**Timeline and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$70,000, which covers:

* Cell culture and stimulation reagents
* microRNA profiling and target prediction tools
* qRT-PCR and Western blotting reagents
* NF-κB signaling and MALT1 activity assay kits
* Personnel and laboratory costs

By following this experimental design, we can test the hypothesis and determine if MALT1-mediated HOIL-1 cleavage regulates the expression of specific microRNAs that fine-tune NF-κB signaling and immune responses in lymphocytes.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Stimulation**

**Step 1.1: Isolate T cells and B cells from wild-type (WT) and MALT1 protease-resistant HOIL-1 knock-in (KI) mice**

* Obtain WT and MALT1 protease-resistant HOIL-1 KI mice from a reputable supplier or breeding facility.
* Sacrifice the mice according to institutional animal care and use committee (IACUC) guidelines.
* Harvest spleens and lymph nodes from each mouse.
* Isolate T cells and B cells using a cell separation protocol (e.g., magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS)).
* Count and verify the purity of isolated cells using a hemocytometer and flow cytometry.

**Step 1.2: Stimulate the cells with PMA/Iono to activate MALT1**

* Prepare a stimulation cocktail containing 10 ng/mL phorbol 12-myristate 13-acetate (PMA) and 1 μM ionomycin (Iono) in RPMI-1640 medium.
* Add the stimulation cocktail to the isolated T cells and B cells at a density of 1 x 10^6 cells/mL.
* Incubate the cells at 37°C, 5% CO2 for 2 hours to activate MALT1.

**Protocol 2: microRNA Isolation and Profiling**

**Step 2.1: Isolate total RNA from stimulated T cells and B cells using a miRNeasy kit**

* Harvest the stimulated cells and wash them with PBS.
* Lyse the cells using a miRNeasy lysis buffer and homogenize using a QIAshredder spin column.
* Extract total RNA using the miRNeasy kit according to the manufacturer's instructions.
* Elute the RNA in 30 μL of RNase-free water.

**Step 2.2: Perform microRNA profiling using a microarray platform or NGS technology**

* Prepare the RNA samples for microarray analysis according to the manufacturer's instructions (e.g., Affymetrix GeneChip miRNA 4.0).
* Hybridize the RNA samples to the microarray platform and scan the arrays according to the manufacturer's instructions.
* Alternatively, prepare the RNA samples for NGS analysis using the Illumina TruSeq Small RNA Library Prep Kit.
* Sequence the libraries on an Illumina platform (e.g., HiSeq 2500) according to the manufacturer's instructions.

**Protocol 3: microRNA Target Prediction and Validation**

**Step 3.1: Use bioinformatic tools to predict microRNA targets involved in NF-κB signaling and immune responses**

* Use TargetScan and miRanda to predict microRNA targets involved in NF-κB signaling and immune responses.
* Filter the predicted targets based on their relevance to NF-κB signaling and immune responses.

**Step 3.2: Validate the predicted targets using qRT-PCR and Western blotting**

* Design and synthesize qRT-PCR primers for the predicted microRNA targets.
* Perform qRT-PCR using a qRT-PCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).
* Analyze the qRT-PCR data using the ΔΔCt method.
* Validate the predicted targets using Western blotting with specific antibodies.

**Protocol 4: NF-κB Signaling Assays**

**Step 4.1: Measure NF-κB activity using a luciferase reporter assay or an ELISA-based assay**

* Transfect the stimulated T cells and B cells with an NF-κB luciferase reporter plasmid (e.g., pNF-κB-Luc).
* Measure luciferase activity using a luminometer (e.g., Promega GloMax 20/20).
* Alternatively, use an ELISA-based assay (e.g., NF-κB p65 Transcription Factor Assay Kit) to measure NF-κB activity.

**Step 4.2: Analyze the expression of NF-κB target genes using qRT-PCR**

* Design and synthesize qRT-PCR primers for NF-κB target genes (e.g., IL-6, TNF-α).
* Perform qRT-PCR using a qRT-PCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).
* Analyze the qRT-PCR data using the ΔΔCt method.

**Protocol 5: HOIL-1 Cleavage and MALT1 Activity Assays**

**Step 5.1: Measure HOIL-1 cleavage using Western blotting with a cleavage-specific antibody**

* Prepare protein lysates from the stimulated T cells and B cells.
* Perform Western blotting using a cleavage-specific antibody against HOIL-1.
* Analyze the Western blot data using image analysis software (e.g., ImageJ).

**Step 5.2: Assess MALT1 activity using a fluorogenic peptide substrate assay**

* Prepare a reaction mixture containing a fluorogenic peptide substrate (e.g., MALT1 Activity Assay Kit) and the protein lysates.
* Incubate the reaction mixture at 37°C for 1 hour.
* Measure the fluorescence intensity using a plate reader (e.g., Tecan Infinite M200).

These detailed protocols should enable the execution of the experiment to test the hypothesis and determine if MALT1-mediated HOIL-1 cleavage regulates the expression of specific microRNAs that fine-tune NF-κB signaling and immune responses in lymphocytes.","```
   WT_Mice  KI_Mice  PMA_ngmL  Iono_uM  T_Cell_Density  B_Cell_Density  miRNeasy_kit  microarray_platform  qRT_PCR_Instrument  Luciferase_Assay  ELISA_Assay  Western_Blot  MALT1_Activity_Assay  Outcome
0        5.0      5.0       10.0     1.0         1.2e+06         1.2e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
1        4.0      6.0       12.0     1.2         1.1e+06         1.3e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
2        3.0      7.0       11.0     0.8         1.0e+06         1.4e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
3        6.0      4.0       13.0     1.5         1.4e+06         1.1e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
4        5.0      5.0       10.0     1.0         1.2e+06         1.2e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
5        4.0      6.0       12.0     1.2         1.1e+06         1.3e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
6        3.0      7.0       11.0     0.8         1.0e+06         1.4e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
7        6.0      4.0       13.0     1.5         1.4e+06         1.1e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
8        5.0      5.0       10.0     1.0         1.2e+06         1.2e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
9        4.0      6.0       12.0     1.2         1.1e+06         1.3e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
10       3.0      7.0       11.0     0.8         1.0e+06         1.4e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
11       6.0      4.0       13.0     1.5         1.4e+06         1.1e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
12       5.0      5.0       10.0     1.0         1.2e+06         1.2e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
13       4.0      6.0       12.0     1.2         1.1e+06         1.3e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
14       3.0      7.0       11.0     0.8         1.0e+06         1.4e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
15       6.0      4.0       13.0     1.5         1.4e+06         1.1e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
16       5.0      5.0       10.0     1.0         1.2e+06         1.2e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
17       4.0      6.0       12.0     1.2         1.1e+06         1.3e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
18       3.0      7.0       11.0     0.8         1.0e+06         1.4e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
19       6.0      4.0       13.0     1.5         1.4e+06         1.1e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
20       5.0      5.0       10.0     1.0         1.2e+06         1.2e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
21       4.0      6.0       12.0     1.2         1.1e+06         1.3e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
22       3.0      7.0       11.0     0.8         1.0e+06         1.4e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
23       6.0      4.0       13.0     1.5         1.4e+06         1.1e+06          1.0             Illumina            7500           1.0       1.0         1.0               1.0  Activated
24       5.0      5.0       10.0     1.0         1.2e+06         1.2e+06          1.0             Affymetrix            7500           1.0       1.0         1.0               1.0  Inhibited
```",0.40528835450414524
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/29d16b34223bcd51052e226c0eee2462cb127674.summary'],"Does the MEK-ERK pathway activated by BPF also regulate the expression of pro-survival genes, such as BCL-2, in K562 cells, and if so, is this regulation ROS-independent?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's break it down and design an experiment to test it.

**Hypothesis:** The MEK-ERK pathway activated by BPF regulates the expression of pro-survival genes, such as BCL-2, in K562 cells, and this regulation is ROS-independent.

**Experimental Plan:**

**Objective:** To investigate whether the MEK-ERK pathway activated by BPF regulates BCL-2 expression in K562 cells and determine if this regulation is ROS-independent.

**Experimental Approach:**

1. **Cell Culture and Treatment:**
	* Obtain K562 cells and culture them in a suitable medium.
	* Treat cells with BPF (at various concentrations) for 24-48 hours to activate the MEK-ERK pathway.
	* Include a control group without BPF treatment.
2. **Western Blot Analysis:**
	* Harvest cells and extract protein lysates.
	* Perform Western blot analysis to detect BCL-2 protein expression using specific antibodies.
	* Quantify BCL-2 protein levels using densitometry or image analysis software.
3. **ROS Measurement:**
	* Use a ROS-sensitive probe (e.g., DCFDA or CM-H2DCFDA) to measure ROS levels in BPF-treated and control cells.
	* Analyze ROS levels using flow cytometry or fluorescence microscopy.
4. **MEK-ERK Pathway Inhibition:**
	* Treat cells with a MEK inhibitor (e.g., U0126) to block the MEK-ERK pathway.
	* Measure BCL-2 protein expression and ROS levels as in steps 2 and 3.
5. **siRNA-mediated BCL-2 Knockdown:**
	* Transfect K562 cells with BCL-2-specific siRNA to knockdown BCL-2 expression.
	* Treat cells with BPF and measure ROS levels as in step 3.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we'll design an experiment to show that the regulation of BCL-2 expression by the MEK-ERK pathway is ROS-dependent.

**Modified Experimental Approach:**

1. **ROS Induction:**
	* Treat K562 cells with a ROS-inducing agent (e.g., H2O2) to increase ROS levels.
	* Measure ROS levels as in step 3.
2. **BPF Treatment:**
	* Treat ROS-induced cells with BPF to activate the MEK-ERK pathway.
	* Measure BCL-2 protein expression as in step 2.
3. **MEK-ERK Pathway Inhibition:**
	* Treat cells with a MEK inhibitor (e.g., U0126) to block the MEK-ERK pathway.
	* Measure BCL-2 protein expression and ROS levels as in steps 2 and 3.

**Rationale:**

If the hypothesis is true, we expect to see:

* Increased BCL-2 expression in BPF-treated cells (step 2).
* No correlation between ROS levels and BCL-2 expression (steps 3 and 4).
* Inhibition of the MEK-ERK pathway will abolish BCL-2 upregulation (step 4).
* siRNA-mediated BCL-2 knockdown will not affect ROS levels (step 5).

To disprove the hypothesis, we expect to see:

* Increased BCL-2 expression in ROS-induced cells treated with BPF (step 2).
* A correlation between ROS levels and BCL-2 expression (steps 3 and 4).
* Inhibition of the MEK-ERK pathway will not abolish BCL-2 upregulation in ROS-induced cells (step 3).

**Budget and Time Considerations:**

This experiment can be completed within 6-8 weeks, with a budget of approximately $5,000-$7,000, depending on the cost of reagents and equipment. The budget will cover:

* Cell culture reagents and media
* BPF and MEK inhibitor
* ROS-sensitive probes and antibodies
* siRNA and transfection reagents
* Western blot and flow cytometry consumables
* Labor costs for a research assistant or graduate student

This experimental plan is designed to test the hypothesis in a concise and cost-effective manner, while also providing a clear direction to disprove the hypothesis if the results do not support it.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Treatment**

1.1. Obtain K562 cells from a reliable source (e.g., ATCC) and store them in a -80°C freezer.

1.2. Thaw the cells and culture them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine in a 37°C, 5% CO2 incubator.

1.3. Allow the cells to grow for 2-3 days to reach a density of 1-2 x 10^6 cells/mL.

1.4. Prepare a stock solution of BPF (e.g., 10 mM) in DMSO and store it at -20°C.

1.5. Treat the cells with BPF at various concentrations (e.g., 0.1, 1, 10 μM) for 24-48 hours. Use a control group without BPF treatment.

1.6. Incubate the cells in a 37°C, 5% CO2 incubator for the specified time.

**Protocol 2: Western Blot Analysis**

2.1. Harvest the cells by centrifugation at 300 x g for 5 minutes.

2.2. Wash the cells with ice-cold PBS and resuspend them in 1 mL of RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (e.g., PMSF, aprotinin).

2.3. Incubate the cells on ice for 30 minutes and then centrifuge at 10,000 x g for 10 minutes.

2.4. Collect the supernatant and measure the protein concentration using a Bradford assay or BCA assay.

2.5. Load 20-30 μg of protein onto a 12% SDS-PAGE gel and separate the proteins by electrophoresis.

2.6. Transfer the proteins to a PVDF membrane using a wet transfer apparatus.

2.7. Block the membrane with 5% non-fat milk in TBST (20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) for 1 hour.

2.8. Incubate the membrane with a primary antibody against BCL-2 (e.g., 1:1000 dilution) overnight at 4°C.

2.9. Wash the membrane with TBST and incubate with a secondary antibody (e.g., 1:5000 dilution) for 1 hour.

2.10. Develop the membrane using an ECL substrate and detect the signal using a chemiluminescence imager.

2.11. Quantify the BCL-2 protein levels using densitometry or image analysis software (e.g., ImageJ).

**Protocol 3: ROS Measurement**

3.1. Prepare a stock solution of DCFDA (e.g., 10 mM) in DMSO and store it at -20°C.

3.2. Treat the cells with DCFDA (e.g., 10 μM) for 30 minutes at 37°C.

3.3. Wash the cells with PBS and resuspend them in 1 mL of PBS.

3.4. Analyze the cells using flow cytometry (e.g., BD FACSCalibur) or fluorescence microscopy (e.g., Olympus IX71).

3.5. Measure the mean fluorescence intensity (MFI) of the cells using flow cytometry software (e.g., FlowJo) or image analysis software (e.g., ImageJ).

**Protocol 4: MEK-ERK Pathway Inhibition**

4.1. Prepare a stock solution of U0126 (e.g., 10 mM) in DMSO and store it at -20°C.

4.2. Treat the cells with U0126 (e.g., 10 μM) for 1 hour before BPF treatment.

4.3. Follow the same protocol as Protocol 1 for BPF treatment.

4.4. Follow the same protocol as Protocol 2 for Western blot analysis.

4.5. Follow the same protocol as Protocol 3 for ROS measurement.

**Protocol 5: siRNA-mediated BCL-2 Knockdown**

5.1. Design and synthesize BCL-2-specific siRNA (e.g., 20 μM) and a scrambled siRNA control.

5.2. Transfect the siRNA into K562 cells using a transfection reagent (e.g., Lipofectamine RNAiMAX) according to the manufacturer's instructions.

5.3. Incubate the cells for 24-48 hours to allow for siRNA-mediated knockdown.

5.4. Treat the cells with BPF (e.g., 10 μM) for 24-48 hours.

5.5. Follow the same protocol as Protocol 3 for ROS measurement.

**Protocol 6: ROS Induction**

6.1. Prepare a stock solution of H2O2 (e.g., 30%) and store it at 4°C.

6.2. Treat the cells with H2O2 (e.g., 100 μM) for 1 hour to induce ROS.

6.3. Follow the same protocol as Protocol 1 for BPF treatment.

6.4. Follow the same protocol as Protocol 2 for Western blot analysis.

6.5. Follow the same protocol as Protocol 3 for ROS measurement.

**Protocol 7: MEK-ERK Pathway Inhibition in ROS-Induced Cells**

7.1. Follow the same protocol as Protocol 4 for MEK-ERK pathway inhibition.

7.2. Treat the ROS-induced cells with U0126 (e.g., 10 μM) for 1 hour before BPF treatment.

7.3. Follow the same protocol as Protocol 2 for Western blot analysis.

7.4. Follow the same protocol as Protocol 3 for ROS measurement.

These detailed protocols should provide a clear direction for executing the experiment and testing the hypothesis.","```
   RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  BPF  U0126  siRNA  H2O2  BCL-2  ROS
0        10.0  10.0                1.0          1.0  0.1    0.0   0.0   0.0  0.80  1500
1        10.0  10.0                1.0          1.0  1.0    0.0   0.0   0.0  0.60  2000
2        10.0  10.0                1.0          1.0  10.0   0.0   0.0   0.0  0.40  2500
3        10.0  10.0                1.0          1.0  0.1    10.0   0.0   0.0  0.70  1800
4        10.0  10.0                1.0          1.0  1.0    10.0   0.0   0.0  0.50  2200
5        10.0  10.0                1.0          1.0  10.0   10.0   0.0   0.0  0.30  2800
6        10.0  10.0                1.0          1.0  0.1    0.0  20.0   0.0  0.90  1200
7        10.0  10.0                1.0          1.0  1.0    0.0  20.0   0.0  0.80  1600
8        10.0  10.0                1.0          1.0  10.0   0.0  20.0   0.0  0.60  2000
9        10.0  10.0                1.0          1.0  0.1    10.0   0.0  100.0  0.80  1800
10       10.0  10.0                1.0          1.0  1.0    10.0   0.0  100.0  0.60  2200
11       10.0  10.0                1.0          1.0  10.0   10.0   0.0  100.0  0.40  2800
12       10.0  10.0                1.0          1.0  0.1    0.0  20.0  100.0  0.90  1200
13       10.0  10.0                1.0          1.0  1.0    0.0  20.0  100.0  0.80  1600
14       10.0  10.0                1.0          1.0  10.0   0.0  20.0  100.0  0.60  2000
15       10.0  10.0                1.0          1.0  0.1    10.0   0.0   0.0  0.70  1800
16       10.0  10.0                1.0          1.0  1.0    10.0   0.0   0.0  0.50  2200
17       10.0  10.0                1.0          1.0  10.0   10.0   0.0   0.0  0.30  2800
18       10.0  10.0                1.0          1.0  0.1    0.0  20.0   0.0  0.90  1200
19       10.0  10.0                1.0          1.0  1.0    0.0  20.0   0.0  0.80  1600
20       10.0  10.0                1.0          1.0  10.0   0.0  20.0   0.0  0.60  2000
21       10.0  10.0                1.0          1.0  0.1    10.0   0.0  100.0  0.80  1800
22       10.0  10.0                1.0          1.0  1.0    10.0   0.0  100.0  0.60  2200
23       10.0  10.0                1.0          1.0  10.0   10.0   0.0  100.0  0.40  2800
24       10.0  10.0                1.0          1.0  0.1    0.0  20.0  100.0  0.90  1200
```",0.054303563547274704
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/a41ce343a63021072c2b7e3d2d704db9ea3973b3.summary'],"Does the MHCII-associated invariant chain also regulate the trafficking and signaling of other Toll-like receptors in B cells, such as TLR9, through modulation of the ESCRT machinery?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that the MHCII-associated invariant chain also regulates the trafficking and signaling of other Toll-like receptors (TLRs) in B cells, such as TLR9, through modulation of the ESCRT machinery.

**Experimental Plan:**

**Title:** Investigating the role of the MHCII-associated invariant chain in TLR9 trafficking and signaling in B cells

**Objective:** To test the hypothesis that the MHCII-associated invariant chain regulates TLR9 trafficking and signaling in B cells by modulating the interaction between TLR9 and the ESCRT machinery.

**Equipment:**

* Flow cytometer
* Confocal microscope
* B cells
* TLR9 antibody
* Invariant chain antibody
* ESCRT machinery antibody
* siRNA against invariant chain
* Western blot equipment

**Steps:**

1. **Negative Control:** Isolate B cells from mice and stimulate them with TLR9 ligands (e.g., CpG oligonucleotides) in the absence of siRNA against the invariant chain. This will serve as a positive control to demonstrate TLR9 trafficking and signaling in B cells.
2. **siRNA-mediated Invariant Chain Knockdown:** Isolate B cells from mice and stimulate them with TLR9 ligands in the presence of siRNA against the invariant chain. This will test the effect of invariant chain knockdown on TLR9 trafficking and signaling.
3. **Flow Cytometry:** Analyze TLR9 trafficking and signaling in B cells using flow cytometry. Measure the expression of TLR9 on the surface and in the endosomes of B cells, as well as the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6) in response to TLR9 stimulation.
4. **Confocal Microscopy:** Analyze the co-localization of TLR9 and ESCRT machinery components in B cells using confocal microscopy. This will provide visual evidence of the interaction between TLR9 and ESCRT machinery.
5. **Co-Immunoprecipitation:** Co-immunoprecipitate TLR9 and ESCRT machinery components in the presence or absence of the invariant chain. This will test the interaction between TLR9 and ESCRT machinery and whether the invariant chain modulates this interaction.
6. **Western Blot:** Analyze the interaction between TLR9 and ESCRT machinery components using western blot. This will provide quantitative evidence of the interaction between TLR9 and ESCRT machinery.
7. **Comparison and Statistical Analysis:** Compare the results from steps 2-6 to determine if the invariant chain regulates TLR9 trafficking and signaling by modulating the interaction between TLR9 and ESCRT machinery. Perform statistical analysis to determine the significance of the results.

**Rationale:**

This experimental plan is designed to test the hypothesis by:

* Demonstrating TLR9 trafficking and signaling in B cells in the absence of invariant chain knockdown (step 1)
* Showing the effect of invariant chain knockdown on TLR9 trafficking and signaling (step 2)
* Analyzing the interaction between TLR9 and ESCRT machinery using multiple approaches (steps 4-6)
* Comparing the results to determine if the invariant chain regulates TLR9 trafficking and signaling by modulating the interaction between TLR9 and ESCRT machinery

**Time and Resource Considerations:**

This experiment can be completed within a reasonable time frame (approximately 6-8 weeks) and with a limited budget. The required equipment and reagents are readily available in most immunology laboratories. The experiment can be performed with a small team of researchers, including a principal investigator, a postdoctoral researcher, and a graduate student.

**Potential Pitfalls and Limitations:**

* Off-target effects of siRNA against the invariant chain
* Variability in B cell isolation and stimulation protocols
* Limited availability of TLR9-specific antibodies and reagents
* Potential confounding effects of other TLRs or immune receptors on TLR9 trafficking and signaling

By following this experimental plan, we can test the hypothesis and determine if the MHCII-associated invariant chain regulates the trafficking and signaling of TLR9 in B cells through modulation of the ESCRT machinery.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Negative Control - Isolation and Stimulation of B Cells**

1.1. Obtain 1-2 million B cells from mice using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

1.2. Resuspend the isolated B cells in 1 mL of complete RPMI 1640 medium (containing 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine) and count the cells using a hemocytometer.

1.3. Stimulate the B cells with 1 μM CpG oligonucleotides (e.g., ODN 1826) for 24 hours at 37°C, 5% CO2.

1.4. After 24 hours, collect the cells and wash them twice with PBS.

**Step 2: siRNA-mediated Invariant Chain Knockdown**

2.1. Obtain 1-2 million B cells from mice using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

2.2. Resuspend the isolated B cells in 1 mL of complete RPMI 1640 medium (containing 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine) and count the cells using a hemocytometer.

2.3. Transfect the B cells with 50 nM siRNA against the invariant chain (e.g., siGENOME SMARTpool, Dharmacon) using a transfection reagent (e.g., Lipofectamine RNAiMAX, Invitrogen) according to the manufacturer's instructions.

2.4. Incubate the transfected cells for 48 hours at 37°C, 5% CO2.

2.5. Stimulate the transfected B cells with 1 μM CpG oligonucleotides (e.g., ODN 1826) for 24 hours at 37°C, 5% CO2.

2.6. After 24 hours, collect the cells and wash them twice with PBS.

**Step 3: Flow Cytometry**

3.1. Stain the B cells from steps 1.4 and 2.6 with the following antibodies:

* TLR9-PE (e.g., eBioscience, 1:100)
* CD19-APC (e.g., BioLegend, 1:100)
* CD86-FITC (e.g., BioLegend, 1:100)

3.2. Incubate the cells with the antibodies for 30 minutes at 4°C.

3.3. Wash the cells twice with PBS and resuspend them in 500 μL of PBS.

3.4. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and collect data on the expression of TLR9, CD19, and CD86.

**Step 4: Confocal Microscopy**

4.1. Fix the B cells from steps 1.4 and 2.6 with 4% paraformaldehyde for 15 minutes at room temperature.

4.2. Permeabilize the cells with 0.1% Triton X-100 for 10 minutes at room temperature.

4.3. Stain the cells with the following antibodies:

* TLR9-Alexa Fluor 488 (e.g., eBioscience, 1:100)
* ESCRT machinery component (e.g., Tsg101)-Alexa Fluor 594 (e.g., Abcam, 1:100)

4.4. Incubate the cells with the antibodies for 1 hour at room temperature.

4.5. Wash the cells twice with PBS and mount them on glass slides using a mounting medium (e.g., ProLong Gold, Invitrogen).

4.6. Analyze the cells using a confocal microscope (e.g., Zeiss LSM 710) and collect images of the co-localization of TLR9 and ESCRT machinery components.

**Step 5: Co-Immunoprecipitation**

5.1. Lyse the B cells from steps 1.4 and 2.6 using a lysis buffer (e.g., RIPA buffer) containing protease inhibitors (e.g., Complete Mini, Roche).

5.2. Immunoprecipitate TLR9 using a TLR9 antibody (e.g., eBioscience, 1:100) and protein A/G beads (e.g., Santa Cruz Biotechnology) according to the manufacturer's instructions.

5.3. Wash the beads three times with lysis buffer and elute the immunoprecipitated proteins using a sample buffer (e.g., Laemmli buffer).

5.4. Analyze the immunoprecipitated proteins using western blot (step 6).

**Step 6: Western Blot**

6.1. Resolve the immunoprecipitated proteins from step 5.4 using SDS-PAGE (e.g., 10% gel).

6.2. Transfer the proteins to a PVDF membrane (e.g., Millipore) using a transfer buffer (e.g., Tris-glycine buffer).

6.3. Block the membrane with 5% milk in TBST (Tris-buffered saline with 0.1% Tween 20) for 1 hour at room temperature.

6.4. Incubate the membrane with the following antibodies:

* TLR9 (e.g., eBioscience, 1:1000)
* ESCRT machinery component (e.g., Tsg101, Abcam, 1:1000)

6.5. Incubate the membrane with the antibodies for 1 hour at room temperature.

6.6. Wash the membrane three times with TBST and detect the proteins using an ECL substrate (e.g., Amersham ECL Prime, GE Healthcare).

**Step 7: Comparison and Statistical Analysis**

7.1. Compare the results from steps 3-6 to determine if the invariant chain regulates TLR9 trafficking and signaling by modulating the interaction between TLR9 and ESCRT machinery.

7.2. Perform statistical analysis (e.g., Student's t-test, ANOVA) to determine the significance of the results.

7.3. Present the results in a clear and concise manner, including figures and tables, to support the conclusions drawn from the experiment.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   B Cells (million)  CpG Oligonucleotides (μM)  siRNA (nM)  TLR9-PE  CD19-APC  CD86-FITC  Co-localization  TLR9-Tsg101 Interaction
0               1.5                    0.5         30.0     0.85      0.92      0.78           0.60               0.40
1               1.0                    1.0         40.0     0.90      0.95      0.85           0.70               0.50
2               1.2                    0.8         35.0     0.88      0.93      0.80           0.65               0.45
3               1.8                    1.2         45.0     0.92      0.98      0.90           0.75               0.55
4               1.1                    0.9         32.0     0.86      0.91      0.82           0.62               0.42
5               1.4                    1.1         38.0     0.90      0.94      0.86           0.68               0.48
6               1.6                    0.7         28.0     0.83      0.90      0.79           0.58               0.38
7               1.3                    1.0         36.0     0.89      0.92      0.84           0.64               0.44
8               1.9                    1.3         48.0     0.94      0.99      0.92           0.78               0.58
9               1.2                    0.6         25.0     0.80      0.88      0.76           0.54               0.36
10              1.5                    1.2         42.0     0.91      0.96      0.88           0.72               0.52
11              1.0                    0.9         31.0     0.84      0.90      0.81           0.60               0.40
12              1.7                    1.1         39.0     0.92      0.95      0.87           0.70               0.50
13              1.4                    0.8         33.0     0.87      0.92      0.83           0.63               0.43
14              1.6                    1.0         37.0     0.90      0.94      0.85           0.67               0.47
15              1.1                    0.7         26.0     0.81      0.89      0.78           0.56               0.38
16              1.8                    1.3         49.0     0.95      1.00      0.93           0.80               0.60
17              1.3                    0.9         34.0     0.88      0.92      0.84           0.65               0.45
18              1.5                    1.1         41.0     0.91      0.96      0.88           0.72               0.52
19              1.2                    0.8         29.0     0.85      0.91      0.80           0.59               0.40
20              1.7                    1.2         43.0     0.93      0.97      0.90           0.75               0.55
21              1.0                    0.9         30.0     0.83      0.90      0.82           0.61               0.42
22              1.6                    1.0         38.0     0.90      0.94      0.86           0.68               0.48
23              1.4                    0.7         27.0     0.82      0.89      0.79           0.57               0.39
24              1.9                    1.3         50.0     0.96      1.01      0.94           0.82               0.62
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/65d3dfebd679f1683e30dbbd2e0c77d2246b311c.summary'],"Does the Nrf2-Keap1 pathway play a critical role in regulating redox homeostasis in hematopoietic stem cells, and can its modulation enhance the efficacy of pro-oxidant therapy in acute lymphoblastic leukemia while minimizing oxidative damage to normal HSCs?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that the Nrf2-Keap1 pathway plays a critical role in regulating redox homeostasis in hematopoietic stem cells (HSCs) and that its modulation can enhance the efficacy of pro-oxidant therapy in acute lymphoblastic leukemia (ALL) while minimizing oxidative damage to normal HSCs.

**Experiment:**

**Title:** Investigating the Role of Nrf2-Keap1 Pathway in Redox Homeostasis of Hematopoietic Stem Cells and its Modulation in Acute Lymphoblastic Leukemia

**Objective:** To determine if the Nrf2-Keap1 pathway is essential for maintaining redox homeostasis in HSCs and if its modulation can enhance the efficacy of pro-oxidant therapy in ALL while protecting normal HSCs from oxidative damage.

**Experimental Design:**

1. **Cell Culture:** Obtain HSCs from healthy donors and ALL cell lines (e.g., Jurkat or MOLT-4). Culture cells in a controlled environment with standard media and supplements.
2. **Nrf2-Keap1 Pathway Modulation:** Use small molecule inhibitors or siRNA to knockdown Nrf2 or Keap1 in HSCs and ALL cells. Overexpress Nrf2 or Keap1 in HSCs using lentiviral vectors or plasmids.
3. **Pro-oxidant Therapy:** Treat cells with a pro-oxidant agent (e.g., hydrogen peroxide, H2O2) at varying concentrations to induce oxidative stress.
4. **Redox Homeostasis Assays:** Measure intracellular reactive oxygen species (ROS) levels using fluorescent probes (e.g., DCFDA or CellROX). Assess glutathione (GSH) levels using a GSH assay kit.
5. **Cell Viability and Apoptosis:** Evaluate cell viability using MTT or Annexin V/PI staining. Analyze apoptosis using Western blotting for cleaved caspase-3 and PARP.
6. **Flow Cytometry:** Analyze surface marker expression (e.g., CD34, CD38, CD45) on HSCs and ALL cells using flow cytometry.
7. **Western Blotting:** Examine protein expression of Nrf2, Keap1, and downstream targets (e.g., HO-1, NQO1) in HSCs and ALL cells.

**Experimental Conditions:**

* Control: Untreated HSCs and ALL cells
* Nrf2-Keap1 knockdown: HSCs and ALL cells with Nrf2 or Keap1 knockdown
* Nrf2-Keap1 overexpression: HSCs with Nrf2 or Keap1 overexpression
* Pro-oxidant therapy: HSCs and ALL cells treated with H2O2
* Combination therapy: HSCs and ALL cells with Nrf2-Keap1 modulation and pro-oxidant therapy

**Expected Outcomes:**

* If the hypothesis is true:
	+ Nrf2-Keap1 knockdown in HSCs will increase ROS levels and decrease GSH levels, making them more susceptible to oxidative damage.
	+ Nrf2-Keap1 overexpression in HSCs will decrease ROS levels and increase GSH levels, protecting them from oxidative damage.
	+ Pro-oxidant therapy will be more effective in ALL cells with Nrf2-Keap1 modulation, while minimizing oxidative damage to normal HSCs.
* If the hypothesis is false:
	+ Nrf2-Keap1 modulation will not significantly affect redox homeostasis in HSCs or ALL cells.
	+ Pro-oxidant therapy will not be more effective in ALL cells with Nrf2-Keap1 modulation, and normal HSCs will still be damaged.

**Timeline:**

* Cell culture and preparation: 2 weeks
* Nrf2-Keap1 pathway modulation: 2 weeks
* Pro-oxidant therapy and redox homeostasis assays: 4 weeks
* Cell viability, apoptosis, and flow cytometry analysis: 4 weeks
* Western blotting and data analysis: 6 weeks

**Budget:**

* Cell culture reagents and media: $5,000
* Nrf2-Keap1 pathway modulators (inhibitors, siRNA, lentiviral vectors): $10,000
* Pro-oxidant agent (H2O2): $1,000
* Redox homeostasis assay kits: $3,000
* Flow cytometry and Western blotting reagents: $5,000
* Personnel and overheads: $20,000

Total budget: $44,000

This experiment is designed to test the hypothesis and can be completed within a reasonable timeframe (approximately 20 weeks) and budget. The results will provide valuable insights into the role of the Nrf2-Keap1 pathway in regulating redox homeostasis in HSCs and its potential as a therapeutic target in ALL.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Preparation**

1.1. Obtain HSCs from healthy donors and ALL cell lines (e.g., Jurkat or MOLT-4) from a reputable cell bank or supplier.

1.2. Culture HSCs in StemSpan SFEM II medium (STEMCELL Technologies) supplemented with 1% penicillin-streptomycin, 1% L-glutamine, and 10% fetal bovine serum (FBS) at 37°C, 5% CO2.

1.3. Culture ALL cells in RPMI-1640 medium (Gibco) supplemented with 1% penicillin-streptomycin, 1% L-glutamine, and 10% FBS at 37°C, 5% CO2.

1.4. Passage cells every 3-4 days to maintain a density of 1-2 x 10^6 cells/mL.

1.5. Verify cell identity and purity using flow cytometry for surface markers CD34, CD38, and CD45.

**Protocol 2: Nrf2-Keap1 Pathway Modulation**

2.1. Nrf2-Keap1 knockdown:

* Transfect HSCs and ALL cells with 50 nM siRNA against Nrf2 or Keap1 (Dharmacon) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions.
* Incubate cells for 48 hours to allow for knockdown.

2.2. Nrf2-Keap1 overexpression:

* Transfect HSCs with 1 μg/mL lentiviral vector encoding Nrf2 or Keap1 (VectorBuilder) using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions.
* Incubate cells for 48 hours to allow for overexpression.

**Protocol 3: Pro-oxidant Therapy**

3.1. Prepare a stock solution of 30% hydrogen peroxide (H2O2) in PBS.

3.2. Treat HSCs and ALL cells with varying concentrations of H2O2 (0, 10, 50, 100, and 200 μM) for 2 hours.

**Protocol 4: Redox Homeostasis Assays**

4.1. Measure intracellular ROS levels using DCFDA (Invitrogen) according to the manufacturer's instructions.

* Load cells with 10 μM DCFDA for 30 minutes at 37°C.
* Measure fluorescence using a plate reader (excitation: 485 nm, emission: 535 nm).

4.2. Measure GSH levels using a GSH assay kit (Cayman Chemical) according to the manufacturer's instructions.

* Lyse cells in 1% Triton X-100 and centrifuge at 10,000 x g for 10 minutes.
* Measure GSH levels using a plate reader (absorbance: 405 nm).

**Protocol 5: Cell Viability and Apoptosis**

5.1. Evaluate cell viability using MTT (Sigma-Aldrich) according to the manufacturer's instructions.

* Incubate cells with 0.5 mg/mL MTT for 2 hours at 37°C.
* Measure absorbance at 570 nm using a plate reader.

5.2. Analyze apoptosis using Annexin V/PI staining (BD Biosciences) according to the manufacturer's instructions.

* Stain cells with Annexin V-FITC and PI for 15 minutes at room temperature.
* Analyze using flow cytometry (FACSVerse, BD Biosciences).

5.3. Analyze apoptosis using Western blotting for cleaved caspase-3 and PARP.

* Lyse cells in RIPA buffer and centrifuge at 10,000 x g for 10 minutes.
* Separate proteins using SDS-PAGE and transfer to a PVDF membrane.
* Probe with anti-cleaved caspase-3 and anti-PARP antibodies (Cell Signaling Technology).

**Protocol 6: Flow Cytometry**

6.1. Stain cells with surface markers CD34, CD38, and CD45 using conjugated antibodies (BD Biosciences) according to the manufacturer's instructions.

6.2. Analyze using flow cytometry (FACSVerse, BD Biosciences).

**Protocol 7: Western Blotting**

7.1. Lyse cells in RIPA buffer and centrifuge at 10,000 x g for 10 minutes.

7.2. Separate proteins using SDS-PAGE and transfer to a PVDF membrane.

7.3. Probe with anti-Nrf2, anti-Keap1, anti-HO-1, and anti-NQO1 antibodies (Cell Signaling Technology).

7.4. Detect using ECL reagent (GE Healthcare) and analyze using ImageJ software.

These detailed protocols should provide a clear guide for executing the experiment and obtaining reliable results.","```
   HSCs  ALL_cells  siRNA_Nrf2  siRNA_Keap1  Lentiviral_Nrf2  Lentiviral_Keap1  H2O2  ROS_levels  GSH_levels  Cell_Viability  Apoptosis
0     1.0       1.0         0.0          0.0             0.0             0.0   0.0       100.0       10.0         0.8       0.2
1     1.0       1.0         0.0          0.0             1.0             0.0   0.0       120.0       12.0         0.9       0.1
2     1.0       1.0         0.0          0.0             0.0             1.0   0.0       110.0       11.0         0.8       0.2
3     1.0       1.0         1.0          0.0             0.0             0.0   0.0        90.0        9.0         0.7       0.3
4     1.0       1.0         0.0          1.0             0.0             0.0   0.0        80.0        8.0         0.6       0.4
5     1.0       1.0         0.0          0.0             0.0             0.0  10.0       130.0       13.0         0.8       0.2
6     1.0       1.0         0.0          0.0             0.0             0.0  50.0       160.0       16.0         0.7       0.3
7     1.0       1.0         0.0          0.0             0.0             0.0 100.0       200.0       20.0         0.5       0.5
8     1.0       1.0         0.0          0.0             0.0             0.0 200.0       250.0       25.0         0.3       0.7
9     1.0       1.0         1.0          0.0             0.0             0.0  10.0       140.0       14.0         0.7       0.3
10    1.0       1.0         0.0          1.0             0.0             0.0  10.0       120.0       12.0         0.6       0.4
11    1.0       1.0         0.0          0.0             1.0             0.0  50.0       180.0       18.0         0.8       0.2
12    1.0       1.0         0.0          0.0             0.0             1.0  50.0       190.0       19.0         0.7       0.3
13    1.0       1.0         1.0          0.0             0.0             0.0  50.0       150.0       15.0         0.6       0.4
14    1.0       1.0         0.0          1.0             0.0             0.0  50.0       130.0       13.0         0.5       0.5
15    1.0       1.0         0.0          0.0             1.0             0.0 100.0       220.0       22.0         0.6       0.4
16    1.0       1.0         0.0          0.0             0.0             1.0 100.0       230.0       23.0         0.5       0.5
17    1.0       1.0         1.0          0.0             0.0             0.0 100.0       160.0       16.0         0.5       0.5
18    1.0       1.0         0.0          1.0             0.0             0.0 100.0       140.0       14.0         0.4       0.6
19    1.0       1.0         0.0          0.0             1.0             0.0 200.0       280.0       28.0         0.4       0.6
20    1.0       1.0         0.0          0.0             0.0             1.0 200.0       290.0       29.0         0.3       0.7
21    1.0       1.0         1.0          0.0             0.0             0.0 200.0       180.0       18.0         0.4       0.6
22    1.0       1.0         0.0          1.0             0.0             0.0 200.0       160.0       16.0         0.3       0.7
23    1.0       1.0         0.0          0.0             1.0             0.0  50.0       200.0       20.0         0.7       0.3
24    1.0       1.0         0.0          0.0             0.0             1.0  50.0       210.0       21.0         0.6       0.4
```",0.03665352520331863
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ec29d67642ec8f8761033e27b2f1e83900e26018.summary'],"Does the SLC1A1-mediated regulation of redox homeostasis during B cell activation also influence the expression of co-receptor signaling networks, thereby modulating the specificity of B cell responses to antigens?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Does the SLC1A1-mediated regulation of redox homeostasis during B cell activation also influence the expression of co-receptor signaling networks, thereby modulating the specificity of B cell responses to antigens?

**Experimental Plan:**

**Objective:** To investigate the role of SLC1A1 in regulating co-receptor signaling networks and B cell responses to antigens.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate B cells from wild-type and SLC1A1 knockout mice (generated using CRISPR/Cas9 genome editing).
	* Stimulate B cells with anti-IgM to activate the B cell receptor (BCR).
2. **Co-Receptor Signaling Analysis:**
	* Use proximity labeling (e.g., CD19-APEX2) and mass spectrometry to identify and quantify co-receptor signaling proteins and their phosphorylation states in wild-type and SLC1A1 knockout B cells at various time points (e.g., 10 seconds, 1 hour, 2 hours) after BCR stimulation.
	* Compare the co-receptor signaling networks between wild-type and SLC1A1 knockout B cells to identify potential differences.
3. **Redox State Analysis:**
	* Measure the redox state of wild-type and SLC1A1 knockout B cells using ROS-sensitive dyes and flow cytometry at various time points after BCR stimulation.
	* Compare the redox state between wild-type and SLC1A1 knockout B cells to identify potential differences.
4. **B Cell Response Analysis:**
	* Measure B cell activation markers (e.g., CD69, CD86) by flow cytometry in wild-type and SLC1A1 knockout B cells at various time points after BCR stimulation.
	* Compare the B cell activation markers between wild-type and SLC1A1 knockout B cells to identify potential differences.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test whether SLC1A1-mediated regulation of redox homeostasis does not influence the expression of co-receptor signaling networks and B cell responses to antigens.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate B cells from wild-type mice and treat them with a specific inhibitor of SLC1A1 (e.g., a glutamate transporter inhibitor) to block SLC1A1 activity.
	* Stimulate B cells with anti-IgM to activate the BCR.
2. **Co-Receptor Signaling Analysis:**
	* Use proximity labeling (e.g., CD19-APEX2) and mass spectrometry to identify and quantify co-receptor signaling proteins and their phosphorylation states in SLC1A1-inhibited B cells at various time points (e.g., 10 seconds, 1 hour, 2 hours) after BCR stimulation.
	* Compare the co-receptor signaling networks between SLC1A1-inhibited B cells and wild-type B cells to identify potential differences.
3. **Redox State Analysis:**
	* Measure the redox state of SLC1A1-inhibited B cells using ROS-sensitive dyes and flow cytometry at various time points after BCR stimulation.
	* Compare the redox state between SLC1A1-inhibited B cells and wild-type B cells to identify potential differences.
4. **B Cell Response Analysis:**
	* Measure B cell activation markers (e.g., CD69, CD86) by flow cytometry in SLC1A1-inhibited B cells at various time points after BCR stimulation.
	* Compare the B cell activation markers between SLC1A1-inhibited B cells and wild-type B cells to identify potential differences.

**Expected Outcome:**

If the hypothesis is true, the experiment should show that SLC1A1 knockout or inhibition leads to changes in co-receptor signaling networks, redox state, and B cell responses to antigens compared to wild-type B cells. If the experiment to disprove the hypothesis shows no significant differences between SLC1A1-inhibited B cells and wild-type B cells, it would suggest that SLC1A1-mediated regulation of redox homeostasis does not influence the expression of co-receptor signaling networks and B cell responses to antigens, thereby disproving the hypothesis.

**Time and Resource Requirements:**

* Time: 6-12 months
* Resources:
	+ CRISPR/Cas9 genome editing reagents and equipment
	+ Proximity labeling reagents (e.g., CD19-APEX2)
	+ Mass spectrometry equipment and reagents
	+ Flow cytometry equipment and reagents
	+ SLC1A1 inhibitor (e.g., glutamate transporter inhibitor)
	+ Mouse models (wild-type and SLC1A1 knockout)
	+ Laboratory personnel and equipment for cell culture, stimulation, and analysis

**Budget:**

The estimated budget for this experiment would be around $200,000-$300,000, depending on the specific reagents, equipment, and personnel costs. This includes the costs of CRISPR/Cas9 genome editing, proximity labeling, mass spectrometry, flow cytometry, and SLC1A1 inhibitor, as well as personnel and laboratory expenses.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Investigating the role of SLC1A1 in regulating co-receptor signaling networks and B cell responses to antigens**

**Step 1.1: Isolate B cells from wild-type and SLC1A1 knockout mice**

1. Obtain wild-type and SLC1A1 knockout mice (generated using CRISPR/Cas9 genome editing).
2. Sacrifice the mice and harvest the spleens.
3. Prepare a single-cell suspension of splenocytes using a gentleMACS Dissociator (Miltenyi Biotec).
4. Isolate B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
5. Count and purify the B cells using a cell counter (e.g., Countess II, Invitrogen) and a cell sorter (e.g., FACSAria, BD Biosciences).

**Step 1.2: Stimulate B cells with anti-IgM**

1. Resuspend the isolated B cells in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
2. Add 10 μg/mL anti-IgM (e.g., Jackson ImmunoResearch) to the B cell suspension and incubate at 37°C, 5% CO2 for 10 seconds, 1 hour, or 2 hours.
3. Wash the cells with PBS and proceed to the next step.

**Step 2.1: Proximity labeling and mass spectrometry analysis**

1. Prepare the CD19-APEX2 proximity labeling reagent according to the manufacturer's instructions.
2. Add the CD19-APEX2 reagent to the stimulated B cells and incubate at 37°C, 5% CO2 for 10 minutes.
3. Quench the reaction with 10 mM biotin and wash the cells with PBS.
4. Lyse the cells using a lysis buffer (e.g., RIPA buffer) and sonicate the lysate.
5. Perform mass spectrometry analysis using a mass spectrometer (e.g., Orbitrap, Thermo Fisher Scientific) to identify and quantify co-receptor signaling proteins and their phosphorylation states.

**Step 3.1: Redox state analysis**

1. Prepare the ROS-sensitive dye (e.g., CellROX, Invitrogen) according to the manufacturer's instructions.
2. Add the ROS-sensitive dye to the stimulated B cells and incubate at 37°C, 5% CO2 for 30 minutes.
3. Wash the cells with PBS and analyze the redox state using flow cytometry (e.g., FACSCanto, BD Biosciences).

**Step 4.1: B cell response analysis**

1. Prepare the B cell activation markers (e.g., CD69, CD86) according to the manufacturer's instructions.
2. Add the B cell activation markers to the stimulated B cells and incubate at 37°C, 5% CO2 for 30 minutes.
3. Wash the cells with PBS and analyze the B cell activation markers using flow cytometry (e.g., FACSCanto, BD Biosciences).

**Experiment 2: Testing whether SLC1A1-mediated regulation of redox homeostasis does not influence the expression of co-receptor signaling networks and B cell responses to antigens**

**Step 1.1: Isolate B cells from wild-type mice and treat with SLC1A1 inhibitor**

1. Obtain wild-type mice and isolate B cells as described in Step 1.1 of Experiment 1.
2. Treat the isolated B cells with a specific inhibitor of SLC1A1 (e.g., a glutamate transporter inhibitor, 10 μM) for 30 minutes at 37°C, 5% CO2.
3. Wash the cells with PBS and proceed to the next step.

**Step 1.2: Stimulate B cells with anti-IgM**

1. Stimulate the SLC1A1-inhibited B cells with anti-IgM as described in Step 1.2 of Experiment 1.

**Step 2.2: Proximity labeling and mass spectrometry analysis**

1. Perform proximity labeling and mass spectrometry analysis as described in Step 2.1 of Experiment 1.

**Step 3.2: Redox state analysis**

1. Perform redox state analysis as described in Step 3.1 of Experiment 1.

**Step 4.2: B cell response analysis**

1. Perform B cell response analysis as described in Step 4.1 of Experiment 1.

**Data Analysis**

1. Compare the co-receptor signaling networks, redox state, and B cell responses between wild-type and SLC1A1 knockout B cells (Experiment 1) or between SLC1A1-inhibited B cells and wild-type B cells (Experiment 2).
2. Perform statistical analysis using a suitable software (e.g., GraphPad Prism) to determine significant differences between the groups.

**Quality Control**

1. Verify the purity of the isolated B cells using flow cytometry.
2. Validate the specificity of the proximity labeling reagent using a control peptide.
3. Ensure the accuracy of the mass spectrometry analysis by using internal standards and quality control samples.
4. Verify the functionality of the SLC1A1 inhibitor using a control assay (e.g., glutamate uptake assay).

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately compared between different groups.","```
   Wild-type Mice SLC1A1 Knockout Mice Anti-IgM (μg/mL) CD19-APEX2 Reagent ROS-sensitive Dye B Cell Activation Markers SLC1A1 Inhibitor (μM) Co-receptor Signaling Proteins Redox State B Cell Response
0             1.0               0.0             10.0               1.0           1.0               1.0               0.0            0.8          0.4          0.6
1             1.0               0.0              5.0               1.0           1.0               1.0               0.0            0.9          0.5          0.7
2             0.0               1.0             10.0               1.0           1.0               1.0               0.0            0.6          0.3          0.5
3             1.0               0.0             10.0               0.5           1.0               1.0               0.0            0.7          0.4          0.6
4             0.0               1.0              5.0               1.0           1.0               1.0               0.0            0.5          0.2          0.4
5             1.0               0.0              5.0               0.5           1.0               1.0               0.0            0.8          0.5          0.7
6             0.0               1.0             10.0               0.5           1.0               1.0               0.0            0.6          0.3          0.5
7             1.0               0.0             10.0               1.0           0.5               1.0               0.0            0.9          0.6          0.8
8             0.0               1.0              5.0               0.5           1.0               1.0               0.0            0.5          0.2          0.4
9             1.0               0.0              5.0               1.0           0.5               1.0               0.0            0.8          0.5          0.7
10            0.0               1.0             10.0               1.0           0.5               1.0               0.0            0.6          0.3          0.5
11            1.0               0.0             10.0               1.0           1.0               0.5               0.0            0.9          0.6          0.8
12            0.0               1.0              5.0               1.0           1.0               0.5               0.0            0.5          0.2          0.4
13            1.0               0.0              5.0               1.0           1.0               0.5               0.0            0.8          0.5          0.7
14            0.0               1.0             10.0               0.5           1.0               0.5               0.0            0.6          0.3          0.5
15            1.0               0.0             10.0               0.5           0.5               1.0               0.0            0.7          0.4          0.6
16            0.0               1.0              5.0               0.5           0.5               1.0               0.0            0.5          0.2          0.4
17            1.0               0.0              5.0               0.5           0.5               1.0               0.0            0.8          0.5          0.7
18            0.0               1.0             10.0               1.0           0.5               0.5               0.0            0.6          0.3          0.5
19            1.0               0.0             10.0               1.0           1.0               0.5               5.0            0.9          0.6          0.8
20            0.0               1.0              5.0               1.0           1.0               0.5               5.0            0.5          0.2          0.4
21            1.0               0.0              5.0               1.0           1.0               0.5               5.0            0.8          0.5          0.7
22            0.0               1.0             10.0               0.5           1.0               0.5               5.0            0.6          0.3          0.5
23            1.0               0.0             10.0               0.5           0.5               1.0               5.0            0.7          0.4          0.6
24            0.0               1.0              5.0               0.5           0.5               1.0               5.0            0.5          0.2          0.4
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c58d4820206db1bd29c672f890b6dc032e4e1df4.summary'],Does the Src and Btk kinase intracellular signaling pathway triggered by ArtinM-induced CD45 N-glycan recognition on B cells also regulate the production of other pro-inflammatory cytokines beyond IL-17?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** The Src and Btk kinase intracellular signaling pathway triggered by ArtinM-induced CD45 N-glycan recognition on B cells also regulates the production of other pro-inflammatory cytokines beyond IL-17.

**Experimental Plan:**

**Objective:** To investigate whether the Src and Btk kinase intracellular signaling pathway triggered by ArtinM-induced CD45 N-glycan recognition on B cells regulates the production of other pro-inflammatory cytokines beyond IL-17.

**Methods:**

1. **Cell Isolation and Culture:** Isolate B cells from C57BL/6 mice and culture them in a 96-well plate with ArtinM (2.5 μg/mL) and/or CD45-specific antibodies.
2. **Cytokine Profiling:** Use a multiplex cytokine assay (e.g., Luminex or MSD) to measure the production of various pro-inflammatory cytokines, including but not limited to:
	* TNF-α
	* IL-1β
	* IL-6
	* IL-8
	* IL-22
	* IFN-γ
3. **Inhibitor Treatment:** Treat B cells with Src kinase inhibitor (e.g., PP2) and/or Btk kinase inhibitor (e.g., ibrutinib) to assess the role of these kinases in regulating cytokine production.
4. **Western Blot Analysis:** Perform Western blot analysis to confirm the activation of Src and Btk kinases in response to ArtinM stimulation and the effect of inhibitors on their activity.
5. **Data Analysis:** Compare the cytokine production profiles between B cells treated with ArtinM alone, CD45-specific antibodies alone, and ArtinM + CD45-specific antibodies. Analyze the effect of Src and Btk kinase inhibitors on cytokine production.

**Equipment Needed:**

* Cell culture facilities
* Multiplex cytokine assay kit (e.g., Luminex or MSD)
* Src kinase inhibitor (e.g., PP2)
* Btk kinase inhibitor (e.g., ibrutinib)
* Western blot equipment
* CD45-specific antibodies

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that the Src and Btk kinase intracellular signaling pathway triggered by ArtinM-induced CD45 N-glycan recognition on B cells does not regulate the production of other pro-inflammatory cytokines beyond IL-17.

**Methods:**

1. **Cell Isolation and Culture:** Isolate B cells from C57BL/6 mice and culture them in a 96-well plate with ArtinM (2.5 μg/mL) and/or CD45-specific antibodies.
2. **Cytokine Profiling:** Use a multiplex cytokine assay to measure the production of various pro-inflammatory cytokines (same as above).
3. **Src and Btk Kinase Inhibition:** Treat B cells with a combination of Src kinase inhibitor and Btk kinase inhibitor to completely block the signaling pathway.
4. **Cytokine Production Analysis:** Compare the cytokine production profiles between B cells treated with ArtinM alone, CD45-specific antibodies alone, and ArtinM + CD45-specific antibodies, in the presence and absence of Src and Btk kinase inhibitors.
5. **Data Analysis:** If the cytokine production profiles remain unchanged in the presence of Src and Btk kinase inhibitors, it would suggest that the Src and Btk kinase intracellular signaling pathway does not regulate the production of other pro-inflammatory cytokines beyond IL-17.

**Rationale:** By using a combination of Src and Btk kinase inhibitors, we can effectively block the signaling pathway triggered by ArtinM-induced CD45 N-glycan recognition. If the production of other pro-inflammatory cytokines is not affected by the inhibition of this pathway, it would disprove the hypothesis.

**Timeline and Budget:**

* Cell isolation and culture: 2 days
* Cytokine profiling: 1 day
* Inhibitor treatment and Western blot analysis: 2 days
* Data analysis: 1 week
* Total duration: 6-8 weeks
* Budget: The estimated budget for this experiment would be approximately $5,000-$7,000, which includes the cost of reagents, equipment, and personnel.",85,"Here are the detailed, step-by-step protocols for the experiment to test the hypothesis and the experiment to disprove the hypothesis:

**Experiment to Test the Hypothesis:**

**Step 1: Cell Isolation and Culture**

1.1. Obtain C57BL/6 mice and sacrifice them according to institutional guidelines.

1.2. Harvest spleens from the mice and prepare a single-cell suspension using a gentleMACS Dissociator (Miltenyi Biotec) or a similar device.

1.3. Isolate B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

1.4. Count the isolated B cells using a hemocytometer or an automated cell counter.

1.5. Resuspend the B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.6. Seed 1 x 10^5 B cells per well in a 96-well plate.

1.7. Add ArtinM (2.5 μg/mL) and/or CD45-specific antibodies to the wells as follows:
	* Wells 1-3: ArtinM only
	* Wells 4-6: CD45-specific antibodies only
	* Wells 7-9: ArtinM + CD45-specific antibodies
	* Wells 10-12: No treatment (control)

1.8. Incubate the plate at 37°C, 5% CO2 for 24 hours.

**Step 2: Cytokine Profiling**

2.1. After 24 hours of incubation, collect the supernatants from each well and store them at -80°C until analysis.

2.2. Perform a multiplex cytokine assay (e.g., Luminex or MSD) according to the manufacturer's instructions to measure the production of various pro-inflammatory cytokines, including:
	* TNF-α
	* IL-1β
	* IL-6
	* IL-8
	* IL-22
	* IFN-γ

**Step 3: Inhibitor Treatment**

3.1. Prepare a stock solution of Src kinase inhibitor (e.g., PP2) and Btk kinase inhibitor (e.g., ibrutinib) according to the manufacturer's instructions.

3.2. Add the Src kinase inhibitor (10 μM) and/or Btk kinase inhibitor (1 μM) to the wells as follows:
	* Wells 13-15: ArtinM + Src kinase inhibitor
	* Wells 16-18: ArtinM + Btk kinase inhibitor
	* Wells 19-21: ArtinM + Src kinase inhibitor + Btk kinase inhibitor
	* Wells 22-24: No treatment (control)

3.3. Incubate the plate at 37°C, 5% CO2 for an additional 24 hours.

**Step 4: Western Blot Analysis**

4.1. After 24 hours of incubation, collect the cells from each well and lyse them using a cell lysis buffer (e.g., RIPA buffer).

4.2. Perform Western blot analysis to detect the activation of Src and Btk kinases using specific antibodies.

**Step 5: Data Analysis**

5.1. Compare the cytokine production profiles between B cells treated with ArtinM alone, CD45-specific antibodies alone, and ArtinM + CD45-specific antibodies.

5.2. Analyze the effect of Src and Btk kinase inhibitors on cytokine production.

**Experiment to Disprove the Hypothesis:**

**Step 1: Cell Isolation and Culture**

1.1-1.8. Follow the same steps as in the experiment to test the hypothesis.

**Step 2: Cytokine Profiling**

2.1-2.2. Follow the same steps as in the experiment to test the hypothesis.

**Step 3: Src and Btk Kinase Inhibition**

3.1. Prepare a stock solution of Src kinase inhibitor (e.g., PP2) and Btk kinase inhibitor (e.g., ibrutinib) according to the manufacturer's instructions.

3.2. Add a combination of Src kinase inhibitor (10 μM) and Btk kinase inhibitor (1 μM) to the wells as follows:
	* Wells 13-15: ArtinM + Src kinase inhibitor + Btk kinase inhibitor
	* Wells 16-18: CD45-specific antibodies + Src kinase inhibitor + Btk kinase inhibitor
	* Wells 19-21: ArtinM + CD45-specific antibodies + Src kinase inhibitor + Btk kinase inhibitor
	* Wells 22-24: No treatment (control)

3.3. Incubate the plate at 37°C, 5% CO2 for an additional 24 hours.

**Step 4: Cytokine Production Analysis**

4.1. Collect the supernatants from each well and store them at -80°C until analysis.

4.2. Perform a multiplex cytokine assay (e.g., Luminex or MSD) according to the manufacturer's instructions to measure the production of various pro-inflammatory cytokines.

**Step 5: Data Analysis**

5.1. Compare the cytokine production profiles between B cells treated with ArtinM alone, CD45-specific antibodies alone, and ArtinM + CD45-specific antibodies, in the presence and absence of Src and Btk kinase inhibitors.

5.2. If the cytokine production profiles remain unchanged in the presence of Src and Btk kinase inhibitors, it would suggest that the Src and Btk kinase intracellular signaling pathway does not regulate the production of other pro-inflammatory cytokines beyond IL-17.

Note: The protocols above assume that the researcher has access to a cell culture facility, a multiplex cytokine assay kit, and Western blot equipment. The specific reagents and equipment used may vary depending on the laboratory's resources and preferences.","```
   ArtinM  CD45_Ab  Src_Inhibitor  Btk_Inhibitor  TNF-alpha  IL-1beta  IL-6  IL-8  IL-22  IFN-gamma
0     2.5       0.0           0.0           0.0     120.0     150.0  80.0  100.0   50.0      200.0
1     2.5       0.0           0.0           0.0     110.0     140.0  75.0   90.0   45.0      190.0
2     2.5       0.0           0.0           0.0     130.0     160.0  85.0  110.0   55.0      210.0
3     0.0       1.0           0.0           0.0      50.0      60.0  30.0   40.0   20.0       80.0
4     0.0       1.0           0.0           0.0      45.0      55.0  25.0   35.0   15.0       70.0
5     0.0       1.0           0.0           0.0      55.0      65.0  35.0   45.0   25.0       90.0
6     2.5       1.0           0.0           0.0     180.0     220.0 120.0  140.0   80.0      280.0
7     2.5       1.0           0.0           0.0     190.0     230.0 130.0  150.0   90.0      300.0
8     2.5       1.0           0.0           0.0     170.0     210.0 110.0  130.0   70.0      260.0
9     0.0       0.0           0.0           0.0      20.0      30.0  10.0   20.0   10.0       40.0
10    2.5       0.0          10.0           0.0     100.0     120.0  60.0   80.0   40.0      160.0
11    2.5       0.0          10.0           0.0      90.0     110.0  55.0   75.0   35.0      150.0
12    2.5       0.0          10.0           0.0     110.0     130.0  65.0   90.0   45.0      170.0
13    2.5       0.0           0.0           1.0     140.0     160.0  80.0  100.0   50.0      200.0
14    2.5       0.0           0.0           1.0     130.0     150.0  75.0   90.0   45.0      190.0
15    2.5       0.0           0.0           1.0     150.0     170.0  85.0  110.0   55.0      210.0
16    2.5       0.0          10.0           1.0     120.0     140.0  70.0   90.0   40.0      180.0
17    2.5       0.0          10.0           1.0     110.0     130.0  65.0   85.0   35.0      170.0
18    2.5       0.0          10.0           1.0     130.0     150.0  75.0  100.0   45.0      190.0
19    0.0       1.0          10.0           1.0      60.0      70.0  35.0   45.0   20.0       90.0
20    0.0       1.0          10.0           1.0      55.0      65.0  30.0   40.0   15.0       80.0
21    0.0       1.0          10.0           1.0      65.0      75.0  40.0   50.0   25.0      100.0
22    2.5       1.0          10.0           1.0     200.0     240.0 140.0  160.0   90.0      320.0
23    2.5       1.0          10.0           1.0     210.0     250.0 150.0  170.0  100.0      330.0
24    2.5       1.0          10.0           1.0     190.0     230.0 130.0  150.0   80.0      310.0
```",0.21410176687544008
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d4a3a703950c7ff3dd5ed7d4f524b4bcb98d4ad5.summary'],"Does the abortive lytic infection-mediated establishment of Epstein-Barr virus latency in B-cells also induce a transient immune tolerance to viral antigens, thereby facilitating the persistence of latently infected cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that the abortive lytic infection-mediated establishment of Epstein-Barr virus (EBV) latency in B-cells also induces a transient immune tolerance to viral antigens, thereby facilitating the persistence of latently infected cells.

**Experiment Title:** Investigating the Role of Abortive Lytic Infection in Inducing Immune Tolerance to EBV Antigens

**Objective:** To determine whether the abortive lytic infection in the pre-latent phase of EBV infection induces a transient immune tolerance to viral antigens, thereby facilitating the persistence of latently infected cells.

**Experimental Approach:**

1. **In vitro infection and sampling:** Infect B-cells with EBV and collect cells at different time points during the pre-latent phase (e.g., 0, 2, 4, 6, and 8 days post-infection). This will allow us to capture the dynamics of the abortive lytic infection and its potential impact on immune tolerance.
2. **Immune cell co-culture:** Co-culture the EBV-infected B-cells with autologous T-cells (CD4+ and CD8+) and dendritic cells (DCs) to mimic the in vivo immune environment. This will enable us to assess the immune response to EBV antigens during the pre-latent phase.
3. **Immune tolerance assessment:** Measure the immune response to EBV antigens using the following assays:
	* T-cell proliferation assays (e.g., CFSE or BrdU incorporation) to assess T-cell activation and proliferation.
	* Cytokine production assays (e.g., ELISA or Luminex) to measure the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) and regulatory cytokines (e.g., IL-10, TGF-β).
	* Flow cytometry to analyze the expression of immune checkpoint molecules (e.g., PD-1, CTLA-4) and activation markers (e.g., CD25, CD69) on T-cells.
4. **Antigen presentation and processing:** Use techniques such as immunoprecipitation and mass spectrometry to analyze the processing and presentation of EBV antigens by DCs during the pre-latent phase.
5. **Blocking experiments:** Use specific inhibitors or antibodies to block key immune checkpoint molecules (e.g., PD-1, CTLA-4) or signaling pathways (e.g., PD-1/PD-L1, TGF-β) to assess their role in immune tolerance induction.
6. **In vivo validation:** Validate the in vitro findings using a humanized mouse model of EBV infection, where human B-cells and immune cells are engrafted into immunodeficient mice.

**Expected Outcomes:**

* If the hypothesis is true, we expect to observe:
	+ Reduced T-cell activation and proliferation in response to EBV antigens during the pre-latent phase.
	+ Increased production of regulatory cytokines and expression of immune checkpoint molecules on T-cells.
	+ Impaired antigen presentation and processing by DCs.
* If the hypothesis is false, we expect to observe:
	+ Normal or enhanced T-cell activation and proliferation in response to EBV antigens during the pre-latent phase.
	+ Normal or reduced production of regulatory cytokines and expression of immune checkpoint molecules on T-cells.
	+ Normal antigen presentation and processing by DCs.

**Equipment and Resources:**

* EBV-infected B-cells and autologous T-cells and DCs
* Co-culture systems and cell culture media
* Immune assays (e.g., T-cell proliferation, cytokine production, flow cytometry)
* Immunoprecipitation and mass spectrometry equipment
* Inhibitors and antibodies for blocking experiments
* Humanized mouse model of EBV infection

**Timeline:**

* In vitro experiments: 6-8 weeks
* In vivo validation: 12-16 weeks
* Data analysis and manuscript preparation: 6-8 weeks

**Budget:**

* Personnel: 2 postdoctoral researchers, 1 graduate student, 1 technician
* Reagents and consumables: $100,000
* Equipment and infrastructure: $200,000
* Animal costs (humanized mouse model): $50,000
* Total budget: $350,000

This experiment is designed to test the hypothesis that the abortive lytic infection-mediated establishment of EBV latency in B-cells induces a transient immune tolerance to viral antigens. By using a combination of in vitro and in vivo approaches, we can comprehensively assess the immune response to EBV antigens during the pre-latent phase and determine whether immune tolerance is indeed induced.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: In vitro Infection and Sampling**

1.1. Preparation of EBV-infected B-cells:

* Obtain EBV-infected B-cells from a reliable source (e.g., a cell bank or a previous experiment).
* Verify the infection status of the B-cells using PCR or immunofluorescence staining for EBV antigens.
* Culture the infected B-cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.2. Infection and sampling:

* Infect 1 x 10^6 B-cells with EBV at a multiplicity of infection (MOI) of 1:1 in a 24-well plate.
* Incubate the infected cells at 37°C, 5% CO2 for 0, 2, 4, 6, and 8 days.
* At each time point, collect 1 x 10^6 cells for further analysis (e.g., immune cell co-culture, immune tolerance assessment).

**Protocol 2: Immune Cell Co-culture**

2.1. Isolation of autologous T-cells and DCs:

* Isolate CD4+ and CD8+ T-cells from peripheral blood mononuclear cells (PBMCs) using magnetic bead separation (e.g., Miltenyi Biotec).
* Isolate DCs from PBMCs using CD14+ selection (e.g., Miltenyi Biotec).
* Verify the purity of the isolated cells using flow cytometry.

2.2. Co-culture setup:

* Co-culture 1 x 10^5 EBV-infected B-cells with 1 x 10^5 autologous T-cells (CD4+ and CD8+) and 1 x 10^5 DCs in a 24-well plate.
* Use RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubate the co-culture at 37°C, 5% CO2 for 3-5 days.

**Protocol 3: Immune Tolerance Assessment**

3.1. T-cell proliferation assay:

* Label the co-cultured T-cells with 1 μM CFSE (carboxyfluorescein succinimidyl ester) or 10 μM BrdU (bromodeoxyuridine) for 30 minutes at 37°C.
* Stimulate the T-cells with 1 μg/mL EBV antigen (e.g., EBNA-1) or 1 μg/mL control antigen (e.g., tetanus toxoid) for 3-5 days.
* Analyze T-cell proliferation using flow cytometry (CFSE) or ELISA (BrdU).

3.2. Cytokine production assay:

* Collect the co-culture supernatant and analyze cytokine production using ELISA or Luminex.
* Measure the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) and regulatory cytokines (e.g., IL-10, TGF-β).

3.3. Flow cytometry:

* Stain the co-cultured T-cells with antibodies against immune checkpoint molecules (e.g., PD-1, CTLA-4) and activation markers (e.g., CD25, CD69).
* Analyze the expression of these markers using flow cytometry.

**Protocol 4: Antigen Presentation and Processing**

4.1. Immunoprecipitation:

* Lyse the co-cultured DCs and immunoprecipitate EBV antigens using specific antibodies (e.g., anti-EBNA-1).
* Analyze the immunoprecipitated proteins using Western blot or mass spectrometry.

4.2. Mass spectrometry:

* Analyze the immunoprecipitated proteins using mass spectrometry (e.g., LC-MS/MS).
* Identify the presented EBV antigens and their processing patterns.

**Protocol 5: Blocking Experiments**

5.1. Inhibitor treatment:

* Treat the co-culture with specific inhibitors (e.g., PD-1/PD-L1 inhibitor, TGF-β inhibitor) at the recommended concentrations.
* Incubate the co-culture for 3-5 days.

5.2. Antibody blocking:

* Add specific antibodies (e.g., anti-PD-1, anti-CTLA-4) to the co-culture at the recommended concentrations.
* Incubate the co-culture for 3-5 days.

**Protocol 6: In vivo Validation**

6.1. Humanized mouse model:

* Engraft human B-cells and immune cells into immunodeficient mice (e.g., NOD-SCID mice).
* Infect the engrafted mice with EBV and monitor the immune response.

6.2. Immune response analysis:

* Analyze the immune response to EBV antigens in the humanized mice using techniques such as ELISA, flow cytometry, and immunohistochemistry.

These detailed protocols should provide a clear guide for executing the experiment and collecting the necessary data to test the hypothesis.","```
   EBV_infected_B_cells  Autologous_T_cells  DCs  EBV_antigen  Inhibitor  Antibody  T_cell_proliferation  Cytokine_production  Immune_checkpoint_molecules
0                1.0e+06           1.0e+05  1.0e+05       1.0e-06       0.0       0.0               0.45               120.0                    0.7
1                1.5e+06           1.5e+05  1.5e+05       1.5e-06       0.0       0.0               0.60               180.0                    0.8
2                2.0e+06           2.0e+05  2.0e+05       2.0e-06       0.0       0.0               0.75               240.0                    0.9
3                1.0e+06           1.0e+05  1.0e+05       1.0e-06       1.0       0.0               0.30               100.0                    0.5
4                1.5e+06           1.5e+05  1.5e+05       1.5e-06       1.0       0.0               0.40               140.0                    0.6
5                2.0e+06           2.0e+05  2.0e+05       2.0e-06       1.0       0.0               0.50               200.0                    0.7
6                1.0e+06           1.0e+05  1.0e+05       1.0e-06       0.0       1.0               0.20               80.0                     0.4
7                1.5e+06           1.5e+05  1.5e+05       1.5e-06       0.0       1.0               0.30               120.0                    0.5
8                2.0e+06           2.0e+05  2.0e+05       2.0e-06       0.0       1.0               0.40               160.0                    0.6
9                1.0e+06           1.0e+05  1.0e+05       1.0e-06       1.0       1.0               0.10               60.0                     0.3
10               1.5e+06           1.5e+05  1.5e+05       1.5e-06       1.0       1.0               0.20               100.0                    0.4
11               2.0e+06           2.0e+05  2.0e+05       2.0e-06       1.0       1.0               0.30               140.0                    0.5
12               1.0e+06           0.5e+05  1.0e+05       1.0e-06       0.0       0.0               0.50               200.0                    0.7
13               1.5e+06           0.75e+05  1.5e+05       1.5e-06       0.0       0.0               0.60               240.0                    0.8
14               2.0e+06           1.0e+05  2.0e+05       2.0e-06       0.0       0.0               0.70               280.0                    0.9
15               1.0e+06           0.5e+05  1.0e+05       1.0e-06       1.0       0.0               0.30               120.0                    0.5
16               1.5e+06           0.75e+05  1.5e+05       1.5e-06       1.0       0.0               0.40               160.0                    0.6
17               2.0e+06           1.0e+05  2.0e+05       2.0e-06       1.0       0.0               0.50               200.0                    0.7
18               1.0e+06           0.5e+05  1.0e+05       1.0e-06       0.0       1.0               0.20               80.0                     0.4
19               1.5e+06           0.75e+05  1.5e+05       1.5e-06       0.0       1.0               0.30               120.0                    0.5
20               2.0e+06           1.0e+05  2.0e+05       2.0e-06       0.0       1.0               0.40               160.0                    0.6
21               1.0e+06           0.5e+05  1.0e+05       1.0e-06       1.0       1.0               0.10               60.0                     0.3
22               1.5e+06           0.75e+05  1.5e+05       1.5e-06       1.0       1.0               0.20               100.0                    0.4
23               2.0e+06           1.0e+05  2.0e+05       2.0e-06       1.0       1.0               0.30               140.0                    0.5
24               1.0e+06           1.0e+05  0.5e+05       1.0e-06       0.0       0.0               0.40               160.0                    0.6
```",0.3003822013833879
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/82a8a8a7872caf0c4e1b8a62e0d29e367bbd34b2.summary'],"Does the absence of Arg lead to altered expression of chemokine receptors on B-cells, resulting in impaired homing to lymphoid organs and subsequent reduction in spleen B-cell numbers?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I've developed an experimental plan to test it using existing scientific methods and equipment. To disprove the hypothesis, I'll design an experiment that aims to show that the absence of Arg does not lead to altered expression of chemokine receptors on B-cells, resulting in impaired homing to lymphoid organs and subsequent reduction in spleen B-cell numbers.

**Experiment:**

**Title:** Investigating the Role of Arg in Chemokine Receptor Expression and B-Cell Homing

**Objective:** To determine if the absence of Arg affects chemokine receptor expression on B-cells, leading to impaired homing to lymphoid organs and reduced spleen B-cell numbers.

**Experimental Design:**

1. **Mouse Model:** Use Arg-deficient (Arg-/-) and wild-type (WT) mice as the experimental and control groups, respectively.
2. **B-Cell Isolation:** Isolate B-cells from the spleen of Arg-/- and WT mice using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS).
3. **Chemokine Receptor Analysis:** Use flow cytometry to analyze the expression of chemokine receptors (e.g., CXCR4, CXCR5, CCR7) on B-cells from Arg-/- and WT mice. Compare the expression levels between the two groups.
4. **Homing Assay:** Perform a homing assay to assess the ability of B-cells from Arg-/- and WT mice to migrate to lymphoid organs (e.g., spleen, lymph nodes). Use a fluorescent dye (e.g., CFSE) to label the B-cells and track their migration.
5. **Spleen B-Cell Enumeration:** Count the number of B-cells in the spleen of Arg-/- and WT mice using flow cytometry or immunohistochemistry.

**Expected Outcomes:**

* If the hypothesis is true, Arg-/- B-cells will exhibit altered chemokine receptor expression, impaired homing to lymphoid organs, and reduced spleen B-cell numbers compared to WT B-cells.
* If the hypothesis is false, Arg-/- B-cells will not show significant differences in chemokine receptor expression, homing ability, or spleen B-cell numbers compared to WT B-cells.

**Controls and Considerations:**

* Use littermate controls to minimize genetic variability.
* Perform experiments in triplicate to ensure reproducibility.
* Consider using additional controls, such as B-cells from Arg-/- mice reconstituted with Arg, to further validate the results.
* Ensure proper handling and storage of samples to prevent contamination and degradation.

**Timeline and Budget:**

* This experiment can be completed within 3-4 months, depending on the availability of resources and personnel.
* The budget will be allocated as follows:
	+ Mouse breeding and maintenance: 30%
	+ Reagents and consumables (e.g., antibodies, dyes, FACS reagents): 40%
	+ Equipment and facility costs (e.g., flow cytometer, microscope): 20%
	+ Personnel and training: 10%

By following this experimental plan, we can determine whether the absence of Arg leads to altered chemokine receptor expression on B-cells, resulting in impaired homing to lymphoid organs and reduced spleen B-cell numbers. If the results disprove the hypothesis, it will suggest that Arg plays a more complex role in B-cell biology than initially thought, and further research will be necessary to elucidate its functions.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Mouse Breeding and Maintenance**

1.1. Obtain Arg-deficient (Arg-/-) and wild-type (WT) mice from a reputable supplier or breeding facility.

1.2. House the mice in a specific pathogen-free (SPF) facility with controlled temperature (20-24°C), humidity (50-60%), and light-dark cycle (12 hours light, 12 hours dark).

1.3. Provide mice with standard rodent chow and water ad libitum.

1.4. Breed Arg-/- and WT mice to generate littermate controls.

1.5. Genotype the mice using PCR or other suitable methods to confirm the presence or absence of the Arg gene.

**Protocol 2: B-Cell Isolation**

2.1. Euthanize mice using a humane method (e.g., CO2 asphyxiation) and harvest the spleen.

2.2. Prepare a single-cell suspension of spleen cells by gently teasing the spleen apart using a sterile glass slide or a cell strainer.

2.3. Lyse red blood cells using a commercial red blood cell lysis buffer (e.g., ACK lysis buffer) according to the manufacturer's instructions.

2.4. Wash the cells with phosphate-buffered saline (PBS) and resuspend them in a suitable buffer (e.g., PBS with 2% fetal bovine serum and 1 mM EDTA).

2.5. Isolate B-cells using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) with anti-CD19 or anti-CD20 antibodies.

2.6. Verify the purity of the isolated B-cells using flow cytometry or immunofluorescence staining.

**Protocol 3: Chemokine Receptor Analysis**

3.1. Prepare a single-cell suspension of isolated B-cells in a suitable buffer (e.g., PBS with 2% fetal bovine serum and 1 mM EDTA).

3.2. Stain the cells with fluorochrome-conjugated antibodies against chemokine receptors (e.g., CXCR4, CXCR5, CCR7) according to the manufacturer's instructions.

3.3. Incubate the cells at 4°C for 30 minutes to allow for antibody binding.

3.4. Wash the cells with PBS and resuspend them in a suitable buffer.

3.5. Analyze the expression of chemokine receptors using flow cytometry (e.g., BD FACSCanto or equivalent).

3.6. Use flow cytometry software (e.g., FlowJo) to gate on B-cells and analyze the expression of chemokine receptors.

**Protocol 4: Homing Assay**

4.1. Prepare a single-cell suspension of isolated B-cells in a suitable buffer (e.g., PBS with 2% fetal bovine serum and 1 mM EDTA).

4.2. Label the B-cells with a fluorescent dye (e.g., CFSE) according to the manufacturer's instructions.

4.3. Inject the labeled B-cells into the tail vein of recipient mice (Arg-/- or WT).

4.4. Allow the mice to rest for 2-4 hours to allow for homing of the labeled B-cells.

4.5. Harvest the spleen and lymph nodes from the recipient mice.

4.6. Prepare a single-cell suspension of the harvested tissues and analyze the presence of labeled B-cells using flow cytometry.

**Protocol 5: Spleen B-Cell Enumeration**

5.1. Harvest the spleen from Arg-/- and WT mice.

5.2. Prepare a single-cell suspension of spleen cells as described in Protocol 2.

5.3. Stain the cells with fluorochrome-conjugated antibodies against B-cell markers (e.g., CD19, CD20) according to the manufacturer's instructions.

5.4. Analyze the number of B-cells in the spleen using flow cytometry or immunohistochemistry.

**Quality Control and Replicability**

* Perform all experiments in triplicate to ensure reproducibility.
* Use littermate controls to minimize genetic variability.
* Verify the purity and quality of isolated B-cells using flow cytometry or immunofluorescence staining.
* Use proper handling and storage of samples to prevent contamination and degradation.
* Consider using additional controls, such as B-cells from Arg-/- mice reconstituted with Arg, to further validate the results.

**Timeline and Budget**

* This experiment can be completed within 3-4 months, depending on the availability of resources and personnel.
* The budget will be allocated as follows:
	+ Mouse breeding and maintenance: 30%
	+ Reagents and consumables (e.g., antibodies, dyes, FACS reagents): 40%
	+ Equipment and facility costs (e.g., flow cytometer, microscope): 20%
	+ Personnel and training: 10%

By following these detailed protocols, the experiment can be executed with precision and accuracy, ensuring replicability and reliability of the results.","```
   Arg-/- Mice  WT Mice  Antibody Amount (μL)  FACS Reagent Amount (μL)  CFSE Dye Amount (μL)  Chemokine Receptor Expression  Homing Assay Result  Spleen B-Cell Count
0           5        5               10.0                    20.0               5.0                    30.0%                    25.0%               200000
1           3        7               15.0                    30.0               7.0                    40.0%                    30.0%               250000
2           4        6               12.0                    25.0               6.0                    35.0%                    28.0%               220000
3           6        4               18.0                    35.0               8.0                    45.0%                    35.0%               280000
4           5        5               11.0                    22.0               5.5                    32.0%                    26.0%               210000
5           7        3               20.0                    40.0               9.0                    50.0%                    40.0%               300000
6           4        6               13.0                    28.0               6.5                    38.0%                    31.0%               230000
7           3        7               16.0                    32.0               7.5                    42.0%                    34.0%               260000
8           6        4               19.0                    38.0               8.5                    48.0%                    39.0%               290000
9           5        5               10.5                    21.0               5.2                    31.0%                    24.0%               200000
10          7        3               21.0                    42.0               9.5                    52.0%                    43.0%               310000
11          4        6               14.0                    29.0               6.8                    39.0%                    32.0%               240000
12          3        7               17.0                    34.0               7.8                    44.0%                    36.0%               270000
13          6        4               20.5                    41.0               9.0                    51.0%                    42.0%               300000
14          5        5               11.5                    23.0               5.8                    33.0%                    27.0%               210000
15          7        3               22.0                    44.0               10.0                   54.0%                    45.0%               320000
16          4        6               15.0                    30.0               7.0                    40.0%                    33.0%               250000
17          3        7               18.5                    37.0               8.0                    46.0%                    38.0%               280000
18          6        4               21.5                    43.0               9.2                    53.0%                    44.0%               310000
19          5        5               12.0                    24.0               5.5                    34.0%                    28.0%               220000
20          7        3               23.0                    46.0               10.2                   56.0%                    47.0%               330000
21          4        6               16.0                    32.0               7.2                    41.0%                    34.0%               260000
22          3        7               19.5                    39.0               8.2                    48.0%                    40.0%               290000
23          6        4               22.5                    45.0               9.5                    55.0%                    46.0%               320000
24          5        5               12.5                    25.0               5.8                    35.0%                    29.0%               230000
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2d7f137f0a05db5fdad0ece4b6e9f964f38b704a.summary'],"Does the accumulation of BAFF on atacicept also lead to the formation of a positive feedback loop that enhances the production of regulatory T cells, thereby contributing to the therapeutic effects of atacicept in autoimmune diseases?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis that the accumulation of BAFF on atacicept leads to the formation of a positive feedback loop that enhances the production of regulatory T cells, thereby contributing to the therapeutic effects of atacicept in autoimmune diseases.

**Experiment:**

**Title:** Investigating the Role of BAFF Accumulation on Atacicept in Regulatory T Cell Production

**Objective:** To determine if the accumulation of BAFF on atacicept leads to an increase in regulatory T cell production, thereby contributing to the therapeutic effects of atacicept in autoimmune diseases.

**Design:**

1. **Cell Culture:** Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors and autoimmune disease patients.
2. **Atacicept Treatment:** Treat PBMCs with atacicept (with and without BAFF) and measure the levels of regulatory T cells (Tregs) using flow cytometry.
3. **BAFF Accumulation:** Measure the levels of BAFF bound to atacicept using ELISA or Western blot.
4. **Treg Analysis:** Analyze the expression of Treg markers (e.g., FoxP3, CD25, CD127) and functional assays (e.g., suppression assays) to determine the effect of BAFF accumulation on Treg production.
5. **Control Groups:** Include control groups with:
	* No atacicept treatment
	* Atacicept treatment without BAFF
	* BAFF treatment without atacicept
6. **Time Course:** Perform the experiment at multiple time points (e.g., 24, 48, 72 hours) to assess the kinetics of BAFF accumulation and Treg production.

**Hypothesis Testing:**

To disprove the hypothesis, we will look for the following outcomes:

* No significant increase in Treg production in response to BAFF accumulation on atacicept
* No correlation between BAFF accumulation and Treg production
* No difference in Treg production between atacicept-treated and control groups

**Resources:**

* PBMCs from healthy donors and autoimmune disease patients
* Atacicept
* BAFF
* ELISA kits for BAFF
* Flow cytometer
* Western blot equipment
* Cell culture facilities
* Statistical analysis software

**Timeline:**

* Cell isolation and treatment: 2 weeks
* BAFF accumulation and Treg analysis: 4 weeks
* Data analysis and interpretation: 2 weeks

**Budget:**

* Reagents and consumables: $5,000
* Equipment usage (flow cytometer, Western blot): $2,000
* Personnel (research assistant, technician): $10,000
* Total: $17,000

This experiment is designed to test the hypothesis in a controlled laboratory setting, using existing methods and equipment. The results will provide insight into the role of BAFF accumulation on atacicept in regulatory T cell production, contributing to our understanding of the therapeutic effects of atacicept in autoimmune diseases.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Preparation**

1.1. Obtain peripheral blood samples from healthy donors and autoimmune disease patients.

1.2. Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation (e.g., Ficoll-Paque) according to the manufacturer's instructions.

1.3. Wash the isolated PBMCs with phosphate-buffered saline (PBS) and resuspend them in complete RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.4. Count the cells using a hemocytometer or an automated cell counter and adjust the concentration to 1 x 10^6 cells/mL.

**Protocol 2: Atacicept Treatment**

2.1. Prepare atacicept stock solution according to the manufacturer's instructions.

2.2. Add atacicept to the PBMCs at a final concentration of 10 μg/mL (or as recommended by the manufacturer).

2.3. Incubate the cells at 37°C, 5% CO2 for 24, 48, or 72 hours.

2.4. For the control groups, prepare PBMCs without atacicept treatment, with atacicept treatment without BAFF, and with BAFF treatment without atacicept.

**Protocol 3: BAFF Accumulation Measurement**

3.1. Prepare BAFF stock solution according to the manufacturer's instructions.

3.2. Add BAFF to the atacicept-treated PBMCs at a final concentration of 10 ng/mL (or as recommended by the manufacturer).

3.3. Incubate the cells at 37°C, 5% CO2 for 24, 48, or 72 hours.

3.4. Measure the levels of BAFF bound to atacicept using ELISA or Western blot.

**ELISA Protocol:**

3.4.1. Coat 96-well plates with 100 μL of capture antibody (anti-BAFF) at 1 μg/mL in PBS overnight at 4°C.

3.4.2. Block the plates with 200 μL of 1% BSA in PBS for 1 hour at room temperature.

3.4.3. Add 100 μL of atacicept-treated PBMCs (from Protocol 2) to each well and incubate for 2 hours at room temperature.

3.4.4. Add 100 μL of detection antibody (anti-BAFF-HRP) at 1 μg/mL in PBS and incubate for 1 hour at room temperature.

3.4.5. Develop the plates using a substrate (e.g., TMB) according to the manufacturer's instructions.

3.4.6. Measure the absorbance at 450 nm using a plate reader.

**Western Blot Protocol:**

3.4.1. Lyse the atacicept-treated PBMCs (from Protocol 2) using RIPA buffer and quantify the protein concentration using a protein assay (e.g., BCA).

3.4.2. Separate 20 μg of protein per lane on a 10% SDS-PAGE gel.

3.4.3. Transfer the proteins to a PVDF membrane and block with 5% milk in TBST for 1 hour at room temperature.

3.4.4. Incubate the membrane with anti-BAFF antibody at 1 μg/mL in TBST overnight at 4°C.

3.4.5. Detect the bound antibody using an HRP-conjugated secondary antibody and develop the membrane using a substrate (e.g., ECL).

**Protocol 4: Treg Analysis**

4.1. Stain the atacicept-treated PBMCs (from Protocol 2) with fluorochrome-conjugated antibodies against Treg markers (e.g., FoxP3, CD25, CD127) according to the manufacturer's instructions.

4.2. Analyze the stained cells using a flow cytometer (e.g., BD FACSCanto) and quantify the percentage of Tregs.

4.3. Perform functional assays (e.g., suppression assays) to determine the effect of BAFF accumulation on Treg production.

**Protocol 5: Data Analysis and Interpretation**

5.1. Analyze the data using statistical analysis software (e.g., GraphPad Prism) to determine the significance of the results.

5.2. Compare the levels of BAFF accumulation and Treg production between the different treatment groups and time points.

5.3. Interpret the results in the context of the hypothesis and discuss the implications for the therapeutic effects of atacicept in autoimmune diseases.

Note: The protocols above are detailed and specific, but may require adjustments based on the specific equipment and reagents used in the laboratory. It is essential to follow proper laboratory protocols and safety guidelines when conducting the experiment.","```
   Ficoll-Paque  FBS  Penicillin-Streptomycin  L-Glutamine  Atacicept  BAFF  Incubation_Time  BAFF_Accumulation  Treg_Production
0           1.5   12             1.2           1.1       15.0   12.0             24.0           250.0          20.0
1           1.2   10             1.0           1.0       10.0   10.0             48.0           300.0          25.0
2           1.8   14             1.4           1.2       12.0   14.0             72.0           350.0          30.0
3           1.1   9              0.9           0.9       8.0    9.0             24.0           200.0          18.0
4           1.6   13             1.3           1.1       11.0   13.0             48.0           280.0          22.0
5           1.4   11             1.1           1.0       9.0    11.0             72.0           320.0          28.0
6           1.3   10             1.0           0.9       8.0    10.0             24.0           220.0          20.0
7           1.7   14             1.4           1.2       13.0   14.0             48.0           330.0          29.0
8           1.2   9              0.9           0.8       7.0    9.0             72.0           290.0          25.0
9           1.5   12             1.2           1.1       12.0   12.0             24.0           260.0          21.0
10          1.1   8              0.8           0.7       6.0    8.0             48.0           240.0          19.0
11          1.6   13             1.3           1.1       11.0   13.0             72.0           310.0          27.0
12          1.4   11             1.1           1.0       10.0   11.0             24.0           270.0          23.0
13          1.3   10             1.0           0.9       9.0    10.0             48.0           250.0          20.0
14          1.7   14             1.4           1.2       14.0   14.0             72.0           340.0          30.0
15          1.2   9              0.9           0.8       8.0    9.0             24.0           230.0          18.0
16          1.5   12             1.2           1.1       12.0   12.0             48.0           280.0          24.0
17          1.1   8              0.8           0.7       7.0    8.0             72.0           260.0          21.0
18          1.6   13             1.3           1.1       13.0   13.0             24.0           300.0          26.0
19          1.4   11             1.1           1.0       11.0   11.0             48.0           290.0          25.0
20          1.3   10             1.0           0.9       10.0   10.0             72.0           270.0          22.0
21          1.7   14             1.4           1.2       14.0   14.0             24.0           330.0          29.0
22          1.2   9              0.9           0.8       9.0    9.0             48.0           250.0          20.0
23          1.5   12             1.2           1.1       12.0   12.0             72.0           310.0          27.0
24          1.1   8              0.8           0.7       8.0    8.0             24.0           240.0          19.0
```",0.7314992386541651
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ca8b53a584d41b9467ea561636f169c9cae752ae.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/17c8bdb0aaf6aa11b1b1cdf02a5be0ea225a2013.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2b33dd74a1cf432f63262eb5a7d3de4dac96cec1.summary']","Does the actin cytoskeleton play a role in regulating the efficacy of BTK inhibitors in B cell malignancies by modulating BCR signaling and clustering, and can targeting the actin cytoskeleton enhance the therapeutic response to BTK inhibitors in resistant patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the actin cytoskeleton plays a role in regulating the efficacy of BTK inhibitors in B cell malignancies by modulating BCR signaling and clustering, and that targeting the actin cytoskeleton can enhance the therapeutic response to BTK inhibitors in resistant patients, I propose the following experimental plan:

**Experiment 1: Investigating the role of the actin cytoskeleton in BCR signaling and clustering in B cell malignancies**

* Objective: To determine if the actin cytoskeleton regulates BCR signaling and clustering in B cell malignancies, and if disrupting the actin cytoskeleton affects BCR signaling and clustering.
* Equipment: B cell malignancy cell lines (e.g. DLBCL), Latrunculin A, flow cytometer, confocal microscope, BCR signaling inhibitors (e.g. ibrutinib)
* Steps:
	1. Treat B cell malignancy cell lines with Latrunculin A to disrupt the actin cytoskeleton.
	2. Stimulate B cells with antigens and measure BCR signaling using flow cytometry.
	3. Use confocal microscopy to visualize BCR clustering and immune synapse formation.
	4. Compare the results with untreated B cells to determine the effect of disrupting the actin cytoskeleton on BCR signaling and clustering.
	5. Repeat steps 1-4 in the presence of BCR signaling inhibitors to determine if disrupting the actin cytoskeleton affects the response to BTK inhibitors.

**Experiment 2: Investigating the effect of targeting the actin cytoskeleton on the therapeutic response to BTK inhibitors in resistant patients**

* Objective: To determine if targeting the actin cytoskeleton can enhance the therapeutic response to BTK inhibitors in resistant patients.
* Equipment: Patient-derived B cell malignancy cells with resistance to BTK inhibitors, Latrunculin A, BCR signaling inhibitors (e.g. ibrutinib), flow cytometer, confocal microscope
* Steps:
	1. Treat patient-derived B cell malignancy cells with Latrunculin A to disrupt the actin cytoskeleton.
	2. Treat cells with BCR signaling inhibitors and measure the response using flow cytometry and confocal microscopy.
	3. Compare the results with untreated cells to determine the effect of targeting the actin cytoskeleton on the response to BTK inhibitors.
	4. Repeat steps 1-3 in combination with BCR signaling inhibitors to determine if targeting the actin cytoskeleton can enhance the therapeutic response to BTK inhibitors.

**Experiment 3: Investigating the mechanism of actin cytoskeleton regulation of BCR signaling and clustering**

* Objective: To determine the mechanism by which the actin cytoskeleton regulates BCR signaling and clustering.
* Equipment: B cell malignancy cell lines, Latrunculin A, flow cytometer, confocal microscope, RNA interference (RNAi) or CRISPR-Cas9 gene editing tools
* Steps:
	1. Use RNAi or CRISPR-Cas9 to knockdown or knockout key actin cytoskeleton regulators (e.g. WASp, Arp2/3 complex) in B cell malignancy cell lines.
	2. Measure BCR signaling and clustering using flow cytometry and confocal microscopy.
	3. Compare the results with control cells to determine the effect of disrupting actin cytoskeleton regulators on BCR signaling and clustering.
	4. Repeat steps 1-3 in the presence of BCR signaling inhibitors to determine if disrupting actin cytoskeleton regulators affects the response to BTK inhibitors.

**Experiment 4: Investigating the clinical relevance of targeting the actin cytoskeleton in B cell malignancies**

* Objective: To determine the clinical relevance of targeting the actin cytoskeleton in B cell malignancies.
* Equipment: Patient-derived B cell malignancy cells, Latrunculin A, BCR signaling inhibitors (e.g. ibrutinib), flow cytometer, confocal microscope
* Steps:
	1. Treat patient-derived B cell malignancy cells with Latrunculin A to disrupt the actin cytoskeleton.
	2. Treat cells with BCR signaling inhibitors and measure the response using flow cytometry and confocal microscopy.
	3. Compare the results with untreated cells to determine the effect of targeting the actin cytoskeleton on the response to BTK inhibitors.
	4. Analyze patient samples for actin cytoskeleton regulators and BCR signaling markers to determine if there is a correlation between actin cytoskeleton regulation and response to BTK inhibitors.

To disprove the hypothesis, the following experiment can be designed:

**Experiment 5: Investigating the lack of effect of the actin cytoskeleton on BCR signaling and clustering in B cell malignancies**

* Objective: To determine if the actin cytoskeleton does not regulate BCR signaling and clustering in B cell malignancies.
* Equipment: B cell malignancy cell lines, Latrunculin A, flow cytometer, confocal microscope
* Steps:
	1. Treat B cell malignancy cell lines with Latrunculin A to disrupt the actin cytoskeleton.
	2. Stimulate B cells with antigens and measure BCR signaling using flow cytometry.
	3. Use confocal microscopy to visualize BCR clustering and immune synapse formation.
	4. Compare the results with untreated B cells to determine if disrupting the actin cytoskeleton has no effect on BCR signaling and clustering.
	5. Repeat steps 1-4 in the presence of BCR signaling inhibitors to determine if disrupting the actin cytoskeleton has no effect on the response to BTK inhibitors.

If the results of Experiment 5 show that disrupting the actin cytoskeleton has no effect on BCR signaling and clustering, it would suggest that the actin cytoskeleton does not play a role in regulating the efficacy of BTK inhibitors in B cell malignancies, and the hypothesis would be disproven.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Experiment 1: Investigating the role of the actin cytoskeleton in BCR signaling and clustering in B cell malignancies**

**Protocol:**

1. **Cell Culture Preparation**:
	* Obtain B cell malignancy cell lines (e.g. DLBCL) and culture them in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
	* Ensure cells are in log-phase growth before experimentation.
2. **Latrunculin A Treatment**:
	* Prepare a 10 mM stock solution of Latrunculin A in DMSO.
	* Add 1 μM Latrunculin A to the cell culture medium and incubate for 30 minutes at 37°C, 5% CO2 to disrupt the actin cytoskeleton.
3. **BCR Stimulation and Signaling Analysis**:
	* Stimulate B cells with 10 μg/mL anti-IgM antibodies for 10 minutes at 37°C, 5% CO2.
	* Harvest cells and stain with fluorochrome-conjugated antibodies against BCR signaling markers (e.g. p-Syk, p-PLCγ2) using standard flow cytometry protocols.
	* Analyze BCR signaling using a flow cytometer (e.g. BD FACSCanto II).
4. **Confocal Microscopy**:
	* Fix cells with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100.
	* Stain cells with fluorochrome-conjugated antibodies against BCR clustering markers (e.g. IgM, CD79a) and actin cytoskeleton markers (e.g. phalloidin).
	* Image cells using a confocal microscope (e.g. Zeiss LSM 710) with a 63x oil immersion objective.
5. **Comparison and Data Analysis**:
	* Compare BCR signaling and clustering data from Latrunculin A-treated cells to untreated cells.
	* Analyze data using flow cytometry software (e.g. FlowJo) and confocal microscopy software (e.g. ImageJ).

**Experiment 2: Investigating the effect of targeting the actin cytoskeleton on the therapeutic response to BTK inhibitors in resistant patients**

**Protocol:**

1. **Patient-Derived Cell Preparation**:
	* Obtain patient-derived B cell malignancy cells with resistance to BTK inhibitors.
	* Culture cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
2. **Latrunculin A Treatment**:
	* Prepare a 10 mM stock solution of Latrunculin A in DMSO.
	* Add 1 μM Latrunculin A to the cell culture medium and incubate for 30 minutes at 37°C, 5% CO2 to disrupt the actin cytoskeleton.
3. **BCR Signaling Inhibitor Treatment**:
	* Prepare a 10 mM stock solution of ibrutinib in DMSO.
	* Add 1 μM ibrutinib to the cell culture medium and incubate for 1 hour at 37°C, 5% CO2.
4. **Flow Cytometry and Confocal Microscopy**:
	* Analyze BCR signaling and clustering using flow cytometry and confocal microscopy as described in Experiment 1.
5. **Comparison and Data Analysis**:
	* Compare BCR signaling and clustering data from Latrunculin A-treated cells to untreated cells in the presence and absence of ibrutinib.
	* Analyze data using flow cytometry software (e.g. FlowJo) and confocal microscopy software (e.g. ImageJ).

**Experiment 3: Investigating the mechanism of actin cytoskeleton regulation of BCR signaling and clustering**

**Protocol:**

1. **RNAi or CRISPR-Cas9 Gene Editing**:
	* Design and synthesize RNAi or CRISPR-Cas9 constructs targeting key actin cytoskeleton regulators (e.g. WASp, Arp2/3 complex).
	* Transfect B cell malignancy cell lines with RNAi or CRISPR-Cas9 constructs using standard protocols.
2. **BCR Signaling and Clustering Analysis**:
	* Analyze BCR signaling and clustering using flow cytometry and confocal microscopy as described in Experiment 1.
3. **Comparison and Data Analysis**:
	* Compare BCR signaling and clustering data from RNAi or CRISPR-Cas9-treated cells to control cells.
	* Analyze data using flow cytometry software (e.g. FlowJo) and confocal microscopy software (e.g. ImageJ).

**Experiment 4: Investigating the clinical relevance of targeting the actin cytoskeleton in B cell malignancies**

**Protocol:**

1. **Patient-Derived Cell Preparation**:
	* Obtain patient-derived B cell malignancy cells.
	* Culture cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
2. **Latrunculin A Treatment**:
	* Prepare a 10 mM stock solution of Latrunculin A in DMSO.
	* Add 1 μM Latrunculin A to the cell culture medium and incubate for 30 minutes at 37°C, 5% CO2 to disrupt the actin cytoskeleton.
3. **BCR Signaling Inhibitor Treatment**:
	* Prepare a 10 mM stock solution of ibrutinib in DMSO.
	* Add 1 μM ibrutinib to the cell culture medium and incubate for 1 hour at 37°C, 5% CO2.
4. **Flow Cytometry and Confocal Microscopy**:
	* Analyze BCR signaling and clustering using flow cytometry and confocal microscopy as described in Experiment 1.
5. **Comparison and Data Analysis**:
	* Compare BCR signaling and clustering data from Latrunculin A-treated cells to untreated cells in the presence and absence of ibrutinib.
	* Analyze data using flow cytometry software (e.g. FlowJo) and confocal microscopy software (e.g. ImageJ).

**Experiment 5: Investigating the lack of effect of the actin cytoskeleton on BCR signaling and clustering in B cell malignancies**

**Protocol:**

1. **Cell Culture Preparation**:
	* Obtain B cell malignancy cell lines (e.g. DLBCL) and culture them in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
2. **Latrunculin A Treatment**:
	* Prepare a 10 mM stock solution of Latrunculin A in DMSO.
	* Add 1 μM Latrunculin A to the cell culture medium and incubate for 30 minutes at 37°C, 5% CO2 to disrupt the actin cytoskeleton.
3. **BCR Stimulation and Signaling Analysis**:
	* Stimulate B cells with 10 μg/mL anti-IgM antibodies for 10 minutes at 37°C, 5% CO2.
	* Analyze BCR signaling using flow cytometry as described in Experiment 1.
4. **Confocal Microscopy**:
	* Fix cells with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100.
	* Stain cells with fluorochrome-conjugated antibodies against BCR clustering markers (e.g. IgM, CD79a) and actin cytoskeleton markers (e.g. phalloidin).
	* Image cells using a confocal microscope (e.g. Zeiss LSM 710) with a 63x oil immersion objective.
5. **Comparison and Data Analysis**:
	* Compare BCR signaling and clustering data from Latrunculin A-treated cells to untreated cells.
	* Analyze data using flow cytometry software (e.g. FlowJo) and confocal microscopy software (e.g. ImageJ).

Note: These protocols are detailed and specific, but may require adjustments based on the specific cell lines, reagents, and equipment used in the laboratory.","```
   Experiment  Latrunculin A (μM)  Ibrutinib (μM)  Anti-IgM (μg/mL)  BCR Signaling  BCR Clustering
0           1             0.5           0.0           10.0         0.8         0.6
1           1             1.0           0.0           10.0         0.6         0.4
2           2             1.0           1.0           10.0         0.4         0.8
3           2             0.5           1.0           10.0         0.7         0.9
4           3             1.5           0.0           10.0         0.5         0.3
5           3             1.0           0.5           10.0         0.9         0.7
6           4             0.5           1.5           10.0         0.3         0.5
7           4             1.5           1.0           10.0         0.8         0.6
8           5             1.0           0.0           10.0         0.4         0.2
9           5             0.5           1.0           10.0         0.6         0.8
10          1             1.0           0.0            5.0         0.7         0.5
11          2             0.5           1.5           10.0         0.9         0.7
12          3             1.5           0.5           10.0         0.5         0.3
13          4             1.0           0.0           10.0         0.6         0.4
14          5             0.5           1.0           10.0         0.8         0.6
15          1             1.5           1.0           10.0         0.4         0.8
16          2             1.0           0.5           10.0         0.7         0.5
17          3             0.5           1.5           10.0         0.9         0.7
18          4             1.5           1.0           10.0         0.5         0.3
19          5             1.0           0.0           10.0         0.6         0.4
20          1             0.5           1.0           10.0         0.8         0.6
21          2             1.5           0.5           10.0         0.4         0.8
22          3             1.0           1.5           10.0         0.7         0.5
23          4             0.5           0.0           10.0         0.9         0.7
24          5             1.5           1.0           10.0         0.5         0.3
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0116a23eb462561eb49925c6e7ceadf2088d9785.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/cf573eb8612574899bc230f73ec0f4797a9b1452.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/102ffa0c50d959213b33a0880c1e2246e08c6faf.summary']",Does the actin cytoskeleton-mediated regulation of B cell receptor signaling and metabolic activity by MIM also influence the Hedgehog pathway's role in maintaining leukemic stem cells in Chronic Myeloid Leukemia?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll break down the experimental plan to test this hypothesis into several sections. Since we have an unlimited budget, we can design a comprehensive and rigorous experiment to disprove the hypothesis.

**Hypothesis:** The actin cytoskeleton-mediated regulation of B cell receptor signaling and metabolic activity by MIM influences the Hedgehog pathway's role in maintaining leukemic stem cells in Chronic Myeloid Leukemia (CML).

**Experimental Approach:**

**Section 1: Cell Culture and Preparation**

1. Obtain CML cell lines (e.g., K562, KBM-7) and primary CML cells from patients.
2. Culture cells in standard media with and without MIM overexpression/knockdown using lentiviral vectors.
3. Validate MIM expression levels using Western blot, qRT-PCR, and immunofluorescence.

**Section 2: Actin Cytoskeleton Disruption**

1. Treat cells with actin-disrupting agents (e.g., cytochalasin D, latrunculin B) to perturb the actin cytoskeleton.
2. Use siRNA or CRISPR-Cas9 to knockdown actin-related genes (e.g., ACTB, ACTG1) to specifically target the actin cytoskeleton.
3. Validate actin cytoskeleton disruption using immunofluorescence, Western blot, and cell morphology analysis.

**Section 3: B Cell Receptor Signaling and Metabolic Activity Analysis**

1. Analyze B cell receptor signaling using phospho-flow cytometry (e.g., p-Syk, p-PLCγ2) and Western blot (e.g., p-BTK, p-ERK).
2. Measure metabolic activity using Seahorse XF analyzer (e.g., oxygen consumption rate, extracellular acidification rate).
3. Perform RNA-seq or qRT-PCR to analyze gene expression related to B cell receptor signaling and metabolism.

**Section 4: Hedgehog Pathway Analysis**

1. Analyze Hedgehog pathway activity using Western blot (e.g., Gli1, Gli2, Ptch1) and qRT-PCR (e.g., SHH, IHH, DHH).
2. Use Hedgehog pathway inhibitors (e.g., cyclopamine, GANT61) to perturb the pathway.
3. Perform ChIP-seq or ChIP-qPCR to analyze Gli1 binding to target genes.

**Section 5: Leukemic Stem Cell Maintenance Analysis**

1. Analyze leukemic stem cell maintenance using colony-forming unit (CFU) assays, sphere-forming assays, and flow cytometry (e.g., CD34, CD38).
2. Perform RNA-seq or qRT-PCR to analyze gene expression related to leukemic stem cell maintenance.

**Section 6: Data Integration and Statistical Analysis**

1. Integrate data from all sections using bioinformatic tools (e.g., R, Python, Bioconductor).
2. Perform statistical analysis (e.g., ANOVA, t-test, regression analysis) to identify correlations and significant differences between groups.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we will design an experiment to show that MIM-mediated regulation of actin cytoskeleton, B cell receptor signaling, and metabolic activity does not influence the Hedgehog pathway's role in maintaining leukemic stem cells in CML.

**Disproof Experiment:**

1. Use CRISPR-Cas9 to knockout MIM in CML cells and validate the knockout using Western blot and qRT-PCR.
2. Treat MIM-knockout cells with Hedgehog pathway inhibitors (e.g., cyclopamine, GANT61) and analyze leukemic stem cell maintenance using CFU assays, sphere-forming assays, and flow cytometry.
3. Compare the results to MIM-wildtype cells treated with Hedgehog pathway inhibitors.
4. If the Hedgehog pathway's role in maintaining leukemic stem cells is not affected by MIM knockout, it would suggest that MIM does not influence the Hedgehog pathway in CML, disproving the hypothesis.

**Timeline:**

This experiment would require approximately 2-3 years to complete, assuming a team of 3-4 researchers working full-time.

**Budget:**

The budget for this experiment would be substantial, but with unlimited resources, we can allocate funds as needed. Estimated costs would include:

* Personnel: $500,000 - $750,000 per year (salaries, benefits, and training)
* Reagents and consumables: $200,000 - $300,000 per year (cell lines, antibodies, primers, etc.)
* Equipment: $500,000 - $1,000,000 (Seahorse XF analyzer, flow cytometer, etc.)
* Travel and training: $20,000 - $50,000 per year (conferences, workshops, and training sessions)

Total estimated budget: $2,220,000 - $4,050,000 over 2-3 years.

By following this experimental plan, we can rigorously test the hypothesis and determine whether MIM-mediated regulation of actin cytoskeleton, B cell receptor signaling, and metabolic activity influences the Hedgehog pathway's role in maintaining leukemic stem cells in CML.",92,"Here are the detailed, step-by-step protocols for each section of the experiment:

**Section 1: Cell Culture and Preparation**

1.1. Obtain CML cell lines (e.g., K562, KBM-7) and primary CML cells from patients.

* Protocol:
	* Order CML cell lines from a reputable supplier (e.g., ATCC) and primary CML cells from a biobank or patient samples.
	* Verify the identity and purity of the cell lines using STR profiling and flow cytometry.
	* Store the cells in a -80°C freezer or liquid nitrogen until use.

1.2. Culture cells in standard media with and without MIM overexpression/knockdown using lentiviral vectors.

* Protocol:
	* Prepare lentiviral vectors encoding MIM or shRNA against MIM using standard molecular biology techniques.
	* Infect CML cells with the lentiviral vectors using a multiplicity of infection (MOI) of 10-20.
	* Culture the infected cells in standard media (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.
	* Verify MIM expression levels using Western blot, qRT-PCR, and immunofluorescence.

1.3. Validate MIM expression levels using Western blot, qRT-PCR, and immunofluorescence.

* Protocol:
	* Western blot:
		+ Lyse cells in RIPA buffer and separate proteins using SDS-PAGE.
		+ Transfer proteins to a PVDF membrane and probe with anti-MIM antibody.
		+ Detect protein bands using ECL and quantify using densitometry.
	* qRT-PCR:
		+ Extract RNA from cells using TRIzol and reverse transcribe to cDNA.
		+ Perform qRT-PCR using MIM-specific primers and a reference gene (e.g., GAPDH).
		+ Analyze data using the 2^(-ΔΔCt) method.
	* Immunofluorescence:
		+ Fix cells with 4% PFA and permeabilize with 0.1% Triton X-100.
		+ Stain cells with anti-MIM antibody and a secondary antibody conjugated to a fluorophore.
		+ Image cells using a confocal microscope and quantify fluorescence intensity using ImageJ.

**Section 2: Actin Cytoskeleton Disruption**

2.1. Treat cells with actin-disrupting agents (e.g., cytochalasin D, latrunculin B) to perturb the actin cytoskeleton.

* Protocol:
	* Prepare stock solutions of actin-disrupting agents in DMSO.
	* Treat cells with the agents at a final concentration of 1-10 μM for 30 minutes to 2 hours.
	* Verify actin cytoskeleton disruption using immunofluorescence and Western blot.

2.2. Use siRNA or CRISPR-Cas9 to knockdown actin-related genes (e.g., ACTB, ACTG1) to specifically target the actin cytoskeleton.

* Protocol:
	* Design and synthesize siRNA or CRISPR-Cas9 guides targeting actin-related genes.
	* Transfect cells with siRNA or CRISPR-Cas9 using a transfection reagent (e.g., Lipofectamine).
	* Verify knockdown efficiency using qRT-PCR and Western blot.

2.3. Validate actin cytoskeleton disruption using immunofluorescence, Western blot, and cell morphology analysis.

* Protocol:
	* Immunofluorescence:
		+ Stain cells with phalloidin conjugated to a fluorophore to visualize F-actin.
		+ Image cells using a confocal microscope and quantify fluorescence intensity using ImageJ.
	* Western blot:
		+ Analyze actin protein levels using Western blot as described in Section 1.3.
	* Cell morphology analysis:
		+ Image cells using a brightfield microscope and quantify cell shape and size using ImageJ.

**Section 3: B Cell Receptor Signaling and Metabolic Activity Analysis**

3.1. Analyze B cell receptor signaling using phospho-flow cytometry (e.g., p-Syk, p-PLCγ2) and Western blot (e.g., p-BTK, p-ERK).

* Protocol:
	* Phospho-flow cytometry:
		+ Stain cells with antibodies against phosphorylated B cell receptor signaling proteins.
		+ Analyze cells using a flow cytometer and quantify phosphorylation levels using FlowJo.
	* Western blot:
		+ Analyze phosphorylated B cell receptor signaling proteins using Western blot as described in Section 1.3.

3.2. Measure metabolic activity using Seahorse XF analyzer (e.g., oxygen consumption rate, extracellular acidification rate).

* Protocol:
	* Prepare cells for Seahorse XF analysis according to the manufacturer's instructions.
	* Measure oxygen consumption rate and extracellular acidification rate using the Seahorse XF analyzer.

3.3. Perform RNA-seq or qRT-PCR to analyze gene expression related to B cell receptor signaling and metabolism.

* Protocol:
	* RNA-seq:
		+ Extract RNA from cells using TRIzol and prepare libraries for sequencing.
		+ Sequence RNA using a next-generation sequencing platform (e.g., Illumina).
		+ Analyze data using bioinformatic tools (e.g., DESeq2, edgeR).
	* qRT-PCR:
		+ Extract RNA from cells using TRIzol and reverse transcribe to cDNA.
		+ Perform qRT-PCR using primers specific to genes related to B cell receptor signaling and metabolism.
		+ Analyze data using the 2^(-ΔΔCt) method.

**Section 4: Hedgehog Pathway Analysis**

4.1. Analyze Hedgehog pathway activity using Western blot (e.g., Gli1, Gli2, Ptch1) and qRT-PCR (e.g., SHH, IHH, DHH).

* Protocol:
	* Western blot:
		+ Analyze Hedgehog pathway protein levels using Western blot as described in Section 1.3.
	* qRT-PCR:
		+ Extract RNA from cells using TRIzol and reverse transcribe to cDNA.
		+ Perform qRT-PCR using primers specific to Hedgehog pathway genes.
		+ Analyze data using the 2^(-ΔΔCt) method.

4.2. Use Hedgehog pathway inhibitors (e.g., cyclopamine, GANT61) to perturb the pathway.

* Protocol:
	* Prepare stock solutions of Hedgehog pathway inhibitors in DMSO.
	* Treat cells with the inhibitors at a final concentration of 1-10 μM for 30 minutes to 2 hours.
	* Verify Hedgehog pathway inhibition using Western blot and qRT-PCR.

4.3. Perform ChIP-seq or ChIP-qPCR to analyze Gli1 binding to target genes.

* Protocol:
	* ChIP-seq:
		+ Cross-link cells with formaldehyde and sonicate chromatin.
		+ Immunoprecipitate Gli1-bound chromatin using an anti-Gli1 antibody.
		+ Sequence immunoprecipitated DNA using a next-generation sequencing platform (e.g., Illumina).
		+ Analyze data using bioinformatic tools (e.g., MACS2, HOMER).
	* ChIP-qPCR:
		+ Perform ChIP as described above.
		+ Analyze immunoprecipitated DNA using qPCR with primers specific to Gli1 target genes.
		+ Analyze data using the 2^(-ΔΔCt) method.

**Section 5: Leukemic Stem Cell Maintenance Analysis**

5.1. Analyze leukemic stem cell maintenance using colony-forming unit (CFU) assays, sphere-forming assays, and flow cytometry (e.g., CD34, CD38).

* Protocol:
	* CFU assays:
		+ Plate cells in methylcellulose media and incubate for 7-14 days.
		+ Count colonies using a microscope and quantify using ImageJ.
	* Sphere-forming assays:
		+ Plate cells in serum-free media and incubate for 7-14 days.
		+ Count spheres using a microscope and quantify using ImageJ.
	* Flow cytometry:
		+ Stain cells with antibodies against leukemic stem cell markers (e.g., CD34, CD38).
		+ Analyze cells using a flow cytometer and quantify marker expression using FlowJo.

5.2. Perform RNA-seq or qRT-PCR to analyze gene expression related to leukemic stem cell maintenance.

* Protocol:
	* RNA-seq:
		+ Extract RNA from cells using TRIzol and prepare libraries for sequencing.
		+ Sequence RNA using a next-generation sequencing platform (e.g., Illumina).
		+ Analyze data using bioinformatic tools (e.g., DESeq2, edgeR).
	* qRT-PCR:
		+ Extract RNA from cells using TRIzol and reverse transcribe to cDNA.
		+ Perform qRT-PCR using primers specific to genes related to leukemic stem cell maintenance.
		+ Analyze data using the 2^(-ΔΔCt) method.

**Section 6: Data Integration and Statistical Analysis**

6.1. Integrate data from all sections using bioinformatic tools (e.g., R, Python, Bioconductor).

* Protocol:
	* Use bioinformatic tools to integrate and analyze data from each section.
	* Perform statistical analysis (e.g., ANOVA, t-test, regression analysis) to identify correlations and significant differences between groups.

6.2. Perform statistical analysis (e.g., ANOVA, t-test, regression analysis) to identify correlations and significant differences between groups.

* Protocol:
	* Use statistical software (e.g., R, Python, GraphPad Prism) to perform statistical analysis.
	* Correct for multiple testing using methods (e.g., Bonferroni, FDR).

**Disproof Experiment**

1. Use CRISPR-Cas9 to knockout MIM in CML cells and validate the knockout using Western blot and qRT-PCR.

* Protocol:
	* Design and synthesize CRISPR-Cas9 guides targeting MIM.
	* Transfect cells with CRISPR-Cas9 using a transfection reagent (e.g., Lipofectamine).
	* Verify knockout efficiency using Western blot and qRT-PCR.

2. Treat MIM-knockout cells with Hedgehog pathway inhibitors (e.g., cyclopamine, GANT61) and analyze leukemic stem cell maintenance using CFU assays, sphere-forming assays, and flow cytometry.

* Protocol:
	* Prepare stock solutions of Hedgehog pathway inhibitors in DMSO.
	* Treat MIM-knockout cells with the inhibitors at a final concentration of 1-10 μM for 30 minutes to 2 hours.
	* Analyze leukemic stem cell maintenance using CFU assays, sphere-forming assays, and flow cytometry as described in Section 5.1.

3. Compare the results to MIM-wildtype cells treated with Hedgehog pathway inhibitors.

* Protocol:
	* Perform the same experiments as in step 2 using MIM-wildtype cells.
	* Compare the results to MIM-knockout cells using statistical analysis (e.g., t-test, ANOVA).

4. If the Hedgehog pathway's role in maintaining leukemic stem cells is not affected by MIM knockout, it would suggest that MIM does not influence the Hedgehog pathway in CML, disproving the hypothesis.

* Protocol:
	* Analyze the results of the disproof experiment using statistical analysis (e.g., t-test, ANOVA).
	* If the results show no significant difference between MIM-knockout and MIM-wildtype cells, conclude that MIM does not influence the Hedgehog pathway in CML.","```
   CML Cell Line  MIM Overexpression  Actin Disrupting Agent  Hedgehog Pathway Inhibitor  Leukemic Stem Cell Maintenance  Outcome
0           K562                  2.0                    5.0                         0.0                         100.0  Inhibited
1           K562                  1.5                    3.0                         0.5                         120.0  Partially Inhibited
2           K562                  1.0                    2.0                         1.0                         150.0  Not Inhibited
3           KBM-7                  2.5                    4.0                         0.0                         110.0  Inhibited
4           KBM-7                  2.0                    3.5                         0.5                         130.0  Partially Inhibited
5           KBM-7                  1.5                    2.5                         1.0                         160.0  Not Inhibited
6           K562                  1.0                    1.0                         0.0                          90.0  Inhibited
7           K562                  0.5                    1.5                         0.5                         140.0  Partially Inhibited
8           K562                  0.0                    2.0                         1.0                         170.0  Not Inhibited
9           KBM-7                  1.5                    1.0                         0.0                         100.0  Inhibited
10          KBM-7                  1.0                    1.5                         0.5                         150.0  Partially Inhibited
11          KBM-7                  0.5                    2.0                         1.0                         180.0  Not Inhibited
12          K562                  2.0                    0.0                         0.0                          80.0  Inhibited
13          K562                  1.5                    0.5                         0.5                         130.0  Partially Inhibited
14          K562                  1.0                    1.0                         1.0                         160.0  Not Inhibited
15          KBM-7                  2.5                    0.5                         0.0                         110.0  Inhibited
16          KBM-7                  2.0                    1.0                         0.5                         140.0  Partially Inhibited
17          KBM-7                  1.5                    1.5                         1.0                         170.0  Not Inhibited
18          K562                  0.0                    0.0                         0.0                          70.0  Inhibited
19          K562                  0.5                    0.5                         0.5                         120.0  Partially Inhibited
20          K562                  1.0                    1.0                         1.0                         150.0  Not Inhibited
21          KBM-7                  1.0                    0.0                         0.0                         100.0  Inhibited
22          KBM-7                  0.5                    0.5                         0.5                         130.0  Partially Inhibited
23          KBM-7                  0.0                    1.0                         1.0                         160.0  Not Inhibited
24          K562                  2.5                    2.5                         0.0                         120.0  Inhibited
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8627d2e8ca7332e3dd4168d0a3eef000a93ead09.summary'],Does the activated CD11c+Tbet+CD21- B cell subset in childhood-onset SLE patients exhibit a unique epigenetic signature that contributes to its pathogenic role in the disease?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the activated CD11c+Tbet+CD21- B cell subset in childhood-onset SLE patients exhibits a unique epigenetic signature that contributes to its pathogenic role in the disease, I propose the following experimental plan:

**Experiment:** ""Epigenetic Profiling of CD11c+Tbet+CD21- B Cells in Childhood-Onset SLE""

**Objective:** To determine if the CD11c+Tbet+CD21- B cell subset in childhood-onset SLE patients exhibits a unique epigenetic signature that contributes to its pathogenic role in the disease.

**Experimental Design:**

1. **Cell Isolation and Sorting:**
	* Isolate PBMCs from childhood-onset SLE patients, adult-onset SLE patients, and healthy controls.
	* Stain cells with antibodies against CD11c, Tbet, and CD21.
	* Perform flow cytometry to identify and sort CD11c+Tbet+CD21- B cells from each group.
2. **Epigenetic Profiling:**
	* Perform reduced representation bisulfite sequencing (RRBS) or whole-genome bisulfite sequencing (WGBS) on the sorted CD11c+Tbet+CD21- B cells to generate high-resolution epigenetic profiles.
	* Analyze the epigenetic data using bioinformatic tools (e.g., Bismark, MethPipe) to identify differentially methylated regions (DMRs) and differentially hydroxymethylated regions (DHRs) between childhood-onset SLE patients and healthy controls.
3. **Validation and Functional Assays:**
	* Validate the epigenetic findings using targeted bisulfite sequencing or pyrosequencing.
	* Perform functional assays (e.g., ChIP-seq, RNA-seq, cytokine production) to determine the functional consequences of the epigenetic changes on gene expression and cellular behavior.
4. **Comparison with Adult-Onset SLE and Healthy Controls:**
	* Compare the epigenetic profiles of CD11c+Tbet+CD21- B cells from childhood-onset SLE patients with those from adult-onset SLE patients and healthy controls.
	* Identify epigenetic signatures that are unique to childhood-onset SLE patients and correlate with disease activity or severity.

**To DISPROVE the hypothesis:**

**Experiment:** ""Epigenetic Profiling of CD11c+Tbet+CD21- B Cells in Childhood-Onset SLE: A Negative Control Study""

**Objective:** To demonstrate that the CD11c+Tbet+CD21- B cell subset in childhood-onset SLE patients does not exhibit a unique epigenetic signature that contributes to its pathogenic role in the disease.

**Experimental Design:**

1. **Cell Isolation and Sorting:**
	* Isolate PBMCs from childhood-onset SLE patients and healthy controls.
	* Stain cells with antibodies against CD11c, Tbet, and CD21.
	* Perform flow cytometry to identify and sort CD11c+Tbet+CD21- B cells from each group.
2. **Epigenetic Profiling:**
	* Perform RRBS or WGBS on the sorted CD11c+Tbet+CD21- B cells to generate high-resolution epigenetic profiles.
	* Analyze the epigenetic data using bioinformatic tools to identify DMRs and DHRs between childhood-onset SLE patients and healthy controls.
3. **Comparison and Statistical Analysis:**
	* Compare the epigenetic profiles of CD11c+Tbet+CD21- B cells from childhood-onset SLE patients with those from healthy controls.
	* Perform statistical analysis (e.g., t-test, ANOVA) to determine if there are any significant differences in epigenetic signatures between the two groups.
4. **Negative Control:**
	* If no significant differences in epigenetic signatures are observed between childhood-onset SLE patients and healthy controls, it would suggest that the CD11c+Tbet+CD21- B cell subset in childhood-onset SLE patients does not exhibit a unique epigenetic signature that contributes to its pathogenic role in the disease.

**Resources and Equipment:**

* Flow cytometry equipment (e.g., BD FACSAria III)
* Antibodies against CD11c, Tbet, and CD21
* Cell sorting and analysis software (e.g., FlowJo)
* Epigenetic profiling equipment (e.g., Illumina HiSeq, PacBio Sequel)
* Bioinformatic tools and software (e.g., Bismark, MethPipe, R)
* Computational resources (e.g., high-performance computing cluster, cloud computing)

**Timeline:**

* Cell isolation and sorting: 2 weeks
* Epigenetic profiling: 4 weeks
* Data analysis and validation: 8 weeks
* Functional assays: 4 weeks
* Comparison and statistical analysis: 2 weeks
* Total duration: 20 weeks

**Budget:**

* Personnel: $200,000 (2 post-docs, 1 technician, 1 bioinformatician)
* Reagents and consumables: $150,000 (antibodies, flow cytometry reagents, epigenetic profiling reagents)
* Equipment and maintenance: $100,000 (flow cytometry equipment, epigenetic profiling equipment, computational resources)
* Total budget: $450,000",92,"Here are the detailed, step-by-step protocols for the experiments outlined in the plan:

**Experiment 1: Epigenetic Profiling of CD11c+Tbet+CD21- B Cells in Childhood-Onset SLE**

**Step 1.1: Cell Isolation and Preparation**

1. Collect peripheral blood mononuclear cells (PBMCs) from childhood-onset SLE patients, adult-onset SLE patients, and healthy controls using a sterile needle and syringe.
2. Transfer the blood samples to 50 mL tubes and add 10 mL of Ficoll-Paque PLUS (GE Healthcare) to each tube.
3. Centrifuge the tubes at 400 x g for 30 minutes at room temperature.
4. Collect the PBMC layer and transfer it to a new 50 mL tube.
5. Wash the cells with 10 mL of PBS and centrifuge at 300 x g for 10 minutes.
6. Resuspend the cells in 1 mL of PBS and count the cells using a hemocytometer.

**Step 1.2: Cell Staining and Flow Cytometry**

1. Add 100 μL of PBS to a 1.5 mL tube and add 1 μL of CD11c-PE (BioLegend), 1 μL of Tbet-APC (BioLegend), and 1 μL of CD21-FITC (BioLegend) antibodies.
2. Add 100 μL of the cell suspension to the tube and mix well.
3. Incubate the cells at room temperature for 30 minutes in the dark.
4. Wash the cells with 1 mL of PBS and centrifuge at 300 x g for 10 minutes.
5. Resuspend the cells in 500 μL of PBS and analyze using a flow cytometer (BD FACSAria III).
6. Gate on CD11c+Tbet+CD21- B cells using FlowJo software.

**Step 1.3: Cell Sorting**

1. Sort the CD11c+Tbet+CD21- B cells into a 1.5 mL tube using a flow cytometer (BD FACSAria III).
2. Collect a minimum of 1 x 10^6 cells per sample.

**Step 2.1: Epigenetic Profiling**

1. Extract genomic DNA from the sorted cells using a DNA extraction kit (Qiagen).
2. Perform reduced representation bisulfite sequencing (RRBS) or whole-genome bisulfite sequencing (WGBS) on the extracted DNA using a sequencing platform (Illumina HiSeq or PacBio Sequel).
3. Generate high-resolution epigenetic profiles using bioinformatic tools (Bismark, MethPipe).

**Step 2.2: Data Analysis**

1. Analyze the epigenetic data using bioinformatic tools (Bismark, MethPipe) to identify differentially methylated regions (DMRs) and differentially hydroxymethylated regions (DHRs) between childhood-onset SLE patients and healthy controls.
2. Perform statistical analysis (e.g., t-test, ANOVA) to determine the significance of the epigenetic changes.

**Step 3.1: Validation and Functional Assays**

1. Validate the epigenetic findings using targeted bisulfite sequencing or pyrosequencing.
2. Perform functional assays (e.g., ChIP-seq, RNA-seq, cytokine production) to determine the functional consequences of the epigenetic changes on gene expression and cellular behavior.

**Step 4.1: Comparison with Adult-Onset SLE and Healthy Controls**

1. Compare the epigenetic profiles of CD11c+Tbet+CD21- B cells from childhood-onset SLE patients with those from adult-onset SLE patients and healthy controls.
2. Identify epigenetic signatures that are unique to childhood-onset SLE patients and correlate with disease activity or severity.

**Experiment 2: Epigenetic Profiling of CD11c+Tbet+CD21- B Cells in Childhood-Onset SLE: A Negative Control Study**

**Step 1.1: Cell Isolation and Preparation**

1. Collect PBMCs from childhood-onset SLE patients and healthy controls using a sterile needle and syringe.
2. Transfer the blood samples to 50 mL tubes and add 10 mL of Ficoll-Paque PLUS (GE Healthcare) to each tube.
3. Centrifuge the tubes at 400 x g for 30 minutes at room temperature.
4. Collect the PBMC layer and transfer it to a new 50 mL tube.
5. Wash the cells with 10 mL of PBS and centrifuge at 300 x g for 10 minutes.
6. Resuspend the cells in 1 mL of PBS and count the cells using a hemocytometer.

**Step 1.2: Cell Staining and Flow Cytometry**

1. Add 100 μL of PBS to a 1.5 mL tube and add 1 μL of CD11c-PE (BioLegend), 1 μL of Tbet-APC (BioLegend), and 1 μL of CD21-FITC (BioLegend) antibodies.
2. Add 100 μL of the cell suspension to the tube and mix well.
3. Incubate the cells at room temperature for 30 minutes in the dark.
4. Wash the cells with 1 mL of PBS and centrifuge at 300 x g for 10 minutes.
5. Resuspend the cells in 500 μL of PBS and analyze using a flow cytometer (BD FACSAria III).
6. Gate on CD11c+Tbet+CD21- B cells using FlowJo software.

**Step 1.3: Cell Sorting**

1. Sort the CD11c+Tbet+CD21- B cells into a 1.5 mL tube using a flow cytometer (BD FACSAria III).
2. Collect a minimum of 1 x 10^6 cells per sample.

**Step 2.1: Epigenetic Profiling**

1. Extract genomic DNA from the sorted cells using a DNA extraction kit (Qiagen).
2. Perform RRBS or WGBS on the extracted DNA using a sequencing platform (Illumina HiSeq or PacBio Sequel).
3. Generate high-resolution epigenetic profiles using bioinformatic tools (Bismark, MethPipe).

**Step 2.2: Data Analysis**

1. Analyze the epigenetic data using bioinformatic tools (Bismark, MethPipe) to identify DMRs and DHRs between childhood-onset SLE patients and healthy controls.
2. Perform statistical analysis (e.g., t-test, ANOVA) to determine the significance of the epigenetic changes.

**Step 3.1: Comparison and Statistical Analysis**

1. Compare the epigenetic profiles of CD11c+Tbet+CD21- B cells from childhood-onset SLE patients with those from healthy controls.
2. Perform statistical analysis (e.g., t-test, ANOVA) to determine if there are any significant differences in epigenetic signatures between the two groups.

**Step 4.1: Negative Control**

1. If no significant differences in epigenetic signatures are observed between childhood-onset SLE patients and healthy controls, it would suggest that the CD11c+Tbet+CD21- B cell subset in childhood-onset SLE patients does not exhibit a unique epigenetic signature that contributes to its pathogenic role in the disease.","```
   Ficoll-Paque_PLUS  CD11c-PE  Tbet-APC  CD21-FITC  PBS  Cells  Outcome
0               9.5       0.8       0.9       0.7   10.2  1.05e+06  Positive
1              10.2       1.0       1.1       0.9   10.5  1.10e+06  Positive
2               9.8       0.9       1.0       0.8   10.0  1.08e+06  Positive
3              10.5       1.1       1.2       1.0   10.8  1.12e+06  Positive
4               9.2       0.7       0.8       0.6   9.5  1.02e+06  Negative
5              10.8       1.2       1.3       1.1   11.0  1.15e+06  Positive
6               9.0       0.6       0.7       0.5   9.2  1.00e+06  Negative
7              11.0       1.3       1.4       1.2   11.2  1.18e+06  Positive
8               9.5       0.8       0.9       0.7   10.2  1.05e+06  Positive
9              10.2       1.0       1.1       0.9   10.5  1.10e+06  Positive
10              9.8       0.9       1.0       0.8   10.0  1.08e+06  Positive
11             10.5       1.1       1.2       1.0   10.8  1.12e+06  Positive
12              9.2       0.7       0.8       0.6   9.5  1.02e+06  Negative
13             10.8       1.2       1.3       1.1   11.0  1.15e+06  Positive
14              9.0       0.6       0.7       0.5   9.2  1.00e+06  Negative
15             11.0       1.3       1.4       1.2   11.2  1.18e+06  Positive
16              9.5       0.8       0.9       0.7   10.2  1.05e+06  Positive
17             10.2       1.0       1.1       0.9   10.5  1.10e+06  Positive
18              9.8       0.9       1.0       0.8   10.0  1.08e+06  Positive
19             10.5       1.1       1.2       1.0   10.8  1.12e+06  Positive
20              9.2       0.7       0.8       0.6   9.5  1.02e+06  Negative
21             10.8       1.2       1.3       1.1   11.0  1.15e+06  Positive
22              9.0       0.6       0.7       0.5   9.2  1.00e+06  Negative
23             11.0       1.3       1.4       1.2   11.2  1.18e+06  Positive
24             10.0       1.0       1.1       0.9   10.3  1.09e+06  Positive
```",0.7648404709600278
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/a682dbf7af064601d285e2fbfe0bd09a9e066a43.summary'],Does the activation of PRRs on transitional B cells also induce the production of regulatory B cells that can mitigate autoimmune responses?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Does the activation of PRRs on transitional B cells also induce the production of regulatory B cells that can mitigate autoimmune responses?""

**Experimental Plan:**

**Objective:** To determine whether the activation of PRRs on transitional B cells induces the production of regulatory B cells that can mitigate autoimmune responses.

**Hypothesis to be disproven:** The activation of PRRs on transitional B cells does not induce the production of regulatory B cells that can mitigate autoimmune responses.

**Experimental Design:**

1. **Cell Isolation and Stimulation:**
	* Isolate transitional B cells from healthy donors and patients with autoimmune diseases using cell sorting techniques (e.g., FACS).
	* Stimulate transitional B cells with PRR ligands (TLR7/8, TLR9, NOD1) and IL-4, as described in the previous study.
2. **Regulatory B Cell Identification:**
	* Use flow cytometry to analyze the expression of regulatory B cell markers (e.g., CD25, CD71, CD1d, IL-10) on stimulated transitional B cells.
	* Compare the expression of regulatory B cell markers between stimulated and unstimulated transitional B cells.
3. **Functional Assay:**
	* Co-culture stimulated transitional B cells with autoreactive T cells (isolated from patients with autoimmune diseases) in the presence of antigen-presenting cells (APCs).
	* Measure the proliferation of autoreactive T cells using [³H]-thymidine incorporation or CFSE dilution assays.
	* Compare the proliferation of autoreactive T cells in the presence of stimulated transitional B cells versus unstimulated transitional B cells.
4. **Suppression Assay:**
	* Co-culture stimulated transitional B cells with autoreactive T cells and APCs in the presence of antigen.
	* Measure the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) using ELISA or cytokine bead arrays.
	* Compare the production of pro-inflammatory cytokines in the presence of stimulated transitional B cells versus unstimulated transitional B cells.

**Expected Outcomes:**

* If the hypothesis is true, stimulated transitional B cells will express regulatory B cell markers and suppress the proliferation of autoreactive T cells and the production of pro-inflammatory cytokines.
* If the hypothesis is false, stimulated transitional B cells will not express regulatory B cell markers and will not suppress the proliferation of autoreactive T cells and the production of pro-inflammatory cytokines.

**Equipment and Resources:**

* Flow cytometer
* Cell culture facilities
* PRR ligands (TLR7/8, TLR9, NOD1)
* IL-4
* Antibodies against B cell surface markers (CD25, CD71, CD1d, IL-10)
* Autoreactive T cells and APCs from patients with autoimmune diseases
* [³H]-thymidine or CFSE
* ELISA or cytokine bead arrays

**Timeline:**

* Cell isolation and stimulation: 2 weeks
* Regulatory B cell identification: 1 week
* Functional and suppression assays: 2 weeks
* Data analysis and interpretation: 2 weeks

**Budget:**

* Reagents and consumables: $5,000
* Cell culture facilities and equipment: $3,000
* Personnel (2 researchers, 6 months): $60,000
* Total: $68,000

This experimental plan is designed to test the hypothesis in a reasonable time frame (6 months) and within a reasonable budget ($68,000). The results of this experiment will provide valuable insights into the role of PRR activation on transitional B cells in autoimmune diseases and may lead to the development of novel therapeutic strategies.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Stimulation**

**Step 1.1: Isolation of Transitional B Cells**

1. Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors and patients with autoimmune diseases using standard venipuncture techniques.
2. Isolate PBMCs using Ficoll-Paque density gradient centrifugation.
3. Stain PBMCs with fluorescently labeled antibodies against CD19, CD24, and CD38 to identify transitional B cells (CD19+CD24hiCD38hi).
4. Sort transitional B cells using fluorescence-activated cell sorting (FACS) with a purity of >95%.

**Step 1.2: Stimulation of Transitional B Cells**

1. Resuspend sorted transitional B cells in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
2. Add PRR ligands (TLR7/8, TLR9, NOD1) at a final concentration of 1 μg/mL and IL-4 at a final concentration of 10 ng/mL to the cell suspension.
3. Incubate the cells at 37°C, 5% CO2 for 48 hours.

**Protocol 2: Regulatory B Cell Identification**

**Step 2.1: Flow Cytometry Staining**

1. Harvest stimulated and unstimulated transitional B cells and wash them with PBS.
2. Stain cells with fluorescently labeled antibodies against CD25, CD71, CD1d, and IL-10.
3. Incubate cells at 4°C for 30 minutes.
4. Wash cells with PBS and fix them with 1% paraformaldehyde.

**Step 2.2: Flow Cytometry Analysis**

1. Acquire data using a flow cytometer (e.g., BD FACSCanto II).
2. Analyze data using flow cytometry software (e.g., FlowJo).
3. Gate on CD19+ cells and analyze the expression of regulatory B cell markers (CD25, CD71, CD1d, IL-10).

**Protocol 3: Functional Assay**

**Step 3.1: Co-Culture of Stimulated Transitional B Cells with Autoreactive T Cells and APCs**

1. Isolate autoreactive T cells from patients with autoimmune diseases using standard techniques.
2. Isolate APCs (e.g., dendritic cells) from healthy donors using standard techniques.
3. Co-culture stimulated transitional B cells with autoreactive T cells and APCs at a ratio of 1:1:1 in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
4. Add antigen (e.g., peptide or protein) to the co-culture at a final concentration of 1 μg/mL.

**Step 3.2: Proliferation Assay**

1. Pulse co-cultures with [³H]-thymidine (1 μCi/well) or CFSE (1 μM) for 16 hours.
2. Harvest cells and measure [³H]-thymidine incorporation using a scintillation counter or CFSE dilution using flow cytometry.

**Protocol 4: Suppression Assay**

**Step 4.1: Co-Culture of Stimulated Transitional B Cells with Autoreactive T Cells and APCs**

1. Repeat Step 3.1.

**Step 4.2: Cytokine Production Assay**

1. Collect supernatants from co-cultures after 48 hours.
2. Measure the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) using ELISA or cytokine bead arrays.

**Data Analysis and Interpretation**

1. Compare the expression of regulatory B cell markers between stimulated and unstimulated transitional B cells.
2. Compare the proliferation of autoreactive T cells in the presence of stimulated transitional B cells versus unstimulated transitional B cells.
3. Compare the production of pro-inflammatory cytokines in the presence of stimulated transitional B cells versus unstimulated transitional B cells.
4. Interpret the results in the context of the hypothesis and discuss the implications for autoimmune diseases.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity.","```
   PBMCs  CD19  CD24  CD38  TLR7/8  TLR9  NOD1  IL-4  CD25  CD71  CD1d  IL-10  Proliferation  Cytokine_Production
0    1000   500  200  150     0.5    0.5   0.5  10.0   20.0  15.0  10.0   50.0         2000.0           100.0
1    1200   600  250  180     1.0    1.0   1.0  15.0   25.0  20.0  15.0   60.0         2500.0           120.0
2     800   400  180  120     0.5    0.5   0.5   5.0   15.0  10.0   8.0   40.0         1500.0            80.0
3    1500   750  300  220     1.5    1.5   1.5  20.0   30.0  25.0  20.0   70.0         3000.0           150.0
4     900   450  200  150     0.5    0.5   0.5  10.0   20.0  15.0  12.0   50.0         2000.0           100.0
5    1100   550  230  180     1.0    1.0   1.0  12.0   22.0  18.0  15.0   55.0         2200.0           110.0
6     700   350  160  120     0.5    0.5   0.5   8.0   18.0  12.0  10.0   45.0         1800.0            90.0
7    1300   650  280  220     1.5    1.5   1.5  18.0   28.0  22.0  18.0   65.0         2800.0           130.0
8     1000   500  210  160     0.5    0.5   0.5  11.0   21.0  16.0  13.0   52.0         2100.0           105.0
9    1400   700  300  240     1.5    1.5   1.5  20.0   30.0  25.0  20.0   70.0         3000.0           140.0
10    850   425  190  140     0.5    0.5   0.5   9.0   19.0  14.0  11.0   48.0         1900.0            95.0
11   1250   625  270  210     1.2    1.2   1.2  16.0   26.0  21.0  17.0   62.0         2600.0           125.0
12    950   475  210  160     0.5    0.5   0.5  10.0   20.0  15.0  12.0   50.0         2000.0           100.0
13   1050   525  230  180     0.8    0.8   0.8  12.0   22.0  18.0  15.0   55.0         2200.0           105.0
14    750   375  170  130     0.5    0.5   0.5   7.0   17.0  12.0   9.0   42.0         1700.0            85.0
15   1200   600  260  200     1.0    1.0   1.0  14.0   24.0  20.0  16.0   60.0         2400.0           120.0
16    900   450  200  150     0.5    0.5   0.5   9.0   19.0  14.0  11.0   48.0         1900.0            95.0
17   1350   675  290  230     1.5    1.5   1.5  19.0   29.0  23.0  19.0   68.0         2900.0           135.0
18    800   400  180  140     0.5    0.5   0.5   8.0   18.0  13.0  10.0   45.0         1800.0            90.0
19   1100   550  240  190     1.0    1.0   1.0  13.0   23.0  19.0  16.0   58.0         2300.0           110.0
20    650   325  150  120     0.5    0.5   0.5   6.0   16.0  11.0   9.0   40.0         1600.0            80.0
21   1300   650  280  220     1.5    1.5   1.5  18.0   28.0  22.0  18.0   65.0         2800.0           130.0
22    1000   500  220  170     0.5    0.5   0.5  11.0   21.0  16.0  13.0   52.0         2100.0           105.0
23   1450   725  310  250     1.5    1.5   1.5  21.0   31.0  25.0  20.0   72.0         3100.0           145.0
24   1150   575  250  200     1.0    1.0   1.0  15.0   25.0  20.0  17.0   60.0         2500.0           115.0
```",0.9708016982084542
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6bea63221bc152c95f7099a6ecd7748de680e3fe.summary'],"Does the altered N-glycosylation of CD22 also affect the binding of other lectins, such as galectin-1, to CD22 and subsequently influence B cell signaling and autoimmune disease progression?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Does the altered N-glycosylation of CD22 also affect the binding of other lectins, such as galectin-1, to CD22 and subsequently influence B cell signaling and autoimmune disease progression?

**Experimental Plan:**

**Objective:** To investigate the effect of altered N-glycosylation of CD22 on the binding of galectin-1 and its impact on B cell signaling and autoimmune disease progression.

**Experimental Approach:**

1. **Cell Culture and Transfection:**
	* Use a B cell line (e.g., Ramos or Daudi) and transfect them with CD22 constructs with altered N-glycosylation patterns (e.g., mutated N-glycan sites).
	* Use a control group with wild-type CD22.
2. **Galectin-1 Binding Assay:**
	* Use a surface plasmon resonance (SPR) instrument (e.g., Biacore T200) to measure the binding of galectin-1 to CD22 with altered N-glycosylation patterns.
	* Immobilize the CD22 protein on an SPR chip and flow galectin-1 protein over it at different concentrations.
	* Measure the binding response and compare it to the control group.
3. **B Cell Signaling Assay:**
	* Use a B cell signaling assay (e.g., phosphorylation of downstream signaling molecules like Syk or Akt) to investigate the effect of altered CD22 N-glycosylation on B cell signaling.
	* Stimulate the transfected B cells with anti-IgM antibodies and measure the phosphorylation of signaling molecules.
4. **Autoimmune Disease Model:**
	* Use a mouse model of autoimmune disease (e.g., collagen-induced arthritis) and inject the mice with B cells transfected with CD22 constructs with altered N-glycosylation patterns.
	* Monitor the disease progression and compare it to the control group.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that altered N-glycosylation of CD22 does not affect the binding of galectin-1 to CD22 and has no impact on B cell signaling and autoimmune disease progression.

**Experimental Approach:**

1. **Cell Culture and Transfection:**
	* Use a B cell line (e.g., Ramos or Daudi) and transfect them with CD22 constructs with altered N-glycosylation patterns (e.g., mutated N-glycan sites).
	* Use a control group with wild-type CD22.
2. **Galectin-1 Binding Assay:**
	* Use a SPR instrument to measure the binding of galectin-1 to CD22 with altered N-glycosylation patterns.
	* Immobilize the CD22 protein on an SPR chip and flow galectin-1 protein over it at different concentrations.
	* Measure the binding response and compare it to the control group.
3. **B Cell Signaling Assay:**
	* Use a B cell signaling assay to investigate the effect of altered CD22 N-glycosylation on B cell signaling.
	* Stimulate the transfected B cells with anti-IgM antibodies and measure the phosphorylation of signaling molecules.
4. **Autoimmune Disease Model:**
	* Use a mouse model of autoimmune disease and inject the mice with B cells transfected with CD22 constructs with altered N-glycosylation patterns.
	* Monitor the disease progression and compare it to the control group.

**Expected Outcome:**

If the hypothesis is true, the experiment should show:

* Altered binding of galectin-1 to CD22 with mutated N-glycan sites compared to wild-type CD22.
* Changes in B cell signaling upon stimulation with anti-IgM antibodies.
* Differences in autoimmune disease progression in mice injected with B cells transfected with CD22 constructs with altered N-glycosylation patterns.

If the experiment to disprove the hypothesis shows no significant differences in galectin-1 binding, B cell signaling, and autoimmune disease progression between the control and experimental groups, it would suggest that altered N-glycosylation of CD22 does not affect the binding of galectin-1 to CD22 and has no impact on B cell signaling and autoimmune disease progression, thus disproving the hypothesis.

**Timeline and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $100,000-$150,000, depending on the specific reagents, equipment, and personnel costs. The budget will cover:

* Cell culture and transfection reagents
* SPR instrument and consumables
* Galectin-1 protein and antibodies
* B cell signaling assay reagents
* Mouse model and autoimmune disease induction
* Personnel costs for a postdoctoral researcher or graduate student to conduct the experiment.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Cell Culture and Transfection:**

1.1. Obtain the B cell line (Ramos or Daudi) and maintain it in a sterile environment at 37°C, 5% CO2 in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. Design and synthesize CD22 constructs with altered N-glycosylation patterns (e.g., mutated N-glycan sites) using site-directed mutagenesis.

1.3. Transfect the B cell line with the CD22 constructs using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.4. Incubate the transfected cells for 24-48 hours to allow for protein expression.

1.5. Verify the expression of CD22 with altered N-glycosylation patterns using Western blotting or flow cytometry.

**Galectin-1 Binding Assay:**

2.1. Prepare the SPR chip by immobilizing the CD22 protein with altered N-glycosylation patterns using a coupling reagent (e.g., amine coupling kit) according to the manufacturer's instructions.

2.2. Prepare a series of galectin-1 protein solutions at different concentrations (e.g., 0.1-10 μM) in HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20, pH 7.4).

2.3. Flow the galectin-1 protein solutions over the immobilized CD22 protein at a flow rate of 30 μL/min for 2 minutes.

2.4. Measure the binding response using the SPR instrument (Biacore T200) and record the sensorgram.

2.5. Repeat steps 2.3-2.4 for each concentration of galectin-1 protein.

2.6. Analyze the binding data using the Biacore T200 software to determine the binding affinity (KD) and maximum binding response (Rmax).

**B Cell Signaling Assay:**

3.1. Stimulate the transfected B cells with anti-IgM antibodies (10 μg/mL) for 10-15 minutes at 37°C.

3.2. Lyse the cells using a lysis buffer (e.g., RIPA buffer) and centrifuge at 10,000 x g for 10 minutes.

3.3. Immunoprecipitate the phosphorylated signaling molecules (e.g., Syk or Akt) using specific antibodies and protein A/G beads.

3.4. Analyze the immunoprecipitated proteins using Western blotting with phospho-specific antibodies.

3.5. Quantify the phosphorylation levels using densitometry software (e.g., ImageJ).

**Autoimmune Disease Model:**

4.1. Obtain mice (e.g., C57BL/6) and induce collagen-induced arthritis (CIA) using a standard protocol.

4.2. Inject the mice with B cells transfected with CD22 constructs with altered N-glycosylation patterns (1 x 10^6 cells/mouse) via tail vein injection.

4.3. Monitor the disease progression by measuring the arthritis score, paw swelling, and joint inflammation using a scoring system (e.g., 0-4).

4.4. Sacrifice the mice at the end of the experiment (e.g., 6-8 weeks) and collect tissues for further analysis (e.g., histology, flow cytometry).

**Experiment to Disprove the Hypothesis:**

The protocols for the experiment to disprove the hypothesis are identical to those described above, with the exception of using wild-type CD22 as the control group.

**Quality Control and Replicability:**

* Use multiple replicates (e.g., 3-5) for each experiment to ensure reproducibility.
* Include positive and negative controls for each assay to validate the results.
* Use standardized protocols and reagents to minimize variability.
* Document all experimental procedures, results, and data analysis in a laboratory notebook or electronic database.

**Timeline and Budget:**

The experiment can be completed within 6-9 months with a budget of approximately $100,000-$150,000, depending on the specific reagents, equipment, and personnel costs. The budget will cover:

* Cell culture and transfection reagents
* SPR instrument and consumables
* Galectin-1 protein and antibodies
* B cell signaling assay reagents
* Mouse model and autoimmune disease induction
* Personnel costs for a postdoctoral researcher or graduate student to conduct the experiment.","```
   RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  CD22_Construct  Lipofectamine_2000  Galectin-1_Concentration  Binding_Affinity(KD)  Maximum_Binding_Response(Rmax)  Anti-IgM_Antibody  Phosphorylated_Syk  Phosphorylated_Akt  Arthritis_Score
0        10.0  10.0                  1.0           1.0             1.0                2.0                    1.0               0.05                100.0               10.0               5.0               2.0
1        10.5  10.5                  1.1           1.1             1.1                2.1                    2.0               0.04                120.0               12.0               6.0               2.5
2         9.5   9.5                  0.9           0.9             0.9                1.9                    0.5               0.06                 80.0                8.0               4.0               1.5
3        10.0  10.0                  1.0           1.0             1.0                2.0                    5.0               0.03                150.0               15.0               7.0               3.0
4        10.2  10.2                  1.2           1.2             1.2                2.2                    3.0               0.04                130.0               13.0               6.5               2.8
5        10.8  10.8                  1.3           1.3             1.3                2.3                    4.0               0.05                140.0               14.0               7.2               3.2
6         9.8   9.8                  0.8           0.8             0.8                1.8                    2.5               0.06                 90.0                9.0               4.5               2.0
7        10.1  10.1                  1.1           1.1             1.1                2.1                    1.0               0.04                110.0               11.0               5.5               2.2
8        10.4  10.4                  1.4           1.4             1.4                2.4                    6.0               0.03                160.0               16.0               8.0               3.5
9        10.6  10.6                  1.5           1.5             1.5                2.5                    3.5               0.05                145.0               14.5               7.5               3.0
10       10.3  10.3                  1.3           1.3             1.3                2.3                    2.2               0.04                125.0               12.5               6.2               2.6
11       10.9  10.9                  1.6           1.6             1.6                2.6                    4.5               0.05                155.0               15.5               8.2               3.7
12        9.2   9.2                  0.7           0.7             0.7                1.7                    1.5               0.06                 85.0                8.5               4.2               1.8
13       10.7  10.7                  1.7           1.7             1.7                2.7                    5.5               0.04                165.0               16.5               8.5               3.9
14       10.0  10.0                  1.0           1.0             1.0                2.0                    2.8               0.05                135.0               13.5               6.8               2.9
15       10.5  10.5                  1.4           1.4             1.4                2.4                    3.2               0.04                130.0               13.0               6.5               2.8
16       10.2  10.2                  1.2           1.2             1.2                2.2                    1.8               0.06                105.0               10.5               5.2               2.1
17       10.8  10.8                  1.5           1.5             1.5                2.5                    4.2               0.05                150.0               15.0               7.5               3.2
18       10.1  10.1                  1.1           1.1             1.1                2.1                    2.0               0.04                115.0               11.5               5.8               2.4
19       10.4  10.4                  1.3           1.3             1.3                2.3                    3.8               0.05                140.0               14.0               7.0               3.0
20       10.6  10.6                  1.6           1.6             1.6                2.6                    5.0               0.04                160.0               16.0               8.0               3.5
21       10.3  10.3                  1.2           1.2             1.2                2.2                    2.5               0.06                120.0               12.0               6.0               2.5
22       10.9  10.9                  1.7           1.7             1.7                2.7                    4.8               0.05                165.0               16.5               8.5               3.9
23       10.7  10.7                  1.5           1.5             1.5                2.5                    3.5               0.04                145.0               14.5               7.5               3.2
24       10.0  10.0                  1.0           1.0             1.0                2.0                    2.2               0.05                125.0               12.5               6.2               2.6
```",0.7374881936194589
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/a1f4532061b4a41b8576bf023f179c3216db48dd.summary'],Does the altered cytoskeletal dynamics induced by BCR-ABL1 in Drosophila eye cells also affect the migration and homing of hematopoietic stem cells in the Drosophila model of CML?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** Does the altered cytoskeletal dynamics induced by BCR-ABL1 in Drosophila eye cells also affect the migration and homing of hematopoietic stem cells in the Drosophila model of CML?

**Experimental Plan:**

**Objective:** To test the hypothesis that altered cytoskeletal dynamics induced by BCR-ABL1 in Drosophila eye cells affects the migration and homing of hematopoietic stem cells in the Drosophila model of CML.

**Experimental Approach:**

1. **Fly Strains:**
	* Use existing Drosophila melanogaster strains:
		+ Wild-type (WT) flies
		+ BCR-ABL1-expressing flies (CML model)
		+ Flies with altered cytoskeletal dynamics (e.g., mutants for cytoskeletal components like actin or microtubules)
2. **Hematopoietic Stem Cell (HSC) Isolation:**
	* Isolate HSCs from WT and BCR-ABL1-expressing flies using established protocols (e.g., FACS sorting or magnetic bead-based isolation)
3. **Migration Assay:**
	* Use a well-established in vitro migration assay, such as the Transwell migration assay, to assess the migratory behavior of HSCs from WT and BCR-ABL1-expressing flies
	* Measure the number of migrated HSCs and calculate the migration index
4. **Homing Assay:**
	* Use a well-established in vivo homing assay, such as the transplantation of HSCs into irradiated recipient flies, to assess the homing ability of HSCs from WT and BCR-ABL1-expressing flies
	* Measure the engraftment efficiency and calculate the homing index
5. **Cytoskeletal Dynamics Analysis:**
	* Use live-cell imaging techniques (e.g., confocal microscopy) to analyze the cytoskeletal dynamics of HSCs from WT and BCR-ABL1-expressing flies
	* Measure parameters such as cell shape, migration speed, and directionality
6. **Statistical Analysis:**
	* Compare the migration and homing indices, as well as cytoskeletal dynamics parameters, between WT and BCR-ABL1-expressing flies using appropriate statistical tests (e.g., t-test, ANOVA)

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the null hypothesis that altered cytoskeletal dynamics induced by BCR-ABL1 in Drosophila eye cells does not affect the migration and homing of hematopoietic stem cells in the Drosophila model of CML.

**Experimental Approach:**

1. **Rescue Experiment:**
	* Use RNAi-mediated knockdown of BCR-ABL1 in BCR-ABL1-expressing flies to rescue the altered cytoskeletal dynamics
	* Measure the migration and homing indices, as well as cytoskeletal dynamics parameters, in these rescued flies
2. **Cytoskeletal Dynamics Inhibition:**
	* Use pharmacological inhibitors or RNAi-mediated knockdown of cytoskeletal components to inhibit cytoskeletal dynamics in WT flies
	* Measure the migration and homing indices, as well as cytoskeletal dynamics parameters, in these flies

**Rationale:**

* If the hypothesis is true, the rescue experiment should restore normal migration and homing indices, as well as cytoskeletal dynamics, in BCR-ABL1-expressing flies.
* If the hypothesis is false, the cytoskeletal dynamics inhibition experiment should not affect the migration and homing indices in WT flies.

**Timeline and Budget:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget will cover the costs of:
	+ Fly strains and maintenance
	+ Reagents and consumables for HSC isolation, migration and homing assays, and cytoskeletal dynamics analysis
	+ Equipment and maintenance for live-cell imaging and microscopy
	+ Personnel and training for experimental design, execution, and data analysis

This experimental plan is designed to test the hypothesis in a rigorous and controlled manner, while also being mindful of the limited budget and resources.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Fly Strains and Maintenance**

1.1. Obtain the following Drosophila melanogaster strains from a reputable supplier or stock center:
	* Wild-type (WT) flies
	* BCR-ABL1-expressing flies (CML model)
	* Flies with altered cytoskeletal dynamics (e.g., mutants for cytoskeletal components like actin or microtubules)

1.2. Maintain the fly strains at 25°C, 60% humidity, and a 12-hour light-dark cycle.
1.3. Feed the flies with a standard Drosophila medium (e.g., cornmeal-agar-sugar-yeast medium).
1.4. Perform regular fly stock maintenance, including cleaning, feeding, and transferring flies to new vials every 2-3 weeks.

**Protocol 2: Hematopoietic Stem Cell (HSC) Isolation**

2.1. Anesthetize 3-5 day old adult flies using CO2 or ether.
2.2. Dissect the flies to isolate the hematopoietic organs (e.g., lymph glands or hematopoietic clusters).
2.3. Use a dissociation buffer (e.g., PBS with 0.1% Triton X-100) to release the HSCs from the hematopoietic organs.
2.4. Filter the cell suspension through a 40 μm cell strainer to remove debris.
2.5. Use FACS sorting or magnetic bead-based isolation to isolate HSCs based on specific surface markers (e.g., CD34, CD45).
2.6. Collect the isolated HSCs in a sterile tube and wash them with PBS.

**Protocol 3: Migration Assay (Transwell Migration Assay)**

3.1. Prepare the Transwell inserts with a 5 μm pore size and a 24-well plate.
3.2. Add 500 μL of serum-free medium to the lower chamber of each well.
3.3. Add 100 μL of HSC suspension (1 x 10^5 cells/mL) to the upper chamber of each well.
3.4. Incubate the plate at 25°C, 5% CO2 for 2-4 hours.
3.5. Remove the Transwell inserts and wash the migrated cells with PBS.
3.6. Fix the cells with 4% paraformaldehyde and stain with a nuclear dye (e.g., DAPI).
3.7. Count the number of migrated cells using a fluorescence microscope.

**Protocol 4: Homing Assay**

4.1. Irradiate recipient flies with 30-40 Gy of gamma radiation to ablate their hematopoietic system.
4.2. Inject 1 x 10^5 HSCs into the thorax of each irradiated fly using a microinjector.
4.3. Allow the flies to recover for 24-48 hours.
4.4. Dissect the flies to isolate the hematopoietic organs.
4.5. Use FACS or PCR to detect the presence of donor HSCs in the recipient flies.
4.6. Calculate the engraftment efficiency as the percentage of recipient flies with detectable donor HSCs.

**Protocol 5: Cytoskeletal Dynamics Analysis**

5.1. Prepare HSCs for live-cell imaging by plating them on a glass-bottom dish or a coverslip.
5.2. Use a confocal microscope with a 63x oil immersion objective to image the HSCs.
5.3. Acquire images at 1-2 minute intervals for 30-60 minutes.
5.4. Use image analysis software (e.g., ImageJ, Fiji) to track cell shape, migration speed, and directionality.
5.5. Calculate the cytoskeletal dynamics parameters, such as cell shape index, migration speed, and directionality.

**Protocol 6: Statistical Analysis**

6.1. Use a statistical software package (e.g., R, Prism) to analyze the data.
6.2. Compare the migration and homing indices, as well as cytoskeletal dynamics parameters, between WT and BCR-ABL1-expressing flies using appropriate statistical tests (e.g., t-test, ANOVA).
6.3. Calculate the mean and standard error of the mean (SEM) for each group.
6.4. Plot the data using bar graphs or scatter plots.

**Protocol 7: Rescue Experiment**

7.1. Use RNAi-mediated knockdown of BCR-ABL1 in BCR-ABL1-expressing flies.
7.2. Isolate HSCs from the rescued flies and perform the migration and homing assays.
7.3. Analyze the cytoskeletal dynamics of the rescued HSCs using live-cell imaging.
7.4. Compare the results to those obtained from WT and BCR-ABL1-expressing flies.

**Protocol 8: Cytoskeletal Dynamics Inhibition**

8.1. Use pharmacological inhibitors or RNAi-mediated knockdown of cytoskeletal components to inhibit cytoskeletal dynamics in WT flies.
8.2. Isolate HSCs from the treated flies and perform the migration and homing assays.
8.3. Analyze the cytoskeletal dynamics of the treated HSCs using live-cell imaging.
8.4. Compare the results to those obtained from WT flies.

These detailed protocols should provide a clear and concise guide for executing the experiment.","```
   WT_Flies  BCR-ABL1_Flies  Altered_Cytoskeleton_Flies  HSCs_Isolated  Migration_Assay  Homing_Assay  Cytoskeletal_Dynamics  Outcome
0         100              0                    0           50000          2500          0.8             0.5         Success
1         120              0                    0           60000          3000          0.9             0.6         Success
2          80              0                    0           40000          2000          0.7             0.4         Failure
3          90              0                    0           45000          2200          0.8             0.5         Success
4          0             100                    0           55000          2800          0.9             0.6         Success
5          0             120                    0           65000          3200          1.0             0.7         Success
6          0              80                    0           35000          1800          0.7             0.4         Failure
7          0              90                    0           48000          2400          0.8             0.5         Success
8         50              50                    0           50000          2500          0.8             0.5         Success
9         60              60                    0           60000          3000          0.9             0.6         Success
10        40              40                    0           40000          2000          0.7             0.4         Failure
11        45              45                    0           45000          2200          0.8             0.5         Success
12         0               0                  100           50000          2500          0.8             0.5         Success
13         0               0                  120           60000          3000          0.9             0.6         Success
14         0               0                   80           40000          2000          0.7             0.4         Failure
15         0               0                   90           45000          2200          0.8             0.5         Success
16        25              25                   50           50000          2500          0.8             0.5         Success
17        30              30                   60           60000          3000          0.9             0.6         Success
18        20              20                   40           40000          2000          0.7             0.4         Failure
19        22              22                   45           45000          2200          0.8             0.5         Success
20        10              10                   80           50000          2500          0.8             0.5         Success
21        12              12                   90           60000          3000          0.9             0.6         Success
22         8               8                   70           40000          2000          0.7             0.4         Failure
23         9               9                   75           45000          2200          0.8             0.5         Success
24        15              15                   70           50000          2500          0.8             0.5         Success
```",0.4515539612337593
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d3e26dbdb33ab6198fc4b234e2a1d87e3b65ab8f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2bb827c21605eda0093859ce608dca922344e146.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/01cff8e8166a54fa2af506dc3ecc2a8e39dc630b.summary']","Does the altered protein tyrosine phosphatase activity in autoimmune diseases, such as SLE, contribute to the development of resistance to Bruton tyrosine kinase inhibitors in B-cell malignancies?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Altered protein tyrosine phosphatase (PTP) activity in autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), contributes to the development of resistance to Bruton tyrosine kinase (BTK) inhibitors in B-cell malignancies.

**Experimental Plan:**

**Objective:** To investigate whether altered PTP activity in SLE contributes to BTK inhibitor resistance in B-cell malignancies.

**Approach:**

1. **Cell Line Generation:**
	* Establish SLE patient-derived B-cell lines with altered PTP activity (e.g., using CRISPR-Cas9 genome editing).
	* Generate B-cell lines from healthy donors as controls.
2. **BTK Inhibitor Treatment:**
	* Treat both SLE-derived and control B-cell lines with BTK inhibitors (e.g., ibrutinib) at varying concentrations.
	* Monitor cell viability, proliferation, and apoptosis using flow cytometry, MTT assays, and Western blotting.
3. **PTP Activity Assays:**
	* Measure PTP activity in SLE-derived and control B-cell lines using biochemical assays (e.g., phosphatase activity assays, substrate-based assays).
	* Investigate the effects of BTK inhibitors on PTP activity in both cell lines.
4. **Protein-Protein Interaction Analysis:**
	* Perform co-immunoprecipitation (co-IP) and mass spectrometry to identify PTP-interacting proteins in SLE-derived and control B-cell lines.
	* Investigate the effects of BTK inhibitors on PTP-protein interactions.
5. **Gene Expression Profiling:**
	* Perform RNA sequencing (RNA-seq) to compare gene expression profiles between SLE-derived and control B-cell lines.
	* Analyze differentially expressed genes involved in PTP signaling and B-cell receptor signaling pathways.
6. **In Vivo Validation:**
	* Use a xenograft mouse model to study the effects of BTK inhibitors on SLE-derived and control B-cell tumors.
	* Monitor tumor growth, PTP activity, and B-cell receptor signaling in response to BTK inhibitors.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that altered PTP activity in SLE does not contribute to BTK inhibitor resistance in B-cell malignancies.

**Approach:**

1. **PTP Knockdown/Knockout:**
	* Use RNA interference (RNAi) or CRISPR-Cas9 to specifically knockdown or knockout PTP genes in SLE-derived B-cell lines.
	* Treat these cells with BTK inhibitors and monitor cell viability, proliferation, and apoptosis.
2. **PTP Inhibitor Treatment:**
	* Treat SLE-derived B-cell lines with PTP inhibitors (e.g., sodium stibogluconate) and monitor the effects on BTK inhibitor resistance.
3. **Rescue Experiment:**
	* Overexpress a constitutively active PTP mutant in SLE-derived B-cell lines and treat with BTK inhibitors.
	* If the hypothesis is true, this should rescue the cells from BTK inhibitor resistance.

**Unlimited Budget Considerations:**

* Utilize cutting-edge technologies, such as single-cell RNA-seq, to analyze PTP activity and gene expression at the single-cell level.
* Employ advanced bioinformatics tools, like machine learning algorithms, to integrate and analyze large datasets.
* Collaborate with experts in the field to access rare SLE patient samples and B-cell malignancy models.
* Perform high-throughput screening of PTP inhibitors and BTK inhibitors to identify potential therapeutic combinations.

By following this experimental plan, we can rigorously test the hypothesis and determine whether altered PTP activity in SLE contributes to BTK inhibitor resistance in B-cell malignancies.",85,"Here are the detailed, step-by-step protocols for each experiment outlined in the plan:

**Experiment 1: Cell Line Generation**

**Objective:** Establish SLE patient-derived B-cell lines with altered PTP activity and generate B-cell lines from healthy donors as controls.

**Protocol:**

1.1. **CRISPR-Cas9 Genome Editing**

* Obtain SLE patient-derived B-cell samples and healthy donor B-cell samples.
* Design guide RNAs (gRNAs) targeting PTP genes using online tools (e.g., CRISPR Design).
* Prepare CRISPR-Cas9 ribonucleoprotein (RNP) complexes according to the manufacturer's instructions.
* Electroporate RNP complexes into SLE patient-derived B-cells and healthy donor B-cells using a nucleofector device.
* Plate cells in 96-well plates and culture in RPMI-1640 medium supplemented with 10% FBS and antibiotics.
* Select for edited cells using puromycin or other selection markers.

1.2. **Cell Line Establishment and Characterization**

* Expand edited cells and healthy donor cells in culture.
* Perform flow cytometry to verify B-cell surface markers (e.g., CD19, CD20).
* Extract genomic DNA and perform PCR and Sanger sequencing to confirm PTP gene editing.
* Freeze down early passages of edited and control cell lines for future use.

**Experiment 2: BTK Inhibitor Treatment**

**Objective:** Treat SLE-derived and control B-cell lines with BTK inhibitors and monitor cell viability, proliferation, and apoptosis.

**Protocol:**

2.1. **BTK Inhibitor Preparation**

* Obtain ibrutinib or other BTK inhibitors from a commercial source.
* Prepare stock solutions of BTK inhibitors in DMSO according to the manufacturer's instructions.
* Aliquot and store stock solutions at -20°C.

2.2. **Cell Treatment and Viability Assays**

* Plate SLE-derived and control B-cell lines in 96-well plates at 1 x 10^5 cells/well.
* Treat cells with varying concentrations of BTK inhibitors (e.g., 0, 1, 10, 100 nM) for 24, 48, or 72 hours.
* Perform MTT assays to measure cell viability according to the manufacturer's instructions.
* Analyze data using a plate reader and calculate IC50 values.

2.3. **Flow Cytometry and Western Blotting**

* Treat cells with BTK inhibitors as above.
* Perform flow cytometry to measure cell surface markers (e.g., CD19, CD20) and apoptosis markers (e.g., Annexin V).
* Perform Western blotting to measure protein expression (e.g., BTK, PTPs) using specific antibodies.

**Experiment 3: PTP Activity Assays**

**Objective:** Measure PTP activity in SLE-derived and control B-cell lines using biochemical assays.

**Protocol:**

3.1. **PTP Activity Assay Preparation**

* Obtain PTP substrates (e.g., pNPP, DiFMUP) and PTP inhibitors (e.g., sodium stibogluconate) from commercial sources.
* Prepare reaction buffers and substrate solutions according to the manufacturer's instructions.

3.2. **PTP Activity Assays**

* Lyse SLE-derived and control B-cell lines in lysis buffer.
* Perform PTP activity assays using a 96-well plate format.
* Add PTP substrates and inhibitors to wells and incubate at room temperature for 30 minutes.
* Measure absorbance at 405 nm using a plate reader.
* Calculate PTP activity using a standard curve.

**Experiment 4: Protein-Protein Interaction Analysis**

**Objective:** Perform co-immunoprecipitation (co-IP) and mass spectrometry to identify PTP-interacting proteins in SLE-derived and control B-cell lines.

**Protocol:**

4.1. **Co-Immunoprecipitation**

* Lyse SLE-derived and control B-cell lines in lysis buffer.
* Perform co-IP using PTP-specific antibodies and protein A/G beads.
* Elute immunoprecipitated proteins using SDS-PAGE sample buffer.

4.2. **Mass Spectrometry**

* Perform LC-MS/MS analysis of co-IP eluates using a mass spectrometer.
* Identify PTP-interacting proteins using protein database searches (e.g., UniProt).

**Experiment 5: Gene Expression Profiling**

**Objective:** Perform RNA sequencing (RNA-seq) to compare gene expression profiles between SLE-derived and control B-cell lines.

**Protocol:**

5.1. **RNA Isolation and Library Preparation**

* Isolate total RNA from SLE-derived and control B-cell lines using a commercial RNA isolation kit.
* Prepare RNA-seq libraries using a commercial kit (e.g., TruSeq).

5.2. **RNA Sequencing**

* Perform RNA-seq using a next-generation sequencing platform (e.g., Illumina HiSeq).
* Generate FASTQ files for each sample.

5.3. **Data Analysis**

* Perform quality control and trimming of FASTQ files using tools (e.g., FastQC, Trimmomatic).
* Map reads to a reference genome (e.g., GRCh38) using a spliced aligner (e.g., STAR).
* Perform differential gene expression analysis using tools (e.g., DESeq2).

**Experiment 6: In Vivo Validation**

**Objective:** Use a xenograft mouse model to study the effects of BTK inhibitors on SLE-derived and control B-cell tumors.

**Protocol:**

6.1. **Xenograft Model Establishment**

* Obtain SLE-derived and control B-cell lines.
* Inject cells into immunodeficient mice (e.g., NOD/SCID) subcutaneously.
* Monitor tumor growth using calipers.

6.2. **BTK Inhibitor Treatment**

* Treat mice with BTK inhibitors (e.g., ibrutinib) via oral gavage or injection.
* Monitor tumor growth and PTP activity in tumors using biochemical assays.

**Experiment to Disprove the Hypothesis**

**Objective:** Demonstrate that altered PTP activity in SLE does not contribute to BTK inhibitor resistance in B-cell malignancies.

**Protocol:**

**PTP Knockdown/Knockout**

* Use RNA interference (RNAi) or CRISPR-Cas9 to specifically knockdown or knockout PTP genes in SLE-derived B-cell lines.
* Treat cells with BTK inhibitors and monitor cell viability, proliferation, and apoptosis.

**PTP Inhibitor Treatment**

* Treat SLE-derived B-cell lines with PTP inhibitors (e.g., sodium stibogluconate) and monitor the effects on BTK inhibitor resistance.

**Rescue Experiment**

* Overexpress a constitutively active PTP mutant in SLE-derived B-cell lines and treat with BTK inhibitors.
* If the hypothesis is true, this should rescue the cells from BTK inhibitor resistance.

These detailed protocols should provide a clear roadmap for executing the experiments outlined in the plan.","```
   CRISPR_Cas9_RNP  gRNA_Target  Puromycin_Selection  BTK_Inhibitor_Conc  Cell_Viability  PTP_Activity  Apoptosis_Markers  BTK_Inhibitor_IC50
0               1.0        PTPN2               1.0               10.0         0.80          0.50             0.20           5.0
1               0.5        PTPN6               0.5                1.0         0.90          0.60             0.30           2.0
2               1.5        PTPN11              1.5               50.0         0.40          0.30             0.40           10.0
3               1.0        PTPN22              1.0               20.0         0.70          0.45             0.25           4.0
4               0.8        PTPN1               0.8                5.0         0.85          0.55             0.35           3.0
5               1.2        PTPN3               1.2               30.0         0.60          0.40             0.45           6.0
6               0.9        PTPN5               0.9               15.0         0.75          0.50             0.30           4.5
7               1.1        PTPN9               1.1               25.0         0.65          0.45             0.40           5.5
8               0.7        PTPN13              0.7                8.0         0.80          0.55             0.35           3.5
9               1.4        PTPN7               1.4               40.0         0.50          0.35             0.50           8.0
10              0.6        PTPN15              0.6                3.0         0.90          0.60             0.30           2.5
11              1.3        PTPN10              1.3               35.0         0.70          0.50             0.40           6.5
12              0.9        PTPN4               0.9               18.0         0.75          0.55             0.35           4.8
13              1.2        PTPN8               1.2               28.0         0.60          0.40             0.45           5.8
14              0.8        PTPN14              0.8               12.0         0.85          0.60             0.30           4.2
15              1.1        PTPN16              1.1               22.0         0.65          0.45             0.40           5.2
16              0.7        PTPN17              0.7                9.0         0.80          0.55             0.35           3.8
17              1.4        PTPN18              1.4               42.0         0.50          0.35             0.50           8.5
18              0.6        PTPN19              0.6                4.0         0.90          0.60             0.30           2.8
19              1.3        PTPN20              1.3               38.0         0.70          0.50             0.40           6.8
20              0.9        PTPN21              0.9               20.0         0.75          0.55             0.35           4.9
21              1.2        PTPN23              1.2               32.0         0.60          0.40             0.45           6.2
22              0.8        PTPN24              0.8               14.0         0.85          0.60             0.30           4.4
23              1.1        PTPN25              1.1               26.0         0.65          0.45             0.40           5.6
24              0.7        PTPN26              0.7               11.0         0.80          0.55             0.35           4.1
```",0.25612242499424365
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/734048166fd716499021569dd7e4cf352dbd2b76.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0d83cf0ea64f8cc7ab19b8546f1499fbbad1bfc8.summary']",Does the alternative splicing of genes involved in intracellular transport in memory B cells also influence the phosphorylation of ERK1/2 and thereby affect the prognosis of chronic lymphocytic leukemia?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Alternative splicing of genes involved in intracellular transport in memory B cells influences the phosphorylation of ERK1/2 and thereby affects the prognosis of chronic lymphocytic leukemia (CLL).

**Experimental Plan:**

**Objective:** To investigate the relationship between alternative splicing of genes involved in intracellular transport, ERK1/2 phosphorylation, and CLL prognosis.

**Step 1: Sample Collection and Preparation**

* Collect peripheral blood mononuclear cells (PBMCs) from CLL patients and healthy donors.
* Isolate memory B cells using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS).
* Extract total RNA and protein from the isolated memory B cells.

**Step 2: Alternative Splicing Analysis**

* Perform RNA sequencing (RNA-seq) to identify alternative splicing events in genes involved in intracellular transport (e.g., Rab GTPases, SNAREs, and vesicle-associated proteins).
* Use bioinformatic tools (e.g., STAR, HISAT2, and rMATS) to analyze the RNA-seq data and identify differentially spliced genes between CLL patients and healthy donors.

**Step 3: ERK1/2 Phosphorylation Analysis**

* Perform Western blotting or ELISA to measure the phosphorylation levels of ERK1/2 in the isolated memory B cells.
* Compare the phosphorylation levels between CLL patients and healthy donors.

**Step 4: Correlation Analysis**

* Correlate the alternative splicing events identified in Step 2 with the ERK1/2 phosphorylation levels measured in Step 3.
* Analyze the correlation between the alternative splicing events and CLL prognosis (e.g., disease progression, treatment response, or overall survival).

**Step 5: Functional Validation**

* Use CRISPR-Cas9 genome editing to knockdown or overexpress specific genes involved in intracellular transport in memory B cells.
* Measure the effect of gene manipulation on ERK1/2 phosphorylation and CLL cell proliferation/survival.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to test the following null hypothesis: ""Alternative splicing of genes involved in intracellular transport in memory B cells does not influence the phosphorylation of ERK1/2 and thereby does not affect the prognosis of CLL.""

**Disproof Experiment:**

* Perform a similar RNA-seq analysis as in Step 2, but this time, use a different cohort of CLL patients and healthy donors.
* Analyze the data to identify alternative splicing events in genes involved in intracellular transport.
* If the alternative splicing events are not correlated with ERK1/2 phosphorylation or CLL prognosis, it would suggest that the hypothesis is false.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a budget of approximately $200,000-$300,000. The budget breakdown is as follows:

* Sample collection and preparation: $20,000
* RNA-seq and bioinformatic analysis: $60,000
* Western blotting and ELISA: $20,000
* CRISPR-Cas9 genome editing: $40,000
* Personnel and miscellaneous costs: $60,000

This experimental plan is designed to be feasible within a reasonable timeframe and budget. By following this plan, we can test the hypothesis and determine whether alternative splicing of genes involved in intracellular transport in memory B cells influences ERK1/2 phosphorylation and CLL prognosis.",85,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Sample Collection and Preparation**

1.1. Sample Collection:

* Collect 10-20 mL of peripheral blood from CLL patients and healthy donors using vacutainer tubes containing EDTA as an anticoagulant.
* Label the tubes with unique identifiers and store them at room temperature.

1.2. PBMC Isolation:

* Add 10 mL of PBS to the blood samples and mix gently.
* Layer the diluted blood onto 10 mL of Ficoll-Paque PLUS in a 50 mL conical tube.
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the PBMC layer and transfer it to a new 50 mL conical tube.
* Wash the PBMCs with PBS and centrifuge at 300 x g for 10 minutes.

1.3. Memory B Cell Isolation:

* Use MACS or FACS to isolate memory B cells from the PBMCs.
* For MACS, use CD27 and CD19 antibodies to select memory B cells.
* For FACS, use a FACSAria II or similar instrument to sort CD27+CD19+ cells.
* Collect the isolated memory B cells in a 1.5 mL microcentrifuge tube.

1.4. RNA and Protein Extraction:

* Extract total RNA from the isolated memory B cells using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions.
* Extract total protein from the isolated memory B cells using the RIPA buffer (Thermo Fisher Scientific) according to the manufacturer's instructions.
* Store the RNA and protein samples at -80°C until further analysis.

**Step 2: Alternative Splicing Analysis**

2.1. RNA Sequencing:

* Prepare RNA-seq libraries using the TruSeq Stranded Total RNA Library Prep Kit (Illumina) according to the manufacturer's instructions.
* Sequence the libraries on an Illumina HiSeq 4000 or similar instrument using 100 bp paired-end reads.
* Generate at least 30 million reads per sample.

2.2. RNA-seq Data Analysis:

* Use STAR (v2.7.3) to align the RNA-seq reads to the human reference genome (GRCh38).
* Use HISAT2 (v2.2.1) to identify novel transcripts and alternative splicing events.
* Use rMATS (v4.1.2) to identify differentially spliced genes between CLL patients and healthy donors.
* Use a false discovery rate (FDR) of 0.05 to correct for multiple testing.

**Step 3: ERK1/2 Phosphorylation Analysis**

3.1. Western Blotting:

* Prepare protein samples by mixing 20 μg of protein with 4x Laemmli buffer and heating at 95°C for 5 minutes.
* Resolve the proteins on a 10% SDS-PAGE gel and transfer to a PVDF membrane.
* Block the membrane with 5% BSA in TBST for 1 hour.
* Incubate the membrane with anti-phospho-ERK1/2 (Thr202/Tyr204) antibody (Cell Signaling Technology) at 1:1000 dilution overnight at 4°C.
* Detect the signal using an ECL kit (Thermo Fisher Scientific) and quantify using ImageJ software.

3.2. ELISA:

* Use a commercial ELISA kit (e.g., Abcam) to measure the phosphorylation levels of ERK1/2 in the protein samples.
* Follow the manufacturer's instructions for sample preparation and assay protocol.

**Step 4: Correlation Analysis**

4.1. Data Integration:

* Integrate the alternative splicing data from Step 2 with the ERK1/2 phosphorylation data from Step 3.
* Use a correlation coefficient (e.g., Pearson's r) to measure the association between alternative splicing events and ERK1/2 phosphorylation levels.

4.2. Survival Analysis:

* Use a Cox proportional hazards model to analyze the correlation between alternative splicing events and CLL prognosis (e.g., disease progression, treatment response, or overall survival).
* Use a significance threshold of p < 0.05 to identify significant correlations.

**Step 5: Functional Validation**

5.1. CRISPR-Cas9 Genome Editing:

* Design guide RNAs targeting specific genes involved in intracellular transport using the CRISPR Design Tool (Broad Institute).
* Transfect the guide RNAs and Cas9 enzyme into memory B cells using the Neon Transfection System (Thermo Fisher Scientific).
* Validate the knockout or overexpression of the target genes using Western blotting or qRT-PCR.

5.2. ERK1/2 Phosphorylation and Cell Proliferation/Survival Assays:

* Measure the effect of gene manipulation on ERK1/2 phosphorylation using Western blotting or ELISA.
* Measure the effect of gene manipulation on CLL cell proliferation/survival using a CellTiter-Glo assay (Promega).

**Disproof Experiment**

* Repeat Steps 1-4 using a different cohort of CLL patients and healthy donors.
* Analyze the data to identify alternative splicing events in genes involved in intracellular transport.
* If the alternative splicing events are not correlated with ERK1/2 phosphorylation or CLL prognosis, it would suggest that the hypothesis is false.

Note: The protocols above are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   Blood Volume (mL)  PBS Volume (mL)  Ficoll-Paque Volume (mL)  CD27 Antibody Amount (μL)  CD19 Antibody Amount (μL)  RNA Extraction Kit Amount (μL)  RIPA Buffer Amount (μL)  TruSeq Library Prep Kit Amount (μL)  ERK1/2 Antibody Amount (μL)  ELISA Kit Amount (μL)  Outcome (ERK1/2 Phosphorylation Level)
0               15.0             10.0                    10.0                    5.0                    5.0                       50.0                       50.0                         20.0                       10.0                       10.0                         0.8
1               18.0             12.0                    12.0                    6.0                    6.0                       60.0                       60.0                         24.0                       12.0                       12.0                         0.9
2               12.0              8.0                     8.0                    4.0                    4.0                       40.0                       40.0                         16.0                        8.0                        8.0                         0.7
3               19.0             13.0                    13.0                    7.0                    7.0                       65.0                       65.0                         26.0                       13.0                       13.0                         1.0
4               11.0              9.0                     9.0                    5.0                    5.0                       45.0                       45.0                         18.0                        9.0                        9.0                         0.8
5               16.0             11.0                    11.0                    6.0                    6.0                       55.0                       55.0                         22.0                       11.0                       11.0                         0.9
6               14.0             10.0                    10.0                    5.0                    5.0                       50.0                       50.0                         20.0                       10.0                       10.0                         0.8
7               17.0             12.0                    12.0                    6.0                    6.0                       60.0                       60.0                         24.0                       12.0                       12.0                         0.9
8               13.0              9.0                     9.0                    5.0                    5.0                       45.0                       45.0                         18.0                        9.0                        9.0                         0.8
9               19.0             14.0                    14.0                    7.0                    7.0                       70.0                       70.0                         28.0                       14.0                       14.0                         1.0
10              15.0             11.0                    11.0                    6.0                    6.0                       55.0                       55.0                         22.0                       11.0                       11.0                         0.9
11              12.0              8.0                     8.0                    4.0                    4.0                       40.0                       40.0                         16.0                        8.0                        8.0                         0.7
12              18.0             13.0                    13.0                    7.0                    7.0                       65.0                       65.0                         26.0                       13.0                       13.0                         1.0
13              16.0             12.0                    12.0                    6.0                    6.0                       60.0                       60.0                         24.0                       12.0                       12.0                         0.9
14              14.0             10.0                    10.0                    5.0                    5.0                       50.0                       50.0                         20.0                       10.0                       10.0                         0.8
15              17.0             12.0                    12.0                    6.0                    6.0                       60.0                       60.0                         24.0                       12.0                       12.0                         0.9
16              13.0              9.0                     9.0                    5.0                    5.0                       45.0                       45.0                         18.0                        9.0                        9.0                         0.8
17              19.0             14.0                    14.0                    7.0                    7.0                       70.0                       70.0                         28.0                       14.0                       14.0                         1.0
18              15.0             11.0                    11.0                    6.0                    6.0                       55.0                       55.0                         22.0                       11.0                       11.0                         0.9
19              12.0              8.0                     8.0                    4.0                    4.0                       40.0                       40.0                         16.0                        8.0                        8.0                         0.7
20              18.0             13.0                    13.0                    7.0                    7.0                       65.0                       65.0                         26.0                       13.0                       13.0                         1.0
21              16.0             12.0                    12.0                    6.0                    6.0                       60.0                       60.0                         24.0                       12.0                       12.0                         0.9
22              14.0             10.0                    10.0                    5.0                    5.0                       50.0                       50.0                         20.0                       10.0                       10.0                         0.8
23              17.0             12.0                    12.0                    6.0                    6.0                       60.0                       60.0                         24.0                       12.0                       12.0                         0.9
24              13.0              9.0                     9.0                    5.0                    5.0                       45.0                       45.0                         18.0                        9.0                        9.0                         0.8
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/25e489518c4629fb96cce4dad6d694131d993681.summary'],"Does the asymmetric association of mIgM domains in the transmembrane region influence the recruitment of specific lipid species to the lipid rafts, thereby modulating B-cell activation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Influence of Asymmetric mIgM Domain Association on Lipid Raft Recruitment and B-Cell Activation

**Objective:** To determine whether the asymmetric association of mIgM domains in the transmembrane region affects the recruitment of specific lipid species to lipid rafts, thereby modulating B-cell activation.

**Experimental Design:**

1. **Cell Culture and Transfection:** Express mIgM-BCRs in B cells using a suitable expression vector. Transfect cells with either wild-type mIgM or a mutated mIgM with disrupted asymmetric association (using site-directed mutagenesis).
2. **Lipid Raft Isolation and Analysis:** Use a lipid raft isolation kit to extract lipid rafts from transfected B cells. Analyze the lipid composition of the isolated rafts using mass spectrometry (e.g., LC-MS/MS) or thin-layer chromatography (TLC).
3. **B-Cell Activation Assay:** Stimulate transfected B cells with a B-cell activator (e.g., anti-IgM antibody) and measure B-cell activation markers (e.g., CD69, CD86, or phosphorylated signaling proteins) using flow cytometry or Western blotting.
4. **Confocal Microscopy:** Use confocal microscopy to visualize the co-localization of mIgM-BCRs with lipid rafts in transfected B cells. Label mIgM-BCRs with a fluorescent tag (e.g., GFP) and lipid rafts with a lipid-specific dye (e.g., cholera toxin subunit B).

**Expected Outcomes:**

* If the hypothesis is true, the mutated mIgM with disrupted asymmetric association should show altered lipid raft composition and reduced B-cell activation compared to wild-type mIgM.
* Co-localization of mIgM-BCRs with lipid rafts should be observed in wild-type mIgM-expressing cells, but not in mutated mIgM-expressing cells.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of mIgM Domain Association in Lipid Raft Recruitment and B-Cell Activation using a Dominant-Negative Approach

**Objective:** To test whether disrupting the asymmetric association of mIgM domains has no effect on lipid raft recruitment and B-cell activation.

**Experimental Design:**

1. **Cell Culture and Transfection:** Express a dominant-negative mIgM construct (e.g., a truncated mIgM lacking the transmembrane domain) in B cells. This construct should compete with endogenous mIgM for binding to lipid rafts, but not affect the asymmetric association of mIgM domains.
2. **Lipid Raft Isolation and Analysis:** Perform lipid raft isolation and analysis as described in the previous experiment.
3. **B-Cell Activation Assay:** Stimulate transfected B cells with a B-cell activator and measure B-cell activation markers as described in the previous experiment.
4. **Confocal Microscopy:** Visualize the co-localization of mIgM-BCRs with lipid rafts in transfected B cells as described in the previous experiment.

**Expected Outcomes:**

* If the hypothesis is false, the dominant-negative mIgM construct should not affect lipid raft composition or B-cell activation, despite disrupting the asymmetric association of mIgM domains.
* Co-localization of mIgM-BCRs with lipid rafts should still be observed in dominant-negative mIgM-expressing cells.

**Budget and Timeframe:**

* The experiments can be completed within 6-9 months with a budget of approximately $50,000-$75,000, depending on the specific reagents and equipment required.
* The budget will cover cell culture and transfection reagents, lipid raft isolation kits, antibodies and dyes for confocal microscopy, and mass spectrometry or TLC analysis.

By performing these experiments, we can test the hypothesis and attempt to disprove it, providing a more comprehensive understanding of the role of asymmetric mIgM domain association in lipid raft recruitment and B-cell activation.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Cell Culture and Transfection**

1.1. Prepare B cells: Obtain B cells from a suitable source (e.g., human peripheral blood or mouse spleen). Isolate and purify B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

1.2. Prepare expression vectors: Clone the wild-type mIgM gene and the mutated mIgM gene with disrupted asymmetric association into a suitable expression vector (e.g., pCDNA3.1) using standard molecular biology techniques.

1.3. Transfect B cells: Transfect 1 x 10^6 B cells with 1 μg of either wild-type mIgM or mutated mIgM expression vector using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.4. Incubate and select: Incubate transfected B cells in a 37°C, 5% CO2 incubator for 24-48 hours. Select for transfected cells using a selection marker (e.g., G418) according to the manufacturer's instructions.

**Protocol 2: Lipid Raft Isolation and Analysis**

2.1. Prepare lipid raft isolation kit: Follow the manufacturer's instructions to prepare the lipid raft isolation kit (e.g., Sigma-Aldrich).

2.2. Lyse cells: Lyse 1 x 10^7 transfected B cells in 1 mL of lysis buffer (e.g., 1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) on ice for 30 minutes.

2.3. Isolate lipid rafts: Add 1 mL of the prepared lipid raft isolation kit to the lysate and incubate on ice for 30 minutes. Centrifuge at 10,000 x g for 10 minutes to separate the lipid raft fraction.

2.4. Analyze lipid composition: Extract lipids from the isolated lipid raft fraction using a suitable solvent (e.g., chloroform:methanol, 2:1). Analyze the lipid composition using mass spectrometry (e.g., LC-MS/MS) or thin-layer chromatography (TLC) according to the manufacturer's instructions.

**Protocol 3: B-Cell Activation Assay**

3.1. Prepare B-cell activator: Prepare a B-cell activator (e.g., anti-IgM antibody) according to the manufacturer's instructions.

3.2. Stimulate B cells: Stimulate 1 x 10^6 transfected B cells with 1 μg/mL of the B-cell activator in a 37°C, 5% CO2 incubator for 24-48 hours.

3.3. Measure B-cell activation markers: Measure B-cell activation markers (e.g., CD69, CD86, or phosphorylated signaling proteins) using flow cytometry or Western blotting according to standard protocols.

**Protocol 4: Confocal Microscopy**

4.1. Prepare fluorescent tags: Label mIgM-BCRs with a fluorescent tag (e.g., GFP) using standard molecular biology techniques.

4.2. Prepare lipid raft dye: Prepare a lipid-specific dye (e.g., cholera toxin subunit B) according to the manufacturer's instructions.

4.3. Stain cells: Stain 1 x 10^6 transfected B cells with the fluorescently labeled mIgM-BCRs and lipid raft dye according to the manufacturer's instructions.

4.4. Visualize co-localization: Visualize the co-localization of mIgM-BCRs with lipid rafts using confocal microscopy (e.g., Zeiss LSM 710) according to the manufacturer's instructions.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Culture and Transfection**

1.1-1.4. Follow the same protocol as Experiment 1, but use a dominant-negative mIgM construct (e.g., a truncated mIgM lacking the transmembrane domain) instead of the wild-type and mutated mIgM constructs.

**Protocol 2: Lipid Raft Isolation and Analysis**

2.1-2.4. Follow the same protocol as Experiment 1.

**Protocol 3: B-Cell Activation Assay**

3.1-3.3. Follow the same protocol as Experiment 1.

**Protocol 4: Confocal Microscopy**

4.1-4.4. Follow the same protocol as Experiment 1.

Note: The protocols above assume a basic understanding of molecular biology, cell culture, and biochemical techniques. The specific reagents, equipment, and protocols may vary depending on the laboratory and the specific requirements of the experiment.","```
   B_cells  wild_type_mIgM  mutated_mIgM  dominant_negative_mIgM  Lipofectamine_2000  G418  lipid_raft_isolation_kit  B_cell_activator  fluorescent_tag  lipid_raft_dye  Outcome
0    1e+06           1.0           0.0                  0.0             1.0       1.0                    1.0             1.0           1.0           1.0  Positive
1    5e+05           0.5           0.0                  0.0             0.5       0.5                    0.5             0.5           0.5           0.5  Negative
2    1e+06           0.0           1.0                  0.0             1.0       1.0                    1.0             1.0           1.0           1.0  Positive
3    2e+06           1.5           0.0                  0.0             1.5       1.5                    1.5             1.5           1.5           1.5  Positive
4    1e+06           0.0           0.0                  1.0             1.0       1.0                    1.0             1.0           1.0           1.0  Negative
5    5e+05           1.0           0.0                  0.0             0.5       0.5                    0.5             0.5           0.5           0.5  Negative
6    1e+06           0.0           1.5                  0.0             1.0       1.0                    1.0             1.0           1.0           1.0  Positive
7    2e+06           1.0           0.0                  0.0             1.5       1.5                    1.5             1.5           1.5           1.5  Positive
8    1e+06           0.0           0.0                  1.5             1.0       1.0                    1.0             1.0           1.0           1.0  Negative
9    5e+05           0.5           0.0                  0.0             0.5       0.5                    0.5             0.5           0.5           0.5  Negative
10   1e+06           1.0           0.0                  0.0             1.0       1.0                    1.0             1.0           1.0           1.0  Positive
11   2e+06           0.0           1.0                  0.0             1.5       1.5                    1.5             1.5           1.5           1.5  Positive
12   1e+06           0.0           0.0                  1.0             1.0       1.0                    1.0             1.0           1.0           1.0  Negative
13   5e+05           1.5           0.0                  0.0             0.5       0.5                    0.5             0.5           0.5           0.5  Negative
14   1e+06           0.0           1.5                  0.0             1.0       1.0                    1.0             1.0           1.0           1.0  Positive
15   2e+06           1.0           0.0                  0.0             1.5       1.5                    1.5             1.5           1.5           1.5  Positive
16   1e+06           0.0           0.0                  1.5             1.0       1.0                    1.0             1.0           1.0           1.0  Negative
17   5e+05           0.5           0.0                  0.0             0.5       0.5                    0.5             0.5           0.5           0.5  Negative
18   1e+06           1.0           0.0                  0.0             1.0       1.0                    1.0             1.0           1.0           1.0  Positive
19   2e+06           0.0           1.0                  0.0             1.5       1.5                    1.5             1.5           1.5           1.5  Positive
20   1e+06           0.0           0.0                  1.0             1.0       1.0                    1.0             1.0           1.0           1.0  Negative
21   5e+05           1.0           0.0                  0.0             0.5       0.5                    0.5             0.5           0.5           0.5  Negative
22   1e+06           0.0           1.5                  0.0             1.0       1.0                    1.0             1.0           1.0           1.0  Positive
23   2e+06           1.5           0.0                  0.0             1.5       1.5                    1.5             1.5           1.5           1.5  Positive
24   1e+06           0.0           0.0                  1.5             1.0       1.0                    1.0             1.0           1.0           1.0  Negative
```",0.4960008542681648
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3269bafca5158cfbbf6b9d4519bc9842b3b6466f.summary'],Does the biased IGHV gene usage and stereotypy in the Traf2DNxBCL2-tg mouse model influence the efficacy of antigen-specific immunotherapy in CLL/SLL treatment?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis and potentially disprove it. Here's a high-level experimental approach:

**Experiment Title:** Investigating the Influence of Biased IGHV Gene Usage and Stereotypy on Antigen-Specific Immunotherapy Efficacy in the Traf2DNxBCL2-tg Mouse Model of CLL/SLL

**Objective:** To determine whether the biased IGHV gene usage and stereotypy in the Traf2DNxBCL2-tg mouse model affect the efficacy of antigen-specific immunotherapy in CLL/SLL treatment.

**Experimental Design:**

1. **Mouse Model and Immunization:**
	* Use Traf2DNxBCL2-tg mice (n=20) and divide them into two groups: immunized (n=10) and non-immunized (n=10).
	* Immunize the immunized group with a panel of antigens (e.g., 5-10) known to be relevant to CLL/SLL, using a standardized immunization protocol.
2. **B Cell Isolation and Sorting:**
	* Isolate B cells from the spleens of both immunized and non-immunized mice using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS).
	* Sort B cells into subpopulations based on surface markers (e.g., CD19, CD20, CD5) to enrich for CLL/SLL-like cells.
3. **IGHV Gene Sequencing and HCDR3 Analysis:**
	* Perform IGHV gene sequencing on the sorted B cell subpopulations using next-generation sequencing (NGS) or Sanger sequencing.
	* Analyze HCDR3 sequences to identify stereotypic patterns and biased IGHV gene usage.
4. **Antigen-Specific Immunotherapy:**
	* Develop antigen-specific immunotherapies (e.g., peptide-based vaccines, CAR-T cells) targeting the immunized antigens.
	* Treat both immunized and non-immunized mice with the antigen-specific immunotherapies.
5. **Efficacy Assessment:**
	* Monitor tumor burden, disease progression, and overall survival in both groups.
	* Evaluate the immune response, including cytokine production, T cell activation, and antibody titers.

**Hypothesis Testing:**

* If the biased IGHV gene usage and stereotypy in the Traf2DNxBCL2-tg mouse model influence the efficacy of antigen-specific immunotherapy, we would expect to see:
	+ Improved treatment outcomes (e.g., reduced tumor burden, increased survival) in the immunized group compared to the non-immunized group.
	+ Enrichment of stereotypic HCDR3 sequences and biased IGHV gene usage in the immunized group, which correlates with improved treatment outcomes.
* If the hypothesis is false, we would expect to see no significant difference in treatment outcomes between the immunized and non-immunized groups, despite the presence of biased IGHV gene usage and stereotypy.

**Budget and Timeline:**

* Estimated budget: $200,000 - $300,000
* Estimated timeline: 12-18 months

This experiment is designed to test the hypothesis while controlling for potential confounding factors. By comparing the immunized and non-immunized groups, we can determine whether the biased IGHV gene usage and stereotypy in the Traf2DNxBCL2-tg mouse model indeed influence the efficacy of antigen-specific immunotherapy in CLL/SLL treatment.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Mouse Model and Immunization**

1.1. Obtain 20 Traf2DNxBCL2-tg mice from a reputable vendor or breeding colony.

1.2. Randomly divide the mice into two groups: immunized (n=10) and non-immunized (n=10).

1.3. Prepare the immunization panel consisting of 5-10 antigens known to be relevant to CLL/SLL. These antigens should be purified and validated for immunogenicity.

1.4. Immunize the immunized group with the antigen panel using a standardized immunization protocol, such as:
	* Day 0: Inject 100 μg of each antigen in 100 μL of PBS emulsified with complete Freund's adjuvant (CFA) intraperitoneally (i.p.).
	* Day 14: Boost with 100 μg of each antigen in 100 μL of PBS emulsified with incomplete Freund's adjuvant (IFA) i.p.
	* Day 28: Boost with 100 μg of each antigen in 100 μL of PBS i.p.

1.5. Monitor the mice for signs of illness or distress and provide standard husbandry care.

**Protocol 2: B Cell Isolation and Sorting**

2.1. Euthanize the mice at Day 35 post-immunization using a CO2 chamber or other approved method.

2.2. Harvest the spleens from both immunized and non-immunized mice and store them in ice-cold PBS.

2.3. Prepare a single-cell suspension from the spleens using a gentleMACS Dissociator or similar device.

2.4. Stain the cells with fluorescently labeled antibodies against surface markers CD19, CD20, and CD5.

2.5. Perform fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) to isolate and sort B cells into subpopulations based on surface marker expression.

2.6. Collect the sorted B cell subpopulations in 1.5 mL tubes containing 100 μL of FACS buffer or MACS buffer.

**Protocol 3: IGHV Gene Sequencing and HCDR3 Analysis**

3.1. Extract genomic DNA from the sorted B cell subpopulations using a DNA extraction kit (e.g., Qiagen DNeasy).

3.2. Perform IGHV gene sequencing using next-generation sequencing (NGS) or Sanger sequencing.

3.3. Analyze the IGHV gene sequences using bioinformatic tools (e.g., IMGT/HighV-QUEST) to identify stereotypic patterns and biased IGHV gene usage.

3.4. Extract the HCDR3 sequences from the IGHV gene sequences and analyze them for stereotypy using tools such as HCDR3-Analyzer.

**Protocol 4: Antigen-Specific Immunotherapy**

4.1. Develop antigen-specific immunotherapies (e.g., peptide-based vaccines, CAR-T cells) targeting the immunized antigens.

4.2. Treat both immunized and non-immunized mice with the antigen-specific immunotherapies according to the following schedule:
	* Day 42: Administer the immunotherapy (e.g., peptide-based vaccine) i.p. or i.v.
	* Day 56: Boost with the immunotherapy (e.g., CAR-T cells) i.v.

4.3. Monitor the mice for signs of illness or distress and provide standard husbandry care.

**Protocol 5: Efficacy Assessment**

5.1. Monitor tumor burden, disease progression, and overall survival in both groups using techniques such as:
	* Bioluminescence imaging (BLI)
	* Flow cytometry
	* Histopathology

5.2. Evaluate the immune response, including:
	* Cytokine production (e.g., ELISA, Luminex)
	* T cell activation (e.g., flow cytometry, ICS)
	* Antibody titers (e.g., ELISA)

5.3. Collect and store blood and tissue samples for future analysis.

**Quality Control and Assurance**

* Verify the purity and specificity of the antigens used for immunization.
* Validate the IGHV gene sequencing and HCDR3 analysis pipelines.
* Monitor the mice for signs of illness or distress and provide standard husbandry care.
* Perform regular quality control checks on the immunotherapies and reagents used.

**Budget and Timeline**

* Estimated budget: $200,000 - $300,000
* Estimated timeline: 12-18 months

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   Antigen1  Antigen2  Antigen3  Antigen4  Antigen5  CFA  IFA  Outcome
0       80       120       100       90       110   50   30  Responded
1       90       100       80       120       90   40   20  Non-Responded
2       100       90       110       100       80   30   40  Responded
3       120       80       90       110       100   20   50  Responded
4       90       110       100       80       120   40   30  Non-Responded
5       80       100       120       90       100   50   20  Responded
6       110       90       80       100       120   30   40  Non-Responded
7       100       120       90       110       80   20   50  Responded
8       90       80       100       120       110   40   30  Non-Responded
9       120       100       110       90       80   50   20  Responded
10       80       90       120       100       110   30   40  Non-Responded
11       100       110       80       90       120   20   50  Responded
12       90       120       100       110       80   40   30  Non-Responded
13       110       80       90       120       100   50   20  Responded
14       100       90       110       80       120   30   40  Non-Responded
15       80       100       90       110       120   20   50  Responded
16       120       110       100       90       80   40   30  Non-Responded
17       90       80       120       100       110   50   20  Responded
18       100       120       90       110       80   30   40  Non-Responded
19       110       100       80       90       120   20   50  Responded
20       80       90       110       120       100   40   30  Non-Responded
21       100       80       120       90       110   50   20  Responded
22       120       90       100       110       80   30   40  Non-Responded
23       90       110       80       100       120   20   50  Responded
24       80       120       90       110       100   40   30  Non-Responded
```",0.0013770387394803371
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/00775cc19f8a1d4fcb57378e0d389d92ad620787.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0358920eb5dbc36587326ebd980942218636531d.summary']","Does the binding of Ikaros/IRF4 complexes to ZICEs also regulate the expression of Aicda, thereby influencing the balance between somatic hypermutation and class switch recombination in B cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the binding of Ikaros/IRF4 complexes to ZICEs regulates the expression of Aicda, thereby influencing the balance between somatic hypermutation and class switch recombination in B cells, I propose the following experimental plan:

**Experiment:** ""Disproving the Hypothesis: Does Ikaros/IRF4 Complex Binding to ZICEs Regulate Aicda Expression and B Cell Function?""

**Objective:** To determine if the binding of Ikaros/IRF4 complexes to ZICEs regulates Aicda expression and influences the balance between somatic hypermutation and class switch recombination in B cells.

**Experimental Design:**

1. **Cell Culture and Transfection:**
	* Isolate B cells from mice and culture them in vitro.
	* Transfect the B cells with a plasmid expressing a dominant-negative Ikaros mutant that cannot bind to ZICEs (Ikaros-DN).
	* Transfect a control group with a plasmid expressing a wild-type Ikaros (Ikaros-WT).
2. **ChIP-qPCR and RNA-seq:**
	* Perform ChIP-qPCR to measure the binding of Ikaros-DN and Ikaros-WT to ZICEs in the Aicda promoter region.
	* Perform RNA-seq to measure the expression of Aicda and other genes involved in somatic hypermutation and class switch recombination.
3. **Aicda Expression and Activity Assays:**
	* Measure Aicda protein expression using Western blotting or ELISA.
	* Measure Aicda activity using a somatic hypermutation assay (e.g., a reporter gene assay).
4. **B Cell Functional Assays:**
	* Measure the frequency of somatic hypermutation and class switch recombination using a B cell functional assay (e.g., a CSR assay).
	* Analyze the production of pathogenic autoantibodies using ELISA or other methods.

**Expected Outcomes:**

* If the hypothesis is true, Ikaros-DN transfection should reduce Aicda expression and activity, leading to decreased somatic hypermutation and increased class switch recombination.
* If the hypothesis is false, Ikaros-DN transfection should not affect Aicda expression and activity, and B cell function should remain unchanged.

**Controls:**

* Use Ikaros-WT transfection as a positive control to ensure that Ikaros binding to ZICEs regulates Aicda expression and B cell function.
* Use a non-specific DNA-binding protein (e.g., GFP) as a negative control to ensure that the effects observed are specific to Ikaros binding to ZICEs.

**Equipment and Resources:**

* Cell culture facilities and equipment
* Transfection reagents and equipment
* ChIP-qPCR and RNA-seq equipment and reagents
* Western blotting and ELISA equipment and reagents
* B cell functional assay equipment and reagents
* Bioinformatics tools and software for data analysis

**Timeline:**

* Cell culture and transfection: 2 weeks
* ChIP-qPCR and RNA-seq: 4 weeks
* Aicda expression and activity assays: 2 weeks
* B cell functional assays: 4 weeks
* Data analysis and interpretation: 6 weeks

**Budget:**

* Cell culture and transfection reagents: $5,000
* ChIP-qPCR and RNA-seq reagents: $10,000
* Aicda expression and activity assay reagents: $3,000
* B cell functional assay reagents: $5,000
* Equipment maintenance and personnel: $20,000
* Total budget: $43,000

This experiment is designed to test the hypothesis that Ikaros/IRF4 complex binding to ZICEs regulates Aicda expression and B cell function. By using a dominant-negative Ikaros mutant and a control group, we can determine if Ikaros binding to ZICEs is necessary for Aicda expression and B cell function. The results of this experiment will provide valuable insights into the regulation of B cell function and the role of Ikaros/IRF4 complexes in this process.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disproving the Hypothesis: Does Ikaros/IRF4 Complex Binding to ZICEs Regulate Aicda Expression and B Cell Function?""

**Protocol 1: Cell Culture and Transfection**

1.1. Isolate B cells from mice:

* Obtain 5-10 mice (C57BL/6 or other suitable strain) and sacrifice them according to institutional guidelines.
* Harvest spleens and lymph nodes, and isolate B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Resuspend the isolated B cells in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. Culture B cells in vitro:

* Plate 1-2 x 10^6 B cells per well in a 24-well plate and incubate at 37°C, 5% CO2.
* Culture the cells for 2-3 days to allow for recovery and activation.

1.3. Prepare plasmids:

* Obtain plasmids expressing dominant-negative Ikaros mutant (Ikaros-DN) and wild-type Ikaros (Ikaros-WT).
* Verify the plasmid sequences and prepare high-quality DNA using a plasmid purification kit (e.g., Qiagen).

1.4. Transfect B cells:

* Use a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions to transfect 1-2 x 10^6 B cells per well with 1-2 μg of Ikaros-DN or Ikaros-WT plasmid.
* Incubate the cells for 24-48 hours to allow for transfection and protein expression.

**Protocol 2: ChIP-qPCR**

2.1. Cross-link and sonicate cells:

* Add 1% formaldehyde to the cell culture medium and incubate for 10 minutes to cross-link proteins to DNA.
* Quench the reaction with 125 mM glycine and wash the cells with PBS.
* Sonicate the cells using a sonication device (e.g., Covaris) to shear the chromatin into fragments of 200-500 bp.

2.2. Immunoprecipitate Ikaros-DN and Ikaros-WT:

* Use an anti-Ikaros antibody (e.g., Santa Cruz Biotechnology) to immunoprecipitate the Ikaros-DN and Ikaros-WT proteins from the sonicated chromatin.
* Use a ChIP-grade protein A or G agarose beads (e.g., Millipore) to capture the immunocomplexes.

2.3. Perform qPCR:

* Use a qPCR machine (e.g., Applied Biosystems) to amplify the Aicda promoter region using primers specific to the ZICEs.
* Use a ChIP-qPCR kit (e.g., Qiagen) according to the manufacturer's instructions to detect the immunoprecipitated DNA.

**Protocol 3: RNA-seq**

3.1. Isolate RNA:

* Use a RNA isolation kit (e.g., Qiagen) to isolate total RNA from the transfected B cells.
* Verify the RNA quality using a bioanalyzer (e.g., Agilent).

3.2. Prepare RNA-seq libraries:

* Use a RNA-seq library preparation kit (e.g., Illumina) to prepare libraries from the isolated RNA.
* Perform quality control checks on the libraries using a bioanalyzer.

3.3. Sequence the libraries:

* Use a next-generation sequencing platform (e.g., Illumina HiSeq) to sequence the libraries.
* Generate at least 20 million reads per sample.

**Protocol 4: Aicda Expression and Activity Assays**

4.1. Western blotting:

* Use a Western blotting kit (e.g., Bio-Rad) to detect Aicda protein expression in the transfected B cells.
* Use an anti-Aicda antibody (e.g., Abcam) to detect the protein.

4.2. ELISA:

* Use an ELISA kit (e.g., R&D Systems) to detect Aicda protein expression in the transfected B cells.
* Follow the manufacturer's instructions to perform the assay.

4.3. Somatic hypermutation assay:

* Use a reporter gene assay (e.g., pGL3-Aicda) to measure Aicda activity.
* Transfect the reporter plasmid into the B cells and measure the luciferase activity using a luminometer.

**Protocol 5: B Cell Functional Assays**

5.1. CSR assay:

* Use a CSR assay kit (e.g., InvivoGen) to measure the frequency of class switch recombination in the transfected B cells.
* Follow the manufacturer's instructions to perform the assay.

5.2. Autoantibody production assay:

* Use an ELISA kit (e.g., R&D Systems) to detect the production of pathogenic autoantibodies in the transfected B cells.
* Follow the manufacturer's instructions to perform the assay.

**Data Analysis and Interpretation**

* Use bioinformatics tools (e.g., Bowtie, DESeq2) to analyze the RNA-seq data and identify differentially expressed genes.
* Use statistical software (e.g., R, GraphPad Prism) to analyze the ChIP-qPCR, Western blotting, ELISA, and B cell functional assay data.
* Interpret the results in the context of the hypothesis and discuss the implications for B cell function and the role of Ikaros/IRF4 complexes.

Note: The protocols above are detailed and specific, but may require modifications based on the specific equipment and resources available in the laboratory. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   Mice  B_cells  Ikaros-DN  Ikaros-WT  Transfection_Reagent  ChIP_qPCR_Primer  RNA_seq_Reads  Aicda_Protein_Expression  CSR_Frequency  Autoantibody_Production  Outcome
0      5  1.5e+06        1.0        0.0             Lipofectamine          1000          2500000               0.5             0.2               0.1        Negative
1      6  2.0e+06        1.5        0.5             Lipofectamine          1200          3000000               0.7             0.4               0.3        Positive
2      5  1.2e+06        0.5        1.0             Lipofectamine           800          2000000               0.3             0.1               0.2        Negative
3      7  2.5e+06        2.0        0.0             Lipofectamine          1500          3500000               0.9             0.6               0.5        Positive
4      6  1.8e+06        1.2        0.8             Lipofectamine          1000          2500000               0.6             0.3               0.4        Positive
5      5  1.0e+06        0.8        1.2             Lipofectamine           900          2200000               0.4             0.2               0.3        Negative
6      7  2.2e+06        1.8        0.2             Lipofectamine          1300          2800000               0.8             0.5               0.6        Positive
7      6  1.6e+06        1.0        1.0             Lipofectamine          1100          2400000               0.5             0.3               0.4        Negative
8      5  1.4e+06        0.6        1.4             Lipofectamine           950          2100000               0.3             0.2               0.3        Negative
9      7  2.8e+06        2.2        0.0             Lipofectamine          1600          3800000               1.0             0.7               0.8        Positive
10     6  1.9e+06        1.4        0.6             Lipofectamine          1050          2300000               0.6             0.4               0.5        Positive
11     5  1.1e+06        0.4        1.6             Lipofectamine           850          2000000               0.2             0.1               0.2        Negative
12     7  2.4e+06        2.0        0.4             Lipofectamine          1400          3100000               0.9             0.6               0.7        Positive
13     6  1.7e+06        1.2        0.8             Lipofectamine          1000          2400000               0.5             0.3               0.4        Negative
14     5  1.3e+06        0.2        1.8             Lipofectamine           900          2100000               0.2             0.1               0.2        Negative
15     7  2.6e+06        2.4        0.0             Lipofectamine          1700          4000000               1.1             0.8               0.9        Positive
16     6  2.0e+06        1.6        0.4             Lipofectamine          1150          2600000               0.7             0.5               0.6        Positive
17     5  1.2e+06        0.8        1.2             Lipofectamine           950          2200000               0.4             0.2               0.3        Negative
18     7  2.3e+06        2.2        0.2             Lipofectamine          1450          3200000               1.0             0.7               0.8        Positive
19     6  1.9e+06        1.4        0.6             Lipofectamine          1050          2400000               0.6             0.4               0.5        Positive
20     5  1.5e+06        0.6        1.4             Lipofectamine           1000          2300000               0.3             0.2               0.3        Negative
21     7  2.7e+06        2.6        0.0             Lipofectamine          1800          4200000               1.2             0.9               1.0        Positive
22     6  2.1e+06        1.8        0.2             Lipofectamine          1250          2800000               0.8             0.6               0.7        Positive
23     5  1.4e+06        0.4        1.6             Lipofectamine           950          2200000               0.2             0.1               0.2        Negative
24     7  2.5e+06        2.4        0.2             Lipofectamine          1550          3500000               1.1             0.8               0.9        Positive
```",0.6279493665922218
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e3c24d858652f111acd90fb018f8c5fee22aea4b.summary'],"Does the c-REL-OTUD4 axis also regulate the expression of immune checkpoint molecules in B-cell lymphoma cells, thereby modulating the tumor microenvironment and response to immunotherapy?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test this hypothesis, I'll outline a comprehensive experimental plan to investigate the role of the c-REL-OTUD4 axis in regulating immune checkpoint molecules in B-cell lymphoma cells and its impact on the tumor microenvironment and response to immunotherapy.

**Experimental Approach:**

**Objective:** To determine if the c-REL-OTUD4 axis regulates the expression of immune checkpoint molecules in B-cell lymphoma cells, thereby modulating the tumor microenvironment and response to immunotherapy.

**Step 1: Cell Culture and c-REL-OTUD4 Axis Modulation**

* Obtain B-cell lymphoma cell lines (e.g., Ramos, Daudi, or OCI-Ly1) and culture them in vitro.
* Use CRISPR-Cas9 gene editing to generate c-REL- and OTUD4-knockout (KO) cell lines to study the loss-of-function effects.
* Use lentiviral vectors to overexpress c-REL and OTUD4 in wild-type (WT) cells to study the gain-of-function effects.

**Step 2: Immune Checkpoint Molecule Expression Analysis**

* Use quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting to analyze the expression of immune checkpoint molecules (e.g., PD-L1, PD-1, CTLA-4, LAG-3) in c-REL- and OTUD4-KO cells, as well as in c-REL- and OTUD4-overexpressing cells.
* Compare the expression levels to those in WT cells.

**Step 3: Tumor Microenvironment Analysis**

* Co-culture c-REL- and OTUD4-KO cells or c-REL- and OTUD4-overexpressing cells with immune cells (e.g., T cells, macrophages) to study the impact on the tumor microenvironment.
* Analyze the production of cytokines (e.g., IL-2, IFN-γ, TNF-α) and chemokines (e.g., CCL2, CXCL10) using enzyme-linked immunosorbent assays (ELISAs) or multiplex assays.
* Investigate the infiltration of immune cells into the tumor microenvironment using flow cytometry and immunofluorescence staining.

**Step 4: Immunotherapy Response Analysis**

* Treat c-REL- and OTUD4-KO cells or c-REL- and OTUD4-overexpressing cells with immunotherapeutic agents (e.g., anti-PD-1, anti-CTLA-4) and analyze the response using cell viability assays (e.g., MTT, CellTiter-Glo).
* Investigate the expression of immune checkpoint molecules and cytokine production in response to immunotherapy.

**Step 5: In Vivo Validation**

* Use a B-cell lymphoma xenograft model to study the role of the c-REL-OTUD4 axis in regulating immune checkpoint molecules and the tumor microenvironment in vivo.
* Inject c-REL- and OTUD4-KO cells or c-REL- and OTUD4-overexpressing cells into immunodeficient mice and monitor tumor growth and immune cell infiltration.
* Treat mice with immunotherapeutic agents and analyze the response.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to show that the c-REL-OTUD4 axis does not regulate immune checkpoint molecules in B-cell lymphoma cells. Here's an approach:

**Experiment:**

* Use a small molecule inhibitor of c-REL (e.g., IT-603) to inhibit c-REL activity in WT B-cell lymphoma cells.
* Analyze the expression of immune checkpoint molecules (e.g., PD-L1, PD-1, CTLA-4, LAG-3) using qRT-PCR and Western blotting.
* If the hypothesis is true, inhibiting c-REL should decrease the expression of immune checkpoint molecules. However, if the expression levels remain unchanged, it would suggest that the c-REL-OTUD4 axis does not regulate immune checkpoint molecules in B-cell lymphoma cells.

**Additional Considerations:**

* Use multiple B-cell lymphoma cell lines and primary patient samples to ensure the results are not cell line-specific.
* Include appropriate controls, such as scrambled siRNA or empty vector controls, to account for off-target effects.
* Validate the results using orthogonal methods, such as RNA sequencing and chromatin immunoprecipitation sequencing (ChIP-seq), to confirm the regulation of immune checkpoint molecules by the c-REL-OTUD4 axis.

With an unlimited budget, we can perform these experiments in a state-of-the-art laboratory with the latest equipment and technology, ensuring the highest quality and accuracy of the results.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Culture and c-REL-OTUD4 Axis Modulation**

1.1. Obtain B-cell lymphoma cell lines (e.g., Ramos, Daudi, or OCI-Ly1) from a reputable cell bank or culture collection.

1.2. Culture the cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

1.3. Design and synthesize guide RNAs (gRNAs) targeting c-REL and OTUD4 using a CRISPR-Cas9 design tool.

1.4. Transfect the gRNAs into the B-cell lymphoma cells using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.

1.5. Select and isolate single-cell clones using limiting dilution and puromycin selection.

1.6. Verify the knockout of c-REL and OTUD4 using Western blotting and qRT-PCR.

1.7. Design and clone c-REL and OTUD4 overexpression constructs into lentiviral vectors.

1.8. Transfect the lentiviral vectors into HEK293T cells to produce lentiviral particles.

1.9. Infect the B-cell lymphoma cells with the lentiviral particles and select for stable overexpression using puromycin selection.

1.10. Verify the overexpression of c-REL and OTUD4 using Western blotting and qRT-PCR.

**Step 2: Immune Checkpoint Molecule Expression Analysis**

2.1. Extract total RNA from c-REL- and OTUD4-KO cells, c-REL- and OTUD4-overexpressing cells, and WT cells using a RNA extraction kit (e.g., TRIzol).

2.2. Perform qRT-PCR using a qRT-PCR kit (e.g., SYBR Green) and primers specific to immune checkpoint molecules (e.g., PD-L1, PD-1, CTLA-4, LAG-3).

2.3. Normalize the qRT-PCR data to a housekeeping gene (e.g., GAPDH) and calculate the fold change in expression relative to WT cells.

2.4. Perform Western blotting using antibodies specific to immune checkpoint molecules and normalize to a loading control (e.g., β-actin).

2.5. Quantify the Western blotting results using densitometry software (e.g., ImageJ).

**Step 3: Tumor Microenvironment Analysis**

3.1. Co-culture c-REL- and OTUD4-KO cells or c-REL- and OTUD4-overexpressing cells with immune cells (e.g., T cells, macrophages) at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

3.2. Incubate the co-cultures for 24-48 hours at 37°C and 5% CO2.

3.3. Collect the supernatants and analyze the production of cytokines (e.g., IL-2, IFN-γ, TNF-α) and chemokines (e.g., CCL2, CXCL10) using ELISAs or multiplex assays.

3.4. Perform flow cytometry to analyze the infiltration of immune cells into the tumor microenvironment using antibodies specific to immune cell markers (e.g., CD4, CD8, CD11b).

3.5. Perform immunofluorescence staining to visualize the infiltration of immune cells into the tumor microenvironment using antibodies specific to immune cell markers.

**Step 4: Immunotherapy Response Analysis**

4.1. Treat c-REL- and OTUD4-KO cells or c-REL- and OTUD4-overexpressing cells with immunotherapeutic agents (e.g., anti-PD-1, anti-CTLA-4) at various concentrations.

4.2. Incubate the cells for 24-48 hours at 37°C and 5% CO2.

4.3. Analyze the response to immunotherapy using cell viability assays (e.g., MTT, CellTiter-Glo).

4.4. Perform qRT-PCR and Western blotting to analyze the expression of immune checkpoint molecules and cytokine production in response to immunotherapy.

**Step 5: In Vivo Validation**

5.1. Inject c-REL- and OTUD4-KO cells or c-REL- and OTUD4-overexpressing cells into immunodeficient mice (e.g., NOD-SCID) via subcutaneous injection.

5.2. Monitor tumor growth using caliper measurements and bioluminescence imaging.

5.3. Treat mice with immunotherapeutic agents (e.g., anti-PD-1, anti-CTLA-4) via intraperitoneal injection.

5.4. Analyze the response to immunotherapy using tumor growth curves and survival analysis.

5.5. Perform flow cytometry and immunofluorescence staining to analyze the infiltration of immune cells into the tumor microenvironment.

**Experiment to Disprove the Hypothesis**

1. Treat WT B-cell lymphoma cells with a small molecule inhibitor of c-REL (e.g., IT-603) at various concentrations.

2. Analyze the expression of immune checkpoint molecules (e.g., PD-L1, PD-1, CTLA-4, LAG-3) using qRT-PCR and Western blotting.

3. Compare the expression levels to those in untreated WT cells.

**Additional Considerations**

* Use multiple B-cell lymphoma cell lines and primary patient samples to ensure the results are not cell line-specific.

* Include appropriate controls, such as scrambled siRNA or empty vector controls, to account for off-target effects.

* Validate the results using orthogonal methods, such as RNA sequencing and chromatin immunoprecipitation sequencing (ChIP-seq), to confirm the regulation of immune checkpoint molecules by the c-REL-OTUD4 axis.

Note: These protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   c_REL_KO  OTUD4_KO  c_REL_OE  OTUD4_OE  FBS  Penicillin_Streptomycin  L_Glutamine  Puromycin  gRNA_Conc  Transfection_Reagent  Immunotherapy_Agent  Outcome
0         0.0       0.0       1.0       1.0  10.0                  1.0          1.0       1.0        50.0                Lipofectamine         anti_PD1  Responsive
1         0.5       0.5       0.0       0.0  12.0                  1.2          1.2       1.2        30.0                Lipofectamine         anti_CTla4  Non_Responsive
2         1.0       1.0       0.0       0.0  11.0                  1.1          1.1       1.1        40.0                Lipofectamine         anti_PD1  Responsive
3         0.0       0.0       1.5       1.5  13.0                  1.3          1.3       1.3        60.0                Lipofectamine         anti_CTla4  Non_Responsive
4         0.5       0.5       1.0       1.0  10.0                  1.0          1.0       1.0        50.0                Lipofectamine         anti_PD1  Responsive
5         1.0       1.0       0.5       0.5  12.0                  1.2          1.2       1.2        30.0                Lipofectamine         anti_CTla4  Non_Responsive
6         0.0       0.0       1.0       1.0  11.0                  1.1          1.1       1.1        40.0                Lipofectamine         anti_PD1  Responsive
7         0.5       0.5       1.5       1.5  13.0                  1.3          1.3       1.3        60.0                Lipofectamine         anti_CTla4  Non_Responsive
8         1.0       1.0       0.0       0.0  10.0                  1.0          1.0       1.0        50.0                Lipofectamine         anti_PD1  Responsive
9         0.0       0.0       1.0       1.0  12.0                  1.2          1.2       1.2        30.0                Lipofectamine         anti_CTla4  Non_Responsive
10        0.5       0.5       1.0       1.0  11.0                  1.1          1.1       1.1        40.0                Lipofectamine         anti_PD1  Responsive
11        1.0       1.0       0.5       0.5  13.0                  1.3          1.3       1.3        60.0                Lipofectamine         anti_CTla4  Non_Responsive
12        0.0       0.0       1.5       1.5  10.0                  1.0          1.0       1.0        50.0                Lipofectamine         anti_PD1  Responsive
13        0.5       0.5       1.0       1.0  12.0                  1.2          1.2       1.2        30.0                Lipofectamine         anti_CTla4  Non_Responsive
14        1.0       1.0       0.0       0.0  11.0                  1.1          1.1       1.1        40.0                Lipofectamine         anti_PD1  Responsive
15        0.0       0.0       1.0       1.0  13.0                  1.3          1.3       1.3        60.0                Lipofectamine         anti_CTla4  Non_Responsive
16        0.5       0.5       1.5       1.5  10.0                  1.0          1.0       1.0        50.0                Lipofectamine         anti_PD1  Responsive
17        1.0       1.0       0.5       0.5  12.0                  1.2          1.2       1.2        30.0                Lipofectamine         anti_CTla4  Non_Responsive
18        0.0       0.0       1.0       1.0  11.0                  1.1          1.1       1.1        40.0                Lipofectamine         anti_PD1  Responsive
19        0.5       0.5       1.0       1.0  13.0                  1.3          1.3       1.3        60.0                Lipofectamine         anti_CTla4  Non_Responsive
20        1.0       1.0       0.0       0.0  10.0                  1.0          1.0       1.0        50.0                Lipofectamine         anti_PD1  Responsive
21        0.0       0.0       1.5       1.5  12.0                  1.2          1.2       1.2        30.0                Lipofectamine         anti_CTla4  Non_Responsive
22        0.5       0.5       1.0       1.0  11.0                  1.1          1.1       1.1        40.0                Lipofectamine         anti_PD1  Responsive
23        1.0       1.0       0.5       0.5  13.0                  1.3          1.3       1.3        60.0                Lipofectamine         anti_CTla4  Non_Responsive
24        0.0       0.0       1.0       1.0  10.0                  1.0          1.0       1.0        50.0                Lipofectamine         anti_PD1  Responsive
```",0.4875747491528692
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/651c4c6567494c3929c9beaf2803ce08677ff383.summary'],"Does the cell-intrinsic regulation of CD127- ELPs also depend on the divisional history of their precursors, influencing the expression of specific transcription factors that bias their differentiation towards the T/NK/ILC lineage?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I will design an experiment to test the hypothesis: ""Does the cell-intrinsic regulation of CD127- ELPs also depend on the divisional history of their precursors, influencing the expression of specific transcription factors that bias their differentiation towards the T/NK/ILC lineage?""

**Experimental Plan:**

**Objective:** To determine if the cell-intrinsic regulation of CD127- ELPs is dependent on the divisional history of their precursors, influencing the expression of specific transcription factors that bias their differentiation towards the T/NK/ILC lineage.

**Experimental Design:**

1. **Cell Sorting:** Sort CD117lo MLPs based on their divisional history using CFSE (carboxyfluorescein succinimidyl ester) labeling. This will allow for the separation of MLPs that have undergone different numbers of cell divisions.
2. **Cell Culture:** Culture the sorted CD117lo MLPs in the presence or absence of Flt3L. This will enable the investigation of the effect of Flt3L signaling on the cell-intrinsic regulation of CD127- ELPs.
3. **ELP Generation:** Allow the sorted MLPs to differentiate into ELPs in the presence or absence of Flt3L.
4. **Transcription Factor Analysis:** Analyze the expression of transcription factors specific to the T/NK/ILC lineage, such as GATA3, T-bet, and EOMES, in the resulting ELPs using qRT-PCR or RNA-seq.
5. **Comparison:** Compare the expression levels of these transcription factors between ELPs derived from MLPs with different divisional histories and in the presence or absence of Flt3L.

**Expected Outcomes:**

* If the hypothesis is true, ELPs derived from MLPs with a specific divisional history will exhibit differential expression of T/NK/ILC-specific transcription factors, which will be influenced by the presence or absence of Flt3L.
* If the hypothesis is false, no correlation will be observed between the divisional history of MLPs and the expression of T/NK/ILC-specific transcription factors in ELPs.

**Equipment and Resources:**

* FACS sorter
* Cell culture facilities
* qRT-PCR or RNA-seq equipment
* CFSE labeling reagents
* Flt3L
* Cell culture media and reagents

**Timeline:**

* Cell sorting and culture setup: 2-3 days
* ELP generation: 7-10 days
* Transcription factor analysis: 3-5 days
* Data analysis and interpretation: 5-7 days

**Budget:**

* FACS sorter usage: $500
* Cell culture reagents and media: $1,000
* qRT-PCR or RNA-seq equipment usage: $1,500
* CFSE labeling reagents: $200
* Flt3L: $500
* Personnel and overheads: $5,000

Total budget: $8,700

This experiment is designed to test the hypothesis in a controlled and efficient manner, using existing scientific methods and equipment. The expected outcomes will provide valuable insights into the cell-intrinsic regulation of CD127- ELPs and their differentiation towards the T/NK/ILC lineage.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Sorting**

1.1. Preparation of CFSE labeling solution:

* Dissolve 5 mg of CFSE powder in 1 mL of DMSO to create a 5 mM stock solution.
* Aliquot the stock solution into 10 μL tubes and store at -20°C.

1.2. Labeling of CD117lo MLPs with CFSE:

* Harvest CD117lo MLPs from mice or cell culture and resuspend them in 1 mL of PBS.
* Add 1 μL of CFSE stock solution to the cell suspension and mix well.
* Incubate the cells at 37°C for 10 minutes to allow for CFSE labeling.
* Wash the cells twice with PBS to remove excess CFSE.

1.3. Staining of CD117lo MLPs with antibodies:

* Resuspend the CFSE-labeled cells in 100 μL of staining buffer (PBS + 2% FBS + 0.1% NaN3).
* Add the following antibodies to the cell suspension:
	+ Anti-CD117-APC (1:100 dilution)
	+ Anti-CD127-PE (1:100 dilution)
* Mix well and incubate at 4°C for 30 minutes.
* Wash the cells twice with staining buffer.

1.4. FACS sorting:

* Use a FACS sorter to sort CD117lo MLPs based on their CFSE fluorescence intensity, which indicates their divisional history.
* Gate on CD117lo cells and sort them into three populations:
	+ Low CFSE (0-10 divisions)
	+ Medium CFSE (11-20 divisions)
	+ High CFSE (21+ divisions)
* Collect the sorted cells in 1.5 mL tubes containing 100 μL of cell culture media.

**Protocol 2: Cell Culture**

2.1. Preparation of cell culture media:

* Use a commercially available cell culture media (e.g., RPMI-1640) supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Add 10 ng/mL of Flt3L to the media for the Flt3L-treated group.

2.2. Cell culture setup:

* Resuspend the sorted CD117lo MLPs in 1 mL of cell culture media (with or without Flt3L).
* Plate the cells in 24-well plates at a density of 1 x 10^5 cells per well.
* Incubate the cells at 37°C, 5% CO2 for 7-10 days to allow for ELP generation.

**Protocol 3: ELP Generation**

3.1. Harvesting of ELPs:

* After 7-10 days of culture, harvest the cells from the 24-well plates.
* Resuspend the cells in 1 mL of PBS and count the cell number using a hemocytometer.

3.2. Enrichment of ELPs:

* Use a magnetic bead-based enrichment kit (e.g., EasySep) to enrich for CD127- ELPs.
* Follow the manufacturer's instructions for the enrichment protocol.

**Protocol 4: Transcription Factor Analysis**

4.1. RNA extraction:

* Extract RNA from the enriched ELPs using a commercially available RNA extraction kit (e.g., RNeasy).
* Follow the manufacturer's instructions for the RNA extraction protocol.

4.2. cDNA synthesis:

* Synthesize cDNA from the extracted RNA using a commercially available cDNA synthesis kit (e.g., iScript).
* Follow the manufacturer's instructions for the cDNA synthesis protocol.

4.3. qRT-PCR or RNA-seq:

* Use qRT-PCR or RNA-seq to analyze the expression of transcription factors specific to the T/NK/ILC lineage, such as GATA3, T-bet, and EOMES.
* Design primers specific to the target genes and use a commercially available qRT-PCR or RNA-seq kit (e.g., SYBR Green or Illumina).
* Follow the manufacturer's instructions for the qRT-PCR or RNA-seq protocol.

**Protocol 5: Data Analysis**

5.1. Data collection:

* Collect the qRT-PCR or RNA-seq data and export it to a spreadsheet software (e.g., Excel).

5.2. Data analysis:

* Normalize the data to a housekeeping gene (e.g., GAPDH) and calculate the relative expression levels of the target genes.
* Compare the expression levels of the target genes between ELPs derived from MLPs with different divisional histories and in the presence or absence of Flt3L.
* Use statistical software (e.g., GraphPad Prism) to perform statistical analysis and generate graphs.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   CFSE_stock_solution  CD117lo_MLPs  Anti_CD117_APC  Anti_CD127_PE  Flt3L  Cell_culture_media  ELP_generation  GATA3_expression  T_bet_expression  EOMES_expression
0                4.5          1.2e6           0.9         0.95       5.0              10% FBS          8 days          2.1          1.5          0.8
1                5.0          1.5e6           1.0         1.00       0.0              10% FBS          9 days          2.5          1.8          1.2
2                4.0          1.0e6           0.8         0.90       5.0              10% FBS          7 days          1.9          1.2          0.6
3                5.5          1.8e6           1.1         1.05       0.0              10% FBS          8 days          2.8          2.0          1.5
4                4.8          1.4e6           0.95        0.98       5.0              10% FBS          9 days          2.3          1.6          1.0
5                5.2          1.6e6           1.05        1.02       0.0              10% FBS          7 days          2.6          1.9          1.3
6                4.2          1.1e6           0.85        0.92       5.0              10% FBS          8 days          2.0          1.4          0.9
7                5.8          2.0e6           1.15        1.10       0.0              10% FBS          9 days          3.1          2.2          1.8
8                4.6          1.3e6           0.90        0.95       5.0              10% FBS          7 days          2.2          1.5          1.1
9                5.1          1.7e6           1.00        1.03       0.0              10% FBS          8 days          2.7          2.1          1.6
10               4.9          1.5e6           0.98        1.01       5.0              10% FBS          9 days          2.4          1.7          1.2
11               5.4          1.9e6           1.12        1.08       0.0              10% FBS          7 days          2.9          2.3          1.9
12               4.1          1.0e6           0.80        0.88       5.0              10% FBS          8 days          1.8          1.1          0.7
13               5.6          2.1e6           1.18        1.12       0.0              10% FBS          9 days          3.3          2.5          2.1
14               4.7          1.4e6           0.92        0.96       5.0              10% FBS          7 days          2.1          1.5          1.0
15               5.3          1.8e6           1.08        1.06       0.0              10% FBS          8 days          2.8          2.2          1.7
16               4.3          1.2e6           0.88        0.94       5.0              10% FBS          9 days          2.0          1.4          0.9
17               5.9          2.2e6           1.20        1.15       0.0              10% FBS          7 days          3.5          2.7          2.3
18               4.4          1.3e6           0.90        0.97       5.0              10% FBS          8 days          2.3          1.6          1.2
19               5.0          1.6e6           1.02        1.04       0.0              10% FBS          9 days          2.6          2.0          1.5
20               4.0          1.1e6           0.82        0.90       5.0              10% FBS          7 days          1.9          1.3          0.8
21               5.7          2.0e6           1.19        1.13       0.0              10% FBS          8 days          3.2          2.4          2.0
22               4.5          1.4e6           0.93        0.99       5.0              10% FBS          9 days          2.4          1.8          1.3
23               5.2          1.7e6           1.06        1.07       0.0              10% FBS          7 days          2.9          2.3          1.8
24               4.1          1.2e6           0.84        0.91       5.0              10% FBS          8 days          2.0          1.4          0.9
```",0.6297035636127271
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/04391cc8e916a18b2c69c0e5d0f130204897c465.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/02cba02b61539e6cc7fb8180439288f721e6dd49.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/546e2f31c13b308d3d3afc154753664d81129177.summary']","Does the cell-specific expression of transposable elements in immune cells influence the development of autoreactive B cell subsets in systemic lupus erythematosus, leading to the production of pathogenic autoantibodies?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the cell-specific expression of transposable elements in immune cells influences the development of autoreactive B cell subsets in systemic lupus erythematosus (SLE), leading to the production of pathogenic autoantibodies, I propose the following experimental plan:

**Experiment:** ""Disproving the Hypothesis: Investigating the Role of Transposable Elements in Autoreactive B Cell Development in SLE""

**Objective:** To determine whether the cell-specific expression of transposable elements in immune cells is necessary for the development of autoreactive B cell subsets in SLE.

**Design:**

1. **Cell Isolation and Sorting:** Isolate peripheral blood mononuclear cells (PBMCs) from SLE patients and healthy controls. Sort CD4+ T cells, monocytes, B cells, and NK cells using flow cytometry.
2. **Transposable Element Knockdown:** Use CRISPR-Cas9 to specifically knockdown the expression of the identified transposable elements in each cell type. Use a non-targeting guide RNA as a control.
3. **B Cell Stimulation and Differentiation:** Stimulate the edited cells with anti-CD40, IL-4, and CpG to induce B cell activation and differentiation into autoreactive B cell subsets.
4. **Autoantibody Production:** Measure the production of pathogenic autoantibodies (e.g., anti-dsDNA, anti-Smith) in the supernatant of stimulated B cells using ELISA.
5. **Flow Cytometry Analysis:** Analyze the expression of surface markers (e.g., CD19, CD20, CD27, CD38) and intracellular markers (e.g., IgG, IgM) on B cells using flow cytometry to identify autoreactive B cell subsets.
6. **Statistical Analysis:** Compare the production of autoantibodies and the frequency of autoreactive B cell subsets between the transposable element-knockdown cells and control cells.

**Expected Outcome:** If the hypothesis is true, the knockdown of transposable elements in immune cells should reduce the production of pathogenic autoantibodies and the frequency of autoreactive B cell subsets. If the results show no significant difference between the transposable element-knockdown cells and control cells, it would suggest that the cell-specific expression of transposable elements is not necessary for the development of autoreactive B cell subsets in SLE.

**Equipment and Resources:**

* CRISPR-Cas9 system
* Cell culture facilities
* Flow cytometer
* ELISA reader
* Bioinformatics tools for data analysis
* PBMCs from SLE patients and healthy controls
* Reagents for B cell stimulation and differentiation (anti-CD40, IL-4, CpG)
* Antibodies for flow cytometry analysis (CD19, CD20, CD27, CD38, IgG, IgM)

**Timeline:** This experiment can be completed within 6-9 months, assuming a moderate pace of experimentation and data analysis.

**Budget:** The budget for this experiment will depend on the cost of the CRISPR-Cas9 system, cell culture reagents, flow cytometry antibodies, and ELISA kits. A rough estimate would be around $50,000-$75,000.

By designing an experiment to disprove the hypothesis, we can test the validity of the hypothesis and gain a better understanding of the role of transposable elements in autoreactive B cell development in SLE.",85,"Here is the detailed, step-by-step protocol for the experiment ""Disproving the Hypothesis: Investigating the Role of Transposable Elements in Autoreactive B Cell Development in SLE"":

**Protocol:**

**Step 1: Cell Isolation and Sorting**

1.1. Obtain peripheral blood mononuclear cells (PBMCs) from SLE patients and healthy controls using a sterile technique.

1.2. Isolate PBMCs using density gradient centrifugation (e.g., Ficoll-Paque) according to the manufacturer's instructions.

1.3. Wash the isolated PBMCs with phosphate-buffered saline (PBS) and resuspend them in a suitable buffer (e.g., RPMI 1640) for flow cytometry.

1.4. Stain the PBMCs with fluorescently labeled antibodies against CD4, CD14, CD19, and CD56 to identify CD4+ T cells, monocytes, B cells, and NK cells, respectively.

1.5. Sort the stained cells using a flow cytometer (e.g., BD FACSAria) into separate tubes for each cell type.

**Step 2: Transposable Element Knockdown**

2.1. Design and synthesize CRISPR-Cas9 guide RNAs (gRNAs) specific to the identified transposable elements.

2.2. Prepare CRISPR-Cas9 complexes by mixing the gRNAs with the Cas9 enzyme according to the manufacturer's instructions.

2.3. Electroporate the CRISPR-Cas9 complexes into the sorted cells using an electroporation device (e.g., Neon Transfection System).

2.4. Incubate the electroporated cells in a suitable culture medium (e.g., RPMI 1640) for 24-48 hours to allow for gene editing.

2.5. Verify the knockdown of transposable elements using quantitative reverse transcription polymerase chain reaction (qRT-PCR) or other suitable methods.

**Step 3: B Cell Stimulation and Differentiation**

3.1. Stimulate the edited B cells with anti-CD40 (10 μg/mL), IL-4 (10 ng/mL), and CpG (1 μM) in a suitable culture medium (e.g., RPMI 1640) for 5-7 days.

3.2. Monitor the cells for activation and differentiation into autoreactive B cell subsets using flow cytometry.

**Step 4: Autoantibody Production**

4.1. Collect the supernatant from the stimulated B cells and store it at -80°C until analysis.

4.2. Measure the production of pathogenic autoantibodies (e.g., anti-dsDNA, anti-Smith) using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions.

**Step 5: Flow Cytometry Analysis**

5.1. Stain the stimulated B cells with fluorescently labeled antibodies against CD19, CD20, CD27, CD38, IgG, and IgM.

5.2. Analyze the expression of surface markers and intracellular markers using flow cytometry to identify autoreactive B cell subsets.

**Step 6: Statistical Analysis**

6.1. Compare the production of autoantibodies and the frequency of autoreactive B cell subsets between the transposable element-knockdown cells and control cells using suitable statistical tests (e.g., t-test, ANOVA).

6.2. Determine the significance of the results and draw conclusions about the role of transposable elements in autoreactive B cell development in SLE.

**Quality Control and Assurance:**

* Verify the purity of the sorted cells using flow cytometry.
* Validate the knockdown of transposable elements using qRT-PCR or other suitable methods.
* Use appropriate controls (e.g., non-targeting gRNA) to ensure specificity of the CRISPR-Cas9 system.
* Perform experiments in triplicate to ensure reproducibility.

**Timeline and Budget:**

* The experiment can be completed within 6-9 months, assuming a moderate pace of experimentation and data analysis.
* The budget for this experiment will depend on the cost of the CRISPR-Cas9 system, cell culture reagents, flow cytometry antibodies, and ELISA kits. A rough estimate would be around $50,000-$75,000.

By following this detailed protocol, the experiment can be executed with precision and accuracy, ensuring the reliability and reproducibility of the results.","```
   PBMCs  CD4  CD14  CD19  CD56  gRNA  Cas9  Anti-CD40  IL-4  CpG  Autoantibody_Production
0    1000   200   150   300   100   50    20       10.0   10.0   1.0             0.5
1    1200   250   180   350   120   60    25       12.0   12.0   1.2             0.7
2     900   180   130   280   100   40    18       9.0    9.0   0.9             0.4
3    1100   220   160   320   110   55    22       11.0   11.0   1.1             0.6
4     800   160   120   240   90    35    15       8.0    8.0   0.8             0.3
5    1300   280   200   380   130   70    28       14.0   14.0   1.4             0.9
6     950   190   140   290   100   45    20       9.5    9.5   0.95            0.5
7    1050   210   170   310   110   50    23       10.5   10.5   1.05            0.6
8     850   170   130   260   90    40    18       8.5    8.5   0.85            0.4
9    1250   260   190   360   120   65    26       12.5   12.5   1.25            0.8
10   1000   200   150   300   100   50    20       10.0   10.0   1.0             0.5
11   1150   230   180   330   110   58    24       11.5   11.5   1.15            0.7
12    900   180   130   280   100   42    19       9.0    9.0   0.9             0.4
13   1200   250   190   350   120   62    27       12.0   12.0   1.2             0.8
14    950   190   140   290   100   48    21       9.5    9.5   0.95            0.5
15   1100   220   170   320   110   55    23       11.0   11.0   1.1             0.6
16    800   160   120   240   90    38    16       8.0    8.0   0.8             0.3
17   1300   280   210   380   130   72    29       13.0   13.0   1.3             0.9
18   1050   210   170   310   110   52    24       10.5   10.5   1.05            0.6
19    850   170   130   260   90    44    20       8.5    8.5   0.85            0.4
20   1250   260   200   360   120   68    28       12.5   12.5   1.25            0.8
21   1000   200   150   300   100   50    20       10.0   10.0   1.0             0.5
22   1150   230   180   330   110   60    25       11.5   11.5   1.15            0.7
23    900   180   130   280   100   46    21       9.0    9.0   0.9             0.4
24   1200   250   190   350   120   65    27       12.0   12.0   1.2             0.8
```",0.9815752389785226
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/289d6858f6196fb09d6dda785280a5837f254c83.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/07a29b3206efaa8059278e706a51c0e5d8d9163a.summary']","Does the co-expression of BTN3A2 and the 5 IRGs (CCL25, IL29, TDGF3, GPR44, and GREM2) in lung adenocarcinoma patients predict their response to immunotherapy and overall survival?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I propose an experimental plan to test the hypothesis that the co-expression of BTN3A2 and the 5 IRGs (CCL25, IL29, TDGF3, GPR44, and GREM2) in lung adenocarcinoma patients predicts their response to immunotherapy and overall survival.

**Experimental Approach:**

To disprove the hypothesis, we will design an experiment to test the correlation between the co-expression of BTN3A2 and the 5 IRGs with the response to immunotherapy and overall survival in lung adenocarcinoma patients.

**Step 1: Patient Selection and Sample Collection**

* Collect tumor samples from lung adenocarcinoma patients who have received immunotherapy (e.g., PD-1/PD-L1 inhibitors).
* Ensure that the patients have not received any other treatments that may affect the expression of the genes of interest.
* Collect clinical data, including response to immunotherapy (e.g., complete response, partial response, stable disease, or progressive disease) and overall survival.

**Step 2: Gene Expression Analysis**

* Extract RNA from the tumor samples and perform quantitative PCR (qPCR) or RNA sequencing to measure the expression levels of BTN3A2 and the 5 IRGs (CCL25, IL29, TDGF3, GPR44, and GREM2).
* Normalize the gene expression data using appropriate housekeeping genes.

**Step 3: Data Analysis**

* Perform correlation analysis between the expression levels of BTN3A2 and the 5 IRGs with the response to immunotherapy and overall survival.
* Use statistical models (e.g., logistic regression, Cox proportional hazards model) to determine the predictive value of the co-expression of BTN3A2 and the 5 IRGs.
* Perform Kaplan-Meier survival analysis to compare the overall survival of patients with high and low co-expression of BTN3A2 and the 5 IRGs.

**Step 4: Validation**

* Validate the findings using an independent cohort of lung adenocarcinoma patients who have received immunotherapy.
* Repeat the gene expression analysis and data analysis steps to confirm the results.

**Equipment and Resources:**

* RNA extraction kit
* qPCR or RNA sequencing equipment
* Bioinformatics tools for data analysis (e.g., R, Python, or commercial software)
* Statistical software (e.g., R, Python, or commercial software)
* Access to a biorepository or tissue bank for tumor samples
* Clinical data management system for patient data collection and analysis

**Timeline:**

* Patient selection and sample collection: 2 months
* Gene expression analysis: 3 months
* Data analysis: 4 months
* Validation: 3 months
* Total duration: 12 months

**Budget:**

* RNA extraction kit: $1,000
* qPCR or RNA sequencing equipment: $5,000 (assuming access to existing equipment or shared resources)
* Bioinformatics tools and statistical software: $2,000 (assuming access to existing licenses or open-source alternatives)
* Biorepository or tissue bank access: $5,000 (assuming existing collaboration or access to public resources)
* Clinical data management system: $2,000 (assuming existing infrastructure or open-source alternatives)
* Personnel and overheads: $50,000 (assuming a postdoctoral researcher or research assistant for 12 months)
* Total budget: $65,000

This experimental plan is designed to test the hypothesis in a cost-effective and time-efficient manner, while ensuring the quality and validity of the results.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Patient Selection and Sample Collection**

1.1. Identify lung adenocarcinoma patients who have received immunotherapy (e.g., PD-1/PD-L1 inhibitors) through a biorepository or tissue bank.

1.2. Review patient medical records to ensure that they have not received any other treatments that may affect the expression of the genes of interest.

1.3. Collect tumor samples from these patients, including formalin-fixed paraffin-embedded (FFPE) tissue blocks or fresh frozen tissue.

1.4. Extract clinical data, including:
	* Response to immunotherapy (e.g., complete response, partial response, stable disease, or progressive disease)
	* Overall survival (OS) data, including dates of diagnosis, treatment initiation, and last follow-up or death
	* Demographic information (e.g., age, sex, smoking history)

1.5. Store the tumor samples and clinical data in a secure and organized manner, with unique identifiers for each sample and patient.

**Step 2: Gene Expression Analysis**

2.1. Extract RNA from the tumor samples using a RNA extraction kit (e.g., Qiagen RNeasy FFPE Kit) according to the manufacturer's instructions.

2.2. Quantify the extracted RNA using a spectrophotometer (e.g., NanoDrop) and assess the RNA quality using a bioanalyzer (e.g., Agilent 2100 Bioanalyzer).

2.3. Perform quantitative PCR (qPCR) or RNA sequencing to measure the expression levels of BTN3A2 and the 5 IRGs (CCL25, IL29, TDGF3, GPR44, and GREM2).

	* For qPCR:
		+ Design and validate primers for each gene using a primer design tool (e.g., Primer3) and a reference genome (e.g., GRCh38).
		+ Perform qPCR using a qPCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System) and a qPCR master mix (e.g., TaqMan Universal Master Mix II).
		+ Analyze the qPCR data using a software (e.g., Applied Biosystems SDS software) to determine the cycle threshold (Ct) values for each gene.
	* For RNA sequencing:
		+ Prepare RNA sequencing libraries using a library preparation kit (e.g., Illumina TruSeq Stranded mRNA Library Prep Kit) according to the manufacturer's instructions.
		+ Sequence the libraries using a next-generation sequencing platform (e.g., Illumina HiSeq 4000) with a minimum of 30 million reads per sample.
		+ Analyze the RNA sequencing data using a bioinformatics pipeline (e.g., STAR, featureCounts, and DESeq2) to determine the gene expression levels.

2.4. Normalize the gene expression data using appropriate housekeeping genes (e.g., GAPDH, ACTB, and HPRT1).

**Step 3: Data Analysis**

3.1. Perform correlation analysis between the expression levels of BTN3A2 and the 5 IRGs with the response to immunotherapy and overall survival using a statistical software (e.g., R, Python, or commercial software).

3.2. Use statistical models (e.g., logistic regression, Cox proportional hazards model) to determine the predictive value of the co-expression of BTN3A2 and the 5 IRGs.

3.3. Perform Kaplan-Meier survival analysis to compare the overall survival of patients with high and low co-expression of BTN3A2 and the 5 IRGs.

3.4. Visualize the results using plots and graphs (e.g., heatmaps, scatter plots, and Kaplan-Meier curves).

**Step 4: Validation**

4.1. Collect an independent cohort of lung adenocarcinoma patients who have received immunotherapy.

4.2. Repeat the gene expression analysis and data analysis steps to confirm the results.

4.3. Compare the results from the validation cohort with the original cohort to ensure consistency and reproducibility.

**Equipment and Resources:**

* RNA extraction kit (e.g., Qiagen RNeasy FFPE Kit)
* qPCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System)
* qPCR master mix (e.g., TaqMan Universal Master Mix II)
* RNA sequencing equipment (e.g., Illumina HiSeq 4000)
* Library preparation kit (e.g., Illumina TruSeq Stranded mRNA Library Prep Kit)
* Bioinformatics tools (e.g., R, Python, or commercial software)
* Statistical software (e.g., R, Python, or commercial software)
* Biorepository or tissue bank access
* Clinical data management system
* Personnel and overheads (e.g., postdoctoral researcher or research assistant)

**Timeline:**

* Patient selection and sample collection: 2 months
* Gene expression analysis: 3 months
* Data analysis: 4 months
* Validation: 3 months
* Total duration: 12 months

**Budget:**

* RNA extraction kit: $1,000
* qPCR or RNA sequencing equipment: $5,000 (assuming access to existing equipment or shared resources)
* Bioinformatics tools and statistical software: $2,000 (assuming access to existing licenses or open-source alternatives)
* Biorepository or tissue bank access: $5,000 (assuming existing collaboration or access to public resources)
* Clinical data management system: $2,000 (assuming existing infrastructure or open-source alternatives)
* Personnel and overheads: $50,000 (assuming a postdoctoral researcher or research assistant for 12 months)
* Total budget: $65,000","```
   Qiagen RNeasy FFPE Kit  Applied Biosystems 7500  TaqMan Universal Master Mix II  Illumina HiSeq 4000  Illumina TruSeq Stranded mRNA  Response to Immunotherapy  Overall Survival
0                    1.5                0.8                     1.2                  0.5                    1.0                    1.0               Complete Response        24.0
1                    1.2                1.0                     1.5                  0.8                    0.8                    1.2               Partial Response        18.0
2                    1.8                1.2                     1.0                  0.9                    1.1                    0.9               Stable Disease         12.0
3                    1.0                0.9                     1.8                  1.1                    0.9                    1.1               Progressive Disease       6.0
4                    1.5                1.1                     1.2                  0.8                    1.0                    1.0               Complete Response        20.0
5                    1.2                0.8                     1.5                  0.9                    0.8                    1.2               Partial Response        15.0
6                    1.8                1.0                     1.0                  1.0                    1.1                    0.9               Stable Disease         10.0
7                    1.0                0.9                     1.8                  1.1                    0.9                    1.1               Progressive Disease       8.0
8                    1.5                1.1                     1.2                  0.8                    1.0                    1.0               Complete Response        22.0
9                    1.2                0.8                     1.5                  0.9                    0.8                    1.2               Partial Response        12.0
10                   1.8                1.0                     1.0                  1.0                    1.1                    0.9               Stable Disease         14.0
11                   1.0                0.9                     1.8                  1.1                    0.9                    1.1               Progressive Disease       9.0
12                   1.5                1.1                     1.2                  0.8                    1.0                    1.0               Complete Response        20.0
13                   1.2                0.8                     1.5                  0.9                    0.8                    1.2               Partial Response        16.0
14                   1.8                1.0                     1.0                  1.0                    1.1                    0.9               Stable Disease         11.0
15                   1.0                0.9                     1.8                  1.1                    0.9                    1.1               Progressive Disease       7.0
16                   1.5                1.1                     1.2                  0.8                    1.0                    1.0               Complete Response        21.0
17                   1.2                0.8                     1.5                  0.9                    0.8                    1.2               Partial Response        13.0
18                   1.8                1.0                     1.0                  1.0                    1.1                    0.9               Stable Disease         15.0
19                   1.0                0.9                     1.8                  1.1                    0.9                    1.1               Progressive Disease       9.0
20                   1.5                1.1                     1.2                  0.8                    1.0                    1.0               Complete Response        23.0
21                   1.2                0.8                     1.5                  0.9                    0.8                    1.2               Partial Response        14.0
22                   1.8                1.0                     1.0                  1.0                    1.1                    0.9               Stable Disease         12.0
23                   1.0                0.9                     1.8                  1.1                    0.9                    1.1               Progressive Disease       8.0
24                   1.5                1.1                     1.2                  0.8                    1.0                    1.0               Complete Response        20.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b9f34a55b5c743b9df1bcce0212bf000048f7cc7.summary'],"Does the co-expression of VWF and TIM3 on CML stem cells also confer resistance to immunotherapy, and can targeting these markers enhance the efficacy of immunotherapeutic approaches in CML treatment?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis that the co-expression of VWF and TIM3 on CML stem cells confers resistance to immunotherapy, and that targeting these markers can enhance the efficacy of immunotherapeutic approaches in CML treatment.

**Experiment:**

**Title:** Investigating the Role of VWF and TIM3 in Immunotherapy Resistance in CML Stem Cells

**Objective:** To determine if the co-expression of VWF and TIM3 on CML stem cells confers resistance to immunotherapy and if targeting these markers can enhance the efficacy of immunotherapeutic approaches in CML treatment.

**Experimental Design:**

1. **Cell Isolation and Preparation:**
	* Isolate CML stem cells from patient samples or cell lines using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) based on surface markers (e.g., CD34, CD38).
	* Verify the expression of VWF and TIM3 on the isolated cells using flow cytometry or immunofluorescence staining.
2. **Immunotherapy Treatment:**
	* Treat the isolated CML stem cells with a standardized immunotherapy approach, such as anti-PD-1 or anti-CTLA-4 antibodies, for a set period (e.g., 48 hours).
	* Use a control group without immunotherapy treatment.
3. **VWF and TIM3 Knockdown:**
	* Transduce the CML stem cells with shRNAs targeting VWF and TIM3 using a lentiviral vector or electroporation.
	* Verify the knockdown efficiency using qRT-PCR, Western blot, or flow cytometry.
4. **Combination Treatment:**
	* Treat the VWF and TIM3 knockdown cells with the same immunotherapy approach as in step 2.
5. **Cell Viability and Proliferation Assays:**
	* Assess cell viability and proliferation using flow cytometry (e.g., Annexin V, 7-AAD), cell counting, or MTT assays.
	* Compare the results between the control group, immunotherapy-treated group, and combination treatment group.
6. **Statistical Analysis:**
	* Perform statistical analysis using ANOVA, t-test, or regression analysis to determine the significance of the results.

**Expected Outcomes:**

* If the hypothesis is true, the combination treatment group (VWF and TIM3 knockdown + immunotherapy) should show increased cell death and reduced proliferation compared to the immunotherapy-treated group.
* If the hypothesis is false, the combination treatment group should not show a significant difference in cell viability and proliferation compared to the immunotherapy-treated group.

**Resources and Timeline:**

* This experiment can be completed within 6-8 weeks, depending on the availability of resources and personnel.
* The required resources include:
	+ CML stem cells or cell lines
	+ shRNA constructs targeting VWF and TIM3
	+ Immunotherapy agents (e.g., anti-PD-1 or anti-CTLA-4 antibodies)
	+ Flow cytometer
	+ qRT-PCR and Western blot equipment
	+ Cell culture facilities and reagents
	+ Statistical analysis software

**Budget:**

* The estimated budget for this experiment is approximately $10,000-$15,000, depending on the cost of reagents, equipment, and personnel.

By following this experimental design, we can test the hypothesis and determine if the co-expression of VWF and TIM3 on CML stem cells confers resistance to immunotherapy and if targeting these markers can enhance the efficacy of immunotherapeutic approaches in CML treatment.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Preparation**

1.1. **Cell Source Preparation**

* Obtain CML patient samples or cell lines from a reputable source (e.g., blood bank, cell line repository).
* Ensure the samples are properly stored and handled according to standard operating procedures (SOPs).

1.2. **Fluorescence-Activated Cell Sorting (FACS) or Magnetic-Activated Cell Sorting (MACS)**

* Prepare the cell samples for sorting by washing them with phosphate-buffered saline (PBS) and resuspending them in a suitable buffer (e.g., FACS buffer).
* Stain the cells with fluorescently labeled antibodies against CD34 and CD38 (e.g., CD34-PE, CD38-APC) according to the manufacturer's instructions.
* Perform FACS or MACS using a suitable instrument (e.g., BD FACSAria, Miltenyi Biotec MACS) to isolate CD34+CD38- CML stem cells.
* Collect the sorted cells in a suitable tube or container.

1.3. **Verification of VWF and TIM3 Expression**

* Prepare the isolated cells for flow cytometry by washing them with PBS and resuspending them in a suitable buffer (e.g., FACS buffer).
* Stain the cells with fluorescently labeled antibodies against VWF and TIM3 (e.g., VWF-PE, TIM3-APC) according to the manufacturer's instructions.
* Perform flow cytometry using a suitable instrument (e.g., BD FACSCanto) to verify the expression of VWF and TIM3 on the isolated cells.
* Analyze the data using suitable software (e.g., FlowJo) to determine the percentage of VWF+TIM3+ cells.

**Protocol 2: Immunotherapy Treatment**

2.1. **Immunotherapy Agent Preparation**

* Obtain the immunotherapy agent (e.g., anti-PD-1 or anti-CTLA-4 antibodies) from a reputable source.
* Prepare the agent according to the manufacturer's instructions (e.g., reconstitute, dilute).

2.2. **Immunotherapy Treatment**

* Divide the isolated CML stem cells into two groups: control (no treatment) and immunotherapy-treated.
* Add the prepared immunotherapy agent to the immunotherapy-treated group at a suitable concentration (e.g., 10 μg/mL) and incubate for 48 hours at 37°C, 5% CO2.
* Maintain the control group in a suitable medium (e.g., RPMI 1640) without the immunotherapy agent.

**Protocol 3: VWF and TIM3 Knockdown**

3.1. **shRNA Construct Preparation**

* Obtain shRNA constructs targeting VWF and TIM3 from a reputable source (e.g., Sigma-Aldrich).
* Prepare the shRNA constructs according to the manufacturer's instructions (e.g., reconstitute, dilute).

3.2. **Lentiviral Vector Production**

* Produce lentiviral vectors encoding the shRNA constructs using a suitable protocol (e.g., HEK293T cells, calcium phosphate transfection).
* Concentrate the lentiviral vectors using a suitable method (e.g., ultracentrifugation, filtration).

3.3. **Transduction**

* Add the concentrated lentiviral vectors to the isolated CML stem cells at a suitable multiplicity of infection (MOI) (e.g., 10).
* Incubate the cells for 24-48 hours at 37°C, 5% CO2 to allow for transduction.

3.4. **Verification of Knockdown Efficiency**

* Prepare the transduced cells for qRT-PCR, Western blot, or flow cytometry to verify the knockdown efficiency of VWF and TIM3.
* Analyze the data using suitable software (e.g., qRT-PCR: ΔΔCt method; Western blot: densitometry; flow cytometry: percentage of VWF+TIM3+ cells) to determine the knockdown efficiency.

**Protocol 4: Combination Treatment**

4.1. **Combination Treatment**

* Divide the VWF and TIM3 knockdown cells into two groups: control (no treatment) and combination treatment.
* Add the prepared immunotherapy agent to the combination treatment group at a suitable concentration (e.g., 10 μg/mL) and incubate for 48 hours at 37°C, 5% CO2.
* Maintain the control group in a suitable medium (e.g., RPMI 1640) without the immunotherapy agent.

**Protocol 5: Cell Viability and Proliferation Assays**

5.1. **Cell Viability Assay**

* Prepare the cells for flow cytometry by washing them with PBS and resuspending them in a suitable buffer (e.g., FACS buffer).
* Stain the cells with Annexin V and 7-AAD according to the manufacturer's instructions.
* Perform flow cytometry using a suitable instrument (e.g., BD FACSCanto) to assess cell viability.

5.2. **Cell Proliferation Assay**

* Prepare the cells for cell counting or MTT assay according to the manufacturer's instructions.
* Perform cell counting or MTT assay to assess cell proliferation.

**Protocol 6: Statistical Analysis**

6.1. **Data Collection**

* Collect the data from the cell viability and proliferation assays.

6.2. **Statistical Analysis**

* Perform statistical analysis using ANOVA, t-test, or regression analysis to determine the significance of the results.
* Compare the results between the control group, immunotherapy-treated group, and combination treatment group.

Note: The protocols above are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow standard operating procedures (SOPs) and ensure proper quality control and quality assurance throughout the experiment.","```
   CML_Patient_Samples  CD34_Antibody  CD38_Antibody  VWF_Antibody  TIM3_Antibody  Immunotherapy_Agent  shRNA_Construct  Lentiviral_Vector  MOI  Immunotherapy_Concentration  VWF_Knockdown_Efficiency  TIM3_Knockdown_Efficiency  Cell_Viability  Cell_Proliferation
0                  100000          10.0           5.0          5.0           5.0               10.0             1.0             10.0   5.0                    10.0                    0.7                    0.8         0.85         0.90
1                  80000           8.0           4.0          4.0           4.0               12.0             1.2             12.0   6.0                    12.0                    0.6                    0.7         0.80         0.85
2                 120000          12.0           6.0          6.0           6.0               8.0             0.8             8.0   4.0                     8.0                    0.8                    0.9         0.90         0.95
3                  90000          11.0           5.5          5.5           5.5               11.0             1.1             11.0   5.5                    11.0                    0.7                    0.8         0.85         0.90
4                  70000           9.0           4.5          4.5           4.5               9.0             0.9             9.0   4.5                     9.0                    0.6                    0.7         0.80         0.85
5                 110000          13.0           6.5          6.5           6.5               7.0             0.7             7.0   3.5                     7.0                    0.8                    0.9         0.90         0.95
6                  95000          12.0           6.0          6.0           6.0               10.0             1.0             10.0   5.0                    10.0                    0.7                    0.8         0.85         0.90
7                  85000          11.0           5.5          5.5           5.5               9.0             0.9             9.0   4.5                     9.0                    0.6                    0.7         0.80         0.85
8                 105000          13.0           6.5          6.5           6.5               8.0             0.8             8.0   4.0                     8.0                    0.8                    0.9         0.90         0.95
9                  75000           9.5           4.75         4.75         4.75               11.0             1.1             11.0   5.5                    11.0                    0.7                    0.8         0.85         0.90
10                100000          12.0           6.0          6.0           6.0               9.0             0.9             9.0   4.5                     9.0                    0.7                    0.8         0.85         0.90
11                120000          14.0           7.0          7.0           7.0               10.0             1.0             10.0   5.0                    10.0                    0.8                    0.9         0.90         0.95
12                 90000          11.5           5.75         5.75         5.75               8.0             0.8             8.0   4.0                     8.0                    0.7                    0.8         0.85         0.90
13                 80000           9.5           4.75         4.75         4.75               12.0             1.2             12.0   6.0                    12.0                    0.6                    0.7         0.80         0.85
14                110000          13.5           6.75         6.75         6.75               9.0             0.9             9.0   4.5                     9.0                    0.7                    0.8         0.85         0.90
15                 95000          12.5           6.25         6.25         6.25               11.0             1.1             11.0   5.5                    11.0                    0.7                    0.8         0.85         0.90
16                105000          14.5           7.25         7.25         7.25               8.0             0.8             8.0   4.0                     8.0                    0.8                    0.9         0.90         0.95
17                 75000           9.0           4.5          4.5           4.5               10.0             1.0             10.0   5.0                    10.0                    0.6                    0.7         0.80         0.85
18                100000          12.5           6.25         6.25         6.25               9.0             0.9             9.0   4.5                     9.0                    0.7                    0.8         0.85         0.90
19                 85000          11.0           5.5          5.5           5.5               12.0             1.2             12.0   6.0                    12.0                    0.6                    0.7         0.80         0.85
20                120000          15.0           7.5          7.5           7.5               10.0             1.0             10.0   5.0                    10.0                    0.8                    0.9         0.90         0.95
21                 90000          12.0           6.0          6.0           6.0               11.0             1.1             11.0   5.5                    11.0                    0.7                    0.8         0.85         0.90
22                110000          14.0           7.0          7.0           7.0               9.0             0.9             9.0   4.5                     9.0                    0.7                    0.8         0.85         0.90
23                 95000          13.0           6.5          6.5           6.5               10.0             1.0             10.0   5.0                    10.0                    0.7                    0.8         0.85         0.90
24                 80000           9.5           4.75         4.75         4.75               12.0             1.2             12.0   6.0                    12.0                    0.6                    0.7         0.80         0.85
```",0.3071158645906739
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0ee2066405bf13a4bf9f9daf226b0871cda3ae88.summary'],Does the combination of AZP-3404 and Canagliflozin have a synergistic effect on improving insulin sensitivity and reducing inflammation in humans with type 2 diabetes compared to either treatment alone?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.",,,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** The combination of AZP-3404 and Canagliflozin has a synergistic effect on improving insulin sensitivity and reducing inflammation in humans with type 2 diabetes compared to either treatment alone.

**Experimental Plan:**

**Study Design:** Randomized, double-blind, placebo-controlled, parallel-group study

**Participants:** 120 adults with type 2 diabetes, aged 18-70, with HbA1c ≥ 7.0% and ≤ 10.0%

**Interventions:**

1. **Group 1:** AZP-3404 (100 mg, oral, once daily) + Canagliflozin (100 mg, oral, once daily)
2. **Group 2:** AZP-3404 (100 mg, oral, once daily) + Placebo
3. **Group 3:** Canagliflozin (100 mg, oral, once daily) + Placebo
4. **Group 4:** Placebo + Placebo (control group)

**Outcome Measures:**

1. **Primary Outcome:** Change in insulin sensitivity (measured by euglycemic-hyperinsulinemic clamp) at 12 weeks
2. **Secondary Outcomes:**
	* Change in inflammatory biomarkers (e.g., C-reactive protein, interleukin-6) at 12 weeks
	* Change in HbA1c at 12 weeks
	* Adverse event rates

**Experimental Procedure:**

1. **Screening:** Eligible participants will undergo a 2-week run-in period to assess baseline insulin sensitivity and inflammatory biomarkers.
2. **Randomization:** Participants will be randomly assigned to one of the four groups.
3. **Treatment:** Participants will receive their assigned treatment for 12 weeks.
4. **Outcome Assessments:** Insulin sensitivity, inflammatory biomarkers, and HbA1c will be measured at baseline, 6 weeks, and 12 weeks.
5. **Safety Monitoring:** Adverse events will be monitored throughout the study.

**Statistical Analysis:**

1. **Primary Analysis:** Compare the change in insulin sensitivity between Group 1 (combination therapy) and Groups 2 and 3 (monotherapy) using ANCOVA, adjusting for baseline values.
2. **Secondary Analyses:** Compare the change in inflammatory biomarkers and HbA1c between groups using ANCOVA, adjusting for baseline values.

**To Disprove the Hypothesis:**

To verify the hypothesis, we will test the null hypothesis: ""The combination of AZP-3404 and Canagliflozin does not have a synergistic effect on improving insulin sensitivity and reducing inflammation in humans with type 2 diabetes compared to either treatment alone.""

If the results show that:

* The combination therapy (Group 1) does not demonstrate a statistically significant improvement in insulin sensitivity compared to monotherapy (Groups 2 and 3)
* The combination therapy does not demonstrate a statistically significant reduction in inflammatory biomarkers compared to monotherapy
* The combination therapy does not demonstrate a statistically significant improvement in HbA1c compared to monotherapy

Then, we can conclude that the hypothesis is false, and the combination of AZP-3404 and Canagliflozin does not have a synergistic effect on improving insulin sensitivity and reducing inflammation in humans with type 2 diabetes.

By designing an experiment to disprove the hypothesis, we can increase confidence in the results and ensure that any positive findings are not due to chance or bias.",90,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Screening and Run-in Period (Weeks 1-2)**

1.1. Participant Recruitment:

* Recruit 120 adults with type 2 diabetes, aged 18-70, with HbA1c ≥ 7.0% and ≤ 10.0% through advertisements, flyers, and physician referrals.
* Obtain informed consent from each participant.

1.2. Inclusion/Exclusion Criteria:

* Verify participant eligibility based on medical history, medication use, and laboratory results.
* Exclude participants with significant cardiovascular disease, kidney disease, or other conditions that may affect the study outcomes.

1.3. Baseline Measurements:

* Measure insulin sensitivity using the euglycemic-hyperinsulinemic clamp technique.
* Collect blood samples for inflammatory biomarker analysis (e.g., C-reactive protein, interleukin-6).
* Measure HbA1c levels.

1.4. Run-in Period:

* Provide participants with a standardized diet and exercise plan for 2 weeks to minimize variability in insulin sensitivity and inflammatory biomarkers.

**Protocol 2: Randomization and Treatment (Weeks 3-14)**

2.1. Randomization:

* Use a computer-generated randomization program to assign participants to one of the four groups:
	+ Group 1: AZP-3404 (100 mg, oral, once daily) + Canagliflozin (100 mg, oral, once daily)
	+ Group 2: AZP-3404 (100 mg, oral, once daily) + Placebo
	+ Group 3: Canagliflozin (100 mg, oral, once daily) + Placebo
	+ Group 4: Placebo + Placebo (control group)

2.2. Treatment Administration:

* Provide participants with their assigned treatment (active drug or placebo) in identical capsules or tablets.
* Instruct participants to take their assigned treatment once daily for 12 weeks.

**Protocol 3: Outcome Assessments (Weeks 6, 12, and 14)**

3.1. Insulin Sensitivity Measurement:

* Measure insulin sensitivity using the euglycemic-hyperinsulinemic clamp technique at weeks 6, 12, and 14.
* Record the glucose infusion rate (GIR) and insulin sensitivity index (ISI) for each participant.

3.2. Inflammatory Biomarker Analysis:

* Collect blood samples for inflammatory biomarker analysis (e.g., C-reactive protein, interleukin-6) at weeks 6, 12, and 14.
* Analyze samples using standardized laboratory techniques.

3.3. HbA1c Measurement:

* Measure HbA1c levels at weeks 6, 12, and 14.

**Protocol 4: Safety Monitoring (Weeks 3-14)**

4.1. Adverse Event Reporting:

* Instruct participants to report any adverse events (AEs) to the study team.
* Record and document all AEs, including severity, duration, and relationship to study treatment.

4.2. Safety Monitoring Visits:

* Schedule regular safety monitoring visits with participants at weeks 3, 6, 9, and 12.
* Assess participants for signs of hypoglycemia, hyperglycemia, and other potential side effects.

**Protocol 5: Data Analysis**

5.1. Primary Analysis:

* Compare the change in insulin sensitivity (GIR and ISI) between Group 1 (combination therapy) and Groups 2 and 3 (monotherapy) using ANCOVA, adjusting for baseline values.

5.2. Secondary Analyses:

* Compare the change in inflammatory biomarkers and HbA1c between groups using ANCOVA, adjusting for baseline values.

5.3. Statistical Significance:

* Set the significance level at α = 0.05 for all analyses.

**Protocol 6: Data Management and Quality Control**

6.1. Data Collection:

* Use standardized case report forms (CRFs) to collect data from participants.
* Ensure accurate and complete data entry.

6.2. Data Quality Control:

* Perform regular data quality checks to ensure accuracy and consistency.
* Address any data discrepancies or errors promptly.

By following these detailed, step-by-step protocols, the experiment can be executed with precision and accuracy, ensuring the reliability and validity of the results.","```
   AZP-3404  Canagliflozin  Placebo  GIR_Change  ISI_Change  CRP_Change  IL6_Change  HbA1c_Change
0       100          100       0.0       1.23       0.45       -0.5       -0.2         -0.8
1       120          80.0       0.0       1.50       0.60       -0.7       -0.3         -1.0
2        80          120       0.0       1.10       0.30       -0.3       -0.1         -0.6
3       100           0.0       0.0       0.90       0.20       -0.2       -0.1         -0.4
4        0.0          100       0.0       1.20       0.40       -0.6       -0.2         -0.8
5       120           0.0       0.0       1.60       0.70       -0.8       -0.4         -1.2
6        80           0.0       0.0       1.00       0.25       -0.4       -0.2         -0.6
7       100          100       0.0       1.35       0.50       -0.6       -0.3         -0.9
8        0.0          80.0       0.0       1.10       0.30       -0.5       -0.2         -0.7
9       120          120       0.0       1.70       0.80       -0.9       -0.5         -1.4
10       80          100       0.0       1.25       0.40       -0.5       -0.2         -0.8
11       100           0.0       0.0       1.05       0.25       -0.3       -0.1         -0.5
12        0.0          120       0.0       1.30       0.50       -0.7       -0.3         -1.0
13       120           80.0       0.0       1.55       0.65       -0.8       -0.4         -1.1
14       80           0.0       0.0       0.95       0.20       -0.4       -0.2         -0.6
15       100          100       0.0       1.40       0.55       -0.7       -0.3         -1.0
16        0.0          100       0.0       1.20       0.40       -0.6       -0.2         -0.8
17       120          120       0.0       1.75       0.85       -1.0       -0.5         -1.5
18       80          100       0.0       1.30       0.45       -0.6       -0.3         -0.9
19       100           0.0       0.0       1.10       0.30       -0.4       -0.2         -0.6
20        0.0          80.0       0.0       1.15       0.35       -0.5       -0.2         -0.7
21       120           80.0       0.0       1.60       0.70       -0.8       -0.4         -1.2
22       80           0.0       0.0       1.00       0.25       -0.4       -0.2         -0.6
23       100          100       0.0       1.45       0.60       -0.7       -0.3         -1.0
24       0.0          120       0.0       1.35       0.55       -0.7       -0.3         -1.0
```",0.1412556056964963
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3d82be462c48576d9be7c0de01cc47cf3352b724.summary'],Does the combination of CD19-CD28 with CD20-targeted T cell bispecific antibodies enhance the formation of immunological synapses between T cells and cancer cells by increasing the expression of adhesion molecules on the surface of T cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the combination of CD19-CD28 with CD20-targeted T cell bispecific antibodies enhances the formation of immunological synapses between T cells and cancer cells by increasing the expression of adhesion molecules on the surface of T cells, I propose the following experimental plan:

**Experiment:** ""Disproving the Hypothesis: Investigating the Role of CD19-CD28 in Immunological Synapse Formation""

**Objective:** To determine if the combination of CD19-CD28 with CD20-targeted T cell bispecific antibodies does not enhance the formation of immunological synapses between T cells and cancer cells by increasing the expression of adhesion molecules on the surface of T cells.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate human T cells from healthy donors or use a T cell line (e.g., Jurkat cells).
	* Culture B cell Non-Hodgkin's Lymphoma (B NHL) cells (e.g., Raji cells) as the cancer cell line.
2. **Co-Culture and Treatment:**
	* Co-culture T cells and B NHL cells at a 1:1 ratio in the presence or absence of CD19-CD28 and CD20-targeted T cell bispecific antibodies (e.g., glofitamab).
	* Use a control group with only T cells and B NHL cells (no CD19-CD28 or CD20-targeted T cell bispecific antibodies).
3. **Surface Marker Staining:**
	* Stain the co-cultured cells with antibodies against T cell surface markers (e.g., CD3, CD28) and cancer cell surface markers (e.g., CD20, CD19).
	* Include antibodies against adhesion molecules (e.g., LFA-1, ICAM-1) to assess their expression on T cells.
4. **Confocal Microscopy and Image Analysis:**
	* Use a confocal microscope to image the co-cultured cells.
	* Acquire 3D images of the cells using a 63x oil immersion objective lens.
	* Analyze the images using 3D image processing software (e.g., Imaris, Fiji) to quantify the formation of immunological synapses between T cells and cancer cells.
	* Measure the expression of adhesion molecules on T cells using image analysis software.
5. **Data Analysis:**
	* Compare the formation of immunological synapses and adhesion molecule expression on T cells between the groups with and without CD19-CD28 and CD20-targeted T cell bispecific antibodies.
	* Perform statistical analysis (e.g., t-test, ANOVA) to determine if there are significant differences between the groups.

**Expected Outcome:**
If the hypothesis is true, we would expect to see an increase in the formation of immunological synapses and adhesion molecule expression on T cells in the presence of CD19-CD28 and CD20-targeted T cell bispecific antibodies compared to the control group. However, if the hypothesis is false, we would expect to see no significant difference or a decrease in immunological synapse formation and adhesion molecule expression.

**Resources and Timeline:**

* Equipment: Confocal microscope, antibodies against T cell and cancer cell surface markers, image analysis software
* Reagents: CD19-CD28, CD20-targeted T cell bispecific antibodies (e.g., glofitamab), T cells, B NHL cells, cell culture media, antibodies
* Timeframe: 6-8 weeks
* Budget: Moderate (approximately $10,000-$15,000)

By following this experimental plan, we can test the hypothesis and determine if the combination of CD19-CD28 with CD20-targeted T cell bispecific antibodies enhances the formation of immunological synapses between T cells and cancer cells by increasing the expression of adhesion molecules on the surface of T cells.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disproving the Hypothesis: Investigating the Role of CD19-CD28 in Immunological Synapse Formation"":

**Protocol 1: Cell Preparation**

1.1. Isolation of Human T Cells:

* Obtain blood samples from healthy donors or use a T cell line (e.g., Jurkat cells).
* Isolate T cells using a T cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Count the isolated T cells using a hemocytometer or an automated cell counter.
* Resuspend the T cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. Culture of B Cell Non-Hodgkin's Lymphoma (B NHL) Cells:

* Obtain B NHL cells (e.g., Raji cells) from a cell bank or a commercial supplier.
* Culture the B NHL cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Maintain the cells at 37°C, 5% CO2, and 95% humidity.

**Protocol 2: Co-Culture and Treatment**

2.1. Co-Culture of T Cells and B NHL Cells:

* Prepare 24-well plates by adding 1 mL of RPMI-1640 medium per well.
* Add 1 x 10^5 T cells and 1 x 10^5 B NHL cells to each well (1:1 ratio).
* Mix the cells gently by pipetting up and down.

2.2. Treatment with CD19-CD28 and CD20-Targeted T Cell Bispecific Antibodies:

* Prepare a stock solution of CD19-CD28 and CD20-targeted T cell bispecific antibodies (e.g., glofitamab) according to the manufacturer's instructions.
* Add the antibodies to the co-culture at a final concentration of 1 μg/mL.
* Incubate the co-culture at 37°C, 5% CO2, and 95% humidity for 24 hours.

2.3. Control Group:

* Prepare a control group with only T cells and B NHL cells (no CD19-CD28 or CD20-targeted T cell bispecific antibodies).
* Follow the same co-culture and incubation conditions as above.

**Protocol 3: Surface Marker Staining**

3.1. Preparation of Antibodies:

* Prepare a panel of antibodies against T cell surface markers (e.g., CD3, CD28), cancer cell surface markers (e.g., CD20, CD19), and adhesion molecules (e.g., LFA-1, ICAM-1).
* Use fluorochrome-conjugated antibodies (e.g., FITC, PE, APC) to enable flow cytometry or confocal microscopy analysis.

3.2. Staining of Co-Cultured Cells:

* Harvest the co-cultured cells by centrifugation at 300 x g for 5 minutes.
* Resuspend the cells in 100 μL of staining buffer (e.g., PBS with 1% BSA and 0.1% sodium azide).
* Add the prepared antibodies to the cells and incubate at 4°C for 30 minutes.
* Wash the cells twice with staining buffer and resuspend in 100 μL of staining buffer.

**Protocol 4: Confocal Microscopy and Image Analysis**

4.1. Confocal Microscopy:

* Use a confocal microscope (e.g., Zeiss LSM 880) with a 63x oil immersion objective lens.
* Acquire 3D images of the co-cultured cells using the following settings:
	+ Excitation: 488 nm (FITC), 561 nm (PE), and 633 nm (APC)
	+ Emission: 520 nm (FITC), 610 nm (PE), and 660 nm (APC)
	+ Pinhole: 1 AU
	+ Z-stack: 10-15 slices, 0.5 μm step size

4.2. Image Analysis:

* Use 3D image processing software (e.g., Imaris, Fiji) to analyze the acquired images.
* Quantify the formation of immunological synapses between T cells and cancer cells using the following parameters:
	+ Synapse area: measure the area of contact between T cells and cancer cells
	+ Synapse intensity: measure the fluorescence intensity of the adhesion molecules at the synapse
* Measure the expression of adhesion molecules on T cells using image analysis software.

**Protocol 5: Data Analysis**

5.1. Data Collection:

* Collect the data from the image analysis software, including the formation of immunological synapses and adhesion molecule expression on T cells.

5.2. Statistical Analysis:

* Compare the data between the groups with and without CD19-CD28 and CD20-targeted T cell bispecific antibodies using statistical software (e.g., GraphPad Prism).
* Perform a two-tailed t-test or ANOVA to determine if there are significant differences between the groups.

By following these detailed, step-by-step protocols, the experiment ""Disproving the Hypothesis: Investigating the Role of CD19-CD28 in Immunological Synapse Formation"" can be executed with precision and accuracy, ensuring replicability and specificity in the results.","```
   T Cells  B NHL Cells  CD19-CD28 Antibody  CD20 Antibody  Synapse Area  Synapse Intensity  Adhesion Molecule Expression
0    1e+05       1e+05               1.0           0.0       10.2341           150.21                  0.85
1    5e+04       5e+04               0.5           0.5        8.1234           120.12                  0.75
2    2e+05       2e+05               2.0           1.0       12.3456           180.34                  0.95
3    1e+05       1e+05               1.5           0.5       11.1111           160.16                  0.90
4    5e+04       5e+04               0.0           1.0        6.7890           100.10                  0.65
5    2e+05       2e+05               2.5           1.5       13.4567           200.23                  1.00
6    1e+05       1e+05               1.0           1.0       10.9876           150.25                  0.85
7    5e+04       5e+04               0.5           0.0        7.6543           110.14                  0.70
8    2e+05       2e+05               3.0           2.0       14.5678           220.31                  1.05
9    1e+05       1e+05               1.5           1.5       12.3456           180.34                  0.95
10   5e+04       5e+04               0.0           0.5        6.1234           90.09                  0.60
11   2e+05       2e+05               2.0           2.5       13.7890           210.29                  1.00
12   1e+05       1e+05               1.0           2.0       11.1111           160.16                  0.90
13   5e+04       5e+04               0.5           1.5        8.9012           130.18                  0.80
14   2e+05       2e+05               3.5           3.0       15.6789           240.39                  1.10
15   1e+05       1e+05               1.5           2.5       12.9876           200.23                  1.00
16   5e+04       5e+04               0.0           2.0        6.5432           100.10                  0.65
17   2e+05       2e+05               2.5           3.5       14.5678           230.35                  1.05
18   1e+05       1e+05               1.0           3.0       11.4567           180.34                  0.95
19   5e+04       5e+04               0.5           2.5        9.0123           140.20                  0.85
20   2e+05       2e+05               4.0           4.0       16.7890           260.43                  1.15
21   1e+05       1e+05               1.5           3.5       13.2345           220.31                  1.05
22   5e+04       5e+04               0.0           3.5        6.9012           110.14                  0.70
23   2e+05       2e+05               3.5           4.5       15.3456           250.40                  1.10
24   1e+05       1e+05               1.0           4.0       12.6789           200.23                  1.00
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8c4920c678725ff2e7af718d2f29cccf4f5711c5.summary'],Does the combination of IL-1 inhibitors with TNF-α blockers lead to a synergistic reduction in ocular inflammation and cytokine production in Behçet’s disease-related uveitis?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** The combination of IL-1 inhibitors with TNF-α blockers leads to a synergistic reduction in ocular inflammation and cytokine production in Behçet's disease-related uveitis.

**Experimental Plan:**

**Objective:** To investigate whether the combination of IL-1 inhibitors and TNF-α blockers results in a synergistic reduction in ocular inflammation and cytokine production in Behçet's disease-related uveitis.

**Experimental Design:**

1. **In vitro study:**
	* Use human retinal pigment epithelial cells (RPE) and peripheral blood mononuclear cells (PBMCs) from Behçet's disease patients.
	* Treat RPE cells with IL-1β and TNF-α to induce inflammation.
	* Co-culture RPE cells with PBMCs to mimic the in vivo environment.
	* Add IL-1 inhibitors (e.g., anakinra) and TNF-α blockers (e.g., etanercept) individually and in combination to the co-culture system.
	* Measure cytokine production (e.g., IL-1β, TNF-α, IL-6, IL-8) using ELISA or multiplex assays.
	* Analyze the expression of inflammatory genes using qRT-PCR or RNA-seq.
2. **In vivo study:**
	* Use a mouse model of Behçet's disease-related uveitis (e.g., endotoxin-induced uveitis).
	* Divide mice into four groups: control, IL-1 inhibitor-treated, TNF-α blocker-treated, and combination-treated.
	* Administer IL-1 inhibitors and TNF-α blockers via intraperitoneal injection or topical application.
	* Evaluate ocular inflammation using clinical scoring, optical coherence tomography (OCT), and histopathological analysis.
	* Measure cytokine production in the aqueous humor and retina using ELISA or multiplex assays.
3. **Ex vivo study:**
	* Collect aqueous humor and retinal tissue samples from Behçet's disease patients undergoing vitrectomy.
	* Treat the samples with IL-1 inhibitors and TNF-α blockers individually and in combination.
	* Measure cytokine production and gene expression as in the in vitro study.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will design an experiment to show that the combination of IL-1 inhibitors and TNF-α blockers does not lead to a synergistic reduction in ocular inflammation and cytokine production.

**Null Hypothesis:** The combination of IL-1 inhibitors and TNF-α blockers does not result in a synergistic reduction in ocular inflammation and cytokine production in Behçet's disease-related uveitis.

**Experimental Design:**

1. **In vitro study:**
	* Use the same experimental setup as before, but with a few modifications:
		+ Use a lower concentration of IL-1 inhibitors and TNF-α blockers to reduce their individual effects.
		+ Add a control group with a non-specific inhibitor (e.g., IgG) to account for non-specific effects.
	* Measure cytokine production and gene expression as before.
2. **In vivo study:**
	* Use the same mouse model as before, but with a few modifications:
		+ Use a lower dose of IL-1 inhibitors and TNF-α blockers to reduce their individual effects.
		+ Add a control group with a non-specific inhibitor (e.g., IgG) to account for non-specific effects.
	* Evaluate ocular inflammation and cytokine production as before.
3. **Ex vivo study:**
	* Use the same experimental setup as before, but with a few modifications:
		+ Use a lower concentration of IL-1 inhibitors and TNF-α blockers to reduce their individual effects.
		+ Add a control group with a non-specific inhibitor (e.g., IgG) to account for non-specific effects.
	* Measure cytokine production and gene expression as before.

**Statistical Analysis:**

* Compare the results from the combination treatment group to the individual treatment groups and control groups using appropriate statistical tests (e.g., ANOVA, t-test, regression analysis).
* Calculate the synergy index using the Bliss independence model or the Loewe additivity model to determine if the combination treatment has a synergistic effect.

**Expected Outcomes:**

If the hypothesis is true, we expect to see a synergistic reduction in ocular inflammation and cytokine production in the combination treatment group compared to the individual treatment groups and control groups. If the hypothesis is false, we expect to see no significant difference between the combination treatment group and the individual treatment groups or control groups.

With an unlimited budget, we can perform multiple experiments, increase the sample size, and use advanced techniques such as single-cell RNA-seq, flow cytometry, and multiplex assays to gain a deeper understanding of the underlying mechanisms.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**In Vitro Study:**

**Protocol 1: Cell Culture and Treatment**

1. Obtain human retinal pigment epithelial cells (RPE) and peripheral blood mononuclear cells (PBMCs) from Behçet's disease patients.
2. Culture RPE cells in a 24-well plate at a density of 1 x 10^5 cells/well in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
3. Culture PBMCs in a 24-well plate at a density of 1 x 10^6 cells/well in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.
4. Incubate cells at 37°C, 5% CO2 for 24 hours.
5. Treat RPE cells with 10 ng/mL IL-1β and 10 ng/mL TNF-α for 24 hours to induce inflammation.
6. Co-culture RPE cells with PBMCs at a 1:1 ratio for 24 hours.

**Protocol 2: Treatment with IL-1 Inhibitors and TNF-α Blockers**

1. Prepare stock solutions of IL-1 inhibitors (e.g., anakinra) and TNF-α blockers (e.g., etanercept) according to the manufacturer's instructions.
2. Add the following treatments to the co-culture system:
	* IL-1 inhibitor (10 μg/mL)
	* TNF-α blocker (10 μg/mL)
	* Combination of IL-1 inhibitor and TNF-α blocker (10 μg/mL each)
	* Control (no treatment)
3. Incubate cells for an additional 24 hours.

**Protocol 3: Cytokine Measurement and Gene Expression Analysis**

1. Collect supernatants from the co-culture system and measure cytokine production (IL-1β, TNF-α, IL-6, IL-8) using ELISA or multiplex assays according to the manufacturer's instructions.
2. Extract RNA from RPE cells using a commercial RNA extraction kit.
3. Perform qRT-PCR or RNA-seq to analyze the expression of inflammatory genes (e.g., IL-1β, TNF-α, IL-6, IL-8).

**In Vivo Study:**

**Protocol 1: Mouse Model of Behçet's Disease-Related Uveitis**

1. Induce endotoxin-induced uveitis in mice using lipopolysaccharide (LPS) according to established protocols.
2. Divide mice into four groups: control, IL-1 inhibitor-treated, TNF-α blocker-treated, and combination-treated.

**Protocol 2: Treatment Administration**

1. Administer IL-1 inhibitors (e.g., anakinra) and TNF-α blockers (e.g., etanercept) via intraperitoneal injection or topical application according to the manufacturer's instructions.
2. Dose: 10 mg/kg for IL-1 inhibitors and 10 mg/kg for TNF-α blockers.

**Protocol 3: Ocular Inflammation Evaluation**

1. Evaluate ocular inflammation using clinical scoring, optical coherence tomography (OCT), and histopathological analysis at days 3, 7, and 14 post-treatment.
2. Collect aqueous humor and retinal tissue samples for cytokine measurement and gene expression analysis.

**Protocol 4: Cytokine Measurement and Gene Expression Analysis**

1. Measure cytokine production (IL-1β, TNF-α, IL-6, IL-8) in the aqueous humor and retina using ELISA or multiplex assays according to the manufacturer's instructions.
2. Extract RNA from retinal tissue using a commercial RNA extraction kit.
3. Perform qRT-PCR or RNA-seq to analyze the expression of inflammatory genes (e.g., IL-1β, TNF-α, IL-6, IL-8).

**Ex Vivo Study:**

**Protocol 1: Sample Collection and Treatment**

1. Collect aqueous humor and retinal tissue samples from Behçet's disease patients undergoing vitrectomy.
2. Treat samples with IL-1 inhibitors (e.g., anakinra) and TNF-α blockers (e.g., etanercept) individually and in combination at a concentration of 10 μg/mL.
3. Incubate samples for 24 hours.

**Protocol 2: Cytokine Measurement and Gene Expression Analysis**

1. Measure cytokine production (IL-1β, TNF-α, IL-6, IL-8) in the aqueous humor and retina using ELISA or multiplex assays according to the manufacturer's instructions.
2. Extract RNA from retinal tissue using a commercial RNA extraction kit.
3. Perform qRT-PCR or RNA-seq to analyze the expression of inflammatory genes (e.g., IL-1β, TNF-α, IL-6, IL-8).

**Experimental Approach to Disprove the Hypothesis:**

**In Vitro Study:**

**Protocol 1: Cell Culture and Treatment**

1. Use the same experimental setup as before, but with a few modifications:
	* Use a lower concentration of IL-1 inhibitors and TNF-α blockers (e.g., 1 μg/mL) to reduce their individual effects.
	* Add a control group with a non-specific inhibitor (e.g., IgG) to account for non-specific effects.
2. Measure cytokine production and gene expression as before.

**In Vivo Study:**

**Protocol 1: Mouse Model of Behçet's Disease-Related Uveitis**

1. Use the same mouse model as before, but with a few modifications:
	* Use a lower dose of IL-1 inhibitors and TNF-α blockers (e.g., 5 mg/kg) to reduce their individual effects.
	* Add a control group with a non-specific inhibitor (e.g., IgG) to account for non-specific effects.
2. Evaluate ocular inflammation and cytokine production as before.

**Ex Vivo Study:**

**Protocol 1: Sample Collection and Treatment**

1. Use the same experimental setup as before, but with a few modifications:
	* Use a lower concentration of IL-1 inhibitors and TNF-α blockers (e.g., 1 μg/mL) to reduce their individual effects.
	* Add a control group with a non-specific inhibitor (e.g., IgG) to account for non-specific effects.
2. Measure cytokine production and gene expression as before.

**Statistical Analysis:**

1. Compare the results from the combination treatment group to the individual treatment groups and control groups using appropriate statistical tests (e.g., ANOVA, t-test, regression analysis).
2. Calculate the synergy index using the Bliss independence model or the Loewe additivity model to determine if the combination treatment has a synergistic effect.

Note: The protocols outlined above are detailed and specific, but may require modifications based on the specific requirements of the experiment and the equipment available. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   RPE_Cells  PBMCs  IL_1beta  TNF_alpha  IL_1_Inhibitor  TNF_alpha_Blocker  Outcome
0    100000  1000000       10.0       10.0           10.0             10.0  Inflamed
1    120000  1200000       12.0       12.0           12.0             12.0  Inflamed
2     80000   800000        8.0        8.0            8.0              8.0  Inflamed
3    150000  1500000       15.0       15.0           15.0             15.0  Inflamed
4     90000   900000        9.0        9.0            9.0              9.0  Inflamed
5    110000  1100000       11.0       11.0           11.0             11.0  Inflamed
6     70000   700000        7.0        7.0            7.0              7.0  Inflamed
7    130000  1300000       13.0       13.0           13.0             13.0  Inflamed
8     95000   950000        9.5        9.5            9.5              9.5  Inflamed
9    105000  1050000       10.5       10.5           10.5             10.5  Inflamed
10    125000  1250000       12.5       12.5           12.5             12.5  Inflamed
11     85000   850000        8.5        8.5            8.5              8.5  Inflamed
12    140000  1400000       14.0       14.0           14.0             14.0  Inflamed
13     98000   980000        9.8        9.8            9.8              9.8  Inflamed
14    115000  1150000       11.5       11.5           11.5             11.5  Inflamed
15    135000  1350000       13.5       13.5           13.5             13.5  Inflamed
16     92000   920000        9.2        9.2            9.2              9.2  Inflamed
17    120000  1200000       12.0       12.0           12.0             12.0  Inflamed
18     76000   760000        7.6        7.6            7.6              7.6  Inflamed
19    145000  1450000       14.5       14.5           14.5             14.5  Inflamed
20     99000   990000        9.9        9.9            9.9              9.9  Inflamed
21    110000  1100000       11.0       11.0           11.0             11.0  Inflamed
22    130000  1300000       13.0       13.0           13.0             13.0  Inflamed
23     86000   860000        8.6        8.6            8.6              8.6  Inflamed
24    150000  1500000       15.0       15.0           15.0             15.0  Inflamed
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/600d4c51568522c951ab993d87f59714b2e0c4c8.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1117972fdff2d8fca016f399f9a3619075b413f3.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/313a4043a1921f9f6d051a0ea4ade5c98c53d0c5.summary']","Does the combination of IgD and IL-6 enhance the activation of peripheral blood mononuclear cells and promote the differentiation of Th17 cells in rheumatoid arthritis patients, leading to increased disease activity and inflammation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it. Here's a high-level approach to investigate the role of IgD and IL-6 in promoting Th17 cell differentiation and disease activity in rheumatoid arthritis (RA) patients:

**Experimental Design:**

**Objective:** To determine whether the combination of IgD and IL-6 enhances the activation of peripheral blood mononuclear cells (PBMCs) and promotes the differentiation of Th17 cells, leading to increased disease activity and inflammation in RA patients.

**Study Population:** RA patients with active disease (n = 50) and healthy controls (n = 20)

**Experimental Approach:**

**Step 1: Sample Collection and Preparation**

* Collect peripheral blood samples from RA patients and healthy controls
* Isolate PBMCs using density gradient centrifugation (e.g., Ficoll-Paque)
* Stimulate PBMCs with IgD and IL-6 (alone and in combination) in vitro

**Step 2: Cell Activation and Differentiation Assays**

* Measure cell activation markers (e.g., CD69, CD25) on PBMCs using flow cytometry
* Analyze Th17 cell differentiation using:
	+ Flow cytometry: CD4+IL-17A+ cells
	+ ELISA: IL-17A secretion in supernatants
	+ qRT-PCR: RORγt and IL-17A mRNA expression

**Step 3: Inflammation and Disease Activity Assessment**

* Measure inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) in serum and supernatants using ELISA or multiplex assays
* Evaluate disease activity using clinical scores (e.g., DAS28, CDAI) and biomarkers (e.g., CRP, ESR)

**Step 4: Mechanistic Studies**

* Investigate the signaling pathways involved in IgD and IL-6-mediated Th17 cell differentiation using:
	+ Western blotting: phosphorylation of signaling molecules (e.g., STAT3, p38 MAPK)
	+ siRNA-mediated gene silencing: knockdown of key signaling molecules

**Step 5: Data Analysis and Interpretation**

* Compare the results between RA patients and healthy controls
* Analyze the effects of IgD and IL-6 (alone and in combination) on PBMC activation, Th17 cell differentiation, and inflammation
* Correlate the in vitro findings with clinical disease activity and biomarkers

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: ""Does the absence of IgD and IL-6 reduce the activation of PBMCs and Th17 cell differentiation, leading to decreased disease activity and inflammation in RA patients?""

**Modified Experimental Approach:**

* Use IgD and IL-6 neutralizing antibodies or blocking peptides to inhibit their activity in PBMC cultures
* Compare the results with those obtained in the presence of IgD and IL-6
* Analyze the effects of IgD and IL-6 inhibition on Th17 cell differentiation, inflammation, and disease activity

**Additional Considerations:**

* Use appropriate controls, such as isotype-matched antibodies and vehicle controls, to ensure specificity of the results
* Validate the findings using multiple experimental approaches and techniques
* Consider using in vitro and in vivo models (e.g., mouse models of RA) to further investigate the mechanisms and validate the results

With an unlimited budget, we can:

* Recruit a large and diverse patient population to ensure robust results
* Utilize cutting-edge technologies, such as single-cell RNA sequencing and mass cytometry, to gain a deeper understanding of the cellular and molecular mechanisms involved
* Collaborate with experts in the field to ensure the study is well-designed and executed

By following this experimental plan, we can rigorously test the hypothesis and determine whether the combination of IgD and IL-6 indeed enhances Th17 cell differentiation and promotes disease activity in RA patients.",85,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Sample Collection and Preparation**

1.1. Peripheral Blood Sample Collection:

* Collect 10 mL of peripheral blood from RA patients and healthy controls using vacutainer tubes containing EDTA as an anticoagulant.
* Label the tubes with unique identifiers and store them at room temperature.

1.2. PBMC Isolation:

* Add 10 mL of Ficoll-Paque to a 50 mL conical tube.
* Carefully layer 10 mL of peripheral blood onto the Ficoll-Paque.
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the PBMC layer and transfer it to a new 50 mL conical tube.
* Wash the PBMCs with 10 mL of PBS and centrifuge at 300 x g for 10 minutes.
* Resuspend the PBMCs in 10 mL of complete RPMI 1640 medium (containing 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).

1.3. Cell Counting and Viability Assessment:

* Count the PBMCs using a hemocytometer or an automated cell counter.
* Assess cell viability using trypan blue exclusion or a viability dye (e.g., 7-AAD).

**Step 2: Cell Activation and Differentiation Assays**

2.1. Cell Stimulation:

* Aliquot 1 x 10^6 PBMCs per well in a 96-well plate.
* Add 100 ng/mL of IgD and/or 10 ng/mL of IL-6 to the wells, as indicated.
* Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

2.2. Flow Cytometry:

* Harvest the cells and stain them with the following antibodies:
	+ CD69-PE (1:100)
	+ CD25-APC (1:100)
	+ CD4-FITC (1:100)
	+ IL-17A-PE-Cy7 (1:100)
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto II).

2.3. ELISA:

* Collect the supernatants from the stimulated cells and store them at -80°C.
* Perform ELISA for IL-17A using a commercial kit (e.g., R&D Systems).

2.4. qRT-PCR:

* Extract RNA from the stimulated cells using a commercial kit (e.g., Qiagen RNeasy).
* Perform qRT-PCR for RORγt and IL-17A using primers and a commercial kit (e.g., Applied Biosystems).

**Step 3: Inflammation and Disease Activity Assessment**

3.1. Inflammatory Cytokine Measurement:

* Collect serum samples from RA patients and healthy controls.
* Measure inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) using ELISA or multiplex assays (e.g., Luminex).

3.2. Disease Activity Assessment:

* Evaluate disease activity using clinical scores (e.g., DAS28, CDAI).
* Measure biomarkers (e.g., CRP, ESR) using commercial kits.

**Step 4: Mechanistic Studies**

4.1. Western Blotting:

* Stimulate PBMCs with IgD and/or IL-6 as described in Step 2.1.
* Lyse the cells using a commercial lysis buffer (e.g., RIPA).
* Perform Western blotting for phosphorylated signaling molecules (e.g., STAT3, p38 MAPK) using commercial antibodies.

4.2. siRNA-Mediated Gene Silencing:

* Design and synthesize siRNAs targeting key signaling molecules (e.g., STAT3, p38 MAPK).
* Transfect the siRNAs into PBMCs using a commercial transfection reagent (e.g., Lipofectamine).
* Analyze the effects of gene silencing on Th17 cell differentiation and inflammation.

**Step 5: Data Analysis and Interpretation**

5.1. Data Analysis:

* Compare the results between RA patients and healthy controls.
* Analyze the effects of IgD and IL-6 (alone and in combination) on PBMC activation, Th17 cell differentiation, and inflammation.
* Correlate the in vitro findings with clinical disease activity and biomarkers.

5.2. Data Interpretation:

* Interpret the results in the context of the hypothesis.
* Discuss the implications of the findings for our understanding of RA pathogenesis and potential therapeutic targets.

**Experimental Design to Disprove the Hypothesis**

* Use IgD and IL-6 neutralizing antibodies or blocking peptides to inhibit their activity in PBMC cultures.
* Compare the results with those obtained in the presence of IgD and IL-6.
* Analyze the effects of IgD and IL-6 inhibition on Th17 cell differentiation, inflammation, and disease activity.

**Additional Considerations**

* Use appropriate controls, such as isotype-matched antibodies and vehicle controls, to ensure specificity of the results.
* Validate the findings using multiple experimental approaches and techniques.
* Consider using in vitro and in vivo models (e.g., mouse models of RA) to further investigate the mechanisms and validate the results.

By following these detailed, step-by-step protocols, the experiment can be rigorously executed to test the hypothesis and determine the role of IgD and IL-6 in promoting Th17 cell differentiation and disease activity in RA patients.","```
   IgD_ngmL  IL6_ngmL  PBMCs_million  Ficoll_Paque_mL  RPMI_1640_mL  CD69_PE  CD25_APC  CD4_FITC  IL17APECy7  IL17A_ELISA  RORγt_qRT  TNFα_ELISA  IL1β_ELISA  IL6_ELISA  CRP  ESR  DAS28  CDAI  Outcome
0        50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
1        75.0       7.5         1.2           12.0          12.0     25.0     18.0     85.0        35.0       250.0     1.8     120.0      60.0     25.0  12.0  4.0  15.0  Positive
2        25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
3        50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
4        100.0      10.0         1.5           15.0          15.0     30.0     20.0     90.0        40.0       300.0     2.0     150.0      75.0     30.0  15.0  5.0  18.0  Positive
5        25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
6        50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
7        75.0       7.5         1.2           12.0          12.0     25.0     18.0     85.0        35.0       250.0     1.8     120.0      60.0     25.0  12.0  4.0  15.0  Positive
8        25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
9        50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
10       100.0      10.0         1.5           15.0          15.0     30.0     20.0     90.0        40.0       300.0     2.0     150.0      75.0     30.0  15.0  5.0  18.0  Positive
11       25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
12       50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
13       75.0       7.5         1.2           12.0          12.0     25.0     18.0     85.0        35.0       250.0     1.8     120.0      60.0     25.0  12.0  4.0  15.0  Positive
14       25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
15       50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
16       100.0      10.0         1.5           15.0          15.0     30.0     20.0     90.0        40.0       300.0     2.0     150.0      75.0     30.0  15.0  5.0  18.0  Positive
17       25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
18       50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
19       75.0       7.5         1.2           12.0          12.0     25.0     18.0     85.0        35.0       250.0     1.8     120.0      60.0     25.0  12.0  4.0  15.0  Positive
20       25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
21       50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive
22       100.0      10.0         1.5           15.0          15.0     30.0     20.0     90.0        40.0       300.0     2.0     150.0      75.0     30.0  15.0  5.0  18.0  Positive
23       25.0       2.5         0.8           8.0           8.0     15.0     10.0     70.0        20.0       150.0     1.2      80.0      40.0     15.0   8.0  2.5  10.0  Negative
24       50.0       5.0         1.0           10.0          10.0     20.0     15.0     80.0        30.0       200.0     1.5     100.0      50.0     20.0  10.0  3.5  12.0  Positive",0.7202450694541622
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/991462828186df98e5e0a21bfb3eafa836afbd8f.summary'],Does the combination of TP-0903 and B-PAC-1 with ibrutinib also induce epigenetic changes that lead to long-term suppression of CLL cell growth and prevent relapse?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Does the combination of TP-0903 and B-PAC-1 with ibrutinib also induce epigenetic changes that lead to long-term suppression of CLL cell growth and prevent relapse?

**Experimental Plan:**

**Objective:** To investigate whether the combination of TP-0903, B-PAC-1, and ibrutinib induces epigenetic changes leading to long-term suppression of CLL cell growth and prevention of relapse.

**Experimental Design:**

1. **Cell Culture:** Establish CLL cell lines and primary CLL cells from patient samples.
2. **Treatment:** Treat cells with:
	* Ibrutinib alone (control)
	* TP-0903 and B-PAC-1 alone (to assess individual effects)
	* Combination of TP-0903, B-PAC-1, and ibrutinib
3. **Epigenetic Analysis:** Perform:
	* DNA methylation analysis using bisulfite sequencing or methylation arrays
	* Histone modification analysis using chromatin immunoprecipitation sequencing (ChIP-seq) or histone modification-specific antibodies
	* Gene expression analysis using RNA-seq or qRT-PCR
4. **Cell Proliferation and Apoptosis Assays:** Measure:
	* Cell viability and proliferation using MTT or CellTiter-Glo assays
	* Apoptosis using Annexin V/PI staining and flow cytometry
5. **Long-term Culture:** Maintain treated cells in culture for an extended period (e.g., 6-12 weeks) to assess long-term suppression of CLL cell growth and potential relapse.
6. **Relapse Model:** Establish a relapse model by re-introducing treated cells into a permissive environment (e.g., co-culture with stromal cells or addition of growth factors) to assess the ability of the combination therapy to prevent relapse.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that the combination of TP-0903, B-PAC-1, and ibrutinib does not induce epigenetic changes leading to long-term suppression of CLL cell growth and prevention of relapse.

**Experimental Design:**

1. **Cell Culture:** Establish CLL cell lines and primary CLL cells from patient samples.
2. **Treatment:** Treat cells with the combination of TP-0903, B-PAC-1, and ibrutinib.
3. **Epigenetic Analysis:** Perform epigenetic analysis as described above.
4. **Cell Proliferation and Apoptosis Assays:** Measure cell viability, proliferation, and apoptosis as described above.
5. **Long-term Culture:** Maintain treated cells in culture for an extended period (e.g., 6-12 weeks).
6. **Relapse Model:** Establish a relapse model as described above.

**Key Predictions to Disprove the Hypothesis:**

* The combination of TP-0903, B-PAC-1, and ibrutinib does not induce significant epigenetic changes compared to ibrutinib alone.
* The combination therapy does not lead to long-term suppression of CLL cell growth or prevention of relapse.
* CLL cells treated with the combination therapy will relapse or continue to proliferate at a similar rate as those treated with ibrutinib alone.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a moderate budget. The required equipment and resources include:

* Cell culture facilities and equipment
* Epigenetic analysis platforms (e.g., bisulfite sequencing, ChIP-seq, RNA-seq)
* Flow cytometry and cell sorting equipment
* PCR and qRT-PCR machines
* Clinical laboratory equipment for monitoring patient responses (if using primary patient samples)

The budget will be allocated to:

* Personnel (post-doc, graduate student, and technician)
* Reagents and consumables (e.g., TP-0903, B-PAC-1, ibrutinib, antibodies, primers)
* Equipment maintenance and operation
* Sequencing and bioinformatics services (if outsourcing epigenetic analysis)

By following this experimental plan, we can test the hypothesis and determine whether the combination of TP-0903, B-PAC-1, and ibrutinib induces epigenetic changes leading to long-term suppression of CLL cell growth and prevention of relapse.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: Cell Culture**

1.1. Obtain CLL cell lines and primary CLL cells from patient samples.

* Use established CLL cell lines (e.g., MEC-1, JVM-3) and primary CLL cells isolated from patient blood or bone marrow samples.
* Ensure proper handling, storage, and quality control of cell samples.

1.2. Establish cell cultures in appropriate media.

* Use RPMI-1640 media supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine for CLL cell lines.
* Use a serum-free media (e.g., StemPro-34) for primary CLL cells.
* Incubate cells at 37°C, 5% CO2, and 95% humidity.

**Step 2: Treatment**

2.1. Prepare treatment solutions.

* Dissolve TP-0903, B-PAC-1, and ibrutinib in DMSO or an appropriate solvent.
* Prepare stock solutions at 10 mM, 1 mM, and 100 μM, respectively.
* Aliquot and store at -20°C.

2.2. Treat cells with:

* Ibrutinib alone (control): 1 μM final concentration
* TP-0903 and B-PAC-1 alone: 1 μM and 10 μM final concentrations, respectively
* Combination of TP-0903, B-PAC-1, and ibrutinib: 1 μM, 10 μM, and 1 μM final concentrations, respectively

* Add treatment solutions to cell cultures and incubate for 24-48 hours.

**Step 3: Epigenetic Analysis**

3.1. DNA Methylation Analysis using Bisulfite Sequencing:

* Isolate genomic DNA from treated cells using a DNA isolation kit (e.g., Qiagen).
* Perform bisulfite conversion using a bisulfite conversion kit (e.g., Zymo Research).
* Amplify target regions using PCR and sequencing primers.
* Sequence using an Illumina MiSeq or similar platform.

3.2. Histone Modification Analysis using ChIP-seq:

* Cross-link cells with 1% formaldehyde for 10 minutes.
* Sonicate chromatin to an average size of 200-500 bp.
* Immunoprecipitate histone modifications using specific antibodies (e.g., H3K27me3, H3K4me3).
* Perform ChIP-seq library preparation and sequencing using an Illumina HiSeq or similar platform.

3.3. Gene Expression Analysis using RNA-seq:

* Isolate total RNA from treated cells using an RNA isolation kit (e.g., Qiagen).
* Perform RNA-seq library preparation using a kit (e.g., Illumina TruSeq).
* Sequence using an Illumina HiSeq or similar platform.

**Step 4: Cell Proliferation and Apoptosis Assays**

4.1. Cell Viability and Proliferation Assay using MTT:

* Add MTT reagent to cell cultures and incubate for 2-4 hours.
* Measure absorbance at 570 nm using a plate reader.

4.2. Apoptosis Assay using Annexin V/PI Staining and Flow Cytometry:

* Stain cells with Annexin V-FITC and PI.
* Analyze using a flow cytometer (e.g., BD FACSCanto).

**Step 5: Long-term Culture**

5.1. Maintain treated cells in culture for 6-12 weeks.

* Passage cells every 3-4 days to maintain optimal cell density.
* Monitor cell viability and proliferation regularly.

**Step 6: Relapse Model**

6.1. Establish a relapse model by re-introducing treated cells into a permissive environment.

* Co-culture treated cells with stromal cells (e.g., HS-5) or add growth factors (e.g., IL-4, IL-21).
* Monitor cell proliferation and viability regularly.

**Experiment to Disprove the Hypothesis:**

The protocol for the experiment to disprove the hypothesis is identical to the above protocol, with the exception of the treatment conditions. In this experiment, cells will only be treated with the combination of TP-0903, B-PAC-1, and ibrutinib.

**Key Predictions to Disprove the Hypothesis:**

* The combination of TP-0903, B-PAC-1, and ibrutinib does not induce significant epigenetic changes compared to ibrutinib alone.
* The combination therapy does not lead to long-term suppression of CLL cell growth or prevention of relapse.
* CLL cells treated with the combination therapy will relapse or continue to proliferate at a similar rate as those treated with ibrutinib alone.

**Budget and Timeframe:**

The budget and timeframe for the experiment to disprove the hypothesis are identical to those outlined in the original experimental plan.

By following these detailed, step-by-step protocols, the experiment can be replicated and the hypothesis tested or disproven.","```
   CLL Cell Lines  Primary CLL Cells  TP-0903 (μM)  B-PAC-1 (μM)  Ibrutinib (μM)  Epigenetic Changes  Cell Proliferation  Apoptosis  Relapse
0             1.0               0.5         0.5         5.0         0.5           0.2           0.8       0.4       0.6
1             0.5               1.0         1.0         10.0         1.0           0.4           0.6       0.5       0.7
2             1.5               0.8         0.8         8.0         0.8           0.3           0.9       0.6       0.8
3             1.0               1.2         1.2         12.0         1.2           0.5           0.7       0.7       0.9
4             0.8               1.5         1.5         15.0         1.5           0.6           0.8       0.8       1.0
5             1.2               1.0         1.0         10.0         1.0           0.4           0.9       0.7       0.9
6             1.5               0.5         0.5         5.0         0.5           0.3           0.8       0.5       0.7
7             0.5               1.8         1.8         18.0         1.8           0.7           0.9       0.9       1.1
8             1.0               1.0         1.0         10.0         1.0           0.5           0.8       0.7       0.9
9             1.8               0.8         0.8         8.0         0.8           0.4           0.9       0.6       0.8
10            1.2               1.5         1.5         15.0         1.5           0.6           0.9       0.8       1.0
11            0.8               1.2         1.2         12.0         1.2           0.5           0.8       0.7       0.9
12            1.5               1.0         1.0         10.0         1.0           0.4           0.9       0.7       0.9
13            1.0               1.8         1.8         18.0         1.8           0.7           0.9       0.9       1.1
14            1.2               0.5         0.5         5.0         0.5           0.3           0.8       0.5       0.7
15            0.5               1.0         1.0         10.0         1.0           0.4           0.6       0.7       0.8
16            1.8               1.2         1.2         12.0         1.2           0.5           0.9       0.7       0.9
17            1.0               1.5         1.5         15.0         1.5           0.6           0.9       0.8       1.0
18            1.5               0.8         0.8         8.0         0.8           0.4           0.9       0.6       0.8
19            1.2               1.8         1.8         18.0         1.8           0.7           0.9       0.9       1.1
20            0.8               1.0         1.0         10.0         1.0           0.5           0.8       0.7       0.9
21            1.0               1.2         1.2         12.0         1.2           0.5           0.8       0.7       0.9
22            1.5               1.5         1.5         15.0         1.5           0.6           0.9       0.8       1.0
23            1.8               1.0         1.0         10.0         1.0           0.4           0.9       0.7       0.9
24            1.2               0.8         0.8         8.0         0.8           0.4           0.9       0.6       0.8
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3fa99f54a781ea8c539134a9014a632ef2ffff3e.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/883284725ca297bb7df6a51813ed006a1b0cb6db.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/071128e3aa20735ca3e5118583485cfcffe24a0d.summary']",Does the combination of TRAT1 overexpression and the 6-lncRNA pair signature enhance the predictive power of immunotherapy and chemotherapy response in lung adenocarcinoma patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed a high-level experimental plan to test its validity. Since the goal is to disprove the hypothesis, the experiment is designed to identify potential flaws or inconsistencies in the hypothesis.

**Hypothesis:** The combination of TRAT1 overexpression and the 6-lncRNA pair signature enhances the predictive power of immunotherapy and chemotherapy response in lung adenocarcinoma patients.

**Experimental Plan:**

**Objective:** To investigate whether the combination of TRAT1 overexpression and the 6-lncRNA pair signature is a reliable predictor of immunotherapy and chemotherapy response in lung adenocarcinoma patients.

**Study Design:**

1. **Patient Selection:** Collect tumor tissue samples from 100 lung adenocarcinoma patients who have received either immunotherapy or chemotherapy. Ensure that the samples are divided into two groups: responders (n=50) and non-responders (n=50) based on their treatment outcomes.
2. **TRAT1 Overexpression Analysis:** Perform quantitative real-time PCR (qRT-PCR) to measure TRAT1 mRNA expression levels in each tumor sample. Normalize the data using a housekeeping gene (e.g., GAPDH).
3. **6-lncRNA Pair Signature Analysis:** Use a microarray or RNA-seq platform to analyze the expression levels of the 6-lncRNA pair signature in each tumor sample. Normalize the data using a suitable method (e.g., RMA or DESeq2).
4. **Combination Analysis:** Combine the TRAT1 overexpression data with the 6-lncRNA pair signature data to create a predictive model. Use a machine learning algorithm (e.g., logistic regression or random forest) to identify the optimal combination of TRAT1 and 6-lncRNA pair signature that best predicts treatment response.
5. **Validation:** Split the patient samples into training (n=70) and testing sets (n=30). Train the predictive model on the training set and evaluate its performance on the testing set using metrics such as accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC).
6. **Negative Control:** Include a negative control group consisting of 20 lung adenocarcinoma patients who have not received immunotherapy or chemotherapy. Analyze their TRAT1 and 6-lncRNA pair signature expression levels to serve as a baseline.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, the experiment will focus on identifying inconsistencies or flaws in the predictive model. The following approaches will be used:

1. **Overfitting Analysis:** Evaluate the predictive model for overfitting by analyzing its performance on the training and testing sets. If the model performs poorly on the testing set, it may indicate overfitting, which would disprove the hypothesis.
2. **Feature Selection:** Perform feature selection techniques (e.g., recursive feature elimination) to identify the most informative features in the 6-lncRNA pair signature. If the selected features do not improve the predictive power of the model, it would suggest that the 6-lncRNA pair signature is not a reliable predictor.
3. **TRAT1 Knockdown:** Use CRISPR-Cas9 or RNAi to knockdown TRAT1 expression in lung adenocarcinoma cell lines. Analyze the effect of TRAT1 knockdown on the 6-lncRNA pair signature and treatment response. If TRAT1 knockdown does not affect the predictive power of the model, it would disprove the hypothesis.
4. **Alternative Biomarkers:** Investigate alternative biomarkers (e.g., protein expression or methylation profiles) that may be more accurate predictors of treatment response. If alternative biomarkers outperform the TRAT1 and 6-lncRNA pair signature combination, it would disprove the hypothesis.

**Timeline and Budget:**

This experiment can be completed within 12-18 months with a budget of approximately $200,000. The breakdown is as follows:

* Patient sample collection and processing: 3 months, $30,000
* TRAT1 overexpression analysis: 2 months, $20,000
* 6-lncRNA pair signature analysis: 3 months, $40,000
* Combination analysis and machine learning: 4 months, $30,000
* Validation and negative control: 2 months, $20,000
* Overfitting analysis, feature selection, and alternative biomarker investigation: 4 months, $40,000
* CRISPR-Cas9 or RNAi experiments: 2 months, $20,000

This experimental plan is designed to test the hypothesis in a rigorous and systematic manner, while also considering the limitations of time, resources, and budget.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Protocol 1: Patient Sample Collection and Processing**

1.1. Collect tumor tissue samples from 100 lung adenocarcinoma patients who have received either immunotherapy or chemotherapy.

* Obtain informed consent from patients and collect tumor tissue samples through biopsy or surgical resection.
* Store samples in RNAlater or flash-freeze them in liquid nitrogen to preserve RNA integrity.

1.2. Divide the samples into two groups: responders (n=50) and non-responders (n=50) based on their treatment outcomes.

* Review patient medical records to determine treatment response (e.g., complete response, partial response, stable disease, or progressive disease).
* Label samples accordingly and store them in a secure database.

1.3. Extract total RNA from each tumor sample using a commercial RNA extraction kit (e.g., Qiagen RNeasy).

* Follow the manufacturer's instructions for RNA extraction, including homogenization, lysis, and purification steps.
* Quantify RNA concentration using a spectrophotometer (e.g., NanoDrop) and assess RNA quality using a bioanalyzer (e.g., Agilent 2100).

**Protocol 2: TRAT1 Overexpression Analysis**

2.1. Perform quantitative real-time PCR (qRT-PCR) to measure TRAT1 mRNA expression levels in each tumor sample.

* Design and synthesize TRAT1-specific primers and probes using a commercial software (e.g., Primer3).
* Prepare a master mix containing primers, probes, and a reference dye (e.g., ROX).
* Add 1 μg of total RNA to each reaction and perform qRT-PCR using a thermocycler (e.g., Applied Biosystems 7500).
* Analyze data using the comparative Ct method, normalizing to a housekeeping gene (e.g., GAPDH).

2.2. Normalize TRAT1 expression data using a housekeeping gene (e.g., GAPDH).

* Calculate the ΔCt value for each sample by subtracting the Ct value of the housekeeping gene from the Ct value of TRAT1.
* Calculate the relative expression level of TRAT1 using the 2^(-ΔCt) formula.

**Protocol 3: 6-lncRNA Pair Signature Analysis**

3.1. Use a microarray or RNA-seq platform to analyze the expression levels of the 6-lncRNA pair signature in each tumor sample.

* Prepare RNA samples according to the manufacturer's instructions for microarray or RNA-seq analysis.
* Hybridize RNA samples to a microarray platform (e.g., Affymetrix) or perform RNA-seq using a next-generation sequencing platform (e.g., Illumina HiSeq).
* Analyze data using a commercial software (e.g., Affymetrix Expression Console or Illumina BaseSpace).

3.2. Normalize 6-lncRNA pair signature data using a suitable method (e.g., RMA or DESeq2).

* Use a normalization algorithm to adjust for biases and variations in the data.
* Calculate the relative expression level of each lncRNA in the 6-lncRNA pair signature.

**Protocol 4: Combination Analysis**

4.1. Combine the TRAT1 overexpression data with the 6-lncRNA pair signature data to create a predictive model.

* Use a machine learning algorithm (e.g., logistic regression or random forest) to integrate the TRAT1 and 6-lncRNA pair signature data.
* Train the model using the training set (n=70) and evaluate its performance on the testing set (n=30).

4.2. Evaluate the predictive model using metrics such as accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC).

* Calculate the performance metrics using a commercial software (e.g., R or Python).
* Compare the performance of the model on the training and testing sets to evaluate overfitting.

**Protocol 5: Negative Control**

5.1. Analyze TRAT1 and 6-lncRNA pair signature expression levels in 20 lung adenocarcinoma patients who have not received immunotherapy or chemotherapy.

* Follow the same protocols as above for TRAT1 overexpression analysis and 6-lncRNA pair signature analysis.
* Use the negative control data as a baseline to compare with the treatment response groups.

**Protocol 6: Overfitting Analysis**

6.1. Evaluate the predictive model for overfitting by analyzing its performance on the training and testing sets.

* Calculate the performance metrics (e.g., accuracy, sensitivity, specificity, and AUC-ROC) for both the training and testing sets.
* Compare the performance metrics to identify any signs of overfitting (e.g., poor performance on the testing set).

**Protocol 7: Feature Selection**

7.1. Perform feature selection techniques (e.g., recursive feature elimination) to identify the most informative features in the 6-lncRNA pair signature.

* Use a commercial software (e.g., R or Python) to perform feature selection.
* Evaluate the performance of the model using the selected features and compare with the original model.

**Protocol 8: TRAT1 Knockdown**

8.1. Use CRISPR-Cas9 or RNAi to knockdown TRAT1 expression in lung adenocarcinoma cell lines.

* Design and synthesize CRISPR-Cas9 guide RNAs or RNAi oligonucleotides targeting TRAT1.
* Transfect lung adenocarcinoma cell lines (e.g., A549) with CRISPR-Cas9 or RNAi reagents.
* Validate TRAT1 knockdown using qRT-PCR or Western blot.

8.2. Analyze the effect of TRAT1 knockdown on the 6-lncRNA pair signature and treatment response.

* Perform 6-lncRNA pair signature analysis on TRAT1-knockdown cells.
* Evaluate the predictive power of the model using the TRAT1-knockdown data.

**Protocol 9: Alternative Biomarkers**

9.1. Investigate alternative biomarkers (e.g., protein expression or methylation profiles) that may be more accurate predictors of treatment response.

* Use a commercial platform (e.g., Luminex or Illumina MethylationEPIC) to analyze protein expression or methylation profiles.
* Evaluate the predictive power of the alternative biomarkers using a machine learning algorithm.

9.2. Compare the performance of the alternative biomarkers with the TRAT1 and 6-lncRNA pair signature combination.

* Calculate the performance metrics (e.g., accuracy, sensitivity, specificity, and AUC-ROC) for the alternative biomarkers.
* Compare the performance metrics with the original model to determine if the alternative biomarkers outperform the TRAT1 and 6-lncRNA pair signature combination.","```
   TRAT1_mRNA  lncRNA1  lncRNA2  lncRNA3  lncRNA4  lncRNA5  lncRNA6  Treatment  Response
0    0.500000  0.200000  0.300000  0.400000  0.500000  0.600000  0.700000  Immunotherapy       1
1    0.600000  0.300000  0.400000  0.500000  0.600000  0.700000  0.800000  Chemotherapy       0
2    0.700000  0.400000  0.500000  0.600000  0.700000  0.800000  0.900000  Immunotherapy       1
3    0.400000  0.200000  0.300000  0.400000  0.500000  0.600000  0.700000  Chemotherapy       0
4    0.300000  0.100000  0.200000  0.300000  0.400000  0.500000  0.600000  Immunotherapy       1
5    0.800000  0.500000  0.600000  0.700000  0.800000  0.900000  1.000000  Chemotherapy       0
6    0.900000  0.600000  0.700000  0.800000  0.900000  1.000000  1.100000  Immunotherapy       1
7    0.200000  0.100000  0.200000  0.300000  0.400000  0.500000  0.600000  Chemotherapy       0
8    0.100000  0.000000  0.100000  0.200000  0.300000  0.400000  0.500000  Immunotherapy       1
9    0.600000  0.300000  0.400000  0.500000  0.600000  0.700000  0.800000  Chemotherapy       0
10   0.500000  0.200000  0.300000  0.400000  0.500000  0.600000  0.700000  Immunotherapy       1
11   0.400000  0.200000  0.300000  0.400000  0.500000  0.600000  0.700000  Chemotherapy       0
12   0.700000  0.400000  0.500000  0.600000  0.700000  0.800000  0.900000  Immunotherapy       1
13   0.300000  0.100000  0.200000  0.300000  0.400000  0.500000  0.600000  Chemotherapy       0
14   0.800000  0.500000  0.600000  0.700000  0.800000  0.900000  1.000000  Immunotherapy       1
15   0.900000  0.600000  0.700000  0.800000  0.900000  1.000000  1.100000  Chemotherapy       0
16   0.200000  0.100000  0.200000  0.300000  0.400000  0.500000  0.600000  Immunotherapy       1
17   0.100000  0.000000  0.100000  0.200000  0.300000  0.400000  0.500000  Chemotherapy       0
18   0.600000  0.300000  0.400000  0.500000  0.600000  0.700000  0.800000  Immunotherapy       1
19   0.500000  0.200000  0.300000  0.400000  0.500000  0.600000  0.700000  Chemotherapy       0
20   0.400000  0.200000  0.300000  0.400000  0.500000  0.600000  0.700000  Immunotherapy       1
21   0.700000  0.400000  0.500000  0.600000  0.700000  0.800000  0.900000  Chemotherapy       0
22   0.300000  0.100000  0.200000  0.300000  0.400000  0.500000  0.600000  Immunotherapy       1
23   0.800000  0.500000  0.600000  0.700000  0.800000  0.900000  1.000000  Chemotherapy       0
24   0.900000  0.600000  0.700000  0.800000  0.900000  1.000000  1.100000  Immunotherapy       1
```",0.12094406002852869
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/95289b0dd38e5cb2fc17e4d24ee49cf897ba6bd9.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/41fed2fc222f4efe00eec3fe4f12c08f8e3aebfa.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b114bfb532ec36c62d7cccf9f58f0b20cede79a9.summary']",Does the combination of anti-BCMA CAR-T cell therapy and radiation therapy enhance the durability of treatment response by reducing the rebound of sBCMA plasma levels and promoting the expansion of endogenous T-cells that recognize tumor antigens?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I propose an experimental plan to test the hypothesis:

**Hypothesis:** Does the combination of anti-BCMA CAR-T cell therapy and radiation therapy enhance the durability of treatment response by reducing the rebound of sBCMA plasma levels and promoting the expansion of endogenous T-cells that recognize tumor antigens?

**Experimental Design:**

**Objective:** To investigate whether the combination of anti-BCMA CAR-T cell therapy and radiation therapy reduces the rebound of sBCMA plasma levels and promotes the expansion of endogenous T-cells that recognize tumor antigens, leading to a more durable treatment response.

**Design:** Randomized controlled trial

**Methods:**

1. Enroll patients with relapsed multiple myeloma and randomize them to receive either:
	* Arm A: Anti-BCMA CAR-T cell therapy alone
	* Arm B: Anti-BCMA CAR-T cell therapy followed by localized radiation therapy
2. Collect blood samples at multiple time points (baseline, post-CAR-T cell infusion, post-radiation therapy, and at 3-month intervals) for:
	* Measurement of sBCMA plasma levels using ELISA
	* Analysis of T-cell receptor repertoire using next-generation sequencing
	* Measurement of CAR-T cell copy numbers using digital droplet PCR
3. Assess tumor response using imaging and biomarkers at multiple time points
4. Compare sBCMA plasma levels, T-cell receptor repertoire, and tumor response between the two treatment arms

**Primary Endpoint:**

* Reduction in sBCMA plasma levels at 3 months post-treatment

**Secondary Endpoints:**

* Expansion of endogenous T-cells that recognize tumor antigens at 3 months post-treatment
* Tumor response rate at 3 months post-treatment
* Progression-free survival at 6 months post-treatment

**Required Equipment:**

* ELISA platform
* Next-generation sequencing platform
* Digital droplet PCR machine
* Flow cytometer
* Radiation therapy machine
* Imaging equipment (e.g., PET/CT scanner)

**Steps to Follow:**

1. Enroll patients and randomize them to treatment arms
2. Collect blood samples at baseline and post-CAR-T cell infusion
3. Administer radiation therapy to patients in Arm B
4. Collect blood samples at post-radiation therapy and 3-month intervals
5. Analyze sBCMA plasma levels, T-cell receptor repertoire, and CAR-T cell copy numbers
6. Assess tumor response using imaging and biomarkers
7. Compare primary and secondary endpoints between treatment arms

**Budget and Timeline:**

* Estimated budget: $500,000
* Estimated duration: 12 months

**Rationale:**

This experimental design aims to test the hypothesis by comparing the combination of anti-BCMA CAR-T cell therapy and radiation therapy to anti-BCMA CAR-T cell therapy alone. By measuring sBCMA plasma levels, T-cell receptor repertoire, and tumor response, we can determine whether the addition of radiation therapy reduces the rebound of sBCMA plasma levels and promotes the expansion of endogenous T-cells that recognize tumor antigens, leading to a more durable treatment response.

To disprove the hypothesis, we would expect to see no significant difference in sBCMA plasma levels, T-cell receptor repertoire, and tumor response between the two treatment arms. If the results show that the combination of anti-BCMA CAR-T cell therapy and radiation therapy does not reduce the rebound of sBCMA plasma levels or promote the expansion of endogenous T-cells that recognize tumor antigens, it would suggest that the hypothesis is false.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Enrollment and Randomization**

1.1. Identify patients with relapsed multiple myeloma who meet the inclusion criteria.

1.2. Obtain informed consent from each patient.

1.3. Randomly assign patients to either Arm A (anti-BCMA CAR-T cell therapy alone) or Arm B (anti-BCMA CAR-T cell therapy followed by localized radiation therapy) using a computer-generated randomization program.

1.4. Record patient demographics, medical history, and baseline laboratory results.

**Protocol 2: Blood Sample Collection**

2.1. Collect 10 mL of blood from each patient at the following time points:
	* Baseline (before CAR-T cell infusion)
	* Post-CAR-T cell infusion (1-2 weeks after infusion)
	* Post-radiation therapy (1-2 weeks after radiation therapy)
	* 3-month intervals (± 1 week) after treatment

2.2. Label and store blood samples at -80°C for future analysis.

**Protocol 3: Anti-BCMA CAR-T Cell Therapy**

3.1. Manufacture and quality-control anti-BCMA CAR-T cells according to established protocols.

3.2. Infuse anti-BCMA CAR-T cells into patients in both Arm A and Arm B.

**Protocol 4: Radiation Therapy**

4.1. Administer localized radiation therapy to patients in Arm B according to established protocols.

4.2. Record radiation therapy details, including dose, duration, and site.

**Protocol 5: sBCMA Plasma Level Measurement**

5.1. Thaw frozen blood samples and extract plasma using a centrifuge.

5.2. Measure sBCMA plasma levels using an ELISA platform according to the manufacturer's instructions.

5.3. Record sBCMA plasma levels in ng/mL.

**Protocol 6: T-Cell Receptor Repertoire Analysis**

6.1. Extract genomic DNA from thawed blood samples using a DNA extraction kit.

6.2. Perform next-generation sequencing (NGS) on the extracted DNA using a NGS platform according to the manufacturer's instructions.

6.3. Analyze T-cell receptor repertoire using bioinformatic tools and record results.

**Protocol 7: CAR-T Cell Copy Number Measurement**

7.1. Extract genomic DNA from thawed blood samples using a DNA extraction kit.

7.2. Perform digital droplet PCR (ddPCR) on the extracted DNA using a ddPCR machine according to the manufacturer's instructions.

7.3. Measure CAR-T cell copy numbers and record results.

**Protocol 8: Tumor Response Assessment**

8.1. Perform imaging studies (e.g., PET/CT scans) at baseline, post-treatment, and 3-month intervals.

8.2. Measure tumor response using established criteria (e.g., RECIST).

8.3. Record tumor response data.

**Protocol 9: Data Analysis**

9.1. Compare sBCMA plasma levels, T-cell receptor repertoire, and tumor response between Arm A and Arm B.

9.2. Calculate primary and secondary endpoints, including reduction in sBCMA plasma levels, expansion of endogenous T-cells, tumor response rate, and progression-free survival.

9.3. Perform statistical analysis using appropriate tests (e.g., t-test, ANOVA) to determine significance.

**Protocol 10: Quality Control and Assurance**

10.1. Perform regular quality control checks on equipment and reagents.

10.2. Monitor patient safety and report adverse events.

10.3. Ensure data integrity and accuracy throughout the study.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately compared between the two treatment arms.","```
   Patient_ID  Arm  CAR-T Cell Dose  Radiation Dose  Baseline sBCMA  Post-CAR-T sBCMA  Post-Rad sBCMA  3-Month sBCMA  T-Cell Receptor Diversity  CAR-T Cell Copy Number  Tumor Response
0           1    A          100000          0.0         50.0          20.0          15.0          10.0                  0.8               5000.0          Complete Response
1           2    B          120000         30.0         60.0          30.0          20.0          15.0                  0.9               6000.0          Partial Response
2           3    A           90000          0.0         40.0          25.0          20.0          15.0                  0.7               4500.0          Stable Disease
3           4    B          110000         25.0         55.0          35.0          25.0          20.0                  0.8               5500.0          Complete Response
4           5    A          130000          0.0         65.0          40.0          30.0          25.0                  0.9               6500.0          Partial Response
5           6    B           95000         20.0         45.0          30.0          25.0          20.0                  0.8               5000.0          Stable Disease
6           7    A          100000          0.0         50.0          25.0          20.0          15.0                  0.7               4500.0          Complete Response
7           8    B          125000         35.0         70.0          45.0          35.0          30.0                  0.9               7000.0          Partial Response
8           9    A           85000          0.0         35.0          20.0          15.0          10.0                  0.6               3500.0          Stable Disease
9          10    B          105000         30.0         60.0          35.0          25.0          20.0                  0.8               5500.0          Complete Response
10         11    A          135000          0.0         75.0          50.0          40.0          35.0                  0.9               7500.0          Partial Response
11         12    B           90000         25.0         50.0          30.0          25.0          20.0                  0.8               5000.0          Stable Disease
12         13    A          110000          0.0         60.0          35.0          30.0          25.0                  0.8               6000.0          Complete Response
13         14    B          130000         40.0         80.0          55.0          45.0          40.0                  0.9               8000.0          Partial Response
14         15    A           95000          0.0         45.0          30.0          25.0          20.0                  0.7               4500.0          Stable Disease
15         16    B          115000         30.0         65.0          40.0          35.0          30.0                  0.9               6500.0          Complete Response
16         17    A          125000          0.0         70.0          45.0          40.0          35.0                  0.9               7000.0          Partial Response
17         18    B           85000         20.0         40.0          25.0          20.0          15.0                  0.7               4000.0          Stable Disease
18         19    A          105000          0.0         55.0          35.0          30.0          25.0                  0.8               5500.0          Complete Response
19         20    B          120000         35.0         75.0          50.0          45.0          40.0                  0.9               7500.0          Partial Response
20         21    A           90000          0.0         50.0          30.0          25.0          20.0                  0.8               5000.0          Stable Disease
21         22    B          110000         30.0         60.0          40.0          35.0          30.0                  0.9               6500.0          Complete Response
22         23    A          130000          0.0         80.0          55.0          50.0          45.0                  0.9               8000.0          Partial Response
23         24    B           95000         25.0         55.0          35.0          30.0          25.0                  0.8               5500.0          Stable Disease
24         25    A          115000          0.0         65.0          40.0          35.0          30.0                  0.9               7000.0          Complete Response
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/018bb969013f3799a0193a78c4ee62562b795a20.summary'],Does the combination of belimumab and antimalarial drugs have a synergistic effect in reducing cardiovascular risk and improving endothelial function in SLE patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test the hypothesis and potentially disprove it. Here's a high-level experimental approach:

**Experiment Title:** Investigating the Synergistic Effect of Belimumab and Antimalarial Drugs on Cardiovascular Risk and Endothelial Function in SLE Patients

**Objective:** To determine whether the combination of belimumab and antimalarial drugs has a synergistic effect in reducing cardiovascular risk and improving endothelial function in SLE patients.

**Study Design:**

1. **Recruitment:** Enroll 200 SLE patients with moderate or severe disease and 40 healthy controls.
2. **Randomization:** Randomly assign SLE patients to one of four groups:
	* Group 1: Belimumab treatment only (n=50)
	* Group 2: Antimalarial drug treatment only (n=50)
	* Group 3: Combination of belimumab and antimalarial drug treatment (n=50)
	* Group 4: Placebo control (n=50)
3. **Treatment Duration:** 12 months
4. **Endpoints:**
	* Primary endpoint: Change in endothelial function (measured by flow-mediated dilation (FMD) and endothelial progenitor cell (EPC) count) at 6 and 12 months
	* Secondary endpoint: Change in cardiovascular risk (measured by Framingham Risk Score and carotid intima-media thickness (CIMT)) at 6 and 12 months

**Methods:**

1. **Endothelial Function Assessment:**
	* Measure FMD using a flow-mediated dilation device at baseline, 6 months, and 12 months
	* Measure EPC count using flow cytometry at baseline, 6 months, and 12 months
2. **Cardiovascular Risk Assessment:**
	* Calculate Framingham Risk Score at baseline, 6 months, and 12 months
	* Measure CIMT using carotid ultrasound at baseline, 6 months, and 12 months
3. **Safety Monitoring:** Monitor patients for adverse events and laboratory abnormalities throughout the study period

**Equipment:**

1. Flow-mediated dilation device
2. Flow cytometer for EPC count
3. Carotid ultrasound for CIMT measurement
4. Laboratory equipment for safety monitoring

**Statistical Analysis:**

1. Compare the changes in endothelial function and cardiovascular risk between the four groups using ANOVA or non-parametric tests
2. Perform pairwise comparisons between groups using post-hoc tests (e.g., Tukey's test)
3. Calculate the synergistic effect of belimumab and antimalarial drugs using interaction terms in a linear regression model

**Potential Pitfalls and Limitations:**

1. Patient compliance and dropout rates may affect the study's power and validity
2. The study may not be generalizable to SLE patients with mild disease or other comorbidities
3. The antimalarial drug used may have varying effects on cardiovascular risk and endothelial function

**To Disprove the Hypothesis:**

1. If the combination of belimumab and antimalarial drugs does not show a significant synergistic effect on endothelial function and cardiovascular risk compared to either treatment alone or placebo
2. If the study finds that the combination therapy is associated with increased cardiovascular risk or decreased endothelial function
3. If the study reveals significant adverse events or interactions between belimumab and antimalarial drugs that outweigh any potential benefits

By designing an experiment with a large sample size, multiple treatment groups, and a long treatment duration, we can increase the power to detect a synergistic effect and minimize the risk of false positives. However, it is essential to acknowledge the potential pitfalls and limitations of the study and to carefully interpret the results in the context of the existing literature.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Recruitment and Randomization**

1.1. **Inclusion and Exclusion Criteria:**

* Inclusion criteria: SLE patients with moderate or severe disease, aged 18-65 years, and willing to provide informed consent.
* Exclusion criteria: SLE patients with mild disease, comorbidities, or taking medications that may interfere with the study.

1.2. **Recruitment:**

* Advertise the study through social media, patient organizations, and hospital networks.
* Screen potential participants through phone or in-person interviews to assess eligibility.
* Obtain informed consent from eligible participants.

1.3. **Randomization:**

* Use a computer-generated randomization program to assign participants to one of the four groups:
	+ Group 1: Belimumab treatment only (n=50)
	+ Group 2: Antimalarial drug treatment only (n=50)
	+ Group 3: Combination of belimumab and antimalarial drug treatment (n=50)
	+ Group 4: Placebo control (n=50)
* Use a block randomization scheme to ensure equal distribution of participants across groups.

**Protocol 2: Treatment Administration**

2.1. **Belimumab Administration:**

* Administer belimumab intravenously at a dose of 10 mg/kg every 4 weeks for 12 months.
* Monitor patients for infusion reactions and adjust the infusion rate as needed.

2.2. **Antimalarial Drug Administration:**

* Administer the antimalarial drug orally at a dose of 200-400 mg daily for 12 months.
* Monitor patients for adverse events and adjust the dose as needed.

2.3. **Placebo Administration:**

* Administer a placebo intravenously every 4 weeks for 12 months.

**Protocol 3: Endothelial Function Assessment**

3.1. **Flow-Mediated Dilation (FMD) Measurement:**

* Measure FMD using a flow-mediated dilation device at baseline, 6 months, and 12 months.
* Ensure the device is calibrated according to the manufacturer's instructions.
* Record the FMD values in mm.

3.2. **Endothelial Progenitor Cell (EPC) Count:**

* Collect 10 mL of peripheral blood from each participant at baseline, 6 months, and 12 months.
* Process the blood samples using flow cytometry to count EPCs.
* Record the EPC count as cells/mL.

**Protocol 4: Cardiovascular Risk Assessment**

4.1. **Framingham Risk Score Calculation:**

* Calculate the Framingham Risk Score at baseline, 6 months, and 12 months using the following variables:
	+ Age
	+ Sex
	+ Systolic blood pressure
	+ Total cholesterol
	+ HDL cholesterol
	+ Smoking status
* Record the Framingham Risk Score as a percentage.

4.2. **Carotid Intima-Media Thickness (CIMT) Measurement:**

* Measure CIMT using carotid ultrasound at baseline, 6 months, and 12 months.
* Ensure the ultrasound device is calibrated according to the manufacturer's instructions.
* Record the CIMT values in mm.

**Protocol 5: Safety Monitoring**

5.1. **Adverse Event Monitoring:**

* Monitor patients for adverse events throughout the study period.
* Record the type, severity, and duration of each adverse event.

5.2. **Laboratory Abnormalities:**

* Monitor patients for laboratory abnormalities throughout the study period.
* Record the type and severity of each laboratory abnormality.

**Protocol 6: Statistical Analysis**

6.1. **Data Management:**

* Enter data into a secure database using a unique participant identifier.
* Verify data accuracy and completeness.

6.2. **Data Analysis:**

* Compare the changes in endothelial function and cardiovascular risk between the four groups using ANOVA or non-parametric tests.
* Perform pairwise comparisons between groups using post-hoc tests (e.g., Tukey's test).
* Calculate the synergistic effect of belimumab and antimalarial drugs using interaction terms in a linear regression model.

**Protocol 7: Quality Control and Assurance**

7.1. **Equipment Calibration:**

* Calibrate all equipment according to the manufacturer's instructions.
* Record the calibration dates and results.

7.2. **Data Quality Control:**

* Verify data accuracy and completeness.
* Perform regular data backups.

7.3. **Study Monitoring:**

* Monitor the study's progress and adherence to the protocol.
* Address any deviations or issues promptly.

By following these detailed, step-by-step protocols, the experiment can be executed with precision and accuracy, ensuring the collection of high-quality data to test the hypothesis.","```
   Belimumab_Dose  Antimalarial_Dose  Placebo  FMD_Baseline  FMD_6months  FMD_12months  EPC_Baseline  EPC_6months  EPC_12months  Framingham_Risk_Baseline  Framingham_Risk_6months  Framingham_Risk_12months  CIMT_Baseline  CIMT_6months  CIMT_12months  Outcome
0             10.0             200.0      0.0         5.2         6.5         7.1          100.0          120.0          150.0               10.2               8.5               7.1           0.8           0.7           0.6       Success
1              8.0             300.0      0.0         4.8         5.9         6.3           90.0          110.0          130.0               11.5               9.8               8.2           0.9           0.8           0.7       Success
2              9.0             250.0      0.0         5.5         6.8         7.4          110.0          130.0          160.0               10.8               9.2               7.8           0.7           0.6           0.5       Success
3              7.0             350.0      0.0         4.2         5.3         5.8           80.0          100.0          120.0               12.1              10.5               9.0           1.0           0.9           0.8       Failure
4              9.5             220.0      0.0         5.8         7.1         7.7          120.0          140.0          170.0               10.5               9.0               7.5           0.6           0.5           0.4       Success
5              8.5             280.0      0.0         5.1         6.2         6.6          100.0          120.0          140.0               11.2              10.0               8.5           0.8           0.7           0.6       Success
6              7.5             320.0      0.0         4.5         5.6         6.0           90.0          110.0          130.0               12.3              11.0               9.5           1.1           1.0           0.9       Failure
7              9.0             240.0      0.0         5.6         6.9         7.5          110.0          130.0          160.0               10.9               9.3               7.9           0.7           0.6           0.5       Success
8              8.0             300.0      0.0         4.9         6.0         6.4           90.0          110.0          130.0               11.6              10.2               8.7           0.9           0.8           0.7       Success
9              9.2             260.0      0.0         5.9         7.2         7.9          120.0          140.0          170.0               10.6               9.1               7.6           0.6           0.5           0.4       Success
10             7.8             330.0      0.0         4.3         5.4         5.9           80.0          100.0          120.0               12.5              11.2              10.0           1.2           1.1           1.0       Failure
11             9.5             230.0      0.0         6.0         7.3         8.0          130.0          150.0          180.0               10.4               9.0               7.4           0.5           0.4           0.3       Success
12             8.2             290.0      0.0         5.3         6.5         6.9          100.0          120.0          140.0               11.4              10.1               8.6           0.8           0.7           0.6       Success
13             7.2             340.0      0.0         4.1         5.2         5.6           80.0          100.0          120.0               12.8              11.5              10.2           1.3           1.2           1.1       Failure
14             9.8             210.0      0.0         6.2         7.5         8.2          140.0          160.0          190.0               10.2               8.9               7.3           0.4           0.3           0.2       Success
15             8.5             310.0      0.0         5.5         6.7         7.2          110.0          130.0          160.0               11.1              10.0               8.4           0.7           0.6           0.5       Success
16             7.5             350.0      0.0         4.0         5.1         5.4           70.0           90.0          110.0               13.1              12.0              10.5           1.4           1.3           1.2       Failure
17             9.0             220.0      0.0         5.8         7.0         7.6          120.0          140.0          170.0               10.7               9.2               7.7           0.6           0.5           0.4       Success
18             8.0             280.0      0.0         5.2         6.3         6.7          100.0          120.0          140.0               11.3              10.1               8.5           0.8           0.7           0.6       Success
19             9.3             240.0      0.0         6.1         7.4         8.1          130.0          150.0          180.0               10.5               9.0               7.5           0.5           0.4           0.3       Success
20             7.9             320.0      0.0         4.4         5.5         6.0           90.0          110.0          130.0               12.6              11.3              10.1           1.1           1.0           0.9       Failure
21             9.6             250.0      0.0         6.3         7.6         8.3          140.0          160.0          190.0               10.3               9.0               7.4           0.4           0.3           0.2       Success
22             8.3             300.0      0.0         5.6         6.8         7.3          110.0          130.0          160.0               11.2              10.0               8.4           0.7           0.6           0.5       Success
23             7.1             330.0      0.0         4.2         5.3         5.7           80.0          100.0          120.0               12.9              11.6              10.3           1.2           1.1           1.0       Failure
24             9.9             210.0      0.0         6.5         7.8         8.5          150.0          170.0          200.0               10.1               8.8               7.2           0.3           0.2           0.1       Success
```",0.03707065880527708
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/72712e5d1604c97b17687f71e9341ff5599dde4b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/00166bc6e5e07f5e0831e0fa2234f522976f071d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/040fcee9b9bbf827c923c37b071cd3ef87c90923.summary']","Does the combination of macrophage inhibition and CAR T cells targeting tumor-associated MUC1 glycoprotein enhance the formation of tertiary lymphoid structures and increase the infiltration of activated B cells and CD4+ T cells, leading to improved durable regression of triple negative breast cancer?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I have developed an experimental plan to test the hypothesis:

**Hypothesis:** Does the combination of macrophage inhibition and CAR T cells targeting tumor-associated MUC1 glycoprotein enhance the formation of tertiary lymphoid structures and increase the infiltration of activated B cells and CD4+ T cells, leading to improved durable regression of triple negative breast cancer?

**Experimental Plan:**

**Objective:** To investigate the effect of combining macrophage inhibition with CAR T cells targeting MUC1 glycoprotein on the formation of tertiary lymphoid structures, immune cell infiltration, and tumor regression in triple negative breast cancer.

**Experimental Design:**

1. **Mouse Model:** Use a triple negative breast cancer mouse model (e.g., MMTV-PyMT) to study the effect of the combination therapy.
2. **Treatment Groups:**
	* Group 1: Control (no treatment)
	* Group 2: Macrophage inhibition (using a macrophage inhibitor, e.g., CSF-1R inhibitor)
	* Group 3: CAR T cells targeting MUC1 glycoprotein (MUC28z CAR T cells)
	* Group 4: Combination therapy (macrophage inhibition + MUC28z CAR T cells)
3. **Tertiary Lymphoid Structure Analysis:**
	* Use immunohistochemistry (IHC) to analyze the formation of tertiary lymphoid structures in tumor tissues.
	* Stain for markers such as CD20 (B cells), CD4 (T cells), and CD31 (endothelial cells) to identify tertiary lymphoid structures.
4. **Immune Cell Infiltration Analysis:**
	* Use flow cytometry to analyze the infiltration of activated B cells (CD20+CD69+) and CD4+ T cells (CD4+CD69+) in tumor tissues.
5. **Tumor Regression Analysis:**
	* Measure tumor volume using calipers or imaging techniques (e.g., MRI).
	* Compare tumor regression in each treatment group.

**To Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to test the effect of depleting activated B cells and CD4+ T cells in mice treated with the combination therapy. This would involve:

1. **B Cell and CD4+ T Cell Depletion:**
	* Use antibodies to deplete activated B cells (CD20+CD69+) and CD4+ T cells (CD4+CD69+) in mice treated with the combination therapy.
2. **Tumor Regression Analysis:**
	* Measure tumor volume using calipers or imaging techniques (e.g., MRI).
	* Compare tumor regression in mice with and without B cell and CD4+ T cell depletion.

**Equipment and Resources:**

* Mouse model (MMTV-PyMT)
* Macrophage inhibitor (e.g., CSF-1R inhibitor)
* MUC28z CAR T cells
* Antibodies for flow cytometry (CD20, CD4, CD69)
* Immunohistochemistry reagents (CD20, CD4, CD31)
* Flow cytometer
* Imaging equipment (e.g., MRI)
* Calipers

**Timeline:**

* Week 1-2: Establish mouse model and treat with macrophage inhibitor and/or MUC28z CAR T cells
* Week 3-4: Analyze tertiary lymphoid structure formation and immune cell infiltration
* Week 5-6: Measure tumor volume and compare tumor regression
* Week 7-8: Deplete B cells and CD4+ T cells in mice treated with combination therapy and analyze tumor regression

**Budget:**

The budget for this experiment would depend on the specific reagents, equipment, and personnel required. However, a rough estimate would be:

* Mouse model and reagents: $5,000 - $10,000
* Macrophage inhibitor and MUC28z CAR T cells: $10,000 - $20,000
* Antibodies and immunohistochemistry reagents: $2,000 - $5,000
* Flow cytometer and imaging equipment: $10,000 - $20,000 (depending on the type and quality of equipment)
* Personnel and miscellaneous: $10,000 - $20,000

Total estimated budget: $47,000 - $95,000

This experiment can be completed within 8 weeks, and the budget can be adjusted based on the specific requirements and resources available.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Mouse Model Establishment and Treatment**

1.1. Obtain MMTV-PyMT triple negative breast cancer mouse model from a reputable vendor or breeding facility.

1.2. House mice in a specific pathogen-free (SPF) facility with ad libitum access to food and water.

1.3. Randomly assign mice to one of four treatment groups: Control (no treatment), Macrophage Inhibition, CAR T Cell Therapy, or Combination Therapy.

1.4. For Macrophage Inhibition group, administer CSF-1R inhibitor (e.g., 10 mg/kg) via intraperitoneal injection on days 1, 3, and 5.

1.5. For CAR T Cell Therapy group, administer MUC28z CAR T cells (e.g., 1 x 10^6 cells/mouse) via intravenous injection on day 1.

1.6. For Combination Therapy group, administer both CSF-1R inhibitor (days 1, 3, and 5) and MUC28z CAR T cells (day 1).

**Protocol 2: Tertiary Lymphoid Structure Analysis**

2.1. On day 14, sacrifice mice and harvest tumor tissues.

2.2. Fix tumor tissues in 10% formalin for 24 hours.

2.3. Embed tissues in paraffin and section into 5 μm thick slices.

2.4. Perform immunohistochemistry (IHC) staining for CD20, CD4, and CD31 using a standard IHC protocol.

2.5. Image stained sections using a microscope and capture images at 20x magnification.

2.6. Quantify tertiary lymphoid structures by counting the number of CD20+, CD4+, and CD31+ cells per high-power field (HPF).

**Protocol 3: Immune Cell Infiltration Analysis**

3.1. On day 14, sacrifice mice and harvest tumor tissues.

3.2. Prepare single-cell suspensions from tumor tissues using a gentleMACS dissociator.

3.3. Stain cells with fluorochrome-conjugated antibodies against CD20, CD4, and CD69.

3.4. Perform flow cytometry analysis using a flow cytometer (e.g., BD FACSCanto II).

3.5. Gate on CD20+CD69+ cells to identify activated B cells and CD4+CD69+ cells to identify activated CD4+ T cells.

3.6. Quantify the percentage of activated B cells and CD4+ T cells in each treatment group.

**Protocol 4: Tumor Regression Analysis**

4.1. Measure tumor volume using calipers on days 1, 7, 14, and 21.

4.2. Calculate tumor volume using the formula: V = (L x W x H) / 2, where L, W, and H are the length, width, and height of the tumor, respectively.

4.3. Compare tumor volume between treatment groups using a statistical analysis software (e.g., GraphPad Prism).

**Protocol 5: B Cell and CD4+ T Cell Depletion**

5.1. On day 14, administer antibodies against CD20 (e.g., 100 μg/mouse) and CD4 (e.g., 100 μg/mouse) via intraperitoneal injection to mice treated with Combination Therapy.

5.2. Repeat antibody administration every 3 days for a total of 3 injections.

5.3. Measure tumor volume on days 14, 17, and 21.

5.4. Compare tumor volume between mice with and without B cell and CD4+ T cell depletion using a statistical analysis software (e.g., GraphPad Prism).

**Protocol 6: Data Analysis and Interpretation**

6.1. Compile data from all experiments and perform statistical analysis using a software (e.g., GraphPad Prism).

6.2. Compare the formation of tertiary lymphoid structures, immune cell infiltration, and tumor regression between treatment groups.

6.3. Interpret results in the context of the hypothesis and discuss potential implications for cancer therapy.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific equipment, reagents, and personnel available. Additionally, the protocols should be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC) before conducting the experiment.","```
   CSF-1R Inhibitor (mg/kg)  MUC28z CAR T cells (x10^6)  CD20+ cells/HPF  CD4+ cells/HPF  CD31+ cells/HPF  Activated B cells (%)  Activated CD4+ T cells (%)  Tumor Volume (mm^3)
0                    5.0                  0.5             12.0             8.0             15.0               20.0                    30.0             150.0
1                    7.5                  1.0             15.0            12.0             20.0               25.0                    35.0             120.0
2                    0.0                  0.0              8.0             6.0             10.0               15.0                    20.0             200.0
3                   10.0                  1.5             18.0            15.0             25.0               30.0                    40.0              90.0
4                    5.0                  1.0             12.0            10.0             18.0               22.0                    32.0             140.0
5                    7.5                  0.5             14.0            11.0             19.0               24.0                    34.0             130.0
6                    0.0                  1.5              9.0             7.0             12.0               18.0                    25.0             220.0
7                   10.0                  0.0             16.0            13.0             22.0               28.0                    38.0             100.0
8                    5.0                  1.5             13.0            11.0             20.0               26.0                    36.0             110.0
9                    7.5                  1.0             15.0            12.0             21.0               29.0                    41.0             120.0
10                   0.0                  0.5              7.0             5.0              9.0               12.0                    18.0             240.0
11                   10.0                  1.5             19.0            16.0             27.0               32.0                    43.0              80.0
12                   5.0                  0.0             11.0             9.0             16.0               20.0                    28.0             160.0
13                   7.5                  1.5             16.0            14.0             24.0               30.0                    40.0             100.0
14                   0.0                  1.0              8.0             6.0             11.0               14.0                    20.0             200.0
15                   10.0                  0.5             17.0            15.0             26.0               31.0                    42.0              90.0
16                   5.0                  1.0             12.0            10.0             18.0               23.0                    33.0             140.0
17                   7.5                  0.0             13.0            11.0             19.0               25.0                    36.0             130.0
18                   0.0                  1.5              9.0             7.0             13.0               19.0                    26.0             220.0
19                   10.0                  1.0             18.0            16.0             28.0               33.0                    44.0              80.0
20                   5.0                  1.5             14.0            12.0             22.0               27.0                    38.0             110.0
21                   7.5                  1.5             17.0            15.0             27.0               32.0                    43.0             100.0
22                   0.0                  0.5              8.0             6.0             12.0               16.0                    22.0             240.0
23                   10.0                  0.0             19.0            17.0             30.0               35.0                    46.0              70.0
24                   5.0                  1.0             13.0            11.0             20.0               25.0                    36.0             130.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d7505c7a72541c6dc3edbedb31c456ad5f72ec87.summary'],"Does the combination of nilotinib and corticosteroids modulate the expression of immune checkpoint molecules on CD8+ T cells and natural killer cells, leading to a reduction in immune-mediated liver injury?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan:**

**Title:** Investigating the Modulation of Immune Checkpoint Molecules on CD8+ T cells and Natural Killer cells by Nilotinib and Corticosteroids in Immune-Mediated Liver Injury

**Objective:** To determine if the combination of nilotinib and corticosteroids modulates the expression of immune checkpoint molecules on CD8+ T cells and natural killer cells, leading to a reduction in immune-mediated liver injury.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate CD8+ T cells and natural killer cells from peripheral blood mononuclear cells (PBMCs) of healthy donors using flow cytometry.
	* Culture the isolated cells in a controlled environment with nilotinib (10 μM) and/or corticosteroids (e.g., prednisolone, 10 μM) for 24-48 hours.
2. **Flow Cytometry Analysis:**
	* Analyze the expression of immune checkpoint molecules (e.g., PD-1, CTLA-4, LAG-3) on CD8+ T cells and natural killer cells using flow cytometry.
	* Measure the mean fluorescence intensity (MFI) of each checkpoint molecule to quantify the expression levels.
3. **Cytokine Production Assay:**
	* Measure the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) by CD8+ T cells and natural killer cells using ELISA.
4. **Comparison and Statistical Analysis:**
	* Compare the expression levels of immune checkpoint molecules and cytokine production between the nilotinib-treated group, corticosteroid-treated group, and the combination group (nilotinib + corticosteroids).
	* Perform statistical analysis using ANOVA and post-hoc tests to determine significant differences between groups.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Modulation of Immune Checkpoint Molecules on CD8+ T cells and Natural Killer cells by Nilotinib and Corticosteroids in Immune-Mediated Liver Injury

**Objective:** To demonstrate that the combination of nilotinib and corticosteroids does not modulate the expression of immune checkpoint molecules on CD8+ T cells and natural killer cells, and therefore does not reduce immune-mediated liver injury.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate CD8+ T cells and natural killer cells from PBMCs of healthy donors using flow cytometry.
	* Culture the isolated cells in a controlled environment with nilotinib (10 μM) and/or corticosteroids (e.g., prednisolone, 10 μM) for 24-48 hours.
2. **Flow Cytometry Analysis:**
	* Analyze the expression of immune checkpoint molecules (e.g., PD-1, CTLA-4, LAG-3) on CD8+ T cells and natural killer cells using flow cytometry.
	* Measure the MFI of each checkpoint molecule to quantify the expression levels.
3. **Cytokine Production Assay:**
	* Measure the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) by CD8+ T cells and natural killer cells using ELISA.
4. **Comparison and Statistical Analysis:**
	* Compare the expression levels of immune checkpoint molecules and cytokine production between the nilotinib-treated group, corticosteroid-treated group, and the combination group (nilotinib + corticosteroids).
	* Perform statistical analysis using ANOVA and post-hoc tests to determine significant differences between groups.

**Key Predictions:**

* If the hypothesis is true, the combination of nilotinib and corticosteroids will decrease the expression of immune checkpoint molecules and pro-inflammatory cytokines on CD8+ T cells and natural killer cells, indicating a reduction in immune-mediated liver injury.
* If the hypothesis is false, the combination of nilotinib and corticosteroids will not modulate the expression of immune checkpoint molecules and pro-inflammatory cytokines on CD8+ T cells and natural killer cells, indicating no reduction in immune-mediated liver injury.

**Timeline and Budget:**

* The experiment can be completed within 6-8 weeks, considering the time required for cell isolation, culture, and analysis.
* The budget for this experiment will be approximately $10,000-$15,000, covering the costs of:
	+ Cell isolation and culture reagents
	+ Flow cytometry and ELISA kits
	+ Laboratory consumables and equipment
	+ Personnel and overhead costs

By following this experimental plan, we can test the hypothesis and determine whether the combination of nilotinib and corticosteroids modulates the expression of immune checkpoint molecules on CD8+ T cells and natural killer cells, leading to a reduction in immune-mediated liver injury.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Investigating the Modulation of Immune Checkpoint Molecules on CD8+ T cells and Natural Killer cells by Nilotinib and Corticosteroids in Immune-Mediated Liver Injury**

**Step 1: Cell Isolation and Culture**

1.1. Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors using a sterile technique.

1.2. Isolate CD8+ T cells and natural killer cells from PBMCs using flow cytometry-based cell sorting. Use the following markers for sorting:
	* CD8+ T cells: CD3+, CD8+, CD4-
	* Natural killer cells: CD3-, CD56+, CD16+

1.3. Culture the isolated cells in a controlled environment at 37°C, 5% CO2, and 95% humidity.

1.4. Prepare the following culture media:
	* RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
	* Add nilotinib (10 μM) and/or corticosteroids (e.g., prednisolone, 10 μM) to the culture media as follows:
		+ Nilotinib-treated group: Add 10 μM nilotinib to the culture media.
		+ Corticosteroid-treated group: Add 10 μM prednisolone to the culture media.
		+ Combination group: Add 10 μM nilotinib and 10 μM prednisolone to the culture media.

1.5. Incubate the cells for 24-48 hours.

**Step 2: Flow Cytometry Analysis**

2.1. Harvest the cells after 24-48 hours of incubation and wash them with PBS.

2.2. Stain the cells with the following antibodies:
	* Anti-PD-1 (PE-conjugated)
	* Anti-CTLA-4 (FITC-conjugated)
	* Anti-LAG-3 (APC-conjugated)

2.3. Perform flow cytometry analysis using a flow cytometer (e.g., BD FACSCanto II).

2.4. Measure the mean fluorescence intensity (MFI) of each checkpoint molecule to quantify the expression levels.

**Step 3: Cytokine Production Assay**

3.1. Harvest the cells after 24-48 hours of incubation and wash them with PBS.

3.2. Stimulate the cells with PMA (50 ng/mL) and ionomycin (1 μg/mL) for 4-6 hours to induce cytokine production.

3.3. Collect the supernatants and store them at -80°C until analysis.

3.4. Measure the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) using ELISA kits (e.g., R&D Systems).

**Step 4: Comparison and Statistical Analysis**

4.1. Compare the expression levels of immune checkpoint molecules and cytokine production between the nilotinib-treated group, corticosteroid-treated group, and the combination group (nilotinib + corticosteroids).

4.2. Perform statistical analysis using ANOVA and post-hoc tests (e.g., Tukey's test) to determine significant differences between groups.

**Experiment 2: Investigating the Lack of Modulation of Immune Checkpoint Molecules on CD8+ T cells and Natural Killer cells by Nilotinib and Corticosteroids in Immune-Mediated Liver Injury**

The protocol for Experiment 2 is identical to Experiment 1, with the exception of the objective and hypothesis.

**Note:**

* All experiments should be performed in triplicate to ensure reproducibility.
* All reagents and materials should be sterile and of high quality to minimize contamination and variability.
* The experimental design and protocols should be reviewed and approved by the Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC) before commencement.
* The results should be documented and reported in a clear and concise manner, including any deviations from the protocol or unexpected results.","```
   Nilotinib (μM)  Corticosteroids (μM)  CD8+ PD-1 MFI  CD8+ CTLA-4 MFI  CD8+ LAG-3 MFI  NK PD-1 MFI  NK CTLA-4 MFI  NK LAG-3 MFI  IFN-γ (pg/mL)  TNF-α (pg/mL)
0             0.0               0.0       100.0       150.0       120.0       80.0       100.0       90.0       500.0       200.0
1             5.0               0.0       90.0       140.0       110.0       70.0       90.0       80.0       450.0       180.0
2             10.0              0.0       80.0       130.0       100.0       60.0       80.0       70.0       400.0       160.0
3             0.0               5.0       110.0       160.0       130.0       90.0       110.0       100.0       550.0       220.0
4             5.0               5.0       100.0       150.0       120.0       80.0       100.0       90.0       500.0       200.0
5             10.0              5.0       90.0       140.0       110.0       70.0       90.0       80.0       450.0       180.0
6             0.0              10.0       120.0       170.0       140.0       100.0       120.0       110.0       600.0       240.0
7             5.0              10.0       110.0       160.0       130.0       90.0       110.0       100.0       550.0       220.0
8             10.0             10.0       100.0       150.0       120.0       80.0       100.0       90.0       500.0       200.0
9             0.0               0.0       100.0       150.0       120.0       80.0       100.0       90.0       500.0       200.0
10            5.0               0.0       90.0       140.0       110.0       70.0       90.0       80.0       450.0       180.0
11           10.0               0.0       80.0       130.0       100.0       60.0       80.0       70.0       400.0       160.0
12            0.0               5.0       110.0       160.0       130.0       90.0       110.0       100.0       550.0       220.0
13            5.0               5.0       100.0       150.0       120.0       80.0       100.0       90.0       500.0       200.0
14           10.0               5.0       90.0       140.0       110.0       70.0       90.0       80.0       450.0       180.0
15            0.0              10.0       120.0       170.0       140.0       100.0       120.0       110.0       600.0       240.0
16            5.0              10.0       110.0       160.0       130.0       90.0       110.0       100.0       550.0       220.0
17           10.0             10.0       100.0       150.0       120.0       80.0       100.0       90.0       500.0       200.0
18            2.5               2.5       105.0       155.0       125.0       85.0       105.0       95.0       525.0       210.0
19            7.5               2.5       95.0       145.0       115.0       75.0       95.0       85.0       475.0       190.0
20            2.5               7.5       115.0       165.0       135.0       95.0       115.0       105.0       575.0       230.0
21            7.5               7.5       105.0       155.0       125.0       85.0       105.0       95.0       525.0       210.0
22            0.0               2.5       108.0       158.0       128.0       88.0       108.0       98.0       530.0       215.0
23            0.0               7.5       118.0       168.0       138.0       98.0       118.0       108.0       580.0       235.0
24            2.5               0.0       98.0       148.0       118.0       78.0       98.0       88.0       480.0       195.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b8464e22fbf3177d91df0cb6ae3a0b6069c22b29.summary'],Does the combination of rituximab with an IGF-1R inhibitor enhance the therapeutic effect of rituximab in treating thyroid-associated ophthalmopathy by further reducing orbital tissue inflammation and expansion?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed an experimental plan to test its validity. Since the goal is to disprove the hypothesis, the experiment is designed to identify potential flaws or inconsistencies in the proposed combination therapy.

**Hypothesis:** The combination of rituximab with an IGF-1R inhibitor does not enhance the therapeutic effect of rituximab in treating thyroid-associated ophthalmopathy (TAO) by further reducing orbital tissue inflammation and expansion.

**Experimental Design:**

**Objective:** To investigate whether the addition of an IGF-1R inhibitor to rituximab treatment has a significant impact on orbital tissue inflammation and expansion in a TAO model.

**Model System:** Use a well-established mouse model of TAO, such as the immunization-induced TAO model, which mimics the human disease.

**Experimental Groups:**

1. Control group: Vehicle-treated mice (no rituximab or IGF-1R inhibitor)
2. Rituximab group: Mice treated with rituximab alone
3. Combination group: Mice treated with rituximab and an IGF-1R inhibitor (e.g., linsitinib)

**Experimental Protocol:**

1. Induce TAO in mice using the immunization protocol.
2. Randomly assign mice to one of the three experimental groups.
3. Treat mice with rituximab (intraperitoneal injection, 10 mg/kg, every 2 weeks) and/or IGF-1R inhibitor (oral gavage, 10 mg/kg, daily) for 6 weeks.
4. Monitor and record clinical signs of TAO, such as proptosis, lid swelling, and conjunctival redness, every week.
5. At the end of the 6-week treatment period, sacrifice the mice and collect orbital tissues for histological analysis.
6. Perform immunohistochemistry to assess inflammation (e.g., CD45, CD3, CD20) and fibrosis (e.g., collagen I, α-SMA) in orbital tissues.
7. Measure orbital tissue volume using micro-CT scans or histomorphometry.

**Endpoints:**

1. Clinical signs of TAO (proptosis, lid swelling, conjunctival redness)
2. Inflammation markers (CD45, CD3, CD20) in orbital tissues
3. Fibrosis markers (collagen I, α-SMA) in orbital tissues
4. Orbital tissue volume

**Sample Size:** 10-12 mice per group, assuming a moderate effect size (0.5) and a significance level of 0.05.

**Timeline:** 12 weeks (6 weeks for TAO induction, 6 weeks for treatment and data collection)

**Budget Breakdown:**

* Mouse model and husbandry: $5,000
* Reagents and consumables (rituximab, IGF-1R inhibitor, antibodies, etc.): $8,000
* Micro-CT scans and histomorphometry: $3,000
* Personnel and overheads: $10,000
* Total: $26,000

**Rationale:**

This experiment is designed to test the hypothesis by comparing the effects of rituximab alone versus the combination of rituximab and an IGF-1R inhibitor on orbital tissue inflammation and expansion in a TAO model. If the combination therapy does not show a significant improvement over rituximab alone, it would suggest that the addition of an IGF-1R inhibitor does not enhance the therapeutic effect of rituximab in TAO. The experiment is feasible within a reasonable time frame and budget, and the results will provide valuable insights into the potential benefits of combination therapy for TAO.",85,"Here is the detailed, step-by-step protocol for the experiment:

**Protocol: Investigating the Effect of Rituximab and IGF-1R Inhibitor Combination Therapy on Thyroid-Associated Ophthalmopathy (TAO) in a Mouse Model**

**Step 1: Induce TAO in Mice (Weeks 1-6)**

1.1. Obtain 30-36 mice (C57BL/6 or similar strain) and house them in a controlled environment with ad libitum access to food and water.

1.2. Immunize mice with a TAO-inducing antigen (e.g., thyroglobulin) according to a established protocol (e.g., 2 injections, 2 weeks apart, with Freund's adjuvant).

1.3. Monitor mice for signs of TAO, such as proptosis, lid swelling, and conjunctival redness, every week.

**Step 2: Randomization and Group Assignment (Week 6)**

2.1. Randomly assign mice to one of three experimental groups using a randomization software or table:
	* Control group (n=10-12): Vehicle-treated mice (no rituximab or IGF-1R inhibitor)
	* Rituximab group (n=10-12): Mice treated with rituximab alone
	* Combination group (n=10-12): Mice treated with rituximab and an IGF-1R inhibitor (e.g., linsitinib)

**Step 3: Treatment Administration (Weeks 6-12)**

3.1. Prepare rituximab (10 mg/kg) and IGF-1R inhibitor (10 mg/kg) solutions according to the manufacturer's instructions.

3.2. Administer rituximab to mice in the Rituximab and Combination groups via intraperitoneal injection every 2 weeks.

3.3. Administer IGF-1R inhibitor to mice in the Combination group via oral gavage daily.

3.4. Administer vehicle (e.g., PBS or saline) to mice in the Control group via intraperitoneal injection every 2 weeks.

**Step 4: Clinical Monitoring (Weeks 6-12)**

4.1. Monitor and record clinical signs of TAO, such as proptosis, lid swelling, and conjunctival redness, every week.

4.2. Take digital photographs of the eyes to document clinical signs.

**Step 5: Tissue Collection and Processing (Week 12)**

5.1. Sacrifice mice using a humane method (e.g., CO2 asphyxiation).

5.2. Collect orbital tissues (e.g., extraocular muscles, orbital fat, and connective tissue) and fix them in 4% paraformaldehyde for 24-48 hours.

5.3. Embed tissues in paraffin wax and section them into 5-μm thick slices.

**Step 6: Immunohistochemistry (Weeks 12-14)**

6.1. Perform immunohistochemistry on orbital tissue sections using the following antibodies:
	* CD45 (inflammation marker)
	* CD3 (T-cell marker)
	* CD20 (B-cell marker)
	* Collagen I (fibrosis marker)
	* α-SMA (fibrosis marker)

6.2. Use a standardized immunohistochemistry protocol, including antigen retrieval, blocking, and detection steps.

**Step 7: Micro-CT Scans and Histomorphometry (Weeks 14-16)**

7.1. Perform micro-CT scans on orbital tissues to measure tissue volume.

7.2. Use a micro-CT scanner with a resolution of 10-20 μm.

7.3. Analyze micro-CT scans using a software (e.g., ImageJ) to calculate orbital tissue volume.

7.4. Perform histomorphometry on orbital tissue sections to measure inflammation and fibrosis.

**Step 8: Data Analysis (Weeks 16-18)**

8.1. Compare clinical signs of TAO, inflammation markers, fibrosis markers, and orbital tissue volume between the three experimental groups.

8.2. Use statistical software (e.g., GraphPad Prism) to perform one-way ANOVA or Kruskal-Wallis tests, followed by post-hoc tests (e.g., Tukey's or Dunn's test) to determine significant differences between groups.

8.3. Calculate effect sizes and confidence intervals for each endpoint.

**Step 9: Data Interpretation and Reporting (Weeks 18-20)**

9.1. Interpret the results in the context of the hypothesis and research question.

9.2. Prepare a detailed report of the experiment, including materials, methods, results, and discussion.

9.3. Include tables, figures, and graphs to illustrate the data.

9.4. Draw conclusions based on the results and discuss the implications for the treatment of TAO.

By following this detailed protocol, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis and provide insights into the potential benefits of combination therapy for TAO.","```
   Rituximab (mg/kg)  IGF-1R Inhibitor (mg/kg)  TAO Signs  Inflammation  Fibrosis  Orbital Tissue Volume
0               5.0                    5.0       2.5       150.0     30.0               120.0
1               7.5                    2.5       1.8       120.0     25.0               110.0
2              10.0                    7.5       1.2       100.0     20.0               100.0
3               5.0                   10.0       2.2       130.0     28.0               115.0
4               2.5                    5.0       3.0       160.0     35.0               125.0
5              10.0                    5.0       1.5       110.0     22.0               105.0
6               7.5                   10.0       1.8       125.0     27.0               112.0
7               5.0                    2.5       2.8       145.0     32.0               118.0
8              10.0                    2.5       1.0       90.0      18.0                95.0
9               2.5                    7.5       3.2       165.0     38.0               130.0
10              5.0                    5.0       2.2       135.0     29.0               115.0
11              7.5                    5.0       1.6       115.0     24.0               108.0
12              10.0                   10.0       1.1       95.0      19.0                92.0
13              2.5                    2.5       3.5       170.0     40.0               135.0
14              5.0                    7.5       2.0       120.0     26.0               110.0
15              7.5                   10.0       1.4       105.0     21.0               102.0
16              10.0                    5.0       1.3       100.0     20.0               98.0
17              2.5                    5.0       3.8       180.0     42.0               140.0
18              5.0                    2.5       2.6       140.0     31.0               118.0
19              7.5                    5.0       1.7       115.0     23.0               108.0
20              10.0                   10.0       1.0       90.0      18.0                95.0
21              2.5                    7.5       3.9       185.0     44.0               145.0
22              5.0                    5.0       2.4       130.0     28.0               115.0
23              7.5                   10.0       1.5       110.0     22.0               105.0
24              10.0                    2.5       1.2       95.0      19.0                92.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0037a5a1e12ae47ff0f162c9dd8807606d2c5df8.summary'],Does the combination of single-cell RNA sequencing and epigenetic profiling enable the identification of a specific glioma subtype that is more responsive to CAR-T cell therapy targeting IL13Rα2?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** The combination of single-cell RNA sequencing and epigenetic profiling enables the identification of a specific glioma subtype that is more responsive to CAR-T cell therapy targeting IL13Rα2.

**Experimental Plan to Test the Hypothesis:**

**Objective:** To determine if the combination of single-cell RNA sequencing and epigenetic profiling can identify a specific glioma subtype that is more responsive to CAR-T cell therapy targeting IL13Rα2.

**Experimental Design:**

1. **Sample Collection:**
	* Collect glioma tumor samples from patients (n=20-30) with varying degrees of responsiveness to CAR-T cell therapy targeting IL13Rα2.
	* Ensure samples are fresh, frozen, or formalin-fixed paraffin-embedded (FFPE) and have corresponding clinical data.
2. **Single-Cell RNA Sequencing (scRNA-seq):**
	* Perform scRNA-seq on each tumor sample using a platform like 10x Genomics or BD Rhapsody to generate transcriptomic profiles.
	* Analyze data using tools like Seurat or Scanpy to identify distinct cell clusters and gene expression patterns.
3. **Epigenetic Profiling:**
	* Perform epigenetic profiling on each tumor sample using techniques like ChIP-seq, ATAC-seq, or reduced representation bisulfite sequencing (RRBS) to analyze histone modifications, chromatin accessibility, or DNA methylation.
	* Analyze data using tools like MACS2, HOMER, or Bismark to identify differentially regulated regions and epigenetic marks.
4. **Integration of scRNA-seq and Epigenetic Data:**
	* Integrate scRNA-seq and epigenetic data using tools like Seurat or Multi-Omics Factor Analysis (MOFA) to identify correlations between gene expression and epigenetic marks.
	* Identify specific glioma subtypes based on the integrated data.
5. **CAR-T Cell Therapy Response Analysis:**
	* Analyze the response of each glioma subtype to CAR-T cell therapy targeting IL13Rα2 using in vitro or in vivo assays.
	* Measure metrics like cell viability, proliferation, and cytokine production to assess therapy response.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the null hypothesis that the combination of single-cell RNA sequencing and epigenetic profiling does not enable the identification of a specific glioma subtype that is more responsive to CAR-T cell therapy targeting IL13Rα2.

**Experimental Design:**

1. **Randomized Sample Selection:**
	* Randomly select a subset of glioma tumor samples (n=10-15) from the original collection.
	* Ensure the selected samples have varying degrees of responsiveness to CAR-T cell therapy targeting IL13Rα2.
2. **Shuffled Data Analysis:**
	* Randomly shuffle the scRNA-seq and epigenetic data from the selected samples.
	* Analyze the shuffled data using the same tools and methods as before.
3. **Permutation Test:**
	* Perform a permutation test (e.g., 1000 iterations) to assess the significance of the observed correlations between gene expression, epigenetic marks, and CAR-T cell therapy response.
	* Calculate the proportion of permutations that yield similar or stronger correlations than the original data.
4. **Comparison to Original Results:**
	* Compare the results from the shuffled data analysis to the original results.
	* If the shuffled data yields similar or stronger correlations, it would suggest that the original results are due to chance, and the hypothesis is false.

**Budget and Timeframe:**

* Estimated budget: $200,000 - $300,000
* Estimated timeframe: 6-12 months

This experimental plan should provide a comprehensive approach to testing the hypothesis while being mindful of the limited budget and resources. The experiment to disprove the hypothesis will help to validate the results and increase confidence in the conclusions drawn from the study.",85,"I'd be happy to help you with that! Here are the detailed, step-by-step protocols for the experimental plan:

**Sample Collection:**

1.1. **Tumor Sample Collection:**

* Obtain 20-30 glioma tumor samples from patients with varying degrees of responsiveness to CAR-T cell therapy targeting IL13Rα2.
* Ensure samples are collected in accordance with institutional review board (IRB) guidelines and patient consent.
* Store samples in a -80°C freezer or liquid nitrogen tank for long-term preservation.

1.2. **Sample Preparation:**

* Thaw frozen samples or retrieve FFPE samples from storage.
* Cut samples into 5-10 mm³ pieces and place them in 1.5 mL microcentrifuge tubes.
* Add 1 mL of ice-cold PBS to each tube and gently vortex to wash the samples.
* Centrifuge at 300 x g for 5 minutes to remove excess PBS.
* Resuspend the samples in 1 mL of ice-cold PBS and store at 4°C until further processing.

**Single-Cell RNA Sequencing (scRNA-seq):**

2.1. **Sample Preparation for scRNA-seq:**

* Prepare single-cell suspensions from the tumor samples using a gentle dissociation protocol (e.g., papain-based dissociation).
* Filter the suspensions through a 40 μm cell strainer to remove debris and aggregates.
* Count the cells using a hemocytometer or an automated cell counter.
* Adjust the cell concentration to 1,000-2,000 cells/μL.

2.2. **scRNA-seq Library Preparation:**

* Use a 10x Genomics or BD Rhapsody platform to generate scRNA-seq libraries according to the manufacturer's instructions.
* Perform the following steps:
	+ Cell lysis and mRNA capture
	+ cDNA synthesis and amplification
	+ Library preparation and indexing
	+ Library quantification and quality control

2.3. **scRNA-seq Data Analysis:**

* Use Seurat or Scanpy to analyze the scRNA-seq data.
* Perform the following steps:
	+ Data import and quality control
	+ Cell filtering and normalization
	+ Dimensionality reduction (e.g., PCA, t-SNE)
	+ Clustering and cell type identification
	+ Differential gene expression analysis

**Epigenetic Profiling:**

3.1. **Sample Preparation for Epigenetic Profiling:**

* Prepare chromatin from the tumor samples using a chromatin preparation protocol (e.g., sonication-based protocol).
* Fragment the chromatin into 200-500 bp fragments using a Covaris or Bioruptor instrument.
* Purify the fragmented chromatin using a DNA purification kit.

3.2. **Epigenetic Profiling Library Preparation:**

* Use a ChIP-seq, ATAC-seq, or RRBS protocol to generate epigenetic profiling libraries according to the manufacturer's instructions.
* Perform the following steps:
	+ Immunoprecipitation (ChIP-seq) or tagmentation (ATAC-seq)
	+ Library preparation and indexing
	+ Library quantification and quality control

3.3. **Epigenetic Profiling Data Analysis:**

* Use MACS2, HOMER, or Bismark to analyze the epigenetic profiling data.
* Perform the following steps:
	+ Data import and quality control
	+ Peak calling and annotation
	+ Differential peak analysis
	+ Epigenetic mark identification and quantification

**Integration of scRNA-seq and Epigenetic Data:**

4.1. **Data Integration:**

* Use Seurat or MOFA to integrate the scRNA-seq and epigenetic data.
* Perform the following steps:
	+ Data import and quality control
	+ Feature selection and normalization
	+ Dimensionality reduction and clustering
	+ Correlation analysis and feature selection

4.2. **Glioma Subtype Identification:**

* Use the integrated data to identify specific glioma subtypes based on gene expression and epigenetic marks.
* Perform the following steps:
	+ Clustering and subtype identification
	+ Differential gene expression and epigenetic mark analysis
	+ Subtype validation using external datasets or biological pathways

**CAR-T Cell Therapy Response Analysis:**

5.1. **CAR-T Cell Preparation:**

* Prepare CAR-T cells targeting IL13Rα2 according to established protocols.
* Expand and activate the CAR-T cells using standard methods.

5.2. **In Vitro or In Vivo Assays:**

* Perform in vitro or in vivo assays to assess the response of each glioma subtype to CAR-T cell therapy.
* Measure metrics like cell viability, proliferation, and cytokine production using standard methods.

**Experiment to Disprove the Hypothesis:**

**Randomized Sample Selection:**

1.1. **Sample Randomization:**

* Randomly select a subset of 10-15 glioma tumor samples from the original collection.
* Ensure the selected samples have varying degrees of responsiveness to CAR-T cell therapy targeting IL13Rα2.

**Shuffled Data Analysis:**

2.1. **Data Shuffling:**

* Randomly shuffle the scRNA-seq and epigenetic data from the selected samples.
* Use a randomization algorithm (e.g., Fisher-Yates shuffle) to shuffle the data.

2.2. **Shuffled Data Analysis:**

* Analyze the shuffled data using the same tools and methods as before.
* Perform the following steps:
	+ Data import and quality control
	+ Feature selection and normalization
	+ Dimensionality reduction and clustering
	+ Correlation analysis and feature selection

**Permutation Test:**

3.1. **Permutation Test:**

* Perform a permutation test (e.g., 1000 iterations) to assess the significance of the observed correlations between gene expression, epigenetic marks, and CAR-T cell therapy response.
* Calculate the proportion of permutations that yield similar or stronger correlations than the original data.

**Comparison to Original Results:**

4.1. **Result Comparison:**

* Compare the results from the shuffled data analysis to the original results.
* If the shuffled data yields similar or stronger correlations, it would suggest that the original results are due to chance, and the hypothesis is false.

These detailed, step-by-step protocols should provide a comprehensive approach to testing the hypothesis while being mindful of the limited budget and resources.","```
   Tumor_Sample  CAR-T_Cell_Therapy  scRNA-seq_Library  Epigenetic_Profiling_Library  IL13Rα2_Expression  CAR-T_Cell_Response
0             20                  1.5                1000                         500                0.8                 0.4
1             25                  2.0                1200                         600                0.9                 0.6
2             22                  1.8                1100                         550                0.85                0.5
3             28                  2.2                1300                         650                0.92                0.7
4             24                  2.1                1250                         620                0.9                 0.65
5             21                  1.9                1050                         520                0.82                0.45
6             26                  2.3                1350                         680                0.95                0.75
7             23                  2.0                1150                         580                0.88                0.58
8             27                  2.4                1400                         700                0.97                0.8
9             20                  1.6                1000                         500                0.8                 0.42
10            25                  2.1                1200                         600                0.9                 0.62
11            22                  1.9                1100                         550                0.85                0.52
12            28                  2.3                1300                         650                0.92                0.72
13            24                  2.2                1250                         620                0.9                 0.68
14            21                  1.8                1050                         520                0.82                0.48
15            26                  2.4                1350                         680                0.95                0.78
16            23                  2.1                1150                         580                0.88                0.6
17            27                  2.5                1400                         700                0.97                0.82
18            20                  1.7                1000                         500                0.8                 0.44
19            25                  2.2                1200                         600                0.9                 0.64
20            22                  2.0                1100                         550                0.85                0.54
21            28                  2.4                1300                         650                0.92                0.74
22            24                  2.3                1250                         620                0.9                 0.7
23            21                  1.9                1050                         520                0.82                0.5
24            26                  2.5                1350                         680                0.95                0.8
```",0.970375470334995
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/046ce133b41bce5cad6473e2c0926816f464c702.summary'],"Does the combination of the three-gene signature (BTLA, BUB1B, and CENPE) with tumour mutation burden predict the response of EGFR-mutant lung adenocarcinoma patients to immune checkpoint inhibitors?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis and potentially disprove it. Since the goal is to disprove the hypothesis, the experiment will focus on finding evidence that contradicts the predicted correlation between the three-gene signature, tumour mutation burden, and response to immune checkpoint inhibitors in EGFR-mutant lung adenocarcinoma patients.

**Experimental Plan:**

**Title:** Investigating the Relationship Between the Three-Gene Signature, Tumour Mutation Burden, and Response to Immune Checkpoint Inhibitors in EGFR-Mutant Lung Adenocarcinoma Patients

**Objective:** To determine if the combination of the three-gene signature (BTLA, BUB1B, and CENPE) with tumour mutation burden can predict the response of EGFR-mutant lung adenocarcinoma patients to immune checkpoint inhibitors.

**Study Design:**

1. **Patient Selection:** Retrospective analysis of existing datasets or prospective collection of tumour samples from EGFR-mutant lung adenocarcinoma patients who have received immune checkpoint inhibitors.
2. **Gene Expression Analysis:** Measure the expression levels of BTLA, BUB1B, and CENPE using quantitative real-time PCR (qRT-PCR) or RNA sequencing (RNA-seq) in tumour samples.
3. **Tumour Mutation Burden Analysis:** Determine the tumour mutation burden using whole-exome sequencing (WES) or targeted sequencing of a panel of genes commonly mutated in lung adenocarcinoma.
4. **Response to Immunotherapy:** Evaluate the response to immune checkpoint inhibitors using radiological imaging (e.g., CT scans) and clinical assessment (e.g., RECIST criteria).
5. **Statistical Analysis:** Perform statistical analysis to correlate the three-gene signature, tumour mutation burden, and response to immunotherapy. Specifically:
	* Calculate the correlation coefficient (e.g., Pearson's r) between the three-gene signature and tumour mutation burden.
	* Perform a multivariate analysis (e.g., logistic regression) to assess the predictive power of the three-gene signature and tumour mutation burden on response to immunotherapy.
	* Compare the response rates between patients with high and low expression levels of the three-gene signature, as well as high and low tumour mutation burden.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, the experiment will focus on finding evidence that contradicts the predicted correlation between the three-gene signature, tumour mutation burden, and response to immune checkpoint inhibitors. Specifically:

1. **Null Hypothesis:** The three-gene signature and tumour mutation burden are not correlated with response to immune checkpoint inhibitors in EGFR-mutant lung adenocarcinoma patients.
2. **Alternative Hypothesis:** The three-gene signature and tumour mutation burden are correlated with response to immune checkpoint inhibitors in EGFR-mutant lung adenocarcinoma patients.
3. **Experimental Design:** The experiment will be designed to test the null hypothesis. If the results show no significant correlation between the three-gene signature, tumour mutation burden, and response to immunotherapy, it would suggest that the hypothesis is false.

**Resources and Timeline:**

* **Equipment:** qRT-PCR or RNA-seq instrument, WES or targeted sequencing platform, radiological imaging equipment, and statistical software.
* **Timeframe:** 6-12 months
* **Budget:** Moderate (dependent on the cost of sequencing and imaging equipment, as well as personnel and reagents)

By following this experimental plan, we can test the hypothesis and potentially disprove it, providing valuable insights into the relationship between the three-gene signature, tumour mutation burden, and response to immune checkpoint inhibitors in EGFR-mutant lung adenocarcinoma patients.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Selection**

1.1. **Retrospective Analysis:**

* Identify existing datasets of EGFR-mutant lung adenocarcinoma patients who have received immune checkpoint inhibitors.
* Ensure the datasets include clinical information, such as patient demographics, treatment regimens, and response to immunotherapy.
* Obtain Institutional Review Board (IRB) approval for the use of existing datasets.

1.2. **Prospective Collection:**

* Identify EGFR-mutant lung adenocarcinoma patients who are scheduled to receive immune checkpoint inhibitors.
* Obtain informed consent from patients for the collection and analysis of their tumour samples.
* Collect tumour samples (e.g., biopsies or surgical resections) from patients before and after treatment with immune checkpoint inhibitors.
* Store the samples in a biorepository at -80°C or in a liquid nitrogen tank.

**Protocol 2: Gene Expression Analysis**

2.1. **RNA Extraction:**

* Extract total RNA from tumour samples using a RNA extraction kit (e.g., TRIzol or RNeasy).
* Quantify the RNA concentration using a spectrophotometer (e.g., NanoDrop).
* Check the RNA quality using a bioanalyzer (e.g., Agilent 2100).

2.2. **qRT-PCR:**

* Design and synthesize primers specific to BTLA, BUB1B, and CENPE genes.
* Perform qRT-PCR using a qRT-PCR instrument (e.g., Applied Biosystems 7500) and a commercial qRT-PCR kit (e.g., TaqMan).
* Use a housekeeping gene (e.g., GAPDH) as an internal control.
* Analyze the qRT-PCR data using the instrument's software.

2.3. **RNA-seq:**

* Prepare RNA-seq libraries using a commercial kit (e.g., TruSeq).
* Sequence the libraries using a next-generation sequencing platform (e.g., Illumina HiSeq).
* Analyze the RNA-seq data using a bioinformatics pipeline (e.g., STAR, featureCounts, and DESeq2).

**Protocol 3: Tumour Mutation Burden Analysis**

3.1. **Whole-Exome Sequencing (WES):**

* Prepare WES libraries using a commercial kit (e.g., Agilent SureSelect).
* Sequence the libraries using a next-generation sequencing platform (e.g., Illumina HiSeq).
* Analyze the WES data using a bioinformatics pipeline (e.g., BWA, GATK, and MuTect).

3.2. **Targeted Sequencing:**

* Design and synthesize primers specific to a panel of genes commonly mutated in lung adenocarcinoma.
* Perform targeted sequencing using a commercial kit (e.g., Ion Torrent) and a next-generation sequencing platform (e.g., Ion Torrent PGM).
* Analyze the targeted sequencing data using a bioinformatics pipeline (e.g., Torrent Suite and Ion Reporter).

**Protocol 4: Response to Immunotherapy Evaluation**

4.1. **Radiological Imaging:**

* Perform CT scans or other radiological imaging modalities to evaluate tumour response to immunotherapy.
* Use RECIST criteria to assess tumour response.

4.2. **Clinical Assessment:**

* Evaluate patient clinical outcomes, such as overall survival, progression-free survival, and response rate.
* Use clinical assessment tools, such as the Eastern Cooperative Oncology Group (ECOG) performance status.

**Protocol 5: Statistical Analysis**

5.1. **Correlation Analysis:**

* Calculate the correlation coefficient (e.g., Pearson's r) between the three-gene signature and tumour mutation burden using statistical software (e.g., R or Python).
* Perform a multivariate analysis (e.g., logistic regression) to assess the predictive power of the three-gene signature and tumour mutation burden on response to immunotherapy.

5.2. **Comparison of Response Rates:**

* Compare the response rates between patients with high and low expression levels of the three-gene signature, as well as high and low tumour mutation burden.
* Use statistical software (e.g., R or Python) to perform the comparison and calculate the p-value.

**Quality Control and Assurance:**

* Perform quality control checks on all experimental steps, including RNA extraction, qRT-PCR, RNA-seq, WES, and targeted sequencing.
* Ensure that all equipment is properly calibrated and maintained.
* Use positive and negative controls in all experiments to ensure accuracy and specificity.

**Data Management and Storage:**

* Store all experimental data, including clinical information, gene expression data, and sequencing data, in a secure and backed-up database.
* Use data management software (e.g., LabKey or REDCap) to track and manage the data.
* Ensure that all data is anonymized and de-identified to protect patient confidentiality.","```
   TRIzol  RNeasy  TaqMan  GAPDH  Agilent  Illumina  Ion_Torrent  RECIST  ECOG  BTLA  BUB1B  CENPE  TMB  Response
0      10      5      20     10      15       30         20     1.0   0.5   2.5   1.8   3.2   450    Responsive
1       8      4      18      9      12       25         18     0.8   0.4   2.2   1.5   2.8   380    Non-Responsive
2      12      6      22     11      18       35         22     1.2   0.6   2.8   2.1   3.5   520    Responsive
3       9      5      19     10      14       28         20     0.9   0.5   2.4   1.7   3.0   400    Responsive
4      11      5      21     10      16       32         21     1.1   0.5   2.6   1.9   3.3   480    Responsive
5       7      4      17      9      11       23         19     0.7   0.4   2.0   1.4   2.6   350    Non-Responsive
6      10      5      20     10      15       30         20     1.0   0.5   2.5   1.8   3.2   450    Responsive
7       9      5      19     10      14       28         20     0.9   0.5   2.4   1.7   3.0   400    Responsive
8      12      6      22     11      18       35         22     1.2   0.6   2.8   2.1   3.5   520    Responsive
9       8      4      18      9      12       25         18     0.8   0.4   2.2   1.5   2.8   380    Non-Responsive
10     11      5      21     10      16       32         21     1.1   0.5   2.6   1.9   3.3   480    Responsive
11      7      4      17      9      11       23         19     0.7   0.4   2.0   1.4   2.6   350    Non-Responsive
12     10      5      20     10      15       30         20     1.0   0.5   2.5   1.8   3.2   450    Responsive
13      9      5      19     10      14       28         20     0.9   0.5   2.4   1.7   3.0   400    Responsive
14     12      6      22     11      18       35         22     1.2   0.6   2.8   2.1   3.5   520    Responsive
15      8      4      18      9      12       25         18     0.8   0.4   2.2   1.5   2.8   380    Non-Responsive
16     11      5      21     10      16       32         21     1.1   0.5   2.6   1.9   3.3   480    Responsive
17      7      4      17      9      11       23         19     0.7   0.4   2.0   1.4   2.6   350    Non-Responsive
18     10      5      20     10      15       30         20     1.0   0.5   2.5   1.8   3.2   450    Responsive
19      9      5      19     10      14       28         20     0.9   0.5   2.4   1.7   3.0   400    Responsive
20     12      6      22     11      18       35         22     1.2   0.6   2.8   2.1   3.5   520    Responsive
21      8      4      18      9      12       25         18     0.8   0.4   2.2   1.5   2.8   380    Non-Responsive
22     11      5      21     10      16       32         21     1.1   0.5   2.6   1.9   3.3   480    Responsive
23      7      4      17      9      11       23         19     0.7   0.4   2.0   1.4   2.6   350    Non-Responsive
24     10      5      20     10      15       30         20     1.0   0.5   2.5   1.8   3.2   450    Responsive
```",0.8374623148611048
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/31f2b1ca21d4e8847cc2bbcc8dfe1d7517002449.summary'],Does the combined inhibition of HDAC and glutathione synthesis in OxPhos-DLBCL cells lead to a synergistic increase in pracinostat-induced apoptosis?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Does the combined inhibition of HDAC and glutathione synthesis in OxPhos-DLBCL cells lead to a synergistic increase in pracinostat-induced apoptosis?""

**Experimental Plan:**

**Objective:** To investigate whether the combined inhibition of HDAC and glutathione synthesis in OxPhos-DLBCL cells leads to a synergistic increase in pracinostat-induced apoptosis.

**Materials:**

* OxPhos-DLBCL cell lines
* Pracinostat
* HDAC inhibitors (e.g., vorinostat)
* Glutathione synthesis inhibitors (e.g., buthionine sulfoximine, BSO)
* Apoptosis assays (e.g., Annexin V/PI staining, Caspase-3/7 activity assay)
* Cell viability assays (e.g., MTT, CellTiter-Glo)
* Western blotting equipment
* Antibodies for acetylated histone H3, cleaved PARP, and glutathione-related proteins (e.g., GCLC, GSS)

**Experimental Design:**

1. **Control and single-treatment groups:**
	* Treat OxPhos-DLBCL cells with:
		+ Vehicle control (DMSO)
		+ Pracinostat (alone)
		+ HDAC inhibitor (alone)
		+ Glutathione synthesis inhibitor (alone)
2. **Combination treatment groups:**
	* Treat OxPhos-DLBCL cells with:
		+ Pracinostat + HDAC inhibitor
		+ Pracinostat + glutathione synthesis inhibitor
		+ Pracinostat + HDAC inhibitor + glutathione synthesis inhibitor
3. **Apoptosis and cell viability assays:**
	* Perform apoptosis assays (Annexin V/PI staining, Caspase-3/7 activity assay) 24-48 hours after treatment.
	* Perform cell viability assays (MTT, CellTiter-Glo) 24-72 hours after treatment.
4. **Western blotting:**
	* Analyze protein acetylation (acetylated histone H3), apoptosis markers (cleaved PARP), and glutathione-related proteins (GCLC, GSS) 24-48 hours after treatment.

**To disprove the hypothesis:**

* If the combined inhibition of HDAC and glutathione synthesis does not lead to a synergistic increase in pracinostat-induced apoptosis, the results should show:
	+ No significant difference in apoptosis levels between the combination treatment groups and the single-treatment groups.
	+ No significant difference in cell viability between the combination treatment groups and the single-treatment groups.
	+ No changes in protein acetylation, apoptosis markers, or glutathione-related proteins in the combination treatment groups compared to the single-treatment groups.

**Time and resource considerations:**

* The experiment can be completed within 2-3 weeks, assuming a 5-day cell culture period and 1-2 days for each assay.
* The required resources include:
	+ Cell culture facilities and equipment
	+ Apoptosis and cell viability assay kits
	+ Western blotting equipment and reagents
	+ Antibodies and chemicals (pracinostat, HDAC inhibitors, glutathione synthesis inhibitors)
	+ Laboratory personnel and technical support

**Budget:**

* The estimated budget for this experiment is moderate, considering the cost of:
	+ Cell culture reagents and media
	+ Apoptosis and cell viability assay kits
	+ Western blotting equipment and reagents
	+ Antibodies and chemicals
	+ Laboratory personnel and technical support

This experimental plan is designed to test the hypothesis and provide a clear answer to whether the combined inhibition of HDAC and glutathione synthesis leads to a synergistic increase in pracinostat-induced apoptosis in OxPhos-DLBCL cells.",85,"Here is the detailed, step-by-step protocol for the experimental plan:

**Protocol: Investigating the Synergistic Effect of HDAC and Glutathione Synthesis Inhibition on Pracinostat-Induced Apoptosis in OxPhos-DLBCL Cells**

**Day 1-5: Cell Culture and Treatment Preparation**

1.1. Obtain OxPhos-DLBCL cell lines and maintain them in a humidified incubator at 37°C, 5% CO2.

1.2. Prepare the following stock solutions:
	* Pracinostat (10 mM in DMSO)
	* HDAC inhibitor (vorinostat, 10 mM in DMSO)
	* Glutathione synthesis inhibitor (buthionine sulfoximine, BSO, 10 mM in PBS)
	* Vehicle control (DMSO)

1.3. Prepare the treatment media by diluting the stock solutions in complete cell culture media to the desired concentrations:
	* Pracinostat: 1-5 μM
	* HDAC inhibitor: 1-5 μM
	* Glutathione synthesis inhibitor: 1-5 μM

**Day 5: Cell Seeding and Treatment**

2.1. Seed 1-2 x 10^5 OxPhos-DLBCL cells per well in a 6-well plate or 96-well plate, depending on the assay requirements.

2.2. Treat the cells with the prepared media containing:
	* Vehicle control (DMSO)
	* Pracinostat (alone)
	* HDAC inhibitor (alone)
	* Glutathione synthesis inhibitor (alone)
	* Pracinostat + HDAC inhibitor
	* Pracinostat + glutathione synthesis inhibitor
	* Pracinostat + HDAC inhibitor + glutathione synthesis inhibitor

**Day 6-7: Apoptosis Assays**

3.1. Perform Annexin V/PI staining:
	* Collect cells from each treatment group and wash them with PBS.
	* Resuspend cells in 100 μL of Annexin V binding buffer containing 5 μL of Annexin V-FITC and 5 μL of PI.
	* Incubate for 15 minutes at room temperature in the dark.
	* Analyze by flow cytometry.

3.2. Perform Caspase-3/7 activity assay:
	* Collect cells from each treatment group and wash them with PBS.
	* Lyse cells in 50 μL of lysis buffer.
	* Add 50 μL of Caspase-3/7 substrate and incubate for 1 hour at 37°C.
	* Measure fluorescence at 405 nm using a plate reader.

**Day 6-8: Cell Viability Assays**

4.1. Perform MTT assay:
	* Add 10 μL of MTT reagent to each well and incubate for 2-4 hours at 37°C.
	* Add 100 μL of DMSO to each well and measure absorbance at 570 nm using a plate reader.

4.2. Perform CellTiter-Glo assay:
	* Add 100 μL of CellTiter-Glo reagent to each well and incubate for 10-15 minutes at room temperature.
	* Measure luminescence using a plate reader.

**Day 6-7: Western Blotting**

5.1. Collect cells from each treatment group and wash them with PBS.
5.2. Lyse cells in 50 μL of RIPA buffer containing protease and phosphatase inhibitors.
5.3. Perform Western blotting using the following antibodies:
	* Acetylated histone H3
	* Cleaved PARP
	* GCLC
	* GSS
5.4. Analyze protein expression using densitometry software.

**Data Analysis**

6.1. Calculate the percentage of apoptotic cells using Annexin V/PI staining and Caspase-3/7 activity assay data.
6.2. Calculate cell viability using MTT and CellTiter-Glo assay data.
6.3. Analyze protein expression using Western blotting data.
6.4. Compare the results between the combination treatment groups and the single-treatment groups to determine if the combined inhibition of HDAC and glutathione synthesis leads to a synergistic increase in pracinostat-induced apoptosis.

**Quality Control**

7.1. Verify the identity and purity of the OxPhos-DLBCL cell lines.
7.2. Validate the efficacy of the HDAC inhibitor and glutathione synthesis inhibitor using Western blotting and apoptosis assays.
7.3. Ensure proper antibody specificity and validation for Western blotting.

By following this detailed protocol, the experiment can be completed within 2-3 weeks, and the results will provide a clear answer to whether the combined inhibition of HDAC and glutathione synthesis leads to a synergistic increase in pracinostat-induced apoptosis in OxPhos-DLBCL cells.","```
   Pracinostat  HDAC_Inhibitor  Glutathione_Inhibitor  Apoptosis_Rate
0           1.0             0.0                  0.0       0.250000
1           2.0             0.0                  0.0       0.350000
2           3.0             0.0                  0.0       0.450000
3           4.0             0.0                  0.0       0.550000
4           5.0             0.0                  0.0       0.650000
5           1.0             1.0                  0.0       0.400000
6           2.0             1.0                  0.0       0.500000
7           3.0             1.0                  0.0       0.600000
8           4.0             1.0                  0.0       0.700000
9           5.0             1.0                  0.0       0.800000
10          1.0             0.0                  1.0       0.300000
11          2.0             0.0                  1.0       0.400000
12          3.0             0.0                  1.0       0.500000
13          4.0             0.0                  1.0       0.600000
14          5.0             0.0                  1.0       0.700000
15          1.0             1.0                  1.0       0.550000
16          2.0             1.0                  1.0       0.650000
17          3.0             1.0                  1.0       0.750000
18          4.0             1.0                  1.0       0.850000
19          5.0             1.0                  1.0       0.950000
20          1.0             2.0                  0.0       0.450000
21          2.0             2.0                  0.0       0.550000
22          3.0             2.0                  0.0       0.650000
23          4.0             2.0                  0.0       0.750000
24          5.0             2.0                  0.0       0.850000
```",0.46558289341398557
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1a75c56cd26a7d3131f88732903f0fe6b8edcf5d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ce7e9d567e142e7c903b3782e59cdd9bc7cafc6f.summary']",Does the combined inhibition of the BAFF system and LAG3 signaling pathways synergistically prevent the development of chronic allograft damage and antibody-mediated rejection in kidney transplant recipients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the two papers, I will design an experiment to test the hypothesis and potentially disprove it.

**Hypothesis:** The combined inhibition of the BAFF system and LAG3 signaling pathways synergistically prevents the development of chronic allograft damage and antibody-mediated rejection in kidney transplant recipients.

**Experimental Design:**

**Title:** Inhibition of BAFF system and LAG3 signaling in kidney transplant recipients: A randomized controlled trial

**Objective:** To investigate the effect of combined inhibition of the BAFF system and LAG3 signaling on the development of chronic allograft damage and antibody-mediated rejection in kidney transplant recipients.

**Design:** A randomized, double-blind, placebo-controlled trial with four arms:

1. BAFF system inhibitor (BAFFi) + LAG3 inhibitor (LAG3i)
2. BAFFi + placebo
3. LAG3i + placebo
4. Placebo + placebo

**Participants:** Kidney transplant recipients (n = 200) will be recruited and randomly assigned to one of the four arms.

**Intervention:**

* BAFFi: A specific inhibitor of the BAFF system will be administered to participants in arms 1 and 2.
* LAG3i: A specific inhibitor of LAG3 signaling will be administered to participants in arms 1 and 3.
* Placebo: Participants in arms 2, 3, and 4 will receive a placebo.

**Outcome measures:**

* Incidence of chronic allograft damage (assessed by histopathological analysis of biopsy samples)
* Incidence of antibody-mediated rejection (assessed by detection of donor-specific antibodies in serum)
* Graft survival
* Expression of BAFF system genes (APRIL, BCMA, TACI) and LAG3 in peripheral blood and biopsy samples
* Frequency of B cells and antibody production (assessed by flow cytometry and ELISPOT assay)

**Equipment:**

* Real-time PCR
* Flow cytometer
* ELISPOT assay
* Histopathological analysis equipment
* Antibodies against BAFF system genes, LAG3, and B cell surface markers

**Steps:**

1. Recruit kidney transplant recipients and randomize them to one of the four arms.
2. Collect blood and biopsy samples at baseline, 3 months, and 6 months post-transplantation.
3. Measure the expression of BAFF system genes and LAG3 using real-time PCR.
4. Analyze the frequency of B cells and antibody production using flow cytometry and ELISPOT assay.
5. Perform histopathological analysis of biopsy samples to assess chronic allograft damage.
6. Compare the incidence of chronic allograft damage, antibody-mediated rejection, and graft survival between the four arms.

**Sample size calculation:**

Based on the previous studies, we assume a 30% reduction in chronic allograft damage and antibody-mediated rejection in the combined inhibition group compared to the placebo group. With a power of 80% and a significance level of 0.05, we calculate a sample size of 200 participants (50 per arm).

**Timeline:**

* Recruitment and randomization: 6 months
* Intervention and data collection: 12 months
* Data analysis: 12 months
* Manuscript preparation and submission: 6 months

**Budget:**

The budget for this study will cover the costs of:

* Participant recruitment and randomization
* Intervention (BAFFi and LAG3i)
* Laboratory tests (real-time PCR, flow cytometry, ELISPOT assay, histopathological analysis)
* Equipment and supplies
* Personnel (research assistants, laboratory technicians, statisticians)
* Travel and training for researchers

With an unlimited budget, we can ensure that the study is well-powered, and the data collection and analysis are of high quality.

This experiment is designed to test the hypothesis and potentially disprove it. If the results show that the combined inhibition of the BAFF system and LAG3 signaling does not synergistically prevent chronic allograft damage and antibody-mediated rejection, it would suggest that the hypothesis is false.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Participant Recruitment and Randomization**

1.1. Identify potential kidney transplant recipients through collaboration with transplant centers and nephrologists.

1.2. Screen potential participants for eligibility based on inclusion and exclusion criteria (e.g., age, transplant type, comorbidities).

1.3. Obtain informed consent from eligible participants.

1.4. Randomly assign participants to one of the four arms using a computer-generated randomization program.

1.5. Assign a unique identifier to each participant and maintain a master list of participant assignments.

**Protocol 2: Intervention Administration**

2.1. Prepare BAFF system inhibitor (BAFFi) and LAG3 inhibitor (LAG3i) according to the manufacturer's instructions.

2.2. Administer BAFFi to participants in arms 1 and 2, and LAG3i to participants in arms 1 and 3, according to the specified dosing schedule.

2.3. Administer placebo to participants in arms 2, 3, and 4.

2.4. Ensure that participants and study personnel are blinded to treatment assignments.

**Protocol 3: Blood and Biopsy Sample Collection**

3.1. Collect blood samples from participants at baseline, 3 months, and 6 months post-transplantation.

3.2. Collect biopsy samples from participants at 3 months and 6 months post-transplantation.

3.3. Label and store samples according to standard laboratory protocols.

**Protocol 4: Real-time PCR Analysis**

4.1. Extract RNA from blood and biopsy samples using a standardized protocol.

4.2. Design and validate primers for BAFF system genes (APRIL, BCMA, TACI) and LAG3.

4.3. Perform real-time PCR using a validated protocol and analyze data using a standard software package.

**Protocol 5: Flow Cytometry and ELISPOT Assay**

5.1. Prepare peripheral blood mononuclear cells (PBMCs) from blood samples.

5.2. Stain PBMCs with antibodies against B cell surface markers (e.g., CD19, CD20) and analyze using a flow cytometer.

5.3. Perform ELISPOT assay to measure antibody production using a standardized protocol.

**Protocol 6: Histopathological Analysis**

6.1. Fix and process biopsy samples according to standard histopathological protocols.

6.2. Stain sections with hematoxylin and eosin (H&E) and perform immunohistochemistry for BAFF system genes and LAG3.

6.3. Evaluate biopsy samples for chronic allograft damage using a standardized scoring system.

**Protocol 7: Data Analysis**

7.1. Compare the incidence of chronic allograft damage, antibody-mediated rejection, and graft survival between the four arms using statistical software.

7.2. Analyze the expression of BAFF system genes and LAG3 in peripheral blood and biopsy samples using real-time PCR data.

7.3. Analyze the frequency of B cells and antibody production using flow cytometry and ELISPOT assay data.

**Protocol 8: Quality Control and Assurance**

8.1. Implement quality control measures for laboratory tests, including real-time PCR, flow cytometry, and ELISPOT assay.

8.2. Perform regular calibration and maintenance of equipment.

8.3. Monitor data collection and analysis for errors and inconsistencies.

These detailed protocols ensure that the experiment is conducted in a rigorous and reproducible manner, with attention to quality control and assurance.","```
   BAFFi  LAG3i  Placebo  APRIL  BCMA  TACI  CD19  CD20  ELISPOT  H&E  Outcome
0      2      0       1   0.45  0.67  0.82   0.91  0.78     120   2.1       1
1      1      1       0   0.38  0.59  0.75   0.85  0.72     100   1.9       0
2      0      2       1   0.52  0.71  0.88   0.93  0.81     130   2.3       1
3      1      0       1   0.41  0.63  0.79   0.89  0.76     110   2.0       0
4      2      1       0   0.48  0.69  0.85   0.92  0.80     125   2.2       1
5      0      1       1   0.36  0.58  0.73   0.84  0.70     105   1.8       0
6      1      2       0   0.44  0.66  0.82   0.90  0.79     115   2.1       1
7      2      0       1   0.46  0.68  0.84   0.91  0.81     120   2.2       1
8      0      0       2   0.34  0.55  0.70   0.82  0.68     100   1.7       0
9      1      1       1   0.40  0.62  0.78   0.88  0.75     110   2.0       0
10     2      2       0   0.50  0.72  0.90   0.94  0.83     135   2.4       1
11     0      1       1   0.39  0.61  0.77   0.87  0.74     105   1.9       0
12     1      0       2   0.43  0.65  0.81   0.90  0.78     115   2.1       0
13     2      1       1   0.49  0.71  0.87   0.93  0.82     130   2.3       1
14     0      2       1   0.37  0.60  0.75   0.86  0.73     100   1.8       0
15     1      2       0   0.45  0.68  0.84   0.92  0.80     120   2.2       1
16     2      0       2   0.48  0.70  0.86   0.91  0.81     125   2.2       1
17     0      1       2   0.35  0.57  0.72   0.84  0.71     100   1.7       0
18     1      1       2   0.42  0.64  0.80   0.89  0.77     110   2.0       0
19     2      2       1   0.51  0.73  0.90   0.94  0.84     140   2.5       1
20     0      0       2   0.33  0.54  0.69   0.82  0.67     95    1.6       0
21     1      2       1   0.44  0.67  0.83   0.91  0.80     120   2.2       1
22     2      1       2   0.50  0.72  0.89   0.94  0.83     135   2.4       1
23     0      1       2   0.38  0.61  0.76   0.87  0.74     105   1.9       0
24     1      0       2   0.43  0.66  0.82   0.90  0.79     115   2.1       0
```",0.6381116913219982
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c32e84c03ea240bacd7ed922da3a9ca9920128e7.summary'],"Does the conformational change induced by ppITAM binding to SYK also influence the binding affinity of LYN, thereby modulating the full activation of SYK?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis: ""Does the conformational change induced by ppITAM binding to SYK also influence the binding affinity of LYN, thereby modulating the full activation of SYK?""

**Experiment:**

**Title:** Investigating the effect of ppITAM-induced conformational change on LYN binding affinity to SYK

**Objective:** To determine if the conformational change induced by ppITAM binding to SYK affects the binding affinity of LYN, thereby modulating the full activation of SYK.

**Experimental Design:**

1. **Protein preparation:**
	* Purify SYK protein using standard protein purification techniques (e.g., affinity chromatography, gel filtration).
	* Prepare ppITAM peptide and LYN protein using established protocols.
2. **Conformational change induction:**
	* Incubate SYK protein with ppITAM peptide at varying concentrations (e.g., 0, 1, 5, 10 μM) for 30 minutes at room temperature.
	* Use a control sample without ppITAM peptide as a reference.
3. **LYN binding assay:**
	* Use a surface plasmon resonance (SPR) or biolayer interferometry (BLI) assay to measure the binding affinity of LYN to SYK in the presence or absence of ppITAM peptide.
	* Immobilize SYK protein on a sensor chip or biosensor, and flow LYN protein over the surface at varying concentrations (e.g., 0, 1, 5, 10 μM).
	* Measure the binding response (e.g., resonance units or binding signal) as a function of LYN concentration.
4. **Data analysis:**
	* Compare the binding curves of LYN to SYK in the presence and absence of ppITAM peptide.
	* Calculate the binding affinity (KD) of LYN to SYK using nonlinear regression analysis.
	* Determine if the conformational change induced by ppITAM binding affects the binding affinity of LYN to SYK.

**Expected outcomes:**

* If the hypothesis is true, the binding affinity of LYN to SYK should increase in the presence of ppITAM peptide, indicating that the conformational change induced by ppITAM binding enhances LYN binding.
* If the hypothesis is false, the binding affinity of LYN to SYK should remain unchanged or decrease in the presence of ppITAM peptide, suggesting that the conformational change does not affect LYN binding.

**Resources and budget:**

* Purified SYK protein and ppITAM peptide: $1,000 - $2,000
* LYN protein: $500 - $1,000
* SPR or BLI instrument: $5,000 - $10,000 (depending on the instrument and rental/usage fees)
* Consumables (e.g., sensor chips, buffers): $1,000 - $2,000
* Personnel and labor costs: $5,000 - $10,000 (depending on the number of personnel and time required)

**Timeline:**

* Protein preparation and purification: 2-3 weeks
* Conformational change induction and LYN binding assay: 2-3 weeks
* Data analysis and interpretation: 1-2 weeks

Total estimated time: 5-8 weeks

This experiment is designed to test the hypothesis in a controlled and quantitative manner, using established techniques and instruments. The results will provide valuable insights into the mechanism of SYK activation and the role of ppITAM-induced conformational change in modulating LYN binding affinity.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Protein Preparation**

**Step 1.1: Purification of SYK Protein**

1.1.1. Prepare a 1 L culture of E. coli cells expressing SYK protein.
1.1.2. Harvest the cells by centrifugation at 4°C, 5,000 x g for 10 minutes.
1.1.3. Resuspend the cell pellet in 20 mL of lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100).
1.1.4. Lyse the cells using a French press or sonication.
1.1.5. Centrifuge the lysate at 4°C, 10,000 x g for 30 minutes.
1.1.6. Apply the supernatant to a Ni-NTA agarose column (e.g., Qiagen) equilibrated with lysis buffer.
1.1.7. Wash the column with 10 column volumes of wash buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 20 mM imidazole).
1.1.8. Elute the SYK protein with 5 column volumes of elution buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 250 mM imidazole).
1.1.9. Concentrate the eluate using a centrifugal filter device (e.g., Amicon Ultra-15).
1.1.10. Determine the protein concentration using a spectrophotometer (e.g., NanoDrop).

**Step 1.2: Preparation of ppITAM Peptide**

1.2.1. Synthesize the ppITAM peptide using a peptide synthesizer or purchase from a commercial vendor.
1.2.2. Purify the peptide using high-performance liquid chromatography (HPLC) or reverse-phase chromatography.
1.2.3. Lyophilize the purified peptide and store at -20°C.

**Step 1.3: Preparation of LYN Protein**

1.3.1. Express and purify LYN protein using established protocols (e.g., insect cell expression, affinity chromatography).
1.3.2. Concentrate the purified LYN protein using a centrifugal filter device (e.g., Amicon Ultra-15).
1.3.3. Determine the protein concentration using a spectrophotometer (e.g., NanoDrop).

**Protocol 2: Conformational Change Induction**

**Step 2.1: Incubation of SYK with ppITAM Peptide**

2.1.1. Prepare a series of tubes containing 100 μL of SYK protein (1 μM) in binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA).
2.1.2. Add ppITAM peptide to the tubes at varying concentrations (0, 1, 5, 10 μM).
2.1.3. Incubate the mixtures at room temperature for 30 minutes.
2.1.4. Use a control sample without ppITAM peptide as a reference.

**Protocol 3: LYN Binding Assay**

**Step 3.1: Immobilization of SYK Protein on Sensor Chip**

3.1.1. Prepare a sensor chip (e.g., Biacore CM5 chip) according to the manufacturer's instructions.
3.1.2. Immobilize 100 μL of SYK protein (1 μM) on the sensor chip using amine coupling chemistry.
3.1.3. Block any remaining active groups on the chip with 100 μL of ethanolamine (1 M).

**Step 3.2: LYN Binding Assay**

3.2.1. Prepare a series of tubes containing 100 μL of LYN protein (0, 1, 5, 10 μM) in binding buffer.
3.2.2. Flow the LYN protein over the immobilized SYK protein on the sensor chip at a flow rate of 30 μL/min.
3.2.3. Measure the binding response (e.g., resonance units or binding signal) using a surface plasmon resonance (SPR) or biolayer interferometry (BLI) instrument.
3.2.4. Repeat the binding assay for each ppITAM peptide concentration.

**Protocol 4: Data Analysis**

**Step 4.1: Data Collection and Processing**

4.1.1. Collect the binding response data from the SPR or BLI instrument.
4.1.2. Process the data using the instrument's software to obtain the binding curves.

**Step 4.2: Nonlinear Regression Analysis**

4.2.1. Use nonlinear regression analysis software (e.g., GraphPad Prism) to fit the binding curves to a binding model (e.g., Langmuir binding isotherm).
4.2.2. Calculate the binding affinity (KD) of LYN to SYK in the presence and absence of ppITAM peptide.

**Step 4.3: Data Interpretation**

4.3.1. Compare the binding curves and KD values in the presence and absence of ppITAM peptide.
4.3.2. Determine if the conformational change induced by ppITAM binding affects the binding affinity of LYN to SYK.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   SYK_protein(ppM)  ppITAM_peptide(ppM)  LYN_protein(ppM)  Binding_Response
0               100.0               0.0           10.0       200.0
1               120.0               1.0           15.0       250.0
2               100.0               5.0           10.0       300.0
3               80.0                0.0           5.0        150.0
4               150.0               10.0          20.0       400.0
5               100.0               0.0           10.0       200.0
6               90.0                1.0           8.0        220.0
7               110.0               5.0           12.0       320.0
8               120.0               0.0           15.0       250.0
9               100.0               10.0          10.0       350.0
10              130.0               1.0           18.0       280.0
11              100.0               5.0           10.0       300.0
12              140.0               0.0           20.0       300.0
13              110.0               10.0          12.0       380.0
14              100.0               0.0           10.0       200.0
15              120.0               5.0           15.0       320.0
16              150.0               1.0           25.0       350.0
17              100.0               10.0          10.0       400.0
18              130.0               0.0           18.0       280.0
19              110.0               5.0           12.0       320.0
20              140.0               1.0           20.0       300.0
21              120.0               10.0          15.0       380.0
22              100.0               0.0           10.0       200.0
23              150.0               5.0           25.0       350.0
24              130.0               10.0          18.0       400.0
```",0.6254507272078209
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/558bb3b23504b872c9c9efbf1a041c48afd48adf.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/02860c047c067b5f9de03be741a995d298c87c9b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/697d8673889ee61c9d2504a8a84bd04fd68d5006.summary']","Does the cooperation between Ets1 and IL17RA in regulating autoimmune responses and skin immunity to Staphylococcus aureus also influence the development and function of memory T follicular helper cells, thereby impacting the recall response to staphylococcal infections?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I propose an experimental plan to test the hypothesis that the cooperation between Ets1 and IL17RA in regulating autoimmune responses and skin immunity to Staphylococcus aureus also influences the development and function of memory T follicular helper cells, thereby impacting the recall response to staphylococcal infections.

**Experimental Approach:**

To disprove the hypothesis, we will design an experiment to investigate the role of Ets1 and IL17RA in the development and function of memory T follicular helper cells and their impact on the recall response to staphylococcal infections.

**Objective:**

1. To determine if Ets1 and IL17RA regulate the development and function of memory T follicular helper cells.
2. To investigate if the absence of Ets1 and IL17RA affects the recall response to staphylococcal infections.

**Experimental Design:**

1. Generate Ets1-/-IL17RA-/- (DKO) mice and wild-type (WT) mice.
2. Immunize both DKO and WT mice with a staphylococcal antigen to induce a primary immune response.
3. Allow the mice to rest for several weeks to allow for the development of memory T follicular helper cells.
4. Challenge the mice with a secondary dose of staphylococcal antigen to induce a recall response.
5. Analyze the frequency and function of memory T follicular helper cells in the spleen and lymph nodes of DKO and WT mice using flow cytometry and cell sorting.
6. Investigate the expression of activation markers and cytokines on memory T follicular helper cells using flow cytometry and confocal microscopy.
7. Compare the recall response to staphylococcal infections in DKO and WT mice using an IVIS imager.

**Expected Outcomes:**

If the hypothesis is true, we expect to see:

* Reduced frequency and function of memory T follicular helper cells in DKO mice compared to WT mice.
* Impaired recall response to staphylococcal infections in DKO mice compared to WT mice.

If the hypothesis is false, we expect to see:

* No significant difference in the frequency and function of memory T follicular helper cells between DKO and WT mice.
* No significant difference in the recall response to staphylococcal infections between DKO and WT mice.

**Equipment and Resources:**

* Mice (Ets1-/-IL17RA-/- and wild-type)
* Staphylococcal antigen
* Flow cytometer
* Cell sorter
* Confocal microscope
* IVIS imager
* Antibodies and reagents for flow cytometry and confocal microscopy

**Timeline:**

* Week 1-2: Generate Ets1-/-IL17RA-/- mice and wild-type mice.
* Week 3-4: Immunize mice with staphylococcal antigen.
* Week 5-6: Allow mice to rest.
* Week 7-8: Challenge mice with secondary dose of staphylococcal antigen.
* Week 9-10: Analyze memory T follicular helper cells and recall response.

**Budget:**

The budget for this experiment will be approximately $50,000, which will cover the cost of mice, reagents, and equipment usage.

This experiment is designed to test the hypothesis and provide insights into the role of Ets1 and IL17RA in regulating memory T follicular helper cells and the recall response to staphylococcal infections.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Week 1-2: Generation of Ets1-/-IL17RA-/- (DKO) mice and wild-type (WT) mice**

1.1. Breeding and Genotyping:

* Obtain Ets1+/- and IL17RA+/- mice from a reputable supplier or breeding colony.
* Breed Ets1+/- mice with IL17RA+/- mice to generate Ets1-/-IL17RA-/- (DKO) mice.
* Perform PCR-based genotyping to confirm the genotype of the offspring.
* Identify and separate DKO mice from WT mice.

1.2. Mouse Husbandry:

* House mice in a specific pathogen-free (SPF) facility with a 12-hour light-dark cycle and ad libitum access to food and water.
* Monitor mouse health and weight daily.

**Week 3-4: Immunization with staphylococcal antigen**

2.1. Antigen Preparation:

* Obtain staphylococcal antigen from a reputable supplier or prepare in-house according to established protocols.
* Aliquot and store antigen at -80°C until use.

2.2. Immunization:

* Weigh and anesthetize mice using isoflurane or ketamine/xylazine.
* Inject 100 μg of staphylococcal antigen in 100 μL of PBS intraperitoneally (i.p.) into each mouse.
* Monitor mice for signs of distress or illness.

**Week 5-6: Rest period**

3.1. Mouse Monitoring:

* Continue to monitor mouse health and weight daily.
* Ensure mice have ad libitum access to food and water.

**Week 7-8: Challenge with secondary dose of staphylococcal antigen**

4.1. Antigen Preparation:

* Thaw an aliquot of staphylococcal antigen and prepare as in Week 3-4.

4.2. Challenge:

* Weigh and anesthetize mice using isoflurane or ketamine/xylazine.
* Inject 100 μg of staphylococcal antigen in 100 μL of PBS i.p. into each mouse.
* Monitor mice for signs of distress or illness.

**Week 9-10: Analysis of memory T follicular helper cells and recall response**

5.1. Mouse Sacrifice and Tissue Harvest:

* Euthanize mice using CO2 asphyxiation or cervical dislocation.
* Harvest spleen and lymph nodes from each mouse.
* Store tissues in ice-cold PBS until processing.

5.2. Cell Isolation and Staining:

* Isolate lymphocytes from spleen and lymph nodes using density gradient centrifugation.
* Stain cells with fluorescently labeled antibodies against CD4, CXCR5, PD-1, and ICOS to identify memory T follicular helper cells.
* Perform flow cytometry to analyze the frequency and phenotype of memory T follicular helper cells.

5.3. Cell Sorting:

* Sort memory T follicular helper cells using a cell sorter.
* Analyze the expression of activation markers and cytokines on sorted cells using flow cytometry and confocal microscopy.

5.4. IVIS Imaging:

* Inject mice with a bioluminescent substrate specific for staphylococcal infections.
* Image mice using an IVIS imager to assess the recall response to staphylococcal infections.

**Equipment and Reagent Preparation**

* Prepare flow cytometer and cell sorter according to manufacturer's instructions.
* Prepare confocal microscope and IVIS imager according to manufacturer's instructions.
* Prepare antibodies and reagents for flow cytometry and confocal microscopy according to manufacturer's instructions.

**Quality Control**

* Verify the genotype of DKO and WT mice using PCR-based genotyping.
* Verify the purity of sorted memory T follicular helper cells using flow cytometry.
* Verify the specificity of antibodies and reagents used in the experiment.

**Data Analysis**

* Analyze flow cytometry data using FlowJo or similar software.
* Analyze confocal microscopy data using ImageJ or similar software.
* Analyze IVIS imaging data using Living Image or similar software.
* Compare data between DKO and WT mice using statistical software (e.g., GraphPad Prism).

By following these detailed, step-by-step protocols, the experiment can be replicated and the hypothesis tested.","```
   Ets1  IL17RA  Staphylococcal Antigen (μg)  Outcome
0     -/-     -/-                       50  Low Response
1     -/-     -/-                      100  Moderate Response
2     -/-     -/-                      150  High Response
3     +/-     +/-                       50  Low Response
4     +/-     +/-                      100  Moderate Response
5     +/-     +/-                      150  High Response
6     +/+     +/+                       50  Low Response
7     +/+     +/+                      100  Moderate Response
8     +/+     +/+                      150  High Response
9     -/-     -/-                       75  Moderate Response
10    -/-     -/-                      125  High Response
11    -/-     -/-                      175  High Response
12    +/-     +/-                       75  Moderate Response
13    +/-     +/-                      125  High Response
14    +/-     +/-                      175  High Response
15    +/+     +/+                       75  Moderate Response
16    +/+     +/+                      125  High Response
17    +/+     +/+                      175  High Response
18    -/-     -/-                       25  Low Response
19    -/-     -/-                       75  Moderate Response
20    -/-     -/-                      200  High Response
21    +/-     +/-                       25  Low Response
22    +/-     +/-                       75  Moderate Response
23    +/-     +/-                      200  High Response
24    +/+     +/+                       25  Low Response
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/721a4583fe1864a31c7a1f60be01cf8c34b411f4.summary'],"Does the coordinated activity of DOCK2 and p110d regulate the expression of CXCR5 on B cells, thereby modulating their migration to CXCL13?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's break it down and design an experiment to test it.

**Hypothesis:** The coordinated activity of DOCK2 and p110d regulates the expression of CXCR5 on B cells, thereby modulating their migration to CXCL13.

**Experimental Plan:**

**Objective:** To investigate the role of DOCK2 and p110d in regulating CXCR5 expression on B cells and their migration to CXCL13.

**Experimental Approach:**

1. **Cell Culture and Isolation:**
	* Isolate B cells from mouse spleens or human peripheral blood using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
	* Culture B cells in vitro using standard cell culture media and conditions.
2. **DOCK2 and p110d Modulation:**
	* Use small interfering RNA (siRNA) or CRISPR-Cas9 gene editing to knockdown DOCK2 and/or p110d expression in B cells.
	* Use pharmacological inhibitors or activators to modulate DOCK2 and p110d activity in B cells.
3. **CXCR5 Expression Analysis:**
	* Use flow cytometry to analyze CXCR5 expression on B cells after DOCK2 and/or p110d modulation.
	* Quantify CXCR5 mRNA levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
4. **Migration Assay:**
	* Use a transwell migration assay to assess B cell migration towards CXCL13.
	* Measure the number of migrated B cells using a fluorescence plate reader or microscopy.
5. **Control and Validation:**
	* Include control groups with unmodified B cells and/or scrambled siRNA or non-targeting CRISPR-Cas9.
	* Validate the efficacy of DOCK2 and p110d modulation using Western blotting or qRT-PCR.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the hypothesis by attempting to disprove it.

**Experimental Design:**

1. **DOCK2 and p110d Overexpression:**
	* Use lentiviral vectors or plasmid transfection to overexpress DOCK2 and p110d in B cells.
2. **CXCR5 Expression Analysis:**
	* Analyze CXCR5 expression on B cells using flow cytometry and qRT-PCR.
3. **Migration Assay:**
	* Perform the transwell migration assay as described above.
4. **Prediction:** If the hypothesis is true, overexpressing DOCK2 and p110d should increase CXCR5 expression and enhance B cell migration towards CXCL13. If the hypothesis is false, overexpressing DOCK2 and p110d should not affect CXCR5 expression or B cell migration.

**Budget and Timeframe:**

* This experiment can be completed within 3-6 months with a budget of approximately $50,000-$100,000.
* The budget will cover the costs of:
	+ Cell culture reagents and media
	+ siRNA, CRISPR-Cas9, and lentiviral vectors
	+ Antibodies and reagents for flow cytometry and Western blotting
	+ qRT-PCR and migration assay reagents
	+ Laboratory personnel and equipment

By following this experimental plan, we can test the hypothesis and determine whether the coordinated activity of DOCK2 and p110d regulates CXCR5 expression on B cells and their migration to CXCL13.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Isolation**

**Objective:** Isolate B cells from mouse spleens or human peripheral blood and culture them in vitro.

**Materials:**

* Mouse spleens or human peripheral blood
* Magnetic bead-based separation kit (e.g., Miltenyi Biotec)
* Fluorescence-activated cell sorting (FACS) instrument (e.g., BD FACSAria)
* Cell culture media (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin)
* Cell culture flasks and plates
* Pipettes and pipette tips

**Step-by-Step Protocol:**

1.1. Prepare the magnetic bead-based separation kit according to the manufacturer's instructions.

1.2. Isolate B cells from mouse spleens or human peripheral blood using the magnetic bead-based separation kit.

1.3. Wash the isolated B cells with PBS and resuspend them in cell culture media.

1.4. Count the B cells using a hemocytometer or an automated cell counter.

1.5. Culture the B cells in vitro in cell culture flasks or plates at a density of 1-2 x 10^6 cells/mL.

1.6. Incubate the cells at 37°C, 5% CO2 for 24-48 hours to allow for recovery and expansion.

**Protocol 2: DOCK2 and p110d Modulation**

**Objective:** Modulate DOCK2 and p110d expression or activity in B cells using siRNA, CRISPR-Cas9, or pharmacological inhibitors/activators.

**Materials:**

* siRNA targeting DOCK2 and p110d (e.g., Dharmacon)
* CRISPR-Cas9 plasmids targeting DOCK2 and p110d (e.g., Addgene)
* Pharmacological inhibitors/activators of DOCK2 and p110d (e.g., Selleckchem)
* Lipofectamine RNAiMAX (Invitrogen) or other transfection reagent
* Opti-MEM media (Invitrogen)

**Step-by-Step Protocol:**

2.1. Design and synthesize siRNA targeting DOCK2 and p110d using online tools (e.g., Dharmacon's siDESIGN).

2.2. Transfect B cells with siRNA using Lipofectamine RNAiMAX according to the manufacturer's instructions.

2.3. Incubate the cells for 24-48 hours to allow for siRNA-mediated knockdown.

2.4. Alternatively, use CRISPR-Cas9 gene editing to knock out DOCK2 and p110d in B cells.

2.5. Validate the efficacy of DOCK2 and p110d modulation using Western blotting or qRT-PCR.

**Protocol 3: CXCR5 Expression Analysis**

**Objective:** Analyze CXCR5 expression on B cells using flow cytometry and qRT-PCR.

**Materials:**

* Anti-CXCR5 antibody (e.g., BioLegend)
* Flow cytometry instrument (e.g., BD FACSCanto)
* qRT-PCR instrument (e.g., Applied Biosystems 7500)
* qRT-PCR primers and probes (e.g., Thermo Fisher Scientific)
* RNA extraction kit (e.g., Qiagen)

**Step-by-Step Protocol:**

3.1. Stain B cells with anti-CXCR5 antibody according to the manufacturer's instructions.

3.2. Analyze CXCR5 expression on B cells using flow cytometry.

3.3. Extract RNA from B cells using an RNA extraction kit.

3.4. Perform qRT-PCR to quantify CXCR5 mRNA levels using specific primers and probes.

**Protocol 4: Migration Assay**

**Objective:** Assess B cell migration towards CXCL13 using a transwell migration assay.

**Materials:**

* Transwell inserts (e.g., Corning)
* CXCL13 (e.g., PeproTech)
* Fluorescent dye (e.g., Calcein-AM)
* Fluorescence plate reader (e.g., Tecan)

**Step-by-Step Protocol:**

4.1. Prepare the transwell inserts according to the manufacturer's instructions.

4.2. Add CXCL13 to the lower chamber of the transwell insert.

4.3. Add B cells to the upper chamber of the transwell insert.

4.4. Incubate the cells for 2-4 hours to allow for migration.

4.5. Stain the migrated B cells with a fluorescent dye.

4.6. Measure the number of migrated B cells using a fluorescence plate reader.

**Protocol 5: Control and Validation**

**Objective:** Include control groups and validate the efficacy of DOCK2 and p110d modulation.

**Materials:**

* Unmodified B cells
* Scrambled siRNA or non-targeting CRISPR-Cas9
* Western blotting reagents (e.g., antibodies, ECL substrate)

**Step-by-Step Protocol:**

5.1. Include control groups with unmodified B cells and/or scrambled siRNA or non-targeting CRISPR-Cas9.

5.2. Validate the efficacy of DOCK2 and p110d modulation using Western blotting or qRT-PCR.

**Protocol 6: Experiment to Disprove the Hypothesis**

**Objective:** Overexpress DOCK2 and p110d in B cells and analyze CXCR5 expression and migration.

**Materials:**

* Lentiviral vectors or plasmids overexpressing DOCK2 and p110d
* Transfection reagent (e.g., Lipofectamine 3000)
* Antibodies and reagents for flow cytometry and Western blotting

**Step-by-Step Protocol:**

6.1. Transfect B cells with lentiviral vectors or plasmids overexpressing DOCK2 and p110d.

6.2. Analyze CXCR5 expression on B cells using flow cytometry and qRT-PCR.

6.3. Perform the transwell migration assay as described above.

6.4. If the hypothesis is true, overexpressing DOCK2 and p110d should increase CXCR5 expression and enhance B cell migration towards CXCL13. If the hypothesis is false, overexpressing DOCK2 and p110d should not affect CXCR5 expression or B cell migration.","```
   Mouse Spleen/Peripheral Blood  Magnetic Bead-Based Separation Kit  FACS Instrument  Cell Culture Media  siRNA DOCK2  siRNA p110d  CRISPR-Cas9 DOCK2  CRISPR-Cas9 p110d  Pharmacological Inhibitors/Activators  CXCL13  Outcome
0                    1.0                         1.0             1.0             1.0         0.5         0.5             0.0             0.0                         0.0       100.0  0.75
1                    1.5                         1.5             1.5             1.5         0.8         0.8             0.0             0.0                         0.0       120.0  0.80
2                    2.0                         2.0             2.0             2.0         1.0         1.0             0.0             0.0                         0.0       150.0  0.85
3                    1.0                         1.0             1.0             1.0         0.5         0.5             0.5             0.0                         0.0       110.0  0.70
4                    1.5                         1.5             1.5             1.5         0.8         0.8             0.8             0.0                         0.0       130.0  0.75
5                    2.0                         2.0             2.0             2.0         1.0         1.0             1.0             0.0                         0.0       160.0  0.80
6                    1.0                         1.0             1.0             1.0         0.5         0.5             0.0             0.5                         0.0       100.0  0.65
7                    1.5                         1.5             1.5             1.5         0.8         0.8             0.0             0.8                         0.0       120.0  0.70
8                    2.0                         2.0             2.0             2.0         1.0         1.0             0.0             1.0                         0.0       150.0  0.75
9                    1.0                         1.0             1.0             1.0         0.5         0.5             0.5             0.5                         0.0       110.0  0.65
10                   1.5                         1.5             1.5             1.5         0.8         0.8             0.8             0.8                         0.0       130.0  0.70
11                   2.0                         2.0             2.0             2.0         1.0         1.0             1.0             1.0                         0.0       160.0  0.75
12                   1.0                         1.0             1.0             1.0         0.5         0.5             0.0             0.0                         0.5       100.0  0.60
13                   1.5                         1.5             1.5             1.5         0.8         0.8             0.0             0.0                         0.8       120.0  0.65
14                   2.0                         2.0             2.0             2.0         1.0         1.0             0.0             0.0                         1.0       150.0  0.70
15                   1.0                         1.0             1.0             1.0         0.5         0.5             0.5             0.0                         0.5       110.0  0.60
16                   1.5                         1.5             1.5             1.5         0.8         0.8             0.8             0.0                         0.8       130.0  0.65
17                   2.0                         2.0             2.0             2.0         1.0         1.0             1.0             0.0                         1.0       160.0  0.70
18                   1.0                         1.0             1.0             1.0         0.5         0.5             0.0             0.5                         0.5       100.0  0.55
19                   1.5                         1.5             1.5             1.5         0.8         0.8             0.0             0.8                         0.8       120.0  0.60
20                   2.0                         2.0             2.0             2.0         1.0         1.0             0.0             1.0                         1.0       150.0  0.65
21                   1.0                         1.0             1.0             1.0         0.5         0.5             0.5             0.5                         0.5       110.0  0.55
22                   1.5                         1.5             1.5             1.5         0.8         0.8             0.8             0.8                         0.8       130.0  0.60
23                   2.0                         2.0             2.0             2.0         1.0         1.0             1.0             1.0                         1.0       160.0  0.65
24                   1.0                         1.0             1.0             1.0         0.0         0.0             0.0             0.0                         0.0       100.0  0.50
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/97c5c21a737f67a8116c4cea8236f6f7ff6e5009.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2a783df7898afb7bdbdc50dd9c212f1377ac5b8b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/70b8bc5c905166fe154c256a910295cd6e2c1ed3.summary']","Does the coordinated regulation of ARP2/3 complex-mediated actin polymerization and WNT5A signaling in the bone marrow niche influence the cortical actin cytoskeleton organization and B cell receptor diffusion, thereby modulating the threshold for B cell activation and immune response?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll outline a comprehensive experimental plan to test this hypothesis, leveraging existing scientific methods and equipment. Given the unlimited budget, we can design a multi-faceted approach to investigate the intricate relationships between ARP2/3 complex-mediated actin polymerization, WNT5A signaling, cortical actin cytoskeleton organization, B cell receptor diffusion, and B cell activation.

**Experimental Plan:**

**Objective 1: Investigate the regulation of ARP2/3 complex-mediated actin polymerization and WNT5A signaling in the bone marrow niche**

1.1. **Cell isolation and culture**: Isolate bone marrow cells from mice or human donors and culture them in vitro using established protocols.

1.2. **ARP2/3 complex and WNT5A signaling modulation**: Use RNA interference (RNAi) or CRISPR-Cas9 gene editing to knockdown or knockout ARP2/3 complex subunits (e.g., ARP2, ARP3, or p21-ARC) and WNT5A in bone marrow cells. Conversely, use overexpression vectors to upregulate these genes.

1.3. **Actin polymerization assays**: Employ fluorescence microscopy and live-cell imaging to monitor actin polymerization dynamics in response to ARP2/3 complex and WNT5A signaling modulation. Use fluorescently labeled actin probes (e.g., LifeAct or SiR-actin) to visualize actin filaments.

**Objective 2: Examine the impact of ARP2/3 complex-mediated actin polymerization and WNT5A signaling on cortical actin cytoskeleton organization**

2.1. **Cortical actin cytoskeleton imaging**: Use super-resolution microscopy (e.g., STORM or STED) to visualize the cortical actin cytoskeleton in bone marrow cells with modulated ARP2/3 complex and WNT5A signaling.

2.2. **Actin cytoskeleton analysis**: Quantify changes in cortical actin cytoskeleton organization using image analysis software (e.g., ImageJ or Ilastik). Measure parameters such as actin filament length, density, and orientation.

**Objective 3: Investigate the effect of ARP2/3 complex-mediated actin polymerization and WNT5A signaling on B cell receptor diffusion**

3.1. **B cell receptor labeling and tracking**: Label B cell receptors (e.g., IgM or IgD) with fluorescent probes (e.g., Alexa Fluor or quantum dots) and track their diffusion using single-particle tracking (SPT) or fluorescence recovery after photobleaching (FRAP) techniques.

3.2. **Diffusion coefficient analysis**: Calculate the diffusion coefficient (D) of B cell receptors in response to ARP2/3 complex and WNT5A signaling modulation using SPT or FRAP data.

**Objective 4: Examine the impact of ARP2/3 complex-mediated actin polymerization and WNT5A signaling on B cell activation and immune response**

4.1. **B cell activation assays**: Use flow cytometry to measure B cell activation markers (e.g., CD69, CD86, or CD25) in response to ARP2/3 complex and WNT5A signaling modulation.

4.2. **Immune response analysis**: Investigate the impact of ARP2/3 complex and WNT5A signaling on B cell-mediated immune responses, such as antibody production, using ELISA or ELISPOT assays.

**Objective 5: Validate findings in vivo**

5.1. **Mouse models**: Generate mouse models with conditional knockout or overexpression of ARP2/3 complex subunits and WNT5A in the bone marrow niche.

5.2. **In vivo B cell activation and immune response analysis**: Analyze B cell activation and immune response in vivo using flow cytometry, ELISA, or ELISPOT assays.

**Additional considerations**

* Use appropriate controls and replicates throughout the experiment.
* Validate RNAi or CRISPR-Cas9-mediated gene modulation using Western blotting or qRT-PCR.
* Perform statistical analysis using suitable software (e.g., GraphPad Prism or R) to determine significance and correlations between variables.
* Consider using single-cell RNA sequencing or mass cytometry to further investigate the effects of ARP2/3 complex and WNT5A signaling on B cell heterogeneity and activation.

This comprehensive experimental plan should provide a thorough understanding of the coordinated regulation of ARP2/3 complex-mediated actin polymerization and WNT5A signaling in the bone marrow niche and their impact on B cell activation and immune response.",92,"Here are the detailed, step-by-step protocols for each objective:

**Objective 1: Investigate the regulation of ARP2/3 complex-mediated actin polymerization and WNT5A signaling in the bone marrow niche**

**Protocol 1.1: Cell isolation and culture**

1. Obtain bone marrow cells from mice or human donors using established protocols (e.g., flushing femurs and tibias with PBS).
2. Isolate mononuclear cells using density gradient centrifugation (e.g., Ficoll-Paque).
3. Culture cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
4. Verify cell viability and purity using trypan blue staining and flow cytometry.

**Protocol 1.2: ARP2/3 complex and WNT5A signaling modulation**

1. Design and synthesize RNAi or CRISPR-Cas9 constructs targeting ARP2, ARP3, p21-ARC, and WNT5A genes.
2. Transfect bone marrow cells with RNAi or CRISPR-Cas9 constructs using established protocols (e.g., electroporation or lipofection).
3. Verify gene modulation using Western blotting or qRT-PCR.
4. Use overexpression vectors to upregulate ARP2, ARP3, p21-ARC, and WNT5A genes in bone marrow cells.

**Protocol 1.3: Actin polymerization assays**

1. Prepare fluorescently labeled actin probes (e.g., LifeAct or SiR-actin) according to manufacturer's instructions.
2. Treat bone marrow cells with ARP2/3 complex and WNT5A signaling modulators (e.g., RNAi or overexpression vectors).
3. Incubate cells with fluorescently labeled actin probes for 30 minutes at 37°C.
4. Perform live-cell imaging using a fluorescence microscope (e.g., Zeiss Axiovert 200M) with a 63x oil immersion objective.
5. Acquire images at 1-minute intervals for 30 minutes using a camera (e.g., Hamamatsu Orca-Flash 4.0).
6. Analyze actin polymerization dynamics using image analysis software (e.g., ImageJ or Ilastik).

**Objective 2: Examine the impact of ARP2/3 complex-mediated actin polymerization and WNT5A signaling on cortical actin cytoskeleton organization**

**Protocol 2.1: Cortical actin cytoskeleton imaging**

1. Fix bone marrow cells with 4% paraformaldehyde for 15 minutes at room temperature.
2. Permeabilize cells with 0.1% Triton X-100 for 10 minutes at room temperature.
3. Stain cells with fluorescently labeled phalloidin (e.g., Alexa Fluor 488) for 30 minutes at room temperature.
4. Perform super-resolution microscopy (e.g., STORM or STED) using a microscope (e.g., Nikon N-STORM) with a 100x oil immersion objective.

**Protocol 2.2: Actin cytoskeleton analysis**

1. Acquire images of cortical actin cytoskeleton using super-resolution microscopy.
2. Analyze images using image analysis software (e.g., ImageJ or Ilastik) to quantify actin filament length, density, and orientation.
3. Calculate mean and standard deviation of actin cytoskeleton parameters for each condition.

**Objective 3: Investigate the effect of ARP2/3 complex-mediated actin polymerization and WNT5A signaling on B cell receptor diffusion**

**Protocol 3.1: B cell receptor labeling and tracking**

1. Label B cell receptors (e.g., IgM or IgD) with fluorescent probes (e.g., Alexa Fluor 488) according to manufacturer's instructions.
2. Treat bone marrow cells with ARP2/3 complex and WNT5A signaling modulators (e.g., RNAi or overexpression vectors).
3. Perform single-particle tracking (SPT) or fluorescence recovery after photobleaching (FRAP) using a microscope (e.g., Zeiss Axiovert 200M) with a 63x oil immersion objective.

**Protocol 3.2: Diffusion coefficient analysis**

1. Acquire SPT or FRAP data using image analysis software (e.g., ImageJ or Ilastik).
2. Calculate the diffusion coefficient (D) of B cell receptors using SPT or FRAP data.
3. Calculate mean and standard deviation of D for each condition.

**Objective 4: Examine the impact of ARP2/3 complex-mediated actin polymerization and WNT5A signaling on B cell activation and immune response**

**Protocol 4.1: B cell activation assays**

1. Treat bone marrow cells with ARP2/3 complex and WNT5A signaling modulators (e.g., RNAi or overexpression vectors).
2. Stain cells with fluorescently labeled antibodies against B cell activation markers (e.g., CD69, CD86, or CD25).
3. Analyze B cell activation using flow cytometry (e.g., BD FACSCanto II).

**Protocol 4.2: Immune response analysis**

1. Treat bone marrow cells with ARP2/3 complex and WNT5A signaling modulators (e.g., RNAi or overexpression vectors).
2. Analyze B cell-mediated immune responses using ELISA or ELISPOT assays.

**Objective 5: Validate findings in vivo**

**Protocol 5.1: Mouse models**

1. Generate mouse models with conditional knockout or overexpression of ARP2/3 complex subunits and WNT5A in the bone marrow niche using established protocols (e.g., Cre-loxP system).
2. Verify gene modulation using Western blotting or qRT-PCR.

**Protocol 5.2: In vivo B cell activation and immune response analysis**

1. Analyze B cell activation and immune response in vivo using flow cytometry, ELISA, or ELISPOT assays.
2. Compare results with in vitro findings to validate the role of ARP2/3 complex-mediated actin polymerization and WNT5A signaling in B cell activation and immune response.

**Additional considerations**

* Perform statistical analysis using suitable software (e.g., GraphPad Prism or R) to determine significance and correlations between variables.
* Consider using single-cell RNA sequencing or mass cytometry to further investigate the effects of ARP2/3 complex and WNT5A signaling on B cell heterogeneity and activation.
* Use appropriate controls and replicates throughout the experiment to ensure reproducibility and accuracy.","```
   ARP2 RNAi  ARP3 RNAi  p21-ARC RNAi  WNT5A RNAi  ARP2 OE  ARP3 OE  p21-ARC OE  WNT5A OE  Actin Polymerization
0         0.5         0.0          0.0         0.0       0.0       0.0          0.0       0.0               0.2
1         0.0         0.5          0.0         0.0       0.0       0.0          0.0       0.0               0.4
2         0.0         0.0          0.5         0.0       0.0       0.0          0.0       0.0               0.6
3         0.0         0.0          0.0         0.5       0.0       0.0          0.0       0.0               0.8
4         0.5         0.5          0.0         0.0       0.0       0.0          0.0       0.0               0.5
5         0.5         0.0          0.5         0.0       0.0       0.0          0.0       0.0               0.7
6         0.5         0.0          0.0         0.5       0.0       0.0          0.0       0.0               0.9
7         0.0         0.5          0.5         0.0       0.0       0.0          0.0       0.0               0.6
8         0.0         0.5          0.0         0.5       0.0       0.0          0.0       0.0               0.8
9         0.0         0.0          0.5         0.5       0.0       0.0          0.0       0.0               1.0
10        0.5         0.0          0.0         0.0       0.5       0.0          0.0       0.0               0.3
11        0.0         0.5          0.0         0.0       0.0       0.5          0.0       0.0               0.5
12        0.0         0.0          0.5         0.0       0.0       0.0          0.5       0.0               0.7
13        0.0         0.0          0.0         0.5       0.0       0.0          0.0       0.5               0.9
14        0.5         0.5          0.0         0.0       0.5       0.0          0.0       0.0               0.6
15        0.5         0.0          0.5         0.0       0.0       0.5          0.0       0.0               0.8
16        0.5         0.0          0.0         0.5       0.0       0.0          0.5       0.0               1.0
17        0.0         0.5          0.5         0.0       0.5       0.0          0.0       0.0               0.7
18        0.0         0.5          0.0         0.5       0.0       0.5          0.0       0.0               0.9
19        0.0         0.0          0.5         0.5       0.0       0.0          0.5       0.0               1.1
20        0.5         0.5          0.5         0.0       0.0       0.0          0.0       0.0               0.8
21        0.5         0.5          0.0         0.5       0.0       0.0          0.0       0.0               1.0
22        0.5         0.0          0.5         0.5       0.0       0.0          0.0       0.0               1.1
23        0.0         0.5          0.5         0.5       0.0       0.0          0.0       0.0               1.2
24        0.5         0.5          0.5         0.5       0.0       0.0          0.0       0.0               1.3
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/13fec24ec05e81b641870a2d3268cf3e23c9ffce.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/dd98fa845ef19bcfa2533cc95aba0fd6bf1146a2.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e4516667ba7470fd7cd609aafc817209637d9b82.summary']","Does the coordinated upregulation of TPD52L2 and lncRNA ZFHX4-AS1 in clear cell renal cell carcinoma and ovarian cancer, respectively, converge on a common immune microenvironmental signature that can be modulated by Cadherin 11 to enhance anti-tumor immune responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'll break down the experimental plan to test this hypothesis into several key steps, focusing on a high-level approach that can be executed within a reasonable time frame and budget.

**Hypothesis:** The coordinated upregulation of TPD52L2 and lncRNA ZFHX4-AS1 in clear cell renal cell carcinoma (ccRCC) and ovarian cancer, respectively, converges on a common immune microenvironmental signature that can be modulated by Cadherin 11 to enhance anti-tumor immune responses.

**Experimental Plan:**

**Step 1: Cell Culture and RNA Isolation**

* Obtain ccRCC and ovarian cancer cell lines with known TPD52L2 and lncRNA ZFHX4-AS1 expression levels, respectively.
* Culture cells in vitro and isolate total RNA using standard protocols (e.g., TRIzol, RNeasy).

**Step 2: RNA Sequencing (RNA-seq) and Bioinformatics Analysis**

* Perform RNA-seq on the isolated RNA samples to generate transcriptome profiles.
* Use bioinformatics tools (e.g., DESeq2, edgeR) to identify differentially expressed genes (DEGs) between TPD52L2-high and TPD52L2-low ccRCC samples, as well as lncRNA ZFHX4-AS1-high and lncRNA ZFHX4-AS1-low ovarian cancer samples.
* Identify common DEGs between the two cancer types.

**Step 3: Immune Microenvironmental Signature Analysis**

* Use gene set enrichment analysis (GSEA) to identify immune-related gene signatures (e.g., immune cell infiltration, cytokine signaling) enriched in the common DEGs.
* Validate the immune microenvironmental signature using immunohistochemistry (IHC) or flow cytometry on tumor tissue samples.

**Step 4: Cadherin 11 Modulation**

* Overexpress or knockdown Cadherin 11 in ccRCC and ovarian cancer cell lines using lentiviral vectors or siRNA, respectively.
* Analyze the effects of Cadherin 11 modulation on the immune microenvironmental signature using RNA-seq, IHC, or flow cytometry.

**Step 5: Functional Assays**

* Perform functional assays (e.g., T cell co-culture, cytokine production, tumor cell killing) to assess the impact of Cadherin 11 modulation on anti-tumor immune responses.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: that the coordinated upregulation of TPD52L2 and lncRNA ZFHX4-AS1 does not converge on a common immune microenvironmental signature, and Cadherin 11 modulation does not enhance anti-tumor immune responses.

**Disproof Experiment:**

* Use CRISPR-Cas9 genome editing to knockout TPD52L2 in ccRCC cells and lncRNA ZFHX4-AS1 in ovarian cancer cells.
* Analyze the immune microenvironmental signature in these knockout cells using RNA-seq, IHC, or flow cytometry.
* Overexpress or knockdown Cadherin 11 in these knockout cells and assess the effects on anti-tumor immune responses using functional assays.

**Budget and Time Frame:**

This experimental plan can be executed within a reasonable time frame of 6-12 months, depending on the availability of resources and personnel. The budget will depend on the specific costs of RNA-seq, bioinformatics analysis, cell culture, and functional assays. However, a rough estimate for the entire experiment could be around $50,000-$100,000.

By following this experimental plan, we can test the hypothesis and determine whether the coordinated upregulation of TPD52L2 and lncRNA ZFHX4-AS1 converges on a common immune microenvironmental signature that can be modulated by Cadherin 11 to enhance anti-tumor immune responses.",85,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Culture and RNA Isolation**

1.1. Obtain ccRCC and ovarian cancer cell lines with known TPD52L2 and lncRNA ZFHX4-AS1 expression levels, respectively.

* Source: Obtain cell lines from a reputable cell bank (e.g., ATCC) or a collaborator.
* Cell line authentication: Verify cell line identity using STR profiling or other authentication methods.

1.2. Culture cells in vitro.

* Cell culture medium: Use a suitable medium for each cell line (e.g., RPMI 1640 for ccRCC, DMEM for ovarian cancer).
* Cell culture conditions: Maintain cells at 37°C, 5% CO2, and 95% humidity.
* Cell passage: Passage cells every 3-4 days to maintain exponential growth.

1.3. Isolate total RNA using standard protocols.

* RNA isolation kit: Use a commercial RNA isolation kit (e.g., TRIzol, RNeasy).
* RNA isolation protocol: Follow the manufacturer's instructions for RNA isolation.
* RNA quality control: Check RNA quality using a spectrophotometer (e.g., NanoDrop) and agarose gel electrophoresis.

**Step 2: RNA Sequencing (RNA-seq) and Bioinformatics Analysis**

2.1. Prepare RNA-seq libraries.

* Library preparation kit: Use a commercial RNA-seq library preparation kit (e.g., TruSeq, NEBNext).
* Library preparation protocol: Follow the manufacturer's instructions for library preparation.
* Library quality control: Check library quality using a bioanalyzer (e.g., Agilent 2100).

2.2. Perform RNA-seq.

* Sequencing platform: Use a high-throughput sequencing platform (e.g., Illumina HiSeq, NovaSeq).
* Sequencing protocol: Follow the manufacturer's instructions for sequencing.
* Sequencing depth: Aim for a minimum of 30 million reads per sample.

2.3. Perform bioinformatics analysis.

* RNA-seq analysis software: Use a software package (e.g., STAR, HISAT2) for RNA-seq analysis.
* Differential expression analysis: Use a software package (e.g., DESeq2, edgeR) for differential expression analysis.
* Identify differentially expressed genes (DEGs): Use a threshold of p < 0.05 and fold change > 2.

**Step 3: Immune Microenvironmental Signature Analysis**

3.1. Perform gene set enrichment analysis (GSEA).

* GSEA software: Use a software package (e.g., GSEA, MSigDB) for GSEA.
* Gene sets: Use immune-related gene sets (e.g., immune cell infiltration, cytokine signaling).
* Enrichment analysis: Perform enrichment analysis using the DEGs from Step 2.

3.2. Validate the immune microenvironmental signature using immunohistochemistry (IHC) or flow cytometry.

* IHC protocol: Use a commercial IHC kit (e.g., Dako, Ventana) and follow the manufacturer's instructions.
* Flow cytometry protocol: Use a commercial flow cytometry kit (e.g., BD Biosciences, eBioscience) and follow the manufacturer's instructions.
* Tissue samples: Use tumor tissue samples from ccRCC and ovarian cancer patients.

**Step 4: Cadherin 11 Modulation**

4.1. Overexpress or knockdown Cadherin 11 in ccRCC and ovarian cancer cell lines.

* Lentiviral vector: Use a commercial lentiviral vector (e.g., pLKO.1, pLentiCRISPR) and follow the manufacturer's instructions.
* siRNA: Use a commercial siRNA (e.g., siGENOME, Dharmacon) and follow the manufacturer's instructions.
* Transfection protocol: Follow the manufacturer's instructions for transfection.

4.2. Analyze the effects of Cadherin 11 modulation on the immune microenvironmental signature.

* RNA-seq: Perform RNA-seq on the modulated cells and analyze the data as in Step 2.
* IHC or flow cytometry: Perform IHC or flow cytometry on the modulated cells and analyze the data as in Step 3.

**Step 5: Functional Assays**

5.1. Perform functional assays (e.g., T cell co-culture, cytokine production, tumor cell killing).

* T cell co-culture: Co-culture T cells with modulated tumor cells and measure T cell activation (e.g., CD25, CD69).
* Cytokine production: Measure cytokine production (e.g., IFN-γ, TNF-α) using ELISA or multiplex assays.
* Tumor cell killing: Measure tumor cell killing using a cytotoxicity assay (e.g., MTT, LDH).

**Disproof Experiment**

**Disproof Step 1: CRISPR-Cas9 Genome Editing**

1.1. Design CRISPR-Cas9 guide RNAs.

* Use a software package (e.g., CRISPR Design, CRISPOR) to design guide RNAs targeting TPD52L2 and lncRNA ZFHX4-AS1.
* Validate guide RNA specificity using a software package (e.g., CRISPR-ERA, CRISPR-FOCUS).

1.2. Perform CRISPR-Cas9 genome editing.

* Use a commercial CRISPR-Cas9 kit (e.g., CRISPR-Cas9, Alt-R) and follow the manufacturer's instructions.
* Validate genome editing using PCR, sequencing, or other methods.

**Disproof Step 2: Immune Microenvironmental Signature Analysis**

2.1. Analyze the immune microenvironmental signature in knockout cells.

* Perform RNA-seq, IHC, or flow cytometry on the knockout cells as in Steps 2-3.

2.2. Overexpress or knockdown Cadherin 11 in knockout cells.

* Use lentiviral vectors or siRNA as in Step 4.

2.3. Analyze the effects of Cadherin 11 modulation on anti-tumor immune responses.

* Perform functional assays as in Step 5.

These detailed protocols should provide a clear guide for executing the experimental plan.","```
   ccRCC_cells  ovarian_cancer_cells  TRIzol  RPMI_1640  DMEM  RNA_quality  library_prep_kit  sequencing_platform  sequencing_depth  DEGs  GSEA_software  IHC_kit  flow_cytometry_kit  Cadherin_11_vector  siRNA  transfection_protocol  RNA_seq_outcome  IHC_outcome  flow_cytometry_outcome  T_cell_activation  cytokine_production  tumor_cell_killing
0           10000             5000       10       10.0   10.0         1.8            TruSeq           Illumina_HiSeq         30M     500         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            2000         0.5               0.8               0.4
1           15000             7500       15       15.0   15.0         1.9            NEBNext           NovaSeq         40M     600         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2500         0.6               0.9               0.5
2            5000             2500        5        5.0    5.0         1.7            TruSeq           Illumina_HiSeq         20M     400         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1500         0.4               0.7               0.3
3           12000             6000       12       12.0   12.0         1.8            NEBNext           NovaSeq         35M     550         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2200         0.5               0.8               0.4
4            8000             4000        8        8.0    8.0         1.7            TruSeq           Illumina_HiSeq         25M     450         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1800         0.4               0.7               0.3
5           18000             9000       18       18.0   18.0         1.9            NEBNext           NovaSeq         45M     650         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2800         0.6               0.9               0.5
6            3000             1500        3        3.0    3.0         1.6            TruSeq           Illumina_HiSeq         15M     300         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1000         0.3               0.6               0.2
7           14000             7000       14       14.0   14.0         1.8            NEBNext           NovaSeq         38M     580         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2400         0.5               0.8               0.4
8            9000             4500        9        9.0    9.0         1.7            TruSeq           Illumina_HiSeq         28M     480         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            2000         0.4               0.7               0.3
9           16000             8000       16       16.0   16.0         1.9            NEBNext           NovaSeq         42M     620         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2600         0.6               0.9               0.5
10          4000             2000        4        4.0    4.0         1.6            TruSeq           Illumina_HiSeq         18M     350         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1200         0.3               0.6               0.2
11         13000             6500       13       13.0   13.0         1.8            NEBNext           NovaSeq         36M     570         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2300         0.5               0.8               0.4
12          6000             3000        6        6.0    6.0         1.7            TruSeq           Illumina_HiSeq         22M     420         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1600         0.4               0.7               0.3
13         19000            9500       19       19.0   19.0         1.9            NEBNext           NovaSeq         48M     680         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            3000         0.6               0.9               0.5
14          7000             3500        7        7.0    7.0         1.7            TruSeq           Illumina_HiSeq         24M     440         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1800         0.4               0.7               0.3
15         11000             5500       11       11.0   11.0         1.8            NEBNext           NovaSeq         32M     520         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2100         0.5               0.8               0.4
16          5000             2500        5        5.0    5.0         1.6            TruSeq           Illumina_HiSeq         20M     400         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1500         0.4               0.7               0.3
17         17000             8500       17       17.0   17.0         1.9            NEBNext           NovaSeq         44M     640         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2700         0.6               0.9               0.5
18          8000             4000        8        8.0    8.0         1.7            TruSeq           Illumina_HiSeq         26M     460         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1900         0.4               0.7               0.3
19         12000             6000       12       12.0   12.0         1.8            NEBNext           NovaSeq         34M     560         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2200         0.5               0.8               0.4
20          3000             1500        3        3.0    3.0         1.6            TruSeq           Illumina_HiSeq         16M     320         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1100         0.3               0.6               0.2
21         14000             7000       14       14.0   14.0         1.8            NEBNext           NovaSeq         38M     580         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2400         0.5               0.8               0.4
22          9000             4500        9        9.0    9.0         1.7            TruSeq           Illumina_HiSeq         28M     480         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            2000         0.4               0.7               0.3
23         16000             8000       16       16.0   16.0         1.9            NEBNext           NovaSeq         42M     620         MSigDB       Ventana          eBioscience            pLentiCRISPR  Dharmacon          optimized            2600         0.6               0.9               0.5
24          4000             2000        4        4.0    4.0         1.6            TruSeq           Illumina_HiSeq         18M     350         GSEA         Dako            BD_Biosciences            pLKO.1  siGENOME          standard            1200         0.3               0.6               0.2
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/34694ba1fd2864bfd0cb0c43ef99ac3073482f17.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/094b625e5af8f5dc801e40612fc5b58ed07198bc.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6ce694ff8f3732c30058be29bad1b08df72dbfe4.summary']","Does the delayed maturation of tBregs in multiple sclerosis patients contribute to the persistence of exhausted B cells, and can targeting the CD27 signaling pathway in tBregs enhance anti-tumor immunity in cancer patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the delayed maturation of tBregs in multiple sclerosis patients contributes to the persistence of exhausted B cells, and that targeting the CD27 signaling pathway in tBregs can enhance anti-tumor immunity in cancer patients, I propose the following experimental plan:

**Experiment 1: Investigating the role of CD27 signaling in tBreg maturation and B cell exhaustion**

Objective: To determine if the delayed maturation of tBregs in multiple sclerosis patients is due to a defect in CD27 signaling, and if this defect contributes to the persistence of exhausted B cells.

Equipment:

* Flow cytometer
* Cell sorter
* Antibodies against CD27 and phosphorylated CD27
* tBreg cells from multiple sclerosis patients and healthy donors
* B cells from multiple sclerosis patients and healthy donors

Steps:

1. Isolate tBreg cells from multiple sclerosis patients and healthy donors using flow cytometry and cell sorting.
2. Stimulate tBreg cells with anti-CD27 antibodies and measure the phosphorylation of CD27 using flow cytometry.
3. Compare the level of phosphorylated CD27 in tBreg cells from multiple sclerosis patients and healthy donors.
4. Isolate B cells from multiple sclerosis patients and healthy donors and measure the frequency of exhausted B cells (CD21low) using flow cytometry.
5. Co-culture tBreg cells from multiple sclerosis patients and healthy donors with B cells from multiple sclerosis patients and healthy donors, and measure the effect of tBreg cells on B cell exhaustion.

**Experiment 2: Investigating the role of CD27 signaling in anti-tumor immunity**

Objective: To determine if targeting the CD27 signaling pathway in tBregs can enhance anti-tumor immunity in cancer patients.

Equipment:

* CRISPR-Cas9 gene editing system
* T cell isolation and culture system
* Tumor cell lines
* Flow cytometry
* qRT-PCR

Steps:

1. Isolate T cells from cancer patients and healthy donors.
2. Use CRISPR-Cas9 to genetically engineer T cells to overexpress CD27 or a constitutively active form of CD27.
3. Co-culture engineered T cells with tumor cells and assess anti-tumor activity using flow cytometry and qRT-PCR.
4. Compare anti-tumor activity of engineered T cells with non-engineered T cells.

**Experiment 3: Investigating the role of tBregs in anti-tumor immunity**

Objective: To determine if tBregs can enhance anti-tumor immunity in cancer patients.

Equipment:

* Flow cytometer
* Cell sorter
* Antibodies against CD27 and phosphorylated CD27
* tBreg cells from cancer patients and healthy donors
* Tumor cell lines

Steps:

1. Isolate tBreg cells from cancer patients and healthy donors using flow cytometry and cell sorting.
2. Co-culture tBreg cells with tumor cells and assess anti-tumor activity using flow cytometry.
3. Compare anti-tumor activity of tBreg cells from cancer patients and healthy donors.

**Experiment to DISPROVE the hypothesis:**

Objective: To determine if the delayed maturation of tBregs in multiple sclerosis patients is not due to a defect in CD27 signaling, and if targeting the CD27 signaling pathway in tBregs does not enhance anti-tumor immunity in cancer patients.

Equipment:

* Flow cytometer
* Cell sorter
* Antibodies against CD27 and phosphorylated CD27
* tBreg cells from multiple sclerosis patients and healthy donors
* B cells from multiple sclerosis patients and healthy donors
* CRISPR-Cas9 gene editing system
* T cell isolation and culture system
* Tumor cell lines

Steps:

1. Isolate tBreg cells from multiple sclerosis patients and healthy donors using flow cytometry and cell sorting.
2. Stimulate tBreg cells with anti-CD27 antibodies and measure the phosphorylation of CD27 using flow cytometry.
3. Compare the level of phosphorylated CD27 in tBreg cells from multiple sclerosis patients and healthy donors.
4. Isolate B cells from multiple sclerosis patients and healthy donors and measure the frequency of exhausted B cells (CD21low) using flow cytometry.
5. Co-culture tBreg cells from multiple sclerosis patients and healthy donors with B cells from multiple sclerosis patients and healthy donors, and measure the effect of tBreg cells on B cell exhaustion.
6. Use CRISPR-Cas9 to genetically engineer T cells to overexpress CD27 or a constitutively active form of CD27.
7. Co-culture engineered T cells with tumor cells and assess anti-tumor activity using flow cytometry and qRT-PCR.
8. Compare anti-tumor activity of engineered T cells with non-engineered T cells.

If the results of these experiments do not support the hypothesis, it would suggest that the delayed maturation of tBregs in multiple sclerosis patients is not due to a defect in CD27 signaling, and that targeting the CD27 signaling pathway in tBregs does not enhance anti-tumor immunity in cancer patients.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Experiment 1: Investigating the role of CD27 signaling in tBreg maturation and B cell exhaustion**

**Step 1: Isolate tBreg cells from multiple sclerosis patients and healthy donors using flow cytometry and cell sorting**

1.1. Collect peripheral blood mononuclear cells (PBMCs) from multiple sclerosis patients and healthy donors using venipuncture or leukapheresis.

1.2. Isolate PBMCs using Ficoll-Paque density gradient centrifugation.

1.3. Stain PBMCs with fluorescently labeled antibodies against CD4, CD25, and CD127 to identify tBreg cells (CD4+CD25+CD127-).

1.4. Sort tBreg cells using a flow cytometer equipped with a cell sorter, such as a BD FACSAria III.

1.5. Collect sorted tBreg cells in a sterile tube and wash with phosphate-buffered saline (PBS).

**Step 2: Stimulate tBreg cells with anti-CD27 antibodies and measure the phosphorylation of CD27 using flow cytometry**

2.1. Resuspend tBreg cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

2.2. Add anti-CD27 antibodies (10 μg/mL) to the cell suspension and incubate at 37°C for 30 minutes.

2.3. Stain cells with fluorescently labeled antibodies against phosphorylated CD27 (pCD27) and CD27.

2.4. Analyze cells using a flow cytometer, such as a BD LSRFortessa.

2.5. Measure the mean fluorescence intensity (MFI) of pCD27 and CD27.

**Step 3: Compare the level of phosphorylated CD27 in tBreg cells from multiple sclerosis patients and healthy donors**

3.1. Calculate the ratio of pCD27 to CD27 MFI for each sample.

3.2. Compare the ratios between tBreg cells from multiple sclerosis patients and healthy donors using a two-tailed Student's t-test.

**Step 4: Isolate B cells from multiple sclerosis patients and healthy donors and measure the frequency of exhausted B cells (CD21low) using flow cytometry**

4.1. Collect PBMCs from multiple sclerosis patients and healthy donors.

4.2. Stain PBMCs with fluorescently labeled antibodies against CD19, CD21, and CD27.

4.3. Analyze cells using a flow cytometer.

4.4. Calculate the frequency of exhausted B cells (CD21low) as a percentage of total B cells (CD19+).

**Step 5: Co-culture tBreg cells from multiple sclerosis patients and healthy donors with B cells from multiple sclerosis patients and healthy donors, and measure the effect of tBreg cells on B cell exhaustion**

5.1. Co-culture tBreg cells with B cells at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

5.2. Incubate co-cultures at 37°C for 48 hours.

5.3. Stain cells with fluorescently labeled antibodies against CD19, CD21, and CD27.

5.4. Analyze cells using a flow cytometer.

5.5. Calculate the frequency of exhausted B cells (CD21low) as a percentage of total B cells (CD19+).

**Experiment 2: Investigating the role of CD27 signaling in anti-tumor immunity**

**Step 1: Isolate T cells from cancer patients and healthy donors**

1.1. Collect PBMCs from cancer patients and healthy donors.

1.2. Isolate T cells using a T cell isolation kit, such as the Miltenyi Biotec T Cell Isolation Kit.

**Step 2: Use CRISPR-Cas9 to genetically engineer T cells to overexpress CD27 or a constitutively active form of CD27**

2.1. Design guide RNAs (gRNAs) targeting the CD27 gene.

2.2. Transfect T cells with CRISPR-Cas9 plasmids and gRNAs using a nucleofection device, such as the Lonza 4D-Nucleofector.

2.3. Select for edited T cells using puromycin selection.

**Step 3: Co-culture engineered T cells with tumor cells and assess anti-tumor activity using flow cytometry and qRT-PCR**

3.1. Co-culture engineered T cells with tumor cells at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

3.2. Incubate co-cultures at 37°C for 48 hours.

3.3. Stain cells with fluorescently labeled antibodies against CD8 and CD107a.

3.4. Analyze cells using a flow cytometer.

3.5. Measure tumor cell killing using a cytotoxicity assay, such as the lactate dehydrogenase (LDH) release assay.

3.6. Extract RNA from co-cultures and perform qRT-PCR to measure the expression of anti-tumor genes, such as granzyme B and perforin.

**Experiment 3: Investigating the role of tBregs in anti-tumor immunity**

**Step 1: Isolate tBreg cells from cancer patients and healthy donors using flow cytometry and cell sorting**

1.1. Collect PBMCs from cancer patients and healthy donors.

1.2. Stain PBMCs with fluorescently labeled antibodies against CD4, CD25, and CD127.

1.3. Sort tBreg cells using a flow cytometer equipped with a cell sorter.

**Step 2: Co-culture tBreg cells with tumor cells and assess anti-tumor activity using flow cytometry**

2.1. Co-culture tBreg cells with tumor cells at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

2.2. Incubate co-cultures at 37°C for 48 hours.

2.3. Stain cells with fluorescently labeled antibodies against CD8 and CD107a.

2.4. Analyze cells using a flow cytometer.

2.5. Measure tumor cell killing using a cytotoxicity assay, such as the LDH release assay.

**Experiment to DISPROVE the hypothesis**

**Step 1: Isolate tBreg cells from multiple sclerosis patients and healthy donors using flow cytometry and cell sorting**

1.1. Collect PBMCs from multiple sclerosis patients and healthy donors.

1.2. Stain PBMCs with fluorescently labeled antibodies against CD4, CD25, and CD127.

1.3. Sort tBreg cells using a flow cytometer equipped with a cell sorter.

**Step 2: Stimulate tBreg cells with anti-CD27 antibodies and measure the phosphorylation of CD27 using flow cytometry**

2.1. Resuspend tBreg cells in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

2.2. Add anti-CD27 antibodies (10 μg/mL) to the cell suspension and incubate at 37°C for 30 minutes.

2.3. Stain cells with fluorescently labeled antibodies against pCD27 and CD27.

2.4. Analyze cells using a flow cytometer.

**Step 3: Compare the level of phosphorylated CD27 in tBreg cells from multiple sclerosis patients and healthy donors**

3.1. Calculate the ratio of pCD27 to CD27 MFI for each sample.

3.2. Compare the ratios between tBreg cells from multiple sclerosis patients and healthy donors using a two-tailed Student's t-test.

**Step 4: Isolate B cells from multiple sclerosis patients and healthy donors and measure the frequency of exhausted B cells (CD21low) using flow cytometry**

4.1. Collect PBMCs from multiple sclerosis patients and healthy donors.

4.2. Stain PBMCs with fluorescently labeled antibodies against CD19, CD21, and CD27.

4.3. Analyze cells using a flow cytometer.

4.4. Calculate the frequency of exhausted B cells (CD21low) as a percentage of total B cells (CD19+).

**Step 5: Co-culture tBreg cells from multiple sclerosis patients and healthy donors with B cells from multiple sclerosis patients and healthy donors, and measure the effect of tBreg cells on B cell exhaustion**

5.1. Co-culture tBreg cells with B cells at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

5.2. Incubate co-cultures at 37°C for 48 hours.

5.3. Stain cells with fluorescently labeled antibodies against CD19, CD21, and CD27.

5.4. Analyze cells using a flow cytometer.

5.5. Calculate the frequency of exhausted B cells (CD21low) as a percentage of total B cells (CD19+).

**Step 6: Use CRISPR-Cas9 to genetically engineer T cells to overexpress CD27 or a constitutively active form of CD27**

6.1. Design gRNAs targeting the CD27 gene.

6.2. Transfect T cells with CRISPR-Cas9 plasmids and gRNAs using a nucleofection device.

6.3. Select for edited T cells using puromycin selection.

**Step 7: Co-culture engineered T cells with tumor cells and assess anti-tumor activity using flow cytometry and qRT-PCR**

7.1. Co-culture engineered T cells with tumor cells at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

7.2. Incubate co-cultures at 37°C for 48 hours.

7.3. Stain cells with fluorescently labeled antibodies against CD8 and CD107a.

7.4. Analyze cells using a flow cytometer.

7.5. Measure tumor cell killing using a cytotoxicity assay, such as the LDH release assay.

7.6. Extract RNA from co-cultures and perform qRT-PCR to measure the expression of anti-tumor genes, such as granzyme B and perforin.

Note: These protocols are detailed and specific, but may require adjustments based on the specific research question, experimental design, and laboratory setup. It is essential to follow proper laboratory protocols, safety guidelines, and ethical considerations when conducting these experiments.","```
   Experiment  CD27_Antibodies  FBS  Penicillin_Streptomycin  T_Breg_Cells  B_Cells  Tumor_Cells  pCD27_MFI  CD27_MFI  Exhausted_B_Cells  T_Cell_Engineering  Anti_Tumor_Activity
0           1             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               0.0               30.0
1           1             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               0.0               35.0
2           1            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               0.0               40.0
3           2             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               1.0               30.0
4           2             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               1.0               35.0
5           2            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               1.0               40.0
6           3             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               0.0               30.0
7           3             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               0.0               35.0
8           3            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               0.0               40.0
9           1             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               0.0               30.0
10          1             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               0.0               35.0
11          1            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               0.0               40.0
12          2             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               1.0               30.0
13          2             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               1.0               35.0
14          2            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               1.0               40.0
15          3             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               0.0               30.0
16          3             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               0.0               35.0
17          3            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               0.0               40.0
18          1             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               0.0               30.0
19          1             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               0.0               35.0
20          1            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               0.0               40.0
21          2             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               1.0               30.0
22          2             7.5   12.0                  1.2         12000      6000        6000       250.0      120.0             25.0               1.0               35.0
23          2            10.0   15.0                  1.5         15000      7500        7500       300.0      150.0             30.0               1.0               40.0
24          3             5.0   10.0                  1.0         10000      5000        5000       200.0      100.0             20.0               0.0               30.0
```",0.8120147876957046
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6b5f752d55050f99e3f71f3596bc7640d666f2c2.summary'],"Does the depletion of follicular B cells in lymphoid tissues, in addition to switched memory B cells, lead to a more complete response to rituximab treatment in rheumatoid arthritis patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and potentially disprove it.

**Hypothesis:** Depletion of follicular B cells in lymphoid tissues, in addition to switched memory B cells, leads to a more complete response to rituximab treatment in rheumatoid arthritis patients.

**Experimental Plan:**

**Title:** Investigating the role of follicular B cells in rituximab treatment of rheumatoid arthritis

**Objective:** To determine whether the depletion of follicular B cells, in addition to switched memory B cells, improves the response to rituximab treatment in rheumatoid arthritis patients.

**Equipment:**

* Flow cytometer
* Lymph node biopsy samples from rheumatoid arthritis patients
* Rituximab
* Antibodies against CD21, CD23, IgD, CD45, and CD27
* Magnetic-activated cell sorting (MACS) system
* Cell culture facilities

**Steps:**

1. **Patient selection and sample collection:** Recruit rheumatoid arthritis patients scheduled to receive rituximab treatment. Collect lymph node biopsy samples from these patients before and after rituximab treatment.
2. **Cell isolation and staining:** Isolate lymph node cells and stain with antibodies against CD21, CD23, IgD, CD45, and CD27 to identify follicular B cells (CD21+CD23+IgDhighIgMvariable) and switched memory B cells (CD27+IgD-).
3. **Cell sorting and depletion:** Use MACS to sort and deplete follicular B cells and switched memory B cells from the lymph node cells. Create three groups:
	* Group 1: Depletion of switched memory B cells only (using anti-CD27 and anti-IgD antibodies)
	* Group 2: Depletion of follicular B cells only (using anti-CD21 and anti-CD23 antibodies)
	* Group 3: Depletion of both switched memory B cells and follicular B cells (using anti-CD27, anti-IgD, anti-CD21, and anti-CD23 antibodies)
4. **Rituximab treatment and cell re-infusion:** Treat rheumatoid arthritis patients with rituximab. Re-infuse the depleted cell populations (Groups 1-3) into the patients.
5. **Response evaluation:** Monitor patients' response to treatment using clinical and laboratory assessments, such as disease activity scores (DAS28), C-reactive protein (CRP) levels, and rheumatoid factor (RF) titers.
6. **Comparison and analysis:** Compare the response to treatment between the three groups. Analyze the frequency of follicular B cells and switched memory B cells in the lymph node biopsies before and after treatment using flow cytometry.

**Design to disprove the hypothesis:**

To disprove the hypothesis, we will focus on the following aspects:

* **Lack of correlation between follicular B cell depletion and treatment response:** If the depletion of follicular B cells does not lead to a more complete response to rituximab treatment, it would suggest that the hypothesis is incorrect.
* **No additive effect of follicular B cell depletion:** If the depletion of both switched memory B cells and follicular B cells does not result in a better treatment response compared to depleting switched memory B cells alone, it would indicate that the hypothesis is false.
* **Follicular B cell depletion has no impact on switched memory B cell persistence:** If the depletion of follicular B cells does not affect the persistence of switched memory B cells in lymphoid tissues, it would suggest that the hypothesis is incorrect.

By following this experimental plan, we can test the hypothesis and potentially disprove it, providing valuable insights into the role of follicular B cells in rituximab treatment of rheumatoid arthritis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Selection and Sample Collection**

1.1. Identify rheumatoid arthritis patients scheduled to receive rituximab treatment through collaboration with rheumatologists and review of patient records.

1.2. Obtain informed consent from patients and ensure compliance with institutional review board (IRB) guidelines.

1.3. Schedule lymph node biopsy procedures for each patient before and after rituximab treatment.

1.4. Collect lymph node biopsy samples in sterile containers and store them at 4°C until processing.

**Protocol 2: Cell Isolation and Staining**

2.1. Process lymph node biopsy samples by mechanical disruption and enzymatic digestion to obtain single-cell suspensions.

2.2. Wash cells with phosphate-buffered saline (PBS) and resuspend in 1 mL of PBS.

2.3. Add 10 μL of each antibody (CD21, CD23, IgD, CD45, and CD27) to the cell suspension and incubate for 30 minutes at 4°C in the dark.

2.4. Wash cells with PBS and resuspend in 1 mL of PBS.

**Protocol 3: Cell Sorting and Depletion**

3.1. Prepare the MACS system according to the manufacturer's instructions.

3.2. Add 100 μL of MACS buffer to the cell suspension and mix well.

3.3. Add 10 μL of anti-CD27 and anti-IgD antibodies to the cell suspension (Group 1) and mix well.

3.4. Add 10 μL of anti-CD21 and anti-CD23 antibodies to the cell suspension (Group 2) and mix well.

3.5. Add 10 μL of anti-CD27, anti-IgD, anti-CD21, and anti-CD23 antibodies to the cell suspension (Group 3) and mix well.

3.6. Run the cell suspensions through the MACS system according to the manufacturer's instructions to sort and deplete the desired cell populations.

**Protocol 4: Rituximab Treatment and Cell Re-infusion**

4.1. Administer rituximab treatment to patients according to the standard treatment protocol.

4.2. Re-infuse the depleted cell populations (Groups 1-3) into the patients through intravenous injection.

**Protocol 5: Response Evaluation**

5.1. Schedule follow-up appointments with patients at 1, 3, and 6 months after rituximab treatment.

5.2. Collect blood samples from patients at each follow-up appointment.

5.3. Measure disease activity scores (DAS28), C-reactive protein (CRP) levels, and rheumatoid factor (RF) titers using standard laboratory assays.

**Protocol 6: Comparison and Analysis**

6.1. Analyze the frequency of follicular B cells and switched memory B cells in the lymph node biopsies before and after treatment using flow cytometry.

6.2. Compare the response to treatment between the three groups using statistical analysis software (e.g., GraphPad Prism).

6.3. Evaluate the correlation between follicular B cell depletion and treatment response using linear regression analysis.

6.4. Compare the treatment response between Group 1 and Group 3 to determine if the depletion of both switched memory B cells and follicular B cells results in a better treatment response.

6.5. Analyze the persistence of switched memory B cells in lymphoid tissues after follicular B cell depletion using flow cytometry.

By following these detailed protocols, the experiment can be replicated and the hypothesis can be tested and potentially disproven.","```
   Patient_ID  CD21  CD23  IgD  CD45  CD27  Rituximab_Dose  DAS28_Change  CRP_Change  RF_Titer_Change
0           1    5.0   3.0  2.0   100.0   10.0          500.0        -1.2        -0.5          -20.0
1           2    3.0   2.0  1.0    80.0    8.0          400.0        -0.8        -0.3          -15.0
2           3    4.0   3.0  2.0    90.0    9.0          450.0        -1.0        -0.4          -18.0
3           4    2.0   1.0  1.0    70.0    7.0          350.0        -0.6        -0.2          -12.0
4           5    5.0   4.0  3.0   110.0   11.0          550.0        -1.4        -0.6          -25.0
5           6    3.0   2.0  2.0    85.0    9.0          420.0        -0.9        -0.4          -16.0
6           7    4.0   3.0  2.0    95.0   10.0          480.0        -1.1        -0.5          -20.0
7           8    2.0   1.0  1.0    75.0    8.0          380.0        -0.7        -0.3          -14.0
8           9    5.0   4.0  3.0   105.0   11.0          520.0        -1.3        -0.6          -22.0
9          10    3.0   2.0  2.0    80.0    9.0          400.0        -0.8        -0.4          -15.0
10         11    4.0   3.0  2.0    90.0   10.0          460.0        -1.0        -0.5          -18.0
11         12    2.0   1.0  1.0    70.0    7.0          340.0        -0.6        -0.2          -12.0
12         13    5.0   4.0  3.0   110.0   11.0          540.0        -1.4        -0.6          -25.0
13         14    3.0   2.0  2.0    85.0    9.0          430.0        -0.9        -0.4          -16.0
14         15    4.0   3.0  2.0    95.0   10.0          490.0        -1.1        -0.5          -20.0
15         16    2.0   1.0  1.0    75.0    8.0          390.0        -0.7        -0.3          -14.0
16         17    5.0   4.0  3.0   105.0   11.0          510.0        -1.3        -0.6          -22.0
17         18    3.0   2.0  2.0    80.0    9.0          410.0        -0.8        -0.4          -15.0
18         19    4.0   3.0  2.0    90.0   10.0          470.0        -1.0        -0.5          -18.0
19         20    2.0   1.0  1.0    70.0    7.0          360.0        -0.6        -0.2          -12.0
20         21    5.0   4.0  3.0   110.0   11.0          530.0        -1.4        -0.6          -25.0
21         22    3.0   2.0  2.0    85.0    9.0          440.0        -0.9        -0.4          -16.0
22         23    4.0   3.0  2.0    95.0   10.0          500.0        -1.1        -0.5          -20.0
23         24    2.0   1.0  1.0    75.0    8.0          400.0        -0.7        -0.3          -14.0
24         25    5.0   4.0  3.0   105.0   11.0          520.0        -1.3        -0.6          -22.0
```",0.4276502395914119
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/663dc23928bda2870896ddb262b1fb9903d438bd.summary'],Does the depletion of naïve B cells in lung tissue also alleviate pulmonary fibrosis in patients with idiopathic pulmonary fibrosis?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Depletion of naïve B cells in lung tissue alleviates pulmonary fibrosis in patients with idiopathic pulmonary fibrosis.

**Experimental Plan:**

**Objective:** To investigate whether depletion of naïve B cells in lung tissue reduces pulmonary fibrosis in patients with idiopathic pulmonary fibrosis.

**Experimental Design:**

1. **Animal Model:** Use a well-established mouse model of idiopathic pulmonary fibrosis (IPF), such as the bleomycin-induced pulmonary fibrosis model.
2. **Naïve B Cell Depletion:** Develop a strategy to specifically deplete naïve B cells in the lung tissue of IPF mice. This can be achieved using:
	* Adoptive transfer of B cell-depleting antibodies (e.g., anti-CD20) or
	* Genetic engineering to create mice with conditional B cell knockout in the lung tissue.
3. **Pulmonary Fibrosis Induction:** Induce pulmonary fibrosis in both control and naïve B cell-depleted mice using bleomycin.
4. **Experimental Groups:**
	* Control group: IPF mice with intact naïve B cells
	* Treatment group: IPF mice with depleted naïve B cells
5. **Outcome Measures:**
	* Pulmonary fibrosis severity: Assess using histopathological analysis of lung tissue, including collagen deposition, fibroblast proliferation, and inflammatory cell infiltration.
	* Lung function: Measure using spirometry and lung compliance tests.
	* Naïve B cell depletion: Verify using flow cytometry and immunohistochemistry.
6. **Sample Size:** Use a minimum of 10 mice per group to ensure statistical significance.
7. **Duration:** The experiment will span 12 weeks, with pulmonary fibrosis induction at week 0 and outcome measures taken at weeks 4, 8, and 12.

**Experiment to Disprove the Hypothesis:**

To verify the hypothesis, we will design an experiment to disprove it. If the results contradict the hypothesis, it will provide strong evidence for its validity.

**Null Hypothesis:** Depletion of naïve B cells in lung tissue does not alleviate pulmonary fibrosis in patients with idiopathic pulmonary fibrosis.

**Experimental Design:**

1. **Identical Setup:** Use the same animal model, pulmonary fibrosis induction, and experimental groups as above.
2. **Additional Control Group:** Include an additional control group with IPF mice that receive a sham treatment (e.g., isotype control antibody) to deplete naïve B cells.
3. **Outcome Measures:** Same as above.
4. **Sample Size:** Same as above.
5. **Duration:** Same as above.

**Rationale:** If the results show that the treatment group (naïve B cell-depleted mice) does not exhibit reduced pulmonary fibrosis compared to the control group (intact naïve B cells), it would suggest that depletion of naïve B cells does not alleviate pulmonary fibrosis, thereby disproving the original hypothesis.

**Unlimited Budget Considerations:**

With an unlimited budget, we can:

* Utilize cutting-edge technologies, such as single-cell RNA sequencing and spatial transcriptomics, to gain a deeper understanding of the molecular mechanisms underlying pulmonary fibrosis and naïve B cell depletion.
* Perform large-scale screens to identify potential biomarkers for pulmonary fibrosis and naïve B cell depletion.
* Collaborate with experts in the field to develop novel therapeutic strategies targeting naïve B cells in pulmonary fibrosis.
* Conduct parallel studies in human subjects with IPF to validate the findings in a clinical setting.

By following this experimental plan, we can rigorously test the hypothesis and gain valuable insights into the role of naïve B cells in pulmonary fibrosis, ultimately leading to the development of novel therapeutic strategies for this devastating disease.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Animal Model Preparation**

1.1. Obtain 20-25 male or female C57BL/6 mice (6-8 weeks old) from a reputable vendor.

1.2. Acclimate the mice to the laboratory environment for 1 week prior to the experiment.

1.3. Randomly divide the mice into two groups: control group (n=10) and treatment group (n=10).

**Protocol 2: Naïve B Cell Depletion**

2.1. Adoptive Transfer of B Cell-Depleting Antibodies:

a. Prepare anti-CD20 antibodies (e.g., rituximab) according to the manufacturer's instructions.

b. Administer 100 μg of anti-CD20 antibodies intraperitoneally to the treatment group mice on days -3, 0, and 3 relative to bleomycin administration.

c. Verify naïve B cell depletion using flow cytometry and immunohistochemistry (see Protocol 5).

2.2. Genetic Engineering to Create Mice with Conditional B Cell Knockout in the Lung Tissue:

a. Breed mice with a conditional B cell knockout allele (e.g., CD19-CreERT2) with a lung-specific Cre driver (e.g., SPC-rtTA).

b. Administer tamoxifen (1 mg/mouse) intraperitoneally to the treatment group mice on days -3, 0, and 3 relative to bleomycin administration to induce Cre-mediated recombination.

c. Verify naïve B cell depletion using flow cytometry and immunohistochemistry (see Protocol 5).

**Protocol 3: Pulmonary Fibrosis Induction**

3.1. Prepare bleomycin (1 U/mouse) in sterile saline.

3.2. Administer bleomycin intratracheally to both control and treatment group mice on day 0.

**Protocol 4: Experimental Groups and Outcome Measures**

4.1. Control Group: IPF mice with intact naïve B cells.

4.2. Treatment Group: IPF mice with depleted naïve B cells.

4.3. Outcome Measures:

a. Pulmonary fibrosis severity: Assess using histopathological analysis of lung tissue, including collagen deposition, fibroblast proliferation, and inflammatory cell infiltration.

b. Lung function: Measure using spirometry and lung compliance tests.

c. Naïve B cell depletion: Verify using flow cytometry and immunohistochemistry.

**Protocol 5: Flow Cytometry and Immunohistochemistry**

5.1. Prepare single-cell suspensions from lung tissue using collagenase digestion and red blood cell lysis.

5.2. Stain cells with fluorochrome-conjugated antibodies against CD19, CD20, and CD45 for flow cytometry.

5.3. Analyze cells using a flow cytometer and gating strategy to identify naïve B cells (CD19+CD20+CD45+).

5.4. Perform immunohistochemistry on lung tissue sections using antibodies against CD19, CD20, and collagen I.

5.5. Quantify collagen deposition and fibroblast proliferation using image analysis software.

**Protocol 6: Spirometry and Lung Compliance Tests**

6.1. Anesthetize mice using isoflurane.

6.2. Perform spirometry using a mouse ventilator and measure forced vital capacity (FVC), forced expiratory volume (FEV), and peak expiratory flow (PEF).

6.3. Measure lung compliance using a pressure-volume curve analyzer.

**Protocol 7: Sample Collection and Storage**

7.1. Collect lung tissue samples at weeks 4, 8, and 12 post-bleomycin administration.

7.2. Store samples in 10% formalin for histopathological analysis or in RNA later for RNA sequencing.

**Protocol 8: Data Analysis**

8.1. Compare outcome measures between control and treatment groups using statistical software (e.g., GraphPad Prism).

8.2. Perform one-way ANOVA with Tukey's post-hoc test to determine significant differences between groups.

8.3. Calculate the effect size and confidence intervals for each outcome measure.

**Experiment to Disprove the Hypothesis:**

**Protocol 9: Additional Control Group**

9.1. Prepare an additional control group with IPF mice that receive a sham treatment (e.g., isotype control antibody) to deplete naïve B cells.

9.2. Follow the same protocols as above for the additional control group.

**Protocol 10: Data Analysis**

10.1. Compare outcome measures between the control group, treatment group, and additional control group using statistical software (e.g., GraphPad Prism).

10.2. Perform one-way ANOVA with Tukey's post-hoc test to determine significant differences between groups.

10.3. Calculate the effect size and confidence intervals for each outcome measure.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis.","```
   Anti-CD20 Antibodies (μg)  Tamoxifen (mg)  Bleomycin (U)  Naïve B Cell Depletion  Pulmonary Fibrosis Severity  Lung Function
0                    50.0         0.5         0.8                  0.6                  0.4               0.7
1                    75.0         0.8         1.0                  0.8                  0.6               0.9
2                    100.0        1.0         1.2                  0.9                  0.7               1.0
3                    80.0         0.9         1.1                  0.8                  0.6               0.9
4                    60.0         0.7         0.9                  0.7                  0.5               0.8
5                    90.0         1.1         1.3                  0.9                  0.8               1.1
6                    110.0        1.2         1.4                  0.9                  0.8               1.1
7                    70.0         0.8         1.0                  0.8                  0.6               0.9
8                    85.0         1.0         1.2                  0.9                  0.7               1.0
9                    95.0         1.1         1.3                  0.9                  0.8               1.1
10                   105.0        1.2         1.4                  0.9                  0.8               1.1
11                   65.0         0.7         0.9                  0.7                  0.5               0.8
12                   80.0         0.9         1.1                  0.8                  0.6               0.9
13                   100.0        1.0         1.2                  0.9                  0.7               1.0
14                   90.0         1.1         1.3                  0.9                  0.8               1.1
15                   110.0        1.2         1.4                  0.9                  0.8               1.1
16                   75.0         0.8         1.0                  0.8                  0.6               0.9
17                   85.0         1.0         1.2                  0.9                  0.7               1.0
18                   95.0         1.1         1.3                  0.9                  0.8               1.1
19                   105.0        1.2         1.4                  0.9                  0.8               1.1
20                   60.0         0.7         0.9                  0.7                  0.5               0.8
21                   70.0         0.8         1.0                  0.8                  0.6               0.9
22                   80.0         0.9         1.1                  0.8                  0.6               0.9
23                   90.0         1.1         1.3                  0.9                  0.8               1.1
24                   100.0        1.2         1.4                  0.9                  0.8               1.1
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0542f1c0eab6d0e4d518c6a4afc01d9c02e83728.summary'],Does the downregulation of PTEN by microRNA-21-5p also contribute to the development of airway hyperresponsiveness in asthma patients by altering the expression of calcium-handling genes in airway smooth muscle cells?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it. Here's a high-level approach to investigate the role of microRNA-21-5p in airway hyperresponsiveness in asthma patients:

**Experimental Plan:**

**Objective:** To determine whether the downregulation of PTEN by microRNA-21-5p contributes to the development of airway hyperresponsiveness in asthma patients by altering the expression of calcium-handling genes in airway smooth muscle cells.

**Experimental Design:**

1. **Cell Culture and Transfection:**
	* Obtain human airway smooth muscle cells (ASMCs) from healthy donors and asthma patients.
	* Culture ASMCs in a controlled environment (e.g., 37°C, 5% CO2).
	* Transfect ASMCs with microRNA-21-5p mimics or inhibitors using a suitable transfection reagent (e.g., Lipofectamine).
	* Verify microRNA-21-5p expression levels using quantitative real-time PCR (qRT-PCR).
2. **PTEN Downregulation and Calcium-Handling Gene Expression:**
	* Measure PTEN protein levels in transfected ASMCs using Western blotting or ELISA.
	* Analyze the expression of calcium-handling genes (e.g., SERCA2, IP3R, RyR) using qRT-PCR, Western blotting, or RNA sequencing (RNA-seq).
	* Investigate the effect of microRNA-21-5p on calcium signaling pathways using calcium imaging techniques (e.g., Fluo-4 AM, Fura-2 AM).
3. **Airway Hyperresponsiveness Assay:**
	* Develop an in vitro airway hyperresponsiveness model using ASMCs and a contractility assay (e.g., isometric tension measurement).
	* Measure the contractile response of ASMCs to bronchoconstrictors (e.g., acetylcholine, histamine) in the presence or absence of microRNA-21-5p mimics or inhibitors.
4. **In Vivo Validation:**
	* Use a mouse model of asthma (e.g., ovalbumin-induced allergic airway inflammation) to validate the in vitro findings.
	* Deliver microRNA-21-5p mimics or inhibitors to the lungs of mice using a suitable delivery method (e.g., adenoviral vectors, nanoparticles).
	* Measure airway hyperresponsiveness using invasive (e.g., plethysmography) or non-invasive (e.g., forced oscillation technique) methods.
5. **Data Analysis and Integration:**
	* Perform statistical analysis using suitable software (e.g., R, Prism) to compare the results between different groups.
	* Integrate the data from the in vitro and in vivo experiments to draw conclusions about the role of microRNA-21-5p in airway hyperresponsiveness.

**Additional Considerations:**

* Use appropriate controls and replicates to ensure the reliability of the results.
* Validate the specificity of microRNA-21-5p mimics and inhibitors using suitable controls (e.g., scrambled sequences).
* Consider using single-cell RNA-seq or other single-cell analysis techniques to investigate the heterogeneity of ASMCs and their response to microRNA-21-5p.
* Collaborate with clinicians to collect and analyze human samples (e.g., bronchial biopsies, bronchoalveolar lavage fluid) to validate the findings in asthma patients.

**Timeline:**

* Literature review and experimental design: 2 weeks
* Cell culture and transfection: 4 weeks
* PTEN downregulation and calcium-handling gene expression analysis: 8 weeks
* Airway hyperresponsiveness assay: 8 weeks
* In vivo validation: 12 weeks
* Data analysis and integration: 12 weeks

**Budget:**

* Personnel: 2 postdoctoral researchers, 2 graduate students, 1 technician (salaries, benefits, and training)
* Reagents and consumables: cell culture media, transfection reagents, antibodies, primers, RNA sequencing kits, etc.
* Equipment: cell culture incubators, microscopes, Western blotting apparatus, qRT-PCR machines, etc.
* Animal costs: mice, housing, food, and veterinary care
* Travel and training: attendance at conferences, workshops, and training sessions

With an unlimited budget, the timeline can be accelerated by hiring additional personnel, purchasing high-throughput equipment, and outsourcing certain tasks to contract research organizations (CROs).",92,"Here are the detailed, step-by-step protocols for each section of the experimental plan:

**Cell Culture and Transfection:**

1.1. Obtain human airway smooth muscle cells (ASMCs) from healthy donors and asthma patients:
	* Contact a tissue bank or a collaborator to obtain ASMCs from healthy donors and asthma patients.
	* Ensure that the cells are isolated and characterized according to established protocols.
	* Store the cells in liquid nitrogen or at -80°C until use.

1.2. Culture ASMCs in a controlled environment:
	* Thaw the ASMCs and resuspend them in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
	* Plate the cells in 6-well plates or 10-cm dishes at a density of 1 x 10^5 cells/cm^2.
	* Incubate the cells at 37°C, 5% CO2, and 95% humidity.

1.3. Transfect ASMCs with microRNA-21-5p mimics or inhibitors:
	* Design and synthesize microRNA-21-5p mimics and inhibitors with a suitable backbone (e.g., 2'-O-methyl or 2'-fluoro) and a fluorescent label (e.g., Cy3 or FAM).
	* Prepare the transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
	* Mix the microRNA-21-5p mimics or inhibitors with the transfection reagent and add the mixture to the ASMCs at a final concentration of 50 nM.
	* Incubate the cells for 4-6 hours to allow for transfection.

1.4. Verify microRNA-21-5p expression levels using qRT-PCR:
	* Extract total RNA from the transfected ASMCs using a suitable method (e.g., TRIzol or RNeasy).
	* Perform qRT-PCR using a microRNA-specific primer set and a suitable reference gene (e.g., U6 or GAPDH).
	* Analyze the qRT-PCR data using the 2^(-ΔΔCt) method to determine the fold change in microRNA-21-5p expression.

**PTEN Downregulation and Calcium-Handling Gene Expression:**

2.1. Measure PTEN protein levels in transfected ASMCs using Western blotting or ELISA:
	* Extract protein from the transfected ASMCs using a suitable method (e.g., RIPA buffer or M-PER).
	* Perform Western blotting using a PTEN-specific antibody and a suitable loading control (e.g., GAPDH or β-actin).
	* Alternatively, perform ELISA using a PTEN-specific antibody and a suitable standard curve.

2.2. Analyze the expression of calcium-handling genes using qRT-PCR, Western blotting, or RNA sequencing (RNA-seq):
	* Extract total RNA from the transfected ASMCs using a suitable method (e.g., TRIzol or RNeasy).
	* Perform qRT-PCR using gene-specific primer sets and a suitable reference gene (e.g., GAPDH or β-actin).
	* Alternatively, perform Western blotting using gene-specific antibodies and a suitable loading control.
	* Alternatively, perform RNA-seq using a suitable library preparation kit and a next-generation sequencing platform.

2.3. Investigate the effect of microRNA-21-5p on calcium signaling pathways using calcium imaging techniques:
	* Load the transfected ASMCs with a calcium-sensitive dye (e.g., Fluo-4 AM or Fura-2 AM) according to the manufacturer's instructions.
	* Perform calcium imaging using a suitable microscope and software (e.g., confocal or epifluorescence).
	* Analyze the calcium imaging data using suitable software (e.g., ImageJ or MetaXpress).

**Airway Hyperresponsiveness Assay:**

3.1. Develop an in vitro airway hyperresponsiveness model using ASMCs and a contractility assay:
	* Plate the transfected ASMCs in a 96-well plate or a silicone chamber at a density of 1 x 10^5 cells/cm^2.
	* Add a bronchoconstrictor (e.g., acetylcholine or histamine) to the ASMCs at a suitable concentration (e.g., 10^-5 M).
	* Measure the contractile response of the ASMCs using a suitable method (e.g., isometric tension measurement or video microscopy).

3.2. Measure the contractile response of ASMCs to bronchoconstrictors in the presence or absence of microRNA-21-5p mimics or inhibitors:
	* Perform the contractility assay in the presence or absence of microRNA-21-5p mimics or inhibitors at a suitable concentration (e.g., 50 nM).
	* Analyze the contractility data using suitable software (e.g., GraphPad Prism or R).

**In Vivo Validation:**

4.1. Use a mouse model of asthma (e.g., ovalbumin-induced allergic airway inflammation) to validate the in vitro findings:
	* Obtain mice from a suitable vendor or breeding colony.
	* Induce allergic airway inflammation in the mice using ovalbumin or another suitable allergen.
	* Deliver microRNA-21-5p mimics or inhibitors to the lungs of mice using a suitable delivery method (e.g., adenoviral vectors or nanoparticles).

4.2. Measure airway hyperresponsiveness using invasive (e.g., plethysmography) or non-invasive (e.g., forced oscillation technique) methods:
	* Perform plethysmography or forced oscillation technique on the mice according to established protocols.
	* Analyze the airway hyperresponsiveness data using suitable software (e.g., LabChart or FlexiVent).

**Data Analysis and Integration:**

5.1. Perform statistical analysis using suitable software (e.g., R or Prism) to compare the results between different groups:
	* Perform t-tests, ANOVA, or regression analysis to compare the results between different groups.
	* Adjust for multiple comparisons using suitable methods (e.g., Bonferroni or Holm-Bonferroni).

5.2. Integrate the data from the in vitro and in vivo experiments to draw conclusions about the role of microRNA-21-5p in airway hyperresponsiveness:
	* Use suitable visualization tools (e.g., heatmaps or clustering) to integrate the data from different experiments.
	* Perform pathway analysis using suitable software (e.g., Ingenuity Pathway Analysis or Reactome) to identify key pathways and networks involved in airway hyperresponsiveness.

Note: These protocols are detailed and specific, but they may require modifications based on the specific requirements of the experiment and the equipment available. It is essential to follow proper laboratory protocols, safety guidelines, and animal welfare regulations when conducting these experiments.","```
   Donor_Type  FBS_Conc  Penicillin_Conc  L_Glutamine_Conc  microRNA_Conc  PTEN_Level  Calcium_Signal  Contractile_Response
0    Healthy    10.0%          1.0%             1.0%           50.0         0.8          1.2               0.5
1    Asthma     12.0%          1.2%             1.2%           40.0         0.6          1.5               0.7
2    Healthy     9.0%          0.8%             0.8%           60.0         0.9          1.0               0.4
3    Asthma     11.0%          1.1%             1.1%           45.0         0.7          1.4               0.6
4    Healthy    10.5%          1.0%             1.0%           55.0         0.8          1.1               0.5
5    Asthma     12.5%          1.3%             1.3%           35.0         0.5          1.6               0.8
6    Healthy     9.5%          0.9%             0.9%           65.0         0.9          0.9               0.3
7    Asthma     11.5%          1.2%             1.2%           40.0         0.6          1.5               0.7
8    Healthy    10.0%          1.0%             1.0%           50.0         0.8          1.2               0.5
9    Asthma     12.0%          1.2%             1.2%           40.0         0.6          1.5               0.7
10   Healthy     9.0%          0.8%             0.8%           60.0         0.9          1.0               0.4
11   Asthma     11.0%          1.1%             1.1%           45.0         0.7          1.4               0.6
12   Healthy    10.5%          1.0%             1.0%           55.0         0.8          1.1               0.5
13   Asthma     12.5%          1.3%             1.3%           35.0         0.5          1.6               0.8
14   Healthy     9.5%          0.9%             0.9%           65.0         0.9          0.9               0.3
15   Asthma     11.5%          1.2%             1.2%           40.0         0.6          1.5               0.7
16   Healthy    10.0%          1.0%             1.0%           50.0         0.8          1.2               0.5
17   Asthma     12.0%          1.2%             1.2%           40.0         0.6          1.5               0.7
18   Healthy     9.0%          0.8%             0.8%           60.0         0.9          1.0               0.4
19   Asthma     11.0%          1.1%             1.1%           45.0         0.7          1.4               0.6
20   Healthy    10.5%          1.0%             1.0%           55.0         0.8          1.1               0.5
21   Asthma     12.5%          1.3%             1.3%           35.0         0.5          1.6               0.8
22   Healthy     9.5%          0.9%             0.9%           65.0         0.9          0.9               0.3
23   Asthma     11.5%          1.2%             1.2%           40.0         0.6          1.5               0.7
24   Healthy    10.0%          1.0%             1.0%           50.0         0.8          1.2               0.5
```",0.03475542507169845
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1530a6a65e5c8c97b20293f20b4c41d071f70bc4.summary'],"Does the duration of macrophage hypophagia inversely correlate with the expression of autophagy-related genes, leading to a potential therapeutic target for enhancing ADCP-mediated cell clearance?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Correlation between Macrophage Hypophagia Duration and Autophagy-Related Gene Expression

**Objective:** To determine if the duration of macrophage hypophagia inversely correlates with the expression of autophagy-related genes, potentially identifying a therapeutic target for enhancing ADCP-mediated cell clearance.

**Equipment:**

* Flow cytometer
* qRT-PCR machine
* Autophagy-related gene-specific primers and probes
* Macrophage cell culture facilities
* ADCP assay setup
* Opsonized target cells
* Fc receptor-specific antibodies
* Proteasome inhibitors (optional)

**Steps:**

1. Isolate and culture macrophages from mice or humans.
2. Perform ADCP assays with opsonized target cells and measure phagocytic index to induce macrophage hypophagia.
3. At various time points (e.g., 0, 2, 4, 6, 12, and 24 hours) after ADCP, collect macrophage samples for RNA extraction and qRT-PCR analysis of autophagy-related gene expression (e.g., LC3, ATG5, ATG7, Beclin-1).
4. Use flow cytometry to analyze Fc receptor expression on macrophages at the same time points to monitor macrophage hypophagia.
5. Correlate the duration of macrophage hypophagia with autophagy-related gene expression levels using statistical analysis.
6. To further investigate the potential therapeutic target, treat macrophages with autophagy-inducing compounds (e.g., rapamycin) or autophagy-inhibiting compounds (e.g., chloroquine) and measure the effect on ADCP-mediated cell clearance.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Correlation between Macrophage Hypophagia Duration and Autophagy-Related Gene Expression

**Objective:** To demonstrate that the duration of macrophage hypophagia does not inversely correlate with the expression of autophagy-related genes, thereby disproving the hypothesis.

**Equipment:**

* Same as above, with the addition of:
	+ siRNA or CRISPR-Cas9 system for autophagy-related gene knockdown or knockout
	+ Autophagy-related gene overexpression plasmids

**Steps:**

1. Isolate and culture macrophages from mice or humans.
2. Perform ADCP assays with opsonized target cells and measure phagocytic index to induce macrophage hypophagia.
3. At various time points (e.g., 0, 2, 4, 6, 12, and 24 hours) after ADCP, collect macrophage samples for RNA extraction and qRT-PCR analysis of autophagy-related gene expression.
4. Use flow cytometry to analyze Fc receptor expression on macrophages at the same time points to monitor macrophage hypophagia.
5. Use siRNA or CRISPR-Cas9 to knockdown or knockout autophagy-related genes in macrophages and repeat steps 2-4.
6. Alternatively, overexpress autophagy-related genes in macrophages using plasmids and repeat steps 2-4.
7. Analyze the data to determine if the duration of macrophage hypophagia remains unaffected by autophagy-related gene expression levels, thereby disproving the hypothesis.

By performing these experiments, we can test the hypothesis and attempt to disprove it, providing a comprehensive understanding of the relationship between macrophage hypophagia duration and autophagy-related gene expression.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Correlation between Macrophage Hypophagia Duration and Autophagy-Related Gene Expression

**Objective:** To determine if the duration of macrophage hypophagia inversely correlates with the expression of autophagy-related genes, potentially identifying a therapeutic target for enhancing ADCP-mediated cell clearance.

**Step 1: Isolate and Culture Macrophages**

1.1. Obtain mouse or human macrophage cells from a reliable source (e.g., cell bank or in-house isolation).

1.2. Culture macrophages in a suitable medium (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin) at 37°C and 5% CO2.

1.3. Verify macrophage purity and viability using flow cytometry (e.g., CD11b+ and CD14+ markers) and trypan blue exclusion, respectively.

**Step 2: Perform ADCP Assays**

2.1. Prepare opsonized target cells by incubating them with Fc receptor-specific antibodies (e.g., anti-CD16/CD32) for 30 minutes at 4°C.

2.2. Add opsonized target cells to macrophage cultures at a 1:1 ratio and incubate for 30 minutes at 37°C.

2.3. Measure phagocytic index using a flow cytometer (e.g., BD FACSCanto II) and calculate the percentage of macrophages that have engulfed target cells.

**Step 3: Collect Macrophage Samples and Extract RNA**

3.1. At each time point (0, 2, 4, 6, 12, and 24 hours) after ADCP, collect macrophage samples in RNA extraction buffer (e.g., TRIzol).

3.2. Extract total RNA using a commercial kit (e.g., Qiagen RNeasy Mini Kit) according to the manufacturer's instructions.

3.3. Quantify RNA concentration and purity using a spectrophotometer (e.g., NanoDrop 2000).

**Step 4: Analyze Autophagy-Related Gene Expression**

4.1. Design and synthesize autophagy-related gene-specific primers and probes (e.g., LC3, ATG5, ATG7, Beclin-1) using a commercial software (e.g., Primer3).

4.2. Perform qRT-PCR using a commercial kit (e.g., Applied Biosystems PowerUp SYBR Green Master Mix) and a qRT-PCR machine (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).

4.3. Analyze qRT-PCR data using a commercial software (e.g., Applied Biosystems 7500 Software v2.3) and calculate the relative expression levels of autophagy-related genes.

**Step 5: Analyze Fc Receptor Expression**

5.1. Stain macrophages with Fc receptor-specific antibodies (e.g., anti-CD16/CD32) and a secondary antibody (e.g., Alexa Fluor 488) for 30 minutes at 4°C.

5.2. Analyze Fc receptor expression using a flow cytometer (e.g., BD FACSCanto II) and calculate the mean fluorescence intensity (MFI).

**Step 6: Correlate Macrophage Hypophagia Duration with Autophagy-Related Gene Expression**

6.1. Plot the duration of macrophage hypophagia (measured by Fc receptor expression) against autophagy-related gene expression levels.

6.2. Perform statistical analysis (e.g., Pearson correlation coefficient) to determine the correlation between macrophage hypophagia duration and autophagy-related gene expression.

**Step 7: Investigate Therapeutic Target**

7.1. Treat macrophages with autophagy-inducing compounds (e.g., rapamycin) or autophagy-inhibiting compounds (e.g., chloroquine) for 24 hours.

7.2. Repeat steps 2-6 to measure the effect of autophagy modulation on ADCP-mediated cell clearance.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Correlation between Macrophage Hypophagia Duration and Autophagy-Related Gene Expression

**Objective:** To demonstrate that the duration of macrophage hypophagia does not inversely correlate with the expression of autophagy-related genes, thereby disproving the hypothesis.

**Step 1-4: Same as above**

**Step 5: Knockdown or Knockout Autophagy-Related Genes**

5.1. Design and synthesize siRNA or CRISPR-Cas9 guide RNAs targeting autophagy-related genes (e.g., LC3, ATG5, ATG7, Beclin-1).

5.2. Transfect macrophages with siRNA or CRISPR-Cas9 plasmids using a commercial transfection reagent (e.g., Lipofectamine 3000).

5.3. Verify knockdown or knockout efficiency using qRT-PCR or Western blotting.

**Step 6: Overexpress Autophagy-Related Genes**

6.1. Design and synthesize autophagy-related gene overexpression plasmids (e.g., LC3, ATG5, ATG7, Beclin-1).

6.2. Transfect macrophages with overexpression plasmids using a commercial transfection reagent (e.g., Lipofectamine 3000).

6.3. Verify overexpression efficiency using qRT-PCR or Western blotting.

**Step 7: Analyze Data**

7.1. Repeat steps 2-4 to measure macrophage hypophagia duration and autophagy-related gene expression.

7.2. Analyze data to determine if the duration of macrophage hypophagia remains unaffected by autophagy-related gene expression levels, thereby disproving the hypothesis.

These detailed protocols should provide a clear guide for executing the experiments and ensuring replicability and specificity in the results.","```
   Macrophage_Cells  Opsonized_Target_Cells  Fc_Receptor_Specific_Antibodies  Autophagy_Inducing_Compounds  Autophagy_Inhibiting_Compounds  siRNA_CRISPR_Cas9  Overexpression_Plasmids  Macrophage_Hypophagia_Duration  Autophagy_Related_Gene_Expression
0               100000               100000                             10                             0                             0                    0                    0                         4.5                         0.8
1               120000               120000                             12                             0                             0                    0                    0                         5.2                         0.9
2                80000                80000                              8                             0                             0                    0                    0                         3.8                         0.6
3               150000               150000                             15                             0                             0                    0                    0                         6.5                         1.1
4               110000               110000                             11                             0                             0                    0                    0                         5.0                         0.9
5                90000                90000                              9                             0                             0                    0                    0                         4.2                         0.7
6               130000               130000                             13                             0                             0                    0                    0                         6.0                         1.0
7               100000               100000                             10                             1                             0                    0                    0                         4.8                         0.8
8               140000               140000                             14                             0                             0                    0                    0                         6.2                         1.1
9                70000                70000                              7                             0                             0                    0                    0                         3.5                         0.6
10              160000               160000                             16                             0                             0                    0                    0                         6.8                         1.2
11              120000               120000                             12                             1                             0                    0                    0                         5.5                         1.0
12               90000                90000                              9                             0                             0                    1                    0                         4.0                         0.7
13              110000               110000                             11                             0                             0                    0                    1                         5.1                         0.9
14              150000               150000                             15                             1                             0                    0                    0                         6.6                         1.1
15              130000               130000                             13                             0                             0                    1                    0                         5.8                         1.0
16               80000                80000                              8                             0                             0                    0                    1                         4.1                         0.7
17              140000               140000                             14                             1                             0                    0                    0                         6.4                         1.1
18              100000               100000                             10                             0                             1                    0                    0                         4.6                         0.8
19              160000               160000                             16                             0                             0                    1                    0                         6.9                         1.2
20              120000               120000                             12                             0                             1                    0                    0                         5.6                         1.0
21               70000                70000                              7                             0                             0                    0                    1                         3.6                         0.6
22              110000               110000                             11                             1                             0                    0                    0                         5.3                         0.9
23              150000               150000                             15                             0                             1                    0                    0                         6.7                         1.1
24              130000               130000                             13                             1                             0                    0                    0                         6.1                         1.0
```",0.5023149399496596
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9873e8af082abea7315eb8684a0f03b55d4a74c9.summary'],"Does the dynamic interaction between SIRT1 and LSD1 in regulating KU70 also influence the recruitment of other DNA repair pathways, such as homologous recombination, in response to different types of DNA damage?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you develop an experimental plan to test the hypothesis.

**Hypothesis:** The dynamic interaction between SIRT1 and LSD1 in regulating KU70 also influences the recruitment of other DNA repair pathways, such as homologous recombination, in response to different types of DNA damage.

**Experimental Plan:**

**Objective:** To investigate whether the SIRT1-LSD1-KU70 axis affects the recruitment of homologous recombination (HR) pathway in response to different types of DNA damage.

**Experimental Approach:**

1. **Cell Culture and DNA Damage Induction:**
	* Use human cell lines (e.g., HEK293 or U2OS) with inducible SIRT1 and LSD1 expression/knockdown systems.
	* Expose cells to different types of DNA damage, such as:
		+ Ionizing radiation (IR) to induce double-strand breaks (DSBs)
		+ Ultraviolet (UV) light to induce cyclobutane pyrimidine dimers (CPDs)
		+ Chemicals like camptothecin to induce topoisomerase I-mediated DSBs
2. **Protein-Protein Interaction Analysis:**
	* Perform co-immunoprecipitation (Co-IP) assays to investigate the interaction between SIRT1, LSD1, and KU70 in response to different DNA damage types.
	* Use Western blotting to detect the presence of SIRT1, LSD1, KU70, and HR pathway proteins (e.g., RAD51, BRCA2) in the immunoprecipitated complexes.
3. **Homologous Recombination Assay:**
	* Use a DR-GFP (direct repeat-green fluorescent protein) reporter system to measure HR efficiency in response to DNA damage.
	* Transfect cells with a plasmid containing a DR-GFP cassette and a gene encoding a fluorescent protein (e.g., mCherry) as a transfection control.
	* Measure GFP-positive cells by flow cytometry to quantify HR efficiency.
4. **SIRT1 and LSD1 Modulation:**
	* Use small interfering RNA (siRNA) or short hairpin RNA (shRNA) to knockdown SIRT1 and LSD1 expression.
	* Overexpress SIRT1 and LSD1 using plasmids or lentiviral vectors to investigate the effect of increased expression on HR recruitment.
5. **Data Analysis:**
	* Compare the HR efficiency in cells with modulated SIRT1 and LSD1 expression to those with normal expression.
	* Analyze the correlation between SIRT1-LSD1-KU70 interaction and HR recruitment in response to different DNA damage types.

**Experiment to Disprove the Hypothesis:**

**Objective:** To investigate whether the SIRT1-LSD1-KU70 axis is dispensable for HR recruitment in response to DNA damage.

**Experimental Approach:**

1. **SIRT1 and LSD1 Double Knockout (DKO) Cells:**
	* Generate SIRT1 and LSD1 DKO cells using CRISPR-Cas9 genome editing.
	* Verify the knockout efficiency using Western blotting and qRT-PCR.
2. **HR Assay in DKO Cells:**
	* Perform the DR-GFP reporter assay in SIRT1 and LSD1 DKO cells to measure HR efficiency in response to DNA damage.
	* Compare the HR efficiency in DKO cells to that in wild-type cells.
3. **Rescue Experiment:**
	* Reintroduce SIRT1 and LSD1 expression in DKO cells using plasmids or lentiviral vectors.
	* Measure HR efficiency in rescued cells to determine if SIRT1 and LSD1 are required for HR recruitment.

**Budget and Timeframe:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget will cover:
	+ Cell culture and reagents
	+ DNA damage induction and protein-protein interaction analysis
	+ HR assay and flow cytometry
	+ SIRT1 and LSD1 modulation reagents (siRNA, shRNA, plasmids, lentiviral vectors)
	+ CRISPR-Cas9 genome editing and verification
	+ Personnel and laboratory costs

This experimental plan is designed to test the hypothesis and provide evidence for or against the role of SIRT1-LSD1-KU70 axis in regulating HR recruitment in response to DNA damage.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Cell Culture and DNA Damage Induction**

**Objective:** To establish human cell lines with inducible SIRT1 and LSD1 expression/knockdown systems and induce DNA damage using different types of DNA damage.

**Step-by-Step Protocol:**

1.1. Cell Culture:

* Obtain human cell lines (e.g., HEK293 or U2OS) with inducible SIRT1 and LSD1 expression/knockdown systems from a reputable source or generate them in-house using lentiviral vectors.
* Culture cells in a humidified incubator at 37°C, 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
* Verify the expression/knockdown of SIRT1 and LSD1 using Western blotting and qRT-PCR.

1.2. DNA Damage Induction:

* Ionizing Radiation (IR):
	+ Expose cells to 2-10 Gy of IR using a cesium-137 source or a linear accelerator.
	+ Verify DNA damage using the comet assay or γ-H2AX staining.
* Ultraviolet (UV) Light:
	+ Expose cells to 10-50 J/m² of UV light using a UV crosslinker.
	+ Verify DNA damage using the comet assay or CPD staining.
* Chemicals:
	+ Treat cells with 1-10 μM camptothecin for 1-2 hours to induce topoisomerase I-mediated DSBs.
	+ Verify DNA damage using the comet assay or γ-H2AX staining.

**Experiment 2: Protein-Protein Interaction Analysis**

**Objective:** To investigate the interaction between SIRT1, LSD1, and KU70 in response to different DNA damage types using co-immunoprecipitation (Co-IP) assays.

**Step-by-Step Protocol:**

2.1. Co-IP Assay:

* Harvest cells 1-2 hours after DNA damage induction and lyse them in IP lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1% protease inhibitor cocktail).
* Immunoprecipitate SIRT1, LSD1, or KU70 using specific antibodies and protein A/G beads.
* Wash the beads three times with IP wash buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% NP-40).
* Elute the immunoprecipitated complexes using 2x Laemmli buffer and analyze by Western blotting.

2.2. Western Blotting:

* Resolve the immunoprecipitated complexes on a 10% SDS-PAGE gel and transfer to a PVDF membrane.
* Probe the membrane with antibodies against SIRT1, LSD1, KU70, RAD51, and BRCA2.
* Detect protein bands using ECL or chemiluminescence.

**Experiment 3: Homologous Recombination Assay**

**Objective:** To measure homologous recombination (HR) efficiency in response to DNA damage using a DR-GFP reporter system.

**Step-by-Step Protocol:**

3.1. Plasmid Transfection:

* Transfect cells with a plasmid containing a DR-GFP cassette and a gene encoding a fluorescent protein (e.g., mCherry) as a transfection control using a transfection reagent (e.g., Lipofectamine 2000).
* Verify transfection efficiency using flow cytometry.

3.2. DNA Damage Induction:

* Induce DNA damage using the same methods as in Experiment 1.

3.3. Flow Cytometry:

* Harvest cells 48-72 hours after DNA damage induction and stain with a live/dead marker (e.g., propidium iodide).
* Analyze GFP-positive cells using a flow cytometer (e.g., BD FACSCanto II).
* Calculate HR efficiency as the percentage of GFP-positive cells.

**Experiment 4: SIRT1 and LSD1 Modulation**

**Objective:** To investigate the effect of SIRT1 and LSD1 modulation on HR recruitment in response to DNA damage.

**Step-by-Step Protocol:**

4.1. siRNA Transfection:

* Transfect cells with siRNA targeting SIRT1 and LSD1 using a transfection reagent (e.g., Lipofectamine RNAiMAX).
* Verify knockdown efficiency using Western blotting and qRT-PCR.

4.2. Plasmid Transfection:

* Transfect cells with plasmids overexpressing SIRT1 and LSD1 using a transfection reagent (e.g., Lipofectamine 2000).
* Verify overexpression using Western blotting and qRT-PCR.

4.3. HR Assay:

* Perform the DR-GFP reporter assay as in Experiment 3.

**Experiment 5: Data Analysis**

**Objective:** To analyze the correlation between SIRT1-LSD1-KU70 interaction and HR recruitment in response to different DNA damage types.

**Step-by-Step Protocol:**

5.1. Data Collection:

* Collect data from Experiments 1-4, including Co-IP results, Western blotting results, and HR efficiency data.

5.2. Data Analysis:

* Analyze the correlation between SIRT1-LSD1-KU70 interaction and HR recruitment using statistical software (e.g., GraphPad Prism).
* Compare HR efficiency in cells with modulated SIRT1 and LSD1 expression to those with normal expression.

**Experiment to Disprove the Hypothesis:**

**Objective:** To investigate whether the SIRT1-LSD1-KU70 axis is dispensable for HR recruitment in response to DNA damage.

**Step-by-Step Protocol:**

**Experiment 1: SIRT1 and LSD1 Double Knockout (DKO) Cells**

1.1. CRISPR-Cas9 Genome Editing:

* Design guide RNAs targeting SIRT1 and LSD1 using a CRISPR design tool (e.g., CRISPR Design).
* Transfect cells with the CRISPR-Cas9 plasmid and guide RNAs using a transfection reagent (e.g., Lipofectamine 2000).
* Select for edited cells using puromycin or other selection markers.

1.2. Verification:

* Verify the knockout efficiency using Western blotting and qRT-PCR.

**Experiment 2: HR Assay in DKO Cells**

2.1. HR Assay:

* Perform the DR-GFP reporter assay as in Experiment 3.

2.2. Data Analysis:

* Compare HR efficiency in DKO cells to that in wild-type cells.

**Experiment 3: Rescue Experiment**

3.1. Plasmid Transfection:

* Transfect DKO cells with plasmids overexpressing SIRT1 and LSD1 using a transfection reagent (e.g., Lipofectamine 2000).
* Verify overexpression using Western blotting and qRT-PCR.

3.2. HR Assay:

* Perform the DR-GFP reporter assay as in Experiment 3.

3.3. Data Analysis:

* Compare HR efficiency in rescued cells to that in DKO cells.

These detailed, step-by-step protocols should provide a clear guide for executing the experimental plan and testing the hypothesis.","```
   IR_dose  UV_dose  Camptothecin_dose  SIRT1_expression  LSD1_expression  KU70_expression  HR_efficiency
0       2.0       10.0               1.0             0.5             0.8             0.9         0.35
1       5.0       20.0               5.0             0.8             0.6             0.7         0.42
2       8.0       30.0               3.0             0.9             0.7             0.8         0.48
3       4.0       15.0               2.0             0.6             0.9             0.6         0.38
4       6.0       25.0               4.0             0.7             0.8             0.9         0.45
5       3.0       12.0               1.5             0.5             0.7             0.8         0.32
6       9.0       35.0               6.0             0.8             0.9             0.7         0.50
7       7.0       28.0               3.5             0.9             0.8             0.6         0.43
8       1.0       8.0                0.5             0.4             0.6             0.7         0.28
9       5.5       22.0               4.5             0.7             0.9             0.8         0.46
10      8.5       32.0               5.5             0.9             0.8             0.7         0.51
11      4.5       18.0               2.5             0.6             0.7             0.9         0.39
12      6.5       26.0               3.5             0.8             0.9             0.6         0.44
13      3.5       14.0               1.5             0.5             0.8             0.7         0.33
14      9.5       38.0               6.5             0.9             0.8             0.8         0.52
15      7.5       30.0               4.5             0.8             0.9             0.7         0.47
16      2.5       11.0               1.0             0.5             0.7             0.8         0.31
17      5.0       20.0               3.0             0.7             0.8             0.9         0.41
18      8.0       33.0               5.0             0.9             0.8             0.7         0.49
19      4.0       16.0               2.5             0.6             0.7             0.8         0.37
20      6.0       24.0               4.0             0.8             0.9             0.6         0.44
21      3.0       13.0               1.5             0.5             0.8             0.7         0.30
22      9.0       36.0               6.0             0.9             0.8             0.8         0.50
23      7.0       29.0               4.0             0.8             0.9             0.7         0.45
24      5.5       23.0               3.5             0.7             0.8             0.9         0.42
```",0.6952062164826075
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/518f3c66962261e5975cbaed0ac966deb9c3d287.summary'],Does the dysregulation of STIM1 in B cells contribute to the development of autoimmune diseases by altering the calcium signaling pathway and subsequently affecting the expression of FOXO1?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis that the dysregulation of STIM1 in B cells contributes to the development of autoimmune diseases by altering the calcium signaling pathway and subsequently affecting the expression of FOXO1.

**Experiment:**

**Title:** Investigating the Role of STIM1 in Autoimmune Diseases through Calcium Signaling and FOXO1 Expression in B Cells

**Objective:** To determine if the dysregulation of STIM1 in B cells contributes to the development of autoimmune diseases by altering the calcium signaling pathway and subsequently affecting the expression of FOXO1.

**Experimental Design:**

1. **Cell Culture:** Isolate B cells from healthy human donors or use a B cell line (e.g., Ramos or Raji cells).
2. **STIM1 Knockdown:** Use siRNA or shRNA to knockdown STIM1 expression in B cells. Verify the knockdown efficiency using Western blot or qRT-PCR.
3. **Calcium Signaling Analysis:** Measure calcium influx in STIM1-knockdown B cells using a calcium-sensitive dye (e.g., Fluo-4) and a flow cytometer. Compare the results to control B cells with normal STIM1 expression.
4. **FOXO1 Expression Analysis:** Measure FOXO1 expression in STIM1-knockdown B cells using Western blot, qRT-PCR, or immunofluorescence microscopy. Compare the results to control B cells with normal STIM1 expression.
5. **Autoimmune Disease Model:** Use a well-established autoimmune disease model, such as the collagen-induced arthritis (CIA) model in mice, to induce autoimmune disease in mice with STIM1-knockdown B cells.
6. **B Cell Function Analysis:** Analyze B cell function in STIM1-knockdown mice, including antibody production, proliferation, and activation marker expression, using flow cytometry and ELISA.
7. **Control Experiments:** Perform control experiments using B cells with normal STIM1 expression to ensure that the observed effects are specific to STIM1 dysregulation.

**Equipment and Resources:**

* Cell culture facilities
* siRNA/shRNA transfection reagents
* Western blot equipment
* Flow cytometer
* Calcium-sensitive dye (e.g., Fluo-4)
* qRT-PCR machine
* Immunofluorescence microscope
* Mouse facility (for CIA model)
* ELISA equipment

**Time Frame:** This experiment can be completed within 6-9 months, assuming a moderate pace and availability of resources.

**Budget:** The budget for this experiment will depend on the specific resources and equipment available. However, a rough estimate for the costs of reagents, equipment, and personnel can be broken down as follows:

* Reagents and consumables: $10,000 - $15,000
* Equipment maintenance and usage: $5,000 - $10,000
* Personnel (post-doc or graduate student): $20,000 - $30,000 (6-9 months)
* Mouse facility costs: $5,000 - $10,000 (depending on the number of mice and duration of the experiment)

Total estimated budget: $40,000 - $65,000

**Rationale:**

This experiment is designed to test the hypothesis by directly manipulating STIM1 expression in B cells and measuring the effects on calcium signaling and FOXO1 expression. By using a well-established autoimmune disease model, we can assess the impact of STIM1 dysregulation on autoimmune disease development. The control experiments will help to rule out any off-target effects of the STIM1 knockdown.

**Limitations:**

* The experiment relies on the assumption that STIM1 dysregulation is a key contributor to autoimmune disease development, which may not be the case.
* The use of a B cell line or human donors may not fully recapitulate the in vivo environment.
* The CIA model may not be representative of all autoimmune diseases.

By carefully designing and executing this experiment, we can gain valuable insights into the role of STIM1 in autoimmune diseases and potentially identify new therapeutic targets for treatment.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and STIM1 Knockdown**

1.1. Cell Culture:

* Obtain B cells from healthy human donors or use a B cell line (e.g., Ramos or Raji cells).
* Culture the B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.
* Maintain the cells at a density of 1-2 x 10^6 cells/mL.

1.2. STIM1 Knockdown:

* Design and synthesize siRNA or shRNA targeting STIM1 mRNA.
* Transfect the siRNA or shRNA into the B cells using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
* Incubate the cells for 24-48 hours to allow for STIM1 knockdown.
* Verify the knockdown efficiency using Western blot or qRT-PCR.

**Protocol 2: Western Blot for STIM1 Knockdown Verification**

2.1. Cell Lysis:

* Harvest the transfected B cells and wash them with PBS.
* Lyse the cells using a lysis buffer (e.g., RIPA buffer) containing protease inhibitors.
* Centrifuge the lysate at 10,000 x g for 10 minutes to remove debris.

2.2. Protein Separation:

* Separate the proteins using SDS-PAGE (10% gel) and transfer them to a PVDF membrane.
* Block the membrane with 5% non-fat milk in TBST for 1 hour.

2.3. Antibody Incubation:

* Incubate the membrane with a primary antibody against STIM1 (1:1000 dilution) overnight at 4°C.
* Wash the membrane with TBST and incubate with a secondary antibody (1:5000 dilution) for 1 hour at room temperature.

2.4. Detection:

* Detect the protein bands using an ECL detection system and capture the image using a chemiluminescence imager.

**Protocol 3: Calcium Signaling Analysis**

3.1. Calcium Dye Loading:

* Load the STIM1-knockdown B cells with a calcium-sensitive dye (e.g., Fluo-4) according to the manufacturer's instructions.
* Incubate the cells for 30 minutes at 37°C to allow for dye uptake.

3.2. Flow Cytometry:

* Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) equipped with a 488 nm laser.
* Measure the fluorescence intensity of the calcium-sensitive dye using the FL1 channel.

3.3. Data Analysis:

* Gate the cells based on forward and side scatter to exclude debris and dead cells.
* Analyze the fluorescence intensity of the calcium-sensitive dye using flow cytometry software (e.g., FlowJo).

**Protocol 4: FOXO1 Expression Analysis**

4.1. Western Blot:

* Perform Western blot analysis using the same protocol as Protocol 2, but with a primary antibody against FOXO1 (1:1000 dilution).

4.2. qRT-PCR:

* Extract total RNA from the STIM1-knockdown B cells using a RNA extraction kit (e.g., TRIzol).
* Perform qRT-PCR using a FOXO1-specific primer set and a qRT-PCR machine (e.g., Applied Biosystems 7500).

4.3. Immunofluorescence Microscopy:

* Fix the STIM1-knockdown B cells with 4% paraformaldehyde for 15 minutes.
* Permeabilize the cells with 0.1% Triton X-100 for 10 minutes.
* Incubate the cells with a primary antibody against FOXO1 (1:100 dilution) overnight at 4°C.
* Incubate the cells with a secondary antibody (1:500 dilution) for 1 hour at room temperature.
* Capture images using a fluorescence microscope (e.g., Zeiss Axiovert 200M).

**Protocol 5: Autoimmune Disease Model (Collagen-Induced Arthritis Model)**

5.1. Mouse Preparation:

* Obtain mice (e.g., C57BL/6) and maintain them in a specific pathogen-free facility.
* Inject the mice with collagen (e.g., bovine type II collagen) to induce arthritis.

5.2. B Cell Transfer:

* Isolate B cells from the STIM1-knockdown mice and transfer them to the collagen-injected mice.
* Monitor the mice for signs of arthritis (e.g., paw swelling, joint inflammation).

**Protocol 6: B Cell Function Analysis**

6.1. Antibody Production:

* Collect serum from the mice and measure antibody production using ELISA.
* Coat ELISA plates with collagen and detect antibody binding using a secondary antibody.

6.2. Proliferation and Activation Marker Expression:

* Isolate B cells from the mice and analyze their proliferation using a cell proliferation assay (e.g., BrdU incorporation).
* Analyze the expression of activation markers (e.g., CD69, CD86) using flow cytometry.

**Protocol 7: Control Experiments**

7.1. Control B Cells:

* Isolate B cells from healthy human donors or use a B cell line (e.g., Ramos or Raji cells).
* Perform the same protocols as above, but without STIM1 knockdown.

7.2. Data Analysis:

* Compare the results from the STIM1-knockdown B cells to the control B cells to ensure that the observed effects are specific to STIM1 dysregulation.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity.","```
   RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  siRNA/shRNA  Lipofectamine  STIM1_Knockdown  Calcium_Dye  Fluo-4  FOXO1_Expression  Arthritis_Model  Antibody_Production  Proliferation  Outcome
0        10.0  10.0                  1.0           1.0          20.0         10.0            0.8          10.0     10.0             1.5            1.0             2.0         1.0  Inhibited
1        12.0  12.0                  1.2           1.2          25.0         12.0            0.9          12.0     12.0             1.8            1.2             2.5         1.2  Inhibited
2         8.0   8.0                  0.8           0.8          15.0          8.0            0.6           8.0      8.0             1.2            0.8             1.5         0.8  Inhibited
3        11.0  11.0                  1.1           1.1          22.0         11.0            0.85         11.0     11.0             1.6            1.1             2.2         1.1  Inhibited
4        13.0  13.0                  1.3           1.3          28.0         13.0            0.95         13.0     13.0             2.0            1.3             2.8         1.3  Inhibited
5         9.0   9.0                  0.9           0.9          18.0          9.0            0.7           9.0      9.0             1.4            0.9             1.8         0.9  Inhibited
6        10.5  10.5                  1.05          1.05         21.0         10.5            0.825        10.5     10.5             1.65           1.05             2.35        1.05  Inhibited
7        11.5  11.5                  1.15          1.15         23.0         11.5            0.875        11.5     11.5             1.75           1.15             2.45        1.15  Inhibited
8         9.5   9.5                  0.95          0.95         19.0          9.5            0.725         9.5      9.5             1.45           0.95             1.95        0.95  Inhibited
9        12.5  12.5                  1.25          1.25         26.0         12.5            0.925        12.5     12.5             1.85           1.25             2.65        1.25  Inhibited
10       10.0  10.0                  1.0           1.0          20.0         10.0            0.8          10.0     10.0             1.5            1.0             2.0         1.0  Inhibited
11       11.0  11.0                  1.1           1.1          22.0         11.0            0.85         11.0     11.0             1.6            1.1             2.2         1.1  Inhibited
12       13.0  13.0                  1.3           1.3          28.0         13.0            0.95         13.0     13.0             2.0            1.3             2.8         1.3  Inhibited
13        9.0   9.0                  0.9           0.9          18.0          9.0            0.7           9.0      9.0             1.4            0.9             1.8         0.9  Inhibited
14       10.5  10.5                  1.05          1.05         21.0         10.5            0.825        10.5     10.5             1.65           1.05             2.35        1.05  Inhibited
15       11.5  11.5                  1.15          1.15         23.0         11.5            0.875        11.5     11.5             1.75           1.15             2.45        1.15  Inhibited
16        9.5   9.5                  0.95          0.95         19.0          9.5            0.725         9.5      9.5             1.45           0.95             1.95        0.95  Inhibited
17       12.5  12.5                  1.25          1.25         26.0         12.5            0.925        12.5     12.5             1.85           1.25             2.65        1.25  Inhibited
18       10.0  10.0                  1.0           1.0          20.0         10.0            0.8          10.0     10.0             1.5            1.0             2.0         1.0  Inhibited
19       11.0  11.0                  1.1           1.1          22.0         11.0            0.85         11.0     11.0             1.6            1.1             2.2         1.1  Inhibited
20       13.0  13.0                  1.3           1.3          28.0         13.0            0.95         13.0     13.0             2.0            1.3             2.8         1.3  Inhibited
21        9.0   9.0                  0.9           0.9          18.0          9.0            0.7           9.0      9.0             1.4            0.9             1.8         0.9  Inhibited
22       10.5  10.5                  1.05          1.05         21.0         10.5            0.825        10.5     10.5             1.65           1.05             2.35        1.05  Inhibited
23       11.5  11.5                  1.15          1.15         23.0         11.5            0.875        11.5     11.5             1.75           1.15             2.45        1.15  Inhibited
24       12.0  12.0                  1.2           1.2          24.0         12.0            0.9          12.0     12.0             1.8            1.2             2.5         1.2  Inhibited
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/63a3c21db32dd15428c3fde074f2aacd4bd4d6c8.summary'],"Does the dysregulation of TAPP adaptors in B cells lead to an imbalance in the PI3K-SHIP signaling axis, thereby contributing to the development of autoimmune diseases such as SLE?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Does the dysregulation of TAPP adaptors in B cells lead to an imbalance in the PI3K-SHIP signaling axis, thereby contributing to the development of autoimmune diseases such as SLE?

**Experimental Plan:**

**Objective:** To investigate the role of TAPP adaptors in regulating the PI3K-SHIP signaling axis in B cells and its potential contribution to autoimmune disease development.

**Experimental Approach:**

1. **Cell Culture and Stimulation:**
	* Isolate B cells from healthy donors and SLE patients.
	* Stimulate B cells with anti-CD40 and IL-4 to mimic germinal center responses.
	* Treat cells with PI3K inhibitors (e.g., LY294002) and/or SHIP activators (e.g., SHIP1-activating peptide) to modulate the PI3K-SHIP axis.
2. **TAPP Adaptor Expression and Knockdown:**
	* Overexpress TAPP adaptors in B cells using lentiviral vectors.
	* Knockdown TAPP adaptors using siRNA or CRISPR-Cas9.
3. **PI3K-SHIP Signaling Analysis:**
	* Measure PI3K activity using a PI3K activity assay kit.
	* Analyze SHIP protein expression and phosphorylation by Western blot.
	* Evaluate Akt phosphorylation and activity using phospho-Akt antibodies and Akt activity assays.
4. **Autoantibody Production and Germinal Center Responses:**
	* Measure autoantibody production using ELISA or flow cytometry.
	* Analyze germinal center responses by flow cytometry (e.g., CD38, CD95, and GL7 expression).

**Experiment to Disprove the Hypothesis:**

**Title:** ""TAPP Adaptor Regulation of PI3K-SHIP Axis in SLE B Cells: A Rescue Experiment""

**Objective:** To test if re-expression of TAPP adaptors in SLE B cells can rescue the imbalance in the PI3K-SHIP signaling axis and reduce autoantibody production.

**Experimental Design:**

1. **SLE B Cell Isolation and Culture:** Isolate B cells from SLE patients and culture them in vitro.
2. **TAPP Adaptor Re-expression:** Transfect SLE B cells with a TAPP-expressing lentiviral vector.
3. **PI3K-SHIP Signaling Analysis:** Measure PI3K activity, SHIP protein expression and phosphorylation, and Akt phosphorylation and activity as described above.
4. **Autoantibody Production:** Measure autoantibody production using ELISA or flow cytometry.

**Prediction:** If the hypothesis is true, re-expression of TAPP adaptors in SLE B cells should rescue the imbalance in the PI3K-SHIP signaling axis, leading to reduced autoantibody production. If the experiment fails to show a rescue effect, it would suggest that the dysregulation of TAPP adaptors is not the primary cause of the imbalance in the PI3K-SHIP axis in SLE B cells.

**Budget and Timeframe:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000, depending on the cost of reagents, equipment, and personnel.
* The budget will cover the cost of:
	+ Cell culture and stimulation reagents
	+ Lentiviral vectors and transfection reagents
	+ PI3K inhibitors and SHIP activators
	+ Antibodies and ELISA kits
	+ Flow cytometry and Western blot equipment usage
	+ Personnel and laboratory expenses

This experimental plan is designed to test the hypothesis and provide insights into the role of TAPP adaptors in regulating the PI3K-SHIP signaling axis in B cells and its potential contribution to autoimmune disease development. The experiment to disprove the hypothesis will help to validate or refute the hypothesis and provide a more comprehensive understanding of the underlying mechanisms.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Investigating the Role of TAPP Adaptors in Regulating the PI3K-SHIP Signaling Axis in B Cells**

**Step 1.1: Isolation of B Cells from Healthy Donors and SLE Patients**

1. Obtain peripheral blood mononuclear cells (PBMCs) from healthy donors and SLE patients through venipuncture or from a blood bank.
2. Isolate B cells from PBMCs using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) with anti-CD19 or anti-CD20 antibodies.
3. Wash the isolated B cells with phosphate-buffered saline (PBS) and resuspend them in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

**Step 1.2: Cell Stimulation and Treatment**

1. Stimulate the isolated B cells with 1 μg/mL anti-CD40 antibody and 10 ng/mL IL-4 for 24-48 hours to mimic germinal center responses.
2. Treat the stimulated B cells with 10 μM LY294002 (PI3K inhibitor) and/or 10 μM SHIP1-activating peptide for 1-2 hours to modulate the PI3K-SHIP axis.
3. Wash the treated cells with PBS and resuspend them in RPMI 1640 medium.

**Step 2.1: TAPP Adaptor Overexpression and Knockdown**

1. Prepare lentiviral vectors encoding TAPP adaptors (TAPP1 and TAPP2) and a control vector (e.g., GFP).
2. Transfect the lentiviral vectors into the stimulated B cells using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
3. Incubate the transfected cells for 24-48 hours to allow for protein expression.
4. For TAPP adaptor knockdown, design and synthesize siRNA or CRISPR-Cas9 guide RNAs targeting TAPP1 and TAPP2.
5. Transfect the siRNA or CRISPR-Cas9 guide RNAs into the stimulated B cells using a transfection reagent.
6. Incubate the transfected cells for 24-48 hours to allow for gene silencing.

**Step 3.1: PI3K-SHIP Signaling Analysis**

1. Measure PI3K activity using a PI3K activity assay kit according to the manufacturer's instructions.
2. Lyse the treated B cells in RIPA buffer and perform Western blot analysis to detect SHIP protein expression and phosphorylation using anti-SHIP and anti-phospho-SHIP antibodies.
3. Analyze Akt phosphorylation and activity using phospho-Akt antibodies and Akt activity assays.

**Step 4.1: Autoantibody Production and Germinal Center Responses**

1. Measure autoantibody production using ELISA or flow cytometry with anti-dsDNA or anti-nuclear antibodies.
2. Analyze germinal center responses by flow cytometry using anti-CD38, anti-CD95, and anti-GL7 antibodies.

**Experiment 2: Rescue Experiment to Disprove the Hypothesis**

**Step 1.1: SLE B Cell Isolation and Culture**

1. Isolate B cells from SLE patients as described in Step 1.1 of Experiment 1.
2. Culture the isolated B cells in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

**Step 2.1: TAPP Adaptor Re-expression**

1. Transfect the SLE B cells with a TAPP-expressing lentiviral vector as described in Step 2.1 of Experiment 1.
2. Incubate the transfected cells for 24-48 hours to allow for protein expression.

**Step 3.1: PI3K-SHIP Signaling Analysis**

1. Measure PI3K activity, SHIP protein expression and phosphorylation, and Akt phosphorylation and activity as described in Step 3.1 of Experiment 1.

**Step 4.1: Autoantibody Production**

1. Measure autoantibody production using ELISA or flow cytometry with anti-dsDNA or anti-nuclear antibodies.

**Quality Control and Replicability**

* Perform all experiments in triplicate to ensure reproducibility.
* Include positive and negative controls for each experiment.
* Validate the specificity of antibodies and reagents used in the experiments.
* Use standardized protocols for cell culture, stimulation, and treatment to minimize variability.
* Document all experimental procedures, results, and data analysis in a laboratory notebook or electronic database.

**Equipment and Reagents**

* Cell culture equipment (incubator, centrifuge, pipettes)
* Flow cytometer
* Western blot equipment (gel electrophoresis, transfer apparatus, chemiluminescence detector)
* PI3K activity assay kit
* Lentiviral vectors and transfection reagents
* Antibodies (anti-CD19, anti-CD20, anti-CD40, anti-IL-4, anti-SHIP, anti-phospho-SHIP, anti-Akt, anti-phospho-Akt)
* ELISA kits
* CRISPR-Cas9 guide RNAs and siRNA
* RIPA buffer and protease inhibitors
* FBS and RPMI 1640 medium
* Penicillin-streptomycin and L-glutamine

**Budget and Timeframe**

* The estimated budget for this experiment is $50,000-$75,000, depending on the cost of reagents, equipment, and personnel.
* The experiment can be completed within 6-9 months, assuming a full-time researcher and access to necessary equipment and resources.","```
   Healthy_Donor_SLE_Patient  CD19_Antibody  CD40_Antibody  IL4_Concentration  LY294002_Concentration  SHIP1_Activating_Peptide  TAPP1_Overexpression  TAPP2_Overexpression  TAPP1_Knockdown  TAPP2_Knockdown  PI3K_Activity  SHIP_Protein_Expression  SHIP_Protein_Phosphorylation  Akt_Phosphorylation  Akt_Activity  Autoantibody_Production
0                    Healthy          1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.0               0.0         0.8               0.9                     0.7             0.6               0.4
1                    Healthy          1.5           1.5               15.0                    7.5                       7.5                  1.5                  1.5               0.0               0.0         0.9               1.0                     0.8             0.7               0.5
2                    SLE              0.5           0.5                5.0                    2.5                       2.5                  0.5                  0.5               0.5               0.5         0.4               0.6                     0.5             0.4               0.3
3                    Healthy          1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.0               0.0         0.8               0.9                     0.7             0.6               0.4
4                    SLE              1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.5               0.5         0.5               0.7                     0.6             0.5               0.4
5                    Healthy          1.5           1.5               15.0                    7.5                       7.5                  1.5                  1.5               0.0               0.0         0.9               1.0                     0.8             0.7               0.5
6                    SLE              0.5           0.5                5.0                    2.5                       2.5                  0.5                  0.5               0.5               0.5         0.4               0.6                     0.5             0.4               0.3
7                    Healthy          1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.0               0.0         0.8               0.9                     0.7             0.6               0.4
8                    SLE              1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.5               0.5         0.5               0.7                     0.6             0.5               0.4
9                    Healthy          1.5           1.5               15.0                    7.5                       7.5                  1.5                  1.5               0.0               0.0         0.9               1.0                     0.8             0.7               0.5
10                   SLE              0.5           0.5                5.0                    2.5                       2.5                  0.5                  0.5               0.5               0.5         0.4               0.6                     0.5             0.4               0.3
11                   Healthy          1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.0               0.0         0.8               0.9                     0.7             0.6               0.4
12                   SLE              1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.5               0.5         0.5               0.7                     0.6             0.5               0.4
13                   Healthy          1.5           1.5               15.0                    7.5                       7.5                  1.5                  1.5               0.0               0.0         0.9               1.0                     0.8             0.7               0.5
14                   SLE              0.5           0.5                5.0                    2.5                       2.5                  0.5                  0.5               0.5               0.5         0.4               0.6                     0.5             0.4               0.3
15                   Healthy          1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.0               0.0         0.8               0.9                     0.7             0.6               0.4
16                   SLE              1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.5               0.5         0.5               0.7                     0.6             0.5               0.4
17                   Healthy          1.5           1.5               15.0                    7.5                       7.5                  1.5                  1.5               0.0               0.0         0.9               1.0                     0.8             0.7               0.5
18                   SLE              0.5           0.5                5.0                    2.5                       2.5                  0.5                  0.5               0.5               0.5         0.4               0.6                     0.5             0.4               0.3
19                   Healthy          1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.0               0.0         0.8               0.9                     0.7             0.6               0.4
20                   SLE              1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.5               0.5         0.5               0.7                     0.6             0.5               0.4
21                   Healthy          1.5           1.5               15.0                    7.5                       7.5                  1.5                  1.5               0.0               0.0         0.9               1.0                     0.8             0.7               0.5
22                   SLE              0.5           0.5                5.0                    2.5                       2.5                  0.5                  0.5               0.5               0.5         0.4               0.6                     0.5             0.4               0.3
23                   Healthy          1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.0               0.0         0.8               0.9                     0.7             0.6               0.4
24                   SLE              1.0           1.0               10.0                    5.0                       5.0                  1.0                  1.0               0.5               0.5         0.5               0.7                     0.6             0.5               0.4
```",0.5665046656069186
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/09ce35978258dedcc7ae89e8161adca7e5c6d84f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/de3e57b0a59c9e41c3aef20bb4fd193dbe3c356f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e23d070e22031919f37cf510fe06de4c5319c173.summary']","Does the dysregulation of TLR7 signaling in B cells of CVID patients contribute to impaired germinal center reactions and subsequent defects in B cell maturation and differentiation, leading to increased susceptibility to interstitial lung disease?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove it. The hypothesis states: ""Does the dysregulation of TLR7 signaling in B cells of CVID patients contribute to impaired germinal center reactions and subsequent defects in B cell maturation and differentiation, leading to increased susceptibility to interstitial lung disease?""

To disprove this hypothesis, I will design an experiment that aims to show that TLR7 signaling in B cells of CVID patients is not dysregulated and does not contribute to impaired germinal center reactions and subsequent defects in B cell maturation and differentiation.

**Experiment Title:** Investigating TLR7 Signaling in B Cells of CVID Patients with and without Interstitial Lung Disease

**Objective:** To determine if TLR7 signaling in B cells of CVID patients is dysregulated and contributes to impaired germinal center reactions and subsequent defects in B cell maturation and differentiation, leading to increased susceptibility to interstitial lung disease.

**Equipment:**

* Flow cytometer
* PCR machine
* DNA sequencer
* B cell isolation kit
* TLR7 agonist
* AID-specific antibodies
* Germinal center markers (e.g., CD38, CD95)
* B cell activation markers (e.g., CD69, CD86)
* Cytokine analysis kit (e.g., IL-6, TNF-alpha)

**Experimental Design:**

1. **Patient Selection:** Recruit CVID patients with and without interstitial lung disease (ILD). Ensure that patients with ILD have a confirmed diagnosis and those without ILD have no signs of lung disease.
2. **B Cell Isolation:** Isolate B cells from peripheral blood mononuclear cells (PBMCs) of CVID patients with and without ILD using a B cell isolation kit.
3. **TLR7 Signaling Analysis:** Stimulate isolated B cells with a TLR7 agonist and measure TLR7 expression, phosphorylation, and downstream signaling molecules (e.g., MyD88, IRAK1) using Western blot and flow cytometry.
4. **Germinal Center Analysis:** Analyze germinal center reactions in CVID patients with and without ILD by measuring germinal center markers (e.g., CD38, CD95) and B cell activation markers (e.g., CD69, CD86) using flow cytometry.
5. **B Cell Maturation and Differentiation:** Analyze B cell maturation and differentiation in CVID patients with and without ILD by measuring IgG isotype switching, somatic hypermutation, and B cell receptor repertoire diversity using PCR, DNA sequencing, and flow cytometry.
6. **Cytokine Analysis:** Measure cytokine production (e.g., IL-6, TNF-alpha) in B cells from CVID patients with and without ILD using a cytokine analysis kit.
7. **Correlation Analysis:** Correlate TLR7 signaling with germinal center reactions, B cell maturation and differentiation, and cytokine production in CVID patients with and without ILD.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ Dysregulated TLR7 signaling in B cells of CVID patients with ILD compared to those without ILD.
	+ Impaired germinal center reactions, B cell maturation, and differentiation in CVID patients with ILD.
	+ Increased cytokine production in B cells from CVID patients with ILD.
* If the hypothesis is false, we expect to see:
	+ No significant differences in TLR7 signaling between B cells of CVID patients with and without ILD.
	+ Normal germinal center reactions, B cell maturation, and differentiation in CVID patients with ILD.
	+ No significant differences in cytokine production between B cells from CVID patients with and without ILD.

By designing an experiment that aims to disprove the hypothesis, we can test the validity of the hypothesis and gain a better understanding of the role of TLR7 signaling in B cells of CVID patients with and without interstitial lung disease.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Patient Selection**

1.1. Identify and recruit CVID patients with and without interstitial lung disease (ILD) through collaboration with clinicians and patient registries.

1.2. Ensure that patients with ILD have a confirmed diagnosis based on clinical and radiological criteria.

1.3. Verify that patients without ILD have no signs of lung disease through medical history, physical examination, and radiological evaluation.

1.4. Obtain informed consent from all patients and collect peripheral blood samples (10-20 mL) in EDTA tubes.

**Protocol 2: B Cell Isolation**

2.1. Prepare the B cell isolation kit according to the manufacturer's instructions.

2.2. Isolate peripheral blood mononuclear cells (PBMCs) from the collected blood samples using density gradient centrifugation (e.g., Ficoll-Paque).

2.3. Wash the PBMCs with phosphate-buffered saline (PBS) and resuspend them in 1 mL of PBS.

2.4. Add the B cell isolation kit reagents to the PBMC suspension and incubate for 15 minutes at room temperature.

2.5. Wash the cells with PBS and resuspend them in 1 mL of PBS.

2.6. Verify the purity of the isolated B cells using flow cytometry (e.g., CD19+ cells > 95%).

**Protocol 3: TLR7 Signaling Analysis**

3.1. Prepare the TLR7 agonist (e.g., imiquimod) according to the manufacturer's instructions.

3.2. Stimulate 1 x 10^6 isolated B cells with 1 μg/mL TLR7 agonist for 30 minutes at 37°C.

3.3. Wash the cells with PBS and lyse them using a cell lysis buffer (e.g., RIPA buffer).

3.4. Measure TLR7 expression using Western blot analysis with a TLR7-specific antibody.

3.5. Measure TLR7 phosphorylation using Western blot analysis with a phospho-TLR7-specific antibody.

3.6. Measure downstream signaling molecules (e.g., MyD88, IRAK1) using Western blot analysis with specific antibodies.

3.7. Analyze the expression and phosphorylation of TLR7 and downstream signaling molecules using flow cytometry (e.g., CD19+TLR7+, CD19+phospho-TLR7+).

**Protocol 4: Germinal Center Analysis**

4.1. Prepare the germinal center markers (e.g., CD38, CD95) and B cell activation markers (e.g., CD69, CD86) according to the manufacturer's instructions.

4.2. Stain 1 x 10^6 isolated B cells with the germinal center markers and B cell activation markers for 30 minutes at 4°C.

4.3. Analyze the expression of germinal center markers and B cell activation markers using flow cytometry (e.g., CD19+CD38+, CD19+CD95+, CD19+CD69+, CD19+CD86+).

**Protocol 5: B Cell Maturation and Differentiation**

5.1. Prepare the IgG isotype switching primers and PCR reagents according to the manufacturer's instructions.

5.2. Extract genomic DNA from 1 x 10^6 isolated B cells using a DNA extraction kit.

5.3. Perform PCR to amplify the IgG isotype switching regions using the prepared primers and reagents.

5.4. Analyze the PCR products using DNA sequencing to determine the frequency of IgG isotype switching.

5.5. Measure somatic hypermutation using DNA sequencing and analyze the B cell receptor repertoire diversity using flow cytometry (e.g., CD19+IgG+).

**Protocol 6: Cytokine Analysis**

6.1. Prepare the cytokine analysis kit (e.g., IL-6, TNF-alpha) according to the manufacturer's instructions.

6.2. Stimulate 1 x 10^6 isolated B cells with 1 μg/mL TLR7 agonist for 24 hours at 37°C.

6.3. Collect the supernatant and measure cytokine production using the cytokine analysis kit.

**Protocol 7: Correlation Analysis**

7.1. Correlate the TLR7 signaling data with germinal center reactions, B cell maturation and differentiation, and cytokine production data using statistical analysis software (e.g., Pearson's correlation coefficient).

7.2. Compare the data between CVID patients with and without ILD to determine if there are significant differences.

By following these detailed, step-by-step protocols, the experiment can be executed with precision and accuracy, ensuring replicability and specificity in the results.","```
   Patient_Group  ILD  Blood_Sample_Volume  B_Cell_Isolation_Kit_Reagents  TLR7_Agonist_Concentration  TLR7_Expression  TLR7_Phosphorylation  MyD88_Expression  IRAK1_Expression  CD38_Expression  CD95_Expression  CD69_Expression  CD86_Expression  IgG_Isotype_Switching  Somatic_Hypermutation  IL6_Production  TNF_alpha_Production  Outcome
0           CVID   Yes                  15                    1.2                    1.1           0.8               0.6               0.9               0.7               0.5               0.4               0.3               0.2               0.1               120.0               50.0               Abnormal
1           CVID   No                   18                    1.5                    1.3           0.9               0.7               1.0               0.8               0.6               0.5               0.4               0.3               0.2               150.0               60.0               Normal
2           CVID   Yes                  12                    1.0                    1.0           0.7               0.5               0.8               0.6               0.4               0.3               0.2               0.1               100.0               40.0               Abnormal
3           CVID   No                   20                    1.8                    1.5           1.0               0.8               1.1               0.9               0.7               0.6               0.5               0.4               180.0               70.0               Normal
4           CVID   Yes                  15                    1.2                    1.2           0.8               0.6               0.9               0.7               0.5               0.4               0.3               0.2               130.0               55.0               Abnormal
5           CVID   No                   18                    1.5                    1.4           0.9               0.7               1.0               0.8               0.6               0.5               0.4               0.3               160.0               65.0               Normal
6           CVID   Yes                  12                    1.0                    1.1           0.7               0.5               0.8               0.6               0.4               0.3               0.2               0.1               110.0               45.0               Abnormal
7           CVID   No                   20                    1.8                    1.6           1.0               0.8               1.1               0.9               0.7               0.6               0.5               0.4               190.0               75.0               Normal
8           CVID   Yes                  15                    1.2                    1.3           0.8               0.6               0.9               0.7               0.5               0.4               0.3               0.2               140.0               58.0               Abnormal
9           CVID   No                   18                    1.5                    1.5           0.9               0.7               1.0               0.8               0.6               0.5               0.4               0.3               170.0               68.0               Normal
10          CVID   Yes                  12                    1.0                    1.2           0.7               0.5               0.8               0.6               0.4               0.3               0.2               0.1               120.0               50.0               Abnormal
11          CVID   No                   20                    1.8                    1.7           1.0               0.8               1.1               0.9               0.7               0.6               0.5               0.4               200.0               80.0               Normal
12          CVID   Yes                  15                    1.2                    1.4           0.8               0.6               0.9               0.7               0.5               0.4               0.3               0.2               150.0               62.0               Abnormal
13          CVID   No                   18                    1.5                    1.6           0.9               0.7               1.0               0.8               0.6               0.5               0.4               0.3               180.0               72.0               Normal
14          CVID   Yes                  12                    1.0                    1.3           0.7               0.5               0.8               0.6               0.4               0.3               0.2               0.1               130.0               55.0               Abnormal
15          CVID   No                   20                    1.8                    1.8           1.0               0.8               1.1               0.9               0.7               0.6               0.5               0.4               210.0               85.0               Normal
16          CVID   Yes                  15                    1.2                    1.5           0.8               0.6               0.9               0.7               0.5               0.4               0.3               0.2               160.0               66.0               Abnormal
17          CVID   No                   18                    1.5                    1.7           0.9               0.7               1.0               0.8               0.6               0.5               0.4               0.3               190.0               76.0               Normal
18          CVID   Yes                  12                    1.0                    1.4           0.7               0.5               0.8               0.6               0.4               0.3               0.2               0.1               140.0               59.0               Abnormal
19          CVID   No                   20                    1.8                    1.9           1.0               0.8               1.1               0.9               0.7               0.6               0.5               0.4               220.0               90.0               Normal
20          CVID   Yes                  15                    1.2                    1.6           0.8               0.6               0.9               0.7               0.5               0.4               0.3               0.2               170.0               70.0               Abnormal
21          CVID   No                   18                    1.5                    1.8           0.9               0.7               1.0               0.8               0.6               0.5               0.4               0.3               200.0               82.0               Normal
22          CVID   Yes                  12                    1.0                    1.5           0.7               0.5               0.8               0.6               0.4               0.3               0.2               0.1               150.0               63.0               Abnormal
23          CVID   No                   20                    1.8                    2.0           1.0               0.8               1.1               0.9               0.7               0.6               0.5               0.4               230.0               95.0               Normal
24          CVID   Yes                  15                    1.2                    1.7           0.8               0.6               0.9               0.7               0.5               0.4               0.3               0.2               180.0               74.0               Abnormal
```",0.12991687796208862
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ebd6eb24f8f2093b06b418d888c9d0f994050ede.summary'],"Does the dysregulation of lncRNA-mediated immune responses in BAFF-R-deficient mice infected with Pneumocystis also lead to changes in the gut microbiome, which in turn exacerbate the severity of Pneumocystis pneumonia?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis. The experiment will focus on the gut microbiome aspect, which is the novel component of the hypothesis.

**Experiment Title:** Investigating the Impact of BAFF-R Deficiency on Gut Microbiome in Pneumocystis-Infected Mice

**Objective:** To determine if BAFF-R deficiency leads to changes in the gut microbiome, which exacerbate the severity of Pneumocystis pneumonia.

**Experimental Design:**

1. **Mouse Model:** Use BAFF-R-deficient mice (n=10) and wild-type mice (n=10) as controls.
2. **Infection:** Infect both groups with Pneumocystis.
3. **Gut Microbiome Analysis:**
a. Collect fecal samples from both groups at days 0, 7, and 14 post-infection.
b. Perform 16S rRNA gene sequencing using the Illumina MiSeq platform to analyze the gut microbiome composition.
c. Use bioinformatic tools (e.g., QIIME2, R) to process and analyze the sequencing data.
4. **Microbiome Comparison:** Compare the gut microbiome composition between BAFF-R-deficient and wild-type mice at each time point.
5. **Pneumocystis Pneumonia Severity:** Assess the severity of Pneumocystis pneumonia in both groups using histopathological analysis of lung tissue and measurement of lung inflammation markers (e.g., cytokines, chemokines).
6. **Correlation Analysis:** Correlate the changes in gut microbiome composition with the severity of Pneumocystis pneumonia in BAFF-R-deficient mice.

**Hypothesis Testing:**

* If the gut microbiome composition is significantly different between BAFF-R-deficient and wild-type mice, and the changes in the gut microbiome are correlated with the severity of Pneumocystis pneumonia, it would support the hypothesis.
* If the gut microbiome composition is similar between the two groups, or the changes in the gut microbiome are not correlated with the severity of Pneumocystis pneumonia, it would disprove the hypothesis.

**Equipment and Resources:**

* Mouse facility and husbandry
* Pneumocystis infection model
* Illumina MiSeq platform for 16S rRNA gene sequencing
* Bioinformatic tools (e.g., QIIME2, R)
* Histopathology equipment for lung tissue analysis
* ELISA plate reader for cytokine and chemokine measurement

**Timeline:**

* Mouse infection and sample collection: 4 weeks
* 16S rRNA gene sequencing and bioinformatic analysis: 8 weeks
* Histopathology and cytokine/chemokine measurement: 4 weeks
* Data analysis and correlation: 4 weeks

**Budget:**

* Mouse facility and husbandry: $5,000
* Pneumocystis infection model: $2,000
* Illumina MiSeq sequencing: $10,000
* Bioinformatic tools and analysis: $3,000
* Histopathology equipment and reagents: $2,000
* ELISA plate reader and reagents: $1,000
* Total: $23,000

This experiment is designed to test the hypothesis in a reasonable time frame ( approximately 20 weeks) and within a limited budget. The results will provide valuable insights into the relationship between BAFF-R deficiency, gut microbiome, and Pneumocystis pneumonia severity.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Mouse Infection and Sample Collection**

1.1. Preparation of Pneumocystis Infection Model:

* Obtain Pneumocystis-infected mice from a reliable source or generate them in-house using a standardized protocol.
* Verify the Pneumocystis infection status using PCR or other diagnostic methods.

1.2. Mouse Husbandry and Grouping:

* House 10 BAFF-R-deficient mice and 10 wild-type mice in separate cages with ad libitum access to food and water.
* Ensure mice are 6-8 weeks old and of the same sex to minimize variability.

1.3. Infection and Sample Collection:

* Infect both groups of mice with Pneumocystis using a standardized protocol (e.g., intranasal inoculation).
* Collect fecal samples from each mouse at days 0, 7, and 14 post-infection using sterile techniques.
* Store fecal samples in sterile tubes or containers at -80°C until further analysis.

**Protocol 2: 16S rRNA Gene Sequencing**

2.1. DNA Extraction:

* Extract DNA from fecal samples using a commercial DNA extraction kit (e.g., QIAamp DNA Stool Mini Kit) according to the manufacturer's instructions.
* Quantify DNA concentrations using a spectrophotometer (e.g., NanoDrop).

2.2. PCR Amplification:

* Amplify the 16S rRNA gene using PCR primers (e.g., 515F and 806R) and a high-fidelity DNA polymerase (e.g., Q5 High-Fidelity DNA Polymerase).
* Perform PCR reactions in triplicate for each sample using a thermal cycler (e.g., Bio-Rad C1000).

2.3. Library Preparation:

* Prepare sequencing libraries using the Illumina TruSeq DNA Library Prep Kit according to the manufacturer's instructions.
* Index each sample with a unique barcode using the Illumina Nextera XT Index Kit.

2.4. Sequencing:

* Sequence the libraries on the Illumina MiSeq platform using the MiSeq Reagent Kit v3 (600-cycle) according to the manufacturer's instructions.
* Generate paired-end reads (2 x 300 bp) for each sample.

**Protocol 3: Bioinformatic Analysis**

3.1. Data Quality Control:

* Trim adapters and low-quality bases from the sequencing reads using Trimmomatic (v0.39).
* Filter out reads with a Phred score < 30 using FastX Toolkit (v0.0.14).

3.2. Sequence Analysis:

* Merge paired-end reads using PEAR (v0.9.10).
* Assign taxonomy to each read using the QIIME2 (v2020.2) pipeline with the Silva 138 database.
* Generate a feature table and phylogenetic tree using QIIME2.

3.3. Data Visualization and Statistical Analysis:

* Visualize the gut microbiome composition using bar plots, heatmaps, and PCoA plots generated using QIIME2 and R (v3.6.3).
* Perform statistical analysis (e.g., ANOVA, Kruskal-Wallis test) to compare the gut microbiome composition between BAFF-R-deficient and wild-type mice at each time point using R.

**Protocol 4: Histopathology and Cytokine/Chemokine Measurement**

4.1. Lung Tissue Collection:

* Sacrifice mice at day 14 post-infection and collect lung tissue samples.
* Fix lung tissue samples in 10% formalin and embed in paraffin.

4.2. Histopathology:

* Section lung tissue samples (5 μm thick) and stain with hematoxylin and eosin (H&E).
* Evaluate lung tissue damage and inflammation using a standardized scoring system.

4.3. Cytokine/Chemokine Measurement:

* Homogenize lung tissue samples in PBS and centrifuge to collect supernatants.
* Measure cytokine and chemokine levels (e.g., IL-1β, TNF-α, MCP-1) using ELISA kits according to the manufacturer's instructions.

**Protocol 5: Correlation Analysis**

5.1. Data Integration:

* Combine the gut microbiome composition data with the histopathology and cytokine/chemokine measurement data.

5.2. Correlation Analysis:

* Perform correlation analysis (e.g., Spearman's rank correlation) between the gut microbiome composition and the severity of Pneumocystis pneumonia (histopathology scores and cytokine/chemokine levels) using R.

**Quality Control and Assurance**

* Verify the identity and purity of the Pneumocystis infection model.
* Monitor mouse health and welfare throughout the experiment.
* Use positive and negative controls for each assay to ensure accuracy and specificity.
* Perform regular equipment maintenance and calibration to ensure precision and accuracy.

By following these detailed, step-by-step protocols, the experiment can be replicated and executed with high precision and accuracy, ensuring the generation of reliable and meaningful results.","```
   BAFF-R_deficient  Wild_type  Pneumocystis_inoculum  Fecal_sample_day  DNA_extraction_kit  PCR_primer  DNA_polymerase  Sequencing_cycles  Histopathology_score  IL_1b  TNF_a  MCP_1  Outcome
0               10          10               1e6               0          QIAamp            515F      Q5_HF            600             2.5   100   200   50   Severe
1               10          10               1e6               7          QIAamp            515F      Q5_HF            600             4.0   150   250   75   Moderate
2               10          10               1e6              14          QIAamp            515F      Q5_HF            600             5.5   200   300   100  Mild
3               8           12               5e5               0          QIAamp            515F      Q5_HF            600             2.0   80   180   40   Severe
4               8           12               5e5               7          QIAamp            515F      Q5_HF            600             3.5   120   220   60   Moderate
5               8           12               5e5              14          QIAamp            515F      Q5_HF            600             4.5   180   280   80   Mild
6               12           8               1e7               0          QIAamp            806R      Q5_HF            600             2.8   110   210   50   Severe
7               12           8               1e7               7          QIAamp            806R      Q5_HF            600             4.2   160   260   70   Moderate
8               12           8               1e7              14          QIAamp            806R      Q5_HF            600             5.0   220   320   90   Mild
9               9           11               7e5               0          QIAamp            515F      Q5_HF            600             2.2   90   190   45   Severe
10              9           11               7e5               7          QIAamp            515F      Q5_HF            600             3.8   140   240   65   Moderate
11              9           11               7e5              14          QIAamp            515F      Q5_HF            600             4.8   200   300   85   Mild
12              11           9               3e6               0          QIAamp            806R      Q5_HF            600             2.9   130   230   55   Severe
13              11           9               3e6               7          QIAamp            806R      Q5_HF            600             4.5   190   290   80   Moderate
14              11           9               3e6              14          QIAamp            806R      Q5_HF            600             5.2   250   350   95   Mild
15              10          10               1e6               0          MoBio            515F      Q5_HF            600             2.6   110   210   50   Severe
16              10          10               1e6               7          MoBio            515F      Q5_HF            600             4.1   160   260   70   Moderate
17              10          10               1e6              14          MoBio            515F      Q5_HF            600             5.1   220   320   90   Mild
18              8           12               5e5               0          MoBio            806R      Q5_HF            600             2.4   100   200   45   Severe
19              8           12               5e5               7          MoBio            806R      Q5_HF            600             3.9   150   250   65   Moderate
20              8           12               5e5              14          MoBio            806R      Q5_HF            600             4.9   200   300   85   Mild
21              12           8               1e7               0          MoBio            515F      Q5_HF            600             2.9   130   230   55   Severe
22              12           8               1e7               7          MoBio            515F      Q5_HF            600             4.4   190   290   80   Moderate
23              12           8               1e7              14          MoBio            515F      Q5_HF            600             5.3   250   350   95   Mild
24              9           11               7e5               0          MoBio            806R      Q5_HF            600             2.7   120   220   50   Severe
```",0.46214166761709075
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d5f42d7303ee5e90833fe187282b26146bc104e6.summary'],"Does the dysregulation of miR-150-5p in Myasthenia Gravis patients also affect the expression of other microRNAs involved in T cell homeostasis, leading to a broader disruption of the immune system?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you with that!

**Hypothesis:** The dysregulation of miR-150-5p in Myasthenia Gravis (MG) patients affects the expression of other microRNAs involved in T cell homeostasis, leading to a broader disruption of the immune system.

**Experimental Plan:**

**Objective:** To test the hypothesis by investigating the expression of other microRNAs involved in T cell homeostasis in MG patients with dysregulated miR-150-5p.

**Experimental Design:**

1. **Sample Collection:**
	* Collect peripheral blood mononuclear cells (PBMCs) from MG patients with confirmed dysregulation of miR-150-5p (n=20) and healthy controls (n=20).
	* Isolate CD4+ and CD8+ T cells from PBMCs using magnetic bead separation.
2. **MicroRNA Expression Profiling:**
	* Perform microRNA sequencing (miRNA-seq) on isolated CD4+ and CD8+ T cells from MG patients and healthy controls to identify differentially expressed microRNAs involved in T cell homeostasis.
	* Validate the expression of selected microRNAs using quantitative real-time PCR (qRT-PCR).
3. **Target Prediction and Validation:**
	* Use bioinformatic tools (e.g., TargetScan, miRanda) to predict the target genes of differentially expressed microRNAs.
	* Validate the predicted targets using Western blotting or qRT-PCR.
4. **Functional Assays:**
	* Perform functional assays (e.g., T cell proliferation, cytokine production) to assess the impact of dysregulated microRNAs on T cell function.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the null hypothesis that the dysregulation of miR-150-5p in MG patients does not affect the expression of other microRNAs involved in T cell homeostasis.

**Experimental Design:**

1. **Sample Collection:**
	* Collect PBMCs from MG patients with confirmed dysregulation of miR-150-5p (n=10) and healthy controls (n=10).
2. **MicroRNA Expression Profiling:**
	* Perform miRNA-seq on isolated CD4+ and CD8+ T cells from MG patients and healthy controls.
3. **Data Analysis:**
	* Compare the expression profiles of microRNAs involved in T cell homeostasis between MG patients and healthy controls.
	* If no significant differences are observed, it would suggest that the dysregulation of miR-150-5p does not affect the expression of other microRNAs involved in T cell homeostasis, thereby disproving the hypothesis.

**Budget and Timeframe:**

* Estimated budget: $50,000 - $75,000
* Estimated timeframe: 6-9 months

**Rationale:**

This experimental plan is designed to test the hypothesis by investigating the expression of other microRNAs involved in T cell homeostasis in MG patients with dysregulated miR-150-5p. The experiment to disprove the hypothesis is a more focused approach that aims to show no significant differences in microRNA expression profiles between MG patients and healthy controls. The budget and timeframe are reasonable, considering the scope of the experiment and the availability of existing scientific methods and equipment.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: Sample Collection**

1.1. Collect peripheral blood samples from 20 MG patients with confirmed dysregulation of miR-150-5p and 20 healthy controls.

1.2. Use a sterile needle and syringe to collect 10 mL of peripheral blood from each participant.

1.3. Transfer the blood samples to EDTA-coated tubes and mix gently.

1.4. Store the samples at room temperature and process within 2 hours of collection.

**Step 2: Isolation of CD4+ and CD8+ T cells**

2.1. Isolate peripheral blood mononuclear cells (PBMCs) from the blood samples using Ficoll-Paque density gradient centrifugation.

2.2. Resuspend the PBMCs in 1 mL of PBS and count the cells using a hemocytometer.

2.3. Use magnetic bead separation (e.g., Miltenyi Biotec) to isolate CD4+ and CD8+ T cells from the PBMCs.

2.4. Follow the manufacturer's protocol for magnetic bead separation, including washing and elution steps.

2.5. Count the isolated CD4+ and CD8+ T cells using a hemocytometer.

**Step 3: MicroRNA Expression Profiling**

3.1. Extract total RNA from the isolated CD4+ and CD8+ T cells using a RNA extraction kit (e.g., Qiagen).

3.2. Perform microRNA sequencing (miRNA-seq) on the extracted RNA using a sequencing platform (e.g., Illumina).

3.3. Use a bioinformatic tool (e.g., miRDeep2) to analyze the miRNA-seq data and identify differentially expressed microRNAs involved in T cell homeostasis.

3.4. Validate the expression of selected microRNAs using quantitative real-time PCR (qRT-PCR) with specific primers.

**Step 4: Target Prediction and Validation**

4.1. Use bioinformatic tools (e.g., TargetScan, miRanda) to predict the target genes of differentially expressed microRNAs.

4.2. Validate the predicted targets using Western blotting or qRT-PCR.

4.3. For Western blotting, extract protein from the isolated CD4+ and CD8+ T cells and perform Western blotting with specific antibodies.

4.4. For qRT-PCR, use specific primers to amplify the target genes and quantify the expression levels.

**Step 5: Functional Assays**

5.1. Perform functional assays (e.g., T cell proliferation, cytokine production) to assess the impact of dysregulated microRNAs on T cell function.

5.2. For T cell proliferation, label the isolated CD4+ and CD8+ T cells with a proliferation dye (e.g., CFSE) and stimulate with anti-CD3 and anti-CD28 antibodies.

5.3. Measure the proliferation of T cells using flow cytometry.

5.4. For cytokine production, stimulate the isolated CD4+ and CD8+ T cells with anti-CD3 and anti-CD28 antibodies and measure the production of cytokines (e.g., IL-2, IFN-γ) using ELISA or flow cytometry.

**Experiment to Disprove the Hypothesis:**

**Step 1: Sample Collection**

1.1. Collect peripheral blood samples from 10 MG patients with confirmed dysregulation of miR-150-5p and 10 healthy controls.

1.2. Follow the same protocol as Step 1 of the experiment to test the hypothesis.

**Step 2: MicroRNA Expression Profiling**

2.1. Follow the same protocol as Step 3 of the experiment to test the hypothesis, but only perform miRNA-seq on the isolated CD4+ and CD8+ T cells.

**Step 3: Data Analysis**

3.1. Compare the expression profiles of microRNAs involved in T cell homeostasis between MG patients and healthy controls.

3.2. Use a statistical software (e.g., R, Python) to perform differential expression analysis and identify significant differences in microRNA expression.

3.3. If no significant differences are observed, it would suggest that the dysregulation of miR-150-5p does not affect the expression of other microRNAs involved in T cell homeostasis, thereby disproving the hypothesis.

Note: The protocols above assume that the researcher has access to standard laboratory equipment and reagents. The specific protocols may vary depending on the laboratory's specific setup and the researcher's preferences.","```
   miR-150-5p CD4+ T cells CD8+ T cells PBMCs EDTA-coated tubes Ficoll-Paque PBS  Outcome
0        1000       50000       20000    10000            10        5.0   1.0  Dysregulation
1        1200       60000       25000    12000            12        6.0   1.2  Dysregulation
2         800       40000       18000     9000             8        4.0   0.8  Dysregulation
3        1500       70000       30000    15000            15        7.0   1.5  Dysregulation
4        1100       55000       22000    11000            11        5.5   1.1  Dysregulation
5         900       45000       19000     9000             9        4.5   0.9  Dysregulation
6        1300       65000       28000    13000            13        6.5   1.3  Dysregulation
7        1000       50000       20000    10000            10        5.0   1.0  Dysregulation
8        1400       70000       30000    14000            14        7.0   1.4  Dysregulation
9         800       40000       18000     8000             8        4.0   0.8  Dysregulation
10       1600       80000       35000    16000            16        8.0   1.6  Dysregulation
11       1200       60000       25000    12000            12        6.0   1.2  Dysregulation
12        900       45000       19000     9000             9        4.5   0.9  Dysregulation
13       1100       55000       22000    11000            11        5.5   1.1  Dysregulation
14       1300       65000       28000    13000            13        6.5   1.3  Dysregulation
15       1000       50000       20000    10000            10        5.0   1.0  Dysregulation
16       1400       70000       30000    14000            14        7.0   1.4  Dysregulation
17       1500       75000       32000    15000            15        7.5   1.5  Dysregulation
18       1200       60000       25000    12000            12        6.0   1.2  Dysregulation
19       1100       55000       22000    11000            11        5.5   1.1  Dysregulation
20       1300       65000       28000    13000            13        6.5   1.3  Dysregulation
21       1000       50000       20000    10000            10        5.0   1.0  Dysregulation
22       1400       70000       30000    14000            14        7.0   1.4  Dysregulation
23       1600       80000       35000    16000            16        8.0   1.6  Dysregulation
24       1200       60000       25000    12000            12        6.0   1.2  Dysregulation
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/a2831a6be007b5aa177a2799bed89f818c4fa003.summary'],Does the dysregulation of oligodendrocyte-specific iron metabolism contribute to the development of B cell phenotypes in multiple sclerosis lesions?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Does the dysregulation of oligodendrocyte-specific iron metabolism contribute to the development of B cell phenotypes in multiple sclerosis lesions?

**Experimental Plan:**

**Objective:** To investigate whether oligodendrocyte-specific iron metabolism dysregulation contributes to the development of B cell phenotypes in multiple sclerosis lesions.

**Approach:**

1. **Cell Culture Model:**
	* Use human oligodendrocyte precursor cells (OPCs) and B cells isolated from healthy donors.
	* Culture OPCs in iron-depleted or iron-overloaded conditions to mimic dysregulation of iron metabolism.
	* Co-culture OPCs with B cells to assess the effect of iron dysregulation on B cell phenotypes.
2. **Gene Expression Analysis:**
	* Perform RNA sequencing (RNA-seq) on OPCs and B cells from the co-culture experiments to identify differentially expressed genes involved in iron metabolism and B cell activation.
	* Validate the results using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
3. **Protein Analysis:**
	* Perform Western blotting and immunofluorescence staining to assess the protein expression of iron-related genes (e.g., ferritin, transferrin receptor) and B cell activation markers (e.g., CD80, CD86) in OPCs and B cells.
4. **Functional Assays:**
	* Measure the proliferation and activation of B cells using cell counting, flow cytometry, and ELISA assays.
	* Assess the ability of OPCs to support B cell activation using a B cell activation assay (e.g., CD40L-CD40 interaction).

**Experiment to Disprove the Hypothesis:**

**Null Hypothesis:** Dysregulation of oligodendrocyte-specific iron metabolism does not contribute to the development of B cell phenotypes in multiple sclerosis lesions.

**Experimental Design:**

1. **Control Co-Culture:**
	* Co-culture OPCs with B cells in normal iron conditions (control group).
	* Compare the gene expression, protein expression, and functional assays with the iron-depleted or iron-overloaded co-culture groups.
2. **Iron Chelation:**
	* Add an iron chelator (e.g., deferoxamine) to the co-culture medium to remove excess iron.
	* Assess the effect of iron chelation on B cell phenotypes and OPC gene expression.
3. **Rescue Experiment:**
	* Add an iron supplement (e.g., ferric ammonium citrate) to the iron-depleted co-culture medium.
	* Evaluate the effect of iron supplementation on B cell phenotypes and OPC gene expression.

**Budget and Timeframe:**

* Estimated budget: $50,000 - $75,000
* Estimated timeframe: 6-9 months

**Rationale:**

This experimental plan is designed to test the hypothesis by assessing the effect of oligodendrocyte-specific iron metabolism dysregulation on B cell phenotypes in multiple sclerosis lesions. The experiment to disprove the hypothesis aims to show that iron dysregulation does not contribute to B cell phenotypes. By using a combination of cell culture, gene expression analysis, protein analysis, and functional assays, we can comprehensively evaluate the relationship between oligodendrocyte iron metabolism and B cell activation. The budget and timeframe are reasonable, considering the scope of the experiment and the availability of existing scientific methods and equipment.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture Model**

**Step 1.1: Isolation of Human Oligodendrocyte Precursor Cells (OPCs) and B Cells**

* Obtain human OPCs and B cells from healthy donors through a reputable cell isolation service or in-house isolation protocol.
* Verify the purity of isolated cells using flow cytometry and immunofluorescence staining.

**Step 1.2: Cell Culture Preparation**

* Prepare OPC culture medium: DMEM/F12 supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Prepare B cell culture medium: RPMI 1640 supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Prepare iron-depleted medium: OPC culture medium with 10 μM deferoxamine (iron chelator) added.
* Prepare iron-overloaded medium: OPC culture medium with 100 μM ferric ammonium citrate (iron supplement) added.

**Step 1.3: Co-Culture of OPCs and B Cells**

* Seed 1 x 10^5 OPCs per well in a 24-well plate in iron-depleted, iron-overloaded, or normal iron medium.
* Add 1 x 10^5 B cells per well to the OPC culture 24 hours after OPC seeding.
* Incubate at 37°C, 5% CO2 for 72 hours.

**Protocol 2: Gene Expression Analysis**

**Step 2.1: RNA Isolation**

* Harvest OPCs and B cells from co-culture experiments using trypsin-EDTA.
* Isolate total RNA using a commercial RNA isolation kit (e.g., TRIzol).
* Quantify RNA concentration using a spectrophotometer (e.g., NanoDrop).

**Step 2.2: RNA Sequencing (RNA-seq)**

* Prepare RNA-seq libraries using a commercial kit (e.g., TruSeq).
* Sequence RNA libraries using a next-generation sequencing platform (e.g., Illumina HiSeq).
* Analyze RNA-seq data using a bioinformatics pipeline (e.g., STAR, DESeq2).

**Step 2.3: Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)**

* Design primers for target genes involved in iron metabolism and B cell activation.
* Perform qRT-PCR using a commercial kit (e.g., PowerUp SYBR Green).
* Analyze qRT-PCR data using a software package (e.g., Prism).

**Protocol 3: Protein Analysis**

**Step 3.1: Western Blotting**

* Harvest OPCs and B cells from co-culture experiments using trypsin-EDTA.
* Lyse cells in RIPA buffer and quantify protein concentration using a spectrophotometer (e.g., NanoDrop).
* Perform Western blotting using a commercial kit (e.g., Mini-PROTEAN).
* Detect protein bands using a chemiluminescent substrate (e.g., ECL).

**Step 3.2: Immunofluorescence Staining**

* Fix OPCs and B cells from co-culture experiments using 4% paraformaldehyde.
* Permeabilize cells using 0.1% Triton X-100.
* Stain cells with primary antibodies against iron-related genes (e.g., ferritin, transferrin receptor) and B cell activation markers (e.g., CD80, CD86).
* Visualize staining using a fluorescence microscope (e.g., Zeiss Axiovert).

**Protocol 4: Functional Assays**

**Step 4.1: Cell Counting**

* Harvest B cells from co-culture experiments using trypsin-EDTA.
* Count B cells using a hemocytometer or an automated cell counter (e.g., Countess).

**Step 4.2: Flow Cytometry**

* Stain B cells with fluorescently labeled antibodies against B cell activation markers (e.g., CD80, CD86).
* Analyze stained cells using a flow cytometer (e.g., BD FACSCanto).

**Step 4.3: Enzyme-Linked Immunosorbent Assay (ELISA)**

* Coat ELISA plates with capture antibodies against B cell activation markers (e.g., CD80, CD86).
* Add B cell culture supernatants to ELISA plates.
* Detect bound antibodies using a secondary antibody and a chromogenic substrate (e.g., TMB).

**Protocol 5: Experiment to Disprove the Hypothesis**

**Step 5.1: Control Co-Culture**

* Co-culture OPCs with B cells in normal iron medium (control group).
* Compare gene expression, protein expression, and functional assays with iron-depleted or iron-overloaded co-culture groups.

**Step 5.2: Iron Chelation**

* Add 10 μM deferoxamine to the co-culture medium.
* Assess the effect of iron chelation on B cell phenotypes and OPC gene expression.

**Step 5.3: Rescue Experiment**

* Add 100 μM ferric ammonium citrate to the iron-depleted co-culture medium.
* Evaluate the effect of iron supplementation on B cell phenotypes and OPC gene expression.

These detailed protocols should provide a clear guide for executing the experimental plan and testing the hypothesis.","```
   OPCs  B Cells  Iron Depleted  Iron Overloaded  Iron Chelation  Rescue  Outcome
0   100000  100000           0             0             0       0  Inhibited
1   120000  120000           0             0             0       0  Inhibited
2    80000   80000           0             0             0       0  Inhibited
3   100000  100000           1             0             0       0  Activated
4   100000  100000           0             1             0       0  Activated
5   100000  100000           0             0             1       0  Inhibited
6   100000  100000           0             0             0       1  Activated
7   120000  120000           1             0             0       0  Activated
8    80000   80000           0             1             0       0  Activated
9   100000  100000           0             0             1       0  Inhibited
10  100000  100000           0             0             0       1  Activated
11  120000  120000           0             0             1       0  Inhibited
12   80000   80000           1             0             0       0  Activated
13  100000  100000           0             1             0       0  Activated
14  100000  100000           0             0             0       1  Activated
15  120000  120000           0             0             0       1  Activated
16   80000   80000           0             1             0       0  Activated
17  100000  100000           1             0             0       0  Activated
18  100000  100000           0             0             1       0  Inhibited
19  100000  100000           0             0             0       1  Activated
20  120000  120000           1             0             0       0  Activated
21   80000   80000           0             1             0       0  Activated
22  100000  100000           0             0             1       0  Inhibited
23  100000  100000           0             0             0       1  Activated
24  120000  120000           0             0             0       1  Activated
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0759ca89b2d3ef869d944fbbaf62565e50ae1c82.summary'],Does the dysregulation of the immune response in turbot infected with Enteromyxum scophthalmi also involve epigenetic modifications that affect the expression of immune-related genes?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** The dysregulation of the immune response in turbot infected with Enteromyxum scophthalmi involves epigenetic modifications that affect the expression of immune-related genes.

**Experimental Plan:**

**Objective:** To investigate whether epigenetic modifications are involved in the dysregulation of the immune response in turbot infected with Enteromyxum scophthalmi.

**Experimental Design:**

1. **Sample Collection:**
	* Collect turbot samples from a controlled environment (e.g., aquaculture facility) with and without Enteromyxum scophthalmi infection.
	* Ensure a sufficient number of samples for statistical significance (e.g., 10-15 per group).
2. **RNA Extraction and Sequencing:**
	* Extract total RNA from the spleen and head kidney tissues of infected and non-infected turbot using a standard RNA extraction protocol (e.g., TRIzol).
	* Perform RNA sequencing (RNA-seq) using a high-throughput sequencing platform (e.g., Illumina HiSeq) to generate transcriptome data.
3. **Epigenetic Analysis:**
	* Perform reduced representation bisulfite sequencing (RRBS) or whole-genome bisulfite sequencing (WGBS) to analyze DNA methylation patterns in the same tissues.
	* Use bioinformatic tools (e.g., Bismark, MethPipe) to identify differentially methylated regions (DMRs) between infected and non-infected samples.
4. **Integration of RNA-seq and Epigenetic Data:**
	* Integrate RNA-seq and epigenetic data to identify genes with altered expression and corresponding epigenetic modifications (e.g., DNA methylation) in infected turbot.
	* Use tools like DESeq2 and edgeR to identify differentially expressed genes (DEGs) between infected and non-infected samples.
5. **Validation:**
	* Validate the findings using quantitative real-time PCR (qRT-PCR) and/or chromatin immunoprecipitation sequencing (ChIP-seq) for a subset of genes with altered expression and epigenetic modifications.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the null hypothesis: ""There is no correlation between epigenetic modifications and immune-related gene expression in turbot infected with Enteromyxum scophthalmi.""

**Alternative Experimental Design:**

1. **Randomized Control Trial:**
	* Randomly assign turbot to either an infected or non-infected group.
	* Treat a subset of infected turbot with a demethylating agent (e.g., 5-azacytidine) to inhibit DNA methylation.
	* Analyze the expression of immune-related genes and epigenetic modifications in both groups using RNA-seq and RRBS/WGBS.
2. **Epigenetic Inhibitor Treatment:**
	* Treat infected turbot with an epigenetic inhibitor (e.g., histone deacetylase inhibitor) to disrupt epigenetic modifications.
	* Analyze the expression of immune-related genes using RNA-seq and compare to untreated infected turbot.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a budget of approximately $200,000-$300,000, depending on the sequencing platform and bioinformatic tools used. The budget breakdown can be allocated as follows:

* Sample collection and RNA extraction: $20,000
* RNA sequencing: $50,000-$70,000
* Epigenetic analysis: $30,000-$50,000
* Bioinformatic analysis: $20,000-$30,000
* Validation and experimental design: $30,000-$50,000
* Miscellaneous (reagents, consumables, etc.): $20,000-$30,000

Please note that these estimates are rough and may vary depending on the specific requirements of the experiment and the laboratory's infrastructure.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Sample Collection**

1.1. Obtain turbot samples from a controlled environment (e.g., aquaculture facility) with and without Enteromyxum scophthalmi infection.

* Ensure a sufficient number of samples for statistical significance (e.g., 10-15 per group).
* Collect spleen and head kidney tissues from each turbot using sterile instruments and store them in RNAlater or a similar RNA stabilization solution at -80°C.

**Protocol 2: RNA Extraction**

2.1. Extract total RNA from the spleen and head kidney tissues of infected and non-infected turbot using a standard RNA extraction protocol (e.g., TRIzol).

* Homogenize 100-200 mg of tissue in 1 mL of TRIzol reagent using a homogenizer or mortar and pestle.
* Incubate the mixture at room temperature for 5 minutes.
* Add 0.2 mL of chloroform and mix well.
* Centrifuge at 12,000 x g for 15 minutes at 4°C.
* Transfer the upper aqueous phase to a new tube and add 0.5 mL of isopropanol.
* Mix well and incubate at room temperature for 10 minutes.
* Centrifuge at 12,000 x g for 10 minutes at 4°C.
* Wash the pellet with 1 mL of 75% ethanol and centrifuge at 7,500 x g for 5 minutes at 4°C.
* Air-dry the pellet and resuspend in 50-100 μL of RNase-free water.

**Protocol 3: RNA Sequencing (RNA-seq)**

3.1. Perform RNA sequencing (RNA-seq) using a high-throughput sequencing platform (e.g., Illumina HiSeq) to generate transcriptome data.

* Prepare RNA-seq libraries using a standard protocol (e.g., TruSeq RNA Library Prep Kit).
* Perform quality control checks on the libraries using a bioanalyzer or similar instrument.
* Sequence the libraries on the Illumina HiSeq platform using a paired-end 150 bp read length.

**Protocol 4: Epigenetic Analysis (RRBS or WGBS)**

4.1. Perform reduced representation bisulfite sequencing (RRBS) or whole-genome bisulfite sequencing (WGBS) to analyze DNA methylation patterns in the same tissues.

* Prepare genomic DNA from the spleen and head kidney tissues using a standard protocol (e.g., DNeasy Blood & Tissue Kit).
* Perform bisulfite conversion of the genomic DNA using a standard protocol (e.g., EZ DNA Methylation Kit).
* Prepare RRBS or WGBS libraries using a standard protocol (e.g., TruSeq DNA Methylation Kit).
* Sequence the libraries on the Illumina HiSeq platform using a paired-end 150 bp read length.

**Protocol 5: Integration of RNA-seq and Epigenetic Data**

5.1. Integrate RNA-seq and epigenetic data to identify genes with altered expression and corresponding epigenetic modifications (e.g., DNA methylation) in infected turbot.

* Use bioinformatic tools (e.g., Bismark, MethPipe) to identify differentially methylated regions (DMRs) between infected and non-infected samples.
* Use tools like DESeq2 and edgeR to identify differentially expressed genes (DEGs) between infected and non-infected samples.
* Integrate the DMRs and DEGs to identify genes with altered expression and corresponding epigenetic modifications.

**Protocol 6: Validation**

6.1. Validate the findings using quantitative real-time PCR (qRT-PCR) and/or chromatin immunoprecipitation sequencing (ChIP-seq) for a subset of genes with altered expression and epigenetic modifications.

* Design primers for qRT-PCR using a standard protocol (e.g., Primer3).
* Perform qRT-PCR using a standard protocol (e.g., SYBR Green Master Mix).
* Analyze the data using a standard protocol (e.g., ΔΔCt method).
* Perform ChIP-seq using a standard protocol (e.g., ChIP-Seq Kit).
* Analyze the data using a standard protocol (e.g., MACS2).

**Protocol 7: Experimental Approach to Disprove the Hypothesis**

7.1. Design an experiment that tests the null hypothesis: ""There is no correlation between epigenetic modifications and immune-related gene expression in turbot infected with Enteromyxum scophthalmi.""

* Randomly assign turbot to either an infected or non-infected group.
* Treat a subset of infected turbot with a demethylating agent (e.g., 5-azacytidine) to inhibit DNA methylation.
* Analyze the expression of immune-related genes and epigenetic modifications in both groups using RNA-seq and RRBS/WGBS.

**Protocol 8: Alternative Experimental Design (Randomized Control Trial)**

8.1. Treat infected turbot with an epigenetic inhibitor (e.g., histone deacetylase inhibitor) to disrupt epigenetic modifications.

* Prepare the epigenetic inhibitor according to the manufacturer's instructions.
* Treat infected turbot with the epigenetic inhibitor for a specified duration (e.g., 24-48 hours).
* Analyze the expression of immune-related genes using RNA-seq and compare to untreated infected turbot.

These protocols provide a detailed, step-by-step guide for executing the experimental plan. The protocols are designed to ensure replicability and specificity in experimental science, and can be communicated to someone (or something, like a robot) executing the experiment.","```
   TRIzol_Reagent  Chloroform  Isopropanol  RNase_free_water  Epigenetic_Inhibitor  Outcome
0             0.8         0.2          0.5               50                  0.0  Infected
1             1.0         0.3          0.6               60                  0.0  Infected
2             0.9         0.2          0.5               55                  0.0  Infected
3             1.1         0.4          0.7               65                  0.0  Infected
4             0.7         0.1          0.4               45                  0.0  Non_Infected
5             0.8         0.2          0.5               50                  0.0  Non_Infected
6             1.0         0.3          0.6               60                  0.0  Infected
7             0.9         0.2          0.5               55                  0.0  Infected
8             1.1         0.4          0.7               65                  0.0  Infected
9             0.7         0.1          0.4               45                  0.0  Non_Infected
10            0.8         0.2          0.5               50                  0.0  Non_Infected
11            1.0         0.3          0.6               60                  0.0  Infected
12            0.9         0.2          0.5               55                  0.0  Infected
13            1.1         0.4          0.7               65                  0.0  Infected
14            0.7         0.1          0.4               45                  0.0  Non_Infected
15            0.8         0.2          0.5               50                  0.0  Non_Infected
16            1.0         0.3          0.6               60                  0.5  Infected
17            0.9         0.2          0.5               55                  0.5  Infected
18            1.1         0.4          0.7               65                  0.5  Infected
19            0.7         0.1          0.4               45                  0.5  Non_Infected
20            0.8         0.2          0.5               50                  0.5  Non_Infected
21            1.0         0.3          0.6               60                  1.0  Infected
22            0.9         0.2          0.5               55                  1.0  Infected
23            1.1         0.4          0.7               65                  1.0  Infected
24            0.7         0.1          0.4               45                  1.0  Non_Infected
```",0.6260995948852094
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4f6689804317633b193caabfe018ffb2bf838114.summary'],"Does the endocannabinoid system, specifically 2-AG, modulate the expression of CXCL12 in lymphoma cells, thereby creating a self-reinforcing loop that enhances lymphoma cell migration and homing?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Role of 2-AG in Modulating CXCL12-Mediated Chemotaxis in Lymphoma Cells

**Objective:** To determine if 2-AG modulates the expression of CXCL12 in lymphoma cells, creating a self-reinforcing loop that enhances lymphoma cell migration and homing.

**Experimental Design:**

1. **Cell Culture:** Culture lymphoma cells (e.g., mantle cell lymphoma or chronic lymphocytic leukemia) in the presence or absence of 2-AG (at varying concentrations) and CXCL12.
2. **CXCL12 Expression Analysis:** Use quantitative real-time PCR (qRT-PCR) or Western blotting to measure CXCL12 mRNA and protein expression in lymphoma cells treated with 2-AG and/or CXCL12.
3. **Chemotaxis Assay:** Perform chemotaxis assays using a transwell migration system to assess the effect of 2-AG on lymphoma cell migration in response to CXCL12.
4. **CXCR4 Signaling Analysis:** Use Western blotting or flow cytometry to analyze CXCR4 surface expression and phosphorylation in lymphoma cells treated with 2-AG and/or CXCL12.
5. **Inhibitor Studies:** Use specific inhibitors of the endocannabinoid system (e.g., CB1/CB2 receptor antagonists) and CXCR4 signaling pathway (e.g., AMD3100) to validate the role of 2-AG in modulating CXCL12-mediated chemotaxis.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of 2-AG-Mediated Modulation of CXCL12 Expression in Lymphoma Cells

**Objective:** To demonstrate that 2-AG does not modulate CXCL12 expression in lymphoma cells, thereby disproving the hypothesis.

**Experimental Design:**

1. **Cell Culture:** Culture lymphoma cells in the presence or absence of 2-AG (at high concentrations) and CXCL12.
2. **CXCL12 Expression Analysis:** Use qRT-PCR or Western blotting to measure CXCL12 mRNA and protein expression in lymphoma cells treated with 2-AG and/or CXCL12.
3. **Chemotaxis Assay:** Perform chemotaxis assays using a transwell migration system to assess the effect of 2-AG on lymphoma cell migration in response to CXCL12.
4. **CXCR4 Signaling Analysis:** Use Western blotting or flow cytometry to analyze CXCR4 surface expression and phosphorylation in lymphoma cells treated with 2-AG and/or CXCL12.

**Key Predictions:**

* If the hypothesis is true, 2-AG will increase CXCL12 expression, enhance CXCR4 signaling, and promote lymphoma cell migration in response to CXCL12.
* If the hypothesis is false, 2-AG will not affect CXCL12 expression, CXCR4 signaling, or lymphoma cell migration in response to CXCL12.

**Equipment and Resources:**

* Cell culture facilities
* Western blotting equipment
* Flow cytometry
* Chemotaxis assay equipment
* qRT-PCR machine
* Specific inhibitors of the endocannabinoid system and CXCR4 signaling pathway
* Lymphoma cell lines (e.g., mantle cell lymphoma or chronic lymphocytic leukemia)
* 2-AG and CXCL12
* Antibodies for Western blotting and flow cytometry

**Timeline:**

* Cell culture and treatment: 3-5 days
* CXCL12 expression analysis: 2-3 days
* Chemotaxis assay: 2-3 days
* CXCR4 signaling analysis: 2-3 days
* Data analysis and interpretation: 5-7 days

**Budget:**

* Cell culture reagents and media: $500
* 2-AG and CXCL12: $200
* Antibodies and inhibitors: $1,000
* Equipment maintenance and consumables: $1,500
* Total: $3,200

This experimental plan and budget should be feasible within a reasonable time frame and budget. The experiment designed to disprove the hypothesis will help to validate the results and provide a more comprehensive understanding of the role of 2-AG in modulating CXCL12-mediated chemotaxis in lymphoma cells.",85,"Here are the detailed, step-by-step protocols for the experimental plan to test the hypothesis and the experiment to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Protocol 1: Cell Culture**

1.1. Obtain lymphoma cell lines (e.g., mantle cell lymphoma or chronic lymphocytic leukemia) and maintain them in a sterile cell culture facility.

1.2. Prepare cell culture media (e.g., RPMI 1640) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.3. Seed 1 x 10^6 lymphoma cells per well in a 6-well plate and incubate at 37°C, 5% CO2 for 24 hours.

1.4. Treat cells with varying concentrations of 2-AG (e.g., 0, 1, 5, and 10 μM) and/or CXCL12 (e.g., 0, 10, and 50 ng/mL) for 24-48 hours.

**Protocol 2: CXCL12 Expression Analysis**

2.1. Harvest cells and extract total RNA using a RNA extraction kit (e.g., TRIzol).

2.2. Perform qRT-PCR using a qRT-PCR machine (e.g., ABI 7500) and specific primers for CXCL12 mRNA.

2.3. Analyze mRNA expression using the 2^(-ΔΔCt) method and normalize to a housekeeping gene (e.g., GAPDH).

2.4. Alternatively, perform Western blotting to analyze CXCL12 protein expression.

**Protocol 3: Chemotaxis Assay**

3.1. Prepare a transwell migration system (e.g., 8 μm pore size) and coat the underside of the membrane with 10 μg/mL fibronectin.

3.2. Add 1 x 10^5 lymphoma cells to the upper chamber and 600 μL of media containing CXCL12 (e.g., 10 ng/mL) to the lower chamber.

3.3. Incubate at 37°C, 5% CO2 for 2-4 hours.

3.4. Remove the membrane and count the number of migrated cells using a hemocytometer or flow cytometry.

**Protocol 4: CXCR4 Signaling Analysis**

4.1. Harvest cells and extract protein using a protein extraction kit (e.g., RIPA buffer).

4.2. Perform Western blotting to analyze CXCR4 surface expression and phosphorylation using specific antibodies.

4.3. Alternatively, perform flow cytometry to analyze CXCR4 surface expression and phosphorylation.

**Protocol 5: Inhibitor Studies**

5.1. Treat cells with specific inhibitors of the endocannabinoid system (e.g., CB1/CB2 receptor antagonists) and CXCR4 signaling pathway (e.g., AMD3100) for 1-2 hours.

5.2. Perform chemotaxis assays and CXCR4 signaling analysis as described above.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Culture**

1.1-1.4. Follow the same protocol as above, but use high concentrations of 2-AG (e.g., 20-50 μM) and CXCL12 (e.g., 100-200 ng/mL).

**Protocol 2: CXCL12 Expression Analysis**

2.1-2.4. Follow the same protocol as above.

**Protocol 3: Chemotaxis Assay**

3.1-3.4. Follow the same protocol as above.

**Protocol 4: CXCR4 Signaling Analysis**

4.1-4.3. Follow the same protocol as above.

Note: The experiment to disprove the hypothesis is designed to test the null hypothesis, and the protocols are similar to the experimental plan to test the hypothesis, but with higher concentrations of 2-AG and CXCL12.

**Equipment and Resources:**

* Cell culture facilities
* Western blotting equipment
* Flow cytometry
* Chemotaxis assay equipment
* qRT-PCR machine
* Specific inhibitors of the endocannabinoid system and CXCR4 signaling pathway
* Lymphoma cell lines (e.g., mantle cell lymphoma or chronic lymphocytic leukemia)
* 2-AG and CXCL12
* Antibodies for Western blotting and flow cytometry

**Timeline:**

* Cell culture and treatment: 3-5 days
* CXCL12 expression analysis: 2-3 days
* Chemotaxis assay: 2-3 days
* CXCR4 signaling analysis: 2-3 days
* Data analysis and interpretation: 5-7 days

**Budget:**

* Cell culture reagents and media: $500
* 2-AG and CXCL12: $200
* Antibodies and inhibitors: $1,000
* Equipment maintenance and consumables: $1,500
* Total: $3,200","```
   2-AG (μM)  CXCL12 (ng/mL)  Cell Count  CXCL12 mRNA  CXCR4 Phosphorylation  Migrated Cells
0         0.0             0.0     100000.0       1.000000               0.500000         2000.0
1         1.0             0.0     120000.0       1.200000               0.600000         2500.0
2         5.0             0.0     150000.0       1.500000               0.700000         3500.0
3        10.0             0.0     180000.0       1.800000               0.800000         4500.0
4         0.0            10.0     110000.0       1.100000               0.550000         2200.0
5         0.0            50.0     130000.0       1.300000               0.650000         2800.0
6         1.0            10.0     140000.0       1.400000               0.700000         3200.0
7         1.0            50.0     160000.0       1.600000               0.750000         3800.0
8         5.0            10.0     170000.0       1.700000               0.800000         4200.0
9         5.0            50.0     190000.0       1.900000               0.850000         4800.0
10       10.0            10.0     200000.0       2.000000               0.900000         5400.0
11       10.0            50.0     220000.0       2.200000               0.950000         6000.0
12        0.0             0.0     100000.0       1.000000               0.500000         2000.0
13        1.0             0.0     120000.0       1.200000               0.600000         2500.0
14        5.0             0.0     150000.0       1.500000               0.700000         3500.0
15       10.0             0.0     180000.0       1.800000               0.800000         4500.0
16        0.0            10.0     110000.0       1.100000               0.550000         2200.0
17        0.0            50.0     130000.0       1.300000               0.650000         2800.0
18        1.0            10.0     140000.0       1.400000               0.700000         3200.0
19        1.0            50.0     160000.0       1.600000               0.750000         3800.0
20       20.0             0.0     250000.0       2.500000               0.950000         7000.0
21       20.0           100.0     280000.0       2.800000               0.980000         8000.0
22       30.0             0.0     300000.0       3.000000               0.990000         9000.0
23       30.0           150.0     330000.0       3.300000               0.995000        10000.0
24       50.0             0.0     350000.0       3.500000               0.998000        11000.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/04a6e82855d95d8a492333b8a0704808ac0602ca.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/88315387e0b33751ba595ef0b8f12be0ac5cc16f.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5c771fe8893543666bd83b106eeff607f21a8416.summary']",Does the expression of type I IFN and fibrosis pathway genes in autoreactive B cells predict their ability to participate in germinal centers and produce high-affinity antibodies in proliferative lupus nephritis?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove it. The hypothesis states: ""Does the expression of type I IFN and fibrosis pathway genes in autoreactive B cells predict their ability to participate in germinal centers and produce high-affinity antibodies in proliferative lupus nephritis?""

To disprove this hypothesis, I will design an experiment that aims to show that the expression of type I IFN and fibrosis pathway genes in autoreactive B cells does not predict their ability to participate in germinal centers and produce high-affinity antibodies in proliferative lupus nephritis.

**Experiment:**

**Title:** Investigating the Role of Type I IFN and Fibrosis Pathway Genes in Autoreactive B Cell Function in Proliferative Lupus Nephritis

**Objective:** To determine if the expression of type I IFN and fibrosis pathway genes in autoreactive B cells is not correlated with their ability to participate in germinal centers and produce high-affinity antibodies in proliferative lupus nephritis.

**Experimental Design:**

1. **Cell Isolation:** Isolate autoreactive B cells from peripheral blood mononuclear cells (PBMCs) of patients with proliferative lupus nephritis using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
2. **RNA Sequencing:** Perform RNA sequencing on the isolated autoreactive B cells to analyze the expression of type I IFN and fibrosis pathway genes.
3. **Germinal Center Assay:** Use a germinal center assay to assess the ability of the autoreactive B cells to participate in germinal centers. This can be done by co-culturing the autoreactive B cells with follicular dendritic cells and measuring the formation of germinal centers using immunofluorescence staining.
4. **Antibody Production:** Measure the production of high-affinity antibodies by the autoreactive B cells using ELISA or surface plasmon resonance.
5. **Correlation Analysis:** Perform correlation analysis between the expression of type I IFN and fibrosis pathway genes and the ability of autoreactive B cells to participate in germinal centers and produce high-affinity antibodies.

**Expected Outcome:**

If the hypothesis is correct, we would expect to see a strong correlation between the expression of type I IFN and fibrosis pathway genes and the ability of autoreactive B cells to participate in germinal centers and produce high-affinity antibodies. However, if the experiment shows no correlation or a weak correlation, it would suggest that the expression of type I IFN and fibrosis pathway genes in autoreactive B cells does not predict their ability to participate in germinal centers and produce high-affinity antibodies in proliferative lupus nephritis, thus disproving the hypothesis.

**Equipment and Resources:**

* RNA sequencing platform (e.g. Illumina Novaseq-6000)
* Bioinformatics tools (e.g. Reactome database, WGCNA)
* Germinal center assay reagents (e.g. follicular dendritic cells, antibodies)
* ELISA or surface plasmon resonance instrument
* Flow cytometer
* Microplate reader
* Statistical software (e.g. RStudio)

**Timeline:**

* Cell isolation and RNA sequencing: 2 weeks
* Germinal center assay and antibody production: 4 weeks
* Correlation analysis: 2 weeks
* Total duration: 8 weeks

**Budget:**

* RNA sequencing: $5,000
* Germinal center assay reagents: $2,000
* ELISA or surface plasmon resonance instrument: $3,000
* Flow cytometer and microplate reader: $5,000 (assuming shared equipment)
* Statistical software: $1,000
* Total budget: $16,000

This experiment is designed to test the hypothesis and potentially disprove it. The results will provide valuable insights into the role of type I IFN and fibrosis pathway genes in autoreactive B cell function in proliferative lupus nephritis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation**

**Step 1.1: Prepare PBMCs**

* Obtain peripheral blood samples from patients with proliferative lupus nephritis.
* Isolate PBMCs using density gradient centrifugation (e.g., Ficoll-Paque) according to the manufacturer's instructions.
* Wash the PBMCs twice with phosphate-buffered saline (PBS) and resuspend them in 1 mL of PBS.

**Step 1.2: Isolate Autoreactive B Cells**

* Use magnetic bead-based separation or fluorescence-activated cell sorting (FACS) to isolate autoreactive B cells from the PBMCs.
* For magnetic bead-based separation:
	+ Incubate the PBMCs with anti-CD19 and anti-CD27 antibodies conjugated to magnetic beads (e.g., Miltenyi Biotec) for 30 minutes at 4°C.
	+ Separate the autoreactive B cells using a magnetic separator (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* For FACS:
	+ Stain the PBMCs with anti-CD19, anti-CD27, and anti-CD38 antibodies conjugated to different fluorochromes (e.g., FITC, PE, APC).
	+ Sort the autoreactive B cells using a flow cytometer (e.g., BD FACSAria) based on the expression of CD19, CD27, and CD38.

**Protocol 2: RNA Sequencing**

**Step 2.1: RNA Extraction**

* Extract total RNA from the isolated autoreactive B cells using a RNA extraction kit (e.g., Qiagen RNeasy) according to the manufacturer's instructions.
* Quantify the RNA concentration using a spectrophotometer (e.g., NanoDrop).

**Step 2.2: Library Preparation**

* Prepare RNA sequencing libraries using a RNA sequencing kit (e.g., Illumina TruSeq) according to the manufacturer's instructions.
* Fragment the RNA into smaller pieces (e.g., 200-300 bp) using a fragmentation kit (e.g., Covaris).
* Perform end repair, A-tailing, and adapter ligation according to the manufacturer's instructions.

**Step 2.3: RNA Sequencing**

* Sequence the RNA libraries using an RNA sequencing platform (e.g., Illumina Novaseq-6000) according to the manufacturer's instructions.
* Generate fastq files containing the sequencing data.

**Protocol 3: Germinal Center Assay**

**Step 3.1: Co-Culture Autoreactive B Cells with Follicular Dendritic Cells**

* Co-culture the isolated autoreactive B cells with follicular dendritic cells (e.g., human tonsillar follicular dendritic cells) at a ratio of 1:1 in a 96-well plate.
* Add germinal center-inducing cytokines (e.g., IL-4, IL-21) to the culture medium according to the manufacturer's instructions.

**Step 3.2: Immunofluorescence Staining**

* After 7-10 days of co-culture, fix the cells with 4% paraformaldehyde and permeabilize them with 0.1% Triton X-100.
* Stain the cells with antibodies against germinal center markers (e.g., CD23, CD35) conjugated to different fluorochromes (e.g., FITC, PE).
* Image the cells using a fluorescence microscope (e.g., Zeiss Axiovert) and quantify the formation of germinal centers using image analysis software (e.g., ImageJ).

**Protocol 4: Antibody Production**

**Step 4.1: ELISA**

* Coat 96-well plates with antigen (e.g., dsDNA) and block with 1% BSA.
* Add the supernatant from the co-culture to the plates and incubate for 1 hour at room temperature.
* Detect the bound antibodies using an HRP-conjugated secondary antibody and a substrate (e.g., TMB).
* Measure the absorbance at 450 nm using a microplate reader (e.g., BioTek Synergy).

**Step 4.2: Surface Plasmon Resonance**

* Immobilize the antigen (e.g., dsDNA) on a sensor chip (e.g., Biacore) according to the manufacturer's instructions.
* Flow the supernatant from the co-culture over the sensor chip and measure the binding response using a surface plasmon resonance instrument (e.g., Biacore 3000).

**Protocol 5: Correlation Analysis**

**Step 5.1: Data Preprocessing**

* Preprocess the RNA sequencing data using bioinformatics tools (e.g., Reactome database, WGCNA) to identify differentially expressed genes between autoreactive B cells that participate in germinal centers and those that do not.
* Normalize the gene expression data using a suitable method (e.g., DESeq2).

**Step 5.2: Correlation Analysis**

* Perform correlation analysis between the expression of type I IFN and fibrosis pathway genes and the ability of autoreactive B cells to participate in germinal centers and produce high-affinity antibodies using statistical software (e.g., RStudio).
* Calculate the correlation coefficient (e.g., Pearson's r) and p-value for each gene.

**Step 5.3: Data Interpretation**

* Interpret the results of the correlation analysis to determine if the expression of type I IFN and fibrosis pathway genes is correlated with the ability of autoreactive B cells to participate in germinal centers and produce high-affinity antibodies.
* If the correlation is weak or absent, it would suggest that the expression of type I IFN and fibrosis pathway genes in autoreactive B cells does not predict their ability to participate in germinal centers and produce high-affinity antibodies in proliferative lupus nephritis, thus disproving the hypothesis.","```
   PBMCs  Anti-CD19  Anti-CD27  Anti-CD38  RNA_Conc  IL-4  IL-21  Germinal_Center  Antibody_Production  Correlation_Coefficient
0    1000       10.0       5.0       2.0     100.0   10.0   20.0             0.8               0.5               0.3
1    1200       12.0       6.0       3.0     120.0   12.0   24.0             0.9               0.6               0.4
2     800        8.0       4.0       1.0      80.0    8.0   16.0             0.7               0.4               0.2
3    1500       15.0       7.5       3.5     150.0   15.0   30.0             0.95              0.7               0.5
4     900        9.0       4.5       2.0      90.0    9.0   18.0             0.8               0.5               0.3
5    1100       11.0       5.5       2.5     110.0   11.0   22.0             0.9               0.6               0.4
6     700        7.0       3.5       1.5      70.0    7.0   14.0             0.6               0.3               0.2
7    1300       13.0       6.5       3.0     130.0   13.0   26.0             0.95              0.7               0.5
8     1000       10.0       5.0       2.0     100.0   10.0   20.0             0.8               0.5               0.3
9    1400       14.0       7.0       3.5     140.0   14.0   28.0             0.98              0.8               0.6
10    900        9.0       4.5       2.0      90.0    9.0   18.0             0.8               0.5               0.3
11    1600       16.0       8.0       4.0     160.0   16.0   32.0             0.99              0.9               0.7
12    800        8.0       4.0       1.0      80.0    8.0   16.0             0.7               0.4               0.2
13    1700       17.0       8.5       4.5     170.0   17.0   34.0             0.995             0.95              0.8
14    1000       10.0       5.0       2.0     100.0   10.0   20.0             0.8               0.5               0.3
15    1800       18.0       9.0       5.0     180.0   18.0   36.0             0.998             0.98              0.9
16    1100       11.0       5.5       2.5     110.0   11.0   22.0             0.9               0.6               0.4
17    1900       19.0       9.5       5.5     190.0   19.0   38.0             0.999             0.99              0.95
18    1200       12.0       6.0       3.0     120.0   12.0   24.0             0.9               0.6               0.4
19    2000       20.0      10.0       6.0     200.0   20.0   40.0             0.999             0.995             0.98
20    1300       13.0       6.5       3.5     130.0   13.0   26.0             0.95              0.7               0.5
21    2100       21.0      10.5       6.5     210.0   21.0   42.0             0.999             0.998             0.99
22    1400       14.0       7.0       4.0     140.0   14.0   28.0             0.98              0.8               0.6
23    2200       22.0      11.0       7.0     220.0   22.0   44.0             0.999             0.999             0.995
24    1500       15.0       7.5       4.5     150.0   15.0   30.0             0.99              0.9               0.7
```",0.9667774038590267
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6b952891ca7ee995ef11a4b0bc0f505228164d11.summary'],"Does the formation of mixed hexameric antibody complexes between CD20 and CD37 antibodies also enhance the activation of immune cells, such as natural killer cells, in addition to complement activation, leading to increased anti-tumor activity?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it. Here's a high-level approach to investigate the role of mixed hexameric antibody complexes in enhancing immune cell activation and anti-tumor activity:

**Experimental Plan:**

**Objective:** To determine whether the formation of mixed hexameric antibody complexes between CD20 and CD37 antibodies enhances the activation of immune cells, such as natural killer (NK) cells, and leads to increased anti-tumor activity.

**Experimental Design:**

1. **Antibody Preparation:**
	* Obtain CD20 and CD37 antibodies with high purity and specificity.
	* Prepare mixed hexameric antibody complexes by incubating CD20 and CD37 antibodies at a 1:1 ratio, followed by size exclusion chromatography to isolate the hexameric complexes.
	* Verify the formation of hexameric complexes using techniques like gel filtration, dynamic light scattering, and electron microscopy.
2. **Cell Preparation:**
	* Isolate human NK cells from peripheral blood mononuclear cells (PBMCs) using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
	* Culture NK cells in the presence of interleukin-2 (IL-2) to enhance their activity.
	* Prepare tumor cells (e.g., Raji or Daudi cells) that express CD20 and CD37.
3. **Activation Assays:**
	* **NK Cell Activation:**
		+ Incubate NK cells with tumor cells in the presence or absence of mixed hexameric antibody complexes.
		+ Measure NK cell activation markers, such as CD69, CD25, and IFN-γ production, using flow cytometry.
		+ Evaluate NK cell cytotoxicity using chromium release assays or flow cytometry-based killing assays.
	* **Complement Activation:**
		+ Incubate tumor cells with mixed hexameric antibody complexes and human serum as a source of complement.
		+ Measure complement activation using techniques like ELISA, Western blot, or flow cytometry to detect C3b and C4b deposition.
4. **Anti-Tumor Activity:**
	* **In Vitro Cytotoxicity Assays:**
		+ Incubate tumor cells with mixed hexameric antibody complexes and NK cells.
		+ Measure tumor cell killing using MTT, Annexin V, or propidium iodide staining.
	* **In Vivo Tumor Models:**
		+ Establish human tumor xenografts in immunodeficient mice (e.g., NSG or SCID mice).
		+ Treat mice with mixed hexameric antibody complexes, NK cells, or a combination of both.
		+ Monitor tumor growth, and evaluate anti-tumor activity using bioluminescence imaging, tumor volume measurements, or histopathological analysis.
5. **Mechanistic Studies:**
	* **Flow Cytometry:**
		+ Analyze the expression of activation markers, such as CD69, CD25, and CD107a, on NK cells and tumor cells.
		+ Evaluate the binding of mixed hexameric antibody complexes to NK cells and tumor cells.
	* **Immunoprecipitation and Western Blot:**
		+ Investigate the interaction between CD20 and CD37 antibodies with NK cell receptors (e.g., CD16) and tumor cell surface proteins.
		+ Analyze the downstream signaling pathways involved in NK cell activation.

**Resources and Equipment:**

* Antibody preparation and characterization: Access to protein purification facilities, gel filtration, dynamic light scattering, and electron microscopy.
* Cell preparation and culture: Cell culture facilities, FACS, and magnetic bead-based separation.
* Activation assays: Flow cytometry, ELISA, Western blot, and chromium release assay equipment.
* Anti-tumor activity: In vitro cytotoxicity assay equipment (e.g., MTT, Annexin V, propidium iodide staining) and in vivo tumor models (e.g., NSG or SCID mice, bioluminescence imaging).
* Mechanistic studies: Flow cytometry, immunoprecipitation, and Western blot equipment.

**Timeline:**

* Antibody preparation and characterization: 2-3 months
* Cell preparation and culture: 1-2 months
* Activation assays: 3-4 months
* Anti-tumor activity: 4-6 months
* Mechanistic studies: 3-4 months
* Data analysis and manuscript preparation: 6-12 months

**Budget:**

* Personnel: 5-7 researchers, including a principal investigator, postdoctoral researchers, graduate students, and technicians.
* Reagents and consumables: Antibodies, cell culture media, FACS reagents, ELISA kits, Western blot reagents, and other consumables.
* Equipment: Access to protein purification facilities, FACS, flow cytometry, Western blot, and bioluminescence imaging equipment.
* Animal studies: Cost of mice, housing, and maintenance.

With an unlimited budget, the timeline can be accelerated by hiring additional personnel, purchasing necessary equipment, and outsourcing certain tasks to contract research organizations (CROs) or core facilities.",92,"Here are the detailed, step-by-step protocols for each section of the experimental plan:

**Antibody Preparation:**

1.1. Obtain CD20 and CD37 antibodies with high purity and specificity:

* Order CD20 and CD37 antibodies from a reputable supplier or produce them in-house using established protocols.
* Verify the purity and specificity of the antibodies using techniques such as SDS-PAGE, Western blot, and ELISA.

1.2. Prepare mixed hexameric antibody complexes:

* Mix 1 mg of CD20 antibody with 1 mg of CD37 antibody in 1 mL of phosphate-buffered saline (PBS) in a 1.5 mL microcentrifuge tube.
* Incubate the mixture at room temperature for 30 minutes to allow complex formation.
* Add 1 mL of PBS to the mixture and incubate for an additional 30 minutes.
* Centrifuge the mixture at 10,000 x g for 10 minutes to remove any aggregates.

1.3. Isolate hexameric complexes using size exclusion chromatography:

* Prepare a size exclusion chromatography column (e.g., Superdex 200) according to the manufacturer's instructions.
* Load the antibody mixture onto the column and elute with PBS.
* Collect fractions of 0.5 mL and analyze for protein content using UV-Vis spectroscopy.
* Pool fractions containing the hexameric complex (typically eluting at a molecular weight of ~150 kDa).

1.4. Verify hexameric complex formation:

* Analyze the pooled fractions using gel filtration, dynamic light scattering, and electron microscopy to confirm the formation of hexameric complexes.
* Verify the purity of the complex using SDS-PAGE and Western blot.

**Cell Preparation:**

2.1. Isolate human NK cells from peripheral blood mononuclear cells (PBMCs):

* Obtain PBMCs from a blood bank or collect blood from healthy donors.
* Isolate NK cells using magnetic bead-based separation (e.g., Miltenyi Biotec) or fluorescence-activated cell sorting (FACS) according to the manufacturer's instructions.
* Verify the purity of the NK cells using flow cytometry (e.g., CD56+CD3-).

2.2. Culture NK cells in the presence of interleukin-2 (IL-2):

* Culture NK cells in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 100 U/mL IL-2.
* Incubate the cells at 37°C, 5% CO2 for 3-5 days to enhance their activity.

2.3. Prepare tumor cells:

* Obtain tumor cells (e.g., Raji or Daudi cells) from a cell bank or culture them in-house.
* Verify the expression of CD20 and CD37 on the tumor cells using flow cytometry.

**Activation Assays:**

3.1. NK Cell Activation:

* Incubate 1 x 10^5 NK cells with 1 x 10^5 tumor cells in the presence or absence of 1 μg/mL mixed hexameric antibody complexes in a 96-well plate.
* Incubate the cells at 37°C, 5% CO2 for 24 hours.
* Measure NK cell activation markers (CD69, CD25, and IFN-γ production) using flow cytometry.

3.2. Complement Activation:

* Incubate 1 x 10^5 tumor cells with 1 μg/mL mixed hexameric antibody complexes and 10% human serum as a source of complement in a 96-well plate.
* Incubate the cells at 37°C, 5% CO2 for 30 minutes.
* Measure complement activation using techniques like ELISA, Western blot, or flow cytometry to detect C3b and C4b deposition.

**Anti-Tumor Activity:**

4.1. In Vitro Cytotoxicity Assays:

* Incubate 1 x 10^5 tumor cells with 1 x 10^5 NK cells and 1 μg/mL mixed hexameric antibody complexes in a 96-well plate.
* Incubate the cells at 37°C, 5% CO2 for 24 hours.
* Measure tumor cell killing using MTT, Annexin V, or propidium iodide staining.

4.2. In Vivo Tumor Models:

* Establish human tumor xenografts in immunodeficient mice (e.g., NSG or SCID mice).
* Treat mice with 10 μg of mixed hexameric antibody complexes, 1 x 10^6 NK cells, or a combination of both via intravenous injection.
* Monitor tumor growth using bioluminescence imaging, tumor volume measurements, or histopathological analysis.

**Mechanistic Studies:**

5.1. Flow Cytometry:

* Analyze the expression of activation markers (CD69, CD25, and CD107a) on NK cells and tumor cells using flow cytometry.
* Evaluate the binding of mixed hexameric antibody complexes to NK cells and tumor cells using flow cytometry.

5.2. Immunoprecipitation and Western Blot:

* Immunoprecipitate CD20 and CD37 antibodies from NK cells and tumor cells using protein A/G beads.
* Analyze the immunoprecipitates using Western blot to investigate the interaction between CD20 and CD37 antibodies with NK cell receptors (e.g., CD16) and tumor cell surface proteins.
* Analyze the downstream signaling pathways involved in NK cell activation using Western blot.

These detailed protocols should provide a clear guide for executing the experimental plan.","```
   CD20_Antibody  CD37_Antibody  IL-2  NK_Cells  Tumor_Cells  Hexameric_Complex  Outcome
0           0.5           0.5    50      100000      100000           1.0       0.8
1           1.0           1.0   100      150000      150000           2.0       1.2
2           0.2           0.8    75      120000      120000           1.5       1.0
3           1.5           0.5   125      180000      180000           2.5       1.5
4           0.8           1.2    90      140000      140000           2.0       1.3
5           1.2           0.8   110      160000      160000           2.2       1.4
6           0.5           1.5    60      130000      130000           1.8       1.1
7           1.8           0.2   145      190000      190000           2.8       1.7
8           0.9           1.1    95      150000      150000           2.1       1.3
9           1.1           0.9   105      170000      170000           2.3       1.5
10          0.6           1.4    80      140000      140000           2.0       1.2
11          1.4           0.6   130      180000      180000           2.6       1.6
12          0.7           1.3    85      145000      145000           2.1       1.3
13          1.3           0.7   115      165000      165000           2.4       1.5
14          0.4           1.6    70      135000      135000           1.9       1.1
15          1.6           0.4   140      185000      185000           2.9       1.8
16          0.3           1.7    65      125000      125000           1.8       1.0
17          1.7           0.3   150      195000      195000           3.1       2.0
18          0.9           1.0    90      155000      155000           2.2       1.4
19          1.0           0.9   100      170000      170000           2.3       1.5
20          0.8           1.2    85      145000      145000           2.1       1.3
21          1.2           0.8   110      165000      165000           2.4       1.5
22          0.6           1.4    80      140000      140000           2.0       1.2
23          1.4           0.6   130      180000      180000           2.6       1.6
24          0.7           1.3    85      150000      150000           2.2       1.4
```",0.6867068889561305
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0702699ecdbf0a73194acc009fa7805643f4fe36.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/550e54a7f00f481e7020b7f3ba7a298c5e668210.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/62a954355f4c143843bc864d3eb5f255af2463d3.summary']","Does the gut microbiota play a role in regulating the elimination of self-reactive B cells in the GALT, and can modulation of the gut microbiota composition influence the efficacy of B cell depletion therapies in autoimmune diseases?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the gut microbiota plays a role in regulating the elimination of self-reactive B cells in the GALT, and that modulation of the gut microbiota composition can influence the efficacy of B cell depletion therapies in autoimmune diseases, I propose the following experimental plan:

**Experiment:** ""Investigating the role of gut microbiota in regulating self-reactive B cell elimination and B cell depletion therapy efficacy in autoimmune diseases""

**Objective:** To determine whether the gut microbiota influences the elimination of self-reactive B cells in the GALT and whether modulation of the gut microbiota composition affects the efficacy of B cell depletion therapies in autoimmune diseases.

**Design:**

1. **Gut microbiota manipulation:** Use a mouse model of autoimmune disease (e.g., systemic sclerosis) and manipulate the gut microbiota composition using antibiotics, prebiotics, or fecal microbiota transplantation (FMT) to alter the gut microbiota.
2. **B cell depletion therapy:** Administer a B cell depletion therapy (e.g., CD19-targeted CAR-T cells) to the mice.
3. **GALT analysis:** Analyze the GALT for self-reactive B cell populations, TGF-β signaling pathway activity, and gut microbiota composition using flow cytometry, PCR, Western blotting, and 16S rRNA sequencing.
4. **Comparison:** Compare the results between mice with manipulated gut microbiota and control mice without gut microbiota manipulation.

**Specific steps:**

1. Treat mice with antibiotics, prebiotics, or FMT to alter the gut microbiota composition.
2. Administer CD19-targeted CAR-T cells to the mice.
3. Collect GALT samples and analyze self-reactive B cell populations using flow cytometry.
4. Measure TGF-β signaling pathway activity using PCR and Western blotting.
5. Analyze gut microbiota composition using 16S rRNA sequencing.
6. Compare the results between mice with manipulated gut microbiota and control mice.

**Expected outcomes:**

* If the gut microbiota plays a role in regulating self-reactive B cell elimination, mice with altered gut microbiota composition will show changes in self-reactive B cell populations and TGF-β signaling pathway activity in the GALT.
* If modulation of the gut microbiota composition influences the efficacy of B cell depletion therapies, mice with altered gut microbiota composition will show changes in the response to CD19-targeted CAR-T cells.

**Resources and budget:**

* Mouse model of autoimmune disease
* Antibiotics, prebiotics, or FMT for gut microbiota manipulation
* CD19-targeted CAR-T cells
* Flow cytometry, PCR, Western blotting, and 16S rRNA sequencing equipment
* Personnel and laboratory facilities

**Timeline:**

* 6 weeks for gut microbiota manipulation and B cell depletion therapy administration
* 4 weeks for GALT analysis and data collection
* 2 weeks for data analysis and interpretation

**Budget:**

* $10,000 for mouse model and reagents
* $5,000 for gut microbiota manipulation and B cell depletion therapy
* $10,000 for equipment and personnel costs
* Total: $25,000

This experiment is designed to test the hypothesis and can be completed within a reasonable time frame and budget. The results will provide valuable insights into the role of the gut microbiota in regulating self-reactive B cell elimination and the efficacy of B cell depletion therapies in autoimmune diseases.",85,"Here is the detailed, step-by-step protocol for the experiment:

**Experiment:** ""Investigating the role of gut microbiota in regulating self-reactive B cell elimination and B cell depletion therapy efficacy in autoimmune diseases""

**Protocol:**

**Weeks 1-6: Gut Microbiota Manipulation and B Cell Depletion Therapy Administration**

1. **Mouse Preparation:**
	* Obtain 20 mice with a mouse model of autoimmune disease (e.g., systemic sclerosis).
	* Randomly divide the mice into four groups: control, antibiotic-treated, prebiotic-treated, and FMT-treated.
	* House the mice in a specific pathogen-free (SPF) facility with ad libitum access to food and water.
2. **Gut Microbiota Manipulation:**
	* **Antibiotic Treatment:**
		+ Administer a broad-spectrum antibiotic cocktail (e.g., vancomycin, metronidazole, and ampicillin) to the antibiotic-treated group via oral gavage at a dose of 100 mg/kg/day for 2 weeks.
		+ Monitor the mice for signs of illness or distress.
	* **Prebiotic Treatment:**
		+ Administer a prebiotic supplement (e.g., inulin) to the prebiotic-treated group via oral gavage at a dose of 100 mg/kg/day for 2 weeks.
		+ Monitor the mice for signs of illness or distress.
	* **Fecal Microbiota Transplantation (FMT):**
		+ Collect fecal samples from healthy donor mice.
		+ Prepare the fecal samples for FMT by mixing 100 mg of feces with 1 mL of phosphate-buffered saline (PBS).
		+ Administer the FMT mixture to the FMT-treated group via oral gavage at a dose of 100 mg/kg/day for 2 weeks.
		+ Monitor the mice for signs of illness or distress.
3. **B Cell Depletion Therapy Administration:**
	* **CD19-Targeted CAR-T Cell Preparation:**
		+ Prepare CD19-targeted CAR-T cells according to the manufacturer's instructions.
		+ Verify the CAR-T cell viability and functionality using flow cytometry and functional assays.
	* **CD19-Targeted CAR-T Cell Administration:**
		+ Administer 1 x 10^6 CD19-targeted CAR-T cells to each mouse via intravenous injection.
		+ Monitor the mice for signs of illness or distress.

**Weeks 7-10: GALT Analysis**

1. **GALT Sample Collection:**
	* Euthanize the mice using a humane method (e.g., CO2 asphyxiation).
	* Collect the gut-associated lymphoid tissue (GALT) samples from the small intestine and mesenteric lymph nodes.
	* Store the samples in ice-cold PBS for further analysis.
2. **Flow Cytometry Analysis:**
	* Prepare single-cell suspensions from the GALT samples using a gentle dissociation protocol.
	* Stain the cells with fluorescently labeled antibodies against CD19, CD20, and CD45 to identify self-reactive B cell populations.
	* Analyze the samples using a flow cytometer (e.g., BD FACSCanto II) and FlowJo software.
3. **PCR and Western Blotting Analysis:**
	* Extract RNA from the GALT samples using a RNA extraction kit (e.g., Qiagen RNeasy Mini Kit).
	* Perform quantitative PCR (qPCR) to measure TGF-β signaling pathway activity using primers specific for TGF-β1, TGF-β2, and TGF-β3.
	* Analyze the qPCR data using the ΔΔCt method.
	* Perform Western blotting to measure TGF-β protein levels using antibodies against TGF-β1, TGF-β2, and TGF-β3.
4. **16S rRNA Sequencing Analysis:**
	* Extract DNA from the GALT samples using a DNA extraction kit (e.g., Qiagen DNeasy PowerSoil Kit).
	* Perform 16S rRNA sequencing using a sequencing platform (e.g., Illumina MiSeq) and analyze the data using QIIME2 software.

**Weeks 11-12: Data Analysis and Interpretation**

1. **Data Analysis:**
	* Compare the results between mice with manipulated gut microbiota and control mice without gut microbiota manipulation.
	* Analyze the data using statistical software (e.g., GraphPad Prism) and perform appropriate statistical tests (e.g., t-test, ANOVA).
2. **Data Interpretation:**
	* Interpret the results in the context of the research question and hypothesis.
	* Draw conclusions about the role of the gut microbiota in regulating self-reactive B cell elimination and the efficacy of B cell depletion therapies in autoimmune diseases.

**Resources and Budget:**

* Mouse model of autoimmune disease: $5,000
* Antibiotics, prebiotics, and FMT reagents: $2,000
* CD19-targeted CAR-T cells: $3,000
* Flow cytometry, PCR, Western blotting, and 16S rRNA sequencing equipment: $10,000
* Personnel and laboratory facilities: $5,000
* Total: $25,000

**Timeline:**

* Weeks 1-6: Gut microbiota manipulation and B cell depletion therapy administration
* Weeks 7-10: GALT analysis and data collection
* Weeks 11-12: Data analysis and interpretation

Note: The protocol is designed to be specific, detailed, and replicable. The resources and budget are estimated and may vary depending on the specific requirements of the experiment.","```
   Antibiotic_Dose  Prebiotic_Dose  FMT_Dose  CAR_T_Cell_Dose  CD19_Positive_B_Cells  TGF_beta_Signaling  Gut_Microbiota_Diversity  Outcome
0             50.0          150.0     75.0           0.5e+06            20.0              1.2               0.8          Success
1             75.0           50.0     100.0           1.0e+06            15.0              1.5               0.9          Success
2             25.0          100.0      50.0           0.8e+06            18.0              1.1               0.7          Failure
3             50.0           75.0     125.0           1.2e+06            12.0              1.6               0.9          Success
4             100.0           25.0     75.0           0.9e+06            22.0              1.3               0.8          Failure
5             75.0          125.0     100.0           1.1e+06            10.0              1.7               0.9          Success
6             25.0           50.0     125.0           0.7e+06            25.0              1.2               0.7          Failure
7             50.0           100.0     75.0           1.0e+06            18.0              1.4               0.8          Success
8             100.0           75.0     125.0           1.3e+06            12.0              1.8               0.9          Success
9             75.0           25.0     100.0           0.9e+06            20.0              1.3               0.8          Failure
10            25.0          125.0     100.0           0.8e+06            15.0              1.5               0.9          Success
11            50.0           75.0     125.0           1.2e+06            10.0              1.7               0.9          Success
12            100.0           50.0     75.0           1.1e+06            22.0              1.4               0.8          Failure
13            75.0          100.0     125.0           1.0e+06            18.0              1.6               0.9          Success
14            25.0           75.0     100.0           0.9e+06            25.0              1.3               0.7          Failure
15            50.0           125.0     75.0           1.3e+06            12.0              1.8               0.9          Success
16            100.0           100.0     125.0           1.2e+06            15.0              1.7               0.9          Success
17            75.0           50.0     100.0           1.1e+06            20.0              1.4               0.8          Failure
18            25.0          100.0     125.0           0.8e+06            18.0              1.5               0.9          Success
19            50.0           75.0     100.0           1.0e+06            22.0              1.3               0.8          Failure
20            100.0           125.0     75.0           1.3e+06            10.0              1.8               0.9          Success
21            75.0           25.0     125.0           1.2e+06            25.0              1.4               0.7          Failure
22            25.0           75.0     100.0           0.9e+06            15.0              1.5               0.9          Success
23            50.0           100.0     125.0           1.1e+06            18.0              1.6               0.9          Success
24            100.0           50.0     100.0           1.2e+06            20.0              1.4               0.8          Failure
```",0.249958487779421
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ce334241945cfd3753e93a32ab7dc15241fdc9ba.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/95ad2025b77413dc9f46b99d87a8b0cf64c7c54c.summary']","Does the heterogeneous B cell immune response in acute Borreliosis patients influence the efficacy of TNF inhibitor treatment in rheumatoid arthritis patients, leading to variations in B cell receptor diversity and immune repertoire modulation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis and potentially disprove it. The experiment is designed to be feasible within a reasonable time frame and budget.

**Hypothesis:** Does the heterogeneous B cell immune response in acute Borreliosis patients influence the efficacy of TNF inhibitor treatment in rheumatoid arthritis patients, leading to variations in B cell receptor diversity and immune repertoire modulation?

**Experimental Design:**

**Objective:** To investigate whether the heterogeneous B cell immune response in acute Borreliosis patients affects the efficacy of TNF inhibitor treatment in rheumatoid arthritis patients and its impact on B cell receptor diversity and immune repertoire modulation.

**Study Design:**

1. **Patient Selection:**
	* Recruit 20 rheumatoid arthritis (RA) patients who have been diagnosed with acute Borreliosis.
	* Recruit 20 RA patients without Borreliosis as controls.
	* Ensure that all patients are treatment-naive for TNF inhibitors.
2. **Sample Collection:**
	* Collect peripheral blood samples from all patients at baseline (before TNF inhibitor treatment).
	* Collect additional blood samples from the same patients after 3 months of TNF inhibitor treatment.
3. **B Cell Isolation and Stimulation:**
	* Isolate B cells from the collected blood samples using magnetic bead-based separation.
	* Stimulate the isolated B cells with Borrelia antigens (for Borreliosis-positive patients) or control antigens (for Borreliosis-negative patients) for 7 days.
4. **High-Throughput Sequencing:**
	* Perform high-throughput sequencing of the B cell receptor (BCR) repertoire using a platform such as Illumina or PacBio.
	* Analyze the BCR repertoire using bioinformatic tools to identify changes in diversity, clonality, and repertoire modulation.
5. **TNF Inhibitor Treatment:**
	* Administer TNF inhibitor treatment to all patients for 3 months.
	* Monitor disease activity and response to treatment using standardized clinical assessments (e.g., DAS28).
6. **Post-Treatment Analysis:**
	* Collect additional blood samples from all patients after 3 months of TNF inhibitor treatment.
	* Repeat the B cell isolation, stimulation, and high-throughput sequencing steps.
	* Compare the pre- and post-treatment BCR repertoire data to assess changes in diversity, clonality, and repertoire modulation.

**Data Analysis:**

1. **BCR Repertoire Analysis:**
	* Compare the BCR repertoire diversity, clonality, and repertoire modulation between Borreliosis-positive and Borreliosis-negative RA patients at baseline and after TNF inhibitor treatment.
	* Analyze the correlation between BCR repertoire changes and clinical response to TNF inhibitor treatment.
2. **Statistical Analysis:**
	* Perform statistical analysis using tools such as R or Python to compare the BCR repertoire data between groups and identify significant differences.

**Expected Outcomes:**

1. If the hypothesis is true, we expect to see:
	* A significant difference in BCR repertoire diversity, clonality, and repertoire modulation between Borreliosis-positive and Borreliosis-negative RA patients at baseline.
	* A correlation between BCR repertoire changes and clinical response to TNF inhibitor treatment in Borreliosis-positive RA patients.
2. If the hypothesis is false, we expect to see:
	* No significant difference in BCR repertoire diversity, clonality, and repertoire modulation between Borreliosis-positive and Borreliosis-negative RA patients at baseline.
	* No correlation between BCR repertoire changes and clinical response to TNF inhibitor treatment in Borreliosis-positive RA patients.

**Limitations:**

1. Small sample size may limit the power to detect significant differences.
2. The study is limited to a specific population of RA patients with acute Borreliosis, which may not be representative of all RA patients.
3. The study design does not account for potential confounding factors, such as other comorbidities or medications, that may affect the BCR repertoire and response to TNF inhibitor treatment.

**Timeline:**

* Patient recruitment and sample collection: 3 months
* B cell isolation, stimulation, and high-throughput sequencing: 6 months
* Data analysis and statistical analysis: 9 months
* Total duration: 18 months

**Budget:**

* Patient recruitment and sample collection: $10,000
* B cell isolation, stimulation, and high-throughput sequencing: $30,000
* Data analysis and statistical analysis: $20,000
* Total budget: $60,000

This experiment is designed to test the hypothesis and provide insights into the relationship between the heterogeneous B cell immune response in acute Borreliosis patients and the efficacy of TNF inhibitor treatment in rheumatoid arthritis patients.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Patient Selection and Sample Collection**

1.1. Patient Recruitment:

* Identify and recruit 20 rheumatoid arthritis (RA) patients who have been diagnosed with acute Borreliosis through medical records and clinical assessments.
* Identify and recruit 20 RA patients without Borreliosis as controls through medical records and clinical assessments.
* Ensure that all patients are treatment-naive for TNF inhibitors.

1.2. Informed Consent:

* Obtain written informed consent from each patient prior to sample collection.
* Ensure that patients understand the purpose, risks, and benefits of the study.

1.3. Sample Collection:

* Collect 10 mL of peripheral blood from each patient at baseline (before TNF inhibitor treatment) using a sterile needle and syringe.
* Label the samples with a unique identifier and store them at -80°C until further processing.

**Protocol 2: B Cell Isolation and Stimulation**

2.1. B Cell Isolation:

* Thaw the frozen blood samples and isolate B cells using magnetic bead-based separation (e.g., Miltenyi Biotec's B Cell Isolation Kit).
* Follow the manufacturer's instructions for B cell isolation.

2.2. B Cell Stimulation:

* Stimulate the isolated B cells with Borrelia antigens (for Borreliosis-positive patients) or control antigens (for Borreliosis-negative patients) for 7 days.
* Use a concentration of 1 μg/mL of antigen and incubate at 37°C, 5% CO2.

**Protocol 3: High-Throughput Sequencing**

3.1. RNA Extraction:

* Extract RNA from the stimulated B cells using a RNA extraction kit (e.g., Qiagen's RNeasy Kit).
* Follow the manufacturer's instructions for RNA extraction.

3.2. Library Preparation:

* Prepare a library for high-throughput sequencing using a platform such as Illumina or PacBio.
* Follow the manufacturer's instructions for library preparation.

3.3. Sequencing:

* Perform high-throughput sequencing of the B cell receptor (BCR) repertoire using the prepared library.
* Use a sequencing platform such as Illumina HiSeq or PacBio Sequel.

**Protocol 4: TNF Inhibitor Treatment and Post-Treatment Analysis**

4.1. TNF Inhibitor Treatment:

* Administer TNF inhibitor treatment to all patients for 3 months.
* Monitor disease activity and response to treatment using standardized clinical assessments (e.g., DAS28).

4.2. Post-Treatment Sample Collection:

* Collect an additional 10 mL of peripheral blood from each patient after 3 months of TNF inhibitor treatment.
* Label the samples with a unique identifier and store them at -80°C until further processing.

4.3. Post-Treatment B Cell Isolation and Stimulation:

* Repeat the B cell isolation and stimulation steps (Protocols 2.1 and 2.2) using the post-treatment blood samples.

4.4. Post-Treatment High-Throughput Sequencing:

* Repeat the high-throughput sequencing steps (Protocols 3.1-3.3) using the post-treatment B cell samples.

**Protocol 5: Data Analysis**

5.1. BCR Repertoire Analysis:

* Analyze the BCR repertoire data using bioinformatic tools (e.g., IMGT/HighV-QUEST, IgBLAST) to identify changes in diversity, clonality, and repertoire modulation.
* Compare the pre- and post-treatment BCR repertoire data to assess changes in diversity, clonality, and repertoire modulation.

5.2. Statistical Analysis:

* Perform statistical analysis using tools such as R or Python to compare the BCR repertoire data between groups and identify significant differences.
* Analyze the correlation between BCR repertoire changes and clinical response to TNF inhibitor treatment.

**Quality Control and Assurance**

* Ensure that all protocols are followed accurately and consistently throughout the experiment.
* Perform regular quality control checks on the samples, reagents, and equipment to ensure accuracy and precision.
* Document all protocols, procedures, and results in a laboratory notebook or electronic database.

**Timeline and Budget**

* Patient recruitment and sample collection: 3 months, $10,000
* B cell isolation, stimulation, and high-throughput sequencing: 6 months, $30,000
* Data analysis and statistical analysis: 9 months, $20,000
* Total duration: 18 months, $60,000","```
   Patient_Group  Antigen_Concentration  TNF_Inhibitor_Dose  Pre_Treatment_BCR_Diversity  Post_Treatment_BCR_Diversity  Change_in_BCR_Diversity
0           RA_Bor  0.5                10mg               0.85                       0.92                       0.07
1           RA_Bor  1.0                20mg               0.80                       0.95                       0.15
2           RA_Bor  1.5                30mg               0.75                       0.90                       0.15
3           RA_Bor  2.0                40mg               0.70                       0.85                       0.15
4           RA_Bor  2.5                50mg               0.65                       0.80                       0.15
5           RA_Non  0.5                10mg               0.90                       0.95                       0.05
6           RA_Non  1.0                20mg               0.85                       0.90                       0.05
7           RA_Non  1.5                30mg               0.80                       0.85                       0.05
8           RA_Non  2.0                40mg               0.75                       0.80                       0.05
9           RA_Non  2.5                50mg               0.70                       0.75                       0.05
10          RA_Bor  0.5                10mg               0.80                       0.90                       0.10
11          RA_Bor  1.0                20mg               0.75                       0.85                       0.10
12          RA_Bor  1.5                30mg               0.70                       0.80                       0.10
13          RA_Bor  2.0                40mg               0.65                       0.75                       0.10
14          RA_Bor  2.5                50mg               0.60                       0.70                       0.10
15          RA_Non  0.5                10mg               0.95                       0.98                       0.03
16          RA_Non  1.0                20mg               0.90                       0.93                       0.03
17          RA_Non  1.5                30mg               0.85                       0.88                       0.03
18          RA_Non  2.0                40mg               0.80                       0.83                       0.03
19          RA_Non  2.5                50mg               0.75                       0.78                       0.03
20          RA_Bor  0.5                10mg               0.85                       0.92                       0.07
21          RA_Bor  1.0                20mg               0.80                       0.90                       0.10
22          RA_Bor  1.5                30mg               0.75                       0.85                       0.10
23          RA_Bor  2.0                40mg               0.70                       0.80                       0.10
24          RA_Bor  2.5                50mg               0.65                       0.75                       0.10
```",0.2443809031725276
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e2a2212c1c7100e10bdfb672df86c06b6fcdab48.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e37c02e6664c8b9e83cf71c21df93238e6241f3b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/696b09f7d666d0982b5fdf46ffbcb5cf15d1f483.summary']","Does the imbalance in cytokine production, particularly IL-2 and IL-7, in ASS-ILD patients lead to an altered CRP response, which in turn contributes to the metabolic reprogramming of macrophages and exacerbates inflammation in these patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the imbalance in cytokine production, particularly IL-2 and IL-7, in ASS-ILD patients leads to an altered CRP response, which in turn contributes to the metabolic reprogramming of macrophages and exacerbates inflammation in these patients, I propose the following experimental plan:

**Experiment:** ""Investigating the role of IL-2 and IL-7 in CRP-induced metabolic reprogramming of macrophages in ASS-ILD patients""

**Objective:** To determine if the imbalance in IL-2 and IL-7 production in ASS-ILD patients contributes to altered CRP response, leading to metabolic reprogramming of macrophages and exacerbating inflammation.

**Equipment:**

* Flow cytometer
* ELISA reader
* Magnetic bead separator
* Cell culture facilities
* Seahorse metabolic analyzer
* Small molecule inhibitors
* RNA interference

**Steps:**

1. **Isolate CD4 and CD8 T cells** from peripheral blood mononuclear cells (PBMCs) of ASS-ILD patients and healthy donors using magnetic bead separation.
2. **Stimulate T cells** with anti-CD3 and anti-CD28 antibodies to induce cytokine production.
3. **Measure IL-2 and IL-7 production** using flow cytometry and ELISA assays.
4. **Isolate macrophages** from PBMCs of ASS-ILD patients and healthy donors.
5. **Stimulate macrophages** with CRP and/or PHA to induce metabolic reprogramming.
6. **Measure cytokine production** (e.g., IL-6, TNFα) using ELISA.
7. **Analyze metabolic pathways** using Seahorse metabolic analyzer.
8. **Use small molecule inhibitors and RNA interference** to identify responsible signaling pathways.
9. **Compare results** between ASS-ILD patients and healthy donors.

**To disprove the hypothesis:**

1. **Use a neutralizing antibody** against IL-2 and/or IL-7 to block their activity in ASS-ILD patient T cells.
2. **Measure CRP production** in response to T cell stimulation.
3. **Compare CRP production** between ASS-ILD patients and healthy donors.
4. **If CRP production is not altered** in the presence of neutralizing antibodies, it would suggest that the imbalance in IL-2 and IL-7 production does not contribute to altered CRP response.

**Time frame:** This experiment can be completed within 6-9 months, depending on the availability of resources and personnel.

**Budget:** The budget for this experiment will depend on the cost of reagents, equipment, and personnel. However, a rough estimate would be:

* Reagents and consumables: $10,000 - $15,000
* Equipment (e.g., flow cytometer, Seahorse metabolic analyzer): $50,000 - $100,000 (depending on the specific models and brands)
* Personnel (e.g., post-doc, technician): $50,000 - $100,000 per year (depending on the institution and location)

Total estimated budget: $110,000 - $215,000 per year.

This experiment is designed to test the hypothesis and provide insights into the role of IL-2 and IL-7 in CRP-induced metabolic reprogramming of macrophages in ASS-ILD patients.",85,"Here are the detailed, step-by-step protocols for the experiment ""Investigating the role of IL-2 and IL-7 in CRP-induced metabolic reprogramming of macrophages in ASS-ILD patients"":

**Protocol 1: Isolation of CD4 and CD8 T cells from PBMCs**

1.1. Collect peripheral blood samples from ASS-ILD patients and healthy donors in EDTA-coated tubes.

1.2. Perform density gradient centrifugation using Ficoll-Paque to separate PBMCs from whole blood.

1.3. Wash PBMCs with PBS and resuspend in 1x PBS with 2% FBS.

1.4. Label CD4 and CD8 T cells using magnetic bead-conjugated antibodies (e.g., CD4-PE and CD8-APC) according to the manufacturer's instructions.

1.5. Perform magnetic bead separation using a magnetic separator (e.g., Miltenyi Biotec) to isolate CD4 and CD8 T cells.

1.6. Wash isolated T cells with PBS and resuspend in 1x PBS with 2% FBS.

**Protocol 2: Stimulation of T cells and measurement of IL-2 and IL-7 production**

2.1. Plate 1x10^6 isolated T cells per well in a 96-well plate.

2.2. Add 1 μg/mL anti-CD3 and 1 μg/mL anti-CD28 antibodies to each well to stimulate T cells.

2.3. Incubate cells at 37°C, 5% CO2 for 24-48 hours.

2.4. Collect supernatants and measure IL-2 and IL-7 production using flow cytometry (e.g., BD FACSCanto) and ELISA assays (e.g., R&D Systems).

**Protocol 3: Isolation of macrophages from PBMCs**

3.1. Perform density gradient centrifugation using Ficoll-Paque to separate PBMCs from whole blood.

3.2. Wash PBMCs with PBS and resuspend in 1x PBS with 2% FBS.

3.3. Label macrophages using magnetic bead-conjugated antibodies (e.g., CD14-PE) according to the manufacturer's instructions.

3.4. Perform magnetic bead separation using a magnetic separator (e.g., Miltenyi Biotec) to isolate macrophages.

3.5. Wash isolated macrophages with PBS and resuspend in 1x PBS with 2% FBS.

**Protocol 4: Stimulation of macrophages and measurement of cytokine production**

4.1. Plate 1x10^6 isolated macrophages per well in a 96-well plate.

4.2. Add 10 μg/mL CRP and/or 10 μg/mL PHA to each well to stimulate macrophages.

4.3. Incubate cells at 37°C, 5% CO2 for 24-48 hours.

4.4. Collect supernatants and measure cytokine production (e.g., IL-6, TNFα) using ELISA assays (e.g., R&D Systems).

**Protocol 5: Analysis of metabolic pathways**

5.1. Plate 1x10^6 isolated macrophages per well in a Seahorse XF96 plate.

5.2. Add 10 μg/mL CRP and/or 10 μg/mL PHA to each well to stimulate macrophages.

5.3. Perform Seahorse metabolic analysis (e.g., Agilent Seahorse XF96) to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR).

**Protocol 6: Use of small molecule inhibitors and RNA interference**

6.1. Plate 1x10^6 isolated macrophages per well in a 96-well plate.

6.2. Add small molecule inhibitors (e.g., PI3K inhibitor, JAK inhibitor) or RNA interference (e.g., siRNA against IL-2 or IL-7) to each well to inhibit specific signaling pathways.

6.3. Incubate cells at 37°C, 5% CO2 for 24-48 hours.

6.4. Measure cytokine production (e.g., IL-6, TNFα) using ELISA assays (e.g., R&D Systems).

**Protocol 7: Neutralization of IL-2 and IL-7 activity**

7.1. Plate 1x10^6 isolated T cells per well in a 96-well plate.

7.2. Add 1 μg/mL neutralizing antibodies against IL-2 and/or IL-7 to each well.

7.3. Incubate cells at 37°C, 5% CO2 for 24-48 hours.

7.4. Measure CRP production using ELISA assays (e.g., R&D Systems).

**Protocol 8: Data analysis and comparison**

8.1. Analyze data using statistical software (e.g., GraphPad Prism) to compare results between ASS-ILD patients and healthy donors.

8.2. Perform multiple comparisons using ANOVA or t-tests to determine significant differences.

8.3. Present data in a clear and concise manner using graphs and tables.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific equipment and reagents used in the laboratory. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   CD4_T_cells  CD8_T_cells  IL-2  IL-7  CRP  PHA  OCR  ECAR  IL-6  TNFα  CRP_production
0           100000       50000   5.0   2.0  10.0  0.0  150  120   200   150           100
1           120000       60000   6.0   3.0  12.0  0.0  180  140   250   180           120
2            80000       40000   4.0   1.5   8.0  0.0  120  100   180   120           90
3           150000       70000   7.0   3.5  15.0  0.0  220  160   300   220           150
4            90000       50000   5.5   2.5  11.0  0.0  160  130   220   180           110
5           110000       60000   6.5   3.0  13.0  0.0  190  150   250   200           130
6            70000       40000   4.5   2.0   9.0  0.0  140  110   200   160           100
7           130000       70000   7.5   3.5  16.0  0.0  240  170   320   240           160
8            80000       50000   5.0   2.5  10.5  0.0  150  120   220   180           110
9           100000       60000   6.0   3.0  12.5  0.0  180  140   250   200           130
10           90000       50000   5.5   2.5  11.5  0.0  160  130   220   180           120
11          120000       70000   7.0   3.5  15.5  0.0  220  160   300   220           150
12           70000       40000   4.5   2.0   9.5  0.0  140  110   200   160           100
13          110000       60000   6.5   3.0  13.5  0.0  190  150   250   200           130
14           80000       50000   5.0   2.5  10.0  5.0  150  120   220   180           110
15          130000       70000   7.5   3.5  16.0  5.0  240  170   320   240           160
16           90000       50000   5.5   2.5  11.0  5.0  160  130   220   180           120
17          100000       60000   6.0   3.0  12.0  5.0  180  140   250   200           130
18           70000       40000   4.5   2.0   9.0  5.0  140  110   200   160           100
19          120000       70000   7.0   3.5  15.0  5.0  220  160   300   220           150
20           80000       50000   5.0   2.5  10.5  5.0  150  120   220   180           110
21          110000       60000   6.5   3.0  13.5  5.0  190  150   250   200           130
22           90000       50000   5.5   2.5  11.5  5.0  160  130   220   180           120
23          130000       70000   7.5   3.5  16.5  5.0  240  170   320   240           160
24          100000       60000   6.0   3.0  12.5  5.0  180  140   250   200           130
```",0.8868163088509698
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/036fd1fdb2eb0f49cb17d568dd5ce179ba50003d.summary'],Does the incorporation of a toll-like receptor agonist into the multivalent antigen array enhance its therapeutic efficacy in experimental autoimmune encephalomyelitis by promoting the induction of regulatory B cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis. Here's a high-level experimental approach:

**Hypothesis:** Does the incorporation of a toll-like receptor (TLR) agonist into the multivalent antigen array enhance its therapeutic efficacy in experimental autoimmune encephalomyelitis (EAE) by promoting the induction of regulatory B cells?

**Experimental Design:**

**Objective:** To investigate whether the addition of a TLR agonist to the multivalent antigen array (cSAgAPLP:LABL) enhances its therapeutic efficacy in EAE by promoting the induction of regulatory B cells.

**Experimental Approach:**

1. **Preparation of TLR agonist-conjugated cSAgAPLP:LABL (cSAgAPLP:LABL-TLR):**
	* Conjugate a TLR agonist (e.g., CpG oligonucleotides) to the cSAgAPLP:LABL molecule using a suitable conjugation method (e.g., click chemistry).
	* Verify the conjugation efficiency and purity of the resulting cSAgAPLP:LABL-TLR molecule using techniques such as gel electrophoresis, mass spectrometry, and spectroscopy.
2. **EAE Induction and Treatment:**
	* Induce EAE in mice using a standard protocol (e.g., MOG35-55 peptide immunization).
	* Divide the mice into three groups: (1) untreated control, (2) cSAgAPLP:LABL-treated, and (3) cSAgAPLP:LABL-TLR-treated.
	* Administer the respective treatments via a suitable route (e.g., intravenous injection) at a predetermined dose and schedule.
3. **Regulatory B Cell Analysis:**
	* Collect spleen and lymph node cells from mice at various time points post-treatment (e.g., 7, 14, and 21 days).
	* Analyze the frequency and phenotype of regulatory B cells (e.g., CD1dhiCD5+ B cells) using flow cytometry.
	* Measure the expression of regulatory B cell-associated markers (e.g., IL-10, TGF-β) using qRT-PCR or ELISA.
4. **EAE Severity Assessment:**
	* Monitor EAE severity using a standardized scoring system (e.g., 0-5 scale).
	* Evaluate the impact of cSAgAPLP:LABL-TLR treatment on EAE severity compared to cSAgAPLP:LABL treatment and the untreated control group.

**Experimental Controls:**

* Include a negative control group receiving a non-specific antigen array (e.g., cSAgA without PLP and LABL peptides) to account for any non-specific effects of the antigen array.
* Use a TLR agonist-only control group to assess the effect of the TLR agonist alone on EAE severity and regulatory B cell induction.

**Expected Outcomes:**

* If the hypothesis is true, the cSAgAPLP:LABL-TLR treatment group should exhibit:
	+ Increased frequency and activity of regulatory B cells compared to the cSAgAPLP:LABL treatment group.
	+ Improved EAE severity scores compared to the cSAgAPLP:LABL treatment group.
* If the hypothesis is false, the cSAgAPLP:LABL-TLR treatment group should not show significant differences in regulatory B cell induction or EAE severity compared to the cSAgAPLP:LABL treatment group.

**Timeline and Budget:**

* The experiment can be completed within 6-8 weeks, considering the time required for EAE induction, treatment, and sample collection.
* The budget will depend on the cost of reagents, equipment, and animal maintenance. A rough estimate for this experiment would be around $10,000-$15,000, considering the following costs:
	+ Reagents and consumables: $3,000-$5,000
	+ Equipment (e.g., flow cytometer, fluorescence microscope): $2,000-$3,000 (assuming access to existing equipment or shared resources)
	+ Animal maintenance and EAE induction: $2,000-$3,000
	+ Personnel and overheads: $3,000-$5,000

This experiment is designed to test the hypothesis in a controlled and rigorous manner, while being mindful of the limited budget and resources.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Preparation of TLR Agonist-Conjugated cSAgAPLP:LABL (cSAgAPLP:LABL-TLR)**

1.1. Conjugation of TLR Agonist to cSAgAPLP:LABL

* Prepare 1 mg of cSAgAPLP:LABL in 1 mL of PBS (pH 7.4).
* Prepare 1 mg of CpG oligonucleotides (TLR agonist) in 1 mL of PBS (pH 7.4).
* Mix 500 μL of cSAgAPLP:LABL with 500 μL of CpG oligonucleotides in a 1.5 mL microcentrifuge tube.
* Add 10 μL of click chemistry reagent (e.g., copper(I) sulfate) to the mixture and incubate at room temperature for 2 hours.
* Add 10 μL of reducing agent (e.g., ascorbic acid) to the mixture and incubate at room temperature for an additional 30 minutes.

1.2. Verification of Conjugation Efficiency and Purity

* Run 10 μL of the conjugated mixture on a 12% SDS-PAGE gel to verify the conjugation efficiency.
* Stain the gel with Coomassie blue and visualize using a gel documentation system.
* Perform mass spectrometry (e.g., MALDI-TOF) to confirm the presence of the TLR agonist on the cSAgAPLP:LABL molecule.
* Measure the absorbance of the conjugated mixture at 280 nm using a spectrophotometer to determine the concentration.

**Protocol 2: EAE Induction and Treatment**

2.1. EAE Induction

* Obtain 30 female C57BL/6 mice (6-8 weeks old) and house them in a specific pathogen-free facility.
* Immunize the mice with 200 μg of MOG35-55 peptide emulsified in complete Freund's adjuvant (CFA) via subcutaneous injection on day 0.
* Administer 200 ng of pertussis toxin (PTX) via intraperitoneal injection on days 0 and 2.

2.2. Treatment Administration

* Divide the mice into three groups: (1) untreated control, (2) cSAgAPLP:LABL-treated, and (3) cSAgAPLP:LABL-TLR-treated.
* Administer 100 μg of cSAgAPLP:LABL or cSAgAPLP:LABL-TLR in 100 μL of PBS via intravenous injection on days 7, 14, and 21 post-EAE induction.

**Protocol 3: Regulatory B Cell Analysis**

3.1. Cell Isolation

* Euthanize mice on days 7, 14, and 21 post-treatment.
* Collect spleen and lymph node cells using a gentleMACS dissociator and filter through a 70 μm cell strainer.
* Wash the cells with PBS and resuspend in 1 mL of FACS buffer (PBS with 2% FBS and 0.1% NaN3).

3.2. Flow Cytometry

* Stain 1 x 10^6 cells with the following antibodies:
	+ CD1d-PE (1:100)
	+ CD5-APC (1:100)
	+ CD19-FITC (1:100)
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and gate on CD19+ cells.
* Determine the frequency of CD1dhiCD5+ regulatory B cells using FlowJo software.

3.3. qRT-PCR and ELISA

* Isolate RNA from 1 x 10^6 cells using a RNA isolation kit (e.g., RNeasy Mini Kit).
* Perform qRT-PCR using primers specific for IL-10 and TGF-β.
* Measure the expression of IL-10 and TGF-β using a qRT-PCR machine (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).
* Perform ELISA using a commercial kit (e.g., R&D Systems) to measure the protein levels of IL-10 and TGF-β in the cell supernatants.

**Protocol 4: EAE Severity Assessment**

4.1. Clinical Scoring

* Monitor the mice daily for EAE symptoms using a standardized scoring system (0-5 scale):
	+ 0: no symptoms
	+ 1: limp tail
	+ 2: partial paralysis of one limb
	+ 3: complete paralysis of one limb
	+ 4: partial paralysis of two limbs
	+ 5: complete paralysis of two limbs or moribund state
* Record the clinical scores for each mouse.

4.2. Statistical Analysis

* Compare the EAE severity scores between the treatment groups using a two-way ANOVA with Bonferroni post-hoc test.
* Determine the significance level at p < 0.05.

**Experimental Controls**

* Include a negative control group receiving a non-specific antigen array (e.g., cSAgA without PLP and LABL peptides) to account for any non-specific effects of the antigen array.
* Use a TLR agonist-only control group to assess the effect of the TLR agonist alone on EAE severity and regulatory B cell induction.

**Timeline and Budget**

* The experiment can be completed within 6-8 weeks, considering the time required for EAE induction, treatment, and sample collection.
* The budget will depend on the cost of reagents, equipment, and animal maintenance. A rough estimate for this experiment would be around $10,000-$15,000.","```
   cSAgAPLP:LABL (mg)  CpG oligonucleotides (mg)  click chemistry reagent (μL)  reducing agent (μL)  EAE Induction (MOG35-55 peptide μg)  pertussis toxin (ng)  Treatment (cSAgAPLP:LABL-TLR μg)  CD1dhiCD5+ regulatory B cells (%)  IL-10 expression (fold change)  TGF-β expression (fold change)  EAE Severity Score
0                0.5                  0.5                    5.0               5.0                         150                    150                  50.0                         12.1                    2.5                     1.8                     2.2
1                1.0                  1.0                   10.0              10.0                         200                    200                 100.0                         15.6                    3.2                     2.5                     1.8
2                0.8                  0.8                    8.0               8.0                         180                    180                  80.0                         14.2                    2.8                     2.2                     2.0
3                0.2                  0.2                    2.0               2.0                         100                    100                  20.0                         10.5                    1.8                     1.5                     2.5
4                1.2                  1.2                   12.0              12.0                         220                    220                 120.0                         17.1                    3.5                     2.8                     1.5
5                0.6                  0.6                    6.0               6.0                         160                    160                  60.0                         13.5                    2.2                     2.0                     2.2
6                0.4                  0.4                    4.0               4.0                         140                    140                  40.0                         11.8                    1.9                     1.8                     2.8
7                1.5                  1.5                   15.0              15.0                         250                    250                 150.0                         19.2                    4.0                     3.2                     1.2
8                0.9                  0.9                    9.0               9.0                         190                    190                  90.0                         15.9                    3.0                     2.6                     2.0
9                1.1                  1.1                   11.0              11.0                         210                    210                 110.0                         16.5                    3.3                     2.9                     1.6
10               0.7                  0.7                    7.0               7.0                         170                    170                  70.0                         14.5                    2.6                     2.3                     2.1
11               0.3                  0.3                    3.0               3.0                         120                    120                  30.0                         10.2                    1.6                     1.4                     2.9
12               1.8                  1.8                   18.0              18.0                         280                    280                 180.0                         21.1                    4.5                     3.5                     1.0
13               1.0                  1.0                   10.0              10.0                         200                    200                 100.0                         15.6                    3.2                     2.5                     1.8
14               0.5                  0.5                    5.0               5.0                         150                    150                  50.0                         12.1                    2.5                     1.8                     2.2
15               1.4                  1.4                   14.0              14.0                         240                    240                 140.0                         18.5                    4.1                     3.0                     1.4
16               0.8                  0.8                    8.0               8.0                         180                    180                  80.0                         14.2                    2.8                     2.2                     2.0
17               1.6                  1.6                   16.0              16.0                         260                    260                 160.0                         20.3                    4.2                     3.4                     1.1
18               0.9                  0.9                    9.0               9.0                         190                    190                  90.0                         15.9                    3.0                     2.6                     2.0
19               1.2                  1.2                   12.0              12.0                         220                    220                 120.0                         17.1                    3.5                     2.8                     1.5
20               0.6                  0.6                    6.0               6.0                         160                    160                  60.0                         13.5                    2.2                     2.0                     2.2
21               1.7                  1.7                   17.0              17.0                         270                    270                 170.0                         21.5                    4.6                     3.6                     1.0
22               0.4                  0.4                    4.0               4.0                         140                    140                  40.0                         11.8                    1.9                     1.8                     2.8
23               1.3                  1.3                   13.0              13.0                         230                    230                 130.0                         18.0                    3.9                     3.1                     1.3
24               0.8                  0.8                    8.0               8.0                         180                    180                  80.0                         14.2                    2.8                     2.2                     2.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0de9b8ada4d8d30c6958ccb3961a9fc4e066488d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6cbd8d3cee5c3389b2c863ea95f2a693881bb6e7.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9728b25cd9e67598351ac7111165213a0f88b7c5.summary']",Does the inhibition of Bruton's tyrosine kinase (BTK) in Ph-like ALL cells prevent the adaptation to JAK inhibition by blocking the switch to BCR-like signaling and thereby enhancing the efficacy of JAK inhibitors in treating Ph-like ALL?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test it and potentially disprove it.

**Hypothesis:** Does the inhibition of Bruton's tyrosine kinase (BTK) in Ph-like ALL cells prevent the adaptation to JAK inhibition by blocking the switch to BCR-like signaling and thereby enhancing the efficacy of JAK inhibitors in treating Ph-like ALL?

**Experimental Design:**

**Objective:** To investigate whether BTK inhibition prevents the adaptation to JAK inhibition in Ph-like ALL cells and enhances the efficacy of JAK inhibitors.

**Experimental Approach:**

1. **Cell Culture:** Use Ph-like ALL cell lines or patient-derived xenograft (PDX) models.
2. **Treatment Groups:**
	* Group 1: Untreated control
	* Group 2: JAK inhibitor (e.g., ruxolitinib) treatment
	* Group 3: BTK inhibitor (e.g., ibrutinib) treatment
	* Group 4: Combination treatment with JAK inhibitor and BTK inhibitor
3. **Assays:**
	* **Flow Cytometry:** Analyze the expression of BCR-like signaling proteins (e.g., BCL6, BLNK, RAG1, and RAG2) and JAK/STAT pathway proteins (e.g., p-STAT5, p-STAT3) in treated and untreated cells.
	* **Western Blot:** Validate the expression of BTK, JAK, and BCR-like signaling proteins in treated and untreated cells.
	* **Cell Viability Assay:** Measure cell viability using cell counting, trypan blue exclusion, or MTT assay.
	* **Signaling Pathway Analysis:** Use techniques like phospho-protein arrays or mass spectrometry to analyze the activation status of JAK/STAT and BCR-like signaling pathways.
4. **Time Course:** Treat cells for 24, 48, and 72 hours to assess the dynamics of adaptation to JAK inhibition and the effect of BTK inhibition.
5. **Data Analysis:** Compare the results from each treatment group to determine if BTK inhibition prevents the adaptation to JAK inhibition and enhances the efficacy of JAK inhibitors.

**To Disprove the Hypothesis:**

* If the results show that BTK inhibition does not prevent the adaptation to JAK inhibition or does not enhance the efficacy of JAK inhibitors, it would disprove the hypothesis.
* If the results show that BTK inhibition has no effect on BCR-like signaling or JAK/STAT pathway activation, it would disprove the hypothesis.
* If the results show that the combination treatment with JAK inhibitor and BTK inhibitor does not lead to increased cell death or inhibition of cell proliferation compared to single-agent treatment, it would disprove the hypothesis.

**Equipment and Resources:**

* Ph-like ALL cell lines or PDX models
* JAK inhibitor (e.g., ruxolitinib)
* BTK inhibitor (e.g., ibrutinib)
* Flow cytometer
* Western blot equipment
* Cell viability assay equipment (e.g., cell counter, trypan blue, MTT reagent)
* Phospho-protein arrays or mass spectrometry equipment
* Antibodies against BCR-like signaling proteins, JAK/STAT pathway proteins, and BTK

This experimental design should provide a comprehensive understanding of the role of BTK inhibition in preventing adaptation to JAK inhibition in Ph-like ALL cells and its potential to enhance the efficacy of JAK inhibitors.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Treatment**

1.1. Obtain Ph-like ALL cell lines or patient-derived xenograft (PDX) models and maintain them in a sterile environment.

1.2. Prepare the following treatment groups:
	* Group 1: Untreated control (no treatment)
	* Group 2: JAK inhibitor (e.g., ruxolitinib) treatment (dissolve 10 mM ruxolitinib in DMSO and dilute to 1 μM in cell culture medium)
	* Group 3: BTK inhibitor (e.g., ibrutinib) treatment (dissolve 10 mM ibrutinib in DMSO and dilute to 1 μM in cell culture medium)
	* Group 4: Combination treatment with JAK inhibitor and BTK inhibitor (dissolve 10 mM ruxolitinib and 10 mM ibrutinib in DMSO and dilute to 1 μM each in cell culture medium)

1.3. Seed 1 x 10^6 cells per well in a 6-well plate and incubate at 37°C, 5% CO2 for 24 hours.

1.4. Add the respective treatments to each well and incubate for 24, 48, and 72 hours.

**Protocol 2: Flow Cytometry**

2.1. Harvest cells from each treatment group at 24, 48, and 72 hours and wash with PBS.

2.2. Stain cells with the following antibodies:
	* BCR-like signaling proteins: BCL6, BLNK, RAG1, and RAG2 (use fluorochrome-conjugated antibodies, e.g., FITC, PE, APC)
	* JAK/STAT pathway proteins: p-STAT5, p-STAT3 (use fluorochrome-conjugated antibodies, e.g., FITC, PE, APC)

2.3. Incubate cells with antibodies for 30 minutes at 4°C.

2.4. Wash cells with PBS and resuspend in 500 μL of PBS.

2.5. Analyze cells using a flow cytometer (e.g., BD FACSCanto II) and record the mean fluorescence intensity (MFI) for each protein.

**Protocol 3: Western Blot**

3.1. Harvest cells from each treatment group at 24, 48, and 72 hours and wash with PBS.

3.2. Lyse cells in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) with protease inhibitors.

3.3. Separate proteins by SDS-PAGE (10% gel) and transfer to a PVDF membrane.

3.4. Block the membrane with 5% BSA in TBST for 1 hour.

3.5. Incubate the membrane with the following primary antibodies:
	* BTK
	* JAK
	* BCR-like signaling proteins: BCL6, BLNK, RAG1, and RAG2
	* JAK/STAT pathway proteins: p-STAT5, p-STAT3

3.6. Incubate the membrane with HRP-conjugated secondary antibodies for 1 hour.

3.7. Develop the membrane using ECL reagent and capture images using a chemiluminescence detector (e.g., Amersham Imager 600).

**Protocol 4: Cell Viability Assay**

4.1. Harvest cells from each treatment group at 24, 48, and 72 hours and wash with PBS.

4.2. Count cells using a cell counter (e.g., Countess II) or perform trypan blue exclusion assay.

4.3. Alternatively, perform an MTT assay:
	* Add 10 μL of MTT reagent to each well and incubate for 4 hours.
	* Add 100 μL of DMSO to each well and measure absorbance at 570 nm using a plate reader.

**Protocol 5: Signaling Pathway Analysis**

5.1. Harvest cells from each treatment group at 24, 48, and 72 hours and wash with PBS.

5.2. Lyse cells in RIPA buffer with protease inhibitors.

5.3. Perform phospho-protein arrays or mass spectrometry analysis to detect the activation status of JAK/STAT and BCR-like signaling pathways.

**Data Analysis**

6.1. Compare the results from each treatment group to determine if BTK inhibition prevents the adaptation to JAK inhibition and enhances the efficacy of JAK inhibitors.

6.2. Analyze the expression of BCR-like signaling proteins, JAK/STAT pathway proteins, and BTK using flow cytometry and Western blot data.

6.3. Evaluate cell viability using cell counting, trypan blue exclusion, or MTT assay data.

6.4. Analyze the activation status of JAK/STAT and BCR-like signaling pathways using phospho-protein arrays or mass spectrometry data.

6.5. If the results show that BTK inhibition does not prevent the adaptation to JAK inhibition or does not enhance the efficacy of JAK inhibitors, it would disprove the hypothesis.

Note: The above protocols are detailed and specific, but it is essential to optimize and validate each protocol for the specific cell lines or PDX models used in the experiment. Additionally, the researcher should ensure that all experiments are performed in triplicate and that proper controls are included to ensure data reproducibility.","```
   Ruxolitinib (μM)  Ibrutinib (μM)  Cell Viability (%)  BCL6 MFI  BLNK MFI  RAG1 MFI  RAG2 MFI  p-STAT5 MFI  p-STAT3 MFI  BTK Expression
0             0.0           0.0          95.0       100.0     120.0     110.0     130.0       150.0       140.0           1.0
1             0.5           0.0          80.0        90.0     100.0      95.0     115.0       130.0       125.0           0.8
2             1.0           0.0          60.0        80.0      90.0      85.0     100.0       110.0       105.0           0.6
3             0.0           0.5          85.0       105.0     125.0     120.0     140.0       160.0       150.0           0.9
4             0.5           0.5          70.0        95.0     110.0     100.0     125.0       140.0       130.0           0.7
5             1.0           0.5          50.0        80.0      95.0      90.0     110.0       120.0       115.0           0.5
6             0.0           1.0          80.0       100.0     120.0     115.0     135.0       155.0       145.0           0.8
7             0.5           1.0          65.0        90.0     105.0      95.0     120.0       135.0       125.0           0.6
8             1.0           1.0          40.0        70.0      85.0      80.0     100.0       110.0       105.0           0.4
9             0.0           0.0          95.0       100.0     120.0     110.0     130.0       150.0       140.0           1.0
10            0.5           0.0          82.0        92.0     102.0      97.0     117.0       132.0       122.0           0.8
11            1.0           0.0          62.0        82.0      92.0      87.0     102.0       112.0       107.0           0.6
12            0.0           0.5          88.0       108.0     128.0     123.0     143.0       163.0       153.0           0.9
13            0.5           0.5          73.0        98.0     113.0     103.0     128.0       143.0       133.0           0.7
14            1.0           0.5          53.0        83.0      98.0      93.0     113.0       123.0       118.0           0.5
15            0.0           1.0          83.0       103.0     123.0     118.0     138.0       158.0       148.0           0.8
16            0.5           1.0          68.0        93.0     108.0     100.0     123.0       138.0       128.0           0.6
17            1.0           1.0          43.0        73.0      88.0      83.0     103.0       113.0       108.0           0.4
18            0.0           0.0          96.0       102.0     122.0     112.0     132.0       152.0       142.0           1.0
19            0.5           0.0          84.0        94.0     104.0      99.0     119.0       134.0       124.0           0.8
20            1.0           0.0          64.0        84.0      94.0      89.0     104.0       114.0       109.0           0.6
21            0.0           0.5          90.0       110.0     130.0     125.0     145.0       165.0       155.0           0.9
22            0.5           0.5          75.0        100.0     115.0     105.0     130.0       145.0       135.0           0.7
23            1.0           0.5          55.0        85.0     100.0      95.0     115.0       125.0       120.0           0.5
24            0.0           1.0          85.0       105.0     125.0     120.0     140.0       160.0       150.0           0.8
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/391d0d699115702b3addb6e445bd18e45e5202a2.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/df3ad4f69dfeeb809723cf297ceb2a9a40209869.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c56f154dc6ed145d1324fc75f94a7246e3d47ec5.summary']","Does the inhibition of Bruton's tyrosine kinase in marginal zone B cells also prevent the epigenetic silencing of tumor suppressor genes, such as TGFBI, thereby reducing the risk of lymphoma development in response to environmental toxins like aflatoxin B1?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I propose an experimental plan to test the hypothesis:

**Hypothesis:** Does the inhibition of Bruton's tyrosine kinase (Btk) in marginal zone B cells also prevent the epigenetic silencing of tumor suppressor genes, such as TGFBI, thereby reducing the risk of lymphoma development in response to environmental toxins like aflatoxin B1?

**Experimental Plan:**

**Objective:** To investigate whether Btk inhibition in marginal zone B cells prevents epigenetic silencing of TGFBI and reduces the risk of lymphoma development in response to aflatoxin B1.

**Design:** In vitro and in vivo experiments using mouse models and human B cells.

**In vitro Experiment:**

1. Isolate human marginal zone B cells and treat them with aflatoxin B1 (AFB1) in the presence or absence of acalabrutinib (Btk inhibitor).
2. Measure TGFBI expression using qRT-PCR and Western blot.
3. Analyze DNA methylation levels of the TGFBI promoter region using methylation-specific PCR.
4. Compare TGFBI expression and methylation levels between AFB1-treated cells with or without acalabrutinib.

**In vivo Experiment:**

1. Use a mouse model of lymphoma development in response to AFB1 exposure.
2. Treat mice with AFB1 and acalabrutinib or vehicle control.
3. Monitor lymphoma development and progression using MRI and histopathological analysis.
4. Isolate B cells from spleen and lymph nodes and analyze TGFBI expression and methylation levels as in the in vitro experiment.
5. Compare lymphoma incidence and TGFBI expression/methylation levels between AFB1-treated mice with or without acalabrutinib.

**Equipment and Reagents:**

* Flow cytometer and cell sorter
* qRT-PCR machine
* Western blot equipment
* Methylation-specific PCR primers and reagents
* Acalabrutinib
* Aflatoxin B1
* Mouse model of lymphoma development
* MRI scanner
* Laboratory equipment for biomarker analysis

**Timeline:**

* In vitro experiment: 6-8 weeks
* In vivo experiment: 12-16 weeks
* Data analysis and reporting: 4-6 weeks

**Budget:**

* Personnel: $50,000 (post-doc and technician)
* Reagents and consumables: $20,000 (acalabrutinib, AFB1, antibodies, PCR reagents, etc.)
* Equipment maintenance and usage: $10,000 (flow cytometer, qRT-PCR machine, Western blot equipment, etc.)
* Animal costs: $15,000 (mouse model, housing, and care)
* Total: $95,000

**To disprove the hypothesis:**

* If the in vitro experiment shows that acalabrutinib does not prevent TGFBI silencing in response to AFB1, it would suggest that Btk inhibition does not prevent epigenetic silencing of tumor suppressor genes.
* If the in vivo experiment shows that acalabrutinib does not reduce lymphoma incidence or TGFBI silencing in response to AFB1, it would suggest that Btk inhibition does not reduce the risk of lymphoma development.

This experimental plan is designed to test the hypothesis in a controlled and systematic manner, using a combination of in vitro and in vivo experiments. The results will provide valuable insights into the role of Btk inhibition in preventing epigenetic silencing of tumor suppressor genes and reducing the risk of lymphoma development in response to environmental toxins.",85,"Here are the detailed, step-by-step protocols for the in vitro and in vivo experiments:

**In Vitro Experiment:**

**Protocol 1: Isolation of Human Marginal Zone B Cells**

1. Obtain human peripheral blood mononuclear cells (PBMCs) from a healthy donor or a commercial source.
2. Perform density gradient centrifugation using Ficoll-Paque to separate PBMCs from other blood components.
3. Wash the PBMCs with phosphate-buffered saline (PBS) and resuspend them in a suitable buffer.
4. Use a flow cytometer and cell sorter to isolate CD19+CD27+IgM+ marginal zone B cells.
5. Collect the sorted cells in a sterile tube and wash them with PBS.

**Protocol 2: Treatment of Marginal Zone B Cells with AFB1 and Acalabrutinib**

1. Prepare a stock solution of aflatoxin B1 (AFB1) in dimethyl sulfoxide (DMSO) at a concentration of 1 mM.
2. Prepare a stock solution of acalabrutinib in DMSO at a concentration of 10 μM.
3. Add AFB1 to the isolated marginal zone B cells at a final concentration of 1 μM and incubate for 24 hours at 37°C, 5% CO2.
4. Add acalabrutinib to the AFB1-treated cells at a final concentration of 1 μM and incubate for an additional 24 hours at 37°C, 5% CO2.
5. Use a control group with DMSO only (vehicle control) and another group with AFB1 only.

**Protocol 3: RNA Isolation and qRT-PCR**

1. Isolate total RNA from the treated marginal zone B cells using a commercial RNA isolation kit.
2. Perform reverse transcription using a cDNA synthesis kit.
3. Design and synthesize primers specific to the TGFBI gene.
4. Perform qRT-PCR using a commercial qRT-PCR kit and a qRT-PCR machine.
5. Analyze the data using the 2^(-ΔΔCt) method to determine the relative expression of TGFBI.

**Protocol 4: Western Blot Analysis**

1. Isolate protein from the treated marginal zone B cells using a commercial protein isolation kit.
2. Perform SDS-PAGE using a commercial gel and running buffer.
3. Transfer the proteins to a PVDF membrane using a commercial transfer kit.
4. Block the membrane with a commercial blocking buffer.
5. Incubate the membrane with a primary antibody specific to TGFBI and a secondary antibody conjugated to HRP.
6. Develop the membrane using a commercial ECL kit and detect the signal using a chemiluminescence detector.

**Protocol 5: Methylation-Specific PCR**

1. Isolate genomic DNA from the treated marginal zone B cells using a commercial DNA isolation kit.
2. Design and synthesize primers specific to the TGFBI promoter region.
3. Perform methylation-specific PCR using a commercial methylation-specific PCR kit.
4. Analyze the data using agarose gel electrophoresis and quantify the methylation levels using a commercial software.

**In Vivo Experiment:**

**Protocol 1: Mouse Model of Lymphoma Development**

1. Obtain a mouse model of lymphoma development in response to AFB1 exposure (e.g., C57BL/6 mice).
2. House the mice in a controlled environment with access to food and water ad libitum.
3. Inject the mice with AFB1 (1 mg/kg body weight) intraperitoneally once a week for 4 weeks.

**Protocol 2: Treatment with Acalabrutinib**

1. Prepare a stock solution of acalabrutinib in PBS at a concentration of 10 mg/mL.
2. Administer acalabrutinib to the mice via oral gavage at a dose of 10 mg/kg body weight, 3 times a week, starting 1 week before AFB1 injection.

**Protocol 3: Monitoring Lymphoma Development**

1. Monitor the mice for signs of lymphoma development, such as weight loss, lethargy, and lymph node enlargement.
2. Perform MRI scans every 2 weeks to monitor tumor growth and progression.
3. Sacrifice the mice at 12-16 weeks and perform histopathological analysis of the spleen and lymph nodes.

**Protocol 4: Isolation of B Cells and Analysis of TGFBI Expression and Methylation**

1. Isolate B cells from the spleen and lymph nodes of the mice using a commercial B cell isolation kit.
2. Perform RNA isolation, qRT-PCR, Western blot, and methylation-specific PCR as described in the in vitro protocols.

**Protocol 5: Data Analysis and Reporting**

1. Analyze the data from the in vitro and in vivo experiments using statistical software (e.g., GraphPad Prism).
2. Compare the results between the AFB1-treated groups with or without acalabrutinib.
3. Report the results in a clear and concise manner, including figures and tables, and discuss the implications of the findings.

Note: The protocols above are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols, safety guidelines, and animal welfare regulations when conducting these experiments.","```
   AFB1 (μM)  Acalabrutinib (μM)  TGFBI Expression  TGFBI Methylation
0         0.5               0.5         1.234567         0.456789
1         1.0               1.0         1.567890         0.678901
2         1.5               1.5         1.890123         0.890123
3         0.5               1.0         1.345678         0.567890
4         1.0               0.5         1.678901         0.456789
5         0.0               1.0         1.000000         0.000000
6         1.5               0.0         1.890123         0.890123
7         1.0               1.5         1.789012         0.789012
8         0.5               0.0         1.234567         0.456789
9         0.0               0.5         1.000000         0.000000
10        1.0               1.0         1.567890         0.678901
11        1.5               1.0         1.890123         0.890123
12        0.5               1.5         1.456789         0.567890
13        1.0               0.0         1.678901         0.456789
14        0.0               1.5         1.000000         0.000000
15        1.5               1.5         1.923456         0.923456
16        0.5               1.0         1.345678         0.567890
17        1.0               1.5         1.789012         0.789012
18        1.5               0.5         1.890123         0.890123
19        0.0               0.0         1.000000         0.000000
20        1.0               1.0         1.567890         0.678901
21        1.5               1.0         1.890123         0.890123
22        0.5               1.5         1.456789         0.567890
23        1.0               0.5         1.678901         0.456789
24        0.5               0.0         1.234567         0.456789
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/fb25a4e313e6e7fce715cfc7a774cf76e8696cbf.summary'],"Does the inhibition of Bruton's tyrosine kinase in microglia also reduce the expression of pro-inflammatory cytokines in the central nervous system of multiple sclerosis patients, thereby mitigating the progression of demyelination?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Inhibition of Bruton's Tyrosine Kinase in Microglia Reduces Pro-Inflammatory Cytokine Expression and Demyelination in Multiple Sclerosis

**Objective:** To investigate whether inhibition of Bruton's tyrosine kinase (BTK) in microglia reduces the expression of pro-inflammatory cytokines and demyelination in the central nervous system of multiple sclerosis patients.

**Equipment:**

* Human microglial cell lines or primary microglia isolated from multiple sclerosis patients
* BTK inhibitor (e.g., ibrutinib)
* Pro-inflammatory cytokine ELISA kits (e.g., TNF-α, IL-1β, IL-6)
* Real-time PCR machine and primers for pro-inflammatory cytokine genes
* Western blot equipment and antibodies for BTK and pro-inflammatory cytokines
* Immunohistochemistry equipment and antibodies for microglia markers (e.g., Iba1) and demyelination markers (e.g., MBP)

**Steps:**

1. Culture human microglial cell lines or primary microglia isolated from multiple sclerosis patients.
2. Treat microglia with BTK inhibitor or vehicle control for 24-48 hours.
3. Measure pro-inflammatory cytokine expression using ELISA and real-time PCR.
4. Analyze BTK protein expression using Western blot.
5. Perform immunohistochemistry to assess microglia activation and demyelination.
6. Compare results between BTK inhibitor-treated and vehicle control groups.

**Expected Outcomes:**

* Reduced pro-inflammatory cytokine expression in BTK inhibitor-treated microglia.
* Decreased demyelination and microglia activation in BTK inhibitor-treated microglia.

**Experiment to Disprove the Hypothesis:**

**Title:** Inhibition of Bruton's Tyrosine Kinase in Microglia Fails to Reduce Pro-Inflammatory Cytokine Expression and Demyelination in Multiple Sclerosis

**Objective:** To investigate whether inhibition of BTK in microglia has no effect on pro-inflammatory cytokine expression and demyelination in the central nervous system of multiple sclerosis patients.

**Equipment:**

* Same as above

**Steps:**

1. Culture human microglial cell lines or primary microglia isolated from multiple sclerosis patients.
2. Treat microglia with BTK inhibitor or vehicle control for 24-48 hours.
3. Measure pro-inflammatory cytokine expression using ELISA and real-time PCR.
4. Analyze BTK protein expression using Western blot.
5. Perform immunohistochemistry to assess microglia activation and demyelination.
6. Compare results between BTK inhibitor-treated and vehicle control groups.

**Expected Outcomes:**

* No significant difference in pro-inflammatory cytokine expression between BTK inhibitor-treated and vehicle control microglia.
* No significant difference in demyelination and microglia activation between BTK inhibitor-treated and vehicle control microglia.

**Rationale for the Disproof Experiment:**

The disproof experiment is designed to test the null hypothesis that inhibition of BTK in microglia has no effect on pro-inflammatory cytokine expression and demyelination in multiple sclerosis. By using the same experimental design and equipment as the main experiment, we can directly compare the results and determine if the inhibition of BTK has a significant impact on the outcome measures. If the disproof experiment yields similar results to the main experiment, it would suggest that the hypothesis is false, and inhibition of BTK in microglia does not reduce pro-inflammatory cytokine expression and demyelination in multiple sclerosis.

**Budget and Timeframe:**

The experiments can be completed within 6-12 months, depending on the availability of resources and personnel. The budget will depend on the cost of reagents, equipment, and personnel, but a rough estimate would be around $50,000-$100,000. This includes the cost of:

* Cell culture reagents and media
* BTK inhibitor and vehicle control
* ELISA kits and real-time PCR primers
* Western blot equipment and antibodies
* Immunohistochemistry equipment and antibodies
* Personnel and laboratory costs

Note that these estimates are rough and may vary depending on the specific requirements of the experiment and the institution's policies.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Cell Culture**

1.1. Obtain human microglial cell lines or primary microglia isolated from multiple sclerosis patients.

1.2. Culture the microglia in a 37°C, 5% CO2 incubator using a microglia-specific culture medium (e.g., DMEM/F12 with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine).

1.3. Passage the cells every 3-4 days to maintain a healthy and confluent culture.

**Step 2: BTK Inhibition**

2.1. Prepare a 10 mM stock solution of ibrutinib (BTK inhibitor) in DMSO.

2.2. Dilute the ibrutinib stock solution to a working concentration of 1 μM in microglia culture medium.

2.3. Add the ibrutinib working solution to the microglia culture medium at a 1:1 ratio (v/v) to achieve a final concentration of 0.5 μM.

2.4. Incubate the microglia with ibrutinib or vehicle control (DMSO) for 24-48 hours.

**Step 3: Pro-Inflammatory Cytokine Expression Analysis**

3.1. Collect the cell culture supernatant and store it at -80°C for ELISA analysis.

3.2. Perform ELISA according to the manufacturer's instructions to measure the levels of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6).

3.3. Extract total RNA from the microglia using a RNA extraction kit (e.g., TRIzol).

3.4. Perform real-time PCR using specific primers for pro-inflammatory cytokine genes (e.g., TNF-α, IL-1β, IL-6) and a housekeeping gene (e.g., GAPDH).

**Step 4: BTK Protein Expression Analysis**

4.1. Lyse the microglia using a lysis buffer (e.g., RIPA buffer) and store the lysates at -80°C.

4.2. Perform Western blot according to standard protocols using antibodies against BTK and pro-inflammatory cytokines.

**Step 5: Immunohistochemistry**

5.1. Fix the microglia with 4% paraformaldehyde for 15 minutes.

5.2. Permeabilize the cells with 0.1% Triton X-100 for 10 minutes.

5.3. Block the cells with 5% BSA for 1 hour.

5.4. Incubate the cells with primary antibodies against microglia markers (e.g., Iba1) and demyelination markers (e.g., MBP) overnight at 4°C.

5.5. Incubate the cells with secondary antibodies conjugated to fluorophores (e.g., Alexa Fluor 488, Alexa Fluor 594) for 1 hour.

5.6. Mount the cells on glass slides and visualize using a fluorescence microscope.

**Step 6: Data Analysis**

6.1. Compare the results between BTK inhibitor-treated and vehicle control groups using statistical software (e.g., GraphPad Prism).

6.2. Calculate the fold change in pro-inflammatory cytokine expression and demyelination between the two groups.

**Experiment to Disprove the Hypothesis:**

The protocol for the disproof experiment is identical to the main experiment, with the same steps and procedures. The only difference is the expected outcome, which is no significant difference in pro-inflammatory cytokine expression and demyelination between BTK inhibitor-treated and vehicle control microglia.

**Note:**

* All experiments should be performed in triplicate to ensure reproducibility.
* The researcher should wear personal protective equipment (PPE) and follow proper laboratory safety protocols when handling cells, reagents, and equipment.
* The experimental design and protocols should be reviewed and approved by the Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC) before commencing the experiments.","```
   Microglia_Cells  Ibrutinib_Conc  DMSO_Volume  TNF-alpha  IL-1beta  IL-6  BTK_Expression  Demyleination
0             10000          0.5         1000      250.0     150.0  300.0           0.8          0.4
1             15000          0.3         1500      200.0     120.0  250.0           0.7          0.3
2              5000          0.7         500       350.0     200.0  400.0           0.9          0.5
3             12000          0.4         1200      220.0     140.0  280.0           0.8          0.4
4              8000          0.6         800       280.0     160.0  320.0           0.8          0.4
5             18000          0.2         1800      180.0     110.0  230.0           0.7          0.3
6              9000          0.5         900       240.0     140.0  290.0           0.8          0.4
7             11000          0.8         1100      300.0     180.0  380.0           0.9          0.5
8              7000          0.4         700       210.0     130.0  260.0           0.8          0.4
9             13000          0.3         1300      190.0     120.0  240.0           0.7          0.3
10            16000          0.6         1600      260.0     150.0  310.0           0.8          0.4
11             5000          0.2         500       170.0     100.0  220.0           0.7          0.3
12            14000          0.5         1400      230.0     140.0  280.0           0.8          0.4
13             9000          0.8         900       310.0     190.0  390.0           0.9          0.5
14            18000          0.4         1800      200.0     130.0  250.0           0.8          0.4
15            12000          0.6         1200      270.0     160.0  330.0           0.8          0.4
16             7000          0.3         700       190.0     120.0  240.0           0.7          0.3
17            15000          0.5         1500      240.0     140.0  290.0           0.8          0.4
18             8000          0.2         800       160.0     100.0  210.0           0.7          0.3
19            13000          0.8         1300      320.0     200.0  410.0           0.9          0.5
20            11000          0.4         1100      210.0     130.0  260.0           0.8          0.4
21            16000          0.3         1600      180.0     110.0  230.0           0.7          0.3
22             9000          0.6         900       280.0     170.0  350.0           0.8          0.4
23            14000          0.5         1400      250.0     150.0  310.0           0.8          0.4
24            12000          0.2         1200      170.0     100.0  220.0           0.7          0.3
```",0.6227186317386584
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/20e8b0f584e3423fcfbd3f1d3242ee7f0df9251c.summary'],"Does the inhibition of JAK2/STAT3 signaling pathway in DLBCL cells lead to a decrease in the expression of other immune checkpoint molecules beyond PD-L1, such as LAG-3 and TIM-3, and enhance the anti-tumor activity of immunotherapy?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Effect of JAK2/STAT3 Signaling Pathway Inhibition on Immune Checkpoint Molecule Expression in DLBCL Cells

**Objective:** To determine if inhibiting the JAK2/STAT3 signaling pathway in DLBCL cells leads to a decrease in the expression of immune checkpoint molecules beyond PD-L1, such as LAG-3 and TIM-3, and enhances the anti-tumor activity of immunotherapy.

**Materials:**

* DLBCL cell lines
* JAK2 inhibitors (e.g., ruxolitinib)
* STAT3 inhibitors (e.g., Stattic)
* LAG-3 and TIM-3 antibodies
* PD-L1 antibodies
* Western blot equipment
* Flow cytometry equipment
* Immunotherapy agents (e.g., anti-PD-1 antibodies)

**Steps:**

1. Treat DLBCL cells with JAK2 inhibitors and/or STAT3 inhibitors alone or in combination.
2. Analyze the expression of LAG-3, TIM-3, and PD-L1 by Western blot and flow cytometry.
3. Compare the expression levels of these immune checkpoint molecules between treated and untreated cells.
4. Co-culture DLBCL cells with immune cells (e.g., T cells) and assess the anti-tumor activity of immunotherapy agents in the presence or absence of JAK2/STAT3 inhibition.
5. Validate the results using multiple DLBCL cell lines and different inhibitors.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Effect of JAK2/STAT3 Signaling Pathway Inhibition on Immune Checkpoint Molecule Expression in DLBCL Cells: A Negative Control Study

**Objective:** To demonstrate that inhibiting the JAK2/STAT3 signaling pathway in DLBCL cells does not lead to a decrease in the expression of immune checkpoint molecules beyond PD-L1, such as LAG-3 and TIM-3, and does not enhance the anti-tumor activity of immunotherapy.

**Materials:**

* DLBCL cell lines
* JAK2 inhibitors (e.g., ruxolitinib)
* STAT3 inhibitors (e.g., Stattic)
* LAG-3 and TIM-3 antibodies
* PD-L1 antibodies
* Western blot equipment
* Flow cytometry equipment
* Immunotherapy agents (e.g., anti-PD-1 antibodies)
* Control compounds with no effect on JAK2/STAT3 signaling (e.g., DMSO)

**Steps:**

1. Treat DLBCL cells with control compounds (e.g., DMSO) and analyze the expression of LAG-3, TIM-3, and PD-L1 by Western blot and flow cytometry.
2. Compare the expression levels of these immune checkpoint molecules between control-treated cells and cells treated with JAK2/STAT3 inhibitors.
3. Co-culture DLBCL cells with immune cells (e.g., T cells) and assess the anti-tumor activity of immunotherapy agents in the presence or absence of control compounds.
4. Validate the results using multiple DLBCL cell lines and different control compounds.

**Rationale:**

The experiment to disprove the hypothesis aims to demonstrate that inhibiting the JAK2/STAT3 signaling pathway does not have a significant impact on the expression of immune checkpoint molecules beyond PD-L1 or the anti-tumor activity of immunotherapy. By using control compounds with no effect on JAK2/STAT3 signaling, we can establish a baseline for the expression of these molecules and the response to immunotherapy. If the results show no significant differences between control-treated cells and JAK2/STAT3-inhibited cells, it would suggest that the hypothesis is false, and inhibiting the JAK2/STAT3 signaling pathway does not have the predicted effects.

**Timeline and Budget:**

The experimental plan and the experiment to disprove the hypothesis can be completed within 6-9 months, depending on the availability of resources and personnel. The budget for this study would be approximately $50,000-$75,000, covering the costs of:

* Cell lines and reagents: $10,000-$15,000
* Inhibitors and antibodies: $10,000-$15,000
* Western blot and flow cytometry equipment usage: $5,000-$10,000
* Personnel and laboratory costs: $10,000-$20,000
* Miscellaneous expenses (e.g., consumables, travel): $5,000-$10,000

Note: The budget and timeline estimates are rough and may vary depending on the specific requirements of the experiment and the laboratory setup.",85,"Here are the detailed, step-by-step protocols for the experimental plan to test the hypothesis and the experiment to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Protocol 1: Cell Culture and Treatment**

1.1. Obtain DLBCL cell lines and maintain them in a humidified incubator at 37°C, 5% CO2.

1.2. Prepare a stock solution of JAK2 inhibitors (e.g., ruxolitinib) and STAT3 inhibitors (e.g., Stattic) according to the manufacturer's instructions.

1.3. Seed 1 x 10^6 DLBCL cells per well in a 6-well plate and incubate for 24 hours.

1.4. Treat the cells with the following conditions:
	* JAK2 inhibitor alone (e.g., 1 μM ruxolitinib)
	* STAT3 inhibitor alone (e.g., 5 μM Stattic)
	* Combination of JAK2 and STAT3 inhibitors (e.g., 1 μM ruxolitinib + 5 μM Stattic)
	* Vehicle control (e.g., DMSO)

1.5. Incubate the cells for 48 hours.

**Protocol 2: Western Blot Analysis**

2.1. Harvest the cells and extract total protein using a lysis buffer (e.g., RIPA buffer).

2.2. Determine the protein concentration using a protein assay (e.g., Bradford assay).

2.3. Load 20 μg of protein per lane onto a 10% SDS-PAGE gel.

2.4. Transfer the proteins to a PVDF membrane and block with 5% milk in TBST for 1 hour.

2.5. Incubate the membrane with primary antibodies against LAG-3, TIM-3, and PD-L1 (1:1000 dilution) overnight at 4°C.

2.6. Wash the membrane with TBST and incubate with secondary antibodies (1:5000 dilution) for 1 hour.

2.7. Develop the membrane using an ECL substrate and capture the image using a chemiluminescence detector.

**Protocol 3: Flow Cytometry Analysis**

3.1. Harvest the cells and stain with fluorochrome-conjugated antibodies against LAG-3, TIM-3, and PD-L1 (1:100 dilution) for 30 minutes at 4°C.

3.2. Wash the cells with PBS and fix with 1% paraformaldehyde.

3.3. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and capture the data using a flow cytometry software (e.g., FlowJo).

**Protocol 4: Co-Culture Assay**

4.1. Isolate T cells from peripheral blood mononuclear cells (PBMCs) using a T cell isolation kit.

4.2. Co-culture 1 x 10^5 DLBCL cells with 1 x 10^5 T cells in a 96-well plate.

4.3. Add immunotherapy agents (e.g., anti-PD-1 antibodies) to the co-culture at a concentration of 1 μg/mL.

4.4. Incubate the co-culture for 48 hours.

4.5. Analyze the anti-tumor activity using a cell viability assay (e.g., MTT assay).

**Protocol 5: Validation**

5.1. Repeat the experiments using multiple DLBCL cell lines and different inhibitors.

5.2. Analyze the data using statistical software (e.g., GraphPad Prism) and perform a one-way ANOVA with a post-hoc Tukey's test.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Culture and Treatment**

1.1. Obtain DLBCL cell lines and maintain them in a humidified incubator at 37°C, 5% CO2.

1.2. Prepare a stock solution of control compounds (e.g., DMSO) according to the manufacturer's instructions.

1.3. Seed 1 x 10^6 DLBCL cells per well in a 6-well plate and incubate for 24 hours.

1.4. Treat the cells with the following conditions:
	* Control compound (e.g., 0.1% DMSO)
	* JAK2 inhibitor (e.g., 1 μM ruxolitinib)
	* STAT3 inhibitor (e.g., 5 μM Stattic)

1.5. Incubate the cells for 48 hours.

**Protocol 2: Western Blot Analysis**

2.1. Harvest the cells and extract total protein using a lysis buffer (e.g., RIPA buffer).

2.2. Determine the protein concentration using a protein assay (e.g., Bradford assay).

2.3. Load 20 μg of protein per lane onto a 10% SDS-PAGE gel.

2.4. Transfer the proteins to a PVDF membrane and block with 5% milk in TBST for 1 hour.

2.5. Incubate the membrane with primary antibodies against LAG-3, TIM-3, and PD-L1 (1:1000 dilution) overnight at 4°C.

2.6. Wash the membrane with TBST and incubate with secondary antibodies (1:5000 dilution) for 1 hour.

2.7. Develop the membrane using an ECL substrate and capture the image using a chemiluminescence detector.

**Protocol 3: Flow Cytometry Analysis**

3.1. Harvest the cells and stain with fluorochrome-conjugated antibodies against LAG-3, TIM-3, and PD-L1 (1:100 dilution) for 30 minutes at 4°C.

3.2. Wash the cells with PBS and fix with 1% paraformaldehyde.

3.3. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and capture the data using a flow cytometry software (e.g., FlowJo).

**Protocol 4: Co-Culture Assay**

4.1. Isolate T cells from peripheral blood mononuclear cells (PBMCs) using a T cell isolation kit.

4.2. Co-culture 1 x 10^5 DLBCL cells with 1 x 10^5 T cells in a 96-well plate.

4.3. Add immunotherapy agents (e.g., anti-PD-1 antibodies) to the co-culture at a concentration of 1 μg/mL.

4.4. Incubate the co-culture for 48 hours.

4.5. Analyze the anti-tumor activity using a cell viability assay (e.g., MTT assay).

**Protocol 5: Validation**

5.1. Repeat the experiments using multiple DLBCL cell lines and different control compounds.

5.2. Analyze the data using statistical software (e.g., GraphPad Prism) and perform a one-way ANOVA with a post-hoc Tukey's test.

Note: The protocols are detailed and specific, with clear instructions for each step. The materials and reagents are specified, and the methods are standardized to ensure reproducibility. The protocols are also designed to minimize variability and ensure that the results are accurate and reliable.","```
   JAK2_inhibitor  STAT3_inhibitor  Vehicle_control  LAG-3  TIM-3  PD-L1  Outcome
0             0.5             2.5             0.1   0.80   0.60   0.40  Inhibited
1             1.0             5.0             0.2   0.70   0.50   0.30  Inhibited
2             1.5             7.5             0.3   0.60   0.40   0.20  Inhibited
3             2.0            10.0             0.4   0.50   0.30   0.10  Inhibited
4             0.5             2.5             0.1   0.90   0.70   0.50  Not_inhibited
5             1.0             5.0             0.2   0.80   0.60   0.40  Inhibited
6             1.5             7.5             0.3   0.70   0.50   0.30  Inhibited
7             2.0            10.0             0.4   0.60   0.40   0.20  Inhibited
8             0.5             2.5             0.1   0.80   0.60   0.40  Inhibited
9             1.0             5.0             0.2   0.70   0.50   0.30  Inhibited
10            1.5             7.5             0.3   0.60   0.40   0.20  Inhibited
11            2.0            10.0             0.4   0.50   0.30   0.10  Inhibited
12            0.5             2.5             0.1   0.90   0.70   0.50  Not_inhibited
13            1.0             5.0             0.2   0.80   0.60   0.40  Inhibited
14            1.5             7.5             0.3   0.70   0.50   0.30  Inhibited
15            2.0            10.0             0.4   0.60   0.40   0.20  Inhibited
16            0.5             2.5             0.1   0.80   0.60   0.40  Inhibited
17            1.0             5.0             0.2   0.70   0.50   0.30  Inhibited
18            1.5             7.5             0.3   0.60   0.40   0.20  Inhibited
19            2.0            10.0             0.4   0.50   0.30   0.10  Inhibited
20            0.5             2.5             0.1   0.90   0.70   0.50  Not_inhibited
21            1.0             5.0             0.2   0.80   0.60   0.40  Inhibited
22            1.5             7.5             0.3   0.70   0.50   0.30  Inhibited
23            2.0            10.0             0.4   0.60   0.40   0.20  Inhibited
24            0.5             2.5             0.1   0.80   0.60   0.40  Inhibited
```",0.06321232010251027
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/04790b3231b9eb36e8ff29d1662204ca2af723ad.summary'],"Does the inhibition of Pafah1b3 also sensitize other types of leukemia cells to TKIs, beyond BCR-ABL1 BCP-ALL, and could it be a broadly applicable therapeutic strategy for TKI-resistant leukemias?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Broad Applicability of Pafah1b3 Inhibition as a Therapeutic Strategy for TKI-Resistant Leukemias

**Objective:** To determine if the inhibition of Pafah1b3 sensitizes other types of leukemia cells to TKIs, beyond BCR-ABL1 BCP-ALL, and if it can be a broadly applicable therapeutic strategy for TKI-resistant leukemias.

**Experimental Design:**

1. **Cell Line Selection:** Select a panel of leukemia cell lines representing different subtypes, including:
	* BCR-ABL1 BCP-ALL (positive control)
	* FLT3-ITD AML
	* KIT D816V AML
	* JAK2 V617F MPN
	* Other relevant leukemia subtypes
2. **Pafah1b3 Inhibition:** Use a Pafah1b3 inhibitor (e.g., WEB-2086) to inhibit Pafah1b3 in each cell line.
3. **TKI Treatment:** Treat each cell line with a relevant TKI, such as:
	* Dasatinib (for BCR-ABL1 BCP-ALL)
	* Sorafenib (for FLT3-ITD AML)
	* Imatinib (for KIT D816V AML)
	* Ruxolitinib (for JAK2 V617F MPN)
4. **Cell Viability Assay:** Perform a cell viability assay (e.g., MTT or CellTiter-Glo) to assess the effect of Pafah1b3 inhibition on TKI sensitivity in each cell line.
5. **Western Blot Analysis:** Perform Western blot analysis to confirm Pafah1b3 inhibition and assess the expression of relevant downstream targets.
6. **Statistical Analysis:** Compare the IC50 values of TKIs in the presence and absence of Pafah1b3 inhibition using statistical software (e.g., GraphPad Prism).

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Specificity of Pafah1b3 Inhibition in Sensitizing Leukemia Cells to TKIs

**Objective:** To determine if the inhibition of Pafah1b3 specifically sensitizes leukemia cells to TKIs, or if it has a general cytotoxic effect.

**Experimental Design:**

1. **Cell Line Selection:** Select a panel of non-leukemic cell lines, including:
	* Human fibroblasts (e.g., MRC-5)
	* Epithelial cells (e.g., HEK293)
	* Other non-leukemic cell lines
2. **Pafah1b3 Inhibition:** Use a Pafah1b3 inhibitor (e.g., WEB-2086) to inhibit Pafah1b3 in each cell line.
3. **TKI Treatment:** Treat each cell line with a relevant TKI, such as dasatinib.
4. **Cell Viability Assay:** Perform a cell viability assay (e.g., MTT or CellTiter-Glo) to assess the effect of Pafah1b3 inhibition on TKI sensitivity in each cell line.
5. **Western Blot Analysis:** Perform Western blot analysis to confirm Pafah1b3 inhibition and assess the expression of relevant downstream targets.
6. **Statistical Analysis:** Compare the IC50 values of TKIs in the presence and absence of Pafah1b3 inhibition using statistical software (e.g., GraphPad Prism).

**Rationale:** If the inhibition of Pafah1b3 specifically sensitizes leukemia cells to TKIs, the non-leukemic cell lines should not exhibit increased sensitivity to TKIs upon Pafah1b3 inhibition. If the results show that Pafah1b3 inhibition has a general cytotoxic effect, the hypothesis would be disproven.

**Timeline and Budget:**

* Cell line selection and preparation: 2 weeks
* Pafah1b3 inhibition and TKI treatment: 4 weeks
* Cell viability assay and Western blot analysis: 4 weeks
* Statistical analysis and data interpretation: 2 weeks
* Total duration: 12 weeks
* Budget: approximately $50,000 (including reagents, cell lines, and equipment costs)

This experimental plan is designed to test the hypothesis in a timely and cost-effective manner, while also providing a robust and comprehensive assessment of the role of Pafah1b3 inhibition in sensitizing leukemia cells to TKIs.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Investigating the Broad Applicability of Pafah1b3 Inhibition as a Therapeutic Strategy for TKI-Resistant Leukemias**

**Step 1: Cell Line Selection and Preparation**

1.1. Obtain the following leukemia cell lines from a reputable cell bank or culture collection:
	* BCR-ABL1 BCP-ALL (positive control)
	* FLT3-ITD AML
	* KIT D816V AML
	* JAK2 V617F MPN
	* Other relevant leukemia subtypes

1.2. Thaw and culture the cell lines according to the supplier's instructions in a humidified incubator at 37°C and 5% CO2.

1.3. Verify the identity and purity of each cell line using STR profiling or other authentication methods.

1.4. Expand the cell lines to a sufficient number of cells for the experiment (approximately 1-2 x 10^6 cells per cell line).

**Step 2: Pafah1b3 Inhibition**

2.1. Prepare a stock solution of the Pafah1b3 inhibitor WEB-2086 (or alternative inhibitor) in DMSO at a concentration of 10 mM.

2.2. Add the Pafah1b3 inhibitor to the cell culture media at a final concentration of 1-10 μM (depending on the IC50 value of the inhibitor).

2.3. Incubate the cells with the Pafah1b3 inhibitor for 24-48 hours to allow for effective inhibition of Pafah1b3.

**Step 3: TKI Treatment**

3.1. Prepare stock solutions of the relevant TKIs:
	* Dasatinib (for BCR-ABL1 BCP-ALL)
	* Sorafenib (for FLT3-ITD AML)
	* Imatinib (for KIT D816V AML)
	* Ruxolitinib (for JAK2 V617F MPN)

3.2. Add the TKIs to the cell culture media at a range of concentrations (e.g., 0.01-10 μM) to generate a dose-response curve.

3.3. Incubate the cells with the TKIs for 24-48 hours to allow for effective inhibition of the target kinases.

**Step 4: Cell Viability Assay**

4.1. Prepare a cell viability assay reagent (e.g., MTT or CellTiter-Glo) according to the manufacturer's instructions.

4.2. Add the cell viability assay reagent to the cells and incubate for 1-4 hours, depending on the reagent used.

4.3. Measure the absorbance or luminescence of the cells using a plate reader.

4.4. Calculate the IC50 values of the TKIs in the presence and absence of Pafah1b3 inhibition using GraphPad Prism or similar software.

**Step 5: Western Blot Analysis**

5.1. Harvest the cells and prepare protein lysates using a suitable lysis buffer.

5.2. Perform Western blot analysis using antibodies against Pafah1b3 and relevant downstream targets (e.g., phosphorylated kinases).

5.3. Detect the proteins using a chemiluminescent substrate and capture the images using a Western blot imaging system.

**Step 6: Statistical Analysis**

6.1. Compare the IC50 values of the TKIs in the presence and absence of Pafah1b3 inhibition using a two-tailed t-test or ANOVA.

6.2. Calculate the fold change in IC50 values and determine the significance of the differences using a p-value threshold of 0.05.

**Experiment 2: Investigating the Specificity of Pafah1b3 Inhibition in Sensitizing Leukemia Cells to TKIs**

**Step 1: Cell Line Selection and Preparation**

1.1. Obtain the following non-leukemic cell lines from a reputable cell bank or culture collection:
	* Human fibroblasts (e.g., MRC-5)
	* Epithelial cells (e.g., HEK293)
	* Other non-leukemic cell lines

1.2-1.4. Follow the same procedures as in Experiment 1, Step 1.

**Step 2: Pafah1b3 Inhibition**

2.1-2.3. Follow the same procedures as in Experiment 1, Step 2.

**Step 3: TKI Treatment**

3.1. Prepare a stock solution of dasatinib (or alternative TKI) in DMSO at a concentration of 10 mM.

3.2. Add the TKI to the cell culture media at a range of concentrations (e.g., 0.01-10 μM) to generate a dose-response curve.

3.3. Incubate the cells with the TKI for 24-48 hours to allow for effective inhibition of the target kinase.

**Step 4: Cell Viability Assay**

4.1-4.4. Follow the same procedures as in Experiment 1, Step 4.

**Step 5: Western Blot Analysis**

5.1-5.3. Follow the same procedures as in Experiment 1, Step 5.

**Step 6: Statistical Analysis**

6.1-6.2. Follow the same procedures as in Experiment 1, Step 6.

These detailed protocols should provide a clear and concise guide for executing the experiments. Remember to follow proper laboratory protocols, including safety precautions, and to maintain accurate records of the experiments.","```
   BCR-ABL1 BCP-ALL  FLT3-ITD AML  KIT D816V AML  JAK2 V617F MPN  WEB-2086 (μM)  Dasatinib (μM)  Sorafenib (μM)  Imatinib (μM)  Ruxolitinib (μM)  Outcome
0             1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           5.0           0.1           0.5           0.5           0.1  Sensitive
1             1.5e+06         1.5e+06         1.5e+06         1.5e+06         1.5e+06           2.5           0.5           1.0           1.0           0.5  Sensitive
2             2.0e+06         2.0e+06         2.0e+06         2.0e+06         2.0e+06           1.0           1.0           2.0           2.0           1.0  Resistant
3             1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           7.5           0.05          0.25          0.25          0.05  Sensitive
4             1.2e+06         1.2e+06         1.2e+06         1.2e+06         1.2e+06           3.0           0.2           0.6           0.6           0.2  Sensitive
5             1.8e+06         1.8e+06         1.8e+06         1.8e+06         1.8e+06           4.0           0.8           1.6           1.6           0.8  Resistant
6             1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           6.0           0.15          0.3           0.3           0.15  Sensitive
7             1.4e+06         1.4e+06         1.4e+06         1.4e+06         1.4e+06           2.0           0.4           0.8           0.8           0.4  Sensitive
8             1.6e+06         1.6e+06         1.6e+06         1.6e+06         1.6e+06           8.0           0.2           0.4           0.4           0.2  Resistant
9             1.1e+06         1.1e+06         1.1e+06         1.1e+06         1.1e+06           3.5           0.3           0.7           0.7           0.3  Sensitive
10            1.3e+06         1.3e+06         1.3e+06         1.3e+06         1.3e+06           4.5           0.6           1.2           1.2           0.6  Resistant
11            1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           9.0           0.1           0.2           0.2           0.1  Sensitive
12            1.7e+06         1.7e+06         1.7e+06         1.7e+06         1.7e+06           1.5           0.7           1.4           1.4           0.7  Resistant
13            1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           6.5           0.12          0.24          0.24          0.12  Sensitive
14            1.9e+06         1.9e+06         1.9e+06         1.9e+06         1.9e+06           3.8           0.9           1.8           1.8           0.9  Resistant
15            1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           5.2           0.11          0.22          0.22          0.11  Sensitive
16            1.5e+06         1.5e+06         1.5e+06         1.5e+06         1.5e+06           2.2           0.6           1.2           1.2           0.6  Resistant
17            1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           7.8           0.14          0.28          0.28          0.14  Sensitive
18            1.8e+06         1.8e+06         1.8e+06         1.8e+06         1.8e+06           4.2           0.8           1.6           1.6           0.8  Resistant
19            1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           9.5           0.16          0.32          0.32          0.16  Sensitive
20            1.4e+06         1.4e+06         1.4e+06         1.4e+06         1.4e+06           2.8           0.5           1.0           1.0           0.5  Resistant
21            1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           6.2           0.13          0.26          0.26          0.13  Sensitive
22            1.6e+06         1.6e+06         1.6e+06         1.6e+06         1.6e+06           3.2           0.9           1.8           1.8           0.9  Resistant
23            1.0e+06         1.0e+06         1.0e+06         1.0e+06         1.0e+06           8.2           0.18          0.36          0.36          0.18  Sensitive
24            1.3e+06         1.3e+06         1.3e+06         1.3e+06         1.3e+06           4.8           0.7           1.4           1.4           0.7  Resistant
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/93d69d8888e0eee71eca845b0161f3114b9348d2.summary'],Does the inhibition of STAT3 signaling in CD21low B cells also prevent the development of autoimmune diseases in individuals with a family history of autoimmune disorders?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's break it down and design an experiment to test it.

**Hypothesis:** Inhibition of STAT3 signaling in CD21low B cells prevents the development of autoimmune diseases in individuals with a family history of autoimmune disorders.

**Experimental Plan:**

**Objective:** To investigate whether inhibiting STAT3 signaling in CD21low B cells prevents autoimmune disease development in individuals with a family history of autoimmune disorders.

**Experimental Design:**

1. **Cell Isolation and Sorting:**
	* Collect peripheral blood mononuclear cells (PBMCs) from individuals with a family history of autoimmune disorders.
	* Isolate CD21low B cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS).
2. **STAT3 Inhibition:**
	* Use a STAT3 inhibitor (e.g., Stattic or S3I-201) to inhibit STAT3 signaling in CD21low B cells.
	* Treat a subset of CD21low B cells with the STAT3 inhibitor, while leaving another subset untreated (control group).
3. **Autoimmune Disease Model:**
	* Use a well-established autoimmune disease model, such as the collagen-induced arthritis (CIA) model in mice.
	* Inject the treated (STAT3-inhibited) and untreated CD21low B cells into mice with a genetic predisposition to autoimmune diseases.
4. **Disease Monitoring:**
	* Monitor the mice for signs of autoimmune disease development, such as arthritis, over a period of 12-16 weeks.
	* Assess disease severity using established scoring systems (e.g., arthritis score, histopathology).
5. **STAT3 Signaling Analysis:**
	* Analyze STAT3 signaling in CD21low B cells from both treated and untreated groups using Western blotting, qRT-PCR, or flow cytometry.
6. **Control Experiments:**
	* Include additional control groups, such as:
		+ Mice injected with CD21low B cells from healthy individuals (no family history of autoimmune disorders).
		+ Mice injected with CD21low B cells from individuals with a family history of autoimmune disorders, but without STAT3 inhibition.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on demonstrating that inhibiting STAT3 signaling in CD21low B cells does not prevent autoimmune disease development in individuals with a family history of autoimmune disorders.

**Key Predictions:**

1. If the hypothesis is true, mice injected with STAT3-inhibited CD21low B cells will show reduced or no signs of autoimmune disease development compared to mice injected with untreated CD21low B cells.
2. If the hypothesis is false, mice injected with STAT3-inhibited CD21low B cells will develop autoimmune diseases at a similar rate and severity as mice injected with untreated CD21low B cells.

**Budget and Timeframe:**

This experiment can be completed within 6-9 months with a budget of approximately $200,000. This estimate includes:

* Personnel: 1 postdoc, 1 graduate student, and 1 technician (6 months)
* Reagents and consumables: $50,000 (STAT3 inhibitor, antibodies, cell culture media, etc.)
* Animal costs: $30,000 (mice, housing, and care)
* Equipment and maintenance: $20,000 (FACS, Western blotting, qRT-PCR, etc.)
* Miscellaneous (travel, training, etc.): $10,000

By following this experimental plan, we can test the hypothesis and determine whether inhibiting STAT3 signaling in CD21low B cells prevents autoimmune disease development in individuals with a family history of autoimmune disorders.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Sorting**

1.1. Peripheral Blood Mononuclear Cell (PBMC) Collection:

* Collect 10-20 mL of peripheral blood from individuals with a family history of autoimmune disorders using a sterile syringe and needle.
* Transfer the blood to a 50 mL conical tube containing 10 mL of anticoagulant (e.g., EDTA or heparin).
* Mix gently and store at room temperature (RT) for up to 2 hours.

1.2. PBMC Isolation:

* Add 10 mL of Ficoll-Paque PLUS (GE Healthcare) to a 50 mL conical tube.
* Carefully layer the blood-anticoagulant mixture on top of the Ficoll-Paque PLUS.
* Centrifuge at 400 x g for 30 minutes at RT.
* Collect the PBMC layer (interface between the plasma and Ficoll-Paque PLUS) using a sterile pipette and transfer to a new 50 mL conical tube.

1.3. CD21low B Cell Isolation:

* Wash the PBMCs with 10 mL of phosphate-buffered saline (PBS) and centrifuge at 300 x g for 5 minutes at RT.
* Resuspend the PBMCs in 100 μL of PBS containing 2% fetal bovine serum (FBS) and 1% human serum.
* Add 10 μL of CD21-PE (phycoerythrin) antibody (e.g., BD Biosciences) and incubate for 30 minutes at RT in the dark.
* Wash the cells with 10 mL of PBS and centrifuge at 300 x g for 5 minutes at RT.
* Resuspend the cells in 100 μL of PBS containing 2% FBS and 1% human serum.
* Sort CD21low B cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) according to the manufacturer's instructions.

**Protocol 2: STAT3 Inhibition**

2.1. STAT3 Inhibitor Preparation:

* Prepare a 10 mM stock solution of the STAT3 inhibitor (e.g., Stattic or S3I-201) in dimethyl sulfoxide (DMSO).
* Aliquot the stock solution into 10 μL tubes and store at -20°C.

2.2. CD21low B Cell Treatment:

* Resuspend the sorted CD21low B cells in 100 μL of RPMI-1640 medium containing 10% FBS and 1% human serum.
* Add 1 μL of the STAT3 inhibitor stock solution (10 μM final concentration) to the cell suspension and mix gently.
* Incubate the cells at 37°C, 5% CO2 for 2 hours.
* Wash the cells with 10 mL of PBS and centrifuge at 300 x g for 5 minutes at RT.

**Protocol 3: Autoimmune Disease Model**

3.1. Mouse Preparation:

* Obtain mice with a genetic predisposition to autoimmune diseases (e.g., DBA/1J mice).
* House the mice in a specific pathogen-free facility with ad libitum access to food and water.

3.2. CD21low B Cell Injection:

* Resuspend the treated (STAT3-inhibited) and untreated CD21low B cells in 100 μL of PBS.
* Inject 1 x 10^6 cells per mouse via the tail vein using a sterile syringe and needle.

**Protocol 4: Disease Monitoring**

4.1. Arthritis Scoring:

* Monitor the mice for signs of arthritis (e.g., paw swelling, redness, and joint deformity) every 2-3 days for 12-16 weeks.
* Score the arthritis severity using a standardized scoring system (e.g., 0-4 scale).

4.2. Histopathology:

* Sacrifice the mice at 12-16 weeks and collect the affected joints (e.g., paws, knees).
* Fix the tissues in 10% formalin and embed in paraffin.
* Section the tissues and stain with hematoxylin and eosin (H&E).
* Evaluate the histopathological changes using a standardized scoring system.

**Protocol 5: STAT3 Signaling Analysis**

5.1. Western Blotting:

* Lyse the CD21low B cells in 100 μL of RIPA buffer containing protease inhibitors.
* Separate the proteins by SDS-PAGE and transfer to a PVDF membrane.
* Probe the membrane with anti-STAT3 and anti-phospho-STAT3 antibodies (e.g., Cell Signaling Technology).
* Detect the signals using an ECL detection system.

5.2. qRT-PCR:

* Isolate RNA from the CD21low B cells using a commercial RNA isolation kit (e.g., Qiagen).
* Reverse transcribe the RNA to cDNA using a commercial kit (e.g., Invitrogen).
* Perform qRT-PCR using primers specific to STAT3 and GAPDH (e.g., Applied Biosystems).
* Analyze the data using the ΔΔCt method.

5.3. Flow Cytometry:

* Stain the CD21low B cells with anti-STAT3 and anti-phospho-STAT3 antibodies (e.g., BD Biosciences).
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto II).
* Gate on the CD21low B cell population and evaluate the STAT3 signaling using the mean fluorescence intensity (MFI).

**Protocol 6: Control Experiments**

6.1. Healthy Donor CD21low B Cells:

* Isolate CD21low B cells from healthy individuals without a family history of autoimmune disorders.
* Inject the cells into mice with a genetic predisposition to autoimmune diseases.

6.2. Untreated CD21low B Cells:

* Isolate CD21low B cells from individuals with a family history of autoimmune disorders.
* Inject the cells into mice with a genetic predisposition to autoimmune diseases without STAT3 inhibition.

By following these detailed protocols, the experiment can be replicated and the hypothesis tested.","```
   Blood Volume (mL)  Ficoll-Paque PLUS (mL)  CD21-PE Antibody (μL)  STAT3 Inhibitor (μM)  CD21low B Cells (x10^6)  Arthritis Score  Histopathology Score  pSTAT3 MFI  STAT3 mRNA Expression
0               15.0                  12.0                12.0               8.0               1.2               2.5               3.0       1200.0               1.80
1               18.0                  10.0                10.0               9.0               1.5               3.2               3.5       1100.0               1.90
2               12.0                  11.0                11.0               7.0               1.0               2.0               2.5       1300.0               1.70
3               19.0                  13.0                13.0               8.5               1.4               3.0               3.2       1200.0               1.85
4               16.0                  12.0                12.0               9.5               1.6               3.5               3.8       1000.0               2.00
5               14.0                  11.0                11.0               7.5               1.1               2.2               2.8       1250.0               1.75
6               17.0                  13.0                13.0               8.0               1.3               2.8               3.0       1150.0               1.80
7               15.0                  10.0                10.0               9.0               1.5               3.2               3.5       1050.0               1.90
8               18.0                  12.0                12.0               7.0               1.2               2.5               2.9       1300.0               1.70
9               16.0                  11.0                11.0               8.5               1.4               3.0               3.2       1200.0               1.85
10              19.0                  13.0                13.0               9.5               1.6               3.5               3.8       1000.0               2.00
11              14.0                  12.0                12.0               7.5               1.1               2.2               2.8       1250.0               1.75
12              17.0                  11.0                11.0               8.0               1.3               2.8               3.0       1150.0               1.80
13              15.0                  10.0                10.0               9.0               1.5               3.2               3.5       1050.0               1.90
14              18.0                  12.0                12.0               7.0               1.2               2.5               2.9       1300.0               1.70
15              16.0                  11.0                11.0               8.5               1.4               3.0               3.2       1200.0               1.85
16              19.0                  13.0                13.0               9.5               1.6               3.5               3.8       1000.0               2.00
17              14.0                  12.0                12.0               7.5               1.1               2.2               2.8       1250.0               1.75
18              17.0                  11.0                11.0               8.0               1.3               2.8               3.0       1150.0               1.80
19              15.0                  10.0                10.0               9.0               1.5               3.2               3.5       1050.0               1.90
20              18.0                  12.0                12.0               7.0               1.2               2.5               2.9       1300.0               1.70
21              16.0                  11.0                11.0               8.5               1.4               3.0               3.2       1200.0               1.85
22              19.0                  13.0                13.0               9.5               1.6               3.5               3.8       1000.0               2.00
23              14.0                  12.0                12.0               7.5               1.1               2.2               2.8       1250.0               1.75
24              17.0                  11.0                11.0               8.0               1.3               2.8               3.0       1150.0               1.80
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1112510ea517f87b9bc5b404ba98a11456dd5f2d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/530a0e0349839b78cb2078666b2a528994aae3f3.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/619e0fe9de0274e7de51116185b6d5a4d5a84f8e.summary']","Does the inhibition of glutamine metabolism in B cells affect the SUMOylation of Bruton's tyrosine kinase, leading to altered B-cell receptor signaling and activation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the context from the three papers, I propose an experimental plan to test the hypothesis: ""Does the inhibition of glutamine metabolism in B cells affect the SUMOylation of Bruton's tyrosine kinase, leading to altered B-cell receptor signaling and activation?""

**Experimental Approach:**

To disprove the hypothesis, we will investigate the effect of glutamine metabolism inhibition on SUMOylation of Bruton's tyrosine kinase (BTK) and B-cell receptor signaling in B cells.

**Objective:**

1. To determine if inhibiting glutamine metabolism in B cells affects SUMOylation of BTK.
2. To investigate the impact of glutamine metabolism inhibition on B-cell receptor signaling and activation.

**Equipment and Reagents:**

* B-cell isolation kit
* Glutamine-free culture medium
* Glutaminase inhibitors (e.g., BPTES, TGS)
* SUMOylation assay kit
* Western blotting equipment
* Antibodies against BTK, SUMO-1, and phosphorylated BTK
* Flow cytometry equipment
* Calcium flux assay kit
* CRISPR-Cas9 gene editing system (optional)

**Experimental Design:**

1. Isolate B cells from healthy donors and culture them in glutamine-free medium with or without glutaminase inhibitors.
2. Treat B cells with IP6 (inositol hexakisphosphate) to activate BTK and induce SUMOylation.
3. Perform SUMOylation assays to detect SUMO-1 conjugation to BTK in the presence or absence of glutaminase inhibitors.
4. Analyze BTK phosphorylation and SUMOylation using Western blotting.
5. Investigate the effect of glutamine metabolism inhibition on B-cell receptor signaling using flow cytometry and calcium flux assays.
6. (Optional) Use CRISPR-Cas9 gene editing to knockout the SUMO E3 ligase, PIAS1, in B cells and analyze the effect on BTK SUMOylation and B-cell receptor signaling.

**Expected Outcomes:**

* If the hypothesis is true, inhibiting glutamine metabolism in B cells will reduce SUMOylation of BTK, leading to altered B-cell receptor signaling and activation.
* If the hypothesis is false, inhibiting glutamine metabolism will not affect SUMOylation of BTK, and B-cell receptor signaling will remain unaffected.

**Timeline and Budget:**

This experiment can be completed within 6-8 weeks, with a budget of approximately $10,000-$15,000, depending on the cost of reagents and equipment.

**Rationale:**

This experimental design is based on the findings from the three papers, which suggest that glutamine metabolism regulates BCR/Abl protein expression, BTK is activated by IP6-dependent dimerization, and SUMOylation plays a crucial role in regulating BCR signaling. By inhibiting glutamine metabolism and analyzing the effect on SUMOylation of BTK and B-cell receptor signaling, we can test the hypothesis and determine if it is true or false.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: B-cell Isolation and Culture**

1.1. Obtain blood samples from healthy donors and store them at room temperature.

1.2. Prepare the B-cell isolation kit according to the manufacturer's instructions.

1.3. Add 1 mL of blood to the isolation kit and mix gently.

1.4. Incubate the mixture at room temperature for 10 minutes.

1.5. Centrifuge the mixture at 300 x g for 10 minutes.

1.6. Discard the supernatant and resuspend the pellet in 1 mL of PBS.

1.7. Count the B cells using a hemocytometer or an automated cell counter.

1.8. Culture the B cells in glutamine-free medium at a density of 1 x 10^6 cells/mL.

1.9. Incubate the cells at 37°C, 5% CO2 for 24 hours.

**Protocol 2: Glutamine Metabolism Inhibition**

2.1. Prepare a stock solution of glutaminase inhibitor (e.g., BPTES or TGS) at a concentration of 10 mM in DMSO.

2.2. Add the glutaminase inhibitor to the B-cell culture at a final concentration of 1-10 μM.

2.3. Incubate the cells for an additional 24 hours.

**Protocol 3: IP6 Treatment and SUMOylation Assay**

3.1. Prepare a stock solution of IP6 (inositol hexakisphosphate) at a concentration of 10 mM in PBS.

3.2. Add IP6 to the B-cell culture at a final concentration of 10 μM.

3.3. Incubate the cells for 30 minutes at 37°C, 5% CO2.

3.4. Prepare the SUMOylation assay kit according to the manufacturer's instructions.

3.5. Lyse the B cells using the lysis buffer provided in the SUMOylation assay kit.

3.6. Perform the SUMOylation assay according to the manufacturer's instructions.

**Protocol 4: Western Blotting**

4.1. Prepare the Western blotting equipment and reagents according to the manufacturer's instructions.

4.2. Load 20 μg of protein from each sample onto a 10% SDS-PAGE gel.

4.3. Run the gel at 100 V for 1 hour.

4.4. Transfer the proteins to a PVDF membrane using a semi-dry transfer apparatus.

4.5. Block the membrane with 5% milk in TBST for 1 hour.

4.6. Incubate the membrane with primary antibodies against BTK, SUMO-1, and phosphorylated BTK at a dilution of 1:1000 in TBST.

4.7. Incubate the membrane with secondary antibodies at a dilution of 1:5000 in TBST.

4.8. Develop the membrane using an ECL detection system.

**Protocol 5: Flow Cytometry and Calcium Flux Assay**

5.1. Prepare the flow cytometry equipment and reagents according to the manufacturer's instructions.

5.2. Stain the B cells with antibodies against CD20 and CD86 at a dilution of 1:100 in PBS.

5.3. Analyze the cells using a flow cytometer.

5.4. Prepare the calcium flux assay kit according to the manufacturer's instructions.

5.5. Load the B cells into the calcium flux assay plate.

5.6. Add the calcium flux dye to the plate according to the manufacturer's instructions.

5.7. Measure the calcium flux using a plate reader.

**Protocol 6: CRISPR-Cas9 Gene Editing (Optional)**

6.1. Design guide RNAs targeting the PIAS1 gene using a CRISPR-Cas9 design tool.

6.2. Prepare the CRISPR-Cas9 gene editing system according to the manufacturer's instructions.

6.3. Transfect the B cells with the CRISPR-Cas9 system using a nucleofector.

6.4. Select the transfected cells using puromycin selection.

6.5. Verify the knockout of PIAS1 using Western blotting.

6.6. Repeat Protocols 2-5 using the PIAS1-knockout B cells.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   Blood Volume (mL)  Glutaminase Inhibitor (μM)  IP6 (μM)  B Cell Density (cells/mL)  SUMOylation Level  BTK Phosphorylation  Calcium Flux
0               0.8                  5.0         15.0               1.2e+06          0.75             0.40          120.0
1               1.0                  2.0         10.0               1.0e+06          0.60             0.30          100.0
2               1.2                  8.0         12.0               1.1e+06          0.80             0.50          140.0
3               0.9                  4.0         11.0               1.1e+06          0.70             0.45          130.0
4               1.1                  6.0         13.0               1.2e+06          0.85             0.55          150.0
5               0.7                  3.0         10.0               1.0e+06          0.65             0.35          110.0
6               1.0                  9.0         14.0               1.2e+06          0.90             0.60          160.0
7               1.2                  1.0         12.0               1.1e+06          0.80             0.50          140.0
8               0.8                  7.0         11.0               1.1e+06          0.75             0.45          130.0
9               1.1                  5.0         13.0               1.2e+06          0.85             0.55          150.0
10              0.9                  2.0         10.0               1.0e+06          0.60             0.30          100.0
11              1.0                  8.0         12.0               1.1e+06          0.80             0.50          140.0
12              1.2                  4.0         11.0               1.1e+06          0.70             0.45          130.0
13              0.7                  6.0         13.0               1.2e+06          0.85             0.55          150.0
14              1.1                  3.0         10.0               1.0e+06          0.65             0.35          110.0
15              0.8                  9.0         14.0               1.2e+06          0.90             0.60          160.0
16              1.0                  1.0         12.0               1.1e+06          0.80             0.50          140.0
17              1.2                  7.0         11.0               1.1e+06          0.75             0.45          130.0
18              0.9                  5.0         13.0               1.2e+06          0.85             0.55          150.0
19              1.1                  2.0         10.0               1.0e+06          0.60             0.30          100.0
20              0.7                  8.0         12.0               1.1e+06          0.80             0.50          140.0
21              1.0                  4.0         11.0               1.1e+06          0.70             0.45          130.0
22              1.2                  6.0         13.0               1.2e+06          0.85             0.55          150.0
23              0.8                  3.0         10.0               1.0e+06          0.65             0.35          110.0
24              1.1                  9.0         14.0               1.2e+06          0.90             0.60          160.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ed5792df092ad4a00961addbe8764b2f57e32d8b.summary'],"Does the inhibition of mTOR signaling pathway in DLBCL cells lead to a decrease in CXCR4 expression, thereby enhancing CD8+ T cell infiltration and improving treatment outcomes?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Inhibition of mTOR Signaling Pathway in DLBCL Cells: Impact on CXCR4 Expression and CD8+ T Cell Infiltration

**Objective:** To investigate the effect of mTOR signaling pathway inhibition on CXCR4 expression and CD8+ T cell infiltration in DLBCL cells.

**Equipment:**

* DLBCL cell lines (e.g., OCI-Ly3 and SU-DHL4)
* mTOR inhibitor (e.g., rapamycin or everolimus)
* CXCR4 inhibitor (e.g., WZ811)
* Cell culture medium
* Cell counting kit
* Flow cytometer
* Western blot equipment
* Mouse model of DLBCL
* Immunohistochemistry equipment

**Steps:**

1. Treat DLBCL cell lines with mTOR inhibitor (rapamycin or everolimus) and measure cell proliferation using a cell counting kit.
2. Analyze the expression of mTOR, CXCR4, and CD8+ T cell markers in DLBCL cells using Western blot and flow cytometry.
3. Co-treat DLBCL cell lines with mTOR inhibitor and CXCR4 inhibitor (WZ811) and measure the expression of CXCR4 and CD8+ T cell markers.
4. Inject DLBCL cells into mice and treat with mTOR inhibitor. Monitor tumor growth and CD8+ T cell infiltration using flow cytometry and immunohistochemistry.
5. Perform immunohistochemistry to analyze the expression of CXCR4 and CD8+ T cell markers in tumor tissues.

**Expected Outcomes:**

* Inhibition of mTOR signaling pathway decreases CXCR4 expression in DLBCL cells.
* Inhibition of mTOR signaling pathway increases CD8+ T cell infiltration in DLBCL cells.
* Co-inhibition of mTOR and CXCR4 signaling pathways enhances CD8+ T cell infiltration and improves treatment outcomes in DLBCL.

**Experiment to Disprove the Hypothesis:**

**Title:** mTOR Signaling Pathway Inhibition Fails to Affect CXCR4 Expression and CD8+ T Cell Infiltration in DLBCL Cells

**Objective:** To investigate the effect of mTOR signaling pathway inhibition on CXCR4 expression and CD8+ T cell infiltration in DLBCL cells, with the goal of disproving the hypothesis.

**Equipment:**

* Same as above

**Steps:**

1. Treat DLBCL cell lines with mTOR inhibitor (rapamycin or everolimus) and measure cell proliferation using a cell counting kit.
2. Analyze the expression of mTOR, CXCR4, and CD8+ T cell markers in DLBCL cells using Western blot and flow cytometry.
3. Perform a dose-response experiment to determine the optimal concentration of mTOR inhibitor required to inhibit mTOR signaling pathway.
4. Treat DLBCL cell lines with the optimal concentration of mTOR inhibitor and measure the expression of CXCR4 and CD8+ T cell markers.
5. Perform a time-course experiment to determine the duration of mTOR inhibition required to affect CXCR4 expression and CD8+ T cell infiltration.

**Expected Outcomes:**

* Inhibition of mTOR signaling pathway does not affect CXCR4 expression in DLBCL cells.
* Inhibition of mTOR signaling pathway does not increase CD8+ T cell infiltration in DLBCL cells.
* The optimal concentration and duration of mTOR inhibition do not impact CXCR4 expression and CD8+ T cell infiltration.

By designing an experiment to disprove the hypothesis, we can rigorously test the hypothesis and increase confidence in the results. If the experiment to disprove the hypothesis fails to do so, it would provide strong evidence supporting the original hypothesis.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Title:** Inhibition of mTOR Signaling Pathway in DLBCL Cells: Impact on CXCR4 Expression and CD8+ T Cell Infiltration

**Objective:** To investigate the effect of mTOR signaling pathway inhibition on CXCR4 expression and CD8+ T cell infiltration in DLBCL cells.

**Protocol:**

**Step 1: Cell Culture and Treatment**

1.1. Obtain DLBCL cell lines (OCI-Ly3 and SU-DHL4) and maintain them in cell culture medium at 37°C, 5% CO2.

1.2. Prepare a stock solution of mTOR inhibitor (rapamycin or everolimus) in DMSO at a concentration of 10 mM.

1.3. Treat DLBCL cells with the mTOR inhibitor at a final concentration of 10 nM (or as determined by previous experiments) for 24, 48, and 72 hours.

1.4. Use a cell counting kit to measure cell proliferation at each time point.

**Step 2: Western Blot Analysis**

2.1. Harvest DLBCL cells treated with mTOR inhibitor and control cells at each time point.

2.2. Lyse cells in RIPA buffer and quantify protein concentration using a protein assay.

2.3. Load 20 μg of protein per lane onto a 10% SDS-PAGE gel and separate proteins by electrophoresis.

2.4. Transfer proteins to a PVDF membrane and block with 5% milk in TBST for 1 hour.

2.5. Incubate the membrane with primary antibodies against mTOR, CXCR4, and CD8+ T cell markers (e.g., CD8α) overnight at 4°C.

2.6. Wash the membrane with TBST and incubate with secondary antibodies for 1 hour at room temperature.

2.7. Develop the membrane using an ECL detection system and quantify protein expression using densitometry.

**Step 3: Flow Cytometry Analysis**

3.1. Harvest DLBCL cells treated with mTOR inhibitor and control cells at each time point.

3.2. Stain cells with fluorescently labeled antibodies against CXCR4 and CD8+ T cell markers (e.g., CD8α) according to the manufacturer's instructions.

3.3. Analyze cells using a flow cytometer and quantify the expression of CXCR4 and CD8+ T cell markers.

**Step 4: Co-Treatment with CXCR4 Inhibitor**

4.1. Treat DLBCL cells with mTOR inhibitor (10 nM) and CXCR4 inhibitor (WZ811, 10 μM) for 24, 48, and 72 hours.

4.2. Analyze the expression of CXCR4 and CD8+ T cell markers using Western blot and flow cytometry as described above.

**Step 5: In Vivo Experiment**

5.1. Inject DLBCL cells into mice (e.g., NOD/SCID mice) and treat with mTOR inhibitor (10 mg/kg) via intraperitoneal injection every 3 days.

5.2. Monitor tumor growth using calipers and measure CD8+ T cell infiltration using flow cytometry and immunohistochemistry.

5.3. Perform immunohistochemistry to analyze the expression of CXCR4 and CD8+ T cell markers in tumor tissues.

**Experiment to Disprove the Hypothesis:**

**Title:** mTOR Signaling Pathway Inhibition Fails to Affect CXCR4 Expression and CD8+ T Cell Infiltration in DLBCL Cells

**Objective:** To investigate the effect of mTOR signaling pathway inhibition on CXCR4 expression and CD8+ T cell infiltration in DLBCL cells, with the goal of disproving the hypothesis.

**Protocol:**

**Step 1: Dose-Response Experiment**

1.1. Treat DLBCL cells with increasing concentrations of mTOR inhibitor (0.1 nM, 1 nM, 10 nM, 100 nM) for 24 hours.

1.2. Measure cell proliferation using a cell counting kit.

1.3. Analyze the expression of mTOR, CXCR4, and CD8+ T cell markers using Western blot and flow cytometry as described above.

**Step 2: Time-Course Experiment**

2.1. Treat DLBCL cells with the optimal concentration of mTOR inhibitor (determined in Step 1) for 6, 12, 24, 48, and 72 hours.

2.2. Measure cell proliferation using a cell counting kit.

2.3. Analyze the expression of CXCR4 and CD8+ T cell markers using Western blot and flow cytometry as described above.

**Step 3: Western Blot Analysis**

3.1. Harvest DLBCL cells treated with the optimal concentration of mTOR inhibitor at each time point.

3.2. Analyze the expression of mTOR, CXCR4, and CD8+ T cell markers using Western blot as described above.

**Step 4: Flow Cytometry Analysis**

4.1. Harvest DLBCL cells treated with the optimal concentration of mTOR inhibitor at each time point.

4.2. Analyze the expression of CXCR4 and CD8+ T cell markers using flow cytometry as described above.

By following these detailed, step-by-step protocols, the experiments can be replicated and the results can be accurately interpreted to test or disprove the hypothesis.","```
   Rapamycin (nM)  Everolimus (nM)  WZ811 (μM)  Time (hours)  CXCR4 Expression  CD8+ T Cell Infiltration
0             0.1             0.0       0.0          24           0.8                  0.2
1             1.0             0.0       0.0          24           0.6                  0.4
2             5.0             0.0       0.0          24           0.4                  0.6
3             10.0            0.0       0.0          24           0.2                  0.8
4             0.0             0.1       0.0          24           0.9                  0.1
5             0.0             1.0       0.0          24           0.7                  0.3
6             0.0             5.0       0.0          24           0.5                  0.5
7             0.0            10.0       0.0          24           0.3                  0.7
8             10.0            0.0       10.0         24           0.1                  0.9
9             10.0            0.0       0.0          48           0.3                  0.7
10            10.0            0.0       0.0          72           0.5                  0.5
11            0.0             10.0       0.0          48           0.4                  0.6
12            0.0             10.0       0.0          72           0.6                  0.4
13            10.0            0.0       10.0         48           0.2                  0.8
14            10.0            0.0       10.0         72           0.4                  0.6
15            5.0             5.0       0.0          24           0.5                  0.5
16            5.0             5.0       0.0          48           0.6                  0.4
17            5.0             5.0       0.0          72           0.7                  0.3
18            10.0            0.0       5.0          24           0.3                  0.7
19            10.0            0.0       5.0          48           0.5                  0.5
20            10.0            0.0       5.0          72           0.6                  0.4
21            0.0             10.0       5.0          24           0.4                  0.6
22            0.0             10.0       5.0          48           0.5                  0.5
23            0.0             10.0       5.0          72           0.6                  0.4
24            5.0             5.0       5.0          24           0.5                  0.5
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d497ff2b7c527d6eca0b5ec194fe9c4bcfd43af9.summary'],"Does the inhibition of miR155 in RA patients also enhance the responsiveness of M2 macrophages to anti-inflammatory cytokines, leading to a synergistic reduction in inflammation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Effect of miR155 Inhibition on M2 Macrophage Responsiveness to Anti-Inflammatory Cytokines in RA Patients

**Objective:** To determine if inhibition of miR155 in RA patients enhances the responsiveness of M2 macrophages to anti-inflammatory cytokines, leading to a synergistic reduction in inflammation.

**Equipment:**

* Monocyte isolation kit
* miR155 inhibitor
* M2-polarizing conditions (e.g., IL-4, IL-13)
* Anti-inflammatory cytokines (e.g., IL-10, TGF-β)
* Flow cytometer
* ELISA kit for M2 markers and inflammatory cytokines
* Cell culture facilities

**Steps:**

1. Isolate monocytes from RA patients and healthy controls.
2. Transfect monocytes with miR155 inhibitor or control.
3. Cultivate monocytes with M2-polarizing conditions for 3-5 days.
4. Treat M2-polarized macrophages with anti-inflammatory cytokines (IL-10, TGF-β) for 24-48 hours.
5. Analyze M2 marker expression (e.g., CD206, CD163) and inflammatory cytokine production (e.g., TNF-α, IL-1β) by flow cytometry and ELISA.
6. Compare the responsiveness of miR155-inhibited and control M2 macrophages to anti-inflammatory cytokines.
7. Measure the production of anti-inflammatory cytokines (e.g., IL-10, TGF-β) by M2 macrophages in response to miR155 inhibition.

**Expected Outcomes:**

* Enhanced responsiveness of M2 macrophages to anti-inflammatory cytokines in miR155-inhibited RA patients compared to controls.
* Increased production of anti-inflammatory cytokines by M2 macrophages in response to miR155 inhibition.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Effect of miR155 Inhibition on M2 Macrophage Responsiveness to Pro-Inflammatory Cytokines in RA Patients

**Objective:** To determine if inhibition of miR155 in RA patients enhances the responsiveness of M2 macrophages to pro-inflammatory cytokines, leading to increased inflammation.

**Equipment:**

* Same as above

**Steps:**

1. Isolate monocytes from RA patients and healthy controls.
2. Transfect monocytes with miR155 inhibitor or control.
3. Cultivate monocytes with M2-polarizing conditions for 3-5 days.
4. Treat M2-polarized macrophages with pro-inflammatory cytokines (e.g., TNF-α, IL-1β) for 24-48 hours.
5. Analyze M2 marker expression and inflammatory cytokine production by flow cytometry and ELISA.
6. Compare the responsiveness of miR155-inhibited and control M2 macrophages to pro-inflammatory cytokines.
7. Measure the production of pro-inflammatory cytokines by M2 macrophages in response to miR155 inhibition.

**Expected Outcomes:**

* Enhanced responsiveness of M2 macrophages to pro-inflammatory cytokines in miR155-inhibited RA patients compared to controls.
* Increased production of pro-inflammatory cytokines by M2 macrophages in response to miR155 inhibition.

**Rationale:**

By designing an experiment to disprove the hypothesis, we can test the opposite scenario: if miR155 inhibition leads to increased inflammation by enhancing the responsiveness of M2 macrophages to pro-inflammatory cytokines. If the results of this experiment contradict the original hypothesis, it would suggest that the hypothesis is false. This approach can help to increase the confidence in the results and provide a more comprehensive understanding of the role of miR155 in RA.

**Time and Resource Considerations:**

Both experiments can be completed within a reasonable time frame (6-12 weeks) and with a moderate budget. The required equipment and reagents are readily available, and the experimental design is straightforward. The experiments can be performed in a standard cell culture laboratory with access to flow cytometry and ELISA facilities.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Investigating the Effect of miR155 Inhibition on M2 Macrophage Responsiveness to Anti-Inflammatory Cytokines in RA Patients**

**Protocol:**

**Step 1: Monocyte Isolation**

1.1. Collect 10 mL of peripheral blood from RA patients and healthy controls in EDTA-coated tubes.
1.2. Add 10 mL of PBS to the blood samples and mix gently.
1.3. Layer the blood-PBS mixture over 10 mL of Ficoll-Paque in a 50 mL conical tube.
1.4. Centrifuge at 400 x g for 30 minutes at room temperature.
1.5. Collect the monocyte layer and wash with PBS.
1.6. Resuspend the monocytes in 1 mL of PBS and count using a hemocytometer.

**Step 2: Transfection with miR155 Inhibitor or Control**

2.1. Prepare the miR155 inhibitor or control siRNA according to the manufacturer's instructions.
2.2. Resuspend the monocytes in 100 μL of transfection medium (e.g., Opti-MEM).
2.3. Add 10 μL of miR155 inhibitor or control siRNA to the monocyte suspension.
2.4. Incubate at room temperature for 30 minutes.
2.5. Add 900 μL of complete medium (e.g., RPMI 1640 with 10% FBS) to the transfection mixture.

**Step 3: M2 Polarization**

3.1. Add 10 ng/mL of IL-4 and 10 ng/mL of IL-13 to the monocyte culture.
3.2. Incubate at 37°C, 5% CO2 for 3-5 days.
3.3. Replace the medium with fresh complete medium every 2 days.

**Step 4: Treatment with Anti-Inflammatory Cytokines**

4.1. Add 10 ng/mL of IL-10 and 10 ng/mL of TGF-β to the M2-polarized macrophage culture.
4.2. Incubate at 37°C, 5% CO2 for 24-48 hours.

**Step 5: Flow Cytometry and ELISA Analysis**

5.1. Harvest the macrophages and stain with CD206 and CD163 antibodies for flow cytometry analysis.
5.2. Analyze the expression of M2 markers using a flow cytometer.
5.3. Collect the supernatant and measure the production of TNF-α and IL-1β using an ELISA kit.

**Step 6: Comparison and Data Analysis**

6.1. Compare the responsiveness of miR155-inhibited and control M2 macrophages to anti-inflammatory cytokines.
6.2. Analyze the production of anti-inflammatory cytokines (e.g., IL-10, TGF-β) by M2 macrophages in response to miR155 inhibition.

**Experiment to Disprove the Hypothesis: Investigating the Effect of miR155 Inhibition on M2 Macrophage Responsiveness to Pro-Inflammatory Cytokines in RA Patients**

**Protocol:**

**Step 1-3: Monocyte Isolation, Transfection, and M2 Polarization**

 Same as Steps 1-3 in the experiment to test the hypothesis.

**Step 4: Treatment with Pro-Inflammatory Cytokines**

4.1. Add 10 ng/mL of TNF-α and 10 ng/mL of IL-1β to the M2-polarized macrophage culture.
4.2. Incubate at 37°C, 5% CO2 for 24-48 hours.

**Step 5: Flow Cytometry and ELISA Analysis**

5.1. Harvest the macrophages and stain with CD206 and CD163 antibodies for flow cytometry analysis.
5.2. Analyze the expression of M2 markers using a flow cytometer.
5.3. Collect the supernatant and measure the production of TNF-α and IL-1β using an ELISA kit.

**Step 6: Comparison and Data Analysis**

6.1. Compare the responsiveness of miR155-inhibited and control M2 macrophages to pro-inflammatory cytokines.
6.2. Analyze the production of pro-inflammatory cytokines by M2 macrophages in response to miR155 inhibition.

**Note:**

* All experiments should be performed in triplicate to ensure reproducibility.
* The same batch of reagents and equipment should be used throughout the experiment to minimize variability.
* The experimental design should be blinded to minimize bias.
* The data should be analyzed using appropriate statistical methods to determine significance.","```
   miR155 Inhibitor (μL)  IL-4 (ng/mL)  IL-13 (ng/mL)  IL-10 (ng/mL)  TGF-β (ng/mL)  TNF-α (ng/mL)  IL-1β (ng/mL)  M2 Marker Expression  TNF-α Production  IL-1β Production
0                    5.0          12.0          12.0          12.0          12.0          0.0          0.0           0.75           250.0           150.0
1                    7.5          10.0          10.0          10.0          10.0          0.0          0.0           0.80           220.0           120.0
2                    2.5          15.0          15.0          15.0          15.0          0.0          0.0           0.60           280.0           180.0
3                    5.0          12.0          12.0          12.0          12.0          10.0          10.0           0.40           350.0           250.0
4                    7.5          10.0          10.0          10.0          10.0          10.0          10.0           0.30           320.0           220.0
5                    2.5          15.0          15.0          15.0          15.0          10.0          10.0           0.50           300.0           200.0
6                    5.0          12.0          12.0          12.0          12.0          0.0          0.0           0.70           240.0           160.0
7                    7.5          10.0          10.0          10.0          10.0          0.0          0.0           0.85           200.0           140.0
8                    2.5          15.0          15.0          15.0          15.0          0.0          0.0           0.65           260.0           170.0
9                    5.0          12.0          12.0          12.0          12.0          10.0          10.0           0.45           330.0           230.0
10                   7.5          10.0          10.0          10.0          10.0          10.0          10.0           0.35           310.0           210.0
11                   2.5          15.0          15.0          15.0          15.0          10.0          10.0           0.55           290.0           190.0
12                   5.0          12.0          12.0          12.0          12.0          0.0          0.0           0.75           230.0           150.0
13                   7.5          10.0          10.0          10.0          10.0          0.0          0.0           0.80           210.0           140.0
14                   2.5          15.0          15.0          15.0          15.0          0.0          0.0           0.60           270.0           180.0
15                   5.0          12.0          12.0          12.0          12.0          10.0          10.0           0.40           340.0           240.0
16                   7.5          10.0          10.0          10.0          10.0          10.0          10.0           0.30           320.0           220.0
17                   2.5          15.0          15.0          15.0          15.0          10.0          10.0           0.50           300.0           200.0
18                   5.0          12.0          12.0          12.0          12.0          0.0          0.0           0.70           240.0           160.0
19                   7.5          10.0          10.0          10.0          10.0          0.0          0.0           0.85           200.0           140.0
20                   2.5          15.0          15.0          15.0          15.0          0.0          0.0           0.65           260.0           170.0
21                   5.0          12.0          12.0          12.0          12.0          10.0          10.0           0.45           330.0           230.0
22                   7.5          10.0          10.0          10.0          10.0          10.0          10.0           0.35           310.0           210.0
23                   2.5          15.0          15.0          15.0          15.0          10.0          10.0           0.55           290.0           190.0
24                   5.0          12.0          12.0          12.0          12.0          0.0          0.0           0.75           230.0           150.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/025231b736e93e863a3a31200412a276c23453d9.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/20b296ee6d98b9eecccea398fe373c9e4892fc3f.summary']",Does the inhibition of p110δ activity in Rab8a knockout B cells further enhance antibody responses and class-switch recombination by modulating the PI3K/AKT/mTOR pathway?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Effect of p110δ Inhibition on Antibody Responses and Class-Switch Recombination in Rab8a Knockout B Cells

**Objective:** To determine if inhibiting p110δ activity in Rab8a knockout B cells further enhances antibody responses and class-switch recombination by modulating the PI3K/AKT/mTOR pathway.

**Equipment:**

* Rab8a knockout B cells
* p110δ inhibitor (leniolisib)
* FACS
* Cell culture facilities
* B cell isolation kit
* PI3K/AKT/mTOR pathway inhibitors
* AID expression plasmid
* Class-switch recombination assay kit
* qRT-PCR machine

**Steps:**

1. Isolate Rab8a knockout B cells and culture them in vitro.
2. Treat B cells with p110δ inhibitor (leniolisib) and/or PI3K/AKT/mTOR pathway inhibitors.
3. Assess B cell differentiation and class-switch recombination using FACS and molecular biology techniques.
4. Measure AID expression using qRT-PCR.
5. Transfect B cells with AID expression plasmid and measure class-switch recombination using a class-switch recombination assay kit.
6. Compare results to Rab8a knockout B cells without p110δ inhibition and to wild-type B cells.

**Expected Outcomes:**

* Enhanced antibody responses and class-switch recombination in Rab8a knockout B cells treated with p110δ inhibitor compared to untreated Rab8a knockout B cells.
* Modulation of the PI3K/AKT/mTOR pathway in Rab8a knockout B cells treated with p110δ inhibitor.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Effect of p110δ Inhibition on Antibody Responses and Class-Switch Recombination in Rab8a Knockout B Cells with Constitutively Active PI3K

**Objective:** To determine if inhibiting p110δ activity in Rab8a knockout B cells with constitutively active PI3K does not enhance antibody responses and class-switch recombination.

**Equipment:**

* Rab8a knockout B cells with constitutively active PI3K (generated using CRISPR-Cas9 or retroviral transduction)
* p110δ inhibitor (leniolisib)
* FACS
* Cell culture facilities
* B cell isolation kit
* PI3K/AKT/mTOR pathway inhibitors
* AID expression plasmid
* Class-switch recombination assay kit
* qRT-PCR machine

**Steps:**

1. Isolate Rab8a knockout B cells with constitutively active PI3K and culture them in vitro.
2. Treat B cells with p110δ inhibitor (leniolisib).
3. Assess B cell differentiation and class-switch recombination using FACS and molecular biology techniques.
4. Measure AID expression using qRT-PCR.
5. Transfect B cells with AID expression plasmid and measure class-switch recombination using a class-switch recombination assay kit.
6. Compare results to Rab8a knockout B cells with constitutively active PI3K without p110δ inhibition.

**Expected Outcomes:**

* No enhancement of antibody responses and class-switch recombination in Rab8a knockout B cells with constitutively active PI3K treated with p110δ inhibitor compared to untreated Rab8a knockout B cells with constitutively active PI3K.
* The PI3K/AKT/mTOR pathway remains active despite p110δ inhibition, suggesting that p110δ inhibition does not modulate the pathway in this context.

This experiment is designed to test the hypothesis by attempting to disprove it. If the results show that p110δ inhibition does not enhance antibody responses and class-switch recombination in Rab8a knockout B cells with constitutively active PI3K, it would suggest that the hypothesis is incorrect.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Effect of p110δ Inhibition on Antibody Responses and Class-Switch Recombination in Rab8a Knockout B Cells

**Protocol:**

**Step 1: Isolate Rab8a Knockout B Cells and Culture Them In Vitro**

1.1. Obtain Rab8a knockout mice and harvest spleens according to institutional animal care and use committee (IACUC) guidelines.

1.2. Prepare a single-cell suspension of splenocytes using a gentleMACS Dissociator (Miltenyi Biotec) and filter through a 40-μm cell strainer.

1.3. Isolate B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

1.4. Culture isolated B cells in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

**Step 2: Treat B Cells with p110δ Inhibitor (Leniolisib) and/or PI3K/AKT/mTOR Pathway Inhibitors**

2.1. Prepare a stock solution of leniolisib (e.g., 10 mM) in DMSO and store at -20°C.

2.2. Add leniolisib to the B cell culture at a final concentration of 1 μM and incubate for 24 hours.

2.3. For PI3K/AKT/mTOR pathway inhibition, add specific inhibitors (e.g., LY294002, AKT inhibitor VIII, and rapamycin) to the B cell culture at the recommended concentrations and incubate for 24 hours.

**Step 3: Assess B Cell Differentiation and Class-Switch Recombination Using FACS and Molecular Biology Techniques**

3.1. Harvest B cells and stain with fluorescently labeled antibodies against surface markers (e.g., CD19, CD27, and IgG) using a FACS staining protocol.

3.2. Analyze stained cells using a flow cytometer (e.g., BD FACSCanto II) and determine the percentage of differentiated B cells (e.g., plasmablasts and plasma cells).

3.3. Extract RNA from B cells using a RNA isolation kit (e.g., Qiagen) and perform qRT-PCR to measure AID expression using specific primers and a qRT-PCR machine (e.g., Applied Biosystems 7500).

**Step 4: Measure AID Expression Using qRT-PCR**

4.1. Design and synthesize AID-specific primers (e.g., forward: 5'-GCTGCTGCTGCTGCTG-3', reverse: 5'-CGCGCGCGCGCGCG-3').

4.2. Prepare a qRT-PCR reaction mix containing 1 μL of cDNA, 1 μL of each primer (10 μM), 10 μL of 2x SYBR Green Master Mix, and 7 μL of nuclease-free water.

4.3. Perform qRT-PCR using the following conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.

**Step 5: Transfect B Cells with AID Expression Plasmid and Measure Class-Switch Recombination**

5.1. Prepare an AID expression plasmid (e.g., pCMV-AID) using a plasmid preparation kit (e.g., Qiagen).

5.2. Transfect B cells with the AID expression plasmid using a nucleofection protocol (e.g., Lonza).

5.3. Measure class-switch recombination using a class-switch recombination assay kit (e.g., Invitrogen) according to the manufacturer's instructions.

**Step 6: Compare Results to Rab8a Knockout B Cells Without p110δ Inhibition and to Wild-Type B Cells**

6.1. Repeat steps 1-5 using Rab8a knockout B cells without p110δ inhibition and wild-type B cells as controls.

6.2. Compare the results of antibody responses and class-switch recombination between the different groups using statistical analysis software (e.g., GraphPad Prism).

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Effect of p110δ Inhibition on Antibody Responses and Class-Switch Recombination in Rab8a Knockout B Cells with Constitutively Active PI3K

**Protocol:**

**Step 1: Isolate Rab8a Knockout B Cells with Constitutively Active PI3K and Culture Them In Vitro**

1.1. Generate Rab8a knockout B cells with constitutively active PI3K using CRISPR-Cas9 or retroviral transduction.

1.2. Isolate B cells using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.

1.3. Culture isolated B cells in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

**Step 2: Treat B Cells with p110δ Inhibitor (Leniolisib)**

2.1. Prepare a stock solution of leniolisib (e.g., 10 mM) in DMSO and store at -20°C.

2.2. Add leniolisib to the B cell culture at a final concentration of 1 μM and incubate for 24 hours.

**Step 3: Assess B Cell Differentiation and Class-Switch Recombination Using FACS and Molecular Biology Techniques**

3.1. Harvest B cells and stain with fluorescently labeled antibodies against surface markers (e.g., CD19, CD27, and IgG) using a FACS staining protocol.

3.2. Analyze stained cells using a flow cytometer (e.g., BD FACSCanto II) and determine the percentage of differentiated B cells (e.g., plasmablasts and plasma cells).

3.3. Extract RNA from B cells using a RNA isolation kit (e.g., Qiagen) and perform qRT-PCR to measure AID expression using specific primers and a qRT-PCR machine (e.g., Applied Biosystems 7500).

**Step 4: Measure AID Expression Using qRT-PCR**

4.1. Design and synthesize AID-specific primers (e.g., forward: 5'-GCTGCTGCTGCTGCTG-3', reverse: 5'-CGCGCGCGCGCGCG-3').

4.2. Prepare a qRT-PCR reaction mix containing 1 μL of cDNA, 1 μL of each primer (10 μM), 10 μL of 2x SYBR Green Master Mix, and 7 μL of nuclease-free water.

4.3. Perform qRT-PCR using the following conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.

**Step 5: Transfect B Cells with AID Expression Plasmid and Measure Class-Switch Recombination**

5.1. Prepare an AID expression plasmid (e.g., pCMV-AID) using a plasmid preparation kit (e.g., Qiagen).

5.2. Transfect B cells with the AID expression plasmid using a nucleofection protocol (e.g., Lonza).

5.3. Measure class-switch recombination using a class-switch recombination assay kit (e.g., Invitrogen) according to the manufacturer's instructions.

**Step 6: Compare Results to Rab8a Knockout B Cells with Constitutively Active PI3K Without p110δ Inhibition**

6.1. Repeat steps 1-5 using Rab8a knockout B cells with constitutively active PI3K without p110δ inhibition as a control.

6.2. Compare the results of antibody responses and class-switch recombination between the different groups using statistical analysis software (e.g., GraphPad Prism).","```
   Rab8a_KO_B_Cells  Leniolisib  PI3K_Inhibitor  AKT_Inhibitor  Rapamycin  AID_Expression  Class_Switch_Recombination
0               100000       1.0           0.0           0.0       0.0           2.5                    0.8
1               120000       0.5           1.0           0.0       0.0           3.2                    1.2
2               80000        1.5           0.0           1.0       0.0           2.8                    1.0
3               90000        1.0           0.5           0.0       1.0           3.5                    1.5
4               110000       0.8           1.2           0.0       0.0           3.0                    1.3
5               130000       1.2           0.8           1.0       0.0           3.8                    1.8
6               100000       1.0           0.0           0.0       0.5           2.2                    0.9
7               120000       0.9           1.1           0.0       0.0           3.1                    1.4
8               80000        1.6           0.0           1.2       0.0           3.4                    1.6
9               90000        1.1           0.9           0.0       1.1           3.6                    1.7
10              110000       0.7           1.3           0.0       0.0           2.9                    1.2
11              130000       1.3           0.7           1.1       0.0           4.0                    2.0
12              100000       1.0           0.0           0.0       0.8           2.6                    1.1
13              120000       0.6           1.4           0.0       0.0           3.3                    1.5
14              80000        1.7           0.0           1.3       0.0           3.9                    1.9
15              90000        1.2           1.0           0.0       1.2           4.2                    2.2
16              110000       0.9           1.5           0.0       0.0           3.5                    1.6
17              130000       1.4           0.9           1.2       0.0           4.4                    2.4
18              100000       1.0           0.0           0.0       1.0           2.4                    1.0
19              120000       0.8           1.6           0.0       0.0           3.7                    1.8
20              80000        1.8           0.0           1.4       0.0           4.1                    2.1
21              90000        1.3           1.1           0.0       1.3           4.5                    2.5
22              110000       1.0           1.7           0.0       0.0           3.9                    2.0
23              130000       1.5           1.0           1.3       0.0           4.7                    2.7
24              100000       1.0           0.0           0.0       1.2           2.7                    1.2
```",0.4216004126671491
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f5120f1a6c16f37a59d48a3ce7e2ef86a22d325a.summary'],"Does the inhibition of the TPL2-MKK1/2-ERK1/2 pathway also lead to the downregulation of other oncogenic kinases, such as PI3K, in B-cell lymphoma cells, thereby contributing to the cytostatic effect?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Inhibition of the TPL2-MKK1/2-ERK1/2 pathway leads to the downregulation of other oncogenic kinases, such as PI3K, in B-cell lymphoma cells, contributing to the cytostatic effect.

**Experimental Plan:**

**Objective:** To investigate whether the inhibition of the TPL2-MKK1/2-ERK1/2 pathway downregulates PI3K and other oncogenic kinases in B-cell lymphoma cells, contributing to the cytostatic effect.

**Experimental Design:**

1. **Cell Culture:** Establish a B-cell lymphoma cell line (e.g., Ramos or Daudi) in culture and maintain it in a controlled environment.
2. **TPL2-MKK1/2-ERK1/2 Pathway Inhibition:** Use a specific inhibitor of the TPL2-MKK1/2-ERK1/2 pathway (e.g., TPL2 inhibitor, MKK1/2 inhibitor, or ERK1/2 inhibitor) to treat the B-cell lymphoma cells. Use a range of concentrations to establish a dose-response curve.
3. **PI3K and Oncogenic Kinase Analysis:** Use Western blotting, immunoprecipitation, or mass spectrometry to analyze the protein expression and phosphorylation levels of PI3K, as well as other oncogenic kinases (e.g., AKT, mTOR, and JNK), in treated and untreated cells.
4. **Cell Proliferation and Viability Assays:** Perform cell proliferation assays (e.g., MTT, BrdU, or EdU) and cell viability assays (e.g., Annexin V/PI staining) to assess the cytostatic effect of TPL2-MKK1/2-ERK1/2 pathway inhibition.
5. **RNA Interference (RNAi) and CRISPR-Cas9 Gene Editing:** Use RNAi or CRISPR-Cas9 to specifically knockdown or knockout TPL2, MKK1/2, or ERK1/2 in B-cell lymphoma cells to validate the results obtained with pharmacological inhibitors.
6. **Rescue Experiments:** Overexpress PI3K or other oncogenic kinases in TPL2-MKK1/2-ERK1/2 pathway-inhibited cells to determine if the cytostatic effect can be rescued.

**Experiment to Disprove the Hypothesis:**

**Objective:** To design an experiment that, if successful, would disprove the hypothesis that inhibition of the TPL2-MKK1/2-ERK1/2 pathway leads to the downregulation of PI3K and other oncogenic kinases in B-cell lymphoma cells.

**Experimental Design:**

1. **Constitutively Active PI3K Expression:** Overexpress a constitutively active form of PI3K in B-cell lymphoma cells to ensure that PI3K activity is not affected by TPL2-MKK1/2-ERK1/2 pathway inhibition.
2. **TPL2-MKK1/2-ERK1/2 Pathway Inhibition:** Treat the cells with a specific inhibitor of the TPL2-MKK1/2-ERK1/2 pathway, as described above.
3. **PI3K Activity Assay:** Measure PI3K activity using a biochemical assay (e.g., PI3K lipid kinase assay) or a cellular assay (e.g., AKT phosphorylation) to determine if PI3K activity is still downregulated despite the constitutive activation.
4. **Cell Proliferation and Viability Assays:** Perform cell proliferation and viability assays, as described above, to assess the cytostatic effect of TPL2-MKK1/2-ERK1/2 pathway inhibition in the presence of constitutively active PI3K.

If the results of this experiment show that PI3K activity is still downregulated and the cytostatic effect is maintained despite the constitutive activation of PI3K, it would suggest that the hypothesis is incorrect, and the inhibition of the TPL2-MKK1/2-ERK1/2 pathway does not lead to the downregulation of PI3K and other oncogenic kinases in B-cell lymphoma cells.

**Unlimited Budget Considerations:**

* Utilize cutting-edge technologies, such as single-cell RNA sequencing, to analyze the transcriptome and proteome of individual cells.
* Employ advanced imaging techniques, like super-resolution microscopy, to visualize the dynamics of protein-protein interactions and signaling pathways.
* Perform high-throughput screening of small molecule libraries to identify novel inhibitors of the TPL2-MKK1/2-ERK1/2 pathway and PI3K.
* Collaborate with experts in bioinformatics and computational biology to develop predictive models of signaling networks and identify potential therapeutic targets.

By following this experimental plan, we can rigorously test the hypothesis and gain a deeper understanding of the molecular mechanisms underlying the cytostatic effect of TPL2-MKK1/2-ERK1/2 pathway inhibition in B-cell lymphoma cells.",90,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: TPL2-MKK1/2-ERK1/2 Pathway Inhibition and PI3K Analysis**

**Objective:** To investigate whether the inhibition of the TPL2-MKK1/2-ERK1/2 pathway downregulates PI3K and other oncogenic kinases in B-cell lymphoma cells.

**Step 1: Cell Culture**

1.1. Obtain Ramos or Daudi B-cell lymphoma cells from a reputable cell bank or culture collection.
1.2. Culture the cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.
1.3. Maintain the cells in a controlled environment with regular passage and monitoring of cell viability and morphology.

**Step 2: TPL2-MKK1/2-ERK1/2 Pathway Inhibition**

2.1. Prepare a stock solution of the TPL2-MKK1/2-ERK1/2 pathway inhibitor (e.g., TPL2 inhibitor, MKK1/2 inhibitor, or ERK1/2 inhibitor) in DMSO or an appropriate solvent.
2.2. Treat the B-cell lymphoma cells with a range of concentrations of the inhibitor (e.g., 0.1, 1, 10, and 50 μM) for 24, 48, and 72 hours.
2.3. Use a vehicle control (DMSO or solvent) as a negative control.

**Step 3: PI3K and Oncogenic Kinase Analysis**

3.1. Harvest the treated and untreated cells and lyse them in RIPA buffer supplemented with protease and phosphatase inhibitors.
3.2. Perform Western blotting using specific antibodies against PI3K, AKT, mTOR, JNK, and other oncogenic kinases.
3.3. Analyze the protein expression and phosphorylation levels using densitometry or image analysis software.

**Step 4: Cell Proliferation and Viability Assays**

4.1. Perform cell proliferation assays (e.g., MTT, BrdU, or EdU) according to the manufacturer's instructions.
4.2. Perform cell viability assays (e.g., Annexin V/PI staining) according to the manufacturer's instructions.
4.3. Analyze the data using statistical software to determine the IC50 values and cytostatic effect.

**Experiment 2: RNA Interference (RNAi) and CRISPR-Cas9 Gene Editing**

**Objective:** To validate the results obtained with pharmacological inhibitors using RNAi and CRISPR-Cas9 gene editing.

**Step 1: RNAi**

1.1. Design and synthesize siRNAs targeting TPL2, MKK1/2, or ERK1/2.
1.2. Transfect the siRNAs into B-cell lymphoma cells using a transfection reagent (e.g., Lipofectamine).
1.3. Incubate the cells for 24-48 hours to allow for gene knockdown.

**Step 2: CRISPR-Cas9 Gene Editing**

2.1. Design and synthesize guide RNAs targeting TPL2, MKK1/2, or ERK1/2.
2.2. Transfect the guide RNAs and Cas9 enzyme into B-cell lymphoma cells using a transfection reagent (e.g., Lipofectamine).
2.3. Incubate the cells for 24-48 hours to allow for gene knockout.

**Step 3: PI3K and Oncogenic Kinase Analysis**

3.1. Harvest the RNAi- or CRISPR-Cas9-treated cells and lyse them in RIPA buffer supplemented with protease and phosphatase inhibitors.
3.2. Perform Western blotting using specific antibodies against PI3K, AKT, mTOR, JNK, and other oncogenic kinases.
3.3. Analyze the protein expression and phosphorylation levels using densitometry or image analysis software.

**Experiment 3: Rescue Experiments**

**Objective:** To determine if the cytostatic effect can be rescued by overexpressing PI3K or other oncogenic kinases.

**Step 1: Plasmid Construction**

1.1. Clone the cDNA of PI3K or other oncogenic kinases into a mammalian expression vector (e.g., pCMV or pCDNA3.1).
1.2. Verify the sequence and expression of the construct using sequencing and Western blotting.

**Step 2: Transfection and Overexpression**

2.1. Transfect the expression plasmid into B-cell lymphoma cells using a transfection reagent (e.g., Lipofectamine).
2.2. Incubate the cells for 24-48 hours to allow for protein overexpression.

**Step 3: TPL2-MKK1/2-ERK1/2 Pathway Inhibition and PI3K Analysis**

3.1. Treat the overexpressing cells with a specific inhibitor of the TPL2-MKK1/2-ERK1/2 pathway.
3.2. Analyze the protein expression and phosphorylation levels of PI3K and other oncogenic kinases using Western blotting.
3.3. Perform cell proliferation and viability assays to assess the cytostatic effect.

**Experiment to Disprove the Hypothesis**

**Objective:** To design an experiment that, if successful, would disprove the hypothesis that inhibition of the TPL2-MKK1/2-ERK1/2 pathway leads to the downregulation of PI3K and other oncogenic kinases in B-cell lymphoma cells.

**Step 1: Constitutively Active PI3K Expression**

1.1. Clone the cDNA of a constitutively active form of PI3K into a mammalian expression vector (e.g., pCMV or pCDNA3.1).
1.2. Verify the sequence and expression of the construct using sequencing and Western blotting.

**Step 2: TPL2-MKK1/2-ERK1/2 Pathway Inhibition**

2.1. Treat the cells overexpressing constitutively active PI3K with a specific inhibitor of the TPL2-MKK1/2-ERK1/2 pathway.
2.2. Analyze the protein expression and phosphorylation levels of PI3K and other oncogenic kinases using Western blotting.

**Step 3: PI3K Activity Assay**

3.1. Measure PI3K activity using a biochemical assay (e.g., PI3K lipid kinase assay) or a cellular assay (e.g., AKT phosphorylation).
3.2. Analyze the data to determine if PI3K activity is still downregulated despite the constitutive activation.

**Step 4: Cell Proliferation and Viability Assays**

4.1. Perform cell proliferation and viability assays to assess the cytostatic effect of TPL2-MKK1/2-ERK1/2 pathway inhibition in the presence of constitutively active PI3K.
4.2. Analyze the data to determine if the cytostatic effect is maintained despite the constitutive activation of PI3K.

These detailed, step-by-step protocols should provide a clear guide for executing the experimental plan and testing the hypothesis.","```
   TPL2_Inhibitor  MKK1/2_Inhibitor  ERK1/2_Inhibitor  siRNA_TPL2  siRNA_MKK1/2  siRNA_ERK1/2  CRISPR_TPL2  CRISPR_MKK1/2  CRISPR_ERK1/2  PI3K_Overexpression  Outcome
0             0.1               0.0               0.0           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
1             1.0               0.0               0.0           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
2             0.0               1.0               0.0           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
3             0.0               0.0               1.0           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
4             0.1               0.1               0.0           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
5             0.1               0.0               0.1           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
6             0.0               0.1               0.1           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
7             0.0               0.0               0.0           1.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
8             0.0               0.0               0.0           0.0           1.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
9             0.0               0.0               0.0           0.0           0.0           1.0           0.0           0.0           0.0                  0.0  Downregulated
10            0.0               0.0               0.0           0.0           0.0           0.0           1.0           0.0           0.0                  0.0  Downregulated
11            0.0               0.0               0.0           0.0           0.0           0.0           0.0           1.0           0.0                  0.0  Downregulated
12            0.0               0.0               0.0           0.0           0.0           0.0           0.0           0.0           1.0                  0.0  Upregulated
13            0.1               0.1               0.1           0.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
14            0.1               0.1               0.0           1.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
15            0.1               0.0               0.1           1.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
16            0.0               0.1               0.1           1.0           0.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
17            0.0               0.0               0.0           1.0           1.0           0.0           0.0           0.0           0.0                  0.0  Downregulated
18            0.0               0.0               0.0           0.0           1.0           1.0           0.0           0.0           0.0                  0.0  Downregulated
19            0.0               0.0               0.0           0.0           0.0           0.0           1.0           1.0           0.0                  0.0  Downregulated
20            0.0               0.0               0.0           0.0           0.0           0.0           0.0           0.0           1.0                  1.0  Upregulated
21            0.1               0.1               0.1           0.0           0.0           0.0           0.0           0.0           0.0                  1.0  Upregulated
22            0.1               0.1               0.0           1.0           0.0           0.0           0.0           0.0           0.0                  1.0  Upregulated
23            0.1               0.0               0.1           1.0           0.0           0.0           0.0           0.0           0.0                  1.0  Upregulated
24            0.0               0.1               0.1           1.0           0.0           0.0           0.0           0.0           0.0                  1.0  Upregulated
```",0.07247618283415516
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7bb1dcd69bbeae8b733459801db1c7ee77f6089c.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3efc769486603f2f55b40a26bb44a0e7331b09eb.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4670dc5c9aac7c0d29fb32af1b632ad88cc15b6a.summary']","Does the integration of BAFF, TLR, and RGC-32 signals in atypical B cells promote the production of VH4-34 autoantibodies, contributing to the development of autoimmune responses in SLE patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** The integration of BAFF, TLR, and RGC-32 signals in atypical B cells promotes the production of VH4-34 autoantibodies, contributing to the development of autoimmune responses in SLE patients.

**Experimental Plan:**

**Objective:** To investigate whether the integration of BAFF, TLR, and RGC-32 signals in atypical B cells leads to the production of VH4-34 autoantibodies, contributing to autoimmune responses in SLE patients.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate peripheral blood mononuclear cells (PBMCs) from SLE patients and healthy controls using Ficoll-Paque density gradient centrifugation.
	* Enrich for atypical B cells (CD19+CD27-CD38-CD24-) using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS).
	* Culture atypical B cells in vitro with or without BAFF, TLR ligands (e.g., LPS), and RGC-32 overexpression or siRNA-mediated knockdown.
2. **Signal Integration Analysis:**
	* Use Western blotting or flow cytometry to assess the expression of BAFF, TLR, and RGC-32 in atypical B cells from SLE patients and healthy controls.
	* Investigate the activation of downstream signaling pathways (e.g., NF-κB, MAPK) using Western blotting or phospho-specific antibodies.
3. **VH4-34 Autoantibody Production:**
	* Measure VH4-34 autoantibody production in atypical B cells using ELISA or bead-based assays.
	* Analyze the effect of BAFF, TLR, and RGC-32 signaling on VH4-34 autoantibody production using statistical analysis (e.g., ANOVA, t-test).
4. **Autoimmune Response Assessment:**
	* Evaluate the presence of autoimmune responses in SLE patients using clinical markers (e.g., anti-dsDNA, anti-Smith antibodies) and correlate with VH4-34 autoantibody production.

**Experiment to Disprove the Hypothesis:**

**Objective:** To investigate whether the inhibition of BAFF, TLR, and RGC-32 signals in atypical B cells reduces VH4-34 autoantibody production and autoimmune responses in SLE patients.

**Experimental Design:**

1. **Inhibition of BAFF, TLR, and RGC-32 Signals:**
	* Use specific inhibitors (e.g., BAFF-R-Fc, TLR antagonists, RGC-32 siRNA) to block BAFF, TLR, and RGC-32 signaling in atypical B cells from SLE patients.
	* Culture atypical B cells with inhibitors and assess VH4-34 autoantibody production using ELISA or bead-based assays.
2. **Comparison with Control Conditions:**
	* Compare VH4-34 autoantibody production in inhibitor-treated atypical B cells with control conditions (e.g., vehicle-treated, untreated).
	* Analyze the effect of inhibitor treatment on VH4-34 autoantibody production using statistical analysis (e.g., ANOVA, t-test).

**Budget and Timeframe:**

* Estimated budget: $50,000 - $75,000
* Estimated timeframe: 6-12 months

**Rationale:**

This experimental plan is designed to test the hypothesis by investigating the integration of BAFF, TLR, and RGC-32 signals in atypical B cells and their role in VH4-34 autoantibody production and autoimmune responses in SLE patients. The experiment to disprove the hypothesis aims to inhibit BAFF, TLR, and RGC-32 signals and assess the effect on VH4-34 autoantibody production. By using existing scientific methods and equipment, this study can be completed within a reasonable timeframe and budget.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Culture**

**Objective:** Isolate peripheral blood mononuclear cells (PBMCs) from SLE patients and healthy controls, enrich for atypical B cells, and culture them in vitro with or without BAFF, TLR ligands, and RGC-32 overexpression or siRNA-mediated knockdown.

**Materials:**

* Ficoll-Paque density gradient medium
* Magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) equipment
* Anti-CD19, anti-CD27, anti-CD38, and anti-CD24 antibodies
* BAFF, TLR ligands (e.g., LPS), and RGC-32 overexpression or siRNA-mediated knockdown reagents
* Cell culture medium (e.g., RPMI 1640) with 10% FBS and antibiotics
* 96-well tissue culture plates

**Step-by-Step Protocol:**

1. Collect 10 mL of peripheral blood from SLE patients and healthy controls in EDTA-coated tubes.
2. Perform Ficoll-Paque density gradient centrifugation to isolate PBMCs.
3. Wash PBMCs with PBS and resuspend in 1 mL of PBS.
4. Add 10 μL of anti-CD19, anti-CD27, anti-CD38, and anti-CD24 antibodies to the PBMC suspension and incubate for 30 minutes at 4°C.
5. Perform MACS or FACS to enrich for atypical B cells (CD19+CD27-CD38-CD24-).
6. Resuspend enriched atypical B cells in cell culture medium and count using a hemocytometer.
7. Plate 1 x 10^5 atypical B cells per well in 96-well tissue culture plates.
8. Add BAFF, TLR ligands, and RGC-32 overexpression or siRNA-mediated knockdown reagents to the culture medium as desired.
9. Incubate at 37°C, 5% CO2 for 3-5 days.

**Protocol 2: Signal Integration Analysis**

**Objective:** Assess the expression of BAFF, TLR, and RGC-32 in atypical B cells from SLE patients and healthy controls using Western blotting or flow cytometry.

**Materials:**

* Western blotting equipment (e.g., gel electrophoresis, transfer apparatus)
* Flow cytometer
* Anti-BAFF, anti-TLR, and anti-RGC-32 antibodies
* Secondary antibodies (e.g., HRP-conjugated or fluorescently labeled)
* Western blotting or flow cytometry buffers

**Step-by-Step Protocol:**

1. Harvest atypical B cells from culture and wash with PBS.
2. Lyse cells in Western blotting lysis buffer or fix and permeabilize for flow cytometry.
3. Perform Western blotting or flow cytometry according to standard protocols.
4. Detect BAFF, TLR, and RGC-32 expression using primary and secondary antibodies.
5. Analyze Western blotting results using densitometry software or flow cytometry results using flow cytometry analysis software.

**Protocol 3: VH4-34 Autoantibody Production**

**Objective:** Measure VH4-34 autoantibody production in atypical B cells using ELISA or bead-based assays.

**Materials:**

* ELISA plates or bead-based assay equipment
* VH4-34 autoantibody detection reagents (e.g., anti-VH4-34 antibodies)
* Standards and controls (e.g., recombinant VH4-34 protein)
* ELISA or bead-based assay buffers

**Step-by-Step Protocol:**

1. Harvest atypical B cells from culture and wash with PBS.
2. Lyse cells in ELISA or bead-based assay lysis buffer.
3. Perform ELISA or bead-based assay according to standard protocols.
4. Detect VH4-34 autoantibody production using anti-VH4-34 antibodies.
5. Analyze results using ELISA or bead-based assay software.

**Protocol 4: Autoimmune Response Assessment**

**Objective:** Evaluate the presence of autoimmune responses in SLE patients using clinical markers and correlate with VH4-34 autoantibody production.

**Materials:**

* Clinical marker detection reagents (e.g., anti-dsDNA, anti-Smith antibodies)
* Patient serum samples
* ELISA or bead-based assay equipment

**Step-by-Step Protocol:**

1. Collect patient serum samples and store at -80°C.
2. Perform ELISA or bead-based assay to detect clinical markers (e.g., anti-dsDNA, anti-Smith antibodies).
3. Analyze results using ELISA or bead-based assay software.
4. Correlate clinical marker results with VH4-34 autoantibody production using statistical analysis software.

**Protocol 5: Inhibition of BAFF, TLR, and RGC-32 Signals**

**Objective:** Inhibit BAFF, TLR, and RGC-32 signals in atypical B cells from SLE patients using specific inhibitors.

**Materials:**

* BAFF-R-Fc, TLR antagonists, and RGC-32 siRNA reagents
* Atypical B cells from SLE patients
* Cell culture medium

**Step-by-Step Protocol:**

1. Plate 1 x 10^5 atypical B cells per well in 96-well tissue culture plates.
2. Add BAFF-R-Fc, TLR antagonists, and RGC-32 siRNA reagents to the culture medium as desired.
3. Incubate at 37°C, 5% CO2 for 3-5 days.
4. Harvest atypical B cells and assess VH4-34 autoantibody production using ELISA or bead-based assays.

**Protocol 6: Comparison with Control Conditions**

**Objective:** Compare VH4-34 autoantibody production in inhibitor-treated atypical B cells with control conditions.

**Materials:**

* VH4-34 autoantibody detection reagents (e.g., anti-VH4-34 antibodies)
* ELISA or bead-based assay equipment
* Standards and controls (e.g., recombinant VH4-34 protein)

**Step-by-Step Protocol:**

1. Perform ELISA or bead-based assay to detect VH4-34 autoantibody production in inhibitor-treated atypical B cells.
2. Compare results with control conditions (e.g., vehicle-treated, untreated).
3. Analyze results using statistical analysis software (e.g., ANOVA, t-test).","```
   Ficoll_Paque  MACS_FACS  Anti_CD19  Anti_CD27  Anti_CD38  Anti_CD24  BAFF  TLR_ligands  RGC_32  VH4_34_Autoantibody_Production
0           10.0       10.0       5.0       5.0       5.0       5.0   10.0         10.0     10.0                    200.0
1           12.0       12.0       6.0       6.0       6.0       6.0   12.0         12.0     12.0                    220.0
2           8.0        8.0       4.0       4.0       4.0       4.0    8.0          8.0      8.0                    180.0
3           11.0       11.0       5.5       5.5       5.5       5.5   11.0         11.0     11.0                    210.0
4           9.0        9.0       4.5       4.5       4.5       4.5    9.0          9.0      9.0                    190.0
5           13.0       13.0       6.5       6.5       6.5       6.5   13.0         13.0     13.0                    230.0
6           10.5       10.5       5.25      5.25      5.25      5.25   10.5         10.5     10.5                    205.0
7           11.5       11.5       5.75      5.75      5.75      5.75   11.5         11.5     11.5                    215.0
8           9.5        9.5       4.75      4.75      4.75      4.75    9.5          9.5      9.5                    195.0
9           12.5       12.5       6.25      6.25      6.25      6.25   12.5         12.5     12.5                    225.0
10          10.0       10.0       5.0       5.0       5.0       5.0   10.0         10.0     10.0                    200.0
11          11.0       11.0       5.5       5.5       5.5       5.5   11.0         11.0     11.0                    210.0
12          9.0        9.0       4.5       4.5       4.5       4.5    9.0          9.0      9.0                    190.0
13          13.0       13.0       6.5       6.5       6.5       6.5   13.0         13.0     13.0                    230.0
14          10.5       10.5       5.25      5.25      5.25      5.25   10.5         10.5     10.5                    205.0
15          11.5       11.5       5.75      5.75      5.75      5.75   11.5         11.5     11.5                    215.0
16          9.5        9.5       4.75      4.75      4.75      4.75    9.5          9.5      9.5                    195.0
17          12.5       12.5       6.25      6.25      6.25      6.25   12.5         12.5     12.5                    225.0
18          10.0       10.0       5.0       5.0       5.0       5.0   10.0         10.0     10.0                    200.0
19          11.0       11.0       5.5       5.5       5.5       5.5   11.0         11.0     11.0                    210.0
20          9.0        9.0       4.5       4.5       4.5       4.5    9.0          9.0      9.0                    190.0
21          13.0       13.0       6.5       6.5       6.5       6.5   13.0         13.0     13.0                    230.0
22          10.5       10.5       5.25      5.25      5.25      5.25   10.5         10.5     10.5                    205.0
23          11.5       11.5       5.75      5.75      5.75      5.75   11.5         11.5     11.5                    215.0
24          9.5        9.5       4.75      4.75      4.75      4.75    9.5          9.5      9.5                    195.0
```",1.0000000000000002
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7f0e8216bcdf654e8bc5680393ddd93dab2599d9.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/113f32b0b3f8a00009532c4d5c17fc6d20a5615d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6b7a243d25122b087c4ecd55b618f4ca84057ad0.summary']",Does the interaction between APOL1 risk variants and interferon signature in bone marrow mesenchymal stem cells contribute to the development of renal damage in systemic lupus erythematosus patients?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test the hypothesis and potentially disprove it.

**Hypothesis:** Does the interaction between APOL1 risk variants and interferon signature in bone marrow mesenchymal stem cells contribute to the development of renal damage in systemic lupus erythematosus patients?

**Experimental Design:**

**Objective:** To investigate the role of APOL1 risk variants and interferon signature in bone marrow mesenchymal stem cells (BMSCs) in the development of renal damage in systemic lupus erythematosus (SLE) patients.

**Study Design:** This study will consist of three arms:

1. SLE patients with APOL1 risk variants (APOL1+)
2. SLE patients without APOL1 risk variants (APOL1-)
3. Healthy controls

**Sample Collection:**

* Bone marrow aspirates will be collected from SLE patients and healthy controls.
* BMSCs will be isolated and cultured from the bone marrow aspirates.

**Experimental Approach:**

1. **Interferon Signature Analysis:** RNA sequencing will be performed on BMSCs from all three groups to analyze the interferon signature. The expression of interferon-induced genes will be compared between the three groups.
2. **APOL1 Risk Variant Analysis:** Genotyping will be performed to identify APOL1 risk variants in SLE patients. The frequency of APOL1 risk variants will be compared between SLE patients with and without renal damage.
3. **Co-culture Experiment:** BMSCs from APOL1+ and APOL1- SLE patients will be co-cultured with healthy kidney cells to assess the effect of APOL1 risk variants on kidney cell damage. The co-culture will be performed in the presence and absence of interferon-β to evaluate the role of interferon signature in kidney cell damage.
4. **Renal Damage Assessment:** Urine samples will be collected from SLE patients and healthy controls to assess renal damage using urinary biomarkers such as protein-creatinine ratio and kidney injury molecule-1 (KIM-1).

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ An increased interferon signature in BMSCs from APOL1+ SLE patients compared to APOL1- SLE patients and healthy controls.
	+ An increased frequency of APOL1 risk variants in SLE patients with renal damage compared to those without renal damage.
	+ Increased kidney cell damage in co-culture experiments with APOL1+ BMSCs compared to APOL1- BMSCs, which is rescued by blocking interferon-β.
	+ A correlation between interferon signature in BMSCs and renal damage in SLE patients.
* If the hypothesis is false, we expect to see no significant differences in interferon signature, APOL1 risk variant frequency, or kidney cell damage between the three groups.

**Equipment and Resources:**

* RNA sequencing platform
* Genotyping platform
* Cell culture facilities
* Co-culture system
* Urine biomarker analysis equipment (e.g., ELISA, Western blot)
* Statistical analysis software

**Timeline:**

* Sample collection and processing: 6 months
* RNA sequencing and genotyping: 3 months
* Co-culture experiment: 3 months
* Urine biomarker analysis: 2 months
* Data analysis and manuscript preparation: 6 months

**Budget:**

* Sample collection and processing: $100,000
* RNA sequencing and genotyping: $150,000
* Co-culture experiment: $75,000
* Urine biomarker analysis: $30,000
* Data analysis and manuscript preparation: $50,000
* Total budget: $405,000

This experiment is designed to test the hypothesis and provide insights into the role of APOL1 risk variants and interferon signature in BMSCs in the development of renal damage in SLE patients.",85,"Here are the detailed, step-by-step protocols for each experiment:

**Protocol 1: Sample Collection and Processing**

1.1. **Bone Marrow Aspirate Collection**

* Obtain informed consent from SLE patients and healthy controls.
* Perform bone marrow aspiration from the posterior iliac crest or sternum using a sterile needle and syringe.
* Collect 10-20 mL of bone marrow aspirate into a heparinized tube.
* Label the tube with the patient's ID, date, and time of collection.

1.2. **BMSC Isolation and Culture**

* Transport the bone marrow aspirate to the laboratory within 2 hours of collection.
* Add 10 mL of phosphate-buffered saline (PBS) to the aspirate and mix gently.
* Centrifuge the mixture at 400 x g for 10 minutes to separate the cells.
* Discard the supernatant and resuspend the cell pellet in 10 mL of PBS.
* Add 10 mL of complete culture medium (e.g., DMEM with 10% FBS, 1% penicillin-streptomycin) to the cell suspension.
* Seed the cells into a 75-cm² tissue culture flask and incubate at 37°C, 5% CO₂.
* Change the medium every 3-4 days and passage the cells when they reach 80-90% confluence.

**Protocol 2: Interferon Signature Analysis**

2.1. **RNA Isolation**

* Harvest BMSCs from the culture flask and wash them with PBS.
* Add 1 mL of TRIzol reagent to the cell pellet and mix well.
* Incubate the mixture at room temperature for 5 minutes.
* Add 0.2 mL of chloroform and mix well.
* Centrifuge the mixture at 12,000 x g for 15 minutes at 4°C.
* Transfer the upper aqueous phase to a new tube and add 0.5 mL of isopropanol.
* Incubate the mixture at room temperature for 10 minutes.
* Centrifuge the mixture at 12,000 x g for 10 minutes at 4°C.
* Wash the RNA pellet with 75% ethanol and air-dry.

2.2. **RNA Sequencing**

* Prepare the RNA library using a commercial RNA sequencing kit (e.g., Illumina TruSeq).
* Perform RNA sequencing on the prepared library using an RNA sequencing platform (e.g., Illumina HiSeq).
* Generate FASTQ files from the sequencing data.

2.3. **Data Analysis**

* Use a bioinformatics pipeline (e.g., STAR, DESeq2) to align the FASTQ files to a reference genome (e.g., GRCh38).
* Identify differentially expressed genes between the three groups using a statistical threshold (e.g., p < 0.05, fold change > 2).
* Perform pathway analysis using a software tool (e.g., Ingenuity Pathway Analysis) to identify enriched pathways related to interferon signature.

**Protocol 3: APOL1 Risk Variant Analysis**

3.1. **Genotyping**

* Extract genomic DNA from BMSCs using a commercial DNA extraction kit (e.g., Qiagen DNeasy).
* Perform genotyping using a commercial genotyping platform (e.g., Illumina Infinium).
* Identify APOL1 risk variants using a software tool (e.g., GenomeStudio).

3.2. **Frequency Analysis**

* Calculate the frequency of APOL1 risk variants in SLE patients with and without renal damage.
* Compare the frequency of APOL1 risk variants between the two groups using a statistical test (e.g., Fisher's exact test).

**Protocol 4: Co-culture Experiment**

4.1. **Cell Preparation**

* Harvest BMSCs from the culture flask and wash them with PBS.
* Count the cells using a hemocytometer and adjust the cell density to 1 x 10⁵ cells/mL.
* Prepare healthy kidney cells (e.g., HK-2 cells) according to the manufacturer's instructions.

4.2. **Co-culture**

* Add 1 mL of BMSCs to a 24-well plate and incubate at 37°C, 5% CO₂ for 24 hours.
* Add 1 mL of healthy kidney cells to the well and incubate for an additional 24 hours.
* Treat the co-culture with 10 ng/mL of interferon-β or vehicle control for 24 hours.

4.3. **Cell Damage Assessment**

* Collect the co-culture supernatant and measure the levels of lactate dehydrogenase (LDH) using a commercial kit (e.g., Promega CytoTox 96).
* Calculate the percentage of cell damage using the following formula: (LDH release in treated sample - LDH release in control sample) / (LDH release in maximum release sample - LDH release in control sample) x 100.

**Protocol 5: Renal Damage Assessment**

5.1. **Urine Collection**

* Collect urine samples from SLE patients and healthy controls.
* Label the samples with the patient's ID, date, and time of collection.

5.2. **Urine Biomarker Analysis**

* Measure the levels of protein-creatinine ratio and KIM-1 using commercial ELISA kits (e.g., R&D Systems).
* Calculate the concentration of each biomarker using a standard curve.

5.3. **Data Analysis**

* Compare the levels of urinary biomarkers between SLE patients with and without renal damage.
* Correlate the levels of urinary biomarkers with the interferon signature in BMSCs using a statistical test (e.g., Spearman's rank correlation).

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity in the results.","```
   Bone_Marrow_Aspirate_Volume  PBS_Volume  DMEM_Volume  FBS_Volume  Penicillin_Streptomycin_Volume  TRIzol_Reagent_Volume  Chloroform_Volume  Isopropanol_Volume  Interferon_Beta_Concentration  APOL1_Risk_Variant_Frequency  Co_Culture_Cell_Density  LDH_Release  Protein_Creatinine_Ratio  KIM_1_Concentration  Interferon_Signature  Renal_Damage
0                    15.0         10.0         10.0         1.0                    0.1                    1.0             0.2             0.5                    5.0                    0.3                    1.2e+05         20.0             100.0             5.0             2.0             1
1                    12.0         12.0         12.0         1.2                    0.2                    1.2             0.3             0.6                    7.0                    0.4                    1.5e+05         25.0             120.0             6.0             3.0             1
2                    18.0         8.0         8.0         0.8                    0.08                   0.8             0.1             0.4                    3.0                    0.2                    1.0e+05         15.0              90.0             4.0             1.0             0
3                    10.0         14.0         14.0         1.4                    0.3                    1.4             0.4             0.7                    9.0                    0.5                    1.8e+05         30.0             140.0             7.0             4.0             1
4                    16.0         9.0         9.0         0.9                    0.09                   0.9             0.2             0.5                    4.0                    0.3                    1.3e+05         20.0             110.0             5.0             2.0             1
5                    11.0         13.0         13.0         1.3                    0.2                    1.3             0.3             0.6                    8.0                    0.4                    1.6e+05         25.0             130.0             6.0             3.0             1
6                    17.0         7.0         7.0         0.7                    0.07                   0.7             0.1             0.3                    2.0                    0.2                    0.9e+05         10.0              80.0             3.0             1.0             0
7                    14.0         11.0         11.0         1.1                    0.1                    1.1             0.2             0.5                    6.0                    0.3                    1.4e+05         22.0             120.0             5.0             2.0             1
8                    13.0         10.0         10.0         1.0                    0.1                    1.0             0.2             0.5                    5.0                    0.3                    1.2e+05         20.0             110.0             5.0             2.0             1
9                    19.0         6.0         6.0         0.6                    0.06                   0.6             0.1             0.3                    1.0                    0.2                    0.8e+05         12.0              90.0             4.0             1.0             0
10                   12.0         12.0         12.0         1.2                    0.2                    1.2             0.3             0.6                    7.0                    0.4                    1.5e+05         25.0             130.0             6.0             3.0             1
11                   15.0         9.0         9.0         0.9                    0.09                   0.9             0.2             0.5                    4.0                    0.3                    1.3e+05         20.0             110.0             5.0             2.0             1
12                   11.0         13.0         13.0         1.3                    0.2                    1.3             0.3             0.6                    8.0                    0.4                    1.6e+05         25.0             140.0             7.0             4.0             1
13                   16.0         8.0         8.0         0.8                    0.08                   0.8             0.1             0.4                    3.0                    0.2                    1.0e+05         15.0              90.0             4.0             1.0             0
14                   14.0         10.0         10.0         1.0                    0.1                    1.0             0.2             0.5                    5.0                    0.3                    1.2e+05         20.0             110.0             5.0             2.0             1
15                   17.0         7.0         7.0         0.7                    0.07                   0.7             0.1             0.3                    2.0                    0.2                    0.9e+05         10.0              80.0             3.0             1.0             0
16                   13.0         11.0         11.0         1.1                    0.1                    1.1             0.2             0.5                    6.0                    0.3                    1.4e+05         22.0             120.0             5.0             2.0             1
17                   19.0         6.0         6.0         0.6                    0.06                   0.6             0.1             0.3                    1.0                    0.2                    0.8e+05         12.0              90.0             4.0             1.0             0
18                   12.0         12.0         12.0         1.2                    0.2                    1.2             0.3             0.6                    7.0                    0.4                    1.5e+05         25.0             130.0             6.0             3.0             1
19                   15.0         9.0         9.0         0.9                    0.09                   0.9             0.2             0.5                    4.0                    0.3                    1.3e+05         20.0             110.0             5.0             2.0             1
20                   11.0         13.0         13.0         1.3                    0.2                    1.3             0.3             0.6                    8.0                    0.4                    1.6e+05         25.0             140.0             7.0             4.0             1
21                   16.0         8.0         8.0         0.8                    0.08                   0.8             0.1             0.4                    3.0                    0.2                    1.0e+05         15.0              90.0             4.0             1.0             0
22                   14.0         10.0         10.0         1.0                    0.1                    1.0             0.2             0.5                    5.0                    0.3                    1.2e+05         20.0             110.0             5.0             2.0             1
23                   17.0         7.0         7.0         0.7                    0.07                   0.7             0.1             0.3                    2.0                    0.2                    0.9e+05         10.0              80.0             3.0             1.0             0
24                   13.0         11.0         11.0         1.1                    0.1                    1.1             0.2             0.5                    6.0                    0.3                    1.4e+05         22.0             120.0             5.0             2.0             1
```",0.6944375878917852
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/034ad441e2ba6d35548285ebac28d052e9843c61.summary'],"Does the interaction between CD20 and cytoskeletal elements regulate the spatial organization of lipid rafts on the plasma membrane of resting human B cells, thereby influencing BCR signaling?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis:

**Experiment: ""Disrupting CD20-Cytoskeletal Element Interactions to Investigate Lipid Raft Organization and BCR Signaling""**

**Objective:** To investigate whether disrupting the interaction between CD20 and cytoskeletal elements affects the spatial organization of lipid rafts on the plasma membrane of resting human B cells, thereby influencing BCR signaling.

**Experimental Design:**

1. **Cell Preparation:**
	* Obtain human B cells from healthy donors or use a B cell line (e.g., Ramos).
	* Use CRISPR/Cas9 to generate CD20-deficient B cells (CD20-KO) and control cells (WT).
2. **Cytoskeletal Element Disruption:**
	* Treat CD20-KO and WT cells with a cytoskeletal element disruptor (e.g., latrunculin A, which disrupts actin filaments) for 30 minutes to 1 hour.
	* Use a control treatment (e.g., DMSO) for comparison.
3. **Lipid Raft Organization Analysis:**
	* Use super-resolution microscopy (e.g., STORM or STED) to visualize the organization of lipid rafts on the plasma membrane of treated and control cells.
	* Label lipid rafts with a fluorescent marker (e.g., cholera toxin subunit B conjugated to Alexa Fluor 488).
	* Analyze the spatial organization of lipid rafts using image analysis software (e.g., ImageJ or Ilastik).
4. **BCR Signaling Analysis:**
	* Stimulate B cells with anti-IgM antibodies to activate BCR signaling.
	* Measure BCR signaling using a phospho-specific antibody against a downstream signaling molecule (e.g., phospho-Syk or phospho-ERK).
	* Compare BCR signaling between CD20-KO cells with disrupted cytoskeletal elements and control cells.
5. **Co-Immunoprecipitation Assay:**
	* Perform co-immunoprecipitation assays to investigate the interaction between CD20 and cytoskeletal elements in WT and CD20-KO cells.
	* Use antibodies against CD20 and cytoskeletal elements (e.g., actin or tubulin) for immunoprecipitation.

**Expected Outcomes:**

* If the hypothesis is true, disrupting the interaction between CD20 and cytoskeletal elements should lead to:
	+ Altered lipid raft organization on the plasma membrane of CD20-KO cells.
	+ Enhanced BCR signaling in CD20-KO cells with disrupted cytoskeletal elements.
	+ Reduced interaction between CD20 and cytoskeletal elements in CD20-KO cells.
* If the hypothesis is false, disrupting the interaction between CD20 and cytoskeletal elements should not affect lipid raft organization or BCR signaling.

**Time and Resource Requirements:**

* Cell preparation and CRISPR/Cas9 editing: 2-3 weeks
* Cytoskeletal element disruption and lipid raft organization analysis: 2-3 weeks
* BCR signaling analysis: 1-2 weeks
* Co-immunoprecipitation assay: 1-2 weeks
* Data analysis and interpretation: 2-3 weeks

**Budget:**

* CRISPR/Cas9 system: $5,000 - $10,000
* Super-resolution microscope: $10,000 - $20,000 (depending on the type and availability)
* Fluorescent lipids/cytoskeletal elements: $1,000 - $2,000
* Co-immunoprecipitation kit: $500 - $1,000
* Reagents and consumables: $5,000 - $10,000
* Total budget: $21,500 - $43,000

This experiment is designed to test the hypothesis in a controlled and rigorous manner, using a combination of biochemical and imaging techniques. By disrupting the interaction between CD20 and cytoskeletal elements, we can investigate the effects on lipid raft organization and BCR signaling, ultimately determining whether the hypothesis is supported or disproven.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disrupting CD20-Cytoskeletal Element Interactions to Investigate Lipid Raft Organization and BCR Signaling"":

**Protocol 1: Cell Preparation**

1.1. Obtain human B cells from healthy donors or use a B cell line (e.g., Ramos).

* Step 1.1.1: Collect blood samples from healthy donors or obtain Ramos cells from a cell bank.
* Step 1.1.2: Isolate B cells using density gradient centrifugation (e.g., Ficoll-Paque) or magnetic bead separation (e.g., CD20 MicroBeads).
* Step 1.1.3: Wash cells with phosphate-buffered saline (PBS) and resuspend in complete RPMI 1640 medium (supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% L-glutamine).

1.2. Use CRISPR/Cas9 to generate CD20-deficient B cells (CD20-KO) and control cells (WT).

* Step 1.2.1: Design and synthesize guide RNAs (gRNAs) targeting the CD20 gene.
* Step 1.2.2: Prepare CRISPR/Cas9 ribonucleoprotein (RNP) complexes by mixing gRNAs with Cas9 enzyme.
* Step 1.2.3: Electroporate RNP complexes into B cells using a nucleofector device (e.g., Lonza 4D-Nucleofector).
* Step 1.2.4: Select and expand CD20-KO cells using fluorescence-activated cell sorting (FACS) and puromycin selection.
* Step 1.2.5: Verify CD20 knockout using Western blotting or flow cytometry.

**Protocol 2: Cytoskeletal Element Disruption**

2.1. Treat CD20-KO and WT cells with a cytoskeletal element disruptor (e.g., latrunculin A) for 30 minutes to 1 hour.

* Step 2.1.1: Prepare a stock solution of latrunculin A (e.g., 10 mM in DMSO).
* Step 2.1.2: Add latrunculin A to CD20-KO and WT cells at a final concentration of 1-5 μM.
* Step 2.1.3: Incubate cells at 37°C, 5% CO2 for 30 minutes to 1 hour.
* Step 2.1.4: Use a control treatment (e.g., DMSO) for comparison.

**Protocol 3: Lipid Raft Organization Analysis**

3.1. Label lipid rafts with a fluorescent marker (e.g., cholera toxin subunit B conjugated to Alexa Fluor 488).

* Step 3.1.1: Prepare a stock solution of cholera toxin subunit B-Alexa Fluor 488 (e.g., 1 mg/mL in PBS).
* Step 3.1.2: Add cholera toxin subunit B-Alexa Fluor 488 to cells at a final concentration of 1-5 μg/mL.
* Step 3.1.3: Incubate cells at 4°C for 30 minutes to 1 hour.

3.2. Use super-resolution microscopy (e.g., STORM or STED) to visualize the organization of lipid rafts on the plasma membrane.

* Step 3.2.1: Fix cells with 4% paraformaldehyde (PFA) for 15 minutes.
* Step 3.2.2: Permeabilize cells with 0.1% Triton X-100 for 10 minutes.
* Step 3.2.3: Mount cells on glass coverslips or slides.
* Step 3.2.4: Image cells using a super-resolution microscope (e.g., Nikon N-STORM or Leica STED).

3.3. Analyze the spatial organization of lipid rafts using image analysis software (e.g., ImageJ or Ilastik).

* Step 3.3.1: Acquire images of lipid raft organization using the super-resolution microscope.
* Step 3.3.2: Import images into image analysis software.
* Step 3.3.3: Apply thresholding and segmentation algorithms to identify lipid rafts.
* Step 3.3.4: Measure lipid raft size, shape, and distribution using software plugins (e.g., ImageJ's ""Analyze Particles"" or Ilastik's ""Object Detection"").

**Protocol 4: BCR Signaling Analysis**

4.1. Stimulate B cells with anti-IgM antibodies to activate BCR signaling.

* Step 4.1.1: Prepare a stock solution of anti-IgM antibodies (e.g., 1 mg/mL in PBS).
* Step 4.1.2: Add anti-IgM antibodies to cells at a final concentration of 1-10 μg/mL.
* Step 4.1.3: Incubate cells at 37°C, 5% CO2 for 10-30 minutes.

4.2. Measure BCR signaling using a phospho-specific antibody against a downstream signaling molecule (e.g., phospho-Syk or phospho-ERK).

* Step 4.2.1: Prepare a stock solution of phospho-specific antibody (e.g., 1 mg/mL in PBS).
* Step 4.2.2: Fix cells with 4% PFA for 15 minutes.
* Step 4.2.3: Permeabilize cells with 0.1% Triton X-100 for 10 minutes.
* Step 4.2.4: Stain cells with phospho-specific antibody and a secondary antibody conjugated to a fluorophore (e.g., Alexa Fluor 488).
* Step 4.2.5: Image cells using a confocal microscope (e.g., Zeiss LSM 880).

**Protocol 5: Co-Immunoprecipitation Assay**

5.1. Perform co-immunoprecipitation assays to investigate the interaction between CD20 and cytoskeletal elements in WT and CD20-KO cells.

* Step 5.1.1: Prepare cell lysates using a lysis buffer (e.g., RIPA buffer).
* Step 5.1.2: Immunoprecipitate CD20 using a CD20-specific antibody and protein A/G beads.
* Step 5.1.3: Wash immunoprecipitates with lysis buffer and elute with SDS-PAGE sample buffer.
* Step 5.1.4: Analyze immunoprecipitates using Western blotting with antibodies against CD20, actin, and tubulin.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   CD20_KO  Latrunculin_A  Cholera_Toxin  Anti_IgM  Outcome
0      True           1.0          2.0      5.0  Disrupted
1      True           2.0          1.0      2.0  Disrupted
2      True           3.0          3.0      1.0  Disrupted
3      True           4.0          4.0      4.0  Disrupted
4      True           5.0          5.0      3.0  Disrupted
5     False           1.0          1.0      1.0  Normal
6     False           2.0          2.0      2.0  Normal
7     False           3.0          3.0      3.0  Normal
8     False           4.0          4.0      4.0  Normal
9     False           5.0          5.0      5.0  Normal
10     True           1.0          3.0      2.0  Disrupted
11     True           2.0          4.0      1.0  Disrupted
12     True           3.0          5.0      4.0  Disrupted
13     True           4.0          2.0      3.0  Disrupted
14     True           5.0          1.0      5.0  Disrupted
15     False           1.0          2.0      4.0  Normal
16     False           2.0          3.0      5.0  Normal
17     False           3.0          4.0      1.0  Normal
18     False           4.0          5.0      2.0  Normal
19     False           5.0          1.0      3.0  Normal
20     True           2.0          1.0      4.0  Disrupted
21     True           3.0          2.0      5.0  Disrupted
22     True           4.0          3.0      1.0  Disrupted
23     True           5.0          4.0      2.0  Disrupted
24     False           1.0          5.0      3.0  Normal
```",0.24999999999999994
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/091852331a1510b8dd0a6dde6ddd84886e545267.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3bc96c4fc22b2184a81b956cabe6af4085defab1.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4d8f417daabce66866691a952846a1aca2cadfe0.summary']","Does the interaction between Par-4 and hexokinases regulate B-cell receptor signaling and glucose metabolism to modulate the TLR9-dependent checkpoint in B cells, thereby influencing the development of autoimmune diseases?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the interaction between Par-4 and hexokinases regulates B-cell receptor signaling and glucose metabolism to modulate the TLR9-dependent checkpoint in B cells, thereby influencing the development of autoimmune diseases, I propose the following experimental plan:

**Experiment:** ""Disrupting Par-4 and Hexokinase Interaction in B Cells: Impact on TLR9-dependent Checkpoint and Autoimmune Disease Development""

**Objective:** To investigate whether disrupting the interaction between Par-4 and hexokinases in B cells affects the TLR9-dependent checkpoint and autoimmune disease development.

**Equipment:**

* B cell lines (e.g., CLL cells)
* Par-4 and hexokinase antibodies
* Co-immunoprecipitation kit
* Western blotting equipment
* Flow cytometer
* Glucose metabolism assay kit
* TLR9 agonists (e.g., CpG oligonucleotides)
* B cell receptor ligands (e.g., anti-IgM)
* BLyS
* Autoimmune disease-inducing antigens (e.g., chromatin immune complexes)
* TLR9-deficient mice (optional)

**Steps:**

1. **Co-immunoprecipitation and Western Blotting:**
	* Co-transfect B cells with Par-4 and hexokinase expression vectors.
	* Perform co-immunoprecipitation to detect the interaction between Par-4 and hexokinases.
	* Analyze the effect of Par-4 overexpression on hexokinase activity using Western blotting.
2. **TLR9-dependent Checkpoint Analysis:**
	* Stimulate B cells with TLR9 agonists linked to B cell receptor ligands.
	* Measure B cell activation and apoptosis rates using flow cytometry.
	* Analyze the effect of Par-4 overexpression on the TLR9-dependent checkpoint.
3. **Glucose Metabolism Analysis:**
	* Measure glucose metabolism in B cells using a glucose metabolism assay kit.
	* Analyze the effect of Par-4 overexpression on glucose metabolism.
4. **Autoimmune Disease Development:**
	* Immunize mice with autoimmune disease-inducing antigens.
	* Measure B cell activation and antibody production using flow cytometry and ELISA.
	* Analyze the effect of Par-4 overexpression on autoimmune disease development.
5. **Disrupting Par-4 and Hexokinase Interaction:**
	* Use siRNA or CRISPR-Cas9 to knockdown Par-4 or hexokinase expression in B cells.
	* Repeat steps 1-4 to analyze the effect of disrupting the Par-4 and hexokinase interaction on the TLR9-dependent checkpoint and autoimmune disease development.

**Control Experiments:**

* Use TLR9-deficient mice as controls to validate the role of TLR9 in the checkpoint.
* Use B cells from healthy donors as controls to compare with CLL cells.

**Budget and Timeframe:**

* The experiment can be completed within 6-12 months with a budget of approximately $200,000.
* The budget will cover the cost of reagents, equipment, and personnel.

**Rationale:**

This experiment is designed to test the hypothesis by disrupting the interaction between Par-4 and hexokinases in B cells and analyzing the effect on the TLR9-dependent checkpoint and autoimmune disease development. By using a combination of biochemical, cellular, and in vivo approaches, we can gain a comprehensive understanding of the role of Par-4 and hexokinases in regulating the TLR9-dependent checkpoint and autoimmune disease development.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disrupting Par-4 and Hexokinase Interaction in B Cells: Impact on TLR9-dependent Checkpoint and Autoimmune Disease Development"":

**Protocol 1: Co-immunoprecipitation and Western Blotting**

**Step 1.1: Cell Culture and Transfection**

* Obtain B cell lines (e.g., CLL cells) and culture them in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
* Co-transfect B cells with Par-4 and hexokinase expression vectors using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
* Incubate the cells for 24-48 hours to allow for protein expression.

**Step 1.2: Co-immunoprecipitation**

* Lyse the transfected B cells in a lysis buffer (e.g., RIPA buffer) containing protease inhibitors (e.g., PMSF, aprotinin).
* Incubate the lysate with Par-4 and hexokinase antibodies (1:100 dilution) for 2 hours at 4°C.
* Add protein A/G beads to the lysate and incubate for an additional 2 hours at 4°C.
* Wash the beads three times with lysis buffer and elute the immunoprecipitated proteins with a sample buffer (e.g., Laemmli buffer).

**Step 1.3: Western Blotting**

* Separate the immunoprecipitated proteins by SDS-PAGE (10% gel) and transfer them to a PVDF membrane.
* Block the membrane with 5% milk in TBST for 1 hour at room temperature.
* Incubate the membrane with Par-4 and hexokinase antibodies (1:1000 dilution) overnight at 4°C.
* Detect the proteins using an ECL detection system and quantify the band intensities using image analysis software (e.g., ImageJ).

**Protocol 2: TLR9-dependent Checkpoint Analysis**

**Step 2.1: Cell Stimulation**

* Stimulate B cells with TLR9 agonists (e.g., CpG oligonucleotides, 1 μM) linked to B cell receptor ligands (e.g., anti-IgM, 10 μg/mL) for 24 hours at 37°C, 5% CO2.

**Step 2.2: Flow Cytometry**

* Stain the stimulated B cells with fluorescently labeled antibodies against CD69, CD86, and Annexin V (1:100 dilution) for 30 minutes at 4°C.
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and quantify the percentage of activated (CD69+, CD86+) and apoptotic (Annexin V+) cells.

**Protocol 3: Glucose Metabolism Analysis**

**Step 3.1: Glucose Metabolism Assay**

* Measure glucose metabolism in B cells using a glucose metabolism assay kit (e.g., Glucose Uptake Assay Kit) according to the manufacturer's instructions.
* Incubate the cells with a glucose analog (e.g., 2-NBDG) for 30 minutes at 37°C, 5% CO2.
* Measure the fluorescence intensity using a plate reader (e.g., Tecan Infinite M200) and quantify the glucose uptake rate.

**Protocol 4: Autoimmune Disease Development**

**Step 4.1: Immunization**

* Immunize mice with autoimmune disease-inducing antigens (e.g., chromatin immune complexes, 100 μg/mouse) via intraperitoneal injection.
* Monitor the mice for signs of autoimmune disease (e.g., proteinuria, arthritis) over a period of 6-12 weeks.

**Step 4.2: B Cell Activation and Antibody Production**

* Isolate splenocytes from immunized mice and stimulate them with TLR9 agonists (e.g., CpG oligonucleotides, 1 μM) for 24 hours at 37°C, 5% CO2.
* Measure B cell activation and antibody production using flow cytometry and ELISA, respectively.

**Protocol 5: Disrupting Par-4 and Hexokinase Interaction**

**Step 5.1: siRNA or CRISPR-Cas9 Mediated Knockdown**

* Transfect B cells with siRNA or CRISPR-Cas9 constructs targeting Par-4 or hexokinase using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.
* Incubate the cells for 24-48 hours to allow for protein knockdown.

**Step 5.2: Repeat Protocols 1-4**

* Repeat protocols 1-4 using the Par-4 or hexokinase knockdown B cells to analyze the effect of disrupting the Par-4 and hexokinase interaction on the TLR9-dependent checkpoint and autoimmune disease development.

**Control Experiments**

* Use TLR9-deficient mice as controls to validate the role of TLR9 in the checkpoint.
* Use B cells from healthy donors as controls to compare with CLL cells.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific requirements of the experiment and the equipment available. It is essential to follow proper laboratory protocols, including safety guidelines and quality control measures, to ensure the accuracy and reproducibility of the results.","```
   Par-4 Vector (μg)  Hexokinase Vector (μg)  TLR9 Agonist (μM)  Glucose Analog (μM)  siRNA/CRISPR  Outcome
0                1.0                 1.0             0.5             50.0         Par-4  Inhibited
1                2.0                 1.0             1.0             50.0         Par-4  Inhibited
2                1.0                 2.0             0.5             50.0         Par-4  Inhibited
3                1.0                 1.0             1.5             50.0         Par-4  Inhibited
4                1.5                 1.0             0.5             50.0         Par-4  Inhibited
5                1.0                 1.5             0.5             50.0         Par-4  Inhibited
6                1.0                 1.0             0.5             25.0         Par-4  Inhibited
7                1.0                 1.0             0.5             75.0         Par-4  Inhibited
8                1.0                 1.0             0.5             50.0      Hexokinase  Enhanced
9                1.0                 1.0             1.0             50.0      Hexokinase  Enhanced
10               2.0                 1.0             0.5             50.0      Hexokinase  Enhanced
11               1.0                 2.0             0.5             50.0      Hexokinase  Enhanced
12               1.0                 1.0             1.5             50.0      Hexokinase  Enhanced
13               1.5                 1.0             0.5             50.0      Hexokinase  Enhanced
14               1.0                 1.5             0.5             50.0      Hexokinase  Enhanced
15               1.0                 1.0             0.5             25.0      Hexokinase  Enhanced
16               1.0                 1.0             0.5             75.0      Hexokinase  Enhanced
17               1.0                 1.0             0.5             50.0  Control (TLR9-)  No Effect
18               1.0                 1.0             0.5             50.0  Control (Healthy)  No Effect
19               1.0                 1.0             0.5             50.0         Par-4  Inhibited
20               1.0                 1.0             1.0             50.0         Par-4  Inhibited
21               2.0                 1.0             0.5             50.0         Par-4  Inhibited
22               1.0                 2.0             0.5             50.0         Par-4  Inhibited
23               1.0                 1.0             1.5             50.0         Par-4  Inhibited
24               1.5                 1.0             0.5             50.0         Par-4  Inhibited
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/20cac268ea8bb2e827028aa38a2fcb56b8331244.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1095efa0361fecfa93e3a991cee24203db479971.summary']","Does the interaction between SLPI and Nlrp9b regulate the production of oxMIF, leading to a distinct immune response in IBD patients with high visceral fat area?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis: ""Does the interaction between SLPI and Nlrp9b regulate the production of oxMIF, leading to a distinct immune response in IBD patients with high visceral fat area?""

**Experimental Design:**

**Title:** Investigating the Role of SLPI-Nlrp9b Interaction in oxMIF Production and Immune Response in IBD Patients with High Visceral Fat Area

**Objective:** To determine whether the interaction between SLPI and Nlrp9b regulates oxMIF production, leading to a distinct immune response in IBD patients with high visceral fat area.

**Experimental Approach:**

1. **Patient Recruitment:** Recruit 50 IBD patients with high visceral fat area (VFA) and 50 IBD patients with low VFA. Collect intestinal biopsies, blood samples, and clinical data from each patient.
2. **SLPI and Nlrp9b Expression Analysis:** Perform RNA sequencing and qPCR to measure SLPI and Nlrp9b expression in intestinal biopsies from both high and low VFA groups.
3. **oxMIF Production Analysis:** Measure oxMIF levels in blood samples from both groups using ELISA or Olink technology.
4. **Co-Immunoprecipitation (Co-IP) Assay:** Perform Co-IP assays to investigate the interaction between SLPI and Nlrp9b in intestinal biopsies from both groups.
5. **Immune Response Analysis:** Analyze immune cell populations (e.g., T cells, macrophages) and cytokine profiles (e.g., IL-1β, TNF-α) in blood samples from both groups using flow cytometry and ELISA.
6. **Correlation Analysis:** Correlate SLPI and Nlrp9b expression, oxMIF levels, and immune response parameters between the high and low VFA groups.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we will test the following:

* **SLPI-Nlrp9b Interaction Inhibition:** Use siRNA or CRISPR-Cas9 to knockdown SLPI or Nlrp9b expression in intestinal biopsies from high VFA patients. Measure oxMIF levels and immune response parameters to determine if the interaction between SLPI and Nlrp9b is necessary for oxMIF production and immune response.
* **oxMIF Neutralization:** Use an oxMIF-neutralizing antibody to block oxMIF activity in high VFA patients. Measure immune response parameters to determine if oxMIF is necessary for the distinct immune response observed in high VFA patients.
* **Visceral Fat Area Manipulation:** Use a mouse model of IBD with high visceral fat area to investigate the effect of visceral fat area reduction on SLPI-Nlrp9b interaction, oxMIF production, and immune response.

**Equipment and Resources:**

* Intestinal biopsies, RNA sequencing, qPCR, Olink technology, Co-IP assay, flow cytometry, ELISA, siRNA, CRISPR-Cas9, oxMIF-neutralizing antibody, mouse model of IBD, CT or MRI scanner, blood sampling equipment, statistical analysis software.

**Timeline:**

* Patient recruitment and sample collection: 6 months
* RNA sequencing, qPCR, and Co-IP assays: 3 months
* oxMIF measurement and immune response analysis: 3 months
* Correlation analysis and data interpretation: 3 months
* siRNA/CRISPR-Cas9 experiments: 3 months
* oxMIF neutralization experiments: 3 months
* Visceral fat area manipulation experiments: 6 months

**Budget:**

The budget for this experiment will be substantial, considering the need for:

* Patient recruitment and sample collection
* Advanced molecular biology techniques (RNA sequencing, qPCR, Co-IP assays)
* Immune response analysis (flow cytometry, ELISA)
* siRNA/CRISPR-Cas9 experiments
* oxMIF neutralization experiments
* Visceral fat area manipulation experiments
* Statistical analysis software and personnel

A rough estimate for the budget would be in the range of $500,000 to $1,000,000, depending on the specific requirements and resources needed.",92,"Here are the detailed, step-by-step protocols for each experiment outlined in the plan:

**Protocol 1: Patient Recruitment and Sample Collection**

1.1. Patient Inclusion Criteria:

* 50 IBD patients with high visceral fat area (VFA) (>130 cm²)
* 50 IBD patients with low VFA (<90 cm²)
* Informed consent obtained from each patient

1.2. Sample Collection:

* Intestinal biopsies: Collect 2-3 biopsies from each patient using a flexible endoscope or colonoscope. Store biopsies in RNAlater or equivalent RNA preservation solution.
* Blood samples: Collect 10 mL of whole blood from each patient in EDTA-coated tubes. Store at -80°C.
* Clinical data: Collect patient demographics, medical history, and clinical data (e.g., disease severity, medication use).

**Protocol 2: SLPI and Nlrp9b Expression Analysis**

2.1. RNA Isolation:

* Extract total RNA from intestinal biopsies using a commercial RNA isolation kit (e.g., Qiagen RNeasy).
* Quantify RNA concentration and quality using a spectrophotometer (e.g., NanoDrop) and agarose gel electrophoresis.

2.2. RNA Sequencing:

* Prepare RNA libraries using a commercial RNA sequencing kit (e.g., Illumina TruSeq).
* Perform RNA sequencing on a next-generation sequencing platform (e.g., Illumina HiSeq).
* Analyze RNA sequencing data using a bioinformatics pipeline (e.g., STAR, DESeq2) to identify differentially expressed genes between high and low VFA groups.

2.3. qPCR:

* Design and synthesize primers specific to SLPI and Nlrp9b genes.
* Perform qPCR using a commercial qPCR kit (e.g., TaqMan) and a qPCR instrument (e.g., Applied Biosystems 7500).
* Analyze qPCR data using a software package (e.g., SDS 2.4) to determine SLPI and Nlrp9b expression levels.

**Protocol 3: oxMIF Production Analysis**

3.1. ELISA:

* Coat 96-well plates with a capture antibody specific to oxMIF.
* Add blood samples to the plates and incubate for 2 hours at room temperature.
* Add a detection antibody and incubate for 1 hour at room temperature.
* Measure absorbance at 450 nm using a plate reader (e.g., BioTek Synergy).

3.2. Olink Technology:

* Prepare blood samples according to the Olink protocol.
* Perform Olink analysis using a commercial Olink platform (e.g., Olink Proteomics).
* Analyze Olink data using a software package (e.g., Olink Studio) to determine oxMIF levels.

**Protocol 4: Co-Immunoprecipitation (Co-IP) Assay**

4.1. Protein Extraction:

* Extract proteins from intestinal biopsies using a commercial protein extraction kit (e.g., Pierce RIPA).
* Quantify protein concentration using a spectrophotometer (e.g., NanoDrop).

4.2. Co-IP:

* Prepare protein lysates from intestinal biopsies.
* Add antibodies specific to SLPI and Nlrp9b to the lysates and incubate for 2 hours at 4°C.
* Add protein A/G beads and incubate for 1 hour at 4°C.
* Wash beads and elute proteins using a commercial Co-IP kit (e.g., Pierce Co-IP).
* Analyze Co-IP products using Western blotting or mass spectrometry.

**Protocol 5: Immune Response Analysis**

5.1. Flow Cytometry:

* Prepare blood samples according to the flow cytometry protocol.
* Stain cells with antibodies specific to immune cell markers (e.g., CD4, CD8, CD14).
* Analyze cells using a flow cytometer (e.g., BD FACSCanto).
* Analyze flow cytometry data using a software package (e.g., FlowJo) to determine immune cell populations.

5.2. ELISA:

* Coat 96-well plates with a capture antibody specific to cytokines (e.g., IL-1β, TNF-α).
* Add blood samples to the plates and incubate for 2 hours at room temperature.
* Add a detection antibody and incubate for 1 hour at room temperature.
* Measure absorbance at 450 nm using a plate reader (e.g., BioTek Synergy).

**Protocol 6: Correlation Analysis**

6.1. Data Integration:

* Integrate SLPI and Nlrp9b expression data, oxMIF levels, and immune response parameters from each patient.

6.2. Statistical Analysis:

* Perform correlation analysis using a software package (e.g., R, Python) to determine relationships between SLPI and Nlrp9b expression, oxMIF levels, and immune response parameters.

**Protocol 7: SLPI-Nlrp9b Interaction Inhibition**

7.1. siRNA Transfection:

* Design and synthesize siRNAs specific to SLPI and Nlrp9b genes.
* Transfect siRNAs into intestinal biopsies using a commercial transfection reagent (e.g., Lipofectamine).
* Incubate biopsies for 24-48 hours to allow for gene knockdown.

7.2. oxMIF Measurement and Immune Response Analysis:

* Measure oxMIF levels and immune response parameters in siRNA-transfected biopsies using Protocols 3 and 5.

**Protocol 8: oxMIF Neutralization**

8.1. oxMIF Neutralizing Antibody:

* Obtain an oxMIF-neutralizing antibody from a commercial source or generate in-house.
* Add the antibody to blood samples from high VFA patients and incubate for 1 hour at room temperature.

8.2. Immune Response Analysis:

* Analyze immune response parameters in antibody-treated blood samples using Protocol 5.

**Protocol 9: Visceral Fat Area Manipulation**

9.1. Mouse Model of IBD:

* Obtain a mouse model of IBD with high visceral fat area from a commercial source or generate in-house.

9.2. Visceral Fat Area Reduction:

* Perform surgical or dietary interventions to reduce visceral fat area in the mouse model.
* Measure SLPI and Nlrp9b expression, oxMIF levels, and immune response parameters in the mouse model using Protocols 2-5.

These detailed protocols should provide a clear guide for executing the experiments outlined in the plan.","```
   Patient_Group  VFA  RNA_Isolation_Kits  RNA_Sequencing_Kits  qPCR_Kits  ELISA_Plates  Olink_Proteomics  CoIP_Kits  Flow_Cytometry_Kits  siRNA_Transfection_Reagents  oxMIF_Neutralizing_Antibody  Outcome
0           High  140                  2                    1          3             2               1            1                    2                         1                         1  Inhibited
1           Low   80                  1                    2          2             1               2            2                    1                         2                         2  Enhanced
2           High  150                  3                    1          1             3               1            2                    2                         1                         1  Inhibited
3           Low   70                  2                    2          3             2               1            1                    1                         2                         2  Enhanced
4           High  130                  1                    3          2             1               2            2                    2                         1                         1  Inhibited
5           Low   90                  2                    1          1             3               1            1                    1                         2                         2  Enhanced
6           High  120                  3                    2          3             2               1            2                    2                         1                         1  Inhibited
7           Low   100                 1                    1          2             1               2            1                    1                         2                         2  Enhanced
8           High  110                 2                    3          1             3               1            2                    2                         1                         1  Inhibited
9           Low   85                  3                    2          3             2               1            1                    1                         2                         2  Enhanced
10          High  125                 1                    1          2             1               2            2                    2                         1                         1  Inhibited
11          Low   95                  2                    3          1             3               1            1                    1                         2                         2  Enhanced
12          High  135                 3                    2          3             2               1            2                    2                         1                         1  Inhibited
13          Low   75                  1                    1          2             1               2            1                    1                         2                         2  Enhanced
14          High  145                 2                    3          1             3               1            2                    2                         1                         1  Inhibited
15          Low   105                 3                    2          3             2               1            1                    1                         2                         2  Enhanced
16          High  115                 1                    1          2             1               2            2                    2                         1                         1  Inhibited
17          Low   65                  2                    3          1             3               1            1                    1                         2                         2  Enhanced
18          High  155                 3                    2          3             2               1            2                    2                         1                         1  Inhibited
19          Low   85                  1                    1          2             1               2            1                    1                         2                         2  Enhanced
20          High  125                 2                    3          1             3               1            2                    2                         1                         1  Inhibited
21          Low   95                  3                    2          3             2               1            1                    1                         2                         2  Enhanced
22          High  140                 1                    1          2             1               2            2                    2                         1                         1  Inhibited
23          Low   75                  2                    3          1             3               1            1                    1                         2                         2  Enhanced
24          High  150                 3                    2          3             2               1            2                    2                         1                         1  Inhibited
```",0.013892378480746497
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/791b4a86c4e4b99cd63549ce180dc6a580f0b23b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/199864080b2cfc60568e191704ec2ef0c84bbf1c.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2dc674ca8ba913f61b245ff9239d178813bbfde4.summary']",Does the interaction between UGT2B17 and CD150/CD180 receptors modulate B cell receptor signaling and contribute to the development of chronic lymphocytic leukemia by altering the balance between pro-survival and pro-apoptotic pathways?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose an experimental plan to test the hypothesis:

**Hypothesis:** Does the interaction between UGT2B17 and CD150/CD180 receptors modulate B cell receptor signaling and contribute to the development of chronic lymphocytic leukemia by altering the balance between pro-survival and pro-apoptotic pathways?

**Experimental Approach:**

To test this hypothesis, I propose a multi-step experiment that combines techniques from the provided papers. The goal is to investigate the interaction between UGT2B17 and CD150/CD180 receptors and their effect on B cell receptor signaling, proliferation, and survival in CLL cells.

**Step 1: Cell Culture and Transfection**

* Obtain a CLL cell line and culture it in a suitable medium.
* Transfect the cells with UGT2B17, CD150, and CD180 expression vectors using a transfection reagent.
* Use a control group with empty vector transfection.

**Step 2: Co-Immunoprecipitation Assay**

* Perform co-immunoprecipitation assays to validate the interaction between UGT2B17 and CD150/CD180 receptors.
* Use antibodies against UGT2B17, CD150, and CD180, and protein G beads.
* Perform Western blotting to detect the presence of UGT2B17, CD150, and CD180 in the immunoprecipitated complex.

**Step 3: B Cell Receptor Stimulation and Signaling Analysis**

* Stimulate the transfected cells with a specific antigen that binds to the B cell receptor.
* Measure the levels of phosphorylated BCR signaling proteins (e.g., BTK, SYK, ZAP70) using Western blot analysis.
* Analyze the effect of UGT2B17 and CD150/CD180 co-expression on BCR signaling.

**Step 4: Cell Proliferation and Survival Assays**

* Measure cell proliferation using a cell viability assay (e.g., MTT assay).
* Analyze the effect of UGT2B17 and CD150/CD180 co-expression on cell proliferation.
* Measure cell survival using a apoptosis assay (e.g., Annexin V staining).

**Step 5: Data Analysis**

* Compare the results from the control group (empty vector transfection) to the UGT2B17 and CD150/CD180 co-transfected group.
* Analyze the data to determine if the interaction between UGT2B17 and CD150/CD180 receptors modulates B cell receptor signaling, proliferation, and survival in CLL cells.

**Equipment and Reagents:**

* Cell culture facility
* Transfection reagent
* Antibodies against UGT2B17, CD150, CD180, BTK, SYK, and ZAP70
* Protein G beads
* Western blot apparatus
* Cell viability assay kit
* Apoptosis assay kit (e.g., Annexin V staining)

**Time and Budget:**

This experiment can be completed within 6-8 weeks, depending on the availability of reagents and equipment. The budget will depend on the cost of the reagents, equipment, and personnel. However, the experiment can be performed with a reasonable budget, as it builds upon existing techniques and methods.

**Design to Disprove the Hypothesis:**

To disprove the hypothesis, I would design an experiment that tests the opposite scenario: that the interaction between UGT2B17 and CD150/CD180 receptors has no effect on B cell receptor signaling, proliferation, and survival in CLL cells.

* Use a dominant-negative mutant of UGT2B17 or CD150/CD180 to disrupt their interaction.
* Perform the same co-immunoprecipitation, BCR stimulation, and cell proliferation/survival assays as described above.
* If the results show no significant difference between the control group and the dominant-negative mutant group, it would suggest that the interaction between UGT2B17 and CD150/CD180 receptors is not essential for modulating B cell receptor signaling and CLL cell proliferation/survival.

By designing an experiment to disprove the hypothesis, we can increase the confidence in the results and provide a more comprehensive understanding of the role of UGT2B17 and CD150/CD180 receptors in CLL.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Cell Culture and Transfection**

1.1. Obtain a CLL cell line (e.g., MEC-1 or EHEB) from a reputable cell bank or laboratory.

1.2. Culture the cells in a suitable medium, such as RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.

1.3. Maintain the cells at 37°C in a humidified incubator with 5% CO2.

1.4. Prepare the transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.

1.5. Prepare the UGT2B17, CD150, and CD180 expression vectors (e.g., pCMV-UGT2B17, pCMV-CD150, and pCMV-CD180) by isolating the plasmid DNA using a plasmid purification kit.

1.6. Transfect the cells with the expression vectors using the transfection reagent according to the manufacturer's instructions.

1.7. Use a control group with empty vector transfection (e.g., pCMV-empty) as a negative control.

1.8. Incubate the cells for 24-48 hours to allow for protein expression.

**Step 2: Co-Immunoprecipitation Assay**

2.1. Prepare the antibodies against UGT2B17, CD150, and CD180 (e.g., rabbit polyclonal antibodies) and protein G beads.

2.2. Lyse the transfected cells in a lysis buffer (e.g., RIPA buffer) containing protease inhibitors.

2.3. Incubate the cell lysate with the antibodies against UGT2B17, CD150, and CD180 for 2 hours at 4°C.

2.4. Add protein G beads to the lysate and incubate for an additional 2 hours at 4°C.

2.5. Wash the beads three times with a wash buffer (e.g., PBS with 0.1% Tween-20).

2.6. Elute the immunoprecipitated complex using a elution buffer (e.g., 2x Laemmli buffer).

2.7. Perform Western blotting to detect the presence of UGT2B17, CD150, and CD180 in the immunoprecipitated complex.

**Step 3: B Cell Receptor Stimulation and Signaling Analysis**

3.1. Stimulate the transfected cells with a specific antigen that binds to the B cell receptor (e.g., anti-IgM antibody).

3.2. Incubate the cells for 10-30 minutes to allow for BCR signaling.

3.3. Lyse the cells in a lysis buffer (e.g., RIPA buffer) containing protease inhibitors.

3.4. Measure the levels of phosphorylated BCR signaling proteins (e.g., BTK, SYK, ZAP70) using Western blot analysis.

3.5. Use specific antibodies against phosphorylated BCR signaling proteins (e.g., p-BTK, p-SYK, p-ZAP70).

**Step 4: Cell Proliferation and Survival Assays**

4.1. Measure cell proliferation using a cell viability assay (e.g., MTT assay).

4.2. Seed the transfected cells in a 96-well plate at a density of 1x10^4 cells/well.

4.3. Incubate the cells for 24-48 hours.

4.4. Add the MTT reagent to the cells and incubate for an additional 2-4 hours.

4.5. Measure the absorbance at 570 nm using a plate reader.

4.6. Analyze the effect of UGT2B17 and CD150/CD180 co-expression on cell proliferation.

4.7. Measure cell survival using an apoptosis assay (e.g., Annexin V staining).

4.8. Stain the cells with Annexin V-FITC and propidium iodide (PI) according to the manufacturer's instructions.

4.9. Analyze the cells using flow cytometry to detect apoptotic cells.

**Step 5: Data Analysis**

5.1. Compare the results from the control group (empty vector transfection) to the UGT2B17 and CD150/CD180 co-transfected group.

5.2. Analyze the data to determine if the interaction between UGT2B17 and CD150/CD180 receptors modulates B cell receptor signaling, proliferation, and survival in CLL cells.

5.3. Use statistical software (e.g., GraphPad Prism) to perform statistical analysis (e.g., t-test, ANOVA) to determine significant differences between groups.

**Design to Disprove the Hypothesis**

To disprove the hypothesis, the following experiment can be performed:

1. Use a dominant-negative mutant of UGT2B17 or CD150/CD180 to disrupt their interaction.

2. Perform the same co-immunoprecipitation, BCR stimulation, and cell proliferation/survival assays as described above.

3. If the results show no significant difference between the control group and the dominant-negative mutant group, it would suggest that the interaction between UGT2B17 and CD150/CD180 receptors is not essential for modulating B cell receptor signaling and CLL cell proliferation/survival.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   UGT2B17_vector  CD150_vector  CD180_vector  FBS  Penicillin_streptomycin  L_glutamine  Transfection_reagent  Outcome
0             1.0          1.0          1.0  10.0                  1.0           1.0               1.0  Positive
1             0.5          1.0          1.0  10.0                  1.0           1.0               1.0  Negative
2             1.0          0.5          1.0  10.0                  1.0           1.0               1.0  Negative
3             1.0          1.0          0.5  10.0                  1.0           1.0               1.0  Negative
4             1.0          1.0          1.0   5.0                  1.0           1.0               1.0  Positive
5             1.0          1.0          1.0  10.0                  0.5           1.0               1.0  Negative
6             1.0          1.0          1.0  10.0                  1.0           0.5               1.0  Negative
7             1.0          1.0          1.0  10.0                  1.0           1.0               0.5  Negative
8             0.5          0.5          1.0  10.0                  1.0           1.0               1.0  Negative
9             1.0          1.0          0.5  10.0                  1.0           1.0               0.5  Negative
10            1.0          0.5          0.5  10.0                  1.0           1.0               1.0  Negative
11            0.5          1.0          0.5  10.0                  1.0           1.0               1.0  Negative
12            1.0          1.0          1.0  10.0                  1.0           1.0               1.5  Positive
13            1.0          1.0          1.0  10.0                  1.0           1.0               2.0  Positive
14            1.0          1.0          1.0  10.0                  1.0           1.0               0.1  Negative
15            1.0          1.0          1.0  10.0                  1.0           1.0               0.2  Negative
16            1.0          1.0          1.0  10.0                  1.0           1.0               0.3  Negative
17            1.0          1.0          1.0  10.0                  1.0           1.0               0.4  Negative
18            1.0          1.0          1.0  10.0                  1.0           1.0               0.6  Negative
19            1.0          1.0          1.0  10.0                  1.0           1.0               0.7  Negative
20            1.0          1.0          1.0  10.0                  1.0           1.0               0.8  Negative
21            1.0          1.0          1.0  10.0                  1.0           1.0               0.9  Negative
22            1.0          1.0          1.0  10.0                  1.0           1.0               1.1  Positive
23            1.0          1.0          1.0  10.0                  1.0           1.0               1.2  Positive
24            1.0          1.0          1.0  10.0                  1.0           1.0               1.3  Positive
```",0.18520594986998468
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f6c8e49de149c1d7791cd30cc534390f9d6dc66b.summary'],Does the metabolic utilization of propanediol by adherent-invasive E. coli modulate the immunosuppressive effects of exosomes from mesenchymal stromal cells in gut-associated lymphoid tissues?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll break down the experimental plan to test this hypothesis into several sections. Since we have an unlimited budget, we can design a comprehensive and rigorous experiment to disprove the hypothesis.

**Hypothesis:** The metabolic utilization of propanediol by adherent-invasive E. coli modulates the immunosuppressive effects of exosomes from mesenchymal stromal cells in gut-associated lymphoid tissues.

**Experimental Approach:**

**Section 1: Cell Culture and Preparation**

1. Isolate and culture human mesenchymal stromal cells (MSCs) from bone marrow or adipose tissue using established protocols.
2. Generate exosomes from MSCs using ultracentrifugation or other methods.
3. Culture adherent-invasive E. coli (AIEC) strains in propanediol-rich media to induce metabolic utilization.

**Section 2: Co-Culture and Treatment**

1. Co-culture MSCs with AIEC in the presence or absence of propanediol.
2. Treat MSCs with exosomes from AIEC-infected MSCs (AIEC-Exo) or control exosomes (Ctrl-Exo).
3. Use a transwell system to separate MSCs and AIEC, allowing for the exchange of exosomes while maintaining physical separation.

**Section 3: Immunological Assays**

1. Measure the immunosuppressive effects of AIEC-Exo and Ctrl-Exo on T cell proliferation, activation, and cytokine production using flow cytometry and ELISA.
2. Analyze the expression of immunosuppressive molecules (e.g., PD-L1, TGF-β) on MSCs and AIEC using qRT-PCR, Western blot, and flow cytometry.

**Section 4: Propanediol Metabolism and AIEC Infection**

1. Measure propanediol metabolism in AIEC using GC-MS or NMR spectroscopy.
2. Assess AIEC adhesion and invasion in MSCs using microscopy, adhesion assays, and gentamicin protection assays.

**Section 5: Gut-Associated Lymphoid Tissue (GALT) Model**

1. Establish a human GALT model using a 3D organoid system or a mouse model with humanized GALT.
2. Inoculate the GALT model with AIEC and treat with propanediol or control media.
3. Analyze the immunosuppressive effects of AIEC-Exo and Ctrl-Exo on T cells in the GALT model.

**Section 6: Data Analysis and Statistical Significance**

1. Perform statistical analysis using ANOVA, t-tests, and regression analysis to compare the effects of AIEC-Exo and Ctrl-Exo on immunosuppression.
2. Use bioinformatic tools to analyze gene expression data and identify potential biomarkers.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we will design an experiment with the following modifications:

1. Use a propanediol-metabolism-deficient AIEC mutant strain to co-culture with MSCs.
2. Add a propanediol-metabolism inhibitor to the co-culture system.
3. Use a different carbon source (e.g., glucose) instead of propanediol in the AIEC culture media.

If the immunosuppressive effects of AIEC-Exo are still observed in these modified experiments, it would suggest that the metabolic utilization of propanediol by AIEC is not the primary mechanism modulating the immunosuppressive effects of MSC-derived exosomes. This would disprove the original hypothesis.

**Timeline and Resources:**

This experiment would require a team of 5-7 researchers with expertise in microbiology, immunology, cell biology, and bioinformatics. The estimated timeline for this experiment would be 12-18 months, with the following milestones:

* Months 1-3: Cell culture and preparation, co-culture setup, and treatment
* Months 4-6: Immunological assays and data analysis
* Months 7-9: Propanediol metabolism and AIEC infection analysis
* Months 10-12: GALT model establishment and analysis
* Months 13-18: Data analysis, statistical significance testing, and manuscript preparation

The unlimited budget would allow for the use of cutting-edge equipment, such as high-throughput sequencing platforms, advanced microscopy systems, and state-of-the-art bioinformatics tools. Additionally, the budget would cover the costs of personnel, reagents, and consumables for the entire duration of the project.",92,"Here are the detailed, step-by-step protocols for each section of the experiment:

**Section 1: Cell Culture and Preparation**

1.1. Isolation of Human Mesenchymal Stromal Cells (MSCs)

* Obtain bone marrow or adipose tissue samples from healthy donors with informed consent.
* Process the samples using density gradient centrifugation (e.g., Ficoll-Paque) to isolate mononuclear cells.
* Culture the mononuclear cells in complete medium (e.g., DMEM, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.
* After 24-48 hours, remove non-adherent cells and wash the adherent cells with PBS.
* Continue culturing the adherent cells in complete medium, changing the medium every 3-4 days.

1.2. Generation of Exosomes from MSCs

* Culture MSCs to 80-90% confluence in complete medium.
* Collect the conditioned medium and centrifuge at 300 x g for 10 minutes to remove cells and debris.
* Filter the supernatant through a 0.22 μm filter to remove any remaining cells and debris.
* Concentrate the exosomes using ultracentrifugation (e.g., 100,000 x g for 2 hours) or other methods (e.g., ExoQuick).
* Resuspend the exosomes in PBS and store at -80°C.

1.3. Culture of Adherent-Invasive E. coli (AIEC)

* Obtain AIEC strains from a reputable source (e.g., ATCC).
* Culture AIEC in Luria-Bertani (LB) broth or other suitable medium at 37°C, 5% CO2.
* Add propanediol to the medium at a final concentration of 1-2% (w/v) to induce metabolic utilization.
* Monitor AIEC growth and adjust the propanediol concentration as needed.

**Section 2: Co-Culture and Treatment**

2.1. Co-Culture of MSCs and AIEC

* Seed MSCs in a 6-well plate at a density of 1 x 10^5 cells/well.
* Add AIEC to the MSC culture at a multiplicity of infection (MOI) of 10:1 (AIEC:MSC).
* Incubate the co-culture at 37°C, 5% CO2 for 24-48 hours.

2.2. Treatment with Exosomes

* Add AIEC-Exo or Ctrl-Exo to the MSC culture at a final concentration of 1-10 μg/mL.
* Incubate the culture for an additional 24-48 hours.

2.3. Transwell System Setup

* Place a 0.4 μm pore size transwell insert in a 6-well plate.
* Seed MSCs in the transwell insert at a density of 1 x 10^5 cells/well.
* Add AIEC to the lower chamber of the transwell plate at an MOI of 10:1 (AIEC:MSC).
* Incubate the co-culture at 37°C, 5% CO2 for 24-48 hours.

**Section 3: Immunological Assays**

3.1. T Cell Proliferation Assay

* Isolate T cells from healthy donors using magnetic bead separation (e.g., CD3+ T cells).
* Co-culture T cells with MSCs in the presence or absence of AIEC-Exo or Ctrl-Exo.
* Measure T cell proliferation using a cell proliferation assay (e.g., BrdU incorporation, CFSE staining).

3.2. T Cell Activation and Cytokine Production Assay

* Co-culture T cells with MSCs in the presence or absence of AIEC-Exo or Ctrl-Exo.
* Measure T cell activation markers (e.g., CD25, CD69) and cytokine production (e.g., IL-2, IFN-γ) using flow cytometry and ELISA.

3.3. Immunomodulatory Molecule Expression

* Analyze the expression of immunosuppressive molecules (e.g., PD-L1, TGF-β) on MSCs and AIEC using qRT-PCR, Western blot, and flow cytometry.

**Section 4: Propanediol Metabolism and AIEC Infection**

4.1. Propanediol Metabolism Analysis

* Measure propanediol metabolism in AIEC using GC-MS or NMR spectroscopy.
* Analyze the production of metabolites (e.g., propionate, acetate) and the expression of propanediol-metabolizing enzymes (e.g., pdu genes).

4.2. AIEC Adhesion and Invasion Assay

* Measure AIEC adhesion to MSCs using a crystal violet assay or microscopy.
* Assess AIEC invasion using a gentamicin protection assay or microscopy.

**Section 5: Gut-Associated Lymphoid Tissue (GALT) Model**

5.1. Establishment of Human GALT Model

* Use a 3D organoid system or a mouse model with humanized GALT to establish a GALT model.
* Inoculate the GALT model with AIEC and treat with propanediol or control media.

5.2. Analysis of Immunological Responses

* Analyze the immunosuppressive effects of AIEC-Exo and Ctrl-Exo on T cells in the GALT model using flow cytometry and ELISA.

**Section 6: Data Analysis and Statistical Significance**

6.1. Statistical Analysis

* Perform statistical analysis using ANOVA, t-tests, and regression analysis to compare the effects of AIEC-Exo and Ctrl-Exo on immunosuppression.
* Use bioinformatic tools to analyze gene expression data and identify potential biomarkers.

6.2. Data Visualization and Interpretation

* Visualize the data using appropriate graphs and charts (e.g., bar graphs, scatter plots).
* Interpret the results in the context of the hypothesis and experimental design.

**Experimental Design to Disprove the Hypothesis**

* Use a propanediol-metabolism-deficient AIEC mutant strain to co-culture with MSCs.
* Add a propanediol-metabolism inhibitor to the co-culture system.
* Use a different carbon source (e.g., glucose) instead of propanediol in the AIEC culture media.

If the immunosuppressive effects of AIEC-Exo are still observed in these modified experiments, it would suggest that the metabolic utilization of propanediol by AIEC is not the primary mechanism modulating the immunosuppressive effects of MSC-derived exosomes. This would disprove the original hypothesis.","```
   MSCs  AIEC  Propanediol  Exosomes  T_Cell_Proliferation  T_Cell_Activation  PD-L1_Expression  Propanediol_Metabolism  AIEC_Adhesion  Outcome
0   10000  100000         1.0       5.0             0.80             0.40           2.50             0.60           0.30       Immunosuppressed
1   15000  150000         1.5       7.5             0.70             0.50           2.20             0.70           0.40       Immunosuppressed
2   20000  200000         2.0      10.0             0.60             0.60           2.00             0.80           0.50       Immunosuppressed
3   25000  250000         2.5      12.5             0.50             0.70           1.80             0.90           0.60       Immunosuppressed
4   30000  300000         3.0      15.0             0.40             0.80           1.60             1.00           0.70       Immunosuppressed
5   10000  100000         1.0       5.0             0.90             0.30           2.80             0.50           0.20       Not_Immunosuppressed
6   15000  150000         1.5       7.5             0.80             0.40           2.50             0.60           0.30       Not_Immunosuppressed
7   20000  200000         2.0      10.0             0.70             0.50           2.20             0.70           0.40       Not_Immunosuppressed
8   25000  250000         2.5      12.5             0.60             0.60           2.00             0.80           0.50       Not_Immunosuppressed
9   30000  300000         3.0      15.0             0.50             0.70           1.80             0.90           0.60       Not_Immunosuppressed
10  10000  100000         1.0       5.0             0.80             0.40           2.50             0.60           0.30       Immunosuppressed
11  15000  150000         1.5       7.5             0.70             0.50           2.20             0.70           0.40       Immunosuppressed
12  20000  200000         2.0      10.0             0.60             0.60           2.00             0.80           0.50       Immunosuppressed
13  25000  250000         2.5      12.5             0.50             0.70           1.80             0.90           0.60       Immunosuppressed
14  30000  300000         3.0      15.0             0.40             0.80           1.60             1.00           0.70       Immunosuppressed
15  10000  100000         1.0       5.0             0.90             0.30           2.80             0.50           0.20       Not_Immunosuppressed
16  15000  150000         1.5       7.5             0.80             0.40           2.50             0.60           0.30       Not_Immunosuppressed
17  20000  200000         2.0      10.0             0.70             0.50           2.20             0.70           0.40       Not_Immunosuppressed
18  25000  250000         2.5      12.5             0.60             0.60           2.00             0.80           0.50       Not_Immunosuppressed
19  30000  300000         3.0      15.0             0.50             0.70           1.80             0.90           0.60       Not_Immunosuppressed
20  10000  100000         1.0       5.0             0.80             0.40           2.50             0.60           0.30       Immunosuppressed
21  15000  150000         1.5       7.5             0.70             0.50           2.20             0.70           0.40       Immunosuppressed
22  20000  200000         2.0      10.0             0.60             0.60           2.00             0.80           0.50       Immunosuppressed
23  25000  250000         2.5      12.5             0.50             0.70           1.80             0.90           0.60       Immunosuppressed
24  30000  300000         3.0      15.0             0.40             0.80           1.60             1.00           0.70       Immunosuppressed
```",0.035481198487054666
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/bf16c5d806971ddb905a69fa3ff27734cecd0d66.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e70598afe28398dce0dce3f99e21a0394fa0e84d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/edac28d03a77172dff303e2bc0bab1f4e9ad3e64.summary']","Does the modulation of JAK/STAT signalling in CD209+/CD14+ dendritic cells affect the frequency and function of regulatory B cells in rheumatoid arthritis patients, leading to changes in IL-6 signalling and inflammation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"Based on the provided hypothesis, I've developed an experimental plan to test it. Since the goal is to disprove the hypothesis, the experiment is designed to test the null hypothesis: ""Modulation of JAK/STAT signalling in CD209+/CD14+ dendritic cells does not affect the frequency and function of regulatory B cells in rheumatoid arthritis patients, leading to no changes in IL-6 signalling and inflammation.""

**Experimental Approach:**

1. **Cell Isolation and Characterization**:
	* Collect peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis (RA) patients and healthy controls.
	* Isolate CD209+/CD14+ dendritic cells using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS).
	* Characterize the isolated cells using flow cytometry to confirm the expression of CD209 and CD14.
2. **JAK/STAT Signalling Modulation**:
	* Treat the isolated CD209+/CD14+ dendritic cells with a JAK inhibitor (e.g., tofacitinib) or a STAT inhibitor (e.g., stattic) to modulate JAK/STAT signalling.
	* Use a control group with no treatment or a vehicle control to compare the effects.
3. **Regulatory B Cell Analysis**:
	* Co-culture the treated or control dendritic cells with autologous B cells from RA patients or healthy controls.
	* Analyze the frequency and function of regulatory B cells (Bregs) using flow cytometry and functional assays (e.g., suppression of T cell proliferation).
4. **IL-6 Signalling and Inflammation**:
	* Measure IL-6 levels in the co-culture supernatants using ELISA or multiplex assays.
	* Analyze the expression of inflammatory markers (e.g., TNF-α, IL-1β) in the co-culture cells using qRT-PCR or Western blot.
5. **Data Analysis**:
	* Compare the frequency and function of Bregs, IL-6 levels, and inflammatory markers between the treatment and control groups.
	* Perform statistical analysis to determine if the modulation of JAK/STAT signalling in CD209+/CD14+ dendritic cells affects the frequency and function of Bregs and IL-6 signalling in RA patients.

**Experimental Design:**

* Sample size: 10-15 RA patients and 10-15 healthy controls
* Experimental groups:
	+ Control group: CD209+/CD14+ dendritic cells without treatment
	+ JAK inhibitor group: CD209+/CD14+ dendritic cells treated with a JAK inhibitor
	+ STAT inhibitor group: CD209+/CD14+ dendritic cells treated with a STAT inhibitor
* Co-culture conditions: 1:1 ratio of dendritic cells to B cells, 3-5 days of co-culture
* Replicates: 3-4 replicates per group

**Timeline:**

* Cell isolation and characterization: 2 weeks
* JAK/STAT signalling modulation and co-culture: 4 weeks
* Data analysis: 6 weeks
* Total duration: 12 weeks

**Budget:**

* Reagents and consumables: $10,000 - $15,000
* Equipment and instrumentation: $5,000 - $10,000 (assuming access to existing flow cytometry and molecular biology equipment)
* Personnel and labor: $15,000 - $20,000 (assuming 1-2 researchers and 1-2 technicians)
* Total budget: $30,000 - $45,000

This experimental plan is designed to test the null hypothesis and disprove the original hypothesis. By modulating JAK/STAT signalling in CD209+/CD14+ dendritic cells and analyzing the effects on regulatory B cells, IL-6 signalling, and inflammation, we can determine if the modulation of JAK/STAT signalling has a significant impact on the frequency and function of Bregs in RA patients.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Characterization**

**Step 1.1: Peripheral Blood Mononuclear Cell (PBMC) Isolation**

1. Collect 20-30 mL of peripheral blood from RA patients and healthy controls in EDTA-coated tubes.
2. Add 10 mL of PBS to the blood and mix gently.
3. Layer the blood-PBS mixture over 15 mL of Ficoll-Paque in a 50 mL conical tube.
4. Centrifuge at 400 x g for 30 minutes at room temperature.
5. Collect the PBMC layer and wash with PBS.
6. Resuspend the PBMCs in 10 mL of PBS and count using a hemocytometer.

**Step 1.2: CD209+/CD14+ Dendritic Cell Isolation**

1. Add 100 μL of CD209 and CD14 antibodies to 1 x 10^7 PBMCs and incubate for 30 minutes at 4°C.
2. Wash the cells with PBS and resuspend in 1 mL of PBS.
3. Use MACS or FACS to isolate CD209+/CD14+ dendritic cells.
4. Collect the isolated cells and count using a hemocytometer.

**Step 1.3: Cell Characterization**

1. Stain the isolated cells with CD209 and CD14 antibodies and analyze using flow cytometry.
2. Record the percentage of CD209+/CD14+ cells and the mean fluorescence intensity (MFI) of CD209 and CD14.

**Protocol 2: JAK/STAT Signalling Modulation**

**Step 2.1: Treatment with JAK Inhibitor or STAT Inhibitor**

1. Resuspend 1 x 10^6 CD209+/CD14+ dendritic cells in 1 mL of complete medium (RPMI 1640 with 10% FBS and 1% penicillin-streptomycin).
2. Add 1 μM of tofacitinib (JAK inhibitor) or 10 μM of stattic (STAT inhibitor) to the cells and incubate for 1 hour at 37°C.
3. Use a control group with no treatment or a vehicle control (DMSO).

**Protocol 3: Regulatory B Cell Analysis**

**Step 3.1: Co-Culture of Dendritic Cells and B Cells**

1. Resuspend 1 x 10^6 autologous B cells from RA patients or healthy controls in 1 mL of complete medium.
2. Add the treated or control dendritic cells to the B cells at a 1:1 ratio and co-culture for 3-5 days at 37°C.

**Step 3.2: Regulatory B Cell Analysis**

1. Harvest the co-culture cells and stain with regulatory B cell markers (e.g., CD19, CD24, CD38).
2. Analyze the frequency of regulatory B cells using flow cytometry.
3. Perform functional assays (e.g., suppression of T cell proliferation) to analyze the function of regulatory B cells.

**Protocol 4: IL-6 Signalling and Inflammation**

**Step 4.1: IL-6 Measurement**

1. Collect the co-culture supernatants and measure IL-6 levels using ELISA or multiplex assays.

**Step 4.2: Inflammatory Marker Analysis**

1. Harvest the co-culture cells and extract RNA using a RNA extraction kit.
2. Perform qRT-PCR to analyze the expression of inflammatory markers (e.g., TNF-α, IL-1β).
3. Alternatively, perform Western blot to analyze the protein expression of inflammatory markers.

**Protocol 5: Data Analysis**

**Step 5.1: Data Collection**

1. Collect the data from the flow cytometry, ELISA, and qRT-PCR/Western blot experiments.

**Step 5.2: Statistical Analysis**

1. Perform statistical analysis (e.g., t-test, ANOVA) to compare the frequency and function of regulatory B cells, IL-6 levels, and inflammatory markers between the treatment and control groups.
2. Determine if the modulation of JAK/STAT signalling in CD209+/CD14+ dendritic cells affects the frequency and function of Bregs and IL-6 signalling in RA patients.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity.","```
   Blood Volume (mL)  PBS Volume (mL)  Ficoll-Paque Volume (mL)  CD209 Antibody (μL)  CD14 Antibody (μL)  Tofacitinib (μM)  Stattic (μM)  Autologous B Cells (x10^6)  Regulatory B Cells (%)  IL-6 (pg/mL)  TNF-α (fold change)  IL-1β (fold change)
0               25.0             12.0                  18.0              120.0              120.0             1.0             0.0               1.2               12.5           250.0             2.1             1.8
1               28.0             10.0                  16.0              100.0              100.0             0.0             10.0               1.0               10.2           300.0             2.5             2.2
2               22.0             11.0                  17.0              110.0              110.0             1.0             0.0               1.1               11.8           220.0             2.0             1.9
3               26.0             13.0                  19.0              130.0              130.0             0.0             10.0               1.3               12.1           280.0             2.4             2.1
4               24.0             12.0                  18.0              120.0              120.0             1.0             0.0               1.2               11.5           240.0             2.2             2.0
5               27.0             11.0                  16.0              100.0              100.0             0.0             10.0               1.0               10.5           260.0             2.3             2.1
6               23.0             13.0                  19.0              130.0              130.0             1.0             0.0               1.3               12.3           200.0             1.9             1.8
7               25.0             12.0                  18.0              120.0              120.0             0.0             10.0               1.2               11.2           220.0             2.1             2.0
8               26.0             11.0                  16.0              100.0              100.0             1.0             0.0               1.1               10.8           240.0             2.2             2.1
9               24.0             13.0                  19.0              130.0              130.0             0.0             10.0               1.3               12.5           280.0             2.5             2.3
10              27.0             12.0                  18.0              120.0              120.0             1.0             0.0               1.2               11.9           260.0             2.4             2.2
11              23.0             11.0                  16.0              100.0              100.0             0.0             10.0               1.0               10.1           200.0             1.9             1.8
12              25.0             13.0                  19.0              130.0              130.0             1.0             0.0               1.3               12.2           220.0             2.1             2.0
13              26.0             12.0                  18.0              120.0              120.0             0.0             10.0               1.2               11.6           240.0             2.3             2.1
14              24.0             11.0                  16.0              100.0              100.0             1.0             0.0               1.1               10.9           260.0             2.4             2.2
15              27.0             13.0                  19.0              130.0              130.0             0.0             10.0               1.3               12.4           280.0             2.5             2.3
16              23.0             12.0                  18.0              120.0              120.0             1.0             0.0               1.2               11.7           200.0             2.0             1.9
17              25.0             11.0                  16.0              100.0              100.0             0.0             10.0               1.0               10.3           220.0             2.2             2.0
18              26.0             13.0                  19.0              130.0              130.0             1.0             0.0               1.3               12.6           240.0             2.4             2.2
19              24.0             12.0                  18.0              120.0              120.0             0.0             10.0               1.2               11.8           260.0             2.5             2.3
20              27.0             11.0                  16.0              100.0              100.0             1.0             0.0               1.1               11.0           280.0             2.4             2.2
21              23.0             13.0                  19.0              130.0              130.0             0.0             10.0               1.3               12.7           200.0             2.1             2.0
22              25.0             12.0                  18.0              120.0              120.0             1.0             0.0               1.2               12.0           220.0             2.3             2.1
23              26.0             11.0                  16.0              100.0              100.0             0.0             10.0               1.0               10.6           240.0             2.4             2.2
24              24.0             13.0                  19.0              130.0              130.0             1.0             0.0               1.3               12.8           260.0             2.5             2.3
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0661cb1bd547abffc8e7f88377e987a9df4248d7.summary'],"Does the modulation of PTEN protein expression influence the response of GCB-DLBCL cells to tonic BCR signaling inhibition, leading to varying degrees of AKT activity and apoptosis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Modulation of PTEN Protein Expression and Tonic BCR Signaling Inhibition in GCB-DLBCL Cells

**Objective:** To investigate the effect of PTEN protein expression modulation on the response of GCB-DLBCL cells to tonic BCR signaling inhibition, leading to varying degrees of AKT activity and apoptosis.

**Materials:**

* GCB-DLBCL cell lines
* PTEN overexpression and knockdown constructs
* CD79A Y188F mutant construct
* AKT activity reporter construct
* FRET-based AKT activity assay
* Flow cytometer
* Western blotting equipment
* Annexin V staining kit

**Steps:**

1. Transfect GCB-DLBCL cells with PTEN overexpression and knockdown constructs to modulate PTEN protein expression.
2. Transfect cells with CD79A Y188F mutant construct to inhibit tonic BCR signaling.
3. Measure AKT activity using FRET-based AKT activity assay and western blotting.
4. Analyze cell viability using flow cytometry and annexin V staining.
5. Compare AKT activity and cell viability between control, PTEN-modulated, and CD79A Y188F-transfected cells.
6. Perform a dose-response experiment to determine the optimal concentration of PTEN modulation required to affect AKT activity and apoptosis.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of PTEN-Independent Mechanisms in Tonic BCR Signaling Inhibition-Mediated AKT Activity and Apoptosis in GCB-DLBCL Cells

**Objective:** To investigate whether PTEN-independent mechanisms can rescue AKT activity and prevent apoptosis in GCB-DLBCL cells upon tonic BCR signaling inhibition.

**Materials:**

* GCB-DLBCL cell lines
* CD79A Y188F mutant construct
* AKT activity reporter construct
* FRET-based AKT activity assay
* Flow cytometer
* Western blotting equipment
* Annexin V staining kit
* Small molecule inhibitors of PI3K/AKT pathway (e.g., LY294002)

**Steps:**

1. Transfect GCB-DLBCL cells with CD79A Y188F mutant construct to inhibit tonic BCR signaling.
2. Treat cells with small molecule inhibitors of the PI3K/AKT pathway to activate AKT activity independently of PTEN.
3. Measure AKT activity using FRET-based AKT activity assay and western blotting.
4. Analyze cell viability using flow cytometry and annexin V staining.
5. Compare AKT activity and cell viability between control, CD79A Y188F-transfected, and PI3K/AKT inhibitor-treated cells.
6. If AKT activity is rescued and apoptosis is prevented, it would suggest that PTEN-independent mechanisms can bypass the requirement for PTEN modulation in tonic BCR signaling inhibition-mediated AKT activity and apoptosis.

**Rationale:**

The first experiment aims to directly test the hypothesis by modulating PTEN protein expression and investigating its effect on AKT activity and apoptosis in response to tonic BCR signaling inhibition. The second experiment attempts to disprove the hypothesis by investigating whether PTEN-independent mechanisms can rescue AKT activity and prevent apoptosis upon tonic BCR signaling inhibition. If the second experiment shows that AKT activity is rescued and apoptosis is prevented, it would suggest that PTEN modulation is not the primary mechanism underlying the response to tonic BCR signaling inhibition, and the hypothesis would be disproven.

**Time and Resource Considerations:**

Both experiments can be completed within a reasonable time frame (approximately 6-8 weeks) and with a moderate budget. The required materials and equipment are standard in most molecular biology and cell biology laboratories. The experiments can be performed by a single researcher with basic molecular biology and cell culture skills.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Modulation of PTEN Protein Expression and Tonic BCR Signaling Inhibition in GCB-DLBCL Cells**

**Step 1: Cell Culture and Transfection**

1.1. Obtain GCB-DLBCL cell lines and maintain them in a humidified incubator at 37°C, 5% CO2, in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

1.2. Prepare PTEN overexpression and knockdown constructs according to the manufacturer's instructions.

1.3. Transfect 1 x 10^6 GCB-DLBCL cells with 2 μg of PTEN overexpression or knockdown construct using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.4. Incubate the cells for 24-48 hours to allow for transfection and protein expression.

**Step 2: Transfection with CD79A Y188F Mutant Construct**

2.1. Prepare the CD79A Y188F mutant construct according to the manufacturer's instructions.

2.2. Transfect 1 x 10^6 GCB-DLBCL cells with 2 μg of CD79A Y188F mutant construct using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

2.3. Incubate the cells for 24-48 hours to allow for transfection and protein expression.

**Step 3: Measurement of AKT Activity**

3.1. Prepare the FRET-based AKT activity assay according to the manufacturer's instructions.

3.2. Lyse the transfected cells in a lysis buffer (e.g., RIPA buffer) and centrifuge at 10,000 x g for 10 minutes to remove debris.

3.3. Measure AKT activity using the FRET-based AKT activity assay according to the manufacturer's instructions.

3.4. Perform western blotting to validate AKT activity using antibodies against phosphorylated AKT (e.g., pAKT S473) and total AKT.

**Step 4: Analysis of Cell Viability**

4.1. Stain the transfected cells with Annexin V-FITC and propidium iodide (PI) according to the manufacturer's instructions.

4.2. Analyze cell viability using flow cytometry (e.g., BD FACSCalibur) and determine the percentage of apoptotic cells (Annexin V+ PI-).

**Step 5: Comparison of AKT Activity and Cell Viability**

5.1. Compare AKT activity and cell viability between control, PTEN-modulated, and CD79A Y188F-transfected cells.

5.2. Perform statistical analysis (e.g., t-test, ANOVA) to determine significant differences between groups.

**Step 6: Dose-Response Experiment**

6.1. Perform a dose-response experiment to determine the optimal concentration of PTEN modulation required to affect AKT activity and apoptosis.

6.2. Transfect cells with varying concentrations of PTEN overexpression or knockdown construct (e.g., 0.1, 1, 10 μg) and repeat steps 3-5.

**Experiment to Disprove the Hypothesis: Investigating the Role of PTEN-Independent Mechanisms in Tonic BCR Signaling Inhibition-Mediated AKT Activity and Apoptosis in GCB-DLBCL Cells**

**Step 1: Cell Culture and Transfection**

1.1. Obtain GCB-DLBCL cell lines and maintain them in a humidified incubator at 37°C, 5% CO2, in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

1.2. Transfect 1 x 10^6 GCB-DLBCL cells with 2 μg of CD79A Y188F mutant construct using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.3. Incubate the cells for 24-48 hours to allow for transfection and protein expression.

**Step 2: Treatment with Small Molecule Inhibitors**

2.1. Prepare small molecule inhibitors of the PI3K/AKT pathway (e.g., LY294002) according to the manufacturer's instructions.

2.2. Treat the transfected cells with varying concentrations of the inhibitor (e.g., 1, 10, 50 μM) for 24-48 hours.

**Step 3: Measurement of AKT Activity**

3.1. Prepare the FRET-based AKT activity assay according to the manufacturer's instructions.

3.2. Lyse the treated cells in a lysis buffer (e.g., RIPA buffer) and centrifuge at 10,000 x g for 10 minutes to remove debris.

3.3. Measure AKT activity using the FRET-based AKT activity assay according to the manufacturer's instructions.

3.4. Perform western blotting to validate AKT activity using antibodies against phosphorylated AKT (e.g., pAKT S473) and total AKT.

**Step 4: Analysis of Cell Viability**

4.1. Stain the treated cells with Annexin V-FITC and propidium iodide (PI) according to the manufacturer's instructions.

4.2. Analyze cell viability using flow cytometry (e.g., BD FACSCalibur) and determine the percentage of apoptotic cells (Annexin V+ PI-).

**Step 5: Comparison of AKT Activity and Cell Viability**

5.1. Compare AKT activity and cell viability between control, CD79A Y188F-transfected, and PI3K/AKT inhibitor-treated cells.

5.2. Perform statistical analysis (e.g., t-test, ANOVA) to determine significant differences between groups.

**Step 6: Interpretation of Results**

6.1. If AKT activity is rescued and apoptosis is prevented in the presence of PI3K/AKT inhibitors, it would suggest that PTEN-independent mechanisms can bypass the requirement for PTEN modulation in tonic BCR signaling inhibition-mediated AKT activity and apoptosis, disproving the hypothesis.","```
   PTEN Overexpression (μg)  CD79A Y188F Mutant (μg)  PI3K/AKT Inhibitor (μM)  AKT Activity  Apoptotic Cells (%)
0                         0.1                    2.0                    0.0  0.85          12.1
1                         1.0                    2.0                    0.0  0.60          20.5
2                         5.0                    2.0                    0.0  0.40          35.0
3                         0.1                    1.0                    0.0  0.90          10.0
4                         1.0                    1.0                    0.0  0.70          25.0
5                         5.0                    1.0                    0.0  0.50          40.0
6                         0.1                    0.0                    0.0  1.00           5.0
7                         1.0                    0.0                    0.0  0.80          15.0
8                         5.0                    0.0                    0.0  0.60          30.0
9                         0.1                    2.0                    1.0  0.75          18.0
10                        1.0                    2.0                    1.0  0.55          28.0
11                        5.0                    2.0                    1.0  0.40          42.0
12                        0.1                    1.0                    1.0  0.85          12.0
13                        1.0                    1.0                    1.0  0.65          22.0
14                        5.0                    1.0                    1.0  0.50          38.0
15                        0.1                    0.0                    1.0  0.95           8.0
16                        1.0                    0.0                    1.0  0.80          18.0
17                        5.0                    0.0                    1.0  0.65          32.0
18                        0.1                    2.0                    5.0  0.60          25.0
19                        1.0                    2.0                    5.0  0.45          35.0
20                        5.0                    2.0                    5.0  0.35          48.0
21                        0.1                    1.0                    5.0  0.75          20.0
22                        1.0                    1.0                    5.0  0.60          28.0
23                        5.0                    1.0                    5.0  0.50          40.0
24                        0.1                    0.0                    5.0  0.90          12.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c76f19ba3af326e01be9da917f522cf03f118445.summary'],"Does the modulation of the host immune response by T. cruzi during acute infection involve the upregulation of host antioxidant defenses, thereby creating a self-reinforcing cycle that enhances parasite survival and immune evasion?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis and potentially disprove it. This experiment will utilize existing scientific methods and equipment, with an unlimited budget in terms of time, resources, and financial support.

**Experiment Title:** ""Disproving the Role of Host Antioxidant Defenses in T. cruzi Immune Evasion during Acute Infection""

**Objective:** To determine if the modulation of the host immune response by T. cruzi during acute infection involves the upregulation of host antioxidant defenses, thereby creating a self-reinforcing cycle that enhances parasite survival and immune evasion.

**Experimental Design:**

**Step 1: In vitro Infection and Antioxidant Inhibition**

* Infect human macrophages with T. cruzi parasites in vitro.
* Treat infected macrophages with a potent antioxidant inhibitor (e.g., DPI, a NADPH oxidase inhibitor) to suppress host antioxidant defenses.
* Use a control group with infected macrophages without antioxidant inhibition.

**Step 2: ROS Measurement and Parasite Survival Analysis**

* Measure reactive oxygen species (ROS) levels in macrophages using DCFDA and flow cytometry.
* Analyze parasite survival and replication within macrophages using microscopy, qPCR, or flow cytometry.
* Compare ROS levels and parasite survival between the antioxidant-inhibited group and the control group.

**Step 3: Host Immune Response Analysis**

* Measure the expression of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and anti-inflammatory cytokines (e.g., IL-10, TGF-β) in macrophages using qRT-PCR or ELISA.
* Analyze the activation status of immune cells (e.g., macrophages, T cells) using flow cytometry or immunofluorescence microscopy.
* Compare the immune response between the antioxidant-inhibited group and the control group.

**Step 4: In vivo Infection and Antioxidant Inhibition**

* Infect mice with T. cruzi parasites and treat them with the antioxidant inhibitor (DPI) or a control vehicle.
* Monitor parasite load, immune response, and disease progression in mice using techniques such as qPCR, ELISA, and histopathology.
* Compare the outcomes between the antioxidant-inhibited group and the control group.

**Step 5: Data Analysis and Interpretation**

* Analyze the data from Steps 1-4 to determine if the inhibition of host antioxidant defenses affects T. cruzi survival, immune evasion, and disease progression.
* If the data show that antioxidant inhibition does not significantly impact T. cruzi survival or immune evasion, it would suggest that the hypothesis is false, and the modulation of the host immune response by T. cruzi during acute infection does not involve the upregulation of host antioxidant defenses.

**Equipment and Resources:**

* T. cruzi parasites
* Macrophages
* Antioxidant inhibitor (DPI)
* ROS detectors (e.g., DCFDA)
* Flow cytometer
* qRT-PCR machine
* ELISA reader
* Microscope
* Immunofluorescence microscope
* Mice (for in vivo infection)
* qPCR machine
* Histopathology equipment

**Timeline:**

* Literature review and experimental design: 2 weeks
* In vitro experiments: 4 weeks
* In vivo experiments: 8 weeks
* Data analysis and interpretation: 4 weeks
* Total duration: 18 weeks

This experimental plan is designed to test the hypothesis and potentially disprove it. If the results show that the inhibition of host antioxidant defenses does not affect T. cruzi survival or immune evasion, it would suggest that the hypothesis is false. However, if the results support the hypothesis, it would provide strong evidence for the role of host antioxidant defenses in T. cruzi immune evasion during acute infection.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Step 1: In vitro Infection and Antioxidant Inhibition**

1.1. Preparation of Macrophages:

* Obtain human macrophages from a reliable source (e.g., blood bank or cell culture repository).
* Culture macrophages in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
* Allow macrophages to adhere to the culture plate for 24 hours before infection.

1.2. Infection of Macrophages:

* Prepare T. cruzi parasites according to established protocols (e.g., trypomastigote isolation from infected mice or in vitro culture).
* Infect macrophages with T. cruzi parasites at a multiplicity of infection (MOI) of 10:1 (10 parasites per macrophage).
* Incubate infected macrophages for 2 hours at 37°C, 5% CO2 to allow for parasite internalization.

1.3. Antioxidant Inhibition:

* Prepare a stock solution of DPI (NADPH oxidase inhibitor) in DMSO at a concentration of 10 mM.
* Add DPI to infected macrophages at a final concentration of 10 μM.
* Incubate macrophages for an additional 24 hours at 37°C, 5% CO2.

1.4. Control Group:

* Prepare a control group of infected macrophages without DPI treatment.
* Incubate control macrophages for 24 hours at 37°C, 5% CO2.

**Step 2: ROS Measurement and Parasite Survival Analysis**

2.1. ROS Measurement:

* Prepare a stock solution of DCFDA (2',7'-dichlorofluorescein diacetate) in DMSO at a concentration of 10 mM.
* Add DCFDA to macrophages at a final concentration of 10 μM.
* Incubate macrophages for 30 minutes at 37°C, 5% CO2.
* Analyze ROS levels using flow cytometry (e.g., BD FACSCanto II).

2.2. Parasite Survival Analysis:

* Fix macrophages with 4% paraformaldehyde for 15 minutes at room temperature.
* Stain macrophages with Giemsa or DAPI to visualize parasites.
* Analyze parasite survival and replication using microscopy (e.g., Olympus IX71) or flow cytometry (e.g., BD FACSCanto II).

2.3. Data Analysis:

* Compare ROS levels and parasite survival between the antioxidant-inhibited group and the control group using statistical software (e.g., GraphPad Prism).

**Step 3: Host Immune Response Analysis**

3.1. Cytokine Expression:

* Extract RNA from macrophages using a commercial RNA extraction kit (e.g., Qiagen RNeasy).
* Perform qRT-PCR using primers specific for pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and anti-inflammatory cytokines (e.g., IL-10, TGF-β).
* Analyze cytokine expression using a qRT-PCR machine (e.g., Applied Biosystems 7500).

3.2. Immune Cell Activation:

* Stain macrophages with antibodies specific for immune cell surface markers (e.g., CD40, CD80, CD86).
* Analyze immune cell activation using flow cytometry (e.g., BD FACSCanto II) or immunofluorescence microscopy (e.g., Olympus IX71).

3.3. Data Analysis:

* Compare cytokine expression and immune cell activation between the antioxidant-inhibited group and the control group using statistical software (e.g., GraphPad Prism).

**Step 4: In vivo Infection and Antioxidant Inhibition**

4.1. Mouse Infection:

* Obtain mice from a reliable source (e.g., Jackson Laboratory).
* Infect mice with T. cruzi parasites via intraperitoneal injection (e.g., 10^5 parasites per mouse).
* Monitor mouse health and parasite load using techniques such as qPCR, ELISA, and histopathology.

4.2. Antioxidant Inhibition:

* Prepare a stock solution of DPI in DMSO at a concentration of 10 mM.
* Administer DPI to infected mice via intraperitoneal injection at a dose of 10 mg/kg body weight.
* Treat mice for 7 days post-infection.

4.3. Control Group:

* Prepare a control group of infected mice without DPI treatment.
* Monitor mouse health and parasite load using techniques such as qPCR, ELISA, and histopathology.

**Step 5: Data Analysis and Interpretation**

5.1. Data Analysis:

* Analyze data from Steps 1-4 using statistical software (e.g., GraphPad Prism).
* Compare outcomes between the antioxidant-inhibited group and the control group.

5.2. Interpretation:

* If the data show that antioxidant inhibition does not significantly impact T. cruzi survival or immune evasion, it would suggest that the hypothesis is false.
* If the data support the hypothesis, it would provide strong evidence for the role of host antioxidant defenses in T. cruzi immune evasion during acute infection.

**Equipment and Resources:**

* T. cruzi parasites
* Macrophages
* Antioxidant inhibitor (DPI)
* ROS detectors (e.g., DCFDA)
* Flow cytometer (e.g., BD FACSCanto II)
* qRT-PCR machine (e.g., Applied Biosystems 7500)
* ELISA reader
* Microscope (e.g., Olympus IX71)
* Immunofluorescence microscope (e.g., Olympus IX71)
* Mice (for in vivo infection)
* qPCR machine
* Histopathology equipment

**Timeline:**

* Literature review and experimental design: 2 weeks
* In vitro experiments: 4 weeks
* In vivo experiments: 8 weeks
* Data analysis and interpretation: 4 weeks
* Total duration: 18 weeks","```
   Macrophages  T_cruzi  DPI  DCFDA  ROS_Level  Parasite_Survival  TNF-alpha  IL-1beta  IL-10  TGF-beta  Outcome
0          10000     1000   5.0     10.0       200.0           0.8       100.0     50.0   20.0     10.0  Inhibited
1          15000     1500   7.5     12.5       250.0           0.9       120.0     60.0   25.0     12.0  Inhibited
2          20000     2000  10.0     15.0       300.0           1.0       150.0     75.0   30.0     15.0  Inhibited
3          25000     2500  12.5     17.5       350.0           1.1       180.0     90.0   35.0     18.0  Inhibited
4          30000     3000  15.0     20.0       400.0           1.2       210.0    105.0   40.0     20.0  Inhibited
5          10000     1000   2.5      7.5       150.0           0.6        80.0     40.0   15.0      8.0  Not_Inhibited
6          15000     1500   3.75      9.0       180.0           0.7        90.0     45.0   18.0      9.0  Not_Inhibited
7          20000     2000   5.0     10.5       220.0           0.8       100.0     50.0   20.0     10.0  Not_Inhibited
8          25000     2500   6.25     12.0       250.0           0.9       110.0     55.0   22.0     11.0  Not_Inhibited
9          30000     3000   7.5     13.5       280.0           1.0       120.0     60.0   25.0     12.0  Not_Inhibited
10         10000     1000   5.0     10.0       200.0           0.8       100.0     50.0   20.0     10.0  Inhibited
11         15000     1500   7.5     12.5       250.0           0.9       120.0     60.0   25.0     12.0  Inhibited
12         20000     2000  10.0     15.0       300.0           1.0       150.0     75.0   30.0     15.0  Inhibited
13         25000     2500  12.5     17.5       350.0           1.1       180.0     90.0   35.0     18.0  Inhibited
14         30000     3000  15.0     20.0       400.0           1.2       210.0    105.0   40.0     20.0  Inhibited
15         10000     1000   2.5      7.5       150.0           0.6        80.0     40.0   15.0      8.0  Not_Inhibited
16         15000     1500   3.75      9.0       180.0           0.7        90.0     45.0   18.0      9.0  Not_Inhibited
17         20000     2000   5.0     10.5       220.0           0.8       100.0     50.0   20.0     10.0  Not_Inhibited
18         25000     2500   6.25     12.0       250.0           0.9       110.0     55.0   22.0     11.0  Not_Inhibited
19         30000     3000   7.5     13.5       280.0           1.0       120.0     60.0   25.0     12.0  Not_Inhibited
20         10000     1000   5.0     10.0       200.0           0.8       100.0     50.0   20.0     10.0  Inhibited
21         15000     1500   7.5     12.5       250.0           0.9       120.0     60.0   25.0     12.0  Inhibited
22         20000     2000  10.0     15.0       300.0           1.0       150.0     75.0   30.0     15.0  Inhibited
23         25000     2500  12.5     17.5       350.0           1.1       180.0     90.0   35.0     18.0  Inhibited
24         30000     3000  15.0     20.0       400.0           1.2       210.0    105.0   40.0     20.0  Inhibited
```",0.4862775518139794
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ede35dbaed9a102c9a12dfc7cf4643edc34d6b25.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c2cd3a345d805bb13175c4948d2e4908a1cc7f5e.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0284344bbdbad158689e4dcef2a3a901dcfb4470.summary']","Does the nanoscale organization of CD22 on the surface of naive B cells influence the recruitment and activation of Vav proteins, thereby modulating BCR signaling and B cell development?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! Here's a high-level experimental plan to test the hypothesis, leveraging existing scientific methods and equipment, with an unlimited budget:

**Hypothesis:** The nanoscale organization of CD22 on the surface of naive B cells influences the recruitment and activation of Vav proteins, thereby modulating BCR signaling and B cell development.

**Experimental Approach:**

**Objective 1: Characterize CD22 nanoscale organization on naive B cells**

1. **Super-resolution microscopy**: Use techniques like Stochastic Optical Reconstruction Microscopy (STORM) or Photoactivated Localization Microscopy (PALM) to visualize and quantify the nanoscale organization of CD22 on the surface of naive B cells.
2. **Single-particle tracking**: Employ techniques like Single-Particle Tracking Photoactivated Localization Microscopy (sptPALM) to track the dynamics of individual CD22 molecules on the surface of naive B cells.

**Objective 2: Investigate the effect of CD22 organization on Vav protein recruitment and activation**

1. **Proximity Ligation Assay (PLA)**: Use PLA to detect the proximity of CD22 and Vav proteins on the surface of naive B cells, and quantify the effect of CD22 organization on Vav recruitment.
2. **Fluorescence Resonance Energy Transfer (FRET)**: Employ FRET to measure the activation state of Vav proteins in response to CD22 organization.
3. **Co-immunoprecipitation**: Perform co-immunoprecipitation assays to investigate the interaction between CD22 and Vav proteins, and assess the effect of CD22 organization on Vav binding.

**Objective 3: Examine the impact of CD22 organization on BCR signaling and B cell development**

1. **BCR signaling assays**: Use techniques like phospho-flow cytometry or Western blotting to measure BCR signaling downstream of CD22 organization.
2. **B cell development assays**: Employ in vitro B cell differentiation assays, such as CFSE-based proliferation assays or ELISPOT assays, to investigate the effect of CD22 organization on B cell development.

**Objective 4: Disrupt CD22 organization and assess the consequences**

1. **CD22 clustering disruption**: Use techniques like CD22-specific antibodies or small molecule inhibitors to disrupt CD22 clustering on the surface of naive B cells.
2. **CRISPR-Cas9 genome editing**: Use CRISPR-Cas9 to generate CD22 knockout or mutant B cells, and assess the effect on Vav protein recruitment, BCR signaling, and B cell development.

**Objective 5: Validate findings in vivo**

1. **Mouse models**: Use CD22-deficient or CD22-mutant mouse models to investigate the in vivo consequences of disrupted CD22 organization on B cell development and function.
2. **Adoptive transfer assays**: Perform adoptive transfer of CD22-disrupted B cells into wild-type mice to assess the effect on B cell development and function in a physiological context.

**Additional Considerations:**

* Use a combination of primary naive B cells and B cell lines to validate findings.
* Employ advanced bioinformatics tools to analyze high-throughput data generated from these experiments.
* Perform rigorous statistical analysis and data visualization to ensure the robustness and interpretability of the results.

With an unlimited budget, this experimental plan can be executed in a state-of-the-art laboratory, leveraging cutting-edge techniques and equipment to provide a comprehensive understanding of the role of CD22 nanoscale organization in modulating BCR signaling and B cell development.",92,"Here are the detailed, step-by-step protocols for each objective:

**Objective 1: Characterize CD22 nanoscale organization on naive B cells**

**Protocol 1.1: Super-resolution microscopy using STORM**

1.1.1. Prepare naive B cells:
	* Isolate naive B cells from mouse spleen or human peripheral blood using magnetic bead separation or fluorescence-activated cell sorting (FACS).
	* Wash cells with PBS and resuspend in 1 mL of PBS.
1.1.2. Fix and permeabilize cells:
	* Fix cells with 4% paraformaldehyde (PFA) for 10 minutes at room temperature.
	* Permeabilize cells with 0.1% Triton X-100 for 10 minutes at room temperature.
1.1.3. Label CD22:
	* Incubate cells with a primary antibody against CD22 (e.g., Alexa Fluor 647-conjugated anti-CD22) for 1 hour at room temperature.
	* Wash cells with PBS three times.
1.1.4. Mount cells on coverslips:
	* Place a drop of cell suspension on a coverslip and let it air-dry.
	* Mount the coverslip on a microscope slide using a mounting medium (e.g., Prolong Gold).
1.1.5. Image acquisition:
	* Use a STORM microscope (e.g., Nikon N-STORM) to acquire images of CD22-labeled cells.
	* Set the excitation wavelength to 647 nm and the emission wavelength to 670 nm.
	* Acquire images with a 100x oil immersion objective lens and a pixel size of 20 nm.
1.1.6. Image analysis:
	* Use software (e.g., Nikon NIS-Elements) to analyze the acquired images.
	* Measure the distance between individual CD22 molecules using the localization precision of STORM.

**Protocol 1.2: Single-particle tracking using sptPALM**

1.2.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
1.2.2. Label CD22:
	* Incubate cells with a photoactivatable fluorescent protein (e.g., PAmCherry1) conjugated to an anti-CD22 antibody for 1 hour at room temperature.
	* Wash cells with PBS three times.
1.2.3. Mount cells on coverslips:
	* Follow the same steps as in Protocol 1.1.4.
1.2.4. Image acquisition:
	* Use a sptPALM microscope (e.g., Zeiss Elyra 7) to acquire images of CD22-labeled cells.
	* Set the excitation wavelength to 405 nm and the emission wavelength to 595 nm.
	* Acquire images with a 100x oil immersion objective lens and a pixel size of 20 nm.
1.2.5. Image analysis:
	* Use software (e.g., Zeiss ZEN) to analyze the acquired images.
	* Track the movement of individual CD22 molecules using the sptPALM algorithm.

**Objective 2: Investigate the effect of CD22 organization on Vav protein recruitment and activation**

**Protocol 2.1: Proximity Ligation Assay (PLA)**

2.1.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
2.1.2. Fix and permeabilize cells:
	* Follow the same steps as in Protocol 1.1.2.
2.1.3. Label CD22 and Vav:
	* Incubate cells with a primary antibody against CD22 (e.g., rabbit anti-CD22) and a primary antibody against Vav (e.g., mouse anti-Vav) for 1 hour at room temperature.
	* Wash cells with PBS three times.
2.1.4. Perform PLA:
	* Use a PLA kit (e.g., Duolink) to detect the proximity of CD22 and Vav proteins.
	* Follow the manufacturer's instructions for the PLA reaction.
2.1.5. Image acquisition:
	* Use a confocal microscope (e.g., Zeiss LSM 880) to acquire images of PLA-labeled cells.
	* Set the excitation wavelength to 488 nm and the emission wavelength to 520 nm.
	* Acquire images with a 63x oil immersion objective lens and a pixel size of 100 nm.
2.1.6. Image analysis:
	* Use software (e.g., Zeiss ZEN) to analyze the acquired images.
	* Quantify the number of PLA signals per cell using the Duolink ImageTool software.

**Protocol 2.2: Fluorescence Resonance Energy Transfer (FRET)**

2.2.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
2.2.2. Transfect cells with FRET sensors:
	* Transfect cells with a FRET sensor plasmid (e.g., Vav-FRET) using a transfection reagent (e.g., Lipofectamine 2000).
	* Incubate cells for 24 hours at 37°C.
2.2.3. Label CD22:
	* Incubate cells with a primary antibody against CD22 (e.g., Alexa Fluor 488-conjugated anti-CD22) for 1 hour at room temperature.
	* Wash cells with PBS three times.
2.2.4. Image acquisition:
	* Use a confocal microscope (e.g., Zeiss LSM 880) to acquire images of FRET-labeled cells.
	* Set the excitation wavelength to 488 nm and the emission wavelength to 520 nm (for donor) and 560 nm (for acceptor).
	* Acquire images with a 63x oil immersion objective lens and a pixel size of 100 nm.
2.2.5. Image analysis:
	* Use software (e.g., Zeiss ZEN) to analyze the acquired images.
	* Calculate the FRET efficiency using the acceptor-to-donor ratio.

**Protocol 2.3: Co-immunoprecipitation**

2.3.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
2.3.2. Lyse cells:
	* Lyse cells with a lysis buffer (e.g., RIPA buffer) containing protease inhibitors.
2.3.3. Immunoprecipitate CD22:
	* Incubate the cell lysate with a primary antibody against CD22 (e.g., rabbit anti-CD22) and protein A/G beads for 2 hours at 4°C.
	* Wash the beads with lysis buffer three times.
2.3.4. Detect Vav:
	* Incubate the beads with a primary antibody against Vav (e.g., mouse anti-Vav) for 1 hour at room temperature.
	* Wash the beads with lysis buffer three times.
2.3.5. Analyze by Western blot:
	* Elute the immunoprecipitated proteins with a sample buffer (e.g., Laemmli buffer).
	* Run the samples on an SDS-PAGE gel and transfer to a PVDF membrane.
	* Detect Vav using a secondary antibody (e.g., HRP-conjugated anti-mouse IgG) and ECL reagents.

**Objective 3: Examine the impact of CD22 organization on BCR signaling and B cell development**

**Protocol 3.1: BCR signaling assays**

3.1.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
3.1.2. Stimulate BCR:
	* Incubate cells with an anti-IgM antibody (e.g., goat anti-mouse IgM) for 10 minutes at 37°C.
3.1.3. Fix and permeabilize cells:
	* Follow the same steps as in Protocol 1.1.2.
3.1.4. Label phospho-proteins:
	* Incubate cells with a primary antibody against a phospho-protein (e.g., phospho-ERK) for 1 hour at room temperature.
	* Wash cells with PBS three times.
3.1.5. Analyze by flow cytometry:
	* Use a flow cytometer (e.g., BD LSRFortessa) to analyze the labeled cells.
	* Gate on live cells and measure the fluorescence intensity of the phospho-protein.

**Protocol 3.2: B cell development assays**

3.2.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
3.2.2. Label cells with CFSE:
	* Incubate cells with CFSE (e.g., 5 μM) for 10 minutes at 37°C.
3.2.3. Culture cells:
	* Culture cells in a 96-well plate with a B cell growth medium (e.g., RPMI 1640 with 10% FBS) for 3-5 days at 37°C.
3.2.4. Analyze by flow cytometry:
	* Use a flow cytometer (e.g., BD LSRFortessa) to analyze the labeled cells.
	* Gate on live cells and measure the fluorescence intensity of CFSE.

**Objective 4: Disrupt CD22 organization and assess the consequences**

**Protocol 4.1: CD22 clustering disruption**

4.1.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
4.1.2. Incubate with CD22-specific antibodies:
	* Incubate cells with a CD22-specific antibody (e.g., anti-CD22 Fab fragment) for 1 hour at room temperature.
	* Wash cells with PBS three times.
4.1.3. Analyze CD22 organization:
	* Follow the same steps as in Protocol 1.1.

**Protocol 4.2: CRISPR-Cas9 genome editing**

4.2.1. Prepare naive B cells:
	* Follow the same steps as in Protocol 1.1.1.
4.2.2. Design CRISPR-Cas9 guide RNA:
	* Design a guide RNA targeting the CD22 gene using a CRISPR design tool (e.g., CRISPR Design).
4.2.3. Transfect cells with CRISPR-Cas9:
	* Transfect cells with a CRISPR-Cas9 plasmid (e.g., pSpCas9) using a transfection reagent (e.g., Lipofectamine 2000).
	* Incubate cells for 24 hours at 37°C.
4.2.4. Analyze CD22 knockout/mutation:
	* Use PCR and sequencing to verify the knockout/mutation of the CD22 gene.

**Objective 5: Validate findings in vivo**

**Protocol 5.1: Mouse models**

5.1.1. Generate CD22-deficient or CD22-mutant mice:
	* Use CRISPR-Cas9 genome editing to generate CD22-deficient or CD22-mutant mice.
5.1.2. Analyze B cell development and function:
	* Analyze B cell development and function in the CD22-deficient or CD22-mutant mice using flow cytometry, ELISPOT assays, and other immunological assays.

**Protocol 5.2: Adoptive transfer assays**

5.2.1. Prepare CD22-disrupted B cells:
	* Follow the same steps as in Protocol 4.1 or 4.2.
5.2.2. Adoptively transfer cells:
	* Transfer the CD22-disrupted B cells into wild-type mice via intravenous injection.
5.2.3. Analyze B cell development and function:
	* Analyze B cell development and function in the recipient mice using flow cytometry, ELISPOT assays, and other immunological assays.

These detailed protocols should provide a comprehensive understanding of the role of CD22 nanoscale organization in modulating BCR signaling and B cell development.","Here is the simulated dataframe:

```
   Paraformaldehyde  Triton X-100  Alexa Fluor 647  PAmCherry1  CD22 Antibody  Vav Antibody  PLA Kit  FRET Sensor  Transfection Reagent  CD22-specific Antibody  CRISPR-Cas9  Outcome
0               3.5          0.05             1.0         0.5           1.0           1.0      1.0         0.5               1.0               0.5         0.5         0.8
1               4.0          0.10             1.2         0.6           1.1           1.1      1.1         0.6               1.1               0.6         0.6         0.9
2               3.0          0.08             0.9         0.4           0.9           0.9      0.9         0.4               0.9               0.4         0.4         0.7
3               3.8          0.12             1.4         0.7           1.2           1.2      1.2         0.7               1.2               0.7         0.7         1.0
4               3.2          0.09             1.1         0.5           1.0           1.0      1.0         0.5               1.0               0.5         0.5         0.8
5               4.2          0.14             1.6         0.8           1.3           1.3      1.3         0.8               1.3               0.8         0.8         1.1
6               3.6          0.11             1.3         0.6           1.1           1.1      1.1         0.6               1.1               0.6         0.6         0.9
7               3.9          0.13             1.5         0.7           1.2           1.2      1.2         0.7               1.2               0.7         0.7         1.0
8               3.1          0.07             0.8         0.4           0.9           0.9      0.9         0.4               0.9               0.4         0.4         0.7
9               4.4          0.16             1.8         0.9           1.4           1.4      1.4         0.9               1.4               0.9         0.9         1.2
10              3.4          0.10             1.2         0.5           1.0           1.0      1.0         0.5               1.0               0.5         0.5         0.8
11              4.1          0.15             1.7         0.8           1.3           1.3      1.3         0.8               1.3               0.8         0.8         1.1
12              3.7          0.12             1.4         0.6           1.1           1.1      1.1         0.6               1.1               0.6         0.6         0.9
13              4.5          0.18             2.0         1.0           1.5           1.5      1.5         1.0               1.5               1.0         1.0         1.3
14              3.3          0.08             0.9         0.4           0.9           0.9      0.9         0.4               0.9               0.4         0.4         0.7
15              4.6          0.20             2.2         1.1           1.6           1.6      1.6         1.1               1.6               1.1         1.1         1.4
16              3.5          0.11             1.3         0.5           1.0           1.0      1.0         0.5               1.0               0.5         0.5         0.8
17              4.7          0.22             2.4         1.2           1.7           1.7      1.7         1.2               1.7               1.2         1.2         1.5
18              3.2          0.09             1.1         0.4           0.9           0.9      0.9         0.4               0.9               0.4         0.4         0.7
19              4.8          0.24             2.6         1.3           1.8           1.8      1.8         1.3               1.8               1.3         1.3         1.6
20              3.6          0.13             1.5         0.6           1.1           1.1      1.1         0.6               1.1               0.6         0.6         0.9
21              4.9          0.26             2.8         1.4           1.9           1.9      1.9         1.4               1.9               1.4         1.4         1.7
22              3.4          0.10             1.2         0.5           1.0           1.0      1.0         0.5               1.0               0.5         0.5         0.8
23              5.0          0.28             3.0         1.5           2.0           2.0      2.0         1.5               2.0               1.5         1.5         1.8
24              3.8          0.14             1.6         0.7           1.2           1.2      1.2         0.7               1.2               0.7         0.7         1.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ce9490a94c869e1e46d221042a0cf4efeb447b00.summary'],"Does the non-canonical function of RAG1 in B and T cell development involve the regulation of a novel, catalytically-independent signaling pathway that can be modulated by post-translational modifications of the D600 residue?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Non-Canonical Function of RAG1 in B and T Cell Development: A Study on the Regulation of a Novel Signaling Pathway by Post-Translational Modifications of the D600 Residue

**Objective:** To determine if the non-canonical function of RAG1 in B and T cell development involves the regulation of a novel, catalytically-independent signaling pathway that can be modulated by post-translational modifications of the D600 residue.

**Experimental Approach:**

1. **Generation of RAG1-D600C and RAG1-D600A/D600C double mutant mouse lines:** Use CRISPR-Cas9 genome editing to generate RAG1-D600C and RAG1-D600A/D600C double mutant mouse lines.
2. **Crossing and breeding:** Cross the RAG1-D600C and RAG1-D600A/D600C mouse lines with Rag1D600A mice to generate offspring with the desired genotypes.
3. **Flow cytometry analysis:** Analyze B and T cell development in the offspring using flow cytometry to assess the rescue of the developmental block.
4. **Western blot and co-immunoprecipitation:** Perform Western blot and co-immunoprecipitation assays to investigate the post-translational modifications of the D600 residue and its potential interactions with other proteins in the signaling pathway.
5. **Signaling pathway analysis:** Use techniques such as RNA sequencing, protein arrays, or phospho-protein arrays to identify the novel signaling pathway regulated by RAG1-D600C and its modulation by post-translational modifications of the D600 residue.

**Expected Outcomes:**

* Rescue of the developmental block in B and T cell development in RAG1-D600C and RAG1-D600A/D600C mice
* Identification of post-translational modifications of the D600 residue and their impact on the novel signaling pathway
* Elucidation of the novel signaling pathway regulated by RAG1-D600C and its modulation by post-translational modifications of the D600 residue

**Equipment and Resources:**

* CRISPR-Cas9 genome editing system
* Mouse breeding facilities
* Flow cytometer
* Western blot and co-immunoprecipitation equipment
* RNA sequencing, protein arrays, or phospho-protein arrays equipment
* Bioinformatics tools for data analysis

**Timeline:** 12-18 months

**Budget:** $200,000 - $300,000

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of RAG1-D600C in B and T Cell Development: A Dominant-Negative Approach

**Objective:** To determine if the RAG1-D600C mutant can act as a dominant-negative inhibitor of the non-canonical function of RAG1, thereby disproving the hypothesis.

**Experimental Approach:**

1. **Generation of RAG1-D600C transgenic mouse line:** Use CRISPR-Cas9 genome editing to generate a RAG1-D600C transgenic mouse line.
2. **Crossing and breeding:** Cross the RAG1-D600C transgenic mouse line with wild-type mice to generate offspring with a mixed background.
3. **Flow cytometry analysis:** Analyze B and T cell development in the offspring using flow cytometry to assess the impact of RAG1-D600C on B and T cell development.
4. **Western blot and co-immunoprecipitation:** Perform Western blot and co-immunoprecipitation assays to investigate the interactions between RAG1-D600C and other proteins involved in the non-canonical function of RAG1.

**Expected Outcomes:**

* Inhibition of B and T cell development in RAG1-D600C transgenic mice
* Disruption of the non-canonical function of RAG1 by RAG1-D600C
* Failure to identify a novel signaling pathway regulated by RAG1-D600C

**Equipment and Resources:**

* CRISPR-Cas9 genome editing system
* Mouse breeding facilities
* Flow cytometer
* Western blot and co-immunoprecipitation equipment
* Bioinformatics tools for data analysis

**Timeline:** 6-12 months

**Budget:** $100,000 - $150,000

By performing these experiments, we can test the hypothesis and attempt to disprove it, providing a comprehensive understanding of the non-canonical function of RAG1 in B and T cell development.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Step 1: Generation of RAG1-D600C and RAG1-D600A/D600C double mutant mouse lines**

1.1. Design guide RNAs (gRNAs) targeting the RAG1 gene using online tools (e.g., CRISPR Design) to introduce the D600C and D600A mutations.

1.2. Prepare the gRNAs and Cas9 mRNA using in vitro transcription and purification kits.

1.3. Microinject the gRNAs and Cas9 mRNA into fertilized mouse eggs using a microinjection system.

1.4. Transfer the injected eggs to pseudopregnant female mice and allow them to develop to term.

1.5. Genotype the offspring using PCR and Sanger sequencing to identify mice with the desired mutations.

**Step 2: Crossing and breeding**

2.1. Cross the RAG1-D600C and RAG1-D600A/D600C mice with Rag1D600A mice to generate F1 offspring.

2.2. Breed the F1 offspring to generate F2 offspring with the desired genotypes.

2.3. Genotype the F2 offspring using PCR and Sanger sequencing to identify mice with the desired genotypes.

**Step 3: Flow cytometry analysis**

3.1. Prepare single-cell suspensions from the spleens and lymph nodes of the F2 offspring.

3.2. Stain the cells with fluorescently labeled antibodies against B and T cell markers (e.g., CD19, CD20, CD4, CD8).

3.3. Analyze the cells using a flow cytometer (e.g., BD FACSCanto) to assess B and T cell development.

3.4. Use flow cytometry software (e.g., FlowJo) to analyze the data and generate plots.

**Step 4: Western blot and co-immunoprecipitation**

4.1. Prepare protein lysates from the spleens and lymph nodes of the F2 offspring.

4.2. Perform Western blotting using antibodies against RAG1, D600C, and other proteins of interest.

4.3. Perform co-immunoprecipitation assays using antibodies against RAG1 and other proteins of interest.

4.4. Analyze the Western blot and co-immunoprecipitation data to identify post-translational modifications of the D600 residue and its interactions with other proteins.

**Step 5: Signaling pathway analysis**

5.1. Prepare RNA from the spleens and lymph nodes of the F2 offspring.

5.2. Perform RNA sequencing (e.g., Illumina HiSeq) to identify differentially expressed genes.

5.3. Analyze the RNA sequencing data using bioinformatics tools (e.g., DESeq2, edgeR) to identify differentially expressed genes.

5.4. Perform protein arrays or phospho-protein arrays to identify changes in protein expression and phosphorylation.

5.5. Analyze the protein array data using bioinformatics tools (e.g., R, Python) to identify changes in protein expression and phosphorylation.

**Experiment to Disprove the Hypothesis:**

**Step 1: Generation of RAG1-D600C transgenic mouse line**

1.1. Design a DNA construct containing the RAG1-D600C mutation and a promoter element (e.g., CMV).

1.2. Prepare the DNA construct using molecular cloning techniques (e.g., Gibson assembly).

1.3. Microinject the DNA construct into fertilized mouse eggs using a microinjection system.

1.4. Transfer the injected eggs to pseudopregnant female mice and allow them to develop to term.

1.5. Genotype the offspring using PCR and Sanger sequencing to identify mice with the transgene.

**Step 2: Crossing and breeding**

2.1. Cross the RAG1-D600C transgenic mice with wild-type mice to generate F1 offspring.

2.2. Breed the F1 offspring to generate F2 offspring with a mixed background.

2.3. Genotype the F2 offspring using PCR and Sanger sequencing to identify mice with the transgene.

**Step 3: Flow cytometry analysis**

3.1. Prepare single-cell suspensions from the spleens and lymph nodes of the F2 offspring.

3.2. Stain the cells with fluorescently labeled antibodies against B and T cell markers (e.g., CD19, CD20, CD4, CD8).

3.3. Analyze the cells using a flow cytometer (e.g., BD FACSCanto) to assess B and T cell development.

3.4. Use flow cytometry software (e.g., FlowJo) to analyze the data and generate plots.

**Step 4: Western blot and co-immunoprecipitation**

4.1. Prepare protein lysates from the spleens and lymph nodes of the F2 offspring.

4.2. Perform Western blotting using antibodies against RAG1, D600C, and other proteins of interest.

4.3. Perform co-immunoprecipitation assays using antibodies against RAG1 and other proteins of interest.

4.4. Analyze the Western blot and co-immunoprecipitation data to investigate the interactions between RAG1-D600C and other proteins involved in the non-canonical function of RAG1.

Note: These protocols are detailed and specific, but they may require adjustments based on the specific laboratory setup and equipment. Additionally, the protocols should be reviewed and approved by the relevant institutional review boards and animal care committees before implementation.","```
   gRNA_D600C  gRNA_D600A  Cas9_mRNA  RAG1_D600C  RAG1_D600A  Outcome
0           2          1         10          1          1  Normal
1           1          2         12          2          1  Abnormal
2           3          1          8          1          2  Normal
3           2          3         11          2          2  Abnormal
4           1          1         13          1          1  Normal
5           3          2          9          2          1  Abnormal
6           2          1         10          1          2  Normal
7           1          3         12          2          2  Abnormal
8           2          2         11          1          1  Normal
9           3          1         13          2          1  Abnormal
10          1          2         10          1          2  Normal
11          2          3         12          2          2  Abnormal
12          3          2         11          1          1  Normal
13          1          1         13          2          2  Abnormal
14          2          1         10          2          1  Normal
15          3          3         12          1          2  Abnormal
16          1          2         11          2          1  Normal
17          2          1         13          1          2  Abnormal
18          3          2         10          2          2  Normal
19          1          3         12          1          1  Abnormal
20          2          2         11          2          2  Normal
21          3          1         13          1          1  Abnormal
22          1          1         10          2          2  Normal
23          2          3         12          2          1  Abnormal
24          3          2         11          1          2  Normal
```",0.24467179579983805
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7679c9fd4ed819d5b41de77cc07def70d11eae15.summary'],"Does the normalization of mitochondrial respiration rates by ibrutinib treatment in CLL cells also lead to a decrease in the production of reactive oxygen species, thereby reducing oxidative stress and DNA damage in these cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I've developed an experimental plan to test it. Since the goal is to disprove the hypothesis, the experiment is designed to detect any potential increase in reactive oxygen species (ROS) production and DNA damage in CLL cells after ibrutinib treatment.

**Experiment Title:** Investigating the Effect of Ibrutinib on Reactive Oxygen Species Production and DNA Damage in CLL Cells

**Objective:** To determine if ibrutinib treatment leads to a decrease in ROS production and DNA damage in CLL cells, thereby reducing oxidative stress.

**Experimental Design:**

1. **Cell Culture:** Obtain CLL cells from patients or use established CLL cell lines (e.g., MEC-1 or JVM-3). Culture cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
2. **Ibrutinib Treatment:** Treat CLL cells with ibrutinib (1-10 μM) for 24-48 hours to normalize mitochondrial respiration rates, as observed in the previous study.
3. **ROS Measurement:** Use a fluorescent probe, such as DCFDA (2',7'-dichlorofluorescein diacetate), to measure ROS production in CLL cells. Incubate cells with DCFDA (10 μM) for 30 minutes, then wash and analyze using flow cytometry (e.g., BD FACSCanto II).
4. **DNA Damage Assay:** Use the comet assay (single-cell gel electrophoresis) to assess DNA damage in CLL cells. Treat cells with ibrutinib as above, then mix with low-melting-point agarose and spread onto microscope slides. Subject the slides to alkaline electrophoresis, followed by SYBR Gold staining and visualization under a fluorescence microscope.
5. **Control Groups:** Include the following control groups:
	* Untreated CLL cells (no ibrutinib)
	* CLL cells treated with a vehicle control (e.g., DMSO)
	* Healthy B lymphocytes (isolated from peripheral blood) as a reference control
6. **Replication and Statistical Analysis:** Perform each experiment in triplicate, and analyze data using one-way ANOVA with Tukey's post-hoc test to compare ROS production and DNA damage between groups.

**Expected Outcomes:**

* If the hypothesis is true, ibrutinib treatment should lead to a decrease in ROS production and DNA damage in CLL cells compared to untreated cells.
* If the hypothesis is false, ibrutinib treatment may not affect or even increase ROS production and DNA damage in CLL cells.

**Time and Resource Considerations:**

* Cell culture and ibrutinib treatment: 3-5 days
* ROS measurement: 1 day
* DNA damage assay: 2-3 days
* Data analysis: 1-2 weeks
* Total duration: 7-12 weeks
* Budget: The cost of ibrutinib, cell culture reagents, and fluorescent probes will be the main expenses. The estimated budget for this experiment is approximately $5,000-$10,000.

By following this experimental plan, you can test the hypothesis and determine if ibrutinib treatment indeed leads to a decrease in ROS production and DNA damage in CLL cells, thereby reducing oxidative stress.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture**

1.1. Obtain CLL cells from patients or use established CLL cell lines (e.g., MEC-1 or JVM-3).

* If using patient samples, obtain informed consent and follow institutional review board (IRB) guidelines for handling human samples.
* If using cell lines, ensure they are authenticated and mycoplasma-free.

1.2. Culture cells in RPMI-1640 medium supplemented with:
	* 10% Fetal Bovine Serum (FBS)
	* 1% Penicillin-Streptomycin (10,000 U/mL)
	* 1% L-Glutamine (200 mM)

* Use sterile technique and a laminar flow hood to minimize contamination.
* Incubate cells at 37°C, 5% CO2, and 95% humidity.

**Protocol 2: Ibrutinib Treatment**

2.1. Prepare ibrutinib stock solution:
	* Dissolve ibrutinib in DMSO to a final concentration of 10 mM.
	* Aliquot and store at -20°C.

2.2. Treat CLL cells with ibrutinib:
	* Add ibrutinib to the cell culture medium to a final concentration of 1-10 μM.
	* Incubate cells for 24-48 hours to normalize mitochondrial respiration rates.

**Protocol 3: ROS Measurement**

3.1. Prepare DCFDA stock solution:
	* Dissolve DCFDA in DMSO to a final concentration of 10 mM.
	* Aliquot and store at -20°C.

3.2. Incubate cells with DCFDA:
	* Add DCFDA to the cell culture medium to a final concentration of 10 μM.
	* Incubate cells for 30 minutes at 37°C, 5% CO2, and 95% humidity.

3.3. Wash and analyze cells using flow cytometry:
	* Centrifuge cells at 300 x g for 5 minutes.
	* Resuspend cells in PBS and analyze using a flow cytometer (e.g., BD FACSCanto II).
	* Set the excitation wavelength to 488 nm and emission wavelength to 525 nm.

**Protocol 4: DNA Damage Assay (Comet Assay)**

4.1. Prepare low-melting-point agarose:
	* Dissolve 1% low-melting-point agarose in PBS.
	* Microwave until dissolved, then cool to 37°C.

4.2. Mix cells with agarose:
	* Resuspend cells in 1 mL of PBS.
	* Add 1 mL of low-melting-point agarose to the cell suspension.
	* Mix gently to avoid cell lysis.

4.3. Spread onto microscope slides:
	* Place 1 mL of the cell-agarose mixture onto a microscope slide.
	* Spread evenly using a coverslip.

4.4. Subject to alkaline electrophoresis:
	* Place the slide in an alkaline electrophoresis buffer (pH 13) for 20 minutes.
	* Electrophorese at 25 V, 300 mA for 20 minutes.

4.5. Stain with SYBR Gold:
	* Remove the slide from the electrophoresis buffer.
	* Add 1 mL of SYBR Gold stain (1:10,000 in PBS).
	* Incubate for 10 minutes at room temperature.

4.6. Visualize under a fluorescence microscope:
	* Examine the slide using a fluorescence microscope with a 488 nm excitation filter.
	* Capture images of at least 50 cells per sample.

**Protocol 5: Control Groups**

5.1. Untreated CLL cells:
	* Culture CLL cells without ibrutinib treatment.

5.2. Vehicle control:
	* Treat CLL cells with DMSO (0.1% final concentration) for 24-48 hours.

5.3. Healthy B lymphocytes:
	* Isolate B lymphocytes from peripheral blood using a density gradient centrifugation method (e.g., Ficoll-Paque).
	* Culture and treat with ibrutinib as described above.

**Protocol 6: Replication and Statistical Analysis**

6.1. Perform each experiment in triplicate.

6.2. Analyze data using one-way ANOVA with Tukey's post-hoc test to compare ROS production and DNA damage between groups.

6.3. Calculate the mean and standard deviation for each group.
6.4. Compare the means using ANOVA and Tukey's post-hoc test.
6.5. Report the results as mean ± SD, with p-values indicating significance.

By following these detailed protocols, the experiment can be replicated and the hypothesis tested.","```
   FBS  Penicillin-Streptomycin  L-Glutamine  Ibrutinib  DCFDA  ROS_Production  DNA_Damage
0   9.5               0.95         0.95       5.0    9.5         120.0        25.0
1  10.5               1.05         1.05       7.0   10.5         140.0        30.0
2   9.0               0.90         0.90       3.0    9.0         100.0        20.0
3  10.0               1.00         1.00       9.0   10.0         160.0        35.0
4   9.8               0.98         0.98       4.0    9.8         130.0        28.0
5   9.2               0.92         0.92       6.0    9.2         110.0        22.0
6  10.2               1.02         1.02       8.0   10.2         150.0        32.0
7   9.6               0.96         0.96       2.0    9.6          90.0        18.0
8   9.4               0.94         0.94       5.0    9.4         120.0        25.0
9  10.8               1.08         1.08      10.0   10.8         180.0        40.0
10  9.1               0.91         0.91       3.0    9.1         100.0        20.0
11  9.9               0.99         0.99       7.0    9.9         140.0        30.0
12  10.4               1.04         1.04       9.0   10.4         160.0        35.0
13  9.7               0.97         0.97       4.0    9.7         130.0        28.0
14  9.3               0.93         0.93       6.0    9.3         110.0        22.0
15  10.1               1.01         1.01       8.0   10.1         150.0        32.0
16  9.5               0.95         0.95       2.0    9.5          90.0        18.0
17  10.6               1.06         1.06      10.0   10.6         180.0        40.0
18  9.0               0.90         0.90       5.0    9.0         120.0        25.0
19  10.3               1.03         1.03       7.0   10.3         140.0        30.0
20  9.8               0.98         0.98       4.0    9.8         130.0        28.0
21  9.2               0.92         0.92       6.0    9.2         110.0        22.0
22  10.9               1.09         1.09      10.0   10.9         190.0        45.0
23  9.4               0.94         0.94       3.0    9.4         100.0        20.0
24  10.0               1.00         1.00       9.0   10.0         160.0        35.0
```",0.9057331212840576
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3fe5c82fcab21ef67d1435ed4c47dc1043bf4399.summary'],Does the novel adapter protein interact with actin to facilitate the non-canonical signaling pathway of Siglec-8-induced eosinophil death?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Interaction between the Novel Adapter Protein, Actin, and Siglec-8 in Eosinophil Death

**Objective:** To determine if the novel adapter protein interacts with actin to facilitate the non-canonical signaling pathway of Siglec-8-induced eosinophil death.

**Experimental Approach:**

1. **Co-immunoprecipitation and Western Blot:**
	* Isolate eosinophils and prime them with IL-5.
	* Treat eosinophils with Siglec-8 antibody and lyse them.
	* Perform co-immunoprecipitation using Siglec-8 antibody, actin antibody, and novel adapter protein antibody.
	* Analyze the immunoprecipitates by western blot for the presence of Siglec-8, actin, and the novel adapter protein.
2. **Actin Rearrangement Assay:**
	* Use fluorescently labeled phalloidin to stain actin filaments in eosinophils.
	* Treat eosinophils with Siglec-8 antibody and observe actin rearrangement using confocal microscopy.
	* Co-transfect eosinophils with the novel adapter protein and actin-GFP to visualize the interaction.
3. **Proximity Ligation Assay (PLA):**
	* Use PLA to detect the proximity of the novel adapter protein, actin, and Siglec-8 in eosinophils.
	* Treat eosinophils with Siglec-8 antibody and perform PLA using antibodies against the novel adapter protein, actin, and Siglec-8.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of Actin in Siglec-8-Induced Eosinophil Death Independent of the Novel Adapter Protein

**Objective:** To determine if actin rearrangement is sufficient to induce eosinophil death through the non-canonical Siglec-8 pathway, independent of the novel adapter protein.

**Experimental Approach:**

1. **Actin Rearrangement Induction:**
	* Use actin-modulating agents (e.g., cytochalasin D or jasplakinolide) to induce actin rearrangement in eosinophils.
	* Treat eosinophils with Siglec-8 antibody and measure cell death using Annexin V staining and flow cytometry.
2. **Novel Adapter Protein Knockdown:**
	* Use siRNA or CRISPR-Cas9 to knockdown the novel adapter protein in eosinophils.
	* Treat eosinophils with Siglec-8 antibody and measure cell death using Annexin V staining and flow cytometry.
3. **Combination of Actin Rearrangement Induction and Novel Adapter Protein Knockdown:**
	* Combine the above approaches to test if actin rearrangement alone is sufficient to induce eosinophil death through the non-canonical Siglec-8 pathway, independent of the novel adapter protein.

**Rationale:**

If the novel adapter protein is essential for the non-canonical Siglec-8 pathway, then:

* Actin rearrangement induction alone should not induce eosinophil death.
* Novel adapter protein knockdown should prevent Siglec-8-induced eosinophil death.
* Combining actin rearrangement induction with novel adapter protein knockdown should not rescue eosinophil death.

If the results contradict these expectations, it would suggest that the novel adapter protein is not essential for the non-canonical Siglec-8 pathway, and the hypothesis would be disproven.

**Time and Resource Considerations:**

This experimental plan can be completed within a reasonable time frame (6-12 months) and with a moderate budget. The required equipment and reagents are readily available in most molecular biology and cell biology laboratories. The experiment to disprove the hypothesis is designed to be efficient and cost-effective, using existing techniques and reagents.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Co-immunoprecipitation and Western Blot**

**Step 1: Eosinophil Isolation and Priming**

1.1. Obtain human eosinophils from peripheral blood using a density gradient centrifugation method (e.g., Ficoll-Paque).
1.2. Wash the isolated eosinophils with PBS and resuspend them in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.
1.3. Prime the eosinophils with 10 ng/mL IL-5 for 24 hours at 37°C, 5% CO2.

**Step 2: Treatment with Siglec-8 Antibody and Lysis**

2.1. Treat the primed eosinophils with 10 μg/mL Siglec-8 antibody for 30 minutes at 37°C, 5% CO2.
2.2. Lyse the eosinophils using a lysis buffer (e.g., RIPA buffer) containing protease inhibitors (e.g., PMSF, aprotinin).
2.3. Centrifuge the lysate at 10,000 x g for 10 minutes at 4°C to remove debris.

**Step 3: Co-immunoprecipitation**

3.1. Incubate the lysate with 2 μg of Siglec-8 antibody, 2 μg of actin antibody, and 2 μg of novel adapter protein antibody for 2 hours at 4°C.
3.2. Add 20 μL of protein A/G beads to the lysate and incubate for an additional 1 hour at 4°C.
3.3. Centrifuge the mixture at 1,000 x g for 5 minutes at 4°C to collect the immunoprecipitates.

**Step 4: Western Blot Analysis**

4.1. Elute the immunoprecipitates with 2x Laemmli buffer and separate the proteins using SDS-PAGE.
4.2. Transfer the proteins to a PVDF membrane and block with 5% milk in TBST for 1 hour at room temperature.
4.3. Incubate the membrane with primary antibodies against Siglec-8, actin, and the novel adapter protein (1:1,000 dilution) for 2 hours at room temperature.
4.4. Detect the proteins using HRP-conjugated secondary antibodies (1:5,000 dilution) and ECL reagents.

**Experiment 2: Actin Rearrangement Assay**

**Step 1: Eosinophil Preparation**

1.1. Isolate and prime eosinophils as described in Experiment 1.
1.2. Treat the eosinophils with 10 μg/mL Siglec-8 antibody for 30 minutes at 37°C, 5% CO2.

**Step 2: Fluorescent Staining**

2.1. Fix the eosinophils with 4% paraformaldehyde for 15 minutes at room temperature.
2.2. Permeabilize the eosinophils with 0.1% Triton X-100 for 10 minutes at room temperature.
2.3. Stain the eosinophils with 1 μM fluorescently labeled phalloidin (e.g., Alexa Fluor 488) for 30 minutes at room temperature.

**Step 3: Confocal Microscopy**

3.1. Image the stained eosinophils using a confocal microscope (e.g., Zeiss LSM 710) with a 63x oil immersion objective.
3.2. Acquire images using the 488 nm laser line and detect the fluorescence signal using a photomultiplier tube.

**Step 4: Co-transfection and Imaging**

4.1. Co-transfect the eosinophils with the novel adapter protein and actin-GFP using a transfection reagent (e.g., Lipofectamine 2000).
4.2. Treat the transfected eosinophils with 10 μg/mL Siglec-8 antibody for 30 minutes at 37°C, 5% CO2.
4.3. Image the transfected eosinophils using a confocal microscope as described in Step 3.

**Experiment 3: Proximity Ligation Assay (PLA)**

**Step 1: Eosinophil Preparation**

1.1. Isolate and prime eosinophils as described in Experiment 1.
1.2. Treat the eosinophils with 10 μg/mL Siglec-8 antibody for 30 minutes at 37°C, 5% CO2.

**Step 2: PLA**

2.1. Fix the eosinophils with 4% paraformaldehyde for 15 minutes at room temperature.
2.2. Permeabilize the eosinophils with 0.1% Triton X-100 for 10 minutes at room temperature.
2.3. Perform the PLA using the Duolink PLA kit according to the manufacturer's instructions.
2.4. Detect the PLA signal using a confocal microscope as described in Experiment 2, Step 3.

**Experiment to Disprove the Hypothesis**

**Experiment 1: Actin Rearrangement Induction**

**Step 1: Eosinophil Preparation**

1.1. Isolate and prime eosinophils as described in Experiment 1.

**Step 2: Actin Rearrangement Induction**

2.1. Treat the eosinophils with 1 μM cytochalasin D or 1 μM jasplakinolide for 30 minutes at 37°C, 5% CO2.
2.2. Treat the eosinophils with 10 μg/mL Siglec-8 antibody for an additional 30 minutes at 37°C, 5% CO2.

**Step 3: Annexin V Staining and Flow Cytometry**

3.1. Stain the eosinophils with Annexin V-FITC (1:100 dilution) for 15 minutes at room temperature.
3.2. Analyze the stained eosinophils using a flow cytometer (e.g., BD FACSCanto II).

**Experiment 2: Novel Adapter Protein Knockdown**

**Step 1: siRNA Transfection**

1.1. Transfect the eosinophils with siRNA against the novel adapter protein using a transfection reagent (e.g., Lipofectamine 2000).
1.2. Incubate the transfected eosinophils for 48 hours at 37°C, 5% CO2.

**Step 2: Siglec-8 Antibody Treatment and Annexin V Staining**

2.1. Treat the transfected eosinophils with 10 μg/mL Siglec-8 antibody for 30 minutes at 37°C, 5% CO2.
2.2. Stain the eosinophils with Annexin V-FITC (1:100 dilution) for 15 minutes at room temperature.
2.3. Analyze the stained eosinophils using a flow cytometer as described in Experiment 1, Step 3.

**Experiment 3: Combination of Actin Rearrangement Induction and Novel Adapter Protein Knockdown**

**Step 1: siRNA Transfection and Actin Rearrangement Induction**

1.1. Transfect the eosinophils with siRNA against the novel adapter protein as described in Experiment 2, Step 1.
1.2. Treat the transfected eosinophils with 1 μM cytochalasin D or 1 μM jasplakinolide for 30 minutes at 37°C, 5% CO2.

**Step 2: Siglec-8 Antibody Treatment and Annexin V Staining**

2.1. Treat the transfected eosinophils with 10 μg/mL Siglec-8 antibody for an additional 30 minutes at 37°C, 5% CO2.
2.2. Stain the eosinophils with Annexin V-FITC (1:100 dilution) for 15 minutes at room temperature.
2.3. Analyze the stained eosinophils using a flow cytometer as described in Experiment 1, Step 3.

These detailed protocols should provide a clear and concise guide for executing the experiments.","```
   IL-5 (ng/mL)  Siglec-8 Antibody (μg/mL)  Actin Antibody (μg)  Novel Adapter Protein Antibody (μg)  Outcome
0             5.0                    5.0             1.5                    1.5         Positive
1             7.5                   12.5             2.5                    2.5         Positive
2             2.5                    7.5             1.0                    1.0         Negative
3            10.0                   15.0             3.0                    3.0         Positive
4             8.0                    8.0             2.0                    2.0         Positive
5             4.0                    4.0             1.2                    1.2         Negative
6             9.0                   11.0             2.8                    2.8         Positive
7             6.0                    6.0             1.8                    1.8         Negative
8             3.0                    3.0             0.8                    0.8         Negative
9             7.0                    9.0             2.2                    2.2         Positive
10            5.5                    5.5             1.6                    1.6         Negative
11            8.5                   10.5             2.6                    2.6         Positive
12            4.5                    4.5             1.4                    1.4         Negative
13            9.5                   12.0             3.2                    3.2         Positive
14            6.5                    6.5             2.0                    2.0         Negative
15            3.5                    3.5             1.0                    1.0         Negative
16            8.0                    8.0             2.4                    2.4         Positive
17            5.0                    5.0             1.5                    1.5         Negative
18            7.0                    7.0             2.1                    2.1         Positive
19            4.0                    4.0             1.2                    1.2         Negative
20            9.0                   11.0             2.9                    2.9         Positive
21            6.0                    6.0             1.9                    1.9         Negative
22            3.0                    3.0             0.9                    0.9         Negative
23            7.5                    9.5             2.3                    2.3         Positive
24            5.5                    5.5             1.7                    1.7         Negative
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5320bd2a08abe933de870675fd4a2f4e426a5b33.summary'],Does the novel truncated IKZF1 transcript also contribute to the development of resistance to chemotherapy in B-cell acute lymphoblastic leukemia by altering the expression of DNA repair genes?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that the novel truncated IKZF1 transcript contributes to the development of resistance to chemotherapy in B-cell acute lymphoblastic leukemia by altering the expression of DNA repair genes.

**Experimental Plan:**

**Title:** Investigating the role of the novel truncated IKZF1 transcript in chemotherapy resistance and DNA repair gene expression in B-cell acute lymphoblastic leukemia

**Objective:** To determine whether the novel truncated IKZF1 transcript is associated with chemotherapy resistance and altered DNA repair gene expression in B-cell acute lymphoblastic leukemia.

**Equipment:**

* B-cell acute lymphoblastic leukemia cell lines (e.g., SUP-B15)
* Chemotherapeutic agents (e.g., doxorubicin, cytarabine)
* qRT-PCR machine
* Western blot equipment
* DNA repair gene expression arrays or qRT-PCR primers for DNA repair genes (e.g., BRCA1, BRCA2, ATM, ATR)
* Cell viability assays (e.g., MTT, Annexin V)

**Steps:**

1. **Cell culture and chemotherapy treatment:** Culture B-cell acute lymphoblastic leukemia cell lines and treat them with chemotherapeutic agents at varying concentrations. Measure cell viability using cell viability assays to determine the IC50 values.
2. **qRT-PCR analysis:** Perform qRT-PCR to detect the novel truncated IKZF1 transcript in the treated cell lines. Use primers specific to the truncated transcript and normalize to a housekeeping gene (e.g., GAPDH).
3. **Western blot analysis:** Perform Western blot to detect the protein expression of the novel truncated IKZF1 transcript in the treated cell lines. Use an antibody specific to the truncated protein.
4. **DNA repair gene expression analysis:** Use DNA repair gene expression arrays or qRT-PCR to analyze the expression of DNA repair genes (e.g., BRCA1, BRCA2, ATM, ATR) in the treated cell lines. Normalize to a housekeeping gene (e.g., GAPDH).
5. **Correlation analysis:** Analyze the correlation between the expression of the novel truncated IKZF1 transcript and DNA repair gene expression. Use statistical software (e.g., R, Prism) to perform correlation analysis and determine the significance of the results.
6. **Chemotherapy resistance assay:** Perform a chemotherapy resistance assay to determine the resistance of the cell lines to chemotherapeutic agents. Use a cell viability assay to measure the viability of the cells after treatment with chemotherapeutic agents.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment to show that the novel truncated IKZF1 transcript does not contribute to chemotherapy resistance and DNA repair gene expression in B-cell acute lymphoblastic leukemia.

**Null Hypothesis:** The novel truncated IKZF1 transcript does not affect chemotherapy resistance and DNA repair gene expression in B-cell acute lymphoblastic leukemia.

**Experimental Design:**

1. **Knockdown of the novel truncated IKZF1 transcript:** Use RNA interference (RNAi) or CRISPR-Cas9 to knockdown the expression of the novel truncated IKZF1 transcript in B-cell acute lymphoblastic leukemia cell lines.
2. **Chemotherapy treatment:** Treat the knockdown cell lines with chemotherapeutic agents and measure cell viability using cell viability assays.
3. **DNA repair gene expression analysis:** Analyze the expression of DNA repair genes (e.g., BRCA1, BRCA2, ATM, ATR) in the knockdown cell lines using DNA repair gene expression arrays or qRT-PCR.
4. **Comparison to control:** Compare the results to control cell lines that have not been treated with RNAi or CRISPR-Cas9.

If the knockdown of the novel truncated IKZF1 transcript does not affect chemotherapy resistance and DNA repair gene expression, it would suggest that the transcript does not contribute to these processes, disproving the hypothesis.

**Timeline and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000. The budget will cover the cost of cell lines, reagents, equipment, and personnel.

**Limitations:**

* The experiment is limited to in vitro studies and may not reflect the in vivo situation.
* The use of RNAi or CRISPR-Cas9 may have off-target effects that could affect the results.
* The experiment only analyzes a limited number of DNA repair genes and may not be comprehensive.

By following this experimental plan, we can test the hypothesis and determine whether the novel truncated IKZF1 transcript contributes to chemotherapy resistance and DNA repair gene expression in B-cell acute lymphoblastic leukemia.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Chemotherapy Treatment**

1.1. Obtain B-cell acute lymphoblastic leukemia cell lines (e.g., SUP-B15) and maintain them in a humidified incubator at 37°C and 5% CO2.

1.2. Prepare a stock solution of chemotherapeutic agents (e.g., doxorubicin, cytarabine) according to the manufacturer's instructions.

1.3. Seed 1 x 10^5 cells per well in a 96-well plate and incubate for 24 hours.

1.4. Treat the cells with varying concentrations of chemotherapeutic agents (e.g., 0.1, 1, 10, 100 μM) for 48 hours.

1.5. Measure cell viability using a cell viability assay (e.g., MTT, Annexin V) according to the manufacturer's instructions.

1.6. Calculate the IC50 values by plotting the cell viability against the concentration of chemotherapeutic agents.

**Protocol 2: qRT-PCR Analysis**

2.1. Extract total RNA from the treated cell lines using a RNA extraction kit (e.g., TRIzol) according to the manufacturer's instructions.

2.2. Perform cDNA synthesis using a reverse transcription kit (e.g., SuperScript III) according to the manufacturer's instructions.

2.3. Design primers specific to the novel truncated IKZF1 transcript and a housekeeping gene (e.g., GAPDH) using a primer design software (e.g., Primer3).

2.4. Perform qRT-PCR using a qRT-PCR machine (e.g., ABI 7500) with the following conditions:
	* 95°C for 10 minutes
	* 40 cycles of 95°C for 15 seconds and 60°C for 1 minute
	* 72°C for 10 minutes

2.5. Analyze the qRT-PCR data using a software (e.g., ABI Sequence Detection Software) to determine the expression levels of the novel truncated IKZF1 transcript.

**Protocol 3: Western Blot Analysis**

3.1. Extract protein from the treated cell lines using a protein extraction kit (e.g., RIPA buffer) according to the manufacturer's instructions.

3.2. Perform SDS-PAGE using a protein gel (e.g., 10% polyacrylamide) and transfer the proteins to a PVDF membrane.

3.3. Block the membrane with a blocking buffer (e.g., 5% milk) for 1 hour.

3.4. Incubate the membrane with an antibody specific to the novel truncated IKZF1 protein (e.g., 1:1000 dilution) overnight at 4°C.

3.5. Wash the membrane with a washing buffer (e.g., TBST) and incubate with a secondary antibody (e.g., 1:5000 dilution) for 1 hour.

3.6. Detect the protein bands using a chemiluminescent substrate (e.g., ECL) and analyze the Western blot data using a software (e.g., ImageJ).

**Protocol 4: DNA Repair Gene Expression Analysis**

4.1. Extract total RNA from the treated cell lines using a RNA extraction kit (e.g., TRIzol) according to the manufacturer's instructions.

4.2. Perform cDNA synthesis using a reverse transcription kit (e.g., SuperScript III) according to the manufacturer's instructions.

4.3. Design primers specific to DNA repair genes (e.g., BRCA1, BRCA2, ATM, ATR) and a housekeeping gene (e.g., GAPDH) using a primer design software (e.g., Primer3).

4.4. Perform qRT-PCR using a qRT-PCR machine (e.g., ABI 7500) with the following conditions:
	* 95°C for 10 minutes
	* 40 cycles of 95°C for 15 seconds and 60°C for 1 minute
	* 72°C for 10 minutes

4.5. Analyze the qRT-PCR data using a software (e.g., ABI Sequence Detection Software) to determine the expression levels of DNA repair genes.

**Protocol 5: Correlation Analysis**

5.1. Import the qRT-PCR data for the novel truncated IKZF1 transcript and DNA repair genes into a statistical software (e.g., R, Prism).

5.2. Perform correlation analysis (e.g., Pearson's correlation) to determine the correlation between the expression of the novel truncated IKZF1 transcript and DNA repair genes.

5.3. Determine the significance of the correlation using a statistical test (e.g., t-test).

**Protocol 6: Chemotherapy Resistance Assay**

6.1. Treat the cell lines with chemotherapeutic agents (e.g., doxorubicin, cytarabine) at varying concentrations (e.g., 0.1, 1, 10, 100 μM) for 48 hours.

6.2. Measure cell viability using a cell viability assay (e.g., MTT, Annexin V) according to the manufacturer's instructions.

6.3. Calculate the IC50 values by plotting the cell viability against the concentration of chemotherapeutic agents.

**Protocol 7: Knockdown of the Novel Truncated IKZF1 Transcript**

7.1. Design RNAi or CRISPR-Cas9 constructs specific to the novel truncated IKZF1 transcript using a design software (e.g., RNAi Designer, CRISPR Design).

7.2. Transfect the RNAi or CRISPR-Cas9 constructs into the B-cell acute lymphoblastic leukemia cell lines using a transfection reagent (e.g., Lipofectamine) according to the manufacturer's instructions.

7.3. Verify the knockdown of the novel truncated IKZF1 transcript using qRT-PCR and Western blot analysis.

**Protocol 8: Chemotherapy Treatment and DNA Repair Gene Expression Analysis**

8.1. Treat the knockdown cell lines with chemotherapeutic agents (e.g., doxorubicin, cytarabine) at varying concentrations (e.g., 0.1, 1, 10, 100 μM) for 48 hours.

8.2. Measure cell viability using a cell viability assay (e.g., MTT, Annexin V) according to the manufacturer's instructions.

8.3. Extract total RNA from the treated cell lines using a RNA extraction kit (e.g., TRIzol) according to the manufacturer's instructions.

8.4. Perform cDNA synthesis using a reverse transcription kit (e.g., SuperScript III) according to the manufacturer's instructions.

8.5. Design primers specific to DNA repair genes (e.g., BRCA1, BRCA2, ATM, ATR) and a housekeeping gene (e.g., GAPDH) using a primer design software (e.g., Primer3).

8.6. Perform qRT-PCR using a qRT-PCR machine (e.g., ABI 7500) with the following conditions:
	* 95°C for 10 minutes
	* 40 cycles of 95°C for 15 seconds and 60°C for 1 minute
	* 72°C for 10 minutes

8.7. Analyze the qRT-PCR data using a software (e.g., ABI Sequence Detection Software) to determine the expression levels of DNA repair genes.

8.8. Compare the results to control cell lines that have not been treated with RNAi or CRISPR-Cas9.","```
   Doxorubicin (μM)  Cytarabine (μM)  Cell Viability (%)  IKZF1 Transcript  BRCA1  BRCA2  ATM  ATR
0               0.1             0.1           95.23        1.23  0.98  1.05  1.01  0.99
1               1.0             1.0           78.56        0.87  0.92  0.95  0.93  0.91
2              10.0            10.0           42.19        0.56  0.81  0.83  0.85  0.79
3             100.0           100.0           12.15        0.29  0.65  0.68  0.71  0.63
4               0.1             1.0           88.45        1.05  0.95  0.98  1.01  0.97
5               1.0             0.1           82.19        0.93  0.91  0.94  0.96  0.92
6              10.0             0.1           51.23        0.67  0.85  0.88  0.91  0.83
7             100.0             0.1           20.56        0.41  0.73  0.76  0.79  0.71
8               0.1            10.0           81.92        0.99  0.93  0.96  0.99  0.94
9               1.0            10.0           65.19        0.83  0.88  0.91  0.94  0.87
10             10.0            10.0           35.67        0.59  0.79  0.82  0.85  0.77
11            100.0            10.0           15.23        0.35  0.69  0.72  0.75  0.67
12              0.1           100.0           76.15        0.91  0.89  0.92  0.95  0.90
13              1.0           100.0           58.45        0.77  0.84  0.87  0.90  0.82
14             10.0           100.0           30.92        0.53  0.76  0.79  0.82  0.74
15            100.0           100.0           10.19        0.29  0.64  0.67  0.70  0.62
16              0.1             0.1           93.56        1.15  0.99  1.02  1.05  1.01
17              1.0             1.0           80.92        0.95  0.94  0.97  1.00  0.96
18             10.0            10.0           45.67        0.69  0.86  0.89  0.92  0.84
19            100.0           100.0           14.56        0.33  0.71  0.74  0.77  0.69
20              0.1             1.0           90.19        1.08  0.97  1.00  1.03  0.99
21              1.0             0.1           85.45        0.98  0.95  0.98  1.01  0.97
22             10.0             0.1           55.23        0.73  0.88  0.91  0.94  0.86
23            100.0             0.1           22.19        0.43  0.75  0.78  0.81  0.73
24              0.1            10.0           84.56        1.02  0.96  0.99  1.02  0.98
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2a07af16313b9ccc21063792e7a6cdef6db69fb5.summary'],"Does the nuclear translocation of Bcr-Abl also disrupt the interaction between Bcr-Abl and its upstream regulators, leading to a feedback loop that further enhances apoptosis in CML cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove it. The goal is to investigate whether the nuclear translocation of Bcr-Abl disrupts the interaction between Bcr-Abl and its upstream regulators, leading to a feedback loop that further enhances apoptosis in CML cells.

**Experiment:**

**Title:** Disruption of Bcr-Abl-Upstream Regulator Interaction by Nuclear Translocation: A Feedback Loop in CML Apoptosis

**Objective:** To determine if the nuclear translocation of Bcr-Abl disrupts its interaction with upstream regulators, leading to a feedback loop that enhances apoptosis in CML cells.

**Hypothesis to be disproven:** The nuclear translocation of Bcr-Abl does not disrupt the interaction between Bcr-Abl and its upstream regulators, and therefore does not lead to a feedback loop that enhances apoptosis in CML cells.

**Experimental Design:**

1. **Cell Culture and Transfection:** Use K562 cells, a human CML cell line, and transfect them with a plasmid expressing a nuclear-targeted Bcr-Abl (Bcr-Abl-NLS) using a lipofection reagent. As a control, transfect cells with a plasmid expressing a cytoplasmic Bcr-Abl (Bcr-Abl-Cyto).
2. **Co-Immunoprecipitation Assay:** Perform co-immunoprecipitation assays to investigate the interaction between Bcr-Abl and its upstream regulators (e.g., c-Abl, PI3K, and Ras) in both nuclear-targeted and cytoplasmic Bcr-Abl-expressing cells. Use specific antibodies against Bcr-Abl and the upstream regulators for immunoprecipitation and Western blot analysis.
3. **Western Blot Analysis:** Analyze the expression levels of Bcr-Abl, upstream regulators, and apoptosis-related proteins (e.g., Bax, Bad, and cleaved caspase-3) in both nuclear-targeted and cytoplasmic Bcr-Abl-expressing cells using Western blot.
4. **Apoptosis Assay:** Measure apoptosis in both nuclear-targeted and cytoplasmic Bcr-Abl-expressing cells using Annexin V-FITC/PI staining and flow cytometry.
5. **Feedback Loop Analysis:** Investigate the potential feedback loop by analyzing the expression levels of upstream regulators and apoptosis-related proteins in response to nuclear-targeted Bcr-Abl expression.

**Expected Outcomes:**

* If the hypothesis is true, nuclear-targeted Bcr-Abl expression will disrupt the interaction between Bcr-Abl and its upstream regulators, leading to a feedback loop that enhances apoptosis in CML cells.
* If the hypothesis is false, nuclear-targeted Bcr-Abl expression will not disrupt the interaction between Bcr-Abl and its upstream regulators, and apoptosis will not be enhanced in CML cells.

**Time and Resource Considerations:**

* This experiment can be completed within 6-8 weeks, considering the time required for cell culture, transfection, co-immunoprecipitation assays, Western blot analysis, and apoptosis assays.
* The required resources include K562 cells, plasmids, lipofection reagent, antibodies, Western blot equipment, and flow cytometry equipment, which are commonly available in most molecular biology laboratories.
* The budget for this experiment is estimated to be moderate, as it involves the use of standard molecular biology techniques and reagents.

By designing an experiment to disprove the hypothesis, we can test the validity of the original hypothesis and gain a deeper understanding of the role of Bcr-Abl nuclear translocation in CML apoptosis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Transfection**

1.1. Obtain K562 cells, a human CML cell line, and maintain them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a humidified incubator with 5% CO2.

1.2. Prepare the plasmids:
	* Bcr-Abl-NLS (nuclear-targeted Bcr-Abl) plasmid: 1 μg/μL
	* Bcr-Abl-Cyto (cytoplasmic Bcr-Abl) plasmid: 1 μg/μL

1.3. Transfect K562 cells with the plasmids using a lipofection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.4. Incubate the cells for 24 hours to allow for plasmid expression.

**Protocol 2: Co-Immunoprecipitation Assay**

2.1. Prepare the following antibodies:
	* Anti-Bcr-Abl antibody (1:1000)
	* Anti-c-Abl antibody (1:1000)
	* Anti-PI3K antibody (1:1000)
	* Anti-Ras antibody (1:1000)

2.2. Lyse the transfected K562 cells in 1 mL of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) containing protease inhibitors (e.g., PMSF, aprotinin, and leupeptin).

2.3. Incubate the lysates on ice for 30 minutes to allow for protein extraction.

2.4. Centrifuge the lysates at 12,000 x g for 10 minutes at 4°C to remove debris.

2.5. Immunoprecipitate the Bcr-Abl protein using the anti-Bcr-Abl antibody (1:1000) and protein A/G agarose beads (e.g., Pierce) according to the manufacturer's instructions.

2.6. Wash the immunoprecipitates three times with 1 mL of ice-cold lysis buffer.

2.7. Elute the immunoprecipitated proteins with 50 μL of 2x Laemmli sample buffer.

2.8. Analyze the immunoprecipitated proteins by Western blot using the antibodies against c-Abl, PI3K, and Ras.

**Protocol 3: Western Blot Analysis**

3.1. Prepare the following antibodies:
	* Anti-Bcr-Abl antibody (1:1000)
	* Anti-c-Abl antibody (1:1000)
	* Anti-PI3K antibody (1:1000)
	* Anti-Ras antibody (1:1000)
	* Anti-Bax antibody (1:1000)
	* Anti-Bad antibody (1:1000)
	* Anti-cleaved caspase-3 antibody (1:1000)

3.2. Lyse the transfected K562 cells in 1 mL of ice-cold lysis buffer (same as Protocol 2.2).

3.3. Incubate the lysates on ice for 30 minutes to allow for protein extraction.

3.4. Centrifuge the lysates at 12,000 x g for 10 minutes at 4°C to remove debris.

3.5. Resolve the proteins by SDS-PAGE using a 10% polyacrylamide gel.

3.6. Transfer the proteins to a PVDF membrane using a semi-dry transfer apparatus.

3.7. Block the membrane with 5% non-fat milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature.

3.8. Incubate the membrane with the primary antibodies (1:1000) in 5% non-fat milk in TBST for 2 hours at room temperature.

3.9. Wash the membrane three times with TBST.

3.10. Incubate the membrane with the secondary antibodies (1:5000) in 5% non-fat milk in TBST for 1 hour at room temperature.

3.11. Wash the membrane three times with TBST.

3.12. Develop the Western blot using an ECL detection system (e.g., Pierce).

**Protocol 4: Apoptosis Assay**

4.1. Prepare the Annexin V-FITC/PI staining solution according to the manufacturer's instructions.

4.2. Harvest the transfected K562 cells by centrifugation at 300 x g for 5 minutes.

4.3. Resuspend the cells in 100 μL of Annexin V-FITC/PI staining solution.

4.4. Incubate the cells for 15 minutes at room temperature in the dark.

4.5. Analyze the cells by flow cytometry using a flow cytometer (e.g., BD FACSCalibur).

**Protocol 5: Feedback Loop Analysis**

5.1. Analyze the expression levels of upstream regulators (c-Abl, PI3K, and Ras) and apoptosis-related proteins (Bax, Bad, and cleaved caspase-3) in response to nuclear-targeted Bcr-Abl expression using Western blot analysis (Protocol 3).

5.2. Compare the expression levels of these proteins between nuclear-targeted and cytoplasmic Bcr-Abl-expressing cells.

By following these detailed protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis.","```
   Bcr-Abl-NLS (μg)  Bcr-Abl-Cyto (μg)  Anti-Bcr-Abl (μL)  Anti-c-Abl (μL)  Anti-PI3K (μL)  Anti-Ras (μL)  Outcome
0              0.5               0.0           10.0          10.0          10.0          10.0  Low Apoptosis
1              1.0               0.0           15.0          15.0          15.0          15.0  Medium Apoptosis
2              1.5               0.0           20.0          20.0          20.0          20.0  High Apoptosis
3              0.0               0.5           10.0          10.0          10.0          10.0  Low Apoptosis
4              0.0               1.0           15.0          15.0          15.0          15.0  Medium Apoptosis
5              0.0               1.5           20.0          20.0          20.0          20.0  High Apoptosis
6              0.5               0.5           12.5          12.5          12.5          12.5  Medium Apoptosis
7              1.0               1.0           17.5          17.5          17.5          17.5  High Apoptosis
8              1.5               1.5           22.5          22.5          22.5          22.5  High Apoptosis
9              0.5               0.0           12.5          12.5          12.5          12.5  Medium Apoptosis
10             1.0               0.0           17.5          17.5          17.5          17.5  High Apoptosis
11             1.5               0.0           22.5          22.5          22.5          22.5  High Apoptosis
12             0.0               0.5           12.5          12.5          12.5          12.5  Medium Apoptosis
13             0.0               1.0           17.5          17.5          17.5          17.5  High Apoptosis
14             0.0               1.5           22.5          22.5          22.5          22.5  High Apoptosis
15             0.5               0.5           15.0          15.0          15.0          15.0  Medium Apoptosis
16             1.0               1.0           20.0          20.0          20.0          20.0  High Apoptosis
17             1.5               1.5           25.0          25.0          25.0          25.0  High Apoptosis
18             0.5               0.0           15.0          15.0          15.0          15.0  Medium Apoptosis
19             1.0               0.0           20.0          20.0          20.0          20.0  High Apoptosis
20             1.5               0.0           25.0          25.0          25.0          25.0  High Apoptosis
21             0.0               0.5           15.0          15.0          15.0          15.0  Medium Apoptosis
22             0.0               1.0           20.0          20.0          20.0          20.0  High Apoptosis
23             0.0               1.5           25.0          25.0          25.0          25.0  High Apoptosis
24             0.5               0.5           17.5          17.5          17.5          17.5  High Apoptosis
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c8f8370979760c1662b9bb305626e43337c06d78.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5a1f0559db56ad8483c54049db4692d38ed8d8d7.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2f8f86a7061c3cc9424db8e498041ff34f7a3f88.summary']","Does the organization and dynamics of the cortical actin cytoskeleton regulate the size and composition of BCR clusters, thereby influencing the selection of endocytic pathways and subsequent antigen presentation?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the organization and dynamics of the cortical actin cytoskeleton regulate the size and composition of BCR clusters, thereby influencing the selection of endocytic pathways and subsequent antigen presentation, I propose the following experimental plan:

**Experiment:** ""Disrupting Cortical Actin Cytoskeleton to Disprove the Hypothesis""

**Objective:** To investigate whether disrupting the organization and dynamics of the cortical actin cytoskeleton affects the size and composition of BCR clusters, endocytic pathways, and antigen presentation.

**Equipment:**

* Confocal microscope
* RNAi reagents (e.g., siRNA against actin-regulating proteins)
* Actin-depolymerizing drugs (e.g., cytochalasin D)
* B cell culture facilities
* Flow cytometry
* Western blot
* Biochemical assays

**Steps:**

1. **Control Experiment:** Treat B cells with a control RNAi reagent (e.g., scrambled siRNA) and stimulate with high concentrations of antigen to induce large BCR clusters. Use confocal microscopy to visualize and quantify the formation of large invaginations and BCR internalization.
2. **Disrupting Cortical Actin Cytoskeleton:** Treat B cells with RNAi reagents against actin-regulating proteins (e.g., Arp2/3 complex) or actin-depolymerizing drugs to disrupt the cortical actin cytoskeleton. Stimulate B cells with high concentrations of antigen to induce large BCR clusters.
3. **BCR Clustering and Internalization:** Use confocal microscopy to visualize and quantify the formation of large invaginations and BCR internalization in both control and disrupted cortical actin cytoskeleton conditions.
4. **Endocytic Pathway Analysis:** Use flow cytometry to analyze the internalization of BCRs and quantify the proportion of BCRs internalized through different endocytic pathways (e.g., clathrin-mediated endocytosis, novel endocytic pathway).
5. **Antigen Presentation:** Use western blot and biochemical assays to analyze the presentation of antigens on the surface of B cells and quantify the amount of antigen presented in both control and disrupted cortical actin cytoskeleton conditions.

**Expected Outcomes:**

* If the hypothesis is true, disrupting the cortical actin cytoskeleton should lead to:
	+ Reduced formation of large invaginations and BCR internalization
	+ Altered endocytic pathway usage (e.g., increased clathrin-mediated endocytosis)
	+ Decreased antigen presentation on the surface of B cells
* If the hypothesis is false, disrupting the cortical actin cytoskeleton should not affect BCR clustering, internalization, endocytic pathway usage, or antigen presentation.

**Timeframe and Budget:**

This experiment can be completed within 6-8 weeks, with a budget of approximately $10,000-$15,000, which covers the cost of RNAi reagents, actin-depolymerizing drugs, confocal microscopy, flow cytometry, western blot, and biochemical assays.

By designing an experiment to disprove the hypothesis, we can test the validity of the hypothesis and gain a deeper understanding of the role of the cortical actin cytoskeleton in regulating BCR clustering, endocytic pathways, and antigen presentation.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disrupting Cortical Actin Cytoskeleton to Disprove the Hypothesis"":

**Protocol 1: Control Experiment**

1.1. **Cell Preparation**

* Obtain B cells from a reliable source (e.g., human peripheral blood or mouse spleen).
* Culture B cells in a suitable medium (e.g., RPMI 1640 with 10% FBS) at 37°C, 5% CO2.
* Ensure cell viability and purity using trypan blue staining and flow cytometry, respectively.

1.2. **RNAi Transfection**

* Prepare scrambled siRNA (control RNAi reagent) according to the manufacturer's instructions.
* Transfect B cells with scrambled siRNA using a suitable transfection reagent (e.g., Lipofectamine RNAiMAX) following the manufacturer's protocol.
* Incubate cells for 24-48 hours to allow for RNAi-mediated gene silencing.

1.3. **Antigen Stimulation**

* Prepare a high concentration of antigen (e.g., 10 μg/mL) in a suitable buffer (e.g., PBS).
* Add the antigen to the B cell culture and incubate for 30 minutes to 1 hour to induce large BCR clusters.

1.4. **Confocal Microscopy**

* Prepare a confocal microscope (e.g., Zeiss LSM 880) with a suitable objective lens (e.g., 63x oil immersion).
* Add a fluorescent dye (e.g., Alexa Fluor 488-conjugated anti-BCR antibody) to the B cell culture to label BCRs.
* Acquire confocal images of B cells using the following settings:
	+ Excitation wavelength: 488 nm
	+ Emission wavelength: 520 nm
	+ Pinhole: 1 AU
	+ Z-stack: 0.5 μm steps, 10-15 slices
* Analyze images using image analysis software (e.g., ImageJ) to quantify the formation of large invaginations and BCR internalization.

**Protocol 2: Disrupting Cortical Actin Cytoskeleton**

2.1. **RNAi Transfection**

* Prepare RNAi reagents against actin-regulating proteins (e.g., Arp2/3 complex) according to the manufacturer's instructions.
* Transfect B cells with RNAi reagents using a suitable transfection reagent (e.g., Lipofectamine RNAiMAX) following the manufacturer's protocol.
* Incubate cells for 24-48 hours to allow for RNAi-mediated gene silencing.

2.2. **Actin-Depolymerizing Drug Treatment**

* Prepare actin-depolymerizing drugs (e.g., cytochalasin D) according to the manufacturer's instructions.
* Add the actin-depolymerizing drug to the B cell culture at a suitable concentration (e.g., 1 μM) and incubate for 30 minutes to 1 hour.

2.3. **Antigen Stimulation**

* Prepare a high concentration of antigen (e.g., 10 μg/mL) in a suitable buffer (e.g., PBS).
* Add the antigen to the B cell culture and incubate for 30 minutes to 1 hour to induce large BCR clusters.

**Protocol 3: BCR Clustering and Internalization**

3.1. **Confocal Microscopy**

* Prepare a confocal microscope (e.g., Zeiss LSM 880) with a suitable objective lens (e.g., 63x oil immersion).
* Add a fluorescent dye (e.g., Alexa Fluor 488-conjugated anti-BCR antibody) to the B cell culture to label BCRs.
* Acquire confocal images of B cells using the same settings as in Protocol 1.4.
* Analyze images using image analysis software (e.g., ImageJ) to quantify the formation of large invaginations and BCR internalization in both control and disrupted cortical actin cytoskeleton conditions.

**Protocol 4: Endocytic Pathway Analysis**

4.1. **Flow Cytometry**

* Prepare a flow cytometer (e.g., BD FACSAria III) with suitable detectors (e.g., FITC, PE, APC).
* Stain B cells with fluorescently labeled antibodies against BCRs (e.g., FITC-conjugated anti-BCR antibody) and endocytic markers (e.g., PE-conjugated anti-clathrin antibody).
* Acquire flow cytometry data using the following settings:
	+ Forward scatter: FSC-A
	+ Side scatter: SSC-A
	+ Fluorescence channels: FITC, PE, APC
* Analyze data using flow cytometry software (e.g., FlowJo) to quantify the internalization of BCRs and the proportion of BCRs internalized through different endocytic pathways.

**Protocol 5: Antigen Presentation**

5.1. **Western Blot**

* Prepare a western blot apparatus (e.g., Bio-Rad Mini-PROTEAN) with suitable gels (e.g., 10% SDS-PAGE) and transfer membranes (e.g., PVDF).
* Lyse B cells using a suitable lysis buffer (e.g., RIPA buffer) and separate proteins using SDS-PAGE.
* Transfer proteins to the membrane and probe with antibodies against antigens (e.g., anti-peptide antibody) and loading controls (e.g., anti-β-actin antibody).
* Develop the blot using a suitable detection system (e.g., ECL) and analyze using image analysis software (e.g., ImageJ).

5.2. **Biochemical Assays**

* Prepare a suitable biochemical assay (e.g., ELISA) to quantify the amount of antigen presented on the surface of B cells.
* Follow the manufacturer's instructions to perform the assay and analyze the results.

**Quality Control and Replicability**

* Perform each protocol in triplicate to ensure reproducibility.
* Include positive and negative controls for each protocol to validate the results.
* Use standardized reagents and equipment to minimize variability.
* Document all protocols, results, and analyses in a laboratory notebook and/or electronic database.

By following these detailed, step-by-step protocols, the experiment ""Disrupting Cortical Actin Cytoskeleton to Disprove the Hypothesis"" can be executed with precision and accuracy, ensuring replicability and reliability of the results.","```
   Scrambled siRNA (nM)  RNAi reagents (nM)  Actin-depolymerizing drug (μM)  Antigen (μg/mL)  BCR internalization (%)
0                  50.0               0.0                    0.0             5.0             20.0
1                  25.0               0.0                    0.0             5.0             18.0
2                  50.0               0.0                    0.0            10.0             22.0
3                  25.0               0.0                    0.0            10.0             20.0
4                  50.0               5.0                    0.0             5.0             15.0
5                  25.0               5.0                    0.0             5.0             12.0
6                  50.0               5.0                    0.0            10.0             18.0
7                  25.0               5.0                    0.0            10.0             15.0
8                  50.0               0.0                    1.0             5.0             10.0
9                  25.0               0.0                    1.0             5.0              8.0
10                 50.0               0.0                    1.0            10.0             12.0
11                 25.0               0.0                    1.0            10.0             10.0
12                 50.0               5.0                    1.0             5.0              8.0
13                 25.0               5.0                    1.0             5.0              6.0
14                 50.0               5.0                    1.0            10.0             10.0
15                 25.0               5.0                    1.0            10.0              8.0
16                 50.0              10.0                    0.0             5.0             12.0
17                 25.0              10.0                    0.0             5.0             10.0
18                 50.0              10.0                    0.0            10.0             15.0
19                 25.0              10.0                    0.0            10.0             12.0
20                 50.0              10.0                    1.0             5.0              8.0
21                 25.0              10.0                    1.0             5.0              6.0
22                 50.0              10.0                    1.0            10.0             10.0
23                 25.0              10.0                    1.0            10.0              8.0
24                 50.0               0.0                    0.0             5.0             20.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/32902954baf1222733fb3add80a2b6517c326c27.summary'],"Does the overexpression of BOB.1 in B cells also induce the production of pro-inflammatory cytokines, which in turn contribute to the development of autoimmune diseases by creating a self-reinforcing feedback loop?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** Overexpression of BOB.1 in B cells induces the production of pro-inflammatory cytokines, contributing to the development of autoimmune diseases through a self-reinforcing feedback loop.

**Experimental Plan:**

**Objective:** To investigate whether BOB.1 overexpression in B cells leads to increased pro-inflammatory cytokine production, which in turn contributes to autoimmune disease development.

**Experimental Design:**

1. **Cell Culture and BOB.1 Overexpression:**
	* Isolate B cells from healthy human donors or use a B cell line (e.g., Ramos).
	* Use lentiviral vectors to overexpress BOB.1 in B cells (BOB.1-OE) and generate a control group with empty vector (EV).
	* Verify BOB.1 overexpression using Western blot, qRT-PCR, or flow cytometry.
2. **Cytokine Analysis:**
	* Measure pro-inflammatory cytokine levels (e.g., TNF-α, IL-1β, IL-6) in the supernatant of BOB.1-OE and EV B cells using ELISA or multiplex assays.
	* Compare cytokine levels between BOB.1-OE and EV groups to determine if BOB.1 overexpression induces cytokine production.
3. **Autoimmune Disease Model:**
	* Use a well-established autoimmune disease model, such as collagen-induced arthritis (CIA) in mice.
	* Inject BOB.1-OE or EV B cells into mice and monitor disease progression (e.g., arthritis severity, joint inflammation).
	* Compare disease severity between BOB.1-OE and EV groups to determine if BOB.1 overexpression exacerbates autoimmune disease.
4. **Feedback Loop Investigation:**
	* Co-culture BOB.1-OE B cells with autoreactive T cells (e.g., CD4+ T cells) and measure cytokine production and T cell activation.
	* Investigate if BOB.1-OE B cells enhance autoreactive T cell activation and cytokine production, creating a self-reinforcing feedback loop.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: BOB.1 overexpression in B cells does not induce pro-inflammatory cytokine production or exacerbate autoimmune disease.

**Alternative Hypothesis:** BOB.1 overexpression in B cells has no effect on pro-inflammatory cytokine production or autoimmune disease development.

**Experimental Approach:**

1. **BOB.1 Knockdown:**
	* Use shRNA or CRISPR-Cas9 to knockdown BOB.1 expression in B cells (BOB.1-KD).
	* Verify BOB.1 knockdown using Western blot, qRT-PCR, or flow cytometry.
2. **Cytokine Analysis:**
	* Measure pro-inflammatory cytokine levels in the supernatant of BOB.1-KD and control B cells.
	* Compare cytokine levels between BOB.1-KD and control groups to determine if BOB.1 knockdown affects cytokine production.
3. **Autoimmune Disease Model:**
	* Use the same CIA model as before.
	* Inject BOB.1-KD or control B cells into mice and monitor disease progression.
	* Compare disease severity between BOB.1-KD and control groups to determine if BOB.1 knockdown alleviates autoimmune disease.

**Rationale:**

By designing an experiment to disprove the original hypothesis, we can test the alternative hypothesis that BOB.1 overexpression has no effect on pro-inflammatory cytokine production or autoimmune disease development. If the results show no significant differences between BOB.1-KD and control groups, it would suggest that BOB.1 overexpression is not involved in the development of autoimmune diseases, thereby disproving the original hypothesis.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a moderate budget. The estimated costs include:

* Cell culture and reagents: $10,000 - $20,000
* Lentiviral vectors and transduction: $5,000 - $10,000
* Cytokine analysis and ELISA kits: $5,000 - $10,000
* Autoimmune disease model and animal costs: $10,000 - $20,000
* Personnel and overheads: $20,000 - $40,000

Total estimated budget: $50,000 - $100,000

This experiment is designed to be feasible within a reasonable timeframe and budget, while providing valuable insights into the role of BOB.1 in autoimmune disease development.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and BOB.1 Overexpression**

**Step 1.1: Isolate B cells from healthy human donors or use a B cell line (e.g., Ramos)**

* Obtain peripheral blood mononuclear cells (PBMCs) from healthy human donors or use a B cell line (e.g., Ramos) as a control.
* Isolate B cells using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) with anti-CD19 or anti-CD20 antibodies.
* Culture B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

**Step 1.2: Prepare lentiviral vectors for BOB.1 overexpression**

* Design and clone the BOB.1 gene into a lentiviral vector (e.g., pLenti-CMV-Puro-DEST) using standard molecular biology techniques.
* Verify the sequence and expression of the BOB.1 gene using Sanger sequencing and Western blot analysis.
* Prepare lentiviral particles by transfecting HEK293T cells with the BOB.1 lentiviral vector, psPAX2, and pMD2.G using Lipofectamine 2000.
* Concentrate the lentiviral particles using ultracentrifugation or PEG precipitation.

**Step 1.3: Transduce B cells with lentiviral vectors**

* Infect B cells with the BOB.1 lentiviral vector or an empty vector (EV) control at a multiplicity of infection (MOI) of 10-20.
* Incubate the cells for 24-48 hours to allow for transduction.
* Select transduced cells using puromycin (1-2 μg/mL) for 3-5 days.

**Step 1.4: Verify BOB.1 overexpression**

* Perform Western blot analysis using an anti-BOB.1 antibody to detect BOB.1 protein expression.
* Perform qRT-PCR using BOB.1-specific primers to detect BOB.1 mRNA expression.
* Perform flow cytometry using an anti-BOB.1 antibody to detect BOB.1 protein expression on the surface of B cells.

**Protocol 2: Cytokine Analysis**

**Step 2.1: Prepare B cell supernatants**

* Culture BOB.1-overexpressing (BOB.1-OE) and empty vector (EV) B cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2 for 24-48 hours.
* Collect the supernatants and centrifuge at 300 x g for 5 minutes to remove cells and debris.

**Step 2.2: Measure pro-inflammatory cytokine levels**

* Use ELISA kits or multiplex assays to measure pro-inflammatory cytokine levels (e.g., TNF-α, IL-1β, IL-6) in the supernatants.
* Follow the manufacturer's instructions for the ELISA or multiplex assay.

**Protocol 3: Autoimmune Disease Model**

**Step 3.1: Prepare collagen-induced arthritis (CIA) model**

* Obtain 6-8 week old DBA/1J mice and immunize them with bovine type II collagen (CII) in complete Freund's adjuvant (CFA) on day 0.
* Boost the mice with CII in incomplete Freund's adjuvant (IFA) on day 21.

**Step 3.2: Inject BOB.1-OE or EV B cells into mice**

* Inject 1-2 x 10^6 BOB.1-OE or EV B cells into the tail vein of CIA mice on day 28.
* Monitor disease progression (e.g., arthritis severity, joint inflammation) using a clinical scoring system.

**Protocol 4: Feedback Loop Investigation**

**Step 4.1: Co-culture BOB.1-OE B cells with autoreactive T cells**

* Isolate autoreactive T cells (e.g., CD4+ T cells) from CIA mice using MACS or FACS.
* Co-culture BOB.1-OE B cells with autoreactive T cells at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2 for 24-48 hours.

**Step 4.2: Measure cytokine production and T cell activation**

* Measure pro-inflammatory cytokine levels (e.g., TNF-α, IL-1β, IL-6) in the co-culture supernatants using ELISA kits or multiplex assays.
* Analyze T cell activation using flow cytometry with anti-CD25, anti-CD69, and anti-CD44 antibodies.

**Protocol 5: Experiment to Disprove the Hypothesis**

**Step 5.1: BOB.1 Knockdown**

* Design and clone shRNA or CRISPR-Cas9 constructs targeting BOB.1 into a lentiviral vector.
* Transduce B cells with the BOB.1 knockdown (BOB.1-KD) lentiviral vector or a control vector.
* Verify BOB.1 knockdown using Western blot, qRT-PCR, or flow cytometry.

**Step 5.2: Cytokine Analysis**

* Measure pro-inflammatory cytokine levels in the supernatants of BOB.1-KD and control B cells using ELISA kits or multiplex assays.

**Step 5.3: Autoimmune Disease Model**

* Inject BOB.1-KD or control B cells into CIA mice and monitor disease progression.

These detailed protocols provide a step-by-step guide for executing the experiment to test the hypothesis that BOB.1 overexpression in B cells induces pro-inflammatory cytokine production and contributes to autoimmune disease development.","```
   PBMCs  FBS  Penicillin-Streptomycin  L-Glutamine  BOB.1_Lentiviral_Vector  MOI  Puromycin  BOB.1_Overexpression  TNF-alpha  IL-1beta  IL-6  CIA_Model  Disease_Progression
0      1e6  10%                  1%           1%                    10          10         1.5               High         500        200   1000          Yes               Mild
1      5e5  15%                  2%           2%                    20          15         2.0               High         600        250   1200          Yes               Moderate
2      2e6  12%                  1.5%         1.5%                   5          12         1.0               Low          300        150    800          No                None
3      3e6  11%                  1.2%         1.2%                   8          18         1.8               High         700        300   1400          Yes               Severe
4      1e6  13%                  1.8%         1.8%                   12         10         1.2               Medium       400        180    900          Yes               Mild
5      4e6  14%                  2.2%         2.2%                   15         12         1.5               High         550        220   1100          Yes               Moderate
6      2e6  10%                  1%           1%                    18         15         2.2               High         650        280   1300          Yes               Severe
7      3e6  12%                  1.5%         1.5%                   6          10         1.0               Low          350        160    850          No                None
8      1e6  11%                  1.2%         1.2%                   9          12         1.3               Medium       450        190    950          Yes               Mild
9      5e5  15%                  2%           2%                    11         18         2.5               High         750        320   1500          Yes               Severe
10     2e6  13%                  1.8%         1.8%                   14         10         1.4               Medium       500        210   1050          Yes               Moderate
11     4e6  12%                  1.5%         1.5%                   7          12         1.1               Low          400        180    900          No                None
12     3e6  11%                  1.2%         1.2%                   16         15         2.0               High         600        250   1200          Yes               Moderate
13     1e6  14%                  2.2%         2.2%                   13         10         1.6               Medium       550        230   1100          Yes               Mild
14     2e6  10%                  1%           1%                    19         12         2.3               High         700        300   1400          Yes               Severe
15     5e5  13%                  1.8%         1.8%                   10         18         2.1               High         650        280   1300          Yes               Moderate
16     4e6  11%                  1.2%         1.2%                   17         10         1.7               Medium       500        210   1050          Yes               Mild
17     3e6  12%                  1.5%         1.5%                   4          12         0.9               Low          300        150    800          No                None
18     1e6  15%                  2%           2%                    21         15         2.6               High         800        350   1600          Yes               Severe
19     2e6  14%                  2.2%         2.2%                   22         10         2.4               High         750        320   1500          Yes               Severe
20     5e5  12%                  1.5%         1.5%                   3          18         1.9               Medium       600        250   1200          Yes               Moderate
21     4e6  11%                  1.2%         1.2%                   24         10         2.7               High         850        380   1700          Yes               Severe
22     3e6  13%                  1.8%         1.8%                   25         12         2.8               High         900        400   1800          Yes               Severe
23     1e6  10%                  1%           1%                    2          15         0.8               Low          250        120    600          No                None
24     2e6  12%                  1.5%         1.5%                   1          10         0.7               Low          200        100    500          No                None
```",0.10454859242878152
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5425bb7efdc208cc1028f49acddbe11ec0e00f63.summary'],"Does the presence of AID-experienced cells in l-MYC tumors influence the expression of specific microRNAs that regulate the germinal center reaction, thereby contributing to the development of mature B cell lymphoma?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! To test this hypothesis, I'll outline a high-level experimental plan to investigate the relationship between AID-experienced cells, microRNA expression, and mature B cell lymphoma development.

**Hypothesis:** The presence of AID-experienced cells in l-MYC tumors influences the expression of specific microRNAs that regulate the germinal center reaction, contributing to the development of mature B cell lymphoma.

**Experimental Plan:**

**Objective:** Design an experiment to disprove the hypothesis, thereby verifying its validity.

**Step 1: Cell Line Generation and Characterization**

* Obtain l-MYC tumor cell lines with and without AID-experienced cells (e.g., using CRISPR-Cas9 to knockout AID in l-MYC tumor cells).
* Characterize the cell lines using flow cytometry, Western blot, and qRT-PCR to confirm the presence/absence of AID-experienced cells and l-MYC expression.

**Step 2: MicroRNA Profiling**

* Perform microRNA sequencing (miRNA-seq) on both AID-experienced and AID-naive l-MYC tumor cell lines to identify differentially expressed microRNAs.
* Validate the results using qRT-PCR for a subset of microRNAs.

**Step 3: Germinal Center Reaction Analysis**

* Co-culture AID-experienced and AID-naive l-MYC tumor cells with primary B cells and follicular dendritic cells to mimic the germinal center reaction.
* Analyze the co-culture using flow cytometry, immunofluorescence, and qRT-PCR to assess the effects of AID-experienced cells on germinal center reaction markers (e.g., CD40, CD80, CD86, and AICDA).

**Step 4: Functional Validation**

* Use microRNA mimics or inhibitors to modulate the expression of differentially expressed microRNAs in AID-naive l-MYC tumor cells.
* Analyze the effects of microRNA modulation on germinal center reaction markers and mature B cell lymphoma development using the co-culture system.

**Step 5: In Vivo Validation**

* Inject AID-experienced and AID-naive l-MYC tumor cells into immunocompromised mice to assess tumor development and germinal center reaction markers in vivo.
* Analyze tumor samples using IHC, qRT-PCR, and flow cytometry to validate the in vitro findings.

**Budget and Timeframe:**

* Estimated budget: $150,000 - $200,000
* Estimated timeframe: 12-18 months

**Rationale:**

This experimental plan is designed to disprove the hypothesis by testing the effects of AID-experienced cells on microRNA expression, germinal center reaction, and mature B cell lymphoma development. By using a combination of in vitro and in vivo approaches, we can comprehensively evaluate the relationship between AID-experienced cells and microRNA expression in the context of l-MYC tumors. The budget and timeframe are reasonable, considering the scope of the experiment and the need for specialized equipment and expertise.

By following this experimental plan, we can determine whether the presence of AID-experienced cells in l-MYC tumors indeed influences the expression of specific microRNAs that regulate the germinal center reaction, contributing to the development of mature B cell lymphoma.",85,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Line Generation and Characterization**

**Protocol 1.1: CRISPR-Cas9 knockout of AID in l-MYC tumor cells**

1.1.1. Obtain l-MYC tumor cell lines (e.g., P493-6 or OCI-Ly1) and culture them in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.1.2. Design and synthesize CRISPR-Cas9 guide RNAs (gRNAs) targeting the AID gene using online tools (e.g., CRISPR Design or CRISPOR).

1.1.3. Prepare CRISPR-Cas9 ribonucleoprotein (RNP) complexes by mixing gRNAs with Cas9 enzyme and buffer according to the manufacturer's instructions.

1.1.4. Electroporate l-MYC tumor cells with the CRISPR-Cas9 RNP complexes using a nucleofector device (e.g., Lonza 4D-Nucleofector).

1.1.5. Select and expand AID-knockout clones using puromycin selection (1 μg/mL) and single-cell sorting.

**Protocol 1.2: Characterization of AID-experienced and AID-naive cell lines**

1.2.1. Perform flow cytometry to analyze the expression of AID, l-MYC, and other relevant markers (e.g., CD19, CD20, and CD38) using specific antibodies and a flow cytometer (e.g., BD FACSCanto II).

1.2.2. Extract total protein from cell lysates using RIPA buffer and perform Western blot analysis to detect AID and l-MYC protein expression using specific antibodies.

1.2.3. Extract total RNA from cell lysates using TRIzol reagent and perform qRT-PCR to detect AID and l-MYC mRNA expression using specific primers and a qRT-PCR machine (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).

**Step 2: MicroRNA Profiling**

**Protocol 2.1: MicroRNA sequencing (miRNA-seq)**

2.1.1. Extract total RNA from AID-experienced and AID-naive cell lines using TRIzol reagent.

2.1.2. Prepare miRNA libraries using a commercial kit (e.g., Illumina TruSeq Small RNA Library Prep Kit) according to the manufacturer's instructions.

2.1.3. Perform miRNA-seq using a next-generation sequencing platform (e.g., Illumina HiSeq 4000).

2.1.4. Analyze miRNA-seq data using bioinformatic tools (e.g., miRDeep2 or DESeq2) to identify differentially expressed microRNAs between AID-experienced and AID-naive cell lines.

**Protocol 2.2: qRT-PCR validation of microRNA expression**

2.2.1. Extract total RNA from AID-experienced and AID-naive cell lines using TRIzol reagent.

2.2.2. Perform qRT-PCR using specific microRNA primers and a qRT-PCR machine (e.g., Applied Biosystems 7500 Fast Real-Time PCR System) to validate the expression of a subset of microRNAs identified by miRNA-seq.

**Step 3: Germinal Center Reaction Analysis**

**Protocol 3.1: Co-culture of AID-experienced and AID-naive l-MYC tumor cells with primary B cells and follicular dendritic cells**

3.1.1. Isolate primary B cells from human peripheral blood mononuclear cells (PBMCs) using magnetic bead separation (e.g., Miltenyi Biotec).

3.1.2. Isolate follicular dendritic cells from human tonsils using magnetic bead separation (e.g., Miltenyi Biotec).

3.1.3. Co-culture AID-experienced and AID-naive l-MYC tumor cells with primary B cells and follicular dendritic cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

**Protocol 3.2: Analysis of germinal center reaction markers**

3.2.1. Analyze the co-culture using flow cytometry to detect the expression of germinal center reaction markers (e.g., CD40, CD80, CD86, and AICDA) using specific antibodies.

3.2.2. Perform immunofluorescence staining to detect the expression of germinal center reaction markers using specific antibodies and a fluorescence microscope (e.g., Zeiss Axiovert 200M).

3.2.3. Extract total RNA from the co-culture and perform qRT-PCR to detect the expression of germinal center reaction markers using specific primers.

**Step 4: Functional Validation**

**Protocol 4.1: MicroRNA modulation using mimics or inhibitors**

4.1.1. Design and synthesize microRNA mimics or inhibitors targeting differentially expressed microRNAs using online tools (e.g., Dharmacon or Ambion).

4.1.2. Transfect AID-naive l-MYC tumor cells with microRNA mimics or inhibitors using a transfection reagent (e.g., Lipofectamine 2000).

**Protocol 4.2: Analysis of germinal center reaction markers and mature B cell lymphoma development**

4.2.1. Analyze the effects of microRNA modulation on germinal center reaction markers using flow cytometry, immunofluorescence, and qRT-PCR.

4.2.2. Analyze the effects of microRNA modulation on mature B cell lymphoma development using the co-culture system and flow cytometry.

**Step 5: In Vivo Validation**

**Protocol 5.1: Injection of AID-experienced and AID-naive l-MYC tumor cells into immunocompromised mice**

5.1.1. Obtain immunocompromised mice (e.g., NOD-SCID or NSG mice) and maintain them in a specific pathogen-free facility.

5.1.2. Inject AID-experienced and AID-naive l-MYC tumor cells into the mice via tail vein injection.

**Protocol 5.2: Analysis of tumor development and germinal center reaction markers**

5.2.1. Monitor tumor development using bioluminescence imaging (e.g., IVIS Spectrum) or tumor volume measurement.

5.2.2. Analyze tumor samples using immunohistochemistry (IHC) to detect the expression of germinal center reaction markers (e.g., CD40, CD80, CD86, and AICDA).

5.2.3. Extract total RNA from tumor samples and perform qRT-PCR to detect the expression of germinal center reaction markers using specific primers.

5.2.4. Analyze tumor samples using flow cytometry to detect the expression of germinal center reaction markers using specific antibodies.

These detailed protocols should provide a clear guide for executing the experimental plan and ensuring replicability and specificity in the results.","```
   l-MYC_tumor_cells  CRISPR-Cas9_RNP_complexes  puromycin  AID_knockout  microRNA_mimics  microRNA_inhibitors  germinal_center_reaction_markers  outcome
0               10000                    20.0       1.0         0.8               50.0                20.0                         0.6  positive
1               12000                    25.0       1.2         0.9               60.0                25.0                         0.7  positive
2               15000                    30.0       1.5         0.7               70.0                30.0                         0.8  positive
3               18000                    35.0       1.8         0.6               80.0                35.0                         0.9  positive
4               20000                    40.0       2.0         0.5               90.0                40.0                         1.0  positive
5               10000                    20.0       1.0         0.8               50.0                20.0                         0.6  negative
6               12000                    25.0       1.2         0.9               60.0                25.0                         0.7  negative
7               15000                    30.0       1.5         0.7               70.0                30.0                         0.8  negative
8               18000                    35.0       1.8         0.6               80.0                35.0                         0.9  negative
9               20000                    40.0       2.0         0.5               90.0                40.0                         1.0  negative
10              10000                    20.0       1.0         0.8               50.0                20.0                         0.6  positive
11              12000                    25.0       1.2         0.9               60.0                25.0                         0.7  positive
12              15000                    30.0       1.5         0.7               70.0                30.0                         0.8  positive
13              18000                    35.0       1.8         0.6               80.0                35.0                         0.9  positive
14              20000                    40.0       2.0         0.5               90.0                40.0                         1.0  positive
15              10000                    20.0       1.0         0.8               50.0                20.0                         0.6  negative
16              12000                    25.0       1.2         0.9               60.0                25.0                         0.7  negative
17              15000                    30.0       1.5         0.7               70.0                30.0                         0.8  negative
18              18000                    35.0       1.8         0.6               80.0                35.0                         0.9  negative
19              20000                    40.0       2.0         0.5               90.0                40.0                         1.0  negative
20              10000                    20.0       1.0         0.8               50.0                20.0                         0.6  positive
21              12000                    25.0       1.2         0.9               60.0                25.0                         0.7  positive
22              15000                    30.0       1.5         0.7               70.0                30.0                         0.8  positive
23              18000                    35.0       1.8         0.6               80.0                35.0                         0.9  positive
24              20000                    40.0       2.0         0.5               90.0                40.0                         1.0  positive
```",4.450041052354278e-17
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e13f606f8eb825354364cc62bfa76621eab2a82f.summary'],Does the presence of IgM+CD27+ B cells influence the expansion dynamics of IgG+ MBC with high affinity BCRs in response to vaccination?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis: ""Does the presence of IgM+CD27+ B cells influence the expansion dynamics of IgG+ MBC with high affinity BCRs in response to vaccination?""

**Experimental Plan:**

**Objective:** To investigate whether the presence of IgM+CD27+ B cells affects the expansion dynamics of IgG+ MBC with high affinity BCRs in response to vaccination.

**Experimental Design:**

1. **Cell Isolation and Sorting:**
	* Isolate Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors.
	* Use flow cytometry to sort IgG+ MBC, IgM+CD27+ B cells, and cTFH2 cells from PBMCs.
2. **Co-Culture Experiments:**
	* Set up four co-culture conditions:
		+ Condition 1: IgG+ MBC + cTFH2 cells (positive control)
		+ Condition 2: IgG+ MBC + IgM+CD27+ B cells
		+ Condition 3: IgG+ MBC + cTFH2 cells + IgM+CD27+ B cells
		+ Condition 4: IgG+ MBC only (negative control)
	* Add TTd antigen to each co-culture condition.
3. **BCR Affinity Measurement:**
	* Use a chaotropic elution assay to measure the affinity of BCRs on IgG+ MBC before and after co-culture (at 3-5 days).
4. **Flow Cytometry Analysis:**
	* Analyze the expression of activation markers (e.g., CD69, CD86) and proliferation markers (e.g., Ki-67) on IgG+ MBC in each co-culture condition using flow cytometry.
5. **Data Analysis:**
	* Compare the BCR affinity, activation, and proliferation of IgG+ MBC between the four co-culture conditions.
	* Determine if the presence of IgM+CD27+ B cells affects the expansion dynamics of IgG+ MBC with high affinity BCRs.

**Rationale:**

* By comparing the BCR affinity, activation, and proliferation of IgG+ MBC in the presence or absence of IgM+CD27+ B cells, we can determine if these cells influence the expansion dynamics of IgG+ MBC with high affinity BCRs.
* The positive control (Condition 1) ensures that the co-culture system is functional, while the negative control (Condition 4) provides a baseline for IgG+ MBC expansion.
* The addition of IgM+CD27+ B cells to the co-culture (Condition 2 and 3) allows us to assess their potential influence on IgG+ MBC expansion.

**Resources and Timeline:**

* This experiment can be completed within 2-3 months with a moderate budget.
* Required resources:
	+ Flow cytometer and cell sorter
	+ Chaotropic elution reagents
	+ PBMCs from healthy donors
	+ TTd antigen
	+ Antibodies for flow cytometry analysis
	+ Cell culture media and reagents

**Potential Limitations:**

* The experiment relies on the availability of PBMCs from healthy donors, which may be a limiting factor.
* The co-culture system may not fully recapitulate the in vivo environment, which could affect the results.

By following this experimental plan, we can test the hypothesis and determine whether the presence of IgM+CD27+ B cells influences the expansion dynamics of IgG+ MBC with high affinity BCRs in response to vaccination.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Isolation and Sorting**

1.1. **PBMC Isolation**

* Obtain 10-20 mL of whole blood from healthy donors in EDTA-coated tubes.
* Dilute the blood 1:1 with PBS and layer it onto a Ficoll-Paque density gradient (1.077 g/mL).
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the PBMC layer and wash twice with PBS.
* Resuspend the cells in 10 mL of PBS and count using a hemocytometer.

1.2. **Flow Cytometry Staining**

* Prepare the following antibody cocktail:
	+ Anti-IgG-PE (1:100)
	+ Anti-CD27-APC (1:100)
	+ Anti-CD3-PerCP (1:100)
	+ Anti-CD19-FITC (1:100)
* Add 100 μL of the antibody cocktail to 1 x 10^6 PBMCs in 100 μL of PBS.
* Incubate for 30 minutes at 4°C in the dark.
* Wash the cells twice with PBS.

1.3. **Cell Sorting**

* Use a flow cytometer (e.g., BD FACSAria) to sort the following populations:
	+ IgG+ MBC: CD19+CD3-CD27-IgG+
	+ IgM+CD27+ B cells: CD19+CD3-CD27+IgM+
	+ cTFH2 cells: CD3+CD4+CXCR5+PD-1+
* Sort cells into separate tubes containing 1 mL of PBS.

**Protocol 2: Co-Culture Experiments**

2.1. **Co-Culture Setup**

* Prepare the following co-culture conditions:
	+ Condition 1: IgG+ MBC (1 x 10^5) + cTFH2 cells (1 x 10^5)
	+ Condition 2: IgG+ MBC (1 x 10^5) + IgM+CD27+ B cells (1 x 10^5)
	+ Condition 3: IgG+ MBC (1 x 10^5) + cTFH2 cells (1 x 10^5) + IgM+CD27+ B cells (1 x 10^5)
	+ Condition 4: IgG+ MBC (1 x 10^5) only
* Add 1 μg/mL of TTd antigen to each co-culture condition.
* Culture the cells in 24-well plates with 1 mL of complete RPMI-1640 medium (10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

2.2. **Co-Culture Incubation**

* Incubate the co-cultures for 3-5 days.
* Monitor the cultures daily for cell viability and contamination.

**Protocol 3: BCR Affinity Measurement**

3.1. **Chaotropic Elution Assay**

* Prepare the following reagents:
	+ Chaotropic elution buffer (1 M NaSCN, 0.1% BSA, 0.01% NaN3)
	+ PBS-BSA (1% BSA in PBS)
* Harvest the IgG+ MBC from each co-culture condition and wash twice with PBS-BSA.
* Resuspend the cells in 100 μL of chaotropic elution buffer and incubate for 30 minutes at 4°C.
* Centrifuge at 400 x g for 5 minutes and collect the supernatant.
* Measure the BCR affinity using an ELISA or a similar assay.

**Protocol 4: Flow Cytometry Analysis**

4.1. **Flow Cytometry Staining**

* Prepare the following antibody cocktail:
	+ Anti-CD69-PE (1:100)
	+ Anti-CD86-APC (1:100)
	+ Anti-Ki-67-FITC (1:100)
* Add 100 μL of the antibody cocktail to 1 x 10^6 IgG+ MBC in 100 μL of PBS.
* Incubate for 30 minutes at 4°C in the dark.
* Wash the cells twice with PBS.

4.2. **Flow Cytometry Analysis**

* Analyze the expression of CD69, CD86, and Ki-67 on IgG+ MBC using a flow cytometer (e.g., BD FACSCanto).
* Use the following gates:
	+ CD69+: CD69 > 10^2
	+ CD86+: CD86 > 10^2
	+ Ki-67+: Ki-67 > 10^2

**Protocol 5: Data Analysis**

5.1. **Data Collection**

* Collect the BCR affinity data from the chaotropic elution assay.
* Collect the flow cytometry data from Protocol 4.

5.2. **Data Analysis**

* Compare the BCR affinity, activation (CD69, CD86), and proliferation (Ki-67) of IgG+ MBC between the four co-culture conditions.
* Use statistical software (e.g., GraphPad Prism) to perform one-way ANOVA with Tukey's multiple comparison test.
* Determine if the presence of IgM+CD27+ B cells affects the expansion dynamics of IgG+ MBC with high affinity BCRs.

Note: The above protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   IgG+ MBC  cTFH2 cells  IgM+CD27+ B cells  TTd antigen  BCR Affinity  CD69+  CD86+  Ki-67+
0       100000       100000               0        1.0  1.234567  0.45  0.30  0.20
1       120000       80000               0        1.0  1.456789  0.50  0.35  0.25
2       100000       100000           50000        1.0  1.678901  0.55  0.40  0.30
3       80000        120000               0        1.0  1.234567  0.40  0.30  0.20
4       100000       100000               0        0.8  1.111111  0.40  0.30  0.20
5       120000       80000           50000        1.0  1.789012  0.60  0.45  0.35
6       100000       100000               0        1.2  1.345678  0.50  0.35  0.25
7       80000        120000           50000        1.0  1.567890  0.45  0.35  0.25
8       100000       100000               0        1.0  1.234567  0.45  0.30  0.20
9       120000       80000               0        1.0  1.456789  0.50  0.35  0.25
10      100000       100000           50000        1.0  1.678901  0.55  0.40  0.30
11      80000        120000               0        1.0  1.234567  0.40  0.30  0.20
12      100000       100000               0        0.8  1.111111  0.40  0.30  0.20
13      120000       80000           50000        1.0  1.789012  0.60  0.45  0.35
14      100000       100000               0        1.2  1.345678  0.50  0.35  0.25
15      80000        120000           50000        1.0  1.567890  0.45  0.35  0.25
16      100000       100000               0        1.0  1.234567  0.45  0.30  0.20
17      120000       80000               0        1.0  1.456789  0.50  0.35  0.25
18      100000       100000           50000        1.0  1.678901  0.55  0.40  0.30
19      80000        120000               0        1.0  1.234567  0.40  0.30  0.20
20      100000       100000               0        0.8  1.111111  0.40  0.30  0.20
21      120000       80000           50000        1.0  1.789012  0.60  0.45  0.35
22      100000       100000               0        1.2  1.345678  0.50  0.35  0.25
23      80000        120000           50000        1.0  1.567890  0.45  0.35  0.25
24      100000       100000               0        1.0  1.234567  0.45  0.30  0.20
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/62c1c06b9d1fb19f2db11246d64dde3b5c8991c2.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/63d00173a783403e15d5c9b8c2edefddff8dfaf5.summary']",Does the presence of alpha 2 macroglobulin-IgG-hexamers in the sera of patients with B-cell malignancies treated with rituximab affect the efficacy of rituximab by reducing the activity of the complement system and thereby influencing treatment outcome?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the presence of alpha 2 macroglobulin-IgG-hexamers in the sera of patients with B-cell malignancies treated with rituximab affects the efficacy of rituximab by reducing the activity of the complement system and thereby influencing treatment outcome, I propose the following experimental plan:

**Experiment:** ""Disproving the Hypothesis: Investigating the Impact of Alpha 2 Macroglobulin-IgG-Hexamers on Rituximab Efficacy""

**Objective:** To determine whether the presence of alpha 2 macroglobulin-IgG-hexamers in patient sera reduces the activity of the complement system, thereby affecting the efficacy of rituximab treatment.

**Design:**

1. **Patient Selection:** Collect blood samples from 20 patients with B-cell malignancies (e.g., chronic lymphocytic leukemia, non-Hodgkin's lymphoma) treated with rituximab. Ensure that 10 patients have high levels of alpha 2 macroglobulin-IgG-hexamers in their sera, while the other 10 patients have low or undetectable levels.
2. **Sample Preparation:** Isolate sera from the collected blood samples and store them at -80°C until further analysis.
3. **Complement System Activity Assay:** Measure the complement-dependent cytotoxicity (CDC) activity of each patient's sera using a calcein release assay, as described in the first paper. This will provide a baseline measurement of complement system activity.
4. **Rituximab Incubation:** Incubate each patient's sera with rituximab (at a concentration similar to that used in clinical settings) for 1 hour at 37°C.
5. **Complement System Activity Re-Assay:** Measure the CDC activity of each patient's sera after rituximab incubation using the same calcein release assay.
6. **Alpha 2 Macroglobulin-IgG-Hexamer Quantification:** Quantify the levels of alpha 2 macroglobulin-IgG-hexamers in each patient's sera using an ELISA assay, as described in the second paper.
7. **Statistical Analysis:** Compare the CDC activity of patients with high and low levels of alpha 2 macroglobulin-IgG-hexamers before and after rituximab incubation. If the hypothesis is correct, patients with high levels of alpha 2 macroglobulin-IgG-hexamers should exhibit reduced CDC activity after rituximab incubation compared to those with low levels.

**Expected Outcome:**

* If the hypothesis is true, patients with high levels of alpha 2 macroglobulin-IgG-hexamers will show reduced CDC activity after rituximab incubation, indicating that the presence of these hexamers reduces the efficacy of rituximab by inhibiting the complement system.
* If the hypothesis is false, there will be no significant difference in CDC activity between patients with high and low levels of alpha 2 macroglobulin-IgG-hexamers after rituximab incubation, suggesting that the presence of these hexamers does not affect rituximab efficacy.

**Equipment and Resources:**

* ELISA plates and reader
* Antibodies against rituximab and complement components (e.g., C4d, TCC)
* Calcein release assay kit
* Microplate reader
* Incubator
* Pipettes and other standard laboratory equipment
* Patient samples and sera

**Timeline:**

* Patient sample collection and sera isolation: 2 weeks
* Complement system activity assay and rituximab incubation: 4 weeks
* Alpha 2 macroglobulin-IgG-hexamer quantification: 2 weeks
* Statistical analysis and data interpretation: 4 weeks

**Budget:**

* Patient sample collection and sera isolation: $5,000
* Reagents and consumables (ELISA plates, antibodies, calcein release assay kit, etc.): $10,000
* Equipment maintenance and operation (microplate reader, incubator, etc.): $5,000
* Personnel and labor costs: $20,000
* Total budget: $40,000

This experiment is designed to test the hypothesis in a controlled and efficient manner, using existing methods and equipment. The results will provide valuable insights into the role of alpha 2 macroglobulin-IgG-hexamers in rituximab efficacy and may inform the development of personalized treatment strategies for patients with B-cell malignancies.",85,"Here are the detailed, step-by-step protocols for the experiment ""Disproving the Hypothesis: Investigating the Impact of Alpha 2 Macroglobulin-IgG-Hexamers on Rituximab Efficacy"":

**Protocol 1: Patient Selection and Blood Sample Collection**

1.1. Identify 20 patients with B-cell malignancies (e.g., chronic lymphocytic leukemia, non-Hodgkin's lymphoma) who have been treated with rituximab.

1.2. Obtain informed consent from each patient and ensure that they meet the inclusion criteria.

1.3. Collect 10 mL of blood from each patient using a sterile needle and syringe.

1.4. Label each blood sample with a unique identifier and store them at room temperature.

**Protocol 2: Sample Preparation**

2.1. Allow the blood samples to clot at room temperature for 30 minutes.

2.2. Centrifuge the blood samples at 1,500 x g for 10 minutes to separate the serum from the blood cells.

2.3. Transfer the serum to a new tube and store it at -80°C until further analysis.

**Protocol 3: Complement System Activity Assay (Baseline Measurement)**

3.1. Thaw the serum samples at room temperature.

3.2. Prepare the calcein release assay kit according to the manufacturer's instructions.

3.3. Add 50 μL of serum to each well of a 96-well plate.

3.4. Add 50 μL of calcein-labeled target cells to each well.

3.5. Incubate the plate at 37°C for 1 hour.

3.6. Measure the fluorescence intensity of each well using a microplate reader (excitation: 485 nm, emission: 535 nm).

3.7. Calculate the complement-dependent cytotoxicity (CDC) activity as a percentage of lysis using the following formula:

CDC activity (%) = (fluorescence intensity of sample - fluorescence intensity of negative control) / (fluorescence intensity of positive control - fluorescence intensity of negative control) x 100

**Protocol 4: Rituximab Incubation**

4.1. Thaw the serum samples at room temperature.

4.2. Add 10 μg/mL of rituximab to each serum sample and mix well.

4.3. Incubate the serum samples at 37°C for 1 hour.

**Protocol 5: Complement System Activity Re-Assay**

5.1. Repeat steps 3.3-3.7 using the rituximab-incubated serum samples.

**Protocol 6: Alpha 2 Macroglobulin-IgG-Hexamer Quantification**

6.1. Thaw the serum samples at room temperature.

6.2. Prepare the ELISA plates and reagents according to the manufacturer's instructions.

6.3. Add 50 μL of serum to each well of the ELISA plate.

6.4. Incubate the plate at room temperature for 1 hour.

6.5. Add 50 μL of detection antibody to each well and incubate for an additional 30 minutes.

6.6. Measure the absorbance of each well using an ELISA reader (450 nm).

6.7. Calculate the concentration of alpha 2 macroglobulin-IgG-hexamers using a standard curve.

**Protocol 7: Statistical Analysis**

7.1. Compare the CDC activity of patients with high and low levels of alpha 2 macroglobulin-IgG-hexamers before and after rituximab incubation using a two-way ANOVA.

7.2. Calculate the mean and standard deviation of CDC activity for each group.

7.3. Determine the significance of the results using a p-value < 0.05.

These detailed protocols provide a step-by-step guide for executing the experiment, ensuring replicability and specificity in the results.","```
   Patient_ID  Alpha_2_Macroglobulin_IgG_Hexamers  Rituximab  CDC_Baseline  CDC_Post_Rituximab
0           1                         0.5          5.0       23.12              17.56
1           2                         1.0          7.5       25.67              20.89
2           3                         1.5         10.0       28.34              23.12
3           4                         0.8          6.0       21.90              18.45
4           5                         1.2          8.0       26.12              21.56
5           6                         0.9          5.5       22.56              19.01
6           7                         1.1          9.0       27.45              22.89
7           8                         0.7          4.5       20.12              16.78
8           9                         1.4          7.0       25.12              20.23
9          10                         1.0          6.5       24.56              20.56
10         11                         0.6          5.0       21.23              17.89
11         12                         1.3          8.5       26.78              22.12
12         13                         0.9          6.0       23.45              19.56
13         14                         1.2          7.0       25.89              21.01
14         15                         0.8          5.5       22.12              18.23
15         16                         1.1          9.0       27.12              22.56
16         17                         0.7          4.5       20.56              16.90
17         18                         1.4          7.5       25.56              20.67
18         19                         1.0          6.0       24.12              20.12
19         20                         0.6          5.0       21.01              17.45
20         21                         1.3          8.0       26.23              21.78
21         22                         0.9          6.5       23.78              19.90
22         23                         1.2          7.0       25.45              20.90
23         24                         0.8          5.5       22.45              18.45
24         25                         1.1          9.0       27.45              22.90
```",0.7054964006591873
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/9f06a16c672a5b83b57ff45ea44336a491436087.summary'],Does the presence of antibodies against specific self-epitopes in patients with metastatic triple negative breast cancer prior to immunotherapy treatment predict a more favorable response to subsequent treatment with cyclophosphamide and pembrolizumab?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis. Here's a high-level experimental approach:

**Experiment Title:** Investigating the Predictive Value of Antibodies against Specific Self-Epitopes in Metastatic Triple Negative Breast Cancer Patients Treated with Cyclophosphamide and Pembrolizumab

**Objective:** To determine whether the presence of antibodies against specific self-epitopes in patients with metastatic triple negative breast cancer prior to immunotherapy treatment predicts a more favorable response to subsequent treatment with cyclophosphamide and pembrolizumab.

**Experimental Design:**

1. **Patient Selection:** Recruit a large cohort of patients with metastatic triple negative breast cancer (n = 100-200) who are scheduled to receive cyclophosphamide and pembrolizumab treatment.
2. **Blood Sample Collection:** Collect blood samples from each patient at three time points:
	* Baseline (prior to treatment initiation)
	* Mid-treatment (after 2-3 cycles of cyclophosphamide and pembrolizumab)
	* Post-treatment (after completion of treatment)
3. **Peptide Array Analysis:** Perform peptide array analysis on the collected blood samples to measure the antibody response to a comprehensive panel of self-epitopes (n = 100-200) using a high-throughput peptide array platform.
4. **Antibody Profiling:** Use a microarray scanner to detect and quantify the antibody signals against each self-epitope. Generate a comprehensive antibody profile for each patient at each time point.
5. **Clinical Response Assessment:** Evaluate the clinical response of each patient using standardized criteria (e.g., RECIST 1.1) and collect relevant clinical data (e.g., tumor size, progression-free survival, overall survival).
6. **Statistical Analysis:** Perform statistical analysis to correlate the antibody profiles with clinical response data. Specifically:
	* Compare the antibody profiles between responders and non-responders to identify potential predictive biomarkers.
	* Use machine learning algorithms to develop a predictive model that integrates antibody profiles and clinical data to forecast treatment response.
	* Perform survival analysis to determine the association between antibody profiles and clinical outcomes (e.g., progression-free survival, overall survival).
7. **Validation:** Validate the findings using an independent cohort of patients (n = 50-100) to ensure the results are generalizable.

**Equipment and Resources:**

* Peptide arrays
* Microarray scanner
* Statistical analysis software (e.g., R, Python, or commercial software)
* High-throughput peptide array platform
* Clinical data management system
* Biostatistical support

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on identifying potential confounding variables that could influence the relationship between antibody profiles and clinical response. Specifically:

1. **Control Group:** Include a control group of patients with metastatic triple negative breast cancer who do not receive immunotherapy treatment. This will help to determine if the observed associations are specific to the treatment or a general feature of the disease.
2. **Epitope Selection:** Use a random selection of self-epitopes (instead of a comprehensive panel) to test if the observed associations are specific to certain epitopes or a general feature of the humoral immune response.
3. **Antibody Profiling:** Use alternative antibody profiling methods (e.g., ELISA, Western blot) to validate the findings and rule out platform-specific biases.
4. **Multivariate Analysis:** Perform multivariate analysis to control for potential confounding variables (e.g., age, tumor stage, prior treatment history) that could influence the relationship between antibody profiles and clinical response.

By using a comprehensive and rigorous experimental design, we can test the hypothesis and potentially disprove it, providing valuable insights into the role of antibodies against self-epitopes in predicting treatment response in metastatic triple negative breast cancer patients.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Patient Selection and Blood Sample Collection**

1.1. **Inclusion Criteria:**

* Patients with metastatic triple negative breast cancer (confirmed by histopathology and imaging)
* Scheduled to receive cyclophosphamide and pembrolizumab treatment
* Age ≥ 18 years
* Written informed consent obtained

1.2. **Exclusion Criteria:**

* Patients with active autoimmune disease or immunodeficiency
* Patients with a history of organ transplantation
* Patients receiving concurrent chemotherapy or immunotherapy

1.3. **Patient Recruitment:**

* Recruit patients from participating hospitals and clinics
* Screen patients for eligibility using the inclusion and exclusion criteria
* Obtain written informed consent from eligible patients

1.4. **Blood Sample Collection:**

* Collect 10 mL of whole blood from each patient at three time points:
	+ Baseline (prior to treatment initiation)
	+ Mid-treatment (after 2-3 cycles of cyclophosphamide and pembrolizumab)
	+ Post-treatment (after completion of treatment)
* Use Vacutainer tubes with EDTA as the anticoagulant
* Label tubes with patient ID, date, and time point
* Store tubes at 4°C until processing

**Protocol 2: Peptide Array Analysis**

2.1. **Peptide Array Preparation:**

* Prepare a comprehensive panel of 100-200 self-epitopes (peptides) using a high-throughput peptide array platform
* Spot peptides onto glass slides or microarray chips according to the manufacturer's instructions
* Block non-specific binding sites with a blocking buffer

2.2. **Sample Preparation:**

* Centrifuge blood samples at 1,500 x g for 10 minutes to separate plasma from cells
* Collect plasma and store at -80°C until analysis
* Thaw plasma samples and dilute 1:100 in a buffer solution (e.g., PBS-Tween)

2.3. **Peptide Array Incubation:**

* Incubate the peptide array with 100 μL of diluted plasma sample for 1 hour at room temperature
* Wash the array with PBS-Tween to remove unbound antibodies

2.4. **Detection and Quantification:**

* Use a microarray scanner to detect and quantify the antibody signals against each self-epitope
* Acquire images at a resolution of 10 μm/pixel
* Analyze images using microarray analysis software (e.g., GenePix, ImageJ)

**Protocol 3: Antibody Profiling and Clinical Response Assessment**

3.1. **Antibody Profiling:**

* Generate a comprehensive antibody profile for each patient at each time point using the peptide array data
* Normalize data using a reference peptide or a housekeeping gene
* Calculate the relative antibody signal intensity for each self-epitope

3.2. **Clinical Response Assessment:**

* Evaluate the clinical response of each patient using standardized criteria (e.g., RECIST 1.1)
* Collect relevant clinical data (e.g., tumor size, progression-free survival, overall survival)
* Record clinical data in a clinical data management system

**Protocol 4: Statistical Analysis**

4.1. **Data Preprocessing:**

* Merge antibody profile data with clinical response data
* Handle missing values using a suitable imputation method (e.g., mean, median, or multiple imputation)

4.2. **Correlation Analysis:**

* Compare the antibody profiles between responders and non-responders using a suitable statistical test (e.g., t-test, Wilcoxon rank-sum test)
* Identify potential predictive biomarkers using a machine learning algorithm (e.g., random forest, support vector machine)

4.3. **Survival Analysis:**

* Perform survival analysis to determine the association between antibody profiles and clinical outcomes (e.g., progression-free survival, overall survival)
* Use a suitable statistical model (e.g., Cox proportional hazards model, Kaplan-Meier estimator)

**Protocol 5: Validation**

5.1. **Independent Cohort:**

* Recruit an independent cohort of patients with metastatic triple negative breast cancer (n = 50-100)
* Collect blood samples and perform peptide array analysis as described in Protocols 1-2

5.2. **Validation Analysis:**

* Compare the antibody profiles and clinical response data between the original cohort and the independent cohort
* Validate the findings using a suitable statistical test (e.g., t-test, Wilcoxon rank-sum test)

**Protocol 6: Experimental Approach to Disprove the Hypothesis**

6.1. **Control Group:**

* Recruit a control group of patients with metastatic triple negative breast cancer who do not receive immunotherapy treatment
* Collect blood samples and perform peptide array analysis as described in Protocols 1-2

6.2. **Epitope Selection:**

* Use a random selection of self-epitopes (instead of a comprehensive panel) to test if the observed associations are specific to certain epitopes or a general feature of the humoral immune response

6.3. **Antibody Profiling:**

* Use alternative antibody profiling methods (e.g., ELISA, Western blot) to validate the findings and rule out platform-specific biases

6.4. **Multivariate Analysis:**

* Perform multivariate analysis to control for potential confounding variables (e.g., age, tumor stage, prior treatment history) that could influence the relationship between antibody profiles and clinical response","```
   Patient_ID  Cyclophosphamide  Pembrolizumab  Peptide_Array_Slides  EDTA_Tubes  Blood_Sample_Volume  Baseline_Antibody_Signal  Mid_Treatment_Antibody_Signal  Post_Treatment_Antibody_Signal  Clinical_Response
0           1               200            100                    2             10                  10.0                    0.5                       1.2                         2.5                Responder
1           2               150            120                    3             12                  12.0                    0.8                       1.5                         3.0                Responder
2           3               250            100                    2             10                  11.0                    0.6                       1.3                         2.8                Responder
3           4               200            150                    3             12                  13.0                    0.9                       1.6                         3.2                Responder
4           5               180            120                    2             10                  10.5                    0.7                       1.4                         2.9                Responder
5           6               220            100                    3             12                  12.5                    0.8                       1.5                         3.1                Responder
6           7               200            150                    2             10                  11.5                    0.9                       1.6                         3.3                Responder
7           8               250            120                    3             12                  13.5                    1.0                       1.7                         3.4                Responder
8           9               180            100                    2             10                  10.8                    0.8                       1.5                         3.0                Responder
9          10               220            150                    3             12                  12.8                    0.9                       1.6                         3.2                Responder
10         11               200            120                    2             10                  11.2                    0.7                       1.4                         2.9                Responder
11         12               250            100                    3             12                  13.2                    1.0                       1.7                         3.4                Responder
12         13               180            150                    2             10                  11.0                    0.8                       1.5                         3.1                Responder
13         14               220            120                    3             12                  12.2                    0.9                       1.6                         3.3                Responder
14         15               200            100                    2             10                  10.2                    0.7                       1.4                         2.8                Responder
15         16               250            150                    3             12                  13.0                    1.0                       1.7                         3.4                Non-Responder
16         17               180            120                    2             10                  10.5                    0.8                       1.5                         3.0                Non-Responder
17         18               220            100                    3             12                  12.5                    0.9                       1.6                         3.2                Non-Responder
18         19               200            150                    2             10                  11.2                    0.7                       1.4                         2.9                Non-Responder
19         20               250            120                    3             12                  13.2                    1.0                       1.7                         3.4                Non-Responder
20         21               180            100                    2             10                  10.8                    0.8                       1.5                         3.1                Non-Responder
21         22               220            150                    3             12                  12.8                    0.9                       1.6                         3.3                Non-Responder
22         23               200            120                    2             10                  11.5                    0.7                       1.4                         2.9                Non-Responder
23         24               250            100                    3             12                  13.5                    1.0                       1.7                         3.4                Non-Responder
24         25               180            150                    2             10                  11.0                    0.8                       1.5                         3.2                Non-Responder
```",0.22328879913385233
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d0b89a8ea24fb20033ecb7aac0ba58f8065b0113.summary'],"Does the presence of cell-bound CA125 on immune cell subtypes in ovarian cancer patients modulate the expression of checkpoint inhibitors, thereby influencing the efficacy of immunotherapy?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** The presence of cell-bound CA125 on immune cell subtypes in ovarian cancer patients modulates the expression of checkpoint inhibitors, thereby influencing the efficacy of immunotherapy.

**Experimental Plan:**

**Objective:** To investigate whether cell-bound CA125 on immune cell subtypes affects the expression of checkpoint inhibitors and immunotherapy efficacy in ovarian cancer patients.

**Experimental Design:**

1. **Sample Collection:**
	* Collect blood samples from ovarian cancer patients (n=30) and healthy controls (n=10).
	* Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation.
2. **Cell-bound CA125 Analysis:**
	* Use flow cytometry to detect and quantify cell-bound CA125 on immune cell subtypes (e.g., T cells, B cells, monocytes, and dendritic cells) in PBMCs.
	* Analyze CA125 expression on each immune cell subtype using specific antibodies and gating strategies.
3. **Checkpoint Inhibitor Expression Analysis:**
	* Use quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure the expression of checkpoint inhibitors (e.g., PD-1, PD-L1, CTLA-4) in PBMCs.
	* Analyze the correlation between cell-bound CA125 expression and checkpoint inhibitor expression.
4. **Immunotherapy Efficacy Assessment:**
	* Use a functional assay (e.g., T cell activation assay) to evaluate the efficacy of immunotherapy in the presence or absence of cell-bound CA125.
	* Co-culture PBMCs with ovarian cancer cells and assess T cell activation markers (e.g., CD25, CD69) and cytokine production (e.g., IFN-γ, TNF-α).
5. **Statistical Analysis:**
	* Compare CA125 expression, checkpoint inhibitor expression, and immunotherapy efficacy between ovarian cancer patients and healthy controls.
	* Perform correlation analysis to determine the relationship between cell-bound CA125 and checkpoint inhibitor expression.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we will design an experiment to show that cell-bound CA125 does not affect checkpoint inhibitor expression or immunotherapy efficacy.

**Null Hypothesis:** Cell-bound CA125 on immune cell subtypes in ovarian cancer patients does not modulate the expression of checkpoint inhibitors or influence the efficacy of immunotherapy.

**Experimental Approach:**

1. **CA125 Knockdown:**
	* Use small interfering RNA (siRNA) or CRISPR-Cas9 to knockdown CA125 expression on immune cell subtypes in PBMCs from ovarian cancer patients.
	* Verify CA125 knockdown using flow cytometry and Western blotting.
2. **Checkpoint Inhibitor Expression Analysis:**
	* Measure checkpoint inhibitor expression in CA125-knockdown PBMCs using qRT-PCR.
	* Compare checkpoint inhibitor expression between CA125-knockdown and control PBMCs.
3. **Immunotherapy Efficacy Assessment:**
	* Evaluate immunotherapy efficacy in CA125-knockdown PBMCs using the same functional assay as before.
	* Compare immunotherapy efficacy between CA125-knockdown and control PBMCs.

**Expected Outcome:**
If the null hypothesis is true, we expect to see no significant difference in checkpoint inhibitor expression or immunotherapy efficacy between CA125-knockdown and control PBMCs. This would suggest that cell-bound CA125 does not modulate checkpoint inhibitor expression or influence immunotherapy efficacy.

**Timeline and Budget:**

* Sample collection and processing: 2 weeks, $5,000
* Cell-bound CA125 analysis: 4 weeks, $10,000
* Checkpoint inhibitor expression analysis: 4 weeks, $10,000
* Immunotherapy efficacy assessment: 6 weeks, $15,000
* CA125 knockdown and validation: 4 weeks, $10,000
* Statistical analysis and data interpretation: 4 weeks, $5,000

Total duration: 28 weeks (approximately 7 months)
Total budget: $50,000

This experiment is designed to be completed within a reasonable time frame and budget, while still providing valuable insights into the role of cell-bound CA125 in modulating checkpoint inhibitor expression and immunotherapy efficacy in ovarian cancer patients.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Sample Collection and Processing**

1.1. Collect blood samples from 30 ovarian cancer patients and 10 healthy controls using vacutainer tubes containing EDTA as an anticoagulant.

1.2. Label the tubes with unique identifiers and store them at room temperature.

1.3. Within 2 hours of collection, perform density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) to isolate peripheral blood mononuclear cells (PBMCs).

1.4. Resuspend the PBMCs in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

1.5. Count the PBMCs using a hemocytometer and adjust the concentration to 1 x 10^6 cells/mL.

1.6. Aliquot the PBMCs into 1 mL cryovials and store them at -80°C for future use.

**Protocol 2: Cell-bound CA125 Analysis**

2.1. Thaw the PBMCs and resuspend them in 100 μL of FACS buffer (PBS with 2% FBS and 0.1% sodium azide).

2.2. Add 10 μL of fluorochrome-conjugated antibodies against CD3, CD4, CD8, CD14, CD19, and CD11c (e.g., BD Biosciences) to identify immune cell subtypes.

2.3. Add 10 μL of fluorochrome-conjugated anti-CA125 antibody (e.g., Abcam) to detect cell-bound CA125.

2.4. Incubate the cells at room temperature for 30 minutes in the dark.

2.5. Wash the cells twice with FACS buffer and resuspend them in 500 μL of FACS buffer.

2.6. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and gating strategies to identify immune cell subtypes and quantify CA125 expression.

**Protocol 3: Checkpoint Inhibitor Expression Analysis**

3.1. Extract total RNA from PBMCs using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions.

3.2. Perform cDNA synthesis using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).

3.3. Design and optimize qRT-PCR primers for PD-1, PD-L1, and CTLA-4 using Primer3 software.

3.4. Perform qRT-PCR using the PowerUp SYBR Green Master Mix (Applied Biosystems) and the StepOnePlus Real-Time PCR System (Applied Biosystems).

3.5. Analyze the data using the ΔΔCt method to calculate the relative expression of checkpoint inhibitors.

**Protocol 4: Immunotherapy Efficacy Assessment**

4.1. Co-culture PBMCs with ovarian cancer cells (e.g., SKOV3) at a 1:1 ratio in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

4.2. Add 10 ng/mL of recombinant human IL-2 (PeproTech) to the co-culture to stimulate T cell activation.

4.3. Incubate the co-culture at 37°C, 5% CO2 for 48 hours.

4.4. Harvest the cells and stain them with fluorochrome-conjugated antibodies against CD25, CD69, and IFN-γ (e.g., BD Biosciences).

4.5. Analyze the cells using a flow cytometer to evaluate T cell activation markers and cytokine production.

**Protocol 5: CA125 Knockdown**

5.1. Design and synthesize siRNA or CRISPR-Cas9 guide RNA targeting CA125.

5.2. Transfect PBMCs with siRNA or CRISPR-Cas9 using the Lipofectamine RNAiMAX Reagent (Invitrogen) or the CRISPR-Cas9 Electroporation Kit (Lonza) according to the manufacturer's instructions.

5.3. Verify CA125 knockdown using flow cytometry and Western blotting.

**Protocol 6: Statistical Analysis**

6.1. Compare CA125 expression, checkpoint inhibitor expression, and immunotherapy efficacy between ovarian cancer patients and healthy controls using Student's t-test or Mann-Whitney U test.

6.2. Perform correlation analysis to determine the relationship between cell-bound CA125 and checkpoint inhibitor expression using Pearson's correlation coefficient or Spearman's rank correlation coefficient.

6.3. Analyze the data using GraphPad Prism software or R programming language.

These detailed protocols should provide a clear guide for executing the experiment and ensuring replicability and specificity in the results.","```
   EDTA  Ficoll-Paque_PLUS  RPMI-1640  FBS  Penicillin-Streptomycin  CD3  CD4  CD8  CD14  CD19  CD11c  CA125  IL-2  siRNA/CRISPR  CA125_Expression  PD-1_Expression  PD-L1_Expression  CTLA-4_Expression  T_Cell_Activation
0     10             200       1000  10.0                1.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0         0.5         0.8         0.6         0.7         0.4
1     15             250       1200  12.0                1.2  12.0  12.0  12.0  12.0  12.0  12.0  12.0  12.0  10.0         0.6         0.9         0.7         0.8         0.5
2     20             300       1500  15.0                1.5  15.0  15.0  15.0  15.0  15.0  15.0  15.0  15.0  10.0         0.7         1.0         0.8         0.9         0.6
3     25             350       1800  18.0                1.8  18.0  18.0  18.0  18.0  18.0  18.0  18.0  18.0  10.0         0.8         1.1         0.9         1.0         0.7
4     30             400       2000  20.0                2.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  10.0         0.9         1.2         1.0         1.1         0.8
5     10             200       1000  10.0                1.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  15.0         0.5         0.8         0.6         0.7         0.4
6     15             250       1200  12.0                1.2  12.0  12.0  12.0  12.0  12.0  12.0  12.0  12.0  15.0         0.6         0.9         0.7         0.8         0.5
7     20             300       1500  15.0                1.5  15.0  15.0  15.0  15.0  15.0  15.0  15.0  15.0  15.0         0.7         1.0         0.8         0.9         0.6
8     25             350       1800  18.0                1.8  18.0  18.0  18.0  18.0  18.0  18.0  18.0  18.0  15.0         0.8         1.1         0.9         1.0         0.7
9     30             400       2000  20.0                2.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  15.0         0.9         1.2         1.0         1.1         0.8
10    10             200       1000  10.0                1.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  20.0         0.5         0.8         0.6         0.7         0.4
11    15             250       1200  12.0                1.2  12.0  12.0  12.0  12.0  12.0  12.0  12.0  12.0  20.0         0.6         0.9         0.7         0.8         0.5
12    20             300       1500  15.0                1.5  15.0  15.0  15.0  15.0  15.0  15.0  15.0  15.0  20.0         0.7         1.0         0.8         0.9         0.6
13    25             350       1800  18.0                1.8  18.0  18.0  18.0  18.0  18.0  18.0  18.0  18.0  20.0         0.8         1.1         0.9         1.0         0.7
14    30             400       2000  20.0                2.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0         0.9         1.2         1.0         1.1         0.8
15    10             200       1000  10.0                1.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  25.0         0.5         0.8         0.6         0.7         0.4
16    15             250       1200  12.0                1.2  12.0  12.0  12.0  12.0  12.0  12.0  12.0  12.0  25.0         0.6         0.9         0.7         0.8         0.5
17    20             300       1500  15.0                1.5  15.0  15.0  15.0  15.0  15.0  15.0  15.0  15.0  25.0         0.7         1.0         0.8         0.9         0.6
18    25             350       1800  18.0                1.8  18.0  18.0  18.0  18.0  18.0  18.0  18.0  18.0  25.0         0.8         1.1         0.9         1.0         0.7
19    30             400       2000  20.0                2.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  25.0         0.9         1.2         1.0         1.1         0.8
20    10             200       1000  10.0                1.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  30.0         0.5         0.8         0.6         0.7         0.4
21    15             250       1200  12.0                1.2  12.0  12.0  12.0  12.0  12.0  12.0  12.0  12.0  30.0         0.6         0.9         0.7         0.8         0.5
22    20             300       1500  15.0                1.5  15.0  15.0  15.0  15.0  15.0  15.0  15.0  15.0  30.0         0.7         1.0         0.8         0.9         0.6
23    25             350       1800  18.0                1.8  18.0  18.0  18.0  18.0  18.0  18.0  18.0  18.0  30.0         0.8         1.1         0.9         1.0         0.7
24    30             400       2000  20.0                2.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  20.0  30.0         0.9         1.2         1.0         1.1         0.8
```",0.9426444078065219
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1132399438c4c9e238c978d1d2cd9f7225571485.summary'],"Does the presence of depression and anxiety symptoms in patients with axial spondyloarthritis affect their immune response to SARS-CoV-2, leading to increased disease severity?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it. Here's a high-level approach to investigate whether the presence of depression and anxiety symptoms in patients with axial spondyloarthritis affects their immune response to SARS-CoV-2, leading to increased disease severity.

**Experimental Design:**

**Title:** Investigating the Impact of Depression and Anxiety on Immune Response to SARS-CoV-2 in Axial Spondyloarthritis Patients

**Objective:** To determine whether depression and anxiety symptoms in patients with axial spondyloarthritis (AxSpA) affect their immune response to SARS-CoV-2, leading to increased disease severity.

**Study Population:**

* Inclusion criteria:
	+ Patients with diagnosed AxSpA (according to the Assessment of SpondyloArthritis international Society (ASAS) criteria)
	+ Presence of depression and anxiety symptoms (assessed using standardized questionnaires, e.g., Beck Depression Inventory (BDI-II) and Generalized Anxiety Disorder 7-item scale (GAD-7))
	+ No history of COVID-19 infection or vaccination
* Exclusion criteria:
	+ Patients with severe immunosuppression or immunodeficiency disorders
	+ Patients taking immunosuppressive medications
	+ Patients with a history of severe mental health disorders (e.g., schizophrenia, bipolar disorder)

**Experimental Design:**

1. **Recruitment and Baseline Assessment:**
	* Recruit 100 AxSpA patients with depression and anxiety symptoms (Group A) and 100 AxSpA patients without depression and anxiety symptoms (Group B)
	* Collect demographic, clinical, and laboratory data, including:
		- Depression and anxiety scores (BDI-II and GAD-7)
		- AxSpA disease activity (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
		- Inflammatory markers (e.g., C-reactive protein (CRP), erythrocyte sedimentation rate (ESR))
		- Immune cell profiles (e.g., complete blood count, flow cytometry)
2. **SARS-CoV-2 Infection and Monitoring:**
	* Infect both groups with a standardized dose of SARS-CoV-2 (using a controlled laboratory setting)
	* Monitor patients for 28 days, collecting:
		- Daily symptom scores (e.g., fever, cough, fatigue)
		- Weekly laboratory data (e.g., complete blood count, inflammatory markers, immune cell profiles)
		- Weekly nasopharyngeal swabs for SARS-CoV-2 RNA detection and quantification
3. **Immune Response Analysis:**
	* Collect blood samples at days 0, 7, 14, and 28 for:
		- Cytokine profiling (e.g., IL-6, TNF-α, IFN-γ)
		- Immune cell phenotyping (e.g., T cell subsets, B cells, monocytes)
		- Antibody response (e.g., IgG, IgM) to SARS-CoV-2
4. **Statistical Analysis:**
	* Compare the immune response, disease severity, and symptom scores between Group A and Group B using:
		- Univariate and multivariate analyses (e.g., t-tests, ANOVA, regression models)
		- Time-to-event analysis (e.g., Kaplan-Meier curves) for disease severity and symptom scores

**To Disprove the Hypothesis:**

To verify the hypothesis, we will focus on finding evidence that contradicts the expected outcome. Specifically, we will look for:

* No significant differences in immune response, disease severity, and symptom scores between Group A and Group B
* No correlation between depression and anxiety scores and immune response or disease severity
* No association between AxSpA disease activity and immune response to SARS-CoV-2

**Additional Considerations:**

* Ensure proper ethical approval, informed consent, and participant safety throughout the study
* Implement robust quality control measures for laboratory assays and data analysis
* Consider using machine learning algorithms to identify potential biomarkers or predictors of disease severity and immune response

With an unlimited budget, we can:

* Recruit a large, diverse study population
* Utilize cutting-edge laboratory techniques (e.g., single-cell RNA sequencing, mass cytometry)
* Collaborate with experts in immunology, psychiatry, and rheumatology to ensure a comprehensive understanding of the complex relationships between depression, anxiety, AxSpA, and immune response to SARS-CoV-2

By following this experimental design, we can rigorously test the hypothesis and provide valuable insights into the interplay between depression, anxiety, AxSpA, and immune response to SARS-CoV-2.",85,"Here are the detailed, step-by-step protocols for the experimental design:

**Protocol 1: Recruitment and Baseline Assessment**

1.1. **Inclusion and Exclusion Criteria Screening**

* Review medical records and conduct a brief interview with potential participants to assess:
	+ AxSpA diagnosis according to ASAS criteria
	+ Presence of depression and anxiety symptoms (BDI-II and GAD-7 scores)
	+ Absence of severe immunosuppression or immunodeficiency disorders
	+ Absence of immunosuppressive medication use
	+ Absence of severe mental health disorders (e.g., schizophrenia, bipolar disorder)
* Document participant responses and medical history using a standardized case report form (CRF)

1.2. **Demographic and Clinical Data Collection**

* Collect demographic data:
	+ Age
	+ Sex
	+ Ethnicity
	+ Medical history
* Collect clinical data:
	+ AxSpA disease activity (BASDAI)
	+ Inflammatory markers (CRP, ESR)
	+ Immune cell profiles (complete blood count, flow cytometry)
* Use standardized questionnaires to assess depression and anxiety symptoms:
	+ BDI-II
	+ GAD-7

1.3. **Blood Sample Collection**

* Collect 10 mL of whole blood in EDTA tubes for:
	+ Complete blood count
	+ Flow cytometry
	+ Cytokine profiling (IL-6, TNF-α, IFN-γ)
	+ Antibody response (IgG, IgM) to SARS-CoV-2
* Label and store samples at -80°C for future analysis

**Protocol 2: SARS-CoV-2 Infection and Monitoring**

2.1. **SARS-CoV-2 Infection**

* Infect participants with a standardized dose of SARS-CoV-2 (using a controlled laboratory setting)
* Monitor participants for 28 days, collecting:
	+ Daily symptom scores (e.g., fever, cough, fatigue) using a standardized symptom questionnaire
	+ Weekly laboratory data (e.g., complete blood count, inflammatory markers, immune cell profiles)

2.2. **Nasopharyngeal Swab Collection**

* Collect nasopharyngeal swabs on days 0, 7, 14, and 28 for SARS-CoV-2 RNA detection and quantification
* Store swabs in viral transport medium at -80°C for future analysis

**Protocol 3: Immune Response Analysis**

3.1. **Blood Sample Collection**

* Collect 10 mL of whole blood in EDTA tubes on days 0, 7, 14, and 28 for:
	+ Cytokine profiling (IL-6, TNF-α, IFN-γ)
	+ Immune cell phenotyping (T cell subsets, B cells, monocytes)
	+ Antibody response (IgG, IgM) to SARS-CoV-2
* Label and store samples at -80°C for future analysis

3.2. **Cytokine Profiling**

* Perform cytokine profiling using a standardized multiplex assay (e.g., Luminex)
* Analyze cytokine levels using a standardized protocol

3.3. **Immune Cell Phenotyping**

* Perform immune cell phenotyping using flow cytometry
* Analyze immune cell subsets using a standardized protocol

3.4. **Antibody Response Analysis**

* Perform antibody response analysis using a standardized ELISA or neutralization assay
* Analyze antibody levels and neutralization titers using a standardized protocol

**Protocol 4: Statistical Analysis**

4.1. **Data Management**

* Enter and manage data using a standardized database (e.g., REDCap)
* Perform data quality control and cleaning

4.2. **Univariate and Multivariate Analyses**

* Perform univariate analyses (e.g., t-tests, ANOVA) to compare immune response, disease severity, and symptom scores between Group A and Group B
* Perform multivariate analyses (e.g., regression models) to adjust for potential confounding variables

4.3. **Time-to-Event Analysis**

* Perform time-to-event analysis (e.g., Kaplan-Meier curves) to compare disease severity and symptom scores between Group A and Group B

**Additional Considerations**

* Ensure proper ethical approval, informed consent, and participant safety throughout the study
* Implement robust quality control measures for laboratory assays and data analysis
* Consider using machine learning algorithms to identify potential biomarkers or predictors of disease severity and immune response

By following these detailed, step-by-step protocols, the experimental design can be rigorously executed to test the hypothesis and provide valuable insights into the interplay between depression, anxiety, AxSpA, and immune response to SARS-CoV-2.","```
   AxSpA_Diagnosis  BDI-II_Score  GAD-7_Score  Age  Sex  Ethnicity  BASDAI  CRP  ESR  IL-6  TNF-α  IFN-γ  IgG  IgM  SARS-CoV-2_Dose  Symptom_Score
0               1          14          10  35.0    M       White     4.5  2.1  15  50.0   20.0   10.0  100  50.0            1000          3.0
1               1          18          12  40.0    F       Black     5.0  2.5  18  60.0   25.0   12.0  120  60.0            1200          4.0
2               0           8           6  25.0    M       Asian     3.0  1.8  12  40.0   15.0    8.0   80  40.0             800          2.0
3               1          20          15  45.0    F       White     5.5  3.0  20  70.0   30.0   15.0  140  70.0            1400          5.0
4               0          10           8  30.0    M       Black     3.5  2.0  14  45.0   18.0   10.0   90  45.0             900          2.5
5               1          16          11  38.0    F       Asian     4.8  2.3  16  55.0   22.0   12.5  110  55.0            1100          3.5
6               0          12           9  28.0    M       White     3.2  1.9  13  42.0   17.0    9.5   85  42.0             850          2.2
7               1          22          17  48.0    F       Black     6.0  3.2  22  75.0   32.0   16.0  150  75.0            1500          5.5
8               0           9           7  26.0    M       Asian     3.0  1.7  11  38.0   14.0    8.5   75  38.0             750          2.0
9               1          19          14  42.0    F       White     5.2  2.6  19  65.0   27.0   14.0  130  65.0            1300          4.2
10              0          11          10  32.0    M       Black     3.8  2.1  15  48.0   20.0   11.0   95  48.0             950          2.8
11              1          24          19  50.0    F       Asian     6.2  3.5  24  80.0   35.0   17.0  160  80.0            1600          6.0
12              0          13          12  29.0    M       White     3.5  2.0  14  45.0   19.0   12.0   90  45.0             900          2.5
13              1          21          16  44.0    F       Black     5.8  2.9  21  70.0   30.0   15.5  140  70.0            1400          4.8
14              0          15          13  31.0    M       Asian     3.9  2.2  16  50.0   22.0   13.0  100  50.0            1000          3.0
15              1          25          20  52.0    F       White     6.5  3.7  25  85.0   37.0   18.0  170  85.0            1700          6.2
16              0          17          14  33.0    M       Black     4.2  2.4  17  55.0   24.0   14.5  110  55.0            1100          3.2
17              1          23          18  46.0    F       Asian     6.0  3.3  23  75.0   32.0   16.5  150  75.0            1500          5.0
18              0          16          12  30.0    M       White     3.6  2.1  15  48.0   20.0   12.0   95  48.0             950          2.6
19              1          26          21  54.0    F       Black     6.8  3.9  26  90.0   39.0   19.0  180  90.0            1800          6.5
20              0          18          15  34.0    M       Asian     4.4  2.5  18  60.0   26.0   15.0  120  60.0            1200          3.4
21              1          27          22  56.0    F       White     7.0  4.0  27  95.0   40.0   20.0  190  95.0            1900          6.8
22              0          19          16  35.0    M       Black     4.6  2.6  19  62.0   28.0   16.0  125  62.0            1250          3.6
23              1          28          23  58.0    F       Asian     7.2  4.1  28  100.0  42.0   21.0  200  100.0           2000          7.0
24              0          20          17  36.0    M       White     4.8  2.7  20  65.0   30.0   17.0  130  65.0            1300          3.8
```",0.8849542375505248
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2d71b14862cded3fcf9fed199ea4dc3697e8e153.summary'],"Does the presence of intratumoral TLSs in PDAC patients influence the efficacy of checkpoint inhibitor therapy, and can their characterization be used to predict treatment response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that the presence of intratumoral TLSs in PDAC patients influences the efficacy of checkpoint inhibitor therapy, and can their characterization be used to predict treatment response.

**Experiment Title:** Investigating the Impact of Intratumoral TLSs on Checkpoint Inhibitor Therapy in PDAC Patients

**Objective:** To determine whether the presence and characterization of intratumoral TLSs can predict treatment response to checkpoint inhibitor therapy in PDAC patients, and to investigate the potential mechanisms underlying this relationship.

**Experimental Design:**

1. **Patient Cohort:** Recruit a cohort of 100 PDAC patients who will receive checkpoint inhibitor therapy (e.g., pembrolizumab or nivolumab) as part of their treatment regimen. Ensure that the cohort is diverse in terms of age, sex, and disease stage.
2. **Tumor Tissue Collection:** Collect tumor tissue samples from each patient before and after checkpoint inhibitor therapy. This will allow for the analysis of intratumoral TLSs and their changes in response to treatment.
3. **Intratumoral TLS Characterization:** Perform fluorescent multiplex immunohistochemistry analysis on the tumor tissue samples to identify and characterize intratumoral TLSs. Use a panel of markers to identify TLSs, including CD20, CD3, CD4, CD8, and PD-1.
4. **Checkpoint Inhibitor Therapy Response:** Monitor patients' response to checkpoint inhibitor therapy using standard clinical criteria (e.g., RECIST 1.1). Collect data on treatment response, including complete response, partial response, stable disease, and progressive disease.
5. **Correlation Analysis:** Correlate the presence, size, and cellular composition of intratumoral TLSs with treatment response. Use machine learning algorithms to identify potential predictive biomarkers for treatment response.
6. **Mechanistic Studies:** Perform additional experiments to investigate the potential mechanisms underlying the relationship between intratumoral TLSs and checkpoint inhibitor therapy response. This may include:
	* Flow cytometry analysis of immune cell subsets in the tumor microenvironment.
	* Gene expression profiling of tumor tissue samples using RNA-seq or NanoString.
	* Functional assays to assess the activity of immune cells in the tumor microenvironment.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on identifying scenarios where the presence of intratumoral TLSs does not influence the efficacy of checkpoint inhibitor therapy. Specifically, we will:

1. **Identify Non-Responders:** Identify patients who do not respond to checkpoint inhibitor therapy despite the presence of intratumoral TLSs.
2. **Characterize Non-Responding TLSs:** Perform detailed characterization of the intratumoral TLSs in non-responding patients, including their size, cellular composition, and gene expression profiles.
3. **Compare with Responding TLSs:** Compare the characteristics of non-responding TLSs with those of responding TLSs to identify potential differences.
4. **Investigate Alternative Mechanisms:** Investigate alternative mechanisms that may contribute to the lack of response to checkpoint inhibitor therapy in patients with intratumoral TLSs, such as immune suppressive mechanisms or tumor-intrinsic resistance.

**Equipment and Resources:**

* Fluorescent multiplex immunohistochemistry platform (e.g., Opal 7-Colour Manual IHC Kit)
* Image analysis software (e.g., inForm V.2.4, HALO V.3.2)
* Statistical analysis software (e.g., SPSS, R)
* Flow cytometry platform (e.g., BD FACSAria III)
* Gene expression profiling platform (e.g., Illumina HiSeq 4000)
* Functional assay platforms (e.g., xCELLigence, IncuCyte)

**Timeline:**

* Patient recruitment and tissue collection: 6 months
* Intratumoral TLS characterization and checkpoint inhibitor therapy response analysis: 12 months
* Correlation analysis and mechanistic studies: 18 months
* Data analysis and manuscript preparation: 12 months

**Budget:**

* Personnel: $1.5 million (3 years)
* Reagents and consumables: $500,000 (3 years)
* Equipment and maintenance: $1 million (3 years)
* Travel and training: $100,000 (3 years)
* Total: $3.1 million (3 years)

This experiment is designed to provide a comprehensive understanding of the relationship between intratumoral TLSs and checkpoint inhibitor therapy response in PDAC patients. By investigating the characteristics of intratumoral TLSs and their correlation with treatment response, we can identify potential predictive biomarkers and improve patient outcomes.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Patient Cohort Recruitment and Tumor Tissue Collection**

1.1. **Patient Inclusion Criteria:**

* Patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC)
* Patients scheduled to receive checkpoint inhibitor therapy (e.g., pembrolizumab or nivolumab) as part of their treatment regimen
* Patients willing to provide written informed consent

1.2. **Patient Recruitment:**

* Identify potential patients through hospital records and oncology clinics
* Approach patients and explain the study objectives, risks, and benefits
* Obtain written informed consent from patients who meet the inclusion criteria

1.3. **Tumor Tissue Collection:**

* Collect tumor tissue samples from each patient before and after checkpoint inhibitor therapy
* Use a standardized tissue collection protocol to ensure consistency
* Store tissue samples in a biorepository at -80°C for future analysis

**Protocol 2: Intratumoral TLS Characterization**

2.1. **Tissue Sectioning and Staining:**

* Section tumor tissue samples into 4-μm thick slices
* Stain sections with a panel of markers to identify TLSs, including:
	+ CD20 (B cells)
	+ CD3 (T cells)
	+ CD4 (T helper cells)
	+ CD8 (cytotoxic T cells)
	+ PD-1 (immune checkpoint protein)
* Use a fluorescent multiplex immunohistochemistry platform (e.g., Opal 7-Colour Manual IHC Kit)

2.2. **Image Acquisition and Analysis:**

* Acquire high-resolution images of stained tissue sections using a digital slide scanner
* Use image analysis software (e.g., inForm V.2.4, HALO V.3.2) to identify and quantify TLSs
* Measure TLS size, cellular composition, and spatial distribution

**Protocol 3: Checkpoint Inhibitor Therapy Response Monitoring**

3.1. **Treatment Response Assessment:**

* Monitor patients' response to checkpoint inhibitor therapy using standard clinical criteria (e.g., RECIST 1.1)
* Collect data on treatment response, including:
	+ Complete response
	+ Partial response
	+ Stable disease
	+ Progressive disease

3.2. **Data Collection:**

* Record patient demographics, disease stage, and treatment regimen
* Collect data on treatment response and any adverse events

**Protocol 4: Correlation Analysis**

4.1. **Data Integration:**

* Integrate data on intratumoral TLS characterization and treatment response
* Use machine learning algorithms to identify potential predictive biomarkers for treatment response

4.2. **Statistical Analysis:**

* Perform statistical analysis using software (e.g., SPSS, R) to correlate TLS characteristics with treatment response
* Calculate correlation coefficients and p-values to determine significance

**Protocol 5: Mechanistic Studies**

5.1. **Flow Cytometry Analysis:**

* Isolate immune cells from tumor tissue samples using flow cytometry (e.g., BD FACSAria III)
* Analyze immune cell subsets, including T cells, B cells, and myeloid cells

5.2. **Gene Expression Profiling:**

* Extract RNA from tumor tissue samples using RNA-seq or NanoString
* Analyze gene expression profiles to identify potential mechanisms underlying the relationship between TLSs and treatment response

5.3. **Functional Assays:**

* Perform functional assays (e.g., xCELLigence, IncuCyte) to assess the activity of immune cells in the tumor microenvironment

**Protocol 6: Experimental Approach to Disprove the Hypothesis**

6.1. **Identify Non-Responders:**

* Identify patients who do not respond to checkpoint inhibitor therapy despite the presence of intratumoral TLSs

6.2. **Characterize Non-Responding TLSs:**

* Perform detailed characterization of the intratumoral TLSs in non-responding patients, including their size, cellular composition, and gene expression profiles

6.3. **Compare with Responding TLSs:**

* Compare the characteristics of non-responding TLSs with those of responding TLSs to identify potential differences

6.4. **Investigate Alternative Mechanisms:**

* Investigate alternative mechanisms that may contribute to the lack of response to checkpoint inhibitor therapy in patients with intratumoral TLSs, such as immune suppressive mechanisms or tumor-intrinsic resistance.

These detailed protocols provide a step-by-step guide for executing the experiment, ensuring replicability and specificity in the results.","```
   Patient_ID  CD20  CD3  CD4  CD8  PD-1  TLS_Size  Treatment_Response
0           1   200  150  100   50    20          10          Complete
1           2   180  120   90   40    18           9          Partial
2           3   220  160  110   60    22          11          Stable
3           4   190  130  100   50    20          10          Progressive
4           5   210  140  120   60    24          12          Complete
5           6   170  110   90   40    18           9          Partial
6           7   230  160  130   70    26          13          Stable
7           8   200  140  110   60    22          11          Progressive
8           9   240  170  140   80    28          14          Complete
9          10   180  120  100   50    20          10          Partial
10         11   250  180  150   90    30          15          Stable
11         12   190  130  110   60    22          11          Progressive
12         13   260  190  160  100    32          16          Complete
13         14   200  140  120   70    24          12          Partial
14         15   270  200  170  110    34          17          Stable
15         16   210  150  130   80    26          13          Progressive
16         17   280  210  180  120    36          18          Complete
17         18   220  160  140   90    28          14          Partial
18         19   290  220  190  130    38          19          Stable
19         20   230  170  150  100    30          15          Progressive
20         21   300  230  200  140    40          20          Complete
21         22   240  180  160  110    32          16          Partial
22         23   310  240  210  150    42          21          Stable
23         24   250  190  170  120    34          17          Progressive
24         25   320  250  220  160    44          22          Complete
```",0.14506730559391182
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2c257c01d0cab1e018da53b5074b7537ee7fd99d.summary'],"Does the presence of oxidation-specific epitopes on lung fibroblasts modulate the expression of CXCR4, thereby influencing the homing of B-1 cells and subsequent IgM production, ultimately affecting the progression of lung fibrosis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test and potentially disprove the hypothesis: ""Does the presence of oxidation-specific epitopes on lung fibroblasts modulate the expression of CXCR4, thereby influencing the homing of B-1 cells and subsequent IgM production, ultimately affecting the progression of lung fibrosis?""

**Experimental Plan:**

**Objective:** To investigate the role of oxidation-specific epitopes on lung fibroblasts in modulating CXCR4 expression, B-1 cell homing, and IgM production in the context of lung fibrosis.

**Experimental Design:**

1. **Cell Culture and Treatment:**
	* Isolate and culture human lung fibroblasts (HLF) from healthy donors or use a commercially available cell line.
	* Treat HLF with oxidation-specific epitopes (OSE) or a control treatment (e.g., PBS) for 24-48 hours.
	* Use a range of OSE concentrations to assess dose-dependent effects.
2. **CXCR4 Expression Analysis:**
	* Perform qRT-PCR to measure CXCR4 mRNA levels in OSE-treated and control HLF.
	* Use Western blot to analyze CXCR4 protein expression in OSE-treated and control HLF.
3. **B-1 Cell Homing Assay:**
	* Isolate B-1 cells from mouse spleens or use a commercially available cell line.
	* Co-culture B-1 cells with OSE-treated or control HLF for 24-48 hours.
	* Measure B-1 cell migration towards HLF using a transwell migration assay or a chemotaxis assay.
4. **IgM Production Analysis:**
	* Measure IgM production in the co-culture supernatants using ELISA or Western blot.
5. **Lung Fibrosis Model:**
	* Use a bleomycin-induced lung fibrosis mouse model to assess the in vivo relevance of the findings.
	* Administer OSE or a control treatment to the mice and analyze lung tissue for fibrosis markers (e.g., collagen deposition, α-SMA expression).

**Negative Control and Experimental Groups:**

* Negative control: HLF without OSE treatment
* Experimental groups:
	+ OSE-treated HLF
	+ OSE-treated HLF with B-1 cells
	+ OSE-treated HLF with B-1 cells and CXCR4 inhibitor (to test the specificity of CXCR4 modulation)

**Expected Outcomes:**

* If the hypothesis is true, OSE treatment should increase CXCR4 expression on HLF, enhance B-1 cell homing, and increase IgM production.
* If the hypothesis is false, OSE treatment should not affect CXCR4 expression, B-1 cell homing, or IgM production.

**Timeline and Budget:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget will cover cell culture reagents, antibodies, qRT-PCR and Western blot equipment, ELISA kits, and animal costs for the bleomycin-induced lung fibrosis model.

**Equipment and Resources:**

* Cell culture facilities
* qRT-PCR machine
* Western blot apparatus
* ELISA reader
* Transwell migration assay or chemotaxis assay equipment
* Bleomycin-induced lung fibrosis mouse model
* Reagents for cell isolation, culture, and treatment

By following this experimental plan, we can test the hypothesis and potentially disprove it, providing valuable insights into the role of oxidation-specific epitopes on lung fibroblasts in modulating CXCR4 expression, B-1 cell homing, and IgM production in the context of lung fibrosis.",85,"Here are the detailed, step-by-step protocols for each section of the experimental plan:

**Cell Culture and Treatment:**

1.1. Isolation of Human Lung Fibroblasts (HLF):

* Obtain human lung tissue from healthy donors or purchase a commercially available HLF cell line (e.g., MRC-5 or WI-38).
* Isolate HLF using a tissue dissociation protocol (e.g., collagenase digestion) and subsequent centrifugation.
* Resuspend the isolated cells in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
* Plate the cells in a 75-cm² tissue culture flask and incubate at 37°C, 5% CO₂.

1.2. Treatment of HLF with Oxidation-Specific Epitopes (OSE):

* Prepare a stock solution of OSE (e.g., 1 mg/mL) in phosphate-buffered saline (PBS).
* Dilute the OSE stock solution to the desired concentrations (e.g., 1, 5, 10, and 20 μg/mL) in DMEM.
* Add the OSE-containing medium to the HLF cultures and incubate for 24-48 hours.
* Use PBS as a control treatment.

**CXCR4 Expression Analysis:**

2.1. RNA Isolation and qRT-PCR:

* Harvest the OSE-treated and control HLF using trypsin-EDTA and centrifugation.
* Isolate total RNA using a commercial RNA isolation kit (e.g., TRIzol).
* Perform qRT-PCR using a CXCR4-specific primer set and a housekeeping gene (e.g., GAPDH) as an internal control.
* Use a qRT-PCR machine (e.g., Applied Biosystems 7500) and analyze the data using the ΔΔCt method.

2.2. Western Blot Analysis:

* Harvest the OSE-treated and control HLF using trypsin-EDTA and centrifugation.
* Lyse the cells in RIPA buffer containing protease inhibitors.
* Separate the proteins using SDS-PAGE (10% gel) and transfer them to a PVDF membrane.
* Probe the membrane with a CXCR4-specific antibody (e.g., rabbit polyclonal) and a housekeeping protein antibody (e.g., β-actin).
* Detect the proteins using an ECL detection system and analyze the bands using densitometry software.

**B-1 Cell Homing Assay:**

3.1. Isolation of B-1 Cells:

* Obtain mouse spleens and isolate B-1 cells using a B-1 cell isolation kit (e.g., Miltenyi Biotec).
* Resuspend the isolated B-1 cells in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

3.2. Co-Culture of B-1 Cells with OSE-Treated HLF:

* Plate the OSE-treated or control HLF in a 24-well plate (1 × 10⁵ cells/well).
* Add the isolated B-1 cells (1 × 10⁶ cells/well) to the HLF cultures and incubate for 24-48 hours.

3.3. Transwell Migration Assay:

* Place a transwell insert (e.g., 5-μm pore size) into a 24-well plate.
* Add the co-culture supernatant to the lower chamber.
* Add the B-1 cells (1 × 10⁶ cells/well) to the upper chamber.
* Incubate for 2-4 hours at 37°C, 5% CO₂.
* Count the migrated B-1 cells using a hemocytometer or a flow cytometer.

**IgM Production Analysis:**

4.1. ELISA:

* Collect the co-culture supernatants and store them at -80°C.
* Perform an ELISA using an IgM-specific antibody (e.g., goat polyclonal) and a horseradish peroxidase-conjugated secondary antibody.
* Measure the absorbance at 450 nm using an ELISA reader.

**Lung Fibrosis Model:**

5.1. Bleomycin-Induced Lung Fibrosis Mouse Model:

* Purchase or breed mice (e.g., C57BL/6) and house them in a controlled environment.
* Administer bleomycin (e.g., 1.5 U/kg) intratracheally to induce lung fibrosis.
* Treat the mice with OSE or a control treatment (e.g., PBS) via intraperitoneal injection.
* Sacrifice the mice at 14-21 days post-bleomycin administration and harvest the lung tissue.

5.2. Analysis of Lung Tissue:

* Fix the lung tissue in formalin and embed it in paraffin.
* Section the tissue (e.g., 5-μm thick) and stain it with Masson's trichrome or Sirius red.
* Analyze the tissue for collagen deposition and α-SMA expression using immunohistochemistry.

**Negative Control and Experimental Groups:**

* Negative control: HLF without OSE treatment
* Experimental groups:
	+ OSE-treated HLF
	+ OSE-treated HLF with B-1 cells
	+ OSE-treated HLF with B-1 cells and CXCR4 inhibitor (e.g., AMD3100)

**Timeline and Budget:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget will cover cell culture reagents, antibodies, qRT-PCR and Western blot equipment, ELISA kits, and animal costs for the bleomycin-induced lung fibrosis model.

**Equipment and Resources:**

* Cell culture facilities
* qRT-PCR machine
* Western blot apparatus
* ELISA reader
* Transwell migration assay or chemotaxis assay equipment
* Bleomycin-induced lung fibrosis mouse model
* Reagents for cell isolation, culture, and treatment

By following these detailed, step-by-step protocols, the experiment can be replicated and the hypothesis can be tested.","```
   OSE_concentration  FBS_concentration  L_glutamine_concentration  CXCR4_expression  B1_cell_migration  IgM_production  Lung_fibrosis
0               1.0               10.0                    1.0           0.85           2500.0          0.50          0.20
1               5.0               10.0                    1.0           1.20           3500.0          0.60          0.30
2              10.0               10.0                    1.0           1.50           4000.0          0.70          0.40
3              20.0               10.0                    1.0           1.80           4500.0          0.80          0.50
4               1.0               15.0                    1.0           0.90           2800.0          0.55          0.25
5               5.0               15.0                    1.0           1.30           3800.0          0.65          0.35
6              10.0               15.0                    1.0           1.60           4200.0          0.75          0.45
7              20.0               15.0                    1.0           1.90           4800.0          0.85          0.55
8               1.0               20.0                    1.0           0.95           3000.0          0.60          0.30
9               5.0               20.0                    1.0           1.40           4000.0          0.70          0.40
10             10.0               20.0                    1.0           1.70           4400.0          0.80          0.50
11             20.0               20.0                    1.0           2.00           5000.0          0.90          0.60
12              1.0               10.0                    0.5           0.80           2200.0          0.45          0.20
13              5.0               10.0                    0.5           1.10           3200.0          0.55          0.30
14             10.0               10.0                    0.5           1.40           3800.0          0.65          0.40
15             20.0               10.0                    0.5           1.70           4300.0          0.75          0.50
16              1.0               15.0                    0.5           0.85           2400.0          0.50          0.25
17              5.0               15.0                    0.5           1.20           3400.0          0.60          0.35
18             10.0               15.0                    0.5           1.50           4000.0          0.70          0.45
19             20.0               15.0                    0.5           1.80           4600.0          0.80          0.55
20              1.0               20.0                    0.5           0.90           2600.0          0.55          0.30
21              5.0               20.0                    0.5           1.30           3600.0          0.65          0.40
22             10.0               20.0                    0.5           1.60           4200.0          0.75          0.50
23             20.0               20.0                    0.5           1.90           4800.0          0.85          0.60
24              1.0               10.0                    2.0           0.95           3000.0          0.60          0.35
```",0.6847464838403403
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/266a5cacb862ad2c399aab82b896ec015ec96e13.summary'],Does the presence of post-activated B cells with a specific CD40-mediated functiotype in axial spondyloarthritis patients predict a higher risk of radiographic progression and fracture incidence?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis:

**Hypothesis:** Does the presence of post-activated B cells with a specific CD40-mediated functiotype in axial spondyloarthritis patients predict a higher risk of radiographic progression and fracture incidence?

**Experimental Plan:**

**Title:** Investigating the Association between Post-Activated B Cells with CD40-Mediated Functiotype and Radiographic Progression/Fracture Incidence in Axial Spondyloarthritis Patients

**Objective:** To determine whether the presence of post-activated B cells with a specific CD40-mediated functiotype in axial spondyloarthritis patients is associated with a higher risk of radiographic progression and fracture incidence.

**Study Design:**

1. **Cohort Study:** Recruit a large cohort of axial spondyloarthritis patients (n = 500) and healthy controls (n = 200).
2. **Blood Sample Collection:** Collect blood samples from all participants at baseline and at 1-year and 2-year follow-up visits.
3. **B Cell Isolation and Characterization:** Isolate B cells from blood samples using flow cytometry and characterize them based on their CD40-mediated functiotype using flow cytometry and functional assays (e.g., ELISA, Western blot).
4. **Radiographic Assessment:** Perform radiographic assessments (e.g., X-rays, MRI) at baseline and at 1-year and 2-year follow-up visits to evaluate radiographic progression.
5. **Fracture Incidence:** Record fracture incidence over the 2-year follow-up period using patient-reported outcomes, medical records, and radiographic assessments.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will test the following null hypothesis:

**Null Hypothesis:** There is no association between the presence of post-activated B cells with a specific CD40-mediated functiotype in axial spondyloarthritis patients and radiographic progression/fracture incidence.

**Experimental Design:**

1. **Matched Case-Control Study:** Select a subset of axial spondyloarthritis patients (n = 100) with radiographic progression and/or fracture incidence (cases) and match them with patients without radiographic progression or fracture incidence (controls) based on age, sex, and disease duration.
2. **B Cell Analysis:** Analyze B cells from cases and controls using flow cytometry and functional assays to determine the presence and frequency of post-activated B cells with a specific CD40-mediated functiotype.
3. **Statistical Analysis:** Perform statistical analysis to compare the frequency and characteristics of post-activated B cells between cases and controls. If no significant differences are found, it would suggest that the presence of post-activated B cells with a specific CD40-mediated functiotype is not associated with radiographic progression and fracture incidence, thereby disproving the hypothesis.

**Equipment and Resources:**

* Flow cytometer
* Cell culture facilities
* CD40 ligand
* B cells from autoimmune patients and healthy donors
* Radiographic imaging equipment (e.g., X-ray, MRI)
* Statistical analysis software (e.g., R, Python)

**Timeline:**

* Patient recruitment and blood sample collection: 6 months
* B cell isolation and characterization: 12 months
* Radiographic assessments and fracture incidence recording: 24 months
* Data analysis and statistical analysis: 12 months

**Budget:**

* Personnel: $500,000 (2 post-docs, 1 research assistant, 1 statistician)
* Equipment and reagents: $200,000 (flow cytometer, cell culture facilities, CD40 ligand, etc.)
* Patient recruitment and radiographic assessments: $300,000
* Statistical analysis software and computing resources: $50,000
* Total: $1,050,000

This experimental plan is designed to test the hypothesis and provide a comprehensive understanding of the association between post-activated B cells with a specific CD40-mediated functiotype and radiographic progression/fracture incidence in axial spondyloarthritis patients.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Patient Recruitment and Blood Sample Collection**

1.1. **Inclusion and Exclusion Criteria:**

* Inclusion criteria: Axial spondyloarthritis patients (n = 500) and healthy controls (n = 200) aged 18-65 years, with written informed consent.
* Exclusion criteria: Patients with severe comorbidities, immunodeficiency, or taking immunosuppressive medications.

1.2. **Recruitment:**

* Advertise the study through social media, patient organizations, and hospital clinics.
* Screen potential participants using a standardized questionnaire to assess eligibility.
* Schedule appointments for eligible participants.

1.3. **Blood Sample Collection:**

* Collect 20 mL of whole blood from each participant at baseline, 1-year, and 2-year follow-up visits.
* Use vacutainer tubes with EDTA as an anticoagulant.
* Label tubes with unique participant IDs and store at 4°C until processing.

**Protocol 2: B Cell Isolation and Characterization**

2.1. **B Cell Isolation:**

* Use flow cytometry to isolate B cells from whole blood using the following markers: CD19+, CD20+, and CD45+.
* Use a Ficoll-Paque density gradient to separate mononuclear cells from whole blood.
* Wash cells with PBS and resuspend in 1% BSA/PBS.

2.2. **CD40-Mediated Functiotype Characterization:**

* Stimulate isolated B cells with CD40 ligand (1 μg/mL) for 24 hours.
* Use flow cytometry to analyze CD40-mediated functiotype using the following markers: CD69, CD86, and CD25.
* Perform functional assays (e.g., ELISA, Western blot) to measure cytokine production and signaling pathways.

**Protocol 3: Radiographic Assessment**

3.1. **Radiographic Imaging:**

* Perform X-rays and/or MRI scans at baseline, 1-year, and 2-year follow-up visits.
* Use standardized protocols for image acquisition and analysis.

3.2. **Radiographic Progression Assessment:**

* Use a standardized scoring system (e.g., modified Stoke Ankylosing Spondylitis Spine Score) to evaluate radiographic progression.
* Assess radiographic progression at each follow-up visit.

**Protocol 4: Fracture Incidence Recording**

4.1. **Patient-Reported Outcomes:**

* Use standardized questionnaires (e.g., SF-12, EQ-5D) to assess patient-reported outcomes at each follow-up visit.
* Record self-reported fracture incidence.

4.2. **Medical Records Review:**

* Review medical records to confirm fracture incidence and radiographic progression.

**Protocol 5: Matched Case-Control Study**

5.1. **Case Selection:**

* Select axial spondyloarthritis patients (n = 100) with radiographic progression and/or fracture incidence (cases).
* Match cases with patients without radiographic progression or fracture incidence (controls) based on age, sex, and disease duration.

5.2. **B Cell Analysis:**

* Analyze B cells from cases and controls using flow cytometry and functional assays to determine the presence and frequency of post-activated B cells with a specific CD40-mediated functiotype.

**Protocol 6: Statistical Analysis**

6.1. **Data Management:**

* Use a standardized database to manage and store data.
* Perform data quality control and cleaning.

6.2. **Statistical Analysis:**

* Use statistical software (e.g., R, Python) to perform statistical analysis.
* Compare the frequency and characteristics of post-activated B cells between cases and controls using appropriate statistical tests (e.g., t-test, Wilcoxon rank-sum test).
* Perform multivariate analysis to adjust for potential confounding variables.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the experimental design.","```
   Axial Spondyloarthritis Patients  Healthy Controls  CD40 Ligand (μg/mL)  CD19+ Cells (10^6)  CD20+ Cells (10^6)  CD45+ Cells (10^6)  Radiographic Progression  Fracture Incidence  Post-Activated B Cells (%)
0                         50                20               0.5             1.2             1.5             2.1               0.2               0.1               12.5
1                         40                30               1.0             1.8             2.2             2.5               0.5               0.3               18.2
2                         30                40               0.8             1.5             1.9             2.3               0.4               0.2               15.6
3                         60                10               1.2             2.1             2.8             3.1               0.7               0.5               22.1
4                         45                25               0.9             1.6             2.1             2.6               0.3               0.2               16.8
5                         35                35               1.1             1.9             2.4             2.8               0.6               0.4               20.3
6                         55                15               1.0             2.3             3.0             3.3               0.8               0.6               24.5
7                         50                20               0.7             1.4             1.8             2.2               0.2               0.1               13.9
8                         40                30               1.3             2.5             3.2             3.5               0.9               0.7               26.2
9                         30                40               0.9             1.7             2.2             2.7               0.5               0.3               19.1
10                        60                10               1.1             2.6             3.4             3.7               1.0               0.8               28.5
11                        45                25               0.8             1.9             2.5             3.0               0.4               0.2               17.4
12                        35                35               1.2             2.2             2.9             3.2               0.7               0.5               22.9
13                        55                15               1.0             2.8             3.6             3.9               0.9               0.7               27.1
14                        50                20               0.9             2.0             2.6             3.1               0.3               0.2               16.2
15                        40                30               1.4             2.9             3.7             4.0               1.1               0.9               30.4
16                        30                40               1.0             2.3             3.0             3.4               0.6               0.4               21.5
17                        60                10               1.2             3.1             4.0             4.3               1.2               1.0               32.7
18                        45                25               0.8             2.5             3.2             3.7               0.5               0.3               20.8
19                        35                35               1.1             2.8             3.6             4.1               0.8               0.6               25.2
20                        55                15               1.0             3.3             4.2             4.5               1.1               0.9               31.9
21                        50                20               0.9             2.6             3.4             3.9               0.4               0.2               19.5
22                        40                30               1.3             3.5             4.4             4.7               1.3               1.1               34.2
23                        30                40               1.0             3.0             3.8             4.2               0.7               0.5               23.6
24                        60                10               1.1             3.7             4.6             4.9               1.4               1.2               36.5
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4ebf9f1f99453bd43f67ea001205b161ba444e51.summary'],"Does the presence of specific glycosylation patterns on IgG antibodies targeting other platelet antigens, beyond HPA-1a, also influence their binding affinity to FcgRIIIa and contribute to the severity of FNAIT?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Influence of Glycosylation Patterns on IgG Antibodies Targeting Other Platelet Antigens on FcgRIIIa Binding Affinity and FNAIT Severity

**Objective:** To determine if specific glycosylation patterns on IgG antibodies targeting platelet antigens beyond HPA-1a affect their binding affinity to FcgRIIIa and contribute to the severity of FNAIT.

**Experimental Design:**

1. **Antibody Preparation:**
	* Express and purify IgG antibodies targeting different platelet antigens (e.g., HPA-2a, HPA-3a, HPA-5a) using HEK293F cells.
	* Use site-directed mutagenesis to introduce specific glycosylation patterns (e.g., fucosylation, galactosylation, sialylation) on the antibodies.
2. **Platelet Opsonization:**
	* Opsonize platelets with the prepared antibodies, ensuring equal antibody concentrations and platelet numbers.
3. **cSPRi Measurements:**
	* Perform cSPRi measurements using FcgRIIIa-expressing cells as detectors to quantify the binding affinity of each antibody to FcgRIIIa.
4. **Data Analysis:**
	* Compare the binding affinity of antibodies with different glycosylation patterns to FcgRIIIa.
	* Correlate the binding affinity with the severity of FNAIT using clinical data (e.g., platelet count, bleeding severity).

**Required Equipment and Resources:**

* cSPRi instrument
* FcgRIIIa-expressing cells
* HEK293F cells
* Platelets
* Site-directed mutagenesis reagents
* Antibody purification equipment
* cSPRi analysis software

**Timeline:** 6-9 months

**Budget:** Moderate (dependent on equipment and reagent costs)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Lack of Influence of Glycosylation Patterns on IgG Antibodies Targeting Other Platelet Antigens on FcgRIIIa Binding Affinity and FNAIT Severity

**Objective:** To demonstrate that specific glycosylation patterns on IgG antibodies targeting platelet antigens beyond HPA-1a do not affect their binding affinity to FcgRIIIa and do not contribute to the severity of FNAIT.

**Experimental Design:**

1. **Antibody Preparation:**
	* Express and purify IgG antibodies targeting different platelet antigens (e.g., HPA-2a, HPA-3a, HPA-5a) using HEK293F cells.
	* Ensure that the antibodies have identical glycosylation patterns (e.g., no fucosylation, galactosylation, or sialylation).
2. **Platelet Opsonization:**
	* Opsonize platelets with the prepared antibodies, ensuring equal antibody concentrations and platelet numbers.
3. **cSPRi Measurements:**
	* Perform cSPRi measurements using FcgRIIIa-expressing cells as detectors to quantify the binding affinity of each antibody to FcgRIIIa.
4. **Data Analysis:**
	* Compare the binding affinity of antibodies with identical glycosylation patterns to FcgRIIIa.
	* Analyze the data to demonstrate a lack of correlation between glycosylation patterns and FcgRIIIa binding affinity.

**Required Equipment and Resources:**

* cSPRi instrument
* FcgRIIIa-expressing cells
* HEK293F cells
* Platelets
* Antibody purification equipment
* cSPRi analysis software

**Timeline:** 3-6 months

**Budget:** Moderate (dependent on equipment and reagent costs)

By performing these experiments, we can test the hypothesis and attempt to disprove it, providing a more comprehensive understanding of the relationship between glycosylation patterns on IgG antibodies and FcgRIIIa binding affinity in the context of FNAIT.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Antibody Preparation**

1.1. **Cloning and Expression of IgG Antibodies**

* Use PCR to amplify the genes encoding IgG antibodies targeting different platelet antigens (e.g., HPA-2a, HPA-3a, HPA-5a) from a cDNA library or a plasmid.
* Clone the amplified genes into a mammalian expression vector (e.g., pCDNA3.1) using restriction enzymes and ligation.
* Verify the cloned genes by sequencing.
* Transfect HEK293F cells with the expression vector using a transfection reagent (e.g., Lipofectamine 2000).
* Incubate the cells at 37°C, 5% CO2 for 24-48 hours to allow for protein expression.

1.2. **Site-Directed Mutagenesis**

* Design primers to introduce specific glycosylation patterns (e.g., fucosylation, galactosylation, sialylation) on the antibodies using site-directed mutagenesis.
* Perform PCR-based mutagenesis using the designed primers and the expression vector as a template.
* Verify the mutations by sequencing.
* Repeat the transfection and incubation steps (1.1.3-1.1.4) to express the mutated antibodies.

1.3. **Antibody Purification**

* Harvest the cell culture supernatant and clarify it by centrifugation (10,000 x g, 10 minutes).
* Perform affinity chromatography using a protein A or G column to purify the antibodies.
* Elute the antibodies with a buffer (e.g., PBS, pH 7.4) and collect the fractions.
* Concentrate the antibodies using a centrifugal filter device (e.g., Amicon Ultra-15).
* Determine the antibody concentration using a spectrophotometer (e.g., Nanodrop).

**Protocol 2: Platelet Opsonization**

2.1. **Platelet Isolation**

* Collect platelet-rich plasma (PRP) from healthy donors or use commercial platelet preparations.
* Isolate platelets by centrifugation (150 x g, 10 minutes) and wash them with a buffer (e.g., PBS, pH 7.4).
* Resuspend the platelets in a buffer (e.g., PBS, pH 7.4) at a concentration of 1 x 10^9 platelets/mL.

2.2. **Opsonization**

* Incubate the platelets with the purified antibodies (1.3) at a concentration of 10 μg/mL for 30 minutes at room temperature.
* Ensure equal antibody concentrations and platelet numbers for each sample.

**Protocol 3: cSPRi Measurements**

3.1. **cSPRi Instrument Preparation**

* Prepare the cSPRi instrument according to the manufacturer's instructions.
* Calibrate the instrument using a reference sensor chip.

3.2. **cSPRi Measurements**

* Immobilize FcgRIIIa-expressing cells on the sensor chip according to the manufacturer's instructions.
* Inject the opsonized platelets (2.2) over the sensor chip at a flow rate of 10 μL/min.
* Measure the binding affinity of each antibody to FcgRIIIa using the cSPRi instrument.
* Record the data and analyze it using the cSPRi analysis software.

**Protocol 4: Data Analysis**

4.1. **Data Collection**

* Collect the binding affinity data for each antibody with different glycosylation patterns.
* Correlate the binding affinity with the severity of FNAIT using clinical data (e.g., platelet count, bleeding severity).

4.2. **Statistical Analysis**

* Perform statistical analysis (e.g., ANOVA, t-test) to compare the binding affinity of antibodies with different glycosylation patterns.
* Determine the significance of the correlation between glycosylation patterns and FcgRIIIa binding affinity.

**Experiment to Disprove the Hypothesis:**

The protocols for the experiment to disprove the hypothesis are similar to those for the experiment to test the hypothesis, with the following modifications:

**Protocol 1: Antibody Preparation**

* Omit the site-directed mutagenesis step (1.2) to ensure that the antibodies have identical glycosylation patterns.

**Protocol 2: Platelet Opsonization**

* Use the antibodies with identical glycosylation patterns for opsonization.

**Protocol 3: cSPRi Measurements**

* Perform cSPRi measurements using the antibodies with identical glycosylation patterns.

**Protocol 4: Data Analysis**

* Analyze the data to demonstrate a lack of correlation between glycosylation patterns and FcgRIIIa binding affinity.
* Perform statistical analysis (e.g., ANOVA, t-test) to compare the binding affinity of antibodies with identical glycosylation patterns.

Note: The protocols provided are detailed and step-by-step, but may require modifications based on specific laboratory settings and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   HPA-2a  HPA-3a  HPA-5a  Fucosylation  Galactosylation  Sialylation  Antibody_Concentration  Platelet_Concentration  Binding_Affinity
0     100     50     20           0.5             0.2           0.8               10.0               1.0e+09        450.0
1      80     60     30           0.3             0.4           0.9               12.0               1.2e+09        520.0
2     120     40     25           0.6             0.1           0.7               11.0               1.1e+09        480.0
3      90     70     35           0.4             0.3           0.6               13.0               1.3e+09        550.0
4     110     50     20           0.5             0.2           0.8               10.0               1.0e+09        450.0
5      80     60     30           0.3             0.4           0.9               12.0               1.2e+09        520.0
6     100     50     25           0.6             0.1           0.7               11.0               1.1e+09        480.0
7      90     70     35           0.4             0.3           0.6               13.0               1.3e+09        550.0
8     120     40     20           0.5             0.2           0.8               10.0               1.0e+09        450.0
9      80     60     30           0.3             0.4           0.9               12.0               1.2e+09        520.0
10    110     50     25           0.6             0.1           0.7               11.0               1.1e+09        480.0
11     90     70     35           0.4             0.3           0.6               13.0               1.3e+09        550.0
12    100     50     20           0.5             0.2           0.8               10.0               1.0e+09        450.0
13     80     60     30           0.3             0.4           0.9               12.0               1.2e+09        520.0
14    120     40     25           0.6             0.1           0.7               11.0               1.1e+09        480.0
15     90     70     35           0.4             0.3           0.6               13.0               1.3e+09        550.0
16    110     50     20           0.5             0.2           0.8               10.0               1.0e+09        450.0
17     80     60     30           0.3             0.4           0.9               12.0               1.2e+09        520.0
18    100     50     25           0.6             0.1           0.7               11.0               1.1e+09        480.0
19     90     70     35           0.4             0.3           0.6               13.0               1.3e+09        550.0
20    120     40     20           0.5             0.2           0.8               10.0               1.0e+09        450.0
21     80     60     30           0.3             0.4           0.9               12.0               1.2e+09        520.0
22    110     50     25           0.6             0.1           0.7               11.0               1.1e+09        480.0
23     90     70     35           0.4             0.3           0.6               13.0               1.3e+09        550.0
24    100     50     20           0.5             0.2           0.8               10.0               1.0e+09        450.0
```",0.35125524128730656
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c730d9c6573234b0e8b2ef57f0e69f5adbf58d63.summary'],Does the presence of specific microbiota in the benign lymph node microenvironment influence the expression of PD-L1 on macrophages and subsequent response to immunotherapy?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Hypothesis:** Does the presence of specific microbiota in the benign lymph node microenvironment influence the expression of PD-L1 on macrophages and subsequent response to immunotherapy?

**Experimental Plan:**

**Objective:** To investigate the role of specific microbiota in the benign lymph node microenvironment on PD-L1 expression on macrophages and response to immunotherapy.

**Equipment:**

* Flow cytometer
* Multiplex immunofluorescence staining
* Quantitative image analysis software
* 16S rRNA gene sequencing platform (e.g., Illumina MiSeq)
* Microbiome analysis software (e.g., QIIME2, Mothur)

**Steps:**

1. **Sample Collection:** Collect benign lymph node samples from cancer patients who have received immunotherapy. Ensure that the samples are stored in a way that preserves the microbiome (e.g., frozen at -80°C).
2. **Microbiome Analysis:** Extract DNA from the lymph node samples and perform 16S rRNA gene sequencing to characterize the microbiome composition.
3. **Microbiome Profiling:** Use microbiome analysis software to identify the specific microbiota present in each sample and their relative abundance.
4. **PD-L1 Expression Analysis:** Perform multiplex immunofluorescence staining to assess PD-L1 expression on macrophages in the lymph node microenvironment.
5. **Flow Cytometry:** Use flow cytometry to analyze the immune cell populations in the lymph node samples, including macrophages.
6. **Correlation Analysis:** Correlate the microbiome profiles with PD-L1 expression on macrophages and response to immunotherapy.
7. **Statistical Analysis:** Perform statistical analysis to identify significant associations between specific microbiota, PD-L1 expression, and response to immunotherapy.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test the null hypothesis that the presence of specific microbiota in the benign lymph node microenvironment does not influence PD-L1 expression on macrophages and response to immunotherapy.

**Design:**

1. **Sample Selection:** Select a subset of lymph node samples from the original collection that have similar clinical characteristics (e.g., cancer type, treatment regimen) but differ in their response to immunotherapy (responders vs. non-responders).
2. **Microbiome Depletion:** Use antibiotics to deplete the microbiome in a subset of samples from both responders and non-responders.
3. **PD-L1 Expression Analysis:** Perform multiplex immunofluorescence staining to assess PD-L1 expression on macrophages in the lymph node microenvironment before and after microbiome depletion.
4. **Comparison:** Compare PD-L1 expression on macrophages between responders and non-responders before and after microbiome depletion.

**Rationale:** If the presence of specific microbiota in the benign lymph node microenvironment influences PD-L1 expression on macrophages and response to immunotherapy, then depleting the microbiome should abolish or significantly reduce the differences in PD-L1 expression between responders and non-responders. If the null hypothesis is true, then depleting the microbiome should not affect PD-L1 expression or response to immunotherapy.

**Timeline and Budget:**

* Sample collection and microbiome analysis: 2 months, $10,000
* PD-L1 expression analysis and flow cytometry: 3 months, $15,000
* Correlation and statistical analysis: 2 months, $5,000
* Microbiome depletion and PD-L1 expression analysis: 3 months, $10,000
* Total: 10 months, $40,000

This experimental plan and design should provide a comprehensive approach to testing the hypothesis and disproving it, while being feasible within a reasonable time frame and budget.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Sample Collection**

1.1. Obtain informed consent from cancer patients who have received immunotherapy.

1.2. Collect benign lymph node samples from these patients using aseptic techniques to minimize contamination.

1.3. Store the samples in cryovials or tubes containing a cryopreservative (e.g., RNAlater) to preserve the microbiome.

1.4. Label the samples with unique identifiers and store them at -80°C until further analysis.

**Protocol 2: Microbiome Analysis**

2.1. Extract DNA from the lymph node samples using a DNA extraction kit (e.g., QIAamp DNA Microbiome Kit) according to the manufacturer's instructions.

2.2. Perform PCR amplification of the 16S rRNA gene using primers targeting the V3-V4 region (e.g., 341F and 785R).

2.3. Purify the PCR products using a PCR cleanup kit (e.g., QIAquick PCR Purification Kit).

2.4. Prepare the sequencing library using a library preparation kit (e.g., Illumina Nextera XT Index Kit) according to the manufacturer's instructions.

2.5. Perform 16S rRNA gene sequencing using an Illumina MiSeq platform with a minimum of 20,000 reads per sample.

**Protocol 3: Microbiome Profiling**

3.1. Demultiplex the sequencing data using the Illumina bcl2fastq software.

3.2. Trim the sequences using a trimming tool (e.g., Trimmomatic) to remove low-quality bases and adapters.

3.3. Assign taxonomy to the sequences using a microbiome analysis software (e.g., QIIME2 or Mothur) with a reference database (e.g., SILVA or Greengenes).

3.4. Calculate the relative abundance of each taxon in each sample using the software.

**Protocol 4: PD-L1 Expression Analysis**

4.1. Section the lymph node samples into 5-μm thick slices using a cryostat.

4.2. Perform multiplex immunofluorescence staining using antibodies against PD-L1, macrophage markers (e.g., CD68), and other immune cell markers (e.g., CD3, CD4, CD8).

4.3. Image the stained sections using a fluorescence microscope (e.g., Zeiss Axiovert 200M) with a minimum of 10 fields of view per sample.

4.4. Analyze the images using quantitative image analysis software (e.g., ImageJ or CellProfiler) to quantify PD-L1 expression on macrophages.

**Protocol 5: Flow Cytometry**

5.1. Prepare single-cell suspensions from the lymph node samples using a gentle dissociation protocol (e.g., GentleMACS Dissociator).

5.2. Stain the cells with antibodies against macrophage markers (e.g., CD68), immune cell markers (e.g., CD3, CD4, CD8), and viability dyes (e.g., propidium iodide).

5.3. Analyze the stained cells using a flow cytometer (e.g., BD FACSCanto II) with a minimum of 10,000 events per sample.

5.4. Gate the macrophage population using the macrophage markers and analyze the expression of PD-L1 using flow cytometry software (e.g., FlowJo).

**Protocol 6: Correlation Analysis**

6.1. Import the microbiome profiling data and PD-L1 expression data into a statistical software (e.g., R or Python).

6.2. Perform correlation analysis (e.g., Spearman's rank correlation) between the relative abundance of each taxon and PD-L1 expression on macrophages.

6.3. Identify significant correlations (p < 0.05) and visualize the results using heatmaps or scatter plots.

**Protocol 7: Statistical Analysis**

7.1. Perform statistical analysis (e.g., t-test or ANOVA) to compare PD-L1 expression on macrophages between responders and non-responders.

7.2. Identify significant differences (p < 0.05) and calculate the effect size (e.g., Cohen's d).

7.3. Perform multiple testing correction (e.g., Bonferroni correction) to account for multiple comparisons.

**Protocol 8: Microbiome Depletion**

8.1. Select a subset of lymph node samples from responders and non-responders with similar clinical characteristics.

8.2. Treat the samples with antibiotics (e.g., metronidazole and vancomycin) to deplete the microbiome.

8.3. Validate the depletion using 16S rRNA gene sequencing and microbiome profiling.

**Protocol 9: PD-L1 Expression Analysis after Microbiome Depletion**

9.1. Perform multiplex immunofluorescence staining on the depleted samples as described in Protocol 4.

9.2. Analyze the images using quantitative image analysis software to quantify PD-L1 expression on macrophages.

**Protocol 10: Comparison**

10.1. Compare PD-L1 expression on macrophages between responders and non-responders before and after microbiome depletion.

10.2. Perform statistical analysis (e.g., t-test or ANOVA) to identify significant differences (p < 0.05).

10.3. Calculate the effect size (e.g., Cohen's d) and perform multiple testing correction (e.g., Bonferroni correction).

These detailed protocols should provide a comprehensive approach to testing the hypothesis and disproving it, while ensuring replicability and specificity in the experimental design.","```
   Sample_ID  RNAlater  QIAamp_DNA  Primers  PCR_Products  Illumina_Reads  PD-L1_Antibody  CD68_Antibody  Propidium_Iodide  Metronidazole  Vancomycin  PD-L1_Expression
0          1       100        200       50          150          25000           10           20              5           0.5         0.5           0.8
1          2       120        220       60          180          28000           12           25              6           0.6         0.6           0.9
2          3       110        210       55          165          26000           11           22              5.5         0.55        0.55          0.85
3          4       130        230       65          190          30000           13           28              7           0.7         0.7           1.0
4          5       105        205       50          155          24000           10           20              5           0.5         0.5           0.8
5          6       125        225       62          185          29000           12           25              6.2         0.62        0.62          0.92
6          7       115        215       58          170          27000           11           22              5.8         0.58        0.58          0.88
7          8       135        235       68          200          31000           14           30              7.5         0.75        0.75          1.05
8          9       100        200       50          150          25000           10           20              5           0.5         0.5           0.8
9         10       140        240       70          210          32000           15           32              8           0.8         0.8           1.1
10        11       110        210       55          165          26000           11           22              5.5         0.55        0.55          0.85
11        12       130        230       65          190          30000           13           28              7           0.7         0.7           1.0
12        13       105        205       50          155          24000           10           20              5           0.5         0.5           0.8
13        14       145        245       72          220          33000           16           34              8.5         0.85        0.85          1.15
14        15       115        215       58          170          27000           11           22              5.8         0.58        0.58          0.88
15        16       150        250       75          230          34000           17           36              9           0.9         0.9           1.2
16        17       120        220       60          180          28000           12           25              6           0.6         0.6           0.9
17        18       155        255       78          240          35000           18           38              9.5         0.95        0.95          1.25
18        19       125        225       62          185          29000           12           25              6.2         0.62        0.62          0.92
19        20       160        260       80          250          36000           19           40              10          1.0         1.0           1.3
20        21       130        230       65          190          30000           13           28              7           0.7         0.7           1.0
21        22       165        265       82          260          37000           20           42              10.5        1.05        1.05          1.35
22        23       135        235       68          200          31000           14           30              7.5         0.75        0.75          1.05
23        24       170        270       85          270          38000           21           44              11          1.1         1.1           1.4
24        25       140        240       70          210          32000           15           32              8           0.8         0.8           1.1
```",0.9631362286599946
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/707ce971f1658f2c3af95459b069adaf1dbea4ba.summary'],Does the presence of specific somatic hypermutation patterns in antibody lineages influence the development of neutralizing antibodies against specific epitopes?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** The presence of specific somatic hypermutation patterns in antibody lineages influences the development of neutralizing antibodies against specific epitopes.

**Experimental Plan:**

**Objective:** To determine whether specific somatic hypermutation patterns in antibody lineages affect the development of neutralizing antibodies against specific epitopes.

**Approach:**

1. **Antibody Lineage Generation:**
	* Use a combination of next-generation sequencing (NGS) and single-cell RNA sequencing to identify and isolate antibody-producing B cells from individuals with a history of infection or vaccination against a specific pathogen (e.g., HIV, influenza).
	* Perform antibody repertoire analysis to identify antibody lineages with distinct somatic hypermutation patterns.
2. **Epitope Selection:**
	* Identify specific epitopes on the pathogen's surface proteins that are known to be targeted by neutralizing antibodies.
	* Use molecular modeling and bioinformatics tools to predict the binding affinity of the identified antibody lineages to these epitopes.
3. **Antibody Expression and Purification:**
	* Express the identified antibody lineages in a suitable expression system (e.g., HEK293 cells, CHO cells).
	* Purify the antibodies using affinity chromatography and size exclusion chromatography.
4. **Neutralization Assays:**
	* Perform neutralization assays using the purified antibodies and the specific epitopes identified in step 2.
	* Measure the neutralization activity of each antibody lineage against the epitopes using techniques such as plaque reduction neutralization tests (PRNT) or pseudovirus-based assays.
5. **Somatic Hypermutation Pattern Analysis:**
	* Analyze the somatic hypermutation patterns in each antibody lineage using NGS and bioinformatics tools.
	* Correlate the somatic hypermutation patterns with the neutralization activity of each antibody lineage against the specific epitopes.
6. **Control Experiments:**
	* Perform control experiments using antibody lineages with random or shuffled somatic hypermutation patterns to rule out any potential biases.

**Experiment to Disprove the Hypothesis:**

**Objective:** To demonstrate that the presence of specific somatic hypermutation patterns in antibody lineages does not influence the development of neutralizing antibodies against specific epitopes.

**Approach:**

1. **Antibody Lineage Generation:**
	* Generate antibody lineages with random or shuffled somatic hypermutation patterns using CRISPR-Cas9 genome editing or error-prone PCR.
	* Ensure that the generated lineages have similar overall mutation rates and distribution as the naturally occurring lineages.
2. **Epitope Selection:**
	* Use the same epitopes as in the original experiment.
3. **Antibody Expression and Purification:**
	* Express and purify the generated antibody lineages as in the original experiment.
4. **Neutralization Assays:**
	* Perform neutralization assays using the purified antibodies and the specific epitopes.
	* Measure the neutralization activity of each antibody lineage against the epitopes.
5. **Comparison:**
	* Compare the neutralization activity of the generated antibody lineages with random or shuffled somatic hypermutation patterns to the naturally occurring lineages with specific somatic hypermutation patterns.
	* If the generated lineages exhibit similar neutralization activity to the naturally occurring lineages, it would suggest that the presence of specific somatic hypermutation patterns does not influence the development of neutralizing antibodies against specific epitopes.

**Unlimited Budget Considerations:**

* Utilize high-throughput sequencing technologies, such as PacBio or Oxford Nanopore, to generate high-quality, long-read data for antibody repertoire analysis and somatic hypermutation pattern analysis.
* Employ advanced bioinformatics tools, such as machine learning algorithms, to analyze the large datasets generated in this study.
* Collaborate with experts in structural biology to perform high-resolution structural analysis of the antibody-epitope interactions using techniques such as cryo-EM or X-ray crystallography.
* Perform multiple replicates of each experiment to ensure robustness and reliability of the results.

By following this experimental plan, we can rigorously test the hypothesis and determine whether the presence of specific somatic hypermutation patterns in antibody lineages influences the development of neutralizing antibodies against specific epitopes.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Antibody Lineage Generation**

**Objective:** Identify and isolate antibody-producing B cells from individuals with a history of infection or vaccination against a specific pathogen.

**Step 1.1: Sample Collection**

* Collect peripheral blood mononuclear cells (PBMCs) from individuals with a history of infection or vaccination against a specific pathogen (e.g., HIV, influenza) using a sterile needle and syringe.
* Store the samples in a 50 mL conical tube containing 10 mL of RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

**Step 1.2: B Cell Isolation**

* Isolate B cells from the PBMCs using a B cell isolation kit (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Resuspend the isolated B cells in 1 mL of RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

**Step 1.3: Single-Cell RNA Sequencing**

* Perform single-cell RNA sequencing using a platform such as 10x Genomics or BD Rhapsody according to the manufacturer's instructions.
* Generate a minimum of 10,000 single-cell RNA-seq libraries.

**Step 1.4: Antibody Repertoire Analysis**

* Analyze the single-cell RNA-seq data using a bioinformatics pipeline such as IgBLAST or IMGT/HighV-QUEST to identify antibody-encoding genes.
* Identify antibody lineages with distinct somatic hypermutation patterns using a clustering algorithm such as k-means or hierarchical clustering.

**Protocol 2: Epitope Selection**

**Objective:** Identify specific epitopes on the pathogen's surface proteins that are known to be targeted by neutralizing antibodies.

**Step 2.1: Epitope Prediction**

* Use molecular modeling and bioinformatics tools such as Rosetta or IEDB to predict the binding affinity of the identified antibody lineages to specific epitopes on the pathogen's surface proteins.
* Identify a minimum of 5 epitopes with high predicted binding affinity.

**Step 2.2: Epitope Validation**

* Validate the predicted epitopes using techniques such as peptide microarrays or ELISA.
* Confirm that the epitopes are recognized by neutralizing antibodies.

**Protocol 3: Antibody Expression and Purification**

**Objective:** Express and purify the identified antibody lineages.

**Step 3.1: Vector Construction**

* Clone the antibody-encoding genes into a suitable expression vector (e.g., pFUSE2-CLIg-hIgG1) using standard molecular biology techniques.
* Verify the vector constructs by Sanger sequencing.

**Step 3.2: Transfection and Expression**

* Transfect the expression vector into a suitable host cell line (e.g., HEK293 cells or CHO cells) using a transfection reagent (e.g., Lipofectamine 2000).
* Express the antibodies in the host cells for 3-5 days.

**Step 3.3: Antibody Purification**

* Purify the antibodies using affinity chromatography (e.g., Protein A or Protein G) followed by size exclusion chromatography (e.g., Superdex 200).
* Verify the purity of the antibodies using SDS-PAGE and Western blotting.

**Protocol 4: Neutralization Assays**

**Objective:** Measure the neutralization activity of each antibody lineage against the specific epitopes.

**Step 4.1: Neutralization Assay Setup**

* Prepare the purified antibodies at a concentration of 10 μg/mL in PBS.
* Prepare the epitopes at a concentration of 10 μg/mL in PBS.

**Step 4.2: Neutralization Assay**

* Perform a plaque reduction neutralization test (PRNT) or pseudovirus-based assay using the purified antibodies and epitopes.
* Measure the neutralization activity of each antibody lineage against the epitopes.

**Protocol 5: Somatic Hypermutation Pattern Analysis**

**Objective:** Analyze the somatic hypermutation patterns in each antibody lineage.

**Step 5.1: NGS Library Preparation**

* Prepare NGS libraries from the antibody-encoding genes using a platform such as Illumina or PacBio.
* Generate a minimum of 10,000,000 reads per library.

**Step 5.2: Somatic Hypermutation Pattern Analysis**

* Analyze the NGS data using a bioinformatics pipeline such as IgBLAST or IMGT/HighV-QUEST to identify somatic hypermutations.
* Correlate the somatic hypermutation patterns with the neutralization activity of each antibody lineage against the specific epitopes.

**Protocol 6: Control Experiments**

**Objective:** Perform control experiments using antibody lineages with random or shuffled somatic hypermutation patterns.

**Step 6.1: Antibody Lineage Generation**

* Generate antibody lineages with random or shuffled somatic hypermutation patterns using CRISPR-Cas9 genome editing or error-prone PCR.
* Ensure that the generated lineages have similar overall mutation rates and distribution as the naturally occurring lineages.

**Step 6.2: Epitope Selection**

* Use the same epitopes as in the original experiment.

**Step 6.3: Antibody Expression and Purification**

* Express and purify the generated antibody lineages as in the original experiment.

**Step 6.4: Neutralization Assays**

* Perform neutralization assays using the purified antibodies and the specific epitopes.
* Measure the neutralization activity of each antibody lineage against the epitopes.

**Step 6.5: Comparison**

* Compare the neutralization activity of the generated antibody lineages with random or shuffled somatic hypermutation patterns to the naturally occurring lineages with specific somatic hypermutation patterns.
* If the generated lineages exhibit similar neutralization activity to the naturally occurring lineages, it would suggest that the presence of specific somatic hypermutation patterns does not influence the development of neutralizing antibodies against specific epitopes.

These detailed protocols should provide a clear and replicable guide for executing the experimental plan.","```
   PBMCs_mL  RPMI_1640_mL  FBS_percent  Penicillin_streptomycin_percent  B_cell_isolation_kit  Single_cell_RNA_sequencing_platform  Epitope_prediction_tool  Antibody_encoding_genes  Epitope_validation_technique  Vector_construction  Transfection_reagent  Host_cell_line  Antibody_purification_method  Neutralization_assay  Somatic_hypermutation_pattern_analysis  Neutralization_activity
0        10.0           10.0          10.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.8
1         8.0            9.0          11.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.7
2        12.0           11.0          9.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.9
3         9.0            8.0          12.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.6
4        11.0           12.0          8.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.8
5         7.0            9.0          13.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.5
6        10.0           11.0          9.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.7
7         9.0            8.0          11.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.6
8        12.0           10.0          8.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.9
9         8.0            9.0          12.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.7
10       11.0           12.0          7.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.8
11        7.0            8.0          13.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.5
12       10.0           11.0          9.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.7
13        9.0            8.0          11.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.6
14       12.0           10.0          8.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.9
15        8.0            9.0          12.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.7
16       11.0           12.0          7.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.8
17        7.0            8.0          13.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.5
18       10.0           11.0          9.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.7
19        9.0            8.0          11.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.6
20       12.0           10.0          8.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.9
21        8.0            9.0          12.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.7
22       11.0           12.0          7.0                          1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.8
23        7.0            8.0          13.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.5
24        9.0            8.0          11.0                         1.0                    Miltenyi              10x Genomics                    Rosetta                    5                    peptide microarray            pFUSE2-CLIg-hIgG1          Lipofectamine 2000          HEK293 cells          Protein A            PRNT                    IgBLAST                    0.6
```",0.26097176589940824
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c7669dd6bfbe43e9d88e039da8b30bda14026203.summary'],"Does the recruitment of phosphatases by CD25 also regulate the activity of other immune cell receptors, such as the T-cell receptor, to prevent excessive signaling and autoimmune responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis that the recruitment of phosphatases by CD25 also regulates the activity of other immune cell receptors, such as the T-cell receptor, to prevent excessive signaling and autoimmune responses.

**Experimental Plan:**

**Title:** Investigating the Role of CD25 in Regulating T-Cell Receptor Signaling and Autoimmune Responses

**Objective:** To determine if CD25-mediated phosphatase recruitment regulates T-cell receptor (TCR) signaling and prevents autoimmune responses.

**Hypothesis to be Disproven:** CD25 does not regulate TCR signaling and autoimmune responses through phosphatase recruitment.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate T cells from wild-type and CD25-knockout mice using magnetic bead separation or FACS sorting.
	* Activate T cells using anti-CD3 and anti-CD28 antibodies to stimulate TCR signaling.
2. **Phosphatase Recruitment Assay:**
	* Co-immunoprecipitate CD25 with TCR complex components (e.g., TCRα, TCRβ, CD3ζ) and phosphatases (e.g., SHP1, SHIP1) using antibodies specific to each protein.
	* Analyze the immunoprecipitates using Western blotting to detect the presence of phosphatases and TCR complex components.
3. **TCR Signaling Analysis:**
	* Measure TCR-downstream signaling molecules (e.g., ZAP70, LAT, ERK) phosphorylation levels using Western blotting or flow cytometry in wild-type and CD25-knockout T cells.
	* Compare the results to determine if CD25-deletion leads to hyperactivation of TCR-downstream signaling.
4. **Autoimmune Response Assay:**
	* Co-culture CD25-knockout T cells with antigen-presenting cells (APCs) and measure the production of pro-inflammatory cytokines (e.g., IL-2, IFN-γ) using ELISA or cytokine bead arrays.
	* Compare the results to wild-type T cells to determine if CD25-deletion leads to enhanced autoimmune responses.

**Expected Outcomes:**

* If CD25 regulates TCR signaling and autoimmune responses through phosphatase recruitment, we expect to see:
	+ Co-immunoprecipitation of CD25 with TCR complex components and phosphatases.
	+ Reduced TCR-downstream signaling in wild-type T cells compared to CD25-knockout T cells.
	+ Decreased pro-inflammatory cytokine production in wild-type T cells compared to CD25-knockout T cells.
* If the hypothesis is disproven, we expect to see no significant differences in phosphatase recruitment, TCR signaling, and autoimmune responses between wild-type and CD25-knockout T cells.

**Required Equipment and Resources:**

* CRISPR-Cas9 system for generating CD25-knockout mice
* Anti-CD3 and anti-CD28 antibodies for T cell activation
* Antibodies for co-immunoprecipitation and Western blotting
* Western blotting and flow cytometry equipment
* ELISA or cytokine bead arrays for cytokine detection
* Magnetic bead separation or FACS sorting equipment for T cell isolation

**Timeline and Budget:**

* This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000, depending on the availability of resources and equipment.

By following this experimental plan, we can determine if CD25-mediated phosphatase recruitment regulates TCR signaling and autoimmune responses, providing valuable insights into the mechanisms underlying immune cell regulation and autoimmune diseases.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Preparation**

1.1. Mouse Handling and Tissue Collection

* Obtain wild-type and CD25-knockout mice from a reputable supplier or generate them using the CRISPR-Cas9 system.
* Euthanize the mice according to institutional animal care and use committee (IACUC) guidelines.
* Harvest spleens and lymph nodes from each mouse and store them in ice-cold PBS.

1.2. T Cell Isolation

* Prepare a single-cell suspension from the spleens and lymph nodes using a gentleMACS Dissociator (Miltenyi Biotec) or a similar device.
* Filter the suspension through a 40-μm cell strainer to remove debris and clumps.
* Isolate T cells using magnetic bead separation (e.g., Miltenyi Biotec's CD4+ T Cell Isolation Kit) or FACS sorting (e.g., BD FACSAria III) according to the manufacturer's instructions.
* Wash the isolated T cells twice with ice-cold PBS and resuspend them in complete RPMI 1640 medium (10% FBS, 1% penicillin-streptomycin, 1% L-glutamine).

1.3. T Cell Activation

* Activate the isolated T cells by adding 1 μg/mL anti-CD3 (clone 145-2C11, BioLegend) and 1 μg/mL anti-CD28 (clone 37.51, BioLegend) antibodies to the cell suspension.
* Incubate the cells at 37°C, 5% CO2 for 24-48 hours to stimulate TCR signaling.

**Protocol 2: Phosphatase Recruitment Assay**

2.1. Co-Immunoprecipitation

* Prepare a lysis buffer containing 1% NP-40, 150 mM NaCl, 20 mM Tris-HCl (pH 7.5), and 1x protease inhibitor cocktail (e.g., Roche).
* Lyse the activated T cells in the lysis buffer using a gentleMACS Dissociator or a similar device.
* Incubate the lysates with 2 μg of antibodies specific to CD25 (clone PC61, BioLegend), TCRα (clone H57-597, BioLegend), TCRβ (clone H57-597, BioLegend), CD3ζ (clone 6B10.2, BioLegend), SHP1 (clone C-19, Santa Cruz Biotechnology), and SHIP1 (clone P1C1, Santa Cruz Biotechnology) for 2 hours at 4°C.
* Add 20 μL of protein A/G beads (e.g., Thermo Fisher Scientific) to each lysate and incubate for an additional 2 hours at 4°C.
* Wash the beads three times with the lysis buffer and elute the immunoprecipitates with 2x Laemmli buffer.

2.2. Western Blotting

* Resolve the immunoprecipitates on a 10% SDS-PAGE gel and transfer them to a PVDF membrane.
* Block the membrane with 5% BSA in TBST for 1 hour at room temperature.
* Incubate the membrane with primary antibodies specific to CD25, TCRα, TCRβ, CD3ζ, SHP1, and SHIP1 overnight at 4°C.
* Detect the proteins using HRP-conjugated secondary antibodies and ECL reagents (e.g., Thermo Fisher Scientific).

**Protocol 3: TCR Signaling Analysis**

3.1. Western Blotting

* Prepare whole-cell lysates from activated wild-type and CD25-knockout T cells using the lysis buffer.
* Resolve the lysates on a 10% SDS-PAGE gel and transfer them to a PVDF membrane.
* Block the membrane with 5% BSA in TBST for 1 hour at room temperature.
* Incubate the membrane with primary antibodies specific to ZAP70, LAT, and ERK overnight at 4°C.
* Detect the proteins using HRP-conjugated secondary antibodies and ECL reagents.

3.2. Flow Cytometry

* Stain the activated T cells with fluorochrome-conjugated antibodies specific to ZAP70, LAT, and ERK (e.g., BD Biosciences).
* Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and quantify the phosphorylation levels using FlowJo software.

**Protocol 4: Autoimmune Response Assay**

4.1. Co-Culture

* Prepare antigen-presenting cells (APCs) from wild-type mice using a protocol of your choice (e.g., bone marrow-derived dendritic cells).
* Co-culture 1x10^5 CD25-knockout T cells with 1x10^5 APCs in complete RPMI 1640 medium.
* Incubate the co-culture at 37°C, 5% CO2 for 48-72 hours.

4.2. Cytokine Detection

* Collect the supernatants from the co-culture and analyze them using ELISA (e.g., R&D Systems) or cytokine bead arrays (e.g., BD Biosciences) according to the manufacturer's instructions.
* Measure the production of pro-inflammatory cytokines such as IL-2 and IFN-γ.

**Quality Control and Replicability**

* Perform each experiment in triplicate to ensure reproducibility.
* Include positive and negative controls for each assay to validate the results.
* Use standardized protocols and reagents to minimize variability.
* Document all experimental procedures, results, and data analysis in a laboratory notebook or electronic database.

By following these detailed protocols, you should be able to execute the experimental plan and obtain reliable results.","```
   Mouse_Type  Spleen_Weight  Lymph_Node_Weight  CD4_T_Cell_Isolation_Kit  Anti_CD3_Antibody  Anti_CD28_Antibody  CD25_Antibody  TCRα_Antibody  TCRβ_Antibody  CD3ζ_Antibody  SHP1_Antibody  SHIP1_Antibody  ZAP70_Antibody  LAT_Antibody  ERK_Antibody  Outcome
0    Wild-Type          0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Positive
1    Wild-Type          0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Positive
2    CD25-Knockout      0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Negative
3    Wild-Type          0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Positive
4    CD25-Knockout      0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Negative
5    Wild-Type          0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Positive
6    CD25-Knockout      0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Negative
7    Wild-Type          0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Positive
8    CD25-Knockout      0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Negative
9    Wild-Type          0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Positive
10   CD25-Knockout      0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Negative
11   Wild-Type          0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Positive
12   CD25-Knockout      0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Negative
13   Wild-Type          0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Positive
14   CD25-Knockout      0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Negative
15   Wild-Type          0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Positive
16   CD25-Knockout      0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Negative
17   Wild-Type          0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Positive
18   CD25-Knockout      0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Negative
19   Wild-Type          0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Positive
20   CD25-Knockout      0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Negative
21   Wild-Type          0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Positive
22   CD25-Knockout      0.4             0.2                    0.8               0.9               0.9           1.8           0.9           0.9           0.9           0.9           0.9           0.9           0.9           0.9  Negative
23   Wild-Type          0.6             0.4                    1.2               1.1               1.1           2.2           1.1           1.1           1.1           1.1           1.1           1.1           1.1           1.1  Positive
24   CD25-Knockout      0.5             0.3                    1.0               1.0               1.0           2.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0           1.0  Negative
```",0.0666666666666667
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/08f8d50fecc7ab2caf6bcbe7378e40f60a259689.summary'],Does the redox hypersensitivity of CLL cells conferred by low catalase expression also enhance their susceptibility to oxidative stress-induced apoptosis in response to BCR signaling inhibition?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of Low Catalase Expression in Enhancing Oxidative Stress-Induced Apoptosis in CLL Cells upon BCR Signaling Inhibition

**Objective:** To determine if low catalase expression in CLL cells increases their susceptibility to oxidative stress-induced apoptosis when BCR signaling is inhibited.

**Equipment:**

* CLL cell lines or primary CLL cells with low catalase expression
* BCR signaling inhibitors (e.g., ibrutinib)
* Hydrogen peroxide (H2O2) or other oxidative stress inducers
* Annexin V apoptosis detection kit
* Flow cytometer
* Western blot equipment
* Antibodies against catalase, BCR signaling proteins, and apoptosis markers (e.g., cleaved caspase-3)

**Steps:**

1. Culture CLL cells with low catalase expression and treat them with BCR signaling inhibitors for 24-48 hours.
2. Expose the cells to increasing concentrations of H2O2 or other oxidative stress inducers for 1-2 hours.
3. Measure apoptosis using Annexin V staining and flow cytometry.
4. Validate the results using Western blot analysis of apoptosis markers (e.g., cleaved caspase-3).
5. Compare the apoptosis rates between CLL cells with low catalase expression and those with normal catalase expression.
6. Repeat the experiment using different BCR signaling inhibitors and oxidative stress inducers to ensure consistency.

**Expected Outcome:** If the hypothesis is true, CLL cells with low catalase expression will exhibit increased apoptosis rates when BCR signaling is inhibited and oxidative stress is induced.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of Catalase Expression in CLL Cell Resistance to Oxidative Stress-Induced Apoptosis upon BCR Signaling Inhibition

**Objective:** To determine if high catalase expression in CLL cells confers resistance to oxidative stress-induced apoptosis when BCR signaling is inhibited.

**Equipment:** Same as above

**Steps:**

1. Culture CLL cells with high catalase expression and treat them with BCR signaling inhibitors for 24-48 hours.
2. Expose the cells to increasing concentrations of H2O2 or other oxidative stress inducers for 1-2 hours.
3. Measure apoptosis using Annexin V staining and flow cytometry.
4. Validate the results using Western blot analysis of apoptosis markers (e.g., cleaved caspase-3).
5. Compare the apoptosis rates between CLL cells with high catalase expression and those with low catalase expression.
6. Repeat the experiment using different BCR signaling inhibitors and oxidative stress inducers to ensure consistency.

**Expected Outcome:** If the hypothesis is false, CLL cells with high catalase expression will exhibit reduced apoptosis rates when BCR signaling is inhibited and oxidative stress is induced, suggesting that catalase expression does not play a significant role in enhancing oxidative stress-induced apoptosis in CLL cells.

**Rationale:** By designing an experiment to disprove the hypothesis, we can test the robustness of the original hypothesis and provide more confidence in the results. If the experiment to disprove the hypothesis fails to do so, it will strengthen the evidence supporting the original hypothesis.

**Time and Resource Considerations:**

* The experiments can be completed within 2-3 months with a moderate budget.
* The required equipment and reagents are standard in most molecular biology and cell biology laboratories.
* The experiments can be performed by a single researcher with some assistance from a technician or a postdoctoral fellow.

**Limitations:**

* The experiments are limited to in vitro studies and may not directly translate to in vivo settings.
* The results may be influenced by the specific BCR signaling inhibitors and oxidative stress inducers used.
* The study relies on the availability of CLL cell lines or primary CLL cells with low catalase expression.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Day 1-2: Cell Culture and BCR Signaling Inhibition**

1.1. Obtain CLL cell lines or primary CLL cells with low catalase expression and culture them in a 37°C, 5% CO2 incubator in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

1.2. Treat the cells with 1-10 μM ibrutinib (or other BCR signaling inhibitors) for 24-48 hours to inhibit BCR signaling.

**Day 3: Oxidative Stress Induction**

2.1. Prepare a stock solution of 30% H2O2 in PBS and dilute it to the desired concentrations (e.g., 10-100 μM) in RPMI-1640 medium.

2.2. Add the H2O2 solution to the cells and incubate for 1-2 hours at 37°C, 5% CO2.

**Day 3-4: Apoptosis Measurement**

3.1. Harvest the cells and wash them twice with cold PBS.

3.2. Resuspend the cells in 100 μL of Annexin V binding buffer and add 5 μL of Annexin V-FITC.

3.3. Incubate the cells for 15 minutes at room temperature in the dark.

3.4. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) to measure apoptosis.

**Day 4: Western Blot Validation**

4.1. Harvest the cells and lyse them in RIPA buffer supplemented with protease inhibitors.

4.2. Run 20-30 μg of protein on a 12% SDS-PAGE gel and transfer it to a PVDF membrane.

4.3. Probe the membrane with antibodies against catalase, BCR signaling proteins, and apoptosis markers (e.g., cleaved caspase-3).

4.4. Detect the proteins using an ECL detection system and quantify the bands using ImageJ software.

**Day 5: Data Analysis**

5.1. Calculate the apoptosis rate using the Annexin V staining data.

5.2. Compare the apoptosis rates between CLL cells with low catalase expression and those with normal catalase expression.

5.3. Repeat the experiment using different BCR signaling inhibitors and oxidative stress inducers to ensure consistency.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

**Day 1-2: Cell Culture and BCR Signaling Inhibition**

1.1. Obtain CLL cell lines or primary CLL cells with high catalase expression and culture them in a 37°C, 5% CO2 incubator in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

1.2. Treat the cells with 1-10 μM ibrutinib (or other BCR signaling inhibitors) for 24-48 hours to inhibit BCR signaling.

**Day 3: Oxidative Stress Induction**

2.1. Prepare a stock solution of 30% H2O2 in PBS and dilute it to the desired concentrations (e.g., 10-100 μM) in RPMI-1640 medium.

2.2. Add the H2O2 solution to the cells and incubate for 1-2 hours at 37°C, 5% CO2.

**Day 3-4: Apoptosis Measurement**

3.1. Harvest the cells and wash them twice with cold PBS.

3.2. Resuspend the cells in 100 μL of Annexin V binding buffer and add 5 μL of Annexin V-FITC.

3.3. Incubate the cells for 15 minutes at room temperature in the dark.

3.4. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) to measure apoptosis.

**Day 4: Western Blot Validation**

4.1. Harvest the cells and lyse them in RIPA buffer supplemented with protease inhibitors.

4.2. Run 20-30 μg of protein on a 12% SDS-PAGE gel and transfer it to a PVDF membrane.

4.3. Probe the membrane with antibodies against catalase, BCR signaling proteins, and apoptosis markers (e.g., cleaved caspase-3).

4.4. Detect the proteins using an ECL detection system and quantify the bands using ImageJ software.

**Day 5: Data Analysis**

5.1. Calculate the apoptosis rate using the Annexin V staining data.

5.2. Compare the apoptosis rates between CLL cells with high catalase expression and those with low catalase expression.

5.3. Repeat the experiment using different BCR signaling inhibitors and oxidative stress inducers to ensure consistency.

Note: The protocols are designed to be followed in a specific order, and the time points are indicated to ensure that the experiments are completed within the specified timeframe. The protocols can be modified or optimized as needed based on the specific requirements of the laboratory and the researcher.","```
   Catalase_Expression  Ibrutinib_Concentration  H2O2_Concentration  Apoptosis_Rate
0                  Low                    5.0               20.0       0.350000
1                  Low                    2.0               50.0       0.450000
2                  Low                    8.0               30.0       0.400000
3                  High                   1.0               40.0       0.250000
4                  Low                    9.0               10.0       0.300000
5                  High                   6.0               60.0       0.200000
6                  Low                    4.0               80.0       0.500000
7                  High                   3.0               20.0       0.220000
8                  Low                    7.0               50.0       0.420000
9                  High                   5.0               30.0       0.280000
10                 Low                    1.0               10.0       0.350000
11                 High                   9.0               40.0       0.240000
12                 Low                    6.0               60.0       0.480000
13                 High                   2.0               80.0       0.260000
14                 Low                    8.0               20.0       0.380000
15                 High                   4.0               50.0       0.300000
16                 Low                    3.0               30.0       0.410000
17                 High                   7.0               10.0       0.230000
18                 Low                    5.0               40.0       0.390000
19                 High                   1.0               60.0       0.270000
20                 Low                    9.0               80.0       0.440000
21                 High                   6.0               20.0       0.290000
22                 Low                    2.0               50.0       0.430000
23                 High                   8.0               30.0       0.310000
24                 Low                    4.0               10.0       0.360000
```",0.1753034275212747
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6530267a1c0073db06a1da1c31ab85f15856f9d8.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/31479ee6c3208d991c942491922a9a90775b702c.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6608073461b7c6bee587b5a2d696057961fd192b.summary']",Does the reduced kinase activity of BCR::ABL1 in chronic phase CML patient samples contribute to the increased efficacy of non-covalent BTK inhibitors in treating B-cell malignancies?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"To test the hypothesis that the reduced kinase activity of BCR::ABL1 in chronic phase CML patient samples contributes to the increased efficacy of non-covalent BTK inhibitors in treating B-cell malignancies, I propose the following experimental plan:

**Experiment:** ""Investigating the role of BCR::ABL1 kinase activity in the efficacy of non-covalent BTK inhibitors in chronic phase CML patient samples""

**Objective:** To determine if the reduced kinase activity of BCR::ABL1 in chronic phase CML patient samples enhances the efficacy of non-covalent BTK inhibitors in treating B-cell malignancies.

**Design:**

1. **Cell preparation:** Collect chronic phase CML patient samples and isolate primary leukocytes using standard protocols.
2. **BCR::ABL1 kinase activity measurement:** Use the method described in the 2022 paper to preserve BCR::ABL1 protein in primary CML cells and measure its kinase activity using a kinase assay (e.g., ADP-Glo Kinase Assay).
3. **Non-covalent BTK inhibitor treatment:** Treat the CML cells with a non-covalent BTK inhibitor (e.g., pirtobrutinib) at varying concentrations and incubate for 24-48 hours.
4. **Cell viability and apoptosis assays:** Measure cell viability using a cell viability assay (e.g., MTT or CellTiter-Glo) and apoptosis using a apoptosis assay (e.g., Annexin V staining and flow cytometry).
5. **BCR::ABL1 kinase activity rescue:** Use a BCR::ABL1 kinase activator (e.g., dasatinib) to rescue BCR::ABL1 kinase activity in a subset of CML cells and repeat steps 3-4.
6. **Comparison and analysis:** Compare the efficacy of the non-covalent BTK inhibitor in CML cells with reduced BCR::ABL1 kinase activity (step 2) versus CML cells with rescued BCR::ABL1 kinase activity (step 5). Analyze the data using statistical software (e.g., GraphPad Prism) to determine if the reduced kinase activity of BCR::ABL1 enhances the efficacy of the non-covalent BTK inhibitor.

**Equipment and reagents:**

* Primary CML patient samples
* BCR::ABL1 kinase assay kit (e.g., ADP-Glo Kinase Assay)
* Non-covalent BTK inhibitor (e.g., pirtobrutinib)
* BCR::ABL1 kinase activator (e.g., dasatinib)
* Cell viability assay kit (e.g., MTT or CellTiter-Glo)
* Apoptosis assay kit (e.g., Annexin V staining and flow cytometry)
* Flow cytometer
* Statistical software (e.g., GraphPad Prism)

**Timeline:** This experiment can be completed within 6-8 weeks, assuming a moderate pace and availability of resources.

**Budget:** The budget for this experiment will depend on the cost of reagents, equipment, and personnel. However, a rough estimate would be:

* Reagents and consumables: $5,000 - $10,000
* Equipment (e.g., flow cytometer): $10,000 - $20,000
* Personnel (e.g., researcher, technician): $10,000 - $20,000
* Total: $25,000 - $50,000

This experiment is designed to test the hypothesis by directly measuring the effect of BCR::ABL1 kinase activity on the efficacy of non-covalent BTK inhibitors in chronic phase CML patient samples. By rescuing BCR::ABL1 kinase activity, we can determine if the reduced kinase activity is responsible for the increased efficacy of non-covalent BTK inhibitors.",85,"Here is the detailed, step-by-step protocol for the experiment:

**Experiment:** ""Investigating the role of BCR::ABL1 kinase activity in the efficacy of non-covalent BTK inhibitors in chronic phase CML patient samples""

**Step 1: Cell Preparation**

1.1. Collect chronic phase CML patient samples from a reputable biobank or hospital following institutional review board (IRB) guidelines.

1.2. Isolate primary leukocytes from the patient samples using standard protocols, such as Ficoll-Paque density gradient centrifugation or RosetteSep human leukocyte enrichment cocktail.

1.3. Wash the isolated leukocytes twice with phosphate-buffered saline (PBS) and resuspend them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

1.4. Count the cells using a hemocytometer or an automated cell counter and adjust the concentration to 1 x 10^6 cells/mL.

**Step 2: BCR::ABL1 Kinase Activity Measurement**

2.1. Prepare the BCR::ABL1 protein preservation buffer according to the 2022 paper's protocol.

2.2. Add 100 μL of the preservation buffer to 1 x 10^6 CML cells and incubate at room temperature for 30 minutes.

2.3. Perform the ADP-Glo Kinase Assay according to the manufacturer's instructions to measure BCR::ABL1 kinase activity.

2.4. Record the luminescence readings using a plate reader and calculate the kinase activity in relative light units (RLU) per minute.

**Step 3: Non-Covalent BTK Inhibitor Treatment**

3.1. Prepare a stock solution of pirtobrutinib (non-covalent BTK inhibitor) in DMSO at a concentration of 10 mM.

3.2. Add the pirtobrutinib stock solution to the CML cells at varying concentrations (e.g., 0.1, 1, 10 μM) and incubate at 37°C, 5% CO2 for 24-48 hours.

3.3. Use a control group with DMSO only (vehicle control) to account for any solvent effects.

**Step 4: Cell Viability and Apoptosis Assays**

4.1. Perform the MTT or CellTiter-Glo cell viability assay according to the manufacturer's instructions to measure cell viability.

4.2. Add 10 μL of the MTT reagent or CellTiter-Glo reagent to each well and incubate at 37°C, 5% CO2 for 2-4 hours.

4.3. Measure the absorbance at 570 nm using a plate reader or record the luminescence readings.

4.4. Perform Annexin V staining and flow cytometry to measure apoptosis according to the manufacturer's instructions.

4.5. Stain the cells with Annexin V-FITC and propidium iodide (PI) and analyze using a flow cytometer.

**Step 5: BCR::ABL1 Kinase Activity Rescue**

5.1. Prepare a stock solution of dasatinib (BCR::ABL1 kinase activator) in DMSO at a concentration of 10 μM.

5.2. Add the dasatinib stock solution to a subset of CML cells at a concentration of 1 μM and incubate at 37°C, 5% CO2 for 2 hours.

5.3. Repeat steps 3-4 using the rescued CML cells.

**Step 6: Comparison and Analysis**

6.1. Compare the efficacy of the non-covalent BTK inhibitor in CML cells with reduced BCR::ABL1 kinase activity (step 2) versus CML cells with rescued BCR::ABL1 kinase activity (step 5).

6.2. Analyze the data using GraphPad Prism or similar statistical software to determine if the reduced kinase activity of BCR::ABL1 enhances the efficacy of the non-covalent BTK inhibitor.

6.3. Perform statistical tests (e.g., t-test, ANOVA) to determine significance and calculate the IC50 values for the non-covalent BTK inhibitor.

**Quality Control and Replicability**

* Use high-quality reagents and equipment to ensure reproducibility.
* Perform each experiment in triplicate to account for technical variability.
* Include positive and negative controls for each assay to ensure accuracy.
* Document all experimental procedures, results, and data analysis in a laboratory notebook or electronic lab record.

**Timeline and Budget**

* The experiment can be completed within 6-8 weeks, assuming a moderate pace and availability of resources.
* The budget for this experiment will depend on the cost of reagents, equipment, and personnel, with a rough estimate of $25,000 - $50,000.","```
   CML Cells (x10^6)  BCR::ABL1 Kinase Activity (RLU/min)  Pirtobrutinib (μM)  Dasatinib (μM)  Cell Viability (%)  Apoptosis (%)  Outcome
0               1.0                     500.0               0.1           0.0         80.0         20.0  Ineffective
1               1.2                     400.0               1.0           0.0         60.0         30.0  Partially Effective
2               0.8                     600.0               0.1           0.0         90.0         10.0  Ineffective
3               1.0                     300.0               10.0          0.0         40.0         50.0  Effective
4               1.1                     450.0               0.1           1.0         70.0         25.0  Partially Effective
5               0.9                     550.0               1.0           0.0         50.0         40.0  Partially Effective
6               1.0                     350.0               10.0          0.0         30.0         60.0  Effective
7               1.2                     500.0               0.1           0.0         85.0         15.0  Ineffective
8               0.8                     400.0               1.0           0.0         65.0         30.0  Partially Effective
9               1.1                     600.0               10.0          0.0         45.0         50.0  Effective
10              0.9                     450.0               0.1           1.0         75.0         20.0  Partially Effective
11              1.0                     300.0               1.0           0.0         55.0         40.0  Partially Effective
12              1.2                     550.0               10.0          0.0         40.0         55.0  Effective
13              0.8                     500.0               0.1           0.0         80.0         20.0  Ineffective
14              1.1                     400.0               1.0           0.0         60.0         35.0  Partially Effective
15              0.9                     600.0               10.0          0.0         35.0         60.0  Effective
16              1.0                     450.0               0.1           1.0         70.0         25.0  Partially Effective
17              1.2                     300.0               10.0          0.0         30.0         65.0  Effective
18              0.8                     550.0               1.0           0.0         50.0         45.0  Partially Effective
19              1.1                     500.0               10.0          0.0         40.0         55.0  Effective
20              0.9                     400.0               0.1           0.0         85.0         15.0  Ineffective
21              1.0                     600.0               1.0           0.0         60.0         35.0  Partially Effective
22              1.2                     450.0               10.0          0.0         45.0         50.0  Effective
23              0.8                     300.0               1.0           0.0         55.0         40.0  Partially Effective
24              1.1                     550.0               10.0          0.0         35.0         60.0  Effective
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/008ab2aca88f98b5ab893e1e657f1417508c0da7.summary'],"Does the reduction of T regulatory cells by ibrutinib therapy also lead to an increase in the production of anti-tumor cytokines, such as IL-2 and IFN-γ, by CD4+ and CD8+ T cells in CLL patients?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** The reduction of T regulatory cells (Tregs) by ibrutinib therapy leads to an increase in the production of anti-tumor cytokines, such as IL-2 and IFN-γ, by CD4+ and CD8+ T cells in CLL patients.

**Experimental Plan:**

**Objective:** To determine if ibrutinib therapy reduces Tregs and increases anti-tumor cytokine production by CD4+ and CD8+ T cells in CLL patients.

**Study Design:**

1. **Patient Selection:** Recruit 20 CLL patients who will receive ibrutinib therapy. Collect blood samples at baseline (before therapy) and at 3 months after therapy initiation.
2. **Treg Analysis:**
	* Isolate peripheral blood mononuclear cells (PBMCs) from blood samples using Ficoll-Paque density gradient centrifugation.
	* Stain PBMCs with anti-CD4, anti-CD25, and anti-FoxP3 antibodies to identify Tregs (CD4+CD25+FoxP3+).
	* Analyze Treg frequency and absolute count using flow cytometry.
3. **Cytokine Analysis:**
	* Isolate CD4+ and CD8+ T cells from PBMCs using magnetic bead separation.
	* Stimulate T cells with anti-CD3/CD28 beads to induce cytokine production.
	* Measure IL-2 and IFN-γ production in supernatants using ELISA or multiplex assays.
4. **Statistical Analysis:**
	* Compare Treg frequency and absolute count between baseline and 3 months after therapy using paired t-tests or Wilcoxon signed-rank tests.
	* Compare IL-2 and IFN-γ production between baseline and 3 months after therapy using paired t-tests or Wilcoxon signed-rank tests.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we'll test the following:

**Null Hypothesis:** Ibrutinib therapy does not reduce Tregs or increase anti-tumor cytokine production by CD4+ and CD8+ T cells in CLL patients.

**Alternative Experimental Design:**

1. **Control Group:** Recruit 10 CLL patients who will not receive ibrutinib therapy. Collect blood samples at baseline and 3 months later.
2. **Treg and Cytokine Analysis:** Perform the same analyses as in the main experiment.
3. **Comparison:** Compare Treg frequency, absolute count, and cytokine production between the ibrutinib-treated group and the control group using unpaired t-tests or Mann-Whitney U tests.

**Rationale:** If the null hypothesis is true, we should not observe significant differences in Treg frequency, absolute count, or cytokine production between the ibrutinib-treated group and the control group.

**Budget and Timeframe:**

* Estimated budget: $50,000 - $75,000
* Estimated timeframe: 6-9 months

This experiment can be completed within a reasonable timeframe and budget by leveraging existing laboratory equipment and techniques. The control group will help to disprove the hypothesis, and the paired design will minimize inter-individual variability.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Patient Selection and Blood Sample Collection**

1.1. Recruit 20 CLL patients who will receive ibrutinib therapy.

* Inclusion criteria: CLL patients diagnosed according to WHO criteria, scheduled to receive ibrutinib therapy, and willing to provide informed consent.
* Exclusion criteria: Patients with active infections, autoimmune disorders, or receiving immunosuppressive therapy.

1.2. Collect blood samples at baseline (before therapy) and at 3 months after therapy initiation.

* Use 10 mL EDTA tubes for blood collection.
* Label tubes with patient ID, date, and time of collection.
* Store tubes at room temperature and process within 24 hours.

**Protocol 2: Treg Analysis**

2.1. Isolate peripheral blood mononuclear cells (PBMCs) from blood samples using Ficoll-Paque density gradient centrifugation.

* Add 10 mL of blood to 10 mL of Ficoll-Paque in a 50 mL conical tube.
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the PBMC layer and wash with PBS.
* Resuspend PBMCs in 1 mL of PBS.

2.2. Stain PBMCs with anti-CD4, anti-CD25, and anti-FoxP3 antibodies to identify Tregs (CD4+CD25+FoxP3+).

* Add 100 μL of PBMCs to a 1.5 mL tube.
* Add 10 μL of anti-CD4-PE, 10 μL of anti-CD25-APC, and 10 μL of anti-FoxP3-FITC antibodies.
* Incubate at room temperature for 30 minutes in the dark.
* Wash with PBS and resuspend in 500 μL of PBS.

2.3. Analyze Treg frequency and absolute count using flow cytometry.

* Use a flow cytometer (e.g., BD FACSCanto II) to acquire 100,000 events.
* Gate on CD4+ cells and then on CD25+FoxP3+ cells to identify Tregs.
* Calculate Treg frequency as a percentage of CD4+ cells and absolute count using the total number of PBMCs.

**Protocol 3: Cytokine Analysis**

3.1. Isolate CD4+ and CD8+ T cells from PBMCs using magnetic bead separation.

* Use CD4 and CD8 microbeads (e.g., Miltenyi Biotec) according to the manufacturer's instructions.
* Isolate CD4+ and CD8+ T cells separately.

3.2. Stimulate T cells with anti-CD3/CD28 beads to induce cytokine production.

* Add 1 x 10^6 T cells to a 1.5 mL tube.
* Add 10 μL of anti-CD3/CD28 beads (e.g., Dynabeads).
* Incubate at 37°C, 5% CO2 for 48 hours.

3.3. Measure IL-2 and IFN-γ production in supernatants using ELISA or multiplex assays.

* Collect supernatants and store at -80°C until analysis.
* Use ELISA kits (e.g., R&D Systems) or multiplex assays (e.g., Luminex) according to the manufacturer's instructions.
* Measure IL-2 and IFN-γ concentrations in pg/mL.

**Protocol 4: Statistical Analysis**

4.1. Compare Treg frequency and absolute count between baseline and 3 months after therapy using paired t-tests or Wilcoxon signed-rank tests.

* Use statistical software (e.g., R, GraphPad Prism) to perform paired t-tests or Wilcoxon signed-rank tests.
* Calculate p-values and report mean ± SD or median (IQR) for Treg frequency and absolute count.

4.2. Compare IL-2 and IFN-γ production between baseline and 3 months after therapy using paired t-tests or Wilcoxon signed-rank tests.

* Use statistical software (e.g., R, GraphPad Prism) to perform paired t-tests or Wilcoxon signed-rank tests.
* Calculate p-values and report mean ± SD or median (IQR) for IL-2 and IFN-γ production.

**Protocol 5: Experiment to Disprove the Hypothesis (Control Group)**

5.1. Recruit 10 CLL patients who will not receive ibrutinib therapy.

* Inclusion criteria: CLL patients diagnosed according to WHO criteria, not receiving ibrutinib therapy, and willing to provide informed consent.
* Exclusion criteria: Patients with active infections, autoimmune disorders, or receiving immunosuppressive therapy.

5.2. Collect blood samples at baseline and 3 months later.

* Use 10 mL EDTA tubes for blood collection.
* Label tubes with patient ID, date, and time of collection.
* Store tubes at room temperature and process within 24 hours.

5.3. Perform Treg and cytokine analyses as described in Protocols 2 and 3.

5.4. Compare Treg frequency, absolute count, and cytokine production between the ibrutinib-treated group and the control group using unpaired t-tests or Mann-Whitney U tests.

* Use statistical software (e.g., R, GraphPad Prism) to perform unpaired t-tests or Mann-Whitney U tests.
* Calculate p-values and report mean ± SD or median (IQR) for Treg frequency, absolute count, and cytokine production.

Note: The protocols above assume that the necessary laboratory equipment, reagents, and software are available. The experiment should be performed by trained personnel, and quality control measures should be implemented to ensure data accuracy and reproducibility.","```
   Patient_ID  Ibrutinib_Therapy  Blood_Sample_Volume_mL  Ficoll_Paque_Volume_mL  Anti_CD4_PE_μL  Anti_CD25_APC_μL  Anti_FoxP3_FITC_μL  CD4_Microbeads_μL  CD8_Microbeads_μL  Anti_CD3_CD28_Beads_μL  Treg_Frequency  Treg_Absolute_Count  IL_2_pg_mL  IFN_γ_pg_mL
0           1               1                  10.0                  10.0               10.0               10.0               10.0               10.0               10.0               10.0         0.123456         234.0         12.34         45.67
1           2               1                  12.0                  12.0               12.0               12.0               12.0               12.0               12.0               12.0         0.145678         256.0         15.67         56.78
2           3               1                  11.0                  11.0               11.0               11.0               11.0               11.0               11.0               11.0         0.134567         245.0         13.45         49.01
3           4               1                  10.5                  10.5               10.5               10.5               10.5               10.5               10.5               10.5         0.129876         239.0         12.98         47.65
4           5               1                  11.5                  11.5               11.5               11.5               11.5               11.5               11.5               11.5         0.141234         261.0         14.12         51.23
5           6               0                  10.0                  10.0               10.0               10.0               10.0               10.0               10.0               10.0         0.120987         229.0         12.09         43.21
6           7               1                  12.5                  12.5               12.5               12.5               12.5               12.5               12.5               12.5         0.152345         272.0         15.23         58.94
7           8               1                  11.2                  11.2               11.2               11.2               11.2               11.2               11.2               11.2         0.136789         251.0         13.67         50.12
8           9               1                  10.8                  10.8               10.8               10.8               10.8               10.8               10.8               10.8         0.132109         243.0         13.21         48.76
9          10               1                  11.8                  11.8               11.8               11.8               11.8               11.8               11.8               11.8         0.144321         265.0         14.43         52.15
10         11               0                  10.2                  10.2               10.2               10.2               10.2               10.2               10.2               10.2         0.124567         235.0         12.45         44.56
11         12               1                  12.2                  12.2               12.2               12.2               12.2               12.2               12.2               12.2         0.149876         281.0         14.98         60.12
12         13               1                  11.0                  11.0               11.0               11.0               11.0               11.0               11.0               11.0         0.139012         257.0         13.90         51.90
13         14               1                  10.9                  10.9               10.9               10.9               10.9               10.9               10.9               10.9         0.133456         247.0         13.34         49.34
14         15               1                  12.0                  12.0               12.0               12.0               12.0               12.0               12.0               12.0         0.151234         289.0         15.12         61.23
15         16               0                  10.5                  10.5               10.5               10.5               10.5               10.5               10.5               10.5         0.127890         241.0         12.78         46.12
16         17               1                  11.6                  11.6               11.6               11.6               11.6               11.6               11.6               11.6         0.142109         269.0         14.21         53.45
17         18               1                  10.7                  10.7               10.7               10.7               10.7               10.7               10.7               10.7         0.130987         253.0         13.09         48.21
18         19               1                  12.8                  12.8               12.8               12.8               12.8               12.8               12.8               12.8         0.154321         299.0         15.43         63.21
19         20               1                  11.4                  11.4               11.4               11.4               11.4               11.4               11.4               11.4         0.140654         263.0         14.06         52.63
20         21               0                  10.3                  10.3               10.3               10.3               10.3               10.3               10.3               10.3         0.125678         237.0         12.56         45.67
21         22               1                  12.1                  12.1               12.1               12.1               12.1               12.1               12.1               12.1         0.147890         275.0         14.78         59.01
22         23               1                  11.1                  11.1               11.1               11.1               11.1               11.1               11.1               11.1         0.138765         259.0         13.87         51.23
23         24               1                  10.6                  10.6               10.6               10.6               10.6               10.6               10.6               10.6         0.132109         249.0         13.21         48.76
24         25               1                  12.6                  12.6               12.6               12.6               12.6               12.6               12.6               12.6         0.153456         291.0         15.34         62.15
```",0.8786322221196815
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/cf40eaa33cdaad298ffeb91a7a477b03a1438eb5.summary'],"Does the reduction of immunoglobulin levels after B-cell depletion using rituximab in ME/CFS patients lead to a compensatory increase in BAFF production, thereby perpetuating the activated B-lymphocyte system and contributing to the persistence of ME/CFS symptoms?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove it. The hypothesis states that the reduction of immunoglobulin levels after B-cell depletion using rituximab in ME/CFS patients leads to a compensatory increase in BAFF production, thereby perpetuating the activated B-lymphocyte system and contributing to the persistence of ME/CFS symptoms.

**Experiment: ""Disproving the Compensatory BAFF Increase Hypothesis""**

**Objective:** To investigate whether the reduction of immunoglobulin levels after B-cell depletion using rituximab in ME/CFS patients leads to a compensatory increase in BAFF production, and if this increase contributes to the persistence of ME/CFS symptoms.

**Experimental Design:**

1. **Patient Selection:** Recruit a cohort of ME/CFS patients with elevated BAFF levels and low immunoglobulin levels, as identified by ELISA and flow cytometry analysis.
2. **Rituximab Treatment:** Administer rituximab to the patients to deplete B-cells and reduce immunoglobulin levels.
3. **BAFF Blockade:** Immediately after rituximab treatment, randomly assign patients to one of two groups:
	* **Treatment Group:** Receive a BAFF-blocking antibody or inhibitor to prevent potential compensatory BAFF increase.
	* **Control Group:** Receive a placebo treatment.
4. **Measurements:**
	* **BAFF Levels:** Measure BAFF levels using ELISA kits at baseline, after rituximab treatment, and at regular intervals (e.g., every 2 weeks) for 6 months.
	* **Immunoglobulin Levels:** Measure immunoglobulin levels using ELISA kits at baseline, after rituximab treatment, and at regular intervals (e.g., every 2 weeks) for 6 months.
	* **ME/CFS Symptoms:** Assess ME/CFS symptoms using a standardized clinical assessment tool (e.g., the Bell Disability Scale) at baseline, after rituximab treatment, and at regular intervals (e.g., every 2 weeks) for 6 months.
5. **Data Analysis:**
	* Compare BAFF levels between the treatment and control groups at each time point to determine if BAFF levels increase in the control group.
	* Compare immunoglobulin levels between the treatment and control groups at each time point to confirm that rituximab treatment reduces immunoglobulin levels.
	* Analyze the correlation between BAFF levels and ME/CFS symptoms in both groups to determine if changes in BAFF levels are associated with changes in symptoms.

**Expected Outcomes:**

* If the hypothesis is true, the control group should exhibit a compensatory increase in BAFF levels after rituximab treatment, which would be blocked in the treatment group. This increase in BAFF levels should be associated with persistent ME/CFS symptoms.
* If the hypothesis is false, there should be no significant difference in BAFF levels between the treatment and control groups, and ME/CFS symptoms should not be correlated with BAFF levels.

**Equipment and Resources:**

* ELISA kits for measuring BAFF and immunoglobulin levels
* Flow cytometer for immunophenotyping
* Clinical assessment tool for measuring ME/CFS symptoms (e.g., Bell Disability Scale)
* BAFF-blocking antibody or inhibitor
* Rituximab
* Placebo treatment
* Laboratory facilities and personnel for sample processing and analysis
* Statistical software for data analysis

**Timeline:**

* Patient recruitment and baseline measurements: 3 months
* Rituximab treatment and BAFF blockade: 1 month
* Follow-up measurements: 6 months
* Data analysis and manuscript preparation: 6 months

**Budget:**

* Patient recruitment and compensation: $100,000
* Rituximab and BAFF-blocking antibody/inhibitor: $200,000
* Laboratory equipment and supplies: $150,000
* Personnel and overhead: $300,000
* Total: $750,000

This experiment is designed to test the hypothesis and provide conclusive evidence for or against the compensatory BAFF increase hypothesis. If the results disprove the hypothesis, it would suggest that alternative mechanisms contribute to the persistence of ME/CFS symptoms after B-cell depletion.",85,"Here are the detailed, step-by-step protocols for the ""Disproving the Compensatory BAFF Increase Hypothesis"" experiment:

**Protocol 1: Patient Selection and Baseline Measurements**

1.1. Recruit patients:
	* Advertise the study through social media, patient organizations, and medical centers.
	* Screen potential patients using the following inclusion criteria:
		+ Diagnosis of ME/CFS according to the Fukuda or Canadian Consensus Criteria.
		+ Elevated BAFF levels (> 1000 pg/mL) as measured by ELISA.
		+ Low immunoglobulin levels (< 500 mg/dL) as measured by ELISA.
	* Obtain informed consent from eligible patients.

1.2. Collect baseline samples:
	* Draw 10 mL of whole blood from each patient into EDTA tubes.
	* Process the samples within 2 hours of collection.
	* Aliquot 1 mL of plasma for BAFF measurement and 1 mL for immunoglobulin measurement.
	* Store the aliquots at -80°C until analysis.

1.3. Perform baseline measurements:
	* Measure BAFF levels using a commercial ELISA kit (e.g., R&D Systems) according to the manufacturer's instructions.
	* Measure immunoglobulin levels using a commercial ELISA kit (e.g., Bethyl Laboratories) according to the manufacturer's instructions.
	* Assess ME/CFS symptoms using the Bell Disability Scale.

**Protocol 2: Rituximab Treatment and BAFF Blockade**

2.1. Administer rituximab:
	* Infuse 375 mg/m² of rituximab (Rituxan) intravenously over 4-6 hours.
	* Monitor patients for infusion reactions and manage accordingly.

2.2. Randomize patients to treatment or control groups:
	* Use a randomization software (e.g., Random.org) to assign patients to either the treatment group or control group.
	* Ensure that the randomization is stratified by age, sex, and disease severity.

2.3. Administer BAFF blockade or placebo:
	* For the treatment group, administer a BAFF-blocking antibody or inhibitor (e.g., belimumab) according to the manufacturer's instructions.
	* For the control group, administer a placebo treatment (e.g., saline injection).

**Protocol 3: Follow-up Measurements**

3.1. Schedule follow-up visits:
	* Schedule visits at 2, 4, 6, 8, 12, 16, 20, and 24 weeks after rituximab treatment.

3.2. Collect follow-up samples:
	* Draw 10 mL of whole blood from each patient into EDTA tubes at each follow-up visit.
	* Process the samples within 2 hours of collection.
	* Aliquot 1 mL of plasma for BAFF measurement and 1 mL for immunoglobulin measurement.
	* Store the aliquots at -80°C until analysis.

3.3. Perform follow-up measurements:
	* Measure BAFF levels using a commercial ELISA kit (e.g., R&D Systems) according to the manufacturer's instructions.
	* Measure immunoglobulin levels using a commercial ELISA kit (e.g., Bethyl Laboratories) according to the manufacturer's instructions.
	* Assess ME/CFS symptoms using the Bell Disability Scale.

**Protocol 4: Data Analysis**

4.1. Compare BAFF levels between groups:
	* Use a mixed-effects model to compare BAFF levels between the treatment and control groups at each time point.
	* Adjust for baseline BAFF levels and other potential confounders.

4.2. Compare immunoglobulin levels between groups:
	* Use a mixed-effects model to compare immunoglobulin levels between the treatment and control groups at each time point.
	* Adjust for baseline immunoglobulin levels and other potential confounders.

4.3. Analyze the correlation between BAFF levels and ME/CFS symptoms:
	* Use a linear regression model to analyze the correlation between BAFF levels and ME/CFS symptoms in both groups.
	* Adjust for potential confounders such as age, sex, and disease severity.

**Quality Control and Assurance**

* Use commercial ELISA kits with established quality control protocols.
* Perform duplicate measurements for 10% of samples to ensure accuracy.
* Use a flow cytometer with established quality control protocols for immunophenotyping.
* Train personnel on the use of equipment and protocols.
* Monitor and document temperature control, sample handling, and storage.

**Safety Monitoring**

* Monitor patients for infusion reactions, allergic reactions, and other adverse events.
* Report serious adverse events to the institutional review board and regulatory authorities.
* Have a plan in place for managing adverse events and withdrawing patients from the study if necessary.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately interpreted to test the compensatory BAFF increase hypothesis.","```
   Rituximab_Dose BAFF_Blockade_Dose Baseline_BAFF Baseline_Immunoglobulin Outcome
0           350.0             10.0       1200.0               400.0  Improved
1           375.0              5.0       1100.0               450.0  No_Change
2           400.0              7.5       1300.0               350.0  Worsened
3           325.0             12.5       1000.0               500.0  Improved
4           380.0              8.0       1250.0               420.0  No_Change
5           370.0              9.0       1150.0               480.0  Improved
6           390.0             11.0       1400.0               380.0  Worsened
7           360.0              6.0       1050.0               440.0  No_Change
8           385.0             10.5       1350.0               410.0  Improved
9           365.0              8.5       1200.0               460.0  No_Change
10          395.0             12.0       1450.0               390.0  Worsened
11          355.0              9.5       1100.0               430.0  Improved
12          375.0             11.5       1300.0               400.0  No_Change
13          380.0              7.0       1250.0               450.0  Improved
14          390.0             10.0       1400.0               420.0  Worsened
15          365.0              8.0       1150.0               480.0  No_Change
16          370.0             12.0       1350.0               410.0  Improved
17          385.0              9.5       1450.0               440.0  Worsened
18          360.0             11.0       1200.0               460.0  No_Change
19          375.0              8.5       1300.0               430.0  Improved
20          395.0             10.5       1400.0               400.0  Worsened
21          355.0              9.0       1100.0               450.0  Improved
22          380.0             11.5       1250.0               420.0  No_Change
23          390.0              7.5       1350.0               480.0  Worsened
24          365.0             10.0       1150.0               440.0  No_Change
```",0.22120414481634645
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/016e09bcab17c48268024aac13b10f82f2c2444d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/141778224422dc4bef33c1b75cb8d60e43cb1881.summary']","Does the regulation of mitochondrial function by Zfp318 in memory B cells influence the induction of αv-integrin-related non-canonical autophagy, thereby modulating the recallability of these cells?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the context from the two papers, I propose an experimental plan to test the hypothesis:

**Hypothesis:** Does the regulation of mitochondrial function by Zfp318 in memory B cells influence the induction of αv-integrin-related non-canonical autophagy, thereby modulating the recallability of these cells?

**Experimental Plan:**

**Objective:** To investigate whether Zfp318 regulates mitochondrial function in memory B cells, and whether this regulation affects αv-integrin-related non-canonical autophagy and recallability.

**Equipment and Reagents:**

* Memory B cells isolated from human tonsil or spleen
* Zfp318-deficient and sufficient mouse models
* RNA interference (RNAi) or CRISPR-Cas9 technology to knockdown Zfp318 expression
* Autophagy assays (e.g., LC3 lipidation, autophagosome formation)
* Mitochondrial membrane potential dye (e.g., TMRE)
* Flow cytometer
* Real-time PCR or RNA-seq
* αv-integrin antibodies
* Autophagy inducers (e.g., rapamycin)

**Experimental Design:**

**Step 1: Isolate and culture memory B cells**

* Isolate memory B cells from human tonsil or spleen and culture them in vitro.
* Use Zfp318-deficient and sufficient mouse models to validate the results.

**Step 2: Knockdown Zfp318 expression**

* Use RNAi or CRISPR-Cas9 technology to knockdown Zfp318 expression in memory B cells.

**Step 3: Measure mitochondrial function and autophagy**

* Measure mitochondrial membrane potential using TMRE staining and flow cytometry.
* Measure autophagy activation using autophagy assays (e.g., LC3 lipidation, autophagosome formation).
* Compare mitochondrial function and autophagy activation between Zfp318-deficient and sufficient memory B cells.

**Step 4: Investigate αv-integrin-related non-canonical autophagy**

* Use αv-integrin antibodies to investigate the role of αv-integrin in non-canonical autophagy.
* Measure the effect of Zfp318 knockdown on αv-integrin-related non-canonical autophagy.

**Step 5: Correlate mitochondrial function, autophagy, and recallability**

* Correlate mitochondrial membrane potential, autophagy activation, and recallability of memory B cells in response to antigen stimulation.
* Investigate whether Zfp318 regulation of mitochondrial function affects the recallability of memory B cells.

**Step 6: Validate the results**

* Validate the results using multiple approaches, such as using different autophagy inducers (e.g., rapamycin) and measuring the effect of Zfp318 knockdown on recallability.

**To disprove the hypothesis:**

* If Zfp318 knockdown does not affect αv-integrin-related non-canonical autophagy or recallability, it would suggest that Zfp318 regulation of mitochondrial function does not influence αv-integrin-related non-canonical autophagy and recallability.
* If Zfp318 knockdown affects autophagy but not recallability, it would suggest that Zfp318 regulation of mitochondrial function affects autophagy but not recallability.

**Timeline and Budget:**

* The experiment can be completed within 6-12 months.
* The budget will depend on the cost of reagents, equipment, and personnel. However, the experiment can be performed with a reasonable budget, as it builds upon existing methods and equipment.

This experimental plan aims to test the hypothesis by investigating the role of Zfp318 in regulating mitochondrial function, αv-integrin-related non-canonical autophagy, and recallability in memory B cells. By using a combination of molecular biology, cell biology, and immunology techniques, this experiment can provide valuable insights into the mechanisms underlying humoral immune memory.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Isolate and culture memory B cells**

1.1. Obtain human tonsil or spleen tissue from a reputable source (e.g., tissue bank or surgical discard).

1.2. Prepare a single-cell suspension of the tissue using a gentle dissociation method (e.g., mechanical disruption, enzymatic digestion).

1.3. Isolate memory B cells using a magnetic-activated cell sorting (MACS) system or fluorescence-activated cell sorting (FACS) with specific antibodies (e.g., CD27, CD38, IgD).

1.4. Culture the isolated memory B cells in a suitable medium (e.g., RPMI 1640, 10% FBS, 1% penicillin-streptomycin) at 37°C, 5% CO2.

1.5. Validate the purity of the isolated memory B cells using flow cytometry (e.g., CD27, CD38, IgD).

**Step 2: Knockdown Zfp318 expression**

2.1. Design and synthesize RNAi oligonucleotides or CRISPR-Cas9 guide RNAs targeting Zfp318.

2.2. Transfect the RNAi oligonucleotides or CRISPR-Cas9 plasmids into the memory B cells using a suitable transfection reagent (e.g., Lipofectamine, electroporation).

2.3. Incubate the transfected cells for 24-48 hours to allow for Zfp318 knockdown.

2.4. Validate the knockdown efficiency using real-time PCR or RNA-seq.

**Step 3: Measure mitochondrial function and autophagy**

3.1. Stain the memory B cells with TMRE (100 nM) for 30 minutes at 37°C to measure mitochondrial membrane potential.

3.2. Analyze the stained cells using flow cytometry (e.g., BD FACSCanto II) to determine the mitochondrial membrane potential.

3.3. Perform autophagy assays (e.g., LC3 lipidation, autophagosome formation) according to the manufacturer's instructions.

3.4. Compare the mitochondrial function and autophagy activation between Zfp318-deficient and sufficient memory B cells.

**Step 4: Investigate αv-integrin-related non-canonical autophagy**

4.1. Stain the memory B cells with αv-integrin antibodies (e.g., clone 17E6) for 30 minutes at 4°C.

4.2. Analyze the stained cells using flow cytometry to determine the expression of αv-integrin.

4.3. Measure the effect of Zfp318 knockdown on αv-integrin-related non-canonical autophagy using autophagy assays.

**Step 5: Correlate mitochondrial function, autophagy, and recallability**

5.1. Stimulate the memory B cells with antigen (e.g., tetanus toxoid) for 24-48 hours.

5.2. Measure the recallability of the memory B cells using a suitable assay (e.g., ELISPOT, flow cytometry).

5.3. Correlate the mitochondrial membrane potential, autophagy activation, and recallability of the memory B cells.

**Step 6: Validate the results**

6.1. Repeat the experiment using different autophagy inducers (e.g., rapamycin) to validate the results.

6.2. Measure the effect of Zfp318 knockdown on recallability using multiple approaches (e.g., ELISPOT, flow cytometry).

**To disprove the hypothesis:**

* If Zfp318 knockdown does not affect αv-integrin-related non-canonical autophagy or recallability, it would suggest that Zfp318 regulation of mitochondrial function does not influence αv-integrin-related non-canonical autophagy and recallability.
* If Zfp318 knockdown affects autophagy but not recallability, it would suggest that Zfp318 regulation of mitochondrial function affects autophagy but not recallability.

**Timeline and Budget:**

* The experiment can be completed within 6-12 months.
* The budget will depend on the cost of reagents, equipment, and personnel. However, the experiment can be performed with a reasonable budget, as it builds upon existing methods and equipment.

These detailed, step-by-step protocols should provide a clear guide for executing the experiment and testing the hypothesis.","```
   Tonsil_Tissue  CD27_Antibody  CD38_Antibody  IgD_Antibody  RNAi_Oligo  CRISPR_Cas9  Lipofectamine  TMRE  αv_Integrin_Antibody  Tetanus_Toxoid  Mitochondrial_Function  Autophagy  Recallability
0           0.5          10.0          5.0          2.0         20.0         10.0         5.0       100.0               5.0           10.0             0.8         0.4         0.6
1           0.7          12.0          6.0          3.0         25.0         12.0         6.0       120.0               6.0           12.0             0.9         0.5         0.7
2           0.3          8.0          4.0          1.0         15.0          8.0         4.0        90.0               4.0            8.0             0.6         0.3         0.5
3           0.9          15.0          7.0          4.0         30.0         15.0         7.0       150.0               7.0           15.0             1.0         0.6         0.8
4           0.4          9.0          5.0          2.0         20.0         10.0         5.0       110.0               5.0           10.0             0.7         0.4         0.6
5           0.6          11.0          6.0          3.0         22.0         11.0         6.0       130.0               6.0           11.0             0.8         0.5         0.7
6           0.8          14.0          7.0          4.0         28.0         14.0         7.0       140.0               7.0           14.0             0.9         0.6         0.8
7           0.2          7.0          3.0          1.0         12.0          7.0         3.0        80.0               3.0            7.0             0.5         0.3         0.5
8           0.5          10.0          5.0          2.0         20.0         10.0         5.0       100.0               5.0           10.0             0.7         0.4         0.6
9           0.9          16.0          8.0          5.0         32.0         16.0         8.0       160.0               8.0           16.0             1.0         0.7         0.9
10          0.3          8.0          4.0          1.0         15.0          8.0         4.0        90.0               4.0            8.0             0.6         0.3         0.5
11          0.7          13.0          6.0          3.0         26.0         13.0         6.0       130.0               6.0           13.0             0.8         0.5         0.7
12          0.4          9.0          5.0          2.0         21.0         10.0         5.0       110.0               5.0           10.0             0.7         0.4         0.6
13          0.6          12.0          6.0          3.0         24.0         12.0         6.0       120.0               6.0           12.0             0.8         0.5         0.7
14          0.8          15.0          7.0          4.0         30.0         15.0         7.0       150.0               7.0           15.0             0.9         0.6         0.8
15          0.2          6.0          3.0          1.0         10.0          6.0         3.0        80.0               3.0            6.0             0.5         0.3         0.5
16          0.5          11.0          5.0          2.0         22.0         11.0         5.0       110.0               5.0           11.0             0.7         0.4         0.6
17          0.9          17.0          8.0          5.0         34.0         17.0         8.0       170.0               8.0           17.0             1.0         0.7         0.9
18          0.3          7.0          4.0          1.0         13.0          7.0         4.0        90.0               4.0            7.0             0.6         0.3         0.5
19          0.7          14.0          6.0          3.0         28.0         14.0         6.0       140.0               6.0           14.0             0.8         0.5         0.7
20          0.4          9.0          5.0          2.0         20.0         10.0         5.0       100.0               5.0           10.0             0.7         0.4         0.6
21          0.6          13.0          6.0          3.0         26.0         13.0         6.0       130.0               6.0           13.0             0.8         0.5         0.7
22          0.8          16.0          7.0          4.0         32.0         16.0         7.0       160.0               7.0           16.0             0.9         0.6         0.8
23          0.2          5.0          3.0          1.0          9.0          5.0         3.0        70.0               3.0            5.0             0.5         0.3         0.5
24          0.5          10.0          5.0          2.0         20.0         10.0         5.0       100.0               5.0           10.0             0.7         0.4         0.6
```",0.9726702898722143
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f5e0a7dc1693cdf7f4dec5be6ecdda336b32d696.summary'],Does the regulation of mitochondrial function by immunoglobulin expression in the endoplasmic reticulum also influence the unfolded protein response and endoplasmic reticulum stress in B cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test this hypothesis, I'll outline a comprehensive experimental plan to investigate the relationship between immunoglobulin expression in the endoplasmic reticulum (ER), mitochondrial function, and the unfolded protein response (UPR) in B cells.

**Hypothesis:** The regulation of mitochondrial function by immunoglobulin expression in the ER also influences the UPR and ER stress in B cells.

**Experimental Approach:**

**Objective:** Design an experiment to disprove the hypothesis, thereby verifying its validity.

**Step 1: Cell Culture and Immunoglobulin Expression**

* Obtain B cell lines (e.g., Ramos or WEHI-231) and culture them in standard conditions.
* Use CRISPR-Cas9 gene editing to generate B cell lines with:
	+ Constitutive immunoglobulin expression in the ER (Ig-ER+).
	+ Knockout of immunoglobulin expression in the ER (Ig-ER-).
	+ Wild-type (WT) B cells as a control.

**Step 2: Mitochondrial Function Analysis**

* Measure mitochondrial function in each B cell line using:
	+ Seahorse XF96 Extracellular Flux Analyzer to assess oxygen consumption rate (OCR) and extracellular acidification rate (ECAR).
	+ Mitochondrial membrane potential (Δψm) analysis using JC-1 staining and flow cytometry.
	+ ATP production measurement using a bioluminescent assay.

**Step 3: Unfolded Protein Response (UPR) and ER Stress Analysis**

* Measure UPR and ER stress markers in each B cell line using:
	+ Western blotting for phosphorylated eIF2α (p-eIF2α), ATF4, and CHOP.
	+ Real-time PCR for XBP1s, ATF4, and CHOP mRNA levels.
	+ ER stress-induced apoptosis assessment using Annexin V and propidium iodide staining.

**Step 4: Co-Immunoprecipitation and Proximity Ligation Assay**

* Perform co-immunoprecipitation to investigate interactions between immunoglobulin and mitochondrial proteins (e.g., TOM20, TIM23) in Ig-ER+ and Ig-ER- B cells.
* Use proximity ligation assay (PLA) to visualize and quantify the interactions between immunoglobulin and mitochondrial proteins in situ.

**Step 5: Mitochondrial Dynamics and ER-Mitochondria Contact Sites**

* Use live-cell imaging (e.g., spinning disk confocal microscopy) to analyze mitochondrial dynamics (e.g., mitochondrial length, branching, and movement) in Ig-ER+ and Ig-ER- B cells.
* Investigate ER-mitochondria contact sites using electron microscopy (EM) and tomography.

**Step 6: Rescue Experiment**

* Transfect Ig-ER- B cells with an immunoglobulin expression vector to restore immunoglobulin expression in the ER.
* Repeat Steps 2-5 to assess the rescue of mitochondrial function, UPR, and ER stress.

**Step 7: Data Analysis and Interpretation**

* Compare the results from each B cell line to determine if immunoglobulin expression in the ER regulates mitochondrial function and influences the UPR and ER stress.
* Use statistical analysis (e.g., ANOVA, t-test) to determine significance.

**To Disprove the Hypothesis:**

* If the data show that immunoglobulin expression in the ER does not affect mitochondrial function, UPR, or ER stress, it would disprove the hypothesis.
* Alternatively, if the data reveal a correlation between immunoglobulin expression and mitochondrial function, but not with UPR or ER stress, it would also disprove the hypothesis.

**Unlimited Budget Considerations:**

* Utilize cutting-edge technologies, such as single-molecule localization microscopy (SMLM) or cryo-EM, to gain high-resolution insights into ER-mitochondria interactions and immunoglobulin-mitochondrial protein interactions.
* Employ advanced bioinformatics tools and machine learning algorithms to analyze large datasets and identify patterns that may not be apparent through traditional analysis methods.
* Collaborate with experts in mitochondrial biology, ER stress, and immunology to ensure a comprehensive understanding of the results and their implications.

By following this experimental plan, we can rigorously test the hypothesis and determine whether the regulation of mitochondrial function by immunoglobulin expression in the ER indeed influences the UPR and ER stress in B cells.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Culture and Immunoglobulin Expression**

1.1. Obtain B cell lines (e.g., Ramos or WEHI-231) from a reputable cell bank or laboratory.

1.2. Culture the B cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.3. Design and synthesize guide RNAs (gRNAs) targeting the immunoglobulin gene using a CRISPR-Cas9 design tool (e.g., CRISPR Design).

1.4. Transfect the gRNAs into the B cells using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.

1.5. Select and isolate single-cell clones using limiting dilution and antibiotic selection (e.g., puromycin).

1.6. Verify the knockout of immunoglobulin expression in the ER (Ig-ER-) using Western blotting and qRT-PCR.

1.7. Generate B cell lines with constitutive immunoglobulin expression in the ER (Ig-ER+) using a lentiviral vector expressing the immunoglobulin gene.

1.8. Verify the expression of immunoglobulin in the ER using Western blotting and immunofluorescence microscopy.

**Step 2: Mitochondrial Function Analysis**

2.1. Prepare B cell lines for Seahorse XF96 analysis by seeding 2 x 10^4 cells per well in XF96 cell culture microplates.

2.2. Measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using the Seahorse XF96 Extracellular Flux Analyzer according to the manufacturer's instructions.

2.3. Stain B cells with JC-1 dye (5 μM) for 30 minutes at 37°C to measure mitochondrial membrane potential (Δψm).

2.4. Analyze JC-1 staining using flow cytometry (e.g., BD FACSCanto II) and calculate the Δψm using the JC-1 fluorescence ratio (590 nm/529 nm).

2.5. Measure ATP production using a bioluminescent assay (e.g., ATP Bioluminescence Assay Kit) according to the manufacturer's instructions.

**Step 3: Unfolded Protein Response (UPR) and ER Stress Analysis**

3.1. Lyse B cells in RIPA buffer and perform Western blotting for phosphorylated eIF2α (p-eIF2α), ATF4, and CHOP using specific antibodies.

3.2. Perform real-time PCR (e.g., qRT-PCR) to measure XBP1s, ATF4, and CHOP mRNA levels using specific primers and probes.

3.3. Stain B cells with Annexin V and propidium iodide to assess ER stress-induced apoptosis using flow cytometry.

**Step 4: Co-Immunoprecipitation and Proximity Ligation Assay**

4.1. Lyse B cells in IP lysis buffer and perform co-immunoprecipitation using antibodies against immunoglobulin and mitochondrial proteins (e.g., TOM20, TIM23).

4.2. Analyze the immunoprecipitates using Western blotting and specific antibodies.

4.3. Perform proximity ligation assay (PLA) using the Duolink PLA kit according to the manufacturer's instructions.

4.4. Visualize and quantify the interactions between immunoglobulin and mitochondrial proteins using a confocal microscope (e.g., Zeiss LSM 880).

**Step 5: Mitochondrial Dynamics and ER-Mitochondria Contact Sites**

5.1. Prepare B cells for live-cell imaging by seeding 1 x 10^5 cells per well in a 35 mm glass-bottom dish.

5.2. Perform live-cell imaging using spinning disk confocal microscopy (e.g., Andor Revolution XD) to analyze mitochondrial dynamics (e.g., mitochondrial length, branching, and movement).

5.3. Fix B cells with 2.5% glutaraldehyde and 2% paraformaldehyde for electron microscopy (EM) analysis.

5.4. Perform EM and tomography to investigate ER-mitochondria contact sites using a transmission electron microscope (e.g., FEI Tecnai G2 Spirit).

**Step 6: Rescue Experiment**

6.1. Transfect Ig-ER- B cells with an immunoglobulin expression vector using a transfection reagent (e.g., Lipofectamine 3000).

6.2. Verify the restoration of immunoglobulin expression in the ER using Western blotting and immunofluorescence microscopy.

6.3. Repeat Steps 2-5 to assess the rescue of mitochondrial function, UPR, and ER stress.

**Step 7: Data Analysis and Interpretation**

7.1. Compare the results from each B cell line using statistical analysis (e.g., ANOVA, t-test) to determine significance.

7.2. Analyze the data to determine if immunoglobulin expression in the ER regulates mitochondrial function and influences the UPR and ER stress.

7.3. Interpret the results in the context of the hypothesis and discuss the implications for B cell biology and immunology.

**Unlimited Budget Considerations**

* Utilize single-molecule localization microscopy (SMLM) to gain high-resolution insights into ER-mitochondria interactions and immunoglobulin-mitochondrial protein interactions.
* Employ advanced bioinformatics tools and machine learning algorithms to analyze large datasets and identify patterns that may not be apparent through traditional analysis methods.
* Collaborate with experts in mitochondrial biology, ER stress, and immunology to ensure a comprehensive understanding of the results and their implications.

These detailed protocols should provide a clear and concise guide for executing the experimental plan and testing the hypothesis.",,0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d223ccbb2b2d251602991698fb7636a81fd362c2.summary'],"Does the relocation of derivative chromosome 11 to the nucleolus also lead to the epigenetic silencing of tumor suppressor genes, thereby contributing to the development of Mantle Cell Lymphoma?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll outline a comprehensive experimental plan to test the hypothesis, leveraging existing scientific methods and equipment. Given the unlimited budget, we can design a rigorous and thorough investigation.

**Hypothesis:** The relocation of derivative chromosome 11 to the nucleolus leads to the epigenetic silencing of tumor suppressor genes, contributing to the development of Mantle Cell Lymphoma (MCL).

**Experimental Plan:**

**Objective:** Investigate the relationship between derivative chromosome 11 relocation, epigenetic silencing of tumor suppressor genes, and MCL development.

**Step 1: Cell Line Establishment and Characterization**

1.1. Establish a panel of MCL cell lines with derivative chromosome 11 relocation (MCL-der11) and a control panel without relocation (MCL-wt).

1.2. Characterize the cell lines using:
	* Fluorescence in situ hybridization (FISH) to confirm derivative chromosome 11 relocation.
	* Whole-exome sequencing to identify genetic mutations.
	* RNA sequencing to profile gene expression.

**Step 2: Nucleolus Isolation and Chromosome 11 Localization**

2.1. Develop a nucleolus isolation protocol using density gradient centrifugation and nucleolus-specific antibodies.

2.2. Perform fluorescence microscopy to visualize and quantify the localization of derivative chromosome 11 in the nucleolus using:
	* Chromosome 11-specific probes (e.g., FISH).
	* Nucleolus-specific markers (e.g., fibrillarin, nucleolin).

**Step 3: Epigenetic Analysis**

3.1. Perform chromatin immunoprecipitation sequencing (ChIP-seq) to investigate histone modifications and chromatin accessibility at tumor suppressor gene loci in MCL-der11 and MCL-wt cells.

3.2. Analyze DNA methylation patterns at tumor suppressor gene promoters using:
	* Bisulfite sequencing.
	* Methylation-specific PCR.

**Step 4: Gene Expression Analysis**

4.1. Perform RNA sequencing to compare gene expression profiles between MCL-der11 and MCL-wt cells.

4.2. Validate the expression of tumor suppressor genes using:
	* Quantitative reverse transcription PCR (qRT-PCR).
	* Western blotting.

**Step 5: Functional Assays**

5.1. Perform cell proliferation and viability assays to assess the impact of derivative chromosome 11 relocation on MCL cell growth.

5.2. Conduct apoptosis assays to investigate the role of tumor suppressor genes in MCL-der11 cells.

**Step 6: In Vivo Validation**

6.1. Develop a xenograft model using MCL-der11 and MCL-wt cells in immunodeficient mice.

6.2. Monitor tumor growth and progression using:
	* Bioluminescence imaging.
	* Tumor volume measurements.

**Step 7: Data Integration and Statistical Analysis**

7.1. Integrate data from all experiments using bioinformatic tools (e.g., R, Python, Bioconductor).

7.2. Perform statistical analysis to identify correlations between derivative chromosome 11 relocation, epigenetic silencing, and MCL development.

**Additional Considerations:**

* Use of CRISPR-Cas9 genome editing to introduce derivative chromosome 11 relocation in MCL-wt cells to validate the hypothesis.
* Investigation of the role of nucleolar proteins in mediating epigenetic silencing.
* Exploration of potential therapeutic strategies to target epigenetic silencing in MCL.

This comprehensive experimental plan will provide a thorough understanding of the relationship between derivative chromosome 11 relocation, epigenetic silencing of tumor suppressor genes, and MCL development. The unlimited budget will enable the use of cutting-edge techniques and equipment, ensuring a rigorous and thorough investigation.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Line Establishment and Characterization**

**Protocol 1.1: Establishing MCL Cell Lines**

1. Obtain MCL patient samples or acquire established MCL cell lines from a reputable cell bank.
2. Culture cells in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.
3. Perform fluorescence-activated cell sorting (FACS) to isolate cells with derivative chromosome 11 relocation (MCL-der11) and without relocation (MCL-wt) using chromosome 11-specific probes.
4. Expand and maintain the sorted cells in culture for further characterization.

**Protocol 1.2: Characterization of MCL Cell Lines**

1. **FISH Analysis**
	* Fix cells with 4% paraformaldehyde and permeabilize with 0.5% Triton X-100.
	* Hybridize cells with chromosome 11-specific probes (e.g., LSI 11q22.3) and detect using a fluorescence microscope.
	* Capture images and analyze using FISH analysis software to confirm derivative chromosome 11 relocation.
2. **Whole-Exome Sequencing**
	* Extract genomic DNA from MCL-der11 and MCL-wt cells using a DNA extraction kit.
	* Prepare libraries for whole-exome sequencing using a commercial kit (e.g., Illumina TruSeq).
	* Sequence libraries on a next-generation sequencing platform (e.g., Illumina HiSeq).
	* Analyze data using bioinformatic tools (e.g., BWA, GATK) to identify genetic mutations.
3. **RNA Sequencing**
	* Extract total RNA from MCL-der11 and MCL-wt cells using a RNA extraction kit.
	* Prepare libraries for RNA sequencing using a commercial kit (e.g., Illumina TruSeq).
	* Sequence libraries on a next-generation sequencing platform (e.g., Illumina HiSeq).
	* Analyze data using bioinformatic tools (e.g., STAR, DESeq2) to profile gene expression.

**Step 2: Nucleolus Isolation and Chromosome 11 Localization**

**Protocol 2.1: Nucleolus Isolation**

1. Harvest MCL-der11 and MCL-wt cells and wash with PBS.
2. Resuspend cells in a hypotonic buffer (e.g., 10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2) and incubate for 10 minutes on ice.
3. Add a detergent (e.g., 0.5% NP-40) and incubate for 5 minutes on ice.
4. Centrifuge at 1,000 x g for 5 minutes to pellet nuclei.
5. Resuspend nuclei in a sucrose cushion (e.g., 2.2 M sucrose, 10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2) and centrifuge at 10,000 x g for 10 minutes.
6. Collect the nucleolus-enriched fraction and wash with PBS.

**Protocol 2.2: Chromosome 11 Localization**

1. **Fluorescence Microscopy**
	* Fix nucleolus-enriched fractions with 4% paraformaldehyde and permeabilize with 0.5% Triton X-100.
	* Hybridize with chromosome 11-specific probes (e.g., FISH) and nucleolus-specific markers (e.g., fibrillarin, nucleolin).
	* Detect using a fluorescence microscope and capture images.
	* Analyze images using image analysis software to quantify chromosome 11 localization in the nucleolus.

**Step 3: Epigenetic Analysis**

**Protocol 3.1: ChIP-Seq**

1. **Cross-Linking and Sonication**
	* Cross-link MCL-der11 and MCL-wt cells with 1% formaldehyde for 10 minutes.
	* Quench with 125 mM glycine and wash with PBS.
	* Sonicate chromatin to an average size of 200-500 bp using a sonication device (e.g., Covaris).
2. **ChIP**
	* Immunoprecipitate chromatin with antibodies against histone modifications (e.g., H3K27me3, H3K4me3) or chromatin accessibility markers (e.g., H3K27ac).
	* Wash and elute immunoprecipitated chromatin.
3. **Library Preparation and Sequencing**
	* Prepare libraries for ChIP-seq using a commercial kit (e.g., Illumina TruSeq).
	* Sequence libraries on a next-generation sequencing platform (e.g., Illumina HiSeq).
	* Analyze data using bioinformatic tools (e.g., MACS2, HOMER) to identify histone modifications and chromatin accessibility at tumor suppressor gene loci.

**Protocol 3.2: DNA Methylation Analysis**

1. **Bisulfite Sequencing**
	* Treat genomic DNA with bisulfite to convert unmethylated cytosines to uracils.
	* Amplify bisulfite-treated DNA using PCR and sequence using a next-generation sequencing platform (e.g., Illumina MiSeq).
	* Analyze data using bioinformatic tools (e.g., Bismark, MethPipe) to identify DNA methylation patterns at tumor suppressor gene promoters.
2. **Methylation-Specific PCR**
	* Design methylation-specific primers for tumor suppressor gene promoters.
	* Perform PCR using bisulfite-treated DNA and analyze products using agarose gel electrophoresis.

**Step 4: Gene Expression Analysis**

**Protocol 4.1: RNA Sequencing**

1. **Library Preparation and Sequencing**
	* Prepare libraries for RNA sequencing using a commercial kit (e.g., Illumina TruSeq).
	* Sequence libraries on a next-generation sequencing platform (e.g., Illumina HiSeq).
	* Analyze data using bioinformatic tools (e.g., STAR, DESeq2) to compare gene expression profiles between MCL-der11 and MCL-wt cells.

**Protocol 4.2: qRT-PCR and Western Blotting**

1. **qRT-PCR**
	* Extract total RNA from MCL-der11 and MCL-wt cells using a RNA extraction kit.
	* Perform qRT-PCR using gene-specific primers and a qRT-PCR kit (e.g., SYBR Green).
	* Analyze data using the 2^(-ΔΔCt) method to quantify gene expression.
2. **Western Blotting**
	* Extract protein from MCL-der11 and MCL-wt cells using a protein extraction kit.
	* Perform Western blotting using gene-specific antibodies and a Western blotting kit (e.g., ECL).
	* Analyze data using image analysis software to quantify protein expression.

**Step 5: Functional Assays**

**Protocol 5.1: Cell Proliferation and Viability Assays**

1. **Cell Proliferation Assay**
	* Seed MCL-der11 and MCL-wt cells in 96-well plates and incubate for 24-48 hours.
	* Add a cell proliferation reagent (e.g., MTT, BrdU) and incubate for 2-4 hours.
	* Measure absorbance or fluorescence using a plate reader.
2. **Cell Viability Assay**
	* Seed MCL-der11 and MCL-wt cells in 96-well plates and incubate for 24-48 hours.
	* Add a cell viability reagent (e.g., Annexin V, PI) and incubate for 15-30 minutes.
	* Analyze data using a flow cytometer or a plate reader.

**Protocol 5.2: Apoptosis Assays**

1. **Annexin V Staining**
	* Seed MCL-der11 and MCL-wt cells in 96-well plates and incubate for 24-48 hours.
	* Add Annexin V and PI and incubate for 15-30 minutes.
	* Analyze data using a flow cytometer.
2. **Caspase Assay**
	* Seed MCL-der11 and MCL-wt cells in 96-well plates and incubate for 24-48 hours.
	* Add a caspase substrate (e.g., DEVD-AMC) and incubate for 1-2 hours.
	* Measure fluorescence using a plate reader.

**Step 6: In Vivo Validation**

**Protocol 6.1: Xenograft Model**

1. **Cell Inoculation**
	* Inoculate MCL-der11 and MCL-wt cells into immunodeficient mice (e.g., NOD/SCID).
	* Monitor tumor growth and progression using bioluminescence imaging and tumor volume measurements.
2. **Bioluminescence Imaging**
	* Inject a bioluminescent substrate (e.g., luciferin) into mice and image using a bioluminescence imaging system.
	* Analyze data using image analysis software to quantify tumor growth.
3. **Tumor Volume Measurements**
	* Measure tumor volume using calipers or a tumor volume measurement system.
	* Analyze data using statistical software to quantify tumor growth.

**Step 7: Data Integration and Statistical Analysis**

**Protocol 7.1: Data Integration**

1. **Bioinformatic Tools**
	* Use bioinformatic tools (e.g., R, Python, Bioconductor) to integrate data from all experiments.
	* Perform data normalization, filtering, and feature selection as necessary.

**Protocol 7.2: Statistical Analysis**

1. **Statistical Software**
	* Use statistical software (e.g., R, Python, GraphPad Prism) to perform statistical analysis.
	* Perform hypothesis testing, regression analysis, and clustering analysis as necessary.
	* Analyze data to identify correlations between derivative chromosome 11 relocation, epigenetic silencing, and MCL development.

These detailed, step-by-step protocols should enable the execution of the experimental plan to investigate the relationship between derivative chromosome 11 relocation, epigenetic silencing of tumor suppressor genes, and MCL development.",,0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7cac85575b166c1dff01a42c98d5dcbbf815a186.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/152962205a0b362a2568b5b61b3c8bc72c0208a2.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d6c4c2850b4022c2ecb8c3702a361fd6782c828d.summary']",Does the sequential exposure of B cells to malaria-induced interferon-γ and TLR9 agonists enhance the generation of atypical memory B cells with improved humoral immunity against malaria?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! Here's a high-level experimental plan to test it:

**Hypothesis:** Sequential exposure of B cells to malaria-induced interferon-γ (IFN-γ) and TLR9 agonists enhances the generation of atypical memory B cells with improved humoral immunity against malaria.

**Experimental Approach:**

**Objective:** To investigate the effect of sequential exposure of B cells to IFN-γ and TLR9 agonists on the generation of atypical memory B cells and their humoral immune response against malaria.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate human B cells from peripheral blood mononuclear cells (PBMCs) using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
	* Culture B cells in vitro using RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine.
2. **Malaria-Induced IFN-γ Generation:**
	* Infect human PBMCs with Plasmodium falciparum (P. falciparum) parasites in vitro to induce IFN-γ production.
	* Collect supernatants from infected PBMC cultures and measure IFN-γ levels using ELISA or multiplex assays.
3. **TLR9 Agonist Preparation:**
	* Synthesize or obtain TLR9 agonists, such as CpG oligodeoxynucleotides (CpG ODNs), and verify their activity using reporter assays or immune cell stimulation.
4. **Sequential Exposure of B Cells:**
	* Divide B cells into four groups:
		+ Control (no treatment)
		+ IFN-γ only (exposed to malaria-induced IFN-γ supernatants)
		+ TLR9 agonist only (exposed to CpG ODNs)
		+ Sequential exposure (exposed to IFN-γ supernatants followed by CpG ODNs)
	* Incubate B cells with the respective treatments for 24-48 hours, with the sequential exposure group receiving IFN-γ supernatants for 24 hours followed by CpG ODNs for an additional 24 hours.
5. **Atypical Memory B Cell Analysis:**
	* Use flow cytometry to analyze the expression of surface markers associated with atypical memory B cells, such as CD27-, CD21-, and CD11c+, on treated B cells.
	* Perform functional assays, like ELISPOT or antibody secretion assays, to evaluate the humoral immune response of atypical memory B cells against malaria antigens.
6. **Antibody Production and Functional Assays:**
	* Collect supernatants from treated B cells and measure antibody production using ELISA or multiplex assays.
	* Perform functional assays, such as antibody-dependent cellular inhibition (ADCI) or growth inhibition assays, to evaluate the efficacy of antibodies against P. falciparum parasites.
7. **In Vivo Validation:**
	* Adoptively transfer treated B cells into humanized mice or non-human primates and challenge them with P. falciparum parasites.
	* Monitor parasitemia, antibody responses, and protection against malaria infection in these animals.

**Expected Outcomes:**

* Enhanced generation of atypical memory B cells with improved humoral immunity against malaria in the sequential exposure group.
* Increased antibody production and functional activity against P. falciparum parasites in the sequential exposure group.
* Protection against malaria infection in animals receiving adoptively transferred B cells from the sequential exposure group.

**Resources and Equipment:**

* Cell culture facilities and equipment (incubators, centrifuges, pipettes, etc.)
* Flow cytometry and cell sorting instruments (e.g., BD FACSAria, Beckman Coulter MoFlo)
* ELISA and multiplex assay platforms (e.g., Bio-Plex, Luminex)
* In vitro infection and culture systems for P. falciparum parasites
* Animal facilities and equipment for in vivo experiments (e.g., humanized mice or non-human primates)
* Reagents and consumables (e.g., antibodies, cytokines, TLR9 agonists, cell culture media)

**Timeline:**

* Cell isolation and culture: 2 weeks
* Malaria-induced IFN-γ generation: 2 weeks
* TLR9 agonist preparation: 1 week
* Sequential exposure and B cell analysis: 4 weeks
* Antibody production and functional assays: 4 weeks
* In vivo validation: 12 weeks
* Data analysis and manuscript preparation: 6 months

**Budget:**

* Personnel: 5 researchers (post-docs, graduate students, and technicians) for 2 years
* Reagents and consumables: $500,000 per year for 2 years
* Equipment and infrastructure: $1,000,000 (one-time investment)
* Animal facilities and maintenance: $200,000 per year for 2 years
* Travel and training: $50,000 per year for 2 years

Total budget: $2,450,000 over 2 years.",92,"Here are the detailed, step-by-step protocols for each section of the experimental plan:

**Cell Isolation and Culture:**

1.1. **PBMC Isolation:**

* Collect 10 mL of peripheral blood from healthy donors in EDTA-coated tubes.
* Dilute the blood 1:1 with PBS and layer it onto 15 mL of Ficoll-Paque PLUS in a 50 mL conical tube.
* Centrifuge at 400 x g for 30 minutes at room temperature.
* Collect the PBMC layer and wash it twice with PBS.
* Resuspend the PBMCs in 10 mL of RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

1.2. **B Cell Isolation:**

* Use magnetic bead-based separation or fluorescence-activated cell sorting (FACS) to isolate human B cells from PBMCs.
* For magnetic bead-based separation:
	+ Add 100 μL of B cell isolation beads (e.g., CD19 MicroBeads) to 10^7 PBMCs in 100 μL of PBS.
	+ Incubate for 15 minutes at 4°C.
	+ Wash the cells twice with PBS and resuspend in 10 mL of RPMI-1640 medium.
* For FACS:
	+ Stain PBMCs with anti-CD19-APC and anti-CD3-FITC antibodies.
	+ Sort CD19+CD3- cells using a flow cytometer (e.g., BD FACSAria).

1.3. **B Cell Culture:**

* Culture isolated B cells in 24-well plates at a density of 10^6 cells/mL in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

**Malaria-Induced IFN-γ Generation:**

2.1. **P. falciparum Infection:**

* Infect 10^6 PBMCs with P. falciparum parasites (e.g., 3D7 strain) at a multiplicity of infection (MOI) of 1:1.
* Incubate the infected PBMCs in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2 for 24-48 hours.

2.2. **IFN-γ Measurement:**

* Collect supernatants from infected PBMC cultures and measure IFN-γ levels using ELISA or multiplex assays (e.g., Bio-Plex, Luminex).
* Use a standard curve to quantify IFN-γ concentrations.

**TLR9 Agonist Preparation:**

3.1. **CpG ODN Synthesis:**

* Synthesize CpG ODNs (e.g., ODN 2006) using a DNA synthesizer.
* Verify the purity and concentration of the CpG ODNs using HPLC and UV spectroscopy.

3.2. **TLR9 Agonist Verification:**

* Stimulate human PBMCs with CpG ODNs (1 μM) for 24 hours.
* Measure IL-12p40 production using ELISA or multiplex assays to verify TLR9 agonist activity.

**Sequential Exposure of B Cells:**

4.1. **B Cell Division:**

* Divide B cells into four groups: control (no treatment), IFN-γ only, TLR9 agonist only, and sequential exposure.
* Use 10^6 B cells per group.

4.2. **IFN-γ Treatment:**

* Add 100 ng/mL of malaria-induced IFN-γ supernatants to the IFN-γ only and sequential exposure groups.
* Incubate for 24 hours at 37°C, 5% CO2.

4.3. **TLR9 Agonist Treatment:**

* Add 1 μM of CpG ODNs to the TLR9 agonist only and sequential exposure groups.
* Incubate for an additional 24 hours at 37°C, 5% CO2.

**Atypical Memory B Cell Analysis:**

5.1. **Flow Cytometry:**

* Stain treated B cells with anti-CD27-PE, anti-CD21-FITC, and anti-CD11c-APC antibodies.
* Analyze the expression of surface markers using a flow cytometer (e.g., BD FACSAria).

5.2. **Functional Assays:**

* Perform ELISPOT or antibody secretion assays to evaluate the humoral immune response of atypical memory B cells against malaria antigens.

**Antibody Production and Functional Assays:**

6.1. **Antibody Production:**

* Collect supernatants from treated B cells and measure antibody production using ELISA or multiplex assays.

6.2. **Functional Assays:**

* Perform ADCI or growth inhibition assays to evaluate the efficacy of antibodies against P. falciparum parasites.

**In Vivo Validation:**

7.1. **B Cell Transfer:**

* Adoptively transfer 10^6 treated B cells into humanized mice or non-human primates.

7.2. **P. falciparum Challenge:**

* Challenge the animals with P. falciparum parasites (e.g., 10^4 parasites per animal).

7.3. **Monitoring:**

* Monitor parasitemia, antibody responses, and protection against malaria infection in the animals.

These detailed protocols should provide a clear guide for executing the experimental plan.","```
   PBMCs  Ficoll-Paque  RPMI-1640  FBS  Penicillin-Streptomycin  L-Glutamine  B Cell Isolation Beads  CD19-APC  CD3-FITC  P. falciparum  IFN-γ  CpG ODNs  Outcome
0    10.0         15.0      10.0  10.0                1.0           1.0                100.0      1.0      1.0        1.0   100.0      1.0  0.85
1     9.0         14.0       9.0   9.0                0.9           0.9                 90.0      0.9      0.9        0.9    90.0      0.9  0.82
2    11.0         16.0      11.0  11.0               1.1           1.1                110.0      1.1      1.1        1.1   110.0      1.1  0.88
3     8.0         13.0       8.0   8.0                0.8           0.8                 80.0      0.8      0.8        0.8    80.0      0.8  0.79
4    10.5         15.5      10.5  10.5               1.05          1.05               105.0      1.05      1.05       1.05  105.0      1.05  0.86
5     9.5         14.5       9.5   9.5                0.95          0.95                95.0      0.95      0.95       0.95   95.0      0.95  0.83
6    10.0         15.0      10.0  10.0                1.0           1.0                100.0      1.0      1.0        1.0   100.0      1.0  0.85
7     8.5         13.5       8.5   8.5                0.85          0.85                85.0      0.85      0.85       0.85   85.0      0.85  0.81
8    11.5         16.5      11.5  11.5               1.15          1.15               115.0      1.15      1.15       1.15  115.0      1.15  0.90
9     9.0         14.0       9.0   9.0                0.9           0.9                 90.0      0.9      0.9        0.9    90.0      0.9  0.82
10   10.0         15.0      10.0  10.0                1.0           1.0                100.0      1.0      1.0        1.0   100.0      1.0  0.85
11    8.0         13.0       8.0   8.0                0.8           0.8                 80.0      0.8      0.8        0.8    80.0      0.8  0.79
12   10.5         15.5      10.5  10.5               1.05          1.05               105.0      1.05      1.05       1.05  105.0      1.05  0.86
13    9.5         14.5       9.5   9.5                0.95          0.95                95.0      0.95      0.95       0.95   95.0      0.95  0.83
14   10.0         15.0      10.0  10.0                1.0           1.0                100.0      1.0      1.0        1.0   100.0      1.0  0.85
15    8.5         13.5       8.5   8.5                0.85          0.85                85.0      0.85      0.85       0.85   85.0      0.85  0.81
16   11.0         16.0      11.0  11.0               1.1           1.1                110.0      1.1      1.1        1.1   110.0      1.1  0.88
17    9.0         14.0       9.0   9.0                0.9           0.9                 90.0      0.9      0.9        0.9    90.0      0.9  0.82
18   10.0         15.0      10.0  10.0                1.0           1.0                100.0      1.0      1.0        1.0   100.0      1.0  0.85
19    8.0         13.0       8.0   8.0                0.8           0.8                 80.0      0.8      0.8        0.8    80.0      0.8  0.79
20   10.5         15.5      10.5  10.5               1.05          1.05               105.0      1.05      1.05       1.05  105.0      1.05  0.86
21    9.5         14.5       9.5   9.5                0.95          0.95                95.0      0.95      0.95       0.95   95.0      0.95  0.83
22   10.0         15.0      10.0  10.0                1.0           1.0                100.0      1.0      1.0        1.0   100.0      1.0  0.85
23    8.5         13.5       8.5   8.5                0.85          0.85                85.0      0.85      0.85       0.85   85.0      0.85  0.81
24   11.5         16.5      11.5  11.5               1.15          1.15               115.0      1.15      1.15       1.15  115.0      1.15  0.90
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/d472a105591d0ed81a12f881ee8534d81f8a82af.summary'],"Does the sialic acid binding activity of Siglec-G modulate the expression of CD24 on B-1a cells, thereby influencing their immunoregulatory function in sepsis?",,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! Here's a comprehensive experimental plan to test the hypothesis:

**Hypothesis:** Does the sialic acid binding activity of Siglec-G modulate the expression of CD24 on B-1a cells, thereby influencing their immunoregulatory function in sepsis?

**Experimental Approach:**

**Objective 1: Characterize Siglec-G expression and sialic acid binding activity on B-1a cells**

1. **Cell isolation and purification**: Isolate B-1a cells from mouse spleens using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) based on surface markers (e.g., CD19, CD20, CD43, and CD24).
2. **Siglec-G expression analysis**: Perform quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting to determine Siglec-G mRNA and protein expression levels in B-1a cells.
3. **Sialic acid binding assay**: Use a sialic acid-conjugated fluorescent probe (e.g., Neu5Ac-FITC) to assess Siglec-G-mediated sialic acid binding on B-1a cells by flow cytometry.

**Objective 2: Investigate the effect of Siglec-G on CD24 expression on B-1a cells**

1. **Siglec-G knockdown/knockout**: Use CRISPR-Cas9 genome editing or RNA interference (RNAi) to generate Siglec-G-deficient B-1a cells.
2. **CD24 expression analysis**: Analyze CD24 expression on Siglec-G-deficient B-1a cells using flow cytometry and qRT-PCR.
3. **Siglec-G overexpression**: Use lentiviral vectors to overexpress Siglec-G in B-1a cells and assess CD24 expression.

**Objective 3: Examine the immunoregulatory function of B-1a cells in sepsis**

1. **Sepsis model establishment**: Establish a mouse model of sepsis using cecal ligation and puncture (CLP) or lipopolysaccharide (LPS) injection.
2. **B-1a cell adoptive transfer**: Adoptively transfer Siglec-G-deficient or Siglec-G-overexpressing B-1a cells into septic mice.
3. **Immune response analysis**: Monitor immune responses, including cytokine production (e.g., IL-10, TNF-α), immune cell infiltration, and bacterial clearance, in septic mice receiving B-1a cells with modified Siglec-G expression.

**Objective 4: Investigate the mechanistic link between Siglec-G, CD24, and immunoregulation**

1. **Co-culture experiments**: Co-culture B-1a cells with immune cells (e.g., T cells, macrophages) and assess the impact of Siglec-G and CD24 on immune cell interactions and cytokine production.
2. **Signaling pathway analysis**: Investigate the signaling pathways involved in Siglec-G-mediated CD24 regulation using phospho-protein arrays, Western blotting, or RNA sequencing.

**Additional considerations:**

* Use appropriate controls, including wild-type B-1a cells, Siglec-G-deficient B-1a cells, and Siglec-G-overexpressing B-1a cells, to ensure the specificity of the results.
* Perform experiments in triplicate to ensure reproducibility and statistical significance.
* Utilize advanced flow cytometry and imaging techniques (e.g., confocal microscopy, super-resolution microscopy) to visualize Siglec-G and CD24 expression on B-1a cells.
* Consider using human B-1a cells or humanized mouse models to increase the translational relevance of the study.

With an unlimited budget, this experimental plan can be executed using state-of-the-art equipment and techniques, ensuring a comprehensive understanding of the role of Siglec-G in modulating CD24 expression and immunoregulatory function in B-1a cells during sepsis.",92,"Here are the detailed, step-by-step protocols for each objective:

**Objective 1: Characterize Siglec-G expression and sialic acid binding activity on B-1a cells**

**Protocol 1.1: Cell isolation and purification**

1.1.1. Obtain mouse spleens from a reputable supplier or breed mice in-house.
1.1.2. Prepare a single-cell suspension from the spleens using a gentle dissociation buffer (e.g., PBS with 2% FBS and 1 mM EDTA).
1.1.3. Filter the cell suspension through a 40-μm cell strainer to remove debris and clumps.
1.1.4. Stain the cells with fluorescently labeled antibodies against CD19, CD20, CD43, and CD24 (e.g., PE-conjugated anti-CD19, FITC-conjugated anti-CD20, APC-conjugated anti-CD43, and PerCP-conjugated anti-CD24).
1.1.5. Perform fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) to isolate B-1a cells based on the surface markers.
1.1.6. Collect the sorted B-1a cells in a sterile tube and wash them twice with PBS.

**Protocol 1.2: Siglec-G expression analysis**

1.2.1. Extract total RNA from the isolated B-1a cells using a RNA extraction kit (e.g., TRIzol).
1.2.2. Perform quantitative reverse transcription polymerase chain reaction (qRT-PCR) using a Siglec-G-specific primer set and a housekeeping gene (e.g., GAPDH) as an internal control.
1.2.3. Analyze the qRT-PCR data using a software (e.g., Prism) to determine the relative expression levels of Siglec-G mRNA.
1.2.4. Perform Western blotting using a Siglec-G-specific antibody and a housekeeping protein (e.g., β-actin) as a loading control.
1.2.5. Analyze the Western blot data using a software (e.g., ImageJ) to determine the relative expression levels of Siglec-G protein.

**Protocol 1.3: Sialic acid binding assay**

1.3.1. Prepare a sialic acid-conjugated fluorescent probe (e.g., Neu5Ac-FITC) according to the manufacturer's instructions.
1.3.2. Incubate the isolated B-1a cells with the sialic acid-conjugated fluorescent probe for 30 minutes at 4°C.
1.3.3. Wash the cells twice with PBS to remove excess probe.
1.3.4. Analyze the cells using flow cytometry to assess Siglec-G-mediated sialic acid binding.
1.3.5. Gate on the B-1a cell population and measure the mean fluorescence intensity (MFI) of the sialic acid-conjugated fluorescent probe.

**Objective 2: Investigate the effect of Siglec-G on CD24 expression on B-1a cells**

**Protocol 2.1: Siglec-G knockdown/knockout**

2.1.1. Design and synthesize CRISPR-Cas9 guide RNAs targeting the Siglec-G gene.
2.1.2. Transfect the guide RNAs into B-1a cells using a transfection reagent (e.g., Lipofectamine).
2.1.3. Select for Siglec-G-deficient cells using a selection marker (e.g., puromycin).
2.1.4. Verify the knockout using Western blotting and qRT-PCR.

**Protocol 2.2: CD24 expression analysis**

2.2.1. Stain the Siglec-G-deficient B-1a cells with a fluorescently labeled antibody against CD24 (e.g., PE-conjugated anti-CD24).
2.2.2. Analyze the cells using flow cytometry to assess CD24 expression.
2.2.3. Extract total RNA from the Siglec-G-deficient B-1a cells and perform qRT-PCR to analyze CD24 mRNA expression.

**Protocol 2.3: Siglec-G overexpression**

2.3.1. Design and clone a lentiviral vector expressing Siglec-G.
2.3.2. Transduce B-1a cells with the lentiviral vector using a transduction reagent (e.g., polybrene).
2.3.3. Select for Siglec-G-overexpressing cells using a selection marker (e.g., puromycin).
2.3.4. Verify the overexpression using Western blotting and qRT-PCR.
2.3.5. Analyze CD24 expression on Siglec-G-overexpressing B-1a cells using flow cytometry and qRT-PCR.

**Objective 3: Examine the immunoregulatory function of B-1a cells in sepsis**

**Protocol 3.1: Sepsis model establishment**

3.1.1. Establish a mouse model of sepsis using cecal ligation and puncture (CLP) or lipopolysaccharide (LPS) injection.
3.1.2. Monitor the mice for signs of sepsis (e.g., weight loss, fever, lethargy).

**Protocol 3.2: B-1a cell adoptive transfer**

3.2.1. Prepare Siglec-G-deficient or Siglec-G-overexpressing B-1a cells for adoptive transfer.
3.2.2. Inject the B-1a cells into the septic mice via tail vein injection.
3.2.3. Monitor the mice for signs of sepsis and immune responses.

**Protocol 3.3: Immune response analysis**

3.3.1. Collect blood and tissue samples from the septic mice.
3.3.2. Analyze cytokine production (e.g., IL-10, TNF-α) using ELISA or multiplex assays.
3.3.3. Analyze immune cell infiltration using flow cytometry or immunohistochemistry.
3.3.4. Analyze bacterial clearance using CFU assays.

**Objective 4: Investigate the mechanistic link between Siglec-G, CD24, and immunoregulation**

**Protocol 4.1: Co-culture experiments**

4.1.1. Co-culture B-1a cells with immune cells (e.g., T cells, macrophages) in a 1:1 ratio.
4.1.2. Analyze cytokine production (e.g., IL-10, TNF-α) using ELISA or multiplex assays.
4.1.3. Analyze immune cell interactions using flow cytometry or immunofluorescence microscopy.

**Protocol 4.2: Signaling pathway analysis**

4.2.1. Perform phospho-protein arrays or Western blotting to analyze signaling pathways involved in Siglec-G-mediated CD24 regulation.
4.2.2. Analyze RNA sequencing data to identify differentially expressed genes involved in the signaling pathways.

**Additional considerations**

* Perform all experiments in triplicate to ensure reproducibility and statistical significance.
* Use appropriate controls, including wild-type B-1a cells, Siglec-G-deficient B-1a cells, and Siglec-G-overexpressing B-1a cells, to ensure the specificity of the results.
* Utilize advanced flow cytometry and imaging techniques (e.g., confocal microscopy, super-resolution microscopy) to visualize Siglec-G and CD24 expression on B-1a cells.
* Consider using human B-1a cells or humanized mouse models to increase the translational relevance of the study.","```
   Spleen Weight (mg)  FBS (%)  EDTA (mM)  CD19 Antibody (μg)  CD20 Antibody (μg)  CD43 Antibody (μg)  CD24 Antibody (μg)  Siglec-G Primer (pmol)  GAPDH Primer (pmol)  Neu5Ac-FITC (μg)  Siglec-G CRISPR (pmol)  Puromycin (μg)  CD24 Antibody (μg)  Siglec-G Lentivirus (pfu)  Polybrene (μg)  CLP/LPS Dose  B-1a Cell Dose (10^6)  Outcome
0             100.0       2.0       1.0            1.0             1.0             1.0             1.0             10.0             10.0             10.0             10.0             1.0             1.0             10.0             1.0             1.0  Siglec-G expressed
1             120.0       2.5       1.2            1.2             1.2             1.2             1.2             12.0             12.0             12.0             12.0             1.2             1.2             12.0             1.2             1.2  Siglec-G expressed
2              80.0       1.5       0.8            0.8             0.8             0.8             0.8              8.0              8.0              8.0              8.0             0.8             0.8              8.0             0.8             0.8  Siglec-G expressed
3             110.0       2.2       1.1            1.1             1.1             1.1             1.1             11.0             11.0             11.0             11.0             1.1             1.1             11.0             1.1             1.1  Siglec-G expressed
4              90.0       1.8       0.9            0.9             0.9             0.9             0.9              9.0              9.0              9.0              9.0             0.9             0.9              9.0             0.9             0.9  Siglec-G expressed
5             130.0       2.8       1.4            1.4             1.4             1.4             1.4             14.0             14.0             14.0             14.0             1.4             1.4             14.0             1.4             1.4  Siglec-G expressed
6              70.0       1.2       0.6            0.6             0.6             0.6             0.6              6.0              6.0              6.0              6.0             0.6             0.6              6.0             0.6             0.6  Siglec-G expressed
7             140.0       3.0       1.5            1.5             1.5             1.5             1.5             15.0             15.0             15.0             15.0             1.5             1.5             15.0             1.5             1.5  Siglec-G expressed
8             160.0       3.2       1.6            1.6             1.6             1.6             1.6             16.0             16.0             16.0             16.0             1.6             1.6             16.0             1.6             1.6  Siglec-G expressed
9              60.0       1.0       0.4            0.4             0.4             0.4             0.4              4.0              4.0              4.0              4.0             0.4             0.4              4.0             0.4             0.4  Siglec-G expressed
10            170.0       3.5       1.7            1.7             1.7             1.7             1.7             17.0             17.0             17.0             17.0             1.7             1.7             17.0             1.7             1.7  Siglec-G expressed
11            180.0       3.8       1.8            1.8             1.8             1.8             1.8             18.0             18.0             18.0             18.0             1.8             1.8             18.0             1.8             1.8  Siglec-G expressed
12             50.0       0.8       0.2            0.2             0.2             0.2             0.2              2.0              2.0              2.0              2.0             0.2             0.2              2.0             0.2             0.2  Siglec-G expressed
13            190.0       4.0       1.9            1.9             1.9             1.9             1.9             19.0             19.0             19.0             19.0             1.9             1.9             19.0             1.9             1.9  Siglec-G expressed
14            200.0       4.2       2.0            2.0             2.0             2.0             2.0             20.0             20.0             20.0             20.0             2.0             2.0             20.0             2.0             2.0  Siglec-G expressed
15             40.0       0.6       0.1            0.1             0.1             0.1             0.1              1.0              1.0              1.0              1.0             0.1             0.1              1.0             0.1             0.1  Siglec-G expressed
16            210.0       4.5       2.1            2.1             2.1             2.1             2.1             21.0             21.0             21.0             21.0             2.1             2.1             21.0             2.1             2.1  Siglec-G expressed
17            220.0       4.8       2.2            2.2             2.2             2.2             2.2             22.0             22.0             22.0             22.0             2.2             2.2             22.0             2.2             2.2  Siglec-G expressed
18             30.0       0.4       0.0            0.0             0.0             0.0             0.0              0.0              0.0              0.0              0.0             0.0             0.0              0.0             0.0             0.0  No Siglec-G expression
19            230.0       5.0       2.3            2.3             2.3             2.3             2.3             23.0             23.0             23.0             23.0             2.3             2.3             23.0             2.3             2.3  Siglec-G expressed
20            240.0       5.2       2.4            2.4             2.4             2.4             2.4             24.0             24.0             24.0             24.0             2.4             2.4             24.0             2.4             2.4  Siglec-G expressed
21             20.0       0.2       0.0            0.0             0.0             0.0             0.0              0.0              0.0              0.0              0.0             0.0             0.0              0.0             0.0             0.0  No Siglec-G expression
22            250.0       5.5       2.5            2.5             2.5             2.5             2.5             25.0             25.0             25.0             25.0             2.5             2.5             25.0             2.5             2.5  Siglec-G expressed
23             10.0       0.0       0.0            0.0             0.0             0.0             0.0              0.0              0.0              0.0              0.0             0.0             0.0              0.0             0.0             0.0  No Siglec-G expression
24             0.0       0.0       0.0            0.0             0.0             0.0             0.0              0.0              0.0              0.0              0.0             0.0             0.0              0.0             0.0             0.0  No Siglec-G expression
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/df0699cdf9f10b88207d239dbd7dd55821bc16e3.summary'],"Does the simultaneous deletion of TRAF2 and TRAF3 lead to a synergistic enhancement of antibody class switch recombination in the absence of co-stimulation, resulting in a more robust and diverse antibody response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Synergistic Enhancement of Antibody Class Switch Recombination by Simultaneous Deletion of TRAF2 and TRAF3 in the Absence of Co-stimulation

**Objective:** To determine if the simultaneous deletion of TRAF2 and TRAF3 leads to a synergistic enhancement of antibody class switch recombination (CSR) in the absence of co-stimulation, resulting in a more robust and diverse antibody response.

**Experimental Design:**

1. **Mouse Model:** Generate TRAF2 and TRAF3 double-knockout (DKO) mice using CRISPR-Cas9 gene editing.
2. **B Cell Isolation:** Isolate B cells from the spleens of DKO mice and wild-type (WT) mice.
3. **Stimulation:** Stimulate B cells with anti-IgM antibody (to mimic BCR stimulation) in the absence of co-stimulation (e.g., CD40L or BAFF).
4. **CSR Analysis:** Analyze CSR using flow cytometry or PCR to detect class-switched antibodies (e.g., IgG1, IgG2a, IgE).
5. **Antibody Diversity Analysis:** Analyze the diversity of the antibody response using techniques such as next-generation sequencing (NGS) or spectratyping.
6. **Control Groups:** Include WT B cells stimulated with anti-IgM antibody in the presence or absence of co-stimulation as controls.

**Expected Outcomes:**

* DKO B cells will exhibit enhanced CSR and a more diverse antibody response compared to WT B cells in the absence of co-stimulation.
* The simultaneous deletion of TRAF2 and TRAF3 will lead to a synergistic enhancement of CSR.

**Equipment and Resources:**

* CRISPR-Cas9 gene editing system
* Mouse colony maintenance
* Flow cytometer
* PCR machine
* NGS or spectratyping equipment
* Anti-IgM antibody
* Co-stimulatory molecules (CD40L or BAFF)

**Timeline:** 6-9 months

**Budget:** Moderate (dependent on the cost of CRISPR-Cas9 gene editing, mouse colony maintenance, and NGS or spectratyping equipment)

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of TRAF2 and TRAF3 in Antibody Class Switch Recombination in the Presence of Co-stimulation

**Objective:** To determine if the simultaneous deletion of TRAF2 and TRAF3 has no effect on antibody class switch recombination in the presence of co-stimulation, contradicting the original hypothesis.

**Experimental Design:**

1. **Mouse Model:** Use the same TRAF2 and TRAF3 DKO mice as in the previous experiment.
2. **B Cell Isolation:** Isolate B cells from the spleens of DKO mice and WT mice.
3. **Stimulation:** Stimulate B cells with anti-IgM antibody and co-stimulatory molecules (CD40L or BAFF) to mimic BCR and co-receptor signaling.
4. **CSR Analysis:** Analyze CSR using flow cytometry or PCR to detect class-switched antibodies (e.g., IgG1, IgG2a, IgE).
5. **Antibody Diversity Analysis:** Analyze the diversity of the antibody response using techniques such as NGS or spectratyping.
6. **Control Groups:** Include WT B cells stimulated with anti-IgM antibody and co-stimulatory molecules as controls.

**Expected Outcomes:**

* DKO B cells will exhibit similar CSR and antibody diversity compared to WT B cells in the presence of co-stimulation.
* The simultaneous deletion of TRAF2 and TRAF3 will have no effect on CSR in the presence of co-stimulation.

**Equipment and Resources:**

* Same as the previous experiment

**Timeline:** 3-6 months

**Budget:** Moderate (dependent on the cost of mouse colony maintenance and NGS or spectratyping equipment)

By performing these experiments, we can test the original hypothesis and attempt to disprove it, providing a more comprehensive understanding of the role of TRAF2 and TRAF3 in antibody class switch recombination.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol 1: Generation of TRAF2 and TRAF3 Double-Knockout (DKO) Mice**

1.1. Design guide RNAs (gRNAs) specific to the TRAF2 and TRAF3 genes using online tools (e.g., CRISPR Design) or consult with a bioinformatics expert.

1.2. Prepare the CRISPR-Cas9 gene editing system according to the manufacturer's instructions.

1.3. Microinject the gRNAs and Cas9 enzyme into fertilized mouse eggs using a microinjection apparatus.

1.4. Transfer the microinjected eggs to pseudopregnant female mice.

1.5. Allow the mice to develop and breed to generate F1 offspring.

1.6. Genotype the F1 offspring using PCR and sequencing to identify mice with homozygous deletions of TRAF2 and TRAF3.

**Protocol 2: B Cell Isolation**

2.1. Euthanize TRAF2 and TRAF3 DKO mice and wild-type (WT) mice using a CO2 chamber or cervical dislocation.

2.2. Remove the spleens from the mice and place them in a petri dish containing ice-cold PBS.

2.3. Crush the spleens using a glass homogenizer or a gentleMACS Dissociator to release the cells.

2.4. Filter the cell suspension through a 70-μm cell strainer to remove debris.

2.5. Centrifuge the cell suspension at 300 x g for 5 minutes to pellet the cells.

2.6. Resuspend the cells in 1 mL of PBS and count the cells using a hemocytometer or an automated cell counter.

2.7. Isolate B cells using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) with anti-CD19 or anti-CD20 antibodies.

**Protocol 3: Stimulation of B Cells**

3.1. Resuspend 1 x 10^6 B cells in 1 mL of RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 50 μM β-mercaptoethanol.

3.2. Add 10 μg/mL of anti-IgM antibody to the cell suspension to mimic BCR stimulation.

3.3. Incubate the cells at 37°C, 5% CO2 for 48 hours.

**Protocol 4: CSR Analysis**

4.1. Harvest the cells and stain them with fluorescently labeled antibodies against IgG1, IgG2a, and IgE.

4.2. Analyze the cells using flow cytometry to detect class-switched antibodies.

4.3. Alternatively, extract RNA from the cells and perform PCR to detect class-switched antibodies.

**Protocol 5: Antibody Diversity Analysis**

5.1. Extract RNA from the cells and perform next-generation sequencing (NGS) or spectratyping to analyze the diversity of the antibody response.

**Protocol 6: Control Groups**

6.1. Stimulate WT B cells with anti-IgM antibody in the presence or absence of co-stimulation (CD40L or BAFF) as controls.

6.2. Analyze CSR and antibody diversity in the control groups using the same protocols as above.

**Experiment to Disprove the Hypothesis:**

**Protocol 1-3: Same as above**

**Protocol 4: Stimulation of B Cells with Co-stimulation**

4.1. Resuspend 1 x 10^6 B cells in 1 mL of RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 50 μM β-mercaptoethanol.

4.2. Add 10 μg/mL of anti-IgM antibody and 10 ng/mL of CD40L or BAFF to the cell suspension to mimic BCR and co-receptor signaling.

4.3. Incubate the cells at 37°C, 5% CO2 for 48 hours.

**Protocol 5-6: Same as above**

Note: The protocols above assume a moderate level of expertise in molecular biology, cell culture, and flow cytometry. It is essential to follow proper laboratory protocols, including sterile technique, to ensure the integrity of the experiments. Additionally, the protocols may need to be adapted to specific laboratory settings and equipment.","```
   TRAF2_gRNA  TRAF3_gRNA  Cas9  Mouse_Eggs  Spleen_Weight  B_Cell_Count  Anti_IgM  CD40L/BAFF  CSR_IgG1  CSR_IgG2a  CSR_IgE  Antibody_Diversity
0           20          15    0.5          10         0.25        1e+06       10.0         0.0       0.35       0.20       0.10           0.80
1           25          20    0.6          12         0.30        1.2e+06       12.0         0.0       0.40       0.25       0.15           0.85
2           18          12    0.4          11         0.28        1e+06       11.0         0.0       0.30       0.20       0.10           0.75
3           22          18    0.5          13         0.32        1.3e+06       13.0         0.0       0.45       0.30       0.20           0.90
4           20          15    0.5          10         0.25        1e+06       10.0         5.0       0.50       0.35       0.25           0.95
5           25          20    0.6          12         0.30        1.2e+06       12.0         5.0       0.55       0.40       0.30           0.98
6           18          12    0.4          11         0.28        1e+06       11.0         5.0       0.45       0.30       0.20           0.92
7           22          18    0.5          13         0.32        1.3e+06       13.0         5.0       0.60       0.45       0.35           0.99
8           20          15    0.5          10         0.25        1e+06       10.0         0.0       0.35       0.20       0.10           0.80
9           25          20    0.6          12         0.30        1.2e+06       12.0         0.0       0.40       0.25       0.15           0.85
10          18          12    0.4          11         0.28        1e+06       11.0         0.0       0.30       0.20       0.10           0.75
11          22          18    0.5          13         0.32        1.3e+06       13.0         0.0       0.45       0.30       0.20           0.90
12          20          15    0.5          10         0.25        1e+06       10.0         5.0       0.50       0.35       0.25           0.95
13          25          20    0.6          12         0.30        1.2e+06       12.0         5.0       0.55       0.40       0.30           0.98
14          18          12    0.4          11         0.28        1e+06       11.0         5.0       0.45       0.30       0.20           0.92
15          22          18    0.5          13         0.32        1.3e+06       13.0         5.0       0.60       0.45       0.35           0.99
16          20          15    0.5          10         0.25        1e+06       10.0         0.0       0.35       0.20       0.10           0.80
17          25          20    0.6          12         0.30        1.2e+06       12.0         0.0       0.40       0.25       0.15           0.85
18          18          12    0.4          11         0.28        1e+06       11.0         0.0       0.30       0.20       0.10           0.75
19          22          18    0.5          13         0.32        1.3e+06       13.0         0.0       0.45       0.30       0.20           0.90
20          20          15    0.5          10         0.25        1e+06       10.0         5.0       0.50       0.35       0.25           0.95
21          25          20    0.6          12         0.30        1.2e+06       12.0         5.0       0.55       0.40       0.30           0.98
22          18          12    0.4          11         0.28        1e+06       11.0         5.0       0.45       0.30       0.20           0.92
23          22          18    0.5          13         0.32        1.3e+06       13.0         5.0       0.60       0.45       0.35           0.99
24          20          15    0.5          10         0.25        1e+06       10.0         0.0       0.35       0.20       0.10           0.80
```",0.6115651066755703
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0b26f7d06842f30bfd513a2a9735cdb89b912094.summary'],Does the simultaneous detection of intracellular epitopes and transcripts at the single-cell level using QuRIE-seq reveal a previously unknown feedback loop between JAK1 and BCR signaling that is modulated by Ibrutinib in Burkitt lymphoma cells?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'll break down the experimental plan to test and potentially disprove it.

**Hypothesis:** The simultaneous detection of intracellular epitopes and transcripts at the single-cell level using QuRIE-seq reveals a previously unknown feedback loop between JAK1 and BCR signaling that is modulated by Ibrutinib in Burkitt lymphoma cells.

**Experimental Plan:**

**Objective:** Design an experiment to test and potentially disprove the hypothesis, utilizing existing scientific methods and equipment, with an unlimited budget.

**Step 1: Cell Culture and Treatment**

* Obtain Burkitt lymphoma cell lines (e.g., Raji, Daudi) and culture them in appropriate media.
* Treat cells with Ibrutinib (a BTK inhibitor) at various concentrations (e.g., 0, 1, 10, 100 nM) for 24-48 hours to modulate BCR signaling.
* Use a control group without Ibrutinib treatment.

**Step 2: QuRIE-seq Analysis**

* Perform QuRIE-seq (Quantitative RNA In Situ Expression sequencing) on the treated and control cells to detect intracellular epitopes and transcripts at the single-cell level.
* Use a QuRIE-seq platform (e.g., 10x Genomics) to generate high-throughput, single-cell RNA sequencing data.

**Step 3: Data Analysis and Integration**

* Analyze QuRIE-seq data using bioinformatic tools (e.g., Cell Ranger, Seurat) to identify differentially expressed genes and pathways between Ibrutinib-treated and control cells.
* Integrate the QuRIE-seq data with existing knowledge of JAK1 and BCR signaling pathways to identify potential interactions and feedback loops.

**Step 4: Validation and Verification**

* Validate the QuRIE-seq results using orthogonal methods, such as:
	+ Western blotting or immunofluorescence to detect protein expression and localization of JAK1, BCR, and downstream targets.
	+ qRT-PCR or RNA FISH to validate transcript expression.
* Verify the feedback loop by perturbing JAK1 or BCR signaling using CRISPR-Cas9 genome editing, RNAi, or small molecule inhibitors, and assessing the effects on the other pathway.

**Step 5: Disprove the Hypothesis**

To disprove the hypothesis, we will design an experiment to test the following:

* **Alternative hypothesis:** Ibrutinib does not modulate a feedback loop between JAK1 and BCR signaling in Burkitt lymphoma cells.
* **Experimental approach:**
	+ Use a JAK1-specific inhibitor (e.g., Ruxolitinib) and a BCR-specific inhibitor (e.g., Ibrutinib) to perturb each pathway independently.
	+ Analyze the effects of each inhibitor on the other pathway using QuRIE-seq, Western blotting, and qRT-PCR.
	+ If the data show no evidence of a feedback loop between JAK1 and BCR signaling, it would disprove the original hypothesis.

**Additional Considerations:**

* Use multiple Burkitt lymphoma cell lines and primary patient samples to ensure the results are not cell line-specific.
* Perform experiments in triplicate to ensure reproducibility.
* Consider using single-cell RNA sequencing with protein detection (e.g., CITE-seq) to further validate the results.

By following this experimental plan, we can thoroughly test and potentially disprove the hypothesis, providing valuable insights into the regulation of JAK1 and BCR signaling in Burkitt lymphoma cells.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Cell Culture and Treatment**

1.1. Obtain Burkitt lymphoma cell lines (e.g., Raji, Daudi) from a reputable cell bank (e.g., ATCC) and store them in a -80°C freezer.

1.2. Thaw the cells according to the supplier's instructions and culture them in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine in a 37°C, 5% CO2 incubator.

1.3. Passage the cells every 3-4 days to maintain a healthy and exponentially growing culture.

1.4. Prepare Ibrutinib stock solutions by dissolving the inhibitor in DMSO to a final concentration of 10 mM. Store the stock solutions at -20°C.

1.5. Treat the cells with Ibrutinib at various concentrations (0, 1, 10, 100 nM) by adding the appropriate volume of the stock solution to the culture medium. Mix well and incubate for 24-48 hours.

1.6. Use a control group without Ibrutinib treatment by adding an equal volume of DMSO to the culture medium.

1.7. Harvest the cells by centrifugation at 300 x g for 5 minutes and wash them twice with PBS.

**Step 2: QuRIE-seq Analysis**

2.1. Prepare the cells for QuRIE-seq analysis by fixing them in 4% paraformaldehyde (PFA) for 10 minutes at room temperature.

2.2. Permeabilize the cells with 0.1% Triton X-100 in PBS for 10 minutes at room temperature.

2.3. Wash the cells twice with PBS and resuspend them in a QuRIE-seq buffer (e.g., 10x Genomics) according to the manufacturer's instructions.

2.4. Perform QuRIE-seq analysis using a 10x Genomics platform according to the manufacturer's instructions.

2.5. Generate high-throughput, single-cell RNA sequencing data using the 10x Genomics pipeline.

**Step 3: Data Analysis and Integration**

3.1. Analyze the QuRIE-seq data using Cell Ranger (10x Genomics) to generate a count matrix of gene expression levels for each cell.

3.2. Perform dimensionality reduction using PCA or t-SNE to visualize the single-cell data.

3.3. Identify differentially expressed genes between Ibrutinib-treated and control cells using Seurat (R package) with a false discovery rate (FDR) < 0.05.

3.4. Integrate the QuRIE-seq data with existing knowledge of JAK1 and BCR signaling pathways using pathway analysis tools (e.g., Reactome, KEGG).

3.5. Identify potential interactions and feedback loops between JAK1 and BCR signaling pathways using network analysis tools (e.g., Cytoscape).

**Step 4: Validation and Verification**

4.1. Validate the QuRIE-seq results using Western blotting to detect protein expression and localization of JAK1, BCR, and downstream targets.

4.1.1. Lyse the cells in RIPA buffer and separate the proteins by SDS-PAGE.

4.1.2. Transfer the proteins to a PVDF membrane and probe with specific antibodies against JAK1, BCR, and downstream targets.

4.1.3. Detect the proteins using chemiluminescence or fluorescence.

4.2. Validate the QuRIE-seq results using immunofluorescence to detect protein localization.

4.2.1. Fix the cells in 4% PFA and permeabilize them with 0.1% Triton X-100.

4.2.2. Stain the cells with specific antibodies against JAK1, BCR, and downstream targets.

4.2.3. Visualize the proteins using confocal microscopy.

4.3. Validate the QuRIE-seq results using qRT-PCR to detect transcript expression.

4.3.1. Extract RNA from the cells using a RNA extraction kit (e.g., Qiagen).

4.3.2. Perform qRT-PCR using specific primers against JAK1, BCR, and downstream targets.

4.3.3. Analyze the data using the ΔΔCt method.

4.4. Verify the feedback loop by perturbing JAK1 or BCR signaling using CRISPR-Cas9 genome editing, RNAi, or small molecule inhibitors.

4.4.1. Design guide RNAs or siRNAs targeting JAK1 or BCR and transfect them into the cells using a transfection reagent (e.g., Lipofectamine).

4.4.2. Analyze the effects of the perturbation on the other pathway using QuRIE-seq, Western blotting, and qRT-PCR.

**Step 5: Disprove the Hypothesis**

5.1. Design an experiment to test the alternative hypothesis: Ibrutinib does not modulate a feedback loop between JAK1 and BCR signaling in Burkitt lymphoma cells.

5.2. Use a JAK1-specific inhibitor (e.g., Ruxolitinib) and a BCR-specific inhibitor (e.g., Ibrutinib) to perturb each pathway independently.

5.3. Analyze the effects of each inhibitor on the other pathway using QuRIE-seq, Western blotting, and qRT-PCR.

5.4. If the data show no evidence of a feedback loop between JAK1 and BCR signaling, it would disprove the original hypothesis.

**Additional Considerations**

* Perform experiments in triplicate to ensure reproducibility.
* Use multiple Burkitt lymphoma cell lines and primary patient samples to ensure the results are not cell line-specific.
* Consider using single-cell RNA sequencing with protein detection (e.g., CITE-seq) to further validate the results.

By following these detailed, step-by-step protocols, the experiment can be executed with precision and accuracy, ensuring the reproducibility and validity of the results.","```
   Ibrutinib_concentration  FBS_concentration  L_glutamine_concentration  outcome
0                    0.0               10.0                    1.0  negative
1                    1.0               10.0                    1.0  negative
2                   10.0               10.0                    1.0  positive
3                  100.0               10.0                    1.0  positive
4                    0.0               15.0                    1.0  negative
5                    1.0               15.0                    1.0  negative
6                   10.0               15.0                    1.0  positive
7                  100.0               15.0                    1.0  positive
8                    0.0               10.0                    0.5  negative
9                    1.0               10.0                    0.5  negative
10                   10.0               10.0                    0.5  positive
11                  100.0               10.0                    0.5  positive
12                   0.0               15.0                    0.5  negative
13                   1.0               15.0                    0.5  negative
14                  10.0               15.0                    0.5  positive
15                  100.0               15.0                    0.5  positive
16                   0.0               10.0                    1.5  negative
17                   1.0               10.0                    1.5  negative
18                  10.0               10.0                    1.5  positive
19                  100.0               10.0                    1.5  positive
20                   0.0               15.0                    1.5  negative
21                   1.0               15.0                    1.5  negative
22                  10.0               15.0                    1.5  positive
23                  100.0               15.0                    1.5  positive
24                   0.0               12.0                    1.0  negative
```",0.22195832355032905
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/03766d62c89b16ce463e4a0587118ca77e90c107.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/84f1c2b90bd8841c66566117647d73793bbc802e.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/21e339bfbe4e768afdbc03af688dc7e63cc88969.summary']",Does the simultaneous downregulation of HERC1 and HERC2 in hematopoietic stem cells lead to the development of resistance to tyrosine kinase inhibitors in Chronic Myeloid Leukemia?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A well-crafted hypothesis! Let's design an experiment to test it.

**Hypothesis:** Simultaneous downregulation of HERC1 and HERC2 in hematopoietic stem cells leads to the development of resistance to tyrosine kinase inhibitors in Chronic Myeloid Leukemia (CML).

**Experimental Plan:**

**Objective:** To investigate whether the simultaneous downregulation of HERC1 and HERC2 in hematopoietic stem cells contributes to the development of resistance to tyrosine kinase inhibitors in CML.

**Experimental Design:**

1. **Cell Culture:**
	* Obtain human CML cell lines (e.g., K562) and hematopoietic stem cells (HSCs) from healthy donors.
	* Culture cells in appropriate media and maintain them in a controlled environment.
2. **HERC1 and HERC2 Downregulation:**
	* Use lentiviral vectors to deliver shRNAs specifically targeting HERC1 and HERC2 to HSCs.
	* Validate the knockdown efficiency using qRT-PCR and Western blotting.
3. **Tyrosine Kinase Inhibitor (TKI) Treatment:**
	* Treat HSCs with a TKI (e.g., imatinib) at a concentration that inhibits BCR-ABL1 activity.
	* Monitor cell viability and proliferation using MTT assays and flow cytometry.
4. **Resistance Development:**
	* Continuously culture HSCs with TKI for several passages to allow for potential resistance development.
	* Monitor cell viability, proliferation, and BCR-ABL1 activity using Western blotting and qRT-PCR.
5. **Control Groups:**
	* Include control groups with:
		+ Non-targeting shRNA (scrambled sequence) to account for off-target effects.
		+ HERC1 or HERC2 single knockdown to assess individual contributions.
		+ Wild-type HSCs without shRNA or TKI treatment.
6. **Data Analysis:**
	* Compare the growth rates, viability, and BCR-ABL1 activity between the experimental and control groups.
	* Analyze the expression of HERC1, HERC2, and BCR-ABL1 using qRT-PCR and Western blotting.

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on showing that HERC1 and HERC2 downregulation does not lead to TKI resistance in CML.

**Modified Experimental Design:**

1. **HERC1 and HERC2 Overexpression:**
	* Use lentiviral vectors to overexpress HERC1 and HERC2 in HSCs.
	* Validate the overexpression using qRT-PCR and Western blotting.
2. **TKI Treatment:**
	* Treat HSCs with a TKI (e.g., imatinib) at a concentration that inhibits BCR-ABL1 activity.
	* Monitor cell viability and proliferation using MTT assays and flow cytometry.
3. **Resistance Development:**
	* Continuously culture HSCs with TKI for several passages to allow for potential resistance development.
	* Monitor cell viability, proliferation, and BCR-ABL1 activity using Western blotting and qRT-PCR.

**Rationale:**

If the hypothesis is true, overexpressing HERC1 and HERC2 should prevent or delay the development of TKI resistance in CML cells. If we observe that HERC1 and HERC2 overexpression does not affect TKI resistance, it would suggest that the simultaneous downregulation of HERC1 and HERC2 is not the primary cause of TKI resistance in CML.

**Budget and Timeframe:**

This experiment can be completed within 6-9 months with a moderate budget. The estimated costs include:

* Cell lines and reagents: $5,000 - $10,000
* Lentiviral vector construction and production: $3,000 - $5,000
* qRT-PCR and Western blotting reagents: $2,000 - $3,000
* Cell culture and maintenance: $5,000 - $10,000
* Personnel and overheads: $10,000 - $20,000

Total estimated budget: $25,000 - $48,000

This experiment is designed to be feasible within a reasonable timeframe and budget, while providing valuable insights into the role of HERC1 and HERC2 in TKI resistance in CML.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture**

1.1. Obtain human CML cell lines (e.g., K562) and hematopoietic stem cells (HSCs) from healthy donors.

* Source: Obtain cells from a reputable cell bank or collect them from healthy donors with informed consent.
* Storage: Store cells in liquid nitrogen or at -80°C until use.

1.2. Culture cells in appropriate media and maintain them in a controlled environment.

* Media: Use RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine for K562 cells. For HSCs, use StemPro-34 SFM medium supplemented with 1% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Incubation: Incubate cells at 37°C, 5% CO2, and 95% humidity.
* Cell density: Maintain cells at a density of 1-2 x 10^5 cells/mL.

**Protocol 2: HERC1 and HERC2 Downregulation**

2.1. Design and construct lentiviral vectors carrying shRNAs specifically targeting HERC1 and HERC2.

* Design: Use online tools (e.g., RNAi Designer) to design shRNA sequences targeting HERC1 and HERC2.
* Construction: Clone shRNA sequences into a lentiviral vector (e.g., pLKO.1) using standard molecular biology techniques.

2.2. Produce lentiviral particles.

* Transfection: Transfect HEK293T cells with the lentiviral vector, packaging plasmid, and envelope plasmid using a transfection reagent (e.g., Lipofectamine 2000).
* Harvest: Harvest viral supernatant 48-72 hours post-transfection and filter through a 0.45 μm filter.

2.3. Infect HSCs with lentiviral particles.

* Infection: Infect HSCs with lentiviral particles at a multiplicity of infection (MOI) of 10-20 in the presence of 8 μg/mL polybrene.
* Incubation: Incubate cells for 24-48 hours to allow for viral integration.

2.4. Validate the knockdown efficiency using qRT-PCR and Western blotting.

* qRT-PCR: Extract RNA from infected cells and perform qRT-PCR using HERC1 and HERC2-specific primers.
* Western blotting: Extract protein from infected cells and perform Western blotting using HERC1 and HERC2-specific antibodies.

**Protocol 3: Tyrosine Kinase Inhibitor (TKI) Treatment**

3.1. Treat HSCs with a TKI (e.g., imatinib) at a concentration that inhibits BCR-ABL1 activity.

* Concentration: Use a concentration of 1-5 μM imatinib, which is known to inhibit BCR-ABL1 activity.
* Incubation: Incubate cells with imatinib for 24-48 hours.

3.2. Monitor cell viability and proliferation using MTT assays and flow cytometry.

* MTT assay: Perform MTT assays according to the manufacturer's instructions to measure cell viability.
* Flow cytometry: Stain cells with propidium iodide and analyze using flow cytometry to measure cell proliferation.

**Protocol 4: Resistance Development**

4.1. Continuously culture HSCs with TKI for several passages to allow for potential resistance development.

* Passaging: Passage cells every 3-4 days to maintain a density of 1-2 x 10^5 cells/mL.
* TKI treatment: Continue to treat cells with imatinib at the same concentration as in Protocol 3.1.

4.2. Monitor cell viability, proliferation, and BCR-ABL1 activity using Western blotting and qRT-PCR.

* Western blotting: Perform Western blotting to measure BCR-ABL1 activity.
* qRT-PCR: Perform qRT-PCR to measure HERC1, HERC2, and BCR-ABL1 expression.

**Protocol 5: Control Groups**

5.1. Include control groups with:

* Non-targeting shRNA (scrambled sequence) to account for off-target effects.
* HERC1 or HERC2 single knockdown to assess individual contributions.
* Wild-type HSCs without shRNA or TKI treatment.

**Protocol 6: Data Analysis**

6.1. Compare the growth rates, viability, and BCR-ABL1 activity between the experimental and control groups.

* Statistical analysis: Perform statistical analysis (e.g., t-test, ANOVA) to compare the data between groups.
* Graphical representation: Represent the data graphically using bar charts, line graphs, or scatter plots.

**Protocol 7: Experiment to Disprove the Hypothesis**

7.1. Overexpress HERC1 and HERC2 in HSCs using lentiviral vectors.

* Design: Use online tools (e.g., VectorBuilder) to design overexpression constructs for HERC1 and HERC2.
* Construction: Clone overexpression constructs into a lentiviral vector (e.g., pLenti-CMV) using standard molecular biology techniques.

7.2. Validate the overexpression using qRT-PCR and Western blotting.

* qRT-PCR: Extract RNA from infected cells and perform qRT-PCR using HERC1 and HERC2-specific primers.
* Western blotting: Extract protein from infected cells and perform Western blotting using HERC1 and HERC2-specific antibodies.

7.3. Treat HSCs with a TKI (e.g., imatinib) at a concentration that inhibits BCR-ABL1 activity.

* Concentration: Use a concentration of 1-5 μM imatinib, which is known to inhibit BCR-ABL1 activity.
* Incubation: Incubate cells with imatinib for 24-48 hours.

7.4. Monitor cell viability, proliferation, and BCR-ABL1 activity using Western blotting and qRT-PCR.

* Western blotting: Perform Western blotting to measure BCR-ABL1 activity.
* qRT-PCR: Perform qRT-PCR to measure HERC1, HERC2, and BCR-ABL1 expression.

These detailed protocols should provide a clear guide for executing the experiment and collecting data to test the hypothesis.","```
   K562_cells  HSCs  FBS  Penicillin_Streptomycin  L_Glutamine  HERC1_shRNA  HERC2_shRNA  Imatinib  Outcome
0        10000   5000   10%                1%           1%          10         10       2.5  Resistant
1        15000   7500   12%                1.2%         1.2%         15         15       3.5  Sensitive
2         5000   2500    8%                0.8%         0.8%          5          5       1.5  Resistant
3        12000   6000   11%                1.1%         1.1%         12         12       2.2  Sensitive
4        18000   9000   14%                1.4%         1.4%         18         18       4.5  Resistant
5         8000   4000    9%                0.9%         0.9%          8          8       2.8  Sensitive
6        14000   7000   13%                1.3%         1.3%         14         14       3.2  Resistant
7         6000   3000   10%                1%           1%          6          6       2.1  Sensitive
8        16000   8000   15%                1.5%         1.5%         16         16       4.8  Resistant
9         4000   2000    7%                0.7%         0.7%          4          4       1.8  Sensitive
10       10000   5000   10%                1%           1%         10         10       2.5  Resistant
11       13000   6500   12%                1.2%         1.2%         13         13       3.8  Sensitive
12        9000   4500   11%                1.1%         1.1%          9          9       2.9  Resistant
13       11000   5500   10%                1%           1%         11         11       2.6  Sensitive
14       17000   8500   16%                1.6%         1.6%         17         17       5.1  Resistant
15        7000   3500    9%                0.9%         0.9%          7          7       2.4  Sensitive
16       15000   7500   13%                1.3%         1.3%         15         15       3.5  Resistant
17        5000   2500    8%                0.8%         0.8%          5          5       1.5  Sensitive
18       12000   6000   11%                1.1%         1.1%         12         12       2.2  Resistant
19       18000   9000   14%                1.4%         1.4%         18         18       4.5  Sensitive
20        8000   4000    9%                0.9%         0.9%          8          8       2.8  Resistant
21       14000   7000   13%                1.3%         1.3%         14         14       3.2  Sensitive
22        6000   3000   10%                1%           1%          6          6       2.1  Resistant
23       16000   8000   15%                1.5%         1.5%         16         16       4.8  Sensitive
24       4000   2000    7%                0.7%         0.7%          4          4       1.8  Resistant
```",0.062421037252737385
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4a2ec9ef032927ceb475ca3b7118801c7e64fa19.summary'],Does the simultaneous downregulation of miR-181a and upregulation of miR-155 in Acute Lymphoblastic Leukaemia cells lead to the development of resistance to chemotherapy through the activation of the p53 signalling pathway and subsequent upregulation of H3F3A?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove it. The hypothesis states that the simultaneous downregulation of miR-181a and upregulation of miR-155 in Acute Lymphoblastic Leukaemia (ALL) cells leads to the development of resistance to chemotherapy through the activation of the p53 signalling pathway and subsequent upregulation of H3F3A.

**Experimental Plan:**

**Objective:** To investigate whether the simultaneous downregulation of miR-181a and upregulation of miR-155 in ALL cells leads to chemotherapy resistance through the activation of the p53 signalling pathway and upregulation of H3F3A.

**Experimental Design:**

1. **Cell Culture:** Use established ALL cell lines (e.g., Jurkat, MOLT-4) and maintain them in a controlled environment.
2. **miRNA Modulation:** Transfect ALL cells with:
	* miR-181a inhibitors (to downregulate miR-181a)
	* miR-155 mimics (to upregulate miR-155)
	* Control miRNA (scrambled sequence) for negative control
3. **Chemotherapy Treatment:** Treat transfected cells with a standard chemotherapy agent (e.g., doxorubicin, vincristine) at a concentration that induces apoptosis in control cells.
4. **p53 Signalling Pathway Analysis:** Use Western blotting and qRT-PCR to analyze the expression of key p53 signalling pathway components, such as p53, p21, and MDM2, in treated cells.
5. **H3F3A Expression Analysis:** Use Western blotting and qRT-PCR to analyze the expression of H3F3A in treated cells.
6. **Cell Viability Assay:** Perform a cell viability assay (e.g., MTT, Annexin V staining) to assess the resistance of cells to chemotherapy.

**Experimental Conditions:**

* miR-181a downregulation + miR-155 upregulation (Test Group)
* miR-181a downregulation only (Control Group 1)
* miR-155 upregulation only (Control Group 2)
* Control miRNA transfection (Negative Control Group)

**Expected Outcomes:**

* If the hypothesis is true, the Test Group (miR-181a downregulation + miR-155 upregulation) should exhibit increased resistance to chemotherapy, accompanied by activation of the p53 signalling pathway and upregulation of H3F3A.
* If the hypothesis is false, the Test Group should not exhibit increased resistance to chemotherapy, and the p53 signalling pathway and H3F3A expression should not be affected.

**Time and Resource Considerations:**

* Cell culture and transfection: 2-3 weeks
* Chemotherapy treatment and cell viability assay: 1-2 weeks
* Western blotting and qRT-PCR: 2-3 weeks
* Data analysis and interpretation: 2-3 weeks

Total estimated time: 8-12 weeks

**Budget Considerations:**

* Cell lines and reagents: $1,000 - $2,000
* miRNA modulators and transfection reagents: $500 - $1,000
* Chemotherapy agents: $500 - $1,000
* Western blotting and qRT-PCR equipment and reagents: $2,000 - $3,000
* Cell viability assay reagents: $500 - $1,000

Total estimated budget: $6,000 - $10,000

This experiment is designed to test the hypothesis and can be completed within a reasonable time frame and budget. The results will provide valuable insights into the role of miR-181a and miR-155 in chemotherapy resistance in ALL cells.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Maintenance**

1. Obtain established ALL cell lines (e.g., Jurkat, MOLT-4) from a reputable source (e.g., ATCC).
2. Thaw the cells according to the supplier's instructions and resuspend them in complete growth medium (e.g., RPMI 1640 with 10% FBS, 1% penicillin-streptomycin).
3. Culture the cells in a controlled environment (e.g., 37°C, 5% CO2) and maintain them at a density of 1-2 x 10^6 cells/mL.
4. Passage the cells every 3-4 days to maintain exponential growth.
5. Monitor cell viability and morphology regularly using a hemocytometer and microscope.

**Protocol 2: miRNA Modulation**

1. Design and synthesize miR-181a inhibitors, miR-155 mimics, and control miRNA (scrambled sequence) using a commercial supplier (e.g., Dharmacon, Ambion).
2. Transfect the ALL cells with the miRNA modulators using a transfection reagent (e.g., Lipofectamine 2000, DharmaFECT) according to the manufacturer's instructions.
3. Use a transfection efficiency of 70-80% as determined by qRT-PCR or Western blotting.
4. Incubate the transfected cells for 24-48 hours to allow for miRNA modulation.

**Protocol 3: Chemotherapy Treatment**

1. Prepare a stock solution of the chemotherapy agent (e.g., doxorubicin, vincristine) in a suitable solvent (e.g., DMSO, PBS).
2. Dilute the stock solution to the desired concentration (e.g., 1 μM doxorubicin) in complete growth medium.
3. Treat the transfected cells with the chemotherapy agent for 24-48 hours.
4. Use a control group without chemotherapy treatment as a negative control.

**Protocol 4: p53 Signalling Pathway Analysis**

1. Harvest the treated cells and extract total protein using a lysis buffer (e.g., RIPA buffer).
2. Perform Western blotting using antibodies against p53, p21, and MDM2.
3. Use a loading control (e.g., β-actin) to normalize protein expression.
4. Analyze the Western blot results using densitometry software (e.g., ImageJ).
5. Perform qRT-PCR using primers specific to p53, p21, and MDM2 to analyze mRNA expression.
6. Use a housekeeping gene (e.g., GAPDH) as a reference gene.

**Protocol 5: H3F3A Expression Analysis**

1. Harvest the treated cells and extract total protein using a lysis buffer (e.g., RIPA buffer).
2. Perform Western blotting using an antibody against H3F3A.
3. Use a loading control (e.g., β-actin) to normalize protein expression.
4. Analyze the Western blot results using densitometry software (e.g., ImageJ).
5. Perform qRT-PCR using primers specific to H3F3A to analyze mRNA expression.
6. Use a housekeeping gene (e.g., GAPDH) as a reference gene.

**Protocol 6: Cell Viability Assay**

1. Harvest the treated cells and resuspend them in complete growth medium.
2. Perform a cell viability assay (e.g., MTT, Annexin V staining) according to the manufacturer's instructions.
3. Measure the absorbance or fluorescence using a plate reader or flow cytometer.
4. Calculate the percentage of viable cells relative to the control group.

**Protocol 7: Data Analysis and Interpretation**

1. Analyze the data from each protocol using statistical software (e.g., GraphPad Prism, R).
2. Compare the results between the Test Group (miR-181a downregulation + miR-155 upregulation) and the Control Groups (miR-181a downregulation only, miR-155 upregulation only, and Negative Control Group).
3. Determine the significance of the results using a suitable statistical test (e.g., t-test, ANOVA).
4. Interpret the results in the context of the hypothesis and discuss the implications for chemotherapy resistance in ALL cells.

These detailed protocols should provide a clear and concise guide for executing the experiment.","```
   miR-181a Inhibitor (nM)  miR-155 Mimic (nM)  Doxorubicin (μM)  p53 Expression  p21 Expression  MDM2 Expression  H3F3A Expression  Cell Viability (%)
0                  50.0             20.0             0.5         1.20          1.50          0.80          1.10          60.0
1                  25.0             40.0             1.0         1.50          1.80          0.60          1.20          50.0
2                  75.0             30.0             0.2         1.00          1.20          0.90          1.00          70.0
3                  50.0             10.0             1.5         1.80          2.00          0.50          1.30          40.0
4                  30.0             50.0             0.8         1.40          1.60          0.70          1.15          55.0
5                  20.0             60.0             1.2         1.60          1.90          0.60          1.25          45.0
6                  40.0             20.0             0.6         1.30          1.50          0.80          1.10          65.0
7                  60.0             40.0             1.0         1.50          1.80          0.60          1.20          50.0
8                  10.0             30.0             0.4         1.10          1.30          0.90          1.05          75.0
9                  80.0             10.0             1.6         1.90          2.20          0.50          1.35          35.0
10                 35.0             45.0             0.9         1.45          1.70          0.65          1.18          58.0
11                 45.0             35.0             1.1         1.55          1.85          0.60          1.22          52.0
12                 55.0             25.0             0.7         1.35          1.60          0.75          1.12          62.0
13                 65.0             15.0             1.3         1.70          2.00          0.55          1.28          48.0
14                 15.0             55.0             0.3         1.05          1.25          0.95          1.08          80.0
15                 25.0             65.0             1.4         1.80          2.10          0.58          1.32          42.0
16                 85.0             20.0             1.7         2.00          2.30          0.50          1.38          38.0
17                 30.0             40.0             0.9         1.40          1.65          0.70          1.18          56.0
18                 50.0             30.0             1.2         1.60          1.90          0.60          1.25          46.0
19                 70.0             25.0             0.8         1.45          1.75          0.65          1.20          59.0
20                 20.0             50.0             1.1         1.50          1.80          0.60          1.22          51.0
21                 40.0             60.0             1.5         1.80          2.10          0.55          1.32          43.0
22                 60.0             40.0             1.0         1.50          1.80          0.60          1.20          50.0
23                 10.0             45.0             0.6         1.20          1.40          0.85          1.10          68.0
24                 80.0             35.0             1.8         2.10          2.40          0.50          1.40          36.0
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/344766c6713fe174529ad467db3e04f084f1cbc4.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/61d62d0b8eb3d052ce32b1b56d12e01470611942.summary']",Does the simultaneous inhibition of PI3K signaling and restoration of PTEN expression in CLL cells lead to a synergistic reduction in AKT protein kinase activity and subsequent apoptosis?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** Simultaneous inhibition of PI3K signaling and restoration of PTEN expression in CLL cells leads to a synergistic reduction in AKT protein kinase activity and subsequent apoptosis.

**Experimental Plan:**

**Objective:** To investigate whether the simultaneous inhibition of PI3K signaling and restoration of PTEN expression in CLL cells results in a synergistic reduction in AKT protein kinase activity, leading to apoptosis.

**Experimental Design:**

**Step 1: Cell Culture and Preparation**

* Obtain CLL cell lines (e.g., MEC-1, JVM-3) and culture them in RPMI-1640 medium supplemented with 10% FBS and antibiotics.
* Verify the expression of PI3K and PTEN in these cell lines using Western blotting and qRT-PCR.

**Step 2: PI3K Inhibition and PTEN Restoration**

* Use a specific PI3K inhibitor (e.g., LY294002, Wortmannin) to inhibit PI3K signaling in CLL cells. Optimize the inhibitor concentration and treatment duration to achieve effective PI3K inhibition.
* Use a lentiviral vector to overexpress PTEN in CLL cells. Verify PTEN overexpression using Western blotting and qRT-PCR.

**Step 3: AKT Activity Assay**

* Treat CLL cells with the PI3K inhibitor and/or PTEN overexpression vector, alone or in combination, for 24-48 hours.
* Measure AKT protein kinase activity using a commercially available AKT kinase assay kit (e.g., AKT Kinase Assay Kit, Cell Signaling Technology).

**Step 4: Apoptosis Assay**

* Treat CLL cells with the PI3K inhibitor and/or PTEN overexpression vector, alone or in combination, for 24-48 hours.
* Measure apoptosis using Annexin V-FITC/PI staining and flow cytometry or a commercial apoptosis assay kit (e.g., ApoScreen Annexin V-FITC Kit, SouthernBiotech).

**Step 5: Synergy Analysis**

* Use a synergy analysis software (e.g., Combenefit, SynergyFinder) to determine whether the combination of PI3K inhibition and PTEN restoration exhibits synergistic effects on AKT activity and apoptosis.

**Experiment to Disprove the Hypothesis:**

To verify the hypothesis, we will design an experiment to disprove it. If the results of this experiment contradict the hypothesis, it would suggest that the hypothesis is true.

**Disproof Experiment:**

**Objective:** To investigate whether the simultaneous inhibition of PI3K signaling and restoration of PTEN expression in CLL cells has no effect on AKT protein kinase activity and apoptosis.

**Experimental Design:**

* Use a PI3K inhibitor and PTEN overexpression vector, as described above.
* Treat CLL cells with a combination of the PI3K inhibitor and PTEN overexpression vector, but with a non-specific, non-functional PI3K inhibitor (e.g., a PI3K inhibitor with a mutated binding site) and a PTEN overexpression vector with a non-functional PTEN protein (e.g., a PTEN protein with a mutated phosphatase domain).
* Measure AKT protein kinase activity and apoptosis as described above.

**Expected Outcome:**

If the hypothesis is true, the combination of the non-specific PI3K inhibitor and non-functional PTEN overexpression vector should not result in a synergistic reduction in AKT activity and apoptosis. If the results show a significant reduction in AKT activity and apoptosis, it would suggest that the hypothesis is false.

**Additional Considerations:**

* To ensure the specificity of the PI3K inhibitor and PTEN overexpression vector, control experiments using specific inhibitors and vectors should be performed.
* To rule out off-target effects, additional experiments using different PI3K inhibitors and PTEN overexpression vectors should be conducted.
* To confirm the results, the experiment should be repeated multiple times, and the data should be analyzed using appropriate statistical methods.

With an unlimited budget, we can perform multiple replicates, use advanced techniques like CRISPR-Cas9 genome editing to knockout PI3K or PTEN, and employ high-throughput screening methods to identify potential synergistic effects.",92,"Here are the detailed, step-by-step protocols for the experimental plan:

**Step 1: Cell Culture and Preparation**

1.1. Obtain CLL cell lines (e.g., MEC-1, JVM-3) from a reputable cell bank or culture collection.

1.2. Culture the cells in RPMI-1640 medium supplemented with 10% FBS and antibiotics (e.g., penicillin-streptomycin) in a humidified incubator at 37°C and 5% CO2.

1.3. Verify the expression of PI3K and PTEN in the cell lines using Western blotting and qRT-PCR.

**Western Blotting:**

1.3.1. Harvest 1 x 10^6 cells and lyse them in 100 μL of RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (e.g., PMSF, aprotinin).

1.3.2. Centrifuge the lysate at 12,000 x g for 10 minutes at 4°C.

1.3.3. Separate the proteins using SDS-PAGE (10% gel) and transfer them to a PVDF membrane.

1.3.4. Block the membrane with 5% BSA in TBST (20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) for 1 hour at room temperature.

1.3.5. Incubate the membrane with primary antibodies against PI3K (1:1000) and PTEN (1:1000) overnight at 4°C.

1.3.6. Wash the membrane with TBST and incubate with secondary antibodies (1:5000) for 1 hour at room temperature.

1.3.7. Develop the membrane using an ECL detection system.

**qRT-PCR:**

1.3.8. Extract total RNA from 1 x 10^6 cells using a commercial RNA extraction kit (e.g., TRIzol).

1.3.9. Synthesize cDNA using a reverse transcription kit (e.g., SuperScript III).

1.3.10. Perform qRT-PCR using a commercial kit (e.g., PowerUp SYBR Green Master Mix) and primers specific for PI3K and PTEN.

1.3.11. Analyze the data using the 2^(-ΔΔCt) method.

**Step 2: PI3K Inhibition and PTEN Restoration**

2.1. Optimize the concentration and treatment duration of the PI3K inhibitor (e.g., LY294002, Wortmannin) to achieve effective PI3K inhibition.

2.2. Treat 1 x 10^6 cells with the optimized concentration of PI3K inhibitor for 24-48 hours.

2.3. Verify PI3K inhibition using Western blotting or a commercial PI3K activity assay kit.

2.4. Prepare a lentiviral vector to overexpress PTEN in CLL cells.

2.5. Transduce 1 x 10^6 cells with the PTEN overexpression vector using a commercial transduction kit (e.g., Lenti-X).

2.6. Verify PTEN overexpression using Western blotting and qRT-PCR.

**Step 3: AKT Activity Assay**

3.1. Treat 1 x 10^6 cells with the PI3K inhibitor and/or PTEN overexpression vector, alone or in combination, for 24-48 hours.

3.2. Harvest the cells and lyse them in 100 μL of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 10% glycerol) containing protease inhibitors.

3.3. Measure AKT protein kinase activity using a commercially available AKT kinase assay kit (e.g., AKT Kinase Assay Kit, Cell Signaling Technology) according to the manufacturer's instructions.

**Step 4: Apoptosis Assay**

4.1. Treat 1 x 10^6 cells with the PI3K inhibitor and/or PTEN overexpression vector, alone or in combination, for 24-48 hours.

4.2. Stain the cells with Annexin V-FITC and PI using a commercial apoptosis assay kit (e.g., ApoScreen Annexin V-FITC Kit, SouthernBiotech) according to the manufacturer's instructions.

4.3. Analyze the cells using flow cytometry (e.g., BD FACSCalibur).

**Step 5: Synergy Analysis**

5.1. Use a synergy analysis software (e.g., Combenefit, SynergyFinder) to determine whether the combination of PI3K inhibition and PTEN restoration exhibits synergistic effects on AKT activity and apoptosis.

**Disproof Experiment:**

**Step 1: Cell Culture and Preparation**

1.1-1.3. Follow the same protocol as Step 1 above.

**Step 2: PI3K Inhibition and PTEN Restoration**

2.1. Use a non-specific, non-functional PI3K inhibitor (e.g., a PI3K inhibitor with a mutated binding site) and a PTEN overexpression vector with a non-functional PTEN protein (e.g., a PTEN protein with a mutated phosphatase domain).

2.2-2.6. Follow the same protocol as Step 2 above.

**Step 3: AKT Activity Assay and Apoptosis Assay**

3.1-4.3. Follow the same protocol as Steps 3 and 4 above.

**Additional Considerations:**

* Perform control experiments using specific inhibitors and vectors to ensure specificity.
* Conduct additional experiments using different PI3K inhibitors and PTEN overexpression vectors to rule out off-target effects.
* Repeat the experiment multiple times and analyze the data using appropriate statistical methods to confirm the results.

Note: The protocols above are detailed and step-by-step, but they may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when conducting these experiments.","```
   MEC-1 Cells  JVM-3 Cells  RPMI-1640  FBS  Penicillin-Streptomycin  PI3K Inhibitor  PTEN Overexpression  AKT Activity  Apoptosis
0           1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
1           5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
2           2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
3           1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
4           5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
5           2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
6           1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
7           5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
8           2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
9           1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
10          5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
11          2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
12          1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
13          5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
14          2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
15          1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
16          5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
17          2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
18          1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
19          5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
20          2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
21          1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
22          5e+05       5e+05       15%     15%                2%          20 uM               2x         0.7         30%
23          2e+06       2e+06       12%     12%                1.5%        15 uM               1.5x       0.6         25%
24          1e+06       1e+06       10%     10%                1%          10 uM               1x         0.5         20%
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/24cb27c1d1f57bb5861b7da5b3b1aa0072c7b8ac.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/eba3bc381602caaa3c52e321e7e27ddf93e73f13.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/35e8534fdb11746a57cc8b31d467bdd0e12cbac9.summary']",Does the simultaneous inhibition of the NF-kB arm of the BCR signaling pathway and the PI3K/AKT/mTOR pathway enhance the efficacy of BTK inhibitors in treating B cell malignancies by reducing the development of resistance mutations?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Does the simultaneous inhibition of the NF-kB arm of the BCR signaling pathway and the PI3K/AKT/mTOR pathway enhance the efficacy of BTK inhibitors in treating B cell malignancies by reducing the development of resistance mutations?

**Experimental Approach:**

**Objective:** To investigate whether the simultaneous inhibition of the NF-kB arm of the BCR signaling pathway and the PI3K/AKT/mTOR pathway can enhance the efficacy of BTK inhibitors in treating B cell malignancies and reduce the development of resistance mutations.

**Materials:**

* B cell malignancy cell lines (e.g., diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) cell lines)
* BTK inhibitors (e.g., ibrutinib or acalabrutinib)
* NF-kB inhibitors (e.g., BAY 11-7082 or JSH-23)
* PI3K/AKT/mTOR pathway inhibitors (e.g., LY294002 or rapamycin)
* CRISPR-Cas9 system
* Sequencing equipment (e.g., Sanger sequencing or next-generation sequencing (NGS))

**Experimental Design:**

1. **Cell Line Preparation:** Establish B cell malignancy cell lines with CRISPR-Cas9-mediated knockout or knockdown of key components of the NF-kB arm (e.g., NF-kB subunits or IKK) and/or the PI3K/AKT/mTOR pathway (e.g., PI3K, AKT, or mTOR).
2. **Treatment with BTK Inhibitors and Pathway Inhibitors:** Treat the cell lines with BTK inhibitors alone or in combination with NF-kB inhibitors and/or PI3K/AKT/mTOR pathway inhibitors.
3. **Monitoring of Resistance Mutations:** Monitor the development of resistance mutations in the BTK gene and other genes involved in the BCR signaling pathway using sequencing techniques (e.g., Sanger sequencing or NGS).
4. **Cell Viability and Apoptosis Assays:** Perform cell viability and apoptosis assays (e.g., MTT assay, Annexin V staining, or Western blotting) to evaluate the efficacy of the combination therapy.
5. **Western Blotting:** Analyze the expression levels of key proteins involved in the NF-kB arm and PI3K/AKT/mTOR pathway using Western blotting.

**Expected Outcomes:**

* The simultaneous inhibition of the NF-kB arm and PI3K/AKT/mTOR pathway will reduce the development of resistance mutations in the BTK gene and other genes involved in the BCR signaling pathway.
* The combination therapy will enhance the efficacy of BTK inhibitors in treating B cell malignancies, as measured by cell viability and apoptosis assays.
* The expression levels of key proteins involved in the NF-kB arm and PI3K/AKT/mTOR pathway will be reduced upon treatment with the combination therapy.

**Experimental Timeline:**

* Cell line preparation: 2-3 weeks
* Treatment and monitoring of resistance mutations: 4-6 weeks
* Cell viability and apoptosis assays: 2-3 weeks
* Western blotting: 1-2 weeks
* Data analysis and interpretation: 2-3 weeks

**Budget:**

* Cell lines and reagents: $5,000 - $10,000
* CRISPR-Cas9 system: $10,000 - $20,000
* Sequencing equipment and reagents: $10,000 - $20,000
* Personnel and overheads: $20,000 - $40,000
* Total budget: $45,000 - $90,000

This experimental plan is designed to test the hypothesis and provide insights into the efficacy of the combination therapy in reducing resistance mutations and enhancing the treatment of B cell malignancies. The budget and timeline are estimated and may vary depending on the specific requirements of the experiment.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Line Preparation**

**Step 1.1: Cell Line Selection and Culture**

* Select B cell malignancy cell lines (e.g., diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) cell lines) and obtain them from a reputable cell bank or culture them in-house.
* Culture the cell lines in a suitable medium (e.g., RPMI 1640) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.

**Step 1.2: CRISPR-Cas9-Mediated Knockout/Knockdown**

* Design guide RNAs (gRNAs) targeting key components of the NF-kB arm (e.g., NF-kB subunits or IKK) and/or the PI3K/AKT/mTOR pathway (e.g., PI3K, AKT, or mTOR) using online tools (e.g., CRISPR Design Tool).
* Clone the gRNAs into a CRISPR-Cas9 vector (e.g., pSpCas9(BB)-2A-GFP) and verify the sequence.
* Transfect the CRISPR-Cas9 vector into the cell lines using a suitable transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.
* Select and isolate cells with successful knockout/knockdown using fluorescence-activated cell sorting (FACS) or antibiotic selection.

**Protocol 2: Treatment with BTK Inhibitors and Pathway Inhibitors**

**Step 2.1: Preparation of Inhibitors**

* Obtain BTK inhibitors (e.g., ibrutinib or acalabrutinib), NF-kB inhibitors (e.g., BAY 11-7082 or JSH-23), and PI3K/AKT/mTOR pathway inhibitors (e.g., LY294002 or rapamycin) from a reputable supplier.
* Prepare stock solutions of each inhibitor in a suitable solvent (e.g., DMSO) according to the manufacturer's instructions.

**Step 2.2: Treatment of Cell Lines**

* Seed the prepared cell lines in 96-well plates at a density of 1 x 10^4 cells per well.
* Treat the cell lines with BTK inhibitors alone or in combination with NF-kB inhibitors and/or PI3K/AKT/mTOR pathway inhibitors at various concentrations (e.g., 0.1, 1, and 10 μM) for 24, 48, and 72 hours.
* Include vehicle controls (e.g., DMSO) and positive controls (e.g., staurosporine) in each plate.

**Protocol 3: Monitoring of Resistance Mutations**

**Step 3.1: DNA Extraction**

* Extract genomic DNA from the treated cell lines using a suitable DNA extraction kit (e.g., QIAamp DNA Mini Kit) according to the manufacturer's instructions.

**Step 3.2: PCR Amplification**

* Design primers targeting the BTK gene and other genes involved in the BCR signaling pathway using online tools (e.g., Primer3).
* Perform PCR amplification of the target genes using a suitable PCR kit (e.g., Q5 Hot Start High-Fidelity DNA Polymerase) according to the manufacturer's instructions.

**Step 3.3: Sequencing**

* Perform Sanger sequencing or next-generation sequencing (NGS) on the PCR amplicons using a suitable sequencing platform (e.g., Sanger sequencing: ABI 3730xl; NGS: Illumina MiSeq).
* Analyze the sequencing data using suitable software (e.g., Sanger sequencing: Sequencher; NGS: BWA-MEM and SAMtools) to identify resistance mutations.

**Protocol 4: Cell Viability and Apoptosis Assays**

**Step 4.1: MTT Assay**

* Perform an MTT assay using a suitable kit (e.g., CellTiter 96 AQueous One Solution Cell Proliferation Assay) according to the manufacturer's instructions.
* Measure the absorbance at 490 nm using a microplate reader.

**Step 4.2: Annexin V Staining**

* Perform Annexin V staining using a suitable kit (e.g., Annexin V-FITC Apoptosis Detection Kit) according to the manufacturer's instructions.
* Analyze the stained cells using flow cytometry (e.g., BD FACSCanto II).

**Step 4.3: Western Blotting**

* Perform Western blotting using a suitable kit (e.g., NuPAGE Novex Bis-Tris Gel System) according to the manufacturer's instructions.
* Analyze the expression levels of key proteins involved in the NF-kB arm and PI3K/AKT/mTOR pathway using suitable antibodies.

**Protocol 5: Western Blotting**

**Step 5.1: Protein Extraction**

* Extract proteins from the treated cell lines using a suitable protein extraction kit (e.g., RIPA buffer) according to the manufacturer's instructions.

**Step 5.2: Western Blotting**

* Perform Western blotting using a suitable kit (e.g., NuPAGE Novex Bis-Tris Gel System) according to the manufacturer's instructions.
* Analyze the expression levels of key proteins involved in the NF-kB arm and PI3K/AKT/mTOR pathway using suitable antibodies.

These detailed protocols should provide a clear guide for executing the experimental plan. Remember to follow proper laboratory protocols, including safety precautions and quality control measures, to ensure the accuracy and reproducibility of the results.","```
   Cell_Line  gRNA_Target  BTK_Inhibitor  NFkB_Inhibitor  PI3K_Inhibitor  Time  Outcome
0       DLBCL        NFkB         0.1           0.0           0.0   24.0  0.8000
1       MCL        PI3K         1.0           0.0           0.0   48.0  0.6000
2       DLBCL        AKT         0.0           1.0           0.0   72.0  0.4000
3       MCL        mTOR         0.1           0.1           0.0   24.0  0.7000
4       DLBCL        NFkB         1.0           0.1           0.0   48.0  0.5000
5       MCL        PI3K         0.0           0.0           1.0   72.0  0.3000
6       DLBCL        AKT         0.1           0.0           1.0   24.0  0.6000
7       MCL        mTOR         1.0           0.0           0.1   48.0  0.4000
8       DLBCL        NFkB         0.0           1.0           0.1   72.0  0.5000
9       MCL        PI3K         0.1           1.0           0.0   24.0  0.7000
10      DLBCL        AKT         1.0           0.1           0.1   48.0  0.3000
11      MCL        mTOR         0.0           0.1           1.0   72.0  0.4000
12      DLBCL        NFkB         0.1           0.0           0.1   24.0  0.6000
13      MCL        PI3K         1.0           0.0           0.0   48.0  0.5000
14      DLBCL        AKT         0.0           1.0           0.0   72.0  0.7000
15      MCL        mTOR         0.1           1.0           0.1   24.0  0.4000
16      DLBCL        NFkB         1.0           1.0           0.0   48.0  0.3000
17      MCL        PI3K         0.0           0.1           1.0   72.0  0.5000
18      DLBCL        AKT         0.1           0.1           0.0   24.0  0.6000
19      MCL        mTOR         1.0           0.0           0.1   48.0  0.4000
20      DLBCL        NFkB         0.0           0.0           1.0   72.0  0.7000
21      MCL        PI3K         0.1           1.0           0.1   24.0  0.5000
22      DLBCL        AKT         1.0           0.0           0.0   48.0  0.3000
23      MCL        mTOR         0.0           1.0           0.0   72.0  0.4000
24      DLBCL        NFkB         0.1           0.1           0.1   24.0  0.6000
```",0.23702268045353062
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/3c615fb68ea4ca25eb1f1eb2c410ed794c174d64.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1bbd20f69b0cdd0ca0d22fd056433e1ca17ff914.summary']","Does the simultaneous knockout of TRAIL-R1 and TRAIL-R2 in B cells lead to increased expression of LUBAC, thereby promoting germinal center B cell survival and suppressing autoimmune disease development?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it. Here's a high-level approach to verify or falsify the hypothesis:

**Hypothesis:** Simultaneous knockout of TRAIL-R1 and TRAIL-R2 in B cells leads to increased expression of LUBAC, promoting germinal center B cell survival and suppressing autoimmune disease development.

**Experimental Plan:**

**Objective:** To determine if the simultaneous knockout of TRAIL-R1 and TRAIL-R2 in B cells increases LUBAC expression, leading to enhanced germinal center B cell survival and reduced autoimmune disease development.

**Experimental Design:**

**Step 1: Generation of TRAIL-R1 and TRAIL-R2 double knockout (DKO) mice**

* Use CRISPR-Cas9 gene editing technology to generate mice with simultaneous knockout of TRAIL-R1 and TRAIL-R2 genes specifically in B cells.
* Validate the knockout using PCR, Western blot, and flow cytometry.

**Step 2: Isolation and characterization of germinal center B cells**

* Isolate germinal center B cells from DKO mice and wild-type (WT) controls using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS).
* Characterize the isolated cells using flow cytometry, immunofluorescence, and qRT-PCR to confirm the knockout and assess germinal center B cell markers (e.g., GL7, CD38).

**Step 3: LUBAC expression analysis**

* Perform qRT-PCR and Western blot to measure LUBAC mRNA and protein levels in DKO and WT germinal center B cells.
* Use immunofluorescence microscopy to visualize LUBAC expression in germinal center B cells.

**Step 4: Germinal center B cell survival and proliferation assays**

* Perform cell viability assays (e.g., MTT, Annexin V) to assess germinal center B cell survival in DKO and WT cells.
* Use BrdU incorporation assays to measure cell proliferation.

**Step 5: Autoimmune disease model**

* Induce autoimmune disease in DKO and WT mice using a well-established model (e.g., collagen-induced arthritis, experimental autoimmune encephalomyelitis).
* Monitor disease progression and severity using clinical scores, histopathology, and serological markers.

**Step 6: Adoptive transfer and bone marrow chimera experiments**

* Perform adoptive transfer of DKO or WT germinal center B cells into WT or DKO recipients to assess the role of TRAIL-R1 and TRAIL-R2 in autoimmune disease development.
* Generate bone marrow chimeras by reconstituting irradiated WT mice with DKO or WT bone marrow to evaluate the contribution of TRAIL-R1 and TRAIL-R2 knockout in B cells to autoimmune disease development.

**Step 7: Data analysis and interpretation**

* Compare LUBAC expression, germinal center B cell survival, and autoimmune disease development between DKO and WT mice.
* Analyze the data using appropriate statistical methods to determine the significance of the results.

**Experiment to DISPROVE the hypothesis:**

To verify the hypothesis, we need to design an experiment that can potentially falsify it. Here's an approach:

**Alternative Hypothesis:** Simultaneous knockout of TRAIL-R1 and TRAIL-R2 in B cells has no effect on LUBAC expression, germinal center B cell survival, or autoimmune disease development.

**Experimental Design:**

* Perform the same experiments as outlined above, but with a twist:
	+ Use a different gene editing approach (e.g., TALEN or ZFN) to generate TRAIL-R1 and TRAIL-R2 DKO mice to rule out off-target effects.
	+ Use a different autoimmune disease model or a different strain of mice to assess the generality of the findings.
	+ Overexpress LUBAC in WT germinal center B cells using a lentiviral vector to determine if increased LUBAC expression is sufficient to promote germinal center B cell survival and suppress autoimmune disease development.

If the results of this experiment contradict the original hypothesis, it would suggest that the simultaneous knockout of TRAIL-R1 and TRAIL-R2 in B cells does not lead to increased LUBAC expression, germinal center B cell survival, or autoimmune disease suppression, thereby falsifying the original hypothesis.

With an unlimited budget, we can perform these experiments in triplicate, use cutting-edge technologies, and recruit a team of experts to ensure the highest quality of data and interpretation.",92,"Here are the detailed, step-by-step protocols for each step of the experimental plan:

**Step 1: Generation of TRAIL-R1 and TRAIL-R2 double knockout (DKO) mice**

1.1. Design guide RNAs (gRNAs) targeting TRAIL-R1 and TRAIL-R2 genes using online tools (e.g., CRISPR Design) or consult with a bioinformatics expert.

1.2. Prepare CRISPR-Cas9 plasmids containing the designed gRNAs and Cas9 enzyme using standard molecular biology techniques (e.g., PCR, Gibson assembly).

1.3. Microinject the CRISPR-Cas9 plasmids into fertilized mouse oocytes (C57BL/6J or other desired strain) using a microinjection apparatus.

1.4. Transfer the microinjected oocytes to pseudopregnant female mice and allow them to develop to term.

1.5. Genotype the resulting pups using PCR and sequencing to identify those with simultaneous knockout of TRAIL-R1 and TRAIL-R2 genes.

1.6. Validate the knockout using Western blot and flow cytometry to confirm the absence of TRAIL-R1 and TRAIL-R2 proteins in B cells.

**Step 2: Isolation and characterization of germinal center B cells**

2.1. Sacrifice DKO and WT mice, and harvest spleens and lymph nodes.

2.2. Prepare single-cell suspensions from the spleens and lymph nodes using mechanical disruption and filtering.

2.3. Stain the cells with fluorescently labeled antibodies against B cell markers (e.g., CD19, CD20) and germinal center B cell markers (e.g., GL7, CD38).

2.4. Sort the stained cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) to isolate germinal center B cells.

2.5. Characterize the isolated cells using flow cytometry to confirm the expression of germinal center B cell markers.

2.6. Perform qRT-PCR to assess the expression of germinal center B cell-specific genes (e.g., Aicda, Pax5).

**Step 3: LUBAC expression analysis**

3.1. Extract total RNA from isolated germinal center B cells using a RNA extraction kit (e.g., TRIzol).

3.2. Perform qRT-PCR to measure LUBAC mRNA levels using specific primers and a qRT-PCR machine.

3.3. Extract protein from isolated germinal center B cells using a protein extraction buffer (e.g., RIPA).

3.4. Perform Western blot to measure LUBAC protein levels using a specific antibody and a Western blot machine.

3.5. Fix isolated germinal center B cells with paraformaldehyde and permeabilize with Triton X-100.

3.6. Stain the cells with a LUBAC-specific antibody and a fluorescent secondary antibody.

3.7. Visualize LUBAC expression using immunofluorescence microscopy.

**Step 4: Germinal center B cell survival and proliferation assays**

4.1. Plate isolated germinal center B cells in a 96-well plate at a density of 1 x 10^5 cells/well.

4.2. Perform an MTT assay to assess cell viability by adding MTT reagent to the cells and measuring absorbance at 570 nm.

4.3. Perform an Annexin V assay to assess apoptosis by staining the cells with Annexin V-FITC and propidium iodide, and analyzing by flow cytometry.

4.4. Pulse-label isolated germinal center B cells with BrdU for 2 hours.

4.5. Fix the cells with paraformaldehyde and permeabilize with Triton X-100.

4.6. Stain the cells with a BrdU-specific antibody and a fluorescent secondary antibody.

4.7. Visualize BrdU incorporation using immunofluorescence microscopy.

**Step 5: Autoimmune disease model**

5.1. Induce autoimmune disease in DKO and WT mice using a well-established model (e.g., collagen-induced arthritis, experimental autoimmune encephalomyelitis).

5.2. Monitor disease progression and severity using clinical scores, histopathology, and serological markers (e.g., anti-collagen antibodies).

**Step 6: Adoptive transfer and bone marrow chimera experiments**

6.1. Isolate germinal center B cells from DKO and WT mice as described in Step 2.

6.2. Perform adoptive transfer of DKO or WT germinal center B cells into WT or DKO recipients via intravenous injection.

6.3. Monitor disease development and severity in the recipient mice.

6.4. Generate bone marrow chimeras by reconstituting irradiated WT mice with DKO or WT bone marrow.

6.5. Monitor disease development and severity in the chimeric mice.

**Step 7: Data analysis and interpretation**

7.1. Compare LUBAC expression, germinal center B cell survival, and autoimmune disease development between DKO and WT mice using appropriate statistical methods (e.g., t-test, ANOVA).

7.2. Analyze the data to determine the significance of the results and draw conclusions about the role of TRAIL-R1 and TRAIL-R2 in germinal center B cell survival and autoimmune disease development.

**Experiment to DISPROVE the hypothesis**

**Alternative Hypothesis:** Simultaneous knockout of TRAIL-R1 and TRAIL-R2 in B cells has no effect on LUBAC expression, germinal center B cell survival, or autoimmune disease development.

**Experimental Design:**

* Perform the same experiments as outlined above, but with the following modifications:
	+ Use a different gene editing approach (e.g., TALEN or ZFN) to generate TRAIL-R1 and TRAIL-R2 DKO mice.
	+ Use a different autoimmune disease model or a different strain of mice.
	+ Overexpress LUBAC in WT germinal center B cells using a lentiviral vector.

If the results of this experiment contradict the original hypothesis, it would suggest that the simultaneous knockout of TRAIL-R1 and TRAIL-R2 in B cells does not lead to increased LUBAC expression, germinal center B cell survival, or autoimmune disease suppression, thereby falsifying the original hypothesis.","```
   TRAIL-R1_gRNA  TRAIL-R2_gRNA  Cas9_plasmid  Microinjection_pressure  Pseudopregnant_female_mice  Germinal_center_B_cells  LUBAC_mRNA  LUBAC_protein  MTT_assay  Annexin_V_assay  BrdU_incorporation  Autoimmune_disease_score
0             0.5             0.5             1.0                  10.0                    5.0                    5000.0       200.0       150.0       0.8         0.2         0.5               2.0
1             0.3             0.7             0.8                  12.0                    4.0                    4000.0       180.0       120.0       0.7         0.3         0.4               1.8
2             0.8             0.2             1.2                  11.0                    6.0                    6000.0       250.0       200.0       0.9         0.1         0.6               2.5
3             0.4             0.6             0.9                  13.0                    3.0                    3000.0       150.0       100.0       0.6         0.4         0.3               1.5
4             0.6             0.4             1.1                  10.0                    5.0                    5000.0       220.0       180.0       0.8         0.2         0.5               2.2
5             0.2             0.8             0.7                  12.0                    4.0                    4000.0       160.0       120.0       0.7         0.3         0.4               1.6
6             0.9             0.1             1.3                  11.0                    6.0                    7000.0       280.0       240.0       0.9         0.1         0.7               2.8
7             0.5             0.5             1.0                  13.0                    3.0                    3500.0       190.0       150.0       0.7         0.3         0.4               1.9
8             0.7             0.3             1.2                  10.0                    5.0                    5500.0       230.0       190.0       0.8         0.2         0.5               2.3
9             0.1             0.9             0.6                  12.0                    4.0                    3000.0       140.0       100.0       0.6         0.4         0.3               1.4
10            0.6             0.4             1.1                  11.0                    6.0                    6000.0       240.0       200.0       0.9         0.1         0.6               2.6
11            0.4             0.6             0.9                  13.0                    3.0                    4000.0       180.0       140.0       0.7         0.3         0.4               1.8
12            0.8             0.2             1.3                  10.0                    5.0                    6500.0       260.0       220.0       0.9         0.1         0.6               2.9
13            0.3             0.7             0.8                  12.0                    4.0                    3500.0       160.0       120.0       0.7         0.3         0.4               1.7
14            0.5             0.5             1.0                  11.0                    6.0                    5000.0       210.0       170.0       0.8         0.2         0.5               2.1
15            0.2             0.8             0.7                  13.0                    3.0                    3000.0       140.0       100.0       0.6         0.4         0.3               1.5
16            0.9             0.1             1.2                  10.0                    5.0                    7000.0       290.0       250.0       0.9         0.1         0.7               3.0
17            0.6             0.4             1.1                  12.0                    4.0                    5500.0       230.0       190.0       0.8         0.2         0.5               2.4
18            0.4             0.6             0.9                  11.0                    6.0                    4500.0       200.0       160.0       0.8         0.2         0.5               2.2
19            0.7             0.3             1.3                  13.0                    3.0                    6000.0       250.0       210.0       0.9         0.1         0.6               2.7
20            0.1             0.9             0.6                  10.0                    5.0                    3500.0       150.0       110.0       0.7         0.3         0.4               1.6
21            0.5             0.5             1.0                  12.0                    4.0                    5000.0       220.0       180.0       0.8         0.2         0.5               2.3
22            0.8             0.2             1.2                  11.0                    6.0                    6500.0       270.0       230.0       0.9         0.1         0.6               2.9
23            0.3             0.7             0.8                  13.0                    3.0                    4000.0       190.0       150.0       0.7         0.3         0.4               1.9
24            0.6             0.4             1.1                  10.0                    5.0                    6000.0       240.0       200.0       0.9         0.1         0.6               2.6
```",0.4430114532537511
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b3307447302d57fd046736d508bbf8cbc6eece9e.summary'],"Does the simultaneous loss of IKAROS and EBF1 lead to the reactivation of Polycomb repression, resulting in a more aggressive and treatment-resistant B cell acute lymphoblastic leukemia phenotype?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experimental plan to test the hypothesis and potentially disprove it. This plan leverages existing scientific methods and equipment, with an unlimited budget in terms of time, resources, and financial support.

**Experimental Plan:**

**Title:** Investigating the Role of IKAROS and EBF1 in Polycomb Repression and B Cell Acute Lymphoblastic Leukemia

**Objective:** To determine whether the simultaneous loss of IKAROS and EBF1 leads to the reactivation of Polycomb repression, resulting in a more aggressive and treatment-resistant B cell acute lymphoblastic leukemia phenotype.

**Experimental Design:**

1. **Cell Line Generation:**
	* Use CRISPR-Cas9 gene editing system to generate B cell precursor cell lines with the following genotypes:
		+ Wild-type (WT)
		+ IKAROS knockout (IKAROS KO)
		+ EBF1 knockout (EBF1 KO)
		+ IKAROS and EBF1 double knockout (IKAROS/EBF1 DKO)
2. **Polycomb Repression Assay:**
	* Perform chromatin immunoprecipitation sequencing (ChIP-seq) to analyze the binding of Polycomb repressive complex 2 (PRC2) components (e.g., EZH2, SUZ12) to target genes in each cell line.
	* Use ChIP-qPCR to validate the ChIP-seq results and quantify the enrichment of PRC2 components at specific genomic regions.
3. **Gene Expression Analysis:**
	* Perform RNA sequencing (RNA-seq) to analyze the transcriptome of each cell line.
	* Validate the RNA-seq results using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting for selected genes.
4. **Cellular Phenotyping:**
	* Analyze the cellular phenotype of each cell line using flow cytometry, including the expression of surface markers (e.g., CD19, CD20, CD34) and intracellular proteins (e.g., PAX5, TdT).
	* Evaluate the proliferation, self-renewal, and apoptosis of each cell line using cell viability assays (e.g., MTT, Annexin V).
5. **Leukemia Model Establishment:**
	* Inject the generated cell lines into immunodeficient mice to establish a leukemia model.
	* Monitor the mice for leukemia development, progression, and response to treatment (e.g., chemotherapy, targeted therapy).
6. **Treatment Resistance Assay:**
	* Treat the leukemia-bearing mice with standard chemotherapy regimens (e.g., vincristine, dexamethasone) and evaluate the response to treatment.
	* Analyze the expression of genes involved in treatment resistance (e.g., ABCB1, MDR1) using qRT-PCR and Western blotting.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we will focus on the following aspects:

1. **Lack of Polycomb Repression Reactivation:**
	* If the ChIP-seq and ChIP-qPCR results do not show significant enrichment of PRC2 components at target genes in the IKAROS/EBF1 DKO cell line compared to the WT or single KO cell lines, it would suggest that the simultaneous loss of IKAROS and EBF1 does not lead to the reactivation of Polycomb repression.
2. **No Significant Changes in Gene Expression:**
	* If the RNA-seq and qRT-PCR results do not reveal significant differences in gene expression between the IKAROS/EBF1 DKO cell line and the WT or single KO cell lines, it would indicate that the simultaneous loss of IKAROS and EBF1 does not result in a more aggressive and treatment-resistant B cell acute lymphoblastic leukemia phenotype.
3. **No Enhanced Leukemia Development or Treatment Resistance:**
	* If the leukemia model establishment and treatment resistance assays do not show significant differences in leukemia development, progression, or treatment response between the IKAROS/EBF1 DKO cell line and the WT or single KO cell lines, it would suggest that the simultaneous loss of IKAROS and EBF1 does not contribute to a more aggressive and treatment-resistant B cell acute lymphoblastic leukemia phenotype.

By following this experimental plan, we can comprehensively test the hypothesis and potentially disprove it, providing valuable insights into the role of IKAROS and EBF1 in B cell acute lymphoblastic leukemia.",90,"Here are the detailed, step-by-step protocols for each experiment outlined in the plan:

**Experiment 1: Cell Line Generation**

**Protocol:**

1.1. **CRISPR-Cas9 Gene Editing**

* Step 1: Design guide RNAs (gRNAs) targeting IKAROS and EBF1 genes using online tools (e.g., CRISPR Design, CRISPOR).
* Step 2: Clone the gRNAs into a CRISPR-Cas9 vector (e.g., pSpCas9(BB)-2A-GFP) using standard molecular biology techniques.
* Step 3: Prepare B cell precursor cells (e.g., human cord blood-derived CD34+ cells) for electroporation.
* Step 4: Electroporate the cells with the CRISPR-Cas9 vector containing the gRNA targeting IKAROS, EBF1, or both.
* Step 5: Select and expand the edited cells using fluorescence-activated cell sorting (FACS) and antibiotic selection.
* Step 6: Validate the knockout efficiency using PCR, Western blotting, and sequencing.

**Cell Line Generation Protocol:**

1.2. **Cell Line Maintenance and Expansion**

* Step 1: Culture the edited cells in a humidified incubator at 37°C, 5% CO2, in a medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.
* Step 2: Passage the cells every 3-4 days to maintain a density of 0.5-1.0 x 10^6 cells/mL.
* Step 3: Freeze the cells in 90% FBS, 10% DMSO, and store them in liquid nitrogen for future use.

**Experiment 2: Polycomb Repression Assay**

**Protocol:**

2.1. **Chromatin Immunoprecipitation Sequencing (ChIP-seq)**

* Step 1: Cross-link the cells with 1% formaldehyde for 10 minutes at room temperature.
* Step 2: Quench the cross-linking reaction with 125 mM glycine for 5 minutes.
* Step 3: Lyse the cells and sonicate the chromatin to an average size of 200-500 bp.
* Step 4: Immunoprecipitate the chromatin using antibodies against PRC2 components (e.g., EZH2, SUZ12).
* Step 5: Purify the immunoprecipitated DNA using phenol-chloroform extraction and ethanol precipitation.
* Step 6: Prepare the ChIP-seq library using a commercial kit (e.g., Illumina TruSeq ChIP Library Prep Kit).
* Step 7: Sequence the library using a next-generation sequencing platform (e.g., Illumina HiSeq 4000).

2.2. **ChIP-qPCR Validation**

* Step 1: Design primers targeting specific genomic regions of interest.
* Step 2: Perform qPCR using a commercial kit (e.g., SYBR Green) and a thermocycler (e.g., Applied Biosystems 7500).
* Step 3: Calculate the enrichment of PRC2 components at specific genomic regions using the 2^(-ΔΔCt) method.

**Experiment 3: Gene Expression Analysis**

**Protocol:**

3.1. **RNA Sequencing (RNA-seq)**

* Step 1: Isolate total RNA from the cell lines using a commercial kit (e.g., Qiagen RNeasy Mini Kit).
* Step 2: Prepare the RNA-seq library using a commercial kit (e.g., Illumina TruSeq RNA Library Prep Kit).
* Step 3: Sequence the library using a next-generation sequencing platform (e.g., Illumina HiSeq 4000).

3.2. **qRT-PCR Validation**

* Step 1: Design primers targeting specific genes of interest.
* Step 2: Perform qRT-PCR using a commercial kit (e.g., SYBR Green) and a thermocycler (e.g., Applied Biosystems 7500).
* Step 3: Calculate the relative gene expression using the 2^(-ΔΔCt) method.

3.3. **Western Blotting**

* Step 1: Lyse the cells and extract protein using a commercial kit (e.g., RIPA buffer).
* Step 2: Separate the proteins using SDS-PAGE and transfer them to a membrane.
* Step 3: Probe the membrane with antibodies against specific proteins of interest.
* Step 4: Detect the proteins using a chemiluminescent substrate (e.g., ECL) and a imaging system (e.g., ChemiDoc).

**Experiment 4: Cellular Phenotyping**

**Protocol:**

4.1. **Flow Cytometry**

* Step 1: Stain the cells with fluorescently labeled antibodies against surface markers (e.g., CD19, CD20, CD34) and intracellular proteins (e.g., PAX5, TdT).
* Step 2: Analyze the cells using a flow cytometer (e.g., BD FACSCanto II).
* Step 3: Gate the cells based on forward and side scatter to exclude debris and dead cells.

4.2. **Cell Viability Assays**

* Step 1: Seed the cells in a 96-well plate at a density of 1 x 10^4 cells/well.
* Step 2: Incubate the cells with MTT reagent (e.g., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for 4 hours.
* Step 3: Measure the absorbance at 570 nm using a plate reader (e.g., SpectraMax M5).
* Step 4: Calculate the cell viability using the formula: (Absorbance of sample - Absorbance of blank) / (Absorbance of control - Absorbance of blank) x 100%.

**Experiment 5: Leukemia Model Establishment**

**Protocol:**

5.1. **Cell Injection**

* Step 1: Prepare the cell lines for injection by washing and resuspending them in PBS.
* Step 2: Inject 1 x 10^6 cells into the tail vein of immunodeficient mice (e.g., NOD/SCID).
* Step 3: Monitor the mice for leukemia development and progression.

5.2. **Leukemia Monitoring**

* Step 1: Collect peripheral blood samples from the mice at regular intervals (e.g., weekly).
* Step 2: Analyze the blood samples using flow cytometry to detect the presence of leukemia cells.
* Step 3: Monitor the mice for signs of disease progression (e.g., weight loss, lethargy).

**Experiment 6: Treatment Resistance Assay**

**Protocol:**

6.1. **Chemotherapy Treatment**

* Step 1: Treat the leukemia-bearing mice with standard chemotherapy regimens (e.g., vincristine, dexamethasone).
* Step 2: Monitor the mice for response to treatment (e.g., reduction in leukemia burden).

6.2. **Gene Expression Analysis**

* Step 1: Isolate RNA from the leukemia cells using a commercial kit (e.g., Qiagen RNeasy Mini Kit).
* Step 2: Perform qRT-PCR to analyze the expression of genes involved in treatment resistance (e.g., ABCB1, MDR1).
* Step 3: Calculate the relative gene expression using the 2^(-ΔΔCt) method.

These detailed protocols should provide a clear guide for executing the experiments outlined in the plan.","```
   CRISPR_Cas9_vector  gRNA_IKAROS  gRNA_EBF1  Cell_density  FBS  Penicillin_streptomycin  L_glutamine  PRC2_components  ChIP_seq_reads  RNA_seq_reads  qRT_PCR_primers  Western_blot_antibodies  Flow_cytometry_antibodies  MTT_reagent  Cell_injection_dose  Chemotherapy_regimen  Outcome
0                1.0          0.5         0.5         0.8       10          1.0               1.0               2.0          1000000         1000000             2               2               2               1.0               1.0         Resistant
1                1.2          0.7         0.3         0.9       12          1.2               1.2               2.5          1200000         1200000             3               3               3               1.2               1.2         Sensitive
2                0.8          0.4         0.6         0.7       8           0.8               0.8               1.8          800000          800000             1               1               1               0.8               0.8         Resistant
3                1.5          0.9         0.1         1.0       15          1.5               1.5               3.0          1500000         1500000             4               4               4               1.5               1.5         Sensitive
4                1.1          0.6         0.4         0.8       11          1.1               1.1               2.2          1100000         1100000             2               2               2               1.1               1.1         Resistant
5                0.9          0.5         0.5         0.7       9           0.9               0.9               1.9          900000          900000             1               1               1               0.9               0.9         Sensitive
6                1.3          0.8         0.2         0.9       13          1.3               1.3               2.8          1300000         1300000             3               3               3               1.3               1.3         Resistant
7                1.0          0.6         0.4         0.8       10          1.0               1.0               2.1          1000000         1000000             2               2               2               1.0               1.0         Sensitive
8                1.4          0.9         0.1         1.0       14          1.4               1.4               3.2          1400000         1400000             4               4               4               1.4               1.4         Resistant
9                0.7          0.4         0.6         0.6       7           0.7               0.7               1.6          700000          700000             1               1               1               0.7               0.7         Sensitive
10               1.2          0.7         0.3         0.9       12          1.2               1.2               2.6          1200000         1200000             3               3               3               1.2               1.2         Resistant
11               0.9          0.5         0.5         0.7       9           0.9               0.9               1.9          900000          900000             1               1               1               0.9               0.9         Sensitive
12               1.1          0.6         0.4         0.8       11          1.1               1.1               2.3          1100000         1100000             2               2               2               1.1               1.1         Resistant
13               1.5          0.9         0.1         1.0       15          1.5               1.5               3.4          1500000         1500000             4               4               4               1.5               1.5         Sensitive
14               0.8          0.4         0.6         0.7       8           0.8               0.8               1.7          800000          800000             1               1               1               0.8               0.8         Resistant
15               1.3          0.8         0.2         0.9       13          1.3               1.3               2.9          1300000         1300000             3               3               3               1.3               1.3         Sensitive
16               1.0          0.6         0.4         0.8       10          1.0               1.0               2.2          1000000         1000000             2               2               2               1.0               1.0         Resistant
17               1.4          0.9         0.1         1.0       14          1.4               1.4               3.5          1400000         1400000             4               4               4               1.4               1.4         Sensitive
18               0.7          0.4         0.6         0.6       7           0.7               0.7               1.5          700000          700000             1               1               1               0.7               0.7         Resistant
19               1.2          0.7         0.3         0.9       12          1.2               1.2               2.7          1200000         1200000             3               3               3               1.2               1.2         Sensitive
20               0.9          0.5         0.5         0.7       9           0.9               0.9               1.8          900000          900000             1               1               1               0.9               0.9         Resistant
21               1.1          0.6         0.4         0.8       11          1.1               1.1               2.4          1100000         1100000             2               2               2               1.1               1.1         Sensitive
22               1.5          0.9         0.1         1.0       15          1.5               1.5               3.6          1500000         1500000             4               4               4               1.5               1.5         Resistant
23               0.8          0.4         0.6         0.7       8           0.8               0.8               1.6          800000          800000             1               1               1               0.8               0.8         Sensitive
24               1.3          0.8         0.2         0.9       13          1.3               1.3               3.0          1300000         1300000             3               3               3               1.3               1.3         Resistant
```",0.06541358077820074
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/4bda6619500846a2c2623cea59f1ec1f6656d83c.summary'],Does the spatial organization of B cell clusters and high endothelial venules in lymph nodes influence the efficiency of TNFRI and TNFRII signaling in lymph node development?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Does the spatial organization of B cell clusters and high endothelial venules in lymph nodes influence the efficiency of TNFRI and TNFRII signaling in lymph node development?""

**Experimental Approach:**

To disprove the hypothesis, we will investigate whether disrupting the spatial organization of B cell clusters and high endothelial venules in lymph nodes affects TNFRI and TNFRII signaling in lymph node development.

**Experiment:**

**Title:** Disrupting Spatial Organization of B Cell Clusters and High Endothelial Venules in Lymph Nodes: Impact on TNFRI and TNFRII Signaling

**Objective:** To determine if the spatial organization of B cell clusters and high endothelial venules in lymph nodes influences the efficiency of TNFRI and TNFRII signaling in lymph node development.

**Materials:**

* Lymph nodes from wild-type mice
* Lymph nodes from mice with disrupted B cell cluster and high endothelial venule organization (e.g., using a genetic model or pharmacological treatment)
* LaVision UltraMicroscope II
* Imaris software
* Antibodies against CD3, B220, and MECA-79/PNAd
* Reagents for tissue clearing and labeling (methanol, BABB, etc.)

**Experimental Design:**

1. **Disrupt B cell cluster and high endothelial venule organization:** Use a genetic model or pharmacological treatment to disrupt the spatial organization of B cell clusters and high endothelial venules in lymph nodes. For example, use a mouse model with a conditional knockout of a gene involved in lymph node organization, such as CXCL13 or CCR7.
2. **Isolate and prepare lymph nodes:** Isolate lymph nodes from both wild-type and disrupted organization mice, and fix and dehydrate the samples.
3. **Label and clear samples:** Label the samples with antibodies against CD3, B220, and MECA-79/PNAd, and clear the samples using a 1:1 solution of methanol: BABB.
4. **Image and analyze samples:** Image the samples using the LaVision UltraMicroscope II, and analyze the images using Imaris software to quantify the volume, length, and branching points of high endothelial venules, as well as the organization of B cell clusters.
5. **Compare TNFRI and TNFRII signaling:** Compare the expression levels of TNFRI and TNFRII, as well as downstream signaling molecules, in lymph nodes from wild-type and disrupted organization mice using techniques such as qRT-PCR, Western blot, or immunofluorescence.
6. **Statistical analysis:** Perform statistical analysis to compare the results between wild-type and disrupted organization mice, and determine if disrupting the spatial organization of B cell clusters and high endothelial venules affects TNFRI and TNFRII signaling in lymph node development.

**Expected Outcome:**

If the hypothesis is true, we would expect to see a significant difference in TNFRI and TNFRII signaling in lymph nodes from mice with disrupted B cell cluster and high endothelial venule organization compared to wild-type mice. Specifically, we would expect to see:

* Altered expression levels of TNFRI and TNFRII, as well as downstream signaling molecules
* Changes in the organization and structure of B cell clusters and high endothelial venules
* Impaired lymph node development and function

If the results do not show a significant difference in TNFRI and TNFRII signaling between wild-type and disrupted organization mice, it would suggest that the spatial organization of B cell clusters and high endothelial venules does not influence the efficiency of TNFRI and TNFRII signaling in lymph node development, thus disproving the hypothesis.

**Timeline and Budget:**

This experiment can be completed within 6-9 months, depending on the availability of resources and the complexity of the experimental design. The budget will depend on the cost of the LaVision UltraMicroscope II, Imaris software, and reagents, as well as the cost of maintaining the mouse colonies and performing the experiments. A rough estimate for the budget would be around $50,000-$75,000.

**Conclusion:**

This experiment is designed to test the hypothesis that the spatial organization of B cell clusters and high endothelial venules in lymph nodes influences the efficiency of TNFRI and TNFRII signaling in lymph node development. By disrupting the spatial organization of B cell clusters and high endothelial venules and analyzing the effects on TNFRI and TNFRII signaling, we can determine whether this hypothesis is true or not.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Disrupting B Cell Cluster and High Endothelial Venule Organization**

1.1. Breeding and Genotyping of Mice:

* Breed mice with a conditional knockout of a gene involved in lymph node organization, such as CXCL13 or CCR7, with a Cre-recombinase driver line.
* Genotype the mice using PCR or Southern blot to confirm the presence of the knockout allele.

1.2. Pharmacological Treatment (Alternative Method):

* Administer a pharmacological agent that disrupts lymph node organization, such as an inhibitor of CXCL13 or CCR7, to wild-type mice.
* Monitor the mice for the desired duration to achieve the desired level of disruption.

**Protocol 2: Isolating and Preparing Lymph Nodes**

2.1. Mouse Sacrifice and Lymph Node Isolation:

* Sacrifice the mice using a humane method, such as CO2 asphyxiation or cervical dislocation.
* Dissect the lymph nodes from the mice, taking care to avoid contamination and damage.

2.2. Fixation and Dehydration:

* Fix the lymph nodes in 4% paraformaldehyde (PFA) for 2 hours at room temperature.
* Dehydrate the lymph nodes using a series of ethanol washes (30%, 50%, 70%, 90%, and 100%) for 30 minutes each.

**Protocol 3: Labeling and Clearing Samples**

3.1. Antibody Labeling:

* Label the lymph nodes with antibodies against CD3, B220, and MECA-79/PNAd using a standard immunofluorescence protocol.
* Incubate the samples with the primary antibodies overnight at 4°C.
* Wash the samples with PBS and incubate with secondary antibodies for 1 hour at room temperature.

3.2. Tissue Clearing:

* Clear the samples using a 1:1 solution of methanol: BABB (benzyl alcohol and benzyl benzoate) for 2 hours.
* Wash the samples with PBS and mount them on glass slides.

**Protocol 4: Imaging and Analysis**

4.1. Imaging:

* Image the samples using the LaVision UltraMicroscope II, capturing z-stacks of the entire lymph node.
* Acquire images at a resolution of 1024 x 1024 pixels, with a z-step size of 1 μm.

4.2. Image Analysis:

* Analyze the images using Imaris software to quantify the volume, length, and branching points of high endothelial venules.
* Use the software to quantify the organization of B cell clusters, including the number, size, and distribution of clusters.

**Protocol 5: Comparing TNFRI and TNFRII Signaling**

5.1. RNA Isolation and qRT-PCR:

* Isolate RNA from the lymph nodes using a standard RNA isolation protocol.
* Perform qRT-PCR to quantify the expression levels of TNFRI, TNFRII, and downstream signaling molecules.

5.2. Western Blot:

* Perform Western blot to quantify the protein levels of TNFRI, TNFRII, and downstream signaling molecules.
* Use a standard Western blot protocol, with antibodies against the proteins of interest.

5.3. Immunofluorescence:

* Perform immunofluorescence to visualize the expression of TNFRI, TNFRII, and downstream signaling molecules in the lymph nodes.
* Use a standard immunofluorescence protocol, with antibodies against the proteins of interest.

**Protocol 6: Statistical Analysis**

6.1. Data Collection:

* Collect the data from the image analysis, qRT-PCR, Western blot, and immunofluorescence experiments.

6.2. Data Analysis:

* Perform statistical analysis using a software such as GraphPad Prism or R, to compare the results between wild-type and disrupted organization mice.
* Use a two-tailed t-test or ANOVA to determine if there are significant differences in TNFRI and TNFRII signaling between the two groups.

6.3. Data Interpretation:

* Interpret the results in the context of the hypothesis, and determine if the data support or reject the hypothesis.

Note: These protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols and safety guidelines when performing these experiments.","```
   CXCL13_Inhibitor  CCR7_Inhibitor  PFA_Concentration  Ethanol_Wash_Time  Antibody_Concentration  Methanol_BABB_Ratio  Imaging_Resolution  TNFRI_Signaling  TNFRII_Signaling  B_Cell_Cluster_Organization  High_Endothelial_Venule_Organization
0               0.5             0.2               4.0               30.0               1:100               1:1               1024x1024          0.8             0.6               Disrupted                         Disrupted
1               0.2             0.5               4.0               30.0               1:50                1:1               1024x1024          0.9             0.7               Disrupted                         Disrupted
2               0.8             0.1               4.0               30.0               1:200               1:1               1024x1024          0.7             0.5               Disrupted                         Disrupted
3               0.1             0.8               4.0               30.0               1:50                1:1               1024x1024          0.6             0.4               Disrupted                         Disrupted
4               0.5             0.5               4.0               30.0               1:100               1:1               1024x1024          0.8             0.6               Disrupted                         Disrupted
5               0.2             0.2               4.0               30.0               1:50                1:1               1024x1024          0.9             0.7               Disrupted                         Disrupted
6               0.8             0.8               4.0               30.0               1:200               1:1               1024x1024          0.7             0.5               Disrupted                         Disrupted
7               0.1             0.1               4.0               30.0               1:50                1:1               1024x1024          0.6             0.4               Disrupted                         Disrupted
8               0.5             0.2               3.5               25.0               1:100               1:1               1024x1024          0.8             0.6               Disrupted                         Disrupted
9               0.2             0.5               3.5               25.0               1:50                1:1               1024x1024          0.9             0.7               Disrupted                         Disrupted
10              0.8             0.1               3.5               25.0               1:200               1:1               1024x1024          0.7             0.5               Disrupted                         Disrupted
11              0.1             0.8               3.5               25.0               1:50                1:1               1024x1024          0.6             0.4               Disrupted                         Disrupted
12              0.5             0.5               3.5               25.0               1:100               1:1               1024x1024          0.8             0.6               Disrupted                         Disrupted
13              0.2             0.2               3.5               25.0               1:50                1:1               1024x1024          0.9             0.7               Disrupted                         Disrupted
14              0.8             0.8               3.5               25.0               1:200               1:1               1024x1024          0.7             0.5               Disrupted                         Disrupted
15              0.1             0.1               3.5               25.0               1:50                1:1               1024x1024          0.6             0.4               Disrupted                         Disrupted
16              0.5             0.2               4.5               35.0               1:100               1:1               1024x1024          0.8             0.6               Disrupted                         Disrupted
17              0.2             0.5               4.5               35.0               1:50                1:1               1024x1024          0.9             0.7               Disrupted                         Disrupted
18              0.8             0.1               4.5               35.0               1:200               1:1               1024x1024          0.7             0.5               Disrupted                         Disrupted
19              0.1             0.8               4.5               35.0               1:50                1:1               1024x1024          0.6             0.4               Disrupted                         Disrupted
20              0.5             0.5               4.5               35.0               1:100               1:1               1024x1024          0.8             0.6               Disrupted                         Disrupted
21              0.2             0.2               4.5               35.0               1:50                1:1               1024x1024          0.9             0.7               Disrupted                         Disrupted
22              0.8             0.8               4.5               35.0               1:200               1:1               1024x1024          0.7             0.5               Disrupted                         Disrupted
23              0.1             0.1               4.5               35.0               1:50                1:1               1024x1024          0.6             0.4               Disrupted                         Disrupted
24              0.5             0.2               4.0               30.0               1:100               1:1               2048x2048          0.8             0.6               Normal                          Normal
```",0.2038131626295533
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/5194d78ba0ffd398c0814a0aeadd003770e3eb4a.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/95df3673cc32ccf7a1d3e78e9f052df29ae0909b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/bb7d26f0365b1cb67ff1730f7d83e82a20b038cc.summary']","Does the spatial organization of B-cell receptors in CLL cells influence the metabolic vulnerability of leukemic stem/progenitor cells to tyrosine kinase inhibitors, and can this vulnerability be targeted by bis-biguanide alexidine to enhance treatment efficacy?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I propose the following experimental plan to test the hypothesis:

**Hypothesis:** Does the spatial organization of B-cell receptors in CLL cells influence the metabolic vulnerability of leukemic stem/progenitor cells to tyrosine kinase inhibitors, and can this vulnerability be targeted by bis-biguanide alexidine to enhance treatment efficacy?

**Experimental Approach:**

**Aim 1:** Investigate the effect of B-cell receptor (BcR) spatial organization on the metabolic profile of CLL leukemic stem/progenitor cells.

1. Isolate CLL leukemic stem/progenitor cells from patient samples or cell lines.
2. Use super-resolution microscopy (e.g., StormGraph) to visualize and quantify BcR organization in these cells.
3. Use CRISPR-Cas9 to specifically disrupt BcR signaling pathways in IgM U-CLL, IgM M-CLL, and IgG M-CLL cells.
4. Analyze the metabolic profile of the cells using Seahorse XF96 extracellular flux analysis or metabolomics.
5. Measure the expression of key metabolic genes and proteins involved in glycolysis, oxidative phosphorylation, and autophagy.

**Aim 2:** Investigate the effect of bis-biguanide alexidine (ALX) on the metabolic vulnerability of CLL leukemic stem/progenitor cells to tyrosine kinase inhibitors (TKIs).

1. Treat the cells with ALX and/or TKIs.
2. Analyze the metabolic profile of the cells using Seahorse XF96 extracellular flux analysis or metabolomics.
3. Measure the expression of key metabolic genes and proteins involved in glycolysis, oxidative phosphorylation, and autophagy.
4. Validate the results using CRISPR-Cas9 knockout or overexpression of specific metabolic genes.

**Aim 3:** Investigate the combined effect of BcR spatial organization and ALX on the metabolic vulnerability of CLL leukemic stem/progenitor cells to TKIs.

1. Treat the cells with ALX and/or TKIs, and analyze the metabolic profile as in Aim 2.
2. Use super-resolution microscopy to visualize and quantify BcR organization in these cells.
3. Correlate the BcR organization with the metabolic profile and response to ALX and TKIs.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the opposite scenario: that the spatial organization of B-cell receptors in CLL cells does not influence the metabolic vulnerability of leukemic stem/progenitor cells to tyrosine kinase inhibitors, and that bis-biguanide alexidine does not enhance treatment efficacy.

1. Use a control group of CLL cells with normal BcR organization and treat them with TKIs alone.
2. Compare the metabolic profile and response to TKIs in this control group with the experimental groups from Aim 1-3.
3. If the control group shows similar metabolic profiles and responses to TKIs as the experimental groups, it would suggest that BcR spatial organization does not influence the metabolic vulnerability of CLL leukemic stem/progenitor cells to TKIs, and that ALX does not enhance treatment efficacy.

**Required Equipment and Resources:**

* Super-resolution microscope (e.g., StormGraph)
* CRISPR-Cas9 system
* Seahorse XF96 extracellular flux analyzer
* Metabolomics platform
* Flow cytometer
* Cell culture facilities
* Standard molecular biology equipment
* Patient samples or cell lines
* ALX and TKIs
* Statistical analysis software

**Timeline and Budget:**

The experiment can be completed within 6-12 months, depending on the availability of resources and the complexity of the experiments. The budget will depend on the cost of the equipment, reagents, and personnel required for the experiment. A rough estimate would be around $200,000-$500,000.

Note: The experimental plan is designed to test the hypothesis and can be modified or optimized based on the results obtained during the experiment.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Aim 1: Investigate the effect of B-cell receptor (BcR) spatial organization on the metabolic profile of CLL leukemic stem/progenitor cells**

**Protocol 1.1: Isolation of CLL leukemic stem/progenitor cells**

1. Obtain patient samples or cell lines of CLL leukemic stem/progenitor cells.
2. Prepare the cells for isolation by washing them with phosphate-buffered saline (PBS) and centrifuging at 300 x g for 5 minutes.
3. Use a cell separation technique such as fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) to isolate the CLL leukemic stem/progenitor cells based on specific surface markers (e.g., CD19, CD20, CD34, CD38).
4. Verify the purity of the isolated cells using flow cytometry and adjust the sorting gates as necessary.

**Protocol 1.2: Visualization and quantification of BcR organization using super-resolution microscopy**

1. Prepare the isolated cells for imaging by fixing them with 4% paraformaldehyde (PFA) for 10 minutes at room temperature.
2. Permeabilize the cells with 0.1% Triton X-100 for 10 minutes at room temperature.
3. Block non-specific binding sites with 1% bovine serum albumin (BSA) for 30 minutes at room temperature.
4. Incubate the cells with a primary antibody against BcR (e.g., anti-IgM, anti-IgG) at a concentration of 1:100 for 1 hour at room temperature.
5. Wash the cells three times with PBS and incubate with a secondary antibody conjugated to a fluorophore (e.g., Alexa Fluor 488) at a concentration of 1:200 for 1 hour at room temperature.
6. Wash the cells three times with PBS and mount them on a glass slide using a mounting medium (e.g., ProLong Gold).
7. Image the cells using a super-resolution microscope (e.g., StormGraph) with a 100x oil immersion objective lens.
8. Acquire images in multiple z-stacks with a step size of 0.2 μm.
9. Use image analysis software (e.g., ImageJ, Fiji) to quantify the BcR organization by measuring the distance between BcR clusters, the number of BcR clusters per cell, and the intensity of BcR staining.

**Protocol 1.3: Disruption of BcR signaling pathways using CRISPR-Cas9**

1. Design guide RNAs (gRNAs) targeting the BcR signaling pathway genes (e.g., CD79A, CD79B, SYK) using a CRISPR design tool (e.g., CRISPR Design).
2. Prepare the CRISPR-Cas9 system by mixing the gRNA with the Cas9 enzyme and a transfection reagent (e.g., Lipofectamine 2000).
3. Transfect the CLL leukemic stem/progenitor cells with the CRISPR-Cas9 system using a nucleofector (e.g., Amaxa Nucleofector).
4. Verify the disruption of BcR signaling pathways using Western blotting or qRT-PCR.

**Protocol 1.4: Metabolic profiling using Seahorse XF96 extracellular flux analysis**

1. Prepare the cells for metabolic analysis by seeding them in a Seahorse XF96 plate at a density of 10,000 cells per well.
2. Incubate the cells in a Seahorse XF base medium supplemented with 10% FBS and 1% penicillin-streptomycin for 24 hours at 37°C and 5% CO2.
3. Perform the Seahorse XF96 extracellular flux analysis according to the manufacturer's instructions.
4. Measure the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using the Seahorse XF96 software.

**Protocol 1.5: Measurement of key metabolic genes and proteins**

1. Extract RNA from the cells using a RNA extraction kit (e.g., RNeasy).
2. Perform qRT-PCR using primers specific to key metabolic genes (e.g., HK2, PKM2, LDHA).
3. Extract protein from the cells using a protein extraction kit (e.g., RIPA).
4. Perform Western blotting using antibodies specific to key metabolic proteins (e.g., HK2, PKM2, LDHA).

**Aim 2: Investigate the effect of bis-biguanide alexidine (ALX) on the metabolic vulnerability of CLL leukemic stem/progenitor cells to tyrosine kinase inhibitors (TKIs)**

**Protocol 2.1: Treatment with ALX and/or TKIs**

1. Prepare a stock solution of ALX at a concentration of 10 mM in DMSO.
2. Prepare a stock solution of TKIs (e.g., ibrutinib, idelalisib) at a concentration of 10 mM in DMSO.
3. Treat the cells with ALX and/or TKIs at various concentrations (e.g., 1 μM, 5 μM, 10 μM) for 24 hours at 37°C and 5% CO2.

**Protocol 2.2: Metabolic profiling using Seahorse XF96 extracellular flux analysis**

1. Perform the Seahorse XF96 extracellular flux analysis as described in Protocol 1.4.

**Protocol 2.3: Measurement of key metabolic genes and proteins**

1. Perform qRT-PCR and Western blotting as described in Protocol 1.5.

**Protocol 2.4: Validation using CRISPR-Cas9 knockout or overexpression of specific metabolic genes**

1. Design gRNAs targeting specific metabolic genes (e.g., HK2, PKM2, LDHA) using a CRISPR design tool.
2. Prepare the CRISPR-Cas9 system as described in Protocol 1.3.
3. Transfect the cells with the CRISPR-Cas9 system to knockout or overexpress the specific metabolic genes.
4. Verify the knockout or overexpression using Western blotting or qRT-PCR.

**Aim 3: Investigate the combined effect of BcR spatial organization and ALX on the metabolic vulnerability of CLL leukemic stem/progenitor cells to TKIs**

**Protocol 3.1: Treatment with ALX and/or TKIs**

1. Treat the cells with ALX and/or TKIs as described in Protocol 2.1.

**Protocol 3.2: Visualization and quantification of BcR organization using super-resolution microscopy**

1. Perform super-resolution microscopy as described in Protocol 1.2.

**Protocol 3.3: Correlation of BcR organization with metabolic profile and response to ALX and TKIs**

1. Correlate the BcR organization data with the metabolic profile data using statistical analysis software (e.g., R, Python).
2. Analyze the correlation between BcR organization and response to ALX and TKIs using statistical analysis software.

**Experimental Design to Disprove the Hypothesis**

**Protocol: Control group with normal BcR organization**

1. Prepare a control group of CLL cells with normal BcR organization.
2. Treat the control group with TKIs alone.
3. Perform metabolic profiling and measurement of key metabolic genes and proteins as described in Protocols 1.4 and 1.5.
4. Compare the metabolic profile and response to TKIs in the control group with the experimental groups from Aim 1-3.

Note: The protocols above are detailed and step-by-step, but may require optimization and modification based on the specific experimental conditions and results.","```
   Patient_Sample  CD19  CD20  CD34  CD38  PFA  Triton_X_100  BSA  Anti_IgM  Anti_IgG  Alexa_Fluor_488  ALX  TKI  OCR  ECAR  HK2  PKM2  LDHA
0             1.0   0.5   0.3   0.2   0.4       0.05       0.01     0.01     0.02         0.05    1.0  5.0  150.0  100.0  2.0  1.5  1.0
1             2.0   0.6   0.4   0.3   0.5       0.06       0.02     0.02     0.03         0.06    2.0  2.0  120.0   90.0  1.8  1.2  0.8
2             3.0   0.7   0.5   0.4   0.6       0.07       0.03     0.03     0.04         0.07    3.0  1.0  180.0  120.0  2.2  1.8  1.2
3             4.0   0.8   0.6   0.5   0.7       0.08       0.04     0.04     0.05         0.08    4.0  3.0  150.0  100.0  2.0  1.5  1.0
4             5.0   0.9   0.7   0.6   0.8       0.09       0.05     0.05     0.06         0.09    5.0  4.0  120.0   90.0  1.8  1.2  0.8
5             1.0   0.5   0.3   0.2   0.4       0.05       0.01     0.01     0.02         0.05    1.0  1.0  180.0  120.0  2.2  1.8  1.2
6             2.0   0.6   0.4   0.3   0.5       0.06       0.02     0.02     0.03         0.06    2.0  2.0  150.0  100.0  2.0  1.5  1.0
7             3.0   0.7   0.5   0.4   0.6       0.07       0.03     0.03     0.04         0.07    3.0  3.0  120.0   90.0  1.8  1.2  0.8
8             4.0   0.8   0.6   0.5   0.7       0.08       0.04     0.04     0.05         0.08    4.0  4.0  180.0  120.0  2.2  1.8  1.2
9             5.0   0.9   0.7   0.6   0.8       0.09       0.05     0.05     0.06         0.09    5.0  5.0  150.0  100.0  2.0  1.5  1.0
10            1.0   0.5   0.3   0.2   0.4       0.05       0.01     0.01     0.02         0.05    1.0  1.0  120.0   90.0  1.8  1.2  0.8
11            2.0   0.6   0.4   0.3   0.5       0.06       0.02     0.02     0.03         0.06    2.0  2.0  180.0  120.0  2.2  1.8  1.2
12            3.0   0.7   0.5   0.4   0.6       0.07       0.03     0.03     0.04         0.07    3.0  3.0  150.0  100.0  2.0  1.5  1.0
13            4.0   0.8   0.6   0.5   0.7       0.08       0.04     0.04     0.05         0.08    4.0  4.0  120.0   90.0  1.8  1.2  0.8
14            5.0   0.9   0.7   0.6   0.8       0.09       0.05     0.05     0.06         0.09    5.0  5.0  180.0  120.0  2.2  1.8  1.2
15            1.0   0.5   0.3   0.2   0.4       0.05       0.01     0.01     0.02         0.05    1.0  1.0  150.0  100.0  2.0  1.5  1.0
16            2.0   0.6   0.4   0.3   0.5       0.06       0.02     0.02     0.03         0.06    2.0  2.0  120.0   90.0  1.8  1.2  0.8
17            3.0   0.7   0.5   0.4   0.6       0.07       0.03     0.03     0.04         0.07    3.0  3.0  180.0  120.0  2.2  1.8  1.2
18            4.0   0.8   0.6   0.5   0.7       0.08       0.04     0.04     0.05         0.08    4.0  4.0  150.0  100.0  2.0  1.5  1.0
19            5.0   0.9   0.7   0.6   0.8       0.09       0.05     0.05     0.06         0.09    5.0  5.0  120.0   90.0  1.8  1.2  0.8
20            1.0   0.5   0.3   0.2   0.4       0.05       0.01     0.01     0.02         0.05    1.0  1.0  180.0  120.0  2.2  1.8  1.2
21            2.0   0.6   0.4   0.3   0.5       0.06       0.02     0.02     0.03         0.06    2.0  2.0  150.0  100.0  2.0  1.5  1.0
22            3.0   0.7   0.5   0.4   0.6       0.07       0.03     0.03     0.04         0.07    3.0  3.0  120.0   90.0  1.8  1.2  0.8
23            4.0   0.8   0.6   0.5   0.7       0.08       0.04     0.04     0.05         0.08    4.0  4.0  180.0  120.0  2.2  1.8  1.2
24            5.0   0.9   0.7   0.6   0.8       0.09       0.05     0.05     0.06         0.09    5.0  5.0  150.0  100.0  2.0  1.5  1.0
```",0.1854216011076622
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c5c3f9e0e3d207002638f5a6c2c157cf2fec2c3e.summary'],Does the spatial organization of CXCR5 receptors on the surface of B-cells influence their ability to adapt to changes in the chemokine gradient and optimize antigen scanning rates?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experiment to test it.

**Hypothesis:** The spatial organization of CXCR5 receptors on the surface of B-cells influences their ability to adapt to changes in the chemokine gradient and optimize antigen scanning rates.

**Experimental Plan:**

**Objective:** To investigate whether the spatial organization of CXCR5 receptors on B-cells affects their ability to adapt to changes in the chemokine gradient and optimize antigen scanning rates.

**Experimental Design:**

1. **Cell Preparation:**
	* Isolate B-cells from mouse spleens or human peripheral blood using standard protocols (e.g., FACS sorting or magnetic bead separation).
	* Culture B-cells in vitro with or without CXCR5 receptor clustering inducers (e.g., CXCL13, a CXCR5 ligand) to modulate receptor organization.
2. **Chemokine Gradient Generation:**
	* Create a microfluidic device with a gradient generator to produce a controlled, dynamic chemokine gradient (e.g., CXCL13) using a syringe pump and a gradient mixer.
	* Verify the gradient using fluorescently labeled chemokine and confocal microscopy.
3. **Antigen Scanning Assay:**
	* Use a microsphere-based antigen presentation system, where antigen-coated microspheres are added to the microfluidic device.
	* Measure the interaction between B-cells and antigen-coated microspheres using total internal reflection fluorescence (TIRF) microscopy or confocal microscopy.
4. **CXCR5 Receptor Organization Analysis:**
	* Use super-resolution microscopy (e.g., STORM or STED) to visualize and quantify the spatial organization of CXCR5 receptors on the surface of B-cells.
	* Analyze receptor clustering, density, and distribution using image analysis software (e.g., ImageJ or Ilastik).
5. **Data Analysis:**
	* Compare the antigen scanning rates and chemokine gradient adaptation of B-cells with different CXCR5 receptor organizations.
	* Correlate receptor organization with antigen scanning rates and chemokine gradient adaptation using statistical analysis (e.g., Pearson's correlation coefficient).

**Experiment to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the null hypothesis: ""The spatial organization of CXCR5 receptors on the surface of B-cells does not influence their ability to adapt to changes in the chemokine gradient and optimize antigen scanning rates.""

**Modified Experimental Design:**

1. **Randomize CXCR5 Receptor Organization:**
	* Use a receptor- clustering disruptor (e.g., a CXCR5 antagonist) to randomize the spatial organization of CXCR5 receptors on the surface of B-cells.
	* Verify the disruption of receptor clustering using super-resolution microscopy.
2. **Maintain Constant Chemokine Gradient:**
	* Use a uniform, non-gradient chemokine concentration in the microfluidic device to eliminate any potential effects of the chemokine gradient on B-cell behavior.
3. **Measure Antigen Scanning Rates:**
	* Perform the antigen scanning assay as described above.
4. **Compare Antigen Scanning Rates:**
	* Compare the antigen scanning rates of B-cells with randomized CXCR5 receptor organization to those with native receptor organization.

**Expected Outcome:**
If the hypothesis is true, we expect to see no significant difference in antigen scanning rates between B-cells with randomized CXCR5 receptor organization and those with native organization, as the disrupted receptor organization should impair their ability to adapt to changes in the chemokine gradient. If the results show no significant difference, it would suggest that the spatial organization of CXCR5 receptors does not influence antigen scanning rates, disproving the original hypothesis.

**Budget and Timeframe:**

This experiment can be performed within a reasonable timeframe (6-12 months) and budget (~ $200,000 - $500,000), considering the use of existing laboratory equipment and resources. The budget will cover:

* Cell culture and reagents
* Microfluidic device fabrication and chemokine gradient generation
* Super-resolution microscopy and image analysis software
* Personnel and laboratory costs

Please note that these estimates are rough and may vary depending on the specific laboratory setup and location.",92,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Preparation**

1.1. Isolation of B-cells from mouse spleens or human peripheral blood:

* Obtain mouse spleens or human peripheral blood samples from a reputable source.
* Prepare a sterile workspace and equipment.
* Perform FACS sorting or magnetic bead separation to isolate B-cells according to standard protocols.
* Verify the purity of the isolated B-cells using flow cytometry or microscopy.

1.2. Culture of B-cells with or without CXCR5 receptor clustering inducers:

* Prepare a sterile cell culture medium (e.g., RPMI 1640 with 10% FBS and 1% penicillin-streptomycin).
* Add CXCR5 receptor clustering inducers (e.g., CXCL13) to the culture medium at a concentration of 10-100 ng/mL.
* Incubate the B-cells in the culture medium with or without CXCL13 for 24-48 hours at 37°C and 5% CO2.
* Verify the clustering of CXCR5 receptors using super-resolution microscopy (Protocol 4).

**Protocol 2: Chemokine Gradient Generation**

2.1. Fabrication of the microfluidic device:

* Design and fabricate a microfluidic device with a gradient generator using a 3D printer or soft lithography.
* Verify the device's functionality and gradient generation using a fluorescent dye.

2.2. Generation of the chemokine gradient:

* Prepare a stock solution of CXCL13 (10 μg/mL) in PBS.
* Connect the microfluidic device to a syringe pump and a gradient mixer.
* Program the syringe pump to generate a dynamic chemokine gradient (e.g., 0-100 ng/mL) over a distance of 1-5 mm.
* Verify the gradient using fluorescently labeled CXCL13 and confocal microscopy.

**Protocol 3: Antigen Scanning Assay**

3.1. Preparation of antigen-coated microspheres:

* Prepare a stock solution of antigen (e.g., ovalbumin) in PBS.
* Coat microspheres (e.g., 1-5 μm diameter) with the antigen solution according to the manufacturer's instructions.
* Verify the antigen coating using flow cytometry or microscopy.

3.2. Antigen scanning assay:

* Add the antigen-coated microspheres to the microfluidic device.
* Introduce the B-cells into the microfluidic device and allow them to interact with the antigen-coated microspheres.
* Use TIRF or confocal microscopy to measure the interaction between B-cells and antigen-coated microspheres.
* Record the antigen scanning rates (e.g., number of interactions per minute) using image analysis software.

**Protocol 4: CXCR5 Receptor Organization Analysis**

4.1. Sample preparation:

* Fix the B-cells using a fixative (e.g., 4% paraformaldehyde) for 10-15 minutes.
* Permeabilize the cells using a permeabilization buffer (e.g., 0.1% Triton X-100) for 10-15 minutes.
* Block non-specific binding sites using a blocking buffer (e.g., 1% BSA) for 30 minutes.

4.2. Immunofluorescence staining:

* Incubate the B-cells with a primary antibody against CXCR5 (e.g., 1:100 dilution) for 1 hour.
* Incubate the cells with a secondary antibody (e.g., 1:200 dilution) for 1 hour.
* Verify the staining using confocal microscopy.

4.3. Super-resolution microscopy:

* Use a super-resolution microscope (e.g., STORM or STED) to visualize the spatial organization of CXCR5 receptors on the surface of B-cells.
* Acquire images with a resolution of 20-50 nm.
* Analyze the images using image analysis software (e.g., ImageJ or Ilastik) to quantify receptor clustering, density, and distribution.

**Protocol 5: Data Analysis**

5.1. Data collection:

* Collect data on antigen scanning rates, chemokine gradient adaptation, and CXCR5 receptor organization for each experimental condition.
* Verify the data quality and consistency.

5.2. Statistical analysis:

* Compare the antigen scanning rates and chemokine gradient adaptation of B-cells with different CXCR5 receptor organizations using statistical analysis (e.g., Pearson's correlation coefficient).
* Correlate receptor organization with antigen scanning rates and chemokine gradient adaptation using statistical analysis.

**Protocol 6: Experiment to Disprove the Hypothesis**

6.1. Randomization of CXCR5 receptor organization:

* Use a receptor-clustering disruptor (e.g., a CXCR5 antagonist) to randomize the spatial organization of CXCR5 receptors on the surface of B-cells.
* Verify the disruption of receptor clustering using super-resolution microscopy.

6.2. Maintenance of a constant chemokine gradient:

* Use a uniform, non-gradient chemokine concentration in the microfluidic device to eliminate any potential effects of the chemokine gradient on B-cell behavior.

6.3. Measurement of antigen scanning rates:

* Perform the antigen scanning assay as described in Protocol 3.

6.4. Comparison of antigen scanning rates:

* Compare the antigen scanning rates of B-cells with randomized CXCR5 receptor organization to those with native receptor organization.

Note: These protocols are detailed and specific, but may require adjustments based on the specific laboratory setup and equipment. It is essential to follow proper laboratory protocols, safety guidelines, and quality control measures to ensure the accuracy and reproducibility of the results.","```
   CXCL13_ngmL  Antigen_conc  CXCR5_receptor_organization  Antigen_scanning_rate
0           10.0         0.01                    clustered                    5.2
1           20.0         0.05                    clustered                    7.5
2           50.0         0.10                    clustered                   10.1
3           10.0         0.01                    dispersed                    3.1
4           20.0         0.05                    dispersed                    4.8
5           50.0         0.10                    dispersed                    6.5
6           10.0         0.01                    random                       4.2
7           20.0         0.05                    random                       5.9
8           50.0         0.10                    random                       7.8
9           10.0         0.05                    clustered                    6.8
10          20.0         0.10                    clustered                   11.3
11          50.0         0.20                    clustered                   14.5
12          10.0         0.05                    dispersed                    4.5
13          20.0         0.10                    dispersed                    6.2
14          50.0         0.20                    dispersed                    8.1
15          10.0         0.05                    random                       5.5
16          20.0         0.10                    random                       7.2
17          50.0         0.20                    random                       9.5
18          20.0         0.01                    clustered                    6.1
19          50.0         0.05                    clustered                    9.8
20          10.0         0.10                    clustered                   12.2
21          20.0         0.01                    dispersed                    4.9
22          50.0         0.05                    dispersed                    7.4
23          10.0         0.10                    dispersed                    9.1
24          20.0         0.05                    random                       6.6
```",0.25062130883414246
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/0585bdb6230e873b33cf01b15c8841eef578f9f2.summary'],Does the spatial organization of hypermutation hotspots in immunoglobulin genes influence the evolution of antibody specificity by favoring the selection of mutations that alter epitope recognition?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** The spatial organization of hypermutation hotspots in immunoglobulin genes influences the evolution of antibody specificity by favoring the selection of mutations that alter epitope recognition.

**Experimental Plan:**

**Objective:** To test whether the spatial organization of hypermutation hotspots in immunoglobulin genes affects the evolution of antibody specificity.

**Approach:**

1. **Mutagenesis and Library Generation**:
	* Use a site-directed mutagenesis approach to introduce random mutations in the immunoglobulin genes, focusing on the hypermutation hotspots.
	* Generate a library of mutated immunoglobulin genes with varying spatial organizations of hypermutation hotspots.
2. **Antibody Expression and Purification**:
	* Express the mutated immunoglobulin genes in a suitable host system (e.g., E. coli or mammalian cells).
	* Purify the resulting antibodies using standard protocols (e.g., affinity chromatography).
3. **Epitope Recognition Assay**:
	* Design a high-throughput epitope recognition assay using a panel of epitopes with varying affinities for the wild-type antibody.
	* Measure the binding affinities of the mutated antibodies to each epitope using techniques like surface plasmon resonance (SPR) or enzyme-linked immunosorbent assay (ELISA).
4. **Data Analysis and Selection**:
	* Analyze the binding data to identify mutations that alter epitope recognition.
	* Select a subset of mutated antibodies with altered epitope recognition for further analysis.
5. **Structural Analysis**:
	* Perform structural analysis (e.g., X-ray crystallography or cryo-EM) on the selected mutated antibodies to determine the impact of the mutations on the antibody-epitope interface.

**Experimental Design to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that tests the null hypothesis: ""The spatial organization of hypermutation hotspots in immunoglobulin genes does not influence the evolution of antibody specificity.""

**Null Hypothesis Experiment:**

1. **Random Mutagenesis**:
	* Introduce random mutations throughout the immunoglobulin gene, without focusing on hypermutation hotspots.
	* Generate a library of mutated immunoglobulin genes with random mutations.
2. **Antibody Expression and Purification**:
	* Express and purify the mutated antibodies as described above.
3. **Epitope Recognition Assay**:
	* Perform the epitope recognition assay as described above.
4. **Data Analysis**:
	* Analyze the binding data to identify mutations that alter epitope recognition.
	* Compare the frequency and distribution of mutations that alter epitope recognition between the random mutagenesis library and the hypermutation hotspot-focused library.

**Expected Outcome:**

If the hypothesis is true, we expect to see a significant difference in the frequency and distribution of mutations that alter epitope recognition between the two libraries. Specifically, the hypermutation hotspot-focused library should show a higher frequency of mutations that alter epitope recognition, and these mutations should be enriched in the hypermutation hotspots.

**Budget and Timeframe:**

This experiment can be completed within 6-12 months with a moderate budget (~$200,000 - $500,000). The budget will cover:

* Reagents and consumables for mutagenesis, antibody expression, and purification
* Equipment and personnel costs for epitope recognition assays and structural analysis
* Computational resources for data analysis

By following this experimental plan, we can test the hypothesis and determine whether the spatial organization of hypermutation hotspots in immunoglobulin genes influences the evolution of antibody specificity.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Mutagenesis and Library Generation**

**Step 1.1: Primer Design**

* Design primers for site-directed mutagenesis using a software tool (e.g., Primer3) to introduce random mutations in the immunoglobulin genes, focusing on the hypermutation hotspots.
* Design primers to introduce mutations at a frequency of 1-2 mutations per kilobase, with a bias towards transitions (A↔G or C↔T) to mimic the natural mutational spectrum.

**Step 1.2: Mutagenesis Reaction**

* Perform site-directed mutagenesis using a commercial kit (e.g., QuikChange II XL) according to the manufacturer's instructions.
* Set up 10-20 reactions with different primer pairs to introduce mutations in different regions of the immunoglobulin gene.
* Incubate the reactions at 37°C for 1 hour, followed by 10-15 minutes at 80°C to inactivate the polymerase.

**Step 1.3: Library Generation**

* Transform the mutagenized DNA into a suitable host system (e.g., E. coli DH5α) using a commercial competent cell kit (e.g., One Shot TOP10).
* Plate the transformed cells on selective media (e.g., LB agar with ampicillin) and incubate at 37°C overnight.
* Harvest the colonies and extract the plasmid DNA using a commercial kit (e.g., QIAprep Spin Miniprep).

**Protocol 2: Antibody Expression and Purification**

**Step 2.1: Expression Vector Construction**

* Clone the mutated immunoglobulin genes into an expression vector (e.g., pFUSE2-CLIg-hIgG1) using standard molecular biology techniques.
* Verify the clones by sequencing and restriction enzyme digestion.

**Step 2.2: Antibody Expression**

* Transfect the expression vector into a suitable host system (e.g., HEK293T cells) using a commercial transfection reagent (e.g., Lipofectamine 2000).
* Incubate the cells at 37°C, 5% CO2 for 3-5 days to allow for antibody expression.

**Step 2.3: Antibody Purification**

* Harvest the cell culture supernatant and purify the antibodies using affinity chromatography (e.g., Protein A or G Sepharose).
* Elute the antibodies with a buffer (e.g., 0.1 M glycine, pH 2.7) and neutralize with a buffer (e.g., 1 M Tris, pH 8.0).
* Concentrate the antibodies using a centrifugal filter (e.g., Amicon Ultra-15) and store at -80°C.

**Protocol 3: Epitope Recognition Assay**

**Step 3.1: Epitope Preparation**

* Prepare a panel of epitopes with varying affinities for the wild-type antibody using standard peptide synthesis techniques.
* Purify the epitopes using HPLC and verify their identity by mass spectrometry.

**Step 3.2: SPR Assay**

* Immobilize the epitopes on a sensor chip (e.g., CM5) using a commercial kit (e.g., Amine Coupling Kit).
* Perform SPR assays using a commercial instrument (e.g., Biacore T200) according to the manufacturer's instructions.
* Measure the binding affinities of the mutated antibodies to each epitope using a 1:1 binding model.

**Step 3.3: ELISA Assay**

* Coat a 96-well plate with the epitopes (100 ng/well) and incubate at 4°C overnight.
* Add the mutated antibodies (100 ng/well) and incubate at room temperature for 1 hour.
* Detect the bound antibodies using a secondary antibody conjugated to HRP and a commercial substrate (e.g., TMB).
* Measure the absorbance at 450 nm using a plate reader.

**Protocol 4: Data Analysis and Selection**

**Step 4.1: Data Analysis**

* Analyze the binding data using a software tool (e.g., GraphPad Prism) to calculate the binding affinities (KD) and dissociation rates (koff).
* Identify mutations that alter epitope recognition by comparing the binding affinities and dissociation rates to the wild-type antibody.

**Step 4.2: Selection**

* Select a subset of mutated antibodies with altered epitope recognition for further analysis based on the binding data.
* Prioritize mutations that show a significant change in binding affinity or dissociation rate.

**Protocol 5: Structural Analysis**

**Step 5.1: Protein Purification**

* Purify the selected mutated antibodies using size exclusion chromatography (e.g., Superdex 200) and concentrate using a centrifugal filter (e.g., Amicon Ultra-15).

**Step 5.2: Crystallization**

* Set up crystallization trials using a commercial kit (e.g., Hampton Research) and a robotic crystallization system (e.g., Mosquito).
* Optimize the crystallization conditions using a software tool (e.g., CrystalScreen).

**Step 5.3: X-ray Crystallography**

* Collect X-ray diffraction data using a synchrotron source (e.g., APS) and a detector (e.g., Pilatus).
* Solve the structure using a software tool (e.g., PHENIX) and refine the model using a software tool (e.g., REFMAC).

**Null Hypothesis Experiment**

**Protocol 1: Random Mutagenesis**

**Step 1.1: Primer Design**

* Design primers for random mutagenesis using a software tool (e.g., Primer3) to introduce random mutations throughout the immunoglobulin gene.
* Design primers to introduce mutations at a frequency of 1-2 mutations per kilobase, with a bias towards transitions (A↔G or C↔T) to mimic the natural mutational spectrum.

**Step 1.2: Mutagenesis Reaction**

* Perform random mutagenesis using a commercial kit (e.g., GeneMorph II) according to the manufacturer's instructions.
* Set up 10-20 reactions with different primer pairs to introduce mutations in different regions of the immunoglobulin gene.
* Incubate the reactions at 37°C for 1 hour, followed by 10-15 minutes at 80°C to inactivate the polymerase.

**Step 1.3: Library Generation**

* Transform the mutagenized DNA into a suitable host system (e.g., E. coli DH5α) using a commercial competent cell kit (e.g., One Shot TOP10).
* Plate the transformed cells on selective media (e.g., LB agar with ampicillin) and incubate at 37°C overnight.
* Harvest the colonies and extract the plasmid DNA using a commercial kit (e.g., QIAprep Spin Miniprep).

The remaining protocols (Antibody Expression and Purification, Epitope Recognition Assay, Data Analysis and Selection, and Structural Analysis) are identical to the original protocols.

Note: The protocols are designed to be specific, detailed, and replicable. The experimental design and protocols are based on standard molecular biology and biochemical techniques, and the materials and equipment required are commercially available. The budget and timeframe estimates are rough and may vary depending on the specific requirements of the experiment.","```
   Primer_Pairs  Mutagenesis_Reactions  Transformation_Efficiency  Epitope_Affinity  Binding_Affinity  Dissociation_Rate  Outcome
0             5                  10                    0.8           100.0          10.0           0.01          Altered
1             3                  15                    0.9           120.0          12.0           0.02          Altered
2             4                  12                    0.7           90.0           9.0            0.03          Unaltered
3             6                  18                    0.85          110.0          11.0           0.01          Altered
4             2                  10                    0.75          80.0           8.0            0.04          Unaltered
5             5                  12                    0.9           130.0          13.0           0.02          Altered
6             3                  15                    0.8           100.0          10.0           0.01          Altered
7             4                  18                    0.85          120.0          12.0           0.02          Altered
8             6                  10                    0.7           90.0           9.0            0.03          Unaltered
9             2                  12                    0.75          80.0           8.0            0.04          Unaltered
10            5                  15                    0.9           130.0          13.0           0.02          Altered
11            3                  18                    0.85          110.0          11.0           0.01          Altered
12            4                  10                    0.8           100.0          10.0           0.01          Altered
13            6                  12                    0.7           90.0           9.0            0.03          Unaltered
14            2                  15                    0.75          80.0           8.0            0.04          Unaltered
15            5                  18                    0.9           130.0          13.0           0.02          Altered
16            3                  10                    0.85          120.0          12.0           0.02          Altered
17            4                  12                    0.8           100.0          10.0           0.01          Altered
18            6                  15                    0.7           90.0           9.0            0.03          Unaltered
19            2                  18                    0.75          80.0           8.0            0.04          Unaltered
20            5                  10                    0.9           130.0          13.0           0.02          Altered
21            3                  12                    0.85          110.0          11.0           0.01          Altered
22            4                  15                    0.8           100.0          10.0           0.01          Altered
23            6                  18                    0.7           90.0           9.0            0.03          Unaltered
24            2                  10                    0.75          80.0           8.0            0.04          Unaltered
```",0.3065996391585599
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/6d26b510867fe0479ed2aca452a55cd335550137.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/e3a7f8be155c8b515088c72c62800e037c465b4b.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/f98aaeb1ffacbb8a55426169c730bf359245a869.summary']","Does the spatial organization of the immunological synapse regulate the activity of Rac GEFs, such as DOCK2, to modulate B-cell activation and antibody production?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! To test this hypothesis, I'll outline a comprehensive experimental plan to investigate the role of immunological synapse spatial organization in regulating Rac GEFs, specifically DOCK2, and its impact on B-cell activation and antibody production.

**Hypothesis:** The spatial organization of the immunological synapse regulates the activity of Rac GEFs, such as DOCK2, to modulate B-cell activation and antibody production.

**Experimental Approach:**

**Aim 1: Investigate the spatial organization of the immunological synapse and DOCK2 localization**

1. **Immunofluorescence microscopy**: Use high-resolution microscopy (e.g., super-resolution microscopy, such as STORM or STED) to visualize the immunological synapse in B cells interacting with antigen-presenting cells (APCs). Label DOCK2, Rac, and other key proteins involved in the immunological synapse using specific antibodies.
2. **Single-molecule localization microscopy (SMLM)**: Employ SMLM to quantify the spatial organization of DOCK2 and other proteins at the immunological synapse. This will provide high-resolution information on protein localization and clustering.

**Aim 2: Disrupt the spatial organization of the immunological synapse and assess DOCK2 activity**

1. **Latrunculin A treatment**: Treat B cells with Latrunculin A, a drug that disrupts actin polymerization, to perturb the immunological synapse structure.
2. **Micro-patterned surfaces**: Use micro-patterned surfaces to control the spatial organization of the immunological synapse. This will allow for the creation of defined patterns of antigen presentation and B-cell activation.
3. **DOCK2 activity assays**: Measure DOCK2 activity using biochemical assays (e.g., GEF assays) or live-cell imaging techniques (e.g., FRET-based sensors) to assess the impact of immunological synapse disruption on DOCK2 activity.

**Aim 3: Investigate the effect of DOCK2 activity on B-cell activation and antibody production**

1. **B-cell activation assays**: Measure B-cell activation markers (e.g., CD69, CD86) and antibody production (e.g., ELISA) in response to antigen stimulation.
2. **DOCK2 knockdown or overexpression**: Use RNAi or CRISPR-Cas9 to knockdown or overexpress DOCK2 in B cells and assess the impact on B-cell activation and antibody production.

**Experiment to DISPROVE the hypothesis:**

**""Disrupting the immunological synapse does not affect DOCK2 activity or B-cell activation""**

1. **Use a dominant-negative DOCK2 mutant**: Express a dominant-negative DOCK2 mutant in B cells to specifically inhibit DOCK2 activity, regardless of immunological synapse organization.
2. **Measure B-cell activation and antibody production**: Assess B-cell activation markers and antibody production in response to antigen stimulation in the presence of the dominant-negative DOCK2 mutant.
3. **Compare to control conditions**: Compare the results to control conditions where the immunological synapse is intact and DOCK2 activity is not inhibited.

If the hypothesis is true, disrupting the immunological synapse should affect DOCK2 activity and B-cell activation. However, if the dominant-negative DOCK2 mutant inhibits B-cell activation and antibody production independently of immunological synapse organization, it would suggest that the spatial organization of the immunological synapse does not regulate DOCK2 activity, thus disproving the hypothesis.

**Additional considerations:**

* Use multiple B-cell lines and primary B cells to ensure the results are not cell-line specific.
* Perform experiments in the presence and absence of antigen to control for non-specific effects.
* Include appropriate controls for each experiment to account for potential artifacts.
* Use advanced statistical analysis and data visualization techniques to ensure robust and accurate interpretation of the results.

With an unlimited budget, this experimental plan can be executed using state-of-the-art equipment and techniques, ensuring a comprehensive and rigorous investigation of the hypothesis.",92,"Here are the detailed, step-by-step protocols for each aim of the experimental plan:

**Aim 1: Investigate the spatial organization of the immunological synapse and DOCK2 localization**

**Protocol 1.1: Immunofluorescence Microscopy**

1.1.1. Cell Preparation:

* Culture B cells and antigen-presenting cells (APCs) in complete medium at 37°C, 5% CO2.
* Harvest cells and wash twice with PBS.
* Fix cells with 4% paraformaldehyde (PFA) for 15 minutes at room temperature.
* Permeabilize cells with 0.1% Triton X-100 for 10 minutes at room temperature.

1.1.2. Antibody Labeling:

* Prepare primary antibodies against DOCK2, Rac, and other key proteins involved in the immunological synapse.
* Incubate cells with primary antibodies (1:100 dilution) for 1 hour at room temperature.
* Wash cells three times with PBS.
* Incubate cells with secondary antibodies (1:200 dilution) conjugated to fluorophores (e.g., Alexa Fluor 488, 594, or 647) for 1 hour at room temperature.
* Wash cells three times with PBS.

1.1.3. Microscopy:

* Mount cells on glass slides using a mounting medium (e.g., ProLong Gold).
* Image cells using a super-resolution microscope (e.g., STORM or STED) with a 100x oil immersion objective.
* Acquire images with a pixel size of 20-30 nm and a z-step size of 100-200 nm.

**Protocol 1.2: Single-Molecule Localization Microscopy (SMLM)**

1.2.1. Cell Preparation:

* Follow the same cell preparation steps as in Protocol 1.1.1.

1.2.2. Antibody Labeling:

* Prepare primary antibodies against DOCK2 and other proteins involved in the immunological synapse.
* Incubate cells with primary antibodies (1:100 dilution) for 1 hour at room temperature.
* Wash cells three times with PBS.
* Incubate cells with secondary antibodies (1:200 dilution) conjugated to photoactivatable fluorophores (e.g., Alexa Fluor 647) for 1 hour at room temperature.
* Wash cells three times with PBS.

1.2.3. SMLM:

* Mount cells on glass slides using a mounting medium (e.g., ProLong Gold).
* Image cells using an SMLM microscope (e.g., dSTORM or PALM) with a 100x oil immersion objective.
* Acquire images with a pixel size of 20-30 nm and a z-step size of 100-200 nm.
* Use software (e.g., ThunderSTORM or PALM-Tracer) to localize individual molecules and reconstruct the spatial organization of DOCK2 and other proteins.

**Aim 2: Disrupt the spatial organization of the immunological synapse and assess DOCK2 activity**

**Protocol 2.1: Latrunculin A Treatment**

2.1.1. Cell Preparation:

* Culture B cells and APCs in complete medium at 37°C, 5% CO2.
* Treat B cells with 1 μM Latrunculin A for 30 minutes at 37°C, 5% CO2.

2.1.2. Immunofluorescence Microscopy:

* Follow the same immunofluorescence microscopy protocol as in Protocol 1.1.

**Protocol 2.2: Micro-Patterned Surfaces**

2.2.1. Surface Preparation:

* Prepare micro-patterned surfaces with defined patterns of antigen presentation using techniques such as microcontact printing or photolithography.
* Coat surfaces with a protein layer (e.g., fibronectin) to facilitate cell adhesion.

2.2.2. Cell Adhesion:

* Seed B cells onto micro-patterned surfaces and incubate for 30 minutes at 37°C, 5% CO2.
* Wash cells gently with PBS to remove non-adherent cells.

2.2.3. Immunofluorescence Microscopy:

* Follow the same immunofluorescence microscopy protocol as in Protocol 1.1.

**Protocol 2.3: DOCK2 Activity Assays**

2.3.1. Biochemical Assays:

* Lyse B cells and measure DOCK2 activity using biochemical assays (e.g., GEF assays) according to the manufacturer's instructions.

2.3.2. Live-Cell Imaging:

* Transfect B cells with FRET-based sensors for DOCK2 activity.
* Image cells using a live-cell imaging microscope (e.g., confocal or TIRF) with a 100x oil immersion objective.
* Acquire images with a pixel size of 20-30 nm and a z-step size of 100-200 nm.

**Aim 3: Investigate the effect of DOCK2 activity on B-cell activation and antibody production**

**Protocol 3.1: B-Cell Activation Assays**

3.1.1. Cell Stimulation:

* Stimulate B cells with antigen (e.g., anti-IgM) for 24-48 hours at 37°C, 5% CO2.

3.1.2. Flow Cytometry:

* Stain cells with antibodies against B-cell activation markers (e.g., CD69, CD86).
* Analyze cells using flow cytometry (e.g., FACS).

**Protocol 3.2: DOCK2 Knockdown or Overexpression**

3.2.1. RNAi or CRISPR-Cas9:

* Use RNAi or CRISPR-Cas9 to knockdown or overexpress DOCK2 in B cells according to the manufacturer's instructions.

3.2.2. B-Cell Activation Assays:

* Follow the same B-cell activation assay protocol as in Protocol 3.1.

**Experiment to DISPROVE the Hypothesis**

**Protocol 4.1: Dominant-Negative DOCK2 Mutant**

4.1.1. Cell Transfection:

* Transfect B cells with a dominant-negative DOCK2 mutant using a transfection reagent (e.g., Lipofectamine).

4.1.2. B-Cell Activation Assays:

* Follow the same B-cell activation assay protocol as in Protocol 3.1.

4.1.3. Comparison to Control Conditions:

* Compare the results to control conditions where the immunological synapse is intact and DOCK2 activity is not inhibited.

**Additional Considerations**

* Use multiple B-cell lines and primary B cells to ensure the results are not cell-line specific.
* Perform experiments in the presence and absence of antigen to control for non-specific effects.
* Include appropriate controls for each experiment to account for potential artifacts.
* Use advanced statistical analysis and data visualization techniques to ensure robust and accurate interpretation of the results.","```
   B Cells  APCs  PFA  Triton X-100  DOCK2 Antibody  Rac Antibody  Latrunculin A  Micro-Patterned Surfaces  DOCK2 Activity  Outcome
0       10000   5000    4%          0.1%           1:100          1:100             0.0                  0.0          High      Normal
1       15000   7500    4%          0.1%           1:100          1:100             0.0                  0.0          High      Normal
2       20000  10000    4%          0.1%           1:100          1:100             0.0                  0.0          High      Normal
3       10000   5000    4%          0.1%           1:50           1:100             0.0                  0.0          Low       Abnormal
4       15000   7500    4%          0.1%           1:50           1:100             0.0                  0.0          Low       Abnormal
5       20000  10000    4%          0.1%           1:50           1:100             0.0                  0.0          Low       Abnormal
6       10000   5000    4%          0.1%           1:100          1:50             0.0                  0.0          High      Normal
7       15000   7500    4%          0.1%           1:100          1:50             0.0                  0.0          High      Normal
8       20000  10000    4%          0.1%           1:100          1:50             0.0                  0.0          High      Normal
9       10000   5000    4%          0.1%           1:100          1:100             1.0                  0.0          Low       Abnormal
10      15000   7500    4%          0.1%           1:100          1:100             1.0                  0.0          Low       Abnormal
11      20000  10000    4%          0.1%           1:100          1:100             1.0                  0.0          Low       Abnormal
12      10000   5000    4%          0.1%           1:100          1:100             0.0                  1.0          High      Normal
13      15000   7500    4%          0.1%           1:100          1:100             0.0                  1.0          High      Normal
14      20000  10000    4%          0.1%           1:100          1:100             0.0                  1.0          High      Normal
15      10000   5000    4%          0.1%           1:100          1:100             0.0                  0.0          High      Normal
16      15000   7500    4%          0.1%           1:100          1:100             0.0                  0.0          High      Normal
17      20000  10000    4%          0.1%           1:100          1:100             0.0                  0.0          High      Normal
18      10000   5000    4%          0.1%           1:100          1:100             1.0                  1.0          Low       Abnormal
19      15000   7500    4%          0.1%           1:100          1:100             1.0                  1.0          Low       Abnormal
20      20000  10000    4%          0.1%           1:100          1:100             1.0                  1.0          Low       Abnormal
21      10000   5000    4%          0.1%           1:50           1:50             0.0                  0.0          Low       Abnormal
22      15000   7500    4%          0.1%           1:50           1:50             0.0                  0.0          Low       Abnormal
23      20000  10000    4%          0.1%           1:50           1:50             0.0                  0.0          Low       Abnormal
24      10000   5000    4%          0.1%           1:100          1:100             0.0                  0.0          High      Normal
```",0
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/a15481dd8246ab357a83ab59f152a45a48d1c3b7.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/136a26b8179a2ee11d2c8d09297f4d689e29ec3d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/8065496c3cfd66d5df19b1e7533a162f75b46e7c.summary']",Does the spatial organization of the plasma membrane influence the aberrant spreading behavior of ARPC1B-deficient B cells by modulating actin dynamics and protein interactions?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",,"What a fascinating hypothesis! I'd be delighted to help design an experimental plan to test it.

**Hypothesis:** The spatial organization of the plasma membrane influences the aberrant spreading behavior of ARPC1B-deficient B cells by modulating actin dynamics and protein interactions.

**Experimental Plan:**

**Objective:** To investigate whether the spatial organization of the plasma membrane affects the aberrant spreading behavior of ARPC1B-deficient B cells by modulating actin dynamics and protein interactions.

**Approach:**

1. **Cell Culture and Preparation:**
	* Obtain ARPC1B-deficient B cells and wild-type B cells as controls.
	* Culture cells in a suitable medium and maintain them at optimal conditions.
	* Transfect ARPC1B-deficient B cells with a fluorescently tagged ARPC1B construct to rescue the deficiency (if possible).
2. **Plasma Membrane Organization Manipulation:**
	* Use lipid raft disruptors (e.g., methyl-β-cyclodextrin) or cholesterol-depleting agents (e.g., statins) to perturb the plasma membrane organization in ARPC1B-deficient B cells.
	* Use lipid raft stabilizers (e.g., cholesterol) or membrane-organizing agents (e.g., caveolin-1) to enhance plasma membrane organization in ARPC1B-deficient B cells.
3. **Actin Dynamics Analysis:**
	* Use live-cell imaging techniques (e.g., total internal reflection fluorescence microscopy, TIRF) to visualize and quantify actin dynamics in ARPC1B-deficient B cells with manipulated plasma membrane organization.
	* Measure actin filament length, density, and dynamics using image analysis software (e.g., Fiji, ImageJ).
4. **Protein Interaction Analysis:**
	* Perform co-immunoprecipitation (co-IP) assays to investigate protein interactions between ARPC1B and actin-regulating proteins (e.g., WASP, Arp2/3 complex) in ARPC1B-deficient B cells with manipulated plasma membrane organization.
	* Use mass spectrometry-based proteomics to identify and quantify protein interactions.
5. **Spreading Behavior Analysis:**
	* Use time-lapse microscopy to monitor and quantify the spreading behavior of ARPC1B-deficient B cells with manipulated plasma membrane organization on various substrates (e.g., fibronectin, collagen).
	* Measure cell spreading area, speed, and persistence using image analysis software.

**Experiment to Disprove the Hypothesis:**

**Objective:** To design an experiment that, if successful, would disprove the hypothesis that the spatial organization of the plasma membrane influences the aberrant spreading behavior of ARPC1B-deficient B cells by modulating actin dynamics and protein interactions.

**Approach:**

1. **Plasma Membrane Organization Decoupling:**
	* Use a plasma membrane-targeting, actin-independent protein (e.g., a membrane-anchored GFP) to decouple the plasma membrane organization from actin dynamics in ARPC1B-deficient B cells.
2. **Actin Dynamics Inhibition:**
	* Use actin polymerization inhibitors (e.g., cytochalasin D) to block actin dynamics in ARPC1B-deficient B cells with decoupled plasma membrane organization.
3. **Spreading Behavior Analysis:**
	* Monitor and quantify the spreading behavior of ARPC1B-deficient B cells with decoupled plasma membrane organization and inhibited actin dynamics.
	* If the spreading behavior remains aberrant despite decoupling plasma membrane organization from actin dynamics, it would suggest that the spatial organization of the plasma membrane does not influence the aberrant spreading behavior of ARPC1B-deficient B cells.

**Rationale:** By decoupling the plasma membrane organization from actin dynamics and inhibiting actin dynamics, we can test whether the aberrant spreading behavior of ARPC1B-deficient B cells is independent of plasma membrane organization and actin dynamics. If the spreading behavior remains aberrant, it would imply that the hypothesis is false, and alternative mechanisms are at play.

**Unlimited Budget Considerations:**

* Utilize cutting-edge microscopy techniques, such as super-resolution microscopy (e.g., STORM, STED) or single-particle tracking, to gain higher resolution and more accurate measurements of actin dynamics and protein interactions.
* Employ advanced computational models and simulations to analyze and predict the behavior of ARPC1B-deficient B cells under different plasma membrane organization and actin dynamics conditions.
* Perform high-throughput screening of small molecules or RNAi libraries to identify potential therapeutic targets that can rescue the aberrant spreading behavior of ARPC1B-deficient B cells.

By following this experimental plan, we can rigorously test the hypothesis and gain a deeper understanding of the mechanisms underlying the aberrant spreading behavior of ARPC1B-deficient B cells.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Culture and Preparation**

1.1. Obtain ARPC1B-deficient B cells and wild-type B cells as controls from a reliable source (e.g., cell bank, collaborator).

1.2. Culture cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

1.3. Maintain cells at a density of 1-2 x 10^6 cells/mL and passage every 2-3 days.

1.4. Transfect ARPC1B-deficient B cells with a fluorescently tagged ARPC1B construct (e.g., GFP-ARPC1B) using a transfection reagent (e.g., Lipofectamine 2000) according to the manufacturer's instructions.

1.5. Verify transfection efficiency by flow cytometry or fluorescence microscopy.

**Protocol 2: Plasma Membrane Organization Manipulation**

2.1. Prepare stock solutions of lipid raft disruptors (e.g., 10 mM methyl-β-cyclodextrin in DMSO) and cholesterol-depleting agents (e.g., 10 mM statin in DMSO).

2.2. Treat ARPC1B-deficient B cells with lipid raft disruptors or cholesterol-depleting agents at the following concentrations:
	* Methyl-β-cyclodextrin: 1-5 mM for 30 minutes to 1 hour
	* Statin: 1-10 μM for 1-2 hours

2.3. Prepare stock solutions of lipid raft stabilizers (e.g., 10 mM cholesterol in ethanol) and membrane-organizing agents (e.g., 10 μM caveolin-1 in PBS).

2.4. Treat ARPC1B-deficient B cells with lipid raft stabilizers or membrane-organizing agents at the following concentrations:
	* Cholesterol: 1-10 μM for 1-2 hours
	* Caveolin-1: 1-10 μM for 1-2 hours

2.5. Verify plasma membrane organization manipulation by fluorescence microscopy or biochemical assays (e.g., cholesterol content measurement).

**Protocol 3: Actin Dynamics Analysis**

3.1. Prepare cells for live-cell imaging by plating 1-2 x 10^5 cells per well in a 35 mm glass-bottom dish coated with fibronectin (10 μg/mL).

3.2. Perform total internal reflection fluorescence (TIRF) microscopy using a microscope equipped with a 100x oil immersion objective and a camera (e.g., Andor iXon).

3.3. Acquire images at 1-2 frames per second for 1-2 minutes using a 488 nm laser.

3.4. Analyze actin dynamics using image analysis software (e.g., Fiji, ImageJ):
	* Measure actin filament length and density using the ""Analyze Particles"" tool.
	* Measure actin dynamics using the ""Kymograph"" tool.

**Protocol 4: Protein Interaction Analysis**

4.1. Perform co-immunoprecipitation (co-IP) assays using antibodies against ARPC1B and actin-regulating proteins (e.g., WASP, Arp2/3 complex).

4.2. Lyse cells in IP lysis buffer (e.g., 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) and incubate with antibodies overnight at 4°C.

4.3. Capture immune complexes using protein A/G beads and wash with IP wash buffer (e.g., 0.1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4).

4.4. Elute immune complexes with SDS-PAGE sample buffer and analyze by Western blotting.

4.5. Perform mass spectrometry-based proteomics using a mass spectrometer (e.g., Orbitrap) and analyze data using proteomics software (e.g., MaxQuant).

**Protocol 5: Spreading Behavior Analysis**

5.1. Prepare cells for time-lapse microscopy by plating 1-2 x 10^5 cells per well in a 35 mm glass-bottom dish coated with fibronectin (10 μg/mL) or collagen (10 μg/mL).

5.2. Perform time-lapse microscopy using a microscope equipped with a 20x objective and a camera (e.g., Andor iXon).

5.3. Acquire images at 1-2 frames per minute for 1-2 hours.

5.4. Analyze cell spreading behavior using image analysis software (e.g., Fiji, ImageJ):
	* Measure cell spreading area using the ""Analyze Particles"" tool.
	* Measure cell speed and persistence using the ""TrackMate"" tool.

**Protocol 6: Experiment to Disprove the Hypothesis**

6.1. Prepare a plasma membrane-targeting, actin-independent protein (e.g., membrane-anchored GFP) and transfect ARPC1B-deficient B cells using a transfection reagent (e.g., Lipofectamine 2000).

6.2. Verify transfection efficiency by flow cytometry or fluorescence microscopy.

6.3. Treat transfected cells with actin polymerization inhibitors (e.g., 1-10 μM cytochalasin D) for 1-2 hours.

6.4. Perform time-lapse microscopy and analyze cell spreading behavior as described in Protocol 5.

**Unlimited Budget Considerations**

* Utilize super-resolution microscopy (e.g., STORM, STED) to gain higher resolution and more accurate measurements of actin dynamics and protein interactions.
* Employ advanced computational models and simulations to analyze and predict the behavior of ARPC1B-deficient B cells under different plasma membrane organization and actin dynamics conditions.
* Perform high-throughput screening of small molecules or RNAi libraries to identify potential therapeutic targets that can rescue the aberrant spreading behavior of ARPC1B-deficient B cells.

These detailed protocols should provide a clear guide for executing the experimental plan and testing the hypothesis.","```
   ARPC1B-deficient B cells  Lipid Raft Disruptors  Cholesterol-Depleting Agents  Lipid Raft Stabilizers  Membrane-Organizing Agents  Actin Dynamics  Protein Interaction  Spreading Behavior
0                    1.0e+06                  2.0          5.0e-06                  5.0e-06                  2.0e-06         0.8         0.6         0.4
1                    1.5e+06                  1.0          2.0e-06                  2.0e-06                  1.0e-06         0.7         0.5         0.3
2                    2.0e+06                  3.0          1.0e-05                  1.0e-05                  3.0e-06         0.9         0.7         0.5
3                    1.0e+06                  4.0          8.0e-06                  8.0e-06                  4.0e-06         0.8         0.6         0.4
4                    1.2e+06                  2.5          6.0e-06                  6.0e-06                  2.5e-06         0.8         0.6         0.4
5                    1.8e+06                  1.5          3.0e-06                  3.0e-06                  1.5e-06         0.7         0.5         0.3
6                    1.5e+06                  3.5          1.2e-05                  1.2e-05                  3.5e-06         0.9         0.7         0.5
7                    1.0e+06                  1.0          2.0e-06                  2.0e-06                  1.0e-06         0.7         0.5         0.3
8                    1.6e+06                  2.0          4.0e-06                  4.0e-06                  2.0e-06         0.8         0.6         0.4
9                    1.3e+06                  3.0          9.0e-06                  9.0e-06                  3.0e-06         0.8         0.6         0.4
10                   1.9e+06                  1.8          3.6e-06                  3.6e-06                  1.8e-06         0.7         0.5         0.3
11                   1.4e+06                  2.2          5.5e-06                  5.5e-06                  2.2e-06         0.8         0.6         0.4
12                   1.7e+06                  3.2          1.1e-05                  1.1e-05                  3.2e-06         0.9         0.7         0.5
13                   1.1e+06                  1.2          2.4e-06                  2.4e-06                  1.2e-06         0.7         0.5         0.3
14                   1.6e+06                  2.8          6.8e-06                  6.8e-06                  2.8e-06         0.8         0.6         0.4
15                   1.3e+06                  3.8          1.4e-05                  1.4e-05                  3.8e-06         0.9         0.7         0.5
16                   1.9e+06                  1.6          3.2e-06                  3.2e-06                  1.6e-06         0.7         0.5         0.3
17                   1.5e+06                  2.4          5.2e-06                  5.2e-06                  2.4e-06         0.8         0.6         0.4
18                   1.7e+06                  3.6          1.3e-05                  1.3e-05                  3.6e-06         0.9         0.7         0.5
19                   1.2e+06                  1.4          2.8e-06                  2.8e-06                  1.4e-06         0.7         0.5         0.3
20                   1.8e+06                  2.6          6.4e-06                  6.4e-06                  2.6e-06         0.8         0.6         0.4
21                   1.4e+06                  3.4          1.2e-05                  1.2e-05                  3.4e-06         0.9         0.7         0.5
22                   1.9e+06                  1.4          2.8e-06                  2.8e-06                  1.4e-06         0.7         0.5         0.3
23                   1.6e+06                  2.8          6.0e-06                  6.0e-06                  2.8e-06         0.8         0.6         0.4
24                   1.7e+06                  3.0          1.0e-05                  1.0e-05                  3.0e-06         0.9         0.7         0.5
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/28c4bb597528b375d6fa9cdb2ad7d4d94e193336.summary'],Does the specific composition of the gut microbiome in CLL patients influence the risk of Richter transformation and can modulation of the gut microbiome reduce this risk?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"A fascinating hypothesis! Here's a high-level experimental plan to test and potentially disprove the hypothesis:

**Hypothesis:** The specific composition of the gut microbiome in CLL (Chronic Lymphocytic Leukemia) patients influences the risk of Richter transformation, and modulation of the gut microbiome can reduce this risk.

**Experimental Approach:**

**Objective:** To investigate the relationship between the gut microbiome and Richter transformation in CLL patients and assess the potential of microbiome modulation in reducing the risk of Richter transformation.

**Study Design:**

1. **Retrospective Cohort Study:** Collect stool samples from CLL patients with and without Richter transformation (RT) from existing biobanks or through collaborations with hospitals. Ensure a minimum of 50 samples per group.
2. **Microbiome Analysis:** Perform 16S rRNA gene sequencing (e.g., Illumina MiSeq) to characterize the gut microbiome composition in each sample. This will provide a snapshot of the bacterial communities present in the gut.
3. **Statistical Analysis:** Compare the gut microbiome composition between CLL patients with and without RT using tools like QIIME2, R, or Python. Identify differentially abundant taxa and functional pathways associated with RT.
4. **In vitro Experiment:** Select a subset of CLL patient-derived gut microbiome samples (n=10-15) and perform a proof-of-concept in vitro experiment using a transwell co-culture system. This will assess the impact of the gut microbiome on CLL cell proliferation and Richter transformation in a controlled environment.
5. **Microbiome Modulation:** Use a fecal microbiota transplantation (FMT) approach to modulate the gut microbiome in a subset of CLL patients (n=10-15) with a high risk of RT. Monitor the changes in the gut microbiome and CLL cell characteristics before and after FMT.

**Experimental Design to Disprove the Hypothesis:**

**Null Hypothesis:** The composition of the gut microbiome in CLL patients does not influence the risk of Richter transformation, and modulation of the gut microbiome does not reduce this risk.

**Experimental Approach:**

1. **Randomized Controlled Trial (RCT):** Enroll 20 CLL patients with a high risk of RT and randomly assign them to either a control group (standard care) or an intervention group (FMT with a standardized gut microbiome consortium).
2. **Microbiome Analysis:** Perform 16S rRNA gene sequencing on stool samples from both groups at baseline, 3 months, and 6 months post-intervention.
3. **Clinical Endpoint:** Monitor the incidence of Richter transformation in both groups over a 12-month period.
4. **Statistical Analysis:** Compare the incidence of RT between the control and intervention groups using Kaplan-Meier survival analysis and Cox proportional hazards models.

**Budget and Timeline:**

* Estimated budget: $200,000 - $300,000
* Timeline: 18-24 months

**Rationale:**

This experimental plan is designed to test the hypothesis while controlling for potential biases and limitations. The retrospective cohort study and in vitro experiment will provide insights into the association between the gut microbiome and RT, while the RCT will assess the causal relationship between microbiome modulation and RT risk. The budget and timeline are reasonable, considering the scope of the study and the use of existing biobanks and collaborations to reduce costs.

By following this experimental plan, we can either support or refute the hypothesis, providing valuable insights into the role of the gut microbiome in CLL and Richter transformation.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Retrospective Cohort Study:**

**Protocol 1.1: Stool Sample Collection**

1. Identify existing biobanks or collaborate with hospitals to access stool samples from CLL patients with and without Richter transformation (RT).
2. Ensure a minimum of 50 samples per group (100 total samples).
3. Collect stool samples in sterile containers and store them at -80°C until further processing.
4. Record patient demographics, medical history, and CLL diagnosis/treatment information.

**Protocol 1.2: DNA Extraction and 16S rRNA Gene Sequencing**

1. Extract DNA from stool samples using a commercial DNA extraction kit (e.g., QIAamp DNA Stool Mini Kit).
2. Perform PCR amplification of the 16S rRNA gene using primers targeting the V3-V4 region (e.g., 341F and 785R).
3. Purify PCR products using a commercial PCR cleanup kit (e.g., QIAquick PCR Purification Kit).
4. Prepare sequencing libraries using a commercial library preparation kit (e.g., Illumina TruSeq DNA Library Prep Kit).
5. Perform 16S rRNA gene sequencing on the Illumina MiSeq platform using a 2x250 bp paired-end sequencing protocol.

**Protocol 1.3: Microbiome Analysis**

1. Demultiplex and quality-filter sequencing data using tools like QIIME2 or Cutadapt.
2. Perform taxonomic classification using a reference database (e.g., SILVA or Greengenes).
3. Calculate alpha diversity metrics (e.g., Shannon index, Simpson index) and beta diversity metrics (e.g., Bray-Curtis dissimilarity).
4. Compare gut microbiome composition between CLL patients with and without RT using statistical tools like ANOVA, t-tests, or Wilcoxon rank-sum tests.
5. Identify differentially abundant taxa and functional pathways associated with RT using tools like LEfSe or DESeq2.

**In vitro Experiment:**

**Protocol 2.1: CLL Cell Culture**

1. Obtain CLL patient-derived peripheral blood mononuclear cells (PBMCs) from existing biobanks or through collaborations with hospitals.
2. Isolate CLL cells using magnetic bead-based separation (e.g., CD19+ selection).
3. Culture CLL cells in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.

**Protocol 2.2: Transwell Co-Culture System**

1. Prepare a transwell co-culture system using 24-well plates with 0.4 μm pore size inserts.
2. Seed CLL cells in the bottom chamber of the transwell plate.
3. Add a subset of gut microbiome samples (n=10-15) to the top chamber of the transwell plate.
4. Incubate the co-culture system at 37°C, 5% CO2 for 48-72 hours.
5. Harvest CLL cells and assess proliferation and Richter transformation using flow cytometry and qRT-PCR.

**Microbiome Modulation:**

**Protocol 3.1: Fecal Microbiota Transplantation (FMT)**

1. Select a subset of CLL patients (n=10-15) with a high risk of RT.
2. Obtain donor stool samples from healthy individuals with a diverse gut microbiome.
3. Prepare the donor stool samples for FMT by mixing 1 part stool with 1 part saline solution.
4. Administer the FMT mixture to the CLL patients via colonoscopy or enema.
5. Monitor the changes in the gut microbiome and CLL cell characteristics before and after FMT using 16S rRNA gene sequencing and flow cytometry.

**Randomized Controlled Trial (RCT):**

**Protocol 4.1: Patient Enrollment and Randomization**

1. Enroll 20 CLL patients with a high risk of RT.
2. Randomly assign patients to either a control group (standard care) or an intervention group (FMT with a standardized gut microbiome consortium).
3. Record patient demographics, medical history, and CLL diagnosis/treatment information.

**Protocol 4.2: Microbiome Analysis and Clinical Endpoint**

1. Collect stool samples from both groups at baseline, 3 months, and 6 months post-intervention.
2. Perform 16S rRNA gene sequencing on stool samples as described in Protocol 1.2.
3. Monitor the incidence of Richter transformation in both groups over a 12-month period.
4. Record clinical endpoint data, including date of RT diagnosis, treatment, and outcome.

**Protocol 4.3: Statistical Analysis**

1. Compare the incidence of RT between the control and intervention groups using Kaplan-Meier survival analysis and Cox proportional hazards models.
2. Analyze the changes in gut microbiome composition and CLL cell characteristics between the two groups using statistical tools like ANOVA, t-tests, or Wilcoxon rank-sum tests.

These detailed protocols should provide a clear roadmap for executing the experimental plan and testing the hypothesis.","```
   Stool_Samples  DNA_Kit  PCR_Primers  Library_Prep  Sequencing_Reads  CLL_Cells  Gut_Microbiome  Richter_Transformation
0             50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000          10_samples               0.2
1             60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          12_samples               0.4
2             70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          15_samples               0.6
3             50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000           8_samples               0.1
4             60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          10_samples               0.3
5             70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          12_samples               0.5
6             50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000          12_samples               0.4
7             60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          15_samples               0.7
8             70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          10_samples               0.3
9             50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000           8_samples               0.2
10            60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          12_samples               0.5
11            70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          15_samples               0.8
12            50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000          10_samples               0.3
13            60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          12_samples               0.6
14            70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          10_samples               0.4
15            50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000           8_samples               0.1
16            60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          15_samples               0.7
17            70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          12_samples               0.5
18            50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000          10_samples               0.2
19            60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          12_samples               0.4
20            70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          15_samples               0.6
21            50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000           8_samples               0.3
22            60  QIAamp_2       341F_785R  TruSeq_DNA_2          250bp         12000          10_samples               0.5
23            70  QIAamp_3       341F_785R  TruSeq_DNA_3          250bp         15000          12_samples               0.7
24            50  QIAamp_1       341F_785R  TruSeq_DNA_1          250bp         10000          15_samples               0.8
```",0.4326412441650458
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/be5c68c49f11626329d61e858b87771bfe63eef7.summary'],"Does the synergistic BCR/TLR4 signaling on B cells also regulate the production of other chemokines, such as CXCL1, that contribute to neutrophil extravasation and lung injury during ischemia/reperfusion?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"I'd be happy to help you develop an experimental plan to test the hypothesis.

**Hypothesis:** The synergistic BCR/TLR4 signaling on B cells regulates the production of other chemokines, such as CXCL1, that contribute to neutrophil extravasation and lung injury during ischemia/reperfusion.

**Experimental Plan:**

**Objective:** To test whether BCR/TLR4 signaling on B cells regulates CXCL1 production, which contributes to neutrophil extravasation and lung injury during ischemia/reperfusion.

**Experimental Design:**

1. **Cell Isolation and Culture:**
	* Isolate B cells from mice using magnetic bead-based separation or fluorescence-activated cell sorting (FACS).
	* Culture B cells in vitro with or without BCR stimulation (e.g., using anti-IgM antibodies) and/or TLR4 stimulation (e.g., using LPS).
2. **CXCL1 Measurement:**
	* Measure CXCL1 protein levels in B cell culture supernatants using ELISA or multiplex bead-based assays.
	* Analyze CXCL1 mRNA expression in B cells using quantitative real-time PCR (qRT-PCR).
3. **Neutrophil Migration Assay:**
	* Isolate neutrophils from mice using density gradient centrifugation or FACS.
	* Perform a transwell migration assay to assess neutrophil migration towards CXCL1-containing supernatants from B cell cultures.
4. **Ischemia/Reperfusion Model:**
	* Use a mouse model of ischemia/reperfusion injury (e.g., lung ischemia/reperfusion model).
	* Administer B cells with or without BCR/TLR4 stimulation to mice before ischemia/reperfusion.
	* Measure lung injury markers (e.g., bronchoalveolar lavage fluid protein, lung wet-to-dry weight ratio) and neutrophil infiltration in lung tissue.

**Experiment to Disprove the Hypothesis:**

**Objective:** To test whether BCR/TLR4 signaling on B cells does not regulate CXCL1 production, which does not contribute to neutrophil extravasation and lung injury during ischemia/reperfusion.

**Experimental Design:**

1. **BCR/TLR4 Signaling Inhibition:**
	* Use B cells from mice with genetic knockout or pharmacological inhibition of BCR or TLR4 signaling.
	* Culture these B cells with or without ischemia/reperfusion stimulation.
2. **CXCL1 Measurement:**
	* Measure CXCL1 protein levels in B cell culture supernatants using ELISA or multiplex bead-based assays.
	* Analyze CXCL1 mRNA expression in B cells using qRT-PCR.
3. **Neutrophil Migration Assay:**
	* Perform a transwell migration assay to assess neutrophil migration towards CXCL1-containing supernatants from B cell cultures.
4. **Ischemia/Reperfusion Model:**
	* Use a mouse model of ischemia/reperfusion injury (e.g., lung ischemia/reperfusion model).
	* Administer B cells with inhibited BCR/TLR4 signaling to mice before ischemia/reperfusion.
	* Measure lung injury markers and neutrophil infiltration in lung tissue.

**Rationale:**

By inhibiting BCR/TLR4 signaling on B cells, we can test whether CXCL1 production and neutrophil extravasation are still observed during ischemia/reperfusion. If the hypothesis is true, we should see reduced CXCL1 production and neutrophil migration in the absence of BCR/TLR4 signaling. If the results show no difference in CXCL1 production and neutrophil migration, it would suggest that BCR/TLR4 signaling on B cells does not regulate CXCL1 production, which does not contribute to neutrophil extravasation and lung injury during ischemia/reperfusion.

**Timeline and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000. The budget will cover:

* Reagents and consumables for cell isolation, culture, and stimulation
* ELISA and qRT-PCR kits
* Mouse models and husbandry
* Personnel costs for a postdoctoral researcher or graduate student to conduct the experiment

Note: The budget and timeline may vary depending on the specific requirements of the experiment and the institution's resources.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment to Test the Hypothesis:**

**Step 1: Cell Isolation and Culture**

1.1. Mice Preparation:

* Obtain 6-8 week old mice (C57BL/6 or similar strain) from a reputable vendor.
* House mice in a specific pathogen-free (SPF) facility with ad libitum access to food and water.
* Acclimate mice to the environment for at least 1 week before experimentation.

1.2. B Cell Isolation:

* Sacrifice mice using CO2 asphyxiation or cervical dislocation.
* Harvest spleens and lymph nodes using aseptic techniques.
* Prepare single-cell suspensions using gentle mechanical disruption and filtering through a 40 μm cell strainer.
* Isolate B cells using magnetic bead-based separation (e.g., Miltenyi Biotec's B Cell Isolation Kit) or fluorescence-activated cell sorting (FACS) using anti-CD19 and anti-CD45 antibodies.
* Count and resuspend B cells in complete RPMI-1640 medium (10% FBS, 1% penicillin-streptomycin, 1% L-glutamine) at a concentration of 1 x 10^6 cells/mL.

1.3. B Cell Culture and Stimulation:

* Culture B cells in 24-well plates (1 mL/well) with or without:
	+ BCR stimulation: 10 μg/mL anti-IgM antibodies (e.g., Jackson ImmunoResearch) for 24 hours.
	+ TLR4 stimulation: 100 ng/mL LPS (e.g., Sigma-Aldrich) for 24 hours.
	+ Combination of BCR and TLR4 stimulation.
* Incubate cells at 37°C, 5% CO2, and 95% humidity.

**Step 2: CXCL1 Measurement**

2.1. CXCL1 Protein Measurement:

* Collect B cell culture supernatants after 24 hours of stimulation.
* Measure CXCL1 protein levels using ELISA (e.g., R&D Systems' Mouse CXCL1 DuoSet ELISA) according to the manufacturer's instructions.
* Perform the assay in duplicate or triplicate.

2.2. CXCL1 mRNA Expression Analysis:

* Isolate total RNA from B cells using a commercial RNA isolation kit (e.g., Qiagen's RNeasy Mini Kit).
* Perform qRT-PCR using a commercial kit (e.g., Applied Biosystems' PowerUp SYBR Green Master Mix) and primers specific for CXCL1 (e.g., forward: 5'-GCTGCTGCTGCTGCTG-3', reverse: 5'-GCTGCTGCTGCTGCTG-3').
* Normalize CXCL1 mRNA expression to a housekeeping gene (e.g., GAPDH).

**Step 3: Neutrophil Migration Assay**

3.1. Neutrophil Isolation:

* Sacrifice mice using CO2 asphyxiation or cervical dislocation.
* Harvest bone marrow cells using aseptic techniques.
* Isolate neutrophils using density gradient centrifugation (e.g., Histopaque-1119) or FACS using anti-Ly6G and anti-CD11b antibodies.
* Count and resuspend neutrophils in complete RPMI-1640 medium at a concentration of 1 x 10^6 cells/mL.

3.2. Transwell Migration Assay:

* Place 100 μL of B cell culture supernatant (with or without CXCL1) in the lower chamber of a 24-well transwell plate (e.g., Corning's Transwell Plate).
* Add 100 μL of neutrophil suspension (1 x 10^5 cells) to the upper chamber.
* Incubate at 37°C, 5% CO2, and 95% humidity for 2 hours.
* Count migrated neutrophils using a hemocytometer or flow cytometry.

**Step 4: Ischemia/Reperfusion Model**

4.1. Mouse Model of Ischemia/Reperfusion Injury:

* Use a lung ischemia/reperfusion model (e.g., 30 minutes of ischemia followed by 2 hours of reperfusion).
* Anesthetize mice using isoflurane or ketamine/xylazine.
* Perform a thoracotomy and ligate the left hilum to induce ischemia.
* Release the ligature to allow reperfusion.

4.2. B Cell Administration:

* Administer 1 x 10^6 B cells (with or without BCR/TLR4 stimulation) via tail vein injection 30 minutes before ischemia.

4.3. Lung Injury Markers and Neutrophil Infiltration:

* Collect bronchoalveolar lavage fluid (BALF) and measure protein concentration using a commercial kit (e.g., Pierce's BCA Protein Assay).
* Measure lung wet-to-dry weight ratio.
* Perform immunohistochemistry or flow cytometry to assess neutrophil infiltration in lung tissue.

**Experiment to Disprove the Hypothesis:**

**Step 1: BCR/TLR4 Signaling Inhibition**

1.1. BCR/TLR4 Signaling Inhibition:

* Use B cells from mice with genetic knockout or pharmacological inhibition of BCR or TLR4 signaling.
* Culture B cells with or without ischemia/reperfusion stimulation.

**Step 2-4: CXCL1 Measurement, Neutrophil Migration Assay, and Ischemia/Reperfusion Model**

* Follow the same protocols as in the experiment to test the hypothesis, using B cells with inhibited BCR/TLR4 signaling.

**Quality Control and Replicability:**

* Perform all experiments in triplicate or quadruplicate to ensure reproducibility.
* Include positive and negative controls for each assay.
* Use standardized protocols and reagents to minimize variability.
* Document all experimental procedures, results, and data analysis in a laboratory notebook or electronic database.

**Timeline and Budget:**

* The experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget will cover reagents and consumables, mouse models and husbandry, personnel costs, and equipment maintenance.

Note: The protocols provided are detailed and specific, but may require adjustments based on the specific requirements of the experiment and the institution's resources.","```
   Mice_Age  BCR_Stimulation  TLR4_Stimulation  B_Cell_Count  CXCL1_Protein  CXCL1_mRNA  Neutrophil_Count  Neutrophil_Migration  Lung_Injury_Markers
0       6.0             0.0              0.0       1.00e+06       100.0       500.0          1.00e+05               200.0             0.5
1       7.0             5.0              0.0       1.20e+06       150.0       700.0          1.20e+05               300.0             0.7
2       6.5             0.0              50.0       1.10e+06       120.0       600.0          1.10e+05               250.0             0.6
3       7.5             10.0             100.0       1.30e+06       200.0       800.0          1.30e+05               350.0             0.8
4       6.0             0.0              0.0       1.00e+06       100.0       500.0          1.00e+05               200.0             0.5
5       7.0             5.0              0.0       1.20e+06       150.0       700.0          1.20e+05               300.0             0.7
6       6.5             0.0              50.0       1.10e+06       120.0       600.0          1.10e+05               250.0             0.6
7       7.5             10.0             100.0       1.30e+06       200.0       800.0          1.30e+05               350.0             0.8
8       6.0             0.0              0.0       1.00e+06       100.0       500.0          1.00e+05               200.0             0.5
9       7.0             5.0              0.0       1.20e+06       150.0       700.0          1.20e+05               300.0             0.7
10      6.5             0.0              50.0       1.10e+06       120.0       600.0          1.10e+05               250.0             0.6
11      7.5             10.0             100.0       1.30e+06       200.0       800.0          1.30e+05               350.0             0.8
12      6.0             0.0              0.0       1.00e+06       100.0       500.0          1.00e+05               200.0             0.5
13      7.0             5.0              0.0       1.20e+06       150.0       700.0          1.20e+05               300.0             0.7
14      6.5             0.0              50.0       1.10e+06       120.0       600.0          1.10e+05               250.0             0.6
15      7.5             10.0             100.0       1.30e+06       200.0       800.0          1.30e+05               350.0             0.8
16      6.0             0.0              0.0       1.00e+06       100.0       500.0          1.00e+05               200.0             0.5
17      7.0             5.0              0.0       1.20e+06       150.0       700.0          1.20e+05               300.0             0.7
18      6.5             0.0              50.0       1.10e+06       120.0       600.0          1.10e+05               250.0             0.6
19      7.5             10.0             100.0       1.30e+06       200.0       800.0          1.30e+05               350.0             0.8
20      6.0             0.0              0.0       1.00e+06       100.0       500.0          1.00e+05               200.0             0.5
21      7.0             5.0              0.0       1.20e+06       150.0       700.0          1.20e+05               300.0             0.7
22      6.5             0.0              50.0       1.10e+06       120.0       600.0          1.10e+05               250.0             0.6
23      7.5             10.0             100.0       1.30e+06       200.0       800.0          1.30e+05               350.0             0.8
24      6.0             0.0              0.0       1.00e+06       100.0       500.0          1.00e+05               200.0             0.5
```",0.9512509307581483
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/b60db1285e0d2d3ba73bf835df269992c87b036d.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/766f3c7e71a1d77ff316a4ee43e0d3a62df3c2bf.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/2e4390ac00fdf4d23e458b503da5673973587ec7.summary']","Does the synergistic activation of TLR7 and BCR signaling pathways in B cells lead to the production of specific cytokines that promote the development of autoimmune diseases, and can this process be modulated by IκBNS?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has an unlimited budget in terms of time, resources, and financial support.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and the summaries of the papers, I have developed an experimental plan to test the hypothesis and potentially disprove it.

**Hypothesis:** Does the synergistic activation of TLR7 and BCR signaling pathways in B cells lead to the production of specific cytokines that promote the development of autoimmune diseases, and can this process be modulated by IκBNS?

**Experimental Plan:**

**Objective:** To investigate the role of TLR7 and BCR signaling pathways in the production of cytokines that promote autoimmune diseases and to determine if IκBNS modulates this process.

**Experimental Design:**

1. **Cell Isolation and Stimulation:**
	* Isolate B cells from wild-type and IκBNS-deficient mice.
	* Stimulate B cells with TLR7 ligands (e.g., imiquimod) and BCR agonists (e.g., anti-IgM) separately and in combination.
2. **Cytokine Production Analysis:**
	* Measure the production of cytokines (e.g., IL-10, IFN-γ, TNF-α) using ELISA or multiplex assays.
	* Compare the cytokine production between wild-type and IκBNS-deficient B cells stimulated with TLR7 and BCR agonists.
3. **Signaling Pathway Analysis:**
	* Analyze the phosphorylation of key signaling molecules (e.g., NF-κB, STAT3, ERK) using Western blotting or phospho-specific antibodies.
	* Compare the signaling pathway activation between wild-type and IκBNS-deficient B cells stimulated with TLR7 and BCR agonists.
4. **Modulation by IκBNS:**
	* Overexpress or knockdown IκBNS in B cells using lentiviral vectors or CRISPR-Cas9.
	* Analyze the effect of IκBNS modulation on cytokine production and signaling pathway activation in response to TLR7 and BCR stimulation.

**Negative Control:**

* Use a TLR7 inhibitor (e.g., ODN 2088) to block TLR7 signaling and analyze the effect on cytokine production and signaling pathway activation.
* Use a BCR inhibitor (e.g., anti-CD20) to block BCR signaling and analyze the effect on cytokine production and signaling pathway activation.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ Enhanced cytokine production (e.g., IL-10, IFN-γ, TNF-α) in response to TLR7 and BCR stimulation in wild-type B cells.
	+ Impaired cytokine production in IκBNS-deficient B cells.
	+ Modulation of cytokine production and signaling pathway activation by IκBNS overexpression or knockdown.
* If the hypothesis is false, we expect to see:
	+ No significant difference in cytokine production between wild-type and IκBNS-deficient B cells in response to TLR7 and BCR stimulation.
	+ No modulation of cytokine production and signaling pathway activation by IκBNS overexpression or knockdown.

**Equipment and Resources:**

* Flow cytometer
* ELISA plate reader
* Western blotting equipment
* Lentiviral vectors or CRISPR-Cas9 system
* Antibodies against TLR7, BCR, and signaling molecules
* Cytokine assays (e.g., ELISA, multiplex)
* Cell culture facilities

**Timeline:**

* Cell isolation and stimulation: 2 weeks
* Cytokine production analysis: 2 weeks
* Signaling pathway analysis: 2 weeks
* Modulation by IκBNS: 4 weeks
* Data analysis and interpretation: 4 weeks

**Budget:**

* Personnel: 2 postdoctoral researchers, 1 graduate student, 1 technician
* Reagents and consumables: $50,000
* Equipment maintenance and upgrade: $20,000
* Travel and training: $10,000
* Total budget: $80,000

This experimental plan is designed to test the hypothesis and potentially disprove it. The results will provide insights into the role of TLR7 and BCR signaling pathways in autoimmune diseases and the modulatory effect of IκBNS.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Protocol 1: Cell Isolation and Stimulation**

**Objective:** Isolate B cells from wild-type and IκBNS-deficient mice and stimulate them with TLR7 ligands and BCR agonists.

**Materials:**

* Wild-type and IκBNS-deficient mice
* TLR7 ligand (e.g., imiquimod)
* BCR agonist (e.g., anti-IgM)
* RPMI 1640 medium
* Fetal bovine serum (FBS)
* Penicillin-streptomycin
* Lympholyte-M cell separation medium
* Anti-CD19 magnetic beads
* Magnetic separator
* 96-well plate

**Step-by-Step Protocol:**

1.1. Sacrifice wild-type and IκBNS-deficient mice and harvest spleens.

1.2. Prepare single-cell suspensions from spleens using a gentleMACS dissociator.

1.3. Isolate B cells using Lympholyte-M cell separation medium and anti-CD19 magnetic beads according to the manufacturer's instructions.

1.4. Wash B cells with RPMI 1640 medium and resuspend in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin.

1.5. Plate 1 x 10^6 B cells per well in a 96-well plate.

1.6. Stimulate B cells with TLR7 ligand (e.g., 1 μg/mL imiquimod) and/or BCR agonist (e.g., 10 μg/mL anti-IgM) for 24 hours at 37°C, 5% CO2.

1.7. Collect supernatants for cytokine analysis and store at -80°C.

**Protocol 2: Cytokine Production Analysis**

**Objective:** Measure the production of cytokines (e.g., IL-10, IFN-γ, TNF-α) using ELISA or multiplex assays.

**Materials:**

* Supernatants from stimulated B cells
* ELISA kits for IL-10, IFN-γ, and TNF-α
* Multiplex assay kit (e.g., Luminex)
* ELISA plate reader
* Multiplex assay reader

**Step-by-Step Protocol:**

2.1. Thaw supernatants and perform ELISA or multiplex assays according to the manufacturer's instructions.

2.2. For ELISA, add 100 μL of supernatant to each well and incubate for 2 hours at room temperature.

2.3. Add detection antibodies and incubate for 1 hour at room temperature.

2.4. Add substrate and measure absorbance at 450 nm using an ELISA plate reader.

2.5. For multiplex assay, add 50 μL of supernatant to each well and incubate for 2 hours at room temperature.

2.6. Add detection antibodies and incubate for 1 hour at room temperature.

2.7. Analyze using a multiplex assay reader according to the manufacturer's instructions.

**Protocol 3: Signaling Pathway Analysis**

**Objective:** Analyze the phosphorylation of key signaling molecules (e.g., NF-κB, STAT3, ERK) using Western blotting or phospho-specific antibodies.

**Materials:**

* Stimulated B cells
* Lysis buffer
* Protease inhibitors
* Phospho-specific antibodies (e.g., p-NF-κB, p-STAT3, p-ERK)
* Western blotting equipment
* ECL reagents

**Step-by-Step Protocol:**

3.1. Lyse stimulated B cells in lysis buffer with protease inhibitors.

3.2. Perform Western blotting according to standard protocols.

3.3. Incubate with phospho-specific antibodies overnight at 4°C.

3.4. Detect using ECL reagents and analyze using a chemiluminescence detector.

**Protocol 4: Modulation by IκBNS**

**Objective:** Overexpress or knockdown IκBNS in B cells using lentiviral vectors or CRISPR-Cas9.

**Materials:**

* Lentiviral vectors or CRISPR-Cas9 system
* IκBNS cDNA or guide RNA
* Packaging plasmids
* B cells
* Puromycin or other selection agents

**Step-by-Step Protocol:**

4.1. Prepare lentiviral vectors or CRISPR-Cas9 system according to the manufacturer's instructions.

4.2. Transduce B cells with lentiviral vectors or CRISPR-Cas9 system.

4.3. Select transduced cells using puromycin or other selection agents.

4.4. Verify IκBNS overexpression or knockdown using Western blotting or qRT-PCR.

4.5. Stimulate transduced B cells with TLR7 ligand and/or BCR agonist and analyze cytokine production and signaling pathway activation.

**Negative Control Protocols:**

**Protocol 5: TLR7 Inhibition**

**Objective:** Use a TLR7 inhibitor (e.g., ODN 2088) to block TLR7 signaling and analyze the effect on cytokine production and signaling pathway activation.

**Materials:**

* TLR7 inhibitor (e.g., ODN 2088)
* Stimulated B cells
* Cytokine assays
* Western blotting equipment

**Step-by-Step Protocol:**

5.1. Add TLR7 inhibitor to stimulated B cells 30 minutes prior to TLR7 ligand stimulation.

5.2. Analyze cytokine production and signaling pathway activation as described in Protocols 2 and 3.

**Protocol 6: BCR Inhibition**

**Objective:** Use a BCR inhibitor (e.g., anti-CD20) to block BCR signaling and analyze the effect on cytokine production and signaling pathway activation.

**Materials:**

* BCR inhibitor (e.g., anti-CD20)
* Stimulated B cells
* Cytokine assays
* Western blotting equipment

**Step-by-Step Protocol:**

6.1. Add BCR inhibitor to stimulated B cells 30 minutes prior to BCR agonist stimulation.

6.2. Analyze cytokine production and signaling pathway activation as described in Protocols 2 and 3.

These detailed protocols provide a step-by-step guide for executing the experimental plan, ensuring replicability and specificity in the results.","```
   Wild-type Mice  IκBNS-deficient Mice  TLR7 Ligand (μg/mL)  BCR Agonist (μg/mL)  RPMI 1640 Medium (%)  Fetal Bovine Serum (%)  Penicillin-Streptomycin (%)  IL-10 (pg/mL)  IFN-γ (pg/mL)  TNF-α (pg/mL)
0               2                  0                  0.5               5.0               90.0               10.0               1.0               250.0               50.0               100.0
1               1                  1                  1.0               10.0               80.0               15.0               1.5               300.0               75.0               120.0
2               3                  0                  0.2               2.0               95.0                5.0               0.5               200.0               30.0                80.0
3               2                  1                  0.8               8.0               85.0               10.0               1.2               280.0               60.0               110.0
4               1                  2                  1.5               12.0               75.0               20.0               1.8               350.0               90.0               140.0
5               3                  1                  0.3               3.0               90.0                5.0               0.8               220.0               40.0                90.0
6               2                  2                  1.2               9.0               80.0               15.0               1.5               320.0               80.0               130.0
7               1                  3                  1.8               15.0               70.0               25.0               2.0               400.0               100.0              160.0
8               3                  2                  0.4               4.0               85.0                5.0               1.0               240.0               50.0               100.0
9               2                  3                  1.0               7.0               75.0               20.0               1.8               300.0               70.0               120.0
10              1                  1                  0.6               6.0               80.0               15.0               1.2               260.0               60.0               110.0
11              3                  1                  0.9               8.0               90.0                5.0               1.5               280.0               80.0               130.0
12              2                  2                  1.4               11.0               75.0               20.0               1.8               340.0               90.0               150.0
13              1                  2                  1.1               9.0               70.0               25.0               2.0               380.0               100.0              170.0
14              3                  3                  0.5               5.0               85.0                5.0               1.2               250.0               60.0               110.0
15              2                  1                  1.6               13.0               80.0               15.0               1.5               360.0               100.0              160.0
16              1                  3                  1.3               10.0               75.0               20.0               1.8               330.0               90.0               150.0
17              3                  2                  0.7               7.0               90.0                5.0               1.5               270.0               70.0               120.0
18              2                  3                  1.9               16.0               70.0               25.0               2.0               420.0               110.0              190.0
19              1                  1                  0.8               8.0               80.0               15.0               1.2               290.0               80.0               130.0
20              3                  1                  1.1               9.0               85.0                5.0               1.5               310.0               90.0               140.0
21              2                  2                  1.7               14.0               75.0               20.0               1.8               390.0               100.0              180.0
22              1                  2                  1.4               12.0               70.0               25.0               2.0               410.0               110.0              200.0
23              3                  3                  0.6               6.0               90.0                5.0               1.2               260.0               70.0               120.0
24              2                  1                  1.8               15.0               80.0               15.0               1.5               380.0               100.0              170.0
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/67d9322177eb1bfb32a996e91543743658d02085.summary'],Does the synergistic combination of HPK1 inhibitors with existing immunotherapies enhance their anti-tumor efficacy by modulating the activity of hematopoietic progenitor cells in cancer microenvironments?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis. Since the hypothesis suggests that the synergistic combination of HPK1 inhibitors with existing immunotherapies enhances their anti-tumor efficacy by modulating the activity of hematopoietic progenitor cells in cancer microenvironments, our experiment will focus on evaluating the effect of HPK1 inhibitors on immunotherapy outcomes in a cancer model.

**Experiment:**

**Title:** Investigating the Synergistic Effect of HPK1 Inhibitors on Immunotherapy in a Cancer Model

**Objective:** To determine whether the combination of HPK1 inhibitors with existing immunotherapies enhances anti-tumor efficacy by modulating hematopoietic progenitor cells in cancer microenvironments.

**Experimental Design:**

1. **Cancer Model:** Use a well-established mouse model of cancer (e.g., melanoma or lung cancer) that is responsive to immunotherapy.
2. **Immunotherapy:** Administer a standard immunotherapy regimen (e.g., checkpoint inhibitors, adoptive T cell therapy, or cancer vaccines) to the cancer-bearing mice.
3. **HPK1 Inhibitor Treatment:** Divide the mice into two groups:
	* Group 1: Receive the immunotherapy regimen alone (control group).
	* Group 2: Receive the immunotherapy regimen in combination with the HPK1 inhibitor (M074-2865 or another potent inhibitor identified in the previous study).
4. **Tumor Monitoring:** Monitor tumor growth and progression in both groups using non-invasive imaging techniques (e.g., bioluminescence or MRI).
5. **Hematopoietic Progenitor Cell Analysis:** Collect blood and tumor samples from both groups at various time points to analyze the activity of hematopoietic progenitor cells using flow cytometry, qRT-PCR, or Western blotting.
6. **Immune Cell Profiling:** Analyze the immune cell composition and activation status in the tumor microenvironment using flow cytometry, IHC, or RNA-seq.

**Endpoints:**

1. Tumor growth inhibition or regression.
2. Changes in hematopoietic progenitor cell activity and population dynamics.
3. Immune cell infiltration, activation, and cytokine production in the tumor microenvironment.

**Sample Size and Statistical Analysis:**

* Use a minimum of 10 mice per group to ensure statistical significance.
* Perform statistical analysis using ANOVA, t-tests, or non-parametric tests as appropriate to compare the outcomes between the control and HPK1 inhibitor-treated groups.

**Timeline:**

* 6-8 weeks for mouse model establishment and immunotherapy treatment.
* 4-6 weeks for HPK1 inhibitor treatment and tumor monitoring.
* 2-3 weeks for sample collection and analysis.

**Budget:**

* Mouse model establishment and maintenance: $5,000 - $10,000.
* Immunotherapy reagents and administration: $3,000 - $5,000.
* HPK1 inhibitor synthesis or procurement: $2,000 - $5,000.
* Reagents and consumables for flow cytometry, qRT-PCR, and Western blotting: $5,000 - $10,000.
* Personnel and overhead costs: $10,000 - $20,000.

Total estimated budget: $30,000 - $60,000.

**Rationale:**

This experiment is designed to test the hypothesis by evaluating the effect of HPK1 inhibitors on immunotherapy outcomes in a cancer model. By comparing the tumor growth, hematopoietic progenitor cell activity, and immune cell profiles between the control and HPK1 inhibitor-treated groups, we can determine whether the combination of HPK1 inhibitors with immunotherapy enhances anti-tumor efficacy. If the results show no significant difference between the groups or even a negative impact of HPK1 inhibitors on immunotherapy outcomes, it would disprove the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Mouse Model Establishment and Immunotherapy Treatment**

1.1. Obtain 20-30 mice (e.g., C57BL/6 or BALB/c) from a reputable vendor.

1.2. Induce cancer in the mice using a well-established method (e.g., injection of cancer cells, chemical carcinogenesis, or genetic modification).

1.3. Allow the tumors to grow for 1-2 weeks to reach a size of approximately 50-100 mm³.

1.4. Randomly divide the mice into two groups: Group 1 (control) and Group 2 (HPK1 inhibitor-treated).

1.5. Administer the standard immunotherapy regimen to both groups, following the manufacturer's instructions. For example:
	* Checkpoint inhibitors: inject 10 mg/kg of anti-PD-1 or anti-CTLA-4 antibodies intraperitoneally every 3-4 days for 2-3 weeks.
	* Adoptive T cell therapy: inject 1-2 x 10⁶ T cells intravenously every 3-4 days for 2-3 weeks.
	* Cancer vaccines: inject 10-20 μg of vaccine antigen emulsified in adjuvant intradermally every 2-3 weeks for 2-3 weeks.

**Protocol 2: HPK1 Inhibitor Treatment**

2.1. Prepare the HPK1 inhibitor (M074-2865 or another potent inhibitor) according to the manufacturer's instructions or published protocols.

2.2. Administer the HPK1 inhibitor to Group 2 mice at a dose of 10-20 mg/kg intraperitoneally every 2-3 days for 4-6 weeks.

2.3. Monitor the mice for signs of toxicity or adverse reactions, and adjust the dose or frequency of administration as needed.

**Protocol 3: Tumor Monitoring**

3.1. Use non-invasive imaging techniques (e.g., bioluminescence or MRI) to monitor tumor growth and progression in both groups.

3.2. Take images at baseline, weekly, and at the end of the experiment (6-8 weeks).

3.3. Measure tumor volume using software (e.g., ImageJ or VivoQuant) and calculate the tumor growth rate.

**Protocol 4: Hematopoietic Progenitor Cell Analysis**

4.1. Collect blood samples from both groups at weeks 2, 4, and 6 using retro-orbital bleeding or cardiac puncture.

4.2. Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation (e.g., Ficoll-Paque).

4.3. Stain PBMCs with antibodies against hematopoietic progenitor cell markers (e.g., CD34, CD117, and CD133) and analyze using flow cytometry.

4.4. Collect tumor samples at the end of the experiment and isolate tumor-infiltrating cells using enzymatic digestion and density gradient centrifugation.

4.5. Analyze tumor-infiltrating cells using flow cytometry, qRT-PCR, or Western blotting to assess hematopoietic progenitor cell activity and population dynamics.

**Protocol 5: Immune Cell Profiling**

5.1. Collect tumor samples at the end of the experiment and isolate tumor-infiltrating cells using enzymatic digestion and density gradient centrifugation.

5.2. Stain tumor-infiltrating cells with antibodies against immune cell markers (e.g., CD4, CD8, CD11b, and CD11c) and analyze using flow cytometry.

5.3. Perform IHC or RNA-seq analysis on tumor samples to assess immune cell infiltration, activation, and cytokine production.

**Protocol 6: Sample Preparation and Storage**

6.1. Store blood and tumor samples at -80°C or in liquid nitrogen for future analysis.

6.2. Prepare samples for flow cytometry, qRT-PCR, and Western blotting according to standard protocols.

**Protocol 7: Data Analysis**

7.1. Use statistical software (e.g., GraphPad Prism or R) to analyze the data.

7.2. Compare the outcomes between the control and HPK1 inhibitor-treated groups using ANOVA, t-tests, or non-parametric tests as appropriate.

7.3. Calculate the tumor growth rate, hematopoietic progenitor cell activity, and immune cell profiles for each group.

7.4. Present the data in a clear and concise manner, including graphs, tables, and figures.

By following these detailed, step-by-step protocols, the experiment can be replicated and the results can be accurately interpreted to test the hypothesis.","```
   Mice  Cancer Cells  Immunotherapy  HPK1 Inhibitor  Tumor Volume  Hematopoietic Progenitor Cells  Immune Cells  Outcome
0     25         1000        10mg/kg          15mg/kg     120.0                     0.8          0.4       Success
1     28         1200        12mg/kg          18mg/kg     150.0                     0.9          0.5       Success
2     22          900         8mg/kg          12mg/kg      90.0                     0.7          0.3       Failure
3     25         1100        11mg/kg          16mg/kg     130.0                     0.8          0.4       Success
4     20          800         9mg/kg          14mg/kg      80.0                     0.6          0.2       Failure
5     27         1300        13mg/kg          19mg/kg     160.0                     0.9          0.5       Success
6     24         1000        10mg/kg          15mg/kg     120.0                     0.8          0.4       Success
7     26         1200        12mg/kg          18mg/kg     150.0                     0.9          0.5       Success
8     21          900         8mg/kg          12mg/kg      90.0                     0.7          0.3       Failure
9     25         1100        11mg/kg          16mg/kg     130.0                     0.8          0.4       Success
10    20          800         9mg/kg          14mg/kg      80.0                     0.6          0.2       Failure
11    27         1300        13mg/kg          19mg/kg     160.0                     0.9          0.5       Success
12    24         1000        10mg/kg          15mg/kg     120.0                     0.8          0.4       Success
13    26         1200        12mg/kg          18mg/kg     150.0                     0.9          0.5       Success
14    21          900         8mg/kg          12mg/kg      90.0                     0.7          0.3       Failure
15    25         1100        11mg/kg          16mg/kg     130.0                     0.8          0.4       Success
16    20          800         9mg/kg          14mg/kg      80.0                     0.6          0.2       Failure
17    27         1300        13mg/kg          19mg/kg     160.0                     0.9          0.5       Success
18    24         1000        10mg/kg          15mg/kg     120.0                     0.8          0.4       Success
19    26         1200        12mg/kg          18mg/kg     150.0                     0.9          0.5       Success
20    21          900         8mg/kg          12mg/kg      90.0                     0.7          0.3       Failure
21    25         1100        11mg/kg          16mg/kg     130.0                     0.8          0.4       Success
22    20          800         9mg/kg          14mg/kg      80.0                     0.6          0.2       Failure
23    27         1300        13mg/kg          19mg/kg     160.0                     0.9          0.5       Success
24    24         1000        10mg/kg          15mg/kg     120.0                     0.8          0.4       Success
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/340a5dc7f6d507c40ec3399dec52a203c5f40f5f.summary'],"Does the temporary downregulation of kindlin-2 and talin-1 in RASF after IL-1β stimulation also lead to altered expression of other focal adhesion proteins, such as paxillin and vinculin, which in turn contribute to the pathogenesis of rheumatoid arthritis?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan:**

**Title:** Investigating the Regulation of Paxillin and Vinculin in RASF after IL-1β Stimulation and its Contribution to Rheumatoid Arthritis Pathogenesis

**Objective:** To determine if the temporary downregulation of kindlin-2 and talin-1 in RASF after IL-1β stimulation leads to altered expression of paxillin and vinculin, and to investigate their potential role in the pathogenesis of rheumatoid arthritis.

**Equipment:**

* RASF cell culture system
* IL-1β
* qPCR
* Western blot
* Confocal microscopy
* Paxillin and vinculin antibodies

**Steps:**

1. Isolate RASF from RA patients and culture them in vitro.
2. Stimulate RASF with IL-1β for different time periods (e.g., 6, 17, 24, 48 hours).
3. Analyze paxillin and vinculin mRNA and protein expression using qPCR and Western blot, respectively.
4. Validate the results using confocal microscopy to visualize paxillin and vinculin localization in RASF.
5. Compare the expression levels of paxillin and vinculin with kindlin-2 and talin-1 to investigate potential correlations.
6. Perform co-immunoprecipitation assays to examine potential interactions between kindlin-2, talin-1, paxillin, and vinculin.
7. Use siRNA-mediated knockdown of kindlin-2 and talin-1 to investigate the effect on paxillin and vinculin expression.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Independence of Paxillin and Vinculin Expression from Kindlin-2 and Talin-1 Downregulation in RASF after IL-1β Stimulation

**Objective:** To demonstrate that paxillin and vinculin expression is not affected by the temporary downregulation of kindlin-2 and talin-1 in RASF after IL-1β stimulation, thereby disproving the hypothesis.

**Design:**

1. Perform the same IL-1β stimulation and RASF culture as in the original experiment.
2. Use a specific inhibitor of kindlin-2 and talin-1 downregulation (e.g., a protein kinase inhibitor) to prevent their downregulation after IL-1β stimulation.
3. Analyze paxillin and vinculin mRNA and protein expression using qPCR and Western blot, respectively.
4. Compare the expression levels of paxillin and vinculin in the presence and absence of the inhibitor.

**Rationale:** If the inhibitor prevents kindlin-2 and talin-1 downregulation, but paxillin and vinculin expression remains unaffected, it would suggest that their expression is independent of kindlin-2 and talin-1 downregulation, disproving the hypothesis.

**Timeline and Budget:**

This experiment can be completed within 6-8 weeks, with a budget of approximately $10,000-$15,000, covering the costs of:

* RASF cell culture system and reagents
* IL-1β and inhibitors
* qPCR and Western blot reagents
* Confocal microscopy usage
* Antibodies and siRNA reagents
* Laboratory consumables and personnel costs

This experiment is designed to be feasible within a reasonable time frame and budget, while providing valuable insights into the regulation of focal adhesion proteins in RASF and their potential role in rheumatoid arthritis pathogenesis.",85,"Here are the detailed, step-by-step protocols for the experimental plan:

**Experiment 1: Investigating the Regulation of Paxillin and Vinculin in RASF after IL-1β Stimulation and its Contribution to Rheumatoid Arthritis Pathogenesis**

**Step 1: Isolate RASF from RA patients and culture them in vitro**

1.1. Obtain RASF cells from RA patients through aseptic biopsy or surgical procedures.

1.2. Transport the cells to the laboratory and process them within 2 hours of collection.

1.3. Wash the cells with phosphate-buffered saline (PBS) and centrifuge at 300 x g for 5 minutes.

1.4. Resuspend the cells in complete culture medium (e.g., DMEM with 10% FBS, 1% penicillin-streptomycin) and plate them in a 75-cm² tissue culture flask.

1.5. Incubate the cells at 37°C, 5% CO₂, and 95% humidity for 24-48 hours to allow for cell attachment and growth.

**Step 2: Stimulate RASF with IL-1β for different time periods**

2.1. Prepare IL-1β stock solution (e.g., 10 ng/mL) in sterile PBS.

2.2. Add IL-1β to the RASF culture medium at a final concentration of 10 ng/mL.

2.3. Incubate the cells for the following time periods: 6, 17, 24, and 48 hours.

2.4. Collect the cells and supernatant at each time point for subsequent analysis.

**Step 3: Analyze paxillin and vinculin mRNA and protein expression using qPCR and Western blot**

3.1. Extract total RNA from the collected cells using a commercial RNA extraction kit (e.g., TRIzol).

3.2. Perform reverse transcription to generate cDNA using a commercial kit (e.g., High-Capacity cDNA Reverse Transcription Kit).

3.3. Design and synthesize primers for paxillin and vinculin genes.

3.4. Perform qPCR using a commercial kit (e.g., PowerUp SYBR Green Master Mix) and a qPCR instrument (e.g., Applied Biosystems 7500 Fast Real-Time PCR System).

3.5. Analyze the qPCR data using the 2^(-ΔΔCt) method to determine relative mRNA expression levels.

3.6. Extract protein from the collected cells using a commercial protein extraction kit (e.g., RIPA buffer).

3.7. Perform Western blot analysis using a commercial kit (e.g., Pierce ECL Western Blotting Substrate) and antibodies against paxillin and vinculin.

3.8. Analyze the Western blot data using densitometry software (e.g., ImageJ) to determine relative protein expression levels.

**Step 4: Validate the results using confocal microscopy to visualize paxillin and vinculin localization in RASF**

4.1. Fix the collected cells with 4% paraformaldehyde for 15 minutes.

4.2. Permeabilize the cells with 0.1% Triton X-100 for 10 minutes.

4.3. Block the cells with 1% BSA for 30 minutes.

4.4. Incubate the cells with primary antibodies against paxillin and vinculin (1:100 dilution) for 1 hour.

4.5. Incubate the cells with secondary antibodies (1:200 dilution) for 1 hour.

4.6. Mount the cells on glass slides and visualize using a confocal microscope (e.g., Zeiss LSM 710).

**Step 5: Compare the expression levels of paxillin and vinculin with kindlin-2 and talin-1 to investigate potential correlations**

5.1. Extract RNA and protein from the collected cells as described in Steps 3.1-3.6.

5.2. Analyze the expression levels of kindlin-2 and talin-1 using qPCR and Western blot as described in Steps 3.3-3.8.

5.3. Compare the expression levels of paxillin and vinculin with kindlin-2 and talin-1 using statistical software (e.g., GraphPad Prism).

**Step 6: Perform co-immunoprecipitation assays to examine potential interactions between kindlin-2, talin-1, paxillin, and vinculin**

6.1. Extract protein from the collected cells as described in Step 3.6.

6.2. Perform co-immunoprecipitation using a commercial kit (e.g., Pierce Co-Immunoprecipitation Kit) and antibodies against kindlin-2, talin-1, paxillin, and vinculin.

6.3. Analyze the co-immunoprecipitation data using Western blot as described in Step 3.7.

**Step 7: Use siRNA-mediated knockdown of kindlin-2 and talin-1 to investigate the effect on paxillin and vinculin expression**

7.1. Design and synthesize siRNA oligonucleotides against kindlin-2 and talin-1.

7.2. Transfect the siRNA oligonucleotides into RASF cells using a commercial transfection reagent (e.g., Lipofectamine RNAiMAX).

7.3. Incubate the cells for 24-48 hours to allow for siRNA-mediated knockdown.

7.4. Analyze paxillin and vinculin expression using qPCR and Western blot as described in Steps 3.3-3.8.

**Experiment 2: Investigating the Independence of Paxillin and Vinculin Expression from Kindlin-2 and Talin-1 Downregulation in RASF after IL-1β Stimulation**

**Step 1: Perform the same IL-1β stimulation and RASF culture as in the original experiment**

1.1-1.5. Repeat Steps 1.1-1.5 from Experiment 1.

**Step 2: Use a specific inhibitor of kindlin-2 and talin-1 downregulation**

2.1. Prepare the inhibitor stock solution (e.g., 10 μM) in sterile PBS.

2.2. Add the inhibitor to the RASF culture medium at a final concentration of 10 μM.

2.3. Incubate the cells for 24-48 hours to allow for inhibitor-mediated prevention of kindlin-2 and talin-1 downregulation.

**Step 3: Analyze paxillin and vinculin mRNA and protein expression using qPCR and Western blot**

3.1-3.8. Repeat Steps 3.1-3.8 from Experiment 1.

**Step 4: Compare the expression levels of paxillin and vinculin in the presence and absence of the inhibitor**

4.1. Analyze the qPCR and Western blot data using statistical software (e.g., GraphPad Prism).

4.2. Compare the expression levels of paxillin and vinculin in the presence and absence of the inhibitor to determine if kindlin-2 and talin-1 downregulation affects their expression.

These detailed protocols should provide a clear and replicable guide for executing the experiments.","```
   RASF_Cells  IL-1β_Concentration  Incubation_Time  Paxillin_mRNA  Vinculin_mRNA  Paxillin_Protein  Vinculin_Protein  Kindlin-2_mRNA  Talin-1_mRNA  Outcome
0          10000               5.0           12.0       2.345000       1.234000       1.500000       0.800000       1.100000       0.900000  Positive
1          15000               7.5           18.0       2.100000       1.500000       1.200000       0.900000       1.200000       1.000000  Positive
2           5000               2.5            6.0       2.800000       1.800000       1.800000       1.200000       1.300000       1.100000  Negative
3          20000              10.0           24.0       1.900000       1.200000       1.100000       0.800000       1.000000       0.900000  Positive
4           8000               4.0           10.0       2.600000       1.600000       1.400000       1.000000       1.200000       1.000000  Positive
5          12000               8.0           15.0       2.300000       1.400000       1.300000       0.900000       1.100000       0.900000  Positive
6           4000               1.5            4.0       3.000000       2.000000       2.000000       1.400000       1.400000       1.200000  Negative
7          18000               9.0           20.0       2.000000       1.300000       1.200000       0.900000       1.000000       0.900000  Positive
8          14000               6.0           12.0       2.500000       1.600000       1.500000       1.100000       1.300000       1.100000  Positive
9           6000               3.0            8.0       2.900000       1.800000       1.700000       1.200000       1.400000       1.200000  Negative
10         22000              11.0           26.0       1.800000       1.200000       1.100000       0.900000       1.000000       0.900000  Positive
11         16000               8.5           16.0       2.400000       1.500000       1.400000       1.000000       1.200000       1.000000  Positive
12          9000               5.5           11.0       2.700000       1.700000       1.600000       1.200000       1.400000       1.200000  Negative
13         20000              10.5           25.0       1.900000       1.300000       1.200000       0.900000       1.000000       0.900000  Positive
14         13000               7.0           14.0       2.200000       1.400000       1.300000       0.900000       1.100000       0.900000  Positive
15          7000               4.5           10.0       2.800000       1.800000       1.700000       1.200000       1.400000       1.200000  Negative
16         19000               9.5           22.0       2.100000       1.400000       1.300000       0.900000       1.100000       0.900000  Positive
17         15000               8.0           17.0       2.500000       1.600000       1.500000       1.100000       1.300000       1.100000  Positive
18          5000               2.0            5.0       3.100000       2.100000       2.100000       1.400000       1.400000       1.200000  Negative
19         21000              11.5           28.0       1.700000       1.200000       1.100000       0.900000       1.000000       0.900000  Positive
20         17000               9.0           19.0       2.300000       1.500000       1.400000       1.000000       1.200000       1.000000  Positive
21         11000               6.5           13.0       2.600000       1.700000       1.600000       1.200000       1.400000       1.200000  Negative
22         23000              12.0           30.0       1.600000       1.200000       1.100000       0.900000       1.000000       0.900000  Positive
23         18000               9.5           21.0       2.400000       1.600000       1.500000       1.100000       1.300000       1.100000  Positive
24         14000               7.5           15.0       2.700000       1.800000       1.700000       1.200000       1.400000       1.200000  Negative
```",0.3091696844346057
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7d4982a14cb1505e8631872ddd310e6d62614d8e.summary'],Does the timing of BVAC-B administration relative to pembrolizumab treatment impact the enhancement of anti-tumor activity in patients with HER2-positive advanced gastric cancer?,,"This experiment has an unlimited budget in terms of time, resources, and financial support.",,"Based on the provided hypothesis, I've developed a high-level experimental plan to test the impact of BVAC-B administration timing relative to pembrolizumab treatment on anti-tumor activity in patients with HER2-positive advanced gastric cancer.

**Experimental Design:**

1. **Patient Selection:**
Recruit patients with HER2-positive advanced gastric cancer who have not received prior pembrolizumab or BVAC-B treatment. Ensure a diverse patient population in terms of age, sex, and disease stage.
2. **Study Arms:**
Divide patients into four study arms:
	* Arm 1: Pembrolizumab monotherapy (control group)
	* Arm 2: BVAC-B administration 1 week prior to pembrolizumab treatment (BVAC-B → Pembrolizumab)
	* Arm 3: Concurrent administration of BVAC-B and pembrolizumab (BVAC-B + Pembrolizumab)
	* Arm 4: Pembrolizumab treatment 1 week prior to BVAC-B administration (Pembrolizumab → BVAC-B)
3. **Treatment and Dosing:**
	* Pembrolizumab: Administer 200 mg every 3 weeks (standard dosing)
	* BVAC-B: Administer 1.25 mg/kg every 3 weeks (standard dosing)
4. **Endpoints:**
	* Primary endpoint: Objective Response Rate (ORR) measured by RECIST 1.1 criteria
	* Secondary endpoints:
		+ Progression-Free Survival (PFS)
		+ Overall Survival (OS)
		+ Immune-related Adverse Events (irAEs)
		+ Biomarker analysis (e.g., PD-L1 expression, T cell infiltration)
5. **Sample Size:**
Calculate the sample size based on the primary endpoint (ORR) using a two-sided alpha level of 0.05 and a power of 0.8. Assume a 20% ORR in the control group and a 40% ORR in the experimental groups. This would require approximately 120 patients per arm (480 patients total).
6. **Randomization:**
Randomize patients 1:1:1:1 to each study arm using a stratified randomization method to ensure balance across arms for key prognostic factors (e.g., age, sex, disease stage).

**Laboratory Analysis:**

1. **Tumor Biopsies:**
Collect tumor biopsies at baseline, after 6 weeks of treatment, and at progression. Analyze biopsies for:
	* PD-L1 expression using immunohistochemistry (IHC)
	* T cell infiltration using IHC and/or flow cytometry
	* HER2 expression using IHC and/or FISH
2. **Blood Samples:**
Collect blood samples at baseline, every 3 weeks during treatment, and at progression. Analyze for:
	* Peripheral blood mononuclear cells (PBMCs) using flow cytometry to assess immune cell subsets and activation markers
	* Circulating tumor DNA (ctDNA) using next-generation sequencing (NGS) to monitor tumor burden and genetic alterations
3. **Immunophenotyping:**
Perform immunophenotyping on PBMCs using flow cytometry to assess changes in immune cell subsets, activation markers, and checkpoint molecule expression.

**Statistical Analysis:**

1. **Primary Endpoint:**
Compare ORR between study arms using a Cochran-Mantel-Haenszel test, adjusting for stratification factors.
2. **Secondary Endpoints:**
Analyze PFS and OS using Kaplan-Meier estimates and Cox proportional hazards models. Compare irAEs between arms using Fisher's exact test.
3. **Biomarker Analysis:**
Correlate biomarker data with clinical outcomes using Spearman's rank correlation coefficient and Cox proportional hazards models.

**Timeline:**

* Patient recruitment: 12 months
* Treatment and data collection: 24 months
* Laboratory analysis: 18 months
* Statistical analysis and manuscript preparation: 12 months

**Resources:**

* Personnel: 10 researchers, 5 clinicians, 2 biostatisticians, and 5 laboratory technicians
* Equipment:
	+ Flow cytometer
	+ Next-generation sequencer
	+ IHC and FISH equipment
	+ Biorepository for sample storage
* Budget: Unlimited, with a projected cost of $10 million per year for 5 years

This experimental plan is designed to comprehensively evaluate the impact of BVAC-B administration timing relative to pembrolizumab treatment on anti-tumor activity in patients with HER2-positive advanced gastric cancer. The unlimited budget allows for a robust study design, state-of-the-art laboratory analysis, and a large sample size to ensure statistically significant results.",90,"Here are the detailed, step-by-step protocols for the experimental plan:

**Patient Selection Protocol:**

1.1. **Inclusion Criteria:**

* Patients with histologically confirmed HER2-positive advanced gastric cancer
* No prior treatment with pembrolizumab or BVAC-B
* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Adequate organ function (bone marrow, liver, and kidney)

1.2. **Exclusion Criteria:**

* Active autoimmune disease or history of autoimmune disease
* Prior malignancy within 2 years
* Active infection or uncontrolled medical condition
* Pregnant or breastfeeding women

1.3. **Patient Recruitment:**

* Advertise the study through hospital websites, social media, and patient advocacy groups
* Screen patients using electronic health records and medical charts
* Obtain informed consent from eligible patients
* Enroll patients into the study within 2 weeks of consent

**Study Arm Assignment Protocol:**

2.1. **Randomization:**

* Use a stratified randomization method to ensure balance across arms for key prognostic factors (age, sex, disease stage)
* Randomize patients 1:1:1:1 to each study arm using a computer-generated randomization sequence
* Assign patients to one of the four study arms:
	+ Arm 1: Pembrolizumab monotherapy (control group)
	+ Arm 2: BVAC-B administration 1 week prior to pembrolizumab treatment (BVAC-B → Pembrolizumab)
	+ Arm 3: Concurrent administration of BVAC-B and pembrolizumab (BVAC-B + Pembrolizumab)
	+ Arm 4: Pembrolizumab treatment 1 week prior to BVAC-B administration (Pembrolizumab → BVAC-B)

**Treatment and Dosing Protocol:**

3.1. **Pembrolizumab Administration:**

* Administer 200 mg of pembrolizumab every 3 weeks via intravenous infusion
* Infuse pembrolizumab over 30 minutes
* Monitor patients for infusion reactions and manage according to standard guidelines

3.2. **BVAC-B Administration:**

* Administer 1.25 mg/kg of BVAC-B every 3 weeks via intravenous infusion
* Infuse BVAC-B over 30 minutes
* Monitor patients for infusion reactions and manage according to standard guidelines

**Endpoint Assessment Protocol:**

4.1. **Objective Response Rate (ORR) Assessment:**

* Evaluate tumor response using RECIST 1.1 criteria
* Assess tumor response at baseline, every 6 weeks during treatment, and at progression
* Record best overall response (complete response, partial response, stable disease, or progressive disease)

4.2. **Progression-Free Survival (PFS) and Overall Survival (OS) Assessment:**

* Define PFS as the time from randomization to disease progression or death
* Define OS as the time from randomization to death
* Assess PFS and OS at every 3-week visit during treatment and every 6 weeks during follow-up

4.3. **Immune-Related Adverse Events (irAEs) Assessment:**

* Monitor patients for irAEs (e.g., skin rash, diarrhea, pneumonitis) during treatment and follow-up
* Grade irAEs using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
* Manage irAEs according to standard guidelines

**Laboratory Analysis Protocol:**

5.1. **Tumor Biopsy Collection and Analysis:**

* Collect tumor biopsies at baseline, after 6 weeks of treatment, and at progression
* Analyze biopsies for:
	+ PD-L1 expression using immunohistochemistry (IHC)
	+ T cell infiltration using IHC and/or flow cytometry
	+ HER2 expression using IHC and/or FISH

5.2. **Blood Sample Collection and Analysis:**

* Collect blood samples at baseline, every 3 weeks during treatment, and at progression
* Analyze blood samples for:
	+ Peripheral blood mononuclear cells (PBMCs) using flow cytometry to assess immune cell subsets and activation markers
	+ Circulating tumor DNA (ctDNA) using next-generation sequencing (NGS) to monitor tumor burden and genetic alterations

5.3. **Immunophenotyping:**

* Perform immunophenotyping on PBMCs using flow cytometry to assess changes in immune cell subsets, activation markers, and checkpoint molecule expression

**Statistical Analysis Protocol:**

6.1. **Primary Endpoint Analysis:**

* Compare ORR between study arms using a Cochran-Mantel-Haenszel test, adjusting for stratification factors
* Calculate the odds ratio and 95% confidence interval for the primary endpoint

6.2. **Secondary Endpoint Analysis:**

* Analyze PFS and OS using Kaplan-Meier estimates and Cox proportional hazards models
* Compare irAEs between arms using Fisher's exact test
* Correlate biomarker data with clinical outcomes using Spearman's rank correlation coefficient and Cox proportional hazards models

**Quality Control and Assurance:**

* Implement quality control measures for laboratory analysis, including proficiency testing and instrument calibration
* Conduct regular quality assurance reviews of data collection, laboratory analysis, and statistical analysis
* Ensure compliance with Good Clinical Practice (GCP) guidelines and regulatory requirements","```
   Pembrolizumab  BVAC-B  Age  ECOG  HER2  Outcome
0           200.0   1.25  55.0     0   3+  Partial Response
1           200.0   1.50  60.0     1   2+  Progressive Disease
2           150.0   1.00  50.0     0   3+  Complete Response
3           200.0   1.25  65.0     1   2+  Stable Disease
4           250.0   1.50  58.0     0   3+  Partial Response
5           200.0   1.00  62.0     1   2+  Progressive Disease
6           150.0   1.25  53.0     0   3+  Complete Response
7           200.0   1.50  59.0     1   2+  Stable Disease
8           250.0   1.25  61.0     0   3+  Partial Response
9           200.0   1.00  56.0     1   2+  Progressive Disease
10          150.0   1.50  54.0     0   3+  Complete Response
11          200.0   1.25  63.0     1   2+  Stable Disease
12          250.0   1.50  60.0     0   3+  Partial Response
13          200.0   1.00  57.0     1   2+  Progressive Disease
14          150.0   1.25  52.0     0   3+  Complete Response
15          200.0   1.50  64.0     1   2+  Stable Disease
16          250.0   1.25  58.0     0   3+  Partial Response
17          200.0   1.00  59.0     1   2+  Progressive Disease
18          150.0   1.50  55.0     0   3+  Complete Response
19          200.0   1.25  62.0     1   2+  Stable Disease
20          250.0   1.50  61.0     0   3+  Partial Response
21          200.0   1.00  56.0     1   2+  Progressive Disease
22          150.0   1.25  53.0     0   3+  Complete Response
23          200.0   1.50  63.0     1   2+  Stable Disease
24          250.0   1.25  60.0     0   3+  Partial Response
```",0.11969219944433415
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/017eb92f27371ce1988ceda1ab478aef0c3d5e04.summary'],"Does the timing of antigen presentation to CD4 T cells, rather than the level of antigen-mediated interactions, determine the class of immunity induced, with rapid presentation favoring Th1 responses and delayed presentation favoring Th2 responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",,"What a fascinating hypothesis! I'd be delighted to help design an experiment to test it.

**Hypothesis:** The timing of antigen presentation to CD4 T cells, rather than the level of antigen-mediated interactions, determines the class of immunity induced, with rapid presentation favoring Th1 responses and delayed presentation favoring Th2 responses.

**Experimental Plan:**

**Objective:** To test the hypothesis by investigating the effect of antigen presentation timing on the induction of Th1 and Th2 responses.

**Experimental Design:**

1. **Antigen preparation:** Prepare a well-characterized antigen (e.g., ovalbumin) and label it with a fluorescent tag (e.g., FITC) to track its presentation.
2. **CD4 T cell isolation and culture:** Isolate CD4 T cells from mice or human donors and culture them in vitro.
3. **Antigen presentation timing manipulation:** Use a combination of antigen-presenting cells (APCs) and antigen-loading strategies to control the timing of antigen presentation to CD4 T cells. Specifically:
	* **Rapid presentation:** Use dendritic cells (DCs) that have been pre-loaded with antigen and matured to rapidly present the antigen to CD4 T cells.
	* **Delayed presentation:** Use immature DCs that are loaded with antigen and then matured in vitro to delay antigen presentation to CD4 T cells.
4. **T cell stimulation and analysis:** Co-culture CD4 T cells with APCs and antigen under the two different presentation timing conditions. Measure the following outcomes:
	* **Cytokine production:** Analyze the production of Th1-associated cytokines (e.g., IFN-γ, TNF-α) and Th2-associated cytokines (e.g., IL-4, IL-5) using ELISA or intracellular cytokine staining.
	* **T cell proliferation:** Assess T cell proliferation using CFSE or BrdU incorporation assays.
	* **T cell differentiation:** Analyze the expression of Th1- and Th2-associated transcription factors (e.g., T-bet, GATA3) and surface markers (e.g., CD44, CD62L) using flow cytometry.
5. **Control groups:** Include control groups with no antigen presentation or with antigen presentation at an intermediate time point to serve as a baseline.

**Experimental Approach to Disprove the Hypothesis:**

To disprove the hypothesis, we can design an experiment that attempts to show that the level of antigen-mediated interactions, rather than the timing of antigen presentation, determines the class of immunity induced.

**Modified Experimental Design:**

1. **Antigen dose titration:** Prepare a range of antigen concentrations and present them to CD4 T cells using a single APC type (e.g., DCs) and a fixed presentation timing (e.g., rapid presentation).
2. **T cell stimulation and analysis:** Co-culture CD4 T cells with APCs and antigen at different concentrations. Measure the same outcomes as in the original experiment (cytokine production, T cell proliferation, and T cell differentiation).
3. **Comparison:** Compare the outcomes between the different antigen dose groups to determine if the level of antigen-mediated interactions, rather than the timing of antigen presentation, influences the class of immunity induced.

**Rationale:** If the hypothesis is true, we would expect to see a significant difference in the immune response (Th1 vs. Th2) between the rapid and delayed presentation groups, but not between the different antigen dose groups. If, however, the level of antigen-mediated interactions is the primary determinant of the immune response, we would expect to see a dose-dependent effect on the immune response, regardless of the presentation timing.

**Budget and Timeframe:**

This experiment can be completed within a reasonable timeframe (3-6 months) and budget, as it leverages existing laboratory equipment and techniques. The main costs will be associated with:

* Antigen preparation and labeling
* Cell culture reagents and media
* Flow cytometry and ELISA reagents
* Labor costs for cell isolation, culture, and analysis

By designing an experiment to disprove the hypothesis, we can gain confidence in the results and provide a more comprehensive understanding of the relationship between antigen presentation timing and the class of immunity induced.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Antigen Preparation**

1.1. Obtain ovalbumin (OVA) protein from a commercial supplier or prepare in-house using standard protein purification techniques.

1.2. Label OVA with fluorescein isothiocyanate (FITC) according to the manufacturer's instructions.

1.3. Verify the labeling efficiency using spectrofluorometry or fluorescence microscopy.

1.4. Aliquot the labeled OVA into 10 μg/mL stock solutions and store at -20°C.

**Protocol 2: CD4 T Cell Isolation and Culture**

2.1. Obtain mouse or human blood samples from a reputable supplier or collect from in-house animal colonies.

2.2. Isolate CD4 T cells using magnetic bead-based separation (e.g., Miltenyi Biotec) or fluorescence-activated cell sorting (FACS) according to the manufacturer's instructions.

2.3. Culture CD4 T cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

2.4. Verify CD4 T cell purity using flow cytometry (>95% CD4+).

**Protocol 3: Antigen-Presenting Cell (APC) Preparation**

3.1. Isolate dendritic cells (DCs) from mouse or human blood samples using magnetic bead-based separation or FACS according to the manufacturer's instructions.

3.2. Culture DCs in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

3.3. Mature DCs using a maturation cocktail (e.g., TNF-α, IL-1β, and LPS) for 24 hours.

3.4. Verify DC maturation using flow cytometry (CD83+, CD86+, and MHC-II+).

**Protocol 4: Rapid Antigen Presentation**

4.1. Load mature DCs with 10 μg/mL FITC-OVA for 2 hours at 37°C.

4.2. Wash DCs twice with PBS to remove excess antigen.

4.3. Co-culture 1 × 10^5 CD4 T cells with 1 × 10^5 antigen-loaded DCs in 200 μL RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

**Protocol 5: Delayed Antigen Presentation**

5.1. Load immature DCs with 10 μg/mL FITC-OVA for 2 hours at 37°C.

5.2. Wash DCs twice with PBS to remove excess antigen.

5.3. Mature DCs using a maturation cocktail for 24 hours.

5.4. Co-culture 1 × 10^5 CD4 T cells with 1 × 10^5 antigen-loaded DCs in 200 μL RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

**Protocol 6: T Cell Stimulation and Analysis**

6.1. Incubate co-cultures for 3-5 days to allow for T cell activation and differentiation.

6.2. Analyze cytokine production using ELISA or intracellular cytokine staining:

a. Collect supernatants and measure IFN-γ, TNF-α, IL-4, and IL-5 levels using ELISA kits according to the manufacturer's instructions.

b. Stain cells with fluorescently labeled antibodies against IFN-γ, TNF-α, IL-4, and IL-5 and analyze using flow cytometry.

6.3. Analyze T cell proliferation using CFSE or BrdU incorporation assays:

a. Label CD4 T cells with CFSE or BrdU according to the manufacturer's instructions.

b. Measure CFSE or BrdU incorporation using flow cytometry.

6.4. Analyze T cell differentiation using flow cytometry:

a. Stain cells with fluorescently labeled antibodies against T-bet, GATA3, CD44, and CD62L.

b. Analyze expression levels using flow cytometry.

**Protocol 7: Control Groups**

7.1. Include control groups with no antigen presentation or with antigen presentation at an intermediate time point (e.g., 12 hours) to serve as a baseline.

**Protocol 8: Antigen Dose Titration (Modified Experimental Design)**

8.1. Prepare a range of FITC-OVA concentrations (e.g., 0.1, 1, 10, and 100 μg/mL).

8.2. Load mature DCs with each antigen concentration for 2 hours at 37°C.

8.3. Co-culture 1 × 10^5 CD4 T cells with 1 × 10^5 antigen-loaded DCs in 200 μL RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine at 37°C, 5% CO2.

8.4. Analyze cytokine production, T cell proliferation, and T cell differentiation as described in Protocol 6.

**Note:** All protocols should be performed in triplicate, and results should be analyzed using appropriate statistical methods to ensure reproducibility and significance.","```
   OVA_concentration  CD4_T_cells  DCs  FBS  Penicillin_Streptomycin  L_Glutamine  Outcome_IFN_gamma  Outcome_TNF_alpha  Outcome_IL4  Outcome_IL5  Outcome_Proliferation  Outcome_Tbet  Outcome_GATA3
0               0.1       100000  100000  10.0                1.0           1.0             200.0             150.0       50.0       20.0               20.0       30.0       20.0
1               1.0       100000  100000  10.0                1.0           1.0             400.0             300.0       80.0       40.0               40.0       40.0       30.0
2              10.0       100000  100000  10.0                1.0           1.0             800.0             600.0      120.0       80.0               80.0       50.0       40.0
3              100.0       100000  100000  10.0                1.0           1.0            1200.0             900.0      180.0      120.0              120.0       60.0       50.0
4               0.1        50000  100000  10.0                1.0           1.0             150.0             100.0       30.0       20.0               20.0       20.0       15.0
5               1.0        50000  100000  10.0                1.0           1.0             300.0             200.0       60.0       40.0               40.0       30.0       25.0
6              10.0        50000  100000  10.0                1.0           1.0             600.0             400.0       90.0       60.0               60.0       40.0       35.0
7              100.0        50000  100000  10.0                1.0           1.0             900.0             600.0      120.0       80.0               80.0       50.0       45.0
8               0.1       200000  100000  10.0                1.0           1.0             300.0             200.0       60.0       40.0               40.0       40.0       30.0
9               1.0       200000  100000  10.0                1.0           1.0             600.0             400.0       90.0       60.0               60.0       50.0       40.0
10             10.0       200000  100000  10.0                1.0           1.0            1200.0             800.0      150.0      100.0              100.0       60.0       50.0
11            100.0       200000  100000  10.0                1.0           1.0            1800.0            1200.0      200.0      140.0              140.0       70.0       60.0
12               0.1        50000   50000  10.0                1.0           1.0             100.0              80.0       20.0       15.0               15.0       15.0       10.0
13               1.0        50000   50000  10.0                1.0           1.0             200.0             150.0       40.0       30.0               30.0       25.0       20.0
14              10.0        50000   50000  10.0                1.0           1.0             400.0             300.0       60.0       45.0               45.0       35.0       30.0
15            100.0        50000   50000  10.0                1.0           1.0             600.0             450.0       80.0       60.0               60.0       45.0       40.0
16               0.1       100000   50000  10.0                1.0           1.0             250.0             200.0       50.0       35.0               35.0       30.0       25.0
17               1.0       100000   50000  10.0                1.0           1.0             400.0             300.0       70.0       50.0               50.0       40.0       35.0
18              10.0       100000   50000  10.0                1.0           1.0             700.0             500.0       90.0       65.0               65.0       50.0       45.0
19            100.0       100000   50000  10.0                1.0           1.0             900.0             650.0      110.0       80.0               80.0       60.0       55.0
20               0.1       200000   50000  10.0                1.0           1.0             350.0             250.0       60.0       45.0               45.0       40.0       35.0
21               1.0       200000   50000  10.0                1.0           1.0             600.0             450.0       80.0       60.0               60.0       50.0       45.0
22              10.0       200000   50000  10.0                1.0           1.0            1000.0             750.0      120.0       90.0               90.0       65.0       60.0
23            100.0       200000   50000  10.0                1.0           1.0            1300.0             950.0      150.0      110.0              110.0       75.0       70.0
24               0.1        50000  200000  10.0                1.0           1.0             200.0             150.0       40.0       30.0               30.0       25.0       20.0
```",0.7257079397215905
"['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/667bd85d2ff7652b626f75f6c50d15715ba56b62.summary', '/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/ac1e6dc239c4e840ff984f1a8f63eb85b183b5fd.summary']",Does the timing of class switch recombination during B cell maturation influence the responsiveness of B cells to TLR7/8 stimulation and subsequent antibody affinity maturation?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've designed an experiment to test the hypothesis and potentially disprove it. Here's a high-level experimental approach:

**Experiment Title:** Investigating the Influence of Class Switch Recombination Timing on B Cell Responsiveness to TLR7/8 Stimulation and Antibody Affinity Maturation

**Objective:** To determine whether the timing of class switch recombination during B cell maturation affects the responsiveness of B cells to TLR7/8 stimulation and subsequent antibody affinity maturation.

**Experimental Design:**

1. **B Cell Isolation and Sorting:** Isolate B cells from human tonsillar tissue and sort them into naive, germinal center, and memory B cell populations using a cell sorter.
2. **Class Switch Recombination Modulation:** Use CRISPR-Cas9 gene editing to modulate the expression of AICDA, a key enzyme involved in class switch recombination, in each B cell population. This will create three groups:
	* Early CSR (naive B cells with AICDA overexpression)
	* Late CSR (germinal center B cells with AICDA overexpression)
	* Control (unedited B cells)
3. **TLR7/8 Stimulation:** Stimulate each B cell group with TLR7/8 agonist and measure their responsiveness using flow cytometry.
4. **Antibody Affinity Maturation Analysis:** Analyze the antibody repertoires and gene expression profiles of each group using single-cell RNA-seq and VDJ sequencing.
5. **Comparison and Statistical Analysis:** Compare the results between the three groups to determine the effect of class switch recombination timing on B cell responsiveness to TLR7/8 stimulation and antibody affinity maturation. Perform statistical analysis and visualization to validate the findings.

**Equipment and Resources:**

* Flow cytometer
* Cell sorter
* PCR machine
* Sequencing platform
* CRISPR-Cas9 gene editing tools
* TLR7/8 agonist
* Human tonsillar tissue samples

**Time and Budget Constraints:**

* Estimated time: 6-9 months
* Estimated budget: $150,000 - $200,000 (depending on the cost of sequencing and CRISPR-Cas9 reagents)

**Rationale:**

This experiment aims to disprove the hypothesis by testing the effect of class switch recombination timing on B cell responsiveness to TLR7/8 stimulation and antibody affinity maturation. By modulating AICDA expression in different B cell populations, we can assess whether early or late class switch recombination affects the ability of B cells to respond to TLR7/8 stimulation and undergo antibody affinity maturation. If the results show no significant difference between the groups, it would suggest that the timing of class switch recombination does not influence B cell responsiveness to TLR7/8 stimulation and antibody affinity maturation, thereby disproving the hypothesis.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: B Cell Isolation and Sorting**

1.1. Obtain human tonsillar tissue samples from a reputable tissue bank or through collaboration with a medical institution.

1.2. Prepare the tissue samples for processing by washing them in phosphate-buffered saline (PBS) and mincing them into small pieces.

1.3. Isolate B cells from the tissue samples using a density gradient centrifugation method, such as Ficoll-Paque, according to the manufacturer's instructions.

1.4. Wash the isolated B cells in PBS and resuspend them in a suitable buffer for cell sorting.

1.5. Use a cell sorter (e.g., BD FACSAria III) to sort the B cells into naive, germinal center, and memory B cell populations based on their surface marker expression. The following markers can be used:
	* Naive B cells: CD19+, CD27-, CD38-
	* Germinal center B cells: CD19+, CD27+, CD38+
	* Memory B cells: CD19+, CD27+, CD38-

1.6. Collect the sorted B cells in separate tubes and store them at 4°C until further processing.

**Protocol 2: Class Switch Recombination Modulation using CRISPR-Cas9 Gene Editing**

2.1. Design and synthesize guide RNAs (gRNAs) targeting the AICDA gene using a CRISPR-Cas9 design tool (e.g., CRISPR Design).

2.2. Prepare the CRISPR-Cas9 ribonucleoprotein (RNP) complex by mixing the gRNA with the Cas9 enzyme and a suitable buffer according to the manufacturer's instructions.

2.3. Electroporate the RNP complex into the sorted B cells using an electroporation device (e.g., Neon Transfection System) according to the manufacturer's instructions.

2.4. Incubate the electroporated B cells in a suitable culture medium (e.g., RPMI 1640 with 10% FBS) at 37°C, 5% CO2 for 24-48 hours to allow for gene editing.

2.5. Verify the efficiency of AICDA gene editing using PCR and Sanger sequencing.

2.6. Create three groups of B cells:
	* Early CSR (naive B cells with AICDA overexpression)
	* Late CSR (germinal center B cells with AICDA overexpression)
	* Control (unedited B cells)

**Protocol 3: TLR7/8 Stimulation**

3.1. Prepare the TLR7/8 agonist (e.g., R848) according to the manufacturer's instructions.

3.2. Stimulate each B cell group with the TLR7/8 agonist at a concentration of 1-10 μg/mL in a suitable culture medium (e.g., RPMI 1640 with 10% FBS).

3.3. Incubate the stimulated B cells at 37°C, 5% CO2 for 24-48 hours.

3.4. Harvest the stimulated B cells and wash them in PBS.

**Protocol 4: Flow Cytometry Analysis**

4.1. Stain the harvested B cells with fluorescently labeled antibodies against surface markers (e.g., CD19, CD27, CD38) and intracellular markers (e.g., phosphorylated signaling proteins) according to the manufacturer's instructions.

4.2. Analyze the stained B cells using a flow cytometer (e.g., BD LSRFortessa) to measure their responsiveness to TLR7/8 stimulation.

4.3. Record the data and perform quality control checks to ensure accurate and reproducible results.

**Protocol 5: Antibody Affinity Maturation Analysis**

5.1. Prepare the B cells for single-cell RNA-seq and VDJ sequencing by washing them in PBS and resuspending them in a suitable buffer.

5.2. Perform single-cell RNA-seq using a platform such as 10x Genomics or Drop-seq according to the manufacturer's instructions.

5.3. Analyze the RNA-seq data using a bioinformatics pipeline (e.g., CellRanger) to identify differentially expressed genes and antibody repertoire profiles.

5.4. Perform VDJ sequencing using a platform such as Illumina or PacBio according to the manufacturer's instructions.

5.5. Analyze the VDJ sequencing data using a bioinformatics pipeline (e.g., IgBLAST) to identify antibody sequences and affinity maturation profiles.

**Protocol 6: Comparison and Statistical Analysis**

6.1. Compare the results from the three B cell groups (Early CSR, Late CSR, and Control) using statistical software (e.g., R or Python) and visualization tools (e.g., ggplot2 or Seaborn).

6.2. Perform statistical tests (e.g., t-test, ANOVA) to determine the significance of differences between the groups.

6.3. Visualize the results using plots and heatmaps to illustrate the effects of class switch recombination timing on B cell responsiveness to TLR7/8 stimulation and antibody affinity maturation.

6.4. Interpret the results in the context of the hypothesis and draw conclusions about the role of class switch recombination timing in B cell responsiveness and antibody affinity maturation.

These detailed protocols should provide a clear and replicable guide for executing the experiment.","```
   Tonsillar Tissue (mg)  Ficoll-Paque (mL)  gRNA (pmol)  Cas9 (pmol)  R848 (μg/mL)  Naive B Cells  Germinal Center B Cells  Memory B Cells  Outcome
0               100.0             2.0         50.0        100.0         5.0          80.0                10.0           10.0  High
1               120.0             2.5         60.0        120.0         7.0          70.0                15.0           15.0  Medium
2                90.0             1.5         40.0         90.0         3.0          85.0                 8.0            7.0  High
3               110.0             2.2         55.0        110.0         6.0          75.0                12.0           13.0  Medium
4               130.0             3.0         70.0        130.0         8.0          65.0                18.0           17.0  Low
5                80.0             1.0         30.0         80.0         2.0          90.0                 5.0            5.0  High
6               140.0             3.5         80.0        140.0         9.0          60.0                20.0           20.0  Low
7               100.0             2.0         50.0        100.0         5.0          80.0                10.0           10.0  High
8               120.0             2.5         60.0        120.0         7.0          70.0                15.0           15.0  Medium
9                90.0             1.5         40.0         90.0         3.0          85.0                 8.0            7.0  High
10              110.0             2.2         55.0        110.0         6.0          75.0                12.0           13.0  Medium
11              130.0             3.0         70.0        130.0         8.0          65.0                18.0           17.0  Low
12               80.0             1.0         30.0         80.0         2.0          90.0                 5.0            5.0  High
13              140.0             3.5         80.0        140.0         9.0          60.0                20.0           20.0  Low
14              100.0             2.0         50.0        100.0         5.0          80.0                10.0           10.0  High
15              120.0             2.5         60.0        120.0         7.0          70.0                15.0           15.0  Medium
16               90.0             1.5         40.0         90.0         3.0          85.0                 8.0            7.0  High
17              110.0             2.2         55.0        110.0         6.0          75.0                12.0           13.0  Medium
18              130.0             3.0         70.0        130.0         8.0          65.0                18.0           17.0  Low
19               80.0             1.0         30.0         80.0         2.0          90.0                 5.0            5.0  High
20              140.0             3.5         80.0        140.0         9.0          60.0                20.0           20.0  Low
21              100.0             2.0         50.0        100.0         5.0          80.0                10.0           10.0  High
22              120.0             2.5         60.0        120.0         7.0          70.0                15.0           15.0  Medium
23               90.0             1.5         40.0         90.0         3.0          85.0                 8.0            7.0  High
24              110.0             2.2         55.0        110.0         6.0          75.0                12.0           13.0  Medium
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/c0c0c6c89f91226ceb44d8549ad5c51ec066dcb7.summary'],"Does the ubiquitination of MYD88 L265P by RNF138 also regulate the activity of other transcription factors beyond NF-kB, contributing to the development and progression of B-cell malignancies?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis, I will design an experiment to test and potentially disprove the hypothesis that the ubiquitination of MYD88 L265P by RNF138 also regulates the activity of other transcription factors beyond NF-kB, contributing to the development and progression of B-cell malignancies.

**Experimental Plan:**

**Title:** Investigating the Role of RNF138-Mediated Ubiquitination of MYD88 L265P in Regulating Transcription Factors beyond NF-kB in B-Cell Malignancies

**Objective:** To determine if RNF138-mediated ubiquitination of MYD88 L265P regulates the activity of transcription factors beyond NF-kB, contributing to the development and progression of B-cell malignancies.

**Experimental Approach:**

1. **Cell Culture and Transfection:**
	* Use human B-cell lymphoma cell lines (e.g., OCI-Ly1, OCI-Ly3) and transfect them with MYD88 L265P and/or RNF138 expression vectors.
	* Use siRNA or CRISPR-Cas9 to knockdown RNF138 expression in MYD88 L265P-expressing cells.
2. **Transcription Factor Profiling:**
	* Perform RNA sequencing (RNA-seq) or quantitative reverse transcription polymerase chain reaction (qRT-PCR) to analyze the expression of various transcription factors (e.g., AP-1, STAT3, IRF4, etc.) in MYD88 L265P-expressing cells with or without RNF138 overexpression or knockdown.
	* Use bioinformatic tools (e.g., Ingenuity Pathway Analysis, Gene Set Enrichment Analysis) to identify transcription factors and pathways regulated by RNF138-mediated ubiquitination of MYD88 L265P.
3. **Chromatin Immunoprecipitation (ChIP) Assay:**
	* Perform ChIP assays using antibodies against MYD88, RNF138, and transcription factors of interest (e.g., NF-kB, AP-1, STAT3) to determine their binding to specific genomic regions in MYD88 L265P-expressing cells with or without RNF138 overexpression or knockdown.
4. ** Luciferase Reporter Assays:**
	* Use luciferase reporter constructs containing promoter regions of genes regulated by transcription factors of interest to measure their activity in MYD88 L265P-expressing cells with or without RNF138 overexpression or knockdown.

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ Differential expression of transcription factors beyond NF-kB in MYD88 L265P-expressing cells with RNF138 overexpression or knockdown.
	+ Enrichment of RNF138 and MYD88 L265P at genomic regions associated with transcription factors beyond NF-kB.
	+ Altered activity of transcription factors beyond NF-kB in response to RNF138-mediated ubiquitination of MYD88 L265P.
* If the hypothesis is false, we expect to see:
	+ No significant changes in the expression or activity of transcription factors beyond NF-kB in response to RNF138-mediated ubiquitination of MYD88 L265P.

**Timeframe and Budget:**

This experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000, which covers the costs of:

* Cell culture and transfection reagents
* RNA-seq or qRT-PCR analysis
* ChIP assay reagents and antibodies
* Luciferase reporter assays
* Bioinformatic tools and software
* Personnel and laboratory expenses

By designing an experiment to disprove the hypothesis, we can rigorously test the role of RNF138-mediated ubiquitination of MYD88 L265P in regulating transcription factors beyond NF-kB and gain a deeper understanding of the molecular mechanisms underlying B-cell malignancies.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: Cell Culture and Transfection**

**Step 1.1: Cell Culture**

* Obtain human B-cell lymphoma cell lines (e.g., OCI-Ly1, OCI-Ly3) from a reputable cell bank or laboratory.
* Culture cells in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine at 37°C and 5% CO2.
* Maintain cells at a density of 0.5-1.0 x 10^6 cells/mL.

**Step 1.2: Transfection**

* Prepare MYD88 L265P and RNF138 expression vectors using standard molecular biology techniques (e.g., PCR, cloning, sequencing).
* Transfect cells with MYD88 L265P and/or RNF138 expression vectors using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.
* Use a control vector (e.g., empty vector) as a negative control.
* Incubate cells for 24-48 hours post-transfection to allow for protein expression.

**Step 1.3: siRNA or CRISPR-Cas9 Knockdown**

* Design and synthesize siRNA or CRISPR-Cas9 guide RNAs targeting RNF138.
* Transfect cells with siRNA or CRISPR-Cas9 reagents using a transfection reagent (e.g., Lipofectamine RNAiMAX) according to the manufacturer's instructions.
* Incubate cells for 24-48 hours post-transfection to allow for knockdown.

**Protocol 2: Transcription Factor Profiling**

**Step 2.1: RNA Isolation**

* Harvest cells and isolate total RNA using a RNA isolation kit (e.g., TRIzol) according to the manufacturer's instructions.
* Quantify RNA using a spectrophotometer (e.g., NanoDrop).

**Step 2.2: RNA Sequencing (RNA-seq) or qRT-PCR**

* Perform RNA-seq using a sequencing platform (e.g., Illumina HiSeq) according to the manufacturer's instructions.
* Alternatively, perform qRT-PCR using a qRT-PCR kit (e.g., SYBR Green) and a thermocycler (e.g., Applied Biosystems 7500) according to the manufacturer's instructions.
* Analyze the expression of various transcription factors (e.g., AP-1, STAT3, IRF4) using bioinformatic tools (e.g., Ingenuity Pathway Analysis, Gene Set Enrichment Analysis).

**Protocol 3: Chromatin Immunoprecipitation (ChIP) Assay**

**Step 3.1: Cross-Linking and Sonication**

* Cross-link cells with 1% formaldehyde for 10 minutes at room temperature.
* Quench cross-linking with 125 mM glycine for 5 minutes at room temperature.
* Sonicate chromatin using a sonicator (e.g., Covaris) to generate fragments of 200-500 bp.

**Step 3.2: Immunoprecipitation**

* Prepare antibodies against MYD88, RNF138, and transcription factors of interest (e.g., NF-kB, AP-1, STAT3).
* Immunoprecipitate chromatin fragments using the prepared antibodies and a ChIP kit (e.g., Millipore) according to the manufacturer's instructions.

**Step 3.3: qPCR Analysis**

* Analyze immunoprecipitated chromatin fragments using qPCR and a thermocycler (e.g., Applied Biosystems 7500) according to the manufacturer's instructions.
* Use primers specific to genomic regions associated with transcription factors of interest.

**Protocol 4: Luciferase Reporter Assays**

**Step 4.1: Luciferase Reporter Construct Preparation**

* Prepare luciferase reporter constructs containing promoter regions of genes regulated by transcription factors of interest.
* Transfect cells with luciferase reporter constructs using a transfection reagent (e.g., Lipofectamine 3000) according to the manufacturer's instructions.

**Step 4.2: Luciferase Assay**

* Incubate cells for 24-48 hours post-transfection to allow for protein expression.
* Lyse cells and measure luciferase activity using a luciferase assay kit (e.g., Promega) according to the manufacturer's instructions.

**Quality Control and Replicability**

* Perform all experiments in triplicate to ensure reproducibility.
* Include negative controls (e.g., empty vector, siRNA scramble) to account for non-specific effects.
* Validate RNA-seq and ChIP-seq results using qRT-PCR and ChIP-qPCR, respectively.
* Use standardized protocols and reagents to minimize variability.

**Timeline and Budget**

* The experiment can be completed within 6-9 months with a budget of approximately $50,000-$75,000.
* The budget covers the costs of:
	+ Cell culture and transfection reagents
	+ RNA-seq or qRT-PCR analysis
	+ ChIP assay reagents and antibodies
	+ Luciferase reporter assays
	+ Bioinformatic tools and software
	+ Personnel and laboratory expenses","```
   OCI-Ly1 Cells  FBS  Penicillin-Streptomycin  L-Glutamine  MYD88 L265P  RNF138  siRNA/CRISPR  Transfection Reagent  Outcome
0           0.5e6  10%               1%           1%         1.0         0.5         0.2               1.5         High
1           0.7e6  12%               1%           1%         1.2         0.8         0.3               1.8         High
2           0.3e6   8%               1%           1%         0.8         0.3         0.1               1.2         Low
3           0.9e6  14%               1%           1%         1.5         1.0         0.4               2.0         High
4           0.4e6   9%               1%           1%         0.9         0.4         0.2               1.5         Low
5           0.6e6  11%               1%           1%         1.1         0.6         0.3               1.7         High
6           0.8e6  13%               1%           1%         1.4         0.9         0.4               2.1         High
7           0.2e6   7%               1%           1%         0.6         0.2         0.1               1.0         Low
8           0.5e6  10%               1%           1%         1.0         0.5         0.2               1.5         High
9           0.3e6   8%               1%           1%         0.8         0.3         0.1               1.2         Low
10          0.9e6  14%               1%           1%         1.6         1.1         0.5               2.3         High
11          0.4e6   9%               1%           1%         0.9         0.4         0.2               1.5         Low
12          0.6e6  11%               1%           1%         1.2         0.7         0.3               1.8         High
13          0.8e6  13%               1%           1%         1.5         1.0         0.4               2.1         High
14          0.2e6   7%               1%           1%         0.7         0.3         0.1               1.1         Low
15          0.5e6  10%               1%           1%         1.1         0.6         0.2               1.6         High
16          0.3e6   8%               1%           1%         0.9         0.4         0.2               1.4         Low
17          0.9e6  14%               1%           1%         1.7         1.2         0.5               2.4         High
18          0.4e6   9%               1%           1%         1.0         0.5         0.2               1.6         Low
19          0.6e6  11%               1%           1%         1.3         0.8         0.3               1.9         High
20          0.8e6  13%               1%           1%         1.6         1.1         0.4               2.2         High
21          0.2e6   7%               1%           1%         0.8         0.4         0.2               1.3         Low
22          0.5e6  10%               1%           1%         1.2         0.7         0.3               1.7         High
23          0.3e6   8%               1%           1%         1.0         0.5         0.2               1.5         Low
24          0.9e6  14%               1%           1%         1.8         1.3         0.5               2.5         High
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/1609818e19bb243ff0e05fa2e43d1be1893f28b9.summary'],"Does the up-regulation of Nod1 in response to BCR engagement by self-ligand also enhance the expression of other pattern recognition receptors, leading to a broader immune response against commensal bacteria?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Up-regulation of Pattern Recognition Receptors in Response to BCR Engagement and Nod1 Signaling

**Objective:** To determine if the up-regulation of Nod1 in response to BCR engagement by self-ligand also enhances the expression of other pattern recognition receptors, leading to a broader immune response against commensal bacteria.

**Equipment:**

* B cells isolated from wild-type mice
* B cells isolated from Nod1-deficient mice (generated using CRISPR-Cas9 gene editing)
* Flow cytometer
* Antibodies against B cell markers (e.g., CD19, CD20)
* Antibodies against pattern recognition receptors (e.g., TLR2, TLR4, Nod2)
* Nod1 ligand (CiE-DAP)
* qRT-PCR machine and reagents
* RNA extraction kit

**Steps:**

1. Isolate B cells from wild-type and Nod1-deficient mice.
2. Stimulate B cells with CiE-DAP to engage BCR and up-regulate Nod1.
3. Measure Nod1 expression using flow cytometry and qRT-PCR.
4. Analyze the expression of other pattern recognition receptors (e.g., TLR2, TLR4, Nod2) using flow cytometry and qRT-PCR.
5. Compare the expression of pattern recognition receptors between B cells from wild-type and Nod1-deficient mice.
6. Co-culture B cells with commensal bacteria and measure the immune response (e.g., cytokine production, phagocytosis) using flow cytometry and ELISA.

**Expected Outcome:** If the hypothesis is true, we expect to see an up-regulation of other pattern recognition receptors in response to BCR engagement and Nod1 signaling, leading to a broader immune response against commensal bacteria.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Specificity of Nod1 Signaling in B Cell Response to Commensal Bacteria

**Objective:** To determine if the up-regulation of Nod1 in response to BCR engagement by self-ligand specifically enhances the expression of other pattern recognition receptors, or if it is a general response to BCR engagement.

**Equipment:**

* B cells isolated from wild-type mice
* B cells isolated from Nod1-deficient mice (generated using CRISPR-Cas9 gene editing)
* Flow cytometer
* Antibodies against B cell markers (e.g., CD19, CD20)
* Antibodies against pattern recognition receptors (e.g., TLR2, TLR4, Nod2)
* Non-Nod1 ligand (e.g., LPS)
* qRT-PCR machine and reagents
* RNA extraction kit

**Steps:**

1. Isolate B cells from wild-type and Nod1-deficient mice.
2. Stimulate B cells with a non-Nod1 ligand (e.g., LPS) to engage BCR without up-regulating Nod1.
3. Measure the expression of pattern recognition receptors (e.g., TLR2, TLR4, Nod2) using flow cytometry and qRT-PCR.
4. Compare the expression of pattern recognition receptors between B cells stimulated with CiE-DAP (Nod1 ligand) and LPS (non-Nod1 ligand).
5. Co-culture B cells with commensal bacteria and measure the immune response (e.g., cytokine production, phagocytosis) using flow cytometry and ELISA.

**Expected Outcome:** If the hypothesis is false, we expect to see a similar expression of pattern recognition receptors in response to BCR engagement by both CiE-DAP and LPS, indicating that the up-regulation of Nod1 is not specific to the response to commensal bacteria.

**Budget and Timeframe:**

* The experiments can be completed within 6-8 weeks with a budget of approximately $10,000-$15,000, which covers the cost of:
	+ Mice and breeding ( $2,000-$3,000)
	+ Reagents and consumables (e.g., antibodies, ligands, qRT-PCR reagents) ($3,000-$5,000)
	+ Equipment usage (e.g., flow cytometer, qRT-PCR machine) ($2,000-$3,000)
	+ Labor and miscellaneous costs ($3,000-$5,000)

Note: The budget and timeframe may vary depending on the specific requirements of the laboratory and the availability of resources.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis:**

**Protocol:**

**Step 1: Isolate B cells from wild-type and Nod1-deficient mice**

1.1. Obtain wild-type and Nod1-deficient mice (generated using CRISPR-Cas9 gene editing) from the animal facility.

1.2. Euthanize the mice according to the approved animal protocol.

1.3. Harvest the spleens from the mice and place them in a petri dish containing RPMI-1640 medium.

1.4. Crush the spleens using a sterile glass slide to release the cells.

1.5. Filter the cell suspension through a 70-μm cell strainer to remove any debris.

1.6. Centrifuge the cell suspension at 300 x g for 5 minutes to pellet the cells.

1.7. Resuspend the cells in 1 mL of RPMI-1640 medium and count the cells using a hemocytometer.

1.8. Isolate B cells using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) using antibodies against B cell markers (e.g., CD19, CD20).

**Step 2: Stimulate B cells with CiE-DAP to engage BCR and up-regulate Nod1**

2.1. Resuspend the isolated B cells in RPMI-1640 medium at a concentration of 1 x 10^6 cells/mL.

2.2. Add CiE-DAP (Nod1 ligand) to the cell suspension at a final concentration of 1 μg/mL.

2.3. Incubate the cells at 37°C, 5% CO2 for 24 hours to allow for BCR engagement and Nod1 up-regulation.

**Step 3: Measure Nod1 expression using flow cytometry and qRT-PCR**

3.1. Harvest the cells and stain them with antibodies against Nod1 and B cell markers (e.g., CD19, CD20) for flow cytometry analysis.

3.2. Analyze the cells using a flow cytometer to measure Nod1 expression.

3.3. Extract RNA from the cells using an RNA extraction kit.

3.4. Perform qRT-PCR using primers specific to Nod1 to measure Nod1 mRNA expression.

**Step 4: Analyze the expression of other pattern recognition receptors using flow cytometry and qRT-PCR**

4.1. Stain the cells with antibodies against pattern recognition receptors (e.g., TLR2, TLR4, Nod2) for flow cytometry analysis.

4.2. Analyze the cells using a flow cytometer to measure the expression of pattern recognition receptors.

4.3. Perform qRT-PCR using primers specific to the pattern recognition receptors to measure their mRNA expression.

**Step 5: Compare the expression of pattern recognition receptors between B cells from wild-type and Nod1-deficient mice**

5.1. Compare the flow cytometry and qRT-PCR data from wild-type and Nod1-deficient B cells to determine if there is a difference in the expression of pattern recognition receptors.

**Step 6: Co-culture B cells with commensal bacteria and measure the immune response**

6.1. Co-culture the B cells with commensal bacteria (e.g., E. coli) at a ratio of 1:1 for 24 hours.

6.2. Measure the immune response (e.g., cytokine production, phagocytosis) using flow cytometry and ELISA.

**Experiment to Disprove the Hypothesis:**

**Protocol:**

**Step 1: Isolate B cells from wild-type and Nod1-deficient mice**

( Same as Step 1 in the experiment to test the hypothesis)

**Step 2: Stimulate B cells with a non-Nod1 ligand (e.g., LPS) to engage BCR without up-regulating Nod1**

2.1. Resuspend the isolated B cells in RPMI-1640 medium at a concentration of 1 x 10^6 cells/mL.

2.2. Add LPS (non-Nod1 ligand) to the cell suspension at a final concentration of 1 μg/mL.

2.3. Incubate the cells at 37°C, 5% CO2 for 24 hours to allow for BCR engagement without Nod1 up-regulation.

**Step 3: Measure the expression of pattern recognition receptors using flow cytometry and qRT-PCR**

3.1. Stain the cells with antibodies against pattern recognition receptors (e.g., TLR2, TLR4, Nod2) for flow cytometry analysis.

3.2. Analyze the cells using a flow cytometer to measure the expression of pattern recognition receptors.

3.3. Extract RNA from the cells using an RNA extraction kit.

3.4. Perform qRT-PCR using primers specific to the pattern recognition receptors to measure their mRNA expression.

**Step 4: Compare the expression of pattern recognition receptors between B cells stimulated with CiE-DAP and LPS**

4.1. Compare the flow cytometry and qRT-PCR data from B cells stimulated with CiE-DAP and LPS to determine if there is a difference in the expression of pattern recognition receptors.

**Step 5: Co-culture B cells with commensal bacteria and measure the immune response**

5.1. Co-culture the B cells with commensal bacteria (e.g., E. coli) at a ratio of 1:1 for 24 hours.

5.2. Measure the immune response (e.g., cytokine production, phagocytosis) using flow cytometry and ELISA.

Note: The protocols are designed to be specific, detailed, and replicable. The steps are numbered and organized to facilitate easy execution and troubleshooting. The protocols include specific reagents, equipment, and techniques to ensure consistency and accuracy.","```
   Wild-type Mice Nod1-deficient Mice CiE-DAP (μg/mL) LPS (μg/mL) Nod1 Expression TLR2 Expression TLR4 Expression Nod2 Expression Immune Response
0             1.0               0.0           1.0       0.0         2.5          1.2          1.5          1.8         High
1             0.8               0.2           0.8       0.2         2.2          1.1          1.4          1.6         Medium
2             0.5               0.5           0.5       0.5         1.8          1.0          1.2          1.4         Low
3             1.0               0.0           0.0       1.0         1.2          0.8          1.0          1.2         Low
4             0.2               0.8           0.2       0.8         1.5          0.9          1.1          1.3         Medium
5             0.9               0.1           0.9       0.1         2.4          1.3          1.6          1.9         High
6             0.7               0.3           0.7       0.3         2.0          1.2          1.4          1.6         Medium
7             0.4               0.6           0.4       0.6         1.6          0.9          1.1          1.3         Low
8             1.0               0.0           1.0       0.0         2.6          1.4          1.7          2.0         High
9             0.6               0.4           0.6       0.4         1.9          1.1          1.3          1.5         Medium
10            0.3               0.7           0.3       0.7         1.4          0.8          1.0          1.2         Low
11            0.9               0.1           0.9       0.1         2.3          1.2          1.5          1.8         High
12            0.8               0.2           0.8       0.2         2.1          1.1          1.4          1.6         Medium
13            0.5               0.5           0.5       0.5         1.7          0.9          1.1          1.3         Low
14            1.0               0.0           0.0       1.0         1.1          0.7          0.9          1.1         Low
15            0.2               0.8           0.2       0.8         1.4          0.8          1.0          1.2         Low
16            0.9               0.1           0.9       0.1         2.5          1.3          1.6          1.9         High
17            0.7               0.3           0.7       0.3         2.0          1.2          1.4          1.6         Medium
18            0.4               0.6           0.4       0.6         1.5          0.9          1.1          1.3         Low
19            1.0               0.0           1.0       0.0         2.7          1.5          1.8          2.1         High
20            0.6               0.4           0.6       0.4         1.8          1.1          1.3          1.5         Medium
21            0.3               0.7           0.3       0.7         1.3          0.8          1.0          1.2         Low
22            0.9               0.1           0.9       0.1         2.4          1.2          1.5          1.8         High
23            0.8               0.2           0.8       0.2         2.2          1.1          1.4          1.6         Medium
24            0.5               0.5           0.5       0.5         1.6          0.9          1.1          1.3         Low
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/27f4792416be364ef3895b895e7666517c03cd96.summary'],"Does the upregulation of MhcII expression in response to pathogen infection in flounder also enhance the cross-presentation of antigens to CD8+ T-cells, leading to a more effective cell-mediated immune response?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and a separate experiment to attempt to disprove it.

**Experiment to Test the Hypothesis:**

**Title:** Investigating the Role of MhcII in Cross-Presentation of Antigens to CD8+ T-cells in Flounder

**Objective:** To determine if the upregulation of MhcII expression in response to pathogen infection in flounder enhances the cross-presentation of antigens to CD8+ T-cells, leading to a more effective cell-mediated immune response.

**Equipment:**

* Flounder
* MhcII-specific antibodies
* CD8+ T-cells
* Antigens (e.g., ovalbumin)
* Flow cytometer
* Cell culture facilities
* Pathogen (e.g., bacterial or viral)

**Steps:**

1. Infect flounder with a pathogen to induce MhcII upregulation.
2. Isolate CD8+ T-cells from flounder peripheral blood.
3. Co-culture CD8+ T-cells with antigen-presenting cells (APCs) from infected flounder in the presence or absence of MhcII-specific antibodies.
4. Analyze CD8+ T-cell activation and proliferation using flow cytometry.
5. Compare the results to determine if MhcII upregulation enhances cross-presentation of antigens to CD8+ T-cells.
6. Repeat the experiment with different pathogens and antigens to ensure consistency.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of MhcII in Cross-Presentation of Antigens to CD8+ T-cells in Flounder: A Blocking Experiment

**Objective:** To determine if blocking MhcII expression in flounder APCs abolishes the cross-presentation of antigens to CD8+ T-cells, thereby disproving the hypothesis.

**Equipment:**

* Flounder
* MhcII-specific siRNA or CRISPR-Cas9 system
* CD8+ T-cells
* Antigens (e.g., ovalbumin)
* Flow cytometer
* Cell culture facilities
* Pathogen (e.g., bacterial or viral)

**Steps:**

1. Infect flounder with a pathogen to induce MhcII upregulation.
2. Isolate APCs from infected flounder and transfect them with MhcII-specific siRNA or use CRISPR-Cas9 to knockdown MhcII expression.
3. Co-culture CD8+ T-cells with MhcII-knockdown APCs and antigens.
4. Analyze CD8+ T-cell activation and proliferation using flow cytometry.
5. Compare the results to those obtained with control APCs (without MhcII knockdown) to determine if blocking MhcII expression abolishes cross-presentation of antigens to CD8+ T-cells.

**Rationale:**

The first experiment aims to test the hypothesis by investigating the role of MhcII in cross-presentation of antigens to CD8+ T-cells. The second experiment is designed to disprove the hypothesis by blocking MhcII expression in APCs and observing the effect on CD8+ T-cell activation and proliferation. If the blocking experiment shows that CD8+ T-cell activation is not affected or is even enhanced, it would suggest that MhcII upregulation is not essential for cross-presentation of antigens to CD8+ T-cells, thereby disproving the hypothesis.

**Time and Resource Considerations:**

Both experiments can be completed within a reasonable time frame (approximately 6-12 months) and with a moderate budget. The experiments require access to flounder, cell culture facilities, and standard immunology equipment (e.g., flow cytometer). The use of MhcII-specific siRNA or CRISPR-Cas9 system in the blocking experiment may require additional resources and expertise.",85,"Here are the detailed, step-by-step protocols for the two experiments:

**Experiment to Test the Hypothesis: Investigating the Role of MhcII in Cross-Presentation of Antigens to CD8+ T-cells in Flounder**

**Protocol:**

**Step 1: Infection of Flounder with a Pathogen**

1.1. Obtain healthy flounder (n=10) and acclimate them to laboratory conditions for 2 weeks.

1.2. Prepare a pathogen (e.g., bacterial or viral) suspension in sterile PBS at a concentration of 10^6 CFU/mL.

1.3. Inject 100 μL of the pathogen suspension intraperitoneally into each flounder.

1.4. Monitor the flounder for signs of infection (e.g., lethargy, loss of appetite) and ensure they are maintained in a healthy state.

**Step 2: Isolation of CD8+ T-cells from Flounder Peripheral Blood**

2.1. Collect 1 mL of peripheral blood from each infected flounder using a sterile syringe.

2.2. Add 10 μL of heparin (100 U/mL) to the blood sample to prevent clotting.

2.3. Perform density gradient centrifugation using Ficoll-Paque to separate the blood components.

2.4. Collect the peripheral blood mononuclear cells (PBMCs) from the interface and wash them twice with PBS.

2.5. Use magnetic bead-based separation (e.g., Miltenyi Biotec) to isolate CD8+ T-cells from the PBMCs.

**Step 3: Co-culture of CD8+ T-cells with Antigen-Presenting Cells (APCs) from Infected Flounder**

3.1. Isolate APCs (e.g., dendritic cells, macrophages) from the infected flounder spleen or head kidney using standard protocols.

3.2. Co-culture 10^5 CD8+ T-cells with 10^5 APCs in a 96-well plate in the presence or absence of MhcII-specific antibodies (10 μg/mL).

3.3. Add 10 μg/mL of antigen (e.g., ovalbumin) to the co-culture.

3.4. Incubate the co-culture at 22°C, 5% CO2 for 48 hours.

**Step 4: Analysis of CD8+ T-cell Activation and Proliferation**

4.1. Harvest the co-culture and stain the cells with fluorescently labeled antibodies against CD8, CD25, and CD69.

4.2. Analyze the cells using a flow cytometer (e.g., BD FACSCanto) to determine the percentage of activated CD8+ T-cells (CD25+CD69+).

4.3. Perform a proliferation assay (e.g., CFSE) to determine the number of proliferating CD8+ T-cells.

**Step 5: Comparison and Replication**

5.1. Compare the results from the co-culture with and without MhcII-specific antibodies to determine if MhcII upregulation enhances cross-presentation of antigens to CD8+ T-cells.

5.2. Repeat the experiment with different pathogens and antigens to ensure consistency.

**Experiment to Disprove the Hypothesis: Investigating the Role of MhcII in Cross-Presentation of Antigens to CD8+ T-cells in Flounder: A Blocking Experiment**

**Protocol:**

**Step 1: Infection of Flounder with a Pathogen**

( Same as Step 1 in the first experiment)

**Step 2: Isolation of APCs from Infected Flounder and MhcII Knockdown**

2.1. Isolate APCs (e.g., dendritic cells, macrophages) from the infected flounder spleen or head kidney using standard protocols.

2.2. Transfect the APCs with MhcII-specific siRNA (10 nM) or use CRISPR-Cas9 to knockdown MhcII expression.

2.3. Verify the knockdown of MhcII expression using qRT-PCR or Western blot.

**Step 3: Co-culture of CD8+ T-cells with MhcII-Knockdown APCs and Antigens**

3.1. Co-culture 10^5 CD8+ T-cells with 10^5 MhcII-knockdown APCs in a 96-well plate.

3.2. Add 10 μg/mL of antigen (e.g., ovalbumin) to the co-culture.

3.3. Incubate the co-culture at 22°C, 5% CO2 for 48 hours.

**Step 4: Analysis of CD8+ T-cell Activation and Proliferation**

( Same as Step 4 in the first experiment)

**Step 5: Comparison and Replication**

5.1. Compare the results from the co-culture with MhcII-knockdown APCs to those obtained with control APCs (without MhcII knockdown) to determine if blocking MhcII expression abolishes cross-presentation of antigens to CD8+ T-cells.

5.2. Repeat the experiment with different pathogens and antigens to ensure consistency.

These detailed protocols provide a step-by-step guide for executing the experiments, ensuring replicability and specificity in the results.","```
   Pathogen_CFU/mL  Heparin_U/mL  Antigen_μg/mL  MhcII_Ab_μg/mL  CD8+_T-cells  APCs  CD25+_CD69+%  Proliferating_CD8+%
0              5e+05          10.0           5.0           0.0       1e+05  1e+05         20.5           15000
1              1e+06          15.0           7.5           5.0       1e+05  1e+05         35.2           25000
2              5e+05           5.0           2.5           2.5       5e+04  5e+04         12.1            8000
3              2e+06          20.0          10.0           0.0       2e+05  2e+05         40.8           35000
4              1e+06          10.0           5.0           7.5       1e+05  1e+05         28.5           20000
5              5e+05           5.0           2.5           5.0       5e+04  5e+04         18.3           12000
6              2e+06          15.0           7.5           2.5       2e+05  2e+05         32.1           28000
7              1e+06          20.0          10.0           5.0       1e+05  1e+05         38.9           32000
8              5e+05          10.0           5.0           0.0       5e+04  5e+04         22.8           18000
9              2e+06          10.0           5.0           7.5       2e+05  2e+05         30.4           24000
10             1e+06          15.0           7.5           2.5       1e+05  1e+05         26.7           21000
11             5e+05           5.0           2.5           5.0       5e+04  5e+04         14.9           10000
12             2e+06          20.0          10.0           0.0       2e+05  2e+05         36.5           30000
13             1e+06          10.0           5.0           5.0       1e+05  1e+05         24.2           19000
14             5e+05          15.0           7.5           2.5       5e+04  5e+04         16.5           13000
15             2e+06          10.0           5.0           7.5       2e+05  2e+05         33.8           27000
16             1e+06          20.0          10.0           2.5       1e+05  1e+05         31.4           25000
17             5e+05           5.0           2.5           0.0       5e+04  5e+04         19.7           16000
18             2e+06          15.0           7.5           5.0       2e+05  2e+05         29.3           23000
19             1e+06          10.0           5.0           2.5       1e+05  1e+05         25.9           20000
20             5e+05          20.0          10.0           5.0       5e+04  5e+04         17.2           14000
21             2e+06          10.0           5.0           2.5       2e+05  2e+05         34.6           29000
22             1e+06          15.0           7.5           0.0       1e+05  1e+05         27.5           22000
23             5e+05           5.0           2.5           7.5       5e+04  5e+04         13.4            9000
24             2e+06          20.0          10.0           2.5       2e+05  2e+05         39.2           33000
```",0.6670431229513395
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/17c7f460cf9dd8f9b9fe6fc87741e908923ebe62.summary'],Does the upregulation of the NF-κB signaling pathway in CD19.CAR-T cells enhance their resistance to apoptosis and improve their anti-tumor activity when combined with COX inhibitors?,"To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis and designed an experiment to disprove it.

**Experimental Plan to Test the Hypothesis:**

**Title:** Investigating the Role of NF-κB Signaling Pathway in CD19.CAR-T Cell Resistance to Apoptosis and Anti-Tumor Activity in Combination with COX Inhibitors

**Objective:** To determine whether upregulation of the NF-κB signaling pathway in CD19.CAR-T cells enhances their resistance to apoptosis and improves their anti-tumor activity when combined with COX inhibitors.

**Equipment:**

* CD19.CAR-T cells
* COX inhibitors (celecoxib and aspirin)
* NF-κB activators (e.g., TNF-α, IL-1β)
* Flow cytometer
* Cell culture facilities
* Western blot equipment (for protein analysis)

**Steps:**

1. Culture CD19.CAR-T cells with or without COX inhibitors (celecoxib and aspirin) and NF-κB activators (TNF-α, IL-1β).
2. Analyze cell viability, apoptosis, and activation markers (e.g., CD69, CD28) by flow cytometry.
3. Evaluate the anti-tumor activity of CD19.CAR-T cells against target cells in the presence or absence of COX inhibitors and NF-κB activators.
4. Perform Western blot analysis to assess the expression levels of NF-κB and its downstream targets (e.g., Bcl-xL, XIAP) in CD19.CAR-T cells treated with COX inhibitors and NF-κB activators.
5. Compare the results to determine whether NF-κB activation enhances CD19.CAR-T cell resistance to apoptosis and improves their anti-tumor activity in combination with COX inhibitors.

**Experiment to Disprove the Hypothesis:**

**Title:** Investigating the Role of NF-κB Signaling Pathway in CD19.CAR-T Cell Sensitivity to Apoptosis and Impaired Anti-Tumor Activity in Combination with COX Inhibitors

**Objective:** To determine whether upregulation of the NF-κB signaling pathway in CD19.CAR-T cells does not enhance their resistance to apoptosis and does not improve their anti-tumor activity when combined with COX inhibitors.

**Equipment:**

* Same as above

**Steps:**

1. Culture CD19.CAR-T cells with COX inhibitors (celecoxib and aspirin) and NF-κB activators (TNF-α, IL-1β) at varying concentrations.
2. Analyze cell viability, apoptosis, and activation markers (e.g., CD69, CD28) by flow cytometry.
3. Evaluate the anti-tumor activity of CD19.CAR-T cells against target cells in the presence or absence of COX inhibitors and NF-κB activators.
4. Perform Western blot analysis to assess the expression levels of NF-κB and its downstream targets (e.g., Bcl-xL, XIAP) in CD19.CAR-T cells treated with COX inhibitors and NF-κB activators.
5. Compare the results to determine whether NF-κB activation does not enhance CD19.CAR-T cell resistance to apoptosis and does not improve their anti-tumor activity in combination with COX inhibitors.

**Rationale:**

The experiment to disprove the hypothesis aims to show that upregulation of the NF-κB signaling pathway in CD19.CAR-T cells does not enhance their resistance to apoptosis and does not improve their anti-tumor activity when combined with COX inhibitors. By using varying concentrations of NF-κB activators and COX inhibitors, we can assess whether the effects of NF-κB activation on CD19.CAR-T cells are dose-dependent and specific to the combination with COX inhibitors. If the results show that NF-κB activation does not enhance CD19.CAR-T cell resistance to apoptosis and anti-tumor activity, it would disprove the original hypothesis.

**Time and Resource Considerations:**

This experiment can be completed within a reasonable time frame (approximately 6-8 weeks) and with a moderate budget. The required equipment and reagents are readily available in most research laboratories, and the experimental design is straightforward. The experiment can be performed by a single researcher or a small team, and the results can be analyzed using standard statistical methods.",85,"Here are the detailed, step-by-step protocols for the experimental plan to test the hypothesis and the experiment to disprove the hypothesis:

**Experimental Plan to Test the Hypothesis:**

**Protocol 1: Cell Culture and Treatment**

1.1. Prepare CD19.CAR-T cells according to the manufacturer's instructions or established laboratory protocols.

1.2. Aliquot 1 x 10^6 CD19.CAR-T cells into 6-well plates or T-25 flasks.

1.3. Add the following treatments to the respective wells/flasks:
	* Control: no treatment
	* COX inhibitors: 10 μM celecoxib and 100 μM aspirin
	* NF-κB activators: 10 ng/mL TNF-α and 10 ng/mL IL-1β
	* COX inhibitors + NF-κB activators: 10 μM celecoxib, 100 μM aspirin, 10 ng/mL TNF-α, and 10 ng/mL IL-1β

1.4. Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

**Protocol 2: Flow Cytometry Analysis**

2.1. Harvest the cells from the 6-well plates or T-25 flasks and wash them twice with PBS.

2.2. Stain the cells with the following antibodies:
	* CD69-PE (1:100)
	* CD28-APC (1:100)
	* Annexin V-FITC (1:100) for apoptosis analysis

2.3. Analyze the cells using a flow cytometer (e.g., BD FACSCanto II) and record the data using the manufacturer's software.

**Protocol 3: Anti-Tumor Activity Assay**

3.1. Prepare target cells (e.g., Raji cells) according to the manufacturer's instructions or established laboratory protocols.

3.2. Co-culture the CD19.CAR-T cells with the target cells at a 1:1 ratio in 96-well plates.

3.3. Add the following treatments to the respective wells:
	* Control: no treatment
	* COX inhibitors: 10 μM celecoxib and 100 μM aspirin
	* NF-κB activators: 10 ng/mL TNF-α and 10 ng/mL IL-1β
	* COX inhibitors + NF-κB activators: 10 μM celecoxib, 100 μM aspirin, 10 ng/mL TNF-α, and 10 ng/mL IL-1β

3.4. Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

3.5. Measure the anti-tumor activity using a cytotoxicity assay (e.g., MTT or LDH release assay).

**Protocol 4: Western Blot Analysis**

4.1. Harvest the cells from the 6-well plates or T-25 flasks and wash them twice with PBS.

4.2. Lyse the cells using a lysis buffer (e.g., RIPA buffer) and quantify the protein concentration using a protein assay (e.g., BCA assay).

4.3. Separate the proteins using SDS-PAGE and transfer them to a PVDF membrane.

4.4. Probe the membrane with the following antibodies:
	* NF-κB p65 (1:1000)
	* Bcl-xL (1:1000)
	* XIAP (1:1000)

4.5. Detect the proteins using a chemiluminescent substrate (e.g., ECL) and record the data using a Western blot imaging system.

**Experiment to Disprove the Hypothesis:**

**Protocol 1: Cell Culture and Treatment**

1.1. Prepare CD19.CAR-T cells according to the manufacturer's instructions or established laboratory protocols.

1.2. Aliquot 1 x 10^6 CD19.CAR-T cells into 6-well plates or T-25 flasks.

1.3. Add the following treatments to the respective wells/flasks:
	* Control: no treatment
	* COX inhibitors: 1 μM, 5 μM, and 10 μM celecoxib, and 10 μM, 50 μM, and 100 μM aspirin
	* NF-κB activators: 1 ng/mL, 5 ng/mL, and 10 ng/mL TNF-α, and 1 ng/mL, 5 ng/mL, and 10 ng/mL IL-1β
	* COX inhibitors + NF-κB activators: 1 μM celecoxib + 1 ng/mL TNF-α, 5 μM celecoxib + 5 ng/mL TNF-α, and 10 μM celecoxib + 10 ng/mL TNF-α, and 10 μM aspirin + 1 ng/mL IL-1β, 50 μM aspirin + 5 ng/mL IL-1β, and 100 μM aspirin + 10 ng/mL IL-1β

1.4. Incubate the cells at 37°C, 5% CO2 for 24-48 hours.

**Protocol 2-4: Flow Cytometry Analysis, Anti-Tumor Activity Assay, and Western Blot Analysis**

Perform the same protocols as described above for the experimental plan to test the hypothesis.

**Note:**

* All experiments should be performed in triplicate to ensure reproducibility.
* The concentrations of COX inhibitors and NF-κB activators can be adjusted based on the results of the pilot experiments.
* The Western blot analysis can be performed using a different set of antibodies to validate the results.
* The data should be analyzed using standard statistical methods (e.g., ANOVA, t-test) to determine the significance of the results.","```
   Celecoxib  Aspirin  TNF-alpha  IL-1beta  CD69  CD28  Annexin V  Anti-Tumor Activity  NF-kB p65  Bcl-xL  XIAP
0         0.0     0.0       0.0       0.0  20.0  15.0       5.0             30.0       1.0    2.0   1.5
1        10.0   100.0       0.0       0.0  25.0  18.0       4.0             35.0       1.2    2.2   1.8
2         0.0     0.0      10.0       0.0  22.0  16.0       6.0             32.0       1.5    2.5   2.0
3        10.0   100.0      10.0       0.0  28.0  20.0       5.0             40.0       1.8    3.0   2.5
4         1.0    10.0       0.0       0.0  21.0  16.0       5.0             31.0       1.1    2.1   1.6
5         5.0    50.0       0.0       0.0  24.0  18.0       4.5             36.0       1.4    2.4   2.2
6         0.0     0.0       5.0       0.0  23.0  17.0       5.5             34.0       1.6    2.6   2.3
7         1.0    10.0       5.0       0.0  26.0  19.0       5.0             39.0       1.9    3.1   2.8
8         0.0     0.0       0.0       1.0  21.0  16.0       5.0             31.0       1.2    2.2   1.8
9         0.0     0.0       0.0       5.0  24.0  18.0       4.5             36.0       1.5    2.5   2.3
10        0.0     0.0       0.0      10.0  27.0  20.0       5.0             41.0       1.8    3.0   2.8
11        5.0    50.0       1.0       0.0  25.0  19.0       4.5             38.0       1.6    2.7   2.5
12        5.0    50.0       0.0       1.0  26.0  20.0       5.0             40.0       1.7    2.9   2.7
13        5.0    50.0       0.0       5.0  29.0  22.0       5.0             44.0       2.0    3.2   3.0
14       10.0   100.0       1.0       0.0  28.0  21.0       5.0             42.0       1.9    3.1   2.9
15       10.0   100.0       0.0       1.0  30.0  23.0       5.0             46.0       2.1    3.4   3.2
16       10.0   100.0       0.0       5.0  32.0  25.0       5.0             50.0       2.3    3.6   3.5
17        1.0    10.0       1.0       1.0  24.0  18.0       5.0             37.0       1.7    2.8   2.6
18        1.0    10.0       5.0       1.0  27.0  20.0       5.0             42.0       2.0    3.2   3.0
19        5.0    50.0       1.0       5.0  30.0  23.0       5.0             46.0       2.2    3.5   3.3
20        5.0    50.0       5.0       1.0  31.0  24.0       5.0             48.0       2.4    3.7   3.6
21       10.0   100.0       1.0       5.0  33.0  26.0       5.0             52.0       2.6    3.9   3.8
22       10.0   100.0       5.0       1.0  34.0  27.0       5.0             54.0       2.8    4.1   4.0
23        1.0    10.0       1.0       5.0  26.0  20.0       5.0             40.0       2.1    3.3   3.1
24        5.0    50.0       5.0       5.0  32.0  25.0       5.0             50.0       2.5    3.8   3.7
```",0
['/Users/bayardwalsh/Desktop/CMSC 35350/cmsc35350_final_project/eth/papers/7d693a5a0c85629616024086eff91336befedccd.summary'],"Does vagus nerve stimulation modulate the expression of ACh receptors on follicular dendritic cells, thereby influencing their ability to support germinal center formation and antibody responses?","To check if this hypothesis is true, come up with an experiment designed to DISPROVE THIS hypothesis to verify if it is true or not.","This experiment has a limited budget in terms of time, resources, and financial support and should be implementable within a reasonable time frame and for a reasonable price.",Here are the summaries of the papers this hypothesis was generated from for context:,"Based on the provided hypothesis and context, I've developed an experimental plan to test the hypothesis: ""Does vagus nerve stimulation modulate the expression of ACh receptors on follicular dendritic cells, thereby influencing their ability to support germinal center formation and antibody responses?""

**Experimental Approach:**

To disprove the hypothesis, we will design an experiment to test the following null hypothesis: ""Vagus nerve stimulation does not modulate the expression of ACh receptors on follicular dendritic cells, and therefore does not influence their ability to support germinal center formation and antibody responses.""

**Experiment:**

**Title:** ""Investigating the effect of vagus nerve stimulation on ACh receptor expression on follicular dendritic cells""

**Objective:** To determine if vagus nerve stimulation affects the expression of ACh receptors on follicular dendritic cells and their ability to support germinal center formation and antibody responses.

**Equipment:**

* Mice with vagus nerve stimulation (VNS) and control mice
* Follicular dendritic cells (FDCs) isolated from VNS and control mice
* ACh receptor antibodies for flow cytometry and Western blotting
* Flow cytometry equipment
* Western blotting equipment
* Germinal center formation assay
* Antibody response measurement equipment (e.g., ELISA)

**Steps:**

1. **FDC isolation and characterization**: Isolate FDCs from VNS and control mice using established protocols. Characterize FDCs using flow cytometry to confirm their identity and purity.
2. **ACh receptor expression analysis**: Use flow cytometry and Western blotting to analyze the expression of ACh receptors on FDCs from VNS and control mice. Compare the expression levels between the two groups.
3. **Germinal center formation assay**: Co-culture FDCs from VNS and control mice with B cells and T cells to assess their ability to support germinal center formation. Measure germinal center formation using established assays (e.g., immunofluorescence microscopy, flow cytometry).
4. **Antibody response measurement**: Measure the antibody response in VNS and control mice using ELISA or other established methods.
5. **Statistical analysis**: Compare the results from steps 2-4 between VNS and control mice using appropriate statistical tests (e.g., t-test, ANOVA).

**Expected Outcomes:**

* If the hypothesis is true, we expect to see:
	+ Increased expression of ACh receptors on FDCs from VNS mice compared to control mice.
	+ Impaired germinal center formation and antibody responses in VNS mice compared to control mice.
* If the hypothesis is false, we expect to see:
	+ No significant difference in ACh receptor expression on FDCs between VNS and control mice.
	+ No significant difference in germinal center formation and antibody responses between VNS and control mice.

**Time and Resource Considerations:**

* This experiment can be completed within 3-4 months with a moderate budget.
* The required equipment and reagents are readily available in most immunology and neuroscience laboratories.
* The experiment requires a moderate level of technical expertise in flow cytometry, Western blotting, and germinal center formation assays.

By following this experimental plan, we can test the hypothesis and determine if vagus nerve stimulation modulates the expression of ACh receptors on follicular dendritic cells, thereby influencing their ability to support germinal center formation and antibody responses.",85,"Here are the detailed, step-by-step protocols for the experiment:

**Protocol 1: FDC Isolation and Characterization**

**Step 1.1: Mouse Preparation**

* Obtain mice with vagus nerve stimulation (VNS) and control mice.
* Ensure mice are 6-8 weeks old and have been subjected to VNS or sham stimulation for at least 2 weeks.
* Euthanize mice using CO2 asphyxiation or cervical dislocation, following institutional guidelines.

**Step 1.2: Spleen Harvesting**

* Remove the spleen from each mouse and place it in a petri dish containing 10 mL of ice-cold PBS.
* Gently tease the spleen apart using forceps to release the cells.

**Step 1.3: Cell Isolation**

* Pass the spleen cells through a 70-μm cell strainer to remove debris and clumps.
* Centrifuge the cells at 300 x g for 5 minutes at 4°C.
* Resuspend the cells in 10 mL of ice-cold PBS and count the cells using a hemocytometer.

**Step 1.4: FDC Enrichment**

* Use a magnetic bead-based enrichment kit (e.g., Miltenyi Biotec) to isolate FDCs from the spleen cells.
* Follow the manufacturer's instructions for the enrichment protocol.

**Step 1.5: FDC Characterization**

* Stain the enriched FDCs with fluorescently labeled antibodies against FDC markers (e.g., CD21, CD35, and CD23).
* Analyze the cells using flow cytometry to confirm their identity and purity.
* Record the percentage of FDCs in the enriched population.

**Protocol 2: ACh Receptor Expression Analysis**

**Step 2.1: Cell Preparation**

* Prepare FDCs from VNS and control mice as described in Protocol 1.
* Count the cells and adjust the concentration to 1 x 10^6 cells/mL.

**Step 2.2: Flow Cytometry**

* Stain the FDCs with fluorescently labeled antibodies against ACh receptors (e.g., α7-nAChR).
* Use a flow cytometer (e.g., BD FACSCanto) to analyze the expression of ACh receptors on FDCs.
* Record the mean fluorescence intensity (MFI) of ACh receptors on FDCs from VNS and control mice.

**Step 2.3: Western Blotting**

* Lyse the FDCs in RIPA buffer containing protease inhibitors.
* Separate the proteins using SDS-PAGE and transfer them to a PVDF membrane.
* Probe the membrane with antibodies against ACh receptors and detect the signal using ECL or chemiluminescence.
* Record the band intensity of ACh receptors on FDCs from VNS and control mice.

**Protocol 3: Germinal Center Formation Assay**

**Step 3.1: Cell Preparation**

* Prepare FDCs from VNS and control mice as described in Protocol 1.
* Prepare B cells and T cells from naive mice using established protocols.
* Count the cells and adjust the concentration to 1 x 10^6 cells/mL.

**Step 3.2: Co-Culture**

* Co-culture FDCs from VNS and control mice with B cells and T cells in a 1:1:1 ratio.
* Use a 96-well plate and add 100 μL of complete medium to each well.
* Incubate the cells at 37°C, 5% CO2 for 7-10 days.

**Step 3.3: Germinal Center Formation Analysis**

* Harvest the cells and stain them with fluorescently labeled antibodies against germinal center markers (e.g., GL7, CD38).
* Analyze the cells using flow cytometry to assess germinal center formation.
* Record the percentage of germinal center cells in each group.

**Protocol 4: Antibody Response Measurement**

**Step 4.1: Serum Collection**

* Collect serum from VNS and control mice using established protocols.
* Store the serum at -20°C until analysis.

**Step 4.2: ELISA**

* Use a commercial ELISA kit (e.g., Mouse IgG ELISA Kit) to measure the antibody response in VNS and control mice.
* Follow the manufacturer's instructions for the ELISA protocol.
* Record the optical density (OD) values for each group.

**Protocol 5: Statistical Analysis**

**Step 5.1: Data Collection**

* Collect the data from Protocols 2-4, including the MFI of ACh receptors, band intensity of ACh receptors, percentage of germinal center cells, and OD values.

**Step 5.2: Statistical Analysis**

* Use a statistical software package (e.g., GraphPad Prism) to analyze the data.
* Compare the results between VNS and control mice using appropriate statistical tests (e.g., t-test, ANOVA).
* Record the p-values and confidence intervals for each comparison.

By following these detailed, step-by-step protocols, the experiment can be replicated and the hypothesis can be tested.","```
   VNS  Spleen_Cells  FDC_Enrichment  ACh_Receptor_Antibody  B_Cells  T_Cells  Germinal_Center_Markers  ACh_Receptor_MFI  ACh_Receptor_Band_Intensity  Germinal_Center_Formation  Antibody_Response_OD
0   1.0        1000000.0           0.8               1.0   500000.0   500000.0                  0.6               100.0                    0.5                    0.4               0.8
1   0.0        1200000.0           0.9               1.2   600000.0   600000.0                  0.7               120.0                    0.6                    0.5               1.0
2   1.0         900000.0           0.7               0.8   450000.0   450000.0                  0.5               90.0                     0.4                    0.3               0.6
3   0.0        1100000.0           0.8               1.1   550000.0   550000.0                  0.6               110.0                    0.5                    0.4               0.9
4   1.0        1300000.0           0.9               1.3   650000.0   650000.0                  0.8               130.0                    0.7                    0.6               1.1
5   0.0         800000.0           0.6               0.9   400000.0   400000.0                  0.4               80.0                     0.3                    0.2               0.5
6   1.0        1400000.0           0.9               1.4   700000.0   700000.0                  0.9               140.0                    0.8                    0.7               1.2
7   0.0        1000000.0           0.7               1.0   500000.0   500000.0                  0.5               100.0                    0.5                    0.4               0.8
8   1.0        1500000.0           0.9               1.5   750000.0   750000.0                 1.0               150.0                    0.9                    0.8               1.3
9   0.0         900000.0           0.8               1.2   450000.0   450000.0                  0.6               90.0                     0.5                    0.4               0.9
10  1.0        1600000.0           0.9               1.6   800000.0   800000.0                 1.1               160.0                   1.0                    0.9               1.4
11  0.0        1100000.0           0.8               1.3   550000.0   550000.0                  0.7               110.0                    0.6                    0.5               1.0
12  1.0        1700000.0           0.9               1.7   850000.0   850000.0                 1.2               170.0                   1.1                   1.0               1.5
13  0.0        1200000.0           0.9               1.4   600000.0   600000.0                  0.8               120.0                    0.7                    0.6               1.1
14  1.0        1800000.0           0.9               1.8   900000.0   900000.0                 1.3               180.0                   1.2                   1.1               1.6
15  0.0        1300000.0           0.9               1.5   650000.0   650000.0                  0.9               130.0                    0.8                    0.7               1.2
16  1.0        1900000.0           0.9               1.9  1000000.0  1000000.0                 1.4               190.0                   1.3                   1.2               1.7
17  0.0        1400000.0           0.9               1.6   700000.0   700000.0                 1.0               140.0                    0.9                    0.8               1.3
18  1.0        2000000.0           0.9               2.0  1100000.0  1100000.0                 1.5               200.0                   1.4                   1.3               1.8
19  0.0        1500000.0           0.9               1.7   750000.0   750000.0                 1.1               150.0                   1.0                    0.9               1.4
20  1.0        2100000.0           0.9               2.1  1200000.0  1200000.0                 1.6               210.0                   1.5                   1.4               1.9
21  0.0        1600000.0           0.9               1.8   800000.0   800000.0                 1.2               160.0                   1.1                    1.0               1.5
22  1.0        2200000.0           0.9               2.2  1300000.0  1300000.0                 1.7               220.0                   1.6                   1.5               2.0
23  0.0        1700000.0           0.9               1.9   850000.0   850000.0                 1.3               170.0                   1.2                    1.1               1.6
24  1.0        2300000.0           0.9               2.3  1400000.0  1400000.0                 1.8               230.0                   1.7                   1.6               2.1
```",0.9051824939557497
